<SEC-DOCUMENT>0001047469-15-003920.txt : 20150427
<SEC-HEADER>0001047469-15-003920.hdr.sgml : 20150427
<ACCEPTANCE-DATETIME>20150427061007
ACCESSION NUMBER:		0001047469-15-003920
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		43
FILED AS OF DATE:		20150427
DATE AS OF CHANGE:		20150427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COLLEGIUM PHARMACEUTICAL, INC
		CENTRAL INDEX KEY:			0001267565
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-203208
		FILM NUMBER:		15793435

	BUSINESS ADDRESS:	
		STREET 1:		780 DEDHAM STREET, SUITE 800
		CITY:			CANTON
		STATE:			MA
		ZIP:			02021
		BUSINESS PHONE:		781-713-3699

	MAIL ADDRESS:	
		STREET 1:		780 DEDHAM STREET, SUITE 800
		CITY:			CANTON
		STATE:			MA
		ZIP:			02021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COLLEGIUM PHARMACEUTICAL INC
		DATE OF NAME CHANGE:	20031020
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>a2224429zs-1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg72301_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#in">  Index to Financial Statements</A><BR></font>
</P>

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;">


<FONT  style="font-size:8pt;line-height:9pt;"><B>As filed with the Securities and Exchange Commission on April&nbsp;27, 2015.

  </B></FONT>

</P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


Registration No.&nbsp;333-203208


 </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


AMENDMENT NO. 1 TO<BR>  </B></FONT><FONT SIZE=4><B>FORM S-1<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Collegium Pharmaceutical,&nbsp;Inc.<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">(Exact name of registrant as specified in its charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Virginia</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 2834</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 03-0416362</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Collegium Pharmaceutical,&nbsp;Inc.<BR>
780 Dedham Street<BR>
Suite&nbsp;800<BR>
Canton, MA 02021<BR>
(781)&nbsp;713-3699</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Address, including zip code and telephone number, including<BR>
area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Michael T. Heffernan<BR>
President and Chief Executive Officer<BR>
Collegium Pharmaceutical,&nbsp;Inc.<BR>
780 Dedham Street<BR>
Suite&nbsp;800<BR>
Canton, MA 02021<BR>
(781)&nbsp;713-3699</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Name, address, including zip code and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="47%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Copies to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT  style="font-size:8pt;line-height:9pt;"><B>Steven J. Abrams, Esq.<BR>
Robert Y. Chow, Esq.<BR>
Pepper Hamilton&nbsp;LLP<BR>
19<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">th</font> Floor, High Street Tower<BR>
125 High Street<BR>
Boston, MA 02110<BR>
(617)&nbsp;204-5100</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT  style="font-size:8pt;line-height:9pt;"><B> Peter N. Handrinos, Esq.<BR>
Latham&nbsp;&amp; Watkins&nbsp;LLP<BR>
John Hancock Tower<BR>
200 Clarendon Street<BR>
Boston, MA 02116<BR>
(617)&nbsp;948-6000</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Approximate date of commencement of proposed sale to the public:<BR>
As soon as practicable after the effective date of this registration statement.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, as
amended (the "Securities Act"), check the following box. <FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of
"large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12%" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12%" style="font-family:arial;"></TD>
<TD WIDTH="100pt" style="font-family:arial;"></TD>
<TD WIDTH="12%" style="font-family:arial;"></TD>
<TD WIDTH="120pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Large accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Non-accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT><BR></FONT> <FONT  style="font-size:8pt;line-height:9pt;">(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Smaller reporting company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>




<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="96" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="96" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="96" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="96" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Title of Securities Being Registered</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount to be<BR>
Registered<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Proposed<BR>
Maximum<BR>
Offering Price<BR>
Per Share</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Proposed<BR>
Maximum<BR>
Aggregate<BR>
Offering Price<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount of<BR>
Registration<BR>
Fee<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">Common Stock, $0.001 par value per share</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,670,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">$14.00</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">$93,380,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">$10,851</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:arial;border-bottom:double #000000 2.25pt;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<DL compact>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
870,000 shares which the underwriters have the option to purchase from the registrant.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Estimated
solely for purposes of computing the amount of the registration fee pursuant to Rule&nbsp;457(a) under the Securities Act of 1933,
as amended. Includes the offering price of shares that the underwriters have the option to purchase to cover over-allotments, if any.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Of
this amount, $10,023 was previously paid in connection with prior filings of this Registration Statement.

</FONT></DD></DL>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file&nbsp;a further
amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act, or until the registration statement
shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></FONT></P>
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT  style="font-size:8pt;line-height:9pt;">
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=825407,FOLIO='blank',FILE='DISK114:[15ZAD1.15ZAD72301]BA72301A.;27',USER='LPALLES',CD='24-APR-2015;12:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_TXTHEX,"" -->


</FONT> <FONT COLOR="#FF4040" SIZE=2>The information contained in this preliminary prospectus is not complete and may be changed.
We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;">

<FONT SIZE=2><B>









<!-- COMMAND=ADD_TXTHEX,"" -->


 </B></FONT><FONT COLOR="#FF4040" SIZE=2>SUBJECT TO COMPLETION, DATED APRIL&nbsp;27, 2015

</FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2><B>PRELIMINARY PROSPECTUS

  </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;">



<FONT SIZE=4><B>5,800,000 Shares

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>
<IMG SRC="g603081.jpg" ALT="LOGO" WIDTH="307" HEIGHT="66">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B>Collegium Pharmaceutical,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We are offering 5,800,000 shares of our common stock. This is our initial public offering and no public market currently exists for our common stock. We expect
the initial public offering price to be between $12.00 and $14.00 per share. We expect to receive approval to list our common stock on The NASDAQ Global Market ("NASDAQ") under the symbol "COLL."


</FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2><B>We are an "emerging growth company" as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, or the Securities Act, and will be subject to reduced public
company reporting requirements. See "Prospectus Summary&nbsp;&#151; Implications of Being an Emerging Growth Company."</B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2><B>Investing in our common stock involves a high degree of risks. Please read "Risk Factors" beginning on page 14 of this prospectus.</B></FONT>


</P>

<P style="font-family:arial;"><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="89pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Per Share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initial public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >




<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">We refer you to "Underwriting" beginning on page&nbsp;177 of this prospectus for additional
information regarding total underwriter compensation.</FONT>

</DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>


Certain of our existing shareholders, or their affiliates, have indicated an interest in purchasing up to an aggregate of approximately $30.0&nbsp;million of shares of our common stock in this
offering at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no
shares in this offering to any of these investors, and any of these investors may determine to purchase more, less or no shares in this offering. The underwriters will receive the same underwriting
discount on any shares purchased by these investors as they will on any other shares sold to the public in this offering.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Delivery of the shares of common stock is expected to be made on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2015. We have granted the underwriters an option for a period of 30&nbsp;days to purchase an additional
870,000 shares of our common stock. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
and the total proceeds to
us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.

 </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=4><B>Jefferies</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=4><B> Piper Jaffray</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><BR><FONT SIZE=4><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wells Fargo Securities</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=4><B><BR>&nbsp;</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><BR><FONT SIZE=4>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=4><B><BR>
&nbsp;</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=4><B><BR>&nbsp;</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=4><B> Needham &amp; Company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"><font> </FONT> <FONT SIZE=2>
Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1009912,FOLIO='blank',FILE='DISK114:[15ZAD1.15ZAD72301]BC72301A.;42',USER='LGADISH',CD='24-APR-2015;23:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG72301A_main_toc"></A> </FONT></P>

<A NAME="bg72301_table_of_contents"> </A>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


TABLE OF CONTENTS  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="BG72301_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->

<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="25pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Page </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ca72301_prospectus_summary"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> PROSPECTUS SUMMARY</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ca72301_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#cc72301_the_offering"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>THE OFFERING</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cc72301_the_offering"><FONT SIZE=2>9</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ce72301_summary_financial_data"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SUMMARY FINANCIAL DATA</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ce72301_summary_financial_data"><FONT SIZE=2>12</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc72301_risk_factors"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc72301_risk_factors"><FONT SIZE=2>14</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dk72301_special_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dk72301_special_note_regarding_forward-looking_statements"><FONT SIZE=2>56</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dm72301_use_of_proceeds"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dm72301_use_of_proceeds"><FONT SIZE=2>58</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dm72301_dividend_policy"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIVIDEND POLICY</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dm72301_dividend_policy"><FONT SIZE=2>59</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dm72301_capitalization"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CAPITALIZATION</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dm72301_capitalization"><FONT SIZE=2>60</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dm72301_dilution"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DILUTION</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dm72301_dilution"><FONT SIZE=2>62</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#do72301_selected_financial_data"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SELECTED FINANCIAL DATA</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#do72301_selected_financial_data"><FONT SIZE=2>65</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dq72301_management_s_discussion_and_an__man03466"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dq72301_management_s_discussion_and_an__man03466"><FONT SIZE=2>67</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ds72301_business"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BUSINESS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds72301_business"><FONT SIZE=2>84</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ee72301_management"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MANAGEMENT</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ee72301_management"><FONT SIZE=2>137</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#eg72301_executive_and_director_compensation"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE AND DIRECTOR COMPENSATION</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eg72301_executive_and_director_compensation"><FONT SIZE=2>145</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ei72301_certain_relationships_and_related_party_transactions"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ei72301_certain_relationships_and_related_party_transactions"><FONT SIZE=2>156</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ei72301_principal_shareholders"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PRINCIPAL SHAREHOLDERS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ei72301_principal_shareholders"><FONT SIZE=2>162</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#ek72301_description_of_capital_stock"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ek72301_description_of_capital_stock"><FONT SIZE=2>165</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#em72301_shares_eligible_for_future_sale"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SHARES ELIGIBLE FOR FUTURE SALE</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#em72301_shares_eligible_for_future_sale"><FONT SIZE=2>171</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#em72301_material_u.s._federal_income_t__mat03201"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON
STOCK</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#em72301_material_u.s._federal_income_t__mat03201"><FONT SIZE=2>173</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#eo72301_underwriting"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>UNDERWRITING</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eo72301_underwriting"><FONT SIZE=2>177</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#eo72301_legal_matters"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eo72301_legal_matters"><FONT SIZE=2>185</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#eo72301_experts"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eo72301_experts"><FONT SIZE=2>185</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#eo72301_where_you_can_find_more_information"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eo72301_where_you_can_find_more_information"><FONT SIZE=2>185</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#in"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INDEX TO FINANCIAL STATEMENTS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#in"><FONT SIZE=2>F-1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>


<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Neither
we nor any of the underwriters has authorized anyone to provide you with information different from, or in addition to, that contained in this prospectus or any free writing prospectus
prepared by or on behalf of us or to
which we may have referred you in connection with this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
Neither we nor any of the underwriters is making an offer to sell or seeking offers to buy these securities in any jurisdiction where, or to any person to whom, the offer or sale is not permitted. The
information in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of shares of our common stock
and the information in any free writing prospectus that we may provide you in connection with this offering is accurate only as of the date of that free writing prospectus. Our business, financial
condition, results of operations and future growth prospects may have changed since those dates. </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=407740,FOLIO='blank',FILE='DISK114:[15ZAD1.15ZAD72301]BG72301A.;27',USER='LGADISH',CD='25-APR-2015;00:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bi72301_industry_and_market_data"> </A>
<A NAME="toc_bi72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  INDUSTRY AND MARKET DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We obtained the industry, market and competitive position data in this prospectus from our own internal estimates and research as well as from
industry and general publications and research surveys and studies conducted by third parties. We believe this data is accurate in all material respects as of the date of this prospectus. In addition,
projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to a high degree of uncertainty and risk due to
a variety of factors, including those described in "Risk Factors." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bi72301_trademarks_and_trade_names"> </A>
<A NAME="toc_bi72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  TRADEMARKS AND TRADE NAMES    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have registered Collegium Pharmaceutical,&nbsp;Inc., DETERx and Xtampza ER as U.S. trademarks. This prospectus contains references to our
trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may
appear without the &reg; or &#153; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights
or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or
endorsement or sponsorship of us by, any other companies. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bi72301_basis_of_presentation"> </A>
<A NAME="toc_bi72301_3"> </A>
<BR>

</FONT>

<FONT SIZE=2><B>  BASIS OF PRESENTATION

    <BR>    </B></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>On April&nbsp;24, 2015, we amended our articles of incorporation to effect a 1-for-6.9 reverse stock split of our common stock. Concurrent with the
reverse stock split, we adjusted (x)&nbsp;the conversion price of our convertible preferred stock, (y)&nbsp;the number of shares subject to and the exercise price of our outstanding stock option
awards under our equity incentive plan and (z)&nbsp;the number of shares subject to and the exercise price of our outstanding warrants, such that the holders of the preferred stock, options and
warrants are in the same economic position both before and after the reverse stock split. In addition, immediately prior to the closing of this offering, the outstanding shares of our convertible
preferred stock will convert into shares of our common stock. Unless otherwise indicated, all share data gives effect to the conversion of our preferred stock into common stock.

 </FONT>

</P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=349183,FOLIO='blank',FILE='DISK114:[15ZAD1.15ZAD72301]BI72301A.;8',USER='LGADISH',CD='25-APR-2015;00:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ca72301_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ca72301_prospectus_summary"> </A>
<A NAME="toc_ca72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>This summary highlights certain information about us and this offering contained elsewhere in this prospectus. Because it is
only a summary, it does not contain all of the information that you should consider before investing in shares of our common stock and it is qualified in its entirety by, and should
be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our common stock, you should read the entire prospectus carefully,
including "Risk Factors," "Special Note Regarding Forward-Looking Statements" and the financial statements and related notes included elsewhere in this prospectus.</I></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Unless
the context indicates otherwise, as used in this prospectus, the terms "Collegium," "we," "us," "our," "our company" and "our business" refer to Collegium Pharmaceutical,&nbsp;Inc. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate our
patented DETERx&reg; platform technology for the treatment of chronic pain and other diseases. Our lead product candidate, Xtampza ER&#153;, or Xtampza, is an abuse-deterrent,
extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration, or FDA. Our new drug
application, or NDA, filing for Xtampza was accepted by the FDA on February&nbsp;10, 2015. On February&nbsp;25, 2015, the FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of
October&nbsp;12, 2015 for completion of its review of the Xtampza NDA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
has the same active ingredient as OxyContin&reg; OP, which is the largest selling abuse-deterrent, extended-release opioid in the United States by dollars, with $2.5&nbsp;billion in
U.S. sales in 2014. We conducted a comprehensive preclinical and clinical program for Xtampza consistent with FDA guidance on abuse-deterrence. These studies and clinical trials demonstrated that
chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not meaningfully change its drug release profile or safety characteristics. By contrast,
clinical trials performed by us and others&nbsp;&#151; including a head-to-head clinical trial comparing Xtampza with OxyContin OP&nbsp;&#151; have shown that drug abusers can
achieve rapid release and absorption of the active ingredient by manipulating OxyContin OP using common household tools and methods commonly available on the Internet. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, our preclinical studies and clinical trials have shown that the contents of the Xtampza capsule can be removed from the capsule and sprinkled on food, directly into the mouth or
administered through feeding tubes, without compromising their drug release profile, safety or abuse-deterrent characteristics. By contrast, OxyContin OP, which is formulated in hard tablets, has a
black box warning label stating that crushing, dissolving or chewing can cause rapid release and absorption of a potentially fatal dose of the active ingredient. We believe that Xtampza, if approved,
can address the pain management needs of the approximately 11&nbsp;million patients in the United States who suffer from chronic pain and have difficulty swallowing. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our DETERx Platform Technology  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In our proprietary DETERx technology, we combine active ingredients such as oxycodone with fatty acid and waxes to form&nbsp;a molten solution which
is spray-congealed into solid microspheres using a proprietary spinning disk manufacturing process. These solid wax-based microspheres are then filled into capsules. Each individual microsphere is
designed to be extended-release and abuse-deterrent. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition to our Xtampza formulation of oxycodone, DETERx technology is applicable to many other opioid active ingredients, as well as other categories of abuseable drugs, such as amphetamines and
methylphenidate. </FONT></P>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=544885,FOLIO='1',FILE='DISK114:[15ZAD1.15ZAD72301]CA72301A.;54',USER='LGADISH',CD='24-APR-2015;23:57' -->
<A NAME="page_ca72301_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Prescription Drug Abuse  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The U.S. Centers for Disease Control and Prevention described abuse of prescription drugs in the United States as a growing and deadly epidemic.
Deaths in the United States from prescription opioid overdose have grown from approximately 4,000 in 1999 to approximately 16,000 in 2012. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
American Journal of Managed Care estimated in a 2013 report that opioid abuse costs public and private healthcare payors over $72&nbsp;billion annually in direct healthcare costs, including
costs of emergency room&nbsp;visits, rehabilitation and associated health problems. In response to widespread prescription opioid abuse, the U.S.
government and a number of state legislatures have introduced, and in some cases have enacted, legislation and regulations intended to encourage the development of abuse-deterrent forms of pain
medications, including certain forms of extended-release opioids. The FDA has stated that addressing prescription drug abuse is a priority, and the development of abuse-deterrent opioids is a key part
of that strategy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Extended-release
opioids incorporate a large amount of opioid with a time-release mechanism designed to deliver steady amounts of opioid, typically over 12 to 24&nbsp;hours. Drug abusers find
currently approved extended-release opioid tablets desirable because of the large amount of drug payload, which they attempt to release quickly into the bloodstream to create euphoria. It is difficult
for drug abusers to achieve this rapid release and absorption into the bloodstream by taking multiple intact extended-release opioid tablets or capsules because doing so often causes sleepiness and/or
respiratory distress before euphoria is achieved. Instead, they attempt to defeat the extended-release properties in order to achieve rapid release of the active ingredient. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2014, there were approximately 29&nbsp;million prescriptions for extended-release and long-acting opioids in the United States. OxyContin OP accounted for approximately $2.5&nbsp;billion in
total U.S. sales from approximately 6&nbsp;million prescriptions. Despite the introduction of OxyContin OP in 2010 as the first FDA-approved abuse-deterrent extended-release opioid formulation,
abuse of extended-release opioids, including OxyContin OP, continues to be a major public health issue. OxyContin OP, even with its abuse-deterrent formulation, remains vulnerable to abuse using
common household objects, like pill crushers. Third party studies found that abusers of OxyContin OP use various routes of abuse&nbsp;&#151; including snorting, injection and oral
abuse&nbsp;&#151; despite OxyContin OP's abuse-deterrent features. In a third party study of OxyContin abusers both before and after OxyContin OP was introduced, researchers found that while
the non-oral routes of abuse of OxyContin OP (i.e., injection, snorting and smoking) were used less after its introduction, oral abuse of OxyContin OP increased from approximately 52% to 75% of
OxyContin abusers. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ca72301_oxycontin_op_tablet_+_$6.39_pi__oxy02648"> </A>
<A NAME="toc_ca72301_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>OxyContin OP Tablet&nbsp;+&nbsp;$6.39 Pill Crusher&nbsp;= Abuseable Fine Powder in 16 Seconds    <BR>    </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g544224.jpg" ALT="GRAPHIC" WIDTH="438" HEIGHT="157">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Chronic Pain with Dysphagia  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>It is estimated that more than 10% of patients with chronic pain, or approximately 11&nbsp;million patients, have dysphagia, or difficulty in
swallowing, because they have cancer, are elderly, have other medical </FONT></P>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=302198,FOLIO='2',FILE='DISK114:[15ZAD1.15ZAD72301]CA72301A.;54',USER='LGADISH',CD='24-APR-2015;23:57' -->
<A NAME="page_ca72301_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:arial;"><FONT SIZE=2>problems
or have difficulty swallowing without a known medical cause. Our preclinical studies and clinical trials have shown that the contents of the Xtampza capsules can be removed from the capsule
and sprinkled on food, directly into the mouth or administered through feeding tubes, without compromising their extended-release properties. By contrast, all other FDA-approved, orally administered,
extended-release opioids have a black box warning label stating that "crushing, dissolving or chewing can cause rapid release and absorption of a potentially fatal dose of the active drug", making
them unsuitable or unattractive for patients who suffer from chronic pain with dysphagia, or CPD. An external marketing study performed for us in 2013 estimated that Xtampza, if approved, has a peak
revenue potential for U.S. patients with CPD in excess of $700&nbsp;million annually. We have performed what we believe to be all of the required preclinical studies and clinical trials to obtain
FDA product labeling for sprinkling Xtampza microspheres directly in the mouth or on food, as well as administering the microspheres through gastric or nasogastric feeding tubes. If approved with such
labeling, and without such black box warning, Xtampza would be the only abuse-deterrent extended-release opioid product addressing this patient segment. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Xtampza  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our lead product candidate, Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone in development for the management of pain
severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The
active ingredient in Xtampza is oxycodone, which is approved by the FDA and other regulators around the world in a number of both immediate-release and extended-release drug products. We developed
Xtampza using our proprietary, DETERx abuse-deterrent technology to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting
Xtampza. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical Development  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In January 2013, the FDA issued a draft guidance document titled "Abuse-Deterrent Opioids&nbsp;&#151; Evaluation and Labeling." Before this
FDA draft guidance was finalized, it was followed by the FDA in the approval process of abuse-deterrence products. The FDA issued its final guidance in April 2015. Like the draft guidance, the final
guidance specifically defines the studies and clinical trials required to evaluate the abuse-deterrent properties of a formulation and the associated claims that a manufacturer can make based on the
results of those studies and clinical trials. This is meant to incentivize the development of improved abuse-deterrent products. We believe that all of our studies and clinical trials are consistent
with the final FDA guidance. Also, because of the Fast Track status granted to Xtampza, we have had multiple interactions with the FDA. Based upon these interactions, we designed our studies and
clinical trials with a goal of achieving a differentiated label from OxyContin OP with respect to the abuse-deterrent properties of Xtampza. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have completed numerous studies and clinical trials on Xtampza, which have demonstrated:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Safety and effectiveness for treatment of chronic
pain.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In July 2014, we completed a prospective, randomized Phase&nbsp;3 clinical trial that met its primary endpoint, demonstrating that Xtampza, compared to a
placebo, was safe and effective in treating moderate-to-severe chronic lower back pain. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Superior abuse-deterrent properties when compared with
OxyContin OP in a head-to-head oral abuse-deterrence clinical trial.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In an abuse-deterrence clinical trial, we measured the drug release of both OxyContin OP and
Xtampza when intact and when subjected to the most effective method of attempting to defeat their abuse-deterrent properties. This clinical trial showed that crushing OxyContin OP caused the active
ingredient (oxycodone) to be released rapidly, with drug release that was bioequivalent to immediate-release oxycodone. By contrast, this clinical trial showed that the release of oxycodone from
crushed Xtampza was bioequivalent to uncrushed Xtampza. Based on this data, we believe drug abusers may find Xtampza less desirable to abuse orally than OxyContin&nbsp;OP after crushing. </FONT></DD></DL>
</UL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=150246,FOLIO='3',FILE='DISK114:[15ZAD1.15ZAD72301]CA72301A.;54',USER='LGADISH',CD='24-APR-2015;23:57' -->
<A NAME="page_ca72301_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Abuse-deterrent properties in an oral human abuse
potential clinical trial.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Consistent with FDA guidance, we performed a human abuse potential clinical trial using the oral route of administration measuring "drug
liking" in recreational drug users. We measured how well recreational drug users liked intact Xtampza (taken orally as intended) and chewed Xtampza compared with crushed immediate-release oxycodone
taken orally. The clinical trial showed with statistical significance that both chewed and intact Xtampza were "liked" less than immediate-release oxycodone. The clinical trial also showed that
opening our capsules and chewing the microspheres did not change the pharmacokinetics of Xtampza. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Abuse-deterrent properties following snorting in a human
abuse potential clinical trial.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Consistent with FDA guidance, we performed a human abuse potential clinical trial using the snorted route of administration. The
clinical trial demonstrated that crushing and snorting Xtampza microspheres resulted in lower blood levels of oxycodone than taking intact Xtampza capsules orally. The clinical trial also demonstrated
with statistical significance that crushed and snorted Xtampza microspheres were "liked" less than both intact Xtampza administered orally and snorted immediate-release oxycodone. Based on this data,
we believe that drug abusers may not find it desirable to snort Xtampza. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Ability to sprinkle microspheres for patients with
difficulty swallowing.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In clinical trials we performed consistent with FDA guidance, we demonstrated that when Xtampza microspheres were removed from the capsule
and chewed or crushed, or removed from the capsule and sprinkled onto soft food and administered orally, the drug release profile did not significantly change from administering intact Xtampza
capsules. Additionally, in preclinical studies we showed that the drug release profile did not change when the microspheres were administered using various types of feeding tubes. We believe that we
have performed the required preclinical studies and clinical trials to obtain FDA product labeling for sprinkling Xtampza microspheres directly in the mouth or on food, as well administering the
microspheres through gastric or nasogastric feeding tubes. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Competitive Abuse-Deterrent Approaches  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To address the potential for abuse, the pharmaceutical industry has created a number of abuse-deterrent products and product candidates, using a
variety of technical strategies that fall under the following categories:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Physical/Chemical
Barriers</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;Physical barriers are formulations designed to prevent chewing, crushing, cutting, grating or grinding for oral or nasal abuse. Physical and chemical
barriers can make it difficult to extract the opioid from the formulation for intravenous abuse using common solvents such as water. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Agonist/Antagonist
Combinations</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;An opioid antagonist can be co-formulated with an active opioid ingredient, or agonist, to interfere with or reduce the euphoria associated with
abuse. Market research studies performed for us have shown that some physicians prefer not to use an abuse-deterrent formulation with an opioid antagonist because such formulations may be less useful
in addressing chronic pain and their antagonist components may precipitate withdrawal. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Prodrug approaches</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;A
prodrug is a drug administered in an inactive, or less active, form designed to enable more effective delivery. The prodrug is then converted by the body into the active ingredient through a normal,
metabolic process. In a prodrug opioid, the active ingredient is designed to be released if the drug is taken orally, but if an abuser or patient takes a large amount of the drug, the prodrug is not
broken down or absorbed rapidly enough to create euphoria. If injected or snorted, the prodrug is not broken down and the active ingredient is not released. To date, the only extended-release product
candidate using the prodrug approach in late-stage clinical development did not achieve its primary endpoint of demonstrating adequate pain relief compared to a placebo in a Phase&nbsp;2 clinical
trial. No opioids using a prodrug approach are currently marketed. </FONT></DD></DL>
</UL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=536041,FOLIO='4',FILE='DISK114:[15ZAD1.15ZAD72301]CA72301A.;54',USER='LGADISH',CD='24-APR-2015;23:57' -->
<A NAME="page_ca72301_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:arial;"><FONT SIZE=2>We
believe Xtampza represents the best-in-class approach to creating an abuse-deterrent extended-release opioid formulation. Xtampza does not incorporate an opioid antagonist, is not a prodrug, and,
based on the studies and clinical trials we conducted, is resistant to abuse through physical or chemical manipulation. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patents and Proprietary Technology  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We regard the protection of patents, designs, trademarks and other proprietary rights that we own or license as critical to our success and
competitive position. Our patent portfolio directed toward Xtampza and our DETERx technology consists of six issued patents in the United States, two pending applications in the European Union and one
issued patent in each of Canada, Japan and Australia. In addition, we have six patent applications pending in the United States, and two pending foreign patent applications (excluding Europe), in
Japan and Canada. Our issued U.S. patents are projected to expire in 2023 and 2025, and our pending patent applications in the United States, if issued, would be projected to expire in 2023 and 2030.
In addition, we use a unique and proprietary process to manufacture our products that requires significant know-how, which we currently protect as trade secrets. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
technology and products are not in-licensed from any third party, and we own all of the rights to our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent Litigation Strategy  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We filed the NDA for Xtampza as a 505(b)(2) application, which allows us to reference data from an approved drug listed in the FDA's Approved Drug
Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), in this case OxyContin OP. The 505(b)(2) process requires that we certify to the FDA and notify Purdue
Pharma,&nbsp;L.P., or Purdue, as the holder of the NDA and any other Orange Book-listed patent owners, that we do not infringe any of the patents listed for OxyContin OP in the Orange Book, or that
the patents are invalid. We made such certification and provided such notice on February&nbsp;11, 2015, and such certification documented why Xtampza does not infringe any of the 11&nbsp;Orange
Book-listed patents for OxyContin OP, five of which stand invalidated by the Federal District Court for the Southern District of New York, subject to a pending appeal. Under the Hatch-Waxman Act of
1984, Purdue had the option to sue us for infringement, and receive a stay of up to 30&nbsp;months before the FDA can issue a final approval for Xtampza, unless the stay is earlier terminated.
Purdue exercised its option and elected to sue us for infringement in the District of Delaware on March 24, 2015 asserting infringement of three of Purdue's Orange Book-listed patents (all of which
stand invalidated, subject to a pending appeal by Purdue) and a non-Orange Book-listed patent, and, accordingly, received a stay of up to 30 months before the FDA can issue a final approval for
Xtampza, unless the stay is earlier terminated. The 30-month stay only applies to the Orange Book-listed patents. On March&nbsp;26, 2015, Purdue filed a second suit against us in the District of
Massachusetts asserting infringement of the same four patents. On April&nbsp;6, 2015, in the District of Delaware case, we filed a motion to dismiss for lack of personal jurisdiction or, in the
alternative, to transfer venue to the Southern District of New York where three of the patents have already been invalidated. Purdue's opposition to our motion was filed on April&nbsp;23, 2015 and
our reply in support of the motion is due on May&nbsp;4, 2015. The complaint in the District of Massachusetts case had not yet been served.


</FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>In
order to commercialize Xtampza, we will need both FDA approval and to dispose of the lawsuits filed by Purdue. The FDA is entitled to give Xtampza a tentative approval before the 30-month stay has
expired, which means the product is approved and the key aspects of the label are agreed upon, subject to the expiration of the 30-month period or termination of the stay. If we receive a court order
that the listed patents are invalid or not infringed, or if we settle the Purdue litigation before the 30-month period expires, the FDA can then provide final approval of Xtampza prior to the
expiration of the 30-month period, at which point the product can be marketed. </FONT></P>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=10301,FOLIO='5',FILE='DISK114:[15ZAD1.15ZAD72301]CA72301A.;54',USER='LGADISH',CD='24-APR-2015;23:57' -->
<A NAME="page_ca72301_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


DETERx Pipeline  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have applied our DETERx platform technology to Xtampza as well as other product candidates in our pipeline. We have an extended-release,
abuse-deterrent oxymorphone program for the treatment of chronic pain for which we have filed an investigational new drug application, or IND. This program has received a grant from the National
Institute on Drug Abuse, a constituent institute of the National Institutes of Health, and has been granted Fast Track status by the FDA. We also have other extended-release, abuse-deterrent product
candidates that have completed preliminary preclinical studies, including hydrocodone and morphine for pain, and methylphenidate for the treatment of attention deficit hyperactivity disorder, or ADHD.
We are targeting to begin clinical trials with our second product candidate in the first quarter of 2016. All of these product candidates share similar abuse-deterrent qualities as Xtampza and are
designed to be suitable for patients with difficulty swallowing. We own all of the rights to our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g118836.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="187">
  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to become the leading marketer of abuse-deterrent extended-release opioids and other commonly abused products. Key elements of our
strategy to achieve this goal are to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish our leadership position by obtaining approval
to market Xtampza with a best-in-class abuse-deterrent label.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If approved, we expect to receive differentiated abuse-deterrent claims in the Xtampza label compared
to other approved abuse-deterrent opioids, which will allow us to detail Xtampza to physicians and highlight its unique abuse-deterrent characteristics. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Commercialize Xtampza in the United States
ourselves.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We are currently preparing for a potential U.S. commercial launch of Xtampza, if approved, in the first quarter of 2016. Our management team has
extensive experience commercializing pharmaceutical products, and we intend to establish sales, marketing and reimbursement functions to commercialize Xtampza in the United States. Initially, we plan
to detail Xtampza to approximately 10,000 physicians who write more than 50% of the branded extended-release oral opioid prescriptions in the United States with a sales team of approximately
100&nbsp;sales representatives. In addition, we plan to deploy a separate, focused sales team to detail Xtampza to nursing homes, hospices, and other institutions treating large populations of the
elderly and other patients who need chronic pain relief and have difficulty swallowing. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish Xtampza as the treatment of choice for
patients with CPD.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If approved with product labeling for sprinkling Xtampza microspheres directly in the mouth or on food, as well as administering the microspheres
through feeding tubes, Xtampza would be the only extended-release oxycodone product designed to be suitable for this 11&nbsp;million patient segment. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish strategic collaborations to accelerate and
maximize the potential of our product candidates worldwide.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We intend to seek strategic collaborations with other pharmaceutical companies to commercialize our
product candidates outside the United States and to develop certain of our product candidates that are outside of our core therapeutic focus. </FONT></DD></DL>
</UL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=754051,FOLIO='6',FILE='DISK114:[15ZAD1.15ZAD72301]CA72301A.;54',USER='LGADISH',CD='24-APR-2015;23:57' -->
<A NAME="page_ca72301_1_7"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Advance other product candidates that incorporate our
DETERx platform technology.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have an IND application on file for COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain,
which has been granted Fast Track status by the FDA. We have also begun advancing our development program for COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic
pain. We target beginning clinical trials for our second product candidate by the first quarter of 2016. In addition, we have COL-171, a proprietary preclinical DETERx extended-release,
abuse-deterrent methylphenidate formulation for the treatment of ADHD, which we plan to advance with a collaborator. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Acquire additional products and product
candidates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may identify and license, co-promote or acquire products or product candidates being developed for pain indications and other complementary products. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risk Factors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our ability to implement our business strategy is subject to numerous risks and uncertainties. As a clinical-stage biopharmaceutical company, we face
many risks inherent in our business and our industry generally. You should carefully consider all of the information set forth in this prospectus and, in particular, the information under the heading
"Risk Factors" in this prospectus prior to making an investment in our common stock. These risks include, among others, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our product candidates, including Xtampza, are subject to regulatory approval
processes that are lengthy and unpredictable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not obtain approval for Xtampza or any of our other product candidates
from the FDA or foreign regulatory authorities. Even if Xtampza is approved, we may not be able to obtain the label claims that we are seeking from the FDA; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we are subject to patent infringement litigation relating to Xtampza and may, in
the future, be subject to additional litigation relating to our other product candidates, which may be expensive to defend and delay the commercialization of Xtampza or our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we currently generate no commercial revenue, may never become profitable and may
incur substantial and increasing net losses for the foreseeable future as we seek regulatory approval for, and potentially begin to commercialize, Xtampza; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we currently have no sales or marketing capabilities and, if we are unable to
develop these capabilities, we may not be successful in commercializing Xtampza, if approved; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we depend, or will depend in the future, on the performance of third parties for
the supply of the active ingredient used in Xtampza, commercial manufacturing and testing of Xtampza, and the conduct of clinical trials relating to our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Corporate Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are incorporated in the Commonwealth of Virginia under the name Collegium Pharmaceutical,&nbsp;Inc. Our executive offices are located at 780
Dedham Street, Suite&nbsp;800, Canton, MA 02021 and our telephone number is (781)&nbsp;713-3699. Our website address is www.collegiumpharma.com. The inclusion of our website address above and
elsewhere in this prospectus is, in each case, intended to be an inactive textual reference only and not an active hyperlink to our website. The information contained in, or that can be accessed
through, our website is not part of this prospectus. </FONT></P>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=47261,FOLIO='7',FILE='DISK114:[15ZAD1.15ZAD72301]CA72301A.;54',USER='LGADISH',CD='24-APR-2015;23:57' -->
<A NAME="page_ca72301_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Implications of Being an Emerging Growth Company  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an "emerging growth company," as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012, or the JOBS Act. As such, we are eligible to take advantage of exemptions from various disclosure and reporting requirements that are applicable to other public companies that are not
"emerging growth companies" including, but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with the auditor attestation requirements of
Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> being permitted to present only two years of audited financial statements and
only two years of related Management's Discussion and Analysis of Financial Condition and Results of Operations, in each case, instead of three years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> being permitted to present the same number of years of selected financial data
as the years of audited financial statements presented, instead of five years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reduced disclosure obligations regarding executive compensation, including no
Compensation Disclosure and Analysis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with any requirement that may be adopted by the
Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  exemptions from the requirements of holding a non-binding advisory vote on
executive compensation and shareholder approval of any golden parachute payments not previously approved. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
may choose to take advantage of some or all of the available exemptions. We have taken advantage of some of the reduced reporting burdens in this prospectus. Accordingly, the scope of the
information contained herein may be different than the scope of the information you receive from other public companies in which you hold stock. We do not know if some investors will find our shares
less attractive as a result of our utilization of these or other exemptions. The result may be a less active trading market for our shares and our share price may be more volatile. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, Section&nbsp;107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the
Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We have irrevocably
elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies
that are not "emerging growth companies." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will remain an "emerging growth company" until the earliest of (i)&nbsp;the last day of the first fiscal year in which our annual gross revenues exceed $1.0&nbsp;billion; (ii)&nbsp;the date
that we become a "large accelerated filer" as defined in Rule&nbsp;12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our
shares that are held by non-affiliates exceeds $700&nbsp;million as of the last business day of our most recently completed second fiscal quarter; (iii)&nbsp;the date on which we have issued more
than $1.0&nbsp;billion in nonconvertible debt during the preceding three-year period; and (iv)&nbsp;the last day of our fiscal year containing the fifth anniversary of the date on which shares of
our common stock become publicly traded in the United States. </FONT></P>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=12,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=215628,FOLIO='8',FILE='DISK114:[15ZAD1.15ZAD72301]CA72301A.;54',USER='LGADISH',CD='24-APR-2015;23:57' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cc72301_1_9"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cc72301_the_offering"> </A>
<A NAME="toc_cc72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="233pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Common stock offered by us</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,800,000 shares (6,670,000 shares if the underwriters' option to purchase additional shares is exercised in full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common&nbsp;stock&nbsp;to&nbsp;be&nbsp;outstanding&nbsp;after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>19,707,935 shares (20,577,935 shares if the underwriters' option to purchase additional shares is exercised in
full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Option to purchase additional shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The underwriters have the option to purchase from us up to a maximum of 870,000 additional shares of common stock. The
underwriters can exercise this option at any time within 30&nbsp;days from the date of this prospectus.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We estimate that the net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us, will be approximately $67.5 million. This assumes a public offering price of $13.00, which is the midpoint of the price range set forth on the cover page of this prospectus. We intend to use the net
proceeds from this offering as follows:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>approximately $45.0 million for the development of our commercial infrastructure to launch Xtampza, including sales, marketing and reimbursement functions, and if Xtampza is approved in the United
States, a sales force;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>approximately $15.0 million to fund research and development efforts of our other product candidates, including approximately $12.0&nbsp;million to conduct clinical development for our second
product candidate through its Phase 3 clinical trial (including Phase 1 bioequivalence clinical trials and abuse-deterrence studies and clinical trials); and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>the remainder, if any, to fund working capital and general corporate purposes, which may include litigation expenses (including expenses relating to the Purdue litigation) and the acquisition or
licensing of product candidates, technologies, compounds, other assets or complementary businesses.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>See "Use of Proceeds" for more information.</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:arial;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>
</font></p><p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=875842,FOLIO='9',FILE='DISK114:[15ZAD1.15ZAD72301]CC72301A.;50',USER='BGARDNE',CD='24-APR-2015;17:49' -->
<A NAME="page_cc72301_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="233pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Directed share program</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The underwriters have reserved for sale, at the initial public offering price, up to approximately 5% of the shares of our common stock
being offered. These shares will be offered for sale to our directors; officers; existing shareholders and their affiliates and employees of both; and business associates, as well as certain friends and family members of our directors and officers.
We will offer these shares to the extent permitted under applicable regulations in the United States. The number of shares available for sale to the general public in this offering will be reduced to the extent these persons purchase reserved shares.
Any reserved shares not purchased will be offered by the underwriters to the general public on the same terms as the other shares.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Listing</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We expect to receive approval to list our common stock on NASDAQ under the symbol "COLL."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend policy</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on
our common stock in the foreseeable future. See "Dividend Policy."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You should read the "Risk Factors" section of this prospectus for a discussion of certain factors to consider carefully
before deciding to purchase any shares of our common stock.</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>


The number of shares of our common stock to be outstanding after this offering is based on 1,316,479 shares of common stock outstanding as of April&nbsp;2, 2015 and
assumes:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issuance by us of 5,800,000 shares of our common stock in this offering;
and</FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the conversion of all of our convertible preferred stock outstanding immediately
prior to the closing of this offering into an aggregate of 12,591,456 shares of common stock (which includes 41,666,667 shares of Series&nbsp;D convertible preferred stock issued in March 2015),


</FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>and
excludes:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  803,565 shares of common stock issuable upon the exercise of outstanding stock
options as of April&nbsp;2, 2015, at a weighted-average exercise price of $4.23 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 18,809 shares of common stock issuable upon the exercise of warrants to purchase
common stock as of April&nbsp;2, 2015, at a weighted-average exercise price of $1.91&nbsp;per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issuance by us of additional shares of common stock (which, based on an
assumed initial public offering price of $13.00 per share (the mid-point of the price range set forth on the cover page of this prospectus) will total approximately 61,000&nbsp;shares), as payment
of the accrued dividend on the outstanding shares of Series&nbsp;D convertible preferred stock payable to the holders of Series&nbsp;D convertible preferred stock upon the closing of this
offering; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,751,803&nbsp;shares of common stock reserved for future issuance under our
Amended and Restated 2014 Stock Incentive Plan upon the closing of this offering; and</FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  200,000 shares reserved for future issuance under our 2015 Employee Stock
Purchase Plan upon the closing of this offering.


</FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Except
as otherwise indicated, all information in this prospectus assumes:</FONT></P>



<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a 1 for 6.9 reverse stock split of our common stock effected on April&nbsp;24,
2015;

 </FONT></DD></DL>
</UL>


 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=295993,FOLIO='10',FILE='DISK114:[15ZAD1.15ZAD72301]CC72301A.;50',USER='BGARDNE',CD='24-APR-2015;17:49' -->
<A NAME="page_cc72301_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no exercise by the underwriters of the option to purchase up to an additional
870,000 shares of our common stock; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the filing of our amended and restated articles of incorporation and the
adoption of our amended and restated bylaws immediately prior to the closing of this offering. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>


Certain of our existing shareholders, or their affiliates, have indicated an interest in purchasing up to an aggregate of approximately $30.0&nbsp;million of shares of our common stock in this
offering at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no
shares in this offering to any of these investors, and any of these investors may determine to purchase more, less or no shares in this offering. The underwriters will receive the same underwriting
discount on any shares purchased by these investors as they will on any other shares sold to the public in this offering.

 </FONT></P>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=415670,FOLIO='11',FILE='DISK114:[15ZAD1.15ZAD72301]CC72301A.;50',USER='BGARDNE',CD='24-APR-2015;17:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ce72301_1_12"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ce72301_summary_financial_data"> </A>
<A NAME="toc_ce72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following summary financial data for the years ended December&nbsp;31, 2013 and 2014 are derived from our audited financial statements appearing
elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future. The summary financial
data presented below should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and the related notes
thereto, included elsewhere in this prospectus. The summary financial data in this section is not intended to replace our financial statements and the related notes thereto. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands,<BR>
except share<BR>
and per share<BR>
amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations Data:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,157</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,959</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,885</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,706 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,665 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,665</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>76</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share<SUP>(1)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.06</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(22.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used to compute earnings (loss) per common share<SUP>(1)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,697,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>933,997</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common shareholders&nbsp;&#151; basic and diluted (unaudited)<SUP>(1)(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.84</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares used in pro forma net loss per share attributable to common shareholders&nbsp;&#151; basic and diluted
(unaudited)<SUP>(1)</SUP><SUP>(2)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,471,303</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">See
Note 3 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate earnings (loss)
per common share attributable to common shareholders, including the method used to calculate the number of shares used in the computation of the per share amount.


<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(2)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Gives
effect to the conversion of all our outstanding convertible preferred stock into an aggregate of 6,552,820 shares of our common stock (which excludes
41,666,667 shares of Series&nbsp;D convertible preferred stock issued in March 2015) upon the closing of this offering.

 </FONT></DD>

</DL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=16,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=626505,FOLIO='12',FILE='DISK114:[15ZAD1.15ZAD72301]CE72301A.;50',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ce72301_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Actual </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma<BR>
As Adjusted<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,634</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">46,634</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">114,156</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Working capital<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5,921</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">44,079</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">111,601</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">50,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">117,612</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Other long-term liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,914</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,914</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,914</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Convertible redeemable preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">77,107</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total shareholders' equity (deficit)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(89,348</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">37,759</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">105,281</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Working
capital is calculated as current assets minus current liabilities.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(2)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Gives
effect to the following: </FONT><FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">our issuance and sale of 41,666,667
shares of our Series&nbsp;D convertible preferred stock in March 2015 at a price per share of $1.20 for aggregate consideration of $50.0&nbsp;million, comprised of $45.0&nbsp;million in cash and
$5.0&nbsp;million from conversion of convertible notes with related parties; and </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">the conversion of all our outstanding
convertible preferred stock into an aggregate of 12,591,456 shares of our common stock (which includes 41,666,667 shares of our Series&nbsp;D convertible preferred stock issued in March 2015) upon
the closing of this offering.


<BR><BR></FONT></DD></DL>
</DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(3)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Gives
further effect to the matters described in note&nbsp;2 above and the sale by us of 5,800,000 shares of our common stock in this offering at an
assumed initial public offering price of $13.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us.

</FONT></DD>

</DL>
 <p style="font-family:arial;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=17,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=270087,FOLIO='13',FILE='DISK114:[15ZAD1.15ZAD72301]CE72301A.;50',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dc72301_1_14"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dc72301_risk_factors"> </A>
<A NAME="toc_dc72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, together
with the other information contained in this prospectus, including our financial statements and the related notes appearing elsewhere in this prospectus, before making your decision to invest in
shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business,
results of operations, financial condition and cash flows, and our future prospects would likely be materially and adversely affected. If that were to happen, the trading price of our common stock
could decline, and you could lose all or part of your investment.</I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Financial Position and Capital Needs  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have incurred significant losses since our inception and anticipate that we will continue to
incur losses in the future.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage pharmaceutical company. To date, we have focused on developing our lead product candidate, Xtampza. Investment in
pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval
or become commercially viable. Since 2010, when we divested our former subsidiary, Onset Therapeutics,&nbsp;LLC, to PreCision Dermatology,&nbsp;Inc., we have not generated any revenue from product
sales as we currently have no products approved by the FDA, and we continue to incur significant research, development and other expenses related to our ongoing operations. As a result, we are not
profitable and have incurred losses in each period since January&nbsp;1, 2011. For the year ended December&nbsp;31, 2014, we reported a net loss of $17.9&nbsp;million, and we had an accumulated
deficit of $101.8&nbsp;million at December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates,
and begin to commercialize Xtampza, if approved. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of
our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If any of our product candidates fails in clinical trials or does not
gain regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain
profitability in subsequent periods. Our prior losses and expected future losses have had and will continue to have an adverse effect on our shareholders' equity and working capital. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently generate no revenue from the sale of products and may never become profitable.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As we currently have no approved products, we are not generating any revenue from product sales. We have not generated any revenue since we divested
our former subsidiary in 2010. Our ability to generate additional revenue and become profitable depends upon our ability to successfully commercialize our existing product candidates, including
Xtampza, or other product candidates that we may in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for these product candidates, we do not
know when any of these product candidates will generate revenue for us, if at all. Our ability to generate revenue from our current or future product candidates depends on a number of factors,
including our ability to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain regulatory approval for, and successfully commercialize, Xtampza; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  successfully complete development activities, including the necessary clinical
trials, with respect to our other product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  complete and submit NDAs to the FDA and obtain regulatory approval for
indications for which there is a commercial market; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=366544,FOLIO='14',FILE='DISK114:[15ZAD1.15ZAD72301]DC72301A.;48',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dc72301_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  complete and submit applications to, and obtain regulatory approval from,
foreign regulatory authorities, if we choose to commercialize our product candidates outside the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> set a commercially viable price for our products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  manufacture commercial quantities of our products at acceptable cost levels; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> develop a commercial organization capable of sales, marketing and distribution
for the products we intend to sell ourselves in the markets in which we have retained commercialization rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> find suitable distribution collaborators to help us market, sell and distribute
our products, if approved, in markets outside the United States; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain coverage and adequate reimbursement from third-parties, including
government payors. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, because of the numerous risks and uncertainties associated with product development, including that our product candidates may not advance through development or achieve the safety and
efficacy (including the efficacy of our abuse-deterrent technology) endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or when or if we will
be able to achieve or maintain profitability. Furthermore, we anticipate incurring significant costs associated with commercializing these products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we are able to generate revenues from the sale of our products, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable
or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we require additional capital to fund our operations and we fail to obtain necessary financing,
we may be unable to complete the development and commercialization of our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our operations have consumed substantial amounts of cash. We expect to continue to spend substantial amounts to advance the clinical development of
our product candidates and launch and commercialize any product candidates for which we may receive regulatory approval, including potentially building our own commercial organization to address
selected markets. We believe that the net proceeds from this offering, together with existing cash, will be sufficient to fund our projected operating requirements for the commercialization of
Xtampza, if approved, and the completion of clinical development of our second product candidate. However, we may require additional capital for the further development and commercialization of our
product candidates and may also need to raise additional funds sooner in order to accelerate development of our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on acceptable terms,
we also could be required to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  significantly delay, scale back or discontinue the development or, if/when
applicable, the commercialization, of our product candidates or one or more of our other research and development initiatives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek collaborators for one or more of our current or future product candidates
at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  relinquish or license on unfavorable terms our rights to technologies or
product candidates that we otherwise would seek to develop or commercialize ourselves; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  significantly curtail operations. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual
results could vary as a result of a number of factors, including the factors discussed elsewhere in this "Risk Factors" section. We have based this estimate on assumptions that may prove to be wrong,
and we could utilize our available </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=19,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=723346,FOLIO='15',FILE='DISK114:[15ZAD1.15ZAD72301]DC72301A.;48',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dc72301_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>capital
resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability to obtain abuse-deterrent claims in the labels for these product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> clinical development plans we establish for Xtampza and any other future product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA's approval of inclusion of claims in the label for Xtampza that will
permit the sprinkling of Xtampza microspheres on food, directly in the mouth or administered through feeding tubes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome, timing and cost of the regulatory approval process by the FDA and
foreign regulatory authorities, including the potential for the FDA or foreign regulatory authorities to require that we perform more studies than those that we currently expect; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of filing, prosecuting, defending and enforcing any patent claims and
other intellectual property rights, including defending Purdue's patent infringement claims against us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost and timing of completion of existing or expanded commercial-scale
outsourced manufacturing activities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of establishing sales, marketing and distribution capabilities for
Xtampza and any other product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the initiation, progress, timing, costs and results of clinical trials for our
product candidates and any future product candidates we may in-license. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Raising additional capital may cause dilution to our existing shareholders, restrict our operations
or require us to relinquish rights to our technologies or product candidates.

  </B></FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>We may seek additional capital through a combination of private and public equity offerings, debt financings, receivables or royalty financings,
strategic collaborations and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest
will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing shareholders. Debt, receivables and royalty financings may be coupled with an
equity component, such as warrants to purchase stock, which could also result in dilution of our existing shareholders' ownership. The incurrence of additional indebtedness beyond our existing
indebtedness with Silicon Valley Bank and our convertible note holders could result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations
on our ability to incur further debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could have a material adverse effect on our
ability to conduct our business and may result in liens being placed on our assets and
intellectual property. If we were to default on any of our indebtedness, we could lose such assets and intellectual property. If we raise additional funds through strategic collaborations and
alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. If we are unable
to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to
develop and market our technologies that we would otherwise prefer to develop and market ourselves. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have a limited operating history, which may make it difficult for you to evaluate the success of
our business to date and to assess our future viability.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our predecessor was originally incorporated in Delaware in April 2002 under the name Collegium Pharmaceuticals,&nbsp;Inc. In October 2003, our
predecessor changed its name to Collegium Pharmaceutical,&nbsp;Inc. In July 2014, we reincorporated in the Commonwealth of Virginia pursuant to a merger whereby Collegium
Pharmaceutical,&nbsp;Inc., a Delaware corporation, merged with and into Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation, with the Virginia corporation surviving the merger. From 2002
until 2010, our operations focused primarily on marketing innovative proprietary therapies to the wound </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=20,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=381997,FOLIO='16',FILE='DISK114:[15ZAD1.15ZAD72301]DC72301A.;48',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dc72301_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>care
and dermatology industry through our former subsidiary, Onset Therapeutics,&nbsp;LLC, which was spun off and became a part of PreCision Dermatology,&nbsp;Inc. in 2010. Since 2010, our
operations have focused primarily on developing the DETERx platform technology and identifying and developing product candidates that utilize the DETERx technology, including our lead product
candidate, Xtampza. We have not yet obtained regulatory approval for any of our product candidates or demonstrated an ability to commercialize a product candidate. Consequently, any predictions about
our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our ability to use our net operating loss carryforwards and certain other tax attributes may be
limited.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2014, we had net operating loss, or NOL, carryforwards of approximately $78.3&nbsp;million for U.S. federal income tax and
state tax purposes available to offset future taxable income and U.S. federal and state research and development tax credits of $3.1&nbsp;million, prior to consideration of annual limitations that
may be imposed under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or
Section&nbsp;382. These carryforwards begin to expire in 2022. Under Section&nbsp;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value)
in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its
post-change income may be limited. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership some of which are outside our control. We have not
performed any current analyses under Section&nbsp;382 and cannot forecast or otherwise rely on deriving benefit from our various federal or state tax attribute carryforwards. As a result, if we earn
net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax
liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Clinical Development and Regulatory Approval of Our Product Candidates  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our success depends in large part on the success of our lead product candidate, Xtampza. We cannot
give any assurance that we will receive regulatory approval for Xtampza, which is necessary before it can be commercialized.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To date, we have invested substantial resources in the development of our lead product candidate, Xtampza, and our business and future success are
substantially dependent on our ability to successfully and timely obtain regulatory approval for and commercialize this product candidate, which may never occur. We currently generate no revenues from
sales of any drugs and we may never be able to develop or commercialize a marketable drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
regulatory approval process that Xtampza must undergo is rigorous, time-consuming and difficult to predict, and there is no guarantee that successful late-stage clinical trials, including the
pivotal Phase&nbsp;3 clinical trial we completed in July 2014, will result in FDA approval of our NDA for Xtampza, which was accepted for filing on February&nbsp;10, 2015. On February&nbsp;25,
2015, the FDA set a PDUFA goal date of October&nbsp;12, 2015 for completion of its review of Xtampza NDA. However, pursuant to FDA guidance, the PDUFA goal date is flexible and subject to change
based on the timing and materiality of any amendments to the NDA, the FDA's existing workload, and other potential review issues. There can be no assurances that the FDA will not extend the PDUFA goal
date that has been established for completion of its review of the Xtampza NDA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
delay or impediment in our ability to obtain approval to commercialize Xtampza may cause us to be unable to generate the revenues necessary to continue our research and development pipeline
activities, thereby adversely affecting our business and our prospects for future growth. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=21,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=602803,FOLIO='17',FILE='DISK114:[15ZAD1.15ZAD72301]DC72301A.;48',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dc72301_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we are able to secure regulatory approval of Xtampza, our ability to successfully commercialize Xtampza will depend on many factors, including but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA's approval of the inclusion of abuse-deterrent claims in the label for
Xtampza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA's approval of inclusion of claims in the label for Xtampza that will
permit the sprinkling of Xtampza microspheres on food, directly in the mouth or administered through feeding tubes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability to manufacture commercial quantities of Xtampza at reasonable cost
and with sufficient speed to meet commercial demand; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to build a sales and marketing organization to market Xtampza; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our success in educating physicians, patients and caregivers about the benefits,
administration and use of Xtampza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability, perceived advantages, relative cost, relative safety and
relative efficacy of other abuse-deterrent products and treatments for chronic pain and CPD; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to successfully defend any challenges to our intellectual property
relating to Xtampza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability of coverage and adequate reimbursement for Xtampza; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a continued acceptable safety profile of Xtampza following approval. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Many
of these matters are beyond our control and are subject to other risks described elsewhere in this "Risk Factors" section. Accordingly, we cannot assure you that we will be able to successfully
obtain regulatory approval of, commercialize or generate revenue from Xtampza. If we cannot do so, or are significantly delayed in doing so, our business will be materially harmed. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to obtain FDA approval of product labeling for sprinkling Xtampza microspheres directly
in the mouth or on food, as well as administering the microspheres through feeding tubes, then our ability to successfully market Xtampza may be adversely affected.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>It is estimated that the U.S. market includes approximately 11&nbsp;million patients with CPD. Our Xtampza microspheres are designed to be removed
from the capsule and sprinkled on food, directly into the mouth or administered through feeding tubes, without compromising their extended-release properties. If the FDA approves Xtampza, but does not
permit us to include a claim in the label for Xtampza regarding the ability to sprinkle the Xtampza microspheres directly in the mouth, on food or in feeding tubes, or requires us to have a black box
warning label stating that "crushing, dissolving or chewing can cause rapid release and absorption of a
potentially fatal dose of the active drug," it will limit our ability to differentiate Xtampza from other abuse-deterrent opioid formulations on the basis of alternative dosing options and we may not
be able to market Xtampza to patients with CPD. As a result, this may have an adverse effect on our business and our prospects for future growth. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the FDA does not conclude that Xtampza or our other product candidates are sufficiently
bioequivalent, or demonstrate comparable bioavailability to their respective listed drugs, or if the FDA otherwise does not conclude that our product candidates satisfy the requirements for the
Section&nbsp;505(b)(2) approval pathway as we anticipate, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly
greater complications and risks than anticipated, and the FDA may not approve those product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A key element of our strategy is to seek FDA approval for Xtampza and our other product candidates through the Section&nbsp;505(b)(2) regulatory
pathway. Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, permits the filing of an NDA that contains full safety and efficacy reports but where at least some of the
information required for approval comes from studies not conducted by or for the applicant, such as the FDA's findings of safety and efficacy in the approval of a similar drug, and for which the
applicant has not obtained a right of reference and/or published literature. Such reliance is typically predicated on a showing of bioequivalence or comparable bioavailability to an approved drug. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=22,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=26213,FOLIO='18',FILE='DISK114:[15ZAD1.15ZAD72301]DC72301A.;48',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dc72301_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the FDA does not allow us to pursue the Section&nbsp;505(b)(2) approval pathway for Xtampza or any of our other product candidates, or if we cannot demonstrate bioequivalence or comparable
bioavailability of our product candidates to approved products, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory
approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates would increase. Moreover, our inability to pursue the
Section&nbsp;505(b)(2) approval pathway could result in new competitive products reaching the market more quickly than our product candidates, which could have a material adverse effect on our
competitive position and our business prospects. Even if we are allowed to pursue the Section&nbsp;505(b)(2) approval pathway, we cannot assure you that our product candidates will receive the
requisite approvals for commercialization on a timely basis, if at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, notwithstanding the approval of a number of products by the FDA under Section&nbsp;505(b)(2) over the last few years, pharmaceutical companies and others have objected to the FDA's
interpretation of Section&nbsp;505(b)(2). If the FDA's interpretation of Section&nbsp;505(b)(2) is successfully challenged, the FDA may change its policies and practices with respect to
Section&nbsp;505(b)(2) regulatory approvals, which could delay or even prevent the FDA from approving any NDA that we submit under Section&nbsp;505(b)(2). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Even
if our product candidates are approved under Section&nbsp;505(b)(2), the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other
conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our decision to seek approval of our product candidates, including Xtampza, under
Section&nbsp;505(b)(2) increases the risk that a patent infringement suit, like the suits filed by Purdue relating to Xtampza, may be filed against us, which would delay the FDA's approval of such
product candidates.  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>In connection with any NDA that we file under Section&nbsp;505(b)(2), we will also be required to notify the patent holders of the
Section&nbsp;505(b)(2) listed drug, that we identify in our NDA if we have certified to the FDA that any patents listed for the listed drug in the FDA's Orange Book publication are invalid,
unenforceable or will not be infringed by the manufacture, use or sale of our drug. If the patent holder files&nbsp;a patent infringement lawsuit against us within 45&nbsp;days of its receipt of
notice of our certification, the FDA is automatically prevented from approving our Section&nbsp;505(b)(2) NDA until the earliest of 30&nbsp;months, expiration of the patents, settlement of the
lawsuit or a court decision in the infringement case that is favorable to us. Accordingly, we may invest significant time and expense in the development of our product candidates only to be subject to
significant delay and expensive and time-consuming patent litigation before our product candidates may be commercialized. On March&nbsp;24 and March&nbsp;26, 2015, Purdue, as the sponsor for
OxyContin OP, the listed drug for Xtampza, brought infringement claims against us in the District of Delaware and the District of Massachusetts, respectively, alleging infringement of U.S. Patent
Nos.&nbsp;7,674,799, 7,674,800, 7,683,072 and 8,652,497. On April&nbsp;6, 2015, in the District of Delaware case, we filed a motion to dismiss for lack of personal jurisdiction or, in the
alternative, to transfer venue to the Southern District of New York where three of the patents have already been invalidated. Purdue's opposition to our motion was filed on April&nbsp;23, 2015 and
our reply in support of the motion is due on May&nbsp;4, 2015. The complaint in the District of Massachusetts case has not yet been served. We plan to continue to take all steps necessary to
vigorously defend ourselves against these claims. The strength of our defenses will depend on the patents asserted and the interpretation of these patents. However, we could be unsuccessful in
advancing non-infringement and invalidity arguments in our defense. Purdue need only prove infringement by a preponderance of the evidence, which is a low burden of proof. If before the expiration of
the 30-month period, the Court issues a final order that any of the listed patents are valid and have been infringed, FDA approval would be delayed until either a date ordered by the Court or when the
Court determines that the patents will expire.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we are found not to infringe or Purdue's, or any other potential plaintiff's, patent claims are found invalid or unenforceable, defending any such infringement claim would be expensive and
time-consuming, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=23,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=124687,FOLIO='19',FILE='DISK114:[15ZAD1.15ZAD72301]DC72301A.;48',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dc72301_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
would delay the launch of our product candidates, including Xtampza, and distract management from their normal responsibilities. The Court could decline to hear our summary judgment motion, could
decline to act expeditiously to issue a decision or hold a trial, or could decline to find that all of the listed patents are invalid or non-infringed. If we are unsuccessful in our defense of
non-infringement and unable to prove invalidity of the listed patents, the court could issue an injunction prohibiting the launch of our product candidates, including Xtampza. If we were to launch any
of our product candidates, if approved by the FDA, including Xtampza, prior to a full and final determination that the listed patents are invalid or non-infringed, we could be subject to substantial
liability for damages if we do not ultimately prevail on our defenses to a claim of patent infringement. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The regulatory approval processes of the FDA and foreign regulatory authorities are lengthy,
time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The time required to obtain approvals by the FDA and foreign regulatory authorities is unpredictable, but typically takes many years following the
commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies,
regulations or the type and amount of clinical data necessary to gain approval varies among jurisdictions and may change during the course of a product candidate's clinical development. For example,
we cannot guarantee that the FDA will not require additional or different clinical trials in support of our submission of an NDA for Xtampza. We have not obtained regulatory approval for any product
candidate, and it is possible that none of our existing product candidates or any future product candidates we may in-license, acquire or develop will ever obtain regulatory approval from the FDA or
any foreign regulatory authority. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
product candidates could fail to receive regulatory approval from the FDA or a foreign regulatory authority, or we may be required to conduct more extensive studies and clinical trials in order to
receive such approval, for many reasons, including, but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA and/or foreign regulatory authorities may disagree with or disapprove of
the design or implementation of our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to demonstrate that a product candidate is safe and effective for its
proposed indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to demonstrate that a product candidate is bioequivalent to its listed
drug; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure of clinical trials to meet criteria required for approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to demonstrate that a product candidate's clinical and other benefits
outweigh its safety risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or foreign regulatory authorities may disagree with our interpretation
of data from preclinical studies or clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  deficiencies in the manufacturing processes or failure of third-party
manufacturing facilities with whom we contract for clinical and commercial supplies to pass inspection; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or foreign regulatory authorities may not approve the manufacturing
processes or facilities of third party manufacturers with which we contract for clinical and commercial supplies; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  insufficient data collected from clinical trials of our product candidates or
changes in the approval policies or regulations that render our preclinical and clinical data insufficient to support the submission and filing of an NDA or to obtain regulatory approval. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=24,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=195220,FOLIO='20',FILE='DISK114:[15ZAD1.15ZAD72301]DC72301A.;48',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_de72301_1_21"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market Xtampza or our
other product candidates, which would harm our business, results of operations and prospects significantly. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, even if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve, with respect to
certain foreign regulatory authorities, the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a
product with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product. Any of the foregoing scenarios could have a material adverse
effect on our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA or a foreign regulatory authority may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and our
commercialization plans, or cause us to abandon the development program. Even if we obtain regulatory approval, our product candidates may be approved for fewer or more limited indications than we
request, such approval may be contingent on the performance of costly post-marketing clinical trials, or we may not be allowed to include the labeling claims necessary or desirable for the successful
commercialization of such product candidate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
order to market and sell our products outside the United States, we will likely need to obtain separate marketing approvals and comply with numerous and varied regulatory requirements and regimes,
which can involve additional testing, may take substantially longer than the FDA approval process, and still generally includes all of the risks associated with obtaining FDA approval. In addition, in
many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. FDA approval does not ensure
approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by the FDA or regulatory authorities
in other countries or jurisdictions. We may not obtain any regulatory approvals on a timely basis, if at all. We may not be able to file for marketing approvals and may not receive necessary approvals
to commercialize our products in any market. If we are unable to obtain approval of any of our product candidates by regulatory authorities in countries outside the United States, the commercial
prospects of that product candidate may be significantly diminished and our business prospects could decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Development of our product candidates is not complete, and we cannot be certain that our product
candidates will be commercialized.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As we currently have no approved products, we are not generating any revenues from product sales. To be profitable, we must successfully research,
develop, obtain regulatory approval for, manufacture, introduce, market and distribute our product candidates under development. For our lead product candidate, Xtampza, and each additional product
candidate that we intend to commercialize, we must successfully meet a number of critical developmental milestones, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  selecting and developing a drug delivery platform technology to deliver the
proper dose of drug over the desired period of time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  determining the appropriate drug dosage that will be tolerated, safe and
effective; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  demonstrating the drug formulation will be stable for commercially reasonable
time periods; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  demonstrating through clinical trials that the drug is safe and effective in
patients for the intended indication; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  completing the manufacturing development and scale-up to permit manufacture of
our product candidates in commercial quantities and at acceptable prices. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
time necessary to achieve these developmental milestones for any individual product candidate is long and uncertain, and we may not successfully complete these milestones for any of our product
candidates in development. We have not yet completed development of any product. We may not be able to finalize the design or formulation of any product candidate. In addition, we may select
components, solvents, excipients </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=278692,FOLIO='21',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>or
other ingredients to include in our product candidates that have not been previously approved for use in pharmaceutical products, which may require us to perform additional studies and may delay
clinical testing and regulatory approval of our product candidates. Even after we complete the design of a product candidate, the product candidate must still be shown to be bioequivalent to an
approved drug or safe and effective in required clinical trials before approval for commercialization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are continuing to test and develop our product candidates and may explore possible design or formulation changes to address bioavailability, safety, efficacy, manufacturing efficiency and
performance issues. We may not be able to complete development of any product candidates that will be safe and effective and that will have a commercially reasonable treatment and storage period. If
we are unable to complete development of Xtampza or any of our other product candidates, we will not be able to earn revenue from them. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We anticipate that our product candidates, including Xtampza, will be subject to mandatory REMS
programs, which could increase the cost, burden and liability associated with the commercialization of such product candidate.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA has indicated that extended-release and long-acting opioid drugs formulated with the active ingredients fentanyl, hydromorphone, methadone,
morphine, oxycodone, oxymorphone, and others will be required to have a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that the benefits of the drugs continue to outweigh the risks. The
FDA has approved a REMS for extended release, or ER, and long-acting, or LA, opioids as part of a federal initiative to address prescription drug abuse and misuse, or the ER/LA opioid REMS. The ER/LA
opioid REMS introduces new safety measures designed to reduce risks and improve the safe use of extended-release/long-acting opioids, while continuing to provide access to these medications for
patients in pain. The ER/LA opioid REMS affects more than 20 companies that manufacture opioid analgesics. Under the ER/LA opioid REMS, companies are required to make education programs available to
prescribers based on the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics. It is expected that companies will meet this obligation by providing educational
grants to continuing education providers, who will develop and deliver the training. The ER/LA opioid REMS also requires companies to distribute FDA-approved educational materials to prescribers and
patients on the safe use of these drugs. The companies must perform periodic assessments of the implementation of the ER/LA opioid REMS and the success of the program in meeting its goals. The FDA
will review these assessments and may require additional elements to achieve the goals of the program. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the FDA determines that a REMS is necessary during review of an application, the drug sponsor must agree to the REMS plan at the time of approval. We anticipate that our product candidates,
including Xtampza, will be subject to the ER/LA opioid REMS requirement. There may be increased cost, administrative burden and potential liability associated with the marketing and sale of these
types of product candidates subject to the ER/LA opioid REMS requirement, which could reduce the commercial benefits to us from the sale of these product candidates. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to obtain the necessary regulatory approvals, or if such approvals are limited, we will
not be able to commercialize our product candidates, and we will not generate product revenues.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even if we comply with all FDA pre-approval regulatory requirements, the FDA may determine that Xtampza or our other product candidates are not safe
or effective, and we may never obtain regulatory approval for such product candidates. If we fail to obtain regulatory approval for some or all of our product candidates, we will have fewer commercial
products, if any, and correspondingly lower product revenues, if any. Even if our product candidates, including Xtampza, receive regulatory approval, such approval may involve limitations on the
indications and conditions of use or marketing claims for our products, or may not include certain of the abuse-deterrence claims that we are seeking to include in the label for Xtampza and our other
DETERx-based product candidates. Further, later discovery of previously unknown problems or adverse events could result in additional regulatory restrictions, including withdrawal of products and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=873610,FOLIO='22',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_23"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>addition
of warnings or other statements on the product label. The FDA is likely to require us to perform lengthy Phase&nbsp;4 post-approval clinical efficacy or safety trials. These trials could be
very expensive. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
jurisdictions outside the United States, we must receive marketing authorizations from the appropriate regulatory authorities before commercializing our product candidates. Regulatory approval
processes outside the United States generally include requirements and risks similar to, and in many cases in excess of, the risks associated with FDA approval. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The FDA may not approve labeling for our product candidates, including Xtampza, that would permit us
to market and promote our products in the United States by describing their abuse-deterrent features.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have invested substantial time and money conducting Category&nbsp;1, Category&nbsp;2 and Category&nbsp;3 abuse-deterrent studies to ensure
Xtampza's compliance with the FDA's January 2013 draft guidance regarding opioid abuse deterrence, and we believe such studies are consistent with the April 2015 final FDA guidance. The commercial
success of Xtampza and our other product candidates will depend upon our ability to do the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain FDA-approved labeling describing their abuse-deterrent features or
benefits; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain FDA-approved labeling that will allow for the Xtampza microspheres to be
sprinkled on food, directly in the mouth or administered through feeding tubes. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
failure to achieve FDA approval of product labeling containing such information will prevent or substantiality limit our promotion of the abuse-deterrent features of our product candidates in
order to differentiate them from
other opioid products containing the same active ingredients. This would make our products less competitive in the market. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA has publicly stated that explicit claims that a product is expected to result in a meaningful reduction of abuse must be supported by randomized, double-blind, controlled clinical studies of
the abuse potential of the drug and that explicit claims that a product has demonstrated reduced abuse in the community will be required to be supported by post-marketing data, including formal
post-marketing studies evaluating the effect of abuse-deterrent formulations. Although we believe that we have conducted all of the preclinical studies and clinical trials that are required to support
certain abuse-deterrent claims for Xtampza, there can be no assurance that Xtampza, or any of our other product candidates, will receive FDA-approved labeling that describes the abuse-deterrent
features of such products. Furthermore, the FDA's April 2015 final guidance on abuse deterrent opioids makes clear that the FDA expects sponsors to compare their formulations against approved
abuse-deterrent versions of the same opioid based on the relevant categories of testing. If a proposed product is less resistant to manipulation than an approved product, the FDA has stated that the
proposed product may not be eligible for labeling regarding abuse-deterrent properties. If the FDA does not approve labeling containing abuse-deterrence claims, we will not be able to promote such
products based on their abuse-deterrent features, may not be able to differentiate such products from other opioid products containing the same active ingredients, and may need to lower the price of
our products to the extent that there are competing products with abuse-deterrent claims on their labels. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
the FDA closely regulates promotional materials and other promotional activities, even if the FDA initially approves product labeling that includes a description of the abuse-deterrent
characteristics of our product, the FDA may object to our marketing claims and product advertising campaigns. This could lead to the issuance of warning letters or untitled letters, suspension or
withdrawal of our products from the market, recalls, fines, disgorgement of money, operating restrictions, injunctions, and civil or criminal prosecution. Any of these consequences would harm the
commercial success of our products. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Even
if Xtampza and any of our other product candidates are approved for marketing with certain abuse-deterrence claims, the April 2015 final FDA guidance on abuse-deterrent opioids is not binding law
and may be superseded or modified at any time. Also, if the FDA determines that our post-marketing data do </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=27,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=573721,FOLIO='23',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>not
demonstrate that the abuse-deterrent properties result in reduction of abuse, or demonstrate a shift to routes of abuse that present a greater risk, the FDA may find that labeling revisions are
needed, and potentially require the removal of our abuse-deterrence claims. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if our product candidates receive regulatory approval, they will be subject to ongoing
regulatory requirements, and we may face regulatory enforcement action if we do not comply with the requirements.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even after a product is approved, we will remain subject to ongoing FDA and other regulatory requirements governing the labeling, packaging, storage,
distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to
monitor and report adverse events, or AEs, and any failure of a product to meet the specifications in the NDA. In addition, manufacturers of drug products and their facilities are subject to payment
of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, and other regulations. If we
or a regulatory agency discover problems with a product which were previously unknown, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is
manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring product recall, notice to physicians, withdrawal of the product from
the market or suspension of manufacturing, among other things. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory
requirements, a regulatory agency may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> issue warning letters or untitled letters; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> mandate modifications to promotional materials or require us to provide
corrective information to healthcare practitioners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require us to enter into a consent decree, which can include the imposition of
various fines, reimbursements for inspection costs and penalties for noncompliance, and require due dates for specific actions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek an injunction or impose civil, criminal and/or administrative penalties,
damages, monetary fines, require disgorgement, consider exclusion from participation in Medicare, Medicaid and other federal healthcare programs and require curtailment or restructuring of our
operations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspend or withdraw regulatory approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspend any ongoing clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refuse to approve pending applications or supplements to applications filed by
us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspend or impose restrictions on operations, including costly new manufacturing
requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seize or detain products, refuse to permit the import or export of products, or
require us to initiate a product recall; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refuse to allow us to enter into government contracts. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Similar
post-market requirements may apply in foreign jurisdictions in which we may seek approval of our products. Any government investigation of alleged violations of law could require us to expend
significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and
generate revenue and may cause a material adverse impact on our financial condition and cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the FDA's regulations, policies or guidance may change and new or additional statutes or government regulations in the United States and other jurisdictions may be enacted that could
further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from pending or future legislation or
administrative action, either in the United States or abroad. If we are not able to achieve and maintain regulatory compliance, we may not be permitted to market our products and/or product
candidates, which would adversely affect our ability to generate revenue and achieve or maintain profitability. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=28,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=75911,FOLIO='24',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to comply with ongoing governmental regulations for marketing our product candidates could
delay or inhibit our ability to generate revenues from their sale and could also expose us to claims or other sanctions.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by, among others, the FDA,
the Department of Justice, or the DOJ, the Office of Inspector General of the Department of Health and Human Services, or HHS, state attorneys general, members of Congress and the public. Violations,
including promotion of our product candidates, if approved, for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the
FDA or other government agencies. Additionally, advertising and promotion of any product candidate that obtains approval outside the United States will be heavily scrutinized by foreign regulatory
authorities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the United States, engaging in off-label promotion of Xtampza (or any of our other product candidates), if approved can also subject us to false claims litigation under federal and state statutes,
and other litigation and/or investigation, which can lead to civil and criminal penalties and fines and agreements that materially restrict the manner in which we promote or distribute our drug
products. These false claims statutes include the federal False Claims Act, which allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the federal government alleging
submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government prevails in the
lawsuit, the individual will share in any fines or settlement funds. Since 2004, these False Claims Act lawsuits against pharmaceutical companies have increased significantly in volume and breadth,
leading to several substantial civil and criminal settlements based on certain sales practices promoting off-label drug uses. This increasing focus and scrutiny has increased the risk that a
pharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting and compliance obligations, and be excluded from the
Medicare, Medicaid and other federal and state healthcare programs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged
off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which
specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which
could materially adversely affect our business and financial condition. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, later discovery of previously unknown problems with a product, manufacturer or facility, or our failure to update regulatory files, may result in restrictions, including withdrawal of the
product from the market. Any of the following or other similar events, if they were to occur, could delay or preclude us from further developing, marketing or realizing the full commercial potential
of our product candidates:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to obtain or maintain requisite governmental approvals; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to obtain approvals of labeling with abuse-deterrent claims; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA required product withdrawals or warnings arising from identification of
serious and unanticipated adverse side effects in our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our product candidates contain controlled substances, the manufacture, use, sale, importation,
exportation and distribution of which are subject to regulation by state, federal and foreign law enforcement and other regulatory agencies.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our product candidates, including Xtampza, contain, and our future product candidates will likely contain, controlled substances which are subject to
state, federal and foreign laws and regulations regarding their manufacture, use, sale, importation, exportation and distribution. Xtampza's active ingredient, oxycodone, is classified as a controlled
substance under the Controlled Substances Act of 1970, or CSA, and regulations </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=29,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=454096,FOLIO='25',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_26"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>of
the U.S. Drug Enforcement Administration, or DEA. A number of states also independently regulate these drugs, including oxycodone, as controlled substances. Controlled substances are classified by
the DEA as Schedule&nbsp;I, II, III, IV or V substances, with Schedule&nbsp;I substances considered to present the highest risk of substance abuse and Schedule&nbsp;V substances the lowest risk.
The active ingredient in our lead product candidate Xtampza, oxycodone, is listed by the DEA as a Schedule&nbsp;II controlled substance under the CSA. For our product candidates containing
controlled substances, we and our suppliers, manufacturers, contractors, customers and distributors are required to obtain and maintain applicable registrations from state, federal and foreign law
enforcement and regulatory agencies and comply with state, federal and foreign laws and regulations regarding the manufacture, use, sale, importation, exportation and distribution of controlled
substances. For example, all Schedule&nbsp;II drug prescriptions must be signed by a physician, physically presented to a pharmacist and may not be refilled without a new prescription. Furthermore,
the amount of Schedule&nbsp;II substances that can be obtained for clinical trials and commercial distribution is limited by the CSA and DEA regulations. We may not be able to obtain sufficient
quantities of these controlled substances in order to complete our clinical trials or meet commercial demand, if our product candidates are approved for marketing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, controlled substances are also subject to regulations governing manufacturing, labeling, packaging, testing, dispensing, production and procurement quotas, recordkeeping, reporting,
handling, shipment and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of product candidates that include controlled
substances. The DEA and some states conduct periodic inspections of registered establishments that handle controlled substances. Failure to obtain and maintain required registrations or to comply with
any applicable regulations could delay or preclude us from developing and commercializing our product candidates that contain controlled substances and subject us to enforcement action. The DEA may
seek civil penalties, refuse to renew necessary registrations or initiate proceedings to revoke those registrations. In some circumstances, violations could lead to criminal proceedings. Because of
their restrictive nature, these regulations could limit commercialization of our product candidates containing controlled substances. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical development is a lengthy and expensive process with an uncertain outcome, and failure can
occur at any stage of clinical development. If we are unable to design, conduct and complete clinical trials successfully, our product candidates will not be able to receive regulatory approval.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In order to obtain FDA approval for any of our product candidates, we must submit to the FDA an NDA with substantial evidence that demonstrates that
the product candidate is both safe and effective in humans for its intended use. This demonstration requires significant research, preclinical studies and clinical trials. Other than Xtampza, all of
our product candidates are in preclinical development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials are time-consuming, expensive and difficult to design and implement, in part because they are subject to rigorous requirements and their outcomes are inherently uncertain. Clinical
testing may take many years to complete, and failure can occur at any time during the clinical trial process, even with active ingredients that have previously been approved by the FDA as being safe
and effective. We could encounter problems that halt our clinical trials or require us to repeat such clinical trials. If patients participating in clinical trials suffer drug-related adverse
reactions during the course of such clinical trials, or if we or the FDA believe that patients are being exposed to unacceptable health risks, such clinical trials may have to be suspended or
terminated. Suspensions, termination or the need to repeat a clinical trial can occur at any stage. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
clinical trial success of each of our product candidates depends on reaching statistically significant changes in patients' symptoms based on clinician-rated scales. There is a lack of consensus
regarding standardized processes for assessing clinical outcomes based on clinician-rated scales. Accordingly, the scores from our clinical trials may not be reliable, useful or acceptable to the FDA
or other regulatory agencies. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=30,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=958307,FOLIO='26',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Changes
in standards related to clinical trial design could have a material adverse effect on our ability to design and conduct clinical trials as planned. For example, we have conducted or will
conduct clinical trials comparing our product candidates to both placebo and other approved drugs, but regulatory authorities may not allow us to compare our product candidates to a placebo in a
particular clinical indication where approved products are available. In that case, both the cost and the amount of time required to conduct a clinical trial could increase. The FDA may disagree with
our trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials. The
FDA may also approve a product candidate for fewer or more limited indications than we request, or may grant approval contingent on the performance of costly post-approval clinical trials. In
addition, the FDA may not approve the labeling claims or removal of certain warnings that we believe are necessary or desirable for the successful commercialization of our product candidates. Approval
may be contingent on a REMS, which could have a material adverse effect on the labeling, distribution or promotion of a drug product. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Any
of these delays or additional requirements could cause our product candidates to not be approved, or if approved, significantly impact the timing and commercialization of our product candidates
and significantly increase our overall costs of drug development. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because the results of preclinical studies and early-stage clinical trials are not necessarily
predictive of future results, any product candidate we advance into additional clinical trials may not continue to have favorable results or receive regulatory approval.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other than Xtampza, all of our product candidates are in preclinical development. Success in preclinical studies and early clinical trials does not
ensure that later clinical trials will generate adequate data to demonstrate the efficacy and safety of an investigational drug. Many companies in the pharmaceutical and biotechnology industries,
including those with greater resources and experience, have suffered significant setbacks in clinical trials, even after reporting promising results in earlier clinical trials. Despite the results
reported in preliminary preclinical studies for our other extended-release, abuse-deterrent product candidates, including hydrocodone and oxymorphone for pain, and methylphenidate for the treatment of
ADHD, we do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety or otherwise provide adequate information to result in regulatory approval to market any
of our product candidates in any particular jurisdiction. If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates,
other than Xtampza, may be compromised. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Conducting clinical trials of our product candidates and any future commercial sales of a product
candidate may expose us to expensive product liability claims, and we may not be able to maintain product liability insurance on reasonable terms or at all.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently carry product liability insurance with coverage up to approximately $5&nbsp;million, which covers liability relating to our clinical
trials. Even if we successfully commercialize one or more of our product candidates, we may face product liability claims, regardless of FDA approval for commercial manufacturing and sale. Product
liability claims may be brought against us by patients enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully
defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. We may not be able to maintain insurance coverage at a reasonable cost
or in an amount adequate to satisfy any liability that may arise. Regardless of merit or eventual outcome, liability claims may result in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  decreased demand for any product candidates or products that we may develop; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  termination of clinical trial sites or entire trial programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injury to our reputation and significant negative media attention; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  withdrawal of clinical trial participants; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=7,SEQ=31,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=89250,FOLIO='27',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  significant costs to defend the related litigation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  substantial monetary awards to patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> loss of revenue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  diversion of management and scientific resources from our business operations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to commercialize any products that we may develop; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in product liability insurance premiums or an inability to maintain
product liability insurance coverage. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
inability to maintain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our
product candidates. Any agreements we may enter into in the future with collaborators in connection with the development or commercialization of our product candidates may entitle us to
indemnification against product liability losses, but such indemnification may not be available or adequate should any claim arise. In addition, several of our agreements require us to indemnify third
parties and these indemnifications obligations may exceed the coverage under our product liability insurance policy. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Xtampza and our other product candidates may be associated with undesirable adverse reactions or
have other properties that could delay or prevent their regulatory approval, limit the commercial profile of their approved label, or result in significant negative consequences following any
marketing approval.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Undesirable adverse reactions associated with Xtampza, or any of our other product candidates, could cause us, our IRBs, clinical trial sites or
regulatory authorities to interrupt, delay or halt clinical trials and could result in a restrictive label or the delay, denial or withdrawal of regulatory approval by the FDA or foreign regulatory
authorities. For example, even though Xtampza has generally been well tolerated by patients in our clinical trials, in some cases there were adverse reactions, one of which was a serious adverse
event, moderate in severity, of gastroesophageal reflux. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
Xtampza or any of our other product candidates receives marketing approval, and we or others later identify undesirable adverse events associated with such product, a number of potentially
significant negative consequences could result, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may be forced to suspend marketing of the product; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory authorities may withdraw their approvals of the product or impose
restrictions on its distribution; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory authorities may require additional warnings or contradictions in the
label that could diminish the usage or otherwise limit the commercial success of the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may be required to conduct additional post-marketing studies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we could be sued and held liable for harm caused to patients; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our reputation may suffer. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Any
of these events could prevent us from achieving or maintaining market acceptance of Xtampza or any of our other product candidates, if approved. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Intellectual Property  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Unfavorable outcomes in intellectual property litigation could result in costly litigation and
potentially limit our ability to commercialize our products.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our commercial success depends upon our ability to develop product candidates and commercialize future products without infringing the intellectual
property rights of others. Our current or future product candidates or products, or any uses of them, may now or in the future infringe third-party patents or other intellectual property rights. This
is due in part to the considerable uncertainty within the pharmaceutical industry about the validity, scope and enforceability of many issued patents in the United States and elsewhere in the world
and, to date, there is no consistency regarding the breadth of claims allowed in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=32,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=279617,FOLIO='28',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>pharmaceutical
patents. We cannot currently determine the ultimate scope and validity of patents which may be granted to third parties in the future or which patents might be asserted to be infringed
by the manufacture, use and sale of our products. In part as a result of this uncertainty, there has been, and we expect that there will continue to be, significant litigation in the pharmaceutical
industry regarding patents and other intellectual property rights. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Third
parties may assert infringement claims against us, or other parties we have agreed to indemnify, based on existing patents or patents that may be granted in the future. We are aware of
third-party patents and patent applications related to oxycodone, oxymorphone, hydrocodone, morphine, and methylphenidate drugs and formulations, including those listed in the FDA's Orange Book for
oxycodone products. Because of the delay between filing and publication of patent applications, and because applications can take several years to issue, there may be currently pending third-party
patent applications that are unknown to us, which may later result in issued patents. Because of the uncertainty inherent in intellectual property litigation, we could lose, even if the case against
us was weak or flawed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are found to infringe a third party's intellectual property rights, we could be required to obtain a license from such third party to continue developing or commercializing our product
candidates, products and technology.
However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors
access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, in any such proceeding or
litigation, we could be found liable for monetary damages, including treble damages and attorneys' fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent
us from commercializing our product candidates or force us to cease some of our business operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


In connection with any NDA that we file under Section&nbsp;505(b)(2), including the NDA for Xtampza, we are required to notify the patent holder of the Section&nbsp;505(b)(2) listed drug that we
identify in our NDA, that we have certified to the FDA that any patents listed for the listed drug in the FDA's Orange Book publication are invalid, unenforceable or will not be infringed by the
manufacture, use or sale of our drug. If the patent holder files&nbsp;a patent infringement lawsuit against us within 45&nbsp;days of its receipt of notice of our certification, the FDA is
automatically prevented from approving our Section&nbsp;505(b)(2) NDA until the earliest of 30&nbsp;months after the lawsuit is filed, expiration of the patents, settlement of the lawsuit and a
court decision in the infringement case that is favorable to us. Accordingly, we may invest significant time and expense in the development of our product candidates only to be subject to significant
delay and patent litigation before our product candidates may be commercialized. On March&nbsp;24 and March&nbsp;26, 2015, Purdue, as the sponsor for OxyContin OP, the listed drug for Xtampza,
brought infringement claims against us in the District of Delaware and the District of Massachusetts, respectively, alleging infringement of U.S. Patent Nos.&nbsp;7,674,799, 7,674,800, 7,683,072 and
8,652,497. On April&nbsp;6, 2015, in the District of Delaware case, we filed a motion to dismiss for lack of personal jurisdiction or, in the alternative, to transfer venue to the Southern District
of New York where three of the patents have already been invalidated. Purdue's opposition to our motion was filed on April&nbsp;23, 2015 and our reply in support of the motion is due on
May&nbsp;4, 2015. The complaint in the District of Massachusetts case has not yet been served. We plan to continue to take all steps necessary to vigorously defend ourselves against these claims.
The strength of our defenses will depend on the patents asserted and the interpretation of these patents. However, we could be unsuccessful in advancing non-infringement and invalidity arguments in
our defense. Purdue need only prove infringement by a preponderance of the evidence, which is a low burden of proof.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are found by the court to have infringed a valid patent claim, we could be prevented from using the patented technology or be required to pay Purdue for the right to license the patented
technology. If we decide to pursue a license to use one or more of these patents, we may not be able to obtain a license on commercially reasonable terms, if at all, or the license we obtain may
require us to pay substantial royalties or grant cross licenses to our patent rights. For example, if the relevant patent is owned by a competitor, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=33,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=50870,FOLIO='29',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_30"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>such
as Purdue, that competitor may choose not to license patent rights to us. If we decide to develop alternative technology, we may not be able to do so in a timely or cost-effective manner, if at
all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we are found not to infringe or Purdue's, or any other potential plaintiff's, patent claims are found invalid or unenforceable, defending any such infringement claim would be expensive and
time-consuming, and could delay the launch of Xtampza and distract management from their normal responsibilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Competitors
may sue us as a way of delaying the introduction of our products. Any litigation, including any interference or derivation proceedings to determine priority of inventions, oppositions or
other post-grant review proceedings to patents in the United States or in countries outside the United States, or litigation against our collaborators may be costly and time consuming and could have a
material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. We expect that litigation may be necessary in some
instances to determine the validity and scope of our proprietary rights. Litigation may be necessary in other instances to determine the validity, scope or non-infringement of certain patent rights
claimed by third parties to be pertinent to the manufacture, use or sale of our products. Ultimately, the outcome of such litigation could compromise the validity and scope of our patents or other
proprietary rights or hinder our ability to manufacture and market our products. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to obtain or maintain intellectual property rights for our technology and product
candidates, we may lose valuable assets or experience reduced market share.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We depend on our ability to protect our proprietary technology. We rely on patent and trademark laws, unpatented trade secrets and know-how, and
confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability to obtain and maintain
patent protection in the United States and other countries with respect to our proprietary technology and product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both
inside and outside the United States. The rights already granted under any of our currently issued patents and those that may be granted under future issued patents may not provide us with the
proprietary protection or competitive advantages we are seeking. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The patent prosecution process is expensive and time-consuming, and we may not be able to file and
prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of inventions made in the
course of our development and commercialization activities before it is too late to obtain patent protection on them.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting such product candidates
might expire before or shortly after such
product candidates are commercialized. If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient,
our competitors could develop and commercialize technology and products identical, similar or superior to ours, and our ability to successfully commercialize our technology and products may be
adversely affected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>With
respect to patent rights, our patent applications may not issue into patents, and any issued patents may not provide protection against competitive technologies, may be held invalid or
unenforceable if challenged or may be interpreted in a manner that does not adequately protect our technology, product candidates or future product candidates. Even if our owned patent applications
issue into patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive
advantage. The examination process may require us to narrow the claims in our patents, which may limit the scope of patent protection that may be obtained. Our competitors may design around or
otherwise circumvent patents issued to us or licensed by us. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=34,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=111304,FOLIO='30',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_de72301_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The scope of patent protection in the United States and in foreign jurisdictions is highly
uncertain, and changes in U.S. and foreign patent law have increased that uncertainty and could diminish the value of patents in general, thereby impairing our ability to protect our product
candidates and any future products.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much
litigation. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent
protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and these foreign laws may also be subject to change. Publications of
discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions typically are not published until
18&nbsp;months after filing or, in some cases, not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or licensed patents or pending patent
applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights, both in
the United States and abroad, are highly uncertain. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Recent
patent reform legislation could increase the uncertainties and costs associated with the prosecution of our patent applications and the enforcement or defense of our issued patents. The
Leahy-Smith America Invents Act,
or the Leahy-Smith Act, which was signed into law on September&nbsp;16, 2011, made significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted
and litigated. Many of the substantive changes to patent law associated with the Leahy-Smith Act and, in particular, the "first to file" provisions described below, only became effective on
March&nbsp;16, 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of
our issued patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to the Leahy-Smith Act, the United States transitioned to a "first to file" system in which the first inventor to file&nbsp;a patent application will be entitled to the patent. In addition,
third parties are allowed to submit prior art before the issuance of a patent by the U.S. Patent and Trademark Office, or USPTO, and may become involved in opposition, derivation, reexamination, or </FONT> <FONT SIZE=2><I>inter partes</I></FONT><FONT
SIZE=2> review challenging our patent rights or the patent rights of others. Grounds for a validity challenge could be an alleged failure to meet any
of several statutory requirements, including novelty, nonobviousness and enablement. It is possible that prior art of which both we and the patent examiner were unaware during prosecution exists,
which could render our patents invalid. Moreover, there may exist prior art of which we were or are aware, and which we did not or do not consider relevant to our patents, but which could nevertheless
be determined to render our patents invalid. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, which could have a
material adverse effect on our competitive position with respect to third parties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from third parties may be challenged in the
courts or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents, or the invalidity or unenforceability of
such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology
and products. Protecting against the unauthorized use of our patented technology, trademarks and other intellectual property rights is expensive, difficult and, may in some cases not be possible. In
some cases, it may be difficult or impossible to detect third party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such
infringement may be even more difficult. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=35,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=520637,FOLIO='31',FILE='DISK114:[15ZAD1.15ZAD72301]DE72301A.;47',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dg72301_1_32"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be forced to litigate to enforce or defend our intellectual property, which could be
expensive, time consuming and unsuccessful, and result in the loss of valuable assets.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may be forced to litigate to enforce or defend our intellectual property rights against infringement and unauthorized use by competitors, and to
protect our trade secrets. To counter infringement or unauthorized use, litigation may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets or
to determine the validity and scope of our own intellectual property rights. In so doing, we may place our intellectual property at risk of being invalidated, rendered unenforceable or limited or
narrowed in scope. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
this can be expensive and time consuming. Many of our current and potential competitors have the ability to dedicate substantially greater resources to defend their intellectual property
rights than we can. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. Litigation could result in
substantial costs and diversion of management resources, which could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our
overall financial condition. In addition, an adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.
Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by
disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have a material adverse effect on the price of shares of our common stock. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims by third parties of ownership of what we regard as our own intellectual
property or obligations to make compensatory payments to employees.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements
assigning such intellectual property to us, we may be unsuccessful in executing or obtaining such an agreement with each party who, in fact, develops intellectual property that we regard as our own.
In addition, they may breach the assignment agreements or such agreements may not be self-executing, and we may be forced to bring claims against third parties, or defend claims they may bring against
us, to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our
technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to protect the confidentiality of our trade secrets, our business and competitive
position would be harmed.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to seeking patents for some of our technology and products, we rely on trade secrets, including unpatented know-how, technology and other
proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have
access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. Despite these efforts, any of
these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim
that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the
United States may be less willing or unwilling to protect trade secrets. If any of our trade secrets were to be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=36,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=560267,FOLIO='32',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dg72301_1_33"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>lawfully
obtained or independently developed by a competitor, we would have no right to prevent such competitor, or those to whom they communicate them, from using that technology or information to
compete with us. If any of our trade secrets were to be disclosed or independently developed, our competitive position would be harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect our intellectual property rights throughout the world.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. Competitors may use
our technologies in jurisdictions where we have not obtained patent protection to develop and sell their own products and, further, may export otherwise infringing products to territories where we
have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents or our
patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain
developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop
the infringement of our patents or the marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result
in substantial cost and divert our efforts and attention from other aspects of our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims that our employees have wrongfully used or disclosed alleged trade
secrets of their former employers.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many of our employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including
potential competitors. These employees typically executed proprietary rights, non-disclosure and non-competition agreements in connection with their previous employment. Although we try to ensure that
our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property,
including trade secrets or other proprietary information, of any such employee's former employer. We are not aware of any threatened or pending claims related to these matters, but in the future
litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to
paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be
a distraction to management. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar
provisions during the patent application process. In addition, periodic maintenance fees on issued patents are required to be paid to the USPTO and foreign patent agencies in several stages over the
lifetime of the patents. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that
could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and
failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely
affected. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=37,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=851726,FOLIO='33',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dg72301_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to the Commercialization of Our Product Candidates  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently have no sales or marketing capabilities and, if we are unable to develop our own sales
and marketing capabilities or enter into strategic alliances with marketing collaborators, we may not be successful in commercializing our product candidates and may be unable to generate any product
revenue.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although our executive officers have experience marketing pharmaceutical products, we currently have no sales, marketing or distribution capabilities.
We do not intend to begin to hire field sales representatives until several months prior to receiving FDA approval of one of our product candidates. Therefore, at the time of our anticipated
commercial launch of Xtampza, assuming regulatory approval of the product candidate by the FDA, our sales and marketing team will have worked together for only a limited period of time. We cannot
guarantee that we will be successful in marketing Xtampza or any of our other product candidates which may be approved in the United States. We may not be able to establish a targeted sales force in a
cost-effective manner. In addition, we will have to compete with other pharmaceutical and biotechnology companies with extensive and well-funded sales and marketing operations to recruit, hire, train
and retain sales and marketing personnel. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to
generate product revenue and may not become profitable. Factors that may inhibit our efforts to commercialize our product candidates in the United States
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our inability to recruit and retain adequate numbers of effective sales and
marketing personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability of sales personnel to obtain access to or persuade adequate
numbers of physicians to prescribe our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of complementary products to be offered by sales personnel, which may
put us at a competitive disadvantage relative to companies with more extensive product lines; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  unforeseen costs and expenses associated with creating an independent sales and
marketing organization. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
we are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure or if we do not successfully enter into appropriate strategic alliances with
marketing collaborators, agreements with contract sales organizations or collaboration arrangements, we will have difficulty commercializing our product candidates. To the extent we commercialize our
product candidates by entering into agreements with third-party collaborators, we may have limited or no control over the sales, marketing and distribution activities of these third parties, in which
case our future revenues would depend heavily on the success of the efforts of these third parties. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If physicians, patients, healthcare payors and the medical community do not accept and use our
product candidates, we will not achieve sufficient product revenues and our business will suffer.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even if the FDA approves our product candidates, physicians, patients, healthcare payors and the medical community may not accept and use them.
Acceptance and use of our product candidates will depend on a number of factors including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing of market introduction of the product candidates as well as
competitive products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  approved indications, warnings and precautions language that may be less
desirable than anticipated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  perceptions by members of the healthcare community, including physicians, about
the safety and efficacy of our product candidates, and, in particular, the efficacy of our abuse-deterrent technology in reducing potential risks of unintended use; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  perceptions by physicians regarding the cost benefit of our product candidates
in reducing potential risks of unintended use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  published studies demonstrating the cost-effectiveness of our product
candidates relative to competing products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the potential and perceived advantages of our product candidates over
alternative treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the convenience and ease of administration to patients of our product
candidates; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=38,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=579246,FOLIO='34',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dg72301_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  availability of coverage and adequate reimbursement for our product candidates
from government or other third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any negative publicity related to our or our competitors' products that include
the same active ingredient as our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the prevalence and severity of adverse side effects, including limitations or
warnings contained in a product's FDA approved labeling; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to implement a REMS prior to the distribution of any product
candidates requiring a REMS; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  effectiveness of marketing and distribution efforts by us and other licensees
and distributors. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
our product candidates, including Xtampza, are approved but fail to achieve an adequate level of acceptance by physicians, healthcare payors, patients and the medical community, we will not be able
to generate significant revenue, and we may not become or remain profitable. Because we expect to rely on sales generated by our current lead product candidate, if approved, for substantially all of
our revenues for the foreseeable future, the failure of any of our product candidates to find market acceptance would harm our business prospects. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently enacted and future legislation may increase the difficulty and cost for us to commercialize
our product candidates and may reduce the prices we are able to obtain for our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the
healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities or affect our ability to profitably sell any product
candidates for which we obtain marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the Medicare Modernization Act, established the Medicare Part&nbsp;D program and provided
authority for limiting the number of drugs that will be covered in any therapeutic class thereunder. The Medicare Modernization Act, including its cost reduction initiatives, could decrease the
coverage and reimbursement rate that we receive for any of our approved products. Furthermore, private payors often follow Medicare coverage policies and payment limitations in setting their own
reimbursement rates. Therefore, any reduction in Medicare reimbursement may result in a similar reduction in payments from private payors. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposes a significant
annual fee on companies that manufacture or import branded prescription drug products. It also contains substantial new provisions intended to, among other things, broaden access to health insurance,
reduce or constrain the growth of health care spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, and
impose additional health policy reforms, any of which could have a material adverse effect on our business. A significant number of provisions are not yet, or have only recently become, effective, but
the Affordable Care Act is likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
legislative changes have also been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions in Medicare
payments to providers of 2% per fiscal year, starting in 2013, and the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other
healthcare funding, which could impose additional financial pressure on our customers, which could in turn diminish demand for our products or result in pricing pressure on us. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=39,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=896361,FOLIO='35',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dg72301_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that the Affordable Care Act, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage criteria and in additional
downward pressure on the price that we receive for any approved product, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may
result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may compromise our ability to generate revenue, attain
profitability or commercialize our products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, state pharmacy laws may permit pharmacists to substitute generic products for branded products if the products are therapeutic equivalents, or may permit pharmacists and pharmacy benefit
managers to seek prescriber authorization to substitute generics in place of our product candidates, which could significantly diminish demand for them and significantly impact our ability to
successfully commercialize our product candidates and generate revenues. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we are able to commercialize Xtampza and any of our other product candidates, our products
may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could have a material adverse effect on our business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Current and
future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale
price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription
pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country,
but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the
sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates even if our product candidates obtain
marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available
from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government
authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring
that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be
available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be and whether it will be satisfactory. Coverage and reimbursement may impact
the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we
may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or
foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates
may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=40,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=186332,FOLIO='36',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dg72301_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>lower
cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or
private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often
rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable reimbursement rates from both
government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize
products and our overall financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Social issues around the abuse of opioids, including law enforcement concerns over diversion of
opioid and regulatory efforts to combat abuse, could decrease the potential market for our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Media stories regarding prescription drug abuse and the diversion of opioids and other controlled substances are commonplace. Law enforcement and
regulatory agencies may apply policies that seek to limit the availability of opioids. Such efforts may inhibit our ability to commercialize our product candidates. Aggressive enforcement and
unfavorable publicity regarding, for example, the use or misuse of oxycodone or other opioid drugs; the limitations of abuse-resistant formulations; the ability of drug abusers to discover previously
unknown ways to abuse Xtampza; public inquiries and investigations into prescription drug abuse; litigation; or regulatory activity regarding sales, marketing, distribution or storage of opioid drugs
could have a material adverse effect on our reputation. Such negative publicity could reduce the potential size of the market for our product candidates and decrease the revenues we are able to
generate from their sale. Similarly, to the extent opioid abuse becomes less prevalent or less urgent of a public health issue, regulators and third party payers may not be willing to pay a premium
for abuse-deterrent formulations of opioids. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
efforts by the FDA and other regulatory bodies to combat abuse of opioids may negatively impact the market for our product candidates. For example, on September&nbsp;10, 2013, the FDA
announced its intention to effect labeling changes to all approved extended-release/long-acting opioids. In particular, the FDA announced its intention to update the indication for
extended-release/long-acting opioids so that extended-release/long-acting opioids will be indicated only for the management of pain severe enough to require daily, around-the-clock, long-term opioid
treatment and for which alternative treatment options are inadequate. On April&nbsp;16, 2014, the FDA updated these indications. It is possible that such changes could reduce the number of
prescriptions for opioids written by physicians and negatively impact the potential market for our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the FDA or other applicable regulatory authorities approve generic products with abuse-deterrent
claims that compete with any of our product candidates, it could reduce our sales of those product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Once an NDA, including a Section&nbsp;505(b)(2) application, is approved, the product covered thereby becomes a "listed drug" which can, in turn, be
cited by potential competitors in support of approval of an abbreviated NDA, or ANDA. The FD&amp;C Act, FDA regulations and other applicable regulations and policies provide incentives to manufacturers to
create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes. These manufacturers might only be required to conduct a
relatively inexpensive study to show that their product has the same active ingredients, dosage form, strength, route of administration, and conditions of use, or labeling, as our product candidate
and that the generic product is absorbed in the body at the same rate and to the same extent as, or is bioequivalent to, our product candidate. These generic equivalents would be significantly less
costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a
significant percentage of the sales of any branded product are typically lost to the generic product. Accordingly, competition from generic equivalents to our product candidates would substantially
limit our ability to generate revenues and therefore to obtain a return on the investments we have made in our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=41,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=281677,FOLIO='37',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dg72301_1_38"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Guidelines and recommendations published by various organizations can reduce the use of our
products, if approved.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Government agencies promulgate regulations and guidelines directly applicable to us and to our product candidates. In addition, professional
societies, practice management groups, private health and science foundations and organizations involved in various diseases from time to time may also publish guidelines or recommendations to the
healthcare and patient communities. Recommendations of government agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of
concomitant therapies. Recommendations or guidelines suggesting the reduced use of our products or the use of competitive or alternative products as the standard of care to be followed by patients and
healthcare providers could result in decreased use of our products. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Dependence on Third Parties  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we encounter difficulties in negotiating a commercial manufacturing agreement with the third
party manufacturer of Xtampza or the third-party manufacturer fails to devote sufficient time and resources to Xtampza, or its performance is substandard, our product launch may be delayed and our
costs may be higher than expected and could have a material adverse effect on our business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We do not own any manufacturing facilities and have limited experience in drug development and commercial manufacturing. We currently have no plans to
build our own clinical or commercial scale manufacturing facility. We lack the resources and expertise to manufacture and test, on a commercial scale, the technical performance of our product
candidates. We currently rely, and expect to continue to rely, on a limited number of experienced personnel and one contract manufacturer, Patheon, as well as other vendors to formulate, test, supply,
store and distribute Xtampza for our clinical trials and FDA registration, and we control only certain aspects of their activities. We are currently negotiating a commercial manufacturing agreement
with Patheon and we may not be able to obtain terms that are favorable to us or enter into a commercial manufacturing agreement at all. Although we have identified alternate sources for these
services, it would be time-consuming, and require us to incur additional cost, to qualify these sources. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
reliance on a limited number of vendors and, in particular, Patheon, as our single manufacturer, exposes us to the following risks, any of which could delay FDA approval of our product candidates
and commercialization of our products, result in higher costs, or deprive us of potential product revenues:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our contract manufacturer, or other third parties we rely on, may encounter
difficulties in achieving the volume of production needed to satisfy commercial demand, may experience technical issues that impact quality or compliance with applicable and strictly enforced
regulations governing the manufacture of pharmaceutical products, and may experience shortages of qualified personnel to adequately staff production operations. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our contract manufacturer could default on its agreement with us to meet our
requirements for commercialization of Xtampza. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the use of alternate manufacturers may be difficult because the number of
potential manufacturers that have the necessary governmental licenses to produce narcotic products is limited. Additionally, the FDA and the DEA must approve any alternative manufacturer of Xtampza
before we may use the alternative manufacturer to produce Xtampza. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> it may be difficult or impossible for us to find a replacement manufacturer on
acceptable terms quickly, or at all. Our contract manufacturer and vendors may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully
produce, store and distribute our products. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> if our contract manufacturer were to terminate our arrangement or fail to meet
our commercial manufacturing demands, we may be forced to delay our development and commercial programs. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
reliance on third parties reduces our control over our product candidate development and commercialization activities but does not relieve us of our responsibility to ensure compliance with all </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=42,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=95599,FOLIO='38',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dg72301_1_39"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>required
legal, regulatory and scientific standards. The FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured
according to cGMP and similar foreign standards. Any failure by our third-party manufacturer to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver
sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be
the basis for the FDA to issue a warning or untitled letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure,
total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending
applications or supplemental applications, detention or product, refusal to permit the import or export of products, injunction, imposing civil penalties or pursuing criminal prosecution. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because we currently rely on a sole supplier to manufacture the active pharmaceutical ingredient of
our lead product candidate, Xtampza, any production problems with our supplier could have a material adverse effect on us.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We presently depend upon a single source as the sole supplier of the active ingredient for Xtampza&nbsp;&#151; oxycodone
base&nbsp;&#151; and we intend to contract with this supplier, as necessary, for commercial supply of our products. Although we have identified an alternate source for oxycodone base, it
would be time-consuming and costly to qualify this source. Since we currently obtain our active ingredient from this manufacturer on a purchase-order basis, either we or our supplier may terminate our
arrangement, without cause, at any time without notice. If our supplier were to terminate our arrangement or fail to meet our supply needs we might incur substantial cost and be forced to delay our
development or commercialization programs. Any such delay could have a material adverse effect on our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on third parties to conduct our clinical trials. If these third parties do not successfully
carry out their contractual duties or meet expected deadlines, or if they terminate their agreement with us, we may not be able to obtain regulatory approval for or commercialize our product
candidates and our business could suffer a material adverse effect.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have relied upon and plan to continue to rely upon contract research organizations, or CROs, to monitor and manage data for our ongoing preclinical
and clinical programs. We rely on these parties for execution of our clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of
our studies and clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory
responsibilities. We and our CROs are required to comply with federal regulations and current Good Clinical Practices, or GCP, which are international standards meant to protect the rights and health
of patients and to define the roles of clinical trial sponsors, advisors and monitors, enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and
foreign regulatory authorities in the form of International Conference on Harmonization, or ICH, guidelines for all of our product candidates in clinical development. Regulatory authorities enforce
these GCP through periodic inspections of trial sponsors, principal investigators and trial sites. In addition, we and our CROs are required to comply with special regulations regarding the enrollment
of recreational drug abusers in clinical trials. If we or any of our CROs fail to comply with applicable GCP and other regulations, including as a result of any recent changes in such regulations, the
clinical data generated in our clinical trials may be deemed unreliable and the FDA or foreign regulatory authorities may require us to perform additional clinical trials before approving our
marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP
requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. While we have agreements governing activities of
our CROs, we have limited influence over their actual performance. Failure to comply with applicable regulations in the conduct of the clinical trials </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=43,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1033770,FOLIO='39',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dg72301_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>for
our product candidates may require us to repeat preclinical studies and clinical trials, which would delay the regulatory approval process. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing
clinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy
of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or
terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, the commercial prospects for our product candidates would be
harmed, our costs could increase substantially and our ability to generate revenue could be delayed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Switching
or adding additional CROs involves additional cost and requires management time and focus, and there is a limited number of CROs that are equipped and willing to manage clinical trials that
involve recreational drug abusers. Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate
their respective agreements with us if it can be reasonably demonstrated that the safety of the patients participating in our clinical trials warrants such termination, if we make a general assignment
for the benefit of our creditors or if we are liquidated. Identifying, qualifying and managing performance of third-party service providers can be difficult, time-consuming and cause delays in our
development programs. In addition, there is a natural transition period when a new CRO commences work and the new CRO may not provide the same type or level of services as the original provider.
Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a
material adverse impact on our business, financial condition and prospects. If any of our relationships with our CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Because
we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risks that third parties may not perform to our standards,
may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties,
which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and
monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our ability to advance our product
candidates through clinical trials will be compromised. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in
the future or that
these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


In the future, we may depend on collaborations with third parties for the development and
commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We may not be successful in establishing development and commercialization collaborations which could adversely affect, and potentially prohibit, our
ability to develop or commercialize our product candidates. Collaborations involving our product candidates pose the following risks to us:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may have significant discretion in determining the efforts and
resources that they will apply to these collaborations. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=44,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=319162,FOLIO='40',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dg72301_1_41"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may not pursue development and commercialization of our product
candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator's strategic focus or available funding or
external factors such as an acquisition that diverts resources or creates competing priorities. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may delay clinical trials, provide insufficient funding for a
clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may conduct clinical trials inappropriately, or may obtain
unfavorable results in their clinical trials, which may have an adverse effect on the development of our own programs. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators could independently develop, or develop with third parties,
products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
under terms that are more economically attractive than ours. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a collaborator with marketing and distribution rights to one or more products
may not commit sufficient resources to the marketing and distribution of such products. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may not properly maintain or defend our intellectual property
rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> disputes may arise between the collaborators and us that result in the delay or
termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may lose certain valuable rights under circumstances specified in our
collaborations. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborations may be terminated and, if terminated, may result in a need for
additional capital to pursue further development or commercialization of the applicable product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaboration agreements may not lead to development or commercialization of
product candidates in the most efficient manner or at all. If a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development
or commercialization program under such collaboration could be delayed, diminished or terminated. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may rely on collaborators to market and commercialize Xtampza and, if approved, our other product
candidates, who may fail to effectively commercialize our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may utilize strategic collaborators or contract sales forces, where appropriate, to assist in the commercialization of our product candidates, if
approved, including Xtampza. We currently possess limited resources and may not be successful in establishing collaborations or co-promotion arrangements on acceptable terms, if at all. We also face
competition in our search for collaborators and co-promoters. If we enter into strategic collaborations or similar arrangements, we will rely on third parties for financial resources and for
development, commercialization, sales and marketing and regulatory expertise. Our collaborators, if any, may fail to develop or effectively commercialize our product candidates because they cannot
obtain the necessary regulatory approvals, they lack adequate financial or other resources or they decide to focus on other initiatives. Any failure of our third-party collaborators to successfully
market and commercialize our product candidates would diminish our revenues. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Manufacturing issues may arise that could increase product and regulatory approval costs or delay
commercialization.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As we scale up manufacturing of our product candidates and conduct required stability testing, we may encounter product, packaging, equipment and
process-related issues that may require refinement or resolution in order to proceed with our planned clinical trials and obtain regulatory approval for commercial marketing. In the future, we may
identify impurities, which could result in increased scrutiny by regulatory authorities, delays in our clinical programs and regulatory approval, increases in our operating expenses or failure to
obtain or maintain approval for our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=45,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=581727,FOLIO='41',FILE='DISK114:[15ZAD1.15ZAD72301]DG72301A.;29',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_di72301_1_42"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Business and Strategy  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face substantial competition from other biotechnology and pharmaceutical companies, which may
result in others discovering, developing or commercializing products before or more successfully than we do.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. In addition, the competition in the
pain and opioid market is intense. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities
and other research institutions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
face and will continue to face competition from other companies in the pharmaceutical and medical device industries. Our product candidates, if approved, will compete with currently marketed oral
opioids, transdermal opioids, local anesthetic patches, stimulants and implantable and external infusion pumps that can be used for infusion of opioids and local anesthetics. Products of these types
are marketed by Purdue, Johnson&nbsp;&amp; Johnson, Pfizer, Endo, Mallinckrodt, Zogenix, Actavis and others. Some of these current and potential future competitors may be addressing the same therapeutic
areas or indications as we are. Many of our current and potential future competitors have significantly greater research and development capabilities than we do, have substantially more marketing,
manufacturing, financial, technical, human and managerial resources than we do, and have more institutional experience than we do. Mergers and acquisitions in the biotechnology and pharmaceutical
industries may result in even more resources being concentrated in our competitors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection or other intellectual property rights
that allow them to develop and commercialize their products before us and limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer,
more effective, more widely used and less costly than ours, and they may also be more successful than us in manufacturing and marketing their products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
if the FDA approves a competitor's 505(b)(2) application for a drug candidate before our application for a similar drug candidate and grants the competitor a period of exclusivity, the
FDA may take the position that it cannot approve our NDA for a similar drug candidate. For example, we believe that several competitors are developing extended-release oxycodone products, and if the
FDA approves a competitor's 505(b)(2) application for an extended-release oxycodone product and grants exclusivity before our NDA for Xtampza is filed and approved, we could be subject to a delay that
would dramatically reduce the expected market penetration for Xtampza. Additionally, even if our 505(b)(2) application for Xtampza is approved first, we may still be subject to competition from other
oxycodone products, including approved products or other approved 505(b)(2) NDAs for different conditions of use that would not be restricted by any grant of exclusivity to us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, competitors have developed or are in the process of developing technologies that are, or in the future may be, the basis for competitive products. Some of these products may have an
entirely different approach or means of accomplishing similar therapeutic effects than our product candidates. Our competitors may develop products that are safer, more effective or less costly than
our product candidates and, therefore, present a serious competitive threat to our product offerings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
widespread acceptance of currently available therapies with which our product candidates will compete may limit market acceptance of our product candidates even if commercialized. Oral medication,
transdermal drug delivery systems, such as drug patches, injectable products and implantable drug delivery devices are currently available treatments for chronic pain, are widely accepted in the
medical community and have a long history of use. These treatments will compete with our product candidates, if approved, and the established use of these competitive products may limit the potential
for our product candidates to receive widespread acceptance if commercialized. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=46,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=96216,FOLIO='42',FILE='DISK114:[15ZAD1.15ZAD72301]DI72301A.;44',USER='DPERRY',CD='24-APR-2015;17:55' -->
<A NAME="page_di72301_1_43"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The use of legal and regulatory strategies by competitors with innovator products, including the
filing of citizen petitions, may delay or prevent the introduction or approval of our product candidates, increase our costs associated with the introduction or marketing of our products, or
significantly reduce the profit potential of our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Companies with innovator drugs often pursue strategies that may serve to prevent or delay competition from alternatives to their innovator products.
These strategies include, but are not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> filing "citizen petitions" with the FDA that may delay competition by causing
delays of our product approvals; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seeking to establish regulatory and legal obstacles that would make it more
difficult to demonstrate a product's bioequivalence or "sameness" to the related innovator product; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> filing suits for patent infringement, like the Purdue litigation,
that
automatically delay FDA approval of products seeking approval based on the Section&nbsp;505(b)(2) pathway; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  obtaining extensions of market exclusivity by conducting
clinical trials of
innovator drugs in pediatric populations or by other methods; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  persuading the FDA to withdraw the approval of innovator drugs for which the
patents are about to expire, thus allowing the innovator company to develop and launch new patented products serving as substitutes for the withdrawn products; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seeking
to obtain new patents on drugs for which patent protection is about to
expire; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  initiating legislative and administrative efforts in various states to limit
the substitution of innovator products by pharmacies. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>These
strategies could delay, reduce or eliminate our entry into the market and our ability to generate revenues associated with our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our future success depends on our ability to retain our key personnel.  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We are highly dependent upon the services of our key personnel, including our President and Chief Executive Officer, Michael T. Heffernan, and our
Vice President, Product Development and one of the inventors of the DETERx technology, Dr.&nbsp;Alison B. Fleming. Each employee is employed by us at will and is permitted to terminate his or her
employment with us at any time. We anticipate entering into new employment agreements with Mr.&nbsp;Heffernan and Dr.&nbsp;Fleming following the consummation of this offering, but we expect that
Mr.&nbsp;Heffernan and Dr.&nbsp;Fleming will continue to be employed at will. We do not maintain "key person" insurance for any of our executives or other employees. The loss of the services of
Mr.&nbsp;Heffernan or Dr.&nbsp;Fleming could impede the achievement of our research, development and commercialization objectives.

 </FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to attract and retain highly qualified scientific and technical employees, we may
not be able to grow effectively.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our future growth and success depend on our ability to recruit, retain, manage and motivate our scientific and technical employees. The loss of any
member of our senior management team or the inability to hire or retain experienced management personnel could compromise our ability to execute our business plan and harm our operating results.
Because of the specialized scientific nature of our business, we rely heavily on our ability to attract and retain qualified scientific and technical personnel. The competition for qualified personnel
in the pharmaceutical field is intense, and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable
replacement personnel. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=47,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=815173,FOLIO='43',FILE='DISK114:[15ZAD1.15ZAD72301]DI72301A.;44',USER='DPERRY',CD='24-APR-2015;17:55' -->
<A NAME="page_di72301_1_44"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need to grow the size of our organization, and we may experience difficulties in managing
this growth.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of April&nbsp;2, 2015, we had 24 full-time employees. As our development and commercialization strategies develop, we will need additional
managerial, operational, sales, marketing, financial and other resources. Our management, personnel and systems currently in place may not be adequate to support this future growth. We may not be able
to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and
reduced productivity among remaining employees. Future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our
existing or future product candidates. Future growth would impose significant added responsibilities on members of management, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  managing the commercialization of any FDA-approved product candidates; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  overseeing our ongoing
clinical trials effectively; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  identifying, recruiting, maintaining, motivating and integrating additional
employees, including any sales and marketing personnel engaged in connection with the commercialization of any approved product; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  managing our internal development
efforts effectively while complying with our
contractual obligations to licensors, licensees, contractors and other third parties; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  improving our managerial, development, operational and finance systems and
procedures; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  developing our compliance infrastructure and processes to ensure compliance
with regulations applicable to public companies; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  expanding our facilities. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>As
our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to
commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development
efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our
failure to accomplish any of them could prevent us from successfully growing our company. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may acquire other assets or businesses, or form collaborations or make investments in other
companies or technologies, that could have a material adverse effect on our operating results, dilute our shareholders' ownership, increase our debt or cause us to incur significant expense.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As part of our business strategy, we may pursue acquisitions of assets, including preclinical, clinical or commercial stage products or product
candidates, businesses or strategic alliances and collaborations, to expand our existing technologies and operations. We may not identify or complete these transactions in a timely manner, on a
cost-effective basis, or at all, and we may not realize the anticipated benefits of any such transaction, any of which could have a material adverse effect on our financial condition, results of
operations and cash flows. We have no experience with acquiring other companies, products or product candidates, and limited experience with forming strategic alliances and collaborations. We may not
be able to find suitable acquisition candidates, and if we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business and we may incur additional
debt or assume unknown or contingent liabilities in connection therewith. Integration of an acquired company or assets may also disrupt ongoing operations, require the hiring of additional personnel
and the implementation of additional internal systems and infrastructure, especially the acquisition of commercial assets, and require management resources that would otherwise focus on developing our
existing business. We may not be able to find suitable strategic alliance or collaborators or identify other investment opportunities, and we may experience losses related to any such investments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
finance any acquisitions or collaborations, we may choose to issue debt or shares of our common stock as consideration. Any such issuance of shares would dilute the ownership of our shareholders.
If the price </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=48,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=742020,FOLIO='44',FILE='DISK114:[15ZAD1.15ZAD72301]DI72301A.;44',USER='DPERRY',CD='24-APR-2015;17:55' -->
<A NAME="page_di72301_1_45"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>of
our common stock is low or volatile, we may not be able to acquire other assets or companies or fund a transaction using our stock as consideration. Alternatively, it may be necessary for us to
raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees, independent contractors, principal investigators, CROs, consultants and vendors may
engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in
fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that
violates:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA, DEA or similar regulations of foreign regulatory authorities, including
those laws requiring the reporting of true, complete and accurate information to such authorities; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  manufacturing standards; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS"
SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> federal and state healthcare fraud and abuse laws and regulations and similar
laws and regulations established and enforced by foreign regulatory authorities; or </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> laws that require the reporting of financial information or data accurately.
</FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive
practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to
our reputation. We have adopted a Code of Ethics, which will be effective as of the closing of this offering, but it is not always possible to identify and deter misconduct by employees and other
third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in
defending ourselves or asserting our rights, those actions could
have a material adverse effect on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from
participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of
which could have a material adverse effect on our ability to operate our business and our results of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and
abuse, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages,
reputational harm, administrative burdens, and diminished profits and future earnings.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we may
obtain marketing approval. Our future arrangements with payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the
business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval. Even though we do not and will not
control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and
patients' rights are and will be applicable to our business. Restrictions under applicable federal, state </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=49,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=423416,FOLIO='45',FILE='DISK114:[15ZAD1.15ZAD72301]DI72301A.;44',USER='DPERRY',CD='24-APR-2015;17:55' -->
<A NAME="page_di72301_1_46"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
foreign healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal Anti-Kickback Statute, which prohibits, among other things,
knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the
purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal False Claims Act, which imposes criminal and
civil penalties,
including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are
false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items
and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal
Health Insurance Portability and Accountability Act of 1996, or
HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal
Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a
violation; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act of 2009, or HITECH, and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as
their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to
safeguarding the privacy, security and transmission of individually identifiable health information; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> federal laws requiring drug manufacturers to report information
related to
payments and other transfers of value made to physicians and other healthcare providers, as well as ownership or investment interests held by physicians and their immediate family members, including
under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> state and
foreign equivalents of each of the above laws, including state
anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private
insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances,
many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that
governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws
and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of
our operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=50,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=875375,FOLIO='46',FILE='DISK114:[15ZAD1.15ZAD72301]DI72301A.;44',USER='DPERRY',CD='24-APR-2015;17:55' -->
<A NAME="page_di72301_1_47"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to comply with environmental, health and safety laws and regulations, we could become
subject to fines or penalties or incur significant costs.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with our research and development activities and our manufacture of materials and product candidates, we are subject to federal, state
and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens
and wastes. Although we believe that we have complied with the applicable laws, regulations and policies in all material respects and have not been required to correct any material noncompliance, we
may be required to incur significant costs to comply with environmental and health and safety regulations in the future. Current or future laws and regulations may impair our research, development or
production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
research and development involves the use, generation and disposal of hazardous materials, including chemicals, solvents, agents and biohazardous materials. Although we believe that our safety
procedures for storing, handling and disposing of such materials comply with the standards prescribed by state and federal regulations, we cannot completely eliminate the risk of accidental
contamination or injury from these materials. We currently contract with third parties to dispose of these substances that we generate, and we rely on these third parties to properly dispose of these
substances in compliance with applicable laws and regulations. We cannot eliminate the risk of contamination or injury from these materials. If these third parties do not properly dispose of these
substances in compliance with applicable laws and regulations, we may be subject to legal action by governmental agencies or private parties for improper disposal of these substances. The costs of
defending such actions and the potential liability resulting from such actions are often very large. In the event we are subject to such legal action or we otherwise fail to comply with applicable
laws and regulations governing the use, generation and disposal of hazardous materials and chemicals, we could be held liable for any damages that result, and any such liability could exceed our
resources. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
we maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may
not provide adequate coverage against potential liabilities. We maintain insurance for environmental liability or toxic tort claims, but we may not continue to maintain such insurance in the future,
and such insurance, to the extent maintained, may not be adequate to cover liabilities that may be asserted against us in connection with our storage or disposal of biological, hazardous or
radioactive materials. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business and operations would suffer in the event of computer system failures, accidents or
security breaches.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite the implementation of security measures, our internal computer systems, and those of our CROs, contract manufacturing organization, or CMO,
and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System
failures, accidents or security breaches could cause interruptions in our operations, and could result in a material disruption of our clinical activities and business operations, in addition to
possibly requiring substantial expenditures of resources to remedy. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug
development programs. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of
confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=51,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=991650,FOLIO='47',FILE='DISK114:[15ZAD1.15ZAD72301]DI72301A.;44',USER='DPERRY',CD='24-APR-2015;17:55' -->
<A NAME="page_di72301_1_48"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to this Offering and Ownership of Our Common Stock  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


There is no existing market for our common stock, and we do not know if one will develop. Even if a
market does develop, the stock prices in the market may not exceed the offering price.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering there has been no market for shares of our common stock. An active trading market for our shares may never develop or be
sustained following this offering. The initial public offering price for our common stock was determined through negotiations with the underwriters, and the negotiated price may not be indicative of
the market price of our common stock after this offering. The market value of our common stock may decrease from the initial public offering price. As a result of these and other factors, you may be
unable to resell your shares of our common stock at or above the initial public offering price. The lack of an active market may impair your ability to sell your shares at the time you wish to sell
them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Further, an inactive market may also impair our ability to raise
capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration.
The market price of our stock may be volatile, and you could lose all or part of your investment. The lack of an active market also may reduce the fair market value of your shares. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock may be volatile and you may lose all or part of your investment.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The market price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to
various factors, some of which are beyond our control. In addition to the factors discussed in this "Risk Factors" section and elsewhere in this prospectus, these factors
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of competitive products or technologies; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory actions with respect to our
product candidates or our competitors'
products or product candidates; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated changes in our growth rate relative to our competitors; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS"
SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome of any patent infringement or other litigation that may be brought
against us, including the ongoing Purdue litigation; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  announcements by us or our competitors of significant acquisitions, strategic
collaborations, joint ventures, collaborations or capital commitments; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> results of clinical trials of our product candidates or those of our
competitors; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory or legal developments in the United States and other countries; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT
SIZE=2>  developments or disputes concerning patent applications, issued patents or
other proprietary rights; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the recruitment or departure of key personnel; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the level of
expenses related to any of our product candidates or clinical
development programs; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated variations in our quarterly operating results; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT
SIZE=2> the number and characteristics of our efforts to in-license or acquire
additional product candidates or products; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  introduction of new products or services by us or our competitors; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS"
SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to meet the estimates and projections of the investment community or
that we may otherwise provide to the public; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated changes in estimates as to financial results, development
timelines or recommendations by securities analysts; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  variations in our financial results or those of companies that are perceived to
be similar to us; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  fluctuations in the valuation of companies perceived by investors to be
comparable to us; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> share price and volume fluctuations attributable to inconsistent trading volume
levels of our shares; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  announcement or expectation of additional financing efforts; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>
sales of our common stock by us, our insiders or our other shareholders; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in accounting practices; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS"
SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  significant lawsuits, including patent or shareholder litigation; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in the structure of healthcare payment systems;
 </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=52,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=312519,FOLIO='48',FILE='DISK114:[15ZAD1.15ZAD72301]DI72301A.;44',USER='DPERRY',CD='24-APR-2015;17:55' -->
<A NAME="page_di72301_1_49"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> market conditions in the pharmaceutical and biotechnology sectors; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> general economic, industry and
market conditions; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  publication of research reports about us, our competitors or our industry, or
positive or negative recommendations or withdrawal of research coverage by securities or industry analysts; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> other events or factors, many of which are beyond our
control. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. The realization of any of the above risks or any of a broad range of other risks stated above could have a material adverse effect on the market price of our common stock. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
we operate in the pharmaceutical and biotechnology industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products. In the past, securities class
action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's
attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a substantial number of shares of our common stock in the public market could cause our
stock price to fall.  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market
that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have outstanding 19,707,935 shares of common stock
based on the number of shares outstanding as of April 2, 2015. This includes the shares that we are selling in this offering, which may be resold in the public market immediately without restriction,
unless purchased by our affiliates. The remaining shares will be restricted as a result of securities laws or lock-up agreements but will be able to be sold after the offering as described in the
"Shares Eligible for Future Sale" section of this prospectus. Moreover, after this offering, holders of an aggregate of 12,787,524&nbsp;shares of our common stock will have rights, subject to
certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other shareholders. We
also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance,
subject to volume limitations applicable to affiliates and the lock-up agreements described in the "Underwriting" section of this prospectus.

 </FONT>

</P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Future issuances of our common stock or rights to purchase common stock, including pursuant to our
equity incentive plans, could result in additional dilution of the percentage ownership of our shareholders and could cause our stock price to fall.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell
substantial amounts of common stock or securities convertible into or exchangeable for common stock. These future issuances of common stock or common stock-related securities, together with the
exercise of outstanding options and any additional shares issued in connection with acquisitions, if any, may result in material dilution to our investors. Such sales may also result in material
dilution to our existing shareholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock, including shares of common stock sold in this
offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have broad discretion in the use of the net proceeds from this offering and may not use them
effectively.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We will have broad discretion in the application of the net proceeds from this offering, and you will be relying on the judgment of our management
regarding the application of these proceeds. Our management </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=53,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=733992,FOLIO='49',FILE='DISK114:[15ZAD1.15ZAD72301]DI72301A.;44',USER='DPERRY',CD='24-APR-2015;17:55' -->
<A NAME="page_di72301_1_50"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>may
not apply the net proceeds of this offering in ways that ultimately increase the value of your investment. We expect to use the net proceeds from this offering in the manner described in the "Use
of Proceeds" section of this prospectus. Our failure to apply these net proceeds effectively could result in financial losses that could have a material adverse effect on our business, cause the price
of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade,
interest-bearing securities. These investments may not yield a favorable return to our shareholders. If we do not invest or apply the net proceeds from this offering in ways that enhance shareholder
value, we may fail to achieve expected financial results, which could cause the price of our common stock to decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our principal shareholders and management own substantially all of our stock prior to this offering
and will continue to be able to exert significant control over matters subject to shareholder approval after the offering.  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>As of April&nbsp;2, 2015, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially
owned approximately 82% of our voting stock, including shares subject to outstanding options and warrants, and, upon the closing of this offering, we expect that same group will continue to hold
approximately 58% of our outstanding voting stock. As a result, these shareholders, acting together, would be able to significantly influence the outcome of all matters requiring shareholder approval,
including the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage
unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest. The interests of this group of shareholders may not always coincide with your interests or
the interests of other shareholders and they may act in a manner that advances their best interests and not necessarily those of other shareholders, including seeking a premium value for their common
stock, and might affect the prevailing market price for our common stock. Such concentration of ownership control may:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delay, defer or prevent a change in control; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  entrench our management and/or the board of
directors; or </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> impede a merger, consolidation, takeover or other business combination involving
us that other shareholders may desire. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>


Certain of our existing stockholders, or their affiliates, have indicated an interest in purchasing up to an aggregate of approximately $30.0&nbsp;million of shares of our common stock in this
offering at the initial public offering price. The previously discussed ownership percentage upon completion of this offering does not reflect the potential purchase of any shares in this offering by
such investors. If these investors purchase an aggregate of $30.0&nbsp;million of shares of our common stock in this offering at $13.00 per share (the midpoint of the price range set forth on the
cover page of this prospectus), upon completion of this offering, our executive officers, directors, 5% stockholders and their affiliates will hold approximately 70% of our outstanding voting stock
(assuming no exercise of the underwriters' option to purchase additional shares).

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, persons associated with Longitude Capital Partners,&nbsp;LLC, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P., and TPG Biotechnology Partners IV,&nbsp;L.P.
currently serve on our board of directors. Following this offering, the interests of Longitude Capital Partners,&nbsp;LLC, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare
VI,&nbsp;L.P., and TPG Biotechnology Partners IV,&nbsp;L.P. may not always coincide with the interests of the other shareholders, and the concentration of control in Longitude Capital
Partners,&nbsp;LLC, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P., and TPG Biotechnology Partners IV,&nbsp;L.P. will limit other shareholders' ability to influence
corporate matters. We may also take actions that our other shareholders do not view as beneficial, which may adversely affect our results of operations and financial condition and cause the value of
your investment to decline. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=54,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=467348,FOLIO='50',FILE='DISK114:[15ZAD1.15ZAD72301]DI72301A.;44',USER='DPERRY',CD='24-APR-2015;17:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dk72301_1_51"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are subject to anti-takeover provisions in our amended and restated articles of incorporation and
amended and restated bylaws and under Virginia law that could delay or prevent an acquisition of the Company, even if the acquisition would be beneficial to our shareholders.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain provisions of Virginia law, the state in which we are incorporated, and our amended and restated articles of incorporation and amended and
restated bylaws could hamper a third party's acquisition of us, or discourage a third party from attempting to acquire control of us. These provisions include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision allowing our board of directors to set the terms of and issue
preferred stock with rights senior to those of the common stock without any vote or action by the holders of our common stock. The issuance of preferred stock could adversely affect the rights and
powers, including voting rights, of the holders of common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advance written notice procedures and notice requirements with respect to
shareholder proposals and shareholder nomination of candidates for election as directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision that only the board of directors, the chairman of the board of
directors or the president may call a special meeting of the shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the application of Virginia law prohibiting us from entering into certain
transactions with the beneficial owner of more than 10&nbsp;percent of our outstanding voting stock for a period of three years after such person first reached that level of stock ownership, unless
certain conditions are met; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision dividing our board of directors into three classes, each serving
three-year terms; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the requirement that the authorized number of our directors be changed only by
resolution of our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision that our board of directors shall fill any vacancies on our board of
directors, including vacancies resulting from a board of directors resolution to increase the number of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  limitations on the manner in which shareholders can remove directors from the
board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of cumulative voting in the election of directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the prohibition on shareholders acting by less-than-unanimous written consent. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>These
provisions also could limit the price that certain investors might be willing to pay in the future for shares of our common stock. In addition, these provisions make it more difficult for our
shareholders, should they choose to do so, to remove our board of directors or management or elect new directors to our board of directors. See "Description of Capital Stock." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may fail to qualify for continued listing on NASDAQ which could make it more difficult for
investors to sell their shares.  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We expect to receive approval to list our common stock on The NASDAQ Global Market. If approved, we will need to satisfy the continued listing
requirements of NASDAQ for inclusion in the Global Market to maintain such listing, including, among other things, the maintenance of a minimum bid price of $1.00 per share and shareholders' equity of
at least $10.0&nbsp;million. There can be no assurance that we will be able to maintain compliance with the continued listing requirements or that our common stock will not be delisted from NASDAQ
in the future. If our common stock is delisted by NASDAQ, we could face significant material adverse consequences, including:</FONT>


</P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a limited availability of market quotations for our securities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reduced liquidity with respect to our securities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a determination that our shares are a "penny stock," which will require brokers
trading in our shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a limited amount of news and analyst coverage for our company; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a decreased ability to issue additional securities or obtain additional
financing in the future. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=55,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=221939,FOLIO='51',FILE='DISK114:[15ZAD1.15ZAD72301]DK72301A.;27',USER='JTAM',CD='24-APR-2015;15:52' -->
<A NAME="page_dk72301_1_52"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities or industry analysts do not publish research or publish inaccurate or unfavorable
research about our business, our stock price and trading volume could decline.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our
business. We do not have any control over these analysts. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts
commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts
who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company
or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase our common stock in this offering, you will incur immediate and substantial dilution
in the book value of your shares.  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>The initial public offering price is substantially higher than the net tangible book value per share of our common stock. Investors purchasing common
stock in this offering will pay a price per share that substantially exceeds the book value of our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock in
this offering will incur immediate dilution of $7.57 per share, based on an assumed initial public offering price of $13.00 per share, which is the midpoint of the price range set forth on the cover
of this prospectus. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in
the event of our liquidation. Further, investors purchasing common stock in this offering will contribute approximately 40% of the total amount invested by shareholders since our inception, but will
own, as a result of such investment, only approximately 29% of the shares of common stock outstanding immediately following giving effect to this offering. Furthermore, if the underwriters exercise
their option to purchase additional shares or our previously issued options and warrants to acquire common stock at prices below the assumed initial public offering price are exercised, you will
experience further dilution. For a further description of the dilution that you will incur as a result of purchasing shares in this offering, see "Dilution."

 </FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable
future, capital appreciation, if any, will be your sole source of gain.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the
growth and development of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us
from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an "emerging growth company" and we intend to take advantage of reduced disclosure and
governance requirements applicable to emerging growth companies, which could result in our common stock being less attractive to investors and we cannot be certain if the reduced reporting
requirements applicable to emerging growth companies will make our shares of common stock less attractive to investors.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an "emerging growth company," as defined in the JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting
requirements applicable to other public companies, but not to emerging growth companies, including, but not limited to, an exemption from the auditor attestation requirement of Section&nbsp;404 of
the Sarbanes-Oxley Act, reduced disclosure about executive compensation arrangements pursuant to the rules applicable to smaller reporting companies and no requirement to seek non-binding advisory
votes on executive compensation or golden parachute arrangements. We will remain an emerging growth company until the earliest of (i)&nbsp;the end of the fiscal year following the fifth anniversary
of the completion of this offering, (ii)&nbsp;the first fiscal year after our annual gross revenue are $1.0&nbsp;billion or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=56,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=735729,FOLIO='52',FILE='DISK114:[15ZAD1.15ZAD72301]DK72301A.;27',USER='JTAM',CD='24-APR-2015;15:52' -->
<A NAME="page_dk72301_1_53"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>more,
(iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion in non-convertible debt securities or (iv)&nbsp;the end of any fiscal year
in which the market value of our common stock held by non-affiliates exceeded $700&nbsp;million as of the end of the second quarter of that fiscal year. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the
Securities Act for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. However, we are choosing to "opt out" of such extended transition period and, as a result, we will comply with new or revised accounting standards on the relevant dates on
which adoption of such standards is required for non-emerging growth companies. Section&nbsp;107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying
with new or revised accounting standards is irrevocable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot predict if investors will find our common stock less attractive as a result of our taking advantage of these exemptions. If some investors find our common stock less attractive as a result
of our choices, there may be a less active trading market for our common stock and our stock price may be more volatile. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
investors find our common stock less attractive as a result of our reduced reporting requirements, there may be a less active trading market for our common stock and our stock price may be more
volatile. We may also be unable to raise additional capital as and when we need it. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to maintain an effective system of internal control over financial reporting, we may not
be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting. Commencing with our annual
report on Form&nbsp;10-K for the year ending December&nbsp;31, 2016, we will be required, under Section&nbsp;404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other
things, the effectiveness of our internal control over financial reporting. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal
control over financial reporting. A material weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting that results in more than a
reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section&nbsp;404 of the Sarbanes-Oxley Act also
generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, for as long as we remain an
emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not
emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
compliance with Section&nbsp;404 will require that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group, and we
will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge, and compile the system and process documentation necessary to
perform the evaluation needed to comply with Section&nbsp;404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion, which could potentially
subject us to sanctions or investigations by the Securities and Exchange Commission, or the SEC, or other regulatory authorities. During the evaluation and testing process, if we identify one or more
material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will
not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely
inhibit our ability to accurately report our financial condition, results of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=57,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=413343,FOLIO='53',FILE='DISK114:[15ZAD1.15ZAD72301]DK72301A.;27',USER='JTAM',CD='24-APR-2015;15:52' -->
<A NAME="page_dk72301_1_54"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>operations
or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a
material weakness or significant deficiency in our internal control over financial reporting once that firm begin its reviews, we could lose investor confidence in the accuracy and completeness of our
financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by NASDAQ, the SEC or other regulatory authorities. Failure to remedy any
material weakness in our internal control over financial
reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to successfully remediate the existing material weaknesses in our internal control
over financial reporting, the accuracy and timing of our financial reporting may be adversely affected.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our management team is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally
accepted accounting principles in the United States, or GAAP, and SEC rules and regulations. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the course of preparing our December&nbsp;31, 2014 financial statements, our management team determined that we had the following material weaknesses in our internal control over financial
reporting:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Adequate controls are not in place to appropriately segregate duties in areas
such as journal entries, cash disbursements, and the calculation, processing and recording of employee compensation and related accounts. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our controls and procedures over the accounting for and reporting of complex
accounting matters were not effectively designed due to a failure to design and implement appropriate policies and procedures to ensure that the accounting and valuation of complex debt and equity
transactions, income taxes and certain other matters is in accordance with GAAP. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our controls were not effectively implemented in the financial statement close
process to ensure that proper cut-off of accrued expenses was achieved at interim periods. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
material weaknesses in our internal control over financial reporting were attributable to our lack of sufficient financial reporting and accounting personnel with appropriate training in GAAP and
SEC rules and regulations. In response to these material weaknesses, we have hired, and plan to continue to hire, additional personnel with public company financial reporting expertise to build our
financial management and reporting infrastructure, and further develop and document our accounting policies and financial reporting procedures. However, we cannot assure you that we will be successful
in pursuing these measures or that these measures will significantly improve or remediate the material weaknesses described above. We also cannot assure you that we have identified all of our existing
material weaknesses, or that we will not in the future have additional material weaknesses. We have not yet remediated our material weaknesses, and the remediation measures that we intend to implement
may be insufficient to address our existing material weaknesses or to identify or prevent additional material weaknesses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
we nor our independent registered public accounting firm has performed an evaluation of our internal control over financial reporting during any period in accordance with the provisions of the
Sarbanes-Oxley Act. In light of the control deficiencies and the resulting material weaknesses that were identified as a result of the limited procedures performed, we believe that it is possible
that, had we and our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act,
additional material weaknesses and significant control deficiencies may have been identified. However, for as long as we remain an "emerging growth company" as defined in the JOBS Act, we intend to
take advantage of the exemption permitting us </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=58,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=834178,FOLIO='54',FILE='DISK114:[15ZAD1.15ZAD72301]DK72301A.;27',USER='JTAM',CD='24-APR-2015;15:52' -->
<A NAME="page_dk72301_1_55"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>not
to comply with the requirement that our independent registered public accounting firm provide an attestation on the effectiveness of our internal control over financial reporting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we fail to remediate the material weaknesses or to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to
accurately report our financial results, or report them within the timeframes required by law or stock exchange regulations. Failure to comply with Section&nbsp;404 of the Sarbanes-Oxley Act could
also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. There is no assurance that we will be able to remediate these material weaknesses in a timely
manner, or at all, or that in the future, additional material weaknesses will not exist or otherwise be discovered. If our efforts to remediate these material weaknesses identified are not successful,
or if other material weaknesses or other deficiencies occur, our ability to accurately and timely report our financial position could be impaired, which could result in late filings of our annual and
quarterly reports under the Exchange Act, restatements of our financial statements, a decline in our stock price, suspension or delisting of our common stock from NASDAQ, and could have a material
adverse effect on our reputation, results of operations and financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon consummation of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and
procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management,
recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived
and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
inherent limitations reflect the reality that judgments can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the
individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will incur increased costs as a result of operating as a public company, and our management will
be required to devote substantial time to new compliance initiatives.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to the consummation of this offering, we have not been subject to public company reporting obligations. We will incur increased legal,
accounting, administrative and other costs and expenses as a public company. Compliance with the Sarbanes-Oxley Act, the Dodd-Frank Act of 2010, the Exchange Act, as well as rules of the SEC and
NASDAQ, for example, will result in significant initial costs to us as well as ongoing increases in our legal, audit and financial compliance costs, particularly after we are no longer an "emerging
growth company." Any changes that we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. The Exchange
Act, requires, among other things, that we file annual, quarterly and current reports with respect to our business and financial condition. Our board of directors, management and other personnel need
to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability
insurance, and require us to incur substantial costs to maintain the same or similar coverage. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
estimate that we will incur approximately $2.0&nbsp;million in incremental costs per year associated with being a publicly traded company, although it is possible that our actual incremental
costs will be higher than we currently estimate. The increased costs will increase our net loss. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these
requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive
officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=59,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=67594,FOLIO='55',FILE='DISK114:[15ZAD1.15ZAD72301]DK72301A.;27',USER='JTAM',CD='24-APR-2015;15:52' -->
<A NAME="page_dk72301_1_56"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dk72301_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_dk72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus includes forward-looking statements. The forward-looking statements are contained principally in the sections entitled "Prospectus
Summary," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business." These statements relate to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain and maintain regulatory approval of our product
candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our plans to commercialize our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the size and growth potential of the markets for our product candidates, and our
ability to service those markets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to develop sales and marketing capabilities, whether alone or with
potential future collaborators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the rate and degree of market acceptance of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome of any patent infringement or other litigation that may be brought
against us, including the ongoing Purdue litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to attract collaborators with development, regulatory and
commercialization expertise; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success, cost and timing of our product development activities, studies and
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain funding for our operations beyond this offering; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory developments in the United States and foreign countries; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to operate our business without infringing the intellectual property
rights of others; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the performance of our third-party suppliers and manufacturers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of competing products that are or become available; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the loss of key scientific or management personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations regarding the period during which we qualify as an emerging
growth company under the JOBS Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our use of proceeds from this offering; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the accuracy of our estimates regarding expenses, future revenue, capital
requirements and need for additional financing; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations regarding our ability to obtain and adequately maintain
sufficient intellectual property protection for our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will,"
"would" or the negative of those terms, and similar expressions. These forward-looking statements reflect our management's beliefs and views with respect to future events and are based on estimates
and assumptions as of the date of this prospectus and are subject to risks and uncertainties. We discuss many of these risks in greater detail under the heading "Risk Factors." Moreover, we operate in
a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these
uncertainties, you should not place undue reliance on these forward-looking statements. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act do not protect
any forward-looking statements that we make in connection with this offering. Any forward-looking statements that we make in this prospectus speak only as of the date of such </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=60,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=118381,FOLIO='56',FILE='DISK114:[15ZAD1.15ZAD72301]DK72301A.;27',USER='JTAM',CD='24-APR-2015;15:52' -->
<A NAME="page_dk72301_1_57"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>statement,
and we undertake no obligation to update such statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events.
Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as
historical data. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with
the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Except
as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=61,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=274835,FOLIO='57',FILE='DISK114:[15ZAD1.15ZAD72301]DK72301A.;27',USER='JTAM',CD='24-APR-2015;15:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dm72301_1_58"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dm72301_use_of_proceeds"> </A>
<A NAME="toc_dm72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $67.5&nbsp;million (or
$78.0&nbsp;million if the underwriters exercise their option to purchase additional shares from us in full), based on the assumed initial public offering price of $13.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each
$1.00 increase (decrease) in the assumed initial public offering price of $13.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase
(decrease) our net proceeds, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated
underwriting discounts and commissions and offering expenses, by approximately $5.4&nbsp;million.

</FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>We
intend to use the net proceeds of this offering as follows:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  approximately $45.0&nbsp;million for the development of our commercial
infrastructure to launch Xtampza, including building our sales, marketing and reimbursement functions. If Xtampza is approved in the United States, we plan to hire a team of approximately 100 sales
representatives for the initial launch. In addition, we expect to deploy a smaller sales force to detail Xtampza to nursing homes, hospices and other institutions; </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  approximately $15.0&nbsp;million to fund research and development efforts of
our other product candidates, including approximately $12.0&nbsp;million to conduct clinical development for our second product candidate through its Phase 3 clinical trial (including Phase 1
bioequivalence clinical trials and abuse-deterrence studies and clinical trials); and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the remainder, if any, to fund working capital and general corporate purposes,
which may include litigation expenses (including expenses relating to the Purdue litigation) and the acquisition or licensing of product candidates, technologies, compounds, other assets or
complementary businesses. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business
conditions evolve. The amounts and timing of our actual expenditures depend on numerous factors, including regulatory approval of Xtampza and the progress of our preclinical and clinical development
efforts with respect to our other product candidates. As a result, our management will have broad discretion in applying the net proceeds from this offering. Although we may use a portion of the net
proceeds from this offering for the acquisition or licensing, as the case may be, of product candidates, technologies, compounds, other assets or complementary businesses, we have no current
understandings, agreements or commitments to do so. Pending these uses, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations,
investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Although it is difficult to predict future liquidity requirements, we believe that the net proceeds from this offering, together with our existing cash resources, will be sufficient to enable us to
fund our operations into mid-2017, including the commercialization of Xtampza, if approved, and the continuation of our development of our other product candidates. We have based this estimate on
assumptions, including with respect to the Purdue litigation, that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=62,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=263927,FOLIO='58',FILE='DISK114:[15ZAD1.15ZAD72301]DM72301A.;55',USER='NDEWIND',CD='24-APR-2015;15:34' -->
<A NAME="page_dm72301_1_59"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dm72301_dividend_policy"> </A>
<A NAME="toc_dm72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to
support our operations and finance the growth and development of our business and do not intend to declare or pay any cash dividends in the foreseeable future. As a result, you will likely need to
sell your shares of common stock to realize a return on your investment, and you may not be able to sell your shares at or above the price you paid for them. Payment of cash dividends, if any, in the
future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital
requirements, business prospects and other factors our board of directors may deem relevant. See "Risk Factors&nbsp;&#151; Because we do not anticipate paying any cash dividends on our
capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=2,SEQ=63,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=931076,FOLIO='59',FILE='DISK114:[15ZAD1.15ZAD72301]DM72301A.;55',USER='NDEWIND',CD='24-APR-2015;15:34' -->
<A NAME="page_dm72301_1_60"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dm72301_capitalization"> </A>
<A NAME="toc_dm72301_3"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth our cash and cash equivalents and our capitalization as of December&nbsp;31, 2014
on:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an actual basis; </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a pro forma basis, giving effect to the following: our issuance and sale of
41,666,667 shares of our Series&nbsp;D convertible preferred stock in March 2015 at a price per share of $1.20 for aggregate consideration of $50.0&nbsp;million, comprised of $45.0&nbsp;million
in cash and $5.0&nbsp;million from conversion of convertible notes with related parties; and the conversion of all our outstanding convertible preferred stock into an aggregate of 12,591,456 shares
of our common stock (which includes 41,666,667 shares of our Series&nbsp;D convertible preferred stock issued in March 2015) upon the closing of this offering. </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a pro forma as adjusted basis, giving further effect to the sale by us of
5,800,000 shares of our common stock in this offering at an assumed initial public offering price of $13.00 per share (the midpoint of the price range set forth on the cover page of this prospectus),
after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.


</FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
pro forma and pro forma as adjusted information below is illustrative only, and our capitalization following the closing of this offering will be adjusted based on the actual initial public
offering price and other terms of this offering determined at pricing. You should read this table together with our financial statements and the related notes appearing at the end of this prospectus,
the sections entitled "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other financial information appearing elsewhere in this
prospectus. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Actual </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma<BR>
as&nbsp;Adjusted </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and<BR>
per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,634</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>46,634</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>114,156</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term debt, net of discount</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
6,914</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
6,914</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
6,914</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock, $0.001 par value; 18,498,419 shares authorized; 9,232,334 issued and outstanding, actual; no shares issued and
outstanding pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,781</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible preferred stock, $0.001 par value; 27,324,237 shares authorized; 27,324,237 issued and outstanding, actual; no shares issued and
outstanding pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>51,212</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C convertible preferred stock, $0.001 par value; 8,658,344 shares authorized; 8,658,008 issued and outstanding, actual; no shares issued and
outstanding pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13,114</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series D convertible preferred stock, $0.001 par value, no shares authorized; none issued and outstanding, actual; no shares issued and outstanding pro
forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value; 72,000,000 shares authorized; 1,006,219 issued and outstanding, actual; 13,907,935 issued and outstanding, pro forma; and
19,707,935 issued and outstanding, pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,407</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>139,501</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>207,017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(101,753</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(101,753</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(101,753</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Treasury stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shareholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(89,348</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>37,759</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>105,281</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(12,241</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>37,759</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>105,281</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=64,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=893010,FOLIO='60',FILE='DISK114:[15ZAD1.15ZAD72301]DM72301A.;55',USER='NDEWIND',CD='24-APR-2015;15:34' -->
<A NAME="page_dm72301_1_61"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


The number of shares of our common stock to be outstanding after this offering is based on 1,316,479 shares of common stock outstanding as of April&nbsp;2, 2015 and
assumes:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issuance by us of 5,800,000 shares of our common stock in this offering; and </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the conversion of all of our convertible preferred stock outstanding immediately
prior to the closing of this offering into an aggregate of 12,591,456 shares of common stock (which includes 41,666,667 shares of Series&nbsp;D convertible preferred stock issued in March 2015),

 </FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>and
excludes:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  803,565 shares of common stock issuable upon the exercise of outstanding stock
options as of April&nbsp;2, 2015, at a weighted-average exercise price of $4.23 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 18,809 shares of common stock issuable upon the exercise of warrants to purchase
common stock as of April&nbsp;2, 2015, at a weighted-average exercise price of $1.91 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issuance by us of additional shares of common stock (which, based on an
assumed initial public offering price of $13.00 per share (the mid-point of the price range set forth on the cover page of this prospectus) will total approximately 61,000 shares), as payment of the
accrued dividend on the outstanding shares of Series&nbsp;D convertible preferred stock payable to the holders of Series&nbsp;D convertible preferred stock upon the closing of this offering; </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,751,803 shares of common stock reserved for future issuance under our Amended
and Restated 2014 Stock Incentive Plan upon the closing of this offering; and </FONT><FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  200,000 shares reserved for future issuance under our 2015 Employee Stock
Purchase Plan upon the closing of this offering.

</FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=65,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=713854,FOLIO='61',FILE='DISK114:[15ZAD1.15ZAD72301]DM72301A.;55',USER='NDEWIND',CD='24-APR-2015;15:34' -->
<A NAME="page_dm72301_1_62"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dm72301_dilution"> </A>
<A NAME="toc_dm72301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the
initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. Tangible book value per share represents
our total tangible assets, less total liabilities, divided by the number of shares of our common stock outstanding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Our historical net tangible book deficit as of December&nbsp;31, 2014 was $(89.3)&nbsp;million, or $(88.80) per share of outstanding common stock.


</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Our pro forma net tangible book value as of December&nbsp;31, 2014 was $37.8&nbsp;million, or $2.78 per share of outstanding common stock. Pro forma net tangible book deficit per share represents
pro forma net tangible book value divided by the pro forma number of shares of common stock outstanding, after giving effect to our issuance and sale in March 2015 of 41,666,667 shares of
Series&nbsp;D convertible preferred stock for aggregate consideration of $50.0&nbsp;million, comprised of $45.0&nbsp;million in cash and $5.0&nbsp;million from conversion of convertible notes
with related parties, and the conversion of all outstanding shares of our convertible preferred stock (including 41,666,667 shares of Series&nbsp;D convertible preferred stock issued in March 2015),
into an aggregate of 12,591,456 shares of common stock upon the closing of this offering.


</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Pro forma as adjusted net tangible book value is our pro forma net tangible book value, plus the effect of the sale of shares of our common stock in this offering at an assumed initial public offering
price of $13.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Our pro forma as adjusted net tangible book value as of December&nbsp;31, 2014 was $105.3&nbsp;million, or $5.43 per share. This amount represents an immediate
increase in pro forma as adjusted net tangible book value of $2.65 per share to our existing shareholders and an immediate dilution of $7.57 per share to new investors participating in this offering.
We determine dilution per share to new investors by subtracting pro forma as adjusted net tangible book value per share after this offering from the assumed initial public offering price per share
paid by new investors. The following table illustrates this dilution on a per share basis:


</FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Assumed initial public offering price per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13.00</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value (deficit) per share as of December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(88.80</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma increase in net tangible book value per share attributable to the conversion of all outstanding shares of our preferred stock immediately prior
to the closing of this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>91.58</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per share as of December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.78</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in pro forma net tangible book value per share attributable to investors participating in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.65</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma as adjusted net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5.43</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:9pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to investors purchasing in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
7.57</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>


A $1.00 increase (decrease) in the assumed initial public offering price of $13.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease)
the pro forma as adjusted net tangible book value per share after this offering by $0.28 per share and the dilution per share

</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=66,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=115973,FOLIO='62',FILE='DISK114:[15ZAD1.15ZAD72301]DM72301A.;55',USER='NDEWIND',CD='24-APR-2015;15:34' -->
<A NAME="page_dm72301_1_63"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


to new investors participating in this offering by $0.72 per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a one million share increase in the number of shares offered by us, as set
forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value per share after this offering by $0.32 and decrease the dilution per share to new investors
participating in this offering by $0.32, assuming the assumed initial public offering price of $13.00 per share (the midpoint of the price range set forth on the cover page of this
prospectus) remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. A one million share decrease in the number of
shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this offering by $0.36 and increase the
dilution per share to new investors participating in this offering by $0.36, assuming the assumed initial public offering price of $13.00 per share (the midpoint of the price range set forth on the
cover page of this prospectus) remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


If the underwriters exercise their option in full to purchase an additional 870,000 shares of our common stock in this offering, the pro forma as adjusted net tangible book value will increase to
$5.71 per share, representing an immediate increase to existing shareholders of $94.51 per share and an immediate dilution of $7.29 per share to new investors participating in this offering.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


The following table summarizes, as of December&nbsp;31, 2014, on a pro forma as adjusted basis described above, the differences between the number of shares of common stock purchased from us, the
total consideration paid to us and the average price per share paid by existing shareholders and by new investors participating in this offering. The calculation below is based on an assumed initial
public offering price of $13.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), before deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us.

</FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="81pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares Purchased </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total Consideration </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Average Price<BR>
Per Share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Percent </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Percent </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Existing shareholders before this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
13,907,935</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
71</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>112,517,440</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
60</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.09</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investors purchasing in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,800,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>29</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>75,400,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>40</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13.00 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19,707,935</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>187,917,440</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.54</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>


In addition, if the underwriters' option to purchase 870,000 additional shares is exercised in full, the number of shares of common stock held by existing shareholders will be further reduced to 68%
of the total number of common stock to be outstanding upon completion of this offering, and the number of shares of common stock held by investors participating in this offering will be further
increased to 6,670,000 shares, or 32% of the total number of shares of common stock to be outstanding upon the completion of this offering.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


The number of shares of our common stock to be outstanding after this offering is based on 1,316,479 shares of common stock outstanding as of April&nbsp;2, 2015 and
assumes:</FONT>

</P>



<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issuance by us of 5,800,000 shares of our common stock in this offering; and


</FONT></DD></DL>
</UL>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=67,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=590928,FOLIO='63',FILE='DISK114:[15ZAD1.15ZAD72301]DM72301A.;55',USER='NDEWIND',CD='24-APR-2015;15:34' -->
<A NAME="page_dm72301_1_64"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>



<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the conversion of all of our convertible preferred stock outstanding immediately
prior to the closing of this offering into an aggregate of 12,591,456 shares of common stock (which includes 41,666,667 shares of Series&nbsp;D convertible preferred stock issued in March 2015),

</FONT></DD></DL>
</UL>


<P style="font-family:arial;"><FONT SIZE=2>and
excludes:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  803,565 shares of common stock issuable upon the exercise of outstanding stock
options as of April&nbsp;2, 2015, at a weighted-average exercise price of $4.23 per share; </FONT><FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 18,809 shares of common stock issuable upon the exercise of warrants to purchase
common stock as of April&nbsp;2, 2015, at a weighted-average exercise price of $1.91 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issuance by us of additional shares of common stock (which, based on an
assumed initial public offering price of $13.00 per share (the mid-point of the price range set forth on the cover page of this prospectus) will total approximately 61,000 shares), as payment of the
accrued dividend on the outstanding shares of Series&nbsp;D convertible preferred stock payable to the holders of Series&nbsp;D convertible preferred stock upon the closing of this offering; </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,751,803 shares of common stock reserved for future issuance under our Amended
and Restated 2014 Stock Incentive Plan upon the closing of this offering; and </FONT><FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  200,000 shares reserved for future issuance under our 2015 Employee Stock
Purchase Plan upon the closing of this offering.

</FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
we may choose to raise additional capital through the sale of equity or convertible debt securities due to market conditions or strategic considerations, even if we believe we have
sufficient funds for our current or future operating plans. To the extent that any of these options are exercised, new options are issued under our
equity incentive plans or we issue additional shares of common stock or other equity or convertible debt securities in the future, there will be further dilution to investors participating in this
offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=68,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=738857,FOLIO='64',FILE='DISK114:[15ZAD1.15ZAD72301]DM72301A.;55',USER='NDEWIND',CD='24-APR-2015;15:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_do72301_1_65"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="do72301_selected_financial_data"> </A>
<A NAME="toc_do72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following selected financial data for the years ended December&nbsp;31, 2013 and 2014 are derived from our audited financial statements,
included elsewhere in this prospectus. Our historical results are not necessarily indicative of results to be expected for the year ending December&nbsp;31, 2015 or any period in the future. The
selected financial data presented below should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and the
related notes thereto, included elsewhere in this prospectus. The selected financial data in this section is not intended to replace our financial statements and the related notes thereto. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands,<BR>
except share<BR>
and per share<BR>
amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations Data:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,157</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,959</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,885</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,706 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,665 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,665</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>76</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share<SUP>(1)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.06</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(22.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used to compute earnings (loss) per common share<SUP>(1)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,697,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>933,997</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common shareholders&nbsp;&#151; basic and diluted (unaudited)<SUP>(1)(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.84</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares used in pro forma net loss per share attributable to common shareholders&nbsp;&#151; basic and diluted
(unaudited)<SUP>(1)(2)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,471,303</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">See
Note 3 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate
earnings (loss) per common share attributable to common shareholders, including the method used to calculate the number of shares used in the computation of the per share amount.


<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Gives
effect to the conversion of all our outstanding convertible preferred stock into an aggregate of 6,552,820 shares of our common stock
(which excludes 41,666,667 shares of Series&nbsp;D convertible preferred stock issued in March 2015) upon the closing of this offering.

 </FONT></DD>

</DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=69,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=190525,FOLIO='65',FILE='DISK114:[15ZAD1.15ZAD72301]DO72301A.;44',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_do72301_1_66"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,551</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,634</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,643</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(5,921</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,034</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other long-term liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>834</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,914</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible redeemable preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>73,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77,107</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shareholders' equity (deficit)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(68,225</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(89,348</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Working
capital is calculated as current assets minus current liabilities. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=70,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=300652,FOLIO='66',FILE='DISK114:[15ZAD1.15ZAD72301]DO72301A.;44',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dq72301_1_67"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dq72301_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_dq72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT'S DISCUSSION AND ANALYSIS OF<BR>  FINANCIAL CONDITION AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>You should read the following discussion and analysis of our financial condition and results of operations in conjunction with
the "Selected Financial Data" and our financial statements and related notes appearing elsewhere in this prospectus. In addition to historical financial information, the following discussion and
analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results could differ materially from those anticipated by these forward-looking statements
as a result of many factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth under "Risk Factors"
and "Special Note Regarding Forward-Looking Statements."</I></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate our
patented DETERx platform technology for the treatment of chronic pain and other diseases. Our lead product candidate, Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a
widely prescribed opioid medication. Xtampza has received Fast Track status from the FDA. Our NDA filing for Xtampza was accepted by the FDA on February&nbsp;10, 2015. On February&nbsp;25, 2015,
the FDA set a PDUFA goal date of October&nbsp;12, 2015 for completion of its review of the Xtampza NDA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
has the same active ingredient as OxyContin OP, which is the largest selling abuse-deterrent, extended-release opioid in the United States by dollars, with $2.5&nbsp;billion in U.S. sales in
2014. We conducted a comprehensive preclinical and clinical program for Xtampza consistent with FDA guidance on abuse-deterrence. These studies and clinical trials demonstrated that chewing, crushing
and/or dissolving Xtampza, and then taking it orally or smoking, snorting, or injecting it did not meaningfully change its drug release profile or safety characteristics. By contrast, clinical trials
performed by us and others &#151; including a head-to-head clinical trial comparing Xtampza with OxyContin OP &#151; have shown that drug abusers can achieve rapid release and absorption
of the active ingredient by manipulating OxyContin OP using common household tools and methods commonly available on the Internet. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, our preclinical studies and clinical trials have shown that the contents of the Xtampza capsule can be removed from the capsule and sprinkled on food, directly into the mouth or
administered through feeding tubes, without compromising their drug release profile, safety or abuse-deterrent characteristics. By contrast, OxyContin OP, which is formulated in hard tablets, has a
black box warning label stating that crushing, dissolving, or chewing can cause rapid release and absorption of a potentially fatal dose of the active ingredient. We believe that Xtampza, if approved,
can address the pain management needs of the approximately 11&nbsp;million patients in the United States who suffer from chronic pain and have difficulty swallowing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since
2010, when we divested our former subsidiary, Onset Therapeutics,&nbsp;LLC, to PreCision Dermatology,&nbsp;Inc., we have devoted substantially all of our resources to the development of our
patented DETERx platform technology, the preclinical and clinical advancement of our product candidates, and the creation and protection of related intellectual property. Since 2011, we have not
generated any revenue from product sales as we currently have no approved products, and we continue to incur significant research, development and other expenses related to our ongoing operations. We
have funded our operations primarily through the private placement of preferred stock, convertible notes and commercial bank debt. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=71,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=71078,FOLIO='67',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_68"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Outlook  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never been profitable and have incurred net losses in each year since inception. We incurred net losses of $16.2 million and $17.9 million in
the years ended December&nbsp;31, 2013 and 2014, respectively. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from
general and administrative costs associated with our operations. We expect to continue to incur net losses in the foreseeable future as we seek regulatory approval for, and, if approved, begin to
commercialize Xtampza. Our net losses may fluctuate significantly from quarter to quarter and year to year. We expect our expenses will increase substantially in connection with our ongoing activities
as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> conduct clinical trials of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> continue scale-up and improvement of our manufacturing processes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> continue our research and development efforts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  manufacture preclinical study and clinical trial materials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  maintain, expand and protect our intellectual property portfolio; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek regulatory approvals for our product candidates that successfully complete
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional clinical, quality control and technical personnel to conduct our
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional scientific personnel to support our product development efforts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  implement operational, financial and management systems; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional general and administrative personnel to operate as a public
company. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
we obtain regulatory approval for Xtampza, we expect to incur significant commercialization expenses related to marketing, product sales and reimbursement functions. Initially we plan to detail
Xtampza to approximately 10,000 physicians who write more than 50% of the branded extended-release oral opioid prescriptions in the United States with a sales team of approximately 100 sales
representatives. In addition, we plan to deploy a separate, focused sales team to detail Xtampza to nursing homes, hospices and other institutions treating large populations of the elderly and other
patients who need chronic pain relief and have difficulty swallowing. Accordingly, we will seek to fund our operations through public or private equity or debt financings or other sources. However, we
may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed
would have a negative impact on our financial condition and ability to develop our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Financial Operations Overview  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since 2011, we have not generated any revenue. In the future, we may generate revenue from product sales, marketing and distribution arrangements and
other collaborations, strategic alliances and licensing arrangements, or a combination of these sources. To the extent any of our product candidates are successfully commercialized, we expect that any
revenue we generate will fluctuate from quarter to quarter as a result of the amount and timing of payments that we receive upon the sale of our products, the timing and amount of license fees,
milestone and other payments. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Research and Development Expenses  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Research and development expenses consist of development costs associated with our DETERx platform technology and product candidates programs. These
costs are expensed as incurred and include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  compensation and employee-related costs, including stock-based compensation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs associated with conducting our preclinical, clinical and regulatory
activities, including fees paid to third-party professional consultants and service providers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs incurred under clinical trial agreements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs for laboratory supplies and laboratory equipment; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  government grants are recognized as a reduction of the qualifying cost being
reimbursed; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=72,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=647334,FOLIO='68',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_69"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs to acquire, develop and manufacture preclinical study and clinical trial
materials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  facilities, depreciation and other expenses including allocated expenses for
rent and maintenance of facilities. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates. At this time,
due to the inherently unpredictable nature of preclinical and clinical development, and given the early stage of our product candidates other than Xtampza, we are unable to estimate with any certainty
the costs we will incur and the timelines we will require in the continued development of our product candidates. Clinical and preclinical development timelines, the probability of success and
development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be
secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
research and development has been focused primarily on developing our DETERx platform technology and Xtampza. Accordingly, historically we have not tracked research and development costs by
project. In addition, we use our employee and infrastructure resources across multiple research and development projects. We expect to track specific project costs when additional drug candidates
enter clinical trials in humans. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General and Administrative Expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation and travel expenses
for our employees in executive, finance and administrative functions. Other general and administrative expenses include facility-related costs and professional fees for directors, accounting and legal
services, and expenses associated with obtaining and maintaining patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
anticipate that our general and administrative expenses will increase in the future as we increase our administrative headcount to support our continued research and development and the potential
commercialization of our product development programs. We also anticipate increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with
exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with being a public company. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Expense, Net  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other expense, net consists of interest income, interest expense on convertible bridge notes, a term loan facility and the change in fair value of our
derivative liability. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Critical Accounting Policies and Significant Judgments and Estimates  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been
prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and
expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses
and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this prospectus, we believe the following accounting policies to
be most critical to the significant judgments and estimates used in the preparation of our financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=73,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=884567,FOLIO='69',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_70"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Accrued Expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing open
contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost
incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when
contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We
periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees payable
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> clinical research organizations and investigative sites in connection with
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> vendors in connection with preclinical development activities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> vendors related to product manufacturing, development, and distribution of
clinical materials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  professional service fees for consulting and related services. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
base our expense accruals related to clinical trials on our estimates of the services received and efforts expended pursuant to our contractual arrangements. The financial terms of these agreements
are subject to negotiation, vary from contract to contract and may result in uneven payment flows and expense recognition. There may be instances in which payments made to our service providers will
exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the
completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the
actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Our understanding of the status and timing of services
performed relative to the actual status and timing of services performed may vary and may result in our reporting changes in estimates in any particular period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differs from the actual status and
timing of services performed, we may report amounts that are too high or too low in any particular period. To date, there have been no material differences from our estimates to the amount actually
incurred. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Impairment of Long-Lived Assets  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Long-lived assets consist primarily of property and equipment. We test long-lived assets for impairment at year end or whenever events or
circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of
such assets, an impairment loss would be recognized in earnings. The long-lived asset would be written down to the estimated fair value, calculated based on the present value of expected future cash
flows. While our current and historical operating losses and negative cash flows are indicators of impairment, we believe that future cash flows to be received support the carrying value of our
long-lived assets and, accordingly, have not recognized any impairment losses on long-lived assets for the years ended December&nbsp;31, 2013 and December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Convertible Redeemable Preferred Stock  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Convertible redeemable preferred stock that is redeemable outside of the Company's control is classified outside of permanent equity. We record such
redeemable preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value is being increased by periodic accretion to its redemption value as if the
redeemable preferred stock is redeemable at that date. In the absence of retained earnings these accretion charges are recorded against additional paid-in capital, if any, and then to accumulated
deficit. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=74,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=409552,FOLIO='70',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_71"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Stock-Based Compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We account for grants of stock options and restricted stock to employees based on their grant date fair value and recognize compensation expense over
the vesting periods. We estimate the fair value of stock options as of the date of grant using the Black-Scholes option pricing model, and we estimate the fair value of restricted stock based on the
fair value of the underlying common stock as determined by our board of directors or the value of the services provided, whichever is more readily determinable. We account for stock
options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting
terms. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Stock-based
compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting
period) on a straight-line basis, net of estimated forfeitures. We estimate the fair value of stock option grants using the Black-Scholes option pricing model, which requires the input of highly
subjective assumptions, including (i)&nbsp;the risk-free interest rate, (ii)&nbsp;the expected volatility of our stock, (iii)&nbsp;the expected term of the award and (iv)&nbsp;the expected
dividend yield. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. Treasury securities. Due to the lack of a public market for
the trading of our common stock and a lack of Company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of
similar companies that are publicly traded. For these analyses, we have selected companies with comparable characteristics to ours, including enterprise value, risk profiles, position within the
industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. We compute the historical volatility data using the daily closing prices for the
selected companies' shares during the equivalent period of the calculated expected term of our stock-based awards. We will continue to apply this process until a sufficient amount of historical
information regarding the volatility of our own stock price becomes available. The expected term represents the period of time that options are expected to be outstanding. Because there was not enough
historical exercise behavior through December&nbsp;31, 2013 or through December&nbsp;31, 2014, we determined the expected life assumption using the simplified method, which is an average of the
contractual term of the option and the vesting period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
employee stock option grants made during the year ended December&nbsp;31, 2013 and 2014, the weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair
value of those grants were as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="101pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended<BR>
December&nbsp;31, </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.09%&nbsp;&#150;&nbsp;1.22%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.80%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>87.8%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77.1%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.25</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>We
had no non-employee stock option grants for the years ended December&nbsp;31, 2013 and December&nbsp;31, 2014.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Fair Value of Common
Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;As discussed below, the fair value of the shares of our common stock underlying our stock options has historically been determined
by our board of directors. Because there has been no public market for our common stock, our board of directors has determined the fair value of our common stock at the time of grant of the option by
considering a number of </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=75,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=728722,FOLIO='71',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_72"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>objective
and subjective factors, including valuations of comparable companies, sales of our convertible preferred stock to unrelated third parties, our operating and financial performance and general
and industry specific economic outlook.  </FONT></P>


</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'>

<FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Expected
Term.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The expected term of stock options represents the weighted-average period that the stock options are expected to remain
outstanding. We estimated the expected term using the simplified method, which is an average of the contractual term of the option and the vesting period.

</FONT>

<FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Expected
Volatility.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Since there has been no public market for our common stock and lack of company-specific historical volatility, we have
determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded medical device companies. In evaluating similarity, we consider
factors such as industry, stage of life cycle and size.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Risk-free Interest
Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for zero-coupon U.S. Treasury
notes with remaining terms similar to the expected term of the options.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Dividend
Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The expected dividend was assumed to be zero as we have never paid dividends and have no current plans to do so. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Expected Forfeiture
Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We are required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual
forfeitures differ from those estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest.
To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes by grant date the number of shares of common stock underlying stock options granted from January&nbsp;1, 2013 through December&nbsp;31, 2014, as well as the
associated per share exercise price and the estimated fair value per share of our common stock on the grant date: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:42pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Grant Dates

<!-- COMMAND=ADD_SCROPPEDRULE,42pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Common<BR>
Shares<BR>
Underlying<BR>
Options<BR>
Granted </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exercise<BR>
Price per<BR>
Common<BR>
Share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Estimated<BR>
Fair Value<BR>
per Common<BR>
Share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> January&nbsp;30, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
66,952</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>May&nbsp;30, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>79,778</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>March&nbsp;5, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>89,641</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2013 and December&nbsp;31, 2014, the unrecognized compensation cost related to outstanding options was $40 and $215, respectively, and is expected to be recognized as
expense over 1.1&nbsp;years and 1.0&nbsp;years, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Based on the assumed initial public offering price of $13.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), the intrinsic value of stock options
outstanding as of December&nbsp;31, 2014
would be $3.5&nbsp;million, of which $1.4&nbsp;million and $2.1&nbsp;million would have been related to stock options that were vested and unvested, respectively, at that date.


</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=76,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1043671,FOLIO='72',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_73"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Determination of the Fair Value of Common Stock on Grant Dates  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We have historically granted stock options at exercise prices not less than the fair value of our common stock. Our board of directors determined the
fair value of our common stock considering, in part, the work of a third-party. The board determined the estimated per share fair value of our common stock at various dates considering contemporaneous
and retrospective valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, </FONT><FONT SIZE=2><I>Valuation of
Privately-Held Company Equity Securities Issued as Compensation</I></FONT><FONT SIZE=2>, or the Practice Aid. Following the consummation of this offering, the fair value of our common stock will be
determined based on the quoted market price of our common stock. In conducting the valuations, the third-party considered all objective and subjective factors that it believed to be relevant for each
valuation conducted in accordance with the Practice Aid, including our best estimate of our business condition, prospects and operating performance at each valuation date. Other significant factors
included:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the prices of our preferred stock sold to outside investors in arm's length
transactions, and the rights, preferences and privileges of our preferred stock as compared to those of our common stock, including the liquidation preferences of our preferred stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our results of operations, financial position and the status of research and
development efforts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the composition of, and changes to, our management team and board of directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of liquidity of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our stage of development and business strategy and the material risks related to
our business and industry; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the valuation of publicly traded companies in the specialty pharmaceutical
sector, as well as recently completed mergers and acquisitions of guideline companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any external market conditions affecting the specialty pharmaceutical industry
sector; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the likelihood of achieving a liquidity event for the holders of our common
stock and stock options, such as an initial public offering or a sale of the Company, given prevailing market conditions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the state of the initial public offering market for similarly situated privately
held specialty pharmaceutical companies. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
dates of our contemporaneous valuations have not always coincided with the dates of our stock option grants. In determining the exercise prices of the stock options on each grant date, our board
of directors considered, among other things, the most recent contemporaneous valuation of our common stock and their assessment of additional objective and subjective factors that were relevant as of
the grant dates. The additional factors considered when determining whether any changes in the fair value of our common stock had occurred between
the most recent contemporaneous valuation and the grant dates included our stage of research and development, our operating and financial performance and current business conditions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include assumptions regarding our future operating
performance, the time to completing an initial public offering or other liquidity event, the related valuations associated with such events, and the determinations of the appropriate valuation methods
at each valuation date. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per share applicable to common shareholders could have been materially
different. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Common Stock Valuation Methodologies  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The valuations were prepared in accordance with the guidelines in the Practice Aid, which prescribes several valuation approaches for setting the
value of an enterprise, such as the cost, market and income approaches, and various methodologies for allocating the value of an enterprise to its common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=77,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=142391,FOLIO='73',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_74"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
considered several types of approaches in the preparation of our valuations as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Market
Approach.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The market approach values a business by reference to guideline companies, for which enterprise values are known. This approach
has two principal methodologies. The guideline public company methodology derives valuation multiples from the operating data and share prices of similar publicly-traded companies. The guideline
acquisition methodology focuses on comparisons between the subject company and guideline acquired public or private companies. A derivative of the guideline public company method is the guideline
initial public offering, or IPO, method, which compares the enterprise values of newly public enterprises in our industry.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>  Discounted Cash Flow Method, or
DCF.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The discounted cash flow method estimates the value of the business by discounting the estimated future cash flows available for
distribution after funding internal needs to present value.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>  Option-Pricing Method Backsolve, or OPM
Backsolve.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The OPM Backsolve method derives the implied equity value for a company from a recent transaction involving the company's own
securities issued on an arms-length basis. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Methods Used to Allocate Our Enterprise Value to Classes of Securities  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In accordance with the Practice Aid, we considered the various methods for allocating the enterprise value across our classes and series of capital
stock to determine the fair value of our common stock at each valuation date. The methods considered consisted of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Option pricing method, or
OPM</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Under the OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each
equity class. The values of the preferred and common stock are inferred by analyzing these options. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Backsolve
method</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Under this approach, the value of the company is estimated by matching value allocated to latest round of preferred financing with its Original Issue Price,
or OIP. In this approach, the inputs of the Black-Scholes Option Pricing, or BSOP, allocation methodology, such as risk-free rate, volatility and time to exit event, are assumed to hold true and the
BSOP calculation is worked backwards to estimate the implied valuation of the company at which the latest preferred series' OIP is met. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Probability-weighted expected return method, or
PWERM</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment
returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Hybrid method</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The
hybrid method is a hybrid between the PWERM and the OPM. It is used to estimate the probability weighted across multiple scenarios, but using the OPM to estimate the allocation of value within one or
more of those scenarios. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
foregoing valuation methodologies are not the only methodologies available and they will not be used to value our common stock once this offering is complete. We cannot make assurances as to any
particular valuation for our common stock. Accordingly, investors are cautioned not to place undue reliance on the foregoing valuation methodologies as an indicator of future stock prices. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Discussion of Specific Valuation Inputs  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Over time, a combination of factors caused changes in the fair value of our common stock. The following summarizes the changes in value since
January&nbsp;1, 2014 and the major factors that caused each change. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> January 2014 to March 2014.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In March 2015, we prepared a retrospective valuation, effective as of March&nbsp;31, 2014, that considered the completion of
enrollment in our Phase&nbsp;3 Study and the positive intranasal Abuse-Deterrent Human Abuse Potential clinical trial. The March&nbsp;31, 2014 valuation used the Hybrid method to value the common
stock. We had two IPO scenarios, a short-term IPO and a longer-term IPO. We relied on market data related to recent public offerings of companies in the pharmaceutical sector. In the short-term
scenario we selected an enterprise value between the 25<SUP>th</SUP>&nbsp;and the 50<SUP>th</SUP>&nbsp;percentile of the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=78,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=368979,FOLIO='74',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_75"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


recent public companies. We estimated it would be approximately 1.17&nbsp;years to the short-term IPO and discounted the future projected enterprise value with a 30% discount rate based on the
Venture Capital Rate of Return Studies. We applied a 15% Discount for Lack of Marketability under the short-term IPO scenario. In the longer-term IPO scenario we selected an enterprise value close to
the 50<SUP>th</SUP>&nbsp;percentile. We estimated it would be approximately 1.59&nbsp;years to the longer-term IPO. We used a 30% discount rate under this scenario and also applied a Discount
for Lack of Marketability of 20% under the long-term IPO scenario. In the Mergers and Acquisitions, or M&amp;A, scenario we relied on the guideline transactions method for determining enterprise value and
the OPM allocation method to determine the fair value of our common stock under the M&amp;A scenario. The selected enterprise value was close to the 50<SUP>th</SUP>&nbsp;percentile of the acquired
companies. We utilized a 3.0&nbsp;year term in the OPM as we believe that is the appropriate time to a potential M&amp;A event. We utilized a volatility level of 87% which was based on the volatility
levels of public companies in our industry. The fourth scenario was a sale of our company at or below the preferred shares' liquidation preference which would yield no value to the common stock. We
assigned a weighting of 50% to the M&amp;A scenario, 12.5% weighting to each of the IPO scenarios and 25% to the sale at or below the liquidation preference based on our assessment of the likelihood of
the four liquidity events. Based in part on this valuation, our board of directors determined the new fair value of our common stock, as of March&nbsp;31, 2014, to be $3.11 per share.

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> April 2014 to December 2014.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In March 2015, we prepared a retrospective valuation, effective as of December&nbsp;31, 2014, which considered the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the issuance of our fifth and sixth U.S. patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the positive Phase&nbsp;3 clinical trial results; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the positive Oral Human Abuse Potential clinical trial; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the positive Alcohol Interaction Study; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the NDA submission to the FDA. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>


As with our prior valuation, the December&nbsp;31, 2014 valuation utilized the Hybrid Method to determine the value of our common stock. We considered the market approach utilizing the market data
from recent IPOs of companies in the pharmaceutical sector to determine the enterprise value under the two IPO scenarios. Under the short-term IPO scenario we estimated it would be approximately
0.41&nbsp;years until this transaction. We selected an enterprise value between the 25<SUP>th</SUP>&nbsp;and 50<SUP>th</SUP>&nbsp;percentiles of the newly public companies in the
pharmaceutical industry. We discounted this scenario with a 25% discount rate which was based on the Venture Capital Rate of Return Studies. We also applied a 10% Discount for Lack of Marketability
under this scenario. In the longer-term IPO scenario we estimated it would be approximately 0.83&nbsp;years until this transaction. The selected enterprise value was close to the
50<SUP>th</SUP>&nbsp;percentile under this scenario. We also used a 25% discount rate in this scenario and applied a Discount for Lack of Marketability of 15% to the concluded value under this
scenario. In the M&amp;A scenario, we utilized the guideline transactions method to determine the enterprise value. Based on the guideline transaction data, we selected an enterprise value between the
25<SUP>th</SUP>&nbsp;percentile and the median. We utilized the OPM to allocate the value in the M&amp;A scenario. Within the OPM we selected a term of 2.0&nbsp;years as we believe that is the
timeframe in which an M&amp;A transaction would occur. We utilized a volatility level of 86% which was based on public companies in the pharmaceutical industry. We applied a Discount for Lack of
Marketability of 25% under the M&amp;A scenario. To determine the common stock value under the Hybrid Method we assigned a 35% probability to the M&amp;A scenario, a 25% probability to each of the IPO
scenarios and a 15% probability to the sale at or below the liquidation preference. Based in part on this valuation, our board of directors determined the reassessed fair value of our common stock, as
of December&nbsp;31, 2014, to be $6.07 per share.

 </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Warrants  </I></FONT></P>

<P style="font-family:arial;">



<FONT SIZE=2>In connection with execution of an amendment, or Amendment No.&nbsp;1, to our Loan and Security Agreement in January 2014, or the Original Term
Loan, we issued 2,091 warrants to purchase shares of common stock with an exercise price of $0.35 per share to Silicon Valley Bank, or SVB. These warrants expire on

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=79,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=274823,FOLIO='75',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_76"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


January&nbsp;30, 2024. The warrant agreement provides for additional warrants to be issued and immediately exercisable upon additional borrowings by us, which in turn are contingent upon meeting
certain performance measures for Xtampza. We met the performance measures, and in August 2014, the Original Term Loan, as amended by Amendment No.&nbsp;1, was further amended and additional
financing was extended. Based on the terms of the warrant agreement, we issued 12,548 additional warrants to purchase shares of common stock with an exercise price of $0.35 per share to SVB. The fair
value of these warrants was </FONT><FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2> as of December&nbsp;31, 2014.

 </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Net Operating Loss Carryforwards  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Utilization of net operating loss, or NOL, and research and development credit carryforwards may be subject to a substantial annual limitation due to
ownership change limitations that have occurred or that could occur in the future, as required by Section&nbsp;382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as
similar state and foreign provisions. These ownership changes may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable
income and tax, respectively. In general, an ownership change, as defined by Section&nbsp;382 of the Code, results from a transaction or series of transactions over a three-year period resulting in
an ownership change of more than 50&nbsp;percentage points of the outstanding stock of a company by certain shareholders. We have not completed a current study to assess whether an ownership change
has occurred or whether there have been multiple ownership changes since our formation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2014, we had U.S. federal NOL carryforwards of $78.3&nbsp;million which may be available to offset future taxable income. The U.S. federal NOL carryforwards begin to expire in
2022. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014 and 2013, we have provided a full valuation allowance for deferred tax assets. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Income Taxes  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We record uncertain tax positions on the basis of a two-step process whereby (i)&nbsp;we determine whether it is more likely than not that the tax
positions will be sustained on the basis of the technical merits of the positions and (ii)&nbsp;for those tax positions that meet the more-likely-than-not recognition threshold, we
recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. We recognize interest and penalties related to
unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. There were no uncertain tax positions as of December 31, 2014 and
2013. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


JOBS Act  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an "emerging growth company," as defined in Section&nbsp;2(a) of the Securities Act, as modified by the JOBS Act. As such, we are eligible to
take advantage of exemptions from various disclosure and reporting requirements that are applicable to other public companies that are not "emerging growth companies" including, but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with the auditor attestation requirements of
Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> being permitted to present only two years of audited financial statements and
only two years of related Management's Discussion and Analysis of Financial Condition and Results of Operations, in each case, instead of three years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> being permitted to present the same number of years of selected financial data
as the years of audited financial statements presented, instead of five years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reduced disclosure obligations regarding executive compensation, including no
Compensation Disclosure and Analysis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with any requirement that may be adopted by the
Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements;
and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=80,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=220188,FOLIO='76',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_77"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  exemptions from the requirements of holding a non-binding advisory vote on
executive compensation and shareholder approval of any golden parachute payments not previously approved. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
may choose to take advantage of some or all of the available exemptions. We have taken advantage of some of the reduced reporting burdens in this prospectus. Accordingly, the scope of the
information contained herein may be different than the scope of the information you receive from other public companies in which you hold stock. We do not know if some investors will find our shares
less attractive as a result of our utilization of these or other exemptions. The result may be a less active trading market for our shares and our share price may be more volatile. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, Section&nbsp;107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the
Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new
or revised accounting standards as other public companies that are not "emerging growth companies." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will remain an "emerging growth company" until the earliest of (i)&nbsp;the last day of the first fiscal year in which our annual gross revenues exceed $1&nbsp;billion; (ii)&nbsp;the date
that we become a "large accelerated filer" as defined in Rule&nbsp;12b-2 under the Exchange Act, which would occur if the market value of our shares that are held by non-affiliates exceeds
$700&nbsp;million as of the last business day of our most recently completed second fiscal quarter; (iii)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt
during the preceding three-year period; and (iv)&nbsp;the last day of our fiscal year containing the fifth anniversary of the date on which shares of our common stock become publicly traded in the
United States. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently Issued Accounting Pronouncements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In July 2013, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No.&nbsp;2013-11, </FONT> <FONT SIZE=2><I>Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward,
a Similar Tax Loss, or a Tax Credit Carryforward Exist.</I></FONT><FONT SIZE=2> ASU 2013-11
amends the presentation requirements of Accounting Standards Codification, or ASC, 740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred
tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if
the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. The ASU is
effective for annual periods, and interim periods within those years, beginning after December&nbsp;15, 2013, which is our fiscal year 2014. The amendments are to be applied to all unrecognized tax
benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The adoption of ASU 2013-11 did not have a material impact on our financial
position or results of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2014, the FASB issued ASU No.&nbsp;2014-09, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers</I></FONT><FONT SIZE=2>. This ASU is a comprehensive new revenue recognition model that
requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or
services. This ASU is effective for annual reporting periods beginning after December&nbsp;15, 2016 and early adoption is not permitted. Accordingly, we will adopt this ASU on January&nbsp;1,
2017. Management does not believe the adoption of this ASU will have a material impact on our financial condition, results of operations or cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2014, the FASB issued ASU 2014-12, </FONT><FONT SIZE=2><I>Compensation &#151; Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That
a Performance Target Could Be Achieved after the Requisite Service Period</I></FONT><FONT SIZE=2>. ASU 2014-12 applies to all reporting entities that </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=81,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=513087,FOLIO='77',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dq72301_1_78"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>grant
their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. That is the case
when an employee is eligible to retire or otherwise terminate employment before the end of the period in which a performance target (for example, an initial public offering or a profitability target)
could be achieved and still be eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted by public business entities in annual periods
beginning on or after December&nbsp;15, 2015 and interim periods within those annual periods. We plan to implement this standard in the first quarter of fiscal year 2016 and management is currently
evaluating the potential impact of this new guidance on our financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2014, the FASB issued ASU No.&nbsp;2014-15, </FONT><FONT SIZE=2><I>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.</I></FONT><FONT SIZE=2> ASU 2014-15
requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a
going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December&nbsp;15, 2016 and
earlier application is permitted. The adoption of ASU 2014-15 is not expected to have a material effect on our financial statements or disclosures. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
November 2014, the FASB issued ASU No.&nbsp;2014-16, </FONT><FONT SIZE=2><I>Derivatives and Hedging (Topic 815)&nbsp;&#151; Determining Whether the Host Contract in a Hybrid Financial
Instrument Issued in the Form of a Share is More Akin to Debt or to Equity</I></FONT><FONT SIZE=2>. ASU 2014-16 was issued to clarify how current U.S. generally accepted accounting principles should be
interpreted in evaluating the economic characteristics and risk of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, ASU 2014-16 was issued to
clarify that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms
and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting ASU 2014-16 should be applied on a modified retrospective
basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all
relevant prior periods. ASU 2014-16 is effective for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2015. Early adoption in an interim period is
permitted. We are currently evaluating the impact of the adoption of ASU 2014-16 on our financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=82,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=895667,FOLIO='78',FILE='DISK114:[15ZAD1.15ZAD72301]DQ72301A.;74',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ds72301_1_79"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Results of Operations  </B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Comparison of the Years Ended December&nbsp;31, 2013 and 2014  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes the results of our operations for the years ended December&nbsp;31, 2013 and 2014: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Change </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,157</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,959</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>802</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,885</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,706</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>821</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>155</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>97 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,720 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2><B><I> Research and Development Expenses.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses were $14.2&nbsp;million for the year ended December&nbsp;31, 2013, compared to
$15.0&nbsp;million for the year ended December&nbsp;31, 2014. The $802,000 increase was primarily related to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in consultant costs of $818,000 due to regulatory consulting,
including costs associated with filing the NDA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase of $797,000 in manufacturing costs, mainly due to costs incurred for
pre-validation batches; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase of $240,000 in personnel costs, primarily due to increased
headcount. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>These
increases were partially offset by a decrease in clinical trial&nbsp;expenses and other development costs of $1.0&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> General and Administrative Expenses.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses were $1.9&nbsp;million for the year ended December&nbsp;31, 2013, compared to
$2.7&nbsp;million for the year ended December&nbsp;31, 2014. The $821,000 increase was primarily related to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> An increase in professional fees including legal and audit fees of $832,000,
mainly due to prior year audits, accounting services and recruiting fees. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
increase was partially offset by a decrease in market research costs of $129,000. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Other Expense, Net.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Other expense, net was $155,000 for the year ended December&nbsp;31, 2013, compared to $252,000 for the year ended December&nbsp;31, 2014.
The increase in interest expense of $176,000 in 2014 was due to larger outstanding balances under our debt agreements, which was partially offset by the decrease to the periodic fair value adjustment
of warrant liability of $79,000. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Liquidity and Capital Resources  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have incurred net losses and negative cash flows from operations since inception. For the years ended December&nbsp;31, 2013 and
December&nbsp;31, 2014, we incurred net losses of $16.2&nbsp;million and $17.9&nbsp;million, respectively. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Since
our inception, we have funded our operations primarily through the private placement of preferred stock, convertible notes and commercial bank debt. As of December&nbsp;31, 2014, we had cash
and cash equivalents of $1.6&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=83,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=480172,FOLIO='79',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_80"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Although it is difficult to predict future liquidity requirements, we believe that the net proceeds from this offering, together with our existing cash resources, will be sufficient to fund our
operations into mid-2017, including the commercialization of Xtampza, if approved, and the continuation of our development of our other product candidates. We have based this estimate on assumptions
that may prove to be incorrect and we could use our available capital resources sooner than we currently expect. Our recurring losses from operations and negative cash flows raise substantial doubt
about our ability to continue as a going concern. We may never become profitable, or if we do, we may not be able to sustain profitability on a recurring basis.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
March 2015, we issued 41,666,667 shares of Series&nbsp;D Convertible Preferred Stock in exchange for aggregate consideration of $50.0&nbsp;million, including $45.0&nbsp;million in cash. In
connection with this financing, convertible notes with related parties in the aggregate principal amount of $5.0&nbsp;million automatically converted to an aggregate of 4,166,667 shares of
Series&nbsp;D Preferred Stock. During 2013, we issued 8,658,008 shares of Series&nbsp;C Preferred Stock in exchange for net proceeds of $12.0&nbsp;million. In January 2014, our Original Term
Loan was amended, pursuant to Amendment No 1, to provide for borrowings of up to $6.0&nbsp;million. In February 2014, we borrowed $2.0&nbsp;million. A portion of the proceeds from the initial
borrowing were used to pay down the balance outstanding under the Original Term Loan resulting in us receiving $1.1&nbsp;million. In August 2014, the Original Term Loan, as amended by Amendment No.
1, was further amended to provide for borrowing of up to $8.0&nbsp;million. In August 2014 and September 2014, we drew down $3.0&nbsp;million and $3.0&nbsp;million, respectively under the
Original Term Loan, as amended. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table sets forth a summary of the net cash flow activity for each of the periods indicated: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(16,530</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(17,947</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12,351</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12,038 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net decrease in cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4,385</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(5,917</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Operating Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cash used in operating activities increased by $1.4&nbsp;million, from $16.5&nbsp;million for the year ended December&nbsp;31, 2013 to
$17.9&nbsp;million for the year ended December&nbsp;31, 2014. The increase in cash used in operating activities was driven primarily by an increase in net loss. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Investing Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cash used in investing activities decreased $198,000 from $206,000 for the year ended December&nbsp;31, 2013 to $8,000 for the year ended
December&nbsp;31, 2014. The difference was related to decreased purchases of property and equipment. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Financing Activities  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cash provided by financing activities decreased $313,000 from $12.4&nbsp;million for the year ended December&nbsp;31, 2013 to $12.0&nbsp;million
for the year ended December&nbsp;31, 2014. During 2013, we issued 8,658,008 shares of Series&nbsp;C Preferred Stock for net proceeds of $12.0&nbsp;million. In January 2014, the Original Term
Loan was amended, pursuant to Amendment No. 1, to provide for borrowings of up to $6.0&nbsp;million. In February 2014, we borrowed $2.0&nbsp;million. A portion of the proceeds from the initial
borrowing were used to pay down the original loan balance resulting in us receiving $1.1&nbsp;million. In August 2014, the Original Term Loan, as amended by Amendment No. 1, was further amended to
provide for </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=84,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=812545,FOLIO='80',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_81"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>borrowing
of up to $8.0&nbsp;million. In August 2014 and September 2014 we drew down $3.0&nbsp;million and $3.0&nbsp;million, respectively under the Original Term Loan, as amended. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Operating Capital Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since 2011, we have not generated any product revenue. We do not know when, or if, we will generate any revenue as we seek regulatory approval for,
and potentially begins to commercialize, Xtampza. We anticipate that we will continue to incur losses for the next several years, and we expect the losses to increase as we continue the development
of, and seek regulatory approvals for, Xtampza and our other product candidates, and begin to commercialize any approved products. We are subject to all of the risks common to the development of new
pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Upon the completion of this
offering, we will incur additional costs associated with operating as a public company. We anticipate that we will need substantial additional funding in connection with our continuing operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Until
we can generate a sufficient amount of revenue from our pharmaceutical products, if ever, we expect to finance future cash needs through public or private equity or debt offerings. Additional
capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale
back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could
result in dilution to our existing shareholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur
indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt,
limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these
events could significantly harm our business, financial condition and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual
results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we
currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the design, initiation, progress, size, timing, costs and results of preclinical
studies and clinical trials for our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome, timing and cost of regulatory approvals by the FDA and comparable
foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than, or evaluate clinical endpoints other than
those that we currently expect; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing and costs associated with manufacturing Xtampza and our other product
candidates for clinical trials, preclinical studies and, if approved, for commercial sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number and characteristics of product candidates that we pursue; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of patent infringement litigation, including the Purdue litigation,
relating to Xtampza or our other product candidates, which may be expensive to defend and delay the commercialization of Xtampza or our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our need to expand our research and development activities, including our need
and ability to hire additional employees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our need to implement additional infrastructure and internal systems and hire
additional employees to operate as a public company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the effect of competing technological and market developments; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of establishing sales, marketing and distribution capabilities for any
products for which we may receive regulatory approval. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=85,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=458805,FOLIO='81',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_82"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be
materially adversely affected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Contractual Obligations and Commitments  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes our contractual obligations and commitments as of December&nbsp;31, 2014 that will affect our future liquidity: </FONT></P>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Less than<BR>
1&nbsp;year </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>1 - 3&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>3 - 5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>More than<BR>
5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease obligations<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>106</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>227</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-Term Debt<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,194</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,033</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Operating
lease obligations represent future minimum lease payments under our non-cancelable operating lease in effect as of
December&nbsp;31, 2014, reflecting remaining lease payments for our current facility in Canton, Massachusetts.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Long-term
debt obligations represent future principal payments under our Original Term Loan, as amended, and our convertible notes as of
December&nbsp;31, 2014. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Off-Balance Sheet Arrangements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the SEC. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Quantitative and Qualitative Disclosures about Market Risks  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are exposed to market risk related to changes in interest rates. As of December&nbsp;31, 2014, we had cash and cash equivalents consisting of
money market funds of $1.6&nbsp;million. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly
because our money market accounts are short-term highly liquid investments. Due to the short-term duration and the low risk profile of our investments, an immediate 10% change in interest rates would
not have a material effect on the fair market value of our portfolio. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in and Disagreements with Accountants on Accounting and Financial Disclosure  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On or about September&nbsp;24, 2014, we dismissed Walter&nbsp;&amp; Shuffain, P.C., or W&amp;S, as our independent public accounting firm. The dismissal
of W&amp;S was approved by our board of directors. The audit report of W&amp;S on our financial statements as of and for the fiscal year ended December&nbsp;31, 2012 did not contain any adverse opinion or
disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, except for modifications for uncertainties related to going concern. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
connection with the audit of our financial statements for the fiscal year ended December&nbsp;31, 2012, and for the subsequent interim period through the date of the dismissal of W&amp;S,
(i)&nbsp;there were no disagreements with W&amp;S on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not
resolved to W&amp;S' satisfaction, would have caused W&amp;S to make reference to the subject matter of the disagreement in connection with its report, and (ii)&nbsp;there were no "reportable events," as
that term is described in Item&nbsp;304(a)(1)(v) of Regulation&nbsp;S-K. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
September&nbsp;24, 2014, we engaged Grant Thornton&nbsp;LLP, or Grant Thornton, to serve as our independent registered public accounting firm, to audit the fiscal year ended December&nbsp;31,
2013. The engagement of Grant Thornton has been approved by our board of directors. During the two most recent fiscal years, neither we, nor anyone acting on our behalf, consulted with Grant Thornton
regarding either: (i)&nbsp;the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=86,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=891601,FOLIO='82',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_83"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>application
of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements, and no written report
nor oral advice was provided by Grant Thornton, or (ii)&nbsp;any matter that was either the subject of a disagreement, as that term is defined in Item&nbsp;304(a)(1)(iv) of Regulation&nbsp;S-K,
or a reportable event, as that term is defined in Item&nbsp;304(a)(1)(v) of Regulation&nbsp;S-K. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
requested that W&amp;S furnish us with a letter addressed to the SEC stating whether it agrees with the above statements. A copy of the letter dated February&nbsp;25, 2015, is filed as an exhibit to
the registration statement of which this prospectus forms&nbsp;a part. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=87,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=276856,FOLIO='83',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_84"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds72301_business"> </A>
<A NAME="toc_ds72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BUSINESS    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate our
patented DETERx&reg; platform technology for the treatment of chronic pain and other diseases. Our lead product candidate, Xtampza ER&#153;, or Xtampza, is an abuse-deterrent,
extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration, or FDA. Our new drug
application, or NDA, filing for Xtampza was accepted by the FDA on February&nbsp;10, 2015. On February&nbsp;25, 2015, the FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of
October&nbsp;12, 2015 for completion of its review of the Xtampza NDA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
has the same active ingredient as OxyContin&reg; OP, which is the largest selling abuse-deterrent, extended-release opioid in the United States by dollars, with $2.5&nbsp;billion in
U.S. sales in 2014. We conducted a comprehensive preclinical and clinical program for Xtampza consistent with FDA guidance on abuse-deterrence. These studies and clinical trials demonstrated that
chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not meaningfully change its drug release profile or safety characteristics. By contrast,
clinical trials performed by us and others&nbsp;&#151; including a head-to-head clinical trial comparing Xtampza with OxyContin OP&nbsp;&#151; have shown that drug abusers can
achieve rapid release and absorption of the active ingredient by manipulating OxyContin OP using common household tools and methods commonly available on the Internet. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, our preclinical studies and clinical trials have shown that the contents of the Xtampza capsule can be removed from the capsule and sprinkled on food, directly into the mouth or
administered through feeding tubes, without compromising their drug release profile, safety or abuse-deterrent characteristics. By contrast, OxyContin OP, which is formulated in hard tablets, has a
black box warning label stating that crushing, dissolving or chewing can cause rapid release and absorption of a potentially fatal dose of the active ingredient. We believe that Xtampza, if approved,
can address the pain management needs of the approximately 11&nbsp;million patients in the United States who suffer from chronic pain and have difficulty swallowing. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Background on Chronic Pain and Opioid Abuse  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Patients Suffering from Chronic Pain  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Chronic pain, typically defined as pain that lasts beyond the healing of an injury or that persists longer than three months, is a worldwide problem
with serious health and economic consequences. According to the National Institutes of Health, or NIH, chronic pain represents a public health crisis of epidemic proportions affecting approximately
100&nbsp;million people in the United States and 20-30% of the population worldwide&nbsp;&#151; more than heart disease, cancer and diabetes combined. Common types of chronic pain include
lower back pain, arthritis, headache, and face and jaw pain. The prevalence of chronic pain is expected to rise in the future, as the incidence of associated illnesses such as diabetes, arthritis and
cancer increases in the aging population. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Chronic
pain leads to over $560&nbsp;billion in healthcare and productivity costs each year according to the Institute of Medicine. Prescription opioids remain the primary treatment for chronic
pain. Chronic pain patients often start treatment with immediate release opioids, but change to extended-release opioids to achieve more convenient dosing with more consistent blood levels of the
active drug. Extended-release opioids incorporate a large amount of opioid with a time-release mechanism designed to deliver steady amounts of opioid, typically over 12 to 24&nbsp;hours. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Annual
sales from extended-release and long-acting opioids represent approximately $6.0&nbsp;billion (29&nbsp;million prescriptions) of the approximately $14&nbsp;billion U.S. opioid market in
2014. OxyContin OP generated </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=88,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=935952,FOLIO='84',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_85"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>U.S.&nbsp;sales
of $2.5&nbsp;billion in 2014, which represents approximately a 20% U.S.&nbsp;market share of all extended-release and long-acting opioid prescriptions. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Prescription Opioid Abuse is an Epidemic in the United States  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Abusers tamper with extended-release opioid drugs to achieve the euphoria that results from rapid increases in the blood concentration of the active
ingredient, a potentially fatal activity known as dose dumping. The U.S. Centers for Disease Control and Prevention, or CDC, described abuse of prescription drugs in the United States as a growing and
deadly epidemic. Deaths in the United States from prescription opioid overdose have grown from approximately 4,000 in 1999 to approximately 16,000 in 2012. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>According
to a 2012 study conducted by the CDC, annually there are 144,000 treatment admissions for abuse or misuse of opioids, 560,000 emergency room&nbsp;visits for misuse or abuse of opioids,
over 2.5&nbsp;million individuals who abuse or are dependent on opioids and over 7.3&nbsp;million non-medical users who use opioids without prescriptions or for non-therapeutic effects. The
American Journal of Managed Care estimated in a 2013 report that opioid abuse costs public and private healthcare payors over $72&nbsp;billion annually in direct healthcare costs, including costs of
emergency room&nbsp;visits, rehabilitation and associated health problems. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA has estimated that nearly 35&nbsp;million Americans have used prescription pain relievers, including opioid-containing drugs, for non-prescription purposes at least once in their lifetime. A
2011 research report from the Substance Abuse and Mental Health Services Administration estimated that between 1999 and 2009 there was a 430% increase in substance-abuse treatment facility admissions
resulting from the use of prescription pain relievers. According to a 2011 study by the University of Michigan, one in 12 high school seniors reported non-medical use of Vicodin, a combination of
acetaminophen and hydrocodone, and one in 20 high school seniors reported non-medical use of OxyContin. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Drug
abusers find currently approved extended-release opioids desirable because of the large amount of drug payload, which they attempt to release quickly into the bloodstream to create euphoria. It
is difficult for drug abusers to achieve this rapid release and absorption into the bloodstream by taking multiple intact extended-release opioid tablets or capsules because doing so often causes
sleepiness and/or respiratory distress before euphoria is achieved. Instead, abusers attempt to defeat the extended-release properties in order to achieve rapid release of the active ingredient. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Despite
the introduction of OxyContin OP in 2010 as the first FDA-approved, abuse-deterrent extended-release opioid formulation, abuse of extended-release opioids, including OxyContin OP, continues to
be a major public health issue. OxyContin OP, even with its abuse-deterrent formulation, remains vulnerable to abuse using common household objects, like pill crushers. Third party studies found that
abusers of OxyContin OP use various routes of abuse&nbsp;&#151; including snorting, injection and oral abuse&nbsp;&#151; despite its abuse-deterrent features. In a third party study
of OxyContin abusers both before and after OxyContin OP was introduced, researchers found that while the non-oral route of administration of abuse of OxyContin OP (i.e., injection, snorting and
smoking) decreased after its introduction, oral abuse of OxyContin OP increased from approximately 52% to 75% of OxyContin abusers. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds72301_oxycontin_op_tablet_+_$6.39_pi__oxy02648"> </A>
<A NAME="toc_ds72301_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>OxyContin OP Tablet&nbsp;+&nbsp;$6.39 Pill Crusher&nbsp;= Abuseable Fine Powder in 16 Seconds    <BR>    </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g544224.jpg" ALT="GRAPHIC" WIDTH="438" HEIGHT="157">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=89,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=747540,FOLIO='85',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_86"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Legislative and Regulatory Actions  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In response to widespread prescription opioid abuse, the U.S. government and a number of state legislatures have introduced, and in some cases have
enacted, legislation and regulations intended to encourage the development of abuse-deterrent forms of pain medications. The FDA has stated that addressing prescription drug abuse is a priority, and
the development of abuse-deterrent opioids is a key part of that strategy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2010, Purdue received approval for a new formulation of OxyContin, named OxyContin OP, designed to make it more difficult to abuse. In April 2013, the FDA approved new labeling for OxyContin OP,
which, for the first time included abuse-deterrent label claims consistent with the FDA's January 2013 draft abuse-deterrent label guidance. At the same time, the FDA withdrew the approval of the
original, non-abuse-deterrent OxyContin formulation, thus preventing the commercialization of generic versions of the original OxyContin that did not have abuse-deterrent properties. This decision by
the FDA is consistent with its public statement that the development of abuse-deterrent opioid analgesics is a public health priority. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Recent
actions to address the opioid abuse epidemic include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>STOPP Act:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In July
2012, a bipartisan group of Congressional leaders introduced the STOPP (Stop the Tampering of Prescription Pills) Act. Reintroduced in February 2013, this bill, if approved, would require that
non-abuse-deterrent opioids be removed from the market if an abuse-deterrent formulation of that opioid has already been approved for marketing by the FDA. Since being reintroduced in 2013, this bill
was referred to the U.S. House of Representatives' Subcommittee on Health and there has been no further action taken. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>FDA guidance:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In
January 2013, the FDA introduced draft guidance regarding studies and clinical trials that should be conducted to demonstrate that a given formulation has abuse-deterrent properties, how those studies
and clinical trials will be evaluated, and what labeling claims may be approved based on the results of those studies and clinical trials. The draft guidance described four categories of
abuse-deterrence studies and clinical trials: Categories&nbsp;1, 2 and 3 consist of pre-marketing studies and clinical trials designed to evaluate a product candidate's potentially abuse-deterrent
properties under controlled conditions, while Category&nbsp;4 post-marketing clinical trials and studies assess the real-world impact of a potentially abuse-deterrent formulation. These requirements
were largely adopted in the April 2015 final FDA guidance, which also provides examples of label claims that may be merited based on the results of the corresponding studies and clinical
trials:</FONT><FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Category&nbsp;1&nbsp;&#151; the product is formulated with
psychochemical barriers that are expected to deter intravenous abuse. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Category&nbsp;2&nbsp;&#151; the product is formulated with
psychochemical properties that are expected to deter oral and nasal abuse. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Category&nbsp;3&nbsp;&#151; the results from the oral and intranasal
clinical abuse potential studies indicate that the medication has properties expected to deter abuse via oral, intranasal and intravenous routes. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Category&nbsp;4&nbsp;&#151; there was a demonstrated reduction in
abuse of this medication in the community setting compared to the levels of abuse, overdose and death that occurred when only formulations of the same opioid without abuse-deterrent properties were
available. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>48 state and territorial attorneys general support
development of abuse-deterrent opioids:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In March 2013, the National Association of Attorneys General urged the FDA to adopt standards requiring manufacturers and
marketers of prescription opioids to develop abuse-deterrent versions of those products. Their letter, signed by 48 state and territorial attorneys general, commended the FDA for expeditiously
proposing guidance that establishes clear standards for manufacturers who develop and market abuse-resistant opioid products, while considering incentives for undertaking the research and development
necessary to bring such products to market. It also encouraged the FDA to ensure that generic versions of such products are designed with similar abuse-resistant features. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>FDA mandated label
changes:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;10, 2013, the FDA announced its intention to require label changes to all approved extended-release and long-acting opioids. In
particular, the FDA </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=90,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=737517,FOLIO='86',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_87"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>announced
its intention to update the indications for these opioids so that they will be indicated only for the management of pain severe enough to require daily, around-the-clock, long-term opioid
treatment and for which alternative treatment options are inadequate. On April&nbsp;16, 2014, the FDA updated these indications. The FDA also requires post-marketing studies and clinical trials for
any such opioids. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>29 state and territorial attorneys general speak out
against the approval of non-abuse-deterrent narcotic:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In December 2013, the attorneys general of 29 states and territories urged the FDA to reconsider its approval
of Zohydro&#153; ER, an extended-release hydrocodone formulation with no abuse-deterrent properties, or alternatively to set a rigorous timeline for reformulation of Zohydro ER in an
abuse-deterrent form, with significant limitations on prescriptions of Zohydro ER in the interim. In early 2014, members of Congress from three states introduced a bill to revoke FDA approval of
Zohydro ER and prevent the FDA from approving any new opioids that do not have abuse-deterrent features and the governor of Massachusetts signed an executive order (since overturned by a court) that
attempted to ban the dispensing of Zohydro ER in Massachusetts. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Health Canada Proposed Legislation Requiring Opioids to
be Tamper Resistant Before Sale.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In June 2014, Health Canada issued a Notice of Intent for Interested Parties on Tamper Resistance under the Controlled Drugs and
Substances Act. If approved, the proposed legislation would require that drugs at high risk for abuse, including extended-release oxycodone, have tamper-resistant properties before they can be sold in
Canada. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Massachusetts approved law to mandate that insurers
cover abuse-deterrent opioids:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In August 2014, the governor of Massachusetts signed a law establishing a drug formulary commission charged with identifying drugs
with a heightened public health risk due to their potential for abuse and formulations of abuse-deterrent drugs that may be substituted for these drugs that have a heightened public health risk. When
a prescriber writes a prescription for an opioid identified as having a heightened public health risk, the pharmacist must dispense an interchangeable abuse-deterrent product from the formulary, if
one exists, except when the prescriber indicates "no substitution." The Massachusetts law also requires insurers to cover abuse-deterrent opioid drugs on a basis not less favorable than corresponding
non-abuse-deterrent drugs. Oregon, which has the highest incidence of non-medical use of opioids in the United States, is exploring legislation similar to the Massachusetts law. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>FDA held public meeting to discuss
abuse</I></FONT><FONT SIZE=2>-</FONT><FONT SIZE=2><I>deterrent opioid formulations:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In September 2014, the FDA announced a public meeting to discuss the development,
assessment and regulation of opioid medications. In its public notice, the FDA stated that it "looks forward to a future in which all or substantially all opioid medications are less susceptible to
abuse than the conventional formulations that dominate the market today." In October 2014, the FDA held the public meeting with key stakeholders to solicit input regarding three primary topics: how to
make abuse-deterrent opioid formulations the standard of care, how to best incentivize the pharmaceutical industry to develop next-generation opioid products, and how to ensure that patients have
access to affordable abuse-deterrent opioids by implementing guidance for the release of generic abuse-deterrent opioids. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Industry group letter to the
FDA:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In January 2015, two major trade associations of the drug industry, Biotechnology Industry Organization, or BIO, and Pharmaceutical Research and Manufacturers
of America, or PhRMA, sent a letter to the FDA urging the agency to take two actions: decline to approve generic formulations of opioid medications that lack abuse-deterrent properties comparable to
those of already-approved branded formulations, and remove from the market any generic, non-abuse-deterrent formulations of opioid medications with abuse-deterrent formulations. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=91,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=468233,FOLIO='87',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_88"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Types of Abuse-Deterrent Technologies  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In response to the opioid abuse epidemic, the pharmaceutical industry has created a number of abuse-deterrent products and product candidates, using a
variety of technologies. These strategies generally fall under the following categories:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Physical/Chemical
Barriers:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Physical barriers are formulations designed to prevent chewing, crushing, cutting, grating or grinding for oral or nasal abuse. Physical and chemical
barriers can make it difficult to extract the opioid from the formulation for IV abuse using common solvents such as water. For example, OxyContin OP uses a cured, thermoformed polymer to make the
tablets harder to crush for oral or nasal abuse. When crushed, the product gels in the presence of small injectable volumes of liquid, making it more difficult to draw into a syringe. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Agonist/Antagonist
Combinations:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An opioid antagonist can be co-formulated with an active opioid ingredient, or agonist, to interfere with or reduce the euphoria associated with
abuse. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The antagonist can be physically sequestered in the tablet
(e.g.,&nbsp;Pfizer's Embeda&reg;). When taken orally as directed, the majority of the encapsulated antagonist is eliminated in the gastrointestinal, or GI, tract and not absorbed into the
bloodstream, allowing the active ingredient to work. However, when crushed or dissolved by an abuser or patient, the antagonist is released with the active ingredient and both are absorbed into the
bloodstream, with the intent of blunting the euphoric effects of the active ingredient. A problem with this approach is that if the tablet is crushed or dissolved, the antagonist can cause the patient
or abuser to experience opioid withdrawal, with potentially serious consequences. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Alternatively, the antagonist can be co-formulated in a fixed ratio with the
active ingredient (e.g.,&nbsp;Purdue's Targiniq&#153;). When taken orally as directed, most of the antagonist is circulated directly to the liver and rendered ineffective, allowing the active
ingredient to work. However, when snorted or injected, the antagonist is distributed in the bloodstream before it gets to the liver, with the intent of preventing euphoria. A disadvantage with this
approach is that it limits the amount of active ingredient a patient can take, which may make it inadequate to control chronic pain. Further, the presence of the antagonist in the co-formulated drug
may precipitate withdrawal, with potentially serious consequences. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>Market
research studies performed for us have shown that some physicians prefer not to use an abuse-deterrent formulation with an opioid antagonist because such formulations may be less useful in
addressing chronic pain and because their antagonist components may precipitate withdrawal. </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Prodrug approaches:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A
prodrug is a drug administered in an inactive, or less active, form designed to enable more effective delivery. The prodrug is then converted by the body into the active ingredient through a normal,
metabolic process. In a prodrug opioid, the active ingredient is designed to be released if the drug is taken orally, but if an abuser or patient takes a large amount of the drug, the prodrug is not
broken down or absorbed rapidly enough to create euphoria. If injected or snorted, the prodrug is not broken down and the active ingredient is not released. To date, the only extended-release product
candidate using the prodrug approach in late-stage clinical development did not achieve its primary endpoint of demonstrating adequate pain relief compared to a placebo, in a Phase&nbsp;2 clinical
trial. No opioids using a prodrug approach are currently marketed. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
believe Xtampza represents the best-in-class approach to creating an abuse-deterrent extended-release opioid formulation. Xtampza does not incorporate an opioid antagonist, is not a prodrug, and,
based on the studies and clinical trials we conducted, is resistant to abuse through physical or chemical manipulation. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Chronic Pain with Dysphagia  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>It is estimated that more than 10% of patients with chronic pain, or approximately 11&nbsp;million patients, have dysphagia, or difficulty in
swallowing, because they have cancer, are elderly, have other medical problems or have difficulty swallowing without a known medical cause. The FDA recognized the unmet medical needs of this growing
population in issuing draft guidance in December 2013, in which the FDA cited survey data that suggest that as many as 40% of Americans may have difficulties swallowing tablets </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=92,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=658712,FOLIO='88',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_89"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
capsules and noted that these difficulties can precipitate a number of adverse events and noncompliance with treatment regimens. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Currently,
all FDA-approved, orally administered extended-release opioids have a black box warning label stating that "crushing, dissolving or chewing can cause rapid release and absorption of a
potentially fatal dose of the active drug," making them unsuitable or unattractive for patients who suffer from chronic pain with dysphagia, or CPD. OxyContin OP's label states that "there have been
post-marketing reports of difficulty in swallowing OxyContin tablets. These reports included choking, gagging, regurgitation and tablets stuck in the throat&nbsp;.&nbsp;.&nbsp;. Consider use of
an alternative analgesic in patients who have difficulty swallowing." An external marketing study performed for us in 2013 estimated that Xtampza, if approved, has a peak revenue potential for U.S.
patients with CPD in excess of $700&nbsp;million annually. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Solution: The DETERx Platform Technology  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Overview  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>DETERx is a novel, proprietary, patented platform technology that is designed to maintain the extended-release and safety profiles of highly abused
drugs in the face of various methods of abuse and tampering, including chewing, crushing and/or dissolving, and then taking them orally or snorting or injecting them. The DETERx formulation consists
of wax-based microspheres that are filled into a capsule. The microspheres are spherical micron-sized beads that are prepared by combining the active ingredient (oxycodone, in the case of our lead
product candidate, Xtampza) with inactive ingredients. Each microsphere, whether inside or outside the capsule, is designed to be abuse-deterrent and extended-release. The active ingredient is
solubilized and homogenously dispersed in each microsphere. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
microspheres have a median particle size of approximately 300 microns and are comprised of the active ingredient (oxycodone), a fatty acid, and wax and surfactant excipients which are all
generally recognized as safe, or GRAS, by the FDA. The microspheres are formulated through a proprietary melt process in which the active ingredient, as a free base, is combined with fatty acid and
wax and surfactant excipients to form&nbsp;a molten solution in which the base is solubilized via an ionic interaction with the fatty acid. The resulting homogenous liquid is spray congealed into
small droplets using a proprietary spinning disk manufacturing process. The droplets rapidly congeal into solid wax-based microspheres, which are then filled into capsules. Differing product strengths
are achieved by varying the weight of the microspheres loaded into a capsule. When administered orally as directed, the Xtampza formulation is designed to be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=93,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=461265,FOLIO='89',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ds72301_1_90"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>administered
every 12&nbsp;hours and releases oxycodone over an extended period of time in the GI tract by diffusion from the microspheres into gastrointestinal fluids. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g846204.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="384">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
of our proprietary technology, each individual microsphere has extended-release and abuse-deterrent properties. The microspheres are designed to be administered in capsule form, sprinkled on
food or directly in the mouth, or administered into the stomach via a gastric or nasogastric tube without compromising their
abuse-deterrent, extended-release profile. These features may make Xtampza uniquely suited to address the needs of patients suffering from CPD. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=94,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=679204,FOLIO='90',FILE='DISK114:[15ZAD1.15ZAD72301]DS72301A.;88',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_du72301_1_91"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Abuse-Deterrent Features  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Abusers often seek to accelerate the absorption of opioids into the bloodstream by crushing them in order to swallow, snort or smoke the drug, or
dissolving them in order to inject the drug. The wax-based microspheres produced using the DETERx platform technology have physical and chemical barriers that are intended to reduce the potential for
these forms of abuse. We believe that microspheres made using our proprietary technology deter the most common methods of manipulating opioids for abuse because of their features described in the
table below. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du72301_abuse-deterrent_featur__du702237"> </A>
<A NAME="toc_du72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Abuse-Deterrent Features of DETERx Platform Technology    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="16%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="171pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="49%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:60pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Method of Abuse

<!-- COMMAND=ADD_SCROPPEDRULE,60pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Abuse-Deterrent Feature: </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Advantages </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Oral</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><I> Particle Size, Matrix Composition and Fusing Effect</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>The microspheres are small and soft, so chewing or crushing them to further reduce the particle size does not meaningfully reduce the particle size or increase the surface area. The hydrophobic excipient matrix of each
microsphere is composed of soft, fatty, and wax-based inactive ingredients that tend to agglomerate and fuse when crushed.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2>Injection</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2><I> Less Soluble Salt Form</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>We created a novel salt form of the active ingredient, which is less soluble in aqueous solutions (such as water) but readily dissolved in fatty excipients, such as those used in our DETERx formulation.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2><I> Matrix Composition</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>The hydrophobic excipient matrix is designed to trap the active ingredient, making it difficult for abusers to extract the opioid.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2><I> High Melting Point</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Melting the waxy composition of the microspheres results in quick solidification when heat is removed, clogging a syringe.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2>Snorting</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2><I> Matrix Composition</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>The hydrophobic excipient matrix is designed to trap the active ingredient, preventing the release of the opioid in the nose and causing temporary nasal side effects that make Xtampza undesirable for nasal
abuse.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


DETERx Pipeline  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have applied our DETERx platform technology to Xtampza as well as other product candidates in our pipeline. We have an extended-release,
abuse-deterrent oxymorphone program for which we have filed an investigational new drug application, or IND. This program has received a grant from the National Institute on Drug Abuse, a constituent
institute of NIH, and has been granted Fast Track status by the FDA. We also have other extended-release, abuse-deterrent product candidates that have completed preliminary preclinical studies,
including hydrocodone and morphine for pain, and methylphenidate for the treatment of attention deficit hyperactivity disorder, or ADHD. We are targeting to begin clinical trials with our second
product candidate in the first quarter of 2016. All of these product candidates share similar abuse-deterrent </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=95,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=322684,FOLIO='91',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_du72301_1_92"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>qualities
as Xtampza and are designed to be suitable for patients with difficulty swallowing. We own all of the rights to our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g118836.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="187">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each
of our product candidates is being developed to seek FDA approval in accordance with Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act. Section&nbsp;505(b)(2)
permits an applicant to file an NDA that relies, in part, on data not developed by or for the applicant and to which the applicant has not received a right of reference, such as the FDA's findings of
safety and efficacy in the approval of a similar drug, or listed drug, or published literature in support of its application. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Xtampza  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Overview  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our lead product candidate, Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone in development for the management of pain
severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The active ingredient in Xtampza is oxycodone, which is
approved by the FDA and other regulators around the world in a number of both immediate-release and extended-release drug products. We developed Xtampza using our proprietary, DETERx abuse-deterrent
technology to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting Xtampza. Xtampza has received Fast Track status from
the FDA. Our NDA filing for Xtampza was accepted by the FDA on February&nbsp;10, 2015. On February&nbsp;25, 2015, the FDA set a PDUFA goal date of October&nbsp;12, 2015 for completion of its
review of the Xtampza NDA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are seeking approval of Xtampza through the FDA's Section&nbsp;505(b)(2) regulatory approval pathway using OxyContin OP as our listed drug, with the goal of obtaining abuse-deterrent claims in
our product label based on three categories of our completed abuse-deterrence studies. In July 2014, we completed our pivotal Phase&nbsp;3 efficacy and safety clinical trial for Xtampza in patients
with moderate-to-severe chronic low back pain, which met efficacy and safety endpoints. We also completed Category&nbsp;1, Category&nbsp;2 and Category&nbsp;3 abuse-deterrent studies and
clinical trials designed to follow the January 2013 FDA draft guidance on abuse-deterrent opioids, and which we believe to be consistent with the April 2015 final FDA guidance, as well as direct
guidance received from the FDA in numerous meetings and written communications, including a pre-NDA meeting in April 2014. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Based
on the results of our Category&nbsp;1, 2 and 3 abuse-deterrent studies and clinical trial program and recent feedback from the FDA, we believe that Xtampza will be eligible for
abuse-deterrence claims in its label based on all three categories of our completed abuse-deterrence studies, which would provide significant differentiation as compared to other marketed
extended-release opioids. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also conducted an alternative dosing clinical trial to assess the feasibility of administering Xtampza by sprinkling the microspheres onto applesauce. This clinical trial demonstrated that Xtampza
microspheres retain their abuse-deterrent and extended-release properties even after being removed from the capsule and mixed with soft food. If approved, we have performed what we believe to be all
of the required preclinical </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=96,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=972532,FOLIO='92',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_du72301_1_93"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>studies
and clinical trials to obtain FDA product labeling for sprinkling Xtampza microspheres directly in the mouth or on food, as well as administering the microspheres through a gastric or
nasogastric feeding tube. If approved with such labeling, Xtampza would be the only abuse-deterrent extended-release oxycodone product addressing patients with CPD. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Market Opportunity  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe that, if approved, Xtampza can capture a significant share of the $6&nbsp;billion U.S. extended-release opioid market, including a
portion of the existing $2.5&nbsp;billion OxyContin OP market. In addition, we believe that Xtampza can become a market leader for treating patients with chronic pain who have difficulty swallowing. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>OxyContin OP Extended-Release Market</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Until recently, no product that uses oxycodone as its active ingredient had been permitted to make label claims describing the abuse-deterrent
characteristics of its product. Purdue launched OxyContin OP in 2010. In April 2013, the FDA determined that Purdue had been successful in demonstrating OxyContin OP's abuse-deterrent characteristics
and permitted Purdue to amend its label to include certain abuse-deterrent claims. Since the launch of OxyContin OP, there has been a reduction in the overall abuse of OxyContin, primarily in the
snorted and injected routes of administration. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA also concluded that the benefits of the previously-approved non-abuse-deterrent OxyContin no longer outweighed its risks and removed it from the list of drugs eligible to serve as a reference
product for future generic or Section&nbsp;505(b)(2) approvals. As a result, we expect that all extended-release oxycodone products, including generic products, will now be required to have
abuse-deterrent claims as part of the FDA approval process. We believe this change in FDA policy creates a significant opportunity for Xtampza, if approved, to capture a portion of the
extended-release oxycodone market. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite
OxyContin OP's commercial success, it carries with it a well-documented abuse stigma both for physicians who prescribe it and for patients who use it to treat chronic pain. In a market
research study conducted for us in 2013, 35% of patients surveyed who were taking OxyContin OP indicated concern that their friends or family have a negative perception of OxyContin OP. Of the 1,021
patients surveyed in the study, 11% of chronic pain patients responded that they have had their opioid medication stolen, most often from their home, and 76% indicated an interest in switching to a
pain medication similar to OxyContin OP but that was more abuse-deterrent. A market research study of 30 physicians conducted for us in 2015 concluded that while physicians view OxyContin OP as an
effective and valuable option, one third reported prescribing it less often than they would like because of patients' reticence to use OxyContin OP because of its reputation for addiction and abuse. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
in a third party study of post-marketing data on misuse and diversion of prescription opioid analgesics, the initial decline in abuse of OxyContin OP by patients who reported abusing the
non-abuse-deterrent OxyContin 30&nbsp;days prior to entering treatment for opioid abuse disorder, plateaued at 25% to 30%, with no further decreases from 2012 to study conclusion in 2014. A
sub-population of participants was surveyed to investigate their continued abuse of OxyContin. Among the 88 participants who abused both non-abuse-deterrent OxyContin and OxyContin OP, their continued
abuse of OxyContin OP was explained by: (i)&nbsp;a transition from non-oral routes of administration to oral use (approximately 43%); (ii)&nbsp;successful efforts to defeat the abuse-deterrent
formulation mechanism leading to a continuation of inhaled or injected use (approximately 34%); and (iii)&nbsp;exclusive use of the oral route independent of formulation type (approximately 23%).
Representative comments of participants who continued to abuse OxyContin OP demonstrated that participants were able to identify methods of circumventing the abuse deterrent properties using the
internet. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Other Extended-Release Opioids</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>While OxyContin OP is the largest selling extended-release opioid in the United States by dollars in 2014, there are approximately 23&nbsp;million
additional prescriptions for non-abuse-deterrent extended-release opioids </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=97,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=275855,FOLIO='93',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_du72301_1_94"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>annually
in the United States. Many of these opioids include active ingredients, such as morphine, that are commonly perceived as having greater adverse side effects than oxycodone-based formulations.
Because of the abuse stigma associated with OxyContin OP and non-abuse-deterrent opioid formulations, we believe that Xtampza would offer physicians treating chronic pain an attractive alternative to
the existing options. Our market research also demonstrates that payors recognize the prevalence of opioid abuse and its corresponding economic burden. This research indicates that "brand" prices
would be acceptable for products that are differentiated. As such, we aim to achieve broad Tier 3 payor coverage on commercial plans and contract with Medicare and Medicaid. In a market research study
conducted for us, 83% of disease specialists (such as oncologists and neurologists) and 67% of pain specialists surveyed indicated that, if approved, they would prescribe Xtampza for patients without
dysphagia. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Chronic Pain with Dysphagia</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In a market research survey conducted for us, of 1,021 patients with chronic pain, 30% of the patients reported that they have trouble swallowing or
do not like to swallow pills, and 65% of the patients did not realize that cutting, crushing or grinding extended-release opioids can change the drug release profile. None of the currently approved
abuse-deterrent opioid drugs has an FDA product label that permits the sprinkling of the product on food, directly in the mouth and administration through feeding tubes for use by patients with CPD,
creating an unmet medical need due to the lack of adequate treatment options. Further, in an effort to make them easier to swallow, some patients with CPD&nbsp;&#151; and 47 of the 1,021
patients participating in the survey conducted for us&nbsp;&#151; crush their prescribed extended-release opioids and can inadvertently harm themselves because of the rapid immediate-release
of the active ingredient. Because our Xtampza microspheres are designed to be able to be removed from the capsule and still retain their abuse-deterrent and extended-release properties, we believe
that they will be an effective pain-management solution for patients with CPD. An external marketing study performed for us in 2013 estimated that Xtampza, if approved, has a peak revenue potential
for U.S. patients with CPD in excess of $700&nbsp;million annually. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Clinical Development  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have completed numerous studies and clinical trials on Xtampza. We submitted an NDA for Xtampza to the FDA on December&nbsp;12, 2014. Xtampza has
received Fast Track status from the FDA. We are seeking approval of Xtampza through the FDA's Section&nbsp;505(b)(2) regulatory approval pathway using OxyContin OP as our listed drug with the goal
of obtaining abuse-deterrent claims in our product label based on all three categories of our completed abuse-deterrence studies. To date, we have completed bioequivalence and bioavailability studies,
a pivotal Phase&nbsp;3 clinical trial of Xtampza in patients with moderate-to-severe chronic low back pain, which met safety and efficacy endpoints, as well as Category&nbsp;1, Category&nbsp;2
and Category&nbsp;3 abuse deterrence studies and clinical trials based on the January 2013 FDA draft guidance regarding abuse-deterrent opioids. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Evaluation of Safety and Efficacy  </I></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


 </I></FONT><FONT SIZE=2><U>Phase&nbsp;3 Clinical Trial</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>After
discussions with the FDA, we conducted a single pivotal Phase&nbsp;3 clinical trial designed to show safety and efficacy of Xtampza in a chronic pain population. The
Phase&nbsp;3 clinical trial was a multi-center, prospective, double-blind, enriched enrollment, randomized withdrawal, placebo-controlled clinical trial that examined the safety, tolerability, and
efficacy of Xtampza versus placebo in opioid-experienced and opioid-na&iuml;ve patients with moderate-to-severe chronic low back pain. This study was designed with acetaminophen </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=98,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1031100,FOLIO='94',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_du72301_1_95"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>as
the rescue medication in order to avoid the potential issue of immediate-release opioid rescue medication use confounding the effect of the study drug. The trial design is depicted in the figure
below. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g156134.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="324">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Of
the 740 patients enrolled in the initial open-label titration portion of the clinical trial, 389 patients met the criteria for randomization, which included stable and effective pain scores,
ability to tolerate the drug at the dose at which effective pain relief was achieved and compliance with all other aspects of the clinical trial protocol. These 389 patients were randomized into a
12-week, double-blind maintenance phase in which they were either maintained on their current dose regimen of Xtampza or were tapered to a placebo. The primary efficacy endpoint of the clinical trial
was the change in average pain intensity from baseline to week 12; pain was measured using an 11-point pain intensity numerical rating scale. Sensitivity analyses were performed to evaluate the
primary endpoint. Secondary endpoints in the clinical trial included </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=99,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=337955,FOLIO='95',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_du72301_1_96"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>evaluation
of safety and tolerability, quality of life, physical disability, and global impression of change. The graph below shows the daily average pain score in the randomized, intent to treat, or
ITT, population. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g477671.jpg" ALT="GRAPHIC" WIDTH="585" HEIGHT="460">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
clinical trial demonstrated that the estimated marginal mean change in average pain score from Randomization Baseline to Week 12 was greater for the placebo treatment group (1.85) than for the
Xtampza
treatment group (0.29). The clinical trial successfully met the primary efficacy endpoint by showing that the difference between treatment groups in the estimated marginal mean change in average pain
score was statistically significant (p&lt;0.0001). All sensitivity analyses showed statistically significant results (with p&nbsp;values ranging from 0.0002 to &lt;0.0001) supporting
the primary endpoint analysis favoring Xtampza compared to placebo. All secondary endpoints were achieved. The p-value, or probability value, is a measure of statistical significance reflecting the
likelihood that an observed result occurred by chance. Generally, p-values less than or equal to 0.05 are considered to indicate statistical significance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
was well-tolerated in this study. No new safety concerns were identified. The most common adverse events, or AEs, (&gt;5%) reported by patients in the Phase&nbsp;3 clinical trial during the
titration phase were nausea, headache, constipation, drowsiness, itching, vomiting and dizziness. Each of these AEs declined in frequency with continued treatment. The most common adverse reactions
(&gt;5%) reported by patients in the Phase&nbsp;3 clinical trial comparing Xtampza with placebo are shown in the table below. One subject was hospitalized for a serious adverse event moderate in
severity of gastroesophageal reflux and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=100,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=592205,FOLIO='96',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_du72301_1_97"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>subsequently
discharged upon resolution of the event. The investigator at the clinical trial site assessed this event as possibly related to study drug, but no action was taken with the study drug due
to this event. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Titration<BR>
Period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Maintenance Period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:61pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Adverse Reaction

<!-- COMMAND=ADD_SCROPPEDRULE,61pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Xtampza<BR>
(n&nbsp;= 740)<BR>
(%) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Xtampza<BR>
(n&nbsp;= 193)<BR>
(%) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Placebo<BR>
(n&nbsp;= 196)<BR>
(%) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nausea</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Headache</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>11.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Constipation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Somnolence</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&lt;1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&lt;1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pruritus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vomiting</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dizziness</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2><U>Phase&nbsp;1 Clinical Trials</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
performed two Phase&nbsp;1 bioequivalence and bioavailability clinical trials to compare the blood levels obtained after administration of Xtampza versus OxyContin OP.
The first, in which we enrolled 48 patients, compared the pharmacokinetics, or PK, of Xtampza with OxyContin OP in fasted and fed states following single dose administration, with results shown in the
figure below. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g961380.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="264">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
single-dose PK profiles for Xtampza and OxyContin OP were similar. However, in the fasted state, the total amount of absorption, known as area under the curve, or AUC, was lower when compared with
the fed state for Xtampza, suggesting a larger food effect than OxyContin OP. As a result, if approved, Xtampza is likely to be labeled to be taken with food. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
performed a second phase&nbsp;1 clinical trial to assess the safety and PK of Xtampza and OxyContin OP in fed and fasted states following multiple-dose administration. In this clinical trial,
which enrolled 45&nbsp;patients, as shown in the figure below, both products were taken with food twice per day for five days, and the PK profiles&nbsp;&#151; which were assessed based on
two variables, peak plasma level of the drug, or C<SUB>max</SUB>, and AUC &#151; were bioequivalent. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=101,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=318214,FOLIO='97',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_du72301_1_98"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du72301_day_5,_all_doses_fed_(cp-oxydet-18)"> </A>
<A NAME="toc_du72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Day 5, All Doses Fed (CP-OXYDET-18)    <BR>    </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="120pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="114pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>C<font
style="font-size:6pt;position:relative;bottom:-1pt;add_sub:1pt;">max</font> (ng/ml) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>AUC (hr*ng/ml) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Xtampza</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77.7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>511</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OxyContin OP</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>531</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Xtampza : OxyContin OP % Ratio (90% Confidence Interval)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>99.60 (93.60-105.97)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>95.63 (92.73-98.61)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Evaluation of Abuse-Deterrence of Xtampza</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza was developed and evaluated in a manner consistent with recommendations described in the January 2013 draft FDA guidance on the evaluation and
labeling of abuse-deterrent opioids. We believe our development program is consistent with the April&nbsp;2015 final FDA guidance. Listed below is an overview of the studies and clinical trials
needed for FDA abuse-deterrent labeling. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=102,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=781803,FOLIO='98',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_du72301_1_99"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du72301_fda_guidance_pre_and_post-marketing_study_categories"> </A>
<A NAME="toc_du72301_3"> </A>
<BR></FONT><FONT SIZE=2><B>  FDA Guidance Pre and Post-marketing Study Categories    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="92pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="25%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="25%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="25%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:30pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Category

<!-- COMMAND=ADD_SCROPPEDRULE,30pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Study Type </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Objective </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Claim Example </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>1 &#151; Pre-market</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Laboratory Manipulation and Extraction Studies</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Evaluate ease with which abuse-deterrent properties of formulation can be defeated or compromised</FONT></TD>
<TD style="font-family:arial;"><FONT FACE="arial" SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;1: The product is formulated with psychochemical barriers that are expected to deter intravenous abuse.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2>2 &#151; Pre-market</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PK Studies</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Understand in vivo properties of formulation by comparing PK profiles of manipulated formulation with intact formulation</FONT></TD>
<TD style="font-family:arial;"><FONT FACE="arial" SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;2: The product is formulated with psychochemical properties that are expected to deter oral and nasal abuse.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2>3 &#151; Pre-market</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clinical Human Abuse Potential Clinical Trials (Drug Likability)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Assess impact of the potentially abuse-deterrent formulation on measures that predict how probable it is the formulation will be attractive to abusers ("liked")</FONT></TD>
<TD style="font-family:arial;"><FONT FACE="arial" SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;3: The results from the oral and intranasal clinical abuse potential studies indicate that the medication has properties expected to deter abuse via oral, intranasal and intravenous
routes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2>4&nbsp;&#151;&nbsp;Post-market</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Post-marketing Epidemiologic Studies</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Conduct epidemiologic studies capable of detecting a change in the occurrence of abuse and abuse-related outcomes</FONT></TD>
<TD style="font-family:arial;"><FONT FACE="arial" SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;4: There was a demonstrated reduction in abuse of this medication in the community setting compared to the levels of abuse, overdose and death that occurred when only formulations of
the same opioid without abuse-deterrent properties were available.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Our
development program consisted of in vitro studies and clinical trials, the results of which indicate that Xtampza may result in reduced abuse by manipulation followed by oral ingestion, snorting
or attempted intravenous injection. The table below summarizes the abuse deterrence studies and clinical trials we conducted for Xtampza. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=103,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=931970,FOLIO='99',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_du72301_1_100"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du72301_abuse-deterrent_assessment_strategy"> </A>
<A NAME="toc_du72301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Abuse-deterrent Assessment Strategy    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="11%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="208pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="47%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Description </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Collegium Studies and Clinical Trials </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Category&nbsp;1</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Laboratory based in vitro manipulation and extraction studies</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Numerous physical, chemical manipulation and route specific studies (IV injection, smoking)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Category&nbsp;2</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>PK clinical trials</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Oral Crushed/Chewed PK Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-17</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Intranasal PK Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-19</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Comparative Crushing/Tampering PK Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-25</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Intranasal PK and human abuse potential, or HAP, Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-21</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Oral Chewed PK and HAP Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-24</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Category&nbsp;3</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Human abuse potential (drug likeability) clinical trials</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Intranasal PK and HAP Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-21</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Oral Chewed PK and HAP Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-24</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2><U>Category&nbsp;1: In Vitro Studies</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
demonstrated abuse-deterrent properties of Xtampza in each mode of physical, chemical and route specific manipulations. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Physical Manipulations  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>One of the key objectives of our Category&nbsp;1 studies was to determine the most effective tool to crush Xtampza microspheres and OxyContin OP
tablets as part of a particle size reduction, or PSR, study. The results of this PSR study informed the design of our PK clinical trials. A range of household tools was selected based upon the review
of the literature and researching the internet for common methods used by abusers. Based upon this, 10 tools were selected that cut, broke, ground and crushed the Xtampza microspheres and/or OxyContin
OP tablets. For OxyContin OP, five of these tools were effective in laboratory tests at substantially increasing the rate of drug release, resulting in "dose dumping" of the active ingredient. For
Xtampza, none of these tools was effective at causing dose dumping. A subset of these tools were also applied to the Xtampza microspheres after pre-treatment by freezing or heating, but were still
unable to cause dose dumping. Consistent with FDA guidance, results of the physical manipulation study were replicated by an independent third party analytical laboratory registered with the FDA. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Chemical Extraction  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our chemical extraction studies were completed using the optimal method of crushing for Xtampza and OxyContin OP as identified in the above
Category&nbsp;1 study. We conducted a series of laboratory-based Category&nbsp;1 chemical manipulation studies to investigate simple and complex extraction methods and dissolution of Xtampza and
OxyContin OP in a variety of commonly used beverages, solvents, and soft foods. Results from these studies show that Xtampza microspheres resist extraction of the oxycodone active ingredient into a
usable non-toxic form that could be abused. By contrast, after crushing, the active ingredient was readily extracted from OxyContin OP. Results from these studies show that Xtampza has a greater
resistance to a wide variety of solvents used for extraction than OxyContin OP. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=104,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=536580,FOLIO='100',FILE='DISK114:[15ZAD1.15ZAD72301]DU72301A.;66',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dw72301_1_101"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Route Specific&nbsp;&#151; Injection  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>To assess the ability for abusers to inject Xtampza, the microspheres were crushed, suspended in water and the resulting suspension was attempted to
be expelled with needles and syringes. Only negligible amounts of the microspheres were able to pass through any size needle, including an 18 gauge needle (which was the largest needle size tested).
By contrast, crushing OxyContin OP and mixing it in water resulted in a gel where a substantial amount, up to 54% of the active ingredient, could be passed through an 18 gauge needle, as well as
smaller 25 and 27 gauge needles. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Xtampza microspheres were then melted at approximately 75&deg;C and the resulting molten material was attempted to be drawn through a needle into a syringe and then expelled through the
needle. As the liquid was drawn into the syringe, it immediately solidified, making injection impossible. A comparable procedure on OxyContin OP was not performed because a substantial portion of the
crushed and dissolved OxyContin OP mixture, without melting, could be passed through an 18 gauge needle. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Finally,
attempts were made to extract the active drug from Xtampza microspheres and OxyContin OP in injectable amounts of water. Both drugs were subjected to three manipulation techniques prior to
extraction in water, consisting of crushing alone, crushing and heating them on a hot plate, and crushing and microwaving them. For Xtampza, less than 10% of the oxycodone could be extracted for
injection regardless of the manipulation applied. By contrast, the amount of oxycodone extracted from OxyContin OP ranged from 17-84%, depending on the method. Approximately 17% of oxycodone was
extracted when crushed, 68% was extracted when crushed and subjected to pretreatment on a heating plate and 84% was extracted when crushed and subjected to heating in a microwave. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g127792.jpg" ALT="GRAPHIC" WIDTH="675" HEIGHT="246">
  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Route Specific&nbsp;&#151; Smoking  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Studies have shown that less than 5% of OxyContin OP abuse is by smoking. We conducted a study comparing the ability to vaporize Xtampza, OxyContin
OP, and a marketed immediate-release form of oxycodone. The average amount of oxycodone recovered from vapor after 3 minutes, as a percentage of the total available in the smoked capsule or pill, was
approximately 17% for Xtampza, 23% for OxyContin OP and 30% for the marketed immediate-release oxycodone suggesting that Xtampza is unlikely to be abused by smoking more often than existing oxycodone
products. In addition, when Xtampza is heated in order to vaporize the oxycodone, inactive excipients are also vaporized, which may be unpleasant to an abuser. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=105,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=919720,FOLIO='101',FILE='DISK114:[15ZAD1.15ZAD72301]DW72301A.;78',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dw72301_1_102"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2><U>Category&nbsp;2: Oral PK Clinical Trials</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>To
support oral abuse-deterrent labeling for Xtampza we performed five separate PK clinical trials, three by the oral route of administration and two by the nasal route. The
oral clinical trials were as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="21%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="21%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial&nbsp;&amp; Category </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Subjects </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Comparator(s) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Key Objective </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Oral Crushed/Chewed PK Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-17)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Category&nbsp;2</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 44</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Immediate-release oxycodone solution</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Assess the safety and PK of Xtampza intact, chewed and crushed</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Oral Chewed PK and HAP Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-24)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Categories&nbsp;2&nbsp;&amp; 3</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>n = 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Crushed immediate-release oxycodone tablets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Assess the PK (Category&nbsp;2) and drug-likeability (Category&nbsp;3) of Xtampza, intact and chewed</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Comparative Crushing/Tampering PK Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-25)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Category&nbsp;2</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>OxyContin OP (intact and crushed) and crushed immediate-release oxycodone tablets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Assess the safety and PK of Xtampza, intact and crushed</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Oral Crushed/Chewed PK Clinical Trial (CP-OXYDET-17)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our oral crushed/chewed PK clinical trial (CP-OXYDET-17) was an open-label, randomized, active-controlled, crossover clinical trial to evaluate the
effect of tampering (crushing and chewing) on Xtampza microspheres compared with immediate-release oxycodone solution. The clinical trial had seven treatment arms, consisting of three fasted-state
treatment arms and four fed-state treatment arms. Because Xtampza has a mild food effect, we expect that Xtampza, if approved, will include a label that it should be taken with food. Accordingly, the
graph below provides only the results of the clinical trial for the fed-state treatment arms. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw72301_mean_concentrations_of_oxycodone"> </A>
<A NAME="toc_dw72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g673771.jpg" ALT="GRAPHIC" WIDTH="565" HEIGHT="330">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=106,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=906649,FOLIO='102',FILE='DISK114:[15ZAD1.15ZAD72301]DW72301A.;78',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dw72301_1_103"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
demonstrated above, crushing or chewing Xtampza did not increase its C<SUB>max</SUB> as compared to the intact Xtampza capsules. All treatment groups had substantially lower peak plasma levels and
longer time to peak plasma level, or T<SUB>max</SUB>, than the immediate-release oxycodone solution. The absorption of oxycodone, as measured by AUC, was substantially equivalent among the crushed,
chewed and intact Xtampza treatment groups. In all Xtampza treatment groups, the extended-release properties remained intact and there was no evidence of dose dumping. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw72301_cmax_ratios_relative_t__dw702357"> </A>
<A NAME="toc_dw72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  C<SUB>max</SUB> Ratios Relative to Xtampza Intact Capsules Baseline    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g520844.jpg" ALT="GRAPHIC" WIDTH="558" HEIGHT="255">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Substantial
early increases in plasma concentrations after crushing or chewing, compared to intact capsules are indicative of dose dumping. As a result, the labels for all currently available orally
administered extended-release opioids include a black box warning instructing patients that "crushing, dissolving or chewing the tablet can cause rapid release and absorption of a potential fatal
dose" of the respective opioid. The results of the clinical trial shown in the graph below demonstrate that crushing and chewing, two common methods of manipulation used by abusers, did not increase
the early plasma concentration of Xtampza when taken orally. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=107,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=70128,FOLIO='103',FILE='DISK114:[15ZAD1.15ZAD72301]DW72301A.;78',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dw72301_1_104"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw72301_graphical_display_of_mean_oxyc__gra02735"> </A>
<A NAME="toc_dw72301_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values from 0.25 to 3.5&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g678933.jpg" ALT="GRAPHIC" WIDTH="535" HEIGHT="304">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Another
measure used to assess the potential "likability" of a drug for abusers is the "abuse quotient," or AQ, which characterizes the rate at which the peak plasma rises after ingestion and is
calculated by dividing C<SUB>max</SUB> by T<SUB>max</SUB>. By manipulating a formulation, an abuser seeks to create euphoria by maximizing AQ. As shown in the graph below, the AQ values for Xtampza
after crushing or chewing were the same as taking the product intact and meaningfully lower than for the immediate-release oxycodone solution. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw72301_mean_aq_values_for_each_treatment"> </A>
<A NAME="toc_dw72301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g605255.jpg" ALT="GRAPHIC" WIDTH="600" HEIGHT="253">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, in this clinical trial, manipulation of Xtampza microspheres by crushing or chewing did not alter the extended-release properties of the Xtampza formulation in the fed-state treatment
arms. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Oral Chewed PK and HAP Clinical Trial (CP-OXYDET-24)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our oral chewed PK and HAP clinical trial was designed to assess the PK of Xtampza following chewing as compared to taking the product candidate
intact and also as compared to crushing an immediate-release oxycodone tablet. The clinical trial design was consistent with FDA guidance. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=108,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=531936,FOLIO='104',FILE='DISK114:[15ZAD1.15ZAD72301]DW72301A.;78',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dw72301_1_105"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
results shown in the figure below indicate that for C<SUB>max</SUB> and AUC, Xtampza intact and Xtampza chewed are bioequivalent with equivalent T<SUB>max</SUB>. These results indicate that
chewing Xtampza does not affect the peak and overall exposure to oxycodone. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw72301_mean_concentrations_of_oxycodone_1"> </A>
<A NAME="toc_dw72301_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g999257.jpg" ALT="GRAPHIC" WIDTH="601" HEIGHT="349">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure below further demonstrates that chewing Xtampza does not affect C<SUB>max</SUB> relative to intact Xtampza capsules. Ratios below 100% indicate chewing does not increase peak plasma
exposure versus baseline (taking Xtampza intact). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw72301_cmax_ratios_relative_to_intact_xtampza_capsules"> </A>
<A NAME="toc_dw72301_6"> </A>
<BR></FONT><FONT SIZE=2><B>  C<SUB>max</SUB> Ratios Relative to Intact Xtampza Capsules    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g13895.jpg" ALT="GRAPHIC" WIDTH="538" HEIGHT="267">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
better characterize early plasma exposure, partial area under the curve, or PAUC (which measures cumulative absorption over an initial period, in this case five hours, after dosage), and AQ values
were calculated for each treatment arm. Over the timeframe of the first sampling time to five hours after dosing, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=109,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=403727,FOLIO='105',FILE='DISK114:[15ZAD1.15ZAD72301]DW72301A.;78',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dw72301_1_106"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
PAUC values for all Xtampza treatments were substantially lower than the immediate-release oxycodone crushed solution PAUC values. The small increase in PAUC for the manipulated Xtampza capsules
relative to intact capsules was anticipated because the microspheres were removed from the capsules prior to oral administration and were therefore more rapidly exposed to the gastric environment for
absorption. As shown in the figures below, the mean PAUC and AQ values for all Xtampza treatments were substantially lower than the immediate-release oxycodone crushed solution AQ. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw72301_graphical_display_of_mean_oxyc__gra03095"> </A>
<A NAME="toc_dw72301_7"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values over the First 5&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g455454.jpg" ALT="GRAPHIC" WIDTH="556" HEIGHT="298">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dw72301_mean_aq_values_for_each_treatment_1"> </A>
<A NAME="toc_dw72301_8"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g112658.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="219">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, the PK data from this clinical trial indicate that there is no material increase in plasma exposure or dose dumping when Xtampza is administered after chewing, when compared to intact
Xtampza. Similar to our oral crushed/chewed PK clinical trial, our oral chewed PK and HAP clinical trial demonstrated that intact and manipulated Xtampza are bioequivalent to each other. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=110,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=856827,FOLIO='106',FILE='DISK114:[15ZAD1.15ZAD72301]DW72301A.;78',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dy72301_1_107"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Comparative Crushing/Tampering PK Clinical Trial (CP-OXYDET-25)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our comparative crushing/tampering PK clinical trial was an open-label, randomized, active-controlled, cross-over, single-dose clinical trial that
evaluated the effect of crushing Xtampza, OxyContin OP and immediate-release oxycodone tablets. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure on the left below indicates that crushing does not materially increase the C<SUB>max</SUB> or materially change the AUC of Xtampza compared with the intact product, which retains its oral
extended-release properties when crushed, confirming observations from our oral crushed/chewed PK clinical trial. By contrast, the OxyContin OP data in the figure on the right below show that
OxyContin OP exhibits&nbsp;a higher C<SUB>max</SUB> and shorter T<SUB>max</SUB> when administered orally in the crushed state, as compared with the intact state, essentially converting OxyContin
OP from an extended-release to an immediate-release formulation. This in vivo observation is consistent with in vitro studies on OxyContin OP, which showed that the amount of drug released in one hour
increased from 17% in the intact state to 77% following crushing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy72301_mean_concentrations_of_oxycodone"> </A>
<A NAME="toc_dy72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g733520.jpg" ALT="GRAPHIC" WIDTH="682" HEIGHT="240">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure below shows the mean PAUC values from the first sampling time to two hours for all treatments. Over the first two hours after dosing, the PAUC values for intact and crushed Xtampza, as well
as intact OxyContin OP, treatments were substantially lower than the corresponding crushed immediate-release oxycodone values. Over this same timeframe, the PAUC values for crushed OxyContin OP
overlapped with those of crushed immediate-release oxycodone. The small increase in PAUC for the crushed Xtampza treatment relative to intact Xtampza was anticipated because the microspheres were
removed from the capsules prior to oral administration and were therefore more rapidly exposed to the gastric environment for absorption. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=111,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=971100,FOLIO='107',FILE='DISK114:[15ZAD1.15ZAD72301]DY72301A.;52',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dy72301_1_108"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy72301_graphical_display_of_mean_oxyc__gra02765"> </A>
<A NAME="toc_dy72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values from 0.25 to 2&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g441803.jpg" ALT="GRAPHIC" WIDTH="589" HEIGHT="316">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in the figure below, mean AQ values were comparable for crushed and intact Xtampza treatments and substantially lower than crushed immediate-release oxycodone. In contrast to Xtampza,
crushing OxyContin OP compromises its extended-release profile such that the AQ value of crushed OxyContin OP increases by nearly four times and is similar to that of immediate-release oxycodone. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy72301_graphical_display_of_m__dy702266"> </A>
<A NAME="toc_dy72301_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean (SD) AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g685216.jpg" ALT="GRAPHIC" WIDTH="619" HEIGHT="294">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, crushing Xtampza microspheres does not materially change the extended-release properties of the product. By contrast, crushing OxyContin OP with common household tools causes it to
completely lose its extended-release properties, turning it into an immediate-release and readily abuseable formulation. The data in this clinical trial confirm and extend the findings from previous
studies, demonstrating that crushing or chewing Xtampza should not lead to a potentially fatal rapid release of oxycodone via "dose dumping" should a patient or a drug abuser crush, break or grind
Xtampza. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=112,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=994057,FOLIO='108',FILE='DISK114:[15ZAD1.15ZAD72301]DY72301A.;52',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dy72301_1_109"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


 </I></FONT><FONT SIZE=2><U>Category&nbsp;2: Intranasal PK Clinical
Trials</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
completed two intranasal PK clinical trials to support abuse-deterrent labeling for Xtampza. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="34%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="17%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="34%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial&nbsp;&amp; Category </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Subjects </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Comparator(s) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Key Objective </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Intranasal PK Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-19)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Category&nbsp;2</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 15</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Oxycodone powder</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Compare the safety and PK of crushed and intact Xtampza following intranasal administration.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Intranasal PK and HAP Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-24)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Categories&nbsp;2&nbsp;&amp; 3</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Crushed immediate-release oxycodone tablets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Evaluate the PK (Category&nbsp;2) and abuse potential (Category&nbsp;3) of crushed and intact Xtampza following snorting and oral administration.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Intranasal PK Clinical Trial (CP-OXYDET-19)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our intranasal PK clinical trial was a randomized, open-label, active-controlled, cross-over comparison trial. The primary objective was to compare
the safety and PK of crushed and snorted Xtampza, intact Xtampza capsules taken orally, and snorted immediate-release oxycodone powder. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Data
from this clinical trial demonstrated that administration of crushed and snorted Xtampza resulted in a lower C<SUB>max</SUB> than both intact Xtampza taken orally and snorted immediate-release
oxycodone powder; the C<SUB>max</SUB> for crushed and snorted Xtampza was approximately 80% of intact Xtampza taken orally and 60% of snorted immediate-release oxycodone powder. The median
T<SUB>max</SUB> following crushed and snorted Xtampza was equivalent to the median T<SUB>max</SUB> for intact Xtampza taken orally, and both demonstrated longer median T<SUB>max</SUB> values than
snorted immediate-release oxycodone powder. Crushed and snorted Xtampza, intact Xtampza taken orally, and snorted immediate-release oxycodone powder were all bioequivalent with respect to AUC
parameters. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy72301_mean_concentrations_of_oxycodone_1"> </A>
<A NAME="toc_dy72301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g453119.jpg" ALT="GRAPHIC" WIDTH="571" HEIGHT="352">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=113,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=449824,FOLIO='109',FILE='DISK114:[15ZAD1.15ZAD72301]DY72301A.;52',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dy72301_1_110"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure below shows the mean PAUC values from the first sampling time to two hours for two treatments. Over the first two hours after dosing, the PAUC values for crushed and snorted Xtampza
treatments were substantially lower than the crushed and snorted immediate-release oxycodone powder values. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy72301_graphical_display_of_mean_oxyc__gra02776"> </A>
<A NAME="toc_dy72301_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values from 0.1 to 2&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g307556.jpg" ALT="GRAPHIC" WIDTH="606" HEIGHT="289">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in the figure below, the mean AQ values for crushed and snorted Xtampza and intact Xtampza taken orally were comparable. In this clinical trial, no increase in AQ was observed with crushed
and snorted Xtampza relative to intact Xtampza taken orally. In contrast, the AQ value for snorted immediate-release oxycodone powder was approximately five-fold higher, on average, than that for
crushed and snorted Xtampza. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy72301_mean_aq_values_for_each_treatment"> </A>
<A NAME="toc_dy72301_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g102226.jpg" ALT="GRAPHIC" WIDTH="672" HEIGHT="232">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, crushed and snorted Xtampza microspheres demonstrated a lower C<SUB>max</SUB> and an equivalent T<SUB>max</SUB> compared to taking the intact product orally as directed. The
C<SUB>max</SUB> of both crushed and snorted Xtampza and intact Xtampza taken orally are substantially lower than the C<SUB>max</SUB> of snorted immediate-release oxycodone powder. Crushing and
snorting Xtampza microspheres did not produce the rapid, high plasma concentrations that abusers might seek for euphoria. Additionally, crushed and snorted Xtampza produced a higher </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=114,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=112834,FOLIO='110',FILE='DISK114:[15ZAD1.15ZAD72301]DY72301A.;52',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dy72301_1_111"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>percentage
of mild respiratory AEs (e.g.,&nbsp;nasal discomfort and congestion) and associated transient nasal events including burning, and facial pain/pressure compared with the immediate-release
comparator. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Intranasal PK and HAP Clinical Trial (CP-OXYDET-24)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our intranasal PK and HAP clinical trial was a randomized, open-label, active-controlled, cross-over comparison clinical trial. The primary objective
was to compare the safety and PK of crushed and snorted Xtampza, intact Xtampza capsules taken orally, and snorted crushed immediate-release oxycodone tablets. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
PK results from our intranasal PK and HAP clinical trial are similar to those observed in our intranasal PK clinical trial. With respect to AUC, crushed and snorted Xtampza was bioequivalent to
intact Xtampza taken orally. However, crushed and snorted Xtampza microspheres resulted in approximately 70% of the peak exposure of intact Xtampza taken orally and approximately 50% of the peak
exposure of crushed and snorted immediate-release oxycodone. Median T<SUB>max</SUB> was equivalent when comparing crushed and snorted Xtampza relative to intact Xtampza taken orally. Both Xtampza
treatments had substantially longer median T<SUB>max</SUB> values in comparison to crushed and snorted immediate-release oxycodone. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy72301_mean_concentrations_of_oxycodone_2"> </A>
<A NAME="toc_dy72301_7"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g267601.jpg" ALT="GRAPHIC" WIDTH="541" HEIGHT="330">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure below shows the mean PAUC values from the first sampling time to five hours for all three treatment arms. Over the first five hours after dosing, the PAUC values for intact Xtampza and
crushed and snorted Xtampza treatments were substantially lower than those of the crushed and snorted immediate-release oxycodone treatment. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=115,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=118645,FOLIO='111',FILE='DISK114:[15ZAD1.15ZAD72301]DY72301A.;52',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dy72301_1_112"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy72301_graphical_display_of_mean_oxyc__gra02768"> </A>
<A NAME="toc_dy72301_8"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values from 0.25 to 5&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g556198.jpg" ALT="GRAPHIC" WIDTH="676" HEIGHT="288">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
mean AQ value for crushed and snorted Xtampza was similar to (and slightly lower than) that of intact Xtampza taken orally. By contrast, the mean AQ value for the crushed and snorted
immediate-release oxycodone treatment was approximately 11-fold greater than that of crushed and snorted Xtampza. These data indicate that crushed and snorted Xtampza may potentially be less desirable
to (i.e.,&nbsp;less liked by) drug abusers seeking to achieve a rapid, euphoric effect. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy72301_mean_aq_values_for_each_treatment_1"> </A>
<A NAME="toc_dy72301_9"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g145435.jpg" ALT="GRAPHIC" WIDTH="678" HEIGHT="261">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, data from our intranasal PK and HAP clinical trial corroborate the findings from our intranasal PK clinical trial. Both clinical trials indicate that crushed and snorted Xtampza
microspheres do not produce the rapid rise in peak plasma drug concentrations that abusers might seek for euphoria when manipulating and administering dosage forms by the nasal route. Additionally,
crushed and snorted Xtampza produced a higher percentage of mild respiratory AEs (e.g.,&nbsp;nasal discomfort, nasal congestion and nose bleeds) and associated transient nasal events including
irritation, burning, and facial pain compared with the immediate-release comparator. The AEs following crushed and snorting Xtampza microspheres, without </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=116,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1020494,FOLIO='112',FILE='DISK114:[15ZAD1.15ZAD72301]DY72301A.;52',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_dy72301_1_113"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
addition of potentially harmful antagonist or aversive agents, may serve as a nuisance to an abuser who wants to snort Xtampza. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


 </I></FONT><FONT SIZE=2><U>Category&nbsp;3: Human Abuse Potential Clinical
Trials</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
conducted two clinical trials&nbsp;&#151; our intranasal and oral PK and HAP clinical trial and our oral chewed PK and HAP clinical trial&nbsp;&#151; to
evaluate the HAP of crushed Xtampza microspheres taken orally and snorted, as described in the table below. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Summary of Category&nbsp;3 Human Abuse Potential Clinical Trials  </I></FONT></P>

</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="27%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="13%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="13%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="27%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial&nbsp;&amp; Category </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Subjects </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial Type </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Comparator(s) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Key Objective </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Intranasal PK and HAP Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-21)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Category&nbsp;2&nbsp;&amp; 3</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Intranasal PK and human abuse potential clinical trial</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Crushed immediate-release oxycodone tablets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Evaluate the PK (Category&nbsp;2) and human abuse potential (Category&nbsp;3) of crushed and intact Xtampza following intranasal and oral administration.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2><B>Oral Chewed PK and HAP Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-24)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Categories&nbsp;2&nbsp;&amp; 3</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
n&nbsp;= 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Oral chewed PK and human abuse potential clinical trial</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Crushed immediate-release oxycodone tablets in solutions</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2> Assess the PK (Category&nbsp;2) and human abuse potential (Category&nbsp;3) of Xtampza, intact and chewed</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Intranasal PK and HAP Clinical Trial (CP-OXYDET-21)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our intranasal PK and HAP clinical trial assessed the human abuse potential of crushing and snorting Xtampza compared with taking intact Xtampza
orally and with crushed and snorting immediate-release oxycodone tablets. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>HAP
trials are clinical trials that determine the intrinsic potential for abuse of a drug formulation. These clinical trials are conducted in a non-dependent, recreational drug abuser population and
are designed to predict how probable it is that a particular drug formulation will be attractive to abusers (i.e.,&nbsp;"liked"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
clinical trial measured drug liking, by which a drug abuser assesses how much he or she likes taking a drug using a visual analogue scale, or VAS, measured from 0 to 100, where 0 means the abuser
significantly dislikes the drug, 50 means neutral, and 100 means the abuser significantly likes the drug. The primary endpoint of this clinical trial was maximum effect, or Drug Liking
E<SUB>max</SUB>, which is the maximum VAS score recorded over the 24-hour period following administration. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Results
of the primary analysis for the Xtampza treatments (crushed and snorted Xtampza compared to intact Xtampza taken orally) were both significantly lower Drug Liking E<SUB>max</SUB> when
compared with the control, crushed and snorted immediate-release oxycodone (p&lt;0.0001 and p=0.0292, respectively). Additionally, a statistically significant reduction in Drug Liking
E<SUB>max</SUB> was also found when comparing crushed and snorted Xtampza microspheres with intact Xtampza capsules taken orally (p=0.037). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=117,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=627594,FOLIO='113',FILE='DISK114:[15ZAD1.15ZAD72301]DY72301A.;52',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ea72301_1_114"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ea72301_mean_drug_liking_emax_(peak_effect)"> </A>
<A NAME="toc_ea72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Drug Liking E<SUB>max</SUB> (Peak Effect)    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g858978.jpg" ALT="GRAPHIC" WIDTH="654" HEIGHT="292">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
demonstrated in the figure below, analysis of the percentage reduction in Drug Liking E<SUB>max</SUB> score for crushed and snorted Xtampza relative to crushed and snorted immediate-release
oxycodone demonstrated a significant response for individual patients, with approximately 58% of patients showing at least a 50% reduction in Drug Liking E<SUB>max</SUB> and approximately 78% of
patients showing at least a 30% reduction in Drug Liking E<SUB>max</SUB>. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ea72301_percentage_of_subjects_showing__per05680"> </A>
<A NAME="toc_ea72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Percentage of Subjects Showing Reduced Drug Liking of Crushed and Snorted Xtampza Relative to Crushed and Snorted Immediate-Release Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g463385.jpg" ALT="GRAPHIC" WIDTH="516" HEIGHT="282">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, drug abusers liked crushed and snorted Xtampza microspheres significantly less than swallowing intact Xtampza capsules (p=0.037), and they liked swallowing intact Xtampza capsules
significantly less than snorting immediate-release oxycodone powder (p=0.0292). Furthermore, crushing and snorting Xtampza was associated with the increased incidence of mild respiratory adverse
events and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=118,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=829736,FOLIO='114',FILE='DISK114:[15ZAD1.15ZAD72301]EA72301A.;62',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ea72301_1_115"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>associated
transient nasal events including irritation, burning, and facial pain among patients who crushed and snorted Xtampza microspheres. These AEs following snorting Xtampza microspheres, without
the addition of potentially harmful antagonist or aversive agents, may serve as a nuisance to an abuser who attempts snorting the drug. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Oral Chewed PK and HAP Clinical Trial (CP-OXYDET-24)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our oral chewed PK and HAP clinical trial assessed the HAP of chewing Xtampza capsule contents compared with taking the intact Xtampza orally and with
taking crushed immediate-release oxycodone tablets orally. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Similar
to our intranasal and PK and HAP clinical trial, the primary endpoint for this clinical trial was Drug Liking E<SUB>max</SUB> over the 24-hour period after dosing. Results of the primary
analysis demonstrated that chewed Xtampza had significantly lower peak Drug Liking E<SUB>max</SUB> when compared with crushed immediate-release oxycodone (p&lt;0.0001). Similarly, Drug Liking
E<SUB>max</SUB> was significantly lower for intact Xtampza when compared with crushed immediate-release oxycodone (p&lt;0.0001). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ea72301_mean_drug_liking_emax_(peak_effect)_1"> </A>
<A NAME="toc_ea72301_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Drug Liking E<SUB>max</SUB> (Peak Effect)    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g671675.jpg" ALT="GRAPHIC" WIDTH="592" HEIGHT="307">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
percentage reduction for intact and chewed Xtampza relative to crushed immediate-release oxycodone as measured by Drug Liking E<SUB>max</SUB> is presented below. This figure shows that relative
to crushed immediate-release oxycodone, chewing Xtampza does not markedly impact reduction in Drug Liking E<SUB>max</SUB> compared with swallowing Xtampza intact. For both Xtampza treatments (intact
and chewed), approximately 29-37% of patients showed at least a 50% reduction in Drug Liking E<SUB>max</SUB> relative to crushed immediate-release oxycodone, and approximately 48% of patients showed
at least a 30% reduction in Drug Liking E<SUB>max</SUB> relative to crushed immediate-release oxycodone. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=119,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=703773,FOLIO='115',FILE='DISK114:[15ZAD1.15ZAD72301]EA72301A.;62',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ea72301_1_116"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ea72301_percentage_reduction_for_xtamp__per04710"> </A>
<A NAME="toc_ea72301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Percentage Reduction for Xtampza Intact and Chewed, Relative to Crushed Immediate-Release Oxycodone for Drug Liking VAS    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g485123.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="358">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
clinical trial demonstrated that administration of chewed Xtampza resulted in lower Drug Liking E<SUB>max</SUB> than swallowing crushed immediate-release oxycodone. Similarly, swallowing intact
Xtampza resulted in lower Drug Liking E<SUB>max</SUB> than swallowing crushed immediate-release oxycodone. This decrease in Drug Liking E<SUB>max</SUB> for both chewed and intact oral administration
of Xtampza suggests that the relative abuse potential of Xtampza is significantly lower than that of a non-abuse-deterrent formulation of crushed immediate-release oxycodone (p&lt;0.0001). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
conclusion, data from these Category&nbsp;3 human abuse potential clinical trials demonstrated that Xtampza resulted in reduced Drug Liking when the drug product is chewed prior to oral
administration, or when Xtampza is crushed and snorted, relative to immediate-release oxycodone administered by the same routes. Based on these findings, Xtampza may result in reduced abuse by oral or
nasal routes of administration, both of which are the most common abuse routes for oxycodone. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=120,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=531446,FOLIO='116',FILE='DISK114:[15ZAD1.15ZAD72301]EA72301A.;62',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ea72301_1_117"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Alternative Dosing PK Clinical Trial (CP-OXYDET-27)  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>CP-OXYDET-27 was an open-label, randomized, single-dose, cross-over comparison clinical trial designed to assess the safety and PK profile of Xtampza
administered by sprinkling the Xtampza microspheres onto applesauce compared with administration of intact Xtampza. As shown in the graph below, the administration of Xtampza microspheres sprinkled
onto applesauce did not lead to any change in their PK profile compared to intact Xtampza. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g706049.jpg" ALT="GRAPHIC" WIDTH="595" HEIGHT="312">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Overview  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our product candidates are manufactured using a proprietary process. This process is reproducible, scalable and cost-efficient, and we believe that
the microsphere formulation&nbsp;&#151; and the related manufacturing process&nbsp;&#151; is unique in the extended-release opioid market. To date, we have manufactured three
registration batches of Xtampza and have 24 months of stability data to support a proposed two-year shelf life. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
date, we have produced Xtampza for use in our clinical trials, abuse-deterrence studies and clinical trials, and our preclinical studies at our contract manufacturing organization, Patheon. The
existing Patheon facility has the capacity to support production of commercial quantities of Xtampza during the first several years after commercial launch. We are currently conducting a commercial
validation program in preparation for commercial launch of Xtampza. As needed, we anticipate working with Patheon to build additional and dedicated manufacturing capacity at Patheon's existing
facility. Patheon has an established record of manufacturing products approved in the United States, including controlled substances. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
own all of the intellectual property, including know-how and specialized manufacturing equipment, necessary to be able to replicate the manufacturing equipment currently located at Patheon's
facility at an alternative location (and with an alternative vendor) if necessary. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Drug Substances  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The active ingredient used in Xtampza, oxycodone base, is an odorless white crystalline powder. We currently procure this active ingredient pursuant
to a commercial supply agreement with a U.S.-based manufacturer and expect to continue to do so as we scale up production in anticipation of commercialization. If our current supplier is unable to
supply oxycodone base in the quantities and at the times we require it, we are aware of other suppliers who we would expect to be able to satisfy our commercial orders. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=121,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=555468,FOLIO='117',FILE='DISK114:[15ZAD1.15ZAD72301]EA72301A.;62',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ea72301_1_118"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Oxycodone
base is classified as a narcotic controlled substance under U.S. federal law. We expect that Xtampza and our other product candidates will be classified by the U.S. Drug Enforcement
Administration, or DEA, as Schedule&nbsp;II controlled substances, meaning that they have a high potential for abuse and dependence among drugs that are recognized as having an accepted medical use.
Consequently, we expect that the manufacturing, shipping, dispensing and storing of our product candidates will be subject to a high degree of regulation, as described in more detail under the caption
"&#151; Governmental Regulation&nbsp;&#151; DEA Regulation." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Marketing and Commercialization  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We intend to commercialize Xtampza and our other product candidates in the United States, if approved, with a direct sales force. We plan to
out-license Xtampza in other international markets, such as Canada, Australia and Japan, as well as countries in Latin America and Europe. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
members of our management team, who will lead the commercialization of Xtampza, if approved, have substantial experience in pharmaceutical sales and marketing. If Xtampza is approved for marketing
in the United States, we intend to hire or contract for a dedicated field sales force, initially consisting of approximately 100 sales professionals, to target the approximately 10,000 physicians who
write more than 50% of the branded extended-release oral opioid prescriptions in the United States, with a primary focus on pain specialists. In addition, we plan to deploy a focused sales force to
call on institutions where patients require extended-release opioids, such as skilled nursing or hospice facilities. In addition, we expect to employ medical sales liaisons, or MSLs, to respond to
clinician inquiries about Xtampza. We also plan to employ a market-access team to support our formulary approval and payor contracting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are continuing to develop our commercialization strategy with the input of key opinion leaders in the field of pain management, as well as healthcare practitioners. Internally, we have begun
pre-commercialization activities for Xtampza, such as developing positioning and messaging campaigns, a publication strategy, initiatives with payor organizations, and distribution and national
accounts strategies. Our marketing strategy is expected to include increasing awareness of differences between Xtampza and OxyContin OP, the hazards of opioids that are not abuse-deterrent, and
increasing awareness of solutions for patients with CPD who require or would benefit from extended-release opioids. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual Property  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We regard the protection of patents, designs, trademarks and other proprietary rights that we own or license as critical to our success and
competitive position. Our patent portfolio directed toward Xtampza and our DETERx technology consists of six issued patents in the United States (four of which claim compositions of matter, one of
which claims both compositions of matter and methods of use, and one of which claims methods of use), two pending applications in the European Union and one issued patent in each of Canada, Japan and
Australia. In addition, we have six patent applications pending in the United States, and two pending foreign patent applications (excluding Europe), in Japan and Canada. Our issued U.S. patents are
projected to expire in 2023 and 2025, and our pending patent applications in the United States, if issued, would be projected to expire in 2023 and 2030. In addition, we use a unique and proprietary
process to manufacture our products that requires significant know-how, which we currently protect as trade secrets. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
policy is to patent the technology, inventions and improvements that we consider important to the development of our business, but only in those cases in which we believe that the costs of
obtaining patent protection is justified by the commercial potential of the technology, and typically only in those jurisdictions that we believe present significant commercial opportunities to us. We
have concluded that some of our technology is best protected as proprietary know-how, rather than through obtaining patents. In some cases, we publish the invention such that it becomes prior art in
order for us to secure freedom to operate and to prevent a third party from patenting the invention before us. Our technology and products are not in-licensed from any third party, and we own all of
the rights to our product candidates. We believe we have </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=122,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=14837,FOLIO='118',FILE='DISK114:[15ZAD1.15ZAD72301]EA72301A.;62',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ea72301_1_119"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>freedom
to operate in the United States and other countries, but there can be no assurance that other companies, known and unknown, will not attempt to assert their intellectual property against us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also rely on trademarks and trade designs to develop and maintain our competitive position. We have received trademark registration for Collegium Pharmaceutical,&nbsp;Inc., DETERx, and Xtampza ER
in the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary
know-how that is not patentable, we rely on trade secret protection and confidentiality agreements to protect our interests. To this end, we generally require our employees, consultants and advisors
to enter into confidentiality agreements prohibiting the disclosure of confidential information and, in some cases, requiring disclosure and assignment to us of the ideas, developments, discoveries
and inventions important to our business. Additionally, these confidentiality agreements require that our employees, consultants and advisors do not bring to us, or use without proper authorization,
any third party's proprietary technology. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent Litigation Strategy  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We filed the NDA for Xtampza as a 505(b)(2) application, which allows us to reference data from an approved drug listed in the FDA's Approved Drug
Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), in this case OxyContin OP. The 505(b)(2) process requires that we certify to the FDA and notify Purdue, as the
holder of the NDA and any other Orange Book-listed patent owners, that we do not infringe any of the patents listed for OxyContin OP in the Orange Book, or that the patents are invalid. Under the
Hatch-Waxman Act of 1984, Purdue exercised its option and elected to sue us for infringement in the District of Delaware on March 24, 2015 asserting infringement of three of Purdue's Orange
Book-listed patents (all of which stand invalidated, subject to a pending appeal by Purdue) and a non-Orange Book-listed patent, and, accordingly, received a stay of up to 30 months before the FDA can
issue a final approval for Xtampza, unless the stay is earlier terminated. The 30-month stay only applies to Orange Book-listed patents. On March 26, 2015, Purdue filed a second suit against us in the
District of Massachusetts asserting infringement of the same four patents. On April&nbsp;6, 2015, in the District of Delaware case, we filed a motion to dismiss for lack of personal jurisdiction or,
in the alternative, to transfer venue to the Southern District of New York where three of the patents have already been invalidated. Purdue's opposition to our motion was filed on April&nbsp;23,
2015 and our reply in support of the motion is due on May&nbsp;4, 2015. The complaint in the District of Massachusetts case has not yet been served.


</FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>In
order to commercialize Xtampza, we will need both FDA approval and to dispose of the lawsuits filed by Purdue (or wait until the expiration of the 30-month stay imposed by such litigation). We do
not believe we infringe Purdue's patents and intend to vigorously defend the suit. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA is entitled to give Xtampza a tentative approval before the 30-month stay has expired, which means the product is approved, subject to the expiration of the 30-month period or termination of
the stay. If we receive a court order that the listed patents are invalid or not infringed, or if we settle the Purdue litigation before the 30-month period expires, the FDA can then provide final
approval of Xtampza prior to the expiration of the 30-month period, at which point the product can be marketed. Our certification letter to Purdue and the other Orange Book-listed patent owners
documents why Xtampza does not infringe any of the Orange Book-listed
patents for OxyContin OP, or the OxyContin Patents, which fall into three general categories, as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>High molecular weight poly(ethylene oxide)/polymer
patents:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Some of the OxyContin Patents describe a formulation containing a significant amount of high molecular weight poly(ethylene oxide) or polyalkalene oxide,
which creates a hard tablet that is difficult to crush. Some of these OxyContin Patents claim specific manufacturing methods and curing conditions that are intended to create hard tablets. The
formulation described in our NDA for Xtampza does not contain any high molecular </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=123,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=693068,FOLIO='119',FILE='DISK114:[15ZAD1.15ZAD72301]EA72301A.;62',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ea72301_1_120"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>weight
component and is manufactured under different conditions from those claimed by the OxyContin Patents. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Oxycodone HCl or preferential removal of
14-hydroxycodeinione patents:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Some of the OxyContin Patents describe oxycodone compositions, formulations and manufacturing processes that use oxycodone HCl as the
active ingredient and thus require preferential removal of the toxic intermediary 14-hydroxycodeinone. The formulation described in our NDA uses an oxycodone base rather than oxycodone HCl, and does
not require the preferential removal of 14-hydroxycodeinone. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Viscosity-increasing
patents:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Some of the OxyContin Patents describe the addition of viscosity-increasing agents as a method of abuse deterrence. The formulation described in our NDA
does not contain any viscosity-increasing agent and, unlike OxyContin OP, does not form&nbsp;a gel when placed in an aqueous liquid. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
certification letter to Purdue also noted that five of the 11 Orange Book-listed patents for OxyContin OP stand invalidated by the Federal District Court for the Southern District of New York,
subject to a pending appeal. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
we anticipated that Purdue would sue us for patent infringement as a possible means to delay the launch of Xtampza, we have engaged experienced litigation counsel, who worked carefully with us
to construct a strategy to prevail in any litigation that arises as expeditiously as possible. We are now in the process of implementing this litigation strategy and plan to take all steps necessary
to vigorously defend ourselves against these claims. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to become the leading marketer of abuse-deterrent extended-release opioids and other commonly abused products. Key elements of our
strategy to achieve this goal are to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish our leadership position by obtaining approval
to market Xtampza with a best-in-class abuse-deterrent label.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If approved, we expect to receive differentiated abuse-deterrent claims in the Xtampza label compared
to other approved abuse-deterrent opioids, which will allow us to detail Xtampza to physicians and highlight its unique abuse-deterrent characteristics. </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Commercialize Xtampza in the United States
ourselves.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We are currently preparing for a potential U.S. commercial launch of Xtampza, if approved, in the first quarter of 2016. Our management team has
extensive experience commercializing pharmaceutical products, and we intend to establish sales, marketing and reimbursement functions to commercialize Xtampza in the United States. Initially, we plan
to detail Xtampza to approximately 10,000 physicians who write more than 50% of the branded extended-release oral opioid prescriptions in the United States with a sales team of approximately 100 sales
representatives. We believe that this physician group also represents a significant portion of the top prescribers of extended-release and long-acting opioids (including drugs formulated with fentanyl
and methadone) currently used to treat patients with CPD. In addition, we plan to deploy a separate, focused sales team to detail Xtampza to nursing homes, hospices, and other institutions treating
large populations of the elderly and other patients who need chronic pain relief and have difficulty swallowing. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish Xtampza as the treatment of choice for
patients with CPD.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In addition to positioning Xtampza as the superior abuse-deterrent, extended-release formulation of oxycodone, we intend to position Xtampza as
the treatment of choice for patients with CPD. There are currently no approved, abuse-deterrent, extended-release products designed for this patient segment consisting of over 11&nbsp;million
patients in the United States. If approved with product labeling for sprinkling Xtampza microspheres directly in the mouth or on food, as well as administering the microspheres through feeding tubes,
Xtampza would be the only abuse-deterrent, extended-release product designed to be suitable for this patient group. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=124,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=296265,FOLIO='120',FILE='DISK114:[15ZAD1.15ZAD72301]EA72301A.;62',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ea72301_1_121"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish strategic collaborations to accelerate and
maximize the potential of our product candidates worldwide.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We intend to seek strategic collaborations with other pharmaceutical companies to commercialize our
product candidates outside the United States and to develop certain of our product candidates that are outside of our core therapeutic focus. We believe that we are an attractive collaborator for
pharmaceutical companies due to the strength of our abuse-deterrent technology. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Advance other product candidates that incorporate our
DETERx platform technology.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have multiple opioid product candidates at different stages of development. We have an IND application on file for COL-172, an
abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain, which has been granted Fast Track status by the FDA. We have also begun advancing our development program for COL-195,
an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain. We target beginning clinical trials for our second product candidate by the first quarter of 2016. In addition, we
have COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactive disorder, which we plan to advance with
a collaborator. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Acquire additional products and product
candidates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may identify and license, co-promote or acquire products or product candidates being developed for pain indications and other complementary products. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
are continuing to develop our commercialization strategy with the input of key opinion leaders in the field of pain management, as well as healthcare practitioners and quality improvement
organizations. Internally, we have begun pre-commercialization initiatives for Xtampza, such as developing positioning and messaging campaigns, a publication strategy, initiatives with payor
organizations, and distribution and national accounts strategies. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face
competition and potential competition from a number of sources, including pharmaceutical and biotechnology companies, generic drug companies, drug delivery companies and academic and research
institutions. Most of the existing and potential competitors have significantly more financial and other resources than we do. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Currently,
the only opioid drugs on the market for chronic pain relief that have an abuse-deterrent label are OxyContin OP and Hysingla&reg;, both of which are marketed by Purdue, and Embeda,
which is marketed by Pfizer. In addition, there is one other approved extended-release opioid that has abuse-deterrent labeling &#151; Targiniq from Purdue &#151; which is not currently
on the market. Hysingla is a once a day hydrocodone extended-release product. Embeda is a combination of morphine and naltrexone, an opioid antagonist that can be sprinkled on soft food but contains a
black box warning label stating that "crushing, dissolving or chewing can cause rapid release and absorption of a potentially fatal dose of the active drug." Also, according to the warning labels of
Oxycontin OP and other extended-release opioids, administration of the active ingredients by injection may result in necrosis, infection and increased risk of heart disease. Targiniq is a combination
of oxycodone and naloxone, an opioid antagonist. In 2014, sales of extended-release opioids in the United States were $6 billion, consisting of a number of large and small companies, including Purdue,
Pfizer, Actavis, Endo Pharmaceuticals, Zogenix, Janssen Pharmaceuticals, Mallinckrodt and several generic drug companies. A number of other large and small companies are developing abuse-deterrent
drugs for chronic pain, including Teva Pharmaceutical Industries&nbsp;Ltd., Endo Health Solutions&nbsp;Inc., Nektar Therapeutics, Egalet Corporation, Inspirion Delivery Technologies,&nbsp;LLC,
and KemPharm,&nbsp;Inc. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=125,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=615739,FOLIO='121',FILE='DISK114:[15ZAD1.15ZAD72301]EA72301A.;62',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ec72301_1_122"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe the key competitive factors that will affect the development and commercial success of our product candidates include their degree of abuse deterrence,
bioavailability, therapeutic efficacy, and convenience of dosing and distribution, as well as their safety, cost and tolerability profiles. Xtampza may also face competition from commercially
available generic and branded extended-release and long-acting opioid drugs other than oxycodone, including fentanyl, hydromorphone, oxymorphone and methadone, as well as opioids that are currently in
clinical development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
approved, Xtampza would compete against Purdue's OxyContin OP for the treatment of patients experiencing pain severe enough to require around-the-clock analgesia. Although no generic oxycodone
products are currently commercially available, and although the FDA has not issued guidance on the regulatory pathway for generic abuse-deterrent products, it is possible that generic forms of
OxyContin OP could become available, in which case Xtampza would compete with any such generic oxycodone products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
we are aware of companies in late-stage development of abuse-deterrent oxycodone product candidates, including Pain Therapeutics' Remoxy&reg;, a formulation of oxycodone, and
Pfizer's ALO-02, a formulation of oxycodone and naltrexone. If these products are successfully developed and approved for marketing, they could represent significant competition for Xtampza. It is
also possible that a company that has developed an abuse-deterrent technology could initiate an abuse-deterrent oxycodone program at any time. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Government Regulation  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


FDA Approval Process  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FD&amp;C Act and other federal and state statutes and
regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring
and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial
sanctions, such as warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, withdrawal of the product from the market, injunctions,
fines, civil penalties, and criminal prosecution. Failure to meet FDA requirements for approval would also result in a medication not being approved for marketing. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
process of developing a pharmaceutical and obtaining FDA approval to market the medication in the United States typically involves:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  completion of preclinical laboratory and animal testing and formulation studies
in compliance with the FDA's good laboratory practices, or GLP, regulation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  submission to the FDA of an IND for human clinical testing, which must become
effective before human clinical trials may begin in the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approval by an independent institutional review board, or IRB, at each clinical
trial site before each trial may be initiated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  performance of adequate and well-controlled human clinical trials in accordance
with current good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug product for each indication for which FDA approval is sought; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  satisfactory completion of an FDA pre-approval inspection of the facility or
facilities at which the product is manufactured to assess compliance with the FDA's cGMP regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  submission to the FDA of an NDA; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  satisfactory completion of a potential review by an FDA advisory committee, if
applicable; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA review and approval of the NDA. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Satisfaction
of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or
disease. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=126,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=750700,FOLIO='122',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_123"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Preclinical
tests include laboratory evaluation of product chemistry, formulation, stability and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of
the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLPs. The results of preclinical testing are submitted to the FDA as part of an IND
along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of
reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
IND automatically becomes effective 30&nbsp;days after receipt by FDA unless, within the 30-day time period, the FDA raises concerns or questions relating to one or more proposed clinical trials
and places the clinical trial on hold, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns before the clinical trial can begin. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials involve the administration of the investigational new drug to healthy volunteers or subjects under the supervision of a qualified investigator. Clinical trials must be conducted:
(i)&nbsp;in compliance with federal regulations, including GCP, an international standard meant to protect the rights, safety and wellbeing of subjects and to define the roles of clinical trial
sponsors, administrators, and monitors; and (ii)&nbsp;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and any
effectiveness criteria to be evaluated. Each protocol involving testing on U.S. subjects and subsequent protocol amendments must be submitted to the FDA as part of the IND. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>GCP
requirements include that all research subjects provide their informed consent in writing for their participation in any clinical trial. An independent IRB for each site proposing to conduct the
clinical trial must review and approve the informed consent information as well as the clinical trial protocol before the trial commences at that site, and must monitor the study until completed. The
FDA or the IRB may order the temporary or permanent discontinuation of a clinical trial at any time and on various grounds, particularly upon the belief that the clinical trial either is not being
conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects, or impose other conditions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap or be combined. In Phase&nbsp;1, the drug is initially
introduced into healthy human subjects or patients, and is tested to assess safety, dose tolerance, absorption, metabolism, PK, pharmacological actions, side effects associated with increasing doses,
and, if possible, early evidence on effectiveness. Phase&nbsp;2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage
tolerance, and optimum dosage, and to identify common AEs and safety risks. Multiple Phase&nbsp;2 trials may be conducted by the sponsor to obtain information prior to beginning larger and more
extensive Phase&nbsp;3 clinical trials. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase&nbsp;2 evaluations, Phase&nbsp;3 trials are undertaken to
obtain the additional information about clinical efficacy and safety in a larger number of subjects, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the
overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, the FDA requires two adequate and well controlled Phase&nbsp;3 clinical
trials to demonstrate the efficacy of the drug. A single Phase&nbsp;3 trial with other confirmatory evidence may be sufficient in rare instances where the clinical trial is a large multicenter trial
demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially
serious outcome and confirmation of the result in a second trial would be practically or ethically impossible. Sponsors of clinical trials generally must register and report key parameters of certain
clinical trials at the NIH-maintained website ClinicalTrials.gov. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The
NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=127,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=318612,FOLIO='123',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_124"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
product's pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial
application user fee, currently set at $2,335,200, and the manufacturer and/or sponsor under an approved new drug application are also subject to annual product and establishment user fees, currently
set at $110,370 per product and $569,200 per establishment. These fees are typically increased annually. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
FDA has 60&nbsp;days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency's threshold determination that it is sufficiently complete to
permit substantive review. Rather than accept an NDA for filing, then FDA may request additional information. In this event, the NDA must be resubmitted with the additional information and may be
subject to payment of additional user fees. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an
in-depth substantive review. The FDA has established certain performance goals for the review of new drug applications. The agency endeavors to review applications for standard review drug products
within 10 to 12&nbsp;months of the acceptance for filing, and aims to review applications for drugs granted priority review, which may apply to drugs that the FDA determines offer major advances in
treatment or provide a treatment where no adequate therapy exists, within six to eight months. The review process for both standard and priority review may be extended by FDA for three additional
months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee&nbsp;&#151; typically a panel
that includes clinicians and other experts&nbsp;&#151; for review, evaluation, and a recommendation as to whether the application should be approved and under what conditions. The FDA is not
bound by the recommendation of an advisory committee, but it generally follows such recommendations. In addition, before approving an NDA, the FDA will typically inspect one or more clinical sites to
assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with cGMP
is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter to indicate that the review cycle for an application is complete and
that the application is not ready for approval. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in
order for the FDA to reconsider the application. Even with submission of this additional information, the FDA may ultimately decide that an application does not satisfy the regulatory criteria for
approval. If, and when, those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such
resubmissions in two or six months depending on the type of information included. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. Changes to certain of the conditions established in an approved
application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be
implemented, which may require us to develop additional data or conduct additional preclinical studies and clinical trials. An NDA supplement for a new indication typically requires clinical data
similar to that in the original application, and the FDA uses similar procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


REMS  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA has the authority to require a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of the approval of an NDA or after approval to
ensure that the benefits of a drug outweigh its risks. In determining whether a REMS is necessary, the FDA must consider the size of the population likely to use the drug, the seriousness of the
disease or condition to be treated, the expected benefit of the drug, the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=128,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=484491,FOLIO='124',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_125"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>duration
of treatment, the seriousness of known or potential adverse events, and whether the drug is a new molecular entity. If the FDA determines a REMS is necessary for a new drug, the drug sponsor
must submit a proposed REMS plan as part of its NDA prior to approval. The FDA may also impose a REMS requirement on a drug already on the market if the FDA determines, based on new safety
information, that a REMS is necessary to ensure that the drug's benefits continue to outweigh its risks. A REMS can include medication guides, communication plans for healthcare professionals, and
elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special
monitoring, and the use of patient registries. In addition, the REMS must include a timetable to periodically assess the strategy, at a minimum, at 18&nbsp;months, three years, and seven years
after the REMS approval. The requirement for a REMS can materially affect the potential market and profitability of a drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
February 2009, the FDA informed manufacturers of certain opioid products that it would require a REMS for their opioid drug products. Subsequently, the FDA initiated efforts to develop a new
standardized REMS for these opioid medications to ensure their safe use, and in July 2012, approved a class-wide REMS for extended-release and long-acting opioid products. Extended-release
formulations of oxycodone, morphine, hydrocodone and hydromorphone, for example, are required to have a REMS. Manufacturers subject to this class-wide REMS must work together to implement the REMS as
part of a single shared system to reduce the burden of the REMS on the healthcare system. The central component of the extended release/long acting opioid REMS program is an education program for
prescribers and patients. Specifically, the REMS includes a Medication Guide available for distribution to patients who are dispensed the drug, as well as a number of ETASU. These ETASU include
training for healthcare professionals who prescribe the drug; information provided to prescribers that they can use to educate patients in the safe use, storage, and disposal of opioids; and
information provided to prescribers of the existence of the REMS and the need to successfully complete the necessary training. Prescriber training required as part of the REMS is conducted by
accredited, independent continuing education providers, without cost to healthcare professionals, under unrestricted grants funded by the opioid analgesic manufacturers. Moreover, REMS assessments
must be submitted on an annual basis to assess the extent to which the ETASU are meeting the goals of the REMS and whether the goals or elements should be modified. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Advertising and Promotion  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and
regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A
product cannot be commercially promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the
labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for "off-label" uses&nbsp;&#151; that is, uses not approved by the FDA and therefore not described in the
drug's labeling&nbsp;&#151; because the FDA does not regulate the practice of medicine. However, FDA regulations impose stringent restrictions on manufacturers' communications regarding
off-label uses. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the U.S. Department of
Justice, or the Office of the Inspector General of the U.S. Department of Health and Human Services, or HHS, as well as state authorities. This could subject a company to a range of penalties that
could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Fast Track Designation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA has various programs to facilitate the development and expedite the review of drugs that are intended for the treatment of a serious or
life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track designation program, the
sponsor of a new product candidate may request the FDA to designate the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=129,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1043053,FOLIO='125',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_126"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>product
for a specific indication as a Fast Track product concurrent with or after the submission of the IND for the product candidate. The FDA must determine if the product candidate qualifies for
Fast Track designation within 60&nbsp;days after receipt of the sponsor's request. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition to other benefits, such as the ability to have more frequent interactions with the FDA, the FDA may initiate review of sections of a Fast Track product's NDA before the application is
complete. The FDA's time period goal for reviewing a Fast Track application does not begin until the last section of the NDA is submitted. In addition, the Fast Track designation may be withdrawn by
the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Post-Approval Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Once an NDA is approved, a product will be subject to pervasive and continuing regulation by the FDA, including, among other things, requirements
relating to drug listing and registration, recordkeeping, periodic reporting, product sampling and distribution, adverse event reporting and advertising, marketing and promotion restrictions. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Adverse
event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-market testing, known as Phase&nbsp;4 testing, REMS, and
surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control,
drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their
subcontractors are required to register their establishments with FDA and certain state agencies. Registration subjects entities to periodic announced or unannounced inspections by the FDA or these
state agencies, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of
production and quality control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory
standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, other regulatory actions may be taken, including,
among other things, warning letters, the seizure of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, refusal to approve pending
applications or supplements to approved applications, civil penalties, and criminal prosecution. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug Marketing Act, or PDMA, and associated
regulations, impose certain recordkeeping and reporting requirements and other limitations on the distribution of drug samples to physicians. The PDMA also requires that state licensing of
distributors who distribute prescription drugs meet certain federal guidelines that include minimum standards for storage, handling and record keeping. In addition, the PDMA and a growing majority of
states also impose certain drug pedigree requirements on the sale and distribution of prescription drugs. The PDMA sets forth civil and criminal penalties for violations. In 2010, a statutory
provision was enacted that required manufacturers and authorized distributors of record to report on an annual basis certain information about prescription drug samples they distributed. The FDA
issued a draft compliance policy guide on the reporting requirement. The FDA stated that it would exercise enforcement discretion with regard to companies that have not submitted reports until the FDA
finalizes the reporting requirement and/or provides notice that it is revising its exercise of enforcement discretion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may require post-approval studies and clinical trials if the FDA finds that scientific data, including information regarding related drugs, deem it appropriate. The purpose of such studies
would be to assess a known serious risk or signals of serious risk related to the drug or to identify an unexpected serious risk when available data indicate the potential for a serious risk. The FDA
may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=130,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=950927,FOLIO='126',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_127"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


The Hatch-Waxman Amendments  </I></B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Orange Book Listing</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant's product.
Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as
the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA, or ANDA. An ANDA provides for marketing of a drug
product that has the same active ingredient in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed
drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or efficacy of their
drug product. Drugs approved in this way are commonly referred to as "generic equivalents" to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original
listed drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
ANDA applicant is required to make certain certifications to the FDA concerning any patents listed for the approved product in the FDA's Orange Book. Specifically, the applicant must certify that:
(i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not expired, but will expire on a particular date and
approval is sought after patent expiration; or (iv)&nbsp;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section&nbsp;viii
statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than make certifications concerning a listed method-of-use
patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
certification that the new product will not infringe the already approved product's listed patents, or that such patents are invalid, is called a Paragraph&nbsp;IV certification. If the ANDA
applicant has provided a Paragraph&nbsp;IV certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA and patent holders once the ANDA has been
accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&nbsp;IV certification. The filing of a patent
infringement lawsuit within 45&nbsp;days of the receipt of a Paragraph&nbsp;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&nbsp;months,
expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Exclusivity</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Upon NDA approval of a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by FDA in any other NDA,
that drug receives five years of marketing exclusivity during which FDA cannot receive any ANDA seeking approval of a generic version of that drug or any Section&nbsp;505(b)(2) NDA, discussed in
more detail below, that relies on the FDA's findings regarding that drug. A drug may obtain a three-year period of exclusivity for a change to the drug, such as the addition of a new indication to the
labeling or a new formulation, during which FDA cannot approve an ANDA or any Section&nbsp;505(b)(2) NDA, if the supplement includes reports of new clinical trials (other than bioavailability
clinical trials) essential to the approval of the supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
ANDA may be submitted one year before NCE exclusivity expires if a Paragraph&nbsp;IV certification is filed. If there is no listed patent in the Orange Book, there may not be a
Paragraph&nbsp;IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=131,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=994012,FOLIO='127',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_128"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Section&nbsp;505(b)(2) NDAs</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Generally, drug products obtain FDA marketing approval pursuant to an NDA or an ANDA. A third alternative is a Section&nbsp;505(b)(2) NDA, which
enables the applicant to rely, in part, on data not developed by the applicant, such as the FDA's findings of safety and efficacy in the approval of a similar product or published literature in
support of its application. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Section&nbsp;505(b)(2)
NDAs may provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section&nbsp;505(b)(2) permits the filing of
an NDA where at least some of the information required for approval comes from clinical trials not conducted by, or for, the applicant and for which the applicant has not obtained a right of
reference. If the Section&nbsp;505(b)(2) applicant can establish that reliance on FDA's previous findings of safety and efficacy is scientifically appropriate, it may eliminate the need to conduct
certain preclinical or clinical trials of the new product. The FDA may also require companies to perform additional clinical trials or provide additional materials to support the change from the
approved product. The FDA may then approve the new product candidate for all, or some, of the label indications for which the referenced product has been approved, as well as for any new indication
sought by the Section&nbsp;505(b)(2) applicant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that the Section&nbsp;505(b)(2) applicant is relying on the FDA's findings of safety and effectiveness for an already approved product, the applicant is required to certify to the FDA
concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. Thus approval of a Section&nbsp;505(b)(2) NDA can be stalled until all the
listed patents claiming the referenced product have expired; until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the
referenced product has expired; and, in the case of a Paragraph&nbsp;IV certification and subsequent patent infringement suit, until the earlier of 30&nbsp;months, settlement of the lawsuit or a
decision in the infringement case that is favorable to the Section&nbsp;505(b)(2) applicant. As with traditional NDAs, a Section&nbsp;505(b)(2) NDA may be eligible for three-year marketing
exclusivity, assuming the NDA includes reports of new clinical trials (other than bioavailability clinical trials) essential to the approval of the NDA. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Disclosure of Clinical Trial Information  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information.
Information related to the product, patient population, phase of investigation, clinical trial sites and investigators, and other aspects of the clinical trial is then made public as part of the
registration. Sponsors are also obligated to post certain information regarding the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until
the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


DEA Regulation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our lead product candidate, Xtampza, if approved, will be regulated as a "controlled substance" as defined in the Controlled Substances Act, or CSA,
which establishes registration, security, recordkeeping, reporting, storage, distribution, importation, exportation and other requirements administered by the DEA. The DEA regulates the handling of
controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion
into illicit channels of commerce. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
DEA regulates controlled substances as Schedule&nbsp;I, II, III, IV or V substances. Schedule&nbsp;I substances by definition have no established medicinal use, and may not be marketed or sold
in the United States. A pharmaceutical product may be listed as Schedule&nbsp;II, III, IV or V, with Schedule&nbsp;II substances considered to present the highest risk of abuse and
Schedule&nbsp;V substances the lowest relative risk of abuse among such substances. Schedule&nbsp;II drugs are those that meet the following
characteristics:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> high potential for abuse; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=132,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=170639,FOLIO='128',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_129"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  currently accepted medical use in treatment in the United States or a currently
accepted medical use with severe restrictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> abuse may lead to severe psychological or physical dependence; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are considered "dangerous." </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that Xtampza, an abuse-deterrent oral formulation of oxycodone, will be listed by the DEA as a Schedule&nbsp;II controlled substance under the CSA. Consequently, the manufacturing,
shipping, storing, selling and using of the products will be subject to a high degree of regulation. Schedule&nbsp;II drugs are subject to the strictest requirements for registration, security,
recordkeeping and reporting. Also, distribution and dispensing of these drugs are highly regulated. For example, all Schedule&nbsp;II drug prescriptions must be signed by a physician, physically
presented to a pharmacist and may not be refilled without a new prescription. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Annual
registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location,
activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are
authorized. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
DEA typically inspects a facility to review its security measures prior to issuing a registration. Security requirements vary by controlled substance schedule, with the most stringent requirements
applying to Schedule&nbsp;I and Schedule&nbsp;II substances. Required security measures include background checks on employees and physical control of inventory through measures such as cages,
surveillance cameras and inventory reconciliations. Records must be maintained for the handling of all controlled substances, and periodic reports made to the DEA, for example distribution reports for
Schedule&nbsp;I and II controlled substances, Schedule&nbsp;III substances that are narcotics, and other designated substances. Reports must also be made for thefts or losses of any controlled
substance, and to obtain authorization to destroy any controlled substance. In addition, special permits and notification requirements apply to imports and exports of narcotic drugs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, a DEA quota system controls and limits the availability and production of controlled substances in Schedule&nbsp;I or II. Distributions of any Schedule&nbsp;I or II controlled
substance must also be accompanied by special order forms, with copies provided to the DEA. Because Xtampza is expected to be regulated as a Schedule&nbsp;II controlled substance, it will be subject
to the DEA's production and procurement quota scheme. The DEA establishes annually an aggregate quota for how much oxycodone may be produced in total in the United States based on the DEA's estimate
of the quantity needed to meet legitimate scientific and medicinal needs. The limited aggregate amount of opioids that the DEA allows to be produced in the United States each year is allocated among
individual companies, who must submit applications annually to the DEA for individual production and procurement quotas. We and our contract manufacturers must receive an annual quota from the DEA in
order to produce or procure any Schedule&nbsp;I or Schedule&nbsp;II substance, including oxycodone base for use in manufacturing Xtampza. The DEA may adjust aggregate production quotas and
individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
enforce these requirements, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements,
particularly as manifested in loss or diversion, can result in administrative, civil or criminal enforcement action that could have a material adverse effect on our business, results of operations and
financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations or initiate administrative proceedings to revoke those registrations. In certain circumstances,
violations could result in criminal proceedings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Individual
states also independently regulate controlled substances. We and our contract manufacturers will be subject to state regulation on distribution of these products. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=133,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=647620,FOLIO='129',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_130"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


International Regulation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to regulations in the United States, we will be subject to a variety of foreign regulations regarding safety and efficacy and governing,
among other things, clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain the necessary approvals by the comparable
regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and can involve
additional product testing and additional review periods, and the time may be longer or shorter than that required to obtain FDA approval and, if applicable, DEA classification. The requirements
governing, among other things, the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. Regulatory approval in one country does not ensure
regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many
foreign countries are also signatories to the internal drug control treaties and have implemented regulations of controlled substances similar to those in the United States. Our products will be
subject to such regulation which may impose certain regulatory and reporting requirements and restrict sales of these products in those countries. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
European Union regulatory systems, marketing authorizations may be submitted either under a centralized or decentralized procedure. The centralized procedure provides for the grant of a single
marketing authorization that is valid for all European Union member states. The decentralized procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder
of a national marketing authorization may submit an application to the remaining member states. Within 90&nbsp;days of receiving the applications and assessment report, each member state must decide
whether to recognize approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition to regulations in Europe and the United States, we will be subject to a variety of foreign regulations governing, among other things, the conduct of clinical trials, pricing and
reimbursement and commercial distribution of our products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory
approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Healthcare Laws and Compliance Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, the research, manufacturing, distribution, sale and promotion of drug products and medical devices are subject to regulation by
various federal, state and local authorities in addition to the FDA, including the Centers for Medicare&nbsp;&amp; Medicaid Services, other divisions of HHS (e.g.,&nbsp;the Office of Inspector
General), the DOJ, state Attorneys General and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs must comply with fraud and abuse laws
such as the federal Anti-Kickback Statute, the federal False Claims Act, as amended and similar state laws. In order to participate in the Medicaid program, existing federal law requires
pharmaceutical manufacturers to pay rebates to state governments, based on a statutory formula, on covered outpatient drugs reimbursed by the Medicaid program as a condition of having their drugs paid
for by Medicaid. Manufacturers are required to report AMP and best price for each of their covered outpatient drugs to the government on a regular basis. Additionally, some state Medicaid programs
have imposed a requirement for supplemental rebates over and above the formula set forth in federal law, as a condition for coverage. In addition to the Medicaid Rebate Program, federal law also
requires that if a pharmaceutical manufacturer wishes to have its outpatient drugs covered under Medicaid as well as under Medicare Part&nbsp;B, it must sign a "Master Agreement" obligating it to
provide a formulaic discount that results in a federal ceiling price, or maximum price that participating manufacturers may charge for covered drugs sold to the U.S. Departments of Defense (including
the TRICARE retail pharmacy program), Veterans Affairs, the Public Health Service and the Coast Guard, and also provide discounts through a drug pricing agreement meeting the requirements of
Section&nbsp;340B of the Public Health Service Act, for outpatient drugs sold to certain specified eligible health </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=134,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=971854,FOLIO='130',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_131"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>care
organizations. The formula for determining the discounted purchase price under the 340B drug pricing program is defined by statute and is based on the AMP and rebate amount for a particular
product as calculated under the Medicaid Drug Rebate Program, discussed above. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal Anti-Kickback Statute prohibits any person from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce or reward either the
referral of an individual, or the furnishing, recommending or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid
programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on one hand, and prescribers, purchasers, and formulary managers, on the other. The term
"remuneration" is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include the transfer of anything of value, including for example, gifts, discounts, the
furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at other than its fair market value. Although there are a
number of statutory exemptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve
remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not meet all of the
criteria for safe harbor protection from federal Anti-Kickback
Statute liability in all cases. The reach of the federal Anti-Kickback Statute was broadened by the recently enacted Affordable Care Act, which, among other things, amends the intent requirement of
the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In
addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false
or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary penalties statute, which imposes fines against any person who is determined to have presented
or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
Additionally, many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to referral of patients for healthcare items or services reimbursed by any third-party
payor, not only the Medicare and Medicaid programs in at least some cases, and do not contain safe harbors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal
healthcare program. The "</FONT><FONT SIZE=2><I>qui tam</I></FONT><FONT SIZE=2>" provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government
alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has
increased dramatically. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor
and not merely a federal healthcare program. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another
to submit, a false claim for reimbursement to the federal government. The False Claims Act has been used to assert liability on the basis of inadequate care, kickbacks and other improper referrals,
improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper promotion of off-label uses not expressly approved by FDA in a drug's label, and allegations
as to misrepresentations with respect to the services rendered. To the extent we participate in government healthcare programs, our future activities relating to the reporting of discount and rebate
information and other information affecting federal, state and third party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases,
among other activities, may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of
such actions. However, the cost of defending such claims, as well as any sanctions imposed, could adversely affect our financial performance. Also, HIPAA created several new federal crimes, including
healthcare fraud and false statements relating to healthcare matters. The </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=135,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=856282,FOLIO='131',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_132"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>healthcare
fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors. The false statements statute prohibits
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for
healthcare benefits, items or services. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we may be subject to, or our marketing activities in the future may be limited by, data privacy and security regulation by both the federal government and the states in which we conduct
our business. HIPAA and its implementing regulations established uniform standards for certain "covered entities," which are healthcare
providers, health plans and healthcare clearinghouses, governing the conduct of specified electronic healthcare transactions and protecting the security and privacy of protected health information.
The American Recovery and Reinvestment Act of 2009, commonly referred to as the economic stimulus package, included expansion of HIPAA's privacy and security standards through the Health Information
Technology for Economic and Clinical Health Act, or HITECH, which became effective on February&nbsp;17, 2010. Among other things, HITECH makes HIPAA's privacy and security standards directly
applicable to "business associates," which are independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on
behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney's fees and costs associated with pursuing federal
civil actions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
new requirements under the federal Open Payments program, created under Section&nbsp;6002 of the Affordable Care Act and its implementing regulations, require that manufacturers of
drugs for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) report annually to HHS information related to "payments or other
transfers of value" made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and that manufacturers and applicable
group purchasing organizations report annually to the HHS ownership and investment interests held by physicians (as defined above) and their immediate family members, with data collection required
beginning August&nbsp;1, 2013 and reporting to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, required beginning March&nbsp;31, 2014 and by the 90th&nbsp;day following the end of
each subsequent calendar year, and disclosure of such information to be made on a publicly available website. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
are also an increasing number of state "sunshine" laws that require manufacturers to file reports with states on pricing and marketing information. Many of these laws contain ambiguities as to
what is required to comply with the laws. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic
reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities and/or register their sales representatives. Such legislation also prohibits
pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing and prohibits certain other sales and marketing
practices. These laws may affect our future sales, marketing and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with
respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or
more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to
penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of
products, total or partial suspension of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=136,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=420597,FOLIO='132',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_133"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>production,
denial or withdrawal of pre-marketing product approvals, private </FONT><FONT SIZE=2><I>qui tam</I></FONT><FONT SIZE=2> actions brought by individual whistleblowers in the name of the
government or refusal to allow us to enter into supply contracts, including government contracts and the curtailment or restructuring of our operations, any of which could adversely affect our ability
to operate our business and our results of operations. To the extent that any of our products are approved and sold in a foreign country, we may be subject to similar foreign laws and regulations,
which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of
payments or transfers of value to healthcare professionals. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Third-Party Payor Coverage and Reimbursement  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The commercial success of our product candidates, if and when approved, will depend, in part, upon the availability of coverage and adequate
reimbursement from third-party payors at the federal, state and private levels. Third-party payors include governmental programs such as Medicare or Medicaid, private insurance plans and managed care
plans. These third-party payors may deny coverage or reimbursement for a product or therapy in whole or in part if they determine that the product or therapy was not medically appropriate or
necessary. Also, third-party payors have attempted to control costs by limiting coverage through the use of formularies and other cost-containment mechanisms and the amount of reimbursement for
particular procedures or drug treatments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
cost of pharmaceuticals and devices continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due
to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. Our results of operations and business could be adversely affected
by current and future third-party payor policies as well as healthcare legislative reforms. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Some
third-party payors also require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. While we cannot
predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, these requirements or any announcement or adoption of such proposals could have a
material adverse effect on our ability to obtain adequate prices for our product candidates and to operate profitably. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Healthcare Reform  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could
affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs. The
Medicare Modernization Act imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part&nbsp;D, Medicare beneficiaries may enroll in
prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Part&nbsp;D plans include both stand-alone prescription drug benefit plans and
prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part&nbsp;A and B, Part&nbsp;D coverage is not standardized. Part&nbsp;D prescription drug plan sponsors
are not required to pay for all covered Part&nbsp;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However,
Part&nbsp;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&nbsp;D drugs, though not necessarily all the drugs in each category or
class. Any formulary used by a Part&nbsp;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription
drugs may increase demand for our products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&nbsp;D prescription drug plan will likely be
lower than the prices we might otherwise obtain. Moreover, while the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage
policy and payment limitations in setting their </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=137,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=435704,FOLIO='133',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_134"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>own
payment rates. Any reduction in payment that results from Medicare Part&nbsp;D may result in a similar reduction in payments from non-governmental payors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. A plan for the research will
be developed by HHS, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to
Congress. Although the results of the comparative effectiveness clinical trials are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the
research will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research
demonstrating benefits in a competitor's product could adversely affect the sales of our product candidates. If third-party payors do not consider our products to be cost-effective compared to other
available therapies, they may not cover our products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
March 2010, the Affordable Care Act was enacted, which includes measures to significantly change the way healthcare is financed by both governmental and private insurers. Among the provisions of
the Affordable Care Act of importance to the pharmaceutical and biotechnology industry are the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an annual, nondeductible fee on any entity that manufactures or imports certain
branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in the rebates a manufacturer must pay under the Medicaid Drug
Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new Medicare Part&nbsp;D coverage gap discount program, in which
manufacturers must agree to offer 50% point-of-sale discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer's outpatient drugs to be covered under Medicare Part&nbsp;D; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  extension of manufacturers' Medicaid rebate liability to covered drugs
dispensed to individuals who are enrolled in Medicaid managed care organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  expansion of eligibility criteria for Medicaid programs by, among other things,
allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty
Level, thereby potentially increasing manufacturers' Medicaid rebate liability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  expansion of the entities eligible for discounts under the Public Health
Service pharmaceutical pricing program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a licensure framework for follow-on biologic products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new Patient-Centered Outcomes Research Institute to oversee, identify
priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new requirement to annually report drug samples that manufacturers and
distributors provide to physicians; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> creation of the Independent Payment Advisory Board, which has authority to
recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs and those recommendations could have the effect of law even if Congress does not act on
the recommendations (the IPAB has not yet been called upon to act as the annual determinations by the CMS Office of the Actuary have not identified a savings target for implementation in years 2015 or
2016); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  establishment of a Center for Medicare Innovation at CMS to test innovative
payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January&nbsp;1, 2011. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=138,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=797812,FOLIO='134',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_135"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. The Budget Control Act of 2011, among other things, created the Joint Select Committee
on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee on Deficit Reduction did not achieve its targeted deficit reduction of at least $1.2 trillion
for the years 2012 through 2021, triggering the legislation's automatic reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of 2%
per fiscal year, and went into effect in April 2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to
several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions
in Medicare and other healthcare funding, which could have a material adverse effect on our customers and, accordingly, our financial operations. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Regulatory Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are also subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of
hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the FDA has broad regulatory and enforcement powers, including, among other things, the
ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect on
us. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Our Corporate Information  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our predecessor was incorporated in Delaware in April 2002 under the name Collegium Pharmaceuticals,&nbsp;Inc. In October 2003, our predecessor
changed its name to Collegium Pharmaceutical,&nbsp;Inc. In 2010, our predecessor divested its former subsidiary, Onset Therapeutics,&nbsp;LLC to PreCision Dermatology,&nbsp;Inc. Since then, we
have devoted substantially all of our resources to the development of our patented DETERx platform technology, the preclinical and clinical advancement of our product candidates and the creation and
protection of related intellectual property. In July 2014, we reincorporated in the Commonwealth of Virginia pursuant to a merger whereby Collegium Pharmaceutical,&nbsp;Inc., a Delaware corporation,
merged with and into Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation, with the Virginia corporation surviving the merger. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Legal Proceedings  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From time to time we face legal claims or actions in the normal course of business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


We filed the NDA for Xtampza as a 505(b)(2) application, which allows us to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations
(commonly known as the Orange Book), in this case OxyContin OP. The 505(b)(2) process requires that we certify to the FDA and notify Purdue Pharma,&nbsp;L.P., or Purdue, as the holder of the NDA and
any other Orange Book-listed patent owners, that we do not infringe any of the patents listed for OxyContin OP in the Orange Book, or that the patents are invalid. We made such certification and
provided such notice on&nbsp;February&nbsp;11, 2015 and such certification documented why Xtampza does not infringe any of the 11 Orange Book listed patents for OxyContin OP, five of which stand
invalidated by the Federal District Court for the Southern District of New York, subject to a pending appeal. Under the Hatch-Waxman Act of 1984, Purdue had the option to sue us for infringement and
receive a stay of up to 30 months before the FDA can issue a final approval for Xtampza, unless the stay is earlier terminated. Purdue exercised its option and elected to sue us for infringement in
the District of Delaware on March&nbsp;24, 2015 asserting infringement of three of Purdue's Orange Book-listed patents (all of which stand invalidated subject to a pending appeal by Purdue) and a
non-Orange Book-listed patent, and accordingly, received a stay of up to 30 months before the FDA can issue a final approval for Xtampza, unless the stay is earlier terminated. On March&nbsp;26,
2015, Purdue filed a second suit against us in the District of Massachusetts asserting infringement of the same four patents. We have engaged experienced litigation counsel who worked carefully with
us to construct a strategy to prevail in such litigation as expeditiously as possible. On April&nbsp;6, 2015, in the District of


</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=139,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=316095,FOLIO='135',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ec72301_1_136"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Delaware case, we filed a motion to dismiss for lack of personal jurisdiction or, in the alternative, to transfer venue to the Southern District of New York where three of the patents have already
been invalidated. Purdue's opposition to our motion was filed on April&nbsp;23, 2015 and our reply in support of the motion is due May&nbsp;4, 2015. The complaint in the District of Massachusetts
case has not yet been served. We do not believe we infringe Purdue's patents and intend to vigorously defend ourselves against these claims.

</FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Facilities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our corporate headquarters are located in Canton, Massachusetts, where we lease 9,675 square feet of office space (including chemistry and
pilot/formulation laboratories) under a lease agreement that was amended in March 2015 to expand the premises to include an additional 9,660 square feet of space for
a total of 19,335 square feet. In addition, the lease term has been extended and now terminates on the date that is five&nbsp;years following the date, which has not yet been determined, on which
the landlord delivers to us the expansion space with certain improvements substantially completed. The lease term may be extended for an additional five-year term at our election. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that our existing facility is adequate for our current and expected future needs. We may seek to negotiate new leases or evaluate additional or alternate space for our operations. We
believe that appropriate alternative space is readily available on commercially reasonable terms. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of April&nbsp;2, 2015, we had a total of 24 full-time employees. Of these, 18 are engaged in full-time research and development activities. All
of our employees are located in Canton, Massachusetts. None of our employees are represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations
to be good. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=140,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=695757,FOLIO='136',FILE='DISK114:[15ZAD1.15ZAD72301]EC72301A.;32',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ee72301_1_137"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ee72301_management"> </A>
<A NAME="toc_ee72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT    <BR>    </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Executive Officers and Directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table provides information regarding our executive officers and directors: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="45%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Age </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Executive Officers:</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael T. Heffernan, R.Ph.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>50</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Chairman, President and Chief Executive Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul Brannelly</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>42</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Executive Vice President and Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barry S. Duke</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>56</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Executive Vice President and Chief Commercial Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ernest A. Kopecky, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>48</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Vice President, Clinical Development and Head of Neuroscience</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Douglas R. Carlson</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Vice President, Corporate Development</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Alison B. Fleming, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>40</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Vice President, Product Development</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Said Saim, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>57</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Vice President, Pharmaceutical Development</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Non-Employee Directors:</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Garen G. Bohlin</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>67</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John G. Freund, M.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>61</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Patrick Heron</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>44</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Hirsch, M.D., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>44</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eran Nadav, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>45</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gino Santini</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Executive Officers</U>  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Michael T. Heffernan, R.Ph., Chairman, President and Chief Executive Officer.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Heffernan has served as our President and Chief Executive Officer and as a
member of our board of directors since October 2003. Mr.&nbsp;Heffernan has over twenty-five years of experience in the pharmaceutical and related healthcare industries. He was previously the
Founder, President and Chief Executive Officer of Onset Therapeutics,&nbsp;LLC, a dermatology-focused company that developed and commercialized products for the treatment of skin-related illnesses
and was responsible for the spin-off of the business from the Company to create PreCision Dermatology,&nbsp;Inc. Mr.&nbsp;Heffernan has held prior positions as Co-Founder, President and Chief
Executive Officer of Clinical Studies&nbsp;Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., or PhyMatrix, and as President and Chief Executive Officer of
PhyMatrix. Mr.&nbsp;Heffernan started his career at Eli Lilly and Company, where he served in numerous sales and marketing roles. Since 2012, Mr.&nbsp;Heffernan has served on
the board of directors of Ocata Therapeutics,&nbsp;Inc. (NASDAQ: OCAT) and currently serves as its Chairman. He also serves on the board of directors of Veloxis Pharmaceuticals A/S (CPH: VELO)
(March 2015 to present). Mr.&nbsp;Heffernan previously served on the board of directors of Cornerstone Therapeutics&nbsp;Inc. (now known as Chiesi USA,&nbsp;Inc.) (NASDAQ: CRTX) and two
privately held companies. Mr.&nbsp;Heffernan graduated from the University of Connecticut with a B.S. in Pharmacy in 1987 and is a Registered Pharmacist. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Mr.&nbsp;Heffernan's perspective and experience as a senior executive in the pharmaceutical industry, as well as the depth of his operations and board experience, provide him with
the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Paul Brannelly, Executive Vice President and Chief Financial Officer.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Brannelly has served as our Executive Vice President and Chief Financial Officer
since February 2015. Prior to joining us, Mr. Brannelly served as Senior Vice President, Finance and Administration, and Treasurer of Karyopharm Therapeutics Inc. (NASDAQ: KPTI), or Karyopharm, from
June 2013 to August 2014. From August 2014 to November 2014, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=141,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=557200,FOLIO='137',FILE='DISK114:[15ZAD1.15ZAD72301]EE72301A.;46',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ee72301_1_138"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Mr.
Brannelly served as a consultant to Karyopharm. Prior to joining Karyopharm, Mr. Brannelly served as Vice President, Finance, Treasurer and Secretary at Verastem, Inc. (NASDAQ: VSTM), or Verastem,
from August 2010 to May 2013. From January 2010 to September 2011, Mr. Brannelly held the position of Chief Financial Officer at the Longwood Fund, a venture capital firm aimed at investing in,
managing and building healthcare companies, where he set up the financial and operational infrastructure following the closing of its first fund and eventually served as Chief Financial Officer of its
two startup companies, Verastem and OvaScience, Inc. (NASDAQ: OVAS). From November 2005 to September 2009, he served as Vice President, Finance at Sirtris Pharmaceuticals, Inc., or Sirtris, a
biopharmaceutical company which GlaxoSmithKline plc purchased for $720 million in 2008, where he managed the S-1 preparation and due diligence process for Sirtris' initial public offering and managed
the company's transition to being a public company. Mr. Brannelly started his biopharmaceutical career at Dyax Corporation from September 1999 to May 2002, and subsequently moved on to positions of
increasing responsibility at CombinatoRx Inc. from May 2002 to November 2005, most recently as Vice President, Finance and Treasurer, where he led Zalicus through the initial public offering process.
Mr. Brannelly graduated from the University of Massachusetts at Amherst with a B.B.A. in Accounting in 1995. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Barry S. Duke, Executive Vice President and Chief Commercial Officer.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Duke has served as our Executive Vice President and Chief Commercial Officer since
March 2015. Prior to joining us, Mr.&nbsp;Duke was Vice President of Sales and Marketing&nbsp;&#151; U.S. Biosurgery at Sanofi,&nbsp;Inc. (formerly Genzyme Corpration), or Sanofi, from
October 2011 to September 2014. From September 2014 to March 2015, Mr.&nbsp;Duke served as a sales and marketing consulting in the biopharmaceutical industry. Mr.&nbsp;Duke joined Sanofi in March
2005 as an area sales director and was promoted to Vice President of Sales&nbsp;&#151; U.S. Biosurgery in November 2007, a
position he held until September 2011, when he was promoted to Vice President of Sales and Marketing&nbsp;&#151; U.S. Biosurgery. Prior to Sanofi, Mr.&nbsp;Duke was Senior Director of
National Sales at Enzon Pharmaceuticals,&nbsp;Inc. (NASDAQ: ENZN), or Enzon, from November 2002 to March 2005. Prior to Enzon, Mr.&nbsp;Duke was Regional Sales Director at &Eacute;lan
Corporation,&nbsp;plc (now known as &Eacute;lan Corporation&nbsp;Ltd) from March 2001 to November 2002. Over the course of his career, Mr.&nbsp;Duke has also held various sales positions
at The Liposome Company,&nbsp;Inc., Astra USA,&nbsp;Inc., Centocor,&nbsp;Inc. and The Upjohn Company. Mr.&nbsp;Duke graduated from University of Virginia with a B.A. in Biology in 1981. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Ernest A. Kopecky, Ph.D., Vice President, Clinical Development and Head of Neuroscience.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Kopecky has served as our Vice President, Clinical Development
and Head of the Neuroscience Therapeutic Area since June 2012. Prior to joining us, Dr.&nbsp;Kopecky served as Senior Director of Clinical Research and Head of the Pain and Neuroscience Therapeutic
Area at Endo Pharmaceuticals Holdings&nbsp;Inc., or Endo, from 2006 to June 2012. Prior to joining Endo, Dr.&nbsp;Kopecky held several positions in the pharmaceutical industry, including Global
Medical Director at Bayer HealthCare AG, Senior Clinical Research Scientist at Purdue Pharma&nbsp;L.P., and Manager of the Clinical Drug Development Unit at SCIREX Corporation. He also held the
academic title of Research Fellow at the Hospital for Sick Children, Division of Clinical Pharmacology and Toxicology, Toronto, Canada. Dr.&nbsp;Kopecky has served as a member of the IMMPACT
Steering Committee and the FDA ACTTION Executive Committee, Subteam Lead on the PhRMA Neonatal and Pediatric LDKITs, and Faculty at the Pharmaceutical Education Research Institute. Dr.&nbsp;Kopecky
graduated from the University of Toronto with a B.S. in Human Biology in 1991, a Ph.D. in Pediatric Clinical Pharmacology in 1999 and an M.S. in Clinical Pharmacology in 2005. He also received an
M.B.A. from the University of Connecticut in 2005. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Douglas R. Carlson, Vice President, Corporate Development.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Carlson has served as our Vice President, Business Development since March 2013, and in
January 2014, Mr.&nbsp;Carlson assumed responsibility for Corporate and Business Development. Mr.&nbsp;Carlson has a multi-disciplinary background in M&amp;A, venture capital, corporate finance and
business development with both large and emerging growth healthcare companies. Prior to joining us, Mr.&nbsp;Carlson was Senior Director of Business Development at BTG International&nbsp;Inc., or
BTG, where he was responsible for global specialty pharmaceutical M&amp;A and licensing from August 2011 to March 2013. Prior to BTG, Mr.&nbsp;Carlson was Senior Director and Head of Business </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=142,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=415801,FOLIO='138',FILE='DISK114:[15ZAD1.15ZAD72301]EE72301A.;46',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ee72301_1_139"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Development
for Lundbeck&nbsp;Inc., or Lundbeck, the U.S. Headquarters of H. Lundbeck A/S, from December 2009 to August 2011. Prior to Lundbeck, Mr.&nbsp;Carlson was Director of Corporate
Development and M&amp;A at Ovation Pharmaceuticals,&nbsp;Inc., or Ovation where he played an integral role in the sale of Ovation to H.&nbsp;Lundbeck A/S in 2009. Prior to Ovation, Mr.&nbsp;Carlson
was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management,&nbsp;Inc. Mr.&nbsp;Carlson began his career in the healthcare investing banking
group of SG Cowen&nbsp;&amp;&nbsp;Co. Mr.&nbsp;Carlson graduated from Trinity College in Hartford, CT with a B.A. in American Studies in 2001. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Alison B. Fleming, Ph.D., Vice President, Product Development.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Fleming has served as our Vice President, Product Development and has led our development
team since October 2002. Prior to joining us, Dr.&nbsp;Fleming's academic research focused on implantable drug delivery systems for cancer therapy. Dr.&nbsp;Fleming is an inventor on several U.S.
patents and pending patent applications, and has authored numerous scientific publications and poster presentations in the field of novel drug delivery systems. In 2001, Dr.&nbsp;Fleming was the
recipient of the Jorge Heller Journal of Controlled Release Outstanding Paper Award. Dr.&nbsp;Fleming graduated from the University of Massachusetts, Amherst in 1997 with a B.S. in Chemical
Engineering and received a Ph.D. in Chemical and Biomolecular Engineering from Cornell University in 2002. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Said Saim, Ph.D., Vice President, Pharmaceutical Development.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Saim has served as our Vice President, Pharmaceutical Development since April 2012.
Dr.&nbsp;Saim joined us in August 2008 as a Senior Director of Pharmaceutical Development, a position he held until April 2012. Prior to joining us, Dr.&nbsp;Saim was a Senior Principal Scientist
at Boehringer Ingelheim Pharmaceuticals,&nbsp;Inc. or BIPI, where he led a team of engineers and scientists in charge of process development, scale up and technology transfer of North American
products. Prior to BIPI, Dr.&nbsp;Saim was an Assistant Research Professor at the Higuchi BioSciences Center for Drug Delivery Research in Lawrence, Kansas. Dr.&nbsp;Saim graduated from the
National Polytechnic School, Algeria with a B.S. in Chemical Engineering in 1983 and received an M.S. and Ph.D. in Chemical Engineering from the University of Kansas in 1987 and 1990, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2><U>Non-Employee Directors</U> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Garen G. Bohlin, Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Bohlin has served as a member of our board of directors since January 2015. Mr.&nbsp;Bohlin has almost thirty years'
experience serving in executive roles at several biotechnology companies, including Constellation Pharmaceuticals,&nbsp;Inc., where he served as an Executive Vice President from January 2010 to his
retirement in May 2012. Prior to that, Mr.&nbsp;Bohlin served as Chief Operating Officer at Sirtris Pharmaceuticals,&nbsp;Inc., or Sirtris, which was acquired by GlaxoSmithKline plc. Prior to
joining Sirtris, Mr.&nbsp;Bohlin served as President and Chief Executive Officer of Syntonix Pharmaceuticals,&nbsp;Inc., or Syntonix, which was acquired by Biogen Idec in 2006, Mr.&nbsp;Bohlin
spent 14&nbsp;years in executive management at Genetics Institute,&nbsp;Inc., or Genetics Institute, which was acquired by Wyeth. Prior to Mr.&nbsp;Bohlin's tenure at Genetics Institute, he was
a partner at Arthur Andersen&nbsp;&amp;&nbsp;Co., where he spent 13&nbsp;years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since
his retirement, Mr.&nbsp;Bohlin has served on the boards of directors of several companies. Mr.&nbsp;Bohlin currently serves on the board of directors of Tetraphase
Pharmaceuticals,&nbsp;Inc. (NASDAQ: TTPH) (2010 to Present),
Karyopharm Therapeutics,&nbsp;Inc. (NASDAQ GS: KPTI) (2013 to Present), and Proteon Therapeutics,&nbsp;Inc. (NASDAQ: PRTO) (2014 to Present). Previously, he served on the board of directors of
Acusphere,&nbsp;Inc. (OTC: ACUS) (2005 to 2015) and two other privately held companies. Mr.&nbsp;Bohlin graduated from the University of Illinois with a B.S. in Accounting and Finance in 1970. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
believe that Mr.&nbsp;Bohlin's perspective and experience as a senior executive in our industry, as well as his board and audit committee experience with publicly traded and privately held
biotechnology companies, provide him with the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> John G. Freund, M.D., Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Freund has served as a member of our board of directors since February 2014. Dr.&nbsp;Freund co-founded Skyline
Management&nbsp;LLC, or Skyline, in 1997 and has served as </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=143,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=624524,FOLIO='139',FILE='DISK114:[15ZAD1.15ZAD72301]EE72301A.;46',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ee72301_1_140"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Managing
Director at Skyline since its founding. Prior to joining Skyline, Dr.&nbsp;Freund served as Managing Director in the private equity group of Chancellor Capital Management,&nbsp;LLC. In
1995, Dr.&nbsp;Freund co-founded Intuitive Surgical,&nbsp;Inc. and served on its board of directors until 2000. From 1988 to 1994, Dr.&nbsp;Freund served in various positions at Acuson
Corporation, or Acuson, most recently as Executive Vice President. Prior to joining Acuson, Dr.&nbsp;Freund was a General Partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to
1988, Dr.&nbsp;Freund was a general partner at Morgan Stanley&nbsp;&amp;&nbsp;Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Freund
currently serves on the board of directors of XenoPort,&nbsp;Inc. (NASDAQ: XNOT) (1999 to Present), Tetraphase Pharmaceuticals,&nbsp;Inc. (NASDAQ: TTPH) (2012 to Present),
Concert Pharmaceuticals,&nbsp;Inc. (NASDAQ: CNCE) (2014 to Present) and Proteon Therapeutics,&nbsp;Inc. (NASDAQ GS: PRTO) (2014 to Present). Dr.&nbsp;Freund also serves on the board of directors
of two privately held companies and three U.S. registered investment funds managed by The Capital Group Companies. He also previously served on the board of directors of several publicly traded
companies: Hansen Medical&nbsp;Inc. (NASDAQ: HNSN) (2002 to 2010), MAP Pharmaceuticals,&nbsp;Inc. (NASDAQ: MAPP) (2004 to 2011), and MAKO Surgical Corp. (NASDAQ: MAKO) (2008 to 2013).
Dr.&nbsp;Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative, and is a member of the Therapeutics Advisory Council of Harvard Medical School.
Dr.&nbsp;Freund graduated from Harvard College with a B.A. in History in 1976 and received an M.D. from Harvard Medical School in 1980 and an M.B.A. from Harvard Business School in 1982. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Dr.&nbsp;Freund's extensive finance and investment experience, his experience as an executive, and his service on the board of directors of numerous public and privately held
companies in our industry provide him with the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Patrick Heron, Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Heron has served as a member of our board of directors since September 2008. Mr.&nbsp;Heron is a General Partner of Frazier
Management,&nbsp;LLC, or Frazier, a position he has held since September 1999. Mr.&nbsp;Heron has been active in company formations and initial investments in various biotechnology companies,
including Marcadia Biotech&nbsp;Inc., Calixa Therapeutics,&nbsp;Inc. and VentiRx Pharmaceuticals,&nbsp;Inc. Mr.&nbsp;Heron also led Frazier's involvement in MedPointe&nbsp;Inc. Prior to
joining Frazier, Mr.&nbsp;Heron helped develop McKinsey&nbsp;&amp;&nbsp;Co.'s west coast biotechnology consulting practice. His projects included mergers and acquisitions, product launch, sales
force optimization, corporate partnering and research prioritization. Mr.&nbsp;Heron graduated from the University of North Carolina at Chapel Hill with a B.A. in Political Science in 1992 and
received an M.B.A. from Harvard Business School in 1996. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Mr.&nbsp;Heron's extensive business experience and his experience in venture capital and the life science industry provide him with the qualifications and skills to serve as a
director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> David Hirsch, M.D., Ph.D., Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Hirsch has served as a member of our board of directors since February 2012. Since 2007, Dr.&nbsp;Hirsch has
served as a Founder and Managing Director at Longitude Capital Management&nbsp;Co.,&nbsp;LLC, or Longitude, where he focuses on investments in biotechnology. From 2005 to 2006, Dr.&nbsp;Hirsch
was Vice President of Pequot Capital Management, or Pequot, where he worked in the life sciences practice. Prior to Pequot, Dr.&nbsp;Hirsch was an Engagement Manager in the pharmaceutical practice
of McKinsey&nbsp;&amp;&nbsp;Co. While at McKinsey&nbsp;&amp;&nbsp;Co., he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&amp;A
evaluations, portfolio prioritization and managed care strategy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Hirsch
currently serves on the board of directors of Rapid Micro Biosystems, Inc. and previously served on Civitas Therapeutics, Inc. and Precision Therapeutics, Inc. Dr.&nbsp;Hirsch
graduated from Johns Hopkins University with a B.S. in Biology in 1991 and, in 2001, received an M.D. from Harvard Medical School as well as a Ph.D. in Biology from Massachusetts Institute of
Technology. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=144,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=838579,FOLIO='140',FILE='DISK114:[15ZAD1.15ZAD72301]EE72301A.;46',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ee72301_1_141"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Dr.&nbsp;Hirsch's perspective and experience as an investor and board member in the life sciences industry, as well as his strong medical and scientific background, provide him with
the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2><B><I> Eran Nadav, Ph.D., Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Nadav has served as a member of our board of directors since March 2015. Dr.&nbsp;Nadav is a Partner and Managing Director
at TPG Biotech, the life science venture investment arm of TPG, a global private investment firm. Dr.&nbsp;Nadav joined TPG in 2007 with a focus on global pharmaceuticals and biotechnology
investments. Prior to TPG, Dr.&nbsp;Nadav served as Business Development Director at Eisai, a pharmaceutical company, from September 2003 to August 2007 and also as a manager at Johnson&nbsp;&amp;
Johnson Development Corporation, the venture capital arm of Johnson&nbsp;&amp; Johnson, a healthcare company, from November 1999 until July 2002. Dr.&nbsp;Nadav served on the board of directors of
Eden Springs&nbsp;Ltd., a European provider of drinking water solutions for the workplace, from July 2010 until August 2011. Dr.&nbsp;Nadav served on the board of directors of
MacroGenics,&nbsp;Inc. (NASDAQ: MGNX) (June 2013 to June 2014). Dr. Nadav currently serves on the board of directors of Ultragenyx Pharmaceutical&nbsp;Inc. (NASDAQ: RARE) (2011 to Present), and
has served as the Chairman of the board of directors of Ultragenyx Pharmaceutical&nbsp;Inc. since January 2012. Dr.&nbsp;Nadav received a B.Sc. magna cum laude in Life Sciences, an M.Sc. magna cum
laude and Ph.D. in Biochemistry, as well as an M.B.A., from Tel Aviv University.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Dr.&nbsp;Nadav is qualified to serve on our board of directors due to his experience in the venture capital industry and his years of analyzing development opportunities in the life
sciences sector. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Gino Santini, Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Santini has served as a member of our board of directors since July 2012. Since December 2010, Mr.&nbsp;Santini has been a
senior advisor providing financing and business consulting services to venture capital, pharmaceutical and biotechnology companies. Previously, Mr.&nbsp;Santini held various positions at Eli Lilly
and Company, or Lilly, from 1983 until his retirement from Lilly in December 2010, most recently as Senior Vice President of Corporate Strategy and Business Development, a position he held since 2007.
Mr.&nbsp;Santini also served as a member of Lilly's Executive Committee from January 2004 to his retirement and as President of U.S. Operations. He joined Eli Lilly and Company in 1983 as a
financial planning associate in Italy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Mr.&nbsp;Santini
currently serves on the board of directors of Sorin&nbsp;S.p.A., a company traded on the Italian Stock Exchange (2012 to Present), AMAG Pharmaceuticals&nbsp;Inc. (NASDAQ: AMAG)
(2012 to Present), Horizon Pharma&nbsp;plc (NASDAQ: HZNP) (2012 to Present) and Vitae Pharmaceuticals,&nbsp;Inc. (NASDAQ GS: VTAE) (2014 to Present), as well as several privately held companies.
He graduated from the University of Bologna, Italy with a B.S. in Mechanical Engineering in 1981 and received an M.B.A. from the Simon School of Business at the University of Rochester in 1983. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Mr.&nbsp;Santini's perspective and experience as a senior executive at Lilly, as well as his extensive domestic and international commercial, corporate strategy, business development
and transaction experience, provide him with the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Composition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our business and affairs are managed under the direction of our board of directors, which currently consists of seven members. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Upon
the closing of this offering, our amended and restated articles of incorporation and amended bylaws will provide that our board of directors will consist of a number of directors to be fixed
exclusively by resolution of the board of directors. Under our amended and restated articles of incorporation, our board of directors will be divided into three classes, each serving three-year terms
and until each director's successors are duly elected and qualified. The election of the classes will be staggered, such that only approximately one third of our board of directors will be up for
election in any given year. Our amended and restated articles of incorporation do not provide for cumulative voting in the election of directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=145,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=617815,FOLIO='141',FILE='DISK114:[15ZAD1.15ZAD72301]EE72301A.;46',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ee72301_1_142"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Role of the Board in Risk Oversight  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a
standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of our board of
directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit
committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including adopting guidelines
and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. Our nominating and
corporate governance committee monitors the effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our
compensation committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Committees  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Each
committee will operate under a charter that has been approved by our board of directors and will be available on our website, www.collegiumpharma.com, under the "Investor Relations" section, upon the
effective date of this offering. The information contained in, or that can be accessed through, our website is not part of this prospectus.

</FONT>

</P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our audit committee consists of Messrs.&nbsp;Bohlin, Freund and Nadav, and is chaired by Mr. Bohlin. The primary purpose of our audit committee is
to assist the board of directors in the oversight of our accounting and financial reporting processes, the audit and integrity of our financial statements, and the qualifications and independence of
our independent auditor and to prepare any reports required of the audit committee under the rules of the SEC. The audit committee has the following responsibilities, among other things, as set forth
in the audit committee charter that will be effective upon the closing of this offering:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hiring our independent registered public accounting firm and pre-approving the
audit and permitted non-audit and tax services to be performed by our independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and approving the planned scope of the annual audit and the results
of the annual audit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing the significant accounting and reporting principles to understand
their impact on our financial statements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing quarterly with management its assessment of the effectiveness and
adequacy of our internal control structure and procedures for financial reporting and reviewing annually with our independent registered public accounting firm the attestation to and report on the
assessment made by management; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing with management and our independent registered public accounting
firm, as appropriate, our financial reports, earnings announcements and our compliance with legal and regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  establishing procedures for the treatment of complaints received by us
regarding accounting, internal accounting controls or auditing matters and confidential submissions by our employees of concerns regarding questionable accounting or auditing matters; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  preparing for adoption by our board of directors a Code of Ethics and
periodically reviewing and recommeding appropriate changes thereto; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and approving related-party transactions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and evaluating, at least annually, our audit committee's charter. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=146,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=793343,FOLIO='142',FILE='DISK114:[15ZAD1.15ZAD72301]EE72301A.;46',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ee72301_1_143"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
audit committe will review related-party transactions for potential conflicts of interests or other improprieties in accordance with our related party transactions policy. See "Certain
Relationships and Related Party Transactions&nbsp;&#151; Policies and Procedures for Related Party Transactions." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
financial literacy requirements of the SEC require that each member of our audit committee be able to read and understand fundamental financial statements. In addition, our board of directors has
determined that Mr. Bohlin qualifies as an audit committee financial expert, as defined in Item&nbsp;407(d)(5) of Regulation&nbsp;S-K promulgated under the Securities Act, and has financial
sophistication in accordance with the NASDAQ Stock Market Rules. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Both
our independent registered public accounting firm and management periodically will meet privately with our audit committee. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our compensation committee consists of Messrs.&nbsp;Heron, Hirsch and Santini, and is chaired by Dr.&nbsp;Hirsch. The primary purpose of our
compensation committee is to review the performance and development of our management in achieving corporate goals and objectives and to assure that our executive officers are compensated effectively
in a manner consistent with the strategy of our company, competitive practice, sound corporate governance principles and shareholder interests. In carrying out these responsibilities, this committee
oversees, reviews and administers all of our compensation, equity and employee benefit plans and programs. The functions of our compensation committee include, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and approving the corporate goals and objectives relevant to
executive compensation, evaluating performance in light of those goals and objectives and setting the compensation for our executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and recommending the terms of employment agreements and other
employment-related arrangements with our executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and approving our compensation strategy for our employees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  overseeing and periodically reviewing the operation of all of our employee
benefit plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and recommending to our board of directors the compensation of our
directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  administering our equity incentive plans and benefit plans and approving the
grant of equity awards to our employees and directors under these plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> when required, reviewing and discussing with management our Compensation
Discussion and Analysis and recommending to the full board its inclusion in our periodic reports and proxy statement to be filed with the SEC; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> when required, preparing the report of the compensation committee to be included
in our annual proxy statement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  engaging compensation consultants or other advisors it deems appropriate to
assist with its duties; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and evaluating, at least annually, our compensation committee's
charter. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Nominating and Corporate Governance Committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our nominating and corporate governance committee consists of Messrs.&nbsp;Heffernan and Santini, and is chaired by Mr. Santini. The primary purpose
of our nominating and corporate governance committee is to assist our board of directors by identifying individuals qualified to become members of our board of directors, recommending a slate of
nominees to be proposed by our board of directors to shareholders for election to our board of directors, developing and recommending corporate governance principles and guidelines of our company and
monitoring compliance therewith and to recommend directors to serve on the committees of our board of directors. The functions of our nominating and corporate governance committee include, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> assisting our board of directors in identifying prospective director nominees
and recommending nominees for each annual meeting of shareholders to our board of directors; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=147,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=8904,FOLIO='143',FILE='DISK114:[15ZAD1.15ZAD72301]EE72301A.;46',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_ee72301_1_144"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing developments in corporate governance practices and developing and
recommending governance principles applicable to our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing independence of the board of directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  evaluating and making recommendations as to the size and composition of the
board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  recommending members for each board committee of our board of directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  determining qualifications for service on our board; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  developing, as appropriate, a set of corporate governance principles and
guidelines, and reviewing and recommending to our board any changes to such guidelines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing the adequacy of our articles of incorporation and bylaws and
recommending to our board of directors, as conditions dictate, amendments for consideration by our shareholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  periodically reviewing and evaluating, at least annually, our nominating and
corporate governance committee's charter. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Code of Ethics  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors has adopted a Code of Ethics, which will be effective upon the closing of this offering, applicable to all of our employees,
executive officers and directors. The Code of Ethics will be available on our website at www.collegiumpharma.com upon the listing of our common stock on NASDAQ. Our board of directors will be
responsible for overseeing the Code of Ethics, and our board of directors or an appropriate committee thereof must approve any waivers of the Code of Ethics for employees, executive officers or
directors. Disclosure regarding any amendments to the Code of Ethics, or any waivers of its requirements, will be disclosed on our website. The information contained in, or that can be accessed
through, our website is not part of this prospectus. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On March 30, 2015, our board of directors appointed Messrs. Heron, Hirsch and Santini to be members of the compensation committee. Each of Messrs.
Heron and Hirsch has relationships with us that require disclosure under Item 404 of Regulation S-K under the Exchange Act. See "Certain Relationships and Related Party Transactions" for more
information. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No
member of our compensation committee has ever been an executive officer or employee of ours. None of our officers currently serves, or has served during the last completed year, on the board of
directors, compensation committee or other committee serving an equivalent function, of any other entity that has one or more officers serving as a member of our board of directors or compensation
committee. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The NASDAQ Stock Market Rules require that each committee of our board of directors has at least one independent director on the listing date of our
common stock, has a majority of independent directors no later than 90&nbsp;days after such date and be fully independent within one year after such date. The composition of our audit, compensation
and nominating and corporate governance committees will satisfy these independence requirements in accordance with the phase-in schedule allowed by the NASDAQ Stock Market Rules. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors will observe all applicable criteria for independence established by the NASDAQ Stock Market Rules and other governing laws and applicable regulations. No director will be
deemed to be independent unless our board of directors determines that the director has no relationship which would interfere with the exercise of independent judgment in carrying out the
responsibilities of a director. Our board of directors has determined that each of our directors, with the exception of Michael T. Heffernan, is independent as defined under the corporate governance
rules of the NASDAQ Stock Market Rules. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=148,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=907209,FOLIO='144',FILE='DISK114:[15ZAD1.15ZAD72301]EE72301A.;46',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eg72301_1_145"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eg72301_executive_and_director_compensation"> </A>
<A NAME="toc_eg72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE AND DIRECTOR COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Summary Compensation Table  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table shows the annual compensation paid to or earned by Michael T. Heffernan, our President and Chief Executive Officer, and Ernest A.
Kopecky and Douglas R. Carlson, our two other most highly compensated executive officers (together our "named executive officers"), for the fiscal year ended December&nbsp;31, 2014: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="31pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:101pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,101pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Bonus<BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock<BR>
Awards<BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
Awards<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>All Other<BR>
Compensation<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Michael T. Heffernan, R.Ph.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>380,380</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>130,851</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,570</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>518,801</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive&nbsp;Officer</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ernest A. Kopecky, Ph.D.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
288,915</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
54,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>78,180</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
421,825</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vice President, Clinical</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Douglas R. Carlson</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
231,750</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
15,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR><SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
67,612</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>69,641</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
4,619</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
388,622</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Vice President,</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Corporate Development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
amounts reflect the aggregate grant date fair value of option awards computed in accordance with FASB ASC Topic 718. Assumptions used in
the calculation of these amounts are included in Note&nbsp;11 to our financial statements.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
annual bonus amounts calculated and paid pursuant to the named executive officers' respective employment agreements. For more
information, see "&#151;&nbsp;Non-Equity Incentive Plan Compensation."
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">This
amount reflects our contributions to the Company's 401(k) Plan on behalf of each named executive officer.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Pursuant
to the terms of his employment agreement, Mr.&nbsp;Carlson was paid a supplemental bonus of $15,000 on April&nbsp;11, 2014. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Employment Agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have employment and other service agreements with all of our named executive officers. The following is a summary of the material terms of each
employment agreement. For complete terms, please see the respective employment and service agreements attached as exhibits to the registration statement of which this prospectus forms&nbsp;a part. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Michael T. Heffernan, R.Ph.  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On June&nbsp;13, 2012, we entered into an amended and restated employment agreement with Michael T. Heffernan, our President and Chief Executive
Officer. The principal terms of Mr.&nbsp;Heffernan's employment agreement are as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> base salary of $350,000 per year, subject to annual adjustments (currently
$380,380 per year); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> annual incentive bonus opportunity in an amount up to 40% of base salary based
upon the achievement of certain bonus eligibility criteria; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an award of restricted shares as described below under the heading
"&#151; Outstanding Equity Awards at Fiscal Year-End." </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=149,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=727828,FOLIO='145',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_146"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
a termination of Mr.&nbsp;Heffernan's employment by us without cause or by Mr.&nbsp;Heffernan for good reason, as defined in his employment agreement, prior to a sale of the Company,
Mr.&nbsp;Heffernan is eligible to receive (i)&nbsp;continuation of his base salary for twelve months, or the Heffernan Severance Period, (ii)&nbsp;a lump sum payment equal to 40% of his then
current base salary, (iii)&nbsp;continuation of his health insurance benefits at our expense for the duration of the Heffernan Severance Period, and (iv)&nbsp;immediate vesting of all unvested
restricted stock and stock options awarded to him, subject to his execution of and non-revocation of a general release of claims. Upon a termination of Mr.&nbsp;Heffernan's employment by us without
cause or by Mr.&nbsp;Heffernan for good reason within thirteen months following a sale of the Company, Mr.&nbsp;Heffernan is eligible to receive (i)&nbsp;continuation of his base salary for the
Heffernan Severance Period and (ii)&nbsp;continuation of his health insurance benefits for the Heffernan Severance Period, subject to his execution of and non-revocation of a general release of
claims. Upon a termination of Mr.&nbsp;Heffernan's employment with us due to his death or disability, he will become immediately vested in all unvested restricted stock and stock options awarded to
him. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
a termination of Mr.&nbsp;Heffernan's employment by us with cause or by Mr.&nbsp;Heffernan without good reason, all compensation and benefits payable to Mr.&nbsp;Heffernan under his
employment agreement shall terminate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Mr.&nbsp;Heffernan
is entitled to participate in all of our employee benefit plans, subject to the terms and conditions applicable to such plans. Further, Mr.&nbsp;Heffernan has executed a
Noncompetition, Confidentiality and Inventions Agreement which contains customary non-solicitation and non-competition covenants, which covenants remain in effect for one year following any cessation
of employment with respect to Mr.&nbsp;Heffernan. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Ernest A. Kopecky, Ph.D.  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On May&nbsp;30, 2012, we entered into an employment agreement with Ernest A. Kopecky, our Vice President, Clinical Development. The principal terms
of Dr.&nbsp;Kopecky's employment agreement are as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> base salary of $275,000 per year, subject to annual adjustments (currently
$288,915 per year); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> annual incentive bonus opportunity in an amount up to 30% of base salary based
upon the achievement of certain bonus eligibility criteria; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> stock option awards as described below under the heading "&#151;
Outstanding Equity Awards at Fiscal Year-End." </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Upon
a termination of Dr.&nbsp;Kopecky's employment by us without cause, Dr.&nbsp;Kopecky is eligible to receive continuation of his base salary and continuation of his health insurance benefits
at our expense for six months, subject to his execution of and non-revocation of a general release of claims. Upon a termination of Dr.&nbsp;Kopecky's employment by us with cause or
Dr.&nbsp;Kopecky's resignation, all compensation and benefits payable to Dr.&nbsp;Kopecky under his employment agreement shall terminate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Kopecky
is entitled to participate in all of our employee benefit plans, subject to the terms and conditions applicable to such plans. Further, Dr.&nbsp;Kopecky has executed a
Confidentiality and Inventions Agreement which contains customary non-solicitation covenants, which covenants remain in effect for two years following any cessation of employment with respect to
Dr.&nbsp;Kopecky. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Douglas R. Carlson  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On March&nbsp;13, 2013, we entered into an employment agreement with Douglas R. Carlson, our Vice President, Corporate Development. The principal
terms of Mr.&nbsp;Carlson's employment agreement are as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> base salary of $225,000 per year, subject to annual adjustments (currently
$231,750 per year); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> annual incentive bonus opportunity in an amount up to 25% of base salary based
upon the achievement of certain bonus eligibility criteria; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  supplemental bonus of $15,000 after three months of employment with the Company
and an additional bonus of $15,000 after twelve months of employment; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=150,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=334193,FOLIO='146',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_147"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> stock option awards as described below under the heading "&#151;
Outstanding Equity Awards at Fiscal Year-End." </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Upon
a termination of Mr.&nbsp;Carlson's employment by us without cause, Mr.&nbsp;Carlson is eligible to receive continuation of his base salary and continuation of his health insurance benefits
at our expense for six months, subject to his execution of and non-revocation of a general release of claims. Upon a termination of Mr.&nbsp;Carlson's employment by us with cause or
Mr.&nbsp;Carlson's resignation, all compensation and benefits payable to Mr.&nbsp;Carlson under his employment agreement shall terminate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Mr.&nbsp;Carlson
is entitled to participate in all of our employee benefit plans, subject to the terms and conditions applicable to such plans. Further, Mr.&nbsp;Carlson has executed a
Confidentiality and Inventions Agreement which contains customary non-solicitation covenants, which covenants remain in effect for two years following any cessation of employment with respect to
Mr.&nbsp;Carlson. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Potential Payments Upon a Termination or Change in Control  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each of our named executive officers is entitled to severance in the event of a termination by the Company without cause or, in Mr.&nbsp;Heffernan's
case, a resignation by him for good reason. The details of such severance arrangements are described above in the section titled "&#151; Employment Agreements." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
certain unvested equity grants awarded to Mr.&nbsp;Heffernan will become fully vested (and exercisable as applicable) in connection with certain termination of employment events. The
details of such accelerated vesting are described above in the section titled "&#151; Employment Agreements" and below in the section titled "&#151; Outstanding Equity Awards at Fiscal
Year-End." </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Non-Equity Incentive Plan Compensation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For the fiscal year ended December&nbsp;31, 2014, each of Messrs.&nbsp;Heffernan, Kopecky and Carlson were eligible to earn a cash bonus, of which
70% of such bonuses were determined based on achievement of corporate performance goals and 30% of such bonuses were determined based on achievement of certain individual performance goals. The target
amount of the annual bonuses for Messrs. Heffernan, Kopecky and Carlson were 40% of base salary, 30% of base salary and 25% of base salary, respectively. The applicable corporate performance goals
were achieved at 86% of target with the applicable individual performance goals for Messrs. Heffernan, Kopecky and Carlson achieved at 86% of target, 100% of target and 200% of target, respectively.
Thus, Messrs. Heffernan, Kopecky and Carlson each earned annual bonuses at 86% of target, 90.2% of target and 120.2% of target, respectively. The amounts shown above for each named executive officer
in the
column titled "&#151;Non-Equity Incentive Plan Compensation" represent the actual annual performance bonuses payable for the fiscal year ended December 31, 2014 to each named executive officer. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Option Awards During Fiscal Year Ended December&nbsp;31, 2014  </I></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>On March&nbsp;5, 2014, we awarded Messrs.&nbsp;Kopecky and Carlson stock options to purchase 19,299 and 23,841 shares of our common stock,
respectively, with an aggregate grant date fair value computed in accordance with FASB ASC Topic 718 equal to $54,730 and $67,612, respectively. The options have an exercise price of $0.28 and are
subject to time-based vesting conditions as described below in the section titled "&#151; Outstanding Equity Awards at Fiscal Year-End."

 </FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Outstanding Equity Awards at Fiscal Year-End  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>The following table provides information regarding equity awards held by each of our named executive officers that were outstanding as of
December&nbsp;31, 2014. Dollar values are based on the independent valuation of our common stock of $6.07 per share as of December&nbsp;31, 2014.


</FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=151,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=105803,FOLIO='147',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_148"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option Awards </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock Awards </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
(Exercisable) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
(Unexercisable) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Equity Incentive Plan<BR>
Awards: Number of<BR>
Securities Underlying<BR>
Unexercised<BR>
Unearned<BR>
Options (#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
Exercise<BR>
Price ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Shares or Units<BR>
of Stock That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Market Value<BR>
of Shares or<BR>
Units of Stock<BR>
That Have Not<BR>
Vested ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Michael T. Heffernan, R.Ph.</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22,101</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.90</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10/24/2018</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Executive</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,246</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.90</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2/26/2020</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Officer</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,673</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3.31</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">11/11/2020</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,246</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,246</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.48</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">01/30/2023</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,873</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">41,735</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Ernest A. Kopecky, Ph.D.</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
23,400</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
12,831</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
0.48</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
06/13/2022</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Vice President,</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">905</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">906</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.48</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">01/30/2023</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Clinical</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,618</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">15,681</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.28</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">03/05/2024</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Development</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Douglas R. Carlson</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
11,096</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
14,266</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
0.48</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
05/30/2023</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Vice President,</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
14,492</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.48</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">05/30/2023</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Corporate</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,790</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">16,427</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.28</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">03/05/2024</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Development</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,623</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.28</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">03/05/2024</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >



<DL compact>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 28,984 shares of our common stock was granted to Mr.&nbsp;Heffernan on January&nbsp;24, 2013. The option was
adjusted to an option to purchase 14,492 shares our common stock in connection with the December&nbsp;4, 2013 reverse stock split. As of December&nbsp;31, 2014, 7,246 option shares were not
exercisable. The option vests and becomes exercisable monthly over the four-year period following the grant date. Pursuant to Mr.&nbsp;Heffernan's employment agreement, the option will immediately
become fully vested and exercisable upon a termination of Mr.&nbsp;Heffernan's employment without cause or due to Mr.&nbsp;Heffernan's death or disability, or upon a resignation by
Mr.&nbsp;Heffernan for good reason.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Heffernan
was awarded 247,436 shares of restricted common stock on June&nbsp;13, 2012. The restricted stock award was adjusted to
an award of 123,718 shares of restricted common stock in connection with the December&nbsp;4, 2013 reverse stock split. The restricted shares vest and become non-forfeitable monthly over the
three-year period beginning on February&nbsp;10, 2012 and became fully vested on February&nbsp;10, 2015. Pursuant to Mr.&nbsp;Heffernan's employment agreement, the shares will immediately become
fully vested upon a termination of Mr.&nbsp;Heffernan's employment without cause or due to Mr.&nbsp;Heffernan's death or disability, or upon a resignation by Mr.&nbsp;Heffernan for good reason.
Additionally, pursuant to Mr.&nbsp;Heffernan's employment agreement, the shares will immediately become fully vested upon the occurrence of a "Sale Event" (as defined in the employment agreement).


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 72,462 shares of our common stock was granted to Dr.&nbsp;Kopecky on June&nbsp;13, 2012. The option was
adjusted to an option to purchase 36,231 shares of our common stock in connection with the December&nbsp;4, 2013 reverse stock split. As of December&nbsp;31, 2014, 12,831 of the option shares were
not exercisable. The option vests and becomes exercisable over the four-year period following the grant date, with 25% of the option vesting and becoming exercisable on the first anniversary of
Dr.&nbsp;Kopecky's date of hire and 1/48th&nbsp;of the option vesting and becoming exercisable at the end of each monthly period thereafter.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 3,622 shares of our common stock was granted to Dr.&nbsp;Kopecky on January&nbsp;24, 2013. The option was
adjusted to an option to purchase 1,811 shares of our common stock in connection with the December&nbsp;4, 2013 reverse stock split. As of December&nbsp;31, 2014, 905 option shares were not
exercisable. The option vests and becomes exercisable monthly over the four-year period following the grant date.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 19,299 shares of our common stock was granted to Dr.&nbsp;Kopecky on March&nbsp;5, 2014. As of
December&nbsp;31, 2014, 15,681 of the option shares were not exercisable. The option vests and becomes exercisable as to 1/48th&nbsp;of the option of the original number of option shares at the
end of each monthly period following the grant date until the fourth anniversary of the grant date.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 50,724 shares of our common stock was granted to Mr.&nbsp;Carlson on May&nbsp;30, 2013. The option was adjusted
to an option to purchase 25,362 shares of our common stock in connection with the December&nbsp;4, 2013 reverse stock split. As of December&nbsp;31, 2014, 14,266 option shares were not
exercisable. The option vests and becomes exercisable over the four-year period following the grant date, with 25% of the option vesting and becoming exercisable on April&nbsp;3, 2014, and
1/48<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">th</font>&nbsp;of the option vesting and becoming exercisable monthly thereafter.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 28,984 shares of our common stock was granted to Mr.&nbsp;Carlson on May&nbsp;30, 2013. The option was adjusted
to an option to purchase 14,492 shares of our common stock in connection with the December&nbsp;4, 2013 reverse stock split. The option vests and becomes exercisable upon the closing of a Sale Event
(as defined in the employment agreement) or a strategic partnership with a third party relating to the development, manufacturing, sale and/or distribution of one or more of our products that occurs
before April&nbsp;3, 2017. If the total consideration received from such strategic partnership exceeds $200&nbsp;million but is less than $300&nbsp;million, then 50% of the option will vest. If
the total consideration from the strategic partnership exceeds $300&nbsp;million, then 100% of the option will vest.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 20,218 shares of our common stock was granted to Mr.&nbsp;Carlson on March&nbsp;5, 2014. As of
December&nbsp;31, 2014, 16,427 of the option shares were not exercisable. The option vests and becomes exercisable as to 1/48th&nbsp;of the option of the original number of option shares at the
end of each monthly period following the grant date until the fourth anniversary of the grant date.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 3,623 shares of our common stock was granted to Mr.&nbsp;Carlson on March&nbsp;5, 2014. As of
December&nbsp;31, 2014, 100% of the option shares were not exercisable. The option vests and becomes exercisable over the four-year period commencing on the grant date, with 25% of the option shares
becoming vested on the first anniversary of the grant date and the balance of the option shares vesting in monthly installments over the remaining three years of the vesting term.


</FONT></DD>

</DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=152,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=811774,FOLIO='148',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_149"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Equity Incentive Plans  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Amended and Restated 2014 Stock Incentive Plan  </I></B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>All of our outstanding equity awards are governed by the Collegium Pharmaceutical,&nbsp;Inc. Amended and Restated 2014 Stock Incentive Plan, or the
Plan. We adopted the Plan, as amended and restated, on April&nbsp;23, 2015, and it will become effective immediately prior to the closing of this offering. The Plan was adopted to enhance our
ability to attract, retain and motivate persons who make important contributions to us and by providing such persons with equity ownership opportunities and performance-based incentives that are
intended to better align the interests of such persons with those of our shareholders. The material terms of the Plan are described below.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>


The Plan permits the grant of (i)&nbsp;options, (ii)&nbsp;restricted stock awards, (iii)&nbsp;restricted stock units, or RSUs and (iv)&nbsp;performance awards, which we refer to collectively
as Awards, as more fully described below.

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to this offering, options to purchase common stock and awards of restricted stock were granted to various participants under the Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


All Awards granted under the Plan are governed by award agreements, between us and the participants. No Awards may be granted after the tenth anniversary of the Plan's adoption by our shareholders,
although Awards granted before that time will remain valid in accordance with their terms.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


The compensation committee of our board of directors will administer the Plan. The compensation committee will designate each eligible individual to whom an Award is to be granted. Any of our
employees, consultants, officers or other service providers, or those of our affiliates, are eligible to participate in the Plan if selected by the compensation committee. In its discretion, the
compensation committee may delegate all or part of its authority and duties with respect to granting Awards to one or more individuals, provided applicable law so permits.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Subject to certain adjustments, the maximum number of shares of common stock that may be issued under the Plan in connection with Awards is (i) 2,700,000 shares (inclusive of shares subject to Awards
issued under the Plan prior to its restatement that remain outstanding as of the effective date of the Plan), plus (ii) an annual increase to be added on the first day of each fiscal year beginning
with the fiscal year ending December 31, 2016, and on each anniversary thereof until the expiration of the Plan equal to 4% of the outstanding shares of our common stock on
December&nbsp;31<SUP>st</SUP> of the immediately preceding fiscal year (or such lesser number of shares of common stock as determined by the board of directors). In the event of any stock
dividend, recapitalization, forward stock split or reverse stock split, reorganization, division, merger, consolidation, spin-off, combination, repurchase or share exchange, extraordinary or unusual
cash distribution or other similar corporate transaction or event that affects our common stock, the compensation committee shall make appropriate adjustment in the number and kind of shares
authorized by the Plan and covered under outstanding Awards as it determines appropriate and equitable. Shares of our common stock subject to Awards under the Plan that expire unexercised or are
otherwise forfeited shall again be available for Awards under the Plan (as amended and restated).

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


An option entitles the holder to purchase from us a stated number of shares of common stock. An incentive stock option, or ISO, may only be granted to an employee of ours or our affiliates (provided
applicable law so permits). The aggregate maximum number of shares that may be issued pursuant to the exercise of ISOs will be 8,100,000 shares. The compensation committee will specify the number of
shares of common stock subject to each option and the exercise price for such option, provided that the exercise price may not be less than the fair market value of a share of common stock on the date
the option is granted. Notwithstanding the foregoing, if ISOs are granted to any 10% shareholder, the exercise price shall not be less than 110% of the fair market value of common stock on the date
the option is granted. Generally, all or part of the exercise price may be paid (i)&nbsp;in cash, (ii)&nbsp;with the proceeds received from a broker-dealer whom the holder has authorized to sell
all or a portion of the common stock covered by the option, (iii)&nbsp;with the consent of the compensation committee, in whole or in part in common stock held by the holder and valued at fair
market value on the date of exercise, or (iv)&nbsp;by any combination of such methods. The

 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=153,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=303384,FOLIO='149',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_150"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>compensation
committee may, in its sole discretion, permit payment of the exercise price of an option in the form of previously acquired shares based on the fair market value of the shares on the date
the option is exercised or through means of "net settlement." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
options shall be exercisable in accordance with the terms of the applicable award agreement. The maximum term of an option shall be determined by the compensation committee on the date of grant
but shall not exceed 10&nbsp;years (5 years in the case of ISOs granted to any 10% shareholder). In the case of ISOs, the aggregate fair market value (determined as of the date of grant) of common
stock with respect to which such ISOs become exercisable for the first time during any calendar year cannot exceed $100,000. ISOs granted in excess of this limitation will be treated as NQOs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Unless otherwise provided in an award agreement, if a participant terminates employment with us (or our affiliates) due to death or disability, the participant's unexercised options may be exercised,
to the extent they were exercisable on the termination date, for a period of twelve months from the termination date or until the expiration of the original option term, if shorter. If the participant
terminates employment with us (or our affiliates) for cause (as defined in the Plan), all unexercised options (whether vested or unvested) shall terminate and be forfeited on the termination date. If
the participant's employment terminates for any other reason, any vested but unexercised options may be exercised by the participant, to the extent exercisable at the time of termination, for a period
of ninety days from the termination date (or such time as specified by the compensation committee at the time of grant) or until the expiration of the original option term, whichever period is
shorter. Unless otherwise provided by the compensation committee, any options that are not exercisable at the time of termination of employment shall terminate and be forfeited on the termination
date.

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


A restricted stock award is a grant of shares of common stock, which may or may not be subject to forfeiture restrictions during a restriction period. The compensation committee will determine the
price, if any, to be paid by
the participant for each share of common stock subject to a restricted stock award. The compensation committee may condition the expiration of the restriction period, if any, upon: (i)&nbsp;the
participant's continued service over a period of time with us or our affiliates; (ii)&nbsp;the achievement by the participant, us or our affiliates of any other performance goals set by the
compensation committee; or (iii)&nbsp;any combination of the above conditions as specified in the award agreement. If the specified conditions are not attained, the participant will forfeit the
portion of the restricted stock award with respect to which those conditions are not attained, and the underlying common stock will be forfeited to us. At the end of the restriction period, if the
conditions, if any, have been satisfied, the restrictions imposed will lapse with respect to the applicable number of shares. During the restriction period, a participant will have the right to vote
the shares underlying the restricted stock, however, unless otherwise provided by the compensation committee, all dividends will remain subject to restriction until the stock with respect to which the
dividend was issued lapses. The compensation committee may, in its discretion, accelerate the vesting and delivery of shares of restricted stock.


</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


RSUs are granted in reference to a specified number of shares of common stock and entitle the holder to receive, on achievement of specific performance goals established by the compensation committee,
after a period of continued service or any combination of the above as set forth in the applicable award agreement, one share of common stock for each such share of common stock covered by the RSU.
The compensation committee may, in its discretion, accelerate the vesting of RSUs.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
compensation committee may grant performance awards in accordance with the Plan. Performance awards may be denominated as a number of shares or specified number of other Awards (such as restricted
stock or RSUs), which may be earned upon achievement or satisfaction of such performance goals as may be specified by the compensation committee. Performance goals may be linked to a variety of
factors including the participant's completion of a specified period of employment or service with us or an affiliated company. Additionally, performance goals can include objectives stated with
respect to us, an affiliated company or a business unit and are limited to one or more of the following: (i)&nbsp;specified levels of or increases in pre-tax earnings, return on capital, equity
measures/ratios (on a gross, net, pre-tax or post tax </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=154,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=958421,FOLIO='150',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_151"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>basis),
including basic earnings per share, diluted earnings per share, total earnings (including total earnings as adjusted by the compensation committee at the time of the Award), operating
earnings, earnings growth, earnings before interest and taxes, or EBIT, and earnings before interest, taxes, depreciation and amortization, or EBITDA (including EBIT or EBITDA as adjusted by the
Committee at the time of the Award); (ii)&nbsp;total sales or sales growth; (iii)&nbsp;gross margin; (iv)&nbsp;customer service levels; (v)&nbsp;employee recruiting and development;
(vi)&nbsp;advertising effectiveness; (vii)&nbsp;development of new markets; (viii)&nbsp;financial ratios; (ix)&nbsp;strategic initiatives; (x)&nbsp;improvement in or attainment of operating
expense levels; (xi)&nbsp;improvement in or attainment of capital expense levels; (xii)&nbsp;the attainment of certain target levels of, or a specified increase in, operational cash flow;
(xiii)&nbsp;the achievement of a certain level of, reduction of, or other specified objectives with regard to limiting the level of increase in, all or a portion of, our bank debt or other long-term
or short-term public or private debt or other similar financial obligations of ours, which may be calculated net of such cash balances and/or other specified offsets; (xiv)&nbsp;appreciation in
and/or maintenance of certain target levels in the fair market value; (xv)&nbsp;the attainment of a certain level of, reduction of, or other specified objectives with regard to limiting the level of
or rate of increase in all or a portion of specified expenses (xvi)&nbsp;individual objectives; and (xvii)&nbsp;any combination of the foregoing. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
compensation committee may impose restrictions on the grant, exercise or payment of an Award as it determines appropriate. Generally, Awards granted under the Plan shall be nontransferable except
by will or by the laws of descent and distribution. No participant shall have any rights as a shareholder with respect to shares covered by options or RSUs, unless and until such Awards are settled in
shares of common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No
option shall be exercisable, no shares of common stock shall be issued, no certificates for shares of common stock shall be delivered and no payment shall be made under the Plan except in
compliance with all applicable laws. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
board of directors may amend, suspend or terminate the Plan and the compensation committee may amend any outstanding Award at any time; provided, however, that no such amendment or termination may
adversely affect Awards then outstanding without the holder's permission. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


In the event of a change in control (as defined in the Plan), the compensation committee may, on a participant-by-participant basis: (i)&nbsp;cause any or all outstanding Awards to become vested and
immediately exercisable (as applicable), in whole or in part; (ii)&nbsp;cause any outstanding option to become fully vested and immediately exercisable for a reasonable period in advance of the
change in control and, to the extent not exercised prior to that change in control, cancel that option upon closing of the change in control; (iii)&nbsp;cancel any unvested Award or unvested portion
thereof, with or without consideration; (iv)&nbsp;cancel any Award in exchange for a substitute award; (v)&nbsp;redeem any restricted stock or RSU for cash and/or other substitute consideration
with value equal to fair market value of an unrestricted share on the date of the change in control; (vi)&nbsp;cancel any outstanding options with respect to all common stock for which the Award
remains unexercised for a cash payment equal to the excess (if any) of the fair market value of the shares subject to the option over the exercise price of the option; (vii)&nbsp;take such other
action as the compensation committee shall determine to be reasonable under the circumstances; and/or (viii)&nbsp;in the case of any Award subject to Section&nbsp;409A of the Code, such Award
shall vest and be distributed only in accordance with the terms of the applicable award agreement and the compensation committee shall only be permitted to use discretion to the extent that such
discretion would be permitted under Section&nbsp;409A of the Code.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Neither the board of directors nor the compensation committee may, without obtaining prior approval of our shareholders: (i)&nbsp;implement any cancellation/re-grant program pursuant to which
outstanding options under the Plan are cancelled and new options are granted in replacement with a lower exercise per share, (ii)&nbsp;cancel outstanding options under the Plan with an exercise
price per share in excess of the then current fair market value per share for consideration payable in our equity securities or (iii)&nbsp;otherwise directly reduce the exercise price in effect for
outstanding options under the Plan.

</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=155,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=171637,FOLIO='151',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_152"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


2015 Employee Stock Purchase Plan  </I></B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>On April&nbsp;23, 2015, we adopted the 2015 Employee Stock Purchase Plan, or the 2015 ESPP, which shall be effective immediately prior to the
closing of this offering. The 2015 ESPP will be administered by our board of directors or by a committee appointed by our board of directors. The 2015 ESPP will initially provide participating
employees with the opportunity to purchase an aggregate of 200,000 shares of our common stock. The number of shares of our common stock reserved for issuance under the 2015 ESPP will automatically
increase on the first day of each fiscal year, commencing on January&nbsp;1, 2016 and ending on December&nbsp;31, 2025, in an amount equal to the least of (i)&nbsp;400,000 shares of our common
stock, (ii)&nbsp;1.0% of the total number of shares of our common stock outstanding on the first day of the applicable year, and (iii)&nbsp;an amount determined by our board of directors.


</FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>All
of our employees are eligible to participate in the 2015 ESPP, provided that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> such person is customarily employed by us for more than 20&nbsp;hours a week
and for more than five months in a calendar year; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> such person has been employed by us or by a designated subsidiary for at least
21&nbsp;days prior to enrolling in the 2015 ESPP; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> such person was our employee on the first day of the applicable offering period
under the 2015 ESPP. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>No
employee may purchase shares of our common stock under the 2015 ESPP and any of our other employee stock purchase plans in excess of $25,000 of the fair market value of our common stock (as of the
date of the option grant) in any calendar year. In addition, no employee may purchase shares of our common stock under the 2015 ESPP that would result in the employee owning 5% or more of the total
combined voting power or value of our stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect to make one or more offerings to our eligible employees to purchase stock under the 2015 ESPP beginning at such time as our board of directors may determine. Each offering will consist of a
six-month offering period during which payroll deductions will be made and held for the purchase of our common stock at the end of the offering period. Our board of directors may, at its discretion,
choose a different period of not more than 12&nbsp;months for offerings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
the commencement date of each offering period, each eligible employee may authorize up to a maximum of 15% of his or her compensation to be deducted by us during the offering period. Each employee
who continues to be a participant in the 2015 ESPP on the last business day of the offering period will be deemed to have exercised an option to purchase from us the number of whole shares of our
common stock that his or her accumulated payroll deductions on such date will pay for, not in excess of the maximum numbers set forth above. Under the terms of the 2015 ESPP, the purchase price shall
be determined by our board of directors or compensation committee for each offering period and will be at least 85% of the applicable closing price of our common stock. If our board of directors does
not make a determination of the purchase price, the purchase price will be 85% of the lesser of the closing price of our common stock on the first business day of the offering period or on the last
business day of the offering period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


An employee may for any reason withdraw from participation in an offering no later than 21 days prior to the end of an offering period and permanently draw out the balance accumulated in the
employee's account. If an employee elects to discontinue his or her payroll deductions during an offering period but does not elect to withdraw his or her funds, funds previously deducted will be
applied to the purchase of common stock at the end of the offering period. If a participating employee's employment ends before the last business day of an offering period, no additional payroll
deductions will be made and the balance in the employee's account will be paid to the employee.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will be required to make equitable adjustments to the number and class of securities available under the 2015 ESPP, the share limitations under the 2015 ESPP and the purchase price for an offering
period </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=156,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=872514,FOLIO='152',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_153"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


under the 2015 ESPP to reflect stock splits, reverse stock splits, stock dividends, recapitalizations, combinations of shares, reclassifications of shares, spin-offs and other similar changes in
capitalization or events or any dividends or distributions to holders of our common stock other than ordinary cash dividends. The number of shares of common stock available for any offerings under the
2015 ESPP shall be adjusted if the number of our outstanding shares is increased or reduced by split up, reclassification, stock dividend or the like.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Our board of directors may at any time, and from time to time, terminate, amend or suspend the 2015 ESPP or any portion thereof. We will obtain shareholder approval for any amendment if such approval
is required by Section&nbsp;423 of the Code. The 2015 ESPP will also terminate upon the occurrence of a change in control (defined
with reference to the Plan). Upon termination, we will refund all amounts in the accounts of participating employees.

 </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Non-Equity Incentive Compensation  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Performance Bonus Plan  </I></B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>On April&nbsp;23, 2015, we adopted the Performance Bonus Plan, which will be effective immediately prior to the closing of the offering. The
Performance Bonus Plan will be administered by the compensation committee. The purpose of the Performance Bonus Plan is to benefit and advance our interests, by rewarding selected employees of ours
and our affiliates for their contributions to our success and thereby motivate them to continue to make such contributions in the future by granting performance-based awards. The material terms of
such plan are summarized below.

 </FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2><I> Background.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors believes that it is in our best interests and those of our shareholders to enhance our ability to attract and retain qualified
personnel through performance based incentives, while at the same time obtaining the highest level of deductibility of compensation paid to employees. Section&nbsp;162(m) of the Code disallows a
deduction to us for any compensation paid to certain executive officers in excess of $1.0&nbsp;million per year, subject to certain exceptions. Among other exceptions, the deduction limit does not
apply to compensation that meets the specified requirements for "performance-based compensation." In general, those requirements include the establishment of objective performance goals for the
payment of such compensation by a committee of the board of directors composed solely of two or more outside directors, shareholder approval of the material terms of such compensation, and
certification by the compensation committee that the performance goals for the payment of such compensation have been achieved.

 </FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2><I> Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the other provisions of the Performance Bonus Plan, the compensation committee has the authority to administer and interpret the
Performance Bonus Plan, including the authority to select the employees (including employees who are directors) to participate in the Performance Bonus Plan, to establish the performance goals, to
determine the amount of incentive compensation bonus payable to any participant, to determine the terms and conditions of any such incentive opportunity; to make all determinations and take all
other actions necessary or appropriate for proper administration and operation of the Performance Bonus Plan and to establish and amend rules and regulations relating to the Performance Bonus Plan.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>The
compensation committee may also delegate to one or more of our executive officers the authority to administer the Performance Bonus Plan with respect to any participants who are not subject to
Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2><I> Eligibility.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The named executive officers and such other of our employees as selected by the compensation committee are eligible to participate in the Performance
Bonus Plan. The maximum amount of the incentive compensation bonuses payable to any participant under the Performance Bonus Plan in, or in respect of, any single fiscal year shall not exceed
$5.0&nbsp;million. All incentive compensation bonuses paid pursuant to the Performance Bonus Plan will be paid in cash.


</FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=157,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=764553,FOLIO='153',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_154"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Bonus Opportunity and Performance Goals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Bonuses may be payable to a participant as a result of the satisfaction of performance goals in respect of any performance
period determined by the compensation committee; provided that, to the extent a participant would be subject to Section&nbsp;162(m) of the Code, the performance goals will be set in accordance with
the regulations under Section&nbsp;162(m) of the Code. Performance goals, which may vary among and between participants, may include objectives stated with respect to us, an affiliated company or a
business unit and such objectives are limited to one or more of the following: (i)&nbsp;specified levels of or increases in pre-tax earnings, return on capital, equity measures/ratios (on a gross,
net, pre-tax or post tax basis), including basic earnings per share, diluted earnings per share, total earnings (including total earnings as adjusted by the compensation committee at the time of the
Award), operating earnings, earnings growth, EBIT and EBITDA (including EBIT or EBITDA as adjusted by the compensation committee at the time of the Award); (ii)&nbsp;total sales or sales growth;
(iii)&nbsp;gross margin; (iv)&nbsp;customer service levels; (v)&nbsp;employee recruiting and development; (vi)&nbsp;advertising effectiveness; (vii)&nbsp;development of new markets;
(viii)&nbsp;financial ratios; (ix)&nbsp;strategic initiatives; (x)&nbsp;improvement in or attainment of operating expense levels; (xi)&nbsp;improvement in or attainment of capital expense
levels; (xii)&nbsp;the attainment of certain target levels of, or a specified increase in, operational cash flow; (xiii)&nbsp;the achievement of a certain level of, reduction of, or other
specified objectives with regard to limiting the level of increase in, all or a portion of, the Company's bank debt or other long-term or short-term public or private debt or other similar financial
obligations of the Company, which may be calculated net of such cash balances and/or other specified offsets; (xiv)&nbsp;appreciation in and/or maintenance of certain target levels in the fair
market value; (xv)&nbsp;the attainment of a certain level of, reduction of, or other specified objectives with regard to limiting the level of or rate of increase in all or a portion of specified
expenses (xvi)&nbsp;individual objectives; and (xvii)&nbsp;any combination of the foregoing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


The compensation committee shall provide a threshold level of performance below which no incentive compensation bonus will be paid, as well as a maximum level of performance above which no additional
incentive compensation bonus will be paid. It also may provide for the payment of differing amounts for different levels of performance, determined with regard either to a fixed monetary amount or a
percentage of the participant's base salary. The compensation committee shall make such adjustments, to the extent it deems appropriate, to established performance goals and performance thresholds to
compensate for, or to reflect, any material changes which may have occurred due to an "extraordinary event"; provided, however, that no such adjustment may be made unless such adjustment would be
permissible under Section&nbsp;162(m) of the Code. An "extraordinary event" under the Performance Bonus Plan is defined as follows:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> material changes in accounting practices, tax laws, other laws or regulations, </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> material changes in our financial structure, </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an acquisition or disposition of one of our subsidiaries or divisions, or </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> unusual circumstances outside of our management's control which, in the sole
judgment of the compensation committee, alters or affects the computation of such established performance goals and performance thresholds, our performance or the performance of a relevant subsidiary
or division.

</FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>As
soon as practicable after the end of each performance period, but before any incentive compensation bonuses are paid to the participants under the Performance Bonus Plan, the compensation committee
will certify in writing (i)&nbsp;whether the performance goal(s) were attained and (ii)&nbsp;the amount of the incentive compensation bonus payable to each participant based upon the attainment of
such specified performance goals. The compensation committee also may reduce, eliminate, or, with respect only to participants who are not subject to Section&nbsp;162(m) of the Code, increase the
amount of any incentive compensation bonus of any participant at any time prior to payment thereof, based on such criteria as the compensation committee shall determine, including but not limited to
individual merit and attainment of, or the failure to attain, specified personal goals established by the compensation committee. Under no circumstances, however, may the compensation committee, with
respect solely to a participant who is subject to Section&nbsp;162(m) of the Code, (i)&nbsp;increase the amount of the incentive compensation otherwise payable to such participant beyond the
amount originally established by the
compensation committee, (ii)&nbsp;waive the attainment of the performance goals established and applicable to such participant's incentive </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=158,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=224502,FOLIO='154',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<A NAME="page_eg72301_1_155"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>compensation
or (iii)&nbsp;otherwise exercise its discretion so as to cause any incentive compensation bonus payable to such participant to not qualify as "performance-based compensation" under
Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


All amounts due under the Performance Bonus Plan shall be paid within two and one-half months of the end of the year in which such incentive compensation is no longer subject to a risk of forfeiture.
The compensation committee, without the consent of any participant, may amend or terminate the Performance Bonus Plan at any time. However, no amendment that would require the consent of the
shareholders pursuant to Section&nbsp;162(m) of the Code shall be effective without such consent.

</FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Retirement Benefits  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We maintain a section&nbsp;401(k) retirement plan for all employees after three months of consecutive employment who are 21&nbsp;years of age or
older. Employees can contribute up to 100% of their eligible pay, subject to maximum amounts allowed under law. The Company provides matching and profit sharing contributions under the 401(k)
retirement plan. The total amount of Company matching contributions under the 401(k) retirement plan for 2014 was $35,000. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Compensation of Non-Employee Directors  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>The following table sets forth in summary form information concerning the compensation that we paid or awarded during the fiscal year ended
December&nbsp;31, 2014 to our non-employee director. Dollar values are based on the independent valuation of our common stock of $6.07 per share as of December&nbsp;31, 2014.


</FONT>

</P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Fees earned or<BR>
paid in cash ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock awards ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total ($) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gino Santini</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>40,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>66,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>106,000</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >




<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Santini
was awarded 10,869 shares of restricted common stock on March&nbsp;5, 2014. Of the 10,869 shares of restricted common
stock, 5,434 shares were subject to forfeiture until vested. The restricted shares vest and become non-forfeitable as follows: 1,811 of the restricted shares vested on April&nbsp;1, 2014, and
thereafter an additional 1,811 vest at the end of each quarterly period following April&nbsp;1, 2014. Pursuant to Mr.&nbsp;Santini's restricted stock award agreement, the shares will immediately
become fully vested upon the occurrence of a "Sale Event" (as defined in the restricted stock award agreement).

 </FONT></DD></DL>


<P style="font-family:arial;">


<FONT SIZE=2>With the exception of Gino Santini, we did not pay compensation or grant any equity awards to any of our other non-employee directors for serving on our board
during 2014. The compensation earned by Mr.&nbsp;Heffernan, as President and Chief Executive Officer, for 2014 is included in the "&#151; Summary Compensation Table" and his outstanding stock
and option awards are included under "&#151; Outstanding Equity Awards at Fiscal Year-End" above. Other than Mr.&nbsp;Heffernan and Mr.&nbsp;Santini, no other directors held directly any
outstanding equity awards as of December&nbsp;31, 2014. In March 2015, we granted a non-statutory stock option for the purchase of up to 28,985 shares of common stock at an exercise price of $5.73
per share to Garen Bohlin, one of our non-employee directors for board of director services.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>We
intend to put in place a formal director compensation policy for all of our non-employee directors following the completion of this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=159,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=605838,FOLIO='155',FILE='DISK114:[15ZAD1.15ZAD72301]EG72301A.;73',USER='DPERRY',CD='24-APR-2015;17:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ei72301_1_156"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ei72301_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_ei72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following includes a summary of transactions since January&nbsp;1, 2012 to which we have been a party, in which the amount involved in the
transaction exceeded $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family
of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are
described under "Executive and Director Compensation." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Series&nbsp;B Convertible Preferred Stock Financing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In February 2012, we entered into a Series&nbsp;B Convertible Preferred Stock Purchase Agreement, pursuant to which we issued and sold to investors
an aggregate of 27,324,237 shares of our Series&nbsp;B
Convertible Preferred Stock at a purchase price of $0.84 per share, for aggregate consideration of $23.0&nbsp;million. In connection with the Series&nbsp;B Convertible Preferred Stock financing,
all issued and outstanding shares of previously issued Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C Preferred Stock, Series&nbsp;C-2 Preferred Stock and
Series&nbsp;D-1 Preferred Stock were converted into 18,464,674 shares of Series&nbsp;A Convertible Preferred Stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Series&nbsp;C Convertible Preferred Stock Financing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In August 2013, we entered into a Series&nbsp;C Convertible Preferred Stock Purchase Agreement, or the Series&nbsp;C Purchase Agreement, pursuant
to which we issued and sold to investors an aggregate of 2,220,670 shares of our Series&nbsp;C Convertible Preferred Stock at a purchase price of $1.386 per share, for aggregate consideration of
$3.1&nbsp;million. In September 2013, at an additional closing pursuant to the Series&nbsp;C Purchase Agreement, we issued and sold to investors an aggregate of 665,334 shares of our
Series&nbsp;C Convertible Preferred Stock at a purchase price of $1.386 per share, for aggregate consideration of $922,000. In December 2013, those investors who participated in the closings in
August and September 2013 exercised their option under the Series&nbsp;C Purchase Agreement to purchase an additional pro rata portion of an aggregate of 5,772,004 shares of our Series&nbsp;C
Convertible Preferred Stock at a purchase price of $1.386 per share, for aggregate consideration of $8.0&nbsp;million. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Series&nbsp;D Convertible Preferred Stock Financing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In March 2015, we entered into a Series&nbsp;D Convertible Preferred Stock Purchase Agreement pursuant to which we issued and sold to investors an
aggregate of 41,666,667 shares of our Series&nbsp;D Convertible Preferred Stock at a purchase price of $1.20 per share, for aggregate consideration of $50.0&nbsp;million. This financing was led by
TPG Biotechnology Partners IV,&nbsp;L.P., which was joined by RA Capital Management, Adage Capital Management, Rock Springs Capital, EcoR1 Capital, Eventide Asset Management and Aperture Venture
Partners. Entities affiliated with Longitude Capital Partners,&nbsp;LLC, Skyline Ventures Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P. and Boston Millennia Partners also participated
in the financing. In connection with the Series&nbsp;D Convertible Preferred Stock financing, convertible notes with related parties in the aggregate principal amount of $5&nbsp;million
automatically converted to an aggregate of 4,166,667 shares of Series&nbsp;D Convertible Preferred Stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
outstanding convertible preferred stock will be converted into common stock upon the closing of this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=160,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=437702,FOLIO='156',FILE='DISK114:[15ZAD1.15ZAD72301]EI72301A.;93',USER='DPERRY',CD='24-APR-2015;17:57' -->
<A NAME="page_ei72301_1_157"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
participants in the convertible preferred stock financings described above included the following directors, executive officers and/or holders of more than 5% of our capital stock or entities
affiliated with them. The following table presents the number of shares issued to these related parties in these financings: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:35pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Participants<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font>

<!-- COMMAND=ADD_SCROPPEDRULE,35pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of<BR>
Series&nbsp;A<BR>
Convertible<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;A<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Aggregate<BR>
Purchase<BR>
Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of<BR>
Series&nbsp;B<BR>
Convertible<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;B<BR>
Convertible<BR>
Preferred Stock<BR>
Aggregate<BR>
Purchase Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of<BR>
Series&nbsp;C<BR>
Convertible<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;C<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Aggregate<BR>
Purchase<BR>
Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of<BR>
Series&nbsp;D<BR>
Convertible<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;D<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Aggregate<BR>
Purchase<BR>
Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>5% or greater shareholders</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Entities affiliated with Boston Millennia Partners<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,881,801</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,988,017</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,862,481</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,564,484</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">712,357</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">854,828</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Frazier Healthcare VI,&nbsp;L.P.<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,019,183</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,929,930</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,533,399</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,288,055</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,705,585</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,749,941</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,676,078</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,411,294</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Entities affiliated with Longitude Capital Partners, LLC<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,095,238</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">11,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,224,261</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,468,826</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,146,509</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,175,811</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Skyline Venture Partners V,&nbsp;L.P.<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,714,286</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,638,030</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,656,310</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,881,724</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,058,068</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">TPG Biotechnology Partners IV, L.P.<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,333,333</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">RA Capital Healthcare Fund, LP<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,833,333</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Additional
details regarding these shareholders and their equity holdings are provided in "Principal Shareholders."
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by Boston Millennia Partners II Limited Partnership, Boston Millennia Partners II-A Limited
Partnership, Boston Millennia Partners GmbH and Co. KG ('BMP KG'), Boston Millennia Associates II Partnership, and Strategic Advisors Fund Limited Partnership, or collectively, the Boston Millennia
Funds. Robert Jevon, a former member of our board of directors, is an affiliate of Glen Partners II Limited Partnership, which is the special limited partner of BMP KG, and the general partner of the
other Boston Millennia Funds.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Frazier Healthcare VI,&nbsp;L.P. is a limited partnership, the general partner of which is FHM VI,&nbsp;LLC.
Patrick Heron, a member of our board of directors, is a member of FHM VI,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by Longitude Venture Partners,&nbsp;L.P. and Longitude Capital Associates,&nbsp;L.P. or,
collectively, the Longitude Funds. Longitude Capital Partners,&nbsp;LLC is the general partner of the Longitude Funds. David Hirsch, a member of our board of directors, is a member of Longitude
Capital Partners,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Skyline Venture Partners V,&nbsp;L.P. is Skyline Venture Management V,&nbsp;LLC. John G. Freund, a member of our
board of directors, is a manager of Skyline Venture Management V,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of TPG Biotechnology Partners IV,&nbsp;L.P. is TPG Biotechnology GenPar IV,&nbsp;L.P., a Delaware limited partnership,
whose general partner is TPG Biotechnology GenPar IV Advisors,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Holdings I,&nbsp;L.P., a Delaware limited partnership, whose
general partner is TPG Holdings I-A,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Group Holdings (SBS),&nbsp;L.P., a Delaware limited partnership, whose general partner
is TPG Group Holdings (SBS) Advisors,&nbsp;Inc., or Group Advisors, a Delaware corporation. Messrs.&nbsp;David Bonderman and James G. Coulter are officers and sole shareholders of Group Advisors
and may therefore be deemed to be the beneficial owners of the shares held by TPG Biotechnology Partners IV,&nbsp;L.P. Each of Messrs.&nbsp;Bonderman and Coulter expressly disclaims beneficial
ownership of the securities listed above except to the extent of any pecuniary interest therein. The address for Messrs.&nbsp;Bonderman and Coulter and TPG Biotechnology Partners IV,&nbsp;L.P. is
c/o TPG Global,&nbsp;LLC, 301 Commerce Street, Suite&nbsp;3300, Fort Worth, TX 76102.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
investment adviser and sole general partner of RA Capital Healthcare Fund,&nbsp;LP is RA Capital Management,&nbsp;LLC. Peter
Kolchinsky is the sole managing member of RA Capital Management,&nbsp;LLC and has the power to vote or dispose of the shares held by RA Capital Healthcare Fund,&nbsp;LP. The address for
Dr.&nbsp;Kolchinsky and RA Capital Healthcare Fund,&nbsp;LP is 20 Park Plaza, Suite&nbsp;1200, Boston, MA 02116
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">These
amounts reflect the December 2013 reverse stock split pursuant to which every two issued and outstanding shares of Series&nbsp;A
Convertible Preferred Stock were reclassified and combined into one share of Series&nbsp;A Convertible Preferred Stock. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Note Financing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November and December 2014, we entered into a Convertible Note Purchase Agreement, pursuant to which we issued and sold to investors convertible promissory notes in the aggregate principal amount
of $5&nbsp;million, or the 2014 Convertible Note Financing. Pursuant to the Convertible Note Purchase Agreement, the convertible notes bore interest at a rate per annum of 6.0% and mature on the
earlier of (i)&nbsp;November&nbsp;14, 2015, (ii)&nbsp;immediately prior to a liquidation of the company, or (iii)&nbsp;upon an event of default. In connection with the Series D Convertible
Preferred Stock financing, the notes automatically converted into an aggregate of 4,166,667 shares of Series D Convertible Preferred Stock. The participants in the 2014 Convertible Notes Financing
included the following directors, executive officers and/or holders of more than 5% of our capital </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=161,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=835094,FOLIO='157',FILE='DISK114:[15ZAD1.15ZAD72301]EI72301A.;93',USER='DPERRY',CD='24-APR-2015;17:57' -->
<A NAME="page_ei72301_1_158"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>stock
or entities affiliated with them. The following table presents the amount of the notes issued to these related parties in this financing: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:40pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Participants<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font>

<!-- COMMAND=ADD_SCROPPEDRULE,40pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount of<BR>
Notes Purchased </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>5% or greater shareholders</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Boston Millennia Partners<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>754,829</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Frazier Healthcare VI,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>924,264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Longitude Capital Partners, LLC<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,826,499</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Skyline Venture Partners V,&nbsp;L.P.<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,494,408</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Additional
details regarding these shareholders and their equity holdings are provided in "Principal Shareholders."
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by the Boston Millennia Funds. Robert Jevon, a former member of our board of directors, is an
affiliate of Glen Partners II Limited Partnership, which is the special limited partner of BMP KG, and the general partner of the other Boston Millennia Funds.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Frazier Healthcare VI,&nbsp;L.P. is a limited partnership, the general partner of which is FHM VI,&nbsp;LLC.
Patrick Heron, a member of our board of directors, is a member of FHM VI,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by the Longitude Funds. Longitude Capital Partners,&nbsp;LLC is the general partner of the
Longitude Funds. David Hirsch, a member of our board of directors, is a member of Longitude Capital Partners,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Skyline Venture Partners V,&nbsp;L.P. is Skyline Venture Management V,&nbsp;LLC. John G. Freund, a member of our
board of directors, is a manager of Skyline Venture Management V,&nbsp;LLC. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>In connection with the 2014 Convertible Note Financing, we entered into a Preferred Shareholder Agreement with the Boston Millennia Funds, the Longitude Funds,
Skyline Venture Partners V,&nbsp;L.P. and Frazier Healthcare VI,&nbsp;L.P., pursuant to which the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P. and Frazier Healthcare VI,&nbsp;L.P.
agreed to vote their shares to waive, with respect to the Boston Millennia Funds, application of a mandatory conversion provision in our Articles of Incorporation, as amended, and other similar
conversion provisions or other devices or mechanisms that may be adopted that are intended to incentivize the continued investment in the Company by existing holders of our preferred stock, subject to
certain conditions described in the Preferred Shareholder Agreement. The Preferred Shareholder Agreement terminated by its terms upon the closing of the Series D Convertible Preferred Stock financing. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Seventh Amended and Restated Stockholders Agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with the Series D Convertible Preferred Stock financing in March 2015, we entered into the Seventh Amended and Restated Stockholders
Agreement, or the Stockholders Agreement, with certain of our shareholders, including Island View Investors,&nbsp;LLC, a limited liability company of which our President and Chief Executive Officer,
Michael T. Heffernan, is the sole member, the Longitude Funds, the Boston Millennia Funds, Frazier Healthcare VI,&nbsp;L.P., Skyline Venture Partners V,&nbsp;L.P., TPG Biotechnology Partners IV,
L.P. and RA Capital Healthcare Fund, LP. The Stockholders Agreement, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> imposes restrictions on the transfer of capital stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants holders of our outstanding convertible preferred stock certain rights of
first refusal, co-sale and put rights with respect to certain proposed transfers of our securities by shareholders other than holders of Series D Convertible Preferred Stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants us certain rights of first refusal with respect to certain proposed
transfers of our securities by shareholders other than holders of Series D Convertible Preferred Stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> imposes "drag along" obligations on our shareholders, and permits "tag along" by
holders of our preferred stock in certain sale transactions that are approved by our board of directors and certain of our preferred shareholders; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=162,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=535787,FOLIO='158',FILE='DISK114:[15ZAD1.15ZAD72301]EI72301A.;93',USER='DPERRY',CD='24-APR-2015;17:57' -->
<A NAME="page_ei72301_1_159"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> sets forth voting obligations with respect to the constituency and size of our
board of directors, and provides for the designation of our directors by certain of our preferred shareholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> requires shareholders to enter into a 180-day lock-up period upon an initial
public offering. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
Stockholders Agreement will terminate automatically upon completion of this offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Eighth Amended and Restated Investor Rights Agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with the Series D Convertible Preferred Stock financing in March 2015, we entered into the Eighth Amended and Restated Investor Rights
Agreement, or the Investor Right Agreement, with certain of our investors, including the Longitude Funds, the Boston Millennia Funds, Frazier Healthcare VI,&nbsp;L.P., Skyline
Venture Partners V,&nbsp;L.P., TPG Biotechnology Partners IV, L.P. and RA Capital Healthcare Fund, LP The Investor Rights Agreement, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> imposes restrictions on the transfer of capital stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants holders of our outstanding convertible preferred stock certain
registration rights following an initial public offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants holders of our outstanding convertible preferred stock certain
pre-emptive rights with respect to certain issuances of our securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> imposes certain affirmative and negative covenants on us, including an
obligation for us to deliver periodic financial statements and budgets to any holder of at least 1&nbsp;million shares of our preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants board observer rights to the Longitude Funds, Skyline Venture Partners V,
L.P., Boston Millennia Partners and TPG Biotechnology Partners IV, L.P. so long as such investors hold at least 2 million shares of our preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> requires us to prepare and submit to the SEC a registration statement on Form
S-1 for an initial public offering of our common stock and to use our best efforts to cause the registration statement to be declared effective; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> requires shareholders to enter into a 180-day lock-up period upon an initial
public offering. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
provisions in the Investor Rights Agreement granting certain pre-emptive rights will terminate automatically upon completion of this offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Participation in this Offering

  </B></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>Certain of our existing stockholders, or their affiliates, have indicated an interest in purchasing up to an aggregate of approximately
$30.0&nbsp;million in shares of our common stock in this offering at the initial public offering price. However, because indications of interest are not binding agreements or commitments to
purchase, the underwriters may determine to sell more, less or no shares in this offering to any of these investors, and any of these investors may determine to purchase more, less or no shares in
this offering. The underwriters will receive the same underwriting discount on any shares purchased by these investors as they will on any other shares sold to the public in this offering.

 </FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Management Rights Letters  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We entered into management rights letters with certain of our shareholders, including the Boston Millennia Funds, the Longitude Funds, Frazier
Healthcare&nbsp;VI,&nbsp;L.P., Skyline Venture Partners V,&nbsp;L.P. and Aperture Venture Partners III, L.P. The management rights letters grant certain management rights in the event that such
shareholder is not represented on our Board of Directors, as well as certain inspection rights. The management rights letters will terminate automatically upon completion of this offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Employment Agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have entered into employment agreements with certain of our named executive officers that provide for salary, bonus and severance compensation. For
more information regarding these employment
agreements, see "Executive and Director Compensation&nbsp;&#151; Employment Agreements" and "Executive and Director Compensation&nbsp;&#151; Potential Payments Upon a Termination or
Change of Control." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=163,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1014764,FOLIO='159',FILE='DISK114:[15ZAD1.15ZAD72301]EI72301A.;93',USER='DPERRY',CD='24-APR-2015;17:57' -->
<A NAME="page_ei72301_1_160"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Equity Issued to Executive Officers and Directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have granted common stock and/or stock options to our named executive officers and directors, as more fully described in "Executive and Director
Compensation&nbsp;&#151; Employment Agreements," "Executive and Director Compensation&nbsp;&#151; Option Awards During Fiscal Year Ended December&nbsp;31, 2014" and "Executive and
Director Compensation&nbsp;&#151; Compensation of Non-Employee Directors." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Indemnification Agreements with our Directors and Officers  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have or will enter into, and intend to continue to enter into, indemnification agreements with our directors and executive officers, in addition to
the indemnification provided for in our amended and restated articles of incorporation and our amended and restated bylaws. These agreements, among other things, require us to indemnify our directors
and executive officers for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of
their services as one of our directors and/or executive officers or any other company or enterprise to which the person provides services at our request. Furthermore, the indemnification agreements
with our directors who are designated by the Boston Millennia Funds, the Longitude Funds, Frazier Healthcare VI,&nbsp;L.P., Skyline Venture Partners V,&nbsp;L.P. and TPG Biotechnology Partners IV,
L.P. require us to indemnify these shareholders for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by them in any action or proceeding arising by reason
of the fact that such shareholders have the ability to appoint directors to our board. We believe that these charter and bylaw provisions and indemnification agreements are necessary to attract and
retain qualified persons as directors and officers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
limitation of liability and indemnification provisions in our amended and restated articles of incorporation and amended and restated bylaws may discourage shareholders from bringing a lawsuit
against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit
us and our shareholders. A shareholder's investment may be harmed to the
extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Policies and Procedures for Transactions with Related Persons  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon the closing of this offering, our board of directors will adopt a related party transactions policy for us. Pursuant to the related party
transactions policy, we will review all transactions with a dollar value in excess of $120,000 involving us in which any of our directors, director nominees, significant shareholders and executive
officers and their immediate family members will be participants, to determine whether such person has a direct or indirect material interest in the transaction. This policy was not in effect when we
entered into the transactions described above. All directors, director nominees and executive officers will be required to promptly notify our chief financial officer of any proposed transaction
involving us in which such person has a direct or indirect material interest. Such proposed transaction will then be reviewed by the audit committee to determine whether the proposed transaction is a
related party transaction under our policy. In reviewing any related party transaction, the audit committee will determine whether or not to approve or ratify the transaction based on all relevant
facts and circumstances, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the materiality and character of the related person's interest in the
transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the commercial reasonableness of the terms of the transaction; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the benefit and perceived benefit, or lack thereof, to us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the opportunity costs of alternate transactions; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the actual or apparent conflict of interest of the related person. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=164,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=375165,FOLIO='160',FILE='DISK114:[15ZAD1.15ZAD72301]EI72301A.;93',USER='DPERRY',CD='24-APR-2015;17:57' -->
<A NAME="page_ei72301_1_161"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
</UL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
the event that any member of the audit committee is not a disinterested member with respect to the related person transaction under review, that member will be excluded from the review and approval
or rejection of such related party transaction and another director may be designated to join the committee for purposes of such review. Whenever practicable, the reporting, review and approval will
occur prior to entering into the transaction. If advance review and approval is not practicable, the audit committee will review and may, in its discretion, ratify the related party transaction. After
any such review, the audit committee will approve or ratify the transaction only if it determines that the transaction is in, or not inconsistent with, the best interests of us and our shareholders.
Our related party transaction policy will be available on our website, www.collegiumpharma.com, under the "Investor Relations" section, upon the effective date of this offering. The information
contained in, or that can be accessed through, our website is not part of this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=165,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=333243,FOLIO='161',FILE='DISK114:[15ZAD1.15ZAD72301]EI72301A.;93',USER='DPERRY',CD='24-APR-2015;17:57' -->
<A NAME="page_ei72301_1_162"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ei72301_principal_shareholders"> </A>
<A NAME="toc_ei72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL SHAREHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth certain information regarding the beneficial ownership of our capital stock outstanding as of April&nbsp;2, 2015
by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each person, or group of affiliated persons, known by us to beneficially own
more than 5% of our shares of common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our named executive officers; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> all of our directors and executive officers as a group. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>


The percentage ownership information under the column entitled "Before offering" is based on 13,907,935 shares of common stock outstanding as of April&nbsp;2, 2015, which assumes the conversion of
all outstanding shares of our convertible preferred stock into 12,591,456 shares of common stock upon the closing of this offering. The percentage ownership information under the column entitled
"After offering" is based on the sale of shares of common stock to be outstanding after this offering and gives effect to the conversion of all outstanding shares of our convertible preferred stock
into 12,591,456 shares of common stock upon the closing of this offering.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Information
with respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of our common stock. We have determined beneficial ownership in
accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those
securities. The table below assumes that the underwriters do not exercise their option to purchase additional shares from us. In addition, the rules attribute beneficial ownership of securities as of
a particular date to persons who hold options or warrants to purchase shares of common stock and that are exercisable within 60&nbsp;days of such date. These shares are deemed to be outstanding and
beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of
computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares
shown as beneficially owned by them, subject to applicable community property laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Except
as otherwise noted below, the address for each person or entity listed in the table is c/o Collegium Pharmaceutical,&nbsp;Inc., 780 Dedham Street, Suite&nbsp;800, Canton, MA 02021. The
table below does not reflect any shares
of our common stock that our directors, executive officers, 5% shareholders or their affiliated entities may purchase in this offering, including any of the reserved shares, as described in the
"Underwriting" section of this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Certain of our existing stockholders, or their affiliates, have indicated an interest in purchasing up to an aggregate of approximately $30.0&nbsp;million in shares of our common stock in this
offering at the initial public offering price. The information set forth in the table below does not reflect the potential purchase of any shares in this offering by these stockholders.


</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=166,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=319123,FOLIO='162',FILE='DISK114:[15ZAD1.15ZAD72301]EI72301A.;93',USER='DPERRY',CD='24-APR-2015;17:57' -->
<A NAME="page_ei72301_1_163"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Percentage of shares<BR>
beneficially owned </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:133pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name and Address of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,133pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
shares beneficially owned </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Before offering </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>After offering </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>5% or greater shareholders:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Longitude Capital Partners, LLC<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,111,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22.37</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15.79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Skyline Venture Partners V,&nbsp;L.P.<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,787,541</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20.04</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14.14</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Frazier Healthcare VI,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,729,598</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12.44</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.78</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TPG Biotechnology Partners IV, L.P.<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,207,729</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.68</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.13</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Boston Millennia Partners<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,080,663</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7.77</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5.48</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RA Capital Healthcare Fund, LP<SUP>(6)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>845,410</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.08</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.29</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors and Named Executive Officers:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael T. Heffernan, R. Ph.<SUP>(7)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>558,121</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.97</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.83</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ernest A. Kopecky Ph.D.<SUP>(8)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>34,872</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Douglas R. Carlson<SUP>(9)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>21,776</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Garen G. Bohlin<SUP>(10)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,415</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John G. Freund, M.D.<SUP>(11)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,787,541</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20.04</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14.14</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Patrick Heron<SUP>(12)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,729,598</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12.44</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.78</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Hirsch, M.D., Ph.D.<SUP>(13)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,111,014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22.37</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15.79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eran Nadav, Ph.D.<SUP>(14)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,207,729</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8.68</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6.13</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gino Santini</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23,188</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>All current executive officers and directors as a group (13&nbsp;persons)<SUP>(15)</SUP></B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,595,479</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>68.28</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>48.33</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
(a)&nbsp;3,049,886 shares of common stock issuable upon conversion of convertible preferred stock held by Longitude Venture
Partners,&nbsp;L.P. and (b)&nbsp;61,128 shares of common stock issuable upon conversion of convertible preferred stock held by Longitude Capital Associates,&nbsp;L.P. Longitude Capital
Partners,&nbsp;LLC is the general partner of the Longitude Funds and may be deemed to have sole voting investment and dispositive power over the shares held by the Longitude Funds. Patrick G.
Enright and Juliet Tammenoms Bakker are managing members and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by the reporting persons.
David Hirsch, a member of our board of directors, is a member of Longitude Capital Partners, LLC. Each of these individuals disclaims beneficial ownership of such shares except to the extent of his or
her pecuniary interest therein.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares of common stock issuable upon conversion of convertible preferred stock held by Skyline Venture Partners V,&nbsp;L.P. The
general partner of Skyline Venture Partners V,&nbsp;L.P. is Skyline Venture Management V,&nbsp;LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V,&nbsp;LLC.
These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC. Each of these individuals disclaims beneficial ownership of all the shares held by Skyline
Venture Partners V,&nbsp;L.P. except to the extent of his proportionate pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares of common stock issuable upon conversion of convertible preferred stock held by Frazier Healthcare VI,&nbsp;L.P. The
general partner of Frazier Healthcare VI,&nbsp;L.P. is a limited partnership, the general partner of which is FHM VI,&nbsp;LLC. The members of FHM VI,&nbsp;LLC are Dr.&nbsp;Nathan Every, Alan
Frazier, Nader Naini, Patrick Heron, a member of our board of directors, and Dr.&nbsp;James Topper. These individuals share voting and investment power over the shares held by Frazier Healthcare
VI,&nbsp;L.P. Each of these individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares of common stock issuable upon conversion of convertible preferred stock held by TPG Biotechnology
Partners&nbsp;IV,&nbsp;L.P. The general partner of TPG Biotechnology Partners IV,&nbsp;L.P. is TPG Biotechnology GenPar IV,&nbsp;L.P., a Delaware limited partnership, whose general partner is
TPG Biotechnology GenPar IV Advisors,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Holdings I,&nbsp;L.P., a Delaware limited partnership, whose general partner is TPG
Holdings I-A,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Group Holdings (SBS),&nbsp;L.P., a Delaware limited partnership, whose general partner is TPG Group Holdings
(SBS) Advisors,&nbsp;Inc., or Group Advisors, a Delaware corporation. Messrs.&nbsp;David Bonderman and James G. Coulter are officers and sole shareholders of Group Advisors and may therefore be
deemed to be the beneficial owners of the shares held by TPG Biotechnology Partners IV,&nbsp;L.P. Each of Messrs.&nbsp;Bonderman and Coulter expressly disclaims </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=167,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=257613,FOLIO='163',FILE='DISK114:[15ZAD1.15ZAD72301]EI72301A.;93',USER='DPERRY',CD='24-APR-2015;17:57' -->
<A NAME="page_ei72301_1_164"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<UL>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">beneficial
ownership of the securities listed above except to the extent of any pecuniary interest therein. The address for Messrs.&nbsp;Bonderman and Coulter and TPG Biotechnology Partners
IV,&nbsp;L.P. is c/o TPG Global,&nbsp;LLC, 301 Commerce Street, Suite&nbsp;3300, Fort Worth, TX 76102.  </FONT></P>


</UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
(a)&nbsp;4,660 shares of common stock issuable upon conversion of convertible preferred stock held by Boston Millennia Associates
II Partnership, (b)&nbsp;8,066 shares of common stock issuable upon conversion of convertible preferred stock held by Strategic Advisors Fund Limited Partnership, (c)&nbsp;127,760 shares of common
stock issuable upon conversion of convertible preferred stock held by Boston Millennia Partners&nbsp;GmbH&nbsp;&amp;&nbsp;Co. KG, (d)&nbsp;42,976 shares of common stock issuable upon conversion of
convertible preferred stock held by Boston Millennia Partners II-A Limited Partnership, and (e)&nbsp;897,201 shares of common stock issuable upon conversion of convertible preferred stock held by
Boston Millennia Partners II Limited Partnership. Robert Jevon, a former member of our board of directors, is an affiliate of Glen Partners II Limited Partnership which is the special limited partner
of BMP KG, and the general partner of the other Boston Millennia Funds. A. Dana Callow Jr., Martin J. Hernon, and Robert&nbsp;S. Sherman are general partners of Glen Partners II Limited Partnership,
exercise shared voting and investment power over the shares held by the Boston Millennia Funds, and may be deemed to have beneficial ownership of these shares.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares of common stock issuable upon conversion of convertible preferred stock held by RA Capital Healthcare Fund,&nbsp;LP. The
investment adviser and sole general partner of RA Capital Healthcare Fund,&nbsp;LP is RA Capital Management,&nbsp;LLC. Peter Kolchinsky is the sole managing member of RA Capital
Management,&nbsp;LLC and has the power to vote or dispose of the shares held by RA Capital Healthcare Fund,&nbsp;LP. The address for Dr.&nbsp;Kolchinsky and RA Capital Healthcare Fund,&nbsp;LP
is 20 Park Plaza, Suite&nbsp;1200, Boston, MA 02116

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
39,769 shares of our common stock subject to options exercisable within 60&nbsp;days of April&nbsp;2, 2015 and 163,043 shares of
common stock held by Island View Investors&nbsp;LLC, of which Mr.&nbsp;Heffernan, our President and Chief Executive Officer, is the sole member.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
34,872 shares of our common stock subject to options exercisable within 60&nbsp;days of April&nbsp;2, 2015.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
21,776 shares of our common stock subject to options exercisable within 60&nbsp;days of April&nbsp;2, 2015.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(10)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
2,415 shares of our common stock subject to options exercisable within 60 days of April 2, 2015.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(11)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.&nbsp;Freund
is a member of a group of persons who exercise voting and investment power over the shares of common stock beneficially
owned by Skyline Venture Partners V,&nbsp;L.P. and may be deemed to beneficially own the shares held by Skyline Venture Partners V,&nbsp;L.P. Dr.&nbsp;Freund's address is c/o Skyline Venture
Partners V,&nbsp;L.P., 525 University Ave., Palo Alto, CA 94301.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(12)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Heron
is a member of a group of persons who exercise voting and investment power over the shares of common stock beneficially
owned by Frazier Healthcare VI,&nbsp;L.P. and may be deemed to beneficially own the shares held by Frazier Healthcare VI,&nbsp;L.P. Mr.&nbsp;Heron's address is c/o Frazier Healthcare
VI,&nbsp;L.P., 601 Union Street, Suite&nbsp;3200, Seattle, WA 98101.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(13)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.&nbsp;Hirsch
is a member of a group of persons who exercise voting and investment power over the shares of common stock beneficially
owned by the Longitude Funds and may be deemed to beneficially own the shares held by the Longitude Funds. Dr.&nbsp;Hirsch disclaims beneficial ownership of such shares except to the extent of his
pecuniary interest therein. Dr.&nbsp;Hirsch's address is c/o Longitude Capital Partners,&nbsp;LLC, 800 El Camino Real, Ste. 220, Menlo Park, CA 94024.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(14)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.&nbsp;Nadav
is an affiliate of a group of persons who exercise voting and investment power over the shares of common stock beneficially
owned by TPG Biotechnology Partners IV, L.P. and may be deemed to beneficially own the shares held by TPG Biotechnology Partners IV, L.P. Dr. Nadav's address is c/o TPG Biotech, 345&nbsp;California
Street, Suite&nbsp;3300, San Francisco, CA&nbsp;94104.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(15)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
145,594 shares of common stock which the directors and executive officers have the right to acquire upon the exercise of stock
options that were exercisable as of April&nbsp;2, 2015, or that will become exercisable within 60&nbsp;days after that date. </FONT>

</DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=168,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=448524,FOLIO='164',FILE='DISK114:[15ZAD1.15ZAD72301]EI72301A.;93',USER='DPERRY',CD='24-APR-2015;17:57' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ek72301_1_165"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ek72301_description_of_capital_stock"> </A>
<A NAME="toc_ek72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following description summarizes information about our capital stock. This information does not purport to be complete and is subject to, and
qualified in its entirety by reference to, the terms of our amended and restated articles of incorporation and amended and restated bylaws, which are included as exhibits to the registration statement
of which this prospectus forms&nbsp;a part, and the applicable provisions of Virginia law, the state in which we are incorporated. You are encouraged to read our amended and restated articles of
incorporation and amended and restated bylaws for greater detail with respect to these provisions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


As of April&nbsp;2, 2015 our capital stock was held of record by 78 shareholders. Upon the closing of this offering, our authorized capital stock will consist of 105,000,000 shares, 100,000,000 of
which are designated as common stock with a par value of $0.001 per share and 5,000,000 of which are designated as preferred stock with a par value of $0.001.


</FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Shares of our common stock have the following rights, preferences and privileges: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Voting Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders. With
certain exceptions, a majority of the votes cast at a shareholder meeting at which a quorum is present must approve all shareholder matters. Our amended and restated articles of incorporation provide
that an amendment to our amended and restated articles of incorporation, a merger, share exchange, domestication, entity conversion, sale of assets that requires shareholder approval or our
dissolution must be approved by a majority of all the votes entitled to be cast at a shareholder meeting. Our amended and restated articles of incorporation provide that an amendment to our bylaws by
the shareholders must be approved by more than two thirds of all the votes entitled to be cast. Our amended and restated bylaws also provide that our directors are elected by a plurality of the votes
cast. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the preferences applicable to any shares of preferred stock outstanding at any time, holders of our common stock are entitled to receive
dividends when and as declared by our board of directors from assets or funds legally available therefor. The timing, declaration, amount and payment of future dividends will depend on our financial
condition, earnings, capital requirements and debt service obligations, as well as legal requirements, regulatory constraints, industry practice and other factors that our board of directors deems
relevant. Our board of directors will make all decisions regarding our payment of dividends from time to time in accordance with applicable law. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Liquidation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to any preferential liquidation rights of holders of preferred stock that may be outstanding, upon our dissolution, the holders of our common
stock will be entitled to share ratably in our assets legally available for distribution to our shareholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> No Preemptive or Similar Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The holders of our common stock do not have any preemptive rights or preferential rights to subscribe for shares of our capital
stock or any other securities. Our common stock is not subject to any redemption or sinking fund provisions. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Preferred Stock  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>Immediately prior to the consummation of this offering, all outstanding shares of preferred stock will be converted into an aggregate of 12,591,456
shares of common stock. Under our amended and restated articles of incorporation, our board of directors may issue preferred stock in one or more series, with preferences, limitations and rights as
authorized by our board of directors, to the extent permitted by Virginia law.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=169,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=846813,FOLIO='165',FILE='DISK114:[15ZAD1.15ZAD72301]EK72301A.;43',USER='JTAM',CD='24-APR-2015;15:33' -->
<A NAME="page_ek72301_1_166"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stock Options  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>As of December&nbsp;31, 2014, we had outstanding options to purchase 281,029 shares of our common stock at a weighted-average price of $0.69 per
share, pursuant to our 2014 Stock Incentive Plan. Since December 31, 2014, we have awarded stock options to purchase an aggregate of 638,095 shares of common stock at a weighted-average exercise price
of $5.73 per share.

</FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Restricted Common Stock  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>As of December&nbsp;31, 2014, we had 15,387 shares of restricted common stock issued and outstanding. In April 2015, we granted an additional 97,347
shares of restricted common stock to our President and Chief Executive Officer.


</FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Warrants  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>In October 2010, we issued a warrant to Comerica Bank, which warrant was immediately exercisable for 33,746 shares of our then outstanding
Series&nbsp;D-1 Convertible Preferred Stock at an exercise price of $1.778 per share. In connection with the Series&nbsp;B Convertible Preferred Stock financing, all issued and outstanding shares
of previously issued preferred stock, including Series&nbsp;D-1 Preferred Stock, were converted into shares of Series&nbsp;A Convertible Preferred Stock. Additionally, pursuant to the December
2013 reverse stock split, the number of shares underlying the warrant was adjusted to 16,873 shares of Series&nbsp;A Preferred Stock. The shares underlying the warrant are entitled to the piggyback
registration rights set forth in the Investor Rights Agreement described below. The warrant expires on October&nbsp;28, 2017 but will be extended until the third anniversary of the effective date of
this offering. Upon the completion of this offering, the warrant will be converted into a warrant to purchase 2,445 shares of common stock.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>


In August 2012, in connection with the closing of the Original Term Loan, we issued a warrant to SVB, which warrant was immediately exercisable for 3,450 shares of our common stock at an exercise
price of $0.48 per share. Pursuant to the December 2013 reverse stock split, the number of shares underlying this warrant was adjusted to 1,725 shares of common stock. This warrant expires on
January&nbsp;30, 2024. In January 2014, in connection with the closing of Amendment No.&nbsp;1 to the Original Term Loan, we issued an additional warrant to SVB, which warrant was immediately
exercisable for 2,091 shares of our common stock at an exercise price of $0.35 per share. Pursuant to an adjustment mechanism included in this warrant, it automatically became exercisable for an
additional 12,547 shares of our common stock. This warrant expires on January&nbsp;30, 2024. Both SVB warrants are subject to cashless exercise. Upon the completion of this offering, the SVB
warrants will represent the right to purchase an aggregate of 16,364 shares of common stock.

 </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Notes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In November 2014, we entered into a Convertible Note Purchase Agreement, pursuant to which we issued and sold to investors convertible promissory
notes in the aggregate principal amount of $5.0&nbsp;million. Pursuant to the Convertible Note Purchase Agreement, the convertible notes bore interest at a rate per annum of 6.0% and mature on the
earlier of (i)&nbsp;November&nbsp;14, 2015, (ii)&nbsp;immediately prior to a liquidation of the company, or (iii)&nbsp;upon an event of default. In connection with the Series D Convertible
Preferred Stock financing, the notes automatically converted into an aggregate of 4,166,667 shares of Series D Convertible Preferred Stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the Investor Rights Agreement, certain holders of shares of our common stock will have registration rights and certain holders of shares
of our preferred stock will have registration rights with respect to the shares of common stock issuable upon conversion as further described below. After registration of these shares of common stock
pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. These holders may also be able to sell shares without </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=170,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=319077,FOLIO='166',FILE='DISK114:[15ZAD1.15ZAD72301]EK72301A.;43',USER='JTAM',CD='24-APR-2015;15:33' -->
<A NAME="page_ek72301_1_167"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>registration
pursuant to Rule&nbsp;144 as described in this prospectus. See "Shares Eligible for Future Sale&nbsp;&#151; Rule&nbsp;144." </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Demand Registration Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Beginning six months after this offering and subject to specified limitations set forth in the Investor Rights Agreement, (i)&nbsp;holders holding a
majority of the registrable shares issued or issuable upon the conversion of Series&nbsp;D Convertible Preferred Stock, (ii)&nbsp;holders holding a majority of the registrable shares issued or
issuable upon the conversion of Preferred Stock, or (iii)&nbsp;a lesser percentage of holders of registrable shares if the anticipated aggregate offering price to the public, net of underwriting
discounts and commissions, is not less than $10 million, may demand in writing that we register all or a portion of the registrable shares under the Securities Act pursuant to the filing of a
Registration Statement on Form&nbsp;S-1. We are not obligated to file&nbsp;a registration statement pursuant to this provision on more than two occasions in any 12-month period, provided, however,
that such obligation shall be deemed satisfied only when (i)&nbsp;a registration statement covering no less than 70% of the number of registrable shares specified in a notice received for sale in
accordance with the method of disposition specified by the requesting holders shall have become effective or if such registration statement has been withdrawn prior to the consummation of the offering
at the request of the holders of a majority of the registrable shares requested to be included in the offering, and (ii)&nbsp;if such method of disposition is a firm commitment, underwritten public
offering, all such shares were sold pursuant thereto. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, subject to specified limitations set forth in the Investor Rights Agreement, at any time after we become eligible to file&nbsp;a registration statement on Form&nbsp;S-3, a holder or
holders of the registrable shares then outstanding may request that we register their registrable securities on Form&nbsp;S-3 for purposes of a public offering
if the total shares registered have an aggregate offering price of at least $1&nbsp;million. We are not obligated to file&nbsp;a registration statement pursuant to this provision on more than two
occasions in any 12-month period. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Piggyback Registration Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If, at any time, we propose to file&nbsp;a registration statement to register any of our securities under the Securities Act, either for our own
account or for the account of any of our shareholders, the holders of our registrable securities are entitled to notice of registration and, subject to specified exceptions, we will be required upon
the holder's request to use our best efforts to register their then-held registrable securities. The underwriters of any underwritten offering will have the right to limit the number of shares having
registration rights to be included in the registration statement, but not below 30% of the total amount of securities included in such registration, unless such offering is the Initial Public Offering
and such registration does not include shares of any other selling shareholders, in which event any or all of the registrable shares of the holders may be excluded pursuant to the terms of the
Investor Rights Agreement. In addition, pursuant to the Investor Rights Agreement, in no event will shares of any other selling shareholder be included in such registration that would reduce the
number of shares which may be included by holders without the written consent of holders of at least 60% of the registrable shares held by all holders. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Provisions  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The Investor Rights Agreement provides that, in connection with this offering and upon the managing underwriters' request, holders of registrable
securities will be subject to a "lock-up" provision prohibiting the sale or other disposition of our securities for up to 180&nbsp;days. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will pay registration expenses other than the underwriting discount, selling commissions and the fees and expenses of the selling shareholders' own counsel (other than the counsel selected to
represent all of the selling shareholders), related to any demand registration. The Investor Rights Agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to
indemnify the selling shareholders in the event of material misstatements or omissions in the registration statement attributable </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=171,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=966299,FOLIO='167',FILE='DISK114:[15ZAD1.15ZAD72301]EK72301A.;43',USER='JTAM',CD='24-APR-2015;15:33' -->
<A NAME="page_ek72301_1_168"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>to
us, and they are obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Anti-Takeover Effects of Provisions of our Articles of Incorporation, our Bylaws and Virginia Law  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Various provisions contained in our amended and restated articles of incorporation, our amended and restated bylaws and Virginia law could delay,
deter or discourage some transactions involving an actual or potential change in control of the Company. Provisions in our amended and restated articles of incorporation and our amended and restated
bylaws include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision allowing our board of directors to establish one or more series or
classes of undesignated preferred stock, the terms of which can be determined by the board of directors at the time of issuance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advance written notice procedures and notice requirements with respect to
shareholder proposals and shareholder nomination of candidates for election as directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision that only the board of directors, the chairman of the board of
directors or the president may call a special meeting of the shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision dividing our board of directors into three classes, each serving
three-year terms; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the requirement that the authorized number of our directors be changed only by
resolution of our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision that our board of directors shall fill any vacancies on our board of
directors, including vacancies resulting from a board of directors resolution to increase the number of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  limitations on the manner in which shareholders can remove directors from the
board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of cumulative voting in the election of directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a prohibition on shareholders acting by less-than-unanimous written consent. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Articles of Incorporation and Bylaws  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Preferred stock  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated articles of incorporation authorize our board of directors to establish one or more series of preferred stock and to
determine, with respect to any series of preferred stock, the preferences, rights and other terms of such series. See "&#151;Preferred Stock" for additional information. Under this authority,
our board of directors could create and issue a series of preferred stock with rights, preferences or restrictions that have the effect of discriminating against an existing or prospective holder of
our capital stock as a result of such holder beneficially owning or commencing a tender or exchange offer for a substantial amount of our common stock. One of the effects of authorized but unissued
and unreserved shares of preferred stock may be to render it more difficult for, or to discourage an attempt by, a potential acquiror to obtain control of us by means of a merger, tender or exchange
offer, proxy contest or otherwise, and thereby protect the continuity of our management. The issuance of shares of preferred stock may have the effect of delaying, deferring or preventing a change in
control of our Company without any action by our shareholders. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Qualification and election of directors  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated bylaws provide that to be eligible to be nominated by a shareholder for election to our board of directors, a person must
submit a written questionnaire regarding his or her background and qualifications and must agree to other representations as set forth in our amended and restated bylaws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
our amended and restated articles of incorporation, our board of directors will be divided into three classes, each serving three-year terms and until each director's successors are duly elected
and qualified. The election of the classes will be staggered, such that only approximately one third of our board of directors will be up for election in any given year. Our amended and restated
articles of incorporation do not provide for cumulative voting in the election of directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=172,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=878584,FOLIO='168',FILE='DISK114:[15ZAD1.15ZAD72301]EK72301A.;43',USER='JTAM',CD='24-APR-2015;15:33' -->
<A NAME="page_ek72301_1_169"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Board vacancies; removal  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated articles of incorporation provide that any vacancy occurring on our board of directors will be filled by a majority of
directors then in office, even if less than a quorum. Our amended and restated articles of incorporation also provide that our directors can only be removed for cause upon the vote of more than two
thirds of the votes entitled to be cast by holders of common stock. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Special meetings of shareholders  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated articles of incorporation provide that only the board of directors, the chairman of the board of directors or the president
may call a special meeting of the shareholders. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Advance notification of shareholder nominations and proposals  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated bylaws establish advance notice procedures with respect to shareholder proposals and the nomination of persons for election
as directors, other than nominations made by or at the direction of our board of directors. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Virginia Anti-Takeover Statutes  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Affiliated transactions statute  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Virginia law contains provisions governing certain material transactions, or affiliated transactions, between the Company and any holder of more than
10% of any class of its outstanding voting shares, or an interested shareholder. In general, these provisions prohibit a Virginia corporation from engaging in an affiliated transaction with an
interested shareholder for a period of three years following the date such person became an interested shareholder, unless (i)&nbsp;a majority of the disinterested directors and the holders of at
least two-thirds of the voting shares, other than those beneficially owned by the interested shareholder, approved the affiliated transaction, or (ii)&nbsp;before the date that the person became an
interested shareholder, a majority of the disinterested directors approved the transaction that resulted in the person becoming an interested shareholder. After three years, any such transaction must
be at a "fair price," as statutorily defined, or must be approved by the holders of at least two-thirds of the voting shares, other than those beneficially owned by the interested shareholder.
Affiliated transactions subject to this approval requirement include mergers, share exchanges, material dispositions of corporate assets not in the ordinary course of business, the sale of shares of
the corporation or any of its subsidiaries to an interested shareholder having an aggregate fair market value of greater than 5% of the aggregate fair market value of the corporation's outstanding
shares, any dissolution of the Company proposed by or on behalf of an interested shareholder or any reclassification, including reverse stock splits, recapitalization or merger of the Company with its
subsidiaries, if any, that increases the percentage of voting shares beneficially owned by an interested shareholder by more than 5%. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
shareholders of a Virginia corporation may adopt an amendment to the corporation's articles of incorporation or bylaws opting out of the provisions of Virginia law governing affiliated
transactions but such amendment shall not be effective until 18&nbsp;months after its adoption. Neither our amended and restated articles of incorporation nor our amended and restated bylaws contain
a provision opting out of the provisions of Virginia law governing affiliated transactions. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Control share acquisitions statute  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Virginia law also contains provisions relating to control share acquisitions, which are transactions causing the voting strength of any person
acquiring beneficial ownership of shares of a Virginia public corporation to meet or exceed certain threshold percentages (20%, 33<SUP>1</SUP>/<SMALL>3</SMALL>% or 50%) of the total votes entitled to be cast for
the election of directors. Shares acquired in a control share acquisition have no voting rights unless (i)&nbsp;the voting rights are granted by a majority vote of all outstanding shares other than
those held by the acquiring person or any officer or employee director of the corporation or (ii)&nbsp;the articles of incorporation or bylaws of the corporation provide that these Virginia law
provisions do not apply to acquisitions of its shares. The acquiring person may require that a special meeting of the shareholders be held to consider the grant of voting rights to the shares acquired
in the control share acquisition. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=173,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=259818,FOLIO='169',FILE='DISK114:[15ZAD1.15ZAD72301]EK72301A.;43',USER='JTAM',CD='24-APR-2015;15:33' -->
<A NAME="page_ek72301_1_170"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
permitted by Virginia law, our amended and restated articles of incorporation contain a provision opting out of the Virginia anti-takeover law regulating control share acquisitions. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Indemnification and limitation of directors' and officers' liability  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a Virginia corporation. As permitted by Virginia law, our amended and restated articles of incorporation provide that no director or officer
shall be liable in any proceeding brought by or in the right of us or our shareholders for monetary damages arising out of any transaction, occurrence or other course of conduct, except for liability
resulting from willful misconduct or a knowing violation of criminal law or of any federal or state securities laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated articles of incorporation require us to indemnify any director or officer who was or is a party to a proceeding, including a proceeding brought by or in the right of the
Company, due to his or her status as our director or officer unless he or she engaged in willful misconduct or a knowing violation of criminal law. Our amended and restated articles of incorporation
also require us to advance expenses to such person prior to the final disposition of any such proceeding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have obtained policies that insure our directors and officers against certain liabilities they may incur in their capacity as directors and officers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have or plan to enter into indemnification agreements with our directors and officers who also serve as directors. These agreements contain provisions that may require us, among other things, to
advance expenses to and indemnify these directors and officers against certain liabilities that may arise because of their status or service as directors or officers of us. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Transfer Agent and Registrar  </I></B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A.

 </FONT>

</P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Listing  </I></B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We expect to receive approval to list our common stock on NASDAQ under the symbol "COLL."

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=174,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=268507,FOLIO='170',FILE='DISK114:[15ZAD1.15ZAD72301]EK72301A.;43',USER='JTAM',CD='24-APR-2015;15:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_em72301_1_171"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="em72301_shares_eligible_for_future_sale"> </A>
<A NAME="toc_em72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SHARES ELIGIBLE FOR FUTURE SALE    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Immediately prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of common stock in the
public market could adversely affect prevailing market prices. Furthermore, since only a limited number of shares will be available for sale shortly after this offering because of contractual and
legal restrictions on resale described below, sales of substantial amounts of common stock in the public market after the restrictions lapse could adversely affect the prevailing market price for our
common stock as well as our ability to raise equity capital in the future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Based on the number of shares of common stock outstanding as of December&nbsp;31, 2014, upon the closing of this offering,&nbsp;19,707,935 shares of common stock will be outstanding, assuming no
exercise of the underwriters' option to purchase additional shares from us and no exercise of options. All of the shares sold in this offering will be freely tradable unless held by an affiliate of
ours. Except as set forth below, the remaining shares of common stock outstanding after this offering will be restricted as a result of securities laws or lock-up agreements. These remaining shares
will be eligible for sale under Rule&nbsp;144 or Rule&nbsp;701 of the Securities Act upon expiration of lock-up agreements at least 180&nbsp;days after the date of this offering.

 </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Rule&nbsp;144  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In general, under Rule&nbsp;144 as currently in effect, beginning 90&nbsp;days after the effective date of the registration statement of which
this prospectus is a part, any person who is not an affiliate of ours and has held their shares for at least six months, including the holding period of any prior owner other than one of our
affiliates, may sell shares without restriction, provided current public information about us is available. In addition, under Rule&nbsp;144, any person who is not an affiliate of ours and has held
their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the
closing of this offering without regard to whether current public information about us is available. Beginning 90&nbsp;days after the effective date of the registration statement of which this
prospectus is a part, a person who is an affiliate of ours and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one
of our affiliates, is entitled to sell a number of restricted shares within any three-month period that does not exceed the greater of:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 1% of the number of shares of our common stock then outstanding, which will
equal approximately&nbsp;197,079 shares immediately after this offering; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the average weekly trading volume of our common stock on NASDAQ during the four
calendar weeks preceding the filing of a notice on Form&nbsp;144 pursuant to Rule&nbsp;144 with respect to the sale. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Sales
of restricted shares under Rule&nbsp;144 held by our affiliates are also subject to requirements regarding the manner of sale, notice and the availability of current public information about
us. Rule&nbsp;144 also provides that affiliates relying on Rule&nbsp;144 to sell shares of our common stock that are not restricted shares must nonetheless comply with the same restrictions
applicable to restricted shares, other than the holding period requirement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Notwithstanding
the availability of Rule&nbsp;144, the holders of substantially all of our restricted shares have entered into lock-up agreements as described below and their restricted shares will
become eligible for sale at the expiration of the restrictions set forth in those agreements. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Rule&nbsp;701  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under Rule&nbsp;701 of the Securities Act, or Rule&nbsp;701, shares of our common stock acquired upon the exercise of currently outstanding
options or pursuant to other rights granted under our stock plans may be resold by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons other than affiliates, beginning 90&nbsp;days after the effective date
of the registration statement of which this prospectus is a part, subject only to the manner-of-sale provisions of Rule&nbsp;144; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=175,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=872327,FOLIO='171',FILE='DISK114:[15ZAD1.15ZAD72301]EM72301A.;24',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_em72301_1_172"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our affiliates, beginning 90&nbsp;days after the effective date of the
registration statement of which this prospectus is a part, subject to the manner-of-sale and volume limitations, current public information and filing requirements of Rule&nbsp;144, in each case,
without compliance with the six-month holding period requirement of Rule&nbsp;144. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>


As of December&nbsp;31, 2014, options to purchase a total of 281,029 shares of common stock were outstanding. In March 2015, we awarded options to purchase an additional 638,095 shares of our common
stock. Of the total number of shares of our common stock issuable under these options, substantially all are subject to contractual lock-up agreements with us or the underwriters described below under
"Underwriting" and will become eligible for sale at the expiration of those agreements unless held by an affiliate of ours.

</FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Lock-Up Agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We, along with our directors, executive officers and all or substantially all of our other shareholders and optionholders, have agreed that for a
period of 180&nbsp;days after the date of this prospectus, subject to specified exceptions, we or they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly,
any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock. Upon expiration of the "lock-up" period, certain of our shareholders
will have the right to require us to register their shares under the Securities Act. See "&#151;Registration Rights" below. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>Upon the closing of this offering, the holders of 12,787,524 shares of our common stock will be entitled to rights with respect to the registration of
their shares under the Securities Act, subject to the lock-up arrangement described above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable
without restriction under the Securities Act, except for shares purchased by affiliates, immediately upon the effectiveness of the registration. Any sales of securities by these shareholders could
have a material adverse effect on the trading price of our common stock. See "Description of Capital Stock &#151; Registration Rights."

 </FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Equity Incentive Plans  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We intend to file with the SEC a registration statement on Form&nbsp;S-8 under the Securities Act covering the shares of common stock reserved for
issuance under the Amended and Restated 2014 Stock Incentive Plan and 2015 Employee Stock Purchase Plan. The registration statement is expected to be filed and become effective as soon as practicable
after the closing of this offering. Accordingly, shares registered under the registration statement will be available for sale in the open market following its effective date, subject to
Rule&nbsp;144 volume limitations and the lock-up agreements described above, if applicable. See "Executive and Director Compensation." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=176,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=517469,FOLIO='172',FILE='DISK114:[15ZAD1.15ZAD72301]EM72301A.;24',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_em72301_1_173"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="em72301_material_u.s._federal_income_t__mat03201"> </A>
<A NAME="toc_em72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES<BR>  TO NON-U.S. HOLDERS OF OUR COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following is a general discussion of material U.S. federal income and estate tax considerations relating to the ownership and disposition of our
common stock by a non-U.S. holder. For purposes of this discussion, the term "non-U.S. holder" means a beneficial owner of our common stock that is not and is not treated as, for U.S. federal income
tax purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an individual who is a citizen or resident of the United States; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a corporation, or other entity treated as a corporation for U.S. federal income
tax purposes, created or organized in or under the laws of the United States or of any political subdivision of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an estate the income of which is subject to U.S. federal income taxation
regardless of its source; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a trust, if (i)&nbsp;a U.S. court is able to exercise primary supervision over
the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (ii)&nbsp;if the trust has a valid election to be treated as a U.S.
person under applicable U.S. Treasury Regulations. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>An
individual may be treated as a resident instead of a nonresident of the United States in any calendar year for U.S. federal income tax purposes if the individual was present in the United States
for at least 31&nbsp;days in that calendar year and for an aggregate of at least 183&nbsp;days during the three-year period ending with that calendar year. For purposes of this calculation, all of
the days present in the tested year, one-third of the days present in the immediately preceding year and one-sixth of the days present in the second preceding year are counted. Residents are taxed for
U.S. federal income tax purposes as if they were U.S. citizens. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion is based on current provisions of the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in
effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the
tax consequences to non-U.S. holders described in this prospectus. In addition, the Internal Revenue Service, or the IRS, could challenge one or more of the tax consequences described in this
discussion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
assume in this discussion that each non-U.S. holder holds shares of our common stock as a capital asset within the meaning of the Code (generally, property held for investment). This discussion
does not address all aspects of U.S. federal income and estate taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder's individual circumstances nor does it
address any aspects of state, local or non-U.S. taxes. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder, including the alternative minimum
tax and the Medicare contribution tax on net investment income, and does not address the special tax rules applicable to particular non-U.S. holders, such
as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  insurance companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  tax-exempt organizations or tax-qualified retirement plans; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  governmental organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> brokers, dealers or traders in securities or currencies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> real estate investment trusts or regulated investment companies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> pension plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  controlled foreign corporations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> passive foreign investment companies; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>173</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=177,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=146537,FOLIO='173',FILE='DISK114:[15ZAD1.15ZAD72301]EM72301A.;24',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_em72301_1_174"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons deemed to sell our common stock under the constructive sale provisions
of the Code; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons who hold or receive our common stock pursuant to the exercise of any
employee stock option or otherwise as compensation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> owners that hold our common stock as part of a straddle, hedge, conversion
transaction, synthetic security or other integrated investment; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> certain U.S. expatriates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, this discussion does not address the tax treatment of partnerships or persons who hold their common stock through partnerships or other entities that are pass-through entities for U.S.
federal income tax purposes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>This summary is general information only. It is not tax advice. We urge each prospective non-U.S. Holder to consult their tax advisor concerning the particular U.S. federal,
state, local and non-U.S. income, estate and other tax consequences of the purchase, ownership and disposition of our common stock.</B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Dividends  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we pay distributions on our common stock, those distributions generally will constitute dividends for U.S. federal income tax purposes to the
extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits,
the excess will be treated as a tax-free return of the non-U.S. holder's investment, up to such non-U.S. holder's tax basis in the common stock. Any remaining excess will be treated as capital gain,
subject to the tax treatment described in this prospectus under the heading "&#151; Gain on Disposition of Common Stock." Any such distribution will also be subject to the discussion in this
prospectus under the heading "&#151; Withholding and Information Reporting Requirements &#151; FATCA." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dividends
paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax on the gross amount of the dividends at a 30.0% rate or such lower rate as may be specified by
an applicable income tax treaty between the United States and such holder's country of residence. If we determine, at a time reasonably close to the date of payment of a distribution on our common
stock, that the distribution will not constitute a dividend because we do not anticipate having current or accumulated earnings and profits, we may elect not to withhold U.S. federal income tax from
such distribution as permitted by U.S. Treasury Regulations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder's country of residence generally will be required to provide a
properly executed IRS Form&nbsp;W-8BEN or W-8BEN-E (or successor form) and satisfy applicable certification and other requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate
claim with the IRS. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dividends
that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States, and, if an applicable income tax treaty so provides, that are
attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30.0% withholding tax if the non-U.S. holder
provides a properly executed IRS Form&nbsp;W-8ECI (or successor form). However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S.
federal income tax rates applicable to "United States persons" (within the meaning of the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also,
under certain circumstances, be subject to an additional "branch profits tax" at a 30.0% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and
such non-U.S. holder's country of residence. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>174</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=178,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=112976,FOLIO='174',FILE='DISK114:[15ZAD1.15ZAD72301]EM72301A.;24',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_em72301_1_175"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Gain on Disposition of Common Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to the discussion below regarding backup withholding and the Foreign Account Tax Compliance Act, or FATCA, a non-U.S. holder generally will
not be subject to U.S. federal income tax on gain recognized on a disposition of our common stock unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the gain is effectively connected with the non-U.S. holder's conduct of a trade
or business in the United States, and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the
United States; in these cases, the non-U.S. holder will be taxed on a net income basis at the regular graduated rates and in the manner applicable to United States persons, and, if the non-U.S. holder
is a foreign corporation, an additional branch profits tax at a rate of 30.0%, or a lower rate as may be specified by an applicable income tax treaty, may also apply; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the non-U.S. holder is an individual present in the United States for
183&nbsp;days or more in the taxable year of the disposition and certain other requirements are met (in which case the non-U.S. holder will be subject to a 30.0% tax, or such lower rate as may be
specified by an applicable income tax treaty, on the net gain derived from the disposition, which may be offset by U.S.-source capital losses of the non-U.S. holder, if any); or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we are or have been, at any time during the five-year period preceding such
disposition (or the non-U.S. holder's holding period, if shorter) a "United States real property holding corporation" within the meaning of the Code, unless during such applicable period our common
stock is regularly traded on an established securities market and the non-U.S. holder held no more than 5.0% of our outstanding common stock, actually or constructively. Generally, a corporation is a
"United States real property holding corporation" if the fair market value of its "United States real property interests" equals or exceeds 50.0% of the sum of the fair market value of its worldwide
real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming,
a "United States real property holding corporation" for U.S. federal income tax purposes. No assurance can be provided that our common stock will be regularly traded on an established securities
market for purposes of the rule described above. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Information Reporting and Backup Withholding  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The gross amount of the distributions on our common stock paid to each non-U.S. holder and the tax withheld, if any, with respect to such
distributions must be reported annually to the IRS. Non-U.S. holders may have to comply with specific certification procedures to establish that they are not "United States persons" (within the
meaning of the Code) in order to avoid backup withholding at the applicable rate, currently 28.0%, with respect to dividends on our common stock. Generally, a non-U.S. holder will comply with such
procedures if it provides a properly executed IRS Form&nbsp;W-8BEN, W-8BEN-E or W-8ECI or otherwise meets documentary evidence requirements for establishing that it is a non-U.S. holder, or
otherwise establishes an exemption. Dividends paid to non-U.S. holders subject to withholding of U.S. federal income tax, as described above under the heading "Dividends," will generally be exempt
from backup withholding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Information
reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through a U.S. office of any broker, United
States or foreign, unless the holder certifies its status as a non-U.S. holder (such as by providing a valid IRS Form&nbsp;W-8BEN, W-8BEN-E or W-8ECI) and satisfies certain other requirements, or
otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected
outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S.
ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>175</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=179,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=880566,FOLIO='175',FILE='DISK114:[15ZAD1.15ZAD72301]EM72301A.;24',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<A NAME="page_em72301_1_176"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Copies
of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or
agreement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the non-U.S. holder's U.S.
federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Withholding and Information Reporting Requirements &#151; FATCA  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Legislation known as the Foreign Account Tax Compliance Act, or FATCA, imposes U.S. federal withholding tax of 30.0% on payments of dividends on, and
(to the extent described below) on gross proceeds from the sale or disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;in the case of a foreign entity that is a "foreign
financial institution" (within the meaning of the Code), the foreign entity undertakes certain due diligence, reporting, withholding and certification obligations, (ii)&nbsp;in the case of a foreign
entity that is not a foreign financial institution, the foreign entity either certifies it does not have any "substantial United States owners" (as defined in the Code) or identifies each substantial
United States owner or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Withholding under FATCA will only apply (1)&nbsp;to payments of dividends on our common stock and
(2)&nbsp;to payments of gross proceeds from a sale or other disposition of our common stock made after December&nbsp;31, 2016. Under certain circumstances, a non-U.S. holder may be eligible for
refunds or credits of such taxes. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Federal Estate Tax  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Common stock owned or treated as owned by an individual (including by reason of holding interests in certain entities) who is not a citizen or
resident of the United States (as specially determined for U.S. federal estate tax purposes) at the time of death will be included in the individual's gross estate for U.S. federal estate tax purposes
and, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>THE PRECEDING DISCUSSION OF MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD
CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL, STATE, LOCAL AND NON-U.S. TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK (DIRECTLY OR THROUGH ENTITIES),
INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGES IN APPLICABLE LAWS.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>176</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=180,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=8843,FOLIO='176',FILE='DISK114:[15ZAD1.15ZAD72301]EM72301A.;24',USER='SCAVALI',CD='24-APR-2015;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eo72301_1_177"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eo72301_underwriting"> </A>
<A NAME="toc_eo72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to the terms and conditions set forth in the underwriting agreement, among us and Jefferies&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co.,
as the representatives of the underwriters named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed,
severally and not jointly, to purchase from us, the respective number of shares of common stock shown opposite its name below: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:41pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Underwriter

<!-- COMMAND=ADD_SCROPPEDRULE,41pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of Shares </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Jefferies&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Piper Jaffray&nbsp;&amp;&nbsp;Co.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wells Fargo Securities,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Needham&nbsp;&amp; Company,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,800,000</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers' certificates and
legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are
purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be
increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities
under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable laws and regulations. However,
the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be
given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when
you sell will be favorable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they
exercise discretionary authority. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Commission and Expenses  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on
the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of
common stock. The
underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock to certain brokers and
dealers. After the offering,
the initial public offering price, concession and reallowance to dealers may be reduced by the representatives. No </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>177</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=181,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=792042,FOLIO='177',FILE='DISK114:[15ZAD1.15ZAD72301]EO72301A.;25',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_eo72301_1_178"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>such
reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this
offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters' option to purchase additional shares. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Per Share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Without Option<BR>
to Purchase<BR>
Additional Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>With Option<BR>
to Purchase<BR>
Additional Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Without Option<BR>
to Purchase<BR>
Additional Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>With Option<BR>
to Purchase<BR>
Additional Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions paid by us</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds to us, before expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>


Needham&nbsp;&amp; Company,&nbsp;LLC, one of the underwriters of this offering, owns, through its parent company, a limited partnership interest in Boston Millennia Partners&nbsp;II Limited
Partnership, one of the entities affiliated with Boston Millennia Partners that acquired shares of our Series&nbsp;D convertible preferred stock in March 2015. Under the rules of the Financial
Industry Regulatory Authority (FINRA), the indirect beneficial interest of Needham&nbsp;&amp; Company,&nbsp;LLC in 6,298 shares of our common stock is regarded as additional compensation to the
underwriters of this offering.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $2,600,000. We have also agreed to
reimburse the underwriters for certain of their expenses in an amount up to $50,000, incurred in connection with review by the Financial Industry Regulatory Authority,&nbsp;Inc. of the terms of this
offering, as set forth in the underwriting agreement.


</FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Determination of Offering Price  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our common stock
will be determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market
valuations of other companies that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
offer no assurances that the initial public offering price will correspond to the price at which the common stock will trade in the public market subsequent to the offering or that an active
trading market for the common stock will develop and continue after the offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Listing  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We expect to receive approval to list our common stock on NASDAQ under the trading symbol "COLL."


</FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>178</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=182,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=518966,FOLIO='178',FILE='DISK114:[15ZAD1.15ZAD72301]EO72301A.;25',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_eo72301_1_179"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stamp Taxes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If you purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and
practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Option to Purchase Additional Shares  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We have granted to the underwriters an option, exercisable for 30&nbsp;days from the date of this prospectus, to purchase, from time to time, in
whole or in part, up to an aggregate of 870,000 shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the
underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter's initial purchase
commitment as indicated in the table above. This option may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus.

</FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


No Sales of Similar Securities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We, our officers, directors and holders of all or substantially all our outstanding capital stock and other securities have agreed, subject to
specified exceptions, not to directly or indirectly:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> sell, offer, contract or grant any option to sell (including any short sale),
pledge, transfer, establish an open "put equivalent position" within the meaning of Rule&nbsp;16a-l(h) under the Exchange Act, or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  otherwise dispose of any shares of common stock, options or warrants to acquire
shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> publicly announce an intention to do any of the foregoing for a period of
180&nbsp;days after the date of this prospectus without the prior written consent of Jefferies&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
restriction terminates after the close of trading of the common stock on and including the 180<SUP>th</SUP>&nbsp;day after the date of this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Jefferies&nbsp;LLC
and Piper Jaffray&nbsp;&amp;&nbsp;Co. may, in their sole discretion and at any time or from time to time before the termination of the 180-day period release all or any portion of
the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a lock-up agreement, providing consent to the sale
of shares prior to the expiration of the lock-up period. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stabilization  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriters have advised us that they, pursuant to Regulation&nbsp;M under the Exchange Act, certain persons participating in the offering may
engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of
stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either "covered"
short sales or "naked" short sales. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>"Covered"
short sales are sales made in an amount not greater than the underwriters' option to purchase additional shares of our common stock in this offering. The underwriters may close out any
covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of
shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they
may purchase shares through the option to purchase additional shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>179</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=183,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=670764,FOLIO='179',FILE='DISK114:[15ZAD1.15ZAD72301]EO72301A.;25',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_eo72301_1_180"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>"Naked"
short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open
market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market
after pricing that could adversely affect investors who purchase in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering
transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to
other purchase transactions, the underwriter's purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or
retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an
arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate
member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common
stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Electronic Distribution  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by one or more of the
underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a
specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other
allocations. Other than the prospectus in electronic format, the information on the underwriters' web sites and any information contained in any other web site maintained by any of the underwriters is
not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Directed Share Program  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>At our request, the underwriters have reserved for sale at the initial public offering price up to approximately 5% of the shares of our common stock
for employees, directors and other persons associated with us who have expressed an interest in purchasing shares in the offering. The number of shares of common stock available for sale to the
general public in the offering will be reduced to the extent these persons purchase the directed shares in the program. Any directed shares not so purchased will be offered by the underwriters to the
general public on the same terms as the other shares. Except for certain participants who have entered into lock-up agreements as contemplated above, each person buying shares through the directed
share program has agreed that, for a period of 180&nbsp;days from and including the date of this prospectus, he or she will not, without the prior written consent of Jefferies&nbsp;LLC and Piper
Jaffray&nbsp;&amp;&nbsp;Co., dispose of or hedge any shares of common stock or any securities convertible into or exchangeable for shares of common stock with respect to shares purchased in the
program. For those participants who have entered into lock-up agreements as contemplated above, the lock-up agreements contemplated therein shall govern with respect to their purchases of shares of
common stock in the program. Jefferies&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co. in their sole discretion may release any of the securities subject to these lock-up agreements at any time. We
have agreed to indemnify the underwriters against

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>180</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=184,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=630659,FOLIO='180',FILE='DISK114:[15ZAD1.15ZAD72301]EO72301A.;25',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_eo72301_1_181"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>certain
liabilities and expenses, including liabilities under the Securities Act, in connection with sales of the directed shares. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Other Activities and Relationships  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriter and certain of its affiliates are full service financial institutions engaged in various activities, which may include securities
trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriter and
certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for
which they received or will receive customary fees and expenses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the ordinary course of their various business activities, the underwriter and certain of its affiliates may make or hold a broad array of investments and actively trade debt and equity securities
(or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may
involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit
exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either
the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short
positions could adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment
recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that
they acquire, long and/or short positions in such securities and instruments. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Disclaimers About Non-U.S. Jurisdictions  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Australia  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus is not a disclosure document for the purposes of Australia's Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not
been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in
Australia: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
confirm and warrant that you are either:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(a) or (b)&nbsp;of the
Corporations Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(c) or (d)&nbsp;of the
Corporations Act and that you have provided an accountant's certificate to the Company which complies with the requirements of section&nbsp;708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and
related regulations before the offer has been made; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a person associated with the Company under Section&nbsp;708(12) of the
Corporations Act; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "professional investor" within the meaning of section&nbsp;708(11)(a) or
(b)&nbsp;of the Corporations Act. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under
this prospectus is void and incapable of acceptance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus for resale in Australia within 12&nbsp;months of those securities being issued unless
any such resale offer is exempt from the requirement to issue a disclosure document under section&nbsp;708 of the Corporations Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>181</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=185,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=510721,FOLIO='181',FILE='DISK114:[15ZAD1.15ZAD72301]EO72301A.;25',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_eo72301_1_182"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


European Economic Area  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In relation to each member state of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member State"), an
offer to the public of any common stock which is the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State except that an offer to the public in that
Relevant Member State of any common stock may be
made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to any legal entity which is a "qualified investor" as defined in the Prospectus
Directive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to fewer than 100 or, if the Relevant Member State has implemented the relevant
provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject
to obtaining the prior consent of the underwriters or the underwriters nominated by us for any such offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in any other circumstances falling within Article&nbsp;3(2) of the Prospectus
Directive, </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>provided
that no such offer of common stock shall require us or any of the underwriters to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive or supplement a prospectus
pursuant to Article&nbsp;16 of the Prospectus Directive. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the purposes of this provision, the expression an "offer common stock to the public" in relation to the common stock in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and the common stock to be offered so as to enable an investor to decide to purchase or subscribe to the common stock, as the same may be
varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (and
amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and
the expression "2010 PD Amending Directive" means Directive 2010/73/EU. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Hong Kong  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose
ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong
("SFO") and any rules made under that Ordinance; or in other circumstances which do not result in the document being a "prospectus" as defined in the Companies Ordinance (Cap. 32)&nbsp;of Hong Kong
("CO") or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may
be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed
or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons
outside Hong Kong or only to "professional investors" as defined in the SFO and any rules made under that Ordinance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not
be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he, she or
it is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he, she or it is not acquiring, and has not been offered any
securities in circumstances that contravene any such restrictions. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>182</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=186,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=80968,FOLIO='182',FILE='DISK114:[15ZAD1.15ZAD72301]EO72301A.;25',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_eo72301_1_183"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Japan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as
amended), or FIEL, and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any
person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to, or for the
benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and
ministerial guidelines of Japan. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Singapore  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this
prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares
be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor
under Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore (the "SFA"), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Where
the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a corporation (which is not an accredited investor (as defined in
Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a trust (where the trustee is not an accredited investor) whose sole purpose is
to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>securities
(as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months
after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to an institutional investor or to a relevant person defined in
Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> where no consideration is or will be given for the transfer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> where the transfer is by operation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> as specified in Section&nbsp;276(7) of the SFA; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> as specified in Regulation&nbsp;32 of the Securities and Futures (Offers of
Investments) (Shares and Debentures) Regulations&nbsp;2005 of Singapore. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Switzerland  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange ("SIX") or on any other stock exchange or
regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in
Switzerland. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
this prospectus nor any other offering or marketing material relating to the offering, the Company or the securities have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of
securities has not been and will not be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>183</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=187,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=437192,FOLIO='183',FILE='DISK114:[15ZAD1.15ZAD72301]EO72301A.;25',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_eo72301_1_184"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>authorized
under the Swiss Federal Act on Collective Investment Schemes ("CISA"). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not
extend to acquirers of securities. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


United Kingdom  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning
of Article&nbsp;2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the "Order") and/or (ii)&nbsp;high net worth entities falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the Order and other persons to whom it may lawfully
be communicated (each such person being referred to as a "relevant person"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>184</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=188,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=744110,FOLIO='184',FILE='DISK114:[15ZAD1.15ZAD72301]EO72301A.;25',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_eo72301_1_185"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eo72301_legal_matters"> </A>
<A NAME="toc_eo72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Pepper Hamilton&nbsp;LLP. Latham&nbsp;&amp;
Watkins&nbsp;LLP is counsel for the underwriters in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eo72301_experts"> </A>
<A NAME="toc_eo72301_3"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The financial statements of Collegium Pharmaceutical, Inc. included in this prospectus and elsewhere in the registration statement have been so
included in reliance upon the report of Grant Thornton&nbsp;LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eo72301_where_you_can_find_more_information"> </A>
<A NAME="toc_eo72301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have filed with the SEC a registration statement on Form&nbsp;S-1 under the Securities Act, with respect to the shares of common stock being
offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock
offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to
are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified
in all respects by this reference. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
can read our SEC filings, including the registration statement, over the Internet at the SEC's website at www.sec.gov. You may also read and copy any document we file with the SEC at its public
reference facilities at 100&nbsp;F&nbsp;Street, NE, Washington, DC&nbsp;20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the
SEC at 100&nbsp;F Street, NE, Washington, DC&nbsp;20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a
copy of these filings, at no cost, by writing us at 780 Dedham Street, Suite&nbsp;800, Canton, MA&nbsp;02021 or telephoning us at (781)&nbsp;713-3699. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the closing of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC.
These reports, proxy statements and other information will be available for inspection and copying at the public reference room and website of the SEC referred to above. We also maintain a website at
www.collegiumpharma.com, at which, following the closing of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or
furnished to, the SEC. The information contained in, or that can be accessed through, our website is incorporated by reference in, and is not part of, this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>185</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=189,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=176926,FOLIO='185',FILE='DISK114:[15ZAD1.15ZAD72301]EO72301A.;25',USER='WWASSER',CD='24-APR-2015;15:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fa72301_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<A NAME="fa72301_index_to_financial_statements"> </A>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


<A NAME="in"></A>COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
Index to Financial Statements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="FA72301_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pages </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#report"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#report"><FONT SIZE=2>F-2</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#bal"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance Sheets as of December&nbsp;31, 2013 and 2014</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#bal"><FONT SIZE=2>F-3</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ops"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Operations for the Years Ended December&nbsp;31, 2013 and 2014</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ops"><FONT SIZE=2>F-4</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#conv"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Convertible Redeemable Preferred Stock and Shareholders' Deficit for the Years Ended December&nbsp;31, 2013
and 2014</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#conv"><FONT SIZE=2>F-5</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#cash"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Cash Flows for the Years Ended December&nbsp;31, 2013 and 2014</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cash"><FONT SIZE=2>F-6</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#notes"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#notes"><FONT SIZE=2>F-7</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=190,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1039600,FOLIO='F-1',FILE='DISK114:[15ZAD1.15ZAD72301]FA72301A.;13',USER='VRIVERA',CD='24-APR-2015;06:42' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fc72301_1_2"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="report"></A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Board
of Directors and Shareholders<BR>
Collegium Pharmaceutical,&nbsp;Inc. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have audited the accompanying balance sheets of Collegium Pharmaceutical,&nbsp;Inc. (a Virginia corporation) (the "Company") as of December&nbsp;31, 2013 and 2014, and the related statements of
operations, convertible redeemable preferred stock and shareholders' deficit, and cash flows for each of the two years in the period ended December&nbsp;31, 2014. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our
audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Collegium Pharmaceutical,&nbsp;Inc. as of December&nbsp;31, 2013 and
2014, and the results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31, 2014 in conformity with accounting principles generally accepted in the
United States of America.

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


/s/ Grant Thornton&nbsp;LLP

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Boston, Massachusetts<BR>
April&nbsp;27, 2015<BR>

 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=191,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=122103,FOLIO='F-2',FILE='DISK114:[15ZAD1.15ZAD72301]FC72301A.;21',USER='VRIVERA',CD='24-APR-2015;06:42' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fe72301_1_3"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<A NAME="bal"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fe72301_collegium_pharmaceutical,_inc.__col03377"> </A>
<A NAME="toc_fe72301_1"> </A></FONT> <FONT SIZE=2><B><BR>  COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>  BALANCE SHEETS<BR>  (In thousands, except share and per share data)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma<BR>
December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(unaudited)</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>ASSETS</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current assets:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,551</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,634</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,634</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Refundable PDUFA fee</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,335</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,335</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">710</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">527</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">527 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total current assets</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,261</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,496</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,496</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Property and equipment, net</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">693</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">514</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">514</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Restricted cash</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">80</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">80</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">80 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total assets</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,034</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,090</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,090 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND SHAREHOLDERS' DEFICIT</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,217</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,208</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,208</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accrued expenses</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,013</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,956</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,956</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current portion of deferred rent and lease note payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">55</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">59</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">59</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current portion of term loan payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">333</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,194</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,194</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Convertible bridge notes with related parties</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,000 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total current liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,618</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,417</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,417</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Deferred rent and lease note payable, long-term</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">59</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Lease incentive obligation</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">135</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">101</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">101</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Term loan payable, long-term</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">640</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,813</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,813 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,452</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">17,331</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">17,331 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Commitments and contingencies (See Note&nbsp;7)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:9pt;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Convertible redeemable preferred stock (See Note&nbsp;10):</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;A convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; 18,498,419 at December&nbsp;31, 2013,
December&nbsp;31, 2014 and at December&nbsp;31, 2014 pro forma (unaudited); issued and outstanding shares&nbsp;&#151; 9,232,334 at December&nbsp;31, 2013 and December&nbsp;31, 2014 and no shares at December&nbsp;31, 2014 pro forma (unaudited);
liquidation preference of $12,277 at December&nbsp;31, 2013, $12,781 at December&nbsp;31, 2014 and $0 at December&nbsp;31, 2014 pro forma (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,277</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,781</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;B convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; 27,324,237 at December&nbsp;31, 2013,
December&nbsp;31, 2014 and at December&nbsp;31, 2014 pro forma (unaudited); issued and outstanding shares&nbsp;&#151; 27,324,237 at December&nbsp;31, 2013, December&nbsp;31, 2014 and no shares at December&nbsp;31, 2014 pro forma (unaudited);
liquidation preference of $49,376 at December&nbsp;31, 2013, $51,212 at December&nbsp;31, 2014 and $0 at December&nbsp;31, 2014 pro forma (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">49,376</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">51,212</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;C convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; 8,658,344 at December&nbsp;31, 2013,
December&nbsp;31, 2014 and at December&nbsp;31, 2014 pro forma (unaudited); issued and outstanding shares&nbsp;&#151; 8,658,008 at December&nbsp;31, 2013, December&nbsp;31, 2014 and no shares at December&nbsp;31, 2014 pro forma (unaudited);
liquidation preference of $12,154 at December&nbsp;31, 2013, $13,114 at December&nbsp;31, 2014 and $0 at December&nbsp;31, 2014 pro forma (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,154</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,114</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Shareholders' deficit:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Common stock, $0.001 par value; authorized shares&nbsp;&#151; 72,000,000 at December&nbsp;31, 2013, December&nbsp;31, 2014 and at December&nbsp;31, 2014
pro forma (unaudited); issued and outstanding shares&nbsp;&#151; 962,960 at December&nbsp;31, 2013, 1,006,219 at December&nbsp;31, 2014; and 7,559,035 at December&nbsp;31, 2014 pro forma (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,313</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,407</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">89,507</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(80,536</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(101,753</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(101,753</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Treasury stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total shareholders' deficit</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(68,225</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(89,348</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(12,241</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total liabilities, convertible redeemable preferred stock and shareholders' deficit</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,034</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,090</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,090 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=192,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=227315,FOLIO='F-3',FILE='DISK114:[15ZAD1.15ZAD72301]FE72301A.;33',USER='VRIVERA',CD='24-APR-2015;06:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fg72301_1_4"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<A NAME="ops"></A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fg72301_collegium_pharmaceutical,_inc.__col03861"> </A>
<A NAME="toc_fg72301_1"> </A></FONT> <FONT SIZE=2><B><BR>  COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>  STATEMENTS OF OPERATIONS<BR>  (In thousands, except share and per share data)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,157</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,959</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,885</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,706 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,665 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,665</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>76</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of derivative liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>155</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share (See Note&nbsp;3)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.06</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(22.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share (See Note&nbsp;3)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,697,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>933,997</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per common share, basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.84</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used to compute pro forma net loss per common share (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,471,303</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=193,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=572336,FOLIO='F-4',FILE='DISK114:[15ZAD1.15ZAD72301]FG72301A.;30',USER='DPERRY',CD='24-APR-2015;18:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fh72301_1_5"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<!-- COMMAND=ROTATED_TABLE WIDTH="150%" -->

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="99%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="99%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="conv"></A></FONT><FONT SIZE=2><B>COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
STATEMENTS OF CONVERTIBLE REDEEMABLE PREFERRED STOCK AND SHAREHOLDERS' DEFICIT<BR>
(In thousands, except share data)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;A<BR>
Convertible<BR>
Redeemable<BR>
Preferred Stock </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;B<BR>
Convertible<BR>
Redeemable<BR>
Preferred Stock </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;C<BR>
Convertible<BR>
Redeemable<BR>
Preferred Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Common Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Additional Paid- In Capital </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Treasury Stock,<BR>
at cost </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Accumulated Deficit </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total<BR>
Shareholders'<BR>
Deficit </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"> Balance at January&nbsp;1, 2013</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">18,464,674</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">23,546</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">27,324,237</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">47,540</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
1,924,845</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">11</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(61,414</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(61,404</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Issuance of new Series&nbsp;C convertible redeemable preferred stock, net of<BR>
issuance&nbsp;costs of $45</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,658,008</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,034</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accruals of dividends and accretion to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">970</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,836</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">120</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,925</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,926</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Performance Adjustment of Series&nbsp;A</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(9,232,340</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(12,239</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(962,962</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,240</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,239</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">62</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">62</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Exercise of common stock options</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,077</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Balance at December&nbsp;31, 2013</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,232,334</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,277</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">27,324,237</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">49,376</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,658,008</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,154</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">962,960</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,313</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(80,536</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(68,225</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accruals of dividends and accretion to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">504</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,836</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">960</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3,300</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3,300</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Issuance of restricted stock awards to employees</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,869</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Exercise of common stock options</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">32,390</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">72</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">72</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Balance at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,232,334</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,781</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">27,324,237</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">51,212</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,658,008</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,114</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">

<!-- -->
1,006,219</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,407</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(101,753</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(89,348</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="99%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="99%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>The
accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=194,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=654861,FOLIO='F-5',FILE='DISK114:[15ZAD1.15ZAD72301]FH72301A.;68',USER='VRIVERA',CD='24-APR-2015;06:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fi72301_1_6"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<A NAME="cash"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fi72301_collegium_pharmaceutical,_inc.__col02610"> </A>
<A NAME="toc_fi72301_1"> </A></FONT> <FONT SIZE=2><B><BR>  COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>  STATEMENTS OF CASH FLOWS<BR>  (In thousands)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CASH FLOWS FROM OPERATING ACTIVITIES:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>169</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>187</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lease incentive</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(34</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(34</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non cash interest expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrual of back end fees related to note payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of derivative liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>183</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Refundable PDUFA fee</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,335</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(822</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>990</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>199</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>943 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,530</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,947</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CASH FLOWS FROM INVESTING ACTIVITIES:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(206</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(206</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CASH FLOWS FROM FINANCING ACTIVITIES:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of convertible bridge note</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from notes payable, net of original note payoff</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,056</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of Series&nbsp;C preferred stock, net of issuance costs of $45</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,955</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of term note borrowings</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(43</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of lease note payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(62</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(62</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from the exercise of common stock options</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>72 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,351</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,038 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net decrease in cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,385</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(5,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents&#151;Beginning of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,936</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,551 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents&#151;End of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,551</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,634 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Supplemental disclosure of noncash activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals of dividends and accretion to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,926</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,300 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Performance Adjustment to Series&nbsp;A and common shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,239</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of term note with proceeds of notes payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>944 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash paid for interest</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>181 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash paid for taxes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=195,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=103970,FOLIO='F-6',FILE='DISK114:[15ZAD1.15ZAD72301]FI72301A.;33',USER='VRIVERA',CD='24-APR-2015;06:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fk72301_1_7"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="notes"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fk72301_collegium_pharmaceutical,_inc.__col04039"> </A>
<A NAME="toc_fk72301_1"> </A></FONT> <FONT SIZE=2><B><BR>  COLLEGIUM PHARMACEUTICAL, INC.    <BR>    <BR>    NOTES TO FINANCIAL STATEMENTS    <BR>    <BR>    (in thousands, except share and per share data)    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. NATURE OF BUSINESS  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Organization  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Collegium Pharmaceutical,&nbsp;Inc. (the "Company") was incorporated in Delaware in April&nbsp;2002 and then reincorporated in Virginia in July
2014. The Company has its principal operations in Canton,
Massachusetts. The Company is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate the Company's patented
DETERx&reg; platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza ER&#153;, or Xtampza, is an abuse-deterrent,
extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration ("FDA"). The Company's new
drug application ("NDA") filing for Xtampza was accepted by the FDA on February&nbsp;10, 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's operations are subject to certain risks and uncertainties. The risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory
approvals, changing market conditions for products being developed by the Company, the need to retain key personnel and protect intellectual property, patent infringement litigation and the
availability of additional capital financing on terms acceptable to the Company. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Basis of Accounting  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The financial statements include the accounts of the Company and are prepared in conformity with accounting principles generally accepted in the
United States of America. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Liquidity

 </B></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>The Company has experienced net losses and negative cash flows from operating activities since its inception, and as of December&nbsp;31, 2013 and
December&nbsp;31, 2014, had a deficit accumulated of $80,536 and $101,753, respectively. The Company expects to continue to incur net losses in the foreseeable future. A successful transition to
attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company's cost structure.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>


On March&nbsp;6, 2015, the Company received aggregate consideration of $50,000 from the issuance of Series&nbsp;D Preferred Stock, comprised of $45,000 in cash and $5,000 in convertible notes from
related parties.

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


The Company expects to continue to incur losses for the foreseeable future. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise
additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic
partners or from other sources. The Company believes that it will have sufficient cash to fund operations and future growth initiatives through December&nbsp;31,
2015; however, there can be no assurance that the Company will be successful in achieving its projections, reducing costs, or raising additional funds with terms acceptable to the Company. If the
Company is unable to obtain financing or increase profitability, the related lack of liquidity will have a material adverse effect on the Company's operations and future prospects.

</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=196,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=720865,FOLIO='F-7',FILE='DISK114:[15ZAD1.15ZAD72301]FK72301A.;52',USER='LPALLES',CD='24-APR-2015;13:16' -->
<A NAME="page_fk72301_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Use of Estimates  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The preparation of the Company's financial statements requires it to make estimates and assumptions that impact the reported amounts of assets,
liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company's financial statements and accompanying notes. The most significant estimates in the Company's
financial statements relate to the valuation of equity awards, fair value estimates of warrants, estimated useful lives of fixed assets, asset retirement obligations and accruals related to clinical
trials. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its
estimates and assumptions on an ongoing basis. The Company's actual results may differ from these estimates under different assumptions or conditions. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Unaudited Pro Forma Balance Sheet and Net Loss per Share Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The unaudited pro forma balance sheet information as of December&nbsp;31, 2014 assumes the conversion of all outstanding shares of convertible
redeemable preferred stock into shares of the Company's common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unaudited
pro forma net loss per share applicable to common shareholders is computed using the weighted-average number of common shares outstanding after giving effect to the conversion of all the
outstanding convertible redeemable preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period presented, or the date of original issuance, if later,
and excludes the gain on extinguishment of preferred stock and the accretion of dividends. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Fair Value Measurements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for financial
instruments with respect to which it is practicable to estimate that value. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts payable and
accrued liabilities approximate their respective fair values because of the short-term nature of these accounts. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Fair
Value Measurements and Disclosures describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used
to measure fair value, as follows: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Level&nbsp;1</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. The
Company's Level&nbsp;1 assets and liabilities consist of money market investments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Level&nbsp;2</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration
with observable market data. Level&nbsp;2 includes investments valued at quoted
prices adjusted for legal or contractual restrictions specific to the security. The Company does not have Level&nbsp;2 assets or liabilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Level&nbsp;3</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity's own assumptions about the
assumptions market participants would use in pricing the assets. Level&nbsp;3 includes private investments that are supported by little or no market activity. The Company does not have
Level&nbsp;3 assets or liabilities. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=197,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=784626,FOLIO='F-8',FILE='DISK114:[15ZAD1.15ZAD72301]FK72301A.;52',USER='LPALLES',CD='24-APR-2015;13:16' -->
<A NAME="page_fk72301_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Transfers
are calculated on values as of the transfer date. There were no transfers between Levels&nbsp;1, 2 and 3 during the years ended December&nbsp;31, 2013 and 2014. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Concentration of Credit Risk  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash
equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and
management believes that the Company is not exposed to significant credit risk due to the financial position of the financial institutions in which those deposits are held. The Company has no
financial instruments with off-balance sheet risk of loss. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Cash and Cash Equivalents  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cash and cash equivalents include cash in readily available checking and savings accounts and money market funds. The Company considers all highly
liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's cash equivalents, which consist of money market funds, are measured at fair value on a recurring basis. As of December&nbsp;31, 2013 and 2014, the carrying amount of cash and cash
equivalents was $7,551 and $1,634, respectively, which approximates fair value and was determined based upon Level&nbsp;1 inputs. Money market funds are valued using quoted market prices with no
valuation adjustments applied. Accordingly, these securities are categorized as Level&nbsp;1. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Property and Equipment  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Property and equipment are recorded at historical cost. Maintenance and repair costs are expensed as incurred. Costs which materially improve or
extend the lives of existing assets are capitalized. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the assets, which are as
follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="40%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="40%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Asset Category </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Estimated Useful Life </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Machinery and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Computers and office equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7&nbsp;years</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Upon
retirement or sale, the cost of assets disposed and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recorded in the statements of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Impairment of Long-Lived Assets  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Long-lived assets consist of property and equipment. When impairment indicators exist, the Company's management evaluates long-lived assets for
potential impairment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those
assets are less than the carrying amount of those assets. While the Company's current and historical operating losses and negative cash flows are indicators of impairment, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=198,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=103693,FOLIO='F-9',FILE='DISK114:[15ZAD1.15ZAD72301]FK72301A.;52',USER='LPALLES',CD='24-APR-2015;13:16' -->
<A NAME="page_fk72301_1_10"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>management
believes that future cash flows to be received support the carrying value of its long-lived assets and, accordingly, has not recognized any impairment losses since inception. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Impairment
losses, if any, are recognized in earnings. An impairment loss would be recognized in an amount equal to the excess of the carrying amount over the undiscounted expected future cash flows. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Initial Public Offering Costs  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company defers direct incremental costs attributable to the initial public offering ("IPO") of its common stock. These costs represent legal,
accounting and other direct costs related to the
Company's efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional
paid-in capital as a reduction of the IPO proceeds. If the Company terminates its plan for an IPO or delays such plan for more than 90&nbsp;days, any costs deferred will be expensed immediately. As
of December&nbsp;31, 2014, IPO costs were $233 and are included in prepaid expenses and other assets in the balance sheet. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Restricted Cash  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Restricted cash represents cash held in a depository account at a financial institution to collateralize a conditional stand-by letter of credit
related to the Company's Canton, Massachusetts facility lease agreement. Restricted cash is reported as non-current unless the restrictions are expected to be released in the next twelve months. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Deferred Rent  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the
Company occupies. The Company's lease for its facility provides for fixed increases in minimum annual rental payments and for additional rent in the form of maintenance and operating costs during the
lease term. The total amount of rental payments due over the lease term is being charged to rent expense ratably over the life of the lease. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Redeemable Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company classifies convertible redeemable preferred stock that is redeemable outside of the Company's control outside of permanent equity. The
Company recorded such redeemable preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value is being increased by periodic accretion to its redemption
value at each balance sheet date as if the redeemable preferred stock was redeemable at that date. In the absence of retained earnings these accretion charges are recorded against additional paid-in
capital, if any, and then to accumulated deficit. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Research and Development Costs  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company's research and development
activities including salaries and employee related costs, costs associated with market research and design, costs associated with conducting preclinical, clinical and regulatory activities including
fees paid to third-party professional consultants and service providers, costs incurred under clinical trial agreements, costs for laboratory supplies and laboratory equipment, costs to acquire,
develop and manufacture preclinical study and clinical trial materials, facilities, depreciation and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=199,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=139309,FOLIO='F-10',FILE='DISK114:[15ZAD1.15ZAD72301]FK72301A.;52',USER='LPALLES',CD='24-APR-2015;13:16' -->
<A NAME="page_fk72301_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>other
expenses including allocated expenses for rent and maintenance of facilities. Government grants are recognized as a reduction of the qualifying cost being reimbursed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent Costs  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Costs related to filing and pursuing patent applications are recorded as general and administrative expense as incurred since the recoverability of
such expenditures is uncertain. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stock-Based Compensation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company accounts for grants of stock options and restricted stock to employees based on their grant date fair value and recognizes compensation
expense over their vesting period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair
value of the underlying common stock as determined by management or the value of the services provided, whichever is more readily determinable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Stock-based
compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting
period) on a straight-line basis, net of estimated forfeitures. The expense is adjusted for actual forfeitures at year end. Stock-based compensation expense recognized in the financial statements is
based on awards that are ultimately expected to vest. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
stock option grants with performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the
performance condition has been achieved. For stock option grants with both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when
the achievement of the performance-based milestone is probable or the performance condition has been achieved. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic
revaluation over their vesting terms. There were no non-employee grants in 2013 and 2014. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=200,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1037795,FOLIO='F-11',FILE='DISK114:[15ZAD1.15ZAD72301]FK72301A.;52',USER='LPALLES',CD='24-APR-2015;13:16' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fm72301_1_12"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data)  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Income Taxes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company accounts for income taxes under the liability method, which requires the recognition of deferred tax assets and liabilities for the
expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences
between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. The effect of a change in tax
rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all
available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent
operations. If management determines that the Company would be able to realize its deferred tax assets in the future, in excess of its net recorded amount, management would make an adjustment to the
deferred tax asset valuation allowance, which would reduce the provision for income taxes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company records uncertain tax positions on the basis of a two-step process whereby (i)&nbsp;management determines whether it is more likely than not that the tax positions will be sustained on
the basis of the technical merits of the position and (ii)&nbsp;for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax
benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with the related tax authority. The Company will recognize interest and penalties related to uncertain tax
positions within income tax expense. Any accrued interest and penalties will be included within the
related tax liability. As of December&nbsp;31, 2013 and 2014, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's
statements of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Net loss per Common Share  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Basic net loss per common share is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of
common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common
shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock
options, warrants, redeemable convertible preferred stock and unvested restricted stock are considered potentially dilutive securities. Because the Company has reported a net loss for the twelve
months ended December&nbsp;31, 2013 and 2014, diluted net loss per common share is the same as basic net loss per common share for those periods. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Diluted
earnings per share is computed using the more dilutive of (i)&nbsp;the two-class method, or (ii)&nbsp;the if-converted method. The Company allocates earnings first to preferred
shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted
earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of
stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=201,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=625341,FOLIO='F-12',FILE='DISK114:[15ZAD1.15ZAD72301]FM72301A.;91',USER='JTAM',CD='24-APR-2015;15:55' -->
<A NAME="page_fm72301_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently Issued Accounting Pronouncements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No.&nbsp;2013-11, </FONT><FONT SIZE=2><I>Presentation of an Unrecognized
Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist.</I></FONT><FONT SIZE=2> ASU 2013-11 amends the presentation requirements of ASC 740 and
requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit
carryforward. To the extent the tax
benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be
presented as a liability and not combined with deferred tax assets. This ASU is effective for annual periods, and interim periods within those years, beginning after December&nbsp;15, 2013, which is
fiscal 2014 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period
presented. The adoption of ASU 2013-11 did not have a material impact on the Company's financial position or results of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2014, the FASB issued ASU No.&nbsp;2014-09, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers.</I></FONT><FONT SIZE=2> This ASU is a comprehensive new revenue recognition model that
requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or
services. This ASU is effective for annual reporting periods beginning after December&nbsp;15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on
January&nbsp;1, 2017. Management does not believe the adoption of this ASU will have a material impact on the Company's financial condition, results of operations or cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2014, the FASB issued ASU&nbsp;No.&nbsp;2014-12, </FONT><FONT SIZE=2><I>Compensation&nbsp;&#151; Stock Compensation (Topic 718):</I></FONT><FONT SIZE=2><I>Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance
Target Could Be Achieved after the Requisite Service Period</I></FONT><FONT SIZE=2>. ASU
2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after
the requisite service period. That is the case when an employee is eligible to retire or otherwise terminate employment before the end of the period in which a performance target (for example, an
initial public offering or a profitability target) could be achieved and still be eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted
by public business entities in annual periods beginning on or after December&nbsp;15, 2015 and interim periods within those annual periods. The Company plans to implement this standard in the first
quarter of fiscal year 2016 and is currently evaluating the potential impact of this new guidance on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2014, the FASB issued ASU No.&nbsp;2014-15, </FONT><FONT SIZE=2><I>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.</I></FONT><FONT SIZE=2> ASU 2014-15
requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a
going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December&nbsp;15, 2016 and
earlier application is permitted. The adoption of ASU 2014-15 is not expected to have a material effect on the Company's financial statements or disclosures. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2014, the FASB issued ASU No.&nbsp;2014-16, </FONT><FONT SIZE=2><I>Derivatives and Hedging (Topic 815)&nbsp;&#151; Determining Whether the Host Contract in a Hybrid Financial
Instrument Issued in the Form of a Share is More Akin to Debt or to Equity</I></FONT><FONT SIZE=2>. This ASU was issued to clarify how current U.S. generally accepted </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=202,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=584745,FOLIO='F-13',FILE='DISK114:[15ZAD1.15ZAD72301]FM72301A.;91',USER='JTAM',CD='24-APR-2015;15:55' -->
<A NAME="page_fm72301_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>accounting
principles should be interpreted in evaluating the economic characteristics and risk of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition,
this ASU was issued to clarify that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the
debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting this ASU should be applied on
a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective
application is permitted to all relevant prior periods. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2015. Early adoption
in an interim period is permitted. The Company is currently evaluating the impact of the adoption of this ASU on its financial statements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. NET LOSS PER COMMON SHARE  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the
net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Stock options, warrants,
convertible preferred stock and unvested restricted stock are considered to be potentially dilutive securities and are only included in the calculation of diluted net loss per share when their effect
is dilutive. For the twelve months ended December&nbsp;31, 2013 and December&nbsp;31, 2014, these securities were anti-dilutive due to the net losses in those periods and, therefore, the number of
shares used to compute basic and diluted earnings per share are the same for of those periods. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


In connection with the Company's recalculation of loss per common share to reflect the reverse stock split, the Company identified an immaterial error in its weighted-average shares calculation for
the years ended December&nbsp;31, 2013 and 2014. The impact of the errors was to reduce basic and diluted net loss per common share from $(4.24) to $(4.06) for 2013 and from $(25.63) to $(22.72) for
2014 and have been corrected in the periods in which they originated.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table presents the computations of basic and dilutive net loss per share: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Performance Adjustment of Series&nbsp;A</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,239</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals of dividends and accretion to redemption value of preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,925</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,300</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,300</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss attributable to common shareholders&nbsp;&#151; basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(6,883</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(21,217</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(21,217</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used in computing basic and diluted net loss per common share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,697,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>933,997</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,471,303</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.06</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(22.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.84</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=203,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=813943,FOLIO='F-14',FILE='DISK114:[15ZAD1.15ZAD72301]FM72301A.;91',USER='JTAM',CD='24-APR-2015;15:55' -->
<A NAME="page_fm72301_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. NET LOSS PER COMMON SHARE (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact
due to losses reported (in common stock equivalent shares): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro Forma Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Stock Options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>229,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>281,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>281,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrants</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,170</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18,809</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18,809</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Redeemable convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,552,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,552,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>55,298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. PREPAID EXPENSES AND OTHER CURRENT ASSETS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Prepaid expenses and other current assets consisted of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>253</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initial public offering costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>233</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Employee advances</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>656</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>527 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. PROPERTY AND EQUIPMENT  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Property and equipment consisted of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Machinery and equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computers and office equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>606</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>606 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total property and equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,409</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,417</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: accumulated deprecation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(716</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(903</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>514 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Depreciation
expense related to property and equipment amounted to $169 and $187 for the years ended December&nbsp;31, 2013 and 2014, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=204,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=504522,FOLIO='F-15',FILE='DISK114:[15ZAD1.15ZAD72301]FM72301A.;91',USER='JTAM',CD='24-APR-2015;15:55' -->
<A NAME="page_fm72301_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. ACCRUED EXPENSES  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Accrued expenses consisted of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>520</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>970</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>449</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>635</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued audit and legal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued interest</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total accrued expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,956 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. COMMITMENTS AND CONTINGENCIES  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Legal Proceedings  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From time to time the Company may face legal claims or actions in the normal course of business. The Company is not currently a party to any
litigation and, accordingly, does not have any amounts recorded for any litigation related matters. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's NDA filing for Xtampza is a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic
Equivalence Evaluations (commonly known as the "Orange Book"), in this case OxyContin OP. In connection with the 505(b)(2) process, the Company certified to the FDA and notified Purdue
Pharma,&nbsp;L.P. ("Purdue"), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for OxyContin OP in the Orange
Book. Under the Hatch-Waxman Act of 1984 (the "Hatch-Waxman Act"), Purdue can elect to sue the Company for infringement, and if they do, receive a stay of up to 30&nbsp;months before the FDA can
issue a final approval for Xtampza, unless the stay is earlier terminated. Purdue has not yet brought such litigation, but it is possible that they will do so. At this time the Company is unable to
provide meaningful quantification of how this potential litigation may impact its future financial condition, results of operations, or cash flows. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Operating Leases  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company leases its office and research facility under a non-cancellable operating lease, which expires in December 2017. Terms of the agreement
provide for an initial two-month rent-free period and future rent escalation, and provide that in addition to minimum lease rental payments, the Company is responsible for a pro-rata share of
operating expenses and taxes. Aggregate minimum annual lease commitments of the Company under its non-cancellable operating lease as of December&nbsp;31, 2014 are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="31pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:93pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ending December&nbsp;31,

<!-- COMMAND=ADD_SCROPPEDRULE,93pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>106</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>111</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>116 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total minimum lease payments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>333 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=205,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1007808,FOLIO='F-16',FILE='DISK114:[15ZAD1.15ZAD72301]FM72301A.;91',USER='JTAM',CD='24-APR-2015;15:55' -->
<A NAME="page_fm72301_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. COMMITMENTS AND CONTINGENCIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Rent
expense under the operating lease agreement amounted to approximately $69 for the years ended December&nbsp;31, 2013 and 2014, respectively. In addition, the Company maintained a stand-by
letter of credit in connection with the Canton facility lease of $80 at December&nbsp;31, 2013 and December&nbsp;31, 2014. This amount is classified as restricted cash in the balance sheets. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
an inducement to enter into its Canton facility lease, the lessor agreed to provide the Company with an improvement allowance of up to $174 towards leasehold improvements. In addition the lessor
provided the Company with a reimbursable allowance of $164 which is to be amortized and repaid by the Company at an 8% interest rate over the initial term of 36&nbsp;months. Amounts provided by the
lessor related to tenant improvements are considered inducements to enter into the lease. The Company has recorded these costs in the balance sheet as leasehold improvements, with the corresponding
liabilities as deferred lease incentive and lease note payable. These liabilities are amortized on a straight-line basis over the term of the lease. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. DEBT  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
On August&nbsp;28, 2012, the Company entered into a loan agreement ("Original Term Loan") with Silicon Valley Bank ("SVB") to borrow up to a maximum amount of $1,000. In August 2012, October 2012
and February 2013, the Company borrowed $250, $250 and $500, respectively. The Original Term Loan bore interest at a rate per annum of 2.25% above the prime rate fixed at the time of advance of the
Original Term Loan (5.50%). The Original Term Loan provided for interest-only payments for the first 12 months based on the date of each borrowing, and, thereafter, 36 monthly payments of principal
and interest. In connection with the Original Term Loan, the
Company granted SVB a warrant to purchase 23,810 shares of common stock at an exercise price of $0.07 per share (See Note&nbsp;9). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
January 2014, the Original Term Loan was amended ("Amendment No.&nbsp;1") to provide for the following; borrowings of up to $6,000, repayment in full of the Original Term Loan balance
outstanding, and an adjustment of the variable interest rate from 2.25% above the prime rate to 1.75% above the prime rate. In February 2014, the Company borrowed $2,000. The proceeds from the initial
borrowing were used to pay down the Original Term Loan balance outstanding resulting in the Company receiving $1,056. Borrowings under Amendment No.&nbsp;1 bore interest at a rate of 5.0%. Amendment
No.&nbsp;1 provided for interest-only payments for the first 12 months based on the date of each borrowing, and thereafter, 36 monthly payments of principal and interest. In connection with
Amendment No.&nbsp;1, the Company granted to SVB a warrant to purchase 14,430 shares of common stock with an exercise price of $0.05 per share (See Note&nbsp;9). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
August 2014 the Original Term Loan was further amended ("Amendment&nbsp;No.&nbsp;2") to provide for total borrowings of up to $8,000. In August 2014 and September 2014 the Company drew down
$3,000 and $3,000, respectively. Pursuant to Amendment No.&nbsp;2, interest-only payments are to be made for the first 12 months based on the date of each borrowing; thereafter, 36 monthly payments
of principal and interest are to be made. Borrowings under Amendment 2 bear interest at the rate of 5.0%. The warrant agreement contains a performance clause that the Company met, resulting in
additional financing extended and issuance of a warrant to purchase 86,580 additional shares of common stock with an exercise price of $0.05 per share (See Note&nbsp;9). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
September 2014, the Original Term Loan was further amended ("Amendment No.&nbsp;3") to extend the loan draw period through the earlier to occur of September&nbsp;30, 2014 and an Event of
Default. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=206,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=623087,FOLIO='F-17',FILE='DISK114:[15ZAD1.15ZAD72301]FM72301A.;91',USER='JTAM',CD='24-APR-2015;15:55' -->
<A NAME="page_fm72301_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. DEBT (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company capitalized deferred financing costs of approximately $38 in entering into the Original Term Loan, of which approximately $16 was repaid at the time of Amendment&nbsp;No.&nbsp;1 with
the remaining approximately $22 being amortized to interest expense over the term of the debt. The balance of deferred financing costs was approximately $15 and $7 at December&nbsp;31, 2013 and
December&nbsp;31, 2014 respectively. The total outstanding amount of the loans was $958 and $8,000 at December&nbsp;31, 2013 and December&nbsp;31, 2014 respectively. Interest expense on these
notes payable totaled $62 and $208 or the years ended December&nbsp;31, 2013 and December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November and December of 2014 the Company entered into a Note Purchase Agreement (the "Bridge Notes") allowing for the issuance of $5,000 of convertible promissory notes to a group of investors
(the "Holders") bearing interest at a rate per annum of 6.0%. The Holders are related parties of the Company. All notes become due and payable at the earlier to occur of a qualified financing, a
deemed liquidation event and November 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014, future payments under the Company's debt agreements are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,194</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,667</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,667</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,479 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13,007 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. WARRANTS  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>
In November 2010, the Company issued to Comerica Bank a warrant to purchase 33,746 shares of a series of then outstanding preferred stock with an exercise price of $1.778 per share through
October&nbsp;28, 2017. In February 2012, all outstanding shares of Preferred Stock were converted to shares of Series&nbsp;A Preferred Stock. As such the warrant was amended to be exercisable into
33,746 shares of Series&nbsp;A Preferred Stock. In December 2013, a Performance Adjustment (See Note&nbsp;10) occurred, pursuant to which the Series&nbsp;A Preferred Stock and common stock were
subject to modification such that every two shares of issued and outstanding Series&nbsp;A Preferred Stock and common stock became one share of each class respectively, resulting in the warrant
being adjusted to represent the right to purchase 16,873 shares of Series A Preferred Stock. The shares of Series&nbsp;A Preferred Stock have certain mandatorily redeemable features resulting in the
warrant being recorded as a liability and re-measured at each period at fair value. The fair value of the warrant was </FONT><FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2> at December&nbsp;31,
2013 and December&nbsp;31, 2014.

</FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>


In connection with the issuance of the Original Term Loan (See Note&nbsp;8), in August 2012, the Company issued to SVB a warrant to purchase 3,450 shares of common stock with an exercise price of
$0.48 per share through August&nbsp;27, 2022.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


This Performance Adjustment resulted in the number of common shares issuable upon exercise of the warrant being adjusted to 1,725.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


In connection with the execution of Amendment No.&nbsp;1 to the Original Term Loan in January 2014, the Company issued an additional warrant to the lending financial institution. In January 2014,
the Company issued a warrant to purchase 2,091 shares of common stock with an exercise price of $0.35 per share through January&nbsp;31, 2024. The warrant agreement provides for additional warrant
shares to be issued and

</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=207,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=22911,FOLIO='F-18',FILE='DISK114:[15ZAD1.15ZAD72301]FM72301A.;91',USER='JTAM',CD='24-APR-2015;15:55' -->
<A NAME="page_fm72301_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. WARRANTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


immediately exercisable upon additional borrowings by the Company. Additional borrowings are contingent upon meeting certain performance measures for the Company's lead product candidate. The Company
met the performance measures and in August 2014 additional financing was extended. Based on the terms of the warrant agreement an additional 12,548 shares were granted. The fair value of these
warrants was </FONT><FONT SIZE=2><I>de&nbsp;minimis</I></FONT><FONT SIZE=2> at December&nbsp;31, 2013 and December&nbsp;31, 2014.

</FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>
As of December&nbsp;31, 2013, the authorized capital stock of the Company included 72,000,000 shares of common stock, par value $0.001 per share, 962,960 of which were issued and outstanding. As of
December&nbsp;31, 2013, 54,481,000 shares of preferred stock were authorized, designated as Series&nbsp;A, Series&nbsp;B and Series&nbsp;C Preferred Stock of which 9,232,334, 27,324,237 and
8,658,008 were issued and outstanding, respectively.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>


As of December&nbsp;31, 2014, the authorized capital stock of the Company included 72,000,000 shares of common stock, par value $0.001 per share, 1,006,219 of which were issued and outstanding. As
of December&nbsp;31, 2014, 54,481,000 shares of preferred stock were authorized, designated as Series&nbsp;A, Series&nbsp;B and Series&nbsp;C Preferred Stock of which 9,232,334, 27,324,237 and
8,658,008 were issued and outstanding, respectively.

 </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The voting, dividend and liquidation rights of the holders of shares of common stock are subject to and qualified by the rights, powers and
preferences of the holders of shares of preferred stock. Common stock has the characteristics described herein. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Voting  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holders of shares of common stock are entitled to one vote for each share of common stock held, may act by written consent in lieu of
shareholder's meetings in accordance with the Company's articles of incorporation, and shall be entitled to notice of shareholder's meetings. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Dividends  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company shall not declare, pay or set aside any dividends on shares of common stock (other than dividends on shares of common stock payable in
shares of common stock) unless in addition to obtaining any consents required by law and/or the Company's articles of incorporation, the holders of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C
Preferred Stock then outstanding receive a dividend payment as specified in the Company's articles of incorporation. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=208,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=503154,FOLIO='F-19',FILE='DISK114:[15ZAD1.15ZAD72301]FM72301A.;91',USER='JTAM',CD='24-APR-2015;15:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fn72301_1_20"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data)  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY (Continued)  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Liquidation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After payment of all preferential amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Company
available for distribution to the shareholders shall be distributed among the holders of shares of Preferred Stock and common stock pro rata based on the number of shares held by each such holder,
treating for this purpose all such securities as if they had been converted to common stock pursuant to the terms of the Company's articles of incorporation immediately prior to such dissolution,
liquidation or winding up or deemed liquidation event of the Company. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Reserved for future issuance  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company has reserved for future issuance the following number of shares of common stock: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conversion of Series&nbsp;A Preferred</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18,498,419</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conversion of Series B Preferred</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>27,324,237</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conversion of Series C Preferred</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,658,344</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options to purchase common stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,412,685 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>57,893,685 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Redeemable Preferred Stock  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Series&nbsp;A, B and Series&nbsp;C Redeemable Convertible Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In February 2012, the Company exchanged all previously outstanding preferred stock into 18,464,674 shares of Series&nbsp;A Preferred Stock
("Series&nbsp;A"), par value $0.001. On the same date, the Company issued 27,324,237 shares of Series&nbsp;B Preferred Stock ("Series&nbsp;B"), par value $0.001 for $0.84 per share, which
resulted in gross proceeds of $20,050. Closing costs associated with the issuance of the Series&nbsp;B amounted to $147. These costs were recorded as a reduction of the carrying amount of the
Series&nbsp;B and are being accreted to the carrying value of the applicable preferred stock. During 2013, the Company issued 8,658,008 shares of Series&nbsp;C Preferred Stock ("Series&nbsp;C")
in exchange for $12,000 in a series of tranches. Costs incurred in connection with the issuance of Series&nbsp;C amounted to $45 and have been recorded as a reduction to the carrying amount of
Series&nbsp;C and were accreted to the carrying value of the applicable preferred stock. In accordance with the terms of the Series&nbsp;C Preferred Stock Purchase Agreement, the Company
authorized the sale and issuance of up to 8,658,008 shares of Series&nbsp;C for total gross proceeds of $12,000. Closing costs associated with the issuance of Series&nbsp;C amounted to $45. The
Series&nbsp;C financing was structured to close in two tranches. The Company determined the right of the investors to purchase shares of Series&nbsp;C in a future tranche met the definition of a
freestanding financial instrument and was recognized as a liability at fair value. The Company adjusted the carrying value of the tranche obligations to its estimated fair value at each reporting date
and upon closing of the second tranche in December 2013. Increases or decreases in the fair value of the tranche obligations were recorded as other expense, net, in the statements of operations. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
first tranche closed in August and September 2013 and resulted in the issuance of 2,886,004 shares of Series&nbsp;C for gross cash proceeds of $4,000. Upon the first tranche closing, the Company
recognized a liability of $266 for the fair value of the future tranche obligations. The fair value of the freestanding </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=209,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=659355,FOLIO='F-20',FILE='DISK114:[15ZAD1.15ZAD72301]FN72301A.;96',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_fn72301_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>instrument
tranche obligations was determined using Black-Scholes option-pricing models on the date of the issuance using the following assumptions: fair value of Series&nbsp;C of $1.30, expected
life of 0.35 to 0.43&nbsp;years and expected volatility of 53% to 60%. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
liability related to the tranche obligations was remeasured at fair value up to the date of the closing of the second tranche in December 2013. Upon the closing of the second tranche, the Company
derecognized the tranche obligation, which resulted in a net increase in the proceeds allocated to the Series&nbsp;C shares of $345. The fair value of the freestanding instrument tranche obligations
was determined using Black-Scholes option-pricing models on the date of the issuance using the following assumptions: fair value of Series&nbsp;C of $1.27, expected life of 0.16&nbsp;years and
expected volatility of 52%. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
valuation of the tranche obligation liability was determined to be a Level&nbsp;3 valuation based upon the use of unobservable inputs. A roll-forward of the recurring fair value measurements of
the tranche liability categorized with Level&nbsp;3 inputs are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance&nbsp;&#151; December 31, 2012</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tranche liability upon issuance</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tranche liability upon close of tranche</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(345</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance&nbsp;&#151; December&nbsp;31, 2013</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
closing of the second tranche of Series&nbsp;C in December 2013 triggered the Performance Adjustment (described below) of the outstanding shares of Series&nbsp;A and common stock to which the
Series&nbsp;A and common stock were subject to modification in which every two shares of issued and outstanding Series&nbsp;A and common shares became one share of each class respectively. In
connection with the Performance Adjustment, the Company adjusted the carrying value of the outstanding shares of Series&nbsp;A to its redemption amount by recording a decrease of $12,239. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014, the holders of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C Preferred Stock had rights, preferences, privileges and restrictions as follows: </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Voting  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holders of shares of Preferred Stock are entitled to the number of votes equal to the number of whole shares of common stock into which the shares
of the applicable series of Preferred Stock held by such holder are convertible as of the record date. Except as provided by law or otherwise, the holders of shares of Preferred Stock vote together
with the holders of shares of common stock as a single class. The holders of record of Series&nbsp;A exclusively and as a separate class are entitled to elect two directors of the Company. The
holders of record of Series&nbsp;B and Series&nbsp;C exclusively and as a separate class are entitled to elect one director, respectively, of the Company. The Company cannot amend, alter or repeal
the preferences, special rights or other powers of the Series&nbsp;A, Series&nbsp;B or Series&nbsp;C without the written consent or affirmative vote of not less than 66% of the then outstanding
shares of the respective class. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Dividends  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From and after the issuance of any shares of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C cumulative non-compounding stock, dividends will
accrue at a rate of 4.5%, 8.0% and 8.0% per annum respectively per share. In the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=210,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=679030,FOLIO='F-21',FILE='DISK114:[15ZAD1.15ZAD72301]FN72301A.;96',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_fn72301_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>event
a dividend is declared on common stock, Series&nbsp;A, Series&nbsp;B and Series&nbsp;C will receive a dividend equal to the equivalent number of common shares multiplied by the dividend
payable on each class of stock. The Company has recorded cumulative accrued dividends for Series&nbsp;A, Series&nbsp;B and Series&nbsp;C of $2,371, $5,307 and $1,114, respectively, as of
December&nbsp;31, 2013 and 2014. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Conversion  </I></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>Each share of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C is convertible at the option of the holder at any time into such number of fully
paid and nonassessable shares of common stock as is determined by dividing the original issue price of each Series by its conversion price of $8.46, $5.80 and $9.59 per share, respectively.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>


Conversion is mandatory for all Series upon an IPO with gross proceeds in excess of $50,000 and a price per share of at least $20.70.

 </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Special Mandatory Conversion  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any holder of at least 1,000,000 shares of Preferred Stock who does not participate in a Qualified Financing by purchasing such holder's applicable
portion of the shares of each Preferred Stock, within the time period specified by the Company, are automatically converted into shares of Common Stock at the applicable Conversion Price to that
series of Preferred Stock concurrently with the Qualified Financing. A Qualified Financing is a financing or series of financings after the issuance date of the Series&nbsp;C involving the sale of
additional shares of common stock (including pursuant to the conversion of debt) with gross proceeds of more than $1,000. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Liquidation Rights  </I></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the affairs of the Company or a Deemed Liquidation Event, the
holders of Series&nbsp;B are entitled to be paid out an amount per share equal to two times the Series&nbsp;B original issue price of $5.80 plus unpaid accrued dividends. The holders of
Series&nbsp;A and Series&nbsp;C are entitled to be paid out an amount per share equal to one times the original issue price of $8.46 and $9.59, respectively, plus any unpaid accrued dividends.
After the payment of all preferential amounts required to be paid to the holders of the Preferred Stock, all the remaining assets of the Company shall be distributed among the holders of the common
and Preferred Stock pro rata based on the number of shares held.

 </FONT>

</P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Participation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the event of liquidation, payment to the holders of Series&nbsp;C shall precede payment to the holders of Series&nbsp;B, which shall precede
payment to the holders of Series&nbsp;A. Holders of Series&nbsp;C shall be paid at their Original Issuance Price plus any unpaid accrued dividends. In the event that the amount to be distributed
to the shareholders is in excess of the Series&nbsp;A, Series&nbsp;B and Series&nbsp;C liquidation preferences, the preferred holders shall participate on an as-converted basis with the common
stock holders in the distribution of the remaining assets. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Redemption  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company shall require a redemption of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C in the event of a deemed liquidation event, including
(i)&nbsp;merger or consolidation, (ii)&nbsp;sale or transfer of substantially all of the Company's assets or (iii)&nbsp;sale or exchange or transfer by the Company's shareholders of a majority
of the voting power of the Company unless the requisite holders (as defined in the Company's articles of incorporation) elect otherwise. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=211,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=430589,FOLIO='F-22',FILE='DISK114:[15ZAD1.15ZAD72301]FN72301A.;96',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_fn72301_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
is an optional redemption feature on or after August&nbsp;27, 2019 for all series of Preferred Stock, upon a vote of at least 60% of the holders of the Preferred Stock voting as a single
class. The payment is equal to the original issuance price for Series&nbsp;A and Series&nbsp;C and two (2)&nbsp;times the original issuance price for Series&nbsp;B, plus unpaid accrued
dividends on the date of the redemption. Optional redemption shall be paid in three installments. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Protective Provision  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At any time when there are shares of Series&nbsp;B and Series&nbsp;C outstanding the Company will not engage in certain activities (including
enter into a liquidating event) without written consent of a majority of the Series&nbsp;B and Series&nbsp;C holders. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Performance Adjustment  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company's articles of incorporation provided that if the Company raised additional capital in excess of $4,000 after the initial closing of the
Series&nbsp;C financing, that such additional financing would trigger a one-time modification of the Series&nbsp;A and common stock shares (the "Performance Adjustment"), such that every two
shares of issued and outstanding Series A and common stock became one share of each class, respectively. The Performance Adjustment occurred in December 2013. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. STOCK-BASED COMPENSATION  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Restricted Stock Awards and Stock Options  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>In July 2014, the Company adopted the 2014 Stock Incentive Plan (the "Plan"), under which 525,700 shares of common stock are authorized for issuance
to employees, officers, directors, consultants and advisors of the Company. As of December&nbsp;31, 2014, 281,029 of the shares of common stock authorized for issuance pursuant to the Plan were
outstanding. In connection with the Company's reincorporation into Virginia in July 2014, each outstanding option to purchase shares of common stock under the 2012 Stock Incentive Plan and 2002 Stock
Plan, was automatically terminated and replaced with an option to purchase shares of common stock under the Plan having the same vesting terms and exercise price as the option that was replaced. The
Plan provides for granting of both Internal Revenue Service qualified incentive stock options ("ISOs") and non-qualified options ("NQs"), restricted stock awards ("RSAs") and restricted stock units
("RSUs"). Stock options generally vest over a four year period of service; however, certain options contain performance
conditions. The options generally have a ten year contractual life and, upon termination, vested options are generally exercisable between one and three months following the termination date, while
unvested options are forfeited immediately.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>In
determining the exercise prices for options granted, the board of directors considered the fair value of the common stock as of the measurement date. The fair value of the common stock was
determined by the board of directors based on a variety of factors, including valuations prepared by third parties, Company's financial position, the status of development efforts within the Company,
the composition and ability of the current scientific and management teams, the current climate in the marketplace, the illiquid nature of the Company's common stock, arm's length sales of the
Company's preferred stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the Performance Adjustment which occurred on December&nbsp;4, 2013 (See Note&nbsp;10) the Company adjusted previously granted and then outstanding options such that for each
option exercised, the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=212,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=794954,FOLIO='F-23',FILE='DISK114:[15ZAD1.15ZAD72301]FN72301A.;96',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_fn72301_1_24"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>option
holder would receive one share of common stock for every two shares of common stock underlying the grant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Stock
option activity under the Plan is summarized as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number<BR>
of Options </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted-<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted-<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Term<BR>
(in years) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Aggregate<BR>
Intrinsic<BR>
Value </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Outstanding at December&nbsp;31, 2012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
323,488</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>146,730</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(9,559</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Modification</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(229,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>229,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7.02</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>117</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>89,641</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(32,390</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(6,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
281,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7.49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,505 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and expected to vest at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
247,139</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,293</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
121,304</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2013 and 2014, the unrecognized compensation cost related to outstanding options was $40 and $215, respectively, and is expected to be recognized as expense over
approximately 1.1&nbsp;years and 1.0&nbsp;years, respectively. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>


As of December&nbsp;31, 2014, the weighted average fair value of vested options was $1.93.

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additional
information about the Company's stock option activity is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Weighted-average grant date fair value per share of employee option grants</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.28</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.76</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=213,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=395155,FOLIO='F-24',FILE='DISK114:[15ZAD1.15ZAD72301]FN72301A.;96',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_fn72301_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Restricted
stock awards under the Plan are summarized as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted-Average<BR>
Grant Date<BR>
Fair Value </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Unvested at December&nbsp;31, 2012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
203,342</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vesting of restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(89,308</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Performance Adjustment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(58,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.62 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested at December&nbsp;31, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>55,298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Grant of restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,869</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vesting of restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(50,780</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.62 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
15,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.69 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2013 and 2014, the unrecognized compensation cost related to restricted stock awards was $73 and $26, respectively, and is expected to be recognized as expense over
approximately 1.2&nbsp;years and 0.2 years, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stock-Based Compensation Expense  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company granted stock options to employees for the years ended December&nbsp;31, 2013 and 2014. The Company estimates the fair value of stock
options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the award. Stock options and restricted stock issued to non-board member,
non-employees are accounted for using the fair value approach and are subject to periodic revaluation over their vesting terms. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Stock-based
compensation for all stock options and restricted stock awards are reported within: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stock-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="97pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.09%&nbsp;&#150;&nbsp;1.22%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>87.8%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=214,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=312818,FOLIO='F-25',FILE='DISK114:[15ZAD1.15ZAD72301]FN72301A.;96',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_fn72301_1_26"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Risk-free Interest Rate.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock option grants. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> Expected Volatility.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Due to the Company's limited operating history and lack of company-specific historical or implied volatility, the expected volatility
assumption is based on historical volatilities of a peer group of similar
companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology and medical device industries. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Expected Term.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise
behavior, through December&nbsp;31, 2014 it determined the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. In
2013, some of the stock option grants were in-the-money, based on the retrospective fair value determinations, so the Company determined the expected life using a risk-adjusted method, which adjusts
the average of the contractual term of the option and its vesting period for risk, thereby reducing the expected life. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Expected Dividend Yield.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to
pay cash dividends. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12.&nbsp;INCOME TAXES  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
For the years ended December&nbsp;31, 2014 and 2013, the Company did not record a current or deferred income tax expense or (benefit) due to current and historical losses incurred by the Company.
The Company's losses before income taxes consist solely of domestic losses. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>A
reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal income tax (benefit) at statutory rate</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>(Increase) decrease income tax (benefit) resulting from:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expiration of state net operating losses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (12.11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Permanent items</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(0.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (0.17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and experimental credits</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in valuation allowance</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (26.07</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (37.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax expense (benefit)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=215,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=663930,FOLIO='F-26',FILE='DISK114:[15ZAD1.15ZAD72301]FN72301A.;96',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_fn72301_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12.&nbsp;INCOME TAXES (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Deferred
taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company's
deferred tax assets and liabilities are comprised of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net operating loss carryforwards</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>21,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>28,419</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research Credits</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,070 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets before valuation allowance</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>23,792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(23,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(31,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December&nbsp;31, 2014 and 2013, based on the Company's history of
operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation
allowance for deferred tax assets as of December&nbsp;31, 2014
and 2013. The valuation allowance increased $7,737 during the year ended December&nbsp;31, 2014, due primarily to net operating losses generated. The valuation allowance increased by $5,081 during
the year ended December&nbsp;31, 2013, due primarily to net operating losses generated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014 and 2013, the Company had U.S. federal net operating loss carryforwards of $78,276 and $60,380, respectively, which may be available to offset future income tax
liabilities and expire at various dates through 2034. As of December&nbsp;31, 2014 and 2013, the Company also had U.S. state net operating loss carryforwards of $34,184 and $16,354, respectively,
which may be available to offset future income tax liabilities and expire at various dates through 2034. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Utilization
of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred or that could occur in
the future, as required by Section&nbsp;382 and Section&nbsp;383 of the Internal Revenue Code of 1986, as amended (the "Code"), as well as similar state and foreign provisions. These ownership
changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an
"ownership change" as defined by Section&nbsp;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than
50&nbsp;percentage points of the outstanding stock of a company by certain shareholders. The Company has not completed a study to assess whether an ownership change has occurred or whether there
have been multiple ownership changes since its formation. The Company has not recorded net operating losses that, as a result of these restrictions, will expire unused. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=216,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=630671,FOLIO='F-27',FILE='DISK114:[15ZAD1.15ZAD72301]FN72301A.;96',USER='WWASSER',CD='24-APR-2015;15:34' -->
<A NAME="page_fn72301_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL, INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12.&nbsp;INCOME TAXES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company files income tax returns in the United States and Massachusetts. The federal and Massachusetts income tax returns are generally subject to tax examinations for the tax years ended
December&nbsp;31, 2011 through December&nbsp;31, 2013. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon
examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. EMPLOYEE BENEFITS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
The Company has a retirement savings plan, which is qualified under section&nbsp;401(k) of the Code, for its employees. The plan allows eligible employees to defer, at the employee's discretion,
pretax compensation up to the Internal Revenue Service annual limits. Employees become eligible to participate after completing 3&nbsp;months of service. The Company is not required to contribute to
this plan. Total expense for contributions made by the Company was $31 for the year ended December&nbsp;31, 2013 and $35 for the year ended December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. SUBSEQUENT EVENTS  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>
The Company has completed an evaluation of all subsequent events through April&nbsp;27, 2015, the date these financial statements are available to be issued. The Company has concluded that no
subsequent event has occurred that requires disclosure, except as noted below:

 </FONT>

</P>


<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
March 2015, the Company sold 41,666,667 shares of Series D convertible preferred stock for aggregate consideration of $50,000, comprised of $45,000 in
cash and conversion of $5,000 in convertible notes with related parties. The convertible notes converted into 4,166,667 shares of Series&nbsp;D convertible preferred stock. The accrued interest on
the convertible notes was waived. In this financing, the mandatory conversion for all series of preferred stock was modified so as to occur upon an initial public offering with gross proceeds in
excess of $50,000.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>On
March 24, 2015, Purdue sued the Company in the District of Delaware asserting infringement of four patents. On March 26, 2015, Purdue filed a second suit
against the Company in the District of Massachusetts asserting infringement of the same four patents.


<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
March 2015, the Company granted a total of 638,095 stock options under the Plan to employees. The stock options were granted at fair market value on the
date of grant, vest over approximately four years and expire ten years from the date of grant.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
March 2015, the Plan was amended to increase the maximum number authorized for issuance pursuant to the Plan to 1,087,005 shares.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(e)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
March 2015, the Company amended its lease to include an additional 9,660 square feet of space for a total of 19,335 square feet. In addition, the lease
term was extended and now terminates on the date that is 5&nbsp;years following the date, which has not yet been determined, on which the landlord delivers the expansion space with certain
improvements substantially completed. At the Company's election, the lease term may be extended for an additional 5-year term.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(f)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
April 2015, the Company granted 194,694 shares of restricted stock to an employee. Pursuant to the grant, 97,347 shares vested upon grant, while the
remaining 97,347 shares of restricted stock vest in monthly installments over a three-year period commencing as of the date of grant.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(g)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
April 2015, the Company's board of directors and shareholders approved a one-for-6.9 reverse split of the Company's common stock. All common stock share
and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse split of our common stock, including reclassifying an amount
equal to the reduction in par value to additional paid-in capital.

 </FONT></DD>

</DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=217,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=299200,FOLIO='F-28',FILE='DISK114:[15ZAD1.15ZAD72301]FN72301A.;96',USER='WWASSER',CD='24-APR-2015;15:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the 25<SUP>th</SUP>&nbsp;day
after the date of this prospectus), all dealers effecting transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with
respect to their unsold allotments or subscriptions. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;">


<FONT SIZE=4><B>5,800,000 Shares


 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>
<IMG SRC="g603081.jpg" ALT="LOGO" WIDTH="307" HEIGHT="66">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B>Collegium Pharmaceutical,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>PRELIMINARY PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Jefferies  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Piper Jaffray  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Wells Fargo Securities  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Needham &amp; Company  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </FONT></P>
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=218,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=966448,FOLIO='blank',FILE='DISK114:[15ZAD1.15ZAD72301]HO72301A.;20',USER='VRIVERA',CD='24-APR-2015;06:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ja72301_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ja72301_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II<BR>  INFORMATION NOT REQUIRED IN PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja72301_item_13._other_expense__ja701986"> </A>
<A NAME="toc_ja72301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth all expenses, other than underwriting discounts and commissions, paid or payable by us in connection with this
offering. All amounts shown are estimates except for the SEC registration fee, the Financial Industry Regulatory Authority, or FINRA, filing fee and NASDAQ listing fee. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount Paid<BR>
or to be Paid </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> SEC registration fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,851</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FINRA filing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,507</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ Global Market listing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>125,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Blue sky qualification fees and expenses, if any</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing and engraving expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>275,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,725,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>375,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transfer agent and registrar fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>39,642</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,600,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja72301_item_14._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja72301_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Virginia Stock Corporation Act  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a Virginia corporation. The Virginia Stock Corporation Act, or the VSCA, permits indemnification of a corporation's directors and officers in a
variety of circumstances, which may include indemnification for liabilities under the Securities Act. Sections&nbsp;13.1-696 and 13.1-704 of the VSCA generally authorize a Virginia corporation to
indemnify its directors and officers in civil or criminal actions if they acted in good faith and believed their conduct to be in the best interests of the corporation if acting in their official
capacity with the corporation or, in all other cases, at least not opposed to its best interests, and, in the case of
criminal actions, had no reasonable cause to believe that the conduct was unlawful. Additionally, Section&nbsp;13.1-704 of the VSCA provides that a Virginia corporation has the power to make any
further indemnity to any director or officer, including in a proceeding brought by or in the right of the corporation, if authorized by its articles of incorporation or any bylaw or resolution adopted
by the shareholders, except an indemnity against his or her willful misconduct or a knowing violation of the criminal law. Our amended and restated articles of incorporation require us to indemnify
our directors and officers to the full extent permitted by the VSCA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated articles of incorporation also provide that, to the full extent that the VSCA permits the limitation or elimination of the liability of directors and officers, no director or
officer of the Company shall be liable in any proceeding brought by or on behalf of the Company or its shareholders for monetary damages arising out of any transaction, occurrence or course of
conduct. Section&nbsp;13.1-692.1 of the VSCA permits the elimination of liability of directors and officers in any proceeding brought by or in the right of a corporation or brought by or on behalf
of shareholders of a corporation, except for liability resulting from such persons having engaged in willful misconduct or a knowing violation of the criminal law or any federal or state securities
law, including, without limitation, any unlawful insider trading or manipulation of the market for any security. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=219,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=507415,FOLIO='II-1',FILE='DISK114:[15ZAD1.15ZAD72301]JA72301A.;40',USER='LPALLES',CD='24-APR-2015;13:26' -->
<A NAME="page_ja72301_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have or will enter into indemnification agreements with each of our directors and officers pursuant to which we agree to indemnify, including advancing expenses to, each of them against any
liabilities that he or she may incur as a result of his or her service as a director or officer of the Company to the fullest extent permitted by Virginia law and our amended and restated articles of
incorporation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
carry insurance on behalf of directors, officers, employees or agents that may cover liabilities under the Securities Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
form of underwriting agreement attached hereto as Exhibit&nbsp;1.1 provides for indemnification by the underwriters named in this registration statement of our executive officers, directors and
us, and by us of the underwriters named in the registration statement, for certain liabilities, including liabilities arising under the Securities Act, in connection with matters specifically provided
in writing for inclusion in this registration statement.  </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja72301_item_15._recent_sales_of_unregistered_securities."> </A>
<A NAME="toc_ja72301_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the three years preceding the filing of this registration statement, we (since our reincorporation in Virginia in July 2014) and our
predecessor Delaware corporation (prior to such reincorporation), issued unregistered securities in the following transactions. None of these transactions involved underwriters, underwriting discounts
or commissions, or any public offering, and we believe that each transaction was exempt from the registration requirements of the Securities Act, as described below. </FONT></P>

<UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;(i)&nbsp;&nbsp;Issuances
of Common Stock </FONT></P>


</UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In April 2015, we issued 194,694 shares of restricted common stock to Michael T.
Heffernan. Pursuant to the grant, 97,347 of the shares of restricted common stock vested upon grant while the remaining 97,347 shares of restricted common stock vest in monthly installments over a
three-year period commencing as of the date of the grant; </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with our reincorporation into Virginia in July 2014, each
outstanding share of common stock was converted into one share of common stock of the new Virginia corporation. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with the closing of the second tranche of our Series&nbsp;C
Convertible Preferred Stock financing in December 2013, every two issued and outstanding shares of common stock were reclassified and combined into one share of common stock. </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On June&nbsp;13, 2012, we issued 247,437 restricted shares of common stock,
which have since vested, to Michael T. Heffernan under the 2012 Stock Incentive Plan.


</FONT></DD>

</DL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;(ii)&nbsp;&nbsp;Issuances
of Preferred Stock </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In March 2015, we issued 41,666,667 shares of our Series D Convertible Preferred
Stock to TPG Biotechnology Partners IV, L.P., RA Capital Healthcare Fund, LP, the Longitude Funds, Skyline Venture Partners V, L.P., Frazier Healthcare VI, L.P., the Boston Millennia Funds and certain
other investors, at a purchase price of $1.20 per share, for an aggregate purchase price of approximately $50.0 million. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with our reincorporation into Virginia in July 2014, each
outstanding share of Series&nbsp;A Convertible Preferred Stock, Series&nbsp;B Convertible Preferred Stock and Series&nbsp;C Convertible Preferred Stock was converted into one share of
Series&nbsp;A Convertible Preferred Stock, Series&nbsp;B Convertible Preferred Stock and Series&nbsp;C Convertible Preferred Stock, respectively, of the new Virginia corporation. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with the closing of the second tranche of our Series&nbsp;C
Convertible Preferred Stock financing in December 2013, every two issued and outstanding shares of Series&nbsp;A Convertible Preferred Stock were reclassified and combined into one share of
Series&nbsp;A Convertible Preferred Stock. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In December 2013, those investors who participated in the closings in August and
September 2013 exercised their option to purchase an additional pro rata portion of an aggregate of </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=220,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=70573,FOLIO='II-2',FILE='DISK114:[15ZAD1.15ZAD72301]JA72301A.;40',USER='LPALLES',CD='24-APR-2015;13:26' -->
<A NAME="page_ja72301_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;"><FONT SIZE=2>5,772,004
shares of our Series&nbsp;C Convertible Preferred Stock, at a purchase price of $1.386 per share, for an aggregate purchase price of approximately $8&nbsp;million. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On August&nbsp;27, 2013, we issued 2,220,670 shares of our Series&nbsp;C
Convertible Preferred Stock to the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P. and certain other existing investors in the Company, at a purchase price
of $1.386 per share, for an aggregate purchase price of approximately $3.1&nbsp;million, or the Initial Tranche&nbsp;1 Closing. On September&nbsp;25, 2013, we issued and sold an additional
665,334 shares of Series&nbsp;C Convertible Preferred Stock to certain of our investors, some of whom did not participate in the Initial Tranche&nbsp;1 Closing and who qualified as "accredited
investors" under Regulation&nbsp;D of the Securities Act, at a purchase price of $1.386 per share, for an aggregate purchase price of approximately $922,000, or the Additional Tranche&nbsp;1
Closing. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On February&nbsp;10, 2012, we issued an aggregate of 27,324,237 shares of
Series&nbsp;B Convertible Preferred Stock to the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare&nbsp;VI,&nbsp;L.P., the Boston Millennia Funds and certain other
investors, at a purchase price of $0.84 per share, for an aggregate purchase price of approximately $23.0&nbsp;million. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On February&nbsp;10, 2012, in connection with our Series&nbsp;B Convertible
Preferred Stock financing, all issued and outstanding shares of previously issued Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C Preferred Stock, Series&nbsp;C-2
Preferred Stock and Series&nbsp;D-1 Preferred Stock were converted into shares of Series&nbsp;A Convertible Preferred Stock. In connection with this financing, we issued an aggregate of 18,464,674
shares of Series&nbsp;A Convertible Preferred Stock. </FONT></DD></DL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>(iii)&nbsp;&nbsp;Issuance
of Convertible Notes </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In November and December 2014, we entered into a Convertible Note Purchase
Agreement, pursuant to which we issued and sold to investors convertible promissory notes in the aggregate principal amount of $5&nbsp;million. The participants in the convertible note financing
described above included the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P. and the Boston Millennia Funds. In connection with the Series&nbsp;D
Convertible Stock financing, convertible notes in the aggregate principal amount of $5 million automatically converted to an aggregate of 4,166,667 shares of Series&nbsp;D Convertible Preferred
Stock. </FONT></DD></DL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;(iv)&nbsp;&nbsp;Stock
Option Grants </FONT></P>


</UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In March 2015, we granted options to purchase an aggregate of 638,095 shares of
our common stock with an exercise price of $5.73 per share to 24 employees and 1 director. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with our reincorporation into Virginia in July 2014, each
outstanding option to purchase shares of common stock under the 2012 Stock Incentive Plan, as amended, and the Amended and Restated 2002 Stock Option Plan, as amended, was automatically terminated and
replaced with an option to purchase shares of common stock under the 2014 Stock Incentive Plan having the same vesting terms and exercise price as the option that was replaced. </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On March&nbsp;5, 2014, we granted options to purchase an aggregate of 89,641
shares of our common stock with an exercise price of $0.28 per share to 16 employees. </FONT><FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On May&nbsp;30, 2013, we granted options to purchase an aggregate of 79,778
shares of our common stock with an exercise price of $0.48 per share to 2 employees. </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On January&nbsp;24, 2013, we granted options to purchase an aggregate of
66,952 shares of our common stock with an exercise price of $0.48 per share to 14 employees. </FONT><FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On December&nbsp;20, 2012, we granted options to purchase an aggregate of 724
shares of our common stock with an exercise price of $0.48 per share to 1 employee. </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On August&nbsp;16, 2012, we granted options to purchase 72,462 shares of our
common stock with an exercise price of $0.48 per share to 1 employee. </FONT><FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On May&nbsp;10, 2012, we granted options to purchase an aggregate of 39,275
shares of our common stock with an exercise price of $0.48 per share to 9 employees.

 </FONT></DD>

</DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=221,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=409194,FOLIO='II-3',FILE='DISK114:[15ZAD1.15ZAD72301]JA72301A.;40',USER='LPALLES',CD='24-APR-2015;13:26' -->
<A NAME="page_ja72301_1_4"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;(v)&nbsp;&nbsp;Warrants</FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with our reincorporation into Virginia in July 2014, each warrant
to purchase shares of Series&nbsp;A Convertible Preferred Stock and each warrant to purchase shares of our common stock was assumed by the new Virginia corporation. </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On August&nbsp;28, 2012, in connection with the closing of the Original Term
Loan, we issued the First SVB Warrant, which warrant was immediately exercisable for 3,450 shares of our common stock at an exercise price of $0.48 per share. Pursuant to the December 2013 reverse
stock split, the number of shares underlying the First SVB Warrant was adjusted to 1,725 shares of common stock. On January&nbsp;31, 2014, in connection with the closing of Amendment No.&nbsp;1 to
the Original Term Loan, we issued the Second SVB Warrant, which warrant was immediately exercisable for 2,091 shares of our common stock at an exercise price of $0.35 per share. Pursuant to an
adjustment mechanism included in the Second SVB Warrant, the Second SVB Warrant automatically became exercisable for an additional 12,548 shares of our common stock.

 </FONT></DD>

</DL>

<P style="font-family:arial;"><FONT SIZE=2>We
believe these transactions, including the issuance of new securities in connection with our reincorporation in Virginia, were exempt from registration under the Securities Act in reliance upon
Section&nbsp;4(a)(2) of the Securities Act, or Regulation&nbsp;D promulgated thereunder, or Rule&nbsp;701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer
not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule&nbsp;701. The recipients of the securities in each of these transactions
represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the
stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about Collegium.  </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja72301_item_16._exhibits_and_financial_statement_schedules."> </A>
<A NAME="toc_ja72301_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>(a)&nbsp;&nbsp;&nbsp;Exhibits.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>See the Index to Exhibits attached to this registration statement, which is incorporated by reference herein. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>(b)&nbsp;&nbsp;&nbsp;Financial statement schedule.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja72301_item_17._undertakings."> </A>
<A NAME="toc_ja72301_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements, certificates in
such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by
a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=222,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=396131,FOLIO='II-4',FILE='DISK114:[15ZAD1.15ZAD72301]JA72301A.;40',USER='LPALLES',CD='24-APR-2015;13:26' -->
<A NAME="page_ja72301_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
undersigned registrant hereby undertakes that: </FONT></P>

<UL>

<P style="font-family:arial;"><FONT SIZE=2>(1)&nbsp;&nbsp;For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in
reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
part of this registration statement as of the time it was declared effective. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>(2)&nbsp;&nbsp;For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona
fide</I></FONT><FONT SIZE=2> offering thereof. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=223,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=684668,FOLIO='II-5',FILE='DISK114:[15ZAD1.15ZAD72301]JA72301A.;40',USER='LPALLES',CD='24-APR-2015;13:26' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_jc72301_1_6"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="jc72301_signatures"> </A>
<A NAME="toc_jc72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the Town of Canton, Commonwealth of Massachusetts, on the 27<SUP>th</SUP> day of April, 2015.

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="46%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:arial;"><FONT SIZE=2><B>COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>  By:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2>/s/&nbsp;MICHAEL T. HEFFERNAN, R.PH.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael T. Heffernan, R.Ph.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>


Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated below:


</FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="35%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="35%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="136pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:34pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,34pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:16pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,16pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><BR>
&nbsp;</B></FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><BR>&nbsp;</B></FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><BR>
&nbsp;</B></FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><BR>&nbsp;</B></FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><BR>
&nbsp;</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>/s/&nbsp;MICHAEL T. HEFFERNAN, R.PH.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael T. Heffernan, R.Ph.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>President, Chief Executive Officer (Principal Executive Officer) and Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>April 27, 2015</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Paul Brannelly</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>April 27, 2015</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Garen G. Bohlin</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>April 27, 2015</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> John G. Freund, M.D.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>April 27, 2015</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Patrick Heron</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>April 27, 2015</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> David Hirsch, M.D., Ph.D.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>April 27, 2015</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Eran Nadav, Ph.D.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>April 27, 2015</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Gino Santini</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>April 27, 2015</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="218pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2> *</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>/s/&nbsp;MICHAEL T. HEFFERNAN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Name: Michael T. Heffernan<BR>
Title: Attorney-in-Fact</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=224,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=170285,FOLIO='II-6',FILE='DISK114:[15ZAD1.15ZAD72301]JC72301A.;45',USER='VRIVERA',CD='24-APR-2015;06:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_je72301_1_7"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="je72301_index_to_exhibits"> </A>
<A NAME="toc_je72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  INDEX TO EXHIBITS    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Number </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Underwriting Agreement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Agreement and Plan of Merger, dated July&nbsp;10, 2014, by and between Collegium Pharmaceutical,&nbsp;Inc., a Delaware corporation, and Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation.<SUP>(1)
</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Amended and Restated Articles of Incorporation of Collegium Pharmaceutical,&nbsp;Inc., as currently in effect.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Articles of Amendment to Amended and Restated Articles of Incorporation.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Second Amended and Restated Articles of Incorporation of Collegium Pharmaceutical,&nbsp;Inc. to be effective upon the completion of this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Bylaws of Collegium Pharmaceutical,&nbsp;Inc., as currently in effect.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Amended and Restated Bylaws of Collegium Pharmaceutical,&nbsp;Inc. to be effective upon the completion of this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Convertible Promissory Note.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Seventh Amended and Restated Stockholders Agreement, dated March&nbsp;6, 2015, by and among Collegium Pharmaceutical,&nbsp;Inc. and certain of its shareholders.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Eighth Amended and Restated Investor Rights Agreement, dated March&nbsp;6, 2015, by and among Collegium Pharmaceutical,&nbsp;Inc. and certain of its shareholders.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Preferred Shareholder Agreement, dated November&nbsp;26, 2014, by and among Collegium Pharmaceutical,&nbsp;Inc., Boston Millennia Partners and certain of its preferred shareholders.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Warrant to Purchase Stock, dated October&nbsp;28, 2010, issued by Collegium Pharmaceutical,&nbsp;Inc. to Comerica Bank.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Warrant to Purchase Stock, dated January&nbsp;31, 2014, issued by Collegium Pharmaceutical,&nbsp;Inc. to Silicon Valley Bank.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Warrant to Purchase Stock, dated August&nbsp;28, 2012, issued by Collegium Pharmaceutical,&nbsp;Inc. to Silicon Valley Bank.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Amendment No. 1 to the Sixth Amended and Restated Stockholders Agreement, dated January&nbsp;29, 2015, by and among Collegium Pharmaceutical, Inc. and certain of its shareholders.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Opinion of Pepper Hamilton&nbsp;LLP.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Office Lease Agreement, dated August&nbsp;28, 2012, by and between 780 Dedham Street Holdings,&nbsp;LLC and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Loan and Security Agreement, dated August&nbsp;28, 2012, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>First Amendment to Loan and Security Agreement, dated January&nbsp;31, 2014, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Assumption and Second Amendment to Loan and Security Agreement, dated August&nbsp;12, 2014, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Third Amendment to Loan and Security Agreement, dated September&nbsp;25, 2014, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=225,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=375915,FOLIO='II-7',FILE='DISK114:[15ZAD1.15ZAD72301]JE72301A.;43',USER='LPALLES',CD='24-APR-2015;13:26' -->
<A NAME="page_je72301_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Number </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 10.6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Fourth Amendment to Loan and Security Agreement, dated October&nbsp;31, 2014, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Series&nbsp;B Convertible Preferred Stock Purchase Agreement, dated February&nbsp;10, 2012, by and among Collegium Pharmaceutical,&nbsp;Inc. and the purchasers thereto.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Series&nbsp;C Convertible Preferred Stock Purchase Agreement, dated August&nbsp;27, 2013, by and among Collegium Pharmaceutical,&nbsp;Inc. and the purchasers thereto.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Amendment No. 1 to Series C Convertible Preferred Stock Purchase Agreement, dated September&nbsp;24, 2013, by and among Collegium Pharmaceutical, Inc. and the purchasers thereto.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Convertible Note Purchase Agreement, dated November&nbsp;14, 2014, by and among Collegium Pharmaceutical,&nbsp;Inc. and the purchasers thereto.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Subordination Agreement, dated November&nbsp;14, 2014, by and among Collegium Pharmaceutical,&nbsp;Inc., Silicon Valley Bank and the creditors named therein.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Subordination Agreement, dated December&nbsp;2, 2014, by and among Collegium Pharmaceutical,&nbsp;Inc., Silicon Valley Bank and the creditors named therein.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Employment Agreement, dated June&nbsp;13, 2012, by and between Collegium Pharmaceutical,&nbsp;Inc. and Michael T. Heffernan.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Amendment to Employment Agreement, dated September&nbsp;10, 2013, by and between Collegium Pharmaceutical,&nbsp;Inc. and Michael T. Heffernan.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Restricted Stock Award Agreement, dated June&nbsp;13, 2012, by and between Collegium Pharmaceutical,&nbsp;Inc. and Michael T. Heffernan.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.16</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Employment Agreement, dated May&nbsp;30, 2012, by and between Collegium Pharmaceutical,&nbsp;Inc. and Ernest A. Kopecky.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.17</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Employment Agreement, dated March&nbsp;13, 2013, by and between Collegium Pharmaceutical,&nbsp;Inc. and Douglas R. Carlson.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.18</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Restricted Stock Award Agreement, dated July&nbsp;18, 2012, by and between Collegium Pharmaceutical,&nbsp;Inc. and Gino Santini.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.19</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Restricted Stock Award Agreement, dated March&nbsp;5, 2014, by and between Collegium Pharmaceutical,&nbsp;Inc. and Gino Santini.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.20(A)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>2014 Stock Incentive Plan.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.20(B)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Incentive Stock Option Agreement Granted Under 2014 Stock Incentive Plan (Originally Granted under 2002 Stock Option Plan).<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.20(C)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Non-Statutory Stock Option Agreement Granted Under 2014 Stock Incentive Plan (Originally Granted under 2002 Stock Option Plan).<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.20(D)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Incentive Stock Option Agreement Granted Under 2014 Stock Incentive Plan (Originally Granted under 2012 Stock Option Plan).<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.20(E)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Non-Statutory Stock Option Agreement Granted Under 2014 Stock Incentive Plan (Originally Granted under 2012 Stock Option Plan).<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.20(F)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Incentive Stock Option Agreement Granted Under 2014 Stock Incentive Plan.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.20(G)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Non-Statutory Stock Option Agreement Granted Under 2014 Stock Incentive Plan.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.21</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Indemnification Agreement.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.22</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Management Rights Agreement.<SUP>(1)</SUP></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=226,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=145461,FOLIO='II-8',FILE='DISK114:[15ZAD1.15ZAD72301]JE72301A.;43',USER='LPALLES',CD='24-APR-2015;13:26' -->
<A NAME="page_je72301_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Number </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 10.23</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Confidentiality and Inventions Agreement.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.24</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Confidential Offer Letter, dated January&nbsp;30, 2015, by and between Collegium Pharmaceutical,&nbsp;Inc. and Paul Brannelly.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.25</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>2014 Transaction Bonus Plan.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.26</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Noncompetition, Confidentiality and Inventions Agreement, dated October&nbsp;5, 2003, by and between Collegium Pharmaceutical, Inc. and Michael&nbsp;T. Heffernan.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.27</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Offer Letter, dated June 26, 2002, by Collegium Pharmaceutical, Inc. to Alison B. Fleming.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.28</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Offer Letter, dated June 6, 2008, by and between Collegium Pharmaceutical, Inc. and Said Saim.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.29</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Offer Letter, dated January 29, 2015, by and between Collegium Pharmaceutical, Inc. and Garen Bohlin.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.30</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Series D Convertible Preferred Stock Purchase Agreement, dated March&nbsp;6, 2015, by and among Collegium Pharmaceutical, Inc. and the purchasers thereto.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.31</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>First Amendment to Lease, dated March&nbsp;24, 2015, by and between Park at&nbsp;95, LLC (as successor in interest to 780&nbsp;Dedham Street Holdings, LLC) and Collegium Pharmaceutical, Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.32</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Confidential Offer Letter, dated March 23, 2015, by and between Collegium Pharmaceutical, Inc. and Barry Duke.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.33</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>2015 Employee Stock Purchase Plan.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.34</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Performance Bonus Plan.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.35</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Amended and Restated 2014 Stock Incentive Plan.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Restricted Stock Award Agreement, dated April 2, 2015, by and between Collegium Pharmaceutical, Inc. and Michael T. Heffernan.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.37</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Indemnification Agreement to be effective upon the closing of this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Letter of Walter&nbsp;&amp; Shuffain, P.C., as to change in accountant, dated February&nbsp;25, 2015.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Consent of Grant Thornton&nbsp;LLP.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Consent of Pepper Hamilton&nbsp;LLP (included in Exhibit&nbsp;5.1).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Power of Attorney (included on the signature page of the Registration Statement on Form S-1 (File No. 333-203208) filed with the Commission on April 2, 2015).<SUP>(1)</SUP></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">&#134;</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">+</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Indicates
management contract or compensatory plan.


<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed as an exhibit to the registrant's Registration Statement on Form S-1 (File No. 333-203208) filed with the Commission on April 2, 2015. </FONT>

</DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=227,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=327679,FOLIO='II-9',FILE='DISK114:[15ZAD1.15ZAD72301]JE72301A.;43',USER='LPALLES',CD='24-APR-2015;13:26' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>a2224429zex-1_1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 1.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[&nbsp;</font></b><b><font size="2" face="Symbol" style="font-size:10.0pt;font-weight:bold;">&#183;</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">&nbsp;]</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Collegium Pharmaceutical,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNDERWRITING AGREEMENT</font></u></b><u><font size="2" style="font-size:10.0pt;">(1)</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;], 2015</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">JEFFERIES LLC <br> PIPER JAFFRAY&nbsp;&amp; CO. <br> As Representatives of the several Underwriters</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o JEFFERIES LLC <br> 520 Madison Avenue<br> New York, New York 10022</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o PIPER JAFFRAY&nbsp;&amp; CO.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">800 Nicollet Mall</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Minneapolis, MN 55402</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Introductory.</font></b><font size="2" style="font-size:10.0pt;">&#160; Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation (the &#147;<b>Company</b>&#148;), proposes to issue and sell to the several underwriters named in <u>Schedule A</u> (the &#147;<b>Underwriters</b>&#148;) an aggregate of [&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;] shares of its common stock, par value $0.001 per share (the &#147;<b>Shares</b>&#148;).&#160; The [&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;] Shares to be sold by the Company are called the &#147;<b>Firm Shares</b>.&#148;&#160; In addition, the Company has granted to the Underwriters an option to purchase up to an additional [&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;] Shares as provided in Section&nbsp;2.&#160; The additional [&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;] Shares to be sold by the Company pursuant to such option are collectively called the &#147;<b>Optional Shares</b>.&#148;&#160; The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the &#147;<b>Offered Shares</b>.&#148;&#160; Jefferies LLC (&#147;<b>Jefferies</b>&#148;) and Piper Jaffray&nbsp;&amp; Co. (&#147;<b>Piper Jaffray</b>&#148;) have agreed to act as representatives of the several Underwriters (in such capacity, the &#147;<b>Representatives</b>&#148;) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on <u>Schedule A</u>, the term &#147;Representatives&#148; as used herein shall mean you, as Underwriters, and the term &#147;Underwriters&#148; shall mean either the singular or the plural, as the context requires.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jefferies agrees that up to [&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;] of the Firm Shares to be purchased by the Underwriters (the &#147;<b>Directed Shares</b>&#148;) shall be reserved for sale to certain eligible directors, officers and employees of the Company and persons having business relationships with the Company (collectively, the &#147;<b>Participants</b>&#148;), as part of the distribution of the Offered Shares by the Underwriters (the &#147;<b>Directed Share Program</b>&#148;) subject to the terms of this Agreement, the applicable rules, regulations and interpretations of the Financial Industry Regulatory Authority,&nbsp;Inc. (&#147;<b>FINRA</b>&#148;) and all other applicable laws, rules&nbsp;and regulations.&#160; The Directed Share Program shall be administered by Jefferies.&#160; To the extent that the Directed Shares are not orally confirmed for purchase by the Participants by the end of the first business day after the date of this</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=953889,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement, such Directed Shares may be offered to the public by the Underwriters as part of the public offering contemplated hereby.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has prepared and filed with the Securities and Exchange Commission (the &#147;<b>Commission</b>&#148;) a registration statement on Form&nbsp;S-1, File No.&nbsp;333-203208 which contains a form of prospectus to be used in connection with the public offering and sale of the Offered Shares.&#160; Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder (collectively, the &#147;<b>Securities Act</b>&#148;), including any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A under the Securities Act, is called the &#147;<b>Registration Statement</b>.&#148;&#160; Any registration statement filed by the Company pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act in connection with the offer and sale of the Offered Shares is called the &#147;<b>Rule&nbsp;462(b)&nbsp;Registration Statement</b>,&#148; and from and after the date and time of filing of any such Rule&nbsp;462(b)&nbsp;Registration Statement the term &#147;Registration Statement&#148; shall include the Rule&nbsp;462(b)&nbsp;Registration Statement.&#160; The prospectus, in the form first used by the Underwriters to confirm sales of the Offered Shares or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule&nbsp;173 under the Securities Act, is called the &#147;<b>Prospectus</b>.</font><font size="2" style="font-size:10.0pt;">&#148;</font><font size="2" style="font-size:10.0pt;">&#160; The</font><font size="2" style="font-size:10.0pt;"> preliminary prospectus dated </font><font size="2" style="font-size:10.0pt;">April&nbsp;27, 2015 describing the Offered Shares and the offering thereof is called the </font><font size="2" style="font-size:10.0pt;">&#147;<b>Preliminary Prospectus</b>,&#148; and the Preliminary Prospectus and any other prospectus in preliminary form that describes the Offered Shares and the offering thereof and is used prior to the filing of the Prospectus is called a &#147;<b>preliminary prospectus</b>.&#148;&#160; As used herein, &#147;<b>Applicable Time</b>&#148; is </font><font size="2" style="font-size:10.0pt;">[&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;]:[&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;]&nbsp;p.</font><font size="2" style="font-size:10.0pt;">m. (New York City time) on </font><font size="2" style="font-size:10.0pt;">[&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;], 2015</font><font size="2" style="font-size:10.0pt;">.</font><font size="2" style="font-size:10.0pt;">&#160; As used herein, &#147;<b>free writing prospectus</b>&#148; has the meaning set forth in Rule&nbsp;405 under the Securities Act, and &#147;<b>Time of Sale Prospectus</b>&#148; means the Preliminary Prospectus together with the free writing prospectuses, if any, identified in <u>Schedule B</u> hereto.&#160; As used herein, <b>&#147;Road Show&#148;</b> means a &#147;road show&#148; (as defined in Rule&nbsp;433 under the Securities Act) relating to the offering of the Offered Shares contemplated hereby that is a &#147;written communication&#148; (as defined in Rule&nbsp;405 under the Securities Act).&#160; As used herein, &#147;<b>Section&nbsp;5(d)&nbsp;Written Communication</b>&#148; means each written communication (within the meaning of Rule&nbsp;405 under the Securities Act) that is made in reliance on Section&nbsp;5(d)&nbsp;of the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential investors that are qualified institutional buyers (&#147;<b>QIBs</b>&#148;) and/or institutions that are accredited investors (&#147;<b>IAIs</b>&#148;), as such terms are respectively defined in Rule&nbsp;144A and Rule&nbsp;501(a)&nbsp;under the Securities Act, to determine whether such investors might have an interest in the offering of the Offered Shares; &#147;<b>Section&nbsp;5(d)&nbsp;Oral Communication</b>&#148; means each oral communication, if any, made in reliance on Section&nbsp;5(d)&nbsp;of the Securities Act by the Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Shares; &#147;<b>Marketing Materials</b>&#148; means any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Shares, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically); and &#147;<b>Permitted Section&nbsp;5(d)&nbsp;Communication</b>&#148; means the Section&nbsp;5(d)&nbsp;Written Communication(s)&nbsp;and Marketing Materials listed on <u>Schedule C</u> attached hereto.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All references in this Agreement to (i)&nbsp;the Registration Statement, any preliminary prospectus (including the Preliminary Prospectus), or the Prospectus, or any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&#147;<b>EDGAR</b>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic Prospectus&#148; provided for use in connection with the offering of the Offered Shares as contemplated by Section&nbsp;3(o)&nbsp;of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company hereby confirms its agreements with the Underwriters as follows:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="2123-2-KA-01_PB_2_130142_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=58630,FOLIO='2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Representations and Warranties of the Company.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Compliance with Registration Requirements</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Registration Statement has become effective under the Securities Act.&#160; The Company has complied, to the Commission&#146;s satisfaction with all requests of the Commission for additional or supplemental information, if any.&#160; No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Disclosure</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Each preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation&nbsp;S-T under the Securities Act) to the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Shares.&#160; Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.&#160; As of the Applicable Time, the Time of Sale Prospectus did not, and at the First Closing Date (as defined in Section&nbsp;2) and at each applicable Option Closing Date (as defined in Section&nbsp;2), as then amended or supplemented by the Company will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.&#160; The Prospectus, as of its date, did not, and at the First Closing Date and at each applicable Option Closing Date, as then amended or supplemented by the Company will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.&#160; The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by or on behalf of the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b)&nbsp;below.&#160; There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or filed as required.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Free Writing Prospectuses; Road Show</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; As of the determination date referenced in Rule&nbsp;164(h)&nbsp;under the Securities Act, the Company was not, is not or will not be (as applicable) an &#147;ineligible issuer&#148; in connection with the offering of the Offered Shares pursuant to Rules&nbsp;164, 405 and 433 under the Securities Act.&#160; Each free writing prospectus that the Company is required to file pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act.&#160; Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule&nbsp;433 under the Securities Act, including timely filing with the Commission or retention where required and legending, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Offered Shares did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus and not superseded or modified.&#160; The</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="2123-2-KA-01_PB_3_130202_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=105260,FOLIO='3',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">representations and warranties set forth in the immediately preceding sentence do not apply to statements made in reliance upon and in conformity with written information relating to any Underwriters furnished to the Company in writing by the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b)&nbsp;below.&#160; Except for the free writing prospectuses, if any, identified in <u>Schedule B</u>, and electronic road shows, if any, furnished to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the prior written consent of the Representatives, prepare, use or refer to, any free writing prospectus.&#160; Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Directed Share Program</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; (i)&nbsp;The Registration Statement, the Prospectus, the Time of Sale Prospectus and any preliminary prospectus comply, and any further amendments or supplements thereto will comply, with any applicable laws or regulations of foreign jurisdictions in which the Prospectus, Time of Sale Prospectus or any preliminary prospectus, as amended or supplemented, if applicable, are distributed in connection with the Directed Share Program, and (ii)&nbsp;no authorization, approval, consent, license, order registration or qualification of or with any government, governmental instrumentality or court, other than such as have been obtained, is necessary under the securities laws and regulations of foreign jurisdictions in which the Directed Shares are offered outside the United States.&#160; The Company has not offered, or caused the Underwriters to offer, any Offered Shares to any person pursuant to the Directed Share Program with the intent to unlawfully influence (i)&nbsp;a customer or supplier of the Company to alter the customer&#146;s or supplier&#146;s level or type of business with the Company or (ii)&nbsp;a trade journalist or publication to write or publish favorable information about the Company or its products.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Distribution of Offering Material By the Company</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Prior to the later of (i)&nbsp;the expiration or termination of the option granted to the several Underwriters in Section&nbsp;2, (ii)&nbsp;the completion of the Underwriters&#146; distribution of the Offered Shares and (iii)&nbsp;the expiration of 25 days after the date of the Prospectus<b>, </b>the Company has not distributed and will not distribute any offering material in connection with the offering and sale of the Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed and consented to by the Representatives, the free writing prospectuses, if any, identified on <u>Schedule B</u> hereto and any Permitted Section&nbsp;5(d)&nbsp;Communications.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The Underwriting Agreement</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; This Agreement has been duly authorized, executed and delivered by the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(g)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Authorization of the Offered Shares</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Offered Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Offered Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(h)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">No Applicable Registration or Other Similar Rights</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement except for such rights as have been duly waived.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">No Material Adverse Change</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="2123-2-KA-01_PB_4_130225_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=970662,FOLIO='4',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;there has been no material adverse change, or any development that would reasonably be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, properties, operations, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company (any such change being referred to herein as a &#147;<b>Material Adverse Change</b>&#148;); (ii)&nbsp;the Company has not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with its business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company, or has entered into any material transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company and there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of capital stock, or any repurchase or redemption by the Company of any class of capital stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(j)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Independent Accountants</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Grant Thornton LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act, the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder (collectively, the &#147;<b>Exchange Act</b>&#148;), and the rules&nbsp;of the Public Company Accounting Oversight Board (&#147;<b>PCAOB</b>&#148;), (ii)&nbsp;in compliance with the applicable requirements relating to the qualification of accountants under Rule&nbsp;2-01 of Regulation S-X under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(k)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Financial Statements</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The financial statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly, in all material respects, the financial position of the Company as of the dates indicated and the results of its operations, changes in stockholders&#146; equity and cash flows for the periods specified.&#160; Such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States on a consistent basis throughout the periods involved (&#147;<b>GAAP</b>&#148;), except as may be expressly stated in the related notes thereto.&#160; No other financial statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus.&#160; The financial data set forth in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus under the captions &#147;Prospectus Summary&#151;Summary Selected Financial Data,&#148; &#147;Selected Financial Data&#148; and &#147;Capitalization&#148; fairly present, in all material respects, the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus.&#160; To the Company&#146;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule&nbsp;5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(l)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company&#146;s Accounting System</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company makes and keeps books and records that are accurate in all material respects and maintains a system of internal accounting controls designed to, and which the Company believes is sufficient to, provide reasonable assurance that:&#160; (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="2123-2-KA-01_PB_5_130241_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=351207,FOLIO='5',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(m)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;"> The Company has established and maintains disclosure controls and procedures (as defined in Rules&nbsp;13a-15 and 15d-15 under the Exchange Act), which are designed to ensure that material information relating to the Company is made known to the Company&#146;s principal executive officer and its principal financial officer by others within the Company, and such disclosure controls and procedures are effective in all material respects to perform the functions for which they were established.&#160; Except as set forth in the Registration Statement, the Prospectus, the Time of Sale Prospectus or any preliminary prospectus, since the end of the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and there has been no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting.&#160; The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(n)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Incorporation and Good Standing of the Company</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement.&#160; The Company is duly qualified as a foreign corporation to transact business and is in good standing in the Commonwealth of Massachusetts and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or other), earnings, business, properties, operations, assets, liabilities or prospects of the Company (a &#147;<b>Material Adverse Effect</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(o)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Subsidiaries</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company has no subsidiaries (as defined in Rule&nbsp;405 under the Securities Act).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(p)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Capitalization and Other Capital Stock Matters</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Capitalization&#148; (other than for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise of outstanding options or warrants, in each case as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus).&#160; The Shares (including the Offered Shares) conform in all material respects to the description thereof contained in the Time of Sale Prospectus.&#160; All of the issued and outstanding Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws.&#160; None of the outstanding Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company.&#160; There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company other than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus.&#160; The descriptions of the Company&#146;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately and fairly present, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(q)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Stock Exchange Listing</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Offered Shares have been approved for listing on The NASDAQ Global Market (the &#147;<b>NASDAQ</b>&#148;), subject only to official notice of issuance.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="2123-2-KA-01_PB_6_130254_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=247967,FOLIO='6',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(r)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company is not in violation of its charter or by-laws, or in default (or, with the giving of notice or lapse of time, would be in default) (&#147;<b>Default</b>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company is a party or by which it may be bound, or to which any of its properties or assets are subject (each, an &#147;<b>Existing Instrument</b>&#148;), except for such Defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.&#160; The Company&#146;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus and the issuance and sale of the Offered Shares (including the use of proceeds from the sale of the Offered Shares as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Use of Proceeds&#148;) (i)&nbsp;have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or by-laws of the Company, (ii)&nbsp;will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to, or require the consent of any other party to, any Existing Instrument and (iii)&nbsp;will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company.&#160; No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#146;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, except (A)&nbsp;such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or FINRA and (B)&nbsp;such as have been obtained under the laws and regulations of jurisdictions outside of the United States in which Directed Shares are offered.&#160; As used herein, a &#147;<b>Debt Repayment Triggering Event</b>&#148; means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(s)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Compliance with Laws</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; The Company has been and is in compliance with all applicable laws, rules&nbsp;and regulations, except where failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(t)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">No Material Actions or Proceedings</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; There is no action, suit, proceeding, inquiry or investigation brought by or before any governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company, which would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or materially and adversely affect the consummation of the transactions contemplated by this Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company is a party or of which any of its respective properties or assets is the subject, including ordinary routine litigation incidental to the business, if determined adversely to the Company, would not reasonably be expected to have a Material Adverse Effect.&#160; No material labor dispute with the employees of the Company, or with the employees of any principal supplier, manufacturer, or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent, which would reasonably be expected to have a Material Adverse Effect.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(u)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Intellectual Property Rights</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">  </font></b><font size="2" style="font-size:10.0pt;">&#160;The Company owns, or has obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement, the Time</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="2123-2-KA-01_PB_7_130312_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=904817,FOLIO='7',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of Sale Prospectus and the Prospectus as being owned or licensed by it or which are necessary for the conduct of its business as currently conducted or as currently proposed to be conducted in the Registration Statement, the Time of Sale Prospectus and the Prospectus (collectively, &#147;<b>Intellectual Property</b>&#148;).&#160; None of the Intellectual Property has been adjudged invalid or unenforceable in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for a determination that any issued patent within the Intellectual Property is invalid or unenforceable. To the Company&#146;s knowledge, and except as would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect:&#160; (i)&nbsp;there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus as licensed to the Company; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property.&#160; Except as disclosed in the Registration Statements, the Time of Sale Prospectus and the Prospectus, there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company infringes, misappropriates or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe, misappropriate or otherwise violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim.&#160; None of the technology employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company&#146;s knowledge, upon any officers, directors or employees of the Company, and the Company is not aware of any facts that would form a reasonable basis for a successful challenge that any of its employees are in or have ever been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where such violation relates to such employee&#146;s breach of a confidentiality obligation, obligation to assign intellectual property to an employer, or obligation not to use third-party intellectual property or other proprietary rights of a third party. The product candidates described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as under development by the Company fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(v)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">All Necessary Permits,&nbsp;etc</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company possesses such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct its business as currently conducted and as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus (&#147;<u>Permits</u>&#148;). The Company is not in violation of, or in default under, any of the Permits and has not received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such Permit.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(w)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Title to Properties</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company does not own any real property.&#160; The Company has good and marketable title to all of the personal property and other assets reflected as owned in the financial statements referred to in Section&nbsp;1(k)&nbsp;above (or elsewhere in the Registration Statement, the Time of Sale Prospectus or the Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except as would not reasonably be expected, individually or in the aggregate, to materially affect the value of such property or materially interfere with the use thereof.&#160; The real property, improvements, equipment and personal property held under lease by the Company are held under valid and enforceable leases, with such exceptions as are not material and do</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="2123-2-KA-01_PB_8_130323_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=166205,FOLIO='8',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(x)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Tax Law Compliance</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company has filed all necessary federal, state and foreign income and franchise tax returns or has properly requested extensions thereof, except insofar as the failure to file such returns would not reasonably be expected to have a Material Adverse Effect, and has paid all taxes required to be paid by it and, if due and payable, any related or similar assessment, fine or penalty levied against it except as may be being contested in good faith and by appropriate proceedings, and except where the failure to pay such taxes, assessments, fines or penalties would not reasonably be expected to have a Material Adverse Effect.&#160; The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section&nbsp;1(k)&nbsp;above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company has not been otherwise finally determined.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(y)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Insurance</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company is insured by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as the Company reasonably believes are generally adequate and customary for its business including, but not limited to, policies covering real and personal property owned or leased by the Company against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company for product liability claims and clinical trial liability claims.&#160; The Company has no reason to believe that it will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to have a Material Adverse Effect.&#160; The Company has not been denied any insurance coverage which it has sought or for which it has applied.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(z)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Compliance with Environmental Laws</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect:&#160; (i)&nbsp;the Company is not in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule&nbsp;of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#147;<b>Hazardous Materials</b>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<b>Environmental Laws</b>&#148;); (ii)&nbsp;the Company has all permits, authorizations and approvals required under any applicable Environmental Laws and is in compliance with their requirements; (iii)&nbsp;there are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company; and (iv)&nbsp;to the knowledge of the Company there are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company relating to Hazardous Materials or any Environmental Laws.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(aa)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">ERISA Compliance</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company and any &#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<b>ERISA</b>&#148;)) established or maintained by the Company, or to the knowledge of the Company, its &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA.&#160; &#147;<b>ERISA Affiliate</b>&#148; means, with respect to the Company, any member of any group of organizations described in Sections&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Internal Revenue Code of 1986, as</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="2123-2-KA-01_PB_9_130339_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=449298,FOLIO='9',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">amended, and the regulations and published interpretations thereunder (the &#147;<b>Code</b>&#148;) of which the Company is a member.&#160; No &#147;reportable event&#148; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company or any of its ERISA Affiliates.&#160; No &#147;employee benefit plan&#148; established or maintained by the Company or its ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any &#147;amount of unfunded benefit liabilities&#148; (as defined under ERISA).&#160; Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i)&nbsp;Title&nbsp;IV of ERISA with respect to termination of, or withdrawal from, any &#147;employee benefit plan&#148; or (ii)&nbsp;Sections&nbsp;412, 4971, 4975 or 4980B of the Code.&#160; Each employee benefit plan established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would reasonably be expected to cause the loss of such qualification.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(bb)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Not an &#147;Investment Company.&#148;</font></i></b><font size="2" style="font-size:10.0pt;">&#160; The Company is not, and will not be, either after receipt of payment for the Offered Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus or the Prospectus, required to register as an &#147;investment company&#148; under the Investment Company Act of 1940, as amended (the <b>&#147;Investment Company Act&#148;)</b>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(cc)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">No Price Stabilization or Manipulation; Compliance with Regulation M</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company has not taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or of any &#147;reference security&#148; (as defined in Rule&nbsp;100 of Regulation M under the Exchange Act (<b><font style="font-weight:bold;">&#147;</font>Regulation M&#148;</b>)) with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, or any action which would directly or indirectly violate Regulation M.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(dd)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Related-Party Transactions</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; There are no business relationships or related-party transactions involving the Company or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not been described as required.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ee)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">FINRA Matters</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers and directors and, to the knowledge of the Company, the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Offered Shares is true, complete, correct in all material respects and compliant with FINRA&#146;s rules&nbsp;and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules&nbsp;or NASD Conduct Rules&nbsp;is true, complete and correct in all material respects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ff)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Parties to Lock-Up Agreements</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company has furnished to the Underwriters a letter agreement in the form attached hereto as <u>Exhibit&nbsp;A</u> (the &#147;<b>Lock-up Agreement</b>&#148;) from each director, officer and beneficial owner of the outstanding issued share capital of the Company.&#160; If any additional persons shall become directors or executive officers of the Company prior to the end of the Company Lock-up Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or executive officer of the Company, to execute and deliver to the Representatives a Lock-up Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(gg)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Statistical and Market-Related Data</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; All statistical, demographic and market-related data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate.&#160; To the extent required, the Company has obtained the written consent to the use of such data from such sources.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="2123-2-KA-01_PB_10_130357_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=48445,FOLIO='10',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:11 2015' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(hh)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">No Unlawful Contributions or Other Payments</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Neither the Company nor, to the Company&#146;s knowledge, any employee or agent of the Company, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ii)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Foreign Corrupt Practices Act</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Neither the Company nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment to any domestic government official, &#147;foreign official&#148; (as defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules&nbsp;and regulations thereunder (collectively, the &#147;<b>FCPA</b>&#148;) or employee from corporate funds; (iii)&nbsp;violated or is in violation of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation; or (iv)&nbsp;made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any domestic government official, such foreign official or employee; and the Company and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(jj)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Money Laundering Laws</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The operations of the Company are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules&nbsp;and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<b>Money Laundering Laws</b>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(kk)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">OFAC</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Neither the Company nor, to the knowledge of the Company, after due inquiry, any director, officer, agent, employee, affiliate or person acting on behalf of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#147;<b>OFAC</b>&#148;); and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that currently is the subject to any U.S. sanctions administered by OFAC or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of U.S. sanctions administered by OFAC.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ll)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Brokers</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Except pursuant to this Agreement, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(mm)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Forward-Looking Statements.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; Each financial or operational projection or other &#147;forward-looking statement&#148; (as defined by Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i)&nbsp;was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statement.&#160; No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="2123-2-KA-03_PB_11_130620_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=3645,FOLIO='11',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(nn)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Emerging Growth Company Status</font></i></b><font size="2" style="font-size:10.0pt;">.&#160; </font><font size="2" style="font-size:10.0pt;">From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section&nbsp;5(d)&nbsp;Written Communication or any Section&nbsp;5(d)&nbsp;Oral Communication) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act (an &#147;<b>Emerging Growth Company</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(oo)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Communications</font></i></b><font size="2" style="font-size:10.0pt;">.&#160; </font><font size="2" style="font-size:10.0pt;">The Company (i)&nbsp;has not alone engaged in communications with potential investors in reliance on Section&nbsp;5(d)&nbsp;of the Securities Act other than Permitted Section&nbsp;5(d)&nbsp;Communications with the consent of the Representatives with entities that are QIBs or IAIs and (ii)&nbsp;has not authorized anyone other than the Representatives to engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials, Section&nbsp;5(d)&nbsp;Oral Communications and Section&nbsp;5(d)&nbsp;Written Communications; as of the Applicable Time, each Permitted Section&nbsp;5(d)&nbsp;Communication, if any, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Permitted Section&nbsp;5(d)&nbsp;Communication, if any, does not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus and the Company has filed publicly on EDGAR at least 21 calendar days prior to any &#147;road show&#148; (as defined in Rule&nbsp;433 under the Securities Act), any confidentially submitted registration statement and registration statement amendments relating to the offer and sale of the Offered Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(pp)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Clinical Data and Regulatory Compliance.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; The preclinical studies and clinical trials (collectively, &#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies contained in the Registration Statements, the Time of Sale Prospectus and the Prospectus, is accurate and complete in all material respects and fairly presents in all material respects the data derived from such studies, and the Company has no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company has made all such filings and obtained all such Permits as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the &#147;<b>Regulatory Agencies</b>&#148;); the Company has not received any notice of, or correspondence from, any Regulatory Agency requiring the termination or suspension of any clinical trials; and the Company has operated and currently is in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(qq)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Compliance with Health Care Laws</font></i></b><font size="2" style="font-size:10.0pt;">.&#160; The Company has been and is in compliance in all material respects with all applicable Health Care Laws, except where failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.&#160; For purposes of this Agreement, &#147;<b>Health Care Laws</b>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 <i>et seq</i>.) and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and all applicable foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section&nbsp;1320a-7b(b)), the U.S. Physician Payment Sunshine Act (42 U.S.C. &#167;&nbsp;1320a-7h), the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), </font><font size="2" style="font-size:10.0pt;">the criminal False Claims Law (42 U.S.C. &#167; 1320a-7b(a)), </font><font size="2" style="font-size:10.0pt;">all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="2123-2-KA-03_PB_12_130644_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=157807,FOLIO='12',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;<b>HIPAA</b>&#148;) (42 U.S.C. Section&nbsp;1320d et seq.), the exclusion laws (42 U.S.C. &#167; 1320a-7), the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), and the regulations promulgated pursuant to such statutes; (iii)&nbsp;Medicare (Title XVIII of the Social Security Act); (iv)&nbsp;Medicaid (Title XIX of the Social Security Act); (v)&nbsp;the Controlled Substances Act (21 U.S.C. &#167;&#167; 801 <i>et seq.</i>) and the regulations promulgated thereunder; and (vi)&nbsp;any and all other applicable health care laws and regulations. The Company has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority alleging that any product operation or activity is in material violation of any Health Care Laws, and, to the Company&#146;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened against the Company. The Company is not a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Regulatory Agency or other governmental or regulatory authority. Additionally, neither the Company nor any of its employees, officers or directors has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(rr)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">No Rights to Purchase Preferred Stock.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; The issuance and sale of the Shares as contemplated hereby will not cause any holder of any shares of capital stock, securities convertible into or exchangeable or exercisable for capital stock or options, warrants or other rights to purchase capital stock or any other securities of the Company to have any right to acquire any shares of preferred stock of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any certificate signed by any officer of the Company and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has a reasonable basis for making each of the representations set forth in this Section&nbsp;1.&#160; The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Purchase, Sale and Delivery of the Offered Shares</font></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The Firm Shares</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters an aggregate of [&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;] Firm Shares.&#160; On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on <u>Schedule A</u>.&#160; The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be $[&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;] per share.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The First Closing Date</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Delivery of certificates for the Firm Shares to be purchased by the Underwriters and payment therefor shall be made at the offices of Latham&nbsp;&amp; Watkins LLP (or such other place as may be agreed to by the Company and the Representatives) at 9:00&nbsp;a.m. New York City time, on [&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;], 2015, or such other time and date not later than 1:30&nbsp;p.m. New York City time, on [&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;], 2015 as the Representatives shall designate by notice to the Company (the time and date of such closing</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="2123-2-KA-03_PB_13_130721_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=233708,FOLIO='13',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">are called the &#147;<b>First Closing Date</b>&#148;).&#160; The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The Optional Shares; Option Closing Date</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; In addition, on the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of [&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;] Optional Shares from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares.&#160; The option granted hereunder may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30&nbsp;days from the date of this Agreement.&#160; Such notice shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii)&nbsp;the time, date and place at which certificates for the Optional Shares will be delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the term &#147;<b>First Closing Date</b>&#148; shall refer to the time and date of delivery of certificates for the Firm Shares and such Optional Shares).&#160; Any such time and date of delivery, if subsequent to the First Closing Date, is called an &#147;<b>Option Closing Date</b>,&#148; shall be determined by the Representatives and shall not be earlier than three or later than five full business days after delivery of such notice of exercise.&#160; If any Optional Shares are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on <u>Schedule A</u> opposite the name of such Underwriter bears to the total number of Firm Shares. The Representatives may cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Public Offering of the Offered Shares</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Representatives hereby advise the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the Offered Shares as soon after this Agreement has been executed and the Registration Statement has been declared effective as the Representatives, in their sole judgment, have determined is advisable and practicable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Payment for the Offered Shares</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; (i)&nbsp;Payment for the Offered Shares shall be made at the First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">It is understood that the Representatives have been authorized, for their own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to purchase.&#160; Each of Jefferies and Piper Jaffray, individually and not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Delivery of the Offered Shares</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company shall deliver, or cause to be delivered through the facilities of The Depository Trust Company (&#147;<b>DTC</b>&#148;) unless the Representatives shall otherwise instruct, to the Representatives for the accounts of the several Underwriters certificates for the Firm Shares at the First Closing Date, against release of a wire transfer of immediately available funds for</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="2123-2-KA-03_PB_14_130746_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=598898,FOLIO='14',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the amount of the purchase price therefor.&#160; The Company shall also deliver, or cause to be delivered through the facilities of DTC unless the Representatives shall otherwise instruct, to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have agreed to purchase at the First Closing Date or the applicable Option Closing Date, as the case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor.&#160; The certificates for the Offered Shares shall be registered in such names and denominations as the Representatives shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate.&#160; Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of the Underwriters.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Additional Covenants.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company further covenants and agrees with each Underwriter as follows:</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Delivery of Registration Statement, Time of Sale Prospectus and Prospectus</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; The Company shall furnish to you in New York City, without charge, prior to 10:00&nbsp;a.m. New York City time on the second business day succeeding the date of this Agreement and during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Representatives&#146; Review of Proposed Amendments and Supplements</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule), the Company (i)&nbsp;will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will not amend or supplement the Registration Statement without the Representatives&#146; prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.&#160; Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement.&#160; The Company shall not file or use any such proposed amendment or supplement without the Representatives&#146; prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.&#160; The Company shall file with the Commission within the applicable period specified in Rule&nbsp;424(b)&nbsp;under the Securities Act any prospectus required to be filed pursuant to such Rule.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Free Writing Prospectuses</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; The Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives&#146; prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.&#160; The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request.&#160; If at any time when a prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) in connection with sales of the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="2123-2-KA-03_PB_15_130800_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=788981,FOLIO='15',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Offered Shares (but in any event if at any time through and including the First Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <i>provided, however</i>, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives&#146; prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Filing of Underwriter Free Writing Prospectuses</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; The Company shall not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Amendments and Supplements to Time of Sale Prospectus</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(b)&nbsp;and Section&nbsp;3(c)&nbsp;hereof) promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Certain Notifications and Required Actions</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; After the date of this Agreement and until such time as the Underwriters are no longer required to deliver a Prospectus in order to confirm sales of the Offered Shares, the Company shall promptly advise the Representatives in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission relating to the Registration Statement; (ii)&nbsp;the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the time and date that any post-effective amendment to the Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="2123-2-KA-03_PB_16_130810_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=19590,FOLIO='16',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.&#160; If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order as soon as reasonably practicable.&#160; Additionally, the Company agrees that it shall comply with all applicable provisions of Rule&nbsp;424(b), Rule&nbsp;433 and Rule&nbsp;430A under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule&nbsp;424(b)&nbsp;or Rule&nbsp;433 were received in a timely manner by the Commission.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(g)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Amendments and Supplements to the Prospectus and Other Securities Act Matters</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(b)&nbsp;and Section&nbsp;3(c)&nbsp;hereof) to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.&#160; Neither the Representatives&#146; consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#146;s obligations under Section&nbsp;3(b)&nbsp;or Section&nbsp;3(c).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(h)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Blue Sky Compliance</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company shall cooperate with the Representatives and counsel for the Underwriters to qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Shares.&#160; The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.&#160; The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof as soon as reasonably practicable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Use of Proceeds</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company shall apply the net proceeds from the sale of the Offered Shares sold by it in the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(j)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Transfer Agent</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(k)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Earnings Statement</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company will make generally available to its security holders and to the Representatives as soon as practicable an earnings statement (which need not be audited)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="2123-2-KA-03_PB_17_130819_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=173183,FOLIO='17',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act and the rules&nbsp;and regulations of the Commission thereunder.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(l)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Continued Compliance with Securities Laws</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company will comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<b>, </b>the Registration Statement, the Time of Sale Prospectus and the Prospectus.&#160; Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule), file on a timely basis with the Commission and the NASDAQ all reports and documents required to be filed under the Exchange Act.&#160; Additionally, the Company shall report the use of proceeds from the issuance of the Offered Shares as may be required under Rule&nbsp;463 under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(m)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Directed Share Program</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; In connection with the Directed Share Program, the Company will ensure that the Directed Shares will be restricted to the extent required by FINRA or its rules&nbsp;from sale, transfer, assignment, pledge or hypothecation for a period of three months following the date of the effectiveness of the Registration Statement.&#160; Jefferies will notify the Company as to which Participants will need to be so restricted.&#160; The Company will direct the transfer agent to place stop transfer restrictions upon such securities for such period of time.&#160; Should the Company release, or seek to release, from such restrictions any of the Directed Shares, the Company agrees to reimburse the Underwriters for any reasonable expenses (including, without limitation, reasonable attorney&#146;s fees) they incur in connection with such release.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(n)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Listing</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares on the NASDAQ.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(o)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company to Provide Copy of the Prospectus in Form&nbsp;That May&nbsp;be Downloaded from the Internet</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an &#147;<b>electronic Prospectus</b>&#148; to be used by the Underwriters in connection with the offering and sale of the Offered Shares.&#160; As used herein, the term &#147;<b>electronic Prospectus</b>&#148; means a form of Time of Sale Prospectus, and any amendment or supplement thereto, that meets each of the following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and purchasers of the Offered Shares; (ii)&nbsp;it shall disclose the same information as the paper Time of Sale Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic format, satisfactory to Jefferies, that will allow investors to store and have continuously ready access to the Time of Sale Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for on-line time).&#160; The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Time of Sale Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(p)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Agreement Not to Offer or Sell Additional Shares</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; During the period commencing on and including the date hereof and continuing through and including the 180th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#147;<b>Lock-up Period</b>&#148;), the Company will not, without the prior written consent of the Representatives (which consent</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="2123-2-KA-03_PB_18_130830_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=608790,FOLIO='18',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">may be withheld in their sole discretion), directly or indirectly:&#160; (i)&nbsp;sell, offer to sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii)&nbsp;effect any short sale, or establish or increase any &#147;put equivalent position&#148; (as defined in Rule&nbsp;16a-1(h)&nbsp;under the Exchange Act) or liquidate or decrease any &#147;call equivalent position&#148; (as defined in Rule&nbsp;16a-1(b)&nbsp;under the Exchange Act) of any Shares or Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any Shares or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the offering of any Shares or Related Securities; (vii)&nbsp;file any registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares); or (viii)&nbsp;publicly announce the intention to do any of the foregoing; <i>provided, however</i>, that the Company may (A)&nbsp;effect the transactions contemplated hereby; (B)&nbsp;issue Shares or options to purchase Shares, or issue Shares upon exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, but only if the holders of such Shares or options have provided to the Representatives a signed Lock-Up Agreement in the form of <u>Exhibit&nbsp;A</u> hereto; (C)&nbsp;issue Shares pursuant to the conversion or exchange of any convertible or exchangeable securities outstanding on the date hereof, but only if the holders of such Shares or options have provided to the Representatives a signed Lock-Up Agreement in the form of <u>Exhibit&nbsp;A</u> hereto; (D)&nbsp;file a registration statement on Form&nbsp;S-8 to register Shares issuable pursuant to the terms of a stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus; and (E)&nbsp;issue Shares in connection with any joint venture, commercial or collaborative relationship or acquisition or license by the Company of the securities, property, business or other assets of another person or entity; <i>provided</i>,<i> however</i>, that in the case of clause (E), the sum of the aggregate number of shares of common stock of the Company so issued shall not exceed 5% of the total outstanding shares of common stock of the Company immediately following the completion of this offering of Offered Securities; and <i>provided further</i>, that the holders of such Shares or options have provided to the Representatives a signed Lock-Up Agreement in the form of <u>Exhibit&nbsp;A</u> hereto.&#160; For purposes of the foregoing, &#147;<b>Related Securities</b>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(q)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Future Reports to the Representatives.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; During the period of five years hereafter, the Company will furnish to the Representatives, c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of Syndicate, and c/o Piper Jaffray, at 800 Nicollet Mall, Minneapolis, MN 55402: (i)&nbsp;as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#146; equity and cash flows for the year then ended and the opinion thereon of the Company&#146;s independent public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form&nbsp;10-K, Quarterly Report on Form&nbsp;10-Q, Current Report on Form&nbsp;8-K or other public report filed by the Company with the Commission or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; <i>provided, however,</i> that the requirements of this Section&nbsp;3(q)&nbsp;shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(r)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Investment Limitation</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Shares in such a manner as would require the Company to register as an investment company under the Investment Company Act.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="2123-2-KA-03_PB_19_130841_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=143341,FOLIO='19',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(s)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">No Stabilization or Manipulation; Compliance with Regulation M</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">. </font></b><font size="2" style="font-size:10.0pt;">&#160;The Company will not take, and will ensure that no affiliate of the Company will take, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(t)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Enforce Lock-Up Agreements</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; During the Lock-up Period, the Company will enforce all agreements between the Company and any of its security holders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related Securities or any of the other actions restricted or prohibited under the terms of the form of Lock-up Agreement.&#160; In addition, the Company will direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such &#147;lock-up&#148; agreements for the duration of the periods contemplated in such agreements, including, without limitation, &#147;lock-up&#148; agreements entered into by the Company&#146;s officers and directors and stockholders pursuant to Section&nbsp;6(j)&nbsp;hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(u)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company to Provide Interim Financial Statements</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Prior to the First Closing Date and each applicable Option Closing Date, the Company will furnish the Underwriters, as soon as reasonably practicable after they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(v)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Amendments and Supplements to Permitted Section&nbsp;5(d)Communications</font></i></b><font size="2" style="font-size:10.0pt;">.&#160; If at any time following the distribution of any Permitted Section&nbsp;5(d)&nbsp;Communication, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule), there occurred or occurs an event or development as a result of which such Permitted Section&nbsp;5(d)&nbsp;Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Permitted Section&nbsp;5(d)&nbsp;Communication to eliminate or correct such untrue statement or omission.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(w)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Emerging Growth Company Status</font></i></b><font size="2" style="font-size:10.0pt;">.&#160; </font><font size="2" style="font-size:10.0pt;">The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;the time when a prospectus relating to the Offered Shares is not required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) and (ii)&nbsp;the expiration of the Lock-Up Period (as defined herein).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Representatives, on behalf of the several Underwriters, may, in their sole discretion, waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Payment of Expenses.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Offered Shares (including all printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the Shares, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered Shares to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="2123-2-KA-03_PB_20_130855_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=657807,FOLIO='20',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:10 2015' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted Section&nbsp;5(d)&nbsp;Communication, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives, preparing and printing a &#147;Blue Sky Survey&#148; or memorandum (such &#147;Blue Sky Survey&#148; or memorandum, fees and expenses of counsel not to exceed $10,000) and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii)&nbsp;</font><font size="2" style="font-size:10.0pt;">the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules&nbsp;and regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the Offered Shares, including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters in an amount not to exceed $50,000 (excluding filing fees), (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148;, any Permitted Section&nbsp;5(d)&nbsp;Communication or any Section&nbsp;5(d)&nbsp;Oral Communication undertaken in connection with the offering of the Offered Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and 50% of the cost of any aircraft chartered in connection with the road show, the remaining 50% of the cost of such aircraft to be paid by the Underwriters, (ix)&nbsp;the fees and expenses associated with listing the Offered Shares on the NASDAQ, (x)&nbsp;all other fees, costs and expenses of the nature referred to in Item 13 of Part&nbsp;II of the Registration Statement and (xi)&nbsp;all costs and expenses of the Underwriters, including the fees and disbursements of counsel for the Underwriters, in connection with matters related to the Directed Shares which are designated by the Company for sale to Participants. Except as provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Covenant of the Underwriters.</font></b><font size="2" style="font-size:10.0pt;">&#160; Each Underwriter severally and not jointly covenants with the Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule&nbsp;433(d).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Conditions of the Obligations of the Underwriters.</font></b><font size="2" style="font-size:10.0pt;">&#160; The respective obligations of the several Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comfort Letter</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; On the date hereof, the Representatives shall have received from Grant Thornton LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin),</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="2123-2-KA-05_PB_21_131100_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=886442,FOLIO='21',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with respect to the audited and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Compliance with Registration Requirements; No Stop Order; No Objection from FINRA</font></i></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company shall have filed the Prospectus with the Commission (including the information required by Rule&nbsp;430A under the Securities Act) in the manner and within the time period required by Rule&nbsp;424(b)&nbsp;under the Securities Act; or the Company shall have filed a post-effective amendment to the Registration Statement containing the information required by such Rule&nbsp;430A, and such post-effective amendment shall have become effective.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">No Material Adverse Change</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date, in the judgment of the Representatives there shall not have occurred any Material Adverse Change.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Opinion of Counsel for the Company</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion of Pepper Hamilton LLP, counsel for the Company, dated as of such date, in form and substance reasonably satisfactory to the Representatives.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Opinion of IP Counsel.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Cooley LLP, counsel for the Company with respect to intellectual property, dated as of such date, in form and substance reasonably satisfactory to the Representatives.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Opinion of Counsel for the Underwriters</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters in connection with the offer and sale of the Offered Shares, in form and substance satisfactory to the Underwriters, dated as of such date, with executed copies for each of the other Underwriters named on the Prospectus cover page.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(g)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Officers&#146; Certificate</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; On each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Chief Executive Officer of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii)&nbsp;and further to the effect that:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">for the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse Change;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the representations, warranties and covenants of the Company set forth in Section&nbsp;1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="2123-2-KA-05_PB_22_131118_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=539347,FOLIO='22',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to such date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(h)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Bring-down Comfort Letter</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; On each of the First Closing Date and each Option Closing Date the Representatives shall have received from Grant Thornton LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives, which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Lock-Up Agreements.</font></i></b><font size="2" style="font-size:10.0pt;">&#160; On or prior to the date hereof, the Company shall have furnished to the Representatives an agreement in the form of <u>Exhibit&nbsp;A</u> hereto from each director, officer and each beneficial owner of the outstanding issued share capital of the Company, and each such agreement shall be in full force and effect on each of the First Closing Date and each Option Closing Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(j)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Rule&nbsp;462(b)&nbsp;Registration Statement</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; In the event that a Rule&nbsp;462(b)&nbsp;Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule&nbsp;462(b)&nbsp;Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective automatically upon such filing.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(k)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Approval of Listing</font></i></b><font size="2" style="font-size:10.0pt;">.&#160; At the First Closing Date, the Offered Shares shall have been approved for listing on the NASDAQ, subject only to official notice of issuance.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(l)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Additional Documents</font></i></b><font size="2" style="font-size:10.0pt;">.&#160; On or before each of the First Closing Date and each Option Closing Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered Shares as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any condition specified in this Section&nbsp;6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;7.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Reimbursement of Underwriters&#146; Expenses</font></b><font size="2" style="font-size:10.0pt;">.&#160; If this Agreement is terminated by the Representatives pursuant to Section&nbsp;6, Section&nbsp;11 or Section&nbsp;12, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves), severally, upon demand for all out-of-pocket expenses that shall have been reasonably incurred by the Representatives and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Shares, including, but not limited to, reasonable and documented fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges; <i>provided</i>, however, that in the event</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="2123-2-KA-05_PB_23_131131_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=104941,FOLIO='23',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any such termination is effected after the First Closing Date but prior to any Option Closing Date with respect to the purchase of any Optional Shares, the Company shall only reimburse the Underwriters for all of their out of pocket expenses, including the reasonable fees and disbursements of counsel for the Underwriters, incurred after the First Closing Date in connection with the proposed purchase of any such Optional Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;8.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Effectiveness of this Agreement</font></b><font size="2" style="font-size:10.0pt;">.&#160; This Agreement shall become effective upon&nbsp;the execution and delivery hereof by the parties hereto.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;9.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Indemnification</font></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Indemnification of the Underwriters</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;of the Securities Act, any Marketing Material, any Section&nbsp;5(d)&nbsp;Written Communication or the Prospectus (or any amendment or supplement to the foregoing) or any prospectus wrapper material distributed in connection with the reservation and sale of Directed Shares to the Participants, or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <i>provided, however</i>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing prospectus, any Marketing Material, any Section&nbsp;5(d)&nbsp;Written Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b)&nbsp;below.&#160; The indemnity agreement set forth in this Section&nbsp;9(a)&nbsp;shall be in addition to any liabilities that the Company may otherwise have.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Indemnification of the Company, its Directors and Officers</font></i></b><font size="2" style="font-size:10.0pt;">.&#160; Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="2123-2-KA-05_PB_24_131142_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=527687,FOLIO='24',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus, that the Company has used, referred to or filed, or is required to file, pursuant to Rule&nbsp;433 of the Securities Act, any Section&nbsp;5(d)&nbsp;Written Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus, such Section&nbsp;5(d)&nbsp;Written Communication or the Prospectus (or any such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action.&#160; The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;of the Securities Act, any Section&nbsp;5(d)&nbsp;Written Communication or the Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in the first sentence of the third paragraph under the caption &#147;Underwriting,&#148; the concession and reallowance amounts, if any, in the first paragraph under the caption &#147;Underwriting&#151;Commission and Expenses,&#148; the first sentence under the caption &#147;Underwriting&#151;Stabilization,&#148; and the first three sentences of the second paragraph under the caption &#147;Underwriting&#151;Other Activities and Relationships&#148; in the Preliminary Prospectus and the Prospectus in the Preliminary Prospectus and the Prospectus. The indemnity agreement set forth in this Section&nbsp;9(b)&nbsp;shall be in addition to any liabilities that each Underwriter may otherwise have.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Notifications and Other Indemnification Procedures</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Promptly after receipt by an indemnified party under this Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section&nbsp;9, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have other than on account of this indemnity agreement.&#160; In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; <i>provided, however</i>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="2123-2-KA-05_PB_25_131152_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=1010272,FOLIO='25',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties.&#160; Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#146;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section&nbsp;9 for any reasonable and documented legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(a)&nbsp;above) or by the Company (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b)&nbsp;above)) or (ii)&nbsp;the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Settlements</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The indemnifying party under this Section&nbsp;9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment.&#160; Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section&nbsp;9(c)&nbsp;hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.&#160; No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Indemnification for Directed Shares</font></i></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.&#160; </font></b><font size="2" style="font-size:10.0pt;">In connection with the offer and sale of the Directed Shares, the Company agrees, promptly upon a request in writing, to indemnify and hold harmless the Underwriters from and against any and all losses, liabilities, claims, damages and expenses incurred by any of them as a result of the failure of the Participants to pay for and accept delivery of Directed Shares which, by the end of the first business day following the date of this Agreement, were subject to a properly confirmed agreement to purchase.&#160; The Company agrees to indemnify and hold harmless the Underwriters and their respective affiliates, directors, officers, employees and agents, and each person, if any, who controls any of the Underwriters within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Underwriters or such controlling person may become subject, which is (i)&nbsp;caused by any untrue statement or alleged untrue statement of a material fact contained in any material prepared by or with the consent of the Company for distribution to Participants in connection with the Directed Share Program or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)&nbsp;caused by the failure of any Participant to pay for and accept delivery of Directed Shares that such Participant agreed to purchase; or (iii)&nbsp;related to, arising out of, or in connection with the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="2123-2-KA-05_PB_26_131205_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=26,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=922979,FOLIO='26',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Directed Share Program; <i>provided</i>, <i>however</i>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in any material prepared by or with the</font><font size="2" style="font-size:10.0pt;"> consent of the Company for distribution to Participants in connection with the Directed Share Program, it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b)&nbsp;above.&#160; The indemnity agreement set</font><font size="2" style="font-size:10.0pt;"> forth in this paragraph shall be in addition to any liabilities that the Company may otherwise have.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Contribution</font></b><font size="2" style="font-size:10.0pt;">.&#160; If the indemnification provided for in Section&nbsp;9 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause&nbsp;(i)&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i)&nbsp;above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations.&#160; The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Shares pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page&nbsp;of the Prospectus, bear to the aggregate initial public offering price of the Offered Shares as set forth on such cover.&#160; The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section&nbsp;9(c), any documented legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim.&#160; The provisions set forth in Section&nbsp;9(c)&nbsp;with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10; <i>provided, however,</i> that no additional notice shall be required with respect to any action for which notice has been given under Section&nbsp;9(c)&nbsp;for purposes of indemnification.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the provisions of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and distributed to the public.&#160; No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.&#160; The Underwriters&#146;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="2123-2-KA-05_PB_27_131216_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=27,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=985077,FOLIO='27',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">obligations to contribute pursuant to this Section&nbsp;10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on <u>Schedule A</u>.&#160; For purposes of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;11.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Default of One or More of the Several Underwriters</font></b><i><font size="2" style="font-size:10.0pt;font-style:italic;">.</font></i><font size="2" style="font-size:10.0pt;">&#160; If, on the First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representatives may make arrangements satisfactory to the Company for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Firm Shares set forth opposite their respective names on <u>Schedule A</u> bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the non-defaulting Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Shares and the aggregate number of Offered Shares with respect to which such default occurs exceeds 10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination.&#160; In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used in this Agreement, the term &#147;<b>Underwriter</b>&#148; shall be deemed to include any person substituted for a defaulting Underwriter under this Section&nbsp;11.&#160; Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;12.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Termination of this Agreement</font></b><i><font size="2" style="font-size:10.0pt;font-style:italic;">.</font></i><font size="2" style="font-size:10.0pt;">&#160; Prior to the purchase of the Firm Shares by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been suspended or limited by the Commission or by the NASDAQ, or trading in securities generally on either the NASDAQ or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York, </font><font size="2" style="font-size:10.0pt;">or Virginia authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or international political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce contracts</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="2123-2-KA-05_PB_28_131227_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=28,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=398850,FOLIO='28',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">for the sale of securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured.&#160; Any termination pursuant to this Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7&nbsp; hereof or (b)&nbsp;any Underwriter to the Company; <i>provided, however,</i> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;13.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">No Advisory or Fiduciary Relationship. </font></b><font size="2" style="font-size:10.0pt;">The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an arm&#146;s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;14.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Representations and Indemnities to Survive Delivery</font></b><i><font size="2" style="font-size:10.0pt;font-style:italic;">.</font></i><font size="2" style="font-size:10.0pt;">&#160; The respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Offered Shares sold hereunder and any termination of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;15.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Notices</font></b><font size="2" style="font-size:10.0pt;">.&#160; All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;width:93.32%;">
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If   to the Representatives:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jefferies   LLC</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">520   Madison Avenue</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New   York, New York 10022</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile:   (646) 619-4437</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:   General Counsel</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Piper   Jaffray&nbsp;&amp; Co.</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">800   Nicollet Mall</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Minneapolis,   MN 55402</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile:   (612) 303-1070</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:   General Counsel</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="2123-2-KA-05_PB_29_131513_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=29,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=253871,FOLIO='29',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;width:93.32%;">
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with   a copy to:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Latham&nbsp;&amp;   Watkins LLP</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">885   Third Avenue;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New   York, NY 10022,</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:   Peter Handrinos,&nbsp;Esq.</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If   to the Company:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collegium   Pharmaceutical,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">780   Dedham Street, Suite&nbsp;800</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Canton,   MA 02021</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile:   (781) 828-4697</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:   Michael Heffernan</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with   a copy to:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pepper   Hamilton LLP</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3000   Two Logan Square</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Philadelphia,   PA 19103</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:   Steven J. Abrams,&nbsp;Esq.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any party hereto may change the address for receipt of communications by giving written notice to the others.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;16.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Successors</font></b><i><font size="2" style="font-size:10.0pt;font-style:italic;">.</font></i><font size="2" style="font-size:10.0pt;">&#160; This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;9 and Section&nbsp;10, and in each case their respective successors, and no other person will have any right or obligation hereunder.&#160; The term &#147;</font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">successors</font></b><font size="2" style="font-size:10.0pt;">&#148; shall not include any purchaser of the Offered Shares as such from any of the Underwriters merely by reason of such purchase.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;17.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Partial Unenforceability</font></b><font size="2" style="font-size:10.0pt;">.&#160; The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof.&#160; If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;18.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Governing Law Provisions</font></b><i><font size="2" style="font-size:10.0pt;font-style:italic;">.</font></i><font size="2" style="font-size:10.0pt;">&#160; This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state.&#160; Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (&#147;</font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Related Proceedings</font></b><font size="2" style="font-size:10.0pt;">&#148;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#147;</font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Specified Courts</font></b><font size="2" style="font-size:10.0pt;">&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a &#147;</font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Related Judgment</font></b><font size="2" style="font-size:10.0pt;">&#148;), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.&#160; Service of any process, summons, notice or document by mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court.&#160; The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="2123-2-KA-05_PB_30_131539_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=30,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=28544,FOLIO='30',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-05_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:39 2015' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 19.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">General Provisions.</font></b><font size="2" style="font-size:10.0pt;">&#160; This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.&#160; This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.&#160; This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.&#160; The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section 9 and the contribution provisions of Section 10, and is fully informed regarding said provisions.&#160; Each of the parties hereto further acknowledges that the provisions of Section 9 and&nbsp;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="2123-2-KA-07_PB_31_131911_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=31,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=776545,FOLIO='31',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very   truly yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM   PHARMACEUTICAL, INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="2123-2-KA-07_PB_32_132002_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=32,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=230737,FOLIO='32',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New York, New York as of the date first above written.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">JEFFERIES   LLC</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PIPER   JAFFRAY &amp; CO.</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Acting   individually and as Representatives</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of   the several Underwriters named in</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the   attached <u>Schedule A</u>.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">JEFFERIES   LLC</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PIPER JAFFRAY &amp; CO.</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="2123-2-KA-07_PB_33_132126_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=33,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=62696,FOLIO='33',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Schedule A</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;width:80.0%;">
<tr>
<td width="76%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:76.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Underwriters</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.74%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of<br>   Firm&nbsp;Shares<br>   to&nbsp;be&nbsp;Purchased</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="76%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:76.9%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jefferies LLC</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:18.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="76%" valign="bottom" style="padding:0in 0in 0in 0in;width:76.9%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Piper Jaffray &amp; Co.</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" style="padding:0in 0in 0in 0in;width:18.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="76%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:76.9%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Wells Fargo Securities, LLC</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="76%" valign="bottom" style="padding:0in 0in 0in 0in;width:76.9%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Needham &amp; Company, LLC</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="76%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:76.9%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:18.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="76%" valign="bottom" style="padding:0in 0in 0in 0in;width:76.9%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:18.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=34,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=996860,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Schedule B</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Free Writing Prospectuses Included in the Time of Sale Prospectus</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[To be added]</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=35,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=215597,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Schedule C</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Permitted Section 5(d) Communications</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[To be added]</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=36,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=424545,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit A</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form of Lock-up Agreement</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&nbsp;</font><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;">&nbsp;], 2015</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">JEFFERIES LLC <br> PIPER JAFFRAY &amp; CO. <br> As Representatives of the several Underwriters</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o JEFFERIES LLC <br> 520 Madison Avenue<br> New York, New York 10022</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o PIPER JAFFRAY &amp; CO.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">800 Nicollet Mall</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Minneapolis, MN 55402</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">RE:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Collegium Pharmaceutical, Inc. (the &#147;<b>Company</b>&#148;)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies &amp; Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned is an owner of shares of common stock, par value $0.001 per share, of the Company (&#147;<b>Shares</b>&#148;) and/or Related Securities.&#160; The Company proposes to conduct a public offering of Shares (the &#147;<b>Offering</b>&#148;) for which Jefferies LLC (&#147;<b>Jefferies</b>&#148;) and Piper Jaffray &amp; Co. (&#147;<b>Piper Jaffray</b>&#148;) will act as the representatives of the underwriters.&#160; The undersigned recognizes that the Offering will benefit each of the Company and the undersigned.&#160; The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the &#147;<b>Underwriting Agreement</b>&#148;) and other underwriting arrangements with the Company with respect to the Offering.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this agreement.&#160; Those definitions are a part of this agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the Lock-up Period, subject to the exceptions set forth in this Agreement, the undersigned will not (and will cause any Family Member not to), without the prior written consent of Jefferies and Piper Jaffray, which may withhold their consent in their sole discretion:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned or such Family Member,</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">enter into any Swap,</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-1<a name="2123-2-KA-07_PB_1_132616_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=37,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=117022,FOLIO='A-1',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">publicly announce any intention to do any of the foregoing.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing will not apply to the registration of the offer and sale of the Shares, and the sale of the Shares to the underwriters, in each case as contemplated by the Underwriting Agreement. In addition, the foregoing restrictions shall not apply to (i) the acquisition of Shares in open market transactions in or after the completion of Offering; <u>provided</u> that no filing under Section 16(a) of the Securities Exchange Act of 1934, as amended, shall be required or shall be voluntarily made in connection with subsequent sales of Shares acquired in such open market transactions; (ii) the transfer of Shares or Related Securities by gift, (iii) the transfer of Shares or Related Securities by will or intestate succession to the legal representative, heir or beneficiary of the undersigned, (iv) the transfer of Shares or Related Securities to a trust whose beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member, (v) transfers or dispositions of the undersigned&#146;s Shares or Related Securities to any corporation, partnership, limited liability company or other entity all of the beneficial ownership interests of which are held by the undersigned or any Family Member, (vi) distributions of the undersigned&#146;s Shares or Related Securities to limited partners, general partners, members, stockholders or other equityholders of the undersigned, provided that any such transfer or distribution shall not involve a disposition for value, (vii) by operation of law, including pursuant to a domestic order or negotiated divorce settlement or (viii) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, the transfer of Shares or Related Securities to another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, provided that any such transfer or distribution shall not involve a disposition for value; <i>provided, however</i>, that in any such case, it shall be a condition to such transfer that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">each transferee executes and delivers to Jefferies and Piper Jaffray an agreement in form and substance satisfactory to Jefferies and Piper Jaffray stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto), and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">prior to the expiration of the Lock-up Period, no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares or Related Securities in connection with such transfer.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furthermore, notwithstanding the restrictions imposed by this letter agreement, the undersigned may (i) exercise an option to purchase Shares granted under any equity incentive plan or stock purchase plan of the Company existing as of the date hereof and described in the Prospectus, <i>provided</i> that the Shares issued upon such exercise shall continue to be subject to the restrictions on transfer set forth in this letter agreement, (ii) establish a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Shares, <i>provided</i> that such plan does not provide for any transfers of Shares or Related Shares during the Lock-up Period and the entry into such plan is not publicly disclosed, including in any filing under the Exchange Act, during the Lock-up Period or (iii) transfer Shares or Related Securities (A) as forfeitures to satisfy tax withholding obligations of the undersigned in connection with the vesting or exercise of equity awards by the undersigned pursuant to the Company&#146;s equity incentive plan existing as of the date hereof and described in the Prospectus, (B) pursuant to a net exercise or cashless exercise by the undersigned of outstanding equity awards pursuant to the Company&#146;s equity incentive plan existing as of the date hereof and described in the Prospectus, <i>provided</i> that any Shares acquired upon the net exercise or cashless exercise of equity awards described in this clause (B) shall be subject to the restrictions set forth in this letter agreement, (C) pursuant to a bona fide third-party tender offer for all outstanding shares of the Company, merger, consolidation or other similar transaction made to all holders of the Company&#146;s </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-2<a name="2123-2-KA-07_PB_2_132637_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=38,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=943732,FOLIO='A-2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">securities involving a change of control of the Company (including, without limitation, the entering into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of common stock or other such securities in connection with such transaction, or vote any common stock or other such securities in favor of any such transaction), <i>provided</i> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the provisions of this letter agreement, or (D) that may be deemed to have occurred as a result of the conversion of the outstanding preferred shares of the Company into shares of common stock or the exercise of warrants, <i>provided</i> that the restrictions set forth in this letter agreement shall apply to any of the undersigned&#146;s Shares or Related Securities issued upon such conversion or exercise; <i>provided</i> that, in the case of a transfer pursuant to clause (A) or (B) above, if the undersigned is required to make a filing under the Exchange Act reporting a reduction in beneficial ownership of Shares during the Lock-up Period, the undersigned shall include a statement in such report to the effect that the purpose of such transfer was to cover tax obligations of the undersigned in connection with such exercise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any Company-directed Shares the undersigned may purchase or otherwise receive in the Offering (including pursuant to a directed share program).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, i</font><font size="2" style="font-size:10.0pt;">f the undersigned is an officer or director of the Company, (i) Jefferies and Piper Jaffray agree that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Shares, Jefferies and Piper Jaffray will notify the Company of the impending release or waiver, and (ii) the Company (in accordance with the provisions of the Underwriting Agreement) will announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver.&#160; Any release or waiver granted by Jefferies and Piper Jaffray hereunder to any such officer or director shall only be effective two business days after the publication date of such press release.&#160; The provisions of this paragraph will not apply if both (a) the release or waiver is effected solely to permit a transfer not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this letter agreement that are applicable to the transferor to the extent and for the duration that such terms remain in effect at the time of the transfer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer of Shares or Related Securities held by the undersigned and the undersigned&#146;s Family Members, if any, except in compliance with the foregoing restrictions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares.&#160; The undersigned will not, and will cause any Family Member not to take, directly or indirectly, any such action.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and other factors.&#160; The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-3<a name="2123-2-KA-07_PB_3_132651_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=39,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=387788,FOLIO='A-3',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement.&#160; This letter agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding anything herein to the contrary, if (a) the closing of the Offering has not occurred prior to September 30, 2015, (b) after being executed, the Underwriting Agreement (other than the provisions thereof that survive termination) shall terminate or be terminated prior to payment for and delivery of the Shares to be sold thereunder or (c) the Company notifies the Underwriters in writing that it does not intend to proceed with the Offering, then the undersigned shall be released from all obligations under this letter agreement upon the earliest to occur of the events specified above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-4<a name="2123-2-KA-07_PB_4_132702_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=40,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=626971,FOLIO='A-4',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-07_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:21 2015' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Printed   Name of Person Signing</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Indicate   capacity of person signing if</font></i></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">signing   as custodian or trustee, or on behalf</font></i></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">of an   entity)</font></i></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-5<a name="2123-2-KA-09_PB_5_132940_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=41,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=929411,FOLIO='A-5',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-09_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:31 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Certain Defined Terms<br>  <u>Used in Lock-up Agreement</u></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Call Equivalent Position</b>&#148; shall have the meaning set forth in Rule&nbsp;16a-1(b)&nbsp;under the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Exchange Act</b>&#148; shall mean the Securities Exchange Act of 1934, as amended.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Family Member</b>&#148; shall mean the spouse of the undersigned, an immediate family member of the undersigned or an immediate family member of the undersigned&#146;s spouse, in each case living in the undersigned&#146;s household or whose principal residence is the undersigned&#146;s household (regardless of whether such spouse or family member may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise).&#160; &#147;<b>Immediate family member</b>&#148; as used above shall have the meaning set forth in Rule&nbsp;16a-1(e)&nbsp;under the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Lock-up Period</b>&#148; shall mean the period beginning on the date hereof and continuing through the close of trading on the date that is 180 days after the date of the Prospectus (as defined in the Underwriting Agreement).</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Put Equivalent Position</b>&#148; shall have the meaning set forth in Rule&nbsp;16a-1(h)&nbsp;under the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Related Securities</b>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Securities Act</b>&#148; shall mean the Securities Act of 1933, as amended.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Sell or Offer to Sell</b>&#148; shall mean to:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">sell, offer to sell, contract to sell or lend,</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call Equivalent Position</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">pledge, hypothecate or grant any security interest in, or</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in any other way transfer or dispose of,</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in each case whether effected directly or indirectly.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Swap</b>&#148; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this lock-up agreement.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-6<a name="2123-2-KA-09_PB_6_133111_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=42,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=723988,FOLIO='A-6',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-KA-09_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:31 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>a2224429zex-3_2.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 3.2</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLES OF AMENDMENT OF THE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDED AND RESTATED ARTICLES OF INCORPORATION OF<br> COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The name of the corporation is Collegium Pharmaceutical,&nbsp;Inc. (the &#147;Corporation&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">II.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The amendment (the &#147;Amendment&#148;) adopted is as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following is hereby added to the end of Paragraph A of Article&nbsp;IV of the Corporation&#146;s Amended and Restated Articles of Incorporation:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Simultaneously with the effective time of this amendment (the &#147;Effective Time&#148;), subject to the treatment of fractional share interests as described below, each 6.9 shares of the Corporation&#146;s Common Stock issued and outstanding immediately prior to the Effective Time shall be combined and converted into one (1)&nbsp;validly issued, fully paid and non-assessable share of Common Stock (the &#147;Reverse Stock Split&#148;). There shall be no combination or conversion of the Series&nbsp;A Preferred Stock, the Series&nbsp;B Preferred, the Series&nbsp;C Preferred or the Series&nbsp;D Preferred Stock in connection with the Reverse Split.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Reverse Stock Split will be effected on a holder-by-holder basis.&#160; In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay an amount of cash (without interest or deduction) equal to the product of (i)&nbsp;the fractional share to which the holder would otherwise be entitled and (ii)&nbsp;the fair value of such share as of the Effective Time as determined in good faith by the Board of Directors of the Corporation.&#160; The Reverse Stock Split shall occur automatically without any further action by the Corporation or the holders of the shares of Common Stock affected thereby.&#160; All rights, preferences and privileges of the Common Stock and the Preferred Stock as provided in these Restated Articles shall be adjusted to reflect the Reverse Stock Split (including the Conversion Prices of each series of the Preferred Stock, which shall be adjusted in accordance with Section&nbsp;4.5 of Paragraph D of Article&nbsp;IV).</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each stock certificate representing shares of Common Stock immediately prior to the Effective Time shall, from and after the Effective Time, represent that number of shares of Common Stock into which such shares shall have been reclassified pursuant to the Reverse Stock Split, subject to the elimination of fractional share interests as described above.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">III.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Amendment was adopted by the Corporation&#146;s Board of Directors on April&nbsp;23, 2015.&#160; The Amendment was proposed by the Corporation&#146;s Board of Directors and submitted to the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=369736,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LH_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 22:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporation&#146;s shareholders in accordance with the provisions of Title 13.1, Chapter 9 of the Code of Virginia.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IV.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The designation, number of outstanding shares, and number of votes entitled to be cast by each voting group entitled to vote separately on the Amendment was:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.25in;width:90.0%;">
<tr>
<td width="60%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:60.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Designation</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of<br>   &nbsp;Outstanding&nbsp;Shares</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of&nbsp;Votes<br>   Entitled&nbsp;to&nbsp;be&nbsp;Cast</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="60%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:60.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="60%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:60.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common Stock, $0.001 par value per share;   Preferred Stock, $0.001 par value per share, Series&nbsp;A, Series&nbsp;B,   Series&nbsp;C and Series&nbsp;D</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">95,965,129</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">95,965,129</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="60%" valign="bottom" style="padding:0in 0in 0in 0in;width:60.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred Stock, $0.001 par value per share,   Series&nbsp;A, Series&nbsp;B, Series&nbsp;C and Series&nbsp;D</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="bottom" style="padding:0in 0in 0in 0in;width:16.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">86,881,246</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="bottom" style="padding:0in 0in 0in 0in;width:16.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">86,881,246</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The total number of undisputed votes cast for the Amendment separately by each voting group was:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.25in;width:90.0%;">
<tr>
<td width="76%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:76.1%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Voting&nbsp;Group</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total&nbsp;Undisputed&nbsp;Votes<br>   &#147;FOR&#148;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="76%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:76.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="76%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:76.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common Stock, $0.001 par value per share;   Preferred Stock, $0.001 par value per share, Series&nbsp;A, Series&nbsp;B,   Series&nbsp;C and Series&nbsp;D</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71,535,900</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="76%" valign="bottom" style="padding:0in 0in 0in 0in;width:76.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred Stock, $0.001 par value per share,   Series&nbsp;A, Series&nbsp;B, Series&nbsp;C and Series&nbsp;D</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68,424,265</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The total number of votes cast for the Amendment by each voting group was sufficient for approval of the Amendment by such voting group.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">V.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to Section&nbsp;13.1-606 of the Virginia Stock Corporation Act, the Amendment shall become effective at 3:00&nbsp;p.m., Eastern Time, on April&nbsp;24, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Signature Page&nbsp;Follows]</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="2123-2-LH_PB_2_221352_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=577217,FOLIO='2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LH_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 22:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF</font></b><font size="2" style="font-size:10.0pt;">, the undersigned corporation has caused these Articles of Amendment to be executed by its duly authorized officer as of this 24</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font><font size="2" style="font-size:10.0pt;">&#160;day of April, 2015.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM   PHARMACEUTICAL,&nbsp;INC.</font></b><font size="2" style="font-size:10.0pt;">, a<br>   Virginia corporation</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Paul Brannelly</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul   Brannelly</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive   Vice President and Chief<br>   Financial Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="2123-2-LH_PB_3_221520_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=867250,FOLIO='3',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LH_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 22:17 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>4
<FILENAME>a2224429zex-3_3.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 3.3</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDED AND RESTATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLES OF INCORPORATION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;I</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The name of the corporation (the &#147;Corporation&#148;) is Collegium Pharmaceutical,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;II</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Corporation&#146;s purpose is to transact any or all lawful business not required to be specifically stated in these Articles.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;III</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Corporation shall have the authority to issue 100,000,000 shares of Common Stock, par value $0.001 per share (&#147;Common Stock&#148;), and 5,000,000 shares of Preferred Stock, par value $0.001 per share (&#147;Preferred Stock&#148;). The rights, preferences voting powers and the qualifications, limitations and restrictions of the authorized stock shall be as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Voting Powers </font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Each share of Common Stock outstanding on any voting record date shall be entitled to one vote on any action of shareholders for which that voting record date was fixed. Except as otherwise required by the Virginia Stock Corporation Act (the &#147;Act&#148;), the exclusive general voting power for all purposes shall be vested in the Common Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Except as otherwise required by these Articles, the Act or the Board of Directors acting pursuant to subsection B of Section&nbsp;13.1-707 (or any successor provision) of the Act:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the vote required to constitute any voting group&#146;s approval of any corporate action except the election of directors, an amendment of these Articles or the Bylaws, a plan of merger, share exchange, domestication or entity conversion, or a proposed sale or other disposition of the Corporation&#146;s property that requires shareholder approval pursuant to Section&nbsp;13.1-724 of the Act (or any successor provision), or the dissolution of the Corporation, shall be a majority of all votes cast on the matter by such voting group;</font></p>
<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Bylaws shall set forth the vote required for the election of directors or, if not set forth in the Bylaws, the vote required shall be that set forth in the Act;</font></p>
<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)&nbsp; the vote required to constitute any voting group&#146;s approval of an amendment of these Articles, a plan of merger, share exchange, domestication or entity conversion, or a proposed sale or other disposition of the Corporation&#146;s property that requires shareholder approval pursuant to Section&nbsp;13.1-724 of the Act (or any successor</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="2123-2-LI_PB_1_130028_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="4",CHK=1037873,FOLIO='1',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:40 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">provision), or the dissolution of the Corporation, shall be a majority of all votes entitled to be cast on the matter by such voting group; and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)&nbsp;the vote required to constitute any voting group&#146;s approval of an adoption, amendment or repeal of the Bylaws shall be more than two-thirds of all votes entitled to be cast on the matter by such voting group.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Common Stock </font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">Dividends</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to the rights of the holders of Preferred Stock, holders of Common Stock shall be entitled to receive such dividends and other distributions as the Board of Directors may declare thereon from time to time out of assets or funds of the Corporation legally available therefor and shall share equally on a per share basis in all such dividends and other distributions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font size="2" style="font-size:10.0pt;font-style:italic;">Dissolution</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of the Corporation&#146;s dissolution, whether voluntary or involuntary, after payment in full of the amounts required to be paid to the holders of Preferred Stock, the remaining assets and funds of the Corporation shall be distributed pro rata to the holders of Common Stock. For purposes of this Article&nbsp;III(B)2, the voluntary sale, conveyance, lease, exchange or transfer (for cash, shares of stock, securities or other consideration) of all or substantially all of the assets of the Corporation or a merger or share exchange involving the Corporation and one or more other entity (whether or not the Corporation is the entity surviving such merger) shall not be deemed to be a dissolution of the Corporation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Preferred Stock </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board of Directors, without shareholder action, may, by adopting an amendment of these Articles:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Classify any unissued shares into one or more classes or into one or more series within one or more classes;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Reclassify any unissued shares of any class into one or more classes or into one or more series within one or more classes; or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Reclassify any unissued shares of any series of any class into one or more classes or into one or more series within one or more classes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board of Directors may determine the preferences, limitations and relative rights, to the extent permitted by the Act, of any class of shares of Preferred Stock before the issuance of any shares of that class, or of one or more series within a class before the issuance of any shares of that series.&#160; Each class or series shall be appropriately designated by a distinguishing designation prior to the issuance of any shares thereof.&#160; The Preferred Stock of all classes and series shall have preferences, limitations and relative rights identical with those of other shares of the same class or series.&#160; The preferences, limitations and relative rights of each series shall be</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="2123-2-LI_PB_2_130227_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="4",CHK=232779,FOLIO='2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:40 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">identical with those of shares of other series of the same class, except to the extent otherwise provided in the description of the series.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prior to the issuance of any shares of a class or series of Preferred Stock, (1)&nbsp;the Board of Directors shall establish such class or series, without any action required by the shareholders, by adopting an amendment of these Articles and by filing with the State Corporation Commission of Virginia articles of amendment setting forth the designation and number of shares of the class or series and the preferences, limitations and relative rights thereof, and (2)&nbsp;the State Corporation Commission of Virginia shall have issued a certificate of amendment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(D)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">No Preemptive Rights </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No holder of any capital stock of the Corporation shall have any preemptive right to subscribe for, purchase or acquire (1)&nbsp;any shares of capital stock of the Corporation, (2)&nbsp;any securities convertible into or exchangeable for any such shares or (3)&nbsp;any options, warrants or rights to subscribe for, purchase or acquire any such shares or securities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;IV</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The number of directors shall be fixed by or in accordance with the Bylaws.&#160; Commencing with the 2015 annual meeting of shareholders, the Board of Directors shall be divided into three classes, Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, as nearly equal in number as possible.&#160; At the 2015 annual meeting of shareholders (or pursuant to written consent in lieu of such annual meeting), directors of the first class (Class&nbsp;I) shall be elected to hold office for a term expiring at the 2016 annual meeting of shareholders, directors of the second class (Class&nbsp;II) shall be elected to hold office for a term expiring at the 2017 annual meeting of shareholders and directors of the third class (Class&nbsp;III) shall be elected to hold office for a term expiring at the 2018 annual meeting of shareholders and, in each case, until such directors&#146; successors are duly elected and qualified.&#160; At each annual meeting of shareholders after 2015, the successors to the class of directors whose terms then shall expire shall be identified as being of the same class as the directors they succeed and elected to hold office for a term expiring at the third succeeding annual meeting of shareholders and until such directors&#146; successors are duly elected and qualified.&#160; When the number of directors is changed, any newly created directorships or any decrease in directorships shall be apportioned among the classes by the Board of Directors as to make all classes as nearly equal in number as possible.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Directors may be removed only for cause upon the affirmative vote of more than two-thirds of all votes entitled to be cast by holders of the Common Stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any vacancy on the Board of Directors, including a vacancy resulting from an increase in the number of directors, shall be filled by the Board of Directors or, if the directors remaining in office constitute fewer than a quorum of the Board of Directors, then by the affirmative vote of a majority of such directors remaining in office.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the full extent permitted by the Act, the Board of Directors is expressly empowered to adopt, amend and repeal the Bylaws.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="2123-2-LI_PB_3_130311_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="4",CHK=639100,FOLIO='3',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:40 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;V</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Definitions </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of this Article&nbsp;V, the following terms shall have the meanings indicated:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;eligible person&#148; means a person who is or was a director or officer of the Corporation or a person who, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, trustee, partner or officer of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. A person shall be considered to be serving an employee benefit plan at the Corporation&#146;s request if his or her duties to the Corporation also impose duties on, or otherwise involve services by, him or her to the plan or to participants in or beneficiaries of the plan;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;expenses&#148; includes, without limitation, counsel fees and expenses;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;liability&#148; means the obligation to pay a judgment, settlement, penalty, fine (including any excise tax assessed with respect to an employee benefit plan) or reasonable expenses incurred with respect to a proceeding;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;party&#148; includes, without limitation, an individual who was, is or is threatened to be made a named defendant or respondent in a proceeding; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;proceeding&#148; means any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative and whether formal or informal.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Limitation of Liability </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the full extent that the Act, as it exists on the effective date of these Articles or as hereafter amended, permits the limitation or elimination of the liability of directors and officers, no director or officer of the Corporation made a party to any proceeding brought by or in the right of the Corporation or brought by or on behalf of shareholders of the Corporation shall be liable to the Corporation or its shareholders for monetary damages arising out of any transaction, occurrence or course of conduct, whether occurring prior or subsequent to the effective date of this Article&nbsp;V.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Indemnification </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the full extent permitted by the Act, as it exists on the date hereof or as hereafter amended, the Corporation shall indemnify and hold harmless any person who was or is a party to any proceeding, including a proceeding brought by or in the right of the Corporation or brought by or on behalf of shareholders of the Corporation, by reason of the fact that such person is or was an eligible person against any liability incurred by such person in connection with such proceeding, except for liability resulting from such person&#146;s having engaged in willful misconduct or a knowing violation of the criminal law.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="2123-2-LI_PB_4_130532_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="4",CHK=639067,FOLIO='4',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:40 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(D)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Termination of Proceeding </font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The termination of any proceeding by judgment, order, settlement, conviction or upon a plea of <i>nolo contendere</i> or its equivalent, shall not, of itself, create a presumption that the eligible person did not meet any standard of conduct that is a prerequisite to the limitation or elimination of liability provided in Article&nbsp;V(B)&nbsp;or to such person&#146;s entitlement to indemnification under Article&nbsp;V(C).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(E)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Determination of Availability </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Corporation shall indemnify and hold harmless under Article&nbsp;V(C)&nbsp;any eligible person who entirely prevails in the defense of any proceeding. Any other indemnification under Article&nbsp;V(C)&nbsp;(unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification is proper in the circumstances because the eligible person has met any standard of conduct that is a prerequisite to his or her entitlement to indemnification under Article&nbsp;V(C).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The determination shall be made:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If there are two or more disinterested directors (as defined in the Act), by the Board of Directors by a majority vote of all the disinterested directors, a majority of whom shall for such purpose constitute a quorum, or by a majority of the members of a committee of two or more disinterested directors appointed by such a vote;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">By special legal counsel:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Selected in the manner prescribed in subdivision 1 of this subsection; or</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If there are fewer than two disinterested directors, selected by the Board of Directors, in which selection directors who do not qualify as disinterested directors may participate; or</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">By the shareholders, but shares owned by or voted under the control of a director who at the time does not qualify as a disinterested director may not be voted on the determination.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the other provisions of this Article&nbsp;V(E), in the event there has been a change in the composition of a majority of the Board of Directors after the date of the alleged act or omission with respect to which indemnification is claimed other than through successor directors approved by the Board of Directors as it existed prior to such date, any determination as to such indemnification shall be made by special legal counsel agreed upon by the Board of Directors and the eligible person. If the Board of Directors and the eligible person are unable to agree upon such special legal counsel, the Board of Directors and the eligible person each shall select a nominee, and the nominees shall select such special legal counsel.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(F)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Advances </font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the full extent permitted by the Act, as it exists on the date hereof or as hereafter amended, the Corporation shall pay for or reimburse the reasonable expenses incurred by any eligible person who is a party to a proceeding in advance of final disposition of the proceeding or the making of any determination under Article&nbsp;V(C)&nbsp;if such eligible person furnishes the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="2123-2-LI_PB_5_130556_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="4",CHK=89442,FOLIO='5',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:40 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporation a written undertaking, executed personally or on his or her behalf, to repay the advance if it is ultimately determined that he or she did not meet the requisite standard of conduct.&#160; The undertaking required by this Article&nbsp;V(F)&nbsp;shall be an unlimited general obligation but need not be secured and shall be accepted without reference to financial ability to make repayment.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(G)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Indemnification of Others </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Corporation is empowered to indemnify and advance expenses to or contract to indemnify or advance expenses to any person not specified in Article&nbsp;V(C)&nbsp;or Article&nbsp;V(F)&nbsp;who was, is or may become a party to any proceeding, by reason of the fact that he or she is or was an employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, trustee, partner or officer of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, to the same or a lesser extent as if such person were specified as one to whom indemnification or advancement of expenses is granted in Article&nbsp;V(C)&nbsp;or Article&nbsp;V(F).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(H)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Application; Amendment </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The provisions of this Article&nbsp;V shall be applicable to all proceedings commenced after it becomes effective arising from any act or omission, whether occurring before or after such effective date.&#160; No amendment or repeal of this Article&nbsp;V shall impair or otherwise diminish the rights provided under this Article&nbsp;V (including those created by contract) with respect to any act or omission occurring prior to such amendment or repeal.&#160; The Corporation shall promptly take all such actions and make all such determinations and authorizations as shall be necessary or appropriate to comply with its obligation to make any indemnity against liability, or to advance any expenses, under this Article&nbsp;V and shall promptly pay or reimburse all reasonable expenses incurred by any eligible person in connection with such actions and determinations or proceedings of any kind arising therefrom.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Insurance </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Corporation may purchase and maintain insurance to indemnify it against the whole or any portion of the liability assumed by it in accordance with this Article&nbsp;and may also procure insurance, in such amounts as the Board of Directors may determine, on behalf of any eligible person (and for a person referred to in Article&nbsp;V(G)) against any liability asserted against or incurred by such person whether or not the Corporation would have power to indemnify such person against such liability under the provisions of this Article&nbsp;V or the Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(J)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Further Indemnity </font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Every reference herein to directors, officers, trustees, partners, employees or agents shall include former directors, officers, trustees, partners, employees or agents and their respective heirs, executors and administrators.&#160; The indemnification hereby provided and provided hereafter pursuant to the power hereby conferred by this Article&nbsp;V shall not be exclusive of any other rights to which any person may be entitled, including any right under policies of insurance that may be purchased and maintained by the Corporation or others, with respect to claims, issues or</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="2123-2-LI_PB_6_130621_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="4",CHK=23860,FOLIO='6',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:40 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">matters in relation to which the Corporation would not have the power to indemnify such person under the provisions of this Article&nbsp;V.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Nothing herein shall prevent or restrict the power of the Corporation to make or provide for any further indemnity or advancement of expenses, or provisions for determining entitlement to indemnity or advancement of expenses, pursuant to one or more agreements, Bylaws, resolutions of directors or shareholders, or other arrangements (including, without limitation, creation of trust funds or security interests funded by letters of credit or other means); <i>provided</i>, <i>however</i>, that any provision of any such agreement, Bylaw, resolution or other arrangement shall not be effective if and to the extent that it is determined to be contrary to this Article&nbsp;or applicable laws of the Commonwealth of Virginia, but other provisions of any such agreement, Bylaw, resolution or other arrangement shall not be affected by any such determination.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(K)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Severability </font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each provision of this Article&nbsp;V shall be severable, and an adverse determination as to any such provision shall in no way affect the validity of any other provision.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;VI</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Article&nbsp;14.1 of Chapter 9 of Title 13.1 of the Code of Virginia shall not apply to the Corporation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;VII</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board of Directors may establish procedures and limitations regarding the submission by shareholders of nominations for director and proposals for consideration at meetings of the shareholders.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Special meetings of shareholders may be called by the Board of Directors, the Chairman of the Board of Directors or the President of the Corporation, and may not be called by any other person or entity.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="2123-2-LI_PB_7_130638_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="4",CHK=608344,FOLIO='7',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:40 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>5
<FILENAME>a2224429zex-3_5.htm
<DESCRIPTION>EX-3.5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 3.5</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDED AND RESTATED <br> BYLAWS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM PHARMACEUTICAL, INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE I</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Meetings of Shareholders</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Annual Meetings.</font></b><font size="2" style="font-size:10.0pt;"> - The annual meeting of the shareholders for the election of directors and for the transaction of such other business as may properly come before the meeting, and any postponement or adjournment thereof, shall be held on such date and at such time as the Board of Directors may in its discretion determine.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Special Meetings.</font></b><font size="2" style="font-size:10.0pt;"> - Special meetings of the shareholders may be called by the chairman of the Board of Directors, the president of the Corporation or the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Place of Meetings.</font></b><font size="2" style="font-size:10.0pt;"> - All meetings of the shareholders shall be held at such place as from time to time may be fixed by the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Notice of Meetings.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notice, stating the place, day and time and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall be given not less than 10 nor more than 60 days before the date of the meeting (except as a different time is specified herein or by law), to each shareholder of record having voting power in respect of the business to be transacted thereat.&#160; Notice of a shareholders&#146; meeting to act on an amendment or restatement of the Articles of Incorporation, a plan of merger, share exchange, domestication or entity conversion, a proposed sale or other disposition of the Corporation&#146;s property that requires shareholder approval or the dissolution of the Corporation shall be given not less than 25 nor more than 60 days before the date of the meeting.&#160; A record date fixed by the Board of Directors with respect to any meeting of the shareholders shall be the record date for determining shareholders entitled to notice of and to vote at such meeting, unless the Board of Directors, at the time it fixes the record date for shareholders entitled to notice of the meeting, fixes a later record date on or before the date of the meeting to determine the shareholders entitled to vote at the meeting.&#160; Notice may be given in any manner permitted by law.&#160; The Board of Directors may postpone any previously scheduled meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding Section 4(a) of this Article I, a written waiver of notice signed by the person or persons entitled to such notice, either before or after the time stated therein, shall be equivalent to the giving of such notice. A shareholder who attends a meeting shall be deemed to have (i) waived objection to lack of notice or defective notice of the meeting, unless at the beginning of the meeting such shareholder objects to holding the meeting or transacting business at the meeting, and (ii) waived objection to consideration of a particular </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="2123-2-LK-01_PB_1_131115_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=814323,FOLIO='1',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">matter at the meeting that is not within the purpose or purposes described in the meeting notice, unless such shareholder objects to considering the matter when it is presented.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Quorum and Vote Required.</font></b><font size="2" style="font-size:10.0pt;"> - At all meetings of the shareholders, unless a greater number or voting by groups is required by law, a majority of the shares entitled to vote, represented in person or by proxy, shall constitute a quorum. Once a share is represented for any purpose at a meeting, it is present for quorum purposes for the remainder of the meeting and for any adjournment thereof unless a new record date is or must be set for that adjourned meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If a quorum is present, action on a matter is approved if the votes cast favoring the action exceed the votes cast opposing the action, unless the vote of a greater number or voting by groups is required by law or the Articles of Incorporation, and except that directors shall be elected by a plurality of the votes cast.&#160; In the absence of a quorum, a majority of the votes cast may adjourn such meeting, provided that no business other than adjournment shall be conducted in the absence of a quorum.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Organization.</font></b><font size="2" style="font-size:10.0pt;"> - At all meetings of the shareholders, the chairman of the Board of Directors or, in the chairman&#146;s absence, the chief executive officer or, in the chief executive officer&#146;s absence, such other person selected by the Board of Directors, shall act as chairman of the meeting.&#160; In the absence of the foregoing persons, a majority of the shares present and entitled to vote at such meeting may appoint any person to act as chairman.&#160; The secretary of the Corporation or, in the secretary&#146;s absence, an assistant secretary, shall act as secretary at each meeting of the shareholders.&#160; In the event that neither the secretary nor any assistant secretary is present, the chairman of the meeting may appoint any person to act as secretary of the meeting.&#160; The Board of Directors may adopt such rules, regulations and procedures for the conduct of any meeting of shareholders as it shall deem appropriate.&#160; Except to the extent inconsistent with such rules, regulations and procedures as adopted by the Board of Directors, the chairman of any meeting of shareholders shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts and things as, in the judgment of such person, are appropriate for the proper conduct of the meeting. Such rules, regulations and procedures, whether adopted by the Board of Directors or prescribed by the chairman of the meeting, may include, without limitation, the following: (a) the establishment of an agenda or order of business for the meeting; (b) rules and procedures for maintaining order at the meeting and the safety of those present; (c) limitations on attendance at or participation in the meeting to shareholders of record, their duly authorized and constituted proxies or such other persons as the chairman of the meeting shall permit; (d) restrictions on entry to the meeting after the time fixed for the commencement thereof; and (e) limitations on the time allotted to questions or comments by participants.&#160; The chairman of the meeting shall have the power to recess or adjourn any meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 7.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Order of Business.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Annual Meeting of Shareholders</font></u><font size="2" style="font-size:10.0pt;">.&#160; At any annual meeting of the shareholders, only such nominations of persons for election to the Board of Directors shall be made, and only such other business shall be conducted or considered, as shall have been properly </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="2123-2-LK-01_PB_2_131734_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=42156,FOLIO='2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">brought before the meeting.&#160; For nominations to be properly made at an annual meeting, and proposals of other business to be properly brought before an annual meeting, nominations and proposals of other business must be (i) specified in the Corporation&#146;s notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, (ii) otherwise properly made at the annual meeting, by or at the direction of the Board of Directors, or (iii) otherwise properly requested to be brought before the annual meeting by a shareholder of the Corporation in accordance with these Bylaws.&#160; For nominations of persons for election to the Board of Directors or proposals of other business to be properly requested by a shareholder to be made at an annual meeting, a shareholder must (x) be a shareholder of record at the time of giving of notice of such annual meeting by or at the direction of the Board of Directors, at the time the shareholder provides the notice required by Section 8 of Article I of these Bylaws and at the time of the annual meeting, (y) be entitled to vote at such annual meeting and (z) comply with the procedures set forth in these Bylaws as to such business or nomination.&#160; The immediately preceding sentence shall be the exclusive means for a shareholder to make nominations or other business proposals (other than matters properly brought under Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and included in the Corporation&#146;s notice of meeting) before an annual meeting of shareholders.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Special Meeting of Shareholders</font></u><font size="2" style="font-size:10.0pt;">.&#160; At any special meeting of the shareholders, only such business shall be conducted or considered as shall have been properly brought before the meeting pursuant to the Corporation&#146;s notice of meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be properly brought before a special meeting, proposals of business must be (i) specified in the Corporation&#146;s notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors or (ii) otherwise properly brought before the special meeting, by or at the direction of the Board of Directors.&#160; Nominations of persons for election to the Board of Directors may be made at a special meeting of shareholders at which directors are to be elected pursuant to the Corporation&#146;s notice of meeting (A) by or at the direction of the Board of Directors or (B) provided that the Board of Directors has determined that directors shall be elected at such meeting, by any shareholder of the Corporation who (x) is a shareholder of record at the time of giving of notice of such special meeting, at the time the shareholder provides the notice required by Section 8 of Article I of these Bylaws and at the time of the special meeting, (y) is entitled to vote at the meeting and (z) complies with the procedures set forth in these Bylaws as to such nomination.&#160; The immediately preceding sentence shall be the exclusive means for a shareholder to make nominations or other business proposals before a special meeting of shareholders (other than matters properly brought under Rule 14a-8 under the Exchange Act and included in the Corporation&#146;s notice of meeting).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">General</font></u><font size="2" style="font-size:10.0pt;">.&#160; Except as otherwise provided by law, the Articles of Incorporation or these Bylaws, the chairman of the meeting shall have the power to determine whether a nomination or any other business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with these Bylaws and, if any proposed nomination or other business is not in compliance with these Bylaws, to declare that no action shall be taken on such nomination or other proposal and such nomination or other proposal shall be disregarded.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="2123-2-LK-01_PB_3_131822_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=171944,FOLIO='3',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 8.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Advance Notice of Shareholder Business and Nominations.</font></b></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Annual Meeting of Shareholders</font></u><font size="2" style="font-size:10.0pt;">.&#160; Without qualification or limitation, subject to Section 8(c)(iv) of Article I of these Bylaws, for any nominations or any other business to be properly brought before an annual meeting by a shareholder pursuant to Section 7(a) of Article I of these Bylaws, the shareholder must have given timely notice thereof in proper form (including, in the case of nominations, the completed and signed questionnaire, representation and agreement required by Section 9 of Article I of these Bylaws) and timely updates and supplements thereof in writing to the secretary and such other business must otherwise be a proper matter for shareholder action.&#160; To be timely, a shareholder&#146;s notice shall be delivered to the secretary at the principal executive offices of the Corporation not earlier than the close of business on the 120th day and not later than the close of business on the 90th day prior to the first anniversary of the preceding year&#146;s annual meeting; <i>provided</i>, <i>however</i>, that in the event that the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the shareholder must be so delivered not earlier than the close of business on the 120th day prior to the date of such annual meeting and not later than the close of business on the later of the 90th day prior to the date of such annual meeting or, if the first public announcement of the date of such annual meeting is less than 100 days prior to the date of such annual meeting, the tenth day following the day on which public announcement of the date of such meeting is first made by the Corporation.&#160; In no event shall any adjournment or postponement of an annual meeting, or the public announcement thereof, commence a new time period for the giving of a shareholder&#146;s notice as described above.&#160; Notwithstanding anything in the preceding two sentences to the contrary, in the event that the number of directors to be elected to the Board of Directors is increased by the Board of Directors, and there is no public announcement by the Corporation naming all of the nominees for director or specifying the size of the increased Board of Directors at least 100 days prior to the first anniversary of the preceding year&#146;s annual meeting, a shareholder&#146;s notice required by this Section 8(a) of Article I shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day following the day on which such public announcement is first made by the Corporation.&#160; In addition, to be timely, a shareholder&#146;s notice shall further be updated and supplemented, if necessary, so that the information provided or required to be provided in such notice shall be true and correct as of the record date for the meeting and as of the date that is ten business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to the secretary at the principal executive offices of the Corporation not later than five business days after the record date for the meeting in the case of the update and supplement required to be made as of the record date, and not later than eight business days prior to the date for the meeting, any adjournment or postponement thereof in the case of the update and supplement required to be made as of ten business days prior to the meeting or any adjournment or postponement thereof.&#160; If a shareholder who has given timely notice as required herein to make a nomination or bring other business before any such meeting and intends to authorize another person to act for such shareholder as a proxy to present the proposal at such meeting, the shareholder shall give notice of such authorization in writing to the secretary not less than three business days before the date of the meeting, including the name and contact information for such person.</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="2123-2-LK-01_PB_4_131915_455"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=929889,FOLIO='4',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Special Meeting of Shareholders</font></u><font size="2" style="font-size:10.0pt;">.&#160; Subject to Section 8(c)(iv) of Article I of these Bylaws, in the event the Corporation calls a special meeting of shareholders for the purpose of electing one or more directors to the Board of Directors, any shareholder may nominate a person or persons (as the case may be) for election to such position(s) to be elected as specified in the Corporation&#146;s notice calling the meeting, provided that the shareholder gives timely notice thereof in proper form (including the completed and signed questionnaire, representation and agreement required by Section 9 of Article I of these Bylaws) and timely updates and supplements thereof in writing to the secretary.&#160; In order to be timely, a shareholder&#146;s notice shall be delivered to the secretary at the principal executive offices of the Corporation not earlier than the close of business on the 120th day prior to the date of such special meeting and not later than the close of business on the later of the 90th day prior to the date of such special meeting or, if the first public announcement of the date of such special meeting is less than 100 days prior to the date of such special meeting, the 10th day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting.&#160; In no event shall any adjournment or postponement of a special meeting, or the public announcement thereof, commence a new time period for the giving of a shareholder&#146;s notice as described above.&#160; In addition, to be timely, a shareholder&#146;s notice shall further be updated and supplemented, if necessary, so that the information provided or required to be provided in such notice shall be true and correct as of the record date for the meeting and as of the date that is ten business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to the secretary at the principal executive offices of the Corporation not later than five business days after the record date for the meeting in the case of the update and supplement required to be made as of the record date, and not later than eight business days prior to the date for the meeting, any adjournment or postponement thereof in the case of the update and supplement required to be made as of ten business days prior to the meeting or any adjournment or postponement thereof.&#160; If a shareholder who has given timely notice as required herein to bring any business before any such meeting and intends to authorize another person to act for such shareholder as a proxy to present the proposal at such meeting, the shareholder shall give notice of such authorization in writing to the secretary not less than three business days before the date of the meeting, including the name and contact information for such person.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Other Provisions</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">To be in proper form, a shareholder&#146;s notice (whether given pursuant to Section 8(a) of Article I or Section 8(b) of Article I of these Bylaws) to the secretary must include the following, as applicable:</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">as to the shareholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made, a shareholder&#146;s notice must set forth: (1) the name and address of such shareholder, as they appear on the Corporation&#146;s books, of such beneficial owner, if any, and of their respective affiliates or associates or others acting in concert therewith, (2) (a) the class or series and number of shares of the Corporation and any other equity or debt securities of the Corporation which are, directly or indirectly, owned beneficially and of record by such shareholder, such beneficial owner or their respective affiliates or associates or others acting in concert therewith and the date(s) on which such securities were acquired, and the names and number of shares of the Corporation held by any </font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="2123-2-LK-01_PB_5_132020_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=523258,FOLIO='5',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">nominees on behalf of any such persons (and the date(s) such shares were acquired), (b) any option, warrant, convertible security, stock appreciation right or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from the value of any class or series of shares of the Corporation, or any derivative or synthetic arrangement having the characteristics of a long position in any class or series of shares of the Corporation, or any contract, derivative, swap or other transaction or series of transactions designed to produce economic benefits and risks that correspond substantially to the ownership of any class or series of shares of the Corporation, including due to the fact that the value of such contract, derivative, swap or other transaction or series of transactions is determined by reference to the price, value or volatility of any class or series of shares of the Corporation, whether or not such instrument, contract or right shall be subject to settlement in the underlying class or series of shares of the Corporation, through the delivery of cash or other property, or otherwise, and without regard to whether the shareholder of record, the beneficial owner, if any, or any affiliates or associates or others acting in concert therewith, may have entered into transactions that hedge or mitigate the economic effect of such instrument, contract or right or any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares of the Corporation (any of the foregoing, a &#147;Derivative Instrument&#148;) directly or indirectly owned beneficially by such shareholder, the beneficial owner, if any, or any affiliates or associates or others acting in concert therewith (and the date(s) such securities were acquired), (c) any proxy (other than a revocable proxy given in response to a solicitation made pursuant to, and in accordance with, Section 14(a) of the Exchange Act by way of a solicitation statement filed on Schedule 14A), contract, arrangement or understanding pursuant to which such shareholder, beneficial owner, if any, or affiliates or associates or others acting in concert therewith has a right to vote any class or series of shares or other securities of the Corporation, (d) any contract, agreement, arrangement or understanding, including any repurchase or similar so-called &#147;stock borrowing&#148; agreement or arrangement, engaged in, directly or indirectly, by such shareholder, beneficial owner, if any, or affiliates or associates or others acting in concert therewith, the purpose or effect of which is to mitigate loss to, reduce the economic risk (of ownership or otherwise) of any class or series of the shares of the Corporation by, manage the risk of share price changes for, or increase or decrease the voting power of, such shareholder, beneficial owner, if any, or affiliates or associates or others acting in concert therewith with respect to any class or series of the shares or other securities of the Corporation, or which provides, directly or indirectly, the opportunity to profit or share in any profit derived from any decrease in the price or value of any class or series of the shares or other securities of the Corporation (any of the foregoing, &#147;Short Interests&#148;), (e) any rights to dividends or other distributions on the shares of the Corporation owned beneficially by such shareholder, beneficial owner, if any, or affiliates or associates or others acting in concert therewith that are separated or separable from the underlying shares of the Corporation, (f) any proportionate interest in shares of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such shareholder, beneficial owner, if any, or affiliates or associates or others acting in concert therewith is a general partner or, directly or indirectly, beneficially owns an interest in a general partner of such general or limited partnership, (g) any performance-related fees (other than an asset-based fee) to which such shareholder, beneficial owner, if any, or affiliates or associates or others acting in concert therewith is entitled based on any increase or decrease in the value of any class or series of the shares or other securities of the Corporation or Derivative Instruments, </font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="2123-2-LK-01_PB_6_132028_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=93693,FOLIO='6',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">if any, (h) any significant equity interests or any Derivative Instruments or Short Interests in any principal competitor of the Corporation held by such shareholder, beneficial owner, if any, or affiliates or associates or others acting in concert therewith and (i) any direct or indirect interest of such shareholder, beneficial owner, if any, or affiliates or associates or others acting in concert therewith in any contract with the Corporation, any affiliate of the Corporation or any principal competitor of the Corporation (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement), and (3) any other information relating to such shareholder and beneficial owner, if any, that would be required to be disclosed in a proxy statement and form of proxy or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in a contested election pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if the notice relates to any business other than a nomination of a director or directors that the shareholder proposes to bring before the meeting, a shareholder&#146;s notice must, in addition to the matters set forth in paragraph (A) above, also set forth: (1) a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest of such shareholder and beneficial owner, if any, and their respective affiliates and associates or others acting in concert therewith in such business, (2) the text of the proposal or business (including the text of any resolutions proposed for consideration) and (3) a description of all agreements, arrangements and understandings between such shareholder and beneficial owner, if any, and any other person or persons (including their names) in connection with the proposal of such business by such shareholder;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">as to each person, if any, whom the shareholder proposes to nominate for election or reelection to the Board of Directors, a shareholder&#146;s notice must, in addition to the matters set forth in paragraph (A) above, also set forth: (1) all information relating to such person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder (including such person&#146;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected) and (2) a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships, between or among such shareholder and beneficial owner, if any, and their respective affiliates and associates, or others acting in concert therewith, on the one hand, and each proposed nominee, and his or her respective affiliates and associates, or others acting in concert therewith, on the other hand, including all information that would be required to be disclosed pursuant to Rule 404 promulgated under Regulation S-K if the shareholder making the nomination and any beneficial owner on whose behalf the nomination is made, if any, or any affiliate or associate thereof or person acting in concert therewith, were the &#147;registrant&#148; for purposes of such rule and the nominee were a director or executive officer of such registrant; and</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(D)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">with respect to each person, if any, whom the shareholder proposes to nominate for election or reelection to the Board of Directors, a shareholder&#146;s notice must, in addition to the matters set forth in paragraphs (A) and (C) above, also include a </font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="2123-2-LK-01_PB_7_132106_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=653289,FOLIO='7',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">completed and signed questionnaire, representation and agreement required by Section 9 of Article I of these Bylaws. The Corporation may require any proposed nominee to furnish such other information as may reasonably be required by the Corporation to determine the eligibility of such proposed nominee to serve as an independent director of the Corporation or that could be material to a reasonable shareholder&#146;s understanding of the independence, or lack thereof, of such nominee.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">For purposes of these Bylaws, &#147;public announcement&#148; shall mean disclosure in a press release reported by a national news service, including the Dow Jones News Service or the Associated Press, or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act and the rules and regulations promulgated thereunder.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding the provisions of these Bylaws, a shareholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in these Bylaws; <i>provided</i>, <i>however</i>, that any references in these Bylaws to the Exchange Act or the rules promulgated thereunder are not intended to and shall not limit the requirements applicable to nominations or proposals as to any other business to be considered pursuant to these Bylaws.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Nothing in these Bylaws shall be deemed to affect any rights (1) of shareholders to request inclusion of proposals in the Corporation&#146;s proxy statement pursuant to Rule 14a-8 under the Exchange Act, (2) of the holders of any series of preferred stock of the Corporation if and to the extent provided for under law, the Articles of Incorporation or these Bylaws or (3) of shareholders to act by unanimous written consent in accordance with the Articles of Incorporation and applicable law.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to Rule 14a-8 under the Exchange Act, nothing in these Bylaws shall be construed to permit any shareholder, or give any shareholder the right, to include or have disseminated or described in the Corporation&#146;s proxy statement any nomination of director or directors or any other business proposal.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The disclosures required by Section 8(a) of Article I or Section 8(b) of Article I of these Bylaws shall not include any disclosures with respect to ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a shareholder solely as a result of being the shareholder of record or nominee directed to prepare and submit the notice required by Section 8(a) of Article I or Section 8(b) of Article I, as the case may be, on behalf of a beneficial owner other than the name of any such entity and the number of shares held on behalf of such beneficial owner.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 9.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Submission of Questionnaire, Representation and Agreement.</font></b><font size="2" style="font-size:10.0pt;"> - To be eligible to be a nominee for election or reelection as a director of the Corporation, a person must deliver (in accordance with the time periods prescribed for delivery of notice under Section 8 of Article I of these Bylaws) to the secretary at the principal executive offices of the Corporation a written questionnaire with respect to the background and qualification of such person and the background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided by the secretary upon written request), and a written </font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="2123-2-LK-01_PB_8_132223_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=241799,FOLIO='8',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">representation and agreement (in the form provided by the secretary upon written request) that such person (a) is not and will not become a party to (i) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a &#147;Voting Commitment&#148;) that has not been disclosed to the Corporation or (ii) any Voting Commitment that could limit or interfere with such person&#146;s ability to comply, if elected as a director of the Corporation, with such person&#146;s fiduciary duties under applicable law, (b) is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed therein and (c) in such person&#146;s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, would be in compliance, if elected as a director of the Corporation, and will comply with all applicable corporate governance, conflict of interest, resignation, confidentiality and stock ownership and trading policies and guidelines of the Corporation publicly disclosed from time to time.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 10.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Voting.</font></b><font size="2" style="font-size:10.0pt;"> - A shareholder may vote his or her shares in person or by proxy.&#160; Any proxy shall be delivered to the secretary of the meeting or to the inspectors of election appointed in accordance with Section 12 of Article I of these Bylaws at or prior to the time designated by the chairman of the meeting or in the order of business for so delivering such proxies.&#160; No proxy shall be valid after 11 months from its date, unless otherwise provided in the proxy.&#160; Each holder of record of stock of any class shall, as to all matters in respect of which stock of such class has voting power, be entitled to such vote as is provided in the Articles of Incorporation for each share of stock of such class standing in the holder&#146;s name on the books of the Corporation as of the voting record date for the meeting of shareholders.&#160; Unless required by statute or determined by the chairman of the meeting to be advisable, the vote on any question need not be by ballot.&#160; On a vote by ballot, each ballot shall be signed by the shareholder voting or by such shareholder&#146;s proxy, if there be such proxy; <i>provided</i>, <i>however</i>, that if authorized by the Board of Directors, any shareholder vote to be taken by written ballot may be satisfied by a ballot submitted by electronic transmission by the shareholder or the shareholder&#146;s proxy, provided that any such electronic transmission shall either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by the shareholder or the shareholder&#146;s proxy.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 11.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Proxies. </font></b><font size="2" style="font-size:10.0pt;">- A shareholder or a shareholder&#146;s duly authorized agent or attorney-in-fact may appoint a proxy to vote or otherwise act for the shareholder by signing an appointment form or by an electronic transmission.&#160; An electronic transmission shall contain or be accompanied by information from which one can determine that the shareholder, the shareholder&#146;s duly authorized agent or the shareholder&#146;s duly authorized attorney-in-fact authorized the transmission.&#160; Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to this Section 11 of Article I of these Bylaws may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="2123-2-LK-01_PB_9_132245_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=1003859,FOLIO='9',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 12.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Inspectors.</font></b><font size="2" style="font-size:10.0pt;"> - At all meetings of the shareholders, the Corporation shall appoint one or more inspectors.&#160; Each inspector, before entering upon the discharge of his or her duties, shall certify in writing that the inspector will faithfully execute the duties of inspector with strict impartiality and according to the best of his or her ability.&#160; The inspectors shall (a) ascertain the number of shares outstanding and the voting power of each, (b) determine the shares represented at a meeting and the validity of proxies, proxy appointments and ballots, (c) count all votes, (d) determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors, (e) certify in a written report their determination of the number of shares represented at the meeting and their count of all the votes and (f) perform such other duties as required by law or requested by the Corporation or the chairman of the meeting in connection with such meeting.&#160; The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 13.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Record Dates.</font></b><font size="2" style="font-size:10.0pt;"> - The Board of Directors shall fix, in advance, a record date or dates to make a determination of shareholders entitled to notice of or to vote at any meeting of shareholders or to receive any dividend or distribution or for any other purpose, such date or dates to be not more than 70 days before the meeting or action requiring a determination of shareholders.&#160; When a determination of shareholders entitled to notice of or to vote at any meeting of shareholders has been made, such determination shall be effective for any adjournment of the meeting unless the Board of Directors fixes a new record date or dates, which it shall do if the meeting is adjourned to a date more than 120 days after the date fixed for the original meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE II</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Board of Directors</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">General Powers.</font></b><font size="2" style="font-size:10.0pt;"> &#151; All corporate powers shall be exercised by or under the direction of the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Number.</font></b><font size="2" style="font-size:10.0pt;"> - The number of directors shall be determined from time to time by resolution of the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Term of Office.</font></b><font size="2" style="font-size:10.0pt;"> - Each director shall hold office for his or her applicable term in accordance with the Articles of Incorporation and until his or her successor shall have been duly elected and qualified.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Organization.</font></b><font size="2" style="font-size:10.0pt;"> - At all meetings of the Board of Directors, the chairman of the Board of Directors or, in the chairman&#146;s absence, the lead independent director (if any) shall act as chairman of the meeting.&#160; In the absence of the foregoing persons, the majority of the directors present at a meeting may appoint any director who is present at such meeting to act as chairman.&#160; The secretary of the Corporation or, in the secretary&#146;s absence, an assistant secretary, shall act as secretary of meetings of the Board of Directors.&#160; In the event that neither the secretary nor any assistant secretary is present at such meeting, the chairman of the meeting shall appoint any person to act as secretary of the meeting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="2123-2-LK-01_PB_10_132303_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=971843,FOLIO='10',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Vacancies.</font></b><font size="2" style="font-size:10.0pt;"> - Any vacancy occurring in the Board of Directors, including a vacancy resulting from an increase in the number of directors, shall be filled in accordance with the Articles of Incorporation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Place of Meeting.</font></b><font size="2" style="font-size:10.0pt;"> - Meetings of the Board of Directors, regular or special, may be held either within or outside the Commonwealth of Virginia.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 7.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Organizational Meeting.</font></b><font size="2" style="font-size:10.0pt;"> &#151; Unless otherwise determined by the chairman or the Board of Directors, the annual organizational meeting of the Board of Directors shall be held immediately following adjournment of the annual meeting of shareholders and at the same place, without the requirement of any notice other than this provision of the Bylaws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 8.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Regular Meetings; Notice.</font></b><font size="2" style="font-size:10.0pt;"> - Regular meetings of the Board of Directors shall be held at such times and places as it may from time to time determine.&#160; Notice of such meetings need not be given if the time and place have been fixed at a previous meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 9.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Special Meetings; Notice.</font></b><font size="2" style="font-size:10.0pt;"> - Special meetings of the Board of Directors shall be held whenever called by order of the chairman of the Board of Directors, the lead independent director, or any two of the directors.&#160; Notice of each such meeting, which need not specify the business to be transacted thereat, shall be (a) mailed to each director, addressed to his or her residence or usual place of business, at least two days before the day on which the meeting is to be held, (b) given at least 24 hours before the time of the meeting by electronic transmission as previously consented to by the director to whom notice is given or (c) given personally or by telephone at least 24 hours before the time of the meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 10.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Waiver of Notice.</font></b><font size="2" style="font-size:10.0pt;"> - Whenever any notice is required to be given to a director of any meeting for any purpose under the provisions of law, the Articles of Incorporation or these Bylaws, a waiver thereof in writing signed by the person or persons entitled to such notice, either before or after the time stated therein, shall be equivalent to the giving of such notice. &#160;A director&#146;s attendance at or participation in a meeting waives any required notice to him or her of the meeting unless at the beginning of the meeting or promptly upon the director&#146;s arrival, he or she objects to holding the meeting or transacting business at the meeting and does not thereafter vote for or assent to action taken at the meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 11.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Quorum and Manner of Acting.</font></b><font size="2" style="font-size:10.0pt;"> - Except as otherwise required by law, the Articles of Incorporation or these Bylaws, a majority of the directors fixed by these Bylaws at the time of any regular or special meeting of the Board of Directors shall constitute a quorum for the transaction of business at such meeting, and the act of a majority of the directors present at any such meeting at which a quorum is present shall be the act of the Board of Directors.&#160; In the absence of a quorum, a majority of those present may adjourn the meeting from time to time until a quorum be had.&#160; Notice of any such adjourned meeting need not be given.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section 12.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Telephonic Meetings.</font></b><font size="2" style="font-size:10.0pt;"> - Any or all directors may participate in any regular or special meeting of the Board of Directors or any committee thereof, or conduct such meeting, through the use of any means of communication by which all directors participating may</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="2123-2-LK-01_PB_11_132315_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=890288,FOLIO='11',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:23 2015' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">simultaneously hear each other during the meeting. A director participating in a meeting by this means is deemed to be present in person at the meeting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;13.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Action Without Meeting.</font></b><font size="2" style="font-size:10.0pt;"> - Action required or permitted to be taken by the Board of Directors may be taken without a meeting if each director signs a consent describing the action to be taken and delivers it to the Corporation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;14.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Order of Business.</font></b><font size="2" style="font-size:10.0pt;"> - At all meetings of the Board of Directors, business may be transacted in such order as from time to time the Board of Directors may determine.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;15.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Resignation of Director.</font></b><font size="2" style="font-size:10.0pt;"> - Any director may resign at any time by giving written notice to the Board of Directors, the chairman of the Board of Directors or the secretary of the Corporation.&#160; Unless the resignation is contingent on acceptance by the Board of Directors, or as otherwise stated in the notice of resignation, it shall take effect when delivered.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;16.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Chairman.</font></b><font size="2" style="font-size:10.0pt;"> - The Board of Directors may elect a chairman from among the directors.&#160; The chairman of the Board of Directors shall preside at meetings of the Board of Directors and perform such other duties as may be set forth in these Bylaws or requested by the Board of Directors or otherwise incident to such office.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;17.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Committees.</font></b><font size="2" style="font-size:10.0pt;"> - The Board of Directors may create one or more committees and appoint directors to serve on them.&#160; Each committee shall have at least two members. The creation of a committee shall be approved by the greater number of (a)&nbsp;a majority of all directors in office at the time the action is being taken or (b)&nbsp;the number of directors required to take action under Section&nbsp;11 of Article&nbsp;II hereof.&#160; Any such committee, to the extent provided in the resolution of the Board of Directors designating the committee, shall have and may exercise the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, except as limited by law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;III</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Officers</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Officers.</font></b><font size="2" style="font-size:10.0pt;"> - The officers of the Corporation may include a chief executive officer, a president, a chief operating officer, one or more vice presidents (one or more of whom may be designated executive, senior, assistant or associate vice presidents or given similar designations), a treasurer, a secretary, an assistant treasurer and an assistant secretary. Any two or more offices may be held by the same person.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Election and Term of Office.</font></b><font size="2" style="font-size:10.0pt;"> - All officers of the Corporation shall be elected annually by the Board of Directors, and each officer shall hold office until a successor shall have been duly elected or until such officer&#146;s resignation, death or removal in the manner hereinafter provided.&#160; The Board of Directors may delegate to an officer the authority to elect subordinate officers.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="2123-2-LK-03_PB_12_132506_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=242829,FOLIO='12',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Duties.</font></b><font size="2" style="font-size:10.0pt;"> - The officers of the Corporation shall have such duties as generally pertain to their offices, respectively, as well as such powers and duties as are prescribed by law or are hereinafter provided or as from time to time shall be conferred by the Board of Directors or, in the case of inferior officers, the chief executive officer.&#160; The chief executive officer, the president, the chief operating officer, any vice president, the treasurer, the secretary and such other persons as the Board of Directors or the chief executive officer may authorize may sign and execute in the name of the Corporation representations, securities, deeds, mortgages, leases, licenses, releases, bonds, powers of attorney, contracts or other instruments, and any officer may sign and execute in the name of the Corporation such instruments as are incidental to such officer&#146;s duties in the ordinary course of business, except in either case where the signing and the execution thereof shall be expressly delegated by the Board of Directors or by these Bylaws to some other officer or agent of the Corporation or shall be required by law otherwise to be signed or executed.&#160; The Board of Directors may require any officer to give such bond for the faithful performance of his or her duties as the Board may see fit.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Vacancies.</font></b><font size="2" style="font-size:10.0pt;"> - If any vacancy shall occur among the officers of the Corporation, such vacancy shall be filled by the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Removal.</font></b><font size="2" style="font-size:10.0pt;"> - Any officer of the Corporation may be removed at any time, with or without cause, by the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Resignation. </font></b><font size="2" style="font-size:10.0pt;">- Any officer may resign at any time by delivering a notice of his or her resignation to the Board of Directors or the chairman of the Board.&#160; Any such resignation shall be effective when the notice is delivered unless the notice specifies a later effective date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;7.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Chief Executive Officer.</font></b><font size="2" style="font-size:10.0pt;"> - The chief executive officer shall be responsible for the general management and control of the business and affairs of the Corporation and shall see to it that all orders and resolutions of the Board of Directors are implemented.&#160; The chief executive officer shall, from time to time, report to the Board of Directors on matters within his or her knowledge which the interests of the Corporation may require be brought to its attention.&#160; The chief executive officer shall do and perform such other duties as from time to time the Board of Directors may prescribe.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;8.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">President.</font></b><font size="2" style="font-size:10.0pt;"> - The president shall have such authority and perform such duties as are commonly incident to his or her office and all such other duties as are properly required of him or her by the Board of Directors or the chief executive officer or as are provided elsewhere in these Bylaws, and shall assist the chief executive officer in the administration and operation of the Corporation&#146;s business and general supervision of its policies and affairs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;9.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Chief Operating Officer. </font></b><font size="2" style="font-size:10.0pt;">- The chief operating officer (if any) shall be responsible to the chief executive officer for the principal operating businesses of the Corporation and shall have such powers and shall perform such duties as shall be assigned to him or her by the chief executive officer or the Board of Directors.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="2123-2-LK-03_PB_13_132522_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=659062,FOLIO='13',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Vice Presidents.</font></b><font size="2" style="font-size:10.0pt;"> - The vice presidents of the Corporation shall have such powers and shall perform such duties as shall be assigned to them by the chief executive officer or the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;11.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Treasurer.</font></b><font size="2" style="font-size:10.0pt;"> - The treasurer shall exercise general supervision over the receipt, custody and disbursement of corporate funds. The treasurer shall be responsible for the performance of all duties incident to the office of treasurer. The treasurer shall have such further powers and duties and shall be subject to such directions as may be granted or imposed upon him or her from time to time by the chief executive officer or the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;12.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Secretary.</font></b><font size="2" style="font-size:10.0pt;"> - The secretary shall be the ex-officio clerk of the Board of Directors and shall give, or cause to be given, notices of all meetings of shareholders and directors, and all other notices required by law or by these Bylaws. The secretary shall record the proceedings of the meetings of the shareholders, Board of Directors and committees of the Board of Directors in books kept for that purpose and shall keep the seal of the Corporation and attach it to all documents requiring such impression unless some other officer is designated to do so by the Board of Directors. The secretary shall be responsible for the performance of all duties incident to the office of secretary. The secretary shall have such further powers and duties and shall be subject to such directions as may be granted or imposed upon him or her from time to time by the chief executive officer or the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;13.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Voting Securities of Other Corporations.</font></b><font size="2" style="font-size:10.0pt;"> - Unless otherwise provided by the Board of Directors, each of the chief executive officer, the president (if any), and any vice-president in the name and on behalf of the Corporation, may appoint from time to time himself or herself or any other person proxy, attorney or agent for the Corporation to cast the votes which the Corporation may be entitled to cast as a shareholder, member or otherwise in any other corporation, partnership or other legal entity, domestic or foreign, whose stock, interests or other securities are held by the Corporation, or to consent in writing to any action by such other entity, or to exercise any or all other powers of this Corporation as the holder of the stock, interests or other securities of such other entity. Each of the chief executive officer, the president (if any), or any vice-president may instruct the person so appointed as to the manner of casting such votes or giving such consent and may execute or cause to be executed on behalf of the Corporation and under its corporate seal such written proxies, consents, ballots, waivers or other instruments as may be deemed necessary or proper.&#160; Each of the chief executive officer, the president (if any), or any vice-president may attend any meeting of the holders of stock, interests or other securities of any such other entity and vote or exercise any and all other powers of this Corporation as the holder of the stock, interest or other securities of such other entity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;IV</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Depositaries; Loans</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Depositaries.</font></b><font size="2" style="font-size:10.0pt;"> - The money and negotiable instruments of the Corporation shall be kept in such bank or banks as the treasurer shall from time to time direct or approve. All checks and other instruments for the disbursement of funds shall be executed manually or by</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="2123-2-LK-03_PB_14_132534_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=803610,FOLIO='14',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">facsimile by such officers or agents of the Corporation as may be authorized by the Board of Directors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Loans. </font></b><font size="2" style="font-size:10.0pt;">- The chief executive officer, the president (if any), any vice president, the treasurer and such other persons as the Board of Directors may authorize shall have the power to effect loans and advances at any time for the Corporation from any bank, trust company or other institution, or from any corporation, firm or individual, and for such loans and advances may make, execute and deliver promissory notes or other evidences of indebtedness of the Corporation, and, as security for the payment of any and all loans, advances, indebtedness and liability of the Corporation, may pledge, hypothecate or transfer any and all stocks, securities and other personal or real property at any time held by the Corporation, and to that end endorse, assign and deliver the same.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;V</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Certificates Representing Shares</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificates representing shares of the Corporation shall be signed by the chairman of the Board of Directors or the president of the Corporation (if any) and the secretary or an assistant secretary.&#160; Any and all signatures on such certificates, including signatures of officers, transfer agents and registrars, may be by facsimile.&#160; Notwithstanding the provisions of this Article&nbsp;V, the Corporation may issue shares without certificates and adopt a system of issuance, recordation and transfer of its shares by electronic or other means not involving any issuance of certificates, provided that, the use of such system by the Corporation is permitted by law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;VI</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Dividends</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board of Directors may from time to time declare dividends and other distributions from funds of the Corporation legally available therefor.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;VII</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Seal</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board of Directors shall provide a suitable seal or seals, which shall be in the form of a circle, and shall bear around the circumference the words &#147;Collegium Pharmaceutical,&nbsp;Inc.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;VIII</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fiscal Year</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fiscal year of the Corporation shall be the calendar year unless otherwise determined by the Board of Directors.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="2123-2-LK-03_PB_15_132559_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=370867,FOLIO='15',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;IX</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Emergency Bylaws</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If a quorum of the Board of Directors cannot be readily assembled because of some catastrophic event, and only in such event, these Bylaws shall, without further action by the Board of Directors, be deemed to have been amended for the duration of such emergency, as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">The first sentence of Section&nbsp;10 of Article&nbsp;II shall read as follows:</font></b></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Special meetings of the Board of Directors shall be held whenever called by order of the chairman of the Board of Directors, or of the president (if any) or of the lead independent director (if any) or of any director or of any person having the powers and duties of the chairman of the Board of Directors, the president (if any) or the lead independent director (if any).</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;12 of Article&nbsp;II shall read as follows:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The directors present at any regular or special meeting called in accordance with these Bylaws shall constitute a quorum for the transaction of business at such meeting, and the action of a majority of such directors shall be the act of the Board of Directors; <i>provided</i>, <i>however</i>, that in the event that only one director is present at any such meeting no action except the election of directors shall be taken until at least two additional directors have been elected and are in attendance.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="2123-2-LK-03_PB_16_132615_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=212723,FOLIO='16',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-LK-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 13:26 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>a2224429zex-5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 5.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="193" height="41" src="g21232oai001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3000 Two Logan Square</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eighteenth and Arch Streets</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Philadelphia, PA 19103-2799</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">215.981.4000</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax 215.981.4750</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">April&nbsp;27, 2015</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collegium Pharmaceutical ,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">780 Dedham Street, Suite&nbsp;800</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Canton, MA 02021</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-1.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Re:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Underwritten Public Offering</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have acted as counsel to Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation (the &#147;<b><i style="font-weight:bold;">Company</i></b>&#148;), in connection with the Registration Statement on Form&nbsp;S-1, as amended (Registration No.&nbsp;333-203208) (the &#147;<b><i style="font-weight:bold;">Registration Statement</i></b>&#148;), initially filed by the Company with the Securities and Exchange Commission (the &#147;<b><i style="font-weight:bold;">Commission</i></b>&#148;) on April&nbsp;2, 2015 under the Securities Act of 1933, as amended (the &#147;<b><i style="font-weight:bold;">Act</i></b>&#148;).&#160; The Registration Statement relates to the public offering (the &#147;<b><i style="font-weight:bold;">Offering</i></b>&#148;) of 6,670,000 shares of the common stock, par value $0.001 per share, of the Company (the &#147;<b><i style="font-weight:bold;">Shares</i></b>&#148;), all of which will be sold by the Company, and which includes 870,000 shares if the underwriters exercise in full their option to purchase additional shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We understand that the Shares are to be sold by the Company pursuant to the terms of an Underwriting Agreement (the &#147;<b><i style="font-weight:bold;">Underwriting Agreement</i></b>&#148;) in substantially the form filed as Exhibit&nbsp;1.1 to the Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This opinion is being furnished in accordance with the requirements of Item 601(b)(5)&nbsp;of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the prospectus that is a part of the Registration Statement, other than as expressly stated herein with respect to the Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection herewith, we have examined originals or copies, certified or otherwise identified to our satisfaction, of (i)&nbsp;the Registration Statement as filed with the Commission, (ii)&nbsp;the form of Underwriting Agreement filed as Exhibit&nbsp;1.1 to the Registration Statement, (iii)&nbsp;the Company&#146;s Amended and Restated Articles of Incorporation, as amended, filed as Exhibits 3.1 and 3.2 to the Registration Statement, as to be amended in the Form&nbsp;of Second Amended and Restated Articles of Incorporation, filed as Exhibit&nbsp;3.3 to the Registration Statement (the &#147;<b><i style="font-weight:bold;">Amended Charter</i></b>&#148;), (iv)&nbsp;the Company&#146;s Bylaws, filed as Exhibit&nbsp;3.4 to the Registration Statement, as to be amended in the Form&nbsp;of Amended and Restated Bylaws, filed as Exhibit&nbsp;3.5 to the Registration Statement, (v)&nbsp;resolutions of the Board of Directors and shareholders of the Company relating to the Offering and the issuance of the Shares as provided to us</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.02%;">
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:12.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston</font></p>    </td>
<td width="33%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:33.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Washington, D.C.</font></p>    </td>
<td width="17%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:17.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Detroit</font></p>    </td>
<td width="11%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:11.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New   York</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pittsburgh&nbsp;&nbsp;&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="19%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:19.98%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Berwyn</font></p>    </td>
<td width="20%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Harrisburg</font></p>    </td>
<td width="20%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Orange County</font></p>    </td>
<td width="20%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Princeton</font></p>    </td>
<td width="20%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Wilmington</font></p>    </td>   </tr>
<tr height="0">
<td width="79" style="border:none;"></td>
<td width="70" style="border:none;"></td>
<td width="25" style="border:none;"></td>
<td width="124" style="border:none;"></td>
<td width="125" style="border:none;"></td>
<td width="25" style="border:none;"></td>
<td width="108" style="border:none;"></td>
<td width="42" style="border:none;"></td>
<td width="41" style="border:none;"></td>
<td width="108" style="border:none;"></td>   </tr> </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">www.pepperlaw.com</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="6",CHK=952629,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OA_ZAD72302.CHC",USER="KBLACK",CD='Apr 25 01:42 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">by the Company, (vi)&nbsp;the stock record books of the Company as provided to us by the Company, and (vii)&nbsp;such other documents as we have deemed necessary or appropriate for purposes of rendering the opinion set forth herein.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In rendering this opinion, we have assumed the legal capacity of all natural persons, the genuineness and authenticity of all signatures on original documents, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as certified or photostatic copies, the accuracy and completeness of all documents and records reviewed by us, the accuracy, completeness and authenticity of certificates issued by any government official, office or agency and the absence of change in the information contained therein from the effective date of any such certificate, the due authorization, execution and delivery of all documents other than by the Company or its officers, where authorization, execution and delivery are prerequisites to the effectiveness of such documents and that the Shares will be issued against payment of valid consideration under applicable law.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We express no opinion herein as to the law of any state or jurisdiction other than the Virginia Stock Corporation Act of the Commonwealth of Virginia, including statutory provisions and all applicable provisions of the Constitution of the Commonwealth of Virginia and reported judicial decisions interpreting such laws of the Commonwealth of Virginia and the federal laws of the United States of America.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based upon and subject to the foregoing, we are of the opinion that when (i)&nbsp;the Company duly files the Amended Charter with the Virginia Stock Corporation Commission, (ii)&nbsp;the price at which the Shares are to be sold has been approved by the Board of Directors of the Company or the Pricing Committee duly appointed by the Board of Directors of the Company, (iii)&nbsp;the Registration Statement has been declared effective by the Commission, (iv)&nbsp;the duly appointed officers of the Company and the Underwriters execute and deliver the Underwriting Agreement and (v)&nbsp;the Shares are duly issued and delivered against payment therefor in accordance with the terms of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We assume no obligation to supplement this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed herein after the date hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We hereby consent to the filing of this opinion as a part of the Registration Statement and to the reference of our firm under the caption &#147;Legal Matters.&#148;&#160; In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules&nbsp;and regulations of the Commission.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very   truly yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Pepper Hamilton LLP</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pepper   Hamilton LLP</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="2123-2-OA_PB_2_141749_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="6",CHK=407497,FOLIO='2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OA_ZAD72302.CHC",USER="KBLACK",CD='Apr 25 01:42 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>7
<FILENAME>a2224429zex-10_33.htm
<DESCRIPTION>EX-10.33
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.33</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2015 EMPLOYEE STOCK PURCHASE PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Purpose.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Collegium Pharmaceutical,&nbsp;Inc. 2015 Employee Stock Purchase Plan (the &#147;Plan&#148;) is intended to encourage and facilitate the purchase of Shares of the common stock of Collegium Pharmaceutical,&nbsp;Inc. (the &#147;<u>Company</u>&#148;) by employees of the Company, thereby providing employees with a personal stake in the Company and a long range inducement to remain in the employ of the Company.&#160; It is the intention of the Company that the Plan qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Definitions.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Account</u>&#148; means a bookkeeping account established by the Committee on behalf of a Participant to hold Payroll Deductions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Board</u>&#148; means the Board of Directors of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Business Day</u>&#148; means a day on which national stock exchanges are open for trading.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Code</u>&#148; means the Internal Revenue Code of 1986, as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Committee</u>&#148; means the Committee appointed pursuant to Section&nbsp;14 of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Company</u>&#148; means Collegium Pharmaceutical,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Compensation</u>&#148; means the regular base salary paid to a Participant by the Company during such individual&#146;s period of participation in the Plan, plus any pre-tax contributions made by the Participant to any cash-or-deferred arrangement that meets the requirements of section 401(k)&nbsp;of the Code or any cafeteria benefit program that meets the requirements of section 125 of the Code, now or hereafter established by the Company. The following items of compensation shall not be included in Compensation: (i)&nbsp;all overtime payments, bonuses, commissions (other than those functioning as base salary equivalents), profit-sharing distributions and other incentive-type payments and (ii)&nbsp;any and all contributions (other than contributions subject to sections 401(k)&nbsp;and 125 of the Code) made on the Participant&#146;s behalf by the Company under any employee benefit or welfare plan now or hereafter established.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Election Form</u>&#148; means the form acceptable to the Committee which an Employee shall use to make an election to purchase Shares through Payroll Deductions pursuant to the Plan or to decrease or discontinue Payroll Deductions during an Offering pursuant to Section&nbsp;5(b)&nbsp;below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="7",CHK=820319,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Eligible Employee</u>&#148; means an Employee who meets the requirements for eligibility under Section&nbsp;3 of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Employee</u>&#148; means any person, including an officer, whose wages and other salary is required to be reported by the Company on Internal Revenue Service Form&nbsp;W-2 for federal income tax purposes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Enrollment Date</u>&#148; means, with respect to a given Offering Period, a date established from time to time by the Committee or the Board, which shall not be later than the first day of such Offering Period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Fair Market Value</u>&#148; means the closing price per Share on the principal national securities exchange on which the Shares are listed or admitted to trading or, if not listed or traded on any such exchange, on the National Market System of the National Association of Securities Dealers Automated Quotation System (&#147;NASDAQ&#148;), or if not listed or traded on any such exchange or system, the fair market value as reasonably determined by the Board, which determination shall be in accordance with the standards set forth in Treasury Regulation &#167;1.421-1(e)(2)&nbsp;and shall be conclusive.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Five Percent Owner</u>&#148; means an Employee who, with respect to the Company, is described in Section&nbsp;423(b)&nbsp;of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Offering</u>&#148; means an offering of Shares to Eligible Employees pursuant to the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Offering Commencement Date</u>&#148; means the first Business Day in an Offering Period as designated by the Board.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Offering Period</u>&#148; means the period extending from an Offering Commencement Date through the immediately following Offering Termination Date.&#160; Each Offering Period will be a six month period during which Payroll Deductions will be made and held for the purchase of Shares at the end of the Offering Period. The Board or the Committee may, at its discretion, choose a different Offering Period of not more than twelve (12) months for Offerings.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(q)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Offering Termination Date</u>&#148; means the last Business Day in an Offering Period as designated by the Board, or the date of a Change in Control (as defined in the Company&#146;s Amended and Restated 2014 Stock Incentive Plan), which occurs in an Offering Period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(r)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Participant</u>&#148; means an Employee who meets the requirements for eligibility under Section&nbsp;3 of the Plan and who has timely delivered an Election Form&nbsp;to the Committee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(s)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Payroll Deductions</u>&#148; means amounts withheld from a Participant&#146;s Compensation pursuant to the Plan, as described in Section&nbsp;5 of the Plan.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="2123-2-OI_PB_2_142001_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="7",CHK=876815,FOLIO='2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(t)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Plan</u>&#148; means the Collegium Pharmaceutical,&nbsp;Inc. 2015 Employee Stock Purchase Plan, as set forth in this document, and as may be amended from time to time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(u)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Plan Termination Date</u>&#148; means the earlier of: (1)&nbsp;the Offering Termination Date for the Offering in which the maximum number of Shares specified in Section&nbsp;4 of the Plan have been issued pursuant to the Plan; (2)&nbsp;the date as of which the Board chooses to terminate the Plan as provided in Section&nbsp;15 of the Plan; or (3)&nbsp;the date of a Change in Control.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Shares</u>&#148; means shares of common stock of the Company, $0.001 par value per share.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(w)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Successor-in-Interest</u>&#148; means the Participant&#146;s executor or administrator, or such other person or entity to whom the Participant&#146;s rights under the Plan shall have passed by will or the laws of descent and distribution.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Termination Form</u>&#148; means the form acceptable to the Committee which an Employee shall use to withdraw from an Offering pursuant to Section&nbsp;8 of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Eligibility and Participation.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Initial Eligibility</font></u><font size="2" style="font-size:10.0pt;">.&#160; Except as provided in Section&nbsp;3(b)&nbsp;of the Plan, each individual who is an Employee on an Offering Commencement Date shall be eligible to participate in the Plan with respect to the Offering that commences on that date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Ineligibility</font></u><font size="2" style="font-size:10.0pt;">.&#160; An Employee shall not be eligible to participate in the Plan if such Employee:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">is a Five Percent Owner;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">has not customarily worked more than 20 hours per week;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">has not customarily worked more than 5 months in any calendar year;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">has been employed with the Company for less than 21 days; or</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">is restricted from participating under Section&nbsp;3(d)&nbsp;of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Restrictions on Participation</font></u><font size="2" style="font-size:10.0pt;">.&#160; Notwithstanding any provisions of the Plan to the contrary, no Employee shall be granted an option to participate in the Plan if:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">immediately after the grant, such Employee would be a Five Percent Owner; or</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">such option would permit such Employee&#146;s rights to purchase stock under all employee stock purchase plans of the Company which meet the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="2123-2-OI_PB_3_142016_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="7",CHK=511685,FOLIO='3',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">requirements of Section&nbsp;423(b)&nbsp;of the Code to accrue at a rate which exceeds $25,000 in fair market value (as determined pursuant to Section&nbsp;423(b)(8)&nbsp;of the Code) for each calendar year in which such option is outstanding.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Commencement of Participation</font></u><font size="2" style="font-size:10.0pt;">.&#160; An Employee who meets the eligibility requirements of Sections 3(a)&nbsp;and 3(b)&nbsp;of the Plan as of an applicable Enrollment Date and whose participation is not restricted under Section&nbsp;3(d)&nbsp;of the Plan shall become a Participant by completing an Election Form&nbsp;and filing it with the Committee on or before each applicable Enrollment Date.&#160; Payroll Deductions for a Participant shall commence on the applicable Offering Commencement Date when his or her authorization for Payroll Deductions becomes effective, and shall end on the immediately following Offering Termination Date, unless sooner terminated by the Participant pursuant to Section&nbsp;8 of the Plan.&#160; Notwithstanding the foregoing sentence, to the extent necessary to comply with Section&nbsp;423(b)(8)&nbsp;of the Code and Section&nbsp;3(d)&nbsp;of the Plan, a Participant&#146;s payroll deductions may be decreased to zero percent (0%) at any time during an Offering Period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Shares Per Offering.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Plan shall be implemented by a series of Offerings that shall terminate on the Plan Termination Date.&#160; Offerings shall be made with respect to Compensation payable for each Offering Period occurring on or after adoption of the Plan by the Board and ending with the Plan Termination Date.&#160; Shares available for any Offering shall be the difference between the maximum number of Shares that may be issued under the Plan, as determined pursuant to Section&nbsp;10(a)&nbsp;of the Plan, for all of the Offerings, less the actual number of Shares purchased by Participants pursuant to prior Offerings.&#160; If the total number of Shares for which options are exercised on any Offering Termination Date exceeds the maximum number of Shares available, the Committee shall make a pro rata allocation of Shares available for delivery and distribution in as nearly a uniform manner as practicable, and as it shall determine to be fair and equitable, and the unapplied Account balances shall be returned to Participants as soon as practicable following the Offering Termination Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Payroll Deductions.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amount of Payroll Deductions</font></u><font size="2" style="font-size:10.0pt;">.&#160; An Eligible Employee who wishes to participate in the Plan shall file an Election Form&nbsp;(authorizing payroll deductions) with the Committee prior to the applicable Enrollment Date.&#160; With respect to any Offering made under this Plan, a Participant may authorize a Payroll Deduction in any percentage amount (in whole percentages) up to a maximum of 15% of the Compensation he or she receives during the Offering Period or such shorter period during which deductions from payroll are made. The Board or the Committee may, at its discretion, designate a lower maximum contribution rate. The minimum payroll deduction is such percentage of Compensation as may be established from time to time by the Board or the Committee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Participants&#146; Accounts</font></u><font size="2" style="font-size:10.0pt;">.&#160; All Payroll Deductions with respect to a Participant pursuant to Section&nbsp;5(a)&nbsp;of the Plan shall commence on the first payroll following the Enrollment Date and shall end of the last payroll in the Offering Period to which such authorization is applicable, unless sooner terminated by the Participant as provided in Section&nbsp;8.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="2123-2-OI_PB_4_142029_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="7",CHK=743621,FOLIO='4',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All Payroll Deductions will be credited to the Participant&#146;s Account under the Plan.&#160; The amounts collected from the Participant shall not be held in any segregated account or trust fund and may be commingled with the general assets of the Company and used for general corporate purposes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Changes in Payroll Deductions During Offering Period</font></u><font size="2" style="font-size:10.0pt;">.&#160; A Participant may decrease (prospectively) or discontinue his or her Payroll Deduction once during any Offering Period, by filing either a written or electronic new Election Form.&#160; However, a Participant may not increase his or her payroll deduction during an Offering Period.&#160; If a Participant elects to discontinue his or her Payroll Deductions during an Offering Period, but does not elect to withdraw his or her funds pursuant to Section&nbsp;8 hereof, funds deducted prior to his or her election to discontinue will be applied to the purchase of Shares on the applicable exercise date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Granting of Options.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Number of Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; On each Offering Commencement Date and subject to Section&nbsp;3(d)&nbsp;above, the Company will grant to each Participant an option to purchase on the Offering Termination Date at the applicable purchase price (the &#147;<u>Option Price</u>&#148;) up to that number of Shares determined by multiplying $2,083 by the number of full months in the Offering Period and dividing the result by the Fair Market Value on the Offering Commencement Date; <i>provided, however</i>, that the Committee may, in its discretion, set a fixed maximum number of Shares that each Participant may purchase per Offering Period which number may not be greater than the number of Shares determined by using the formula in this Section&nbsp;6(a)&nbsp;and which number shall be subject to Section&nbsp;3(d)&nbsp;above.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Option Price</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board or the Committee shall determine the Option Price for each Offering Period, including whether such Option Price shall be determined based on the lesser of the Fair Market Value on (i)&nbsp;the Offering Commencement Date or (ii)&nbsp;the Offering Termination Date, or shall be based solely on the Fair Market Value on the Offering Termination Date; <i>provided, however</i>, that such Option Price shall be at least 85% of the applicable Fair Market Value.&#160; In the absence of a determination by the Board or the Committee, the Option Price will be 85% of the lesser of the Fair Market Value on (i)&nbsp;the Offering Commencement Date or (ii)&nbsp;the Offering Termination Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Exercise of Options.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Automatic Exercise</font></u><font size="2" style="font-size:10.0pt;">.&#160; With respect to each Offering, a Participant&#146;s option for the purchase of Shares granted pursuant to Section&nbsp;6 of the Plan shall be deemed to have been exercised automatically on the Offering Termination Date applicable to such Offering.&#160; Notwithstanding the foregoing, upon the occurrence of a Plan Termination Date as described in Section&nbsp;2(u)(3), all Shares or Payroll Deductions (to the extent not yet applied to the purchase of Shares) under the Plan shall be distributed to the Participants as soon as administratively practicable following such Plan Termination Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Fractional Shares and Minimum Number of Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; Fractional Shares shall not be issued under the Plan.&#160; Amounts credited to an Account remaining after the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="2123-2-OI_PB_5_142041_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="7",CHK=98805,FOLIO='5',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">application of such Account to the exercise of options for a minimum of one (1)&nbsp;full Share will be automatically refunded to the employee, without interest.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Transferability of Option</font></u><font size="2" style="font-size:10.0pt;">.&#160; No option granted to a Participant pursuant to the Plan shall be transferable other than by will or by the laws of descent and distribution, and no such option shall be exercisable during the Participant&#146;s lifetime other than by the Participant.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Delivery of Certificates for Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company shall deliver certificates for Shares acquired on the exercise of options during an Offering Period as soon as practicable following the Offering Termination Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Withdrawals.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Withdrawal of Account</font></u><font size="2" style="font-size:10.0pt;">.&#160; A Participant may elect to withdraw the balance credited to the Participant&#146;s Account by providing a Termination Form&nbsp;to the Committee at any time prior to the close of business on the twenty-first (21</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font><font size="2" style="font-size:10.0pt;">) business day prior to the Offering Termination Date applicable to any Offering.&#160; The Participant may not begin participation again during the remainder of the Offering Period during which the Participant withdrew his or her balance. The Participant may participate in any subsequent Offering in accordance with terms and conditions established by the Board or the Committee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amount of Withdrawal</font></u><font size="2" style="font-size:10.0pt;">.&#160; A Participant may withdraw all, but not less than all, of the amounts credited to the Participant&#146;s Account by giving a Termination Form&nbsp;to the Committee.&#160; All amounts credited to such Participant&#146;s Account shall be paid as soon as practicable following the Committee&#146;s receipt of the Participant&#146;s Termination Form, and no further Payroll Deductions will be made with respect to the Participant for such Offering Period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination of Employment</font></u><font size="2" style="font-size:10.0pt;">. Upon termination of a Participant&#146;s employment for any reason other than death, including termination due to disability, all amounts credited to such Participant&#146;s Account shall be returned to the Participant.&#160; In the event of a Participant&#146;s (1)&nbsp;termination of employment due to death or (2)&nbsp;death after termination of employment but before the Participant&#146;s Account has been returned, all amounts credited to such Participant&#146;s Account shall be returned to the Participant&#146;s Successor-in-Interest.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Interest.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No interest shall be paid or allowed with respect to amounts paid into the Plan or credited to any Participant&#146;s Account.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Shares.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Maximum Number of Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; No more than (i)&nbsp;200,000 Shares; <i>plus</i> (ii)&nbsp;an annual increase to be added on the first day of each fiscal year, commencing on January&nbsp;1, 2016 and ending on December&nbsp;31, 2025, equal to the least of (x)&nbsp;400,000 Shares, (y)&nbsp;1% of the outstanding Shares on such date or (z)&nbsp;an amount determined by the Board, may be issued under the Plan.&#160; Such Shares shall be authorized but unissued or reacquired Shares of the Company, including Shares purchased on the open market.&#160; The number of Shares available for</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="2123-2-OI_PB_6_142100_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="7",CHK=481314,FOLIO='6',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any Offering and all Offerings shall be adjusted if the number of outstanding Shares of the Company is increased or reduced by split-up, reclassification, stock dividend or the like.&#160; All Shares issued pursuant to the Plan shall be validly issued, fully paid and nonassessable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Participant&#146;s Interest in Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; A Participant shall have no interest in Shares subject to an option until such option has been exercised.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Registration of Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; Shares to be delivered to a Participant under the Plan shall be registered in the name of the Participant.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Restrictions on Exercise</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board may, in its discretion, require as conditions to the exercise of any option such conditions as it may deem necessary to assure that the exercise of options is in compliance with applicable securities laws.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Expenses.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company shall pay all fees and expenses incurred (excluding individual Federal, state, local or other taxes) in connection with the Plan, provided that the Company shall not be responsible for payment of any brokerage fees.&#160; No charge or deduction for any such expenses will be made to a Participant upon the termination of his or her participation under the Plan or upon the distribution of certificates representing Shares purchased with his or her contributions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Taxes.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company shall have the right to withhold from each Participant&#146;s Compensation an amount equal to all Federal, state, city or other taxes as the Company shall determine are required to be withheld by them in connection with the grant, exercise of the option or disposition of Shares.&#160; In connection with such withholding, the Company may make any such arrangements as are consistent with the Plan as it may deem appropriate, including the right to withhold from Compensation paid to a Participant other than in connection with the Plan and the right to withdraw such amount from the amount standing to the credit of the Participant&#146;s Account.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Plan and Contributions Not to Affect Employment.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Plan shall not confer upon any Eligible Employee any right to continue in the employ of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Administration.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Plan shall be administered by the Board, which may delegate responsibility for such administration to a committee of the Board (the &#147;<u>Committee</u>&#148;).&#160; If the Board fails to appoint the Committee, any references in the Plan to the Committee shall be treated as references to the Board.&#160; The Board, or the Committee, shall have authority to interpret the Plan, to prescribe, amend and rescind rules&nbsp;and regulations relating to it, and to make all other determinations deemed necessary or advisable in administering the Plan, with or without the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="2123-2-OI_PB_7_142119_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="7",CHK=15568,FOLIO='7',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">advice of counsel.&#160; The determinations of the Board or the Committee on the matters referred to in this paragraph shall be conclusive and binding upon all persons in interest.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Amendment and Termination.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board may terminate the Plan at any time and may amend the Plan from time to time in any respect; <i>provided, however</i>, that upon any termination of the Plan, all Shares or Payroll Deductions (to the extent not yet applied to the purchase of Shares) under the Plan shall be distributed to the Participants, <i>provided further</i>, that no amendment to the Plan shall affect the right of a Participant to receive his or her proportionate interest in the Shares or his or her Payroll Deductions (to the extent not yet applied to the purchase of Shares) under the Plan, and <i>provided further</i>, that the Company may seek shareholder approval of an amendment to the Plan if such approval is determined to be required by or advisable under the regulations of the Securities or Exchange Commission or the Internal Revenue Service, the rules&nbsp;of any stock exchange or system on which the Shares are listed or other applicable law or regulation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Effective Date.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to approval by the shareholders of the Company as required by Section&nbsp;423 of the Code, the Plan shall take effect immediately prior to the closing of the Company&#146;s initial public offering.&#160; The initial Offering Period under the Plan shall commence on a date determined by the Board or the Committee</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Government and Other Regulations.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">In General</font></u><font size="2" style="font-size:10.0pt;">. The purchase of Shares under the Plan shall be subject to all applicable laws, rules&nbsp;and regulations, and to such approvals by any governmental agencies as may be required.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Securities Law</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Committee shall have the power to make each grant under the Plan subject to such conditions as it deems necessary or appropriate to comply with the then-existing requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, including Rule&nbsp;16b-3 (or any similar rule) of the Securities and Exchange Commission.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Non-Alienation.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Participant shall be permitted to assign, alienate, sell, transfer, pledge or otherwise encumber his interest under the Plan prior to the distribution to him of Share certificates.&#160; Any attempt at assignment, alienation, sale, transfer, pledge or other encumbrance shall be void and of no effect.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">19.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Notices.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:75.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any notice required or permitted hereunder shall be sufficiently given only if delivered personally, telecopied, or sent by first class mail, postage prepaid, and addressed:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="2123-2-OI_PB_8_142156_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="7",CHK=669186,FOLIO='8',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:23 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to the Company</font></u><font size="2" style="font-size:10.0pt;">:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collegium Pharmaceutical,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">780 Dedham Street, Suite&nbsp;800</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Canton, MA 02021</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; Employee Stock Purchase Plan Committee</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or any other address provided pursuant to written notice.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to the Participant</font></u><font size="2" style="font-size:10.0pt;">:&#160; At the address on file with the Company from time to time, or to such other address as either party may hereafter designate in writing by notice similarly given by one party to the other.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">20.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Successors.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Plan shall be binding upon and inure to the benefit of any successor, successors or assigns of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">21.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Severability.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any part of this Plan shall be determined to be invalid or void in any respect, such determination shall not affect, impair, invalidate or nullify the remaining provisions of this Plan which shall continue in full force and effect.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">22.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Acceptance.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The election by any Eligible Employee to participate in this Plan constitutes his or her acceptance of the terms of the Plan and his or her agreement to be bound hereby.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">23.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Applicable Law.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Plan shall be construed in accordance with the law of the Commonwealth of Virginia, to the extent not preempted by applicable Federal law.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="2123-2-OI_PB_9_142241_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="7",CHK=49531,FOLIO='9',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OI_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:23 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>8
<FILENAME>a2224429zex-10_34.htm
<DESCRIPTION>EX-10.34
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.34</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PERFORMANCE BONUS PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;1.&#160; <u>Purpose</u>.&#160; The purpose of the Collegium Pharmaceutical,&nbsp;Inc. Performance Bonus Plan (the &#147;<b><u style="font-weight:bold;">Plan</u></b>&#148;) is to benefit and advance the interests of Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation (the &#147;<b><u style="font-weight:bold;">Company</u></b>&#148;), by rewarding selected employees of the Company and its subsidiaries and divisions (each such subsidiary or division is referred to herein as a &#147;<b><u style="font-weight:bold;">Business Unit</u></b>&#148;) for their contributions to the Company&#146;s success and thereby motivate them to continue to make such contributions in the future by granting performance-based awards (&#147;<b><u style="font-weight:bold;">Awards</u></b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;2.&#160; <u>Certain Definitions</u>.&#160; For the purposes of the Plan the following terms shall be defined as set forth below:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Applicable Employee Remuneration</u></b>&#148; has the meaning given to such term in Section&nbsp;162(m)(4)&nbsp;of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Base Salary Percentage</u></b>&#148; means a percentage of the Participant&#146;s annual base salary in effect as of the later of (i)&nbsp;the first day of the Performance Period or (ii)&nbsp;the common salary adjustment date within the Performance Period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Board</u></b>&#148; means the Board of Directors of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Code</u></b>&#148; means the Internal Revenue Code of 1986, as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Committee</u></b>&#148; means the Compensation Committee of the Board.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Covered Employee</u></b>&#148; has the same meaning given to such term in Section&nbsp;162(m)(3)&nbsp;of the Code; <u>provided, however</u>, that a person will be considered a Covered Employee for purposes of this Plan only if such employee&#146;s Applicable Employee Remuneration for the relevant Fiscal Year is expected to exceed $1,000,000.&#160; No person shall be considered a Covered Employee during the applicable reliance period under Treasury Regulation 1.162-27(f).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Eligible Persons</u></b>&#148; has the meaning given to that term in Section&nbsp;4(a)&nbsp;hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Financial Criteria</u></b>&#148; has the meaning given to that term in Section&nbsp;6(a)&nbsp;hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Fiscal Year</u></b>&#148; means the calendar year or such other period that the Company may hereafter adopt as its fiscal year.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">&#147;<u>Participant</u>&#148; </font></b><font size="2" style="font-size:10.0pt;">has the meaning given to that term in Section&nbsp;5 hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Performance Period</u></b>&#148; means the period of time over which the Performance Threshold must be satisfied, which period may be of such length as the Committee,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="8",CHK=329101,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OK_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in its discretion, shall select.&#160; The Performance Period need not be identical for all Awards.&#160; Within one Fiscal Year, the Committee may establish multiple Performance Periods.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Performance Threshold</u></b>&#148; has the meaning given to such term in Section&nbsp;6(b)&nbsp;hereof (in the case of a Covered Employee), or Section&nbsp;7(b)&nbsp;hereof (in the case of a Participant who is not a Covered Employee).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b><u style="font-weight:bold;">Target</u></b>&#148; has the meaning given to such term in Section&nbsp;6(a)&nbsp;hereof (in the case of a Covered Employee), or Section&nbsp;7(a)&nbsp;hereof (in the case of a Participant who is not a Covered Employee).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;3.&#160; <u>Administration of the Plan</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Generally</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan shall be administered by the Committee.&#160; The Committee is authorized to administer, interpret and apply the Plan and from time to time may adopt such rules, regulations and guidelines consistent with the provisions of the Plan as it may deem advisable to carry out the Plan, except that the Committee may authorize any one or more of its members, or any officer of the Company, to execute and deliver documents on behalf of the Committee.&#160; The Committee&#146;s interpretations of the Plan, and all actions taken and determinations made by the Committee pursuant to the powers vested in it hereunder, shall be conclusive and binding on all parties concerned, including the Company, its stockholders and Participants (as defined below).&#160; The Committee shall have authority to determine the terms and conditions of the Awards granted to Participants.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Delegation</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Committee may delegate its responsibilities for administering the Plan to any executive officer of the Company, as the Committee deems necessary; provided however, that the Committee shall not delegate its responsibilities under the Plan relating to Covered Employees.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Reliance and Indemnification</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Committee may employ attorneys, consultants, accountants or other persons, and the Committee, the Company and its officers and directors shall be entitled to rely upon the advice, opinions or valuations of any such persons.&#160; No member of the Committee nor any executive officer of the Company shall be personally liable for any action, determination or interpretation taken or made in good faith by the Committee or such executive officer of the Company with respect to the Plan or Awards granted hereunder, and all members of the Committee and each executive officer of the Company shall be fully indemnified and protected by the Company in respect of any such action, determination or interpretation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;4.&#160; <u>Eligible Persons</u>.&#160; All employees of the Company shall be eligible to participate in the Plan (&#147;<b><u style="font-weight:bold;">Eligible Persons</u></b>&#148;).&#160; An individual shall be deemed an employee for purposes of the Plan only if such individual receives compensation from either the Company or one of its Business Units for services performed as an employee of the Company or any one of its Business Units for any period during a Performance Period.&#160; An Eligible Person who is a Covered Employee shall be entitled to participate in the Plan with respect to a Performance Period which has commenced only if he or she commenced employment on or before the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="2123-2-OK_PB_2_142528_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="8",CHK=569448,FOLIO='2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OK_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">beginning of each Performance Period or any later date described in Treasury Regulation 1.162-27(e)(2)&nbsp;(or any successor thereto).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;5.&#160; <u>Awards; Participants</u>.&#160; Awards may be granted only to Eligible Persons with respect to each Performance Period, subject to the terms and conditions set forth in the Plan.&#160; An Eligible Person who has been chosen to receive an Award under the Plan shall be referred to as a &#147;<b><u style="font-weight:bold;">Participant</u></b>.&#148;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;6.&#160; <u>Determination of Targets, Performance Thresholds and Base Salary Percentage for Covered Employees</u>.&#160; Prior to the beginning of each Performance Period or any later date described in Treasury Regulation 1.162-27(e)(2)&nbsp;(or any successor thereto), the Committee shall adopt each of the following with respect to each Participant who is a Covered Employee:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">one or more Targets, which shall be equal to a desired level or levels (as may be measured on an absolute or relative basis, where relative performance may also be measured by reference to: past performance of the Company or a Business Unit, a group of peer companies or by a financial market index) for any Performance Period of: (i)&nbsp;specified levels of or increases in pre-tax earnings, return on capital, equity measures/ratios (on a gross, net, pre-tax or post tax basis), including basic earnings per share, diluted earnings per share, total earnings (including total earnings as adjusted by the Committee at the time of the Award), operating earnings, earnings growth, earnings before interest and taxes, or EBIT, and earnings before interest, taxes, depreciation and amortization, or EBITDA (including EBIT or EBITDA as adjusted by the Committee at the time of the Award); (ii)&nbsp;total sales or sales growth; (iii)&nbsp;gross margin; (iv)&nbsp;customer service levels; (v)&nbsp;employee recruiting and development; (vi)&nbsp;advertising effectiveness; (vii)&nbsp;development of new markets; (viii)&nbsp;financial ratios; (ix)&nbsp;strategic initiatives; (x)&nbsp;improvement in or attainment of operating expense levels; (xi)&nbsp;improvement in or attainment of capital expense levels; (xii)&nbsp;the attainment of certain target levels of, or a specified increase in, operational cash flow; (xiii)&nbsp;the achievement of a certain level of, reduction of, or other specified objectives with regard to limiting the level of increase in, all or a portion of, the Company&#146;s bank debt or other long-term or short-term public or private debt or other similar financial obligations of the Company, which may be calculated net of such cash balances and/or other specified offsets; (xiv)&nbsp;appreciation in and/or maintenance of certain target levels in the Fair Market Value; (xv)&nbsp;the attainment of a certain level of, reduction of, or other specified objectives with regard to limiting the level of or rate of increase in all or a portion of specified expenses (xvi)&nbsp;individual objectives; and (xvii)&nbsp;any combination of the foregoing (collectively, the &#147;<u>Financial Criteria</u>&#148;).&#160; With respect to any Covered Employee who is employed by a Business Unit, the Financial Criteria shall be based on the results of such Business Unit, results of the Company, or any combination of the two;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a Performance Threshold with respect to each Target, applicable to one or more Financial Criteria, which represents a minimum amount that must be attained for a Participant to receive an Award;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">either (i)&nbsp;a Base Salary Percentage, or (ii)&nbsp;fixed monetary amounts, which, in each case, shall be payable as an Award in the event that 100% of such Participant&#146;s Targets are achieved.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="2123-2-OK_PB_3_142542_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="8",CHK=520245,FOLIO='3',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OK_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a mathematical formula or matrix that shall contain weighting for each Target and indicate the extent to which Awards will be paid if such Participant&#146;s Performance Thresholds with respect to his or her Targets are achieved or exceeded.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee may provide, at the time of the Award, that adjustments will be made to Targets and Performance Thresholds to take into account, in any objective manner specified by that Committee, the impact of one or more of the following: (A)&nbsp;gain or loss from all or certain claims and/or litigation and insurance recoveries, (B)&nbsp;the impairment of tangible or intangible assets, (C)&nbsp;stock-based compensation expense, (D)&nbsp;restructuring activities reported in the Company&#146;s public filings, (E)&nbsp;investments, dispositions or acquisitions, (F)&nbsp;loss from the disposal of certain assets, (G)&nbsp;gain or loss from the early extinguishment, redemption, or repurchase of debt, (H)&nbsp;changes in accounting principles, or (I)&nbsp;any other item, event or circumstance that would not cause an Award to fail to constitute &#147;qualified performance-based compensation&#148; under Section&nbsp;162(m)&nbsp;of the Code (to the extent such Award is intended to be &#147;qualified performance-based compensation&#148;) (each an &#147;<b><u style="font-weight:bold;">Extraordinary Event</u></b>&#148;).&#160; An adjustment described herein may relate to the Company or any Business Unit, as determined by the Committee at the time the Award is granted.&#160; Any adjustment shall be determined in accordance with generally accepted accounting principles and standards, unless such other objective method of measurement is designated by the committee at the time of the Award.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;7.&#160; <u>Determination of Targets, Performance Thresholds and Base Salary Percentage For Participants Who Are Not Covered Employees</u>.&#160; Prior to the end of the Performance Period, the Committee shall adopt each of the following with respect to each Participant who is not a Covered Employee:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">one or more Targets, which shall be equal to a desired level or levels for any Performance Period of any, or a combination of any, quantitative criteria (the &#147;<b><u style="font-weight:bold;">Quantitative Criteria</u></b>,&#148; which Quantitative Criteria may include, without limitation, any Financial Criteria) or qualitative criteria (the &#147;<b><u style="font-weight:bold;">Individual Criteria</u></b>&#148;).&#160; With respect to such Participants who are employed by a Business Unit, the Quantitative Criteria may be based on the results of such Business Unit, consolidated results of the Company, or any combination of the two;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a Performance Threshold with respect to each Target, applicable to one or more Quantitative Criteria or Individual Criteria, which represents a minimum that must be attained for a Participant to receive an Award;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">either (i)&nbsp;a Base Salary Percentage, or (ii)&nbsp;fixed monetary amounts, which, in each case, shall be payable as an Award in the event that 100% of such Participant&#146;s Targets are achieved.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a mathematical formula or matrix that shall contain weighting for each Target and indicate the extent to which Awards will be paid if such Participant&#146;s Performance Thresholds with respect to his or her Targets are achieved or exceeded.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee may make such adjustments, to the extent it deems appropriate, to the Targets and Performance Thresholds to compensate for, or to reflect, any material changes which may have occurred due to an Extraordinary Event.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="2123-2-OK_PB_4_142553_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="8",CHK=244223,FOLIO='4',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OK_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;8.&#160; <u>Calculation of Awards; Certification; Payment; Deferral</u>.&#160; As soon as practicable after the end of the Performance Period, and subject to any necessary verification, the Committee shall determine with respect to each Participant whether and the extent to which the Performance Thresholds applicable to such Participant&#146;s Targets were achieved or exceeded.&#160; Such Participant&#146;s Award, if any, shall be calculated in accordance with the mathematical formula or matrix determined pursuant to Section&nbsp;6 or 7, as applicable, and subject to the limitations set forth in Section&nbsp;9 hereof.&#160; The Committee shall certify in writing the amount of such Award and whether each material term of the Plan relating to such Award has been satisfied.&#160; Subject to Section&nbsp;9 hereof, such Award shall become payable in cash as promptly as practicable thereafter, provided, however, that any Award shall be paid within 2 &#189; months of the end of the Fiscal Year in which the Award is no longer subject to a risk of forfeiture.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;9.&#160; <u>Limitations; Modifications to Awards</u>.&#160; Each Award determined pursuant to Section&nbsp;6 or 7 hereof shall be subject to modification or forfeiture in accordance with the following provisions:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Limitations</font></u><font size="2" style="font-size:10.0pt;">.&#160; The aggregate amount of any Award to any Participant for any Performance Period as finally determined by the Committee, shall constitute the Participant&#146;s Award for the Fiscal Year; provided, however that no Award for any Participant for any Fiscal Year shall exceed $5,000,000.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Modifications</font></u><font size="2" style="font-size:10.0pt;">.&#160; At any time prior to the payment of an Award, the Committee may, in its sole discretion, (i)&nbsp;increase, decrease or eliminate the Award payable to any Participant who is not a Covered Employee and who would not become a Covered Employee as a result of any such increase and/or (ii)&nbsp;decrease or eliminate the Award payable to any Covered Employee, in each case to reflect the individual performance and contribution of, and other factors relating to, such Covered Employee.&#160; The Committee may make such adjustments, to the extent it deems appropriate to any Award to compensate for, or to reflect, any Extraordinary Event.&#160; The determination of the Committee as to matters set forth in this Section&nbsp;9(b)&nbsp;shall be final and conclusive.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;10.&#160; <u>Employment Requirement</u>.&#160; No Participant shall have any right to receive payment of any Award unless such Participant remains in the employ of the Company or a Business Unit through the date of payment of such Award; <u>provided</u>, <u>however</u>, that the Committee may, in its sole discretion, pay all or any part of an Award to any Participant who, prior to such date of payment, terminates employment, so long as the Performance Thresholds applicable to the Participant&#146;s Targets were achieved or exceeded, the Committee may, in its sole discretion, provide for payment of all or part of an award upon any event, to the extent that such provision does not violate Code Section&nbsp;162(m)&nbsp;with respect to a Covered Employee.&#160; The maximum amount of such payment, if any, will be calculated, and to the extent determined by the Committee, paid as provided in Section&nbsp;6 or 7. The determination of the Committee shall be final and conclusive.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;11.&#160; <u>Miscellaneous</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">No Contract; No Rights to Awards or Continued Employment</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan is not a contract between the Company and any Participant or other employee.&#160; No Participant or</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="2123-2-OK_PB_5_142603_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="8",CHK=13299,FOLIO='5',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OK_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">other employee shall have any claim or right to receive Awards under the Plan.&#160; Neither the Plan nor any action taken hereunder shall be construed as giving any employee any right to be retained by the Company or any of its Business Units.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">No Right to Future Participation</font></u><font size="2" style="font-size:10.0pt;">.&#160; Participation in the Plan during one Performance Period shall not guarantee participation during any other Performance Period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Restriction on Transfer</font></u><font size="2" style="font-size:10.0pt;">.&#160; The rights of a Participant with respect to Awards under the Plan shall not be transferable by the Participant to whom such Award is granted (other than by will or the laws of descent and distribution), and any attempted assignment or transfer shall be null and void and shall permit the Committee, in its sole discretion, to extinguish the Company&#146;s obligation under the Plan to pay any Award with respect to such Participant.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Tax Withholding</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company or a subsidiary thereof, as appropriate, shall have the right to deduct from all payments made under the Plan to a Participant or to a Participant&#146;s beneficiary or beneficiaries any Federal, foreign, state or local taxes required by law to be withheld with respect to such payments.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">No Restriction on Right of Company to Effect Changes</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan shall not affect in any way the right or power of the Company or its stockholders to make or authorize any recapitalization, reorganization, merger, acquisition, divestiture, consolidation, spin off, combination, liquidation, dissolution, sale of assets, or other similar corporate transaction or event involving the Company or a subsidiary thereof or any other event or series of events, whether of a similar character or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Source of Payments</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan shall be unfunded.&#160; The Plan shall not create or be construed to create a trust or separate fund or segregation of assets of any kind or a fiduciary relationship between the Company and a Participant or any other individual, corporation, partnership, association, joint-stock company, trust, unincorporated organization, or government or political subdivision thereof.&#160; To the extent that any Participant is granted an Award hereunder, such Participant&#146;s right to receive payment of such Award shall be no greater than the right of any unsecured general creditor of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">No Interest</font></u><font size="2" style="font-size:10.0pt;">.&#160; If the Company for any reason fails to make payment of an Award at the time such Award becomes payable, the Company shall not be liable for any interest or other charges thereon.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment and Termination</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Committee may at any time and from time to time alter, amend, suspend or terminate the Plan in whole or in part.&#160; No such amendment shall be effective which alters the Award, Target or other criteria relating to an Award applicable to a Covered Employee for the Performance Period in which such amendment is made or any prior Performance Period, except any such amendment that may be made without causing such Award to cease to qualify as performance-based compensation under Section&nbsp;162(m)(4)(C)&nbsp;of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Headings</font></u><font size="2" style="font-size:10.0pt;">.&#160; The headings of sections and subsections herein are included solely for convenience of reference and shall not affect the meaning of any of the provisions of the Plan.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="2123-2-OK_PB_6_142619_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="8",CHK=76362,FOLIO='6',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OK_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:27 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Governing Law</font></u><font size="2" style="font-size:10.0pt;">.&#160; The validity, construction, interpretation, administration and effect of the Plan and of its rules&nbsp;and regulations, and rights relating to the Plan, shall be determined solely in accordance with the laws of the Commonwealth of Virginia, without regard to the choice-of-law principles thereof, and applicable federal law.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Severability</font></u><font size="2" style="font-size:10.0pt;">.&#160; If any term or provision (&#147;<b><u style="font-weight:bold;">Provision</u></b>&#148;) of the Plan or the application thereof (i)&nbsp;as to any Participant or circumstance (other than as described in clause (ii)) is, to any extent, found to be illegal or invalid, or (ii)&nbsp;would cause any Award to any Covered Employee not to constitute performance-based compensation under Section&nbsp;162(m)(4)(C)&nbsp;of the Code, then the Committee shall sever such Provision from the Plan and, thereupon, such Provision shall not be a part of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Effective Date</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan will become effective immediately prior to the closing of the Company&#146;s initial public offering.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Approval and Reapproval by Stockholders</font></u><font size="2" style="font-size:10.0pt;">.&#160; To the extent required under Section&nbsp;162(m)&nbsp;of the Code and the regulations thereunder, (i)&nbsp;any change to the material terms of the Financial Criteria shall be disclosed to and approved by the Stockholders at the next annual meeting of Stockholders to be held following such change, and (ii)&nbsp;the material terms of the Financial Criteria shall be disclosed to and reapproved by the Stockholders no later than the annual meeting of Stockholders that occurs in the fifth year following the year in which Stockholders approve the Financial Criteria (provided, however, that with respect to the first year in which the Company becomes publicly traded, such disclosure will be made and approval will be sought no later than first Annual Meeting of Stockholders that occurs after the third year following the calendar year in which the Company became publicly traded).</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="2123-2-OK_PB_7_142633_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="8",CHK=942690,FOLIO='7',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OK_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 14:27 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>9
<FILENAME>a2224429zex-10_35.htm
<DESCRIPTION>EX-10.35
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.35</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;1.&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Purpose</font></u></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">; Definitions</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The purposes of the Collegium Pharmaceutical,&nbsp;Inc. Amended and Restated 2014 Stock Incentive Plan (the &#147;<u>Plan</u>&#148;) are to: (a)&nbsp;enable Collegium Pharmaceutical,&nbsp;Inc. (the &#147;<u>Company</u>&#148;) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b)&nbsp;provide those employees, directors and consultants with an incentive for productivity; and (c)&nbsp;provide those employees, directors and consultants with an opportunity to share in the growth and value of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of the Plan, the following terms will have the meanings defined below, unless the context clearly requires a different meaning:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Affiliate</u>&#148; means, with respect to a Person, a Person that directly or indirectly controls, is controlled by, or is under common control with such Person.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Applicable Law</u>&#148; means the legal requirements relating to the administration of and issuance of securities under stock incentive plans, including, without limitation, the requirements of state corporations law, federal, state and foreign securities law, federal, state and foreign tax law, and the requirements of any stock exchange or quotation system upon which the Shares may then be listed or quoted.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Award</u>&#148; means an award of Options, Restricted Stock, Restricted Stock Units or Performance Awards made under this Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Award Agreement</u>&#148; means, with respect to any particular Award, the written document that sets forth the terms of that particular Award.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Board</u>&#148; means the Board of Directors of the Company, as constituted from time to time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Cause</u>&#148; means (i)&nbsp;Participant&#146;s refusal to comply with any lawful directive or policy of the Board which refusal is not cured by the Participant within ten (10)&nbsp;days of such written notice from the Company; (ii)&nbsp;the Company&#146;s determination that, in the reasonable judgment of the Board, Participant has committed any act of dishonesty, embezzlement, unauthorized use or disclosure of confidential information or other intellectual property or trade secrets, common law fraud or other fraud against the Company or any Subsidiary or Affiliate; (iii)&nbsp;a material breach by the Participant of any written agreement with or any fiduciary duty owed to any Company or any Subsidiary of Affiliate; (iv)&nbsp;Participant&#146;s conviction (or the entry of a plea of a nolo contendere or equivalent plea) in a court of competent jurisdiction of a felony or any misdemeanor involving material dishonesty or moral turpitude; or (v)&nbsp;Participant&#146;s habitual or repeated misuse of, or habitual or repeated performance of Participant&#146;s duties under the influence of, alcohol, illegally obtained prescription controlled substances or non-prescription controlled substances.&#160; Notwithstanding the foregoing, if a Participant and the Company (or any of its Affiliates) have entered into an employment agreement, consulting agreement or other similar agreement that specifically defines &#147;cause,&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=10711,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">then with respect to such Participant, &#147;Cause&#148; shall have the meaning defined in such other agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Change in Control</u>&#148; shall mean the occurrence of any of the following events: (i)&nbsp;any &#147;person&#148; (as such term is used in Sections 13(d)&nbsp;and 14(d)&nbsp;of the Exchange Act) is or becomes a &#147;beneficial owner&#148; (as defined in Rule&nbsp;13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total power to vote for the election of directors of the Company; (ii)&nbsp;during any twelve month period, individuals who at the beginning of such period constitute the Board and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in <u>Section&nbsp;1(g)(i)</u>, <u>Section&nbsp;1(g)(iii)</u>, <u>Section&nbsp;1(g)(iv</u>)&nbsp;or <u>Section&nbsp;1(g)(v)</u>&nbsp;hereof) whose election by the Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the period of whose election or nomination for election was previously approved, cease for any reason to constitute a majority thereof; (iii)&nbsp;the merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to 50% or more of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); (iv)&nbsp;the sale or other disposition of all or substantially all of the assets of the Company; (v)&nbsp;a liquidation or dissolution of the Company or (vi)&nbsp;acceptance by shareholders of the Company of shares in a share exchange if the shareholders of the Company immediately before such share exchange do not or will not own directly or indirectly immediately following such share exchange more than fifty percent (50%) of the combined voting power of the outstanding voting securities of the entity resulting from or surviving such share exchange in substantially the same proportion as their ownership of the voting securities outstanding immediately before such share exchange.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding anything in the Plan or an Award Agreement to the contrary, if an Award is subject to Section&nbsp;409A of the Code, no event that, but for the application of this paragraph<u>,</u> would be a Change in Control as defined in the Plan or the Award Agreement, as applicable, shall be a Change in Control unless such event is also a &#147;change in control event&#148; as defined in Section&nbsp;409A of the Code.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Code</u>&#148; means the Internal Revenue Code of 1986, as amended from time to time, and any successor thereto.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Committee</u>&#148; means the committee designated by the Board to administer the Plan under Section&nbsp;2. To the extent required under Applicable Law, the Committee shall have at least two members and each member of the Committee shall be a Non-Employee Director and an Outside Director.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Director</u>&#148; means a member of the Board.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Disability</u>&#148; means a condition rendering a Participant Disabled.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="2123-2-OM-01_PB_2_132321_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=906955,FOLIO='2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Disabled</u>&#148; will have the same meaning as set forth in Section&nbsp;22(e)(3)&nbsp;of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Exchange Act</u>&#148; means the Securities Exchange Act of 1934, as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Fair Market Value</u>&#148; means, as of any date, the value of a Share determined as follows: (i)&nbsp;if the Shares are listed on any established stock exchange or a national market system, including, without limitation, the Nasdaq Global Select Market, the Fair Market Value of a Share will be the closing sales price for such stock as quoted on that system or exchange (or the system or exchange with the greatest volume of trading in Shares) at the close of regular hours trading on the day of determination; (ii)&nbsp;if the Shares are regularly quoted by recognized securities dealers but selling prices are not reported, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for Shares at the close of regular hours trading on the day of determination; or (iii)&nbsp;if Shares are not traded as set forth above, the Fair Market Value will be determined in good faith by the Committee taking into consideration such factors as the Committee considers appropriate, such determination by the Committee to be final, conclusive and binding.&#160; Notwithstanding the foregoing, in connection with a Change in Control, Fair Market Value shall be determined in good faith by the Committee, such determination by the Committee to be final conclusive and binding.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Incentive Stock Option</u>&#148; means any Option intended to be an &#147;Incentive Stock Option&#148; within the meaning of Section&nbsp;422 of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Non-Employee Director</u>&#148; will have the meaning set forth in Rule&nbsp;16b-3(b)(3)(i)&nbsp;promulgated by the Securities and Exchange Commission under the Exchange Act, or any successor definition adopted by the Securities and Exchange Commission.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(q)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Non-Qualified Stock Option</u>&#148; means any Option that is not an Incentive Stock Option.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(r)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Outside Director</u>&#148; means a member of the Board who meets the definition of an &#147;outside director&#148; under Section&nbsp;162(m)&nbsp;of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(s)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Option</u>&#148; means any option to purchase Shares (including an option to purchase Restricted Stock, if the Committee so determines) granted pursuant to <u>Section&nbsp;5</u> hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(t)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Parent</u>&#148; means, in respect of the Company, a &#147;parent corporation&#148; as defined in Sections&nbsp;424(e)&nbsp;of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(u)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Participant</u>&#148; means an employee, consultant, Director, or other service provider of or to the Company or any of its respective Affiliates to whom an Award is granted.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Performance Award</u>&#148; means any Award that, pursuant to <u>Section&nbsp;9</u>, is granted, vested and/or settled upon the achievement of specified performance conditions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(w)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Performance Goals</u>&#148;&#160; means a goal that must be met by the end of a period specified by the Committee (but that is substantially uncertain of being met before the grant of the Award) based upon one or more of the following business criteria: (i)&nbsp;specified levels of or</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="2123-2-OM-01_PB_3_132409_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=804988,FOLIO='3',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">increases in pre-tax earnings, return on capital, equity measures/ratios (on a gross, net, pre-tax or post tax basis), including basic earnings per share, diluted earnings per share, total earnings (including total earnings as adjusted by the Committee at the time of the Award), operating earnings, earnings growth, earnings before interest and taxes, or EBIT, and earnings before interest, taxes, depreciation and amortization, or EBITDA (including EBIT or EBITDA as adjusted by the Committee at the time of the Award); (ii)&nbsp;total sales or sales growth; (iii)&nbsp;gross margin; (iv)&nbsp;customer service levels; (v)&nbsp;employee recruiting and development; (vi)&nbsp;advertising effectiveness; (vii)&nbsp;development of new markets; (viii)&nbsp;financial ratios; (ix)&nbsp;strategic initiatives; (x)&nbsp;improvement in or attainment of operating expense levels; (xi)&nbsp;improvement in or attainment of capital expense levels; (xii)&nbsp;the attainment of certain target levels of, or a specified increase in, operational cash flow; (xiii)&nbsp;the achievement of a certain level of, reduction of, or other specified objectives with regard to limiting the level of increase in, all or a portion of, the Company&#146;s bank debt or other long-term or short-term public or private debt or other similar financial obligations of the Company, which may be calculated net of such cash balances and/or other specified offsets; (xiv)&nbsp;appreciation in and/or maintenance of certain target levels in the Fair Market Value; (xv)&nbsp;the attainment of a certain level of, reduction of, or other specified objectives with regard to limiting the level of or rate of increase in all or a portion of specified expenses (xvi)&nbsp;individual objectives; and (xvii)&nbsp;any combination of the foregoing.&#160; The Committee shall have discretion to determine the specific targets with respect to each of these categories of Performance Goals and may apply to the Company as a whole or to any Subsidiary, division or other unit of the Company.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Person</u>&#148; means an individual, partnership, corporation, limited liability company, trust, joint venture, unincorporated association, or other entity or association.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(y)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Plan</u>&#148; means the Collegium Pharmaceutical,&nbsp;Inc. Amended and Restated 2014 Stock Incentive Plan herein set forth, as amended from time to time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(z)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Restricted Stock</u>&#148; means Shares that are subject to restrictions pursuant to <u>Section&nbsp;7</u> hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(aa)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Restricted Stock Unit</u>&#148; means </font><font size="2" style="font-size:10.0pt;">a right granted under and subject to restrictions pursuant to <u>Section&nbsp;8</u> hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(bb)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Shares</u>&#148; means shares of the Company&#146;s common stock, par value $0.001, subject to substitution or adjustment as provided in <u>Section&nbsp;3(c)</u>&nbsp;hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(cc)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<u>Subsidiary</u>&#148; means, in respect of the Company, a subsidiary company as defined in Sections&nbsp;424(f)&nbsp;and (g)&nbsp;of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;2.&#160; <u>Administration</u>.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Plan shall be administered by the Committee. Any action of the Committee in administering the Plan shall be final, conclusive and binding on all persons, including the Company, its Subsidiaries, Affiliates, their respective employees, the Participants, persons claiming rights from or through Participants and stockholders of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee will have full authority to grant Awards under this Plan and determine the terms of such Awards.&#160; Such authority will include the right to:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="2123-2-OM-01_PB_4_132426_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=125538,FOLIO='4',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">select the individuals to whom Awards are granted (consistent with the eligibility conditions set forth in <u>Section&nbsp;4</u>);</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">determine the type of Award to be granted;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">determine the number of Shares, if any, to be covered by each Award;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">establish the terms and conditions of each Award;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">subject to <u>Section&nbsp;9</u>, establish the performance conditions relevant to any Award and certify whether such performance conditions have been satisfied;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">approving forms of agreements (including Award Agreements) for use under the Plan;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">determine whether and under what circumstances an Award may be settled in cash;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">determine whether and under what circumstances an Option may be exercised without a payment of cash under <u>Section&nbsp;5(d)</u>;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">accelerate the vesting or exercisability of an Award and to modify or amend each Award, subject to <u>Section&nbsp;10</u>; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">extend the period of time for which an Option is to remain exercisable following a Participant&#146;s termination of service to the Company from the limited period otherwise in effect for that Option to such greater period of time as the Committee deems appropriate, but in no event beyond the expiration of the term of the Option.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee will have the authority to adopt, alter and repeal such administrative rules, guidelines and practices governing the Plan as it, from time to time, deems advisable; to establish the terms and form of each Award Agreement; to interpret the terms and provisions of the Plan and any Award issued under the Plan (and any Award Agreement); and to otherwise supervise the administration of the Plan.&#160; The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any Award Agreement in the manner and to the extent it deems necessary to carry out the intent of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee may delegate to one or more officers of the Company the authority to grant Awards to Participants who are not subject to the requirements of Section&nbsp;16 of the Exchange Act or Section&nbsp;162(m)&nbsp;of the Code and the rules&nbsp;and regulations thereunder, provided that the Committee shall have fixed the total number of Shares subject to such delegation.&#160; Any such delegation shall be subject to the applicable corporate laws of the Commonwealth of Virginia.&#160; The Committee may revoke any such allocation or delegation at any time for any reason with or without prior notice.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Director will be liable for any good faith determination, act or omission in connection with the Plan or any Award.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="2123-2-OM-01_PB_5_132444_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=151694,FOLIO='5',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;3.&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Shares Subject to the Plan</font></u></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Shares Subject to the Plan</font></u><font size="2" style="font-size:10.0pt;">.&#160;&#160; Subject to adjustment as provided in <u>Section&nbsp;3(c)</u>&nbsp;of the Plan, the maximum number of Shares that may be issued in respect of Awards under the Plan is:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">2,700,000 Shares (inclusive of Shares subject to Awards issued under any prior version of the Plan that remain outstanding as of the effective date of the Plan ); <i>plus</i></font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an annual increase to be added on the first day of each fiscal year beginning with the fiscal year ending December&nbsp;31, 2016, and on each anniversary thereof until the expiration of the Plan equal to 4% of the total number of outstanding Shares on December&nbsp;31st of the immediately preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January&nbsp;1st of a given year to provide that there will be no January&nbsp;1st increase in the maximum number of Shares that may be issued in respect of Awards under the Plan or that the increase in the maximum number of Shares that may be issued in respect of Awards for such year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to the provisions of <u>Section&nbsp;3(c)</u>, the aggregate maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options will be 8,100,000 Shares. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued Shares or treasury Shares. Any Shares issued by the Company through the assumption or substitution of outstanding grants in connection with the acquisition of another entity shall not reduce the maximum number of Shares available for delivery under the Plan.&#160; In accordance with the requirements under Section&nbsp;162(m)&nbsp;of the Code, the maximum number of Shares underlying Awards (including Options, Restricted Stock, Restricted Stock Units and Performance Awards) that may be granted during a calendar year to any individual Participant shall be 1,250,000 Shares per calendar year.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Effect of the Expiration or Termination of Awards</font></u><font size="2" style="font-size:10.0pt;">.&#160; If and to the extent that an Option expires, terminates or is canceled or forfeited for any reason without having been exercised in full, the Shares associated with that Option will again become available for grant under the Plan.&#160; Similarly, if and to the extent an Award of Restricted Stock or Restricted Stock Units is canceled or forfeited for any reason, the Shares subject to that Award will again become available for grant under the Plan.&#160; Shares withheld in settlement of a tax withholding obligation associated with an Award, or in satisfaction of the exercise price payable upon exercise of an Option, will not become available for grant under the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Other Adjustment</font></u><font size="2" style="font-size:10.0pt;">.&#160; In the event of any corporate event or transaction such as a merger, consolidation, reorganization, recapitalization, stock split, reverse stock split, split up, spin-off, combination of shares, exchange of shares, stock dividend, dividend in kind, or other like change in capital structure (other than ordinary cash dividends) to shareholders of the Company, or other similar corporate event or transaction affecting the Shares, the Committee, to prevent dilution or enlargement of Participants&#146; rights under the Plan, shall, in such manner as it may deem equitable, substitute or adjust, in its sole discretion, the number and kind of shares that</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="2123-2-OM-01_PB_6_132536_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=592880,FOLIO='6',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">may be issued under the Plan or under any outstanding Awards, the number and kind of shares subject to outstanding Awards, the exercise price, grant price or purchase price applicable to outstanding Awards, and/or any other affected terms and conditions of this Plan or outstanding Awards.&#160; The Committee shall not make any adjustment that would adversely affect the status of any Award that is &#147;performance-based compensation&#148; under Section&nbsp;162(m)&nbsp;of the Code.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Change in Control</font></u><font size="2" style="font-size:10.0pt;">.&#160; Notwithstanding anything to the contrary set forth in the Plan, upon any Change in Control, the Committee may, in its sole and absolute discretion and without the need for the consent of any Participant, take one or more of the following actions contingent upon the occurrence of that Change in Control:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">cause any or all outstanding Awards to become vested and immediately exercisable (as applicable), in whole or in part;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">cause any outstanding Option to become fully vested and immediately exercisable for a reasonable period in advance of the Change in Control and, to the extent not exercised prior to that Change in Control, cancel that Option upon closing of the Change in Control;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">cancel any unvested Award or unvested portion thereof, with or without consideration;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">cancel any Award in exchange for a substitute award;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">redeem any Restricted Stock or Restricted Stock Unit for cash and/or other substitute consideration with value equal to Fair Market Value of an unrestricted Share on the date of the Change in Control;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">cancel any Option in exchange for cash and/or other substitute consideration with a value equal to: (A)&nbsp;the number of Shares subject to that Option, multiplied by (B)&nbsp;the difference, if any, between the Fair Market Value per Share on the date of the Change in Control and the exercise price of that Option; <i>provided, </i>that if the Fair Market Value per Share on the date of the Change in Control does not exceed the exercise price of any such Option, the Committee may cancel that Option without any payment of consideration therefor;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">take such other action as the Committee shall determine to be reasonable under the circumstances; and/or</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">notwithstanding any provision of this <u>Section&nbsp;3(d)</u>, in the case of any Award subject to Section&nbsp;409A of the Code, such Award shall vest and be distributed only in accordance with the terms of the applicable Award Agreement and the Committee shall only be permitted to use discretion to the extent that such discretion would be permitted under Section&nbsp;409A of the Code.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the discretion of the Committee, any cash or substitute consideration payable upon cancellation of an Award may be subjected to (i)&nbsp;vesting terms substantially identical to those that applied to the cancelled Award immediately prior to the Change in Control, or</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="2123-2-OM-01_PB_7_132558_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=684981,FOLIO='7',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&nbsp;earn-out, escrow, holdback or similar arrangements, to the extent such arrangements are applicable to any consideration paid to stockholders in connection with the Change in Control.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;4.&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Eligibility</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Employees, Directors, consultants, and other individuals who provide services to the Company or its Affiliates are eligible to be granted Awards under the Plan;<i> provided, however</i>, that only employees of the Company, any Parent or a Subsidiary are eligible to be granted Incentive Stock Options.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;5.&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Options</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">. </font></b><font size="2" style="font-size:10.0pt;">&#160;Options granted under the Plan may be of two types: (i)&nbsp;Incentive Stock Options or (ii)&nbsp;Non-Qualified Stock Options.&#160; The Award Agreement shall state whether such grant is an Incentive Stock Option or a Non-Qualified Stock Option.&#160; Any Option granted under the Plan will be in such form as the Committee may at the time of such grant approve.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Award Agreement evidencing any Option will incorporate the following terms and conditions and will contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee deems appropriate in its sole and absolute discretion:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Option Price</font></u><font size="2" style="font-size:10.0pt;">.&#160; The exercise price per Share under an Option will be determined by the Committee and will not be less than 100% of the Fair Market Value of a Share on the date of the grant.&#160; However, any Incentive Stock Option granted to any Participant who, at the time the Option is granted, owns, either directly and/or within the meaning of the attribution rules&nbsp;contained in Section&nbsp;424(d)&nbsp;of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, will have an exercise price per Share of not less than 110% of Fair Market Value per Share on the date of the grant.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Option Term</font></u><font size="2" style="font-size:10.0pt;">.&#160; The term of each Option will be fixed by the Committee, but no Option will be exercisable more than 10 years after the date the Option is granted.&#160; However, any Incentive Stock Option granted to any Participant who, at the time such Option is granted, owns, either directly and/or within the meaning of the attribution rules&nbsp;contained in Section&nbsp;424(d)&nbsp;of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, may not have a term of more than 5 years.&#160; No Option may be exercised by any Person after expiration of the term of the Option.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exercisability</font></u><font size="2" style="font-size:10.0pt;">.&#160; Options will vest and be exercisable at such time or times and subject to such terms and conditions as determined by the Committee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Method of Exercise</font></u><font size="2" style="font-size:10.0pt;">.&#160; Subject to the terms of the applicable Award Agreement, the exercisability provisions of <u>Section&nbsp;5(c)</u>&nbsp;and the termination provisions of <u>Section&nbsp;6</u>, Options may be exercised in whole or in part from time to time during their term by the delivery of written notice to the Company specifying the number of Shares to be purchased.&#160; Such notice will be accompanied by payment in full of the purchase price, either by certified or bank check, or such other means as the Committee may accept.&#160; The Committee may, in its sole discretion, permit payment of the exercise price of an Option in the form of previously acquired Shares based on the Fair Market Value of the Shares on the date the Option is exercised or through means of a &#147;net settlement,&#148; whereby the Option exercise price will not be due in cash and where the number of Shares issued upon such exercise will be equal to: (A)&nbsp;the product of</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="2123-2-OM-01_PB_8_132624_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=281402,FOLIO='8',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;the number of Shares as to which the Option is then being exercised, and (ii)&nbsp;the excess, if any, of (a)&nbsp;the then current Fair Market Value per Share over (b)&nbsp;the Option exercise price, divided by (B)&nbsp;the then current Fair Market Value per Share.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Shares will be issued upon exercise of an Option until full payment therefor has been made.&#160; A Participant will not have the right to distributions or dividends or any other rights of a stockholder with respect to Shares subject to the Option until the Participant has given written notice of exercise, has paid in full for such Shares, if requested, has given the representation described in <u>Section&nbsp;15(a)</u>&nbsp;hereof and fulfills such other conditions as may be set forth in the applicable Award Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Incentive Stock Option Limitations</font></u><font size="2" style="font-size:10.0pt;">.&#160; In the case of an Incentive Stock Option, the aggregate Fair Market Value (determined as of the time of grant) of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year under the Plan and/or any other plan of the Company, its Parent or any Subsidiary will not exceed $100,000.&#160; For purposes of applying the foregoing limitation,&nbsp;Incentive Stock Options will be taken into account in the order granted.&#160; To the extent any Option does not meet such limitation, that Option will be treated for all purposes as a Non-Qualified Stock Option.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;6.&#160; <u>Termination of </u></font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Service</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.&#160; </font></b><font size="2" style="font-size:10.0pt;">Unless otherwise specified with respect to a particular Option in the applicable Award Agreement or otherwise determined by the Committee, any portion of an Option that is not exercisable upon termination of service will expire immediately and automatically upon such termination and any portion of an Option that is exercisable upon termination of service will expire on the date it ceases to be exercisable in accordance with this <u>Section&nbsp;6</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination by Reason of Death</font></u><font size="2" style="font-size:10.0pt;">.&#160; If a Participant&#146;s service with the Company or any Affiliate terminates by reason of death, any Option held by such Participant may thereafter be exercised, to the extent it was exercisable at the time of his or her death or on such accelerated basis as the Committee may determine at or after grant, by the legal representative of the estate or by the legatee of the Participant, for a period expiring (i)&nbsp;at such time as may be specified by the Committee at or after grant, or (ii)&nbsp;if not specified by the Committee, then 12 months from the date of death, or (iii)&nbsp;if sooner than the applicable period specified under (i)&nbsp;or (ii)&nbsp;above, upon the expiration of the stated term of such Option.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination by Reason of Disability</font></u><font size="2" style="font-size:10.0pt;">.&#160; If a Participant&#146;s service with the Company or any Affiliate terminates by reason of Disability, any Option held by such Participant may thereafter be exercised by the Participant or his personal representative, to the extent it was exercisable at the time of termination, or on such accelerated basis as the Committee may determine at or after grant, for a period expiring (i)&nbsp;at such time as may be specified by the Committee at or after grant, or (ii)&nbsp;if not specified by the Committee, then 12 months from the date of termination of service, or (iii)&nbsp;if sooner than the applicable period specified under (i)&nbsp;or (ii)&nbsp;above, upon the expiration of the stated term of such Option.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Cause</font></u><font size="2" style="font-size:10.0pt;">.&#160; If a Participant&#146;s service with the Company or any Affiliate is terminated for Cause: (i)&nbsp;any Option, or portion thereof, not already exercised will be</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="2123-2-OM-01_PB_9_132648_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=831475,FOLIO='9',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:20 2015' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">immediately and automatically forfeited as of the date of such termination, and (ii)&nbsp;any Shares for which the Company has not yet delivered share certificates will be immediately and automatically forfeited and the Company will refund to the Participant the Option exercise price paid for such Shares, if any.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Other Termination</font></u><font size="2" style="font-size:10.0pt;">.&#160; If a Participant&#146;s service with the Company or any Affiliate terminates for any reason other than death, Disability or Cause, any Option held by such Participant may thereafter be exercised by the Participant, to the extent it was exercisable at the time of such termination, or on such accelerated basis as the Committee may determine at or after grant, for a period expiring (i)&nbsp;at such time as may be specified by the Committee at or after grant, or (ii)&nbsp;if not specified by the Committee, then 90 days from the date of termination of service, or (iii)&nbsp;if sooner than the applicable period specified under (i)&nbsp;or (ii)&nbsp;above, upon the expiration of the stated term of such Option.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;7.&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Restricted Stock</font></u></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Issuance</font></u><font size="2" style="font-size:10.0pt;">.&#160; Restricted Stock may be issued either alone or in conjunction with other Awards.&#160; The Committee will determine the time or times within which Restricted Stock may be subject to forfeiture, and all other conditions of such Awards.&#160; The purchase price for Restricted Stock may, but need not, be zero.&#160; The prospective recipient of an Award of Restricted Stock will not have any rights with respect to such Award, unless and until such recipient has delivered to the Company an executed Award Agreement and has otherwise complied with the applicable terms and conditions of such Award.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Certificates</font></u><font size="2" style="font-size:10.0pt;">.&#160; Upon the Award of Restricted Stock, the Committee may direct that a certificate or certificates representing the number of shares of Common Stock subject to such Award be issued to the Participant or placed in a restricted stock account (including an electronic account) with the transfer agent and in either case designating the Participant as the registered owner. The certificate(s)&nbsp;representing such shares shall be physically or electronically legended, as applicable, as to sale, transfer, assignment, pledge or other encumbrances during the Restriction Period and if issued to the Participant, returned to the Company, to be held in escrow during the Restriction Period. As a condition to any Award of Restricted Stock, the Participant may be required to deliver to the Company a share power, endorsed in blank, relating to the Shares covered by such Award.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Restrictions and Conditions</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Award Agreement evidencing the grant of any Restricted Stock will incorporate the following terms and conditions and such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee deems appropriate in its sole and absolute discretion:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">During a period commencing with the date of an Award of Restricted Stock and ending at such time or times as specified by the Committee (the &#147;<u>Restriction Period</u>&#148;), the Participant will not be permitted to sell, transfer, pledge, assign or otherwise encumber Restricted Stock awarded under the Plan.&#160; The Committee may condition the lapse of restrictions on Restricted Stock upon the continued employment or service of the recipient, the attainment of specified individual or corporate performance</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="2123-2-OM-03_PB_10_133106_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=42073,FOLIO='10',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">goals, or such other factors as the Committee may determine, in its sole and absolute discretion.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">While any Share of Restricted Stock remain subject to restriction, the Participant will have, with respect to the Restricted Stock, the right to vote the Shares, but will not have the right to receive any cash distributions or dividends prior to the lapse of the Restriction Period underlying such Shares unless otherwise provided under the applicable Award Agreement or as determined by the Committee.&#160; If any cash distributions or dividends are payable with respect to the Restricted Stock, the Committee, in its sole discretion, may require the cash distributions or dividends to be subjected to the same Restriction Period as is applicable to the Restricted Stock with respect to which such amounts are paid, or, if the Committee so determines, reinvested in additional Restricted Stock to the extent Shares are available under <u>Section&nbsp;3(a)</u>&nbsp;of the Plan.&#160; A Participant shall not be entitled to interest with respect to any dividends or distributions subjected to the Restriction Period.&#160; Any distributions or dividends paid in the form of securities with respect to Restricted Stock will be subject to the same terms and conditions as the Restricted Stock with respect to which they were paid, including, without limitation, the same Restriction Period.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant&#146;s service with the Company and its Affiliates terminates prior to the expiration of the applicable Restriction Period, the Participant&#146;s Restricted Stock that then remains subject to forfeiture will then be forfeited automatically.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;8.&#160; <u>Restricted Stock Units</u>.&#160; </font></b><font size="2" style="font-size:10.0pt;">Subject to the other terms of the Plan, the Committee may grant Restricted Stock Units to eligible individuals and may, in its sole and absolute discretion, impose conditions on such units as it may deem appropriate, including, without limitation, continued employment or service of the recipient or the attainment of specified individual or corporate performance goals.&#160; Each Restricted Stock Unit shall be evidenced by an Award Agreement in the form that is approved by the Committee and that is not inconsistent with the terms and conditions of the Plan.&#160; Each Restricted Stock Unit will represent a right to receive from the Company, upon fulfillment of any applicable conditions, an amount equal to the Fair Market Value (at the time of the distribution) of one Share.&#160; Distributions may be made in Shares.&#160; All other terms governing Restricted Stock Units, such as vesting, time and form of payment and termination of units shall be set forth in the applicable Award Agreement.&#160; The Participant shall not have any shareholder rights with respect to the Shares subject to a Restricted Stock Unit Award until that Award vests and the Shares are actually issued thereunder.&#160; Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant&#146;s service with the Company terminates prior to the Restricted Stock Unit Award vesting, the Participant&#146;s Restricted Stock Units that then remain subject to forfeiture will then be forfeited automatically.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;9.&#160; <u>Performance Based Awards</u></font></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Performance Awards Generally</font></u><font size="2" style="font-size:10.0pt;">. The Committee may grant Performance Awards in accordance with this <u>Section&nbsp;9</u>.&#160; Performance Awards may be denominated as a</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="2123-2-OM-03_PB_11_133141_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=709948,FOLIO='11',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">number of Shares, or a specified number of other Awards, which may be earned upon achievement or satisfaction of such Performance Goals as may be specified by the Committee.&#160; In addition, the Committee may specify that any other Award shall constitute a Performance Award by conditioning the vesting or settlement of the Award upon the achievement or satisfaction of such Performance Goals as may be specified by the Committee.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Adjustments to Performance Goals</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Committee may provide, at the time Performance Goals are established, that adjustments will be made to those performance goals to take into account, in any objective manner specified by that committee, the impact of one or more of the following: (A)&nbsp;gain or loss from all or certain claims and/or litigation and insurance recoveries, (B)&nbsp;the impairment of tangible or intangible assets, (C)&nbsp;stock-based compensation expense, (D)&nbsp;restructuring activities reported in the Company&#146;s public filings, (E)&nbsp;investments, dispositions or acquisitions, (F)&nbsp;loss from the disposal of certain assets, (G)&nbsp;gain or loss from the early extinguishment, redemption, or repurchase of debt, (H)&nbsp;changes in accounting principles, or (I)&nbsp;any other item, event or circumstance that would not cause an Award to fail to constitute &#147;qualified performance-based compensation&#148; under Section&nbsp;162(m)&nbsp;of the Code (to the extent such Award is intended to be &#147;qualified performance-based compensation&#148;).&#160; An adjustment described in this Section&nbsp;may relate to the Company or to any subsidiary, division or other operational unit of the Company or its Affiliates, as determined by the Committee at the time the performance goals are established.&#160; Any adjustment shall be determined in accordance with generally accepted accounting principles and standards, unless such other objective method of measurement is designated by the committee at the time performance objectives are established.&#160; In addition, adjustments will be made as necessary to any performance criteria related to the Company&#146;s stock to reflect changes in corporate capitalization, including a recapitalization, stock split or combination, stock dividend, spin-off, merger, reorganization or other similar event or transaction affecting the Company&#146;s equity.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Other Terms of Performance Awards</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Committee may specify other terms pertinent to a Performance Award in the applicable Award Agreement, including terms relating to the treatment of that Award in the event of a Change in Control prior to the end of the applicable performance period.&#160; The Participant shall not have any shareholder rights with respect to the Shares subject to a Performance Award until the Shares are actually issued thereunder.&#160; Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant&#146;s service with the Company terminates prior to the Performance Award vesting, the Participant&#146;s Performance Award or portion thereof that then remains subject to forfeiture will then be forfeited automatically.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;10.&#160; <u>Amendments and </u></font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Termination</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Board may amend, alter or discontinue the Plan at any time.&#160; However, except as otherwise provided in <u>Section&nbsp;3</u>, no amendment, alteration or discontinuation will be made which would impair the rights of a Participant with respect to an Award without that Participant&#146;s consent or which, without the approval of such amendment within 365 days of its adoption by the Board by the Company&#146;s stockholders in a manner consistent with Treas. Reg. &#167; 1.422-3 (or any successor provision), would: (i)&nbsp;increase the total number of Shares reserved for issuance hereunder, or (ii)&nbsp;change the persons or class of persons eligible to receive Awards.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="2123-2-OM-03_PB_12_133203_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=908007,FOLIO='12',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;11.&#160; <u>Prohibition on Repricing Programs</u></font></b><font size="2" style="font-size:10.0pt;">.&#160; Neither the Committee nor the Board shall (i)&nbsp;implement any cancellation/re-grant program pursuant to which outstanding Options under the Plan are cancelled and new Options are granted in replacement with a lower exercise or base price per share, (ii)&nbsp;cancel outstanding Options under the Plan with exercise prices or base prices per share in excess of the then current Fair Market Value per Share for consideration payable in equity securities of the Company or (iii)&nbsp;otherwise directly reduce the exercise price or base price in effect for outstanding Options under the Plan, without in each such instance obtaining shareholder approval.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;12.&#160; <u>Conditions Upon Grant of Awards and Issuance of Shares</u></font></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The implementation of the Plan, the grant of any Award and the issuance of Shares in connection with the issuance, exercise or vesting of any Award made under the Plan shall be subject to the Company&#146;s procurement of all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the Awards made under the Plan and the Shares issuable pursuant to those Awards.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">No Shares or other assets shall be issued or delivered under the Plan unless and until there shall have been compliance with all applicable requirements of Applicable Law, including the filing and effectiveness of the Form&nbsp;S-8 registration statement for the Shares issuable under the Plan, and all applicable listing requirements of any stock exchange on which Shares are then listed for trading.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;13.&#160; <u>Limits on Transferability; Beneficiaries</u></font></b><font size="2" style="font-size:10.0pt;">.&#160; No Award or other right or interest of a Participant under the Plan shall be pledged, encumbered, or hypothecated to, or in favor of, or subject to any lien, obligation, or liability of such Participant to, any party, other than the Company, any Subsidiary or Affiliate, or assigned or transferred by such Participant otherwise than by will or the laws of descent and distribution, and such Awards and rights shall be exercisable during the lifetime of the Participant only by the Participant or his or her guardian or legal representative. Notwithstanding the foregoing, the Committee may, in its discretion, provide that Awards or other rights or interests of a Participant granted pursuant to the Plan (other than an Incentive Stock Option) be transferable, without consideration, to immediate family members (i.e., children, grandchildren or spouse), to trusts for the benefit of such immediate family members and to partnerships in which such family members are the only partners. The Committee may attach to such transferability feature such terms and conditions as it deems advisable. In addition, a Participant may, in the manner established by the Committee, designate a beneficiary (which may be a person or a trust) to exercise the rights of the Participant, and to receive any distribution, with respect to any Award upon the death of the Participant. A beneficiary, guardian, legal representative or other person claiming any rights under the Plan from or through any Participant shall be subject to all terms and conditions of the Plan and any Award Agreement applicable to such Participant, except as otherwise determined by the Committee, and to any additional restrictions deemed necessary or appropriate by the Committee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;14. &#160;<u>Withholding</u></font></b><font size="2" style="font-size:10.0pt;">. No later than the date as of which an amount first becomes includible in the gross income of the Participant for federal income tax purposes with respect to any Award under the Plan, the Participant will pay to the Company, or make</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="2123-2-OM-03_PB_13_133216_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=387955,FOLIO='13',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">arrangements satisfactory to the Company regarding the payment of, any federal, state or local taxes of any kind required by law to be withheld with respect to such amount.&#160; The minimum required withholding obligations may be settled with Shares, including Shares that are part of the Award that gives rise to the withholding requirement.&#160; The obligations of the Company under the Plan will be conditioned on such payment or arrangements and the Company will have the right to deduct any such taxes from any payment of any kind otherwise due to the Participant.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;15.&#160; <u>Liability of Company</u></font></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Inability to Obtain Authority</font></u><font size="2" style="font-size:10.0pt;">.&#160; If the Company cannot, by the exercise of commercially reasonable efforts, obtain authority from any regulatory body having jurisdiction for the sale of any Shares under this Plan, and such authority is deemed by the Company&#146;s counsel to be necessary to the lawful issuance of those Shares, the Company will be relieved of any liability for failing to issue or sell those Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Grants Exceeding Allotted Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; If Shares subject to an Award exceed, as of the date of grant, the number of Shares which may be issued under the Plan without additional shareholder approval, that Award will be contingent with respect to such excess Shares, on the effectiveness under Applicable Law of a sufficient increase in the number of Shares subject to this Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Rights of Participants and Beneficiaries</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company will pay all amounts payable under this Plan only to the applicable Participant, or beneficiaries entitled thereto pursuant to this Plan.&#160; The Company will not be liable for the debts, contracts, or engagements of any Participant or his or her beneficiaries, and rights to cash payments under this Plan may not be taken in execution by attachment or garnishment, or by any other legal or equitable proceeding while in the hands of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;16.&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">General </font></u></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Provisions</font></u></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Board may require each Participant to represent to and agree with the Company in writing that the Participant is acquiring securities of the Company for investment purposes and without a view to distribution thereof and as to such other matters as the Board believes are appropriate.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All certificates for Shares or other securities delivered under the Plan will be subject to such share-transfer orders and other restrictions as the Board may deem advisable under the rules, regulations and other requirements of the Securities Act of 1933, as amended, the Exchange Act, any stock exchange upon which the Shares are then listed, and any other Applicable Law, and the Board may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Nothing contained in the Plan will prevent the Board from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Neither the adoption of the Plan nor the execution of any document in connection with the Plan will: (i)&nbsp;confer upon any employee or other service provider of the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="2123-2-OM-03_PB_14_133248_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=76315,FOLIO='14',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company or an Affiliate any right to continued employment or engagement with the Company or such Affiliate, or (ii)&nbsp;interfere in any way with the right of the Company or such Affiliate to terminate the employment or engagement of any of its employees or other service providers at any time.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;17.&#160; <u>Effective </u></font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Date</font></u></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;"> of Plan</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Plan will become effective immediately prior to the closing of the Company&#146;s initial public offering.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;18.&#160; <u>Term </u></font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">of</font></u></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;"> Plan</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">. </font></b><font size="2" style="font-size:10.0pt;">&#160;Unless the Plan shall theretofore have been terminated in accordance with Section&nbsp;10, the Plan shall terminate on May&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;], 2025, and no Awards under the Plan shall thereafter be granted.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;19.&#160; <u>Invalid Provisions</u>.</font></b><font size="2" style="font-size:10.0pt;">&#160; In the event that any provision of this Plan is found to be invalid or otherwise unenforceable under any Applicable Law, such invalidity or unenforceability will not be construed as rendering any other provisions contained herein as invalid or unenforceable, and all such other provisions will be given full force and effect to the same extent as though the invalid or unenforceable provision was not contained herein.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;20.&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Governing</font></u></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;"> Law</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Plan and all Awards granted hereunder will be governed by and construed in accordance with the laws and judicial decisions of the Commonwealth of Virginia, without regard to the application of the principles of conflicts of laws.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;21.&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Notices</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; Any notice to be given to the Company pursuant to the provisions of this Plan must be given in writing and addressed, if to the Company, to its principal executive office to the attention of its Chief Financial Officer (or such other Person as the Company may designate in writing from time to time), and, if to a Participant, to the address contained in the Company&#146;s personnel files, or at such other address as that Participant may hereafter designate in writing to the Company.&#160; Any such notice will be deemed duly given: if delivered personally or via recognized overnight delivery service, on the date and at the time so delivered; if sent via telecopier or email, on the date and at the time telecopied or emailed with confirmation of delivery; or, if mailed, five (5)&nbsp;days after the date of mailing by registered or certified mail.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="2123-2-OM-03_PB_15_133307_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="9",CHK=457011,FOLIO='15',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OM-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 15:21 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>10
<FILENAME>a2224429zex-10_36.htm
<DESCRIPTION>EX-10.36
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.36</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Restricted Stock Award Agreement</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THIS RESTRICTED STOCK AWARD AGREEMENT (this &#147;<u>Agreement</u>&#148;) is made as of April&nbsp;2, 2015 (the &#147;<u>Grant Date</u>&#148;) by and between Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation (the &#147;<u>Company</u>&#148;), and Michael Heffernan (the &#147;<u>Participant</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, in consideration for the Participant&#146;s continued and future services to the Company and to further align the Participant&#146;s financial interests with those of the Company&#146;s stockholders, the Company&#146;s Board of Directors (the &#147;<u>Board</u>&#148;) has approved this award of restricted Common Stock to Participant subject to the restrictions and on the terms and conditions contained in this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of these premises and the agreements set forth herein, the parties, intending to be legally bound hereby, agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Award of Restricted Shares; Termination of Transaction Bonus Plan and Any Rights Thereunder</font></u></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company hereby awards the Participant One Million Three Hundred Forty-Three Thousand Three Hundred Ninety One (1,343,391) shares of restricted Common Stock, subject to the restrictions and on the terms and conditions set forth in this Agreement (the &#147;<u>Restricted Shares</u>&#148;).&#160; The terms of the Plan are hereby incorporated into this Agreement by this reference, as though fully set forth herein.&#160; Except as otherwise provided herein, capitalized terms used herein will have the same meaning as defined in the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Participant acknowledges and agrees that any and all rights and claims of the Participant with respect to that certain Transaction Bonus Plan adopted by the Company on July&nbsp;23, 2014 (&#147;<u>Transaction Bonus Plan</u>&#148;) (including, without limitation, any rights created by the amendment dated September&nbsp;10, 2013 to Participant&#146;s employment agreement concerning the Transaction Bonus Plan) are hereby terminated, cancelled and of no further force or effect effective as of the date hereof and that the foregoing termination of the Transaction Bonus Plan and Participant&#146;s rights thereunder is partial consideration for, and is a condition of, the Company&#146;s award of the Restricted Shares to Participant hereunder.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Forfeiture; Vesting of Restricted Shares</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">No Transfer of Unvested Restricted Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; Six Hundred Seventy-One Thousand Six Hundred Ninety Six (671,696) of the Restricted Shares shall be vested on the date hereof and shall not be subject to risk of forfeiture pursuant to the provisions of this <u>Section&nbsp;2</u>. Six Hundred Seventy-One Thousand Six Hundred Ninety Five (671,695) of the Restricted Shares (the &#147;<u>Vesting Shares</u>&#148;) shall be subject to forfeiture to the Company until they become vested in accordance with this <u>Section&nbsp;2</u>.&#160; While subject to forfeiture, the Vesting Shares may not be sold, pledged, assigned, otherwise encumbered or transferred in any manner, whether voluntarily or involuntarily by the operation of law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="10",CHK=134286,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OO_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Unvested Vesting Shares Subject to Forfeiture</font></u><font size="2" style="font-size:10.0pt;">.&#160; Subject to the other sections of this Agreement, including, without limitation, the acceleration of vesting referenced in <u>Section&nbsp;2(d)</u>, upon any cessation of the Participant&#146;s service with the Company (whether initiated by the Company, Participant or otherwise): (i)&nbsp;any Vesting Shares which have not vested pursuant to this <u>Section&nbsp;2</u> will immediately and automatically, without any action on the part of the Company or payment of any consideration to Participant, be forfeited, and (ii)&nbsp;the Participant will have no further rights with respect to such forfeited Vesting Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Vesting of Restricted Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; Subject to Participant&#146;s continuous service with the Company through such date and the acceleration of vesting referenced in <u>Section&nbsp;2(d)</u>, the Vesting Shares will become vested (free from forfeiture pursuant to <u>Section&nbsp;2(b)</u>) as to one thirty sixth (1/36</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font><font size="2" style="font-size:10.0pt;">) of the Vesting Shares shall vest at the end of each monthly period after April&nbsp;2, 2015, with all of the Vesting Shares becoming vested on April&nbsp;2, 2018.&#160; For purposes of this Agreement, service with an Affiliate of the Company will be deemed to constitute service with the Company, for so long as such entity remains an Affiliate of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Acceleration of Vesting</font></u><font size="2" style="font-size:10.0pt;">.&#160; The vesting of the Vesting Shares is subject to the vesting acceleration provisions contained in the employment agreement dated June&nbsp;13, 2012, as amended, between the Company and Participant, or as set forth in any successor employment agreement entered into between the Company and Participant</font><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Issuance of Shares.</font></u></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company will cause the Restricted Shares to be issued in the Participant&#146;s name either by book-entry registration or issuance of a stock certificate or certificates.&#160; While the Vesting Shares remain forfeitable, the Company will cause an appropriate stop-transfer order to be issued and to remain in effect with respect to the Vesting Shares.&#160; As soon as practicable following the time that any Vesting Share becomes vested (and provided that appropriate arrangements have been made with the Company for the withholding or payment of any taxes that may be due with respect to such share), the Company will cause that stop-transfer order to be removed.&#160; The Company may also condition delivery of certificates for Restricted Shares upon receipt from the Participant of any undertakings that it may determine are appropriate to facilitate compliance with federal and state securities laws.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If any certificate is issued in respect of Vesting Shares, that certificate will include appropriate legends and will held in escrow by the Company&#146;s secretary or his or her designee. In addition, the Participant shall be required to execute and deliver to the Company a stock power with respect to those Vesting Shares in substantially the form attached hereto as <u>Exhibit&nbsp;A</u>.&#160; At such time as those Vesting Shares become vested, the Company will cause a new certificate to be issued without that portion of the legend referencing the previously applicable forfeiture conditions and will cause that new certificate to be delivered to the Participant (again, provided that appropriate arrangements have been made with the Company for the withholding or payment of any taxes that may be due with respect to such Shares).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Substitute Property</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; If, while any of the Vesting Shares remain subject to forfeiture, there occurs a merger, reclassification, recapitalization, stock split, stock dividend or other similar event or transaction resulting in new, substituted or additional securities being</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="10",CHK=273202,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OO_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">issued or delivered to the Participant by reason of the Participant&#146;s ownership of the Vesting Shares, such securities will constitute &#147;<u>Vesting Shares</u>&#148; for all purposes of this Agreement and any certificate issued to evidence such securities will immediately be deposited with the secretary of the Company (or his or her designee) and subject to the escrow described in <u>Section&nbsp;3</u>, above.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Rights of Participant During Restricted Period</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b><font size="2" style="font-size:10.0pt;">&#160; The Participant will have the right to vote the Restricted Shares (including any Vesting Shares) and to receive dividends and distributions with respect to the Restricted Shares (including any Vesting Shares); <i>provided, however</i>, that any cash dividends or distributions paid in respect of the Restricted Shares that are Vesting Shares while those shares remain subject to forfeiture will be placed in escrow with the secretary of the Company (or his or her designee) and will be delivered to the Participant (without interest) only if and when such Vesting Shares giving rise to such dividends or distributions become vested.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Right of First Refusal</font></u></b><font size="2" style="font-size:10.0pt;">.&#160; Participant acknowledges the vested Restricted Shares are subject to, among other things, the restrictions on transfer, rights of first refusal and co-sale rights set forth in that certain Seventh Amended and Restated Stockholders&#146; Agreement dated as of March&nbsp;6, 2015, as may be amended and/or restated from time to time (the &#147;<u>Stockholders Agreement</u>&#148;) by and among the Company, Participant and the other stockholders of the Company party thereto.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Market Standoff Agreement</font></u></b><font size="2" style="font-size:10.0pt;">.&#160; The Participant agrees, in connection with the initial underwritten public offering of the Company&#146;s securities pursuant to a registration statement under the Securities Act, (i)&nbsp;not to sell, make short sale of, loan, grant any options for the purchase of, or otherwise dispose of any shares of Common Stock held by the Participant (other than those shares included in the offering) without the prior written consent of the Company or the underwriters managing such initial underwritten public offering of the Company&#146;s securities for a period of 180 days from the effective date of such registration statement (plus up to an additional 34 days to the extent requested by the managing underwriters for such offering in order to address Rule&nbsp;2711(f)&nbsp;of the Financial Industry Regulatory Authority,&nbsp;Inc. or any similar successor provision), and (ii)&nbsp;to execute any agreement reflecting clause (i)&nbsp;above as may be requested by the Company or the managing underwriters at the time of such offering</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Securities Laws</font></u></b><font size="2" style="font-size:10.0pt;">.&#160; The Board may from time to time impose any conditions on the Restricted Shares as it deems necessary or advisable to ensure that the Restricted Shares are issued and sold in compliance with the requirements of any stock exchange or quotation system upon which the shares are then listed or quoted, the Securities Act of 1933 and all other applicable laws.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Tax Consequences</font></u></b><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Participant acknowledges that the Company has not advised the Participant regarding the Participant&#146;s income tax liability in connection with the grant or vesting of the Restricted Shares.&#160; The Participant has had the opportunity to review with his or her own tax advisors the federal, state and local tax consequences of the transactions contemplated by this</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="10",CHK=400371,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OO_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement.&#160; The Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.&#160; The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#146;s own tax liability that may arise as a result of the transactions contemplated by this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state or local taxes of any kind required by law to be withheld with respect to the award of the Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state or local taxes of any kind required by law to be withheld with respect to the purchase of the Shares by the Participant or the lapse of the Purchase Option.&#160; The Participant has reviewed with the Participant&#146;s own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Participant shall make an election under Section&nbsp;83(b)&nbsp;of the Code with respect to the grant of the Vesting Shares, the Participant agrees to notify the Company in writing on the day of such election.&#160; The amount includible in the Participant&#146;s income as a result of that election will be subject to tax withholding.&#160; The Participant will be required to remit to the Company in cash, or make other arrangements reasonably satisfactory to the Company for the satisfaction of, such tax withholding amount; failure to do so within three business days of making the Section&nbsp;83(b)&nbsp;election will result in forfeiture of all the Restricted Shares.&#160; PARTICIPANT ACKNOWLEDGES THAT IT IS SOLELY THE PARTICIPANT&#146;S RESPONSIBILITY AND NOT THE COMPANY&#146;S TO FILE TIMELY THE ELECTION UNDER SECTION&nbsp;83(b), EVEN IF THE PARTICIPANT REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON THE PARTICIPANT&#146;S BEHALF.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Consent to Electronic Delivery</font></u></b><font size="2" style="font-size:10.0pt;">.&#160; The Participant hereby authorizes the Company to deliver electronically any prospectuses or other documentation related to this Agreement and any other compensation or benefit plan or arrangement in effect from time to time (including, without limitation, reports, proxy statements or other documents that are required to be delivered to participants in such plans or arrangements pursuant to federal or state laws, rules&nbsp;or regulations).&#160; For this purpose, electronic delivery will include, without limitation, delivery by means of e-mail or e-mail notification that such documentation is available on the Company&#146;s intranet site.&#160; Upon written request, the Company will provide to the Participant a paper copy of any document also delivered to the Participant electronically.&#160; The authorization described in this paragraph may be revoked by the Participant at any time by written notice to the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Entire Agreement</font></u></b><font size="2" style="font-size:10.0pt;">.&#160; This Agreement represents the entire agreement between the parties hereto relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Severability</font></u></b><font size="2" style="font-size:10.0pt;">. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="10",CHK=574505,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OO_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Governing Law</font></u></b><font size="2" style="font-size:10.0pt;">.&#160; This Agreement will be construed in accordance with the laws of the Commonwealth of Virginia, without regard to the application of the principles of conflicts of laws.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Amendment</font></u></b><font size="2" style="font-size:10.0pt;">.&#160; This Agreement may only be amended by a writing signed by each of the parties hereto.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Changes in Capitalization</font></u></b><font size="2" style="font-size:10.0pt;">.&#160; In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, the number of shares subject to forfeiture and other rights of the Company hereunder and such other relevant terms this Agreement that are affected by such stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event shall be equitably adjusted by the Company (in the manner determined by the Board).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Execution</font></u></b><font size="2" style="font-size:10.0pt;">.&#160; This Agreement may be executed, including execution by facsimile signature, in one or more counterparts, each of which will be deemed an original, and all of which together shall be deemed to be one and the same instrument.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[<i>Signature Page&nbsp;Follows</i>]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="10",CHK=94670,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OO_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the Company&#146;s duly authorized representative and the Participant have each executed this Restricted Stock Award Agreement as of the date first set forth above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM   PHARMACEUTICAL,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">By:</font></b></p>    </td>
<td width="43%" colspan="3" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Paul Brannelly</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Name:</font></b></p>    </td>
<td width="43%" colspan="3" valign="top" style="border:none;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul   Brannelly</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Title:</font></b></p>    </td>
<td width="43%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:14.44%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PARTICIPANT</font></b><font size="2" style="font-size:10.0pt;">:</font></p>    </td>
<td width="35%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:35.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michael   Heffernan</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:14.44%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="35%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:35.56%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Signature:</font></b></p>    </td>
<td width="40%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Michael Heffernan</font></p>    </td>   </tr>
<tr height="0">
<td width="374" style="border:none;"></td>
<td width="50" style="border:none;"></td>
<td width="25" style="border:none;"></td>
<td width="33" style="border:none;"></td>
<td width="266" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="10",CHK=625604,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OO_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;A</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FOR VALUE RECEIVED,&nbsp;I hereby sell, assign and transfer unto &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) shares of Common Stock, $.001 par value per share, of Collegium Pharmaceutical,&nbsp;Inc. (the &#147;Corporation&#148;) standing in my name on the books of the Corporation represented by Certificate(s)&nbsp;Number &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herewith, and do hereby irrevocably constitute and appoint &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; attorney to transfer the said stock on the books of the Corporation with full power of substitution in the premises.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michael Heffernan</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:6.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="374" style="border:none;"></td>
<td width="33" style="border:none;"></td>
<td width="17" style="border:none;"></td>
<td width="324" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="10",CHK=186372,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OO_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 23:00 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>11
<FILENAME>a2224429zex-10_37.htm
<DESCRIPTION>EX-10.37
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.37</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INDEMNITY AGREEMENT</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Indemnification Agreement (&#147;Agreement&#148;) is made as of April&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015, by and between Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation (the &#147;Company&#148;), and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&#147;Indemnitee&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">RECITALS</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, highly competent persons have become more reluctant to serve publicly held corporations as a director and/or officer unless they are provided with adequate indemnification against risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Articles of Incorporation of the Company and the Virginia Stock Corporation Act (the &#147;Virginia Act&#148;) expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification and advancement of expenses;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Company and Indemnitee recognize the substantial increase in corporate litigation in general, subjecting directors and officers to expensive litigation risks that may not be fully covered by liability insurance;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Company and Indemnitee further recognize the difficulty in obtaining and accessing directors and officers liability insurance that fully and adequately covers directors and officers for their acts and omissions on behalf of the Company and its subsidiaries; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, it is reasonable and prudent for the Company contractually to obligate itself to indemnify, and to advance expenses to, its directors and officers to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be protected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Services to the Company.</font></u><font size="2" style="font-size:10.0pt;"> Indemnitee agrees to serve or continue to serve as a director and/or officer of the Company.&#160; Indemnitee may at any time and for any reason resign from the board of directors or as an officer of the Company, as the case may be (subject to any other contractual obligation or any obligation imposed by operation of law).&#160; This Agreement shall not be deemed an employment contract between the Company and Indemnitee. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as a director and/or officer of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=469473,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Definitions</font></u><font size="2" style="font-size:10.0pt;">.&#160; As used in this Agreement:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A &#147;Change in Control&#148; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company&#146;s then outstanding securities;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Change in Board of Directors. During any period of two (2)&nbsp;consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has effected, or entered into an agreement with the Company to effect, a transaction described in Sections&nbsp;2(a)(i), 2(a)(iii)&nbsp;or 2(a)(iv)) whose election by the Board or nomination for election by the Company&#146;s shareholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a least a majority of the members of the Board;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Dissolution or Disposition of Assets.&#160; The approval by the shareholders of the Company of the dissolution of the Company or of an agreement for the sale or disposition by the Company of all or substantially all of the Company&#146;s assets; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e)&nbsp;of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of this Section&nbsp;2(a), the following terms shall have the following meanings:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;Exchange Act&#148; shall mean the Securities Exchange Act of 1934, as amended.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;Person&#148; or &#147;person&#148; shall have the meaning as set forth in Sections 13(d)&nbsp;and 14(d)&nbsp;of the Exchange Act; provided, however, that Person shall exclude (i)&nbsp;the Company, (ii)&nbsp;any trustee or other fiduciary holding securities under an</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="2123-2-OQ-01_PB_2_135812_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=30678,FOLIO='2',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">employee benefit plan of the Company, and (iii)&nbsp;any corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;Beneficial Owner&#148; shall have the meaning given to such term in Rule&nbsp;13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the shareholders of the Company approving a merger of the Company with another entity, and further provided, that any calculation of securities beneficially owned by a Beneficial Owner shall include securities that are the subject of a derivative that creates for the Beneficial Owner the economic equivalent of ownership in such securities for the Beneficial Owner by tying the value of the derivative to the price or value of such securities.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;Corporate Status&#148; describes the status of a person who is or was a director, officer, employee or agent of the Company or of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise which such person is or was serving at the request of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;Enterprise&#148; shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;Expenses&#148; shall include all reasonable attorneys&#146; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding.&#160; Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for and other costs relating to any cost bond, supersedeas bond or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;Independent Counsel&#148; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past three years has been, retained to represent:&#160; (i)&nbsp;the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#147;Independent Counsel&#148; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="2123-2-OQ-01_PB_3_135832_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=5310,FOLIO='3',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the Company or Indemnitee in an action to determine Indemnitee&#146;s rights under this Agreement.&#160; The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to indemnify such counsel fully against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The term &#147;Proceeding&#148; shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise (including a derivative lawsuit) and whether of a civil, criminal, administrative or investigative nature, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by Indemnitee or of any action on Indemnitee&#146;s part while acting as director or officer of the Company, or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust or other enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; except one initiated by Indemnitee to enforce Indemnitee&#146;s rights under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Reference to &#147;other enterprise&#148; shall include employee benefit plans; references to &#147;fines&#148; shall include any excise tax assessed with respect to any employee benefit plan; references to &#147;serving at the request of the Company&#148; shall include any service as a director or officer of the Company which imposes duties on, or involves services by, such director or officer with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed not to have engaged in willful misconduct or a knowing violation of criminal law.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Indemnity in Proceedings</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company shall indemnify Indemnitee in accordance with the provisions of this Section&nbsp;3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, including a Proceeding by or in the right of the Company to procure a judgment in its favor.&#160; Pursuant to this Section&nbsp;3,&nbsp;Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, liabilities, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on Indemnitee&#146;s behalf in connection with such Proceeding or any claim, issue or matter therein, except for indemnification of the Indemnitee for Indemnitee&#146;s willful misconduct or Indemnitee&#146;s knowing violation of the criminal law.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Settlement</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company shall have no obligation to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding Indemnitee effected without the Company&#146;s prior written consent, which consent shall not be unreasonably withheld.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="2123-2-OQ-01_PB_4_135927_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=447219,FOLIO='4',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company shall not, without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld), consent to the entry of any judgment against Indemnitee or enter into any settlement or compromise which (A)&nbsp;includes an admission of fault of Indemnitee, any non-monetary remedy affecting Indemnitee or any monetary obligation for which Indemnitee is not indemnified hereunder or (B)&nbsp;with respect to any Proceeding with respect to which Indemnitee is likely to be or is made a party, witness or participant or is otherwise entitled to seek indemnification hereunder, does not include, as an unconditional term thereof, the full release of Indemnitee from all liability in respect of such Proceeding, which release shall be in form and substance reasonably satisfactory to Indemnitee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Indemnification for Expenses of a Party Who is Wholly or Partly Successful</font></u><font size="2" style="font-size:10.0pt;">.&#160; Notwithstanding any other provisions of this Agreement (other than Section&nbsp;6(a)&nbsp;or (c)&nbsp;of this Agreement), to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee in connection therewith.&#160; If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall, subject to Section&nbsp;6(a)&nbsp;and (c)&nbsp;of this Agreement, indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#146;s behalf in connection with each successfully resolved claim, issue or matter. If Indemnitee is not wholly successful in such Proceeding, the Company also shall, subject to Section&nbsp;6(a)&nbsp;and (c)&nbsp;of this Agreement, indemnify Indemnitee against all Expenses reasonably incurred in connection with a claim, issue or matter related to any claim, issue, or matter on which the Indemnitee was successful.&#160; For purposes of this Section&nbsp;4 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Indemnification For Expenses of a Witness</font></u><font size="2" style="font-size:10.0pt;">.&#160; Notwithstanding any other provision of this Agreement (other than Section&nbsp;6(a)&nbsp;and (c)&nbsp;of this Agreement), to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of Indemnitee&#146;s Corporate Status, a witness in any Proceeding to which Indemnitee is not a party,&nbsp;Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#146;s behalf in connection therewith.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exclusions</font></u><font size="2" style="font-size:10.0pt;">.&#160; Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision[, provided, that the foregoing shall not affect the rights of Indemnitee or the Fund Indemnitors set forth in Section&nbsp;12(f)&nbsp;below];</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">(i)&nbsp;for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section&nbsp;16(b)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="2123-2-OQ-01_PB_5_140009_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=817248,FOLIO='5',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law, or (ii)&nbsp;for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Securities Exchange Act of 1934, as amended (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 or Section&nbsp;954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section&nbsp;306 of the Sarbanes-Oxley Act of 2002); or</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee prior to a Change of Control against the Company or its directors, officers, employees or other indemnitees, unless (i)&nbsp;the Board of Directors of the Company authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii)&nbsp;the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Advances of Expenses</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding any provision of this Agreement to the contrary but subject to Section&nbsp;7(c)&nbsp;of this Agreement, the Company shall advance, to the fullest extent permitted by applicable law, the Expenses reasonably incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within 30 days after the receipt by the Company of a statement or statements requesting such advances (supported by statements in reasonable detail of Expenses incurred or to be incurred within the next 30 days) from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee&#146;s ability to repay the Expenses and without regard to Indemnitee&#146;s ultimate entitlement to indemnification under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed.&#160; The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall constitute an undertaking that the Indemnitee will repay the advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event the Company is obligated under this Section&nbsp;7 hereof to pay, and pays the Expenses of any Proceeding against Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such Proceeding, with counsel approved by Indemnitee, which approval shall not be unreasonably withheld, upon the delivery to Indemnitee of written notice of the Company&#146;s election so to do.&#160; After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same Proceeding, provided that (i)&nbsp;Indemnitee shall have the right to employ Indemnitee&#146;s counsel in any such Proceeding at Indemnitee&#146;s expense; and (ii)&nbsp;if (A)&nbsp;the employment of counsel by Indemnitee has been previously authorized by the Company, (B)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="2123-2-OQ-01_PB_6_140133_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=420346,FOLIO='6',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense or (C)&nbsp;the Company shall not, in fact, have employed counsel approved by Indemnitee to assume the defense of such Proceeding, then the fees and expenses of Indemnitee&#146;s counsel shall be at the expense of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">This Section&nbsp;7 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section&nbsp;6(a)&nbsp;or (c)&nbsp;of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Procedure for Notification and Defense of Claim</font></u><font size="2" style="font-size:10.0pt;">.&#160; To obtain indemnification under this Agreement,&nbsp;Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such action, suit or proceeding.&#160; The omission to notify the Company will not relieve the Company from any liability which it may have to Indemnitee otherwise than under this Agreement.&#160; The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Procedure Upon Application for Indemnification</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Upon written request by Indemnitee for indemnification pursuant to the first sentence of Section&nbsp;8, a determination, if required by applicable law, with respect to Indemnitee&#146;s entitlement thereto shall be made in the specific case in accordance with the determination process set forth in Section&nbsp;13.1-701B of the Virginia Act.&#160; Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&#146;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.&#160; Any costs or expenses (including reasonable attorneys&#146; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#146;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;9(a)&nbsp;hereof, the Independent Counsel shall be selected as provided in this Section&nbsp;9(b). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board of Directors, and the Company shall give written notice to Indemnitee advising Indemnitee of the identity of the Independent Counsel so selected.&#160; If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board of Directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected.&#160; In either event,&nbsp;Indemnitee or the Company, as the case may be, may, within 10 days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; <u>provided, however,</u> that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="2123-2-OQ-01_PB_7_140428_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=334190,FOLIO='7',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">requirements of &#147;Independent Counsel&#148; as defined in Section&nbsp;2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.&#160; Absent a proper and timely objection, the person so selected shall act as Independent Counsel.&#160; If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section&nbsp;8 hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Virginia Court (as defined in Section&nbsp;20 of this Agreement) for resolution of any objection which shall have been made by the Company or Indemnitee to the other&#146;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&nbsp;9(a)&nbsp;hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section&nbsp;11(a)&nbsp;of this Agreement,&nbsp;Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Presumptions and Effect of Certain Proceedings</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;8 of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption.&#160; Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to Section&nbsp;11(e), if the person, persons or entity empowered or selected under Section&nbsp;9 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#146;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law; <u>provided</u>, <u>however</u>, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and <u>provided</u>, <u>further</u>, that the foregoing provisions of this Section&nbsp;10(b)&nbsp;shall not apply if the determination of</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="2123-2-OQ-01_PB_8_140442_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=278155,FOLIO='8',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;9(a)&nbsp;of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of <u>nolo contendere</u> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee was guilty of willful misconduct or a knowing violation of criminal law unless a court in such Proceeding made a specific determination that Indemnitee engaged in willful misconduct or a knowing violation of criminal law.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Actions of Others.</font></u><font size="2" style="font-size:10.0pt;"> The knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Remedies of Indemnitee</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to Section&nbsp;11(e), in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;9 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to Section&nbsp;7 of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have been made pursuant to Section&nbsp;9(a)&nbsp;of this Agreement within 90 days after receipt by the Company of the request for indemnification, (iv)&nbsp;payment of indemnification is not made pursuant to Section&nbsp;4 or 5 or the last sentence of Section&nbsp;9(a)&nbsp;of this Agreement within ten (10)&nbsp;days after receipt by the Company of a written request therefor, or (v)&nbsp;payment of indemnification pursuant to Section&nbsp;3 of this Agreement is not made within ten (10)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification,&nbsp;Indemnitee shall be entitled to an adjudication by a court of Indemnitee&#146;s entitlement to such indemnification or advancement of Expenses. Alternatively,&nbsp;Indemnitee, at Indemnitee&#146;s option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules&nbsp;of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within one hundred eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section&nbsp;11(a); <u>provided, however,</u> that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce Indemnitee&#146;s rights under Section&nbsp;4 of this Agreement.&#160; The Company shall not oppose Indemnitee&#146;s right to seek any such adjudication or award in arbitration.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event that a determination shall have been made pursuant to Section&nbsp;9(a)&nbsp;of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;11 shall be conducted in all respects as a <u>de novo</u> trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.&#160; In any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;11 the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If a determination shall have been made pursuant to Section&nbsp;9(a)&nbsp;of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="2123-2-OQ-01_PB_9_140510_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=408394,FOLIO='9',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">determination in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;11, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#146;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;11 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.&#160; The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10)&nbsp;days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Non-exclusivity; Survival of Rights; Insurance; Subrogation</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company&#146;s Articles of Incorporation, the Company&#146;s Bylaws, any agreement, a vote of shareholders, a resolution of directors, any liability policy or otherwise.&#160; No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in Indemnitee&#146;s Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Virginia law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company&#146;s Articles of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change.&#160; No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.&#160; The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees or agents of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves at the request of the Company,&nbsp;Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="2123-2-OQ-01_PB_10_140539_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=161577,FOLIO='10',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-01_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:17 2015' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">available for any such director, officer, employee or agent under such policy or policies.&#160; If, at the time of the receipt of a notice of a claim eligible for indemnification pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies.&#160; The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company&#146;s obligation to indemnify or advance Expenses hereunder to Indemnitee with respect to service at the request of the Company as a director, officer, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise with respect to such service.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">[The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided by [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] and certain of its affiliates (collectively, the &#147;Fund Indemnitors&#148;).&#160; The Company hereby agrees (i)&nbsp;that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii)&nbsp;that it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the Articles of Incorporation or Bylaws of the Company (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and (iii)&nbsp;that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof.&#160; The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company.&#160; The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section&nbsp;12(f).]</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="2123-2-OQ-03_PB_11_140949_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=1013928,FOLIO='11',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:36 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Duration of Agreement</font></u><font size="2" style="font-size:10.0pt;">.&#160; This Agreement shall continue until and terminate upon the date that is ten (10)&nbsp;years after the later of the date that Indemnitee shall have ceased to serve as a director of the Company and, if applicable, the date that Indemnitee shall have ceased to serve as an officer of the Company.&#160; This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and Indemnitee&#146;s heirs, estate, personal representatives, executors and administrators.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Severability</font></u><font size="2" style="font-size:10.0pt;">.&#160; If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section&nbsp;of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b)&nbsp;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section&nbsp;of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Enforcement</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to continue to serve as a director and/or officer of the Company and/or to confirm to Indemnitee that after Indemnitee ceases to be a director and/or officer Indemnitee will continue to be entitled to indemnification and advancement of expenses by the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in continuing to serve as a director and/or officer of the Company and has provided other good and valuable consideration in connection with this Agreement, the sufficiency and receipt of which are hereby acknowledged.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; <u>provided</u>, <u>however</u>, that this Agreement is a supplement to and in furtherance of, the Articles of Incorporation of the Company, the Bylaws of the Company and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Modification and Waiver</font></u><font size="2" style="font-size:10.0pt;">.&#160; No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;17.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Notice by Indemnitee</font></u><font size="2" style="font-size:10.0pt;">.&#160; Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter that may be subject to</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="2123-2-OQ-03_PB_12_141039_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=95696,FOLIO='12',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:36 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation that it may have to the Indemnitee under this Agreement or otherwise; <u>provided</u>, <u>however</u>, that a delay in giving such notice shall not deprive Indemnitee of any right to be indemnified under this Agreement unless, and then only to the extent that, such delay is materially prejudicial to the defense of such claim.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;18.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Notices</font></u><font size="2" style="font-size:10.0pt;">.&#160; All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a)&nbsp;delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b)&nbsp;mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c)&nbsp;mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d)&nbsp;sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if to Indemnitee, at the address indicated on the signature page&nbsp;of this Agreement, or such other address as Indemnitee shall provide to the Company; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if to the Company to the Secretary, at 780 Dedham Street, Suite&nbsp;800, Canton, MA 02021.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or to any other address as may have been furnished to Indemnitee by the Company or vice versa.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;19.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Contribution</font></u><font size="2" style="font-size:10.0pt;">. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i)&nbsp;the relative benefits received by the Company and Indemnitee as a result of the event(s)&nbsp;and/or transaction(s)&nbsp;giving cause to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s)&nbsp;and/or transaction(s).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;20.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Applicable Law and Consent to Jurisdiction</font></u><font size="2" style="font-size:10.0pt;">. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the Commonwealth of Virginia, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section&nbsp;11(a)&nbsp;of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Circuit Court for Henrico County, Commonwealth of Virginia (the &#147;Virginia Court&#148;), and not in any other state or federal court in the United States of America or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Virginia Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Virginia Court, and (iv)&nbsp;waive, and agree not to plead or to make, any claim that any such action or</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="2123-2-OQ-03_PB_13_141108_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=210796,FOLIO='13',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:36 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">proceeding brought in the Virginia Court has been brought in an improper or inconvenient forum.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;21.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Identical Counterparts</font></u><font size="2" style="font-size:10.0pt;">.&#160; This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;22.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Miscellaneous</font></u><font size="2" style="font-size:10.0pt;">.&#160; The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[<i>Signature Page&nbsp;Follows</i>]</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="2123-2-OQ-03_PB_14_141130_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=1038943,FOLIO='14',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:36 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">INDEMNITEE</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="11",CHK=1026156,FOLIO='',FILE="DISK125:[15ZAD2.15ZAD72302]2123-2-OQ-03_ZAD72302.CHC",USER="KBLACK",CD='Apr 24 17:36 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>a2224429zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> Exhibit&nbsp;23.1  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have issued our report dated April&nbsp;27, 2015, with respect to the financial statements of Collegium Pharmaceutical,&nbsp;Inc. contained in the Registration Statement and Prospectus. We
consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the caption "Experts." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>/s/
GRANT THORNTON&nbsp;LLP </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Boston,
Massachusetts<BR>
April&nbsp;27, 2015 </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2224429",CP="COLLEGIUM PHARMACEUTICAL",DN="12",CHK=698134,FOLIO='blank',FILE='DISK114:[15ZAD1.15ZAD72301]KA72301A.;5',USER='VRIVERA',CD='24-APR-2015;06:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g603081.jpg
<DESCRIPTION>G603081.JPG
<TEXT>
begin 644 g603081.jpg
M_]C_X``02D9)1@`!`0$!`P$#``#__@!%35),3%]'4D%02$E#4SI;0T],3$5'
M255-7U!(05)-04-%551)0T%,74-/3$Q%1TE535]02$%27U!-4U],3T=/+D50
M4__;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_``!$(`$`!,P,!(@`"$0$#$0'_Q``?```!!`(#`0$````````````(
M!@<)"@`%`00+`P+_Q`!@$``!!`(!`04%``<1"P03```#`0($!08'"!$`"1(3
M%`H5%B$Q%R(D05&!L1@9(R<R-C<X87)U=GB1LK6W)28S.496<7>6MM5"55=S
M&C0U.D1%25ACB968H;C!R-/7\/_$`!T!```'`0$!```````````````!`@,%
M!@<(!`G_Q`!!$0`"`0,#`@,$!P4%"`,````!`@,$!1$&$B$`,0<3010B46$5
M(S)Q@9&A,U*QP?`6)&)RT1<T0D-4@I324Y+Q_]H`#`,!``(1`Q$`/P"_E)DQ
MX<<TJ4<4:-'$0\B0<C`@`$+'$*8Q2.:,0A#8XA2D<T8QM<1[FL:YR5S^8_M(
MG%/0][:X-QZQ:UY3Y;5/DPY^2T5Z##=/P;*.5\<D2+G$RLN+3,%CE8Y[YN'X
MY88Y)9X4AY,=7.\`'^T:]Y;DGQ5([OW3612J6CJZFKN>2]W43'Q9E],OH`+G
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M#T'X7V)E6'P_=_OR;86?W3`H8TJ3ZF8;[K,?R58'RQM:RN[F/NP*JOAUX.&F
MHI`8,8<81[2-D=Q9&8%O1"SK6TR&78V$I_ZHTR;)/),Y5<0CEZ=.Q1<@-$\/
M8DGC?J71<K#L"U=:VU52T&)3:J#CT0EK/-DMH:MB3I)Y863K:ZFSC-.5SEDR
M#/3PM<UJ0.J;OHFY4$-/IC3E5::V.L262IGD#>92+#.CPG-94>\TLD#YV\",
M^_C[5FT98O$*SW2>KUCJRCO=!+02014=-$Z>57--2.DX/L=.I1(8JB+N"?-!
MV8R5DU[9VCD_/%L0_P"C++?_`&QC_P#^3MNZ?O#-92C,'=X9G%*)[_"LD+*.
MX$)J^!&D(*-9QY;D15>KV`CF>C6HK&O<[PMH/EO^Z?TZTWSXC_QC\B/XCY_U
M@]2`=N%^GXV_E3LBL#V-A6S*5M_@^0P+^M\:!,^(]S9,*0K4>L2R@G8*;72V
MM7Q+&FQPE5G0C&O&J/5:K]/QM_*G9!!'!&#\#TX"",@@@]B.0?QZ9+CC^PGK
M_P#@F3_6]EV'GO#.\"U%W=^CC;7V0,V1Y+>S#8_J[6%1/APLDV)E3`-D%BQ"
MR_,;5X]1QB"L<NR<L65&H:X@&LBS[>QIZJP(7CDO32>`*OWJB2O\UM9=J5G>
MVS\KY[]]9@O#]+NTKL/Q++=2\>J)&EBC'0`RZ%1Y[MS,JV,Y2QO>I(5T=6FD
M(65,9B%'&()6@#$2YZ'T_2ZAOCQ7&1HK5;:.INUT9"5=J*C*;XT88*F622-7
M92'6+S&0AU4B@>(FJ*S2^G(YK5$LUZNU;1V2S(ZAXUKZ[<$F=#PPABCED16!
M1I1$D@*,0>K4;&[[+OLYN5FUS<2]=\=CSY%!:0\?MOL.\?JUOJ1ND8[,R-T>
MRS_;-S!8\3[L`"Y4^(]$2978\R3'@*H1^S3=X7K8<+.-:;YX_)GM$C)E6#%\
MSVCAEW$E>2YA64N6'P($<,A$<Z.,IEK0G$]RD*!BN8MVK5.KL"TKKG"]4ZPQ
MNLQ'`,`QZNQG%,>J8[(T.MJ*X+1!;T8UKCS)3_,G6D\ZOF6EI)F64\QYLLYG
MN#VGY/%*YT4DE-INV6>RV8,4BH%M\,S5$(&T-7R.29YI$_:LNW[17<YR[5>'
MP7LUQBBK-6W:^:@O[HKS7)[E+"E-.2)"MMB5?[O!#)Q"'+\`,$C&(TJV=USM
MOO?M3\UZ#B3SZ3/+S661:]V1?8]E6PJ&@S(,VWPR!42*],*WKB0_2W[##D/?
M8TF0V]Q<LCN85\"L,YY'I?O6N_@SK!MIVG$3N_`0\AV957R83FNX8N/"SV4#
M.S2%K7Z[TSB30V4'),MK+5[*JVR*SK+R$"^'*QRAQVQL(DBWBSP=X_O6ZXS\
M&>4&[<7,>'EF%:FR)<1L(SE:>JS#)/2X?BMR/HPC?,I[_(*ZS1SV.8GH_P!$
M5!^)4K4>S%\2<4S7(=V\SL\KQY+DN`Y%&U-JR7<!=.)2Y);4<?*-CYL(\MI$
M7)9E7>4%!#M1$=.AQ;/*6J0;[9SWR%JDLMRI;OX@WNPVY*>T1TENIK);XQ3V
MZYWN5BWM$\&&"1B.:`S1,9D<"25_,*B)HV]1:@M%78?"[3VI+I)57R6MNE7J
M&Y2^T72SZ>A"CV6FJ`5,DK205*0RJL#*3'#&8@S2J/<+N->]OYN%B;=Y3[;Q
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MW34*761Z]JEE`,LX"QI*C,H+QIY+,N565#AA"CW17?!8=WA^.6&NMA5=)KGE
M#A%0.VR#$ZJ25,5V)C0WCC'SK7#+"3*L@`@231@95B4Z78SL:).KYD:TN*:<
MV9%`'VHO/<YP;!^'!<*S+*<0+8YANT=@3&;ZTHGSAQL7P)T8<QU9*C+)9'<<
MSPM,KT$\KWC1KG*JQ4\QL"B]U#WV&`YKI>'(QO7DK.]:;KQ?&*IKHD2)KO:]
MW/Q':FN*T3/31TQYQ!9W2U%<,GIZ^HF4\%'B6O"HI*?:L^OP'PKZ_>S3>J??
M7Y)B^OD3YK\^JHB*O[O:SV^P6FB\0-%72SQ$6+4U+4W&EHYP)/9)1;ZGVFC(
M8ON2%I(F4,6*,S1J2L:,U.NVIKU<?"_Q!LU^D!U%I"LH[56UU.3&*V+Z4HC1
MUP*!-LDZ1RABJIN5%D8!Y'`L3\`K&PM^#7#JUM9TNSL[+C!HJ=86,^067.G3
M96M,;/*F3)1WO-)E23/>4YS/>4I7N>]SG.55+=WT3]\S^DG8/.[R_:%\+OY*
MV@O[+\9[&&[Z)^^9_3;VQ:Z@"Z7(```5]8``,``5$@``'``'8==!6,EK)9R2
M23:[>22<DDTD)))/))/))[]4C>Z?V=LC(._.W?B][L#-+G&8F3\V!QL>M<GN
M9])''7;`GBKV!JY4PL(;(`V-'":P*)%8U&`0;?EVNZ=J*?=$?X^O>_\`&KG+
M_:'8]KUG:^>*44<5\M:Q1I&ITW:&*QJJ`LR2[F(4`%F]6QD^IZS;P7DDETS=
MFD=Y&&K;ZH9V9R%5Z<!06)(`'`'8>G0Z<P)LRNXF\G["OE2(,^#QXW9,A38A
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MPN/T9&IAIC-3[ZIGCCCW5,<*#<??+",9+`%SF]P#WMZ*BKR_U3T145?T\]]_
M1%_U;]K6?'>DG<0N%.J:+DAL'&QS]!:,Q^'M_94F_L9F+M-A..M^*,G)D.00
MZZUEUOW*>4V;90(UA);X4?$]21H7"\[OP^ZL:USW<PL'1K&N>Y?A3:B]&L:K
MG+T3`%5>C45>B(JK]$15[1O>TC\JB1N#^@,'UCD!S89RVR^%E$W(:UTF)%R?
M4^'8M5YY!KRBDMBS6U^1W628+<DBR(@R%BU+XLU@O,)&+'U#ZMUI=+#8+[;A
M:H:NX?53_0IM;;5B+5;HSQ1B=H:4/(L62-VW.`<]2E'!H7P]L^I=3Z8NGTU/
M16L>?3C4"7=-SS(E&CK'-(:=9ZMHHVEX.POM#$8Z`7D;WRG/OO%MYOXY=V3C
M&=Z_P^1*F,I9^&5]9'W-FE)".P!\SS7,[EQ:+3.%(1T>0(,6?32Z]LF-&O\`
M,)5C-90QV\)[-5WBFQ(5EGVPMS<?/LAY`9;*UK<KSW9.4W]A,.T:'??9A#P"
M?`-8^%/+>\1+2._RV,;.<-6O;8+[AWAWB/&K@GK/8CZ2(FV>2V/U&X=@9(0(
MWV9J/(1EL-;XH*4OB,.EQS#Y=?,9!:]`NR&YOK)[7'EHYDUZKT3JO7\2*J_S
M(BJOXD[>RY:^_LO7U%GT/;K;;:"WRM1R5\M(E5<;K+3OLFGJ:B7EHI)48Q)@
MMMPZM&&6*+Q6GPQ_MG;:2_>(MTNMUN=SB2OAML%8U);+-#5Q+)!3TE-&N%FC
MB9?.8$)YFY-LA5IIJ)\G"O:`NZBI`W=+89?L_2N.1R2YM1CDJ)R8U+`@0VJ4
M\:VQ>561]F8/5^%C'2+:EA8Q""+[=;@:C(UIO>TO[2V%1Z?X*W^+Y;DF$V&4
MV6U+"Z;B5Y<8^R24^"ZYG)'.D.:(YH\.1-D^E%+(9X/&Y?%YJO>ML]7,7ZM?
MU^B*@R(J=?KT<C45.OW^BIVJ2>U:?K#X5_QSWG^Y_DKKW[R_/LYI;48U1K?2
MK5EFM%)615%R]KJZ"D6G%R66W3&,U<!WH\L+1NRRECGS2`J;02UK/21T=X<Z
MS2@OU[KK?-2V<45#<JQJGZ*>"ZTHD-%4#8Z1SK)&&B"#;Y2DNY8GJ6[XBO\`
M\XU^*??=M\3?G8/OSXA]X2O??OO\S3ZWWO[T\WUOO/UGW7Z[SO4^I_1_,\S[
M;M%[[+IGN<YS@_,<N:YEE.7EKLPTD.O)D]]:7KX(Y.+YZZ2R&ZSE271F2'`"
M\[0JQI7B8]Z.<U%[24_^07_]5;_]L':*KV4O]8G-3^.>B_\`=787;RQQ1?V'
M\1'\J/?'J2@6-]B[T4W*(%4;&Y5(X(4@$<$=>J267_:/X4IYLFR31]Q>1-[;
M7<6J4AG7.&8'G<P)SSGJV_V@N]HARG)L/[N/(;G$LBO,8N&;ETQ'9:X_:SJ>
MQ;'D9'+:<#9E>>/(0)VM1IA>9Y96HC2-<GR[3H]H$/:1/\6AD?\`KKTG_O)-
M[4[1*J^K=.HZJZM=Z`,K`,I!J(P000001W!'6A>(+,FB-5,C%6%CN!#*2&!\
MAN01R#\QT`>J-A9[)]F,VSF\C-LL-F8';%0&6ER&V?DH4%REJX`O*O'2ULA^
M5!<Z&/P26^7%<H&>$2^'M'[W*_?`9-Q=W&_2_)K/K[(^.^X+V,-<LRRWEW$K
M36P)J1ZVNRU]A8%/+'@5^T,.JS>(\RQZ-0P,OB,$&#D`YQI:B_[UDV]^_P!D
M_P#S8578/."'=?T_>$=U%MB_P2%4UG)_47)O9,S55]*0$,6:TS]8ZHGVNH,G
ML2>$24^025)*Q:=.\0,9RXS)CC1J>WR)LC:J>/3JVS7<%_IT2W5GB!<+::N.
M.-9;:T_D"FJXGVYCCII@CN%]T1ERR2)OC?G>IDU0;SX:5&F*AWNM#X86VZ+0
MRN[179*83-54,J[U#O50&14+'<90@5T?;(M]>/)CRXX9<8PCQI`1G!("1A0F
M`5C2",(PW.$41!N:091O<,@W->QSF.1RU6^_[[VLNJ:FYX.\;<L6-L[(ZT8=
M_9[12D;+UQC%H$1X^MJ.>)W6)G>70"CD9),"K9>)XI+!%C/!?Y""13QF<9._
M>Y`<0N&FT^).=8G?7'(#5_77/'O,<PC#\_5U<*3.I,CQO:59<%993;/31(K_
M`(`@'CS63%6'BV1>GH\:`Z=O>+W=B9&/N\>;'>1\JX-G>;%SOC7NG*-!T^;+
M(L+\/Q/CUC+MN065K8.66;+LP]5+7`B3VN-!I)\S,T$DV\QR35UJR:&IM)W1
MKMJTPU%'37.FHM/TD;(ZWZMJ7B--5A"7'L4$<J3S*^X"1'1O,$)CFN&HO$>J
MUM95L>B!/2W"KM%7<-45DJ21MIJ@I(Y1641D`3-?4RQ/30NA!,;QLFQIP]/`
M=^:"WS_TU;6_%G^4HG\R6G1/]"=L[-&Y$1SD1.B(Y41$^B)U^G;.W3'T?0?]
M#1_^-#_Z?(?EUQW](W#_`*ZL_P#)G_\`?J0/3997>!]YGK>9MEBF;R?Y58Y9
M[!A,?%<SW!D&4`L[ZB`YZ0(RQ1XQ7%H`#$(/6&Q@HD1QE!%?Z@4.+&A18T2%
M'!$AQ0"CQ(L8(X\:-&"-HH\:.`36""``6,"$0V-8,3&L:UK6HB>9!R)P:\[L
M;O/;R'C=5(+'XW<@L/VAK:'/"QK<BU^"RI<_P\0WG:4!A6V,RWX^24UY6!L`
MS&J5),,BL])?2FY->\@M4X%NC5>01,GU_L?'(&3XS<1"#<A84YGZ+"F"&0BP
MK>GF,DT][5G5LRIN8,ZMFB#*BE&WFGQB4U$.D+A0*PL$MHV6\*#Y4+.L,JH<
M95'>D]G"@DEA`X!/EMCL#P$84L^N+5<W4ZG@O?F74R,IGG2,RPM*#PSI'6>T
M>80-JO.A.TRJ&=!WT7_0OY.T`G(@#)7([9<8GB0<G/@1B>%>CO+DBIP$\*]%
MZ.\!'>%>B]'=%5%Z=%G[=]%_T+^3M`5O_P#;+;#_`-8T'\M)VQ:#[9_RG^(Z
MZ#J>R?Y_Y=2,_F!-&KU^[,_^J_Y3Q?O*J?\`,B_E[)K*N[XUO+JCMP[*,MHK
MMC".BGN94._JS$1JJ,4V(R!72V!<]$1Q8<P9F(Y7>6?PH)T@*?3\;ORKVY[(
M\Q_WCTZ88CQL7\!C]1SU`%BN1[!XL[A,DX)X5GCTX-?EM((SR5^28Z51R",&
MOZ&.9'EP")98_/>-I(LM8YO`%Z3(JSUU-I"O*FLNJTR2*ZW@0;2`=.B(>%8`
M%+BF3HJIT(`PW_)51%7HB]H>^?DJF-NJJ%`4*V,+!*D-^X:IU;():7$JO'(1
M'+T,.L,,OVR([TTB,OZA6+VDOX\`G1M%ZG#8HK9;<#QI7-5CV.:$D`1(C7->
MY[O&V(\"/55Z.<BN:UC7(QKDO*HQ&&(Y^?'']?`],P91Y(\Y53D']/\`]^8Z
MZ_'-/%I+`6_AJ)2?SVUDG:D;W@TLW!'O\ZGD+F=3('KZQV_I[D."8D:5X;+`
M,BI*K#MB6%?XU*Z3.HK*LS?J(+GL;.KXPV@&(P0+=SXX_L)Z_P#X)D_UO9=@
M%[VONP\7[QO3%?&I9U9AW(/5S;:ST_G<\+TK9/O$(GV^O<S+&$68[#<I-"@%
M]?&%)GXK>1(5_`C3(Z7%1<7+0-^H;)>YTNI9;3>*"KLUQD7<33P5FS%2`H+$
M1O&HD*@LL3R,JLRJIH7B7INXZATY3267:U[L-RH;]:XF("U510[MU*Q)"_71
MR,8PQ"F9(U9E4EA*I27%3D--57U#90KBCNJV#;4UO6R@S:^UJ;***;6V4"9'
M>^/+A3X1P2XDD#WB.`PRC<YKD7MM.U!S1O>%]Y]W+R)QXY":1LLKT]CLPD+%
M\4VN*ZBTE''>;S7`TUO?&A6^/3,6E="&B8\]V4TU>0S_`';68V<LV(0S\B]J
MY\ZA:+#^&<,&5F`]B$R/?\6=C\66Y6H%PXU)KB+<V8?U7B"I:HSG>!K"M155
M)*J\*]4&?-FCH[Y;96)I+G17"@6":$^\CR+-4QM&X7'F*OF('RJ22<$Q-%XT
M:.%+MOTEPT[=J=`M=:+A:[BU1!.N%D2-Z>EECDCWY$;.8G9/>>./#`6#^]5T
M]D.^>[QY9ZQQ*(2RR>VU);WN/U<</J)=M;X%/K-@0:F#'097FG6IL62M@L&S
MSGRY06!<PKF/;`M[+=R3Q-F*\AN*=O<Q:_+"Y?7[VP2JEF"$V14-KCE/A^;M
MJV.<TDB5CDO'<8GV$9B$*.!>LEHU(\64\6S[N+EIWK_>"<[M)[DVEAN;8+PX
MPC[(-K?U.&8M<:QT<=UKKC+:7&'R;#*[!N0;DMA9+8TWI1-M,IB4TA&70:FF
M&!\MK+=Y5W.');BUO^7SC[M:-E,BFC9'.V-*P36"^'9NE<HE^<?(9>"4*/.7
M/-<WQ9EBXV'U4&RL::OLK'&Y6-7N'.8^%/VVV4=OMUU\.K_=[72UEW2EO-!6
MPU(GH[=>(Y&A^C:^=<+'-+%2TY;@!4F=49Y&@$E7N]XK[I=+)XKZ9L=WK*"Q
MR5MAN=OJ*1J>ON=BEBBG^EK;3D,\L$$]95`>]N9X%9U6)*@1W1.W#G(U%5?H
MG\ZJJ]$1$^JJJJB(B?-55$3JJ]J6NH_:A=SZZJPX;RDXKT>7YM1C%7VN0XKF
M,W35W+D18ZB)(OM>Y=B^11:ZVEG:PTUM;85-<-[C>CIH@_*CL:?>_?M\^^?D
M65H+A9H6ZU>[,AMI[0^H39'M_<\N#.8Z'+APLSKL?HZ+7E;,:=4FW\2FB6U=
M'1Q`994#0TCM7X_"C5_M!2IIZ*CHD(:6ZS7*B-#'!GF?*3-4,FWW@/(5L8W!
M`0>K3+XV:&]D$M)4W&ON#@I#9:>U5XN,E0`/[M]93K2K(&(5B*AE!#[2Y4CI
MK^],S2'W@_?2X'IO4<@.55F-Y5ISC%`MZUD>RK9<['<RL<DVK;#>%CA2J;%)
MV0Y5$LI12&A^3B=G(\UL)>O:1'VK%$;@/"IK41K4S/>B,:U$1J,3%M?(Q&HB
M(B(C>B(B)T1/E][L5O<G]S/;\+)!^3')9E9*Y*7U'+H\1PRKL`755I;&[H2#
MR!LN\A'/6Y!L/)0>&NM[&I+*I\?I6R:>GM+8MS<SR"G[5L\;,%X4H0@Q^/-=
MYHBD(QG7^];7B*J>-S>O3KU7I^YUZ=>UTMUWME5K_0MBLLXJ[7IBEJZ".O'"
MUU5);J@UE3'@D&)FAC"NIV.XD:,M$8W;/;I8;Q1^&'B1J74%,:*\ZQK:&Z2V
MTY+V^CCNE&M!22Y`99D6:8NC#>BF-9<3"118<[O+]H7PN_DK:"_LOQGL8;OH
MG[YG]-O:D?QZ]IG#H?0NEM)-X@1LG34.JL!UG\2+R!CT_P`0+@^,5N-^^DJ?
ML5V*UB6:5R3/=ZV$]8GF^1ZR0C$(IB\=?:8Q[^Y`Z-T6G$"/C"[EV_KC5GQ(
MW?X+IV/_`![EM5C/OI*=NJZY;5:SWEZQ*Y+""LU1>G29'4B%;2[OX:ZT%5<Z
MXV;%**BMJS+](6OBG$DLQDV"M\S]G[VW;O\`3;NXZT&P^+GA\:&S6T7X^V^R
M6ZB\GZ*O(_O7DP0>5YAM_E?M3LW[_+X)W;>>@`[HC_'U[W_C5SE_M#L>UZSM
MYL>I>;<;N_N]4Y)<B'8`':ON?<'+3#?A!,S!A+C/R_9F1PV6+KM]#DWE)6O@
MM*^'[J>Z6CU$DF*YJ%[3%_\`97X__,CC?^\E'_\`T_VM^N]$:GU#<;77V>V>
MUTBZ?M4!E]LH(/K8XW9TV5-5#)[H=3NV;3G`)(.*+X:^(VCM*V>[6N^W<T-<
M=3WNI\CZ/N=3]3+-$L;^9244\/O&-_=\S<`I)`!&;/O,S]J#RI_DW[S_`++<
MK[4C^X>[N#C3W@0N2R<AJ_-YRZJCZ9^$O@[-[+#O*^,P[!6[]X>[A%]X>/X:
MK/2J;IZ;PG1B*IW*VPGQT[SEO>9<!N\%S;[#PM.MU;J3:V(>@9L(>?MN4NM$
M93D*V+YC<4Q1M9Z;Q+%],H9B%:GJ/4#^8FU6.Z?[V('=CAW6Y-*Q]SKN>-K+
MI^F:#`/ASX!#EWUZXAEOO7WJF6_1/=ZPO0_62DGH)&C[-JB@TWKNS6V.:EU+
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MV!C>)SLVU=GF*1YAY-12[PU[7$?;83D=6AGB9>,?6`@RYDUV%YTZ)93Z]#7Q
M3VK>7&QWR,\X;U4[,``:U\K$M\CI\;FS/&_S'/K<@U_:75.!&>!&A2?=G:3S
M&O*K$:Y7+AH6[5-X&IM#RT-^ML]P2Z4;15-&LM%.TZU0IJVEK)(EQ#,=AC;<
MQC7%1'&P=0S:O$BRTMA;2/B)#<=-7>FMKV>O62CKWAKZ=*<TAK*"KH(9W!GA
M`<2*$42L#3R.K1GJ)KO'^&?-CNUQ:J3:_+&ZSO[,4?8'N+['6V-WM6K^!`XT
MMBMM\3S*CYR_BJ$L#T2'^<:4LCRD\GS)&>_UF2[#@AW1<^?+E3YTW5)Y<V=.
MDGF39DN3HK2QY,J7+DD+)E2I!B/-(DR"D.<KWE*1Y'N<H`\Y^;'*;OL<VU;C
MVM.)ULX6JOCJ-AV-ZBAYIM&Z.[8*8ZV>7-,L2GK,<@@B-Q6!Z>2ZNH*^&TL\
MTV:4+1K'D2]H7QJ\P/A=W4N%Y?`=0Y1B.`76+Y'3S)$1TBJO\>TMIVIN:PQ8
MLB1$,:OL8<F*8D23(C.>)7!.43F$=H<;5ZWCPTAOHH(M0BNO\ERIZ0T:O&C4
M54*4O'1DHJ^SB(;AE"X;WBV>LJF6WR6+Q<GTX;I/I9K=IJ*T5-?[>ZRR)7VW
MVP1R5P$A;VKSSM($@3;E0``)Y<<HY.2]QI4X_"54F7/=>`KHB-`62YTF3QA5
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M+2RO(P*;6CCC9\3`K?4[5]O:5L@J:GNXTIYTL0K'+-^ZBJJ.*I!(:9+JR9%D
MT_P"<1I7BC5--,.9XF%\I?)0B,83QMCQJ_:N7#Q1H[OAI7GSD84$0U7O^/$Q
M$\E&-1\E(\[7,K(80O-\;D@.?.(QB-$M@]RN*@&Y(;O(_:"=\8*61@I-?Z(P
M^<2)7W=92Y#6Z)U#46AH[,ER=^2WZI(V;LZ?6@$$$.L/(L+%T2)70JG%,>?:
MS&JTQH"^6&]T=\U*M+8[19JE:ZHJZFNHY/.-,?-C@IXZ>:9Y'FD"*,A<KN$>
M^4+&QZP\3=/:DT]7Z<TB:S4-]O\`2FWTM%2VZOB$`JR(I9ZJ6JIX$CC@C9F8
MJ7VML,FR(F02$:XHI]+[*]L,\YB#;?TV>9#!:K#,>M=8<MHHHI'H80T7S?1D
M*QX5*`@7B>(ST<O0N?9?D1>"&W$5.J+RNSA%1?HJ?8PU'\E[$IWI^G,)X[]R
M5O?2.OHGNW"-5Z3UKA./"D/9ZA]?0[%UW#2=8&1&,-9VDAIK.TD]$659391N
MG4G3L-/LOCV/X(;<5CV$3\U?G"*HWM>B*FL-1=456JJ(O147I^!47[_8JZX)
M==`ZQN4:E$N&OWK8T;`98ZE*>6-6`)]Y4=5;!(R#STBVVN2R^)V@+3*PDDMG
MADM!-(N=CS4KU$$C+GG:SQL5S@X(XZ+/D]W)?%KE%S.UURYRUIJJ/5D9/W5J
M>NJ(KL8WS>T`@?!-ODD[U0"TY(SP!@YX&/!GIL*AKZFKE%J3BLK&T)+O3(X(
MG=K\UHL4(H\:/QCVH```#8((0AQ24,00B&UHQ"$-K1C$-K1C&UK&-:QK6I(+
MV`#O551.[>YNJYS6HG&?;*JYRHUJ)\+S/FJKT1$_=543M0Z"[7*XW/3--75L
M]33VRLH*6@BE?*4U.:V)S&@P,\D+N<LXB2*$,(H8D33+G8[3:K-J^KMU!3TE
M3>*&XUERFA3:]74BWRQB20Y/H"VQ`J>;)--M\V>9W\O!_P"K=^^=^5>V=OD\
M\?QN^Z8WZIW_`(0'\*_^D[9V[JR/B/S'7S8V/^ZW_P!3_IUZ%G?9=TP?GO@M
M+M[28*V%RBU53GJ:>!82XU55;:P-9)[,N`6EI)\N-5Y#56)Y-E@=Y/.*KCRI
MUO0W+X]=>#MJ2I7P[[R#F[W5N=93K&K@3A8]"OI#MB<:=W4M]"JJ[(6(2-,L
MH$`A*_)M>9(9'(23:8^5E5D+@PY5U5Y&*/",/TN^PK<D>$/$_EW"B1.1FB<!
MVA)KHKX53D%U5OA9E2PWO>5T2CSBC/59?3Q%,1QUB0+H,1QE\QT=SE55X^TK
MX@06ZUMIO4UK6_:>9B8HFV&IHLL7(A\PJLB*Y+Q`2P2P.S&.<+M1>\]:>%U1
M=;RFK='WE]-:I4*L\R^8*.X!55`:CR0TD4C(JI,?*J(:A%598-VZ1JWE9[5E
MC"UT%+GA3DZ6RQ0I9>ZMYT9*SUG@1#K`=/UP*:Z*K^K@I*&P[6*C"=7-5SI!
M^/=);<_--U7/+'EK]:8_M*QS#,@ZXO"R,DNZ5F`Y3;XQ,KRY%6BK*Z<ZQ/AQ
MY<22RMC(`,X(CA(4!%?V;CV<WNQI[AEA:_VK0H$)&N%5;OSP@Y#U<KVE-[ZE
MW!4>-/T-B`*$2L^;QO)]OVKQ[<[P;ECW>7(W97=X<8=D5V,<8--[FL=;8-B^
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M?*;Z3')]JB((\8$R*`X45/%Y9&.1RJJ$5[.C$Q_=#^XWZ_S;K=MM2>[J/G@?
M+_#^/Y_+J,_3NI\WY-;+EV=V>PF4Y[=+78F8R45C$$5Z$/5PS-&V.ZXL`L2!
M7U\1B#J87AE/""%#"(L[<2'&KX<6!#"R-$A`CQ(L<2*@P1HPV``$:*JJC!"&
MP;45?U+4[=*BH*3&*N)28[4UU)401H*'6U4,$&%'9]504:,P8FJ]W5Q'^%7D
M>JO(Y[U5R[9?I^-OY4[(=]Y[8`X`_KX_Z=.11",')W,QRS?R^[Y]R>?D&2XX
M_L)Z_P#X)D_UO9=M=OW?M5H2JQVUM<=M,B'D5I+JPAJY<&(^,^)!=.<8SISF
MM>Q[6^6UH^KD<O5?EVV/'']A/7_\$R?ZWLNPG]XW^LS6_P#&B]_W<-V"@&3!
MY!8Y_7HG8I!N'<*F/Q*C^?76E=X%J^["6NR+5N0S*PZ)YT25)Q*WCF,PC7B:
M6OG2A1GJA$\:$=XB,>UJM:J_-KTZ03BAM9K[W76K=:U60X^4$B972-9X52Y3
M1D.KV1YK'0ZIZN`9[2L#95DTX%(UX7E$='"[/)K[&L;L]5X&"TH*2PCR,$Q-
M9(9]3`E@.CL<K_&IV28Y!D1R.=XU)U14<[Q+T5>T;6BF4M'S;LZK6SVNPMUC
MG58)D`JGKTHQ4A)<@$<S"O86J@Y%%CBKBJ0K$&"&UBN1PU5Y)'595B>6(8.X
M)(P5P,@[@"`21D8^&?3(Z8DB1GB:>.&<DA59XD+H2005)!Q@XS@C]>CTU+R$
MIMJYWGV"5V,VM-)U^:5'DSYTR!(BS_2WLVB<L,,5SC`8XD%QVM*C4:)[&*B.
M;T0BU1%^O_\`?N_Z?W>T4'&W.<2UWN7DMD^:7L''Z6+8V@GRYKW>(T@NPL@\
MJ)#C":25.FF\+O*B0P'D/1KWH/P,>YIN:]Y1:6V9=CQO&LL\-W)>1E?7W%;8
MTA;91HKG)5DL0"CS3*Q'/;#&9)[AL>](JM8]6M,A!)53M`'."0/=!//YGI^*
M0%0&8;B6`'`)`)`P.G'RC5NM<WD!EYGK[",ME1VJP$G)\2Q[(9(6JU&JT4BX
MK9IAHK41JHQZ)X41O3HB)VW.-X?BF&P$JL1QJ@Q>L1?$E=CE-644#K]LO7T5
M3%AQE7JYR]5$OS<Y?JJ]=)L+9^"ZLJ!7>=9%#H84DKH\%AD-)G64EC/,='K:
MV&*1/GF8Q4>5L:.]H6.0AWB&J.[-?AW+#1><7L+&Z;,O(MK(HXU<"ZI[BB#/
MEE>T88469:0H\,DT[W-9'BJ=AI#W(,#2$5&*9>9HPA>5HE.0FYB@/R7.T8^[
MCGX]$(J9)3((X%F;NX5!(<X&"V`QS@<$\XXZ([MIKC',?R%H&7U'3W38KB/C
M-MJN!9-CN*UK2N`V='.@7$:QC2.&C5>UC4<JHU$1&;!W!KO5AJ$&=9`E(7)C
M28]*Q:VVL/6&B$A"D,ZUD&8T'EDL8;>LE0M=YO5JJC"*U%YCR@TE@F4&P_(\
MT#&NHA1@LF0ZRWM8E2<G3[GM)]9"E1(4@;7-?(CD(IXK'-=)&+KT[(4.""H8
M'G!7.?@<$??@_?CIQS&05<H1D;E;!&<@C(/X'G[^G*^QKKS_`#%PW_9:@_X=
MV^\77^"PI,>9#PS%(DN(84F+*C8W21Y$:0![2!.`X8#"A,(C6O&43VD&]J.8
MYKD142>1;UU3BUCB-5<Y?"'*SL44^)O@QK&VA70)LZ/713QK*JAS:]@#2Y0!
MM,>2$?A)YKG()KWM0EOR]X^TM\;'I>?1RRXLIT.9+KZF[LZ>+(&5P2H6X@UY
MX#Q"(U4+)C&D1F?-5,J-=T7NF/&Z4\?%SQP/CV[#\NFO*I5(]R`$$8]U`0>,
M>F<\`_KT\I]>8%).:3(PK$3R)!2'.<V,T93&,9[B%,4I(#B%*4CG$(1[G/>]
MSGO<KE55^7V-=>?YBX;_`++4'_#NR/SWD#J+6\&GGY/F=:,60PPV5(&J:>]E
MV=7(1%#:Q8M..85U45.OE6+T9#,Y'#"8A&N8FUUIN;7&W(LV3@F1@MR5KV,L
M8!HTNMM8*%_P)I%98@C3&Q3_`#:&8P1(A2-(%IE,(@VC?,!G?*%]#N?'IZYQ
M\/TZ'DTQ;'EPEN^-J$^AYXSZ`_T>EI78OC=1$F0*K'Z2MA6*.;/AP*FNA19K
M7B4#FRX\6,(,E'`<X+D.PB.$JC7JQ5;VTWV-=>?YB8;\ODG]ZM!]$^B?]SOO
M=D+L7D;I_5EI[BR_+@QKQHPF-3UL"RN[&&$[/,"6>"IBRO0-,Q6D"R8\)3#>
MTHAO$Y']MKK/>6L-NNFAP7)P6<^N'YTVIDQIE5;@C*1HFS%K+,$:66"XCV#2
M8`98R$>P3R,(YK%+=*,MND&<9;+#.,8R?7TQ^'1F.G.U"D1V9"J54[>02`,<
M<X)`]?QZ4OV-=>?YBX;_`++4'_#NRK@P(59$!`KH<6!!BC04:'"CAB18XFJJ
MH,$>.P80C15548-C6HJJJ)\U[(/8NV]>ZHKP6&>9-"HV3'$97Q'-/,M+)XD1
M2I7U,$4FPEM#XF(<PHZ@CJ0:',-2,ZMKB7+316:7U?C5/F!!V]M*CP*L%K0W
MU0*=/E%:&-!!+G5XHOJY!7-&`)3"4Q'-&-7$5&*1,CCDNX'/)9@/3/.0/AT:
MI!$WNK%&Q&/="J2/=X.,'GW>/7CHD%:B_5/G^%%5%Z?@54Z*J?A1?DOWT[-3
M9:'TE<S9%E;Z?U;:6,MWCE3['7F'3ILE_A1GCD2I5(4YG>%$;XBD<OA1$Z]$
M1.WQV5O;5FI21HV<97%K+*8)#QJ>-'F6UP2,KU9ZM]95@E2H\-7-(UDN4P$<
MKAD8$A'L<U-9KGD9I_:EFM'A^7`E7?EE,&GL8-C26$P(6^(I:\%M%B>\4$Q'
M$,R$\Y0C:XI1L$BO[*C>>++Q-+'D8+(67(!!P2N,C./ET)8Z>;"3)#*0<JLB
MH^#VX#`X)[<<D<=.S34%'CL`-504]71U<9J,CUM/7Q*NO"Q$1J,%"@!CQ1M1
MJ(U&L"B(U.B)T^7;\7&.8_D+(X[ZCI[ID1Q'166U7`LFQG%:UI7`;.CG:%2-
M8QI%&C5>UK4<JHU$1&Y3N#7>%Y=C>"Y)D"5V4Y<Z&W'ZSW;;2O7NGV*U,1/5
MPX,B%&\VP10?=<D'@_PC_"+[?LLLCR&GQ.AM\FOY?H*2BKY5I:35#(D>E@PQ
MJ:0?R(HCR2^6-JN\L`2%=TZ,8Y?EV1EPV_+;B<ALG<2>YSW)/QSTK;'L*;4V
M*`"F!M`7!`*]@``"`1P`.MG&C1X4<$.&`,6)%"./&C1A#!'C@"Q!B"``FL$$
M0F-:P8QL:QC$1K6HU$3M]7,:]%:Y$<BHK51?HK5^K7)]'-7[[5ZM<GR5%3LV
M51N;6MY@=ALVORB*N#U;I[)U]+BV%<`)*TJ`E"]/81(LTIO4.9'C!%'>6;((
M,$-IR$8U1<U]SDU_?7N<GS>P'AF.1YU5&P*$:HNK*WL*YH)WO.SN#5,.QCQI
M<F1Z1S*_J)D$#A@:^69LJ2X!&.3M/'?@YS\/CGG)^7/1EXUV@LH!'N\@#`'!
MSV`]!Z'L.GTS35W&C%8%CF><ZUTS5PAR1R++(+S7^%>,DV;)8,1#RS41),F;
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M+'!S;)B9E2NP>-YZ2,B*=\6%'-&*@#1#,E##*'.;(5L=M>Z.DTDAXP"`0I&-
M<WAP,88*3VYP3Z<=B>/OZ<S$S[LQEU!&[W2P7N1GN!\?3O\`/IQ^R3SVWKL?
MPC+KZWK&75728W=6]A4/'&*VSAUM?(FR(*CF-?$?ZH8'!1LEK@*KD\U/!U[,
M)$YG\>)=@*`F;2(R&/Y#9T[&LD@U@U55:PTB?)K!@BQG+T59,E1!&U?&9PV(
MYS71W')C3=)[.F0SAE1)>L\NDQ948K#QY,8^-3R@.`PG.&8)A/:011N<PC'-
M>QRM5%4;64KD%<D8R"/AV[?IT>Y65MI5N#D`@^GJ/]?NZ$*AY'Z8OJJ-:BT3
M`CLDOE-0):G!WD;Z:6>(Y7.9!5J^-P%>WHOR:Y$7YHO;.P2Z[_6A5_\`6VO]
M<V';.WLPW_R2#_O?Y?XOE_#X<^`+'@?50]A_RD_P_P"'Y#]>I[>V=L[9V\/4
MEU^"?X,G[QW]%>WF==YW_C;>3O\`*BI?Z>#=O3&>GB:YJ?\`*:J?SHJ=JH_+
M/V>S=O(GF?MKD]1\B-4XYC^Q-NP-C0,7ML-S6;<UM?#=CJOK9D^%.'`-,?[F
M,C3`&@$\X:JB>%W34?"R_6FP72[3W>L2CAJ+/-30N\<T@>9ZBG98P(8Y""51
MCE@J@#EL]8[XS::O6IK-9*:R4+UT]+?(*N>-)(HS'3I#*K2$S21J<,RC`)8D
M\#JUPWZ+^^?_`$W=OUVX1.B?C<O\ZJO_`->W/;+NMBZSMPOT_&W\J=N>W"_3
M\;?RIV'0Z9+CC^PGK_\`@F3_`%O9=A1[QE?#AVM7*G5&Y5=N5/PHW'2JJ?C1
M.GX^Q7<<?V$]?_P3)_K>R["AWC2*N&:XZ(J_WT7OT15_R<-^!%[.)^U'^8_S
MZ\\O^[_]J?Q7I$8UPFS[*,4QZT=O*='J[_'Z:R2H)`R25'BPK*NBS&0%"N6L
MAG'%$9H&L].,#T$WH$;%1C3#T/QFPO1+)L^MES,BRJSCCA3<DL@@C/%`:5A5
MK:BOC>(-9`*88S2&J:5+DO$%)$L@@`$-U=6?L9:[_B+B'^[U;V7:_3\;?RIV
M#.YW`GC)]`/X#/2TBC7#!?>P.22<<>F2?Z^741W'#6.&[&Y&[D-F52&]C8ED
M&2VU;53FM-5'L)N;W$-#V,-[59.9$$%71HQ_%%4Q%*<)E&)&;KG+A6,:WO=6
MY]@]1"Q6Z/8V23%Q^*"H`<^,NJ;>IL&QX#(P16,=Y#@=+$UAC@<)A2+Y`E:I
MN'**G(3D9U1R?=]O]45.OZ8-_P#151.OXNW[[QY%6DU7T15_NGF?T15_\4U'
MX$7LX"?-`R<8`QZ?8S_'GI@*/9V.!DOW]?V@'?[NBBVIJ#6VS;/$=A;0FB%B
M^'4%D1U38SV4],8MX:IF+*O;3U0'^BALAH-L!AXX91BHLHQ@C2,6-OE7;<=)
ML2E=HROKXMU2V,N->6^)4DVLQ>1%]":1%![R\J-`GW42PCB/$D0F%-Z59+EE
MN&(34>SG0Z^9$TD2?'LY>M1QVEO(D!7CCGN0NIG/%*D,;Y0)QZ#UP:0LQ[6#
M,Z<^(K3-*Y&UY0[8UCGVK<0Q/4&-W4+&<:OF2Y4\>)RL?Q>JDR\?LX,.A=**
M(8SWIT.62940C3#BG/ZN6\GC41@C8<L<YX!]U1ZY[Y))[<=NYZ$K`B084,`I
M)(R[$@<KVP`!R><>H&>EUSEE3YU#QQFH9Y+695VLIDA>BO=928F$%$=?$O17
MK,>PGVR]/%]5Z?/L5`N'6F9>&#QZ^H26>12F),N\^29(%F-CD$ERR+2V][.+
M(423)AI+_=SF'KF#*C71R%8T_8$^1&S:'9^-<?9N-Q+H<#&["1C1Y=K6&KQ3
M[&)`UX:>ZL0G5TN)!.18!I2(T3Y83-"I!-:5\S"?3\;ORKV2Q94C&2#ELCYA
MN,].1A7>0D!AA!SR.4&2/O\`C^745G,O%:5^V./6$1HJ5V.GK8&+"A5RI&2'
M3R,OI*CR(;O"]`N!"(K`$5KU8]K2*CW(O4BM\Z#U#2:"SAE%@>.TLK$\6GW-
M';5U='%>1IU,)902&NGL)9SO5(-T>?ZZ5(66$K_,7S$&\;,<Q45>0O')4153
MWA4?-$543IL*@7YJB=$_'V,?D6BKHC;:(BJOP#D_1$3JJ_W/-]$3YKV!9@(A
MDX[]_7/<_'\>@%4^>2`>2.P[!`1^O0A<(]0:ZRO7MGF^68O697?.R*TQF*3)
M8X[N#64M3&KW18=;6V#3PHO4DT[R%:%QNCO*"\(/$-R6P;&:_57/(F'8>UU9
MC5M6V2+5B(3R`5]SA3LD=6-1SG*^)#NJ\<B$%[G-CC8$;%\(FHCZ<!>J:/G=
M45/TP,G^2HJ+_P!JTGWE1.S73T7\\7JUZ+T]S1_GT7I^Q?9_?Z=/_C]?EV5D
MEY022-C<>G&,<?+TZ2%`C@(`!WQ\@8/)YY^?K\>GCRG3G';`LFS;:NZ[#&K*
M=F.02[6"'+WL2LKHB1(D7W?3X\AC.NI[6B::9.=$G24<\;(P80A_H@88-?X$
M'F3@UKIJ!+I,+N[*-!!"-7SJ>*9EM06L2Y+65\WPR!TLXH@S8`WM9']0Q[XX
M1"$)@]WFE_0XOS'R2[Y"U5A;XK#-+3%&S*P]Q4PJU\6$7$YL:K1I!6%3$9ZU
M)<>&&4T=X8TJ7%)*"5S$WF^W\7F<JL(VX^JR:DP2N9C9X)[3'9L"=:TM/77$
M#WM3U"C\^172IAUCP/*17O0#G.8+]0TU4XY+-F/N?LX(&%`[YQ]WW<](=ER,
M!4VRC(Q[YP>7+>@_,=N?3I:8AB<?D[RQV*?/B29>+X8:X:RD22<##U5!=IC=
M!0M+&(PD6"<XY-M:^D>%\R0LA'/8Z61Z'G(XU:0#-H;NMP"FQZTQ2WK,@JK'
M&@NII;95-+!/"*7Z1[1644SHS12(\\4A'L>]PW"/X3-CWN)V;\;MQNWGCV(7
M5CK7:$)U_P"DGQCPB"K,S2/D,_%KV0,4],=R.DMG))AK-1\>0P;`,+(:Z8T!
M!"Y^XA<RJ2HQO7>83[BYM*JK?&LCU$2'%2RL0P2F4U<>ZERTCB,AT&*`QI?F
MPA`(US^R6#L5V$D;0.#@`XY![8/H<_=TN-HUW"3&_>3EADD'!4@X[?`#MWQT
M'.L-@:SN]I9UL[?&/Y+G$NRL'RZ2FK<<)DU1'D2)<CHZUBK)#'4%-6`@5E%7
MR&FBL$ASJ!Q``<SO;MS75LW)L+S[0F%9;A.48[:+8VH687(QVID>[U!+JIL6
M'!(>,.<PHI$&:@`1VS:^6]DE7N&WQKR';9KPDW'E?JL8L;[5^82R>D,!7@C6
M-2R;(FU!Z^T43X(<DQT4Z373:J<L=)H7/>A!1RQ)K'DM>>JY`X%'J;5>4WV4
M6+@`@LN&CD!$8CD0KDJ<;/9V%@@$ZJC?4UP'(CB&DA$W[9?J"JD@KP=^%`QV
M*XXQSZGT]1CIH8VE'8(^[/[,ERV[@A@023R!CT/YI[D?,98\H^,%@-JM9/!@
MDYC51R*ULO/?4-:J/:UR>%"(G1S6N3IT<B+U3L:/(S]@G;?\0,F_JXO81N:U
M%E&.9SJ'>573GN*O"BP`W(@"D$'!F5.01\AKUL7`"7T-?9JZ9!2P(YP(\M@!
M%\+S!:;I[<Y@4&S]8YAB&M\(S2UL[C%[)F1S;.J#&J<3Q]T5775G,DPITU3D
MBQO,%$<[TL,LAPWK(([RX<AO:6$1'('!/P.?7^N?3IXL%,RL<%N5X/O93''?
MU_KCI7\2\!P_8?&ROJ<UH(&1UD/-\PLH\"R:4D8<\,H@0RO*&4;7E"PY4$XB
M/\M7J]GA?T<C*<(=4:YV1!V83.<0ILF)37./`JWV@'F6"&5#MB2!@\!!^%IG
M@"YZ+UZJ-OX.Q.\%&*_0$5CD<WQY;F+5^71R(ZQ8BJG5/JB*JIU3HO3L(.B=
MN@XFY=M/"]G8MDR/GV,-\=U5#BDD>IIC6<>/(&VPEU@)E5<5TP,J%90SE`JC
MZ>7T*Y0J)8F55)SE2H!.>_./TST@;`*=F`P58$D`C.!MS^7'1><O,>I<4XP6
MV.X[71JBDJ+'"H=;6PVN9%AQ1Y37N8`+'.>K6-5[E1%<J]57Y]A(W'FEK4\1
M..F$UIC`CYI4&DW/ED<)LZ!CGEOC5<AS7)XXLBSM(<HXG(K'K!$C^K.K7/OO
M+:/V9.(>2YN+'+#&HLK,Z6O@5]B3SY9H-9F%8`%B1S(X`_=K?$5&1EDQA_J!
M3)*-4BH7+M,7VU.'VD;7%(9++(\&QUT]E.!GW?;TUHP@+:+7)]JI+&,Z)"L(
ML7JCY;8QX\='2R`&0E&-H;TD;.>>=HQ^N.>B?WF?9D@PKC`(R-Z\`8_=SCCH
MH]=\2M-8QAM947V$T667AZX#K^^OX;;"=-L3B0DQT-Y7N2KAB,]XH,>O\A0@
M&-SR&DJ627:WO&;7TO6K=5UYK&BP=,W#FLV&R8^5(8(4YUE*IX%E,>Z3`A&*
MUHF2C$ERH,13-$92((H1;U]SW@8_C,*@V=A.4$RFCA"K9$^F'`&VU+"&R.P]
MA6W,FHETUB1@_NT",DQTD-(4:A:5(P=CNG;N6;MXL7V98ACMUC=8W8#*2]@B
MD&F6,K"8`FND3YCX0([4@2K*57LM01?611P1F&>4:,DI["VR;@&)`+#DG(SZ
M'&>?EQ\N.G0T.T[5!(0DJ%YQQD$X_//)Y[](?D:[B+4X#=8EKBKQR5L&L'%)
M4SL'A2[,E42/.B)*-D>4QWGB'@FBODQ)"6%E/(^40**QDAHR,>;3ME+L>"E^
MDLBE]WX#MBIC.<JN>V#7/R0$(+G.55Z1P>$`FIT:P(QC:U&L1$&Y=JZA3BO:
M:QU_B.0KGEIBU?\`&;Z[%9,AL>75V5?.O,FR+(PC>!]-XHYB07)(,V&$\6&D
M6`,3V"<70.QJ&RXL[(UI##;%O\<UMM>^N9/NT[*6("TD6SJR&EH]&AD6,P$S
MU3(L="*,$<ZF<Q[6L<I@0G9N)`26.2?3/W$]N_QSSTA&4OG*>]$>%&`&R#M^
M9`[]B.>PZ%37?ZT*O_K;7^N;#MG;->(J8A5]6N_PMK_R7?\`/-A^YVSMZ.F5
'[#[A_#K_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g544224.jpg
<DESCRIPTION>G544224.JPG
<TEXT>
begin 644 g544224.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`_1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]/6%E#3TY?1E!/7TM?4$A4+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_`
M`!$(`)T!M@,!(@`"$0$#$0'_Q``?``$```8#`0$`````````````!08'"`D*
M`00+`P+_Q`!,$``!!`$#`P($`P4$!@@""P`!`@,$!08`!Q$($B$3,0D4(D$*
M%5$6%R,R87&!D;$8&B0S4L$9)B<T0F*A\"4W-D5867*5EYC5UN'_Q``9`0$`
M`P$!`````````````````0(#!`7_Q``R$0$``@(!`@,'!`("`@,````!`!$"
M(3$200-181,B4G&!H?`R0I'1DK'!X11R!*+Q_]H`#`,!``(1`Q$`/P#?XTTT
MTB----(C3332(TTTTB----(C3332(TTTTB----(F'GXHO5[DVSSF([*X/>1<
M1M\NI3FF2Y;^<R(5I&Q^+92ZNOQ^KC5[8FL&[L(LB186AE14HA5I@1TOF9)7
M'U[VMP,+J(>0/3KS$7&I$2TE/^I`LI*VD-1([\WEMTK1.5+?LHT?M?*0IV0\
M%*]-LZNR^.C;O.]8&,P$/)":G8/$0E"1VJ29N79]*45*X!6%=B>$DJ"0#V\=
MR@<#.0RY!KKD>H0%5UJ..X_4#.QAKR?`_P#*`?OR?)X`1,IN*9WL#06@I)F*
M['7TZ;D%3A3$J;@+I?C7EK5)M'Y4:8I7H1XU%'<'S:GHK@E.)4F.MM/!U-V,
M;I].T^900W<0V.R1O*LJR+%:MZZPZ?6.P$XNS,79WS+U(Y":9JU*AO,Q6)C,
MIY2E-J5R`>[#DJ:^<O@DNK\;O6:D@+4.3&Q!G@\>?)Y`YXY!Y!)]A+^(6$QN
M=M20^O@6N[4D$*(YY_.4^/8)))Y4?'//L?NB9E++=[`[1FF3B5WM?48]?9])
MVVHL=D8]9RVF$U+\J/)MENJ++8I4+@NN,-%HOA'II5RKWALS=BGK,<S>UDY%
MLQ=4^#Y9`P]5$<<O$?GSLE=&VF57(;=2TW7QEW0]4J6E23%=6$CO;*<..,V<
MSY79M)DN</;J9J_QW'D*3*O3W!/ZD$@$<<%7M[<\WMM+_8#-U"2Z%2-ZXK2O
M)2>U%QBJ`".?(*6PDI/GP/)X&D3.#993L*]D.;8Y)P/IP3;X/A\+,IV45,/,
M^Z[=D,VCZ8$");&QC&R955E;SJTMQU)>;*/+2N)BQ/J`L:)_;/&:'=#;G&ZO
M<FFM<FKV(,;)8M?3.1(E3*>BVL:*MM`GR46#+2E1P4N+BK'<`I/&%.?<S3FF
M^9+RBF+MY4-M_4H'A5/DBN"?)X"G#X'_`!*'(US6VDE>5=/+/K.'C$KMWZG%
M<`J@8^WSQSP/Y!XXX\`D^PTB9_<3Z[K1[&<6O+3+]J9,"\W"7MTY#_)<M9L:
MR<B7;04VTZ6BZ4E^M>>JE+4AAOU5M2V0L$MKXG%GKMC5PS1[(K/9>RKL/W)K
MMO;.!%8SVKF,JMY<6'%R*OF0[E8>JR9C"WD-ML/\)6I7">$'6LJ+23^[_&0)
M+O>O?5"D<$A*0;C)E^PX!^HD^0"/MJ-7]C+#&]R?7=X7NEA_(Y44@"WH@>?/
MGGM!`5R4E/'/DZ1-BJ7UAUM3E64/5.>XQB2Z'.:3;E8K<IW"?6DY;$:EU5R[
M8/6H6]CK[I;;D>E"$V$^M`="D([E=:1UL[@\O)K]YDFSA3LRJY$)6=9LRTU,
MP@)=N(:%ID2`^Z]`<1:5+ZD^G+CH=84$OI"=:\V339(N]QSZSGG<?:L^Y\`1
M(1'(/]OL>>.![ZC\:QE?M)9K#[A)SS=/DA0`)7BZN5`^>Y1\A0'V/;R.=(F?
MR/U:;N6*U2HV]SR7P6'6GXVY^9K:6%LUUI`EL1Y24L-E^-*C*4EQE;?8\^R^
MPX4.I&>+H4ZBKGJ'V?DV&82*V9GV$9'.Q/+9U*CBHLRMIFZQNUB.(;:94_.Q
MBQJU6[;3+"&+IN>VW':9+(.BI06,Y,>O(DO?17T_`+I'@8M4'['@CR?'V]OZ
M#:E^!!+D2]F]_E2'%N%&\-*$=Y)[0=M\9)`!]O/GQ[CCG2)G;TTTTB----(C
M3332(TTTTB----(C3332(TTTTB----(C3332(TTTTB----(C3332(TTTTB--
M--(C3332(TTTTB----(C3332(TTTTB----(C3332)I\?'$]$]:PX:"71L5MX
M%N=_=ZI3=9^M!4C@E'8DA``X[_?WU@ZON/D[5)[3S&FCQQR"O(<;9X!/(\]I
M/]@X`Y/.LW7QP04];$H^`5;+;?$'M(Y2B9EW;RKV)[R[X(Y'CP>>1A#N^2Q/
M3V\]Z7`!X)[5Y?1H\>/;A'M[^_N!P$2$?2<OKSW!1_>QER^>>.X,XHRE)[3S
M]QP1S[CQQ[ZEW$%#Y_:8]J@`G=9WVX/<7+CSX/O]O/@<<\:F-OA65UJB/!W+
MW!<Y('<2WC38/<.#_P"(<>_N/;4MXES\]M*02`:G=1\\^0>YZV'(X\\_5S[_
M`-?TTB0K%%=Z-CN5'ZMQ,[)///*A(OSR2?!X`\'D>_D?<_NZ\[?Y+P02O?1A
M"OY0HC]H<<2`!Q]AXX`'/!'C3$`"-B4GD%6:9\]S['COR/C]0/8'D'G@\$_I
MQ9@G`;@!//?OPUQR>.>,HHAP1P>[^4^YYTB3=,/&5]0J@#R,%J4J)X('%#>G
M@$>`D#^W]>>/;M5P[<RZ?4#C@83=*X'/GB-CJ//)!/')'/V_QUTYY2,CZCU'
M@D854@`<^#^SEVH@\>WTJ'(]QR..==ZM\YOL'X/<G`KH@<<#CT<?!/CN(Y5X
M)/V'/OI$EFHX5M]B('N=]4<'@^0;/)E'[CDCR/?C]/T$<O?^[[V'GVW7Q$>>
M"1Q=4J1SQSQQP//MQ_B(%1J'[OL'/;SZF^*3P?J_^L<G43Y]S_EX_74?NTI^
M6WK(\D[NXF%<#E/'YY3C@^P']A'/VTB1#)0!=;C%!*BK<?:[E120`?E(7@GD
M_I[_`&^WD\ZC44`W]D0``,\W2/@@@?\`5A0YY`\)Y']_/]FH+DI[;K<3@^3N
M;MAR.3[?)01W'GP!QR$CC]3[C4=B!1R*>KGD?M]NDD$C]<8/N$\@)_M)Y/GC
MQI$FVDY^7KP2`#`J/'/CDXK3'G_$*[CQX\_TXVJ/@*=QV:Z@2H$?]L5(.?/:
M>-N,;YXY]CY'</[#[$:U6Z8%,6OYY"ORZH(X'MSBE8!S[<\=OC]2!Y'C6UC\
M!QLIV1WV41P%[R5BO;@]XVYQ=*_'OX`2`2//'/)//")G:TTTTB----(C3332
M(TT)X_Q`_P`3QK2AZY_Q96X_2#UG]2'2K5]$F%YW6[#[GWVWD;-)N^N34$[(
MFZ9J*XW:2:*)M;;1:Q<DRDI5%9M9J6BDD/N<CFV.+DUB6U?(:^LKED8#DW1S
MI9NO::\^H_C7-W>]A`^'OMKR\4)X/4OEH4E9_F2H?N9X3P?'<2$\J3Y\CGM+
M_&J[MMASN^'QMRI;/`>;1U*9:7$*\]R0@[,@E:2/J1SW`$<^XYM[+Q/A^Y_?
MK*OB^&?NYXT^GIKGOOR)Z!>FO/Z'XT_=H\%7P_-MFTE3:5+<ZE<N2A!<4$H[
MR-F#QRH\#WY/@<G7[<_&F[MH<<;_`.C\VU66U%*E-]2V7*22/N#^Y<<C[@\#
MD>?;3V7B?#]\?[E?_(\+XG_'+T]/7\U?H!::\_G_`%U#=O[_``^MMQ_;U*Y;
M_A_\F/?^G]#^FOFG\:EN^I0(^'QMJ62.4N)ZF,L45?<*"1LQ_*?[>1[G3V7B
M?#]S^X/'\)_=QYB?[-OH;::N>@5IKS^1^-1W:4`4_#[VW4#[$=2N7$'['@_N
M8\^?O[?IR-?-7XU+=Y+@2?A\[:A"DD-D]2^6!2G`.0CM.S'CD!1Y\\!))_J]
MEXGP_<U\]P>/X2UU5\Q/+7'.^/1GH%::\_@?C4]UD@!_X?VV[2U'L;2.I/+G
M.]P@D#QLTGM2>#]1Y`_S_+GXU+=U"5D?#WVZY22A//4GEO"U@()XXV9)[!WI
MY<(2D<*)("%$/9>)\/WQ_N3[?P[KJ^6FGCC6^?LST"=->?@Y^-8W;80MQ_X?
M6VJ4-GL4E'4OEBW0LJ"$\H&S/`2I04$J[BA7`(4>"!VC^-0W;!`_Z/O;?DCD
M#_25RWGCQ]OW,<^.0#X\'P>#I[+Q/A^^/]P^/X13U:>X*:JRPY!%)Z`NFO/T
M1^-6W84XXV?A];<M^EQW+=ZD\M0T>XD)[%_N9(5RI)21X(/`(&OJ?QJ.[0'<
M?A][;A(')/\`I*Y=QQ[\_P#R8]M/8^)\/_VQ]/7UD>W\+XG=?MR[UZ>OYJ_0
M&TUY^Z_QJF[#?ESX?FVS:3[+7U+98E)/_#S^YGGGCS[<<??7`_&H[O%?CX?&
MVQ:*20X.I?+%<GZ>/`V9\`@JX/GGCGP".7LO$^'[G]P>/X3^ZOF/IZ;=\'^I
MZ!.FO/Z/XU#=H'M'P_-ME$)0I03U*Y<>SO[NU*N=EQPKZ22!SP.//D::>R\3
MX?OC_<?^1X7Q/^.7IZ>OV^5^@+IIIK.;1IIII$::::1&FFFD1IIII$::::1&
MFFFD1IIII$TZOCAJ8'6M++7=ZJ=F-OTR/46"@/"3E:D^DGE78DQW&.4]J>5A
M:^."%'"-9N%/S!0>U?J,H"D^_P#$SBO2$@>0KN"/J)''V/'VS!_&?4D=>FZ/
M:%^<(VP"RMPJ'J##60DMIX'IMI24@H)4"KN5_P"+@8=K-0*U`>WS<`*^W!5G
M<=(`'/W[.>?OQY\@:1(4POG)*DG@\9SN@[W)\CA-&E''N0>.WC]?OR.-2[B*
ME*F;4D<)(Q+<U_GD@<JDVA^P^X(XY\<^.1J.15\W].1VI[LHW;>]N2.VL4D`
M^!SSP//CCC4!Q103+VN)X'_9[N&L\<]H[WYQ"N#Y!5W>#^OO[Z1.EA@[W-A`
MH\$Y!GSX`]N.S(E$GGGV/`/GQ^OVUQ.(5@+WG_?;^)3['@@9;4#R//'`1XY^
M^F$#N=Z?0%%),G<!P'@$$EK(#S[^Y)Y_4'^FOS*X&"0_!"GM^R>">`2,O@H`
MY]^>4'W\\)]_<:1)IL%*%]U)JX2`<1JD<\<@?]5K=7WY)\<<^1SSXXU%((*<
M_P!B$CCA.W=P>>`#V]M$!SX'/('GQR?O]M0FS619=2Z^>%#&JU!/W"/V0M#S
MSY(Y)'W_`$]OM&X8XW%V02``4[;W1[1X!!./@]W/]/;M]A[<Z1)/Q\E6WVW9
M/COWM#G@GCA,[)O;D^QY/V/Z>./$>MU<1-Z/_-O#C`2>//*;ZI_N(XY/D>./
MTU`L>/.WVV__``JWH!X\#N!E9,3P/L`>?Y>/U`U&[8_[#O#R/?>7'`>0"21>
MUA``_P`/)Y_32)%,D4!=[A*4/4)W-VQ20H]OE,.$!_8`."/U(_0^9B@GC(;$
MJ/:#N%N8.//`[L96GGM)Y_L//DCQJ5LA/=<[A@^.=SMMAP?/GY2&$^YY!)]O
MMSX]M3)!6$Y#/Y`/;N!N83PH<=PQE?OY/@>>."3S_;SI$G6I7S"K#W<D5M,>
MXGR0,4AC]/)^G^O(UM6?`>/.S&_/'/!W<I5<'CD%6W]"2.>!X!'`''`X\:U3
M*9?,.L'G@5E23R#[C%89/C@GCSR/L#]M;5OP%W`YLQOYQS].[M*/)Y/'[OZ%
M2?U]P01_0^PYXTB9X]---(C3332(TTTTB<'V_O3_`)C7C;_&[:=5\73XA+0<
M;2E_J9SE[EM91)4V&*=(91Q]2UN+2.$$'N)0V"/Y3[)!_P"8_P`QQKQT_CD/
M-H^+'U^(HXLU,=/4MEDBZD6+$!_ONA!A-RDQ)L9H2(M:ID-_*P'5^J5AR1([
MEI0M&W@?K?\`U>]5[V/\^5>M]ICXZF.-5;EJZJZ4=\5YA_$QA&Y,+$V\3J*V
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M2.>"#S]EPVDA"$+"%/)2&D+65I6AI/I]H0%!P@E`]0\E9`X!"2-5%IL4C9+3
M9A:UE[B="_05U;-K<+>>O;'*LUL'%PV9\?#HE92V29ORJ1*OKER=-JZ^KJ$.
M,HERBV@.3/LUCF4.V=QNS7X/MON;ANPD*LSC<?'=RK.!$QBQQ^PM4TT.LM*E
M5_C^192NZL)D>,W38<[)O$DJE-B,PT'D.JA=?6N]5O@VU9_,5DY:]W%N@W^D
M!:#G6RK2C=DHZ6D+;+3C:%)4/K0`0DDGR0/"OY_8^#S[^>=?)M#<8M,-^FAH
MI7PE3@]12RH$!*5'E8/*BH@D\^X`\ZG["MO<WWIW.HMM]N<7;FY=N1F<>DP[
M$:%]#$>==Y'.>%;C>/R;J<%LL(=6W715VMHH-14,AV2ESN6NN^ZO0#UE;`8C
ME6X&^735N?MWA^(64&FO\FS.KB1J^FGVDM#54VY$1*<DR84^8\U#9M8,=^L#
MSD>/(F,/.MA<J%"@M4*6K7X5?WN08*-=66/-8BG!OL6"*7=:])::ZA"D<*6I
MM*`#W()'8$\$'M3_`#!/:/H((4`4D$$@Q!VGMH,*!:2XEE^47)E?DUO(KGH]
M79KK?0;M&:N>6TQ9KU6[)C-6K+#BW(#TF.'DH^91SUU_2I*7BGD*]4!Q*&R5
M!14I3:%%"BD.(6&P%>/3[4*^GG5V,YO)K>'TT[,[_P"_%!0[%4$')<PQ&RQ*
M/3[FS=GZS<JQ189C'O,<Q4Q+@9=<6V,U<R7A]G8OR8:9<.5\S#:=>0F%I*I'
M;S=!;TZ;?PN1C2)9L*XJUQ+MKI/-OC7%LM&+#1=6\I(4I3095S[!ON4I0X_\
MW=PKS[`<<>29NPN9@-'>R96XF+6N78O*H,E@JQ^HR!RAFG(;+'["'CUR+!D%
MYMJDOG*RWL(2F_3N(,-VK;<)D*#DM.A2774!?KH0\XAE2(_RZA%]5T1W%M*6
MIP!320ZM2U*4@J+:U$M]QATV/+G,J<:2!7,N-HG3BA0C,NN`EJ.J2H%A#KS*
M2M+94%J""KD(2>)Y&_*OY0UZQCU=1OCIMY*$K2;[!1:NN9UVZI@)82MWU^UF
M.IWM7RAUQ"`@J6TI/T(4D)[6_I4R24@I)4D?MF!Z<OUC+<4ALGL;*RXMON'#
MB7"H^4G@CM!2H@#N7R.=$-):0CY5]:UME`6!PXA3;JT*6>P`A*>P#L4V2$@(
M3Y(.NS\LAA3SD=L*?<0./46LH/GP@J)64@?=(_1(]N"!QKM]C7_YN6<W?OK9
M19ZEW9PC8_S4_2([(+QX]5#Y[U(6HK;"R.0XA))"5>001X\#@#@:^CB.]*D^
MHI'>DMCM*?=?@$!0([_<#CW!/@D`BJ]!L#O-E&TN?[[XIM]?7NS>U5QC6/[D
M;@U;4>10X-=Y8"UCM?DK"9:;*O:N7B&(5@JL<@F6AJ.]+;4XTTJD+R`'6FI2
MFT24N!R.W_&1RM/<"""#WI/(22GR"%`$'D!SPG-<FGU\OK*TKC:[!+%4HV%;
M"J?EN=:1!!;07WW'6H\<`-H\+<=`Y*BH\J4M9"4A')Y6``H_?MPNQ45KLY2E
M*.$A?\P[5%/8.$CGM(*05)22$\JX/.NHEV2F3(]6.ZX@@>DA(44$-J':M!4"
MA(5S['ZRL)5P0KEOLRWG&VBF.E2Y"QRVA(X(`([G#SVCA/(!'/=W*3R..=)*
M*8XN[1'72"%W7DNWT[]OVVE/KON>LE:E!"2VD('II1W=H5QRLJY4L\J(Y)/T
M^W#4,>B#M9=4ZMA[TD-O>B%DJ5Y4.[L!(X\I'(\]ON>--/K_`+_K\KY1T8M>
M^]C]"\4<FGN_3SGO)Z::L:ZFNO[9'IK?EX[82Y&;[BQT(/[#8TXT7X2W4%QL
M9!<.(=@T@4@!186F58A*D+,$-J[QY\]27RZX[D_\0_Q&M:?<7XN'41E4J8U@
M%'B&VU4XE;<)*(7[5733)\>K(M;5*(*I)224&/4Q4-G[+("C02-U\=8*5*=.
M]^1**UI>*5U]`XW]+@4&T(-0`ALGZ5H3R"W]!]^=(FVIIK7!VW^*]U!8RIF/
MG5/B>XL)):#STF$<:MRPWRE88FTZ1#]9Q/DN2JZ6HK3W(2E/<DY:>G3KMV7Z
MAI3&/U\N3AV<.H)1BF2.QDKL%I`+B*.T94F+:+;Y_P"[%N)/6GZT0U)\Z1+U
M=---(C3332(TTTTB----(C7!/`)_0$ZYUP0""#[$$'^P^-(FC]\6FZF7?7IU
M`_/+;6:A>&TL0-(4GL@0,+I4QT.`DA2^Y]SO6.`I1Y`!YUBIG!1D-@\]JIM0
M.X\$GNSDKY'/GSV`#CQ[_;6V)\3SX2&6[N6N8]0W2:B)=;QY7;MW6X&UN<Y>
M_4TN;K3`CU[D_",HLFIT;$L@:C0(:&\?LPWB=CVJ4S+H9!=<EZ@O4U:;L]'N
M<4^#]5?3_N9LAD-TQ$NZ%F^=QRTB9%25.6EVRML>L*BP?@VL2.X\(SJXSYXD
MI+1;"5M+4B1J*D&YHRE7)7=[ONK)'''^QK04DDGN`/![DCA7/CG@G4%Q('YK
M;,<$C]V6=N<_<<R9`(X]QSSY//DCC5"*;JOV;DSJEYZXM828TG<AZ0N14*=0
MV,@9(JOKAOR/JDI4#R$E+:CVJX3]6HGC'47LPS(PI<G-XD$5&VF35DXRX%DS
MZ%I825JCP_\`NJ_4??2>\=I4CCGN*3P=(E7,'0HR.G\>3PWGKGC@)X+%Z>/<
M]I((Y\>`/UU\I2"<$HR0D!W?WQX/)[<S:/)(\^.SCP`?(/VU3S#-\]GH\G93
MYC<+'(HI*K+5W)E.RHZ:UR?%M$QD2UKBA+;CYDMI:03_`!"M(*DJYURYO/M(
MYAF.0_WB8J9:-YE7C\55@$26ZK]JS-_,'$+;3V1C$3\QZI2$AHA9*4@@HE9+
M3D2NIQ8`_P#H_6MD`?KB4\CWY(X[ON>21YYYU,45"U;E;*)4!]&V=P3P>#R7
M:+V[O_PGVYX]A_2C=EO%M*\>H9;6X^%J5D%7!CT:1>Q.+5UO&),4_EI409JT
M2%_+J2QR?5X00%$ZF>+O=M''W`VLLFMS<'1#K-N+6LG3%7T!<>'-DJJ0F%)<
M5W-,RUI;=*&"H/#MY`!!&DBSS)V<=2H[?;5D<DN;Q+('`()]?)B"1Y/_`(N0
M1Y'D>//$<MA_L&\*ON=Z\<20H%)!_/*\?;[`)]AP?T\\<TFH]W]JHV";:0I&
MXV'-2*K=(6-DP;IGUX,`KO@)\UH)4Y&C?[0R0^Z`D^JCCE*N==JVWQVB^5W4
M9&XF,NN6.[%#<03'FJ=;F5[5Q`>>EL+2RL.,(:"G?4'<.Q"B.[@\),JS?\BZ
MW``[23NIMP`4@CD)B1#[>>/8>2">?[M3#%2HY!//G@YYN@4GD`$C'"?/(\D'
MD<^.?;SQJ@V0[^;-_FN;2&MP**0W+W&P2R85&3-DE^OAQXZ9DIH-1`5-1UI6
ME[P.SM/("1RKX.]5&R5=;393F4/R6QE^X$])A5,YP*AVM,J+!D!3C32%I=D?
M0DI/N?J^GGA$NNJ$K$.!V\\?EM3^H4.<5@#@<<^Y[CY_J.?(UM5_`2^G9SJ"
M01P4[OT1\<<$';N@X\^YYX)\_KX\<:U1^E6)O!UE6<O'^E+I_P!TMYW\71BM
M;E5]61:3',-Q:3<4S%=7C(\MR*SC5->VZY$ER>Q#DF8FOCO31$+*4*7O&_#9
MZ,<GZ--H<AH,XRJKR/-MQ,AK\QR6%0QGDT.,3(^/U](W05EG*4F5?".W#]25
M<.PJQJ1)6M$6"W';0ZZB9%M---(C3332(TTTTB<'V_O3_F->0O\`%=P1K<WX
MT'7WAJ=Q,'VU;L.I'.43\NW.MEXSA]-'].F%A)E6C$:RD2E1("WI8C18+D^8
MAIV+`C29BVFG/7H/M_>G_,:\?GXNB*F9\;'K1J<CQ5G*X5AU:Y#!8H)5XUCD
M*Z7;R*2!"$ZV?#;4>N1.>:39CYJ"XJ"A]*;"$D+D-Z^%SE7;%>!X2].G7GJ8
M>."867[QW"O7U^CY\S'-'VB8A[AV^%Y/N)MU1P</LKF,YN-(F3\EVZOIU)"L
M)M.,=FXW`LK&VJ\\,.)4T"V:E,>),MH[>2)KVA*6S?7\/K9GH.S%W-!\0_)=
MY.G.O,3'\GVNW`I_2@4.;4]L_;55CB\:@G8W8V5]"<LV%V,7,L;<E5]=^4O4
M,I`3.;<<MJZDNF;+>DC>'(MGMVQW9EMW?"\N<4@NU-I@>0[:6L.IN<2R##L]
MKK28_=O9)'L)5<8\.K1&BEC\PC6,\MR(R-C^!U_]"7Q"-B]K]N^HC;-[9[(=
ML[VUQ';W$L=W6A_MQ!L+6JHX.`95MV^Y24\2YJL/>K7IN0)R%YBEI(SLJ3-J
M[-+J5&^>;0VO4BIKBM=[7NI7!7GCX9BY.+TB76+U([+&_=K'7NE_JYD2W#ZE
M?A_]*6WL+:SX6O3R_N=G&>;-99MOU";MY#A>8JRG;'9&WQZ3)G[L6]C8P*<V
M^>0#;V=VBC8-'(L*:!#JXRW&!%2-6'<^BVVQ:+1XIC]5F=?FM!89+$R>_P`A
M<@U5=F-'\\Z,!R>GP"?4UN2X"]+Q=J)+NJJWDW@4\^TY6RT-J<2[OP95G!R#
M!KSJ$V@ZC]L=Q:/,MC&]G-J+I#^'V43<#.MN\8OK5.0+R&NQ?&[G']W:)U$Y
MK'J;):W,<:GK;>0RS254Q$:-;ET#=0NT?5?E.YNU_4_T5Y=?]16VVTJ*?->H
M[JFVZVT@Y_)VSS:2UC^V,6^PF'"J+9NV<I;QF<\*&*\4LJEOMW#,1UJ8C/#-
MQW2U5O55O:];.=<;FWB>$9UCU&-_IK`0-+5M%AR4UPT,U_?@M]$=]U0;\66Y
M5;/RF`CIE5BVY].[!PNUR*DS*\9MU15XDQ:XS?4.0TF6F.]&R7'54<\V/97/
M2'F'F`RT]F#^*9TU._$?W9Z2=J.D>^Q/!L&HL(W?B66YF]VZ^;T5-99?BV;*
MK-R,`DXK?-VZ[W,J#)$INKE['6KO)K>7:Q*V7\HS#A14Y$-B^D7)?AS[H8JK
M;#<;+W=K*;$6'[S$K/9BGQ;;F9MU:V;\.TI\RR_&Y]CN+N9O=C]TY*R/%+VQ
M,-K#,!F3Z"0U;1UPULW_`&';&81M=M%LS08Q@3NXV/X/G,G)\0@T*<5JLJPJ
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M?:X2]A)>^L#`K'&7,+O)-Y0BXRS-UT-G84^/[:R51GTVS<FWB1(\QCYA6QGU
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M),U<7YU^K#[JX"[!4`B*BR^5#(LF(9<CM2%EM#ZD*[%')Q])MAR0Z"RHO?Q)
M3O84N=J#RTXLL$O=B6WU\%4A(0V[R`GFQ8B/_MJE\GDI`JZ>VM0Y#JLEJO=R
MO&KM\['TT>3R?$*4K@\I4GM`Y"5I42GA((2I*2$D`GA0"^>/'!)U\GFT.-+?
M"%NJ84>WT5]CH6/424()(`)X6E7CSP`>?IU^T@GL4%+2GCGTRE(\$>`>4]R>
MW[`*''`'MXU^5(6@I6A:4,-]ZGD*0I94%<JY"PKE)!Y*1VJY]CR/:?S\N4&G
M7T]?1KZ=M^DZS<V'7D(E)F/%Q`=[6R/43ZG!3W+<':4H"2CM[BH'@^1YTUV8
M[_K)4M+8+*NU;3BVRE2OYDJ2`H!0"2.2?`7W)X'T@EIOU/JGD_\`!)O']V.2
M]_?KR>#'TJNVR>QE\2/K=L>G.@J]LMM'XZ-U\]JI4U=RI;;IP?&%.F"+=J/W
M'_X[:/B2S1J?3Z,01)4]3;CC<9)UH5N3[NS?GV4V9:6=I(D3)DV<^N3+F2I#
MA>>DR9#BEK=?>=4M;JE*)4I7=R2=52ZDM[)/4/OON)NLZU)8JLEN$#&8,Y2%
MR*_&:V#$KJ&"MQM;C0<;B,^L^&26?FG'W4I"EJXI_4J$1QIX)`]+L_A>%$GD
M<^?90(!)/V)\>WGSYZTBHC5U7VMRE+>E^FA?R37*UH;4.6PXI`(2">.XDCL_
M3D>/K,9EM0G;5#+;:8J`XF(%)(<:*@DI[P0"ZGGE/)/@'WX\=1$?LL9TU*G)
M*)SWKEMU'\1I1(4EE#O)^A!!"1QP0?;4P):?FMMF8L,1@H=K(3PA7OQWJ4$E
M?CD)!]C[?<:1/@RUZ[+3W([%,H6E'`3V)7PH`#@$A/)')/)/G]-12O<G54R+
M909S\*;`?9F0I45U3$F-*CNH<8D,/-J"T/-.H0XVH*!"P"".==>0\F%'^888
M5(CLK4)/HJ[WH\9/\S_I^Z0V"%*2!SV<J''&HJTAMYM+[90XRM*7&5(4"E2%
M>0HJ_EX5]O8@<`C2)L(]`76E:;W-2MKMT9;#FX]+!$RDNDM(CG,*>&TE$P2F
MFPEK\]K4AN1(<:2C\PBN.R5-(?CO+?R?:T_MFLWM-M-U=OLZJ%EN7C>45<Y2
M4J2VEZ(M[Y>RC.%27$%N57OR8Z@6U)X</<.W6WS$D(EQ8\IL$(D,,OH!XY"'
MFTNH!X\$A*P"?N1I$[&FFFD1III[>^D1IJG.-;P;4YGG&>[9XCN3@V3[B;6N
MT[&Y6#4&4TMOEF`OY#!19T3.8T$"8_9XX];USC<ZM:MHT5R9$<1(82MI25&H
MVD1IIII$:T//Q<\!4WJ+Z3D(:"D-;"YZ3QV\`JW!AI2/J*4IY/L0H$^?^$$;
MX>M(+\57#^?ZB>F*.VUW/HZ?\Z65)91(<6T[N-6I[0RX0%^CZ:E)X^K^*H)[
M23RB:@.!;7QK^"[+=*$N*?0V&U-))2DQ5MI!4I(6HE`Y!Y*?_-QYU=3LWL37
MN-V"9<"MFI]4>F)L=B5VCL)"4^LTM*0/<)2K@`<\\GG45VKP=E=(E;4AEPN/
MDN(8B/09#2^%(4B1'<4>'$_RCM40">1R.>;P]K<+5!:>*4K*5NH5P%<$#TP"
M2#R./L3SYXY''W2`#B8[,WV*CM.W;L>N:0F/,0ML10EILH+BDE*4)"4`>>2E
M('/`'`UCOS/"LRK+VR8CSK9B.B5(2SVS5J0VSW@);2CTEI#:5<\<'O424J(`
M`UGZS3#W$1[LJ;/#TY"4`'E0'J$D`*/N">2>0/U'CQ8IF>W`E39)4V3Z;K@)
M2E25=JG.2%*"2%#D_2H@D#P`1JV.3BW0_,OO*9^&9U:XTV)7?D1$;^7K,6WY
M7GZ`@?GD]*VW$>D>]0^APDJ61PIP+0I('!"1Q])\GS7O!\$O9L)2[*:[,6XI
M@J]5U!05!OPI0;``4M1*5'CP5<J)(YU<.O:IA8>!8)"%\I)3V\#CRDGZ5'D>
MW!Y!\:KGA.U\5B$CAKZ"EH@'C@`)XXYX'(XY^G^8?<>_-LO$<BJQ/.CGC_G^
MOG&/A=*+DM=JQ"^^@+]+XYYI+6U;53BTA3;RT.N#W2MP<J3R`D$`E7:2!VJX
M)`[O=6ITP7969*>!G.29K?;.<+3RUNCN;8<2A"!R!PE2NX)(\$D^1P-7K0\)
MC,IC'T@H#D@<`IX^_"N`0D@A)//)'GWXU/\`B./HCR%A+"`?E[#D=B0%?PU<
M$'GSQSQ[@]OW]N<YI7'I^?7ZRR#=;9!7[M*]%=$7&E&VB.+EQV0Q(=2E#O?Z
MCJ`'5H4>$J2KD%*0%'@G5&<.VH11T.0F8UZDF5&"TJ>)6M"4-O-%QLK+A:4H
M'E2$=B20..5#65+="$$X;%9#;1#;[3BNT)0.X=XY)X]_OQP`02/ZZML32(DT
M=FH1RZ\ZRAKZ$I0$)6M?DDJ^HD<D<<`<'D?4-3;57IY)'3CU=='557W!\O+C
MM-X+\+;CE72_#-F28D%IB=;=1FZ;]I)]-/S$MZNJ<)JH1>=[0XM,:#%::80X
M3Z*2M*.`=;(.M?'\-$PF)\.6SA)X!B=2>\+*D>?X:C#PMT(/N">QU"R0>/J_
M7G6P=J):----(C3332(TTTTB<'V_O3_F->1=\6K>2SP_XQG65`OE8A>83C74
MYO%#_)-P<)A9MBE?5;BL4]?F(ETC"JZVL_FD^C.9:9NX5C&LH4272SH$IKES
MUTC_`%_I_GX_]=>7#\=ESI0QWK"ZR<4I<!Q^YW2W%ZEJ[-,\W$O<C_-,_P!M
MW785GC^3_L-C6-W26K'$DL53=Y?XON"8T@WCU.U65]?$?CV+^GAH9;%LHHX5
M-^GSF/C#TB9=/2WS5^1P\M:F(GJ-L,4Q_:7:#;O#,ONMWL*AS[RVV\WBRK:B
MMPBY54OK83E.&89;/9':[DV.%5.5ONL*BYM"15Q+!#AQ-9C.25FV/(<>KZ^H
MPB35-LNW-U3?,W-6W>Q<BFF=8SK*)$LXL&'`;301Q$CUE0]CUG-D9#%N&Y$I
MSFOMJ]*(Q`V8R3*]U&-H,;JLKN<GL;QZKQBHE85D+F;VZ7H\JVQGG`*A%OD,
M9=U7AFQCUD+Y]$6),+SBW&$KDC(7A'1GU$]4W4KCO2[DV[G3_"R#IPV)Q)UB
M=0Y/AM70U6'*AQ\NK<-J["/%HWLIW8KIV02*?)(=ZE[)JW*&)D"PE/BI+>M[
M,#'8\YJ\HW5!YW7WYT\CCEGED]+>O#`V"57O+U;+KJUNK[S*UT8;H=-NV_PC
M]ZL3R"HS+!>K/9_+[_;G*(%A"1M':6EIOK<1*>FPR7G=W5VC,=S),<8=K)Z)
M\*GR.+$K'HE#(HH)F61S$=)&S.T^(XQANZ&T^'0\]WKL=U*O8GJSG[O._O&W
M+B8CLXE6/9%DCF35V<Y+`P)BH774PQV;1S,APW)$N4#+4*,I;;T#%[L'3Y)U
M!?$OZT.F+>'!9^7[14NZ&QVY6<9]/9P39+'(-_T]U<.OVYRC>.`[%RZJOLAS
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M3*R+*,0?AY*G%%R9#P?L(3+",O\`E^%MP5X]"3#9G1D2E3Y,AV*W-=-G'9Y+
MCDMPJ=CRIG<B97H'HJ:=8=1RHIX59EOQM_U6RYE8_LQD.UTJ$_=;9,9%B6XM
M*Q,K]L*BLRQVRRO=+%W0B6U>[@2&'?G*NJR)E.-1F8;*5I=M"75)"#S^4B?<
MFE7M[T66VV?4!TO[M_$NW6Q6YQ&UWU=VKZA-M\SS&WS_`'3V]Q;"JJ17T-[O
M!*E&=`H-G+B0Q456.9!'L409M)85\VMF%"W&XEMFY6>XAT5==&Z>6_#[RB]?
MI=M,IW>J[>%GZ<#R?;^?BK&22*^/CM/:)LIU=NMMWEN+*8=29#$#(UL*6S#5
M-<:8EKW(?B<8KM)M5T"9MO\`;F[.8C>9!MMF@F8OMQAL3(Z/$MU(V1[GJ:QW
M"M[(U(W"M\FP"V<LI&2Y-BOKQ\:QW*K$6%&DA+,61H7Y'@M3U';B[D6>PNUR
M-M)#%+NKO!EFU$K(:V-BV#4^-S+3(9V*[7KO5UF03ZJBQ1Z-"I\<FIF93/EP
M9BHB'8Q])G?PURYUC73V<>1+/0:OMK9.;Q,<<`QQ_4HE=3GNA>H[J;%WMIK5
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M#%FM%/046<BU2/G5#V.`KUWY<U.J-E+TO8&M9+;0II*RW=U*9/6;$Z9:3XU=
M4542;.FN1JBO3.5%IFI4M:F:J$JQ?D30Q7-OMQ(_SDB1*#3;9DO//E3RX8Q*
M6^\MM##GI)Y[7^%)"E`@=O8L)4I7/=PI'<DI`(/DZN0W:O\``+?;/;H8?TUV
M>S3*K.PL*[=>SR*ZR)W=EEJGK*O*6YTNQ@1*1Y^LRII<^#$H40TT<6R_*[)B
M9)2Q/-OADF,UZ(4.Z46VO52@E;:OJ\+'@`+[>5I![3R@#QX`5+JNU+Y:Y+O_
M`)9&12@"M<71=-FC8;?J4\O3?<5&1WM,+>*W/J2E83P2GRKZO`![?(''))5[
MDDM=IN.\$A)49![0H'AON`\@E?:0`HJY^D@$#CW'G34U^6?GYZ,J./<'UM++
MQ\T\ZX_ZWA<%GB=30`MQMQZ.DQY2&NTA1;[U)X0>2A32EM\+;Y;6%%)Y*=54
MBJ2M*`OM3X^E7''((!]^0!SY/:?/Z>=6K[=WCM'*72VX5"E'AI]#[2TKBRTE
M/KLO=W"VBKD<CSP.>X)U<M$D!33?IE*D.$.-.)4'&5M^!]B1VA0/`/D'W]SQ
MY\]:3M6K0EYOY@]S;8[R@'SW``]W!Y)41^O''!X!(.H^PGY],AITGY5_O::6
M"`^T2@^FM/'\-/I\%:NU*>X`)Y)(YDUAU))4".XK4!PI![D<@D>#S[\@?5]Q
M]@=336OI42@%8;((2!P/XH`!'=SP4A(]B.>?;[Z1/S4.2J]+M;9PG7%H0XAF
MR80A<.:R5$(7([R.%J1X>0K@`D^".!KM8[$?CUZF2%,QS+D/1&W1_NV5*^AM
M*@#R$\GM'D=O\O(&H\VVRIHE:D)')(0?J\\)(/`!!"SR3]@..3YXU$08Q9?[
MTN)#:4A"0`.>/TY(\`$<\%)'!X\@<HG190X'V2@J4Z5?P0E92M3@2>WCE;?:
M>?"3RD_?N2?)W'L5*SC./%U"VW#1U!<;<4E;B%_ET;O0M:?I4M*N4J4GZ2H$
MCP1K3^P*LDY1N#A>*QFP]-R'*:2G91V*=26YUK&94'&T=[A!86X'$IY44`E/
M]-Q>)'1%BQXS8`1'8:CH`'`"6&TM)`'V'"!Q_32)V----(C6/;JP^*K\/CH@
MSZKVIZJNJ#`MF=P[W$8><56*Y+#RJ792\4L[.WI(%VDT./VT9J)+M**WALI>
MD-OJ<KY"O1#80M>0G5`MU>E7I@WPNX^5[T].&PN[^4U].W0U^2;H;/[>[@7\
M&DCR9D^/30[C+,=M[&-5,3I\Z8S7,R40VI<V7(0REZ2\M:)I^]`7Q@/AL[4?
M%V^,KOWN%U9;>8QL_P!0N0=-4S9?/)M?E[M3N!'PS;6+1Y,Y3(A8W)GMIJ+-
M*HLD6,.$I3B2MD.('<=N/I3ZR^F/K@V]MMUNE/=_&]Z=O:++9^"6^3XPQ<QX
M,#+JNKI[N?1OM7E953!+CU604TY2DQEL*8L&"V\I16E&M]\.'HYZ4<E^--\<
MC`\MZ6.GO(,$P'(^E-.WF&9'L?MQ:XCA4:\VGB6-JG#,>L\7?IL;9N):_GK%
M-'#AHL9"OFI/K.'U#M,;8[0;3;)XZ[B&S6U^W>TF)O64FY>Q?;+"<:P+'7;>
M:U'8F6KE)BM94UKEE*9B169,Y<94I]J-';==6AEL)1*BZ:::1&M)+\5#6O3>
MH#IO<C%"WT;!Y='2THJ00I[<)IUMTNC^7M$9P)`/\WE7"1SK=M)X\_\`O_W_
M`$UI\_'5;V\ZM>H>@V^VWOV\CS/9O;>3CF1MPV'G*=B\N<BF6BZ--PRA2';"
M%$9!F*BJ<CPY2C#D._,-OM-HFL)L0U-AT)79MN(=,EP]DJ0VN1Z3:2D.(4ZX
MGUD*3X24+=Y`YX'&KZ-OK&N;BAYU/H-.K);4ZTXA*OI^@A024J"N/8*))]_!
MUU-I>EEFKPK+8&8WEEC.75!BNXG56$5-A6Y,VJ06IT1$Q3GR@?2VKU&W%H`[
M&E)`2LD&L&+],N1L8W:V4*55NO0[2,W$B-.NU+SK#K87(0N1'48A=;<[BRI3
M2(SZ!V@H6D]R)1C-TUKL9Y7K-A2YCA+?<A)X'\JNQ0!*/(`5P!['VU9=EJZX
M3)2&D(Y]4CU"IH@I)5P0IMSG@$*Y'/'/D\\<:R79]L/F<B*[&J,HFSHS4$/P
M6)MJRRM4SM29,"-ZHY::#P["_P!RDK:2%I25'C5CUMT>[R7N499%JER(\ZE8
M;FPG'IM:S2Y5\RI`3%K)()=3)CLK<5)1+8:0'&2A*RI8TB6^AF(4D*4WW*()
MX6WR/OR023Y]@0!P?`'G@UDQ>+#3#8(4T#PE2@I8!_D[0..2.#SQP?)\^!XX
MATOIUWUI)=KC5A"^0BQ/RV=7W=E44+-/D4.:XELR*ZQ?A-6S;L%*EN6E?):9
ME15(#*FE..-%=5\/V$W)5;RZ5I#C5I`FP4HM)<6L313XSY+;TV,^I!D/-PVP
MMR0V8R%LI'8X@+X&D3I&)$3':47&T@E*O"T#GZO(!)Y)XXX`X'`^Y&IDQV/%
M^9/IN(*.QU'!X4`M2O*!VD@E:1Y`^K@'QQSS4RKZ=\ZMA?*8F9,B_HKB/']%
M<2DCUMG!#"7'+BELT!9M83(2&4PHK1FAQ2&W6$<J.JFGIZW0HY./3K2UNKFK
MF6,>MLJR':M5$W&?50TY^92("H3)>BI6YZ"9B4>NG@/);>9_B:1+8]S*F3*I
MI##$*0I3:^1V17DI3PGCE2E(0C@GD!/(/U`GA.J!.8-<(J%MO5D@=ZXJE*:=
M;>2A"BXOM4XV[V=_8DCL!)3SQX)XUDXRWIW-BNTKLLF6*W(C*)"HKEA.EAM(
M6HO)?L'76OFUNH]%QN0S'2%?Q$)`21S0Z^V<OH,.%^SM3.?QVJKT/V<UJ,ZF
M'!['RA#;\MX<J>]/M7Z;?>ZHJ`\J(&D3:\_#E5KU7\/RX8>0A'J=1N[,AL)'
M#GI.5N$I!D'QW/%2%<G_`(/3'VUGMU@;^`GE^(U/3/FNTBLCH6\PK=Z\TR"+
MC/S[3-_+HK3&<(?5:MU#[B9SL1$U$ME3[;*DI2TI;G8GDZSR:1&FFFD3%Q\1
M6I^+G96FU:OABY7T<8Y4-0<L3N^WU3UV<39TFP4_2'#G,.7B-=8-)B-QQ?)N
M430RX7E0%,EQ/>$XU_V6_%A^?^U#X0W_`.0[T?\`/'/\]9)_B+]+GQ#NHNRV
MJD]#7Q"6>B"OQ2%EK&XM<[L?CF[G[PYEL_1KQN:)-W*BNTG[.,P;=@L,%;<W
M\U#BNQ4?Z\:?_1C_`(@3_P"_XA__`++<!_\`Y;2)FHZ$8/717[$ML?$.N]@K
M[J&.99,XY.Z;HN1Q-N1@RU0ABC!;RB%7V1R!L)GJM5)C_*A"XC;3KZT.NJO,
MU9CT'[,=5.P^Q#>!]8G5.GK!WA3F>3W2]WT[=5.V`.+6BH)H,5&,TKKT0BA]
M"819+69$H30TYRF.A2KSM(G!_P"8_P`QKRS?C)]!.8?Z4OQ+.MK-,XK=I<('
M4[?T^SE+D^/39[W4/FK\KY>WQC"K2G=EKIK&HKZMV>U(R>M8I;5$::PBQ87%
M;+OJ9Z\O#XB`HMQOB;?$ZV?W&R[++[;W$M_[O=ZK^>NHLK97:.YBO89639>>
M55Y:U60P*"Y2]*I]P[';N)97T?&TQH^.,+4J?(%\%&R]5=%V=05^?*9^*&6/
M2U>2AU<72W]/3^9B]SV5N)9L],VTNP5_CF^&Z&.9!97&';F;&_GE+OY<;L[M
M5T#)+W;J);0+"NR#*:G:F12-5U-E<&.BF8GSK.DC2F(:E14]'+MZMD\HV&V^
MV>L=BI.SV\6R\?);)>[6&8]&ML_ZB]X\AS9+&>C='<#*K5BSQ"#AT=J.NH;J
M!=R(]ZQ9LRC7Q+%IM.1#?167=`N[O1UO+L7FNRF]6RN`PLPPG$^IW`>EV149
M985JH<XYBEYNRL6IF[+NSV*Y!-FU6X&.6$2JB_)(I+J[D6*93(DE_I1W#W#Q
M#=SJSVY<VWW"VFZ;Z9G*+%W<K+Z?<[;/>7J0ZCLD9;RB1BVV6,!NMP>;>1KF
MADU6W%M*>@G+:J$X9"Y3*V6;CC0/%*-I^YUP=G8=E1$N8."=5*I1D)U%5C2;
MMJGWMK0-U4D[IFQRNFBPZ2\-B)QVSZL]Q=TL*R#/<ZWVH!`VSQG&8;-;/:W#
M8B5LZ-+R*5+#-EBV72;I5?9\*K\=8%U<NR$;AO3!C?4QL#6XQTN97LYM1<5^
MWW2CB6(8+O\`3LB#^,[I;E1[+(Z1ZJ8P1Q#F9Q<92I5!<99(6EJYHX8FN21:
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M\KX5M74L8UZJZ`[!LK":_+7=)C&:;89AC=;<8%DDEFDR*%/E5TN,+F,JPB5M
MJ(=O:(K+N$TE#E;/1)8?+7$B$\''6&'&VTK%B^RW4ETT6'4;U>[0U.^NV]UO
M;C.0XZ_DN*X)B.,X9;4]U)IY5D_7[>W*I<G)=T;2:EEJ#EM?82+1VJRQE^!#
MB0D28L-JZ/`!NO<8Q79EN%@\K;Y<2#D]C#Q9FP:S;-L%@VS\IEF!0QJ:&S7H
M;O,<;B2WZ*7)5D>-2Y4FL:>EKAE`SG1*E8C!AY;6Y+1^B^ZR]6V,3';!3:E,
MQ&)T-TU]K(9?DHD3K6)8K*93D629?R[KJ'U,-.J4U`F<VQ^1FDO`;%>0U.58
M)A+UW=94]77M/26K$JMC8J_>XPZZ[)JKV512'PQD$=I4@4,B55R'@Z9\=>K*
M<MZD]S-L<&Q]&7["6:7(FX.08QD6WSF25+6X6\&#(+>/Q\EV&G,OX]16ES-=
MLJ:^5C3$Z!?SEN/T;(BSF7Y<NFG3)N_N%DUYBL?:["=U[[`NG=&[VV^4[B]4
M&3VUKD601\^:5<UKF+98]%6[E4O99--`J]VL7NHK4I$9RKK::XM[G&Y$A:)D
MM2\W5;67VZ$'(I>XJ<-P;(G$Y94S6K.TR2!A%=(M+&4Y!CL_LY*R)RRJ9C;:
M*VL1Q,0F(A9^M.L9'3[\5?:W?#:=C?+<S`]SML)*T8K07VW-31VN12XV$[NY
MHK&=I<LO5TT1DR$7,J&J[K+ZF<CU=)&D3_FE.>DI@W=;O=0E;L#LQA-_F$.%
M94V<8[+J9M[BD2GQ7:RHA7./3\@M\FN\B#;N*8VJ_KV[IC"6IREM7=T(M*\M
MN59,R'\*'5;U==073=NK#J=I-M\5W.Z`MY>F;$LIK;V?B[3-_M9MUEFW]I&H
MJ"-74-)/L\+I,9EQK"9MS)S''',7N<IO669TVL8KWI#:0M?8JKY0'6Z._I;V
ME9MV=G/A]?$)ZJ<TM=Q]^LRK-R=G-PZO9%W9VFZ@9^VF-;IUF*+@6.`93BK<
M*-+I,FR;(\DMH&/)L\4DN-5<C')2+"/^T<(MC2\ZB+.SV;Z@^K/;6>C:_/LN
MO,VS*KL<_38/[O7.`O6-Y92+J-0[DV+&/J=RZ"W)=QC+\@F4:Y#]K&GR:YF)
M*=^93L7=#6W'PV<3VMWSR#JQJMU;BKVJWESS8#I$;ZH]R\=A0,2BY'@$3<Y=
M!MX<3OI.!;>;S.V3\C*\ASN+,8@XO=3Z*QK[-%TJ0M&$OJTZI\7ZA>GW:&1M
M7T08+L+-V%SQ59GW4EM[45TZ9G-O(@I9P2AS',8-3`+%RK\JM,HMUWBK:1DE
MXH6T64E++ID;>'?56W'7.CD3OPZNKT[)S>+3B)[N=N58EME&VJT+RFK2N2VS
M(>D;<F@V(7U$/9?M#;[:%O"(,IJEW#IIN5M9%E\21-=P^!B$V4WD5E;85$^0
MF9VU51':S''+FL:D3'I"I;;5%',VB?LWF=)-VUP>PM,DBX8QCF9MQGJ6[P1W
M$'4M6+]+'JGT5$I&9UZ7*[+_`,SARY=O)^7N6W84QIU3M_LS%>EK=+'L!VFV
MDV=W/SWJUB;JX1+R&U$2RP!&^^T$S&XCDFJP_#V49!6;29._.LW;O/<YR9]=
M;<5E6UE\>R:?M78$:RG?Z5LS+W1OWM@L;R[!=KOE:9QG`]P[J#EN88OE'Y<8
M6;8VQFD+Y2-DU-$R&-8O4.1F)%=FP7&E.L-+B)<=VQ;YN^35:'&NZMZV]A&J
M289XN%Y8N-:Q1MM!Q4*Y+#E`;-;D4W!K<7QK;3&]O\@D;KU>]>*Y'/DYA@UU
M9X_>;-,8SEU/7WU%E>&R*VV?FT.8V(D0(-]418,NKM*H1+5RVBS4*K&J!%)*
M%!)4GZ>P*"N%))!X()Y//@^>#_7W'/>@1_S%Q,2H8E6,Y]34>'75L9V5/FRI
M#H2U\NPRT\_,<6WWI8C1VBZZ3Z;;?J!'/2$.7Z:+)R+/:A//2H4:0\PZW">D
MQ"U\Y':=+:6URXI6T9+'J+>80ZA2TI#@`OB5>[;MK6Z-US7E_%J,S55:<3&@
M[\4%\=JW7!WJ=<LH`27''.X)2CO#CJ5*X!Y[E-D=W<?/E`XX'))TU,5!BF39
ME/=J<3@2;2SCQ'+!^'%5$:<3!;=CQUR2[/?BQRAM^5&:4VAY3Q4^@ALI0M2&
MIO$Y0?IZ>IY_S7G+8XY9`_\`#K>/EBGK]_._0J^+[TK6_3_U-6^YU-6>CM;O
MQ-?RFAEPH@9KZ3-6HT5K+<7=3&99BQ'5R`W?U+0(,F!.D-L)/Y;+(QX8=N>N
MD9:K+AAR7!0X"B4RM(?CI40/3*5>'&R05<^Z2>WCSR-^C?+8_;CJ)VTR/:?=
M2A9O\2R2-Z;S1*6;"KGL\KK[RCG]BW:R[JY!$B!.9!*%!;+R'XKTB.[IT=9'
MPM.H?I@R*UL<7QF_WAVAY=FU>?8C3R+*?4U_>Z$0\WH:]#\ZFL8C(3Z]E&8E
M4<P%#S4R*XM4-GSYZ<I;099C]P4NP;F#V+>[&V7WV8LE:EJ!!"'G$)()Y0$\
M]RE>?'MJH,1\E?:5)2X$DMJ2M/"E))`[EI7Z2B4^X"@>#X^QUC93ZK:SR%(6
MEQ06%`AQM:"4+2M*AW)6TH=JPH=S:P4+`4"D3+6V=AV):$R<64D%*?FG"@'@
M]I2@+"0%#N'(X\>.00=(F1T7T>MY=DRX<;TP"?F7FG`KALE*%#N[NW^XCCC@
M^/,M2MQ8SH#-6VMYQ06AQ_N[F$E0X[VT<<K`'D=X2`0!SQ[6@5JW77`IUQU2
MPD$E:E.*/``))))"0%>.>`!^@UD>Z..BS=CJ9RZJCUU-;8YMW%?0K)]Q;.LD
MM4L&&RXAR3$J79"&F[J^D('9`@0RZPETB3/=8BH6XI$O%^%]LO<[D;ZUNXLZ
M#).,;8\Y!+LG6E"*O(G6'H]#6,NGAM4DO.*LEM(*E,L04.K[4K0%[-`'``_0
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MQEK(U_2-$2VZ\V])W1QT-AKN(<^5QK,I?8ZE/A3:%-(?*5`I[FD*(Y2"-,:B
M6N)E%).B+?9DP+N[G*<".WT9,+!7E)DMJ;/<'@XX4MD<*0%K\@'@HF76KLH]
M[&KZK*+#%<FJ)3JC"<R2`W(@3'>Y*"\Q81(TAT.?RH$P/K^762DK*5#52;G:
M/:"?"K'<(;G5ZY#*DW3<+(:^/&CV;:PE:X"G9;PDPNP<H,IEE?U%(;4C^7&Y
MT^Y=>USVU"&)SSD5&RN:SOEG%)6VV\J?-=$AA'TJ0\V02A[N]1+B?I*0$G5R
MU'N-9+VLQ22_3TS[E?93P.YM1^=0]`I0A4YSL6]*6"TZXA+CI3'??=4V>5K"
MD2IFX^S%1B].U<U6[D6;,>;"SB:FX\Z4R>4`!#S3/RB7$GW*5A'/("S[:MO%
M=?M641F!&KY\N0V8SUFFFEJ])E:^?4D2(TMI3*VP>U2V>%MH!]-22!JL^1WE
M>;_<"OBTZULT6-6=W73W?DRX^ZG\I"*YY"(K#+4$"4L-2&64S$]@4IPJ4>9&
MN<XQ>'74-PG%GH[=I%RWB%7.H]>++@6E=#AR?GC)1WJ_VTOJ;#++8#"F4-E+
MJSI$C,CI$W=FTD7*'\_QRFI+"0IV*Q*IG9KD=Q?E;Z'%N*G+8=`"PMQ2E.D`
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M$<*`+O:Q4/.S)+:"H]RXXX;225]J?!MPS>BQ>/`E8WC$]->Q81)$MZSHJDWG
M9!@*XGRZBZR,KIVIK*0CYB0PQ/?C`*4J.$H5VP2[W5NT0MLETK#D-8W`EKBM
MKDETU;+=JB.*F&ZTW&[:=Z,7!(A_5\QW'U5CD)%DV99MDUK=(:E6<OY2#OG?
MIAQV2IMB"S.QWMD1H+/("(TI(7Z['<IM:U$D<\]R)?=-ZC\=V]FXW)H'Z3&[
MO$I%3<5#>'\JRK(K>HKFY%-.OK^M<CQD1;,,HDVS<60INVBF5%]-L%3&MR';
M3)I>:[=8#F-A&8AS\LPO%LEFQ(Q48T69>T<&SE1XY6XXLL,OREMLE:UK]-*.
MY2E<G7F[X(E<G*,,C.)6?X4.,M3BRZV`)-XTE(05`I"`I"4H/T@@!/'@:]$S
MIEG*LNG;8R:II+"G]I=OR6DJ*P@MXQ7-=H40.?Y.?8<$D<>-(E<M---(C333
M2(TTTTB<'V_O'^//C]/OKR^OBD91M^WU-?%:VNKMQ#:[G;U]?*:+'^E[$L'F
M-YIF%E58WC5)2[A[@;R.U-O\AM=3Y-8.S\>VXQJ/%L+[+7VWI]B84);#OJ"G
MV_O3_F-:+6[N_/2[2;W_`!8>GO`H6W<+XCVX?5CN0[M3-W5Q&A<B9#*E7>'6
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M+6,^#BV01*_&:>$_/IK*M$6*_=9&X]ET^P<1%E0(\.-#5JC&YN`SL-N*MMK'
M-U*3')6*8YG->=T,.F8C?2DRZ^)`OKE%4%>@[BL?+V+6CQ_(1P+.MCPWI8:D
MN+CM[XX8(7MR%W?)0U72(WKOSS.?Q/$\3#]!6)H:<DL**;>>=^0'GM)8!\7#
M>#JAVSZB^J+:SI[Z?=H>KW;';#&*.;D&-9S)L-W=\W[?+F:&HI\+VKM*IYS.
MW,>QJ?;2X#4R/;9'`R$U\VB3,KXBZ[6*?J=Z6^I3>1F+U?=-&Q_44[T\;I95
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M.LC`>B;87([RP^'ATU9EU?[(Y)LC<[:]8&\>&YGG&9X3AM':(Q?(;*TPS.JY
M<^!2[N(BTZ<QS'(0U:U./2;*-76Z(\>;,A#'/AO5?T47]-ET;,MEMP=C<QQS
MJ$V/S7IMR[8"'BL?(JS9'`9T*)EL;<"PM%(HMQ=Q:ZDKH>6T5UE-3)I[7-TR
M[%B-"<FN.+JG4/NU55D%9:J^K$5KBN-;W:-L7H>GK`!L6PQ.GIZ<D-F(G#O5
M!LV%?BJ8QE<#<&[R'>'>/I<.V.T>TN4YMLELCNY@^Y5%N0[3YICLC$E[CG<K
M;_(DU;>ZMCN12.6>W#,R2FTD9'!=,MBL6\EAZ1>CGXBO6AU+T&\F^LMR!CD7
MICQ;;:IW&Z1,1V^HW<SRO::3AUC*K<JV@S?<F^C70W)SN51Q8V<G(HUB;/'4
M?.8HW-L4L19&O5UD9SU>=6V;;37>_P#FEED5K>V-?MSTV4N\]33[>;A9/M'F
M643[G"]R92H=-38$YC5M*?A1+[,I=@A$+(Y+87#C0`W*-9^IC;GH3Z==E<-V
MTQZVZBMU.K^="R/%M[6YFYB\+QC9;=K%GZA-'$R")0Q,C1GE1B,M5E"HZZHG
M3HMG33G;RHO4#THC`Q*!IR:JNQKG8(CRTWKMM[1<E#HQ-9=60.2U5<[-=(ZI
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M`]/];5TR<WW=P.?CL-=$O.(#5/=Q<44O<F+$GVN79O!>=D-7EG3+QUAB._+6
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MIW,S(L;,[K'("M7:'`8UC:!2U95,N6P+/.LW:[?/?7->E7:3<'I_MY=9=9#N
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M8K0;VZ-+1?%[O7?<KEO7AN657ENJ+IUBV5L-T#5`@R5>F#%\":W9VL>Z@,)W
M#D[1-;HU]?FD#:MV:WO=?K5B<FYQ_$\0QF.\K(/R^Z?74OR;R'2<,QK!]Z+,
M6X68BY1WYI*>\WPW\7L?47CFUF,9#D&7UE+80'J&1B&)N3*Z'(8E8O9/L3HB
MZ&QG1L?3Z45<VQ89:GN1HS9DMQ>OL?OWE^Q6_.$]3%&M&1YO@\UVSCQ<DFS'
MHUA)523,=A1+>>\IV<]4-UKZ(S\-IU+DR`VU!BNP&5-.IZ&Z6_\`NSO7EM5F
M&XN;/Y#;T,>5!HYPIZ6NDUE+(L9<]NA9D5M=$ERZ^G<E.1JO\V>FS:^(K\NC
M2?E5.H;'49V&D[NAO>F^VKT.D*(Z_#]G7[G+WA,KT8V.39KD_4+54<4;AN!+
M;X3_`!`X^%J#O>%MK0V$^DXTH)"'FPHH6`5`$<@GN)TU]'E\*4OE;G<KQY[B
M`1SX*E+(0"#VI+CG8"$)6I"1PUI,:799Q^[RZ?4.QQ_SOW>-<$`^X!\<?UX/
MN.?T/WUSIKSYZ\LDWG^'3T<;\V\S(\^V4QW]J+`'YW)L6D66&7$QTI2D2)[F
M,RZZ)9R4A`[7[*'+<Y4M2BI2UDV7V'P)ND)^P,JKRK>NEAE2%?ED;+J25'`"
MB5(#T[&7I)0H$I`4X2G^8$J)4<U>FD3'[M7\+_HLVG<C2ZW:&#EEM%3'[+;<
M&QL,O=+\<*'S2:VP>%$P^Z5%3ACU322H)[4I"!J_F)#B0(S$.#&CPXD9M+,:
M+%9:CQH[2!VH:8890AEEM*0`E#:$I`'``&NSII$::::1&FFFD1IIII$::::1
M&FFFD3$]\8BB7<]+].XWZBEU^X<9X-)2HI6)&'Y=&)60H`=G<%))23R>!V\D
MG3?=J5U]T7'6D*](;@@A:%*[7(U`U$2I78I/`[N4CP>"H$DZW0OBG6JF]F\.
MQ[N*F;_,9Y=8[4A+JJ[%K8LK6X>5I$=R<'0A*2EP^'"D)'.IYF.'/Q)%Y++3
M2O\`JSN3:K`!Y++MXW7H*//A:NU2$]H/T\D$D#2)"-G668TK!%%"T_*;`Y*5
MI"TH#:I#]BI!!//*??\`7SQSQSJO5<[\M@N)UZ&T-L,S)"TGDJ6OZ*0]S@'T
MA2B5#RDIX/`]CJE&(4RZN0^5?0JIV,;8[1SR$SG'TE*0KW(]4A9/!\\\`D<5
MEIZER134L0<=Z,;:N5$\E*N458">"%'N*>[GM(!(!X/'A$G/(O3.8;J]J1P<
M(F#M2ON'J/.TQ)3P.`$J'D!/'V'`&J-WT=(QK#^2#PUEW*/NE2\EIT<'@^RN
MTGG_`-=5HEU<AR?=SBDN_M/C\F$DGW^F?`0">"2/]UP`"!Q]M2G8XE)=@QXG
M:`:X7:.220/F+Z"^"``1Y6A*//W`X)Y.D2G3L11L%I!'<J5D([P.2>ZT:"O'
M@^0D<IY_OXU4W!&2[E<YLIX/RV4\_2">[\N<')XX^_Z<^??G[=9>,."6S(*2
MD/2K92..5!27[!*U<^X\+\$``\>W`)YJ+@M(ZQDUFIT<*^3R`#N1QPMV$I/L
M.#Y"AY))//'//'")+UF`86*<(2%1XK92H$<+2)D5?''/(\I2#SX''@<<#4&F
M++L_<DD!M<A-H%`<J"U&P]=7E(X*>`GWX\_T\&IRL6F64:A4VSVLML%I:P>$
M^HMQ3S:$?;DHBJ/M_*/ZGGI.818./3I@8"49+,DQVD]Y/<J6I^2QP/T7'CK7
MP3]N`"-(EO5Z78\/#U*0ME==G2E]I)3X=LH:O'CZ4_QCVJ/((\CP1Q;!DL(N
M7EBD`\-[Q27UE//\KE,WW```\*\<>#]0)'&KSLUQV6S7../-K0JGW&KJV2LC
MDI<?FQ?32"3P>X-I']A'('()M\RG%I"+Z_2A`2J'O1#:_F/^\D5+B0"/)\=O
M'!X!\CC@:1+<\#@._M#BKZ65\JD,K0$@@GB^L6RV"!R%!#O((`4`1XY\Z]"'
MI4+AZ:MA_5;++@VFP1*VE>GR@HQ^$GM/HJ6V2./=*CS[GA1(&C5MQ@<D76-N
MR&4(^3N)(5R"2M,?)F$N)X('N)7'D#P?<:W?>CCYO_1;V)$YPNR4[<8\A2R7
ME$MH84B.DE_ET]D=+2.5>#V_1]';I$N7TTTTB----(C3332)P?\`F/\`,:\J
M[XK/23U<N_$LZR^K/;G'Y>(X95]<LVDP'="XR^KV\A8[E_KU<BGR;'[7*5P:
MC\KDW-<Y!E96N6]2P;MA598);E+92OU43_S'_J1KRA/BX[S[X7GQ$OB(;*HZ
MIV=MMK-N^K#+MX\6VTS6YR!O&+W.J--/*B1\7KZB@O6%9+\W%CSJV+;F!CSU
MDAA^0X)"WGE7\.[:KC=EB6:UY\=M6+4Q\9Q`OJVH=-'!?+\M5WU,9VYK..;3
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M1DQ&(BW0&-5`GY;MNW4X?BM4QGV-QTR+G&=],AP2[,G'-WJ"ERMZWP3/<>QG
M(C4.QK1IIXA5%DS0K.V#6V<-B!:+G(7+&,#$)\B!+S"FSG(\ADRF:JMQ[&9E
M-CIM&5T4FMQJQAS_`)67V659E?Y*U(JVJEV-<U:7D&P@SI#2E1/.>GW>G"HN
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M?KQX(/H+8F^#J>^WJ0-A;S;_`-<0VF)U>Y@.58V9%I1DF.VB_+CCB2_+R*WN
M$4\2YR6]N(=%$-=15MK?V4^-509+R93[5='F//\`R,.1)_C/1X@80ZXKU6P%
M!LIR0=`D>^PC?"9OGM1)VYF[Z=+UA/W8E[.;GY)1U.VE]MKAF/KE9M<)RV_5
M8P<FM4UBI5:**E>BW;-I94]M13+)4>7!;QITT7YE^(W6UAN)3DIR-"@0Z]^T
M=L3$4[(?+2(X<F27"RP[ZK2$(>1%2I9*/HYF7)943*[3,\[JZ3%\#J;&]AQH
M.W^.3Y9K*N-80Y+@ATE1;29ETY3,F"3)=LIDWY20_$9?6#(C)1.>-ZNKT\O*
M58(;WOF^$[QAETKD]65)5]T#?#^G2[.GR0UD/VPZB.C#<VZZT]]^N#:.[RO=
M'=>/8W6S."[-(I\)P;'<IREBQ1\[2U"(R6J6SQR=$H7X5PVAY@PEW4N?5V$B
M;(:3CH_:S)+3':3#GK!;-!1V-ME-5"?BPA*CWN01H<>ZE2)L6(F;*0N)`BH+
M,B<_5Q?2]6`U'<D2>[J8ID\?%7LCDHJ\1NG\CQRTQ62,LQR+DWY1&N&@TY=8
M\B:ZTS3Y-!5&[ZB[9+LFN>#B@T&W`3/NY>#9G$R?;VNR/;Y_;:9FF%X6O&H4
M_%K+;^GM(4R`:>+?1WLJ>$>=)R%YIJRMLK:FLX[86$A^1'1':!2@!BO8:K?!
MCB:#MJ[?YK4LKF`<T]28TO4CNM95H+[51<EK,FJ1[(,?EX9A^<8SC=SC=.]6
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M<,CH==S$]VJ=8J!?'I6FN-7&XEGB\%V0PC#YMY`.90;2-:S;!^!=+Q6JEO!=
M2_'A.OTS4F^@/-RITHQY2ZN6T$5RC!4IMZ8=Z,RQ#<'=3,<OVWVQB;+[:W4Y
MI>/[8UF56>5P,8@-L(]6,Q>7P<M'Y,N6'K&20VS`:?E/-18[<<MMF1[.HE0F
M8K[\9Z$Q:5;<ZL?+R.V7"=D/,*DM>@Z5QP'([[*V)*&W4I4OA"VE!9@:F"XW
M&;B.>@PD^HHME0<<;/@`$@J5W$'ZEJ^GW`4.`+4.^?K9V[<<G,KU)9HNK4V:
ML1MIVT>G:BJTXG8['Q]M<VJ=PL(W,L]S+.;6_NTS;$<JQVJQ/'(L!MPVE?EF
M,6M7)?O_`,]?<0TNRB6-::-AM$AIF9)"T"7MSZ'"L1SZ_P`7VZR^ISS#8*:F
M54Y-4RI\QM[\QJ(EB_3RY<VCQ_YZRQU^8]3V4V)7,UCTZ+(54*D5Y9E/T]F-
M.MP2M+:Q%4XF/]*"XVAP@@%MA7+:W%<=KQ*>5-E7>HD`'Y1#'[&4-/>LI#:T
M)4?YRGN1W`C@$<%*`D$`E*1QR`3J*;OJ:W9V[51VT;\_+<7?A_I-*#C>J^)V
M/*;W0;HV>G,,++9[UN``J2V$J*01SRHE20/<>.>?/M[\-=?\N<0ZZ\VM2G'7
M%E2N4I[$$@A!!:<25$^5'M21PD`<$DM6BO#UN]'F;U?W?RI[QNFFFO/GJ1II
MII$::::1&FFFD1IIII$::::1&FFFD1IIII$QN?$<PVURG%-KI#$%Y_'ZS++A
MG()R`TIJL<NJ=JOJGY0)#Z8[RTRV/6:X0A\M)=(+C8.`O<_8#)&JNV?KG&+.
M*]B=91-EELNO.2LHR]^4Y#C=B>Y8AQTM/NK([5-.A7/N!N%V%?`M8<BOLX42
MQ@2T>C*A3H[,N)):41W-/QWT.,NMJ^Z7$*'/!XY`(UA=U-R;3;'>?<JF%`];
MX93[IY%3P&:APR[3'8./7$AJ#5,MH!+D2'#<#8B(0M;,8LA!6$?2B6+7.)OT
MV3YQ`G0G&GV,+8PYM?I*0P)M>?7E%"Q]+BSX'8%'M0E*N`#J*U\N-`FXLI78
MJ,NFC8^Z1P$J<1;)BAL\D$.*;:"@/'';^AY%X4?<?;#*)U1-3\G=UL)Z_L+*
M$Q6"78*D6<;T@PY6LNL7#+E8`5-/2X4E;Q"BZA*4!2K8,TIL1>PS;NO@S\?8
MRIK?F1=Y&RK(6J>97[>V60V$]B0XWD**=KLBU\F,'6&%/N(]-3J5%+:F](G2
M7=PHL6\!4E#V.LUJD()"2TAZ6\@I6.[Z$EP(*CX"@``?/&H+(S2M;BU3RW6P
MY<4YD.*[FU?Q1G<&,XL<]J2"EOT5*"NY)60`3XU"MPL4K',EZR/V;E+ETK6,
M8F_M&JNN:>U;R6>;NI;E1:^4W.0J<J/'5.E.L0XZY'H)4]V%H+6FWO)\!W"K
M\'VJ#6.Y9*RA[!\ADWU,Q7_.R:OY??R"N*7/E'Y"`\O%PJV4S]+P@`O(2Z@*
M4A$NN1D]4[+K8'\(B-)SI"_J`*EQ,P:B1@/O_#;24$>0$^>?8:J%C-U!L<VS
M)B(RWQ%7D;J4I*5EMJ-71D@#@>23VJ/!''((U:NWAF1L;F&*W79!(IV8^]<\
M7+5-/%=ZC6YC2:Y#RNQ1"I4`&9$2RE:GF%)6@%(616+9##\XA[G[BIN<?NH3
M-VC<&5CZYD"4PU85R(U7"@2XCCS80IJP?$@PP%E3J8[Q2.&U'2)4A5PXSC.$
MMAPH$IOYM8;!"W&V2(Z%<<'N*0L@^WTK(/CW[R<C;5?7ONJ+C+,>6&QP$L.1
M:&?7-.]H!X"I;P\C@D\DG4O9%C-VQB.P;$6+/3(L*C(ZO*WC$63C\^JOJ)A$
M>:I*E(CRGX[E@4,NJ;Y;CEU"UM]Q1-<3;CT-P.L^`\Y*9KY&.6L+9F=/7!@5
MF3RQ81OD5L2),LQN7XSDIR.IA]:5)1WMJ/(242FN41I5M7.UX9"W<FSYG(_K
MX!<C5S584NH(/(Y<<Y`)X\CGSQJ#S-HK#*[/)K*MAR75R<GC9TXVAA7<8L`+
MK''4*X"7`E2N]2D^P2ZD@%).KX\6<V<Q^7L?>Y5^52V*;;*YI]QJ%^S9L+2/
MG%E"IVJR='APV5KG18S\-UQ8B//N>/I:"_:<,>WWQ/$\>QR%0T#,^70U.08U
M,LY-,NEA7]/<2WIJ)*I-NE%DN7'DNN,(;17K]5I7J>NA:4-E$H3B/2FNL?>L
M[MY"(L5R1):>5RRTINTB1K^-.:)/U-ER-*;Y!*>^(H$C@'6Q)TBU=E2=-FT%
M3;0K2OFUV),1%1KE+:9_R[,V:(,A26E$"-,A?+RX`6$/?(/QB^VAXK0G'ET.
M6<+>C=7)HV;5,"XJL9V]HYM'628[[L!N9#R"3`;ES&G1\G82H\::IMEN2T$Q
MD+;<2PIQ:E,YFDI"4A*0`E("4@````<``#@``>````/;2)SIIII$::::1&FF
MFD1_[_PUA*WX_#S?"OZD]Y=RM_=W-B\HO]S]V\IGYEG-Y#WCW3HX]K?60CIE
MR6JBGRB'5P&74QF1\I"BLQD\*X;^M?=FUTU(IPI\FO\`4AQQRUD">2#_`+F`
MB1^&3^#C)QR!BSW3/;FNKKNSOF)*=W=T6[MR9;,1F)L>9?HR=-S.JB(K+L>H
MF37JV%)#DF'&8>>>6N"I_"Z_!F2`!TWY;XX]]]MY">??DJ.8\E7/DJ)[B?//
M.MA'34]67Q9?R_W*OAX/.&+7GB/_`!-?9'X7_P"#>U*AS6NG;,6I=>_'DQ)#
M6_&\K;K,B*XEZ.\A:,Q2H.LO-MNH7SW!QMM?/<D'52\]_#Q?"^W0W!R7=7<#
M:S<S*=P<QR.JR[)\GM-_]XG)UWD]&TPS47L]IO+&X3UE7M1F6XLDQ0MI"5(2
M0EUT+S?::=63SED_5_.Q_$GHP"C'$/+I*_BO5_F8!\F_#+?""S'(;S*\EV"S
M:UR');67=WMH[OMO`R_96L]Y4B;-?1$RV.PER4^M3KR66FFEK/);U]G_`,-!
M\(Z9"HJR?LCN/95.,&0<=IK3J(WOLZ6D^;6RY+34U$_-I%=7-RW6&G934.,R
MV^ZGU'4*62HY\M-1U9:]YUQMUJM>6M?*.C#?NX[Y]TW\]3!;=_AP_A+7&?L;
MG1NG[(<3S.$Y!?K;+`-W=S<"8J9-=':CQI=55XGDE35P)?:T''I,>(A^2^MU
M]];CCJU&07/PN_P:'GW9+W3AECLEY:ENR7-]-XE/N*6>Y96Z<O[U=ZCW*Y/U
M*X)]AQL(::DRR.,LCY+#A@Z<,:N_TG//EW[^<U[_`/5=_@T!IQE'3CEK:7#R
MM36^F\+;I(X`(=3EX<3QQXX4./MYU66=^'^^&W;Y3C>:WV"[OY/E&'XXWB&*
M6V6=1.\F5+QW&68"JN-2T\3(<LLJ^#!B5ZC&AML1$F*GM<84AY#;J<U>FH5>
M5?FL&&!=8XEHNC:</S.SY[YF!G+?PV/PG,[_`"TYCLWN5D2ZAJQCUSMCU";S
MKD1V+>WEWUJU\PUF#3[R+"XGS+"7Z[CJG9$A9*NWM2F5?]5V^#/P!_HWY8``
M``-]-X@`E(X``&7^`!X`UL(::DRR"C+(/(4(<,';CB[O>)Z'EZ'Y4U[O]5U^
M#-SR.G#+1[^!OIO&!]7')(_;#R?`\GD_UUS_`*KM\&;_`.S?EG_ZZ[R?_P!Q
M_P#]UL(::=>?Q9?Y/]R/9^'\&'^)_4U]7/POOP:7%AP]-N4(6&$Q^6]\-X$)
M*$I".Y2!E_87E)'"WNWU5^Y63KIH_"W_``86_4[.FS*@75EQ:AOIO'W%:AVE
M0/[8?2>TD#MXX!/''.MA;33KS^++_)_N/9X?!CV_:=N.W::]J?PN?P94CA/3
M?EB1_3?3>/DG@#DG]L.5'QY4>5'[DZ:V$M-.O/XLO\G^X]GA\&/^)_7H?Q&F
MFFJR\::::1&FFFD1IIII$::::1&FFFD1IIII$::::1&M>+XD6T/[G-SIVYJ:
M:\A;5;F/*N[G.*N*[;5N([@/R'4W4'*HC+17`H[9@1+>JL%*:0B2JTBB6RAA
MEL[#NNE8UM?;P9=9:P8=G6SX[L2=7V$9B;!FQ7TE#T:7$DH=CR6'4$H<9>;6
MVM)(4D@Z1-+J^V\R#+83=]ADW#L[B2$I<A3H5D\9+@6>6TQ9E>XQ9+D*920E
MJ3+>;0$J0`L)(--+ZLW%A5[L&]QG-H*`A"&'B8=U7L!'A+3,:3'+Z4)X'IMS
M'0D!:1W*4KC6T!N)\*_I!S6S7=XSB.1;*Y(ZM]]RYV3RZYP)A]YZ1\RM<S&H
MKTG$IB2\I:PV[1=H+CA''=XL1W]Z`MS-F*9RTQ3JMM;S'G"3^SN?;0X[>RBP
M)#:4,NW]!E&(275I;'89"H8=<)*W2ODC2)K*YW52'\CAM3[*NAF7("41,VV:
MIV&6GDI7WB1D4.9&<KRX.$M.2%-E0X"%`>!:%NWD%=C^6V5&UDFR%5-@(A>I
M6W<S>W%;R.HUL527'DX9<B@<;="_4KVX3Q[8;S)><]5QQ1S+;XV8QR33P,KH
ML;RA=@\^[\U2MY/AJVTM.%*6EM-99>-O())6L$(25>0E.K;9^WVW6;29UI^6
M991F`\XRJ+#RR#91W%I0V.]E=[BMG)C(X2L!H2'>WO\`I6`A*0B6-XWN+-Q2
MLJK&#GFS#KQ0U,F1LAWQZC,0JX4E!Y8=K+`Y+9_-(;4\?H>BM1UJ')0I0X,]
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M.V4\VE:K"%3S(50M"`DH0Y:9,LRGVVN"H-1/1=65!/UE7;J^/JWDU7[5XA`N
MOVKG-P*"=:1V*O)H%+!7^96`?+,IA6,6<QY3"&$1@\U8Q_58"0XV7!ZAKCT[
M;=Q=V(<&DIH&#X[ZT9IYFPRO%+C<:7&4DK25-HDYKCD0K(:':H1T]A)(!X`"
M):MC%C?R:9+$9NX6\I++@=J(DN+%;<0DH2$DKD-N%`/\/L2UW$D!0!!-6,8Q
M^320#=Y7+EP(+SGJ.6&87$3'JMQ8/^ZCUD9N1;7#ZUJ"4,Q5>H^OM0EOE?*<
MQ6WWPU;+)V4V-]U%75/7LR7(DBMVRVOQ#!9,AIL^`W<3Y^72XG//A;2%/)(!
M0\GSS=GL]\.;I7V>R:/G$+#[O<#/J]U;L#-=W,LN]Q;BN>6E8+U5#O)*\>J'
MD]ZO2?K*2*^UX+;J2.=(EO/PUMH]SJZ]S?>W(7I^,;;91B-)A."8):XTJILL
MA7762\AE[G+<E2/GJNF?3/-#CM6]%3*M&46%Q9.]B:I&LN.N`````````!^@
M'`_P'C7.D1IIII$::::1&FFFD1IIII$::::1&FFFD1IIII$::::1&FFFD1II
1II$::::1&FFFD1IIII$__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g118836.jpg
<DESCRIPTION>G118836.JPG
<TEXT>
begin 644 g118836.jpg
M_]C_X``02D9)1@`!`0$!A0&%``#__@!!1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]/55)?4U12051%1UE?2U]"05(N15!3_]L`
M0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``"P@`N@)H`0$1`/_$`!X``0`!`P4!
M```````````````%!`<(`0(#!@D*_\0`6!````8!`@($!PP'!`@$!@$%`@,$
M!08'`0`($Q0)$1(5%A<95UB6F!@A45-9D9+1U-76\#%!87&7TM=6F;'3(B-4
M56*!E)4D)3*A)C92<X2S0C4W=H>B_]H`"`$!```_`/OXTU9S</+I/`*'N6=P
MM2THY;"*NGLQC:A^:CWQD"\Q2*NLA;RWAH2NC(J<6Q0H;0)ER5*\-:HQ,<9R
MS@D/P6<'YV=L?3E7VAIYYW5;NJ7Q*-G4>V&[<MT<]OZ@:3L"`H:YONX9VTPF
M4[:&-):]CND<O`,>0/[3/12F`2E,LAS$8)BDJ-\?%240?1$73+[>6V<H()-:
MGW%UFXHG:GT%FJK#A<-9"*6;]R5QNE);9Y%8Z1'8;JYE,]ZR9LP^1HJ+HI*]
MQ"%.+;(;39X-@Y0C2X[2?IHS'3>5ML@E3P)>Z[4K`3=)VQV%.Y+%&\J7SF5=
M'5$&EVD+CM]7([03ILQU5+CI!$U@[*BC)B0":D2]C5-:!2:X:R"AG37;2IU#
M)-,VF.72A3,E-[,;D9&IZB<43NLY1;^I*&%;:X5%BVZ>NJ8,XDTR-31Z0))"
MI8H[$AGB>G62^#2%R>4?<:QZ3IKMS=]1FU"-[>KOC#[9^V&X]RDY,L]AC\!D
M54-M6;@F_;AEB?XP^2I*O<P'SE'+%9[Y&`2%O>HSF"RB!^%L;EBMY8_4[_V_
M/[------>5?2G=(RHZ.V`U+8J.$8G4=47)61FX=87C*C-0;57*P(Q7MH7,<C
M2N"=P4+&&03R%,\=0E)%A2]>YN"E26!M9714EO986_RIX-N(A^VUHB-K6I,'
MQOI9\F;]4L.+FT3J.+;BYS(JXI696&K1.I3H5$IA*HG(0N+[&&J2((%'&[,S
ML$Z,Q56@=5?G)4G3,N5_..Q.8Q"M)="8/NLM'I#&.-UTX5['+"L*ZX?LTC5J
M'-K97\F8;P9FZL;!7JX$G<W!!-8L]-$C=%!\)CSBG3812YVR#3]-7M0=Z2IR
M\HRQ6<_Q^_V"$.%3-&`5<RN<CE,Q0W6^JZP<W=^M%!"8=8D&B5`6)*IXURZ6
M-#,QI`1I@3O[E,Y4S1I1Z44/=<`W(4M5%_54YGO%;W/7L1LZ#.2M&:W+E47F
MK&B?V8;@VGYRH;'("-<60Y-JG_Q#>O*4HSO]80+.;L::::::\Q>F!W=6YL3V
M'V7NFI4F!+II6\SI%MRSV3&WF2Q9W8K.NN`U.^E'IH_*H>[(W!L;YP:_-2].
MZG$A7-)*18VK$JHWAXB5[TOUDU4RO^-W^W.UY"GG.]Z;[2=F,ZH:E9!#U^ZY
M$U01SG,0DS=2UQSQ!+(N2_',CG"6R;)W]UKF7R(KOEO61N+)W%Q2W==.G1V4
M121V.PV+FR*W+JJ$W*_35=*&:)JCVB?[=*^K:QKUHU1'8M-9%*0VA7;9:3$P
MB-RR^+R93-EF4:@,\DRF-'G*;*;CNEXLZO[IV[1"-5(^U##[`JGI3G>XV*_Z
MF=55I0R;;!Z0B=HQ9ZKTN-V:RP.QJ_DYLJ`N$ZQZ5/$<G;,FRSQ^;Q5\3.QJ
M'M,;Z<2CH1`:%1V_&;=F4QF.VK8)>]A6A6]6QB-52BC6^N01VMJ_L`F-2*XW
M6:Q]CS8SQDI[@9!<LF<=:1"-;BY60A5*PS48Z7^&1=RW,L\X;YM=DXA.^+=E
MMSJ>F*(I,YKM-1$MHE%P^Z[@*RA?;5?&NT76$Q1R4O),CCZ^*NUBN$JAT&AE
M9BE:D;>&]DEZ6"C4NY1MV@ML:M5BMZ>L]O)JN?)K`L1R+2"85)MY8=R#XC-C
MC\^LME%1L$#DR7"";*X<A@SU+([,8"EDQ,G9.647AZ,+<]/]YVP3:QNBM)KB
M;+8-UU2TS>6-<%;W5JB*)X6N#HC/)8&Y[>Y&[(V[L(2QE$+WQS4`$,?:5F8R
M'LYYZ:::::::\F-X>\B\:9Z1WHQMH-?9KPFN-[Q.Z\BQ7R21)W?9K%3]N]7-
M=B,2F#N"67LC(GQ(5+MAK>R']@?0DI$P3VT9"DT?9PPV\]*]N8>K:C^T+=>Q
M4]3FY*Q[!IVQMM4YBL0E"BH=V&T*QYNW1J49KYLD,]6+8SN!J9&L4"L6.+I0
M\E-HT^7]KC#HPIEN,6DF73+;LZ<@_2'[E9U'J-F5#='CTDR/:'.*]CT%ET7L
MJ9T2]2:O(D78S'.E=IO;&3:T9=;%;ERAC/@PHG*VM`K0E$QE8:!T)^HP@X"@
MDH\O/:+.+`:6+J$'M%F!P,`NR+&!![0!!SD(L8R'.<XSU]77KETTTUA]O^W=
M1_8;LVW"[N9+&UTQ;J/KU=*DL2;U06\^3R%4N;X[$8\8YY3K.YT+S*WME;W-
MZPA<!,S8>L=`MZ\:0*,_"*X[FZ1"@-B<UWDOD^VTS:30C:==VXVSJV*J&4-$
M3B<FC&W:<6M7\8K61(;8/?)7$F2PT44A4U5R\S+_`#6+#<Y5'G&"KQ`9L6*J
M;IJ$#,U7#8.X-,MD$=KBH^B;<G>`4G31B62Q.RND2KTUX2K4\GEUUGI+#A+S
M-'-I;&AL0L<;DT`0I%"9S+FG,`>3+H'],75TILG:,8SO#M3-=3^W>D4K2^HW
M<%3DO\L8EW1^5A-)+::$B;0"VG*,P8,:/C!LW*?F]GMANFT2)$P(PQN1B$0.
MX3YTS%&QN@E.X1^HK=*Q13)R->R)Y#6C)'44F@;OMHSNSCUDM=B/4S25`FB\
MBJ;LMK8F>+";I&7;AA5-.;(@G8A-X);9ITA[[NWWE7Q6<81QD_;>S[/=C.ZR
MBI$.,OS!93NT[M(S-)4H*F_>,A5MX4Y+0QL)[4TDQQF=&52J<DCJL=<X(RG\
MV)GTR^[.FH-TA^Y:=QZC9E0W1X=)*CVASFOH[!9?%[+F=$O,EKV)@L=BG*JT
MWMC)M:,NMB-R\]B/@HHG*VM`J0$DQE::!T*]![?Z;O:'3T^O6`K66V9VMH)N
MOP<D5UPQPI\,D,EVKQ.`6!N,AD7C[M/X_*1/%4P.PTLK<G:1,L>ATC0Q&Q44
M+DTA=H:K0JI:[.FDVC49'VN421-/WAA=H>\VFWND<+KY8W.U,0VMJ;LRR;7C
M;DKL)"WRMCKQNO>!1QSC4;4N5ARB89DK/74/F2>*O3BFQ[J7IID2!TW/QV[X
M:*9S"'](WN\VF[:(%03&A*EEC4YM3V]Q+<I-+$DBJP;#;(B8Y1.MG1X=GYU2
MO\>2R(Y1%V:*Q4UU<30XN=.NG>V<PM`\RU/%;XE]2Q"IMHM_6#=,8A43Q`8%
M1F]5S1LE/V<_HY!8#%/SFM"[N"5'/HZS0=SFD4+"X+A1U>B9G4Y)6R/IOMN;
M%8LSK-+2NYN0/D.O7<WMC$O:(I5F&.0WYM6JE%=D\KQ@7.-PH5.<O5:+,R2+
MRQ\0,D-P408DE#Y&UIA"<SMR3IHMGC@Y;742`Z='$;HJ]VLV8TK%;=%FD5:1
MO>A-E59[=\V(U.TO1O:E=+K";W*-OJ:N&Z?@@25%X834YEA"YJD*^T*CIZ]M
M"J#7%+F*G=Q(3JOVR;M-RS2DE,>KIC13UJV:VD*F;BB+&O:[,DJA$]M4Z,38
M3.#NWHF)R8LK5K2XN#J@-9!^MNWVRWFY*0JBU9!$%L$>;"K^(S%QB:Y:SN)K
M.ID;"WNXR"5K&[OC>I0&Y6<PV&]X"6B;C4N71*W.?-MZ:\.FFFL1=\TSW'5_
MMNETGVEYJL[<$"0US'*T:KK9WYXK!_D4\L2+P%"R2S$8DL3?6I`M/DY7#?4#
MOCNE240I6)%:#"LK7C'Y:"V;(V>;LMP5>1^"U=?NS/9_94OW#;4;5AKT^2JE
M=WU12IP:)%!9XL03:+N3C5LI:VPUTA"AK3MCD]-"DIU!*RG-O?(NVW^VZ])[
M;"#<'MWI;=<FJT^([J>CD:M_D#M>MX[(H076ZJ-,3/(+FJZP8P^3*>X>F)E9
M'@$EAMAL[BRJS$J91&WJ*KE@`R'.3W1H;_W3?"T[FV"PJ],IVZ]L^Y2>U7-*
MJ7F!&^,]=O*D<SV^RYUP0N=$>54UJAT:A.IZ)P-1'2MCDV4)*5%RR<OTZTTT
MTUM[6/@%]`?\NG:Q\`OH#_EUT*TX$@M>MYW63H[OK`UV!$9#"W5YC?=I;^WM
M4G:E;*Z'LYKVT/K22X]WKE):4]>SN)"<T83\I3!E@QC!^8=&)0,XZ.AMZ,-]
ME%M"V[-E;P:I27E(_1=+:1L&KM]8GZ,MATGQ!AL7-$'QMH1JW,F(DK%B%,+!
M@PJSSE@N"Y^BZVY7I<Q%SS1?/PN;T5MN#;D6:7)B0Q.\S]HT\<;,V_J[%3"C
M!SJE%#)HZJW)P301VAR*7HBFYADZ9P9&Q(B!:*,]"WMCB]Q0^U$U@WXK8ZYE
M>]:45W3:N30D-7PTG?\`-A"+<;%VOE*V33XZ-/BX*U]CA2^=*7B+N;B<6@>1
M-:9$W$6_8.@2VCLU,6=2JRS]S4@:;-H;:[0`Y6Y3F#-\S@T?V92,R5;<)=7;
MC&:L84$>GE?O.2%.754VNS5(LINN0,:\:]V&OS8B.PNO(UN-IO=HZVC>4ZW`
M5-0,RVW.D]ETFBHLV]7$UFJ2QEQ%H1V/0*/QL3@U3A$1(&`=>-E?-S>,!;6>
MVKF1.E;B<Z>UC_B^@/\`ET[6/@%]`?\`+IVL?`+Z`_Y=.UCX!?0'_+IVL?`+
MZ`_Y=.UCX!?0'_+K"Z\]B-$[D3K[S=#>MGJ*_J;0T8YMLC8X$\%5U"4R*6)5
M9E4.#I!UC]$WQX5S1X?'-R5/#R$4@)9W5$F0FLR`!5C*GZ*JIJ3MG;Y<M?7M
MN@:YE1.W6&;4GDY3-X.N3;@*-K*3GRNKHK?.#JO"H?7*OEZ@Q`S3&"J*^F#K
M'QG,$J?'YO6+P*HZG>B#VQ46^[3'B`RJ[DZ791;NYZWJ"CKO+HV\L<=6[M4K
MNEM6&.?-0/#P]P@D$A?S8HD5.X9(S*W=4K5RAU.+293<;YT/FU7Q;,<`K%TM
M.A72&;UI=OZKNR*D?(TEFT`W`3=S?U$@4L:2;0J:P)S@RN/R5T@F8#+83(H[
MX&"2MHDXU2%*N!Z>QEE+C,>9(\!R>WH+*UHFW+Q(5ACH^NHTB<!)CD\.&22`
MJW)<8$2I:<4G3$"4&F83)4R?!2<N<[6/@%]`?\NG:Q\`OH#_`)=.UCX!?0'_
M`"Z=K'P"^@/^73M8^`7T!_RZ=K'P"^@/^76)N]?9[6V_"@)!MLMV13^/5S*I
M'`I+(15RX,++(7)16\V8;$C*#+K(HK+"$C<7+HPQ.:X")O3K5I:#"`2XM"J6
M$*&X#9_7FY&8[6IU/I/8"-]VDW2AONO,QE9&VY$_6`ABKQ#0&S=,OB+L)Q9C
M6.0OI)K6P'1K_7N0U!2DH21!A+C:]=$SMRD"O>VT.<ON@VG=_1LS?[SV^%2>
M,IZJ)LVPHNUQ296["SR8*&R&.;/:5D:7@2)?8+S!$,K;T<G00PAV2HSDL%*>
MB,IRQVJ@R;=OO=);<HV\4QN4H:)V!-IA7(Y8_P!?;IZK:*8L=-+L,-1LL>5N
MB*`L+2AB[HR,3"H2/"91)W_PE?W5W7+[?O'09[3WR/,T876-N*RUL-";,]MS
M;P937!:DFL=B,_0V50Z49^:C'QGHJ3-J,R9/)@!&R5"5RA9+7Q#31]J>.AJV
M[&S5PM.%VON,JRW3-[5J[\8]:<$E->AEL(MN]8`T5==$6BX)35,GCPJKLB!Q
M]C8'V*21BD;@E+:R%;/(&]6:L,52+CT0-$NN[!#O"<+FW+K[+9[7L>V6%J=I
MG"7Z,L:^U]LJ/:K,XDB/?JS<IHH@RFO6]$Y,S"ZS%PQ%9.6L5Q90S-CW(&QV
MS8VC[8Z_V8[<:EVOU8YRYXKRF(L7#H>OG*YL=I68QD+UR]*2\N3(PQMM7*$H
MEYJ<M20RHAF)RR>8"<?@P\S([M8^`7T!_P`NG:Q\`OH#_ET[6/@%]`?\NG:Q
M\`OH#_ET[6/@%]`?\NG:Q\`OH#_ET[6/@%]`?\NG:Q\`OH#_`)=887EL@K*^
MMSVU7=I)9=93!:.SD%K8IU-%5\43Q,([JC26'V$;*V=^A4@6OXG6.(DC<C"4
M[MI;1DGG6\!2XPU0.G7[#*,D$9VFLLU\*)W(=EEB,EF439<B-CZ:Q&-^9T+B
MSG(W%VC$7CK0N89#'W(;'*&5,Q-R%\3(F=Q4E8?F5K=TN,Y?0S[5UKU;9TRE
M=WV+`[WW=(][UOTS+91#BJLG]\M!B!7'ULD;XK7$9EKI!&!T:&1X2UBKF1T(
M=W)E;#Y6T2$M+@D?K=@6,8ZO]+_F`?Z_?S__`!^'_E\&,8UKVL?`+Z`_Y=.U
MCX!?0'_+IVL?`+Z`_P"73M8^`7T!_P`NK8W13M9[AJGL*C[CB3?.JNM.)O,)
MG,3=@*@HWN.OJ4:1>ERH1F)EZ!4`(@*6]T;52-T:7$A(YMBQ(X)$RDK#_'1Z
ML#MMMDNTRP-Q>Y&R:3>Z&F6W%O9Y&^5TW2)HK>:05?62D3A+(I6#`Z3V5,<"
M<5$=CDAL7$IPE,P1*G1N>9TF32DG'LWH1-JAK38#+X?[@BT%G-NPEJEY8)1`
M!#7)>C@(1IMM_+F&U48)`:24A)Q/3$O8Q+<Y&(L#.(0<@["U=##M,0R&OI"Z
M/MR2L5>W1O<N\AHD<CB)K')WWI!8DZP?<?&)6A:J]:1K(6]1I_?4$9;VI0S/
M,:$ZGJ"I`L.3H1)88_H9*<<MN=%[7)#N9WC2BJ]N[C*$U<M[[8%:J#BJXD-,
MR^B&RH'I&GIM+''F'06`S5W)@$C5L`[7B[N6W/""Q@+&Y`)+?G9ST:U*;*)=
MB;5K-K>E+V/:]MKVE*L6&[PYQ0JZTVIQ]=&*H<1)HS`8H:1+2&9S7)7YQ3J@
M-3M@\)N&5*>04=BT(>AFVK+WJW#9G*KOL6!7SNZ2;W;@IB6RB'$U9/[X:3$"
MN/K)&@BM<1F7.<$8'1H97=+62N9G0EW<F5L/E;3(0)<$CO[571\U%3UT;EK2
MB<QM4R%[KI?([*MK;F\.\6<:)76E.(JBA=@6"@:\PDFP>\9XP("2I)&7:Q7:
MOS'$0WI!$$3N4A6(;*,O1`;;8''MD[+3$XO2BW'8A%[%KZI996DMC.)')*SN
M#"0RUJ_LK,V@DR99&TSA>@0O:A];69AFT:D*0A]A4GCCF'"C$)(>ACVP.[O/
MI<TS6[8M8,ZW,;C=TZ>P&F00Q9(X1.]VU&CVX[@V*&!?*]<VDF&SRI@M[24A
MDK;)GN-/K(S2N/R!$])U)RW$O'0A1Z4;@MQE<RXMUC'1YV%M7Z/G;M#*^@D[
M0&2F4QC9'(5$E#7%F&R6(O,I30^2JB(\C<9'&I2DF4H0I94F=WEOS(.:,RX5
M=#/ME4SI[L'%@7XG?'_=/N3WA+229)`!-Q=P[J:0#M[L\Q*0HJP]05%B:W+)
M215A&K-$RNQ!;JH7N@\FD&]GI7HG*2V\V)MWLBH;?W&1%UH#;77^TI8VIY5`
MU#)=]'5)*ULTJR-W*D.K#)ZAU@SVXK@(996JJM9*],:U=&9.Y/+`N5H#[8L'
M0:;/V5E<XTKEM^2*//=#[O\`;L\-#S+X8G(<:_WN6:JMZZ!FJX_6;&Y)G\N=
M*0.,-<V]:C(8$:1,V*F]X1\R!3ZJ4_6[?3=5UY4[4_RB5-5;PV.PEKD4S4-J
MZ5N[9&6M,SMRR0+&-DCS2I=!HDB<"DYO9&M(,0,9)1$A_P!'5Q^UCX!?0'_+
MIVL?`+Z`_P"73M8^`7T!_P`NG:Q\`OH#_EU;*V:U3VS%T$74RN60TIOFU>SH
MIUAX(YWJ:Y5M-F*?L;>?X5QB5-HFA8_1QK"\DEMI2Y4W`/2)'%O$H$HQB/>G
M1I;9;Y<]V[\]-LGA4EWOT%%MN6XF25XN:61VF4$AZF1X9'/J=8Z_MI,W3,4I
M=(@*6J&Y:O,BQ3,VC!DV/LBI#;9CZ(_;DU9PY.<VNR93-#0%4[4(S/IH_05Y
M?8;MDJI[8'\NCHRPD5FW5XGAUBK(ZC3V^O<H2Z3&QVE2X,SU*,-AY:4B]U:[
M`J*IS=[9.\FJQR>O9M;U6Q&J+'K>'DPZ/TO*VF!+%*V'R=SA;9"D[D*>L`UR
M](AE),E*/[I7*6<]*<@,X6,X.UCX!?0'_+IVL?`+Z`_Y=.UCX!?0'_+IVL?`
M+Z`_Y=.UCX!?0'_+KSF\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A7
M07J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5
MT:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_
M:]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=
M!>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R17
M1H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]
MKT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T
M%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=
M&CZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?V
MO3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A70
M7J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5T
M:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_:
M]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!
M>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171
MH^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]K
MT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T%
MZEE_:]/)%=&CZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&
MCZ%=!>I9?VO3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO
M3R171H^A707J67]KT\D5T:/H5T%ZEE_:]/)%=&CZ%=!>I9?VO6`N^2C.B-V$
MJMOKI;/1_P!6.U=W+9DD@4OF\3@"A[.IU@C58RVRW:U)-&&TA<ZO%?1=!%%!
M\_7M(\+HC%Q.$QRA=$#(N1YSD8>BIZ+:4LC/)HSM#VW2&.R%K;WQA?F.-H'9
ME>V5V2$N#4\,[JWN*A`YM3F@4)US<XH5!Z-<C/)5)3C2#0#%+>2*Z-'T*Z"]
M2R_M>GDBNC1]"N@O4LO[7IY(KHT?0KH+U++^UZ>2*Z-'T*Z"]2R_M>GDBNC1
M]"N@O4LO[7IY(KHT?0KH+U++^UZ>2*Z-'T*Z"]2R_M>LE+8W-5O2MG495L_)
MES4Y[BIDHKJLI.3$W)=7RVP"&!\E1,*D$Y(SEBB,D>(_&WQPC#;)#VXV7&MJ
MEIBV7E\#W7FHK3<M5EH`BV&AR<F-9/U=@!KAIF+2?%WJQV.LE;>CELV@S0O&
M)?(8$F&[-*EMF:4G#$^M;RQO3*K7L[ZS+U]\2W-O.2@7%+DAJ(P)@RUA:DD:
M08"L#R:,"D(\D"`7@LS)@@F9"#!8\BSCL#[/-A6E%D[`5!.<IA!`HQ@P&<D#
M&`)H`G8QGK*$(H8#`A,P'(BQ@&'&0B#G.\L\DXLLXHTLPHX(1E&%C",LT`\8
MR`98PYR$P(PYP((@9$$0<X$'.0YQG/&2L2*#5)!"D@XY&,)2LHHTLPU*8,`3
M0%J2P"R,@P10PF@`:$`QEB"8'&0"QG.)C3O-KE]L6P:V:87<[@XU3<$>HZQW
MU)5KXHB<1G<J9X/)&$MR?23C`'1]9&;)@\B.E+:E7,+:S2`E:[+4`4#N%NZO
M772%;=['M&-U"D46%&9=-;)N^FH09-*UE,>C<NMK;D-[%<=<LDK$E6,`I7$T
M$9D;TF0."YO+EC!'GYZA2B1(&5S.2YR::::Z_+97&X'%9+.)D^-D9B$-C[S*
MI5)'I64@9H]&XZVJ7A]?'=>>()")L:6M&J7KU9P@E)DJ<TXP6`@SK%^M=[%2
MV/,*SAHF>RX"LO.+/,TH=QL^!.4*:[DC\?;,2!Y%$#%QY[@V2!#$S$\T%!9\
MVPF?J8:8IDR*+*FMFD)[/EYQ2_T=L/7C/5G'7CKQG&<8SC./TXZLYQ@77_Z<
MYZA=6N(U8D(&G+.4D%#5'93I0&&@`-2>$`S<D)PB%@1QV"BC#,E%8&/!98S,
MA[`!"P+6)#CE*<E20:H1Y+"K(*-+,.3".+XI(3R@"R82(XK.#"0FA!DTO/;+
MP('OZLM6&X.`6N^WE'V#+PVJ]OML$TY.E,C1I&EN/E"NO*^L]`LCJX+BK*=H
M^XQ6S8J:B=#.2&>N4*D6$@3$W:-O6)2G":60(XL)QN>HHH0PA-,SV!F9P66+
M.!CS@!9@\X"'/4`LP6?]$`\AVD+$BDQ22G4ISS49N"%91)Q9AB4_)8#L$J0`
M$(1!N2C`&X*-P`>2Q@,P'L""+-3K8,60AQG'_P!98?\`D(P(<_\`MG.OEXIC
M<UTC5YUPS6P'>U'X,1,7RR#4</;MGM2R%%&VV.VO/(6T-1#ZZ39&Y._`:8RA
M$<XKDJ=2J4F'&&%`Z\==T?&%TC7R@K9[$E+?C_3QA=(U\H*V>Q)2WX_T\872
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M;(YS6<GJI:O='^,RE[<%29#')<[F)VSD@IU*P9(E1N2B\`UV:@MP2CHQWH30
M[(E2GHYI0\JW)_3H,KG`_8?+9`XY/<I:QLX`J#"]F,G=%0W*7L+.6+&V64+G
M*6-B#%+/;PEKGZ16IT;7QL;WEF7HG5H=D25R:W-N5)US>XMRX@M4B7H%R4PY
M*M1+$QI2E(L2G&IE2<TL].:828`8J_333336`6^O;>];TXPW[3Y'''!GH*P6
METDMI70QO44(FL*DT*5H'FI&FLVIU$M>&V7AGA#;,U4^*:3DL>:HIF.(,&+Y
MFH>(MY\V=M9WJ7=&]MUGVAMIH>5[CZ5VK[]=LTR`HGK%"HY,Y%95;01JI>RX
M:^0`TB5UU#K%<Z^<"'>&Q.61:74X^6&K0QZ2%,+89/`VRJWH\KP>)_#/''M=
MCZNH([O`W/7.9!91)*`=&,=0;@=@;-4YD'Q6\(<$]=(DZG<`!>=)X$W-PXF2
MM*.EP7&5&%%2IZQSL39]86V>N]K3I;-.L8BWYIZ#ZCK:0(IW!5:ZX=S=+[L)
M$UVFL?'%;)$:66O#Y4TS3Q-%/IDY)L2:()E$'?G)OBB`LHC*0/1Y6BA8XA72
MW:K'Y!0HK@OB]C:[03.HFZ95_7;C=2VSMO&Q2+.KK(>X:TIG,I4GV+>2JJ5C
MDT-S+A'M^@X9=`5[ZZXR%V5;:=S-8[X['M^?T@UUC7L_JR[XI)W.-6C%)5'G
MR;E;Q9]:-8R4I'EW<[2E7A?4\Z"Y!DED*%#S%GX^:0ULC]:P=##(FLD4FVV[
M&O<MN4MD=$SUZ<9YO=J^\::>4NY=LBM5(8O%-NE);>E\GM6KFV=FI'W+<.*3
M^7D,`*_?92[I2X:20\,KXF2B8+4TCLCW*T]NA8]V!U>8G(%.[+>ZM?Z8F]F1
MEW2UQ5.Z&V)#,H1N7V[X'(%$.@=VM,75%U]>$3,4I5,^KN5/#:QOI+S'QXFG
MOQIIIK&7>AMV*W;[2MR6V(R1FQ`5]TE9-3IY44EY_$;73>+.+(W/A[=VRLN:
M)K<%258X-83TXG-`4I0@4IQJ`G%X4SJF]QNY:<[('6TZ(;Z[8=G<DFEZ66B,
MF]:2-!<EIE[=[2V^Q>K*@"T.+H=XM)*.T9)+)));4::O4$Q]%%8R;$5"YW?Q
MQ#`^0;9'S:AMIMV"V6&O:RDYUE4#<?1PSUUEB&7/[=N,A/?5NT_T>[<P&+':
M9SJ.U),H[*JHKA<S]XJ[.I2R):WA:4$E9U3C)<AI#LINY%<=7'S+;M!=S%6V
M;5T(/G^%5L)X`9M7W<E;FI?N<N*\V?`E+0]O43L9[FL<9R'*I25=FC\0E=PU
M];S(,[GNS+:F1;`M[;A`YHVPLYLAE^L57[^89,[W\-F=D0;VC+UMABGU!H9*
MKCC@\3I@$W15.\1UZ?IXVLZN@WE8X,--D2*%/(W1%*0#9Q?22S))/'/9G'(M
MMSDN]%??LRV;ERR@W0$TA%E[`JCV[9,-C#3+D](+9%1]U5^]R4^-R*4A8)"S
M2YTF,15*9BPL2=PM[7O1E[G(++:XETDAS38%@U[)NB9<2[846''7.6X1;8I_
M<RS<=AGDLC<&V4J5*:E)_&*3`].!#,\71'8Z-OD!!++DI/C-OHWMJ5OTK/9M
M,+XK1V8K5:(,;3,GNX5ZIII&]SJ)JLM^F<:M)GK2/\`;*:H2NSB[.#K="/QK
MQ=[E;Y7\;6.,!1B>GCV#UQF_^G'_`-PG_P#:#7QL;0=T>V.&;=8%%)CN2V]Q
M&4L#W<S<_1F4W?5T=D3&X%[@K;-,0/+$\RM$ZM:T!1I1@TB](G4!+-+&(O`1
MASG)/W9.S[TM-KOM$4W^-=/=D[/O2TVN^T13?XUT]V3L^]+3:[[1%-_C73W9
M.S[TM-KOM$4W^-=/=D[/O2TVN^T13?XUT]V3L^]+3:[[1%-_C73W9.S[TM-K
MOM$4W^-=/=D[/O2TVN^T13?XUT]V3L^]+3:[[1%-_C73W9.S[TM-KOM$4W^-
M=/=D[/O2TVN^T13?XUT]V3L^]+3:[[1%-_C73W9.S[TM-KOM$4W^-=/=D[/O
M2TVN^T13?XUT]V3L^]+3:[[1%-_C73W9.S[TM-KOM$4W^-=/=D[/O2TVN^T1
M3?XUT]V3L^]+3:[[1%-_C73W9.S[TM-KOM$4W^-=/=D[/O2TVN^T13?XUT]V
M3L^]+3:[[1%-_C73W9.S[TM-KOM$4W^-=/=D[/O2TVN^T13?XUT]V3L^]+3:
M[[1%-_C73W9.S[TM-KOM$4W^-=/=D[/O2TVN^T13?XUT]V3L^]+3:[[1%-_C
M73W9.S[TM-KOM$4W^-=/=D[/O2TVN^T13?XUT]V3L^]+3:[[1%-_C73W9.S[
MTM-KOM$4W^-=/=D[/O2TVN^T13?XUT]V3L^]+3:[[1%-_C73W9.S[TM-KOM$
M4W^-=/=D[/O2TVN^T13?XUT]V3L^]+3:[[1%-_C73W9.S[TM-KOM$4W^-=/=
MD[/O2TVN^T13?XUT]V3L^]+3:[[1%-_C73W9.S[TM-KOM$4W^-=/=D[/O2TV
MN^T13?XUT]V3L^]+3:[[1%-_C73W9.S[TM-KOM$4W^-=/=D[/O2TVN^T13?X
MUT]V3L^]+3:[[1%-_C77:H9N/V[6._IHI76X"C+`E2PA6J21B"W!7$PD:M*W
MD"5+U*9BC<F<W50G0I0#4K#R4@RDJ<`CE`RR@Y%CBD+Y8=LVFW[3-M25"\7I
M*6-(\S^:N;21(J]VIU#(LJVW-SVXW*#"FY]?'PDES14?1ZE22ZW1(TJA4ZE-
MU3Q^:20CWSVL;;J\V@[>JGVU50*0FU_3\4312.*)8]GR"1+20*53@N<'1P,`
M0E*/<75>O7EL[&@9XI'"%)4>AT?CL5;&=C09`:::::::::IE2)(N`$I8E3*R
MP#P8`M204H`$S`1!P,(#@#"$>`B$'`L8P+`1"QU]6<XS4Z:::::::::V#+`9
MV.V`(^P/!@.T'`NP,/7@(PYSC/9%C&<XP(/4+&,YQC/OYUOTTTTTTU;913=2
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M8[Z`LO+E('?*9.B;6Y*!-'87%T#)!H6ULD0CS,TI<IM------8Y-%370@,9Q
MN.Z6>O8$!\>,<2E5:T@C"^%-1M4C>"%8FV!)1HP28N$3\E<-L$D-;@7))!LH
MT)D2KP49F0UM:V$B4@6XF9&*"0,@3U@H%4F#%@FX=:"=##20PW"<K+^&(3@M
M8%.44!#BV)")JPC%&()F/0J.I;J(Y'F=T\^7<MW5S?%K2CB>\>2\!.\.-RT!
M*X'?/@U+>9Y3@\IXQWKN_ENX(AW+-MM;6JD2-I"[</,G50D3-A*U:H@=2)C7
M4]&3'BURM02AAJ=.F,=C&IY/4%(2TY"4<H7`0%IBFUE`@@O%)=>,8Q[JB?9Z
ML8QG/BTHWW\XQCKSG_X!QCKSGW\XQC&,9S[WO=6JE)55R$&B&HW.SI87DA85
M@DVN:5)"$Y0B4)TRG`TT%+,R-"I-)7E%Y%DDXY*60I+.2F'DF5;S6%N.!!Q3
M9N2FS":9ERR6H25]3JT9&%;?+$J'`2W2$JR1X:5CY'G-/DP`LJCX6V)UV5")
MWD1#G%KJDNI2%PPEW43YORJ"[81B*K2CC^[<KL3S#<(C"J`G8499,R:)92X6
M8/PLS6[+ARPJQ()?AZ[`\5Q::\A[*;=PDQ8S7$B1%-:A)!*G6F,!KJ59@&90
MD+<X<K)7#C!DP@YR`MU+5DN0JFCP'L"\N3SP$A@7&I;I5]Z<ENGGS7SO?W(<
M"M:/4]S]Y^-3NGE^=@)_-^#GAM`N2[PYGO#Q.1OO?G?"RPO"62Q6%N8$\Y]T
ME-LX<.]>[`YKZG>IBYXZU3&_E,XA.!+>YBYM`"$W>F5?-AIN-#<>:,EEACDN
MQ]JZWW(]8:U;EIO'2E!3L!,G15Y3:\"$Q<JL8YN-*,=X0M..$RD2R%I$H%0S
M@+"ZL837(*I1)9N8_<.*KN/"PP_W3LZRF&H<#0(?%S2V"BB50YT)&F"=B"\R
M(ML!)8F608,T1RC%<LPEHSQ/\NR]2#C6MK*RC`(MQ$R:S!J<'`.(@51J1%$8
M4O)W*!`MAAY8B\D.#8DXHPB/X;"D-P9@]:Z&*X3Q2W7Z5$^_AI1OX"U-MU:V
MLD*+`MW$3)T,`IR<,X^!5&F$:1E2S'<H("*&$%A+P0WN:3B@"$_AORLW)F3T
M368DC\U7<>5A9_NG9UA,!0WFC0^+FELE&DI1P42Q,([,%YD);F"-2PL\P!H3
MD^+&>1(AD"8(CEEV-=4W*B4M!J_=!.W@E"H8C7%*IK>DTA;T2VG0`QU3*36^
M")CT8)"7%Y>0L-;C$QR`%EO8VD:,V/0X;)69K"W,B9L^Z2FV,-_=7>8<5]3O
M4^\B=51CAS><PG(D7?)<)GY"GNO*3E`W))1MW*F1.O!QJ-;JENE)W7SNZ>?.
MG)=P\_QZUH]-WQW9XJ^]N8Y*`D<IX1^!,]YWN_EN[_'').Z.2\$Z]\&IYGKB
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M.,X]U1/L=>,XQGQ:4;[V<XSU9Q_\`YQUXS[^,9QG&<X]_P![KU.N5;6JK2.1
M"'</,FI0K3.9*):G@=2*36H]83(2T*M.2NAJA.I,:3'5F/3E+BU!"H<70@7E
MJ2G)Z`OA%E2W4?SW+;IY\AYGO7E.%6E''=W<[X=]W\'F8";Q^YO"6)<MS?&Y
MOQ<,O>',]_R_OJ1!6%NA`[A%N3FPQ+L..&X>:]IP.63FR;)+192X!"<!69:S
M)="3T_>6%6%(ZI8`+L*"I-.02"A=:GN=<:\C;]T<\9BW`V1#;2DU;4BK"Q%N
MQEK"9B4@G&!*3%H(N";P`M`)T$K,<@TU&A/8EXY;8F9-S&U7<8U2T\&YR=%$
M*!OXDR,-<TJ(M`%S+M<+064:9!1*#\1L<XK\Q")4:<)P%3,:"\97`EUBXD]<
M^5I;#D2N+:]QDSCYJE0YFI#T<!J)>)O)69LOD4Q(':&+"SP-'A?".6-5A..5
M8J>/\^-3F3SOP@B%E2W4?SW+;IY\AYGO7E.%6E''=W<[X=]W\'F8";Q^YO"6
M)<MS?&YOQ<,O>',]_P`O[ZFRZVM4!*@L>XB9&F&J'8T@X4#J0(DI*Y9)E#<F
M+`7#`EF%LB9X8T*4PX)ARPF)-YSD-4J='XYQBUE57(>K5'IMSTZ0ISU*@Y.B
M*KBE#BD9!IQAA*0LY5!35)I:4H0""S5!IIY@"PC/,,-$,>:EKK"W49XC5^Y.
M;.Y6<$8PF4U[3B4`<E."%4=G!B"$ISLY4HTRML'UCS@LAQ.4$X+6D)#R=Q]8
M6X:<W#)W)39.4DRDRM(!7U.F`=.`OARE3@\9T)&:FYU)'Y*W&\D,C))$[=E"
M?AK&6,'-,:CJ6Z4_(\SNGGJ_ENZN;XU:4>3WCR7@)WAQN5@)/`[Y\&9;S/*<
M'E/&.]=W<MW!$.Y>PM==6BB`SA7[@)>\"0%L`7$Q3!JI29>QM8*T"[F*@M\0
M3`1YDHHA-QK0MH4H&_-L2$+/A$&,03$>ZZVU)=23#5A;NHGSKE%A@PORHK2C
MDV7G+7BJ\.^5.$,!3X29DF83/LK<-V$V&_QQR3#/R.(G7G@S*L%96TUD("G?
M<?-9(:F-9!JU"ZOZ?;QN1;<EJTET*.+9H4A*3AD!\+GJM6)(`@Q"9<$D*:A(
MT\4KXN-T>*JN/"A(;G<[.LDD`8@J4WBYI;L+A-J6O2789IF(+QB<R(^*S)6L
M"F&4%`99[Z4T81IXY"RV*G15+=*?*#*K=-/5^$N6G*O!M:T>1WEA#F!Y<,'Y
M2P$G*?#UB,RW"K*/)&4>+(>N[<I<Q^(999H^M;6,1C(*W$3(A2).24%<"!5&
M,T!Q8&()BK!)L,$FR,\3:[&#+$5DD&9&M"46`*!HPB@_%+=?I43[^&E&_@+4
MX16MK%HP$&[B)D>I"G.*$N'`JC`:,XP#Z$M5DDJ&!38&0)R:3`%A*P2/,<1!
M-+&%>[X6PJVI;I497Y2[IIZ@PJR[928*K6CS^[<+LSS+?@C*J`G9489<2:)8
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M6@Q*%PB"D"S,:%+X0-$%R"J`X9J>/!>,+0R>=XD/7EE2W2HY[EMT\]0<SWKR
MG!K2CSN[N=\.^[^#S4!.X_<WA-$N6YOC<WXN&7O'F>_Y?WU)$5A;A1SB,[<E
M-E!2O*O*(@=?4Z6!KXZ^8J4V"!DPD!JGDDD@C3<5SHS\G$01I4*.(L>I.<[;
M72L+=6'A-0;DYLT%8P?C*9-7M.*@"R:X+E1.<F+X2H.QE,C4I&P'4/&#"&XE
M0=@Q:>K/.ID=57(0K2GJ=STZ7)R%*<Y0B-KBE"2EA!1Q9AR0TY+!2E)1:HH(
MR##4YI1Y8#!#(,+-"`>)0RMK5&2G+!N(F11A2AI-/.#`ZD$)42A61E0XIC`&
M0P199;VF9WQ"J,)"6<C)EK@<VC2JFMA.;H1'4MU$<CS.Z>?+N6[JYOBUI1Q/
M>/)>`G>'&Y:`E<#OGP:EO,\IP>4\8[UW?RW<$0[EEV.M+8;24);IN,F<@-3*
M&PU6>L@-1(!.!*/-:<\F.`TPQ&60!W\$)OS)J0))R7%L2#D!ILQB">#]"55=
MQ@5(CQ[G)T:0G&P"4HQ5S2H2UX6PNJ`NY9II<%"H(Q)!P>P#%PDII(F\5S24
M+/E""(UUB,;V&K+A;#FXQVW,SF2%I$[04L)6UW3#>!T.0>*C#BI/&SP9$:F,
M>_`BP,JBT0R"4?CFDN&TM)X)5UX,\IE86Z(+1@.Y.;`$APW8<1XKVG19>N5)
MK8M;E3@<)R%'WH9$9L>H[MPFPF':S^!%A.5&8,&/QR.I;J(Y'F=T\^7<MW5S
M?%K2CB>\>2\!.\.-RT!*X'?/@U+>9Y3@\IXQWKN_ENX(AW+-MM;6JD2-I"[<
M/,G50D3-A*U:H@=2)C74]&3'BURM02AAJ=.F,=C&IY/4%(2TY"4<H7`0%IBF
MUE`@@O%)=>,8Q[JB?9ZL8QG/BTHWW\XQCKSG_P"`<8Z\Y]_.,8QC&<^][W5J
MI255<A!HAJ-SLZ6%Y(6%8)-KFE20A.4(E"=,IP--!2S,C0J325Y1>19)..2E
MD*2SDIAY)FYWJNXEQJL;=N<G3(6>F5$IB4M=4LL"B/.33<DA64)R@JHPXQ&?
M(XLK+*4"-3FF5\SE'EF$/LK+>*1=4EU*0N&$NZB?-^507;",15:4<?W;E=B>
M8;A$850$["C+)F31+*7"S!^%F:W9<.6%6)!+\/78'BN+37D/93;N$F+&:XD2
M(IK4)()4ZTQ@-=2K,`S*$A;G#E9*X<8,F$'.0%NI:LER%4T>`]@7ER>>`D,"
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M>*6Z_2HGW\-*-_`6IQMK:UDA905NXB9.HP*N.,U1`JC2B.(YIE.Y,04,-3@`
M5P&]S1\4L(5'#?U9O%XZ)K-20B.I;J3\CS.ZB?+^6[JYOC5I1Q/>/)>`G>'&
MY6`D\#OGP9EO,\IP>4\8[UW=RW<$0[ED&*KK?;3T9KKN6F\B*3E-(%*=;7E-
MH`+C$*JN3G$TTQHA"(XD3T1$YHD5`2C)`C+M-^-;0I5$:A!C#J.K[>%W/V=R
MDW!R&&O#EU5[3@N_,HCJJ,7Y5]J$9RCR\%PF?D*>[,I,)`W')1M_+&1.O!1J
MYDXL6OZQ:"9!9$YA]?L*AP2M!#Y-I,RQ1H.=5H3AHVPIR?ER!$:X*P)U`DJ$
MLX2I0$@X1)(PE&9#UAUONC6**-D\?+EJIF@[RM6-K1,G6Q(>WQ1T<6X"TQ>W
MMTB5/)3.N6H@-S@-8D2+#CTH$*P:@LL"4\1?8#+/K<ERB#.;/X24[6`A"YP5
ML,ED?+<9FVC(+4@<(FA&XA521"-.<2H`K925R<1!I1P3,E&`&+O.K7O-W4U'
M88DL9_MFLV2OW!T-9$,Y=Y]$FR'+'DA<X-AS0EE"YX(8E#F2Y-+HWFH"7`:L
M"YM7I!$X4(U)94:GW#T&K>:[CJ6[:B4R&WDCHOJAB3V7"3WFSD+'DS#TMKQK
M*?!K9LD9\DF]ZJ8R0Z$M_#,PK&3D`\!O%^G]&FFFFGZ/TZMPWW%4CK.%M9-=
MH5VY60VX7"<:^03:,K)N@`V%(CW(:V)IW0Q_2A;R'%O.79/;R^3*7HS57"+5
M$",N-UX^''SZ9SC'Z<XQ^G].<8_1CKS\V/?S^SW].T'W_?Q[WOY]_'O8ZNOK
MS\'O>_[_`.KW].T'WO\`2Q[_`.CW\>_U_HZOAZ_V:ZE+Y_!:_2LZZ=S.*PQ%
M(I1'H2P*Y5(&F/IWR92UQ):(M$V@YU5I`.<EDCJH(;F)C19/<W9<<6F0I3S1
MX#KMN<XQU=><8Z\]6.O./?S\&/AS[V?>_3IUXZ^KKQU_!UXZ_P!7ZOT_KQ\^
M-,9QG]&<9]_J][/7[^/TX][]>M!"[..OJZ_]((?I"P'&?^6<]>O"6(]+]>MD
ML1<SK?H^9!(X*Z/$O01A_<=V%"1A:]MT2FTD@YCJ?'G5/ES9>?7QE:I);U^<
MJR$QA.#O](77GLOE1=U?R<#G[9NW3[-IY47=7\G`Y^V;MT^S:>5%W5_)P.?M
MF[=/LVGE1=U?R<#G[9NW3[-IY47=7\G`Y^V;MT^S:>5%W5_)P.?MF[=/LVGE
M1=U?R<#G[9NW3[-IY47=7\G`Y^V;MT^S:>5%W5_)P.?MF[=/LVGE1=U?R<#G
M[9NW3[-IY47=7\G`Y^V;MT^S:>5%W5_)P.?MF[=/LVGE1=U?R<#G[9NW3[-I
MY47=7\G`Y^V;MT^S:>5%W5_)P.?MF[=/LVGE1=U?R<#G[9NW3[-IY47=7\G`
MY^V;MT^S:>5%W5_)P.?MF[=/LVGE1=U?R<#G[9NW3[-IY47=7\G`Y^V;MT^S
M:>5%W5_)P.?MF[=/LVGE1=U?R<#G[9NW3[-IY47=7\G`Y^V;MT^S:>5%W5_)
MP.?MF[=/LVL5=[6ZG=7O*VOVOMF%L-3P4BW6V.QI=*Y)NLH.6L#,TD3B+/CV
MI=XRV)A+G]`-E:'!.>S)R5&73!^$(R!E*#,A[MMGW+)NCEDJ:J[*>'DWH_)K
M*>[JOGCXL$X(MB$BD#H%,R5?.'5:,YU(VA2YT7DH:TFSNJ4I-M,B/35O+%R:
MGW:&O$&^BD`P&`",`@C`,.!!$'.!!$$6,""((@YS@018SC(18SD(@YP(.<XS
MC.MVFFFFFFFFFFFFFFFFFFFFFFFFFFO)6^G(VJ.E"HR];R[P(VV"VBV-5-2S
M=<VN;U7]2;G7NVXT_3%1*E2-M7-]=22VZ;1-$:@D^>CFQ"O1PN;P$MZ1+I,E
M:9';]*57M-]()'=QDGBQ,!VG3+9[(8I0,U7QE0T0:!7O*-Q<_MS<FO4MR5N-
M!!'O<Y$WRLYFSR21E1TZQ$M?.S$E"-T"%K785;<VN0TS;VQ&7V-%)5`:A%N;
MZ76S:1CCI`)@G-I':[<SHN5[>X_)VHJ*X65,WR],I,=(5")(6TJV9I?6J&DH
MDRIB-8VKW:@EPW#:$WBLAAE7P<O:P_L+RL-M"86#.X9=F'EJ<9`V)#&J@W>E
M@M:B%/YS6V.#1)7VVHV]J(Z[9>!Q`O!2-*X^;VVF,P=EZ+%P=)E0,?LU[J&R
M][$FJRI9]4H7[L3Y\W1W^"I$[-!I#'#AMHI2@FL6(9'E*T$E`A\J[R1*P,2X
MX\WJ-ZUKM%I2-;0=DLMAIH95`?<K220V;7^V*Z;`E";%"V.WSZ!--=S*KJBD
M\=ATKLRYVY\PYX52^(I*^@TSGLE7$HO"5JRN]\@_H^'WQ=?O9Q[_`&L]KJQG
MW\8Z^OJ]_..KJZLYQU9UNTTTU#R!.[*V-X2L*XEL?%#6XD,SDH(`I(;W4Y$>
M6VKCDYA9Q9Y2-<).I,)&4:`P!0@"+'C.0Y^:>'Q9Z4[!^CKVAP^%/[%TA%+;
MD=I3S9Z$UF>#)75%I5A<4<E6]W<1.)=W(>WFPBU8`=<9JJR5"Y1&[O1W$W1Y
MA=94KEQ#>IR;K&<[SK04[OJ2:+^MMHG#O6DRLCHZKJE%11*-QB6P99.Y!W"?
M;`5]4"9D=EU]/FY'4J^*O3/&UTJVQK(?;R.+N5C/4ZD,4@E-Y[J+X]QW8Y=B
M7[MPK?=S-K]=Y/7,;CM=N$CI.H8ILSE>(@0\S%SJB98C[RNW`PT,VC<E<W1Q
M2O2B;LL;;RUV%+8TM]AJ^W1[XVR(0%\G<]NY^8+6VL=&-<&X]]<JL;&9XVY+
M;&MB=5QO1=JX0,\`CA\571J(MM<OEA1)W32Z254TN\AM=`RMR<HTTNZD&LG>
M7,[C31B2;A[TC-6PBD]\U@5Q+6"$ULU)[G9::W%0AJVMRJRY#**>?FU2[3NI
MG&Q$RY*T&Q4NU(="VFU6)G:B7!6[NF*[5:&XS<1MXJAV<;PM"^8!940Z$VZ)
M5,76MXX>[TMNZ=MX5(2:[F:NR8I6T>1I8XW4LUN%MS:*25DE">K,L222N[RW
ML<U,;%]^EFY+>`EKH,4>[2NV/*(K!>DB04A;WBU;5\QN3<Y0>[":1;:95]G-
M1,!3-<K#/-MR"$RJ+1EKAL91[AD;U*'QG>CWEF0#1RCU?^_]DMZ62!LEMIR"
M4D;E9Q53%M^,@,844^6WO'1#IKT0L2&1)Z[;G%RCL;Z09I35+";%76#EORXJ
M7&O'Z3/R]]5*`YZ]&99D^M^'618+_>\YN>%2)P@2J+M$_H*8TP]U',B884AM
M^NC'2?C;Y3+3D\S2!>7AC5QA&AJR0N3O"&B1/C>24S1'TX-_]./_`+A/_P"T
M&OE)V.F`QM7JW&1@QG"^X\9QD6,9QGW0UO\`O9QU^]K*_B%_&`^D'Z].(7\8
M#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].
M(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D
M'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_
M&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O
M3B%__6#Z0?KUTNRY-7\,KN<2JV%\>;*P8XJ]*[!62Q&4Y1D,1.1C0/21\:34
MC@%\0.Z99EE%'0MSDHDI[D1'D;8YK71,@4YS]$)76X.MML[DUVVURJ!U&YS=
M:\[0Z/M56M>[THC;>K:6L$6KNU'U6I-.;\`="G5^KRJG<;_+Z+KIWCU3R^;O
M[K&L,\5]6---------------------------:"#@7Z>OWOUX$(.?G#G&>KX<
M=?5GJQUX][6F0!SC&/?][WNO`A8%]+&<"SU_ISUY]_/OY]_W],@#GJ_]6.KX
M!B#\_9%CKS^W/OZUQCJQU8_]\YSG_GG/7G/[\Z8#C&.KW^K]HA9S\^<YSU?L
MZ^K6F0XSGKSVO^0A8Q_SQC.,9_;UX]_]>MVFFFFFMO8#U]?5G]/7U9$+(<9^
M'`<Y[.,_MQC&>O.<_KSUVSN&G:^OFNG^J;19US_!9.)F&]M""32N)*EF6!^;
M)*V!P_PM\CLD2%%N[0@.5$H7A,4Y)2S6MS`L:E:Q$H[ZU-#4Q-;8QL;:A9F5
ME;T;2SM#2E(;FQK:VY,4B;VYO0(P$I$2%"C()2HTB<DM.E3E%DD%EE@"'%?V
M`YQU9[6?>ZO?&+/_`#QGM=>,_P#%C_2_;J&D,>:94P/D8>TYJIED;.YL+NF)
M6+4!JAK>$1[<X$EKF]2E7HSCDBDXH"U$J3+DXAX.3*23P%F!@:UK>'5#7L)J
MNOFHUB@E<Q9BA,,8S'5X>,LD5C#<G:(^RENCZX.;RL2M+4D2MZ0;BXK%(4B8
M@HP\S!8<Z[MD`<_IZ_>Z_P#^0NOW_P!.,YZ^O(?^'/6']FM>SCKZ_P#2_3U]
M7:%U?NZNOJZOV=75^S6N`X#^CK^'W\Y%GYQ9SG]V.OJQ^K00<"QU9_1UA%_S
M"+`L?^^,:\?FWH8Z.CJ<YKANY/?;!HUAVD;LUQ"([H7EHB\>S*)*\2US;F!J
MQ%S\-S4%Z?G-0D18.-"F`HX01B"'&=5_D?JT]+WI#_:R>OPEIY'ZM/2]Z0_V
MLGK\):>1^K3TO>D/]K)Z_"6GD?JT]+WI#_:R>OPEIY'ZM/2]Z0_VLGK\):>1
M^K3TO>D/]K)Z_"6GD?JT]+WI#_:R>OPEIY'ZM/2]Z0_VLGK\):>1^K3TO>D/
M]K)Z_"6GD?JT]+WI#_:R>OPEIY'ZM/2]Z0_VLGK\):>1^K3TO>D/]K)Z_"6G
MD?JT]+WI#_:R>OPEIY'ZM/2]Z0_VLGK\):>1^K3TO>D/]K)Z_"6GD?JT]+WI
M#_:R>OPEIY'ZM/2]Z0_VLGK\):>1^K3TO>D/]K)Z_"6GD?JT]+WI#_:R>OPE
MIY'ZM/2]Z0_VLGK\):>1^K3TO>D/]K)Z_"6GD?JT]+WI#_:R>OPEIY'ZM/2]
MZ0_VLGK\):>1^K3TO>D/]K)Z_"6L)^D6V*,6SS9C>FYB"[O]\1<FIQ@CLQ1&
M3S<H\2>&EI$D_B"1\%)H^.+EA=F3,>6NP'%%G!HSDHS,$E#48*ZKY;.]H<VW
M*63&-V^YB*OD"IJ`RD4QV@[6Y0D,;7Y:ZH%"G$5W3;EF(W(LE3_E#@NE"4@X
MX-24@VJDL]FQ"J[ER%)67NQC&,8ZL?7\^<^_G.?UYS[^<^_G6NFFFFFFFFFF
MFFFFFFFFFFFFFFFFL?&J2;H3C&C#U4=(H"CCF`+X-MOF:.@V\A0;5^)*8V`4
MT$U8=36HEVN(QF*4C:@OAD'KPI8<QALJ0&UE+@?=PN4J48ZSJ0*P8&;*P@-R
M2L2<@P\=<8?PIU.:8"8I`W%N=K":AF)4V7<<.@@%0&?%@O@Z]ADDDW1CY+GJ
MBI!/Q.Z^\.6OJ:*^6XO@1WQRG%H%)SG(\_8?=_%Y+O+P9B/,=V>&CMX%3;<^
M[A#4C<-UK2ID:TU,W"="$-Q2I>F2*S2F`3J2A4GTP@,7D(SU,G+0*#TR`;@4
MTLIIZ=N$^K"F&"\)=TG5CKJ*C\9ZL=>,7W-<XQGJQUXQGQ`AZ\=?Z,]6.O'O
M]7OZJ4DBW-#-SA95%+DD\!6+!B>\YBI,RI`C4#0E9*,HA.'!*A<%,G4G<7(T
MJ4TY660K-(`D/JWA_P!QQ!!HF*KJ?<%&,N/!*<[JES228$I!*3&K)AR:D749
M65CDDAJ5=@))O=Z-]D2XC+@=&6]#)XQ9)-TH`K^0J&CU(BPNN6W"N^YJCPJ$
M3B<=RX6"*V_K,H<+Q(*[PY9)"NRV8D\ORGPZ>!;3B;3KN^;@"2'D3'6U4."@
M@B0"8"G.X)2U$N*A,59&8P4ZG)J<=AM!+L<V506]')2'<;$7,9V:C)?A5\QE
M6'!N$DW1E]Y]V5%2"OA=^=T<[?4T0<[R_C/\'>\.#0+AW=WGW53W>_+]Y=R^
M&]A<IWWXM8_XS)'$@W']IXQFKJ>P`GO3N(6+KEV1.."C;0PS]Z!\2.,-//$-
M-.F..$PG;NPV;V&4GRYAK6/G69L>Y!N2(.5ACU64XYIP%NN4)KM=TO9CE!I*
MJP@,P%)*2C7H"4M<C;:O/<3"CU8FQ1+9NG3ENA<#95,^XL2+<SS8P9JBE\(L
M*%X2S\7E,<J1IBQ3?#::-+XB<%EG*@(*\$L("J,`A%)I<`D]=B&-(YI(.+[N
M%**,RUUG4BLW"GLE`77)*T!8TG,/`<G#,)I=>(!^$A#$=A/@L9>3W!T3\S@#
M2F4NT)X2[I/-'2'\>YI_0+4VW/NX4THO+I6=2)#<J>R:!#<DK7E@2<PSAP<`
MPZET`AGY2'OIV4^2P%X/;VM/S.0.RE2TQ^9%N9YL`,512^465"`)A^;RF.%(
M$Q@H1AR-`E\1.2S#DH%]AB1D"5%@7"C,1`<>AQ,W8<+V-DCW.&J&H+Q4U*HD
MIRAD"]'-]ZS)Q/0)3SH(&0G-Q!]"MH',]L3N%D&-)"@]K`\FQ:'%*SV8,W=S
M8/5YD&X_M,^,5=3V0G]U]^YS=<N[3=Q3:OP\=UA\2.<.W(D.UQ&-W,B:>\S8
M/7A2CNP-E2`ZLXYODFZ,SNSO.HJ02<7N/O?DKZFB_DN8\6'A%W?QJ!;^\>[.
M];A[HYCNWOKP(KWF^Y/&5(/%G.-#YN`.(9A/E;50WJ#R(^)_*;+@E+J2W*%)
M5<9DY34<IIQI&[DM)SG:Y;*<J(:!OI<.@AJPEA%8+X57D$CDFZ484'/U#1Z8
M1@6K+EA)?<U682B.Q!^^L(Q&[?T>5V$`E]B8;<G!0Y<\1B(948:_#1VQ":II
MD6Y@XU+AZJBF$!(TR<2T;;>4Q=#"%8DT,$K)3%J:):PJB"52Z?DD*##$HU!$
M;BB@Q.F,F#HGAVU7(MS0#<81U12YQ/`2"R8HO.8IC,*1HTXUQ6"BZ(4!R2G7
M"4ITQW%P-4E*)5F$)#3QI"*;PEW2=6>JHJ/SGJSU8S?<UQC.>K/5C.?$"+JQ
MU_ISU9ZL>_U>]J=<7W<(4D<1M5:5,L6E)G(360NN*5($RM644_B:B5RDBF%Y
MB`A8>FC!:]00F7C;RG9Z-(3N(F)&4_0BN2;HP<[R-14@HX?>G=_,WU-$G,\+
MPW[GYOA4"KY/GN0KSO#A<[W;X32[E^\_`MI\-9`$@W'Y`ZY,JZG0C)PX=RA#
M=DN&%?DLFQ1-F'(6:0!EKPK/;*K+6Y3!=>0*E\Y-)PO%`&0JP*)TD>Z`HUWP
MS5)22XDDV088QN-\3-L,<"4QEHXC`W,M/0;F%J,=BVFG!O9:8QV"PCG%B`1&
M/^*TCX[.Y39%N9PJ6`*JBEQHP#?<(#S+RF):A0!.7:68X)4F#1)A:03H8TTV
M%X`4I689`3FQ!I!O>:SCP+/KGI^W$$%+<Q^LJC<CBU#D%O+=KFEC.6I2E>,;
MNDU6:DI5Z$C.68;*IY\@HI8!N\,9UP#W'Q?L?C"B5<DW2`YWDJBI!1P^\^[^
M9OJ:)>9X7AOW/S?#H!7R?.\A7G>'"YWNWPFEW+]Y^!;3X:S13[N%R4H$;6E2
M@."H=@I2P7%*C"SDQ*R2`933S14P`1!R]"EB:AR(`6H`UJGE^2)SW0J/(5<B
MC%DBW-`5J0(:HI90B"I4`1GJ;TF252>D"<8%,<H2ET2I+3*#2,%F')RU*HL@
MT0R0*3P@P:.I;)!N0-/$%VJZG4:?&".HU!=DN<3NL:]$6HP(@^D&\`<%-@W!
M61GCYXZQ,D0BP02L-7H]RA_W'A.;PIJNIXT@SE>\S#KJEQ!J3MKH@6LY(H%(
M'!7<!O6SE2FXQJ'F5<?C"(S*4F5N2V)QR.2;HQY0\]45()\&9:^\.5OJ:*^6
MP;X$=\<IQ:`2<YR//V'W?Q>2[R\&8CS'=GAH[>!4\V/E^F@:<O%<54B,.`PY
M>PM]O2AR`@,4`KG,D"VC44\VY=`-0W.U@LPU(&K+V&'042P#'FP'P->]?;I)
MNE-PU]ZU%1Z,1N&+OC"&^YJX80Y48K#PCPWY/H!O[RPUY=KAPSY48;.^\0BO
M<K,,?C*D&*RE&)_W&*"4(I)6%0-:@PUFPXE,]T2U[*2DGIJR&_#1G+*38QK3
M&Y6ZV^0U%G$H@NZ>$U^I5&,YECOZ:MJ3$BW,\=('-44ORPP,F5IN+SF.3B!G
MI8".0A3$>(C`%06Q8XV80T",/2Y>4\4A:A6!E,G3RF@G`CDFZ,>4//U'2*?!
M@FKO'*6^9HLRE"=F#]]91X-H%'SN4(5]B9;L'91=YYC$0PHRU^&CMF$S)[[N
M%"D$-/6=2&+L$$B`G-N.5DIA*1!9,G%"5`I<XT))9A\A"6=A(,9H6QH$(@K+
MRK`RP?A+ND\T=(?Q[FG]`M3A#[N%$D"-16=2%KLD'"&G*N.5G)@J0A>\DE!5
M#I<DT1)AA$>"8=E(`907-W$$@W+,D`]0RR2;HP97<A4=(J,%B=>[LJKYFB/*
MH).9QW+E9@J@5G)97!05WEQP3E;W9F3R_"?+IX%M.9MSYD6YGCJPXJBE^6`!
M[RB-S><QP<>,A+/AQX*DCQ$9`E"YK&ZLR'<19ZK+,GE<T4)`/1D%9DT[C[`(
MNB4,#U'E5(4+/6=:8Y!Q'9W:;]EA>"&[-C.,7$\(5%%R9(`:EX8*7-7%Y1.(
M6(4MG+BA,=E-91PFQ^9PD>Z0D+IAIJ&CU>2L/N6?"Z^YJWX7"(\:&8[WCDB@
M'#+;WJ)JI_+R(C#GEE\.+#RDP^9K9@\9O87-\OTH#MEGKBJEIA('[+(%PMZ4
M-H%YB<%C9C87(:>GG++6!U&V52%Y&F`ZY9`S&="1@?,U^QAL*!623=&#*[D:
MBI!1@O+IW?S5]31)S."O#?N?F^%0"OD^>Y"O.\>%SO=OA-+N7[S\"VGPUD4[
M_N/$<X!4U=3Q1!?-=V&$W5+CS5?872\M'SI0Z0)"AX[>B@RE3P35W+*Y!)T1
M>51,4;5LLVN<@W(%'X"TU;3JQ-U']HU?=DN;CL9"O7%IL8((I!P!G!K86WJS
MLY/QDE:I5H08/)1E+UE,CD6YH:M*!;5%+$(AJ4X5AZ:])DJ4D)!'%A4G)TIE
M$IBU)Y1&3#"4YBI,6>:$!(U)`1Y-#)FONX7!2<15:5*,X2AI"J+'<4J++)3'
M+(V!Z-(-#3`Q'G($*J6*&T@9:<#HJ9F%(H/:RI"N5QV%223=(/DN=J*D$_$[
ML[PY:^IHJY;B^!'?'*<2@$G.<ES]A]W\7DN\O!F(\QW9X:.W@5+,K]N(/*19
MD%95&VG&*&T+@6TW-+'@M,E-\7/>QJ0U72K*)8<CPYVMR!!I2,#CX'07CGMW
MC`?/%[0ER+<SE4C`;5%+@1C&Q87GEWE,3%"<"@NK<R,25,*B2RU8FLQVN0+.
M`U2CP]@@U=C5C9,V9(05AO8Y#N64&MX9'55,M9!B=I$YF,]X3!Z,2*3O%=WV
M4B*5T6R!7DH.]KD[M/.-0#=,0:N\J2&KQER#%8\PY!N/P%JR75U/"&=AO[Y"
M.ZY<`*#)A-="<\-PL4@9ESPD/<[4+194!:^?*B$&-.Y`4_>RJ_CDDDW1CY+G
MJBI!/Q.Z^\.6OJ:*^6XO@1WQRG%H%)SG(\_8?=_%Y+O+P9B/,=V>&CMX%3;<
M^[A#4C<-UK2ID:TU,W"="$-Q2I>F2*S2F`3J2A4GTP@,7D(SU,G+0*#TR`;@
M4TLIIZ=N$^K"F&"\)=TG5CKJ*C\9ZL=>,7W-<XQGJQUXQGQ`AZ\=?Z,]6.O'
MO]7OZJ4DBW-#-SA95%+DD\!6+!B>\YBI,RI`C4#0E9*,HA.'!*A<%,G4G<7(
MTJ4TY660K-(`D/W.TBW,$FJL,M44PO)`F4B1#<KRF+68>K"FF8DA*DM-1+H%
M*0<J0P`D]068J&G(DDK4%IU)D/:T\QI5DDW2@"OY"H:/4B+"ZY;<*[[FJ/"H
M1.)QW+A8(K;^LRAPO$@KO#EDD*[+9B3R_*?#IX%M.)M.N[YN`)(>1,=;50X*
M"")`)@*<[@E+42XJ$Q5D9C!3J<FIQV&T$NQS95!;T<E(=QL1<QG9J,E^%7S&
M58<&X23=&7WGW945(*^%WYW1SM]31!SO+^,_P=[PX-`N'=W>?=5/=[\OWEW+
MX;V%RG??BUC_`(S)'$@W']IXQFKJ>P$CO3N+.+KEW:<>$;:&&?O0/B1QAIYX
MAIITQQY83MW8;.+#*3]YAK6/G692.<CW.%*'4+/4U*K4I*A["RG.%ZS)N/7I
M2#IV&/'.)!%"N0&P]S3M];F.Q"<]T`S&RF8E)#WD,(:#9QOQ(MS/-C!FJ*7P
MBPH7A+/Q>4QRI&F+%-\-IHTOB)P66<J`@KP2P@*HP"$4FEP"3UV(8TCFD@XO
MNX4HHS+76=2*S<*>R4!=<DK0%C2<P\!R<,PFEUX@'X2$,1V$^"QEY/<'1/S.
M`-*92[0GA+ND\T=(?Q[FG]`M3C:^[A32R\NM9U*C-RI[!H$-QRMP`!'S+.'C
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M-Y^2\#`%2W.:)6@5EA&+)*I,<2/.!EBQBB\L3T7OIT[;OXBMW^7IY8GHO?3I
MVW?Q%;O\O3RQ/1>^G3MN_B*W?Y>GEB>B]].G;=_$5N_R]/+$]%[Z=.V[^(K=
M_EZ>6)Z+WTZ=MW\16[_+T\L3T7OIT[;OXBMW^7IY8GHO?3IVW?Q%;O\`+T\L
M3T7OIT[;OXBMW^7IY8GHO?3IVW?Q%;O\O6PSIB.B^R69C&^G;?UY`/&.JQ6[
MKZ^SGJZO]7^GK_1KRJV]=(-(Z,MC<CN:<+5?MPG1V6_NIND;XX-0E$Y-VOLS
M*^-$>9-PE3K4!2AWD6UY>F0*";RA"`MV/KAP*-NV"`.CIEF,@/IK87YDE+(S
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M"'!\381CG;+"G]I9`R\F3-C:0C9TK>C2^N:S<E1*"\6C;0JM2')[[?HX=+F>
MJC'8O$S<(RG)<E"E[3-7#%VT)"=G=#QF9,QD($)^<@_T>K/E?!=T&Y"2[5-I
MLKFLVGF6:Q]V>YVF=R&XNL:ZB[A-*R@%=V7NEA=021/$FJ#2B*QQI?9K7-35
M]*9D=`'UH8$#N8H>"6[+THE35;YEWC;TIK3O1U;CY8*6UUMNL6-UJIW#6U3#
M'3CQ('296-;4>KNNGJ=T[=$)=)5']NMCLQ[&_/DGI)T#95?G6LB<3FHV(1%>
M\)?H!#GKQU]?7[XL?![^,YQG'_+..KK_`%]77UY_3K733337DO<&Y:WX%NOW
MD5@A>+AD$-ANR&EKAK1MKNN*]DR>LK%G3]NH8I"_KW1=&^]%I2HJFH:M86>6
MK)(REK,2;`D!B-82E1Q>WKI$'O-6;?8G:\2EDSO.S=H6S&_HR^875]'$>X%]
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MTC3`Q2(UO#5<OD<'/MF[-LL6L5I>6,LJ3[EZ!JZ8V3+8"OC[F!O412,R+-:V
M+#(;8KLY&MCA.(FI0O#.PL#W$Y(_VQK3I:HW8L=2'#H.Q8S.)FT;3)#4<+6N
MS=*ASICWAU!/;AKM4XK*V:9J]QE7'F&I+2Q.&M)$94N:TT;;7)K`\@?A)6GT
M<H&U7&[J=@5IO%86-3#Q+V;*YWJZV63P>G\*=4JY8UN3*_MN##`=9:U`>>UN
M).0IWID4-KTF*)(<"R2[NF_^G'_W"?\`]H-?*IL:5JP;5:K"!6K`$*^X\!"!
M2>`(<>Z&M_W@A"9@.,?LQC&-98<ZM_VY;_U:G_-TYU;_`+<M_P"K4_YNG.K?
M]N6_]6I_S=.=6_[<M_ZM3_FZ<ZM_VY;_`-6I_P`W3G5O^W+?^K4_YNG.K?\`
M;EO_`%:G_-TYU;_MRW_JU/\`FZ<ZM_VY;_U:G_-TYU;_`+<M_P"K4_YNG.K?
M]N6_]6I_S=<`S##!\09AAAGQA@Q&CS[W9ZA9,R/M!R'.0""+M`$#.0"#D&<A
MSUK8Y8LDVB[IJ]V@5NG<Y_MVW'`G<RBU&,HBECSLP6Q@A6]S*S8B2>:44Q;-
MIS(UB.+KX@O6I$M5W?(F-GJ!"\Q^=.\.A7T5XSUXQGJSCKQU]6?TX_9GJZ\=
M?_/33333333333333333333333333333333333333336/-R;8ZRNN55_8;]X
M5Q:T*L+D2*!6A7$O?(%.V-BF/=.9C$#GIC4%%/\`!Y:8P,"R0PJ4(7R+N#M'
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M-ZF;-*UH9;EH8V"#,*"JB9O)R*-)#63Z;(Z^=R:8*<`UZB?HF[#(4MKHVL:$
MP\31&,NI;EF(103+D!C'5[WY_/[=-----8\NNV"J7BP;BM!6GEY<SO>JX]2U
MCN2.P)FB3N%<1/,O,C+$QM29Z+:H>H9%%@SI8C?HFC9I!E=*W9:H=#U.4AJ2
MP<"V6E1JZZ2=7)%6WB'V75Z&&[+6!$AF[W<$*4RBNF^LIQX>V),I([IG9@:H
M>T)X["VQH0=X+D:HIRF#NM=X\UG*>LNO1-[,GHV7$N$7L_P<EZ"\60^"M]^W
M6R5^P1C<E+8E8%W0Z'0UEG#>RQ.&SZ?0QFF[A%69.F8VV485.S`B:3SPX)O]
M(]F=$2JU#K?>8\['R=X%5:R<(29,])(I9S_1CN%_IJ6V;%$RDIEFLMK1X+3K
M8Q('5,)<#+>R)703H@CD<2--I8QT8VTF&PR8U_'8K-T,2D4L89K$&4VV[,<D
M-#/\3G.+/B9NV=*ZR9<FV]M\8L?'AFRLM7$Q]G2.@2$8T)T?1H65-I9'1B[2
M[48V]DD\8G"4>(G>\%EK[$K7L6$2>THAN:7!>[TCEMOT3D#0NL9IL&5$-\O6
MI)()46S29J:W&,!8RT1277=6W8+MQ:9&_2%"Q2X&)`Z/\L5,I]C3=<Q);+EU
M9+:;F5Q-Z)>]*CDEP3*MW-TCTHL;"PR1/"AY?I.I4YF,A?I$Y='<>B_VA+HH
M?$TD1G4?*+A^W.%QV0Q>Y+6CLX@:':4A>6O;N\5W.&N6IY1!Y;6S7))(V$2Z
M/N:-_E+9(GUMG2V4H'9:G.S9@,%CE:0]@@T33K$S#'4(4*+O)V=']V5"$::J
M6.3T_OBQP?']]=G!0K=7Q^>EZYX>G98L<W-8J6JCSA]M&'(L8QC_`.H`O?\`
M@",(L_/C'5C]NOG!JSH\NDMI:#-M819)L+E,:B[U/S&"02.V-R;(_NC/*K+F
M<Z;CGII::.<VMO="$LI*1+DS>X+485"48DZHXL01YN#[D/I2_P"RO1Y?QLW1
M_P!`-/<A]*7_`&5Z/+^-FZ/^@&GN0^E+_LKT>7\;-T?]`-/<A]*7_97H\OXV
M;H_Z`:>Y#Z4O^RO1Y?QLW1_T`T]R'TI?]E>CR_C9NC_H!I[D/I2_[*]'E_&S
M='_0#3W(?2E_V5Z/+^-FZ/\`H!I[D/I2_P"RO1Y?QLW1_P!`-/<A]*7_`&5Z
M/+^-FZ/^@&M,[1.E*QC.<Q7H\O>QG/\`_>S='^K_`/T#K#&-[@K6?BE%/I*W
M@DFWH/-^;@]NM>TM!I?*'.OI#(-O\W5PV6V_(YD[QQKE<,V\0X@M-)K(GCM'
M$ZYO`I;H+$T3]8LIBK"O]XMC^R"-[28W))'(I(9;VY>WAM+ON`W`/#02T.TX
M=6DDX#%#X>Q`.6%5S2-<DK%C15%4-"PYNC+:>M>7I9(IY(I;+'S.S3333333
M3333333333333333333333333333333336/C5N7KQY,:"DD?NTH3T<PD(\N6
MW&_6<!(Y&;5Y*`3F8ZUPC`SE$#MR+Y>3G42,F/EMEAG/@V\JJ+,'%)<%^P@:
M5*KPRVU@I6!F,*`*BKG"H"%]'7):+"A(*"X5)!DBM&-Y=0*22AL@&Z=#>`H@
M5G80HU#I-S->+>2X,?NX'/\`=G`YG;A?R/L=[>!'*\WS=<$\CPO#]C[PYW@=
MU<E+N\^4\`YKW#--U]PAT2-RQ.RVR64YIFY4G"NHRYFU066Z%,!R8*Y(X05,
MI;3RP21OPN3+RDRAL,3O1+B6F-CK\!N@_=-UWG&,XC]W]6<8S[^V^_L9]_&,
M^_C-<8SC/O\`OXSC&<?HS[^JE)N0@"PW))3#=`1X(5J,Y4;>+V2E\-$C4+C@
MX.4UX65DX9*8P"9/@?'6*A$HDA9RM00295/&X6",A!JA8QW`<`K+B$86R@[M
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M@VT"57=8\P'`7GBCJ.49;\M.5N'8ISKTYLYLFUJS,E>U[W$P-@.5D+F*XSQH
MBW4TX33M^O%])&%G56"D583'LU?KB%AAIM:2$3<4D,.,=T[A"536!6FL>`FR
M/AQN/@&58T7<-S\4L]>G$/.WF]L)LF-PIL$\0%F:\Y4PDS,`>\HU!9PB'`*V
M)#0F*`3N%B?9!QOV$-A1AJADMHP):GE18145<[D9DW*AX2X$`I!!%!AA'%9%
M@LJ@!$FPG.;%.3<)WEI-60ONFJ\_L_=WLWW[_3G4TW7["',HLU.R6T6$Q3RH
M<+:*N=M,P;A0SI<B&4O@B<PLCBO:,6%0PA393DNBG!N4[,[&HX_.X^`85@1=
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M,P2/<U7:X*`1,>N\&'$+4(CFMMU_H<EX>,0<23G`K*W($WY*Q8#'WB%=A/EH
MRBEV'3"3,"FW<-4T[CX`\FI24C#<Y0EB9.J*RY;>;U:"P%JD\,5%A4FNE>)"
MTAX2YVRA/3*A%*$IZ.5)5)92B#S$IDVJ]R$`1FX)-8;H$/)"11C*?;Q>RHOA
MK4:=<2')R:O#"L'`)4E@5)\CXZ-4$Y$K+)5ISR2Z;W3==XQG.8_=_5C&<^]M
MOO[.?>QG/O8Q7&<YS[WO8QC.<_HQ[^IQQON$-:1Q6*&6V3"FQ,XJE`4-&7,Y
M*#"VLI_.4A0I&^"J5+D>8"-N&$*9`4I4.9BAE);BU)LB80.,*KW,UXBYWC1^
M[A\AWGQ^6VX7\L[?=/AOS7*<I7!W/<7P`?.[^2X_>O.Q'NSF_#R%=_2`-PT$
M&!U&%CN'&&?#AE7@=`W>`1N&TFQ#U'=H1P`(G?)@*PD046&O"S+B:XP<E!S!
MME5^"243IN6KUH-=RE4?NPT3(;("5F6[;G?;L6<*-&6@6X9;#6RN59;R6H%4
M4IRR&M(EA<C`Z5X8PB<06Q6(I9RF;D(`4J6)!,-SY-0C?0'"+V\WL:G'F/%V
MB8ORE5%UX),M">&H93AG&C-/`_C=*[`R"7CMFL<2RN>K_@["4M.6LEN'`0*'
M),=AIH>Z7TP9C5XQN9$D)9H(N-7$F>*Z1\@H1@/(<^\8+W<8I\9=>^$L2KW,
MUVBYWC1^[Q\AWGQ^6VX7\L[?=/AOS7*<I7!W/<7P`?.[^3X_>O.Q'NSF_#R%
M=_3)5^0@TI0<%EMK`$Q[JG,P.B[F+,$8S+)&B5B(*'!0F*233HLY#;E"<)A#
MNF4L*UK,5I)-'3G.,6;D*_1JE2(YAN@1J50H2'#3;>+V5IQ&)SC"#!)U:6O#
MDJH@0BQ9)5)C3DR@O(3B##"A@%G#_:Q36T;;?9VXJVJU@]WK;<W.VM+;4L^Q
M)Q15T#?S`S6<J'Q#7L:<EU;-J6.5I%7R4*W!JB37@HC*U:_3B2&.3L:[/969
M:C<-!$YS>28QW"(;ERO+Y)H*[CRR^;71%O*YTXF`C*;NP?-6@:G*\:?"1(DD
MZ]5P44-EA[-'(]S->+<HL$Q^[@<_EKP1S6W"_D?8[W\".5YOFZX)Y'A>'['W
MASO`[JY*7=Y\IX!S7N&?;+UACL!I&E9K4*"\@8C$F'"D;@:AE!D0*Y&@PY%N
M4)2C9QD8M&.8>`.H48X^)NG0'P+>*M+"Q&NOMVYJNW/#7E-'KO+P[X8LI>>V
MWW^VY*Q(<5AE#WAAPK=-EJR1XVXOWQASPDRP9;+"P^8;\U39G@I*,6X."R(E
M"H0,=O$`<#68H@+Q0EV1\T`GU-62M%E80^0)O.0%DE6S&`NIBTL@MD4-E@)7
M@2%35EDE1:DQN0@&3TB?N&Z.(L`R#*%G;Q>^"08?TL!5H<*5&:\X"01!5CL`
M78"HPH;$H03-*]80J:\G94>IT>YBO%V4."8_=P,N`FH)'-;<;]18!EXS!PI.
M<RLK@C"#!6;`8^\<K<I\-.$,NRZ<IB!3;+#,GWY""$@EHV2VA$@()49`515S
MGJ<EG`9!@"%&3!!JQG8"_H<&)PDY/)&0[@-+`-B>@H(3W35>?V?N[V;[]_IS
MJ;(OR$'I`K0,EM!)&0<HP`VBKG(4X+)`]C&$2,Z"`5@.R%@78+3B)P><,]H`
M46,;ZRA7PRS<Q7B'*[!T?NX>6\3J$_E=N-^K<#RSYG`5?)Y1UP?A?@W-?OG=
MV465&';"Z(Y:^;Q/83E^J,[D(!@]6G[ANCB(P/8S18V\7ODD>&!+/E:["91B
MO.`K$>57#^%I`E,-&^J%\,2LN%RFPX(5(:M]W!P6.DKE"]CMX\#>:\E'A9Z$
MNR0&C$Q)K-5K<I"&.!.!R\LXJII.%J,1%GEO:ASK]*SB7*;3K8J4Q;CN:KML
MPZ94QZ[S,-&'W*KD=M]_N63<1[%GY7=WX;ZW4Y=<G^*24=SX;,*\O^7.O<,>
M'#-K5GX5]@<[UAC2!V&J9K4-"S`?3%>&^D;@=1FACH+&&OPVEML)5#>!GXJZ
M1X9P-05@Y`)Q@H&,+@*RZ]Q)8!9N9KQ%E;@Z/W</D,NF#^6VX7\L[?='AOS7
M*<I7!W/<7P`?.[^2X_>O.Q'NSF_#R%=_2)&X:"*#G`DMCN$(VWFN8R=05W$%
MF<HNES>;R1QT!`4X]L^%.XT^4`U&%:17&%Z7C(IE$SWG:Y[AX(U'X3J6*X3#
M!8/S@2"@;O<R>I.O6MQG6H;X`I(QD2A`<83C)F,J$0TC@1@Q"N1J#Z9)N1@"
MU6E1E,-T`-5J4Z4H:G;Q>R-,$U2<`@L2A6JKPI*E(",S&3E2DTI,G*P(X\TL
MH`QXDS;\A!12<X3+;60*3VI.7@%%W,88$QY61Q$D$>4""B,3$E'2EM&XJ%`2
MR&A,F?EKH8D21F1'-D,DW,UVMY+@Q^[P<_W9P.9VX7\C['>W@1RO-\W7!/(\
M+P_8^\.<X'=7)2[O/E/`.:]PRS+?\'?BD1R)DMPD"]0VIB<.U#W2Q&`,=?%S
MRPE9+S!$)J$DOQHQSGU"P!!#9W=.N\3$WBTL+P:H2]R$`-5(T@6&Y\&KAL0"
M1&;>;V*3@S(2ZN,095*C*\"F1!(#;T6P\#6&D`8!M=B`>Q(!U-9V(GO8]QD!
MD)K>2A8;E(&Y)VE2GR\;>[S8"RRWGQ7<H%:<]U\@*;CBO&]%N\DZ\:8]GRUV
M)AU+1YJ>SL1/E'N&@A86H8F.X<X>,(,I,`H&[S!%=Y$UV>G[Q""`"$T9+!9\
M=PMPZ82=W&MTX)7\N;6U@`C<>DW,UXMY+@Q^[@<_W9P.9VX7\C['>W@1RO-\
MW7!/(\+P_8^\.=X'=7)2[O/E/`.:]PS3=?<(=$C<L3LMLEE.:9N5)PKJ,N9M
M4%ENA3`<F"N2.$%3*6T\L$D;\+DR\I,H;#$[T2XEIC8Z_`;H/W3==YQC.(_=
M_5G&,^_MOO[&??QC/OXS7&,XS[_OXSC&<?HS[^JE)N0@"PW))3#=`1X(5J,Y
M4;>+V2E\-$C4+C@X.4UX65DX9*8P"9/@?'6*A$HDA9RM0029N=MQ\`9C51*M
MAN<T2-,I5&Y;=O-ZNY8RTJ>9JC`IC6NO%9:L\1<$>@D)DHC5"H]9%4J8LU1.
M(<4]TJS<U7:$*\1T>N\>&X+J(_E=MU_KLF89\3@2ODPHZW/$X9-Q7[YW<%#A
M1EWRMB.&O"O,]A/?TZ[WQ"F4AY4+&:USBV(B0*%H6RCKC>#C@1HJQSG`+4G:
MH.L/>SE`*MDF&4AH+6G2(QQ@A3"6XFV;7@)-!N&YFO&WO/F(_=QG=7?G,\EM
MPOYQXO@_XSN>[OY"N%/>G'\4DH[H[MYKO[O.O>Y.?\:U9^%<AC<-!,B>`X8[
MAZV/O3G,YH*[L!.[H-M`E5W6+,!P%ZXHZCE&6[NG*WO8ISKTYLYLFUJS'*Z5
MSW)5^TJ'5,J8+J-,9U#VF5B;]NM\NA!IC`=.B%PFY0VUTJ(=R#QUX^B:5#68
MK(?2ET..9C%Q5@0<;_NQN/@&58T7<-S\4L]>G$/.WF]L)LF-PIL$\0%F:\Y4
MPDS,`>\HU!9PB'`*V)#0F*`3N%B?9!QOV$-A1AJADMHP):GE18145<[D9DW*
MAX2X$`I!!%!AA'%9%@LJ@!$FPG.;%.3<)WEI-60ONFJ\_L_=WLWW[_3G4VW7
MY"'0LLU.R6T6$U3R@<+J*N=M'@WF6=)VC"W""IAE)^*^(Q<T8$*;ER715Q>6
M978Y%"H]S5=K<(LDQZ[P=X8:\D<SMPOY'V.]_`C*7F^;K@GD>%X?L?>/.\#N
MGDI=WGRG@%->X:]DW$P-_.2$(6*XR!K2VLTD3MM^O%B)`%X55\D2X4GO-?H2
M$9A1MEQX3B4K,),:$[?-E3H!(FKB?&QS46X>!@RTXRQ7%GOK#9E)V:`N\?"[
MV-K`I-WEV(`+N?)0K;B^7##KR>6LMLL(YRPE*JFRQQ6^O5^_Y\_G]7^/PYTZ
MOW_/G\_J_P`?ASIU?O\`GS^?U?X_#G36G5C]OSY^O3J_?\^<_P".=:Z=7[_G
MS^WZ_P`]6-.K]_SY_;]?YZL:=7[_`)\_M^O\]6-.K]_SY_;]?YZL:=7[_GS^
MWZ_SU8TZOSUY_/Z_SU8TUIU8_;\^?KUKIU?GKS^?U?GKSIU?O^?/Y_5_C\.=
M.K]_SY_/ZO\`'X<Z=7[_`)\_G]7^/PYTZOW_`#Y_/ZO\?ASIU?O^?/Y_5_C\
M.=:=>/V_,+ZOS_SSK3KQ_P`7S"Q_AI[W_%__`-ZUZ\?M^87U:=>/^+YA?M^O
M\]6-.O'_`!?,+]OU_GJQIUX_XOF%^WZ_SU8TZ\?\7S"_;]?YZL:=>/\`B^87
M[?K_`#U8TZ\?\7S"_;]?YZL:=>/V_,+ZM;#!=D`Q8Z^L(!"Q[PNKKQC.<=>/
MUXZ__;WM>1NWSI*75^W;W-M=W$1%J@;:LW"VO5FTNXF0Q3X$VD;6@4.7FEYU
ME:J4CAM^H$V'.4P]$887'[A@Y#@HB&4\KALF8!^NN,XSC&<9Z\9QC.,XS[V<
M9ZLXSC./>SC/ZL_!^S.M>K]_SY_/ZO\`'X<Z=7[_`)\_G]7^/PYTZOW_`#Y_
M/ZO\?ASIU?O^?/Y_5_C\.=.K]_SY_/ZO\?ASIU?O^?/Y_5_C\.=-:=6/V_/G
MZ]:Z=7[_`)\_M^O\]6-.K]_SY_;]?YZL:=7[_GS^WZ_SU8TZOW_/G]OU_GJQ
MIU?O^?/[?K_/5C3J_?\`/G]OU_GJQIIU=?P_/G'^&M.K]_SY^O6NG5^_Y\_G
M]7^/PYTZOW_/G\_J_P`?ASIU?O\`GS^?U?X_#G3J_?\`/G\_J_Q^'.G5^_Y\
M_G]7^/PYTZOW_/G\_J_Q^'.FM.K'[?GS]>G5^_Y\Y_QSK7J_/7G\_G]F-.K]
M_P`^?V_7^>K&G5^_Y\_M^O\`/5C3J_?\^?V_7^>K&G5^_P"?/[?K_/5C3J_?
M\^?V_7^>K&G5^>O/Y_7^>K&FM.K'[?GS]>M=.K]_SY_/ZO\`'X<Z=7[_`)\_
MG]7^/PYTZOW_`#Y_/ZO\?ASK"RW-SLG0;DX9M"I.*Q^2W"^U$^[@)J_SIT>&
M:`UG431,FZO&9>OPP-KB]R>96#-EJYHAD60"9T.&J*362/DC0!9&MGD=MDNZ
M_<#(KK3;4V:H*S8-P;'5<FO.TES[8DG?*FA57++=E]34.I:'=C@Z"32F47L?
M!Y-*RF14V1@JN(S'GX3\K>GDEE:'WHU2])`ZVW9FVJM&ZIVEA>K0L_=_1=YM
M[K.G!4Z4G<6S`XY+8;#'\(X:!KLV-RM044NADH&X0LPR,NC&]KV<"Y<N8&GU
M2$/`>K'5G.<]6/T"[/7G/9QUC[.0X]_]/O\`7C'ZLYZL9\NXCT@,PL.H-L3P
MR5I#8I<VZV_]Q&W^$QZ4SMZ<*NC$CV[NFX<Y]5OTW;H>VR%VQ)(YM[=QQMM;
M(B@<%KR_$`&20VM"XXWJ,&Z6BJ+07;;HJR!BM;S"Z*PA-J3TRWY<!EBE3I)S
M9[_2$2@:9Y;D0RY]8MDW%"I]#:Q;TIT887UMASI)G!];U3A$8G*_77&>O]'Y
M_/Z]------><]S[Q9U1V^:A:2E3!$3-MEX1E%"CK%`G?$LNKW<C.'>9!I..R
M)?WLICBJ!6ZEK2;0QG.[A;W9OL\^%LN7-<1*"2"+75#TE!\MMS<ZTSN-M+;6
MT4LC;I7VTIFAZ!S<[7OSQ]01\DL<=#BWI[;8Z4JF1L4D<MB:#*>--$=J1*GF
MTVDQ"8#N:TW3:.D]VXR:21J*1%HNN7O+W`YG8;Z1'*;EJ\NMV6L[#FM1V@BL
MTP9:;P1D-;6E`GR!S)@/"J<&U]$W#3@6M+@2Z8QSLGI9XC(62J7#;^@ER%T?
M;8V$O[U&;7I*9MLAM+:EO1L]MKN/V32;>-\9U:X:YV5+X^G=U*!U41R3M@6V
M21-N;WV/R-7=MQZ3ZB$K)'+H,D=A-]2E[3]SNXV5PH_;],5DV(;-MEJ5Y6=J
M'J'U.]A+9)/3,D<Y!&)C6J:.R,V09=2):@EC7'XR2;*>]O?29;<([#9I*7LJ
MQF5X@MG3&J'>N)!#`Q:R%4DA%51J]'4YFCTJ>6-(ZMJRG)K#K`8QD/&')[12
MECC2!J,GRS$1+S9KBP(G;%?0:TH&Z9>X/9$/C4\A[SE$O;1.L7ES,B?V%Q$W
M.J9$Z-XUC6X)3S$#FB1N*,8Q)ER5.J*-)!W/6PS.<!QU9SC_`%A6/>][WLF@
MQG'[LXSG&?AQGJU\@FVJO7BX:5BEFS[<)O5<YC,7ZVW%]6MN^G=S&FTPY%>-
MG,:$ENCT<N)K865O0M#2VMR%L9VY$WHTB,DE,F+`'JU?3W.C1Y]=\7]X)O3_
M`*X:>YT://KOB_O!-Z?]<-/<Z-'GUWQ?W@F]/^N&GN=&CSZ[XO[P3>G_`%PT
M]SHT>?7?%_>";T_ZX:>YT://KOB_O!-Z?]<-/<Z-'GUWQ?W@F]/^N&GN=&CS
MZ[XO[P3>G_7#3W.C1Y]=\7]X)O3_`*X:>YT://KOB_O!-Z?]<-,[<V?.,XS>
MF^+.,XZLXST@F]/.,XS^G&<>/#W\9U6G;<*H6U1*J8>4$NE$,FS\]2Z3KIC9
M=A3&Q'*;/D@32TV?XMF4R-XLE+8+/*T+9)XE-B))B0Q!_:&AR8%B,;:F`'.'
M8AO/L:,3ABV9;P)&9*)TX)%P-LVY]P(;FA!N=C[$D&M60&PTJ,*1IC.[6$L)
M!SI*H^UITS!=$2;'*VZY1H\MT_B$-]G/T_HTTTTTTTTTTTTTTTTTTTTTTTTT
MTTTTTTTTTTTTTTTUA?;^UJ2ONY"`[MZ2L!EKNYHS5[]1$W132'KY[7MK4P]R
ME!/&Z//S.T2V$O[!+8%.$*A_K^:,;^(IM3R>;,;]')$AD"0UDAW_`&IV$ENQ
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MVK#N$E^@T/?YA(F5LLVO9!8*PB`3=T6NC>UGMS>]+XLY#"K:5MJYST4E>+XV
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MI*U:5(`A[00Z/1$+<PI64D#86Z9L/MVZ,)1BC]J1FX*Q9X.[J2K38Q&A]V`K
M7DXLDV8O3%9;+5Z54QL"QGD43D5P-6'J72TG"*6RF.-,8;$3C%3$*O)_>'/H
MF*L=*\65F?<]SEQY=1F];;Z>>255V'7,'WYVNTW#=*P*DVO34P)&U29D0HJ]
M7A18;V!C":F>&J2+S<N6.ZROHY&YUF<AM:$[CKMJVXW>^"+[:[&BK53KHHCK
MJY[>*^VNV!"$T3F5:22&/L`L.JZNA)[LVRID>WICGK"WS2*/K,>G"W9]$(\S
M%QUA96`IP=W4MD:F]I+=']Q/>'UQ`WI"4@5[R[*LY4N;JLP3S+BX*,Y.6+#3
ME!G4(S.,3&MAF,Y#CJQG/^L*S[WO^]@T&<Y_=C&,YS\&,=>OD$VU6$\4]2L4
MK*?;>]ZK9,8<_6VW/J)MV+;N9*VEG+;QLY\0G-TACE.NC"]-ZYH=FUQ0N;.X
MK6]8D6$G)E)@!=>KZ>Z+:/,5OB_N^]Z?]#]/=%M'F*WQ?W?>]/\`H?I[HMH\
MQ6^+^[[WI_T/T]T6T>8K?%_=][T_Z'Z>Z+:/,5OB_N^]Z?\`0_3W1;1YBM\7
M]WWO3_H?I[HMH\Q6^+^[[WI_T/T]T6T>8K?%_=][T_Z'Z>Z+:/,5OB_N^]Z?
M]#]/=%M'F*WQ?W?>]/\`H?I[HMHQ^FBM\7]WWO3_`*'ZY`;G*=Q44IN]>]29
M@@L+DTB@TE3RFNI_%)^W6!&)6&!KZW#54ECK38RJR%\Y-2PR-0,B.9DDIE+@
MW,S&B5J%I.<YV[#]F,_DTS8]YF\.'IXW8C>2L.VP;<'0:%YQM6C+\@/;W29S
MA<C/5LDAW66(Q*,-\VD#6)6ST[%3E%15PYJ2UUARJ<>S/Z/T::::::::::::
M:::::::::::::::::::::::::::::ZN1-X:IR0%/+(RHRI$F`GP2_M!N3Q+1
M,X4@2<%K19-$J%(6#"8)?:R?E[:,%8'ES0X/Y\2Z*Y``S$E8,EF83Y`/#TV9
M`/"K+2%+D`N:[(L*!/S)@C(<YP=EW:\%]K+BCX]."<0PWA\.61DSC<'A=B0-
M`^+S'=W+\/LK<]OC]\-/![/7Q>\V_L=KG4O%J"I;%CP%&$R1@.+/`482,IY;
M#`'`/"F$0,H0%0@F!."M1B*$#(@F85IL@R+!Y61TWAS#/[61G]6?_F!G_7_^
M;K>":P\T60ERJ-C%@(QY"!^:1YP`HL9I@\X"LSGLEE@&8,75U``$0Q9P$(LX
MY#YC$TH1#4R>/)P!XO:$>]M9(0\`I8<?VA&*PXQP26YP--Z\_P"K+0K!C[($
MIXB^$R<PPK!N39;&2\$\;)V3)`S@P5A-WCS&3.TMQP^!W.[<;M]7"[L<>)V>
M25<*I/ED72A4#4R-A("D"J&J$<\MI04X46'82P1^3%0<$A2A87L2D1N08(PT
M.F3L@PW+>!3&SB&$<;C2R,D\OS''XK^T%\'D^^.;XW;6XX?*^#S]S';[/`[D
M=^+V.[5O`Y?#&)]9^/">/=:7C<S_`.>-7_A^7$\!4<?_`,7_`*G@"CS\$[B=
MGA"97?`^SEL7<OHHF412"&!5*(ZF&4$\1@5#XU$B+"F&Z%J!#":K!D`2!L;R
M`[(L8P4-I<PF=D3>KP3IX:1#MY*\*HWQ`B-`(OOUI[81DY<<'!R#G.U@166A
MUP8'..LO+8X8'C&42GA<ILNBI&,B.DC`4$(^&+)KTV%XP/MGE]C.1J@XP/B)
M5)?9SGK[:<\/5UDF8#3>',,_M9&?6!G^VZJ2I=%3\8$3)&`T(A\,.2GIL,QD
M?;(+[&,@5"QD?$5)B^SC/7VU!`>KK.+P+B\-(AV\%>%4;X@A%@"7WZT]L0SL
MMV"0X!SG:R(W+NU8+#C'69ES;\`QG*U-Q="9M#E`R"R)7&CAJ1IP)P%/S2:(
M\:L3:%*`D(%@A&B4B>6@*<)>!".$Z-V"L#RN2X.W^&,3ZR,>$\>ZU7!Y;_SQ
MJ_\`$<P)G"GX'_B_]=QQ2%A"3P^UQ1/31@':RYH>8XBIQ##^#P99&3N8Y?@<
M)_:#.-SG<_*<'L+<\3FO"%AY?L=KC]]M'"[?>2+CU)$LBZH*<::1L)X584HT
MHB7EM-"H"MPTB1B(R6J%@X*H+\R"3"*R/!^'=KR3D>'%%QZ8N<PPW!62I;&3
M,'<').2Y`SCP;A3W=R^2^RMSQ./WPT\'L=?%[S;^'VN=2\7<1,X>IR`*>51T
M\1@`&%A)?VLW)@#`-YA8P8+6BR,(RW5K&`0>L(@.*`0<Y"L39-T'-(<4+`3)
M5'`"R$`\!&_M0,Y`:6`TL>,"6XSV3"Q@,`+JZA@$$8<Y"(.<[/#B%_VMC7Z\
M_P#S"T?J_P#SM5)LLBQ`#3#I(PDED`-,.&:]MQ8"0$!4B/&:(:L(2PDA1+!&
MB'D(2\)%.1Y#@@W(*<R;PPKB<26QHO@\;B]N0M(.%R_>/,<3M+L=C@=SNW&[
M75PN['#M]GDE7"Y<3")9P?G$GCV<)N+S&</K9G!'`"ZB.XV<+.HKA!8GH1G$
M[/#PT.F1]G#>LR3QG36&I\GA42R-D"3"5!4X.D#25D@2++P%9@[`UH<E92YC
MS_A3@S`<I\LCO@[`,MB[!&[,SAX1F%BE4=P85E3@T&7]JP,O*/#R)7@P.5O:
M!E-B.O\`E1@6,9(PR.^3>QAL79(Y%$NBB0)@U4F8$P21F@-$>^-I(2QD=[<<
M!F358,`$3W$]\4(LX$7W0Z=O`>[EG`X#)O#"N)Q);&B^#QN+VY"T@X7+]X\Q
MQ.TNQV.!W.[<;M=7"[L<.WV>25<*HQ+(J((A8DC#D(!'@&+#VW9"`:8:LI0$
M6<*\X"(@Q`N+.#G.,E#1JP&8").=@'`;,X>6(PDR51PLT&1EC`8_M0!EF`R(
M`P#");@01`%C(1!SC`@YQG&<8SC.->,FT3H]$D1W07?N3W'VG!IZG3;K]R=S
M;2:8CCV@4PJK2+JL%U=S;LG>3C"Q3*_WAK>3(O#U)Q66.F8<O6ML5`=,IA)W
MX/M!F81(O)(,R:.@R=@O!`,O;4')F##$))6"@Y5XR/`S7-M*+P#&>T8X(2P]
M8E:<)G$"<0PWA\.61DSC<'A=B0-`^+S'=W+\/LK<]OC]\-/![/7Q>\V_L=KG
M4O%JB97&%&",D2)B.PIPF$GR4\-IN#PK,-.4F2<@5"XN%6'UDRGR7VL'X=VO
M)7;PXH^/2E3B&'\'),LC)O,839(X4@9S.-SG<^4G!["T7%YKPA8>7X?:X_?;
M1PNWWDBX_,FF$46!+&DDT>4@.$G"4).]M9X31*P,YB7!8BE8\#RI+D#$,C`<
MYR<!Y:1%X$%R0Y/V>&L/[0`>%4;[9F$V2P=_-/:'A8!L,29`'G.L>%('IG&G
MR'&<'@=6T17;"O29.V%SB&&\/A2R,F<;@\'AO[0/B\SW=R_#[*W/;X_?#3P>
MSU\7O-OX?:YU+Q:@4NBP`9-%)&`)>`A'DP3TV!!@`L)\A'D>56`X"+"M)G`N
MOJSA4GSC.>,5VJ;PYAG]K(SZP,_VW52&7188,&ADC`(O(1#P8%Z;!`R`.%&1
M#P/"K(<A#A(KSD77U8PE49SG'!-[-.9.(85Q.++(R7P>-QN(_M`.%RW>/,<3
MM+<=C@=SNW&[75PN['#B=GDE7"W^&L/[0P>%4;[9>%.3`=_-/:!A&!S,5Y&'
MG.L&$P&5X&HR+&,$`:G(1O8"@5Y)WJ9A%$83!JY-'DP"1*`FB4/;60$H20#P
M8JP8(U6#`,IBX^^C/P+.,D@9G81F`A;5V2.$V<0PCC9.ED9*Y?"G)_%D#.7P
M>3[XRKXW;6AX7*^#S]S'$[/`[D=^+V.[5O`JCI7&$^#\GR)B)PFPI$HR:\-I
M6"`H\.V5>3LC5!X6$N&)[RHR9V<$8:'3)O8PW+.!2F3B&%<3B2R,E\'C<7MR
M!H!PN7[QYCB=I;CL<#N=VXW:ZN%W8X=OL\DJX7*&8Q,8C0@D\>$(CM\8(7MK
M$(KA&+B3.+C"O.2^&:V.10^WC'8,;UP!=0TBC!8Z91).+L'R>/$CSVNH)KXU
M%BSV#3"1_P"B8K#G_0.)-*%[W^B:687G_2`+&-A<UAYHP%ERJ-F&&#"666!^
M:!C&,8L`````K,B$,0A8"$(<9R(6<8QC.<XQGFS+8L$(19DC!@(Q$@`++RV8
M",:D:0I.$.<JL8$(\Q>A+)#C.<FC6)`%X$)03@=."<0PWA\.61DSC<'A=B0-
M`^+S'=W+\/LK<]OC]\-/![/7Q>\V_L=KG4O%YT\OBBL)8TLECZD)PR@%"(>F
MPX)@S^Z>``O)2L>!B.[]9.$$.<B,[W:^Q@7>*/C\>)I$!#++#*8YDPW*;!0,
M/K3D9F5F&823!8<+.T/*G$B8,I\!QG)^'MHR5V\.:')^J:9Q!8(H*24QQ2(\
M)`R<)WUJ/R:!3W-RXB\%+!Y,"?X1,&21`P+!N'MHX>1=YH>8US,8EC!&<R>.
MXPIX7+YR^-6,'\<+4(G@YRKZC>*%]91%\/M<3#NUY!VL."/)W$"<0PWA\.61
MDSC<'A=B0-`^+S'=W+\/LK<]OC]\-/![/7Q>\V_L=KG4O%J"I;%CP%&$R1@.
M+/`482,IY;#`'`/"F$0,H0%0@F!."M1B*$#(@F85IL@R+!Y61TWAS#/[61G]
M6?\`Y@9_U_\`YNMX)K#S19"7*HV,6`C'D('YI'G`"BQFF#S@*S.>R66`9@Q=
M74``1#%G`0BSC4^:1!-D85$ICA`BP#,,"<^M)62P%@<##!CP8L#D`0%M3H,8
MA=00@;EXA9P%&IR5L,G,,*P;DV6QDO!/&R=DR0,X,%83=X\QDSM+<</@=SNW
M&[?5PN[''B=GDE7"J3Y9%TH5`U,C82`I`JAJA'/+:4%.%%AV$L$?DQ4'!(4H
M6%[$I$;D&",-#ID[(,-RW@4QLXAA'&XTLC)/+\QQ^*_M!?!Y/OCF^-VUN.'R
MO@\_<QV^SP.Y'?B]CNU;P.7PQB?6?CPGCW6EXW,_^>-7_A^7$\!4<?\`\7_J
M>`*//P3N)V>$)E=\#[.6Q=R^PZ;0Y.,\L^5QHD:8:@"@!K\TE"(&D$Y!5`."
M-8$10DPF9W"H"9@(B1-;C@W`,H56"=?#2(=O)7A5&^($1H!%]^M/;",G+C@X
M.0<YVL"*RT.N#`YQUEY;'#`\8RB4\+E-ET5(QD1TD8"@A'PQ9->FPO&!]L\O
ML9R-4'&!\1*I+[.<]?;3GAZNLDS`:;PYAG]K(SZP,_VW525+HL?C`B)(P'!$
M/AAR4]-AF!#[9!?8QD"H6,CXBI,7V<>_VU!`>KK.+P*G!.(8;P^'+(R9QN#P
MNQ(&@?%YCN[E^'V5N>WQ^^&G@]GKXO>;?V.USJ7B\B>91%6(`$LHCJD9H2!%
MA3OC4<(P*D;66G$`)2L>1A/&^,P"<AQG!HW9L"7VA."3!VN9E$L<#KD\=QS/
M!RGZWQJQQ^8$SA3\'K5_ZWCBD+"$GA]KBB>FC`.UES0\Q;]OVZ;?F@;<8U49
M3K88SFM!S2-OK&$(AM9T?,@1K":W"3,10D1K(;5=8F-!B7)0FTRN8(-%D@4/
MCN6V1#1M*`3D)05!5P$J4+8!,G#7T2P0F`RBA(V8!!.&?ADA:1UK70FP)80X
M0"@,*$DP3F*L64$:GVY[?$?*\I15-I>1Y#DN7K"#D<GW5X*]V<KPF(/+]W>`
ML(Y#A=CD_`V*\OP_!YHY.314=2K:0B2MU0U>@2MI"%,WID5?Q)*G0)VPMG);
MB$1)#0`M*2@*CS`4B*("66D+8V<"<)86Q%@B+]SEM[QC&,433>,8QC&,>*^#
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MG`<RY]-0+0GAE3]A?%+-N>WQQY[O"BJ<7=Z=Z]Y<Y6$'5=X=^^'G??/<=B,Y
MOOCQIV;WKS'$[Q\8L[YSC>%\A[RK,4)1N!.0L4S5&!///][BQ74.P)U[U,GI
MSGWEG#-UKN\3;4LXU?S63><,L:=C4<0<OD67':ZT%13X:I/>J6J9X.6`<"U9
MKI7$-<#51;L?,E3J6H,5LIPSP.:FQ;`4.`#1""L/G4Q-4X,,D[V)=QXV^4)A
M0-9BD:BYLPU8>8J\6L+Y@9[@*5#7GC/PR<41RT<ZFPE9@A9&I%,93D[(\R%W
MYRL6492CB`93A4%7+BC#\*3"UE?1%2`:G![DIPH&`]G&$1^%#R\*,&BQDS![
MJY&]KB+E0C8SW.6WSS%4W_"^#_<6I-'1E*-P`%-]05<A*+/RI++1U]$4P`*<
MGMJG*@`"&<`0GY4,S.HR:'&#,GM3:;VN(A2B*H\[?*$RH`LS2-1<V6:C/+5>
M+6%\P`]O%%1H#P'Y9.*$Y$."PD20P(L#3"AT6R3D&8\T<GM0;>:":SF]0V4?
M4#<H:3FM0UGH*SA20YM/8S(D<RG-YJ=C+&C-:#8#!36LU,(H;>9"XF-((D<<
M9\HZC-"4;D3:+-,U1D3-R'=`LUU#LB:NZC($<V=VYRS=:'NXVJZQ-0<KDKDS
M*Y@@T_#'$([ENHT>W/;XW<CW?15.(>Z^ZN[>3K"#I>[^XO`/N3D>`Q%\IW/X
MK*R[JY?A]W>+J"<GP?!"/=VRK=2-,,Y380TU'6#60RE,Y#.2W0&)H2FDB/%P
MDI@);2TK04!`4QE5I7);06D"2!L+@,*`B"0&*L.$$2EVY;>T6$@4=%4VDP@P
MWA0X35?!R,(L-.(IAJPDP4Q`PFPV8@D'PWX)P#"+$-BF$V"L1UHY/G;]OE"M
M`TYK5251-AJ0@A,E,;ZUA:(Q,F3$QA,F3IQIF0H1)"=-"88G(*+R$LHB)1@H
ML(0,#4%)HHV]T(K,P:JI&H5)N"DR?!BBM(4<9@A&F)1)"<#,9!"P4E1ITZ1,
M7C/8(3$$D%!"44``>'W.6WO.,XS1--YQG&<9QXKX/U9QG'5G&?\`R+W\9QG.
M,X_7CWM2BVCJ5<B%J5QJ&KUZ5R(7)G!,MK^)*DZ].YEO!+B0M)/:!EJB5Y4A
M?REI1X3"U9;X\`4!,"YK<'QBC;GM\6<US=%4VJY[G^=YBL(.?SG>OA5WGS7%
M8A<QWCX=3?G^+V^<\,I5S'$\(7?G*P-"48`+@`%,U0$#MA9AU"&N8<$+EAQ+
MFA+AAP#AFQA;A<59%AE+,*<&X5%SR9@.[8)2^87TJ_;MM_=1N1KI1M/.)CP8
M\FNYB^L80L&Z&R(<^,?S'$:AC,$N,?#+5L\;P-5DT3F.QIX)=D\4PD67+D'M
M\H0T]2J,I&HC%*T3L-8H'6L+&>J&_`GQ;X)2<)DR8>)Y!:UH`=A&B'EQ!8\]
M"LR=B8R/#E5NE%4D^%JB7JGJL=REQRY0M*<Z]B+@6L/<\S7+D<J`K9S@J#7#
M-DV)E<:;@8U>9[-.8$9X5/O/QRC;GM\6<US=%4VJY[G^=YBL(.?SG>OA5WGS
M7%8A<QWCX=3?G^+V^<\,I5S'$\(7?G),%&TJ66<474%7%E*#7`]06"OXD$L\
M]V4O:QU/.`%GP$TYS5R:1JG`P>,C6J7][/4Y,-=5XU%`KV^4&I.4K5E(U$J5
M*#3U:I2HK2%'J5*@\P9ZA0><:R",.//-&,TTTP8AFFC$,8LB%G.<5=O-K[%K
MTMG<)2M:US5[)<>VB?K('9T%=:QA,?DP$K>Y)#V2>1\@AN&*25R]O+>$EGE3
M:8:D1RR/KF%U`UR5E$C#ED;0E&GF(SCZ9J@XYNRGR@--KJ'&&(>451Q<EY,8
MV80DW++H=$5B?@9!P546CB@OLG,;8-+1IMN>WU'RO*453B7D>0Y+EJP@Y')]
MU>"O=?*\)B#R_=O@)".0X/8Y/P-BO+\/P>:.3F$%*4VUA;@-E2UFW`:`-(&H
M*&!15(%L`P!A06(#>%.TEX1!9@UK706D*;!06X,"A>$>"<15BP@AD6W+;VVX
M08;J)IM!AJPTX;,(JO@Z7#=AAQ`L,>$&"&(O"/#-BJZQPU83\/#=BNH)A'P?
M!".]VU[30]'L!24ABINJF8E"-L-0DM-=P]N*1F,A$$2LQB4M&S$`3C:4U75F
MG;!DA`)`17<%*29)+B,?"W4^-O="8.3J,4C46#T@6L"0[%:POBI0,9$02LH4
MYG<G;)"SIJ^@2=K"6(.&\B$1`E)@DN-,H47"FVZ;?464F4=%TXDR@RWB0Y35
MA"",HLM.8IEJRDR4Q`RFRVY@D'RWY)[&4>8;%,IN%F/-')R1M&4H<G$C.J"K
MC4@R2TXTIM?1$Q.(@D+4`H@1`F?)0B2@,3($LO(<@`%G:@A#C#>DP3&>YRV^
M>8JF_P"%\'^XM29=&4H2G"C)J"KBD@"3$X$I=?1$M.$@X+J`T@)`6?!0230/
MKV$PO`<`&%X=0B#G#@KP=&J=NFWU;E7E91=.*\K\N`EV5-80@_*W+MF5Y=<J
M\FL0\J<N69W.,N&3NWE9F92O*GBYD+OSG-G;W0F3E"C-(U%D]6%U`K.S6L+X
MJH#X1+TKT%09W)VS@O":P9ZG=`F"%AP(F\O)5X.+DKT%;4.U#T>_E*R'VFZJ
M>25PW,U<2[5W#W$I88]D3M*\F*BUC,>!0-V36C9B=S&<$8EY%B3HI7DXN72`
M+C0+=N6WMRPOPXT33:_#KAVPYX6U?!U6''#]B>X?,+\'L1F%F'G%J6=AUPHX
MF''%BSO"SC>%\B[RF5]*4VZ!<0.=2UFX@=P.P'4*Z!156%S`_AFH7T#@%0TF
M86A>0V58H78*G!H7$,]FF%F#L2I]POAU.W/;ZLYKFZ*IQ5SW/\[S-80<_G.]
M?"KO3FN*Q"YCO+P[F_/\;M\YX92KF.)X0N_.5A5"4:08L.(IFJ"3G'*C*\TJ
MNH<68NYM5(URKG!@9@B4\RNF,N6*./D?&52F1J#.T<^.8U1=0=&.9N#W*F*G
M<#PX-P$Y=7,.5FXP>L5.!^,&'LI@\8.7KEJXW&,_ZQ8L5*1]HY0:,?`GV]T(
MC4$*TE(U"E5)3R5*52GK2%$*$RE.:$Y.H(.*9`F$GD'``:2:6()A1H`F`$$0
M<9Q7#HVE3"R2C*@JXPI.:WGIRQU_$A%D'M*ED6-1Y(!,^0E'-BN,QQ4WF`Q@
M:)2P,AZ;)9K4@&GC$^W/;XCY7E**IM+R/(<ER]80<CD^ZO!7NSE>$Q!Y?N[P
M%A'(<+L<GX&Q7E^'X/-')R+715),9:4EEIZK&@I"<A4(BFRO8BWEHSVS,*RV
MG)0)&<D*<UOS6U=Y0FE8`-)F!0OEQ%^"K%R%(#;Y0A1Z9472-1%J40FD:-0"
MM86`]*-A!`2V,28X+)@P@3,"J:O`U"*$#+<"N($%'DG$.CF&W<T[?J'83$9S
M'2E2,QK<2W)T!K56T,;C$)#1X`]U$(QHV0D28EL\5-7]WE$9+`B\7$#Y8)7@
M?'>[>0="48,+>$=,U0(+3A'AJ"*NH<(+;AN+A9+?W?@3-G"/D2JWKPI'RW"Y
M8N!PP!/8!%V/""C3[<]OB/E>4HJFTO(\AR7+UA!R.3[J\%>[.5X3$'E^[O`6
M$<APNQR?@;%>7X?@\T<G)HJ.I5M(1)6ZH:O0)6TA"F;TR*OXDE3H$[86SDMQ
M"(DAH`6E)0%1Y@*1%$!++2%L;.!.$L+8BP1%^YRV]XQC&*)IO&,8QC&/%?!^
MK&,8ZL8Q_P"1>]C&,8QC'ZL>]KF3[>Z$2&9-2TC4*8W)2E/DQ/6D*),R0L3'
M(E9.1EL@19*5(U"A(I+SGL'ICSB#0B*-&`6KAM\H5W&H-=:2J)S-5D'IE1CA
M6L+6F*4RDF3IE*=0-2R&B.(4)IM,TYY1F1%FD2V3E&!$!_=0J^!5MRV]K<*P
MK**IM7A?AP"NPIJ^#GX6X=L2O#KA7@UB'A3ASQ.YQAPP=@>%N)E*\*<&XD3O
MSDLXTC3#P4YD.U1U@Z$/13P0\$N,!B:XIV(D)<V*?R7,M4T&@7E/A5EV,6[E
MJPG`<RY]-0+0GAE3]A?%+-N>WQQY[O"BJ<7=Z=Z]Y<Y6$'5=X=^^'G??/<=B
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M,P>ZN1O:XBY4(V,]SEM\\Q5-_P`+X/\`<6I-%1M*MH"RV^H*N0%E'\T66CKZ
M))0%J>.VJN8`$AG+P`_F69G4<8.,&<=J;3>UQ$*4148FVY;?$?*\I15-I>1Y
M#DN6J^#D<GW5X*]U\KPF(/+]V^`D(Y#@]CD_`V*\OP_!YHY.K:J"HIC-3'LM
M+5,SG(P-Y:0UKKB&MYJ4MI/AJIJ+3F)&4D9`&Q375?J&\!0@A1GP6'&IL%F1
MAD$AU%0=%CRW9'2]3B[GP@PT]JN8<+NO#69`C6S#=ULV>2PW&U76)B'"7A<H
M97,$&GX8HA'LMUJ;;W1$0V[(+MGK>%GVG?<X@<DMPV*>$2*&1J#U#$GYGB;G
M8,]EZYM?#&Q$ZR]_:XC#V-CCDDD<I?!.9J=L2,$<DC\TVR)WIRUYL1BH*-[>
M9/G<@JA$ZM285G+)Y$HXQ5O5<6LA\JJ'3>5V`UIY8E/37C*6!S.IILCL<>U[
MZPM;Z]RC$.2L:X&H*M^D8@]JS?;=!HO74P3N]\2[<K6<I1/SM%F]WHBU]I)Z
ME#=5<V6TH7!X$J>VIT1JF]@6Q%:^LL@`%(\$N"6/.K4[K/1C(L8_3G'7[V.K
M&<=?7G/5CWO>_3G.,=?Z/?Z\]6.O.,"HMO1F=G[;H3?=+;5;8M-ZE]D6;`%E
M3-TUI>*R.'$518UD5I*9/*)?.)]'ZY+:R7VNC2TJ-FDSPYKAOK:!N3K4R5T7
MI%<[ZVZ=(-BBQQIFPX6;OI+L(R+I7UX@:X5=A@]62VW6[$M/C\C="'D$VB42
M5+HRNAPGIHR0I3J')R18.2%+<]]----8?XWB0]'O5,V2R"*R2/S)XI@%S5U.
MUBM@'!K%2M[MW9+X(RB`X@?DEAQ!*8EE#@Q+6K*5?#U(GYK<E`6YX2MW5*7Z
M0*D[>0[D96L4YK"L]NEUGTFKLBR7N.,,<GSBD@$3L<<TB&0N)YF(&X1R8MJZ
M/O#L8C6/C:F<)`2VIX^6E<E?2K9Z3K;O`Y5X'PN3Q2T7>,7;M0JBWLL\[8F=
MMK"/;N5B$J`V8J>%)+@V2..H&MX87]R*:U2=-W4^M1PGI/S`N'E2R;H]M<D8
M%$I8-P%+/4<1P9BLY<^-=H0E>TH:XDZY6V1V>K5Z9[,3HX:^N2!P;F>2J1E,
M[DX-Z]"D6&JT2HDG'^"](=0BMMN)?>$VK/;;XIKYO&E@AM6W84R$RIOH]WBK
M8]V"UJGHV.@*830S6-'.A`0+`Q4UW0(WARR:J*&*?@>^"L)1N:N+;%)7&'02
M6P1]JIHK$YXLN+FN%]%6C5+E;!"FOHP8%N=5)["QLSL)>W(#'X\U$A.>`FDH
MNR'5V5FZW;(VF/9+GN"IAK.CDDCL/?"G2S(<VF-<IEPG0$3CZH"YX($!VE!C
M&^%1Q'C`C7TUD>2FO"HUI<`)HV.;G:QFDQCR"%6#2\NKR144]7PAGD?NZ$.:
M]3$&R5-4=(DS;#41BA4YU@>6K=#%]L$/((LRO+4"-+0"7KP')K+5;TC&W*?&
MWNND5C5?7L,I[<,/;^PV`]VU#%,1L]R#3]3V^)\CCQ@Y`WI`HVVV&YF>&4Y8
MM5LC@UJC'-604I3@#=YCWD;9Y`[WXS(KB@Y*K;+/4%9W2->_-J`B%S)PBS#+
MB6A<8H5`$8(#=(DB,\\DL2<M\1/C&$P;DPNZ=)D$PR-AE<?9)5%7IHDL9DK6
MUOL=D+"Y(WAC?F)Z3D+6IY9G9N/4H'1J<T"DA:W."%0>D6)3B5"<XTDP`\_.
MS5G2&]);=,&;;/BRO87%HU*'J?EL$?D=3[DWM_:V>*V7,X*W$O3LTWBV-;@Z
M'I8L4M7*6]O1(Q*%0PITI)80@Q<'W7G2E_VJZ/+^">Z/^O\`I[KSI2_[5='E
M_!/='_7_`$]UYTI?]JNCR_@GNC_K_I[KSI2_[5='E_!/='_7_3W7G2E_VJZ/
M+^">Z/\`K_I[KSI2_P"U71Y?P3W1_P!?]/=>=*7_`&JZ/+^">Z/^O^GNO.E+
M_M5T>7\$]T?]?]/=>=*7_:KH\OX)[H_Z_P"GNO.E+_M5T>7\$]T?]?\`6T6[
MKI2A!$',KZ/+&!!R'.<4GNCZ^K..KS_:Q)3TG;0E0[N'84"BF])BNBX+UKRY
M*ZBLL:*]C[U;#HB7O]222(/4C=Y9,]O<X;VEL8;5@#O(U*AV$4GFL151Z>QF
M)/3;[E['][\;W;1J21R1QL=0[EZA&TL^X#;^[NQ+NZP=U=B#S&*80]]`2C*L
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M8'3V)WQ;-F6`IMEKC[VR.M>P"W[0;-L?+.+E(C&HD--KUZ2*R-Y8&5X0MH)[
M(HT"3N;BTIGXTI$80@;T-E*HVI7+76Q2>;84\RA+594L=MR@6V?,BB2G,L?:
MMP]UV38AKNB+4M#8\%R6&QNSG%"VEX*&A725B;EXU:1O7G$H+AV7MC>':W=B
M<JKG,0CU>;1Y=/7%?&%Y[PF7JHK)=O,UH:.LD3"A:G%"6;'TTL3NQF'92D(4
MIF<+64828MY])FI^_33337F!NSV*6!N6GKQ,8_9R.FI'&);MTG-'VM$Q+W*P
M(2]5\.TH5=K:O9US.0S#:+8HJYK`K5,)&^J!(%3@B?G)$K$WHDR:P\[Z.2\"
M'6<RBJSJ!,PBWB,=YUC4,U?+79ZT>J9)V0P#8ZXUE/))#V(V81J6,T4@#?/X
MA+(TBE3<!T/6PY^:E[8YKGXS>KZ+^PFB7(3(,^T4PUP38W1>6(1!F.(2:%,T
M4'L"=T)[]%(2P-V)$S-,5DS>QM?@`A&9Q8NK4#+=#U9;20J=+95/L;>62[MO
M]1KD\G*>:B<;]D.ZB5,M:SA%0MU;<KHW'6!NUI"IT5B3)BCT<DM@5_?QL4&X
MLD*5R5RC\+,MYJEY#*PVHA2*NNS#:)?E=[TZT-9(=65H>..;=+'9IJV4-MD9
MJ6!Q[<K$]L++$H[/YFU5](4[7+7'P-E"8MA4I&M#/F)')F-G?&]08)25<6`=
M$S8U6R6M,1FP*Y>XO5%@=&<N8W%\1R5OEK[!-@]#2FF'4IW`D:W1(@DLV,D1
MC_'TZ=V<FM@RH<$JYP5&GB5'457]%A<,6@=61&5D[6%<JH^YMF8H]<<=:;&Q
M9%MT1M`O(BX&05D+)(W.X(;-)"%O1%!KB%JG6M&2>KY59"61#[^219EA%71(
M7F[UY)8*9:]8Q5:X[9=Z=+L\D84\N<\`E6Y+>LT;O(4L?6-6RLH'.`,9;(57
M-@QH+L6MD[.[OJAL4)"%G(B@[NZ-#?->+/NE"Y27:/$E^Z\V]'&6-;(ZVZK.
MB#Q<>Q^A]M!)#-9A=<LDR=X8U3ZC4DDE,&2ML/9[-8G>/K)Z-ZQ7;9"'R_UE
M[`]S;\Z6184:E=!N\P?=UU*;MV&O)4?;,=@+^_,NS..;/K@K*83B)DJI<QL?
M=+,9/*EGD:C3D]-<F`C*E,65-8EJ`_T\H"J&VCJ4K:IVEA@<700>-M;*5':P
MC7@?7C*8$\2M4VPV-"4*S6F.I%BI02UIU2D]:-,$"A<:-8>?G7S2;'W!O*VL
MU<6:X-Y1@'"Y`C+-<$11@!8W#6]GLC+,4!&`75G&>R(.,]6<>]K*WO1K_P!Z
M-?\`W-O^TZ=Z-?\`O1K_`.YM_P!IT[T:_P#>C7_W-O\`M.G>C7_O1K_[FW_:
M=.]&O_>C7_W-O^TZ=Z-?^]&O_N;?]IT[T:_]Z-?_`'-O^TZ=Z-?^]&O_`+FW
M_:=.]&O_`'HU_P#<V_[3IWHU_P"]&O\`[FW_`&G3O1K_`-Z-?_<V_P"TZJRC
M"SP!,(,*/`/K[!A)I1I8NSUY%U&EC$5U!QC.1BR/`2PX$(8@A"+..J;):G?-
MXFZRK=YU?+5L$V];8!V+$(7=+(D"BD.\AVEC>ICLT@41=3\B(?-ET+>2RWI>
M_+&UP26Y><;9I#5B]DCU>GR^;?1KC'5C&.O.>K&,=>?TYZOUY_;G]>M=----
M-----------------------------------;.(7\8#Z0?KTXA?Q@/I!^O3B%
M_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^
MO3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@
M/I!^O3B%]?7VP=?Z/_4'Z_G^'JQ\&G$+^,!]/'UZ<0OXP'T@_7IQ"_C`?2#]
M>G$+^,!](/UZ<0OXP'T@_7IQ"_C`?2#]>F3"L_I&7GW\9]\0<^_C/7C/Z?TX
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M]?9SU=6VJGNOKZO_`/$]>)>T;87)]PUA;H]NKU5KGMZZ/6J=\6[DN1-S`B)K
M4O<\S+[I>'*.[=J@9(^!M4Q/:RSM)H"[MF#.6R"L)3U4=`N!&RK*>A_4NPLK
M!%F1GC,9:VB/1V/-;>QL+"QH432RLC*TI"6]J9V=J;RDZ!L:FQ`G3H6YN0IR
M$:%&02E2DE$%``&6XA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B
M%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!
M^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q
M@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KT
MXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z
M0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7
M\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z
M].(7\8#Z0?KTXA?Q@/I!^O3B%_&`^D'Z]?.SX[KG\[MG^OTK^]M/'=<_G=L_
MU^E?WMIX[KG\[MG^OTK^]M/'=<_G=L_U^E?WMIX[KG\[MG^OTK^]M/'=<_G=
ML_U^E?WMIX[KG\[MG^OTK^]M/'=<_G=L_P!?I7][:>.ZY_.[9_K]*_O;3QW7
M/YW;/]?I7][:>.ZY_.[9_K]*_O;3QW7/YW;/]?I7][:>.ZY_.[9_K]*_O;3Q
MW7/YW;/]?I7][:>.ZY_.[9_K]*_O;3QW7/YW;/\`7Z5_>VGCNN?SNV?Z_2O[
MVT\=US^=VS_7Z5_>VGCNN?SNV?Z_2O[VT\=US^=VS_7Z5_>VGCNN?SNV?Z_2
MO[VT\=US^=VS_7Z5_>VGCNN?SNV?Z_2O[VT\=US^=VS_`%^E?WMIX[KG\[MG
M^OTK^]M/'=<_G=L_U^E?WMIX[KG\[MG^OTK^]M/'=<_G=L_U^E?WMIX[KG\[
MMG^OTK^]M/'=<_G=L_U^E?WMIX[KG\[MG^OTK^]M/'=<_G=L_P!?I7][:>.Z
MY_.[9_K]*_O;3QW7/YW;/]?I7][:V`NZZ,]KKMVS\_Z8L?\`S]*_T=>?>_\`
MZMK?X[KG\[MG^OTK^]M/'=<_G=L_U^E?WMIX[KG\[MG^OTK^]M/'=<_G=L_U
M^E?WMIX[KG\[MG^OTK^]M/'=<_G=L_U^E?WMIX[KG\[MG^OTK^]M/'=<_G=L
M_P!?I7][:>.ZY_.[9_K]*_O;3QW7/YW;/]?I7][:>.ZY_.[9_K]*_O;3QW7/
MYW;/]?I7][:>.ZY_.[9_K]*_O;3QW7/YW;/]?I7][:>.ZY_.[9_K]*_O;3QW
M7/YW;/\`7Z5_>VGCNN?SNV?Z_2O[VT\=US^=VS_7Z5_>VGCNN?SNV?Z_2O[V
MT\=US^=VS_7Z5_>VGCNN?SNV?Z_2O[VT\=US^=VS_7Z5_>VGCNN?SNV?Z_2O
M[VT\=US^=VS_`%^E?WMIX[KG\[MG^OTK^]M/'=<_G=L_U^E?WMIX[KG\[MG^
MOTK^]M/'=<_G=L_U^E?WMIX[KG\[MG^OTK^]M/'=<_G=L_U^E?WMIX[KG\[M
MG^OTK^]M/'=<_G=L_P!?I7][:>.ZY_.[9_K]*_O;3QW7/YW;/]?I7][:>.ZY
M_.[9_K]*_O;3QW7/YW;/]?I7][:>.ZY_.[9_K]*_O;3QW7/YW;/]?I7][:>.
MZY_.[9_K]*_O;3QW7/YW;/\`7Z5_>VGCNN?SNV?Z_2O[VT\=US^=VS_7Z5_>
#VO_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g846204.jpg
<DESCRIPTION>G846204.JPG
<TEXT>
begin 644 g846204.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`^1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]$151%4E]&4$]?2U]02%0N15!3_]L`0P`!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``
M$0@!@`*L`P$B``(1`0,1`?_$`!\``0`!!`,!`0$````````````)!@<("@$$
M!0,""__$`%80``$$`0,#`P(#!@$(!`@+"0(!`P0%!@`'$0@2(1,4,2)!"151
M%B,R87&!D0H7)$*AL='P&"4SP28T-E)BDN'Q)R@U-T-$4U5R=7:".$549*.T
MM=+_Q``5`0$!`````````````````````?_$`"41`0```P<$`P``````````
M```10?`!(5%Q@9'!,:'1X6&Q\?_:``P#`0`"$0,1`#\`W^----`TTTT#37"_
MR3G_`-R_^[^^L7>ISK%V$Z2<9;R#>',F*V;/:>.@P^I;2WS7)3:$E4:;'H[@
MRC80A[';*8L2KCEX?F`OTJ&47*<JGW3^2_\`*_V_G^BZQ>Z@>L[IEZ8()RMZ
M=W,7Q2?Z1.1,7"45SF%@0HJMC#Q:G&9<DCI"K82)$6-#1SA')+?*+K6#ZL_Q
MG.H7?`+3&]GGUV`VYGH<>,_3/A-W(M8B]P%^;Y0"^C2^X!2[XF/,1G&.Y&EL
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MU';GWKI*1/13MXE;5`X:B),M5\.OBLD2FB?PMB*(/''A$U8MW>??Q;$FWL\R
M9V<RJ<=]DKCKO;]2HJ-@OU*JKY+M_1>..-4`IU[$"2H#.]X9BZ*QP3Z%!$55
M%U54NU/A1145/GE$UYXRWHQ1WV)[S;$DD.0#;1N2"<Y1$!)'E`)25$-.[X5?
MTT&6&'=775=@9I,Q?>S<?#2`P01K[D6UD*(JKK1C)CN@HDB*J@3?8HJHKX7C
M64V'_B]?B`8:\TH;L5N:0>]LAK\^PW&KUN0"(G<T_85<&FM1$T0N3"Q`A_C1
M5745\B2^^ZEA/9L`B\J(MHVZIFB\CWKW<HB((\]PCW$7T\?"Z^CM4@28LZ/*
MM0A.(CKL-ATG7^U03EPP\BVA(O*`7"\>/&@V5=FOQ^LE9=BU^_>Q%7*BH'^D
MY/MAD10'!`"3U'AQO)U=9?,1[OW+5W$`B[4%Q%)>)<.GS\33HZZCY$>IP_=2
M#C6625(6L+W':'"\@?(>Q.R`5@^=+:N.&2(TS5V\N0X**8L""*NM%AB@9>..
M9V`L-$ZOIL23!$(5;[A)YQ>5%5+A2;3E./E>>47TCQZO?!5"QBQ)<<%0FXP'
M(9<=0D^OA$1$(25.2XXY^H5YT'](\7`,1,"0A(4(2%45"%>%0A5.4(51442'
ME"145%5%37[UI"=*OXDW4-TK,Q:BNSJ3N+M_`$`DX-N!-D751%#O'O2AL77C
MO:,U`.T!A37(32JBK7N^>=HGI#_$"V?ZLZ6)^61[7`LW)H$E8?E0"R$M_L%7
M#QB\1&X&0Q"55)I`2+8H'_:P`5.5#/+37"+S_P`K_?YUSH&FFF@::::!IIIH
M&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF
M@::::!IIIH&FFF@::::!IIIH*5O,ZPO&9;,#(LMQBAG28WO(\*ZR"GJ9;\3U
M39]TS&L)L9YV/ZS9M>N`$UZ@$'?W"2)^:3/,(R60<3'<PQ:^E-HJN1J7(J:U
MD-\(JKWL5\V2Z/""2KR">!5?LNH)O\I`QC')G0(QDDO'Z.7D-?O3ME6U][*J
M*^1<P:^4SEARH$2T>CG.CPI1DI2(K+X,.ER1MJ2JJU7U(]*NVN<?A.X=N9BV
M.UN`;S;.])>W>\FW^Z6!18V&9K27^&;78_DUBB9!CX5D^7#N*^#/BS84R0\T
MX[("4`^[:;/03>7V4XUBS,>1DN0T>/QY;ZQ8C]Y;UU0S*DHV;RQX[MC)C-OO
MHT!NJRT1.(V!&H]HJJ4NN[^U`FC9;F;?"XO"(V6;8PAKS\<"MKW+S]O'G6N=
MM'U76/77^"'U87&]D2FS7=38[;/<S#;W(+JJ@6,RSFP</8O<0S5Q)3+J0\GD
M4\UIJ;/B#'==FPBG@:.230:,_"QW&Z1ZOH'Z6]A]T<)V:W.W'ZC>HO<C9\-N
M[NLQ6TR=K'\BRS*IUSE%K$6KL;BNKJ?&X2NULF9^6I,DRJ^/73VU<;>:#:"F
MYMAU;4P;^QRO&H%'9]J5UQ-OZB+53N\#='V=C(FMPI?<VVXX/MWW>0`S3D1)
M4\%=X-J$%#7<S;[TU5$$_P!ML7["5>>$0OS;A57A>$Y^R_IK#^D_#PV@9VJZ
M0=H,N&MSS`^C^_EY/B6/9%BT"54Y%/CX[D]!B0VE;+F3HK+>*M9&,MH7`L0L
M95;'-X&5<)0A4Z==N]OK3_*'.L+$[/`L*L<5':7)&QQJ=B=!*H4;/".G]#!*
MAVO.`@.#)DBXB1T5Q)$CU%+UW5,-GZ1N-@$2OK[65F^(1JRV<E,U5C(R>B9@
MV;L$NR8U7S';`8TUR(2]LD(SKI1R^EY`7QKS5W?VH0E;7<S;Y'$^6US;&.].
M4Y3D?S7GX\_T\_&H9?Q%.D_:SIM_!_ZJ=LL5HL?GXOB9YSG^WL27C-6T&`#N
M1OI5YE^38YZRSC@!0I>O4T6QB.Q'Y4%EM'&6`7T1QZ_#NL^CG<3H0Z&^C_<+
M"]FMR-Q>I*LWSP[(\8>KL0L,RP_&:,=Z,NGYC:ML5TNZJ9T5*BAK:,["13S3
M.WCS:Z8J00;<#8\M<WPVBBUDZ[RO&JB'=`KM/+M+^HKXUJVC#<E3K9$R8PS/
M#V[K3_?$-X?1<!WGTS$E\J)NIMG/EM5\'</!ID]XNQF%%R_')$MTNU3[6XS-
MF;SA=B*?:`*O;YXXU%C^)YLWBV`?A`[M[=3X=1ER[+=/&'8CC.07&/UQS67L
M1=PG&F+VN8D)/*DL)L2N`G5@RE<;1Q6?<.@**N&'1?A72O)_`MHKC?BAVO@5
M[6V^_P#*<R*VK\>K<GA7T/<?<;]F9-#=LM,9`QDS5D%2S2%6R4L''#CQ&D..
MZC9!LL"0F*$*H0DB*))Y145.45%3PJ*GE"1514\HJIK]:@"_"&W>ZL<,_"[<
MW&W/VQW'WGM,/RC)I6T^*R;F-6;DY9LQ65=/*-VH>S4HP63%7=CE$3#($N5[
MJ\I8<%FLDN@Y#;7)7I-_%+9ZT:W'[+9+IUS:>3V:Y)B.?U5_N#MU37FUD7'V
MJ:8UE>6U92Y#[N/7T*W(*0ZE9=A)N(,FF<@LO`;[82T::(O/^W_G_P!GVTT#
M3330----`TTTT#3330----`TTTT#1?\`G_V:X5>/]R>%^5_M_+_E53G"W?GJ
M%C5\N7@6'S!.6!.1,CMV#1/:EQVOU,%X5X1]5Y:L)`$AM]RQ8Y`]ZKS(>=U8
M]0.XV+X5?8[TX,8K:[J/-OPH]_ER2Y&*8PZ31MN24BP5]2YMXYDA18Y*M1&E
M`/YB<D1<AEIO;Y]/76W<9ODFX>]<'*-QK^VEE+L,OC6#>2.2>Q.$:"/'$)%?
M%9!$;B0&8,>'#!`9::%$X79XC7#$H^$+O00[511Y#@27N[41$1`[_J0?]5>5
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M1B<[C4F!GK(N&4=BME-T-EZ(<]K7M[`PB$XB<HHC,5%\H@JJZP4S?:7<?!DE
M-YOAN4XQ)541Q^ZJ7F(RBGT'Z%@WZD,A[4[5,7^POXD14304;!G0%;DS9K<9
M.&W`CLQ2,T3N)4(715$13+A.TQ7L3X15\:Z(2F21LO1?`?=$K+C;#:,-H2=I
MBC:*2F8^%[NW^-$7QKH1P<B`#==41W'.6U8D27SF$8<*1DVUVBPJ%PBDHJ2>
M>Y/A=58Q77$&L?EVKZ0(#Y^LA1A;:%21$[1<(UX0G%51%L$4CX5?E>-!^0L)
M[A"!RC9"*A"B28P.JC;8D9*/A$$NXA5$7S]E^.%\9^Z?1"1R0V".J".NB)!_
MV?(HA1VD3E2%$3E2X'RJ^/&ORTL2>V`1'BGO.DZ\^KOK-I'%")L2,OI0Q%>!
MY!.25."^=?*FQ+(+*R>9IV)LV?,:-IF-$9=-$/GM!595I7#1Q53ZA3@.Y2Y7
MA>`_16#<A6BD,@TTVJ-H](F&)EW$(J;;2"GCCE1147A?//">;MX1MTN86+</
M$&[6[4N!E.QP0(H.$HKZDFP=$F05L_",MH9GPB]J*J(F4VQO0EDN:I#N,SHY
MWHFL8W8?IHRI**BO8XJ%PC:*B(?9RI!RJJO*HLS&T?37C6%5L9ANE8C`TVB#
M&:CM-`*-=O:*H`IRZI#SR7UESSY7SH(Y=D^AJ.<F-<92RY;234.89@BU[0IP
MJ?NE`2<<%4Y4G4Y0E5!`?/,K>VVQU;C8PECQ@CE&]+TD:$6_3)KCM5OL1/35
M%[4$@[.WSVDG=XOA18O$C>D$:(#8B@DH]G"BI<=PFO!?IY3[K]OGF[M12MCV
M\@O<0JB\<+SX7A%3X7YX1.$X_JO&@O-M5NG>5#$:CRIUVWJF&P:9M%]1^UK6
M@00%)"\*[:08XBOJN*I6+`(3B%-:;40RQBRH\V.Q+B/M2(TEIMYA]DT<:=:=
M%";<;,?!@2*BB2?/]>4UA)$J5%L%%M$;7M52)$%%1"Y%45/A.4YY3X5$^_&K
MK8;D$O'GU907YE8^X3LR`V!..1R[5<=LJ\1\(:HBN/PFT+WP`3C()-%0D!D;
MIKX1I,>8PQ*BO-OQY+0/L/-$A-NLNBAMN`2>%$A)%1?Y_JBZ^^@::::!IIIH
M&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF
M@::::!IIIH&FFF@::::!IIIH-?C_`"C#):*7T0P-LH5FQ8;AW.[6W635>%UP
M/V633<=K$RJ-8WC--7LR9WY3$D*D=VP-D8HR%1A75=X!:LW@ZFL5NOPML<V+
MV,.;O5U`[E=*NW&S./[5[;5MGD^2PKG*,`H\.R5W*6J^$]'Q"'CL%;MVPD9.
M]5LMR88Q#,7'D49U_2!20B`%)![>5`5+CE55.Y44N.Y>>.43G[:`RVVI*``"
MFJ*2@`BI*GW)1%%)?GCNY^?C0:U>(=)Z?A\?@M=26V^\%U15.]&^NWVY%Q;8
M\U*C293N97N*-5.,;;X_[%9#V47-33064E+7-R>Z6]/]!"KX?NBHS\+)_I/8
MZ!NFV?OSG^%;;;F=.G4;G>\E*E\U#@Y_6/P<NR10KDJ9L1<G<I<KQJ_=9=&O
MB/\`NV3CNQ`=DQ6T:VAU:`NWN$3[5[A[Q$E$EY15%21>.454\>>/'/'*:_*Q
MF%)#5IKN3X+TFU)./CA5#E./MYT&+W2WU&5?4CM)<[WUC$VGVYM,TSR)@$O(
M:B=B]A*P##)Q8\SD5I`MFV9D5NTL:>\MV"F,1C"K?B"\TV31\Z]G3)N;@)_Y
M0+U,;E!E54.WF>81=8KA><N&^UB&4Y%,Q;8ZMA5-%DCK(4]E+L+&BMH5<$:8
MX%C)@NLP3D&K0N;7':G';X[.%Y'A.%YYYY1.$X\^4X\\KSKYI':1$'TV^U.W
MM'TP1`[>..U$'A../"HB*/\`JJGC@(IOQK<HQ^K_``Y.H[$I]O#CY1G^'P:7
M"L=[S>NLJM8F:8?/F0:&JC@[.LWX<(')<L8K#J18HJ_))IKD]81?AP9AT@8=
MT.=#6Y.\&Y&$;?[L=,4K=O(7XDN(RFXC;&42-W<4L\5LJ(*]W,GH5G19?`O(
ML:%!DNS)==4^U!T'5XV.#:`U!2$%4%514@$E'GGN[5)%5%+QRJ<>$U^%CL]W
M>C37J?8U:;[D^R+W=G/A/CS^GVT$$W77U.T>^_X0.]6XEF1XQ(ZA,8S"/LGA
M5S6RZW-,CQ^OW&KX^-PVL;)IVUE7;^.U@7EFPW%$X3,H?<@R+:GJ+O9O\/;$
M.L[\*;9;)MCGZW'^MKIND;@WCM=6QXM)D>3)+W4S'(*+$\_A3(T68-Q.J8D*
MTVXR.T;<]%^(U5H])IWGX\7<@5H"[>X07LY[.0!5%5^5151>.?OVHG.@M`*D
MJ""*7'<0B(D2#SVH2BB=R#R7'/QSXX7SH(7OP_OQ6,(W8Z<;RQZIY#6RF]>P
M\<L?W:I\@I[>E3)6J06ZZ-F>)4KL!9DUZWDM+6W6,4K4Z34Y8W)@1&?83JI7
M(H>G+>&DZ`?Q2;O(X4^L;Z1.NO'V]QG)N,A.OJ+;&-G%YD-KB/[2RJ]A]BBF
MX1F#5OCN2^[5F/4U=S8^%8I7W@V_59;(D)0;)47E%)L%5%Y1>4)45>>43SSS
MSYYY1-<HPTB=J-MHGE%1&P1%155514[>//*\_JJJJ_.@_$63'F1X\N(\U)BR
MF&9,:0PX#S#S#[8.LO,O-J0.M/-&#C;@D0F"B8JHJFNQKA$1/"(B)PB(B>$1
M$^$1/A$1/TUSH&FFF@::::!IIIH&FFF@::::!HO_`#_W_P"SXTU;?=[='%]E
MMM<QW0S*4D;'\-I95O,3N07ICK0H$&LB(J%WS+2<<>!$#M7N>D"I)V"2H&-O
M6+U,0]F<<:Q.@G-?YP<LB.^W1MU$>QZD<[F';AW^+T94MU'(E0A>4<"1,\)%
M!7(B:S-%E/(\\\1ND1..$KA$OJ&JJ9D7*^J1\DJD2D2EP:D1$2K'YN9U29!N
MQN1D^XF4N.K89+9R)B1?<&\Q60%,@KJ6+ZGD859$%J+&!`$%%M7D`7'#752X
MINO%GDC8R01P1'O:Y^H1^/\`6\*O/_!.55%T$DE5EK?"+ZB(B`@_21\KY\]R
M)QY3RBKSPORGZI<.MRQ"%$(T+QRB]Q(J"B\*BK]T0O*JOQ\*OWU@)3YZ*H"J
M]R*J/A"X5//E5^Z<IQ\HG*?"<?-R:O.`)13UUXX1>%-53ZB153QQ\K]E145?
MC[:#.>#D;+G'+H%QSX4D15[D\>.[RB<?;[_TU4D2Q9D?=%7N45%/XN5[>U$%
M.XN2Y%$7Y4B1!%>=8=569]W8B/K\)Q]?GPJKX7PJ\<>>4^_W1%XI/>7J`<P3
M'VZ:HFH.6Y#'7VYBI*[44I^HT[:LEX!)S[H''KB[U0`!^2@H3;2J&1NX.^%)
MCDUW'J$(-M<L(X%C+>47H-4]RH+'$!01G6#:^9'!E'C>&R[W4-`L1(S23=H^
MEK*&T9D=PO198,R(;H.\HXVL)YDH:MJ'T>EZ"H@\H7=RFL$JS-31U"<=(R-2
M(E,R4R554R53/GE5)5(B55(R52555=5U!S855/WJI\(7U<?P_*>/"<\HG*)P
MOSXT&-?65L#B6.L+N=@M+$H*RVDC`RRMK46-$K[66I.P;FH9$49KF;%P#C2X
M4<&8:34%QIID7B;6-:P?C.P"(Y7#,9[TWXT@4DJ[+%>$<1D2\J2JBEW_`,'R
M':B\I-3NQ:QLLV=W)I)*))!_%9DQI@RY!)54['LV'D7@E1QDHQ$A=I*G)(GA
M5U##2U#E[?5L'TIS\20Z<F;-2&46.RU&1'#X=<$5=5UE$9;5M$55(4+CE$T'
MOX1B26HA;6KKM-1.=Y1ACAVSIH`JH10V23MCL*0DB29"&BERC31JG=K-K;?<
M'&=NQA_EF",3&D`4>D2K`OS*6@GW"])DE',G7"52Y0R1$3@1[$35BC8%LXS`
MMH#8*(-M\(B`V':@@/DNU!%$'M\(O"?HBZJH64[014_A`43Y^%Y_5/'A4X7R
MJ?I^H3&[,=7^UMN$*FM6!Q":I`VVS9&K<!UPB[1`+!1.,/*KW+ZJMH"JJ<KQ
MW:D:QH6;V-"FU11I4&4G>V_'>;?95OM[T,7&^1,"\*)"JB7/A5\HFK&RJ-K]
M2HB)PG:H\^/GC[??^2?JJ_IF5TU=6N7;&6L6%.>F9%@CSW9-IG))'*K67'!1
MR93F^I@R;8\\Q2_T9WR/TDHGH-BV#1`HAVIPX(BJJ*`GQPOQ]_/V\>4Y7PNJ
MNJJ*0YW$@&H-%VD@*BFG/E?IX0E1!7N)4%41$557A-=#:BWI-U,)K<^PRSB7
M=-9-LE">C*I.EW(/K,$SRJM2XSG>U+:E(VC3HHBH*&/==.LNF\8GNJK33[!=
MX.,H;*R!541#)?2[OJX4AX51%%4DX)$X4/.BP8T-"5`[X[S;BH9(R0EV\$'8
M+ABGJH2$"`A(2HG*)YXUQ*L&A;0DDB)HR*@01Q8,WE(A5M?3)MQ$`21%<->2
M051/"IKQ,AO:Y^0]^7-F$9XR=]-QUM29-5^H>U!$$%5Y+CMY15Y%?UMY8WXM
M<*;A$CIB'J(2KVD1*BC\+X^/T3]=!??!,[:KK)BFG.(%;;.@W%)?I;@W#Q]J
M@RVB<,5UBZ0BC2+Z<.<0J(@Q+56\A$_QX7C_`)\)_LU&Y/MQ(D7[`1&B^H8J
MO/DD11(5$"[44_J!!1$5/J[=9D[/9V&9XTC4J2K]W1JU"LS-.UR4T8D4"Q5%
M^5E,@H/K\^\8D\H*$/(7;TTTT#3330----`TTTT#3330----`TTTT#3330--
M--`TTTT#3330----`TTTT#3330----`TTTT#3330-<*O'GS_`&15_P!B(JZY
MUCKU98O2Y3TY[RQ[N*[)"HVTSW(ZQZ-8655-KKVCPV^ET]K`L*B9`GQ)M?+0
M9$5]B2!M.@)BO>(D(9$=R?H7_J'_`/\`.OUSSK5__`KVLJ^JOH;W:L=Y,JW-
MR#-"WLR+%Z3<IO=+<*-N%BD`MK]MYT,L=R8,D6;!_++.VGVD6*JNUY2Y#ZRH
MC[;[@+=O\+SKQW:J>H_J@Z!>JS<$L]G].'[?6^%;TY8ZQ"O)>(;:7K5?DM?F
M\\Q`9YPJ"RJLEBWLQTI$>(U;QILB0RS#=0-B736$^W'X@?31NCD6WM-C>56[
M%/O+;Y)C^Q^?7V.SZ/;[>J[Q`W@R2JVVR6=VC<3:XXTE&&9\2I6Y2-(.@6U!
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M`DLS(,^,Q-A2XS@O1Y424T#\:2PZ"J#K+[+@.M."JB;9B2+PJ:U:?Q"H!XU^
M-5T*[=X]=9?28!N^>W5UN9A-7G6:P,2S.SO=S<\KKB3=8Y%OVJ>0MC"@1&)K
M00VX[[<=OU63[550VGT)%\>?[B2?[51$T0D5>//]Q)$_Q5$3_;J,?:_9?:?.
M.IFEWWZ<<AM*"FZ=LWW?V(WAH(F?YE8X)G]G/VWQR>T[48M^?7&+N76"Y5>P
M:Z18S85?)86/>,LD^;<-2C8Z6;>_H?\`*`>JS:VLRC,0VWI-I,CM*;`I.995
M9XA53[2BV+NIDJMQRTN)E1!><M+JVEM%%B-)%*PE-1488=)O0;,&FL%Y?XC'
M2O$O+N(N;SI&%XMN)6[099O'$HY;^S>+[L7,EB'6;?7.>(0Q&KR1,E1HCTJ+
M$E8_6RY$>):W<&3(8:<IW??\37IHZ:^H+#.F_>%=R,6S;<%<>>Q"\3`9]I@E
MQ69'-_*XUVUE%7+E@S50K<)%39.2(34J-.BO`W$D-%'>?"0K34>F,_B?])F0
M;K9QL?/R'.\)W8PB/%F_L!G^UF<XKEF80K!B)*JY.`8]-J#N<M*VCSH<BL@0
M(`VLZ,][MB`45E]YJNNGKK\Z;.I2=N_28-E%SC^4;#2[%C=G$-S,9M=NLHPJ
M+5/S8TVWN*C(VX[K%/&?KY;<J<I\0C:].>U%<,`(,T=-82[>_B#=,VY618!3
MX_E=M&I=X;^]Q;9/<"]QVPI-N]YLCQGUOSREVXR>;VMW,Z*D=]8@3(M6%VC+
MOY`Y:*V:#;.;^*GTPTW4K<])62P=Y,<WNIDL_P#P9G[2Y%.;MBAU"WU4UC\O
M'3O5NY&65"LS<4C0&'7[1N2R#K<-WU0:"2;36`^V7XD/39N_@^_.78-*W#G7
M739$MI6[>UD_;;*:G=['$JOS$2:+`YD-+)XI+U5.9;?`O;0BCO.V[E<PRZZ.
M'GX;'XH3/4Y@74SO1O#29S@&`XYN#GN=T^86^.SY&R^W&SF(X?M]'KL-?W-9
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MU#LLV:"M;1/H!FMHV:Z&T`"*(#"+PKBF1![S&21Y:"XS(%2)$+P?U#PB\>"X
M7X_GQX_GRE34F3NU\YMP))-HB<'RYSSX543CX5/Z\<*B<?":QGCH\)(K9'\<
M<HJHOPO_`.'PG].%\)_3WXLV2T2D2DJ>$^>5^$\\E]TY^$7]?OH,]:;<4>T.
MZ3PJ(*(JN(O*>$\\*O"?;Y\^.-73I]Q.>U/<(2*B(G"HOA...>51?C[KS_QC
MG@Y#*8[5[S3MXX^I.WC].%5>%^/'RGE.>%U7=5FKS9`2N%_J_/RO*I\\K\HJ
M>>//GSH)1,8SP'5-Y]_NCPX<J;*<1Q!].-#9<?<YY5.U%0$!.%Y[S:1.>?.&
M^3YE<95?S;VV>)9$YTS99,U)N!$%52+7QT7^%F,RHM"@H//U'\FNNQC^0ORL
M*L7T,A*UL(U0T:$B*4=L2G36U3E>>]&V0(4X[AY%>$7E*BI<$O[V.X5/BUO<
MJ"(;SL&JES090T0A]=Z.TX,9$'DD[^WE$7M3CR@4<S<.,IW*9HO/*IQRG/\`
M+[JG\EY_PXU[+67C&`5<<)1(A!#0#,4(E%!$D$2457]5^E/U15UF?LGTA3\I
MB#E^:/#78R(R6DKQ%(EW).,ZVR](:9DM&V##!^KX)">7M4D%&Q(M,JZ/_=N9
M86".S;<XCQ.8^XZ[#A!(`.'%CS6>"!)/MD<%Q&7.Q'Q'L^A>5#&?&;UNXLFJ
M"2;4AF^4ZI]AU\66G&[(5BJTXX1(+0*CG!&O"-C]2JB(JZM'N5L9%V[R^?DE
M385\>G8!:4L<49-E.A2W@05D,W(R"@.0U.,X!,*P3RHZTX#R")(M33MO,OPO
M)6S?9?;N*Z2W+BLQXZS(A'P38>H0H0F(OF@*)=J"8HC@IX37@YFF[T[VN'OT
M-YD-A:R8TR+$BP'IEL+$5'"-]MB,T2NP#4U'U`Y%D@0"-%)-!9Z0\`O-FI<K
MWBB*J_*\*B**KY45_P#27E$3SSJIDD`K33@KW(2(G/QQP*+Y7XY_[D^>=>=,
MQBPKS5+FNLH<ADE9D,3&'H#\>6V78XT_&D-@XV0$JH2*/<*IW<<+Y^Z5DJ&3
M;4IF5&!T!>:]S'=94@+X-M70#U05/X3#D23@O"+H.RCWGA30U\^?''PJ^?\`
M@B_;PO&ON#PI]_/"*/RB<\>47[\?/*<\HJHJ?HO0EQBC"CHO@37IJX2]J\MH
M!<'W*O'E4^%7E./*^%\?H(S[H`ZT!$V2"J&J$@JGW4>!\BOV7PGQSSXT$A?0
MWU?W_3_ER8G;VTI=L,QFM!:1R>3T\?N74&-&OXR&)=C3@$L6T8!$&0P3;Y(C
ML<%U/P&8-6:1IC+C1B^T#JJP8$)-NHABX)BJ(X"]Z$IBG!]R*G`JJIJ!LLN&
MXK:O`"CVD0%WIQX)$\HB*B<_=?"?*>414G+Z*=Y9F:[60Z>XE&]=X>XM`^Z9
MHKLFN:!LZV4O*J9HK"K'[E5?J:)5\*B($B5W:J+OJ"8JT1?20?2J+\^?')+\
M\+]N=4A*M%>Y'D1\\IRO*JO/*$OGR7/E47GGY7XY7Q[*R!ZN+O7DP5##ZNU$
M%$3PJ(GE53RJ\\+]D^VK?3LE%H!Y<$1[23RGE5XX\KSQQ\>%3_>G`5K.OFV'
M$$R-3-MPE<[>6_H)1[%5%3@UX\)VHG:B+ROPOO;4[P-X7N)2O2I'IU5M)9H[
M=OU$]-(=F^RTU)).5!#@3%8F(?@D;"2TA\/*AXJY#G+,83_><JB+S]8CY7GD
ME5.%5"Y\\HB?/A?MC+FNZ\:"A_Z2J%R?E'.TD5"0D^H53MX41X453M44(4]3
M@M!M-_.FL:.D3>*-OEL%@><!(%^R&`YCN0HAH9MW^-N?EDY7^%7M>EM-1K%0
M7R@31YY3@ER7T#3330----`TTTT#3330----`TTTT#3330----`TTTT#3330
M----`TTTT#3330----`TTTT#3330-6'ZG[.OJNG+?>7:SX-9$39[<]I95A+C
MPHZ&Y@N0>F)/RG&FA(U3@14^55%X3PJ)?C5+Y=@^%[@5*T&>8AB^;42RF)JT
MN78_4Y)4^]BHXD:9^6W,2;#]U&1UU&)"L^JRCCB-F/>7(:WG^3F;F;<;?=`^
M\5SG6=XABE53=0606EK.OLCJ*UF!`;VDVO<*4][F6V8@H09B,H@J;[D9YMD7
M'`,$C[P_I5ZA.J6P_%3Z]\"PK*L>Q3<_!]Y*_89B;16</)=T8>;YIC<W)Y.(
MU!BQ*GU#^V&)6U6DH&W$L+;(84.`CYQ)W;N`P.F?IPJY#$RLZ?\`9*NF17PD
MQ9<':G`XDF-(;Y['X[\>@;<9>#E>QULA<'E>TDYU>EEAF.RVPPTVRPRV#3++
M("TTTTV*"VVTVV@@VVV*((``B(HB(*)H-6W\,7$.D+J-Z2NCZGW#W)W$RS?7
MIAW+LI.([%XYN*E7D.`YVQFUG.C9+7X#%C55PF)N8S8Q+.^LKN7-QZ'7+:"<
MEF<;D5*9ZP=IK2DWEZO^NK\/?J`BXEN+M3F68XKU>]-&X#M6L'.[#$:Z*.86
ME=06-C9U^78KF%&_%E1,:M:Q'+F4Y.8Q^?571+3!M#T>VNW6,7EMD^-8%A>/
M9)?\)>Y!1XK15%Y=(B]R);6U?`CS[%$7RB3)#WGSKK3=J-KK*>Q:V.VV`S[2
M+;2K^+93<.QV5/BWLYTGYMW'F/UKDAFWF/F;TJR;<&9(>(G'7C,E50U4.LS/
MBR'\63\&K*LTJZ3;;(Y>UO3U<9IA+EG616MOKFXS?++.7C$MM7FQKFZHYHQ8
MT=]&?3C^@`"JJ/.14['-N]J?Q3^L3>;:K?CI]GV.6;:6.U^\>#[^;MPMFY&`
M[A;BU>-6,>1A=M:P[Q-P:FGCXS$E9+6PX5,-(5@-&Q8N3'45G8$R3I\V%S"Y
MGY)E>R.T.3Y':&#ME?Y%MIA=W=6#S3+49IV=:6=+)G2W&X[###9R)#A`RRTT
M*H#8"D2>_'X5VTN[>_>\^\F^?2Q5=1TS<+*Z>9@]GM_NN_LS,QC#:[&*RG;H
M<LQQ;_#JRZR&-95\R5)R]NVN9EW"FUT4XU8-4K3@81[D])^V?15^!CU88/0[
M]X-O9>YY98+D^3YCAN154C"7LC?W"VWBPJ##FF+BP0FHM'5K)-UQT+.V1)%@
M]%:9:%`Q;ZU;2L7_`">'H`;;LZ]77<\Q06@"PB]SKL*EWJ"6+7:]^\=AO.MC
M)0$(XSI@C_IF0\SP=*7X5_3[L1G^<9?4;/UN+;:Y?B-!2M;`YSDZ[Y8S'S"I
MMI\YW<EU,R8NJZGR-JFEMXI7!43;`PJGK99$]0FM1FI$)?3_`+#SL?J,2G;*
M;23,5Q^786%#C4K;?#)&/TD^V+OM9M13/4IUM;+LSX*PDPHS#TPD0I)N+YT%
M+=)=A%LNEKIOFPID>QCO;$;2=LR++:FLON-8#0,O\2FG'0=-M]MQIXO4(A>`
MQ/ZT)-:X7XHSF!Y5^-[^'ICV32\5NL==IMJZ'+ZBTGUDJO&/+W5W#635WL=U
M]081YE]@BBS$;(P<:/L5";YVI,9Q;&,+I(6-8=CE%B>.U@O#74&-5%?14L`9
M#[LJ0,*JJH\2!%1^4\])>1B.VCLAYUXT)QPR6VMMTW]/%]:S[V\V&V8N;NUF
MOV5I<6NUN#6-K96,ITGY4^?8S*)Z9,FR7S-Z1*D/./O.D3CCA&2DH8-8#:=-
M_P"'R^&Q&V&48,_==4_5@W9;0;.4]Y'D6E$6X=3B89N)0&+"PL&,<QB'B^4Y
M0S/5IF`PW*JJ9%]8T0XD=MYIW_X_'7A58;D])&RC).G#<3&L-FA:P'$_;%[;
M'9*#6,Q^R6BOS8-I'-Q^&R2R6E@2D,6UCO*WLN4G3WL'C-W79-C>R&T&/Y'3
MO+)J<@H]M,+J;NLD*TZPK]=:P*1B?">]!]YGU8TAH_2>=;4NQPQ56=/>P=+?
MQLKI]D-H*G*(5BMQ"R2MVTPN!?0[973?6TBW$6D:L8]BK[KKRS6I(R5=<<<5
MWO,E4-2K\+C">FK<WIJZ@^BCK0SO<;$\_P`5WVE9K<]/H9L_@=]GMP,;'8];
M+Q;%AA,91D69P\VQAU@Z^GMGC>>>IG)</V?^EO7U_$K?H*;\9+\)^G6<W$BX
M]3;%ULJ)D-M!>N:V.SO/<A$CY"Z[+=1;-8J,G+=><-)+_<^TXZ)H9;1);:[=
M'E[>X!8%A99XTR<9K-BQ6A++FXSB"+D=O)%KUN08,1$3:&:@$(BA"J(G'@9!
ML3LAEF1N9CE.SFU>29:Z]!D.Y1?[>8A<Y&[(K`8;K7W+NQIY-F;U>W%C-PG2
ME*<0([`QR;%EM!#7$LK"L3_*=J9IZ?7BXFS,:&+3DR-ZPV)]-^0JS&%HW/5&
M:2.AZ3(BDDN]%`50UYP!<HLSW%ZS_P`>#!-I;#WV?97MAO6QCE#2R6YUSE#-
M)OYMS=Y=CU%619"2;.XLL/K,DKV8L0'90J^^/IDB."NZ"6RNSAYDFXA[3;9G
MN`EB%NF<E@>*EF*6S<<8C=FF3K4K=_F(10",$WWWN1CB+*.HT*"GQJ=B]DZ'
M*$SBCV>VLILT&=.LQR^JV^Q&NR@;*T22EG8#?PZ=FV2=8C,EC.EI+]>6DJ2D
MAQSUW>X-;_\`#$QWI"ZDNE+I%Q[<;<K<3)-\NEO=`)&([$T^XBU=WA>X-;EL
MR;6914[?PX=7<GBB4-@$Z]F7$J=00*UJY]U(8E=T9.CC=O3R/\ITR8H]M5OI
M_FPLJ\49L83I+8L].>/L/P1%MXB]\RZT\TY%#_26S;>!QM%!Q!V;*/;;;O&;
MZURG&\"PO'\GO?%YD=)BU%4WMRG<I\6MO`@1["Q^M5+_`$N0]]2J7RJZIVOV
M&V.J<H;S>KV:VIK<S:LI-RUEU?MWA\/)V[B:L@IEJW?QZ9NV"REE+E%)G#,2
M4^LF0KKI^LYW!J_=$$Z-<_B,?C@TU181+2RR+`]]8E!5U]A&F3+R<N996V#%
M5#8?-RQDCZ@AQ&!TV_405)$/7D?A#9AT\,_A$]6FUW43:6;>'IG6:2]V*3'F
MS<RK%<,N\<V>PZ/D<AI38:JGX61NE*@,V+S;TY<>N2B0K`:R9'UM,T.Q&R&+
M9&WF&,[-[58[EK+\V4SE%%MYB%1D3,JQ!]NPDM7=?3Q[-M^>W*DMS'AE(Y*"
M0^+Y.(\XA5!"VTVYK8=[7UV`X5`@9/8-VV2P86*T,6'D-JT^$IJSO(S%>VQ;
M6#<EMN0W,L`D2`?;!T7$<`20-<OH;V^ZG.B_K2V$Z91W,P[K!Z2MQL1W,RO:
M'/XQ4]QD6R]%54$<[>ZKIGN+6?A%?82)U%C=A60[B3C66C<BM(S!E09L%C9I
M3RB*J<*J)X_3^6J3Q_`<%Q.?:VN*X7B>-6EZ8NWEEC^.4]-/N71X[7;6970H
MTBQ<'M3M.6X\2<)POA.*MT#3330----`TTTT$97XO.[J[2="F[;D5_V]ON'^
M2;75+@O(VZ)9?8MMVY-HBHX?&/0[9LNQ1]/UA<4D0>%T>V`;<(414(515X14
M551$1!\^5\(J)YY\KK8,_P`I\ZDZ;:C"^DW;*PGNQTS/,MP<UG1F`)SOCXE2
MU%'7N25%5)IM9&4RUCJH]CCK#G*H3:+K6-PO=;',IB1Y=-:Q98D@<^FXG<T1
M#R@/!QZC9^?@Q%21.4Y\Z"_S$12Y[$XX5.4[2^57CRJCYY^%3E?A/C7J,02)
M!5&UXY7R2(JC^O\`M3A/'///]-4U3Y(+R@**)JJ\JG/<BJO'W3CRB_PKY\\+
MQQQJ\F/UCMT30L,F/<@JJ]J\?;^+POCA4XYY55X1?OH*4&N+Z?!+^B(B$O/*
M<<HGG^7V_DO'QZ<>EF%RH-FB<\_P=G'S\KX3^Z??Y764N-;0D\(/O-@2***G
M(]J>5Y5/A$5?E%Y^?"<_K6TK;,6&Q$(RB(>%-!5>47[^>?O^B?;X705[L7TX
M9=GVWN.VT-HW*<GKAYU6&C=?9L!DMQFE1M#!#1UL`!"$E1H`<-SL%?,P^TV,
M-;2;;5]3^6O0+J1PU91Y++;92;!Q@0F%*5PO6,O:$R<?EM61`B%#1!4EM3TM
M5%S2[,X_[2F=GP:QNVF/*#[##9BY)?-Y7"-P41QH6U5H3'E[M(`$G$1-70N,
M]F-W-9)E5SBA-18T&<1I-4"BDB-C/)Q7$5.T1!M'&@[4(445!5X"Y>)8^U%B
MNQ+(FE9DE+=%EUP)Q$DTC)UH8SC@$B>IV`HBB$0$IM\J/.N@=)7XS,LI$,8K
M$*4L1XZ9F6LIYMV0JJDMJ,ZCI(PT@*W*#D@8!4$T$DU;3(-PHT%B&PW(4I9L
MQY[KS($"B^V;HN"BF!>F\*HJ!*CF8&JK]+9(2:^%3FLBPC2;=9#I6,YIF+"K
M%6(B3?7>]-^'+?51E"^W^[<;5H#%U4+U4$%4]!4<#'ZNT6Z`*6K"#*.:_+,V
M8X([ZXMO.`RPH>J;ZH*$A-*B.N&?MQ5!5$[</$L713LZ^-7PY<2`]6M/L1F&
M7D3N9=;8=D&02Q@/OB+QHWW]BB*ML$:&FN_7TM@-2<HI)0#!@W1B^JKD9P%<
M;<(4<8'O)EUT20>5!1]$D_A_CXN+A^F?I7'&#GUTYIQD6F`)N;723?:D,JIJ
M)-^R?!]'@!"(NXE[NPD1-!8/='I^++F9UY80:;*I[[WYXW"1Y^#*C3ZOT$CM
MMRY"($]QYL2,AD=@R14T>810!%L+N-L--SJ+BM/8S*>/$BR+60XZR@.W,%WT
MVD6#$806T)MU55Y'WGBC\,N<,"0JFI.?S)J9#G!+9&2]8&ZS,DR1!YU]I2:]
M=T&!5MUJ1W>F#!IV*\'>@HB]Z:PRW5P;)Y^?A<0JV4N$5,NHDNT[$PPFQOJC
MQ[045/1DJT1#P!&1&VCCP<`WRJA%WN7LF.W^6VV/0[A+FH8BQ9$2=)AI%FNM
MS`$W&YD'U76H[C!=S3@@Z8FV@.M_Q*(VK;@RJT3!QOAAE5;$AX]%10E[5$>>
MX04?**O"*G*\\)QJ>\\<PW*3A3Y^/T\R73E-?C++KXK\P(S[/'^F*+;ZS6&F
MVC1(Y@:L\*32`BJJV/W'Z?MLL4M9>>5L>-`CW$YM2QF6,;]GH3+S(//R*\G^
MQZ,Q),2-Z/)4VHHN]K1`*(B!$>Y20+9^)(D*Z!,-FVK;#J-#($E$_P!Z@>7`
M!4^$7E$7POE4UEOTCW3^*;F3*IGANGOZ9XQ!314296N(X(BBKW`JMN'YXX,>
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M&VU^E2Y52)1Y1L%-4YA`WPZ_LBS:SDX=L!7O6,QXSC/9Q/C$<-L35!-ZBK'4
M52147N:L+,10E0%8CN=_*8Y6$7J`ZN[YBWW"LI=;B@/.2(./P&'J^CAQ4)%7
MT8)F129*"J`LV;[F6ZJ(O[M5[=9?[?[&8[MR,6)1U\$I?8#TB18M#,?`VD55
M;)2_=-F7CT5+U%\IZ@HHHBAL/?Y-5E.Y%3@747M+N?D<W(+)W)L8W<IOS&0;
MTN(620I..9.V".KZR13D4M$^@((,-/O/$TVVCW"[0FM2/\'/+IF)]8]30S5&
M,WN/M]F&/OB3R&#DRNAL957M#Z3+,876FZ*8(B)'W>LH-]QB2ZVW-`TTTT#3
M330--.4_7^7]_P!-?@S!L",R$1%%4B,D$!1/E2-?I%$^ZJJ(F@_>N%7A/]W\
MU_36,6Z?5GM+MF%A#;NXV79-!BOR"Q['9T20K2LBJHW8VG><"`9$*AZ/>_.0
MN4&&2^-1B9OUP=0&Y#UO%Q6&F(T+0KS&QEMP;)F,H**K+R!\')A&H'RXL0*\
M>Y.0'Z47038Y'FV(8@RDC*<FH<>:4.\2N;:#7$8]R`BMMR7VW7>27M_=`:]W
MCCYXPYRO\2CH[Q/(VL3>W8A7U\[+*#['%*^=D"MRP)1<8>=AM>DR;2HJ.>H8
MH*_2J]RHFH1\ES/(+!FPF2AD6F2E'>[)5A,D29#CA]R*Z<I\W'B='O7GN,^_
MQRB(B(EE]MMJ,.KL7GVE[($\O*6];M/(T2OSILV4XZ[ZSH`B`#+;?"(A(B$@
MJJ<*J:#8;<_$CZ6VS]-<BR8B\HJ-XG8N(/"JB]Q`JH/\*_*_[TY]V)U_=.<Y
MCW,2YR5]GSW&WC,LD#A$)$<X=Y;(D5%$3X4OLB\+K7%OJ9N'6R+".\D1\XQM
MQW#'U&5D=G(#VIQW&1*/*$O*=RJJ^$U[O39C,6AJP;W'N+&576EC93["77F2
MO^V+E(4=@.U0;-%5>>?X4X'PB<Z#96PWK&Z=LWF2JVKW%JX%E"1%DP,@%VED
M-BJ(O<JRQ1A1X7Y];CPO'/"ZR*JKJHO8@SZ6SKK>"9*(3*N=%L8AJB"JH,B(
MZ\TJHA(I)W<HBIS\ISJR.1:[\SF+1K):K'9+B,^Y5$?*,AD+(23%>'#5M>25
M$1$5.4X%/->81.W0J/S;(MO<ILL42G1MZ9)I;?\`*R[0Y%M%C@OIS?`_O0>!
MT7!+M<;(4'0;.2>4334)&T/XCNXU#+"GW4IHN=P6"9:=LJF/&I<A980>Q7^&
ME2LMG^$1QQIQB`;A=Z^X1211E<VJWOVWWDK2GX/D,>;(8;`Y]'*4(F05:DJI
M_I]69D\`*2=HR65?B&O_`&;Y<Z"[>FFF@::::!IIIH&FFF@::::!IIIH&FFF
M@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@:::
M:!IIIH&FFF@::::#0(_RNF]<>ZO>EK'T=Y;K>G&XMFFC+AMN7;;FW48G$57`
M1%=:K66C1!53$1)?^S%$U+X-I8TD@9E?.EUTMO\`>`_$DR(SO>G`CR;!)W<]
MO"HXAMJGTDB+QQM7?Y6W6S2ZYNG&8TCC@2>EUJ*RV+;CBJ;.Z.7J\8"V)DO:
M+@^HJ"JM\MEYY76KS38\(`\],CG*;5Q6")MMYT(I&G:C;DA&E%MQ>45"3A4[
MD^E.>=">_#(+!.J3,</AP#L#@Y28%&!V%.18DLU<1/W+<EI>$<X[?K,.WZ^Y
MPDY1$E"VF_$#V?IH]:WF%1:8U:2!9:-N2`RJSW!*B*V-DRABVWSSV$^RVJHB
MDI<)W)$=6;?T&1%6PXT=RM.%+C-N2(IMC)>4R`5;<<[G!-QPD3TW4$7A-40>
M27QG/B72!=VLZL5G;2^>2<RPQ"D3XINL1G9;@@=C.==<=6`#?>CSKDAIL@90
MW!$0%14)O]ONKG`,HJO=U$:OM8*--FW(J;*)(<:15Y19``;@\*@J(N(B+\]W
MZ:R0QW=K:_*V6$CS9)6!*(O5XP''W&%5LW'/5)@?0%MMH%,WAY)$1>!5.[47
M>T'X>E=MI/BW=[D,1&78XCZM!5/E#&T-P7C;?1'&BL9),(3`L/-^JH.*^*@G
M")))1X74PH<5J^H*V''D0Y!UK[3D'TO9,'Z?,B7`=;DP)3;C)$W'GBV^C1<B
M+@J)F%VO\\E]"JZFGI;"PIZ*D>F+%2O?<::MU>E"Z;KQ"0C($`/L"*]ZC38(
M2JWP7F]\[<AQ8M7)8M4FR#F..>E'2,\Q-B)'7Z>Q@&W67A17#=4W4$T,/390
M@76/E?B6,5IE[L7%B7+_`*4-J3-E/-PCD1Q;CK$DM]K:-H\"N-^H*":D@R"5
MI!UV)&$28-C);IIZ.UIPQ5T)DF,VZ$X.$=8%0[T46>15L^X'75<[#!"1!0+I
M,[QP,A]<Y\.>)1@"'&AND!-#!;=<4%KYKZFM>V1D:JVC8IRXOE212U?G%[!H
MBBK#@LN-*VDF(,GVRRXDER."H+;#BO%(;D,MK'<<!5;,NTO"$XFL9\@QVTLJ
M_'H$1VHKDCF^4M]D?4ELJPV@N-H(--&^S]*.-`;A&)*A%V#W:NMATVFI:.56
MWTAR>]%@M-.30"84JI<DOM%%GUXM-DLI(S(DVK+CAM,(XZX[V<"I!D?%L7D0
M)4LE)Q%&/'E/>I$A-R#Y?]L;`&TTZ3C:.L-!)'AU0]1OM-`XZKE].F2U.`42
M7WV:0(<40>@282"#:_FTQ_U705AQTR]-MA#?56D(2%2XU8W+P)Z##AUEZ^-<
MK4@IISP><]1QF0!1?1D"*$_&,C=$NX!<BOJT@F0$7%38E.=;BQX;DM^8\+S'
M:^X/:B#ZK21VS>`S=%R2YZC#:HT)QVP4S[2(.T,F8TE!BPW";<`FW(\66\YZ
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MG/\`2"-[ZHY,-BZVT*(9HJ*BZQAO*Z@FTD)FEOWY61!<LUU<T%B\VTS(66\U
M-]S7N*KL4&&NY8C[3B-HVV3:F\A"B7`II+M"%7%G22LD0FO5,N[W`QR=[0::
M+M664GN1?6;(R%140!P4)=!74EMYO';&"%65;$8=;C,1Y#2+`E)#)&V)+#;1
MJBK$9,%5%1GVY/`XH_6/-`%A!93<4\J8I%65\)VN:>17&IHF\ONY,.&;R.MI
M$%U?!MN@)&9N(*D2MC6<RWA6(QI4571BF91ACD"-&[+8?],BDQ7S7V[A&`BZ
M+JJVZ``O:2*B)53L]?RZ'8*X*B#DYIAL1:;:`W"(7'5;5H8;!.&;C3:L"2MJ
MWZB(*JVN@LMN]TU;<;C;7YIM]:-V[4O*,?L*JLR''LBNZ2]K9\V*XY"=C7=8
M<%V,5=,1H);)L.QIC7J,/C)`M6`Z8?P\-L=B^G#'=DLVPS"MR?SRO*WSC*9-
M'!FR\TO+&>\_8RY%G-B)=5CU<+80ZUPY3<YJ/';?CDR;IBYG['M:]YU4=20_
M"/VON9Q0Y+;4640*AL/-.<]K*&*\RQ005114'L<$D_=OE%9%-D:Z*;P``*X#
M[DM8K3",BZTT<86P=5)AH3H2`56VX[G@E!%%0C<W&Z`-J6J>JBX%,M\'>B'8
M^[;D/?G5?8P^!]FQ`;D"VXQ*8-$!PG'O;JP#;9H3[BN:C6W5V9R;9;(9%*,9
MZZ:66OY+:XQ7BXYE#3IM1P!2D]Y1)CK\AEA6K`XB))X[%-A$<'812XE3FI[&
M0#51B=EOE510569C=%,-@82R%DN&XS:..`XT]*@<BRV3)J(*?C#?JWMLCQS;
M'(<AVWPJ#E%[5E+;CLI*A19KT.U+L"79R##U;AJDDLL]K<9AJ6(K_HZ\$2H%
MK.A[;MO`]]^F7*+C%YM?F$K<2K@37Y%RES-JY&1UUK5RXLR7$<6K5@H$EQKT
MXH(+;R^D!GP9GMFCPHBJ?=$7^OCQ\:U!NBOJ+RK+>I'IMQ3(L#>QNWN-S,49
MLR=NH4^"P<4G'I)06H:D\BNG&5QL)7*M"1"1*0JJ;=TN?#KHI2["9%@1604W
MI,R0S%CL@*>2=?D&VV`HO'<2DB(OA530=W36.66]4NT^+D\Q'M)>436N\/;X
MW$*:PKPJHH!V3IQX`IW(B*3;[_TD+@(8\KK%#-NM;.+!7HV&T=1C,8N/3FV'
M_7MJ*)SW<@7MZMHTXX4/1DHBHJHXB_(2:O268S3C[[C;##0J;KSQ@RRV"?)&
MZX0MB*?"J1(//WUCUG/55LO@ZO1W<G#)+5E3$JG$V_SI\7`4A5M^6R85D<D,
M>'&W9R.@GU>B2**K$5F>XV=9HX;F59;?78DJI[:79/C!0>$3M"NCJQ!%..$7
MB/QPB=Z&J>;><H**O@0`?/:*J(B/'"(@HO"<>!$1(N51$\\"H9]9MUZY)*%]
MG!<6JZ".B%VV>0NN7$\!Y11<2!$<B0(Y"!(I-F_+'NX0355[%P`W4W^W5W$=
M./<YE?V<8G"]1A93E?7`I)VF,6KKDCP(X$``JIZ!NKVHL@T<[EU9_<VMF99%
MKZMN=95M0S;PY=FE<1,3K`8KJN)7MN#];/D$>,EY1#Y!04D7BU&2L;G([VXS
M(H0A,,FJPKAI];24XB$+)#-;4&R>)I!1Q#_=D\JD2)RO(>CD6>5&+6F+4<U4
M>LLKM6JUE@"54CBO`.R98KR8-\J@J9?0:J2=RIQJ]N/;A9#A<&UA44A&VK1M
MR+,[6VW4>;7D5!4<\^$4NWM3GMXYX3SJ*)^^>G;AQ**=;6$O.9EF!+$>59#$
M:2C_`*+,,3[52'%:)"(61\HWRZJ\$BZS3M=PZ[;BMK1W)GPXTUQT8DF71LNV
M]43WI(;+??%$S]5ME.'30%;0T55-/JT%Q")R5)]R9GZQ$IF@^.Y5<52%!3GA
M.%Y413E/'A$37L87,KGZK)(80X]M,*:_$%UXR;.J5PA5OT!`@5PP7O[!)%:1
M47N3A%35GH>[%+DTNJBX:XEI'MG'O<S7&ECMQ(S8JKKP^KPX3@HG:*"**BK\
M<ZO-/K\-@8G72*J=9AELJ696<1&4;AHQV*3+PR1,2<=<+CO%SN[$7[KXT'@7
MV/U,NW&SGW1QF,?CA(@U<=A7XD^T)0:&+-1HU'TU5$55).4(%Y_B\=BYR>`U
M*CJY5%&9?;1^6=;$58E>*@(`3B=Z(/JFBJ3:KY0EY1.435KKJSE8G=54EJ<V
MQ#NYCL:7$F-I+60\C*.(D9MU>U'W>TB)>?"(BHGSKRJX,UR-NZL9#5@E&KZM
M+*1D(\51]5"9@=C:(B&:(AM@J?P\*J^%30>AE^^6.4U3.;QIQ+.\;=1F,R\P
MXQ'&0XJ(0OF2JJ#V=Q"B(B*0\?RU[..Y/,R"J8?@S3'W30)8!'DDC+<MQ.3;
M-`[1$$430$(?4\*G*IQJQF?81%;A.VM>[^96S;)/E2DW[<69#+B-A'<D+]!>
MIW#W.+RH)_%\ZLIC>T^[E-NC7':9&55C]W,CK<,X?:/3&X#*QA?:A'R"12E-
M-N<.N"J]KGTJO(^`D2KXX-\`9]KA@O"J2(8(GA2$55#(?'<OGDE_OJ]U<6/8
M=1TV7XUF5S4;DQ)02(QUI%#<AJR2JBA+;<$R%!%.X#%QIPE1IYL@4A7"J-88
MOMMDT?U9^2NEE5H%97I>/G9R'48;(P?99(D2,KR$JO=B(*JB)SY35_FV6K!`
ME-$CW"H7`J1(B??E$Y[5^>Y%%45>1^V@F2Z8NN2%G#T'!=W'(5/E#KK<*HRT
M!:AT^0OEVBRQ:M(21Z>VDDO8#K:A5RGOW:>S?<;;=DA14).4^/E%^RHOQ_BG
M"_T5-:D.69U48:$?UT"38/.M#[2,:"^+/A3=+CA6E:!1<;Y02-1[5143S+]T
M5=8`V,>GVWS^W2=7S`C1,+RZ5(5QQJ2^H@SCUW(=)51HG"1FMFO\&PZ0P7U)
MHH[C82PZ:X%>4Y^/_9\\_P!%Y3[?TUSH&FFF@::::!IIIH&FFF@::::!IIIH
M&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF
M@::::!IIIH-/S_*;]@3S?<+INW,-N36Q8FWN:8BYDL:ND6`QGZW(6+F)5RQ8
M)%;:FNW@^W5.'"/U4;[D0AU!5TQ;#X#FFV$S$K:DJ7\M*$;>4S9<R4T["N+"
M>:,S([`M"XM<<4``&G6%5HD,B<,P3G=E_&#P<;O8_`<W.,S+9P;<./'G,2P!
MZ`4'*8#L(';".XOIO16+*#`(^X5[.[E$3NY34-61N3CVXV3;G0\&@QQN)C&,
MP6JUR&XS+A,FJ06'ZZN*.L-PO3"5&?;$E%E.YTT7D5#U<YV6IK25A-;C6+XA
MBUK@>7UT\+291A`B/P(1!'EU#SE>TP<R$^K;,B._);(&GP]TI=Q$BY$X1)R"
M$Y*HF)[$F]]W+>DS629&)!C)S&DFQ,:<1N3%`S%IH2`T<%TC[T$>S6($F;NC
M)RW(+K*+:TQU]YH6`A/M\1U8<;]:,L-M\7XZQFVA!4D(AND[SR:FA*OM;6YC
M/K<R1UV+:6H38[C$I(P.2GF#[A7WC\=OL61'=<$FY+2$A?6A"A&*`H9P,;KV
M4>\3%9L)MT*>0$1B8CWK`[,;85LSL3!!:1!3CT9;2=SG>"%\$2Y#XGDJ7]19
M1'G(@G*BE$FRW&T-EUI8PNB/H#ZSOIM.L`V$@720Q#O(6P[QUASCV7,7]^00
M(1PO80'(CMA^7I#-]]AUUB0,H#;(?<JQ)5KN?=(W&P$43O1%2N]N;['<#D7E
M`K<ZWCE,)JNDV,(Y<8PM(2-_E(JT\+33E=(==-A`7TE1P7%(7Q]/09F8?4TS
M\"NDU\M];-QL7&I`2#E1XY,H\U*::B/`]%;C\J@-J/+**O)=XD/;;G-:.ZQ.
MR*!CUW,D4=NS^:A,FU3S2,3E=DLS(<5X5=!QQHV@_>L*L=L70`A20V2IV\'E
M9)&8@-2H==71@8)&CBG))YKB0C3D=Q@NT4$F>'N`,U1%^M&B5!6L9N36=NZ_
M!A#"@,U$F5%9DVDM\8[S[+"31<8-IMU(;#R*HO-NM`X4DT1U%5"<4*#P[+Y\
M"'"R"Y.3,K8\98CBR9`G*CN.N*RDZ,)]PE'1]L`)215%LN3%>WA<AJO(ZZ54
M.V%+.==6T"1+=DM/BVV#<H?2M8KA&`$\0R`4%CMCZ(ML]I-D"(J8\14P*^Q>
MRB-&X;X19IQX5?)<8DPKPW%,4>A.BJS&$DKVJRTOHNBJ*#@^>*ZQ.H=@U$"H
M:E/P_25EZ2CK33J'`E<-.NLM(BR6Q*3ZJO*TI\\$T/)DJD%9W=K86)5S]*\<
MZ%!:<&_('8A_O0<:]1^,,<0<-YD7&G$C!ZCHD1FG*IXK2IL9%;*JD1D$+E7W
M"GO$*RW'G24UB/JWZ@.DTX7/!&OK-JIN)W**6YF1[3'V"G.N1*^BIQ:6>]7'
M$ANRD-\G6[:6;PKW2W1!EA_QWI$$6)'"M!W<U67/94_!GQF%G%!:>CA707P&
M,+<U]/5=>*27>$@#:!R(VVOHD!OCQW$!:#)QK)S80$9<BRF7!:)R,XW(<*`R
M#BMJCZ`#2.$Z@@Z0QT-GN<%PR!Y#35Y*G+FIH1G80O0E=1I5=)\6Y##[J$!)
M&<`2(W6%`28<=)$`2%4%5^K6`TB;E3UZDZ#$EJT*1WF30E=B.-]R-.Q)"B8*
M;C;W`R&U;1KDT4#-.52^]7;3H<)B,XL:,[.:8>?%J8?I167O59,47OD.,)WM
M(*"X`/AZ8!V`+J<A^MW<5MS;CW>"T;4VSD2C63$C2V*M2>C1T,IX-$G+\QV2
M"A)**1>L^IH2HYSJWV)Y[)E.Q$N2EM*]'6'8C.1Y^5"G117TS1MSN>4$?Y/N
M1'%])%7@C`>+V4LMYZ-)C0TF2WU!YEB"W'%'5EB"""*CQB@J0J;B''-7>\FW
MW6^>56@IS$%JRJVI4>&R<UJ<#3DE(K;BOQC]9^NE&)-/B\0+Z[#CZ@#XH0MD
MB(O(7+@+!CPY<M5(WI"@V'#XNJV0*T0N&V\@H?(.DJ"X($XX7A7?3(4NS'FL
M4D>M@6(Q6I11(L^TF-(W(_*!>0G(L:D]V#H0WGHY-RK2=[-V2+KR11]$(Q*>
M+=>MN4V=5V"/OLLNR5J+CTFF&"B*#8L1W^PW"]5A#`5=0W"0U]1"44[M76R<
M[")9LVDJYF^C8QXUHM?&;CS823(T&/7V5$Y.5SU'W&Y@&8!&4Q2,<&4ZPC;Z
MD`7DB9_927EC3GQNJ-\#$8T\&9A/PQ;15<5U]0=;EKZ(<HRK1LJX1H8N"H.>
M595H0;*#,@M..U]M""3#<=<<,8S#+JA,A/.]JM29==*0F5$S;(609E`TK3BM
MI;R--)FN:GN1'TDNC%9KJIQED;-PW"=!N.C"@L8Q1%0W",T(O4;1$=)6U'+G
M;*/M[DC-/AF1RK1V^K(3ULS329918*39BK,FQ7@CF)NW53%1@);"/]@LN&(B
M3D.2(A8.QA/SF(2BT^LQU"<")&%'_?MJ1Q2#TFFW)#S;CH]P=B-N`8^H('X3
M7ER=L,XO7R655QX,!1%I9UI.$)#H,`+3!!#%HY*--M``"+T=EWM1$,?.I!'Z
MNFQ^*3-/5P:R.T*IQ%8!M25$5.73%$=-T_*$KAF2\*BKRBIJT=]/;5TE[D04
M15\KPB(OU<#Q\\>.U%7E?U5=!A_#Z?L4Q?-L*W2]R\>=;>WDB^QNPK85=6PF
M9TN.]&-)T;VTD[.(WZJOQV)3H,-2D1UH1^IK5897E%_D3I.WMY:7)"1$VME-
MDRQ;)!1E.QIT_0:)`110F6FR]/M%5)4Y6M\FF(L5!YY554D)/]=$$N4_7R1\
MBG"\HGE>=6=L7%_B_P#Q(J+\+Q^GQRI>5+GSRJ^/.@IJ87<HCW<H/*BBJB"B
M)S\IRG//GGQSY\\\)Q2TQU54EY5%15X%2YX1/X>$7E%^Z_'RJ\HJKSKW91$O
M<JJJ<)V\IY3E5X7E%X7S]^?CCA?Y4O,<524>4^47QX3MX\+X^Z*GZ^.$^?.@
M\607+G"KX$?/PG"??PBIY3C^B?WU;JURR;'MTCT[#\F/7B939$06W7$E<?3Z
M`.%VF4/M5PD/MY=Y1"4FT37&Y^5'BF(VMA",@MY(+6T_8WZSJ3YJ>FS(;:YX
M=2()'*057A7&Q$OI55UC%M-`MW)3SL19@UXM#72WI[DP)4B>\:NR)3GN$!''
M9,E3=,A`FFR,Q`D'A%#)2%=&W8P+ZM)XW8K[<X2GQD1#F,N>H2'%<Y9=`R54
M/A%$D147E%77PN)LV]F6^3VJL,.R)!SI+T=AF+'`T$C%6XS"JTV"DB`X#:"'
M)<H*HO.JHR;#K3!V:L9\VJFI:5[<]IF"\CXL-N"A`CX-BA,2?"]S7''"%RG*
MZQIW!NLMIW'G`CVN34=FC+<2GHJYE+!F2K@"[#[&C9"2VWRCBNO&*>F)"J<I
MQH+*4NS;#NX#F;U!DEY<WJS')$Y!:"+/D.H(&Q()5!8@!V\\$)CW$B^-9*IA
MF4QK2116ZXS-%#;8.3`C,OMLONBA...ON^JR3?I'V*^PG`F2HOA5YJZAEQ&<
M0>IRQF&LNQ9B$DJP$F;"I=1>]X1%EPQ]<57L,27CRJ)SPBK4]#75BQ7PM;)^
M`T,%]Z,K$<I3SLMKZ8\$3$U5IM\D[7'$11`5'GE%5$#&:EVXL8&8W=E.>@5<
M.!(C_L['K&VWG+-M`]&<#PL"#;*":=J'PB$:H/'"\I?.TQ:SK8T.7:5$NOCV
M;2R(4B4SZ+4F**=JO-IQV.?5P*DT1BJK]:IYU[#]57OQ&ISD=&[*.9,,/H[Z
M+"130G%CDSW>F4D7T`B<%>21%7YX15S<9+?1ZB':V;TZ'2MC'@,/.$;4**JJ
M3C49I.T$$G.%%2XY^57[:#&S>':^TW`@0;4+&174&&3&K&2D!^*S-E39"%%B
M(P+C@.KV<F9+'[^T5%3X3A5^V"VL>KKZK"9#][8FHN.M''8>>]Z+7*@DH^XF
M2E(A**FXG"<(B?;7:W9R^FHK&IHY,YQEY]LWGV8R=Z-\\"T,CTU,6W%\^FA\
M$J<>!3SJG=F=X:6YR2YB8LXK%QBKC+L21.A*GN9!&J2?31YHFG$CKVF:=W:?
M<B")>40/.KH66#N986>;U\>+@0/*_#JED-^FT*#Z;!62`0RHW)H+CPNJ("OP
MJ)JX%QNW@.(6T7'5LX[ZW+;\N2]CD%+5J,@GR$09`*I-.F*)^]$E5$%.25.>
M*RR)V9/C9%>70?FT^Q;ENNQFT:4[&3(!45I`0!$?J53$4%`045.%\:M.ULQC
ME6S37+,J(]?3:MZVG0XK*JY2O\DGL9Z.@VUZA!Y9-@G&57O#@33R%(XIM??;
MR9;D.YE<X]"QS&Y7N*<+EY0568BHP[(9A&JNM(;I(O#8D2_':GPG:RZ)E$%#
MI78TR"T\Z+OKU%G(9*>QW*2RH[[1>HR!<$AMJ'T.=W<J>$UF#M#C%19LQJBZ
MO6<6JSB.O.SD;[FVB=[GFFS8:4E>4U%.!5?WBDA<^$UYEO512L9<..K$YMI3
MCLR7&E1XV%,U%UH'$564?!._L7Z4'A%5>?`1.5U3:5627E=CUG:95)=LB?FM
MS[!VUG5I(WZB14]8W'$01-.\U4%^W`\)QGKMYM8LK%*&\FWM_"R"68OE209#
ML6/&%GEP%)17TS-3;1%0B$E[EY+QQKT:GIOQ&HS'*]T8-P]`R&_@P:Q:&)'[
M&'3'N:<M8BMB:?F!H@MR2+Z/31"Y[N$U?'#J2;MR<6%DD6YMJEYUN5[66B0G
M5B*O*^W?45,4<4T%31.%151?UT$QO0OU10-Y,;L-N[^[&?N'M^VK#[DE'6YM
MWCS+@1HT][U13U["M-0@V)BI%)!8L[DE?>49`-:U-;N;/V4LGMZL)IV'['&Y
M;,QBH&0L=ZYJ7)S3=C1R'VQ#URD0'7V05\%$I'IDG:H]R;%V%9=3Y[B6-YIC
MT@95'E%+7W=:\B\DL:PC-R`!S_S7F%,F)#:HAMOMF!(BBJ:"J----`TTTT#3
M330----`TTTT#3330----`TTTT#3330----`TTTT#3330----`TTTT#3330-
M---`TTTT#3330----`TTTT#33308U=8.V3^[_33O)@<&-'E7%IA-K-QYF1'"
M2)9%1`-Y2B`&)<&].KVHJ$/!(+YHB_4J+H?W^;9;A$>!?O0">C-6#<-RNL"4
M4;G.M=I1949H?=-.(VAM(ZJ<([^[Y0^U%_HJ+_S_`+/O^B\>=:4/XI>UE5TM
M[^YM4/XPLZ@SO(&MQ]O9CL5X0:B7,^1/F0(=HA#'8_);4[*O)AQHOW,>(`M]
MB(>@Q,8SK$<M&+.RN+-FRX<(Y[,1YFU/\OKH\1')=4[#!II$CQ@0G(\DQ)Q%
M'Z2!%Y3];<XX]7SIF48A%B6(9,D=]B$]*<B3XT7O<G0WVIB>JP7`*C4B(7I\
MFH*1*H]VO!Q*TI]S:J<]80^^-5>^JHXNS^TV22`W*8<:FUX$I_O'DXCNB027
M&G6'#$254N:R5;C+-1"QZ]AQGKIX(SH2TBOL#&;@J3#]>R+K7M)+9BH"S(0H
MQ$0(H$:*F@[^#2)UY(M:.YK#B5DYV6K\^"XXR+Q2Y+9^R>11$E<22OI>[Y%5
M=05^A>%U??)\.K:_'<>QZ%9N1:6U>C..G%<)NVK)E%+"SA`L\VR5TY8@HR9C
M"]H@1,24(WDXLK1OQJ"[D22N6K^EAB1$JPE;FR9#\<')38JT^XR,IF::^BT7
M[IXQ$D]/O01R'QZWC2IGYWW/17O19C06)*-MJX++9/..LQW$.,$E'$8220>7
M$`6R[DY5`K"D_*\OG1R2[DHM-8F^[$JB1DW!=:(/5EB:B4EA.7/W<<VV1)40
MT^D47V+"NEWUI!A4#;%1#@R7AMGE?&.$]MUDF5B2^"-'T%T!.%*`A>],S%\E
M4UYLM3$Y&S:YE7[4<ANU>G5DN(!A#)E\A]2%)2,:*V\\2&)J/;PKA$K((J=M
M_P#$(,5Z6]8QWWHXD)`S7"0N(;*FC2N/*CJJPW%<(``GA[R;5'E,U$E4/"G8
MY&A64,VJL8<E;"#%<R2-%*/!=]M'<?;BJ:DW%?=G*"`TXX@O/OF0\JO"+V;"
M]KJ'.H*6%H@QBI!>C&/[MN%)-X2<@6`,N&1-FHJ+1<((*8J0":H6JSR`)<BR
M@128CN4AHPU):;84I7YBRXCC,]DB[FE;BKP+3(</(ZHN@X2%]/1L:+%JUR^F
MPZ2)92[&!8R[BOD1VDC.*,182-P!>>18TA>?6X:,#:L%5Y0(F51`[-H[1YOC
M5UBP3'([=HV;<:,RZ*G&:"7&EB+*O(<B9%`FS!QA\_7=!Q54^`0DI&L;D8U=
M6E/1RSLG1A<-^U9])QQ7P)RM25`)'7407D,!B&OK.\(C;@=GFB<5P.]G'37%
MY<PV_9N#=Q:Q&9+;K9QXCYQ&7+%ESB3);$@87Z/1>->U[D"YU<:(<6JRRP?F
MUR5Y6%942QF1T,FI4B"ZX@NONMN$XW()MU4-45LD435$;)4)0N%BER<JL8G3
MI+,66810?!1X@"\<@FIT5]U7Q=@R8Y(*`(MO?O4('4;3ZD]^V67%N&Y$!\)<
MF4H=[BR5!8#31&XZVK#<A&YB3`X(1=0G%44(51!0ULZ-;1C,>GRGD9!RPD3&
M(KCCXHX\\'>]_P!FJ>M'-KU/30E<=]9%>)>]4)/2BW33TV6X[(2O8==:[)<(
MHOO#K'8XC'D,A(1MIJ6`M@@D:JXJ(!&9$9H@9'XYDR^[<]5I6WFFXA@XPXH#
MZT@Q:?1PW"6,Q(%H43UC7N$>WE>$X7R[R-#G^XDM3+1R8VV^Y'=DOM&VV\LA
MT1;!A6Q!X50P:-R,"][:DX/<"*FJ&AW<AN"`"K#\E'&!-QM2">_%!I'94X1+
MNBFPZ`DCC*EZZN]BL+PJ#KV(^45,8VA.([9`TC:2(YFY%!YM]Y2==<,VE=BN
M"PJ-=K0((H7JD)GPB!5YW4ZNAG,D0IMBU6C_`*8U&A(][9`C-M.G*A-*VZV#
M7*G*[^XFB5I[TQ(137YV^W#<(7T=>8LH\J:<A*RWBC/JI?(HRVJ,N()0YC*`
M;3,R-Z$MHO/KHO@O,J+UH/SZ1`L52)/=DS(-=*;=E28$@$8;=AO6*DT;@^DH
MNH\^T0%P!$*D2*GD-RF@D-=WH+8V9$7<,5SNCR''#7N[T%L6)"(SY>%#;[72
M0.XW%[0OO8[FQHKBLU]/C]7>&L)EM^`MK;3(\=4,64A+<V]K'B3D]3TAFP2B
M2P7Z7NU>P6J2O\LD5\FAFXS>6,')ZM\;1CVKO8\V\A<C*<(P]<'HTDI,-YQY
MQUB:Z1B*$R:\V9LI4NLMZBN)@7X-B;H'8DJI#C/.H4D(Q^H0N+-+M)`1/H54
M5.XO"Z_=M>-0K:C@`["CMNF2S'"C"3C\88[JC`<>[N]@`F>B\#B&J"+1]@HK
MR\!+1MMN]"W5QISWHMPLGK6@;R*M059[W506TLH3*KP$24Z)(X`(K<&21,GV
M-FPI?FX])$)$%'!15(.?)$G*HVO/SP0\+X3E//V\:BSQ3/[C#KL+NJFONO0I
M9.M,(0-K,@N"J/USCP`;)07U16S;<;)X6_X3)Q`,<_:+<*HS7'XE[7N$TKJH
MQ.C$1NG76(@VLB&ZJ-@1#W."L=U6P%]E$=!$X-!#R\CE*Z[VJ2*C2=GRBHBB
MG'':*IRBJOA?GN'E>$U;2>XO'SS_`!(JHBJGGE$_J2>4_IQRG/Q5EO)5QUPU
M%..>.47GDEY4D_54Y5%5?A.?'QJ@)[BJJ\)X4O/WX3CGE/*\K\KQQSY5/NN@
M\647`+SPOE27Q_=47X^W\OZIRFJ5E'QZBJB=RIQQRJ_U7E?*<?X(GC7OS7$%
M55%X[5\?=%\<\+SV\)\>."^>/E-4K*<1$523GM0G%^W@45?XO/RJ?'_*!;;(
MJ5<AR#'"CK)DO4$]R4U$;;1UE^;(9]!MEQE>Y7W.YQHP'M1>!+A%5577YE5D
MJ/->8GA*"P)YXI39QDC+&E$1<QS:%4-LFE\?0/:G"*7'GCHPKXZF1874F>Y7
M1H;Y33FBZH^S)DD+W1.(/(*T)*7>B_2'E..U52K\;SF/*@V]O06='DT3(([D
M2;?.BQ;O`#KH*^4:8;BI%L0+M[W.T#$30DY0TT%*&U-4_P!\^LCL/E%(B/E4
M'M5%-?*&B*H\<(B_TXUZ%9^60KBKDV\1R95QY@N2V&>0%QL5%7&?45$4.>_C
MO147ZE3GCXI?+GKE:ID<2F1PL&[:,[)23'%]'8`*230BH\H![UP/I8<\MH2_
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MU&PX%4Y%#Y!44D'A?`JI"B_;5C=Z]X\'VXH6:JYO(D:9?R4K4,$64W7@X*O.
MO3W&3,8C;PL"PRKXHBN&J@A<<:"Q.X46)%#(+V1(E6CU4Y+L);X/B^4YN/Y,
MQ<7PJ]H(3':G:@&B+Q\K<G8S,L'R[%J9S'%H:JP<E/S+"(VC;62*^;(C):E(
M2`\[$5M&G4,$(0=0D%/]9<?\LRF'E.`Y/"P&PK[*U>9"O&1*==88;"U0&S[>
M\$)YPF^6VF01>2-#7@17B_&PW3E(VZQ#%,VOI\)F^D.G&.IC26'ID`'V$+A\
M57US;-I4(G"!6^U41"[D5-!F;83,,/$X5?%JYX94U))Z==O3B**;!"H-LQH(
MJHL.=Q$KCW/<:=JJGA>:%L:<+/'[&NDK)!;`1BB_%+LE(AEY)HP'U0^53N;^
MKNX)!3^)?TQD>,R[JPH693I6U43;=A"]L^+C#9M(<9QQTFR:47P)2;("3NY1
M..>4U4]K%O!KX>15S;D*NA359CRXIL++":UVNLEZ9N=PFVJ(Y]32B:<+Y%%1
M`\G'R;.K8BLD:/5X,USJD2J^Y[-M(K;K@_09D8-"9<CSW$JGQRG'JV$^)C\1
MZTN94>NK(S9O39DMP66&@$%+EQPR%$,DY[6U557GA$_6@*VFIG;YE^_>N9#D
M,W;QE8;Q02FN2R-"17&C09BA+47'@=[0027QV\)JC\MP"IR*Z2[R5BYRN*L5
MZ(&&3+5X,<2:"$$2W?B-$HC)85>3;+U(KZCP0(BHN@O7B5@Y.:?MV9;=C[B<
MDR&`-^B$>O<1'(:H@>5$E0)'=RB'\DBHJIJYN69ID6<3(KM_(;?>KHD>`PX(
M"RC4*,VB-M((=J*H]J$I*BDJ_/Z)0F![<Y2.+VEQ1QP"IQBLB.6KA.-M,Q&D
M#]W$1LR0C(40@``4B413M3MX77EO9!91(4J4S`2SF1FB>:@@X,9R:2\(#2N.
M"J-M<*IFYX441>5\\:#T\BQMNSIJPID^*Y"=MG4.OC3E2;W1$%Q%FPT'O&$\
MI(0%PI..`J"O'Q,ST$9C7+@\W:]J[:M9&*LQ<@K&@!P%@5&0$X4FJ'U"+O&M
MLP)Q7!X%?S$$$!'CF#]_*8^.0:VWR&E_TJX8<>BE%L&I;*JV\K1PW5!/<,G'
M=11!Y13U!3D$4>"UE-T2;[45%U(X30+%LH4G/$L,3E^N3*PW$L8BRZM0$74-
MOBT@PVFU,2(E?-$55+R&PUIKA//VX\)_[O[:YT#3330----`TTUPJHBHGZ_\
M43_#_GSH.=-8^Y_U3[";:.''RG<G'V[`#-LJFH?/(K471;D&C3T*C"<Y%4SC
M.1Q<EJPR,GL9=<;,TUB1?_B?[91),AG&MO<YOV/:>I#FSG::@!Z8K1$L=^(]
M*FS&&&G>QMV2V#Y$"FXPRXH(!!)SIJ'Q?Q3;$0)P]D(@@`$X;A;C&#8@(J1&
M3A8B@B`HA*1DJ((HI%PB*NOM1_BKQ+!V'*E;.J]1R0)U;#'L^B7#KC2@XC+L
M%'J&#7R@<>$14UL&P])3-LS,1`@E]TU'KA?XDVQ&0*C.50LOP"03LI$=M:H;
MJM;889%QEQZ;C[DUX'ICGJ,,1@@ND+@@KK@`XA#F=A6Y^WNXT7WF"YCCN5,H
MWZS@4UK$F28[?<V!%)AMN>[C=CCH,N(^PWZ;R^B:HZA`@5YIHGG]/[+SIH&F
MFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@:
MB._%_P"DBBZB.G67GR4+USEFR$>VRMF+!24EC9X?[4W,F@QDAB;S\BM9:#((
M;/IN":P)3(CW2>4EQU\WFFGVG&7FP=9=`VW6G0%QMQLQ47&W&R11-LP50,"1
M1,5451454T'\VO9_<W$*AROHZ2B?E.%,`[!'&SB26&(S4GUIWKK(2--:D`;<
MDVA`W.\@%/2],QU?EVRPW*KBSN[>&V+81QB(V,MFNF`#,8P;EJ^T(L$_ZQ)R
MZ+9DK+(`J]Q*:WY_&(Z`<\Z4=[&-S=GL<%O8;/[6RMZFYQ]@8KFW-O/F@]8X
ME<1D[EE5S$N<Z]2R6>Y&Z(FHKS1)$>,8X,4LLE@N3H-CZMK9/1W9$=^Q8C0&
MQ61&-K\M>9*.@JW]!&$MMHQ4751"5Q!5`S(H9^V<FM@5=%.@Q["1+BO1Y+<]
MT9SCD9%-^++8>,63=?>!'%?>'O$Q!&T47%U6MEF$.GNX,;\Y-6VVHKS@BVK1
M,RI'+1C(=;5T.!<5'&OH;(V1]0Q1%1$Q0P?$J2)&8?M72>R5`]]%JPFQFDD$
MR@N`X@*G)QS-'&W#1`>:[6E)!3E"[M_DMP_N'68Z_4QJ=YJ'%D/A8''<67#+
MOD,20?B#Z3XB+;S`<*Z\3G`NB"(@H&<(),FVD$OVB.6](YE^R;:CMI"&O1M>
MZ"3'/<$ILD(@?[S5Q%7N415$OEC=V%&%J[9V#1HS/9BPYT*,[$]Y%DL]S`$V
MH^K[AMQ#]9'&Q9-$$U/A436&6)Y?`9M`K)C(NR8K<=J!(",KK3\>81NE"4HP
MM2&RBR9#AN./&2('D2]-.W7O7%S/QI^KK;2U6=`M/6*&3(*Y)!SWZ"W"ED`"
M^@`*AV.(ZYRRHERB+QH,O+#))3C5>Z4MQX7I$B,O83?N([;/8+4IUM!!6'?4
M3D.2)7&^"'M(>4]ROL5>;=FR5BM5@.--(V<QAMUU65%)'<+INR@!\W!,W"0D
M(S)6D+@A3&@K"W!DADO+9RI'NCA1&4-0B(R`(VP;CW9Z9*Z2JU(-35SE>Y54
M51?4QC);*"RU'R%"FV3:-QI;$:*RRZ9._P`8$8]RC(AD38B*"22`]5>1\:"]
M5S</6L['@HY[=9'J&I3TY8BHIS#!YL6P6.JB+K37<1..'PJM)V`U\*E45EU[
MZ5+-N:S)5EQ^)VM-L*ZVX3(B@.-&2\,%RX:/(A.JAH")WMKQ:^P[9SS=DT(R
M77!BMI7@K2%*CN`K$IQLQ0`!6&OXT+ZN1$DY,17580(;&/RV'XM0U&>>B-F$
MAI#5U]MPTD07.P^^.^I()`3G>"*@(+B*I&JA\K.LM:Z=^61PA/V$T&Y53(*0
MX[`A>ZD^BT(/O*#<>:B*K,F(XA`T"D@>F*JNJ'W!K;O''JQ^5*6WB3'#AV+4
M&'V+53HA(SW23:0F3@NN*HLN"ZHH:]J.&9@.OS59=*R3.KM^>Y-@1F1%I(KS
M0%%..LA675@&8I!-QMWU))-L$B=Q=A%Z?.KAY(==E=&M)'D>C"!SU_<LNJVE
MB$(N4@..0T4@"6\R!.MHX+8OM&*$"$2J'G;<7\IMF=*GV\IV/']PPM:KK1,1
MF6XQ/-&KKH+PVKJ<N$R?<#0J0B2HB+Y;6ZL:QLK>S;DH^Y`8=*1#C.$Z2CQQ
M&<-QL'6W5+L05$C150T56P^U$M9JC--+BTU&ZQ735.`,DDELQ9)$X(6#9$\T
M+R.*ZR]*CF1`!?4#1*R@)JG,JS.EQ"!78_CT2LI+R4R-H*M>W)3J9+8M*<F2
MP[[>2J.\<L.\/,J1C,\$F@RRHLHBW\9L),"TJ&I45J0]'G-MQG5]1?3FMM20
M<<`I49.(_JHHBVI"B@2<HGOMWU%,,!KFV9#=+(?CK+=-9,IGVHLN,QG9,8C%
MUTFE`7'B[6DD*Z2+QW"F*>1;NKMQATC,+V!97`0O:(_58I7NV=F_*<)I`D1*
MZ02B[%*08$;8_4"(3SH>W;5=>1<YL=73#9Q(C,&1+LH4Y8B/"#K4A120L>7Z
M!`,EDT<(9#0(J/NB?IKPVBZ#+&^S^!6U$QR6@SXUJ"0QCDTP\X,97FY021-Y
M''F'&'&TY5M&G$9$40Q1XAU;:'>4#K[:UTT_160Y*FHT?8:F\^KSC\?WB^DC
M[1D*.AZBM1O!/=@^-6)JMR*S*)3%'(5UBYN@EH^<865&.4-LW4)IYUQ$9]\A
M>C'CJ*F9"8&JJ*"O92_BX#D,BJ9];**Z3&J7VYR0F$F5A25*+/2TAF#J>T5Q
M5>1]KL7T`-PXZ(B*(9%TN0,.5W<W9#8M$^\TRY#1M/J;?,`%\$,C&0VA(H^%
M`E4G%^E459,^B/8>]W$QG/\`*I5G+JZ86&:/&>UHPB7.1QC67)D3E<]7W5?"
M9)N%(5E07W4\GF#$H:LN1?=.>*2MW]TL9V-P4$.TNFIME=6T1IN17XY2-3FW
M+>QL284Q9;CQ7^Z&KI-.R'FVXK?[PVD+;`V\P7']L\*QS!<7BK%I,:K&*Z&!
M^7GE;12D391\)ZDR=)-V9+<X3O?>-41![10(@<H@6-%:SZ6XC.0;2O?<C3(C
MPEZC3H+W<\D@]S9@HFR\/+;S2MNM*H$BZMY*/DU^W8BKROGCA.$14X\JG/"^
M?Y_RU*SU$[(IN+4_M%C;+3.:4T8^P$'L3(*]D2/\K?,4Y28TBF56^0D@N&49
MS]TZ!-1-3!>:5YF0V\T\V^\TZS(:)EY@VS4'&WFCX=:<;(2$P-.\?`N(AHJ:
M#PIKG<B\_P"LJ<>5^R\_?S]_//\`?SJB[Z24>NGR&T13%CL!%7M3O)4!$4E1
M4'E3\?S3X_6J9A^2'RO:G'W\JJ>..55?*>?UXXY^-6_R[U/R*5V$O*R(0JB)
MSR"R07CQ\=R<I^JI^J?`6I=LJ^X?>Q^ZQ^R=QJ;!63;3HJLO!*$Y:,/U$<"4
M5220<O.$_P#NW&%5M./.OMB.+XM02;3]EZIJJJ)4A39KR58PN,1S1(KLB)'<
M6)[GL$0<=0$<X`4Y[13BW>?3+BOJX3..W)4E^=@C\9PHC4YEYIEI[MCS8KJ\
M.P93B"S(X[76^X5;54052X%/=26L>J_=QEDY(ZRR=M+A"`TQ]S2*ZS`C&VK_
M`-+Q=Y*X:%Z:DA`B)Y"ZV39%+RZ4S(6GJ*MN-$BP49J8ZQ6A&(@BVZ7*DIO.
M<=SCA$O>J^5^VJ%CU&/N9DQ+D18%A=5T"-8C"D,BZ_&0I!L_F#+BH:QG)#8^
MA[ALD?/M7CCPNO>OL?S_`!:IILAMFX,:'D$4)M6TT<>0CT;CP),LFJLJ0^"]
M447GM\>$UY\&]:MFX'H5X1;MAR0%A:`Z[ZD]A#$H[",.?N8S<?ZA``Y0_P"(
MD1>-![^1S&9CTY\8\;'(,QLV@9KC07&%-AQ"<8]07"!T.4-OGZO6%.TE[B1<
M.YL+/BQ^/795=S;PJ_W"R;+N90);;3[AL/SH\8`;1P(GI(\B-IQZ:HBJ:DJY
M=T>0U-'D!W>1T,+*66&WFQK)AF,=LC0D:5P&5[7^TU%S@47DNXB^/%!3W6;&
MQER$B,MQI9N*Y$9%$9!MPC]000>/I0"[$15\"B\Z"-Z3MINGO3NW%LMI;(:O
M%,<KPJ<@M795R$.VG1S<DR(T2J@-@]8.+'YX],.P%!#(D1%U[6X_3_&JZ9J;
M;D&1PV[F$_82#;DHL>6T3RQ93ZONF2ML2..?70@143N%4547/7!YI86EB&&S
MG*JPJK*QC$[">%J5%2>1"J\"BJVKD=TV4>4!5`50$_/&NM<!4UU+,?R4!<K7
MT;CR&^4=%YR6XC<="%%X5SU$0D,T44(%)>=!'97[*;K2XM7+Q,H306UTRHG<
MH2G'KQ+E92-H(@#;2*GI/$*B0BJ!QSJ3P<6LL<K\;6Z>KK9^?3QW?=P)+!N.
MJRV,=YQ^,B&["(B;4FV'E0R;43[4$D37VD31FU5-0QJFMC1:]UR0U-CL]EE*
M%YL&VFI4@5)IUAH0%8[(=HMCY157E-?.5+BP7%E/))=""VD9]^.T9--.D/\`
M`Z\J$R#Y#\(9(1`JHB<>-!56&-;>Q$R23EU9,D2ID!PJL:YQN$A6G"MLOS#%
M%]1&A%%4>/@43Y5>:''L<EN-`I$PZX0B(JBBX`^0,Q150N4X13X0E5%^W*:Z
MS=FQ9"OIU\XT0R]-D&B-T6U+E#+TT42[N$X[4X3ROA-=.PR*LIJR=8^TDN/P
MF546$`U5'!4D$33ZB0$+A735$0`14Y\KH%'?8K/R&=&AMM6DW$I(0K>.:.BV
MJ2E;DN0S-$$4\-J)$VA)RBB!(2*B5I9VU9=WCTR%1PZ&-(;])FL@JXY'CD"\
M=RNN_OG%=X4U0R4D)5051-8PXI0[H-2I-S7UN-04OY;<J'69EEU%B#^11Y<E
M"!^"W;S6;+V@(\:MV*0O0=3]V#I=P\W=S6TS;;ZYJJFUP1^(EBCWNKAFW@3:
MZ&T$5"1Z!*@E(C7`]Y*)K&D(3)J)/`((2Z"NGK6VCLOP8<Y\*V>(#(89?5([
MACSVJ^"$2>%\(9?PHBH/'W\.6^U75\NSLD!8T6-)D/$1\E[=IIPWNQ57ZD,>
M!$17E%5.5^$2SD[.7Z)NP;PB+.=KHU>]-:A9`@/N':JR;\L!=BJ1K$=E(H,(
M)>H(*GT\IK%K*=X=PL[J8M=D,/\`)QMX91W:R!$D0D!9@FPK8.R!1XW6D5$Y
M001345[>?JT%V96[&!/PF+:WR6%5L$YZ3;-LXD,VO47N;BLDXO:XX2JB"/T@
MYVEPJ>5UE-TXY'A$'*,,SB9665C.6]HW<9GUTN,RL.:W>04:F2R=%W_1F`[G
M39:+O<%1#E$523&+;;HYC9KC5Q^;0!R5*BA638U4J8D6MB5$<!1QDE5X7ITU
M&^TWB`^[RJL(IHJ+=';+&8>'VM!3XTTXW51L@J1:KYK[LEF&R,J*AA7OO+ZZ
M`GICRCBDI(**1)PN@W#A\HJ\\^5_PYY3_8J>4^W'SQSK]:IR7DE#15[,N\N:
MRI:2*P\Z]8SXT,$0F@3O7UW07A2\=PCQRG"^4U9G)^J3:''$,&;N5D4D4<1&
M<?@2)C2N`GT"LUX8T+L<7P#[3SS7"*2KPH\AD3IJ/'*.N*4`DUB6"-MEY5)>
M1V??])`J?5!JP1!<$OJ3F6Z"BG!"*ZQDROJLWPR!#;',%H(JDB^AC4")6*B#
MW)VI.[7K#N)2Y7B4`'P*]G"<($R]C<5-.R4BVM*^KC@*F;]C-C0F1!%1%(G)
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M+Z!%:3TD:Q\N*F\GTMTSCMC&J\EEP)K=3<3X:6K$&VD,N#$L)<(G`68U'DF+
MSS"F).")(JISRE14M%;K00J^YL/<W94C<.UN:Z.,%'[8H2,2K2OB&KH0%<EJ
M<V'&57$C$K;1>`'0="LI/:QH\<W7)3K,=IHY<A1]S+<;:;!R9(](!!V1,(2>
M?(0["?<)4%/''E9!C^6RK+$7<:NJ>IK(=X4G,X=E5.6$J\Q](;K8552^+C25
M,\;!6G_>NMNMJ`*TB(0J!UK@V'2L5QNFH)60W66R:B*,1R_R62$^]M70=(RD
M6TE@6VS=7O[.&Q%Q0%$,E+D5[F`X,[AM(]43\JR7-)#US=6HVN8RV)ULPS:3
MBFMU#3S+30)5U7J)'KFT%5981!,_4X%`\QZB9G1I$28PW)B3(KT24PXB.,OQ
MI#1LR6'4_P!=LVS-MQ/E4)4^WFWUG!J-GL/QNJQ/!+FRHH5IC^)56-877A+>
MI:^TFI$_,W6I3[:C3U'J+*LGO5<>;:52$"4EXR22#P*_0/"K\+RJ+RO]/NOP
MG'*^5^VOF=:*\(30DHJJIPG':7'"HGQVJB+Y\\JGS\^`M>=8JJ2B`GVD8=PK
MQW(!*/<!(GU`?"J!*B$HJG(HOC5'U%KN+CNY#S]##7&J"#CC$RMSJER>7692
MN1ORCBRZ3V$!(\N/`"L-7TGI+1MTW'&4$E-4U?-ZN#X1.Q4151$X3PJ^.%14
M^Z<?/V7G[ZMRL?-$S6;"?HJ9O;T,:8DP<@&V<+(7LJ6P(9-:]3*RC#56W7=L
MAF?ZQ/')Y:4>U>P`SZV/_$-W(PJ;`I=X&SW`Q+N]!Z]C1HL;-:QM&^UMU#`H
M5;?MMNH/JLS4B6!@\XX%@\K;;&IAMM-U<#W>QN+E.`Y%!O*Q\&R?;:-&K*L=
M<)T$AW54ZHV%/-4F'2&+8,,.FV*/-(XR0N%JX97*@8Y27-]:&3%;25<VUL'6
M8[\MX(-;&>E22;B1A<?D.(VT:MLQVC>=<%&T[2(=>;M[U'YQLU8[>;H[,M91
M:,9O9X[#EA40E:K5Q:S;?GI99[33SB.R<<8](6Y(*U^95[\L'H;T>0#9F&W+
MIK'OITZB</ZAL+#(*,@K<BKO3BY=B3\@'K''[`N]`)>!`Y=3/0"?J;,&T;DL
MJK+J,S8\J.UD)H&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF
M@::::!IIIH&B^?\`9_L7G3306=WXV2PGJ%VORC:O/82R*3(X1MM36!#\QH[5
MH2*LOJEPT7TK&LDJ+[*\HV\".19"''?=!='KJZZ?-PNE[>"]V9S&G*SMUCMO
MX9F+E5.&CO<?FR#"KR.CF\$T8@311[&M"0<BID(_%F--\LNN;\^L;.I_I=VW
MZJ=O'\(SR%Z,Z&LF;B&5PP'\YQ*\<8)INPA%R/N8;RHVW:U+QI&LXPH#GIOM
ML2&0T6,OL)\6MQ-J)0/UUBEJXU'G%4PWG84@JMPWZTR$D?<B6C+1.1A>5&&V
MP%_O200">-UUN!`H-U:QW+#>LH3*M/.RPAA#8K!4"1(3]>+Q2VSKY"B^<D15
M)K2*\(HJD.I0NJ39[+>D7<F3@^]Z18J2VGSP_*Y926,:SBDCBC,:SQ^T=)6W
M),`40IU*Y)"QJ.QEN9&&*0O.1WXWBE3E(YUO",^+;VN9OE+IZ\8T"RK@@XS&
M=QZKHSDHZY%<D3_;R9LV4ZZ(A*DM1SY;9[D"NJK?W"[B\JK;'#K[NAB19]3.
MN*<@)R1,]8>YLE56$1V`7>U(5T0=5IS@37LY*]6Z58Y<5;.3Q9+1/10:"9WO
MNC(?C.-M+&6&R#?M@&,2HCCB*!&V2%P;BKQA-M]L)1_L^[53<6/!2EV;=O95
M;\R0$PYCR.RW&)LJLE$Q-@R%?;:'T77&'8PHP(HT/"9`XU:'F%1VQ\J=@T,9
MN951*A66Y,+W>-O.U[S2NLD[,($<B$L4'#<1D4%7&Q$A00R'Q?*)LS'H]O'A
MM-QFS81YRQ]-UXF(9#%=D1WC>1YZ(ZYZOJ-$0D9(KACP*%JWM5F,\,[N`E2)
M;L:UENBV^$1R-VK$$?:26!8(U8;$/]&<>:(U0N5Y(D37G)17;V/K'K\O<6M>
M6)/CP?RQGT7&EDB](C-RF51UME\D[ECN$+;BKV+VB2Z\9:R[3.VHL2ZJY=1!
MJ83T<8#4V1-]6X;>=F1K2O=!IV*,*=&!N(Y!<="7RZ^!(#9BH9)UV=R8D22Q
M#%BJEM28X,E:')=0HYSD=>!UDFT=,V#5PU0WV/H5M5(D0QU4U]E]I#E19@7R
M1HDEF1'<JH[,=Z`H=@%%F)(X<D,*CKCJ.*9"!>JP'\/A(_JS)L^<=N,_G-$.
M+5I7#-@$PGH3(1ZR2<3\T;BO<R6FF94/M9L%;('F"-[M])2>3U-IMX85Y,MK
M*N5JTB6YMVT6Q@RF9$1ETA)@FT=<[T%MXNSN46D/U#-PVTX)-!(;-J*G,L;L
M:R^EV5>S(;5MHJ>6VS+8M#;:-MUDE'UD0E`$7CM%.50"Y5-4]@EA3XY)/$\?
M*<ZW2JXEBU(L)$HH$YLF)(,OL3B</W$X9`/R0;)QDN4?<;03X6P.([@Y5&F#
M*R-ZG@52$^PY%<?"8,9A7S!B4%C%$6WT!0$NY4'M`NUY!\*E[(EK7D$B?!*(
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M'49)52B,AW;P4<JP_&8=A,O+&T8?&$S`8D6]1"=8#U%6?+B^X@Q_I9-J&^^^
MCPMBZT^(EQS;;+QER9<C,L$S*^N6\@A2%R&GK[J%)QI6X%:C4"97,HT<B`[[
M/N&='1Y'9#W"F"=I:PQO))VLFBMJW)+3"YN/G(ETT2CD%65JRPCDC+MI7O0B
M&U8>D(2/,BTJBRX8B/:7=H)*H51C.03LCA7>.O5C$HH\EEZOF.Q&I$"Q1'W7
MZF?6R`.K>1T7VI,-7&7X;BJ;O8+C1+=3;P+3(<_CX)@\2=D<S*[:+1XY7Q&S
ML[Z7-<:.#"8:-A320D81*/.D/&349M')+A`TVXZ.`/0_N3NEU`9[;;!=K>9;
MPE;DUCE/B\`V9U_42FB2P=C@3+4*-`J'!!R5+E(TU&@.>O-=5L.]-T7\,+\,
M3$>A?`F[O++`L]WXR9ZUMLBRFP=29%Q`<@D'*E8KB/=W-,-1VG!B6MQ&%DK5
MQMP6`9A%VNADAT5](V.]+^"/NR(%<[NEF[4&QW"NX8BX(R6VA)C'JV6H"X=7
M5FI>HZBI^83_`%99?NABMLYK(B)SQ]UY_OIIH."5$157X^/\5X_[]8#]6.PA
MV$:;NCAE>3EDPAOYA4Q1)2L(P-HBW\1A.?\`3H@!Q8MCPLJ,GN.TGFW/4SYU
M^2%"3M5$45Y0D7A45%3A45%145%3PJ*BHJ+PJ<+X#7,E.HO*\JG<7CRG_P"R
M/WX^E"7RJ(B(B<\KYHK+QEECEF4%MAR4TTW(9"2AJT3C3P$G>@?62(B\HJ*O
M*_/"<IJ0/JSZ>%P6Q>W"P^&O[&6TKNN:Z,*J.,6LDB57`;'GTJ.Q<55:[?H@
M3"*.O8P\QK!:PC)*A28I]R(_&=97CP2(8$G=PO*\@7:2*B+S\(GGG08%RLAL
M9=C:/7-#:G;4:E'?0?3]@U&<0?;S6G`(U;B&3B"RZZ@$3@$'"$*JGJ[7W0@D
MZHL+-/>3II2H3,FQ<><D`HJK\:"P?/$AKA'3;#_Z,5_B3QJT]]N)C^6YS94-
M#:@U+6:U4?EDA\8$^P2,;XC*"`3PN28CY"]Z2J)H)-O."(EY7*S%]AL7CXJY
MN-96>/OV.-R!2MB3GC3(`L9`,M>K51$3TCCBKQB^[W^H@`O=PG"Z#UYDVUFM
MHS+G/R&V`#TFS<50:]-?I;;'GM$>U!%1%!Y54\:IO)YA5M%,,'#%V<*Q`%IT
MV9)(\0BZTTZV0N`2MJ2J2%RB)POA?/BY5DMU45SLBJB0I\AEUKW(/"\+C;3K
MBMI(;1E24^%X4FE7PG:7*#SJU\[(,PMG&;"?12944!5UMMEAN/W*TG*"VA&7
M[TD\*7'*HGGE=!<*LW(QVA"GQR_=.M]2(H5DE]7I+,EH7U9;8>=%3>69W+_]
M(BJX**0DJH2I5][E4*FK795<Q(LI8=KD6+!!'3?_`-8"57%:461(44U[54@[
MD%.=8QX"Z>;Y3-R6^JQ@E0JE7C=9(Y,ZQUYLW)5JX+B(,B;P:BTJ(OI*J*UY
M7C65&XL[;F5%QN-A=?;19<.@BPKAVQD-/(_;"9$[(C*'UBR:.)V`^BEW<HJ^
M$X#$[;R[O)>Y;QOR)$"?:RU<L'!(VGI0@XKJPB1SD2;)$4`$QX$$Y!5/CC->
M[.EGU]7"A4C[%E%!\;J?.D%*:MGWS(XYMQ3!68[<<21M01$!4_>&:+JUT7:Z
M@M:UW*+BX;J;FJ**Y!:B..1K.R)U[TVQ;[&'6C6,**\_ZY`2HHHWRG*:]^XR
M.[IX`K`KH4V?):=9AR)PR>T3[%`"D`RT/+BD@D2B"-JJDBJB>-!X[N*9]D>0
M_P";_;C)[2JER68[TTTJX!)3.S$5V)64TI\G5>"4RVZ;G<+2LBO'>(JJZJ>4
MYDU-2/8DY;R4@1)G9>UI&!%86L-&FBF.*`FCCB&WZO`NJTRO=V<(O&K<;6.Y
MOZUZ[F*K"MK&P"T;FMR@C(^T\BL@,463%P1C`/:V*H/:*K]*=RIKWLQGX\]%
MN<!8R=B/EM_73([81G5=G5U?,)IN3;%Z1$<3TT3O!]Q45S^%L5)2307=PW,;
MK;R4[8T"M-R9,)^+ZC\6/+`HTIDFWFV@DMEQ]!JHF@B8&7A?":_.$LMS++(\
MBD0F):X[1R+=(DD/4CR)LJP@U-7ZT<T5E^/%L+)JP=CF/8^L00+O;,VRM0Q"
MF;94#5`2V.<U^,58-E=U[R6EI8BR'K+V"9-NRI)-D2?NQ(D,/2)%3A==+#]W
MH.0M6,"B@7T*JRJLL,9M[>37=\^H!TVWHMG!JVG''9DRDN(<67)BEV";+,AE
MGU)#@((6,QC`<NL\USO<RUW`2;34TFS5C';)]E'IYOSG8WOFI1AZ\Z2KI"C,
M5M>8XBJCPV/`Y!;9-,93<K@=A^>E7YTC\"1,9='LKK@FB2AMX;CQD;-O#FHP
M"O>DJ2*YR9#E^K'=1-6S+`<SQ=`A6%#=VL11=?AWE)52;&GN6.]7/<P9-:Q)
M8,GS[G29>-J4RZI,2H[+S;@#DCMA+/:R;1;D9!3N19M>V=IBU#>0/:VL^U02
M:B2IM3)%9$*DKR7W4M^6TR4YUEJ#$$S=<-H*3VZQ#(G<H:2)A-OF333D=4IZ
MNKL)BNCW$1LOR8[#H--/*'/K/N-"G=RICPNKS-]%V[N=3G;*^Q*#@]9'L&[&
MK+);.*W)K39?]9B,$5CWMB0H!*"@Z':7A.4)$34FO3-U2XYO'2.8U*AUF*YY
M41WG7*6M99K:J]KA<4QM:-EE``7T'C\VK$[WF'1*4RAQ'.YB\>0B,I3CN/H$
M=&C=X$O3]0N27M(T12XY1>WRGGPB_9`C;H^C]:490Y#N%.5J4`)*@8S%6.P2
M_P`1@DVQ<=-1[O"BL-10$5.$5$U6-?L9M?B3:2X6/E.G1NUX)MM.DSGE>`D7
MUA!3:CM.=W!CZ;2=I]I`B<:O_D$XZ]E7`3UVA\$V1*A@'GA1<5>3`?")RG(K
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MTX%H`\CR;CI`VG/Z\HJ)H+:9]G]=1RJK%6K:%"R3)6ICE=$?E1F9TB)`;4YZ
MU\8W$DRI#+?#KPQFG#AL&+SJ!ZC2ZM+:3'Z+'[J]8J+/(GZBMDV+5+1B$BWN
MCCL'("#7`\;33\Z1V>FRA.B*J2*1%RB%T<FAU,R2[N'<8T-_D&,Q+RTIW(56
MW89#'*1#4IU?CR&0NMR[)B,U";8;=;5_M:94T5>5N#A$H<IQVAO0I[FD6\KX
MEFE/>Q/87U?[IM'!@V<(3-69\5%1'F14E$_(KR2)H/OB[KEK45%JY665,_95
ML*>_36@MA:5;LUAMXZZP!E7HX3(A.*S(])UQL70-$+CXN-!B)PV3:*BHJ*B*
MB=R?!)RB<I_-1^$^%^%37AWF.)<X[=TOYI:4"6M7.K3NZ20D2YJ/=17HY6%;
M((#&-8PT)7H[I-DK;@(J@2HB:^VS%]BF:[>XS>83DLK,\:]F=)#R>P20MA;O
MX\XM/82[(I46&^Y8+,AO^\>..TC\A3D-"K3@KH.<%VMQS`8=M`QB)-BP[S([
MG*K$)UM9V[KUS>O)(L7VW[*1(<B1C?`28KHQ##C"I"T`<IKTWMI,8FY[3[F2
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M[:HL(=G73F4E0+&LF,RX,QA55!D193#A,R&54.U3`U'Z%#E.U>*+RC&]PI^4
MX-98QF%=0XI4V%BYG>/3,9:MY>7UTB`;57!K+AQ]IVC<@SR]TZ^TV^+S+9-J
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M*,+4?3<BRYP55BV,NO!Z;'DK[1]ON;$VP$U4`)?#S*8[C.-W=]'H;?(G:6LD
MS6\>H@"1<VKD9"1*^M9>=9:>G.B*(V!O<*`HB`B@`+>++,>2YI[:C]]84HVM
M5.K&;*F?"%:5?OHSS`3*IXFR;C38Q.(]#<4'!:D"!*VO'"VTLHR[:;>'*?;S
M#.G,+QH%5(S?YYFN2I4QD1.UL/;?F-Y-5L'BY1D'7.`544$0P\/#NH.RZ?\`
M)=N=QZRTM,+O\FLZBAJZJ;629YSYE\R,UW#\FAP!D10B2&6#CSW)3K<6));:
MD1I+4MMEUO:.V9W=QG>_;^EW`Q/W#,*S61&GU<Y&4LZ&WA.DQ8T]DVPZZVDF
M*^B$TXV9,RX;L:<PI1Y+9:U@T?:G4D.\EQ9%6U)K8]I(CW33<:56`Y"28ZS9
MLD9!!EP`)WWO>XJLN@\!*(@J:S,Z!M_V=M=RZ_&95G"D;=;MOP8:SV'`D0HF
M1&RK&,W422U(2/[6R(VZ>=(Y?$F'8+J(`1G#$-@;31/.F@::::!IIIH&FFF@
M::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::"RF_W3OL[U/[;W
M>T^^&#4V>85>-$+U=:LHLB!*[%!FTIK!M$F5-I&YY9F0W6S(%./(%^*Z]'<U
M1>IK\%K+NDO-LGW1V)I[K.]CY==&;:Q_'I4L9N%<(\Y:V-]AS'?$=-WTXH%D
M='&.*C+1G*@5SKY*YN2ZX(4)%0D0D5%147X5%3A47^2IX5/NGA=!_/#K,IKI
M%;*BA+@VDYYR5538<:3#<>8`'G(5DQ)17#?CRJY4;`U$67FD3ALVB4%U0%;5
MXW@$S\CV\QF%3@XDQVX>@2W6&(]F;;8Q7S9-QSW,^<V:!+<;-&E:[9,TWW#)
M%W$>KO\`!KZ2NJ;)G=TZ>LM]@-].UU7-TMF_R^D_:(W6D:-O/,+?BNXGF#3P
M"`R)DFOAWYH`]MR/:G.LGO?^#1^)KTLY/EF08M"Q_JSVXN+5JS#*L(=M%S>B
M@-JZV3$K;)YYFT-QJ*C9&WCCUO&5U.0]1.YL0Q?S+<&!LYMW*S2_:>FQZ>=#
M0H$2>YWK+LW_`&9,QU]083K(^LXTVBHO+H"\TV(\&E;PL[KLHQV)D^&28-I(
MMJR`_62O4[62B]HO$%FY&'W#2U[3KI''%1=9('$3O(UU@EN->6E9<7N+9A1Y
M,P^_,5R9C>X`3X+<6;'-!?@P<;M8<1^L")RV;S!Q25HB4`>5Y2XH':S*\RV]
M9M::1ED2?C#YS)<*L*@8:M*LWT/B'6/,S6V(C"`J*GJL2%!0%P`%1X4)%POJ
MNMBP,.W&O:G))F;N7=9!J;"L2"U=QY;#[CM(,:,:C+"+",T8<-Y''F`;1TC?
M$^^V5!LIMWMA,@.;<8C["S593<UZ'<V#/NJ^Q:5R2$YBP?.+8OPWF65A,=C+
MT<D%6'T%.US$MK"6=Q@QV*L&YAMTKDFPK;N?=7<6QB^HX'J.Q;)7R><]>7V$
MVBJ0MMB3C:LL(/%VL"P#<W#\DN;QW<"TNJ9USMG8[<V"78VL2M:4O4H[*23S
MK,@$<)&`[VBE&",F1IZ>@RQS"I++FH>44UW80;.(-4R_CD'THF&6E>3*1)4J
M?';8<?8N&"$'63C/*P_,!P93:$:*E5,6<?%L4DROS&0!4HMVL]JME\A-F14%
MU8I-FR]Z\:Q1&XKD=E`,C,.Q>\51<--TMXLDB8\M-AK4G&[.RJ7/8S[JLF5T
MMN44IL6%BQSY3UW&R=-9)M.H9\(#2*V9E0629WG6?8E4XK-NZW%LIB3*N:]=
M8FY,LBESX)-M,^[CR8K;,0)CZ-.S(P&:&8J*$(*H:#.#.(DO*[S`\AJ<PE87
M<4ZV3QQXM="?._H9T9D9],\U,1`>:B3/2<<=)IY(KP<L"VZ2$EG,JSG<S;'/
M;47KN%N!A=Q"@V5=(M69%/:8W*428=AM!6QU@N1G>"$`4F79*(KB$KG.NAA%
MIN*S;SYNY>0XR_6]M?7XR-1$2#8.2R=[Y[DMHS<XL9CB-`U%AHK#QHJM(JH@
MKE_L?^'U^(/U>X_EN/4>PDC;?&KUVWK*/>7<F46)X>_12I:I67<:CLA'*K>7
M'B$CPG3U\EAQ]`=:<115M0P:VPPS=^JMLDM9.9-M89D\\[)JNE4,-Z15RI+9
MFW'KUCNLE6-!'<4W!]!XG`;0S%'T(URPZ2OPW>J'K5S657X;BT:EVOJ[>17W
M^]N8C-9Q6#Z"HKBTJJ#,S*[A4,C_`"BB:>9:?-MNSL(+*..CLM]&GX'VT^RV
M-8M*ZF\N7J4W!I&8)OLE6/8KMHW-KT#VCKF.L2W;/)W(OIM]SN03TKYSB*](
MHT(NT)PZBFJ:"NAT]'65]-4U[(1H%950HU=7PHX(B`Q$A1&F8T9D43Z6V6P!
M/TT&$/1%^'ET_=#&)OUVV=)^=Y]>18C&:[L9)%@OYIDJQF@$H#$EIE!Q_&6W
MQ<>AXY6FD=LC1V?(L9@>[7.]$X3A/A/C_A_;7.F@::::!IIIH.C9UE?<5\RK
MM8;$^NL(ST2="E-H['E1GP5MYEYLD5#`P545%\HO!"J$(JD*?49L-,V9RCU8
M`296#7CCCF.V3Y>J]#=+AQ^BGO(G'N8B*BQGG.WW<1>]%]1IX1FZU2F;X7C^
MX.,VF)Y/""=4VK"MN"J"CT9\>2CSH;JH2QYL1WM>C/"BJ)CP2$V1@0:IUQTV
M8K0Q+/<]B)B:/!DDABM2<Q$D94S*?5)8G7&:)(BPP"3V*;?';VDJFJN+W>2W
M8+-;]D\1$XTJ\&!=OU<H78*$OI_5XY)41$3^)43A=92=6&R>4;4W[E79H;[4
M15<KK0!)N'>44E\AB6+(_4`2&71]I9L=Q.1Y'8*_N28)8_=ULR@[?;:97DLJ
M4U'DQ:Q^/5@1=K\J\L&TBU34`.%<<D#,<0Q0$^E`5P_H%=!>9]MI![4(",0`
MG`015P4,N!(Q1>X@0E4$5/!<+V<BFJLS>5MR5/C4;#X-BW;M0&QR&992&7B?
MM%55,HGI@'I,-JI(`&G/9V"7)"JZB=Z/=S+][,\KQW+;*ZR!S)8C5HW;SWIE
MFY"GU:H+S<B5RJ16'@<)IH0%J*)>1$S3E9&EB-.J+B*G9QW$J&BJH(B\(J^$
MY3E.%0>4^5YY\A3-VZS6P6K8F>TPDQ6ILH`$G%!\Q9!Y_L0>&VR7EYTOX!3N
M4E3A$]*H@2;\#=KV'9K+;1/([$;)]I6`-0-Q#;1>`3A34B011%1>?NEJ=V\W
MJ*RMB8O[EI9LR>U(F^@ZKBQXC#BD++RIP@K(4>SL15)$Y+XU?W!\TL\;H33%
MWVXD2]J684E(OIB+L%QKM=:4R%PA0C[A[Q5%-/T70=EJYA0(_%C$GO#"[E=6
M&T)&,5%1$=<!UX$5ILD3N=%2).?`HFO3@YE56<JJES<<C2*>MF"Z;;C[C4VP
MB(HF<9Z0+YJVT;8EV`VWW)RJH2H.J+;$GB>D2.4;`5(_4+PGT&"HJKQWM@*\
M$A<"BJBJ*ZQ<Q3<ZIVX69C]XU*C80U8^VJKJ2C\LVIDV:\X\LN0:NG[%Z0X3
M<9XU`(J"VB&+(F"AF)E=W4WV3S;*@HEHJU736%6LO.24ALEX%D7W51U[L5$7
MU%7DE\J@JFNO46N+TASZ>6L&%=V<Z-<&Z=<W+E2UD`C;<%VQ(3<9BL>GZWH&
M0M][BDH$J(NK9.[H89%B>\C6;,IUTA%@&&GD(E+SW..F`MHV!(@D0JHFJHK9
M$B*J5MMC@2[F9''G6=M5U4NZ;<.-.MY01JF'%8$E!'%-1$G25$%L35%553N+
MGQH+VR95I=,4U>ZU!:A58/C&.'#89D*V^ZKZOS)+*"Y+)"'E'77.&6D[4415
M>;!4V;3-O<UFY)A0U+<F#93VX9.UT6?7=W!,RG2@2/4C/J9FX:*8%VFOJ`)&
MJ*GOY+$G5TNQQ=F^DE$;=>K''ZR2X".MMFHN/,F!<=A<?0@J@."2)\*J+B%B
M.+Y;@V7W%3=9.[9U.196\YCU99L*Y(AP'0)]U\9_J**"A=PK$44).1(5+NXT
M%\BR?*G[&?8P[VVK7+&4]-D,TMA-JF7WGW"=<7VT%]B.A*XJJ'`=R`J-HB(F
MJ!KM\L3D9A:85;W:?G<:>S`8D3I+\EZ=-5L7I3$F:X;YD^"F/_C"\<(J*2=O
M;KX;TR+6@Q*R?P^<L47[&/C\:^>B<3(\FP951G08+A"KCK)*K7!<]B$CW8BH
MG&"72LN6,;X6N.58I;9<ZQ;Q4O'FXLSVDAHU<ESY/Y@#K*B\#CC3[R#RRZ0-
M]R*(]H2=3=[<)VJLJNT_;:#3Y/#G,2JABMLFY-XMDR?=#6+$@FY)0W21$4B`
M6":4A=[@<(=2B]*_6]CW4957%%D;<6BW1HU,K&BCMN-Q[NF9<[(]]3"Z?;WH
MTC*758TI.U\I%=:$XKH>G#EA6-XWCE]:75OAU-D^2#5O5;=C.`5<<B/D:@[$
MDLBC@-Q9A]Q*TC1G):4#<5E5%?;H\"K+3<'",JGY#:8E,PRV8R:3^R\DJZYF
M)&+TZN5+]H;4EV!"FB;DADFR8GB7L92FRZ8$&PI(F1)HH]R1QE[N544121/I
M140Q\BGZ^$7GE.?G5MK5Y%/Z4%$#O[>T41.%10!>!1$_AY[OLG*?.J&VKWLQ
M[<B!8PF'$8OZHI"O0_;>S2TA-N"(V\&.9FC(N]_,J$)N%">(1559<`TJ6R?5
M2=<^$[E[4\<=J)VHJ)\^5^?/E>?LN@IF<[Y(EY5$Y3Y3[)X3A%5?NOE47RO'
M*>=4M(-4!53PJDO/*IY[57QS\)X1%\\\K\<?;VIKB\&B\*2K\)Q]UX7A41"X
M5?/S_;XU3<P_XN/'"\<JJ_""GV5?G[JOQY7Q\Z#Q)3B]Y??CDO[_`#X^WCRG
ME/']=8O[^95D=)406,5Q21FEH5G5O2**':1ZIPH,FP"%(G/29W$=6:N,<FP5
M@E0GE8!&_`+SDI)/P2I\KQVI^O'"?*\<KSPG/*>53X36(6Y^2Y!!E6UQC.'S
ML\L6[FJJVZ*NLX=6Z-<<MJNGVK<NW,(J#6Q_5GR(J+ZC@@81A(E$E#Z9-E=9
M@&-S\JM8&06M?6NP6'(&,4LB^NG2GS8T-HHU7"09$CT79('*<4N&8S9N+X#M
M*YMQBD+,<8NL9GO6,2NR>FEU$R54SI-3<,Q;&.XP^Y"L&.V573@`^6GP3O;<
MX[T)![-=>I90R014^$[4Y;,@1!3Y[5X$V^>>\D15Y7DT5%/C7?J\VJ'=PI>V
MK<*[&\K\4BY@]..EFACIUTNP*N:C,Y"X"5[UJ+P*Z_7"XLEM@O6420200KC$
M<6C8]24M!`.;)A4=7`IX;]I,=LK&1$K8S<:.[/G2.7Y<PQ!"D2S3U7W?4>)1
M4Q0;CU58S#;5MEAB-%%3)MAAEIE@2(N\R%EL`::0U4B+L%`]125%5>56W&(V
M^;3<SS"DN,*;J</J&L>7#LP:NHDUW,#GP3>O6W:9I$DT@TLP4A@<DE&9SWMJ
MHKW#5&&AN=%3/9&:%BF0,+?6$O;>NQ"),K)R8FW7@5;5Y)(MI)17KZ58MNL+
M-CHU`!76B-.PE(`]C*MO\4W!QJ?B><XY795BMJ,=+*AMV$>KI7M)K$^(4EI'
M$4O0D1VI#1B8DCC8\(J>%N$%%"G5KM8_`C/5TR"5<_#D,B["D5[D<HAPSC+]
M*Q"CH4=6$)6T1/'=PO%*[;VF491BF.7^6X38;>9)9Q4?M,*L[*MN;''9C;I<
M095E6&M9*<5H6W45HO3[7`%54T<`>YM1MOB.T%*]A6)2K,X=C>9'EA1LCR2P
MR.Y*9D%B4^S<BOV\QZ>%4Q)<].-%83VD(51A"!PB1P/O@M'M_BE:NVNWH8W4
MP<#APZQS$,>DQ#7%FI@',@0YU:#SLJM&6TX<V/[UL')3!JXT9(J+KJXU6;H#
MF&X19A^Q?["N3:7_`#8I0?FBY,$`:WB^_;`IBK#]<K1$*M&O$0&-_P!KR?G5
MPZ?!,1I;[(LMI\9I:O*,T.L?RV_KH33%IDKE1$]C5%<S01#GI7P_]&A^JJ^B
MUR(_/*^_/=CP8TB;*>9C184=Z5*D/$K;+$:.T;S[[[GP#+#+9O.FJ<`T!DJH
M@KH*'GQT`.4%>2\<^5^R?42(B]W:J=R(B*JKSPBKJBYL123@?J7GN<X1$%./
M"B7SPIB7<"\*HEVJJB7*:][&\KP_=/$8&7X5D-;EN)91"E?E5[222=@64,R?
M@/NPI((VX#C;C;S*F"BXRZ"D!(2"6J8V_P!K,>VKPRIP7&/SARBQ]N6%>M_>
M6.06B^\G2+!Y9EM9O.SIAI(E.HR3YJC3/IL#]#8(@6CJJO<@\RSE<E+#TP/M
MI/\`-\5.%@.5&21#2_7+SD$<`_\`3.TJ[V`@8M=P$J":\=3.L?N;G&+VGQS(
MY&(WUC52HE5E4:!#M95'/=;X:LV*Z<BP99QC^L8[X^D2?3VIX5+]SX_:A)VC
M\JGA$3CE?*+PGE/GRJ<\>57PFK>V9M(\Y'0V%?!OUBCMNM+(;8)2`7C80_6`
M"<14!T@%EY0-&C51/M#'_(Z:8QA<N!91$SNQ;Q:7#G1I34*N',9C-0<>3%DL
MHK<&*YD3W>#C7'M8BR#X,6@Y2W.$P3@8'AL1K$@VY=AX]5HUA<>7%D#AQLM]
MP4T>9#56'4JW$1&WV544,452)Y#75X*.%F_&4)G,K&IHN91:N8D&-PY\/VV'
M."RM/#O_`'SKR2K]I$?*?*BJ$-[O;1MH51>+>W6-6I9I#RAO+KEFCB8Y*I7L
M&%J#^STRQ=FC,;R*3(*/[\;2*P/L6F1=&.3*]Q*AJ:$&SATT;H)O!LI@>;/O
MB]<2Z@:W)40VR,,EI#6KN5>%HC%ER3*C^_%A2(V69C0.$KG=J_&HFOPM\Z8E
M46YVWISVGBAVE5FU*R,M^2KE?;QEIK<XP!ZE>S$CV-9",CCN-NR9=@\ZX#J(
MK@RRZ!IIIH&FFF@::::!IIIH&FG.OD\^S':)Z0ZVRR"(INNF+30(JH**;AJ(
M"BJJ(G<2<JJ(GE410^NFO*_/:7_[VK/'S_UA#\?_`-_7*7E,JHB6M:JDJ"B)
M80U525>$1$1_E5551$1/*JO">=!ZFFN.4XY^$_GX_P!_&N=`TTTT#3330---
M-`TTTT#3330----`TTTT#7"IS_;_`!3^B_*<_"_R\:YTT%G]S^GS8O>N,47=
MW9_;7<MLF?0$\WPK'LCDLM>>`CSK.OD3HR"B_3[>2TH*B**HJ(NHU-YOP*/P
M\MWF'$B[;Y'M7/07_:6&UN7V-'[1Q_M4E&MM0NZMYE"1"&*]&)@/(M`V*J.I
MB]-!KX3_`/)[MDP`&L:W_P!U:MAF.#+#%U0XA=H*@V#7J$Y"CT1*9@VB.(*"
MB_`(`^$L/??Y-W*>RQW),.ZY,PQ&%.DPY5OC:[-U%S33WX;8L^J#$G.V2A%*
M8`6I@0S9:D<"?:#@H2[0^F@UM[+_`"<C:W+DB)G?4YN):-1&0C@SC^"8M2J+
M2&INHP[;6&2''(E7M;415&1Y5L>\B(KWX3_D\G0'CZ5Y9>F\^YQ5\J+*2-DF
MYL_'ZR44,A-@)T'`X>,'+;`P$E%Z4J$J)SRO*K.SIH,<]L^D7ICV=;BCMML7
MMGB\B$39Q;2/BM9.O6W&B0VW?S^W9L+HGA-$(7BGJX)(BB2*B<9%]J<\_?XY
M7E5_Q55_Y_V\Z:!IIIH&FFF@::::!IIIH&FFF@LYOALUCF]V$6&)WC3;,PF7
MG*.Y1H3DU%@3?:+H%VJ:Q)'`LSV!7AYG@A1'FF3#3LZS.F;)(F5W^V&:65S0
M9513&YM"^]P]4-*A.%73(S'8V+U?:L(JE-9+O["1![>PTUN[:P8ZV^D*GZEL
M)&UIH\:%NMB$20[B=D?:TW=1."?>Q6V>X1?:RS4SJWS+MKK,Q/D(TB4N@TR>
MEC"]TJ>MR^TL<>G4]''?E43^2`J,HX_`E+"E@PJ(;AUS[BH0F_V,&9((JI)X
MN=N3>Y9[B!08WF>58ZY#1YF4[718TQ+@C!%]-V-*;=<*"PBJ('%)HR(C+DQ%
M%2[^%Y3?VC.9X-;Q+[`,APS(I]-N%@EZS)K)578U,UYF,5PR(I&(R;;:E-N*
MCA=Q^H*&V0/.5;@%I@$I]_*BJ6,SK6TL:<7&9)Q/4L*]#C'^^)IUQ&XDP_57
MD6EE(GIJ()Y0([K2Y@^]E+9Y#$:FU[SB6!VTE83R.L=J/2'6YZM.FCBJOU,(
MXV'<@@J^-=S;[K!L<7O)&.!2,9ABR2XT"E5N8L*R1Q50"5B28JT[#]PZ1!ZG
M:2@/V%>=9%=1&T57NSMKD(!35YY/6"-CB<YUAMN9$LTDL-,UP33`C;A3D/TI
M0NJK8M"JBJ'PNJ5Q+H2P3"H^)VV59E89/=R'0L7ZO')L.NBP9$(@1&#B=KTY
MED9"$VV_(5"E-@I]J`J(H71JMULLW4R*%BF+4U?14)Q9;F3VASG)=Q#8Y`6X
M\5L0"$,=UY]&2<^I]>`X+L[E2]N?;!PZJHJ:?)6(BLW./K%08DJ!*65$D*XV
M)6<-GO9<>D-D2FXZK;H+VDB(NL>MLU;Q[>3.<7@P76Z`*B*W6VP-N(+60HK<
MQZILIR(C1=I(X`=G`$O8"\(/.LK?RZQE.MJ^\IHUVJJOH9(VVW]2F1(O\"(I
M(O*H"IVJG/E-!A=E>+'BSS-)Z;#3-<U%"(HBH-E!!M&XR(:JK9J#2HAD7"BX
MBJJIRG.4F#2G9F,5+8L.MR`@>@C9`K9FVP2H1-*B"+B)S]782\DB\\ZMSNW&
M:NXEUZ,5VZA56/6$)84)LC?N;)!]1F+!0%$Y)-.JVV'IN(IHBJWW*BHOC;(/
M#N:,-V;E,K;5RFCM5SC.2,V$2-56BQ@D'7"HKRJ%]1^X1HF_5[@)>>%T&14:
M*HF;SB@0!SWJ78*"H`7'U$J<(*HBKPJ<)\IQSK&'<NIW8W6?G-[4@S54F&R7
M?<Y2ZRTD:TFFK8N2$LG6C?@^P<!68KD=E1=Y,'").U=5ZW@NYNX]ZUC='F%U
M<14D2(1"ZZH1[(6E<2._#;@L,ORO5;0E;9=7@N$1PN$757TN/O;>8_,I+NVF
MO!7V+_OCB0G45QMUP!]*16QW2!TV)"]I.F:)W<<HA"JJ%M<@J?S;"L>QS+Y-
MW83:*'(?RG)I$^-'0C;C`\<N#[9F.W'DL@CZE)D(A&SZ8(:GP*W$Q[&H[L'%
M+=JJKJJKLJRM&KCPJ>)!LG*5XU&3+>1H6Y4BR>;07'B=47GW"!QU"YY3SLMP
M/'KO)FIF5)+M:*XQV-%JL;C9`L6K=)J3VLVF4P8<@7D>;+D6X$E&24!%PA/C
M5YH>$NWR5^+4$1J5<6L0*:$<%QU)L(9`!%86NE.*I-ND'>@.*7*(HNJI$**H
M6DR[9/*<]R=BXV[OLCI*[&JZ6U+=B5KCCJT;;P2CFS(H&;#:&1&U(=E*0@G*
MM*)<CJN:7%0>R"%,ER*NNC,P8U3(N#@>K,*(V\+\E9?:IRGQ,A]1P$-&7'/X
M`15U7<6;E6VGYKB1V$Z$811QVU;&<3CLV(P*-G%G2A/B4A&'[\B^EUSE2%%7
MC5;;5;4Y;NUE5'@N#QHTZYMY4:18290NE!H,;!]!M;^T1M1-NNAMDC3*F0'+
MF&U!B]\AY%$+V]$_3I;;T[JQ<A=,ZS:C;ZTE6&238`2X$W+;86.W'\<AV#3K
M3T6"\X[^<7<<$(G(46/$<5!FJBY@;U;476UERHF+\[&;%PDI+SL^@S/O-:^;
MV?0Q9M`)$0<`U+;_`-(CC]#C;4D&T>UF+[-8)2X%B446*VK:)R1)5L6Y%K:2
M$$["VF]JKW29KZ*?"D2,L"S&`O39#569/C%'F-'/Q[(J]FQJK%E6I$=X4515
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MJN<VBP":R7(:ZLJ;B>LN6X,JOI2>_+&`B&\4.,L<I!D3S#(.O\JCA*G'`5WE
M-/E][BLZMP3*(^%Y.\Y7G`R.34,WK,)MB:P[.:<K'S;"2,V$+\1"]1/0)Q'4
M0NQ.+X50&(-@1$?:@KSVH`J2(B*:-HO:)*J<^.21%X0B5.5H:G5>P./L/G^G
MZ_;_`+_\?BX-4J+QSSY%$\<\+]E3[_;QSS_/[:#U9.8X=C5EC5)?Y%2TMQF4
M]ZHQ.LM)K,2;DEI%C%.D5]-'=X*?+9B`;YLL\D@CPB]ZH*W=@"TH@J`A(J>%
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M4W!"BR?)<>7*J2K)NQBNS_>42R(_O5EUH2H3)*Z7M77P?0%4/%T("/`T`OJ+
MCHM,(Z\@^DVZZ,8?5,6^Y4;0GD<=](2)&1<`.\O*Z"CMQG-RZ_`LFE;34F+9
M#N2Q6-N8A49G:3*;$Y]F,J,!-75E!19L6,D$IK@.L@)J^,9HE$2,]55&CSY5
M7$"WC1&ITBNBK;0V#*77M3G(C7YG&CG(!3D0&Y*R6F'G10GXP@X^U]9`50`X
M"`I\CQVJGE>>$XYY+A$X04Y7PGZKS]]==)+;@"H*T8F'(J+HN"?U<(8&"DT8
M<^$7E>5%?IX3G04M64=)CE<Q1T596TM=7LHS#K*>%#K84-L_4=$(E?`:8BQ1
M,E<>7V\=MLR4W.U5(N;9;K/[F0Z_'W=K*3$KRT?S+&H^2LY=;3::-$P1^6K>
M5V=0_";<.7D,*%VN54-]!C2'#<4VW%[12HX6V6$XQF^X.ZE13RFLSW"KZ)G,
M;!J=8SCN(^&P7V:*/#K)4TH$.0RP;K`C"9C>]<=9%\N1$D\7`,\/<C"J7,7<
M/S'`GKH9;G[*9_5-TN75(Q)LN`HVM6$B2$8I)1AEQE%]SU(;[#A=JD2('@6F
M68I'RP,#<R.G#,GZ23E,3%%FMI?O8Q&GA6.7C5<I+(.L;FN-1')*=PI*,F@1
M4`U''W,XFUVVVX$/<FRHI43/-U;+&]HSR*MJ;VUE6BL+8S\?K;1F"4F)55<1
M6GS.ZD1HS+!JRU*?,2;XRH/#<7FW<G.K2KKF;6IJEHSR)FN@+DK]5,FA*#%8
M-N]'*2S!L)K12Y$<W_:1VF)$Y63>`4+R[3*&HXNA%Q?$6H7=Q[672A:/$T'*
M(C]E.?*>\\JDJ*Z#S*\^&Q#Z1`,?\IB6$NJM(E-."KM)5=/CUUHY'&6-;8.1
MGFH<YZ(9`U,"',]-TV"+A\&%'@?4U8^NL&*R'CFW.9YK2Y-N6N'C87+3;<>H
MLLCBQ4_+K?)(V/QS(H=4[*<*.:M$0,FJ]O:JEVY66[%5<5L^]H&6X:U3S+-_
M1M2UFL0$E$K+5G7.D;DD*]V23427!F.'*K9LB*!.'&F,&-@;:CI#N6LC<J:P
ML@8@NU3-U[&*=PS5/O\`N'JQJT5M9@5[DKA]R(#HL&ZG<3:ER6@R_P#PL(-1
MMKN](VYQ&EA5.,2MM[F-'A-.RW$KV:>ZK[5KVIOR'C-9,N:^KWN3<(07AM45
M574_^H"/P[E1.IAA4XX7;_,"553CA$>I$^57^2JO"+PJ\+QJ?-UYID>]YP&@
MY1.YPQ;'E?A.XU$>5^R<\KYXT'TTU0MIN=M[2J0V69XW&<!Q6G&EM8KKK;B>
M5%QJ.XZZVJ?^F`I\^?&K1WO5=M13)VQI-[?.]SP]M53/``JUP@DKUF=>V;3J
M\]CC"OIPA$H\(B$&2VFH^+WK@D(ACCV`"'`&@R+J\$Q%Q47TS]M714Y0?XG&
M3D(1?`FB>=6)R;K#WHM1<:@VE-CC3H('93TS)NB/^L3<JS<G/MN+_P#:-DWQ
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MVH7GT@%.PYB]R&:H2BJC'%41%<3ZWR5$:7@%-;G1XK481:9:;:9!$4`$!!L5
M[4)5[01`]0_J]0^.\U0._E1$D#(Z\ZJ]UKAI68#>/XVAMJ/J5<"1.E\F0J#C
M4BU=>;;<#E0]3VZMJB*JL>=6.OLFRG)UD+D=]=7B3!1);5E.E/PGQ1XI`LK7
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M/A:_E+<@A8:KHD;WL@69;B!Z:L*$DFV'4=O,&>Y911EW`Q^OIY58;)6$^#-C
MURRZCU'$O(K]G9,2G;->':Y6H[PQF4#U5;>553/K".KN\BN,Q,_I8MG"5.QV
MUHFBA6#:FYW(ZY6O/G#E-@V2`HL.17R4"<1"(Q;U@#02,O?NIPW&W]3CE:Z#
MQK=P\IK[69/>BDC%<#T2+7Q7T]5A>1=??-(W;Z#BJOC5:&RBBB(/J#Y4N>!+
MN7CNY0%7DN>>[ROGGG0318GFV+9Q7!:8O<P[6,J#ZP,N(DJ&X7/[B?#/MDPI
M`DA`34AH%[Q)!4NU5U56H4,7RO(<*N6+_&+2563F2:4T;<(6I[;1]P0[-A21
MJP@D2_7&DH38JJFV39BT8R;;+;WU>Z=8L26D6JS&"VA65,+R]DEI$!?S.I1[
MEQ^$7=P^SRZ]`=_=/.&V33[@7YTTTT#3330----`TTTT#3330----`TTTT#3
M330----`TTTT#3330----`TTTT#3330----`TTTT#14Y_P"?\4_NFFF@C^ZM
M^A_%-]"L,[Q.-&Q_<YR$VW9O0VHL1C.VJYAP:N'>/$C;:V4/N1B#:R"5?:J,
M*47H-LN,:V.Y6)9)L@N9B.%.5>0U%F3V48A.:E53]@Z3I-/RD:;`Q8GN+^]&
M1'!UF6'#X&ZR?JENGZQ0ZI^D+;'JMPN=CF6_F&-9$K`C2;@8NK43)J9]@Q>C
M-2#(4:N:A'P$I--8*;#S?>+#L1TT>0-3^N,<_P`+H[FY8DT1E(J\BATE;8N%
MZ[T&83L&+;3'$8,T1T%==9)KVKB(`*G:/"5JEHVQ^=6$7%,ALIE.S&>F*TRU
M!K">G"IPVTMY1I$%WU",'6B3EM501,R5!U<KJ,Z.>JOI!KW+)S#*O>;;^&1J
MUFN,0K64S7M-FI-R;ZCCB=A4JH?O'FI*/U@.J8LV#H_6N(&(;XQ7Z*2UN5+O
M<??<EN>Z]K63_P`IMV$>)R(RS&B=X"]"$@$&9/8J*'J(XA<"H9(C-*1`"MB8
M]!ARY\P+-^W90UDJS(;07J\G17L-D9!JKK[@%((V>446U%%Q-W+L-UJ?=J'&
M;M,SC;7/V]&S8RF"<6D3UVA63#=-OAQF&;HH)N$:,`2FCA=VJJK4WSRG(?VQ
MQ=RRQ;;"5/@)65MQ)CQ95E4PR!LY81RBR$AO3T`GN7'FB5"3@41=9(SY;]PY
M%K[F;$FM5]>[%8K1"(KS=<](]?NGL,F#LEKU'.`F/"3KI<(*]J^`\B;;395!
M`QQBFIX,.KFNR1L&&02VEFZV(JU)F_\`:N,1^5)H$+A#<)>>?&J@IL1QPZB5
M8V#TE;B63"1HPQ0*+);05;)79'<V;!,-H:(BBO=W(GPJ:J._=P$<6K8E/#L5
MR4'%]]-D/-+"-GGCL8CBB.<CY1#,E3CQQSPNJ&LLSL<8HTEQX5?9BP\VTK<]
MM\59!TQ[O2)H@!.U%`NXE7R7A%305+$%K&)'LX]DS52FE8E0G?=M0G6SD_NF
MVVC<=9-'BY[6A`N\^5$45535([BS(=+B.1MK;U362VE=)A5S2RF),E)LP@1F
M<]$&0KZMMO-BX\XYV`Y\=ZJJZH.IR:RSV_=2[K:B?'9GL39@S8YN17DA*ILP
MT;50+M;/M7O;(2[@0D-"1.+J9?LGBV/U-+?.KC-M/R>.X_+CQB<D6]>TT\I,
M1+`SY-EMD"(8K:N*7IHGJ$2JJJ&/5=EB38OU1$.>->TS.FM.B(E-`&VG7_;K
MR\HFZA&V($:MBOT^$Y7(+!,BGE4LS(\QYB?7"#1RF"5I]LVQX8<5Y%%QHN/I
M`U)"+MX^4XUY>W>'XO1W8RW,?EY*U)7VS%'&>-'W))B01_9^WCONFJ2"%3!L
M'.X!(6E4T34B.QOX;.YVZ$ZBS'/+.UV9Q>):,35@LM-/9CD=%WJ<BH.HFLG%
MK(<P4`8MC=1RGPD7W$>`X9<"&/VT.S.XN_>7Q\<QJME3'S?%VVNI:/)6T4'U
M4)ZSN9Y(0-"7*JRTGJ39[J>E$:<(C<#89Z>^G7">GO$_R7'8[4V_LA8>RG*W
MHX-V=]+90O2;(NYPXU5!0R:K:P'%9C@INGZDIYYTKB;<[983M3C<7%L&H(E'
M5L<&\C(H<RQE<<.3[6:7,BPGO+R3DB09JBDH-(VT@-C7N@::::"FLNQ&@SG'
M[#&<E@-V%39->F\T7TO,N#RK$N&^G[R+-BN</1I+:H;3@\^14A*&'?397(=F
MLA6+,1^RQNQ)PL=R(&#%B4V)$7L;`DY9C7$5M!]PQW",D%]S$$FC)&YP]4IF
MN%8[N#C5GBF40`L*BT:['6U7L?CO#]3$V$_PI19T1SAV+(#RVX/!(;9&V0:\
MZ]JB2$BKQ])<^$X5>"3E/J5$3GY7QX\>-8CYEE^-;:1K&VRV>5/3QK^'2>JD
M6?8&W,MK)*^KB^A61Y<E!>>=:4GT`@::X]P8*A<R1;W[)Y#LMDHUE@1V./6:
MO.XWD(,JW&L(P'YARD1%;BV\(.U)43N[717W$3NCFB!'KNUBF2R<ZQ.TILJ2
M@I&;,+?)*5*2NLV<L@!".,M4Z_*53K7&[!&+#W[`$Z1%R""XR!:#UK:US6NF
M8DWB>/5=Y$G9'&AY?(L;Y*@\?Q<H[IRKNO8]O)6WF,.BVT-8A`9*1J+A]Z$-
MT+6?DD'&KN;BE7#O<HBU<V304L^Q2H@6EHW'+\N@R[/L>]G&E2$`'72;[@15
M)5'O^BC*UY>$0E$B[A7NYY4N%12->4^E4%2Y[%52$00!4W#Y];;>3G+F/B>X
M36,Q\A*RM!]/$';-ZI6K&RD)3EWVJ#,685:D99X\HP,M748$11!0+UX=.N9E
M-22LCKF*B]DU%:]=U<*:EE"KKEV&RY808L_L;*:Q#F$[';E$VR+Z")`VB(JE
M[V91\VLL.R&#MQ?4N-9U*JW&<7OLEJY-YC]7;JZTC<JWIHCC$F?&;9]<48;D
M":O&TXHJ#9"5/PIK;8*9GV((D9F1<-B`\J1.+Y04$44D55X$4555.-?K;W<G
M$=Q\:AY?@E]&O\;LG9S$&YBHZD.6]4SGJZP:9&0VRZKL>;'>8<0V@Y(.X%(%
M$E"]E5(F1JR"U:2H[]DU!AA/?BQBCQ9-F#+(S'H\8W'"C1I,I'38:,S-B.Z+
M9N$0J2^/AMUN#9Y'GL'+,6I<>QFKO8,7;JXKLC6XGYACS]4S)L;B[K2ALKCL
MR+;F]7M5ZF^CC`BZ"]JHX]\6)2ERJN"OD?!*2=R=W<HD0\\\`BIVBB\\=OQS
MKS,#P6!AE_N#DL:_RRVE[BWL#()T#(+U^TIZ%Z#4LU#<+$JYX`:H*Q]E@'Y,
M"*1-.R>'4[$1!T%W;*!$MJJQJ)S9/0+2NF5LYEI]R.;L6?%>B2@;?8)M]DCC
MO."+S)@Z!*A`0F@KJD-O\"QO;'",;P'#F9<3&,3J(]10,3)\RUDC713<)OU;
M*Q<D391D3A>HZ^9O%R@DHHB(M4+([A5!+M4A5$/N#E%5.$(55.$5.%_5>4Y3
MSQS;C&,!KL4S'<7-HN1998RMR9M%.LJ:XOY%CCN/%05:549C$:ET?2I(TQE%
M>LFV"))4I?65!5$1`^6Z&XL_;V@9O8F#9KN$3V08W2%08!7M65\RQ?6L:JDW
M<J+)>C@%'0"^L^WDB2$W%;,D%4#O&K)KS7<JH0\(ABKBK]*JG*<B2_'<J_3Y
MX5%_1-=>?(02[A(E1?`H*<""_<E5%4_'""*DG:(J:]JKPNJ6L)I"UW*?*`J*
MH\J@N*BKP/''*H2_P!\F2"B=W*BH=Q,HQZVI,IQRMO*BPR'%LAI+/)J:%80I
M5M2P;:JG0ZQZXKV7W)->$B40>V&8TR#_`+ALVE52#NMI;.\MFJ+Y3GQS\$G"
M<KVJB(J$BHO*H@\*B\)YUU,68PVIR/*<YQ"LQ9G)\GDL5F=W=6U`F2<D.B;2
M(%+E$AAUPYJUK2^S<@3D:D1B$#,`>!EX/,R+'-N+K.\5W#GQ]R*NTQ"HOJF-
MC&.9VW$P:X;R`HZR95O43J>6^[(AI%!*YUYZQ=C"X8(\K8,BV'D[9[2X37P=
MV::NLF-L*C<N/?\`[4YB+EP\+.=;@2:N*U?BXV5A)CSV?9+:"D%D8<`:LIQL
M---D:Y9X-^'S1XUB.-4V0[QY)FHUE#`BLWPQ83UE?-,L(C=G9W<EZ8DR1-'Z
MSE1V6A,23MX4>5Q.RC(RL66H42&Q4T\4R<A4\9QUYL'3!`>FS)3ZK(L;&0"(
M#\Q]4[6NV-&:C1@!E+G[(]4%MM:X&,9/[R[P!\E%EH21ZRQHC).^15*X8^K7
MH7[R54(2!RI/1!;=-QMP,FML^GC">GRTM,BPK(=Q;#)+%Z\_Z\RC*9%M80H-
MT49R344BQX5?'JZ8#CQU@5S;!'##N:%T2]3BL<@N;.S=D%965A8>L0F[[V9)
ME"Z30=@.$TZX;2FBJOU*T))PO*)PNJFG9%4W\&'<4T]FSJIT<9L.=%<1R/(C
M.BCP.`2+RG**@*!(A"0N(7"@2);>Q>5!=555%Y(45>.55$\\?R4BY^.>$7SY
MT%%VSZ(7P@_2I(7`HO8B\-KRB(BIQX\KX5%1.$3C5!3S12(N$)"1?*+RO*<I
MQRG*\_=?[\K^M46CO).>4X3E$3G[(G*>.>$127CY^4^VJ)F$OU)RJ+RG"<HO
MGCGGQQX7GE>$_P`=!X4CM3DN$[BY12^Z\+X7E%^$%$3G]./E/&J;F']2KSX3
M[?HOPG*?T3^JIKVI;BIRG*)PG''VY\+RGGSR//WYY1/UU3,HN>414^HOUX3C
MX\I]T_7[*OW^^@\_Y)>>.>>45>$^?M]E\IPGPO'*I\+JJ\8I1M)1/R&T.##(
M?5;+N%)#I*JML<BB<"*(CKZ=R_NE0%5.Y.:9::<=<;:;Y(W7!:$>"Y4W"013
MM1%).5)%1114X7E414U?6IK1K(34`>W]VVBN&@\"\X2(:OJB(BDI$X0']2$+
M*BB\((IH.XV`BJ)]0AP(B@MKPV(\"*#X$0]-$$>$^E.$05[>%U2>YN33\)VZ
MSG,ZNJ?O[/%,3R'(X5+%[E=MYM56OS683(BWR'NB:`"$4,U!3[$5Y01:\;;[
MD54%47M)/Z*J_"+YY1.W^)%^P)Y[TU]U:%SZ>051Y$DX51).."4![N"^GE/L
MB*O*H?'"A`!T'_B%=1F]_4I4;:;B.5&48KG,?)9@Q:7'X=2_@JUU=)MF9D&7
M%0GW*2/Z05DMNW<DO&+[)A*"7P)3)T&/;D-[L9%:3[N"[BCU%C;3()1N-M3&
MV9>1D%;"<_.WT@6M:V]#>M;)87_6K+S#2,,^ESJIL,V5VHV^N;G(\&VTP7#[
M_(5=*ZN,<QNMJ+&U5QY7WDL)<2.V1`]()9#[+!,,2))>N^P;J":>I!Q/)(.1
M_G$C<+(K:I5Z0X.+2:V@;K&V9`&+,-)D:O&T-B"1B3!'))UQ6&_6,^5305CX
M(>$1.0]1%X(4%$45[4[5)5%.[CM1$^WC7S4>$7A155!>%1%->>]%3QQW%X^G
ME/*B2\\JJ:[YH)$*]HJJH/@T44XY1/I1>%X3GN5%;_FG/V^:"!#P@HO"%SPJ
M(B?3Q^HDO'">>$5>4XXXT'FHV@(JDB"GRBB*'PJ\HA**(A()<J*\IR/=RG"^
M5ZJ@H\)P@$JIRHIQRGW5$^.$XX5?/GY7E->HZTOTD")SPBDCG"\DG*\$G"_4
MBHB)VKPG^[IN-CWHJBGE$54\FOE.?X>1!/*_*)SY\JO&@Z!,ISRB<K\(HJ2J
MGGCY7X7^7/U(O^-LLNWAL]ILAP^PHZO+'K9[(ZEIJRHL=M;"/&CRWI+<EF++
M@)Z4J]-MI48H7!/\PC.O`^TXTJ"MUC'@2Y'G@4Y%"3GN5>/J7Q_%QROGQX\?
M"ZH3,94V&=2VUM]:9P#+P6S<B#-HX[=39Q7.(CRA;S8IK,$",H[\<"$`[Q<(
M>41`F4V5WBH=Y,0BWM=_U?=1V889)C$LQ:NL?ES&3?B#:5Y]LF"%E&;*;!&0
MV)&SWM\D]'D"%XM:_NQ&*9WMMUQXKU"T&;_EFW6XV`1-J-\MM;IR63<H(:39
MV"9=3O1?=U;=WC5]-:BV'KM,N.5#]JW7V(MS'XTC8!3E?G_9_P`^?]G]$T'.
MFFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@
M::::!IIIH&FFF@::::#\.-@Z!MN")MN"0.-F(F#@$BB0&)(HF!"JB0$BB2*J
M*G'*+@]O7^'ATO[V%,GVF`Q<4R*8ZLE[(,+5NE<D2?LY/ID;=H)_*JI.$Y7M
MR'%^9"*B+K.3300HY]^&KNS!K/R3`=P,;R7$V93,F/0W3+^-3VG&FE9;(#;8
MLZ\U;:[6N$EQ&21.X61+E5P,S7HAZFL.SR-=QMD\LN&4HRK)USC9U%O&?9]U
MRD8F:^?(E=P`#9M&L9445[>.>23:AX_[_P!/OKA$1/M^O\OG^G^S]-!J@O\`
M3[O*VZV4K:;<2,9MJ!BF(7Q*VXJ\@+@)!10)%10=[%5M"3D.>$5<<=]MENK6
MRK*[#=I>GG>:]O;&>Q,L[B+@ETS4PH$,^\8A2IS$>,Y(FO(@E]2=C`IWD"<K
MK=,043[E_<B7_OTX3^?^*K_O70:C/3%^']U[Y%-LWMQMHH6!U\F'%6OF9!;T
MU(XW)`T60DN!'LK.>I.-$7:8QA074X1"155)3-O_`,*JP>=8D;K;G`$4/3-R
MEPJ*](DNB@CW-.WUTRRTR0KW`I1Z=WD551=_A5)FNU.>?NG/WY^?U5?*_P`O
MTUSH+"[5=,NRFS(L.X+@U9#MF6P`LALO4N<@>,$[5>6SL"><C.N)_'[`(;:_
M"-H/":OUIIH&FFF@::::!IIIH*0SK!L;W&QFQQ/*H`3ZFQ!$).>R3#DMH2QK
M"`^B*46?$=5'8[X>45";<0V7'&S@4ZH]@<FVGLUA3Q*P@,./SL;OVF3&-=TZ
M$@R6'P#Z(]M":]%R;"#RA`3L8SC/-+K8:U1&X6WN+[G8Q/Q3+(`3JZ:V7IN(
MB#*KY2"0LSX#_"E'EL*2J)C]+@*;+PN,F8$&J%4YYCS^:RL!&1+7)8%#"R>3
M%6!+&(%7,DN1(KC5F3"0'GC>9<4HP2/691$4D\<I6N49I.PNA&Y@8KD^;O\`
MYI2UOY)B3,.1;(W;6#$-^S[);\9M:^J;>.;9$+A.C%956D[E(DNQU![$9)T\
M[A2\>MH[DC'+4GIN&Y(+7^AW58*B3\9'.%1FPK7#$;"N,NYA#;?8%R.Z+QVO
MK[,414$E4FS1MQ$4%)M2\AWHA*H*0J)")(AD*B0BHKRH7=9F>FO'>O`N*G`'
MPI*'(\KRG'8:*7*%RJBOA4\Z]VH*'!C!$KXL2#%#N-N%!B-1(K2O.*;JML1P
M!ILG'>7'%;:3N,E(N24E6P6-[BT=[E>689%B7C-KA#5(Y;S)E1+A4DI+^)[Z
M%^3W+J^SMW&VN`FMQ>XHKRJT?/:2C4^";C4^8S,KAU,3((LC#,EDXI:'=TDN
MF8?LHK+,DWZAV:B-VM6K;H]EA&5&S-5%!\(JA?*@R^CM+BXQZ%<U4^WQLHA7
M]3$L(<FSH3LF2D5H7%>RZ4JK6<P)NPQE`"2&@,FE<3N4;CLSDX0OJX^.$7]/
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M-&LL6PPG+<+7&\ON\7BMY5&A1_VFB51--Q\KHTB/OD6/6ZN*[!60821]$E<`
MT7E>_82552[B0B#ZD4U^$;^M'01/*]J*A\>4`50OI3A5^<BS%>]%)5^E4).>
M?I[?GGX$.%X%?/<O`HBJJ(EI,HPS'<@RW",WM6;![(-O#O7<9>CW-A%B1CR*
M`-5:+/JXSS5=<@]`16&&[%B0,0S5^,V+W"Z#Z4.,8CM]%N8>&8[7X_$R#(;7
M,+MBJ;<;2UR.Z(7+6U?!UPU6;/)II7$`VFB4`%L6$556D\1SF7F>/Q;V=BV2
MX4\],LX9T.6,Q&KIAJOL)<%F:^$)^1&&-9-Q6YU>:&+IL2%1UL51LCJB1,9$
MG!$VR5KE7&VS13:[DY;$VT(C:(Q5.U%1`/ZB`B%%5+?W.98]"O*S&)MW60\@
MNXLV=34CTUH;2TA5:@EI)A1%-7I#%<CS?N7&D(6U,5+@51=!Z]I+Y(E$N>$1
M1\+]7"?P\<(/E.>U%,>Y4\*GE=6]V?3(-\;_`!O%XV*9)AEQE.;/8=%K<HB,
M#8HTW;+!_:`6JPK!"J3KQ?N`=1IQQN`P^;K2MM*X7BY'EM[$R^@Q^+B<ZPQR
MWK[F9<9BU.A-UV-R:YMDH-=-AN$,R0[<(9I'>84091LE<3GA4FH_#JZ>)5'6
MRM],SJ#AVV01C@8!`LX2!,@8X^C;LK*6O5-78[F1<I#@&<>-*_*8SKP$Y#LP
M(PS6R+8G'W\.HZ#%VV:B;B=#68_1R'5=-F565$5J)$@6Q<N.O`0,BH3.7),<
MR5>YYE29+!/*ZNWQR=)I[N&<"SAJ7N8[JJO`CR02(Y^1D1WNY58D-%Z;P=HC
MR2D(2T:MCN;M;CNYE3[.S`H=K';,:J]C`*S8#A*A(!IR(RX3ABBOPGN0/R;2
MLO(+J!$58&2(2*J_IPG"HBJO>2JOCGYX^4^...?BD)A<DO*\BGQYXX^>>?GS
MYX\\KQ\^/.KI[DX-D>WEX[29'"-ATD==@SF4(X%I$;/A)4%]4'U`1%%'633W
M#!%Z3P?2)+:%]Q>#5.414(57GE%\_9%5?NO'GA>4X\>=!XDQSGGCA/!<(G''
M/PBI]E5/A5_3CG5-2"52045.$3RB_'/C[+YY\+\_V^->S-/ZU']%4OU1$^R)
M^GPO/''\TUX)KWDJ_P`U7QQ\?W7PJ)\\?R7]$T%5X=""59J^XGTPH[DA$427
MN>,Q::7A%X7CN(^TD45["\*@(6KPL(:MEY)2;0N%+M44;7GN!57ZD5.54!YX
M7A47E/&L:<AR>_Q#"KV[QNG=GV+,ZF8<GC)KO0JF)-G71A]Q!GN@<M9J2I$=
MA(S;A1C/W+GIM-F:62ZI/Q"L#Z4K?$\7RG`LLO\`.<AK"OY^*T]K0MICE`,^
M3`C2+&[?)ZOF3;-V*\<*%#0B&.B27I#(]@N!(@'<J^%5U4$%'X'Z>$44[>$0
MB0N$<051$%!)//U:[38(GE.5%/A2X'E>51%'A$^E.23M3PO(\_"ZM=LMNGB6
M]^V>([G8*<IS&,QK%LZUF<PD6?'('SC3ZN?'1UT6I=?*CNQ9(^LX"N-^JV9`
MX"ZNR(H2?5RI<^%Y5!(/E?NJ(J+PB]GPJ$BK]7.@X$1%$7A$0@553SSRJCSQ
MPJDBKQ\]I)QPJ?"BGT1!'GG@N]5^DN>`'SRB?'SX3GQY1%\?9X1%^E>?XD7E
M5_DB(OE/E$7CCA.>?Y:^XKWK]2]OPB<JO"KPB\)\^/LO8B<*OA/'&@ZZ"B<B
MA>$\ISXX3A21%7X)45.4Y)>4\*J<^?FXG(\DB\(GA$X0N?E>>%7A1\KPBKW<
M>53SKLI\<*B<^?"K^B\>?]?[<\JB)_-55-?)1X4E\BB^5X141?''E%Y[43[]
MP\(GZHBZ#I.!W+PIH:*O/;QY1?'U?3SQPGPB+QSQQSSK\*V2JO@B#E%4D%20
M.?'"JB<)R2+PB\<EX^4\?:2I"**GU)]2HJ"JI\*G*BWVF8JBJA#SV_PK]7\)
M:S?7ON9UFT'65=5>'WF[%/75]E2?YE:O$ANAQ^TJY%=7K'>C1:UE:B[DV%L<
MMJ__`#!)1(7JQ9@LQ6A``V1IEE71K"!2R)#3=E:,SI<",J%ZLJ/6`R=@XR(+
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M`%N%5.%^E.5Y34A/2!/E2,`R"`\0+'JLNDL0T$$$D;F4U18R.XTX5WNER7B`
MB3D05`%>P11`RSTTTT#3330----`TTTT#3330----`TTTT#3330----`TTTT
M#3330----`TTTT#3330----`TTTT#3330----`TTTT#3330----`TTTT#333
M0----`TTTT#33306<WSV5Q+??`;3"LIAM*Z;3TK'KE`5)^.7PQW`A6L%X.'0
M03(6I\821NP@&_#>%1<$@UD<LV'F=/&YV?T>14!T^89/:U]SDE@Q+L)5;D_L
MX+4&LOZ-9+B1QJ9,%EL!2`RP+3[<B)-;;E,/-AMH*G*<?KJS.]>P^WV^^*R,
M;S6I8<E!&DA0Y)&892_QB:\K9C-IYIBIMIZS+!2X+A%"L6FU8EM&!<B&L+>Y
MUC6"TGY_F%[&H:5B9`A?F,XGEBA-LY3<.`P@,@X2'*F.MMAPB(I%R1B**J7*
M;N6(45Z9+D`Q&CQW93S[SADVU&BLN//..%PJ(Q'9%QT_X"015QM5+RM6[[]-
M&XO3_8O0\VJ&;_#21F1`SBOKG9F*2NW]X+<Q93+WY)91W&E5V'9JV@O"V[7R
M)#3D=5L+AN>8YF]#%R/$KJ%D%!/=FL1K&$2NQ7W84EV#.917&P+EB2RZPZ)`
MG))PG(DBD%28C,J,[R/']X\1W(R"[Q.PP^53UV/UT]M<"M!DV*R!R4H+L-J<
MMVR;!PFWE-D$:;X)H4%$*\KM_'BG$:D2XC!S'O;0PDR&F#DR?3)Q&(P.F!2'
MD:`W/08$W5`"-0%M")+7U\UB(VU&B,L16&106F([#;$=L4_U6V&`!H!\KPC8
M(*<_PIKJ75%CF4V.+65]20;>SPVX+(<5ERFC611VYPW(1V4%1(.Q\HCALDI@
M8)])$G<(\!>X+3D17GRJ)Y1?I5%^_P`KPG'RG*\<^/"\:%:+POE$5?'U+^O'
M"_*?/*ISY_I\\6^&U'L1>$_A1.]%\?9.[GE$\>5^$3G]/C5#N1<H+/&\D'-)
M`X<UC153N`)40/;O7ZSED!E!W)$D\7AAD,+\M[/:JC8ND2=R@@5=F%!+R/(,
M'NX^9Y7CC&&7<NXGT>/RV(]1F<>37+`"FRQMZ,^Y+K&#<25%8BNQW!D*X1$7
M<"M5)+EH8D#AJ@KQR2+POCPG\TY^%5/J15\*B_%M\MR6XI,9OK:FHY646]96
MR)=?CT*9'@2KJ;':]1JL9FRU"/&*07*(_(511$5>X45$3IP;V9.J:V=.@/U<
MV7"C2)=9)?;D.UTMV.TZ]!=?BJK3YPGG"8)QA4$R:4@Y[TX#J1L+P^ARS,<Y
MJJHXF39Y^4IE=F5A8/I9#0L'#K"2$_(.'#5E@U$UALL^X)>7$)4U0NXV04&(
M5_[?VF.2\CG8ZRL2([28\%[E;$.YEPXDQBE%IKWX,R5)IVP:CN@VK+*F\)H`
MHO:@;@UN0Y7E&%P(M\5WBIT[$]9-!8L5D]V^9]>"S061`K-Z^H\LNQZ]'C9D
M$#!-ND0J,G_2WT%9!G$RMSO>Z!,Q_"05UZ%@TM9-?DN3B"-^T=N/2].318_(
M[W3]!7H]W.:9940AQ9*/*%LNC#I3L=]\EAYWFU2^.SM-(<=DA,)^"YFEJP(E
M&I(#:#ZKE9"?1L,FD(XVRI-.T[#IRBD%$V!8L:/#C1XD2.S$B166HT:+&:;8
MCQH[`"TRPPPT@M,L,M`+;338BVVV(@`B(HB="BHJ?&:>MH*"NAU%+3PV*^LK
M(#`1H<*'&!&V8\=AM$```4_F1$I&9$9$2^MH&FFF@HK/,!QS<;'Y6.Y+#21%
M>Y<C26^T)U;+051J=7R%%28D`O'*>6W6^YI\'&S(5B*WEV;RC:&W]M:@MACT
M]U[\DR-@%]M,;'ZDBS!1/]"M&T5%>CF2H\BH[$)X%-!FJUX>28U1Y=33L?R.
MNCVM19,JQ+AR0[@,5\B8$G!M/M%P;+[1`ZRXB&V8DG.@U[)1^35>?NGG[K]U
MX\_/]_E.=>5W**?9>?M]T3]5X1$3GGQRB*B\??65'4/TX7VT<QV\I@E7FWTE
MY!C6?EZ;2/.JOIP;Y`!!$.]>R-:*@QY"(VV]Z,GPYBQ\+]7*_'GX\)SY1/'C
M[?U7CRJ>0J''Y.71HUN.(TU)<NO3:Y+!J_MGJB*S'9@ON-.,N-09J2'O71$4
M"0/3'@@5>%1<=.J+H"V^ZN;'#\TS>\OMN=P**D&ELY>'G67M=/J@D.S&*M];
MB.VV]^7.NR%@6[:,O-,R'6I$:0`M]F8>VKC2Q[:,H]SB/1'U[A[FT:](P0D^
MGA34P(>%0DX$2\%QVW2%/XD'CZAX+D45%1$1$11X3E//G^7CYYY"UFSFU6*;
M)[:XEM?A$23%QC#JM*V"Y->63/EF;SDF986$A`:%Z=83'GI,LVFVXZN.=K(`
MR`#JZR`JJJ\\HJJ0KX^E"1.4%%Y[15?/`\)\JJKRJ)\^UP40@X(51>1)?I3M
M7CAOPBH(KYX7RO\`?G78;$104X<X+A>%^I$55Y-17P2#Q\"7^Q>=!3>6Y;28
M11S\AOY81X,"*_+-M%:67*&.`F;<%AQYHI<G@A5([7UJ"J2D*(B%])>5XY"H
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M%9=DJ$AUP`DTX12^47E5^.?U_GRO*)RO"KRHHI?&@^)@)HB$GPHFBI\H8+R"
M]R<%]*^>$1$)>$+N1$376**""B=[J()$3:(X2""FO)=J(G*(O'E$5/'"<KQK
MMJB\<JOA$7S_`#7PG*?ZW'*>/'Z_KK\%W*B(H\DH+QPORJ^"3CCQPGGS_1-!
M;FVVRV_N+MO*+/$*6?D+9PU;N944W9OJ01%N"OJ>H/*1!%/0$A0`4.>TN/-9
M.J*HI>2_?&)>>.5\BBK]U$N>41$3GE%_GKT33P:(O*$J*/'/(*@(OG^JI]_U
MXYX^.L0+W$B\<EV$J?3Y(%7_`,Y/U5$^$_GSRN@\@A4241054>!(1[D$T7R7
M\0JO*?\`XN/'A.?.L_>CX5'#LQYY3G-.1151>T?V:HD1$5/LG"_WYU@:;:JJ
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MO;5^04[!I64U,5IE\[[!#+)(1,NN`PJ!!!IB^1]MUQ!-A:CU$05?1%C)ZVL#
MK"CSO+L-L<9W@@7>T]^UEDD/2Q/()]=8,0J"^;DU/J6DV%$DL2[%B+Z-Y4^B
M9,@;C+H@O=V[E7"+_P`?O_C\Z\:VQO'K\&6KRBI[EN.X;L<+:K@V0,.N"@..
MLC-COHVZ8(@FX"(1BB"2JGC0:H"7L1!01F,DB((IW2HZ\_3QRO+J(JK_`*RJ
MB(JJJ\)]J3I[#)(6195,OLKH[/')DBL<PZGAP&HD_'X;,)6[-JSL?<N)<G*G
MJDF&:MMHRTBLHOQK;/3;7;M$_P#(/#%7[K^RM"G*_KXK]?C_`#9;=(G"8%A7
MA.$_\%*!$3SS\?EW_/SQH-6#:S']\-QY5_7IMC83)S6328F/CB+-ID3,[%Y4
M@6<=O+F8<)F%32+0O50V9$D8;2`JD^(H1KG;MM^'EOGG(LSLU=J=L:HR<$F[
M8PN<D4`,!4F::K>*(P!CZXMN3[5EUMP6GTA2([W=J>&-#CPV&HT2/'BQV&VV
M6(\9EMAAEAD!;99:::`&VVFFQ0`:`1`11!!!%$1.UH,4]CNCO9_9#V]G75CN
M69>TC1IE^5"Q/L(K[9(YZE)"1M*Z@X<%%%RN8&;VB`NSGB0C/*M$1.>$XY7E
M?YK^O]=<Z:!IIIH&FFF@::::#J3X$*TA2JZQBQYT"<PY%F0Y30/QI,=X5!UA
M]ET2;<:<!5$P(514744W4=THSL&6;FNW,:398;W.RK6B%#?G8L/\9NQ$[B>G
MTB*JKY[I-=PJ.H[&_?MRR:_)@+@D!B)@8D!@2(0D)(J$)"2*)"2*J*BHJ*BJ
MBHJ:#7PP6S"#>L(9?NI[10A7A>$<<,2C^>[@0<?`6R(D-44D1$%54M9`+PO`
MI]2JG*<<<+\?P\JO*\*B\(O/GE4\ZOGU&])A@Y.W`VDA(#R.E876&0FQ!!<#
MEYZUQQM%1$<]1/6D4PH@FO>=>/<2QEQSH+ANYKF92#V26T)FP9<1?48F,#PX
MTYW=OIDJH;HMJ*$@."AH*IVZ#W$$4Y5>47^'E%7GRO*IY^5%%^./CGYT'SS\
MEQW<^>.41?GX\JJ(G*<)YYX5?&OOV)P*+YX02\(O!=R)P*?951`)57[\JOW3
M7*H"BJ>43CNY/RJ\*J=JIX7@E025/'TKW(GQR'6..Q*3L>:;=$E5>QYH'`14
M7N0A[A7@D\CS^G@NY%5-=IAED05IL&FVFD[1`$`4153X1M`05'PO<O'/*JJJ
M2^=?I43G@>%5.Q!($5/'<B+_`/M=I<DO'GA/CA-?E$1455(4^Z<^"1%7GM55
M\]J<\IX\]ORF@_)_4@\)PJKS]*<^45412^/""O"+Y7@?/PG'R+_604440A15
M^5\\JO*<HGCRB$/E$Y%?E=?7M14)%441$'MX+CD5+E?/"IRJ<]OPG'*JB\:Y
M4>].5+CM%>`X^>>$^E.![N$5./U[3X\^-!TW%$!(RY040B553X$14E7CZE)$
M1%\"O=SV\<\JFK,X=O/19GF628E"B6#+M._7A62)%3=Q2L&7Z?W\\YR3:]AF
MJ<BRE]O%;?=`K!E/<1Q<1475[B01'A.5X\JH\\FB\]P\)X^!3Z>4Y\?4/*KJ
MW&.6]3(R2^>@X;F=':7#L:3:W5UCDJOK;%^DB#7UY.SW+"0T[V0T]**#<8%>
M9^LD4E[D"P61=='2YB^ZY;)WFZE7!W""Y8Q^9"*KNW:2!=ODVTS46>3LP3HZ
MZR5UQF.['D2^R+*>;9E.MDAH.5_<JJ:J@J@+V<(JJ2$BJI(2IRB*JHO:@JOT
M\+YY\P7[B?@_Y%F/49=[@0MU:.NVLRK-Y.9VD*77VTK.:TK"S*WLZ6`K0+33
MFG92/,0K:3-9=9CN`;\0WFA%R<X61999:!2$&O3:`75^OM;1EEON7RIDK8\^
MHB<&I*2"BDJ('Y)LW'/2;0G#<<1MH>413==<%MH!7N`4)UQ1;#N-!%>U25!Y
MU+EM]C@XEA6-8ZG=WU=5&:D=ZDI>\=19,U5[G'51%EO/\!WD()P`+V"*)@;T
M];?NYCF3%Y.99.DQ*0Q.E^JA^G,LC;=<JX3;:"K;GHN",^1WKV]C8(0DCB"4
MD>@::::!IIIH&FFF@::::!IIIH&FFF@*J)\JB?UUQRGZI_BFHWOQ"-[-R]FH
M>V4C;O))./N7TS(V+3T6&'AE!"C078W<CP&@DT3AJ*HB*HJJ+^FHS%ZY.IKP
MO^<B>O/GA(,#[\KQ_P!AROA/[:#94Y3]4_Q33E/U3_%-:U:=<G4TJ_\`SDSE
M^_\`XG`\^>/_`+'^7\M<_P#3DZF^?_G)G(B\JG^@P%XXY3C_`,7_`.Y45?*?
MS#94TU8CICRR_P`YV&VURW*+!RUO[RC=F6=@Z(`<E_\`-)[(F0MB(#VM--MH
MB"G@$5>5Y5;[Z!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!KCE/
MU3_%-4YF,R57XED\^$Z3$N%CMY+BOAPILR8U7+?8=#N14[FW0`Q14XY%.?'A
M=<T>N7J;[`4MR)JJH"JJD&#Y51\K_P!@B>57G[)\<(B>-!LJ\I^J?XIIRGZI
M_BFM:M>N3J:X_P#G(G(GG_ZC!Y\KX\JQY_1..?MSKG_IR=32<_\`PDS_`(\*
ML"#PG'/'/[CQS]_"K_OT&RGRB_"HO]]<ZB+Z#>HS>'=W=6_HMP,NE7E5#Q"7
M81H3D>*TT,L)L!H'E5EI"4Q!QSM^H4437D5XU+IH&FFF@::::!IIIH&FFF@:
M:::!IIIH&FFF@:XY3]4_Q372M'G8U;/D,EVO,0I;S1<"7:XU'=<;+M)%%>#$
M5X)%%>.%1454UKHY%UL]2E?D-]!B[C3ABPK>RBQQ6'`(A98FR&VQ)583D@`!
M'X3PB>.?@-COE/U3_%-.4_5/\4UK6+UR]32)Q_G(G<\<JOLJ]?OQX_<<?U_O
M_=_TY>IKQ_\`"/.\_P#]%!_3^3/]^$_KQSH-E/E/U3_'7.H/NDKJJWUW'WUP
M_%,OSB9:4$]R9[R`Y%A-C(0(QJ(F0,H2B!?5R*@2&G*+X1=3@)Y1/Z)H.=--
M-`TTTT#3330----`TTTT'"HGE>.5X_I\?']_Y_;6)F\O3K"OYDO-L#BQZ[*'
MVU6]I6NV/790V*(J3`;!0CQ,BCJBJU,44:L@4XTQ!<-N2WEIKA4Y^/G_`'_R
M7^6@AX>8?BO/1Y3+T>3'DN1WX[[3C#T=]KZ767F7.TV7.Y$Y!0^0%`7A40OQ
MW^/'CDOE2(E\+YYY1/"^4^WS^G.I&]U]EZK<1O\`,XCHU&41F#;8GB*%'L@!
MLD8B6[0IW&V!*B,RV2&2P*^F7KLH+0X`Y+BM[AUH[49!7.U\]I54!)?5C2F3
M%"1Z%)1/2ELJJ$GJM$OIJBMN-@::#Q$+N[5+S\_2B<JJBB\(JIRGGY3[_'G7
MU$.[O7Y1$[A%5X54\*2<(J]XC_"OE$7GZ45%\?!%7O$D0B3N0>1Y1>$7@N.$
M5%-!3CA4145.%^%U9BE>W?#=C)0MX&.CA`4F/*R3,O*%C@R<S)$5ZF63&""[
MD;HMUZY.P\ZD&*TD1R(9D:+H+U^.[A%Y1>"Y053ROCM15^$\*B*O"+^G/*Z_
M"DJJJ\\B*B(JG"(J*BBBKW<IQRJHOA?'A$U:6)O_`+)6.XDK:6NW6P.9N;")
M^,_@S&203R5N7&^N1"<KQ<Y]_&#]Y(@@2SF10U..A"B)=SM;4`7@NXAYX551
M>?U(47^)/NG'T^4)55%70?-2X3A/E$^?LJ>/A$541?\`>//PGC7S)>>?//*K
M\^/G[<\)QQPJ\^4X1>-?0T`!7X1>4X7E5^Z\_P"/^WQQKKJ7A.>.U!5>5^55
M5^$3GY\^45?U^$5>0Y5.W^'XY5.4\]JJ1*G<G/"I\^>[QRG/VX]S%<3L\UR.
MOQVF;0ILYP$*2XVZY'A10X5^?-1D>\8C`@+AGP*HXC;`DA/HFO=P;;;+-PYH
MLT<!Q(+3J-S+B2AM5D3RSZPNR43TGY+;;@N-PF%<D."*$2"**IR*;?;98YMS
M7NQ:9IQZ=+1I;&XF$#DZ<;8IP"J(($>(#G<;,-E$;!"3O)QQ/4T'LX1AM1@F
M.U^/5#8^E%:!9,M66FI%C,4421/E>F(H3[Y?957TFT!D%[&QU5NFF@::::!I
MIIH&FFF@::::!IIIH&FG/'_N5?\`=KCE/Y_^J7_#01$_BLIS6;-?_F>6\_T]
MC6I^B_K_`.U-0UKS\)RGT\?R_LG">5^R^$XYX^-3)_BL_P#R7LTO'_\`$\MX
MYY3RD&M^/A47_P!WWU#;\<_KSRBISPJ_HOZ<JJ)X7[*B^/&@XY1>45>41>$3
ME.5X_G_/GPO/GC^O///*^$\*A<<\^%5?//G]>/CS^FN/OQQRO/E.?'QX54X5
M/NOQQROE4\II\(BEX\*B>/U3PJI_3[<JGQ_8-G+HV_\`W8]GO''_`(,N^/T_
MZXL]9,ZQEZ-U3_HQ[/\`RO\`X,N_"+_]\6?Z<_[]9,\I_/\`P7_AH.=---`T
MTTT#3330----`TTTT#3330----`TTTT#33E/UUQRG\__`%2_X:"E,]_\A\R_
M_2N1?_Z:;K4>#A&FT\*GI-^.>/D!X7S^O]N/Y^-;<&>*G[#YC\_^2N1?9?\`
M[FF_RUJ0-^6VN/\`[-M4^R)^[%/'/A%Y^$7E$\KSH/UYYX3Y_FJ_;PGCA?A/
MIY7A53GCQYTX7GRG'/\`BO/*IV\>?O\`U7Y1.573]/E?*_/]?GA/MS\+PO'\
MM%\\<+Q]T7^7CE?C_8O'^Q%T$DWX8:__``V9.GG_`,@YOSX^+&OX7_#E%^/Z
M>-3R:@;_``PU7_/7D_SQ^P4U5\\^/S&NX7X_HG\_'Z\:GCY3^?\`ZI?\-!SI
MKA%Y_7^Z*G^]$USH&FFF@::::!IIIH&FFF@::::!IIKCE/Y_X+_PT'FW7_R1
M:?\`Y=/_`/\`$>UJ4Y?Q^UN4_P#Z@M_GXX_,)'\^?[\>/G6VK<KS46GS_P#)
MT_[+_P#RCW\M:E.7^,NRCE%3_P`(;CGQX\V,GRJKX3QXX^>%_704^J\\_HO*
M<??Y1%\JJIX5>$3Q_+QQKA..?A?*(G/'*IQQ]E^53CGQQX\JGWT7QPB)QPJ^
M5YX1.%^_\T_JB??XUSSPOG[^$YY\JGZHG'**B_;^7*\\<!F%T(I_\9?!%X3_
M`+2<G*JJK_XJYQ\_;_G[<:V1Q^$_HG^[6MQT(^.I?!?O^\F_"JO_`-5<3S\_
MI\_;XYXULC"J<)\_"?ZI?\-!^M-<<I_/^Z*G^]-<Z!IIIH&FFF@::::!IIIH
M&FFF@:IW)L5H,OK':G(:UFQA.\*@.=S;K+@DAB[&DM$$B.Z)(B][+@=R)V.(
M;:D!5%KCE/CS_P"J7^_CC_G^::#"[<#IK8K84^]Q*Z<2'709=C*J+@G'G":@
MQRD&W#L61Y[G&FB'_3F3)"3_`+?M/AN-6GW,KW\AFS)F\.(?D4>QDL.8V_C#
MV.7;7<I!&BLWDZV<%Y^"[Z0N3&JY^,^\SV\-BXO$ZV9*G[(96B(O*XW>HGTD
MG*_E<K[\?X?K]M:EUX*%<W(JO@K6R[D7RJI[Q[QRJ*O'CCA.$X7CPB(F@P:V
M^_#BWKQKK`ILSLL]V^';G&-VPW'_`,YH[@49W=O5P\D/(FHS-`$URZ9RFS%1
MK)C,@$AL..R9*SGHJ(A;&KF8X@T#T@\GQUH&A==-2O*Q09:1",_X9*EVMBA<
MH@JJBB<#SX2);T655%[&_I4>WAL.4X14^P^$5%Y\_'Q]N-?M&VQX[6FA055!
M06QY3^)55%[>>>?YKY\I_()<\$MZ+='+X6#X9D-+<9!/C/SF6F99E#;BQ&WW
M'5?G,,O,,.*+)=C)*L@_H7TQ`T),\,,Z7\?KC;FYE//(I"`'_5L47X-4V:JI
MF+CB.>]F!W(/:JG%;0>X2:-"Y6(S\.I%_P"DA3+RJ_\`4MVGZ^%K9J\\I\HO
MSY^/[ZV'.4_1?_57_AH.E7UL"JB,P:V%%KX<<4!B)#8:C1V1X3Z6V61!L4\?
M*#ROW5==[3GG]?[HJ?[]-`TTTT#3330----`TTTT#3330----!16X&$P-P,9
MF8Y/L+>J21^]BV=%/?KK*OF@TZVQ+8>9(4<]'U3(H[Z&P\GTF*+VD,$O49A'
M5-T\V3C]GN#EM_ADMWMJ,OK[*:44D(C0(MJ"HA5MB`\=[1CZ#R&V33A"BHNP
M?KQ,BQZERJGG4&154*ZI;..Y%GUM@R$B-(:=115#!Q"X)%7EMP.UQHD1QLQ(
M470:H.3;AYMFS,2/EF3V]^S`>=D0V[24Y)2,\\`LNFTCJ)Z9&V*-N(//*I]7
M)<*-'>4_WJGE$\_S_3[DO]^.=26]5?0/>;=+89YM&Q,R'!Q]2598X2E*O<;;
M54,SBH`=]G6-_7P0I[J,VHBX)B/>4:7GDO"IP2HG/<B\\\>4(45%Y5442%.T
MDX445%70.?MYX1/T_7S\(GDD3X1$7]%T7A45%X1%^WW7GY7E$Y14^4^WSSQS
MKE/]J(OCQRJ(OCS]U^4X3[JG\DU[6,XSD&8W==C>+5,V[N[60$:%7P6#>>>=
M+[J@(7IMBB*3KQ\-M@!D:^/(5C5;Q;JU$&#34V<Y-"@0V6HD"N@SGV6&&47]
MVS'887PI*J\`VB=YD1*1&:JLIG2QTZ;\YRL#.MZ,_P`TH\/=%N768B-S-B7M
M^V7!`[9&"@Y55C@]J(VA>\D@I*VC(D#VKF=*/0?1;8A7YSNI&A9'GO[N57TW
MTRJ+&"Y5P"4'&T"PM1^A3=)%C1S0Q;1PB[ADE1$3X3X3C^WZ?T_3]/MH/E'C
MM18[$9E"1J.RTPTA&;A(VRV+8(3CI&XX2`*(IN&1FO)&1$JJOVTTT#3330--
M--`TTTT#3330----`TTTT#3330<*G/\`S^BHJ?[O]NHV.J?IKW=-+'/-A\^R
MIHP"5/NL!=O9KGJJ/J2'I&,O.F;GJDJD2U;[J]Q)V135%!EN2C7"I\\?/''/
MW_E^GW_FF@U59^]&]421,K;+/<PCR&#D0IT&7/E`ZR2B;#\>0PXO(EY<:<`P
M5/*JB*GS9]%\HB<<_"HBJJ>/**BKRJ(JK]^?"IQ_+8IZH>BO#-]HTS)<?;C8
MIN6#7<S<-,H%;>J#1",2^C-@O)F2-=EBS^_;4>'A=0B((#=P=N<RVKR:9B6<
MTDJDN89D)-/H1L264(D&7`E<(W,B.(G<V\VJ"H\JJ\*/(42B>?/*^%^5YX_J
MGQY1?'''CQQ\Z<JJ+YX\HG*)QS]OY^%^RI]^?'C3E>/CGCCCY3X7S^G'">>?
M"?V1=.41514_5>4X^.>//QPHJJ>5)$\^.5YT%2XSF>485)DS<6OK*@DRV48E
M2*Y\H[CL=#0Q9-P%$U3U.%X%5%41%45X3C*C8R#U2=0.1A2X;G65QZV*XW^=
MY/.LIK5-31S+DC>='E),GM;+T(K/<ZZZB-$(B9$-0=+'1)EF^+T;*\Q25BFV
MK3HDDI6R9N<D0"X)BF:=;[6HRJA([9.(K0IRC*.*J:GJP/`,2VUQN#B>%TD.
MBI*]L09BQ6P0G7!`0.3*>X]67*>[45V0^JN&O")VBB"@4[M'M<QM9C+-.>07
MV57$AMAR[R"_L),R383&Q).YAATR9@Q6U<<%EA@!)045?<=,44;JZ::!IIIH
M&FFF@::::!IIIH&FFF@:P3ZH^F[<?,FI>9;);@9#C>5]QRK'&';V<W27JBVJ
ME^7*1N#5V#I"`^GR,)WE4$&BX$L[-<*B+X5.4^>%T&K-?[L;^8Q;3L?R+,\X
MJ+BN?<B3ZV?+EL2F'0Y$P=:,E7M+RHJB$!A\$H\ZLK(DOS)#\J2Z3TF2\X_)
M>)$[WGW34W'"^5[G#(C)47A"4N/")QLL]2'2?@'4'5.R9<=JASJ)%,*;+H3(
M@_WC]342Y;`>;&`1*0*A*DAA#4FB)!1M=??>#9;/]C\I?Q?.J@X;G<1UMJPB
MN5%S#0R%J76RTX;<1SA"<951?9<4FW&TX[T"U'*\ISSQY^?U3YY^R)^G'RJ(
MOWUQRG"(BK_)/CRG"\<\_I\_W^Z>>45%Y).5Y3^O/'Z>$_DB+X5>%_GR5%5%
M1$^WRJ<?'*>51%7X^/'''/SY30>S09'>XK9MV^/6<NFM&6W`:G07/1E--NH@
MN^FZB(0\JB(2HJ$G;_$(D7&1>U5SU/[U9,QBF`Y=F5E-<5LILPK.8Q65,4G`
M$YEI/12;CQ@4Q54\N.HO:V!=R<]WIIZ2,\Z@[9B:VT[C^WL&6VEQE<MI1]PU
MQWN1:%A4_P!/G&"H"FB^V9Y$B<X+N'8$VEV<P/97&HV+X+3-0(H@"SK!P1=M
M;>4*+W2[.;VH;[I*I*+?T,LH78T")H*0V#V1F[24`KDN:Y!GF9SXH,W-W:V4
MQZO`?4!\HE17.N>DQ&!X45)3K:S'D3@C!M>Q<A$\?S_KIIH&FFF@::::!III
MH&FFF@::::!J/[JDZ;MT<C2=G&Q>>Y%37JH_*M\+<O9X5UVZJDZ3]*ZZXZD"
M>?)I[-42(X2B+/I\"WJ0'30:KESN_OI23Y]%?9OFM;90''HEC66$Z6Q(9-$5
MIYF3'=55^$)%0D4.U50%/DN;-O/.ONNOON*;SYDZX9^2)UXE<<,T7_6,R(E7
MX^KRGC6R/U,](."]0-<]9MMM8UN##C&E7D\-EL0FN`ADU"OV&P0IT5Q25OW"
M\R(PDIBKJ"C2Z_\`NKM+G6S.52L1SRG<K+%DW/:20Y<KK:(!*@3JN7P@2(YB
MH&';]0(2@X`$/&@MJOW^?*KPG//\OY>//E%\?/CC15_1?//'^WCXYXYY^_'G
M[<?*<KS\*GZ?S\_/Z+X_GX_W*G'GDN/Y?''/QYX153E?CPJIX^Z?.@]['<JR
M/$)QVF,7,^CL"8-@IM>\4:1Z!$BFV+H_6/=QV^"1>TE'RI+K)79Z7U0[XY.U
MB^"YEE\MP?2=LK:1:S`J*2&3B`4NSF(I-AQSR+:*KKQ+V"'=KU>F3HZSK?Z=
M%NYP/XOMQ'D"EAD4EEP)-H#9?OX./LF(^Z>)$]-R42#%C*2J1D8H"S][7;48
M/L]BT3$<%I6:FLC"BO/+VNV-E(Y)2F6D[M%V7*<(B)2->QON461`/&@I'8K9
MMW:3'0BW.7Y!G.6S([87N075C,D,/.`9.HQ5P'G%8A0V3(D;+L64Z*<O.<(C
M8WUTTT#3330----`TTTT#3330----`TTTT#3330<$B$BBJ(J*BHJ*G**B^%1
M47PJ*GA47Q^NHQ>JWH%H\\9M<[V?C,T&:\/39V+LJU&I<C<4O5?6$/8@5MJZ
M/J=B(J19!J("+)K]4G>G"?IH-6_;/IKW:W0SZ5M_58U/JK*FF#&R>;;Q78E?
MBX$I*3M@^X"(I=@&<9AM''92(*!SQPL^W3MTM;?]/-+V4K'YQELY@`N\ML&F
MCG2#[.'(M<B`GY?6H2EVL-+ZCJ+W/N%RC89)-0XC#TF0Q%C,R)A-E+?:8:;>
ME$T"MM%)=`4-\F@50;5TB4`51'A%XUV-`TTTT#3330----`TTTT#3330----
M`TTTT#3330----`TTTT#5DM[M@=O=^\:/'\UKE20PA.4]_`1IBZII7:J"[%E
M$V??'(NWW$)Y#COBBIV@?#B7MTT&L?OYTJ;E[$Y,S63*Z3DF.V\P(N,Y-51'
MGX]FZ^9"Q`D--"X46U0D1M8QIR:JA-=S9BB9Y=*7X?+;"5FX6^D0RD@XW,IM
MOB-/0`4;$V)63$'U..HX2FW6MF@AVB3R^>S4NLF'$F"T,N+'DBP^U*9&0PT\
MC,E@NYB0TC@DC;[)>6G@[7&U7D"%?.NSH.M%B1X,>/$AL,Q8L5EN/'C1VP98
M889$0:98:;$6VFFP%!``$1$41$3].SIIH&FFF@::::!IIIH&FFF@::::!III
MH&FFF@:MON?M1@^\&,3,3SJECVU=)%58?41"PK)'"H$RKF=A.PY`<\]P$H.)
MRVZ!@JIJY&F@UO>IOHXSK8*>_:UXRLIVYER5&NR&,RKDJO\`5=X9@7D9D5*/
M)X,`;D`*QI)(J`7(J(W[Z4N@&SS<*[/]YX\JFQ4_1F5.(=RQ[6_CDB.M2+,T
M%':^NDCY5E.V2^T2(V0"OJ#-_+AQ)\=R+.BQYD5U$1V-+8:D1W40D)$<9>$V
MS1"1"1"%>"1%3RB:^XB(H(B*"@B@BB(B(@HG""B(B(B(B<(B(B)]DT'F4M)4
MX[5PJ6CKH=355T<(T&O@,-QHD5AM$06VFFQ$41$3R2HIFO)&1$JJOJ:::!II
MIH&FFF@::::!IIIH&FFF@::::!IIIH&K4[N;,8!O7C#^+YW3,SXR\N0;%H6V
MK:HD\\^YK9R@;D<E\HXWPK+PJJ.`J]I#=;30:U?4CT@Y_L'=$^RU+RK!K"8K
M5'DL.*;CC:N.J$>ON([*&K%BO((JCRW)\^APOU:RFZ4_P^Y>0#6;@[WQYE=4
M$4:PIL&0T:F6C2]KK3N0&@^K"A&B"OL0[9#XF7<3*<.%-++APYS*QYL6-,8(
M@-693#4AI3:)#:-6W@,%)LT0VR454#1"%45.==G0="LJZ^F@Q:NJAQJZM@L!
M&AP8;(1XL5AOP#3++2"`"*?H/*KR2JJJO/?TTT#3330----`TTTT#33308:=
M(_79L7UG;29SO1M@>6XYA^W6>9S@&6!N52PL7M:Z9@;;,V?D0QXEQ=PY.'W%
M+(CY#CU^Q8&U/J72]PS"L(D^!%J'I3ZN,(ZPMK\#WEVOPC="HVXW%QO)<BQ_
M(,^H\=QQT#Q;<;(]MYM#:4<;++?(:Z_E3L9F9!!CNU10"QN5`<F64.\<DT46
M"/I%Z=>I#;[IOZ:]F)6U>[V.T'6=5;A;`]2,(\*MJU_9:IVXZKMYMTCSC<%B
MRCQ7\.H]Z^EW*]S-GXF1RP!RRR&9LK#A"Z,N(XMP-O-C]Y:/%<Q8E[&[R?LV
MWMUOY%R3#,7I+[%[W)MM9_XNFYNY68[;8FX3U&4FYSSINF6<W&<<@3F;'+<.
MNX<>D%YB_@.N!L>1YL.9'&7$E1Y,4N_MDQWFWV#](S;<['FB-L_3<;<;<[27
ML,#`N"$D3\_F,#U(;7O(OJ6`&[`!)#*G-;:;%YPX@H?=*!MDQ=<..C@MM$+A
MJ($A+"9N'LSM!N[03\8V'Z5]U<&V6S#JHZ'WMQ(#FVFX6RNWVY%1C.>2G-S)
M=-L'?U>(7V)XK088Q04&\&<2L#Q;'-RZF0SC]C(R.%B-A+#H[Y[00:ZXZM\,
M>Z>\YO.H/+9>W]9^'ON5ANTF476*[68E0[2;=XYM#58#NQCE)8X5TSU6QV]=
M3G6:9_5WUU@+,VKG.Y&W&RZNR"'4($X:3892S@#*CE-;8"2<-'FEE!&<,FVY
M!QT/UA8-P";!X@1HS%0$U)%1`3H;DIR"$J.4UEEJ0]$%YLI++#Q&++SK`DKK
M;+Q-."TZ8"TZ0&+9D0JB0FX[@$S&.M([JFV8S;,LUM^K/(,DNKC+]@-P\"S3
M!L*R+%KBLR+="@ZWL/NRVIW2V`2F2NBXET[9ZQ*OQKIE=@4R(SD^$4@Q,=NA
M7#Z')=C_`,-=_:K87=O"^I^CN\!SC>;>[*\#S-@G-FG:6]=W1EYIU)65$6'[
MQ89O!C`4..;=[<56<9?8TTZUP9PL:Q5S:JRD8D$^>S.[^);Z;88!NQAGYC'Q
M[<;"L;SVEK[UF)"R&%1Y57C95*75;#G6+4&8;!$)MMS),<G6W1CR9`MD>KDQ
MYD27Z_M9+$GVTAR))]!UM[V\IGM]6,_Z9%Z4AKN'U([G:\WW#W@/<G,`.*=(
M^X>W71/TK2NGS:>YVTZLYW2?O/A.3YE&H[.BW!BYGF'3=D]M5T^Z5[+>K;(S
M;W7J,4:Q:-FUBS&Q7)X./5]#)QUA@!;MA?[$Y%E^W&[=)L[M]N1B^*7FQVV&
M`99B^SO1AO1T4L2LAD]2^REC5C<IG.[F3YUN+O'ME@=?N8^6X>"8W9Q,?QV]
MR27E.ZEE*EX[#,-DDK*O$8QE-BB$Q_VL4UD,H,F5RXGMHY*?:_(Y9=1([2F\
MJM.(@?NS[?V<Z&W*9@G*CA,D-./,1#>;&2\RRH(\\RP1(ZZTTK@(ZXV!`TIB
MCA"I#S!IU6[#U^)[M7>-!M#1N['PNG#&L+Z=L6Q[H;W4ZGL?Q6[CW>XLG<'#
M]MF]H=T=OJC8;=3(K6?A%[%SK(*W&`N(T/&I<+=6N#$+R)5>'E.V>78UOW6Y
M#>;4[H;P[RNV?1C*KAW"V)S.9=7]MAM!MKCV69]M#UJ[09788ETZ4&*HUFMW
MO#L]NA97&-95ED'<!H7;["MY6)5V$]4J5&A,.RI;[,6,P!.O2)#K;##+8)R3
MCKSI`VTV*>2-PQ`?NJ<IK\A,BN/N1FY#!R6F69#D<'0)]MB03@L/&RA*X#3Q
M,NBRZ0H#JMN(V1*!H.!_4ULK`WDZGNC6/F>W;VX.U>,AU'6>:5MO2R+[;INP
MG8!BU3B3>>U;[4C&K&/+DOV9X_69/'E0G+F(W.A1BLZN,_'CEQ#ITS?:+9#I
MNSO;[I\W&E;SL-]>%#N/'QX\MP/=3*\*?VLZ@8VSVW&4[DQ&_P!J<9QIZ?BV
MS%#L](LI#L3#':?;QO`X\63#I67!.&>5T//VV"8\Z'+60D65'DK$?.+*2.\V
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M[VG1)MQ!,5%!S8C<EJ$<E@9C[3K[,576TDO,L*V+SK3"DCKK3).M"ZXV!`T3
M@"X0J8HL6?0E@LRDW;W6R/"Z=[#=J9NW&!T1X_C/1MG_`$7[7V^?UMYDCC5G
M5[?;M[AY!FMSG.+X@<+&<JRVIPC&L:LZ9_%:B=DV99!C#L;&[`;W[8W\_)^H
M^C=V;W!R+K1S;J)Q/)NES?NGVMR^TJ</VWC3<`7;RWK>H*'CO[%[781M)2L9
MS"W+V^MLRQZPOS+*HPXSEKFY%>F0A+3M+OKBV\]YN]58A59`-;L[N38[46V4
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MD&$R6*`-A@9D4W!91]GUB051E76T>7O;)X?W7=W^6@(TX'R`D:<B*JGX?L8$
M5@Y4F9%8C-O)'<D/2&6F&WU?2,C)O&8M`ZL@A81HC0U?5&4%750-0C[7;-+T
MX8CT2;Q3]JMR(2U>\6_N6]3%Q2;=[@;C[KN7.Y&W.[6'8/DN;XOBE'DNY^2T
MU;(D8SA=*L*BN8N#8Y,QN*U$IL1B/3(%!8%CL63ENVV<]4G3KNWDFQF1;H_B
M/9=2[5Y/L?F6Z=W@V=[F]6EEDNU.ZNXW3WB]#F&:3*O,]D9\ZBP;+W,-OJ_;
M:??R*>T7%;3/F)$D-@!%14Y1>?\`N7[HJ?**GW1?*+X77.HK?PWMRL,Q;:#'
MMMY%#G^!3=R>IGK]+:S!\YA7MQ>T6)[>]2VY,UO',DOEDW\"AE4>+2ZQBGH;
M;(7I$&!$+&8;C\K')T>+*EH.%5$3E?U1/[DJ"G^U=8I].765LUU.[<;E[HX$
M]DE+CFT6Y^[.T^>Q\VJ(]);4N0[.VTROR.Q*+"L;>/)QRVKHS&4XO;1YCGYI
MC=E`DR(T"Q][60\JS151.//UMK_9#%5_P1.=:X.Q/3YOUAV'X+ME#VPW+I<=
MZX-Q=Z=MNH4AQ:YHVML,5VKZV-^=U)6XN<6$IIDL7B;[]*N1Y!L_A]TK;;N0
MW,W:=^*4J(W&]4)F.E7JUPGJ_P!I=KM[=L\'W1H\`W7Q;,,FIYVX5!08S:4#
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M2P\(M%J`FR2SKR<ALC.B$[8-./0&TDL*<UED0-UV(".=TIMH'`-UQA'`:`Q-
MPA$A5?H,V(<MR`,E@IK3+<AV(CS:R6V'3-MI]R.A*\#+IMN`V\8"VX8&($1"
MJ)!AOALM$I'^J/;ZJZ?\QL.H[(\@V\K>@+<?;[:#)',8VFP#'=O]M*#9VMP7
M>?'\;3`NG7%]B-Q:O/\`),^Q6VR;"1F4S]I/8K<OBYG7U<_V<&V\<Q3K'EV\
M+9W-\ES"TZL-V,HN\@SCI^W$PW.<"P3+,=SINRW'B=:>'7:;0;S=/\^`&/0=
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M,H3^,3(DI9"1I+#ZQ7SC2D9=;=6-);$#..^C9%Z,@`<;(V'.UT!,"($0A5?P
MY8P&@9<=FQ6PD21AL&Y(:`7I9.&R,1HB-$<E$ZVXT,8%)\G&S!&U("1-=C'M
ME<AOML-X*?;/`\]P\[#HVRC;_-J7;[HJWEZ3<CMLVNKO`F<9H\OSC.=X,SN]
MW]\,,-C/KJOW`VXJLJ<CR+?*[JTW8D1LDQN)<WCZIM@HN";R0<;C;24)]+]-
MTQU6%;$836]%FY_5GB>+[F+G>Y%INW4XSC.T6YV$O[/[FY_56^V$NIW.R.JB
MMWX5%B$/<K%[*KO&[H)QSFQ&Y+$-R2P$N4+IQHQNMC(D`P@J^;#!$CKP,(8*
M\30$+*$*NJ"$BKS*EQ8,=V7-D,1(K`*X_)DNML1V6Q_B<>>=(&FFQ_UC<,13
MQRO*ISKVY1M)G&*9QCMQENU6\&]6^3.W'1K#K8NZ.PV99+DV9YGMY1XE"MLE
MVBZTMCLVO*?I*O*"Z')+#>+&\\R2[Q6SS1C(<GBV=[@^X4RPLI$>NYMN<>QM
M;DFT[N>;?#FN5W5[E5EM'NAU)X9@645.(2XN!.Y7TX;2*F1[C?M%,N+=K';N
M[5<-V]NZIBWL`7(9V**(2!%)C@R,@WF@8-6D%TW`!HO6,&V>'")`7U3<;%K@
ME]0C`6^XC%%X;EQ7GY$5J0RY)B^E[J.#H&_&]<%<8]PT)*XQZP"1L^J(>J"*
M;?<**NH%>D3I[RC-\QZ?(V[6T6:UE7L-*_$<L,+H,_VHR/;;;'#[^RZI=D\O
MZ79L/;BSM<QQ*#4T&W<H\FV+IV,DR]K`(E?;1*"=6Y/BEU4X\Z&-K-Q*+<_I
MD>RS%,IQ_>?#:7/?^E-D<'HYW*VFO<BR2QP*ZK\T3?/JKS7>V\P/J/J\XW<D
MU.<8A-V\JMQ)5S>5U#E=+`V]Q&!<-UP3U2)4:*C927V8XO/,QFB>=;:%R1(-
M&F&`5PA0WGW"1MEH55QTU0&Q(EXUX%_DX4U;*GU]/:Y;)AVU%4RJ7&'*1VWC
MG=7%75O3'V[FYI8+$6CB6G[0W+;T]NP2B@S'*J!:V10*R=%_U4=.,;>+J-WU
MR7+-I9^XM/3_`(=EQCNV,NVQN?D&.0MV;'<'=2S[,.9=9D5;&ZT2/%Q653V=
M0V&9TL65$<IYD)NQ)7\9LMZ;<NPBNV)A;;[-9I6QLHZ=NCVUWS+&\4OSL<RW
M6PGKBZ1\OOKS=29'CE,R;=&GQ*;O!D=]?Y4[+RX:5W-[.VGG!:L7&@GW29%*
M4<%)#"S`9&0<3U6_<A',S:;D$QW>J+#C@&V#R@C1F!`)J8J*?A^P@QFY3TB9
M%8:@MH]-=>D,M-Q&5!7$>E&X8C&:5L2<]5]6V^Q%/N[4YU#ALIA&)56Y.(5^
M>],^\EYUE5?59NOE6:;ZUV#YGB<%,,M\QW!<J=R;/J5.LJL$S;9"QV=EX=BE
M'L3$S*YG$V-!@I;:5MAATV316NVYZ;(.U'3QT+V^XNQV:9-MJEWD><=9&%N;
M=Y3N7N/D6Z-M@]G`VCW#WFP.!2WVX&ZV+;7W+3F-L8N_2966$_F&W=W&QYC'
M-O1GT(3Q/S8<:,4V1*CL0P!'3E//-M1P:+M[7#?<(6A;7N'APC0%[AX5>X>>
MSSXY\_K\+S_AQS_;CG4..SW391[A[@[/_MKL=?M=-E/D'65E6SVT>YN(W,/%
M<&PS)+38"MP&OS/:[)F2K<?9O;B)NMG.U.W^<4T:PP;%[R'!@8WBUE0G3TER
MML-N<UB?AE9CM5D.*[OQ[B#BO4=@M1A^.M.,[K1,!@[K[GTN`TV&UN92&`LR
MB;8LXZQA./6L@8&28VU44#+AP+2,I!(U;96W`B5,VJI[7+F+7(ZC'C+%WJ*2
M-6W9V*5TN^L7K.[J8ZTN/EWR;Q*UZQN6X[3@5U/93!2(O?KLFQZW?<BU=Y3V
M,EH2-V-`M*^;(:$5[25QF+)>=!!)%$E(41"115>=02X+M_DLIFNK]O-E9T;%
M:WJQZ`,SG[@8!TS[U=)^,9A)QK<&];W)?<Z8-QI<UG"W=KL1J,3EYUNOB<*M
MQ?-H5_545J/YGMU(1FC\*Q.#O+C_`%6[S[([%YMT\]7>;]/N\NWO2KMLO2KN
MAL;(V@P-YH9$NPO]PKG:O;?;QSJ1WSM8-%?9"Z6XJKAK$#"\!Q/(V#QW-\PO
MPV'8TR),1Y8DEB2D=]V*^K#S;R,R6"[7H[JMD2-R&2X1Y@^UUI51'`%51%[.
MH3^ER1CFP^5[E;Y+09#MKL-MYTV"&Y=7B'0[NSTJ8H>0U.65]M3O9-BNXNYN
M<9SN[NMMWBD/*X5GF6&8?:50T&03&<EW(R2R*DA1)L-!B?N9U6Q\$WH:V%Q;
M8_>?>?<`-JXV\=HQMJ>SM?54F&SLSL,$KRFV.Z^[VV*2K:=?5<]&JZG9LU9A
M1RES'HH$`E<C97?C!-]<-M<OQ0KBG/%\JR7`<]Q3,:U,?R_;G/\`#901,IPS
M-*HI,N+7V]0;T66W,@6-GCU[1V-1E&,7=WB]W47$W"C<C,XVS?XC,O<K-L0W
M=DX%DW15B^"T^58#L9O1NY2O9C3;_P":Y#88W,E[38#FXU-NS26]=:!#MA@N
M2H4E'XB/BV[Z>,E3T^99OWU"X%NINSL=FT+9_>GK)W[WV+;+-::W9A0,`Q'H
MNVOZ?=I;/?C"'8S,.C/<?*=J5W.K-NL_8.576ECA,?)*F#FE',J:X)U%D1T'
MN5]E!5[VZ$KK:(LA7/11CGNX]97?W?I<^IZGT=O?XU^`FQ')+T,),<Y<<&79
M$87FRD,-R%-([CS*$KK3;ZMN(P;@B+RMGZ2GVEQ#)F%SF[;M1L'7;+[\V^=Q
M_P`4;$]UKBR@[4YJFW53LC/ZH8F\([KGNRY6#MM9XHQB<F-"GU%-E,_,:VW*
M97V>+0HU/<2X.*3M7AV,4'1G47>RNYL?JY3\0O9QK?+?J-AV445/F\RPWTN9
M63YO<]0<F#"PW?7;/<BNKJMW!ML<8S7/YN'P2QFMGXCB0[2W@8F&QS)MG8]W
M5TXT]K)8LJZYGNWL=*U::J<J7JAIJNLO6LF;7W]R-JZ]4I7U4^&K5/:_F4RM
M=_+6K'O19T.='27!DQYD4O40)$1YJ2PXK1DVXC;S)FT:@X!MF@FJ@8D!<$*H
MD>?7/M_D^>MNP:?&=U[^HG])75MB=L[LZS"_;AN7E5KTZE`J<5EW+T3'7,NN
M*NER1^CQRZFQF\QA5-[CK'JE-<#7F]`-,M)8;YQ*7;&%BN%2CVQGU>X&.;#;
MN])&&;DY86/Y!5Y9'INEO=BPE.8+;X;656(1LCS_`!2-`H=R7+NMKI+3EY@5
MF0!F9M5O5AN\#68N8N-K$/"-S]R]IK2->1HD&5+R3:C(UQ?*IM2Q'GS2F4/Y
MEZ:P+`O0==COL'+B0GG18U=,)L1R4]""2P<R.VT\_%%YLI#++ZN"PZZPA*ZT
MT\33HLN.`(.JV:-D2@7$)&/],4NFA9ANS7[,7<#?"5^+T&=P<^:Q.T8W%;V8
MNNJ'&L?R:WJ[\8HWD;:&ZV:E9%^>QX<@,)M,5L+RVGQW@G3IIV]Q_;&PB83@
M>*Q=@=VXO7#C%IOI:]1F]B[5YPQ'R^%9;<;N0LSN[+?9RDBXIO-B.]$V7A=9
MM#MWCF5938X[9V&"/-X;AI;73PQ45@GS.TK6QDDY/A@,)]J+,(Y+(C%DO^CZ
M$>21&B1WW_<Q_19>4''?79],2]9ON^K\V)&<C-2)+##DQWV\1MYUMHY+_IF]
MZ$<'"$WW_2:<=]%H3<1MLW%%`$B2$79_H1VQ:RCICILJZ;HC^(!^'!-A;H5>
M1XA8R,<R#?F%)V>JZ6PW7A6+15V5[UU5-D.ZK%!?YHU8Y]41[O-W*NPC%)L'
M`MX&W4B-MFTQU0=/>\V].Y.4]#73;B?3?*J]I]P<ZRW"L_J=GQ@9S@#&?0Z6
MU_Z/^];>][,+.+K<S.KC`2"/*QFWF9R]_F_LF<="?YR9$9D1XKLEAN5+]7VD
M<WFP?E>@"./^V:(D<?\`1;(3>](31H"0W.T51='9D5E^/%=D,-29?J^UCN.M
M@])]`$<?]NT1(X_Z+:HX]Z0GZ0*AN=HJBKK?]4&+1,4V&_$,3JDV=W/WEZG9
M/3<P[L_O=@^&93E,6DCXYT?XM`>H<!W[QZ+)Q7I9O,%WTKMR]P<O?S#(]L)%
MS'S6KSP2RN!?PZ^)VL_VEW9NLLW9:R/&LB>W&S"IZ>_^BMG%;T5[G;VY]BV,
MUNR.T5=2_P":#J*B;QXAMATW7&W>]<#<?+LJJ]RXV!1H=O8R\QREW-\8OH=>
MT&QN4N*$AJ(4AD93X.NLQE<!'W6F%;%]UIE21QQIDG6A><`2!HG6Q<(5,47\
MC-AE+<@C*CE-:9;DNQ$>;62W'=,P:?<80O6!APVS!MX@1IPP,`,B$D2%].F=
MV/1;R[Q)L]D3F_$?\4#$,\PK.CQV]E;D0=JQZIMGZ&]GX9:FV=W!VIL-FYF?
M?G]32.LX/;8I99=9VL&2S-M99X]85LUU#OYC`K68]EC75[$WMWVR#(MU*CHT
MW$H\@?K;8]VTQR\SCK4R7==O:+-MC,IQ>;MS05&*8W0Y7D%/50\(H,=VFQO*
M<!GRL4#8D"?"<66(2XQ%`/TYPB^TJPS]$)"!+1#58QJPX#R`_P"F:LF+O;Z9
M(2_8GFA/TR<!'/3)[TU,>_TA(1)SLY[O3$B%"/CL%51").4U`+1[.,9/MU68
M9T^]-.[.V.ZL/HHZB-O>I.URO;K*=L1S+<7*MJ(U3C6$9IFF65E12=16Y=YO
M9)L<TH]R\;R+<*MIX<?*;]S-8,//X:7ON=2%C=]5&;99<8ILKU<Q=KJSHE+%
M;[)6=B<KQ"_D9M:=3NPV67N`0]L-VZO%+7=!<4Q#"[*]W.V[A5<BNW=V\?R?
M;;!+G(LAL+"#`"9[*-T<6Q.PVS@3W9,Q-U\RDX1C%A5I#EUC5I%P7--PG9=I
M-*:RW'J5HL$NFAF1$G&MBY`CJP++S\F-<%7FD-IM76T<>$S:;4Q0W1;05<)L
M%7N-`0P4U%%04(>Y4[DYA4V>VJ',2QW%&]B1A;/6G578.9->8_LAO!TY[>;B
MXKFO0SO'@6XN31NFO=*RL;;96C&\OH&`WMS3'68KN'EEBWDD42R6;929%?\`
MX?P9_N9N;F.1;KQ[EZZZ)L2?Z!J>\GR&EILYSG&;V%D^[^[N/UQ-DZTSGN&U
M?3PP=C[AYQNR@911/.-RH$^,T$N&J#W3W$H=H=L]Q-U\J:LGL8VRP7+]PLB9
MIXS4RV=HL*QZRR:X;JXC\F&Q*L7*ZKDA!C/2XK3\HFFG)#`&3H5YK&OK,Q^]
MRSI"ZJ,6QBGLLAR3).G#?.@Q^AIH;]C;W=Y<[6Y76U-15U\4'),ZQLK"3'A0
M8<=MQ^5*?:89`G'!%0MSBG6[C]G/VA;W%V/WUV*H-]Y^.4>UF<;F0MI[7"\B
MRO,J,LAQ##K&XVCW;W1?PO(,I@-N1\>3.H&-T]SD"1\1K[A_+;&KI)V:23(J
MO)'22QZZB!(SZS:/*+@NF!(TI>IVF#+Q"O;P0M.$G*-FHQ`O9_8;_P"TO1ML
M!M9M5O1*R/']S.CG/=U<HW'V'WCV=PO:7$>F_,-MMVLPEVN2[NX+A,"[RF\F
M8$WM[B>+8<YD-[+O,A6SG0X&,5%S<1+;[1[0/=.V%]*6^=QL]N3'M(O4QU/9
M5U'V]#MSG.X.[GL-P8/49AVV.193C&.TU[N9DF$8TS?XGC>-0Z>FNX^#XA<4
MLBLJ86+!8V44)PG["#%8=E2)D5B,PYZ3\AZ0RTPR[Z@L^F\\X8M-'ZI@UV.&
M)*X8MHGJ$(KVT5%3E/\`V_T5%\HJ?=%\I]]0$87C]?8Y9C&X/4WTX;NY%L5D
M/4C^(3F-;M?E^P^:[I75)E.:;DX">P^]V8;`XW2YAF4W%K+;*OW*HL;OG,&N
M&\!MMRJ)C(8F-W%ZDJHS"_"P2.FR6](UN+9GA..L]9G5K$Q+#\_GR++)\9Q.
MOW:LZ^AHY:R+"U=JHE;!B!$JL0<GO2<#JFHF!SV8-EC<RMAAG7M%NOBV].W&
M!;G8DEA&I-P\)QG/J:LO&H</(H5#EM<%E4+<UL.=8-0I)L&0."U+E1E?:>;C
MRI"-J6JKILA;LZ2BN+"NGXN_>QH3H461N53-S`F365>&GFI5VEM5NVK':;;K
M%7:63!FVXL63):%7-0(](&TL/&<3_#QQ'`.FC>?9OJEVTO*2QZFL[S?:W,<?
MEQMMAV]RZ#NC6[C[]6U`N'[L4FXURYAC."[=T^;9'<4EJUB<[]F<03;.VBX[
M5.'])7[=[>;PS-VMC+S),HIOPS.EW!=LF\RQ:\ES,?W-HL3ZEK'(H>W<.<TB
MX_NQ2Y))P4K.YQ=J#GE5,7$XZV,54JV]!--N?N5C6TN`YKN)E3DDZ;!<+S#.
M[2#6#%D7<^EPC';#)[QJD@2I<)NPL!K*Y]6(ZR6&E>-D9$B,T:O#[6.993Y1
M3XY<U[RLMY3C];DM5`G$PQ:%5V<*).:==A@^\7+#<UAJ63!OL,2"5M7R^DBU
M_P#?W;4LPVAZRJ/?SIFW]WNZC-W.FC$(?2_D5+MAGF9Y*D+_`*)6,TIX)@N[
M51`?I.G;.<>ZBF-SLESV#E.9[<V&1V.41\B1J_BW,.HCUW.VVM\9ZC:_(!V5
MS?.=Q96>]']E05&5=/.XS,Z'!QW!]I,0RO-]E.M';ZUB8YLEMA@=1'S:PS_I
M^WACI&R3)JG<JADTRXWO15,V03Q2I<6"P<F;)8B1FD179$EUMAAM%(017'G2
M!IM%,A!%,A13(115(D1:!E[HXQ!W)C[72UG1K^3@\G/PG/MQ6*(::-E-7B'M
M7)[TQMX+5^XMX8Q8GM%;?94U&1Z_8PYAKU>T-2_O5T]9/O1MAE>\/2[1XYO#
M`RK$L>VRR?>RBQO>NU7`7=J<_P`]V?PVBRW(<MHXN(5VZV)4%PUB&15V$99E
M=;8SX]:Y90[VLM-MITO[4[GY[LJN8=,655.R^+],>ZN/87MAOO73LKKL.BY5
MOC6/4%1?T>1S\AJZG(RP%A)N'8I=O/9-M5B%G(PZ$U2.0+."P$L#\V)%6.,F
M2Q'*6^,6*+[K;)2))@9A&81PA5Z00-F0L-H3Q"!D(*@$J'9D5AZ/'>D,M/RR
M<"*RXZ`.R3:;)YT([9$AOFVR).N"R)D#0JX:""*2:SD+:S>^1@>U7_2(P?+L
ME9D=`FP>`[4P,ZZ,-ZNJW-\5W.HZ+-J_=S%ZB?B&YF"O[$;[7.2%MW>-;B;A
M,TCUK&J,.F)NI6LX1?U]->K<;I$R[)]K.M#*<XVZW,SO?_\`,>B^IVXW%MJZ
MRD[I-RL*V2Z9J_/LKVDN<8M+L,4OI&5M9X.X=YM-D+L.SMZZX@6EW=U]4):"
M=NPR8(K^.-5U1:Y''O\`('J"18T+E*_`QI(]7<6#]QD#DZXKWDJFI=0-"Z-*
MQ=6S5U9US3E4$`;*PKO>:F1'GY$9J2PY)B(RLJ.#K9OQDD`KC"R&A)7&$?`2
M-E71!'0$B;[A15U#VNPMYMWU:5M+M/M+9X5LM4]4FQ.=4D##L.FU&V%*^[T4
M]46"YEE\"!4Q8^.5\(<B';6CR^=!;BQI-Z]C[-J9W5FT[)HC8'&*+$L2VG2B
MZ.]_9W6YM]LWO`/4#GR5.7[,/Y9NJYMG<MYBN<=1EVS7X9U`M;[[PQZN7M5)
MQW(MSF,3?M:'<MB#AT#"'8\4):-X]Z\+V0VPSS=G*ULK/&]N8`V&21,89A6M
MXT)2H,1(K$%^P@,>^[[".Y[:7,B'Z"DYS_"A=[;W=G%]R[;<ZEH&;6/-VGW(
ML=K\D&VC18H2\@J\6PW+I4ND]";+<FTJ5N=4K`39#<)];`)L<X8-M,/R=;[-
M=L\PGQ+>MV;V!S6IQ/,^A?=[;K)ZO;[HHWSV:9D[SUFX_37F>&X?N1ENY%O:
M9OO1GU755F\<^CW+R##J>HG3967A$S2SRK,96,%EWO0SN5TT7>]W6G085ED_
M(=N.LO<+%8>'#`GPG-X=J^IG97IVVGQ6MH8Y157((`]3U-LQ:Q+!CUX4)O&<
MR1HO6;EJV2>EG/I.<DB.H(XC[*MJZK"&CK:@KZ/+'5E"0NU74?165;Y[T=16
M^WO11T*0P/J<NMIZ3C;3O[QM/3-U01L7.23L(_4!1$N"-"'L$E(47!;(>E_)
M*[H+?Z=\7NE7=2AVPA6E3EE0^_6!=]0^.6$;=,,W-Q\S=C!E>^5<YDUHA&BH
MS<3&T4!5.,`=CMI-^LRWSV^S7)]N]S<(Q#K8W`QCKEWV2]K<DJI.UF2]-.3V
M_P#FCV?S.+8HR&&95>86_P!(E'*Q*:Q'D7:[,;JR%8]2'-02I3LFZM=KL)A6
M368Q<KQO-:?:H]Z+;:Z;65DK.J_``S-K`EM7ORB[LL1==+(Y#$88L7+)#BM.
MB_SVBX(9+,3(TI'"C/M2!9??BNDP8OBU)C.$S(8<)I30'F70)MUDU%QHT47`
M$D5-:T%5TTYD]MYAT'*MB-Q1S_+_`,-#-MG8V11-L<M'-*W(8748=]=87+SB
MJHSM\#R)[![URTH(5K<45A;1'9IXM[V5"F-L6D_%AZ1-VL?ZC<0C]'>Q6\6/
M;<2MEL8DY''Z;L>W!H,,FYY'S'<"IF6%]'VU.OIIV:.8E68=%L[2R;>OYE1$
MH5L)3[+<,D%MW;O;!MA\?\\KKQ,AR3'<2JI%YE5[38Y21"9"7;W]I`IJJ,4E
M\(\<9%A9R(L)DGY#K;#(NO`KKS@--H1D(K[>H]^K7&D;WSZ?-SMP]G,JW[V#
MPS#=[*"\P[$L`<W;E83N]E[VVA[>;HS]JH35C;Y7%:PVAW2VZCWE/CU]8X1*
MSM'G(D.CR.]NJL,Y[O+,6QF'!L,BR.AH8%I/@U=;.NKFMJHEA9V9=E;70I5A
M*CL3)U@:]L&''<=D2U\1VG.432VRK%Z*560KO(:*HFW5E"IJB):6]=7RK6WL
M!?.OJJZ/,DL/3[.:,62<.OBMO3)(QWRCLN(TYVP_O[=4&&W.U.7[G]$6=Y'T
M_N=-V2[<;7=/%1A#'4?8[#9+;;EY7D-SC5W@[J6]=ACF\FU5C@.+A(KW9.![
M8IALO:BXRVBQ"OI;"WL>UT2;ASMC.JB/NCLQ9Y;O1'_"[V`V@VPMYG.9Y!`W
M.Q6KZJ;O]C]NLP]U*<E;C;?V>0;854G.,<F,9!*O:O&;>)?R/1J9;03-;C]0
MN`[=UV,V?N"R]G(][]NMA70PZPHK9S'\WW&RNOQ*(&0HMHR%>U0S;*/+R&&I
M'=0H/)M5K[JMM'V<5MMN<!VSV]JMEJ.AN]MZZTP_;7%:W;W(<.;QO&Z-VXBX
MMZL"98Y%"JI-;B+:F<VEIYUEDDEN&[6TE1:W"LU[L1O5_P!'[K&37E%M+TJR
M\RVD=9_#&N\KVZV[K*7%*G/X>R/5ONEDVZ420^[-I:J_R'&=J)-=+R2#<2TF
M9AC<BNPVWG2JZ\1MGWW]IKO-=RLHW%V2Z<MP-I-FKSJ#_#HG_LK=;<.;62\M
MSC9W?>VR#>'?!C:.8%;=8A18]M=/P+"+G++K'J"=F@8.LIN)846)45U9A,^Q
MEV+2KQ<7CY'0OY*-:=P>/,W-8]>!4MRRKW+,ZEN4=@E<W/`X+DY8WM!F`48G
MD>%03Z0<GQJSN;C'JV_I9]_CZ0ROJ2%:P)=Q2#/;5^`MO61Y+DZL&:TBNP_?
M1XZ26T4V/4#E=0W[?=+&0X;AG3AE^-;,.XOO*Q^(UU)[C9WF4?%(S.<0,"W'
MW+ZO(T?*LIO$!+E_!;S%<DVY(X$J:]32L=?QJ,U7"PS`:8QKZ:>F/J1JPP#%
M8]-GN"]0.![-;[8[FFYDOI@PG:JIK-V,RVDR7&964Y'U/1<\O;'J-J-QMZ;.
MBW2B.8>UD]K9VM/39KG`8'8T3U*83G9#U!;?TNXNV.VD28.37FYF<YEMX#^,
MV-':P\0R7"-M<CW0M:_,Q:M$F5,AVBQN3&CP$BO6*3I<)9,-B$XY+;NU+R+'
MH`V;DV\IH@4GL_S@I5I`CC5?F"`M?^9D](;&![Q'&UA^[5GW"&"L=_</,*.T
MFTV.V?41^'ID.TO0WN/L"ST_TF\>+;S9=D6!P=M(6&CD&PE_CL'!;*5$E)&W
MT6YS_P!2UB[GT4C-,7@63DN;"S`[3<&U:EW5ZV^FK+=Z-[(&T$';RQO=C^LK
M`ZO%M^,YIH(-U6U^3]+TK*-U=ILHSF>VXW-?CYM=W>/X531(@O>ZE8PS'G*Q
M%::]0)$]R-Z,5VN*1,R8F6<:HL;R[+,[R?\`:#$XD/`*'%,=>R3\PR"HL[Z#
MDDEJZBQ)S%65%3VJ-NPWGK)8$)6Y)V^V^ZO=D]R\B@U&-Y-"6DO=H-CMY<3S
M6TLZ6KQ?+Z+J`N]SJ/!J.@>FV;<Z3E2R-K;LK&D<AMNM+,@0XI2K!NQBPHK:
M;8+J(W7BX'NQN9M+D#.Y6^U+UD2MT,;R*CK6'L29E=+F+].NSN*YD,B1*K*U
MC,(V!_M*Q5/RY-2%YGM^Z7HG.G(M3;.=)5)GF+6UIN)TTN20C?A-=,&P^)4^
MX^U_Y9+I,]H'NIMO<_`*C&[^"R5'E,>ZG8C+MCKX<:5+8LL;LH=E*KYM?),)
M6>HW?K$.FK:7(=V,P;2=$K)-)24M"&08CC,[+,LRJZ@8YB^+5MUGF08OB<"9
M;7%E&;.;?7M;55<!N?;6,N/`@2G0N%$SK%G)N/T<Z]H*W*LFI6[NLQ-_(J-^
M^G0DC#(EO5L&-.<?N8<)5<;>L:IN77DC1.MR"9437"S-]KLGW!Z%]BL(SC!9
MV;9S!C]%UAE^-9731\CO&+K&-P]F9VX4ZZAW#<U2LJ>KA95(R.8^KDAJ*S<$
M\X8D\CF`74_MMN9<;N[@VV*=.67Q,OI.JOIXW2:L=O>FMO-;C*-L-H<XV4=#
M<N)U39EF+S%=(K=M\<R&#7[,;)U%3F])'"VPBKP:UDW>1Y7?!*-6==O2G:Y/
M28?$WDQ#\_R'>3<[82MAR+.'%[]SMH:>ZO<WH9#TB2VW$;KX-%-2'8R%"#:2
MW8$*`\])LH+;^5(W%.:5)!9UII?<+2*,Z(27'^@N6:+5JCRI8_\`5K#U@BP_
M7X@M.RT7V[9N)!]C.P[^+;WX';Y'TUW\RLQ#\3;JKS+);&'LTE[7.X1U$[0[
MH0ML=Q8EA74TR->X1+N\CQ:NRW)ZUV<S@%J*!GB4(U;LB/=;HFVXSV+O_D^V
M&7PIZ[7_`(=%1EO3QL=:6#S5C$S%K>:9C^Y>'WD.9'Y0)VR_3(FU.R'IS36U
MBV5MGCLA"C7;!D2SI9'!*[;9;BU#9TE-=Y)0T]ODTER%CM7:7-;7V-_,:$2=
MB4D&9*9EVTEH2$G(]>S)=!"%2!.Y.?U)RC&8>05V*2\@I(N47$2785..R+:O
M8O;.#!_\>FUM.[)"QG1(?/\`IDJ)%=8C^?7<!474%WXCVT^Y^Y.0]4U1@W3_
M`)->;A99LUBU!M+E6)=/4;=N[W$CXSC%UDE?[7?G<3.(NVG3Q*P?<*;:)4XS
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M?:BYV.:7?'JKR?&]J+]^KD6F$X)G74]NWFVWM4\Y26EU4`R6$W]#+APJRUGP
M*J%)CU$.0<>"UP&5VW^UFW>UF)X=@^WV'4&*XMM_2GCV'5-57M-M8_4/*T4N
M)`?>]>:*V3S#4JVDNRG9EQ-%9UK(F3"-\J_TTT#3330=21-A1'(;$N7%C.V,
MDH4!F1(99<G2TC2)A18C;IB4J0D2)*DJPP+CJ1H[[W8C3+ICXMGF.(TL&UL[
M?)\=JJVC*6-W865Y5P8505>Q'E34M9DN6TQ7K#CRXK\I)CK*QV9,=UY`;>:(
M\6^KR-D55.Z9]U*?",QS^DV7ZB(F;9W3;>T$C+<TA8=?[/[O;6OY#1XA7=]]
ME*4%YN!13[FGQF':9&M`-I/JZFR<@G$<CVVRV*S+>7J7V^W1W7Z:,QH]O'^L
M/K$W;JJ3=;&JF4%=CM]TZ;/X!M;GV78V,VVK:B1EDVCO9.,4V2L.7U!9"VU:
MUE+E%6;%>$HV^W4M@W3Y@V:;I9W&D?YM<%V>S#>"XS"OO<+2))BXN]2LUV*U
M%=99-76UG?YB=TTWB\]J$F)'+;:@6N25<ZSJ&)]>8KN?C618UMQ89#)H\/OM
MT*"%:TF%VF8X9;VLJ5+J6K.QIJ>?C5[;4.8R:EA\@FV&&65[4/M@4R!82H#C
M4ER#G<GI3W+E[*[Q[=TVQ5],I&NE7\57;;;_`!!C$XLJI8',.N"IS#IZPG'*
MB0)PHT>UV^JJVZVSI8S34.+C57`*H"#&@1&6;X]36SR#D76%AUATL9CN_G>^
M&%83CO1_GN%X!"L,;VWK*3;"BQ+$<#'=`"CQNFX=H=]X63[['D,Z5B\!F)ED
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MR0L@29?!;XQ`@8VS14KEPDBQA6]W7WEBS8$TL%E,:J[HX#J^]N0K:H#G#ZM5
MDV-W\RYKZ6^I+B?CDT*W((57;5]C+H[!U@)3=?<QH4E]ZLF.1C"0$2>##YL&
M+PMDVJ%J./\`$.VLW&W(D[<N8)AF298E7M/UN5$]S'H3LER#:9UTM9?B>'0C
M=9<:<CS<CR.9%HZ5&S%R19R&6&S`R0D]W8_IOI-F]\^F6SV_VAA8!CU7T/;@
M[<[A6]!C\>I8>R>NS3IIM,'Q_.+)A$DW>3Q_2W0M*:7?NV-NCTC-YHS_`%[2
MX.:&?<W*L7K;VIQ>PR&BA9)?-27Z3'Y=O71;NXCPD[IC]74/R6["Q9AC]4IV
M'&?;C"BJZ0(G.K6[*]06`;Y4?YICDP:FU2^W1I5P^\L:-O+QB[5;M9GL[=9$
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MK,IQBXM;BBJ,AHK.ZQY8:7U176]=.M*,K%CW,!+>NBR7IE6LZ/\`OXB3F(ZR
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MHR6F6SQ^JC65-%A5^),Y!D5Y+M`.KJWJ^OMIT&,O#-M<U@UN`YWG/35;Y7L)
M@W57G><9)BF+=/ESM]DFY4C+-A\?QK$^IF^Z-;&XRF=$L-O=T6LAQ^RQS&J*
M);9!93H?4'1[8P;R-*L7O9VRZ7\IN=X-CLPF[!/8YM))N_Q`+[;G;_+<)H8A
M;$[<;LX]L]#P##,@HG&YE?MZ>>9?4;B[@5.$1G!3'8F9/45G!I[.%:TE>*KH
MF#VCW8P'?/;/"=W=K\A@Y5@.X6.5F4XQ>5[@.,S:NUC!*9]5L#,XDYCU%CV-
M=([)M=.:?@S669;#K0>_2YIA^2Q)T['LIQR]@UEH[264RGO:JUB0+EIYJ.]4
M3I,"9(8B6;3[[++E?(<;EMNO--DRAN`*QY[18GDE/^%1C6W5+L5?CF]%TH.[
M;6^QM[27NUUW:YE2X4[AV:4:P:2SPV[1+VYC7,NML\9R6@>S6+*BV..9?!&]
M@Y"W&;>=.NZ.X.1[ST=!L1GY[*[J;,=*N*.5U?TL5O2SA&12]H^M3;BVRS&7
MMKH=U)SU"Q7:3(+9VOM=R8\(K'"F,F@X5+N:BAR&2H;(%5F&)7E-*R.DR?'K
M>@@N6+4V\J[NLL:B([3..MVS<JTARWX,<ZIQA]NQ!Z0"P#:="6C*@:);K`]]
M<*W'W)S_`&WQ4W[1W`,.VKS9_*84NILL2R&FW<7/4Q\L<LZVRF%/*&FWUJMD
M\;#,/B97^QD3.Z5[:+K?_ILOJ3=3>V;A/3Y89)TXEFW0EN1N;LMM_C-5!HM[
M\7V^=WSJ=S:W'L*;.NQS.;K#W0V.S/,,(*.DC<+&-NZ;!5B7C\ZKIY-]NBC`
M&:KJ:ZSMUL3Z>\NV%VKW:I^F9W$5RG$QV[_SB9'AV/[K5F=9?"VV=2+9X.XC
MUEC]98UV046-9!;28PY-8TP_G3,^>$E=C65UO#?KK6!"LZ^4(A)@V$5B;#?$
M'`=`7HLIMUAT0=;;<$7&R$7``T1"%%3O:::#CCG]?\53_<NK&;I=06`[5OT%
M?/D_M!=W.Z.T&UDO'<:L:*7?8W9;TY?!P[%+S)*J3:19=90)-GC-DR76O=28
M+#YU46PD"+!7R+GCQSX45\<\\(2*OQRJ\HBIQ]_C[ZUZ(^Q5]-I^DC;Q[HZW
M&G]3FS'7+M1NCO\`=118=$QRCM(]?NW,N-T=^&]ZG#BN;T8]NM6S85G^Q%?/
MO+JGA/5[N:XSB4C;RLCPPG*H-TL<L*7$['*':[;^US2RLJG'L9RC+,*=MK2R
MK[2;7C#J7Z#([BHO)TIF*U8MPJ*QL9L6/-8CSV(E@U*AQ[-U_3KTE[?;DX=E
M4?&L-Q_.(^;YQD&VU+8YC:A34VXV=19DO/KS;/;.WRAS#,>SC(8>06\O(+/"
M<4@7\AC)KV2\Z`9':N6$+.1=.^Y>/[:84ECT][DY'GDO8+<+!:[#\CV#KM\=
MLL_N%ZB]],TI=L+]^IGXYN)TIY)+/*L3R)G?RKSK$L>N*?(:6[G35NMFZ@F:
MROL5QS*\]_%.Q?(.C7.]V-V]U]V\,PS:S/L>QB-NI35>=)T6],$:GQY=P+$V
M&>G_`/S.[DV47.I6XUZ[A$'(?29W'QVTN,TA/4\(-@J7D^-U]W58S.OZ2'D-
MZS,D4E!*M:^-<W$>N;%RP?JJEZ0$^Q8@MD)S'849]N*"H3Y-CYUT;/.L*H_S
M1;C+L7J4I:QRZN5L\AIX'Y33LSG:UZULUES6?85K5BP]`<GS/1B-S&G(A/)(
M;-I(`=[^F_J$LMW]XZ/(Z3<3+-P,_P`NV,G[;;J8-TOX)G,Z=!Q+;K:FCB93
MC'57DN806.G.1M=N'CNX&6N4N55M$[56%G<9=A6.[@6><NP+"Z&6=)<:IVKW
MAS:?L7GS&X.6_B.;J;PY#F^![<XEN9N*>&U>Y6X*[39SD&U>95=V[OSM#30+
M*GD0=KJEL[.F:NAW-P.OBY;CB33";&RS;#J;'&LOM\JQNJQ1YJ#(9R:ROJJ!
MCSK%F;3=:^W=RYC-6;-@X^P$%T):MS#>:",3JN`A=JYR?&\=8K95]>TM+'M[
M2NI:F1;6E?6,V5Q;NHS65=>[.D,-S;*Q<+MA08I.RYI<C&9=+A%U[+?9??/\
MAZ=LIL-G+'!=G,,R'JWACB^)=();QQ&,DW"S#!+;;7?.RZ-LAW#N\FVC=W"Q
M:%NOCQTF-1<C+:^?E$]YS&<$H=U+N)C%TMK]F[;:6PV*N>HWIDW<WWVZ;Z<\
MHV]VUQ^=M9BFZMAL3E>0;V9WE]QA-_LWB=KF>-;<P,_VDN]K\&QB[KYUWC>W
M>+;8IM=FN=UL1INPO`EWV:WRQ+>;:B@W>K&9V+XWD$R[@1V,N=JZ^=&DTN:W
M."$U,./82Z\'+"ZIC&N;":XZ^$R$RH!,=*,-SY&04$5;-)5U41UI3A-7'N+.
M"TM4=BC15X6?JR!6"4T7VCB!+](I0NME'%WU`[HS.EWI;R"Z_"TQGI9W"PNT
MV>R6YVDW`PV/B=_/8NKS:>WL\MS.SP!X[>!-M8]A<[?RY&+75;<P9]BT[.J(
M=E%ERQ5MX\4]I-J>J'/MT]L<]W,V7RO#EZY<VQ[=?JVJKRBJIE-LD715F<2U
MVHP;+1>DOMR"W?J(6(X[C$F&+R/4V.S'9[1!W$895=2-YT.TZ9CN-OKMU%D;
MH7.RUAU`YGLY'S2(MWNQA_3M/A#6#F.&8QN'&VOW;LZ!YZ%$QMK,FLDA.UT!
MZO\`=E58[+BU\A]IN#1,U%]9XTY`S>3C>00L9NZK',DQ0959<R+BNJY]?:2K
M:\K:JLL:9NQ_,9]59SXMJ;#!18,*5:28,&5"'O7T_P"=V/39C^+S-A\VR7<7
M+?P[>L/8ZODTNWLBWR.AS[)[3$+ZCQ:XR2KCE9X+*R>D9RQO%YDJSJX4ZUD3
M*RNGLW=C%8F7LW^Z69F*;M7,;8/9-:'`K?ITV<QFS:V]Q>-6T=WDFW?6#M?D
M5%%NQKACM760XMM^[F5M#GV@2[6-0.WKY33!Z0+A)Z54OF-TMY97C`7</&3R
M*B#(K%FQDU]"5Q6C=3HU0X#5I(AU2ROS"4Q6NN-MV#K$=QN$;@!*)HB0=?7(
M,CQ[$ZJ3?91>4^.4D'TEF7%]9P::JB>X>".RLFQLI$6%'5Y]UMAI7GP5UYP&
M@[C,16'=SI2FQ<'WWSZ+L@[_`)[[/\4#$]Y<1S`,99=W%+"(75%L]`D9ECE^
MYW7,'$FMF&<S;F-5TV+3OX=+RSW5>^U<7`S;J?B(;<[FY1GO37F5-`N+O:;!
MAW?CYG5TO3K7]53U#N'D\+!H^V.?O[+RK:%8V,>HH*O<_$&\NQVLR*XQ"3G+
M0'3M4F07-[2%25WV7XEBE?$M\FR;'L<JI\R'70;*^NJRGKYD^Q54@08DVRE1
M8LB7.5%]G%8=-Z5QRPVY\Z^USD^,XZ_41;^_HZ23D-BW3T,>WMJ^L?N[9T2<
M9JJAJ=)8<L[%P!(VH$$7Y1"A$+*IRNH`CV3W,H,!V)PS)^GW.+*N#9_?:MP?
M(,BZ:,<WXR+$IF[.^%W;P=B8VRM1N--V&Z9,99VS/#DI[O.EOXU#AJPMI;//
M\<A;?W=3>^]MOM[*IMJMNH751T1;R=0=G?=!O3_L7B]%8;=Q,\ML?W"VXKLP
MQ7>/9V^>D2SA[*V669>6*YA&WP>FT6`YG3-TEP&>M-[>8RV03$8[OWM_D^Y6
MZ.TC\HL?R3;G+\8P-T;ZSIZM,RNLMVOQS=-AG"FQM?S2U.OQS)H[5@T,6/81
MYD2:ZS'."TU-<KC;3;#!=H,3C81MU0,8YC<:RO[I8;<JQLI,V[RJ\L,FR:]M
M[BYFV5U>7N0Y#;65U=W=S8S[2TLILF7-EO.N*6HA-V^DNTRK&?Q,,TG;`G:[
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MSZ?;=-X`E[8V-%O(Q*A[7WF.XE7,/[AU%!BV)'8WDSC9/,HV\V32:GI\RNDO
M<IQ+\)FZK+NJJ9.X4&H8V"ZG9TW=O%+7>A8[SF07NVN/NXQ86DC(K)NZR?&J
MAG*X;%C#KY;D$)G4O:(HL&<EQ5%"M);,&MEI8PRBV,V0Z;,>)"D(^K,R2^ZT
MXVQ'8-QYQQLP;`C$A3X5.3XU?3KNLI+^DM[+&IS=;D<"KMJ^PFT-BXTC[4"[
MB0Y+TBJG&QP\W$L6H\@FOW@MJ'U:B&K>F_J&_P`]6Y6Q^+1K/"-E]C7]^>H[
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M^*_.I=XV[7=R9NO-FXS&<BYG4Y)C][<Y/MTS3UE";J[/Y`[E'4QAN1]-69[C
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M;31IDEA^TG"R)/+"@-R)`MBKBM(*=VK?[A8_L_F.3;:P=PI=%.R/%\U;R_;K
M';/+)%><G-\<K2FQ;*/B3%W"B9=:8U$F-WM9'M*F\3'9OL<EKXT&RC0+)F`'
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M:=%#;=;<!2!QMP%$P<`B$P)"$E$D58!MR=@KB!F.[LV;LCNU4R:;\0#<'>Z#
MGV#;$46].*.X_N;L)2X]C.9WVR]A06$?J$QFVFO9ABMS)PB66YNS>9SHE]/_
M`">HL+:<_+!T:T^1T'37M?393MO6[26=;`OHD7`*B!84==2XXUEV0IB#\7$K
M3(,JF;>A>XFM+D1;6GD=TUM6Y;'MW%L9$3&6%0,GN$_V<?VUQQS^O^*I_N77
M.F@I3+L[PG`8+%IG.88MAM;)D^SCV&5Y#3XY!?EJV;R169=S-@QW9*M-N.HP
MVX3JM@;G9V`1)Y]]N;MKC+->_DV?810,6K5>_5NWN5X]4LV+5LKPU3L!RQL8
MX3&[-8\@:]R,KH359>2,3OIGVX`]9^*;HVN^VSF0XUM;EUYB]?MUN#BC&YVU
M>W.V&[FY>.9)FN28<-K@_P"0[V9'%VWV]PS,\8HT?NMPY.'Y+(FO588];WN)
M4C;D'+K#=*W2=E#\67-WKV`5FR@?AK[7=+C$?<2GP"]E,WV-[H]4<?/MNH*T
M1OXN[1VE+9;=V1+CE?4X7>XW8XP57`KZ]@*.H"6'<O=W`-KJJ;+RG),<@VP8
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M-I(L&8#\&]FC-G!7R9#V@SB#+\1>[U#)L<=1O(UPYQ0NZH^S+`5$+%S5):]N
M0B1(BT9<6B*J(L1%5-4]%W;VGF.9`Q"W*V]DNXFH_M2S%S/&'W,;(YR5C:7[
M;-H9TQ'8\0`_,AC*4WB(G,C]WJ'C9;IFZBL=W&JY-OM=)=@7&&7_`%_VS^06
MU%0XI*Z^-QMO<XVDL=G,D<H9L^ZI+2BJ\FJ,MFYU0QY4:'=U?YW6V[MI"A$M
MG<!VCWHQ^9MU/M>D7=[.<'QOI3WXZ;KS9:3M;T[[-;;5MWN+!VB.EVCQL<5S
M#(]UK;:.9;8CD27NZ6:Y_F>.UT=B'?0I659?8E:MAL.1[FGEV=E21;2MDW-,
MS7R[:I8FQ7K.KCVZ2UJI-C`;=*7!9LT@SE@/2F6FYOLY?MB=]N_V>)^W>"CE
MPX'^U^*#G3D-;`<._:"F'+#@(TLA9R8[[U+HH?HBKZRDA*QZ0J\KGIIW:PCZ
M`ME=RNGG']S=K-XXMAG6YS618WEN0]44A`D,=1D&\Q>%4X\U+?FVMCD<"\V-
MH\:B;(A37PBDO!L2P/.VITNZSG*(E5@Q1=,&_,;?.RQ3+*[?>6],ZW[/J63<
M+&-O.EZ/ME+QD-U9&;8UG);XV=#;;TP;&KVN;K]D[?:X8I9P]3,S]N\;F0]K
M)D#*X@JH)R(F:89-;H'X&48S+9RMF;(Q=Z)>5,AO)&*Z,<RP?H'&99A<M0H8
M.2YCM:4H(L4#D/DVR)&E%S=Y,/L,7F9-MW>X9N6W6Y1B&,V`8]N%A;<*O?R?
M*Z+'92S+U^U<J8L^KA7#MNQ1/R&[?('(C5%21Y%Q9U[#L)-CTB=0UPSOUD-+
ML8[CU;U2[<[QP-A]M7LO9K7^D.KN<SB;B[B;/90ZWD-A0X7#Z[X==.R3<JVP
M'W]9MQNA8L[;V+L_$6ZN[C9&[C8)>;U8KEEWM?T4Y/LK(8ONA^@DV67Q<2P7
M/<JJ=H.KK;;<6WQ6!MOB=Y=XQ*P+93`ZZ_LHF<6%]'=E/2K&BV]@6^/L'.>"
M4V1N7MU$R"NQ*3G>%Q\KMY$R'48P]E6/LY!:2X#LAB;%KJ5RP&RFR(CT22U*
M8BQ778[D=]MX`-ET1IV+NYC=;2Y'?[@6.)[;TM'G>0X3&M<@S_#2JK#\GG.1
M*^6[9LV;<"GL+@&W7TQ6T?9R*J('(UE$:?`Q&#*CV[OMQ<"ZZ-EL%Z5[J?N;
MO?U_[^VN#]2$+]DY^#XSD&*[OTX4&]6:9?+R*+F.`9+T_P`JBE3\7PZ%0296
M1RL>I2PH[!W+LE6JK#.>G7J`QO<:!NJSA6[,3',?ZB?Q`+9I-K=MMAMX<RKG
M=]=Q=JK;;7="'M[N^L^#.H\APG$\UP][)<5%O/<49R9($FO3#\KS&57B>_%:
M)OKW<[;?%H,&QR;/L)QVNLHT&96SKW*\?J(4^+9*J5LB%*L;&-'E,3U`D@OQ
MW'&92BOMS<X7BA%ZCMEPW=S39*5G&.0L^P#;+&MW<K@6%S1PV*O!LHL<CKH5
MM)?D68.L-PTQF3/MRE1H\:MJK&BL7Y7MK>*2QT]*'1S)Q?</#YNYNRLR1CE5
MT:YAMQ7.;J5FTV03\==W0ZD]T<_R#:IZNV_AM;?T$=,(N\:KYN%X55NX9CV-
M,56$0+F^A4JS)5FJGIYW3KMM<1Q+-NG;=?*9D[\/;H<Q>Q>P^9MY#R*BW)Z7
M=Z[C-LKQM;?,'L@QJTW$Q")<XCF&%[?9K566W&\7[(S\`O;R/6O2P4)T,:RC
M%LTJ&,@Q'(*#*J*4X\$:ZQRVK;VIDNQ'28D"Q954F7">..\!LO"V^1,NB;3B
M"8D*6PVMJ]@]KIEUM#M7)P''[U+B_P`XR;":?(JV9F,B\R:8W;Y#EF40)-K.
MRN;8VLB;&>F75WZSQL%7L>X"&U!9#'WH4Q_<NIQ[>6TW!PN?CC&7;N)DV,Y1
MEV`XCM/NON?`+`\*J;7-MU]N-O;"9A-'DXW51,Q:NM*J!BL_*,8QZEN+W%($
M]Q;*XQ_Z=]N,MQ"SV9VDS3I`MK7=;:;?#=G<C,>J"]L\<KL&<=S`]RTM=^,*
MW!K;:SS?/\_WCI,LJ\=L=KKC'Z=^G"XOJW-WZW',)QI^Z"2R9NWM1`J;'(;#
M<G;Z%14]G'I+:[F9GC,:IJ[F7#8L(E18V;UH$*#9RJ^7&FQZ^4^U+?AR69+3
M)L.@X7<R+<G;C$:JIO\`*\ZPK&:6\%I:2YR'*<?I:NV1^,,MC\JLK.PBP[!'
MHAC)9]D^^CD<A?!59)#6#ICI&W3V=V._#EG8/@6?X)6[(;(Y75[KX/LSM;LI
MN9N!BF^NX^+[7M2-R[;`]SV;.CS"W),?S_$,FS''Y4_/:)[+%=B.V&,9#ETF
M#Q$Z>]\\!J]E*"-LQNR-8>T6[^/4>2T.W'2SNCNMB\_>C>_)\SO=ALJJLCE5
M73GL1M;^Q[F$/L.8S@.74L9N.]@%GGK5+MS3Q,W"9!GJ&VAD;T7VP*9?2AN3
MCFUV.;Q65._9U#8#A&46^54T&R9(K'W+I1SQ&RGV?^AC'@U$JJLG92Q[%E4J
M^%NMM?88M8YO7;BX'-PNH?\`;6N6PLPQN3B]9(]2.VK%A?L6;E1">1R7%;5J
M3,:<[Y+`]JD\TAP-773/U'9+LS0;=1]F-PZ7)<B_#LZ/=FK\G(FV,H)%WTL[
M]Y%D.^NQUQ9W4^7@K=ANGMU8I1X`N25([4Y_!M#A6[]#0%/CP[C5>Q&X]SBF
M[&Y]GMQU4V\R3DW3A,JDF;:]'VTFZ4>XV=N<OL(NZ&$;)XWBUGA>XUMMI%OZ
MC&Y-7O`Z:YKBD)R+MU6!88+@]G<!.317]'E%1!O\:N:K(**S9616W-'8PK>I
ML&$<-I7X5E7/R84MGU&S#U([[@(8&"EW"2)ZVL)^@_&=P\9VERUO<3`8N"2;
MO>'<#*,<<?PW&MM\TSG&\A=JK%-Q]TMNL*N;O#<+W)R_(7,AEY!6XT_71;:,
MQ69;:8WB.29'=XQ4YL:!IIIH.%1%3A414_14Y3]?]^B"*<<"B<?'"(G'/A>/
MT\>-<Z:#CA/T3[_9/NO*_P"*^5_GYU1V>9-)Q#'';Z'41KR2U:XU7!`E9!1X
MNV;=]D]/0/R?SG(I$6K:<KV+1RQ9@F\DRY?BMTM4V];6$%AVLM8J=:&#97N-
ML+88MA5%*R._>W-Z>;ENJAE%%\ZO$^HO:?+LCFHLQ^,QZ53C=%;V\A%=1U8\
M!U(X/2%:9<"_+.X>`2,F:PMC-<0>S!]N;(9Q1K)J-W)'F*YZ0S/D-4+<\K5Q
MJ$_$E-2W`B$,5Z,^V^K9L.H'ZHMP<"RBTO:/&\TQ+(;K&'#:R6HH\DI+>TH'
MFWWHIM7E?7SI,RJ=&3%D1R"P9CD+\=YE41QIP!BT@]*E]2;>[<SZ+9MBLW##
M\5?/>H[+;*)`HFLF3#\GZK]W;"7N5,M_>+)6)<;-9!5-R!CS5G'AEDE&58#1
MR*M,8*'I?ZA+[%<YV7V_V>S7!J^MZ3=]]F:>7O75;4UK^U-ME,C%7Z/:797J
M2VT;I\PWMVTW4F4UI%RS,-Q\4LLHBT[./YUD.4U6>?G&.Y"$T&9]1.V^/;>Y
M#N)C5]0[E5F,7^(X[;Q\&RC';QR%89?E]#B$9F9)@SY<6$]%>OFYS\66;4AV
M)%D"PV3B@FKNO9-CL>.Q*>O*9F/(O!QB.^[:0&V7LA.S.F2B9=.0C;EPMHTY
M7)5-D4]9[9PDC^Y`FDB!RS;',=W[G(,SVPZ1<OV#I,=VAVJVDG4>35N!81D6
M;6N/=2&T.=TF.4.'X1DMW06&%;#85BF;-567R;&+4R/VTG5>WHVM2EH^/WS[
M&-]KRXP78BHZ;MS9*8C^);C_`%%9#NJ]*P*-M0&R,KJ(O-Z@S2EO7LL&XO+J
M-#NX&/6>#1<>#+*FUBW-E*BK2Q(%A:A(/L1U,[:[\8QC=Q46E-293D3>1R&=
MNK3)L<E9U$@XUE=YB\BP?HX,YR>L%YRD<LFI+<166H<EE7C`T/C\;4]3NV^X
MFR^#[UW]G4[6X]G4JZA5,7<#)\;IC2?39)>XZ<(;"3/BULN9*<HI$UB-$><>
M]LZ/<'<#O;%-L7L-N)2;;=.?3X?1ME&WNZ^WG6.YU$Y/OC*<P0,`HL69ZD<P
MW(S+<&'N7491/RV_SC>3:6QD[7S=OVJ1+U@,XG8]D;<7;FH6X=MU7=,G4G@=
M9TXYC?X;O*F/X]L!N[M),PK;/;'I\WMRK!LSS/?S*\QN`OL)WJ.95P<=W@V\
MF8YCTS*L.L28C-XTQ4;AN0*"?!E-!//NC>QZ+;Z_MDQNIS*([%A0)&/VE_C>
M-U5S79!8P:.<Q+NLID1\?:BE7VLAXF9KZ#:`/Y7%1V7/C-.?6GS#:^JMJG;.
MCRC!8%]#@.5U)@=;?X\Q<L5>-LG"=BUN,QYJ6(PJ2/7G&>9CPO3KFH9LNBRD
M<Q"/K<?ITW*@?ACX[T]45#EN6Y_0X3LK2Q\7O;W$<BRF(&.;H8#?RJ"9<4$'
M%\(E%AF/5TBN%,;AP\>BU]`W"Q]9D*/!?ET/5]*^3U&#V5A5[/M5^X%K^+9(
MZC+*U8@T3623=OI'58Y,?W)=N$FE+*`_LFZ]&)$F#9'ALB10K6HS)D5K@2RS
MYV/J\]164NG61,J)]B_3SI$!7I-'$<8BV<YVND'WOU49V=%CSI1L'"9<EL,R
M'!*0V)^8]GF#L5T>VD9ABK55,QM[,8MB]D5,W7RL2C^P61D\>8Y-&*_CK"6M
M9ZUXTZ=6U^8P.^6/O(WJX,]?VSN[.<4VV.9[#4K]ON97S\MV*N5:?A-A5;-=
M3]'$VZW#RF2U82X;,B#MID=?MQNY9LLN/6#E/@%M'JH%E8RF:Z7@[5=*V\VW
M>VFZ^(M=/5??[?;"95METS].-).IL?W-RH^DS`]XI6^C6Y>#8+:9+44&<V&/
M1[39O#*/`<OLJ2-)O.GR5<RL7R>/7TF/Y:$MN=]4^PNWE/MM?W>XN*2L>W7W
M5Q_9S#+RER'';6DL,YR1;!(4`K1BW2`C4<JV0-BXP_(?@F3(NQN74XNQ#W`P
M.=DMCA<',L3E9A2Q%FV^*1LBI7\EJ(2!'-9=G0,S3MJ^*@2HQ*_+ALM(+["J
M?#S2G!/AFRW4/`O<\S>_V;WOR"I_Z?/1SU+UK^6XGL909ME.#U^T='MAG^80
ML`VCLJO%Z6_QC**5^?DN.3(P;C,XJE=?7#]U.D?E\'[;`]*W4#CFX>TN);@5
MV^\[*=G-Z=VMV,GW!;P3IAI=J,@G95'W,.XRZLWHC44G>O<2#OG!RJMQ^_V^
M=:K\Q;9LG:O/+>BI\1@V$P)XJ#*<6RENP+&,AH,A;J9R5EHM%;UMN%;8G"B6
M25\]:V3)&'-*OL(,](DE6I!0YL64C:L267#]Y`!/@13^@HGW1?T_5$7^J)^F
ML1^@S9:%T_\`1WTX;6MX'"VYO,;V:VXC9QC4:'!C36=P/V1J4S23?OP'9`6N
M1R<@2<=U</3)\BQG>J^[.D]PN+EUH.%1%YY1%Y\+RB>4_1?UT01'^%$3^B(G
M^[^J_P".N=-`TTTT#7Y[1YY[1Y^>>$YY\+SSQS\HG^":_6F@_*@"\<B*\?'(
MHO'].4UX--B>,8[-R6QH<?IZ>?F5\.4Y9,K:Z+#DY)D@TE+C0WUV\PV#EG;#
MCV.4%(D^63LE*NFK(*.>WA1VPJ#304KE>;85@T+\TS;+,7Q&O1%+\QRB_I\?
MAH@N-,J7N[B9"8X1V0RUSZG"./-`JH3@(5(9)N]A\&DW`=Q:]P[-,LP/$K'*
MI^$P\^PZIL4;CUQV%<W=3K2T"!B<&U)&&FL@R3V5-%;?&;*DC%%36V&XNS=7
MG_5)L;GF3X#5Y9CFWFS/4741;J[KJZTK\<R?</(=B($>*U%G$XJ3\CQ2BRZ%
MZP0W@_*HUK$=?8":3,N+U[HVW%QSH2V?VRP?8]RDW"K^@#K$VGRRBJH6.1KM
MO.]S]JZ4:##[BP6R1)TC*<\K(KS3;EE,K2MZV#,F28Z0HK[83;V.X&!4^15&
M&W.8XA4Y;?`T[28I99)1PLAMQ>)T&SJ:.5.:L[(#<9?;`X41X7#9=$%)6S0?
MG-W'VZKG[R)8YSA<&3BU;^<Y'&F9101G\>I_?2:K\UNF7[!MRHK?S*%+KO?6
M`QHOOHLB'ZON&'6@C%S7;?**W/.H_!<LZ/;/J/NM^][MO=Q]MMQYZ87CFVM?
MB&-T>VD3#ZW<'<]BXDY[MK(Z<<@Q/(K^@BU>+V=M9.S(%IMJQ:9#D>0,UWB-
M]+=_B>&[BYT&PSF6V,S\2/<?J3W4VZBQ<7FYAOWM/`R[-6,`?KTR&WC4M\6'
MS++`]X\*P^[N:MA^?M^U&JHD3*;&.W)"4Y_=7;")B<;/).XN"1<&F2$BP\R?
MR_'&<4E23>>CBQ&R)RR&F?>.0P^P+34TW%>9=:[?4;,1_=WN=MKC-7%O,BS_
M``>@I9<"#:0[>ZRS'JFKDUMKW_EL^-83[&/$>A6/IG[&6R\<:9V$L=UU!7B'
MK,=G\XMW+C?FBZ=M[]JH-QU0V&ZN!5^VM5LW>[Q;;E9].M'M%E6\>3].V<Q,
MQVYR8=XKF';5&1XG'ECN3B58M)N<*0<HR/.J^LL?M33Y'M/U:;'V^Z/1LF6W
MV%_A\9[52\+V<QC!IF0[8PLSZO,F=QB9`V@M,]E4%?-W0Q)F,6XU;@F4Y%"V
MJR:=8XK5$6W4ZWL*ZXY>*T+_`#^>TU5UU)[:XWNDUMSDMQ28_7R-JJK=2!GM
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MZ8$UJ#71;.ME3YCC`QX<>PA/R76FI<<W/UBN9X=GM65UA64XUF-,$EV&5KB]
MY4Y%6#,8$#>BK/IY<V(DED76R=85Y'FT<`C!!,%*%[,>AO="=MCUZ1Z+%K.;
MN[N3?](%'5[AW$K",DW$WKVBV2V4Z5HNZ&%LY5EM?#QJ^_;B?@VZ>)RZO-JC
M&\%S3++*<&6U4#&;B3+9R:Z%]L,VJ-QM[=W<JK-[*5C.\;VMQ)K_`#P;?[![
M.2<HG8$>9F5ZSMALA31WVIM'4Y#5X8N;YS:E;9#3U%5245/'Q;%JBVM0DL41
M7A%$51/"(J(O">/">/'PGQ^B?IIV`O"*(JB<\)VIXY7E>/'CE?*\??7ZTT''
M">?">?GQ\_U_77.FF@::::!IIIH'"?/"<_K_`+/]WC7Y417Y$5\\^41?*_*_
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MBRI49VRBH[&3L7TO=16`.[;[.[E56^FXD_!>IF;O+DN^:3>DNBVES<X^?7FX
M2;S/W88I?]3QYYEU-,BX#D.WC_;=R)4FUQ63N(UM8;%X_3!='?4-%Q?K%LTV
M2H'9W69T[=1$3;O"*?)Z(G^DO(+FQO\`):+I_BRKN_2B&CZ@[7(EW8W#N<+D
M#BE/U('ET*<X6W[N#7E.$PDSJ)V!KG-O&;;>?:BIE;KU]9:;8P[;<#$:Z;GU
M?<G$9JI6&Q9ENR_D;%A)G08D)VG"6U+F2XL.,;LJ0RR?=L=_=C*C-Z[;.UWE
MVJK=Q;>U&AJL"G[A8E$S*RNS9CR`I86,/VX74FV./+BO-UC<(IKK4AEQI@Q=
M!5B7WBV!WZRO,>INP:VDW[NL:ZMMH]HZ;'L?PZ^Z0ZVNQ1BJVJ3`;K:#>VYW
M:HLYRS;4<-RP['<2)E6T3NYN--_M1>66,5,K/:MF-D%Z8G2EFT+`^LN&YMS#
MM<OW0ZO-GMSL0N+2=B\_(LZQ?;/$^DFHK\SL\C?D-R?S2IF[7YE(B2+DZN];
MGULFTA5T63:0_<AE#U`]9NR^P\*^K7,RP'*]T\?M]N:N7LU!W%Q:MW&&-N'G
MF%X;&L7<<<?G7D6/7PLRCY0K;U0BS:J(IM$S'E-S6[T!O3LV>Y"[-CNEMNN[
M8LE++:\<UQE=PACA7%<K)+#4LOVA1M*8%N.Y:[E*I%LN/8HLA(F]Y]B]Z,EV
MLW!Z=*GHY++\FLNMW&.H:#OA+RC9>#MYD6+CU>8?OJ>ZGYE.R>'N+!W?PW;J
M*]@T7$Y.#1E=GXG%KJK*?V,DP'U]''NG'?6/N`SM[E.&;W7]7"ZY[KJ3#<.-
M==)=#LH]C+^_5QO/C>:IDZ8;?]3CV546%3JO:*;MY(A-6-V59(Q$,VI]GIS=
MO##/+<_K'V:P'*\:V^H\RP+/MRK;>/;':+(-N<=W%Q4\XPQS<7*ZS&'<@O\`
M&8\FQNHT;&5N(-A95TF!#?)J7#:=D0EFQW7+[YYN=MIM;5!D&YN?X/MW2N*;
M87.=9508E6F;8@3C03[^?7QG#`7`4FVW2-$<#Z?K'F&NIZ<M\O\`-WT9]/TK
MI2<<R?IBZR-M]V,_W]L\KVR#!+['<5W#RRYRW>_;RQB9R[N9D&X&ZM;D8W64
MXOE>"T,^&_>9U"N)]K-K,;>RG-/-.FS-;C>;I,R#+[V_Z@L?VMW7W3S^VO\`
M<JHVCA'M\5OL-EN#XJ=158=A^#QYQ%?W11H<XJF\O($BQ<E'-BPFD<:#*]S>
M;:!K<AK9P]T-NQW;<B#.9VO+,\;'<(X)0#M$F-X:5BF0E'_*&W;3U!KU1:QI
MV>G^A`3Z66P'K'V7O-G,!W>W/S#`=BJ[<:VS&FQZKW*W$Q2A2PL,-R^^Q:;'
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M9LOSJD)K);.8UB%[(&TN]\+>Z9;TFPVYM9"W`Z@MA=Y<AC9?9=-VXG3Y.BTV
M*;:5F:;JY"E]<_Y]-G^H?$*;'+/'&JG:ZSS/#3S7%<.O<;=R2@R;,+.`$GE7
MO1L_=;A6^TU/NGMS:[IT$=V3>;<5N:XU.SNFC,-0I#[UIB46S=OX#4=BSK9$
M@I4!I([%C`>?1MJ;%-[Y;B;U[,[1,@_NMNOMIMJR<<)+9Y]G&,8@)PW'SBA(
M;_/[.`IQ2D-.L>LV)->HRZ"DBM.=L3NP_2]OIB^1;"[;YUC.^TMW93J&SK=>
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MY]D>+;A9=<U^^5M99YB^'2(CV$T(Y+`<SV4+%8$S.%[Y[)[DY%=X;M]NYMAG
M>5XU$"=D.+X?GF*9/?T<$Y`0VYEM34MK.L*^(4LPB#*DQVX_NU2*KB2/W6NE
MCO4)L'F$?*9>*[U[1Y-%P6="K<SDT.XV'6\?$;&RLG*:M@Y(_!N7VJ.787#+
MU3!9LCC',M&'J^-ZLQEUD(E<1V8WAW_V"Z;-O<-Z;4Z6[7;3HTW!PYO=>9DF
MVJ8M5WVZ73&WM;BVWFT,[;J^R?,KK!;#*+VLW*R&^R'#L&6IC;>8J94CV;2%
MK:.ALRZ0-X=Z<`J,4O-A]YHK.';/;;;0SL7W8R#HZK,.F4"]0_37DN7;:8E5
M;%XW4V&X&WV,8?M=E64U^29SD.*0X#;-7"Q["KW)<LR!C'0DRN.NS8*3F%YM
MMMON#M?G^X%9M-@.]E9%+=K`\=P[(=O<_P!P;;`8MI59PY8V\-UR#(HK"R?$
M*UV'*:FXU%C3C=R*,XQD/+WEV@KMQ(.S\_<_;F!NK:QAFUFV4O-,:C9[8PW(
MLR>U)A8>]9-W\IEZOKI\]HV:\T=A0)TIOOC0Y+K4;/6+T\[OYSN1O#&VVVHG
MWV.;B=,73K@V+WM398-58_59)LSU79+N3D>*6D:UR2IN*MR7A.70K;''HE)+
MHIJ5-O7OV-=91H,2PH/_`*,6^C&X6YV`WF+;X7U5N!UO1^HNNW)Q/(.E:FVD
M'$2W;Q;<O$\IO<LR3#;OJ5I,ZV9Q:AA;:UV(5E9;.9(F(8S3XQEF-X'D=K.Q
M$)8<<WJV=R[-\BVSQ/=3;C)=Q,028N58%C^;8U;YCC25TIB#8K?8S7V4BYJ?
MR^=+BPI_O83/L9DJ-%E^A(D,MG<[42NQFS^]F';_`.VT$=FLKIMOL&W&ZB[_
M`"";NA*V`SS;7;BAW%;RZ;7V/2-N1C;E7U%U\C<?*;2EGW>'[H4,VNK<0L\Q
MQ^ZETLW'\+&UEJ_KH&FFF@::::!HJ(ORG/\`7330<<)^B?//Q]^>>?Z\^>?U
M\Z((HJJB(BK\JB(BK_5?OKG30<((ISP*)RO*\(B<K^J_JNG:///:G/CSPG/C
MX\_/C[:YTT'':///:G/''/"<\?IS\\:X415$11%43RB*B<(OZHG'C7ZTT!41
M4X5$5/T7RFN.$_1/GGX^_P"O]?YZYTT!41?E$7RB^?U3X7^J?;7'">4X3A?E
M.$\_;S^OA$3SKG30?GM'CCM'CPG'"<<)Y1/C[+\?I]M<\)RJ\)RJ<*O"<JGZ
M*OW37.F@(B(G")PB>$1/A$_33330----`TTTT#3330----`_Y_Y_P37':/''
M:G"(J(G"<<+\IQ^B_=-<Z:#A1%5151%5/A51.4_HORFG">4X3A>>4X^>?GG^
MOWUSIH..T>.WM'M_\WA./\/C7C?LUCOY^65_D%+^U!T[>/'DGY5!_/SH&I[E
MHU1E<>A^8E3MV;KMBW6+)6$$YPY8L)(,G%]K30.$_1/CC^WZ?TUQVCX^E/I\
MIX3POZI^G]M<Z:#CA//A//SX^?''G]?'C^FB(@IPB(B?HB(B?X)KG30----`
LTTTT#3330----`TTTT#3330----`TTTT#3330----`TTTT#3330----!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g156134.jpg
<DESCRIPTION>G156134.JPG
<TEXT>
begin 644 g156134.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`^1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]02$%315]&4$]?2U]02%0N15!3_]L`0P`!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``
M$0@!1`*L`P$B``(1`0,1`?_$`!\```$$`@,!`0`````````````!!P@)!0H"
M!@L#!/_$`'D0```$!`,$!08(!0H+$0X$!P$#!`4"!@<1`"$Q"$%181(3<8&1
M"108H;'P%197E<'1U>$B(S=4\1<D)2<R-4)24Y8F,S0V14958G;2U!DX.41'
M969R='6%DJ*DI;2U"BA66&1S>(*$AI.4ML(I0V-WH[-HIK+%XO_$`!@!`0$!
M`0$````````````````!`@,$_\0`+A$!``$!!@0&`P$``P$```````$"$1)1
M89'P$R&QX3%!4G&!\0.AT<$B,F)"_]H`#`,!``(1`Q$`/P"J3RC?EHMK_:KJ
MA-#)-,TM[=(:$U(C(I>REK2:=,AR>!.IC3H&6-8*QQ5DJ`AC6/CZXKW-:J#H
MP1)4:9,E+K!':FJ=_(2D/:QJ/M0<-M5_\JE1/\+G?_\`F08;G':*8LCEY1/3
M?V\=7Y*[TV53$6S9$3GVZXI'^E-4[\WE+YC4?:F#TIJG?F\I?,:C[4Q'#!BW
M:<(W]=<99OU^JK7>'7&4C_2FJ=^;RE\QJ/M3!Z4U3MZ>4OF-1]J8CA@Q+M.$
M;L_F[9+]?JJUWAUQE(_TIJG:]1*5_P#>-1K\Z8/2FJ=_(2E\QJ-VG]E-V(X8
M,6[3A&_K=LE^OU5:[PZXRD?Z4U3MY$I?,:C=I_93]&#TIJG;D\I?,:C[4Q'#
M!A=IPC?UUQDOU^JK7>'7&4C_`$IJG?F\I?,:C[4P>E-4[^0E+YC4;]?[*8CA
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M?E$:1BE23V!VFB9GM66G/6&)6=@8D:]W<U):1,I51D(49YL*9.>?%`!1)D<+
MR.>R)M9LJUE;GG99VE&APF1SA9)=0.M!*M-RU_>HTRA;`SLB59)Y![L[1HTB
MI9`V-Y:A=&E3'J(2!)),CA7:<(^K.VY6*ZY\*JI^9G#?W+]/I2U-_D)2^8U'
M=_93WYX/2FJ=^;RE\QJ/M3&/0[)VU2YO<SRRV[,>T4XS)),#.9.<NH*&U36/
MTGES"@,=6`R:V9-*9KE+9;XUDG.;,8]I4,#HW%&KD$2A*7&:#-?%J8QE\Z;0
ME]]&5$SZ5*RB9_@=R^+B>9ST!KJ3+9S]YK\$E3`<UD'.93(8LA=#&XDY=`DB
M2%1G0KM.$;LG?<OU^JK6<NVYD^OI35._-Y2^8U'VI@]*:IW\A*7']XU&O']]
M,-^CHC6EQE!NJ"WT>JNOD!WC4%M,](J;3JJDMT,2.B9C5%MLV$,9DOKHTSVL
M2,RB%*XFB0[*TK:;T%J@DB/N4U;)>U9(K"]S5/&S!M&R9*TM(8W28YEFZA55
M)9EZ7FLLZ!.8YOKV]RD@;&=N@4&EIXU[BJ3(X3S("1.`V.&`5VG"-V=M<R_^
M3U5>%OGX8]_[+]WI35.WD2E\QJ/M3!Z4U3OS>4OF-1]J8:N5J6U/GIEFN9)(
MIK4.<Y<D-!\*SU,,HR/-,SL,E-8%&GBY3>\L32O;980`20>=YX^*D";J233>
MMZLHR*'"RG*,V3[,33)\BRM,L[3:_J11L4JR<P.\TS,]JP(-4BE9Y?84;@[N
MBD$Q!Z@2$*-0:!!)IPP`67'%"NTX1NSMN2_7ZJLN<[\NN,GN]*:IWYO*7S&H
M^U,'I35._-Y2^8U'VIC",&R[M-S6YOK+*VS?M`3,\2L:UD3.T2[16ICXZRV<
M^$JU#(2_MS7*ZI8S'/*=`O4-!+D2E,="$2PY!"H*2GQE]J@V(MM(V+H%;'NU
M:;$(C"$)>SA6<R(1"/JA#HP23$-P-N5$%OP30$N*T8##A=IPC=G;7/FO_D]5
M6LY=MS+\'I35._-Y2^8U'VI@]*:IVXB4M_\`8-1I\Z>..+1L=[7<P-S>\,&R
MEM,OK0[$QJ6IU9:`U;=FQT3EFF$&GMJ]OD]2D<""CRC2#349QY91Q1A1D4,<
M$4(=05;/=?D4_M5*%M"JT)*IOJ(QR8Z9*J43^GJ(]MQ296M-<&:1SI=@FAU0
MEHT"]68L;VI2F+2H5BB,V$E*?&6NTX1NSMKF7_R>JKRQRL_SWMS=Q]*:IWYO
M*7S&H^U,'I35._-Y2^8U'VICJ3AL[[033!/1CK0>M3872XA$JJ;&XTGJ`A@I
MNF<DD"]N4U`B52Z2$E)UZ$PM8A.F<6HI6E,@4)HS28X8QRJ#99VGG63TE0VO
M9MV@G.GZ]E&9$$]MU$ZGKY+72X">)6,P(IK22J<P*V.%)!&JB=DS@:WPIH(U
M`J`)@CC!=IPCR_RS_/>W,OU^JK6<HZQ9]RS'I35._D)3O_O&H[_[*;PU]QP>
ME-4[\WE+YC4?:F,!)&S%M*U-EI+.=-MG6O50Y.7*%21%-TB4:J3.,K+%:%2*
M-:E2S%+DL.;,H4HUD,214G*6QG)U0"F.@@.#H8Q2"@%>G289SE%KH=69SFRF
M\9!51)5;J53\NF60#51L!"8J>&!++QKM*!J@\PL@@N8D;:8<<9`45#'''#"*
M[3A&[.VY+_Y/55K.7;<R[IZ4U3MR>4OF-1]J8/2FJ=^;RE\QJ/M3'5R]F_:)
M.DETJ630"N)M-V.!],>JAETBJ)'(;,7*[BJ9YFC=IRAEL9;;()<=T*YJ?XES
MF0#,YHE;>Y"E5ICB8$8=G':(FF5VB=Y7H#7"99*F#K_@"<9?I#41[E1]!+$I
M@4Q,TR-DMJF5U@31HED"@Q`N4%D1HU4!L4$2<X(%VG"-V=MR7_R>JK6<K-^?
MS+M/I35._D)2^8U&GSI@]*:IWYO*7S&H^U,=84;-VT4DG=EIDJH!7%-4F969
M3,4N4[/I#40F?)AEY&6>:L?V&3C);AF-Z9$A2548I=VQL5MZ>!,HC.4P0D&C
M`U\PR[,$HOKQ*TV,+U*\SR\XJ6>8);F1I<&*8&)V11]4L:GIE=4Z1S:G)&:`
MEJD"]*G5IC`&`XF",!AQ;M.$;Z[Q+]?JJUG+MN9/OZ4U3OS>4OF-1]J8/2FJ
M=_(2E\QJ/M3$<,&%VG"-#B5^J==[]Y2/]*:IWYO*7S&H^U,'I35._D)2Y_L&
MH^U,\1PP87:<(W]=<9.)7ZIU2/\`2FJ=^;RE\QJ/M3!Z4U3OY"4OF-1W?V4_
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M`$IJG?F\I?,:C[4P>E-4[\WE+YC4?:F(X8,2[3A&[/Y&YDOU^JK7>'7&4C_2
MFJ=_(2E\QJ/M3!Z4U3OS>4OF-1]J8CA@PNTX1NS^1N97B5^J=4G&[:VJTTN"
M)T;XI:1+VY40M1JTC0I(4I528P#25"<^%S&(HXJ.&&,LR$+P1!<-,[YMEG_N
MCW;DII25!);O4:7)E.971<0F6U"E$F<7I,AC(1&)T"1\B6-ZTUG3]*.)$E<A
M7*T)AJA*4MC;RD*=-J^X[S*G]0JO]WQ_]41XE5,6>'G'A\1/ZWXM4?DKB><V
MQYWI]N?C'/OR?MJ_^52HG^%SO_\`S(,-SAQJP955J)K_`%W.^H6'^F08;G&J
M?"/:.CG5XS[SU&#!@Q4&#!@P!@P8,`8,&#`&#!@P!@P8,`8,&#`&#!@P!@P8
M,`8,&#`&#!@P!@P8,`8,&#`&#!@P!@P8,`[^S]+4\S?7*D,NTT:9D?)Y<*E2
M3'+S9*/G03$>H;IB;W58<V1HCDZDF-"U(7!P5*(#R84R!(K4'&0$%&Q!N?>4
MUVU'^GNWQM&[$-'J,5EGB;MNG:&V$J@(JKNE4TCK3!LD^CI=)5;\_P"S33^7
M6Q.:S.Y!,EOS54>=E\W'=8IEY\+6)2$K0C)@T88H88P&&.&&.$<AACA".$0X
M##$`PB'(0''`"2(8!+A((A+B_=%PDE0EQ7UZ180A!%>P7O"-[!P#$F+9B<.M
ML3_G@U%4TQ,1;SG'*8PGQB9Y^V#>BVF4AD^[2'_=*DOT9I'/@5.FS9?I$R,L
M_2O528)F"L;N^,4D.4OL$@204U-38SO!DOM[J:C2RU,CZK=VYN<!A))@4J2(
M8TTRV5$4W^38VL/)-G$2LNVGJ2TFH]MY2=*R669T0S>W[2SDH.=:C20NGU^E
M!FIE,Y\U24XM5**7-$G3X\KW!4U3@@C_``6U='!IX^;IQAAA%,G&&"_0A$@D
M82[YCU</0Z,%QS'H@%QS&XX!3IHH`+B3)HBH?W)42<D2X><)8P#!"([Q"$!'
M?B7>7CA/.+><69Y3JU?M\8MMO6\XCE5;;Y>/.+)Y^'@V[(DD]5;\D;/M,*T(
MGJA-1]FWR>%/&&C]4J:3C`OH]M1TFJ5.+)/$G[(%4Z5S"9`2Q;64N5`8I;0*
M'"5DA,]DS+&J=&]9\#KS6][S/E7&*I*?9/HPU-=*JPL]5I8\D7L:R_7#:&4U
M#<@ITQ4ZITJJ/!M#[+-2Y95*S&@*KS3-#W3I84FZY_FZ8%I"=L7(Y<2,9;TI
MT^P(("+I@G(`S/\`&`04!EX@M$/3"#I7B#*(;WB#41PD*=/`(10)D\`PQ=*$
M8""8!ABM;I0C#``PQ6$0Z06BL(A>V%WG;$^<SY^=F>7MS\$O^5G_`,Q3X\[(
M^+/#ERB)\<6TA_W/[,-8)%@F5=4.;JER)L5U1;MHBEJFM,F5OD27J;;+]3/U
M*C'V>*JU[HS,12MLFEEF:7FZ7)>D&;*G(#F!CF)&/Q*C%U6+TQM:ODI)]GS9
M[V[)@J'L_2W)5>TE)J5;2)ZN2YN?5TB*JXT-;T,$J3(R4V?T0"KENK<^RDO;
M'.G6L0N!RIF$LXY66F/J;B))CCA,C()C,AL$)D9)<1D(`/2``,BA&,`"+\(`
M`<HK"%A"^.4<$!@=$R"`R&X1=$R"$R'I!F$5HP$.D`Y@-K@.8#BV>.<6;Y_Q
M+W_7_P`S;X^V67+Q;AC-)BZF?EY-@FF]%JQU@GFBKFT[,VT=4VE-0IK1OTU[
M-:"2Z.S](TKT[K],21;&8\OM$9(?6IA(?)W7*GUH9YP:&5W/<W4"W9<VNQ[-
ME8VOR@/ED=F>=9VFN69GJ#LD^4ZEK95IC.$[_%D'^>:Z5;1U)DM)30QT>$+?
M&XU#:289REA0E<N@<BB4.3.:D+4+A.U.NH(Z'5=01U0#<"NH*ZJ][WZOH="]
M\[]&]\[X7J21+ZH221*_DA)+$K6_]*Z/5ZY_N=<]<2[GY1'AYQ,3;^NZW\I_
M[3-EL^$Q$3'ZMB9MLF6T=Y)F5*X2+Y0#R0%-9T*GN7W.@,O;5,\URDMUF97`
M71J1ZH3A5J*2W"I[2+W&W26FFSSV6S$+6]PIUBJ%SETPQ"'GJ$,8:M]>*@;*
M_DP]G5!/T^&R1Y0:D_E+JK5DV0FMQ=E+A7.CVS0H63$0_JYO9U2]6[2S3JHD
MTQN*:7&"8TQ+'.DK*DZ-I2&I`40PZQ(D$#!U8D$"6`C$!8D%"6$0ZQ!`,`P=
M(=\5ND.=QSQR@+++`0++++`1O$!9<$'2&UKQ=``Z0V``N-QL`!H&$Q;//*V+
M,)M^/X7[*;(B?>W*F/*(BW_C;[MG_P`M?,DYME%:55ZE&A4V;/,Q^4\E6GM6
M=OU(2]JUC8AK+3%!$WRO1%P)+,*.E=%-#E`Z5L=93>"XCWQS:V50?"$<OJ8#
MGXV3)<VF&CR5GDCW"E:F8),G.3O*M3-61PF1_F!3+TLR/L[+D$Z*UU2:A+U#
MJF3,-#G&73'(#'-[ZF5E\"P@KJ3@7$P'Z@\!))8C$6025%%^ZB+)++BBSO\`
MA100PC%GGF(YYZXXBG3C$,<29-%'$(#%'$G)BCB$!`0&*(8!BB$!`!`1$;"`
M#J`87>41A-OAXY>.'+SY07YMF<8B.4V663$\K(Y6S%LV1'.9;W5,'RA4QR!Y
M=6IM.:(S]7_8XJGMS;)\X4=I;1%^=I3,KPVR)4*5QKU,&S^6U*B#'MI;JC(G
MN<G@B78&IAFIJ3EM2IZ:&1P^$VR)/DR77:GEVKNU;03:45J*GR_7G;@H?)%>
MJWTIK,2R;4U`MHJ0)!9:JTRVA$C]`:3+L\4@IE`S2S+E7(7&%U:6I[:W'X:*
M>V%Q7P/FGY$01'%TXR"(X].G&25'':UK=.*`8K6RM?3+3"1)TT00PQ)DT4,$
M/1@AB3DQ0P0WOT8(1@$(8;Y]&$`AOG:^%WE,8X^5EF>7SRP7B<XMCPMY1-EM
MLS,^$9V1'A$:MNEUIHOD7R4'E&9763?,5>:-(/+)2M4-94&6>K3M-:=FJ3IV
MDN*OE597E:5W>-$=3M<ZH9U)F(B5(#Y;@=TZTE)$:"8#B7`K_2N>JR;?6U7M
M-4BVV"MEO8HE39/01[.=5I4DB"J6R--VRO#L^LU+9]H9+R!LJ_)$H2_4Q"X/
M,QL+-2-1*YCPY5`+.=6Z)OF]B2G'Z:XD$#&!@D$=8%K&=25UD-@L'1CZ'3A"
M$,H0`0``R"P8.H(Z8F=01U@CTA,ZDKK!BL`!$,?0Z0Q````1"/2``L`X7>=M
MOOR]N<>43,QX_P`.)X19RBRSG,3R\K8YV98\[6Z]L[GT]G+T%]B/:;:779VV
M@]DRA=!MH_8!VCYP;55/9YJ,RRT@73+M)[--0/-IE7"C=']E:5JPJ554SK39
M>F%3&SF^=KV*/XQZ5$2Q6XC\(KU2M<N7A"M6+5ZD]8N6*E<(*%"I:K4F&J52
MH\XR,U0H4&F''&QQF&QQ1Q11#\`((AAB@A(("",0BC@`DH((X@&X11P!#T8X
M@$`'I1`(W`!O<`Q]<6(L\[?[YS\LU57K.5EGGC%D1%N,Q9XX68#!@P8K(P8,
M&`,&#!@#!@P8`P8,&`,&#!@#!@P8`P8,&`,&#!@#!@P8`P8,&`,&#!@#!@P8
M`P8,&`,&#!@#!@P8`QWF5/ZA5?[OC_ZHCQT;'>94_J%5_N^/_JB/$GPQYQUC
M<+$6S'.SGNS-*BH>QUM&3%/<X/[73&93&UXF!P<$)AS*^$FQIE$<,141A434
M(EQB$(W@B&X;\=.]"':;'_4NF'?_`&*>]W_!/?[<>I-T0X!GR#+ED&GO?/!8
M`OH/:`9<\@#[[8Y7YBR.7)ZI_#1,S//G-OB\MGT(=IOY+YA^:GO+M_8GWO@]
M"':;^2^80_X*>_#]Z=<>I-:'@&_=PY>_KP#"'`->&[U^(_4&+?G"/W_3@T9Z
MO+9]"'::^2^8.WX*>_LGQO@'8AVF@_U+Y@[/@I[^EIQZDW1#00`.X-^Z]K6W
M6$+X2V68!II8,LAU&UN&ZP#RPOU9'!HSU[/+:]"'::^2^8/FI[^R<'H0[3?R
M7S#V?!3W?_LFWKQZDU@&V0:\`'Z,AW#VB&ML'1#+(.8V#O#(`Y6[!RRPOSEO
MY.#1GKV>6QZ$6TU\E\P_-3U]DX7T(=IOY+YA^:GO[)W_`*;8]280#^*'+(-<
M^S3M#!:$/X(!;D%N=K!]6_"_.$?O^G!HSU>6SZ$.TU\E\P?-3W]DX3T(MIKY
M+YA^:GK[)QZD_1AS_!#+?8+COW!QY:[L'1#+(+[Q"$+CD-MPV[>X-<+]66]_
MOV.#1GJ\MGT(=IKY+Y@^:GO[)W?HOC]"786VI5IO4HJ2S2L.""(P2DC%,*DT
M"X;!%&)9#*9'T(1BA"*+H]&$8@N(7#'J/=$`W`%QW``7[<AW>-MV'GH$%JB0
M;OZ''O<`7LH:>S4<].S+/"_5D<&C/7L\GE1L,;4:,Z).KI/-"0^`(1C(5,<P
M)SH0CA"*`8BCF:`R$(X1"*$1A`(H1`0N`WQ\/0AVF]U+YA'L:GO[)QZOU;@`
M:EOXV`1\W9`S`+V^"$N_7CEOPU%@X!X![^_BOSEOY.#1GKVW;[/+8]"'::S_
M`&KY@R_UJ>\^S]B<'H0[37R7S!\U/?V3CU)K0Z6#*VL/KTMNW87HAP#=N#3W
M^FV>%^K+3>YG*QP:,]>SRV/0AVFODOF#YJ>_LG!Z$.TU\E\P?-3W]DX]2:P;
MP#0;Y!EIOY9_3@L'``UW!KKED-_;D.0X7YPC]_TX-&>O9Y;/H0[37R7S!\U/
M?V3@]"':;^2^8<_]:GO[)]F/4FL%]`WZ@&_N[;#J'.^"W(-<\@S#/3??3ARR
MPOSEOY.#1GJ\MGT(=IKY+Y@^:GO[)]_'!Z$.TU\E\P?-3WGR_>GWOCU)K0WT
M#+EENY:_7@Z(<NVP?5A?JR3@T?\`K7MNV<K/+9]"'::^2^8/FI[^R<'H0[37
MR7S!\U/?V3NWX]2:P!E8!&W``S&^8Z9#RSRP=$.`;]P7Y;K<^[3,<+\Y;^5X
M-&>KRV?0AVFODOF#YJ>_LG!Z$.TU\E\P?-3WEV_L3CU)1``'0!RMF`!K?4;;
M\@L'?NPM@$0L`<[AGOW6OKV<KX7YRW\G!HSU>6QZ$6TU\E\P?-3WR_UIY^^5
MU]"':;^2^8`_X*>_')IQZDH0A?,`WVR#(.X-^0[M-^>.4,`Q##!"'2CCBA@A
MA"$!&*.,0AAAAAM<8HHA``AU$1``X"OU9'!HSU[/+8]"'::^2^8/FI[^R<'H
M0[37R7S!\U/?'_>GOXVQZ1S?MH;'SK-ALAMFU-L]KYW3O94MJ903U9DJ.9$D
MPGJ#DA#$L:!=H%B)V4JDYZ=(@6%$*59Q)A24LZ.$0Q)<80`1`0"X"-P&$`R#
M(0$-0SRSSN`X7ZLC@T9ZO+:]"'::^2^8/FIZY_ZT\O6&#T(=IO?2^80[6I[^
MR?>^/4E`(?[W2^0!8.SE[+9CANVJKM)GVI,ST;9:F2"[U=DAE03'.5+FV:V1
M;4*5)>=A0`UOLQ2@0KC?6=F<1=&T$+FM1%(E<2]'"2>8)Y81+]61P:,]7F3)
MMA7:F6F"4BI)-2PT(1C$I(Q3"I,""$0`8Q+(9HXPA`1`!BZ/1`1"XA<+\5&P
MSM1I#HDZND\SI3X``8R%+(_ISH.D`10],HYF@,AZ4(A%#TH0Z4(@(9"`CZQ-
M`A`*A``6SEUYS`0S_7#6-M`'*V[OOCJ]?7=H8)RG-]?G-M96-E;BW=Z>7=8E
M;6IH:FUG@5N+FZ.2TPE&@;D"0DU4M6*SBDZ5.48<<;`7`(@OSEOY.#1GJ\I?
MT(MIKY+YA^:GK[)PH[$.TU\E\P#V-3U]D_?CU#V!_8)K8V>9Y7>F>99:F)L0
MO4OS"P.2)X8WQF<T\"MN=F=U;SE"%R;5Z4TI2C7(SSDZDDR`PHR*$;XRT70`
M(HAZ`0P@(Q#%T0"$``1B&*(;!##T<XAB$`A`.D.07!?JRWO]^UC@T9ZO+:]"
M'::^2^8`_P""GOZ&G!Z$.TU\E\P?-3WG_P!$^W'J!()QD]VF:8I+:YJEIRG&
M4$3$XS9*;>]M:R9I8;YI(4JI:73"Q$*3'-F13$F1JE#&J<4J<AU)3'F(C#H"
MHQ#L=@N&0;AM8-,]+`-^[ASPOU9'!HSU[/+:]"'::^2^8-+_`+U/7A^].N#T
M(=IKY+Y@^:GO[)QZDW1`>%NP,[Z:ANRSSO@L&M@MV!WW]\K<Q#"_5D<&C/5Y
M;/H0[37R7S!\U/?V3@]"':;^2^8;<?@I[M_V3CU)OP=/P0RY7#+@(>_L!`.&
MZ^0!W@`#G<??FOU9;W^_8X-&>O;=OL\MGT(=IKY+Y@^:GO[)P>A%M-?)?,'S
M4]^/[T]^/4FZ,([@Y9!ES#+ZPX8Z[-LVRQ(<O.$US@\H9?EUJ\S!<ZKQ,ZDH
MUQ7I&EM2EE)RCU2I<YNJ]"UMJ%&G4+%[BL2HTI!IYT$`K\Y;^3@T9Z]GE]^A
M#M-?)?,'S4]_9.$#8BVFATI?,`WTLU/?&W]R??MQZ>\G3[*,_A,4,J.D3DIE
M![+EJ;6XYK=FEWE>836AKF`ME?FAY;T#@VN$;(]-#H64>GZ!J%R2*"33(#H1
MQB'6KE,6*JLG4-=YS9VZK]09:F6<I(IXI+<(9CFB5Y/B@AFE\:"H&^-">C81
M-+%RA,7$J288X3($YD`C%A?JR.#1GKV>9!Z$.TU\E\P?-3W]#3@]"':;^2^8
M/FI[^R>&?WY8].XFI,AJ*E+Z/DS&C,J8VR2@J.NE`$SB"]-)#F^'RT@F&)5$
MAA:8TJE]3G-T*<MQ,<(3H0C,1P)XH3HN]]3&$<4'4F`9"`Q1P"5$$<,(!<8H
MX.@$<,,("`C%$``$-A$;#<5^K(X-&>O9Y:WH0[3?R73"&G]BGK>%_P"Y.#T(
M=IKY+Y@^:GO[)QZC*1Q;5SBYLZ%8D6.S+\&`\-B0V!0O:A>4AK@T`X)2>F<D
M%S0$FKD$)\,$2M&7$I)",@.F/[P+$8@@`N(8QBZ(0!`(QC$(_N0@`.D,5]P!
M?OPOSEOY.#1GJ\M?T(=IKY+Y@^:GO[)P>A#M-?)?,'S4]_9./4HZH1",>JB$
M"[=8(%Q"!?X5@ZP0AL7>(.C^&,-X@$-0$,+U)EK]4;:\`!%U,=A&/*`.D,%A
M$P<H,_PQR@OIA?JR.#1GKV>6MZ$.TU\E\P?-3W]D^_9@]"'::^2^8/FI[^R<
M>G"?5JF9$RR1)XSDS'3)4=XGU@DEL0BI<QF!\I:G5**AM"=:VI5;:E<)0!"L
M)>DKDM1')UR50W%PFKR8TT+D]08`@`DF@(@/1`28P&+H_NNB`P7BZ.D5K]'^
M%8<+\Y;^3@T9Z]GEJ^A#M-?)?,'S4]_9.#T(=IO7]2Z8?FI[R_Z)[/''J4]3
M&,4,(%&#%%G#"!40QQAF-X8>ATHX;7$(H0$+`(WR$<)#!TAA@@@&.*(0AAA@
M@&**(=P0PP@(B([@A"_`,+]61P:,]>SRU_0AVFODOF#YJ>_LG!Z$.TW:_P"I
M?,&_^Q3WN_X)[/'MQZE4))D0B$))L8A$,(A"5'$(1`(WA$(81$(@TZ(_A!;3
M(<-?6"L=+*`4^?JKUHG5GIS3:5P013'.<P$NL;(QP.:].UH3G,QG;'56D3J7
M%6E1`J,2^:E*%!,*@XF$R&+"_.6_DX-&>KS)?0AVF\_VKYAR_P!:GO=_P3[<
M'H0[37R7S!\U/?V3CTUFNM%)WL]40TSVQ+@0TY9JNKUA0.$#0@IC,*)8YL<[
M.$PJ&\J7T+$YMB!<Y)#%CJ2LC;DBA?&C@2%Q'X<X@2U:4E<E_7")0G3*B59$
M`FIC4RTB!2C40'PPB7$2J3G%GIS.ET#BC(#"QB@B`17ZLC@T9Z]GEM^A#M-?
M)?,'S4]_9/OVX/0AVFODOF#YJ>_LG'J5`09E8@W,88`_$&9Q1!>&$+09Q1!G
M#"&<09P@(8`(,B`1`DT0`(A$0)C$(0@$>G<>@(0]#^'TOW`!>*V8X7ZLC@T9
MZ]MV^UGEJ^A#M-?)?,'S4]>.;3ZM>6#T(=IKY+Y@^:GO[)QZE/4QA!TQ),ZN
MW2`P28P+Z-[7`SH!!T;Y7Z5KY7P1E1%CT3"XH(A`(@A,+&"(88LX8@ABA`1A
M$,X8K6$,P$=<+]66]_OVL<&C/7L\M;T(=IKY+Y@^:GO[)P@[$6TT'^I=,/S4
M]>&;3CU*NJC'HV*C_&`(EV*B'K`#42_P?Q@!O&#I`&_""6,-NE!%#<+ATX.C
MT@`1"X=*$+A<!"X97A$+W`<+\X1^_P"G!HSU>6OZ$.TV/^I=,.[^Q3WO_P""
M??=?!Z$.TU\E\P:@'[U/>_M:<>I/T0X!X!]6$L&^$+9W`0#CER]>65\+]61P
M:,]>SRV?0AVFODOF#YJ>^%_[DX/0AVFODOF#YJ>_LG'J3=$+6ROQL'U6UW#G
MSP='LSS#\$,N7#W'M!?JRTWN9RL<&C/7L\MGT(=IKY+Y@^:GO[)]_#!Z$.TU
M\E\P?-3W]DX]280`/X,(Z;O$=!L`<=WM.C#?0,@O;HA<>>G+0.7+"_5EO?[]
MDX-'_K7MNV<K/+9]"'::^2^8/FI[^R<'H1;37R7S!\U/?V3CU)>B`Z@`<K0\
MNW?[<$4(6B$0"W1'<'`;[NSMX<5^K)>#1GKV>72HV#-JY*2"A51R<4R>+H]%
M0HER92"(AC`8H``XYC@+$8P`1@`(OPPSAN&>/P>A#M-?)?,'S4]_9./7CK5G
M2J6;_P!TI:X?W*6<;AB(0PAP#/\`O0'7</+2_$`M>^%^<M_)P:,]>SRV?0AV
MFL_VKY@R_P!:GO/L_8G!Z$.TU\E\P?-3W]DX]2;HAD%@R'+(/JR#<&@CZQ+0
M\`W[@SX^L?$,^:_5D<&C/7L\MGT(=IKY+Y@[/@I[OV?O3@]"'::^2^8/FI[^
MR<>I+8+[LLQ"T.F>6F[*^?KMA>B&>09_WH6OQM;VB.%^K(X-&>O9Y;/H0[37
MR7S!\U/?V3@]"'::^2^8/FI[^R=WZ,>I+8`L`VSR`.B%NSUVW=^%Z,([@`<M
MP=W+C;6PX7ZLC@T9Z]GEL^A#M-?)?,'S4]_9..SL6QKM&H$IY2JF$R!&8JB-
MAZ#*]QAT!(3EA<?@H+#TBX\N%AWX]/\`Z(;PA$-!$0#Q'*VN[=WY`P\`#U!_
M]H^^[$FN9BSEY8^7R1^&B,?UKX>/L7ZM`"WZ.68;]=W5YVG:4J<RH_3S/<P-
MDJRA+"`UT?I@>%`)FYL1$C#")QYEHHXHC#8X"$Z<F`Q2J4F%)DQ)IQL$`DZS
MI*=.I4?IXGE_;)6E&6&X]U?GYW40I6]M0)X?PS3C8LXHS(Q@)3)RH8U"M284
ME3%&GFEP15[TMI5.7E,)R:JPUD:GZ2MB"2G\MQI!1EV3J6AZVAGAKBZ2>H]1
M28^J-AD'K8H3&!FAZ1;C!":02:)0KEQV75T,S:!VYZ@I5VV31^E4*S8]DI5&
MA0T@=V^-+6"M5."XXHYNK5+J2.`3TL3-"CA/E-MA.@\Y;16C`@>806*8;'J.
MUCIY7FGS%4VF$P)YCE-_*CZA44`DK$"].(0.+(\(8['MCVU'B*9Q0GPA$4:`
M1E1G)S"3C)O)$:5O2I4*!,G0HD2<A*B2(R"DJ5&E2EP$I4J1,1!`2F3)B2X"
M4Y!,$)1)4$)<$,,,,(8IQVD]G:HVQ_/DS[7NR$Q*)@D&8%I;YM/[+K40,2"8
M6XD0%SJ929M3%V9YP1$B<N>6U$0=`H`5"U.F-0QK$*8)_7#LWAIGO$0^G!XW
M[0WY7U[1"X;L-91FM-.J_4]8ZG4NF%-,4KOA8P`9!%`6O:7,F`N)>P/R`(XS
MFI^:XS(2E[<>'3@&(L\D34IY!YCICW6L&HY6'QOW]V_`)Q&XC;F.H;LAUXY=
MVN%TT#?N`,QWC>_=GSURL7\<P$!Y6ONSW6RSONSP9[_>PY<?;PP!D&606]0<
M???OP9"'+*ULK!N]F[`';?(/#<._UCN\5W_=[\_'`<;YY\[#K:U[[LMP#X<<
M*(Y7N&0Y[_9IZ[<,%]<]`]FOT7X=N#AW[^_Q]F=AM@$RST'=?Z]W"XA:_*V'
MIH&-ZAP#_L<>_P#K#1^CMPRX:<0$.\>T0Y!81WCPP\]`_P`HD'^#CWO_`/UV
MC7=>VX.0\,!CJW?E+?\`*_ZW9?\`LA+K?+U]V>;4:;\QTOGWVOPUMVV`,.Q6
M[\I;_E?];LM_FA+EP'?V<0OAJ-^6>>>FF?9D`_5F-\`!RR]?&UM,LLN7#``[
ML]-!M<>>N_G;/MP7Y9<\O#+Z?581+9W[]^N[+=;WT#`%PT[;Z6YWSOVY;\`Z
MCORS#=V<A&^_4`PFO98>S/3L'6]N_=A?"UA`0\-VFF`!N.7$,],KZ97\=PV'
MC@'00XWYZ^KD%\L)?(-0N&>>8<`SXZ7&W;>V%W\+^XY6M?/<.=NW`+X^_ON]
M0X3WS'VZ]W9K@X^O?<.'W!O]:6'(+\.W+6UK#GST[\@74+#:_P!(AGI;//=;
M":YVN&M\M?NL%AU]>%RT'?<.&6E@]7"^H8!SOV\!',,_JM;+MO@"]O;PXCNN
M.[.P#<>^QEQW\<A',+?=Q[\%M`'AKO'7(;YWL.[GIO-V_,-X>W(;>%L`:_5<
M-WWA;.V@X4(8C!Z$(7B,$(((<KQ11B$,,.MKQ1"`!F&>^V>$]GZ/;GQ[0P97
M&P`-POV[@XY>X7SP&G%M"+HZC[:'E?FZ)`KG?92KC/.P$%<H9+E"H`UKF.A]
M#I6205;J%LPOD;?!+3N_T/GAL:DM36PZ7Y@F".6EKLHD8U.\((3CK$JG[=5<
M%.V!2QAH7/%3EVQ^95Z7Z2U+J'!18$%,I?IA.NSDIFAFF^4IPF22)BG*8YKI
M_-DK/+JXU6?%3++);TY(I">*;/\`$S+'1VV%8E[@(00Q.#A%##%!$7#$O5C"
M7&4'XJ*`!.$((B@OU44$("7_``!APD2U:,?6Q+EPF"`AUL2U2)MHH@B$.LB-
M&(0&*&&,0Z5ABAABL,4("`:E&QCY1?RF4S$[*94ZJ9EK-.57]G;;V7S7),]4
MB9Y'3JJ]T:7SR\;-TO@YRK3^4(Y1=YS;FJ466)(O-B;)C9WJ$PM'`]*"5L'1
MJ,U.V^&ZLVU5MK2Y2BJ%3MIE_P#(_P!%"V\^9J(S,U2U'M(M<\2*[5!I:E9&
MF3Y>:CW^F;&WS6H::>B(/;N;*Z9A-5N[HI$Y9N(1K%ID,<)JY<;":`0FP&K%
M)D!T,.<$)L,9L4)H09C##&$4,(W&$`Q\8S38["8<<:,(!T>F:9&(!#;HA",<
M<0AT;!;HVM8`"P!;`:[%)-NO;=:MLS90E--5RHANSC.6V!!23]5E32F4(E];
M]GV8:&RD\3K,<W0GT31IY=34SVB7B&F\MU)EE')+<O.4#*CDC>%DL.;PN@([
M>4O\I/4^DLHN&T'.#\4X5TV+-N27JF2RX;,\L-[<QUSH4EFQGH2C-EUPI<^$
M'3;7N%OE9FG259D;ULD3DUSH:WRO*TJ*#DC@DWC:#*%)M01`U2J-ZQ@=XS.M
M4GF=;&4:UP%QF],R+K(RX(HH"XC.E$7`(PP#"`B&,56)8M(J*_P$+W`F`(6X
M.B2N5E0]$$!-H;0'0@,(=./HPYPP]**P!TAN&GIL'[9.T/,=4]D>G#QM`3_3
MFD4A[-5&":HTM1;,DHLDOSQ7V<),:97EK9VI-)+-1AC>&:5J:N*!SGRMLU,L
MULK:A4+2I#EWXNEHB/A%G:U;97E(JY[+OE%94;2MH,EC,V<-G.I]#']10O\`
M4OJL\-TUUBE*F>T*ULC1+4O'*&:4':529ZFV&1A>)LGR1&",$JB>G5(E<(3M
MQ^-P<C((H#'-R,@CA&&(LQP6&01P9?@QEQG##'#I^!%",.X0''S\Y5"(1"K5
M#$!@FPQ"J4#%";;H];#$)EX31A``ZV$0,Z(0P](80#`:N$T[0^U)1NM_E45&
MS:KF*O,\2I1+83.I9.LX4.DU14A[:H')F9*^/1KW(]':9K*L'T&EJ<5!K-*C
MT4\I)11"E7$M;D0C<X5O7YJVY_*!E;25')"8JJU,(H9,56]NZ2I1J$52B25B
M^N=!J:T\/<-EBM\RFJZ+%%RX_3A4Z-WD]K?VA%*<O5*@EI$<GDQ`24M4.VUA
M$K5QP001K%D99401EEQJU$994<(C:,N"(T8"XX1BB$(X`AB`8HK#>(;KYZN_
M&!Y\O_'1=,_]>JOQT8@`=,\.N_'1B$(!TC.G%T80AZ5H0#`0%\F/76JNTGL(
M[.=9JZP`56::I1=DM32_BRHDX^":I;G"8Y;.-72RH2H09W)>U-32[N*9(C3-
MT:MR,4-:=,@.3IB9XC8-;;AMWZV[1W!CF8:<?'UB@XT\P;`)IYQAYL00@(`$
M1AL4<8A"&0`,8@`9!ED/'3LL%O?PP";^W?E^G<'JYX0+Z7OZP#B&M]0&WTVP
MOT!:V@7W9V[LKX`Y=OC:X!VZB-[7XYV!<1@VR*52[7'9WGFDDW2=4*=Y7GU5
M*3(^M])G(AGJ8R(X9N97$F>Y&<E"I&4EF&GCBA03FF&(V.,XAE4IR4JTXXM(
M?)X--;^_T:840`=0OVX"AM11CR@DBL]+V%?.E8]HR0Z+^4(HZ^,-2#D3;+>T
MA578_BI4^-]0B:S,K:ZRVFJ(CE6=W%DE1*N>"$#Y,S&QEO3@V>;(4AX0HE+9
M!VXYD8-DF:*VTEVBWR<J;;*_E,)'FQPAG0[]4J7*E55G1Y7[,[.9,S7.Y#J*
MM>0G8#I;=$[NJ99>@3-JA[5MZ5,$1>UT(`.0@`AK80#7C@Z,.G1"UA"U@T'4
M.P=X;\!K".2S;\/K-7.A4GU1FB=]IV7O(?4@B7(I7G@"V)RVK&6NDKRY49>Q
MK(W"&666J[G+:.8Y0^,D<2-QA=CHE1YI(&C$$JZA4KVEYI5;,*!I8-ME)LP3
M[Z0$%8),E=QEZG&T?L]U$GMCDUSI#,S6E;9J4GP2%3B:V6<&N7%#J\3%&R+)
ML53"L;#F$Q`0GND9I!D:7'^9)KE^3)58IHG(TD^;IC:)?:FY]F@Y.,<1!LP.
MR1*4N=S"HC(XX(EQYP@9'&:-S(XHQ[9T8=.B%@S`+!D/'`]^:@J;=F3:=9YC
M\HPLD66ZGRK.=7=J2CE6Z,5"4-L=4Z>3S(,H4E85:J1:A,#1/#1,[A)+S.4N
MN$G3PBE.!B?98<71E>&.-8T%1(QF!6A/M9G;#VSBXR]2R93JK,DU;,,S[3M`
M9(FTZ8I[?Z5M[Z@5;0%)Y.G!U>6M;,3R*`\(#8CY@2N[\U-SBSEO)RTZ,Y;8
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MZ:6HIF-0MTAJZUF0J6]*0U0O#8]E`[ITJ,LN%1%;A'M5[+Q1KNG,VBZ%%*)?
M;YF='X@RJTC%G,;9)+BG:9R7O!4;U"8V))1=5:5OF@Y;"1!+RU2G(=_,XS8+
M]S7UDI"UHXG)SJ?3YN00(F1TB7+IL9$J4&Z969;,4O.(''*X8(T#W+K:XS`V
M+H!B3+&!M<'LHT6E`K6$CPLCXAKV;(NROMG44IWL(2&YTRK+*1LANOE1X=I8
MA),\2QB>%=3$%2ENSB].T:.;%A,Q)WYX=Y=,DMR@*B5HWTPQS70-IHGN!D>I
M?V;O*S-NS)6F5T31M2E5-FCR:M%$;88]U.=%DPG;8DH;3CJ]S>GEUX73FIC:
M)^"BAJ)&8I:E*)`[L4);**M4JA%/C:!==H2@##,:J3WVMU(66;4/P?YY*[I4
M24D4Q)`=Y><9N:XSV,]U@=("W24V=VF=N-!)$6X2^V+G=)$>@3&GP]5D[:PV
M>YYV>%FU:Q5)E\:`()>FF:EU25QP(61++,H+G-"ZO*D3!B.(2'1-9BEL+-@A
M5KTBMM,@30'+2R`"HM9*.W7$_58?7"0-I0VATT^4M?)J>Z=-H('*JRK8_FW9
MV"3Y8=:>RJKG4HH99DBMJPF=W>0V^8&UQ)6MI+U"DC@;CTRB?-=J>;004#V2
M9.D1_J1/<$GUXV6H=IU5,!K6DK!4G9WEA[)(JV,RA*2M`WK'US1%-;M49EE1
M0!\P-Z=Z;VR!88<H3*I-R/M$T1J%+%-)IEZI$H>8U=E"4YYD1N='QJ;'YXE^
M=X$H2X?$R*%GGB90X+U4#$40="'73(4HEY(8J=B(TN&ZVFMJA+LWS+LWR?%3
M9[J(_P"T_6>&A,@IFB:)?E=(W3P=*CS-Z..8ES^G4%HV12WL:M.+DF*4QIEQ
MB8LY+YN88I("D.KNS]Y2J:*?;.[6>W;03@ZLU(O*>))B*D^H"]H<VH9H-FP_
M8.E6HJYGFU`<\SBTD&2W`P1J%+F8QF%(D[XX)Q2JNE<C*3?4)=L$4LDFO%+9
MHJS4Z<=GNF-+:S4ZF!"6\.#O-TTR>RR94-14B,I7%9C:5RAV?Y\>4*A:Y"@1
M+U[*4O>#T)9K247\J90VN$U;-<NR_*,YL#?M)2)M)SFV31-Z^4FIGI^=LJS:
M,EU79)S-)=5:,THAX@--99I9'1;+;@UE&KSE*.$LPJ"<Z"ME&G67'>;FNJU.
MG&59?>"I=?)A0S>Q*FAFF`\E*I3,3DK(61P(WE4F7(52)K."%<N2+$:Q"0H2
MJDYQ@:]3YL>;7U.]A#RAGDP96I5/E4Y1;)"@=]BW:!1+"VF"JLKNI<N.AE!Y
MM<G69X7$F<*8@4NDZ22W`2Y<>).2%R\:H)A2%`O=>?I%VSR=INA3E2"C>U3*
MM,Z85.\G_&O4O+PTNLCETD1R).K%M+LLM-:>;4PRRT)71Y8@JS)LR0U`=9U>
MDJ69&UQEIIE1`WJKRVRK-+'U5*J)@J33Q]7SXV-;O(R9KG275X3BUOT"N.7W
M*7U"%<K*<VI^\P7`SN2,5"5TA0N`MHK8T"LLJ,^R'M[4"VPJ4L%2Y3F!DD=V
M=VVHC\MIA.DY2?#4&6Y8IC/+[(<R38]MJ%Q`")7(<F$U<8^!!"@;FY:@-=#D
M<2B`(@J&(V;-N594RG[BXL&T\$JN&TKY50NIA(U-FE.TF4!F^FI0['3?\'))
MWA)(E)QGXH3Y';VLDIP;',(3G(IL3]"T/HF[;U?YD.V>7-;M/*]K:7O(TT%F
M>5I.9Y_?4;Q*FUDR;2[-+#74Z>E!4V)F&)6C84T*699J?#W9&ZLD*HIW@6@I
MB@,VZY3G>2I\0GNDD37+<WMJ15`C5+I:>&]Y3)5AR%(YE)51B`\[S50H:W!O
M=$Y2@"XU;6X('-,!R!:D4G8TJEM,R*B*JO$T]DHJJZZ62)*6U,+EII@GU9)R
M55"N32HIFN%*#T?+B=;!`L(93%<3>4JAA40$0FAT\!3=-,@;7+WM'5RJJ]4^
MVE$$M4KHI,]-*!RQ16:4LK'UZKM.-(ESS4S:*F1^>WASEMH8Y;FDF&FVS4VN
MK$XE,TP*DDS12N(9@XWDL)9VOY4=-JEOVAY4JY)LIOJS9^F>AB*L!4)L"!Q5
M4#8&FKA!$`S-,JN%P_54;U:^>8(8VU%,;]&X36B9&,'_`."$MPW1AX!GF.09
MCI?PRP``!H`!V``>S`:T9E$/*I&41K$TN`U<45'>-A':DEJHBA/-H@X5)VQW
MC:-FUTV>9CHVXHYC`6UR:J9G(3VN86$QB9V2GZN6Y5<327%NA;FZ\?9+I8NI
M71.4$LP.52G*?)O8)/G&I\=4YT?9SF)+4=1(<JL<UHR8GI<N(EQ`4N8QBBEF
M7A32VC<HW!8VI8!7'1F25L&>09ZY!GG?/O$1[<\+@#"6]89B&OCD/9E;6^["
MX0>'N`ZWYY^OOP!K].GA[=-+:X`MNW:<K;AOG?Z,&Z^7OW?1GE@W]@:Y9^KC
MN#E@#NONRY7N&=LM=?IP:CV=G?S#AKQRP:6"W?ES'E?PWWP9:`''LM?/3C;+
MOYA@$MIIIG<`'L#4-^0:Y[]^"*UH@M?\&+@&H>.8[^.%W\@]7=V#^C?QS$!O
M_%BT]H"&X0MSRO@)?UJ_)5+-]/A*6_\`LI9B(6FZV@?4&5\2]K5^2J6?]\I;
M_P"REF(A7W[O5V_5Q\,`9?5GW\QU#U:983@-M?&PV`1#?E<->'9A(HX8?W44
M,(B`B'2$`O8+#<!MRTYZ;P(X8K]&*"(`UM$`[AR&U^'A?++`<N[*W=81[L@#
MP"_.Y<`OOUX=HAEW:\0SP@:CGKG:P!;<(9:\!X>&%N`<N7+LW<^&`+::7[..
MN_(>\<`Z!IRX7L/JM?N[L'$-;<??VY\=;B<?'7P]GZ<\`"&\=`S\-X[Q'U<L
M+A/'MYA]P!IEJ':"%^&F\+^N^`KLVQ-C:K^U;,,O%%[0;)(]+Y2<&I[9Z9'4
MU,F1N=IC;P@-B>9X-.?DR2;8(5,,7P<S*T4+2@1Q1EBF4*3SE,7Z]GZH^UI3
MW;RI_LRU@V@FBL,@3%L^3I44A$TTIE:G29K52^XIV1D0IRV<N-3"G;RTQL91
M1!Y*3J38$X)^B3!BPCMRSSOOR]GCH.NN*_R`_P#Q@J+`&GH:U+M;=_1='GGE
M]=L!<QO#U@`VWW$=?'*^>N*D-M*K.T\5MC[/>SG0.MJ.C#34>CL_3P^.ZN0&
M">NF[2B]JBR1!,[P0*2P4(BX$@0D+"B2Q`3HRS(A'%MP!ENT`;"%Q[\PN(VU
MRQ3SM/?Z*UL<VR'T::W:CO\`AE9O"^H9;\AM@&WV<]A^NE`*U3+5@G:7EE^:
M*C.\;K56G3?2`J4I3FU2="9UCJV-C,^%M<JS*4?&*HAX:4$$!D<:E.K3'I%4
M9<%F]@RUTUX_1F.?/LO@`=`MNOK<=VOCZL'AGF`9<QOOO<<[_2&8'8(;Q_3K
MEORM;+!]]_>_AK8`ME@$,K:Y:<1W\AS'A:^>$OF%L@`,^`!PX7T'7(`RO?,%
M^_GV]F?U<,+SW<ONUQQOEI;D%AN'+=S"X<<L+RR'<.G?P]]V`,_4/KM;CPSP
M=X>]\M>%A_3D7W;QW99<LOIUW7P`'CJ/$===?I#A;*P'Z-1]P[=</10/\HD'
M^#CWQ_.&CWRPRX>S(-.?#PT#0<//0/\`*)!I_6X]Z?[H:=?JY:X#'UM_*6__
M`.YV7_LA+G[VYWRLU&?OIOL/?EE?#KUN_*4_YV_6[+G<`T:$W$!'MX8:?>%M
M,[@&6=\Q[+Z_3I@%U]>@CF&[>&>F?A@]OONO;!OW9!GRX;\O#PPOOX]WT[\]
MV`X\0RWY9\`&V=@[LKZY9AA?</OUSRU$.%L)?(+AGK;VCGD&N\=.>6%[M]\[
M9>K4-`Y!K@"^>[WT[/TVTP=_B.F5]/T99X-X?3KOT&^N6?$,&>N5\^P/5QM?
M3VW!!#3Z!$!SO?CEP"X:6OA1RX!W9`&?,+8!\1\/;R\;8,LL^/#/CQ'+?:P>
MP`,_`<];VMI>^NF=\`7OR',+VRTOO&^O=;A;!;V6OO\`J#Z>[!OW<.%Q$?:`
M!^C`'#?EEO'AQYZ^(YX3.P[Q&^FEPRW]GU8Y9Y^KW]_J00"PY`%P'/+>&HX`
M"V5N[Z>_UZ\\`>WUZWU$>>6H6SRM@MEGWWX:C?.V=LN%]V"_MXAQY\\O9R!`
MYY7W6W]H"(#]6>6.79S[._"7$0'(+VTY\!#EE?MW8+:6`,O5V98!?JX^]M=0
MP@:6Y`&H@'9?W'3E@XAH(ANM<??U7R'"=F8:;K6&]]^>8!>]^6`>J@5OU0@'
M?\77D-,_Z>U"%[^VU]W'&&K/?]4>8+<&^U[V_>]/IGGX!:^_&9H'G4&$<OZW
M7G3B)[4/O]^,/6>_ZH\P=C=O_P!;T^O`,PTSRO@&NSTW\KZV]_5GF&%XAZ_?
M?A-P7W\>-N'T!@#]`99AEI]&@9]@X!,QOSN''2^H7X[]X99984!R"XZAWCP[
M[:VWZ8`O;QRWZ]MO?=@#0/?G?=OY:[L`6W<+6'>-N.7Z0$>>#=QX>R^GK`-.
M6#F-@#.^?,+#ZO7@W]N5[9Y<?9R&V6N`!&VH:CQOZAMX!?!;ZNWAG[0'V:H&
M[NTL&X<A"XCEKEA;YVX\1]F_U6YX!0]]_O\`1NP83CQUM?\`3;V8+]UM>7OK
MV8!<&$OG]_T<]V%P!@PE_5J`"'TV]=L%]-^[+=[[\!##;#V=9^KBIV=IRID^
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MGAOJRLG!ME"MU%JE4Y?*&(I/>W>3H2YD;'FG-&S);9944P)S4*A21-:)1`E)
MFA0NANPO]^F7;G@OR^O[]WKWA;`WOWLYJS*-[`!=-]H_:UJRY14\42;7BA>S
M?1NF;8WLJUPF&DY5"J53;2]8K0FS(2O,*1.J.9TYS*"1[-=4J%C3('9:J,4Q
MG%?.EVP5-LJ^2R7^3NFJH,JGOQNS[4B@R&I4ML;N#-`GFD9E@EZ95S&ZJ`7F
MJT\#PC.>T:<\LL(RU!+<:/0).BLWOR\!`=1R'L'LW#@N'KMWX"BQV\DI428Y
M>5RT\5CEY`5479R\GS0:HCU+1,QI7.0C=@^H39.!$R4G\^A.C4_JF-C64C!&
MZG,@RE,ZA9,73>4A_P`'%SDVV]DY^VJYVV.GI(HE&"5MG3:;+KS/#!,ZEY)B
MG1@&29CDU3)[0+0C-\U5'0S#$N\^7*2DO5I/-(RHP/&*&=]P[>S4=^6"_OE]
M`]^`J>VJ_)[3/4^J-&YRH,506G\G48V4=J?9[8*:SA(\:VGI[GM!(F@AJ-52
M$P-B=@4R4SG-:B*8F8TR"-WC=33Q3J!+5%JXZ4^\EUM-R`EGV:T-6:/J*C*-
MJ[94VJ)'851D_.%-'@ZB5!5-!Y_I74"%4VENI$JS#+SNZJ))<&5`IAEM<WRT
M:#22B:$R`F^P1'<%^\/?WUPM\!5#*'D]'R3=K]%6M$DH<91!^D79D2.U(&QO
MGN54U%:B;);S-#M3)ZH0U2^M2L"R7CH9N=>FV36"&%G?#(WZ%(Y%'&-L4.F'
MR(TZNU"::4,GRN+!+J>DNS[MLTE8IWIHW/<#W,TQ[8U10GJ%S?$KA`WQI)-I
MZCZ;"YRV"UR/G<\V)U(/E\HHE&&Q'?WY>X#A+\N_+QU]]V`@=L=[(LR;/-0=
MI*J\X38V.<Q;1*R@0'R=*PN$4G2<@H+0:3Z*(E+>>Y$(U"]VFXR6E4P+310)
M(6AN4MLO`8XQH#G`Z>6"_O[]WB&$OE?=V^-]`"W;@%P82_?V=][^'?N#"W]M
MMV?K^_E@#!A+AGROZM?#!?Z+#N&^GKP"X30/5OO]>"_N.7OQ[,%P$-0"X#8;
M^/#3]-L``([P[/<!'QRP6U`=-V8W'+.^?/+]&#4==0X\;6$,^0VRW"/:>WM_
M1EENU'=@#6_J^O=;>&N#+(>^V=^>0=N?KP7O>V?+Z/?CPMA+`.H!;370`L-A
MMP[?;@%X#EJ''2]@RMK81X9\L)$/X,0Z#8=>0#K81OO[,^>%WCORURS[![LP
MRSQQB'(=/W(VUSRR#GQRO;3??`2_K5^2J6>;E+?_`&4L[?9B((6SW]]]+<;#
MJ/9V7MB7U:OR52S;^Z4M?]E+.8>W$0@^C]/*X;[<<]V`KA\J-!463]D':+V@
M::USK)22::![-=9IQE)JI?-L<HM#U/I)$ON4LS3.<1"=2?,A$HD-+F@;984P
MP,ZN&97%6N&(]*D@&%LO[<+]L1;"=`-JZL4Q5TVEU5>]E:D=8YI15.K!+Y;;
M+DXR](3-,=2D%,W%];7!^/FZI:*=CIH9J:M\O!*:5#39S4JYLE=/&)AERE=*
M'4YVD*6371:KC>^O--YZ0BU3BPL$YS;(ATQLL?2!6P.CU)+RQ/A\O.D$8E/+
M*#C`@=R(2R'`D\N""&&-DR^3.V*9VIU2FE,\4;-GF2*'R//M-*4-LZ5$J7,J
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M[KC<1S\,<1&P_NK?^K>_/Z-VF`Y`'/=;<'LTQ7^G_P!&"HMD/^<UJ7_]71\+
M:;]UMV)_[^P>(CNYY!J%@SU&V\<0`(N/E@J+7_\`$UJ6/A-Q@\1[-<!<OES#
M0,MVO=>][YCH&\<4\[3HA_FK6QR.5O1HK?:V=_V86!NWW]6+A[:<`'Z[?1;V
M!8,4\;3G^BM;'/\`Z-%;[9_Z\K+YVSW]H[[9X"=X9@'9VW[1$-^_+CRMQZR`
M(NKB,+`SHPQ="(PN$SHQQ]7!'U8Q!'T8X_P((@AM''^!"(QY8(LH8A&(0`(8
MAN`C<``,Q#6]M0`;V'+,!QKJU)>6>D_E));J##,A.T733:C\H;2&BCC+B)V6
ML6T!LF[45`)15(VAL:6PPI2FG[9'2LS@LF&;F"!`W)FB)41-)+W$\F)5ZP-B
MRU[@.6X+<.67B'+AJ<+:AIV<+VX>OC;&N-77RGVURQ[*NV7M6T]>-G:FQ&SA
M5&JU*D6S[5.4#WBL<ONU,:J4YD:453^DCFYI&8"ZMRQ-DP3>[E&IF890*:9?
M&1QFQ"O>529VJX>4!VX::;1>SKLY2/3*A]1GJL--77:*1SBL>6&GL@3[3(B<
M)/3#2Z6IRG^HLML2"HLJT[<IIFR9G-@,F9<O=H9$3,;&>P.4T*T87O\`(<QS
MS`!MW[N6HCXX6PCH%QR#(-XB`!XB(``7S$0`+B(`.M'6/RKVW&W2YY0>I<C4
MMI%3:E^R>[5BD673:FGR,MJ(R5!I+,DEPRB5-5.'"JK5/4X,%=)2?W58E=&B
M44#9+IH2^Y2>XOZ&&8(2&6VJ?*251J(PUCI9/AE#G=%0C:6\D--[$J))<I?+
MGM@VH))8*M3`7!#+U3V1S3C26>T<;@WS*V.;FSN+(K3,LYLD:8D%)P;8FG/.
M][;K:]N[+MTRP7X\@'(;9\..>-<^BWE5]HZ9=H>2:<SF_P!"INDV8_*Z[4'D
M^ER]BE5OE1P7TQIK(K',%-*C)7EOGEX:FV8WI_=383C2DRR79E10&(FV$L\L
MM1`\WDV=LCRA6UEM$5-)K[3B1:6;/\FL$Z*$;=+4DH3U9<^MU69TI^ST])J:
MNF\]=.R1OE-A99Z43U*\M"R.BM<>RJQ0$JD4!`7E^KZ/:%\/-0,+5#@_P<>^
MW^J&C4=_U6##,#[0&P9@(VW7OD/'?X8>>@?Y1(-+?%Q[WY_U0T#]5@X>&`Q]
M;K?JE/\`_P"89,M<A:$OJXX:@1MV`%Q]?CZK=^'7K;^4M_U_I#+OR_>A+J&G
M9KZL,=,KLH89;F)]1M*U^5L<O/SVD86T`C<GU4SM"US3,;;",0!$X/)Z0MK0
M0C$$(K%9(",(#<`S/2A`>B`A?7HYW`-XVS[@L%]=^.7O[[N[&NXS;;&T03Y+
M6G?E2E4W3O,E8YKJ5(XO6SLT*2C*0KY/FO:M,H8IHQ+%+S4A42&=$4K*X3&R
M=`=BYX6S>B2QNSD:W1*$0RJ;O*P-2+:"F*A]0:$.,F-LO;>TI^3]43\UU.0S
M<GBJI4R0IBGJESV,L#(4N.,#%,7Q=.EQ^*A<33Y5>%Z$T5+TA\Z.3!;QNOKO
MN/MP<K:WY![C]^*$JD^76EJ5GIS42)LD5GJ12=%M`)=GA'7`7-?*5.7.<2:H
M1TE?4HOQM.)A86M])?@@F"6)5<YB(7S/(_6/2M9+3N7!+QL\]G7RB=`ZVN%2
M98G%^ENB,]TSVL:M[(BR3)UGMF%5.D]4GFMFEE:Z4[<!2LQ\PM;_``S++YB*
M$MI3+6YU=(&<Z%2<06L4A/D(@B"\`PQ0WUABWZZA<.WC?Q2X#>`(H>F`9PA%
MF%[9VU`,PMEI8-,:[.S3Y1RIU#=C_:;JQ6:"H>TDNIIMV;<U+)8=)XJ2SLRU
MEIQL^L"*<):D=PG!W:WAY<WUQ86=\:)$;FZ5'HYZF<T\9A<):98E;ZB;)!Y6
M]\E+:]KYM%KW*KDV;$I'DZ-D;:H(HNZS(VDJ:6D5LJ+2&2)CGB79<C2KT*N8
M6>&;Q-=)6;79.2[EGOJEN<X3SR"C0V=1$(0O%D`!<1$0`/$;![-0P`(16&&(
M!`0U`0$!SXY\!#+GO#%*NT_Y39O73?M:;+='::U_4/U(J.SD7,>TO3`ET2,M
M&ZE.NS+,^T-3!\=53<PK8Y8D\\MB;Y;73F^O31&7-[@3+9<MN;*K<7U"UQ&W
M[7ZB?D)-GG;1..2UAK]-TA4<9'2:*D.AOZ]FJJM7ET@_'-]!*W*1?5+6F-(&
M%MBA1D'QE)SU)IQ*4U$L"_H!#0,Q``ROF`VN`#P$0[...0<??V!C7/KSY4':
M"H7/'E"I=32$)E6*,UP\G_1EFD29JNLT\T3IPKVG6I>6#O3IQ0T6D>;G(MR;
M&10XS>DFY&I+)FIW)7M91C>SG)'><,N>4<GYRJCMD4M>=D&9HWC8DFU-+=7E
M=-*T2G/;7`2[TDFBJ[&Y-"V=)0H_UZ-6,OII.CB70HXDSHZP.JH2FQ$KAP%I
MPYA<.[3/*V5]-=?:`X3*]LAW:[[9A;32VG'3,<4%5&\LS,#I*K`AHA1Z6552
M%'E'-GO88=S'BIT#]3EP15D105$9IYDR<D4A$J'9DG:GS0\,1;HJE$DV2'AQ
M(?D;?.B%.AC6.)2?REC@SNNT%+,^2I-K]65Q\IX7L&T@I4\U-EYYD=/5-_E1
MD6D2O*]4&>D$J*I4HK+<*)W>E+_-TF31-G24'1$)5ZI66VEA=F'9;W]O'GA.
M[772_KM<`[^S&O+!_P!T$2`YIIB>Y:V99O=Y7ES9+GW:N6+5M56)G?BFZE5:
M5%"*AT_6,`R,XHR'YNG)K>ELNNZ28G-LF&7BV1<<0R*G9<A8;"MHC;]1T5D+
M8<J/*M)UU2Y;VY*TT)HK)Y:J>D<@O,GNVT5+A$RT[>79"IE::DSLA+2Q*4\R
MIB7%J/:3RDXI3'2!49YH%B%\["'$.-^'+0!N'9@TSMVVW;QX=]LQQ2=,?EL:
M8,U$:&5"9-GZL,_5<KM5BO\`1R6MG20(TTT3J,W;,)Z^"K);.[M3,J@FLDTI
M,VP2`G:I>*<)J<9F8$CJCE-(#XY,?92/*<SM40O;AEB3=ER?&A5LD2^J435-
MIM3FB6W-B99FV<9QKS*DUO+%-M,`=)%FM.VL*>65,IKI>G0Q@J,L0MKGY^R)
M')?`%Q=[VMH(7`0&X>.@_?F`AH#%"`@$0@`Q#^"`B`"(AP#?^C?C7RDCRV--
MJ8;->S\]3A*E7*O32GV)93VOJ\/[_,LI0SU+=(G"L++09'-"U6@E67I:J14V
M8)Q?V]X-E=C022VERPE=W%4\ENR1(W/7TVB_*(S/5#:>V0);V:9EJ'*5-Y6\
MJ-2/9"J[,;3-GF,L5U:Y[I(W53FR57&G4;/"NC8F0M:SMR%_=%T#@H50S*E3
M-Z%$>4K6!LYT"O\`J@PA8,I<>;C;3]<-5K#IGE<`Y[L8>L_Y1Y@OI9OU'+^H
M$_AIZ\9:@$5Y_+SOTI<>(KWXGM0]]Q'+=[<8FL_Y1Y@WY-_=^QZ?+?V]^`:X
M;B'?8=?;D-MUP`>/8F?#0,K]PWN&0::9]@!?!J(^K+PWWN&8"&5[YX4!Y^R_
M.]O7@`-1RMI].6\,N0[]V$'+,0TN-POWY>S4`#ACEX7ROEK[[N&$'(.'B/CG
MGD';@"V\=>>[/L#QMXV#!W#IKEX#;?GV:VPF?;F(<->.X0`/'+M%<[Z<MU^W
MF&>^UN&>`.%\N(7#LS'?NP"(A;[_`*A[LPN-@P6\-./M&WJSPG_W:]H>(7`+
MWXB&`Y834==+9<^WZ.P<L'+?VWW]U\]0[M,%O`;W#/._#/+?@#.P=V_CE8;\
M.W,<`!IE;B&N0[K]HW]F`>ZV=[^KENUL/MP:YAR\-=]O5Z[8`R\-]],AOOW?
M3X`9CINMO"_<(=N_VX34,M,PWCW!NMP'3=;`&8WMF%]]]1'PT^C=@%OG;3?X
MC^CQP=G,`S'U\+6M?Z1P=NH6SL(:CN[>T>?#!S#3E?/NYC?37+4!P`''CV^L
M-+@%@OW<,%K9Z?4%]=,K#W#K?!?4-]K_`%;_`!S#P'!KNOVA:W+/74<^T,`"
M%[;QT`.(CD`=NX.T<,H7M*[.,<W*9`@V@Z%13XB<U3&KD:&L-.8IR1O2`PXE
M:SJY7^,GP\E=49Q!Y*IN4("UB<TDXLTF&,N,(7KUTSOD`<;Y``=HVL/AC5'J
M#1V7-LCRMOE2MFEMJK2:0I,VB]FC9KI.]3BZ2VJF>;3W2GD4A/U0VJBP)G)F
MER.J\EKI1<QFP][-7_`"!"\*%"<%Z.*.`-H:1JC4\JBRF3)3*?I(J-+I+DM9
M3W^0)NEZ=&,AY;0)B<6@YWEER<VXIU;P4IHES:8IA6)`4$><D%`<7TNY=V0<
MN%K6#Z>6-/38\KS4?93V"*\RILQSM,KW4)1M]>4&;:>HDE,X*NS9/,,NT;AG
MZD,T/<RN[<YR\P,;[\0XYC6N+A+3TNJ^F%3+$G1M"]2>^M=BVSSMQ;9E?ZJ[
M)\GSF]RKLZ2O5O8CHC7U'/"^C)\S2I6^O+K/<NDURH\C+7]-9*BF7J?QS06S
M2>ROC9-3&]E))V6J'>6DOP,J"\.>JC4]I<R0S/4V?I(IQ+<;@C:()BJ!-TO2
M4PQNKAUPH&N%YF9Q:FR)R7`G4>8H05"K5]2=YN49U9ENY`(1`$4(@,,00Q0Q
M0CT@BABA"*&*$<P&&*$0BA$+PB`@("-\:>^V=5CRCVV3L([?C!4R0Y`,9D$Y
ML<CLVR]*,LS*Z[3M,I]D/;+DPZ2U02TRTV(AF"0IKHI"WN(S(JG"85,R+&YR
MGV6(DDNO)K`S64/&VWMA-]-JE3.S-*1UHNU^4HH_L_RKM5)Y482$C%L.34O8
MD55J^ELI[.HEB8$5*G6)=)953%+&HE=+"X&3$^)'`N37DY2%\&H!V@.607OG
MVA[?7@U'7CNOI;PL/"WM'$&?)TUJK?7_`&7V6I-?V`66=E=2:R2\S.`RR9)O
MQXIE*E0WACIC4:&6HDZ6!O@G*5$R-=`J2I4S9,$!(32S)R&=]0%%SFWC;4-+
MB-KV]60]_KP![]^8C[WS]IGQ#4;:ZV'(?7?LTO@L/'U>%\_'2_9J<^.[,/#A
MZL]X8`M;=<=^Z_'QRP>'#/?EPOGV9;\\)I>^FF0CINYW$1^_+-<[CW6^D=V6
M8:#Z\`;MUMV_+AJ'8&N[7!I<1L`<K^S<`<,_K`TRT$,@&^7K[,M.&N#3,?&X
M\]VGUCSM@%]GOXX/H]_9A,^W=P&W;<1&W=O[S3+=H'U:Y^^N>`-_AJ';IP'/
M/!W>SWW>O!D.8#J'/0?8(_1D&6#LSW6WY<Q&W;OYX!,]P;@RX:VMD'#,!MVX
M4.5K9Z>K@''V<\%N(WRSW?3E[\,'`--<K;NX;!V^K``\>[=X=F_7QPD5["([
M@$<O]J/&V_Z,+E>V_7?N_3KQ[,)'?HQ"&O1BMI:X`-M1^D,M<!+ZM6=*I9#_
M`%REO_LI9B(?OW>^7U;I>5J_)5+/^^4M?]E+,1"&^X0[_;K[\0O@`;6XVSMK
MIVWX"'COP9;O'*^[[O5@SRR"X<[9\M<AT'3OP#;>`6Y^O7++MTOPP!KNY]_9
MIZ]<`\O7]%[<\^&X<%N\>/W=V8!@X7N/CKQMI;++*P:[\``(!8-!X:;_`*=W
M'!<;\0]09]XZ#ZN%[%ARS[[7[AN-\\O#7,,`B/L]?#CSX:YZ8`'01S"U_`!S
M\;9#SP9[@#O$?J'`-QTL(??K>X6MNM<;[L+QY_4&`2_O<,\MWN'AK7^G&_E@
MJ+CI_P!YK4OUS;']=NW%@''*]O6/OOQ``C_1@J+?^AK4OG_;<9[^O`7+VTS&
MUL[YW]]^6=^(!:GG:=_T5K8ZW#Z--;K`&^[PLN(CEH/>/#%PH:^'$+!G;M'U
M96RMG3SM.Y>5:V.;?^+16[3A\,K`YWR]7#<$[LK6MD.N@ZA<;ZZZ9_4.,!!*
M,I0/!,Q02G*L$Q)XG.)/,,$M,4#^GB>S"SGJ).^0-X.Q`O1Q11SP)2V")V-+
M+,<A51EP##V`+7`>6[2P<.V_?;"6TSWANUWY[[WS$>6@9X#I3U32FLRQNIDR
M4WIU,1K^8V'/IDQ2%)[^:^FL@10LAKV8\,JV-Y-988H@9S'.)7&TA'$#=$F"
M*(!R44FR=&GEQ)')\I1HY.C3&R>DCE>7XT<H&HDWF2(R4DL3=$1*YJ)'=&C,
ME\MNC2)+I4\12?\`%8U_MMGRC^UO0C;"VR*+TA<)/FA%1;99V:*W42I.X4S9
MWV9JEU+J;6*DTC3/3!.\-X$34Z$OTL3;-#BU0H(SWQF5(X'!)&+>UJ"HFY\H
M5Y2[RB%%*B[9Z.D#7L_4?D397I]2F<VMLK7$QGU"JA+E1I+3&JYOI6U/;<LA
MJ0L9*M+DTE+VQK,3L;0T(W!N<2HIK=6AS0!L63')5*'=:>5-\F4N=G&=8T#>
MI+FR5)&<W"<CI=@-=&M`I+?VQ0KFPV7BTYSHV(C@<S&,M.<XHB4<!)I\.&54
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MJY/F]OA4I4!SN@EYG4FRO-C6"=62@,<D[>^H!3*B$_5`0H+AA/LI>2"V1-CN
MN2W:&I&T3,@J2L3S8A%P"8IF;TBU!.A)L#^EF=F)FI7*TU0&J#HW)M".669,
MQN8$JF=$AA3)BBH_>2N4J5^VIY6J9U*TIZ35%J/LCSJS3>VRO!+LL3Q?9]-"
M;7V6C6I"3*RTE+,CZ2F=@95B@2G%;">>6$2N(V*\W?W>^7WX!``>^W(+ZZVO
M](;P##ST#_*'!K_6Z]Z_[H:-.7OSPS&>_7E<`]_;ROAYZ!YU#+_P<>^_]<-'
M(/4&N6`Q];A#]4I_TOYNR=O[T);9:ZX:L"S8?PNK.AZ`_NQ@BAZ$4(ZC%8!@
MBA&P9B$0"(:".&^\H%4=YE&H%.J=2PGF\N9]HVLU/J(H9EDM*!KI3N6UDE/L
M^5+J1$NZ0BQ_%6G$D3(#:_>;J09WUQ:G+HD&)"E$%=51XTU(MH]#,=.Y"J+,
M:2F3ELE[,4AT99:MU:EJ5'&H-:$<^SJ[.I<CPSC%3A_42]1A+*<:.<*ALT3*
MBF%3.SO/7P@K4)9M2A,9NV2=GMJF5/,C?3U.BA23H?4EOE(E[F.*F#14Y8J6
M*UM46:DL;O\`J=-M25:IP6*E,X(Y=3NYZH[SD5$"J$M1!##9P\GHNDS:LVL=
MHZOK/2N<C*K[52#:AH$5+$W5$=UE,9G0R2_TX)4S++C]*\IRDNFI)*[L>M99
MC3Q3"HE]P>WYO:Q(*`MW69N9MK^OJ2GLOS5\2*'-JU0IVR75S!OGVIZE,2R;
M&Y+D>L6H8`E`'!Y)FIX9%LONLF*RFYV?F\](\,#HW(%"@A/W*6ZY[34OS%2F
MG=7I4I;,]25E$9/G)8W40G6:VLB=:Q3[,JJE<LR<ZIISE1*PER.J=$TTSG-#
MDU'HCI!52DG5MJ:9DBMG85H=DJ-Y-C8ZJFWS(S373>92)?FVL27:"?97E"L-
M7Y`E116M(`&0U*22S)<[,C*VS.I70%/+DJ;D28AT?R$[\O3GNI$"H'QH;LT4
M>V;EU7W&C;$^RLHKQ5)[K;5&!3/4[3,EF*JDS7^,L[I44SOSLDE]XF&("#'H
M9?);4K@:C;S#TT<:%+$7$Y@VJMH"9)WIBJ5,FS_*5)FI!M23K7!_(F*I,UQS
M!2?9T?&VGZNHU'UR>4R_.FR9IE=R9QIVSK8(G*99321G.;@:D-A*.D=LV5QG
MNOBJ=GQ?3`9,IK:1%E(9B6&3*E?YS;YM;71S<4TP-<R,C*B*<61$$I.$;M)9
MS_(YT4W&RPDF9UF*39GB)!FVCR7&PXT,!DKQT;<)A83:F5/K"8WSI5&JT[01
M5'K5)#E3JK<S";,\YN1_75$E%V5M\U(>M^#7)5"D=Q1ENJ!&K)S#5Y-38C92
M):3H*%M@$RK)E-J<)"U<U3RY`\4XH^J;7*F]/)TA<)E4PSW(TJ/+*R/Z&5IM
MA=VH^8F1E?5Y"MQ:T9Y6>+VI757-TH."&69:/HK4,NMR.2IB,=I@*J@L&@4K
M3H^3U4]RD@6P&E-1$9AD=PIVUN0NB6;XYL=I5-<T#6FFEE1*?T4=VBJD+]FA
M3M);3-+I;HLU1R'*52VZ5Y%G-;5%]&4YEEAF<RH7DCX*:TS=-#B].Z%(QRZA
M<7=,0WN[46_/R9Q2/1J8,].NQ?LZ3]-E89X>Y+>6^:=H&14E.*UN4FU#J%(0
M5+E5N:3Y>:X)J0R=,S,WKWIIEU4KEYJF<$I<PM[`M6LZ9Q@1*C2HL5!L)[+?
MHL->Q6JINJ=MFID+;26.GC]/4^OI[&4R33#.C`4SSDZ3(IG=NAER9H87.7@2
MS!`+-$`I4(E)!$@?TPU=K\W+E%/YQI'3V2ZS3C.4QM]'V1=/CX]4^"09.D.3
MYXJ!/58IJ:FB!VEK]2@^9E<FSJWRPTKHG^9D*)=(A:Z47%1,2",`[?M6WM(O
M5R/065G1(V2)L]O[E,DQ3G-#))""9ZY5CF.D[2RP3$3+IX/C'.136QSK3!X8
MR3EB22W^.;J@(4LNHVE3,X.\\>3.V,)B?ZU3-,5+GZ8'G:&=*:OE6E+Y5NK;
MH7,;]1MP(<:4OZ%,LG0U/+#[3PPB)'*3O+!;2M:6=6YLA)L34YKDI_9T.P!L
MJ(H]J$8I`F!V)VSFPMFVE$,Q54JE,C;4E$F0*6I!UK>]S>M32TK:6=4:R,[A
M*D#*N:V;JVQ&>6E*++#JLR[84ST_F%5+LXR'*;JX22]5E:*LMU/)BF5W7RZ2
MS/LCL.SH[,1SNR)$()*VO%29/E9Y1S3\&NLL3&;-CG+Z&9I-I_-#V3^);M);
M42UHH*PR90*G#G5^N$[UW9B6"<YNJ;2^29;D*DDL1O#34AV43C)2*IC6D>GM
M;+4LKI;=Y`(F)3$^?&!E;B6-."DP.P$^3<V*DS8M9TM#FM(WKJET?K)$2EFB
M>"(T=4J#2^EE2ED\LZDN9`5,;_+DMI"V12I:3D<$P-QRXB8"G('!9$=]V'R=
MNR9+:"IK>TR)-D`5<K(R;0\WN:RL-7'.8DU=Y<.4G,=7Y*F1QG-4^4YJ&V`I
M%,FF61E[&M\R(1(C1,3(4T!>2V>:LU\G&A%2*O57;J+D+X'VL,P4M;9,65`^
M!8)!D1VFAK;FV?XG-E1OI*DM?*#F4F6L1;@\.\OGHW58*=U5D)"VKE?:AK\T
M;/[#,$]2U168*T2]0)!M.5A5H9BG"4Z32S2&9!?UE/FZ!>IEZ)Z-K+4@6%UD
MV7I3;V^*4F2;&<^.8WR$E6THWT,3,_DGO)U'1G+GRD'Q<0.%&W/9PC;D%;*K
M21*Y]()@=U<T/D@DLK?4!J90(F";%;A/+RK((^'G2=52V;E"\QY.-5XZ-MK;
M"CM6NGVPI0C9\F.FTORUL>;2M$Z\!+U5*K5$/FQQI]0]J<&N6Y(E][:F>>YV
M4J5K6]F(TLWOBX@V74;.RPHU#@$<(M[V>4':UE5]C:?),E-A<55:YLD5AJO1
M&1XVXI?-;=4JF#A+=8I96.*$V`J%L1RN^RVE8YK<U7F20%2DV7"8XW1U1MYS
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M8TC8TR82=\*S(XK8'9H?&Y`4:C`DS9SY[]_#Y_Q.1-Y,/8>)DFFM.SZ(E.TG
MTFE%;3J36B8)\J,_B%,5T\(JE1TJFAP=9K4N4]TM33\V-<WMM/YS5O<M-;\U
M-BY"A(C0IX8._P`V;!VR//4_'U-FZB$M/LX**E2Y64Q6J<)E):OU693ELB4&
M"HY<N(7M(P$3DAEM(@:1?4[>6L5)FUL%7&>8@3QP1KJ7M;;2DGM]=E*67*5-
MD6SUL=49JE.YSBPS2^I'+:OJJUKG9IV?92A;YF0J'I+,D3<F:&@(`^,+<MFV
M6NH)F!8>6WJG=FFM]>)(>U-19X=:)23L^T_DI142N[>XR[-J^?*>M$NTUAFR
M:9);)S&:VZ6IFJ3"^)W(@&I!+0I);82$Y[Z9$XK41"DJUN@G3CJ%$9$`Q",O
MO44<8VN,1BEKB&*P"&<472$<N.08PE9_RCS!I_8ZVNHMZ<,^T,@YX@WL2[3E
M8*D[8\A4J6L5/&1E=MDAZVCJL2R2#NOGND'QZFN56FA--'5[@=H65PFB:I=-
MF6<9K.,9D43>,OFMK*WJFDPN8#9RUG']L=_[&_3_`'O3WO\`0%N'<#7=F8AK
MSR`1[+Y#PP;M-V07N/;OT&V=QUN.$WASX7US]7`.8CSPO$=,LKVL'++NOZL`
M@@`Y"&7'G?EQ_2&%X<=<P"^EL_IM;A@T]=^S/M$1S\;CR%.WLUW"&=]W',-`
M#A@%`>(ARSUO>WB'B-[8-P]]K:W"^@9YA;[@P97MO'/4=W/4-=-.&_!D.?=>
MXAOTUXAWX`A"***&$+=**((80$;7BB&P7BN(6SW@`!KEB,[=M84Q44_?:M.S
M)5>5J5-3TTM#+4-^I=,"R7*@H7][/EU@G&G14DQSG,4P4_>W:%`F:)P<9?E]
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MI/M)3:_S33F7Y<HE5%TCFMHKQ-+=,+ZK>I*BF`JGRR6)G>)[^$)HE69*GK:>
M0,;=2=@IP=*CLQ-:Q.Z21&]<VR;7!KFU@J!+R+:IG$QWVJI>32)2)XFR;FAJ
MER0J`T,^+*A\K!,[?.*]G*35TGJGR%+%-#^NBI)-+;-3Q,ITOK)YG@F8U(62
MS945CDV::7RD[(I@.<JMS*^RI+"II:BG!K1.<ORD[SHL/F54*].J9V@YI8UR
M5*[D('-%`]1M[6YQML;HWG'N#`7&8867#!&$1L4$)8#`9<0,$+1A###%'%!T
M1Z=X8(AZ`11``Z8I"E\_:533K4^I=/Z<;1$VU0EG9>)F659ZV@I.JBSR;,&T
M74Z>V-NKD$A4T?'`EHD*3J:TWE,^1I!I5(,IK76<X"&V:4\MSHWA+TV3K^J;
MTE=I0HRN)1-.V34PIVENK%;I+:Y.:*_RI-]0-H-$I1LU/I$G1P630[UKI!1J
M5&Y@_5E,EV:5E.(JUS8_JVIHI1*2A"TT-<@MOIE4EAJQ*<,XRTBF!"V13%.4
MK^:S(V$-3K\*2+-KQ)CR86F2.+LB5M:EW8U:AB=F]R6(7MH-1.:4V$M5U)?[
M)4GMGG)[J++S4C?B'"F$Z%2),0NK4*%(M>3I2EJ=(%$MJX%2J![:`:)J;B#U
MT,*0]&\)W5H7(4RENC$V%\X2],DK;,>S929OEVO#/3YS9Y8E"MB^C#+,R>O+
M.Q-\E*7>)FEU#*SBMF^G2VM%3X2FJ8IV;G5*=1Z7WUPA?'63T9ZYQE^.LA*J
MY>C[3%DJ!1+:>C33[)U;:AO-,*>J:B2O59SVBW"J:I536CU1*N.LUM$VT^D"
M5J:'-J2.IT]SC(DNU!F.G[>]/TYS*VNZ5EG0+C^C$,(QA!$)8#88@A$8.EK^
MZ`!AN("`@%[C<--ZA#&(P`$$8Q&='H`$,5S.D(A",$.L?2$+0C"$72'*&^>*
MCD+=M*F3=.\S-;)7::Z]T*HA-33+[W-RNI4G4&JC6&1:3):<,B8V4UZ^7*/5
MFIC7F:'MUK5*ZR2VM+4VF\\RJY-<^S0+&\R<TDN?($NS[+>R-M+SV]..T'4R
MH-26*?9H12HX,5<9>FU--;;)$$M,:"D\C32[2_6F7VUZFDI._.)+(T4G5/YR
M5S=Y&I?);:<V('@+&$:M(XI4J]O5)G!"M3E+$2Y`H)7(EB0^"&,A8C6)##TR
MI(?!%#&2J3&FIS88H8BS8@B`1_4)<<-XA+C"W1`1&"(`#I@(PB(Q6``C#.#/
M\(`_!N`94K/L@5(E*B%-=GREDD[:,FR4@IC0ILHZOIH%2ET^,<[3)/#M*]>9
MQJA,SC,"V9F5)*\K0,$%'J934?+J274E5%$WN%-DB>G;\II-W^@C>]3?/#_4
M.E2/:L5+3*Y[0<]H`KA/%5R*-2I2AIAG:1I$IA3=,_36;3>I$-7YXE:7USZ5
M"]SLMIH4OFV943_2V`ADE-0%M(0Q9"$$0WZ0@(0C80@OTX@&P`/0SZ8PWM81
M&P`-L5,4RM$IL+K,4V/R27I98$!SH].[TMB1M+0W)888SUBLPT1`LDL!AA++
M**,4J#C"4J(E0L4)DYM2LATLVE:N4<FYTGN>]H&2:QU[J-LX2=4(^7(JG4K9
M:.-4D327/%89MHN1/JTQ?+2E`TES!3UOG1GIW+%,)H.;Z?RRB9ZMLOPA5B<)
M5U9DGXGL^R51%B?7QXDR<=K>46Z<HJI.KG5=[F64&%CK-M%F2J]3+-RT]X4-
MIDZT^EA$B<5JEP42]+#4B:DI!Z9`G@@"7\N3"=,S(U/Q*&:&@MX20JDS9-+:
ML8IB3I8CS8$GPFR*CC%C:8J+++7ID2OJUA*52E%:E0+O.$*;,B8?"$0QF'P]
M9$(QC$8;"!D4&40QC$/XR*`?P8QCO$`WZ5ARQ294VM%9J?2]-"PZD.V-,5*U
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M:HE.42(QB,-35*668)7IFWK%M&MKQND6M-;-H-^KS+:8^O*BM+R;`^J'39\E
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M6M[10F7ITH^P3S*$H*JMK9=DRF<IJ6MNG]S;IX-A5N).<B3_`$ZH)1>E+TVU
MA>V"<9EJ'..T8OV:"9H+J(HG&<GQ\K5!221GB4EB*;Z;R+4BL$XNTF.54BGM
MM@DB0I8^!9GG=D13HIG!*$Z).GQFGA;/R!G2OB=13BH#O39_%X:O@\E4_LC-
M+SZL6,!\"E64\R_&AF9N@(=H(D\8.!+HV+4*%<UJB(>ZB`A<(@$+``Q7`8;`
M.D0W#*$?X,5[#N'%'CHX;3:;9)IW+CE(.U3+<R3I1A\G&".DDLU)CJ9*6T_4
M"M$PE.CE5!Q$Y74`B3Z!T^F5BGEI9YG+9U597^55*]R;YU,,/8"W;C9*P,%4
M*ZN,LJ-J5XHULZ+6NIDKMC#4I?.U2YRJA.^RO+-/9RH5+S6N5SBFGM7(3]-C
MO7.9)<>VV;I/EBLS5)T$B-ZT)B<DK.%GTZSG+]/&0)EFU68TL4+S+#(K=#$\
M<21K.FZ8FN56A>ZF#T`0,OPV\MB9<Z1C$0BA5%&F010C8?G/,Z--/V@'1Y2O
M"Y6J<"V-AEB76T7F<)MF904H.22I*;"!Z6)WF%44C5G@FC5HD"!"B7.[VYM#
M&WN#HDK0)IV_JMG%#1AGF:H(U`VC]H&13F1-7.*L;FYGTXHK4:DS[5BJ$OR3
M55R<*I4EE]^D"G1L^.TF3@Z'-<H54GWS=C1Q2W-,HLZEVMJ!FF2=MH27IMI4
MR.$SU9V9MG^MU:Y08#9KF5)*JFJ=3DBZGE#I??I5;9K:91FA0[M)E9E3DSS,
MC;UB]E.EE2A>UK*"EL+"3<Q5PE^4Z2L%7IDD^J3.VS&MD%J12(ND6,BK:=]J
M1-[3(\N2XX4_.=BU!,Q0O[RD+<6A*YKE)".!0J;_`(4$LHE1W>5)V:IP=:@-
M#2A?BC:<3ZOIR[+G)H%$T/3\V,K$^."F37&!2I+F5A103`E:53H5`DC33"B>
M&52B*4-D<9M;"%NGU5/,M*I<IEM1U$I%.-=:$N:-LK4,RLCO,<[4P1U*J9/-
M>IP23ZJ0.6SI(!4VG4GEMFEE5*4C2R]S12<V.3Z=&M$U,QTW?NEB9:OKZ5RH
M=4:CFT(ED"J%:]IV8JJ-,E,DU,FT+-C>[3>I?:`,*YKDY>P3E0YKG%)"CI[.
M,R@\,"-E024TO;M4:3Y/FJ.8'P+2K1`/[F+,!$`L("(0C$$0YZA",(@(_P`$
M0B"*P@-E"&(1Z/0BZ5A$8>C$$0``7$>C:X``?A7T`+17MGBE-\D7;JINJEE=
M+(5HFQL>J1;,E1:R2H5/:^>)E"ITE;8\NH8**TO6OCT,FRX_&[,K@$L;0TYM
M\SF2M,[13+XXN2!Y^/[_`#K&XTRTFVFHIGHML^S+.E3VRE[^`U(G"H])'"L<
MS3*W5<F>N$ZSM-TB-]50F%"GE"D-))%5RNT2*962;?@Q4S'JT$OR)7)8A02-
M+@6:S?.K7)44FPNR1Y4A/$^R]3EHC:$)"V%._3-"OB;U;K"<O1FIV,@6XR%T
M<$)3HI;(#B59[<+<6O6H?P-]1F)RJ=,E)R$4P0S+*TBRG4-Q7G-102N<PSD^
M/TOM29"^$KU$<3^0XRXMB<65P;FT\I`<@<D!KDC4&FIJSJ1I:ISOM<TFG&H]
M,MI(E>>S5=J?5IUG1OJ,VT+IO6HE$13VFM(Z/L3D\HZ9M$F4=I\_39`74N7&
MQ8HKT^3LOF%G<)X@/FJ"G7>W609RG3:9JPX-""O<LU0<*S4>2RC-",FIDG[/
MJ#9]I<R23"[N[\XMQ;-32J$^5`:GNL%,&MEB=Y_F-,DG*3W(IAD)UE!\?V(+
M-!Z0!$/1B"PB`](!#HB&L(WTBR$>B-A#.]L%Q[NWMU'@.0Y7'CBMW8:D.?UC
MQ-55I@J15J8:8RN-6J`[/"&<*JOM0&BI]%FO:"F^;Y,KA,8.ZI0+_-2)@@9:
M6T^J.X"=.$V4V95:^9W9V!Q:XDUD7#//?I?ZN7TX!>6OT;POCC$(A#$-M`'P
ML.G?]/+"A?W'/L$`"WKPD6@\1A$.&X=-1`-.0=NH2^K5^2J6=_[)2WE_P4LQ
M$+A<`O[.>>>[$O:U?DJEG_?*6_\`LI9B(6E_TC?7V;@P"![;6WY!;>/TY\-+
MX4!#CXZZVWYZY=N$TTTWCD-\\_"UNP<M`#"[\^ZU]W$=^NG;K@#?]/CX]@A;
M?G@Y9C>^>7CE;6_;OYX4/>]_ISP8!.W6P^`:]@:;\`VMD`7SX!:X9C?.P^/A
M@#=KIG?GZOJ[\`;_`*_?=8?&]AP"=W#34-!'33C8!$1P6Z5AN(9;A]\\+V=W
M`,N6[Z\`VOF%^X1^NW9]>`-^6O9NSM<!'<.ML^S$`",_+!47`<_^\UJ9N_V6
MF;AX>KMQ/^^MA#+7EK]6F6(`)_\`1@J+?^AK4S_ZMCWZ^O`6?SW7:C%,9QIC
M3RH=4)*DZ?JU/JB5Z122^O1">;*D3`C)A4+6R3I?*A/='DU"2:7&O4$)@0(>
MN3EJU9!BDB`VL+:*<V]Y\J5L6.S2M3N36Y;,%:5C>O1F@>E5I3W=9$2>0;#E
M&7$&ND4$01EF0PF01P0QF\M&Y[#Q>T5LC(MJS:\J-L,3$TR7.$[R?7ZC,^O\
MMU+*22_.Z*%BEI!+[30VJ4"M"3-,3PZ(9Q233)+Y)[FI5')VR;D:DQ,AR<J.
M-&G7:J\E:X[.S@^NU!UNP5/QU(7B:!7C,KU(7GJ\ID?9@C=@A<SGI]A+/>G)
M0X%E+5:MP-5*"$II\28D+@_7</'E81ROP\<&>=ARTTOG?,>[3AX830`W6MF(
M[M]]/9K;N7E8?$-!OSO]-]+X"*3#L>TTEW;#GW;>;W^?XJO5'I/+E%YC9E3I
M+1]/0D>4C6A6P$MC)!*)4PH'="XLJ5QB=@FX\U2>8I(.*B0'0I"Y3FIDQ\4(
MGIDI\4,(PP1*$R<^*"#I0Q#!!$<5&,,`QA#&,`"$(QPPQ]$8H0$/J`6O>W=V
M9B([KB`Y^L<K&HY@%L]]\^SC;/0<AU#.X?G\Q1?BK(D/XB'HD?K%)^(`#!-"
M$C\3^)A`T>M"$KH`!US0#K!&+'WAAA@B-B@AA+C/C`P\R"&&",\V$L"X35$<
M(0QGF0EAU4!IPQQ@4`%A$!=H<<KWRUW]VZPAZK<..>`>_AK]8VW>WG@"`.@6
M!,(!`3"-X28/P"H1Z(0`,)4(0EP#T`"'\&$+0@$(6A```Y!^@1XAKGKXYX,]
M]M!RN&?;ED`:>WF;]P^L0SX\-?8'#``\QXCEV6RUX^S#ST#_`"AP?X./8!G?
M10T>N]PPS&G/AX:!X;_'#ST#`/U0X,O[7'O_`*PT_7Z\`SNU;3D^<J\4PG!&
MZIFY;1NH2>>"TBU$<L2O:"8J/S?2]^;@C3J"#43D0S3PJ=6-69"K;P=4"<AU
M1GH#SNBPLC[,]"J;S8IGJ3*>(6><%4PO$WG/ZB8Y[F-9#,\PLJR6WQ\2ES=-
MDP(F]>ZR^O4LBTQN2I(#6H4R`"X4[>VP))F5M_*6_P"6?F[+;3.S0ERX_1AJ
M->`]]@$>&6X<\AOV#@(KJ=B#9(5R\RRHHH#(4<O2W+DT2FPMT`3(G^"&&<I@
M:YHF5*B7IIB)=BE[B_,C0XE3$+A%,[1\')4<OO;2V01(H^QJ-D[9N4FK5!M'
M)0!4XRG*$BJEQ,3\D<AE61'90^RLTI71&^)W)MB;W=6K<%CNUJT4P3(<J4P3
M6[OQ!YQ,;R3;-#')$J33.DS.B1DEN3Y;?IKF!Z7EK#D+.Q2XT*WEV=EY+:2I
M<34+:WHE"Q86WIE"Z-*0;"C(.4B47%6`Q;0]69R?]GYD?-IND<M15,V@6F4A
M52%+DCOK8>;(%-7.8JBL<ONZ68'9FJC2R:IYF6D+#(#TT.QTV)6NHR1+5AH;
M)OEIR9DH3-E'8\V7)!<I==I.H9(4OJY1EYWE26RDB5V.:&J6GM?,#DO9"I;<
M'=;+*E!`HFJ8R6DMQ95L<M-;TN8)7,99=,@:2W7IU3&0:2LADN4YEI+*K0H<
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M/C&Z)H%38Z-BXL2E2)6EB`((R3(1"*`8.K-3G0$J4IA"D@@XJGN7=J+:4CIV
M3/C',E&Y<D1UE39/6S)4Q93SS\EXVC=J2=TJBH+'+4G$3(GA=%-/I.FJ6G"?
MVGSZ!.Y&R^!U.C&9PJ"0GDZ3>SK7>L^T9/93_+KLT(:42G.-2Y>JFB(E20'>
M3(UK(L>9=D.3:256:9X?)UG1P,<41$RSO.LTRA(37&QIS`EN74Y+XS$P`]<Z
MT-V6Y?IG+LL5%E*26JF$H3,EC8XIVF>82T269Y_>TDNPHW2;GV:8YCF4RHKX
M\MLLO+%-\Q/K94(U:U2U,K<_(H&UM)<-[H92!^E]1)CW364E4K&3%)LSGRM\
M%>8L`/\`3EO8F223Q96XY$WE))69I6E]C;&`M,7+D#*TIF52S*&L5",ZOJ?M
MI%'4:O-,Z+O-0Z?.DE5.K],DK0[/R25VDRHZ*2]EH9CFF:YQJB_+9Y,=$SA4
MBKTI4Y9Z>4KADQLB<Y$=C)IZM\2Q!-S']#-MF>IB;VR9)5J-0V\[4O1SZ[L;
MX8TH6G9_?YWG*0DE(:7SE5=XF)KDMPK?4255-6VMUERH*^6Y:E2KLFLK?,B6
M3Y%70N4Q!8BZTEIJ\M]0FQPDMDC358=4C[4@U$6K9G2<'UN;6=H:GUW?V)8V
M3$#XRMLO,2-@>6]W0.DO%M*&-B5MIQ`&BDL4FII)<3+'*LELK*=+TE.-.V8]
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M<:5M,ELN!,_A"R)&HMB:/@I.U)T:3]1FRILYGP244IH]*"PBGJ44<L)7`'MR
M2%I_AD^9(()D1N#RJ2U%C3S,J532C45-)G-2@FM4JFM`<EF14I=3H`R%7:LF
MS53><*63D?3QYF2@=+]CFFR*2I>9VHN*29VJ\W."-_G2HLX.LYRJUO1<LM[>
MU.T^HW1\E5O>IYF(]Q:9F02TXP."OX35M6[5[-),\S:AF:B<,LT[H$@J--M0
M#VF7)C0H)YJQ5E\14(D-O+EIU32L]3U'2B"47J=86I6X4\?$<PE/\F*X%KK+
M!;L%ID--)"AG*9ZA0RVE">)Q84LK31-`KGJ)V>)=1GQJ4C.<;&Z1$)41"LPU
M7!`VIT1@K#35<9D2HTTZ/I$I;,E`9`24T1R;2&3Y;04@.G(ZE21O1N$*&18Y
M])3IIX+EE.I<%"9*FF(M.E^%4,1:A$!Q12DA,F5V/%K]INHKM*"G9BE1GK6S
M4Y=JHURE>7UDR%L+&L&;9>EV5G2<7LQDEF8EHJCVN8WILE65SY=1*E:R!-4M
MJ(<8G!,@.*5PPD#:F!]VI:W3$NVF9"@DRB$I;0<;Y)#(SR>D,J2CD%[7,<BI
MIF7)74\TASE-AIK.DV,DW0LIY36US6KE5;=U,=%;X$^9<V-=E642T9,LT$IP
MR$-[%/TKH"$36M`I)+E45,*N?F%.6<Y'0%-,R'00B>A@A`AM)Z:1@@9T1AJ:
M/N[OL_T2?FR8&9XI=)J]LFJ4I$D.8D1K7T"G:2J8+Q=:=2LI$@XDV!CDIS&)
MPEU`F,()0+!B4`$9@B(P+FW:<VAJ!46E9WVEZBT-DZI\V42F"MR]W54^<)-D
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MUQ"3977%GL3!&M=7%R4FI&PQU7`G4'FF.1A2CS54N4)2$I!#GUG`?U1Y@TL(
M-^N?]CR+Y9<M_MQF*!?E!AMH,NO6=[A?SAJTSX<=VEAOC#5G']LB8.QOOF`?
MV.('/?[W#?@&OSY7'PX^S?ZMV"UQORXC[>%N`:\1`,)?.V0[K!J&?T``9!OP
MN??E>WKU'EV@`AE@#U"/L`1X9?5?LN"&8#VZ[N8>`>.#MRS'VB(#V[\'$,]+
M::Y=EOHOJ&F`.7#OOP&_Z<[]N#MUSXZ7]0V'!H&OCR]\\'MR[.Z]]-?#`=/G
MZ0)/JC*+O(D_,9,R2D^@WBZLYZYY:X5,;4ZH7QL.+<I?<V=\;U+>\-C>Y(U;
M6Z(5B94D),+40@$4,6;8F-KEMD:)=94L:-G86Q$S-*0U:Y.9B5M;DY:1&GC<
M7A8XNRZ,I.47!&L<G!<O4Q0]:K5J%$49L65#OW7SO;+QX7[;\<?.,THH8`,C
M*+".+HP=..&#IQC_``80$0`8@`!$=]KVTL(<\M+``6`.&07`+B-N&7#UXPQT
MQ2VG`V-1,4N)X$XNXG1J9A94\"<9?ZD)@ZZ,Y>7"G^+XJ4X3")PP?`(J4X/'
MF0J2.GF(3$\<<$)BDLHJ.,N$PR&*&.(LJ*,(3#(2PCA$R*"`8HX2PBA$P80A
MZ0!%<*1*H^3PJ#48NHU0'9C9G.I$Y,=:YF*E954YD&6%$_;1M;6GX1D1Q6FM
M25&%/:+4*E4J!<<F(2%5\?9Z=$DX(UJB3V=J5!=8H=6A$:20M=F9"<J2J%J<
MEP=VQ`8H0)(TQ2UP)A6*R(C6U%&M1PKW"`(D*&-:D!8H(%4GZSJLK5/IK.\H
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M$K<2IFELIM1=$V-Q53%+R=M.;3UL+8WS`C<!=8D2J5WERB%L8IB@/A:WIS+/
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MH<%BS1-J.?D=;V2=9=02Y),GSO,U*#'IPG`HA#.,OIY0EJ.:GM:>67+BV0RD
M[M-+M*$:8YU-.-!J*F1EF*-(\(!2Y>GDETNHG(<I4ZI^C89&I^PC!+$E2_\`
M&14I;DL9JA7&FEMC7S4_.SDO4`<2M*;V(IT6J4Q20Y`W(R4K>*9-7ZHI+M;Q
MT184CA3VCLZ3,IJ)M25%F&@LQU&00R,MF*JC[,T[4845/G<](YL]3Y>IA.;T
MZ*#6!K;6Y.Y(#Z:Q+6,YSDM>XRWFJ4[+*YA/H53NIE$97F^D5.Z=T!1R6)E5
MY?.+V=YMI.\G3W/[RE:T[>TNTYU7JM41ED:9E]0I*3BVF*")GEEPFA!([@>F
MF()C5NK$FI))+S,#.VLD[S>V.<@MJ&FX3F@ER87LZ?IX8I,:DZ,`;9@6I%RX
MQX./E[X39DC,_KT0-)[\S$*#7=#WQ]&GCXV-$SN[E);U+<MOR&;I8G)2]LD<
MNM[PWJ%;.SS0RS5\(PM24TT7%8TD+$[KU*PIU6,!XJR7%4@451)MD:JZMU6U
M!K71YCVDY\^/:1-/<#O5.C<N%UAD@B9GN?"HI>11RU+J%#*#?.;'1%U;&.M4
M\J7^6S*9D(Z?T\D]F!:CFEY9LV?:N(FN76=AI=06H#`\,U87J"CKT[M$I;.-
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MXB36!?'F>*`;1BRL*R;V.EE,'1SE./:?<J;UP3U4EV49V)<)^DY?3/9R8$;&
MGER)QE*1:%4JFQ4@EMB;S4<)56I373>>*)M>T4TS,$WZ(UZERK%)Y+J4_'2;
M3Y=-\JJ)\"5%=29;>%+5(ZAU6ERU-RY6K)E=Q1,DQRR#',XG/DNL<;"#^2Q/
M,!3FB/ZQX_C)+(#!#\9):_&+V]J+`9B8PZ;HZHQ<&EJ*#S_\8Z.S=^R+2V0=
M)<ZMUW!N3J4?X_%/"C88JQ+,G2S3]FE21)S32;,\RR7-=4RE%`);JOM'4[&3
MFN6Z-3%.D,X4OFB4I!I]1IL:V"6G&DQ;9.9KT=*Q$Y--+GIX(8#P=Y'L.()/
MGAGFN7Z<2/.I:O:1H><C:)QG%&##1;9OV;J<R])M/5LK%K&5S=IQGMR74]EU
MU%8NZ<]LPO:!@*>T<KL#]"Z!9JY.;6SHSW%X<VMF;DO5^<N3RXH6AL2@<<60
M3YRXN2A(A3]<H.)3D]>H+ZY0<405TCCBRXOF2],BF-(60],B@Q>J7(6\M.\M
M:DQP7M@1BZ-[<62K,C7KVP"XQ<T2.$]6V@69Y\0G`N,0A7MC40J-7=PIS+#9
M"7,]&EC=.S!5.1!F*GDO$+G>:%$LH6.=YB/G^4YW3.4NRU)T-1&2-!*LMS!/
MB!ZFUM?I);V:8FY!/<J-'479%JV[.M:3::O4F4\EN3IO)J/LAMS`J0%3(US_
M`#50^G]*ZIOZMV6)1(IXJ<&E+6!"W1HW0Q9/=0JG**E5&>4OP"R.V`L>7/$G
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MFT@GER)Y0=;HTEK1.%3'.H=>J*HJ?.;2US`VR+$IK53VI+%)+2X.L*1(TT\8
M9&2&FPS+-+"G+<:M5*G)0U/2HP&F2))1A)Z5R3&`[DOU<(>*P55I@K:FEG:Z
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M4]DUU+I-3.>G],^2RZ.ZF7BY5E26VQE;W$+@5KRR-O2^$WEE;>K`>F#F[M;=
MT`A1JG(>GY\K("#H-J!>YQ].P0MJ!<Y#9$A5J">*5\8%CBI:4CXQK'5$F2+5
M[4A>6I<\H4"TLH]&N6-*5::Y)4:U.H(4-ZM2F)2KB3TYJ0\TI029'60U[,%5
M*R5E5Q[55,Z2.M)XMH)UK6^+6Z;T<SL\ULDFT<*I'02C373P^$QW44TD.";Y
MXG:-QGU<@6*YN1N[4Y4T/EJ=RG)+^FD+'+NRO%47:#KU2^BM!%[+*4RL$GE,
MM29*7S9/:]W?QG.:)`D5Y!]`Z8Y-FDV1J5I:'TWGA:^U+IY,!\RR:PEL],(F
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M>O73+OUX=:5KUI06"_\`3(+AO_C<O5;`!I7\J5RL9!:PVT_"&]MX[L!SUR'Z
M0UR'WO\`0(I%H/8-[7`0"PVRU\+#>W#''K2LKFDY@`WZR"U\Q'^%RN%\<!.)
MZ(AUI-Q`;V,@W@.[I9[M!&][Z8"8=:OR52S_`+Y2U_V4LQ$(+W&_'AN#3QO?
M>&H98EG6%<B6TLEZ!&K2JXD[I+4!X)5)*@28A:EP!";U!D?5B/0BL$?1$>B-
MKV'$31ABSR$.=MUA]@YYV[;98!-+"/8.>0:ZZ=_.V"WW\-VZ_AK;"]$1#00X
MV"^[F'#U80`$-0B#*P!KV\\O``X9X`X^O+ENX]ML],]P&@9"&>\=,MW+=;+L
MPH`([A#(-._+(-`XAORY8!A&V81#OWW$0SR\-`M@$T[+<1R`/5W]V=KX`^@,
M]V_3U;\+:*^@\=-UMULQ&]K]N6/BH.)2$'*51I29*G*,/4*%)I:=.G(*@$PX
M\\\Z*`DDDF"&*,TXZ.`LN"&*..,(0$<!]0TMGS[=^>5^T,((<`_Y0AZ@"V.!
M9I)Y11Y)A9Y)Y99Q!Q,<)A1Q1L,)A1I)D$0P&%&P10F%F01#!'!%#%#$("`C
M]--P^KPUW:8!+CX#]X!IP[-V>N(`I\O+!46WCZ&M3`__`+M,S]\^0XG_`)A[
M1M<>VU]-PV[0`,0!39^6#HJ&5XMC:I0!>P9Q3=&`9B(`%Q'>(!Q'?@&K\L;)
MM7WJ?MGITI])6U/.30M:'!F^#]A*HNSO2_:243G+<[(IO;39R=*XR!/KI-&S
M[+S6IB>7%IE)*@EB4ID4OLSU9-/E9P1`G8JLD^.^RSM`^30?:ORJV_&>4MB2
M9Y?G*6:;$2NVLZ.97IR6"J*9BF(E)*$!1!Y_7/!TMIT\OKWHQU7R\G*:E:(J
M%_/*=U?H_*IL@[4\C[?S!L9U/IQ-,Q[*<<Z35LGG[1RYY@?W<7R>Y1IC3Z>)
M)@F-'/4NP%JG"9J@4P@<F,R6(4K-/BU:P$-":.!WE%FN3F6<_)Y-5/:BK:P2
M,CV13X95JLXN)#NX5*9E#ZM6IYX6.*<LI*<HF8U2<ZQP)R24Z`%`-A"=.4B@
M)@"P$/*C4KT"F=0KA:]E\M^SK0TO<;`&>6N6`/*D4KM?]3.H0VO_`&0EO.PY
MV`#L[?HQ2$$(WR',0TBU`-XB/,+CD.>0;L<KWN,0;AL.^'/4(=U\OP@L(Y"&
M>`N[_P`U'I5>PTTJ"(A<?WPEO+GD=H`Y7U[L)_FI-*M?U,ZA`%A$;KY<XANZ
MT>?#B(:#BD4<@Z5M;16`!&\6D(6L/1$!MVB%A$1'"#F`7`0$1O"`6$;!N"]L
MQL/1N`C"`=V`N]_S4>E>=Z:5""W%PEL-;VM<[7MUW:X!\J/2O=3.H-[VR<);
MU_\`B[K\]=,4@W"UHA"]POJ`W&V8"&MPT[1O:^2WN(7L(`.0B(AN$!L-K#SM
M<1`;AOP%W@>5(I6(B`4SJ%E_KA+8VL-LK&C<!SSTX#@#RH]*A$0"FE0AL'Y_
M+8AP_EA'B`WQ2'TM+[[VZ(@(V`=`O:P6O<1S`+!;/-1U`!MF.71R$(O5;(`O
M?,0OH.H7>?YJ/2L0_)G4*PY?OA+>_=_3O9XX[Y3?RNE'9*F,U_7TPJ4>22R.
MJ6`A*JEDXTP]1&B,+A'I+"(2BPA2F#$;$,71O`'0BZ65`W&X7BA"_P"#T;!%
M</X6H1!PW!>W''$P1$DT=X%'!8=X#`(#8<K`.ZXAGG<+A@-KAVVMZ*U8F)9,
MB"9`E8Q<0QDGLTY0%LJ]$K"7VE48GB4]:H:%H`6N(BA-;G%5"$/61G`3"0IZ
MGO"):C<DB=P;5B1P0*R`4I5R!20L1J4T60*$ZI-&:G.)Z0PP]:69&7TAZ(Q=
M(0`:!4(@+:-A$P.I8(HHHX>K$`\XE8(3(H`(3`!D9OZTC(ZJ$"TD/PB"-/&/
MQB%R&B:9DEB,J.7I@>V"*!K=UPBSN*U(!2Q*?,`P+2RD\1I1BUO-,,3(C.I5
MG+$YYZT29@BBC>R@NW-*)4%&)U))1Y!Y1A)Z=066H(/)-@$LXE02=!&2<2:7
M%$6:4=!&4:7'&69#%!%$`X='*\KMQ;42VRO*[:2PGJU3"2VRTPMQ+"J<(#2W
M!4PE(FX@MD5.)9QY;@I:849[@6>>6L,.@.-".N%MVOJH,0-H/*:7IF(!4J3K
M(%*&)L6*"B'.!(9`"]C!07":F3!TDJM.A5PKE)T<1<$Q1$>8)Y'REM=TUF`^
M%&])7J3SPBC@/4N9:=S:DQI;<F=#`4N#2:=&2FA2JBOU]$C\TA.-+2'&$*RU
MA*,)+@QL<)JI1"R,<*APA50+U$+,U0J'"%:L@<ET"]1"CZY?`N<B27)=`LC.
MA6.1!+BJ`Y:24?#R4,K,J6F.2IF9E3D<VJ64YS5-#8I<S659$!BQE.<5"0Q<
M<RK#``Q8S&*(VM68`1J4AL0=+&.89PE.:0_H:F5C?1!/`J$MK<DRL[S4P`Z"
MD4Q9@G^;"$4`B?U0E0=.`(XH!C@OV/2]]PB`[A#D.@@(;[YY:7P#>U(I=)E4
MZ:SG2B:VHD9.GJ5E\HO*5L)0-ZDAL6M8,Y1S0;YD<G;'%I10)BV-:4EBC:`1
MHRT,))*4@N!KZ:;,<GTXJ/%5DMX6/,Z!3>.DR2)#)U+Z:RRDDB.8FF:A2&RE
M2V2I4;WE\+=V5$"297U0Y.*!HA.9D4!"90HC.DEGW]WB`7'B%\\''7Q'+UWS
MRM;3=K@,5`PL1;D8\%L3&6\'*X'`YX+9&DMX.<"T$;26X'N\",'(YP*:3#&@
MM<:KC5P-!AC5`>#>88F'XGRS+"EK6LBF6)85,;DO4NSDQ*9;8E+&YNRLV`]:
M[.3*>W&-3B[+3RBCUKHM1J'!8>44>I4G&E%QPYSWU[??]&$^_GV[\[7T\-V`
MQQS.T*534M4M#0I7,('`PKE+4W*%K""A,6C4`Q+#DIBEC\X1$DHE'P2<B\X1
ME$HS@C3%EE0<3F5E4+OA12R,JAT\R%L^%%#.V*'3X-B4E+(FSX2.1F+_`(-B
M6$$+8FX%/F(K4Y"L2!4D%'09/CE>V[/7+CKGH-L''OWVSUW9YZCGPRP&+7,;
M&YIW1&YL;&YI'T"(7U$YLK6Y(GX$I<!24'Y(N1GIGL$I)99*4'8I8"4HLLH@
M"RRX(0^IS8UJ"3DREL;%"=1"BA/3J6Q`H3J`;0)!M!0G-3QDJ(6V%*F!M`Z"
M,&V%*E!%YN"<@"OWA;4---1MD(!D&GOE?!]5[!GVCEKK[C:P?D5-Z!<I0+%J
M!`N6-:R)Q:UJY"D6K6MPC*C(C<6I8J).5-;E&2::3&X(#DRR,DTTJ(^(LTR"
M+'$2Q+"50I5)98EA,J6I53>M5)9;8DRI8A7+!<EZ%:J(;RSU:%<XB+BN1*3#
M4JYQB%>K).61">.<&^[7G?0>?<`B'TCA-X;P&]K>O._A;,,]U\!CW-G9WHDL
MAZ9V=Y3DQGFDIWIH;7A.28I2'MZDTE.Z)%91)JEO5*F]485!`8H;U:M`=$8C
M5*"3/@=+LNJ"7E.HEV75)$RPDP3(G4,#,H3S*6F3PHTT$R$'(8RIB@2HH84:
M:![@7PIT80HR`@3`!6,Q>U@S$;>-A`!WZ]^6_`.NZPZWWA;U=G:/'`=";*<R
M\V5`>*EP>>*9E<I.8J=M_7QIRFJ5)#8%IKP5*TJM:-*E3-J!SF$^-_>CS?.E
MJ]40TH"E"5D8FIK3]]OK[^^_ANW#?`'+>'N.N>8A?VCE@TR^BV@>'L#PP#U4
M#_*##_@Z\[P_.&K=]7?NQAJSA^V/,`\F_P!3>1ZOIS[,Q0,/VPH1_P!CKUG_
M`.T-06'A]=\L\8>L_P"4=_SW-_\`V>1V?2&7+`-<'T6[MVN?Z1P7]>>H^W3=
MIO#,0S'"6RM;(;Y9\QUW7R[-,\'9PL&>?/(;6'=?,;ZX!>W0./OPWWP6#ARY
M>&_OT'0-^#/>&0AGRUO?CN#QP6SU'CKX:;M>WNP!?*_UCOW6X[A[!P6OOW6U
MOX\=^N68W#'$R*`N$8S(H88((1BBCCB"&&$`S$8AB&P0\QTMX=$>9J$1B3-<
M0`'X4)BRU]=R8!"V\?QP@(C_```_A8#/O#\E:X(H`&%0MBA`(4\,5P@$0N$9
MXA_2X+9A#^[B_@@`",6&R7."IQ/$]4;TXM((8;PEEP_Q2X+B$(`-[C<8A&XC
M$(CC\D44<<0QQ1#%%$/2BBB$1BB$;W$1$<Q'B-\\)@%Z47$?$?T^H<'2'B//
M,<90ID=CBX32T"@8(P`8(AA"#I`.8"`1Q0Q6$-!$`ONQS^+SSD/P>?ERAW[K
M!'V:A@,1<>(^(X+CK<?$??=C+C+[S;-N/MV0?XVGJP?`#S_<\_2^D&7;:+WS
MP&(N/$?$<`11`-PBB`0&X"$0@("`Y"`Y"`A8!`0T',,\\9?XO/7]SS_"`>-O
MX?'W"]\)\`//]SU&_P#B:Y9?N];B'UX#J;8Q,3(I<5C(Q,3(L>3`/>5C(R-+
M,L>CX3S5<)[TK:T:12\'PJSSU<![D:J-A5GGJH8P4'FF1_1L9F9EA4P,K*RL
MD"U2*Q;`R,[:SP+5D4`%Q+%L#8E2PK%D4$,,$2M4!RF*"$((C1A``#M7Q>>O
M[GG_`/(_Q\($OO0_V.4!VA!_CX#$7'B/B."XW',=V\=-WTXR_P`7WG46X_2^
MD&5L\_P_<>=L'Q?>KV^#E'_(MD%_X_,`]PP&(O%Q'Q'Z\'2'B/B.,Q\7GK^Y
MY_\`R/\`'PGQ>>O[GG\?X''+^'OMIXX#$7'B/B."X[HA\1'Z<9CXO/7]SS_^
M1_C^_L3XOO0_V./W[H-W_K^^>`Q%QXCXC@N/$?$<9?XOO-P_8X_E^XY_W_#W
MUP?%]Z_N<HW;H`UWYQA@,1<=+C;A?!<=PCXB'L]F,Q\7GK^YQ_\`R/\`'P@2
M^\C_`&.4!IJ$&@Z"'X?KY9X#!*""%B<](L(3K$BHDU,J2+""5:14F.@$L],J
M2J8#4ZE,>7%$6>G/*,).+BB+-+C@BBA'Z0`!<$!9<,)999<!19980P%EE%00
ME$E%P0!#"6445!`447!#"645!`67##!!#"&9^+[U?][E'A!NY]/??+L$-<`R
M^\A_8X_NZ'^/GEZ@P&(N/$?$<%QXCXCC+_%]ZM^]R@!MK:#(<O[_`)^H<\L`
M2\]7_>Y1J.Z``_\`YF=[Z[^&6`Q%QXCXC@Z0\1\1QE_B^]:?!RC0!`;0=U_P
MP'7=PUWX/B^];FY0.H9=7N[8PP&(N/$?'&-<F=F>02PO+,S/4*!5`N00O30V
MN\*!>4`PEKT$+FD5`A7EPC%"4N2`2J+AB&&`X(1$![1\`/5K_!RC70.A??\`
MW_+,-V@XY?%YZ_N>?_R/\<._CI@,/TAO^Z$1U&XB(C?>(WN(B-\QU'!>+B/B
M.,O\7WK+]CS];:0=G\?*P\<`2^]#_8Y0`<^A>^7]_8`MZ^>H8BX\1\1PEQXC
MD%M1TQF/B^\CG\'G\-(-]K?PN88/B^]"-O@U1EQ""VO^W[\!B+CQ'Q'7U^W+
M!<>(YZY^W&5%A>@_L:J_XL(__?A!8GD`$1;50!J(]&'<&O[K@&`QD,<9810P
M1QEPQQ0Q1PEQQ00QQ0W"&*.&$0"**$(H@ABB`1A"**P@$45UZPW^5-_^*9_C
M8[FY4VG]G0DN;I*+R@;U!A!1"Q26G@(-,4EQFD0010*(X[FEP1QP7@`!"',0
M$0`<"+`\@-O@Y1>U\@@_Q]<!BNL-_E3?_BF?XV#K#?Y4W_XIG^-C*_%]YS_8
M\_//((-X<H[WL'+4,`R^\Y?L>?\`\C?EG^'SW^VV`Q76&_RIO_Q#/\;!UAO\
MJ;_\4S_&QE?B^\Y?L>?G?^)NW_N]/KPS%::MRG0B7OAN=U'5+599OP#+28Y/
M$_S$>6(0"6WHQ,&,M*49'!"L<U$$")'"(C''&;T28P[E-$WL,E,2^9IK?4S$
MQMI76K'%>KB**@UZ!)4(11&J59T0"6F1IH#E*@T0+)*CB$0"F;:.VNIGK!&X
MRC*YJN7J:1&0EQ)(XHR7B:2RHX8P/?C0.CA*0&&0PFDL1`@3###!$X&*S1$H
MIGZTUWGFN#["XS*JA1LZ$PT6&56^,P&9F@,$0Z80Q"$;@Y&%A#`J=5("H,`!
M+*A3$]$G#*A;H@`[[B("(CK8+7#,.T+;KY"(B%O?D^=JB"$4-`9_70P#$)D-
M-I@7*0#K(@`8QDQ<<H-RC$+C*P@/X00Q,O0&($0XM\&(`_2`>H1`<:N-#J&5
M'KE-R=AI^WG%`B4I5#M-B@%*9DE,D(^N)<7%S(A&(M9")(G-R%)%$YK%)9<*
M6"`;G%[-LJ-3JQ2RP,K[,2F:WEJ:42!RF58E3H5;XK3$PE&N2E(G&,DDY2,(
M1&!#%%%'%<TR*(V.,1#L-N8Z^_OQWCB`26(8/+"T3,A'\.#8XJ29`-@$`B@F
M^**$>B-P$`B`!$(@$!"X#D%L3]\=<_<=W9O[\0`3@(^6$HK#"`Q11;&U2H88
M0`1BBBCF^.&&$``+C%$(VA"V8Y!@.^)?)_T!H/M`SOM6S!M8519ZH34QSY)F
MSFOVB*LT]FB1-D>*IKT,TS]!LORM57X+9$;D\NYD2TA,\JGLUA;S(VY*`M1Q
MY1L&MHNB5+ZR[57D\:52Y4N&;J8Q;(,_'RY5*0$4FHTLZHY=F!T,+FEJ1,"&
M*24Z>97,%[@OAEU"2RQ+%"LUH)3I3"RX8R^7`?J)[1-=Z#J&.;O)&5.E:0Y!
MJ?(#NX;>VTO5"2&26ZHL%9(6:>9-D9NHG5B4(XIGECS5"FJ,?,#.L.:QC0M)
M#P2>E,;87MV9%I#C4KR,JY*U24Q)E'DW9P\V9Z;1.1E/&T@AS>4A*61#7ER>
M'<^30+3PFRTK='5Q<5C,:C6+EJA0H-,$)0CY+BCXWO4JJ`A;(.IDW+*VOP)>
MW>`:WPG^9;T@^4JJ&@A<"9.N(#H%_@41L&[UWRQ9J&F7#=8-UKV'2^[=E@MI
M;(+[N\=W'??+OP%90^2XH^`#^V54\+<"9."V=]/@76X7`>(9;[\O\RYI``!^
MV55#(=1(DW2V@_L)I<.EVYB'"S,=W?;/?8>7"_9SPOO[Z??@*RO\RXI`-Q_5
M)JA?3^DR:%PR#*S)^#<`OE;,=;8!\EQ1_*U2:H`.=AZJ3ND`"&?]A<QOJ.N>
MN+--_'3?]'U:CEIF`%@MEV\K`/;8-=_'.^H5E_YEQ2$?]4JJ`;A_$2;80UL`
M?`F7MOH.N#_,N*0VM^J55'>.1,FW&]Q#H_L)<.C?+U8LTM;+(/J&^65K9Z9C
MZ\&^W"WTV'*W#,-.&F85F?YEQ2"^=2JH#K_^3)W$+`-V0?4`;[\,=RD+R1-'
MIY?C9>&J]4FZ(QH<EA:P$<FJ(2S$YB&`(3"/@8L32XH51EX2S2(P,Z$0&!##
M%!%8"/=GSM?+LX8>B@?Y0X/\''O_`*PT!@*;:K["U6*8O3U+30N9JA$MT+,8
MF6-IL#"X+2?V!.*$6EQ/B+*7Q-B0TA2E^$(VZ`2P5(5ZIW4IVP8X/DJS-+AP
M$O[&[R^:6W*D48N[><B+3*W!-,BMO@//60E)`B3H232`A//+(5#%"I<(TZR)
M.4;L(5M"]2W_`""WF[*'_1"7V8:%4E2KTYZ-<F3+D:@@Y*H2+""E:4],I`(5
M"8Y,H@-(-3J(880.)C+B+-Z$'3AB&"'HA1&O`326N(J'J835\'5PFV`2`5S$
M<4B@-%8),01MIA1ARL%0$FP%G%_&"!M2"E..^+='#TG488(BP\U.CZ`@;#$!
M9C2RHX(+FP0Q@84M_9..\('@CO&H++8`^$<6US3LRTAF@DN"!@-EM0G.(/3*
MY76'-O4Q$*85<)4:*+SA"H2"9"(^;1D0BG$T\]L.;5JE0K.C?,VQ@]MI:Y5)
M,U(WSS@J,D6I^3P-*R"&*-)#">0Y)04-YPEI4D"50D4)T8&0B<Z-YL+Q$2GP
M$/DJQ0VK$2](>K2+D+6K5)UC<H5(UY4:--,J57$A5MT4*M.H<#S15I34$8JX
MTG6@RP+V>-0KA=>4=I>K\FQFE&3'#-*"%UA0"WS`E(<B2BDBI+`IC;%#?"*I
M$*I.>!#60C-5-(Q%0ELS<]1%')"\'-M)JCR;%TI@E%X1)(6%TBB=$J,79J)B
M-+>E,$,3@@A6I(5+>4>2FC0JX@-5B9&L5)G0],8X)V@5A$2:J@,A%)$5,KD4
M;`(1&QIC$REK%229"=YS&)C5#%`=&!P&QKP.A*6_"L$!9)06(R/MG-JWSE+/
MDKFMAZ;K(P=99/!P;S2BFU"YG`:UJCXUR:.$I8*=&:0N<D[@X%%M<4:%Q-/)
M2R1EBM-+YM3D&-,Y-!1YQ,)\;:[*(65T30"6:9$*I(X1$`663"G-!0I*..0I
MS(84YJN!0:02;36BABZUW`2^KL2LAZ`1Q16BAE5E41E]*(R,?Q1`?"O6#%TC
M`'X-C,.2?L3C(E`,4:$`A$T?@TKJP".(H3(S6J93B(8(BXB1)B<"@%PA.*B)
M,0"7YHD/;"#(D!@7J:6&PA<(1S"UX8K#".@"(##^X$,A`;YAG@W;N-]W;[^.
M*39-JU4>2RDR25IR>DR$I[;B$C>)Q*AKA(<')+!$60UKR8T"0A[$H2#4I*<E
M*D+(Z!*=N(4*/.I*R?MIS9#&87-LL,CXF2E%FJ%3%$H85IJ;HI"HCB4ZF-P0
MPJS%ZV%*65&!"412]&.!&0K%T1!8[ER#/C8=X`(<QW;[>&#+Z==WML&O#/(>
M#"2YM+4BF(U.F,F*.7%:A.J4@5,Z46I.7`@--3+8%+GUBAI31)U1*A,)AZXM
M*>:G,C1*526-*J4O>A<&]T*C.;ER)Q)+C$HTU`J3K"RC8#(BHBS8DYAH%QPF
MP1EC`8,,4)L$9<0`9!%"`?LL&5M-V>7&]M-=.&H8-PW^@/#AW^.$O?3/A8<M
M]A'*V=A`=;96UPH:=P#ZMULATT"P=E[X!!O;@(:#EEQU'+Q'MW`9=G$0L%K9
MV'Z==^F%OKVV[]<O'!?=;Z<A]\[VWZVP!:WU`.H[^%Q[1YVRP=N@Y;NX-]]_
M8&[7`-A\,N&EN`_2&>8:8.7N'J'3=SP"!IQ#=H''=NX>T`S'"]F8\Q]0B'"_
M/CSP>_ONW<?"^9<->&?/EK:V\,\`]-`LZA!REUY#,0_.&K2WKONW8PU9\JCS
M!D&8-V^PC^QZ?+MX!D'/7&9H'^4*$;?VNO5]_P#IAJW^.,/6:WZI$P!O`&^X
MA_O>GU]EL^/,`:[WW9AG:P_?NT"^#>`]W9<0]N79;=@OG;WY??PN&NN"P#NU
M#V]G?GX:X`YASMIF-]P@.\=V5]^/PKW%(W$B<J-AA"T70+A$!,-B`/W$!>L0
MZYY0AO'+&(>9D3MT,1"88%"W,.B`](HBV5S1A'.(/Y(!"+^,,.]M52M0M.B4
M*38C38KYCI"&Z&&$,H8(=`A"V6MQSP&4=WU4Z1"7_2$8#^`F@'*(`TB.B_\`
MS(KA>U@@A$<H;ATAP>#W#&7:F96ZF`!4(EIP'\8JCA'JX;#^%#!IUA@:="$<
MK@,8@&>`QJ=.<I-@(3E1G&QC:&"`+B/$=P``:B(V`-1'#BLTKDHP@4KNB>K"
M\0%7").2.X<P$#8X=>D/X$(YPPB(!'C-MK4D:RNK3EWCB`>L/,M$<:.6L6D,
M&MBX;0A_?#>(<GKW=G#[_<,`F0>W,?KX6OW98`_3IK8-^7U<PTP:_4-M+VN(
M;P]PU&Y;3=;E;.PA^C,<`6`1SMV9>.FN6`0`=P;N%\\M_9W]V#B(7"_?V97]
MO8-@`+&E_9EZNWVX!,@O8;[@"X9<L^8@&_=A<QT$+V^JW.PZ]P=Z!H`#G<->
M.6?#NW^`CA?5PX^L/KP!D-[V$!'Z=/&]@[L'$<@Y[]_L#"6ROI?6UQN&>6E]
M_"^%R&V[7+3EZM+AQ[,`"`9B(!S[NW+"Y9]F?9GA-;Y]U@MIH(V'7?W=YOM]
M._LX9;N>6N`30<^7?[+#>W(-UKCCE[^_MP@WMQMK]-OH]N`0'=EGN^D;=FX>
M&F>`-;A[^_$,\NW!NRSW"%],LPYZ;^.X,&_[NW6WCWYVW@CK;7=<!MZO??I@
M"P:9:WTX6SW9^K.V>\#=]`6#P]MM!UL&%]_?7"=MK7YAK:V6=\QSSM@#M[<[
M6#7(>SOSS[#AH'+D`?7V9#;7!IW9CQ]7*_;;MP>&[B/T9;P`?T8`R\1L%L\P
MY6L`A;7EGI@'7,-,L^?#OL&>#[NP._+WME@X;[;^[P'?IIPX`!KIEGGW^S7O
MOD`83+73OW^.H#D.MPN&>Y1ONM?=?WX8+#>_T^&[M^_<!NYVWCXY_H[L)8,L
MKZA<;"`>]N&5[9:87NUY<<QX>NP\;W"X&7Z;]NO/WSP`%\\LKY6]8CIVY>W`
M(`/#>`=^0WTWY<<&_+=OW;[AOWZY<-]L`[]W$<M._`(%[CZN06[[!<-P:A?3
M"C;/<//GQU#.W;;""`!<0R$=_,1#MU&V[!>_*^^PAGIE?>.=MX<PP"CH.E["
M&FO+?X8,[]_+2P9\=<N^_#!;+2X#ESMNW;K[["';A==0\<`@]E_?+733QSPD
M7[D1MNB"V6>6G"^7=QMA;6MG8,\KZWXW[\N_'$;V&_`=W`!`;Y97UU[!M@)?
M5J#]JJ6;6#]DI;W?ZU+,1#`.5KAGNS[A[?KRQ+RM>5*I9U_?*6]+7_>I9QRQ
M$._W9Z\?#`&@#IQ]QRSYCV\@!R#=E[+_`'9<^&.,<<!<$9AD4,!9<$9ID9D4
M,$!99<(QQQQQQ"$$$!<$,4<<<400P00C'$(0@(A5-M8[?9+`8ZTXH0X)%[Q`
M`HGVI2:,I:W-<<<`=>BDZ*",U.X.9(1=2H?3`.0H3@-+0$JE!7G)(2%VHMLR
M3:"I%TM2]&@FZJ\4,!9,N`888V2V)Q99D*^;SDYI49`=3%"8E94YP.*R**#K
MQ0INF?%0E4"H4Y53FQSG6>7M2^S`Z&")RH_HEDIDQ0CYNWMJ0N'S=N;$<`]4
MC0)X(2B8`$8NL-CC-CZHL6*G%8J<'!6J7+UAYZM:L5GFJ5JQ6I,ZXY2H4G11
M'*%!YD41AIQD<1AD8B,0B.>/@7#%$(0A",440PPP00PC$,4<400A#"$(",1D
M<0@$,$(#%$(A"$,5PN''?"(@'2_<B'`0"^07N&H!;<&</*9FR]L<SI7U>B?W
M@MPE2E14<42R;(R"X%;[U$<4!C=*)"J&.!8H$T(BE+L<3$UMX!$(BL5`"7$@
MME#8$537`VU$KJWK6N6X@@5L5/3X3V]W?H!C_%JYJ@BA+5-+.;##UA#47U3D
MYDF%F'F(DL00GW/($"!J0I&QK1)&UM;TY*)"WH4Y*5$B1IX`+(2I$J>"`DA.
M26`0%DEP00PPZ!<;B'4*<4UDNDTIMTE2(RD,C`W0C%"3`(FJEJPP/URYNJV,
M.N<'-6(=)2L/$1BR+*A*(A+)@[V&8>_CWXXB&6>60:;K7'U<K:8+A_&MQ#+Z
M0S]PW8!>`ZY#;4->_AEF&OABO]/_`*,%1:^OH:U+'+</QNC]@XL`TM?L#ZL[
MC]8AW8@.V00&^6.H468`"4=L@U`+-#I!!<HV=H8#0&/^#<L8@Z0Y0ZY6P$>O
M*XT'KB^3Q)[ULET=H:I<99I14F>)R5AY/VD^V94*<)A@FXR='Z2D334*%)(5
M,Y@F9FZV=Y:<9@,9)HK_`#V:,J(ID5GLA!$&*I_+2R3=I;R3<K.#"]RNXLGD
M^9P1N4MS)3IMI`_,3F9&J5N36[TI95KBSTW6I%ZM27'([4N5-TM0=6V(SA((
M@AA@W2F+RA%)=L";-L6A'D7:XU<J'/-6-H67ZLUZ4;:J66I>VK:6*YXGJ4Y`
M)2T=G@I4RTB12BJ8)%=Y.-1,BE4E02XXI2Q-139$XIY]R]4NI-9-K?R7M5ZQ
M2F5(=5JA[#M5)IJ+(Y"0]"5)TWKY@?('B5X4JH1/@%A.(A;#33!#STU-&X%P
MP%*RBX`MZ#+,,[!:V_+CS\+=XX7EQN(Z[Q]NN>ZVF@8`\>`Y>.7A@SROWYAE
MP#3//3.][8`#/U[QS'3P\=VEL''2^[NTO@SUMGW!KJ.\0M;=?OW'#W_2.HW^
M\<`!QWY<>([AS"^?9NO;`&[B(>SLN`=V#6]\[7X\>'9;Z,M0+:<.(]O,=+>K
M+3`+[^^N[QPEKYCPTWWY9Y=WCD&$#74<@\=+^P+Y!K?>&`>7JM>PC8+9Y`.N
M@Y!N$,`O'[_I^CU8>>@?Y0X/\'7O_K#1I]/.^&8TYV#O'O\`T?4\]`_RAE\/
MBX]YB.=O.&C/3WY:8#'UM_*6_P#^YV3</]R$N_3U=^&I]^WW[L^6KJUNRJ6_
M#_\`H,H6RS_8A+Q$/5AJ!RSM<=VE]--^\=V\0#3``=^[<.F[+*P\0`+<>2Z_
M?O#/=P'<(ZYY8,^(9:C]/+?Q#!OU[LMUQ^D![N>`!"X10C80CA&&*$<PC@UZ
M,<(W".&^8PQ7AR#+@VDVT<IE/*@%DS2<TK7#KB#XW1-`<U.AT:91`H)\Z<&L
MU&I610&!$!1RN,Y4E@-4?!ZE":<8<+E@&H"&6X>(#N'LYZX+YVSOGK;3CESL
M%LAX[L!"F8=BZ68S5ZB3IK=F0%:2(DM`]$DO29.HLG'K85I/F*TP@X$1"2).
M=`8*,@Y0XICSG,M.`QTF;9MJ]+T2H0EJ*8$R9J=R//95/@=P/A/!U40G)4)A
M(.ID9'GJ9&G0J&TY>JB--B-:YB.2'OB.V'(,QRTN.FGO[Y8.&^PCG<,L]][9
M!ZA`-;8"A5T0JV]0>F<T2QI4?&5R@%,J3*"SH8B535$K+@)50JS38FV$PLPH
M+*HUD1P$J(IDZ,*5/]472ZUV_`"&(2EH='I].$!^*S)>#I"><(PP$B*V`SK1
MB.5W;?.54']#`7D/\L2Y-*,]!,C&TOJ)5`3">0Z(B%0F0I38CTH@?'""@J-(
M>88H1G$GE&HE!D:A+&2?%$:,=)AV1*7N12PR7HWR5%RDH\N&-(N%T;@B-3DI
MX0/;W+K38H"Q3E&0Q)5R8^$8(21,.0PB@-"M2"+\8DM:,1:2P`(HA+Z0BTS+
M&7#%^&E`F!67TE"DR$Q**!1#"CA4R_!&+&=^>6)B?Y7<$[I+#RX-"\M]:R2U
M")1$WQ')SW),`)59`0H$JA$YA")+DVK4X($Q$`"<CEXLZ)0JE?-^R54%B`I;
M+:ENG5*2AC3'I$<<32]11>8.Q)PD(%441"DIQ6+BE``B71N#5##"D3(UJ*)6
MK31?FB1IQD=043.$LO3.<<^P'D1K$!Q2=P)0."*)><A5H04HU,#@5$6606C.
M-C*$(8F>%::;%!@'_D?:UJHTQ*BWQ0V3D@2(HHX8'=%$C=(C`(00%'Q/#>4F
M4&#$N5Q0JB5213%&D`38`:T<9<P$R<E+:ZD)V@A3S4WNDIKX25:H30+A=V<Y
M(B/5)CC(%B885"13"8EC&)&H31IHBNFI;G=W0$BN,K&;H8H8G4(XX(_UL?`)
MD'4]$8BVMD61F`)4<9?0-1`#9`/2$D5EX$\9DP!\'8RHATXR0@$"^FS+82HX
M^B$!<:I/,:E*;'U\4$(%H$T(HE(JA*(A41PPO1J!V$E'$%U4MSU)DX$B?*TT
M,;Y!`=$F-+;UY4:DA3"9`4*90A,$E<E4":9`660I2E&GQ1!"3`98;=LY"&8"
M("`AF`[X1#<(:"`[\4%P&1Q&&&I8XTD4;_T8(XXHH#"RW%6C3)23#%?FT?5H
M8>O%>6KZL.H/ZJ8X$",PJ,Y]I)VB:MRT4<E2S4J=&]N)ZU&@F<HQ]@+3DM;0
MD3M\2IPAA=HDA*U0I<1(%9"J)1F@:,21D3(G5*%OFZPYY;KW$.&M[Z7N.^V%
MT'MUOVY;^(V#(<0:ES;-(&-"GG"2S2@C3*%#@XRNK%6!<*0Y:4>>B9W&(#E`
M#`AB4)V^%U.5.!1_6M"EQ0(C'!5(N6JZTEFQ8G;F>=V<7)6K,0)6Y=$>UJU*
MTN,(`3$0KR4Y1IYPQP"D*A-$U<)L!:2`Y1UA$`.W]?/W^C?A+=XVXCGV9Y9[
M]VF.,$<!A<!Q4<!A)H!$4<7'"829"("/2*-+B&`P!"XA%!'%"-K@.N.7T7`1
M^_EJ(6M?LP#TT"_*##Q^+KUS_P!,-5P[`TOJ%@#>.,/6?\H\PVULWW&_^MZ>
MW$0\.S&8H$'[8,-\Q^+CQGEG90U7Y[[^'/'5*].R-KJ%,,:@P(C8H&\2TT(@
M)IG['I[6#^!!O&.,0A#.UXLA!O3CBDY49QQD!198=*.,R+HPPA>P7$1XV``#
M4<@"XX;YYFDQ1UB5N$2DXW@C46Z)IH6"_5:"3`.87_ID09_@7MC!NCRL=3`$
MZ(("81$2DQ8B!<&[I17&YD?&.+_U880RQB<`>T;CV\1\1SPH`(B```B(B```
M!<1$=```S$;CD'/'Z$B-2N.A3I"HC3!"]H<H8(;V&..(?P8(`WQ"/9<<L.2S
MRXF;A@/.&%2M`+],0N23$%\B8!SZ4.@FQ7$;7@Z`#@,"S2K&?T5+G#&43K`E
MS@.,SR$T=2X(LA"$+1Q!KT0U<`HJ`DN`HDN`HJ`+0%P!T8(0W!"`>L=1US$1
MMSOE>PWX:7&VF?M#A@X=_(,MVFG,`T"^``OGI?VY!].79@XY6`-^G'3A;CE?
MLP@#NM8(>/"PYAVY^XX4-]LNVPAKGH/CG].`![+]_'6X<@XX!OWVY^&0V#MO
MESP7XV#*]K\[:^H=<_6;LP[0^CGPSRP`.5QWV&WT!:]\\M-<`;NSL'WXVURW
M8-^[CIO^X+<^P+8!OP[-_;PMESSP!P'OYA<.WAD(<<\'</OGNRUR'>.^X9X`
M#3EKOSY>_*W`OZPO[]F`0=0SXB'`.(CV`-M>RVY>?+0!'3EQ[<MV#?\`?Q[_
M``RP7[0MN"V=[Z!OX^XA@#30`[@\=/JP?3;WMEN"W'PP:?3G:VGU96#7AG@R
MOD%QWB%O;W6[L[8`'Z]=UM^H>.5N.@"<\_7[-_=GNY80<\[6SY#GH&\<[CEP
ML-[86^>?=]/OW\;`>_U^&6[ZL'$/NUY_5@W\^[G;Z1#OPF>0W`!SROD/+MY[
MAW8!<K9:!W6OQ#+M[,\+]^_W^[0,(`\[WM]0\/4`=E\%\]=;`&?,;_?[.()G
MN^FW:.>G(+VUQRT[,)EKE?,`S]7:.#+P]7;V^&7+`'W6U'CNUX7'?KE;!D&@
M>'C@RW?7QSY7SS]N#0,[9#RL'#LY9CKNT`"X9#Q#U:]_9F.MM^#CORX=W'3+
M,/I'`'9;/?PUXYYCW7TRP9]]O;I?/=G]&_``?HRW=F0@-M=P:X-!XW[+AII?
M=D%PYWP@A;/AF(Z"-NS(;<!#0=0PN8<!R"W$;:AS&UQ"V6N`!X^_9KS$`W!?
M"7TOO#F%N-PSRT#E<<<N[W]\N/*V$R&_W:>VP[P'GNP">P-1N.Z_:';<;\0T
MPH;N8#V^VX:Z9VTOI<[MWN&5^_NM?!O#U^P+]N[>/<.`+<<_?=GD/O?!>^6_
MQL(6'/=ZPY8.%_;E?AS\-W9A`RRS'7+*X`'9KG]65LP6_`-./'AG;7<.?UI$
M/X(YAG"-N>6ZV?AGA=>7'3QX]@\@[,(.4-N0VOGG8<_:(Z7ON&X8"7U:OR52
MS;7X2ENW;\%+.88A',\TRY);"Y3/-CVVR[+S.1YRY/#LHA2(490Q0P0`8;%G
M$::9%"4G3E0F*%)\<!*<HPV*&`7_`-LVN%.Z&4$E^9)\>B4D1BQD%E8$QA)L
MPS.K2M"@3$#"W1F01JC8!-)\Z51]!$WE&`H6GEP=&&/4\VB-J"H>T.]@<^GB
MQR<WJ!-EZ1FU0:+8WWOU:YS-$81>GR."P'.*F"$HBW5-Z=*2`A&#Z[5^W%,%
M7C7:0*;'*9=I69%`E6+1*,13%.D!)@1FF+C>G"<UL!ID(`4RD]`Q<G@@B>(Q
M`V)'#7L&0WAZ6@VAL%PTR``T'AI8+@%K6PMP'EGD-K"`97$;CD`9B-K;NYTZ
M0T9G^M\U)Y4D%D-<%'3)B=78Z$TABEM`=$,(N3ZO"".!(FAAA,$HF$#%BV.Q
M"-.<9%D'1I>EQ_F]\;9:E9G<'Z87E0"5K:&I,8K7K3A@BC$L@@L+Q0P%01G'
M&1#`203#$<?&43!'&%X^R?L,,5+"VBH-4TR68*FEC$M;V<32ULNR9&=!T2>B
M4)8IWF8R"QZ4;D9TDC6IBB@;(3#"P6Q/OLX[*\@;.[*$367#,$\N"<"Y@GAQ
M3P0K5'60P]:VLB>((_@1CA'\"%(5'$J6!<UQ4GQ10E%2?[L`@C<;B(Q7$1O<
M1N.=QB'?QO<1$<%M_M#]%M1YY]V#3C;GF`?HMKNO?C@^O*WOX\L`#?=:_.]O
M?7=GEPP6TN(Z<1#V#@SWB`Y!?D-QSW9>`Y;QPF7\8`[+>.8#[=+8!==0R]O=
MRM[YXK_(`?\`-@:+9!;T-:E@(<OC;'<+#G:U]?;BP#2^6N>N_O[`#ZL5_D#_
M`/C`T6UL.QK4L?\`^[H[>&HYX"Y:,`,$8C``R.+**,S\../H@$`!%%%THH@"
M$`A`1$>C"`!;H@`!3WM/Q11^5;V.XC(HHXXMFJMPQ1Q1111"/PRLSBBB'I"(
M```%Q'*V>@8N%#A?=IH/&]M0'CQY6Q3SM.6#RK6QS;/_`+VBMVE][PLXB/:.
M?=@)W@/?;?GX9Y\-X\[980-V=]=<A#7=EGE;N&P9CA;6#<'9KINWWM<.(AF%
MM,%LQW\>&>8Y7MGX[QO?`&X`M]7`0YY7ME;?@#EV#QR]]X\\\&[7*XC?B`Y[
MM-=>5]^"_B&O(!W_`%V[\@N`%[B(<N68#[VP=^>8<0$=>7`>%N&F#F//2^_E
M:XY`'+4=P8334!^KGJ-M1OGH&66>`7PN/K$/?PP>_N.?=X98,@'WY>W+P[,%
MO#*V8W#CH/'?KKG@`0OF&O/=<+<P[M!XX>B@?Y0R_P#!Q[TTOYPT7]>&7X>_
MA[Z7P]%`_P`H<'^#CWO_`/*&CP]^T0QU;OREO]K7ZADUX`T);]FO?AIQOGH(
M"&7:'<-^.@Z:8=BMWY2G_P#\PR:"/]R$O#V[NR^&HW:Y<KVMRSR[?<`+^K+/
MN]],^P0P;^[Z1]^_+?<R'3W]PW\+6P:VM<>8?7O#B`<,\`=P7$1'ER$1\.?+
M+)<O?W[/5A+<>.Z^?`>0AVZYZZ'9[1[=?HX<LA`MW#KJ.OJN'W8+AI;*VZ^F
M_=II:U[WP!8?:`]_;?+*^[V8.7'7,1[@'7]&G`#3V[@UUTRRWZ9<1U/"^=OI
M'CV\\K[\&E],@]].`6P;_;J/TY?3W8`M<+#8>T`X?I\<?(\@A43$G4DE*"(H
MH8XB#RX#21C@$1*,ZLP(H0-+$1B*-A`#"H[Q%1P1!?'UMEV7[>5A'3+].`>(
M6YB/#C??;W$,`QTT;.=))I5*%YTLP,B]80:0J4RR?$R0*0,3%I`..0IX(FWS
MHHHH@"UA*,A2<"<A.X&+VWKV]1'N9]C166I./DV;TIZ.%%$4B;9F(/3*@C!$
MXI_,U#JT%B3&F4G.,:DQS(;DRUNA3%-[<W"C5J(R)Z[@\=X:]@!?G?=F."^5
M]`SYW#U=N7<.>`I??Z'U8E0TZ%XD5\4$IGYM.-6M:8'-O-(@<"8Q5EK&,8T_
MFRXHDR(XTCJX&0@GSH08`/!0H;%K,@B!UL8!@@WB8,00P@(0])F2P&C#"7``
M0FJH8F?J^@!91L`KX"R5P"ZA?>$0PB`A$,(A80&$1A&][A80$!U"X!?4`'=C
MH,T4OI_.2=4GF*4V9;$L`\8UI*2!O="SSRB2#%:=T;_-EI*P24Y)/G(&Q1&)
MBQ0J0/0'*$AX4RFAT!`;]6(,+^(QB$)G50E'S`4>9:.$T#?@TV*%",$8'0+Q
M,\]5E.1Y<*^#`JH!")46>$!4$4Q.$!I48`JA+ZA0W1'EQ0G^<@="UA%"='U@
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M5CK`;#$4?#DUE=Y>6N[8^MKDSN!3<$<:-V;SVY7"5'$R%0'>;*4B6*.$Q5=M
M,Z!0E$E!&K$A(IABF(.1H6MTNE`/P$_"(PP],8`A/?P-B@AZ"CK8DA@PIDT$
M4"KX03QQ+(DTP10`]D!:;(&W)(S9%&]-!A\NS$<67+@$S"WJUZ1&;,2Y$F1.
M*%2W)XBG-,)I`AUJY.UQ(H0B4.;>26!91_0EVTC3N9ER]Y<IU5N;@HA@7KUJ
MUI?14&><.1+5#TNDW``1%G*"#A3%`$*9KBA50%PIX.A#6BI#H1G](`*'XRN`
MCU5S^K"%2V"=U8C$X`;YE#T8TL?25?"<<<94<<S]6"5-D401`:ZAT881ZI6`
MA`9T_P`+XJLD0PW$\X!@+)NM+-ZV(3E@_!H*%<`?%D`L5-KE2X@#8HYF$>I1
MNZZ/JVEZCZ2=D7FMRT2P!!:,R,\DXU$4'XQ:C+C5$@)?1Z7TAKI2`E0:6X3G
M"G)3*G9(>8G9']7%&>R0IHUA2>$EKB`P3_.R8&\P;%+3.M@*BN5$&*^"AL8B
ML`QC\%E@`11=5#&,33,L14$8C&FZF!67=2HC`Q(*!1#"AA4R_#'\"'==36'H
M]$8C8?C`S]'K?Q'3Z;JE$J*((86\2A6Q=*!6``E^#2X(3(()9ZWSI4%N3?M#
MT(;RS4J*<8+D1J(3X@8YBCCBC3,)$QFF1FBTP]9`+<H)@*CA_`C<(_@TN$%$
M,0!D"MI2BI\::""<PAB5?!T1738YB@`('-L6NR<PR(6JQ<!*5O50+ABOYFL@
M@2&PB:;!>H9LR^%;1#T?,8@O'`$(A",+)#T@AZ@K\*,[]9Q%]4`$I/V2!.EB
M$)G'*FW"P]+H`#&^](0`#1+"$Y_A,CAA&!1UD:0SHI4Q75JO/R(HED::8!@!
M[("UE-M0T-5]4)4[='K3V=/"!\O3*2,)[ZJC1(2S.DTCU0E'PV<1BR0%1EFG
M"$$8#@(VH:&J8#8RITC&$@@I2:$<NS*7%`4>YDM0=*&)I"\<*A22H,+"\1;=
M&"Z+\7#$$-1*JW6*+_BA"8W#I=7%UX%C`I;0/"#-Q$Z%%"$)B41%5\)QQQE1
MQS-U7FB;]Z&X&NH1!"%RE8_@F#'"`_%5CB&`!$\X>A`3=9`8!L0F*_V-%2JA
MM+(!;<;M,43(A.BCG.*("4;NNB"!@F*.*).QKS6Y;$6`-8=888<2::B*`0C6
MI"HU1`"7T;_)7M/T-1Q*(39V"(4RIV1&"2P3(==2S0IHE9971:?QH'^=DP-\
M</X"\SK("8OQ<0A5/!_3$8@`Q])K+"&$R((`B$6B98BH([&)A*@5E74*S`C2
MB@/A@10J)?`SX$/ZZ1$(B7U=S0^,#/T>L`4PQ`+HE`J*.$`;^JB6C^*5@$*;
MX-+@@-A+E@314J`N!#:8HC%&?!!.Y<<2>-06;T6.8AAA%*PD3&;'TA:@",L6
MY23`5%#<#7",6^$!401!#R)VDZ*GQ$00SF`"J!NB+ZQBF*"$('1L6NR<PP8F
MJQ<!*1N50+A$?UFLA@2&`)IQ?2J&;0AL["!D0W0"%XH!AO#T64(8QA%.2`1&
M'!YE&7U8=4DNY0IDL?\`1..3.B'41BAA^`GT8NC^,$N&$]_`V.`!@4B;&E,$
M$R4L2U8+T\<2V)-,$18/9`6MI=J"AJOJ1*G;H]><S)H>OE^921A.?%4:-"6:
M$;3^`)1P!\(Q"'10%1P&G",$8"")]J&AJF`R,F=8A`D@M2=TI>F2"*`LYR):
M@_!B:;B9"H4%*#"PO%`WQ@N$!*ACA"HI2,4,2@(P$D`F1PN!(@?T`!4VB<$$
M0Q.(F@BAZ)B01B5BY1QQE1QS,!0)$W[T5^L=LH0'JEH]$#>G##%\562**'I]
M>;^#`39;`:!L76JQ^#?.%4']#(!;<;M,43)`T8YRB'J4;PNC`M@F,P8D[(N,
M;EHE`#7^&88>2<:A*#\8M2%&*281@M?Y*MI^AR03P-G8(HDRIW1&`1+TR'74
MLI::-7`4,#5^,`[SLF%OC@O`NCZPLJ(!*B'%4Y=^L2V`([M90`$40P=8,35,
MPE0&1=8GZN%5``JE1G32^8'PPHH%$OPQ_`AW7D^8AU=S0BF!G"$#0`B(R[HF
M`D8PAA;^J%8(#`KALE^#2X(#H"Y9$T52D+@`VEZ)#&?!#.\$8IXU$!P0L4Q"
M$/FK"GF,V,(A:@Z4`MRHF`N.&X&N$?P?"'G$,0!R*VE**GQ)X()TAAC5`W1%
M`8QS#!"$#FV+7<@PV(6K\7`2D0*H%HQ"`HUD$"0P.M-@"*H5M$+.G1,,B#S&
M*X]#H"(=%CAZ?1Z@B\49OZRC+ZD`+26<@3I8OZ)QRAG`1&`/@-]&(8`ZSJX0
M-?P,C+A&!1UIB8P03)8!+50KR(HEL:>8(H`>R`M<2[4%#%H$B3.W1Z\YF30=
M<P3*2,)[ZJB2(BS.DT_BQ*.@#X0&+\%`7&68?$$$8#CZ0[35$HBX3/CE$$,;
M>G<P`6"8PB!&J=09RAB#X*$0.!3%">:2-C2VZ(%\0`7<`J$49QG],82A^,:\
M(@)$3Q@$%+;UX%C=P$WS,.C$EB$57PE''&5'',P%`E39\>D,4816"+X#&\,,
M8B`##+C?'$6$8FQC$642'GI9HFF":K$6T5BR&'XL0!:RKVGZ'H8.FIG./HB6
MXF0]5+TRFB9"V.)K6H`N&%J'I1'*"3C$09"L1EQJR_Q00W15M/T-1B<!D[A&
M)"IW11]1+\RG])0RP)HU<!?1:?Q@'"L(@01@/17F=9`2-RXK5,K!B$67H0]9
M^&TB`1Q=4$8Q()F$N&.+K4G5PJ2[JE,01IQ1'PPHH36*$SX$/QB:*+\4,/XT
M1F!G$!.#S<8PC=$W4C%:%OZN)9$$4"N&R7X.+@A.`N61,%4I"X0=I*BL$4<`
MSG",18'1",+',0PB6G8RIAB-AB%J`(BHF\\LHJ,!_&N(Q-\(><0Q`'S@VEZ)
MQ1HX!G2$OSV-K*3B:Q3%!#TGAM6NJ3K(O@FQ4,"9N5%K8H[`C600I#?QAI=Z
MFB^CU-^G%T1E=*-XH.B(P]:C"$T8.K@Z)AIP^9&$]47U:0`=(4:.,1F>+\+O
MHV]**.#\`^XP0]=T++W^$V(`$I4!D28RR9-`):D5J6(5T13[%!\.$!;4DVHJ
M&K>J$F=NAUQ[,F@Z^7IE(L<^JHTB(LP8VG\7$4="'GXQ6@0%F%FGCT(P$/M#
MM-T1B+@,"<XK1H$SD`#+\QPQ@C5.T+.5%%#$UWA,!3'"H-)'\84W1`OB`"K@
M%0:B\$1UP$F\QK^D!(B>)8PJ6SKN@/2<.L!':"-&-U7PD89&5&9,P%@E3=AO
M$,<=[!$#)$$4(Q#$`"$N((HRX8NL,Z<!9/Z^A.ZR.(Y9^QHK5D(?%B`+5U>U
M!0Y%#TU$ZQ``P.$<`%R[,AL48-CD8UGA`$#2(Q1'*2C8T<.0JD94:LK\5:ZJ
MMIZAJ(3P-G<(^H5NZ,SJ&"9#[J&6%-$K+*Z#3^,`X5A,#?'#^`N,ZV$H0$N*
MU2ZT!Z3*(!"8(QLX=&(SJ0,'S&9A*"(0-2=6"DNZI3'UB?S%1#"BA-8@B^`S
M\:FU+Z(Q'@,PLW1B,LG&,(G)-U0F6!!U0K8KEK(0!(#;!!"=!!+(F>=J0N#B
MVE**0QQEC.D(C!"=&(@R3#%")9#$5,,9H1?!=A*B;SBRRHA_IKB(H(8>OABM
M\X-IFB,422`9VA+B6F-92?K6*8X`Z3NW+71()@BTCU4,"9O5%K8C!_6:R&!(
M;^,-@Z53D`?B@'I"(#+"3HQ6M%T.N1P@:,'50##&8?9"84)1?4I`!R!(DCB^
M,\6/=Q``;NG%%``P']**&$#1@"%?,'6B7")*OK(DAHPIDT/04>?)QB6QE/T1
M8/A`6V)=J"ABT">JG88.O.9DT'7R_,A(PGOJN-$B+,Z33>"(D^']D!BO"WEQ
ME''#T8KA]0VFZ)1%PFA.8A#&W)G0`BE^9`C!(J=86<J**'X*O":"F.$\TD0`
MPEOB!?&'598J$4!:-1TQZG^B1=?H#U_0Z*EL$Z&`1C<.M!$'1,1Q"*KX2,CB
M+BBF;JP2)\^(Q`)D-LP8QRZ72A"()<01Q%A%UIG2@@('STL_KC.O67;15K(`
M&6(0M86[4%#T,/243I&`"6XQP@5+TR'11@V.1K4HZOH-0](35))QJ*'(5:0J
M-46(%VZ2JMJ"AB,3@-G?IBG5NR*/J&"93@B4,L":)7!`(-/XP#A5DEMYD(]!
M>8,<!0W+B$*EUEQ^!`"&`R\;0`=9&)0&1"AF>(L(K&I.KA5%CYRIC`Q.*!3#
M"BA-88(O@,_')AN)?0'K0^,#-;K0\V&*[HFA*&,`!O`H5L0#`K``3`VP%P&0
M0RSUGG*H+@HMI.BL$<18SI!TH`.B&S',0P]60Q%3#$<$7P6%RHF\XLLN.US'
M&+X.``4`..$.TM1**)*7\=88!6Q-D!'6,<Q00B+PVK71&)D7P3^*@@3-RHI7
M%'8$BR"!(;^--+Z5389EB/2BZ(RPC$8AA`.E!UJ."$P8.J@Z)AAX>9&%`26!
M*2SEYHCC'XT1XYY$`!O&*.(NT!_2B@@ZX80!<_PF10PB2K`R)(:()D\`PJ`6
MIHHEL13[%!\.DA;:DVH:&+!)ZJ=A@$\YF3P@?+TRD#"H?5,2-$6;UC5^*$HZ
M`/A#I!9`7&6:=%T8PQ]8=IFB49<!H3F(0QMZ9S`(I?F,(@1JG6%G*BB+%KN!
MP*HX#S2,C2F^(%\0=3<,5"'AT1/Z8]5:8EX1@3^N`@LJ;!.Z`Q1.`G>9`,,2
M01B5?"4<<14<<S`4"5+GQOTC!&``'X#B"*$(KA#%\76\8BH8^MCZ4)9(^>P&
M]=&)RL1;?/%D`?%>$+6%FU!0U%#TSYUBMU;B9"!4OS(:)@-CD8U'A!#"U#TH
MCE))QB.&UU2,N-658L`Z2J=IZAJ03P-G8!%.J=D4?4,$R&@*AEA3&*X"A@:0
M`R$[SLF!OCA_`7F=9`4-RXAQ4PL`!%EM"!GXQGM#'&!01B*"9HBX(HNO2=7"
MI+`5"B(#$PH5$((H36((Q8SL8EB&\'1'K?Z(&>PF_B!C")T3`2,=O@_H"MBN
M6L@LE^#2X(388)9ZP52H+@XMI.BL,4<`SI#^+A.BB&%CF(0$M.QDS#&="/P7
M^$5$WGEEE1!<3'$8FX`$^$0PQ=<-NZE5-I9,&4%1LZSRY($A[`Q&-;RU-A9;
MBDA4%.;TXK4:4N!(@A,@!6WHHSG(Q9^L0A3`!BHN!<.<`=&***\KI(@BL`#%
M#UZ((3!@ZJ``C,/_`%D85U1?5)`!S!&DB$9GB;&JLFE36W-9Q`PD/*$M2"(^
M+KS2S$QCF]1+D)I4!XEA!"I)2BG60EJ5J@E*!I0O)!RIX`&.K976IVT).JF?
M:IS$<_/)B8AO0)2H/,V-A:$T$):5FEUIA,,3-#82$$,<1)(F'JU,1JM:H4J3
M(SHFCU$0Z/2M:X@(VR'\'(-^0VS``[,?=2E4H%*A&N2FHEB4V,A4D50"6>G.
M@$`-(.+BS+-+B#H&0#<0BOJ(7Q93LH[!3K4`&^H%:D3@PR,846K9I0BB/;)A
MFPN/\,A4Y9%JF*7C8>B;#"(%NCN3%#U0)$<?G)@,!LR[)<\;0KR4NC+62S35
M(IL\SN>DZ1:KJHA`YIEDE0!93P[QC#$2<86,;<U"/6.$8Q@4D-O^I92B1Z-2
MBBDN0F>%K:4T41ZD\Z.!2ZNZ^/(US>W+JRS7%P,#\`#3(82R"88$R4E.G+@*
MA[JSLS3+S4@8V%M0L[,TI2D+8UMJ8M*@0)"8882DZ5,2$!91<`:@`=*.(1,,
MBC,BBBBR5_4'OD&0Z#V"&`.X-W"^N0^%[#?+ANP#QY>^\.6NEATO@'GIKPY6
M&XY\1[.882PVSMGD.6>??:]Q]>0;A#EV>_OGA-XWT[MXC[?>^>#[_:.^_P"C
MV`A;/AGQ^G@(\?4`""<``.>?JOE?=D/$.X5SY#VC;V!@M?77OR[!R[[=^`0'
M=[?_`/D<`#V\O7F%^>G;B`"?_1@Z+?\`H:U,_P#JTSMQ/\>.O?[+!K8;:ABO
M]/\`Z,%1:_\`XFM2]?\`"TS=V^O`7,:Z6XY:Z_I[;CF&>*>-IT0_S5K8Y'_^
MFFM^8V_NRLO<+!G;+ESQ</RRTS"^=O;[^-/&T[EY5K8YO_XM%;[<1_9A8&8\
M?'<&`G<&@9!EF`7`>P;_`$VUOA>/9K?MOX<?JP!NOWY6N.5ASMPRP6UXCKNT
M'WSWZAR!-0'P`(M,O;OSSN.^V%[`TW!;GZAL&_7A8<)GJ'`;7MKV_>(#ZQ6W
MWY;MX<K^^>`.P.Z_;F',<^%]XX0!'PN`CE;+3?ESR'NPM_?LXCGWCQP!H(;P
M][[[=F[A:V`--<O8%@TW<!][8`]_$;>.OMP7&UPSOW9>_OQ-_P!&0!F/>-_4
M(ANP``Z=MLQ[?7R#3=IAYZ!_E#@_P<>^%[^<-%[VROAF-_KYWTT$.SAPP\]`
MP$*AP7&_]#CW;_YAH]_7?<`8^MMOU2W_`(^;LHZ9V^"$N_3WW8:C7?EOTW@.
M\!YA:V?;>^'7K<(!4I_N.B=DRN`7NT)>(A?O]>YJ/OUX\AL&7=@"P<`L'Z1N
M&@>_'!V;[Y\_I^K.^F#?KKN[.'#4+X/?P\,Q#[M,`@#R[-U[WOV`-M^NN%_1
MNTW\K#O^O!V=P:`&65]_Z?!<`G?:^8=VZP:\\QORPF5M;Y9VM8,L\LKAX\@P
MN>79G[V\._@&"]Q"V@@(W]^WE@`0R'(<N'9NYVTY]N#.X<-X!N$1R$>W/3??
M,=<+[Z^_OOPG=Q]>H9\?>V`+_?IES'/+?EGIKA+COARWW'[O'ESRP6'+QU'7
M0.%@MJ%LMP8Y:\!`??OP"<;Y![Y\O'PP!IW96MIN#6WA8,+Z^7,+W]^6$OKW
M_1OO;Q^C`&65LP`,ONS[ATOQRP7'VY;\AMO$`"V_4.&"P:<,M<^SCPWYX,\L
MMX_5?O\`NT$1`#E;L#+=]6N@96RO@RRX@(#NR$,P'D(:@(<-<%[AF`Y@.7Z/
MT\M<`_2`Z;@'V\/<0#$/4OL4QIH4<P,S6]I"Q,ZLAT0IUI977!U9X$]>7'&0
M"@NY"N$B,N%6GB,3*X3DQAA,;!S/LLTM>XU*MI0KI:7F)5!94#8XG"SB:8E7
MDP#&UJ`40)B##ET9BN!OB3E10Q1=0E@-A(,)DG;<-]^HYYWN'@-@S]F$SSX6
M"U\LM^?MR"VZV`A%(/D\G^='Z)C+J:SHC`*4/Q:A5+JY=#&:U*F\Y,D/+(7M
MOX*R,P2G=21$6)Z>$H&I.TG0&FG?.9]@)\DF8GF7XJE-3C$4E3%1J185:>/I
MJ6]L-BM#"HCAB$M0FC)C.M#"H9XH$A:9(Z7>L6ET#_*%#_@Z]#N_EVKEW^X6
MP]9ORCS!IHW@/S>GUW#D/T;L!5?%L7O8C"`SXU!9`K1Q=4T+88@\\%R&,PGK
M#CX2XR3%T,#=&;"H@2H(#4J\EV7&%.A..BV(GR.*.**H#-#%&Z1N$4*9D<"0
MA`T].::42"A4L$L"H2/V)B-$\41QAICI$^%1EIR;$+!K8+\;8/;F&6[3NOH/
MUX"O=-L4OI`JQ&?F014EGPV+8W*"&$36Y`WQ!T3%QD8E00(XE),'3$V!V,!6
M:>H;(19,?IAV,'L(BA^/;,(EI(DX0FLSC'",?F[FG*B.`M62,91A;@!KF47&
MG,6.!4*EO/9T/2:S)_Y]M]=``/?M'NP:!IW!GI[<L!7=#L0OL`]*&H+1$(.2
M=>`*F1<;$,*942H**.%*H1A'$=U44#J:3"GA6%=3`VP,II9QY_Z$VQ*])_/+
MS^UQ`I)B(`8F=6,<$/4((`CBBA,@AB,$Y$,!T4,$)<;08"`HDATA^'!L)WWX
M^X?3I;!QR^C>/JW]^`K_`(MB]Z$0$9]:LD*Q%%U;0M@B#SL'&*,PD33CH2S"
M8UT$#;$;"H@2-Y1B5P)=UQI;H5CX]B)\,BC&*H#-",3I&OB\W95Y000FJ$QI
MA1`*%*OJP+A(LTQ&B>*(^,TQT%\*C*()L0'.UAUROZQT[.5MPX/?LR'7=W]G
M`!P%>Z?8H?28UD0SZR#YT6;`/08W*&"'K&U"WC:&-:9'U4):2)25!T^MA=C/
M/#35#;"+'C],.Q>]PQ%10SXS"!:*-*`&LKA'#&/F[FG+$WJU1$41,<+AUKD4
M5&0:K7DP*&X]G1=)L-G_`+^SV?7<,[W'QP7X_2.0Z"/+6]\!7?!L1/A8W@J`
MSQ?LDG70BJ95QPC"F4DJ2RS13J$81QG"7$6ZQ%`1`M+ZF%K@9#"S3C_NFV)G
MI."P/C\UQ@J)B*`8FA6,<`"2@A"***`PN"(T3TD4)L4,`%F-)@(2BB'2$7P;
M"0RR"PB'=KXV#A@'7A>V=N8^^F6O8%?T6Q>]1=$1GQJ`00K$8B2S+"Q'SL'$
M8SBNL-.A@,),700-HFPJ"TJ`LU,X$O"XTMU*_`9L1/ID40C4!F@Z3I&X1`F9
M'`@``PY,<:45YPJ6"7U4*</@@3!4>9'1F&.8O9,92<FQ#N]^'+!KKG[.&5[]
M@Y\>>`KW(V*'LF)8(SXQQ"H+.A#JV-R+A@$YN0-XCT8UIL0DPEHA/)+Z?6P.
MIGGAAQ[9#\"8_4&Q@]A$4(3TS?BT<28`-97`R&,?-W-.6)H%*B1C)CA<`-<R
MBHDYJM>3`I;CV=%TFLR?WLSYC>^?OZL%PW#V?7V<]!XX"N^#8A>X1`8:@,\=
MG%.O`5+*O-BCA3J25!19PD*$?61G=6,#N84!$"PKJ8&R!B,@-//_`'AL6O0P
M]$)\:\VLIN&.-H6"9^*A)"$^**$V&&(V,TD2SQA+@)C9Q@0DD)G0!?8K`?5[
M>T->0:![,-E6.LE-MG^FTTU?J],8R?3:2493C-LU&-#Z]I)>;351"(')R1RX
MV/#H4W%*52<M4M+0&IT<!L*A7&2E@,.+"(:K8G>U7FEY_:RP3PVC$AG6P11=
M(QS.C$D33%$)<<$:^`MNC-@/@2-Y9J5>4ZKC"W4G\\6Q"^QC$,506>$8W.-?
M$*5D<"H0`PY.8:43YRJ6#`!4)%F@3(C_`#$Z,TQS%\*C+3DR(E/:PH)/DCT<
MJ1)4[G3;(^T"\&L-'9AEZ5)P=$L\NI*5R7&ID"=,Q1KFZ`M"S/"TU4^I6I(F
M2-+B<K/3@EC##ZI7IF6N;LS(W1`J=V,MNC>FU.K*-7-,#P0:K:HG%-!$)B,7
M%*2:J1@?#!&>GAZ^"$28H(XP@F&Q>]ATA">V:XMX(1Z+,Y`6!@(4Z&*.&")7
M%'"G`LD5"<F*.(\IVCB6G*5+99BA^"G8I?#?,^C/C)=)$GC_`![(XG0FBG+=
M"H`,`A8E$8#H''K7&&"(J-4X%0*4)C4AZ;698,,4(`(C$`!"-A$1``A'*UQ$
M=;B&NMPXX!BAUZ0::W#QY@&?(+#SP%>$&Q$^EC",%0&B*SBG7?KEE7FC%"F4
MDJ"RSA(/1].,X2XH'6,H""UA74PMD#(:6<>?^WT+GOH_U^M8_L66V@,30KBC
MM!"G$#3!A,@AB-C-*$LZ*""`F-HBA0%)T[H$3Y%8%TX`'HC'#>U["(7MQ$+Z
M<[`%L(,<$.L<(9`.<0!EQS'0>/KP%?"K8G>E`I`"?FHL"`L(E-"V&,0$QR,,
M$D33%$!9D$:^`INB-@/A1M\!R5>6ZKC2W4KX1[$3['TP&?V:`(W,Q>()61>4
M$(1GIC32RO.%*L8.JA3V:!-%0*(Z,TQS%\*B+3DV(=(,AZ09VMF%AOH(?[;=
MGGH&>"WA;2V_C]V`K_\`0P>A`;SVR@,3=YE:%F<(8`B!$G1QQ00Q+(HP3A`0
M*D@B,PP\MVB\].5*6L`8@_.IV*'LX48A/S+^LXDP_KAE<3H3/-RG,J`#(25J
M<1A-@<0,<(2XB8E+@3`J0F-2$8FHRPC2UK<-?>XV`/NP6#+?;3Z-,AMNP%=\
M&Q"]EB'1J`T1@#FG7@"ME7'=*!,I)/++/\W4(@CC.$L8'6,D$\"PH2(&R!D-
M*-//_<&Q:]A#8)^:_P!ZRVZ$1:%D1GXJ$FQ\<0&P0B=&<5$6?%"7`68T10H"
M4Z9T")\BL"S[!\=_'+MX]N88,[APS$1]EO&_=@*]5>Q,]JP2A\?FHKS?*,26
M=9!$(1&.1IG4Q&FJ(2XRXU\);?$9`?"E0%G)5\#LO-+="?B.Q$^1#&,506:"
M[G&O$$[(X$@$!IR8PTHGSE4L$L"@3A\$B:)_F1T9L;H+V5$6038AIX::WXZZ
MWW_7@MNL&F[MTYAGRW\<!`'T+WS\(/CVS9MX(K0LC@$`1>8IT,44("LBCZB$
MHD3B"1,C/+=8A6G*5+79B#\JC8I?#P1]&?F412"F$>O97$V$T4Q;F46!@$K4
M\44!L#@!KC`7$3$J<"8%2$QJ0=)K-L(N&@ZZ^VP]_P!-AUP:B`WR#Z0[<AWZ
M:#;C<*[H-B%\+SAJ`T1`#DG7AYRR+CHNBG5$J"RSQ3J$@&QG=5%`[1E>;P+2
MA(A;(&0TLT\_(!L6O8!;X^M0A\%EMP#&T*QC#JX$]CS!A,@@B.B.)$L^*`LL
MHQHBA0DIT[H$3\-@(:CH'9[>W,-W;<+8+<?T#IEVW'41P%>RO8G?%()0"?FH
ML$W[H26A9!$(1&.1QH$B:8HA@B@,70EML9L!\*1O@-3+X'9<:6Z$_`=B%\B&
M/IS^S0]-SC7CYJR.!`0@:<F--**\X5*^CU4*>S3$;$>*(^,PQS%\)C+3D6(:
M`&FX`S]^[C@#LW\>P+[^'UX"O\=C!\L/2GMES;01#T61Q`L#/,4Z**.&")9%
M%YMT"`4$$1F1GE.T8K3E2AK_`&##X*=BE\-!((3XQ_K0"!Z)[&XFPF"F*="X
M`,A)6)A&`V!PZQQA+C*B5.!,"I!&U(1B:S+!],@W[^^X^T;!;CNPD5^C%NR'
MC8=>_P`.Z^`89@\F93"D!9-8)W6D5(G)1,+$;*\!R#X,EYH2J4"U68N=V*&(
MQ',$SQJQ`R)V5A"B@`HB-,UISRNMB?L<Q$1&XCJ(YWXWXCE;/$O*U?DJEG_?
M*6O^REF(@C>]K99<[AG<._=:X\;7P'+/C[^_9W83MY^%_9;=XX.89[OK[\O5
MNP#]'9OXAGV]F[>"!GZ@W#:V[+@/+2V_,`-X9!P#AE8+V[/#0<L+I;(+=V0^
M]]./B"/.PY;@&U_T6WZ\,`N[/OO;U[L(&NO$+7$=/TY]P=J``]H6N%^(<]]]
M;[K:8`RU',1RWV][7'0.S`+PN%O#+W_3;"X3?]78.H;@RRU]N%UP"<-=V@C]
M89<<L]^F*_R/]&"HO_Z&U2__`*NCMGGKZ]]L3_Z0`/X0P@/:`6`>T;^R_#$`
M$W1'RP-%K"$7_>:U+S`<LINC'=?M`+\M+8"Y@!SME?+E?4-]Q&P!SOBGC:=R
M\JUL=``Y^C36Z]QO?]F%FNF8!H&+AK=MMV686SW7UM<`M;(`MNQ3SM/#;RK6
MQT-P`/1IK<-QL`6^&%F_Q`!'C@)WVR`!^N_;?7!KZ]!N.0ZA]-L]+9AA.G"/
M\*'/4.D`^P>%^WEA?5PM8!&VX+WT#E;/=@`+^XC[!]E_9@WY\.>[E>V_O[L&
M?U7'EX^T;\M#WUU'EZ[Z9\<\`O/PW^^N$W::[LPY_IS`!&_'!>P>T!L&H\L@
M]=^W!;+GGRUSMOL'L#`&N>X;#OORWY6Y:X3(;C>_*^0ZV`<[6'+*W;?/"@.O
MMO<.?9;NPFF=AM:WTWUSW\]<AOD"\.WG[0'VY;L//0/\H<'#XN/8?\X:-;YW
M_1:X#=F.'@-]^0^_9?#ST#"U0X-/ZW'O3_=#0'OX9ZX#'UMO^J6_C_Y.RY_\
M$)<K7]>>&HSMNO;?O'WW!?ED&;KUN_*6_B%OZG9.W-H2\P#O$>[#46X^&X/?
MGW`&`7L]_K#"#Q'=:W&XC].7TY8,KVU&PY7`1W99YZ=V\<\\(`#:PY\]PC<=
MP<+!?/>.`4`WZ#OX#QRY[AUTOPP`-^WU?7EO`;<,]<('&X!;P`>&O9ED%POA
M=^@7USY9!QW7MV8`W:\^&O+7//7/G<,C/<%AU'U\-1RY:]V$`0U]=PR$;Y#I
MNR#6V8;KBN[=IV!X9V#C[,`OO[^K"9:?3X;[W'Z,%KY#[1XW#WW:8+\KZ:6Y
MB'LR'B.`!MJ.[/LR[=.(;\%QO;MOST[>.FN@B.X2^=NW+EQM?3=G].`;Y6XY
M]EA[<`6W"(ZB.MA[[#SW6W9!IA,^%]=X]F^^=M^6_M%0[-<_'C?>`:^`8-^[
M,-<LQ[;\`X;M<`6X97&XYCV^_+D%L)8>([^-[Y_\G@`\M<+>UNS4>5M>>O@.
M"X#X:<;W[AO;PX9X`WB%PY!;[^W@(Y\,);/@'&XAK]XZ`-L\]V%TM>VX._@'
MT8.ZU@TL%[9>H+Z!OTY@97#O']`]_KX8!W<M;7]F=_HP#?@%[C;LXZ@._/OR
MTP@;[@-AOKQT`-VH`%KV[1O@'JH$%J@AI_6Z\V[.O:M`T[1'33AC#UG#]L>8
M.-F_>/Y@0''3NXCF.,Q0(/VP0'?\7GD,O_/M7T!?.^O#&'K/^4=_#DWWY?L>
MG$/?].`:T;:;PSWCR#3/ML-^=L+GRW_=EXAKN\$$.7'.P7UN%O??>X#A??GW
M_=W98`]]]OITMPRUXX.=L^%]_L]^08`[;A]^?<%P#+LPG`!SMF(CV#GKQ\,^
M0X!=;^J]]!XAIK?+4`L&6#(<ASU^H>SQPV\P5;D"5YQ02&]/AZ>9ETN*YQ.3
M)F*8W-KE^4D:R-O/FB=IF;&A7*]/Y?%80J)3.T\/4O(EH(UYZ(U0G;G`Y-B9
M4K_1">).?JARK5B0W>196/B23/-D3^0S,<NJ`+(-@+?54QPLPM,*DM2G%O/7
MED)G83BRFHY<9$)8`[V?;PW6Y#[-_9OP=WLW#[V^@<=,D*HDBU2EE'.5.IJ:
M)QE5P/6I4CXS&GQHS53<HB2+TL92U.C7)52-2'5'IEJ-,?``EF=4)!Z<TSN0
MQ0@`B,4(0WM<1"U]+7O:]\K:WP!D.=KWR[LPXCQ&XASY!A;<-;;K@%P[^SNR
MO;"`("%^D`A8!N&F_/ANX]P8;]+5>F:ZHCE2-%/4M*:H-#42^.<AE+A&8DC8
MH)(4E*8DL14)!Y@)5298>WHU2AU1(5!#@N0)D)L"@0<'70<A[;]V>7A@#Z^S
MGVYY7RTR``U;>2ZQ4GJ.\S++M/ZCR7.SW)QJ8N9VZ5G]$]&-$2N*.!.9&H11
MFH'!-$<48E.7,RMS0HW`LQK7*DKK!$C!Q@BA',!A&P`(B`AIF'2&XZ!;6X[^
M`X#EV:^JX\=,M^?MM@]]>&X,[!GKZ\<88@BSA'I9[H@'=_>B(=E^W&"F>:Y8
MDEE43).$P,TKR^E5LZ!2]/S@G;&PE=,#VW2TPHHU:F.`OSQYF%X:6)J2PC$>
MO=G-"A3%QJ%)<`AGPR`/7N]QOK?G@RMH/KON[]W?;CJW3A5VEC54=LI"XU!E
M-)5)W3G*FZ0#'8J.9S24Z4Q?'UZ$B$Z!M4'H"35R!`['M[B[H"C%K.D<$H"<
M#B=*$;6BAS&VH#>X7"UAU$+"&N0Z9X!>SNX;N'L[;98;FKLTTLDVF<[/];7N
M46"E),N.B.>EL]+$*26#Y==DIC6X-3G"X&%DKX7HE8+20T%`<L=E*PIO1$'*
ME!4`N*$4(B(!%"(AN`0$<M;@`W#AR]6.L3BU20[2\X%U$:Y+=910$B[NT-06
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MM+*^"$<UK5#6J&;6M`46G%K3O)SD@30%IC4<,$)9,<+>_P#2.7)JX3CM\;2H
M;&WELG^7J\3++4Q[,D_T,>=F]Z8ZL,<_3?3EAJ4-.E+ZP-M4&Q&2$YL*@YX<
MH`*$'9M;5SBXLS`].#>E3*C.C;0^U=M.R2'E$&F7MLJMZ<NDOD\MA_:VINJ&
MH\L&.;=6V?V&FL<Y`W+RV*$R*2GM3,RJ)UILW0EL:U28VQJBHS`LKVPS*44G
MC(>TAM+:8&)9G)9DTR)#Z>22:DF--+A994OIGY&<Q1I7M-+Y1))3&G<RE9#-
M`27`VEI0)+"'\BZD-%>I<53G26COFYS0G;W=4Y4SIR"<V7V4L@](A=E2Z7P)
MC868IO3'I4C@8+2T%($YQ)24M$3&2&NA6S:HK3,>V3+TA.NUM4VCU*IT\B,\
M;7"I/(]3&>1Y:)VA&=N>W!JG!@5*4JA*C$Y4QIU"UA;5<*=]*(7MXP^;N"XD
MWI#QMJ;3%:]GOR<]+V/:8J+2;;OVU*9R1-=4'Y)/353:0=G79WIF]3:ZU*VF
MIIE`&]*PHYMJ[)K0E,8C9D%$WN($GK65.D3&(XC[*C=GC9-JQMA&>4)(KC0&
M9Z/4FV;`V49CI$[T\E\VF4O2N?,BF=&YV5JYB6M[8W/<3\MA(D].@DDYD=4L
M!33+)+J\#$(V0L\N;/5:F5JJ*UR;1JI[-,3(6VM4WJZ=R7,8N;`AC/;(&<%L
MP2R8[%-C>80I;OB^O@3%-\11J.-M3@`E"&N#MY^4(G^C\_3ZS[.NV/,L^1TF
M=_)VK&8MU>)=84$M2=5-S@;)O.F(Y>"N/:I<Z_2\XIYSG1Z"7I>EFEC,>TF)
M9@B<7-J;H-J,LXE1!"H3F%')SX83DYI!@&D&D&@$91A)L,48&DQP1!$48$<8
M1EC#$$<5^D+>N5(Z1O`KC'BE=+G471K9V)R-<Z=R2OB<6273"39?95\:MC-B
M5L["<E3&,C2>)K>T&)4T3<F2BG)ZMP8`+@@AA*A+@*@+"$N`J&"`N`HJ$`AA
M*++`(("BX`"&&&`(8"X(0AA"&``L'//.W#+77V#V[M,\\%PUOEKX:]N>/F<>
M4G*./.C"`I.0<H.C$0_`)(*C..,$+WM`47'&/*$;8ZS)$[2Q4:3I9GZ37,7:
M5)P9$4Q2XZ&MSJSF+V5Q@&-(LC:GU"UO+?UT$(Q0IW-N1*H8>C%&0$$<$48=
MJMEPXVOPW?1PL``'`MKV!VY7WZ\-^.(10B/[H,QL'X09CD(`%AOF%AMO`<\<
MA$(0S$`#=<0`.07Y[O>X%N%@#A:^>O$-_+PP9^KF`W'7F`>S''I0C8`&XB`Z
M"`7Z.H!F`W#>&H7SP=.'/.$<[7Z4-@ST$<K"`"(VX!QO@.6H=MN8<_?[\%M;
MZ:\`[-=`#N&^F$"*$;=$0&X7A$!`;PWW#?,`XZ!<+XP#Q-DLR^YRJROCVWM3
MM/+TKEV3V]:9&6IF1^0L;G,RMG:H82HRSW`B7V9V>!3F&$Q&(6U682)IA75Q
M!V#=<-]N.FN[0;>NV#?X^H<M_CQROPPV$N5KI%-\]3)3.5JD2A,%0)1A4Q3+
M*36YBH=VD$1Y25>!ERH$2\QL5'DI78EH6N)S*H,\V=RT)\)A</8&.>Y5F.99
MWD]F=(EDPTX7R^USF@B;G5*6SKII8H)E8D\#@L0IVIWC6LAL"PWX$6N0-HQE
MIG;S%88408';PW#RTO<`'+3+UW]N`>[O]O=[B&$Z0`&8P@,(!>XA^"(Y!?/?
MH%QSXX!$`S$0#,`U"P:#80$=>`AH`WW7P"V^J^>G;<,^>Z^F>:1?N8KZ=&+0
M,[6[<<(S2RX#3(A&("BHS8P+@C.-&`N"(P0@))AC--C&$+%%%01FG1C"65!&
M9'##%TR1*ARK4MF7ODH*W)4A;']YE5S+>);F:5'-NF%@%/`\M*YEFQG8WA,J
M01JTY9_6H`*`V,PB$R)0G4E$A/2M7Y*I9W?LE+?/^Q2S$0K9YV[0U$;6[M^\
M>[$O:U?DJEG_`'REO_LI9B(6HZ:<]<MX<LK7[<`6MQ&]MXW"^0YZ\_'/@<AS
M"W/D'$1WZ^-MYGVZ;K6[;CP[_9@[OT![Y!]]@,K^KGS[M/5Q#!:V@7UMNUUS
M]PTX7P<QW:]V^UQRRR#,;YX-X:`-N^U].SV;N.`.6GJX:6X7M@S]6N8=F7MS
M`?5@WZ]GAO\`NX=N`>RXAGNYV]_OP`._??MU[=VZVEMV"U^/B(>P<`!:PC;+
M>.ML]_'CNUM@&(`UR'Q]_5@*R-ON6]LF6$$%9-FJN%2&Z4V(I,;4ZDTL,DBO
M;JBEU"$'PG-]-D[]+QRAR<$J*`Y4[2NXN9OG)H"O;CRRO.$9;A["6S\T5'J-
M(^W>BVV9QVJ2BJ=332]K2312Z3I&72Z6\G(EKI+C[#+;F!S6_P`MKXHXE;8J
M;3A/C6`>G7&H#$AQD]`R$-P@-P$+W#.^0[K9:#RX7K4J136I6Q94E\VK=DQB
M63#(<PK"G3:=V7VJ&(6Z=FHN..)=46F*&"",ICGEG+,-7K4J`@(51!2@PLHQ
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M<K#Q^X,M-+X^*=.0C()2I224R5,24F3)DY4!"=,G(@A*((3D%!`42005!`44
M25!`667!"65!!"`0X^WU!Q#C:_T[^-\`#H&[33=]V[337*^%]^_].$SST[`O
M?LUUTL.7=?!RR#U<LN=Q]>``O]/+4=,@OSORUO?"^O":?H$=??N#!D%N`=O#
M?;Z<N.`+=GMX6S'LX<.&9KX>W777=N]HA@YVS"]O`.>?J^D2P\;=N?'GKGF-
M\[8`U#3*P9#^@?I[L//0/\H<'#XN/?\`UAH[O>]\,Q;U7\1WC:W>&_N##ST#
M_*'!O_H<>^S^J&CM[.[(`P&/K;^4M_\`]SLF_P#UH3;M,N//GAJ.=@R[+[\O
M'F';NPZU;OREO^0#^MV3?F`?!*4=-X7MZ\-3J-],@X9@/CEZN&X0`X]N68]G
M++Q`=<&?/+/NN/"]]+6X#?6V#3A[,N8Y]XX-,A&_`1ROP#F/'+/@.>`!]EQX
MCGPOZO#![`X^-\^'N.69Q'Q`+WN&MLPX6#(,\\'?GG:V7;QW]MNW`'9KSX7S
M]^R^[`&MO$=+\P"UAW!KE[0;6&XA:WOG@TM>VN7KRO;/?8=]\\\Q`MQS]5M,
MM=!L&7;?6V#0+[];"-M_AOUWY7P>&@Z[P][7UP:]G>'CQ#U=N`-;#R'+3U<M
M+#I?!G;Z^WCJ/+COP:^]P&]A[^6X/5@L&=@`/?AE?](98`]?;;=OW>^F$$.P
M!SMS`?IXY#QMCE[^_OPX80<PXZ7MO]8:^S`'MX<_"_9EG@'A[^SZL`WO]?&X
M6'NY#F.6[(L`V',=^H[^7#ENOPO@`-+ZW`/4'K\+^H`.'OWW#+/Z>0X/$!S'
MB`9;\[=W?@S'7[]W`1[^/#`'#++PT[]_?E@U[!#+[^(#[[L'#CX9<P[!X:VR
MX%\AO?2^5P&V[.][Y#PP#TT"_*"&>DO/0"`7S$3VH?O^D<8>L^51Y@UT;^[]
MCT^F_P!N>,Q0(?VP0_P=>N/YPU<^0VR'3*V,/6?\HS_V-_K0$!F&\/?7`-=W
M:Y7RY]O;GEWY8.?#6UL^6$"_9KKF/#C[+6S#0<*/#//OU]^P.66`,[^^?'PR
M[]^$$0`!B'0`$;;A"U\\O;EOP!S]0B(@(Y]P:?3A<P$!RN%ATN`VW"`W"U[#
M8;@(7`<KX"%YTZ2_3-VVS-HFHR%Y=I8;)ED>D*)DE*57B=YB>)7I!**1#`P!
M(4OM+HL=GAVJU5ZHR=&YJBCD"B4'5F6S&:PRXR+5)+'.LQL,WM\@5^GV&*9Y
M%J_7J1PVA($]-:GS))4K2U0BF]25.SO)J>7I@I_'/4X-DKUG7R2V3+/(207+
M\ZS[U2EL;V&669K/)GK32E3%2A5.JF5Y@J,M+GJ<7J>G!NFZH#[-K6QO\QN;
MB[OHR4C=8QCE1K='!T/.4M:)0<FZE.V(RA)0M:%,2Z7G*F(WS@5*D5%AA%0*
M@X5`PC`)8PB=T^M$!+$2QA&,0Z%X+#!D(4W/YNVK.]4:D/5.IPJ!05FJ9,M,
MRD$K31)3DX/"&I-6JK-OF;C-4;HPO94L.$L[+U)VF;JK/J=R7LC&XSNIH4<X
MIII4%/S+T!PVM*@.4O4TDH^N<V)7N=7[:(F";YM<)E2;,<Q4F3$5B>$%"7>K
MDSS)1V>FNEM'7VEYJ)TE6CTR,<FS[,L)!S@7/A\L,B8Q1>6$400A"`Q!#T1@
MZ`11!"!<0]**`(;@'0BBM%%!8(8HK1#",6(Z5!V7*75.>YT=)K6U-B9JH)6Y
M'5VG+%56<Y9I36,AK84<K)8:JR*R+DB:<!BE=K9Y;4B8O1`J8V1H;CH8BDQP
MJ0[;1M>4C9PI*OJ'-55Z@4A9Y"EFH]19O:(FY=-\TS)+!$P%S"<ZI6QNE18L
M>$YT3DXM<O&GP26G5-C*]PI3XDARZ!-2)[FFKKC6:J]`#JGSFV21L_UEEF6R
M9CI-.-,W&B5<39ODR2GPRDK/-,GR1-TP3Y42DAM3'EXJ,4@GEP32[*$@$25,
MK*SO`,TW6AMS4ULY2DAI;6]K)6N"QV6%-Z-,C+6.SB)0N+JK@2EE`K<W&(DF
M)>XJ.L6K8BBHE1QL1<`PY2,TXT88C#CS(BX0@+B-.--B+AA'I0PEB9'$,$$,
M7X00P"$(1?A``19X"G^=U4R&3[2"<=DN*;*64+IA)L-(Y8F-'1Z;C&V:-GVG
M;3,]=*RS"R4Z=):97!R:2W]CI)3F56-6PL,PU@J?,$^+V=L5C(JE4^-@SUUV
MF*(4\G=KVAJS5!F6L$$C;)$K-DFHT[9+KJN?:@)7><:]Q4JFZ&F,RC,E5J8L
M,URLGGZKC1*$Y2?*LL,9BQ3(R:8$;4X+;SXCCXC(S8CSXC3(X3##8SC8C##(
M+=".,R*/IQF0``=".****"WX(PB&;35)I!+U3E\JO:V9*ER3-<D0S`GE:>:2
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M28IO<XG)R/(-F5_>'1.F3&+8X`<>X@`@`Q!"-ABA`8@"(0SA$80$`$8;Q#"(
M@(PB(B%A$<!3C.,W5<<*%SRP4YEBHX[39M8JLU8JO-L$FSBRI94K0WODVR)L
MURJGF-7+8M"]R?89BHRFDLEK,FV3:74H;9OG9U>VUHE8YG7<CJB;2=)ZD,"F
MK6T[,AL@IIWK</PJYTB<&2G4:*@>SVT2-"YU&<"902JTU+9ZVG71.4Q24T/+
M;/-6EJ>&<Z=/YT<W-;`TW'=8;$!?2--'J8(BB0B,,$"BHQ$8RR0&,>J+C&(>
MF7!T88A$>E"-Q`>HSW)K3425'63I@4/B=K=8FH_SV77Q=+TP-+FP.J%]EY^E
M]]0Q"J9W^7'IL;W9A="8##&U>C(.++CAA$N(*UMDRLTQS.D<-H:JE;JIE2Z#
M-)<C.VSL]3HUU/>V*J55IL:$;5-;Y2Z5:,4_G:DB85!T<N2#3,Q#,<+5+_QH
MG!UF=Y9I>A<(7FVSVY7,DTT!D.;YGJA*-!WB8IY>ZE**-RNMF:=Y\J'*224P
MH92%(M32W.S(UMTTS$\33.8PS/*JR5IA>:;,+4\/4OMT9ZP^1,@T&IY3]V=Y
MG3%3-.L]S`OEYS?JFU9G![JE4MW6R>V3`QR:8IFZ:CE*A)\3V&;)F89:%E3-
M1C<S/[NBC-4_"*LTYYX(S"^EU1D9?3+B*,ZN.,L(RX[=(J/H1!TRH[!TRHKP
M1`$(Q`/1#`5*$FU95GU'D>LTKO,T;5,_;--.MGFD'P=+#LLEYGD6J4FJV:ND
MY&3U+K`9(<FLTIS2_E'UN=T,P-I[ZGIM+,NMTO/["P2T;$PJ]UV[6R4(5C%6
MNK+/(;1(CF2Q-K#2-9\?"I<JQM0RQ2C9G;&-`XR@\KOU2$U");F.I*@7-&K)
MH8V*FV0)Y87%;,1;A#?,$9@%Q$@88!,4<)D1(&1@3$9`%H#(B;@6)D(6"&,8
M1CA#((K!CG`>>69`:6>?`:7$,<!L!T8&P1Q"`Q1PQ7$0BCZ(=8(WZP`"&,(H
M<L!4C.=:YDJ_M33A2"3-HV:Z9R;)<W2VD8*D4_J5+,C2>_2[++8VS14^GQ4J
MS92:86NN-806,,X2?,DPRI5E@9J>IG52G0R:H>J45!++FA5:J[),FS`[5-E"
M7E$X294F3FY,6GF.5)]2I$%.ZH'E2H_SG.DDM38GJ>=*<HRF_.4T3/+C`W))
MS=I>0'IF$Q&H7)7,GZH-DZCZ1T3'K()]F24VJ87V;)9H].%1IFF>@\FS+,AK
MZ:\/DIT@<3XI5;UJN.:IMN6XDO""#XUS#'"A$U<4:EDI!%&6,$1<41<970$J
M,N.*",H2P"$L2XX1AB@ZN$(0@&`81@``"&P`&`J"E#JI?FRD\^5">JLU8HJ5
M/Z)B9*TOU.YH6315)KH3167T6RA+Z^D\M2.D<&=%*M8I^KPWRF6^2:QD3I4F
M66"I;L_(36V570<8UQ;:;S468W1HJ!.5#)3G.LE,'15)+G3]TG(R6GR8G^H>
MTSM$QNXJY>7G"1*M&E,F29.!:)UC;*J5'7QT:E5_;GZ77%X=+E.O/$PPWKU`
MFFPQP''">:)IL)D,,!D!I@Q]89!'!###'#&,4$<$,(1`,(`&.`11A"$(1QA"
M$(0@`1Q!"$$,73A@``BL$,$?X80@`0PQ_AP@$6>`I!5[5=0$-(-ER57NLL\?
M'FI<K3Y/U7G=]G-MV?:C4QB>)D,?Z5/E5ZAO%&)R8Z042.EM6M9&&5IND:4Y
MSGEK1-C@DG.!BDJ<UQDI:RRM-3-*FPG2"9MH3:+F%]?:WRFFG^L]-$YL,U3V
MGEJ29GG8^:W]?+M.YHEEB;(I^)D()83NJ-I002PL<H(%+H<V+ER"2=1-F6FU
M3WZ;GN9G*J"1'4EF;Y=JW)DI56G&3:?5G8VIH/EU(UU;E1@6I"YS2?%@^.5C
MH8W!O,.EWHMD9ENL.,?Y`F):T"5K;8/,F]$@1M:5&GBC+3DMS>F*2(44,`1"
M$29*F3D$DEF=8$,!4%[Q`$6`IVG^MM?)FF&<&MD5UG;IR448VDV-XH:NI7,J
MRAT-15TU#0+9YDHN;RJ=0JW"(2)M&J=9)R0SXV-QT4QTM<P<2)2EY]9TGXH9
MRVA*?41IZ8U3!6=NF5RF&/9BJHRNBN;VJENS%'2R3()8E$NDL;+06=YWGEUF
M9XD^697/K3+K7-C;-R^;7UUE5)*\:YL32Q=!UIW1`OKSNKA``A@ZXSH0PPPQ
MPPPPP=/HPPPPFF00@``$,!AD`!T3(^DD)QL$01P''PQ@7$0$<!ID,8$C",`D
MA'TPBA)&"\`E!$!8PB,(P=$;8"J:GZK::89VH0CGJOU9IX9INVJW>24"*"G"
MB7XI@I?2&B3XS5$F6K1ITB#\69=G:K\EI7-AEUQ62^C$A_F2;97?GD'QG02>
M[>U9.M?%%4J5T,I<\/%*9<J7+\;D-=&!`^.[\CGQNG%,E^)+>TME/YU;EB9N
MD].HF]];WU=(S*^(W%(C?IU9)>0NL*R?H1F`$4/6&!#'#!#'#UD8!'"7T1+@
M,`(K&0EC#")<,5X2^C#T0"P6(8S(83((3#((#H8838(#(X"SH8(NG!";#`(0
MF0A'^'##'TPAB'I0@`B(X"N":ICVI)+45D>I"+JI4IMV<4VT2YRZUU`,:H$.
MT,[3LR4_F*D$BB8T2XUN$S-M%C)BG9:GG>64+="A8I5EVG+D,X3*\3.^,F"D
MLW:,GR2Z+IFJOM35KA7+:2>)T>9JEJ63S%%.MGV2*8O\$Z2.PO4[TMD=N);I
MBJ"GE@)>,=Y"+%N<YK7%TO33JS2.6]A9T(C<!$1Z0`'1&XWAZ`]*'HC>X=&(
M1BAZ(7`1N``-QQU6?I115(E*89-?'F;VQOF9*G3+GB2YO?9*G%%$D<$3FE7,
M,Y2^K3/K$Z)UB!-$2XH5,*B$GKTL0QIE)Y1@0UV6B*X/,[.:N9JQ52GZD]&T
M-5:)-<RU`AIRJ':6F<FKSD>SUF6K)(E"5T_P[2J5Y=BIFY3*PIVV5)Z<G]T(
M32V0YR>ZNRCND_U#9';:VH_3,UQ?T":DU.ZL5XFN*&5)^-EAR>%LKIY*DED4
M/A$O#);H[L4M/T_U'0%-KN]3.PJV%&V0,R-?-S>)\HI7EB7I*EYHE24V=!+\
MM,"$MN9F9L($A$A20F&G10%PQ11F&FJ%)ZA:M5J#3EC@XJE;BX*%*]6I4G=C
M`]0!8$@>>!(1@9"3">:!(1PQ=((P)","X3`B_"AC"'I!$'2`0&V`A#0BI$G;
M4-14U4Y?/F1"S4D2SJRTIDQTII42FQK.DJO\'M,X3C4(V?I5EI$$T5$"7$SE
M*TB,5CY0E4DR9IY/.G*9'%JEMBFE96%@K>P3HQ3!449?KYM5;2]0FJDLJ2:_
ML;%,U/J3;/RZ0I=,JX]/\I+E+$KJ).M*Z4I&%L7K93@1HG-PFF7!?XW-;\6[
M5#E"A0("H4'J(H`$(!4'FGC`$0W$(1-CC&$(A`!B"&P1"`"-QT^8F&"!@"89
MT3.CUD(QQB!G0_<=;#TK&A!J6$8#T/X(`(8"G&9:S5S=V&5YY9:I[03++,WK
M-GUGK0\-M)GAM9J;U0F:M<@IIUIAL^RR[4M>)G3H*?TS;*N2Y6)U<TDWM+^_
M'T\4IYF5.<V&)$+LM54ZT;0K@U2Y)KY7.A+O,VVA.K!."4V2(&U92?9ZI-3Z
M8FMTE]OF*:I.,DDMUG28DLE/K@<8OJ!&W3%/1CG(ZR8D,OE0(K.`/4=/K>O4
M=:)0%=;UYW6]2$/0`@8^GT^I"`1@`F_5]&\(0!#ECC$89&$(1G&QPPPP%0PQ
MF&1PP%E]+JRH0&(0A++&*(2R[=`H8HA@A#I#@*SZ&U:=4<W5EJA.%7]HB9Z6
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MO*U?DJEG*_[)2UE_P4LQ$+3<(]G=V>]\`ENR^_E?+(+:96W:87[^-\AR\=?K
MO@"V[/QW]M_#!?LSOVY>WU6]@)??;4+Y[[WL%KC]-\\KX7AEWZ6X^/?GK;7!
M]68AEQY_>%^8X-._V]E_4&`,O;XCGW:\M<+P]_?AWX3MM?>%_;I?*VH<.6#V
M"._G?U#]V\+`FF?'L"XCP#6^6@C?,>&.7O[\,):^>7;;?N'/AG;C?`&7W!:V
M`-.W=S'L$=.5\`"-P',!"PAGF`@-X8@MD`W#M`0RRU0,NP=+9VXZ<^''MP#E
MO`+`-KWWVSTW"`<=>P!"NZ<?)OT?FVLT4^@]3&R4IF%[13U4S9T:%BA%2VHM
M3F(R(9=G)U:"%121.43"I6&/3,2C%.ZJA+,+-2%'*R3+"TZ=,D()2I22$R9,
M24G3)DQ19"=.G3EPE$$)R"88"R22"8("B22H8"RBX(8"X(880`*9-K?:\KW2
MVODZ2/),WI&N6F@B7HT"$U@:%QA,:]C1K%,0J52<P\SK%!ID8!'$(0!%T8?P
M0`,1M]/[:FR_;!1#81M_0I+X!<,L_P!:<?<;7P&QF`AQ#=E?ZQ"V6ZWC@N`[
M[9<>-O`0SXXUS1V_MJ;Y0$0<OBJP6$1UO^M![N(X3T_=J;Y0$5]_]"K!QO\`
MFF?`-,LLL!L9W`;YPY\;>'CGG?4<@P7AXAOWA[.>?N.-<WT_MJ;+]L!$.8C_
M`%J,'/+^I=P[];]N#T_MJ?Y040Z`-Y58._\`TH-^P>>>`V,KP\A[POGKKW!Z
ML@#!<.("-AWV\!OEC7-]/[:F#_5`19_[%&#_`"7].7#">G]M3CK4!%_-1@YA
M;^I;=X;MP8#8SOS#_C6]E]+9]NNMP1#/,,N8=NE]<M^@XUS?3_VIKV_5`1#_
M`.ZK!?P\TPGI_;4XZ5`0WTO\5&``"U]WFO=J.M[8#8SN'$-^@Y;[7]G;AZ*!
MB`U#@L-_Z''OU*&G&K+Z?^U-H%0$5K96E5@RX?Z5ROGQ#+%F/DHMJ.M=9=IY
MSE:H4TIGID2TFF]X)2%,C6W10."5YE).2?UZ(@HV((251\`EQ#T!Z8",-X0'
M`6LUN$`J6_Y_Z79-X6_>E+N$=W&V&HN&68<L^WQ#=E?/LQ3?ML;;FT?*&UA7
MJ49?G=$A895GY7+[(D&66,^)*U-K:V0I"#%!R:(Y1&6!D?2.-B$R,1#IB(AB
M+@;?VU-;\H"+//\`K5E_PR2;MW9K;`;&5PSS`>5PT^L<^66["W#^,'B''W^G
M&N9Z?VU->_ZH"+^:K!GV_K3=N'<&#T_MJ;Y0$7\U9?\`\D]O$<!L97`,P'0-
M`MIGKQ`-P!O[0P`,(:6#O#Z_NQKFCM_;4VOZH"++_8K+^0VT_J7??.XANP>G
M]M3?*"BO_@HP<<_]*B-M+]V>_`;&5P_C!IRMV_=?!T@XA<.8;^`C:^-<WT_M
MJ;0:@(1_]U&#,<Q'+S7OP>G]M397J`BO_@JP#?C?]::<=`OSM@-C+I!Q`>\.
M7/MRS[>)<+ZZ[\K#8=,M]K6O[;@.N;Z?VU-\H"(,AM_0JP<O_)=VF_!Z?VU/
ME^V`BTS'XJL&8AN_J7C](6P&QE<.(!RN&F[Z^P;6WX.D'$.>>GAKC7-]/[:F
MO?\`5`1?S58.?_DG,1UOW8/3^VI\_P!L!%R'XJR_GE_N3+/WM@-C+I!Q`.T0
M^@?>_;8N`V&X!80OGVV`1"WU=N-<WT_MJ;+]L!%V_%5@$<ATOYJ',--^%]/[
M:F^4!%K_`."K!I_\I[\<!L8A$`VN(<<AR[,\_$,NT+X`$.(9C?=QY>JXB/AC
M7,]/[:F^4!%O_M5E_(>']27SU\+AA?3^VIOE!1;@_K58``.S]:#[]U@V,K@/
M#,;ZA?3+L'=].%N'$/$/K]]V-<L=O[:F&X!4!$(#_L5E^V>?YH/;^D!P>G]M
M3Y_M@(M=?BK+^G_R@9YB.@\-<\!L9W"^H;K9AEKIOPMPXAW"%_?WMC7+';^V
MIOE`16W6E67]1$<_ZDRMNSU#>(X/3^VIL_VP$0ZA_6K+XV#/2Z3?OOPS$;8#
M:>H%8:@!80&TNO.\!_TPU=_T]U\8:LXA^J._A<`R;^']ST_OV\0UK\\D/M`5
M3KC42IL-2I@)?0ER6T7P3U+2WMGF_P`(GEBK&,4)177"9YL5T>LOT`@'HZCB
M,OE(MKJO-*ML.ITD21-Z5IEMK020<A0F,#0N,*,<91;%JR(52HB,XSK%)IA@
M!'$(00CT(?P0"P6EW#B'JYYZWWYY]FN$O#Q`=]ASU[[7OF(\QXWQKG>G]M39
M?M@HM]OZ%9?TY62=G#U8/3^VIOE!1?S48`U_]E'F(>N^N`V,KPY9AXA]>7+@
M&6$N&\8;=N_LN(`%A$!O;B.-<[T_MJ;Y0$/\U&"UL[?Z5X#IW9`(X/3^VIOE
M!1?S48/\E][CIE8-C*X<0'/B%K".>_A?U\;8+AJ`AI:UPM8+VT^_+=C7-]/[
M:F^4%%_-67_\DP>G]M3?*`BW?VJ2_IP_J30/',<!L8W`-!#EPOON-[W'B/KS
MPMP$=0\<KA^G?;0!`-^-<WT_MJ?+]L!%EG_6JP>SS0>>@]^>1Z?VU-OJ`BSW
M#*LO\1_\EX>SMP&QG<.(>(6RT]_NP@B'$/'MX#QX7QKF#M_;4PY?J@(M_P#:
MI+^=M`&Z4=+\!XW#05]/W:FS$:@(OYJL&0=Z30=X#<+^.`V,K@&\-UKB`\AM
M<0'3,>_7/"W#B'B&-<OT_MJ;(/U0$0<OBI+XW_YI;++3LX#A?3^VI0N/ZH"+
MC?XJ2_SN/]2![B.F`V,KA_&#Q#P]\]=,+<.,-NWMO]'KQKE^G]M37#]L%'_-
M27]U\OZDO;/GW#;"^G_M3?*`B#*X_P!"C!:X\_-<Q`=0RO>^`V,A$.(:YW$-
M+Z_5P[K8+A>]PMG;3O'+PT$>>8XUS?3^VIK_`)046[^U1@YY_P!2;[<K:\,(
M.W]M3#?]L%'N_M5E_7M\T$0W;@MJ&`V,[AO$!U'4..6_=[VP=+.V7;TON]^[
M&N;Z?VU-\H"+^:K!EE_N7//C^D]/[:G^4%%_-27\_P#FOOGRL&QET@XA8>>8
M#ZP[],%PRN,.78&_(-_+0;W`..-<P=O[:F^4%%V_%27\L\@_J32_/<&%]/[:
MFRO4%%N_M58,Q#/\TY<?O#8RN&EP[QO]>`8@XA;MSONMF%KW]FFN-<P=OW:F
M&W[8*+?E\56`0_ZJ%PSM]0ZKZ?VU-:PU`1:!_:JP#IVI<[\\!L9`(`&0AXV#
MVB(<[^O!>'B`\[AXCIK;*P;L:YOI_;4^^H*+(;C>59?X#I^M/JWX/3^VIOE`
M0WW_`-"C!GKG;S7??.UM1"^`V,[AQ"P9=GT#ZM-^Y+A?4-^\+[M+CH(@/"XV
M'GC7-]/[:FU^/Z*_'XJ,%^&OFO?V;L'I_;4WR@(KZ7^*C!_DOW`/'`;&5P'>
M`:6N/.^X>5N0@.H8+AG<0Y9A]UA[^_&N9Z?VU,(?E!19AH,JL`#_`-5&W/(<
M\PM@';^VIQTJ"B#+_P`%&`,PX_K70<N-P#7B&QG>'2X#WASYZ\>-\+>'B'B&
M-<ST_MJ;/]L%$/(948+<O]*[M^_33>>G]M3?*`B_FJP9:7`/UIOP&QE<.(9<
M1#Z-.W=?NP7#>(>(6YC:_=G].>N;Z?VU-D/ZH"*_'XJ2_P#2E'WXX/3^VIOE
M`1#_`.ZC!VZ`DW`&6>>7'(-C*X<8;[LPRXA?7OMOWZ8+A?4,MV6H=^[Z=>&N
M;Z?VU,.85`1=OQ48+VMS296'=R[L`[?VU,(6_5`1<+!*C!V;TN[4.S+`;&5P
MOJ&0#PL-[<\M-_T8+A<!N&^]Q#C>VMM_/(+8US?3^VIAO>H"+7+^A5@T_P#E
M=X9#WVP>G]M37RJ`B#?E*C!GV_K3EN&_JP&QGT@XAXAGZ]_/"7#B';</$+WT
M'Z>&>N9Z?VU-H%0$-Q#_`,%&#O&WF@\0R$<_:OI_;4WR@(L_]BC!_DF_??U8
M#8RN'$`O<<A#E;?KOTM[101"T5XOX,6@\;^L+;NX+6QKG#M_;4WR@(AW?UJ,
M`ZVO_I0.=\[=N0!P-V_]J>$HV(*@HKPE&1`/Q48!SA@$0'^I>7W8#;SK2`C2
MN6;!?]DI;_[*68B'8;7$(@URL.7=W>L=V.L^4TGN<97V")5FZ69C=I=F10^T
M>B,>6-68VK@^$FPZ-=`6>F&&(LI2,<0&%PVA&$>A;HY8UEO29VA?EIJ4(_X5
MN7&]OZ;[CG@-HZPY7`<[6R$=,P'0._(-<%AL`C"//\$<N///V:XU<1VF=H7Y
M:JE<`'XUN7K_`!MAOPL&`=IG:&^6JI0<OC6Y>O\`&^KV8#:.&&*P9#<,Q``U
M'4;@'L#41#/?@S'^"(\@"]P]5]_N(7U<?29VA0_U::D]OQK<@RW!_3>SWL&#
MTF=H7(/U::DV`!UFMR'A;_\`-"W=PW8#:/$!S_!BUTM>^G'=QM;?A``0U`0"
MP!<>0VL(\;[LPOH.-7'TF=H77]6FI7?-;EE__%\<2SV(*WU@G7:1DR79NJ;.
MLR,*QIG,U6SO#^M7-Z@Q'*[@I2F')CXXBS(B#RX#B8A"\!L$,<(](,!>WV6O
MN\!MPY]U\&FX>ZWTB&"UN5K7TS``[_<._`-KYC;AF(9>/&^`-!#CZP#GK?/Z
M]PC@MKZN/OPOSSSR.ZWA]?O;`._,,^.F7Z!O;G>^`UQMOJ_I3U&`/S:4K#K_
M`&LM_9F'Z+YXAQSN&0C?*P#EGZ]^[3CB8^WS_GIZC?[FE(,MW]##??NX!8?J
MAQ[_`$_1[YX!;"(@$("(CD```B/@&8CV!QS#&+1/;.XJ5R-O<T*U2V#!"XP)
M%$"B%%&8`Q0%J3RAC3%F]`.G$2)PG%P?AFEEP"`CAYW0-#G+#FA?!?@:SX4L
M*L)9+>CWB.&%81&660GE]*M<U1!AT)<"]*6C4I5"$3R7`F-#&>&,#3]='$6M
M9RO.#FEK)),;C5-/)@I^K"!28<!R8UO7LS0PN!D(0=(%++"2>:,81.2,LPSS
MP\.E0;4%#0&I$*N>(&F*E#2D?YTA?65^8XTDNKS$Z=OF-H)<FU.IF)A<%BM(
M@0NK,2K3K%ZM(F3C'$J3Q&N+)51)9GSX3*9(G5&Y,I;,H=V"8V5;+LQ-B.9$
M$;K+C@M9G""%22WS"VEFKF58`Q$KDY)\4`PQD&P009-DRI-1%FTZ^O6S@_M<
MYU1EU!*;8KJ.NDE1)RRF,H.K4U,$F,2%J?7%<=-3LT?"TX*%3N4U(")C@:DT
M"X"&=!$8\6R=2J9Z5%UA;CVZ866GSQ/R-92-OJ$I2NM34,I():1-()IP<TZY
MT-.;D*M,6EE)J6."H]K9R#X`$HE:66`/@Z5>DEDJK*]&'12\))\G27W6:982
MF,#D+,[LS(4M.=CT\P`6+;"<@A0*`4)C#(#83.J*AABB/@NZ0$*(HN@!!XQ]
M$(P@A).&/HCI'T`@Z0P#<+16Z(B-KCEBGR1Z`[33/5&G\_SC*$P3=,4HRYM.
M-LYS6FJ$RL2Z97:H:N9H)(7R@Z*75<J:2#&QQ:"&_P`R1)HY>`J$LE'`8VA#
M&K+2.JBN3:[RG6Y<JI&%36:D+M0$ARG6(QN:JWHI*=%DU2TPB1,RQR=GI<ZM
MA:6:42B,XB:X%"YWC)--.$N`+@NH/S_$'Y0=8/XDW(O.Q@AT,BQL/XP;0#8<
MQL-OGBO5VH?458DH"_$L*M7-Y4PHJ@U?8$+VX(J7+'N<7>5`FH2#H9B2O\M/
MLDH&DAUE%P:DZME5HVUT85K7#%-JT(K"XX@BCCBO?I1QQ`(@$`B$40B`]&'\
M&&]PO##:$+V#(`#`<<]^7?V]GB.^^09#BWKR*/\`GP'S_P#9*=__`*@DG%0N
MGB(CGIOOBWKR*'^>_?/_`-DYW#G_`%P25]7JP$1-O[_/K;3>OY6'GC;][FCN
MQ$"P=EN=@Q+[;^_SZNTY<;?ML//A\'-''AX=V(@Z?5]6GN&[`'/W]0Z^.^VN
M%P@!8-+>K!]?'?I;Q'3E@"^G$=W.V@X-P99#ROKZL^.G$<\&?N/OKVAN'>(8
M-._(-UK</N#Q#0%X=W/Z\\8J%[:(G:)A@<T1CT6G%4:UE'`:M3IPZ0`<K)*Z
MP4D$44(PP>=B1$;'",)0&1!8!](2J65W3KHW0I$H;5I*N-D,<B7F!,8G,A/C
M:364(G@MR`L8A1QM4(N,)X0"C`3^@`ME3]0F:EY4ML7PM'+<2=0I@A?:<3A*
MSLF/(*ABA%5,BU@:V9],4!T88CW:`A],BZ44*IP&&$@H.PS'5*092G*3)`?Y
MC1H)PG^%\-E=B'K#EBU'+;0L>GES4PE!%"W-*)`@5=-R6B4F-5P0HR8S%,70
M#&4]K/3FJ#K-K%)STK5/LD*D*>961V8WJ6WA"0Z$`J9W>!L?D*!8JE]Z($36
M=[()B0N,$,8D&"`!TH73E0:OOIHT+J^I>D<_4_EMQJT[.:]FD)E85TCR^\,J
MM(TR.ZK%$T'*YN7.Z`$;`PO!*-`2U*8(EQR(!5JA%Y=FY+/2Z<ZOS[4>BLX4
MVG6H3H@7NC]-"^4CF\^6I<*"7Z>R/+1$N/CRL/@EMA3F.#^YNT+8*YW<S#"2
M#H(2^J!^IYJI)].7FGC'-A[NB5U3FPF1Y-4)F)P<&M;-*B"`Q.T+7)+!$G:C
ME!441Q,:SHDQDD*C!CA`B/#DPE&Q=6,))P]:`B58DP>LMF/5VA_&6_A=#I6L
M-[8J_GBB-=WRO37-ZN5G&;T<O;8$D5699ABF)G;V)%1)BDF%M12XW)7)XA+2
MNDON@KBER*%L(-7*U$2X5"GX3&(KK[336IB:JTYS'70B8Z7[/4\TNJ%*$Y.#
MU53SM.T34-3%::FTT/LS`_$JOC"XMBYH5RT])$B.!*3&@EB),4E0B6<%L7FZ
MCI0AYLH&*(8@AAZ@X8HA@_=A##T+Q107O&`!>`!O%8+8^687N%K7`0$+"`@(
M@(#?00WAN&^N*OBJ`U7(V:"&P$2J:ZPEO1#22I9%BN&69XDVE9<RM4BHY_;E
MLSMAB=NG=$8::\NTNK4KPW32ZL4S'^=P2\$6+*V%,:A8F)$>F@1G(F1G1'I"
MUJAR*1G(VQ(F-2%N2R.-6Y%I3"HDY;BKCC5KX"X5BJ*(\XR(0RNOAEZ^'M`?
MO.6O;?UCG?=KS'/!P[/#@%O'EE@T]PRP!QM:^G?[;?7A;>]QP@6]^&[3=PP!
M?C?V^H`^[OR`MQ]HAO'=R]>_!IGWCKNY9^'?J`8,^W7V]_?V:7RP!??GGKXC
MGPRMWC@+Y_(5C^V+6K_!MEME_P#KQ\]_+OM<,0W\K-_G[ZO\/@NG7'7XCM'J
M_1B9/D*_RB5IR_M;9>&G71Z;^&F[AIB&WE9_\_?5_P#WKIW_`/0[1@*X+=GL
M[1^KVYX7/W^K/VX3GOTYCRW87`(%_;ZAYCOW<..#WR[??MSUP<M]M?>^E_7V
MX._CVV^X=^?KP"^_CK]'N&.-^(:#;GG<+]@Y;O5F'+W]^W=A`SX9"/=KZ[>W
MNP!E>W#WT]G?@L&OOX:8,^6F_CN]_#!KS#U8`#QOG]7++EVX!\<M-<N_6]K8
M+YV[?5J';G@&^[@/CNP!;._#3Z?'Z\&F>?B/LT#F-L&\/?W^_G@XW]_?=RUP
M`&>8VY"'#!IE[V[??Z<'+CS]Q\+X7W]_?QP'&*.&"&*..((88(8HXXHAM##!
M!",<<40Z!####%$(CN`1W8:5LKK2U^99YF"7)F&9FNG;T$M3,9+C.]O2HN8H
MD2=?"Q-+:C;XW&8'6(E43!"D9TRL8E,42>&,8BC(H78,B&$LR,(8C!@+,CZL
ML`B-,&&$8@@*A&*&&(PP0Z)<(QPA%'%#",4(",05XTL*K?39JVR)D9Z*5$,G
M*H=9)DJ=2-N=$,KDP.J9_2-C*U'KHXIM,3HG1F-$][7LJTXH#$*"(F%;%$H"
M#`3;IM424*NR>RS[3QU^,$L/\"OX/60)%:13UZ)2:C7H5;>J)*7('%O6$')5
MZ%23`>E/+B@CA$.C%%WSJ%```BG4``]*PB0;8>A<8\Q@SZ``(QZ]"P]*UL1'
MI%1UO4[+H46<I,G*FK>L99B8SD4SO+87/0O#HJ4.:^>EJV3'1<WM:]UFM4HF
M%N2MCLIA2(BTB,SH%!$E".U!MGJO+!.5'7>J!!;BRNDB`U5F1&.Y\0,\P4CF
M,F.EJ]K%.OABC=IS;D+>JF)81%&6X0"K!QAA%.26<%GO0CZ,,71BZ,=P@B&&
M+H1B`V$((OW,0PC8!"$1&'0;".&PF"KTDRO5&1J./:EY1SW4E`\N,F(A8',U
MK=R9?2JE;R4#V65$A2JV],DB-/2*A+-_7"((.G$K*#%?ZFA>UB:S;2SNWU!J
M,AK%,<<Z-$IJ('*6TM,9LE%?,*5ZE%1+*[S_`.&V"<&UA^$97;8H266&5(32
M4HGGHH^NPVLX[.>T#',VSVLD)MJHI^*$E5S4NDP5'9)+=!D5XJ5+BDM/(4+6
MTS*6>IE\]Y+=6I#$2I6+&!LF!`Y)%<19:1.F"YP23X0C&(@\.K$`-&(DV$"A
M&U@-O"'5B-PL$8PB.['R]_T_7R'/$!9/D2H;G52@$^DTIFNGC!+\L(I8G>GD
MUNZ97+T@FI6B;7#XRR(Z-<UJ5BAR^'U"5E>43VA<DLY-;XV*E$*)2P&]3/JV
M6ZX!OT#3U7#`+A,[;A'P#7O_`$X7W]_?+GA,N7WX`YA[A[]MMVHX/;^FWJ'!
MZQUME?7M`.WC[2W#+`''=W>L>.#W[`RR]N`,@MPR]_>_/!NN.>68`(6SMK<;
M:<]^HX!??Q_1A+>]QOXWP>O33]/OSP9!ZQMJ(]GU!@#LW<K]N?'7/GF&%][=
MOZ,(.@WT^CW]N`!\?;S#,<OJ'A@"WAN`,OTX`'UYAKQUS[0RW;LL%]W9W;\[
M#R[!YX.?K^OWX\<P6V#W_1PPEO?=[\[7P6MI8..7Z.?C@`/#Q^[V`.N#/,/#
MLYZ!W</'`/W[MW;@YVX_1PRW8!<?([^DG?\`F3>(Y]7%ZO#'TO[\^';CYG?T
MDZ^7XD[?EF7%V#?N[!P&UEY5'_0Y9.SM^S=$-]K_`+$QY8U41L`"(B$(``B(
MC%T80#48HA$0```+B,0B`0A<1$`"X;5WE4O]#ED_3]^J(6OH`_!,=NS&J@/[
MD>D`B%A$0A#I"(`%Q"&'+I"-K!"(ATA'HWL.`:F2:WTTJ'-DU2-*S^<IFN3B
M$:YY97%F>6)9&SN`E0HIA9X'E$A%[EQ48<400^MH'H##C2H831A.(C-=SJ%`
M9BG/``@`P1$@[*`<@,$1A_<"&01B'1'^-NQ#2AJ&<7&ME7*CSS0^>9"F&<24
M3,@FV9W*3S&%+3R1XBFN2I584;$].KL<\NT41TUS*I<4J%+";'"B)..*:4!:
MAA:A[.U>&V>:Q/5+B(%#`US[36M-&&UQ>UJ@MUG%Q,;F.I<DKXU;C'$5)25K
MA>7LQH/`M(6L4H#&Z&+JQ)*"T02C81B"(HT(BPN8`E1PB6&5A,`8;E@(B%NG
M8!$0"]Q"[:U/JI)]'V1HF2>SGA`R/4RL\H)'%N87)Y3E/C^?$E:"%XH8(Q1)
MEJJ'S:!8;")$*@82S(X1B#$.YVH)5R&MU&D;!-%0&ZA\FR`@1MZBGJYE\\EZ
MJ+/,J=\<'B:$DSN`0G,<Y(`7M:ASA(=HDC6K42X"<E`M,M&BJ^SGM,OQ<X.C
MF-89UG177YC=@;F,)(7TL>Z8,<WG37*\R("79\1NJ=\E1LCC8D+)`2@B0P#`
MQQ`H0*14@%U$293"8)(ISQ,A&,.@!)HQ1`7$,$4<`!"/6%A$`_C(.E!H(1#<
M!Q,SR?(?]]7(5_[C3V&^X",I.6^_'ERTQK[3336M4T4Y4RR932:CZ@RW6*:Y
MK<'GSA)*=-J^MCBXJD21VF=*USH5,$H"X2Z]F&H/@0TJ*29BE^!Z0IE:<U-`
M&P1Y/>'H;5$@0AI`QSQ``=**.W1D]P@`.G%^%'I;IQ_A1_NX_P`*(<!L7>S*
MW'OOZL`AR`>8_H'Z.S`/OG;+ES#+6P9ZX-=!'NM]0X!,_9;*]MVH9C?B/?A?
M;;=;?POV#O[<(._2X9ANSM;.^X+Z\+=ZY`.O*PCQL(\^&6FF`I,VO]E.O]2]
MH&=ISD>G:Q]EIV3RY`WNA3Q+J6!3&A84:15"!"]V3*H!)4%&%1=83`$0PC%!
M>`0B&,_H+[5GR2.&7^R"4N>O[/>]L;)71AX=HZZ#OOZ_7NP=&'6P;]V[+GR"
M_'OP&MKZ"^U9\DCA_."4OM[!Z"^U9\DCA_."4OM[&R5T8>`</?G;/](X.B%]
M`W?5[-.(@-]V`UM`V%=JL-*1KPW93!*(?_[[`&PMM5@``%)%]M/ZX)1S_P"G
ML],;)80AO`->%LMWOXAKA;!P#P]_'U8#6S]!;:KO?]2-POI<)@E+U_L]GISM
MC#O'D]-HR80;0?Z#IWL&9U1OK0#NND9Q^"GMO&*)`[MHJW@X4+FB&.(4JY,)
M2DCI1=6;"$0@.S':&^@!VA].@AGINRTTP"`6T#,<K!]6G;IRP&MIZ"^U7E^U
M&X#<;A_1!*.6_P#N]VCOWX7T%MJO7]21P[?C!*6GS]C9*``W!"/#*P99<\K\
M-+AEOP6#<`7SMEOSUY>_#`:VOH+[5GR2.'\X)1S_`.GOJQ9SY)C9JK=2+:B=
M9FJ+(JJ6F1322<&@A<>ZL*V$QQ4O4HJ"4P%-KFL40C&2F/CZ<10%`$%HHP$8
M0&Q'HAP#36V7A[]N'GH$`!42`;!_6X]C?7(5#3RL'8&[`:^>VYL;;2DV;6M?
MIJEZF*UR8)FJ$M?6-Q+?98*@7-2]M:Q2*X25#T4H)`T"XQ`I044=!:T9<%PO
M%GT%MJR_Y(W#^<$HY?\`3P#G?GC:BK<$(U+?\@$?-V4?^B$H=F&H&$.`=P!G
MEW6SP&MKZ"VU9\D;A_."4OM[]&#T%MJS+]J1P_G!*0!GO_?[C[ZXV2@"&P97
MRX!RUYV&_B(8+`.@0\<POD/+7AK;(<!K:^@MM6?)(X9?[()2^WL'H+[5GR2.
M'\X)2^WL;)-@M^Y"X996S$.?KL.>MP&V:V#2P>%_'U\LK<,!K:^@OM6?)(X?
MS@E+[>P>@MM6?)(X?S@E+[>QLE=&'>`;]VFOZ+AW98.B`VR"VN@9Y#]PX#6T
M]!;:K'/]2-?<+AG,$H"(7RR_9X==![,PPGH*[58:4C<`W?O_`"C8,_\`?Z]^
M&H7U#&R9T>0<LMV6M]1]P$+WP6AX!8>7$;>O=;+?@-;7T%MJL/\`4C<-?_""
M4;W^?N>,._>3UVC9J9U\O3/0@B9&!S*A3N3(^N$C.K2X$PFEGP$K6]<\G)5)
M<!Q11T$)Q44,!I99@6C@AB#9AZ(!N#@.0Z9Z!?7UYB..5H>`>`8#6P@V$]J@
MLN`HJD"TLHJ"`HLLM^E"&`HLN$("RX(`?0A@@+@AA@A@``"&"$(0"P`&/H&P
MOM6#_J2.'\X)1^A^QLE]$.`>'O[/JPE@X`._(/IT'OM?7*V`UM/07VJ\_P!J
M1P#.W]<,HYY!_K]KA?06VK/DD</YP2E]O8V2NB`C^Y`.?LTMWAV:[BT/`,PY
M>KQU#A@-;0-A?:L'_4D<+_X02CD/<_>J_KPOH+;5GR2.'\X92W]K]OQLE]$.
M`>'Z,((`.X+`.=@`=,P#>/JN-MV\-;0-A;:K^21PU'^V&4AY?W>&V#T%MJSY
M)'#M^,$H]F7[/:[\@TO?&R4(0\`USO>^@Y@'CW`([@'"]$,].5PO;UW'`1"\
MCY0JJ]%ZB50&ILHJ)6"8)<0_`XGN#0N\]%`=""OH_!:]:)8D^<%7Z[JPBZ?X
M'3L-H4^5#HM5R<-MBJTP2K3:<YA8UC=():1V:&)4M0*8TTFM2=1"2H*A&".(
M@^",DT`'\`R$81SUO]H$`!4$,K",NO.G#KVK(;#Q]G?C$5F$?U1Y@`(H@_>^
MX!%$`?O>G$!``&P=UKCGJ&`U&!V;Z^YA^HW44+Y?ULKNRP7A\`[\'HWU^#_4
M;J+</]C*^W_^(\.8^.>TM>/+\.._^WBX#_?>^F#I1#K'$-\_W<5ATYVWX#5I
M]&^OWR-U%_FROX_[2_OK;/"!LWU^L'[3=1K_`.#"[?N_<`'?EVYY[2_2BW11
MYV_A1^O,/7X#@Z48VM%'SO'%<.5NEKGW8#5I]&^OWR-U&_FPN^B$;]W#!Z-]
M?OD;J+O_`+6%W+/]SS#EF/#&TM>(,QCCR#,1CBSYWZ66>Z_=@Z4=_P!U':W\
M>+7_`(U\O#,<\!JT^C?7[Y'*BWM?.6%V5^-H;9=N@:[\'HWU^^1NHNH?VL+Q
MW_[7>`=VN_&TJ,406#IQ;\NG&(B`<,P"_+"].*_[N/\`XT?'C<0R`0^X,!JT
M^C?7[Y&ZC#I_:RN#4?\`:[N&`-F^OVGZC=1;6'/XLKMPZ6Z`!V8VENE$/\*/
M=ETXKAV_A=_+MP#%%8;QQ9!KTHMV87L.=A^X,!JTALWU^^1NHN=[?T,K]W;#
MEXYVOOP>C?7[Y&ZB\?ZV%P__`&Y"&6[Z;;2UXK_NX\_[^/0/_6UY]F6`(HOX
M\?\`QXL[CVVS[1'//`:M/HWU]O;]1NHN=_[6%V=K?WO#ZNQ/1OK]\C=1K6R'
MXL+AX?WE[Y[^';C:7"*++\*,-P?AQ<\LAW6^C=@O%E>*._.**_J'+V>.`U:?
M1OK]\C=1?YL+N.?\'L[<[7PGHW5\M^1JHEK!I*Z[3=_`W:VW8VEQBB_CQWU_
M=1C_`/=V@/;NW@C%G^%'I_'B\/W0>_#`:M'HWU]R#]1JHH9:!+"ZP7W#:"UM
M?JPOHWU^^1NHNO\`X+K\K_\`J\0N(XVEKQ?QHO\`CQ>&O#V:<#I1#_"BM;?%
M'E?=KGGNRM@-6D=FZOP#<*-U%OE<?BPNO:^EP@&_9WX3T;J^!_J-5%R`=)77
M9`.X/P-]]W.^-I:\0_PX@[(XA[!#/=E8<PU#=A>E'_'B_P"-&.7_`!M^79SU
MP&K0&S=7WY&JB_S77_XF7;V\,*&S?7ZP"-&ZBAEF'Q87:_\`%OE8>W&TO>+^
M/';_`&\7?_"PG2B&_P"%&-O[^+GSUMKVX#5I#9OK[8+T;J+?_!A>.F>^&^7J
M'+7!Z-]?1"WZC=1;6#^UA=:P\/P?T8VEABB#^%&.X/PXO\;33LWY:)THM1CB
MMK^ZB#,>8#;3+GJ.`U:O1OK];\C=1@RT^+"[Z(1\-0X8/1OK]>WZC=1?YL+[
M;K?P>?=C:6O%_'BN&GX4>7_*^G!THL_PHQW9QQA[1T\>_`:M/HWU^^1NHPZV
MO+"[P_<9=^?;@]&^OUOR-U%S#3XL+N&_\`?6'=C:6O%G^%'8+6_"CW?^MX99
M<\'2BT&.*]KB`1Q=^5\!JT^C?7[Y&ZBW_P`&%^O_`!1M]&_!Z-]?LA"C=1M_
M]K"_U_@_1?AE?&TL$46G3COJ/X46O'4.&79@Z45_W4>>H].+_&OR\=VH:M/H
MWU^^1NHH_P#NPN]G1_3X77T;Z_?(W4;^;"_A?^+[CEKC:5&*/^/'?_;1V]0Y
M![.>F`8HM!BC_P"-$/#=>X[MUL!JT^C?7[Y&ZBY6_M87\1#^+G;7O[\`[-]?
M@'\C=11R&W]#"_\`Q;!I^C?M+=(1_A1Z?QH[<.(=ELAM@O'NCCWY=*/NTBOV
M\<!JT^C?7[Y&ZB_S97_XGT]V#T;Z_6_(W48/_=A>(]_X(^O7&TMTHK_NX^%N
ME'K:^?X7#].#I1:=*/3^/%:P_P#K;[:<L]V`U:?1NK\(6_4;J+V_%E<.7_$M
MGP#Q"X8/1OK];\C=1>5Y87WW6O\`@COWCZ]<;2W2'+\*.V?\*.]PX9W"V??;
ME@O%_'BR_OXLLNWZLL!JT^C?7Z]OU&ZB]OQ879Z_WN6?'7=KCYF[-]?A*.`*
M-U%$1*,#*5U^8B7$`!^Y\-=0XXVFNE$`_NXPR_C1@'<-[:;O98<(,40PB/2C
M_<B/[N+@/]]@,5Y1:F,]5,V#Y.DB2)>4/<U"ZT?.^!P4(D)\);8SFQ+QC,<5
M*1/!$F"$0,+B.AC$0&&&&(0MC7)'87VK/DD<`_\`>"4OM[PQN$5JSI5+._\`
M9*6]<_[%+,1!Z(<KVX!OO8;9A?70?HP&MH&PMM5AI2-?V_&"4<_!^^KEE@]!
M;:K^21PS_P!D$I=W]GN/K'B.-DL(80W`%]WT!?3P#LP=$.`:\L_&]@WVY6[0
MUM?06VJQ_P!2-P&W^R"4<N.K]]_?A!V%MJO?2-?F(:S!*.N[5^W?HQLE@`#N
M#ED%NW7,!W<NW-.B%M(=^0^-[VOE:_U6P&MJ&PMM5_)&OOO_`*()1OWV?N/K
MQ*+8VV5J^TOV@I0G.>J>K&"66QLFU.N=3WB7E99!SE+BY"B@B(0.JM5&)ZLX
MLD!+(CA@&((HQ@@`8@NHL&E@]=P$,ASMRR'*X@/&^%L`"%@#GEGF.5N&_P`-
MVX%^[?PSX9[^VP<[*'OE;U82P\=>WOMGERMIA<L[<<^W`)GNX7`=U_;GW\L\
M'J'Q$+W^_EJ&F%]PM[^^G:>_?@./KN`!<1"PZ_<'>-@UORW;^-M1QQ#>`:!F
M%K>`9[AO>^_EEA;\`OQ#PXVMEG:P=V\"W:&=[=@ZY\];<=^N`+V"^N_/3O\`
MT\QU'!H/"^_?<1O;0>8\L],('?KF`WTL-@]@CZQ'`+NS#QL(;^>GU]MB_KO[
M?KMVWR$<`:6'F'OK8._PTP<;^_A^G/``<L\@MPR[QU[.V^6#/QM?/3C;*_ON
MP9AEKS][WL'?IQR.W2PWO;U[M^[(+<!P#0;0%74=`:'5;K<NE2:IZ1THI_,D
M^*),D=!$Z3=,Y<NH3%GP++Z"$!ZU>MC"`L38P$E$E!2O4!YNC-`8_;*NVFQ[
M15%5^T',#1)U.J0)Z>4PJ`BJ<DJ4CFNG2TF<I2<)AJ"Q'S6I9):3-3U1%[2I
MI$J$A7$P*T<U&FE1)DZ4QK-<I)UDEVI$UTPG"7*03XWTPJ6ZHFTF4)^=6+XS
MMLLKT\PLJ]>K7RZ!A(O:5:Q(WAF/;?.$?G<#H)?GS?\`U<GJAJ)Y(]1462_*
M"2^CJPS4A';0G6C\\RM(E)6-\043IK,E$UK2])9I>))7J4IKV^UF?VHM96E$
MQ`T-9S?$E;&50Y'MY3H<$_VK;IV,GQ]02NT;45$%TQNC`,TM['!/"(AR5R["
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M+)<!%+ZZ`!E65G-"%JM;MOS8CAJ4JZW:MH23&]R`;4EK@,GUN&);(<ILRR*;
M9I(C*A-)C:93%@?()ICZT%,N',[DG>4J$](<7#%AU\I%L]2K7FJM,I]G^D,E
M4KI=1&DM85E>':M4H'M*L^K+V4VM#"ODA"4?,,O,@M[K*[HSU"7'F2K,44R-
MR!$H+4JDH&POVI_(F3NZUJEYRI1,%`*.2RT[+&U!2"=I2@>-HR?3W>K6VE3:
M:66J]66^8I\<9N>U`%3/,B::"DCH\$JGPT77X3(2.$<*UPB>X^0QVJ7&GM39
M`BKULSDD5+V!Z"[!RISA;JYQ'M$O4)GRG<](*CIDPR["4L>)F4T]3-R^5SXR
MF=M(<SU:5:I.2E%&AL)*=J/9N1RA/E0%5=*6IY(I<^MLL5&F@V;4,+5)$R/)
M+.H9F"8XA_7+<\/2>8&(]E;A3&*GDIW;S&LM9"I@'':Z25HI+7N32*AT3J+*
M=4Y$5+US6DG"2G&)VEY6X-PD@O3(W/J"25D205!,)QJ7KDP&1]7"?&86;"7K
MO;9VPS7VBU-ML*O!4IR5M"OE:*_[!%=93D.E[]/LH332J>-E>54TH+IC2/4R
M25,4ONLNQBG6&HH'=@7QQM[L4A<6F-<":`NT+R1DOO,G;"E*Y*>=G>:=F3XI
MNDY-S;3R;:DD57<'5N<WN*9OC^FFXI$U&Q()R<7YQ50,JMBE\UB6)%R`EE2H
MH4L9P6699YY;PRMK](Y9C;!;AW\>%[\O?2PF^^N5N?$?HU_26R\=,M^M^/'B
M.`,]0MIWW`1RW>W7!V9C8<QMKPR]>6$L.0;NT<K#E;?IQ&U[6TP:9Y:Y!<=<
M[APW<-;Y7&^`6_@`Z^WP'+Z<&_7NX?7?/7Z,&>6[D&8;NS=?=;U7+:=HZ:!>
MXW'[]_#7`%\@OK;,--W,>W7ARPGMRWAQ&P;K\,[<`',1POOX>W/CQ'!D/OG[
MA?QX"&``[;Z<\POW!NT#MXX,M]M,^_7AP'PPN$Y9!G;7=P#2P^.``'3L[1R&
MV=N%\^'//`'1"((H@C&$(@Z80Q0PQ#``@,001"$4,,40!8(HH8@`;",,0`,(
MIH&=@UL'K#PWC;+=8`QRAMTH1C`8H;P].&&((8HX+_A0@(PQ!`(@(A#$(1=$
M1`1ABMT1#7^J)Y3_`&K:<5_V[*-)I4V::F/>QQ-6R\WR5265V*I<NUMVID.T
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MH<_R8*IKG.5BIED^DCDM:JF/K2HG*5Y>(4II'6MR\)B3B;`O2)$:ARA2&MI,
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MQ4SU1FJ8*,R7+T<D5,@>UM54\L2]/X2`[MIDE0JI2F=9([FUS<U-LW%L4;W+
MKHVNC/$O3K"!BA]M@^6/V,2I"J75#9WVDJ$S_.)U+?U2:6D3J%6V^G$SHFMU
M99;>37A^E.0'-W@@EA>N%'-K(T$F3+*SE&C33,B84QBE<EZC1[R.BAVVM:0;
M21.TK"35B1]H1JVI9^7*:)DFRW4)\D.E<M4*E*3&27TU6D<=/Y:;:;IW/SM3
M$Y3F]NTZOBJ8U*\EF0MLI)H+U5_[FE86^G],]GHO;0?_`((HM(E=J<-[_'L_
M-![@]2UM"5!*JD[1JD@UD(3HWB77(]8VHG`@PU.Y(C2##FY"8EC+5!;N3MS[
M,Z.>:94DF:J38UU8JBWI#)7EM+*E35+',#D53:7JI3)!+\W'R,1+RAEEV3YD
M;)A<W=T<6LEG9UZ`)A!H>#C&LEJ*N>50V,J746KI6=OJFCJ,EH)),B3S-$HR
M:U3'%,[@S5;,9TM''1H3N[(VD+)3J8X3$PI9>GM(8KE02W(L\URZP($IK9R#
MY.&JLE[1[5M)*MK1L>YJ:J.T?V?6T@-FQH1J)/HU3)L:4<R2G31<X5A?VN4G
M"L:QG3.52)K=I9F][6PC&SHHR6OI$11H7^0;E&89*VH):G;:SJS/$Q;5]&:3
M4SJ+/\PR/+!DQES11^KS35R7)^1E$/\``A-2JEDO,,MK9&Z*9$E84)B=I?F\
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MF<4BUUF"8WZ)P@3(`N'I;5*GE;:>2A5FDTW,T^TWGUG)F"3YP8#3SFA^:#C3
MT\*M(*I.E5E1%*DJE&J2K4J5:B6)E"-8F3JB#28._:!H%@SX!O[>_P`>6(E[
M"^RU#L4;*=(-ELF?3*FH:/M3ZQM<ZJ)4)DI6\-SQ-K]-9`+I?3S%-1"=6B/F
M%2B,4DO!L"THDD\4Z6/IP12TMP[_`'&]]W/G@"VF6F8!EZ]`O?[L%_T;\M?J
MP9[@#?XYY]_>/B-B^?/P"W/76PB'T8!+;]XW#4=`O;,+VTST\<L+D.06'//E
MD/T_3@^_>/LW[K\..#+,0M<=_/3W[\`=_P!=^/#GINP<-?'VY\N?A?"Z=F?O
M[Z83?O'?PU&W+AO[0O@"^0Y7U#M]]!L&N5L'K$`$+W`+CE[?5WX`WY\>ZW;W
M7OXYAA>X/?+V?5@$TOO'PRN-K\@SSP6#>`7U]^S+/V836V7&X=MP&_$!U#+<
M(\L+QWAN"UN.6^_#3`&7CSW\-_8/+L#!RRTO;AGW9!E;+=G@#U!X<>'"V^WA
M@$-0'.^[V[[[\^65N(%],PN/T[[9CZ[:W'!RW"';E;OO?=<-PZX2X!K8-+7$
M->&5[6R]NF%X[[=^@;N?AQ[0,N6_UVO[<^-PP;@OOM?3+2X=@\,[Z=B7Y>%]
M0[KCSX6TRP7^FU[W'C>P9=GJ`0M@%[`MK?CVAKZ\%@X<N[/ZQTP![Z\OOOK?
MCE;!W9Z[K;\@$>RW'/P`X]OKW?1;!PM;6WA?AI@#@&X`RX<AW]_9D.>`+WS\
M0W99@.8VT#?8;A@`-.S6^_=??D/T8/?CW?7?/``:\^X>SCE[@%L`!8-PC;/G
ME8/T]N6`+]^F>[/!OOPRMP'>/AZM+WP6URUUW=^6_P`!\`P>(Y[]W(-,QO8.
M-]1`,`"`#;?KW#Q[K6Y".#/B&ON'+*PCKOMNPFN8[AOE?L`,]^X0#/72]AY>
M_+W&_MP"7OIG^@!#=Z\K7XX,M>=N\/JS#AKQP?2/N.ZXV\.=LSNN-]V=K^''
M,=1#7`&@\<A&^HAGIW[NS!]>>FG$;]F[LW7P:]F0\.SPL-^[`&[B```\;AS]
M[WP&$F9P=FB6ID=6%C-F=]:I=?G5BEDA62WGS,]MK.M7-$N$+U$)A"$Z8'-.
MD9BER@N,A&:NA5'PQ%%1@-2,L^4;VEG;:4KULT.^R=2-OFG9DI)0JMU75[7M
M)3@Y%E2/6`V3U4PII33KJ!-*=TF.E,N3,YO\R)G9Q9VEY*E-V2,3F>:I;HE-
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MTW"K.SU7UAK.S5.E!%4A@E.J;-+569LJBW4XJFH:S);J@1+L9D_S2W)3)6>`
M/E=W(8ITE^,'HM427EJ[>1WFB?6J39$HW4JD%"J)T_;-GM?*M)9>D>>UX03C
M1BN+I593%,]2':87RH,]2@B8Y@F26J7LLSNRE)(JR8'=:V,3,2OCB*"YJ?\`
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M`O2.+-$Y-YT*K'3G[RA&QZR31LXRD37.2IC<MJM\>V:BZB45I\RM,RDRZ0]E
MO+Y$Z-*92D2,J"8&49+4'GQPJBIO<$+4<C*AA6J$E7M.O(PSO2.7]AM'(LXT
M'*FW97VE*.UUJC/"XW:'B7;0*/9^85TB4S3KF1YF&=&*2IB^(#NI:5Y$MI6V
M7F(UG8FME-<F&(8&?L&S#Y(&K-`IYV#)]75UINZ.6Q-4G;&=H$K3+4\F)Z@4
M_P!K)0[.B@H8W`QJ-8YWE1<]+D$9'Z[EAT:X4RJ)?Y["H1J`OP$(@B$(@$!A
M$81A&UPBA$0$!ME<!#H]F81:X!#Z\M]K?4&"P:`&6X+WL&X+Y7RWV`!M>P9!
M@S]6H?1]&O/F`&=M!$-_B%^\0Y=N$WAPW6T$+9\[<0'(1Z.#V#WWN.7<(#SX
M7"P84+^KAORXY]G??/``6L`C8-!Y7M;[L*&@80.5K=^FGOX<\`A$.^W*U_6-
ML`>L?T7MX7MOPOJ'WUMKKA.`#G^C77WO@L(W[_`=P=F6NHAV#@#@/$.._72]
MKCGGZ\'`,^[+3U^&6>>[`&HCGF`<,K7"WOESPEQM?W#MN.[>.O+`+F-[\\PY
M\/IY\<%MW#3,=,[<+;PXVU$<'+36P96\,M=;=M\%\]VF?WY[[Y!VX!>'O^CM
MT]6$$`']/;]>FF#ER][\.5M1`=+8.(AJ(9<_H'=;AWX`SO;ED&ZW'0.60?3<
M#/34+!D.H<Q&^=[6'</C<N'9KOMV^&_!GE?EIQL-[\N'/`',,]=+;\_J\;XI
M%V[-MW:+V=MNJB6S_*54)`D^D-8MFJN];%CJ\;-CI5Z;I-F&B4MS.M1,B,)<
MFQ*Y3$Q3L[RZ0#LM4,R(Z4D;BH,(5^9H//0NZROS'W_1OM>V_%>E=]@%/7':
MKIWM;1[1%3:?SK2FEL_4=D:6I6D6DKK+;5)-5F-V8:D$JUDT,#B]NSQ,:5^=
MCF]X7J3#)5.5%`SIQ*2$08#H5*O*62/+VR-06O>V9$R4?G2I5*FNJD\MM,R'
MJJ]/I(DYUG9OD)MJ"\3=*Q;VT,$F.#R_RN0O`YY>5DN.CY$UGBXDMJQQ+G[1
M?;=V<F6M-8)>=)P>$3;L^4OFJ=*UU'.D^8?U'J9M+;*DEU#4I)NJ?`E,EYI?
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M'5XBDTMSPQ!.S>;,$$LE3`^2[+[ZJ4P"8D=`=E\"8&Q.,>)#5R\CE34F;=E]
MGEJN4\R*IV+4YIM,G25:/[/293,[@\2$R2(D>JGEII#:D\Z/39(K2VL,2]<3
M"<YKBE$QK3!=%JKK82R%_P!SM[.]/J?U;IFV;2NT(OE6L>SXBV;9D(<9<H\"
M]%(K55UAK:SK6EQ22N0>5,3?.["5$:M/ZTEP9E:AL5$A"4G-@"V`_;FV7F_:
M,E[96AJXUA7.8X6R!FEM"F<S443N^RDIGR7I8/FA,3\$H)OF"2$BF:V27E"D
MM8X,A?6PQEJU"1$IE?$9$9$,<4<1D4?X44<8Q1Q1B.^*.(1BB$=PB(CEJ(8@
MI2G8%I923:$FS:49WM4]S[4>6:5(*E!,5/Z6N)4RSQ2*4()&EZJ,N/2B5U,T
MTJF)UEZ"!/-+'3MZ:99>CB4RD4B8Y-!'%.D,N5@#+*P!IE8`MIPMKW`NX>_>
M/;KKI;=ENOE@^[VY<N.Z][9Z#@RY#PL._7L`?7SUP!KX6'CKXY`'Z+8`SW<_
MNL%[<-X=U\DRMI?*P!<<\MVZUM^HA<.6%#7<(6S$+:A?7EGQR[\'@&X./T\!
MRSRMP'`%[6O[A:^0B-QME<?<`,N^XVX>(^/:&09X.&_33Z>5N8ZX-_'=KVZ\
M;6L':.8YX!`[@$+@`9[N(>'MWX77M#U<0]\M!SRP"(!NUO?3UWXZ7[`WX.&O
MB'`<N8^K??+`&MM.._N[,N.NF5\'>(Y;M<K@-M``<P^K+!S'L\1T]@#V;L\%
MP#E]&GAJ&`4/4&7OQPF_7NOIS]FOM',R"UQM;N#/E[,)?@(7MD(VSN/;?4-V
M7;;(%#/7.PV[[9Y6R#776_9@'WU#?RN.\,_<#N'ANS#O'3UAV7N6Y9V&W#</
MMY7R'`5%>4%VD*V4(VK_`"=U/J>SU5-%3K:=J%6>2*JR-2:DM.*K5#6-M.*:
MM\VL:VE[5,4C3!,$4TK'=U`75*"]6WJ6M#`!")O`M6:HZK1/RF#I3W8$8-J7
M:L)752<1?Z]&OSY0J5Y=3));DFD\T*2$[;5$Q<]RU(,G5H;9;`I._4Y1NZ=V
MF*9TBYFD]H<'1*K30SUK3LA4YKM5VB%;YMFRK3+/NS@ZS#,%&5,C3DR2\U2;
M,<VLGQ;F>8"6M=);\+DZO3'`G;U)CJL5I$L"5.>UHV]7":>:P,W>24V(IVI!
M(="'R19Z&F-/'ZM,UM3`@JW/"0UZFO:!:GIGJ?-$ZN42\];-C^ZIW]S-:')Q
M,`R6CSH"62!*V%`VB$A-F;RF&SU-&T6Q2%+:.<W"7UNS.S[2\R57<@DR4I"D
M*AD]4\<ZHL-3IF1SE-[#/:^2$[/+`,4U35)\I3,QR1.C_+<L36J;%K@>8BK"
MVJ_+7R97^<]E&;MA6=YC(;ZA^4'V2J"U+8IPD.4.A4JA.T`V3*:D=&!1,"=Y
M.EE2^*I.5,B13`Z2K.TC.D:Y).3.VG&H(D]N.S!Y/C9E8*DT6/62U,LY%[/=
M&III12!!/\W*9I;9.I\\TIERAS]*J9(8A1`X,<P4_1J$[ZR.ABQB<IB>Y@G`
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MCO3-X1KJYJSJ0S?7R>Y#2.=4VQ2@:IGVGVH66N2]021(2-0X03RW]`HU,I5B
M2S1EP&,0-T0F=8XNS/Y,W9?V1'Z6)FH05524GV7*7IZ,K%T=3EROXZTV;IQ<
M9[89=G]*G:&]',,<N3$ZJXV5Y3)VA]@:>HE]R<G1E2IT186!"`PQ1!$'1BAB
M&".&*]X8H!$(H1#2\(W`;9!81N."PV^H1[L]>T<*(YYVSOED`=@!D%MU@TR"
MUM#V?IT]7+A@$X#E;=F._0>`WW<-U\)8`MP#+LN.=_?ZP77(=<LN_OR'?GI@
MY#?V;]0M[->-]X'LMH.8_3?GKWX-,N0VWY!X>WOP>`:`%]^O?Z];Y!O0<]X<
M1R`0MNU]0Z9#@%X<,[WX9ZW'QWB.N`;=N[GGNN([\N%^=\&_P^GE[1MV;TL&
MM@OXVW\MXZY#G@.7N%N'CGVX3/.WKOKVWT[`XX-U^P=0Y6][YCOMA,M;VL(W
MTWCZO;81#4<`>]M+!NL%[9#;,.[2V%M[Y]^\+\AW8+^(WX7WB`<-`',<LL`_
M=?0>(6XYY6'+`&F=N/CV#;,>7$<\[B?0%MXVX\QW<!\<&\-<@]Q[=V7'G@[+
MZ\N668^S@/>"^_C]_P!6$WZ>W?:]MPA](<\%^&>5_?[_`*,`]GL\==WZ,`:[
MN\>SAE8;Y#I<,+]>_/WY</5A`'7/A<.''/WTYX7W]_#`<=>`ZAVZ:6O8+ZZV
MMX+NMD&O=SRM]'<.$R]=\Q#6V_L#/LSSPO;H/O8=WZ;=H'K'+]-O?3?;`'?W
MZCV\?9P'`-N?//(.T+V]N"X7W"._CD(>S]&`,_?/UW]>#LR^[+=W8![-1#A]
M/OGEG@OX^H1S"U^5N&F`+?=EW7XB(97'V9X3(=]PR&P;N`WR'3</#+3"]@<1
MX>H;:^W7!OU#+[]>6F`7WW_7X<,)R[-;CX\!OH(B-\'J[;<Q^_UX,]^>7*_9
MV\<P#2V_`&@96TOR'2_9?Z;YYX,^[V\PSRL/Z>!EV7N(Z:7S`=>/WA@#=F`V
MRRM[[N0;[:!@"]^S,.T>79;OX6P>'TY#8?H#Z=,(`AIV[[WMNS&_`>`<=<*-
M_7EG[]]K9"-KCF(%^.6=L_5;C?7U;L`AIIKS'.]PWA??EN[L(-_6`99AVVY#
M<`OE>PCH&%&^ZW(>`A]>@\,^.`A=MK[43CLTRS11FDUI8GJKNTUM%4SV9Z/H
MYJ%T"44$V5`6'FNDVS5\#B6X*&.3)80.CV:U)5*%0^+H$#44L30J338/H_U4
MJ=LV&SO4;:IJC2*/97IW1`F:'^M1,GF4[F=-54RHB5L/:'F3$,RS0D)ETZ4%
MZ%-*9,MEK5;S,!XIW-2#L>B1FNQM`[/%/-I*4I<E:H$+XB/DBH<EU;I]-DJ.
MOP)-TA5,IZZ`ZRE.$MND2=626L;U,1J=:WKDBMJ>FQ4K:W1(<E4"$#:5JV/6
M#:;V>*F[..TI4F=:LRM5)F1L[R\I6:2J9N#3$T3,W3?+[RP,LDLQ,NI)B9'U
MG:5)+NJ2+!5DHO-#DY2=2H@B#H1OE,MDPF<Y(IRH?ZED5`GR::DR"WR2;1N>
MH)HE^HE)I1)GZ>J<3ZSBC\YDF>FN25C;-:-A>``'=C=FU:V+%'G$99#(O7EP
MO)N,DG(Y]5UDG`^4W6G+;59D>D%%JFJD[](J^;AD!R=F'I,9$;N;)L[0Q2I/
MZ!$$:J4'PLY$O@,%,KC3AODBZ8FUKD3:%BKC5,*KRU5VIM<IUF&&3Z4P)JKU
M$JO3]OI-,2M_9RI?+0RI+[?31N+EJ698DZ%&A9%REQFJ`Y2]KHXH*HMO;R!4
M<I[#[+*VR9-5?:\UDHS2U506D].EC/2!.5-DA5(VD#JX3JHF]R/*E@MO-E96
M]3$L0/[:XI54:<AH:3TBN$\^(0OE\I-Y2\R6J$4&F#96G.5G![9O*(;,FQ_M
M$T\J+3IWBF>74%96B-R+$6IT<9>=99=%TGK6><)&F4E.\,[^S/R=2GA-$@\L
MAJMH7RNFQ/01%M*)3JC'3O/.S9+<[O+_`"!*C0M5+IG>))?&F4WJ4I3?E4*9
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M]34LHME0$DD3PS&HX54EOLQ2&\M4YRG`ZAYG,<N+BUR%:!A*Q.FCO-_D:J%5
M+G*K4S56JQ5:H+-6K92IGLASG)JYEIJQ-T$AT?)D=13>:6![8I;)>6>>Y8F:
MG[#-9#B'G;>L6P1MC@@4M<,,`Y;_`#(^F?ZL%-*^!7*J$-79%KHU;0<R38$D
MTDAAJ=.TN4]9:1RHWS$S%2X0VR]*4M4Q:#Y<0LDJPI8E#L]O$XK5AKT<060%
M@NS[7^DVU+1V2*]4.FF&<Z75"1+UTKS!\'.#,>I!I>'"7W9(N:'8A,Y-3FTO
M34XM;DWK"8#TRM*:6/3AZ,43R!GZAR$,MW',!S'[P#$2=A[9$E785V<)/V8Y
M#G>;9^DB07:<G"5G:>&^6T,R(4$ZS0Y3BN95ATKH6]"Z%(GYY=ST;DJ30N,:
M5:6B41Q$H4MI;`%@#+,.S.WUV_0.`-.S=D/T#H%],O5?"\^[?[^K+CA/7IOS
MUUMIN&W9S&R#E:W&PY\>5\Q'CKOSSP"VW"&0\[AO'N#(.6=L&?(.5KV[[A@O
MO[M0MKJ`^_9?!:^8W\1#U`.6`[`#*0&7G*OO\U_R7!\"D9?KE5EN_6N?;^M>
M_MUP8,`?`I%K><JM_P":[_\`V7"_`I%K><JA[?-<^W]:X,&`/@4C\Y5;_P`U
MW_\`LOOV8/@4C\Y5:W_TK_DO?VYX,&`3X%(_.5?BE_R7[\+\"D?G*K_FO^2X
M,&`/@4C\Y5?\U_R7"?`I%K><JM+?Z5X6_->&#!@%^!2/SE5_S7_)<'P*1^<J
MO^:_Y+@P8`^!2/SE7_S7=_[+XWP\%#6LE//0GPG*(XH6%U@"&/J.A8U0V](1
MZL@N*X=6%OP@#,1$!&UC!@.JUN_*3,`\$[*/_0Z;#4`%K\_?W^X,&#`%M.06
M]GU8`S\1TY#]V>#!@#?;D(^P,M^\?'"`-Q"_\4![[^'T\\&#`*.09<0]8Y^W
M'&$;C$&X,@S'GW[N[=;!@P'*P>]_>_/7`'TB'@(A[[KWP8,`6RM<>W?^G!O'
MM#OR`<_'!@P"0YWY1#;W[\%_PK<K^O!@P'+WX^V^#!@P"!H'8'LP#D%]X!?P
M`=?$<&#`)P[8@[L^/8&.5LK?5]5O5@P8!Z*!A^V##_@Z\A__`!VOW#M'&&K,
M/[9$P!_O<'_1Q`_1[<&#`-??\&_*_JP;P#D(ZCN$+;\^_!@P"V#A[CKA-X\A
M^@/?+!@P!O'D/JL'TX`T#F%_',<&#`('"P9:6[8@]@84!&T//7P$<&#`+8,N
M6G=@P8,`F^W"PAZP]F.(Y"%LKB%P[;AW:;K<[X,&``$1$.[UPB/M#'(-`W9;
MM..F#!@`=P<1^@1W_3<,)O`-V7/B/CE]>ZQ@P'*W;X]GU>WCA-X]@>T?J]8X
M,&`7!8/'7!@P";P[!X[K;M-_#""-@RYZ\@$?HP8,`O'D/T`.%P8,!QN-NV$1
M\+9=F?;SQRP8,`E@[??Z=X:<M<%@WY]OONP8,`G\8=X7`/`!]N%O^%;=:_??
M!@P"^_ONP@[N8_0(_1@P8!`S$>6GC$'K``QRP8,`8,&#`<1RB#@-[AS#.X<!
M]]<<K=_AEV98,&`,<8P`8(K@`AT1&PA<,@X#@P8"9U6$12REK#!'&86!)\N'
M0"5U0#TH&\XL(1`PLR'H=$R*X!"`W`+"`7`8I_`I&GG*K._YKOU_TK@P8!/@
M0C+]<J\O]RZ<!_6N88`92`_TRK_YK_DNGOK@P8`^!2+6\Y5A_P#*?Y+W>W"B
MRD#_`*95AV>:_P"2^XX,&`/@4C\X5?\`-;>'FN$^!2+W\Y5Y_P"Y?\E^[!@P
?!\"D7_JE5EN_6EO#S3N[,+\"D?G*K_FO^2X,&`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g477671.jpg
<DESCRIPTION>G477671.JPG
<TEXT>
begin 644 g477671.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!"1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]$04E,7T%615]&4$]?2U],24Y%+D504__;
M`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`?_``!$(`<P"20,!(@`"$0$#$0'_Q``>``$!``,``P$!`0``````````"`8'
M"0$%"@($`__$`&H0```&`@$``@@/"P<*`P0%#0$"`P0%!@`'"`D1$A,9(3%7
ME]44%A<8.#E16'9W>):TM;85-T%4@9&4L;/2U"(V87&8M[@C,C0U<G-T=;+P
M)#/1)29"H5)E:)+!X4-%1DA68F.%DZ73\?_$`!0!`0``````````````````
M``#_Q``4$0$`````````````````````_]H`#`,!``(1`Q$`/P"$>??LV>4O
MQS6?]E'Y(N5US[]FSRE^.:S_`+*/R1<!C&,!C&,!C&,!C&,!C&,!C&,!C&,!
MGD`$P]10$1]P`$1_,&>,ZA=$/J;66[N73K7^W:#5=CTU71.Z[0-?ML2E*L$K
M!4H&.D:]*MP.9-9NZ8.U5#`9%4A5TU#HKE4()>Q#E\("'>$!`?#U"`AWO=[^
M>``1[P`(CW^\'?\`!WQ_,'?'.O4!QFU-R/X!:=Y(.4M;\<]G-N9D/Q2O-SA(
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MC4RM&LA)%=A3YMV\K)I#MR*DF\BW2_H%F4Q$0#`L9UBY"\&8&A]'_J7?51J]
MX8;9U7M.PZMY@H6>&E(1$DSL)E"VG6DK6T9`IVS^FU8SUIK=*U1AB1DG./I%
M1R456X*#KZ\]'X>,<<;G&N-D2-^J_+FAZ<?Z&MDG36M2C)W;NTMAHT&=U%/E
M],4S]RG&K%"2<K=9I@M*/"-&+<[:`!.22[2'-[&=<ZYT6C6>Y`4_1:W(*&C'
M%G;<KV$C(*5^MO[)4;+Q8-(J+/;)1X38DN_C==;6C619FBV=Z_:6!LS^Z#65
MJHR40X:K8CQMZ/?7/*R\M:AIKDXK:&DA/4NG$ECZ4G:Z]K\_:=;3MN>V*Y0M
MGML8C&ZTCKK#$UA$3,5-RMPMDN\4F8:G'CXUVD<.76,Z74?H[#3^IX79=JW"
MG7%9GCIRMY+&80-%);8:)JG%*[QM!L-/D[`^N=113OUOF7JZ\(Q[4E'QK9.-
M9OEWDM,(,VV'\G^!5@XNTM],VS8]8?7:L2FFXJW4(YX.-?NAW+JY#9+:7URD
M6TR%EMU>H+EPA2K[)354J9V\V[82D4U=P;D5DP@,"'$.L"F$/=`HB'Y^K/SG
M>CBYJSBLQX/<3=\;YHG')G`2/-W8FM-_WS:L(Z-8+'H.%I=AEG%=K'I=`]MF
M+^S=IM5:DI4FQK(FY;-E53JQS9^*DRT;@)2.1T%NW:N@=G2$=1(!MRKO^NZO
M8*D]>FKU)T7((3E+I&T;=*3<2[9WO9.O7IYZO)U>&N2L.TB>WW9&/-(D6('+
M(0$.KK`0ZPZPZPZNL/=#W0_ISQG;&X=']KBZTW4]F;VV&U%%P'1,-.<]HD*3
MJF3F9.[FJMG1C["VN#&5VPLF_P!A33&>9&+8Z^I`P+E2/*S4K<:B)'R<#<G>
M-L3Q6Y.I:5G;3);&J+5'3=P5L,1`&K%BG*%LV!K-S6:(U].5L(1=K;P,P]B2
M-FDQ*(FET$%F;@Y5B$($D"4P>$HA_6`A^O/&=X=S<`8;;BM:D^&OK8=K<?.0
M?(;6VN-/[JUZG*TS8/'0+(_F1/K#D!27C]U.2I30H)+/[:]C'5P>R%;[8Y+%
MK6I*)5B-IPJI%EMFRHO7V_!M=<T#HO?^[N1+EWK9Y7KGK-/0=YEJ&O38^L.[
M,YA[;,[%?HUZ4I[YC9VT?&0\^X/9O0SJ#71?ASZQG6Q3HR*K5Z]O>\[6Y)*4
M'76EX?A[L%O;V&GI*ZKVS4O,!)52MSI*G#6]&<B[M4EV4G'2U0(>1C9!XQ.Y
M;6-K&J)+J:=M_`>0I>C&&Y)O:4)%FL>FFW(FDQ$XPAH-C;]2RNVU]<0+*)</
MKB2T.]M2U50-MY.@1]0?L4JBD[A`LJMG:JM2ASUSR("4>HP"`^X("`_F'-K[
M*KVN:1MJ6@-1[/8;UUW#S,(2M;*5HDM3(ZY-G#:+<OSKT6V'=R3!!G(N'\(N
MUDC*D?%8F>)`#=TD!>U_+KH^=.W?I`.8&H=;.H7C;J_C+PTB>3B$31-<-K*T
MDT*U2:O.W&)^YAK16W8R4VXGEWK.15DWW:E6Y6'H=%`Y5B!\_&,[*VOHZ]-Z
M=UCSDM][V9?;LIHOCYQ+W!JB8KU'A(`SB+Y36-@2-?V2JO[RZ+Z9(-..DZR[
MBT[*K#,H^47L[=>8E4&,(W]"/10S,)LC4NI[UNN`K-XNNU..NL+E!MXJN/Y*
M&-R)H/IT8VC6\.O?6=@V1`ZT?N(RI;$6DH:E"63DD9*".ZB4CKG#D1C.YFH>
MBGUE(<@.%\#:]RV2_:CY&;?Y.:KG4HBB)4"RM+9Q4DK,C.Q!#O;980])=[)5
M7@-[,CZ%LD>U4,W)`(.7*+]C&7`3CMIWD]SQUAH>UREW/J>V6>VJD,A'Q$%:
M)MA4:[-6QO!3*;6<F&E<83`P;B*E'D)*S,DV8'($<J1XY,\8!`&>0*8W^:41
M\'@`1\/@\'N_@SIGK[HZ9#;-,H=TIVPG3%;?33EO/\?ZW8*BP;JSL!Q)A8R7
MM1=@R49;Y)O2Y*W/G<K`T]K#)VUJV&(;2,\]11E.TL9IXES-=?;;U/KB?UKK
M>[Q>T][:+@YN2OE3;6>5CZ=)7)E!6"M5T7BY6\$2T-;$!IV2;I+2)PBHY!FX
M:$35.L$Q"4Q?\XHAX?"`AX/#X?<_#GC.U5KXK:\Y(](#R7X84V&UMQTK^EKS
MR@N5-OM+ULFX>*4G6<)"J16M[@R9SD4K,0[-=NXD(NSE.ZG8E1_)(G8S*2Z"
M*&DM6]'C5-S5]38]!Y'QIM)RFSJKI*I[>NVOB:U@#;*DM+/ML71U?8V[7N*?
MTS75$E4H:B*61D>R3UB?6-C.QM:2C&+Y,P<PL9T9:='^J]XI7;D^TVJE(,M<
MZTUYM&V1$94`7KYF=KV8_P!:W*A5NU/K+'.[#L35[IO'2<ZHSKIM>RXR[>'8
M7)J_05,/J>DYX\:HXF<DU]+Z>=VA[&U#3FI)2:>6YE&&<2EIG-?QUA>V('+6
M3D$I!>QNG:LE+LE(V'C8=R*<)$LWL8@5XH'/X2'`.L2F`/=$H@'?\'?$/PY^
M<^BOEUJG@EI:(OT3L.@:,HXW;HZ-);#T+7M<Q$BSWN\Y<VU&<=*6!HE73*IQ
M.MY5)JW],PWI5"HN@0%O%"#Y)Z164`Z)FRM=@L-;2NV4$+!6=Y\0=&;M.PIR
M3EA2);F+2XNT5&?H[A>T(GOD92I*6:UJU-)1*HNWK@WW5ACBS[)%,.0>>0`3
M#U``B/N``B/Y@SK[`=%I!V^[:CA*?R#D)FHWCFMM3@M>[,\U*G!2U"VEKF&F
M[(PL,/7'.P7A+G3+-!0RBQ%EY6L2L:]5(W49KIF[:GO#A]T=6M(/DMP16V?(
MP^[=><F-@\VM<6C7%OHZ#"*BUN+YK14T90'K>QR:DF%@F&#&R1_8H1+N`.W!
MB=21*<ZQPX(YYZA'P`/>#K'O>`.OJZ_ZNOO=?NYT8KO`%:V\3-G<J(3:";IG
MK#4J>Y9^O-:6O]P4V*&RIND6G6S:TR%AC'KO95-B8YA:I%&.KCZGJ)SD57EK
M)'R1U'06MMW@AQZUE9^5-$H*#BP+Z6Z*JK\CG$IM*J&E7YKN^<0\W(WJH259
MV)#DA+[+H.G#%,DA!2M2K4:!8EI$3A#+2"@<$,9UI[E1:DRR;-QM)J:PZYE>
M$J6\HIG4TQ94R#YOR2<549*D2KNS(#>W^O'DC`I7&-?,*NC)C)N5*^],E%*&
M=Z_YE='Y%\6=?3&P:WN9YL]A5.5^R.)=K8RNMBT%PTN%#J+6ZH6"$61NUN),
M0DI$.1:N"N48I=E)I&(V%^S,5P(<UL8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q
M@?SO/]#>?\&[^CJ9VHSBN\_T-Y_P;OZ.IG:C`AGGW[-GE+\<UG_91^2+G>OD
MST1'.W?'(7<^YM::KB9F@;,V#-VVH2KFXQ<>X?P<@#9)JX78+('69JG,V5[)
MNJ83DZ@$1$#`.:.[A=TDOB8@_G[#_P`-@<A<9UZ[A=TDOB8@_G[#_P`-CN%W
M22^)B#^?L/\`PV!R%QG7KN%W22^)B#^?L/\`PV.X7=)+XF(/Y^P_\-@<A<9U
MZ[A=TDOB8@_G[#_PV.X7=)+XF(/Y^P_\-@<A<9UZ[A=TDOB8@_G[#_PV.X7=
M)+XF(/Y^P_\`#8'(7&=>NX7=)+XF(/Y^P_\`#8[A=TDOB8@_G[#_`,-@<A<9
MUZ[A=TDOB8@_G[#_`,-CN%W22^)B#^?L/_#8'(7&=>NX7=)+XF(/Y^P_\-CN
M%W22^)B#^?L/_#8'(7*'XS<G=F<2]A.]I:C0IGIS=56>IA7]SK2UI:LX"T)(
MMK"V91Y9B);)K2S1!)FX<N`='3;%$K4&ZASJFO/N%W22^)B#^?L/_#8[A=TD
MOB8@_G[#_P`-@1O%<UM\5F4T8ZI4C3:!7^-UW7V1I_7E+HT/%:XKMZ>JB>3M
MLK6WAY1W<['*(F.Q=3MSFYZ8;1IQCX9_$-B(E2VR7I/.4Q[!1+*[-IU[(ZUK
MF[:E2D@T[7(:.A:YR%>J/=H12;"J.JX1=M+&7=(LNWJ'.R([<NUSOY=0LH3=
M_<+NDE\3$'\_8?\`AL=PNZ27Q,0?S]A_X;`TIKOFHZ).::V3>IZ4I>Q^%5"J
M%6X@L-2:]B?2_,1T#./G3^C;;D[%:G[M&&.PD'*C*<:QTB9X,C.Q\XR=MW$>
MFG$E3O<O5=@0FRE&%=M=AA;4C=1:7:(4L5;F+$C)FFP<S\*9\R-+-3S)ONBJ
MQ7?%1<+$(1T+A'MJ2O4;N%W22^)B#^?L/_#8[A=TDOB8@_G[#_PV!&.N>8^W
M-8USD#3X-E09BI<FX\T1M>LW:N35OA7L860E)=JVK[22MI1KRT9+R[N6B95%
M1U.1TB1HX0E0%HB4-:>K]N`E;TE4V]ZF64)QSG[':],H,5$VJU(L]KMS"\S-
M@CW!""9:65LT8P?M7+DJH,B-2-$$RM3K)J]&>X7=)+XF(/Y^P_\`#8[A=TDO
MB8@_G[#_`,-@32UZ0G?S/?BW)9K#Z/9;6?0=UB)N2A]+5FLP]HD-D0X0%_NM
MLA:DY@"6._VV&%5A+6:3=+=2;ER>/8,55A4#&^/O.?D'Q@@TJUI^3HT/"-=P
MPF](YI/:XK%O5AMA0%;D*:R?P<A8D'LG$LU*G)O:\Y09O$Y#[EN72+*68*/Y
M-5]77<+NDE\3$'\_8?\`AL=PNZ27Q,0?S]A_X;`]%2.8/%131=.UENK0,%LQ
MPE%;@D]@F8M-D:YLCB\[*N5EMH>DAQK;84'JUY#E=.*B=E.7ZL+S4(E#&B%X
MN2C(:!*M&&Z^5>WN0\/3F&V#:_FYVI5FLU-SL**UG3Z[L^[PU-CB1=39[&V!
M$QS>?N:5:8E%M#E>JMB%*)7#])^]22=)W9W"[I)?$Q!_/V'_`(;'<+NDE\3$
M'\_8?^&P(1E>4&QICC96.*3N*H(:GI]YE-EP/H>L/T+@VODVU=,)BR+V<+$<
MCMU(QKUQ&N&JT2,85F8A6S%NLBDX+L;5G/[DEIO6E9U)29:@$I=1A]V5Z$;S
M^KJA99E"!Y!M6[;:$,I891HI+&C)M5FR?$:(KMTA>L(\LH$Q',&4<A5'<+ND
ME\3$'\_8?^&QW"[I)?$Q!_/V'_AL"<3=(CR`4KS>K*1NHSPK7BD]X5(MAU^_
M`Y./$D\9OW]2!8EO(<)-R[8-5CV0@$DB"F)4>U%,(9I;<G)K9V\]P06\[J%3
M:[#KL?KB-CGU8K9H:*,EJ="/:4==Y#.Y.8;NG48RB8QBX,*I&\BU8H)NFQSF
M<*+WOW"[I)?$Q!_/V'_AL=PNZ27Q,0?S]A_X;`A]'EUNN(45<TB3K&K'\AM2
MH[OL4AJFGQ5&7MFUZ#(2TK2+C86[`7$692J2$[,O(6N0<=`TILXDW:IZPL<R
M8I9!9^;F\;7MFR[C=I:OAK+>ZA=J+LB$I^JJK3:+M&M[,9^@]DMMDU6O),26
MY_?>I)[89Q]($FB2C5C)03^#=,6AT;`[A=TDOB8@_G[#_P`-CN%W22^)B#^?
ML/\`PV!(-AYP;ZME,WO1+,]IDU"<BBZG;;`.ZJ((/V,/HIJW9:?KE$4CY9DP
MIM<U^V;E3A(IG&.R+"HX4EUI-9RNH?$9WE3MFSZ8H.C;&%`GZQJQ![%ZYM$U
MK.G2NU:95)&7+/OJ#`;,?QSBQ,Z&ZF"E>K5SLCE.0!C1>?<4QXPUV=PNZ27Q
M,0?S]A_X;'<+NDE\3$'\_8?^&P.<>TMW73=&WYK=VQVM1F[E8Y6(EIMDPJD?
M5Z>_6A(V.BF34:M5#PC5HQ.SBF97J3!PT<O%@6<K.Q7744&H+'TE7)2U;6W%
MNJ71U.IL+?6BI'CCM&4;Z\=-V<_JV4CV40ZCD(L+6=K%3'W)C6$:E.,.U+IM
M6B7^0.OVQ=3?G<+NDE\3$'\_8?\`AL=PNZ27Q,0?S]A_X;`EVX](!R'O+;94
M=.J:V/![=TSJ[1-]KB.NV"T!,4?2CQ1]JITG'S$C,&96RDKK*C$V)LX("@'`
MTA'/54FZJ/EST@/(B1N^C]G31M63^S-`FJ`T_9$MJ2J#L&Q):\04;T!ILVZQ
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MV1!TDX;@=!3J)W"[I)?$Q!_/V'_AL=PNZ27Q,0?S]A_X;`D^O\ZMX5?DCL7E
M;#,M9M]N[5A[O#79PI27:]6DR[(;MFEXDD*T>S@#"7L35L"+MRWD@:H`LX,Q
M8-%%0.3`-8\I=J:GU;L#2M>1U[.ZMV+.PMND:7L;6M4V3#5V\5MJJPKU]HJ%
MP:2?I3N<-&JFC6DTV%UVQF1`K]J]6;HKDN_N%W22^)B#^?L/_#8[A=TDOB8@
M_G[#_P`-@2L]Y^\D9+3;K0\A+T!YKU]HN`XYODE]74\]F?:OJEK=7.LQ[RW>
M@PG'$K`3S^0=Q,DHX%NR5D'[]*-"==JS)M0[]Y%;-Y-WF/V/N1U7;'<6E4J]
M.D)EC6(ZO+V>)J,6VA8M>U_<46IIB64B&C>.>R)#LA.V2`K)"/,90Q^@_<+N
MDE\3$'\_8?\`AL=PNZ27Q,0?S]A_X;`@_DCR?V/RIG*C8]J1U#2F*50H'6$,
MZI=7=5@IZ+54G*%:@9%LK/3#=ZE!H/'B+)T";=Z9)TJ5XX=]20I4AIOI!=F(
M[NX_67>5I5D-=4+>_'C;.VI*M55NML#:"''2.CZO075R>I/$%;E/5&CL1K]:
M*)X5JN[43F[`:2FTQF"[@[A=TDOB8@_G[#_PV.X7=)+XF(/Y^P_\-@:-VYT@
M6X'^Z&EMT[:(>I4;6?*3:G)W3;2$UK7Z<HO?=B65\_->=BP/8/DK+;UZJNUJ
M$LC(K*1!8D))FP:)A*/7KOV#+I2.4<?;]-7AFTTFSG^/]DW):M3_`'/U"PB8
MJLRN^EG3G9/90L-.QL;)MY5R]<NFH2*"[UH[64=KOGKE114^XNX7=)+XF(/Y
M^P_\-CN%W22^)B#^?L/_``V!+R?2"<CD=/2&AD'6LD]92>F9K0+N('4]2<2J
MFK9BW2%V)7AM#U%U8S_<.;EI)2NKKR2Q(XKQ=TX;R$T?[LA_;(=(AR/FU+VZ
ML:NM+)*;-XW,.*%[G);7+(DW9=-1R*;=O%R3^&E(<%Y\4&[!)2Q*(&7*6.:F
M;M6ZBLD>0I3N%W22^)B#^?L/_#8[A=TDOB8@_G[#_P`-@2>ASWY+)QM9C'%J
M@I$E?F=&3<J_?U=H:9V,KQH4=*Z'CMJ2S)TQ>72'UJ=VH:'9&4BU9(R+!6SN
MYYQ&1RS7^+>'-[=W(6D6.@;%3U\:!M>^;#R4F5*Y3G$'*K;;M4"2LS\VB_-8
M9$B$=(0B:;$T,#0S9(I"JHJ)KAVS*][A=TDOB8@_G[#_`,-CN%W22^)B#^?L
M/_#8'(7&=>NX7=)+XF(/Y^P_\-CN%W22^)B#^?L/_#8'(7&=>NX7=)+XF(/Y
M^P_\-CN%W22^)B#^?L/_``V!R%QG7KN%W22^)B#^?L/_``V.X7=)+XF(/Y^P
M_P##8'(7&=>NX7=)+XF(/Y^P_P##8[A=TDOB8@_G[#_PV!R%QG7KN%W22^)B
M#^?L/_#8[A=TDOB8@_G[#_PV!R%QG7KN%W22^)B#^?L/_#8[A=TDOB8@_G[#
M_P`-@<A<9UZ[A=TDOB8@_G[#_P`-CN%W22^)B#^?L/\`PV!R%QG7KN%W22^)
MB#^?L/\`PV.X7=)+XF(/Y^P_\-@<?7G^AO/^#=_1U,[49BCCH*^DG5;N$BZ8
M@NS5;KI$Z[]#`'9JI'3)UB+?J`.R,'6(]X`[X][+X]8%R@__`'&8?.%E_P#Z
M\#ZUM#@'J04#O!_-]#\'_P#/<9MSJ#W`_,&:DT/]Z"@?!]O^W<9MS`UA8=U:
M:J4X[K-JVOK.M61@W9NWU?L%\J<+-LVL@0RK!RZB9*7:OV[=ZF0ZC199N1-R
M0ICHF.4HB'J/7%<??'CIWRG4;S[G)V,XI<;N0W2M<Z'6[M*Z\V>ZA]%</QBW
M-PK[:778BYC=A(+BW46$#)]M19MDC=B(#VM$A>OJ`0&TNY<]'I[S[1/S(9?O
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M7[^.Y<]'I[S[1/S(9?OX%(>N*X^AUB.\=.@``(B/JG4;O`'?$1_]O>``[XYM
M.'EX>PQ4;.P$G&SD),,FTE$S$.]:R<5*1SU(J[-_'2+)5=F^9.D#D6;.FJRJ
M"Z1RJ)*'(8##!DMT7W1[HQ<DJGQ`T44Z<>^.0P4AD`E,5HL)1#^7X0$`$/P]
M[O"`]0AD?1G))(='MPJ003(B@AQATN@@BD4")(HHT:(3223(7J`B::92D(4.
M\4I0`/!@7"(![@>$OX`]T,A#J#W`_,&7@/@_*7]89"&!2FA_O04#X/M_V[C-
MN9J/0_WH*!\'V_[=QFW,#ESH?VU/GU\1/#?Z%LO.HV<N=#^VI\^OB)X;_0ME
MYU&P&,8P&,8P&,8P.<6Q(J\[6YXV;4J.Z=M:YHM6XB:NV&Q@M;68E=;NKA:=
MU;?K4M,R0BS<G>+*0=5B&"1!.0J1$`.'\KK`VT_6D3?OJ>5'E,)YLS%8?VSO
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M;,LK&!&OK2)OWU/*CRF$\V8]:1-^^IY4>4PGFS+)ZP]T/SAGG`C7UI$W[ZGE
M1Y3">;,>M(F_?4\J/*83S9EE8P(U]:1-^^IY4>4PGFS'K2)OWU/*CRF$\V99
M6,"-?6D3?OJ>5'E,)YLQZTB;]]3RH\IA/-F65C`C7UI$W[ZGE1Y3">;,>M(F
M_?4\J/*83S9EE8P(U]:1-^^IY4>4PGFS'K2)OWU/*CRF$\V996,"-?6D3?OJ
M>5'E,)YLQZTB;]]3RH\IA/-F65C`C7UI$W[ZGE1Y3">;,>M(F_?4\J/*83S9
ME>GD6"9SD.]:$.F/4<IG3<IB"'>$#%,H!BB`]X0,`=_/ZDU$UB%42.11,X=9
M3IF*<A@ZQ#K*<@F*8.L![X".!''K2)OWU/*CRF$\V8]:1-^^IY4>4PGFS+*Q
M@1KZTB;]]3RH\IA/-F/6D3?OJ>5'E,)YLRRL8$:^M(F_?4\J/*83S9CUI$W[
MZGE1Y3">;,LK&!&OK2)OWU/*CRF$\V8]:1-^^IY4>4PGFS+*Q@1F;B5-D*8P
M\J>5(@4HF$"[+*)A``$>H`",ZQ$>KO!^$>]DA/;#16%B-5%]_=(F-@!D_DDH
MQ*+MZKES&QKXT<[D6J9*\)G#$CLO:BN4P,D<3$ZC?R@SL3DNR@B',.J$`QNQ
M];_:1['LAZA'T]1??$.OOC_3X?S8&%1O%:7E(]C)(\I>6*",@S;/4D7FQ!:.
MTDW2)%B)NFJL6"K9P0IP*L@H`*)*`9,X`8HAG]OK2)OWU/*CRF$\V996,"-?
M6D3?OJ>5'E,)YLQZTB;]]3RH\IA/-F4'LK9T3JZ+8RTO7;_8D'[PS)-OK^B6
M:^R#<Y$%'!EWS"L1\@Y8LNP3$H/'*:;<51*D!^S,4!PS3G(JD;R$5:3`[-:Q
MIXL9=I/6[65RIM>DVA72;,2Q4U88IC'R+KMR@_\`A&JRBXII+J@3L$%1*&K_
M`%I$W[ZGE1Y3">;,>M(F_?4\J/*83S9EE8P(U]:1-^^IY4>4PGFS'K2)OWU/
M*CRF$\V996,"-?6D3?OJ>5'E,)YLQZTB;]]3RH\IA/-F65C`C7UI$W[ZGE1Y
M3">;,>M(F_?4\J/*83S9EE8P(U]:1-^^IY4>4PGFS'K2)OWU/*CRF$\V996,
M"-?6D3?OJ>5'E,)YLS5.\-#W/5NJ+ML*`Y1\F7,S48E.;CF\KL)-[&+N&<@Q
M-VA^S-&E*Z9KIBHBY0,8H*)*'+U]?>'I!DX<N_8U[A^"#GZ:RP-UK+*.:HJX
M5-V:J]?.LH;J`.R45BC*'-U``!_*,81\`>'P9(G1I^U^<+_DS:;^Q,5E;%_F
M:'P:#ZGR2>C3]K\X7_)FTW]B8K`MX?!^4OZPR$,N\?!^4OZPR$,"E-#_`'H*
M!\'V_P"W<9MS-1Z'^]!0/@^W_;N,VY@<N=#^VI\^OB)X;_0MEYU&SESH?VU/
MGU\1/#?Z%LO.HV`QDV2_,7BO`;2+I2:Y!:DBMK&>)1HT1_=X1K8"2:Y3&1C%
MFJKHI$)-7L>Q3CEUDGAE!*EVCMIBD&D\!C&>G<V&!92C*#=S42UF9$AE(^)<
MR3%"3?)D$0.=G'JKD>.B$$!`YD$5"E_"(=0X'N,9ZR4FH>$227F)2.BD5UB-
MT59)\T8)++J=XB"2CM9$BBQQ[Q4B&,H;\!1SV0"`@`@("`@`@(#U@(#WP$!#
MO"`AWP$/#@09#^V=[+^0?HO_`!#<A,O3(+A_;.]E_(/T7_B&Y"9>F`QC&`QC
M&`QC&`QC&`QC&`QC&`QC&`S^"49KR$:^8M9-["N7;5=NA+1I&"DA&JJIF(1Z
MS)*,I&..Y;&$%42OF#QJ)R@"[99/K(/]^,"-J;7MGO-W[&IC_D3M9_7J%6M2
M6)@S<0FEDU)-S<'-_";9RSIGJ9JNHP4+5(\C8K`\>[;$6=]3PYU$E$;)R=*-
M[)CD!\77'OZ5N;*+P&,8P&,8P&,9^>S)_P#2+_\`>#_UP/UC&,!C,(OTW<H&
M&3>T>E$ODN9ZW0/#'LD=5P(U5-V*KS[H29#MS=H[PBW`.VJ`/40!$,TCQPW[
M=]^0D?<7>GUZ+2)=G*J1TV\O%?G7BS^+DQC#L%8>,#T4AVU1)TH5R8PI%*@4
M#``JDP*EQC&!S8Y-\:]&R.X>.$L]US"+R&Q=]R3.[N1._(>RM%=6;!ESMI,J
M;PA%41DXUB][`I2`"[=,P>#.@=/J-<H=:B*C48EM!5N#;"UB8EF!P;,FYUE7
M!DD04.H?L16654'LCF'LCCW\FWD=]]#AW\H1]_<WL_*U+X`_J#]6!YQC&`QG
MCK#^G\P_^F><!C&33RAG]LT35]WV9K6YU6!+KZC6BU.X*R4%Q;"V!U"1RTBW
M;$DV]QK9X=%0&YD%3%92)A[8"I0`2=@8*6QFK-4--D)P))+8MVKUR<33&'DH
MP*_15:2G$)N60KNVK@JMMM0RHJJ+H]I7`S#M!4#@*2PK=:6T\!DN2OLQ*G\G
MZT_;J+RH\ER5]F)4_D_6G[=1>!4>,8P/\7/^CK_[E7]F;)UXA]_C;J01$1_]
MVU/"/7_^E9$,HIQ_HZ_^Y5_Z#9.O$/V-FI/@VI];26!2&,8P&,8P&,8P&,8P
M&,8P&3AR[]C7N'X(.?IK+*/R<.7?L:]P_!!S]-98&YB_S-#X-!]3Y)/1I^U^
M<+_DS:;^Q,5E;%_F:'P:#ZGR2>C3]K\X7_)FTW]B8K`MX?!^4OZPR$,N\?!^
M4OZPR$,"E-#_`'H*!\'V_P"W<9MS-1Z'^]!0/@^W_;N,VY@<N=#^VI\^OB)X
M;_0MEYU`<B((+"7LNL$E1#L>OLNL$S"'5U=_KZ^KJ_IZLY?Z']M3Y]?$3PW^
MA;+SJ$L4QDE"D_SC)G`O?ZOY0D,!>_\`@_E"'?\`P>'`^>75NW-0K<:(37-X
MZ*KF1L!6R5AW(7^SR'%6(FWMYNTT9T^GK^\M$A,-;1(3LQ-'&=:6I3T'.(*B
MT>,#-%&S4$^XFA'TA)Z/T_(RJ<VE)O\`65&>2"5E372L*;US6XY5RG.IN0!R
MG,$6,<LD1P';B.P5!3^6!LX?U/C1MF^0KACR0T!O2"T[QCA)DM=UC2MES]EN
MW*3DW:#+(6#=IY:O6B.E#4"L,DXLNNXJ0E&S%.7?S<O(QZC:-9-3]V-2HV%O
MJW7+>W#)C:4*/54;&,TH5:8&<3A&1)0918H`561%Z"WHQ0``#N.V&```<#86
M<3>D7CF;_>W&6T:QK^N-@7;6G)K1TGN"IQEBL\5R7&%GI4L73DM=/(PBJ+"C
M-D57\Y?X-RJR@K/#,E&KTY'``J?MEGJA@H49<)\8B,^[H-@9!,_<]G]U@9@(
MCZ$^Z7:?1OH;K$1]#]O[3UB/\COC@<%>E_M[ZW,./]BT=.#99V.:\DT).-D_
M0:^HK/0(.L0T=M^N-Y647;QL3R02C.H_'5ZF11X6V,Y-%LJGVQ,RO5B8<;S2
MT9JM3BU#Z]D)@]8I7_@^35CO\(Y0JIJO'"V^[$C2*Y9YMS=$TO0Y)<KYFD@K
M(`\467!4>H:/=5^"?-$V#R&BG;%%XG((LW,:R7:I/T5171>IMU4#HINTEA%9
M)T0@+IJB*A%"G$1SW&!RCXZK\AG'2*[@-R2BM,1%O+PKT<6"0TC8+U8JZK6_
M5XWT)59=W?ZU5Y1":^Z8O2`W9LW+'T`5LKZ*[>=1%/JYD%P_MG>R_D'Z+_Q#
M<A,O3`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`G2C>R8Y`?%UQ[^E;FRB\G2
MC>R8Y`?%UQ[^E;FRB\!DF<K7V_JK29_8FG=@TFJQM&IEAGIJ#M=$4M:\Z]C4
MC/FP-'R<Q&C'(^ATCMU$^UK"<YP5[(O8]65GFA>4OL<-X?%C</J9U@>>/[?<
MAJ>A,;AO-5NK^PLH6:ASU:G'J",2SD8=F\68.D32DF+Y0CE=3L'7;$A[7V)1
M3`0'-\YA.M?O>47X&U7Z@CLS;`_"A!43.0#G3$Y#$[8F(`H3LBB7LR"8#`!R
M]?9%$2B`&`.L!#K`88E=?7%+D)5-<H\@M\)5J=U)L.[O4266H>BBS5=N>NX2
M,!NZ-0S*(LTV-HDB*MNHP**>AU#&$R'\NZLFB9]F!KKY.FX/[R=,8%',FQF;
M-HT,Y<O3-6R#8SQZ<BKQT9!(B0N7:B22*:CE<2"JN=-%(AU3G,1-,H@0/Z<8
MP/R;P!_M$_ZRY&W`3V+NO_\`B[?]K9?+)-X`_P!HG_67(VX">Q=U_P#\7;_M
M;+X%EXQC`DGD=]]#AW\H1]_<WL_*U+X`_J#]625R.^^AP[^4(^_N;V?E:E\`
M?U!^K`\YC-PK"5QKTA75IBPP"<@1,AI:K2IX2=:=K5(J!F,FFDL=L<PD[`YB
MIF[),QR=X#=>9-C`YXT+5#YWR(VI3WFY=\.Z_0XS6LU!Q[G93M5$74LS"0DD
MG_\`[.*=ZT=K)`15NH<""@=1(H$*?K+T.R3]=>ROY$_!74GU(KE88#)SY>^Q
M;Y"?$[L'[-O\HS)SY>^Q;Y"?$[L'[-O\#=-._FC5O@Y!_5C7,CS'*=_-&K?!
MR#^K&N9'@,ER5]F)4_D_6G[=1>5'DN2OLQ*G\GZT_;J+P*CQC&!_BX_T=?\`
MW*O_`$&R=>(?L;-2?!M3ZVDLHIQ_HZ_^Y5_Z#9.O$/V-FI/@VI];26!2&,8P
M&,8P&,8P&,8P&,8P&3AR[]C7N'X(.?IK+*/R<.7?L:]P_!!S]-98&YB_S-#X
M-!]3Y)/1I^U^<+_DS:;^Q,5E;%_F:'P:#ZGR2>C3]K\X7_)FTW]B8K`MX?!^
M4OZPR$,N\?!^4OZPR$,"E-#_`'H*!\'V_P"W<9MS-1Z'^]!0/@^W_;N,VY@<
MN=#^VI\^OB)X;_0MEYU&SESH?VU/GU\1/#?Z%LO.HV!H+:EDV9';.X[UO7B<
M*X@;#L"T.=SMWXL_NBUU1#ZONJB,O#E<=2WHAOM9UK*-='9];@&<JL4P>AS+
MB7?@>`.OW`R7+1HIU-;RJ=Y3LNR$81K3]EM)55CL>PL6\=+6&>H+^)C8R.1=
ME]"QCA"'E3':LP(S2!FV353$`1RI,!C&,!C&,""X?VSO9?R#]%_XAN0F7ID%
MP_MG>R_D'Z+_`,0W(3+TP&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,9^%5$TDSJ
MJG*FDF0RBASB!2$3(`G.8PCU`!2E*(F$>\``(CW@P)WHWLF.0'].NN/G5_3_
M`.*W+E%YPWUEK+?='YD;VY'ZSNL;O>HN:S5;-(4UK*3$;8-AT/8LS=UH5M"R
M$D\<0"DQ06=9<(UR,]"L8B:291;=FM'+.W;Q?LEKZ^PVR*RSM$(SL$8W<G5;
M.HFU5^5K%@B)%MV!7L9*P\NV;N$';-4_:E3HBY8K&`5&+UVV,1<X9MFA>4OL
M<-X?%C</J9UF^LT+RE]CAO#XL;A]3.L#8FM?O>47X&U7Z@CLS;,)UK][RB_`
MVJ_4$=F;8#)HF?9@:Z^3IN#^\G3&4ODT3/LP-=?)TW!_>3IC`I?&,8'Y-X`_
MVB?]9<C;@)[%W7__`!=O^ULOEDF\`?[1/^LN1MP$]B[K_P#XNW_:V7P++QC&
M!)/([[Z'#OY0C[^YO9^5J7P!_4'ZLYU<S-]ZGUCNKA]7[Q;FT%)H;>>7)ZDJ
MSD7"4=6%->7ZJ)S,BX:-%V[-FI.RK5F4RJ@'[$'#D2`V;+*DZ*%$!*40[X"4
M!`?Z!#K#`_6,8P)/UU[*_D3\%=2?4BN5ADGZZ]E?R)^"NI/J17*PP&3GR]]B
MWR$^)W8/V;?Y1F3GR]]BWR$^)W8/V;?X&Z:=_-&K?!R#^K&N9'F.4[^:-6^#
MD']6-<R/`9+DK[,2I_)^M/VZB\WO=;W3=<0#JT7NS0M3K[0R::LI./T&#8SA
M<W8-F;<5C`H\D'BH@BRCVA%WSU<Q4&C=98Y2#R'W@\YLM^D9H]ET[$,;?K4F
MI(Z9C:\[G(6K1DM0@<NANT)+.9./<2,?/R%B6A',0Y=1SE<AT"H)JQS8S@0#
MM)C-,Z\W/'7.(F7MEJ5RU-)U=-N:SQ.RXDD$WB^W@8.WM+,FY=U:;C04(8I)
M&,EU2B04E'"#052IYN-)5)=--9%1-9%4A5$E4CE4343.4#$43.01*<ARB!BF
M*(E,40$!$!`<#\./]'7_`-RK_P!!LG7B'[&S4GP;4^MI+**<?Z.O_N5?^@V3
MKQ#]C9J3X-J?6TE@4AC&,!C&,!C&,!C&,!C&,!DX<N_8U[A^"#GZ:RRC\G#E
MW[&O</P0<_366!N8O\S0^#0?4^23T:?M?G"_Y,VF_L3%96Q?YFA\&@^I\DGH
MT_:_.%_R9M-_8F*P+>'P?E+^L,A#+O'P?E+^L,A#`I30_P!Z"@?!]O\`MW&;
M<S4>A_O04#X/M_V[C-N8'+G0_MJ?/KXB>&_T+9>=1LY<Z']M3Y]?$3PW^A;+
MSJ-@<?\`G%)\AG6Z+[7M!H[QV-...(QH:`USJ'9M<U[&Z]VG;ME.'.N=OW56
M9ME5>)Q*Z]+E8IY(Q25F=K5^$L4`,"X:2[U!WU+UNA=6VO:,WV2]C9'82%1K
MJ-YD(=(J$4^MR<2T)8W<:@1-(B+!Q+`[5:)%23*1`Y"@0H`!0XS=(5J>3O?)
MI.U0FTG.H8NCZ)I[S:L_,<U=F<88";H2]QV,9M#UV%UQ%/DW5B;ND9-:5M=L
M,YC"(.H**91CE3T6=+KOH=*&0TGJ)&NGFSP"6M*0G"'LKP9"PGBB5R.+'GG7
MXII"]ES-02&1=BF07#L551(7L^K`VOC&3EL[E7IO3MXI="V%*6F"DK];JY0J
MY.!KN^R5$5N=N5,A6ZU);"C*\[I<',3"Y?0[)G,3;)51<Z:/8@HH0HA1N,UG
MLS;U"U(RA'=UEUVCBSS2-<J\'$Q$O9;1:)U9%5R$56ZM7F4E/SCM)J@N\=)Q
ML>X]!M$5'+H4D`[9F?1L@C*1[*2;INTD'S9%TDD^8NXYZFFL0#D(Z8/44'C-
M<H#U*MG2*2Z)NLBJ93@(8$,P_MG>R_D'Z+_Q#<A,O3(+AO;.]EC_`/8/T7^#
MJ_\`VAN0?NY>F`QC&`QC&`QC&`QC&`QC&`QC&`QFB=@\F]#:JGE:QL/9M<J<
MZB@Q<JQTLHZ25(C)!UL#"<C91$1=^!`@*"<YA`H%[(0#-A4/8=+V=`DL]#L#
M*RP*CEPT)),`6!`SEJ?M;A$.WI(J=DD<!*;K)U=?@$<#-,G/DI,RZ]1B-6U5
MW-1EOW7/MM>Q<W"M5%EZS"NDSR%XM"CD#%1CS0M+93CB.<N#=@K,C'LR%,HX
M*&468Q2%$QA`I2@(F,(@`%*'?$PB/4```=\1'O``"(YH+1]^L>U7>Q+VL+9+
M6ZEM7JVJ&Q4$O1C^*IYG4)9[>Y=%+V9V]EM)))"&2!0Z!H*&CI%`PEE#=88S
MJ.`BJIOC<E7@FQ64)6]1<:H&'9D[Y6L7$EW`Q8-RCX1!)L@F3LA[YNKK'OCF
MU]GZT1V1$QC9O:;52)ZOS*-AK5JI\D#*2BIAN@LV(HZ9.4W4/88M=!PJA(0,
M^PD(B01-V#EJ8Q$SDP&C>R8Y`?%UQ[^E;FRB\">M86W<L;-OZ!NJKMGSJ/0<
M/H'<--11;T2V0S<!$I9Z(=O/NK3KFB0O9/XQ-&0KKLHBZBY9+K-'(_T<H%4E
MN-N[%45"*I*ZNMRB:B9RG(HF>%=&(<ARB)3$,40$IBB("`@("(9OA=!!TBLV
M<HI.&[A)1!P@NF15%=%4ADU45DE`,11)1,QB*)G*8AR&,4P"`B&<F.;5.VEQ
MCXZ[(?\`'I1>PZKG8B2K=BU!88^3L,7K:+LI77HZXZ_DX]0\]"P,2(K$?5)V
M$K!MS2#56("!9M%45`Z;:U^]Y1?@;5?J".S-LA73N_-N>H9I:;D>,&T[&^FM
M95I_*J4U_KB/:1SM)F1DFT4AM@7VHVE!5TS;-Y),@Q"R)4':9"N5#@8H;[UM
MMZPWR:=P\UI';.LP;1RC\LI>F]+^Y3HY%D$@CVSFKW"QG.^4!8RQ"'231%)%
M416`X%(8-WY-$S[,#77R=-P?WDZ8S_,G**OIKK(26JN046**JJ1EC:7N<J@;
MM2ADQ4(I`L945$S=CV9#)E-V9!`0[X]60K>.>%2A^<FNX1EK'9\TAZE]MUVD
MW1K[F'O#J<NEBHEF9.F^MK$A$VM*%:IU@&AY61;,4'1GBSMF59I'+J'#L+C)
MUJNW=M6Z=C&J7&R[U&L.71"R-HV!<M=Q*S1B)3"=TRK5;G[;,O%@$"`1F_3A
MSF$P]FJEV`Y_G?8KE3-V*0:Z\MNEZ'3P%,D?+6"J6N^VQ1(4B=N5-&-YRGPS
M)P"PJ=H`SZ31(0I#J)JB84RA1"ZR2"*BZZJ:*"!16665.5-)%)+_`"BJJJAQ
M*1---,ICJ'.(%(0HF,(``CG/OA%M;657XF:_E['L"FP48$Q;XT7\K8XIBU^Z
M'IIE518E6<.B$,\[6<AP;E$51*<H@40,41WNOI&[VO4FQM;;1W58[:^V-!2$
M`M8H:OP%/"KMY!D9D<:ZPC$#N>P,8_;G*<M*R*C@AE6R:[=)7K+"W13<0M::
MQTBQV3(1D+<;[;)B3.WLLQ!-UWU<C(!RM76T9!+22TFXC2/`CQDI,6"S1NY>
MKB*;9))-,@!T+V/M*\5Q\R@]<:8M6T):4BV\FSFD9FNU?7K$CIPHBDE.VF1>
MNY9LKV"8N11AJI/+`W.BH9,A52FS_&@0.])J.LQMWV2EL`L<4>,C:MJ1K/QG
MI13<HN4'3M._2S\)R7G!373,WDV,976[%9!-9HP(M_E,WL``````````````
M```>``#\`!^#JSS@<E.27!_C<ZOW$:/DJ.]F'$IN22K-@GIBUV>3M%IBE-=7
M:S@E:;(]E%I>?51FH&/>-UY!TJLWZG""*B:#MP0]I7;:5RTE84%K730F./J4
M+"L4]@5I>5F[;0'S1,S:2D=EP[LRSB0J:I`9J$M,"=X]C3%=K3T:+832*/HN
M1WWT.'?RA'W]S>S\K,2%.3L3E*<IB]B8I@`Q3%$.H2B`]8"`AWA`>\(=X0$,
M#UD%/0EHAX^P5R6C9Z#EFY7<9,1#UO(1D@U.(@1PS>M5%6[E$PE,!5$E#$$2
MB'7U@.>VS0LO0IS5E8>CQQJ-(9.G5T<76R4F57D(6)M)9%(!L3.OR#87C&H3
MLL=NW69N2PZ\$,@9=5ZR0,\=/L]CJK>E/VHI(0K9&8J5^@&[=6V:UN<>I!7.
MN&7ZR`LHP7_R,S#F7(HDTLL`XDJ^_P"HIFD@?L^Q`-<:Z]E?R)^"NI/J17*P
MR3]=>ROY$_!74GU(KE88#)SY>^Q;Y"?$[L'[-O\`*+ZP_J_!W^L`ZQ'J`.L>
M]WQ'J#W?P9!/2#\A=2ZIXS;JA[5;X<EFL="GJE"5%C(Q[JSR$Q9V1X>.3)$>
MBB.$6Y%GA'#EPY!%--JDJ<HJ*=@F<+4I_P#-&K?!R#^K&N8:KN*DN-BAJ2$E
M?NU?2QTA(RC&)9.I:/J*+1J*S<]TD60"SKZDBL9%"-CGKI&2D3*%,U;]I$5R
M:#U#L!SRZX]52Q:VFMB:;K$@Z:0Y["XBX!G<+#"5Q$(BQMZ]VQ[,&K0*S;5_
M"C,.V24JB>.<N8Q),BK1^-)ZWU?1=25EO4M?U]M`0Z*R[M<"*.'DC*R3LXJO
MIB=F'ZSJ5G9F06,99]*RSQV^=*CV2JY@`H%#5%3X^$=6LVR]USR6V-@D$$X)
M%Y'%:Z^U^R0>N'+)"A4QRJ];1TF"2B)9&UR:TE:)%5("J2:;)-NT0_AE0#UX
ME3[P>Q^M/VZB_P#U'\^5'DN2OLQ*G\GZT_;J+P*3E8F,G(U[#S,>SE(J2;*,
MY"-D&Z;MB\:K%$BK=RV6*=%9%0H]B=,Y1*8.\(9-BO%^)K4VO9-*7RYZ4?N4
MBI.J]6G3:;UF\`@$$3J:SLJ,E5X]VL9,H.92OM8>753$Y/1Y0,(Y4>,"6^0?
M(>7X[PT[<;1J:WV_5E?J"TW.7FB/H&0DHA^V%8CMK+U&7>P;E&-%(&RJ$M%R
M<J<55U$7,:T1;BZ4UWT=>VXG;/&"G.(V)E(9>GK+U.5:2AV*IS/1;,[,W<-U
M6#ITD9!>)L4:<R:HHNFSH7#1RW350-UVQ+,64E&2$?(M&S]@]9.6SQD]02=-
M'399(Y%4'#=<AT5D52")5$E"&(<HB4Q1`>K.%$5SXB^%VMZ_J^$TG5I>(J'#
M"T\N/_9ES;TB6N:L)N1OKB0UG5:VC3Y1O+[#L3F6+*5I3T<<TVY;$@U&:"K@
MD@D'>?&<_P#772`Z[L%XY$U39C%CI]CI'8=+H4$_LLZLYG;^YM>@8[D+((HU
M!"$2E8RQ4ZG*S:MGKL:>R*Q["K3L\X=MXUDY%"C@Y,:"/-T^NI;<HB\K?F%5
MDZ@@VGVKE&<97N!G[11UFKYN*L>F-SKE5LLY4DG;MLM9(J`F'T,F];Q[E1,-
MY8R"=P<_=6:ZD="!4G$+LJ!V_O2H:=L<K#3CY!Y1(V^ZIM^V:A?4(5O7I20M
M<-9:_5DW%8)'I-65JC99*7K\R_;M%4E-Y,N5O'*0A:?8V6YM?O(&]P4#9ZU,
MM+`V=13VO6>TM*-7YMS((@=K$14Q=GS:G1S^;4C&SJUG-74U!F$5V:04)C'_
M`'^;PXP&,8P&,8P&3AR[]C7N'X(.?IK+*/R<.7?L:]P_!!S]-98&YB_S-#X-
M!]3Y)/1I^U^<+_DS:;^Q,5E;%_F:'P:#ZGR2>C3]K\X7_)FTW]B8K`MX?!^4
MOZPR$,N\?!^4OZPR$,"E-#_>@H'P?;_MW&;<S4>A_O04#X/M_P!NXS;F!RYT
M/[:GSZ^(GAO]"V7G4;.7.A_;4^?7Q$\-_H6R\ZA+%,=)0A1`#&(<H"(B`=9B
M&*'7U=_J`1`<#A_TI-!B[W9(Z?G="V#?R\)KULRXYIT3CY0=N$@^0YK.Y>D-
MLN^VM&785+7RK%*M-)6`FV<9%2<7(3K]G+$F&C0[;LEKH]O4H%)4V!&P\->C
MU.O&N417E.VP,7:31349Z/A5>S4[9%,Y,7+>//VP_9-4TA[,P#UCP_KO!7:]
MOABL.0G&EG9M<<=ZB\BM-Z,JF[HHA-[[VL[]^IL+DM:K(O8(%M"@O'C$LM;P
M%JD$YJK$^[3E9JR.I%-&W;+4\3/P.L-=PEK[=Z9HBD5:,L/HF2"9<!-,85FV
MDP7E@,<)-8'B:P*2`',#PX"X[(>SZQ#8&<W>:NB]M\A[3IM+7$%<J?/:,WKJ
M/:%:V*^NE1-JF;CHZ;2>7(+!KA6<DI.>D:]$).48%S)4]M*1TR^(^K4H0"+G
M#I%C`Y7\H]`;KW5N?5&X82D6Q%E0].<F]>PL$PV9!5"X4#9=\:0[?7NU(*2A
M;DSB5FLHG$)QLEV,PYE(F-,F#V">D,Y8J5DSTK?+SH?5-&VUMW8D'LJNU6HA
M?;SJ2PM:?*6.WQ\$V:6!59U]RY-NM'/Y(%UU4T6J!'"P>B$RH$."1:>Q@<M]
M%ZL)J3I'-MP!-@[.V,60X2Z-E?NOM2T(VN;8]>^]^M?N='/D8N**VB@%`70-
M!04'T6NX6[;_`)3L0ZD9!</[9WLOY!^B_P#$-R$R],!C&,!C&,!C&,!C&,!C
M&>.L/=#\^!YQC&!+O+<I?4TKHB4HB.W]0=?64!__`%\AO=`<J$H``#U``=9C
M"/5^$>L>_P#UY+_+?[V==^-_4'V]ALJ`/!^4WZQP-4[3GZ\=M&:LD+%,UVQ;
ME;V>FU9]76JCF9CW"=7E9*2G45"(K(QJ,,Q;'5+*/BE8HR2\8S4/Z(?M4U,S
MI]3@J)5:]3*RQ2C:_6(=A"0[%$![!LPCFZ;9`G683'.<2)]FJHH8RBJICJ*&
M,<QA'1&OZU,7#>NRMQ6-.69QE736TWJ^"DVQFJ"$3%KLY&]W5FD<XG,-QLQ4
MHENX$I4W,)48MVD7L70CE-X$Z4;V3'(#XNN/?TK<V47DZ4;V3'(#XNN/?TK<
MV47@,T+RD]CCN_XL;A]3.LWUFA>4OL<-X?%C</J9U@;$UK][RB_`VJ_4$=F;
M9A.M?O>47X&U7Z@CLS;`\=0?T_G'_P!<DN=JM96YM:ULJU>A%;$AQSVR5&>4
MBV*DRD5KL'5#1L"<F9`7I`;M)>5:H`58.U-Y)^BGV*;M<JE:Y-$S[,#77R=-
MP?WDZ8P*7QC&!^3>`/\`:)_UER-N`GL7=?\`_%V_[6R^62;P!_M$_P"LN1MP
M$]B[K_\`XNW_`&ME\"R\8Q@23R.^^AP[^4(^_N;V?E:E\`?U!^K)*Y'??0X=
M_*$??W-[/RM2^`/Z@_5@><PZ9I5>D)M"ZHP4+ZH$1`3$!7K:XC6Z\S&,9<I%
M'$>1Z()N3Q:[U!JZ<1YUP;**(E4[$BG^4#,<8'!;C;>>DALG+W=T/:J5JRN/
M5:[$I665LT#8HVO1D/$*F94"3BE(=_+DE9NP1/9/7,2$D1'_`#SK_<I,J?7V
M"F]?[*M%*B("1W-,5.S(/1<3EOUE5Z[!N)-H(G_]F,8ZX(WYI%D`IBE,]*#I
MT8Z?;4P;B;L"ZVUU[*_D3\%=2?4BN5A@:`JG'2IUN2C9V2N.W[Q/Q;Y"1;2M
MSVK<7:1W3<1,D+JM0DC`TMTD!Q%06Z]:.@)AZA3[`"E#3',W0VE)3COR6M#[
M5.OU;1+ZRMT[*6@E4AF]FD)F&B%9&*DWEA;-$IAP]8/631=JNJ],=(6Z9`'M
M9>PRYLG/E[[%OD)\3NP?LV_P-DZEJE;H^LZ-5ZC"1U=KT568A./B(IN1JR:@
MNS2=.#$2('?5<NEUW3E8XF6<N5EG"ZBBRISFV'F.4[^:-6^#D']6-<R/`9+D
MK[,2I_)^M/VZB\J/)<E?9B5/Y/UI^W47@5'C&,#_`!<?Z.O_`+E7_H-G+[BU
MQ3C9R^:$Y?2=F:/5ZUQ;F-$1=`>5)F\0:A);54V$%Y:VAQ*G=,Y]F_9#%M4&
MT,FD2,<N/_%>B3]LSJ"X_P!'7_W*O_0;)UXA^QLU)\&U/K:2P))OG1NOKC<M
M]VACO^:K3#D'OBO;AN5>9:]A'K=6!A="2.B5M<*R+N>))*1D@U=M+:O-1Z\.
MY<2D>6"F(Z;J;V0AG/\`1J7HVFFJW+Z/)N:4L=(OW&K4O'7==2D*%"-E;L72
MVL9[4--V!2[&A-*2NK;&XHT\XC+`V8%LC-\J0'L<>'<JJ*!T^Q@<LZ1T9L53
MZQQTB_5*@%[3QIVCK^_5>\PVDZG4YS8$/JC6MWUCKRM;A7A9[T==7D-"7F14
M=V-G)U_MRJ!20\)`>CY55[Z")Z([4]?U]ZF\+LBZHP=CU#K/3NT'3YE%O9:X
MP>N=_P`[R(++0:Y%6C&E3,]:[A<H1^9LPF6+6N2[`&34DU"HRSOK7C`\`'4'
M5X>^(_G$1_\`EU]6><8P&,8P&,8P&3AR[]C7N'X(.?IK+*/R<.7?L:]P_!!S
M]-98&YB_S-#X-!]3Y)/1I^U^<+_DS:;^Q,5E;%_F:'P:#ZGR2>C3]K\X7_)F
MTW]B8K`MX?!^4OZPR$,N\?!^4OZPR$,"E-#_`'H*!\'V_P"W<9MS-1Z'^]!0
M/@^W_;N,VY@<N=#^VI\^OB)X;_0MEYU&SESH?VU/GU\1/#?Z%LO.F,[$I3T+
M+P:[I^R1F(Q]%K/(IXI'R;1)^V5:G<QS](!59/D"JBHU=I@*C=<I%2`)B!@<
M9ND$Y(\J-<<@FE`U#M6=U51$-,URX&>5KA'>>5#Z8M,O:;U%RR3^P0$I&1-3
M1CHN"A%H^/4]%O'"SAVZ<)$;]H[9U8T3+RM@TIJ.=G)E_8IJ9UK2)26GY6(-
M7Y.:DG]<CG3V5D((Y$SPSV0<*J.G44<A#1ZRIVIBE%(0S@QTBM*K-0VSKO7D
M>7DK;G-(XVU""1D(;I&JUQ=9K0<3*[%%G-7!"S(A,7>S/5(MRUG;O)."1SAX
M\K<*`$DGQ"J]TN-H,B\>]'%C7)GD>&I->`Q='FALAW+0*I%@W7-8#)HC.&52
M[`YI<4DQD1$78ID[;V(!NO&,8#&,8$%P_MG>R_D'Z+_Q#<A,O3(+A_;.]E_(
M/T7_`(AN0F7I@,8Q@,8Q@,8Q@,8Q@8/L6O6RTU&4A*3>7&N+(\%IZ`M[6"CK
M*O%`B[16<]A#RJJ+%WZ*;$5:&[<H':2K"L0#*$*48IXT1')&T7*]RUVY.R-I
MK>KMR677KFJ#JNG0Z5LC(2!K4BDY>2K%ZH\BEUEY]0#E9%5*!6J0@/6H<`Z'
M9)?%/_2N3'RI-@_9+7>!6F,8P)>Y;_>SKOQOZ@^WL-GM.2UXMM=I<92]9+-T
M]L[<G"4"A+++D2&!4?-W#FR7E0@@<QFU&KB#^<3,*9D%9HD)&KF(,DD!O5\M
M_O9USXW]/A^>^PP!F755I0=F["7VW'H3+R:UT-TU'#/GIQ3@DC!-M#7&0KK<
M#F3<J/9")91#J9+_`.<C$E:(_P"3(H=0-P0C!:*AXJ,<2+R7<1\<R9+RT@8#
MOY-9JV305D'IR@!3.GBA#.5Q*!2]L4,!2@'4&?X6-I-/H&89UR5;P<\ZCG:$
M/,NXXDLUBY)5$Y6;YQ&'6;D?HMEA(JHT,NB5<I13%0@&ZP]UC`A>K:!Y306Q
MI78#[DS39-:SMJ5%6J/3T7&LDY&$I3B=58LV*Y;2J>-<KIV2636>@#@0%1N<
MB100`IKHQC`9H7E+['#>'Q8W#ZF=9OK-"\I?8X;P^+&X?4SK`V)K7[WE%^!M
M5^H([,VS"=:_>\HOP-JOU!'9FV`R:)GV8&NODZ;@_O)TQE+Y-$S[,#77R=-P
M?WDZ8P*7QC&!^3>`/]HG_67(VX">Q=U__P`7;_M;+Y9)O`'^T3_K+D;<!/8N
MZ_\`^+M_VME\"R\8Q@23R.^^AP[^4(^_N;V?E:E\`?U!^K.?7)?=6IF>W.,,
M>ZV%5D'M,W[(NK6V4E$06KS9/4^Q(XR\N0.L6*(/WS1GVU?L$Q<.$4@-V9P#
M+LKMB@[9"1UBK4JRFX*50%>.E8Y8KAD]1*H=$RK=8G650@*I*)B8.]V1#!^#
M`]UC&,"3]=>ROY$_!74GU(KE89)^NO97\B?@KJ3ZD5RL,!DY\O?8M\A/B=V#
M]FW^49DY\O?8M\A/B=V#]FW^!NFG?S1JWP<@_JQKF1YCE._FC5O@Y!_5C7,C
MP&2Y*^S$J?R?K3]NHO*CR7)7K]>'5#=0]7K?K2'7U#X?3U%_T?\`?>]T,"H\
M8Q@?XN/]'7_W*O\`T&R=>(?L;-2?!M3ZVDLHIQ_HZ_\`N5?^@V3KQ#]C9J3X
M-J?6TE@4AC&,!C&,!C&,!C&,!C&,!DX<N_8U[A^"#GZ:RRC\G#EW[&O</P0<
M_366!N8O\S0^#0?4^23T:?M?G"_Y,VF_L3%96Q?YFA\&@^I\DGHT_:_.%_R9
MM-_8F*P+>'P?E+^L,A#+O'P?E+^L,A#`I30_WH*!\'V_[=QFW,U'H?[T%`^#
M[?\`;N,VY@<N=#^VI\^OB)X;_0MEYU!7.*:*IR]0&(FH8.L.L.LI#&#O?U@'
M7_1UYR^T/[:GSZ^(GAO]"V7G480`0$!`!`0ZA`>^`@/A`0_"`X'SMZ-WYK"P
MS`7CDGM[8?)?7V^=26.P[%HE]XD;-LNO-9V]G9Z[.5VGZPE6&H'I4Z,LS<33
M4L4M)S40_<56/L17Q'ISK+][-96B"N^N:'<JNP-%5NU4^MV*`C#M$V)H^&F8
MAI(1C(S)(B:306S-=%$6R:9"("3M92%*4`"2>0'-/47$2TMZCLQ.#CZ>K3:R
MYJD!1)5E9-K/Y.4FIZ'6C(S1400MOD*JW9Q;0T?.5IG+IKNQE&!HU`D8JX&I
M]7;&H>RJPVE=?NEON2S2:,SPTC7ING3E?[)HBNRCYBGV:,A;#753,5$%VC24
MB61EF2B+AL51LHFH8-CXQG/SDYRXV-QZWCQUI1*-K::UYN_:E7U*F$CLYO!;
M:D).T&4([M%/J#Z.2B'U:HP%27LI'LV1^_;.`&.*V6(FBY#H'C(TYW\M&_#/
MCK<]T(5HUWL$`G$'AJ<1SZ$-)(/+37:_*RCMR'6=K$0*%@0>2+LI#]K.=H@)
M0,X`2T-/[4H-&J\+:MD72H:_BYA&/*A(6^QQ5;CE'[YFF[!BW>S#MH@JXZC&
M[!`JAE3$()@*(`(X$H0_MG>R_D'Z+_Q#<A,O3.:^KMCZ^V;TE&U9K7%YJ%^B
M&/!S1D:^E*99(BS1[*1#?^_W(L';R&=O$&[ST,LBX]"K'(OVA5);L.UJ$,;I
M1@,8Q@,8Q@,8Q@,8Q@,DOBG_`*5R8^5)L'[):[RM,D?BRLDV5Y.+N%$T$4>4
M.PU555CE33233J&O#G444.)2$(0H"8QC"!2E`1$0`.O`KC`CU9.:G)BE35I]
M)>KHJR[AG&ZJ99E]0F*#BEUI`RY4%5YJ_P`HYCJDHJ@(G,K$04G.6`H$_EQ)
M"&!3/];CHAYLVT/'>Q]BVR:UT1VDO%:EAED:I55B)($(<EN>P9&EAN3=5<#K
MC$RTJ>#Z^UB:..<@&`(#Z4;D=+,-'QD)HMQ%7)[,7M[`2=QJKAW9QH5\IQX6
M3K\#V59%XBPMDI)/3(1B4B*@M9-@FW.P674$J/2?0U6C:7IO6]:B8![6&<;4
M8<!@Y)8[B38/'+8KR1))N%"E5<22K]PY7?KJE*JHY54,H4#=89I?DA4*K2M.
M52`J-=A:W"M-OZ?%M%PL:TCF21PO<*';2H-4DR"L;J`3KG[)8XAUF4,/?RPP
M\'Y3?K'`\XQC`8QC`9(7-#;>KZ+H_:%6N=_J56L=JUE<`K<).SC"-DIP?N<N
MTZHMHZ636>#Z*4(WZD2G_P`L<I/\X>K*]STLI7(";416F(2(E56Y#)H*246P
M?J(D.;LC$2.[;K&3*8P`8Q2"4IC!UB`CW\#5''_9^NMDZ[K9M?W>L7,L!6ZM
M&39JW,L9<L5(A7HTYF+\S)98&SHI1`3(*B50O?`Q0$!`-XYZN+@X:$(JG#Q,
M9%)KG!18D;'LV!%5`*!0.J5HBB50X%`"@8X&,````/4'5GM,!DT3/LP-=?)T
MW!_>3IC*44*8Z9R$4,D<Q#%(J4I#&3,8H@50I5"F(82"(&`IRF*(@`&*)1$!
ME%WQSV`\O,?L0W)G9:=GB:U.U".<DI.E?0[>OV.6@YJ39"T-KPR"RBC^N1!T
MG:Q#ND2-SIIJE*NL!PK'&?RLD5VS-HW<O%9!R@V;HN'ZZ;=%=ZNDD1-5VLBT
M20:I*N5"F643;(HMTSG,5%)-("D+_5@8-?[[$Z[A4YR8CK')-5'S9D"%8@)&
MQR!5%SAV*IV$8DLY*W)U"*J_8"1,.^;(]X#W`6FH:IJZ:J&P:Q;(5"T2D@E:
M*5-04<FW<V5TZ03))OD$VBKI9!^@JFV(<53$!4W8]29LOOJZ_P#_`*(?JSQU
M=7N_G$?UC@><8Q@>A<56LNUUG+JNP3EPX,)EUUX>.666,(]8F554;&44,(@`
MB)S&$1`.L<]LU:-6+=)HR;(-&J!>Q1;-44VZ"11$3=BDBB4B:9>R$1ZB%`.L
M1'JZQ$<_HQ@,8Q@2?KKV5_(GX*ZD^I%<K#)/UU[*_D3\%=2?4BN5A@,G/E[[
M%OD)\3NP?LV_RC,G/E[[%OD)\3NP?LV_P-TT[^:-6^#D']6-<R/,<IW\T:M\
M'(/ZL:YD>!X,4#%,4>OJ,42CU#U#U"'4/4/X![_>'\&2&\X4:A?3BEE7F=L?
M=T[9\R)*)[7N"3QM'R+P[]U'-5B/@,W8'=F[<#5,02*8I!`O\D,KW&!_%&L$
M8N.81C<[A1"/9MF2*CM=1TZ42:HD03.X<K"95PN8I`,JNH(J*J"8YQ$QAS^W
M&,#_`!<?Z.O_`+E7_H-DZ\0_8V:D^#:GUM)9L+:6V:-J2&:RUZD):/8RSE6,
M8GB*E;K<LH\!LHOVM5G3X*>>-4Q3(;J<NFZ#43]2?;NV&*49TX1;:I5GU'1M
M=1BME0N-4J:CF?B9VA7RKD8I?=E=/L0DK-6HB)=K]D];#Z&9/G+GL#F4[5VM
M)4Q`MG&/!D167I$N)U1Y`J<9K#L";C=HL]BT[4LP"VMMDC0Z[LK9%)9;!UK2
MK+M8E5-K2`L6Q:R\]$TF,D[2W=6%XT?1C),SYL9$0MW&<R=H])WJF/KDNOQY
MK5@Y$3Z^TM,:(H<_$MI:HZ"NNY-X;$)KZ!JD3O\`DH-_5;(TIP>BK;L>7ULP
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M$^+G,:R\@>07,K0=NT?*:;F.)UMU;!HKS-ZK-RD+U`[7JLY;JW97+.I)NH:J
MG=0T2UD$H1.Q6)VBREVA)-RPDT7L<WNS`8QC`9.'+OV->X?@@Y^FLLH_)PY=
M^QKW#\$'/TUE@;F+_,T/@T'U/DD]&G[7YPO^3-IO[$Q65L7^9H?!H/J?))Z-
M/VOSA?\`)FTW]B8K`MX?!^4OZPR$,N\?!^4OZPR$,"E-#_>@H'P?;_MW&;<S
M4>A_O04#X/M_V[C-N8'+G0_MJ?/KXB>&_P!"V7G3:7)*J14DG!N6#.:.P=DB
M'<HT7?QK:3,W4!BO(,6KR.<O&2+D4E'39N_9++H%.FDZ0.8JI>9.A_;4^?7Q
M$\-_H6R\Z9S3%S*0\K&LI5[`O)".>LFDW&D9*R,.Y=-E$4)-BG(M7T>H\8*G
M*Z;$?,W;0ZR1"N&ZR0G3,'#:?-SSHFP]B;FV!LCHKZ'N2GZ+J;G9MVF-6[Q(
MM4-/(V2^O:B@O;9O=\>S2KX6<+>9!<6C+T;)"8KAH8!:(CU9XY0L"_H<#N8K
M*O.-A[SHVL+ELZY5YBYCVMWG&E%B8^/E4FKH>W-HY!A_D8AF<B1FK(Y2*$[:
M*AC?/KS,XU[PB+D]@-W\\-\[2+I/C].<JY2V36J>'U6ISYA2+>WCW5.:UV3H
MKA2RR<:R-)6Z`AKB9[5FM@C8!<DBVF5DY./^BWCY(-)71&F)1A/2UH8R.K*"
M_9V2>C$8:;GVSNKQBZ$U,1#<QV\7)R:9RO'T>@<Z+-RLJ@D8Q"%$0W!D4<B>
M*-BY.3+"O;*V#5UM'PFP=3[/K],C=;+-]C0]HU=-DL92M=GJW5:/)'3TNV9'
M7[50T9:.:(KM&DJ8KHRA+7Q@<UN8O1Z!S6TI:-?;+W-;*UL*8C)&MQ.P-;O=
M@4>L-JJZOT'=&<-;-40.SF5=V$9@G!H,47%G?.$T9`R<ZQ:L7;9%(M]U&FQM
M2IU9IB2\C-,:O"1<(V?663D+),/4XMFDS3=R<Q/.I*4DGZQ4^S7>OWCEVJ8P
MBHL<0Z\R[&!`L`W0;=)QLM-N@B@0>"&C#"1%)-(HF'D+R#[XE3*4HCU=[KZN
MO+ZR"X?VSO9?R#]%_P"(;D)EZ8#&,8#&,8#&,_S%5(!$!43`0[P@)R]8#[@]
M_`_TQG@!`0`0$!`?`(#U@/\`4(8,8"@)C"```"(B(]0``!UB(C^``#OB/@``
M$1[P8&#[+O$%K:AVF[V.33B(FNP[Q^N^.B+DY%BI&39(MF90,H^>NGIV[=DP
M2*=9ZY43;)$.=0"CRAZ-_5FX+M2N5D1RE5+:*ML#;3IK,T.??!(."V4:_79&
MV'DDVR#8D<VDVSV`2<0J+IPU1%M]SRIH)1_4YZ$UF4H_)DJL\]JPS-#UULL'
M.O)U\_>DCK7:J4J\C)"SMX1,S=K(0D%.BY:5]U*%?-'LE'JS#)LEZ%CWBF,\
M4_\`2>3'RI-@?9+7>!4<3$14#&,8:$CF43$QC5!E'QL<V29L631LF5)!LU:H
M%(BBBBF0A$TR%`I"E``#J#/8XQ@2]RW^]G7?C?U!]O8;*@#P?E-^L<E_EO\`
M>SKOQOZ@^WL-E0!X/RF_6.!YQC&`QC&`QC&`QC`CU>[^81_5@,8Z^OW?R@(?
MKQ@,8Q@,8Q@,8Q@,8Q@,Q:YW&#H-<D;79%7B,/%D3.\4CXN1F792JJD1)VF-
MB6SQ^Y$3J%`2MVZABEZSF`"E$0RG'4`^$.O`YMZ[Y%ZS+R7W!/G/=4H>Z1&K
M(:N2*VM-@HM)"19L"L':`*JUP@-P:NER)+K.>U()]1E!5[6039TD\.>.H/<#
M\P9YP&3ER+U/L_<M/FZ%3=H5S7M8MU6G:M;$Y;7"UVDWC6<;'9*.(I\2Y5E*
M+60:JJE*"S20*=0Q5/Y/8=B-&XP-2:CJNTJC$.8O9>PZUL#T.C%LZ\O7=?KT
M/[F,F#51LNF^26MUK^ZBSKJ:G(L11B5OVE0O:ENW`*6V\9IO<.VGVIHDLVEK
M+8&P8U!C*2<NXI"%?7"#CXAFL^=.9`LY.0PB46R"IDB-?1"BAB]@!`,(!@;D
MQF@=#[W'?$`TMD?K'8M(J\O`PUCK4W=FM?:M;)%SB7HAFK&)P\[+N2F!L9)P
MJ1ZBU$J:Q.KLC=D4N_L!D4SF^N2L1?HB@I<9ZP[D+)%W">K[HV\F3=!Y#4U[
M7F<BX=%&D*>@7*IK1$&;M!,L)NV+E[;_`)'K-:V3Y;O9,:3^*C?OU[H[`WA"
MN)-W#Q;J:CDH>8<Q[->4BD'I9)&-D%6Z9WC%&0(BW*^2:N#*($=E;H`X*0%0
M23`W8![/&,#P/?`0]T!SCJOT:5EVCS$W]NG<6SK*QT?.\N^.O)VAZ0K"U)?5
M?8EEX_\`'C5%,IMDV$]DJ6M>:VO`;,JTNX>U:OVU.#N,-7ZJI+MRH*/VSOL7
MC`YK7/HO=%O:=8*AJ2U[4T%&JWW5>X=<P&O[>K+ZUTGN73M[)L"H[#U#J*]M
M[/K^A@]DRJ1-PH=9BHG6ML@';I!_4DI4Z<PEZ5ET7U+4TEL?05GWIN6ST#>%
M7Y"K;V:JIZ[A7^SMX\BMB1&RISD6O)0M,:/:K?J/+198K7-9JR\?K2#KQD6$
MA49==N+Q?J'C`X_/>B70>2CC;GKM-Z-N7,ML.Q7:R\I&U:TV2R3T-9]'0?'6
M0U\MK(U$-J=C5&FM*U"*PZC*LIS;"\M#W0\FZ>.EV9O]X_H<]%5B4I4/0=D;
M5I>DXZJ\2*QM71K0],EZYO(.$$BG+\?I2Z6Z:K#R^PKUC(-H\]_3ID[!-MA-
MHF-:2J39(CP7G7K&!"/'CA5)Z'Y+\EN2[[D-LS9\WRB&IJWNG6NJ:CA*O&N]
M=,AKVMG-><4FCUZPMS4^D*N:B1-[*NTI]NN,U8B2-@32D2W=C&`QC&`R<.7?
ML:]P_!!S]-991^3AR[]C7N'X(.?IK+`W,7^9H?!H/J?))Z-/VOSA?\F;3?V)
MBLK8O\S0^#0?4^23T:?M?G"_Y,VF_L3%8%O#X/RE_6&0AEWCX/RE_6&0A@4I
MH?[T%`^#[?\`;N,VYFH]#_>@H'P?;_MW&;<P.7.A_;4^?7Q$\-_H6R\ZBB(`
M`B(@```B(CX``.^(C_0`9RZT/[:GSZ^(GAO]"V7G4!QWD%A[`%`!)01((]0&
M_D&_D]8=\.R_S>]W^_@<).DJ9DN]W2N"VLY[D#KMYQ@F?6[QVL-))[?;V/D^
M-]82-+8S=JCFLO#2E2DVK-@B\JMN(6DA'?=N6>+INP2=,^T>JCVQ366O#WN&
MC*Y=CTFK&MU?A"(IP\)9C0K,9R)BDVYU$$XZ.DO1#1F1%0Z16Z294SF*`"/S
M0V+?^X=3UK6"R_J2]%=1)EM5$*LG4+;8^5NX)>(65.9:JI\?D.V4ZCPSU$S5
M\1W(-UY)91<X>C6SML[!7Z>*<]4DJE69%67"?5?0$0\4G2Q8P@3)W+!!8TH$
M,*BHQ0/Q.+D(X5%!9=M]#B<W:^L0R3&,8#&,8$%P_MG>R_D'Z+_Q#<A,O3(+
MA_;.]E_(/T7_`(AN0F7I@,8Q@,8Q@,YX;UXXZE6W!I%R,5:T3[)VC9D[JFSV
MEM5@TFDO2-8IH$!8L;JV9,&Y)-HV=)MXMNR02,D5--,J(F3'H?DQ;P^^SQ8^
M-.S?W96K`W[5:Q"TRNP]6KK=PTA(-DDPC&SJ1DY=PBU1`>UD6DYEY(2CU0.L
M>R</GKEP?PG5-FIMK1;K<$=*ZKH^T&M3<L9B$;[:/7ER+W%C299J\<.J[&N4
M3F&KS5I:I%:HRRI0?1\2LZ?QY"NA9JYENV++<:Q2W;G7M75MMVDW<=`5N/,1
M8(AC)S+@C1.>M#E`#+,JO`)G4E9IPB11P=LV]"-2&<ND<]9I/4<;IZFD@R/3
MS]IF7BMCV#=7B?8RUZNT@FD68LLH/9&`AW(HI-V3)+L&D;'-VC!FDDW0(0`V
M/7X"'JL'$5JO1[:)@X&.9Q,3&LTP2;,H]@@FV:-DB!UCV*2"1"=D81.<0$YS
M&,81&8^*?^E<F/E2;!^R6N\K3)+XI_Z5R8^5)L'[):[P*TQC&!+W+?[V==^-
M_4'V]ALJ`/!^4WZQR5.0VO\`>VS$FU<I!M1LZLQL-+M+=];7]W)/GD:M,M)M
M9FJTA(M>.(T=+M"MDER.CK$14.H=`5"E+F_J4:]'A2FV&A4VUA%RX$Z5,=S+
MV&!J*@BV$B\ZR8/A7[6(=O`6Y4@/U@F(EP,NQC&`QC/YW;9-ZU<M%14*DZ;K
M-E#(J'16*FND9(YDEDQ*=)0"G$2*$$#D-U&*(&`!P/\`;L@]PW_W#_NY^LY<
M,.-5*]=M,:W-:]P'J+'0M;O[6,/MZ]F!.T.]D2T0Y?BM]UP5.16-8H-3-53*
M->U@<02*<W9!U"01(W01;D$YB())HD%0YE%!*D0I"B=0XB8YQ`H"8YA$QC=9
MA$1$1P/]<G?DGJRO[$H$O*3$Q>X=]2ZY:I:#<4C8=SH2@/5(KMH*2(U&:A_N
MN1%1B@=JC)@Z2;&%84")^B%^SHC,`VM][#8?P*L_U,\P-!\.=70E2U'K^\MY
M_8D_8[]K*C2=D=W?9=YO2"\@ZAVTDZ=L6-KG)5E$K.'3I4ZYXQ!J*A!(D?K3
M3(4*[S1G&/V.FB_BDU]]F([-YX#&,8#&,8#&,8#&,8#&,8#&,_CD1?A'OABB
MLSR@,W0QI9`ZZ;`S\$%/097IVQ%7)&@N.U@Y.W3.N5$3F2(=0"E$/[,9#-;V
MORNF-R6C4CNK\>4%J76:3;IJ6;6C9RI'45<92PQY&D:W6JZ8A(,B5QTJ87)P
M;*F<($`Q0*J8MRE[+L2]GV/9]B'9=CU]CV75_*['KZA['KZ^KK#KZO#W\#SF
MM]Q_>EVA\7=X^RTMFR,UON/[TNT/B[O'V6EL#6/#7V)_''XE=<?9B/RELFGA
MK[$[CA\2NN/LO'Y2V`R?+=[)C2?Q4;]^O='90>3Y;O9,:3^*C?OU[H[`H/&?
MGLR^Z'_X#W^KO#X!ZA[P]77U#WAZAS]=8#X!Z\!C&,!C&,!C&,!C&,!C&,!D
MX<N_8U[A^"#GZ:RRC\G#EW[&O</P0<_366!N8O\`,T/@T'U/DD]&G[7YPO\`
MDS:;^Q,5E;%_F:'P:#ZGR2>C3]K\X7_)FTW]B8K`MX?!^4OZPR$,N\?!^4OZ
MPR$,"E-#_>@H'P?;_MW&;<S4>A_O04#X/M_V[C-N8'+G0_MJ?/KXB>&_T+9>
M=0U$P53.F81`#D,01#P@!RB4>K^GJ$>K^G.7FA_;4^?7Q$\-_H6R\ZC8'/73
M>B.!O!-O$T:OM=95.^P]3&W2EON:\;,[<D*UZ8(ZN.[Q9K=+E?65E7AL<VR8
MKR2CV.K<:X<'*D#5LV<F0Z"MUT'2"+ELLDX;.$DUV[A!0BR*Z*I`.DLBLF8R
M:J2A#%.10AC$.40,4P@(#G"'I'8U];.4D;081QM+6\5L_CS":.W1O>FZYU9=
M:Y5];;IV//P<!4)!_=''IBK]ENEIAE:W7)6&BYIA%O9Q&2=LTE&Q'"?2/A=N
M"F[(U'6JO5J_,4XVNJ'JMLVJ=CL+:TS[.CVFA1,[KJ6E)UHDD@^=2U?$R3TP
M]DX3E8R327$X%276"P,\=8`/4(AUCX`ZPZQ_)GG.3G2!;,VCHG:/%R^5V\[N
MKM&M?(;6=,V).5R'@)_2%+H$S*H0LC!;%K/9DLKZ5V)*OVL97[8S2=(U1V`.
M7ZC>/`"'#K$(@'A$`_K$`_7GG(@YU,+JEINR66B[CVAK.Y1<*\CM61>K&T<[
MF+1N"66*A1F$A$/(^1-;8A9\F5K*5E1,K(88TM,+F*=B15+:EKVQ>=0ZGH4_
M:M1[5W->GD56HVX0&C*[6I^59V52#:'L,F=C/VVH1Z,&29*](15M(KG(4Z1$
MVYB?R@#2T/[9WLOY!^B_\0W(3+TSE5Q]VT_W%TC&W[#(:@W#IA6,X4Z-AR5[
M=->KM<L,JF7?.^GGW9BFE:MMQ9KP_9.19=O<2#5T#ULX3]!]J*FNIU5P&,8P
M&,8P&1ARJO\`4M;W3CE:[A,M(J)@;]<9AWVU9(7J[9IK*T`*4<P[,'4B]<+J
M(,V3-HFJN[?.6S1$IEW"136?G$3F;I0.0'/S1==3E7C.MP3&BA;)ARQ3DD(&
MQ0<M:=BP4/4!7,*$?8IB+ATEK(LJD;LH![''3$52E$@=+M"0M_E%+-N/9$A-
MQ\QM(L4YK^LG;XBT1JZD1A7AJS"$;H`"![9*-'P3%UD`$W9S#D8UOU-(U$34
M;GX3*!"$(7K[$I"E#KZNOJ*``'7U=0=?4'?Z@`.O/W@8A>R7L]8D2ZV7JS>X
M"+;[E*W-&57KI0]$I>B_1Z4*8LB;K:=N!OZ','4X%,5![6!LE31.J^4&M+1:
M%K38]&RM3O\`LR=V/;$H")OK6P-5YV)@XM6-@E9)PI'=J0^X#99-5Z4#'%PN
M4X?R$LMK&`_KQC&`QC&`QC&`QC&!'S'V>%C^2E4_[VK#E@Y'S'V>%C^2E4_[
MVK#E@X#,`VM][#8?P*L_U,\S/\U9O";AJWIW9TW8)6.A(=A1[(H^E)9XWCX]
MH12+<()F<.W2B2"0*+JI(I]F<!46432(!E#E*(8_QC]CIHOXI-??9B.S>>3Q
MQ*G(:Q<9=#RL!+1LW&*ZII#=.0BGK:09G<,8%FS>MP<M%54>WLWB"[1VAV?;
M6SI%9NN1-9(Y"T/@,8_[_/DSS?,3C=7)IS79O9\='S;5](1BD<M"6PS@[Z)[
M/[I-VP)5]0CPS(J9U'!F9UTTT2BL)^U"!Q"F,9ZB!G8JS0\=/P;LKZ(EFB3Z
M/>%270*Y:K`(I*@DZ20<)@<`Z^P6134#_P"(H9[?`8QC`8QC`\"8H=X3``^X
M(@&`$![X"`A[H#UY!/*:H7:)L.N+'6=Y[@J2.Q-[:IU[)UZOS\<V@(^NV5=W
M'S)(AHO$N56CQR5HDN1V990R+@ZQRD,"@%)86OZB[I-;;P+VWVJ\.$5W"YI^
MY/D)&<6*X,4Q4%G+=NU3,BW['L4"@D`E*8P"(]?>#-<8Q@2)2/9I[Z^)31OV
MCVCE=Y(E(]FGOKXE-&_:/:.5W@,UON/[TNT/B[O'V6ELV1FM=S'*GJ+:2BAB
MD33US>3G.<P%(0A:M+"8QS&$"E*4.^)C"``'?$0P-9\-?8G<</B5UQ]EX_*6
MR/\`B]>:71N&O'6QW2W5FI5]+2^NDU)NRST7!1)%"UA@`I&D91TU:=MZRF*"
M0*BH)BF*!1,'5GZE^8=4DDDT-)Z\VCR#DW)1]#J:\JKB.J*'6J1)%S)7VZ#7
M*T2.7[(YTGT*O/E,1,Q@2$!*)@K[)-OFP:+&<N=$U.2N-986=]JW=B#.`>3<
M<VEW*\M,ZA6BT$6"S@CE1:22AI91@B5,5'A8YX+<J@-U.KURD1S+V0F0DE9]
M:<>8)ZJ=8Z%1C5-F[,CFH%.4K!6:L:9:!Z(7ZP%5ZQ@U%&P]0MCB<G6,IV'@
M;2$^<&B=GS6SMLVVQ*42XV2P*6J<CI<\_+ZLG-=C7>Q>*1J;RO19E[.FLZB*
M\=@S.2);MB]BB^E`=!H7EV2HZ!Y43')=J\>SW$G:4WKC0W2#U^/=M7U;J-U0
ME&SS5U^;L$5EW;48Y](0,-OEC$,DE7%9GXU9P9Q).YE6+V.MRLV7KO<G/.1G
M]H0QZA0][\/M?:R@YZNKN8R&UEM^H48QGU(0BG#*,6=STY<Y=A"W6V23'7Q9
MI$DE;YYM"PRC!MV8]!,^I4/0K;J64%98.T(]2JHB8144#L.HZ@B8PB<X&-_*
M-W^^.?ZE01*``5),H`1,@`"9``"(CUI$``+U`1,>^0H=12#WR`4>_@?/?*])
M9R=?:CUW>XA;4T#/NN!_,3DE<HQY1IB;9O=F<6MC0M3C*U'D&Z13J"CK@U5D
M49>/5-*/V#DP*1!E1:]@?9MIZ0;?T%1]N/A?ZH;S-'Y/<$Z!&V):HROW"9ZY
MY;5C3UGM32:B5;F11U(T,=@ST=&69.:CB/21#=>3C$%T7B9^WYF;0X]:C9N<
M>Q$O6=!(P]1C"<P=9B"/4)S&,(>`3")A`1$1'3>[M`:_W]5(>FWE&71B(/8.
MNMFL35N2^X3T+3JVUQ]TJ*R[I!NL+EBTGXQFY=QZJ9F[]%(S1R!FRJR9PY3N
MN?F]7M3J%3C[%K.)VY=>2'(#4E3N4O43,]6/N/''O8[IO?.8MA1?VPAF-+BJ
M#%.:]$P,;9$X^W;*?LEX2>6A"N6+7=>A>=-QVAS@L/'9R\H\W0&]7Y!':3D-
M`V"O23*YZ9VK3ZY&5Y`]A>$D)1RXHEM!_:S/(./8R$[&.YF@.9"EIE?.^IZS
M!DX``7:-E@+U=B"R"*H%[$XJ%['MA#]B!3B)R@'4!3=\H`/?S^@$TP-V8$+V
M768>R[$H&`3]CV0]8!U]9NQ+V0]?6;L2]EU]B'4'[QC&`QC&`QC&`R<.7?L:
M]P_!!S]-991^3AR[]C7N'X(.?IK+`W,7^9H?!H/J?))Z-/VOSA?\F;3?V)BL
MK8O\S0^#0?4^23T:?M?G"_Y,VF_L3%8%O#X/RE_6&0AEWCX/RE_6&0A@4IH?
M[T%`^#[?]NXS;F:CT/\`>@H'P?;_`+=QFW,#ESH?VU/GU\1/#?Z%LO.HV<N=
M#^VI\^OB)X;_`$+9>=1L#Y\NE9?61MOR)G6M*T*6$UGHAK;E=E;2XD;?Y%S<
M.>?LESK"\8RF-;V1@TAFRLJ>KQ,?"JP,I+E4M4M9NR3A8236:];^)6J=?ZWU
M#6)BE4MA3)'9-8HUPN35E7G=3%Q/#2H*+(F:KO7;YQ5D(]DR09M:L#E1&!`J
MK,@BIVY13FQSIL6[J!RFV?>=,;DL^GVU7X-Q^S=E.F&I-5W>+GZEJ79ET559
M,IS8DNV4):8^.NL_*L(5%"-C%4FHHO)HCB4;%0ZX:+G%;/I;4MC7M"EV6G];
M4F95N*T<>(6M2DG7(]X>Q*Q:@`>-4FC+#('8'`#-#.!0$.LF!M7-"3G&K4ME
MV6MM.?@GDQ8'#RJ2R\;)3<J\J*D_1C+'J-D&H+.30(6*`,NH>.ERM`<I'[%0
MPG.0I@WWC`D'8_![0NT6-2C[)'W1!O2)*XS%<&`V+<:^NRE+XJ*EF?&<1DHD
MLX<OR"9N158YC,FIC-F8HI&,`U)7J_%5>`AJS#-0:P\!%L8>,:B<ZPH,8YLF
MU:IF56$ZJRA4DB]L66.=5503**',<YC#[K&!!4,`!TG6RP```/6'Z+[P!U![
M(;D)^`,O7(+A_;.]E_(/T7_B&Y"9>F`QC&`S7^Q-@):[BFDJI4;Q<?1;Y)@2
M-H<$2?E4CJ_YJZ[11\P*FU`>HIE>VF$#"`=B.;`S\G\`?[1/^LN!-6D^4M*W
MRW"3J-0V=#UP[67<IVRY5-*O5I4T')*1,FT3D3RSDWHQN^0<H"F=`A.MLL;M
M@%*`FT&UUY9J1L#14U>)1K+W;9O)'8M_L"K%<[J/BF[_`%M:&E9J\6[4`IW4
M36*\W:1K!<Z9#J$[,Q@[X9HC44T_L?%C0G'FOM57LWO'9.TVMC734.0*WJ:I
M;<L4Q?K(N)%DC=2W7$UEHV4$$WYIQXFF;LVQP"YMSH(M=H<46S9(B+=OLZQ(
M((IE`I$44=86E-)$A0[Q2I)E*0I0\!2@'X,"HR^`/Z@_5GG/!?`']0?JSS@,
M8Q@,9B=XGYJKU>5G*]3Y>^R[!`%6=4@GD+'RLN?L@`4&CNPR,3$(J`41-V3V
M0;)]0=79]?4&2]I_E;<=NW.8JK;C1M*L,*G=Y/7]XM4U8]6+Q%2L40Q(]>HN
MT(F\/Y24;D!=FB5S!,9)$YW:9B',F14Y`LW&`\'@ZOZ/<_HQ@3ANSDS5M#!(
M.[?1=KRL%$Q+>9D[34*:2>KK!LY<';%1</@E6BH.TU2D[<@1L?L"K(F[,>S'
ML=DZTV.VV;"N9MK4KS4$6[P&A&5\@25^2=E,V0=$>LVI'S\%F*A%RD(N*I!%
M4BA.P#L>L=.<VQ$.*VYQ`1#_`-V$@[P__7$;E,1'^JXW_@&7T5'`]C@1Z@$1
M\`=\<9+NV=W6`UD<:5T)'1MOW8L@T4FWLH5=6A:<AI%,RB%KV4]9G(H9PJW`
M5:Y26"OW>LS@R1A(QB"NI%,(PL?-GCG0>D0O=;M=T>QKZ#T'#Z^>G1J]EETC
MW2'NTA:Y"N,$(6+D9*3D4(:68*E(P8.$W"ZX-6ZJJY1(%@,.4CNZ1+N2U+H3
M>%Z(4PHQCZ=J[754$_<?_!VY?8\A!V9DS,'\H7A:@[`"B`@D81`,DO27$O6N
MK^?,Y:I0CW8.U7/'>,OEDV7:EU7$I,WZR;`DZ_.65I$D4"%@15A8YG#Q[&+9
MI-X^.:HE2[)UVUTKUDZ@_K_K$1_7UX$:LC<Y+\X<FD":,X^0*JR146K0L]NV
M^(-^Q'MRB<RLXI=*0<B8?Y!'%7DT4Q*`"*I1$1U=R.X:R&V=1['9;:Y([UM;
M?TIOGK>)B)&KT>I%>01234<M)4RJ0+""L)$7\<V6]#SB+Q$YB@<X&6*50.CF
M8!M;[V&P_@59_J9Y@<R.#J4CPQU1J6AWV5&6T-MR'J]EU[M600;-'E/V3L!@
M$Y-Z]V09H9*.9QDS*N%5:-;BMF3%=TX"N2XEDE&#A[UVR;=&U:OW;BEJ6I6N
M)9SE<L6DJ1$S,2_1*NT?,'E3CT5T%2&`>KK*;LDU""55%4J:R)R*ID.75-9L
M]BXC341K/:$Q*V3CU,/6T/JO=%A?JR,KKM\^7;LH75NW)-5(%#Q:KA0&5%V(
M_66*NF"$%;':,@#)\\"Z,EW;#=`.0'%D`12ZCS6YQ,':D^H15U0^*H(_R>^)
MRE`IQ'K[,H`!NL``,J$!`0ZP[X#W_=\/?_!WO!DR;9]D#Q7_`.=;D_NID,"F
MRE*0H%*4"E*'4!2@!0``_``````?T``!GG&,!C,"V,[V2SKP+:KBJ=,V<'[<
MIF=XEY:$A?N8)%A=JE>0T;*NQ>D."`((BV!$Y3*BHJ02%`TZ\7MS[YW:Q6M5
MVHVKJM2V]@V#4E35JV669L?W=HEKD:DJH5I(P#".&+?/(IXNFMZ-]$E;B@)T
M"'.8I0L?&,8$F<L/_(X[_*OT9];RN5D7P!_4'ZLDWEA_Y''?Y5^C/K>5RLB^
M`/Z@_5@><8S#[WL&D:PK4A<=AVN!IE6BB%._G;%)-HN.;@=0B21#.'*A`.LL
MJH1%NW2`Z[A8Z:**9U#D*(3I2/9I[Z^)31OVCVCE<*JI(IJ++*)I(HD,HJJJ
M<J::29"B8ZBASB!2$(4!,8QA`I2@(B(`'7G!_5_*[DQL_I!]X5S5.AV$97+#
M1JW7X&Z;/B-B5V/CJ95)*R/J=M64;&B6;A_"7(DQ(J1U?,G7W[PR\6U:R(>@
MY-TIT87XG/MEK,W?)C;%LW.S052>^ILS30U_IM%\FZ*Y*DXIU9.WD+A&HBFD
M5%GL2<MA0[`3]8"<2@&5S?+?5)+&2D:[&>W?=U$%UQ@-/1R5N81Q4"J]F%AN
MQ7;2@5I4ATC%.PF;0UEQ\+>,<#U%&4.2^KN5?*'0NX878\I3..%$/4)N6BJ5
M62CM"\3:M=CE)QDC>+8JO"0#&&?K,S(2$'6(LK\A3$`;"N0BB2W3.OUFNU2-
M;P]8@H>NQ+1%%NVC82-9Q;%!%NF"**2;5DBBB4B210(0.Q'L2@`!WLQ/<?WI
M=G_%W=_LM+8'.SHXN$NFJ%QBTI:K/`Q>S+S8JQ&WP+/;X_[JJP2=J9-91G6X
M!K)*NT64-!(J`BT(8JJQW*CER*A4U$44>JJ+=!NBFW012102(5-)!),B:*29
M.\4B:)`*FF0H=0%*0I0``#J#)OX:^Q.XX?$KKC[+Q^4M@,GRW>R8TG\5&_?K
MW1V4'D^6[V3&D_BHW[]>Z.P*#QC&`QC&`QC&`QC&`QC&`QC&`R<.7?L:]P_!
M!S]-991^3AR[]C7N'X(.?IK+`W,7^9H?!H/J?))Z-/VOSA?\F;3?V)BLK8O\
MS0^#0?4^23T:?M?G"_Y,VF_L3%8%O#X/RE_6&0AEWCX/RE_6&0A@4IH?[T%`
M^#[?]NXS;F:CT/\`>@H'P?;_`+=QFW,#ESH?VU/GU\1/#?Z%LO.HV<N=#^VI
M\^OB)X;_`$+9>=13=EU#V(`)NH>H!$0`1ZAZ@$0`1`!'JZQZN\'?[_@P.-G.
M]OJW8'()CJ>5T-L+EIL5]J2G2"VA*C!V.GU8]!D;U:E%9G9>[1L=1UJE4Y2:
MK93'HFPY&;07>5=!6)@3.9@ZBG76JHIMZQ7D$8)M6$4(2+22K;,[%1I`)ILD
M2$AFJD68T:=O&E`&:)V!C,S)HE%L841((\8]I1'-._['?0W+/;9N-O':V35A
M@%H;BS%N%#J:WCJW8'L=,W[E1.0H3]4EI.::,44ZU`U>JO2IR2K9E-*"NJH;
MK;I6+JL)I_5L/1IIQ8Z9%:\IT=4[`[<&=.YNMLH!@WA)9RY/_+<.)".3;NEE
MS_RE5%3'-_*,.!L[&,8#&,8$%P_MG>R_D'Z+_P`0W(3+TR"X?VSO9?R#]%_X
MAN0F7I@,9&5FY;S%9V)&:S6XY;I?V&PDL[NLF8EI)F,]%5-PV1E)5HLM:4CH
M->P>LUT".TT7"B3@O6D4P&*%=PSY>4B(N2=1KR&<R$>S>N(B0[0+^,6=-TUE
M8]Z+959N+IF<YF[@4%E4>VIG[6H<G480]EGY-X`_VB?]9<_62!R,Y`.H1I8=
M,Z12>W7DG9*W*-*E7J\:-,WH\C(1K@L/;+_-RJJ<%4H=JX$KEH$NHH]E%TB-
MH^,>J'*00TIT:*S:UZ6],4A2F$;(4>];AUK6K8NJ5Q,S$(WVA8Y:?%),S<@Q
ML4>?<F3;)IKK#(%;^BE!(`$3#=5[XT;&O%RB+>?D_LF&&K6:3L],AX^GZD58
M5AQ)1[N(,S04?4-T\E&B$8^<-$@FW$@J/9]N44.N4J@<_NB)V5L?7FIHS4/)
M.7;1$I<K+89;2#]\\AW$;=`0FY2/V+%1\['-6:)[,G?&\Q*$JKX3RJ<*Z;2#
M(5F"Y2H]P<#'ZK%2T'78B(G+(_M\O'LDFS^S2;.*CY":<)]8&?.V<(RC8ENN
MKWNS38,&K8!#^0B7K',@QD@;2YD5+4EP)3K%J3D7).7M@;5>"FJQIV?GJU:)
MQVR4D$&%:FFQ@;RZIVR#D_4@'A:N"^%(V!7^,PC7=W)L.J1]K3JUUII)`[H@
M5_85;=U.U-/0KA1N)Y"#?"+EH1<4^W-C*#_EFYTU2_R3AF;X'Y/_`)AO]DWZ
MAR*N(0!Z:>7_`'@]EA?OP?\`U)6O_4?SCEJG_P`PW^R;]0Y%?$+^=/+_`.5A
M?_J.LX%K8QC`E;FY[%;<WP82^N(S*8B/]5QW_`,OHJ.2SSJDXV,XI;B5DG[)
M@DK7VS5)1XZ1;$5<K3$=VINF98Y`.LIV)A(D41.8"F$"B!1$,->;*N_(N4/K
M#0,D:!UG7EVD#N'?R*A2J`J1@D:4H>E04;.FTY:R%ZHZQ7)4/N)33KJHLQDI
MY$K=`,EV-N&X[*N<MH;C8_CO3-#"BCM[<*R:4K6-,,'A#"6&CTB*BA/[<DVX
M*J0=>`KF/KI2%F;65)#T(R>[WU5J6I:@KRD%62R3YY)/5)FU6RQ2"\W<+M97
M*223^SVR>=B+J5F'P(I@8W^19,D"),(MFQCF[=HE[;7>N:9JFI1-(H<$S@*]
M#MR(H-6I.M=VN!"E<2<J]/UNY>9D#E]$2DQ(JN)&2=G4=/7"RYS''-\"/F/L
M\+'\E*I_WM6'+!R/F/L\+'\E*I_WM6'+!P&8!M;[V&P_@59_J9YF?Y@&U@$=
M9;"*`&,8U*LX`!2F,(C]QGG>`"@(]?\`W^`<#"^,?L=-%_%)K[[,1V;1MU1K
M-]K,W3;E!QMEJUDCG,3.04NV3>1TG'/$S).&KE!0!`Q#D,/8G*)54C@55$Z:
MI"'+J_C(`AQVT84Q3%$-2:^ZP,4Q1#_W8CO"!@#O_AZO#U"`^`0'-Y8$)0EL
ML'$"P0VOMIV*3LW':S2:,)J[;UC<%6?ZGDG(F3B-6[5G%U#+/J\Z`$F-"V#)
M=B=-0I*Y:'AG!XY\KL_:QRJ;_P"*IR&`Q#S.XS%,40$IBFU0_$I@$.L!`0$!
M`0$0$!`0$0'*%L->@K9"2E:LT1'ST!-LEXZ6AY5HB^CI%DY()%FSMJN4Z2R1
MP[_8G*/8F`IRB4Y2F#@+N'D#L7A;S'T#I"1KDSL'0=-F7#_7%AE@G'UZB:CL
M2GR5?L=5:R#=I)#<8G5Y?_'M9N3.W>Q\1VJ(EW*Q$&CHH?0GC,%H.S=?[2AB
MV#7EPK]QAS',F+Z`DF[]-)0IA**;E-(XKM%>\(BDY22.'?#J'JZ\SK`_)_\`
M,-_LF_4.1MP3^\?*_'?R)_OLN^62?_,-_LF_4.1MP3^\?*_'?R)_OLN^!9>,
M9AMYV%2-:0+FT7ZTPE1@&G4"TI.R"#!KV8B`%22%8P'<KG$0*1NV(LL<P@!4
MQ$<"?N6'_D<=_E7Z,^MY7-]7[95!U56GEOV-;8*FUN.2,JYEI^008-_Y)1,"
M+<%C`J]=J]78-F3--=VY5$B*"*BAR%'B[SQW%RHW8UT%)<5Z;;ZE02;TIC.&
MO=V@ZG77ECV4,DN6A2T'5+P"DW)4HA@?B,J^:0L._4.1?MKY!-(@].];<8ZE
M!S3#9FR7$OMG<:\3%%?V[8,@WL+2NR239%1^CK^MHL6%2I;,)`7`(O*]!LII
MRS!%"2EGY2=8ABB&^-O;F*1MQWU;(P5><=K[;N+?$%-TZL(HJ)$5[96=<N1B
MMB6]T*:B:[1=RSK=7>(&*=&RJ&,"69)5^*U65EXB[;KGYC?^R8=X,E%6&_E0
M&LU1\(D$#4+7+`J%.J@("FGVF0)'/K(H*:9G\\]43(<*GQ@2'1RE+S3WUU%*
M`^HIH[O@``/5Z8]H=[K\/5W@[W@#J#JRO,D2D>S3WU\2FC?M'M'*[P&:WW']
MZ7:'Q=WC[+2V;(S6^X_O2[0^+N\?9:6P-8\-?8G<</B5UQ]EX_*6R:>&OL3N
M.'Q*ZX^R\?E+8#)\MWLF-)_%1OWZ]T=E!Y!%IV=M1SNNC71GQ@W&\@Z73]JU
M5VNDXHI5'[NW2VNW,2\CT5;.05&1D:@_,N=<S=5+M[7J14$RA2!>^,];#/UY
M2(C))U&O(9R_8-'CB)D>T>CXQ9R@FLHP>^AE5V_HIH<XH+]H651[:0W:U#DZ
MC#[+`8QC`8QC`8QC`8QC`8QC`9.'+OV->X?@@Y^FLLH_)PY=^QKW#\$'/TUE
M@;F+_,T/@T'U/DD]&G[7YPO^3-IO[$Q65L7^9H?!H/J?))Z-/VOSA?\`)FTW
M]B8K`MX?!^4OZPR$,N\?!^4OZPR$,"E-#_>@H'P?;_MW&;<S4>A_O04#X/M_
MV[C-N8'+G0_MJ?/KXB>&_P!"V7G4;.7.A_;4^?7Q$\-_H6R\ZC8$1<@N9B>F
M-C!JF"X];VWC8R4:+O<V?6$!6G$#"P=AEK#!0[>0E;18X)LN_?/:S+@NQ9%=
M'9M"-W#SM:;M#LZHUO*)S>O:/,I5<])2E:E7I%.G*$CTU*J1[%-7):Z<D2JM
M%D/#%4"/,6.558E%`0:J'0`AA^>#I>J+#SO)=&RV#7VG'4-!<;()Q*;(W75.
M6-BK\)'-[GL-$C.*=Z%M-:JT?(%L$E7HL6DR24FY!Y;8ERLV2A(Q94>\7&-L
M@SXXZ%:MFJ[)NVTYK9!!FY8R$8X:HI5")(FV6CI4QI-BJB0`349R!C/6QBBD
MZ,*Q3C@;RS%I"\TN*GHZK2=NK$=9I<R9(JO/[!$,YV3,J!A3+'Q#EZE(O3*`
M0XD*V;*B<"F$H"!1ZLI\&<5ND9A*I=]I<?WVK6FN;ONC2W*KCM/W_6IJBL&V
MIN*GI])2N+PNS6*!;)48&'CT9&:FVK-56KS,0T7BYUW&HKG(Y#LA,V.OUU-!
M:?G(>$1=*]H;*R\HQC$W"_4!NTH'?.&Y%E>Q$![6F)C]0@/8]6>W(<BA2G(8
MIR'*!B'(8#%,4P`8IBF`1`Q3%$!`0$0$!`0'J'.*?,VSU?8.[=8WATY&Z:00
MXS<V:7!ND&;QY76>^&D5`LVC%5%RU*@C<)",;N8>E*G0]&O99-TUKBRSH5`-
M;6LJ[R>3XD\=X:`ME)KVY8W6&MF]]DMBUB:L3-5RA48Y.39JL8V0B'J<TDN"
M2+QTNL<!=(N15*HH<3X&/P_MG>R_D'Z+_P`0W(3+TSEIHB.W-&=(UMM'=]GH
M=JLJG";1JD4]U]6Y>L13>$]7O?A0:O6<S*2SA=_Z.!RKZ)2721]#G22[3V9#
M*'ZEX$@[%]F3QK^+?>WZJ3E/VBU5NE04C9K;.1=<K\2W.ZDIB9>MX^/9H)@(
MB=9RY.FF`CU=BFF43*K'$$T4U%#%*/)WE?S`@-4<\./E#AJ+:-@79I4[+4D8
MN)7CXI@I:]RN(AE08M>4D1,DW;OW<`L21D3I@VC4UT3*"JH8J1K`KV@+3LN:
MA=A<II.)MTI$*DDZGIJ!04-J.@2!A%0CN0;/.VK[)MK(O:D4['8DRQ;!9-1:
M"A6QS)N@#TCVX;=Y0%&)U*I9-+Z1>I!]T-X/F?W'V5<&_;`'T/J*K3;)PK"1
MCHI#)KWBVQK<RC5=->MQKPPG72]!6]55**W[1]5:^KIVE#TO'*[?V5/.7K]]
M)7';=K:+P5'5N4PY.,A9K@UBRO[@:6EW+KL$5$VZ((H$09IW5)RD?"1DA,23
M@C.-B6+N2D':_6FBU8L4%'+IPJ<P`!4T4$E%#"(@`%*.:JTY98&]4J*VZUK2
M-4=[4;L+`OZ)6(9_*QJ1EF%3?.W)^U]N]&5M-@^9(E*4&[5^F@4HB4QC!*/$
MG5U)W!PJK%(OL*C,0CVS;270'LC-Y*&E&NU;F:.GZ]*(]B]@K#$+&]$Q,U'*
MH/F#@H'25[`RB:FPM;[-OFE;#&:2Y&OW,NS=N4XC4G(9RDDA!;%;]@O]S*KL
M5X4R;6M[?(T:',N*R+2"N1B^B(1P:1,JQ'_#H^'+<_%ZDHD71.J%DVJ84R*I
MF4`H[4MY@,)"F$X`(&`>L0ZNH0'\(==4WV@U'9U2FZ/>8-E8:S8&9V<C&O4P
M,4Q1_E(NFRP=2[&18K@1W&R3-1%]'/4D7C)=%PDFH4,P`>L.L/`/?#)!Y4?S
MEXL?*4K/V/N6>BKFPKGQKM57U+NJ1<VC5=D=I5W4^_'YNQ=1[X$P+$:_W2X[
M`K)G87)0+'5:[@9M'VP6P-Y1-M/*"+KWO*?OV3BN/_VE*S]C[E@5]C`CU9-&
MSN45%HL^VU_5F4OMK;DF8Z,9K/72)9F605(43'<VR62!2$HT0W*`J/)*R.FI
MT40,JBS<]0%,%(N%4D$%EEE"))))*****&`I$TR$$ZBAS#WBD(0!.<P]XI0$
M1[P9QLXH<\>,L?=.5T:O=I526G.1EVMM<B&5+MLI)66!=A%0#=]`M(N)>JOB
M'DXQT@8#E;BD!4U%>Q*J7JL=[IK>.]&:Q=^;`-KZD/U#*JZ:TL_=QCEY'"7K
M3A[YM8QRSLT14AC(S$?46]?BWG_YAZ*(]B.D^CVX]:=T]=N7<AKBDL*PZ0Y!
MVJB-%&KF0<"RI\*TA9:-K[07KMR9)@WDW[M\(=D999RL91953O``4,_Y+WB6
M[2AK#B_O2Y.5TC*>BK1%0>HH-`#$[)NHK([#EXM9=%0H@H86+1=8I.Q`$Q4,
M!<]>1;G1;VJ(A'<>]/MWJ@*'%W(W#9=LB$"F$O:%F#5E#U!VZ.'\L5&TXL@4
M.P*`]?9]5C]0`/6```CX1Z@Z_P`^><#B5TA'"*^['XZW&V;1Y2[!OTG1Y1I=
MHVIO:E3875@G!)>`69EIT4T&2*Y(UFUU&,JXLSQPR.0Q4D0,X,JGU6T!J^+T
MMI76.JH5XM(QM&IL'`(2#ANW:+R!FC)+M[U5LU`&Z"CI<ZJYDDQ,!!/V(J*"
M`G-K7FY[%;<WP82^N(S*8B/]5QO_``#+Z*C@>QS_``=+BV;.'!4%G)D$%EBM
MVY0.X7%),R@(H$$2@=942]K2*)@`RAB@(AU]>?[XP.;#+9M]+RCEMKJ<:^0*
M=5D-(U_6[=4:C&"Z"P,=A24\Y46;_=OLDHTL6_(L#S^6!E$S)`F`CUEZ1(*B
MLBDJ*:B(JI)J"DJ7L54A.0IQ34*`B`*$$W8'`!'J,`AUCU9^^P)_]$O_`-T/
M_3/U@,UELO3]"VZS8Q]]C96491P/BH-HZW7*K(JIR22*+U%\2I6"!^ZB"R2"
M9.T2?HQ%(.V=I33%983[-Q@:CU=HS6FFDEV^NX:4A&B[!C%E8.KC=[''-(Z-
M[(&+.,CK39)QC$H-RF[6F2+;L_\`)`1(W9)IID+MS&,!DQ[9]D#Q7_YUN3^Z
MF0RG,F/;/L@>*_\`SK<G]U,A@>RV)Q?U=>Y&1M,:TE=9;)?D[(-I:JD3TJ[^
MC"&`[=Y*.HX@1-K.@8H$(A<HFP-@1$Z)$DP,!BZ\0F^5VEQ;(6N"C.35#;"5
M!:U49NSJ6Y(]F3M(#(S-%?.4*O:Q12`_;25&33FI!QUG1A4R&[$+-P(`/>$.
ML/<'`T9KGD9J7:3Y_7J_9!CKG%*J-)F@6Z/>T^]P[Q,%14;/:M8$6,D8Z94C
MG,HQ3>MNP`#@N)1`<F3B9MG6NM>.,S9KU>*U6H1/=G(PQ'LA+-/_`!8DW3<5
M11C6R"B[R5=&3<('3:1C=VZ5!='M:)NVI]E2^]^/.N-^4^<@+9"LF]@=P4G&
MUK8$>W%G=J1(NF;A)A-UNQQZS"<8N(MVL1\1FWE$&3TR7H=\BLV453-S4Z)S
MA?3=7ZNLUUNYXS9MU-M[8T17)>=8NI-M3FE%MLA4EEZPUGEWJ,1)3TM!.)Y_
M*L&;*25,NV17=K"W[+`M=?;'(#<JA6FB==EUQ2W38IC;CW?&OHMRX0=E1,B\
MHFK4CEL,RH5LN5ZS>6X*]!NPZB=M.8HIFS'7O%FB5:2B;C>Y"=W;M2-7-($V
M1M)T6=D(^54`G9NJA7`!.HT5)#L>TL/2Q"LI%NT[%!S*/C`*PTR``'@#P^'^
MG^OW?RYYP),Y8?\`D<=_E7Z,^MY7*R+X`_J#]62;RP_\CCO\J_1GUO*Y61?`
M']0?JP/.,9ZV8DB0T1*3"K5\]2BHY])*,XMJ=]).R,6JKH[:/9)B"CQ\X*D*
M+1JF('<.#IHD$#'`<"5J1[-/?7Q*:-^T>T<KO.55(Y.,@Y0;$OJVC.3[2MWS
M7^J*9"OGFC;(W*E,5^?NJ\H:1*9P86#!LA8(]4SU?L4C%%<2@/:!`W5,A@.0
MIP`Q0,4I@`P"4P`8`'J,`^`P=?4(?@'K#\&!^LT%R'N2U?U]9X!G2-C7*2MU
M0M\-&HT*ERML*@_>P$@S9IRBD<`DC4W+IPDDDLY$J0]D)CG(F4QR[]SP(`/A
M`!_K`!_7@2+POGI5+1>K=<6'7^S*/9-=:NHL!/IWNE2-98JRT=#-HY\UB)%T
M=5I+BU<ME.V'9*J$[2*:P&[%0`"N\\`4H>``#^H`#]6><!C&,!C&,!C&,!C&
M,!C&,!C&,!C&,!DX<N_8U[A^"#GZ:RRC\G_E2V2=\=]O(+=EVLU+DSCV!NP-
MV2)D%B=1NH>H.S3+V0=7?+UA^'`VN7^9H?!H/J?))Z-/VOSA?\F;3?V)BLK8
MH]=,*/NUD!__`,/DD]&G[7YPO^3-IO[$Q6!;P^#\I?UAD(9=X^#\I?UAD(8%
M*:'^]!0/@^W_`&[C-N9J/0_WH*!\'V_[=QFW,#ESH?VU/GU\1/#?Z%LO.HAS
ME3(8YQZBD*8QA\/4!2B81[WN``CG+O0_MJ?/KXB>&_T+9>=1#F*4IC'$`(4I
MA,(^`"@`B81_H``$1_HP/FIYK<N>/N[I][?]&<I>--IC=E<:YG2AH':/*)]J
M.*U3.O[U&7!CMGTC,XY\YM%I@',4W!.,8*1L\9["LHQ9V$:Y<I*_0-HY^K*:
M9U/)+W(=BK/]<4IZK?C-3L1NJCFNQZQ[6+-3K4:C8#'&4]#''LT?17:S?RBC
MG##8VW="[HLDJGT>.G=`C(A:'D9LOD3MNN:ZU[QI%%)V4UG?-:U984+3N^QM
MP!^V0?56!C(LCSOMK@X2%T0G>/51X4^LM>GKBU<<P!Z56#0CBH,58RJ+Q(PS
M,8]6M1JYU%F$"HU[6:)9*G.HU8B@B<QC$$1#/L_C&.8&>EDA9M1D"(BW*^%L
MCZ,*W$>R%`KKL/1`(B;^4*0*=K$>^)1S^S&!_(LP8N$TT5VC59))8CE-)5NB
MHF1PF83D7(0Q!(18AQ$Q%2E!0AA[(I@,(CG]>,8$%P_MG>R_D'Z+_P`0W(3+
MTR"X?VSO9?R#]%_XAN0F7I@0;MO7-$G>=7%VV3%3@Y&RQFOMQ.F$TY8D._;N
M(0U55AU^W`)065BU7[Q6..X*L+)5<ZS;M:O8G+3FW-04/<=?;0E^C'DI'13M
M678I,IN:@U$GY6+EJ58SB$?,'"I0174+VE50Z/6('[`3E*(3[L>RUPG,?CD8
M\_"$*VUWO5%R8TJQ*5NJ8:80J2XBN`)*"=,Y`(H)3"8AR@'640"P963C6<(_
MF'<@R;1+:,=2#B3<.T$8]!@DT474>K/5%"MDFA$0%4[DZ@(E2_R@G`O?P.1?
M'SBK$;#XEU-6M'F&M@VS+S%/VS:)*ZV9[)*ZJC-MV0D\SB$960DF195Q%0$5
M#MA3;H*&:F6`S@"B<BG32_Z.U3M&K0]*O=*BI^JU\[,\+"+'?,V48,>V(S9%
M:EBWC!1--JU33003[9VLB9"E`G>#.>W1?.)F]TR0V`>50<T:F)VO4=!:Q[XB
MS9R^'9=FM^PIYVFW.9NZ*_?.:LE!/1,J8K!-\FW.1%8X'ZP8$]:JXI<>M(SA
M['JG5M>I$R=@[BQ>0JDL3_P#Y9)P\;@V=23EH4KA=%-94Y$"J&4`3]GV1SB:
MA<8P,>MM3K=[K,Y3;?#,+#6+)&NHB;A9-`KAC(1[M,4UD%TC=_P"!TE2"19!
M8B:Z"B:R::A>#?-W>ENX$V3C?KJ7:R^\M<P^PE-KZW=2D['PM[K%4I,8[K\K
MKJ:L$PH+2YF;FM,>YJ\Z<A)LK4BT9,(/.P8N3?0+D2\P:S7+%9.*06"`A9P&
M_)*ND0"8BV,D")%JG:UE2)@]07`B:JK5LJJF7J(HHW0.<IC(IB4/+*B\@>0L
M9'2VU[@IH_7TRQ)(DU5J&67/>7K.00,HT97C:KELF*`IME4AD(>G1#-NJ=11
MNI)G[250:9UOJS7^HJVVJ>NJM%56#;!UBVCD.I=XL)U5#NY206%20EWRJBRI
MU'LFZ=.3&4,`*`3J*&P`````````#J``[P``>``#\`!C`_)_\PW^R;]0Y%?$
M+^=/+_Y6%_\`J.LY:A_\PW^R;]0Y%7$(0]-/+_OA[+"_?A_^I*U_Z#^8<"U\
M8Q@2MS<]BMN;X,)?7$9E,1'^JXW_`(!E]%1R-.9K_:]HUM?-1ZZT=;[\M;:N
MT296F,G*E&039\>32758.B34PR?@JW19@<ZA&QD3>B$@(<Q@.!:+U-;+3;:X
M9Q;-;6/63^.60C4HBROX*0=OD4&+832+=6`D)%J5J98RB!"JK$7$R)C"F!!*
M(AM'&,8#&,8#&,8#&,8#)CVS[('BO_SK<G]U,AE.?]_^N0U>M/<LK1L:IWF/
MVII./0U],W9]48YWK6W.UA86Z#<5LK:;=(V]!-RY81BQ507:HHIKO2F,9,$!
M*F4+EQGI*VC8$(**1M3V,D;&FS2+,OH9FO'Q;I^`#VY9BR=.'3ALV./5VM%9
MPLH0.\90V>[P/R?_`##?[)OU#D;<$_O'ROQW\B?[[+OEDG_S#?[)OU#D;<$_
MO'ROQW\B?[[+O@67C&,"3.6'_D<=_E7Z,^MY7*R+X`_J#]60?R?E]O6.PZ]@
M:9Q_O-MC-=;NU?L=S9X^<I3.+FH2JK.I"60C$)2?9R`/2"[*U03<MDB*K)*B
M!P3`ACUYK^S3MMK;>9L=(F]>RBJ[A%2M6!W$O9)NF@8"I.%%X5X^8F3<E$3I
M%(X,<H%$%"E'J`0S7&,8'CJ#^G\X_P#KGG&,!C&,!C&,!C&,!C&,!C&,!C&,
M!C&,!C&,!C&,!FAN4'L?=N_`B8_9DS?.:&Y0>Q]V[\")C]F3`V>3^9A?@R7Z
MG#)*Z-/VOSA?\F;3?V)BLK4G\S"_!DOU.&25T:?M?G"_Y,VF_L3%8%O#X/RE
M_6&0AEWCX/RE_6&0A@4IH?[T%`^#[?\`;N,VYFH]#_>@H'P?;_MW&;<P.7.A
M_;4^?7Q$\-_H6R\ZBF*4P"4P`8I@$!`0ZP$!`0$!_H$!$!_HSEUH?VU/GU\1
M/#?Z%LO.HV!AD/KF@UZ#C:S!TRKQ5>AXXD3%0S&"C&\='QB9#$(P:-2-030:
ME(<Y01(`$ZC&ZP$3"(Y'$Q4;!1D="PS%K&1,2R:QL9',42-F;!@R1(W:,VC=
M,"IH-FR"9$44B`!$TR%(4```SV&,!C&,!C&,""X?VSO9?R#]%_XAN0F7ID%P
M_MG>R_D'Z+_Q#<A,O3`E67X/\1Y^8D+!-<>M62<W*O7LE(2KRKM5W[M](KF<
MOG2KDQNV"J[7.95P8!*"IQ[(P#WLVK?-5UJU:;LFG&Q#5JJ2U$>T5DE!I-TO
MN%##$&C&2<8W<)KMBDCFR:)&[=9)5$4TBI*%,01`=JY_,\_T5Q_N%_V*F!SV
MZ,+5\?KSB]%2K>2<2<GL&Y;#M4XJ=JRCF2,@2^6:',E'1T>B@U:MC@P,Y$`(
M)^S<"EV7:D$2$Z)9'O`CV*&L?^,V/_>K>,L+`8QC`9(/*C^<O%CY2E9^Q]RR
MOLYA\N>2NM(S9.G:HJVV,\E]5[W@++=!A]1[+FXV.A&]5L""KYI,1E8<Q4PF
M1>69)"2(>/5>S4.':_\`(J]B'3S&8'K79%8VQ4(Z\4\TR>`E5':;,T]7)ZJ2
M8F9.5&J_;X2RQ\7,-2]N2."9G+)(%B=2J79)F*8<\P,6NE53NM:E*RK/6BLD
ME$.T&FZ9..:Y9&(=D!NV1DRS`7#)8>KL142#LA*(AX!R==8</Z;J:V.+?6=G
M;]=.I*S/KC88B?VW8)FN6JQ2+0&3V2LT*Z`6LJLND1`R@*=@056K93L0%$N5
MGC`8QC`\=0#X0`?R9YZ@#P!U8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@8E=+Y1]=P
MWW?V!<JK1H)1TE'$FKA8(FM1)Y!RFL=LQ+(S+MDT,\<$06.@V!85E2HJF3(8
M$S"$1='WMC5MAUC)5"`V509RV*;<Y!3:=8B+A7Y*PGAG6XK<_;2Y(5G(+21H
MMRQ>-'C=^#;T*LU<MW":IDEDSFO&=KE>M#((VS0,-8HX%DW(,)V+8R[('"0'
M*DX!K((.$`63*H<$U03[80#G`I@`P]?IX37>OZR^^Z=;HU/K\D")V_W0A*S"
MQ3[T.IV/;$/1;%D@X[2?L2]FEVSL#=B7LBCU!U!F.,8P/'4'N!^;//4`>`.K
M&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!FAN4'L?=N_`B8
M_9DS?.:&Y0>Q]V[\")C]F3`V>3^9A?@R7ZG#)*Z-/VOSA?\`)FTW]B8K*U)_
M,POP9+]3ADE=&G[7YPO^3-IO[$Q6!;P^#\I?UAD(9=X^#\I?UAD(8%*:'^]!
M0/@^W_;N,VYFH]#_`'H*!\'V_P"W<9MS`Y<Z']M3Y]?$3PW^A;+SJ-G+G0_M
MJ?/KXB>&_P!"V7G4;`8QC`9)NY.9.JM$7>N5'8D/LZ.B;!9*I3EMF,=;6B4U
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M4[!2/W+<MWZS5)!/IRKJ6/O&M*14-L`[D)6#@ZV$TK2[3;Z$T6LD?",V<JNP
M<4J;K<@$2J_(Z.TCEEQ:$;F1*9L`IE`H3E#=_I.MEC^#UA^C`\'X0Y#<@^L/
MR9>F<@YA&)X;\YK;=(;1W*:\ZUOW$S5U79V'6E`W7R1;(7BL;FV_+S,'(S!W
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M<]N\(AWN%>\![X#U#WP@1`>^'A`1#W!P+\S\"FF81$R9!$?"(D*(C_6(AUY`
MW=!*K[V+GM_8JWCY@QW02J^]BY[?V*MX^8,"^P*4H=10`H>X```?F#O9YSG`
MCTFFJG%J>T5#0G-]:YQT*SLC^K)\-]V&G&E?D'2S%E,KL`@>VIQSIXW7:HN1
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MP+\QD!]T$JOO8N>WA`._PKW@'?$>H.^,#U>',?K'28:MNL2G/5#0/."S0JKI
M\Q3E87AMNU\Q,]BWBT?)-072@1+V]@^;KLW2?A1<(J)&_E%$,#HYC(#[H)5?
M>Q<]O[%6\?,&.Z"57WL7/;^Q5O'S!@7YC.<5AZ3'5M2)$JVC0/.&OISTY&UB
M$/+<-MVLRRUBF%#)14(P%2!#T1)R*A#D:-2?Y18Q#`4.]F0]T$JOO8N>W]BO
M>/F#`OS&0'W02J^]BY[?V*MX^8,=T$JOO8N>W]BK>/F#`OS&<WXOI-=4S<_9
MZK#Z$YO2=EI1X5.WP++AQNIQ*5I2R1GW9@"3#0D$*C,TQ$_^T6(*!_EFO^4#
MJZP#,D[H)5?>Q<]O[%6\?,&!?F,@/N@E5][%SV_L5;Q\P9ZJ=Z2'7=7A9>R6
M3COSG@J]`1KV9G)J4X9[N:1L3$QK=1W(23]TI`@1NS9-4E7#E<X]@DBF=0P@
M4HC@=$<9`)>D&J9RE.3C)SU.0Y2F*8O"O>`E,4P`8I@$(#O@)1`0_H'/UW02
MJ^]BY[?V*MX^8,"_,9`?=!*K[V+GM_8JWCY@S&QZ3751;<2@CH3F\%W4K:EP
M)4QX<;J^[QZJE+)0*MA+'_<+MPQ2<TNC%G==CV(/%2)=7\H!P.D&,@/N@E5]
M[%SV_L5;Q\P8[H)5?>Q<]O[%6\?,&!?F,@/N@E5][%SV_L5[Q\P9ZB%Z237%
MD:+OZ]QYYS33)K*S4&Y=1O#/=KI!"9KDL\@;!%*J)P(@1]"S<>_B9)`?Y;9^
MS<-S]1TC!@=$\9`?=!*K[V+GM_8JWCY@QW02J^]BY[?V*MX^8,"_,9S=LW2<
M:GI@0`VW0W-VMA:K1#4FM#,\.=U,0G;?8CK)P5;C!6@B^BI>64;+D8M"?RUC
M)'`.KJ[^3!T@M4$`$.,7/80$.L!]97O'O@/_`/0,"_,9`?=!*K[V+GM_8JWC
MY@QW02J^]BY[?V*]X^8,"_,9SEB>DLUC.R5EAX7C]SCE):FRK6"MD<QX:[M7
M>5V9?0D79&<9+HD@1,S>N:_-P\RBBH'9'CI-DY#^0N3K]]W02J^]BY[?V*MX
M^8,"_,9`?=!*K[V+GM_8JWCY@QW02J^]BY[?V*MX^8,"_,9`?=!*K[V+GM_8
MJWCY@QW02J^]BY[?V*MX^8,"_,9`?=!*K[V+GM_8JWCY@QW02J^]BY[?V*MX
M^8,"_,9`?=!*K[V+GM_8JWCY@QW02J^]BY[?V*MX^8,"_,9`?=!*K[V+GM_8
MJWCY@QW02J^]BY[?V*MX^8,"_,T-R@]C[MWX$3'[,F3YW02J^]BY[?V*MX^8
M,UUMOF5&[-UM<=?5[C+SE2G;C"KUV)5F.'NY(:)2?RBJ+9NK*2\C"H,(R.2.
M<%'L@\63;LVQ57*INP2$!#HN3^9A?@R7ZG#)*Z-/VOSA?\F;3?V)BLKHZ*C>
MHG06*)%4:Z9%4@^$BB42)#E'^DIRB4?Z0R1>C3]K\X7_`"9M-_8F*P+>'P?E
M+^L,A#+O'P?E+^L,A#`I30_WH*!\'V_[=QFW,U'H?[T%`^#[?]NXS;F!RYT/
M[:GSZ^(GAO\`0MEYU&SESH?VU/GU\1/#?Z%LO.HV`QC&`QC&`QC&!XZ@'P@`
M_DQU![@?F#/.,#P)0$!#J#OAU>`,T+JS3*^N]G<@-@*S2,FENJVU:RMXXC4Z
M)X,M=J;.M':K+&$2NC.3M1=%.0"@F4_:QZQ#KR=.?O2&:PX+TF$;NXB8VMR*
MVP\"H\:.,U(1<.]D[YV1(JECX>O5YNBW7*P@6LDNT-;[8Y*:/K$:H55<JK]Y
M&,GG/WHRND'L5FV%J?CKOOE%IWDWR.Y25S?7)*=HG'X&4Y7N&3*OV**<HZ)L
M=B8RK]VK6HPDC-5Z'<W$C:T1ER@)*#1-*UE]`/D0^@?J#W`_,&.H/<#\P9YQ
M@:<WWJY7<FK;!KMO*I0BLV^J;LLDLW,Y30"MW2NVHY#(D$#&]$D@S-"CU]29
MURJ&ZRD$!W"!0`!ZP`>L3#X`_P#B,(__`"Z\XE]*ER1VBTWIP5X2<>=NIZ5V
M5NO;[;>VYMM(2,(U6T_Q4X\/F5DO%@ET+.4M:5B]AV0T;0&[2?5/%6`0DZVY
M:.RRO8!<W"/FYK#G50-A;&U.PL)*I0=V[1TNTLLE&.4*SL,-;6):%2V!KN;,
MDFTL--LC4&SM!5+L'L/("]AI)N0[5N[?!9_4'N!^8,=0>X'Y@SSFJMY[BI?'
MO3>TMY;%D4HJC:CH-JV+:GJKALV$D+489W-/4$%':J*!GKTC0&$>@90IG+]T
MV;)@914I1#$HK2:\=R:M?(`9Q%5K8]05K6!*X#0Y5FJT!9I.?-*F>";L#IN"
M2!6Y6X$[(@IB?LA*8,H'J#W`_,&?.?T:G2%WJ#@>)VNN6=UL^R^1W227OD-R
M(I^IZRT9VB1XDZ:F%%ME:]K%R90Z2]CA-<H5>29%:/[`M(+59:::-"F;5B+?
MJ1?T8`/6'6'X?^_^Q#O#X0[V`Z@]P/S!F![3II]B:SV)0$7A(Q:\T6WT]*14
M1%9-@I9Z[)0A'IT2]1E2-3/@7,D`@*A4Q(`]8YGN<".4_.&Q-^E&K.L(#=3;
M2G&SH_>.EVY&<UK3)247'U^]6K:M>,CJ#0<PC.H.VS]12J1$EL(B4`V4MC<Z
MR;F$.V>L2`Y#N)KJJ&HU`I%+5=$?JU&GUBL*/B)"D1X>OP3"',Z(D;K,D5P9
MD*Q4Q$1(!P*(]89F74'N!^8,G?B9R,@>6O'+3W(VMU.Z46&V_18*[L*GL"#=
MP%HAF\TT3<IHNVKI)(CUDJ!O1$/.L.V15AB56<Q&JF:O"$)1.!XZ@]P/S!DT
M['T&XO?(KCOO)*PH1[?1K3:+5S`'9'56GAV'7&\&B=%V4P$:!&F1%P<#E-V\
M#=@7J$.O-Y7.VUR@U&T7FX2[2`J5-KTU:K1.OU.TL86NUZ-<R\W+/%A`02;1
M\:S<NEE![Q2)".?.1T?'2:V=C':PV#R5OEKO<_TJ?,K94QQ0XVU=BQM=NX[<
M;B0$XM0KL^@(Y%6\LM?V*'J,1:K*WEE':$(WM36S5Z/036M+<P?2V!2@`!U!
MWOZ`QU![@?F#!3%,`&*(&*/?`P#U@(>Z`AWA`?P"'>$.^'>SS@?DP%ZOP!U"
M4>OJ#\!@'_\`#-$<<--+:)UBWU^YFD;`JC9[K8?NBBU.T()+9:).PD;=I4,8
MP&9DD`;&/U]2IDQ4```W5G,[I<>3NQ:O8N'O"KCSLY;4N^^6>]JW-3.U(]>&
M![I'C=HJ9B]B[JVJZ2G5BPH,Q;1D94BMI]!Q!S;.5G8AZW<%6[4:S>%/-W6W
M-*+W6ZUHULCV'T5O*\:&<[`=Q@#1MIR%#6:MW-UUO:&"18*PPKWT4FG)M8\Y
M%X"6*NT5;FC58I^^"W.H/<#\P8Z@]P/S!GG/XY%^RBF#V2DGC6.CH]HY>OY!
M\NDU9L631$[AV]=N5SIHMVK1NDJX<+K*$2213.H<Y2E$0#2.^=,K;E;:M;MY
MI&$'76YJ#M14RK4[H))&FO'#I2)(!#%[2H^!8"$<&ZR)"7K$!_!OGL0]P/"(
M^`/PCUY\Q7%;I7'4;.[%Y9;@V%<KMJ3GOSQK>@N!W%>HLXZUWR)T[5VI]2I<
M@:O3V38]V6@;]-U!];[/#-U#1Q635U)0T<XL<EV,M].::A52%.4>LI@`P#W^
M^`AU@/?`!\`_A`!`>\8`,`@`?KJ#W`_,&.H/<#\P9YR4><?*:K<*N)N]N3EM
M.U.TU-K^:GX6*=`J8+/=5T@BZ#4$$6RB3I=S;+F_@X%)%H;T0)7RBB?4"1C%
M#+-<:4<T7=O(?;2LVA(-MWO-4.FL.1J=):"#6]!"EK$7<&'L'(R2@>C4Q(`=
MH)UI'_E90/4'N!^8,X2=&GS&M=#4XJ<`.3>S;=R%YDWOC99N1VV[1"-8VV1^
M@U'=G:.F6H=L3-;;@M730B-@-4ZU,VE1Y(*2-=4AIN3[&2JZSKNX`]8=?N]_
M`\=0>X'Y@S6.ZM?*;8U!M+5Z$BE#K[$U[<*2C*JH"X3C5+/`OH8C]1N42F7(
MT.[!<R11`5`)V("`B`YLX1Z@$?S!W@ZQ'O`'?[W6(]0!U_A'/F,4Z59Q1.1?
M2%<W[IM>;DN%.AK1JKA!Q]XZUA6M/9KDANNJ75&-W-LK7$:[,O+R4]6;7=I*
MHPSB$5C8FWM8PD+8'Q3UM@JP#Z;&R`-VZ"`B!A1122$W5U=?:DRI]8!^`!['
MK`/P=?5G^_4'N!^8,]9"2J,[#Q<RW;2+)&5CV4BFSEXYW$2S,CULFY*TE8F0
M21?Q<DV!4$7\:]12>,71%6KE)-9(Y0]I@>.H/<#\P9/RFE'"G*)KR%^[:`,F
M^A7^FQKGH53T09R\V3&WP)GT7U]J!%-)@+`6W5VP5%`5_P`TO5FL^D'Y<U[@
MSP]WGR9G$T'[_7E-=#1ZTH</1-UV=8%$Z]K6EL&X#Z(>.K)<Y*(8J(-$UER,
M1>NNUBBV5,2(>CGY=S-6?<=.C\WYM:T\D^8!^*I.0.[]E0<?'V&OZJE7UD:L
MAU;LV:K31,M;D(QQ++5NH2EH,M)3!JPZC[!)?=AW"FE`[5]0>X'Y@QU![@?F
M#//_`'[GZ\8'@0+WN\`=\/P!X0'K#-5:>UNIJ^LS=?6DDI8TOLS;U_*X30%N
M5%+9NS[7L%&.$AA$3*12-C)&J+`/8N%&IEB@!3@`<D^D7Y0;%7YN<$>%>D=O
MHZ2<I625YC<L=LFE(2/943C'J5)_7&-3L!Y]5Q`F8;HN<X>K>@)Z,40<^@6;
MAJHD9,[E#H#P>YDT#G5HMGOC6<+;(FHO;A?*C%/;-`OHEA;$:+;9>J>G2DOW
M296]DHUF-$FDJ_-M%#&[2J>.DT6<JR=MB!8'4'N!^8,=0>X'Y@SSG@1Z@$?<
M]SOC^0/PC[@?AP)UY$:.<[O+I(C6=;P0ZFY$:KW@X[>U4<_=AKKEW*N5H)'M
M8AZ'7D0D2E3='ZR(]K$3!_*#*(*0"E*7J`>Q*`=?4'X`ZL^;S:'28OJ/SHYY
M\@9S<!ZKPHZ-S1D=HZ=UFV?5Q9/E'RPM+EO?+-5ZPUE55I-2Y:P;.:U28L]6
M*S=H6"PFC[(X"$<O4#?0GKJ[QVRJ'3M@1,79(..N=:A+.SA;C`OJO;(AM.1S
M>11C;)7I$A'D/-,DW!4)!BKV94G!#]I6<-S(KJAF74'N!^8,"4!`0Z@[X=7@
M#/.0YTC_`"VC^$?#'>7(,R8/[76ZHI`:JKB::;EY<=RWE=.H:HJ;"/.<AY)Q
M,7>8B"JLD!%92/0?'(`]K'`WMK'4Z]!O_(*ZK2Z$BCNO95>OK5BFW.D>#2@]
M1ZZUF>/74-UE<J+KT964!5/J*1-^1`0[-(PCNSJ#W`_,&<6NCJY;R53L6C^C
M<W9M*V\E^6=+XA5?=N\]T1:$19ZU2K-)3ZL.]U5L6RU9(S2.GX056T56+#-N
M7CZXHQB_W>D$[$X9EE>TV!XZ@]P/S!CJ#W`_,&><8'CJ#W`_,&.H/<#\P9YQ
M@>.H/<#\P8Z@]P/S!GG&!XZ@]P/S!CJ#W`_,&><8'CJ#W`_,&.H/<#\P9YQ@
M>.H/<#\P8Z@]P/S!GG&!ZN;_`-3RO_+7_P!#7R-.C3]K\X7_`"9M-_8F*RRY
MO_4\K_RU_P#0U\C3HT_:_.%_R9M-_8F*P+>'P?E+^L,A#+O'P?E+^L,A#`I3
M0_WH*!\'V_[=QFW,U'H?[T%`^#[?]NXS;F!RYT/[:GSZ^(GAO]"V7G4;.7.A
M_;4^?7Q$\-_H6R\ZC8#&,8#&,8#&,8#&,8&`7G7%:O)X.5D(N(].-+5GI+7-
MS=P[*3G-?V2?JTS4'5BK3AR4JS%\>%G'[%V1!P@G(LEE&3L3(G`2?*"]O>S>
MB-J&CN)%*U%8FFWM7DK=3A]RZVU]K26VKTKNS-GQ.QKRKJC5<':J-8[%':SH
MFW;96[9ORY/;W&RFM8QH\B&<:1G.0<^Z^OW-$<@-%1N\J1)P[*QR.L=ELH.U
M,M6;VJ$)5)':&E+#;*^ZK,A;]<R-L@YYI#R[B&>.(F3,@V16DH9PY8%=LUC-
MGS0/\M$;XJFX&-AK1;50'^Y]1&J-3Y%Z_HMI9V@NI-L35)@[;+TJ2<MU5%0(
MS&653C'BX`#U!JL03>C6C]!OOS/D7UMJ;=O1V<K])4Z@Z"-,6-R[WOI+A#Q8
MU_M!#[M<@HI\-'L7*/I%^D.Y12E;=NWT.N\=5I]5:JK5I:4JLK-H0T-!EFDR
MA(]L^$/2)+<WMI[9JU$TM.,=5:/B4Z3L#?J%EC)C5S_D_!VJ4A=@Z7U3,^A8
MU]MFMUB%;QT^3:L+$1L&;T42*DF$?)O&C8`S'F%PR;;5JF[[UQ^JNG:;S*V[
MJQCH^$Y+;(KKFS3>LJ.[5>Q+^3KIO0LI)(*5>!L5FFH&JUQ:KQ]DMJK!2P2S
M4G9R3?GUI[8?$;HY'^G>!4WL#;%]>\-M/5G8%X>:SA6FOM"Z!C)!L=BC?=TS
M#Z]QDY;MD;7D;38;.GK(;-MBUVAG9%IV,U4BV;QK\/H)$.L!`?`/>'.,G2.<
M,)IGH_F7M[BEK=C>>0O(>;XYVVSU:QU6J;,AF%QTW8Z?5&7(;76O;3!NRR&\
M-4ZJ8K3M-A4)48JP6*EUY9&MRMC%1G/AV:`0'P?@$0_I[PB'ZP[P_A\.:PW'
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M*PD:0=`U0Q>M7D`YW!R$O;N/<24)4M8NUXP#MJU%V,L6C)S(=5>'.X=3[.UD
MM!:OB[K4CZS?1U?MVN]EV:.M^Q*#-6RN0^SHV$N,]$7S9L:I+/:U=8B;^Y2-
MWEEJVA(IUMXU@G,2>"C\\Y#<=*%R3JU0KEZ4FX]QKO:^M=W:_LE;=L6L[4=F
M:GL:%FI]BCBRT;,PKP$723B/DHR9B)*-E(:1D6#AN45TW"'S_P`^RWQP[W-S
M$Y8[2V#7.+.B];\O(ZSGH2I;GJOCN[XHO7E-M>PN2-:C]919J%RIYD\F!;3&
MMYZC[%]$6"L62025J\?`.X*)-,!]/8@`@(#WP$.H0]T!SCSS]Z+F&Y+ZIOVH
MN/L;J#03GE+N"#N?,K=+JJOYS9VR]>1#]G/SU"1>L#,K),FO\C$058<@YO==
MA*;3V\@W@HY<'"4:&V>CKY0;^Y4M-N[-W57-=ZFIURE*=>^,V@TYUE*\BJ)H
M"PP;AG7KAR*8QLF\C:_,[5D8=W;:M6FS<757:+2D#*RTDY9HH,.E@@`AU#[H
M#^4!ZP'\@@`X'';CSS`XH(\@Y#3E6MVU;H_TY:XCB!';0;LH>C\7Z_LF0:G3
M;\;]25!A;(N2OLM6"Z[+'35DCZ/L]EK^1AEHF=VI#*/GS-;L24P&`#%'K`P`
M(#[H#WP\/?\`S]_.!/-7@-/Z\JO'ZB<4&ETHM`LW.?9.VML[KI-;CMA;WXAU
M7?D#L.R[6LW&EXUKR]_ID?L_9,NVJ=VL<$[L-HH=/N4EZ77$#7VOW4K6#ZTY
MZ<DD-N5_A=K>U:#L5KT-O,9OFMO*^;/M=PT=QHX]SUX<Q6I^-S#:VPI=CL?>
MO*W857%BHY=3#E!>@V*2+%VM_)J1BK4@=[-L:HU]O+7-MU+M:KL;KKF]Q)X*
MX5&55>I15DA%ED5W,-+%CW;)P[B9`6Y&\I&G7]!RK`[B-D474>[=-5N*6[>*
MU9XO\D+]TDV[]J:KXZ<5N*''L^EN-FM]/ZJ*_GM15>U2T.&P+K7&J$>C4D-O
M;CL+QOKJLU^(UO='+&"5@(>+=KRDB^[7WO#P?G_7^'^D/`/]/7FB.2?';7O*
M;4LSI[9B4J%=DYNE6IE(P#MJPL%?MNN;G`[!I%E@WKYA*L49*!M=;B9!-*0C
M)&,?H).(R6CWT8]=M%@TWPBY#ZCW=19./UW%[7J$_`H5V\7'7^])9C)[<K[?
M<J$K<*Q.7-G%W:_,JB[N:329F$J&O*PDM3SIN(J1I-0*#6,&W,^9_<5'Y,Z+
MY0\X>24EL.N<7M4Z_N&F[U3I.2/:]1<<]D:U=P.MTN0?,7=EOU/`)5_?O*>*
MCJ].ZOKFC-J$0@WC)C`M8*N`XF(.P.^AW1Z<S=R<S[AM;:]E@:-JKC;>8&J6
MCAYJBRR;0>4MFU<Q?2\).<@]F5=C)*(T[7NTI,T6?7M9>-'<Y%(LU'$K*@67
M:-1#>O*SB=&[0B-D[3T]3-21_,Z8U`[TYJ+?VTH%>SN=01TJ\D2ISE=,LWEW
M<*E6%K'-6X(:J-H5:Y3S2.CIR42;G3D(_EQIRP<5NC,C^/\`T?EUV=LO<5RX
MV:M2WQL%+4<-$ZUUEJ5@R6E+-/<@^1=HF]CPTK(V;94^O;Y^/U[)7^\3]]9N
MI%"&U#+1Z;(ZGT29QCZ3'A;,/M*\T=Q<8==-[WR!Y,UGCO6-DTRP5NK[,KLR
MQT_>(J+CMS5;75NA)`)7=.G=92L_-4.-CY=M'SDQ5:P<*U.66,CD)(.RZ*R:
MZ2:R)@.DJF11,P`(=DFH4#D-U"`"`&(8#``@`@`]0@`]89B]^HM6V?2+=KF\
MQ03M,O=;F:C;(,[R18(S5;L+!>+FXARZB7C"03:2<<Y<,7@-7C=15JNLB*@$
M4.`_-[(\N>3?$^?MO!+2&U:UR9Y/;#A*5;-"2V_=CWV97T-HV`J#1_N/F-SS
MN&TPCK#0%;=8G[I2M<=J\DV03"";C26D+#60&K7Z3*?+'GJE6)Q27KM@/,UV
M$E33U06,XJDV:1C&KPTO65S/)`R]>DC+"]A%C/WIE(Q=J<SMR8PK'#B5O#@Q
M4=-\CJ=S0M-\T!Q3X/='MH*[ETIKFF:O:`E1+-:89KZJF_G[,"Q5'B+BQK;;
MU/\`7T0-8V"X[$`L*;<]GE&S!*S^!7*'26^JS+MM;QV[:O9)F*AMURM>Y%.6
M"6UIZI[!?S%4K6SI*IQ]NM`ZWB+H^U[,A'4.3B]<2<<:/6EU=<024T1U(5'R
M&T+KGE!I78N@]M1CN6U[L^NK5VQ-8]^K&2220N6TA'R<5()%4%E,0DNQCYF(
M='0<H(R+!L=RT=MP5;*\*^5&F^5E.Y7<G=OTK93'1-7I/&O4%BUCLBQ.)K2^
MEM];&BH:W5O9.^>9^[-+5Z-;3UFXPP3>)=:ST9L!**UK<(AP1B:$D&LZ\=U\
M/HZS3VZ-`:8Y%0%?JF\M;U;:E5K-R@M@155NT>$Y5_3;60=_<"8DJZZ.:%GC
MPZKU=Y',I]C)QK>1*VDBLO1[)FY0YU\`.>&T>;>V;?>V#&@4WAM+:]!GQA6M
MSQ*)Y&<FI>DV=.)V%R6A->)RRBE(X^OCOVL%6HR98NI^1<J0\Z=>(:/5&+CK
MK@?.C.:PC.CDNO)OG-R^V_V=]YC;4H&H=6Z8XG:R/.;2+K>K,'T9IKB9I^1G
M5&Y'[9O",G]SV'.P-3UVAZ+0FYN2MD+"0K%^EVPXU;2UMM/5[!QK$\JA$464
ME=53-?L%C:7&R4VV:\53@9^F6.VQUJO<799VNKI),Y&;C;O;FD@K_EBV&16%
M=0&Y^.-`W=:-'7JR'FHF\<=MF'VEJVUUYQ'(R<).2%4GZ)9&#AO,Q4W$R<%9
MZ=9YF%EV#N-.L3MC.3BG<9,QK"00^<.C7'>_1SUVP<GN1MZ8\>M:57E7N.+O
MW%V(C;?3]8533(S^S'6EM,<#M&5U".TYR)V-ROLT[5;O<]KR,FK?:?-NI>2>
M2,2U;6*!B`^K)TU1>MG#-P!S(.D%FRP)K+-U!273.BJ!%VZB2Z)Q(<P%5143
M53-U'3.0Y2F#B3R!Z+6J.]B\3#ZN4X\<7N#W"J9FN1E@H;.A*.W&P]XPC"7"
MIW:_B$E6(4U<TZR(M?23]TL=J=VBW2#E]98P&T`@[DK*Z/O<G(S=NK+A;^4<
M=J>C;+D=C2\W#Z-U]9FEKNF@]66J,BK#K/6N^)6/=JQKC<+6`>C+3QXIC'1Z
M;"2CF0$>/6+U\XL:_P!&JNT*)=-:WF)2GZ3L.I62C7""75<(-YJK6V&>U^PQ
M*ZS15!TDC(Q,@\9J*MET7"95A.BJFJ4IRASIX#\S..'(Z;L"VJ);>$S,[+:V
M>YUN_;N)&P9]\4K4\K6J7*[1UKKUA/@\IVMVKB\5./K4S+:PU8AL*(DHV9@D
M+>A&OI9GU$SYVN0O#?>6O.2_'*MZ.E+12]&:-X/OJI`;99.9&@V?>^P--65)
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M">O=LC66JHYD1*2LLY;X1NQCW"GT=9/&Y.,NM]V[`T!M6S!-1VQ.-%[L%[U5
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M+BY7O$7-[%V??0N$8]D:,#O>MKC"3C6VR5>JZC4)%OWB$`$!`>^`@("']`]X
M<X@=(1PAL-2TOO.W</:@LYV1O_EKH3?>PGB]+KFW)C15I92U1H^S.6W'6B34
M`^FW&^J70(9M8J_$LI*812F&<I/U6KJSSA6.DP[?E$!#O#U]0B`_T"41`0'^
MD!`0SR(=?A_H'\P]8?\`SSYG'W,[DKQSG[5P(TKM#7FY^2I;#6]C1&Q-Z;,O
MEOH_$OAI6JO0BVS?O-O8.TUX^]-MI;DGVETLL7H"-?.GE7+:6S:O3,+5H^%*
M?Z58QXC(QS!^W>,I!N]9-7:#^-6(XCGJ+ENFND[8+IJKD69.4U"KM%2+*E4;
MJ)G!50#=F(<6>6_1,U?;BO'_`%II-CI#CQQDHV_?73\FH_TDOY^Y<CK_`%F<
M5M%/A+I+-96NS4Q#I6>0G+S<[/=+[,+S$DE!QZT2LR9*.$-K\*.;/&;?^SK,
MIK2X;HV'+7.4L^OJSO/8IX:NZWWPOI4BLU:_4+U[%V..=J46FJ6:3!ALWU(X
M*O6<JSR'8;%NBL6W32ZFRT5'SD9(PTLT1?Q<LQ>1DDQ<%[-N\8/VRK-ZT7)U
MAV:+EJLJ@J7K`3)J&`!`1`0^?;?71_WC4VQN`^F.-HW:A<<-.:]W'3W^ZZ>A
M*>KHRAXJ?I-JU!POLV\M55Z/W#JKBULERWF?3IL*OK+V<KFG0+2P7$DBX;*6
M$/H9S3.X^/>E.0+>E,]V:PJ&U8W75T9[%IT'>HM.P5Z*N\9&2<3&6,:](&5@
MY&4C&4O(IQ2\O'R!(MPZ,_8IH/DT7"?&+AST@_(/?.Y='Z0JUTT/;M7Z!?2.
MJN<?)^5M8NZ/MWDE+UN:6KO&;AN]?*PUBVQ9-;2";(]QV]),TXNPM(%ZD,;)
MR\XFZ4^@,/`'7U>#\'@_)_1@?-\36<1T;CG>V_>9>W7]UW=TBO(".@8W2G$>
MA*K[&ME<C(48/6_&K7-CM4O$O&>J]/T(\J_N5Z8---QL>@^E+?8K7`'59`?N
M]H/9-!VMJJM6K6KEXXJK12=I*2,E+M[%)Q4UK6PRNO+37I.QLIRT1]CDZW9J
MQ+04A88VT6:,G7<>K*QUCG63M&4=8[MOC1KC<6S=#;CL1)9AL?CE-WJ3UO8X
MA>/,*$7M*G+4/9-4F8F:C)F&EZW<:VHV1D45F"<DR>Q<7)1$G'N&JH.?F\TQ
MLK>W1D:SI7(/D[;7.NJTOMK=M1N_"Z*:6JEQL"NFXOM6XR\0NC\X^P3)/26Q
MHG:%AFJ=MRP[W82SJUQHQ<@6QVY2+GK!',0^LC&17P.V?R&VQI-W9N4S?3=<
MW0K?;8K-ZKT]:4;EZB-=F%VMBHVHMG6%L^=LI3;E0J4O&(7-_&-HJ+>J.&3A
MDQ.0YW[VU,!C&,!C&,!C&,!C&,!C&,#U<W_J>5_Y:_\`H:^1IT:?M?G"_P"3
M-IO[$Q667-_ZGE?^6O\`Z&OD:=&G[7YPO^3-IO[$Q6!;P^#\I?UAD(9=X^#\
MI?UAD(8%*:'^]!0/@^W_`&[C-N9J/0_WH*!\'V_[=QFW,#ESH?VU/GU\1/#?
MZ%LO.HV<N=#^VI\^OB)X;_0MEYU&P&,8P&,8P&,8P&,8P&,8P)(YD<-=8<U-
M3S&LK_*72D2CJ'G(6N[5U785Z7M:DQ]H38M[=%UFX,4S/VM>O,9'-8&^UHQC
M1%O@"_<^31[8BQ=L^"S2%WEP4WZV31B]J4G3NO\`92B,4TC9"XZ<Z,WH]^C6
MU':CE>66R2"SNOT[DIR0W_1H)>3DF<F\NETC[C<Q=._N9.P2*\Q]4&2;S!XA
MZHYBZWBJ5M&IP%Q&DVR)V;1(6Z&L;_7;G8=2[8^JA-E4V`G($FPZ":6(T/9:
M3+.A92[-+LFYVDD@S>H![#B7R\T]S+U/`;9U(_F&S&;B6$XXIUSB5ZIL2N1$
MXYE2525LM+E#)SD/#W:-B'%CHTR\:IQ]OK*C><A5W30Z@I5$(`/>'O\`_P"0
M>L!_K`>^`_@'OY\@-4LF]^"/(:[[IW[L6SUR?UM-4K9?28\Q[_#2\)K/D6#^
MCW2-XU]'!T>^CE$CHW"CQ3JR'<5^UP5?2L%>L#.06;+FF'DU`K_1CPRWEM/D
M#5KCL'9,93:0RF)FJRE&TR1H\C=ZZ1KDYKNK3$AKGD_%&LUCAXW<$=:74ZZ,
MU@!C&)*JY@P=QK67+(-FX:#VQT8.G;AS$X^\IJ?6-:TUM2]S;*WAR%KJ%$CU
M)C?6P+)H&5TG0[3/65510"DHC1XHY6KBT>:)F74H\LASM[`@LO)X?RWYU637
M.T]1\'.CSH]"W9R\GGU2M%FH`@1II/COQS3D6J=DV1OFP5=1L-"BI2+<^A-=
M5^".>W3DRO'OHV`E8T[>,G.O(AU][_O_`+_IR?-.<5]!:`N>Z[_I_6-5H=JY
M"W=ML3;4M`135D[MMN;Q+6("2>KD3[<1)1-L9^:-143BTYI_,S+=FC(S<HNZ
M#?C7T3Z&;^C.T^B^T)>BA;`H#<7':R]O%`%A%4$15[,4@5$5`3[$%![/KS0'
M(_C+JCD[48>O[*IM0LDO1K$GL'5$_;*PSMB6N=JQ45)Q]5V!'PKU9JUE'=><
M21GAH=ZX)&S":0,I`!2$ATJ&Q@<MN,$-QGZ,SCSQQXM[/VKJ=GO:FZ'AZ^[6
MBV2)]K;=;5<7;FWWFO4>)82FS;/`O+,>4FWI6<9,-HIXX.D[6]$$%53^_H[-
M^<EMX6GER3;-<O;W05*W'%1G$K=NTM/.=![`W%0I2OG?7)*2UF^CZZ_-7]?V
MM,L%3=@NZ53%K]`/&[MS#&D(YZ]7I;DUP\TIRP3UF[V?&V*/N&F+[%;(U+L[
M7EJF->[3UU96#AN,EZ4K]6UFL]$Q-OBT5*W=85)P:-LM?=+,GS<5DV;II4"2
M94DR)D[,2ID(F45%%%5!*0H%+V:JICJJFZ@_E**'.H<W68YC&,)A#RJDFLF=
M)5,BJ:A3$434*4Y#D.42'(<A@$IBG(8Q3%,`E,41*8!`1`>2$-T>'&+BER&V
M1R_6@-.T#C70N*%TK2FMR:Z:(P6N7;W;]AY$;WVS+NA3F"6,;8)(]PH=:-+(
MU-A60AX4%89=JR8]<L_CD8Z/EV#V*E6+.3C))HYCY&.D&R#U@_8/4%&SQD]9
MN2*MW31VV55;N6RZ:B*Z"BB2I#IG,40Y#\W^<VT:5MSC9H'A3!R^V.1>S4*!
MNR-UBXK%8]1_8?%%S>(ZI;?NDYM&9F()[07%`A):.FX-W"O5YA62DH)).EW2
M,?2"43V##KZN^'4/6/Y@$0`?RAU"/]?X,G:@<3>/.L-FK[EI6L82+V@IK:`T
MXUNSIW.3D[!ZGK#GT9!:TJKBP2TJG4*)'O`([3JU71B(=9TB@X=-5U6Z!TZ*
MP-,;UX_:@Y(TQG0]T:^J>QJW$VZI;!A(BXPR$Y%Q=ZH4VUL=-LJ;!<R::SF%
MF6+=<[90X-91B+R&DTW$5(O6RO,_5-"HW0U\'*$ML:O--LV>O[*M,5LK>E7K
M$56(]B\WWN2U6I_M?:-AD_1KS6.IV+F=@F=TE$AG(.EF/'BY1&NLEYMEV7S2
M7(OC]KKE+IJ[:&VTA87FN=ALV$9;HZL6RP4N2EX=E,1\PO"+SE9?1\I]Q9H8
MXD78HH'`L9Z!=R,+)HN&#YPD8)$X0\][5SAONV'U$T,I#<6=>*K5:G\HU[\Y
M?U[>NQXR1296:.T]57E"KSRSZXJYDI%F]VR$HC7IF:;H1U6;3C<S^0CNE`@`
M]X>__P#D'K`?ZP'O@/X![^:YU'J37.B-:TW3^I*I&T?6NO8-M6J948@79HRO
M0+(RAF<6P%\Y>.P:->VG*@19RL9,@@0I@(4I0V-@<Q=F=&3IFV\OM%<GZS4]
M:5AI4-L[2W9O.LA0V*TMNW:5OT4.DJ'<IFR=M$P>D2+,[4-6'3%:$F9&;>V=
M3M%A2<+2L^<R^=>X:(MQ%H'!5CH<=7<MK=L'CSJSDC)H25SH.O.3%&-:B4S4
M]IU370J0LJ)<IG7UMH\W>8>?E)2CRT;+=KHCX\>U,^[>B'7X<F`.&O&X+M3K
MYZF,0,KKW9MPW71HL7<MZ4*IN2_HR[>X[6A*25^%59[!GD[!/G=68(DSY!W8
M+!),!9RD],/7H;$T-:-K773FNK3O+6;+3FWINKQ[S8FL8VWQ=]C:;:1*=.4B
M8VWPQ2Q\]&@JGZ*8/4BE5!FY10>%*\1<!GC>.A]/\D];3FH=ZZ]K6S]:V1Q#
M.INGVMB#Z(D'%?F&,]$+*IE,FLFLQE(]JZ060534*8ADQ,9%59-3;8`````'
M4`````>``#O`'Y,\X'#^$IM*Z&GB?L*^6"C)\F-\;,Y:;8F=3U_5E%C*_?\`
M<.UN5&U9$VJM3TULHU?M:$BPIQ(2N316;WTKP5<ITO*-TEVJ;=BI1O`WE3R<
MY+%V`]V[0N/%1=:OVG9])[:UYJW9EZN%TTIM2K,(::D*=8YZ>ID91MAF:PMA
M@7;V;H\HSC2'EB(,_1KV/E&36X-O:=IF[*JG5;DE+(E82:$_6['69J0J]SI5
MH:,I".8VRDVR'5;S%6M$>QEI1HRFXI=%XW;2+U`IQ3<JE-B7&;B_I'B!J>)T
MKH"E-Z11(N1F)Y=L,E+3\W8;38WAI&RW&X6JPO9.QVZX620,+V=LM@DG\K(K
M]@"JX(HHI)A0&0USOX.:YYJZCL5?DX:E1FZX776X*UH'<UGJ*%N?Z5N&V==S
M>O9"WPT:LX:@X43CY@R@I"KVQH]093D89O.14:[1N7&!(FO=>Z=X4<7:O7WD
MYK#2=?U9IJA:_F]G3!:[7X%EZ1J?'U6*F;%.31X8DR5!Z@=PT+.OP</UW(H=
MY=VH0TT]&OM_EW>C;@I^_P`LMNG457G6LYQRYPR&OVNB'/(6D6XRLLI79W0<
MJPK=GKLYK-5P,"VV!$U..UYL>!1CY>N*N#E._E>@MXTUJK9=CHELV%KZI7:P
M:PD)&7U[)6J$93RE.F95-DD\FZ^A)I.6D;.&2CVR2$T@V"48IE4(P=M0<..V
M[+`H!U]0=77X1_"/]8^$?RC@83LK6U%W#K^YZLV;5XBZZ^V%69BGW.J3S4'<
M3/UR>9*Q\K%O4>LI^U.6JQR@JBHDX;J@FY;+(N$4E2<KM>\:N/7190G-[E3L
MEI4UM:V#;%`V5KB(HNI".YK5]'JNJM9:%U/IK7U0A6LM*R=M&R,#0D`O7#MW
MEOFK6T=NDV<E(29L[$9BUTI57V'692GW.&9S]<F"-BOHQ\F)T3J,7K:3CG:1
MRF(JU?Q<HR92D6_;*(O(V39,W[-9%TV15('!SC#TB7+7=_/O?&MG>MMDFUS4
MN0NOM)Q^BU=*H5]'0VG9C02>X)7D'OK=I5)=A#[%FIJ1AJ[!ZD/:C'D6[M1A
M"5=P]9R$\Q^@L!$0`1#J$0`1#W!ZN^'Y,F'C3Q!TKQ11V>OJR+L2]FW7L-]M
M3;E_O=QL6PMA;$N[UFC&)2MGN%J?/Y5XA$Q#9M#P$2BHVB8*+1!G&,FY#JBI
M3^!!?/O@K0>:VGKC`J1%$AMZM-3[CU_H_<ULIZ%N>:ED]Q4E[2+'*QC$[AJ?
MK?PSU=F#M-0[V"<+)V"$*288-Q4U7RAF[/P2X-SK7AI0]/\`JMT"MZ'UFF\M
M0LF-*UM674K4=8/-V[C"'4C+'-4;4%/=2-[G57CE!9:$AW;I=XA')R"A.I&3
MUO7B9QEY.(Q2'(30VJ-RIP:S=:)]4:CP-I48^A7!W:*"*\FT5<>@BNCF<FCS
MJG8*+CVY1J=0.RP(^Z+3EK;N6NM=L3CRWO=W:VUCM$-5:SY7.:+#ZPC>4"E=
MJ<$OLO8=/HD"4L1'Z_A]DO)^H4N9C@%O88:(1=**O'J#M^[ZBB`"'4(=8=[\
MX#U@/]`@(`(#X0$`$._GI:Y6J]3X*)J]3@H>L5J!8MXN#KU>C&,+!PT8T3!)
MI'143&H-8^.8MD@!-NT9MT6Z)`[%-,H9[O`Y;6?HQM/^O5T[RGI56U74*=5#
M\FKCN+7B-`C2N-J[FW[4Z542;;L$\KZ(0DWD%6ZI(0IX&38ECD?N^_G(]5%^
MZDTWF'<CN>EX8\E-4<%.CVHE*W5OR)EZE8N0QI8RK/0O%[CV8HMW+O:5GJRB
M;JO7JQ,!;EU90JVD_L#I1%%X^@%81=!%?KUG&SF/PJ8:HXO[JHG">NV#CU'\
MFM]M-@<K;;QHHKR=WHIKVPL'3G;KG3L%7T%9AWL.]?<:-HM<!J8(^AM[U8+)
M%M63%@X0$.J5,VQJ[8DG:H.@[*H%YG*')E@[U$4ZX5RRR=,G!`X_<>UQT)*2
M#NN2ANUJ&+'3";5WV)#_`.3'L##F4V"`A;7!3-9LD4PG*_8HJ1@IR&E6J3V,
MEH>6:*L9.,D&:Y3HNV+]FNJV=ME2F3614.F<!`<XJ=$;Q;W7K!W:MH773S+A
MWQ]8TEMJ7B+PD:KQ,C==>T!2QIVB][FY(V2'=2;6S\B-V3\7`2E@[9/3Z]8C
M(W[G+2'H]](&<=P\#F)Q:Z-[4_%'?/(S9<'`ZK;ZJV'`<7ZCHS74;0HJ&:Z)
MJN@*E8JRVK$8N\]'(OG4Q9Y\]O+:T56D]+3,JN65*J_8MG[W#*'T@6PN3?.1
MUI_AW4JEL3B1H%*SUSF+R?M+A^SH;':+8C9>'U7QUGX<XH[#OU;_`/$&V8X<
M)O*+"L7*"99AE+LDTIWJA:*O7;M7)RH6Z$B[+5[-%/H.P5^;9-Y*(F8>3;J-
M)",DF#HBC=VR>-E5$'""Q#$43.("`#U"'('D/J;DAQYU+H/H]>B[T_!:(H>Q
MSV"F.^4XN8Z0J7%#7K))[8[G-,::4!LEHW38FCEXWUC)2H.81]8`/*V6PEF6
MR9#!V*AYF)L$8SF8*4CIJ(D$2N&$I$OFTE&O4#=8%79OF:JS9RB80'L5$53E
M'J$.OK`0"!.D2Z/S6_.K2U^KRT+1(+?:NF=MZHTUO"S4Y"U2^JD-P0K:#N*L
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ML8>6F*NB^F%X1L=.4E6$CRPBM6\B^EMK&N&/*U2?X>P7&'E%4[UMGC/`:+M#
M6V3^VM$V,EAI*=*Y;W"YN:I?-5/')8ZRQU[TUKB*?RD5(FAY&1@I`%&R0=]<
M9X`.H.K^D1_*(B(_DZQ[WN!GG`8QC`8QC`8QC`8QC`]7-_ZGE?\`EK_Z&OD:
M=&G[7YPO^3-IO[$Q667-_P"IY7_EK_Z&OD:=&G[7YPO^3-IO[$Q6!;P^#\I?
MUAD(9=X^#\I?UAD(8%*:'^]!0/@^W_;N,VYFH]#_`'H*!\'V_P"W<9MS`Y<Z
M']M3Y]?$3PW^A;+SJ-G+G0_MJ?/KXB>&_P!"V7G4;`8QC`8QC`8QC`8QC`8Q
MC`8QC`COF)Q(KO*"JU:6CDZ57>0&E)F1O_&3<%RU_![,;:=VJO$.(EM:DZ=8
MRJ0\XU4;+]J=,GJ9Q:.THVQQ0M[%`P[QOP;=\A9;@AN*T["W)RUY.;BY*ZYI
ME,E>4L/RR]+]#XNZ7XL7RT6H&M]BXWBEJFS4&0NMDNU0D8?0,)-68+M-.+!(
M@_08@Y?0SSZJ,DWDSPVT9RCD=46O:.O:[=KAH2]([4U66S^B%:P-ZB(&>C*Z
MC>(9$BS6VU5A(S*<TG#RC1X$9-,&$]"^@I=FFNH&9:>Y):UVY4M1S!9F-I=T
MV]K6G[+B-07&:AXC:D5'VZJMK:G&2E)=NV]B+(1<<LN,@!(L"$(R<N!`B*:G
M:Z`\.?&7-S<IP\WM,V_?5JLKCE_?&\6ZZ4OI";X2\U*D:3TYN1I*U36W#K@C
M7Z;$N[-?KW:CQYG_`!EC-1-9*P5N6K(7NZ&770M=1AOJRXOV"C2VDJ%#4*V;
M*M\90J_":]?R.[/3,EO!*7JT'%H+(;G97:,A+DQV8Y8+QTQ9D[1#1<N\6E49
M55F1O(-SG"@L8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,
M8Q@,8Q@,8Q@,8Q@>```#J````\``'4`?D#/.,8#'5^'\(?\`?_?]0>YC&`QC
M&`SP``'7U?A'K\(__+W`_H#J#\/A$<\XP&,8P&,8P&,8P&,8P&,8P/5S?^IY
M7_EK_P"AKY&G1I^U^<+_`),VF_L3%99<W_J>5_Y:_P#H:^1IT:?M?G"_Y,VF
M_L3%8%O#X/RE_6&0AEWCX/RE_6&0A@4IH?[T%`^#[?\`;N,VYFH]#_>@H'P?
M;_MW&;<P.7.A_;4^?7Q$\-_H6R\ZC9RYT/[:GSZ^(GAO]"V7G4;`8QC`8QC`
M8QC`8QC`8QC`8QC`8QC`DSE;Q:9<CXO7DO#S\'2-NZ5NSG9>D]B62@Q^U86@
M;"<4ZS41O<5M<34S!P5FF*]"VZ7D*DK)OBA7;.E'3K=-R+5=@]^:UCN3EET>
M&SHO6]5<;.D@BM]7VLTC4>W1A+IRWZ9WEQN%6$3V-N^QIU5[+0>A.+&MJR>.
M?T[8C`IF5;2K<;&R8+,F+ZN-OL%S74[K:B.[K%[A4H%8FML4^GVBI5.X.(R+
M3MK&MV9Q&2LW4XZS.4!>1T-/RD%$+O6HN"LO1+5)RH0H=O%0,L=ST;%)Q`3;
MUE$.)I\UB6"#UX@EZ*F7:"RZ,2U5.9--T^6!LY*V01_RCP4#^ADSFZB9[GP^
M#/CJY6;;WQR'W_KW=W,77K>(UM2>6P\;N#O18J<A:WJ/;E^Y(^@IF-IG)?>U
MQA906`I1UB;QLG1(]A+FK]9K%A@+S7IZ2([:(;`^G;AC)[SDN,&ER\GI&ER/
M(Z.HD)%[P&A33&?K[/8S%N",XQ^Z4:8S!:6;@#<)WT&!&0S)GRC`GH`[8PA3
M^,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P
M&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P/5S?^IY7_EK_`.AKY&G1I^U^
M<+_DS:;^Q,5EES?^IY7_`):_^AKY&G1I^U^<+_DS:;^Q,5@6\/@_*7]89"&7
M>/@_*7]89"&!2FA_O04#X/M_V[C-N9J/0_WH*!\'V_[=QFW,#ESH?VU/GU\1
M/#?Z%LO.HV<N=#^VI\^OB)X;_0MEYU&P&,8P&,8P&,8P&,8P&,8P&,8P&,8P
M&,8P($YK<)HSD-7G%^TXWU%J/F36B5Y+4G*R?TIKW8FR=<,(ZPQ[Z=CJO/6J
MOS#J"?3%:+/5ZO6([6;+0Y*<&SQL$_<-5&+K@9Q'WER(X+[*H25ZU=`5ZR<P
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M(.BH^B4VC8*<QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`
MQC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&!ZN;_`-3RO_+7_P!#
M7R-.C3]K\X7_`"9M-_8F*RRYO_4\K_RU_P#0U\C3HT_:_.%_R9M-_8F*P+>'
MP?E+^L,A#+O'P?E+^L,A#`I30_WH*!\'V_[=QFW,U'H?[T%`^#[?]NXS;F!R
MYT/[:GSZ^(GAO]"V7G4;.7.A_;4^?7Q$\-_H6R\ZC8#&,8#&,8#&,8#&,8#&
M,8#&,8#&,8#&,8#&,8'.?GAP?K7)!K3]PP5$J>RM[\>7$YL?1FL=N6ZT0_&^
M\[B:P2\90)K=]1@&TDSL[FB.%W#VC3SR)=/JR^=N$06+$NG!$.'?$SE/LOA_
MR8NMAWSN;<=UHEQV1/:NY3[#VC2KFI*<O.D9L#.M0=&T7T<_%II6E;]6=>Z`
MK[(:=8+<P0:UF\0B%?5DT%3-X*;1^MS(ZW_PWH^]=S\?-]/7Z,??./B6V(*%
M:3,`TMU-L=+WA7X:O;$A9NMNGT2=";6;UN"<UFWQ<HUE(!9L]:K-Y>(E7T:<
M*1U]L"J;1J,5=Z7)?=6ORYI%!!<S=PS=-9"%EG\!/0\FP>)(O(R:K]@BI2!G
M8IZBB]BIF-?1[M)-PV4*&:9K/3NGM;Z!UG4-/:CJ[2F:ZHD6,15ZXR<OWJ4>
MS4>.I%P95_*NW\K)/GTB^>R,E*2CYY)2<B\=/W[IP[<+*GV9@,8Q@,8Q@,8Q
M@,8Q@,8Q@,8P(]7AP&,C5_T@W#:)A]ZV&8WY2H6"XR6N.H_(&9FB6"'B]/VN
M6<K-8Z$V`^DX-JVKCQTJB`I^C5"H@BY8.3K$;24>LZHF$VI0+%)U>%A[(T>2
MUSI!MD5B/!"00=2]'37C&REE;I.F:!B1B;B:B$3J.`05(I*1Y3)%%VAV8;!Q
MG@3%#K$3%``Z^L1$`ZNQ[YNO^H.^/N?AS4NNM[:DVU9=JT[7=YAK3:-(71/7
M>UX./%Z21HUT6B&D^A7IU!ZS:"B^<P<@QEVW:!<-W,<]:O$%U$'"1SAMO&,8
M#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8'JYO_4\K
M_P`M?_0U\C3HT_:_.%_R9M-_8F*RRYO_`%/*_P#+7_T-?(TZ-/VOSA?\F;3?
MV)BL"WA\'Y2_K#(0R[Q\'Y2_K#(0P*4T/]Z"@?!]O^W<9MS-1Z'^]!0/@^W_
M`&[C-N8'+G0_MJ?/KXB>&_T+9>=1LY<Z']M3Y]?$3PW^A;+SJ-@,8Q@,8Q@,
M8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,>'PX
MQ@?/%R7X)[-MO25;CI-=@)!7ASTJ7#J8I'+B:BFQ466N]A\?741!L+@D1(I&
M9;GLRA72(HT&\<G3=+G).SIT)(U3+VG5.ONZ):@Z&2S;"EJG<F_+S2M;IW&:
M&]+-<D+)MMSQYX\\B`U_L/9=;B6R+VP2%RNVKV-JM<(RBF4A*O(V$J]BKI9.
M0=QI2?3GU?A]S_O_`+'^OW1SQU!U=7?ZOZQ`?=[P@/6'5^#J'O?@ZL#YFMQ;
M6Y;L+!H^OU_DEND.,O(>%YZ>D#D37M`<@E);3.U+BXHC_B73;]#),U=J7&%U
M&P>W]*A3FR(ZLU;9$VW0JER!^K#QSI?&-(;'W_H7GOR8?7O6.UG/&_<G21TF
M#V+N.B5K:-:L*%^+P\UA7M<V=[26,.Y2E.*MBV)`7&$V79HJQV.)IML9UJ(L
M#LE<BY>4D?J+[$.]X>]^'LC=8_UCU]9@_H$1#'8A_P#Q>'K[QS!X/<ZC=X/Z
M`[W]'>P/T'@_#^7P_P#R[WYN][G>QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`
MQC&`QC&`QC&`QC&`QC&`QC&!ZN;_`-3RO_+7_P!#7R-.C3]K\X7_`"9M-_8F
M*RRYO_4\K_RU_P#0U\C3HT_:_.%_R9M-_8F*P+>'P?E+^L,A#+O'P?E+^L,A
M#`I30_WH*!\'V_[=QFW,BW6.SIZ#H-5B6C2(4;L8HK=$[A!\98Q$W3HH"H9*
M013$P@'?$J9`]PH!WLSOU8[/^(P7Z/)>=<"42:?Y::_YV<GM^:]HNJ;+K?<.
MKN/E3KKJRW^1AYXDQK-I:T["5Y#LH9R#5J"L\D1FN9V<712"<")]B8IJ#]-W
M-OQ/Z-\IUA\Q9E?JQV?\1@OT>2\ZX]6.S_B,%^CR7G7`Q3TW<V_$_HWRG6'S
M%CTW<V_$_HWRG6'S%F5^K'9_Q&"_1Y+SKCU8[/\`B,%^CR7G7`Q3TW<V_$_H
MWRG6'S%CTW<V_$_HWRG6'S%F5^K'9_Q&"_1Y+SKCU8[/^(P7Z/)>=<#%/3=S
M;\3^C?*=8?,6/3=S;\3^C?*=8?,697ZL=G_$8+]'DO.N/5CL_P"(P7Z/)>=<
M#%/3=S;\3^C?*=8?,6/3=S;\3^C?*=8?,697ZL=G_$8+]'DO.N/5CL_XC!?H
M\EYUP,4]-W-OQ/Z-\IUA\Q8]-W-OQ/Z-\IUA\Q9E?JQV?\1@OT>2\ZX]6.S_
M`(C!?H\EYUP,4]-W-OQ/Z-\IUA\Q8]-W-OQ/Z-\IUA\Q9E?JQV?\1@OT>2\Z
MX]6.S_B,%^CR7G7`Q3TW<V_$_HWRG6'S%CTW<V_$_HWRG6'S%F5^K'9_Q&"_
M1Y+SKCU8[/\`B,%^CR7G7`Q3TW<V_$_HWRG6'S%CTW<V_$_HWRG6'S%F5^K'
M9_Q&"_1Y+SKCU8[/^(P7Z/)>=<#%/3=S;\3^C?*=8?,6/3=S;\3^C?*=8?,6
M97ZL=G_$8+]'DO.N/5CL_P"(P7Z/)>=<#%/3=S;\3^C?*=8?,6/3=S;\3^C?
M*=8?,697ZL=G_$8+]'DO.N/5CL_XC!?H\EYUP,4]-W-OQ/Z-\IUA\Q8]-W-O
MQ/Z-\IUA\Q9E?JQV?\1@OT>2\ZX]6.S_`(C!?H\EYUP,4]-W-OQ/Z-\IUA\Q
M8]-W-OQ/Z-\IUA\Q9E?JQV?\1@OT>2\ZX]6.S_B,%^CR7G7`Q3TW<V_$_HWR
MG6'S%CTW<V_$_HWRG6'S%F5^K'9_Q&"_1Y+SKCU8[/\`B,%^CR7G7`Q3TW<V
M_$_HWRG6'S%CTW<V_$_HWRG6'S%F5^K'9_Q&"_1Y+SKCU8[/^(P7Z/)>=<#%
M/3=S;\3^C?*=8?,6/3=S;\3^C?*=8?,697ZL=G_$8+]'DO.N/5CL_P"(P7Z/
M)>=<#%/3=S;\3^C?*=8?,6/3=S;\3^C?*=8?,697ZL=G_$8+]'DO.N/5CL_X
MC!?H\EYUP,4]-W-OQ/Z-\IUA\Q8]-W-OQ/Z-\IUA\Q9E?JQV?\1@OT>2\ZX]
M6.S_`(C!?H\EYUP,4]-W-OQ/Z-\IUA\Q8]-W-OQ/Z-\IUA\Q9E?JQV?\1@OT
M>2\ZX]6.S_B,%^CR7G7`Q3TW<V_$_HWRG6'S%CTW<V_$_HWRG6'S%F5^K'9_
MQ&"_1Y+SKCU8[/\`B,%^CR7G7`Q3TW<V_$_HWRG6'S%CTW<V_$_HWRG6'S%F
M5^K'9_Q&"_1Y+SKCU8[/^(P7Z/)>=<#%/3=S;\3^C?*=8?,6/3=S;\3^C?*=
M8?,697ZL=G_$8+]'DO.N/5CL_P"(P7Z/)>=<#%/3=S;\3^C?*=8?,6/3=S;\
M3^C?*=8?,697ZL=G_$8+]'DO.N/5CL_XC!?H\EYUP,4]-W-OQ/Z-\IUA\Q8]
M-W-OQ/Z-\IUA\Q9E?JQV?\1@OT>2\ZX]6.S_`(C!?H\EYUP,4]-W-OQ/Z-\I
MUA\Q8]-W-OQ/Z-\IUA\Q9E?JQV?\1@OT>2\ZX]6.S_B,%^CR7G7`Q3TW<V_$
M_HWRG6'S%CTW<V_$_HWRG6'S%F5^K'9_Q&"_1Y+SKCU8[/\`B,%^CR7G7`Q3
MTW<V_$_HWRG6'S%CTW<V_$_HWRG6'S%F5^K'9_Q&"_1Y+SKCU8[/^(P7Z/)>
M=<#%/3=S;\3^C?*=8?,6/3=S;\3^C?*=8?,697ZL=G_$8+]'DO.N/5CL_P"(
MP7Z/)>=<#%/3=S;\3^C?*=8?,6/3=S;\3^C?*=8?,697ZL=G_$8+]'DO.N/5
MCL_XC!?H\EYUP,4]-W-OQ/Z-\IUA\Q8]-W-OQ/Z-\IUA\Q9E?JQV?\1@OT>2
M\ZX]6.S_`(C!?H\EYUP,4]-W-OQ/Z-\IUA\Q8]-W-OQ/Z-\IUA\Q9E?JQV?\
M1@OT>2\ZX]6.S_B,%^CR7G7`Q3TW<V_$_HWRG6'S%CTW<V_$_HWRG6'S%F5^
MK'9_Q&"_1Y+SKCU8[/\`B,%^CR7G7`Q3TW<V_$_HWRG6'S%CTW<V_$_HWRG6
M'S%F5^K'9_Q&"_1Y+SKCU8[/^(P7Z/)>=<#%/3=S;\3^C?*=8?,6/3=S;\3^
MC?*=8?,697ZL=G_$8+]'DO.N/5CL_P"(P7Z/)>=<#"GUFYN.V3QJ&H-&@+AH
MZ0`?5.L`=1EFZB1>^,"(?YQPZ_Z.OOAX<S+A?JRW:0XE\;M/WY*,0NVL])ZX
MH]L0AGXRL2C8JW6(^,ETHV2%!L+]B1ZW6*U=BW0%PB!%!2()NQ#]^K'9_P`1
M@OT>2\ZX]6.S_B,%^CR7G7`I8?!^4OZPR$,VT7<5F,8A18P74)R`/_AY'\)@
6#\,H(?G#)4].DI^+L/\`^VZ_C,#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g961380.jpg
<DESCRIPTION>G961380.JPG
<TEXT>
begin 644 g961380.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`^1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]#3$E.24-!3%]+7TQ)3D4N15!3_]L`0P`!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!_\``"P@!"`*L`0$1`/_$`!\``0`"`@,!`0$!
M```````````'"`8)`04*!`(#"__$`&,0```&`@$``@H-!@L$!P0)!0(#!`4&
M!P`!"`D1$A,4%QDA,3=76!46&%%VAY:7F+;5UM=!5F&1E;4*(C9(=X&AI[?'
MU"-QL?`E)B<R.$?1)$*RX1HS-$-%4F=XDG*"HL;Q_]H`"`$!```_`*`>'$Z6
M#UU)_P#(>D?PLQX<3I8/74G_`,AZ1_"S'AQ.E@]=2?\`R'I'\+,>'$Z6#UU)
M_P#(>D?PLQX<3I8/74G_`,AZ1_"S'AQ.E@]=2?\`R'I'\+,>'$Z6#UU)_P#(
M>D?PLQX<3I8/74G_`,AZ1_"S'AQ.E@]=2?\`R'I'\+,>'$Z6#UU)_P#(>D?P
MLQX<3I8/74G_`,AZ1_"S'AQ.E@]=2?\`R'I'\+,>'$Z6#UU)_P#(>D?PLQX<
M3I8/74G_`,AZ1_"S'AQ.E@]=2?\`R'I'\+,>'$Z6#UU)_P#(>D?PLQX<3I8/
M74G_`,AZ1_"S'AQ.E@]=2?\`R'I'\+,>'$Z6#UU)_P#(>D?PLQX<3I8/74G_
M`,AZ1_"S'AQ.E@]=2?\`R'I'\+,>'$Z6#UU)_P#(>D?PLQX<3I8/74G_`,AZ
M1_"S'AQ.E@]=2?\`R'I'\+,>'$Z6#UU)_P#(>D?PLQX<3I8/74G_`,AZ1_"S
M'AQ.E@]=2?\`R'I'\+,>'$Z6#UU)_P#(>D?PLQX<3I8/74G_`,AZ1_"S'AQ.
ME@]=2?\`R'I'\+,>'$Z6#UU)_P#(>D?PLQX<3I8/74G_`,AZ1_"S'AQ.E@]=
M2?\`R'I'\+,>'$Z6#UU)_P#(>D?PLQX<3I8/74G_`,AZ1_"S'AQ.E@]=2?\`
MR'I'\+,>'$Z6#UU)_P#(>D?PLQX<3I8/74G_`,AZ1_"S'AQ.E@]=2?\`R'I'
M\+,>'$Z6#UU)_P#(>D?PLQX<3I8/74G_`,AZ1_"S'AQ.E@]=2?\`R'I'\+,F
MUAZ9WI0E?'6T9BHY@SHV3,5QTE'&EW%#*:T>A9)/$KG<'YN+)!6848RG);&F
M)0:8>F-4%";B@ICB"S5(#X2\.)TL'KJ3_P"0](_A9CPXG2P>NI/_`)#TC^%F
M/#B=+!ZZD_\`D/2/X68\.)TL'KJ3_P"0](_A9CPXG2P>NI/_`)#TC^%F/#B=
M+!ZZD_\`D/2/X68\.)TL'KJ3_P"0](_A9CPXG2P>NI/_`)#TC^%F/#B=+!ZZ
MD_\`D/2/X68\.)TL'KJ3_P"0](_A9CPXG2P>NI/_`)#TC^%F/#B=+!ZZD_\`
MD/2/X68\.)TL'KJ3_P"0](_A9CPXG2P>NI/_`)#TC^%F/#B=+!ZZD_\`D/2/
MX68\.)TL'KJ3_P"0](_A9CPXG2P>NI/_`)#TC^%F/#B=+!ZZD_\`D/2/X68\
M.)TL'KJ3_P"0](_A9CPXG2P>NI/_`)#TC^%F/#B=+!ZZD_\`D/2/X68\.)TL
M'KJ3_P"0](_A9CPXG2P>NI/_`)#TC^%F/#B=+!ZZD_\`D/2/X68\.)TL'KJ3
M_P"0](_A9CPXG2P>NI/_`)#TC^%F/#B=+!ZZD_\`D/2/X68\.)TL'KJ3_P"0
M](_A9CPXG2P>NI/_`)#TC^%F/#B=+!ZZD_\`D/2/X68\.)TL'KJ3_P"0](_A
M9CPXG2P>NI/_`)#TC^%F/#B=+!ZZD_\`D/2/X68\.)TL'KJ3_P"0](_A9CPX
MG2P>NI/_`)#TC^%F/#B=+!ZZD_\`D/2/X68\.)TL'KJ3_P"0](_A9CPXG2P>
MNI/_`)#TC^%F/#B=+!ZZD_\`D/2/X68\.)TL'KJ3_P"0](_A9CPXG2P>NI/_
M`)#TC^%F/#B=+!ZZD_\`D/2/X69Z\>@/Y;\C^6'#>P+'Y$VN]6G-VCDC-X8V
MR%Y:(DTJDD7;*\J=X0,X$T4CL>;AD)G-_>%8#CD1BT0UYH#51A):<LG_`#M<
M8QC&,8QC&,8QC&;,:!X(07DOQ,L.]*KMM\4W!0DRAXN0U)29#$(\VPNA)`N4
M$OG(R+R\:]6X22%Q!"0>JE#68P!<X[[&/0U6G'M;&ED$,#XD.$XJ:[^1U'/2
MN0T+5US0.DX@;8BF'1BWK,DT_3O"]H"WU\T/RP*)S4-#6E<VZ*HE+U(7L]_:
MX['DSX[H'XQN_N?T>?,,J=5O6A-.G.,YMJ1V9"(''VJ;5RX'NMA4R$T=K5FO
M5DR[39'++@`"3!R."R-<U2`DL/;4*5>5O0\X7='MR];XDMG)E3$K(LAI.3\B
M=.;-8E6/^W*H8*]:CUARB/HF.;.#A)3ZT>-A1V3'F!*Y2*#B,),?VQ(6H3".
M^*4\!.6\,@N['D52#2Q/4+JJR@*44[K)\=CJTNQZ+C57V41&6":.DD,K^520
MY/'2);MK`TMSTH*0/)[</MHB?Z+>`'+A"AA[J.IBUC//9+943BCTR6)54F9W
M1VIEM>G>WS_9&,3EY(2Q^K6V.O:F?2]3VN)QL3<<C6/7LB:E1J(%MVG+%HJ9
MB@5H,`(_(Q1Z*R]`%(\,DD9GV(3EB22:&RV-26-.+M'Y'&9.PKDSDSO+0XJD
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M>RW./"1+ULH1,K6B4KRY@J7HSN5UI<F67BJJAS5`+&/MDRGY@.5RJ*JT==R%
MMKX5MR97(4L9?7E>X-\<K$LR5*%3`4X-JLTUM8"W8AX=4I.H[D5;<6W5WMN&
M5%/[\?IG$CB&*DM2F&0%0W\D99NQXS!!-3.Q0]<HD%<+WQO='B7PB/'K;$52
M!"A2L2Y[9G@>^[>TUT>O,(^R(K4;93BI_L";.EM1V+,<=F5>/9+M,*%T=NZJ
M_*?D<LW'";%J[1`Q3&"J'<J1H2^P/2(5Z<THX>0PSHY>3$I<9,D<V:'P]NC?
M$F0\TBY(]V-7RJ,2*E6C9C6VN4=DC3*E<?6+'>8]SPUR`>ZIBH,Z#4J)J)I(
M2DEK_OG?1_VP7N``I^(SR:&+^%\1YB6:9+UE0Q=OC<(<GEY9)9-H4ZM]DN3;
M+*98E2%O&EEJE4CD91*M2>^L*%.GV>"%UG$*_6KD[%.'S[#4[%>\TF%?0M@C
MRM_9'%C6+;1(9U\+?$\NC:U]C[E$79F?4$@*DC(M=$)C+W0H3]O4)S$FKM-_
M1P5_8G(;E#PUI:UYQ(>1_&6#V)(D;O+F"(-=27I+J3.:2+@@,)1,:Q?-(*H2
MG.#B77$@D;M+$TI-CRLN3ML.*<R%;;(54]%!!+BJ7C!.&"Y[-C3]R>XJ<C>2
MR!UD]<1-73E2;XWKTB![8+<F:"3-KFP1F:&GF%1Z;%I]"95(T:9U87(XPP.M
M))8^V%%&=CL';2BS>P%OK$#M@`C[#>]:UK>P]EV.]]6NO>NOJUY,_>,8QC&,
M8QC&,9[OOX,1_P"`&T?_`-W%C?X54?GA!QC&,8QC&,8QC&,?[\V,<+^<;)P@
MG5/V)5\3FBY\3/CT3RG;7Y5!7&/WW53ND&WZI9@3*VXPV*P<M(:I<7`MY`[J
MGR9F-,O<CC"HC&HPG[LSF7QO;:SO^BXEQOLABI*U>7-)\J8'#R;D:FYWKQ/6
MR->T2.H5LG;8F<ZN,56,SLXIX')V!2PRZ."*9R7!6:)O&YJ+N'],Q337<W%>
MS(IQ[MHM@XL<H.3EZ1N'N\YK,DQYB'(&NS(DWPH;HSQ<L:5UB;LJ.6*7YZ]M
M3Y)$9)SS*I=*IB_.;BFKQ!NDQK*"UA`J])IRQW$4"Z/OE[P5`[;E4'3Z<B>4
MDV+FA5CZ1`:S1)10C>CVX<8`H-"_]D0I+<VL03"C+!\Q>6U05M7D4AD3[=9,
MSOOH>^#7#Z92"#3VN7F&UB1!WPN57`WKPLRQY?$URL29L3QALCCR4!G9'1S3
M2!S4GD)5$?5PX^](]Q6DMTU%/'#CA>;=6%"U$XT52%,LMIU\CBM25\HJV0Q@
MUP0(4\;2HK1G$PLEY)L.S5MH=V1":HT:>-2"(2%N3&)7*E?.[E2P<P;:@EIL
MD3E4041[CU2-.2%#*WB-/2ES?ZFC)T<62)O519EC[<%N?0C+6Z)&SM9H%0U`
M2FIJ2!3H@4KQC&,8QC&,8QC&,L5&?_"A<_\`3]QU^HW(/*ZXQC&,8QC&,8QD
MB5%:<QHZU:VN>O5B9OG=43B,V%$%BY+I<@)D,4=4[LW!<$.S">[6U2:G[D<D
M>CB1*F]0I(`>0,P)P-ER/I'Z]KWD+RAYDTG4TZC?(_DW!+#C:5HF$AA[M4M&
M3&[#6H^XK!@ZYB0MTTG!RLY`X&UM'9&TQ4B*&2%6.3NTS+;"$KE'B7DC4UQ<
M.J>Z/5PBTC9'.(7#'I+2G(&T+,CT=BE1R>S3=QVYDL]/*1.I+91,@/=P2`D3
M,C;7ROPLP)`K42-:8Z!53U9W2@6W5W-[C/R*C[=5\FM?C)4\-K6ZW2.O::60
MGD59":%`JZXY6[3-I"I1O)TLK5DA4*;)>P=WIFHZ*)'!K,>4I)A*VD[/>5"T
M[?,<Y#\?();8I/#+KAES5Y#[??H/[48"=%;":[#,C"IQ@!.WBR$XMH#(8SN;
M@@@J=`P*1/[@PNTA(2)DNP"!]+C6U77'64UBE&6$YP"'\C.=7*211Y^F,-2S
M%SGG-6#/]>%0UC>43:X,R2%U3'I`I'IZ<$@GN>NA2=6H8HH03W(;%D6Z2VNH
MQ`896(Z6G[M%F?HPK$Z-^3J@SR(,C^Y)YC/4-BMMJQTTN+O;6V"2.Z3;0YQA
MS0KM[:3-+4#H:X%[(,^I1TFE=JX8IAI]-S\M.LZ(Y7T7)JLJ70XP12E5+1RH
M-S%%'M'8GHR1F#0^TP_9:LXL`#Q/Q9A@PEU\Y$<['*Q^9]<<S*:C3K6DMJQD
MXZ%1)IEZUGE84TGX\1-ABK8Z+!LR=J2+V:2E1Y.I<VG920\HAP<6TM5HO297
MJ;D/205[7G(;E!S+I.IIU'.1_)J"V%'$K/,)##W:I*,F-V&M)]QV#!US&A;I
MI.3EAS>X&UM')(TQ5/%#)"K')W:9EMA"5R@?D!S+;;8XD<-N+<-;+6AB#BW`
M9Q`90I<9TA-AMP)IO+44V]DG>(1WN`HHZ-/"4U&RI7[<A*&W*-JS#4;GHSMU
M!/+Y<8QC&,8QC&,8QGN^_@Q'_@!M'_\`=Q8W^%5'YY!">CRY[J2BU"3A5RJ6
MIC@!,(5H:'L=>B4E"\8#DJU$P*$:L@>O&`],><2/77L!@M:Z\_?@[N?GJ1\L
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MK/SKH[.?(>OL>$/+`/7Y>QX]V<'KZO)U]C&M=?5X^KK\G7O/UX.[GYZD?++Z
M/UH?=K'@[N?GJ1\LOH_6A]VL>#NY^>I'RR^C]:'W:QX.[GYZD?++Z/UH?=K'
M@[N?GJ1\LOH_6A]VL>#NY^>I'RR^C]:'W:QX.[GYZD?++Z/UH?=K'@[N?GJ1
M\LOH_6A]VL>#NY^>I'RR^C]:'W:QX.[GYZD?++Z/UH?=K'@[N?GJ1\LOH_6A
M]VL>#NY^>I'RR^C]:'W:QX.[GYZD?++Z/UH?=K'@[N?GJ1\LOH_6A]VL>#NY
M^>I'RR^C]:'W:QX.[GYZD?++Z/UH?=K'@[N?GJ1\LOH_6A]VL>#NY^>I'RR^
MC]:'W:SG71V\_=^+7"/EGO?O:X^VAO\`_P!:RP<.Z/CG<NX[6O"D_#?DN&7N
MUQ4?)FJ,K:=F30].D=C42NAND+VVH7IM;C%[:QN$ECR)V5).W`0*7MK*4=@)
M:3V4*.O1G=(FR!(&Z<&N52<*D1@"=D4K,W38A%:"(>A!9VYQ&3K6AAZA*`E!
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M4CY9?1^M#[M8\'=S\]2/EE]'ZT/NUG.NCMY^[\G"+EGO_=Q]M#?_``C6>T3^
M#K4M<-*<(K*B-QU98%4RM3RCGCZGC-BQ1XAL@-95M8TTE1NP69_2H7'3>K4M
MZXE*K$G"4H&E/[2(80=EO?'2`A%TC79@-["(N"M`P;U^00$'9!WU>3?5O6O+
MKJR)*EK!VFU6UU,7NY+O$\RJ$QB0NPDD^TD2[<7AG2."S:9*4S=K3)]J%!G:
M2"^H!)?8EAUV(==<A=XD7ICO?YQA?8V.\2+TQWO\XPOL;'>)%Z8[W^<87V-C
MO$B],=[_`#C"^QL=XD7ICO?YQA?8V.\2+TQWO\XPOL;'>)%Z8[W^<87V-CO$
MB],=[_.,+[&QWB1>F.]_G&%]C8[Q(O3'>_SC"^QL=XD7ICO?YQA?8V.\2+TQ
MWO\`.,+[&QWB1>F.]_G&%]C8[Q(O3'>_SC"^QL=XD7ICO?YQA?8V.\2+TQWO
M\XPOL;'>)%Z8[W^<87V-CO$B],=[_.,+[&QWB1>F.]_G&%]C8[Q(O3'>_P`X
MPOL;'>)%Z8[W^<87V-CO$B],=[_.,+[&QWB1>F.]_G&%]C8[Q(O3'>_SC"^Q
ML=XD7ICO?YQA?8V.\2+TQWO\XPOL;'>)%Z8[W^<87V-CO$B],=[_`#C"^QL=
MXD7ICO?YQA?8V.\2+TQWO\XPOL;'>)%Z8[W^<87V-CO$B],=[_.,+[&QWB1>
MF.]_G&%]C8[Q(O3'>_SC"^QL=XD7ICO?YQA?8V.\2+TQWO\`.,+[&QWB1>F.
M]_G&%]C8[Q(O3'>_SC"^QL=XD7ICO?YQA?8V8DIBSQ75JTP0ALJSY`W2Q^FC
M0^-$NE>GUK5I4-=21]1"[F&W)A%J$KFVICRCBS`BUV(@"[,`NQU,KEK6[2B&
MMZZ_^H\]\OC_`/QJO_?Z_?W_`%>+(IFC4\3*\D4-U.9U%&!%5!TETCA3\"/[
M5O!TU+:>ZEQP4*HU3VI`#9!)8A:*+T,8]%]L%V>N^[Q(O3'>_P`XPOL;'>)%
MZ8[W^<87V-CO$B],=[_.,+[&QWB1>F.]_G&%]C8[Q(O3'>_SC"^QL=XD7ICO
M?YQA?8V.\2+TQWO\XPOL;'>)%Z8[W^<87V-CO$B],=[_`#C"^QL=XD7ICO?Y
MQA?8V.\2+TQWO\XPOL;'>)%Z8[W^<87V-CO$B],=[_.,+[&QWB1>F.]_G&%]
MC8[Q(O3'>_SC"^QL=XD7ICO?YQA?8V.\2+TQWO\`.,+[&QWB1>F.]_G&%]C8
M[Q(O3'>_SC"^QL=XD7ICO?YQA?8V.\2+TQWO\XPOL;'>)%Z8[W^<87V-CO$B
M],=[_.,+[&QWB1>F.]_G&%]C8[Q(O3'>_P`XPOL;'>)%Z8[W^<87V-CO$B],
M=[_.,+[&QWB1>F.]_G&%]C8[Q(O3'>_SC"^QL=XD7ICO?YQA?8V.\2+TQWO\
MXPOL;'>)%Z8[W^<87V-CO$B],=[_`#C"^QL=XD7ICO?YQA?8V.\2+TQWO\XP
MOL;'>)%Z8[W^<87V-CO$B],=[_.,+[&QWB1>F.]_G&%]C8[Q(O3'>_SC"^QL
M=XD7ICO?YQA?8V?!3Q+PR6#<<-6R^6RQICJBOE#,9+W?3TX(-OL64+'(@E;W
M*E,VF/5D!/T4/0]%CV+M>PAWH&L[1_RAG7PE0?4F(9U5)>8ZO?@&U?N_'';S
M!TM_1;!/JRVY,F,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9!-E^=?CI\,I]_A
M%,\S1R\Z<0^`\]_?=?9@O\YOXB_\QLGS&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,9`=?>>V_?BG^IJ_,M2?RAG7PE0?4F(9U5)>8ZO?@&U?N_'';S!TM_1;!
M/JRVY,F<;WK6M[W^3]>_>UK7Y=[WXM:\N]^+6:R7CI.*Z23'DA$&6!R&0=Y>
M4\4*YKA[3/#:0U<@;'Y<V%*JD@S7"!]RJ3FR',EEQ9=''R>KBUR)4E:I3(F)
MJ<V-C;U<AMEQTOY#?;#/Q&Q\Z(SBH+;G%'6M$A+SGE$P6%!!MJI7[`R$]HCY
MTDB4EC,@BTVAK^I8(^X.D5E#0>[QY@>-.#,AL)U_D\?ZM_\`'JZLYQC&,8QC
M&,8QC&,8QC&,8QC&,8QC&039?G7XZ?#*??X13/,T<O.G$/@//?WW7V8+_.;^
M(O\`S&R?,_BH4$)"#E2HXI,F3E&'J%!Y@"2""2@",-..-,V$LHHHL(C#3!B"
M`LL(AC%H(=[UKH9.DDJJ95/WZ8$UERJ$S:U*RI?C^41+F%-*KHF]PR5OC%;N
M7M8"6L55K`)@!Q!-V*03L]%)U56I%D_-@B5`:SHG>U/'V]X]?\,>I"TH%3#(
M(38=@U#9,07*"5JR&V=5DF6Q291\3BF`6E=V[2U(2\1Q]3%)R9#%7AB?0HV\
M3B-O2SGUZZ^KQ_JWU?KZNK^W.<8QC&,8QC&,8QC&,8QC&,8QC&,8QC(#K[SV
MW[\4_P!35^9:D_E#.OA*@^I,0SJJ2\QU>_`-J_=^..WF#I;^BV"?5EMR9,Z&
M4QY)+8S(HJO5NZ!#)6)WCZQ<P.Z]@?425Z;E+:H5LKZUG)W-E=DQ*H9S:[-Y
MY"YM6@(6I#BE!!8PZ@RNB.;8Q,K?FL(O*Q%BAZ1\$W>E66RI-*)XW5_,>"ME
M/]FPXM_-<G46WR)R<]8W0P:)`C1.$8BBV6#;#%;B[)NYKZ\5:`=*+8;7=)8^
MII!8U^WE/>0=F'M(E@HPU2B:I(['FV)Q';BG2N9T;A,$A<,B*)S<4J!?(3V9
M9)5;4S'/`F=O_<GAT8CG(BI9(Q,J)I?)?WU-2AS0@&G5/^B8FU*"`NHP#T%8
M$@],2<2$X(@E'%A-+T`?7O=HL8RKEE\Q:'J:UHM3\SEP$$IDFR]+E)191S#"
M]K@`VQ:G+MM0`$>W(3#`%MFC"C]D$C)<G?38TJ4R\VT>O'C&,8QC&,8QC&,8
MQC&,8QC&,8R";+\Z_'3X93[_``BF>9HY>=.(?`>>_ONOLP7^<W\1?^8V3YF%
MV/"&VS*^G-=/"E<B:)[#Y1"W18UG:3.25NE;$X,"Y2WJ!!'HA<G2.)QR,[8!
M:+4@*'O6]!WK--,-Z*^PFH%:3!?(*EBEE<>ZRX/US6[=6B=_9JZMA=P>LJ32
MR.SBV&TV,I#(@MG\%E<EJ]L8(\TSP^FFV6R1X:Y;89(VJ/M^R7B=Q^<:!AEA
M%R5Y2/D]N6]+BY"6&<TF*38XURBW9:>]EQ.+FKDB!>LCT'C*>-PQ`\N"!M7R
M43"?)UC0RJ'DQG0?TDL188UR'JB0,B50WNLR[Z7MG.)='<1#QI+$VM0FTK;S
MEYK=O2<\DLXC120O1)NMC*T`0Q[':'&,B^V[FK:C(KN9VA)TD78-KTC60><2
MJ6JUS@M'V)*-M:V\E4Y.2@)035:@I$E/&F0)E2Y1HM*F.,#AU7<HJ-N:8RR"
MUQ/&N2R"(`3GK2DG;`)'5`<44(YTC"\T($TE:D"DX#>YKV@:A.A7;`2>+0#D
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MC&,8QD$V7YU^.GPRGW^$4SS-'+SIQ#X#SW]]U]F"_P`YOXB_\QLGS&,9`=@^
M>V@OC8^IJ#)\QC*F\LN,E:\G8U&(Q,W\V(REK=E)D#DZ`]")V2J%I)!DA:DC
M2Y'`2/B=U:FX(E*/98STIB)*YD#+TB-+/K:FI?AQT><IW<\BD#XF7R(2.)P)
MK>C#I8Z1TH]"F1RQ?&F]O2;>585A.A.,H?E@#RV1L.,:F\21*N*;U>S!D>VB
M2-#8_L#DB>61Y0IG-I=6U24L;W%O6E!/2+4:H@0R5"902,!A1I8MA$$6M^+?
M7K7:8QC&,8QC&,8QC&,8QC&,8QC&0'7WGMOWXI_J:OS+4G\H9U\)4'U)B&=5
M27F.KWX!M7[OQQV\P=+?T6P3ZLMN3)GQN!A!2!:8I3F*TY:12,]*2D&O-4D@
M(,$:G*1%@-,6&'%Z$4!*668-0,>B0`&(>@[TC(H!#+0%SNGUMM7(64<3.547
MXEL;.:QT!=U!\D*_5L;Q,HLZ5&@9ZSBL/O\`U5U-Z5029'2Y=$T3G#U<WM-,
M]2&2QQO>RV38CPICMQ1*B4,8N:6RR>.;%.+1;8#-K(2IDELRBEB+!D&J8>+=
M`C:V,A191]=B8@29S4,C,_/1I2=YF#4WS)?(4A7V2EHE"+D;4#B[2[V98G`5
ML;8X[[7VUN]K^M0]JWO7LNE-&M=NR"`T/6L+!O7;>ORE@Z[48QFM1SB:+D;R
MZY35%8JAW?ZHB]*4]'-1;;HM(;&B7/RY=,4DM9$P-]S-DN;>QT<WOQ)0UP`A
MTF-,4(-B1Z@OA?;U7\7[AM+AS(W%L4JU%OKTD(M1"2VB32A:M0-21LATY<40
MRMI)<W'ATP(RPI?8I,\!6QS0T"G2(A7;WF;S19N*;9%42..>W.=3%0<J;&`]
MP$SMB..,ZI(%\=G5T"0J.(-.`?M"QI2DANU:[MZI2,EO;5@AP'R,Z21QJYCH
MJ6P6J79PBEI1Q'/W%UGJ)PCI1\>T><G<(;'#23.P!-TX2N[SG!8%6SD-JAE<
M6](^-;Z6X(]H49?"9/'&"2)TJM"GD#*U/9")P"0!>C)=D"=P*2K@)3U28"Q.
M6H"2I"G4J"-'`'HD\TOL3!=YC&,8QC&,8QC&,8QC&,8QC()LOSK\=/AE/O\`
M"*9YFCEYTXA\!Y[^^Z^S!?YS?Q%_YC9/F-[ZO[->3>_+OJ_)_;OR:UX]^+*"
MQ;I%*6F$)EUELT5MH5=-D_@]8UA.%D29T,7Y)S2R;`55C!FGCL\J)9I+/RI!
M,2"&\#JX"C+0T(UZ5[D*UH92UZY%:.FKEAEYPXZ8PLY864V2J9P&4L#N4E32
M.%V!7,G<X7/8/)T:):XHDS_%I.SN#6L$WN+DSN!92=X8'5W87)L=5F-6#O7?
MNH+Q^EGZFH,GS&,HS<$*E<^YJ<6S3(J\JJZJ>)VG8SA*=-IXHZGF3HE21:/M
M(W?M>TA;V4#>G`E!LT*HQ&,P\!8B`G"#D',CBU7?(NO%*J2+B8A+(,TO+I%[
M$!LD@;"F+2#7.2!],,+,"LB:W:(E0ZIS`Z.0C3%NS:<F6I][.@GHXN5\'L^O
MHW18F1OAL^K6%H"2&QG()*C<QC[3I,B6RN.;3%@`G.&M6)U+XVK`@5#4N8'9
M,8K(6G]R;/,8QC&,8QC&,8QC&,8QC&,8QC(#K[SVW[\4_P!35^9:D_E#.OA*
M@^I,0SJJ2\QU>_`-J_=^4JNOD^#BAP1I:?AL;CM4*^0QNJ8&S6?RIFZB&4K"
MG-\AQKCIYDI#6L;I+-UI*!C<-,%=QAU87*7.W:$:R5PYA*>)0U4NX0<SKOM*
M\$D2A_2D]'?TEZ-2UJI;8-*T'3QE,6I7L$2/+`R/4T@\SCM[V]&75KB;A*6D
M.X]9T?9CID684V-DU8GGK-.]!6O^?_7R[\OE_P"/CS\_Q>K?DZM=6_T_HWU^
M7_=O\OY,YUU=7B\G_/7_`&^7].0)8/GMH+XV/J:@R?,8R,Z\LV`66MG^H0OT
MXK()-W.NYF=MH7-HB)5'"4^UJ#2E:C3!=B49:LLLI<C-5(M[V862=_%%K*"\
MY^$2BRD[M<%%LB!+<@B2R9(W)C@-JJ;,^B3$RL]D4GJTC4TS[2<1*4+ZHVF5
M.S(6H9]NC>J&G6[R7C3P1BK1"1R;DY'FBWKKF>D*R3NLW5K9P9'6Q`:A41Z(
MH%[RK5D#-9"T"8MT<FXH@M<?L]M+-5LI0-*;T3JM(%9<940Z=Q-BE$</)-*"
MUN[<F5$(QFHE#<%6V"&7LUJ<4R-6H)0N3:-*N0:,V)&H)%H.]8=%`U1Q\8JF
MI`B4$L9:].HB%8L\LD9Z]]D6V%-W>>V(7!U,$H=%2)(H+T61LP.P$"2HD978
MA3I]35Y?)C&,8QC&,8QC&,8QC&,8QC()LOSK\=/AE/O\(IGF:.7G3B'P'GO[
M[K[,%WOJY-?EW_V%^37E\XW_`#Y?%KR[WK64QMZ]>DYDD[>$O$WBUQ8;:KC#
MPM;2I?S$Y(3^M)Q:13<86G5.4*K*HZ>LU3!X\M5%+"XX[V5(4L@>D@2G9?!H
MZA.1!<;A4C:5DVC5*E[L"G"*VM-O2*4;S`?;TVSBO7IS-9R7-H<H!;S.R$M\
MUKB4IUJ037*C8DS/B(HU8BDL):'IM5-(]8B?H^9`N]E[PKBB()Q?DYMW<+N2
MI_%6'R.*'P:1VYQKD<_4W%)QND.2-M:,\WNB!6`E@K3,FUC:5#XMJFN)798F
MTQ8N;8YL`X8T5+*5A5K.<].2$S:^>1UX\C9!'6]2G7HH."UY;M;&8*!V2EE)
MGEQBL):HPVR1X2!&W.,K`^J&@]4T"0*C^]E422LW(RGY`4\2I:H?Q6QL]N=Y
M0\NS"W=4/:A:TQ,2Y4:V,>NLGJWIM3D;$$PX(MB"8+66FQG&_)^K^W?5U?HZ
M_)U_DZ\T\\/F7D#-N75^6D=;BR1U/&)U*ZYDBY6G&!HL18Q".*8&",QCNL]O
MC":#!5IS1/J`WL_$8A)TY:D#J<DW#;UH0=A%U;UO75O6]:ZMZWXMZWK?BWK?
MY=;Z];UXM]>LUXV6"!\$GZ+V37U2Q5GJZU+,VT\@Y8D]DA/<-(?RBR8@YL2?
M2@Q"S0I"_FN"IX9TY!+0E/5!"W(TZYR`;K840<4I)*4$&EG$'%@-).),":4:
M48'0RS2C`;V`PLP`@C+,#O81@$$0=[UO6\_KC&,8QC&,8QC&,8QC&,8QC&,@
M.OO/;?OQ3_4U?F6I/Y0SKX2H/J3$,ZJDO,=7OP#:OW?D''16*2G@]%A2N/Q)
M_+C5`()8Q#F5=MUJ-<?DK)5JP;3)R(,XH7#3^X,PCSC2&U&1[(.91BAH2CUM
MQ&$>B[H4UUU/')9K>[/C_2%-J)WXS2=U"[<K>!G#7BE3+N^.CS3ZTT^K)[QQ
M&3-IBX*"S%JQCC,M;TS."'&*7=04E?$*<HSU0G@$82:`!PTXQEF!"H*T5LP@
M0@;T$XO1Y9Q&QE;WH8='$FE;$'6C"S`=D`7GIL*5WC2-@\P*B027D%$8C,>2
MO1=,#3*9Y<[E<"-#0_)N^!4C<=P5G+U$H=)?3+]:+C&9A#G^`]468*P4@C%A
M5VD:ULJ5Z;=C?`";2J0M/*B"O4D>Y?%*'YFW12=32&2*G5V>SZWC3/`)$ECB
M^3OBA:\2X5;RZ7S&K4\D=W!S>%:*%)4KTYN#NA6JC)9E3V_K^1E/M;C#7-C:
M6P5L::9*J=HZL0R,.X>U:ZT+>V.BMY0;#HPT0M/"!#XB=ZUL0C"P[M/C,0L`
M<V+A,J,K<AB4ST#$Y"B!$F-4DL!LA"F'MK`[&(PB4A0[5=AV[9?8]?B",PHK
M8S`:^>C9B'(6'QFVB[FB((NV26R'F7(A/B/39-G>;.IW:9RYJD"30F[<54*$
M2/;`K*[2!2<%<8U!5L1B!6+9KC&5YY,<?6'D56ZJ)K%8V"5M"LF2US.$81@=
MX1-FO_;-#V@4$;`I"0(X`$SHF*,!M4A&+9>RU9"-01)M9I)XW5_#D%H.3&\6
M$CCS8EF#M&RE1+&YOZ=.`IP7MX%A*<\)*PT/;Q=FF2!$<8:(I(F*$6G+SG&,
M8QC&,8QC&,8QC&,8QC()LOSK\=/AE/O\(IGF:.7G3B'P'GO[[K[,%_G-?$7_
M`,+'SQ==.'QMZ.CC?S/,2+*\Z*2L)->,#>^1-A2OG(MZ2:PK&LJQY[9L[*ES
MJT,'$F?(V*",&E").L2#?411LK7.#Z5$D9*.&N9)7LJX7:;]</N*FFDV.GM?
MN;J,]C3X@G?4D3.;^]=%>X38NEE&@R9-&QI.TB82))K4@):=HRWO7LH%7EE\
M9`=@^>V@OC8^IJ#)\QE6.77)9FXQ5<.6K&=T?WZ0.`HQ#VA!VU$F4OZE"I5A
M.=7[:%>C9$*!&G4+=FFIE:Q:<06C;6]8>8/16)]'VA@:/BQ7I\`-DRMO=CI&
M\O;G+VL+6_NLN<'Y<9)EJON;0FUQ)"XZ$B;W9H/5-K@W(TIQ*@1G;RRKIY'%
MP1!)/JNGL.61-CG14@BKP@*B,E<%;0Q2!:)(8:VMSD[H"CE[0G.<2DN_9=`#
MN]K,"!<B&2I(*.+UU]'-;M\OTBM2E[A;FYM3U8F:@-C,Y#*99="MC-`TH88V
MQP0E"UY@"%M1!VQRA2K5[3[*(3!?).%U`I;]K>,8QC&,8QC&,8QC&,8QC&,8
MR`Z^\]M^_%/]35^9:D_E#.OA*@^I,0SJJ2\QU>_`-J_=^5LE!UJH>#,">:ID
MM21I2P4U'GJ;BNA@GSQ$7:MT%:*S)>V%.E:OS5+(8\A1;`YH)<@9IWM`6W*4
M882[*'!.I0:0^C1?NATXC7!64_IKC_0W'^9\BPRSC-6/([C-RU=N7=`VW(&L
MJ`SR:5*K>7"1(;)@4K:DJ:'S)Y6V=14+C\=;1I1/%@HS7I$D=_58I3)ER90C
M5D$JTBHDY,J3*"P')U"<\L9)Y!Y1FA%FE&EC&4:6,(@C`(0!ZWK>]9!T+XP\
M?:[K-VIN%U#!(]5SXW!9W:#(&%-[7ES04E"A1M)Z%1V_LFMK0@*1,K=VS2-C
M1DD)68E`002`N2X+!(?6<49X/`H\UQ6)L)1Y34Q,Z8*5"E[L6*7)>?V&MB,/
M6.3FL6NCHX*C#U[HYK%CDXJ52Y4H4&1A8/GMH+XV/J:@R?,BJP[D@E;.3+')
M$^M:"7R]CG#Q!(\[.*6/`F2B`,I3\_LK7(WT2&+)G@AM/+<>X7-X1JO89.[R
M`!!C''9`O;-72?IP>$TXC$_-K"SV%7*X%QRGMW2Q'(W%F;DT!D$7,+9&ZKWL
M@3N$^93Y9*##DYK)6)DO0^PR-&_%O6V>7PA=(-B]'7,AF="PFS9]((HR/7>T
MA,QM'0U1,;0P5PDT&8YT>GE+<\KQJX.82POK:\'M<E4IU3<VK4QYXQ)C"CS+
M!:WK>M;UO6];UK>MZWUZWK?CUO6]>+>MZ\F\YQC*B<NXW=^XU%+3H)_=]3:G
M7E7*5=;$K%`(];47/3$DR*)O+84+0')R`@3#41WLM"4$J1JRFWM;HJ1'E6#K
M2;E61`(?/261\C9<MCS8_:8)*WJ6M]9Q."8!PVYS0JR2#R520S8RA;&2#1P`
M@4%A[6<#,XQC&,8QC&,8QC&,8QC&,9!-E^=?CI\,I]_A%,\S1R\Z<0^`\]_?
M=?9@O\YKXB_\Q_'_`,_\,TK\WJ6NBX>1ZZ?63(ND^XM(8Q!6ZNT\HZ*:_P"M
M+&C,OK<FP)X]1.>7!4!U;[Y+AE1FW5:G;4L.J.<LD:&CDC,RR1_,-6+%6Z;B
MT_0![X]U""M+.67#%(]7T1B"6Q'DXS<KDBF)QYL8UKC.T2M.A=6.?J3T>U,W
MC[^V-$A9)(>XH'MG:W$D]$3_`"<N57'UJ<+D:%5GL!CMQ_>8!&K=:4!;HZND
M/E5J)&M97$/.;FIN6K'>9S<M\8RHU#H\2[R9V7/K&VI6H;B\MJ55*,`L&'VC
M%6Z:P1[(?XVYG.B0A<40L1GIW)B=ES!(&5U:W-,B=F.0QR0-CG'Y)'7I`WOD
M=?VQQ9'IO0NB%4E*C6P?/;07QL?4U!D^8S7ESVV=/%/&_C<G`(PN\[K9C).6
M`.AZ,KVMP%2J6EF@Z]"[28$2#9G8B!O99(P]GK6]A'?YK;&YF;D#2T(4C8U-
MB-.@;6U`F)1H6]`D*`0C1(TB<!9"5*E3@+(3IR2P%E%`"``=:UK6??C*7VQ2
M,\(Y.4GR)J),VF+"@J*QO%K6NA302]56Y=FJ2/8-"+W[).L3<-;4)$0-C5+!
MZ;"B]!(2G[#<_7D\O7[^_)X__GY<YQC&,8QC&,8QC&,8QC&,8QC(#K[SVW[\
M4_U-7YEJ3^4,Z^$J#ZDQ#.JI+S'5[\`VK]WY'D2+C9O"]@*F(7@42,XW)RY0
M&/I#USZ*.CK007P+*B3)UBE6[":]J]-J5.D4GJ%VR"2DYY@PE#\RW"[CFCYE
M7/3)4C*Z86J'JM(;:-B12[>7_%'AM1M36?5L^B].4NZU:PIJC9EJD^5O''LA
M-'&1YT4U.J5(>^3XT0'1G:X\E]@RH:@A(I-2)^[%)9*@Y.EV<!/W2?H`S"D_
M;S-;+([<9V).CC`B`5V7;!Z$$.];U8NG+?F!6!G+R.3RC(I=LPI2C:IN2L4_
M%]CL%^.=Y-;KK/HX70\HB+PXO$CDDPKQ5#44T=)9"5*)5.*S?D[XEK*#O`FI
MF>;5<*;Q>^17'2%VU(Y/6<J>W]?,$+HMJJ/6A#HZVKXQ+WN,+HRZPRZ4#3:<
M*G$56LZB/V!#IRSM#_&)@WN[,M;DPD>M"^Z6S&)/?(>FHVS2=@=9#'16P%_8
MFYW0+'ADWN'M8=>RS:G/,6-VA"/*"#:LDG0Q&!"#8M^++09Y_.F68W'EO=_`
M'HS&>0$E1/DA:,BMOD6U-K87N4(:%HE,@?E#ZTRU2)2FB@UKJ)U9&K930L5/
M+^)MT)>F;&]Q:7Z*^6708\.?<]L"R5677''^9T;Q^.K6F[::(S%J8C3?8D:D
M+M.&2V[3.2+U[O8LO5L+.ULD@*6NBPI)HVPI?#V=`[25N;X_KV"+I*KKCLEY
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MN/*:)2_L3<FG4H9`B">R2"7.+2Z%A>D;GDBRQA=&[D13CJKF,B>T+H.V1(8V
MY)HN4S1W6X<U;[%H/:HZVOQW7HH81>SCV\AT$\>R@E#UH>6BSC?D_P"?Z_\`
MY=?B]_-2]>V/R\EW2"V##E)\95UI7)Y""6,99H5$/BL%>$(W"(.C*X;2A>MV
ME(4RHHY:'>@E*1:=FQS(3,+4W'DYATE/-^1\'F2B9?"F=-;LWLRSA51%.*K8
M@4AL;D"\2="24B[W4D0$.BV*.==.(4#R[JUL:?8^^-+P9&%13=(7>+.B:/\`
MHW^D\C/-1EAU?(&V8/M_19EDKIRV:'F$E50FXY24IW<TC5#G&/O;@J6R$#L_
MA.BD&U&E<C=#([&UTGLE;&'XP#*Y;>=;UO77K>MZ]_7CUF"6>"P3*]F1=4G,
M2>QQQYR#"SY,6::QE2#:<7L>8X`*WU[*";_]7LT)B8"CM(UA1R0)Y0]<?1P6
M/>BU]NBGK\D+L=*X$L9WU/&)\!6;8Z#4K.7+'5P]DA&"1.,,4*1IC6D"82HM
M">O#ML-3QY8TI0[5\8QC&,8QC&,8QC&,8QC&,8R`Z^\]M^_%/]35^9:D_E#.
MOA*@^I,0SJJ2\QU>_`-J_=^0(I)N@SA?61E$QB"SV9DU5"0K*YL&7.]=,UA1
MA;"0MC]%FZRF:/RY17DG4)UI:Z-R=7$9*S@<D!;4\MZ%`Z&2!ET]=')P?7<<
M>0Z*7<>.A49.C?6KH:H@%F\@;,YJQN]Q.]>*W^*OS]%()5%<3^S%$T?W];$6
MW;5)9>ZU8@C)@]2%;N0;+40MV]+:LI0<D4E)E&DJDU.<60IV2%2%.>,L823M
MD#$`!X23-A,V2,0`G:!V`A!T+>]43KSBE?E=1Z9HD',V8/LDD[FP/Y$AD-&4
M2%.;)29BU2"=2"8M,:C<;439SL6--*:NW!0<]LID0B1:8NOAQAP;VY6EL_3M
M1QZFHNXQ]C.4N"V1S*;6/,7U:$@E7)9[8TD7RR8R`U(D`4A;BW!Y<3]HVM`4
M6C;&\I(A)[;V@2@[%[```-W4&((`AV+=M"%L(=:V(0H:W]EO>]:Z][%V(>O>
M_'OL0]?DUU3X+>M!WO?DUX]_HZM]?7^GJ\O5^7JZL\M_1]U<Y61TP?,2ZSZ!
M2IZZXM25%QBJ^/N=N;E:GBVX2B-R>S),\09G5"-B)S%+W!Y=T\A@\-?5@J9=
M[+"RP5"\QD<@6L^RKI#N,4NO6T>./M?=YB:V2&2G0-[3DM*E^B%<(223I0;9
M!:9*4`AH>A@0";Q+7%244O6((^2G7(#$>P*=A<FI"O)["&>"60RZLAG;4\.`
MO%,3AK54M-@[HV2!G,FPD>T":4)E,B:43\]L3NF4QIZ<R]F.;*J*WVG//QT>
M\]*Z/?G-S9Z.@ZGK.5EVWR*9.1G%!D8B"W%&YTI:@Q-]CRU2Z*I)[1(G7%/"
M:#7%>Y*#V>3.P$YL5VS/D_,96$STR:\?_P`_^?\`Y^_C&,Q6<1=+-8;*8BM(
M:E":2Q]X8S2GQI*?6C>G-`>D`-R93CDQ;JB*--+.4-XE*;NHLO9.E!`A!-!I
MLXT-EP='\HE+MR2>WQNHITE*"OFXIB1JIW'RI"867MKM8P\A8);7T"]C$86#
M9.T1CD[."U"WJH\ETQ)W!3NK9WAID#6WOC$YH'EF=DA"]L=6M60O;G%"J+":
MF6(5J4PU.J2GE""82>28,LP&];"+>=EC&,8QC&,8QC&,8QC&,@FR_.OQT^&4
M^_PBF>9HY>=.(?`>>_ONOLP7?_B:^(O_`#&S0CTD4QH=VY.'/O(3E+TQ'1Z3
MQ@@:*HV)-PGK&VWVI+\CS7+97+V*7-5G5+QTOR-S=W_ZV!2MC(\KH1+:_,4.
M+0]QI$>ZG*%6\7AI*'&4<=ZUV?$[DC;+'(K&H;$W3D'']PFY[`CT2C3,Q$V5
M8->JBRGR!/<T7(ESJ..2M*U2SM1@'5]CL:4.8&1':3JUX_%KQ^+?BUX]>3JW
M[_B\7CSG6M:UU:UU:UXM:UY-:][(#L'SVT%\;'U-09/F1I:5NUY3#&U2:SI$
M3$8N[29FB.Y.Y)'#<;9W>0C.3LPY6_)DI[7#F5P7E%-!<GE*IHC93TX-#0I=
MD[@\-I"GR/L'/+FU,>2LZ2<`86RVM&[4Z0US9F'F98(G:$<9K/CS9!I,G:^.
MTI2BCR8AU2,;=I:-%846>4[R].<:9"H"R+I:]C3OEM.C:X*<RR^1M9<T.=B,
MJTI4QR/D?`X73YXEK`EX.R"5SF1/[G/84VR=0&/V#!IJ8%VCT9-A;B^[@\;E
M<07Q!QF;"8XB@<I=(/PUL+CS8M$\HNBZJV4ZYB5XT6D&<-"1J>)3"K^I-<!7
M*+#;>0,QD[^D-FUG+ID\('.MP.\I<;-L"4+#4J#8V^,@?(I?;H[><]-<JZKK
MMDJB36[9DJ886H/N]RM%O;$E@5+.DKF-O61.]`D%1]L9)_)Y$"1BBT9A[&:U
M#CD?4N;<@8XH0S"4[+\BJ6MM4UTOE7(*3M#*RO$?@2IND\_`T'JGPB",AXWY
M0WFB;DZEQ6(4R@K:L*1,F4*31EE%EA,T624'-XO)V&:QQBET6<TSS')*U('M
MD=4FQ;3KVMR3%JT:HO1@0&`T:2:#8BCBRSB1]D2<66<`8`]]C&,8QC&,8QC&
M,8QC&,8QC(#K[SVW[\4_U-7YEJ3^4,Z^$J#ZDQ#.JI+S'5[\`VK]WYC54DRE
M1Q5K\B#K&ANF9U%,!42<'\@]4Q(9.9!2`1]8])DNMJ5#2F=Q(CW(A/K9YR(L
M\LK6S!!UFG?HN+NY\3&]TE2<@%C/WN:[KZ]724S:R.8W%'DC<M]S:4657[E#
M'")03BZE8T5?P6F@FV$R"?9!%8-W3$9O7T-5P=.\QX#@1Z"5:I.A3*%BLXM.
ME2$'*5)YHM`*)3IRQ'''&#WX@EE%`&8,6_\`NA#O?Y,HPR](E0*Y-;(9"@M>
MNI!4K=5S\LA5DU7*(A,YM%;VEZJO**E-:L*TDPR9-=NV(B45_%$B8])(&^:@
MU&ILQQ%T&$C=E:9NF$WI$E<KA:A:7MDE,I@4PC;TF*;Y3!;`@SN>PS&#RUK)
M5+B6^01YU3B)4!2KG!K<41R![871WC[JU.JW';!WKOW4%X]?^;/U-0?^NOUY
M/!HPEEB,&,(``UV9@QBT$`"P?QC!"%O>M:"$&A;%O>^K6M;WOQ9I,Z"DM3,^
M.7(KDRXE&B7<N.='*:[DB\X.M#6Q<N="KV*;+%K6MC3%-T--"1O>@Z"$0BP`
MT6$.][2W>[V-JOR(\?Q,KTJD4JKJ2V1IZ3!2[96EIC[NC9BTSAV1P5G=#HI/
M4Z3&$D#()&F+*/%H:LKL9LWX];U[_O>7/.YTM_%<FA`P3I+./<C>4_+6E.1+
M+/SD;[)7]]F?(:OI.0DC4DXJP)(6)4HVR%0Y"Y+(76+"SGLZ=H*L%R&E(='Z
M0R<S;'P3Y)ZY>\:(%R.(>X"YM=K;>9*Q,]?FNBU)!&,;HH2-U=RAY=S@*7VP
MX:4FVU3]U3LT::C9,%<G8V0#,F0.;I<#&,9UCTRM$B:7%B?FQ`\LKNC4-[JT
MN:0A<W.*%66(E4C7(U(#"%2904(19Q)P!`&'>];UU]6]0="J\K3B/4LT!$$$
ML!`X\?+;&4,*=0]35Q:R#$P7%R9XBUCVH7`;2"T.Q-C"DV+03S#S1&#.4*#Q
M9]55LU_=<+:I_6LD0R:,NP-]I6)!;`>D5%ZUW2VNB$W05;6Z(Q;T%4WK2B5!
M?6`T(1D&DG&2-C&,8QC&,8QC&,8QC&039?G7XZ?#*??X13/,T<O.G$/@//?W
MW7V8+_.;^(O_`#&S7/T@?2'W!PRY$5''C*Y<U?'F4PQ^4O+[$>-W)GD7:EE6
M,X1NS"(U"ZP#2C4*MH&LA$S8*M-D[=;+\D>[,9;*[C@I3&BBLEE2#9[14UF5
MBTC4-AV17[C4M@3BKX',9W5SR<$YUK>7R2*M;U)H*Z']>M&KXD\+%K&L-%V(
MMGH#.VA`9H8==5'.2?'N81";V!$KPJ:40>M'A?';"EL=L**/4=A#^UDHU"]C
ME;PVNJE"P.Z9.XMR@;:YGIE@D[BWGE$F%+D@CI.B\IC<UC[1*X@^M,FC+\B)
M<F5^8G!*ZM#J@/UO9*M`X(C3DRH@?4+6C"C!:T,(RQ=B8`80Q#8/GMH+XV/J
M:@R?,T"_P@GD*LC7#>.\>JTG*1JG_+^X$-`&$MX6=S[JKQ$%2==Z5Q5JQFE,
MJ)M;1-;&^*"`^R9"MY(9!!2"<#SB+H=%!%G2(<+:[AB]+(28Q$'!T9JU325F
M8VW1,#0&)#F,3`>U$)5CY'MN!KFI:7^3HP2A288>6N<Y&2D0R=WV4ZUK7_'_
M`/Y[W]6?,M3F*DBI,2L4MQRA,>02X(PI!K$)IQ0RRUB4#@E7(1*4HQ!/("L1
M*TNS2P:4I5!.S"1Z2.2_11H80X)N6'`JXEG%'F#7D?7+919$K>U3S5_))M3&
M'O\`)TW+1N<QF(Y,KDJW2QV?[/-3;<T"DT;DX(E9+8S&L/:]&;TGL[YM69*Z
MMN*'0OC_`&=5]41>0/=0[,D#J^V^9+EI:I!R!J"2/&VM"JX[J6)*FU%BTJ*5
M/;_N7H)$JD2.+)8VX3+<^Y-J!X;E[2Z)$[@V.B-4W.*!64$Y*M0+2#$JQ&I)
M'K8#4ZI,::0<6/6PC+,$$6MZWU967BK1TNX\1>9UJYRA!(J[0SUZ=*:3A$N,
M>HU!'K1;A[6GTY442G&>WO1[AM)W%L\H9)HU0CP;5A1([3XQC&,8QC&,8QC&
M,8QC&,8R`Z^\]M^_%/\`4U?F6I/Y0SKX2H/J3$,ZJDO,=7OP#:OW?D;QAN97
M?A4RM4D7-+7'G+C46WOKD_KU+4QM[,MK$Q*ZKGES1FD*VYJ2(#5"EQ7I3BE*
M-$4>I(,`:4`>O.=T%-8U[7W*53IB6T0W."3C=(8XPJXUT2MH='5-[@CI#Q48
MS)]#+=GIIQ/(""%!;$+C(VM4BC<D$LD$6GYS(%*K6=S>M94::0F4'$IC5AI1
M!QI20@:<L]2866(9:<D:LY.E`:>,(2BQJ3R2`C&$1QI9>A##I6F%$<G>0Q$K
ML.;<;4=8W*RVQQ"O)K52.ZJ_FK5+V/BGR(1VW&>-$2(B&U*=F9$C"9/'=/8$
MN/CNWBX)^!U<T*:,(R@QN\/#&F9S5S?R+FMB(BF"2<D^4=E\A-0D)[4L6P&.
M/[!!*]A,5?G%@<GF/KY:"%UFPOLS,C[P],*26/KPULCZ_-C>F>E^3RF*[:.1
MM0/_`+9)6Z>SHK7W["N[SW<P,W5#VL74PMO<Q7L=K?:MA%KMYW\4PW77_M/X
ML==)-?DEXT<-KTMYBAJN5H8Y6T^!(%S9(&QG=(0E<X3(&QAFR=N=-)P29"T3
M-7&B7YG;71#("61:N>(^DD#DUE1YRBGH7X7(Z\Z,3AY$))$!0U0VU"R+D*,Z
M2-,E6/C?)QGRX$S6G,83&QJ-F2M_62!-'RG%V5L[8M0)W=:4\[<&QNM^31?5
MR?6\BE4DTJ"*FD=4-<4$U@T)K,#*CY&XO0'C:D0A@6E[3I`(0HRC"Q=TFC5&
MEC+)+L)G4KV!C=%[*[.3.U+W6-JU:^.N:UO1JG!A7+VU6S+EC*M4$F*6M4L:
M%ZUK5J$)A!JEM6*D!XS$BD\DSSIW>>JZ#KDZ]<FXLWKE71G<N9IVOD)6$;3A
M5'<9^1CNE.,9;6K:+@-+,.BMIGI#&F0QAC``LESZB"BB@)(BCS?E2L\?[0JF
M!V+)8:"OW:;QMOE`H>"6,<X&QM[V`3@R)E,JC&A1MW7G,9[:L<38\J=&-.O4
MJ432]OR%*0\KY0QC&/\`GWO^&5]@/&BLJMM>:6U`$SO%G"P6D""5Q%I<=)J_
M<G0+B4X:E>HL%/VA')Q;+$EVN1GD)>Y5*WL40#UJDXW)JYO6K;6>YQ&81*4S
MG)*XD3C&9C'U*9:TOC.XMJL:$X\UI=4Z-><TG*2C"D3TG(,:UHBQZ3JA[UK6
MY<QC&,8QC&,8QC&,8QD$V7YU^.GPRGW^$4SS-'+SIQ#X#SW]]U]F"_SF_B+_
M`,QL\^'3?M5EM?)NKI0=8B.+5;)J0:X9$VF6],NNZ+A@<+1;9_-ETE3Q&*-J
M)3NVI(Y1M\AA$A=EI2@QM)*BK<B-3EEJTZKT%40R+(7Q9IN.3]A<4KA$J"KQ
MDFD85.:RU79,L8:Z:$,C85+TB1*EUC.))J1:VG.J-N/53%2$2Q,B-.<P)Q:1
MGFN+&F$PM2_(2:OL[CK(N8W1K<JETL0T1-J0GP:MJF0/L?G%/O$*5ID#Y8L:
MXL1F(4M:(3MP%DEVCELXATA1/LBB`6ENV>]'E%9JPUS><BDS8[,,9M;F)RGN
M&H6-Z"X)5Z2H[$M)Q>(H]"9G4A*OCR6P%FGRT&]B6)4JQ"W3A+M:C1K#U"0F
M5I4VRY+R,I]:\R=L=8\L%;&X^QI8QMI7,FO:>U;$%<^^SKAI[UL(#M!WII:M
MZV;H0NR[4$(K3"WK01;WU=6M;WOK\G5K7Y?+XOZL\HKM0,=YH]-1R1D3O5%(
MN=+<17&K*DD$(?YS(VAKLVX[S:BWV8VM&EC;I"SLO(Z(PAA1.:ME0,:\R3(8
M.T,;](D\@]C9=&_5@@0HVQ"C;F].4D0H$J=$C2D![`E.D2$@3IB"@Z\02R2"
MBRBP_P#N@`'6M[ZL^O&?&X-Z!V0+FIT1)')L<T:EO<6Y>F(6(5Z!:2-,K1+4
M:DLU,K2*DYAA"E,H*,(/),&4:6,L8@[U:=)GP9C%[09KY'UM8;-QCY=<565V
MF]&<GS')#%6F)H(^B5.CK![;=5!(F]QI)\1@6IY&C>R5:".)UBYR(2J&Q7(&
M1\P/HO.DCF7-M[G\)N9DB5$774$-K]NF7')R0R1)9KP[NC44]/%^-!TC(8RN
M\Q-B'-G(@4>:F9Y=&-+O;S*Y-M/)(ND,V`\L6NX%M+2%UHJ2.+!9,.5M4X9D
M;>4G.U+T\64^R3K"5I2@H[1R.1MP%"?N8H(3%BLI*B$8$E2;F9T+<#'?-1PB
MUF``DZ.6-`5*IO-Z^W-#TB/.;9`RG=EH(]C:7I(N0Z,&`&SRB2U'8ZT;K62_
MC&,8QC&,8QC&,8QC&,8QD!U]Y[;]^*?ZFK\RU)_*&=?"5!]28AG54EYCJ]^`
M;5^[\I->]NW32O1[UW+Z2XL,O+US,K&)MD\JR1W"PTBP(ZG'5;TYV!+GB82*
M,RU$K1-+4UEMPXRG9CG)^$]A(0BT85L!FGOH:)ZF+Y@,<;D/&A36Q%F<<K!L
M&F9'+>FA1])P?"XFR.U2%*X15M5=UJE-2Q=S89$S%NTW/->G!:BCS#$=2@]$
M%4D4^L'/X`5)C.Z>P4$C[C,V2K[$TL6TQNB2E&RU&@BWL@S1!Q)VP&Z`/M)I
M9O8]K,`(1.I3JRM'I3R5)(MBT$U.:6<5O8=["+6C"A#!O8=ZWH6M"WO6]=6^
MK>058/GMH+XV/J:@S6#_``A9GC3OT7MTEO*!4X/QTGJ./U^$MU=T:5#-IS:$
M6@Z!W4-R%Q1-CRI;&M^>#V<I_)6(6IV$E>T>D+N@0.B+:/3U/P+C55`(76<2
M/:(XQHUCZ&'QD2Q0D]F1-:8UZ2PZ.KG4]ICX'UT1'N!4<8C&I@'(71Q<@D%K
MW=S7JJ3\&^6\\O\`NWD$SRYBF"!G&>U/\09528DYCJMM9NV1M7"GU8!&@4H9
M4^J0EO!J96`\2IR02(HC1!#<`1^TO&0/<7&.B>02YD6W56[%9H(Y'IS&69HF
M`G!XC"%NL9K2L<N4@B:A;N-#?W%B3#8TLK.:C)0QLK@]M;`\-:-^>2ENAB%W
M?-.@LLG?$^[39A;?`^T1O:C@19)K@A5R^M9SO9*@KB'83R^',K(WM"I6J,40
M.=/CDACD?:3!NS^X-D:+D6X;Z1(TO=72.L3B^MB1D?%[,UK'IF0.P7]"T.RI
M"0>XMB)]`B;`O2-`L,.2I7<+:W@<R"BUP$24!X20=WC&,96RP.+E>SBV8+>#
M>KD$!M"&.B(]7*H*M3LZR:Q],(&E$0FY1B12F?F->G*+0J!GDZ<@MVMMY:W2
M3111,CK+CK)OL]!3*^9-"&S76/`E37$EHSDK@YLABI8D"H;3CR2T*]3VUO6C
MVV)51KH%,D4+-H^Y2AG!DSR^3&,8QC&,8QC&,8QC()LOSK\=/AE/O\(IGF:.
M7G3B'P'GO[[K[,%WXN37Q%Z_ML?JSRC]*G<++R3Y42-SK'CMTA;;+:CC;Y1E
MG+WOH(:BZ1ZI+$@<(L*>`:)G2LEN![1.,#CDE>CYXC!+6AQ5UW9K<B:ESI#S
M'**&+#/5-P[#$M<2^,6X"CF3=!Q\?:<-A[=8B)$VSUOC!M>QXUC03-L:TJ%H
M:Y0B;1IDKXULR%`RMCB4>A9D*-K3I$Q=C.Q#K6]>/Q^7>][WO]'\;>]B\7Y-
M]?B_)U9SK6M:ZM?^OZ][\>][_+O?CWOQ[R!+!\]M!?&Q]34&??R*MQ=0M.S>
MY288KGC-6C2=,YLQ-;\TL+\57L?")RG+['1/VB&5Y>HW&TZ]\21IQ=X^&0A0
MG-:-Z2N2A"2I\P/1)+GFW'>@9G8*1D;9ER4Y>\DN?DK<_;DUO[M)4KZS&L]2
M;6MB4GML2"@2,KBU1>*N;FNE2UK2N$@<VB.HER!(?ZZM>+6OR^+7CSG&,Z]U
M:6M];U32]-J!W:UQ7:5K:Z(TS@@5D]D$?:E2-84<F4%]F``^UG%#!V00BZNL
M.MZUH]()T<K/RL,BU[TM+3./_.ND"].=`\CV'1I*I,H1#/5!KRSD:<!I<PJZ
M2;/5MCJWN2-R4,R9T<#F].M;%S]'7_X^CYZ0U1R/6R[C=R2B!-`\]:)T6U79
M1CDH"0ED*<HH/<MM4\J//-U+JOE1':G5*I;%+D./@6IR5*I:T*F9]=;IV#>D
M'I^>U!7$D;'5K(N!V>X]&I*D1(2X@UR1`2E5H6%Z4Z5$GH7"2F+1EL_:4)Q"
MA46;I0<3H6QZG?6^OQ_\_P#/Z,8QC&,8QC&,8QC&,8QC&,@.OO/;?OQ3_4U?
MF6I/Y0SKX2H/J3$,ZJDO,=7OP#:OW?F+5>HDR3BA`U4+:&]_F":AV-1%6-V.
M"F:WB2$P(HUB:G%2(],%.@<G4*1$M/$I3Z*3'FCV>3H/;`^='H*ZJMNMN6%\
M/#AQUL"N6N;09R67,\VMT3_'[HYRX/80I.V.#-":.LJHK'EKQ>M>N3AN3EN;
M"<EF48;R(_')N&T"W5<4DF/JY'U]@+J\O8[ZOR[[+J\75KW^OJZOTYHD@L8J
M!_IWI?*MF-X)N,4`LCI"IG!7*SHVOKUE,CJNUJ?XI1\28G5@LDAK\8;%F:MY
MA;LGE#$N:7Y4^2%H4]K<%!YR:]71N19V@?%B/P-S@U20Y-!Y]<,2C;O1M81^
ME:OM>'L-GR=!$KPC=3Q70H[!16\Q%(IH\M<?.4QI:^N#D_1(\<3=V/09,E1L
MW'R,I\M^019/&"Q6Q[65;0[/"Q^5AW#VKK]G6Y:RH6YOWH/;]ZVWNCGH0M%!
MZ@ZV8(.O7IN20R^N^"])%"V-5>'28<18H:EUH76>S1J2O,^>A;&`@XPH"<F.
M$'&&$"*.``.Q;V:FTI('NB7+T+0W+G1S5D(FYN2K'%>M4F:*3)$20LU6J5'F
MB_BED)TY9AQI@M]B`L`A;\6LPBL!U@[QS4YJ@B*F1NR%1LX,D$30HTB.7+WC
M6NZ)*L4)4Z<;FX+^TATH7J]#5&;+[$T76'>LD;&,K3>/#[C?R3#*"[UJM@M`
MB75T953HEEAKHXI$<+/>A2-6BC202\*:'.R]\`WNCC*8H2SREP6,$5&N>5!<
M5CQ;=IBC5DWQT($G8ZNY!O<UY!]%B^.B6/5+R.4(U<DM/AJ)<=VIGKR\R&IM
M&IDM2EJE!39&9R1K9S,D+)1IDY/8I(@'T+QJ31V9L#-*XB^M$GC$B;4;RP2%
M@<D;PR/;0X$A4H'1I=6\Y0A<&]:G&`]*L2GFD'E"T(`]^/J[S&,8RO?(7C57
MG(V-I6J6%+&>2L)VW&#V%'3=-\R@[V6,!Q#BQN@-:,[3M0208M;#A;2+0E`'
MKN=84E6ILH4S*)T?"J_;;:M-!W6I,CD`3S6;JVUC5S27F-PBP'J=$!(;R71Y
MV@5N"@`.UI2>HT9I^@AV:*6PB"+6A!WK>MZUO6];UO6];UK>MZWKKUO6];UO
M6]>+>MZWKKUO6<XQC&,8QC&,8QC&039?G7XZ?#*??X13/,T<O.G$/@//?WW7
MV8+_`#F_B+_S&SSH].A(JA3<F:U9G5QJ.GK`)IAH=939ET=)M?/1RM-TU>?-
MIJE3TS$=5-&WUDMQ;%7,A\<I*[2$]`LK@N?1U,G+7-TE4[1>BKBBHAJKC#QX
M45Y7ZNJ($;256CA=8KC%!RVOHJ*$LFV"&*E"O8E2P^.-?<K2)<H$,]P[ETO-
M&(Q2+>YB32B-K6QQ>D;^RJVAH,<B75T3.K>>W-IS,(P+N4X+B5(TB(QJ$2;I
MR+5'%#0;*,[L"3V`NKM42U(XHTK@@5)UJ%<F(6(EB0\I2E5I%)03DRE,I(&8
M0H3J"1@-(/),&4<4,!A0Q@$$6X,L'SVT%\;'U-09I6Z=ODI74[IB+='W%)JM
M2V]R=Y/4E0TT8VQOF^I7#ZY='*.SR434J*,*0N0S6-.K(>TL3&>S-<CBTG=E
M+^SIC%SQ$']"TV+ISA/Q)8^;LX8ZPKY]AJ*AX]4LP>8XTKT1%</MD*V)$@B\
MB`VIC2W-J?6]B8&IRDB=&6G;)E(B02%["-<%?[-[FM>+&,8QFM?I!>CKBG,=
MKB]F0"3'T3S,I,P+[QRY.1<D2>30U[0&GK4\4E@DH-G2FKWY0>I2/\<6EK0H
MR'!<M:TYFE+JUO54Z&Y,)^>L1G_1^<V68GC7TA-/";5TABJ82<*:3KX[UKHW
MR*X['JU)*>70]V2%'.:UM:U9Y[&A7+2MG^PQR9Q3[OV-"J:V9H;%[HI?%S>U
MMZ)8]+"B25;NK2)"4ZET5%)PA3EJ7`XL:L\M.$)(#3AA*#H&M:SM<8QC&,8Q
MC&,8QC&,8QC&0'7WGMOWXI_J:OS+4G\H9U\)4'U)B&=527F.KWX!M7[OS"Z^
M:"Y!Q"A[$:KDB`IZX^MC28NARDI'+$9;E7@40U485GC+)2R%.$_9S(I-&`HA
MT`D-,$$`1"UILZ,6`)H)R,AL#FW/:G7)QXP<;%E&4[T>\!HEJXF6/6D0L%?7
ML@=)?=U=2&WK/G<\DVMP%C+;S&)P7URSOSK(WV.+2O9_2,7HKSYSDB502<G4
M)R#DYX-EGD'%%FDG%BZ^R+-*,"(LPL79"[(`P[!OLA;WKQ[Z_P"X=:#K6@ZU
MK6M:UK6O)K6M=6M:_1K7BU^CQ9`E@^>V@OC8^IJ#-9'2*$!G720]"[4I8P':
M37KR)OQS2;V6;LM/3=(&>Q*LQ/ONCL0@=)"+M"@Y$$!:DL.TSDB6`!HVYG2!
MWA'ZBXWSUD->B$\[LN)2"%01C*WLUS=%CLB"VNS@6G!UC(;&9N7FGKW,[L$R
M<\Y"C"8-<O1ISISXQD1-)QZIA%"'9M?HPWUM$FYM>&D_2A"OVWLZ9&O.`/J"
M,!VG0E<6L3G`*4I%@%"9422I)-*!.F,8S'Y5%(Q.8V^0^9QYEED3DS6M9)%&
MI&UHGIA?69R(&F<&IX:7$E0A<FY:G,&2J1JR#2#RQ;",&_%U>>N1U]>_0?2I
MULFB6:<<@NBG>W18_6IQ]1'JI5;/"P2\]P<G^P*3VO5EFR.FREBC3C(H>K4C
M4LZ?MQZD],8!1+U&^"E;MJGD36<3N&E)S'[&K:;-H'2-RN-+0K&Y<1V6RE"<
MT.]`4M[FVJ@&H'AG<2$CJS.1"AN<T:58082&5,8QC,!LVKX)<4-=X!8\<02B
M+/178*VY>`766:$(M$+D"HH0%3:YI-C$-$XH3B%B4>][*-T$0PCC2CZR4\;:
MU?8Y*[=>)O"8LN>'F-/4\`A1+(%7B-"4>3'7:0:/WIW0QXI*M5:>EH41:9$8
M%(G1HF]$0G+G%@D#%*F9LD4:>&U_87E&2X-+RSK4[BV.2%0'LB5:):E,-3J4
MY@?^Z84,0=[UL.]Z$$6M=QC&,8QC&,8QC&,@FR_.OQT^&4^_PBF>9HY>=.(?
M`>>_ONOLP7^<W\1?^8V:H>D9?>3B7EQ`6"AZUJ?ERY/7'IQ;8/Q<L/E!1]"(
M:MGSW,7PD?*=[A%D4_,+)LXYM3,[>RP^0T[8K`Z0<48EC.OA:I3,&Z6MNVNK
MVF=1[CE7S%R2F;"_V6QTO%FF^+!CZE5%(R\S=M@R))9TP9EO9M*R.LJ][)>W
ME`MUMI4-B(TM4$#<82$!'G*8%/$.7*K+L7A(_P!2-?'B7\L.CB5<C:6H]G3L
ML&8>.536M+FQUO:[8]M"ABC&YW)*7R/=]U*Z-R:0J>/%1QEYLLP]*@DA3)N6
MZ-P,CW5-U*CBEA%7N',+E6OX[E'A3EM>Z'4VP["B"J&DINH@NMG-\#+76L>X
M]::3J_71U3'@ACI[0'4S2GV\>Z-J#V>]JOM6[*V/:Q[$>S/L_P!7M/:NR]GN
M[O\`HWK[#M_8^QWB[+M7Y.V9I[NFK;+M_P#A`-5%L=T*6!?0G!>171"#&^"1
M1Q:8$3+K1;ZY6PF3MRU2J<YNVV,B'*CY$L5/,0>4"=Q9Q0)9'%+$J<G3=?5=
M&)JULR^[-%)%$@<[QE<=?STI[8F0AC;;&(Z6QMK$G4DGG#<BRS!+%?=AI:47
M:SR"!)Q&D&JE$^XQC&,9KJZ0+H\H)S8BT<DK*_+:8Y44ZJ!)>./)N&E=R3VK
MY8WGB<$")2M1[)6O\!=%^Q`D<25'F)325*E<V`3.>Q"4ZAZ9Z1^SZKY4MT9Y
MF,ZNK^5<.8&ZHN3E5H#E9\*N^"H`+UM<<K.-:0T6FQZ;%^B%GMKB[&40N9U&
MU0$23N9V<TL=],4(G$4L>*L<VA+X@D48D2`EQ:'9N-[:G5)S=>,.PBT$U.I3
MF:$G6(E)9*M"J+-2JR"5!1A8<KQC&,8QC&,8QC&,8QC&,@.OO/;?OQ3_`%-7
MYEJ3^4,Z^$J#ZDQ#.JI+S'5[\`VK]WY@L%$G!P\B@U8B0I0<>$`E`E!RE.0$
M@-<=9VSE",H]605HK0]F')2#E!0-"&048:$`!:!NC:;>*5\'POC#0W1H2OAI
MQ%?:G8+Q0WU)U<QI6Z^4]DTW8]/21@>:_=A'L7(2R*,TL-`[R&V+9D*)ZL%J
M>8JPN<)8FR0+"U_J5%_$`+>OR:$+JZ_+X]BWKKWU]77OK_W?DUU:UK-+#ORT
MY!,,#Y7M`YRF=98CZ6"H>$=5S)7&HLUAJVK[S<.)[><O*;T+/MK?WN"MMPS<
M^)KY0C>#763CC^Y+[*-Y1K>9<WA)<$YLEMY(0:P'XF9/'&KE59O'IOGO:6U.
M[3B+QV.P"?Q-YE*=C0-3$":-<?LI!#IB>QM+0UN4CB[@[)6AJVO,;T^<RV6M
M;QR'IQ@2)I"2N816T!<H<XG)V=F.WJ'-6NMHD+JT(F!_UK:@&Q:8W)PV6$)@
MS=``#8LT#7%=DGF_\((X[P%%R#I<#30=?V:Q`E?M/DJ[<3-NF41TAWH%[&%X
M*@1=X.I"!MKR,3(UX(9BDDJ0-+[%U5MI66./FY'G8S0*>//&.GY;`T4O<;5N
M8IE2.NG1Q87^)19J:QNTW=&%X:==V%B4(`(4:]O4Z,;%R48A'DEKT[<O0WOC
M4;8(@P-$8BS0@88ZQ($[:SL[8F+2(&Y`F+T60F3)RM:`66`.O'OQC,'L1AHA
MFC&,7>8QC&?S.)*4%&$G%@-*-`(LPLP(1EF`&'8!@&`>MA&`8!"`,`M;",`A
M`%K81;UO0%=G$2^NC1M&8<RNC2BJB=TE+G(^6<L.CR2K#4K#*"BPK%K_`&MQ
ME`,:A-";)2IA;./A#4W&-[X63M(TMR](%%%TNPKBATD_%;FD=%4-`S);*WEZ
M@*N=RIA/;=-#W4XDCNG8`PRT&QS5)ED?G;@\:>"6B.H"'DQT;8V[R5.?J,&L
MSP[WVT(.]]77KKWKK['?B%U>_P!COJWK^O6<XQC/D<$"%U0+6MS1I7%M<DBE
M`X-ZY.4K1+D*PD:=6C6)3P&$*4JE.880H3G`&4<4,99@!`%O6ZH4CQ=/X]V1
M*5=:SQ>AHB5(%:_5'N:0YT;XG-SUJ0WV:A3ZH7]T,K,H1@6E+F,Q,JT<8:EU
MM2(I"D[GM`TR./OQSLG8WQG>3V%S/9'LEJ<D3@:SO*4(1*6EU+2'G#;W-.$8
M!'(%FB5101A$,K6M]>=UC&,8QC&,8QC&039?G7XZ?#*??X13/,T<O.G$/@//
M?WW7V8+_`#F_B+_S&S29TQ[CPR%<T-9>D%Y@\CJRX_`K"%/<-X>T@\N$:)Y6
M6ZFL2=`;FTLZJ`+^0TSE)&BXZRML+B9D!CX%RR//&YV:N+<4C/MTX:1&3,56
MAD[A+Y\M@=H$0>PZ@J.S&9>DFG'&O'FK8.032THD,DDTQF\TD[-(4CZ]2A\E
M[\->D?GI='D;>B;V8D2JVQI!1Q1A)Q83B3@#*-*-UVPLPL8=@&6,`^R",`P[
MV$8!:V$8=["+6P[WK?)111!19!)8"B20`***+"$!9998=``66`.M!```-:"`
M`=:"`.M!#K0=:UJ!["WU7;06]_DU;._U0U#FH2K;*A\=Z7_I5K^G+ZF;HCQZ
MXW\.J'3N)YP3^ITDS7)[471IK3%J%"A4[.CN:D((:D)1)RI7U`-2`.")4?L:
MZ/FR7ZT^-S#*)?.CYQ,E$GG.Y(->N3+'6.&J)6Z*FF-.`"-:,2Z0,1S<:W$*
M=;%IL4I-D#,2=HWJ[N,8QC&,U:=*'T?D>YYP"N8JU19G8;?8[!95,.Y,`6E-
MDKXZ,",2A\DDG:DJ(:5]L8AYTWD1Q+56W!LCKR_/;=(WM[CY$>$Z:TV1^NNF
MZZ-=B3-4*J>%<C:-@#W+R!NG'?36HL>R4SQ(5$D76W:].R=0I>IE.I>)R[0\
M.,7<SI0WELQ+26<2T(FU6X;:^%'3#\4^3D1`S6#:4'I/D5'2'LRPZ+L@QXJ^
M:L.F94LZU*..6*0V+G/LVM,%>M0L*^2&M@^W)CE`QE;T':#![#@UEL:>20"6
MQ^8L:D(!%N<==$CHF`(P&C-$J-IC!C1J0AWKMB5860I*WUA,*"+6]:S+&,8Q
MC&,8QC&,8QC&,@.OO/;?OQ3_`%-7YEJ3^4,Z^$J#ZDQ#.JI+S'5[\`VK]WYK
M.YAS@Z,\$.,$0=.58^#M<7&HJJK;9Y7)RHZF<:KA#M5TC>_8YFE\R"9":M?;
M/?X^R5BSVK,2C6B(*Y0$#:4.7.L9ZH9Z.]-7]'<I4]`T+TIUH]);`)14\SFL
MVAMU757_`"FL#CHY1I?!D47FB.[8(@)5PV)V&%]61$FK)B((7]2E12*%C+)B
M4I*4;^]ZUO75OQZWY=>_^C?Z/?U^7*R;XA46*.7C%S(VZJ6KD-:!%UV4%;*Y
M,N4J+90%PT+)/HPK5N9Q\'?HT?74`<8N.(#9T<==X<Q/#2D2N28U2?)50T]!
MJ0B&X;`VX]*C5OTCETA=W-8>[R:8368NZE_E\UF$@6;$X2&4R5Z6'KG1U6F;
M%O7<Z%&4C;$*!"EQ2P?/;07QL?4U!FK>AFQ%-.G5Y]OHD2%2WU'PXXFU>,&D
MR,28EYGLLDEP+MFDE)S2S5YBE&WN9IZPY.Y$J0%'[(/*$C5$;&%*CCU;')F/
M[*FI;Q=G'!ID@DT30O`@H&PN?(4[8]*EC>-,)(\.S0G)3IE86Y:)3&3G%,6\
MD$FK$0`VLQC&,8SX'5(I7MC@A1N:ME5K$*M,E>&\EN4+FI2>G,*3N2(AW1.3
M4<K0'#`K2E.3>N0&'DE@6(U2;9I!FG*Q^@6Z/&TY6PSR50:>!G;;$GEDD,YC
MUE2.)S6PID^/)$A5W/.I7'#&UZ=;@$\C>5*B5)%3<A=$S^J:'AC7LS/$V^/X
MX+HQ.:-':$?PPZ5WD;'VI$3H#55_+J.13E;`]%`_[C86_/B=@F[,@#K6BP&H
MU2Q647XPC$/6M[_!G(3IMN/`3._%PFX[<T8HUD:[IF'$"XG"LI\I(#O0=K-U
M5<J,\MQ<-AWV8FQ@<0`$/K+)'H/\;.XCG3M\/V1R(C'*F&<DN"TSWV))[/RI
MHF;Q%@VKWU!V%%/XX@D\04I-BWO1:Y4O;21!#LP02P;#O>SVG^2G'SD$U%/5
M&W;55NMAJ<"GNFNI[&)?LHH>NO6U29D<EBQ&/6MZ[,I8F(-!O^*,`=ZWK)LT
M+6]]77KKZNOJWXM]7^[?C_LSG&4IE_%)V9+L;[\X\3-+5DK?W]`9<\67MZIU
MK^UF$U<6:\K7-B2'IQ()IM,)2:C?$@R]J%XBU!QB)08O6+KD;<F\+@!I&N1Z
M=#$IB\MNVJ(TO&A+."0-8%'LSND24LX8"3%.BMD`.$$L0]#$$._NQC&,8QC&
M,8QD$V7YU^.GPRGW^$4SS-'+SIQ#X#SW]]U]F""WV/)KK_\`T,UK7Y/&*Q]:
MUU[\?5KKWKKWU;ZM>/JWFD.RX5TGO)7D:\\UN-W''HK%M:L3+(:,K-HY2)K3
MEO)RV:0B4\FK7,FDVT(JPO$#HINM-X,D#FPQAI;7W9*1='B+;.>#FHUE:MYG
M&M_BLIX\T=((-%S(/#7:I:]5QB$G+"W$V&,8XJUA;8B:XD'*4SB.,)@`8A.*
M14K1+_8_NQ&J4I3R3AS9L6M:WO?7U:WU>3?7U_HUU=>^O\G5U]?Y,:WK>NO7
M_I^O6_'K>ORZWX];\6\@.P@['=E!@UOJV+5LAUOWMBAJ'6M_E]_WLTE<+VBD
MK&?^FBN#D&N:2*OL?I&76ID\B<SSQ&(#*5AT/K:(.#`X)A."Y`[-[\]C"SK$
M!.@)1#-+%O;3M4C(WC4)05><=8$C@E>H#0)M&=W/;ZX[(/D$J>AE`*/>WY<0
M0F+4JS"BRR$Y"<A.WMR(HA`VI4R0D!>39C&,8QC&<;UK?BWK6_R^/W_?U[V_
MTY4KD_P3XC\RF73-R2H:`6>805HMLDCJTZ;YVP;+"/M)D<L%C,;)HPF$#%VT
ML+<^$D;,"#9I!H0]CFG8OH:^3O#2P&ZXNC2Y<+E0(\M&O+XW<O3'N75Y(4&T
MB@I1&>^A"36F8)6L\)YA2%,]L[EM,?W,I/>M&IQ'CR*5=-C>7%=^88]TAW1Y
M6UQU:=`"@D-RP61E6[23@X[/*`%SBTT964+0G;3B!;.VS29[0O:89A9)IHNP
M$,6Y_C?R@H[EI6C9;5"3UHGL+<C3THEK:<'NML<$HNQ5-CR@V(2AL7I]["+9
M2C6BSBAEJ$IIZ<TLT4_=?7C&,8QC&,8QC&,8QD!U]Y[;]^*?ZFK\RU)_*&=?
M"5!]28AG54EYCJ]^`;5^[\Q&M(!!K4XHUU7=EPZ,6!`IA2\.8I9"YHPM<GBL
ME95L7;`+&E]8'I*M:G5N4AUK1R1<E.('L(1;!V8`"#]G'CB5QBXDL#U%^,=`
MU#0C#)7`AVDC;4T`C<'(D;FD*,3HW"0#8D"10]JT*8XU*@/=#U8T*4PQ.CV0
M2,98K#9!W)7D#7_%>B+0Y"6BOTW06JXJLDSX?M0B1;/V`U.@:VP"]T4(FAN.
M>7I<VLY#D]KVYC;C5P%[TY-S4F6+2/Y\:[E7<@:7A%PK(4"!D3M`>]LS*18]
M76VA5QPY8>"/R-IL*F95-:XDK-*&H"9^:%T;DSH1MO7)P*3"5@3TY7S6)O\`
M[:Z$ZO+H-M=7^_4,0^_XLUE=&J:=,>>_33VH;H9P%/*JGZ60J]]T#)TGI&CF
MQN/1EG#"24+:1?(1A.)"E[:E&+L=K%B4U,,,H<0.,,/)Y-<C[J.B#Y'D$!N.
M60NH&IQT[(FY.,Y!U3.6I"W'0%CN4Y*G56E93S#U+0F1N*[N0!QP$IB#;'Y,
M8QC&,8QG&]:WKJWK6]>]O77K]6\Z9_C<?E34K8Y.QM$C95Y>R5S._-J)Y:EA
M6];ULI4VN1"I$>7O6]ZV`T@8=Z\6]=6:QKBZ%3HUKC=5,H/XT1BJYX</MR>P
M^/CH_P!"3%"KZ^RTM3K:O<H\VFJM#ZA]L7-*P.QZ[(8!>/K@PSHTN>5$FF*^
M&/2N7@6R(@E!:ZFYH1".<GH:(@K6NIL]NJ@#%/6E!XNUA,0A/6DE;_BGB&'L
MA?VWR>Z:+C]LT%Z<`:6Y;1AO``M1.N%-V#BLJ/)!XA+M5!=*8MS7*S`:V,3>
MT.Q8-F;T64/6MAWOOH]T[?"IJ=R(IR89^0G"":#V`@Q@Y9T3.:];N[M[T$9"
M6;-"&30Q20$77V"TUW1D#+#LW>P`Z]ZVBU-?U'WPR$R.E+>K6V6,Y.6I"YUU
M-XY,4P"C0Z$#9^V%Q7&I1]6]:$4J*)-+%UA&`(M;UJ)N2/&$BY%\?LF!2Q?5
MW(&O4AA-?66U#.WVM&(XY89%)6VZV(MYB+FH//[L2#)&:1W2H$$"M&H7-BZ:
M6>2.D%JQKDE\22#L;RPQQ$HL.2MRTUH@R9T)*`6XK4*I]VE.2MARC8=IPJPE
M#[,S1196M;*+R0T2U&Y)$K@WJDRY"N3$+42Q(>4I2JT:HH!Z94F4$B&4>F4$
MF`-(/*&,HTL81EB$$6M[^K&,8QC&,8QD$V7YU^.GPRGW^$4SS-'+SIQ#X#SW
M]]U]F"[UU\FNK?Y:+_W?^8WY-Z\>M^]O7CU^3-;]U]"#QXN6Y)99J7D7SOIJ
M`V7(%\KM_B]0G*V;U=QEM>1OZ]2YS-VDU>-"<YQ9C;!7K5BR=$0221)*_N"Y
MR=]DHWAV<W!5M[C48C\(BK##HBSM\=B\18&J-QA@:$Q:-J8F!@;D[6R,[8C*
MUHI*W-;<C2H424L.BR4Q!10==B'//\GE\\#4]X11)+)<X0-_Z=]/25ON:V32
M:3+F2@IE<%:EO<%6/Z]Z6/4<A<J?G6.5PY)`+T[:U0^;+&%.0WL*OM9.Q_HZ
MI'+'JLKO9W92YN$#KSF)RKJ^C'!S[H.V;34`M=U88VSM;FJ-./=XW"'XB5UY
M%%PS30EQJ(M3:2<H3MQ*@WO[YM.15E9\%G,KK9Z=(1`T5JO)!E=KPS><OK&G
MC+$![=$T"]C616+<?:3W"0+&9E=I%)'%M9UB6.LKV^'M[0KT0=%L6MY$\/ZI
MA"0!:`Z[.D)NKE3.CY:O;HR98D#W:\K?'1;6S<\.HW^PD+"0W1M#(G)`UHVH
M#HIVU-BY]<XQ--LGK"UY/]_7O]>^O]/OYSC&,8QC&,8SX'-J;'IO6M+NWHG1
MK<DQR-Q;7%(G7-Z](H!LH]*M1*BSDJM.<7O99I"@HTHP&]A&#8=[UFH6Y>A-
MXF2J7K;<XUN=F\#+X/[I/!:/$&7*ZQ2KEAVM]CJ35LFV.OGUNV/8AK$25G8S
MENA#":NUL6AAK(U*.G`Z/YR3ZDJ"*]*MQQ;3S-KEL0VG@'+%I8@[&':E/'W]
M7I%+'@O8BS@H$;W-3'#0#4X-MG;"S2+ET-TS_`NZY&FKA^LUTXYW;W4:W.M'
M<HXL[T=8;*Z$!#VU`J]MA1435F&F[V2A&VR=7IP,#LM.#9W^RUM3(4$*BBCT
MYQ1Y)Y0#B#BAA,*.),"$99Q)@-B`:48`01`-+$(L8=Z$$6];Z\_MC&,8QC&,
M8QC&,@.OO/;?OQ3_`%-7YEJ3^4,Z^$J#ZDQ#.JI+S'5[\`VK]WXX[>8.EOZ+
M8)]66W)DQD>V>.SRXH894+;`GF9EO4:$!JLEYD4=B[A'M2!N]MZ8;]%V"5.K
M0\CBWLMN-KO:V^-Y3_INT[-QS8)5L,9<6N/S3QMK%?`V@#6B(?K,MRUED>C*
M;V.A,2=[BL:160]12"-7<Z7V.BC*YR-4G0`VF1B7JA+WH3<U"=-M:+JI/!XB
MP<CJ=E#-'FMMD,G,M84@>$J;1:YWWJ(-0@]W']>Q':").2+6M^+6P:WK6M]?
M7J@Z*2ZH#67&_GEREL9S):VNU^DOYB2M'VL!)SW(A-TM;85'8XS(MJ#W!Q=U
M8HRJ*0MZA:<!(1V]8(](R$F*BMVU.6I'+KK2(V?%0GDL\N:27,I"L/0'N+2H
M%L12UH=-MJQ>C)<VQ46:D7IB51G:#RQ`%V(NL.I-QC&,8QC&,8QG&]:%KJWK
M6]>]O6MZ_5O,=E,/B<X9U4>F<9C\N8%P>Q6L4H9FV0,RL'5L.P*6IX2K4!P=
MA$(.]&)Q:WK>]>3>\U>6QT(?1M6@\*98U<?4E&6`>=W238G&:4RGC_*T*KK[
M+NI-WN71ICXS]#ZC-;6,"H&Q:UV0-ZZ];B8?1U=(A1>C3N(/2O6N],R;L`MM
M7\WZ\BW(V/#3%=7:F\=CH2X[83:F"'02M')2U*@)?C[(0M>/7MT@EG],0VP^
MIX9R2XI4;8L6+N)I9T<MXBVFZ.;U:[Z\L3LV,+#&J*GK@CFBJ6I#=*I64)O0
MR%`UM3>\J'#<::"%\B3=MT?G2B]X>G2G*X^/W2>29C=!R9"WM<9XK*9Y1E:"
MB<M>4J^.PZ2L,A7RE6YL2;K0SG;H@C*)ND"%V;@Q5H4I22!2?/\`^$`P&/SA
M_6,,B98_!1FE[98A?W&GE94<Y;"D[<D,4)7"1!AKO'%:YR-$K<6W82R`[:NU
MC4)TO:#!J+KQ3IV.C3=JR+E3ORSHPN=M\-,?7^N6B:'DN9L@0-A2MQC<6431
MIB`7XXY89I$S*1`3%N@]B[FV;VDT6I/H_I@>"%\R1GB$7N-F99"^#4$-R25.
M,<0(CE25N/=#DXWQOD#HS)A]QICC"]K%B8!@PA)"+MQI18[WGW73R90U)%-J
MUNF5/I&U+(F/G46*/>$X0E"V<V%B=="7%:">1OMB?M@-Z.+WH6]##UR(E6I%
MQ!2I$H)5I3PZ&2I2F`4IS@;\@RCR!&$F!\6_XP!BUXO+GT;&#7BV(.M^]O>M
M;_5OJWG.MZWY-ZW_`+MZWG.,8QD$V7YU^.GPRGW^$4SS-'+SIQ#X#SW]]U]F
M"_SF_B+_`,QLGS&8&15E9IFB7,">O(,0Q3]4X+ITRD1&/$M,S6.Q`4KJJEC<
M4W`1R10Y)@A3N![T2N.6D!T4I&:7K0=9.Q,+)%V9LCL:9VN/1]E0IFQF8V1O
M2-+.TMJ,L)*1O;&Q`2G1($*4D(2DR1(02G(*"$!180ZUK-7'2W2TF`\:;+GA
M\HD\.U">._*.4DOL->-Q^1@7M57IQ-#8A>RTZA8UDOSR:W,;DK;.Y7<#8X+`
M-;@W+!E+"=8/1?\``.(II%1T>1/<\9VVFN-'%JS;>2D21U$2;R`FL1+G[@S0
M]2(X"VNVY7M\3+94U1]<%&>L:G`UI1LJ^0O:T[U,ZUU?V[_7OKWG.,8QC&,8
MQC&,XWK6]=6]:WKWMZZ]?VY6?DCPVXN\O(UN*<D:.KVW&P!(B4*J5,1!LB9`
MB%L0AQN8(=HI;&CMC%L7;F)[0#V+QBV+R9JU3]%KRTX=$F+.B^YQ2N(0U*8-
M61Q.Y?IU-YT&<(PS9Y[?%9:`LFQZT3G;`6`(FC;F8(>^S4K.QV,6_P!H.E\M
M_C&N217I3.%-I<9@;4!1:Y'TLD<.0'%AW'L>Q>R2F018E=+H*F$GV$_;<\HG
MUP2E]F):%-V`P@VW41R8X_\`)^($3SCW<5>7!%#RRC!NL"E#8_Z0".[+9:=Y
M0I3]NC$MZ@[[-`]H6]:7U=0R`Y.6MZWKKUO6];\F]>/6_P"O&,8QC&,8QC&0
M'7WGMOWXI_J:OS+4G\H9U\)4'U)B&=527F.KWX!M7[OQQV\P=+?T6P3ZLMN3
M)C,<E\OB\!C+U,IJ_M,6BL=0'.;Y('U<G;6EK0$:UVQ2M6JAEDDEZ$(!8-"%
MV9IQA1!(##S2RQ_-!IU$++BC1-X'(6N511^*4&M3XSJ0JD*K:-8I;5Y'9ZT$
MPA:VN:-:UNC>J+(7M;FB6-KBF2KDJA.74GF+;FZ%4P"Y38N[RYHK5@N682MK
M85S"A>$<,8X,E72N2-^I*XM+2YG1=G*4/IC$)R2N#TF1*$#+I:\FH&Q=YR.B
M]LFH;_X'T)P^GR"155('NT9?8;->KLQQV0-#].+&MJ:R)Q98PVZ<T;M&D;^@
MD2:')).XIB6=P>@*T.FLQGVE4*/613=.P6B8`S5S7C5IM86@)IIIQPPGN;T[
M*]A&Z/[XNT``G!Y=3PZ.6*1!`6'02DB0E,A3)4Q,HXQC&,8QC&,8QC&,ZQ6R
MLZ]>UNBYJ;5CFR#6&,S@J0I5"YI,<$HD*\;:L.*&I0#6HA"1K!)#2=JDHA)S
M]F$BV#9N96AH"L"TMB!L"XN*QW7Z;DB=#I<ZN)FCG!S6:2%D]U.*XW6C5BY1
MVQ4J,UH9YQ@M:WGU*$:544(E404I)&$81%*2P*"Q!&`18PB`>$P&]#`(0!:V
M'>A`%L.^L.]ZW#LGXV<=YOL6YI0],R[8]E"'[9ZM@C]L0B"!)21;$Z,"H6Q$
MIAC3E"Z^LL@8B@;"6+8<K!,>B<Z-&>!V&2\%^+ZGL@)2]B;Z@B<?'LM&8,P@
M&S(ZA:3.PT,P6S0=EV*C78A4:-"``0URD'\'^Z)M["+:+BLDAY^]D["I@=HW
M'$1@[2<,W>P$M<^"D"(X!@TQIG<VS-I-Z3%B++`#6L59>@5XO0,K9=+<B.?U
M"@">!62GJCF!/FEN)6$J.W)5FFEY2O;:8>C)V-&F[:0,K2<79'%GJ0A/U\3C
MT3_,"-J.VTQTT'.R-)$YA0D+7;2>OKO2EDIE6CTR<]2](&-0J"`L1I:DQ22:
M-RUV!:X0R`!*U\<VXD=-E7+%M72G2G0ZZ7!,I$`F+7?Q*J..G*$!BO2C1HYA
M&U)NCEY6NR3G`-;T9!J(>RT1J,XHH>\-KQU_A&R=Z=660-W1]O*9L:E:XA^L
M.-3^*MCTH$J)$E;6U96,UD1@7$8.WD)]*F=*WD(P[5N*P:OM)!L96CTH/2Q\
M;Y^JKZZN%W$23+DJ-&NV^5]R"LJ)Q8TAX;M+FWM#Y-X*X$G"1#`8E<]EDC[-
M48407I,$HX_4=UGTUW*:P;]64?958U#QFA]D36FAL%]N5@L-WPSCS'I@VDEN
M4&GBZ"`0QZ03BS'EE&VUTHF"J``K-SGC8HM5$N94\8#(O4YKQZ_)OR^3_?Y/
MZO)^3?B\>M>3.<@FR_.OQT^&4^_PBF>9HY>=.(?`>>_ONOLP7^<W\1?^8V3Y
MC&]ZUY=]7^_&>=K^$D2A8T<-X5"6X.AK+TM1DHX9>QB!LQLEZ]B>7@&NPWH0
M@G((J:F-UK>NQ)4&#Z]""'+\=&;(VN:US8\S*K=;#I%(9X4;*92G4KU$,GB]
MJ9$K$B40@IT6K%K2WQQN;B&ER8"S5C6UN1AFT#JJ,4JT#7LMQC&,8QC&,8QC
M&,9\ZI&E6IU"18G(5)59)J=4F4%`.3J2#BQ%'$*2#0B*4$FEB$684<`98P"V
M$0=AWO6]/W(OH3N)MK3`5QT*IFG!SD4G&<J17/Q.=1UDJ6+S-@&$Z6PMC,;H
MO)"=&!$8I[G(9')?VPPM8Z'EC['4!J7[IR^"L6>G>4HZ$Z4&IHNSO"\Q>VKS
MN/\`R59VEE0*#$J]P)VTG0N<EED%%K'9*W(G66*^P4EH5"U4(K9D85'_``F+
MB?,)$WMUNUY:="-:.#B<Y(<]PR86,Y+9ZH=4C4GC$.25K&WPM7'D.TDE4.$M
MD@V(*TQ,TMC(V+'(4@*8KJM73U=$TYFA(,Y?Q=A4#VFT`B70*WHD8/2KKT$T
M/L_7R$&TQ(M;`K6]GI&D%H7=!X`ZV+4WQ7I:^C-F9I!+%SHXQ#.4G*2""G6V
MHQ'###$A7;S]Z!)%;0+102_&`\6M$&BZP$FF&:V'5@8]S$XERXLHV*\G^/,D
M`<DVO*VQW56KIL:'0]%[6!"DDQ@^Y=&""#9^PZ+T,00[%UBUUS8TS"*/X-FL
M<EC[R6$L@W8VIZ:W(&BU0=C3&;$B5GAT!0'6Q$"Z^Q.#K>R]BUK>\R'L]>3J
M%_\`P'_Q['JSGLM=77O?5KWQ:V'_`(ZUG'9@_P#SA_\`Y:_]<_77K?DWUXQC
M&0'7WGMOWXI_J:OS+4G\H9U\)4'U)B&=527F.KWX!M7[OQQV\P=+?T6P3ZLM
MN3)C*,=(1`)K/J-B(X:S.LI)KSDSQ)NB<PUC[K->)96%+\CZVLFPVYL;46A*
M9`X-L9CJV4HXLG*4K)0HCI;"VHUSHX(49_3='_#)<PM'*B=OT:=X=%KWYFW3
M=521Y_1N;.]$UE(FB`1M!)'&+O:1O>(B?94JA\NM0$==VUM>4J>;$*WQO1/"
M]<0#3WTI?1K<NN7G*=T=X.7(U/'IU(BAT\B"2:H(FAN'<;9V\YS9T[6D>3&=
MM4MS`4EC""4S8Z*+[1?4**#/^F6)0R*ST%_^*'11LO&5:EG3!/&MIL91K:P]
M`UPEK?Z]B3N-.4WF.-?L<@/3Z9'52UIB$KH]DI$BAR/,6K-)4RI6>H-V$][Z
M[?3[_=/#?]=C5?7;U^?[^Z>'?Z[?_#?^[,4AL7Y$OS0K6R"X1QY>3)9@TD(#
M*EB@!'L['*GAG8'C6E"_8]@?V1"@>RQ!WVD8%X1$:T1LO,K[WUV^GW^Z>&_Z
M_'>^NWT^_P!T\-_U^8E*(SR*9U<.(9K?,>R'V7I&20*`5+%1:C[`<ROR\]^,
MV0NV$`"7%N;&[8U'9$:$YA#L&S!%;#ENJ^N[JUUW[^3T3PW_`%^.]]=OI]_N
MGAO^OQNOKNZM]5^_D]$\-_U^8E%XSR*>%DR(>;?,9$[%+U;)'SS*EBH=2!@)
M96%>G?B]GKM!&`YP<7-N[8GT$C8FP0=`"8$WLLM[WUV^GW^Z>&_Z_'>^NWT^
M_P!T\-_U^8C.8SR+CT</=(W;YDE=RW..(RF@NI(J,9B-UDK.TNZWL4R_1NPM
M#.N<'@>];T`($`AF[V2$P(LN[WUV]>^J_?%U[ZO^R>';\77OJ\?=VNOQ=7CZ
MM=?EZM>3'>^NWT^_W3PW_7X[WUV^GW^Z>&_Z_,/9HWR,7RN9LKA;AK<QL/M:
M]KSZ.IHKHN1>RK4<L>>UB,6Z('[#KP%HM]S]CV&S.Q.[8/>AZS#O?7;Z??[I
MX;_K\=[Z[?3[_=/#?]?F,3:*\AX_#96^QRXQR20,T=>'1CCQ=2Q09CX[(4!Z
ME`T@`F7Z4"&X*BRDH0D[";O9O47OL^QUO)"X!=XRRQCOOL!B+`(8.]/#OX@A
M!UL0/&NZ_P"*+>P^/WO+ORY^^]]=OI]_NGAO^OQWOKM]/O\`=/#?]?F'^UOD
M9[?O:UWW#?:Q[3_9SVT]Z:*]J]L'L]['>P'9]V]R]G[%?])]K_\`M'5_'[/M
M7^SS,.]]=OI]_NGAO^OQWOKM]/O]T\-_U^?$Y0:]4C<O5)+TVL5ID2P]*D#4
MT0WM4I)3&FIT^M`7;'O9YP0%=0>H6^SZ@[#O>A:ZN(Q+D$]Q2,O+[<XV%[=X
M\R.;RQF5+$P&,SLO;$JMR:1A/7=O"-N6G'HQ!.WLT.R=A,$(>A"WD/>^NWT^
M_P!T\-_UV?,KK*XUZ<:5;>I"M,9KJ,3JJ@A"D@S6_+H9)ZPPH6M_ET(&\JXL
MX.1%7R/K:P)NSM,^;RV*5*WXIOKR.PR(#D,:W&/:,ME[3'>MMD#@`*QQ+;@N
M9/8*BF)`4L+6$M"4LO91K75Y/^?^?RXR";+\Z_'3X93[_"*9YFCEYTXA\!Y[
M^^Z^S!?YS?Q%_P"8V3YC*)<^[(G,$@E&QV$N[C&";KY><9*)G$O9E3@VOD;K
MFR;&2HYAIB?&PPA7&WN7H4!=<-,D2J4CDQKYJ0X,2U'(B6A25SP&LV:V#!+S
M89B[.,G34GR[Y-4+!Y>\FKUKY)*]J^QE37%0OCRY&'*Y*]P].J45LZRA4I5N
M<C6PDYW?EJR1JG=2;Y\.G/M:T+9YF<8N,^F5@2U34MKP.X7>6J6Q2)?%E,B0
MG0M*.:J4<K.C)48?S5*Q;`W.1.E;+BWDM65*RF>&I$DX5^FR.V,*),;7&HYQ
MPN9E8V-$0V-;4WL-<IT:%&D!HHE.0419`20A#H.]BV7K83#!#-V(8C!#%W7?
MH?/0)>?['K[\2<=^A\]`EY_L>OOQ)SJ$O(<Q:].\=2TG=Q[VPI&=<[MX62":
M-0I'_3CMG.,,%8H2#`K=-+CV(2#C1D[2C"I"2(96C.W[]#YZ!+S_`&/7WXDX
M[]#YZ!+S_8]??B3COT/OH$O/]CU]K_C9.=2R\A3I&C.<&2D;O<$9#H\LIQY;
M)!"P@=(\[+&)Z1["HL4DS8T#LWK41@]`V288G&-.8<0(!H^V[]#YZ!+S_8]?
M?B3COT/GH$O/]CU]^).=4^\@SXTRN\B?:0N]N9&)M6N[NX&LD$,+1-K<G,5+
M59A:>Q3E!@$Z<HPT0""33A!!O198Q=0=]H&ZGL80C#0MY[",(1AWIGK[JV$6
MM"#OSD_EUO7BWX]>3>M;SGOT/GH$O/\`8]??B3COT/GH$O/]CU]^).=0Z<AC
M&0YE3NU)W<A.D3R3'F4LUE@@MN#RH0N#D2A+V58I@2AC0M3@H[:HV2F"%,((
MS@F#*`9V_?H?-_\`D)>?['K[\2<=^A\]`EY_L>OOQ)QWZ'ST"7G^QZ^_$G.G
M]T0/VP>U7O*7;[8?87VQ>Q?L+!.W>POLC[$]W=L[XO<W8^R'_L_:.W]U?_>]
MH[1_M<[COT/GH$O/]CU]^).._0^>@2\_V/7WXDYU+]9A\F8WF./O'B[W!D?V
MIQ97A`<TP,!2UK=49Z!P2&#(LTHX!:E&H.(&(DTLT(#-[+,`/6A:J]4%;<78
M#(5<IJ+A'+&>0Q)SD$-*=&J#UT%3$=`]KVW:$Q[:RP^ULD4;SF9D5-L=9`%Q
MEM6@.6LA!"I2N.-FFP`5Y:[;MGL[AG,K!:][*%I!,JVIZ1I@")V9LD98'6<J
M>U#+[<=H`BM@V$)QP=;[$TS0H$]RMPI$<XGG]%W%E@W7:$2\+AQYX^.1)XFW
MMW<8^YU\K4D%&%;/,WLP@LH9W6'MXC>UE]A6ZPNBSZ+R;GNL@D_17N#2H-`>
MO7*XC&8O!4A`2"Q'J5)+1#K>:&<DP118]FB(;.V&]8MA#LX6M[C!)T/?14R:
M+-RZ*='C>;(B>XVB/995#+!E4;=SDCBD"O:9($XGD*2!0\EE*REB)6[-QYJ<
M7:BCDN@EB3ZQ-LZ&#C-'%Q2R%J^EV@82%G=J9)#^4B)I(3'C(TG4C(,W-U"P
M!JP&M]TJ=JA*Q=EL!9Y9.@%![1WZ-"T6=,C(IKF[TV-;;2FK"M$/MT5O9S46
MTJA]M`W)$#_+FTX@T@_>S`N1R]8L'H6PBWK8A#%TJGB?TB]=M^UR;I4>D)0I
ME2N/1]`?.>,_%B>IP.KLZH6*/)E6EMD&KCAN3RX)$2E2G,2'*M*2A.*X.BS5
M69$OKCIX(XK.%#>;+'/T!;@6>E(MC@G5#`K5)1$!"H3N)U?VDI+((*/T(28A
MM4=O,T+1ACB5K8D^NS)EO\(:BA16T:+AC;@D_=A6R9!2U@UVJ7`-`,U,K/4L
M]P'H4YQ!NPI"DA!)1(B^Q4*E!FPF=E]Z+E#_``@YJ*W[-='7Q-E^P)-:T.-7
MH\1(T:HG8>VG;)?)*]E=BM#H6TR()A84@]]1Z\P.NQW5;PF_2L^ZN,JJW*$8
M>.U7&36O6>P7UH6Q"XT-*M,@)AQDH(.LYO8BHCI20D7L3B:]RUN=&VDRK/)<
M+3+?6ETA1+1ZM->/7O\`C%_9O>O[/)D"5]Y[;]^*?ZFK\RU)_*&=?"5!]28A
MG54EYCJ]^`;5^[\<=O,'2W]%L$^K+;DR8QO77XMXUKJ\G_/_`#^7*'W+SSK^
MG;/ET*7QMU>XE3FJ#%R+L5"Y-R9OIT')Z;.,`J`T]C4%B<Y46)U0%/\`88VX
MU`&!0)S:Y6+;_L]0TI+WZWH6NO7O[U_6'>P[U_5O6]?U>+.<_!I@"2QFF""`
MLL`AC&,00!```=B$(0Q["$(0AUL0A"$$(0ZV(0M!UO>JK\8.64*Y5++\]HC%
M(&QDH^YP5"2_OH4126Q"%%4UC;#98<23I3U!X8/(V:SFW<67.7<ZM^;4H)&G
M2EL[NU&'6KQE(.5/-B,\89/&HBNBALI?WNM;,N`+2*4,\1<WZ%U(MB2.8,57
MIWY,,FS[;'J8MRMAK!J5M:QS1%''JGMK[I;`+[MDFZ.*+-"$P`3``,T$TL91
MH=##H6@F%&:",LP/7V)A8PA&6/0@"UH0=ZS^F0+RCO=%Q@X[71R(=(?(IXST
MK7$KLQ[BL45Q]$_NC'#FA2^/.F]3*'5F9BQI6Q&J6&:/7=O,)(&6A2+UPB$1
M\2<@^7#]0#S!G9QH6>RNE7>4T_#;"M]@>XN27`7N]I^R5A`S6V!N:I/*K$9V
MJ82:,E6*NC.B5<4:)$W.+.V3%0CD3:PW4UOKUU_IWK^O6]ZW_;KQ>_Y<YRM!
M/)B.`Y*V;QR>HX[QHZL*#@?(1RL9^=(REA3G$)O,+'AYH4>R7=0[-FXNMK1Z
M42!=)4;(E`G-3G-^EJ0!RS7Q\5N4<6Y;0QPM2N$"8-6K%J8$#?5,G95TFE3(
ML1$NK7)WJ$M/=BZNV^4,"YEE<28YBY))VKBKZU.<FB$/5*@-F6CR/+2ELIA4
M,<GJ$5^ZV?+NW(&^/0MK=&Z/A=')S6DHRCG>3/`3&R,QUK+,-=9"^J4Z\Y"T
MHU.VQG?'@QN97#7VEZ35H<X/'7!KH6R3K;`T<K9+:%(J7B)`D]=QO@_83?5?
M(U>C?VU8[QR?'IYX\,L>J(J.*"6^U53NG%MWAY3>_C9MC4!G,7LZ#0RR(.ZD
MOL+L"*1R;Q%\3@.*3O,7EC,BD$?=2"U!91X"7%H<4:PL!Q8#0!.T`P`1A$'6
M6Y2VT^6SW45\576\IHB>=Z>V;,8*.8KU1/464-R:W95$GR8QY`KKKNL,U,KQ
M<G8%L8460E`:0W33_P!B51S46(63%/DE3\MX/<G(Z_N/$19'\:F@(C5<E>)\
MIVWZB$N661)K?B+BRPT9"D]:Y;@$CIV01R5NYQ2=LU)]+X^VC5+(\\C)M=F(
MSR2.<1A\@D;+$GV=O+4VG*&B'1L3>4]21T%L!#>T(E3NK;VA`)8L.)*/='=<
MC:FI)M0YN2DE$D/'K7>5TD2=''MMDTIQ35]T-_)R4<3G^#V/9\.CU<HK-C=+
MH^0J,]LO4E$XQAVCT[JAW8'.O!G1]ID3Y)74R'N\;CCJQR$;9?ZI["0VU5]=
M6DV,L@CC=8T'BLY0Q^5H`M<G9$DK8T+XG:9"W%G*2D3RWDK@)7%.2I4D%JBS
M-)U*@GM9PY`RJ?(+D?)J*EM/MR>D9?8,'L6TZPJJ43F.2&*HCH.ZV_,28+%G
M-%#G547(9VVL+LH(?+(VPA2'PV";5RY.&0E-+RWMV/Q7E>_K>3B'CI/Z'GE;
M)9[#;2G='V.Y/46?F:Q&*E9+"HQ8),ACK(K,DE7O`Q6'$)/"T4D3KDDJB+KM
M0I<H]*D2V'D7,SX71:-M;7!P+0KG0Q`A5K`-K8`@QQ<!I4YAX4*`M4I1IC%J
ML1>DZ0"A6F($H,+"<H(+V(T&OA/TA4?B%;<@)QR!JB84L\T-=47H@$3'((?-
M^^Q/+)8:\?:L8*HEC4X-,7>GV5G6=&8P^MCVMCZ2O)2GD.YB\((>QJ)D.[-8
M2]9/X#%IJL1,*`4H:$SVF3QF8-T^9/8]P#W0VG()>SHT3,^EJ$(R#QK6<*II
M$:,86UR=$827!3GF039?G7XZ?#*??X13/,T<O.G$/@//?WW7V8+_`#F_B+_S
M&R?,9B<Y@L2LJ*N\)G+$ADD8?"TP'!J<`F=J&:A6IG1L7)CR#"%C<ZM#LA0O
M#(\-JE([,CR@0.[2M1.:%(K)X@L$B-:11HA$%84$:B[&6I`W-+<6,)(#5ZY4
MZ.:Y2<<8<K<'5X=ER]X>WAQ4*W9[>5Z]X=UJUS7*U9V(2C5&E3-CCDR'5Q,^
MG1<AU'8](S8J3*YJ4='2(_*=-3*Y#`ZRDO<51I6=\T0D<0A84Q"!9V+>2`D,
MM!``(0A``(0!#H(0A#K00A#K6@A#K6NK0=:UK6M:\6M:UK7BSGJU[VOU:QU:
M][7ZM9B92F#H)JI;2E<:2V#)(\6[J6P*QM*ECU%HJN`V`=1-O;@NJYB8'*3D
MMXW`*<Q`VKGU.D-/*4.)!9N6=6O>U^K6.K7O:_5K/P:84068<<,LHHH`S3#3
M!!`6666'8QF#&+>@@``(=B$(6]!"'6][WK6M[R/JREE53*/JG.H)1`Y=%POK
MSM8Y5Z_L$C8P21S5;D#Z!0NCJU>B`[JE;S[+.))AH50S'("PT'8JBQCD3JU[
MVOU:QU:][7ZM9B4@<8,XK`5O)7*,*7*:,3Z,B$N[@V;<Y/'$($J*2&I8^I/"
MO=FA"!U1IGD].D/2(]."4I885M61HSJH7:U56&\3>,U[8]?S=_J]\#%+&8(;
M,8W)GBO9+H!NPQN;-3&Y+ET2?=%ISA:9W].W.'8$F[TFZBC.QD+JU[VOU:QU
M!][7ZM9AX%T#F3JL;R'"+R5[KF1HS'%`E7M;LZ0J4G,HST&G)&F//5,#V='W
MT2A(2N*2K36IUTH)+$E6`,,^Z.2V)S`A>IB<C8)*F:G1:QN:B/N[<\D-[RVF
M[(<6A:>VJ%)29S;S@B)7(#A@5(S@B)4%%&A$#61=6O>U^K6?`Z.;6QMC@]/2
M]`T,[0A5N;JZN:I.@;6QM0)S%:YP<%RLPE*B0HDI)JE6K4FE)TR<HP\\P!0!
MCU#K?<?'%VAJ#D4UVM3+E73JVA8FR[6^?PE;!'%K&^&$`;4%B)7DV-+$@Y&4
M8F`G3NQ@1/!8T^@]U@&6&;23"5!11Y`RCB3BP&DFE"`84:48'0RS"S`;$`98
MP"",`P[V$8=Z$'>];UO/Z=6O>U^K68'9-HUA3D553FW;#@E6PE$J0H5LOL:6
MQV#Q9(M=5($+8C5R"4.+4T)U3DM-*1H$YRP!JQ486G3@,-&$&_[A<:^AJ$ET
MVY12--TTD[=M,X'.#4U(I-+YNK1H&<M*K/4$IW9^E:\U`B:DZ8P]:]JS4B9"
M6I.-*`+->H/O:_5K'5KWM?JUD;R^TZCB,FAM<SNQ:[C$QM4US::^@TKF$98Y
M/8JA`G`)Y;H9&G=R2.\N4(4BDLQR2,*)Q-2ISP#4EE@-!L7](I.*I4/3A5<+
MF,"5R2OVY&B=Z^CLDCZN00UK1E(T3>0ZQ=O7'.C$C)(-0ITP5R),6`LU*6'J
M[:3H<B=6O>U^K6.H/O:_5K(N'/J9FDID]6[FU;R:;5\"/2V9UZ5*8RZRR%$D
M+T[U%I#)XH2XG/<<3^R#>G<65S=T"-.8H2`4)#A[*UO79UM:M77-&"YM4-C0
M*U(:>N<&LF6UQ,(Y.8R<Y-1^TKHWE/\`%W)U:3%S:JUM,X)`J]J$:C6R5)99
MG\7,^ZM>]K]6LX%V``[$+L0A#K8M[WU:UK6M;WO>][ZM:UK6M[WO?BUK77O(
MMA\XI:V48K&@$RK:R&Z)KI3%C)I#)/&9@VQ]S*TWAF<?4/[`X.*%M<4W<#<"
M1M:A42J2;2I?9`DK19>\S>-RB-S)E12.(O[+*(^Y`$:W/D>=$+TSKR@#$6,U
M"YMIZE"L*"8`0.VICS2]B#O6A[ZLB"OO/;?OQ3_4U?F6I/Y0SKX2H/J3$,ZJ
MDO,=7OP#:OW?CCMY@Z6_HM@GU9;<F3&,9JYY$<`Y);]C7H)@E[,U51RY,XH[
MO\IR4N14TC)7%B<&R,\%9)D;*L:W@5SPY,PUP]^V!ZCH*YTU*INSAF"YT''4
MVT0(>QUU>_L0OZQ"V+?]N]Y^LC6XJQ:[HJ^=52]OLLC3-/XVY19V>H,^;C<K
M1-CL5W.OVS/>DB[V/4J4@CD9AVTB@(DJE02(L03195_AUP]?>+,[Y:RAUN6=
M6PW\A[CAMC1U--U[6M7Q5IBE%594W<JT33&(TWB?%BJ"*"A'M24IH*AS="&5
M.@3+65Q5N-ZL9K)Y\\');S`DU>*B'F,*XM#8!:+5'&V12"50V04C?DA=J^>:
M?YCTO*84R.SN3=E&CB3^T1Q">KC`EK%-']K0S6/-KW*V^2;)6A*N0M3:C<W,
MQZ<4J!&F7NYJ5*A-=5I"8HE4Y&HD)92)(8O4`,5F)4A9:5.,X1*<`20`UKL<
MK3S+IB2<C>)G)'C_`!!T9&.27=2=DU,TODDVX[8V13845<HKMY<2VE*M<5)#
M44Z&+^XTA&C5IB<"3MZ0)PE1,1W'6/*^9V!4Y\51<:5E9P%'"'T338;A:3DY
MH;5;W'0'F=!962.IF"8%0=D#W1432[N$<]C9P/VZNZHEQ;XX&/WQUXM?D_+U
M=7DZNOQ?V=77^GR9SFOVV.'+[<5]<EYA(9&SM-7<B.!J'ALK)9SW,R>LBL4I
MNMX=I>04>V$L/<PVRXST;>E"Z#5D+F`M6<(9+EM.@ZKAMP[F%%6));8G0ZQC
MLD>^-_&?C6LB='IW=M@,J3\:R[`+;KAD#:ZL4<TW2Z2I)V"-LD21M[J37$'C
MC9%/;Y.B.XU+1L7R(;V17,Y5A)&V@5T$:K/<0MZ)C>+&.D!4;:$:AQ3%O[EK
M49;75S&^)F+:_<8$)&>WI9")N7NJ9>W(U+8NUTN'"/D(-MBDQBCC0=>6FVT%
MR;XI*H_&3;"65\SU?R#D4%ES3:`9%(&)?+9Y<4%FT#]ODG(>62*H+B=IE*$#
MU*(NNTGEJC9/2E6,E&TY4]*QE4N6QNH:T@=7QY8Z#+,<E3'7\5:8BTJ7$PH`
M"S%RA`SISE@RP!`)089L`=!ZM:DW*)6;5'*.>\AV>0@/H@NDHT:G;X6M4N]G
M$VW`44DC*ABLZ>1IM0L888.XG!"XN46KR7*'TE)7\57/``(7<Z425$XX7Q:X
M!*N+_)2P[@:KSM.?P*2<:*'H"+0BQ']J?ES'JH9E<$D-<G!>W1&.DN"8E)8:
M$B,'=L$ZE.+C8+G(CWA5(T)Z#9#F!V>"R#*^EY50#AA5G&L2XJ#GV)I[%"$T
MC-+[6W*Y03'"3GQ6SHS!;5*D+9HI4O"3I$%4C"H$K(U:3W@?<ESTQ#:KNF,<
M:9S"FR^WNQ+:HTQ_LTN#<E8Q):KE<=<'RW[0<82NEX[:8K@DS9=L->6J!^PL
M=?H%"DS3[&NS!%))$-E%`5]*ZGI*J:RG%A/EKRR`P&+Q!^L>3&G*9#,W!@:D
M[::_/:Y6:>X.CJM"0#:UX=E*MZ>3P#=7I8K=EBU09+^41Y8\9I9RBEE<QA]B
M]0EUA7DTIRY89;Q[O)B>1%26_6%I))DZ+ZR;2(@HCZ1/*X@QH(5J2D6!&G%$
MBD,L12".S*.*@L*[L:RKCE"GY)2NT;42\<SXBYIY9'&%XBRJRWBR6*N"G0E9
M`("RII"R,T7C)*U46"5VV_(%SF?.94@92B6M"S,4<)8;NYT4HW)-1J0;AQ;(
M;+M,CL*+%R8UP(CADCTWJ-L0'\YI)4.I+*)TTDTZFMJ<]P+0;4#1$F*0E`%J
M)4=&Q)%IKA;S>PT=7]O./+SC_P`T'"D(HLD3GQM=;8J2OW*MIZX*7M;`6=Y2
M2VX&B3R&0+[.0U.%R89JQUQ*'6,S5\C3TZR2\_#3CF;Q=I<RM3W!J--=K2NZ
MV#8_%BU::`P`V[;<F%L'5M6Z%<4G5(X'!3I:9'V#MJ-LTO"D4NY+%'"'$J/-
M=K,@FR_.OQT^&4^_PBF>9HY>=.(?`>>_ONOLP7^<W\1?^8V3YC&,\_O-*!6X
MMNOF;&VMJDSA:?('P8Q/"YT0B<C"TX:4OAPD=C'1QZ2)34L5W24F42*Y+,TH
M/3`)AS^VNZW:U$O`E!Z``:WK6^R\O9#WK_\`IV,6P_\`^.]>+\GDS]9QOKZO
M%Y?%KK][6]^/>NO6]=>M=>]=>MZWOQ;S1E1<3Y7$]+)'K0NZAB67VY\.^1L>
MDUG,UG:G4/C\?1<AJ4=*DKE@-35[&T;80QLS<<)'&5:PA_D3Q)K%L5<:HT0I
M0)]YV,A3DHWE.W':^FH^!R&TR7.E[3;SJQB+NHC\KL8I;!'],9!(R_)`B5LD
M@F`3=QYE=TVNZ&US<4JTCK-)!K>M/HADUC%LUS*;-?"KE>E[1QP5MO*$EI=8
MBOL9B+IM.WM]/3Z!JF"/M;#;_&P:)5$[&>FA$D,FQTJ9)#)8]`)@:^UQ$=R^
M,ULWNW`UTFO`-^(8EIPB:(YTQEUDZ*/KU*5K$_>YJ=HPR/LG1H#4;&!],BDL
M51Y"\N2`MW6,KM[%EJ5B8T.H6XA/O%FR.<UBV%2D)DM?/<)HARH:/,J/C9<5
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M)B[N3<;%25L596M26G:W#=-4]0J"XK/JQ@2^8M*!@8"HW-;"9(RICKMR`MIU
M<"S>[9`6)'M@Z-*%6;77!+C%#+>:GN/SABJ]L3JHO)%!ZF0P]A/<'1="(4^"
M5=:HAWAD$5QF+.*%5L2EM5M!S<H&8<D,'N\V4=YZ693M45*W22U:[;+,=%[V
MLBE:,+[3E@W;'$4RE,;>6@]^ED8KB!60^M4-;(VH>M2R0!C8Q"8E"V+MZ@3K
M*$2!?IJM"I[L;Z@Z.B/T'2\LN;B_QTN;HXV[CP^R1[E-9S,T$2MV,-]A6[8U
M'3"J2)Q`C3(Z@,BL=.D1X6>L:Q<9(]Z;D@9"84V>G8.NH.M>]K6O>\GBUOJ_
M)U^7J_)Y,YS3ITF#WQ8?9/`*0MV(20<OG[O4,SD%GQ'C?=-P2R(P*H[;13N'
M,$$FU955/$L7LF46$TB:(NE4OL<%#V=XEMEK1]N;V)'((2XBHK)2](;-1NS0
M_2&N2K3Y_!C%7S`#HBL7AF[RRV(K*I!/E4AVPM[=9])<VSD:2S*N2.*TXRI%
M#^&(P)\L.-;D`ZTW\8\F:490;!WOGJ[6VQ)J^LGC]#..?+V@.2D6;Z$G3/.J
M0/(E$'LBR5\@D:09IUR)[WET:0L:.M_:&I=Y*E0F2RK'&4M3E-SW26NC6<:+
MFTEY7W+3T:D\(<;DLB!RJ709915IT5%(@@CU=H:^KUM3-MD5S7".564YQ&*%
MR2VGJ)H'5O97AY982<ZKT479'1UVJ9C,T71QLA\K<I>1I5$V^-OJZ3IA-"Y_
MTHCJ1J5J'LC;$V(W%R>>W-9:LOV*;V]>N<="[C2(E1YQ:<SS4S2'V!(6F^G1
MF?H_(.&O(CGGPHN.X+]IFF7N`%/_`!D<Z]*C4QJB505]<)0QR"%U>=5?'&&7
M18R)E*8G:LI]8C5:T7+%#)ZV$;N>"LPN2;<?&YSNS87)^;K"N*+0R;;BB>`J
M+3IJ(6K+8W25LKX(D2-R.)N%C5:VQ>3K&QM:V9E5'+=O<?8V-@=VMI1R/7WG
MMOWXI_J:OS+4G\H9U\)4'U)B&=527F.KWX!M7[OQQV\P=+?T6P3ZLMN3)C&,
M8QC&,8QC&,9K7Y>=(6MXB2Z!LTHXVV?)HI:7(WCQQ4KN?-LE@#.S2JWN1W=Y
M<9"A;WIV+>"X5$UJ(#;-Y4>G`8B<5&TK$SR#:%Q$DS.%\ZX\9,9?%KWA*+BZ
MFKRK(W8$^?KCO+CXB20]WDUNSBJ6N*O[4U6,KD+4C?-Q5FEL,L%S:D,"G+)-
M6-!''E3(25[43,D/YC<2[!E;!!8'R;H&9S:5N,U:(S$(O<%?OTGD#K6P316"
MV,S"V2!2Z.3A"`$'F2M$E2F*6$D@X]Q*((),,#(M7714-WL;A)J;L^`6K'6I
MY.CSD^5W+F&9-*!]3I$3@:TJW"/+W!*G7Z;G)M<@IC30&&-CBWN)6C$*U*H-
MUN/73'<88U)N)I\E[MC%(\R9-RE:*HY&2N30B)U:CB_%.*N,FE=HS-;(WUM/
MCM;SH#,Z%5H]C,4+7I$!N?'AJ8&MZ;C#;XK.5O&!ND$?B;AR,HE#*I9N#:C$
M966Y`$TAD6[.1JG"M],;*;(`.3MJP$"%:LA0D"4\$I2HU9[&-<4F.$"-E_.:
M@29+1J9DG$5FU>7]9*VCH;;<$F$9E<(;[T%$%%@Q2KI.J;'`PQJ=K%A:!P=(
M(X$[7(7=86U-:GV/-EL-/D%QM;UO6MZ\>MZUO6_T;\F<XQC&,8QC&,8R";+\
MZ_'3X93[_"*9YFCEYTXA\!Y[^^Z^S!?YS?Q%_P"8V3YC&,XV'6]ZWORZ_3OJ
M_1UZZ^K?5OQZZ];ZM^/75O.<8QU>/K_J\N^K]7D_K\N,8\OESC0=!\G7X_R[
MWL6_UBWO?5^CKZO'OW]YSC..K77K?CZ]?IWK7]>M;ZM_UZWG&@Z#Y-B_K$(7
M_P`6]Y^LB>5WQ2,$?#(Q-KAJR(2,DI`>:P2FQ(='GLHEU"<)L.,:7AZ1.`"G
M`*=0)"8)-H"S1!VTVS=%&;#VL3MFJYZXGL\(LJ`S)V)C3!,U#7%IK')&XD1"
M5J75'%Y4:A9W1<I)C<D6,3VE8'W906MX4L[H0W*U)K<K`3(`1%^((1AWO?7O
M7\?LA"ZO%O?7O>Q"ZO)O?7OJ\6L_6A!%KK"+6]:\6]ZWK>M;UY==>O>S!QV;
M6X94F@8Y_"P39:J6H4L/%*V$N4J5K:UIWQP2)X_MQ"\GJD+*K2NZQ.2C&<D:
MU*=P4`*1GE'#S7_9]75V7EWK>O\`:;V+KW_W>H79=EKKUU]6M;\>M[ZO+OK^
M`QZ9R71&Q&NK:4\N")8XH&@:U*!R6M[::E(<%R1`(W2I2C0'+D1*Q202,A(:
MK2EJ!EB4$Z'V><;#H7EZ_P"H0@__``[UCJUK6M>/Q?IWU_U[Z^O?Z>O>^O\`
M+G.,_.PZWOKWV7]0Q:U^K0M:_LQH.M;Z]=?Z]]6NOR]6NOJUU_EZM:S]8S\]
M@'KWO^-U[Z__`'A;ZNOR]CX_XO\`_;U9SH.@]?5U^/WQ"%_\6]]7]6<X_P"?
M>_X9^>P#U=7C\?Y>R%V7B\G\?K[+Q?DWU^+.=:UK75K_`-?U[WX][W^7>_'O
M?CWD"5]Y[;]^*?ZFK\RU)_*&=?"5!]28AG54EYCJ]^`;5^[\<=O,'2W]%L$^
MK+;DR8QC&,8QC&,8QC&:VNDEX>V?S%8N)376<C@484\=></';E\]'SLR2]ID
M2/C\^N+\F@[67&VAR,2*I4>Y"3'/RT>R&0I-HP#6[#4[`EHMTC_1`W+S8GW.
MZ31&U*RA37R\X5\>.+3&5(T4M<%\-?*7Y$"NQSE;L4U-0DSHU/3>L61]"WHE
M1"Q.K(2N"D?:#CDY.!2_H3[CG=^3>SW"V*QB4;L7FOR7Y+NQ<2)EPIA'(;R$
MX.;X>%QF/+SHZW(%$HAJI4OL%&X*36]I7&B+:B](#3#E^KR=&GT?4MXBT%)X
M!;9=2CMB65Q4M-3*S:>?+C?E=EQ:A:H[RU;3R5#MYZ5)8W*/:*4@2EP.#1MJ
MA\-`ATTMKQ)&W;<%EURMG1(\CK;XR]'#4$E>X!7LOZ.FAN=/%&8!DJ"4*F6S
MUEY<7I5Q7KFT*_6-;>N3'P\4=?8];1JE2<)T&K/70A6@CDH9G4IOLCQ9Z).P
MZ,L=DG\Z<^/UGFP[HE^,O1Y1=N?X]*7AO,G_`!V9W!(98+HF<&=&>FA$Z6+2
M"W1F9W)-*6YL0A`E<S%1VC4\.0+HK+UJ^`\9^*B:6J'JNXCTD]`<U&1*9()+
M9$9XM\<.*\7BKXWT7';KG3#$9S."I%:T5;(?340?6)Q=Z\J21J(T>ZO+-7JV
M7N?I2UUZUKKZNOR[ZO)U[\>^K]'7Y/T9SC&,8QC&,8QC()LOSK\=/AE/O\(I
MGF:.7G3B'P'GO[[K[,%_G-_$7_F-D^8QC&,8QC&,8QC&,\]73EU*E<'SHPI1
M!:K5/TB!TQ7"BU+A?X;7SC)7A-657M4T9WJ<6`XQ]D<UB*%0=J7,Z%6]/QI+
M*R)UI!>S2>Z1]G2_GY*^5''&XNE97\-8K-*T?([2O1<)^,+]3''6.+W5>ID/
M)IZ-Y#Q6'/*"J7H^Q&%@@]@2R8O\&=5<G8:_%(G:3-K1'QK%1^XL2\F>EF@W
M(Z1-E:2GDU;C7%^6_3)TY5$3L>OE+M`9S4=?\18_:_!UYD[\&`L261))#R>=
M7&&5C8J^0D$2I&@#63"ZJ6LE0F'MVZ'&VN35P<89Q:-E6K*[7<I%$:D=(U#K
M3@UE1JPJNO=!230U<AJ^ETDL*"58@>D;K>C.ME:&*0ML60^K_;,Y0^/2I?%M
M1TEMT3S5LN>;\6N@DN*LE5X*+D8..W2T7-<%NU]%W]UL6)<I)GQ(LU<_'2UY
M3Q-[]K<QFO*8IUKI*A=D*=V=I!VR),'9.)*;M&P?C-9W/F^;LKQ3;W)/E/2T
M`@W1%\*^5LW;H_3K"0QR7FH5%'7=Z0V7M\DJE:ZO:9.+N1UM#CS#'>+R5W<C
MVPA`NC(BSRE4>1>V^64AXI\?9#:B^>/O+*G>EQX.U'6-K(GEXEL!OAJE3/5,
M-O"75&YR&'Q"=,%7VE2$ONMTO*N)6C)-JR:`LV(J7=H;H@1%(?ZU`?\`=U[W
M7O6O'U]8=;WH.^OKWU]8>K?7U^/RY^L8QC&,8QC&,9`=?>>V_?BG^IJ_,M2?
MRAG7PE0?4F(9U5)>8ZO?@&U?N_'';S!TM_1;!/JRVY,F,8WOJ]_]6]_\,PJP
M;&@]515QFUB29KB46:NT:7/+N:(E,48I."0F(+`66:H5*E!PPEITB0D]2<+K
M[64+01[#DS8Z-STW('=H7)'-J=$:9P;7)O/*6(5Z!82!0D6(U:<1A"E*I(,`
M<0>2,91I8PC`+8=ZWD>739BJG:PF5FI:ULFW-0IB<9$L@50M3`_6.^-K0B4.
M#@5$HY(I-$DLD>0)4Q@D4=0.^WUZ4=K;F)O<W0],A.K,P=(GQL?X2]6^7(SF
M_C[&*,KJ^91R+<E\33TXP,UI)C5T3@JQ\!)S7Q1::A#I`M6PILCBY0WE2&)I
ME2L#I*X\W.-J^^Q5^EKPV[L:":<8]&4TT?T&YC&]+62(+"BSTDJ=TNW3M[9&
MU1)I9J=]7%D-)Y0P&%+!@&$6_P"*&X*G=')O9VVS:^<'9VD#U$VML0S6,*W%
MRE$;:R'R0QQ`A3NIBI8_,+,I3N[TS)BC7)J;#R7!P2IT9I9POTCMVJW$J0GM
M]E0!<3$B653*C4<SC*HJ-)Y(#9L?.D!A#H,ME*?2@B-9C7,24MU+"(;>)2$.
M]Z_L1:M9*G".-":Q(*>ZS!0YI8FVDR^.&N$G4LA/=+RGCR,MS$I>SVE/U'N9
M+64K-0$[T:K"27OLLZR56S'8W-XQ6B9.MDMA2N/R>7MT18S&O3D3$(@8UHGJ
M3N1[LXM;:VM6GZ01N+MYJQ:4-RD+^B3)@;1HWM>TP-QYYJ0WD3!X;:3765KU
MO5D\JDZX8_9%I:JMHB@8N4X-Z'25_.B]J3!RB+T>4N.<D:>5-K.WK6YH?#$C
MH<H:E*;7?\D>8E0<::0#?$B<RYG%5YL4#&6^"R"%K7B:(Y7*8W&"G:&^S4G9
M&N4-K/J4(7]XVQ.+BO\`8`E2J:4#JKVE0J9=@5KQB?OUCQ!`(]OF53RHN*3F
M+N/:0.34:YM261Q5[)T28:4NC<RBS@@?XX[IQ[+.*,7,[@6WR5AD+*UR=C&<
M;WK7EZ_ZM;W_`,-;R&Y)R#IB'[L@$GL2.,9]1[B6K"1N*DY.X1[V_A3A@FS&
MT2?V0<M358H"T1+;*F<]220%*HXS;6/Z%:VIYBT,.]=>M"ZM^/\`[@];\>OR
MZ['6]"UY-ZWK0M;UU;UK>MZS#K"EJ^#0J23!L@\PLA9'FI6ZE0>`E1XZ:23N
M,H1PVV-))7(HDQ+7@\`!:1(5T@;-+C^P2ISAJC22C*;5YTD7'.R82UVJT*)&
MU4^5QY5<D+'MR3E1B/P6B8JC7N[4MA=U+%TJ"[PVUT3G&Y4W.<!(9W=P9ET0
ME*5Z/;SFH(55LV2Y*ID0HV4T6)#%2N7PPJQ(TV;DC.G>7F#&IP*?;6A9%*TI
MV.822AZTK=`HMHD9H3"%9Q)Q1@`_Q37;3BTU.0CM>M59RM]C,82E)IY$SS%,
MDFC6-[A\?3EE/`QGO<J9BQNT;:"M#<7YL`)P:4RQ('9VON36U5RQ6^-Z2QX&
MI7QAJ(?9(B3S*-'JX^RJEZYK3.[VF*=!G-+6H<FMR0$.+@!,C.6MZY(4>-0D
M4%%\;MNK`EL9HK)@(2Y-("8G'#!3.,Z`_P`H4E)U">-L@]NG8NS^>0K2GDLS
M?M0YFDJ"#`)1`/*$/^$YM2-05]@416".<YI9SVO9(1$FTQ%[,/(F-I/D$G=>
MQ6JT:=(PQ9B3C<7UV5'EITXE#6U)]*GM\96QPKS1G->*7LS,\O:ZEN*"UV[#
MN,@=D6$74J"(L:VC9N^5[.$LI%&;:E;[&2?;+&)(F9GMY8TD;<B68\W;TF&L
M:2G"R:>U*R5D0Q2EL2"J4UC=ENOU">7QTXB<=AHK8_:><4Y#+E'8Z/(V+V"$
MO['1Q6Q=6C`=EA,$Y,\?;-B<?G4$N2MY)$);-)#743D*"8L.VJ4S:+R5RB#Q
M&HRJ/7$ER!U*?VE<C1I6C:PQU*`0O:M+6Y:B5J(VM+F37U97G$^/I;!)IS/Y
M/65N6H<C@RJ(/2A@9J;#72N0L3U'MR<B8)Y8^,EDM;[#&O<="@DJ)O<4R1W`
MZB;T"VRT*F47L6'Q6?PEZ1R.&S>.,DMBD@;Q&"0/D;D;:F>&1W1"-+*-$E<6
MU8F5D=L*+,T6;H)I99FA@#DV,8QD$V7YU^.GPRGW^$4SS-'+SIQ#X#SW]]U]
MF"_SF_B+_P`QLGS&,_B-00`6PC-*"+75UA$86'>NO6MZZ]"%K>NO6];UUZ\G
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MM.GD*P^RH`2DB3HA9)4J.F<:+31IY<TQ"UN:I`>-ST6RN2]&J3*T:!R$E6*T
MR@@],0:6<6(=5ZIYKJKE::ELJ#<?+:<N/MZR!G;ZPN<:B%)2'*'R1"O7Q&WI
M!7ZN0IYW&*MG)*)..(.:ML52E2F?8XX2.'Q5O=1*4ED"[]HPUN='8NY:J$UL
M<I;H*^.(;%AVT++-W8PHEKAKLLT]=S-TK<3CR"4$=6&DO"PTXH"9&:(P.MQ'
M+N;W&EA51Z/L-S5-+IK/Z7L^]JM8&ZT80D:I_`:LVVHWV0H)PI=AQ!KCACV\
M(&<B3.3D!GV82_+0&G(HK(S6Z2XOR#J.0+XA%%EE5@U6;+FYD/2UB7:,#>Y=
MMV>(0EL+;(VM[0^'J)"H(B2@4D)5,J94E<XN7J4MXC6`\E<*/[4Y1HX=<C%Q
MSKJ`/]Q7BZUJX7*[0YA?(K%6V$58DD08<URZ9RB7N:!$WAFDQ"NBT#9FI&]O
M$D<F.3K1I6V/19^?$-<CND_KYS0T\*NZ3NJSY+;IW)./>T".CJEDF]?V=Q(&
MM3WI4%@-DWLR,-C78$=<&QS:&<MM>G:,2)<C*4HI*4P.S&^.EB8[S+I><<=Z
M0Y)0-V6R2&<EF^MS:':C$8F&36&]VTWA<H1&$C4][2#:G=0CTM7OWLF(I)%V
M9DD3\[GEM#&M5AP^-\S5\IM*QZQ9^.MN..ZBY!1#CG/Y6@?Z;,9$$IF$!KVT
M4\M96M;9;=,)%`F2!69')-(UB&-@EC6V)I"?J''Z8%V@V)!>])FM4P?";>J\
MYGKYQ2,\\="[!B(VR$O#@842@:9>X`>!)(RXK3E"<E*C>CD1YYB@G1)8^V!Z
MZZ<9N=%<\DXG04J3L3U!2.2L+G$OJ8E\<F9U32(ZM9"XLTVC!+U'E:IH-D38
MUI$TR;4R=0>DDL/.<WJ/JW`F+R4+;>#8=;Z][V+Q^\,>O)^C0M:U_5Y?RY^>
MH&M^/L_%O\NS=A_KZ]]CU?[_`.+U?HR%]<B:4"#>M6$R]T[N+O`>QF_9$3]W
MXNZ>T^T'V`$CV_:>>XO^LFMZ;^X-0G_K]I9[2/\`K!F=Q6!P^$G28V),22/Z
MF,H<II(D[4$]*@<96]Z*V^2#V/+,TWI'-^4E:<GY4A3I1/;R<K?'3NMX7+5Z
MBO-E\IT\:N?W.M6UO*+MNAMK)+<4RB\<?XG%FB`5V\OKQ%H6XRR4S-Y;6Y*^
M65)HW)F6O8\@3N"QV'%Y([O2F-QYI,>#>AJODIQ(Y&,-<7XEE$/;G^,-=@K6
M=HL]W88U8E1.K5+%M+6ZA?8J\/9NXG)XK.&MXJ66/Z7:E,2M$X1QIDJUFD74
M[V*<[FJ1G99!(W*S("D8HH\/<=DSJ;+X_P!PL,AC36M>Y`P.QX'$0$+\RL[<
MO='1C4=@[HD")4J/1`*(,$&ME1<QW:XT=,SB/<=[:24AR"6(S*QMEQ608H'M
M1>X<]S6&6'.H#J2:G,%B-AM+2DU#]+6QQDA*F21I+.(]"%C@<E26`+Y`T0<S
M*9&5=-3&1]'*RH&L?`6/#!,Z.<'I@K"88J<]/>T)$L-2B"I+CIIX7@Q.()Y:
M,1(M&;B"<<XN-\:,]K\=MZJ)E8#YQTG/)VNHJEM2#,C1/JNAQB5O3R=%8;N[
M`@S/%I$_+B&MIESH[!81D))"]]T&M$5D"E#,3)>M0O,E:(""SZT!9CN`995;
M)[%ACG-?9%)%FR9NS8F8$#R<Z."EHC#PVR!;M$C-"7'UR%_WH+0O2*SHELSE
M21&KG]SK5M;2:[;H;:S2W',HO''R(15H@%=O+Z\1:%N,LE,S=VQO2O=E2:.2
M9EKV.H$[@K=AQ>2.STHC<=:3'@VN+ETIU8*6"IY%7--7;;)-KUMR1L).R10F
ML&260Y?Q$D3+$^1%8S2/SZRHD)NM&`25ZTP>U]`M<VEY=VEX2MTA&46VJ76U
M*/EC4\AI6B+P@[DKE\<Y1M]<J^/+:G1J&=ZLU1:T.-L&'(T:!Z*2*647M%2.
MTRD@WDA,9%HQ'Y"Z.:?K:34QD7PWFWN:V!/86U<?K9VU5=R-7<9Y[.-O]-:8
MF65ML,C5@+YHG:E%FI9<[5J@B<PCKPYO""/#DK4C5+E#C$4R9E=CTEA`<C./
MQD*W9`+RI\5>A?C8J*=!LV$BAP9006(P^-BDX7P3)I_(``8CF?:[V1*"`8QI
M@@#L6L48N8/&"0EW`I0WM5Q+?0ECGU);;PZS6/,C+";"2L35(5<;>7AW<$3<
M0L2HW8M,H'M1W.6[-[ZS[.VY1]Y3(L<NKF#6E.V5QSJ42QGE4ZY(6@@K:,QY
MHF<5(>F-.[UO95B-,[=X^<N.D:R#K"JS=&7V:8FAQ+)7K4IPNR3%G"U,E0VW
M%;GB(Y7%AJ2!-TBE,)E+`Z%EIW^'3N"ORZ+S.'R%$6::%,[,#\VJDHC"33V]
MT0B0/K*K<&-U;'!7*&,@.OO/;?OQ3_4U?F6I/Y0SKX2H/J3$,ZJDO,=7OP#:
MOW?CCMY@Z6_HM@GU9;<F3&,A.Z>/M:W\@86VQT4@6)HVN5N+5I@F,IB)A:E<
ME"C4[4CC+JV;7@$0`.BRUO;PIQ:$-/VH1ANQU,LWHT*5E5=+8?!7:9P=[W($
M$F:I`ZS"83Y"E<4B,YJ.*6QZ32(]$J2J6I4J)"8D,0.255LE0G7A(TJ2*^^:
M>C1XP-K0W-9K=8BP:)O3HCE@;8L%KVM-*("6>M$W,S\@:$)BPWMBDQ*UH4:`
M@PT0$B8DH(0:L]8#=8\0J74<X_L,8>)DU-+-%X>18DM=VM@9D28E.T@D+T\`
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MUUO4,&;*[3<J(43QK>[";T]KV4QU==2SC?;ZNR]P`ZSVI@+F,(8YL@>).A:I
M>SP$E5%9`ZM;FNC+HW-`DID`6YT8_)E;`I3"J?I[C:S16Y*,CS)NNWV\;+<V
M_C';\<YD2;EJ^*X;,Y?7\X=9ZUW,NF90+&DK,TP<3=9->1J11^&^UI4@0,.V
M6E*^EJGF7RQY"K6U$T06=UAQAI.)B1JNW^V]]HY9?$GGDS#OM28Q0U)7:[$=
M=,KDL1(ECB9!7E021MG]BCU-X,8RKG+#AW1_-.!L=;WPV3%TC$=EB6:-9,+L
MNP*Q<"WU&U.K,2:J=:^D,>7N*/2!Y7`VVN!RI!V\92P)`%:8@XO3Y-/X.)Q'
M?W6?OT<E-GQM>/O?:IQ$LM6YY0W1#VFK@2!^W-W!ZLTV5R_<Y?53HWGZCTAA
M.H-'_8]P@'L+/?9>7.E@?`#]'%OQ^T^^`]?C['7+7DIO0>OQ]CK8K*V+>M>3
M6Q;V+>M:WOQ]>7JK+CFU\->-[E4O#V&@>EC,=(GN$1BX[BL)U:ELGE+GM>N-
MDMBR4BR9>A8B5)PUFT+:VK]%D$;;FM(A$J$K*H(MZ.V^8P7SEIZ`26`2/C[T
M@''*SGJU5=C/3BEE,.Z0&R(/(H/,+?B$,8H>YQ\%16NV&PYTF\6)D*53"YC#
MD#Q!696G>I!VW"1<%.5AG(>@YRLJ?C$"N:PD=//<F:X]8BMM$^-0>C[NCB7:
M["\H%E%#66"O9);,XT7$W!W=8O$7.I6UN9DM?QZ2ZE#LYP:T=#Q<[/3$>@#?
M!^,K;+F7@3P(XZA>D3TN3H=\@.+7(E9:DWLP+DEJ<+L2UN4;6%;B4R+0&S4Y
M_0@0.#&SH=EO`.DXJ<1[1M6N6*\J?I+CO&9G5R_I2HG#QV6L%J/7L]<@N9LP
M?JTCUZ1IEKY2X:K.J=Q2-W`4S/*21&2%Z:*^!`%C"V.BN6-^57)T9_+1TIMN
MJBIZNXVIC3(78IDQL:3VB-ON.TKF?;OXS\@W.SK(FC/09K<C(M.<U9,CW6'5
MZS1]OB:UAIY"6]**[C**$1_;/<D'F+=S$XC<@]M9+G!H?67)ND9L62>8J##9
M%>2RBIC")@`PP@G13,:\T@X5NY/6TA)B11.H^>L+1M1[F:DIC"NCWM"N.$%G
M1-EKJCGGES+9;/W\?MAF#]**O?&5_P":DHY1QQM]DY)#36INDL:9Y6HU''1S
MK!QCC59[8W.3\PRN)$GHEL6U;T??+B#2NF'M,C@D+>JYOB^I(HD3+;Y%G0N4
MT_;?2`R?E=N$6Y4L]I-G;I,<V0J0^R$!GM8+ZSMRMKU:6]Q02A17;HYL;9CA
M'177:PML2KMZK;C]<U-/*GE56LX@3I=UPU:QQN(VYS`>.3=5WB6TU["&0=@/
MK:Q.J2$V)3!SC&S$[I"8`[PFW@$)E>FN8J>XG\E*.Y-UM;]D16H7ZO:%E'2+
M'+;A8)V\K[KNR'\R+-K^VZO&X0537!1F["BCI'$=0/,=<+#5-#J!KCTBC;V!
M&))%TFP#H^J1FG'3AKQ^IVQ=(R)Q#X(5J4-3<H`K;HT\/[P[RM7#6U62<H3*
MFZ$B?M1!`H1FB0GI&,DU!H"(:<`;DXQC&039?G7XZ?#*??X13/,T<O.G$/@/
M/?WW7V8+_.;^(O\`S&R?,8\N5+G_``;XQ6A,'Z>3>MS7F4R924L>G,,TGC;I
M8H)1)F\LS2%JDJ-O3=21&G*V!*E)+WLOMFP[,&,0H8EO1C\?)3:$:F_:GMKB
M36R(VN0UNC='0;9*53&W(VF-+CI(:YBDK5I$W)2D[L2A6]N>A(VT\*QO-+<Q
M.DV5UPCXSU3,F6?P2NC6661\:LQH=!3*=N>DHUR%2VJ1;0.TD6MRCMB)8H)Z
ME*0X(-F=L+T$T!8PQ[8?'VT(KR_,YD4DDB4T>)EQV8>-UIU=.Y@YP!`O9*\L
M*7V;5,YB<O;(3/\`N5X8GFQ;!C<JCSFP%I'U@DK:]-STA=8CIFE-$I1T5EKN
M=+,[.ADU.*;\0W]R+YY+;(=DLEW&5/*RZ;$W+BJ&.811YQ>%?"V1P]W=*JNU
MK.<0RVS(I'8TK'%43FL4^Q$A!XZ1_DESDN5Z*)F#%5!]6-D:YB0-37T[CD+E
M7+J/05RK2JI;5-EV)$H@FL?4:HFTYDDDTW@#([QX]R@?'=P.=&B41!6RDSOQ
MWH#E%7O%V'\+9\ZUPGB=8TX+CTQ\CX!*I,FG<MKJ-U^HK>OI>151\19T=<VF
M!B`R+I)W+9<LC+;(654Z1TY<F>T[8PTUUT8-XR>,UMJ8D4,GDU:UKT;M#.#*
MW/DE40*R(GP.Y6QR_G:VG-`?6X@,4JF40CJR!U[7VV5V*@J>=3)L>K&>V(U)
MH>1ZZ-.[B6T:<@RA1]U0/IA:U4M)[O*_8]*P](I?;??%4.#:I+K7L`'P%4W!
MA\^9CFH","%P<WF+KGH9@6@_'8?T7-ZQZPH3/%CA1IRZ-6YT9L]<5B9\EFWA
M<S<**`E506&G)7&UJ4:-SD3E(AJH&2H4`2GL9Z\M_6QY0;M$??NP>/EHQ/EZ
M+F-226)35YF''5@XVVI5T[F#G7Z!P9*[L&7V95,YB<N:X3/^Y'AB>;$L&.2N
M.N;"6D?&"2MKTW/2%UB.F:4TKB7132,$PX^O%K&U9:;(&YN>?(OE<VK728-3
M3)+&YQDJR%\.K.+:CZLMVK>`LZPN'B#,Y$QJY:Q-1;BXLR=<]KFY#=[E-3[D
M5[C"8UI&6TN(\2N2D3L%WKZ/-`4R--4RJD[@X\.8(A&F5*4F`.L6FWD$X:F5
MM2AV!AAKBVL;>H<!-J(W`ZMX/I`7WRQOVRX_`@2^W[Q-LZCK&@DA?UL^@<77
M\2J\XM*4KFI7QB-I$CP<UQB325,A2*9*Q)ARM&$)HW1D*<ATGJWHY.5%;1ZC
M9D3$N*([VX[61QS(<UZ:U;V=&3ES55#0>Z*P0NMG2*80)^54M)&1JN=7:53U
MS&HA:,8KRUF!=K4U<&B4HE<3EKC;PWNFL67HUZ8EJ6O`*.%=E\B+CL655^Z/
MB^-^PD]K_D!6M6P:,*WZ*Q)?IQDI%\C>9&TIVE0V,K?6JPE0X:TZQL2[=%U>
M+6O>UK^S-3%J="AP+N2RIY;$WB]TJ)E9$K>II*5+3R>Y!L#6>_OZH2US.;V)
MHL)*TLR(Q2,8DS4UI4K:@*V%*@2IDA11!=2__HX?#KVR>VKVUVSW;WW?;1[&
M=].X/8WO0^U_VH]ZSV7[YWM[]L/L/_TKWT_;A[,>V#_HKV#[V7_9]EM:KZ%#
M@73=E0.V(1%[I33*MY6S32+*7;D]R#?VLA_8%05K8<XL3O82II>41:D`1*6I
MT2JFU>5H25>E4I#3B#)REE`VQ7?+J=<MZ);(5.U-T4/6U)VQ6,]G#Q6Z<#E1
MTMLJ65)8,6E[9!+*!UC)MV;0^>1E9'483FK<;D[`Y#<V1RC\DHD;T65TQZ"T
MFKBDJI>0WK2MLVYRP'.I45*6F+6G?O)KD<MN6_:6F[&FC,G=&_BBI8WA1J)M
MR)P=90;:D-IFTG5B1/-4I02#-67BG#>47)?FL6F76"S\7IW')9$K.@KK6\TK
M$O?-V75;,N*-VVE4TAG$4C`Y6R@XW%Q]D.F469G>`R:9/HYI'98^N"U_3H+"
M5O07*Q7Q+UPSMA\K..(FF@9!QT'R1J^1R93*Y:Q@JMSJJ'V4SU4OBL;(K.<F
M$GM$SD3,79$K9F)[:U3-&'9U1.J9U8ZIF]&O=TR5UQ,I@UT!')7$77HOX[)(
M=&7F1JZ[D$:Z/:XYM9;]9S<2?6Z32.=3]DEB>!P")&,*5/"8HV:9WZ?/",:%
M.UXBDZ*F^$-7/D++<J!5+Y+P[Z37BTK2*G.8!9F53S-Y#K;TJ.3-"L-;FF*&
MV&EN`H]-6HYE0&MHT@EL5&_!6A(2R5'>CANEJOQ@N90.D2A(>8/%3D&YG(WV
M3CD9\-HW@4^<1I8QEKA5JE[ID"^5OBR6QI.H6DM*J.*UR9T<69U4FIC;A2J@
M+8KCEQ..6M$ML*G:FYJ%K6DK7K*>SAXK@@+C1LLLF5U)846E[;!++#UC(MR;
M0^>1E;'4@3FL4;D["YF.C(Y1^24X@'11N39)>,9%P=ZV[(3%"^D!GW)@E\52
MIJ33VX^?UI1BUIDCB$`$RNC0X57%5K?((F4SS&6)E#_&%S;MU9SE@'(*BZO)
MRI78F?<(K:A#*`</XMWB].TNAD?;@EA;ZRL/C[:U`&OL:9FTL(.NLUT_CC^>
MV($0Q$09%*O8Q*-0D2HSX%C/1^.7=W.6Q99"Z!=[GO>TK\GU!RMY`_SJ/L+)
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ME`NKC(#K[SVW[\4_U-7YEJ3^4,Z^$J#ZDQ#,;I9U:RJ4K\@UR0%G!@K4`11B
MQ,`P(](-AV`18C=#T+0M;#L.P]>M^+?CUO(<I/DE2D:IRJX\^SI"V/;'7L0:
M7=M5-DA`I;W)O8D*1:C4!"S"T$Y,H*,)-UH6]:&`6M;WKJWN3_=6\?\`TD-7
M[.D7V)CW5O'_`-)#5^SI%]B8]U;Q_P#20U?LZ1?8F/=6\?\`TD-7[.D7V)CW
M5O'_`-)#5^SI%]B8]U;Q_P#20U?LZ1?8F/=6\?\`TD-7[.D7V)CW5O'_`-)#
M5^SI%]B8]U;Q_P#20U?LZ1?8F/=6\?\`TD-7[.D?V)G&N5G'_6M:U9#7XO?;
MY'O?]>]LN][_`*]YS[JWC_Z2&K]G2+[$Q[JSC_OJ_P"TAJ\7D_Z.D?V)CW5O
M'_TD-7[.D7V)CW5O'_TD-7[.D7V)C7*SC_K_`,R&K]G2/Q_[_P#H3QX]U;Q_
M])#5^SI%]B8]U;Q_])#5^SI%]B8]U;Q_])#5^SI%]B8]U;Q_])#5^SI%]B8]
MU;Q_])#5^SI%]B8]U;Q_])#5^SI%]B8]U;Q_])#5^SI%]B8]U;Q_])#5^SI%
M]B8]U;Q_])#5^SI%]B8]U;Q_])#5^SI%]B9QKE9Q_P!:ZM60U_EWXV^2;WX_
MT[9=[_W:\FO)KQ9S[JWC_P"DAJ_9TB^Q,>ZMX_[_`/,AJ_9TC^Q<>ZMX_P#I
M(:OV=(OL3'NK>/\`Z2&K]G2+[$Q[JWC_`.DAJ_9TB^Q,>ZMX_P"__,AJ_9TC
M^Q,>ZMX_^DAJ_9TB^Q,>ZMX_^DAJ_9TB^Q,>ZMX_^DAJ_9TB^Q,>ZMX_^DAJ
M_9TB^Q,>ZMX_^DAJ_9TB^Q,>ZMX_^DAJ_9TB^Q,P%UN6M+&MZB$T,E:-\-9I
M)/')U[2E=$Q2!`95TJ;RE*I2X($:<DLU<K3)2]C-ULP\X!8-"%O>M3BXO#3N
MSXD;IS;MEAA,[`(S2Y+L`1C>8$(`!#T=V.A#T49L(=[ZQ:`/>NO0!=403"Q8
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M1R46;=\J:5AX6!T45JE;7!W:W:-Z7'-<25D.&DB>2(6E6>!(>:`DXXM.(G1H
MNUZ,V/0@AE)L/)5/LX.3'%*"129%H)I!@#B][#"HAH6M&%B$#>P[UO6]:WOJ
&WKJWG__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g127792.jpg
<DESCRIPTION>G127792.JPG
<TEXT>
begin 644 g127792.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`\1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]355-014Y$7TM?5$),+D504__;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(
M`/8"HP,!(@`"$0$#$0'_Q``?```!`@<!`0``````````````!P@!`P0%!@D*
M`@O_Q`!D$``!!`$#`P$$`0\)!`0("`\!`@,$!08'$1(`""$3"10B,146&!D:
M(S)!45568967U-8*%S=8<9&3MM$V0G>U)#AT@24F,U)XH;&W)R@T1E1F:)*F
MTO`U0V)RF+3&.41'2*/_Q``9`0$``P$!`````````````````0(#!`7_Q``W
M$0`!`P($`P8%`P4!``,````!`!$A`C$#05%A$G'P$R*!D:'1!#)2L<$40N$C
M0V)R\9)3HL+_V@`,`P$``A$#$0`_`$M[P.]?NOTZ[I=?,$P?77-<:P_$]2;>
MEQO'Z]&/+@T]5'B5SC,&*J912I19;<>=6GUY+SF[BMW"-@&X_9"N]C^LCJ!_
MA8K_``WU;._3_KI=SO\`Q=O?_P"!J>FE=$3R/LA7>Q_61U`_PL5_AOH^R%=[
M']9'4#_"Q7^&^F;]'1$\C[(5WL?UD=0/\+%?X;Z/LA7>Q_61U`_PL5_AOIF_
M1T1/(^R%=[']9'4#_"Q7^&^C[(3WL_UD-0/\+%?X;Z9OULA[&NS:@[I<0UZJ
M;-R[BZJW&D>?S^U*-&@V;E-D>IFC2\8SS/H-M+B1W8_&TQ*4WA%%&?*TRK&X
MR9]M+<['(ZP1)-]D*[V/ZR.H'^%BO\-]'V0KO8_K(Z@?X6*_PWTK&BO9MIKJ
M?VP:'ZLWFH.68QFFNW?QC/:5%9BX>Q<5^'4$C&JJPLYHBO9-4)FWL^1EM;9.
M3K)E<>K7CXQYJJWF6-J[E>:>S>L;#.-<)FG>>TV-Z4X9W/ZZ]MV`V^HL5-1'
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MK$JFF5ZA$WC[(5WL?UD=0/\`"Q7^&^HGVA'>R/GW(:@C^UG%1_\`RUUC&<]O
MD;175/M\J=3+6TR;2G6O"-!-<H.0X'3RX65W6B>K4B%,N&J7&YCMK+@:@4D"
M+D^/?1/KVC#N2U;+U9*LH4N,I>P?5_V?%1E&H&@&,:*6.@MYH;W8=QZ\`T`[
MN-%YF5Y!05&.S\?R6SJ='=:M,KK,U6E;J=CT%FJO+.\]]AWV1IK[UNYE"56M
M5<8B8]]D*[V/ZR.H'^%BO\-]'V0KO8_K(Z@?X6*_PWTM&-^S*U$R^QT8IL;U
M-Q"SR#7#3'N1U&P[%C1/5V2W$[MNU+FZ:6^G6)0;;+(-?F6=YO*@3,@Q2O-Q
MC++5+"GIG*<DP_\`I%TTH]F+D.KT;$F:'7''J;)M1M?M?NW'3K%LITDSZEE7
M^?:"8!.U%GJOI,FX1.P&%E%/7O5T>+DN/_2V,Y`INMM(4]`DR8Y$@?V0KO8_
MK(Z@?X6*_P`-]'V0KO8_K(Z@?X6*_P`-]*S(]FGJ?21M)6LTS[#L,R;5*7VI
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MF=67FI&I`I\XTZT+Q72_3[L+EVM3C^%ZH:A5]Q;=WDVKT\H;:#]+YQ)OXUV[
MF+R;G+8+TM5`RU8+553*]J/(+A$R(>T)[V3X'<AJ"3^(,XJ?_P"6NC[(3WL[
M[?7(:@[_`"V]'%=]_P`6WU-=*QVL]M-!2^U#P+M!UOI<4U.QZG[C,GT,U)KU
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MI)>"8VUBL"OF1\DL7Y=G!OK&'`;AA$.78]$3,1[0CO:/R[C]03M\]F<5.W_X
M-=0^R$][(^?<AJ!_A8K_``WTLWLX-(-+=7>_F/HWJ?@6.YUIK90^YSU\8OF+
M!34=>G&(:A9'ASL"=765=:07:RQQVJ0\6INUC`:=@3TR&7UGJIT?]FYE.O&B
M6`:WTFK^$X]:ZN8SW.Y?BNFS^G.01V`YVPLM6&:4[F3U>0KI:.-=Q93/U+O&
MD+453C,*1#<2W(DL$2(?9">]G^LAJ!Y^7W+%?X;Z/LA7>Q_61U`_PL5_AOI;
MHO8];:IZ-=J&7:>UF+42LP[1NY[N4SZ_J(69W67Y%0Z#ZC2JJ;]+XS89,_0S
M<WL'K"GP?!JS$I6*45A'6Q9Y,_7*:=6Q@V4=ADS`*6WRS437W2K$,$5JAD>D
M>$9ZJOOLCQ+,<MQW02!KVMJTL\;ESQ@;,F%=T.FST><C(K:HU/FV=+/K358[
M8W#A%A7V0KO8_K(Z@?X6*_PWT?9"N]C^LCJ!_A8K_#?7KNX[>\#T`H^U!6)9
M/D&176M/:EIKK[F)NZ%%0S'M=3++*)L:/6*;OK1J/$J*Z%!QP4XBAY#E2]?2
M[>=(O#`K&:]$3R/LA7>Q_61U`_PL5_AOH^R%=[']9'4#_"Q7^&^F;]'1$\C[
M(5WL?UD=0/\`"Q7^&^C[(5WL?UD=0/\`"Q7^&^F;]'1$\C[(5WL?UD=0/\+%
M?X;Z4A_OO[PT:.562I[@LZ%](U:R#'7[0-XU[RY20\#QJWBUJA]3_H^[L64Z
M9,04LATNR%A;JFPA"==_2N2OZ`*3_CIE'_NRQ#HB6S[(5WL?UD=0/\+%?X;Z
M/LA7>Q_61U`_PL5_AOIF_1T1/(^R%=[']9'4#_"Q7^&^C[(5WL?UD=0/\+%?
MX;Z9OT=$3R/LA7>Q_61U`_PL5_AOH^R%=[']9'4#_"Q7^&^F;]'1$\C[(5WL
M?UD=0/\`"Q7^&^C[(5WL?UD=0/\`"Q7^&^F;]'1$\C[(5WL?UD=0/\+%?X;Z
M/LA7>Q_61U`_PL5_AOIF_1T1/(^R%=[']9'4#_"Q7^&^C[(5WL?UD=0/\+%?
MX;Z9OUY6M#:%N.*"&VT+<<602$-MI*W%D#R0E"2H@;D@>!OT1/*^R$][/]9#
M4#_"Q7^&^C[(5WL?UD=0/\+%?X;Z5/6#LZH\1[%].NX/$Q>R]1].]6KW3#NU
MI[&NLX3&+V>I6-XOGVB;M+[TD1YF/453(D8)?Y!7M+@S<[M+&/[RXS5QN;D*
M/V=.@KF>P\:LM3<YDP,<]E/8]^64*3AJ6'+_`"^QPFUR2IC1ULYJA<"AHI%W
M1O*Q:![M,L6,/%=+R4N9183X1$QS[(5WL?UD=0/\+%?X;Z/LA7>Q_61U`_PL
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MJD>[>\X/W;=MNG6@^N^FFC>(9UD]O`R/2CMRR7*<FNL1CLSX5UK'B&/Y'9WU
M;5,Y,]%L(W+(EO0<73)JVZ9BLCU#]W<R)$FZZ(K?]D*[V/ZR.H'^%BO\-]1'
MM".]D_+N0U!.WSV9Q4[?_@UT\/5#V6K3_<1J7IWI5J;"Q_`Z7N^P+LCT^F9Y
MC=U96M[K3E&DSNH;R;B137,DU^(QX%5]*W&8B.XXU/RR+2TF%+@TCK[C6NRN
MKT;P_N1M:+NWTLI<^TOQ02\;U2QBZ?L&)N*R6]4L+TTN<DI;NAMZ>9%L,)E9
M%9VCQ:L!76D.M=1*0M`CK:(K"/:$=[)^7<AJ"=OGLSBIV_\`P:Z@/:$][)\#
MN0U`)_$&<5_AOK8[B_85I=H,?:CZ<:TX)6:A:G:!:`:G:OZ#Y%D?TNFNQO!\
M?NF*_2[45NGBSXM7?OZBQ+F9.WGFUKHOU$O0W(Q<?DAQ%NW;V<-O7ZG]HV1:
MTV6`VV*ZJY7VB9EDFC.1(DUTW*]'>YO4^RP6-645TY>07,ES&CJH,._S3',>
MK8\S$Z3**:\@7M@]4V[44B:7]D)[V?ZR&H'^%BO\-]'V0KO8_K(Z@?X6*_PW
MTM/=GVJ:1Z1Z"MZT8I<7C&2YSWR]V^C5-B!J'$XOB6GNA>8W&,5&,5]DYD$B
M2^^PAIJX7D=E"G3;5IN%0LQ:E$*=;6Z04_95E=]VJYUW65.?8O88UIYIG5:H
MY'C,*HN'I42!.U;?TGL,.=R9Z5%K4:D4#HK<RM,:9JY=2C%KVH2K*&+:4B&H
MBI?LA7>Q_61U`_PL5_AOJ/V0GO9VW^N0U!V/R/HXKL?^_P"IKIP.KOLL=0M-
M_?:[&-6\2U,RNLUF[9=$K#%X>$Y+ACC62]UV$P<TTVF1KFVN[NNL8D&/81H.
M3L14<J];J)4>5*7Z]?&G=W':IIOV]=I.`I@O8_EFLN*][_<OV[:E:GT>.9!B
M9OH>E&/5A;QT5]O>6K%G6TV0/3Y--DS,>%-M*Q^"B4S&7&7"9(F\'VA'>T!N
M>X_4$#\99Q8#_+74/LA/>S_60U`_PL5_AOIYD[LYP;6S2SV0&#:=4V#:4:J=
MZ59W!U^H>I[6+V5NFVR+3C,E56'V-Q4M9)`$2`UC]?.BVD?&UU:;*TELW$Z-
M+>82A*::<]C=55:E8746.281K'C.L'97W1]PV#2;K&]0\%@U4G1Z+FV-279]
M=795%R&/D>.9%B,J\Q%]V7-Q^]2N$C(*.*PM;2")OWV0KO8_K(Z@?X6*_P`-
M]'V0KO8_K(Z@?X6*_P`-]*UIK[,C6/4O&]#IE;FN!TF7:\8GH7G6&8=ERWJ%
M<W$==]0,AP2EF5U^Y.6G)\EQ2NQ\ZD9UB&.XX\_48%:1)L.SG6<>;6,^-'NT
M'17+:[N8N;77<9I%T1[/]2M=&H&&8-;UEOC.>XWJ-_-7'QW4*BM\FBO-2**2
M[%S>NIZF^?BY=46E2+*QHT0K&ILR)*/LA7>Q_61U`_PL5_AOH^R%=[']9'4#
M_"Q7^&^F<K`"UA)W2%*"3MMND$@$CSL2-B1N=OEN?GUYZ(GD?9"N]C^LCJ!_
MA8K_``WT?9"N]C^LCJ!_A8K_``WTS?HZ(GD?9"N]C^LCJ!_A8K_#?1]D*[V/
MZR.H'^%BO\-],WZ.B)Y'V0KO8_K(Z@?X6*_PWT?9"N]C^LCJ!_A8K_#?3-^C
MHB>1]D*[V/ZR.H'^%BO\-]'V0KO8_K(Z@?X6*_PWTS?HZ(GD?9"N]C^LCJ!_
MA8K_``WT?9"N]C^LCJ!_A8K_``WTS?HZ(MY&@O=;W'99I7CE]D>K^56]S-EY
M2W*L)2*0/OH@9??5T-*PQ4,M;1X,2-&1Q;2?393RY+Y*)TWWMD_H4Q+_`+=F
MG^?,GZ.B)MW?I_UTNYW_`(NWO_\``U/32NN@W7GV,_>_W):VZL:\:6XW@$_3
M[5'.[G*,4EVN>0JFR=K%B/7'WZM>AK<AR42Z^4VMDK<`"$J2M25`])-]K\>T
M=_,_3']IM;^X]$6DOHZW:?:_'M'?S/TQ_:;6_N/1]K\>T=_,_3']IM;^X]$6
MDOHZW:?:_'M'?S/TQ_:;6_N/1]K\>T=_,_3']IM;^X]$6DO_`/+\?_MZ7C`>
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M-/ZP*<T+P7*_JWQG$77VYS;KDR%DX%F_DJE?3TXCW>3,5&`:#N:3VE^2-:(Z
MWY??7M)8]YVI7>7HSW/TMU)T4I;/`:^3I3IY68%&R=IF=+?QJFSN&Y7UUW0&
M/4/PV':8JEH5(LELN9_]K\>T=_,_3']IM;^X]'VOQ[1W\S],?VFUO[CT1:L;
MK7[4_)=)H^BN16]5?81"U.S+6&`Y;8W33<NK\_U$]P5GEM"S5R-]/L1LO?K(
M$N^K1(5&ERHX6V6&GI+#ZB8=WI]Q.`XQHSB.*Y?35M3H`YJ:WI>\YA6,3;BG
MI-9#8*U/PVTNI<%V;D6"YDY:SWK?%;<OPUO/H=:=:5$@&)L*^U^/:._F?IC^
MTVM_<>C[7X]H[^9^F/[3:W]QZ(M65]W`:I9'J5I[JQ9W5=]5VD\#2VGTV;AX
M_51,8PNAT7:K&=-<=I,32RNG108ZFIBK76RVI:;I]R?*O7;*59SWW\HQWNOU
MIPR[PB]P2WQC3]_3[6?ZX?':S!\&QS'\:.LXK6J1&=W&,-Q9-+;SHU`VO':^
MJ?BMXY4X_,LJBHIJ^+8RDN;)?M?CVCOYGZ8_M-K?W'H^U^/:._F?IC^TVM_<
M>B)A65=\FO&:/X&[?MZ3/,:95N8U6"UE?H]B--3XU&SG4:IU:O'ZNOJTQ40K
M9O42E@Y139!!<B9!2S53D0[7T+*<V^Y[[(YEM)VVXFK&<V4]W?N=U7<;KUFF
M>7NE%%8BKA]P.GIP*VNL`RN8A=9C.;)BN6[3KE+218]=47C46JXRJIM3"K_:
M_'M'?S/TQ_:;6_N/1]K\>T=_,_3']IM;^X]$6O*5WEZ[6+.A)N+'!;ZY[;F\
M%A:3YM>Z8899ZD5=!ICD3.68!A]_J&Y7MY;E>%XMD4>-:UV-W%HY&<?C--6#
MLZ(7H[N83/:%=T\K*-/\T9S/&ZK)=,=9-7=>L2LZ7`Z"`6=1]>I<R7J_*MXC
M@EP+W',[5/F1[C$+**[1)@OK@PX\:.$H#W?M?CVCOYGZ8_M-K?W'H^U^/:._
MF?IC^TVM_<>B+5GK!KYJ%KG3Z:X_GB,+:HM(,+G:=Z=U&&8'CN"P,<PB?<2[
MYS&FF<>CQS+K8]I/F28`FK>?A&5(#;REO/.N+W:>T4[HKJ7ETZSO\!DR<ZK^
MWRKR=9TTI$"Q@]K.0L95H:PE"):1#^H^^BQYLAR+Z3F0I91&O#,C`M%Z/VOQ
M[1W\S],?VFUO[CT?:_'M'?S/TQ_:;6_N/1%K4J.Z?6.C[F9'=Y`M<<&NTG4*
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M_'M'?S/TQ_:;6_N/1]K\>T=_,_3']IM;^X]$3*7_`&B'=++U+U(U9G9-@MEE
MVK&8:0ZBYHU:Z68?;8S)U%T&16LZ3:@TV+6<:768YF>'Q:F%!B75.(WOD%#D
M:PC24NE02_'^ZW6;&=8]4=>*NPP\ZA:T4^J&/ZE*LM/,3ML3R6FUF8<8U*KW
ML)GP'L=B1\G2\^J4B)%:2A4F6A*51IDN._LF^U^/:._F?IC^TVM_<>C[7X]H
M[^9^F/[3:W]QZ(F.V'M`.YFUN\]R*PO\%D76IN*Z(87FTY.F.+057./]NMY4
M9'I+&]WJFZ^)#D8];T-,_+EQ([;MQ'K8E=+":UE,07"E]HMW5T.;9CJ!#RS"
MY.0YOKO2=S=FFZTOPZ_IJC7FAI96.0]3,,IKF),CX=D,C'YTRGM54SC46S@O
MEMZ.EUME]IZ7VOQ[1W\S],?VFUO[CT?:_'M'?S/TQ_:;6_N/1%K%T>[D]4M"
M-9).O6F<C%*;4N1]7/I64S#JNTI:X:D0[6NS%%3B[JV:2`U:5UW:U[3*8[C-
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M1:J=3M<]1M8:+2G']0;"EN6-%]/*C2G!+5C&:>KR5G`,>=F.XYCF09%`8:L,
MGBXZ+":Q2.6JEO0H\EY!6\ZM3Q2'K=I]K\>T=_,_3']IM;^X]'VOQ[1W\S],
M?VFUO[CT1:2^CK=I]K\>T=_,_3']IM;^X]'VOQ[1W\S],?VFUO[CT1:2^CK=
MI]K\>T=_,_3']IM;^X]'VOQ[1W\S],?VFUO[CT1:2^E<E?T`4G_'3*/_`'98
MAUM8^U^/:._F?IC^TVM_<>LM=]AAW^O:?P=,T8MIQ]54#/+74.1'.HM<(HQN
MWQ>FQ.&ZB5[EP5+5;TDY+D4)YHCI;D%12X`"+0]T=;M/M?CVCOYGZ8_M-K?W
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M_'M'?S/TQ_:;6_N/1%K6Q?NIUCQ'$>X+`:JTQ]_#.Z!EAC6/&KO'$7M1=HAW
MMCD]:Y119]BI.)RJ?(+67:TTZE+4ZMD",B/)$:(Q'3F]7WW]R=3:4-TQDV(R
MK*B[=)?:<])M--L.LE99H%+JVZ5&`Y^)$#;,H]=5--0:BQL2W.KV6]DN.J=D
MF0_+[7X]H[^9^F/[3:W]QZ/M?CVCOYGZ8_M-K?W'HBUZ2>\W7:P_F1DVT[`+
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MY1J&YF6(HRG+=3L7UNL),?3#"8]?`ULP_&;;#J/6''Z=NN%?1ZCHQN\L:VPO
MX[+D>V:5"^D*M\554F"TNGS&VIX^;QPS4W'\X6,V>*9-)R2O<NYS]9<W%9?6
M<F%-=F,O0;N9;4\"6]=_](FJ*'VB?2FS$/[BOM?CVCOYGZ8_M-K?W'H^U^/:
M._F?IC^TVM_<>B+7M6]ZO<3`E:PV$K,*W)++7C1K'>W_`%.L\OQR%D-A>:28
MICU;C%'B<*0\]&%&F-5U,!3UK5ML6\NQ:<M'YBIDB0MVLKN]_N#KFM`%FUP&
MTNNV!6,,:+9I?Z581<:A8M1X7D7U68GATK/7ZYO*+W!\?R-+-M78O9V+D-+\
M:-'DN2:]#D)U_OVOQ[1W\S],?VFUO[CT?:_'M'?S/TQ_:;6_N/1%K3U"[IM8
M]4M/G=+\UM,9L\.5K#J#KO"B,8500;*DU&U5L5W&H<W'KUIA=Q3T>4VSBK*Q
MQMB8NM$G9,<,Q![H<H=[U]?W]'G]")-K@DK3B5HG`[>)D*3I9@Z\@FZ24^92
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MUG++T+W=O=@KQH%WM4>-I?R[6>;=6.6Z4]N.OW;MH)AF#8#20,7G8CW`XMG1
MNHN3Y-]-)LZVSH=2\EA9/%L)\.RAN8S)R*L9#MH*>,AP7VOQ[1W\S],?VFUO
M[CT?:_'M'?S/TQ_:;6_N/1%KKK.\?N`I\6T'QJ!DN,1IO;.U3P]%-06M.<)_
MG;P>FH\B&75V*5^J#U0]ELC"V,D!L4XO-FOP5M;U3ZG:9;U<[<7N]37)S-=6
M,[CC2FKL]<<`RK3;56FI-%M/*7"LTQW-KR!DV4RK;#Z^J9J5Y/<Y)65][*R@
M`V8LHC:T%,4N1%[`_M?CVCOYGZ8_M-K?W'H^U^/:._F?IC^TVM_<>B+28I2E
M$J4HJ4HE2E*VW4I1W4H[`#=1))X@#<^`!L!#K=I]K\>T=_,_3']IM;^X]'VO
MQ[1W\S],?VFUO[CT1:2^CK=I]K\>T=_,_3']IM;^X]'VOQ[1W\S],?VFUO[C
MT1:2^CK=I]K\>T=_,_3']IM;^X]'VOQ[1W\S],?VFUO[CT1:2^CK=I]K\>T=
M_,_3']IM;^X]'VOQ[1W\S],?VFUO[CT1:2^CK=I]K\>T=_,_3']IM;^X]'VO
MQ[1W\S],?VFUO[CT1:2^CK=I]K\>T=_,_3']IM;^X]>A_)]O:.J&XQ#2X>=M
ME:GUH/\`;M[@?'_?T1(?VR?T*8E_V[-/\^9/T=;%=+_9:]V>DV$5.`YA282Q
MD5)(O'Y[4#,XDZ*A%[D%ID,`-RD14)<4:ZUB*>2$CTGRXR=RV23HBZP^UH#^
M87`"0/\`Y->'Y?\`UFNNC*.Y73+$,TD8%<.7J;^+.K:YU,:D=DP_>+5$1<3C
M*2\E*D$36?47P'IGF"#Q\Q[6O.@N`#\<:\_S-==6;,.UG",TS^3J)8WF41K>
M58U-DN)"D5B*]+U.B$B.A*'JQZ1Z;@@M%X&05$J7P4CX>)$YG9/XA_</P=-A
M[N\T[A=-=$\IU&[:\-P[4G.<$B.958::Y17Y!*L\[Q:F+<W):'`WZ"^I2UJ`
MNC9LI.(5UFB569'?,5^.27Z9-F;B&Y\>/_7_`.L[](YK/I_EVIM)3XA1Y=7X
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M,"HEUD=V6EK[?L[,HBX-J'A<76&E6WG=1V+UGO\`*P&<ZNL7V5R,.FM/^[(S
M%EN8G4J5A\?WADNQCB;%A(;2]D*V&W5XEH?VX9SJE9ZJ9!DDRTP%C37O][G.
MX'1.'FFDN4T\N5F>0XCD6`Z8:A35WUSCDG,=.ZQG.LFRF'64C%(UE;S5542[
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MYH--)V,6]3?46:Q<\RNM9N\7QA_"+JJ@98W99+0R&\@H`JG$>WQ_U;V"^]51
MY,MEL^LW8_DNO;^-/:BZR-O3(7;EK!HED5UC>"IQRRF91JGJ)HYJI7:BXQ$&
M3V59C\7`<PT/Q!5)A5JC)HUS3R+&MR.]L%K<E2D3[H>V_-\>AN:PQK/(;[7/
M4C6SMHM\LU7TNT%R'4ZHTFJNW2CS5[$,IK]#<9U"CZFW4.\LL@R3%<G>Q;(L
MBM&(>I:XMQ53<`I+1B01/>Q'O$[=<^C8Q-PK/EY1"RVV32U4JEQ#.)K4>6YG
MTO2MI^^X8R%XQ4O:E5]E@C=]D3=91*RJJMJ8V(EU5BB+B?<CW60=(;/+],<7
MI["?K#'[7M<.XW$)-OB&4VFF;,/2*/71FH67Y!1B$Q#;L[VV@PWXS=U7RXS"
MV$K>9F7%%'L&PZ-]E>37\?0S-\FDXGIE>:%9>Y+T_P`NTYTUS?1_5#(,,=U'
MDZBYLC*HESJEE5[`H.X25;W-5JYI-JE8ZB5DYXIU*CQ<8SRW75T#GNX/M8N-
M8\Y<SK'=0XF(2[/MJU\[:,AJ[;$%Y1"L,<UM<Q&Q8OZZ3%R3'9=/<8I?8?`F
MJ:=^E8=]6O2:HM54A35LR12]'.]S0W4;26GSNRU`QR-D4*NTJK<\QJ#!OV;6
MJS_5'`*3.L?QNCQN=7G(;]O):ZU<G8;)I(US#R*KC2I%586":ZQ<CJE([GNW
M^-H1]<VYJGBB]!4UC5PYJ?&DOS,:8KW+Q.,N.R78<5^7%>@Y$I5%:PY$1J93
MV[$NOM8\*5#EMLL-3[,[*(-AD.2T6O=949>M/:/8X;-M-(Z_,,3KK[M=T=RS
M1*=&SG"[G*XS>=89JGB>=Y0NSQ^%>8C=8E/D5TRBRF18UC<]QT^L?:U;ZM=H
M.8=L;V?U-->9KC*:2TU`K=/JVII(D^5D</([:PI].:&UK8-=7./QWHE73)OW
M9$6,ZT[;7=Y8HF3YY%E*N\?MJ3B5MFIU1J!2T67Y9@5NRNJR-G(H.78+1C*,
MNI'L/D4K.7>\T.*K9RV:XFC5&^I.77Y,P^]2V==-E3?KQ.U\V&G->C6S3]].
MKC6&N:<6\:Z:DXSECFHV/3LLT\AUF6,(7C1L<^QJMG7>%5TBU8FY17QEOTS$
MOFREUJ65^SWS.XU&RW5_&=;L9QK4"U[@LQUJH6LBT9A:E8`C'M2M%])]&\\T
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M*'0I?M7:X1(LMQAAV1>S>U&S#3'/\`RWN0I;B5EO9C2]EM5=PM%?H,5>*8UD
M\ZUI,_N(+>IEDFYS)=+8/5UY!K7,=QJQM$-6M?7TL-)J%.`TM[0LFTUUNS/4
M9O5/'KC3_--0+_6%S`IVCF,OYOCFI68UK+67Q,?UJDVSUTUIE87BK'(ZW$Y.
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MV#XM@\ON`?2WBW;]KYHM7Y!3Z?MQ;>/=ZP=T.)=U6-Z@1XUCE-E6K^H',\%Q
MNAEXE/:EP,THDV1GV=4N8U'C$3T.V[N3NM:M6>[_``VU@T\#&.W_`%4P7"L2
MFIQ[+<2R&3495HG@FJ-@,WJ,T]VFP[VIL\LEUJG(U=5USU9$B36F%%]QTYK'
M[O>WB<F8*[/VK.5'>PMJ'6UN-Y=/M\D:U&CY3+P*PPJIBT#EAG-/E\7",PE8
M]=XC'N:BTC8O?/QIRVJR4M&'Z/=KV1XADG=!E>JNI53J/9=U$["K'+Z_%\!D
MZ<4N/O8QHUCVC-G%H$2,WS>W7!O*?'8UFRFPM7IM1,??;1-FH*5(2;%>R_7;
M'])=+=(K3NP8RS&]'[G#*?'X5MHA65]9FNCF$8Q>8I3X1J_`H=0*R3FV6-1;
M"CMUY=3VF'8?/O<1J'KG2^UK9MW6SR);['OC[3ZJ1BT>;K3BR/JSP[2W4+'I
M;$6_F5DO`M:KYW%M,,UE7$.ED551B>69(T:*)D5S,KZF%:N1H-M+KY$N*V]?
M*KN^[;+G4J3I%`U6QY>H$/)M0<+DT<F+>5[+.7Z54$'+-0,77>V-1$QP9!C.
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MAHIV/VLZ2U:28#56S;(9'3><V]FV_J?I;<X=GFM"IV<QNVO"^V'`]1:G`8M:
MW68A@>HF,:F5^2YAB9R61$RG)KW(\'PUO)F*FTQ2E$&LLV\:AT#U\\N$[C7+
M0J_U@KM$)T7-J_'LVT0UBQ/6FLLG<5<M,8R._H<3S3#[2ELZ`9#"M(%'<5N=
MW+L1<')'+*GF1ZMUR5;LL3&)Q%8?KY>TQ.(X+G;FN&$MXAJ)"I[''<@=?GLU
MS4&^S+^;FJFY*X]`;<PB+)U#2[@2WLT:H$0\SC3<8G&-<0)T2/ENK.N&,:5Z
MA:7X]D^HN"X=6970ZOY+88_D>.Y1991E5-I?AK>5W4[#+JGFMTM*WA=>B3>Y
M8S=U=Q*M:@LQ*1F)-2I]QIU+[.Z7A6I+&H^!:OTM?)S9JV/<#3YAHAAN>U^H
M%S<:NY[K'(S'33Z2N(!T7R]NZU0S?'FG6TYUB[^,2Z15CBL_)Z%G(IB\]QG;
M-=:X:A:-9S69S`Q5&DE+KM7"KEX]+N57\O6C2JQTN;E+F,7E7]'LXNQ8KN_1
M$>:]</-)@"35-K5+!%:KGO;T"R#2S4+/M-=;L`@Q-/XVE-G>9;F.)9[88I34
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M#!\>EX376E<F3"QW(LGR;&*UJI?(ENL.]71&/GNENG=?(RVYOM3\_P`MTY0(
M>!9G'9PR]P[2QG5^?]7:+&AAR\7C3\)L\?OJ63:QHT6SQZ[;RAB2<>K[*PC9
M+0=WO;=E*\D8QW57'+F?BR<%>L*FN192KN=$U0GS:O32QQBE:@*M,QJM0[*M
ML:["+7$XES7Y-85UA#JI$F1!E-M(QD/:!J=J;'T3L];-?*C.\UTORG4.3D=S
MC^C[&`8_F>#:GZ-W^BN5X[7X[`S^VLL3R6117S^01,P5E.01(>4%]<?%$8^8
M5!"33'O9YYQ1::Z=8BYK_CLW+M!,_P!)LTT&S>'H!C6-"/$T?AWN/4E7KI44
M&8Q)FLMCD.$Y+;XSE-U47^F<(2G8^58KCV.9$T_*E$3H>T/7*][A-+\ASK(8
ME%&E56M>ONFL(X_69#30Y=)I/K!E^G='/DU65.+OJZXG5F.QI%["GICJBW"Y
MK#46,PAII+I=A^(?W#IO/;5HE=Z$89EF,Y!G,;4"QRO5_5W5IZXB8FG#6(+^
MKF>7&H%C0LU:<@R13\6GM;R=%@SW[#WE^`F,B0V765/O.'Z(H;#\0_N'1L/Q
M#^X=1Z-P/F=OP?\`?^+HBAL/Q#^X=&P_$/[AU'<?+?R?D/Q[?/HZ(H;#\0_N
M'2=-`?SK3_`_H^J?P?\`UGNNE&Z3IK^E>?\`\/JG_,]UT16S5#63"](44CF7
MJM$)OW)[5?\`1E8NQ)77(BN2?6"'6_1`3+9X$[A9Y`;%/G+<)R^ES_%JC+\?
M]Y53W33[T(S8QB2BB/+D0G/5CJ4M31]>,[Q!4>2.*_DK;K`M8-#\9UH;Q]K(
M[*[KDXX[9/0S3/0FB\JS;B-O"1[Y"F!00F&WZ7I^F05+Y%6Z=LVT^PFMTYPZ
MDPJHDS9E=1,R&(LFQ6RN:ZF3-DSEE]<=F.R5)=E+2G@R@<$I!!5NHD5]NVK=
MRHLF\>DUD*\7#D)J9EQ72[6JBSU-D1G["M@65--GQ&G-EOQ(MK72'T`MM3&%
MJ#@UN=M/=?W"ZX9>]HSD^)Z78/KCH'J1EV.]YM`FKS2;CF*XBZX].T,NM(IT
MK)(L^_3K]A\BLS?$+NZ9D5E;1Q<NCW5?#R#&XU)=['LB9OWZ*V8Q6;45V1NP
M)+=)/OZV9<4L*R6V4Q)5I4U]G2S;.#'=*79%?%N*MZ8A!CHL(9<]=#%*3LKR
M##]:]"NX'!]4JZEU*Q7%<PPKN?LIF(2[5CNNH<SLX.3J3DK:<GA.8E<X+G3,
M[*=*KSGE#V!5%E8:<0(LC"Y\F*"+-<-[\^W;*M-X.J=C?7^$8Q8W6J%>R<UP
MG,*.PBTFDNHQTQR_-[B$_1%ZDP2HR2131KG,+1,;'<>E7U=5WMG`M!*BQ[]:
M=\/:S3Y78X/,U5A+RRKRG.L%D4=?BV=6\U_.M-:V%=9G@E4FIQ:<U>9S54EA
M&NV,-I79^2W--[S:T=995\&;)8:/F/LT\WR726WT.B=RR86F=C2=T-!#QZUT
MABWK-<>X75&5JK1YHM"-0*F+8ZDZ9V5K?XK!OYD8T%IAUS(168GBV5AS*I*L
MXKV4YAC^JF.ZH2]5J&UF4O=QJEW3S:QK!K&NC6,C4OMVD=OKN%,N?5A/77,5
M$6;*RQJ[7](*DRE,4IK&8S3L^01*3D_M`>SC#J#'<IR#7;$HF/95IE5ZT4MM
M&AY+:PW=)[6X30(U$FN5%#/-/B-9;*]TR:[N4U\+$"W(?RMRFC19#S>8VO=W
MV_4>8TN#769S*FZR2?FE;CLJQPK.8F-7SVG.+2<VSR74Y@]C:<5FT>)8M#?N
M+O)F;=6-Q&/09-NJ7+AQY&L/".R_4?3W5O".VN+D=I8X2/9RZS:`Y5K.]HMD
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M%ECVBN+Z*Y/(@S9V?9W?V2<RKL4A9`Y*N;>9?PKN;:2)M[=O2T/1\'Q7LZUW
MQK1G3K1R1W7HNZG23)M*(F(*D:*55=6Y1HUI.U*KX&F.LE;69W'L,[L\DJ%U
M+&4Y9C5]I]46<[&*5T8.U5S,JJ,B(E2LN_GL_J:G&KV9KEB:J;+<&IM3:2SA
M1,BM(3NGU[F*=/XF9SWZNCF-TF.0\T6,=R"VO#6Q,5L4NMY.Y4(9=6G.(7=?
MV\V.JB]%(FIE,]J8WG%OIF[C7N%^V6-0J3"HVH\W"I-P]3MX_&R=S`Y2,MK*
M5^V;G7E$Q83Z1FP9J[)477C3^RANJ#1J=HU#U\@RZY[M2U&[7(=])TO,*7'K
M\^UVFZRLY<]4UV;)KGI-%$F?4G]"QG(,:S+2;OWR`V33EP=OV/9#D6H5QFMW
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MZRIU&[?=9L4UQ@WR,*7(Q'+<FH\'SS`K:GL\3^J=FUJ<=N*C4*Z>@BORM^VI
M9T6I>>G7++$V-/(J/Z^GM(3AV#Y^YKG@S6&:@Q*:=C^2.RIK%4Q#O\R<TZJI
M>3/OP6U81&D:A,2<#==S1%`F#F42;C5C[I;P)L6/G.L_<[H5V]R\?K]7L\BX
MC8Y739KD&-5II,GOK.]J-.:N/>9S-JZW%Z.[FS$XQ32F;6U:984^Q`*Y0:4P
MT\MMF>'^S73IEJ*YJ!IQJ]70%ZAN75AW$TV;:,XGJ)$U"R6^U8S[5Z=FNF:[
MB[BM:*93],:G9?C:/2B9WC+^)_4ZFQQN?D]`G))Z_P#<EVLVVN^H^CV?5V=P
M\41I/B7<+C8JI6.2;HWTC7C3!6FB9ZYK-Y5FO;Q-OC=)C"/,=NW>4`RJE*A,
M!%E%)WH=K^1IR4T>KV-V)Q6OT_MYP:C730MJ?5:;+K--KK"URZF.C4*ESBV@
MS:?&KG`U9'56EU#E5#$PV$9]AMLNI/M%\*QC-=)<LP:XQ'4KMCR[MO[U=;<P
MR[$*[(+[.H-OV@3--H]_CE#7PI#;7O\`%D99DU'E.,6E"G)*;(\>]PE>X%F>
MTW@-M[,#(K.-I0]%U[@4N2Z(]M_:WHII[?-Z51+VN3EG:_D63VU9F^68E>Y6
M_591BFH-+FF2XGF&G/O-9)C5DYNQH<VK[R%!GQE1U%[`K759[3_ZL-5Z2-'Q
MWMV[O=!\L;PC2BIPF+=.=WM3AU7D638G30;^=58A&PE.$5SE!2VB<PL;GWZ:
MO)<FGSDHG.D2ZXOWK=O=W4:.RK[-Z_!K[6JJTVDXWBV5LSZRRKL@U7H5WV#X
M5D,F1`9KZ'*LFCQYS6+U=U(K9.6>Y^\8\U/CS:]<K&M-NZYG5+NOO-'L/>Q^
M]TK9[9L,UPH,LCT>5UMO:V.2ZHYC@ID5UI<"-CV4X':5>-L6>-9!C,1Z-,?,
MXFREQ?=%*0W$_9QW6/S7H5CK7C][A&?:4Z<:>:X4$K0ZD^J7([?3C2*#HBSE
M6D.H$O,["XT71E&"4>-,Y'3/P]051KJG=O<0M<6GVLU05'MG[.,ZT,SS#,SS
M#7"!J<W@/:_B7:M008VEK6$S9V(Z?YC,R+#\KR*S9SG(H\O+TU,EJCR0U%12
MT-S(C"XKZFB4XJ"2)<+7NO[>J/)<PQ*VU+I8-W@E)J#D&2LNP[I4.+7Z3U./
M7NI[<*U:JW*NZM-/:?+,9LLQHZ69876/P[RN?L(#27CPMN(=XO;9G]7D%MAN
MI]5D#.-3=/($^'$J,F:NIDG5JKCW6EXQV@FT<2[RR/J'6R!(PR=B\"X@9"J-
M9,ULI]ZGMD0FOYI[/_/LUU.R;4FY[B6;F38H[M*?'V;S2Q,N\J,%[H,)QK%:
M[!)F3Q\]CMR*/1B1C%<]@K=-CU`S94QF0LCB3LGM+/,Y%DA^SBR>LN,;RZGU
MQ@UF;:>4/9DSIU:.Z<OVE%#R?M%PS5;3YZ=F./+S2OD9-C&JF*:T9O`M,>K+
M[&+7$91IK.HR:?.KE.OD3A^V_NB3J)H'J=KCJM.Q7'L=TRU2[F,;N<AI*;*J
M:DBX#H/J?FF)-Y-8TV1F?D]?.;QK%OI+)HLIA#T>S;L4QX,>.AIA-WQGOL[3
MLQ#YQO6"FM/=LGT?Q)]+=)EL=UNS[@+!%/HK.#$['HK[V*:EW3@H\4SF.V]A
M=C>-R:A-^BPA3(["9Y#H%E>D/9?W>X+]4-GJ]EVI5=W=:CP48Q@DJJM9N1ZZ
ML9OE:,-Q_%JBTRJQLG8^29*Y4TJVY$B?+CN1&WVBZRY(=0?`NQ;)-6-"](,X
MRK.7\#USJ=`^Q_%,3E6.EEG70\"D=K.H&-:[Q*;/=.+W*(-Y>S;W4FOD5&8U
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M:_)0Y&(K+I3WT8Y>=S/<!V^:HVN+8?.Q?6G`=,]!F?H#-J6WSB/F7;7ANOAJ
M<J=OHSM;49\H6V61*;'9:L=L+V#C,IBJIIEI"L&T*GB'?;VJ:@4$C)\$U39S
M*F8<E-M2<9P_/[AVT%;'OY=V]CL&'B;D_*(V-1\7OG,JE8Y%M(^+_1Y;R!RN
M?E0693=[_P!GQEN1ZO6>KUKK)1.VMMWCZ`=W\ZKB:<SH4!RWT-[?(^@BL(CE
MW-K)V)6Y5'C-Y4BY6Y-F8])_\$>Z7C24V/5[T7[#,FT/PSMKBXSK#7S]1.VJ
M1W#U5/DEM@<IW$LRP7N1S!>;Y=0Y!A[.8L64&ZI+^#BDO'\BJ\K'C&'8D^M?
MAY%-:@D3EU]W/;JE,EU&I%;+AQ6M!Y;EI6U606M*[5]SMW)QC0:^A75;42JJ
MQQS4G)8<G'Z3(($N341[AE4&VEUSVR3BVK7=YI=A]!E%9B6745GJ@[C.O:M-
MJ6RI\IEXWE.<Z`XW<6N=X^NZJH#%<^C#;*L,#,6(U[$E5RD3(S<A,V,ZAIM,
M_P!FBJIIZK$M,-:WL)PUK`NTK$[RLMM.HF7VT^Z[0NX&\U_PK(:JW.74$>DA
M95>Y=E%;F%"JLLR&'Z=_'+6E;JY$*R0#3_0S67-]4=2ZCZ'EXS095G_=G"^H
M753MEU#H&^W['NX!63UV49_I=KNQJY::-ZDV>72V*/)VZC!<9>>O866Y%36$
MO3Z9899<SB+8EV9=V>$=U^C^#9/77V/O:H#2+0[.M7L+I(=Y7M89>ZQ:;U><
M0$5\?((S4N=BEF\[=1L8R")*MJNR^A;.`U;RK.GM6HZK8;W!:.9_G5OIMB6;
M5MOF=-`R:U>IT1;**;"JPK-)&G.9VF/S9L&-79/6XAG\5_#,IGX]+LHM!DR4
M4]F['F.LMN-P[2.R^T[8<NEY))U(AYI&E]K':1VTF"WB3U!(;3VH4N>TM?F(
MF*R&V;4<X;U`L)-A0>ZA%"[7Q&XEI8A^2Z;-HCV2Y]I?W%UO<'F'<&K52V@X
M!KCIE.%SIE&J<KRC&=6-7Z'5K'7\ER^/F<V&NVT[500L,K&J'%:+&9>*Q*^/
M78WCTAJ:[-(ETS?O"[=].XF<V>69T_#I=-D72LUR&NP[.,BQRB<Q>^H<8RV-
M)R#',:M:=V=AU[D]#`S"OC3'IN+&Q3*O6(,*+/DQ(ZC]X7;KI)=S\;U#S\XS
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M,/FEQM:FP0^P;+(6H<//&]7:99@=PG=;KTQ6*P>R`6_W,Z6V.F3.+NRT9>%!
MG!&K%RY3;MLI>R)QM%<W!Q]OE*4S6?VP:N::9_A.DN-0)5M7Z7=MW9OI*AZ^
M[4<]S[2/NUO.V2RNLHP/)<KSO`-:\=QK2:1@.0KJJ]^NU;<E.UZF7+>DCY=C
M(C8U+(MQ=)W*Z$Y%JH=%*?4G&YFIRHV82HF*I>?:E6HT\LZZFU!BT<Q^.U67
MEE@5M;UE=FM34S9EGBTR:PS=1(:BO@N>P_$/[ATR+MV[2<@T%SK*+)O4JBR3
M36=E&I.:83A\O2G'&=1\/M=6,JL,URC'[K706*[S/,+ILAOLB^HZ)(Q+'<DC
M5D^%7Y-DF2QZB$WT][HBAL/Q#^X=&P_$/[AU'HZ(F6:L?[?WW]E3_P`DK>CH
MU8_V_OO[*G_DE;T=$2I=K/\`0+I__P!FN_\`,]UTX'IOW:S_`$"Z?_\`9KO_
M`#/==.!Z(CIHW=9W$9=H'9]LE5B>!Q,T7K]W-81H-:2Y=]&IAB=9DN-YEE4Z
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MEAY":S'+/(U]@.BSN/\`U-+O=4E5:L![FM-G$'-P'W,8[M\P3G6LK2GS2\Q/
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M<2PZ!C?<7/128/J`U<Y/]$IMJ['\HF46)ZF8Y5,R<EP6ZRC&WY42=06@O&7$
MX/VW:98/1ZW8TS!LLEQ[N$S_`#W474ZDS&<B_K+FWU+IJ['\PK68CL2.W#QJ
MTIZN+`./I#D)ACUPUL9+Y6G^-=D^C%'H=G_;M<R=2-1]+=0\2EZ?6-1JIJ;E
MVH%A2:?NUC]35X;B-Y?3W[7&:G&HC_+')5?)%]7SHU?9NW4NRK:^5&(L.R;O
MJQO&[U6.1M*=5<WN8<RLL[>ITTQR;GUK!TWR;4W*=+L.U%8A8_"D)L(F0V6%
MY7E`QEN0QDL#!<;N<@=AONQXM=-\Z>]^F%9_KE`T3_FQU.QERYU.[B-'*#-[
MY&%NXS;ZC=M:(-AFE,U&I,MMLAAPK;'),O(,8O)U1'KIK%7.K)KE?;JBPWU(
MRCL]T?R34'!-2XB\]PW)L'P>CTN>^H#43+,/JL[TNQF?(M<<TZU,J*JQ1!S?
M%J*TFV4VI9M&Q:03<W\)FU369#=P9]HQ;LHTAQ'47&-4*V?GKV48GK!KIKC6
MF?EAE5CN==Q%-]`ZCN3JP5C,>33/UI<9H:9)9B8ZMU;U9Z;@0I!$U#OB[LM8
M\+K>\3`<`JY^`)T(T(T%U:QW5K'KC';3(KFYU+U5MJ&;C+&*V]=-3"B2ZC$K
MJH1+4TJ4IY4EYJ?5+EU<EM8A[0[`Y%?ED"MTQU5GZG8?JMK;I19Z31Z:OM<H
M=N-"ZS%LGRB7!L<4FY1CDJ%:XGGV`3\8<19^E.N,PJ<8L)-79M6*X:M:T=FN
MD>NEMJ)<9=*SJO>U7TSQ'2G/HN*YC-H:Z_QG`\VEYYB,E^`B/*CL9!16]G<Q
M8=[%2Q---=658\76G6%Q\'M?9[:&6-SD&5PKG5S%\YO==,Q[A&<_PK5+(,/S
M3'\YU$Q+%\&U`K\?O*!,)V)@^9XKAF-5E[@TQJQQYUVH@V\2+#O(D6R9(I7=
MUK!ET#M4PO5S36VS?2^VR35CLZ6F+=X\QCF8P\8U2[C-'<5RO"\RQO*JF;.Q
MNPF8KEMMC^3U:F*^_IIAE1FIT.1'6M6*:F^TCTSTBN=8J3,=.=31.TFT_P`\
MU/,&F3A=M;9'B&F^K>(Z/9-,9K&LK0[CLV1=9YBF4XM49,[7VN3:?VT?(XL.
M-)4BG6Z[5/03!]6M-:C2F]>R2JQ.CR;3++*]..7TB!;(M=(\UQS4+"S(N)K5
MI,G,1<JQ2CL;-$U<AV[]T<8M'Y+,R:F0U3(?9@]MN2P\IKIUCK"W`RF@UEQ%
MV'%U9R)$:HQ+7?53'-:\_P`;I&7FY#<*ODZG8U%RFJ??3-M*=^7.KXEC]$KB
M0(9%>,L[^*+"7,BJ,ET9U2J\VPK(=`\=S33]R7I_+R:E?[G-6KO2+1J;`<J<
MNLZ+*8%W:U<.^NW<9N;%>,T=LB-8-KR6FR2@J)I]H)ITM.H-]`TXUEO],<%P
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MV(YCD=O4:_:/]N&12*]--`139[K9A$;4'$K+W&XLH=G;85&QR=$<NLEIXLM,
M>9](1X$*R:H;^3691@?9UHSIGJ#C&I^$0;_'LKQV/K(S+75WKE;298YKOGD#
M5#4*1E>-5L6'037)VH%>SE%<W6UU1#J;!R2F'$3%D.1RU[(.U?7>^[L,\UA:
MR#),/%QE^`66%YA@FLS<3"XNG^#5%+4(Q_.='LCTYO+"SRZ<R_G,2T9H\B:Q
M6]J\B;+=OBU@]8.*(LJRGVDNGV(1=7EW&F6HD6UT@QO!,[M\=<EX:;F;@^;:
MVW&A/ORD1<AF0:+**+)J"PO;;!\@G0+MO%9--*"T7-B]1P,UB]]^"R<ON].3
MA67QL^A:^ZS=O]%32'Z)JGR3(-%='Z[7&]NV<M7/314E3<8+:PE443('H%V_
M<JEQ)-='KZNVMH-AJ?9E=LM5B^386&]4+#&LET7D:`?1MKJKELY-'IG&U%L-
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M.&[)OX421`I7)=LXU$%MTJ[(<5Q/)L=U2RC+M3)FI_T515FHGT7JA?QL2U79
MP>9.3I6[JYC]+78EC>IF3Z:8T]68E!S>5BN/66455)7,91`L:^)"KXJC:X=H
MNEW<!=9'=YW.S=I_*NWW5+MEN(N.90JC@OZ6ZR6&.66>Q&F&H#ZX][9R,3HD
MQ<@:>$^J9B*;KRQ[S)4Z18#DW?EI?C.<9#1.8EJE=8%A-EG^/ZAZP8W@61W>
M`Z=7NFFG3NI^5KS2;$K"JIQ:!1MIHEY>ER16LYY*K\1F,Q7Y\::Y:,8[\,=S
M'*ZK3.)I)K-C^HF<6<2+IA6Y)BPQ:IU!H7\&L=0KW)L9RW*FJ['U.:>XY7^A
MJ!1S$/6N,Y3:XM1N0;2-DU98O9Y![(]$X>:9SESGU>6%=JE6/,:HZ;6&H&22
M-(=1<BFX/"TWN,^RS3%,EG%9V<9#A-=!H\CN(T*'$O3$C6]E6/W\=BU:Q&J]
MGOHI2TFG%="RK75V\T;RF/D6C^H%OK;G&1ZB:95K%'-Q1S`\4RO(IEK*1IY8
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MHUR[J=4-/.\['M%UY)`QO!\ORCMII\)S%,&JM=+:.=E^492UJ9I5KS8IKY63
MX5K!JOCE0VSVSCWZKQ7,+IRIK/I"LMVY$/+W%4G:-36';!@7:IG^0Y+-PS2:
M;IE`Q._QJ[12WUUC>AF68]EFCJKJ4*Y]QB=1.XEB$?(8C:7(UY,QYQYV2]6V
MTF#TH63]K>DN79MD6<7-99/2<UN-+\CSV@19J3BN<Y)HO8QK73*_R6D<8=1(
ML\6F0*E3+D"171[-FCHXUY&LX]1!;9(L0[C.\3`.W%_)J^_H<HR>ZQ#0#4_N
M6N*>A9JXDA_3#2*PQ^NRY5)+OY]56W>5A_(H1KL8ARQ)?0@JFOUWOE2+#'9_
M>WC%1JQIKH_<Z=YK3Y/JY'LH."_2$[$D)L\KJ]";#N"D54J`Q>R;BJQ\XC37
M^.M9O8US%&]J!CUUB[+;B8:;)W`>[KMPU4UKUCTMR.F%^<#Q'"LJH84O3S6D
MZ19G1YCE][32[FSR-JUP7-:7(\)DT>-4$9CZ'93D]3:,6"S4W4":PB'D>$>S
M_P!-*;-<)U<R_*M2<JU9QO4*!K7;6PSNWK\2NM:Y6B1T#SO.5X7#:B4B&]0=
M/5)I\GQ]J)&QA\QVYE10T+LB<S)(DZQ'VI6C^28G19K8X'J'C=!DO;%VW]SM
M1(G_`%+S'!C_`',:J2=&<0Q6U17WCC53>T>;LLIRNV??7B-5C\CZH#>*BPY[
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MCE@W9/4><:`8YW(Z?KOJB5CV48W`=RH85FV%9#33HT:QBJJY=EAUU#C6T>/>
M4\Z\R''K%M;57`3'Q*M[W<<FZBHT[?TWS9B8CN1U>[9Y=A$DX_;M(R[2S0-S
MN+CW,"LKYZ[JVI<RP9EZOHXL*"K((N5>A3V52TW):F]*OB6AS-7KMD6M-B8C
M"H6E&,:%:<4,%R2\FDP&DOI^6WMC9RI)4MZXRG()53&5':6XU"H\0I%OR9-G
M86'H83/[(=$Y^J=MJX'-0X&16NHMIJV:VHU&R:HQ>!J1D.C5GH)E&75M!`DL
M1HEIDNFUBBJM=W'8WTA75]W7QZ^U1)E2R)#:KVF^FN1XG$R/#-/LVU&L+ZIR
MS*\,Q?3&51:A7F5XE@%5BTS._P#HF+R9\C$,_P`2OLQI--[S2S4"-BV7U^J$
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M$3*5ZO27K;23NHU'B8_@OU%KPC):K0_`L8SC*8N81KYZ-?/Y9$K'&$::HJ+"
MHI386EV,EG%CW7W;+NV_NOQSN.M<VHJW!<XP.VPW&-',[1#S,8RM5[@FNF%R
M<QP+(X#F,Y!?LQ%OIJ<BIK:CM5PKFILZ1Q;\54*?7R7KGKGVH:7]PF48?EN>
MOY<W:X/@6M>G-"G'<C51PT8YW`8E!PG49,R,U"D";83*"MA,4\]Y9<H)+/OM
M8EF4XZXNXZ-=LNGFAF29!E&%S,L?L<ETYT:TOLV\@OQ<Q#C.A-!<8W@!C,+@
MQU1K2/6W]L+BQ;="[R3*$JP;6]'C%DB<1TG37]*\_P#X?5/^9[KI1>DZ:_I7
MG_\`#ZI_S/==$2B]'1T=$6*9W?66+85EV2T]4F]ML?QF^NZRD7,9KD6\^JJY
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M;M,L>TKU'JJ;0;/,BTNS'4Z^=P:-ATK/:/&=,,RC4=%`@Y?89G.1>XKJ="NZ
MNV=QF/5,LTUG#MI5=:NU]?*0V%WE4>+Y/E&&X[@^OVK>:9/W5ZVZ&8]CMA.T
MJC,P,[TST-3K9*Q_';6=D6,5M)IK9XO2RAALO()4^WC6TR?]4TF"RY%:;==I
M5H3AFCV0ZU9+B<K)'INO6J+^L&=,7ETJV@IS25B6+8/(D4$=<9DTE:[C6%XU
M`-4RZ[$0NL$MM*)<J:])2^#V9:65F>1M1H-QJ$QDD+7C4/N-B+&5-+@LZEZF
MZ42]%\EE"$Y3K;72#`IC]=5X^ZI=?635_2[*38CUB1(G&[\=&I=_@NI34_6O
MZG=0NS_"=>,8Q?Z)H7L/L*K4G5G#,"Q&J3CT)N9F;FM<[,,VH<1]VCRW<6%9
M.#<9<^6?>VU#I>]1&15DJ%2Z":V2=3("M3YCFE=A15V+9#?XKI)-Q2!D&<X)
M89I/QJJS/$,DF9KCE7IS;P7(K>77TV12/"CETU\JK0W$O9YXW89(_A.:8],B
M]O>`=K*>T/`Z25J):76>9'C-7JAC6IF(ZCM9K0,8Y>X?D.).8O1-T$IJ0C*J
M7*:MB[B6\E4*):2W!W'8SI7>P-,G++-=>'LXTMGY'(J-7$:VYPSJO>U>9Q*:
MOS3%,PS%F:AW(L/RJ!C>-1[/&WX;%?&=QZFLZ1%1=06[,D2(YCWCY"_D/<-C
MN7X+J)@F':*=RO9SI)C65Z99%ARLWR>RUXFZ"W=7$RVDRYAR-08O,M-6*O'L
M]A0VI5R,-7<1:62WD+C<J$K3O?AIQ'FT\ES#\\D85G*=>H6E&=5T6BFU.I&4
M]M]?FMOJ-B%?#-TQ88[;3JG3S-K7`I65-U5/EM;BMQ)584ZA6,VF19?V1:-Y
M=8ZCV#LS4&B1JEF>@.H.45>.9O85U,,R[;)>&2=,[ZHK7X\YFIEL-Z=8'`OD
M1?N&05V*UT2:T$/VBK"IC=E&B4,W3$2-E4>FFV>L5]C.-IR>8[CNF>1Z^P;N
M#JSD&F=7)9?1BEEE:<HRQY*&W)M;C[N6Y2G%Z^DC7]C&?(K;VK]Z&']T\^XJ
M:;`\]T^M8.D';[KU50,X3BSCE_I5W)8Q>W^GN0PWL4R+(XT*:B=B66T%[06K
MT*WK)U,W+,9RNM(,A3R^FN:$]HNE7;QD1R7`).9+G?S&:']NZ6<BR9R[@HTV
M[>(F30M,8J8KD*./IJLCYAD"+.^4XJPOE3@[:KD.QXRVG1]$1T='1T1'1T='
M1$='1T=$1T='1T1'1T='1$='1T=$1T='1T1'1T='1$='1T=$1U#8#Y`>-]O'
MX_G_`'_AZCT=$1T='1T1'1T='1$=0V'GP/.V_CY[?+?^S\'XNH]'1$='1T=$
M1T='1T1,LU8_V_OO[*G_`))6]'1JQ_M_??V5/_)*WHZ(E2[6?Z!=/_\`LUW_
M`)GNNG`]-^[6?Z!=/_\`LUW_`)GNNG`]$1TQ7O9U5U:TSN^S&JTMR?'\:CZO
M=YVF^DF?JN\;?R!^TPBVP;4[,;"LJW&KZF%:[+DX/&CRWPB2^]$>6TP[#2'U
M/OJZQ',L`P?4.#5UN>8AC>95])D-)EM/"R:EK[N-593C<L3\?R*N:L8\A$*[
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M1O'<9M,<[2HV;Z5XA<YC-L,!K>YSN7NM`*!N!*L3'@XA2UD.`YE^%R,C?R>Y
MU-D5.74T>BQ6LH%Y0]MMQOMH[?<.O8&3XCHQIIBV15>-9'AM;=XYA]+26=?B
M>7W4G),HQJ#+K(L5Z)0W^0S)%[:U4=3<*9<.?23S*IB&WD8]$[.NU&!`I*N)
MVWZ(LUN-TM5C>/P$Z98@J)2X_19@C4"BI:QA=4IN%5TF<(&74T)A*(]5D2G+
M:O1'F//.K(D-]G4T(VG?</";4^8U?WW]\5=!;?DR91C0(/<9FT:%$9=ENO/)
MBQ8[;;$5@.%J.PVW'82AIM"$[`^L&P+3/3[2VON*G3G#,<PBLR')[S-;V!C-
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M&05%)F>`C*8D&/DU(Y?8O=TF95\"#>5EFQ`FU-Y72D/5%/8UEU36C,B*]"?@
MRXEA764IA!$H&'YCC.?XU4Y?A]Q$OL<O(RI59:0E.>C(;;?>BOMK;>;9DQ94
M27'D0I\&6Q'FU\Z-)@S8\>7'>91:=4<@N<4TWS[*,>^C#>XWAF3W]0FZC2YE
M2Y8TM).M(C5E&@3:V:[">>B):D)B3HL@-+4IIT+2`JVZ4:>.:<8W.K9MNF^O
M;_*LMSC)[=B"[50)N29G>S+ZV54TSMC;&GJ(SLI$*MKS8S7D18J'YLV;8R)D
MMZ^Z@XU*S+!<RQ&%/8JY>48MD&.Q[.3#<L&*]R\J9=6)SL%J5"<F)B"6I_W5
M$R(J06PU[RR%%8(F8X!W]:/U.C6A>5=Q6HF%X'J7JAV[:8=PV18]1T>:N4..
MXCJ.J@KOJ@+YBY&]687C^39'`QVXRJ_M(T"K4I%Q?.TM<^"TZO5/6G3;1BNI
M['4/(TTHR*PLZS'Z^-6VU[>7LRCQF\S2^;I\?H(-G=62:'#\9R'*;MZ)!=9J
MJ"EL;2:XS&CJ6=>V5^S4MLKTUK=.Y&MD2&('L_V>Q!5PSIT\X7H$:]Q6R:U0
M37.9J$MSUP<4C0GL1,QR*J3,>F(ODL,MP5.S[CNWS+M>Z[!*V+JM]1-50_5H
MC.<75AS&58AJ''S#3RZPN/\`257)OJ:7'E87:VZ<QQ$3+*WHQ;PF4Y!071;@
MR:XBE2N^'M4B952X8[K-C;E]D*=&G:I$.'D4^J?B=POOJ-$K)[)(-)(QN#4:
MF2H#];BMS/MHM787#L"E][;MK2MA2LNUEUNQ?2#)]*8N6:B8=A%/EMAJ*[85
MF1XYD]Q=Y;4X%I=E>>W,7#K.BD)K\?LL9@T+N87DB]K[=J?BE)=5U;";LWX\
MZ*R:)[-O((>(N8J-<Z^4G^;;V>NG35BYIG)946.P'4B9J12VKD)O4!UHNZHR
MYSE5=1&Y`9QEAM,ZO79OK+"'4]R_;=::^6^CUO6YQ#PU6E%UJI=J9EXV_D*;
MYW4[0C4O0IR/ZC-]1&M125VIUEDC+O&:N=85,"O4F)&D29`(L6G=\O;WF.D&
MJNHNE6NV`0HNFV$8'G-QF.98GG<S%<;Q752O:N-.,ZL\?0SB>0Y)@^7UWOGT
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M5$2OW_?1HA5Y%IABU,YF667FI6NT;M]<K*/`<T-G@V:2M++/6:,YGM3,H(UI
MC5=8:>08>3T;\^&U]4%%;1;ZG][I8EK.@72B[N-(:S3=C.\VU8Q*\KUS=89\
MO(L)Q#-X]-5X?I-J);X?E^0W5*\C([RBQO2]YJNQG4K/[=V)A\3(V)5G[Q3U
M=C"@Q\7F]K>JN7IT"R#5#N`@YGJ/H5KE3ZQ1LBK-(:O$,7R2/!TBSG1^VQ][
M#H>8V4RLL<@J\^M\EFY*G*Y[<7)6(+5=C\3&8[=`$LH?9]6&/KM;.%JZQ]4.
M4:?=T^D&62EX0Y*J;+3?N<UJOM<RF!33,LD(KLSTTRC)[RMH;YZ3.ILFI)[L
M?)<;6\W7/5Q$YN+W@]M\W5%&C,35*GD:BKRNKP<4S5;D:H"<NO\``/YTL:QY
MW*OH7ZD6++*]/^63XDR]?(&5P6I#>.JLY<=^.W;(7=+@]9:7[>:VS-9$F9OD
M=+@<"CI,AR6ZDX9AV046F=YGN3Q*"!:2*/%G]6I5KCL7*;*+78RU"-+(79.-
M2WI:&T57LXVL2LX;F"ZGQJ;'L<UL[8M5\*H;7#Y5XJDJ.UW0"KT#Q+"[.R&6
MP'KLW=915&1V61>E`>BSFY4!JLE(?:G1U0U/[':+/SH9'KLO.'-Z"4M!!T^R
M;'<?^C=4L1R"IO**PMLEQ34:ON8=FQ!S:FJ)&,YYI_DT/*<`R^#8B9D%'8R*
M]IF01*-([UNVZ%A:-0K#/I=7B`GZR5TVXM<'S^M32R.WPW"-9EY)"F8PU98S
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M`XYW:=O>6PY4O'M2*ZQ=B:H,Z+FH-7D5?DDO5"7B:<^K\0K,8M:>#D%K/M\#
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M2Z<YQ`=SK/NW^HR:_P!0H.*/(H7H4\1J/"\NN*MER4S-M*^A?,>-[[)B0G9O
M=%VF-]REE@5B[G,G!;#3E<BSPG+L:IW(6J&GV7/7-#.^K#3W4:MNJJWIUS:6
MHF8KE6&73&0X#GE-:(9R_'[-BL8B24C<[`K2'DN/Y;C^M(K;K".\#7CNNPAR
M=IS&M8L,=QN":E8+J%@.111E\!%^W7,:H7=EAF31%43M5(KJAB\I<D93.]Z(
MJ[N$[^\"Q7MTJ=:-`\IQC4"?EE+H/G^&ILL:SJ?0V6F.M6K>*:>4F2WAJHU5
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M">YK7+2;2ZJ@UV4U$?+<!T@P3`,_DS[2XOO?*-O.X&.978WN0T";>OG"BJ9U
MU!H6JFJLI+"TZAZ):@:Z=MF'Z;ZDYI1T&K4.7H1G61YEC>+JGXHYJ9H]J!@F
MJ;C\;$95['?.+WN486F'+IF\F:F1*FP?9@WA?CL3%M:<]FDBQSN9E=[J^Y+J
MKGNH[E.Y*^HJ[#'*F3*A=RO;+9]LE_@=;<C*I;E6[C-!<3\JI\N,2;(E6_NU
M>]2L0V79$@B?7IAW`Z0ZQW&5X[IWF<&^R#"86)VN342HEI4W%;0Y[7R[7!,G
M^C+J#73)>*9K6P)\S$\H@LR:*_:K[%-=/>>@3&F$.=]HEV<MMVRT:RPY9IJ7
M.\ADM5N&ZCVLB95:6Y7(PK4U^ABUV'2I&3O:=9%%=C9W`QQNTL,1@J8N[^+7
MT<J+8O9?VPZ!YWH7C#5%G^K-1JY95N.XQB-5D59I'B^E-A,I<48D1X=IF0Q^
MTNSE&:6K;K*[VYCO46.JDLN/T&'4!G3TR6VX[[/B^H%8TI6L5=-^IS&^_N@;
M_P#$"6P92^^O4ZNU1L9RE?5J_P"@=,;*KCU%:PE*SEE<X^]+?I)9;4V1.,I>
MZ;2Z?G>HD%.LFG.0XUCV"]OF64N/XO19-,RV.SKU+RR)I]:JOX\VRI,_A:Q2
M:RO@Z4T.$TB;MV?5W##[ETY;5K4"C9[[NU!^WT]H&=7JQ^\U2K[.UPVICX]F
M<F=+K:'40Z39//MV8^-N_4I"P[4<+Q#-Y>6*I(V$VS3Z,J=J&&''TL_J_9<7
M5-642Z?N%=I\PP/2KL'P?3/*X>F<>2SCN6]A$O40XOF-]CD_,78.44>J5/JA
ME5#FV$"53N55<\R_CF4Q[=MBSCN)O.S.TSS4RKU`U1U2:RMB7VIZZ]KF>U%+
MA36&.Y+6:]YIC.7Y#DN.SH.1V+>(?0#&*0,=QZG=BY'-57R'K&XR.RMVA*>(
MEJJ^ZG0JYB9%+K\X0XK&J[!;F57OT62P;BTI-4KGZG=,+[%::?3Q;/,*#4;(
M-J'!KS%XMM59/=;U=7+?F@LA.[[V@/:/BLR%6Y3J[&QBSEQ</GR:W(\/U"I9
MV.UV>YG?:=8M:YM'L,285@5+89YC-WB+U[F9HZ:KOX;=?;SX+\ZO3*3Y78;5
MW^+1*;4O(\1U/LZGM_P'MCBN95IFU)Q?(M*L/S2BS"\1FF)JREUBPRO-UXQ1
M,2+^CL*)O#+2`G),)@5DY8CM-IH^R[+)^K^M';K=Y/GM[HUD_83HCH/D.J&>
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MUH#G^/Y"QH1CF%W&1XYV_6UG9T5%G+N-97M?9?D;<N#`O,SAFFQV*BN,^GTX
MAV5C,D$B<M"[R.VF;9U-5_.O0U[]]CV5Y-22+R+=X]76D'`<9B9GJ!`B6E]5
MUU>O)\`Q6='OLZPY4A&5X?6B6]D%-7FMLT0L^:URT]7I[FVISLC)X.+:<M7S
MV9BSP'.JW(J5K&JIB^MW#AT['6,LL4,T4J-<1#44UA]*US[4BI]^2XD%KV.]
MEN78KD6LWT3K72RM/=2LGUGSW%L7R;0G`LHRG!,MUP8NI64U<[/+.>KZN-+H
MV3Y-D>00<&M<9KKA^-:N8G;9O88G'8JPNG;9V\TO;EIW:::4-I+G8A)RR\R#
M',2<DW4S$].J.ZC5S2]/<`A9-=9+;TVG\*;$L+6HQB3=3:Z@>OK&GQYFKQB+
M44L`B\XYW7Z'9>Y.;QC*+:\5`IM%<B<-?A&;NHE4'<.M*-'KJJ<./);N:S,B
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M)6]'1$J7:S_0+I__`-FN_P#,]UTX'IOW:S_0+I__`-FN_P#,]UTX#<?I_N/^
MG1%'HZAN/T_W'_3HW'Z?[C_IT11Z.H;C]/\`<?\`3HW'Z?[C_IT11Z.H;C]/
M]Q_TZ-Q^G^X_Z=$4>CJ&X_3_`''_`$Z-Q^G^X_Z=$4>CJ&X_3_<?].C<?I_N
M/^G1%'HZAN/T_P!Q_P!.C<?I_N/^G1%'HZAN/T_W'_3HW'Z?[C_IT11Z.H;C
M]/\`<?\`3HW'Z?[C_IT11Z.H;C]/]Q_TZ-Q^G^X_Z=$4>CJ&X_3_`''_`$Z-
MQ^G^X_Z=$4>CJ&X_3_<?].C<?I_N/^G1%'HZAN/T_P!Q_P!.C<?I_N/^G1%'
MHZAN/T_W'_3HW'Z?[C_IT11Z.H;C]/\`<?\`3HW'Z?[C_IT11Z.H;C]/]Q_T
MZ-Q^G^X_Z=$4>CJ&X_3_`''_`$Z-Q^G^X_Z=$4>CJ&X_3_<?].C<?I_N/^G1
M%'HZAN/T_P!Q_P!.C<?I_N/^G1%'HZAN/T_W'_3J/1$=)TU_2O/_`.'U3_F>
MZZ47I.FOZ5Y__#ZI_P`SW71$HO1U`D#Y[_\`<E1_]@/4.0_$K_[B_P#\7HB]
M='7GD/Q*_P#NJ_TZ.0_$K_[B_P#\7HB]=)WJ[J-7:/Z5ZDZL7%7;7=1IG@>7
M9_:U%$(!N;*LPZ@L,BL8=6+2=6URI[T*N?3%3,GQ&%/<4K>1N-U"Y#\2O_N+
M_P#Q>L)U*P.AU5T\SK3'*%62<:U#Q#),'R+Z*DKK[)=#E=/,H;EJ#/##RX,I
M^LGRF&9K39?B+<$B.I#[;;B")B51[1JGL;I^NEZ`ZNT];4:@]M&)93?3[33!
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M7HWJ5C%Q0RZ^9C.H^)U2OHM61TSD5JYK2]"O*VPCS)[<KSF?LZ]`<\KKF!D%
MKK,\O,M-:O2S4VS8U@S=JZU8QRAS*;GV.SM1;9<IZ9>Y5CV3VMR_297'<K;N
MMI[B=B<>4G$?=:**1++W*]Q5=VW86C-;?"\DRVL;CY?96<FHE4-354-3A.&W
M^<VTFYNLAL8$./,M*W'I%)B55&1+FY%E<ZLJN,""Y/N*Y/-"^ZVWUQU\U2T]
MIL`$#2[#]&NW#5;%,_E7D=%Y?HU^H,QR:'#ML2+)D4YB0L=1":;3+D+8E0K%
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M4&LT?1+"L;=[D<^]_P`LK33W>G&B>,2<:J\4P:/C-E85]\UFD)Z'J%4M>B_*
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ML9`YR93D>)#A,-M-QX4"N@P:RNB0ZZ%%BM)([VPZ=1=2<_U4Q.?G&GF3ZM(J
M%:K-X#E5ACU+J'9T-1&QVHR6_I4L2H<;,XF-0H&-JS;'10Y9-HJRGK+&XF1Z
M6H$$BN.8ZBY/HGI1A%AE]9)U,S9TX=AV1V]"JAP[')&43JTLW.;9!99!/@TV
M#8:]8P)<N0^\N:N`_8UM)`AV$N5%;6SNJ]J=I;D-/@>5X]I)K%:81F.G/:MJ
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M)M$/VD.(66IU]I?`T@U+;L(NHG=-HWBM_;S<(A8YE^K7:QA36HN28O'<@Y);
M7=-499B*;*RQG++:D;KF':J377,>%9/1(K^):7>TLC7W;5@NNV>Z47S$J'VX
M:+]S?<)`P.SIKZ%HYIGK?!N+/%,@:9FS85EEG&BQZ]S&XQ^E;?NZ/#ZJ3+?$
MV[=KJ.R7ZI[#M":G.JK4-L9O+OJG6C7#7EMN=E;[]7)SWN'P=_3K5!<RN1`9
M:>H[;%)4J!74:%,Q*%Z0N?4&+-2T^W;\8]GMVX8CB]3A=/59F,8AZ)XAVXWU
M3.SK(+)C/-#M/;J?<:?Z=9TJ:Z\[?5&%M6UQC]%/0Y`OV\/N;C$9UQ.Q^TG0
M7R)5NY+N)KNW+!OJZL\/O\LK&H>4VD]ZHFT536U=7AV'7>;63MA>9!/A5[,^
MWKJ*148A5-EZ3D>3S*ZK28$1R9:0<9U/[O\`3K3C0?3;7Z0S(.(:M_4`C#I6
M23Z[!Z:"YJ9C;F38DO/\NO7%XWIS76#*8]$+K)YD>F;RVVH\<<G(EW$1:LKU
MS[8]+^X69B-CGZ,K:GX77:BT=3+Q;+KW%'GL=U8Q![!]0*&P54OMIEP;_'W&
MV!("6;>HDQF)E'9UD@OJ?G?6WX$UI/IEHW#G9C&PW2B@K\5QYA62RK*5;XU7
MX'::;G'\X5=QK6!G=+/Q6WE1+*JRJMM*^7,;@V:HR9];`?CD2(4G>X[:Y5FF
M`6&A^=8WJ%CCO;-)Q[#+K(\)^ELZQSN4;D^XY10.UMI80$5&GDZASRFSAV5*
M_P"CVFGN4?1RY58*FTLD^P'OII==J[MMSV#IAW`::X-JQW%R],M.;N3<:2QJ
MW/KNHP[N/AWU?G%)697E&0QL(J)VD5P^Y%3%I[6?E+F"6=;+E8\S;N+573GM
MLKZ;6C"<@>T@Q'3S".U72I_0?MFOJ3.K+*LER3`;^AP:/+EY+1R\=K6,;9PF
M/BSV*XI!M[O-[-9M<INVI]6QD$N+/R##>RK1_`\"T+TWQV9G4?&NW;5:_P!9
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MN,V$&396UF_*L[:REKYR;&TLI4FPL9KS\V;(>DONN*ONX_3_`''_`$Z(H]'4
M-Q^G^X_Z=&X_3_<?].B*/1U#<?I_N/\`IT;C]/\`<?\`3HBCT=0W'Z?[C_IT
M;C]/]Q_TZ(H]'4-Q^G^X_P"G4>B)EFK'^W]]_94_\DK>CHU8_P!O[[^RI_Y)
M6]'1$J/:T0-!,`)^0BWA/]@R:[W_`/5U\V[VY_M$>]+2'VH_=CI9HWW8:Q:>
MX/BV1TE<WC&'Y;(JHU%>6>.P;.QCU\U+)L:V8(5E4RV54TZ/[@F3%<@2(S[0
M0S])'M;`.@F`@_(Q;P'\'@Y-=[^?P>.OE0_RB")`@>U_[SIL+@)4_*,4LK4>
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MS+>G.6=7R9582$,QVH<J$VVF.ZIL/)3#Y(4M:"`%$*4H?$0GY=7Q2**J3333
M9R&@SG;3*1K99X`-=%3U5'O=TO(#-!\!>-!JPASO*]L?6V$IY[N6[OI+LIM?
MIQ?YU+/),?C%]Q+Q-?CLJUML<K%,A/IQC6U$`0F5.1HGH,.N,JL]AWQ>U]BS
M/I%WN;[X(KJ$`BK;RW.I>,[H;](H5B5;'7B3ZG4$.^HY1OJ7*!GOK=F)3)#U
MU:BZ7N[+D5\^.">*7&I4Y/Q%7CP[$<2D^%`[[;J)W/+QU=H>9Z</+08=MD<,
M`_#Z4@*5N=B2%*C-;;G?;S\(^7SZS[3_``H\N6KY!OMO;L/IQ<42\U//C_W>
M5KZL/:&^U;0I+\WNO[RZM<1UE9:A95J9BM1+8:6'BFRIJ>LJ*JS2X06I2K2%
M-7*C<H3I5#4(_6,7OM/?:7./@3N]KNBQID/OK;-/J7DV#*+;X3P1(=QLX[)E
MQPGQ$:L7)C<!>\A#2'N;CF_C3V/@MOAU1ME=\_,FXM?9"GWBTE19;DNDR.96
MQX:N#Z4I0ZPH.?`4ATIX%/R/5IQSMPJ=;\I7!K<X..3I+<V0Z[=SC4TKZ(K;
M2TJ]*_8G19$I]9+:GXK#,62L(4VE7):NI&*!^RGTVD=TM9U4_#U?_/7-WG(2
M)#6]5H=E^U/]HU.B+2>^ON+K4!3"W)5!J?84UBV63L4KN\9147/IRN8]Y8,U
MUJ8M`7,2^2#U6M^U.]HJ_"1":[X>XUQ!1[LJR_G,MD9"@(!473E&XRQRQ5S2
M/I0W0L=PH&64$)/2"GV3R+6%'=D:FZ36,Y^,E],.PHM++)MN3ZA9+*["9BSH
M"``%>\*2CEN"!L>1MDOV,=A=-2*YN=HC9MR5OQ5)B0=)ZYUR.M"6YBFIL+%X
MLN$X/6<2VJ.\S,Y#UH[B%>FL3VE+-P`90`TLY,.\.)R&[T/PV-E\15_]@XT/
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M3`[-)8<M7ZF@@$XL$V-1I+%RQ!D>SQ8.!:]J%[1^+SF)[X^YZ6IQ:-XUEJUD
M&1P$)+P+GNE/D#EK35`2O=(%)"B%F*#"CJ;B)#`FH]J)[1_WAV:KO=[G$K6$
MI]Q5JSD2L:XJ9;"GHF).K7B[24;A:"W0!29.\L*1+4Y(+2WM-M1H949.G&H<
M'9?!PRM/LUBE&X&_+U*,)"%**E%90$@D*]0*^(V>7CU]`;=$R@R*(E)1Q5)H
M;B,`TC8*)3*A)<V*@4;!(V&^Y*D^)B.[29T&S#7:7OL%GQXS?-B07!XJG#ME
M=HN=8,!/2=]J#[1E^6Q)'?#W-,F,4A<"!JKDE33OE!2XD3\>J'Z_'+,N\P)(
MM*F;[VP$1Y0=CMMLH\2O:B>T8FK0V[WQ]R];Z+BD#ZG=6,CQ-<A;H2OTYB<3
MD49GAM"$J9^DC*0TE;RHJ(WK2`ZP_<AYU$A8AI#K);6YZC2UI20I7J)>0WQ0
M?(('E2N0"_'FG,J,'%O)EQE<D*WY24-H01Y2EQLJ4MYTA)5ZJ0A"4'CN=_(4
MTR``7`R'^.;1F.;7*CM,5IQ*_P#W5L==QT$_]WVHOM'93*67N]KN2A*]4J]X
MQ[4FUQ><HA:P$N66,BGM%Q2VM+BHJY:XSSC25R6)#B&5MR7/:A>T=5$$57>]
MW(MM*4B.+%C4FWB7?!M:"VLY/%3#RI-@\6U(D68N%S9@6IN8_);D.AQB##S*
MT-[N,.%X*+?%T*2E:N9+J%$\ALA13Y4"@G9*4A(V](2VE*D!/P(0VXVCGZH"
M4G=*T)!6OF"2`D[N-[$[;$;0PD\(\@S/N-6;1D[7$^O$Y\=67,S<>613\HOM
M0_:.Q(ZV'>]SN2?#GJI]>UU*L[JYC^LM1Y-9-;-R\A]0>H!$<^DR[7!+2:QV
M(AAA+?B![4+VC=>TVVKO?[E[)U3B75N9!JA=Y>YLV$-E#<S+?IN;&CK0E*G(
M$:0Q$=>4[)+9D+<=4Q(QW5+4HA0>W6A+CO)S9MP(5]Z@CBV-@E((Y)2DG\74
MY302@N*0L>FDK;!0YR"./%2P"G=?)/(;\0?!W^(I!$#(4^`$6:?YN)F2[7%,
MC$Q(_P`JA$"SQD#FGS,^U`]H[#>5(C][O<Q9I>3]U8R'5O),FBQTK6%!5=#R
M1ZWAU/$K4E2*R/`YLI8CJW889:15,>T_]HNF6J6OO>[GE!S?_H,G5?()>/IW
M(Y^ABLUV3B\+BD`M&#31U1%E;D8LNO.+4PEIQ#B'%MA81R4@K7ZB'-SQYAQ+
M@Y-E((20"E(`4K?RH"+:=UK?]YY-)Y)2T`GTT*;4E*UAQ.ZG@XX..W@)'(IY
M).Z3#Z0&VOH#ER?(<D&)B#]]<?YU7<:O,?>X#)]TKVH?M&%SDSAWO=S3*VVF
MN%5!U8R2#CK@:!!5*Q:%(8QB>MQ3N\AR?2RO>BEKWOUO19].AF>U&]HW-E,.
ML]\O<]&8CMN(+&.ZJY%C+,E3BD*!LD8Q(I(EJXE3?%L6;<HL-K<992EB7)#C
M(FU>ES<2A'INE94DK6EUI:C]T2$K2H)04@D'[WR>*MR#U3I4X0X4)0>`W04K
M0A#C@!*6DH2>2`4\=N7D@*6`$[;2&:P?=FR^S7!!MD(=IB3_`%*\Q\Y;*9.?
M@0SI\]A[4;VD%@"E'?!W'U<9#B]Y&.ZHW6)3.7I.MJ1)FXG]"3GF$.K2$PWI
M3L5+[;;R62\VTXW7/>U#]H\N*8;G>SW'LMK;:2JQKM3+2IO6%Q^"PIO)*E$#
M(U*?*")LIVW5*G-K<%@N4V^^AW7[/6D%*2D>IZ3;BD*7Z:0D<UH+;NX`4AY1
M*QOS6G9*03OM`'U8BVF9$=Y7WY4I+P+*W5+23Z?E:>&X"2I2R4E84K;CU/""
M`6`D`=T:`/$N(DL#EF%(Q,5@^)B,6![U3,&8DO[;&2`_?[*A[1:/'57'O;[D
MI6\=Y*K)[4JSG7K"'G%<9'U3SQ)R7WMOUN$:P5=&;#0ACW%Z.TQ&#5-"]J?[
M1Z&)$-'>WW(SPTZMSWR_U+N\OL>2P&RTQ.RGZ8L6XX5Q,>$U,9A1E^L\VSZC
MSKBV`!)#;BI,5L/M-LH)5ZK27&%<VB7$MIV2ALH0DJV!&R%.`<-^IOIAAE;B
M^,9N2QL.:ENOI'%L(9<!3LM*5I62\VGX6SR4E)(!OP4Q%)AG:DRPYR!+>:MQ
MX@;^I6\?W";M(:K2P:S`C(]('L2.]CO![B_:<]IVBFN7='W`ZLZ2ZB9;EU?F
MV#:C:MYIE=1=QZK3'.[ROAD7-G(F0&F[6M@V;@HIE:B0]!C-2TOQX[3(UL=P
M?M.?:*X/W,]P&.8MWN]R]=C=!K?J]BN/8PYJUD]UBN/T%+J3D5/35E1C%]+M
M*&L9JJV!$AP#"KV'HL9LM,.MH>>2XX;^3P)D_9BNQ?F$(93G.=A*>*PX0G1?
M4D;@*&WIJ4H$J3\SX*B/AZ;+W+:,1Y/<?W!6;N"X_($K7_6EYM][*XS9?=D:
MG98[ZCB4/\XZE<@5(6C[DK<;#CR&1-%%9>D$$``!B!WB[NP>,^3KM^'-=6&>
M]Q$8E5S42S4D`EB8<QY.5A$CVIOM+434V3_?EW.M+2M!;AMZKY%%QA(0R6>,
MC"V'D8E-]3D7%JD4CBG)7IS'B[*;;>39I_M7_:62YK+SG??W1Q$Q%`-MX[JS
MD&+UTL)=]3G95..NU=7<I40&U"XASE+B\X:B8KBV58HQHT0L(;TVQ-;:EJ2K
MWO,F@EM9!.Y>]8C92U+"=UI\D#XMAUE#.BD=*W%G3S3=9:94H,*S%+P?5Q`#
M?(N-H0$K/E?)6_D`<1L!Q,+Z!Y4;;G++^6O33B"#554[N6KI\?E=SG+/-RYO
M[WM5/:5V)2S+[Z.YNO+3Q6P]C.JEUA3LIMYE2"F2YARZ*9+8;.ZF8TU]^.P\
M?589;?07!YM/:O>TI?<8K5=\W<I!87[HMV94:E6./7`])WP#D%$W67Y1(*4)
MFH-DI-DE2_I`2DK<*L.=T=GE\>AI?IN.;X#+8S:.4A*=@6RHJ"0$$'[IR2DD
MI.P'(].E[7^UO23-\RDLZ[5.GF&8]&8B_1\:OS.$N3>SGG#Z\)VQD2&V*IJ.
MRVE7)(?=EEU3;*H_I!2I[3#']NF"#'`?L<MMW(90*,0U<7&7(8@\=(L!#TL+
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MH%88=7$`<2MQ2)#M##3A)S8N3X%:[:_VHWM1*[=QSO0[M)<9YT+<<R3.LWS#
MTVVFR$H@SLUB79@(6.3C[4*3%:E*+;DIMUUII8N-%[5CVBB9,M]??3W03G'7
MUM.P+C57([ROB+6I+@,"ANY%C1TR4+5Z;8J*N"8\<F)&4U#*XYV^X-K5W(W+
M];"N(V:P4+;Y.^]X?(F5:WMRK>971L$#3+*@?2'%EX-)2A;G)(41G.58YIIF
M5?.D]QNE6AJ:Y<3WE=QJ'C."X7:HFI9W])BY@2L/R2*DMAUQ5DR7U-%*BW&<
M6M+8#$H,'#`!-PSM$,:6*5X-1`;%KI:S$AI<R[^)<ZK38_[4'VCC3\BP1WO]
MS9=;CR%(KE:K9"O'0M,9:4<<04\K$@H*`=2I-$%IE;S$J$TF0?K4=B4^;;]F
M/:U=VMK.NKK(-!],<COY]E->L9QR/(L4KKO(H<F7(6Y)4NLNY\^L#4E:Y45,
M-,62HOLN'KY+'=WB'8CC]2_*[<,XR!.=H>=5*P?%[&TS?2MV,MH>^N-93?PX
M5C6NQTAQ3;<6;>L/+"63Z7(.H^LM[/N(J+V/=IKJUA1M^W[2W)@D)XF.C+<3
MKLH1#6=R''(*+=,-U]/%,AQA3Z6VDN!M%*P!PL"'>]/"<O,;OJJ?#"JFK$HJ
MQ.T84$$5&H2:P6<EC`</S=D\'I.FOZ5Y_P#P^J?\SW72B])TU_2O/_X?5/\`
MF>ZZS76M'7MA]3LAP#5C2%FHS#(,9BS=-\@DRT5.1WE1'<]'+&FO>#!JID9F
M7,2E89:=>2M;:%$`E"2GK5CA.J>J=VPX_$U,U$LB9TD>HK.<J(:2$A3?)Q5P
ME(;;94`?3!!40D#D20\GV]3,Q>N>@K[#D6-'B:390X[+>;>E/)4[FS+?I-0^
M0BGFGR7WTJX$>`-@>M&:=6;F%7_0=3=-U#[8]W95']!3TI+*.1*WF@E+)5X;
M!/WP^)2?)W(MEUIKSG^+L2TS\]S!^<^EY*(+>=Y4M>Q2?1?4ZFY5Z(Y("=DH
M#B"YN=ATE+?<)J_9R(K@SO-GDH0LV$%&HF9H3#;2Z``E1M=I3J4JWX@H45;!
M!'D],:P>5E,J&_;9'+7.>5+FNN*4RY(+;BG?4;1(<>]'WA*4<>2FTI:1ND<R
M24]*=83)$I##\6_;94VCDXW716%>Z-+;)<]0.**%@^F0DMI6M"CN5;!.Y$\=
MS67.K!/*IU6U"9]-"6IBQG.5*0S(6HI](%5NHMN-G;<'=(V&Y)W'5:QJSJ=!
M]W9.I>H,T+6$N$YWEA]-"P?PJMP%JX@JY[_-6X`\=,UI,L:A.10VE4=F3R4I
M3Z'7RI*7"E4B6TE"1[P\K?T0HI.Q)5\'R5MJY%BRTN.^VB2P#[N%(2EY_="=
MRH;J2A/P@$I'P>4G?YDB=!4:T9S&0[&:SG..,I04F1*SK*W7FN!W4D%RW/+=
M7(#@$`<AMXZNK&KN=\0EG.\W6XJ1LOU\[RH\3_\`LBV],)4?GNLI`_\`U3TT
MVINDR)?IR7E!]3JBVQ&"RD(!XK2'74GDD%+@4D;>`5#YCI2*MQ"I;2XC;C?%
M\[AQIQSU%*4.:UI7\*DCY);'$I&Y.P\]$2S66I^HZY*FV,\S=*7&4+/N^>90
MA3+RRH(XGZ7*2A1`!.QWVX*VW!.'6.JNKL9]B(C4+.Y3@0HSE#-,I;2TT3R"
MP4W&[[W@)`;(2`1X`/7N6P0AL.H!:>W2ZZP0%+;WY%+"#\16@C;@A*N.QW\>
M>J1W&W'A%].=*<#OE:W>',LK0>)*@D)2L`%*@1X*0"`=MB*ZUFL&IJ2>>=:@
M./,@NN>OFF4K++?G8@"X'P?(GD%D;#=6PV.<56IN<OQT2+#47-%.2W7`E8S?
M*6U)6G8H0!]+%)#@)')MOD`!N-R.F^Y/CMW&<KWJ9]9DL/$./EQ7N[T(J"9,
M>6H#CQ4@G@4GPH#X2DD=5TN8Y%@-^Y,H6\'"5A"D+*D);]3BVI*E@<=B?.P&
MRDD$[[$3GQ?Y)*0U-DZB:A5JT**4/.Y]E#B"H)*0/-RDI2KER2%`#8[!/(;]
M8A,U:SEAQ<)G4#/'VVGW&E/.9AE*%$CPE05]+%2T'<A(0?\`S3N1N`@KEA8S
MD>\2"KX&P6U-OJ#2BE0!W8"TH6K=`YD@#?R3U+DY*ZRRVS)0K[D%GU$DI'IN
M$`*4M*26U)W^%221][MN0-R)8;?4O41CTV/YS=0F%R^"6TIS++-D)6?"N2;8
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M2H.HX+5RY`GD`L*)V(Q&RAR(TF2P@K0II03$=(7NA825!?'RVA*?]P$*(5R4
MK8`=$6>3\KU8B5(4G4S4:6^RH/*2SJ#FGO;K3KOWA6J^])A("ME`I<*$I^$;
M[;6_'\\U:FQ7[)>HVID:)'EB.XT_GV9-NMO-I25MI`NPM:0OAN\-TNI)/$))
MZPRA%H\Z&IBWV'F'2F).=<6I*W#Y4[,8=V;=B*"CS1Q`X[!!2=E=9FVW+$2;
M&Y)1/>47'FFUA;2TMA/%R&XX0EMAU!2LA:MD;I2L\DA*B)1Z#6O4@E$:1J%F
MLE]*W4(6,ZR<DMK("5/(%T"CB`KCOY)!"@/'6?HU*R^7[G*3J)G7&8CA%;1G
M65K,@E7%Q88;M@3P4DG<E)2!OR((!:K(JI4<R+548-1WVW(+D5M27G%NED-J
ME%X!M16$E13P+8)'$;[`G-JBUCX[6*"GO6;JXC*XKS;2&@TE390AI3I44I<4
M[]SV.V_/[H"0"")7\SRC46533HZM0M0&6YD"PB)+&;Y4VZT%PWT^OS;NTNM!
M*5%1<Y!Q)VXD+`/6V?OZN+C&^UKMA757UU`?+N+Q9$R!<VL29.;;TL=)][G1
MY;<N5ZCC:7W%RGGE.._=G"MW=9TS,VBK:OF.!E2Y*:]Q>Q"EM^L8Z_50RYL`
MZ6%DH<6D%/S()!'6XOVCR5)[8>V-&_GZ3QY*N(/$[:72=Q\QLDD;`'Y[@$'H
MBU#N9_G*RE(S?,VDGSNG+\DV(^7D_2G(_AV`\@G<]4KV<YPDA/U<YF5$$<#F
M&1^1][NI7TGNK?SOQ^1^7GY8N5A0(6005`(2@;MI2!R\[^2HGR1N0/D0?F:9
MU*%^$)4HGB3QW2D`_AY;%:=_EQ0#OOYV!Z(LJ&>YSQ2IO.<T4X-QS.7Y+Q2/
MGQ"!:%(V`W&VY4-BH[]2UZ@9XV#_`..^:J)!V/U7Y,D;D;^3]+`'\!_!Q.^X
MVV`Q(`$#TT+(3\&_+CY_M!XA.XV&_P`]@2!OY".7WQ]1P$;-\1LD$;_?>/`/
M_J'C\?1%F[&>Y\L`KSG,6TIV*DKR_)1N`/D#]*_$21L-MA^$)\;FJ&H&;A6Z
M<YS0-C[[?+LC)_3N/I0_,^`-QL-OP[])^VMU7(*25*YE.W+9(/X`-P5;)V'R
M!_%N!TVO63N&K=/G9E'4%F5>1$-?2%@M<=Z!62'PHJ@M1TO%R7;QT);<?;>0
MB-`+S:7A(D%4=HB>-=:SV6.1#*O=3,DJV4A)X2,VR$2G04N*06(B;54N070T
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MEAS7%+Q_`GFG$L7=L^L`$%&/2E1SNE6YYI*N`40G91'D;[[>-T=R7"UMH>D4
M=@5D!0V`>A/^#R!^ZI;))(2H)23ML-R>/DBZ3,+UODZ@U2KO#M5;^_KDK;:D
M.PLSR3UX#RT<TQ;6O?LFI]7+V&_NT^,PZHI7Z8<"">LM^KC-?`3F>9%8VVVR
MW(@3L-SX^E"/(&X4?F#^,]<KV$ZY:D:-91"NJ>VE0YT-UD//'UW(MK%9+A36
MY+6-O-,9!4$+7RB2CZK!47X+\28AI]&_WMWU[Q?N`P"-EE*68=U`]&MR['DR
MD/R*2Z+7-*TKV2MRGM6T+G4LQ2-W8Q=B/D3X,U"")T:\VS<>?JTS([@*)&6Y
M&"!MX!_\*;#P/)\C?S_;X.;9L$`_5KFFYW('U69)\6V^^RC:'<?H`\']'6,A
M2MMBK9``"N7Q)_$?T['Y`?@V\>-AUX4O?=.W([CR/'P['_N&_C;;Y;;[$^.B
M+*$YWFJTIYYMFC:O"0/JNR($[_@\VH`_W=SL=]]^)^743F^9I02,WS(\?ON6
M7Y$GQ^A7TGX(V^+P/P>?)'6*\"I/D#P=]SN?GX&WS^(#YDD>/E^+JA>_\HEM
M.Y^/DI'R^$#?D2=@?/GSN2/`_">B+-1G.:'8G-LR.X!`&79&`/EOO_X4)5^'
M<GP/&PV\]=$_L]+&PM>UK")MG83[.8Y<9LER993),^6M+>6VJ&TKDRW7WUI;
M0E*&PIQ00A*4IV2`.N:H*"2!ON2#M\_'Z?E^#^[]/723[.4D]J.#$^2;K.O\
MX6WZ!_\`E^$_/HBNFK'^W]]_94_\DK>CHU8_V_OO[*G_`))6]'1$J/:V`K03
M`4GY*BW@.WSV.378Z^4]_*&:>-7^V%[T)#;[BAD>98GE#[,A`#4>:_AM)0@1
MG6D-%QI+6,Q'6_54I2GWY25+*$M(3]6'M;!.@F`@'8F+>`'\1.378W_[NOE.
M?RA>JDQO;"][CCTQ,F/D&<8E?1VG$N\H,1S!L=J17**W5H4$RL>DS>+)3'";
M)7`)?]8N:X/S^!\;+#XANSGZJ9S$AVW6J#1XK.K&E[*VHRY#NH6.-/-J6MU/
M_2;-AHD-@E1+[:B0A:>+2-R0`-^M[E\6VUJ;BUDBW0"XM+C;#*V&D\RA2%+?
M*#OR`">'PJV\G8CKG]Q'))V%9=C>:4\2*_983?P,AA1+'U'XTJ?42F9T5F8&
M'4/N1)?I%A]M#K<A$5;B$.-J6DC.>XCN0S_N0RRKRS*H>/XLBFJ45%9C^#MV
M%311F3(<?DRE1Y-E,DO3ISZA[V^^\06F6&D--M)/J;8M!KJI:P#$Z>!+_C3)
M4P:J::2+EWR:0&&VP#ME>=Q<Z6[$'&3CD:,/GSF+J(F_D?[SLAL$?(CSM\R?
M(ZF1K6O<9><>EX36>[-%9C3\VQ:"^XDCP(\5ZW]60K8[`-(X\O`(.X'/6ZE4
ME7J/E3ZME$*D+4[OL"I6Q>4KD=D_I/P@#J1[FTDJ3Z$)P<0L*9C(!2D^5!>Z
M/!02$%2=DD_$/"@.L^P/U#R6W:#0],_\:_;J)QG/<?K\9C/.Y9AD69]!2J=B
M))SG%F6VD6%C/L775NNVW%"4J0PVO914CUTDA(!WJ6>\[3+3N6PY,RJOLIT%
M"(:)%9D6G"JI264A*@P[;Z@19,E)X!(?$)EM(\M)*2E77+K'K(Z_+D5M*%<B
MV4PFG"L\5*"4$M@;`(.Y*E*!\;*/@037I]5MGT&6W.00!P2D-*>^%07LD<20
M?C2?)!\@'?:>P/U#RY;\]/NT=J)&8OU_);>RZL97M6M,3%=AF?5M+<9#*'EV
M^ETK9?,%2@VWG9*R=N(2'/A/S).P.*R_:B:7PX=A8*LH3S4,O6):CL83*+B8
ML):FXK'T5G3[RY$A;09C(0VOU9;S+);/([<PHHBMTDMM*0A:DN.-J&^Z2DG@
MT=@5@(;*0I(V.R>7SVFHK8:UA<=AQU2BTE9XK;<C?[WI/'CP"/4W4I38]4;\
MA]ZGIV$S5&@#'U<#:Z@X]+1-K2`]GF'EG:6B5M*[JO:R:[Z[9+#BX59/8QIA
M0M054=#D55#E7LZS1#VFVUZ["M7XP6);\I%5#BR2*^&&TK?=?4M0;?!]H#W/
MU:F?<\X]$H">+4:5ED(!*`4[M(AYA$;2D%>YVXE/S20HD%J[=&EU:?CV"C]T
M;YM->E\)6H)7L4+*4E)"=D[I^(';8&Z1J>(&E0U>L$!Y/):$(>2DO'F.*V4\
MBXI0^$(41Y<"MB./6G9T0.$6DF26:X8N^;#9I6)^)&I-B0`8!+&P<L[;G-V3
MW*_VI?>C5+0ZQJ;<)X)*6PJXSHM$G;X%H>S%U"TJ*?`XE7@;<AOUF,;VNO>.
MT[SL<G8M2IP!Q,R1;.-K6``$*][DV*2HD)!!*B1L-MO)U^BJ42A"TNN)6$)+
MCKSC91S!4$A3N_I.$(^(H02=B$;D]5B*BL=Y*DN.-(2"MULN(4Z%H42X%-I0
M&2'%A("D[*//=:DCSU)P\._"&BS]7T?Q5!\4'%^?$#<M;\EA:5L>B^V&[@VW
M.-W@FGE\4[I6;:KI)OJ%).X*+'%)NWQ[H)45#8>#L/%WC^UWOGTK%_VLZ$W;
M/+BXJ3@FFDCUBM&W!3DK3LJ\[D!:E\_`.VX&^LPT\/WD1FV^37!#CZ3Z>[((
M\;\TJ*PZ?CXC<!Q2O"0.HKH&&>"(S9](N)6\.92LDJ'Q@@<=T<?D?D.("=_)
MIP84!B,[D7U?:WF\S'ZP.'!+W=F#M?3(CS=BZVA,^U)TCFI*<F[!M"K0D*:=
M+6$Z9QW#N/O2J)BD%86D;'<%)V!!`))ZB/:(=FECM],^S5TKE%:B2_6-0JYW
MX4A"PW]%65>D#Y;A!0`I6XVWV.LHTT5`D+"I!2]S=5S<2H^L!N5IXM\^:RM8
M<4`KDCBCC\">O:*F$U'*?3(7P21R"N:=FR=DE(`2%J4"06RI12@KW&^U>###
M,:WY@1&<<O!0?BZ#_;I)&PT!S!SM&Y6U.I[Y_9G2&+%NY]G/*QVRF16VZW(:
M.5"S*-42FY;:Y,M6&Y;G#%);^K'2[##:Y<549;GKM*4ZTELX]GVM'LLM3X30
MKM/>X[3;(VH,P1IFFFE^G.'PWICW%;+5O3RM2K>CMRP4J])QKZ.>#:GFB\I#
M@+>LSZ&C)<^YLI5ZJ=EH7R=:4M*3]TXI6G[HXI0+A1XW3R"`=B*H1&V$MF&P
MRZH+94VO?=')"TI4V%*`"0I*OC42LI(;2!N1M/#0X[U9YD-XQKSL853\314&
M&#1,2!J#Y/XG97RV8HX]E+C4$JRE4JI<E<!^[A1*^X>BK62A=G`@SK*%#EE"
MT!]F/82V!N?2<4@["W+0E"%MI"?"5!*F74E'(J&SC:TIXELI'+B$A7(D*4/(
MZENJ<4XX\6R2MP)D$-K<*G5`);2E0^!83\0623Q0`02/FM=/VVZ^VM=II:P]
M(<T%+J[C6I.:::VTJ`U5463X'HQ&?GZL9S!NK>3`KX&%:=U[$B=EV5WDBJQZ
MIC19;SEB68LA:%I.UX>'.?VRF%RL:B13028+4@E@8L'8$D-S9RD64IMIL*+N
MR7"ZL.$*XDJ2A/@@$):`V2E8W"@-D\U[GJF*8Z6U)X*0B.I#JE/*<!]4)0IU
M3G#B5.[I(!W*@%)2?)*1E6H.#YAI?F%K@&H%#98MEE2:UJ;16K3#KJ&KNEB9
M-46<.572I57;TMQC%E7Y%4W-1-G4]G23(-S5S9%>^A\X/$:;D!26'%.1E2$&
M.^SQ?;FN1DI??5'>05QW`PA3;K[#(<<0PMM]00TM*S8,SN;.X>!#-;(M#P7L
MC$.XJ#$<P0PS`F2`!8C,2O+CJW6T)C(0X`\C=3JE+#SH=24EHJ5S+3:U`DK.
MZ?EL0E74&V5I+J'#(5("T.K#?Q(<0L+`*D(4T$`*2HA7J!9!2I*>0(3%3J6U
MNEQAB*MI+#SCTDJ0VU'0ZVI3KB'U)]V980M!??;*([9<:Y.)+J"J,EY*FW'P
MWNEU#>^Y5NMMIX);4T\RKBEI>ZDE8*P'VUHWYH4CJPT``D;L[')W#.7\(8)9
MF$0T9]TR8>XS$D0`R@RL1BN.M38?7R:3S"Y"76B>1:*$D@!2CQ"$@K6[N5DE
M04:=#'O<@I>2XTVRE2$I0A20E*=CL0HN*03S0I)(^Z)"CON/%`I6Z5N)4XRT
MTTTX.2&D\EMJ6P2IWB7".;@6CBM/,)W5L1L(,R)3#[K"H[HY-(6@NO+X.NK*
M5DCCLZE2RE(2ODIM""DD%/CJS7:[7WY1;<G.6*OPF2+PY)#`GA=@9=C(!JC-
MF6Z[^3T-M->V4[$D+^!]C-]1(Z6R'!X7HWJ,M2]UK4E?,(2H*3N3LK=0^1U?
M=U[3R.Z+N7*YT]A)[B-<U!#4YY*-E:KY@4``+5\:@?#8.^Y`"`3MULZ_D\KR
MG_;)=BB'U'FSGV?*9:6V%*'/134KFHOI^'="3MY\*W!225#K5=W8JD([G.YU
MU1*TCN.UZ6A?)9#93JSE24H5L0.2_N@1\(`\GDA8!%`_:'_09?Y&UN><YQ/1
MABHX5(%3?U*GW)%)<.P:YASH]DAL*09#+N\Z>VM*RG9RR?!VX_"1S6@'?R5`
MMG@H;;[>#(JW)+WJA4RP2&U#92);P0K=1W20=TD@`;[$_,'B-_,F)'<E1)"4
MH:;0\L;'PI06T4DHV404)4G;=1*R5`E6W+?JZQ(*(_(M.OE)XJ6DJ'$<"=R>
M*=MB5`+(VW`"2H@[=:*U50IXPY<D,+LPI-])(\-5%TNH<:VFSN+SJD**IKOI
MM@H4HD!04D_$D#99"1ON-B`DU3:RM!3ZK[FR>"B\MS=06D*V.Q0"-E`$I"5#
MRGEXWZEAM*@M!4>"QR4P>&R>2N6^X2%GXDG92E$$@D'P-IQY$>/)`_WMSXW\
M[[;GSY\_C^?X>G6@6)J=I+C/R.CQGR!"N=7F6>86')F&YSF>,+;XN%G'LLR6
MG:(01]ZW7VS`V3NI7`)\[GR#NKI;*SNX[K:I#7N7<MKDTT4(^XG4?(7FD@M`
M#B'Y3R@$`!*/BW``!)\DM[?6E#+I4I*!P4DJ65)0.8X[E24J('Q;<@D['KRP
MIIU+:V7O40VWZ.R%;MD@(\D%()6D)V!^'PH_#LH;1PTM8>0]NF5N.O@#&J"1
MQ!]*6#Y-+9REHR#NI[E,C8?JL@[A-<;J$\M`57O9]D;,-PJVX\EQYC0*2%;\
MB?`*@1L2`D3LV7:NB99SI5G)>6E:Y5E*D64I!7QY<Y$Y^4Z5I^:]W$@GR4C<
MDR02I2]E'=(*#LH\AR"5@^-@D[$*&Z5$^#RV.W4849AI1;*^#:BMQ:U;<E+"
M/PE*?+CBDC=122I2CN1N-I8"0`.0L(9NLE%59JI8FJ-W!@.2(F(8$R768N!M
MF"\EL[M-1'RGALKDE#*U;C;9*E*VWWWV43\]NOM#>SYCNL=D':FZZ04V>A&G
M&01-E*4H5F2X[#R"I0X%`>D\BLLXB'XX*D1GDN1VUN(:2M7Q:8KSRX:TN-(1
M'$*2D'@Y\FV5!14KRC98))2>).YX\E=?:7]GT)([(>U0R.1:7H3IR[5;J2IO
MZG7L=ANXN(O$D(@#'%U0KF=DEB`(S*FVU-EM/+B@@@'<OJ[>RU^!<'%!(+<#
MV))[TN+[IX72=-?TKS_^'U3_`)GNNE%Z3IK^E>?_`,/JG_,]UUBO07-G[?3-
M)V.ZOZ*5$1+/IV^D>3JD%UE#OJ(;S1M/I`^FIQ(`^-6R@G;YIWV4.;AJ0B++
M;=BE#9]3URZ(R9`0XL*YM[!"E'?[Q(W"22"HC8CKH3_E"S<AS7+0+T@M:?YG
M\G24%.S7)6>,@<G`0L+7X2$HW.PW/C?K016O*AML1E.M,//.K:6MMIL/-`<M
M]EJ*0TGDKBI8"E\N`V&_1%7_`$_8*:8C(*HGOR%QA+6ZIIQ;BE)]-/NP4KBY
MR6E"G2GC\2=_*0GK.J2(]&?C08RBZI3*53W&$JW>+/!:D*6Z@GBVI/Q'D%%"
M-B"5]);,8GL2VK6,M`2IMN)ZG`>NXM,C[L6UK6$J]3PI1+2B@)1P65*"`H-)
M77,F9(=ENKCPT%#<?B5%QQQ2%+*W'^6R4J^]0>"7%'\'PI/1$I)KWYL]*QZD
M=')H*92%[S&RM*G@.)],*`XK"4)._$\EI&X*K1*A]M$YZ`ZW7+2HB0XF.J3(
M6T0@H#A=W2A1*AQ+!&Y`Y))!VLN'X-.;5&D63ZY,-2TR1#B%8<:8*O(<W>"G
M>>_E:W5^=U*0#\"7!1<>J@TX(,$S(Z6W$+*%N+?*2VHN(0E)*W5^5)6R$J"%
M)`_WM^B+"Z6FCI2W*0E;TDELBQDNDD@@I!2PG<?$`2I8`2>04D[D=+-2U-@]
MZ`DEME3H]9LJ=V6&-@I"FFPKD.1)3N=C\DGR">O=720ZR'7.[)80X>:&9"2$
M*(2>+2BXA')XE1'!""TWQ4.8*1ODU@Q%:;@K,M$:5Q"TI"5.1T;A*5,!*3N\
M>)5LLI!:44*)W*NB*YBM/O#00EDJCH4M/#D]Z:U)&R23N&ED@*4M2R.9V43\
MNJ,*88<]$*DQU>JIXA])>2\7`I#B6N*$I)Y+'R(2$J3L.1W.24LII^N6Q!E.
M/2V&R3%D\6V'%\@H)4$@I6HIW6E2@M9("3L1XK;6<[!L&D(>@ST1DMO<4*2D
M+!;*74'CSW5Q40$M*6.:4;A(&_1$GSS<@1FHOHMN.H?>=>5,6M?*.I)4&T04
M\4;\CNVDE9&^ZR.0"<'D5<Z,Q#=BM/K;GK<;::<#,.*D[K64,(:!<W"2ILGB
MK?8)!.YW6=3-I<<Y<*OF(86UZA<B5DU2_26-Y"G7EL%3:#P"2HE"4@>"=^K9
M>US,.%$8%5:`O-\@X(DX.1P>13PD.,<&FTK*=@WQ6\K9`<!`Z(D6]S;CNML2
M$OA!#@2TTE3*4!2?`)=;"BE:AQV`W*AND[D@4[41;CSS#RRV\PE<=+;Z%+)8
M>V4PZAH[D+2H>GR6L\=@4['I3V79*9(CR8BB'4.,K][0KU4ED?"742D;L$I3
MS:2.2UIV5N.6QLUM6S'UL^F^ACD^6C(BH0GU65<"P'%(W*5*<!3NE*4^MLA2
M@1N2+";^OGLP5)@.!N:A"2/=6FGVG4H2%($A(4`$.J2I*UNMD^25)*@";IBU
MPA$B/&B)]5N9[LI]AAI188DM!2EIXA1+;8>YG9:O3&YX\?`ZJG*UJL`D3BKU
MVPX6W%<RI;3BT<RI2`4KWY)!2H%``\;<E;TD>`H(F)B+]%+R"HR60&2P%$(4
MAU21ZR5%94XGAQ)((0"#L2)9'L+1(CLR(+S0<4XJ0L^L9*4O.`+4R>)/%*"%
M(2E1^Y$@*`VWZQ2[QV3&82RJ.A:Q]V;<3NHLE0"GG`L%:GG"!Q2A>X0/A3^#
MK-L(48M8Y6+<><1`<0XJ.`I#;[4AM1=>23Q6M4@I*TE:P4J)"D#??K,5LPY,
M;U8ZP"DI4TI:?+8/WR/NB22I0)0%!*B"1L"//1$W-ENO#@C2'`VXXEWXWREI
M2U`$ALJ(V3Z@&Z1MMY((^0-`_`#$OFXW(=*.#D58;=*D1UD./Q@MS[FIIY3:
M7$I""M*TI\@>"I5_51XBE%^%Z[S[CBXC_(-K`0$KYHXA&Z@1L%.E+:]SX"4I
MZH(U86DBQ:;<F-R-HZXL@E,IQ22I;12ZLA"BE_<N>BE)"-DJ<6``"+$UI"WT
M-2X[CJ7([I(=<0$^DD`>HID%):="""HJ(5N4G<#<]8T8$R6AUB*R!#"A[K'4
M1[O+6T[ZBRX#NH!*T!3("5AQ2=R0`.L^M_NI7(DJ])`947([2$.<EMJ2@,M/
M*`=]5>Q2I*=P6@=]T\>BF=/H-OVGN]<CDL"(!LZECD4M;(!#_,#8(00@(1N1
MY`Y$5S:BH$))=>D09L>*Y)::YMH]8)9"Y$=32@H%"T**'5DME04E8XE!/6X_
MVD25N]L?;5Z)^^M:`\@`=DJTQE;$;;[$[@`I^1/SZTRQ9`*)I>"N89E/QVDK
M2LO-!I22IY:T[);2E2>;3?+XCLI17N!N:]HVK_XL';20VIPF?0E+:-PZ2=+Y
M!2E`VX;_`(%<RE*4[G?P!T1:3#%=*SL"CTR">1&_$[^$D>$HVVW`\G;[Y(\]
M!9>4HA*$AHDA*]_A'CSNA/QK)/R'CB=@H[>>JMO=M:TEMQU2T@AI*@M:3MY+
MKHXH;"A_N[D^/&^X/4X*44$@LMCEP6!X;2222`Z!\:C\E*`"2KY$]$5L#80%
M%PJ2GD$D$)"B0=O"4\@G8C;R3X'XOE3NMR-TE(0$JY;%((6I(V!4?EXV\CY@
M'Y*.X'5P<3LIP)2I)1MQ*P.*R#L"&U;G;8;!2@$;`J"3U(<5RV*4K'@E6Q"2
M`#Y(`Y>!^D`>.*?/R(D$U[U6A:4X3(M$RG(^0VZ9=7C7%IMPLV"(Q?DV[Z'5
MH2F'2Q3[PX4EQ1F.U['!1DCK2VO(9F9W"Y<IUSW!MZ0XVX\M:G%A;BG'9DEU
M6Q>D275+D.K<!6X\XM1)).ZT]_6JDNYUA7@L9](K\0A0L?2VGU$@3I4>-=Y&
MZ\A2PTXXZ]-KZ]*TMI*8\$MJ6Y^!#<#H9>4SX=%!0M#"O1>GNQM^7#F$M1FU
MD\$+D;$!2O#3:77U[(;()$N.%_3^1N)IL,;?@Q'%MQG[1#1583W^*ON$#QZ@
M)\A3;:VDH`"I#B&P=W7XYV^8Q10T6V<6[4>3(;$A]D*;ES>*B/CE3GBY':D*
M<"PN+%8=<&Z7"]PW4;EIY4P<9CQZ/'X<=5Q*2R%2W>0AUD3<KV>]%*WD1PZA
MHD)1[Q-<YETA3O!#@K&IP73^.FYU$NSD&7O-QY$7&&6A/N&/5:*URGZ-Q:(&
M-P4(6$0WKQ3DMQ9CO-5RF%*4")O<BOPQ,:6Q2XY-FJ2KBQ(5'F3TAI)5L%/.
MEE*OA!`6$A"3Q"=OF4FR&MK'DNI<IVVSZ:BD.0I*$`[*XA;C2G-]MB5K`W!*
MAMXV*TY9J'*R(J134LJI@J*6U%$]^=*<4.14'Y,6(U%8;5S0M4:,PVVVI">.
M_P`RCEP[8*W]Y;G-I\J`0^IL@J42O@E^.A(((&Z0I'$^$C<C<B:QGVF%7D;#
MC3+)KIZPZ8[J#ZK"G?3.R5.#BML*&YXOH;WY#XN7R0K0G6W+^TS6RJM[13C>
M+29;%/FU<M<ER!8XA.DM-3[!N/%=0'["@:4[=4KBPM46:PXSQ2U-E<GG3IA;
M]0%]=DRI1+D:5Q3*0/)*VWD_$%H`^`M.>2-@@A2ATVO6["*C*,1M9P2XM=9&
M>F-/%'_2X;J6UJ<@RTM[!QB6@+::?0GB/AYAMP#D1=(K4R-.B1I\.6A^OF16
M)L.:RH*1,A2V428<F.H>"S+BNM2&5[!2FG4JV3N.JI"MDIY;CR#XW43OX!._
MRVW\^3\SM\M^F8=@6I;VJ?:SIE86<[Z0OL1BS]/;]]3D(R#,PV6JLKE2689(
MC![&ET3D<24-3);(3/?0M4KUG7FE)_`H[`*^$'PI6W@*)V.VWR!\>?P^1T15
M!<(3Q&VWG?8_?`'<<M]__;UYVY'?DE!`"0KBGQO\P/GX^'R?D2#U1.2`#P^1
MW'$IW&ZAOONHCR!XW^0\[!)`\S0X$I))XJ(W*E*'CY#D!^/;?9())(W(/SZ(
MINW$A/DDGY@)W\?A)&VQ/X`/P^-@.NDCV<O_`%4<&_1=9T/EM_\`/"V_`>N;
M%,E*U>FA)6M*D[J)!2`=MEE6PV*?.PVW^>P`VZZ3?9R'?M1P;R"?IK.]R/EO
M]6-ON/\`N/C]/SZ(KKJQ_M_??V5/_)*WHZ-6/]O[[^RI_P"25O1T1*CVM[G0
M3`0GPKW6\V/Z?JFN]O\`U]?*B_E![-JU[8CO6<LGTN0Y.<XP_CR"ZR4Q\>7@
MV.,1HP`2T8B4WL?)'A%?2'4F6)!<4U(:2CZKG:X2-`L"(\$1+T@_I&2W9'7R
MPO;VZ@7=;[:/N[MDQ,8DN:7ZJ8Q7XU&M<5H[6ID0HF$XGF+;&4U4^*[!RYGZ
M:R>V+B<@;FI76N1JE0%=!B1V=<%^./I/X_.BY_B&[-B2'J%ISF,_=:/0L!I3
MC;B%>HLMH6APO!#B_#)4K9*PD?#S*P2#L!R'5IBM<FG6D1XKP'`N*#BG%25A
M02XI'IN*44)/(AQ.R2K8!'GPX#5;7'+]8DXXC*,?TMJV\;?L7X"=/M*<%TV1
M)78>Y*?%TG$:BN3>MH<KHR8C5D'VX'JRU1PCWJ0%W?4SN)SC5O%8>+Y+B>CE
M)"@V<6U;G8!H]IOI_="=#8F1F(LBYQ*EK+:57+8F+=D5Y?\`<I$EN/*D)6_&
M8*.J8@7F3`>]OY>)7(*A2"Q-P18$@,0"U0(9B,[N')3;0I$A#S"7(R5,I6B$
MAM20^E7HK]9H[J6M*RD*:>2-U;'<*V"5=18A-F0X2F.VTH-1G(JG/3*E%M+W
M@*5R\*XI(Y@*4A2E*V4$=.6NNX[/[[3C^:J7C&C;>.BBJ*%%M4:)Z;5>=JB4
MZH+T9]&>U],UEJ;AY5>PBSN#/$^T0Y,:G/NHF24K,1[CL_P_3Y>FU=C6B\JA
M7%O82I^0Z*:<Y1F2V,C<F/371F]Q12,D;DQ#.>34RS.]6C2B&U6N,B*P&Y[S
M.P@YF,MI-H:VR"H"!40"`\9EM"YL2\,2=2F[IC;(<$A]HIYK,=)>:8++*&B!
MZ;:RE*5)07$EP!0/@#XAL/:843T^);'I.D*)<<);66TI^Z$J4.:D@I*E\CL%
M`J`2KRXK2?N$RK2"IL*+&<9TDN*Z=:?2JY6HFD6G^I-VEUN%#@I8BVF84EE.
MAP%-1&W/HIA]$)<M4B6I)DOOJ50:;ZW9?IC.RRYQ:DTOMW,L++MK#S_2_"-0
M(%>XW83IS0QNLR:IFPZ!#K]@ZEU%0S&2[&;APG.34.*A$$G31B3>VQ(VRRAU
MGQ?+-0L\,!9F[PGR8\P$C"(#8]3@M*'W/3`Y+3Z;BFTJ#@202E2&D\4I=2H)
M4I83Q(/+JI8K2\R5A2`TM'+F7BM<="5!*E*=0`A*^6R2HE0"5$*3OLHK/C^N
M69T6I=[JG&H],5Y7D,*P18UEMI5@EEIY!59"$W(=J=/;"MD8OC[I;KXYB+AU
MC2X:UR%15-F8^I=7::YYG:ZH5.J4JGTQC9%15L!IBIKM+,&J\!<^CFYS;*[/
M3N%4LXC<+D-3W#.>FU;JIBT0GY/-<6,M%2:F$"P-\X@:B8_D*A(^LW$\+O2&
M'$.\`!L01<`EX11F*VXAU*VV5*9:>2B0T`XA1;3Q"@?6477%!)+:?31QX^"-
MN/4(T5E90VEU$E90HN)!6@-I&Q"E*;.X<;2A2&R2KBI8`^:ATN.<ZZ9;J9:X
MI=WM#I95R\5DID5,7"=,<%PFOF\K"%9'ZI*G&:B!!R-MM^"PAQBX;D-B"N="
MW]WER&G:O4WN!SC6*L@4>44&D=+6U]G(N&'=.]),!TWMWYBHDRM*)%GA]573
MI56&9;SK=9)>7"9E)BRTH,F,PXFIJJEV&K&QB,S(LS9OFU21WN^19APW+2">
M(FEC&?A(2&+C1Y9/Q_=4K*RAUYOU)"$)5Y0PES<!)X()X!;:3N1NHDSF7$;!
MA2F5@M-K=6I;3:"\0%C9A6RB5'XG"D;A03\`\CI?<O[CL_S#!?J#L\6T4A4B
MXU-%>L<?T8TYQ?+$1:-R*["=&:5%%&R%N1(7"9%S)3,+]LVJ6Q.5(1+D;QJN
MXG.(&GATPBT&C<G'S0V&/(L9VBVG4[-T5EFF6)$KZO9E*[E/TPE<IP0;LSA8
M0@B/[J\V8[135R1(#"TNU@[L^K`L#Z*&I^LD,X/#<Z?-`:QL=(A!0XPH.^FM
M)/)SF''Q'6H`IWV6XH*``4%,(!22DGB!OU-#@0ZP`ZRTA39+Z7#P<2WP*6D!
M)^Y\AQW6G?ELH*/WP/2XZ9]PN>:5XX[C./X[HU9URK";8KDYKHOI]J%?&5-;
MC-.-KR#**2;;)B,HC(+%>VZF-'6IUYEM"G5A5)ICK=E6E#M_]3-'IA;#(WH,
MN:WG^EN$ZA&(N"9@9^AG,MJK%5)'?]\?1*8K0PW)X1R^%&+'"'@[-+O$7AFT
M#:`G)`*'I>LC7NF+'(N<Q#9'5D>04I;2XIU2E+"F_52OTV#OM\1^+T1N.2=P
M22>/D#KVD@H^?-M&X#I<0H#;?PIT?"4I.^X^#^T>#TL6/:TYEBF=9)J35X_I
M;*L,N%B+&MO=-<&R7$8,BTG1Y\Y-+@=M52<?QST)$9ANI<KX,7W:"\_$A\6G
M7T*EOZWY8_J;$U<=J-+D9,PPB''J&-+\':P*0RS5O56S^FK54,0?=]V>7(<E
MNUJG7)J6IY6)32'.HGTY];Z*330&>HY?LO2?W`\1=P78@:9,D@1Z;J7G$.,N
MI66TA27$A"-@2DH4A:>`XCDM:E;D>22`!UY0J)L6F?2*TJ*SZ92H*5R2`H!*
MB``&QL2/B\?[P\JWG&LV7YUE&*Y;;4^F%?;8>]"760L4TLP;$,:EF!;LW37U
M18QCE7"I,F0N6VEJ0W>1Y;<NM+M3)2J"XIKJHU/USS'5ZNK:G)J+2NEC5%C(
ML(<S3[27!-.)DF3+A"'(1/F895UTB?!;;*O0A3%NL1GR)4=*'TI6)G5M9M;:
M?O#LH:EBU1@0#2.]8ZQ,9F-#"(R'5<N0>BK4CU]U)6M2PXX`$K"$*(4V5`!S
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M]/KJQKJC0ZXM-+("48A`]YC*F?:C]M>EC%5B]MA^0:M:GZ==[';_`-Q5]J+I
MAB>F&)Z"Y'.T&[S]7]7]1X/;I!F9#29-C&E^K&CFH;&#8;]5N$M9J_"KHV+Z
MF95D^%M8W]3.D3#>X[.M/L2.%5.,:,6M8Y)M'S)S'1/3?-KTJMEK<DN+RK)Z
M&PM&VF4)<56Q3*4*H<3`]%:!M;-,M?,LT@J[2NQ.@TFOE6TR#/E#473#!=19
M32X4;W1INML<SI[.571%LK4Y(C1"VS/D<9#Z%.CEU4T.;'(`/D&#\O%CD=-A
M\34*:0"')JJKJ-`+&JH%AWF8$D.2!`\.DG33OQ[:^X+5O6'4[#,QTZ[?D4.F
M?8Q@V(.=V^EN.9&Y?9%HE)[ASD-SFE3IEJ6_-G=OKJ,SQJRU)QJ([?0;N?58
M:J^@(EX]2,76DSO5[I]+-?\`3?M\P'3'#YN#0-,,=Q5C+*NQQNB%)`U`I]*<
M,TKSNRTMSROS"QM;33K5R_PD:RR<3M]/].7ZK/<FO[NV3D^16\ZX6UC#M;\L
MPC*LFS.AJ-)[&?EJ)#D^%FNE^$9GC4&1+NU7,A>.XUD%7+J,;7'=YL0C3Q(R
M8M>45T?A""6>JAG73)F=37]7H5-IBO(YJW6I=4_IAA<G3]@2ZAFG6XSII(JG
M,1B;Q(Z7V'&ZQI4:S6NX9`FN+=-A0U3M9@&-BPO!_+V#E*OB*JZ.$D4DN*R*
M26!X9#U1`^6;,)$H?(\K:3"#186TE1;6&@I!0'$\WPX//A1.ZU[`_%L%*3UX
M;++AD%\MN^@PSZ+`F%7WZ=@E&SA!2L<5$I\[@H2`".E<RG7'+LPU$QO4VQI=
M,X&28LFE3!JJ+3'#,?PJQ:I[&5:PS=8/1U<?&\@4_*D.MV7TI7NFUA>[5\_U
M8T9M`\:F:X9KK`JFD97CVEU0UB[L]^L&G6EF$:<>H;%4$*-Z,4JJQ60(9,1G
MW://#[<<+DICE*9;^^P?,,&DN7!<:,[B'B_@L12&/>,,SAB7(N>(N2,P_.5M
M#_D\C+;/MD>Q)&[8>&?:B'@'D..>DO1749PJ*$J)3Z:^+>YWV&P5Q*@.M6?=
M-)CJ[I>YZ)+6V''.XO7<AD*1\;*=5LO5R*&SR!"@H$GXU$#?[WK>%[#'N)SW
M5?VN_8ECF18UH_44[.J&;VC4W`]%-/-/;IR5%T/U28;;7D&*TM;9O0G4R'7)
M5<Z\J+)=2PZ\VMV,VH:O.\+N/U$R+5SN;TO5CFBK6,?SX:P8RNT@Z%:95.>B
M#5:L9&6YB-0H%&SE/TNY[FP9ER9YLK'U9/OK[RI,@+H.+M)`?@#@'_([.6\O
M$@+JI%/8_/\`W">(TD$5$4D`=XC+6<K.F%-E4:6J,VVTAA2RM:UNIW\H2$<0
MIPJY\@4J!2.>Z2-D@*,Y4AN&OE*?`7)<++9+WIM-MDE2-VEN;;J(#:E`$%1W
MV`WZ<#A7<9GV%8"G3FLQW1F;2)A7D15CDNA>FN3YD4Y$_-=EO?5O>T<O(_>8
MPENHJI"9GJTX1&$!;*8S"4V[337_`#W2&KE46(8]H[<Q)M@FX>DZE:+:>:GV
MC<UB-%@I8B6^9TUG80*\QF4.+@1'1%<DK>D*:+SSJSK.@\[A^7NLVI)8U`!F
MJ+$69B[DESX$`0D3F26(;96[(:;)2OTG'%!*%KX%03YV"@DD`[@#?8GP=S3@
MJ7&CREAHR5(9"E[M)0$J=2I>QY!)3PW4$A1\^1NH;=+5IKK3EVF%IDUW3T6E
MUS.RX#Z59SS2;!<^JHO&REVJ?J?I\JJ;"#C*?>)CC1:J6HX$)N-`4"Q%90B9
M4:Z932:I76JT2DTN?R>\:L7)M/9Z3X-:Z=QFK2/$AR%U6G<VH=PZG++<%I<`
MP*]E4!Y<J3$X.2I"U1.@\S[=::0.``-4215WCPP:?,%CF-[)&75,R$/,*4`T
MH%)=2XV4D#@3LL<DMK25)\+(4?FD$=>&&XD1K9MT>GZ@)474N`..`(`)3X2%
M;>`=AX)^0\+3>ZUY=D.J%!JY,I-+XV14#54B'3U&D^#4^`3!3"7[BJWT]KZI
MG$KDN"=(-B;"M?\`I4B*9I<]T8X^M2M:\LU4ML9N<CH],JJ5BGJ?1S.":5X1
MI]73"Y/AV2OJ@K,5JJ^%D>TB"TTCZ7:D<(3DJ"G:++?;7,O8#Q,:,&F,W\U!
M(9A54SB&@V!)F##LQ:-V1ULM`K])Q"BM16L)<2L[D)23L%$A)"1X^6_]NW4Q
MG:0\F.RMM;R@HAL.(Y;(VYDC?<!._P`7C<?BZ7+57N"S76&EAT.48[I#30X5
MJNX:D:<Z,Z>:9VKDIR))A%F3;X;2UD^57):E.+16/O+AHDH8E):#\=I:;M=]
MQ6?Y;@C6GD['-%(-"U%H:WZ3HM%-,\9S4Q\?5!,-TYK54L3)G9DE,)H6\T3C
M)NO4EIL%O>]OA<3H/,^&2J>&>\8$.+G0]Z`(US;)T:B-AN*_'E.I:W:>04K?
M00&UM*W*$IW4A6RE;_/<@$>".OM)^S[=?<[(>U5M\$(@:%:=4\#D@H)I:3'X
ME/0JY'S("J2#7J$TE7OX(F\U^\<U?'PK^X3-:73:5II'QS1]['ACMY1FTL]%
MM.[;-O<[5N>Y)>.=S:5W*/I1HS'4P+;W\SJY*(R8CK:8K(3]A_L)`3V-=F24
M^$I[4.W<)_L&D>)`?^KKEQ2203O^%T?!,^(TDBDF&8RX$EPY,Q:VCLNDZ:_I
M7G_\/JG_`#/==*+TG37]*\__`(?5/^9[KK)=ZYC/Y0%:0(?<)V^1Y8<6M>CN
M4/(:W(9*#GK+*G%$I+:EM@DA!4%E.Y`V!/7/M;K9:LW"VRI'ILLJ+@"75.I5
MR7\*D#BDJ)*OB5Q<2V2GDH>=T7\I5SV!B/<;VR1;#'\BG-2M&<OE"VI4,.-0
M?1S]II34AIWBI9*3ZXX.)^$<0"2#UH7QON`P"W]&IL+EJ#*7(:1!1?1'ZQ#P
M8(4TF2\X@U@4>)0`],9X[GB>2NB);<7HI5\I2XR'4LB+ZLF3)*D--%*QQ+*O
M_)ASFGR%G=*T`^DLCX5OQVJF6F0<$QFK.MK&*]IR*0AN`T])!<++A;""M[=*
MG]E[)#2D;+47-DHEC5A*8FJ8CR'GS<)4_$9A+<5!F".K=(9]-:H@0EITNN.*
M6L/I*0I2EJXAX6D#=E$:=:FPB[(C!$Q$NPC,%V1(5(4Z'$M,(0TD(:+3:TK2
ME7A"5$;)'1$I%!3!X(BQ83LU;;@X(:`8KX#2DG=II+GHLI]WW/)U*WE`\@-B
M5;+K!JZVMV$=;\F5P;0AJ,0Z$CB7'RIY2&V4)*N:%+2H(`WW!2=^K"U`DV\-
MCFVP(ZE!+H?"VF8ZEK"RRPVR&V&]EE3BRM0*0"75*0-PE]=JC39M:2JK&+!J
M7CE18K;<(XH;RB3`>+,T-.(5XHFGFUL1$)6INU+9E+48+C*5D2KY6B>U43KR
M)&*JR&URFEI,>0_/8CH6M^/#?=!:0A12EOU8S:@%$H2X"-Q@>E6H^&ZGS6*R
MTN;&AE,R0T:.'$7*L7G4/-QQ&4I;?%*UK0/45L>3@'(!"?B=DU98E=8I'+,E
MMY<Z`AM$5*$A(4O="(Z6P$A`'$)]/9*4D$!6P\:^=5](K_26<[J'C%@Q$?7/
M5,?AMDA2$/*)<+2T%)]7DLJ44[<B0D'?=71%TO\`;?VF:,5M#!M]3<.Q1<RQ
M#+M='S+(9DV[>2IMI*7E57OT2*TN6/4(:$=82ESTTI4E"07N7>DV`XKC#CNG
M.F.FT"4U#*(LERBIH3,=L`A*TOKAK>4&TE:@%+`/@E7CQSE]M/M(])='L)39
M:BX+99?JTAQP1[NRNFG*>.QLW[H&H+OO$QAYD)^-384I?Q[N(W*1AVK_`+9N
M\S^U;H4W*J2IEN+814XS%#<I3;GCT_5YNNE:$CB'U@%`W4>/@]$3UM;\TO(.
M46,/(+"NAP*)I=E+K**PWFWR5>H&79SD;T4L06W&W$MUB$E#VP<>*D%)ZU8Z
MTZ_3\KMFJZ(Y*KX#;K>S(=7S;!'B2ZTPL//I:026F6]T#CORY?)*,WUTU.U>
MM)4+!:V"$/LD2'IEVW"F*8"5!*G?7+CDF6^=U.N)4M1*?C*-ANC6.X1J%`R&
MNM,FK7E6,&TCOQUR9D-NJ3':>07^;S<AV3+0ZTHI4TI2$.-E6R`O8$B7;'XN
M997)C6*A.,/GLJ3,>=9)0ATM,.^DE9YJ?84VKAS*4DA!42/+EL`T[8:F-6F:
M2VDT\)3CYA.I>2BPX/%UI*RG@X&4*2"XXG<)6DJ'('?JP7VK>C&FE5)O[J_K
M6FX<=,E<>?/91`KW`@<FT(6I!=0VLD,APK5QXA(*MM];6LG?SGVJJ9F/Z`X\
M9%>M3D5S.\HCR:3%H+!2MM3T!+W"=>J3N5-MQ&415IVWD*3T1/J[E];=!-/*
MF9D:LFI<?;JRVEZ.J?RC3'PO@NHB19+I>592'./NS4<K<4KR6"@':?IAJ#B&
MK6&4^<87.,^GMX1]W>=8=;DMNIW#D2=#2CUH\R.]R#S#J$\`$NH)9<0M6AKZ
MDL>9R!&5ZKY-)U)S*,^9#;MD0JEA2#LY_P"#Z917&91L.(*@75MI(6HD^=F_
M:!J<W=6V80*^.S"JFJ&@MU18S2&6$V+-C/I1P:;`::#T-"$\&DA2@RV5`E((
M(G\-.R8K;,@27-FVVRZ\H@J`5R"$%*$[-E.W%2@@%2-AR^+J^1<G<BH#;CSL
MM:U)/A(7P4M?Q(2HD*#:?A1NI"=CQ/X?&./!<Z*E#"%-$DEQ862RXH*#G!"B
MI"BE*$DKYC9)Y`D>>D68U.K,CEVL;%1)L'8,AB.FS>"(]=+6A;D<R(#J2Y+?
MBK>:4TR^\TP'D-+>0/127"1.(79H?<+;\A#;ZRY[MZZ25-+W4M+"`E'-[EQ(
M4A9"2DCFD`;BXLR5..1HS49ATH2ZEV4M206EI0'-PCBEI+:D\_5.Q4GBE20L
M^0W.1D^04=>_/4BN*DE*&I2X#T^0''$EU"$!T\E%Q*@YR2`EMLA;IW)0E.I.
M>WL^>PFSR:T@,6$6R<9E,,MQH1=JH,FVEPB&0]);E+J(5A.BM^F?>TU\R.UO
M+90RX1.XNJ^OEQVOI*5%:0B0T_&4PI+"`Z0M25N.+]%ATM`E2%*<<2E/$\.0
MV*%Y5G>"XVV5WF6XY!;B3%K>7+LHSDQR-Z92O93#BGWO3`)0E#:TI(`(!WZ;
MGE.*Z6V]@G+,INLCO;JEKK1<-_WJVL&$1H=#"R=QR+$4_'BR_4Q^T1:UR&N"
MK2)'LXT5Y;D&4VSBZ<UTSQ^.EJ7BT4VE:;!FW>KX;:X9%%;T42]EP'U,*?D1
ME8[DM5FM8EQT^_4#DO99=@.I41676;VH/:EI?+&+1+C+<RRERMX-8]AN-2)<
MUUN:VZF`T)5L]40FWK!YM0CMJD**DI,AP)8'J'J>[[[49#VA]IUVS%EQ$7,?
M"K9$68E+,R*W8Z1&:F/,2A3B&I#*7PS(2A:TI=2M*5D`*Z^8C4VK>;>T9U'G
MY0W$<:C:DZKS&(,8^A6QE8="LZ2B9BH6>(8BL0F5QT!*."D@IW.Y/TY^^3TU
M]G/:*`MQMM=?@?$,K(40='T%(Y)!44`?,I(W&Q)VWZM4`&&;`FV<Y;3XJM))
M=[/$%VW?-W$:+4`4I2UZ/!"D[[J::3Q2"23NZO8K/CSPWY$^0#YVH'2TA`4>
M*U(`'%O?TV2GPD`@*3R`\*YE2E>2GSL.KRN*X6E*04M,I!"DJ(4I?S)6M6_%
M"2=@H)"E>3N1\NK,XRDMA,=@(8`V+I3OS`WW#:$^%@J.P6$$`#RK<]55E;G`
MX2D[D()W)5R"OD/"4_'ON1L/4^+;R-SU!M9<Y):)V40"I225E.ZN03Y'PCR$
ME7P^5'\/GTEIZ2`I*2A`'D[G<J22!\P5#<[D(`/XOD.H<'&O(2%H20'%H(V`
M2!X(23R4D;C9?@^?`/1%S']Q%Y*LNY?6-<Z0[*<A:CY-!*WBE3O!BW?C,MG@
MGCLS$9C14E&VS;38^(@]/%T9I_J=HV9)2VFQG%,HNDE/%M;8#3:E#\24;+4?
M"64.*'AT\F1ZMULV1WAZOT4QDM.RM;<F2ZR5)7M$=MG+)A94A2@$O0GH[IV)
MX>H4J2%`A+_;!R/C;JJQB2'G8S$1HJ;!2VF1[HP\^RT%^2VS*4B$5$<G/=W7
M$G@Z-R)<8.8R:1L5U*YO<S5(==LDDF5$7OS+J-T\6W"GTT-..!8B,[%I`?<2
M4*!B>&65\_(<G>O9SIKAFS2_ZDIU]]PE:Y$A3I4MUU:U%1?G+><4LA?IH/'K
M!]#\"L<IL4/\2E`]*79V2TI4($1PN%`2E7PKFS%!0A,?)#:7)+HX('+8-0Q*
MG'V&:FC@(=4V$\BK[H%N`^79CQV7*=</WP*@@#Y;``=$2;U^CS;[#3+H6^GX
M#[L@.J0VL^%I#+0<:"BD!(4$-^02=P`.K'D6@9?8<]TEQXJAMLB7#5P2K?X-
MUL/(<!X@)W*2H$<@`?DY=,6WMWEAV0^XXE!<,.GCK0VPV@'<AB&G[FT`H%2W
M%?,[*5YVZLMACA8W+J9D9?XY;3Z1N?\`]LGXM_EO_8!^'HBUJ:CZ%9/3,29X
MK0ZRT'%KGU/.9&;;;05A3T<-(L(R>8W+SC$AI!W+CB1\89U=R#`E2$.I]1A2
M3'EQWDA29;;C80^T\C<A0=`4I&Q4GXOA6>`4K>%-8LH8*N29#/RV60H<2/("
M@24\AO\`"H$;>-OD.F,=QVBM;;4UGG.(0E1K2"E4F^I8S:0S*A[%<NPCLH`4
MB3'*4R'D-`-O)2M00AS<K(JGV<6**Q#3_5V!`>]2CF:OHNZ2'ZO-V-`L\)QP
M.H+*5;M!,R,ZS\0'KF,5)4H-J4-CRG2@#F`>/Q!03L.6P``^:N2OT#Q\_)WV
MU.]AV6NU>I^388Y.83%R3%94J''6XA/OUAC4V/8150RL!UUR/36%TX\R@;^[
MMK><XB.!UMB*^)`5NM2?FK;9L`G_`,[;??QML//Z#N-B*0UNZ4.%"0//DGY`
M_)*$?(>=@2?)\G8';KVZTA2DH4G<;[@\=DI&XW4A(!&X5MR4KY`^3\@*CAL"
M4$`J5][Y(&_C?SXW_#L"G?;S^+JD7S;!]0^=P"D@E.XV(VVV&QW^:MT@@^#M
MN"+TRV/4(C\=MB%*)V0"-Q\6X25+VW/$$;[_`'WG<]*/LX@1VGX+OL3]-9WN
M0-@3]6-OYV\[?WG^T]<U84XHCTU!+862%@^2-CRV3N-DC?;SX!)W(.^W2A[-
M[_JFX)]T]3_PWG>R_P`8^K&WV_`!X_1N/Q$C8]$5ZU8_V_OO[*G_`))6]'1J
MQ_M_??V5/_)*WHZ(E/[7?Z`<#_['??YEN^OE$^W_`'&A[8_O^"_`.L=$V4K`
M/J*.C^F9XH3YYA2?`3L2H[C;R!U]7;M=_H!P/_L=]_F6[Z^3M_*"I+\?VR??
M^$(;>9&L6/+?2I@*],_S1:8+97ZGDH*BCCS&R@4J_`4@;8'SG_4_<+#XBGBI
M`_RW_P">>;,M2"G0@`N;)"4I'+8)3N3L$)!//D5;#8IW)4/)42!4+2XTT^N3
M&DQGVFVU)BR6O<G]RX6E<FI(:5X+:T*4`=G!\>Y/6.U<IU5O4,J4MIQ5K6LN
MAQM"F$%=C&"PI"DK6E`V3S"0`2DK'$D];EM?=!Y>9PJ.)DV(6..VJ2FYA3VJ
M*37/V-9+8VD`!^,[[Y6R7EM/H.WHJ<0VIKP"3M7B"@T@V,G:V6;\\I>RYZ?A
MS522\@TD#4/(OF,W6I)#B&'7-H_HK*4D(<)(90M)4X05*0HN/)W"5A8XA1X[
MDIWBI,9[EZG,%<=3J.?`)3[NA2N"_3VW(2A"4`E"E_?*2H[I4[J7VBS@73'R
M"Y:*TG@W(@-*2T%%(!;]*-%7R3Q/E2U<?B```V%N<[1,@=0E"<C<3]S&Y=H]
MU**5!:7-DV$?DH!*4I!4#L/ERZCM<-KD3H26B/29#YZJOZ7$!%GB15R.<W%O
M4NZ:@F0PK[NRTVM+O%;`*5<6^(!05I6YN$+VW6@A2^9*24@$F(4R$N>HHI67
MVB'4(=*UM+*N2DHV#:4I5LL\E$I\>=MMWBUG9Y?*BO*.42G7'BHA)QIQYUMI
MMT\VF@J]27>"T)4'5$*2@>E\2=R;+D_:C=8V)-B]D=A8PRAMR<[%Q9T&J=<`
M]'WACZ8+X;=0H+]9OFUZBE)W24@=.UH^IO`OEL?&;N1=U!^&Q0_=+!IXJ7,B
M+G)W+-%I3:8RH^WILEV6#ZOJ@MMA+RG-B@K2XODKTME*"EA20"KY*V!G,/J(
M#;D-3;/`LJ6L*2N0V%K;0ELJ+?WR075()W0A7W,E*00JT/1:2J8B0UE144ME
M/%S"\@7ZBE;A+BE-V3K1<XJ`("$\DC??<DF^Q=`;-Q251\@;4H.$DNX=DCO$
MJ2E'J--FP92CYJYA""D`;E!(Z'$H^I^?%^&^QDP&I5#\-BY4\6;\5(`,$@]X
M#Q#EN02(MB.T_P`T14,\ON;B4K=4&2@\T^H5K5Q96A"5ET<E>IR025#XIK*V
M5(=DML!+DI:E%M&Q0I"`."4+4$DE0*UJ"N)4E((:"P>4;B$Y46DR#,94AV)*
MGQ9:U(>2TIR(^ME"VTOH84HJ,90:0A)"FUCXN06D>0$++OIR"74D\@H^&U2-
MEIYHX\/B20D*""L)3Q"@0>I.X,R\F.[N6<YW`:"N>H$."""6=PS,SVM.5A`T
M;R7'%MM.LMM)4I`V+K:R."DE:66RE''9104JY#[FI0V"B1UZ;(7Z+_PB2\0T
MM8;<;#I3X7R;("U(0E&R"H)2@`.#B-@KRRF074NAQ;>X;82TC@H.%GD'"ZD<
MD-G;Y!*DJ0/!/)02:@1^;2D.R/C6XHE7'BEL*`7Q;YE0X[I(2DDJW43M^*+:
M`$Y:;M<"T$.0;F17\MY>@B-/:">(+H;8V!2M2E-+"GUJ4H**`D$E2@25`H*B
MG907Q2$CKVXI1#?%M:4\^2G$'TU!M:0$@!0)<`.Q""D\5!1Y!2?,8[L5J,N6
M4<I#$M@L,H::=AK<2K=9<<(*EH+G!MSTFP3NOGN`%)E+XK:0K=3Z4+"W"VD*
M2L$H<;*6D?"KTE;;%L[!&^Z.1.T7\R)=RX&[>+L7T"$0"]W/JWG?P;69OW%U
M\,K5Z:PE&ZDJX*4@+0L%(!V6@K;`<7QW22K8C<]5*D\`6OA.Q4`.(2E7Q%*%
M$[IX@H)*2#Q'PGCMN.J1+B7%!20KDVLI4HI+2D*X$^?4"5\2%;CC\B4DGP>O
M3TIUY8?#B0AL)<>"F$K44I2X%)"SP0>9!*4A/('9PDCSU%]1`U.@]?8)M+N&
MY'QY-JYFRD-K+2%..1_=_NRG'4IY/>KR)^,I:*UI6O9/J?"A&VW$;DD0;?Y(
M1ZRF65[%]7$A*U,^IQ:;4E:BOT25<M^._JD`+WW'4J0XO@J2M:V/4::"V2PV
M7%E*"EI*G5\6]RU\DG\&P*CX'4AOT'!'(<^!<AH*;<:XAM322HJ4A`4X0L@#
M9'W%*TI7Q"=^K@/YAV<VN)?PN"REH?6]XM!D@27FH@ZAIK''8K:@""LH?1ZG
MIAU2/5*N(2HI(`<!V(0KEYV)05;`P=<6AXO>J0HM->LVI9]%"5O;+=!4`DDH
M2I*2!N"G;B=P.J>090;3[NX'G$O!:D-QD;K*_C2H(;YI],;%7JD@K\#?<`FG
M=4%H?:D.N;.)C%):AE*W%*4M02$[GFA.X0$**>*@2/(/(`[9Y,YVD=T;9VS9
M`';/4!WN)`9V-Q-CS>I<XOL;H;,A+A24*;*FSX?6K9+2]AP2TISF\-E$@#P"
M.O;A4A;AX-I4K?WM84D>CZ:4EI267UD<UM[*4=N)`)!W\]2D!Y"@A+#SKP4M
M49UQE.[<=MLMDJ"^*F0E8*BE.Q5S2!\R.J=TKG<D-Q>90=FI"VUM@-;A3B5H
M'-1`0E26E@JV5QY!/(CH!D[TB9T)#_;:7@L0@!\+N]G:\BQ'F#=D",@SDJ1Z
M*6^0=]`AL+;1PXH'IGX5(=="0VM"UH4I0\!(7M-])M+;Z6HR%%"0&U(6KWAX
M$`K0ZIOR7$)*_405;'CL`=MNJ!TE4A2EH?4DE"N"O^CA(0E1;"7%%12EHD%K
MY`D\MN6Q/H[K9XMG::74K:\A#B4+66U*=*2@../K^:DJ+BE)&R0CEO9CF;`>
M<.3(>S%\C9U:>Z22S![ZOD?4LPU*@IE@+>4I`;:+:O0;7(2U(:2A*2KBT$E:
MG.14M`>7YY#8A&P%K9+7Q.>AR4L[H+CSG-"#L`0E#I3Q<"0HH5R',$@[\CU5
MN.-,J>0^ZYZ4>1[M)<<22R2L(6V2M*O57]T6E7#?_=2E"M@>J%8=3(4V'P4_
M[JA$2KFE*E@DOJW0@*\%/'@H`DD$D=6',N6<EP^YTL"1S??2D$@AS(!?O`$!
MFMG()S+NMU_\G@><3[9+L48^)39SS4+DM0<4%+5HQJ2XE.X^Y(+0V2``"4DG
MD02D:O>Z29'C=T_<Q$)7ZA[C-=25A._);FK.7<1X*E!7WH4=D)"1RW(^>SK^
M3NM-_9F.Q9T?&I&>Z@)'JDJXI5HKJ9R<;"CN'.0X*7Y^!6VQ'GK5SW2MM?75
M=S;KFY=3W&ZZJ;46)&_PZL9AY*P5I(```"6TE()^(\2#1OZI@?(##"]1Y>FF
MBWI%/8YMVE187-34L^S7G.+0D#KZ@ZM;RRH*2CT]AR/W-.S@V0GYDE/$#<J`
M)&VRNO>VQ\'8;[J&P/+QL/._C;8'<;[@;?([]6N))6^\7''T*"4%"&FV7T(2
M=PI:B5I2%+)&R"2I:4J*`2-AT29SA2@0T.K7S!<Y1UE(;\@@_+97+;<#R!\B
M#\KK,T%Q2+L'R`B,AEG8E5KZRD!M)`<>)0R2CDD.!"E\G-_`2.'WWS!V(!.W
M5`%/E]F*M&R0RCUG%[("F_#;C+26]VE)<X@CEQ=&ZBG@#QZNT9!=CMR'E!"@
M/B/N[OPJ/P^`H@H*@=N*E!7DCR".I3R&77$+^+[F0$A+SC:"XA1XK4VI925J
MW)\[IV&P&VVT\IGU@MZV_#.%0!((!8G*7AIB&FYF3=>68S3((0TE`"OA`6M8
MXC8I.RR0A7+?<)&W@$D_(3E)2H;*&^QW'D@@^1N"""#L3Y!!\]>'AQ4%KYA+
MB5(0E*5J;!Y`E1*=R"GX0-U?%Y!)('4YI1.Z@$.)2VI;BE*2@!*.*E'CNDDG
M_P`U/D`D[#;<0JER7UEYEKR<_P`V7A1(22E/)0'A.X&YWV^9\`#YG]`('G;J
M:D_&ULE/)*D#QN`M07N"HDJVW)"3\@$@>/!)O$#&\BN$!VKQG*9Y4.:6:_$\
MIF\4D$IV>BU4AA:5)^,*]=2.)!*M]@)-E27%(A#ES57%*5J2&Q<TUK3A1.Y'
M!RTB0PI>Z?"$!1)\@_+<X/6P/Y%H0@B])%LCGZ-O9\U?TJ6N),$J,`LQ9?AM
M9<"4AAXE7CR3L-R-R3MN/GMU]I/L*V^L;[,]OE]:CV[[?V?S28EU\6**H_1K
MZW/>'%+B2O3#BAS2L,+"B%%/)2%*!4V"20%;;]?:=["_^HYV9_\`HI=O'_ND
MQ+KDQ8(&CV?;5='P3`X@B&L-S?,YYED['I.FOZ5Y_P#P^J?\SW72B])TU_2O
M/_X?5/\`F>ZZR7>N5'^4<X%GF3Z]=O-MAT'%;1,'1G+H4B)=9+;XY9(>=SUE
M]#\9V%"EPGXA0."T25-K#X&Q2WNH<K&8XQER5O-95I1F$%^&5MRY-1`J<ZIW
M6_F'U2:PMS$QBG99E.S$2&TJ*W&4J"0.Q?V\T9Q[631!P$I;1I-D_J*#I;Y!
M&:-.%L!)"UJ4$^$CD%`D%"O&VB#'93KK@F6,=L%3;;4=UE*FWO/)D,.J<65B
M2QP;*.0')E*5^""$D6H3"\QS33>W];2_-)+#YF.N)J6P+9E(4H^I#DXK>A$]
ML%*@T50DSK!M!;]/@C;IZNEO?[F&(Y$Q_.MA5G8T*(Z&+:?@RF4A2GANN1*I
M[A^*I+R0A!,1N=$*"D;H5Q2E2_Y9I]H_J5(>J\OQ*LMIKFZ'+B,A;&0PW2KC
M[TS;5GNTH+1P!69+[J7R4,R4NH(2E`\K[*\BJV9TG2S.8V55Z$O+BXIJ651K
M%4=I?-,>LRV`VHQV5H!90U<1$P>?!`:4>:NB)==:/:.Z46^%6&'Z9'-G<GR6
MG<AN6-O2&DAXQ`L6O=YR7&G9!)N/<5NM117-2(B%O)F.6*UM)2K&NWS/V&HD
M),:0D,)90B-P6$I0AI"6TM\1OQ6A`"2/]XC<$@@G4QJ7B4B-;3HDBED:?ZCT
MCCL6XPJ3(9D-W<2.T5.VV,6L%Q^%:L,(;'K,L/A]6R'HC3O!]AC*=$-754SK
M5/93'0^VKE%*@L'9&R%-@@@+<:6-E-GBK??9(YA((NABJU9L,69+T22PLM25
MRHS;KV_PN[N.-)&VR2ATKXK)/SX[#B"I%M?=>LKRFA9A5PF3Y=A+;WB1E)+B
M8Z.2G"HE2&V&N02%.+4&P#N0?'6N#/=8L^I,9DY"_(KS6,<E,&"F27X4-0!0
MU9-I]0..CXN3S(#21LE83\RT;Z]!A+SBY&667J%2TNA#=?\`!L=BV@K84I#:
M"#Q2%JVVV)*MSU(!-@2UV#J#532W%4`]G(#\G6Q55%:V2T3LSR9<%.Y4NDI9
M!4\IOSLW)LU;%(*>1<1&:0`1L'2.BU[@]*-"Z:39_14=<"*IM-LFH1%MKY$=
M9+;TUZ,X\;&4PT>*Y7I+6XVC[H&BD+*=663=W&(RUDR;[)[QQP*0F)](+B0G
M"4D%"XU>B*E:0-S\:U@GR`3L>D,O^ZI4)IQK&L>HZ]#Z5->N]$#SA!2I.SO)
M+CCNZ=PXA:BE22>1))'5AAUENZ?MZF%2K%H$<0)R`!J]*?<:.M]TKVANC^*8
M3%N,,N::7D=NVRBOHEUTZI>=]0A*GU6\Z(F*6(G/E-]!;RD[*2VA2N*2UO-N
M]FYRZ23<ZDS9+"P%+H<%?8IH!^%24LOW]FH6#IXE066&&`2K?8;#K1=.UNRN
M916..1Y`@P9TLRFHU:RU&A0)2G'%)731E)6NK0LNO*6U#6TE;CRU+0">/2E:
M':8Y#E%C$RW+[&2Q4Q%A;4>5*+TF2\V4\E%E9W0E2"?C<2%+*N2$C=1ZL<+A
M!-1;0"7,<M_O8%0,2HLU,N'!B,R&>!=RVAF%M9Q'5S2*R>F6635.-1K-E:7X
MAR7,&KZ9)*N1+[IF3%I7+!`^Y%D-LI(XC8)WN%]KM$M72S#RBE9@-H4&H=98
M02AMM(V0C@RX&VD<=ON:$D>>)4`.FVW5QCK#*(K%-2J:8'P+=J:]QUS9(WY+
M6P5J.P^+<[[^3L?!PR7D.)8HVG)[^=78G"#Q8@QJ:#7_`%:9!(/I.O0,:IF4
MM.<C'6IQR[NEP,<B!`0[-ERBU7OYLY`#N<O+\^4*Y/"Y)`I#DDZ-[_AI2XR=
M0(DB2X^NT;92E+TA^0MWWA266$+4K@TV5.ON*`*8\:.A;TAXI8:25+!&S'L9
MU"PRIH7WCEU`WF>9SXZ6L;G3/=;"'#CM.,U-4\ZTA]M*WUJDSY[RRTAN7*>:
MC.*:C-+<T3U>HN?ZKY=61<>FY+45T>4MG'L<JK6RFNP8[RD*>EVTMA,9ZUMI
M*"TJQL5QXS`])J)`BP(33;/73QV+Z?3$:47E%E1NGZZ;'7"L&9TN89,Z/)AL
MM2X:XGJ**6274/("G=VUM!:B%(((ABQ2BH5TBJGY38ZC5KCQG5)'EO<S;S+^
M71.YE%9E+GKIWH>-2W8<=?HO/1%)2J&52G`^L+]9<F:2_N/4"$'TQGVC>7)K
ME7"%N>DQ]%R$--!F2XA<EU?H(6MMIDMAYF(^ZF.I3@*`Z2GAN3TZ*3VN:>,Q
M68M0V&;"4GU'Y*Z]E*G5RDE*YM@F(_&>=G/C=V4ZP4,+?Y/!">:TA',0T(N<
M=RZZQ.[D-16_=9<F@R25#F-TUXS7AL+AR;-++T&IMID(!UB+9/,(1/96V'RV
M\PZJ%99SG-PY<8[#;KU.%E^<VHO);6D(:4I+:V]@5*(3Z2$+]3AN@A.Y!Z2N
MYJK(U57(1$DV4VLOL:N(3;7O#CIL*;(H+T%_=M:5)`"7$O*6E:5Q52&GTJ8<
M>27)4..8A41)==D<^5;1%.E?*J24!IQ"N,@QWU,+CJYI])\)1R]*0AYODZAQ
M*^E?BV6@5&S&4S49=.6(Z"G_`*3%9]=LJ!!4H%+C*%E10X4M[!&Y(`!W(F=5
M';C#K$PF7KJ5*%.BKKXR`TVE#D7'&\[J:MAQU]Z4^ILXMFSU#)*22ZS717TD
ME:D(PQK16IBW=C67LU$F)';QFBQZ/-M$JL;!O^;QG"YC<R*B0RLN6<"$W#0'
MT#WQ,426=E(;*=C=9G>&6+I1CFG4$%*0XAZ\M7GW"WXV<+45`"MQLHJ)(5X2
M-N0)M#L"9(LY]M34>G-%.GJ]X>L&,<:D7,QYM/!(,RU?DNN-L,H;0RGTAZ/$
M(;0V$DDBX;^['3.Z[=>^3+,NQBLEO8+?7=AGU'9Q&9#L=['<C0_$S9J*Z6W4
M/N8[>2;>-/\`24X8X;CNJ(8>2X?IU]YO&3V5]FC[2B^DT6G3S:T[`.(<T69(
M</(;E*TJ!VVW^+;;?QUSQ=PVE6$:N4C,746(YE#N."QGT?ND2!3S,=LDPY$2
M4F!.H(]>Y#CRV'GH,YE,M;$QE2VIL9QKBI/1=WT,IKNT'M+A06VXL>-$PB(R
MVM*EF/'CZ0AIIIM&Y!<0A"6T^HOB`"3S("3)((`:0[EW>S90`T*`"Y.K-_._
MX`6H1QWTSLXA3AXJ4EL))05)("`V@;E>Y)">0W)&_P`(VZEJ9DO;*4PXD'=:
M4%1*_P``3SX#[F/OBII&Y`W"ECSM)2$!U7WR5G<_="%O/D$D+(5Y*/EL1P;\
M`!"0D]5JI3[*"G@LA"2H)Y<B4[[_`'1P#9"E#[T;$_(`>>H4JB7'8;/_`$IL
M,^0K@E02E9/Q$<P=PD'<\$^"1\2E>3U:W75)Y$K(8XD-MH6D)4GR2DJ('P<=
M@4)3SWVXD@GJXRYJ'FP'XH2E:MDA:]W&U;@\]B3Q.QWV)Y!.Q*1N!U(3!;D,
M_$XDJ7MZ27%*YIVW4E2-OO@/(!4-AY!V"AT1:%N[_3<XAWHP,W:8**?4^ABY
M1#4II26_IRDI58WD<=3A'`OMOU];8\$J*_=[%#ZT)"OBH*>[E93:M/2U+D3K
M":V)'IE9#BRH\FFTDJW4^.*=N2B"L`>?GL][QM+(>5Z8'*'(27<BTJG)RFBL
M/>50TPZB>J+6YDPX@H>:DMSJ/[HF(XA#KEA70%,/-\5<M<';93?3.K6)P)*`
MY'BVMC/DHVV212L(DM`@@?`7D,KW!V6-R4C\)%MKP3'6<,QBKQV)Q-C*:3-N
M)2$!*W)DAM*WQX`^YQ_AA14JWXQVD`??$]*_!7#KV5*>4&H[''WJ1XYK6=MV
M6SMY=6K9`X[DJ^$>?/295DT/2I,C<$\E!"M]^(0HH0D_A(!(V/XQ^GK/<.I)
MF<98FF;Y(I<=B1YUM)V^!VPF+*F(X.^RGO=TJ4@%6S86MQ0`2`2)4:/+\K<C
MKB8A`;IHSZ"VJ4U$1(LGD'<$*D.(6EA"_)6EI*?D"7"H;G',L5J+7L+FR94F
M>T`%N(D-HEM$JW^!20"I/,C;='Q)^8!W\+1-MJK%6V:RN9:4ZE!*6&"HI2=E
M'=YWB2ZM0!!".14HG<@;]8^C(Q=+^CK"($L/K9]5*D%*6VTNH`>6YNGTDM+*
M?NNX"-R5^#T1->I,X@9(Y,@.,&MNH0<,FN=)]VEM))"GH*U<2ZE)\K9(#S)V
M*N21RZL=N4PY"9+:$J;4-G$+"5I6RLE#J'$G<+''=*D[$*!\C8[].\RW0O#\
M@E5UU7QEXY>1EB4NVJ4M@20$E*VYD)1#+X=1\"W2`ZI!4%+4%>&OZDXU:8NX
M(]@R/=GGG?<)B"%,RV4^%*0/B+:TC@5M.;+3R^13\?1%KUTKPYC`>]FFI8B!
M'J+/'L^NL:YK25NUUEBUE(+#6Q0"8#OOD,I`^YLQTD_"/.U-IQ*5!)44I2-M
MRL$JW5L.1^38&Q\;!1)/X]BVW$<<B2=2Z+-7&FU2:S3[)Z!IU:&E!I4W(\><
M0M#A25I=$5$Z.WZ)2IQJ3)0X5)5L''MK:.Y<V4LD+^/8^F/(!4>(XE1)(*M]
MA\]@!T152GD$`*!&^^R-B$[CY<3L"21MONH)`\_HZE.%8V<>)#?P^FV20=]A
MLI2@1LD>=D$`J\'CO\X(W<64^2T.2@#N>.X'G;<D;CY#P=_.RAXZF+!>''<<
M$^"O?[H4A)VW*0``-O"$'F"`24_A(HE6Y)44!*CL$CX@C<[)!!V"0?!(`)W\
M$'<==*'LX4\>T[!!NH_^&LZ\J^?^V%OX_0!^`?@'7->@--[I:`4H@['8D>-M
MPM7G8>=]S\SX))\CI0]G#R^M/P4KXA1NLZWXG<?[86^WX_\`V]$5WU8_V_OO
M[*G_`))6]'1JQ_M_??V5/_)*WHZ(E/[7?Z`<#_['??YEN^OD]_R@3@?;(>T$
M4&R\XC5VE2-RI*5*<T@TR0&U<0D+"$>H=UJV:'CYN`]?6$[7?Z`<#_['??YE
MN^ODY?R@WUW/;)>T!;9;W;3J_0^JMP-!D!6D.F2E'FOBM#B"E)\$I`'(#<C?
M;`^<_P"I^X6.,'I`<#O`DDL&<1J7LP(GTTUUC;TJXHX[*EF5(N:6-'4UR4ZF
M0_9Q&XIY`[N.(6M"AMN24!"N1!!W>)SC4MN,ZY!O"F:F2IE1DR@SZ;3#?!Q@
MEYT-M@/CX4*42=B`D=:.8:WF;*H=C%8<:N:A]IP<>:7&IT=>Y(("$(=2%(/Q
M+W`43MX&TS5_4J-IA%@G(BY7NWCSQB5E9'CV5C(3$0EQV6ZVX^UZ+#9<#3LE
M2DEQ]Q+(!^()G'!-5.X+1F\SY<O%6H9B>FAH^T/DED&HNMZR.&05)/(`^K8P
M'"G\`\J?/_=Q^1^0\><CAZB:K`-B5=17"!N0'(&_+P"E"RVYN`3N-PHJ\$?A
MWUM2.YZJ6LF/%RUP>IZ02&J.$2M8*D@>I)>`!&RAR!"C\*3R!!M*^YMIXGTZ
M3*7$)4H[B]JVU%2=P4?<X:PA1'$[`**O(2#XWRX:H@S;K7:ZOQ#K+1]'ZL6W
M"T6JEJV_2.6J(\R8W!REN4\LL<'O_+>[\PPRRTL(+P"?A2?@03R.W68XIEU)
M+LVK&:XVNP:B0R['=;COL<&6VRHN,AM2EMJ0@<T.G;TP5<0GR=-D+O&<J8'N
M$/3J98.,MO-^\6&8/I=5[T\'G&@(U`#L!Q"PA]*`A/`GEUA&6]V>:Y(AQAK'
MZG'X*VT,NQX5SD;1D*`2`B6^U)C.2EJ:;V#:@B($)*O2!"BIP5:;[26N'\=&
M*.(WY;;[]0_2#%S+2U4B-:RX5$+!J.Y&/NL.3$85OZFRW6H5C$84X$.+2'/1
M)`(`5N!U1R,TTG4J048_2R7I#ZG.3@O3R*_FA'#(&T--DDJ!2D;*(\I(ZYA7
M-:,N]#U4UM)\3B>`]YO)?)+A2E!'.X*".2OB``41Y0$?/KS_`#S9DI#C(K:5
MEPC@VKW2>HEU+G(AM;MFZD[)"74%QM2%*V;(4?A,C#J.63SU?37)1Q!LN0(T
M!.@A=%W<_JI[+")V]2)6LN@Z\O[B$7T:HT[K](-1;;"<_D5$:GC_`$G;99DB
MG\DB5F`LV$F7Z-=D-3;2G[=3AHV2^9+S&ER?J]VQ/39+-!VU9*BL3\44WG<'
METV:B,HI:4S+DU^.0XTI:4$(2^VPR5;%0;;6%(Z9TS7V$V2]-?0D/S)+\F6X
MI#;0=??6I]Q3J4`+0OFXH%.YXJ6L`)2GB,CB0'X82M8:4"ELG<A):*'%D*(V
M<^Z\G0G[Y('P$$\AUT48;"35K\QI:P@`^&NRY<:J@RU!J#%B*28:[@VRM%DY
M5&J.A/)Q[ZV5UIP.!(+NN&H`')T>GZGILPDA16E*?44`0#]T40?!BK5#0]3C
MB_K9VN?%242'-<-2%J*U(XE(2A"0E`;`2I10E2_*0O8G=!!&D!;8)2CU`MKB
M%Q^94MI:PE7J*W3\B#L%*^(I`Y>.JJ/7*<4I+CA97N$H2DH)]12"XH>GNE2&
MB@;H!"5A/A7R!-N&@.7J##ZZG`=M7(Y<URG$#`MAP,J*(#@?3-MQXI<&=5-)
M6VY#3?;?`9"@KU6GM7]3W$[%0]3F&Y+`*`.`"_F%)W^$C?J@_G.TR0KT&^VS
M$FTA2EH+FJVL"U[E(2DNB-D44DJ:)4L*(4@`GR2#TD\J$L./*3+2M\.(;<)4
MAE`:4"/NFR@""E*?A"MG$_)/XZ-^N;;"5+YJ:4OF^I"V5+65$+;#+8]->VP2
M?NA5Q1MMS2-R`IR>;]ZK;4[ACNJ]J"T4<AATECM&YN))R+I:QJE@BW$LQ^W;
M3\DL$),G4C6ET'@G;9:VLZ8W1Q2?))<4/'$%6YHCJOA!+*AVVZ0J=4ZE'%>9
M:XJ+3*MDN*<2K4QI#B`0%>JD<D?`DCXNDL77QBVE07Q<4%H;0VX@I==')8'-
M07\9;`/$GQL$[IWWZE-1VB`^ELOI#1].."VVMSTE+0XX2CD"0I.^Q4''`%$<
M@DI4'`S@$<ZB]ISL6GE>"5`Q!E33E_;H$Q:(=M;`N[I64:PXD&?11VVZ'('-
M0;;D6>M#[9(40EQ:G-52>/#XE`C<GYD;[#VG7''HS:'FNW/MV:"EI*E.U^K4
MII0<4!Q!=U3!)5X\%(W.Z5G@3LECR&?A*(T<,.*"5M.,J2\N27$\2A("5!M"
M07#L0A8\;I!VZ\R64-ML@E2W&'&_7(0IP!E`*?63'2ZAH)6!Q2%\SQ206]MC
MT'"6@R2TG(`.9:&R?\">V<AQ2Q-N&D$LP/[3.IW>;!6QKO4I`*.W'ME0A)(;
M#N$:AR%@%/!7+U=5-QOQV2=PE0.Z2%$;^6=?882REKMJ[5VT!"D.J<TRRUYT
M*"BM"2E_4I?J(!7NI?)7%>_Q'CMTD9=;]*2B&PXX0K[DVF,R4/*94E:6E.;;
M@/J^$J<Y!I!Y((5Q!VK:6Z`]AN38CV79?JKF>L';_7ZB:BZGP>XV^U/R-N[P
M>[T<PO#8DO#M4,-FZ7Z)93DNC$'4O6*!FFC>-U=I0ZNJ^B<,O-0VG+&%0V[J
MH)II#D57$.7?NWF\Q>1E<:X=6)B<0`H#-%0I%V`,4D.Y><PF)H[C'6`YZ7;A
MVA*:0A06I[1^X<66U.@`.I?U`65)W6HG92]E`).^X(J%]Q\E@K([<>SIM0)0
MI+F@[JEE``""XES,7Q\B"4DJX#<DGR"[BZ]G^SF/=IW/:,:79+@.$8;HO38W
MGV(`ZFK[AG\^TUSW)=*,7P.VTORG$\-P.?JI!G1-7L=U6RW(V\-P5.`Z5(OK
MW(,<B2\<<JI:DXA['34W.:W';B@[@-$LCHKSNFT2[74Y7C-?G<^AE6VOO<9J
M9VPX;GV.R[6KH)V98?"U$TPL;BWE5U6Q`DX+D>/W&)Y)E-W'R;%Z"KX0S()`
M,U5O/>EJB'\?!UH!C$GAHH,D$BC##L0#=BPJ=W`>"`&3!F>Y>:PB/)9[>.S1
M0<2ZI/+MQJGMD@*2M9#^2.?-?E!*1X2'$@!(!3+,,[3F\P6ZL0TWPV7&81&;
MC:>X8QB,"7S0VE+TN''L)PER$\"E,@K06MU%()=4GK:K8>QBU-JM3+C`)W<C
MV_T*:7`^V[4)[*,G:RNGJJZF[DAJ@BJOKZ"(<RQHM/M,V-*[G^=34F4B32T<
MS)<&KX]=+EY*W[HS/N5[,<U[6,%TPRG4',].[6UU/@XW;G!J>>TG-\5QW/-*
M,+ULP#*)=,_*<FSL1RO!\ZK(;63FOJ8L'/*;*</9CV!J46TR:3AN`"Y)CYN;
M/4XM</J&EE3$HQS2>(=T,X`H=G$%@':'EBYJ8A,\6EK@]NT)!62`M^.7?NZ>
M)=0T"D%M;`*GBLI\I*4J&Z%=6IUH!^4A*U%MU82SSY.?`$(]13H!X<U'<)4>
M!6V$@@@;&O:4AHEH)2IS9UWF@I4@K"4G_P#2$,$'RETE/JJ3N$*.W+J@6I9=
M:;0DCF'5I4E2&VCZ:"M;2DGY)],E:`G8<D)2"/`.O67X6-+O&D.1L7TR!Y/`
M#+=5_)WA'1[9SL:4HI2Z_G&H'%*0HE:FM%]2!LH`A*.#:BH'R.)`VY$;,-[G
ML]EL]S?<FR*JE<0QW#:YL`^[.A:@UJKE[8*UB01ZG@*<)2>2M]TIW\/Q_D[W
M#[,SV+@*"E(SC/T`$[K2V-&=22.9V/WRO/E:E<@=]MAOK-[EDA?=3W/1G%%"
M!W(:\*#WIJX['5;+M]]P@$[I/@*)_"`1QY9D`XDAVH!&H()\;.S:"--P2,!P
M2"*R[?ZTC2P@<[.L+&HM@PE2C642$[#FM<9\`_%X*C[R``21N!XW^0\]"-3+
M9X*0[24;3B3RXICR@DMJ*@A04F4D;K"2H#8@)*=P#X&#+#84`VHK3\R5H"?P
M^/`4K<$>?F/^_J2$A((0`E)).PW`Y';R-OQ[;'\8V_3O/9T?2%08M;?,=03E
MX6G-QI9IS]>?R=BI=)5.J(.Z4^_;JW^?!)G)"3\B-B-O.P\@"6QGI6V5KQ^I
M6HG[GR7/X)(W"DJ2F:%?"O=!')6Y2H;@$$X,MMEP)*V@MQ"MT+5Q4$^=SL"G
M<$[(V(5_N^=]QM[:1&05@,K1R`5S;4W\3NRN14WZ0W25<=SSY;%7DD;F>"C3
M<ESMODWB+J..IKEW>U+2SY_AX-X2@-ZCJB.&0YBF+.M(Y+6'_IT<4;#EQ+%J
MDG<`;I(V`'C<[JZOU;JRY7V,.XKL(PUF?52H]O"6^F^D1V9D%]N1%<,=^W>9
M?"'@A8C2VWXKP3Z+[2FB1TC_`%Y',$'F?`(.P`WW`'S'R_#N!\]]C\NG!0[\
M(\SMOFS':$&)6,[;`W8Z:CVS6U"U]KEW(Y700L;SG'L%O:R&X'$*Q2WU)T<L
MD;-AOA](Z5Y?CZ)+)2E!,:5!7%"N2D,).V]>/:G7:<>>HI6@.+9<Q)CEF36Z
MJ:K:E:JXI()2I),C',O5*5(0$D;(7:!?@?=4E()U1#;?R-Q^+<C_`-G_`.7X
M_'5QAQ$21ZBGTM%MQ(""$[JX\5_#NM/S/@[`^3_W=5.'AW-,!GORL[*Q^(Q0
M)K8:L,V&GES679'D'U67>794,>Q;$$9#*GVB,3PN))K\5HP[%($6DKY4R;(@
M0`$_<XIDJ"%<U#B5<4_:'["O^HWV9_\`HH]N_P#[I,2Z^+5+V]UF';;>+*/_
M`/P<Z^TKV%?]1KLR_P#11[=__='B76&(7;+*[V`%U?X*HU5XM1#$BF/-.RZ3
MIK^E>?\`\/JG_,]UTHO2=-?TKS_^'U3_`)GNNLEZ"YU_;N+XZJ:,A$@Q'5Z6
M9*D.IBMR''D#,$+,1+J@%1`]P/*0"4I3N%!/A1YF'<EOPY:%YE*4QRZMIIEQ
MI9;05K:VDO,I#48I<0E04XZ2H*(2GXCUTS^W6@3[+670EF$AHI:TSR9U]2UE
M?-LY<A!0N&5M-R&D;^H?5<],G=*DJ!`ZYZI&)%5Q:PI$^'):6VZMHLP&FV(S
MK:GSNN,AIMLEW='J-+)4E<=*T;^$DB1VLR2W]0&-*C1FRM`<B^JER6J0A2$-
M/J8:2Y+6%J2>*D'ANA:G%(0D$6#,L^U`EM^I&E2454X6S$A[D8DIQR"HLN(2
MV9`+7K+:<<0\EQQF4D(]`#<D+]6X?6)EH4VEIIU!45R'6$LK4I24)!2$("BZ
MH*Y(W<5N?A"1LH=7/)\!80Q734%MV.TP6IY#;"7VX;+0<:<D-I0A(?2I/P*0
M&DI25+/)HE0(M-O<0]85T>)>1?N-F\E"TEUAR0T^AV*OUB\[(2$N>JE'&2VA
M*&G$*3N.:4DI15YCB^MD#'J"/]3NG.N-17R*Y$JUE1L<PW5J/7+1]#Q19D-1
M,;U$AP$+@HM)Q3#S%MB*+%:;9#TY_8?J-I7'U8R!U46')DT%+6S)3:0RH0&Y
MBG$MLQ42`'"].<'JOD*#,8%9;0AQLHWUY:D]J%VQ:(B>[/H7.@.VD&,[%"RM
M"7I"4LL+BH<2A?PM+0"M')96E!X-=32S]ZVHR]9&HOH1=9X@Q(-!#AP:2P<%
MG:JX(9P2X>"&5DLM5\WPR<[IMJ+$N\)MV_4B3,>S.M1`F6<5]`^Z5[\E/H6D
M)Y!2]!M:J0]%>;4EUM;B2G=LF;Z+P[ZSEW>.V\.`Q.67'(LM!+*7%@E3C4R*
M5)',G<[MIV5Y!!W'2U0];M>=&6ZO3ZZB8SK#@<68`O3+7/#ZG53&8D5#)0IB
MG;R)B1=8RPM+(;6O%KBI`+0"E\F]S;\QUX[>,CK`P.S&#I?ED=P(F7&A^O6J
MN.T,S9[G+7*T_P`Y3J)2U@4V5LQ/HB;70XY+)$-Y#9;=VIIJ#&@WT-)B+@D$
M3S.0)SR.(!%<5`N'+$6_=0*@;@F`#=@P39D:#9:M26S8T`;)"?539K)X_+D%
M);"POYD`G?<;E767UO;[&CE+F19A`::2`5,UZ#(>5MX(]1;@^+8$DE.Y_%N#
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MSJO2?`M&>W:FFI"40="M),7IKYII:4H"$:AY/%R_482%[E9?8REF25J44O)W
M2D6+$NV+6_6>Y-M946:9A*GR`U-R3+Y<QQME3C@6X_/O+I_U5,MI#TA?JOC=
M*'"DJ.[:\ZJ0'XZY+%WXB06@`0+:F(90*Q550:*26D&D$42&)JK,U$NS.^;$
MK&;77!27VH&G,`64]MYP.YE>1&7HS+904<ZK'GT2(K:PI9=3+M'9SR7DL*:9
M8XJ"JG`M&\KU`NF;B:[)GS+JVC,6V47`>E2),N;,9CI6I_9:U-10\26&`4MM
M(/QM(1Q&SS2?V;L/'(:Y&6R6+2T2XE,:`RVMNA0XEM3KZFGW4QWIA0D@MOIC
MN1!P(65!1ZV:8]VNT611:2LJ($.!`C2(ZUNU,5$:LC1V7&Y"'6T>FYZ[BG0M
M3P,EX>HZ&F&D`_#0UTTAL,,,ZC<]2XL2;!:C#JKG%+Z4`P&+CB(9S9P&$,>)
MTRW2CMHCXI>HPK3:-+7D3JH$:WNF/36\IQ*`](E,2V7)#K"'&MRIAMQ264J:
M*O3*3OT$:1X>G!L'KZ&*9<>8^ACZ6L9H]:39R%)070DR%I4E#BDEMLI"2I(]
M,`;$]8OI?I!78.U*M:UN5+EH@M-HF-LLL*D*!:9]T;6R6G-GFRYZV_$(;!"^
M2N.RVS9K5:S7H=C@/S5,^DW)<>DB$&B^Z\TA:7`](X%02%*XI2TX%<P4K(S6
M]K*_O-PF?4><6J,ZAAAEU>ZDE\-H#B2VEM.ZDA*G/3<4`VI94'=^)0,4N76'
MF5L1ENJ9D$%+[S:G#]T6D!*8J=G'7D;!#I=4AE*?!)5N.K5>V"5UT>^CONLI
M2[Z(:0H.^H]R4H--CFHFM*&W''>`<<9V]9IP%#A*:S<Y79TDJ(0TU8(;=96J
MK*WYSCS"?4;4&0I4-Q+R4.LONJ8)2CT$>H#ZBDD6/9A>M0&7`X>4IUQ4-!V"
M`M9*&B\Q&/I-J4I"DI:]-)2%-J4XISB2I-I>0M,LJXB,A3ZD-`..>H^T4*^Z
M+4\3]Q*E!8'!M*5;^F'>+90FFO9B[-J0B=*=:DL+;4@&2'G&&-^:8\AW@M1]
M)3BDNQZY)'%8077$HX(2&[F2/2<77M!R>\H&.B7R:*@AXJ4MF&E++I="'?4C
M+4IMM;;B5K:4E*DDB6F#ECL"6S&7-4A^2P@(G*(0V$^JVE`+R4)C)"G1L6D.
M.^DEY$D`I0>KO.U'OZF,XZE"6VHCD=V2_+=5+1/C.*YJ,!;)==D^FI/H+4\V
MRD.E''GQV4V9VRN;%B4]92A#0M$)<&N5!90B,"XY'?4DAM"XGK-<0XX7&0AU
MML!!<*3U1OV!@PZZ%'=:EO*=4H\)[C$&7%9*&I<5^:\Z)@DJ2M"2M8V2^I"R
ML!M;?1$OV07UG>IMI;DAF17*B//-/1W&H[<AI]EX$)4TP\SZ24.)4\VG;W:4
MV6W7`\X%'HW]H(VH]J?:RAEQ24AW%!R'`N%M.D[GR.Y0%$#<K&^PW*?!WZYI
M*BZ:B4;:ZZ`Q:-F!+2VRZ&51VF5QWER8R([B8\;[@M*!ZJ6"IT!UYQPA/72O
M[0<!SM1[6.;')/JXHI;*%)2A`_FG<)Y*2K8-M[^.!.X``W'S(M-Y?2H\F0$H
M`]-3Z@H>F-BI:D+`*E\1]\Y\*$[[#X@>I*YJ(R"W$)6OBK9Q2N3!/^^5`D\1
MX)'C<D[;?)77IYM!;#2G2VI25)2AI9!X^0=PIL<T@[%0Y>?)W3MU;A'4P[R^
M`)._`A:E%T@;>0I7E+:2%'B@(VVW*CY)%Y7)=>2I]W8K]3<R-DGEMOR;;21R
M63MQ"E)/S^>Y"NJ^,]Z[RE`*"%H!6D*25O$;_P#E74;EIH*(`0U\2CO\2=BG
MJA;2IQ#BBM#2`5>I(6OTP&U;G=&XXCU"?B/Q@D>4-$)Z]-/&)Q5P4I)!`<<`
M2IP'?RVWML"1L?5<`6?!V&^W1%<+>%765/9TDY)-?>5EC536(P+CAAV<5Z%,
M+?-*REQ++[I0XKD>80?P<>M+&AV/V&GO<X,-O&%Q+*J?S*E4VXM:E*/T,X[`
MD(6I#(>;GQ(C,QF0AM*'FI*'4I"5)ZW.)L"%_<64E'$!:BZE(2?!V`)')('X
MRE)43N%$D=,O[C]-YM5G6#=QF/QI<I[%;BHKM0H3+*WW9&'EU<!62M-,H4^M
M6.Q)[[%QP;5_X$4Q+*$QZI]:2)1L?L"W(F,*4KP4$).W+X9"0M(!/X2=S^/<
M_A^3SM%68+.*7$UA23-G9#9.3U\]UM+CQHK45I2?]U(AH94A)'R65#PK?IE\
M7TJ3*8\UY#;\%3Q6ZC<*;>B2`07!\TK2IE96A0!/WBDGP%=.ETPK+>@SE4",
MH/XIE<%V7R6@J1[U%C>O626G`1P>7%4N'(0I*DR&FV5`A3&_1%E]DL/SH\YX
ME3Z2WR4$I1&:8;'I(9"4DJ2LCGZSBA\:G`4^=^JW*6@741:]+*VG849Q]VL=
M][`:E`)$=]QA2AR+W!LM.`**N16V#Y*GS<-@&(Y(90&UN.D/)4E)(#V^RV`K
M<(+93\)!^YE1XCR-IL.CBQD;()2IM(<"2AK9)\JYD(1\!"MB2D`G\8)WZ(KO
M6Q;"-3UZ)!!>1`82LI!Y<_2&Y6-P4K`XAP'RE04!X^;8^Y=7IXQ0`((]2\DJ
M4O;8MI1`)"2?D/44H@^0#Q.P.WAR<N],,L(6R]P6PZX9#;Z''D.,[<E)85P3
MZ3BMP>:@XH$\05)(+)^Y;.%9'84V#5L,)D0WVI<Z4TL\G)=@R$L,!L'[D(D5
MPO/GDI1<=0DA/!0Z(L(P(*;>K5<5J;<J+1]2]B6PMVR@(BE2N)X[H1*6G=20
MH)4?.VP5D(4H)+1W6K8`(&Z>)W)Y`#?Y`[*)`&WD[';K#<3KH[33JFY"4M,-
ML4[*N;OIN-U:5^L2T$@<ESGY0"@%H<0VA?,@;)S5M)<'%#CB_/QA"0E'(?"H
M%84E*R!XW4K=(\)0`1T15`/%"OD2#\2D\2"-]U#=.W(D[?$#MML$I2/OIZ6U
M*22HA"%^0E"BE:_AWV`(W/DG<^`=O(*3U2I>"7$LI'J$$@%(4D)/R)YI^$I`
M&Q``4H@G8[]7)*EK()3Q\#B-AR5N!MN`-T_@WY$$C?P-]@12A$"E^IL$$)+?
MPJY%2"OD0L>4#BKR"05`#;FE)(/29[.-OTNT_!4<BHBYSHDD;>3F%L2-OT;_
M`-_7.`./`<TD)W/WAX\5>-M_.ZBKSQVWV/Z?(Z/_`&<:TK[4,&4E)2/IO.T[
M*^^W3F-NDD^2=R03YV/XP#T1775C_;^^_LJ?^25O1T:L?[?WW]E3_P`DK>CH
MB4_M=_H!P/\`['??YEN^OD[?R@I+K_ME._UC?CMJ_0J1R6P65J.D.F80%)<2
MIQ*]]@"GPKY?#QW/UB>UW^@'`_\`L=]_F6[Z^3[[?Z.G[,Y[0!U+J$NJU:HD
M,(6-P'/YH=,U+</-.VZ5%"PEM7+?8J('PG;`^<_ZGQD+#'+4@Y@N()#^$_PZ
MTN.1C'6$\BIQ32>)'!'HNCYH>2?4^,;>>*@LI5R_LM5A[]/<<?D2'I4A;!2I
M4AUR7(>4O=2EJD37G%E7IJ(1LXA.P`XA1)5DLYI0>0I;BG6QR4IIM'%Q(*0A
M+SZ/`6IYP;*=*`DE*1ML$]6SW)UI2FU-.-I"2M0X-J+3.Y4A2ED\4'X2%_>_
M)0&_(#KI(!N.NO!9T5P*B0[`^["\!LA,NY=61V*E;B7%I2ZDCBHNNEDM`**D
M;%`*2E`/!(4LD'R#Y/4U$-I!V2AH-@$)0&DE0*CN5%Y1+G(J\@`[``;>?EDH
MIVE?`MTK)\J2D('W(%04ZI"]U>DX0$-%`5ON%D_-(\MUJI33+B5[D-K#FY0I
MP+0E/ILH4-N*5_""ESRCCN2"0#'#2]@YSS\3F.9/H%/:TG]T1J,G$>'.SB76
M/.1VU\E<64*"'%I6IE"U>N-E-'SX(*@0K?\`"0HJ\;*K&X;SJD*+#BFFG0IQ
M;84D@I;))\(WWW.ZD[@E.Y4=B0<CB5ZDM@.I9"PXI*B64N*]((V*4.;)`*G%
M$ASRL)!"21U<U1FTH<`;XIW4'?B6%?=P$.;;$J*UA(((2H(4D+/$;DV8"8R]
M+;=<EG5CBP<RP(,2S-8ODP,&RP]F"X[Z*>'%IT?<U!`4G<)44$-[_>A:1R/R
M;3\9.P&]PCP7PZETL*X!3?#@XTI)+#P*TG=8.Q(4"I6YY$G90`2,B;:X<U!2
MBD>DD()/%H);*$A(^7QC[XG\(3MN?E%0*''5*+A'%L@$H+8'`#9L()4%``>H
M%>>1W^9/14JQJBX#,T"7DA\Q.1O:+KVTTVTT4I:""ZIQP;DJ27%J0%E'Q(X_
M&'.2U!0)41P`(VG,I4E9?2$>2A#BG>)#B6R%ALI60EPM@\D)^:5%!!'P[>VV
M'78ZI*4.N0X_I-N26&5/,L.S"XMEIUT`--K=4T[P#CB>1;6&BOBH`0E`9*7W
MU,MI(?2M302AY6X:*>2E$(+JDH0WQ"MG"`".))>>WVZT6!G6XR=V(CIVA>RX
MVEQK=MAQ3;Z%?%&90II275+]/U4^HI2AS;Y.IV6IL`'Y["MC/27O72M3/!;A
M22E*%+"@%%#C"DH:Y@A`!4H%2$D$$\5'JE2\0M#?$.M%2W2'BXOTO63L\V"5
M+6TF,GY*0..^RP%<>/51';*905MP:;+W%M3;A?\`14%!#A2$;J25*V2H^2%+
M0-O/52(,2SB'Z-OY95JL=6)#@&QT\O!GM`?37ZH>:95)<#:BT`%K<*F=RI*N
M7$+"SZCS2/B"$*2#Q&XJT--,KY.2&U%82A:?42VGXD%M"@WP7R*D[)05>&TC
MBKD`.J(EZ&$D-%M(;0H-*XJ4XK8[O%Q+2@AOBHE39<#FRN/(`CJ2A0<4'"Q&
M0%KX<U>$J4@!P-.%:U!IHE6X6``E0V"=@03$M+!@8;:!I-F)]`JL39V#9B;.
MSF&:&>UX95L9T):=90MMG@5/..N);*BE*G&UD)`]%P+"$,?"4K"EJ6.0V!IQ
MZSRDM@N;!`6PD--H0@OA90[NVK[F&`5J;4`I1V7PX[[GPZVIMI"4+0&4O>GZ
M?I?&DRUJ?7R4H!+H"AR"DA*"=BWLG?:?%9#3G-++KCJ'_3"@[Q2TA7P)6ZWQ
M*RE>ZRG<%*2"E7C<EJ0TMI>&=VN]MXER427DZ@?XC-F=Y:)C4S)#Y>2OT6T3
MG04,);;5Q#+:TE#K@?6V$I]9?'DHA2FT[\05#?J<@I)/!R*AEM"69#)02I`1
MY/%_<*DA:0$@`CB%%8Y;<>J)WDASE&44OJ0A00PVAM"&$H*U*?1MQYK('@^/
M'R'-*>I;;CTU?HH#1)=#Y"FTI;4AM*B6U\./PN+45<Q\22-MR%;=`(#&-_Y#
M;@L)#RY4<+@:,"2\AR!G&4$`/F^=:I88/NR&0&7G77%!+CB"(^Z6TGU&>*VT
MK(44E1"@D`$I'3LGN_;O3G8WI+0/]S&L#U)H376E-HKC3N1PF\?TZJ;;#7].
M[REQ2CBUK-/]#VF!RI6)653:0K&OL*&7-K941Y$J6'FAMR3($I24)_Z0&^+3
MGJ*9'H)Y<0IQ7JK62"EN.!P)^([I&QE-+2XC<I#JF6=UI+*N`2)"5K6E+3@*
M5-I<)Y(XDI2`4C<[.$&XTOWC8/R>QU`G:])KI^6HTEQQ$$N68AV.X&5GY/%[
M7^\G/>US/=4=1:JBQC4>]U/P"7@.5_SE5M%DJ'ZZSRS#LPF2Q"S'$M0,6L)K
M\["ZZM>C9!A=S$34/R&*M%/8L5EC",E[Z.[')_>XM#K-FVF>G$3*ZS/L0T8T
MUO;C$M(](3C&K%IK%IU1:685"D)B8E0Z9:E9%.R/3>MK5!>(3GB*E^-'<5$Z
M9N])=6XH/.I6VH`E*`E;?`D+20/A(6```I1YIV*5[[*'5475)C2(,,&0A_W1
M2UAWFXX65E]L-ME(*$-/!+SB&R4I<:96M2@CB:\%(N`2>$2S,&&88;9P.2N*
M\0`4FL@.2X,N1G4=:F/B<G6R?3+VK'<GATS4"XU;CXAW76>I,32FHM[+N8H\
M.U0<D8WHY)SR1CN"SZW-<&S&LL,#ER=1,@;M*^+#H\L9B^A`QO-\<@N28S[%
M-1]=-6M4J/`L7U"U!R7*\<TRK%X_IK0Y'<RI])@6(-/OO-XKC#,I,B1"QRF9
M>56T%>]+EC'Z1#-)4KBU<9N*E.5,2G2AIQ!)2XY(`4TE"7'$I6XI;:ANE:TA
M*0'`%<OF`0LGH<2%,^BM3#K:P%DI`3P$A&RFU%"%".A+W_E$I`62KD`0I0%A
M32"X%+EMF&37`B]@6G:>UJ(IIJJX@#K<%F);YC`(!O+%E;QS2ZI!XR$;DGX%
MMLH4I?-#C?J-D/.-M[H2"HH.VYW).WEWU"5-I2DI2!R:4M'(**P!R4D+``:!
M.P!0YRV!3MOU4.HV4`HJ#K:ME!I3984G@$['8**E;[*"DJ2!Y\>=A;VD@+DN
M>J#R6D*4V@H>;#8`;2X5`E?P*W*N"4\-E`D'D+#KWR0,9S`#7DN`_=`:[PV5
MS?=1_)VI9?\`;.=C3:$A3;6>9ZDN)7\*2O1/4MP[`H25*!"4J3]\DG<@`>=;
M7=,$)[I.Y@J5Q2KN*UY4I(V^(C5C+]W/B('P[)2L_+;R2"!OLE_D[R-O;/\`
M8J5N'<9UJ'Z204I2\E6BVHY2XXDD%;X0.2B$\0%;@C?8:U^Z0(=[K>Y>/R:+
MKG<-KF@()67.*M6LPW)1_P"3+0!*E<?BV^_WW'5?[AR(HIVSJ]M%I4!V0:!Q
M5$L_TT.Y/F8`!A@R0A'WSAY*(44D;I(2-D\2$$GXMBD\B`GS^`_,S?\`\O\`
MV=37V2PX6RMMPI`W4VHJ3Y'@;[`$@;?+<>1L>J5*BE"2Z>)4O@.0`'(G9*1M
MOY5MXW._GSU98N\[#[=?E3D\>0Y;A.XY%.Q4$[^>._C?;Y;^-_GXZ]*4GRE&
MY1R*@5A',_@\J2-_EM\()2#^,^3*0OF.0"MMR`5#;D!X"D_AXGY#?97@[@>-
M_71$?A'X?(\?C_0=MCL?D=B#^(@^>@_,_@W).WXO/R_[OET='1$=13]^@A/)
M04D@;;DD*!`\>?)&WCS^+SU#J>RP^X0ME'(H4""%H20I.RALDK2H_@^0(_!O
MT=I=MT63+<4_`?6I/!Q<.25(V(XK+#FZ?BV/S^6Y.V^VY(Z^TSV%?]1KLR_]
M%'MW_P#='B77Q9TJ<<A2#+1Z;AC2TK"5``#T7-E'<*`W'^[R.VWWWX!]IGL+
M\=C?9F!Y'UJ7;OL?Q_\`P28EUR8EQXV+Z9K?X$3B6M2(+C-FVT/V3L>DZ:_I
M7G_\/JG_`#/==*+TG37]*\__`(?5/^9[KK)>BN>?VYSZXVJNCKR8I7PTKR58
MD-MEYW=K+T.*CAK;BE!:#BRM:MEJ*6PVZM20GF].16%G9\TLO,Q8[J8Q)*E(
M*BEM.[T!*`I)<.RT(XK6"KE\3@=3UT0^W>L9%=K9H>6W6T,R-(LJ0Z%K6.*6
M<S:6I:D(VW0>:$`E23R/@\N/7/=$E6C,!QR3,A1JV8IV2)$,0F[)Q(6S(]9/
MJ%;I>D<Y#;3".+B5@LN%*GDGHBNJI[D)MB15KA-6;ABQ([MN\ZD,LNN+;=1'
M;D?&E39<2I#OW-:RIQI8!7R;Q]^)(R.XJ8[\F98QT)DQ;".E+,-J-,W5M)0A
M"DQ[)UY+"PS&WFI]-`5S1MR-S@TM1E;L^'&EN2YKCT9R)6M-N27X@8;08[_H
MR7UI#[7-(>:F-.MQ91Y-[`)(7BDTS@MR([\B<$I6Q[U:EHJF24K40S'B.25%
MEJ%+DO#[D([?PI*VT(64J<!%04NFT9&$R*E^2(5C;3:_E6UZR]/2D2$O*<X0
ME-")#,..4/MVUBPXXI3X:;#(037S-$:Z58R1:6=9507ZJ7#IZ^NBBRM78U>D
M27IB[!Q`BPX,=YQGTFZJ")"FW4AJ3)4'TET<&-1)A4=?61F(]3315>J:]U"G
MTR$)0M9DM2T+D24K4DJ'W-L+6YR6-@KJKA0J65EKULU%F2(-;CK2/?PRTA";
M.3+,Z86YSB5+0XRRB-%#;"0II2DI!(^%)%I>U([&8%UEEX^T(Z&(\ZOALIL&
M9<.58&YBJFOEMH-KGST1HJ2MUY,3TVUNMMN&+LKBSG5GV:V6T$ECW6(&V+&4
MW`A6#S+K=<ZI\H?F!R6YRCQTQ8G*0M2C+=;0DA;9"5K'23'JH3UGD$^KA/6V
M56#\EIV2TR9L.`T['3&];DXI,>2\[$3P6P^\\&W6DI7';;W!3C)=*K_(;TFS
MF.V,R'';CQF'ER;1^&P&FGI+]7!:/T%1+F+W:D>BRV[Z7IH>!0RL.2"18D<H
M5:J::@U5((T(<=0%S^L>S)<77P;25?UWNTMY4=V4U);C0HT=K8/.ID2FTN2E
MQ^2$/-Q2XTXXH(0.6R.E0Q_V8N!B6AA%I:Y"D,)E.RZY#;=>R@+7[PA3KSD5
MJ(D-#U7GI$AAEGXF@@.)])S>/%T:K(L*$Q$2&9D5EQLQK68N\CH65)><DK0/
M=JR,^MU3<AE$(*W"R7VGT\EHOL#"W*RU9<=@L/JBH>@-2TQ5QJ^.RA`8FQHB
MIKHKVH:6$!32E,QXSZFMD+()6MQ5:GS*CL\,?LH_\CVR<MIDM>VB_9/IA@#+
M<FLQ"N=OB^RTQ.R(_34N*@O%M2'ZITLPU/MN<5Q7HJ51D-\5(]4*<=6[=.E#
M34F,**$]/B/P4*<7*80QRDN.!$E*5!EN/$BA*0AMVL1'=0%*2X`D)6XY+&H]
M6^M^PKX3TR7'*F=UA-1#06PV&(J9)C(D37D%*5A#+#K(V24+4T$DY>N?(5";
M:ER'XS`4H-MM[IAA][D`VI"DHEN*:60M7/@A>S)+"E!0$*Z;A$TC8KFF95U#
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MO$>IZ"-T1P2I+;?SW2?4)M5^AD^F4,+D,/6<KD&5!.T7TF6E<6R%NAUYLK`2
M^M"24#BPA9!416)0,&GCP;&2RU%%U*<D.2W6_?UQF8;RUJB1HLAU3`6E;ONS
MC\AEY33KB!'5LE!;YD=Q]&J:>C,J:KY3KK"Y2;6)$48;2T/M"%":4TB`R.16
MZ[.9??27FTM+"RM*E8NA%X284=E]$V/)>9B-1$+<;3("$QRXMX^O_P!)2E6X
M=CI>>X(].0J.VOF&C9K13V9#4Z=(]^9#+C"8:WB8W-*T#A'9'IL.*]!AEU)>
MF3'VVP$A*5`-((L^;N4%%BY!FU<9#C*'40?4;4J3OP#K\N2B2E]:5N\MU+<C
M^BEM"PTXV3RL46RD0Q:/NQ%IA2BPJ)[L%.R'9-DKG-DIE376U1(S2)!??E%E
MAR,%;(><);80FM>MVO0^^B*A:YDA#[Q2MIM0CA&SHW4RWR,2,VVAMIA@-I=!
M"W%(2$ISCW=3TAIE;R7FUI:=+#*W75.LN*2&D[$I+BDN-^HI:VS'9+BN16X0
M4$5T7%CJ:*U3E&7P?^ZRT>I6M*`;1&0RT6EL/I<6-G)$CWE]82I#*DK>2YUA
M\VN9:E29KC;;[\=QU"2X4+KA)<4E9=B"0MR2]&)]1E$![@T`@%U',-N+R:.X
MU&3)80\$K2`VN('52I190I3/J)0E/N[)4E24%MEIA26W%DIW7SZE/Q!Z*'?3
M?*&W"B.XI4=I37-7W-2DI((X+(6XDA1\!?-*D[@BMU5)E353U3E)2PU53TJ9
M$GA#1&7&*/2:B!EM,=Y*5AM*U-A*V]FFMV]E]=4OM"$J/:1VGELN;(7ARR4E
M"-TITC7MZJU\6T-[[%?(@'[T)5OQ/**Y.:C(GL649Z/&ELR6FID5!4[)=W26
MN14I:4A?`$)8:7N%`J>)^`=8/?Z4M]I/:>DA2VQ]1R2M7@CCI&KBM:E[<2=O
M*MN84?&QWZ(M,ZB\Z0AI)=<*@5`*4DI2-E`\ECGMN!LI?!O;<!(&PZ-@YR$A
M8D.I*F@QN$M(*2`GFX5-NN^"DE*3P5YV!2CJ:)2/NJ6QZ8&Y/A3KC@\`+4ZH
M^4[_`#)Y`[`$>"D>4&-L%.I`WXD!.YY[G;DV-R5*'Q!2E*V;22L`;IW(K6Z'
M9!7N2YZ:E(2E.WI_#NDI;;2D#FHG_P`JLDC<%!/E(E+:=5L"TI7(?&.92KX`
M$\%G[U(*MSLE`((VW*=RG(&G8Y40RCU$`J24(0023Y)#I6%;`??$I2K;Y!94
M"*>8^D.!+#964`)4A("&R/*DE*MT\E$';?XB#N5<3OT18^B,\DD-DD`J```1
ML%??(*CX*4$$A8W).Q0%J!'476@$^D_Z<EE:5ID15E:D.L.)4VZQ)0L)+C+[
M:EH>95LIQM7%:$)^=T6XII&^P"N6ZN12!\9V0&TI5R#@V)&Y&X'WQ^75&XAI
MQ>P*$^IL2I2=W/EOR!'DDJW"D[A2E'ELH)Z(DTG84W`I:^%`>DS$5C'NU:[-
M+3DLPV2H1X#SC++#;PBQ0W&@N%M+BHL9M#RW9*77WE1TAU'@52F,6S"2J(PP
MM!HKAU7'Z+<0L[5\Y20%HC>H>4>2K<,+W;=V85NFD6ZVTVJ.E27&B0%,+5N`
M3\1*U`[#XAR]/9*T$`I7N`KI-,CIU/R'?7JYS3*DI5'N(01*#BBVE3B)\.,G
MWN+P=Y(9?+#[#[20ZY(C%1:Z(MDSUVF3"BIV2^%N)6Y*8<;+#[*0?34UP4I"
ME+)W4I"RCP./S^&CD6C2@KBE)!0`$@!*D)3OLA1/GX5'<K_WMOBWV&VL.NRG
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MEUU3BE.JE/AM+7KO+.W.06D)3\*$A"0EII#:$A`(IS,8,MIC)9*4I0A,=E/A
M00A(2A1<)*BD#<G[IR6?C"CU-6M:-FEN+#0)^YIW;2C?SQ*D@<O()"EE(43X
M225;RW)ZD[--)"4I`1ZJP`2?`"D[[DD;;^HKX@?!2`-^C<K0@*'/<_?J.X'G
M[\I(!!)WW6KES'D$[A((KFB8VE'%#6P``21MR5R'S"%$!"C^%:@>0'S.PVFI
M<<*5H6ML)7Q*BDJ4L`_A4H%14H'QN`GR-@!MXL[>X)4=DJ!6/.V_'])5N5$`
M^!\(/E20D;]532P"D#DE2DJXKW0$*5OOX\_&I.WC;PCY;C??HBO[94I.W/DT
M$^GZCFZ5J/X0WY.X(.W+8$G<J/S/725[.5*4]J."I1]Z+G.1\MO/U86V^X&_
MG???R?/G<GKF:AN.1R0\OWA25;^>(W2LD;%&PY!))^!(X`$!2U+WZZ8_9Q.>
MKVGX(O;CO<YT"-P=MLPMQMX``^7R_!\NB*[:L?[?WW]E3_R2MZ.C5C_;^^_L
MJ?\`DE;T=$2G]KO]`.!_]COO\RW?7R>?Y0&\X/;+>T#BI+8WU=Q]T*<<^Z*Y
MZ1:9)4TP%+0$N$;%LJ4$A7G[WY?6&[7?Z`<#_P"QWW^9;OKY-'\H-5O[9KV@
M"5<R%:PXT/@`V/#2734GDOBI8*6TK*`CR#N3N!MUM@?/SI/X*RQ1Q!O&?]J9
MN+`E:A$S7'0`H-$(D1VN*W5*6"%J*'G5H0I*TJ6.)0/@\'8$['JK=99+A01Q
M*V_3"E2%%SCZB_4'HN;>H@*5\@HN.%>R2$@$8\X&B6TMNE*G25%ESDA&R5J#
M6RRD'9#)Y*620>1(.YVZOB!%;2\J+(CK7Q==;0'&I!0ZL)XE*R2M"@@%):&Z
MN/QJ.XZZ_+RY;=3K/+4!20SA[!C!'"SGTS!'[E7)<;;0VE:T*4X$^5\65^FI
M)*E%"R%)0G91]-(^#?B$_"3U,`;:2I&[;*5JV;*5<5\E`\OO_@Y$GD-@K?8$
M_A!IWMG=D+*5`H25;@^@I2_#;;3NP6"IU)W*.;G`[*`2>II6@IW>#(6.:$I]
M1*@%*0.;?,CBA9&Z2-_B2`/P[=#SZ`'_`#P6+92Y/>`'(B"PYY![R`IJ"21\
M04"#LGSR^$\=P"E)(/\`ODC;D1PV2>O/+U'$+3P/%M7)*5N%?`GX5!H@$E:D
M;[N!('Q!OQ\X**?22H(2M`2CX4E2]F]T[A'I\E+X@`@#Y\?)\=>'&4_<4)2C
MB%("G'-_A;;\@*4/NBN8);1L"4K6%JV2%'I&_3?SZ*``=0\!F\7L\'*^[LIZ
M%D!#I;2RXM'I*\J=)"@OX5%0"4KV6H'CNE'DI)/GJ9N"0%_$`G;@-DE20"!^
M`@@'8*)22K?8G?SU)7Z;7W39*5*/!:U'@GB1Q;2%`D[J60DDHV2DCY['J:E*
M-B2I:%*"@L;AQO97!(^8"_@0E220-UA6^P).T>.R@]7VC,QXPUE.#RFXJH[2
ME-QG9"7UMMJ6Q'6XPE2&$J82H(5Z'JK+1="E-J<5Z>R5^9B$I;;27&U.DI3S
M9>2DL%:MSN@*<2YL``I#R6SL3S^8!ZI$>1\*-VDI2`XE0*4[_>I&Q))XI\$D
M@I^1\=>G%!:BI+:$>`$MDEQ((`&Q6M)5Y`4K?B/GP`"=NG1WYMR4:A[WG5CX
M',[[JK:DAAUQ"3'4W))1SX<DI*P?32DN-K7P#A2EQ''=83\P#R/EIYQ(0W'"
MPZX=BH[%1*TE"6F@5%*6@%G9)'WYY_"0#U(02D+6E2@M(^`(23ONE0(4OY(Y
MG9M)`4=U<CL$^9(<^YK44@*;*2O@%K*"G;U&T^$<]N7A24_?!.Q^^23>+Q:]
MO#KDG"^\M:YUM-QJ`6L65R<4A#+?!12]Z1:4XM7IN<&B&UMK2.2%.J*0$*04
M'TP>0'A1\(<86CDH)]%E7);2`T3Q6A!4Z'EKYJ4M0W4VD*2&U`I2!LH6]X@!
M*VU)*'`_ZB%;+2MUU:E(=!YE00D>2TCDISE\/CJ<$)2`GBK<I&R0TO9(5L&S
MX&W`H!45CX0@#YC?9;:.FZLH%,.2;GG>V;0=`P,,20KBMQ+P06T-M)>;3'#O
MK+=`9W4[S+7!1`0D#=1/).XX_A5UY/H_"E#S+CSBT;J4F44D\>+82O8+2A!'
MJJ#BE#U5`)'`;"V!2`I#:CQ2XL(0XCF0E`2I1Y)2!L5)22@#?<)`'DJZG)4C
M<A02M"?44V'`LCD1\!^YD%*E`)23OP'DD=&M)9WYF+DART"_HG"S7UREFS9\
MA`+0KS)9<YEY4E*?22RCFI*?NZB$I?6O?X'$)2X4G=*TCX0$_"2*1#B&WD,J
M4TOT)+(0ZRL(X\B2M6X2KDA1*5K2H\1L$IV"M^K>G;T@5-N%:4%2E(4%`E)'
M(-H4$<R`=@@.!1)"MPGX>H_"#NA/J\3RW4D[%(XG9:-CQ23\*CN00>(._4`0
MQ/E'V4`:GT:P#,1;/S.2F/I0I:EF0C=3ZUD)0MXI;.Z@DD<4A9.R04J5MON4
M\1N:MB24E2G%`+3'0EIGCR4HK<!3P`"$CU`D\^8*T)VX%6PWI4H;=<+KCS;"
M7I*$>F5$<0O;8,HX\4-C8@J6L#F=SXZEE'#AZA`Y)42$;E:.*B`'`HC92O"@
M0=BV01Y&W4Q;1N3:2)T-U+4VDL!_^2UID3^%5.EHL!*5MHX.**8QW+K7/RH!
MW@E3G$[`I7N4CEN=P@"2\E#*$@2`XH*41Z22VA(('-:G5;*6E7A*.)W\*"@D
M>.O(4%;!*@R2@-J4=BE:3L7"ZLDJ`)`"$I00/E\R5&6TL)^-7I)V23M(`XCY
M`@@G8J`)/SV`"C^#R$:CGX9L^^LYH!;32'G=CO-R\DYU#("E$&0ZEUOBJ.V`
M5\E[_!L"LI;X_AW'$)Y;G8$=>7)"5I2ZE32%)=47$H04\'?!65EQ2POU0K8D
M`)*=N&QV/4D$I2I//?<I`*`D-.<=R"%`D'Q\2"G?F-U;]>%+0&G!Q07/4;/-
M1WV3Q.S12`22ZGRD[%7P@('X>F;^Q+1&3ZSIR",Y<N9@!K%@1:!O)>!$+VI2
ME*;`4E26VN"0@$*;6DJ4V@IXA*MPDN*7N5\3XW(.TG?93BEJ0E2@IU:DG]"0
MMQ05MOQ(&RCL`DI2=COO+4XD*;4GTB'4K3Q=*V7%I<"`D(2$K(7Q!"E%)4V`
M-BD$]4*4\)$TNN$MH:0&F4IY<&@&E)+?-)0?B^$I*MUN'XPH@'IU;KK-7%+O
M?EKWJ0T\WTCFV['^3M*8<]LSV+A"FUN,9YJ&%GPI[F]HMJ,5+<44A8*TH1L`
M$H`^$?(]:UNZ9C_XU_<I):>*$GN'US;>2XA!Y!O5?,B0A8W*$K*B/EOMPWW(
MVZV2_P`G<?<5[:+L8:#;"VSG6H+BWFN7-(_F6U+2@+)`YD$<5*!4$J5Q^$D@
MZW.Z=I;G=)W-D.+"!W":\<FT\1MQU:S`J<!XDC9!'([@`;GP=CU7^X;/P4_>
MIS=O^PM3&$)8&JJ[&"*'>-7(S$%\T@Z$@*<("P"4D<EE23\`'P)/W@3MQ4D!
M(*AR`\DD3OS42%`;``J(\D$C8)'G;8!25?AYG\6P]-Q_1\<E;N`+^-84=TH2
MC;9(W02$I^%>QW\_(]02X%(2X/O5#<;D#Y;C;<D?A!`_'U;KKT6)\PP#ML/6
M/NO9_!YW\`_V$CR/[1\O&X_$2.H[IX^1N0=SY.Y'X0/.P_N)_#N-MCXYI*>8
M4"C8JY`@@@>201X(_P"_J7[RR&6WN6[3RF@A0!*B7?"!XWX[D_$"#L1Y(V.Y
M&)@`O9FST4]HI<<`6"VWN`5*W^]4=R2$A2T\!X(&Y)\C;Y=17Q"E\?*0I?'\
M/PA1X_+Y_#M^`']'4`H@*`.P4`%?+R`0K;^](/C\74!\_EO^C\?Z.BCK^5Z4
ME2%%*ALH>"-P=C^+<$C^X]>0=B%#Y@@@[>=P=QX.WX1OL?!_#XZ@I?`[A(4?
M)2WN-U?H')20=AY\D?+SU%!!*"H$`E/(>"4@D<OEN"0-_EN"1XWZ(LM+BGX<
MH)/);D)][@!L4I=C.J0D_(';BOS\_!WV\=?:9["O^HWV9C_[*/;O_P"Z3$NO
MBRB6T8<@1%E*51);24\>.Q:C+44D*W("4D$*/SW^?GK[3?85O]8WV9[_`#^M
M1[=]_P"W^:3$NN3$RAK[:#09K?X%@<35J7VDLG8])TU_2O/_`.'U3_F>ZZ47
MI.FOZ5Y__#ZI_P`SW762]%<SOM^\;M;[7;0?Z/8<FH3H]D[#L"*AR1)>+F=M
M;N+CHX-HC--J*_>WWD1V74I]78<5#29IS0TD64Y56S;#<J(W,KHRY#29J%-L
M%*$MORH:PE;_`*2EB2RVMHLNM.%#J2Z`.C/VT=793-3]*GZ=3HL_YK[Z%&6V
MAU;,1+^8(6_.GEM"?3ALM(4E2E/J0MQ24*84/B.DYK31BC5"DL(][YB.Y)MA
M+09#ZG6FT27'`GT78KD92'1&5#;CH(+4MUTGTU`B2K&8&.X[8R9L)+SJ8@3'
M0ZVRFK5)=$O=$IX[2)3K2/24`TX$.+:05^HH\=EECRZO(74IAPG768I:6^XT
MZS!BEUQ\NHE24*4%I6EYM2F838YJ+JO`\#K75C^?6.&YSGFF-WG5WG#-=7ZA
MZF=NV:9%(?5!U:QM4)]RQH<HFM.UYRF;H_/AO1*Q->X6\HJ[1K*(CKC<%M3V
M9:0=STJ;<:&X*(>"9/DFH-3I_$O;N%D2V9=)D^;:19%JBT[952N<:"8GT(U6
MM4B'7A.9L#;-3*EYABLG&]^O-0]AF7C<7'5_);-*A,BODQ9R%M2FO7>>EPG(
M25^Y)<;3$2MQTM(;>>>7ZJDI4WR;2DNJ'%&W5LLGI.4W3=/`BR&JF!8"38KC
M.!B!)]#T@FO8])P*DN!PH7(="FVRT5I=42%;L#PWO_S3(JS3J3<:;Z=&)ED7
MMJL)WT=D^1R+%F!W"ZN7VCJ#&;G5R(TFXQ>[KV<@0XZX*^=7.KJ4+3/*)@S#
M37O0<:D2YN>4N!8QB==@VO&H%MD<.XR"?&PZNT!U@;TUN%9/0*,*4Y)SN._'
M?P.'%M(TBTS1R+B;CC[,SWM@S=>/Y05`V/5NOY6QZGB1H%RSC[MO/BB;'+ST
M:N0VE"F'4*:+4F0A8!4I:=DI0DI*]QR4D<BJ*ZAJEKC',V)1X^ZPE,=I^-&D
MV<MYGBV!M$>DS']T;.NM+\LCPL`*.VNRA[SK^MRG13&,YP/2^IS_`%/R#1BF
MU`Q>JS5Z?DNE2-:\GRJHQ>LNH%@PD5>1XO54M38WE6^U;1[&[G9%01I%*QC\
M2WOLE[B=5,_T0[AM/L^@WN6Y;I-&>Q72C4G2R`M5I41[+5N#F1P#4VOI&$KF
MLV\'4&CJJ*WD0G8*%X_;KXQ%R&DOOD?\:YM^#[LG06:[&N<A.1:MTM2C](.3
MKB*9=G:CU"6C78]&,CA'9;)4W*L5N-(0`%1VD<09$JX6\TXZXE$R8&C[H;)]
MH39CZ@>#;4!D*9BMI6H--MQXH:4G[HIUMI(6-9&$=U6H.#P-2*BZLI6HV;9!
MW2]Q&GV&3LXRIF(S6#3'3:ERR@TS186,N#!QN/E-M(?QW#D6L],:K:<EW%DU
M9L8Z[#?I,/UTU,B]R.4XE(O#+QZW[NM1L(]'(6DW.1T.(XCVC8%JS7Z=8A+C
MS8]8P_*RFYMEQHD)Z8].O"VU`>542W691`7#\O5O=;5FZ9<J;QEIFI4VS%(9
M;6(;)DAKWN7*C.-.>HN.E<E?K-F641@EN/)+B$)*;\Q7PV!,FSEM)4O=IID*
M:>+*$N!/O"7$-+AH#*E).[:G5KY$JX@(!UG1^]N^RW`<2MJG"*+$F-8<3U!D
MXAG<K.HYK<47C>C&7:C6V.V;L%]RZK]3Z?(<?9QZ'7V;-)77-DU-MHE<ZW2N
M5SKD].\GN+KM4T#RK(+V5D>HFHND&F4.EGN-.7%ODN?9OB,64F[L:^`XB7>-
M5A59Y?D3,)MMZ974=FF.GFM`!`0;)U$&PKB\J+3MO2"F2VE]XA>WJ!(0K[IR
M^Y-\D`K+"%I!/Q(3S)&/728<.:9CD1N19"<$NLQRM*F51U.*3'CSRA1<D#U5
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MDNA+1<>\<=U!7%&^!]X>8Y[CF$97"T@<F6V>X\Y)SN)21*MN6)&!87<1YU[`
M?J8PE?0K6518LS&ZBSDI0B*9%E,=7*EPP&F2Z\=P5_8TLC(=.K'%W\-5V:9K
MW#8NU*CNS9=W8Q;F#$K68KS-J@R%8_&6ZQ(AMQ_4C/?2J[.*I:&4Q0!-NK#\
MA"0')R3VG\_<<KH:(KREOND6"VGE-.AI!;XH;6P"Z](6I3P<4A2#&0$CC"2I
M*7>DQG-NRY3"1+7,BAMJ,$/,.%3CRE`J>5'W=;W:"O2"Y+C8V2%%``2$LS;[
M@K.DL\KJX=)77\G!]+:C*+BX7<,P(]FX_I5;:@Q;FJK/?!)L,4?MJAO%;636
M*DR8ME+ERV3#AU#T-Q0=-NX^^MLIPO%+O$\3;K\HR_%\07/J[VXDR*^9FVB`
MUMI9K+$JOBM2!6)4]26\0OAZ8/1G5BV$(6'C'T?P+>X1Q$WMUKM=.?E4C"WE
M.O1C'4F.VD,AS?UUM<RVR'4E(C<@A2BZ$O%"3P6`I?FAGPJV$$-<4(?=C*;D
M""\XI])7&*N*@XPV7%-DI;2@+0AM6P2@%)6&JQ^Z'-,@PS&;&OIL1HKG,FM`
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M@UM#`DM.O.*IJR,Z16%]:UM,.E)ERMBXM66:^P5.#CC"(K)2L/AE?!+*D*24
MGT$@/.*Y+0@N.NMMG?=QM7D]#"D2`=5;;"(XW!E3G77!&$24^(K?HJD[MQ93
MQ<9<?^Z(C-`!N/ZO#=QY22@.E)3U?^T"<2]V@]I+B00EU&%K2D';8+TA*D[G
M[T!.XWW.WX0%$;'E5RFQK5P7HS+:'P\Q,C*4X\5L(]&,M]N2E;9(;=;^-#;+
M4=31D@K<0Z`0.K7OV`/:)VF`-K<!9PL!*BD*"3I"0?4W'$>#LL_)/D@;[;$6
MFD.I`2.:4I!!"E>%DD'8H2"2I(W'):]]N6R4#[WH4M#:2"V%J()6E145*V/C
MFD%:U*(\D;I/R200-Q42H8*!R`7R4-D)20TT=AYVV*W'"LCBHD@*\*/C<426
M'.*ANYZH4$#U%\BH*V!"E!02D'BE(*?A'S6%'=71%)+A;<4%;MEUM2=D$HY`
M$#TRA&Z!Q!W&QWW^>^QVJE*`0H?<T+2A2PHJ45A/IJ5R'^ZI.X\!("?`)4!U
M.3#:8=0^YLMP)(6IQU"6PK?<\$^0`GSQ45!)/GBX2.F%]S.<9;I1JA0YXQJ!
ME"-"\@HZS`=>*R!82U1=`SD5Y%B8;KM02F@ZWC3U@]ZN-Y$W*Y(BUJQFZ8;$
M9A;KQ02W5M^2?"AM+JO42%%"D?"VHA2U$[*Y+^0\^#ND#9.VQV5N8N,I],+)
M!V'$H2E*"E0"?B`)W'+<@G[WQN!ML>M>V<]V-WI9GFNU=+D:>6M)@D[%JS`*
M2VOY,*]NP="+O5Z3-BOB9*DY<YD$JN^BY=P)$"OIJQ+-ZTNR=9-+;YY.[M\E
M&=56+4.'8#,JK_,.W3#Z^PN,GO6;5B?W$Z19?J57393-=6S:^57XK/Q;Z.G>
MZKCR[NOF%<&-#ELE\F]^O-'%MV^_L4\Y$1GYM-#B>:E+/$J2KD$E*$C<*(_`
MX!ND\N2@>(ZD/(]-HK4$J.RN(X<@@D`)6HCRH@;JV;/'R``2#UKTJ.^7(+BH
MQS)6M/L2166ND_;3JA84,;*;9>6V"M>M7\BTBM,;PB+[FN'D%EC=A1-Y%5>]
MH9-G!?55S&XTE+=@B[Y7W9WE)8:FNKK=,)&&X'G472ZJRN7E5I5'-M26&[25
ME=)B%2XN4K,*O"%MT.-7$^+,I6I&76-O';D0H6,243"$@7ZZU3VI%=`?6[(E
M4=/(DNH\RWZ>N5+<Y(">#LEUE3[A"4@`*>(*?]WP`)4*I@5CRWJZO@5\I+1#
M[L2M@PU(0L@J;]XB-"3P40VIQ"G`GF$J""4IV:1J#KEE5SH7VW:AXU)?P>JU
MPSG0R%J+E-;81)C^F^#Y^A%A=^X7TF&N)`5)MOH_"6LG?B,.U:;=,P)A3U,K
M8QO)-><YTQU3U^I`E68Z>85E/:?55T_++24ZC`\CUQS:OP;/\,&1IVEJ:Q2E
MM*C4AFMOY$R33&6J'.FPJNYA^[2U]OX'Y1[;^SI\ZR>8W==<<4DJ0=TI*E#<
MDAL[)*MM@"0=U>5*VV'58PXZH\W"%E`.S9*5#B3Y)&^R2H\N03ML?'GSUK9A
M]W-VNOQS5:PHISE7]:[KMJS*PG&<C<>I;&9IWKW4:9,2Y,617293ZFZWE<G(
M?>VA0TSM['-?:(5'DLW;)^Y/(\-UNQ9&0Y1BK6'Y1I(TU'?Q?)IN9:,PI]SK
MY'Q'%]4\CLX@B2L>:LL6=C5,EYYZ1"H\@N:VBL+&3"4[;-PIZZ\EL86$/;N(
M;2%@G<M$_`GB=TA*`0%'R4IV4I15N"-@KJD8:E!;O-"FFT@+V43ZG@^-RL@J
M6005'S\^/+<)'3!\<[@]1,+RG41JPBO9SACO>)F>C'TA.G64^VTZ8LL'Q:5I
MA5UL6!R;5B]CGDSZGK),M9=IE9#'FQW5L>J&=@!+DN)%1+#"I_N\?WYZ(I2H
MJ;!#"/?1$#JUO&&F27$1BZI2O0#2G%..<EDBFM.-@A.W'?D3R'($G<[)W^)9
M5N4E6P;`\;]5+3R5[A`V`!.Y'S3N`0`-_!`W(W!.VVVW@V]:PE"4J272"2E*
M01\O"4D;;J*0"24\N0/C;;;KT%2&D[%*4#X=^8V2C<>5.<=P21LA`25_I((*
M215SCR5*YJX`<E!*R.#I`)^YH(`*6U'YHW/G<[`^#TO^S6<]7M(P)?IEK>ZS
MSX%$$^,RN!R\%6W+;EL2%#?924G=(YHVV]@2\X@*='``JV)`'DH)"0$@@?#_
M`/I%$D@#P>ESV:W'ZTC!./$#Z=S[[T;?_/2XWW!`V5_YWZ=SOT19!JQ_M_??
MV5/_`"2MZ.C5C_;^^_LJ?^25O1T1*?VN_P!`.!_]COO\RW?7R:?Y0;LGVRWM
M`5;IW.L6.I*"0DE`TCTU6HH)^(*40$%0&R4DIW^/S]9;M=_H!P/_`+'??YEN
M^ODP?RA'_P#K-=_^WS_G?Q_8?('_`."734'<^=MD[GY'<C;QON-<'YQR*SQ`
MX]?*JF.O=]-;JE.^H3MR6E82H[J*.25`)1\2=DCEMQW2-@`"D#<=D4?L=TPU
MQ[7\%Q?*L;K*>7/Q_"W9>3X51T5+?LS*)N&ZV]`N?H1R0V)0CML3PL.>^,+>
M:>Y>IS'&PKBM&X(X[A045AI'PG?XUJ*4I1X^,K(3QW*O'7>YH?=S:G1K"X<N
M2\EZ%1UJ%[O*5P*V&'4I2H%0XAMQ*00=QX_'UICD@T$&0201J.%B"HH`[P(B
M`QMGDM6L[V(NCDH*$'4G5>`22I)>D8U,X!2E*405TK*^2M]B>0)2`A)2>L0L
M?8:8V^E::C7#,HJ5$@)FXECTTD'<*W+$F&K;;_>V"]QN%CK>",\2`H+E+W(V
M/W58W`WVW.VX!^>^Y_NWZ/YP&1N3)<5MM]ZIW8^?P#B-@2"3O^/Y?+K'M*[\
M14G"PS^P7?0OS$K019^PORMP#Z'UWBK+:TE'O^!.L%7#<I*C`O%)0=]@K@V0
M=N1!)V",Y7[%'N;K93;6+9OIYD4-;)4J9)^J.B>9?#A"FG(JJZT"VRV-VG$/
M\4_$A0Y`*ZZ<(.?L%IXEQP@O1MCR6-@0H$$D'<[>=QMY'XMQUCN5YDM\Q$PU
MO^HI3^R&BX5;$#8J`&Q3R).ZMD^>I&+B#]S\P/91V&%]/J=M]O)<O<GV.'>,
MVE"&T:;S"G?DM.2V;9/S'()D4+:@M'X-G$[@GY^.I\;V.7>,ZH"0QIPP@>=T
MY3/=*D@`'GMCZP/BW)"=CML-]MSUTS(R.46D$U\QQXI'SD+"-^*23LDIV"CR
M/XA\OT]3F<@EE20NLD[$$CD[XV&_X>9&YVW'@;[C?SU/;5[>2C]/A?2?,Y\E
MQ.:R:$:L]OF4OX/JWA]OB=RVX\J(9<</TEU%9"2BRQ^_BH53W<5;$EM2U5TA
M;D-+C34Z/%?^#I(@#NE('Q*/%*0/*E;;[)'S)V\[#<[?HZZ6/:S=U>@>+T>C
MNF&9Z)Z<Z\YE0V^29:_A.;9+J+C:<0J<DQX5\/(ES=/+W'9[J[:2PT(\"QGR
M8<IF&ZZB$A38E(T/H[A])%%Y<3LQ[?('%TNH1+RKN)M8[)VW(:0YJNR&VTGX
M&T*5L4JXA96"3O1754`309S#-SD@CU7-7\.*26KA[$%P2P%@7RR=@UT@XW/,
M;$!*MCMY)\[`[;?"3YV"O.XV^9VZF/#@%%EN4XT6?60@'U'4)5Q"MB@!*%[I
M*MEC9"/C6!L-E:3W!8RP^XN%VK]LD5E1!`5B6J=HHD**TJ4BXU;EM.*!W5NM
M*BH$;CX3O7?7)WL5*A6Z$=K54"I(97_,)C]HA)4M*DA)R>UO/6)V&_JM'D4E
M2R0D$6>JXI,"0](TW.<?Q*KV`!!.(`-P0[M!$2)SM:2R1!:&V6U%4A`05J2A
M3CS;:VR`G;@'`DH203Q*MSR*MMMNO4=]N3Q4Q*0M"DA)6E]*VT%+9Y-K4T5@
MA)W0C?<*W!2`E0Z</4=VNL-'+:FT^%]LE,\A+@YQ>U#MY=6SS;6V7$R+#`K-
M]+P2HJ:=;7ZS"^+C,AIU*5(3;4;5+--7KU&09O(Q]VRC0XM=$1B6!XA@-8J*
MUZKOJ/5V%U%/#E/I"PA<^Q$R<1QCHD(8;0TB02;TL/\`8&8VGT_"K530`6Q!
M48M3J:09<R'Y7U)&`*"5J:<1P"0@I.W)2E[J44JW)X)("BG=*0HI"1N`I85-
M(!XI'E?(CYI"3N1QV4=M_.X45'B!L-]M^I22-@E:U!*3P"TI2I9"OBW(2A"4
MD<R=R-N*0"?(`E?&%M?="M(1LI&R`7!\U/*5Q'Q)40D)04I4E0/$$'JU_(>R
MSOGY]??S54II:E-A3RTI0E;J&DO!;1)2H*26@5)0XL@*.VRO`5MQY;RBM+1(
M"G$M+4"E#I#BOB<(::6Z@`*6@JX!`!\;$GQOUY=4^IDD**WCR:"VF6TH0EL`
M`\5K"#Q'P+40=U$*W4I0XS3RYJ)`2"C8@%.P)(&P3Q)"MCN5!6PV(V!/F%&0
M=BT1M.8U,.HA:T#QR!20L)"O(6G_`,W901R/WNY/$_A5MYZV'47:3VSO:5]M
MFLN;=YUACV':TY9JYIMJ/6TG;'G.6:A:;:AZ7X1AV7Q(.G>&/YY1OZ]8IDUQ
MG..Z:S,YC3M.ZO&LV=L8DB#818T-R?KL<?;`("N/%3;/)OTE!"W4DJ7ZR$I;
M^!>X"EHV0=DJWVV+UL@[[=2+S&>V#$(NEG;/BD7M+N,2NM.;?"M!*2CRG)9&
M&RY%SC\;5W+GKBQN=3JQG*9MOFEE56LN'$MLONK.^LT2),EEEBE8JCA<.2Y#
M6;?=K66N$,,&HX@^D@M4<P3\K9-?;DKGF?8OG$GN5[FM!]`+QG67&.V*\%9F
M&K>21Z'1NB3"=SK$-)JZ;<5U_EU]$QVPOM7LRJ]-<>QYK([R?99`M(*X\9$Y
MV!?XOLL>]^RE0(L;2W&TRIFNN`=N$F$-6=-);=3JSJMJCG.B.GM#D,J%D<^)
M10,DU7TXS/"6+J5)]RAV].V_<"NH[:DM[*B[$N\G&^UK675K5/5'3BTUJ?U,
MTRR+#Y$9W+LPQ5Y62Y7J3A6?V^76=YI]G.FV:-RW5XM9EB3CV75DJ/>V4:<^
MU(K6Y<1Y1IOM7NX+&83.#:%4V":6:/8AK-@.L>E..VN'56;:CX[;Z)]R>:]R
MNB<W/=4+%Z/9:IYKC&7YM;P<JS?):YVUU#I'UP,H>L7VH=HQ![4%@*3%,G,D
M!S!UEF@>#Z`8#<53@DGN@N6N(8LXWC(O(QH>R?[ZW,X>T\8TEHY&3)K-#[&.
MTWJGIJBLL9'<<,X5HUCU;=OY%'JI66YHWIKG\J)CB9")=;!Q2UEW"Z]I,7WI
ML&JG:YK9HOA&%ZB:CX?]`8KJ)-;K**<S>U-E+8M9F"XKJ=4U>0UU;,D3<:L<
MATQS7$-1,8CV;;1NL,R&NNH+G%V0PQL^TW]L>U8Y'JOG'=]H-6:OVVHN`:#:
M1,1-%LFU&[;8U)I3H]-U.DNTE9/TIU9Q*YJ\OLFM1DU]5DDF3D&-PX];[Q?X
M==S&H[CVM37SNIU0[DZ_32!J6C%WW]*L)QC3NEOZVA159=?8C@U#'P[3UK4:
MYBS/HS+\@PO`*ZHPN%E$>AQ^TN*:H@NY(;>R89G,J3BD@&D-#F<QDQ+GP454
MX(H-5%51,@3<@TR0T"7EMI(3:`T/4*G"E:$M.M#<DK^ZK0OXU;'X6D_"$G<N
M!0Y*2-^5#)<4Y+$=2T!DDC@V.:(Z6V]TNKY;H"TN(/)+FX2%)&Q(!2/.AUV,
MD*#,MTK;)&[B4L!U04A21ONIT)2M#A2E(`W"TI&YE.3(J7Y:E.%07'+*V0DI
M2XXDJV2E:4@J)W6E:W`""K9)4GY:*M(+V=J8#&'(#P#N7S(-@Q6[;^3P!)]M
M!V(\71O]7>H[G'R.;2]%=1P0GB`E20XI"P5;E1*E`G8]:Y.ZP)'=+W+>@0>/
M</KFHEM*ALH:K9>MPJ')84$*/Q*.R"1Y2`/.Q#^3H_<_;+=AR5/JYO9QJ$X6
MU)4L+0-%-20D-J4@>EP"4DHW!5L3L?ONF9=T&"LK[E>XR4<MPZ(X]W#ZXOJ:
M?NFTN#UM5LN<;COH<<2$N)4"%M`$@J4#N-DC/B`Q"Y;N"+RY]_(YJ:J"<.D`
MNU=8>*1:F99Y%P3<SHSQ:DI"G'%`!*=U+4?DD#\*C\@`/Q[=2MF_22`A26TA
M*T``IX\5@HVW(((6`=M^0&Y(V/E2Y&",J/`Y=AN[:5!7&RBE"EE7-/,%]`W'
M(I^%(^]`2/!V\1=,TJ+KSF=X3]V6`F.JZ@(6WY2/OGK$!+0!/!"`-SN3N=B+
M<=-G/_FII9I;=4%!`=P&8MQT@$0(G)[^DI,C&=45%4AS9P;*:!'HMA0V<"$@
M)4I!&Z0E2M]E%7($>9H9"4(:'IE"$H"&U-I">:%`I6-CNG8#X0`?B\E1.Y*H
MG2UL_"-1<(;"5;<3D-,WMR6005OV!4L)\$%1\I)""KP.J]G32*VVME>IVGB0
M5J^)634A'+;BHN+:F'@CB`>(^6X)`/3M*<B?_-3R!H.IW3@K:.$V_=3H)OD!
M>_F2DEW!^1!Z]$I/R`!^1VV`W_0D#9.P^?X5'<G8]+(G3&KD)]-W5;3IGD2`
M59!5!((0?BW;FD\02/2V`"@1N-QN'7UG:MVGOXC36]QWQ8O;9A+8BBSPJ@@X
MYAQI5NME3T=619_-;I[9Z(XDMK<KE\)(/JL[('Q.TIGYM/EKRDY?\]4&'62Q
MX`XSQ*=M#OI&YMKKZE-I=2I[U%<@IY2FAORX-%*`E&^P^2@H[>=M_F>M@FHO
M:;V[8[@%[F>(][NCCUO35$NUBX%EV1XO>Y-DC\9KFW24;NE$_)"U:RUCTHC=
MK3L1/64EJ5,AM$OMZ_8ZE.M)=?6&G'0EQ+0;*U(2M"5!"U!SB5I)(44;I^1'
MCYS34*@X?Q!'W_"BNBJ@M4TP"[O:0SG.[65]BA!AS"EM0X0I*DN+2D$K4R\V
ML)*2=TE"$<RH;\PH?(#K[5G83_U&NS+_`-%'MW^7R_HCQ+KXJ,`_]!LQNG_Y
M.^>.WW0;QG1R)_\`,/R2/'Q!1_M^U=V$_P#4:[,O_11[=_\`W1XEUS8_S#K(
M+;X/Y\7E1]BG9=)TU_2O/_X?5/\`F>ZZ47I.FOZ5Y_\`P^J?\SW76*[UID]K
M)7QY>JFESLI*E-,:<7#@#:Y14MQ&6!3;:F&%I0ZAQ:D`I>'IKV4%'BD).DC4
M*ZJJ.-(K7D/K6EE/J,MO)6I]$]MP-HBPT-.MO0'76G8DD-^JAE:7A-0ECDD[
MT_:K+2-2-,$.NH;95@=Q]S0E;DR2Z<D2AMEA"`2A(*^:GCQ"2!Y)`'6FN7IB
M]D%G`<R.(N,W#:=0VP\7/3<;6O9N)&24!X`[H5(DLN<2V`TY\1V21-2Q+':B
MZLV,M5B-+#A8M%1"QST:*!#9KG4/)2\*(F`E5>X@-NLH-?Z2%<G`&^`X(4AI
MK'&Y,>+C^(4R'V4M-N!O'J]ANH:8:?;8<5(8K_3]9M,J2W6LI<*VVI+_`*:&
MVGG4*7.PJX]?7)KV`VVRTE/IQ_=`EAA`V;:1"+?I$#B%)4IE"G4A9V23N>DK
MFSY$7E64SS[,A3C2)#ZUNH<0HJ`!CL(23ZH00P7`4)""V>;BUKZ(L+QW#:*+
M.,DX9C338<AM16Y&.T<E4#Z(EHL:]A$>)!:\P9F]A`9;0U'KI+ZGV`T^5`YC
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M/335AG/<T=@UHK+"._(SS'1'CQI+"&9#\JLB19C8BML+04`N\$<\^NI<#8;(
MQ_%:#T:YO%,7D(5;B]74M8Q3)I)%W7*+T&PG0T5XAR;9!4%LV<DR;)`4VIJ8
MT%I6O.J:I3.E.6==B%&PN5=(R-]2J"O9M47B&?1D7*7W:]R4+VN2J2V+$[VB
M(3HCJF(8<+73&_K9,BB8AFM_%H<7;U!R#N7R_+83EQGV2)B(T$RK4>1FC-,8
M:!/HY-A2UDCU4X798X_CLNY=4U9R["/'BQ'$ZM.T37#(].=+X+.?(KL[I.V2
METFS2W^E[.QKK?5K1G*J#4'0S/V+F0W`L;&-"R")=0<KF3HR;*UQ&8U16")\
M=9*"3IZ^[?C\+9?D[N`8FBIAY/4XW5Q,IS*KJZN._C$6=%M\YR%,M34J37PZ
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M0UW5F<#(L2$&5C\-N1`TTEV6-4;=A49?'GQ<.E6]Q20;E&-S_3D/'KTZS1RQ
MCUOY`_9T^W(XE-56$=URFJ9LB;&<KK>1$B0W&'822[(%=-L'8BYLBMDJ2IUV
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MUO1JJ+'QQ;\GTG6PY):@0_HJ5<20VAI#\F`IV6VA:93SKR?*16$"3/CNH77O
M,`ON..1%.F*4)0@IC+"I+@F3$J(&\GU$M(;'%+:`%)*KWMC)@N1IWO%6TJ8Y
M&B[/N>FW%Y-*<:82PM1$IUP)4A2?>(;2E(XI4H!*5I?D(>L92G(D'UD)=X,3
MGE'TG)#J05!H.`1X2(H5LHH*GW%+"4-<OCZ(D@M([]8)(D,I5Z+=@EL++*T[
MF"ZE*>:VPM:0L[H4OD%I;?=9*@V5#K4[]-U=H':;NL(68^%'?SLI?\T.^P^9
M!^?%1\).Q)V!ZY4)TZ\AM.1U-N%_W:4R4>LMXNE]+J'E!E\;HCQT>%K26_4"
ME\?1*UD=6W?JKTNT;M1Y*0E(:PT.+VYA*1I&=U(YDD[$;@J*CMY(4>B+3S[P
M&PG9>WR!3Q^,;['@V=@-U>4@#Y[>$DG;J#H8;4'7?5904C9I#3ZUJ"MP%(2$
ME04-E>5``GGY!2K:TV\<VU1<1H#:R]-J;2"RZ)C]2Z9$R!)BM!FR8:>=KG2X
M\.%A'9=?@.<9K3*W&$(5K:=[4->F<(.)-YU53#&QO6/&,:>EV[E=;5%OF&/Z
M?UFFVJ&4V]'"8K;W.,!=QJ]@2)U)754FQKWZ^^1%;R:UOUJ(>3I]-5JKI[DU
MNK'ZR_;DVS.=97I@JN>JKM,IK/,'I&,DRC'YA77-QX[]512&;'WR1)9K)R7V
MF8$V;*7[OU9;++-(F\BRS#[1NBDY!$R?3G%,TJ['$Y4U4F\U%A+F:<U]NE5$
M]&N6KN!#6Y6SYBYE3`9C!N=,KBTA(:E-[:M<59#:SZ3**O'I=EW&=S.J;67Q
M+Y;5I"H-7.W1>EF$Y"[418C34C(:G/A%RVPQQ3ZHE8S$:F09LB:U':3087VQ
MZO4:Q(DUN*54M[4#L+R.<FISJ9/>EP^V_'11ZPV,JP>J(#\B?FL@2+6MA2.:
M+T6+K5T_'D%]3D^/4=0YBR@DAH^Y:SV$YZ<BG356?:#Y/ERL)I',7N,DB-VL
M!F#%PMYZ.&\'DR:2TKH.0O8XF@>1C4MZ=3.5]?<.*KY:;&M9:"A)9*BM8QBK
MCBGSA>/.O,NQ'6I@QJJ]=EVMCJCU[A>%<5I7`B.J8KU(7ZD"*I3,-R.PXI!8
M1]:_K+`Q\56'6.-X=;II^\J''GUN2R41HL_7#5"BS33A3K%=!;6I#..U<R@R
M">PR96,.3B:SZ00E2U*)3Z#:EQL[TAS.!-12P,;R.\L\UPJ\S5C,,9K*7*\A
ML<JLZ3"F(6-8Z_5VF,7:*Y>G]G3N1JEBALK3$LDA3JF#&+D("6#B_I:#///)
M.&KM(<&J-1)NID+'VV+J=BF+X0(R(E2QCE-3X5:Y+<4+N.546I;%+<,V68WR
MY=E7RVERF)HC<&PPE1OZL.Q>.Z0Q@V-LORG"\$Q<3IDRG'!+,Q#P0W5H6X\)
M^\T+`]4S_P#I9<$DEWIK>8:):S77<?0:FQ301,`HLPE/RHC.>WSEIE&G\_03
M)\`?J)F-SJ^15U*F\_M*NVD8_`F1\9L&*UK)WFW\I4_+0WS1WM'[@=.L)I<>
MNK?%Y[%?:=HF09#BZ=0+F149X_I#29!6:S5=C9R:QQV$C,+"1B]S#DNQI$3*
M7,8BQ+R+"9.RI'-O^C_J/MFWI?K_`+L(P7)\+SO"*NZPM5;=X-=L6$6N0W4B
M-4R(D&QFTME"70V-?&"8[-C7SH4B$_7H94XPXKT7&U)4I-M-,:TMP63F&A>"
MNVBHV,QZO*KC3>_?GY%58O4ZAS[FTJ4T:,AKW@FCNY]9;R8T%RTN?H]V`ME/
MN+,6*TE,\?T/U5Q[M#Q?1VJG8W7ZCXYD=?>OQTWMBK%\HIJ_6.5J!/PF5?0Z
MT3(-3EN-O_4[8R#6/)0MY^-+BR8#CX72M=M6?P\ZR2]H8M=C&&3H7:*P,.D9
MY:9--R/&=$L\S+*-2M,K[)[6&BQ<J,CILCBUE?:S%O5]L:]518PXE"4H,:^G
MF/PZ3$#?T=MO*R=O6X_15[Z7HF,U<61%8FPF'(-!6QI$2)/<<E6,)IZ-#;<:
MB37W%RK**GBU+?4Y*E,N.*+IIYF&XQ(0B$YB&,*BB`FK8BG%*(,&K]X3)-8E
MM=:&E5IE;2%5*6S!$L)DEE3Z$N=:U+?3;-<1R72O!=1&]7M3',>PW17Z6L\'
MET]W3-V&-ZZYSGC-'25&3VU#>6[+5'+QS"]1[BGB9+.M\%J(#DF%4KAQF9CG
M\"T0U#QG1[7;3^ZMH-O:YS7YK#P"5+O?I&YC*R3#)M>Q$RW-(\*$W=,TN764
MIBARGZ*CY!)Q>/7R<A3)NFDE!2EZ&FV/?35/:1(EO3+K79TYZCJ7#3X[?V,I
MVN<;N,HIHD%IJ_L:N161C1V3JVI-652&BIUF1Z14!$!6Z4I0Z`L\`6VW`UN/
MO6VO`))XD*'E3JDE2^1W!URP^UO6:MH(]-#LJB)C?U4:3664XI#U`FUOU3UM
M9VU*TAU$GQ;^92W;%/D434-Y.H6.OV-=,B7EE!A7[[<.[BQ`WE67]M>NE[_/
M<W69_8.R<FIJZ!ICDLO/[6/)GX^O%=*:"]TZSRI1C";!IJ5,T]NY=9F];9Q8
M\-W.<BNT4";.[M6E/'K^%#['K,:CUV3J86L>F4C(X>)M9*4Y!.S_`"G2>-6N
MU-VPZ]J'A>.-YCDV+K=?K&H[$ZMQEU%VA]]YJNFPU*$"7*=!92JR6W`M2@V5
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MG\7CHI5ZU8_V_OO[*G_DE;T=&K'^W]]_94_\DK>CHB4_M=_H!P/_`+'??YEN
M^ODQ?R@X)5[9SO\`P2K;^=_'P2E*R$<M(]-PE;A#:@EI*AQ6KQL5)"=RM._U
MG^UL!6@F`I/R5%O`=O!V.378/6G[NL_DU'LU>\GN&U4[G-98>O;NIVL.01LE
MR]>+:PO8YCYLHE#3XXT:NF9QR2(+'T=1P@IM4F0M3WJK]0(4AMN]%7!4]X5:
M@XOTXFXLR^2(XUZS2T()4M;3C+:CZ@)+B"V#Q4$J.YV(Y("CXVVWZZ^,6[K\
M,P3LMQ75NY<FR:6#B]%:OQ:X1K&VD-O.0*;C#B+DPR^XN9]T<94M!90'"3]S
M4!T@#^2'^R)!W$'N<!\[;:^S!L3^$'ZE=]_^_;Q\NJIS^2/>R6>C-0WD=TST
M5A(2Q&=[A;);#*0HJ"6F%8R6FTA1)`0A(!)(&Y)ZMB5TUM!#&;6+>L**00+B
M?0Y]9[+C&R'VR^FD??Z$T^U"L@%(0E<AJAJ&U%>_Q!;UA,4A.WPDEM1!(3Y!
MW"86'MI&?E!T=OU?#ND3,MK6P=_(W3&I7"`!MX"B0?']G;XK^2&^R&5MRKNY
MI7%7)/+7N6>*O_.&^*^%?I'GJ/VH=[(?<'Z/[F]P20?Y_)>X*O"B/_%7P2/F
M?F?P]4/#D3Y.<MP.KV5ISZM;/6_+=<(=G[9'5^0MYK'=*,=K4*3R;>N<CM[`
M[@`I*TQ(=>TI0&VR4N)\DCQLKI++?VL/>#.>Y55U@N.-J!26H&**G+3L.0<]
M>ZL9BG"CDA`"&P@G<J2=B!]`\_R0[V1!_P#[#N;_`&^2_/\`^"O1]J'>R(_)
M_<W^WR7_``KU8'#%P3:YY:#GX.)4=XY@=!\VU;D-2OG86OM*N^6V2X#KW:5(
M4?A11XQA]<@).W(;IHUO@G;P0\=MS\R?&)2._?O0E%2'>Y;5E`*02N)=QX*?
M)V(28E<R$G<$[)(V!V``^?T?/M0[V1'Y/[F_V^3/X6ZC]J(>R).V\'N<(3X2
M#K[,V3Y*OA_\5?&ZB5?V^1Y)ZL*\*.YZV;/J?10U7U9CT:WCR=MU\OS-<WS;
M4[);+,]1,NR+-,NL6XK<S(,FL)-S<3F8C0CQV52)*MDL08S80Q';2W'99;"&
MT("E$R(+*8P0D.+6VZSR<44A+;A0GFE?$,_?%L**DES?8[%/(;=?40'\D7]D
M:`H&%W.JY;@E6OT\D@^%#?ZF-QS'A6WS'7I/\D9]D<C?C"[G0DHX!'UP%CQ2
MG8C9(^IG<``D`;D`$[#SU<8U(8"D@!O"<K\^IRKPJZG#]1-G@N<Y<Z+Y?CKK
M:"3S<*"!S`*U(;XL[*Y!IHJ0TL+'PJ62#\0.WCJ#;:BD+4ZV[LH+CJ0VEM+*
M"DI^XDI6H@H)`*P5;>/A\GKZ@X_DCOLD1O\`]#[GCN=_/<!8^/'';QC(W!3X
M(.^X\=1^U'O9(;DB%W.`D@DC7^QW/$<0#OC1\!/C8;>!^/<FW;T?Y>0VWZ;D
MLOTU;!B!J;Z9-&;S(#,;KY??K)V!XN#<$\2VM*@D)Y%7%24J4@>$\DA0Y*2/
MP]>F9*'`I32MTE`"U<3QV4`M3?+;;DG8!U`)*?O5@;[=?4#/\D?]DD5!7NG<
M[R`X@_7`6)^'<'CYQHD`$#8#;;;KRC^2.^R105$1.YXA1)XGN`L0E*E'=2DA
M.,C92CY4?))\GSU';4:5>0]U'Z6IKAXSBXVRF=19?+_V2I)*@I*5>5<BI"AM
MMY^+92-M@?P>/[3UY4LN/-.<G%!3;JOA2?17RX`%:ALA*T_-M)V)!41X'7U`
MOM1WV2)5R,3N?)\__P"P-CML?FG;ZFO(/X=]R?Q_+J!_DCGLCRL+]R[G0L#;
MD-?[#<C?<[[XR?F=R3\R2?P;`.WITJV@/EOTR#X6N.\+'P)AOL_+5E\P`K`V
M5_NG8<AY/(JXI3Q`Y>2?G\D['D!\QY4XEO;U"K=;J4-A"2I'%9XI#AX$A0)"
MB0H)`'R^>_U`Q_)'_9)#?_HG<]Y_^T!8_#XV^'_Q9\;G=1WW^(D_HZ\H_DCG
MLD4`@1.Y[8E2C_\`&`L/*E$$J.V,CSN/G^'<[[_@=O1H?*TC0]!PTH/A:S<T
MBVNQNT%_/E!^7\MP(XA3:U<MR0EI;J1L-R%<$*'GR`#MR\_@WZ\H6LMM*`#I
M<5Y4E*F0&RI0#H0[\92G8`CYK(44_B'U`E_R1OV1ZRDJA]SIX[;?_&`L/)!W
M!/\`XL^2#_[3U,5_)'_9)*W_`.A]SH)^2AW`6/(?B()QH_(DD;[^23T[>G0[
M0/=OO8[._2U,)#YO;:TYS.6<+Y?27DJ]4'DD-.<%<?4*CY&R@`@'BO\`"$A6
MZ=_.QWZ]*>;2M#95\3GW@XKV/XMSQV1O^#F4DGQ\_'7U`A_)'O9(#C_T+N=)
M2"`3W`61V!VW_P#FUYW(W)/G?H3_`"1[V2*00(G<\=]]R>X&Q!.Y).Y&-#?Y
M_P#=\AL.G;T1%6]MM3S?[,GZ:O4>?*;'<[VB'^7F^VU.:4CDXGC]ZHAQ""5>
M.6Q"4/#8'B05`;\@?(/4YQ?H);W"5,[H:6I:R2@'<<U\@KFG;8*W.^Y)5\.Y
MZ^H&/Y(W[)$;;1>Z`$'R1W`V')0"BH)4?J8W*05'8?\`?\]SU!?\D:]D>LA1
MA=SH4E7-*AW`6')"N/`%).,DIV&_R\[D_@.W3MZ=#EIK+3][[*?TU3@$CA!,
M2\L#YL]XTR/R_$I0I:764)<44KX/DDI"5$;I^25#?RE*4CPA(3R"0!UC\F*T
MRJ:ISU%JYMF,5\MW5+W<>`\$.>FD_&K8H`^>VXZ^I']J->R1V*?=NZ$))W*?
MK@;`C](\XP3L3Y(W\GKRO^2+^R-7RYPNYU>YY#EK_//`D$*X?^+'CDE12K??
M=)VZ=O3H?3WZF-;4X%=)?B#0&EV!!$R+."!#6DN.)?\`DZ3[KWME^Q)2WF0@
M9UJ`A+*6W$.%:=$M25$$GBC9*3R2$(]/AMQ(VVZUT]U;JWNZ'N6+I"RCN'UU
M0/A&P2C5C,.(V`&Y2/PD;[^=_D>OJ$]I'\FY]F]V5]Q.F'<_HM&U\;U/TCM+
M6WQ!66ZQR\EQU$NYQNYQ68+*D=H(B)S)J;R<EILR6O3?]%X*/I<%)1FG\E4]
ME9GF;YGJ!?1.Y%60YWE.49A?+A:ZSH<)5QE]U/OK@PX;>-E$6,J?923'8"E^
MBSZ;?-925JJ,6DUFH@CNBG4P?M[<E-7PY-(I!$5$Z012+@'1[?9E\L[U4AU+
M7X5M^HD['SL2"GY>"!LKR1N#L-R#M+:?+SKB4H4EMEQQLN$C9Q:.`V2/OQQ*
MMU$CC\@"23Q^H3]J0>R2_P#H?<[_`/O`67_K'U->?^_J'VH_[)'??W/N<_#_
M`/Y_L?D=O_JU^CJW;T:5>0]UF/AJ\S382Y@N,FYCUDD-\OY:MOF?*B$IW&^Z
MC][^/\/G<[`;;DC;?J:TZZTA2&W%M)6-U(;44I43]\5<"$J)W.ZMOB^1W!\?
M3]^U(/9)?_0NYS]O]C_#74/M1_V27G_H?<[Y_P#M`6/CQ^#_`,6O^_\`MZ=M
M1I5Y#WZ;DH_2UZTY9\MLI\@R^8,W(?95S:=6A6VVX.^WXM@=P"/P';<?@_!U
M+6XMS_RBUN>>6SBBL!7_`)P"B0#^(@;CSMU]/T?R2#V20&WN?<Z?TGN`L=__
M`%8T.H_:D'LDO_H7<Y^W^Q_AKJ>WHW\AM><OP6W?I:]:=_3:6GRW7R^DH4%K
M)*"VI)2$!I(/DI)"E`;K2=CND^"3N=R!U,&Q.P`)!X_(;@_B'XM_'C<?I^77
MU`?M2#V27_T+N<_;_8_PUT?:D'LDO_H?<Y_^\!9?PU_ZO]>G;T;^0]]_3DGZ
M7$-S3EF=MLI\MU\PEE#[(?+[:V@N#/&VYV41&<V`)"0HC??R-@?&^^W7VN^P
MC_J,]F/_`**';M_[H\1ZTAM_R2OV3#3#D=$3N;#;B74K!U]L"2'4%"_*L9/X
M#X_`"`1UT::6Z=8[I!IGIWI/B'OXQ33#!<2T\QCZ5F&QM!CV%T,#'*464]3;
M2IT\5M;&]\F*:;5)D>H\4(*^(PQ*Q600"&<3Z=.MOA\&O#-9KX>\*0.$G)SG
M:]G/,K.^DZ:_I7G_`/#ZI_S/==*+TG37]*\__A]4_P"9[KK-=*U'^U&KDS-3
M]+'41URWF\%N.;)*DLHCM9&'BZHAM27G`L`)8<6VE0!4A:70@G6K8PUNU:??
MDK,M+)+<-HN2GV8RW=FW'%)6M:?4XJ<<8W6M14"7`0">EO5WMETPULR*CRC-
MF+Y=OCU1*I*UVHNWJMM$&9,3/>2ZTVRX'7?>$`H=)"DIW3MMYZ2-[V??;X\E
M2"QF[;2FO16RSE\III:/P)<2F(/4`'CBX5)(^$I(\=$7."<9L9CSPFS7(S*E
M("C.0VRZ&%;<%",E?JD.)/)7$CB#Y'-.YJA#QS"$-27(J+*P:6E;;K,9!FNA
M8]-"EJ4TZY"902VEYQ90>"U?<G#]UZZ,8WL]NWB&H+C1,Q:6G;90REQ2ALKD
MGB5P5>F$'_R8:X!OSZ83N=\/O/9@=LF12'9%F=2W"XX'4LLY[+C1F7$@`*98
M9@(;3Y2E1"@L%Q(</QE141<\UGEE_D#"US(?KURD+#E>F-';;$5YI8<92XDR
M)<Q+S2$EMQ3B6VG%(46VRE0Z2BLKV<7I\CDM<\4:84IV`94\_2$R/]S]VC@,
M+*@)#:U%)0'6_>?37Z<1E:2OICB>RR[78+DAZ,K5)J1)26UO)U%L4\&2X'2R
MTPF&F(ALN)2H[1RM12D+6H#8V9SV2?::]-382?YU94P)DH6](U'GN*=3+6M;
MZ7-X`W0OF4);3Q;:;"6VD(2D`$7,DP]772:URO?BMUUS%D6,Y^_:=NK-I2@]
M$;CMIAI:D5SSBVWU.QWCRAO+6TL)<0M*?5/79&NR`L66S"3`@09"Q)3!M93R
M%R5MM2'I*%H@Q'D".^W(:XR%-LM-%1CA!'34S[)+M)8KEU:&=3Q$<]]"]M0I
MB'2W.]0.M!YNO0XEM"'`VUQ(6&VFDN+<X;G(HGLN>UN"VPU%C:AM-L#8#ZNI
M:UN@,)C)#SSD%3Z]FDA.X=2H[GD5`[=$7.F["$=@P.+DU$.6E,5U4Z--Y'T3
M):DSU(46G9<1I:4AIEIU]7H-./):4H)%A?LH,9R1,$IR1:)DNM17)"7PMFO9
M0PIZ04-(0E@RY2E(?=*U+<;9*&EI2RRL=,RO9L=M"@H&'G0)9+#2F\TEL&,T
M4E*TQ@Q$:2R'-U%SBG[H5JY[@[=8V_[+'M<?<4X4ZE-\@4EMK.G4M;%\2/\`
MR:JQ0)]0)V)W(2E*`0D`=$7,<NYBS+&565L6?(F.2&G'6F@S&*9SFTAU]Q9<
M6XVEQYIEU<=*'5<$<BE*U(WR"5:.1TK8;=0T]%W5*?=0X^AA2$[3$,MJ"W%.
M/%Q.SKB/7:"O2"CL=ND>J]E'VG4\M4V)!U!,E:GEEQ[-%N?&^H+60D5:4IV4
M-PD`(.YYI7N>HV'LINU6TD&1.;U,>)4%%I.?26(YV5N$>C'KFD!H;)!:`#:@
MA!6E2D\NB+F%FV4NPL4H;E/,(;>4PN0^6Y#AE1D+D;OJ6VH18Z2"K_HS"F%.
M%)2!SYBZU\65(E2):7Y*6E("U//O(;9=#(65,GTW-RT^I)4_&:?6#Q]1?W=9
M0>E8>R3[14-AMF#J/''-;BU,9]+;6ZI:PO9Y0@'U$)4!Z;2MVD#=*4`$@WEG
MV6':K'9?99A:@H3(<]5U7U;/J<*]B%*2XNN4I)7O\7$C_P#5X]$7.5&>:;=6
M@I>C!?I!A!:!0[P;"W%M*/$&.M3BU,R7E)2Z?44$KV2".5:[1;'T7!L)#[2Y
M24+5X0TTE7'U/6<'NZ&UK0-W'2EOF"4!2R0>C1KV5W:FTI9]QU"<0YL%LN9U
M-+1`2A("0B$A3?$-H`4TM"]AMSV)!REOV;_;<S'5%8C9TPPL<2AC,9#0">(1
MQ1P@C@GC\)"..X*MR>1W(N:VCP92HD67E+[KMF%3&78<"0'*,+]<\O4?EE$B
M6D\4I3$9;$98+GET\>64/1(=9*1'<@5CE8T#[G&>2Z&UNI1R$A#+3L9WUDDJ
M265J]!)&R?NB.NBP^SB[<./%,?.FTA2EI#68/-^FI1!);X0`$;;>..Q&Y_#L
M1:)/LQNV*5R+D?4)*U)"/51G,P.I2%%6S:U0EEKR3N6N"COY)/1%S)Y';JCM
MN%IQMF(R?30WQ<3Q#;BU-I82MQQ:4I<<5L-R4\6^/)6Q4A63YC?0F)$=I^-6
M,.MM^I-L9078J@E(4X^6))!90`H*;*FDK0@%XI"E^KUU>S?9.=I5@T&9,+45
M24!0:*<[DI4SR\DM[5_$'<\O*5`J^(@GI,;KV(?9)D,I4NV1K-*6M$A#B#JK
M8H;=3*::9=2\$5H6^@MLH2EM];C:/BXH'([D7*O'U`J94YWT646SR9,M+=B7
M&*YH)AM(9EO+7)),QYX+]9A"&&(H^%U;:T^GMD#2XCBBXY+=B)>04LQWW??E
M(0HJ3_T@Q5J]!2?@*4\&U.ET>C%+9&W4!]@W[%_10P:_5HMM)*6Q_.9,!;!3
MQ^Y%-6GT3]\26?3*E*)5R(1QO]1[%WLMI"XNOC:L-ONIX.2G-2IKTI2"HK4G
MWARM4XDK<V6M:5)=4M*%%>Z4[$7*#/QYR(7I%.Q#ME/5$Y]3DH!:VDNM.M*5
M(A2667HDEILK<C"2EM#82'4(//QT[]_C;8[2NU)+_`A/U'`ETD@J&DJAMQ;W
M<<6HCX4M['?XMPD%05]/L>>SM'/C%U3'J(=0X3J18**RZ@MK=4I<%2O6XJ(#
MFX4-_GX'3O\`5CM9TOUFP;!M/<P5DZ,?T]7`7C_T/>&OGDUU$<=CBPF*B2%3
M$_1YW<"D-EV0`ZH_-/1%RNN!02TV%F-RW44<4)>&X^!.[9+<=K;;D4E;IW`4
MO\5"69+CBBO8H02@-I*D-K\#RA'Q'D=]N6Q<\[JX`[]=%;/LONV1HA17J2Z0
M21ZV9(<(W._A1J`KY[$'<D'Y'J)]F!VSE:G%/:EJ6M7)2CFB#N-]P@#Z(`2V
M!X"$!*0-_!)))%SL)66TDO,NH*4@@)'JH0%%(V`XD)4D%1V<*W-MSY`\4+[B
M70I325[.$I^Z?<R"/FYQV'-)&Q25`*.WX!Q2.C57LP.V=0`+VI90"2EOZM$A
M"3YV*4IIP`1OX_\`-^:0#U+7[+OMC<*2IS4H\=P`<U2L;'<D;+J%``D[E(V2
M=AN"!MT1<Z[3#+31^Y%3:VQSY*^6Y&SA4.0W/G[SBD`<1O\`?"69"&"4A!W(
M2/4)2HE(&P2AI!W)^>R4^0#Q2GD5$=%)]ESVRJ`!D:GG;EL/JW2D?&3OX33@
M`^?&P\;>/Q]2T>RT[84G?UM3B?P<LW2KCX(W2#3[)5MXY)V4?PGY[D7/$XI,
MM0Y%A"P@;M`%*T\.*"M:AYW">(*.1V))6=QN+;8H96DI9<)>0HAUP;*0E"D[
M!E`4IWB5\CLAH%3B0"-@-^NC(^RV[823LYJ6D$`*`S5`"@`=MQ]#D';Q^@D;
MG?;S+3[++M?0X7$.:F))_P!U.:I2C\9(2*?9*B?F4D$CP3MXZ(N<B"51U*V8
M+BCN`HH*"AOQLA"?B(4=OO4E2U).RU#P1/<<:*>;KJW%K.[;7@(0KY*#86LH
MW3Y"GE[AH@@@J/P]&"O99=L*U;E[4X#8I*4YP$@I4=R-A3CQOYV!`.YWWW/4
MD>RL[7@%#UM4`5$$J^KE)5X^6V]-LD)\;)2`GQ\OGT1<Z3<E]Q.Y"E-*V<0V
MV5-L^FX/"W&AY>YI/EYSX5)\[*&W&1ZH83S</KJ2H``$(0V"K8)3\RKB=TJ6
M`K;<!"4`$GHX;]ECVPM(#:)&J`3OR4/JX2?4/S'J*-,5+`/R"B4@;C;;QUY7
M[*[M?6=U.ZG;G[XC-T`J/X"=J4?+\`&P'X`.B+G*2EQU(6XIH(20MML-CX%$
M$\D)(*.?'8(?=]105L$H/GC=FW`AI?)92M0"RA1*G7$K&Y+BM^)^$@*4I0"2
M./X4CKHB3[+'M@0%!+VIP"]PK;-D))22"4<DTP4$D@;@'XMARW\]>D^RT[8D
MG</ZG\__`#_JX3R!W)&W_@;C^(#X=DI`"0-AT1<[+B4`!+JE@EL*2``MT).V
MP<<``2?'PI*0=OA:9)!4F*5)9="DM\]]G`E/)`2`@G=:MP?4.XY*(Y$>-TDD
M'HI/LN.V,C8.ZF!.Y^$9J@)._E1(^A]E*40"M2MUN$#FI0\="O9<]LBAQ+VI
MNWGY9LGR"""#_P"!_`V.WCY#Y$;=$7.MX<&^ZSQ.X`W;:0HJ"E`*^2B5#X@`
M/&X5X)/72M[-P$=IF"`[;_36=_+Y?[8V^WG<[^-O).Y/X_GUB(]EQVQ#B/4U
M,V2"-OJV3LHG?RH?0X"]A^/QY/@GR7F:.Z18EH=@=7ISA!M3CM/(M)4/Z9GB
MRG^I;V$BSEAV6&(X6@29+GHI#2?3:XHW5QW)$WS5C_;^^_LJ?^25O1U-U6;Y
M9]?'DD;BJ\'Y_P#YDK1T=$6':,]QF%Z<:;8YA-W4Y1*M<?%M%FR*J)4OU[CC
MUW93$F*]+N8$EQ`;DH2HNPV%!:5`)*0%%3_KP]-OR#G'ZNH?XDZ.CHB/KP]-
MOR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'
MZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'Z
MNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XD
MZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ
M/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/
MKP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-O
MR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR
M#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZN
MH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH
M?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.
MCHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/K
MP]-OR#G'ZNH?XDZ.CHB/KP]-OR#G'ZNH?XDZ/KP]-OR#G'ZNH?XDZ.CHB/KP
M]-OR#G'ZNH?XDZQ)'=1I^G.)60FFS'W-[%(%,EH0*3WD2HUU8SUK4CZH/2]W
M4Q*0E*P\7"ZE:2T$`.*.CHBRWZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CH
MZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\
M/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/
M3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@Y
MQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ
M^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^
M).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^)
M.CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(
MCZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3
M;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;
M\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^
MKJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^K
MJ'^).CZ\/3;\@YQ^KJ'^).CHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).
MCHZ(CZ\/3;\@YQ^KJ'^).CZ\/3;\@YQ^KJ'^).CHZ(F\9UKOB-_E-G;0ZS(V
GX\L0/31)C5B'D^A6PXR^:6K5]L;N,K*>+JMT%)/%1*4G1T=$7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g673771.jpg
<DESCRIPTION>G673771.JPG
<TEXT>
begin 644 g673771.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`^1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]-14%.7T-/3E]+7TQ)3D4N15!3_]L`0P`!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!_\``"P@!20(U`0$1`/_$`!\``0`"`@(#`0$`
M```````````'"`8)`04"!`H#"__$`&\0``$$`@(``@0(!PD+!`P%%04#!`8'
M`0(`"`D1$A,6(105%S%15Y;405:1E)?5U@H8(EAA<8&FYQDC,C=457)VL;+'
M)#-2H30V.4)S=)*SM+7!\#4X=X*#E;?3)B<H1$939F=U>'G#X82VN,+1_]H`
M"`$!```_`/OXXYKLBDZNN<]O/$#I`;:[L("B5)]13=-JN(G#RR5122VQ/809
M,CH=IL&:K2QTY>P,#(FC*=O9&P3+M4F.6_L[LJ(4I;!;1[,#9A677%WV0GUC
MU%?7?FQ*JJ'M'+QE<B+QDO7VI^G,GNJP18@_!H!$Z[/.'79*"RRMX%9#&","
M!2K0<C4:Z$5$8Y,WVQSH#=DQ["=4*ULNP'@DI,E"5H0.1'@;5%B+E1*GK@L"
MG59FT9-MMF332::0).5;M1^J0UNL852'-VS'1NV2F56[XPA,,P=P`L9L=4^/
MMQ^KBN9:D/--XVNS0+O`A38=AB59M\D&*FCEHLHDX0=MUD-E-%,9YD_R@,OQ
M<G?V'D?W/CY0&7XN3O[#R/[GQ\H#+\7)W]AY']SX^4!E^+D[^P\C^Y\?*`R_
M%R=_8>1_<^/E`9?BY._L/(_N?'R@,OQ<G?V'D?W/CY0&7XN3O[#R/[GQ\H#+
M\7)W]AY']SX^4!E^+D[^P\C^Y\?*`R_%R=_8>1_<^/E`9?BY._L/(_N?'R@,
MOQ<G?V'D?W/CY0&7XN3O[#R/[GQ\H#+\7)W]AY']SX^4!E^+D[^P\C^Y\?*`
MR_%R=_8>1_<^/E`9?BY._L/(_N?'R@,OQ<G?V'D?W/CY0&7XN3O[#R/[GQ\H
M#+\7)W]AY']SX^4!E^+D[^P\C^Y\?*`R_%R=_8>1_<^/E`9?BY._L/(_N?'R
M@,OQ<G?V'D?W/CY0&7XN3O[#R/[GQ\H#+\7)W]AY']SX^4!E^+D[^P\C^Y\?
M*`R_%R=_8>1_<^/E`9?BY._L/(_N?'R@,OQ<G?V'D?W/CY0&7XN3O[#R/[GQ
M\H#+\7)W]AY']SX^4!E^+D[^P\C^Y\?*`R_%R=_8>1_<^/E`9?BY._L/(_N?
M'R@,OQ<G?V'D?W/CY0&7XN3O[#R/[GQ\H#+\7)W]AY']SX^4!E^+D[^P\C^Y
M\?*`R_%R=_8>1_<^/E`9?BY._L/(_N?'R@,OQ<G?V'D?W/CY0&7XN3O[#R/[
MGQ\H#+\7)W]AY']SX^4!E^+D[^P\C^Y\?*`R_%R=_8>1_<^/E`9?BY._L/(_
MN?'R@,OQ<G?V'D?W/CY0&7XN3O[#R/[GQ\H#+\7)W]AY']SX^4!E^+D[^P\C
M^Y\?*`R_%R=_8>1_<^/E`9?BY._L/(_N?'R@,OQ<G?V'D?W/CY0&7XN3O[#R
M/[GQ\H#+\7)W]AY']SX^4!E^+D[^P\C^Y\?*`R_%R=_8>1_<^/E`9?BY._L/
M(_N?'R@,OQ<G?V'D?W/CY0&7XN3O[#R/[GQ\H#+\7)W]AY']SY[HZ9-23UNQ
MT"2]KNXVVTU<$(F;'LDLZI[J>;AXY:Z((:YQIG7797?7793;33&?2VQCF8<<
M<K<;ZI5"=F-[3URA.!\J[(5Q&*HM@M';/L.+KE85"VDD815I'?9V2#,0(P#:
M3*6I,I7!,QV5XVD1!PL95=:,EV<6QWP\^ND2A*4(`;W1A(7*X?-H;*)3V.OB
MRYW6<D@4<+0^)O*KF-IV!-S-<LA41D,DB^0,36&QTA'Y+(1)02^9&7R2MK*U
MK>#U!`HG6-;1L;$8+!P;&.QB/"DMDV8T6P3]!%/TU=U7+MTMOLJ[($7J[D@3
M(.'1(BZ=/W;EPK@$Q_Q_4G_J;=?_``RY.W''''''''''''''''/@Q\4;M)V4
MKWOQV1B$#OJV8=%`\Q8:B8Y')L8%AANKR-AWSK5DP;KX1;ZN'CA=TKKIC&-E
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MT"*?.$(_%068VX,F7""3X\F,8[(/=?\`..\O84@^#.J^[`=DHNRWC`G61ACU
MS'I3\'FFC@G@ZJ!,;MQCM2+NFV1*X5H3;*%A^-G3,@_*K)8).L+_`'['<+^-
M!>GZ13WWCC]^QW"_C07I^D4]]XX_?L=POXT%Z?I%/?>.70Z)=AK@OGL14E#6
MG?G:$IM;UIQV))2&-7Y)(EF)Q?:/RH@>=-V2(XKJ<D+\HS`HC?C#=N,&#VY3
M=1!ZZ>H?!(/N[N5V!$3PW&Z[O?LA%FT/D$YAYU`Q>4GF.A4C%Y_)@PL\.?/&
MHUX/2(QEF'U)AUDW*+4VW(.6+O9D]2;-8@_?K]Q/?_\`?/WK[OG_`/NB'_=Y
M_-Y_\H]WGQGNOW#Q\_9^]<?SV(>Q_M<<X_?L=POXT%Z?I%/?>.6`ZH=NNT\I
M[.4#&Y+V*N4]'CMLPT6:"E9Z;=C2HUV3T3=,'[7=QZ#AJXT_@+([?P=]?=GW
M<_HC(YSE%+.<^><IIYSG/SYSG7&<YS_/S].....03,O\?U)?ZFW7_P`,N3MQ
MQQQQQQQQQQQQQQQS^=SXN_\`W1KM'_KD'_\`[1!<UN\<<<<<<<<<<<<<<<<<
M<<<<<<<F6A[YL7KA83>QZT?#42V0A^*'@LA%)'XC-(7*V&PN50F9QY=5NF:C
M,@8;81>M=7+-ZW71:D1;\>29-7:4FT[/Z&>V4AI:-65O"ZJ:P>Z76@1JSLZ8
MMGED$*JES"G=B9-]()3.M@@&QUXE\$$CR#($P&I/W\@T**Y7>YNYB2>%:K9=
M>EE@D28P4>_GJT\#MJ\OY^R+B7<9ZYNHJQ;C<.DEFY/$O;]D&8LHHD69`@+\
M&V="/25B!<#4FX2'5E[0C(=5N(0.M^/W98R2RP^&67J;G5!EI&:=54Z<RF2Z
M9""IQ"V*#9E+V^S4>K*8L8C/H/'4DC<H1>TGXXX^;_\`G_\`S_\`;[OIY;NF
M.ZUPT#.ZJG=7I`0*M1Q@A&0T/V?6`YKJ39-)'TCY^>PO$]0&R602/,F*KGG&
MFXT>0<_%JN1J7Q0/T1Z83VHDC.H)_0)BO*WE%-3BW6UYL8&12FPIE`+&;#W`
M7=[!R<=F8LVW`/X\YS'2D8/$#K)V'1012<M'6FSM3\H]VNL<?$;>KB5C(I95
M97;*`\]F4!E;(N/$C+`CF/51N<P`E$#,?.P&0!!NJ4=2P'(*!B46;M8^<$%&
MC1KNC`,E.IR(KN0;@0,89:-V[(>!C;9V@+&,6NNV$4-%R;XH:*.M]U%5WQ@Z
M6*&"3E7=5T]V2T;-VW0>6?HSQQR7:&NB4==[?@=VP@?'B4SK<WK(XLE*FI1^
M"0,I-'3)!V_'B#`%T_310>N<:M=B2+????51753*>F,6MZPV!U(-2^SY=VXB
ML.54FEST_)FP]2.VD<:#H,9F$X*=C4XUO%B!`H->O0Y0`K'4RQ9V_1(I:9!*
MZK,]U,2"Z+>',M#KI]!"--9@9H:!LZN;,(-=V=`U_-J!RA,2XHPXW<!@L:WO
MMAJOL/(A\M"C(ON_R8<1/U@%O6/M>3Z^FS=;F.O2$+#BWE:1]&QXI#XC.XXT
M`6T,3^+IJ]'$IUE=Z>A4N<MT)3!T47?PR+L"#^-FF39XS36=50Y9;IE_\;;K
M7_\`+1!?_6R?/Z9J'_,(_P#@D_\`<UY^O''''()F7^/ZDO\`4VZ_^&7)VXXY
M\]W:']TG>'IU6[[0OHY,I,]-Z*OWD8O&^H\_'O*KZ\3U=5%L`A\T61U7>&5T
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M8CJ_K>)%8[V22ZEHJR64OG8R0WGO%Y3-]XX#?Q`#*,[!$HE$GYO,M>MFHIPF
M^$,F&CQ\Y?(B\@&=%#EA5?UR,P#>+`3]D5#VMN61328V2:6A\LB/6^>X"'G@
M6.M*Q^,Z_<``>NV=&91X9TEV,;D?A`5PGABIV>_A7]BB&R[:$R6HK%+:E.M*
M+,'%I+*&A%]&>V+-^[J*<[;2R%QQB,`.,B2VDE'$WC>5QYL.7*K@%QRS)9U%
MJ/0VWG-F9K%&0UXW>..OLE[-B)$;(2V.@BE5PYJ4<R9PX8/X;O+XO)1/Q&81
M6C$PC`)ZIECHZ24V8D!KIU"'8*BI;UQLY_5DT(1XP6:QR$2YF9BKDDZ`F(Y8
M42$S.,DF63(L*7;[+B"Z&CQB3%,7C)ZBY042V3U276A7CCCCCCCCCCCCCCCC
MCED>IE+![ZN\)!I.1?"X8+BEEV=.W(K?5(RM":@KV1V/(A(-;=)?5L9D+:/)
MQT>]V0<8&*ELE?4+_`/4[V.@_0$W;?7UIV7%6+$(JA,*6[67S&ZL:0R3*I,!
M74\M'6]@1'VH=25ZDT1=,Y,SQ#BKE$L](KHX2,M4/3=DT/.SO#>E]>A`&B-J
M1Z33.1W'UZHD;'@<7(Z!C<P[$U8!MH0:@LY=&]ATOA\)C4B9MI-(6P1!')O1
M-+#5FP?,W"DCLO#\B-\DLV#4MKQBNX!9LO[8@J5A[R!2T]K@5U$"X?F",DDS
M61N/@S&<1@9B4(F&S`F0WD)W=DWCJC3.ZC'+Q_2&MJJZY=R9G+VL<N4R`Z<=
M1NTO7J=OA4QAA&-#>RDD,"W"!R'#YLL.6+C!PU5+`\P[D8Q!ZFV)I:Z;KN!R
M-#*<I@=:M0=FB*K%<1,:+J-EV*BIS.KM!"50<+8\;K>QHJ3274^`O6Z*,H:R
M"*&&"*3UC((X<`N5WS,LLW%U;VQZ.V=<_/C.<9_HSY<LQ7%5A%NMO8GL;(D4
M"^:QD52U3!8PZRY^*WT]MU25%'4ED*;)=JY>"X9"X29<"Q.';9J5E!H0L0V<
ML`[D:_VE]GO"HCAGL(S$==9?#*SA$K[#4;UJUA,L3E>S"!2NQ>JD;OU>2-Y:
M;D!PA,6QC720^HCB>6#K!\H"C0DDX^%*_%E$)!T=1$DX`S2ORNANL_INM;J'
MAK!%$:^L#</:=KZU3'H5'X*[*F7,OLMNMJXF9.+H%`6FD,3;%&3]YH^04UF*
M6>%E*(Q*@\<2N^(F6^91V[B<L(HPF0C78PKT[CK>5S=I#8^Y-.7U@$)0(7RE
M%1R+B/+[D6A'9?940S^-5L"=]/`%7R6SHW,90QF'IP#K#$H6;7BI8'I%;@[H
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M^0<ICOPUPW9-4W9UN<<M$=F&:J]C*E!0`9U\L2)Z_`XMV-H4#;[6.96=.=8=
M)FLIE%=V#%Q[I_NJ0=1Q"70YX9BBQ%9R0;@3C00\>OW`A1\YK/RRW3+_`.-M
MUK_^6B"_^MD^?TS4/^81_P#!)_[FO*P=H.[74GI:!#23M5V&JBB1DE7=MXQI
M8DN'!"LI6'_!?C+2+Q[.Z\ADGQ7J]9[E=P8I^F+3=ME"&[;1=+;?).N7:OK?
MV[@V]D]9+NK.\X2@_P`B2!^M):*D[8,9PV1>;!)"W8K[$(X<T9N&[O<*>9C2
MFC5P@YV:81634VL!YX\\X\\>>/+SQ^''G\WGC^7RSY?S<\?3T]'TO2U]''S[
M>ECT?G\OG\_+Y_=_/SRY!,R_Q_4E_J;=?_#+D[<<XV\L8SG/S8QYY^GW>_W>
M7O\`/'X/+W^?S<^$.4^$WT^[^?NE'N<E)*N1@?5_J)6M26]V5`A6SN*0VZ^Q
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M:FK/LG25<-I-*4B$A:U5V<.K%IR/E!,5/Q;(Q*46_P`&;BSK)D/;"W&KG=)B
M]142UTS4+#?&.C+A1]&*`J./%-AO5X2F58EM7#M!CU#W?8J-))(I8K]EMZUH
M4*C9KA=HMI*!Y%PCJF+4U061A0#T^\1R&6U85LUYTYHBO%;&K>RJM)P2*&%F
MT%%1RWARXZ?.PZ#JQW,FV/%4G;O8>_+R4HS`:*-QX46T$CF`]"-[\\/[Q+.Q
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M=_?J5:_;F*_?>2]1'AV^)!0-J1FTXQ1`,L\!I'Q)6/F9Q&_B:51&91LM#)M$
MBVS=]ARBPDD4/%Q6SQMYNAKA=L4;:*N&*26\I!.JOBZ02!LJAKF#CQ551N#W
M95D.!G\4H6-,JW[!+#U;3`FS>!V[HJ_F7Q.&V.&,.-723H:F[CVX+579MI9"
MXZ$[>2N/1W-5=#ZW@%E0EQ!\5Q:F6U5AIU`AD?KM:O96T?2"/3,B)L1_*ARJ
M.S$CO!:Z;1E^P'R@:*P<8#D6%7:VZF^+]4<2@4'@4"C8B.5EK:>L(:NDJ<-N
MPORV!,1NTL_&AD<]($-I<!QH+=;$W#S(]NFEL&^+5],+9R1?KOXR+N+FH4^K
MJ`DHG(ZCK.ACP`G'*((#BU04XX>NZQ@SQ-R'45V&P]T0>.1KU)5(TLLOG<B4
M?>@EC3'5>F'B9KPBT([O0\7;'K7K6`T26*1\E5D*CT;HBOI*VF[:"12)P]L(
M'($Y5+6`IQ+9.^U5?/0XU9EOA\3D!,PWJ_GPB>_V<YSFE6N<YSYYS[<Q7WYS
M_P#UO)J@'AU^(3$JPN&FBU!LC5?W%B#&R+;6<0_XPC]@5:5(EX#+A7PE[EHZ
M0U2-2&)RX(Z]4F=B,D?Z-GC$J-&+YM1$*F\6<G9\6E'8"H`%LP)G<,,NZ8PI
M!K0P_:33RNJO5J:"&=_2%L&JFD>B*(<*X#:.@S0V%&;I9?B9`NVD["*.PG1G
MN=9]AU?9%7],JVJ&55^P9+'"\1W@L3#SR6!)-J=BLE)USB;3\$Q<QA@U'A<*
M*2,OO)$V_KBK=JV0:#DY:KFF/%#S90Z7]A*'BMQQT47OV>#HVX%43NQ2MR_X
MJK')9.2H?3,5U.CB"FZ;TO&&<FBF/7(MW,?*A%$7+<E&%]=->^MB2^/%:FZD
MUW2<9`RB$VB\CD.<P(&&E-XQ$/J%4M(C%]Y)+6(O5XQ19MVT*^/Y"#:+)%3*
MCA8C*C26.X9T]XVH^2MY@SC$5;R5K95F7"W*IA:(]<E95R1)>"69*]4LA,M<
MO);$G3@*]9[(;"6B"NZXH>/>9PYQA*/57Q<T6E.L\U!53W3K[&U8E2BQ:&]?
MS#NN`*JN[G+("\)@GCC?=-[OD@@_*;DB3,CJD_9.V[M!NJE'MH^'1XAE@Q:F
M:[9T0@(K^AH(1A4%%N)_$79-TZE,I)3J?S"0.T7*3=8[,)>677^#M$L-`T?&
M1X"BL^4'.BA"&?[D1W]^I5K]N8K]]XQX1/?W&?/Y%&F?Y,SB*9QG^?&7OEG'
MTXS\_+<I]3O%,'MJ_,Q^G`X>Q85UZ,=3"<J<'*SDC*9=?WR11D,!%1DCT(8'
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M/&?GQ_`U]V?Y<?AY\Z?BJ67V`Z56_OVO8=D?#\ZZUE8F(94L1D=Y]0^R_9[L
M$:DXR)%S9>+A%J2*%I"-@Z#<0:D*$?C,::1P7GXYD4B7R9-.73JWOA)6&%[/
M4V3[8&K`I:ZK5/3*P:S,751=!6EUFC<GBL>)1U\.BQ>N+=&`[%*.H<7V(;,S
M,_;%WC(@9DBD2)-`Q\@B\PSL?VLO"B9#XP\MCDP='D.N/3CKA;E)1>3,PR\1
MKB:2V)]E$#Q=-NR#-GI$$H5@\:ELC;R!\67<ZBG+/4BQ#Y0:,XZ)W7<0#N;'
M/#X3NR:&JYD]X4B@9MMS)E=+:;1:6=,>T5ZRVL&$]9X3?C2LULGKH!F`Q^/<
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MB2#&818#N\C<_BCO!2*%VWPK9PP?[IZ^I,`'C1^DT?CETG;-9!JJEMIC0'X"
MSJU^B-[=_/"$L.%6F=K;K98FW8'J7.W$>)D&3WKO=IK"@Z,N2*ZB;%D00>N!
MDBT8)N5EW4I(6JGOJFH"6US]-/M[G\3)[]F\_?N/;W/XF3W[-Y^_<>WN?Q,G
MOV;S]^X]O<_B9/?LWG[]Q[>Y_$R>_9O/W[CV]S^)D]^S>?OW'M[G\3)[]F\_
M?N/;W/XF3W[-Y^_<>WN?Q,GOV;S]^X]O<_B9/?LWG[]Q[>Y_$R>_9O/W[C$\
MSYX_^TR>_9S/WWFLN]+4LN&VUT[C<%,M`8&_^W-I5;8H8O"1<@./(T/I^_[H
M9-X^](E&.8K)59!5HN/+.\Z$VOQ8;)_\F1(-V+]"#<>+#0GL4[L+-3]IL1-K
M2$D[(Y)8JJ)*9WI*N[&6J^XYUALC:RKA!"F)-HTVG`-WJC)B@HH.(5J'L+11
MQJVSYWXBU8:3)]`P].]G93(4['ORFP2,?K>%J-I?;?7*,)SN>0"/.2MK"=42
M+^OOALYB1R2ZQR'&`8H@Q>R01*]$(RX]&)^*)U+FA2!HA)),,Q>>Q',N1L1W
M$_4PR'(I4<AV*>B[*T1,.IA`W`NK%MWQ4Z8B/L.PE+=:"+2SVIW:,'4&$?$`
MEJ78*=A)"TMVLZ89M?#<D%=LG?7V&26>GFW;&=W\%)L"#0?/#AE2&VB-KB(A
MVA9LUUMRJI,_>QUM7:LD6^"\E![XFT!(.HB"@E17#))B4[2]<>M$XB!1K7H8
MU72W9&%O+&ATK,_![+?BG"Z\6'/!RT21+ZR:)3=N_C=E"8?L+4W>RW5GB!=:
M[9DDP!AY8ZC0:(PIC8VMF3W:/1*H9'"G\V7KU`P)LAY)E0(9]O*-6*;:)6!O
M")H3"'HY)A$>(!"^'+7KI5XA%(1&<V5#GH*UB@BJ1]7OI3;$=C43,TPNK>,=
M$2&DQ\?L!&P=$3J]K[&FH*'OVHS0%DXFMJ>+`@R@XT0@8]XE$02L3KM-&98[
M&>OT]BG<B.V%$IG7HX986+GH2;4!`X*,C$EVD3@$5'2.36TL.#D8U(2E=3$,
M2!R]M--!;9]EI)Q[Q.>O<:J1I=IJ-7<PK]`A/Q\S+.Z^&,D:]4K.PH[6DGW+
MDB,Q91V9JNCDH&F84+IX[9ARQH$@:G<(%&@0$HHWSTEWYH849NX8X6E"H_K_
M`"LK7E@29BG#7H9E:`R?1*LVU8.6",X]KXI,Y3*YH(S`$;*BT$!S^*H&9[$S
MI.'!GA?7V7/=^LU>GEY=R@<=G3J&T-"+^E,IADA$HQ>6NC'7H1("$FC3!TFZ
M/1PDQ.N`B*<8GD8,2B%G0Q=C(PI0HVPNU3ATY??8FC`G3"SK;D\7LD-VHM^C
MZ/LVLHM"(U$VU13'LM$BYBN2M-R]$M@[,P4*G+,7`9<RLXF:<2^-%5I^/.0U
MV)6%NI!'^(?1I"LYK;>T9O`7"JOL.,U-;#P]6K,&^J:R9#8V:P)1"R!I"8)+
MQA_7AUU'#5IO%-G0>#06<06</"3P'(TU6F;N^Y==XL,O64<@]W6%)8O+1T8F
MNM<5TG+T88/,W`1H4-/"[4?(\'"$"(VG'IJ"V*1@,>,B`U<V+-Y#'A$+B3LX
MOB4G\0SKO#'B.\F<SH7$3SJW@=:V7K%6Y*!7+.J*E"4*LFM:L=BSKR1FYZSE
MBBP.("3<9C0ZRW`TVX@!D^/"OWB<.U7WUD69_P!O(+:5>6L8FU4W_8H.LZ1B
M5>0-.X1U(U1UQZY6W8\@-MA5ENH-+6L6D-U-V(61C)\^,V*I)H='8B%)G%U1
MK/-`7B?]8Y"^'NV&MHZ5F3F*<%;WN]A(YK3NILGU@'=PHDJJ8]K59>F)G-$/
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MV9MD@HY&3X*IZ'F`<*8P*A_$9J&:U-24H7)V]8PR=E8549*ZE:EB,(`K=AYI
M!_;V*U-,(F!G#I"#V/,A3D.(:,`#4S6(2<R&,0(Q8`N1&]&R$Y]:>Z-8=I7B
M;&#1BUXFN2HZG>R$6^4Z(B8PG-:8N_8\RATRC6P>62K.=&D@C!R,2,0>T`FQ
MI=FDY:#RD?(CCCJW/GGZ<_ESQYY^G/Y<\>>?IS^7/*J77:]@07L7TFKZ//H\
MG!;XGU^P^Q6#^/K/I$OBONMTYMR(NX](LF$&P%NW/Q1-$TU^(B#LRV<)I)%!
MC=!RW(1J/OR_7![Q)0,<APVWY9UKEE:ANNU=1(>#AQB3[6+UBKZUAT8D)N93
M0?'S)A"92]ZN]/%Y%#A+P(RP,:-@6_JE%,^Z26S*+FH=C,9Q/WL[G32:SJ&S
MIN:H1'K/+JXF<++)!))4<]I]M8=J-`,U@9!+=(L5&SR1`Y2R*"9#&R3Z.$!1
M%];?SS].?RYX\\_3G\N>///TY_+GCSS].?RYY@EF63$ZC@T@L.;DTQL=CK9O
MNMG9TQ;.RI,B];"8_&0N23EFR<226'WPV-QMDNY02=FBC)-PLW:?"'*&CN8^
M)M=T2HA"RIG*ZGBS[3M#WOI(](:Y'PVQXM"Y%3$B68]8(?-M3IW14+2$BSHL
M`O7LPX:C1T7VQ&Y:5DU;0R8)RH;8[/>V=C>S,6KB32:%!"9KO;'^EKCK-F-Y
MTEI.OIA02UF1SM5!YR_31E4ICKF4CBAQL_;(;5D_J9D3#;ILK$!.RSC;?KOG
M;77;SSCTM<;>7GGW>>//R_HYY>>?IS^7/'GGZ<_ESQYY^G/Y<\\%%TFZ:CAQ
MLKALV25<N<HXUV6^#-D]UW'J=5,X3V6]2GOZG53.--E/1QOG&N<YQK1ZC=LK
M8MJ1];%++TCV`W<SI_,NW\%!!!;-@O3>L3GU5CDJQ4*-E/A4U$OZZO"#OW$D
MD.[@_K/(U*-FSQ&.2`;'XQ'_`&SO+N]UKE4QF4=L6K+9A@^KNP]Z)T&`ZPG%
M93!*IKS$3B$-+%+/#6L2E]AD1<UL(!(9(R$5S'%Y<!B-@!P28O#%J]WLCU![
M'JW/..U5:HVC$[Z!]>+%JH)%;VA0H&#%SV/7#2T>MIN%,#8GKK$-)=`7A!Z.
M(NXSHW9$8T:ACDBP92'!K9U>#SS].?RYYBTXSGV-D_OS_P#`SS\.?^CCES4_
M^;3_`-#7_=QS1QXQV;`MV+4[6W6&0]E)I<-77Z*D]J5QT#O&B*?[90R#'*3L
MW05)7<YMIJ>;5_$'C\O'DR8MT(9JV.(.H!D'>S!;?UED/";A]P0KJ^2$W>$[
M?@YNM;<^(;M^\=N0"\.P3D0Y;QO08\/V-5XH/"#`)71!9**M0C3.@8.W2$N5
ME7C1?.+CK=;:6=SBX;#(PI`S([_@0"KKB1/&)">B\^K^+L9(-!18U!3!=["/
MBQB.F,L8YPRCK1P]:24VW(+NTB+C7:/6?2#KDPAKB&M8>83V6FT=L=*<;3R=
MKVX/G,/C2,'A\H%7"XD2MF#"\3@"&M>1YRRDZ/Q;`%GT-2UR`*%6+VPT`@$,
MJR%1BNJ\C8F(0B&!6$=B\:!M=&8L,'&(:H,V31#7SSZ.FFN=U55=U'#E?=9T
MZ67=+K+*1O,<8^7VD_=CWPV[,Y]WSYS\F7GG/T^?)V\L?1C\F./+'T8_)CFF
M?]T#6E854^$9W)=U3&IA*)]84##T@$'0D`4/ETVUWS`!64C>;-A#9T[;-T(I
M(CR6KS">-='[E@WTWU<.6^,W!\.'K0ET]Z(=3NM66>61.HZ+@$;E*.V$\94G
M:X5$Y83S.J6,)XW?3HO(GF_H^?GLMG.=ML^>V=??CB>-Q6/A"5''4V,:;VEV
M?MQN_5INJW^Q1E%DA(AZW92"PK$-CO5*CHB"7738-1`ISK)96=<-Q@W4>-0-
MR`/;OPM_$SHKQ4^KX3L13.C\`38/M(?;=9'/-4]5EFM!C$D6BKHCHW;LI")6
M:/VAB+RD9IHU.@'S-=TS#FDBP(7L@\L?1C\F./+'T8_)CCRQ]&/R8X\L?1C\
MF./+'T8_)CCRQ]&/R8X\L?1C\F./+'T8_)CCRQ]&/R8X\L?1C\F./+'T8_)C
MFM.RJ8&VC8%33IZ:MP$6ZZ7[8ELP72"QID_CQ67D1=BUHKO*%"L!E638A"(3
MR5#]!@8H#RD_(:OUG6[T<T]35K7PTZ6UKE6K?C[LUF+..KUV]1%\Y!ALE%*C
M[`V:VM>Q-OAWR->K3EZTF:-VX*0)-$VP4-ILTP&>/%%"6TAA.D4!`2X).&<C
M[$K2(#>5[]AVCEW$PBC5:Q^Q53N::L)9VQ2J!!#<"G$'CI2.!4/@_P`4FUOC
M!T^*MT6X]+!*@\-^IZ7!&*[CDV[<&*&EE9LZZGO7.1[^LJ.P'C6GFE!N;#E"
M(&J`$TQ,S=5#1`22L`$O!5^?D`43/2,)5EK79^KC;;PQ*^78-FDKNSN_.7C.
M,=:(8V.GTHHP/HQKJ'*)O*:':Z%HS0@5[H:B[J?&FI29)N-)9)M=$"A8MN?V
M4+<[BO?#3J2OQ@]HE-.U1XN'EW4B=A)4^!QH(;"R?IC'2T-JIZ.:1.D`<8U;
MFH<9=1ZQ&+J.NTI/KNX.M-PLH(/3:DQTQT]@5.1F25PN1OFXJ5>9<CZ^H6]X
MHRLFH*6A[J2[R[6!U_&'E6LG!J/"CF6NL8>VN3L>3Q(`)#1B-GAHAANF\ZR8
M=(ZIE[7L"SQB\X>EV`2H-;?:NXSK"%J:D/5UN.3H.743N$K5#6$G:X>AQ!86
M@5UE$?=/1K=N]"*"-W`Q;%+2Z"P^[1-=:6K:W<>7S>LP5@M@%NJZL`UEXF]@
M2>M)K\K#<B"IT>!CDW@LLIVM#%:C8;'XW7\8UB^!CN%G!YN0)$^MN?P]XO?T
M5"QVTKJ[FR<HA55Q5+,IL_&19U);'#765AIR1G#+-Y1KF(0N2!2D"C2,6=U'
M&*]9L(JW(P4@R*Q@V7:O.PGGA\U99LELN;3>0=C2<]G@@J)CUE"HN)B=I55J
MXN>*=@(JZAMC1BIQLEDFU2VG!HF=I0=:[BP@E7L1Q./`!N0<F.,G%J(O6J(Z
MKR%7V(]N*_FDG$24-8LFNN(.SQVS6<R8NA4H9RL=&(1$88S!E0KM4#K%(C%8
MU&!H/R9#QB*RCMZ[A6*]0HI'MZ88F9-V#L&']:7+8IUP@T[BC4H)J21!HB6@
M$)ERAIG6@^5VE+:QA!PI&*T-6T:E^8VS=JDR#60RGU<C2AJ;]."=>Q"Y&O7V
M#2ZTC'9V"QZFK[@UZ'SL-JN6H.HO*H9*NULQTC=%R>23+L3L&/-$IDF"<1).
MVQ`L$$V=19:(QA\PS8/T+KN+2REI=!IEVKKMY55'5_UWF8V"JG!8KL;6%92%
MS-XD-O%T9A$BF#TNTL$Q+I@]ET&E\+FIS>>SF/R*3%PDD?H[XQ._#3H&QHO*
MH!)].PF]<OY-<M@5E"!`XF%8]?;0OB18FT_LJGS3."^T;:2MYXL6F4#0FA.7
M@:\(R22C(\(Q'2340+]L5X?46$V`>N?2X>WCR^)7)Y;(I-<KR-P]*0E&EC5'
M6--6;%D(P'HX/`1$>G$?IBK9#OJPC6"<2G,'`R*&$`R7QR+-^NV\-'KHSCFL
M$;B+R3K76U8I:N*WS'\[QG9>&]6L=-1$'W=;UIF3J056A,;`"C?>0;2LC(55
MI>I+DRZNV>6:Z]4V3H*&)0Y]9_:6^]F2(<2'E%^L%9-)0L1C+'XKBT.8[PZM
MH&$68"&&=]'\@)!7\WF+Y38K-).<>)L\LZZG?#RJ>?Q.-P.Z3_9*\8C`J;L2
MD*U96`";,Y!`8S:3:-,Y<<&SJ#5?$9@;F.C2&Q1M%S,F*%6L8U`L7FHPJ;QN
M9V_"Q_#KJ>Y?CLA;DA[(3J7S)"?-['G"D8%1H[8:<]ZT'^I:B9EI&JH8A`+:
M+T_*#Z<590D?&6K:;F"LW+Z&7Y%PTYV<2Z$PV,V0*N5]:';V76T,M")V_O.3
MP^/LU2,QB_7%7JPZT>1N-T@%C",:EM4;-V4HC8P8/:[$A[)V!7!:[$TRF,T_
MX:5*4?'P<(A)?L?O7@290*V,P,\`9E`I:\ZOC243@ET%G"-6#WZTH#"A<0=O
M8TU49UW()/`H?+3,2<EVQS:033U^ZC0'K@6AY6$N;U,9@_5^J^HP%C+HSJ^9
MZ513<DD4IA*[W8'6T>?/)BB3E1K0L>R\29%&:Z".P1NJU27Y:[8GZ"J2&X:6
MZ+KX5V01WALHU67U0UUW7RBGL*QNKA'3?39;.FNV$]=M=M_1QMC.?U^&K_Y@
MF7V)E?ZHX^&K_P"8)E]B97^J.0U8=/A[(L>AK.*;6\(-]>)=-)G#1P&'N4@A
MDG/J[/59(VTN1+04P3(#%H;)"[-HV#%8^X9OUT2FCW=PU1UQA*O7/X$9[)2J
M%V/V3KJ9=F9'6LLD<JBT,C3IY!CM5Q"-P"/*P`;*:<D`;`XI"8J)C4N$39E,
MVQ]AE^LBH)(/E'VDJU?7XRJHX\!"F-G2$B=DI^<S292F)'7<KGL^E:S=>332
M2K"HN&"IDRN68]F@-CX0)'`(04&CT?##1`EFVTD;X:O_`)@F7V)E?ZHYQE\M
MKC.VP&8ZZZXSMMMF%2K&-==<9SMMG.1/EC&,8SG.<^[&,9SGW<\$B6SA))=`
M)+ET%D]%45D89*%4EDE-<;:*I*:"MM%$]]<XVTWTVSKMKG&=<YQGSY^GPU?_
M`#!,OL3*_P!4<Z"3`8Y-@SF.32N'DRCKW=NJ\C\OJ<A*P#M5HKJX:*N@<AC)
M,2Z5:.--'#11PS4W:N--%T-DU=-=\483\.#KT"T)[5K&K+J-_(2_:)25/H)5
MT=20E4)[AOPY&[*K-Q\I5+Z+NH0LM&HRC7^Z@962UR/`M`X4ZY!NS`HG8H/0
M$+&SBM)L]%6A(-:+AZT%Z_Q`O$S^8928%[$QD$*OXH,;1Q%\;G!:&BD8FXL.
M;%)')AT6>G`$;6`LY-*=CL^?#%_Q?F7V)E?ZHX^&K_Y@F7V)E?ZHY^7QG_?\
MMOB:6_"<(X<9;^QLH]?AOLIE+5?*/Q5ZS".RNNR6%<Z^KRIC.F-O2QG'/U^&
MK_Y@F7V)E?ZHYY:OW&F^F^(_,,[:;Z[ZXW@TH5TSMIMC;&-TE`^R:NF<X\MT
ME-=DU-,[:*:[:;;:YI/">D=>5MELI7YWL;#746A(^IJ?(@0ZVA2B:22ML)<L
M@IJMGA6NS&F\-FTBCXJ-RE]+FTEEJM;C0T'$2$0U"LB'+%+5\EI8<_M03M9H
M><3B!0NNF)/6`$2K&"1Z#F)G(V"<2#E8PNUVW*22<$SY](]N6;$GX\%KE))H
M+3;*?A4E5Q6F01T1%8_9+\C,9G(K)L*92B-2DU-;'L>6[M/:*;S,UK'V*+XN
M\;#Q08<R'#Q4=B\6"1^(1(&#C($6+;2G\-7_`,P3+[$RO]4<QF:.EE(C)-,A
M94AC<0[URL[B4D9M4L9UQCTW#MT,2;-D=?/SW675323Q_"WWUQ[^782SYI)Y
M\LX\T],^6?=G'GKCW9Q^#./P_P`O-#OCM2.M:?I>J[ADM;=0-RSRU&D!(W5V
MMK:]RX:`AGD+F!@".`6IU3A$L[!59+)#,A@,9$I``<`@JCW9T(7+ZFB@(,;Q
M'PI.XDVL'M1V4ZT[R,LXJ2%KH$*KK2S#=VV/>5?-@%3=<S-D%#5P7<6Q,I-6
MK6V[6EE2QN,RF)!)'#Y#!";)\1W>K$`0SZ%...03,O\`']27^IMU_P##+D[<
M<K9)>W772)=GJYZ9R*S1@WLK;5=2BV*_J[8=(52A^`PUPZ;'CVI=H)6C@["*
M@\MNP'%C3`H:;A#SD.R?-PA)1O9/FO[Q'O#5ZR>*%03JANR4<>*(,G^#M?61
M%MQP^RJIE'DDDM(8,<(C2K9ODBQ3R-D`(F/)1Z2#LIH%AB[AD*=CZ)_N>[K!
MVMZ.]3K<Z:]F*P'Q(+0'9VUPM!6.,>139K=M/RA\A*V$[^`@%%"WI*FR!+9`
MK*O4FEQY!E'EFS=2)K();[>..........:[[?M6T*\LGI!$8%(@X:,WMW&N*
MJ+09DHNU//B,4$5+V5NYIF.$G!!EF.&E3M/C`:I!1L7:[!CA3.!Z1!)B_;5S
MFGC.58TJUG/*\HB^I,6DL6K6<P(')`<$B2,PA\Q[4Q'J1,BS!VI8[Y1L]JFS
M9G'F<ICY9$66+HR2,DH?I(HX[,2`%90[XE?7V%S*RX38PNS*W)5I5]L6^[5E
M\4'H;R6&4Q9<2J*8N(Y'A$C,S?1Z]G\\AP6O&\GBL:2N!K(A<DJ9S,XLYT,Y
M\#'?-VSMSK'4Z?6J_`1*_+WN:D9`M/@,5BFU?/*<J,]:+N0([YF;X18<9E+)
M@U=QN7UL8ET0>!!DQUR9Q+0;:*$(Y[[]JKEZ/3^H[Q-EHW*.G4U,+4Q9<2P/
MC$8L*L[;G+#=E2%D-;`DAIL#(5"3F+?:*6LT)BD2-<HFA-HN#+R`1N9BFWN`
M^YUG4W;);K1>]>S:VIY6_6FG+KG5P5-$(N.B$REUSW'(:D91J$0C>;;E(G#H
MR<`/=2\TL1^'#`@K`S,YH=C\/"$3^O5E?%^ZW#X1BP64#ON21MG3]TWG)G<7
MA40,Z1&N^MU];]=^P)4FY1L;0<;4J>:I*E2Z,&?2[25PY+X_K-:<[.6;!?-U
M_$UJM.6N*V;4QV5)6OK;LII0=5S"OHFI*S<Q!=?&?:("LP>+V.WA[,%85+O=
M9-$B9Z5!MF#M%U'9^V@\@:JC<=XQ\2"ECL&Z_65$H5=,NA'9E6IQ-5F@D%%I
M*%9G;A.1#A]?.`AV6A)%K,H*G$)6:M]@/$$QU31F-FI-."PD$P6?8DBA>ZE6
M=@K-GM01T%8D0G\`@\,LM_'K%C;&.$GT!G\IGL/B\AR*9G31J)/'AFNCWPN#
MV4+@]D"1S@(6*PUH/-,E]JRUG<':WMPP[76=1EDPJJQ%0WE?O6V@*XDE=BY@
M$G$OZX2,E6DOF]WR-<VSE3<7-[9!R,9$X[7[J#*Q"##0LB-O)B5,NQC+/IMX
MFM&UF9N..SV(7!'S%)TE>?8`\U4B`EP[D]8];IB`@UNR2(@<RAO,=&`LS)!)
M"(.9S%X*A:<0>)3:LE)7%\Y)8QLAXK_7T1."]3&8-=@*ZAT@1$#*8D<:@L:L
M.:"24`869&9/7K*064-!3K6:11T^6B%?1L^_NHV6C,TCJ57)'X=(AP_F]O$8
MK\/6ML#*V<RH#;C`AW,I^"$9#!VI6.AKWZGT=*[E-H'VNI[")"/.8_'%C0)R
MBMEC(6S988Z=!2*R"&^%5UXM]`(P",.K0=2_8X)Z]';4LF=Q:(-C%<M)+4]2
MPVQ+GCBK@":(%8@]"Y/E4A+V:@XO"#CV.R@,`EQ![&B"6FQ&C+G"7W7[*QXX
M`D@`$4(%&HGVBWBKU(X/'N?4LY1&9#!93-H5+H;(VVR1.,2N*RDR%-C5M'#=
MUJIJL@E,/''''''',-,_]N$._P#%93_Z(.YF7'*J=V>RV_47K-9-ZL807LR3
M1WV1B]?5P"T=;$I[:=I3F-575</TW8-")!LS/V',XVP+OQPPJ0&AE2#]B+).
MVR#%QKCL3LIVY(=;9M;E"=B:^D=M=;Y](83;5-S3J](X^7MSLXR)0](+U&C,
M4>R0?+JMA4U%R8#O6<V2+6K/9.E9L)G>)D_B`AZ-DF\)'93=)/=9/U*NVFNR
MB7I8W]7OG&,[)^GC&,;^KV\]/6:XQJIZ/IZXQKMC'/UYZK[_`+">?^*N/_,[
M\Z2&?]J$6_U>#?\`J]OS)>1U;TDF\/JRQ956L#>VC8<>A4F,06N!Q0`$>3F7
ML!#MQ&XJB9E1J.QP3DV8T9L%"1LX+&LD5E'#IZ@FGG?&B43XF]P#*\K:#'I7
M,#]M&7G:&PNTDTQTR.Q:>=,::ZI,:]96C$I%UTAMI70PDEN+RBR(:VK^6,K!
MF5;R&)2;>R@8NQ@[.*QJ>;'*][(RV7]U8S40&9Q.=4#+NAD,['PJ2C`*29^2
MGC=L)Q/27K2ED2P')QR5Q%X)+!Q0>,`&PY99TXV6()/&B`S8'QS#<?XP%_\`
M4]G_`.O'G,RYX[YVQIMG3&NV^-<YTUVVSKKMMC'GC7;;713;77;/NSMKIOG7
M&?/&FV<>6=</6FZ[@>=QNT/6VV+D@EC9KNM:0M0(`1J21TY,HH1M`S9`V1"8
M;DLN[$7'18MO%XLQC]GCGY,N-GKJ6PR4&B!%AHT#P5$N^%A7KV"LRMH?)4J-
M%N+3[#=8NHOM]2TJD,3ORX.MPU1C>D^E$_U6;"'0J$&QU@.ZMIJ'F(.=GXFF
MII("]CO&KPE%X);/HK/+^F$1N<!?<IC5HN:I[!3:K:XO>*P?:MQMY0"/1^&D
M%Y<YAJ!,N$&&H?81J>TV?>Q5]F+GS-9/C8EH.^&.6"%XN1Q;W^+">?ZK&/\`
MT7;DB)_\VG_H:_[N.:CO%N7[3FZBK(-T\>]J2\H:WFS&6Y'^E$HH*(7.VA2E
M534^T5(3;L`)/0J)@V4CVA!$@'W;#Y!+&Y86R'O463G?+C.O"O2N@)UY5!]D
M].SHNWGEE62]:B^YL\JJ>7T]B3#V0U;O=C=/,A=?D8>S4)MM!&D09J#PR;]%
MF6<9-.'&5-G7''()F7^/ZDO]3;K_`.&7)VY@EGV=7U+U[,;7M:81^OZXK^/D
M93,YG*B3<1'HX`%(;.'Y0H0=;:)(-T$]?+&NOIKN%MTFK1%=VN@@I\:_A!]X
MNO7B>?NACNQV\%RYH&:Q7J]&Z'Z95_/=TPDYFU<BC8U:Q9Y'`CE?.VKM!6/G
M92\CV-O:(3&+/V4?#T<#)!LR^V/CFM?Q0/$?BOA>TI778*PJGF=D5C)+ZKJH
MK(/0X@-98J*+3K4Q\*M,^V=MGKLR,#JB4AS8(Q0:J&3!(<,V,BU73;9?8P(+
M#3PL<;#/FI,088,R@HDR63<LB`T@W2>,'S1PEMLFNU>-%D7+=;3;.BB*NF^N
M<XVQSL..........4+G,`KBR932LGE$YL^*2+K/?MG6Q$&$)`-W@,Q*S8JTJ
MP4UEBI.OI7DL)T@]DRQBDP!%@BB3TIJ^7=;/AK'+6J:WAU=/G$)BL$4LGLGJ
M,A-2GJBBY%NT:-38H>:[,03MFWER;Q"FM&KB91^X*VA[P(N[8+QGX@&*A#,6
M,:D'[IQQ(?#NZE31_;.\[M3LM,@%NQGM9$3,8+,VC9`.%[>S>J[-L'8/*0].
MC+`<FHA8E/PZ3U/)))+3YR")CF$6;/7D+`QR.B9VC_7ZIF>M!F)I?W:2UK*Z
M_P!M&KA#6Y/4D]II,SLBK`S39R/S(9%ZBC5?-H84KHSL%<@H#"8,IJ]::21`
M@C)B<A+F9!L^M*,N:26"8L^26'-H]/:3F%$Z5K(H"T*UY#XK8@Y</81>*AWE
M7*DMY1.A"R0>3OI4:E`UX$9-`;40Q$;/V3^I[_H!UP?0>.1%7L/W!<EHQU_J
M;KBUGYE49))>>@U#W(TNVGWL[T/T<0B\^.0^1HD8\_Q*8V_CUAPB0'`5IQ^;
M.'+<FT_=7P_^K+N,6'%"-O=ER`ZS*E[>4L?5<"`6KUO"N[=X*=@;MP*70H]+
M1N94G:RZ<2(N47B4=!KJ#_@3U;5!VAB]N]5MG/:"DKOIBU[5CVZG8(_=%XS-
MP&BNQ^,+#^CLCZ>P;Y.8A)*5(@3[8@R=1AU,@I=J0WT2&$CH1TQ([LA2\TQ;
MJ/UT@4FIV2U_:_8J%_(33^],5L#8AA1X)'@AN1XE%E2X>G-:7E!$79]R/TF;
M6T+$"DADC-"![40)=`6&SQ%YV75SJ]0?52=O[`BUL=@9V4=5=\CC9G9`)F29
MLH.UN6RKM"ZJNXU4<5/'9.)DEK2T:YFDH,G)3*Q2S1Y-RDDDR&T@5RP!2M10
M6PK7F%6VQ=U7Q2]IF\LJW*FB<73V@LALDRQ9CI?/(\Z-UD7FM=2&PVHT=O/]
MX'*P8X\7;+RUH/#S8N>DY6F'8SH57\@K3MR3I^T[IE=PW;1??FLZ\BEEI#15
M=A"O?)2%GIDQ+RIG3"$Y=@HO-H#&R,,,2N3RL_$(JV]B&;DK%A$7CHR2)5T7
MH"W04B^66UKWF)RUP$9CUVMI-"()(!T[CD1!`!4!C3P;K1RL:C9BGG+&2':L
MLZL6<2L.*36?3B:"Y;N0+#L"??FG0GK#-[`F$W>7%V9#CY79EYVVC`08L0E#
MHY-.R=!DNN]T/A."E*%I(^;RV'ER)EHUDLB.Z166.W3^*[!QCIP(5[JM.FU.
MT\(G<3K;M+W.B4`F4<4:"8")7%M8Y7%@$8['(W)+D@:B5'Z'$)O*M(Y[0%XW
M)C,FIY"82.72@-6`LD?6V1L_UHA5#=6*\>US7*DA2$EYQ-K%+^A7C^/#5I98
M!M4_)G0:(0V&1V$P\:\(J[.L`HA'0HG9\J^,NFSH\8,E"%A?E?@_^4GOL=+_
M`-1\?*_!_P#*3WV.E_ZCX^5^#_Y2>^QTO_4?'ROP?_*3WV.E_P"H^/E?@_\`
ME)[['2_]1\?*_!_\I/?8Z7_J/CY7X/\`Y2>^QTO_`%'Q\K\'_P`I/?8Z7_J/
MF-$K/B3B21I^DH>V:#VY_1VK[(RS7U6SQLRT:X]#8+A3?UVZ2FN,IZ[XTSKY
MJ9TUSC.<E^5^#_Y2>^QTO_4?'ROP?_*3WV.E_P"H^0W?PVD^QU4R:HIX^G3(
M'(5XX5:&HN`EX:4Q65PF4A)U`YK%BFT;>(,9-"9Q&H]*P"[QB1'?&@ALF3&D
MAJCM@XIO).FE6R$FWE+'MQW/@$]>3F9VI-IM6XR!A"5A6E-(=&*RVL"0#)%U
MQEX$3((E4\,CE70#,+&1=G$(@V)_%S;,@D\I/&=CHJT(**&#QFA.6/M!S%FQ
MU>%(Q-'Y)WJS;)-M7)!\L#]<\>N,)86=NE<Y4<.-U%M_X6^>>_\`*_!_\I/?
M8Z7_`*CY^#JW(2HU<IZ.#V=U&ZVFF/8Z7X]+;9+;777SR#\L>><XQC.<XQCS
M]^<8\\\ZJ,VG#Q\<`,':IY)VR##&KE+V0EF_JEV[-%)9/TTPNR>_H*:;:^EI
MOMIMY>>NV<9\^=Y\K\'_`,I/?8Z7_J/F"6;+H[8$$D</`V9:=3F#;)-N-L2N
MX:IM,HJ[1>-GB1$&E.:ZFL177SEM\%<-3\6-#W3!R[;*M,;*Z+)4S/=3:%,[
MBY&SN#L''[<6'W&$L2[0H%NC8%NQWL`P@PVU@4X;+54O"6K$DWK"MLP_V,B4
M44K/:!QM*";AF295F6F"#U#UTK6XH1;\%)V-&_DZZT@>J$.KIG&S*U>AZDBQ
MX=(8VV3;OH.[EZQT*Y%-&3,FO,5$-QFN[9X/=+[_``K%I_E?@_\`E)[['2_]
M1\?*_!_\I/?8Z7_J/F-8L^)>V"I3UA[X#M&FS#5;V1EGO=IEG+C='U?Q+ZWS
MP@IHIZ>=,)9QGT<;YWQG7F2_*_!_\I/?8Z7_`*CYQFWX-G'E\)/^_P`\>Z'3
M#&??[OGP#\\?SXSC.,_-GE*@M'5ZR?EYD<[%=EI3=!*(P.MF]]/(S'`EE":O
M@5I_*NE!![6*4D"KK5E,BZCH+8AU:!*RF51UUJSP9&O!H=^.P<WU"Z_$CTL)
MA;C[(P485GEU7%`04*9;#TJ/O+L/&)#$+:N&I2I6K#1D7+3HB;V2Z#,I,]E4
M6ATDL^;2F+@!IM:.NHW/O6:'P'K/#'<(:7;V&N$9E<4F#7N,*S>J0T`#",P0
MJ(P\77%05I%PT<:(,]GFVF(^X+OB+MRY)%WFNK1)K9'Y7X/_`)2>^QTO_4?,
M&LRSHB6K^8C63@SL[>QXDU;ZKQ:4-$=EET?5IX4=.@Z+9OIG;;'I+.%DD=,>
M>VZFN,>?+!I9\TD\^6<>:>F?+/NSCSUQ[LX_!G'X?Y>:W^^'6;K#-&0ZY;>[
M/VMT:D#%09#U>P-*]K7_`%*)2!JME\H"A<W,.C#6N;&1;J*$U8D-GT<DI2/*
M."RD07$_#26%^_Z$4AU:@<3D4_Z_7],^WIB1DG$6EO96S^R)7M;.#BT?51=K
MPMI93TV8CL<CX)X^3<N8%73.,11F:75?/@>QWUSC38+SCTM?^EC\'X<?AQYX
M_+C.,X^G'.?G^;D$S+_']27^IMU_\,N3MR&.P_7^I.U%*6/UZO:'#Y]4MKQQ
M>+36*DMG"*)$<NNW=M7#5XS40?"S`<HT8&X^<'+MR8$Z.'&!KA!\R05U^8[]
MSL^$1X;-*2.Y.\/6F[C'<<\+N2UZ9IZQ)W7!:OW5!@8THF(D48'@3S=JH=LT
MF*,ICI';[4>'8G8F_181"/Q9B;E38M];''-9_C(`:3DGA>]WQW8<!*Y%4Z?7
MZ;DSS6"Q9693(84$-4R4-E,8!)[))*%X?-FT=E*!$DZ'@@B0A<S(B@N/L2;]
MO\R?[ED\=&P;R=P3PO.Q,7/RR10.N-VG7>Y(N",&L(U[6@%'5:#7/NS^'IAT
M(Z';MF4,LQQ\!"/4?BR%2/+<XM'2!W[G/_?Z/]O'''''''''-0MZWC/05]45
MU:J-S'X]8?821=H+!,V++(ZK,`];TWU[*`W4Y)!(=@W'6DML662>QX'#(<.-
M%V\:!-",CF)YF<3!,@)+U#?925]?)@"K"_Q<QMN66U-)4QZYN^N5&G39R=PN
M#0&`2*:;3^(CI65&1*;10Q(9(X?[#B;2.GX>)1.@Q0U=%<2KZ;GQ'NJS4'!)
M`M+I*W86?$&TSK]0M%\1AO)63J]@G6M(3@U+C4?BT=D.+DD8.+K,IG(8R+10
M)-C>QO85OAQR-=O$`1BG8F7QBQX]/Q%($:JZ42>%O,TJ=&3&J);VDN&\Z34T
M["N%).^VCL:>3B`P,0+>-Q&%X\[DZZ[MF5CZ;R2LI*">(_U7D1Z8QH)+),4,
MQ4-&3HEJ.BJI9.SFDRM-.DXHQJMT#)E4)#(I#:CD7$1D3D&T0E2NIX#+%`J<
M$):RE+WNIEY6MV,KCL62/*M*^F%>]L^R-"PYR;K!5@[C4>JPI&F<57F]>*3Q
MZD>.,OC=VF;="YRS&3!FFT.Q]^-8$6.VE0H7W\[!M(+V'(6G&8DO9WAQ12XB
M??2NZSB+8DK9$B#!B$THG/6'<I9FQ"+5W9%7!R-H2*6V&B;=Q(7A6!.M'$_`
M2;`RXP7O74SN25E!S\9N&*S.TQFB4:&EZS)-V)6>-:#3[(FZW!+*$\&#D@85
M?J[+-"[$$K!GQ-#2'[S)K.]EHPA&@_Q3NL)$(,DV`G8EC&BT$H2VFTA(T+)&
MXE.FNR!_,0K>XG;A(HY60KW6:ZJ0^4NM&ZTICYI!RZ3B12,-UI'IGT-\0>@I
MS(&<;#"KS;D#L7OB30A0U1\O%M;-7ZR3AU7MZPRL]MMW#J7V'7LB;:_#XBV9
MM5BPM?XRCKXPB..Z".MD_B-=?HC%[)F)H'?"`&GS-GAK,??(X0T9Q%6DHR%E
M=P.GAE>0(1@BE7(^1!1AX:`D!>3OYB[<0**QV23,+(@8;M^\EYWE3?7)A<75
MR-Q&T)PG,JZ(,J]E(LRZ1M*N2C0C+)?&HB]&F`1&.V$<@08DM6Q-VW*,<R]4
M.).`'#1^X^#1D?[ROISV*Z*0+KFM%I?1W98!(;#GEEKB",C-J1DUURG/8&D(
M)7[%F:#,!\UFL<@I`[+GIE$PM'01*+CV8'4K)$G;+*NO?>ZLK4@]2[BB=KW&
M5E47C6LDLZ%]=I!&X:RG<AJTW<PB+3:-BY#*LU%,9%7(;!UM%B)(Q&X^]-0^
M+R.<B93-8V'?_B"\3#KI(JO2MX:`["^QRE6+W_OJ\HF2,I&CUR8@8G("O8C,
M97):E'E0"F\P9CURXA,G*2!L),A<>AIQ2(&54>^+^(IUJ%";"E#<E8$J@E8R
MAA"918E?056P88G+R%BP"K&\;;KQ(R4D;<PM+;-B&1S(_&`"\GC1!28PK241
MI#4BO`,Z\36/@+<AF`D=LUW5L9C7=L5V0JYQ11O/9"NK*ZK`>OLY063!9EZ;
M/2-*5Q<N\[409ZDVLMB;N-%X[(%B3U*-+SFKXE'4[VG(Q8;,9-)7#.O+2LD>
M6B427D@22BJ8KUC:EC@@"@TFH:TEX2#/OC9B'E(**L)0Z&GP,3-&Y!'BXQKU
M>_B;=7V;&`$3RMMQ%"QG5?;A&\QJU_'33.*VW*!4-JJR2T7>&LRO>M+"/ET4
M0$HC8.3+-!C$[()2(C0``7)-;#T?V5K;L1F2.:OQ*2T>CCEXTTFCL.P1A<B=
M"Y=*H,;81PX-.F-MCL=DT--L)-$9*RB\VCJ.P<B8C+,>?$.74_>>?IS^7/'G
MGZ<_ESQYY^G/Y<\>>?IS^7/'GGZ<_ESQYY^G/Y<\>>?IS^7/(UN673."5-8\
MRKNOC]LSZ-0TX6A-9Q?`S<_.)4@TV3!1\;J:-1P5MNY(JH+.]7I\.FH.;O$T
MB+9SN@IC3U,?$>M6OZ1H^>';,K@D7LR1W]7CR1DNM<@H]`#V@KDM"`%:=/+Q
MJ.S;XE4@ZWO)#(24RC-E7I()Z2A\3D+:$MT#D?&3&+$YCO/SZW7.=5M/4K:Y
MSJLCJILKJBMKGT5D=5MDD-EM45<;I:K;((;+:Z84V01VWREH\\_3G\N>///T
MY_+GCSS].?RYX\\_3G\N>8-9\GDL,K>?2Z&P<[9TOC,-D9R*5Q&E1J!^>28<
M*<N`,2$+F20<2W>'2NK1AAP2*CF;=%59=5XCA/&W-1I;O;V'%=4(M;>IX<],
MIW#/(?V2N''1.SVL7Z+`JZ#"\R<!V=ZLY[5K6X-(A)&59[2BRXA8TMC$=KYQ
MBS$HV7A6[$X\MH:O2V(=W5Z^4L<M6C#$"OV#VZ9'5\E`I9&YGHPK"!B)`&G\
M"N!>3$8A8$DF$A4(JFZ4;B?A8&M%U9G'RA!C"#,BE%]_2S].?RYX\\_3G\N>
M///TY_+GCSS].?RYYX[J8TUVWW4T33TUVW4465T1123TUSNHJLNMOHB@BEIC
M919=;?1%%/7957?1/3;;%%Z![52:[.U782M$V<2:TQ"Z2Z[VA21AD[W7FD['
M69->P,1D\Z/XV=?!V,7D*]4"2=:A6S/5_I"70R7'7";F:-1(N/>P?<BU:+E_
M?31&,1681?K+U`Z\=AJY$C0$K4/[E[3G5Z0J</;$=#"Q)Y((M#6M8,YRLRAP
M4&0:Q$9(&GK7A-?XU;2WU/[&N;CF_:"L'%C5Y=6G76?U:$$795;02-B-A1NX
MZ>"6N&;.1,>D,JCPZ60U5V3$&L@CC@<5!/(<:W9BRS\LTY='SS].?RYYBTXS
MGV-D_OS_`/`SS\.?^CCES4_^;3_T-?\`=QS1QX\5:PRQ^N=,Z2&616/'XI?*
M,FB04OT#&>)C)9ZXQ5UC!341A_5$RV<"#CK`@NI)3<\)J#VL!"QY=_J49O'S
M+5>5?!2CL;B_3'XHC4VB$R3;VY8BAEK%>E@CP]GD&/N=(ZN_@4TZDA1PYG5D
MS!Z;-W)+.-7GMD-*!IRD3)M)$V>*;!^R\K5@O76^9JWL0/4+F)4S:$C;6M(1
MC@V"K1V%@YT@TGID(S:O79D9$'3=$^]$-&;MT4;C]V#9JY<.$T%-$'77L#?U
M@2VBJ%LTU=M$/K8[;QRM+\I>9VC,Y99]9L(GT`LCL,B.AG8QP7Q-7,*[4S>$
MA)Y$G\/D@)W%(O%)U`T4(I-B-AP:%;</#HMV:WAT_JV?V$>UEDKR2M6$OIC\
M%09*3AE5%S6+5`&>.&[31)EH[G,>A`J6/-V"28Y=X77<#]<,U4<8R:3SH@Y[
M$UFUVKFP&N@*-W8S;O'3.,Z-)$GA:O$LOX_LE*EEUF6-6VB_IDD!;C9%VU]%
MME799)">_;9]]7\\_,X[^TO.AE,XD2<9D2H2MYP[,H@#BPEHJT`XT=DT1+Q4
M>TSE&3ZJ^;MYH@VUPGMKOG97&-=],YQOKHJ_<U507/U?\*RM(9=]$W!75G2:
MV+VGLFATPAR40D@O8W8#H:*6(@)02#R-IH2$`F3YEN:8(NW#-9)='UHU0>Y<
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M;-#AKHDE?66R<V?65QT?9-JR"JK4A<(1DI:.,K!=$8W94`D08R`D<+G5?6#'
MT6(N;0XAG.FI8&`D,?-@)1&QA=']]Z$<D;9H6ZY--KKDLYH,I:A@/AS6+(=&
MY(ZMZ&!8%(V;\`QAF<QP$+CP%A[."(J18*MR^Y`X>)R,B2<J\I\*\+F(`]@J
M`VY>RCF/16'V/5L9@4KI2L)S7&*9LZ\AU]R*H9S#9'3ZZ%H0]U)QJ0(FI*2.
MAB017+=L2?:EQS$PEEC/PUJP%Q1[#`TP["B`#RL^I]5(LF]?!W>@>,].[SD/
M8:KT@GQK7;_=BBZG\H*C2XA55V%&UZD#@<39Q\>`8/>>YCP]QWR02.C][Z[>
M*P(7,8?.>MK+>'QI-UU*.5U:K&YJ]WKAXUJMLYLY*%S$8P$`]KY7L!RE6:"M
M:J.,BB)8D0GFG^O!.F(+<\8CEHW\2E=V6Q8MV&+1-55$U9+$[$L]H!;R,M#(
MXUJU""HLFSB/M"0,1*`$J8#'N^4U-'H]+1EM"TQ\/"KY<9CIE.0]@(FHCU:M
MOJ%:*$/@XX9^^%JNZ<O2$O?W20>UR3+'9TPF!:06/#I6)>B',6L"63,VV0=L
M9::#..J$^'@&%VK"K:<75V?D9^`2"!2J/)2JJ:Z++)&H/U@E_5-1NH>;4V+-
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M$XC3D4;FK6$[4U)JIE(TZUK/5V2D[VI1.!`EK(&Q&'N1;1@=1V55.XCS04]T
MW5]`,]&:I)[8K7`?#_J&GR])$*8Q<57C*(NB][VBL6%P#21`"DOOZ+RB"GPY
MO250@F1;P:%P65+PZLXI&7\>:Q,$&CK3U[Y(5HDKA_73PY8]U;(HI5-=_;<=
M`W46B`^7U8^AT:5AT_GU>PC-;0BUY0Y8U4PDJ9L="&T=%26#1\T%K.PWT*B!
MJ81AZL/(LS'?LO#[@X.`U#`XK-^PD;^2[J@=Z.EI2V@#![(;-ZPR!`7HXA<J
M1<P;2/!9B+>"&Y2-VC$`HJ0A7S\_C=@28&U6+:O?9/PVEG\`LTO1C.Q2EN2A
M"FX%"=\5O"X&3B%1P?M31EVM8R<GCV),5[C'T=$*CTCO7IG<SB5$80,^$Q5F
M[),922596$,=`(;)I5)K`D,WOQY/I\%[1#+!DC>L`@WVK==KJTJ^G)>6W"Z0
M9^Q`+0:L*8K6+5N*$.U1(O8"_+2?69$)`464_*M>@C&K(A956QV].V2U*6-`
M9=%,4^_@D2VB\3E-C5TC6UBV2$,-*G:2\B2E3'!.7(P"2G2]61BQY">EX*))
MY5%"@V:#.G2<9G%/3:"V_P!H(%M7E,55U^L:/QF$`]!'8>K:1<OG59C;!<$Z
MS(&(/)`63,E&O9M3)"!R`U&Y9(8\X6;H+C'8C)NOG52,]?YU:%F,GEE3.>VX
M,C`>;R<C3X^%OY4A$#$H+@3\]3KZ'`F5E66T2E*\9WMB6M5YL\A`>/1@@\>Z
MCW1$E;'X:O\`Y@F7V)E?ZHX^&K_Y@F7V)E?ZHX^&K_Y@F7V)E?ZHX^&K_P"8
M)E]B97^J.?EL3]!5)#<-+=%U\*[(([PV4:K+ZH:Z[KY13V%8W5PCIOILMG37
M;">NVNV_HXVQG/Z_#5_\P3+[$RO]4<?#5_\`,$R^Q,K_`%1S"+'"2N90PU&X
MA)[2J62$=6&15@Q>JFLJ,Q]9B39$%/51RPX9(X@:9%6S18(88%A6^RP@D^P.
M>B2F&15G3J9=!(!-&;S8C(KJWDDV@78"L;SE)2KA<D4O:%]HR4(,W2TD\7*P
M?V/AY@L2KB%XB!N!AA6D&"Q\;&VX@X):-TTKWC$T@XP8''QR:HCPXP<''HJQ
M"8NU41XEBW&L$57;H8JY=JI,VJ":KIRJJY=*:[.'*JJZBBFWN_#5_P#,$R^Q
M,K_5'.,OEM<9VV`S'777&=MMLPJ58QKKKC.=MLYR)\L8QC&<YSGW8QC.<^[G
M@D2V<))+H!)<N@LGHJBLC#)0JDLDIKC;15)305MHHGOKG&VF^FV==M<XSKG.
M,^?/T^&K_P"8)E]B97^J.8=8(B32^%R*-160VE5<B,,-6P>PXK6"4B/Q1ZF\
M:NM"0\#/H;)(<8]9HW4'O!QX*\:.ASUXFELR>Y:D&E8R?4TH1CQ"*ZW3V,'A
M;'>6"1[+I,JAA&'W9)]90.,Q*0NC99S5K@E4"K2"14=6\:UIIQ&VX"OU'`E)
MN[D>K.9-<\TH#X?9L*GDPE-NS..4],R\ZH&K754L8W$Z9,F:I?TSL@-,1:&C
MI5.18&"G98-A[6<$2#L#O+"BK\E(MF$;R"LC\,7Q_P#B_,OL3*_U1Q\-7_S!
M,OL3*_U1S\OC/^_Y;?$TM^$X1PXRW]C91Z_#?93*6J^4?BKUF$=E==DL*YU]
M7E3&=,;>EC..?K\-7_S!,OL3*_U1SUWF4R#1V/?Q:4OF#]HZ8/V+R!29TS?,
M7K=1H]9/&JX91!TS>-5EFSMLNFH@Y;JJH+:;I*;Z9IB&Z+47`+0GMRT9`C?7
M:QI[`*CK-604SU_@D:S&8I5E@2.=$6L58N*C>M![FV6<G>06U'3C1WL:B`V-
MZ"M0YN."BR$MI4NH-OBV.PL?D%J!YC:M15O3ZH->JM3,.BPJJ)'84HAQ\0Q7
MC#*1$S:)&TIDD5;FY2X#%F#H8UW8-]A*3AQW5+T[$J-!R89%0%ADS4^G)^T+
M,F\@A9M656-8\G28-"TKD2@B,"0[3"`D0#C$8C<?$B(K"H7'H]$8N('B1"6B
MDP_#5_\`,$R^Q,K_`%1S&9HZ64B,DTR%E2&-Q#O7*SN)21FU2QG7&/3<.W0Q
M)LV1U\_/=9=5-)/'\+??7'OY=A+/FDGGRSCS3TSY9]V<>>N/=G'X,X_#_+S1
MEXIR?8>V$'E.@.C>]S?%L_K0EUJGU:>(PWZ67>_*$*MM@S>,KCDV%0]V;KA.
MNAP4=#7<>(D#HJVHW,C3]5@V1BV$M;*^$P#/QCJ\4CDPI':@YP"N2RPLYA9?
MM>[[L6`\EH=P&&%Y+:O8LDI\;S6P"JC71!ZR)M!F\4`CX[%APQF#%"M=MC\H
MB\<F\9D4,F`,3)XE+@1>,2B-'F#8J#D,</CW`HV"-"WJ:S,D)+C';E@18.T5
M6SQFX6;KI[I*;:YKVSZ9]<F$05A;>`NMF.Y^(REO(74ZL9]90N10`.G'8,9`
MV\^E[BUHZ0AL=T5CL6<`9H.W`Q]\7!C<MQ1LRT?SW#(9%*[B<<@D&CPB)PZ(
MA1T=C,:`L4!H8&$$MDV8X8-8MM=$6K-HV2T2223UQC&,9VVSMOMMMM%\QQCY
M?:3]WSPV[//^7_%ER=?+'T8_)CD:7-;M>4!4UE7?;!]"*UG4D'D]BSR1+MG3
MW4/%(@(=&SC_`$8L$7!`@NBQ9J_!AP]LY?D'.46;)NNZ722W]&B+LK;LE358
MWY4!S>35A<$(CMA00\L+*!'!2,2<>B2$NG(<VT8EA;G9NMKJY'D6C=XS7T40
M72UWTSR6?+'T8_)CCRQ]&/R8X\L?1C\F.>N[:-'K9PS>M4'C1TBJW=-7**:[
M=RV7TV2<(+H*:[)KH+([[I+(J:[)K);[I;Z;:;[:Y_F)=M/%![+^"UXFDFZX
M=+>N2W3_`*K5!?4VL5_U:F!XD4B/;!&UMQ`8S;!^1E2)9D!A4TC$8!-:.'5X
M_:1.DV(9'&S1]*DY^V>_TMZJFVMF5C7=C8'M!6)[!HC-,#&,CCTQ9#O:F/CC
MF1[271-X1BTI;,=GV6B,BC1!\`-Z(8)AGCD<Y;J[Y]Y8^C'Y,<>6/HQ^3''E
MCZ,?DQQY8^C'Y,<>6/HQ^3''ECZ,?DQQY8^C'Y,<>6/HQ^3'-;-N7]94=MSK
M7U,I=6/1VP^R,A[4V$:LN6`E96(KBFNO4F#9G;\+$DS<=2DM@2B5VC74.B30
MD72!`FI60S,RQ/(QMM&CD6W-VT[-]3+II^+7%I&K7K&7N^TA/.*@J,VXM^95
M]3/76M[1CA5L`UL-Z$$S(7-'%I!)*,9IZAY>$'Q<D!3BC]U\0D)K:>)_U1+S
M:#0>,2.43%]9(#):$OHE$GIYJ;,JT4CV2&0KXM9N,RL5+#E.N$I&$2-QH8`(
MF%$H$E(L6$NWBRN85_X@_6VT2#09!S\C.O"L4ZIST$DC$R2&TA@G<Y0XC14Q
M!8<[);$8^96BTJ2DCQ+7&\)VC)W,G1'Z#U=^84"\47J7)3<TCP.3R,L3C(&*
M22-)B8PX--K8'3JU-:0AS:LGP%T5:E#\EM5R)B(N*R-2*RE320QZ5J!4X*6;
M2?/[=,^PUR]HZU[0OSFXFO9I6W;'L;1$#<%ZX>,UHV`K(Z+&Q1:;PC>>/<2`
MJRT>JZ&'H6:CQ$R:)MST;>#!I5ANG3&%>)%V.:0#L03M:(PY>T/#3A]S&/$#
MKRLXQH]^4F0B`SV:4$IU?7,VCN]BU>6=6`QY9IF1V*G)WT88;*5V[QF>QZ6J
M!;PQWQ"ZG(22K8/)(?;,3F-L"=D8PQ)5^3U'%K"8]>_WSANM`3A9=`L=.CZG
M2>&4SK`&K!'19KO",2].P=58HG%0OQ?.K!,,(DOL_?[",F83UUMEO(2-(R=N
M+2I3LZ;S$JWN5TJFNNNE`T9OJK#I1G5NK+`15NY(XBC^+-UI$G(L%\2[KQ8,
MG0B@4-=;4B:A]_2N"JF*9F(UK9[OJ]/'M<WK"*W]-!1Y++!@,C:I?"8FT9I.
MS@QW\:1A8TU&']@_6R;Q/^O43B5FS0O'+NT!4R7M`5:3Y*J2>1\-TI")AIE<
M9!X>6)(Q<HC7(R0AQA@9'3QF2EYBX?0"'@)-.(_)H^%[OOYV(OFENM0BY^I$
M7AUK3SVQ@)5E7DM&''"-I5LY1>2:;Q:(.1)@"0`6.<@8PHI6Q1\D6&8F'Q.+
M-QU\S(+Y;0_(_$+*3SLGT!@G6S:(R^@.S@`W85CV>[#EC1G>.'>N,[[!TG":
M[:LSPEF-ELTC<"*2"6.S[,QO'HV]C35J%R0E34B.S3K5XAM96M!*<T&$+3NP
MM+8;%MI-:D*Z]R2-0]A/)'4!>[Q$8G$:8'I<O4DHD5<A\2#0$9*DX]&WIZ&Q
M*1S(9+9O$@ICU@/BO]:9'5"%RCHW?>L.5J]6_P!1-]2TE821#K8RCL+DI;L5
MB,.EDS#^J13:;-&"CP.V)RTF8!3$;'8@;6B1O9KE9SQ-NL8458\K1>3J45[5
M\K&P21V/`(<K8,2S-B5EUY4Z440S#")J1-3RDKM"(JBQYV.A%I9%WJTT@^)1
M%&^2RE9I_P"+$#`6_"EP,6L-S4L4B?>$9V6K!U2<BSV'KRS^J8GKO.$O@XS,
MF1&[QU2K;EVL#9%BU,(RZ+%HD5C$@5(/V\=?6+?>*=U#;2DM&&,MD,CPRK>U
MK*$G8I%W,E"RAC2E>C;3L:.A?BETX--)8&A!/4H.&2H+&64J=CCX*)%3A^.'
M!C#J=?%<ZM(#J[*FTK6BC:R"->X$MI;6Q"/G6$2M^7"8-4EEDHJ^(:2I>N;%
MD9=)N$D<>"R#<8.8'9#+1T:CT>-%&-G:`[35KV55E;BKD),3C4:=O&;:<KBV
M/L7)G(N8S*!'6($V-+E<)'XU*8(='2B&R9M&IQ&T]PQ`U&60Z0!73VR7''',
M-,_]N$._\5E/_H@[F9<<B2^9M.*XIFS9S6=<GK;L*+PL\6A5:QG`?8W,Y0W9
M*8!@F.#\AB@C.SLCNAE?#Z1AD=FB;C7!!NKE/?&EQOXJ,O;0FIHT:L@(4EL@
MB?8NZ^RUW#^F5\05'J'2?7"4A:ZGT=LCJ\G8-WS>/W8)LHSF+D%9;8GR>QX`
M`F%I/M3T5$QL5,M]`%^S*A!!,>89R!B0%CGS,Z/5:KL#+1XS0<MBS)9CMNR6
M:$D%4WK95IONU4073W;[;(YTSGMN>J^_[">?^*N/_,[\Z2&?]J$6_P!7@W_J
M]OS)>1S;\ME,#JNQ9I!X&;M&9Q6$R8]$JXCBPEN=G4E%B';L%$Q;DZ5"!FKP
MZ43:CDW10N.8ML+[+N7:*:>=\:6#?B)]CQ'4>*6\C(Q1`LG<D\B/92Z/WAEH
MM8YT9`5V#';R6.]G.IW[\!Q<@P@$D)!NM)K/A=G2Z*`J^<Z6GI&2-?\`P*1D
M)`0\1Z8L>S(.`&9/6FS%UWF`]&W5#[!E15M&@$LZ^Z6W#^U<9>NI0L^>1"5E
MTE3XP<R`&(,XIY=XX92]S-(R35=[J]-O3TUV\O+TM==O+Z/2QC/E_P!?/+F&
MX_Q@+_ZGL_\`UX\YF7/S662;I*KK*:)(HI[JJJJ[ZIIIIIZYWW444WSC1-/3
M37.V^^^<:::XSMMG&N,YQKSZV]O9A?/;KLA5_P`71-C2<+HWK;:U$%F:RZ\T
MG0:TIIV.B,FGLBUR]49,8Q(EZC"$JV$M6FK[>&.QTM-.TU9FS#AOS96=V^BW
M=^'U9+BU-SFDKF@]Y2EI%X;`Y,#GO6P95Q:&CJSELWL!]8)@3:(NWEI,^!%P
M^L)K9R$EK9!K#'LB#@96^2DOP_[VG_9;J/4%U6DC%T)_,V,MS)TX6+(A8K\8
MQVPYA$?6`Q1<S(2C!@LVC[=9)N_-E'6FRF_KGJ^^<[<N3R.+>_Q83S_58Q_Z
M+MR1$_\`FT_]#7_=QSYU?W0Y2E-S^I>O,LEG4SK)V&M?:XF]65E(NS)KL!&(
ML&(3H"9V#UFQ(=96ORBR:7W'+68:$U?$9$6!5SI/"+4V=-C'35MEY-W[G^/1
M$IT0(`(-"^LT#C5>=AKK@+(#U-"]@AM48<!B0-Z3=ZE>SK1C<$LE#@F6=XD1
MZ1-6_P`&72;Q;1JR7C3IBUW?\<<@F9?X_J2_U-NO_AER=N:L/&WB]H3?PH^]
M4+IJ#32RK'F%"R&*1V#5W'W<JF<CQ(R88.89`HX/;NR1E?2/O"SIPP%M7)5=
MDW=8%MEW^&Z6TY^&I4QVB?#VZ14]*P;V,RVN>JE#1271TEAUH1!2T76L=TDX
MA^D]T3<H/1Q[<@T=ME4]-FKA%1MC375'&,7<XXXY6'L-TNZJ=KFKE'L/0576
MR\7@,WK!L?E\2%/Y:%@UC,TV4R`QB8X;Z2B*)&4T4'&SJ.E1SUF1;-R;!PV?
MHZN.?+I4MR=A?W,P>MVDNWDL*7YX2^D9DTOZ26?L;`N[SB=BKD-7X?J8'B)$
MPQ(&R9E!<HZ=:)HH5[&T&&;/;G8;'RDRC(CZCNG_`&^H7O30,&[)];YNRG%:
MSEEZ:2Z?H-C<9/M4T<'H5,PFRF[N-S*,.UL,C81[C&Z>V6[]BJ^#D!A)[9OC
MCCCCCFO^VZ&A]J%ZPG*QFSJLO?KU9-LR2H[7@\$?2%\'%640*B)U#BPPW$Y%
M#YG6UG1?XI2E4==H:K;/0\:DD?,QV71@(;8=+/\`K=$[4D]83J?VK?)B95F&
MO86T(-:RU'BBF]_UBQJ>2;J`?D[=-1+&+1P<V>0P4&7:H)GMG9:7K3%4@]T7
MPSK1TZAO5B6!7%<WYVJ<50/B]=-3-&&H*)VA,KL6M:@AM&"[4,'Q5.B[%:EC
M\#KZ(/)E"`$N#U>>G(;29:P]DZ>DF+STZ/\`#]ZC]?K4K>W:^%W*VDM7.^Q.
MT>;/PT_>!EPU_3=K,1\2+,,QS74A$:);ID8K0$>7WR.K6.2&1)"T-B)AV0WP
M]#H!"&]+R:AM.R_<'>`!)=!YIU=9JPH'\.ZC%JOM03<]:Z5P2;TPV>V&UA,U
M!B10;Y=%[(=ZUPRS7J[M462.NRUC*1I`31-=WA$HO<O8$A,;VM2P;H.VF9J@
M`M)8E/[*:!4#Q&%`&]/(05%BR<A4B8,5*XU+6;-ZMND\U)#-$A^(.FWA_=?I
MF<C)S2:=A8DLWZJV_P!/K51AT'U%_OB*KN[5Z]F#^ZGSNK"18].!DP+2&R89
M)P;^/J1JP)C.S&C1\-FLA"O>J"=!("&N"$7&MV![0R,]7TCKZ71U&3U-!R"F
MAZ#]5YQU+<I*F65%"C#6(R2%39]-'=>@G06$!K0<R"81X(.7EAEOOU*7AL4$
ME78^LLV?V8VCXWJIUMZ?-G?L&,U-)UEU>M1>V8$<PYQ3^[':>$S+MV)E)106
MJ`?@U==!L7$%D]"V,3ZL=.)8*KIN]O>?WA![4C!?O<C3NL"B$><.*&_?B7S8
M,])V9`I.$@TC''9TV@Q^/LHKI.VT@90,BYE(]Z'D7KF9!/NYMX;%4S.G:\HC
M:]NS`&L:WA%LUH$B8.GX.D%6A]RU2;K*8$"(U]1[QN1M)9T=(3UM<Y'#ZQ])
MB9F#Q4TJVG4J1(WO.PF,&H/2<*TE5L#<4K)JPD[$XTK,@L2ECBL1N!K0?)$'
ML%<C$!LB3RIN>Q'F04AILIG`,@'QKKG%88#T-ZXTX7HU_2A.ZJP$T'=]^7Y%
M8F)@I$W'BLO[`QB60,T%-IR:`%2+6#02`RYQ#*PBT3(QA"*@`L:'J.230.DW
M4POK5X>U<=4#3/-1=B>WHZOUHA$ATOJDA#0ZT/L&Q*\@>*N@UM2ATPIH;*$S
MS"!LXV)DL.CQX'6<\>0J)%99$""C0NV-]RCT#I@-7M,P"(V3V&C6:KZG&^C!
MV4I0%5](K1ZOG609HI$98FM7:4?%3,,J`8D8S8\1!@S0A^]D'K&;]@<78(UT
M[/\`AT!B,!M$U0*T^*V_*<4K!(.MO5\3@QF)T_!>UE%7:WC)F>/X(*S:[.B(
M=4&D>ZZL[B=2XE"ABI&),WI!E,"ZS>QA3H944HDLEG\ILJ_WM@6`#[3#+#D#
M.MTQZ4G>]L*TJ>G)46V$?)V09AW=>UE1U6Q:M&8I?46PS''1&7(S=X9(+*^%
M:=$H15L2M"J@'8OMJZHJR:\E<33IDE`P.T9A\NL2NTJXL6S(^:8TPQF3LM*&
MV"$T3@\ED!RJP%CR`]*0\)114#"`F<#.ID6BDZI2:UW?7:6NDZXI>I^OMFQJ
M-00=D+V)JVCGQ0G6(^Q%BM1D3,2D@1W(96U>3&GBE>'BP&8R($LX0;?$"H#,
M^M/7.M>N-B6U:S20V7-)_<C*,C9S*"-/[Q$E,4X@6EA4!(K%TK^!QL=9-DL6
M\O<Q7Y4)8P=3)S"`<9CKT@ZR.>$"ET/E%`_Y!,?L!-_U!Q\HH'_()C]@)O\`
MJ#CY10/^03'[`3?]0<?**!_R"8_8";_J#F-DIH+<R2-OT1DPV:CFQ_5XI["3
M/7*6SQNR3:X]7L"PJIA51/?3TDM-]4\XQE7*>NVNV<D^44#_`)!,?L!-_P!0
M<?**!_R"8_8";_J#D>VJ8>3J`R&+0B>VG3\I*),?B>Q8K4F\E-1UPR*,2*GJ
M0-A5_*8B49%FS1<&8:$PRJNX<F_R*>AS&K`PQHU)^C=4'6^Q$;9E_1VP)C![
MMK*^;&8UJFX.7O!NQA>/';58RD:ZK;,?C!?0I&1NU;FX,-`YK8?N]#BF#\6^
M<ME-@T2-0&"Q:-PJ)QZ6!HO$``:+QP0A!9^LB+`QX:U#AAR2SL,X=*I,1K)J
MUT4<KK+J:HXW6545VWWVR'Y10/\`D$Q^P$W_`%!S\'5A`E&KE/5A,/2W;KZZ
M^<!FV,9VV2WQC&<Y`8QC&<^[SSG&N/GSG&,9SSJXU.!(Z.@1[P;,4G;(,-:.
M4O8.:*>K7;LT4E=/32!;I[^COIMCTT]]]-O+SUVVQG&>=W\HH'_()C]@)O\`
MJ#F!V<;7FT"DT6ATXM2I).9'?!@EC1*J53\@BK[1P@X2(,0M@U[+(>3U4PAN
MR>,C8%Z@NP=NM&^[)]EJ0:5!*]8&!2+N8?KV![&,@=F$+`*=J$&U/1?=UV8?
MV2!C$2.NCY-U3[@I5ZX^$10?7,:S4#V)(A8&JX9ZHNI6@,F8^8-JBJXI<U?7
M%*_;V0JT@-,#*`@_R8R,3"ZD5D481AIV4#60^,8(R.<NHCDA#Q<EDA)ZG$XB
M<D86(B@F\IE#\W9KY1`'^03'[`3?]0<?**!_R"8_8";_`*@YC>)H+]KUBOQ9
M,/@.8VU886]A)GY_"]"KISLCE+XB]=CR0WU4PIE/".V//753*FN=,9)\HH'_
M`""8_8";_J#GJ/YK$BK%X,*!),1&D6KEB0'OZXF+QB^9/$=VSMF\:.(ZHW=-
M73=51!PW7341714W25TW3WVUS18+TMZL5W:T^NV@H>:ZWV5/J_IFLEC]+]=X
M;'-8S$:DLF36"39Q0>]I4FQ'.;;9REU!;3=N47VY>(AXK@+H!/QD2<;Y'":+
M<0SL).;[V[/]L)(VGTA(GS%/FZFK!O6V$DPC\#!8O@U'NMP*YW,)JYF0<.X3
M%WUM.6&#C@@?D7Q\6,FW9"3>K5>0'JI1\/HF*FK:F,=A2\H4$G9I7YC,D70E
M,O/3-PU?J1B"QT,JF/(R)\R'J(!VJ_Q8BS3?*/7J:[]S83Y10/\`D$Q^P$W_
M`%!S"[%EK`_!98%%"I>Y)%`1!@Q;[0:8M\+NW27J4$LKN`:3='T]]L8]8NJF
MEK\^^^N.38EY^K3\\9USZ&GGC;'EMC/HX]V<?@SCYLX_!GFF3Q=K3/Q!?J**
MIGM3T]ZY]C(O?ZEOQ9OW)MJ70BJ9+!8_4%MQJ2-)7$(++HR5EH4@\D#-F+6/
M>4>'2)LW<CB#26H!=%K,^&S=]MWW09V7W9;75*YYV)N"RH4^F/2_,N5H;+>)
M/1@]$7'7<V>E3S\FR6V=*G"*AHRQ?/'>'(HBJ.4;)(;!>..03,O\?U)?ZFW7
M_P`,N3MRKW;_`+D=>^B=,$+^[-3=6`U@.DD3B3@XVCDCE3K8]-3*(0"R;A8J
M,+%U\KNE-UG"Z;3*#)DU=/'*FB2.?2LZDHFLGHJEMC=-3351/?7_``=M-]<;
MZ;:_R;:YQMC^3//TXXXXYI*\;/P7ZG\7BBA89R80K?LG4S8T[H2W%]'[H.-6
M-;,USL%GX=CZQ4M`)<L-'[/G;!LI)(L59L9`!V>))%XY(=%L:ZW=\_W+,!)7
M!2(2*][?#>DPN#23N!'TQPB`W[5]CL0`>,2NV(T7U:JNG$!U()[^R(IX[EX0
M,%);QV6B(Z3VWM,CN6\+C]T.]*_%)N.R:(K]C+J9LV/OW9&J(A;[F/L3MWU^
MP'I.B<BBZ(9\_&,9='UDR"\DK74N:+L8XBWE0HH=&I232+[\>...........
M..........................................:(_'F?1,%277P_)JEZ
MHV+NM>[R)M3_`&EZ46'WS'0%F8JJ>R5^_AU(UBP>R7#P\XA8T2?DZFK@2#%^
MJ=KC'9'`QV-G+P79>TEO3)'(MO2PX&`MFR0`,)U^ZG2SI35@-@BX#%%1\?Z_
M3D8)EL764)%R!(N3--<KR0J0=F6ZRK!PTSC;5SCTL?/Y^>//R\\>_P!_GY>6
M/+Y\^?NSY?-GY^<_/\W()F7^/ZDO]3;K_P"&7)VY\[_[I2H*ZNS73CK93E+5
M3.K8<RCQ`NL^E@,('%BLQ=1>N4T)ZW,3&1AQ:"VB,/$$WP?4^9-9;1T.BX1=
MF'K%OC#I+Z'$M<::8TUTPGKIG;3337&-===--LZIXUUQC&-=<:8UQKC&,8QK
MY8QCRQCGZ<<<<<<CBWJBK.^ZRF]-7'"@%BUA8\>?Q6;0J3LM7X20`R2>-'#-
MVCG.BR*B>^J3MB09+-B0HBV:%!;QF29M'2/S^=`?W.CUP\+FR.Q?:*C%,]A>
MQ#IC8*O3]G>#9N-`42.)1@BG'H7N:&.7:Y>2'C#C,9EUS89ACND!=*!@8,(L
M]E;^3Y=X?7CL#K8NW?H9XD%/.>@GB)"2"(AI6TO5<-:ANM9^NLF$?4G."KX@
MU6=G]=-=0$<)'S+26Y5:YKJ9SEPX=#A?T.<<<<<<<<<<<<<<<<<<<<<<<<<<
M<<<<<<<<<<<<<<<<<<<<<<<<<<<U&>+\XL-2I:+C53W$'KZT)YV(B,'K*ORU
MKW-2"=V6.:!R!6%Q':R*$B$YG`]C&R[).<E@$BCJM02P<#6#6N2#`%&Y-O,W
MAO$+[)U9<3SLS9M93>Y%^S]T+2F!5$3E1Z#]<=5W8%R,Z^#9).1(&72?>)C5
MVTJ5/E@HL>0UG*6\,8M8!K%$=)I[NWO(>L'4#LQV'B,<:2Z5TQ1]DV/&(X24
M51#EY'%HN0)`FIYRBLW59QWXU2:+2)ZFX0V9`TB#G"Z/JO6Z:A8M:=K8NFAN
MC5PR*R!]C'^QL`'=N[A&7%)I"*[`1Z9=(^Q/8.O4:UE4=95UI0X:56S3DD`%
MJQK>-0AD$!5PU!QTO*@4N?E'>SGPW;4FMS=-JGG=@2)U,9(H_M2(^V;]OJV?
MS<!6ESV-6<-G3[71)%-=[-8;#P$G=OTD_4$W)54DBHLF[U64S23RX^X[#U@W
M5K.:,TA$:NUJP>KOH%LVDJ&%*ZT^,`VJ$U6=HM/1027SH=:AGN4GC?5-HHOJ
MZ0;3U[5G?JZE_P">0G]K^5@O#OE2/7.U>ME*W"C+8I9/;>=F:WH6.X&BS&\Q
ME8!@.?E&CAX%-OV,>8H8,AF?QJ?<#QVY`JS:_",>DLHC9[$L.;8QMBNI?Y9Q
MC./^60G'NSCSQ[O:[G/M6=^KJ7_GD)_:_CVK._5U+_SR$_M?Q[5G?JZE_P">
M0G]K^/:L[]74O_/(3^U_'M6=^KJ7_GD)_:_CVK._5U+_`,\A/[7\>U9WZNI?
M^>0G]K^/:L[]74O_`#R$_M?RN=V=<*`['2:J9I>O48%:DNHZ8#I[4DFF8*N"
MYZ`2H6^:DV9*-EU95J_9)X)L!Q%P,RX4#O2`T<^?#G+I@S61UG^-+XY\2\(B
M!5EN4H:363;5Y-K'TK:*/9=%HY'QFT%8Q_56231Z(>R8U[/9-2H4S^""6"1`
MAL@_01?,5/4N.6$\*CQ<:C\57K@UN:I8/*14WB;@9%KRJU5]'52%96`Z&8(?
M`FQ`F9#YDL//H)NB4+E;5HC@L-0<-BK$.>&E!379Q[5G?JZE_P">0G]K^/:L
M[]74O_/(3^U_'M6=^KJ7_GD)_:_CVK._5U+_`,\A/[7\>U9WZNI?^>0G]K^/
M:L[]74O_`#R$_M?Q[5G?JZE_YY"?VOX]JSOU=2_\\A/[7\>U9WZNI?\`GD)_
M:_CVK._5U+_SR$_M?Q[5G?JZE_YY"?VOX]JSOU=2_P#/(3^U_'M6=^KJ7_GD
M)_:_CVK._5U+_P`\A/[7\>U9WZNI?^>0G]K^/:L[]74O_/(3^U_'M6=^KJ7_
M`)Y"?VOX]JSOU=2_\\A/[7\>U9WZNI?^>0G]K^/:L[]74O\`SR$_M?Q[5G?J
MZE_YY"?VOX]JSOU=2_\`/(3^U_'M6=^KJ7_GD)_:_CVK._5U+_SR$_M?Q[5G
M?JZE_P">0G]K^/:L[]74O_/(3^U_'M6=^KJ7_GD)_:_CVK._5U+_`,\A/[7\
M>U9WZNI?^>0G]K^/:L[]74O_`#R$_M?Q[5G?JZE_YY"?VOX]JSOU=2_\\A/[
M7\>U9WZNI?\`GD)_:_CVK._5U+_SR$_M?Q[5G?JZE_YY"?VOX]JSOU=2_P#/
M(3^U_'M6=^KJ7_GD)_:_CVK._5U+_P`\A/[7\>U9WZNI?^>0G]K^/:L[]74O
M_/(3^U_'M6=^KJ7_`)Y"?VOX]JSOU=2_\\A/[7\>U9WZNI?^>0G]K^/:L[]7
M4O\`SR$_M?Q[5G?JZE_YY"?VOX]JSOU=2_\`/(3^U_'M6=^KJ7_GD)_:_CVK
M._5U+_SR$_M?Q[5G?JZE_P">0G]K^>XPD19X\0;.(1)1B*VVVJC]ZZBF[5MC
M&F^^-UM&$E>O-M=MM<)ZX0:K;>GOKG;773&^^N5\TI>.39T8JWK;6),S!LF3
M\CNEO$H78J/B"1_PQG]4&7M=SPP3,#NUYIVCD(XE<8!FX8I!<M"`J=MBRS`R
MWU39LU-<A\#C-=J=*'#NMZUKZM1Y*[;4)R-.`=R`O?K,XFCU8"O)+(FG:N/N
MW0JT)[+7.Z:T@5;X:>S*34=%-F#/8-E'&WHR&#R,05C\@%#CH$Z-?!S04PQ;
M$Q)<04:JL20LH.>I+LWXX@R<+LWS)VBJV=M5E6ZZ2B2F^F:ZCNF_6H17SJL!
MM4@VD2=&8W(O4I/Y'\?-#L,&#@<*+"YIL;VFX9_"8\)&1F%N1$D8J1&+,6L8
MCFPP`E@;FP$8C,>A<<!1")!!<:BT8$#@$=CP-BV&!@802T28C!0H<S31:,1[
M!F@BV:-&R2:*"*>B:>FNNN,<B69?X_J2_P!3;K_X9<G;GSK^)%0MY79XV/@?
M2.+5584DI"A7G:RR[-LT1&'RM>P(JK$(_M'&TKF[5JLP!DS!*-AVH8$9<L=Y
M%NZPW"Z$%L$_@'T2IX]'337/SZZ:X_)C&.>?''''''''-?OB/^&KUF\4.@'M
M"]D(Z[W39.]SE=V3&/B]C9%42O9--'>0P@T_8D&Z."+1/`V0@";-]'I*-]6@
M6'JN&0MX/B[PZ/!SZ9>%R6GQWJL(LD,1M"&5U$IRG+K,D4M$&G%>MG>N);J`
M>[)"F,KE1%\Z+R%XV0PP:N%U!T2&Q<`JN(6QBS?&UZ24-WRD'A_]CC,YZYV$
MU#0LK!+:N:,(Q#KU;2DQ#,C&K&#6DJ3<,6^`V[_4"1.3!E&(HI*F):,LSZQA
MAJT<[<&[UF[1;.6KE!RW>(:.6CA!9-9!RW43T537;JI;;IK(*)*:*IK);;I;
MI;Z*:[YTWTVV]KCCCCCG&VV-<>>?+^3&<^7GG\&,>?X<\U!]B/%YKCJO>[GK
MO=%4R@'8960O$JN8")3&S*5PPDM$2;RMI-#WFR8\8%.3"T&#:GCD.L,E"MX`
M8*CYN:/OJY6]IL;5H67.G8C%C,I!,HM)B\>#DS\9'GT94Q`&7P]NZ)AF4F;L
M!3:1-1;M55DB<:CF34IHCAZW;)(+)Z\R?CCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCFFGQM4)FZZR0U.,UTWDP="UASF7V+IT@#>(H=I(;[*2=N.F\
M;ZJGI-&F4H>&2SA""%)KKI)\UZ!DY(FO&%6[Y4Z!DCP>ATU&].1B4TK4;7VR
MMA31>-%&O4QAT7+6M&-]`NC2VY7U/''Y"WIN2RLFF68NA>JX_25#@0NP$`89
MK+&[+3:=QQR"9E_C^I+_`%-NO_AER=N57V[H==->X:70[,Y5SV=4HY3L5K`=
M8W)=FFM5IR?6(X-*RW45F)ID-R^VV$X_N7P:V9:[/_@>&V==][4<<<<<<<<<
M<<<JEV_Z1=6^^-5/Z:[5TY$[=A3G#A89J=:;H2.(%'".$,R"!R\<HTD\(D6B
M6,)_&\:*#G#A#&S)_P##!ZSAHM_.1[Q]4/&8Z$^)GU3ZP]32?8"00RJ)/.<>
M%3F.2TO/HW\EI8Z\E4R"2$N89"XXL=8#'N['L-'IP.91L7$$VHY)K\DN(FNO
M]D/AQ_N@OIOW"]F:(N^5[]4>\X1@$B5J4!?(!W3WQE;;-@U93`=5;^5E7XTF
MP=2C5\G&(4>D`^T=&&R"+Z+JJI[N%-[TCDT<AX0A)9:?"Q>.B4,.2IZ1%6`,
M*,;Y530PN0*%'#5BR1RLLDCA5RX2T]:JFGZ7I[ZZYZK>Q(`F0;B5)O$$RCN6
M*P-J-4DH71^YG"`':4K0Q!GL^PY6EB49TWD2L<32V,I@M-R^[+4?KESC+_3Q
M\_OSCY\9QKMMC./IQG7&?/\`H_GY67LAVQK+JLPCIJUV,U;1N3-Y<B-E`*-;
M&@"<KC8!20@J](O4WJ&XR;V@FU(!*H'OT$!<TF+%.$MS+25FXP).:P+S_="G
M1JK9/*:PKEC;W8^Z`BPH8'KBEH/O(4Y+(2@70LY$L9AH]5`YUBSA1(%,UF&I
MAT'._"QC`<:<#">K37I.KX\=OQ!-UAT+B@WPX*.***)HJ-7WJ+H*BU5==T?A
MDT-:I2IFZ]1OCR4AL>@6^V<[Z:J.]<:;YZ6#_N=N**5[;C>X;`D%K6I<C-#0
M?:$DC!4Y)(@4'E&DA7)ARILTD5D!1ZV'NAYLRZ8X<EA+UTQ62^`Y^`+1G&.F
M7B\>'*DU6Z6=I3UKP(&CIA[4$V;JS*"O4T-=5'NK:KY&H0)PI-WMKOZ3>#;-
M7+3SRGK(]]<:*9L_!/W28:J<.:CW?/I?9E;V("&/-F)VFEFD@@4Q.-<8RB)W
M8S4B)(P)9_G7=-OL\D,K9HK^AJ^<,4MME4]N?6KQ6.N_<:Q&%>=8V$NME?4D
MT>2V0"FH\8"KNN7=<1V8(V).5BSQLY!INYG(MJ=%091NK/RU@1F;KLP.8?$"
MTE3V<XSYXQGZ<>?NSC/_`%X]V?Z.<\<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
M<<<<<<T>]B/$%ZK>&MVTNN9]WP5EU(-NT%6"=']CVE9V):E932%12$L1Q>E6
MY&L0$K=P6RHK9;>7R8T#D`<9[71Z9P@PS/%FHOXNC=U?#\MA[?%236ZAL'M*
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MC6/M;:`%HS*WXYUZ"J3>&N2I<>\75\V079_A!72D=[>)U85AU\]Z]^&_X?%H
M=IH4YB.M:ZVOV&@QV"]67<4T#:1U9CNUMQ:.2>WP+@'IA@Z4/O(P(D2:BBNY
M8VBOONZU=T[X>G;F-S*H2%W^(BYZ766>CQUF*AT7M.M)Y92%PV1.<PQ6%TJ$
MDTFC[T4/.5-!:1A;4V%E,YGA+:/[U6J]<@6NC56[EB^%*_!!_CSM)XL/B#/`
MJB>?A.9OV"#5@P)I:[Y=DV8T%L4/EG:;@AA%TT:BF1!=EE--JFDXV4TRG42"
M=8?"VK:TH!*<E>VE\R@%8D9*1^R[4N>0MX0TDXF3A#+:4+ZO%XAH28`S;8>=
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M;HE5!V+7R#]@?L'642",S26FW9,J:1.NSD1<,8LR*Z,BH84JW!H1V/K`Q^K5
MQ',I+(8;=_%?$_\`%N\.]\QB?>6A$>VU4MLX;MK6AR#*(6IL-;Z:-\/4C`)H
MZK^>[(Z)[*[I*"69!VMMMN0EVF^V<<VY]?O'8\-[L*H"#!;F(0*>&`\Q+N*Y
MM"%2:*2D+M!0BDB-BGSI-B2BCXRX#MB#R.C0,E+NI1L+),@J3DHT489V%TGV
M9IGL4O-=:;E:DW'P![&1,CD(\$?;Q5,Y*8J/F;>.C9._&M09N1A`)84I,P(=
MZ]*08D2:`9:V#G=E!R<]<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<UX^)!
MW?;]$:?BUI/XG"#(8U8`R-R"2VM/]ZOJ^%@DA[\Z4?F9CI%9AKM,33,6M'ZM
MBCM@'83*</F(5S+`.=TOATA='^YL![RUG.;<JIL[>UK'+ML^IX18:38@E$+C
M`U\29,D+0KAX4:,GAB%%UWS@$D6]1NP=22-R34(_,`DAAE_<SG&=L8QY^?X?
M+W8SG.<_1C&,9SG/\WG\V?HSSG&<9]^,^>/IQR"9E_C^I+_4VZ_^&7)USG&N
M,[9^;&,YS\^?=C'GGW8]^?Z/?RK%']T.N?8NY.S-"5%/?:FT>H<NC$'OF/?$
M,@%IQ&0RX<3(A6K4J5&LQ4C25^)#3!VZC[L@@/)B7C%[LBIJALO:CCCCCCCC
MCCCCF`2FS8=$6KYT5,-<:C4-W!#*3AMA$>AIC.=UR;]PL@,$M]/+&=UR;QLE
MICW[9YI2=>(_3@+6_"-6W=-NQ\<'6@F\*DADA'K5UU]2LY=C'I5&T>S"@MC$
MVE?5P\<YL:7Y:/)V=Z^0HX@3<+-8"R"X&;0XW0,?E*49G-H(`I+,APMID283
M=(S;<&PT:I)LM@<XE`Q0NHLLQ305(2(4V`K&E]]W[C*^ZVSE:O%Z=ZNG/7[=
M\*1>-;:GC)!77:,Q!="6;-=]4\XSJ?EI1VM&02&N^?@[]/1^\)-,*8QL(WSG
M">?G<ZL]?:AO?LK`8[#HEUYI:9!7I,G1L_+5L.LB>U"V`V)85UCHC3,JEKXF
M5C<A9R:R)K)AT@2>#S[YPR8H:FTD(_&1+':[W!\*"\WM,IR;IE<4)DW<<;.X
M[+7D\[IB'%I0&<144W+K2"`J`LB9&*CF9,15#+9.E8[+G"3-B\$HO`WQI\=C
M],_9[Q[>V_AWUPM3?B>>$)4\:[!IPV2I=6YS!'\0/]5K",#'@-B4>8#*+RDC
M&HV&0(#SLC%0J<OY$25R("/@,)3*HFQ._CP4?$LZS^)GUD=6U2M;QVE[/B[X
M#%NQ=1@HZP$:1*?K"G3T:X&F!HL<WET+D+%`F4A1O?TB"`_5\*-,QQ@<01WW
M*XSC.//&<9QGYLXSYX_+CG/''/558LEDW*2S-JLD\VQN[350243<[X332QNX
MTWUSJMMA)))/&RF-L^@GIKY^6NN,1%+*3BTA8/F+9!JW9D=-M7X(FP;'8N2Q
MMKMC.CX&33<-5,;>EG77;&NVJ.,^:*.-O+//G^\0#P/*;OCXC?0.*16G)FO+
M!+Z72@&T+$192`M'7IR1")M4T724:F:NZC/`MQ(_C*(MFV'>$XRBYRW?M]<E
M/=/?&EZ8*34#T_ONPV50021O=J]K:1Z0VSXF:C!E^1+*NTJZ>8.(#G[A]LJX
MDCN`!$U7CXGN^<MQ+Y973>R<.\=?Q&Z#)[1CMUT<BEK:"\[-2)VDC!VN)OIZ
MO'H[/'E?2Q&5:.5\;8SNHEHVC"&=<XUU]5C&NVTJ`/W4!2#TR:$'J,G$4>YG
M3,=%!DR=M8<Z>1`Q7QY9GO*B[W<G&8@>C]PLHY%9:5)%<0QI6\G4LE@2</HT
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MW6NA)9[IK=RZK%>5+54YL4;")C9!.*`7)$7!H!'S,HEDG*;*)-!HD4%CP\L:
M<X7?.6^2"XX8_7&BM'Q3X(OHRW2V^=>@;PLBV;<Q05C61>LB@ED^+[<$+MP]
M/X#<M.X,Q(=X>6EX0*BXKM+@L1)5]7J]N115Z(KM@[:RMM$HU'VLR34VG[Q_
M+=QOAIV7,[<Z75!-9W(R4Q-*NK1C(^9&4MM"TTA<`N:Q:^KB:$EU$4%2+V75
MW%HM(G)I;7=4ZJ1V-*KN52&[E;-9/*I@OV)K-!Q6)YFW%1N[&P=]O(H4LE)F
MOKJ\3P08HH']W(Y'":#=?9`TBQ=XT>I:80V52<)I3U[2RW;.-=JX-XUVVUUV
MSD_$,XQKG;&-LYQJ:]+.,8SG.?1_A>6/=[_+GS[^"E3G8JK^ROC573;'7VTH
M+GL%XC,R(5_B9#!T-1EM?Q%W.%PTJBR)YZTUD$:<MYBR38S$&N5C4DRIOD23
M65&D,8^@CVFEWU;F_M!#_P!=<>TTN^K<W]H(?^NN/::7?5N;^T$/_77'M-+O
MJW-_:"'_`*ZX]II=]6YO[00_]=<>TTN^K<W]H(?^NN/::7?5N;^T$/\`UUQ[
M32[ZMS?V@A_ZZX]II=]6YO[00_\`77/S4E<I13W56KPNDDGKG=11210U--/3
M&//.V^^QO&NFN,>_.VV<8QCY\\C&17\&&HX&O&R8(B;*,HD`</Y/&T$"<H/Z
MKH!0X1TW?KZ$SS]9);4.(9;*$"SI#+<<BX4QMZ.D?L9XTJ)>T3_5?I96DX[L
M=FVCKXB;Q>I$]=*4!D4T4DR1686:+>N5C8.-/%=&LD<"UF$7:DVQ(:1G8'+)
M1SCHZK\*3M)V4(MK.\7&RY=;@K5[\<A.F-+3@%`>MD:0QOLXU96`X"'0KZ<K
M,M-L(JC&NZC;/P778M.9:W453WE:ZNYM'4%.JUJ+K9U_H9_7E?#)R'DT0#`*
MY'PU$U/A*$5UCL8D49%$`@5+1NEK\HSL;A1M)&:N(X==[(MG2[>=&_5SN)?;
M1B-[)2AS65/CV0\>$Z^=:24,BX!L$8(:HC@!(KDI\$2%C6:35DT;:;2IIHV0
M2T8)CDTD<Z7;J?K[5M)1U:,UWUF'B63YIHS,O7KZ$'#4@2U]5G;4Z:-%WQ$F
MFHHEJMEHNOE@FK_"0:(XQKKK)P^/C1+UL2%T`*'$&:GKFCY@WK)F\;*^CMIZ
MUNZ;.DET%/0WWT]-)33;T=]M?/RVSC.9^TTN^K<W]H(?^NN4P[X]*Z:\1SK[
M)>N/9NAST@AYI30H`D8620,;/:VF#5%5$5/JZD3IV1U`RL2FNNAHJLR?B#`U
MP]`244:CQ$@+<ZU;@\`'K9*.KW7+KKUUV[+],Y'U/*2R7TW>U$VG$A]C/++G
M(^/L9?8MM>H.@L6/)I+M&`ZCPNS*P\V!9M4X]"B\<B*2<:Y/7AH5AXSG725V
M/6'?RXZA[AT2#BPW6C[C`MQ\5["D#VIA!/<=9#%300"<"4(UAZJ]?DBDPD^Y
MS4=C25FVBY!9OAW=7]T0=%^B':NL.I-TKR92>RI^@E:QF)OXG(8QUS&&D--(
MH0MIXP,++M'AATNV)$H\'2?G8Q"E=9D89:-W0D:5W.`[!*R8,)D<<AS@_'SX
MQ@:!'0DO@I4,;#%6J3X67$%&)]=D2%DV*Z#T>09K+-7K1=%RW5424TVSVGM-
M+OJW-_:"'_KKCVFEWU;F_M!#_P!=<>TTN^K<W]H(?^NN?BX/RIT@LV5K<[E)
MPBJ@IC60Q#7.4UD]D]_+.#7NSZ.V?+/O\L^6?P<P\B`T*()I.:>)Z*)))):/
M&L@B#5[_`'K37313==`WIZY7T=,>>ZVJF<Y\\_/GD73>GW<X'X$2"LDYN%_P
M=0MF:5Y+VC73;7U>=F+IZ]<O6.^FN<XTW'[,5\8QKZ*^NV,;8TS]AO!`JJ?G
M[+EVP)RJ6GC)%G#(Y*]R1:+UF\:>HU^+H*2C)%<VQCJ8?:3N&HPHU./4Y`:S
M)7!5VN%$:#:"J^`28@KB/'Z!NN1559XX8/R\E\7GIRKC.AUN@CAPM@L-76;$
M==W>FRN76&\3T=8QHNJ.9J*JH)3A'6'[HXZC(HK1"?1ONE`Q:GK<`K,'1:S#
M3IOIC;S;XET,.,+&5WVU\L8W?'U5/68QG5'.FN<;2_&?W1-/:<<I1_O[X>E]
M4:0;[91?S"MTU)7%U%<;:Z;+?$DY:0U^Q0USC?;T&DED*OHYUUUQO[]N;**`
M\:#H3V9PS;5?=L+;R%]G31"$63+HO4TWV7W]#&&J(.P"0)$DX]/?5/70(1*Z
MJ;XVPENIY>?-@!"U=Q#=N[*QU(:U=C"9MJX?3BOFJ+D.%9Z$3!5NHO(]-7`X
M4P4T?$GJ&5&S%IOHY<JI([Z[YY`VFK*DD%XS&])"@Z"`Y*U5"S:`$]'$=DZ#
MAS&SR/P.0K;;AC[9HZ7"DO1PS*(MG&[)9;5!;T,A]II=]6YO[00_]=<>TTN^
MK<W]H(?^NN/::7?5N;^T$/\`UUQ[32[ZMS?V@A_ZZX]II=]6YO[00_\`77'M
M-+OJW-_:"'_KKCVFEWU;F_M!#_UUQ[32[ZMS?V@A_P"NN/::7?5N;^T$/_77
M'M-+OJW-_:"'_KKCVFEWU;F_M!#_`-=<>TTN^K<W]H(?^NN/::7?5N;^T$/_
M`%UQ[32[ZMS?V@A_ZZX]II=]6YO[00_]=<>TTN^K<W]H(?\`KKCVFEWU;F_M
M!#_UUQ[32[ZMS?V@A_ZZX]II=]6YO[00_P#77'M-+OJW-_:"'_KKCVFEWU;F
M_M!#_P!=<>TTN^K<W]H(?^NN/::7?5N;^T$/_77'M-+OJW-_:"'_`*ZX]II=
M]6YO[00_]=<]T<>DCMZW;O8,5%M5=MM5B#@S&7*+;7">^VNZB#$HN[4QMOKJ
MEC"*.^V-M\;;8QIKMMC,.?-=X]_8/IS-($*ZFV+VKZ8Q*U(M*H=9\IZR]S9I
MV,A-,VW##`4TV!-;!.]:"82P!WQ([<-I["_6:32+.9"!:)2&&*.%`TBCUN_`
MFTK5MT0&#:HMNDK1AXFV+''-0_6<_>TJZ[4V[2W!+/:>I>2=CY!(;6,0L'NX
MTE.7AA00'WD,S/:1"-1V*IB13?<KG&,XSC.,9QGW9QG'GC./HSC/S\B.3T%2
MTPC\OB\AJ^$/@<^ES>P)FRUC[!G[23UHV",FDX+.1Z31ZYF35E&X^S;2G+G4
MZ@T"C&J3_1!D@GI)00*'C883'8\+'@P`$8P"A`HEFW'"@X@6U28C18P>S31:
M,1X]D@@T9,VJ*3=LV13113T3TUUQ#DR_Q_4E_J;=?_#+DZ;[Z):;**;ZZ)Z:
MYWWWWVQKIIIKC.VV^VVV<:ZZZZXSMMMG.,:ZXSG.?+'*Q]1^XG7SO)46EZ=9
MYQM8-9+2^90=*1;`9!',+2""&E01Y%)A)1HL@HTU<IIN&#_1MEH18.FSQJIM
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M/6FQSK8)H+P@J/,5'*G%2&B+HVV*5R4J`'KF_KY!EQ;,@V)76-U9HI$IF&DI
M`U'!U@KR!.,R^,M@IAJ&BAMT^C.<VUK;N#WP5U?7*1*]6>M3Y319O4L<<;Z6
ME.Q.V^-]-)>07005'M7B6N?6(&6C1HGYZ>C"7>VJ)C:8/[E-TLREZK:O9'G3
M*6$=M?E(G>-=M/5X3VQZ.IO737&^//.VNFFFF,[9QIIIKY:XV`QL`.BL>!1@
M1ASJ*C@88"&X>O79)[@>(8H#V6'9%^JN^?N<-FZ6%WCQ=9TY4QLLNJHKOMMG
MNN....,XQG&<9]^,X\LX^G&>?,GXC'[F"Z?]_P#N?!NVF\ND=)(G3K@KVK@5
M?BVFB-]+-FF-AD@`F%G&B593LP[1083^3-1)YO*1FN"R(H9-?ATB+[3_``V?
M#;@?ADU9,Z8JR\.Q=N5P<F.DDA4;OJ?,9JTJ0&W$("V\&KA$<#`L@49SNFH0
M=MT626'K_?1RJEHMHHJXHWW(\=UMX>O:>:51W!Z*=J('U<8N8PRKKO!!`:5G
M5),U38$42*N#@U@P#:15`$5?NP>XH=*99,UU1JKI6(M='+9//<>'O^Z(NA7B
M+=H[2ZLU29D$/E<?(*;4<:L5NG&V/9>,C!NCB2&:_&$$FA4(<#NT2#Q&`R9)
MO+BL+2;RYJR340DX"+;Y\;:YSC&-M<YSCSQC&<>><?3CZ<>?N\\>[S]WS\\N
M..?DH@BMN@HJEHINV5RLWWWUQMLBKLDHAE1/.??KOE%95+.V/+/H*;Z_-MGG
MJ/A(LGIZ!$<R?:>7EY.VJ#CRQ_)E73;.N?Y=<XS[_/Y^8,]JB'.M\+-F;D0Y
MQG.VK@4]7;;Z;_/C;33?*R6OEG'GC&FFN,?@]_OYCYBLCKQBX&^U"4A%.=<I
MK!9N(92,>LGG&<936U)(D$MM=L?P<_\`)-<>CMG&<>_RSKMO3PG.E%Z;.W-M
M=':2.OW">VBTFJEN\J23[*^C_!=[/*]?QQ5VZUVQC?.SMBYT4V\_6)[^EG.=
M*O;CP)W4)C$>?=%;D[1Q<V,E.&OR-VK:@U>!12)RX22B5A&(7("?Q`30<+P\
MF\`/HSOH0S,`CYV!*K+L%,XTQ_IY!_''Z;R"[J]Z[U=0MI1*-3,4V9E;]8A8
M?,[P@XIL^CU:%(K8>)2`:E`L4AP5F`8UVM,VR%3(.D0H@"@P):OR%_,>,5XC
M-'Z.$^WG@X7XR8#U-<%)SU[+NK$C3='&<^M=(MV(>5"MT/+7.Z>5)MIIC7T<
M;JZYVQGDK5U^Z1O#2E3Y$+8\FN#KP?SE--T)NBH)*PRT<;^6-]%7D+S,DDTD
M]LY])9TDT_@XSMG37'NYLTJ+Q`.DM\)MMJD[54--G3OT/4"!EFQ=M(MLJ>_7
M7:,ER`V0I;Y^;.B@S3?7;^#MKC;W<M<]+BQHQX:(D&0\./8KDWQ9ZZ0:#&0U
MJWW=.2#LBNHFR;L6[;3=PN[67T;(H:;*J*ZIZYVQU_M;%_A"[3VC`_"FSD*R
M<-OC@;\(;O)'C7,?:KH_"?6HN3N-],AD%-=52F-M<L-'&-L>>0\<<<<<<<<<
M<<<<<<<<<<<<TR^+_']A=;5K)Z54OB/=M"-I*YII3JS0E`7W9,X)M:TDXJ9#
MYE`.QB#2JC\%"5C\:O7Q61R`&:CRX\-I$W[IVX4`%I(\()HDWZP2=<^9[!%;
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M9PFDGKLIOGS]'7/EGRK%;9NWI37$VD=7A(RHY!`GA:)QN?2-_#`$[?#%$G:H
MH_+!S0@XBPT@.1?-T)!E@0$`R*C-^3:%1[9_HEH6SXS_`&&[2')!UH\*GJ@0
MDUN*RHLR/6I9*Z;NIJ1B*L:C#1&7R\JQ>.XB\E;*:;347LUQ(C,(+-8D,/PA
MW:J<J3#-;M]*O!IA%0V'OVO[K6&_[K]VC#E`R_M*R-%2<%KP@AKE1JTJV'F4
M\MFNP+.<I!9&68M]PJ2".T*C<";>M9;_`)=\NVAB\P$VZP]5(?,;;SC9JSN&
M;U^"*2<,/$I/]<K1$4N%9/LD=3+QK\`/&<KMQ6S)%T(&J&-G1!0=FOA>]>(\
M)CA^P[7I:<`>P`.2;C?:NVP<@U=*1U1@VVCKZ":R9JDB.^"L4E09-PPT7*M5
M6&J/QB@,>,V*>XSR\N..........1W;-35Q>E;3BG[=AP2?UI9$:+1";PV1-
M<NPTBCIIKLT(#WJ6FZ2VF=TML*-7C59N0'/$FQ`:Z:/VK9RE\^/AG?N9OJ)X
M<_;6Q^U;>5';P,M)"\<=6X_/@[1-'KZ`*-%DWSM\\2>.D;#LEHF\=`0,\<CP
M20@!ZUXV`Z2D@L::=OV)\./QHH'>]M=@?#^\6YZ^!V9/I)/$NJO<6#)3:IHF
MU-OL/TX+"):D-GBL7AXE'&HB.C([!H@X'#&S9)T:<O%'I-?=%T\(=JR/6VK7
MO=T'4T=[0*BB*=K"J.?%R-8HDDI"6;`EHZN;7>/]%'L6T!O3C7X:^8LS[@HV
M&.UAJ37.-=E??NA;PEIQ;4ZHXQVL`4_94`GDCKXN&ON-2RFQ;@S&#3T`_683
M"9B64+PS6(,5M6:9:0""BB>R6ZPMOLIC3FY2/2$!+00>414V(DL:D(QD:`2&
M/DV)H&<#DFZ;L<5#EQJ[H>3&OVJJ3ED_8N5VKINHFL@JHGOKMGML[ZXSC'G\
M_P!'GG'T>_.//&,>>/+SSG&,Y]WS^[GEQQQS\'+9%V@LW7TUW263W3WUVUUW
MQZ.^N=<YQKOC;7SQC/GCSUSCSQC.<9YAZM<0QPV0;N`3)79!NBA\)T3^"NUO
M4I:)86769Y;Y56WQIC93?;&?3WSG;./?Y<Z+-4#&>=]X^=DD>4WSG_L`FKZG
MRSGS]'9/^][[ZX^?T=EL^?\`+R,+#ZZB[)9_%UB1FIKE%:I[)?%EMUK%9<DH
MAMG&=D-E#@<PKG7;.,>>/A&GEG&,ZYUSC&>:TK9\$3P\K-^&N91T4@T=)N<9
MPF>HF62NKW+13/EGX0T"Q<[J`RIKY8SKZ\`IKY^>-M,XSG'*>'O`^AM>C"['
MK-WL[^=9VI`,5'DH(=DK.T*]-LG@YTU=1U[&%W$&9%11ELLH+=CC^[T:[;.U
MF[_&6BJNVNIFG>HWBY=7K0Z_3^+#!%FRJ22UC'FL>OT$8L>NZ>+UJV=5QU^F
M5EOXE(9((8/QE?NR(&O)V@_,,Z+#&G8A`F+:.]CS+>"CX@WC@TWJDO>7A-1*
M[`:"6,N)#U3N-J34=)I8SC==J`;E;/*95VQIZ66N1Z&_GMCT$\8VQKS]V7[H
M[HB#.LB.U?4'NUU:-);ZI//;>H<E`C-;STU4PH_4=QHLHDGG;.?6)`-]ML8U
MSA/SVQKRYM5>.1X6-O?`T0';VO8\0>9UUP,LAG)ZT71WW_P4UGDS""@WI?/C
M.4RJB>,XQ_#\MM<YV*P*[*<M1NFZK&UZUL5LKKC=->"SN+2U+?7.N-L9UV`E
M7_O]';&<XSC&<>?OQCDF^ECY\^>,?3MC.N/^O&.<XSC/S9QG^;/GSGCCCCCC
MCCCCCCCCCFHKQC8M#)W0M61"Y.LX'LCUP?WQ%"?8AB[HZX^Q$S@U:@@4D?K2
M&IZ^Z_2"-VV&L@X7PPA(JTX^[*!*X'2$H1G$;.1`@412S/PC%HSCJ@X&5GU`
M,]*J'`V]9P?KK5TLK\E5D\DM+(D!SN.6E/H">(%9.!E,U,O)'A=U*R#B22L6
M)$S0KHR6D6!S3:%QQR"9E_C^I+_4VZ_^&7._O6ZZYZWTW9]]V\<4C584_!I)
M8D\.HBR9M<7%HJ,7*EW;<.%:OBQ1RFU;[X;CQS1P\>+[)H-TMU-\8YYT=<]=
M=BZ=K&^*D.;26LK@@L9L:!GE!Q$0L5BLM%-S`9XX$EVS,J,<JLW*?PD<1:MW
MK)QJHV<HIJI;:XE3CCCCF"2R?"HIE'1;7#Y=?1[C1NU<(96T<MO4X21<:>EG
M*":^ZNVN5U/+U7J=]=4U5-M4\U>[`7I4'6VMB_8GM_8@*OX#']/,6'?N,K;O
MR"Z>ZX^/@`#3X05ETJ*:IYRRC@1L^).]$]W+_P!4.;N/@FD35'O-X\SU+11&
M==%/"B=+Z9PCKLV8W[VQ!MEO+37&-<*LQL')82\T\;:.J\::*Z*::6\0;:;`
M=LE`>'#U*Z"D5[/I(S*J/C0%21DYRQVF;).!RJ%OXP&$MXS9>)`.=*R$1"SP
M;>?0N4DR>)_&99(9BR&R[$1F9^)/XGDMFW3XC$@+5Q0#LY5'4X6^5#V)>#EF
MN.D=EZI*>@_C<):.-4'20]RGYIKL_P"\J90\]IDNR:N4HD4V84M1]:=?X*-K
MVKHXVCP%AC"CA37/KRILCLGHFX-2`IMKJY+EW6J>FJCIQG&B"&B+%BBT'MFK
M1&6_+R^G^G.<_P"WCCCCCCCCCCCCCCCE/NROA^])^X;1=MV:ZNTG<SI9+5#2
M0S*!`W,T8):ZZZ8P(GS%LPG`7?&FNNF%!,A9[ZZZZZXV]'7&.314=)USU]I^
M&T91<8%UK6];Q1"'U[&1FCTB-BXABBMH-03P6?NR)/#9=;9VX5)DW#TDOLLH
M]>J+.%5L_P`YCQ9)7^Z1NJ7>/J97<Z[*VAV",,+#6?=*K,H:NPT'AEU3$\^;
M_&$7EU;0<(-!GYV,9+^S$BKNR4Y*S8P1X[5'D"</.%#SK^B-3DPM]KUNKV=]
MGXE'XA=C6I0LINV%58N3FP"/SMK&-"TU`0S+9-\2/HL2"+QF,9#EC>[EUK@>
M)*'TO@A4AI>JK]U&^#Q8I12/RN]YO0,H3=;,U8Y?=+V+#W35?13=/."!B.B)
MG%Q6N,IYV4^,SS/9OKMKJZU0WU4UT^@"-26/S*.`)?%#(V1Q:4A!4DC<@"O$
M2(@Z`.,&Y4,8%/VVRC=\-*#7;9\P=M]]T735=)9+;;137.>X]9K[\YSG7&/G
MSOKMIC\N^,8_)GGGQQQQSP4235TVT5TT4TVQY;:*:Z[Z9Q\WOUWQG7/]./?^
M'F'+0"+.G;YTZ#L%\//@_HI8:(M]6_J4=TE/4;ML(J:_"<[^L7]^,;[XUSG&
M?+'ETSBHX6KOA1LT?#5,9\\*#R3I+;7./+RSKZW9?&,X_D\O+SS]//0?5:Z<
MH*L])J><,5=/5J#3^K>1C54_/W)+,"/I,U4\>6/X"C??3W>?HY\\XY2NU?"]
MZH7#ERK8W5[JQ/7;C"GKBKZGP4/D2N5<[;*;YD4`:1LSA;;?;;?"V26RF-\^
ML]/&WOSKCL#]SE=(2SI<M`J[MZD#?\+9J6I"_3B2+-;&,8U6:AK#;S/?&,;>
M>V4='S?&WEG7&R?EC.8GV\(_OQ2&F^W5WQ6>V<)8MM\9'Q>Y8\7G4=23TW\T
MT'#P)+"`U5/37'EE36%^K4QCT<H:ZYQCGYZ3/]T=T3C71M-^I';<2PSY:-BJ
M`>'2=ZBCC.<8W2*B:F=;N%\8QKC'QFZ4PKOKKZ6<?WS&3#_&J\26I]M4NS?A
M#VLX:(>6KV14J^D)L9G7&==5'#?1D)GHW?'I9]+5/X]UUVSMKIA3&,XWS+L.
M_=+/1U59$==%>]D>OAC;.NCEO8%8+K,&BF<?P\*O&3M%[G33SQMC;XJUVVTS
MC/H8SGT>7]JOQ@/#9N/5MB%]N:G^%NO0QJ/DI1U#WJ>^_P`R:FDE9CD<;^_'
MNU7VQCYO2\\9\KW1.SZWGJ.CB#S^%3%!33UFBT6E((^GMI[OX6,BW[K/EY9Q
MG/NQY>>/PYQS.?2Q^'W?SXSC_;C'.?/&?FSY\<<<<<<<<<<UO>)'%KGG4-H^
M$]?9AUNK:U)1<ZPT+9W9!">OT*Z&IU39+Z02ZFPM>2R$%CUX#!35;:)BB4G#
MQ_<'M*G99WZIGJW<8GX?,LN%_J)B+3MJ`\0JC(?#YQ$)_P!O7[VMH_+5>RT(
MFP`6XK&,PJIX./C!V&#(F3*K'IH1GTU-#9&*9QQV;.%=C;QOM-^;GCZ>OEZ7
M\+R^CT=O2_\`(\O3_E_P?F]_S>_GEC.,X\\>_&>03,O\?U)?ZFW7_P`,N?,%
M^Z[^['9'KWTTC_7BK:8(N*@[7ZDX1<?8UZU0+QR*,1SYD4:T\(8M]U]@DWL!
M%AN3UDDF0:LLQ@66'0M(O(MBK^(['_W.1V3LOLIX3_6DC9-&'J;S4<3"4'"3
M3_T4H[=4!J:-`XS&[=AC5VIJ9;B3"#90$7V=MMA;N6@#[R-$'P5=%)CO4XXX
MY&TFG"J#WV:BC;4U)EO23SKIGTV0OR\L;K/E<9PGZ:7I8SLEMOJFCGRRZWUS
MG5%70IW+\562=(^R..O"O6<C?W82<,I(\JB+5_)49BO9NDM91A&G'ZXL4/P?
MA1)S(&UE"[%B)&+%#C<7'8Y(*_?R&,R0H1C7O=:_"BNCM%:<>[I>,3*1EO6@
MPSJ0J?J`)PCMU]H,<HHFY9BS`%H\>@Y6;;>K:_&`-%8J"</&FJ\SD=F/=&JH
MK=]<UWU1UN@2TRL@ZRC,?8)88B1C5'50J;>(H8PU`18(V]!<B_V2TT31;-=$
MV@]OK\)?+,1R"KA+0'0$[/>(9V()5AV`MR5#:K(R&4VY'J;'/MTATE>L5F&C
M.`MS"*FKID+CL<;ID<-LY=;;Z-9&0`8$&2#PQI](T7B\=A4?$16)A1L>C@%B
MB-#A1#1)B-&L6^OHI-FC5'75-+3'GG;;.,9W55VW66W464W4V[[CCCCCCCCC
MCCCCCCCCCGJ.&#)VJS7=-&SA8>XV=L%ET$E563K=NNTV<M%%--MVSC9JY<-M
MET,IJ[-UUD,[Y165TW]OD&6YUBZWW\R5&WI05+W*/6TRFJSM2KH-/T-]-M,)
MYQG65`BNV//3&-,YUVQMG7^#G/E[N9O(*WBAVLS52(LEHQ"3$&)5TD/A#I6&
MN(_%B,>7B^C.)/8_\"6BRPD.MA``Z"Y:*@]VS-4;E#9HAZ'S7:_N<"S:271<
M]#O&/\1+K&BTSKNRBLSFB-UUXAZ*OK-&^8<P+U2+=--,Y_Y@FU):K^CZ+G*F
MJBF<_1M)T[6B5(R!*";AK3NV-U<33A^\X=)PR/V%:`>)*I@E):\`M'"47$RV
M5MFRAU<.Q42#-2#K+!OZMNEC7YRV?B]>-30KIB.[A>`Y:TN8[JM$",XZ86BP
MM]M_?EM$E'0^#`6MGJ:)[>LUR@V*SL;C7;RU<O$=,[JI_2%/[;@E351*[KM<
MVWK:NH#!R=ASP[+,_!4H=%P8?<X=>&]&.2&^%0[));5VV88?+*.4=FS'5VKN
MCJK3FB_%I\-+LFHS:4SWAZURXP1W;I,(PO:4=B<S=JNO0PW12A4X<QF6;.-]
ME-$\M\!LK:+9]1MIA;&=,;#LYQC&<YSC&,?/G.?=C^?/&-M=O/T=M=O+Y_+.
M,^7\_EQC;&<YQC/OQ\__`+_A\OFSY?-GW9]_.>....>LX9,W>OH.FK9SIGY]
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MIG;;TM/+1O\`!,*;9W3T\L9VSZ$FBO%0APU/36X>KW<"F5_+_E#D[21R41]M
MY:Z[J;9D$0R1:J(Z:[8SA;1+RSKKOG.N,IJ8UFR(>)+TEF2J+9EV!AH)^KG&
MN1LXU+P)^BIG;;3U:R4O&B$]-\;Z;Z;8RMY:[Z;Z9SZ6FV,6PBUCU].$=7$+
MG,/ER&^N-]5HQ)@AY+;3.//&V-A;YUYZ^7O\_=[OP<S+TL>7GG/ECZ=L9U_V
MXQSGSQGYL^?''''/GL\82;J]C2\:Z@0CH3V[[\`:MF42M'L9#J0M<3UMI9^S
M(Q(TO&*0M^U9&_%.+#U+BI`$LX_342WQE1FA79*3&&291@,>WX\+E*EF?6%(
M/1M1V-URC$>GLH`FNL5K0D5!)KUOES!C'M3%3OA8ADBV*B6C787+8G+]BDG4
MFD2EP23Z2@RV)-U4KQ6:*"G*\FPB2RDE"8V0BQQK(Y:(DN\,)1Z/*CU\'2S.
M8HK-74169B</%<2EB]'D8]IC<N.)#GS-N^;_`#ZUE&X_'YC0M-0R;%]^D'9/
MQ$I,1CE/%;.DEBJQNFQW1:R)-7,&E)"1R(],(?7?9'LA51Z_XW64K)[M]FFP
M4+LV&.)%(H>SVG^&3/9?9?26F9;-)`:EC]=6S@@"6R/+A4Y+JYA]R6)#:DEQ
M1Z[33=EW<HJL!#3JAYWC=U(/A^#CA9=8ANNIG4FDD]6[$UHBZKCX(T&QN[&X
M%[[8A''M$S]=7FGP[X.DWPH'\DD6J_P5]E1;_EGJ\[>DW4SFO/=+LSU12EM$
M]"NX=7AYX1[]EY5`:WI\^R8SJ,S=6`M14C+.)AA!BNVC`D<_<@]`I]SCUZ$D
MW:.&>[+0<\*C[U`5ST:"!X]&ZH&@8\"%C@P$&&/QP6(#!1;-%@*$BAC)D@S'
M#1K!NW9L&#1!%JS:HI-VZ2:2>FF.V]HIS]7W];@OW?CVBG/U??UN"_=^>N\E
MDR8-'+YU`,Z-FB"KEQOK+`V^=$4=-E%-L:X0QZ6<::YSC'GCS\O+SYA3J:36
M<,W0^)`=QWJ,J:$7^"S3?533TM=-&XXIA-)JGNOIG93T],;N/0QC.N6^F?6[
M:S>^'B+9Z1CHIU^HZILV_P!Y;[VU"T?30HVPE!A=\0RLV:6%9303\$<BH,-7
MT=N&+3=V,UD*HLKK\-"QX7)I4(K[U>\&'<.D?OWN45L&Z^\UNMI`=L:ZXW;C
M*,;5[)CZT9(Q?>G'C0:B\C,@IIY%0Z\%FPA,1NP>_&@-@+Q72C*-9V.7CW9_
M>^)QVI!\4-7)V#,#1X6-0D:?CYF6F"_Q>DBUD4\:0T(P9A,&E=-BKAF'##U'
MVV[M42'$!$]GK")*LZ>6A/)UK?O=8`SN6QUTO*+UJM(0>M75J+6QZQ,5I'%=
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MM:%]+R^CS^#^?E_3ST##J12$04`'JK'&P1P<]#F@I>01PF)+B2395D1&$QKU
MDNR(#G[-99J]9.T%FKILJJ@NDHDIOIG4_;?@>^%Q=91,W,_#$H<<72>M2'PZ
MM2VM,[K.FCI!WIN\;U"1A#)]JJJWTU<I/6KA)RCLJ@OINDLIKML8O&-6U:U,
M6=5D*(2RBY-.X')(?&[<K^2Q=Q,:R*FA*XX=,8LU()MVBA>/K*IO&">SI@IC
M=+'P4@.=80?-_G?:=)?W3/UC],C1/B;4QV_B`!1(DTK#MG700-+98S&9RZVC
M"\\:A9F;3('4T-1.A1S:`1+1P\U=."PG5)1^GH?\-/Q4?']/>*%VW?.J"M'M
M<<8LY47[.=*9":4JZ'TJV@Z9`?#0%5D93H2!TQ+`[I-*,18*W:&G]U,L$=R[
M":2-1M,A/T7Q+Q_NSPB61&&=B_`R\2FI2DGD`B.9*PB$/K;BS5V3(LQN[Q,U
MM"H,W=,&BBSITOLBLHI\`;HN4_6ZN]<I;SK[[,QWK#3]B7Y>C!K`ZCJF//95
M.I@Y.9+(B`C)9%MLX2$`0I0\3<NG;EJS'CA@MV0?/';9L@VV55QC%%*E\=?P
MRKO?!Q->=Q^M+DX?>,AP>.RZWFE82`@3(N<,F`IJ,M".PY18F\>;:-&K!+?=
MPY<JH(H:*;NFN%]H^)%.<_-7WG[\X]TN"Y]^,^6<?]C_`#XSC.,_1G'.<R&<
MXQYYK[.,8^?.9:&QC']/P?G'M%.?J^_K<%^[\>T4Y^K[^MP7[OQ[13GZOOZW
M!?N_'M%.?J^_K<%^[\>T4Y^K[^MP7[OQ[0SCZOOZVA?N_'M#.?J^_K<&_P#L
M'/3<D92]QG5Y6#-WKGY]7,DCZ^,_SX5:;XSS'EPSE?.V<4^Q;;[?.H/E@L:I
M[_P^FPT;;?\`7S`I#4(J4Z;I'*@0)I;^[*9:21,^GGWXS[])$'+8SC&<8SY9
MSY>?O]V<8\J^'>AU.E5E';;KE"&+[;.V^CMDM&HX\PKY;^CM\8P[0`Z1SY[_
M`/.HZXWT]V^NN=DTO0ZQGU6L6'Z9Q!25]PM+3'II,H)V3=EQNF=5===-$HW9
MCXB!SKJGME7U.==$O+"J6,[;81SOZ3V<=FZWVSL4L^VLL66$\J9M/JPA8@I-
M+T-M\_"Y90B([.-<:I[Z*NEU\8PIC3SVSE9/&_LQ_O8>3?\`Q62F/4J9$L;>
MJV$M;;,TO)\JZXTSLEB*V&-D;M-QCUB>-FRKE+.F5=/3SKCTL:SPW[53#1OH
MZ>=<[#(LMM?3P4@\JKJ;B]M//_G$E61\>^63SC&=L9T&Y4SKC;^]XVQZ',>D
M?>F)QOU*I."3,2S8D=%)B]DH63QQG$8BS"O)'(9:\)D(EH$?,@PE@XUSHS+[
M-%"B2@QX2&[ZX5VM'4-O5Y?%=QVV*HD2<NKR7Z$G$6E+8<7'CY"/&F"`38R&
MU,L!SHA'R+H8X=1^0-F^X:3!5&,ACSTD")CB+K7#VUZE>(40MPW;OA^=W811
M#:RV(=*WJ>ONCAMV5R0ET>`CHD(M>O2S=R/ED(EJD1"@H])8WE8E#I1@"#,[
MM1A5L2W,7%ZB4'.>OM4;1^VKMD/8VZIC)25@W-=<@C@*$^W<^,#PX51>/P"+
MZ:1N`PZ.QF.1J'P^)",N-1D>CS%0D1+G'14L]L'*HG%IU&SD.FT;`3"(R88[
M"R.+2D..D$<D`=^EL@^$FP9=L\&%ACU#;9%VP?M7#1REMLDNBIIMG7,+@NHO
M56*PF45K$^ME#1*O9L3'FYA"8G44`B\6E!L3EML*-'P4?CXT<6,#,LF>1Q1Z
MW6?L<M6_P5PEZE/T9[&C1X8<P$"&+,6*%LVHX:-'MD&3`>/8H)M63%BS;)I-
MFC-HV22;M6S=--!N@FFBBGHGIKKB%IE_C^I+_4VZ_P#AES2O:75SL#?/[HXZ
MZ]@9;4TG8]4^F/1^6E*[M`DW34@DBOFTC,NBI82(=ZJJ)YE;('+=7+L4IJD^
M9-8:R,+))LWHAP\^A[&,8QC&/=C&/+&/HQCCGKNG3=BW6=NUDV[9NGLJNNKM
MC1-)/3'GMOOMGRQC&,8_GSGRQC&=LXQF#7Z16V'6Z@[&1,9&Z.V[9\Y]=HL9
M=9\OX&44]O++/"J:7K-=M%,M]<;9SG=WMZAOKT\2?Q)8OT1CT8HN@X9K<W=F
M\U40]$4!&T')EW\:&U-Q;&=S@>Q<:OFL82>H*_%@S+AB^FC]B\;MW@P",E,I
M`?KX9_AIO>LCF5=H^T<IS>7?^^DLF+CMPTH@43A:!1-NJI5M:[ZIZM1<;#I(
M-!1,@(08MSFHQD,%-!<-$`@C>`N[OB'S=G>XVN>NMHB8[$(\)>0^83ANU:'H
M^K*Y8^:L29I-SHW?ZK)5DP03W:D1VCK1`NN>\FY#=FBGKLWZK].ZWZZCW,F1
M?+V3;DMT4?S.YI-O\8R.1."7H.7>@ERX</E!()VKG"_J47KI\5QE)P;*%%$V
M^4+C<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<QP;#XF&.263"(Q'Q<CF:HI>
M7GQP4:Q-2I<$-T#!%I(5:M4GYU4.(23%"E2KAWN-&Z:,&6R#37".,A]#7YL8
M\L8_!KG.N/Z<:YQC/]/GSJSH$)*`Y./200+/@3+-<<7"&Q[,L(*CW6F4W+$D
M,((.6+YFX3SE-=J[06063SG11/;7.<<H7)_":\,J7R0),#70GJ9F41TR(/B3
MPJBJ_CA-N5!$&),6Y5<QL*'V>ZMG8UGMLU?X=,W**/P1VW<-%5D%;(=GNND!
M[:4%:/7&T'<N'P*VXRM%Y(]@4I(0J7LV:CUF13=`I*,QLY'/$'K%LMG15%X.
M?H:K#3`\D)>/6#C1/6G[G`C/7^R8+..N?B>>)Y5P")3&,R,C7"M^,)!#9&%`
MGD3#R(O1[,!%FNP@RU;(A76A1@<:Y&[O$G8XAJ\W3TWG]J8YV,EG7JTXWU)L
M.$55V-+1W+:J+"LB.[2R%1>1Y*,%MWYX!J.,8?-]A.A)DVRH',(LWSEH^<""
MB#51BOHUJI;]U'UI9U?@+:9>%]V(JAW+8RTL"9@G]AP.7L86H9&:2DDQ30:0
M=HB>2"*D5AOP.#GVN"#?.-A3M/=NDKO$[877,^NG7>T[KK^BK$[+S*O@*)@%
M1M3)IK6#8+A8R-&;C8XDJT?[;K,&;]<X_P!&PXF0R+%OL#!9-_\`!V2^D.IO
MW1]7DCM:OJ5O7PY?$QZTSNR)S%*]!*S_`*Z*OXPE(IB=3`"-'C](J%D66>7;
MA#==8?$G[A-+1]OHS5PRSZ[?3>E\T]UGJJ67??=AQJJJG@R#!Q*YU,'V1P$*
MF5,,(^+PZ<:I+J[+$S90<*'MFZ"[EZ_>MFS=%15;77-<*:\3WP[.P9(0#IKN
MYU<L"2'WK$8$B@.[(%B8%29/=JD/&,(B1-,),Z)/%WC=JW'(BMWJCQ3X'JAE
MUHHCI>K.<8QG/OSC'T8SMGZ/=C7&<Y_HQSCT]?=YY\O//ECTL9USG.<^7EC&
MV,9SGS\L?TX^G'/+CCCG'HZ^_P`L8QG/NSG'NSG^G'EG_KYBDM@4'GPW<-.H
M?%IF)4UWT4&2V/!Y*/WT5QG533=D;9/VVVBFN<Z[ZY2SKMKG.,XSCW<J1)?#
M<Z42-[L39T0`KXKM_"P6I0[,Z&*:*84RMA;5Y3$E@F^5<*[;;YW4PIZ>=]\*
M8VUWWUVUS3'P_.]`R][("T;V<MR*]5R$$'P.)![8M76\CFDLG\1,,9!9[',X
M4=S%G'*4,IAG;2)$IAK(;.?$R(]F\C(0$T*&]LW3Z/7-$^MU61?L"FR2MV.A
M7H.8:CBK0\+V7%'"K$8X$&6>4\$@SL*@.=A7+UF+,_%"[%$^'%'42+%"RW''
M''()F/OOZDL?_F;=?_#+D0=&>^M!^(97-AVOUW5E[R&UO=D_H4L4EL:UCN#$
MKKO4,L5+QC9(B40,Q$FT/#'P0OAPW=+(K[(D1@M\@LTTNKSTB!%D*9KOR+E)
MHS;Z>FJNMMZ.NN//&-=<8]^VZF^V<:)IZ8V44WSKIIKMMMC&8A10*6D[T>O]
M5Q4%9.<[LV6<[).CJB6V<877VQMCT$<9QG&=]<YT1QG9%KMNXPJ[2T">-YXA
M<<H5<+3'4ZZ[$QW)4BTBAQZJZI)+EJ[B%7RC48[+RJWT&I-DRK2?PQ5B-E%<
M3`"\83&/-LD4)]HE5$I(;N)G\&WI_!(X*L?OGV"L;%X=];(D<P$=A)G.6VXH
MSUGD0E3"$OHE"/&D63B!&(R.3'MI*3RR%#B42Q'V\"U1J3<`Z.6!L:\+6[WS
M,U0/4\J\A]'!W&XNY>R.K=XBF10QG.KV(0)37=JH[2*-%,:Z[-54'Q]NKARH
MY#Q+.79^SL8\./IO'(X)CRU)162[#!Z3%8[*4W160%]M=,ZK/2S_``Y;IK.G
M.VVVVVC9LU9M],Z-F39LT111TN@($C0`H8##,T!P@,/9"A8]KIZ#9B.'-DF;
M%FWT\\^@@U:H)():^>?133UQYY\O/G8\<<<<<<<<<<<<<<<<<<<<<<<<<<<<
M<<<<<<<<<<<<9QC./+/OQSQ]#'GY^>WG_I[^7_D^EY?]7,0L&NX!;,,D%<VE
M"(C9%?RQC\62B#SN.!Y=$9&.]>BYPP.QP^S?B"S/#EN@XPW?,UTM5T$5M=<*
MI)[ZZW&O@@^$X-LJ%6Z#Z(T'%;`KN8`)]#C<*CI*$(");%RC<T!+[`HD9#1P
MEL.*M&S])F6$/ARCE!)1=HMG37&+?]O^LD?[B]<;.ZVR>P[9JD%:`P8-(3ZC
MIA[!V<`T%2$3)--X[)=F!1!JF17$)BCC)X.>LC`!\4$.T?4O=]]-,5%>!IVA
MZYW#6<XKKQM_$.,UA!9I%Y(>I>W#;2U0<Y`@S")$M"R3PY*D(^R$25CL2$/E
MO89^HU1(:O&R&SQ@T4UW+=Q$>VJW76P].CCVE679W5$&K6RO81K)G54J;)20
M4K)FDBUB.^II)P[B6IMJ`<IZ+-$#Z@Q4FGEAAPHGIFHR_P#]TK1FY*NA/9;H
MMT7LRGC,]B\>L>X*.NUS!WD2A+TD@TD\[T"3"P394HH$%)O3"`1A`-G99RHP
M$-V;915==MN/[G]G%>GO7*?]A$Z1NOL/M!/9[.U4=>XFG-K1D"1Z3"HZJ\"1
M]1VRPX8`$BFQ^0N,**;#P0]^\U07RCZ&=0'7S]TQ]#KSN>K.OAZK>Y%`VU;\
M^BE9PZ.WAU]<!&KN7S,DQ#`F3DG&)/*/@#-P2)CD5B3]DV:LF[YN_?9;,L.%
MF^]*YKPIWKM7AJV;XLZ"T_6<=5%MSD[L>3B8C%!;DV4:!`[9Z;,N6K%%R5+O
MF8P<WRKE9X]<HMF^BBN^->855W;OJG=[EDSIGLM0-M/".?18LZUN2NIN\=[>
MKW6]%NRC<D(O%MO4I[K>BFAMMZK397R]7KG;EB//\/\`L]_^SF.2&81.):A]
MY5)X]&M)!(!$2`[GS0T-J:E4@7RU`QH1L2=-L$I`;<Z[-Q`5EE<F37UV18M5
MU-<ZXR/&<9QYX]^,\<<<<<HSW+VM!,:45I`3N?NE+K!W!4J$"F]8C=SEH:P2
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MR#AI4S_U&^"I]5LFND$D;-F\+&-TMW%=A\B$\64)M_1O2GJ#X0_6NQ[`?AWE
MOV))V".ERW#/FXPW:E[2:0%M%,1W&YYP_:"09B0.MGR<41>N6>VR2I^7$I*<
M0>GU^J=/[(\2B6'(_7;$K2W3/4RW4L>?:"T@D[["$QS=FQU'-<JLMLKM![<8
MT%^K?*/6`EBT:[R'<F^0&Q%AMKK:M814<-"P&O(\/C$6`M=6S`8/2QKC.WHZ
M^O>O7&WFX(E'RN,N211ZHN^(.M]W#M=13;SQG7''''''''''''''''''''''
M''''''''''''''''''''''''''''.,XQG'EG_JSG&?Z,X\LX_HSS\-VK=3=)
M11%-51#;.R*BNFJJB.V?+.=DMU<;[I[9\L>>=,ZYSY8\\^['E%=YT+3/9BLI
M'3-_UE#+>JV6ZL,2&"ST&TD$=)*"B#8L)=*L7>FV$GXDJS:$Q1!KN@^&D&R#
MQDY0<):*:ZNXC^Y[_")KN[:Q["USU"`U]:50V!&K.A):'V);H@*/E\0)Y-1Y
M\O#O;US$WC8>8U:D=1RH?#%=5@S0<H+,4U6BU].Z?6N1=M>N\THV)]AKKZMR
M"4NXP]'71U_DBD5LJ,JQN2C)`HU&E4%FJ_Q8?18*A#S-!\QW?"7KAMEUHGMN
MFI\%_C9>"KXT$8(=9A,'[:=I_%`J#:QQ8:`:2%^<TL2B[ED3EN+!G90/VE9Y
MJSC+H>S:8'WDZ.,Q<%<HFV\D4A;8@S)R/[Q>B=>=FZJZCT37G<2W`UY=DHK!
M1XRT[/""%!C.1'-%%E$$5%EE,+R0@"%J,8^3G+ED(>3U^+<3!^$%/33AII;?
MCCG&<XQ\^?+W^7]/]'.<9QG'GCYL\U4^(EWVJ+H9<'1LW:H">RK;L+<)KK%"
MPU="@YDRWEUINZ^9CI`49&#H'&T9"*-4OCC(Q4B:WV?,D1@A^LMZO&PZ76&Q
MC^CEF-23)%VR2F[G3*J:(P,DGKMG9T<(J*)-![=/7793;#APWUU2URHX6:I?
MWWFC3NKXN/0*FH=/8Z:[F$BW81P*<I1U;JT'C]S2"M3HQ5,DT>X4*Z[4ZNW&
MOF6C.4`93*!S1Z#5,"E-V:SO8PAJGJZWNW7C*'K"JWN/V+!]+NFM?&WEBV[6
MK5QO7-LW!'RBP-).`"$9,@@NYJZ)DM$$W6I50\I#G<TCHR5,;'D!"*&F6[JI
MNP4)KN%"^K_A1]7-95$H7A9CI+W#!]%JC"/U]?-X>-'3+AD<F4A**:X=E3LK
M-BS1]QIE?"YG79/&O16MX;_</L,H)DUS]HHJ8/[I+.G$4^(Y*I"XBY5W\DF,
M68"W(D2IIJVSKHZ)[`63]5;7*>[E^G_RI38ETLH:R.MM08J>?S@!.V80^3>0
MUZ#&%1F0\?+YT(.03G0HY<;+:-SJQ-ZQW2SIJDV(9:[8SA%/.+><<<<<<<<<
M<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<XSKC;Y\>?E[_
M`/W_`/;CYL_AYSQQQS7/WDW<&;>\/NMI5KLO0]H=J)-&[E"/$-'$4FJ@GK%?
M$OJ2!SULOZQB1BAZV8]&R"8,LV7%2"6`(L*=:JJ+MF;OO/#"E<NFO1RDY!,2
M\BD#E?Y21T4D4K4=.9!(ZH`7%8<>I*3$G[W'PPNO(*<%00SH:=9W<GF[Q`LO
MONH^VWVT*6%:?71_?_8BW>Y5B3.ZHSTB[LPX_P!=(PD!.RH!U%L0A+9>Z6=B
M;L<31PM8(I:5-$CUAMCJHN*U$+%0JMW8@>'A;4`+[:]/":\1SO=*-YUV2NB!
M9K9SOAQ"Z"JVT3\<I\?&WNZ1)@H2=BQ9]Y8)0FUW;JF)4<75($G&^VXERP$:
MLD=)&$>%UV.ZQ5))&%5U)U:9@46(?):,UG4</L"RIQD8>%$1C5R9G=;G95(]
MVYEJ-,.FK^2)B<:"='BS/.C7**G0]9NF-DR?L"PD'8WI_/;$2?FIS/&A2PW)
M:!1QE:4I;INY/-I7(41)91X[F3!@J(,)Y01]H7VP1N6W>,V39JE]"T<=6U#P
M[*/1/KI6D9`#4_5#P@"V68@2Q2\\[9T:CA]6-VB&,[9SMME-+7;?;.=ML[;9
MSG/>^V-_?4G#?TU_V9<>V-_?4G#?TU_V9<>V-_?4G#?TU_V9<>V-_?4G#?TU
M_P!F7'MC?WU)PW]-?]F7&9E?N,9S\B4-]W_Z:_[,N8S';?N:4.I4S%4I%LJP
MZ4.8@8RXN71+3)9H)"FE<M,Z5NKLJTRR/,?055U;K96POILWTTT345R;VQO[
MZDX;^FO^S+CVQO[ZDX;^FO\`LRX]L;^^I.&_IK_LRX]L;^^I.&_IK_LRX]L;
M^^I.&_IK_LRX]L;^^I.&_IK_`+,N/;&_OJ3AOZ:_[,N/;&_OJ3AOZ:_[,N/;
M&_OJ3AOZ:_[,N=')[2NV)1N0RLO2<4^*HR"+R$G\%N?15S\7A!SDF]PV24K9
M%-1QELU5PCHHLBGNKG7519+3.RFO8L)]>Y)BR(M:3A^6S]FU>M\J73Z&_J7;
M=-REC?7%9[8UWPFKKC?&NVVN-L9QKOOKY;9]OVQO[ZDX;^FO^S+CVQO[ZDX;
M^FO^S+CVQO[ZDX;^FO\`LRX]L;^^I.&_IK_LRX]L;^^I.&_IK_LRX]L;^^I.
M&_IK_LRX]L;^^I.&_IK_`+,N/;&_OJ3AOZ:_[,N/;&_OJ3AOZ:_[,N8V<MRZ
M8\3B`DA2<6^%S>0.(T$]1<VBB6"36-GI4KEYOO6Z>R+?XKCA+T5$='"F7/P=
M+*.J:NZR62>V-_?4G#?TU_V9<>V-_?4G#?TU_P!F7'MC?WU)PW]-?]F7'MC?
MWU)PW]-?]F7'MC?WU)PW]-?]F7'MC?WU)PW]-?\`9EQ[8W]]2<-_37_9EQ[8
MW]]2<-_37_9EQ[8W]]2<-_37_9EQ[8W]]2<-_37_`&9<Q<5<-R&9++(HRI6+
M9+0SV>^.<*W+KHVS[3#%BH[X&KBM]]UO0;([ZNO6HM_06SKJC\(3SE77*/;&
M_OJ3AOZ:_P"S+CVQO[ZDX;^FO^S+CVQO[ZDX;^FO^S+CVQO[ZDX;^FO^S+CV
MQO[ZDX;^FO\`LRX]L;^^I.&_IK_LRX]L;^^I.&_IK_LRX]L;^^I.&_IK_LRX
M]L;^^I.&_IK_`+,N>*DTOQ--13:DX;Z*>FZFWE=?GGT=-<[9\L?)E\_EC/E\
MV//Y\XQ[^8_$;9NJ;12-3()2<5^)Y6"%R(5\,N?1%W@>89(OV?PE%*MW"23C
MX.NGZU-)==/3?TM=55,8]+.1>V-_?4G#?TU_V9<>V-_?4G#?TU_V9<>V-_?4
MG#?TU_V9<>V-_?4G#?TU_P!F7'MC?WU)PW]-?]F7'MC?WU)PW]-?]F7'MC?W
MU)PW]-?]F7'MC?WU)PW]-?\`9EQ[8W]]2<-_37_9ESJB-L6G&'D7VF521X0#
MD4TB<,5)BK63./&#J7&$`C%YJ+4@8C5XD@[<I971U(MU=DLYREZ>VOH\L7C/
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MWJ?@7P+*._POX9\(_P"3_!<-_69<^O\`[QA'&^5O[WC;F(UE8\`MV`1"S:KE
M(.;5S.`(^1PJ71ETF^CLCCA%+U@LP#?(ZZH/13YOC59@[;^;=RVV36;[[H;I
M[[9UQQQQQQQQR+[.M6KZK0C+ZR)('".#TB1`PD>Y;N"LDD<I=,W?D)A4;%,R
M<FD1S`GXR=NF<:%OWS0&B3(O=$!#9\Y3E#CCCCCCCCCD'Q*^Z0EUG26KHG-0
M!&R!.AS<R(:M7S=P0S!BK.,RY,89<#6PB5KP$Z381V9-H^5,N(08?M`TD2#O
MG*3;><.........8'*;/KN%2>NH1+9C'@$NMTZ8C%9QDH10;FIT=C\6,34\-
MC8[;.7)1</%`!<\4R@GE%B-9*KN5$_22U4QB/WA31*Q2-)1V:QQ6>QAJY1<Q
M!CZQ#+3(1D#>%PS!?5HB$=EXP+DL6?R2-"7SHW%!<FC+\^+%,3P=9Y,?''''
M''''S?/R'E[MI!Z_MP0[L:!JN^O"8@U=*+TR,PC4NCJ-[ST20G#EWMAG%]M(
MLWS*DW#]=NHR$:I%5=FZ"B*N_IT'V.I#M#!EK(H.R8U9\-:2`M$R1:-N'.VX
M:4@O@VQ:-GQ9!JP-1X\R0>CWRH@X-'O\C20LHDW4&DV#IQ-O''''-"_8RD;E
M(W[VY@X"N9.2D7:CLMX8%MTI9H\>7>Q.-U[UIF=-OKE6D$O18K@H`_I[6IIM
M-6`$H4$E9FYM`,VA+4T6+%DVN^;7&<8]_P"'.V?Z-MLYQC^C&<8_HYY<<<<<
M<<<]$IJSW&O]"+;X:PV9.]7K3X$L1^%,]FZF'3?XO;HN%WWKD,J)?`T4%UG7
MI^H21544U3VU=]+9D#N3LS>EX/J&[(U#+S=6UO5$69V]UQL2D(I%:,J.8SY[
M!8NB?FX&.-)M8<LD]AS.P#`Z.)&!$"B;B,Q!)TU<BR!.5[4N........5=[7
MP&Z;-@(2'5!O6JS,G,!>]I`;-+3(&(F5;-&K]R0A2!:$AS9-FC)#J8%I*$W#
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M'OSY>6/?S1%TDK*YXWWDG4MDD*F;6`R`YW;,D:BGD:E:<6Z9S&2=@HZ1CTEZ
M^VF;;YC5CQ3N_#--+:L"/A21W$$FJ1;$`4@<2*3:!:;WN........4%[AAY"
M0O?PW#`:*S&0BH7W#E,FFA.+Q&228=#HP3Z=]HZX9R*6O@(P@VC8!6;6!#@&
MQ4RJS9)NS2"JJNC1L^<M*-4I2MNBNQ-&5T]JR3BC=(>([XB':^T;5>CW^D3.
MT7V&CG9?6H'P29NF^H*4F)ZI?]91E]"0QDB<B*E4R;$A&CFD:'[N-[^/FQY_
M1QQQQQQQQS59!$'\![8^*)8<ZJ:TY)7Y**]79/'&P>HYA+=+50KBF3[*2`:P
M9I!%AUC2@?(M&`G6/@5WKK4PZ8:+ZHHY4<HYCX>A5G-5^R]Q$ZJO"L;/O*V8
M]8]HM[BI6=TL/2>M:RB%=0>#01E8`:-&YRTK6MH!$P$PL34&FRE<V<&R(]YJ
M-48@8[LBXXXXYQY8\_/R]_\`[^7Y///E]'GGRYSQQQQQQQQQSC&NN/FQC'\V
M,8_V<YXXXXXXXXXXQC&/=C'ECZ,<<<<<<<BN7WG2U?&<1R=V[6$+D&S5B^P#
MEE@Q"-F,LB:KI`<\P+-F6+[+5^NQ>(LG&&_J7:K1RFWW4W;K:Z=M%+5K&=.T
MF$*L6"2]\O'FDM19Q>81R0NU8J0+%`+"2I-PY-ZLI'WIP(9#M#6FFPUR5$$Q
MR+K=XP=HHY[Z6OGY>ECS\\X\O/'GYX^?'\^/PX_!^'C^#MG/S9SCW9^;/E_)
MG_;Y9_DSS"B5E5V&D8V'EYW#1<L,OFXP1&"4I`L)"4(NV:Y%JQ&A'9!$H_>.
M6#5R];M6C59PNS;KNDD]VZ2BFN:^EKY8SZ6/+.,9QGSQY9QGYLXS\V<9\\>6
M?P^?NYU[LP)8.AK%\3'LWIETLQ$,W3ULW=E7C=FN0<-!K95719\Y;L&KE\N@
MUT6529MUW2FFJ"*BFO8\<<<<<<X\L>?GY>_W_P#7GSSY?1YY]^?+Y\^_/.>.
M......./_9\W./+'GY^6//Z?]OY?P_3Y8\_FQSGCCCCCCCCCRQ[_`'8]_P`_
M\O\`/]/.,8QCYL8Q_-C&/]G.>.................................?/
M)X_U?1O-8]-90"A@]U+RGBC="9)/#`B.ZD)&[KZKY/,57YR2.6+-R2WAT#%F
MG:KT@^S@)'6YAQNNHUR54RYJWW^M6\>K_8_Q2Y!U%"AJX.5[X65'6-0DQKKK
M_5A>3:6V>[13Z02X"$EJ]8G"T[8%UY9B3$JQ.D)/&F1&7.I2-CHLB94*;X2E
MW'\06']I@L<#=A;AM6"A/%FZBT.PCLAK^L-04ZZU=ANFYBQ+D7.&XU4P!76+
MQJ]68<!%IJQ?CQ-6OBBH(H^?969I-K[>"#VA[6=IXW,9OV0N%O()<RB@V.WA
MU]/5Q*XM/^N_:`%:UF-)J$46<U_"XS#8.9KQS!`\7J_)6?F$VL,3G^DL<+RJ
M2Y7U<+J65:?6CPA+.EQN8@.PTM\7KN39O8J9"Q39_+8%8D8(=OZZ,?&29T$?
M%1T97;8!7521K4X+=!X]'A4)",L+(-Q.=[%=.^S'B'=KY]X6U73;LY;E-#;D
M\..66_V6-Q6HJE:R8S?E2W7'Q(1F]?6%4LE'P66SB+C3C*91QLS',S,71D[L
M''@979C(1>"6IV=[32OIYXOS:Z9M-)#/NLD:!WOU3OFOT62=>N)LM?UK2;KD
M/AT;Q!X]8]&=A($6C,$IJS:-ECN0/7X(+'9BR6U%VB0.S7ZWHZY+/`(9V>9I
M#S;D4-<&&"&WIHL2J[)!4DS1VRLXSLDU?;N&Z>?7K?P$]<>M4_P\]SQQQQQQ
MQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQSC;7
M&WEY^E[L^?\`!VVU_+Z.<>>/Y,^[G&=<9\_/.WOQY>[??'N\_/W8QMC&,_RX
M\L^7N\_+G'H:_3O\^,_\YOG'GCW>7EZ7EY?3KY>CG\.,\YQKC&,X]^<9QY>6
MV<[>[/X/X6<^[^3YOR<P>*5I"8,8FQN(@F\?>6+(M9?,41:KEJ--2W+!N,>R
MA80FM@8A(#+)DP2D!9HT;O)`H.8.C*KYZVT<\SC&N,9QG&=O=CRQY[[Y_E]^
M,[9QG/\`+GSSCYL9\N87-*ZAEB)1YM-0+.2,8M+`<Y#C2F5G`M*5Q=S\81@T
M[&95PQ*.HV6U;G0&I1N];B)$/$R%@@@;#"7[+-N.....................
M............................................................
M...........................43NOQ//#SZX6,;J&^.Z'6ZI;0C2`EQ(8#
M/;7BT=E8-(Z+:FP^2P5\]T>#]B0=\R*LTW2::JXYZS>Z:9;ND%%*>=P?'V\.
M+J]U+E7:2(=@ZL[+9;G"=?UO6U)6+&Y/(K'MAF'9F=(=\*&*D\100+'E1)J9
MS(N/5&QB//VCE!J:-E(_'S75=6_W0_X578RBH#;DD[9TOU\E4G%:YEM-798T
M>B%@P"4L\:('`3]H14:)FQ2+STE(_+16FPB2B%&S]#5D]^,!([9UUW[;=9>W
M,</ROK!?547O'XN92CLB,U;,PTT8`3CA@D2;#2^X=VKLR=.&"Z;UNBX]5ERV
M]/=#?;&BFR=2JK\2.$-:WVDW9;<?`IF8M3O!"X-":JB5O6X3ET4Z,6A+Z[LF
M2BQT9A)D\[-*B8>M/-XDU&[DD@Y'+$+B2J!BI#26QWB/].RN-=V5J/E$7)_K
MU'PCG>M+91:2U3M<D6VZZG(0Z6@NB$TA5M.P!X/$I[&5"<+>2$&6CJQU`VSW
M8;?I!_$9ZAV!G&0UF%1:/R:VW:JKR;5C;%=CVT9H&5(PF]!KLC.X1'F36>TW
M)W3(79M7JKXL6&;OV+@W&&K5V@OOY%>_O7=2(20E&)B\?S</.)I42=;/(#9F
M]C#[9AM=8M,K&Y)6`F)/K)&#A%>NP]A&C>D;W&(0,R'D+1\X2-AM'T"=<?$N
MA]D5W`;(M4_!XJK.^KG0ZVTZHA48MR3V6RL_N:-L!]'8J#SM'%A-A@Y>YBFX
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M^J6"K0$;-+"/6!"V/56G^U!.7^S`$(2.+.HU"['+D)3\0#WP0<%`-GZ+UPL5
M9(NL]3\0OI^N;&B6USAG8TP$W.CIZR$2=Y5#E).B=NT&1N+9:A%J\3/[]==<
MW6D`5D295:N<Z2-)KNW43UW_`#D7B"]7H?"2\^EDMEL8!QO,G7E#:0U+:X:1
MQD%"(;";$FLT.10A#$)&SK^'P6QX-*I)/?BU2)BQ,F&J+%LN-U6Z7GV![6*0
M><]8J3J%C')I:W;HO-_DT.%W[QQ64;KZL(#K9%@VK(R$:V5(GPH\(^C(>*`H
M^Z9*S"4S2---I#'P6Q.0L(RC7B"1*`SB^*>[6885M.NOTRZY@#$ZB@*;':IF
ML6[=$"D>Z_3IHJ@,.FJY92"?Q^3U9+&\Y>*1F(34$VV6GSX-)1#O2<&O=WK4
MZ?(C<3PHU>.:)G?9AJD3KFT`^CJCJT/ZQB;3]HX+0MDV=,`AA=@EL,;K*2!^
MR-1TR+$/@DD`D2/7O.^/589*I!#S%IMP1*+Q*=3$X\D$9F0(`Q95='XO*K/"
M;R,M'F83><5M'IK%B4]KU-[O-XK@OHR+@6Q-@68C^P;]U.OKP(Y(I2H\S-MK
M6%48XKXI6]D,K:96R>BNL]"PQW3ZT63LS!)_7>^;-0RE&=FR]:-WTZ1=;1QD
M[((5IZQ^)[45G]=*$MRZ"@JM91;L8"R8^P!!9^:@M>BYE;DLIRNY!.Y>]C::
M-:1:P9C%W`"+&K14B:;\\@6'*X:[A2V&$SBO$8Z?%Y9((8C:S@>6BS?L"J;>
MR&O;0B\8;/.JY=`+V"!(3"20L5%R$HJYPX1>R.*CBSN1?$>^)"/&O0>-G^)2
MA/9^M[5A%N2JI?C^?'J5+2B)SFL4`!6,6:(L*-Q5C,F]?$8?,6H$J'DDG`&8
MV3BV"J#4<;%2<":8O5Q3]-SRG'4'Q$Q][T\5["SB5T+I3HF$1PE,25;R28/)
MW2MUEI'D)(.K]O5=(QN9R(M:*N2,;`#FBP8%*IW*R"XH;68+98"F<D`_WZBS
MRTNL,>K1NRE,%MFT>QM16_L5#SH':M23BB*%F%TK1AW6+D`C(T).HE$O@Q*-
MG!34PZ#GHV<BS,T..C7CCM)UXEW5>)0V/S(+)Y582$KC_5";1L9!JTLLT3,U
MWW.M-C4E'S]@@G#]?A,>-RAP^0((H^L."'8O<`1#MI,4!!RB.]^*A%!+*-V-
M8<>+XC%YWQ7`<)5=:W<9EPJ/T7J)=SG$QA+V(.I<N6K`820=VE+XZ%5KD=L3
M!H"2:[DHQ;O<L(^(9U#'3P577RLX*G3!?K^&;$XW"+&E$%06[4HN]^NQ`E9D
M>B)*NA4>N!TSR'@\G?RE".EY"Z'QW0IH;(-F.]T\9\_?_P"__O\`R<QZ62V,
M02.E9=,SXB+Q@&WP[,'SK]N,$C6^RR;?15X^=;IH(:J+K(H)^GOC*BZJ2*>-
ME%--<P%^_3ZE_P`8NG_MR$^\\BC3Q&NLN]S+5?FQ(CK&TX(E*-+7VDX_$&6D
M.Q+9!2#ID?1^"9,)B-DBWK\/<I;J94%>KP_2SIM*_P"_3ZE_QBZ?^W(3[SS!
M+=[3D`$SZ4LZ@^3NQJ_[57G(ZD*3'$@*.=0`V.TG<-T.)%%,QU!^/DKW9&ES
MD15"OW(O#<J7:/-GN_Q:[%NX?DOBZ]+!57S.THS,IK/!D3K(3;K(7'ZBMD>3
MFL&+VZTHC<W`LR>$A&LO:QRU7[&)3O(!4BO`7KUCO+6PI,BP^$SKOWXZI-YO
M)X$2M1L"+PX)99R0DY'&YA'(@.3I>*QR<7"(6FIN/L8KB4U7$9:`/6#$LEL2
M.*LW3Y,H,1>`)&U$8^AX@_7\G/*:KD#\I)B47%=L[H),7\DEF"2=?V#7M.[W
M@:'V:&-11@:A6CF!O8J?$*FF#1$C'9:/EJ:VL6''2HW'NW';Z:]/+$J.661"
MP2O3F=&E:^L.Z0V96:FM-6>?8J-JB92:"BF#EL4@MN3C+"L1,O'/M',>L60P
MF.E@BK*8)R$-ZZG>H;2[JLH7W#"MZGL>;T1=W9.7+P\3.YC5535I3!F!L##.
M9V+K&]F.)0U0L:.M"Z+;34:WDWK0(]R0R8A+N7Y`0\27J,)8Z+$IS+VYO+^[
M0ZT#2IBZ2%G-#_76*QZ=7!&WM;"Z_?3)K(XG"97')>F"5$:DY'&2[4Y%6YL;
MZYRC[8_Q'>G1)J\?MK8<:CVY;KN)8D'5=6FQ82;3MDL\9]<Y!"7CR$H-YO"K
M;*C2H*)3N*[EH>[D(<L!7-MRP]=ICTWGB5=.AM<KVJ2L:5,84.2+:R1\M2-\
M*$8.8!V<]I8I#[#CS6LW,@KZP6]L#W=?)UU,1@:<O93IH+'1]XJX;96ER`=M
M:(LVU#%,PZ7/B$\$,[%?)-'40F0<+($:>G`JLK>TB$L,@&$7ESNJK%."(/8;
M&/%R#V)RA\D)*H(.-%\(UO"]I^PM[27M&YZMP&I3<&ZOV%-:+9IVE(9F!/7O
M>];Q\25L&-Q\J#&+":L@D6DAII7"$Z,B+&?R&7#I4Y3B0:.@QI229N8\1?JQ
M"7$S#V98>L+/U?![)F-F:[1B;'(Q'5Z-A,6GM\Q@9-0<:(QF72JGXY+@Y6:1
MF+$BQ\<.4=N?BY3(8^F)[13Q"^J.C.7KZ6`;<$H-,U81(8@VK*TEK#T()5L\
MN30V'KG6&^W$HA#^IAQ"Q0D^C``Q#I%%&+HB`-$]T=F_,N1[E]?"I0?%PE@:
M9E9^W6W7V/CRT.L,<T4NHQ2K+L'&X84>+Q1)`9J?J$H-G@8T[7;@385QEN&+
M/3.FPS6O%">)94,KZY]8+:OHT#JJ8WY7E0RTZ'$M)8>A$`(W/+]JW@GM-,=@
MZC.(1>965IM!X;(YRY!M#1[7=EE5%1%SE"WU/=C*HOAR?;5F9,&L1X9'9`J_
M?0V8QT(;BTO(2P7%)=#9!(@0L).(I(GD&E.@N01)^8&K:"LK*+)).V&[J<N.
M....................42NOPP_#S['V,;MZ^.F'6ZV[0DJ(EO(9]/:HBTBE
M9M($+:A`^"QI\RW>$-AH=BR%,U'2BJJ`YDS9:;X;M4$TZ.]V?W/9X<7;'JN9
MZWP.B*OZKF&D@)3ZL;5HZM8W'ST!L@B,&B7AL@+&_$VDWC)\8&$")A##!1LT
M-"Q@U4:0`2`,"/#/;ZN?N>#PJNNE%P&HY)U,I?L'*8R+U]K+ENVNH],+!G\H
M>>@N;.OW9%)VF%%K//23`1,3OJ(C8A-LP0V>//C`J1V===^I'67J/')!%.L%
M#510T?E)A.0R(15L)#0Y@=.-V"0QJ3+HAV[?9^Z;,4$V:"CC??*#;&Z2'J\*
M*9VI+'O#2E(E6MG9._`A1Y7=A^(18*6[2GG8IL57[]E9G("XM1NI;!-1FA6)
MR<%%!;K#ETK*Q39@/>I`GFCDLXQ\)X64@")U"W1[`"EVU50/PR8+C56GW6JY
MU'PTK$L"PXL2V5TM?*8Q6UW=@OALB;:H$-(LV'M%Q:Q=91?7/A(_"?S,HUO#
MY-?&^03L-XE01^L`K306;U2\1:U1]PO"`IZ2GQX<S)TM+1(WX@^,0YH7-A[;
M+60"QNB[C53)`OA[70)5H2QDNP5,A^P-.26TM3TC@'4D;6]*6+7%SUU$*\G\
M;)4Q&K@3-CIFZ<5[";"$V"O:AKXLF89<5I&MZ\>)0]EA$'\+6U*W@$+BD6[5
MA]2L.H?H#UZ=/GE&OD04[K[HU/+4E#@%-PHNZ&1-T!NP#;!2-S`.`DD?RPW`
M!G"KX]'B4HAYG"QO@NZCJCC=8H=DG#-U'.M$LZ_M3["EXWADD48]K&G;6C)\
MRB9*7D0236LYP.'@IE79)$U%[3BR2XI-6"H+YQBZU=]$(.U&U1*KJ'UA/+VJ
M"2GYO#)G5=;FNO57Q>6&EPSC#B-TU#[',-UQNBT<".7^M@2ZP3I1VB\SN>:C
MEV0H95]MX4LDC,#Z?1J$WK7BD@ZSTW,.NDN)VIUC`6]$+3J.8EXZ>R^$P&16
M.V0K>VHF8BXXC$9LD>E\=QL\.#99!I2#(MQ@_([9\,J7S.?2RVH5>%=!9\4[
M/N+_`(Z/L[K>QN&KT(O(.KU1=5YG5LVK]W:,4S+<DXQ2D'G,<G``[`B<3G+)
M=)`00BCQX!<=58WA@V7.;5`6"W[,1%N/@)(<1JP5)NMD>E;B"#U>F%C=2Y;`
M&8O6P@=7;U9)BT]7N5W"A]7"$2!]8U#Y8_E,5S$4HCB[#PD3\1$U?FL;FJ^)
M/:YE%Q-F%<S3KP^O/K=&J<O`'5C275=4%26E<Y,_4Z(2:U&$MBMMQMC%H77\
MHD<VAXV`.:N.)Q%K?*[^I[*R#G7&S(1*](-=?5`R>(U',R<>;2"./04V@:M;
M6/7\^A@=[#VY:&3J,;#W+E"-$8H1CTMC41D@!T@@#5!$X6)^'JRGR'8XC<$Y
M#S62]SG=:P[M,BTAI81$97UHK&-R.,!NMM=C-YZ]D%>@2C.62AW))ZK)I'+"
M16;STD*1CJY6+XA-?Y3TPLB5E^CG6JPU;5M77K&\5ELH[GH!*[KV%S/KZJ/D
M\.-=1YV$3LR1SV:RRRA4?J099NS.$#(C*0,;'V(XDXB7,%(^YSF3>&/+Y4)[
M=U"][/F!_6+LY.+4N8%7@:M&"%IU9=%O/@\L/E&]P/YB1%RJM@%JBU[7B->[
MUC'B;>1$E`DAFY^),FP;?(#/A[V&5L41V68WK%@';)GV'KV\R<O:5$1>TR8$
MPWKE).JYFM'-4K6@UD^`\KK*:RTUM(]K15D@&?NP9!DY=Q>.(QA]"T+\'PA%
MZM.4P5[%[2:!W#2\/H7L@CM5;400FD*K>];<N*$%ZTWS.##6LYGN"NN:5G+B
MI%*;#B[#2-3("(B\B`*-RN3S7PDT[$&'`4GOI=(/))OXBDS*9C]:I#R[=7O^
MV?[K(!7Q.=&Q[5U39QX@9"NR@8TPFVK!`8<""VBSS+FXE%];K.K*AYY7LJM6
MN%K8G8PVW7L^B>OH'KS%@IMU#48D%EPFM14PF;K>2LW#9&4EB!>=D_AQO?=D
M$3C4;:"0S"I\Q\+8I:,GL>T9[<L8`WC,*MH*%(VC2].)5SM+;`ZX7=`>Q%:W
M3>4:)3Z8-;5E(:QZUC8H:)^-(]H$K@M8,,&R#5.8-'L8E2/^'^2:W#`KU/VL
M-<S9GV6MKM!:HX-7^PV-3&76;U/%]/64=AJ*TP<$(."B=8@`#[#XRO/#$DD[
M%R0?JL&Y#9HVK/#_``BK$`PJ/1,MVN#O5Z_H+I=0=;DA/7Y,<F(&]#^U2/96
MF)7*&!"X3&9.;/(M&T-LMBQ=QH697RI(HPG$DM=02LU,O#EFT3LHK=%?]@!X
MFRB=M]P9=OH;JKXZ@F];=SVE0*SN!DHS[>MR).20N54974NADXQ(&0]QLP,Q
MP["G`PYNZ8="Q\*EG%A6T3@=T;!X6+CWA@P^(C)!7GM$:#1CPQY[B>PMH5-L
M9S&FITE:#O1,9(2#<(#;QIEKLH+&E%]M?5[=<8\ORYS^7.<\QZ61*,3N.E8C
M,P`B41@XWU:F`!U@W)B23?59-QHD\8NM%$%]=%T45T_3TSE-=))9/.JB>FV(
M"STLZF>6?1ZZT]C;Y]<[00'MKZ6/?CTM<MOX6OGY>EKYX]+'GCSQY^>-:R7@
MU[IRS25YOD$KG22:R+,=4I%IF*J:8+X*Y`;@L3WX)F.[)^8O(K&N$,"\_!L>
M[&-N;*L=+.IGSYZZT_Z7SYSB"@\8\\^_/HXPV]V//_!Q^#'ECSSY>?,8M#J<
MA)I-U#(5<<A]21+J?<AZWQT&8UQDJ,E3@[4-KU`M'FJHR711O$FN!MP2:0+D
MTQD@=/#S<:HJWU;_`!@F^H*]\&]8A4X.KW/8[=+V<ZMVUUV%2%C4:.B^IBR.
MTD#[2BK!=#'EDO&Z[2+R.NP,9=PS5TEM(@[@J\UEH%XNT39=K>GA*2OL?9=E
MRRUNT"I"-3X7V:BP]`+4N@ZQH?!.R_7Z+U(]A$=GKRR"@@<`K";Q9"S:_9L(
M.R0=[$BHR;Z2F4.E9^M9</T^O@^9ZP6/>':`#8-R==[F.62]D<1H=M7T$F,8
MDM#R>A)##AL">6?,B4/+'1<G>S<C,%)K*44IJY?ZCHHSB^1$?#2EV'ZFB^U#
MN2Q"\B<9G?7<U6$GA[>C2,1,(-E9Q*F*X=Q9$HE32<I:R)S'0KITA`1#*-1Y
MY!CCI:;"))O+FD>*Q^K!'P\.PA>N:7&$^]$B=7C4'4KLAU*V["Z4R-3F$P`W
MBUJ56.V.58+6.[^+;-A!NEX<_.R(>654G2"\A5::0B3$F$H#X;7GA0GH7-E)
MTM><.U=.+)[,6>M'8K1Q*.QMJ:[-=8:LZ\2`<,T?W+(2FHV-D:VWGK-T5?ES
M\B5/.A4A,K%=7,K>1'<_AW754T'H3-03;%H22($O!VI!?#2I=_4QJ#>'Q?,L
MFQJZ9`,S:Z*Q868BT_DJTHA0AXT*M=!PY&+FWY1?"2MBV7AL3UG)H3+];Z@[
MAR!N>\^U4BAANBBYRMS7;.XY%J\`7(TC:5W!%-$J(B>JD=IN+GW<A:CI,]?6
MQ(WYV?(QI[&,YJ#H78-?=OL=J9C?XNQ7+1EVGB[0<[JA<1-B5>]B9_4=AQ:(
M22>[627&;M:2=5:E%8<WBD%B4>>Q-\DHO'&4M5D\FDTAPGJ5/Z2LJ^C5`6U'
MH;5G92R#%USF`RNNGDQ.P2YY@)&![)G%22U"<@&(]A8.0@J4D(;-XO+PX2Q-
MC4H&.%0QUY#=->'?;PT;XL0#VQNJ-7$O;DV,4]W7C]+56WJ5CFQ'0WL[U4%T
M2*I-"Q25G,XTUCD7F01O,8VZ8PN+C5=I#(%9HW*R%3><ZRS8_A>2?L&%E$RL
MRSJ_=6=:SVHRDD*[TE)XLXAC&EZAEL%I\W5)..7.'M.F;TK^661.K!4M:*V*
MF2>8+[5@J)1AJ*JSB1B'AQV+O>(VSAO99HK%AO:>DNWBP"44^F?G$CL^K>H;
M;I_)64EG@ZQXT'7CT]BP@-.M\"("(+`IPM(5</RX-^.##,)K/PJ)-4Q+K4I&
M[Y@!P/4M"5EUWM)E8/5^)SDE-XM3-C3*PJYFM.&3L[=*4'9S3%@S",R(VY;6
MK'3@LD+*H18;(HN!(MK0=*.EKOJ0]M=_M-X\32M1U%RQ>&5G"S56U`E-Q&\F
M<2ZV`E2OI]/8M7]A6TZD316S&M6Z0J!2![%P\AS$-)._.%GM]>..........
M...........<>>,?/G&/Z>8^4EL6!O=!QJ2`!)!4*:DB;$F9&L'BD=C>6.LA
M/:-7;I%?8*!V)C=3175/+`5L08X?N&^7;?UGD,E<7-$RP4/(P)4P!1$.3@D:
M8'/B89O(&JKX"N58-7*KL<@;9(+O!"KQ%%,FU15<L=ET4]]\=]YX]_OQ[L>>
M??CW8Q\^<_R<KPZ[:]9V4[?5H\O*LFDU&2T17Q`(ZE@Q#9G8A]T.9A*Y</U%
M=1*=B%G)86D/@.Q#$P=;$67J0FV'*.=[#>GIY^7I:^?OSY>ECS\L?/GR\_P?
MA^C\/,3GD^A-70N4V-8TKC\'@4(!$I/+YA*"K0+'(U'0[;=Z4-FRSY5%F.&#
MVB>[AV\<JZ(H(ZY4WVQKCSYD(\BQ*L61,:[;O1Y%HV?,7C9755N[9O$$W31R
M@KKG.JB+ANJFLCOKGRW3WUWQ[L\Q2=V77U8,`9.Q)I&H2/D\QB5?1UY)C#(.
MW.3F>&FT=A<2%JO%4M7TAE)UVV$@A3?UCLF073;-4E%-L8YTTBNZH(E8\+I^
M469"(_:ECH$7->UT9D8P=-)TW#MUGAI:'QQTX3*21(&R06?F]P[9YJ&8)[/B
M>6K3'KN=K!;1KFSV!,I7<XB\V&AI1((06?Q@TQ,LQTQB;QP-E45=N62RJ2$A
MC))H\&2$/OM@@%),W@\DW;/&KA!+.O2U_P"EK^7'T>?T_1[_`.;W_-QZ6O\`
MTM?RX_#GRQ^'Z<XQ_/GRXSOIC'GG?7&/?[\[8QCW?/\`A_!YX\_Y^,;:Y^;;
M7/G[\>6<9]WEC/G\_P!&<9_FSC/X<<C\/;57R&PIG4H.PX46M*NAD=-SVN!\
MF$.IU#0DO3=*Q,U)HHD[V.!0TGT8O\Q\J_8H#S&6+[4>X<;M'&J>'*=FNONI
MEY'4KCKQ\<&6X$H0L+%2<<8>!;JD0U4R'JPVB)5>Y"SMX(2R3Q&BOP,F@P4;
MNG:#=%TVW6G#&VF?+?&=??C&,;>>/?C.<^6//Y_G\_+'T^?X?/GEZ6O_`$L>
M_P!^/?CWX\O/S_)[_P";W\X]/3_I:_\`E8_D_E_EQ^7'TXYA(2S*^DLUG-<1
M^:1HS/:R1BB]A0\:89/)%"TIRP?E8=O)A2*N[L/B3#1A!^$^&II9(LV:[AMC
M=)/.W,W]+7'S[8Q_3CZ?+_;[OY_=QC;7/S;8S_-G'T>?^SW_`,WOXQG&?FSC
M/X/=GS]_T<YXXXXXXYX^GIZ?J_2U]9Z'I^AZ6OI^AY^CZ7H^?I>CZ7N]+R]'
MS]WGY^[GER/+.MJM:8C&9C:DWC<"C6Q,8#;E9,4;C4'YXVYPS"1\4FKM\)+R
M`T\SAH'!"D'I<JY\T&#)PKC.N,%BO:?KC-S<7C$3NZLC\GF9^3Q.-1@;+Q"\
ME)RN$Q%C/9E%=(_\(U,-I-$H84&R>2QY\R:F`00@Q($V35N[;[*3YZ6N/?G;
M'E\_SX^;.,YQG\F,Y_FQGG'IZ?\`3U^;&?\`"Q\VW^#GY_FV_!G\/X.<^>/I
MQ^7'T^7^WW?S^[Y^12+O6G#D5G4X#6;"BT/K&1RV(6')1D@8/@L+D\"=X8S8
M#)"#955N)*Q)YG+:1,W>Z:H=;7?1]A'*:GH]3'NRG7Z6LZE(Q6Z*RDH^^TRJ
M](/P$S!&&-OM0;3)$R\K-X/>.&\X8BAN,DR#Z-J$6;09CXQ77T9?W_DSIJH.
M$]%$U$EDM\8VTWTWT4TVQG.<8SKMKG;7;WXVQC.,Y]^,XQ[\9Y^GIZ?]+7_R
ML?\`_><^EKY^7I8\_?[O/'G[OG_)^'Z.<8WTS\V^N?YML9^?S\OFS^'RS^3/
M(^L^VJMI6)+3RX;#A-7P9L2#"'<QL&3!XC%69.1$FX8"Q?2`\[8B63@R8=LQ
M(O1V[1^'$WC1@VRHZ<H)*>Q-K0KBM58<VL"=1*%N;#F(VNX"TDQ\8%=S:>F&
MKY\*A<1:/W*#F1RH@P%E'[,`'2>$UF`PB]T;9:L72J7L06PX39@1S(X%)14I
M!LY+,8<Y)B5\KM$9-7TL,0:9AMM]M$\_#8]+`!@$1TQKG1-\P7T3453QHIOF
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MF(F9&`S#I_T?\<:'`K(BD6[P0*A3K"P%"LSWGG5D/.']I/I%'P[^/V*TN@S%
MW#ZRF^\8T&1+<22=H%JEWC&M9J@PP@*"R_VJ=3NNOBX5_=063]K_`!`ZHO6E
M6@*4-3E;1;KG'(6<*FWXO9M%R323L!8AP,T`%]DRSG7"CQ,B@WW%[L=L/</&
M6,>&_D%6_3ZG.FG8>M9;GL95$A1$W;%#L#F!H?,K8%7$[L(WV>'3L@#0A<MA
MTYE2J/8%E:#*2.-FI(AD.[W:V0)<1)&FL"DG;2N:?Z@6G/[#[SR$M=L>[K5Q
M?`TP-MR1&H_-V4(LQ+K$BA7(>()EJO,DG`4:K&)CI'H^U)G$@#TJ<R^.,]R<
M6&9WW(LZEK.C4]9]B[+>SGPU9D),Q%Q'[]K^>0NX"OALQE@>B,\HZ10A6MKP
MAMA7D:-O(I9\"=12[@7868*U,;ADNAH)N7C<BE)GV:I[:908K+NWX[K+BQNJ
MF)78:5<=F+6EM:1^S.B<O8R-S`TJ@<1*X4:]#=FP<`UG0&JRZXJG9X68L3,9
M!08C+(]G\+L+=B#!")5C>Y3M_94JKRQ/!KL&ES8:D+1!1*Z*WAU\TH?[2VC9
M];U4%ED%&6XPG;"3R*VH++'69%6,>"5X\A+(".?'MRNT7Q&ZK)]GX]$NN%4O
M3M=]F6)#>\Z*[,ZQ>88C75V95^U(MQ=CXF0\6G&2LCDFI-]6KFI%)$D3FT`F
M,V?&PQ"'!2B#NB`Z56#:@GPNK8B_7_M;UZWJN.=R8/:E.0J!6MN[K*\V77PD
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M3F`35\F`F-B2S:'I#C-.0?8I%9`HBV+YSX@]8P\,7[G%:=1EE\57/5K[BMK*
MART4&];J9GM"R9^W<0<34\4$N"X^2>SU@)OWMJ3Z5DI\WL\\)*9V@@W(.T5?
MWK$^\)CN'U4JHW/;RK=W4G7J>1Q9@5CP.UNM5^PU^"SA*1DAS6.2MKUO[%)5
MA=YO`LPZ<Q*$,K<'.-ACZ4HYWANDH5;'7Y>0P6JT;\$-W?CBP@U/C@ROIV)1
MN.H9W0=:,;EM>6O%(MNT.53-K@&R^1RR9,2'L@/DR&6SR0:-4$V[KJ8;;'9>
M>]6AAWVM\0F(=G5;,Z'PCMK%"U?6"*C=<VNS[=@A_:G>G%"M=K?"83(:3-S)
MX<<TLJ6Z]`*3@\(EB2XF8R!\7EDK$CO;N`V08AP67]F]+'J;LK((:QU,M)I:
M\-EWAT,.J!=2-W%JV*:+UO9=HC;&',Y(I*7CMQ<\I[%#MZLE+O2%R]`&I6F(
MW7=;4OU=@78BY.R<&@UDSKM7#+'G-23WL@5UM,/&NC]72:/3V`#YA"F/9:DW
M`:=I&2T@KU\L:Q5_8=Q)X+#[!E80B@-1]NOQ7<45-H[=5FJ=E@%_L(IX"HFV
MWD)B,_$1ZRR.]MV'&^Y;.>QN+QEQ&9PUBM*6";-V['D=7\:J<V3W/-D8X9%!
MGS;WR]A=U3T)O@\A<O<:,7O&9K`Z]MRD8SUVNH?'(E(4O$(K-1G8-2V;*59K
M!I;&R75IU83=LVZV`=J_D])K9EUKIB)9%6;PE-!0KV3AO82XJRQ?G<:%%*('
MVB1JS1GU\NGL?';BZP/.IGH0N<$++-2YO0\VGL"O-1])\LUQJ7962VC$QM:K
M/#<#GR+3?85X:Q^UC]+312WDI$YD0ZTW0IE*'L]MF?0B;"F5<ULEM*JH<7Y'
M8U=<4B!$QJ7S(Z\L1`X1@-M:63&`\QEL:'ARZFQ#CCCCG6ET"+@:[0$/4QY)
M1/&&CQ9##E-!3&^N<[;(;?P=_2TQOICSQMC7.V-_1W]'T<Q]\16C^.XS_P"H
M2/\`]@YUGL]9?QSZWVI9>O\`BOU?QE\1H?!_5?#?3^`^CZGR]?Z?_*?3\O2]
M7_!_P?=SL_B*T?QW&?\`U"1_^P<U[=O`,VA/;3P]>QTZ$2&>4-2C?M)%K3)1
M..'Y)M5]J7/$((`I:\RL(B8PR=<QP`""6G4AJ8CQ+KY/4;>P?,8&11])38F,
MNW$6C]VW5TSD5=`+FB<0/7?V6E%E6U5<:L*!29PV_>!V+6@2Q=IU'@J,JB:3
MY_O#*QB,S?[QXN?*"!PF&.B;!0>Y?51Z[3GN+<$TZLP6^+:[?4[81.D>F\I2
M:">OMTZAK>AYCK>TC/;T'9E@M#$7I:G[.!W6_GQ29OK*BHBZ*^,@JN/U!LY:
M'&,?,9;US?\`B/%[IK.KK?0OEG!90*$]>;$M)>1'FS,98?A_6_K(YSV48*ZK
MX1!0?Q#:E?!H&P29:)OW\JCTI))LA`,DD\=1I'+A[G;U1:]EG9]W#6F0$E2<
M'[KT8'ZV72&(U`R:=L!:78:R^L\SDY27(3@UGKH7F>L4:=0Q"\.>U(*CMD"!
M`RTV,94-[`_#A)L*LJ7N_,CXFZ&D(0[S]GK*C9.=5U<16>2VNI+O#9%%S\6#
MFHJO9-HCWHY;`R,/`HN4'3>K!$0X<E)&@_\`3KKU7@4MZ\]K#T()U198CKYW
M/JRS+.ZEZ0T'8SH-T'/RJ1^T5N==),:8CE0=(9["&CH6^(F0U?P]E&;+%3RE
MAR*02OJZ<$J@4=/>S57Q'PYZXC[?O-'Y%`81X8C2UP=@0OL*K&=0TLM655/W
M`![`=X.L.DN1CASJO:4CO`X05KH(PK(E180='#CB=K=N_P!^ZY&GR3]6SN_F
MLX*]+?%;,+ILUKE%%,WA0G:)`KT(39,1L388`3>50$H=VC84*W$NK]@C$:#D
M@N<1`:,%:RW7%S]A+)[#G=(Y<G9-_.(%XACN)SVOMQ,]3K*-].9)T'J.<W)H
M^C^8JC#VAB!6I($Y!7F[],E8$3MK8;7<>')LII((\>Z./V1=1&)M)P8EOB#@
MQET737->0^GSS'L\BI3%--J\M8!!9=V0FH2`.;?CUNW79+419UD1^DR(8=#)
M6I3E!FSD)@2ED2617@W9$.RWA$=<8SVUB,\G1FZJTZ:Q+LM%957,PUG1QX9F
MU3#[R<RN#CHWB1A7B+9K+Y`;?Y!L6P+1HO(L;LF;1)UI1B,5IVQ3E_ARX[1P
M6=&9'TI[L"NLT'G;".228;6+5<0J3L'%)!W7DSV-ARFL8C=Q14SUI@Y$W,W(
MO0)-!=GJ.%6X:5ME-.]%VYV:9N:VA=R2COD"@TE/]_!-5V=5E;V<>LM[V$AG
M?PR[ZRQ6PFK.O"`1"$R[J6D`;5"O=`$9UGD\5)RMS+'3A\*CA./R/J1[*C9-
M95BSR;]NWM1O/$]LVH+4:CRMC`4X!TC5"'9%7$RJ\/'!023,:]UN_6!QB07/
M6ZKT^.J`M*TD96VA@@H9`XQ7,\[L(6OU<`V1*+MF`-5PB'="W'RHU'832L<=
MDNR#.I+RD1`7'RE(7>YDO7H+4COMC5=P)UY9U7QT"&L>&'E9;/3,/D%)8_+N
MSO8OII5\@!3[M'>47M+IWX;DKOKVKB\\E)4'VQ"=R^NI_:35:P*193+$@I2@
MJU)G:C>`@UX9\10V`6E+D7!*4^T4DLA-)MVX"+26FRUL=T*SK9;L#WQKBCKW
M`TIV,[#6&&G;2RJ6E759J4<Q0L"*S>!NXN:M0;44HNA>;=?IFR$F(389)^DP
MB[AG*5C23L_$E>S=O'I]V^6@D;\0IA5LK'"8C=<K$PWI8?J&I#):P*KJ6HG$
M.LN51H)V)8/!!.?TI)#$OBM>/[1:`9`0C8XIE3*NO,F[2ANT766&R^VNP?8>
M`H1&!BB\CET*M7K5.QX_Y*K>,#;&L"L2`Z04M=5;3)J5A:-G.Y?):\[,U!;0
MF")G!9[$B6B33?YCYL>[./=CW9^?'\F?Y?IYSQQQQQQQQQQQQQQQQQS\U/F_
M^;O_`+O.=/\`OOY\?[FG//GY_P#>_P#TG_\`%YY;?A_T=O\`V<;?/I_I9_W-
MN-OGT_TL_P"YMSQU^?'_`,W_`',\_3GAO\W]&?\`;KSG'^%G^G_9IS6/XQW_
M`'.;L/\`Z-2?_7[JGFS5'_!W_P#"J_\`G-N>7T?SY_W]><[?-C_2T_W]>>7/
MST_[W_P>O_LYX_A_^F__`-.:QNTW_='?"Z_F[R?_`%@8OS9]K\V/YL?[.>.O
MS:_S;?[<<8_PMO\`3_\`X>.<Z_/O_I8_W->>7''''''''/';Y]/]+/\`N;<:
M_/O_`*6/]S7GCG_"S_I:?[,\8_PL?Z6_^S'/'_H__-_\[CGZX^;^G;_;GC;Y
ML_S9_P!G/#_O?_?_`/)\Y4_YM3_0V_W<\UK>'K_C#\3C_P#>56#_`/XP]3>;
M*MOF_+_N[<YQ\W].W^W//'3Y]_\`3S_LUXV^?/\`H9_V\;_/I_IX_P!FW,?E
M'_:M(/\`]2&O_5SSE'O"@_[F1X?/_P"QCUN_^M/%N;`=OGQ_H;_[=.<[?][_
:`*6/_;SP_`G_`*?_`+-N?KQQQQQQQQQS_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g520844.jpg
<DESCRIPTION>G520844.JPG
<TEXT>
begin 644 g520844.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!`1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]#34%87U)!5$E/3E]+7T)!4BY%4%/_VP!#
M``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``+"`#_`BX!`1$`_\0`'P`!``$#!0$!
M``````````````@'"0H!`@,%!@0+_\0`8Q````4#`0$)"@8+#08$!`<``0,$
M!08``@<($0D2$Q075UB6UQ48(3%4DY67TM46&5F!L=8*(CA!459S>)&RMR,R
M,S0W4F%Q<G:4H;,:5722T=0D=[2U)28G-C5"0U.&P?'_V@`(`0$``#\`S^*5
M$/6!ES4?A_'KC+=.F%L<Y<<HG%YED28E96S`MPU%RXM`FHMX619BD+5!,B*S
M\A3$D52>*B],S1!&DML<G.82MK*L;T3E$M]W49->V/&1HAB=>HQ%A[!NDW/F
MI%3*W)P8\BP>,ZNC35\?CL9BR%D=&AZEF)H$F49)RBD<WYO2=RS&N.L1USHO
M/7MM3L7Z\W&?9;@34MQPE:L(YPSWJ9TS80R$G?UBR1/63]*]^1BI6OE<?.9D
MC0SQ#(1N%,VCCU8W/C@N!'`F56Z%'F3TI'%KC]YI9=N_,,L+LV@&^,NMLMVC
MX@VW"`;1^\'C&N$5B0/&J3!_6>5[5..H_*TWGRO;IQU'Y6F\^5[=..H_*TWG
MRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[
M=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQ
MU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_
M*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F
M\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGR
MO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=
M..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU
M'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*
MTWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\
M^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO
M;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=.
M.H_*TWGRO;IQU'Y6F\^5[=:@K27#LM4IQ'9MV`<6([/P[`N\7A#]-?12H0ZW
M,8:G<Q1"-0#`QFG\Z%O"]PNS5'<Z*<JI$L\C2<I*8RP9(IQ=9:L*BKVY`==D
M9O<#;R);&DXPI0GN8WY_`Z,.4=`.:LHWY=2NLWQ<WH-9^*]+L&U=F1XB:L9$
M6?<!OJ^^8/.!6%38^]TFG*^-W<W%EC/+Y#%E$*N9&2?@ODYQCG"3O;XOT*9`
MA66L1$NLSB:G3_IPU(ZK]4F(&]NODEV0':8ZI+,K<!")B@6);&%!%\/W:A,U
MD,+^CD<B<IJB6P,I:QQ-1&7A3(KDDEBD7F38+++HZR2=G%2E5W-4@:T3PW7*
M4AG")3[T3@2H37FIS!&\J^XL;K+A$;1`1&HK8"P7A9ZQFA7N^)L<N:ZZ59-3
M7+%\,CZM5<G091F:!"3>>>WWFW%(T*9,C2V77#:0D3D)R@M))+LMK-WNV`^9
M;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/
MF6Q;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8
M#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWN
MV`^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=
M[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NV
MG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[
MMIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,
M^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$
MC/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]
M1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%
MO42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6
MQ;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#Y
MEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MJG>6-
M.\7#'LEY$L+Z;0RG<F260^[*<#`8!:OO<D5BJZ2!#V^R2"DM;+EPD`UWV'"N
M!(!M]J;AQ"'>YO)G?5%@9'G/4!IXT>QA!.5*Z_'C%AV&OBU4WH(W*9?#));,
ME4Z;A*.5J7:-D+F06.TLFQO5&DK[!4%EF7W".]VP'S+8MZB1GW;3O=L!\RV+
M>HD9]VT[W;`?,MBWJ)&?=M.]VP'S+8MZB1GW;3O=L!\RV+>HD9]VT[W;`?,M
MBWJ)&?=M.]VP'S+8MZB1GW;3O=L!\RV+>HD9]VT[W;`?,MBWJ)&?=M?6BP+A
M!N.%2WXBQLB4"5>0)R6%1T@T23+RS+RA,*;[;A+OO)*ONLV[T;B[!$-MMNRK
M-*T$0#QCXQV!_2/X`_"/]5:#=:`[!'P_U"(!^#:(!LMV_>VB&W[VVM=\`CLV
M^'_IX]@^(1#[X`.T/O[*#XOGM^D*H7IO_DH0?WQRQ^UN=576E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4IXO'6W?V?SK?\`F#_K3?V?SK?^8/\`K3?V
M?SK?^8/^M<9EUHV@`76[>$)^^'_[MG]-6VMR&NM#<]=/NVZT/W/*GC$.?/*-
M7*=_9_.M_P"8/^M-_9_.M_Y@_P"M-_9_.M_Y@_ZUJ`@/B$!_J';]%:TI2E*4
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M&DA'<6.J(ZF<KBSS0L-56FRA^CC4!"2W]T/M,<RSKK1`""S;MMH11P'DB8(,
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M(S$EN1'NY26R+4Y+E>GM9G:XZU,-@-JW?<7OP7+=V?W4`;+!'5_.MHV6"(_!
M+$GA$;0$1_DZ^^/A_P#Z"MWQS^Z?]+Z==4L2=G5/CG]T_P"E].NJ6).SJN5/
MNS^Z?\83".KR<7`"E/=O;X?B$RR[>G67`%]E^.+K+[1$`WUE]MUEP;;;[;K1
M$!H%ICW6/=$<9X*Q]"8)JAE\:BK(FDUK6SHHMB\XA+W1G4K>5H@>O@2Q:?<H
M<G)8INO4JC[[>&`DNZQ,40257CXY_=/^E].NJ6).SJGQS^Z?]+Z==4L2=G5/
MCG]T_P"E].NJ6).SJLI;<1=:&IO43I7GLUS<CR?J'E39GB31E!,D5F'&,IM8
M4<)@#BFC=R0U]Q]<88B7.:]PN4`S*K;[72TONF:)?%DUX_E5G'1WRWZ7PSVL
M4Y59QT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]
MK%?8AR9,E9XE'X&RBW%@5>8"A8ZXDO)&^V\JVTD`19.5G<(9:9<9:(E`4%I)
M@7F6WB7;?6&E4PS!AK&^>H0KQQEB-ERZ%+W6//:U@/='QJ2JG2)OS=*8TL/.
M8'1H6F&LDE9VE_;0N5"6E>&MN<2[`5H4QI7A<C:4,`Y9E9,UR!C\B0R`66*Q
MMX.-D,N;VV;1N#28V9PZ.9.C[1(&^/97CT7E*I>^L+'DIJE;6UN+J\GI$I0/
M3M8M[*/:9<%Q7*KOFM@QVTMV2'E3)EZA[*5O)J%$[S8J/D3F0L,74N9\1B\I
MGI,5CA4]E4:86F13BQE;K94YNP)K=M=A\7SV_2%4+TW_`,E"#^^.6/VMSJJZ
MTI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E1$W0#[A;63^:YGG]F,EK\
MNBS^#+_)E_J6UNI7(3=;:<1===;9:!Y.VZ^X+;0_=;`\-UP@`?.(52_#EUHX
MTB@6W6W"!#QM"VZVX;=LG?1#?!:(B&T/"&W9M#PAX*J92E9S_P!C*_<*Y4_.
MGF_[-,35D8TI2E*4JCN<<\8RTZ0Q#/\`+#TM8(NXS;'^.TB]#'9');[I9D^9
M,L`A2%0DC34[*D"-TEDB9VL][<BD;"TBML4O#F@2@)M<.3,]8]Q9(8+"GQ4[
MN^0,F*78J"8]B#"YRJ9R%#'+VT)9(RV9J),%LA\/+>&F^53)^4-,79#G9E;%
M3J#T_,;8Y>0B6KC!TURZY868),M/EJ)\GD3;ERJ//B"'RJ:8I[G\JL*ALR6(
MB8]*99C471*7,61I6GJ6U0G?TA`K%<.FA$=DL/B^>WZ0JA>F_P#DH0?WQRQ^
MUN=576E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J(FZ`?<+:R?S7,\_
MLQDM?ET6?P9?Y,O]2VMU*^%S:VUZ0*6MX;T;HVK++2U;>X)RE:-47:98;;8>
MF/MO*-MM-++,MMOM$`,LLO`-]:`AUS#%8Q%K%)49CK)'RUMY1BPME;$;;8J,
M(MOL)O46I"BK3;RK33+2[KPN&RTR\+1`+AV]_2E9S_V,K]PKE3\Z>;_LTQ-6
M1C2E*4I2H`[IO%9?-M(TAC<$ATLGDG.R_I8?TL:A;"X2)]5-4"U487R)+%A*
M!O*,NX%GA\2?WD^\Z\FPVQ`*--<<X*D2-3"?6)A740;JPS;F+#Z+-B?*T^T_
M:0XKHUR'CPR56P"(S/%>?\F2S,^-L[-Z`2H>SX\F#7-HA)YL7E]*;&Y;#4[\
MCB]AN2X8PHK>3!&`\PQ_*>D_#"[%\H92=*6NS="-3$ZRTOCRM)"I5BS.MFJN
M[#I\3FQJDUKDDGR59JNCETKBS6Z/+]%%^-)L7-43.01&%+]>OE#(Y/S5W/:Y
M6^PU5QI(>#U'4\=4N5I2<T+S4EI4H8I&TB0KM_<SQ,;##K;0`2#2KMMPQ1P'
MC>8+\9H%"7.F3F<GX4Y-)XBWM>)C$P&)LHS1.<IMO<<9KE8FKC2KURH+U5Y5
MBI0=8D+2HK4Z1/63DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9
M/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PS
MV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,
M,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?H
MC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RW
MZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,
MM^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(
MC+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'
M2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*I
MQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2
MJ<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3
MDJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3
MTY*IQTB,M^B,,]D]13UV8VF*#1/J[6JL[9/>$R73/G!0>U.#7B4M"XDD8XD1
MIJ%88W8R0.%B5799<G47H5R)9:49>*940:%IEOYHUG[PO\F7^H%;J4I2E*S7
M/L<*%R.1Z)<GK&C*DY@Z<O4Y,DU[7&4&/U2$\XO'.+3+UQIDJA$D<`5'6'%D
M&6$KBD8%)B1L26'"<:;D#\E4XZ1&6_1&&>R>G)5..D1EOT1AGLGIR53CI$9;
M]$89[)Z<E4XZ1&6_1&&>R>G)5..D1EOT1AGLGK[$.,YDD/$T_/.47$L2KRP3
MK&K$EA(7W7E76G`*+&*0[A"[2[B[0$T2AM.,&\NZ\"[K*PB.P!'\`;:BF5K.
MP2NU`D:6F-]>Y+G<EU<4THQ]'(I('=SQS&F^.FR$C).3E25#>UX_QE(0XBPP
MN:29>WMLYEKFFB\1[LO"9U3-LJQ`+@V7``@.P=EP`/\`2&T!^^%!`!\8`/\`
M6'X!`0_0(`/]8`--@`.T``!'QCL\/AV;?T[`_0'X*#XOGM^D*H7IO_DH0?WQ
MRQ^UN=576E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J(FZ`?<+:R?S7
M,\_LQDM?ET6?P9?Y,O\`4MK=2E*4I6<_]C*_<*Y4_.GF_P"S3$U9&-*4I2M+
MMF]NV[-F]';M\`;-GW_Z/P_T58_(E"=KW31F@3/D?%JUI>=04GE+_BV$,&)$
M+ZR2T-,;\"R73Z5IVYWRX^3%^;AB#=W+%R17MB6/+$DD(8X'?CZURGKKRS=D
MO3OI]#*F++(<:^-V8]-T1>")JTN[R@40W*VH7&&(Y;8U)V=[8#$TE)9)VK6L
M#DN4K6M`X)2CE[,ZD[4U4XUFZN9WA.8Z?X-B5BCS\MEFI_2UCO.#Y)4[F<V0
M3%V>LP-V,4B-B!$>D*<,GRQ2K4*(^W'*3$D<C#.^2]^3W@;$VR1THPOK;R].
M\EX.F#\V1:W`>JG5!JVTMXRC:5F4H9K!%NFDK-YL-R#(9%<^+BI"7E<K33E=
M6],);$WD1@F28Z2MZFPQFDJV2W29++(O#6L7J72)DB[."E*EN=9`Z(FANL4J
MS.#2D7K5YQ":PU08`V%67&!<9<`A:`B`U%;`.=<*L^,D*%VRUCAM6A*\G*;D
MBZ:1Y*IM3KLHS1<B.N(.<+#+2U:)0G5IK[K0M.2GDJ"QN*-+ONK-WQ.`^>G%
MO7N,^\J=\3@/GIQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3@/GI
MQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3@/GIQ;U[C/O*G?$X#Y
MZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3@/GIQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.`
M^>G%O7N,^\J=\3@/GIQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3
M@/GIQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3@/GIQ;U[C/O*G?
M$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3@/GIQ;U[C/O*G?$X#YZ<6]>XS[RI
MWQ.`^>G%O7N,^\J=\3@/GIQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\
MJ=\3@/GIQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3@/GIQ;U[C/
MO*G?$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3@/GIQ;U[C/O*G?$X#YZ<6]>X
MS[RIWQ.`^>G%O7N,^\J=\3@/GIQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.`^>G%O7
MN,^\J=\3@/GIQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3@/GIQ;
MU[C/O*G?$X#YZ<6]>XS[RIWQ.`^>G%O7N,^\J=\3@/GIQ;U[C/O*HHZ[L[X3
M>-$VKQJ:<MXW<G-QTS9Q0M[>AFD>5+5RU7C>1)TJ1(F)<+SE*E2>8620039>
M::9?;99;=<(!7YG]G[PO\F7^H%;J4I2E*S8?L;[*N,H/HDR>US/(,,BCF?J=
MF:\AOD4E9V9:<B.QQBP@I84E<%B<XQ*8<F4%6'VV"5<80;8%V^LN`,@OOB<!
M\].+>O<9]Y4[XG`?/3BWKW&?>5.^)P'STXMZ]QGWE3OB<!\].+>O<9]Y4[XG
M`?/3BWKW&?>5?6BSUA!Q.%,WY=QLM4`5>>)*6:QT\T"2[RR[S1+*<+K@+LO.
M*LNOV;T+C+`$=MUNWE:<RP"093F&%V9>]+I_`X_&9)+D9<.F14?8VN9DN)\8
MXQ.5$?*@JES=R&IP/)86^1+7XA.FO4K6Q,GN*,,@7CS"F6G#5Y.\I)C$R['K
M9J(DKJZ'EZOM1;6H9D-F'&N,)&-PT=)<;L6GL]6:Z*$CVD>'61N+F\-+NVY1
M*>WM[.:MDLM6NGL_5#A-TPZ5-+X`#G,L43$9*3'")2I3*L2Y5A>7&9*0UJWA
ME27E.,@@K0@<C#U!H]QU#B4F*)7&I5R2.VJO<L-(&KR6QS).4,20)1E1MREA
M#(TDR+9#FY;))J@PM(F5V30=\4KE!EXQJ2,[,5$7']T/6)8_?:048H,3$76]
MQCC0%',>9:@TM3S]P<,4X;R[J$SU@[#PQEO168_RMJ;)DQ62')7,"G,^^0Q=
MHNR/ETS&T9(C4?4Q6W*+^F=WZ5I6F*DLEP0RRR^T`OLMO`+K+@"ZT+@"ZVX!
MMN`!`0`;1\("'A`?"%4&TXI4U^*6\;TY%PA,,KV@-Q)=PA:&6YUL`!&T=@!]
MX/$%5SXDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8
M*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L
M4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$
MD?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\
MD3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;
MS!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*
M]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4
MXDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D
M?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D
M3>8*]BHC:_DJ6S0QK(NM3)[;@TN9Y$!M)+M$!#&4E$!`0M`0$!`!#\`@`^,*
M_+OL_@R_R9?ZEM;J4I2E*SFOL9D@@W0ME0322C![Z>;!M,+LO'8&-,3[`VW6
MB.P-H[/P;1_"-9%O$D?DB;S!7L4XDC\D3>8*]BG$D?DB;S!7L4XDC\D3>8*]
MBG$D?DB;S!7L5J"1):.VU,G`=FS:!)8#L_!M"WQ>`/T5;0STDW0'`67)OD[2
M'AS!FJ['.9U4>?9SB7)^:5^FS(>/LC1N%QW'ELEA60R<;9-B<S@4FB<1C=[M
M$9$T,$DBLE:E[@R/LA:I9>V1.N.D+'NH1D;<D94U4*L<(,UYKEC5)'/'&'5S
MT^8UQ!$(S%FN(PK'K3,Y*VLL@R-($Z%`MD$VGZY@C*%XDS^K;8Y&VR-L;48L
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MS+B-QS"T0#,,/:6XR5%F1')..76%Y&4#$[#;U5R.&N!IB]38Z`4(,%UA@`[W
M7EVD;T;PJ+<#W3?&\_F,-AB#3=K?85DUD+#'$;Q+M+\QCT:9U$@7)D)#C)GM
M4KN3LC,@O4VGN[DHMN);DA9Z@T!L*NJ0^I35/&=,2*(+9)C'/&2;)DM>$*0G
M!^*7K**IHO94R)4<?(R&<XFYF2K+5MA38>H&ZU:>2J*+`+B+MK37JGC&IU%+
MUL;QCGC&UD.6LZ%63G#%+UB]4[WO29:J)/CA#P<=<\I4=J*\IS/3C;:A/.3%
M&;;C[=D;97NH6-(C)9/&%>FG7.ZJ8L_/L?5.4>TLS-X8W,]@<E;8>O8G0A7:
M2ZM"XU'>I:7`FVTIP0G)E10!8=:%2ZS=GUBP5C`K*;W!<M39L-71Y`$8Q7C]
MTGD\MODEX6)S[XHVF%K;$K<-V^>5`W[UMM"X3@'95+M.6M.':EI4_1*.8=U+
MXY51^/6R,]US7A*0XRCZ]/<YI6L&YH=W<\TAP>0-56J1;2K0.!"4>K$=X5<`
M^-S1N@\"PCDN18O><":O9HYQON3QB2XPT[RF<P9Q[L,Z!Y*[BREN4EHG/BA+
M@6C<>!L#B;F0K0F;3$]XU73OC8_WNW?(\GV9/@]\#OAIR=\F[MRT<3X?B_<?
MDTX7NO\`"7??;]Q>%XQP7[IOMG@JA>%]T'@6;LEQW%[-@35["W.2=UN+R7)^
MG>4P:#-W<=G7O)O=J4N*DQ$V<;);S$;=PU@\<<STB$O88HL&O9:C=:<.TTRI
MAB4CP[J7R,JD$>ND9#KA3"4AR;'T">US5-8MSN[M!Y1#>\B:EN4@VFVB<*$T
MA6`[PVT`J1@G4.P9\QJY9.8H!F&"MK8[OK.;&\LXZ=<?SA2:PHTBP]6AB[F:
M:L5-RZQ782TK;+P+<%)2@DH`N)N$8G13=0L:2Z2QB,)--.N=J4RE^8H^E<I#
MI9F;.QMA[^Y)&PA>^NAZNXEJ:$)JRQ2[.!UMQ3>A)4JC0&PFX*DWJ1U/1O3*
MS1=ZD>-<XY()E3PM94J/".+GG)[FUG(6ZYRO6/R%G.),:6P\NP4Z5:>-Q9ZT
M;4UH!>.VOFTUZIXSJ=12];&\8YXQM9#5K.A5DYPQ2]8N5.][TF6JB3XX0\''
M7/*5':BO*<STXVVHCSDI1@#<?;LCQ/-TWQO`)C,H8OTW:WWY9"I"_1Q8\1'2
M_,9#&GA1'URE">XQE[2J[4[VS+[TUQ[0Y)[;27%(80H*`+#;:E)F#40P8:Q&
MW9A=X!F&8-+B9%2RXCC;'+K-,C)QEEA5Z6Y9#6\TM>FL:P-`'^Z\P0:+K#+3
M]\-@U3#3MK=AFI&:N<'CN&-3V.UK7&E4G->LT8-D>-(NI3)')L;+FQ`^NZ@U
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M@F6H`WI7]VC]S!F+'SICF8&'LY")0<O(CKL::J-:%=JZPMN<0O`I8:2J++`!
M(N$8?-.ZE8S>'QJ82=,NNQ(>[/3<QE+G'2K-$;4D/<W,AK+6N"\Q8)2-K3&J
M+5*Y<8`EI4)9RJ\!L+$*E'J1U/1K3,S1=ZD>-<XY()E3PN94J/".+GG)[FUG
M(&^]Q,6/R%G.*,:6P\NP4Z5:>-Q9ZP;4UH!>.VNMTUZL8MJ=^&7P:Q9G_&WP
M*[A<<Y<,2/F+N[/=\'42/@SW9.-[N<0[DF@[\6WO<\5;>!NWCA=4*R1NEN.L
M9SF:P-RTYZV)(N@[\ZL"U\A&F27R>*/1[3?=8:OB[^C5V)7QH5#;M;W!-;:4
MLM$+BP`!J4^5\^,6(\.VYH=8+EF5L]R>*J/@?CW'[I+\E!;+5#>F2EC"D)EC
M@!S5<XEF2`OA-K00G6&GC=:FOVT8T^ZZ83J)GQF/H_A+5/C]>7'G.1B_9BP/
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M35*QD/+="DR1SLN`E0N3+DMH`8D,VQ':=U*QF\/C4PDZ9==B0]V>FYC*7..E
M6:(VI(>YN9#66M<%YBP2D;6F-46J5RXP!+2H2SE5X#86(5*[4=J2CNFF,,,J
MD>.\TY&2R"1#&T[9A/&CODU^0*`;'!T[H.[4T&E'-[,)3<8E!R-N$D5ZA&DV
M<(HL$/+:;-7T3U-N$N;HWB?41C<R'HF9<K/S?AU^Q>C=['M0Y)R28XH>#CK7
ME4CN;##',A.%MR$E2A,,VVJK-E%\C[I9CK&DZF<!<=.>M>1KH2_ND>6OL)TR
MR^3Q-Y4-1@EFKXQ($:NQ*^-"H0WR!Q36VE*[-EQ8``U*B?YZ8\>8,Y>7"#98
M?V/X/Q*0_`>'P!SD65^+R\]G3I&_X`)#+7/NPTW/1)DB;N$X5F)1N9B@;K4)
MNVBVG[73"=1,^-Q['\)ZI\?KRH\Z2(7[,6!Y+CF(7)VI2VI36^R0NJ@U+>\J
MKG,LU`VA;PRLA,N-+$`2W@/R9XUZP;`&1%>-WW!NJ^=N"1H9GF^18DP#)LA0
MLTEZ+4&$HT\E:U):0YR1@FNM<T5M@&(KS";3!$3`JM,.U"L$TP"IU#(X#E]G
M8$L:E\GN@,EQTZLF8#4T-/>"%;:1CI0;<ZFOCO<S'&1MJM-X=Z*6-IB80!:7
MLC9B_=(<>95R##\=->GC6?%W"9O!3,CD,]TU2V)PUG.-2J50+)))%RJ](RMM
MMJ6XHQ:HMN+L4&$%"&^-MJKVI+5]$],B^(M\DQ/J(R09,43RN2'X0PZ_902-
M%C*>VISB9&H9SR;&94LN<RC&PA0%URXE,N,+V6I;]L>L[:A&#4EN<.MR<1V`
MY?QVB:L`ZA8P:RYHQVZXTE"I2BQ`Y.5[D@8G<TU2K8SBW0I.E=++@)/6I5Z:
MT-^D,K\YJR#+^+EF]VHKLXN6;O>[R??[.!"_>[S>;=_L^UWGCWWVOCKHF9G.
M>CS4Y"MN1W$D@>-[FML0DWVC?:7O"S#`N"\W;<%W!AX=X%UWB"OH>8^H9+4]
MQZYH6`IO,LM!K<2EUQ8E6V7")X%VV\%;=OP`NZ[P7B%P!^]K[T$.6N"-,M+=
MHV18J*`VPE6]$)U)8#==;O3R;K!$HP!M$1L$1V`(#M\-=.G:#E+M<SV*F\LZ
MTY00*H]984W#<F`P;[P6W!P8E&<&($F;-A@W6`&S?>#L76*JVA'<M.<V%59:
M:44)+>[$K%(B<(A;=:39;:(V6B&TR[;]H&P1\=:-,75/"059+DQ)+`.,)X)R
M=242C?%A8(W@29:-PE7;\`L,V[+A"X`_>UUJMK-1N?<J]2@-.X5.3QE,KL.0
M;Y2!8VW\;M`+.#+`T.&OV;"AMOV@.]\.8-]CY:CH_AS!Z[3\\8\S-+G[)6IY
MW5-T]QQC9WF>(HY9(H;CYD3E3;(:`PMJC*A`<RG+7@E67?<W-:MM7&[XI:6`
M9`FI/5]$],CA$6Z28GU$9(,F")Y7)#\(8=?LH(VBQD4-J<XF1J&<XFUF5++G
M,LQL(4!=<N)3+C"]EJ6_;ZG3CJ2CNI:,/TJCF.\TXY2Q^1!&U#9FS&COC)^7
MJ!;&]T[H-#4[FFG.#,!3B6E%R*N`D%Z=8DV<(GO$8HNVZE8S9WQU83M,NNQ6
M>TO3BQFKF[2K-%C4K/;',]K,6MZ\M8!2QK4FI[E*%<6`%JD)A*JP`L,`*EQJ
M&U$,&G&#M,[D,`S#D)"[R-!&BF3#..77),J2*%[:YN9;BX,+0:4I1LA!;6:F
M5N=]PDIURE"EN`3%9>SP&G#65$-2[])F".8AU(XX/BS,@>E*_-N%Y!C%H<R7
M!><WEHV)P>#S2G5S(,)N/5HB0`Q.DO*47"-MX!7D9-K[@L7RM,\2*<%:LW-U
MA2I8E62MBT_2=UQZ\W(@:!O-C,O)4@A>R#N[!()C4]EH'BD<=Z'_`(,S;6C4
M;GLW`L48%['BO)&<L@SN5$0?&^),4EQ$N6S"3',KU(U6_>\@RF$P&(QQACL>
M>G^22V9RME96QO0<6(,<7UP9F5RHGI0DF3Y]D;.DRR++,Q1!_ME;*W/FE+*Z
M+"CFUX';UF/(0OBB*`S3"[G(6R5-4D-*D4U-E3G,Y"YN1LK71E[9X\LB#<G(
MI[NN;6QK]%[@X/:9"<$9U&:))&U*U]UEA;0[(]:FGY,2[$FFWV%$*4Z5:L)L
M/O'[0M2=:`@%]P#13="8+HVF.;L-MTX?L*0W5$VY5T]YD39PGV38;#\FZ=L.
MX6RLURY4?CUWDCT3+(N5F@6.5XC8H9"DI3/D9WG4W>)8W.[%'I&-L<]-:I07
MF;1K*[!5%ZG)[NCFZKQG5%>5<DMD2O$D;)U-&6QV<7E&=T5$$@Y<<T5)L<DJ
M3SV]L:!Q7<W6VI7EO!3D#RA3*TC5PL.9V)\>>-)+`0R*0+HRVBDO-`%AUSHW
M1R4J;#R2]EQ!-K2;8??MMO-)``N&*&!'C.9>,T%K/C[&2U%\*<FW`H7Y7DS:
MI%3?E*:7KBKDB?$S@5:4G6W*$Z4X%9ERI*42K-*2&GWHDU9.[NH?9LY,L2^N
M25[?T\C&W_.@/FH<!V\F6)?GS++!#]`X9$*"^:AQ\>,L2_-F66!]&&0H#[J'
M`-G)EB7Y\R2L1_2.&!'_`#K3NYJ'YL\3>N66C].&:U%]U#CX\98E^;,DL#Z,
M,!0'W4.'BQEB7Y\R2P?IPP-:=W-0_-GB;US2WL9K47W4.(;.3+$OS9DE8#^D
M,,`/^=`?-0X>+&6)?GS++!^G#(T%\U#B.WDRQ+\V998`?H##(!3N[J'V;.3+
M$OKDE>W]/(QM_P`Z`^:AP';R98E^?,LL$/T#AD0H+YJ''QXRQ+\V998'T89"
M@/NH<`V<F6)?GS)*Q'](X8$?\ZT[N:A^;/$WKFEO8S6HONH<?'C+$OS9DE@?
M1A@*`^ZAP\6,L2_/F26#].&!K3NYJ'YL\3>N66A]&&:U%]U#B&SDRQ+\V9)6
M`_I##`#_`)T!\U#AXL98E^?,LL'Z<,C07S4./AY,L2_-F66!_D&&0"G=W4/L
MV<F6)?7)*]OZ>1C;_G6@/FH</#R98F^?,LM'_(<,[*U%\U#CX\98E^;,LL#Z
M,,A0'W4.'@Y,L2_/F25C_F.&!&M.[FH?FSQ-ZYI;V,UJ+[J''QXRQ+\V9)8'
MT88"@/NH</%C+$OSYDE@_3AD:T%\U#CX>3+$WS9EEH?Y!AG96HONH<0V<F6)
M?FS)*P'](88`?\Z`^:AP\/)EB7Y\RRP?\APR(4%\U#CX>3+$OS9EE@?Y!AD`
MIW=U#[-G)EB7\'\LDKV_IY&-OS[=M:`^:AP\/)EB;Y\RRT?\APSLK47S4./C
MQEB7YLRRP/HPR%`?=0X>+&6)?GS)*Q^G#`UIW<U#\V>)O7-+>QFM1?=0X^/&
M6)?FS)+`^C#`4!\U#AXL98E^?,LL'Z<,C6@OFH<?#R98F^;,LM#_`"##.RM1
M?=0XALY,L2_-F25@/Z0PQM_SH#YJ'#P\F6)?GS++!_R'#(A07S4./AY,L2_-
MF66!_D&&0"G=W4/LV<F6)?7)*]OZ>1C;_GX/O5H#YJ'#P\F6)OGS++1_R'#.
MRM1?-0X^/&6)?FS++`^C#(5%/76\YU,T3:O"GC'F,$349IGSA8XK$&6),Y+D
MJ&_'$AM5J$:!1B5N)6JB4XF&ITASB@*4&VVE7K$UMXFV_FC6`&\+\`?P9?W@
M_F!6_8`^,-M:;`#Q``4V!^`/T!6NP/%L\'X*TV!^`/T4V`/C`!^:M=@>+9X/
MP5FM_8X+CE-%HER>7!X?!W]K'4Y,KSU<EGSW%5I:X<<8NM.3E-[;CZ5D');"
M;4QEBN]Q)-,---*N166D6'&Y`XOFH<?'C+$OS9EE@?1AD*`^ZAP\6,L2_/F2
M6#].&!K3NYJ'YL\3>N:6]C-:B^ZAQ\>,L2_-F25A]&&`H#YJ'#Q8RQ+\^998
M/TX9&OL0O.>#%`@XX[Q>E3\%>(&H\M2A8:)X7E`66)!N)$5@%W%B==<:!PW6
M76%V`5>!EUY=O_=$YLYIH^V8VG!VCY$9-\VPN_`IN8]5V7]+DF:V&/8OD4@G
MF1BLF8PCP3['F0HM)V]Y8(ROQP]$H'>'2`&E[E#8\/QD:<^[W*QKC;!B_-<<
MC16FTP&/.ZTF0/.G'4!EO5*1(Y.[8QQI(W)ZRKGO.:<K)V1,FFI'IM2WK7Y4
M\$-$)2PV/MCN8F:[D#=<@ET*AT_9[H_.8I&IFPWJ$ZR]EE;"TR-IN5I+^%2J
M;FUZ1KD5RA,9]N0>)`FDW_;E7V7>&O"R/3U@682=%-I9A/$<FF+:+0+=*Y#C
M2$O<E0"P7%WL0HGYT8E;LE%EO)*N:1(6%BVW%%W(N`&RT0]@@QW`&N9/>16R
M$1!OR!)6](TR*<H8TR))B_M3>"<&]L>I.G0EO;JWH02)@1HEZY0F3`G(`DNP
M""0L]@/B^>WZ0JA>F_\`DH0?WQRQ^UN=576E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4J(FZ`?<+:R?S7,\_LQDM?ET6?P9?Y,O]2VMU*4I2E9S_P!C
M*_<*Y4_.GF_[-,35D8TI2E*MK;IEC7(N1L<X?2XGP_BK)DW29K:&XF2Y1TZQ
M_4VBQ0TRB(3%ANEB;'K_`#W'%C>S.LC51F)3J<)7M[,@<)?'J6&PB0E-(JF?
MRVY6*,J)X)GF+Y,85<6"(YM*:H[&QTKP?1^RLQ2G%\`<)2BCF+(G.)\M>VJR
M;J)"/*FXOBE@R.IX9]QRK<8%<RKSIFZG-14>TN8R393E44F,M8CLBXEQPJ2P
MI*RJ5[2LS#DZ)XI8I"Z]W7MB2D1IHD4R:#W]0D/7NQ+<)IC8S.BBT$]4DS1K
MMQGA7),J@KS'Y,],N)63$$GU"3]F/COP;P;'L]SEVQ[BMQE*1<\I7YX%U=F)
MYD$A21QL7J(A`VTV6NMMY2MK;W#=`-=..,@9B;<8H8S+6V.S')F<\)XLRHO!
MENAN3<O::;W@K-4)84J-T4R)`;'#XID%,R.SRUHVZ5'8MR*8@O3HVM@5RB;H
M^+Y[?I"J%Z;_`.2A!_?'+'[6YU5=:4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2HB;H!]PMK)_-<SS^S&2U^719_!E_DR_U+:W4I2E*5G/\`V,K]PKE3
M\Z>;_LTQ-61C2E*4K'FUSXWUH3/4QDW(N!HANAIN1L9DX,:--F1,)Y6T^M^E
M>)LBQL;7?-R"9Z;,R:BL*1_.$JD*5]E*5Z<)U%I@S`L18Y:H_*(T?&',I/<'
MW.2$'X^QWE1@<L+:D,4R=3EHR13:6:M9WC_)6>\_3%^Q_!E+OF>9RW%,^R-C
M825Q92*#L49A3TS1N$-$(31-A@\*8FIK9"?;;H;BG(^:]+[[CS%$8LELU690
MTYRQ$T'/K%&TQC7BS4;BC+4DN.=Y`M1(B##(W!79*VEVB<8J>%#<EOL(2G*5
MZ.(NJ?1MG'($[UF,>.V5,Y0G=!L?:6X;)9HL?8JVWX%78B?WJ,9762-H7*K7
MF2MDAPTZH%>.K(8EE:KE.;7)FD*6-QEU(F"7[L/:0L[17*6G?'KZQ-J##&E+
M6!K6U6L64"Y''EEV36G4<7J#'%4!21Q&/PI;)5#+=5<Y39+<'ID88^:9CAA7
MQ=WE`S14FCEV641=MEK7W(=%+\E2\:2*^&CLFD42<@-2&@85;:\1=T:'4LFZ
M[P'D%K+"5%NRP^PRT``+1D#W/Z89%9G.9L^O+6[C1K>YUE`U!`X)E5"DB,92
MI<F2]O*;F0AS9G!R!,-J3C1QJ]>M6JEJE4K5*33C[Q#VGQ9&0_E*]T*];K']
M6J?%D9#^4KW0KUNL?U:I\61D/Y2O="O6ZQ_5JGQ9&0_E*]T*];K']6J?%D9#
M^4KW0KUNL?U:K0=S*R"'CW2S="0_KR\QA],:K3XLO('RENZ$>M]B^K=/BR\@
M?*6[H1ZWV+ZMT^++R!\I;NA'K?8OJW45M4FDO+V!+].-K#NA^N]]#-&J_#&`
MWT7G,:.P6F,9(&4`\O#-W/82-DA1=Q$O<HU?QQK*X13QQK7;\K@)3V;F;D"Z
MRRX=TMW0@!NMMN$`R^Q[-H@`_BW6[XLO('RENZ$>M]B^K=/BR\@?*6[H1ZWV
M+ZMT^++R!\I;NA'K?8OJW6[XLC(?RE>Z%>MUC^K5/BR,A_*5[H5ZW6/ZM4^+
M(R'\I7NA7K=8_JU3XLC(?RE>Z%>MUC^K5/BR,A_*5[H5ZW6/ZM4^+(R'\I7N
MA7K=8_JU3XLC(?RE>Z%>MUC^K5/BR,A_*5[H5ZW6/ZM4^+(R'\I7NA7K=8_J
MU3XLC(?RE>Z%>MUC^K5/BR,A_*5[H5ZW6/ZM4^+(R'\I7NA7K=8_JU3XLC(?
MRE>Z%>MUC^K5/BR,A_*5[H5ZW6/ZM4^+(R'\I7NA7K=8_JU3XLC(?RE>Z%>M
MUC^K51=U>Z:)[I`PO*,[.^K[=:\TPJ`LTDEF1",-9EP38^0:#1&,NLID$V=4
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M0_E*]T*];K']6J?%D9#^4KW0KUNL?U:J/&KG<]IQ`=*VI.<+M?\`KCGB*'X(
MRQ)U<'FN46ARATQ3,4(>G,^,2IN(CY!R^./I:6YM>491Y!BAO4'E6&EWW6W5
M@G6S!`-M@_`B)!MLL'8"13L#;:`[`_\`$>(/$']%:_#!!^)$2_PBG_N*?#!!
M^)$2_P`(I_[BGPP0?B1$O\(I_P"XI\,$'XD1+_"*?^XI\,$'XD1+_"*?^XI\
M,$'XD1+_``BG_N*?#!!^)$2_PBG_`+BLJ'</]*$DU*Z59].([JFU*Z;$37GJ
M3Q<V#Z?ILBBD.=%*&$0!ROE#DW+VIS-.D:PMV*;5:RU187>WM;:3:4%Q5]]U
MY;XLC(?RE>Z%>MUC^K5/BR,A_*5[H5ZW6/ZM4^+(R'\I7NA7K=8_JU3XLC(?
MRE>Z%>MUC^K5/BR,A_*5[H5ZW6/ZM5[K'FY\S&#OYSTZ:]-;^0$QK.L:[6*9
M951*6@D]4M:U=CL44WLZ$\')(6W'(TQEQUQ5J5S7VW%77WEWE^[U_:GY-I7Q
MCCZ51B3::(`?/,PQ_&;ADK5KD]3B[#,$0.D5FDF!Q<5C7L?Y3(7I9$TD3C44
M93D%UZY_ND3PYH8_'W6^_705J,E.I.`Y!E$HRWI)S-?&\BA%FR5Z-9=(IQC!
M*B"$Q%_-9'I_D:YP47S=&O>E:IS0I%/%4;*NCX7E%K#%05.RM!$`$`$0`1\0
M"(;1V>/8'W]G]%-H;=FT-H>$0V^$`'Q#LH/B^>WZ0JA>F_\`DH0?WQRQ^UN=
M576E*4JTKNHN:LL8?'"?)A/I#"/A!=D`'KN$:C*[I=S+8@+?QKC2)7ON*"N5
M\#P?![.,&;_?[0WMICOU-5_/YD'_`!3/[FIWZFJ_G\R#_BF?W-3OU-5_/YD'
M_%,_N:HM:H]5NI:27Z7KGG,,W>`9]:NGIY:Q5"U*`1/"(9L*-60-K,`<.5PM
MXVEW\(29MVFD&[VS>RCLUI:L+;+;1SWD(!MMM`0%4T`("``&P0%FV@(>+8/A
M#Q5N[]35?S^9!_Q3/[FIWZFJ_G\R#_BF?W-7(3K3U77'D6W9[R`-MQY%MP"J
M9]@VW'6!<`__``;Q"`B`_P!`C66.GNNN3D77"-UUQ)5UPCXQ$;+1$1_I$=HC
M_2-<U*4I2E*4I4>-3V?TNFO%JG)JR+JY>2F?F!C%F1.B=G/ON?EER2Q2"U4D
M6E6V)AMX2\H2!N-#[6V^T?#5N3XXJ/\`,%(NO[+]7:?'%1_F"D77]E^KM/CB
MH_S!2+K^R_5VH?[H1NK+%D+0AK-@I6$7YJ-E^ES.D:*<CINT*RD!CYCB0-EB
MPQ,6Q$F'V)KE0'7$V&V7F!8-EM]@W!<$L&G=A(^G:VPGD$D5W!-K?9O@GS-:
M`[U$0&T`&/#L`?Z_T>*NP^.*C_,%(NO[+]7:?'%1_F"D77]E^KM:ANQ,?$0#
MD#D7A$`_^_V7[X_W=JZ=A+)Q&9\4P7**=F/CQ$W8$SZ6RJ5I3@>VV*##BP3&
MK2"$Q2F^S@1$32R"K1"X`"WP;1JG2E*4I2E*5$3=`/N%M9/YKF>?V8R6ORZ+
M/X,O\F7^I;6ZE*4I2LY_[&5^X5RI^=/-_P!FF)JR,:4I2E6Y-TQ?\GQC$&,W
M?&^2HMAJR[.\$8I+EB0I-.2Q9`BY>W2:&P5Y92M4;LU8U"U1E6005GE0,Y;[
ME97!7.3M>(HM(ITX-;:;Y_<R%&>7&+ZAG//"_)[R[\O2J/,SOE?O7D#^<,&Q
M["(7,6]MC>EAK215DC;+/V22MK*?+5*>;2-,4$C7Q:'H7!$UFW.ZL3Z^=5F?
M<&ZOHK!V_(WP!@4SCVF1OP[,TAK*JP5B[(DWU`NT/R4.O)/<PNTOBL2S5$$Z
M2"Z79.4YL<-E>0F*8P=,[PR?`W3`OU&"M4F<9'DS3)EB1SX]SA.KS6GKGTN&
M876)F$MFQM"=/=NIV_#K]%P1-:=\LFJ(G2DNNR>H<GYR(=W'+#V2<GM31:')
M&6\5+)<R0MH%\D!C@4WVJDB0;FQC?9$JX=89P9%MK;'6UU<KK!O#9>=:D$@D
M/MSS"[/MJM>8QW3W0?BF+K8%D349%(E,8S-LHIY!'G9EFY3BSJ%&3)@Z%IUY
M1<6-M(4`A6ICS2+K^%3B8)1]A9UAA=LN)'K@TQQ"!<J4HR*L8,<]SF5W^&SK
MCW*".-=RY%>B+87#NL="K4G%'>]R06MYW";Q3<L3@4-PFV;?$8YW2O1'EZ17
MQ+%V=FF?R<ML6/-[#%(CD9Z=+&EOO3%+G&Y&BAQIP)$ABQ+8>>-N\+N4%!<(
M#?;MX<A;IEH<Q-)38;DS/;-!)60A;W,Z/2F)Y%9W<IN=2[SFU;>A60XH^U,N
M*+,,3&C9O#;;+AL$0`:]NRZZ-+DCQV=EMAR4H>,8D-;T]'3UOQ_D]5%BFB.F
M+"7YRO>2H5<CM1M!K>N+7GB;P::Y(>!HVB5=LIE$MU0T!SV2L<-A>H^,2B5R
M5<6V1^/,D;R"X.[RXFEFG%HFY"GB%YZI3>42:9:459=>-A=]P!L`:MN[K]J)
MP^N48`2C*5;:H*(R2LX!_B,WC9IR4TR%IK3TMD@C;9<L*M/)O*-O2@<!)F\M
M.X,3"]_:4C4KCLQ0FN48=4[PA)5WH35*>P\NRQ7864=>0(*22+]]:6>3>(A:
M-FPP`"X1V@'C>6[%/#<6^&K9P_#\6X+B[ION'X7@.#V\0WN^X7[3;MWN^^_L
M\->PD\NC4,2)UTH=T[.D5*A1)SU%B@RTU5:48>)-H)B3[@N`DJ^\1NMMMV6B
M&^VB`#19^Q_IAU(NMCG*81C_`"P\Q=N(1DKG]F7+%3.V*%BM0G(3&*!16E%W
MK3%AQ=Q(7'EG&&W6F6!?L'VYF3,2P@;(?=(F=@MBZ=*Q%,929Q`IH2MB0A,C
M;2;2TAUEI*-%8G()MM-,"TJRRW?W"`U[1;*XZW1VR6KG5.GC9B5$ML=K[%`I
M[DKC<38B."RPFY1O5%R@D+`$D+@$RW?VVAMV=)'LH0"5N5C/'9.A=7.\A0JL
M1IR5UAEQ"6VV]0:%RA(27O2K;K1N`;PN';]J%P[:YWW)L"A[NG:Y-)D30O"Q
M$OXLH)7&7\4./NX(_?)TIQ>]OX`W8&_&_P"T';:&T-N7?%=;VF668[)R?&<B
M+'['=C0ZNMTU:L>Y/6QH&R-@K+?UXNQ$*O1\59S&UPL<#@-$M-<C4`:-HE7@
M%*XQNK.Y]S60,44B6I6*2.2R9Q1M$>8V>/9`7.;RZ.%P6(6]N1D1"\Y4K5WB
M%I!)5MUYHCLM`:]OD_=#M'F%5#*ERWF-/CA3(TZY6PD3"$Y*8C'=,V')T[@>
MWVKH82*DI&>K3%*;RM\!1AY5MX@-X;>XQCKNTKYI:U[WB7)QV1FAK=;&-Q<H
M?`,G/B)$\&)2%I;8I4(84:64MO1J4ZFU/?<!@DG%F;-[<`U2,_=:=SM3.AS(
MHU00TEW3N9K*>VF,4]M6$NQ"ZYL.;C"!B(&6+"W"RY'>0(!?:HM$H0WW@JL.
M2]<^EW#;(FDF5LE*<>L"QU*8DCQ+<?Y/9&]0\GIE:LEL)5+8445>M-2H5BBQ
M/;<)EQ24^\`WI=PAYW&6Z*Z-<T+W=KQ+FA'D5Q8$"=T>T4/A>27U2U-RM4*)
M*M7$H(8=>G3*%=HIBC3`MLO.`;+1&[P5Y.6[JAH#@4E?(;--1\8B\KC2XQLD
M$>>XWD%O=V9Q*+*.,1.*%1$+#TJFPHXHRXHVRV\+#++A#8(55-UUPZ8F/'G*
MV\9&6-F,>X;9)?AXMQ[E!/%O@^]"CM:7GNP9"K4?<YQN<$((U7"\$>*LC@[A
MX2W;3V!;IUH6RE*$<*QQJ`8YO+G%.O5(8Y&HKD1V>%:9K2WKG(].A20XP\TM
M"C+,4J;[;!`DFRXR_9:`C7UY&W2O1'B&0V1/*.=VF`28QL1O-C#*XCD9E=+V
MEPO4EH7&U&MAQ1PHU9B-580>%O!F7)S0MN$;+MGN(?K?TR9`A?*-",B+97`N
M">COA>Q8]R@Y1_@8Y<HM?C.Z::%&)=XT7)%-KA=PFQ*)!H&C:-@[+7VNG=%]
M%.?\$\G&'M0$2G4V>IQ!5+5'VMOE1"M:0E<[SU!I1KG'D*0+2RKK;Q&]19MM
MN#9M'P#94E$ZB,+XC\*7Q*S=TN,<1XR6J,XSQ3@>,;SBJ<_9P7&"=]O]YMX2
MW>[[P[.:+S*,30A4IBSPF>2$2@E(J,3%J2[2%)Y7#$E7`I((N&Z\K[<!M"ZT
M`\`W`/@KR1V;<4ISSDI\U;"U!!YJ8XH4[F-Q9Y)MQ!I8C:@&T;K#;+K!$!&W
M:&T!$-@UX+58ROTKPM+(2SS>`8_09!9WR!R213Z-RR3DD,<M8'%LN"/(XF],
MIZ>0EF&<92J745[3P)!I)Z(3;RS+?98AG%TF82FMZF,$ETQ:2+C'A3CMCE<>
MCEK:*D4C08G;9@X/+L4>">PLI?>:[*"SEH&FIB4J:ZPJWNGG+6.(\Z+&5ZEB
M!O=6\RTE8B.(<+C"#+RBS[;+KB41I0B)1I=_VAEP;+P`1V[0#T9\LCB:-6S`
M]U3EQFY"G<K7>ZQ0*<4*HPLHA3P8$BIWAAAI=H!P&_`;@WUH``B'1Q[*>/90
M[)V5@E"%S=%%IQI*(@E?8:86E+$]1<%QZ,DO845;=?<`W@(@&RT!$0"LC3`>
MZ#:.].VGW!./,V9N9,<S(O&+2Y`QR%@FI9ZAM-<G=$4Y(5"6,JD+@W&JT2Q,
M4N0JE"4P]*H*L-NO)O"V8<*USZ7<CPU1D2!9)4R^"I;GNQ3+8_C_`">YL!%T
M;*N.?[37-+"C$M@M!5MQC@%Q@<6LM&XS>@%4DC^ZP[GI*WIDCD:U-1%]?I(Y
M-[.P-#6P3]8X/#J['E)6QO;TQ,0N-4JURDXDA*05;=><:9998`W7`%5*RAK^
MTDX4(9E67,LVXX32)0N2,1\P@N3&(MW5-A2<]Q(;[UT+*!2:B)5)C5-A6^$J
MP\JZ_8%X;>;&&O;2AFM"ZN>(\IW9';V-P2M+PMAT#R:^IFQS7)A6(T*TU!"S
MK$ZI2E`5!))@VWF%?;V@(52IWW6C<[F!T=&1[U00UJ=V1P7M3PVKF*>IEC:Y
MM2HY$Y(%I!D1M,3JD*M.>F4DF!;>2<487>`76B%5@R!KGTNXJBZ:;9*R2I@T
M16+&UO22.3X_R>T,ZA<\ISE;4D)7+(461>H<$R<X](5;>-QY15]]@#;:(UY?
M&>Z.Z+\S.SBPXGS:@R(]-#8#RZ-<1AN2'M<@:;E9*`'%4G0PTTPE&*U00E`^
M^T"^'-++V[ZX`KI9QNH.A#&DI<X3D'4+'X;+V848.T;D47R&UO#<+@B3N*+C
M:%5#RSR.-(%:981O[`X1.>4;;MMOM$:@=_5I;Y-.67E+4<E'<'X4<H?)_D_X
M(_!WC'%.[7=OX%<1[F\9_<.-<+P7"_:;[;X*I_!]U!T(9+E#9"<?:A8_,I>\
MBK!IC<=B^0W1Y<10(E#BMXF@2P\P\_BJ!(I6'\'8/!IR#3;MEM@C7:Y)W231
M3AQ\2QG*N<FS'TA7-9+VC9I;#\CLCBI:%"E4C(<B4JV&E&F(SE:%8G+/MM$N
MXY,=8`[XNX`H9JGUBZ=<ZZ!=6;SB&?*I^QOFGG/L:;'Z/0;(JEA4/A./GYO4
MM][X9$26I*8D5JB"5IJM80G1"8%ZLXDH+K[?SL+X)+DZ:X\]B5%DITXFG&"8
ME$"RR2M^;>.]4"(A9;;<([T!$0#P`([*ZMH87=^N/M:$!JZY-87>>!5Q5O!V
M&C=:7==PIA8"%XV7`&]V^+P[-H;3LPO#%<18[H#4-RJTR].!MQ5PFVE76VF#
M;P1A@`%MU]H#OMFW;X-OAV=HF@TM5IR%29C5&IU)19Y!MIB4+323K0O+OM"Y
M1;<`7VW`(;X`$-OA`!VA72-S2XNRP6]N2&*E@6G7B07<7;<%J?\`AAWQE]EG
M[G]\-]M'[P#7WNL7D#(GL5.K6>B3F'6D6&FWD76W'767WVE@!1IEVT;"[[O"
M`!]KX]H@`\S?#Y,Z)"E[>T*%2,_?\$HLO36V7\&9<5?L`P^RX-Z99=:.VT/"
M&T-H"`CU=S2Y6.G<6Y(9:Z<9M1\3&XOA.-7;-Z3O@O$K?#O@\/";WP^&X/#6
M8C]CX:H,%8+TY2G`F4YZFC&8YSJ)E\GB&.[623OTDD+$KQW`TQ#@V)8RR/5A
M]EYT9?@X$#04V6-BDTPFPH++[[Z&3-T=T7X9=FUBRQFU!CMY>&P7EK;)=#<D
M,BUP:;59R`7%(G70THPY&"U.>E$^RT2^'*O+V[ZT0KU>.M<>F'+D<,E^,,CJ
MY[%R7%<T&O\`%<?90>6HMT;2DYS@@O6(X4:3:K1E*DQB@D;M^58>5=<`!>&V
MCS7NLVYX/;LVL+1J>A[D]/#FB9FIK1L,^/7.#LXK"F]`W)$Y<1N,/5JUQQ25
M.19:-YIYEA=H#=<`55/)^O;2AA1"U.>7,IW8X;WQP5-+.MF,#R:Q)G-S0I@6
M+$*(U?"R;%"I,E$%!Q)8W7EE?;W``5\F+]T&TAYK[M!B/+Q61QCG<_N]\#H/
MDM][C]UN-]S.Z'$88=Q7C_$%O%>%WO#<5/WFW@[MG#%]T.T<36=R'&,6S8U/
M.0(F6\F26()HO/K7QCMCSLA8GL')$?$R3$M[6\.2%N6%&[TTE4I+*NLV[[>P
M3W2W/&"Y_)"](TVB&I!FS9'%C+E+"TKA^C2>:EXD\*76%/C(\/L.9VIO+9I@
M]QY@DLLCSFFC$B9LB0!V$B1M;BU%;T]57_<R[;W=IU.Y#DSMG:1Y<R7J#)D^
M7))G'3R_:4`<GM-A_&+!$$&+L!22]2]13&<5QJU0^)(GY[>)7()I)V24/CW,
M'Q6(6H[G]0PS;H6P[GB73B3RQSG36WY=AN.<>9TA,9>65##LX0?%$M>IA!8[
M/4SG&GE\0E-"V32=K/=L?/\`!I"\QM_71]Z=U[>G:K&WM8?HJP["LQEYC:CY
MD>J:9ME[)\+@+E("%>.<>90S\%@YJR+#F:UK(>D\ER*:>_*'.QYD;XQ,:J9S
MQ3#66-'S>2WN$N;O$']=OTA4:]/D4C#CC!*K71QA6*CYEEBXY0J9FQ2>==RM
MSH-\:<>E,-,NV;`&Z^^X1`/"(CM$9#*&MM5H>YBI`C4-W!E%<0/2D'(N"(&P
M22^*&EWIN#)$NP2K."WI8V6#8%HVV[/B;XU'FI1QIL8V=N4B7<4*A`UH$1XE
M7C;=>6)R5,4;P=]UE@W6;_>W#9:(@(VALT71B..BBY6Y,+*X*KK+"[E*YJ;U
MBBXLL!`NP3U*8TT;+`$0LM&_>V@([T`VC7VDM+8G0"U$-Z(ALN+-)%N)2)RD
M`E'C>)Y0HBRK4HEG"9>)I8E;PT;[Q,MN&Z[;UJ6(Q9$H)5HXVPI%2>\#"%"9
MF;$YY)@`(!>2<2D+-*O`+A`+B[[;@`1#;L$:LP;L@E3&WZ>KC4Z<ZX.4ZVVX
MY.0==;;L@UPVVB:7>-H"/A$`$`$0`1VB`59,+**)#>DE%$VB.^&TDHLFT;O`
M&^&TJRRT;M@`&^$-NP`#;L`-G#Q%%MV\21;=NW;Q))MV[=NW;P&W;M\.W;MV
M^';MKF-**.`+3BB3K0'?!:<24=:%VP0WP6FV7@%VP1#?``#L$0V[!&M"B""1
MN$DA.2-P`%PDD$DC<`;1`+A*+L&X`$1$`NV@`B.S9M&MER1)?==?>D2&7W#M
MNO,2)3+[A_#=?>3==</]-PB/]-<EQ15Q?!7%%7%;`#@KBB[BMENS>AP5U@E;
MVW8&]MWFRW8&]`-@;-A:5,5<%Y29*5>`"&_*2IRK]@^`0WY95EVP?OAMV#]\
M!KFL3)CE2:\Y,F.OXPFMWYR9.=?O0/LV6[\TJ^[>AM'9;MV!M'8'A&LUQN;&
MY*TIVU,@1IVX4@%"@(2D$HA*/+VGE\4++M3\&<)A@FV<'O#!,O&\!WP[?A30
M^*(SR522-1],I3F6FIU"=D:R#R#;!VV&$G%)+#2C+!\-MY=]MUH^$!"OL<F!
MD>+B;W9H;'.]/;?:1<XMZ-?<3:8-HF6E7*R#A*"\;+!O"P;0O&RT;@$;0V<K
M<SM30482U-J!L)-,X8TIO1ID)1AN]MLX4PM(439>9O+++=_=:-^]MMMV[+0`
M.K&&1&XT3KHO';C;C!.N-N8FFXRXT;Q,$T3!1C>)@F"-XF#<-XWB-PW;X=M=
MLXM+8[DVIG5O1.2>PRTZPAP2)UQ-IMMMUEIMI2LHXNTRVV^^T#`M"\+;KK0N
M`+K@'YVZ/,308::U,S4V&G66EG&-[<B0WFEVW#?;89>D()N,LMN$;K;;QNMM
MN$;@`!$1KY541BRU0<K61MA5JE%XF'J%+,V*#SC!``&\XXY(8:;>(6@`W&7W
M7"``&W8`5V9K6VGH.Y1R!&:V<"6G[G&I2#$/`$[W@B>)WEW)>"*WEG!E<%P9
M>\MWEMN]MV?`ABT;;%-BQN8&1`K+MOM+5(FEN2*;+3+1L,ML/3)BCK0OL$;;
MPMO`+K1&VX!`=E;G"-1YU4<:<V-G<5(%VE`H7M:!:>!5@W76%@<J3&F\'9=?
M>-MF_P![:-]P@`#<.W[4C4VH4?<]$@1I$`@:'$DJ5.F2;#QN$X.*D%ED;#AO
MO$T.#V&#?<-^^&X=MM;=/8Q'&O2RY*6Y@9$"BR?X]"P]&T-J4ZP.[!MNRPTA
M*7?9]J(AMMN`=G@`0`1`<<(T@@[9PQ!!V]V[WAB"3M[MV;=[PME^]V[`V[W9
MMV!MV[`V:E$DD`($DDDA<(#<!))1(7"'@`;@*LL"X0#P`(@(@'@`=E<7$D0B
M(BB1"(B(B(HD@B(B.T1$1($1$1\(B([1'PB.VN4PHHVW>&E%&V`(7;PTHLVS
M:&W8.\-MOMVAM'8.S:&T=@^$:VE)TY(B)*=.2-P;+A)3D$C<`#M`+A*+L&X`
M'P@`B(`/A`-M;;TB0RZZ\Q(D,ON';=>8D3&7W#L`-MU]Y5U]P[``-MUPCL``
M\0!7()10E\")10D[T+>!$HL2=Z`@(6\"-@E;T!`!"W>;T!`!``$`K0E*E*-L
MO*2I2KPN``O*2IRKP`?`(!>65;>`"'@$`N`!#P#M"LJW17'6!XTH8"4NK(T.
M2@O'+606>X-B!<=83:L<#`*L-5)SC+2@O,OO`NVX+`NONN"T!N$1END:&MO2
M7($+<A1H;Q-&]&D2)TR6X3P$#AN3$%%D")P"(&[2QX3:._WVVNL(AT32G$J$
MT9CR<].86:0<0R-1)Q!I5P7%F$FE([#"C"[@"ZR\NZV^P0`;1`0`:[!R9&=Y
MM)M=FMN=+4]U]Q%KBA2+P)N,``,N)!62<!0WA;:%XEA:-P6VA<(@`;-6UE:&
M>PTMI;&]LL/OM,.L;D25#8:9;;O+;S;4A1-IE]MGVMMUX77!;]J`@'@KK#89
M$3S#3CXO'3C3C+S3C36)I,,---N&\PPTR]'=>889?==????===?<(W7"(B(U
MVRYI;'--:B<F]"X)++[#+$JY(G6)[+R@&TN^TA24:3;>7;==;9<%@76!<(6B
M`"(5\S='6%G-,/:F5I;#S2^"-.;VU"A-,*WP7\'>8D3DWWE[^VV[>77#;O@"
M[9M`!KA6Q6,N*DQ:OC[&M5G;SA52QH;52DS@[+2[.$4*$IAU^\LMMLLW]]V]
MLMMMMV6@`!]W<AJ[G=R.YR'N7P/%^YO$TW<_@-N^X#B7!<5X';X>"X'@]OAW
MNVOA116,MRDM:@C[&B5D[_@E2-H;4JDOA++B[^#4)TI9UF_LNNLOWE]N^LNN
MMNVVB(#RN,<C[N=:I=&1H<E%A8$V'N#8A7'6%6W77@5::J3G&6EA???<!=MP
M6!===<%NVZX1BCKP;6]JT'ZR$K8B2-R8-+^?#03H4Q",@##,926Z\P"4Q910
M7WW!MOO"P+KA\-PB-?E]6J%`EV`*@\0$JP!`3C1`0&P-H"`W[!`?O@/@&EAA
MA>W@S#"]OCX.^ZS;L\6W>B&W9][;XJ7F&&;.$,,,V>+A+[K]FWQ[-\([-OW]
MGCK<"A1:`!:H/M`````#C0``#P```%P```'@``#8`>`*V6WWV7;^R^^R_P`/
MVUEUUMWA\8;ZT0'8/WPV^'[];KS33`V&&FF``[0"\R^\`'PAM`+KA#;L$0V[
M-NP1#[XTM./L`+;#CK+0V[+;#3+;0VCM'9;;<`!M$1$=@>$1$?'6W?W[_A-_
M?PFW?<)OKM_OOYV_V[[??T[=O]-9Q_V,ZV-RO1)DUU5(4:ES2ZI)L4E<5"4@
M]>F*MQGBO860M-+O4DEAPYVRPHVVT.%-V`'"&;[(F<8ZPO!I9[JRM+F>47P1
M1S@VH5QI96^&_@[#%:<Z^PO?W77;RVX+=\(W;-HB-?4WM3:U)Q2-B!$W);C+
MS;DR!*G1$7&F``7F"2E+**$R\+;0OO&S?7!;:%PB`!LZDN&1(DTL\F,1XHXH
MRPXHXMC:BS2SB[P,+-+,L1VWV&67@%]AEEP7VW@%UMP7``UV3DRM#Q846[-C
M>YV$7W&$V.*)*NL*,NMWEUY5JLHZTN^ZS[6ZZP+;AM^U$1#P5M;6)F9N&[DM
M+:U\8WG#]SD"1!PW!;[@^&XH23PO![^_><)OMYO[M[LWUVW81'F%,L/<$[*T
MDKE7"\96%-J$I6HX<RTXX3U):>T\X33;+##1-,OX0RRV^_?7VA<%H_7=,=9^
M7YR[:9<':-X0]8<1MD:<YMJOSS%XEF^+-+Z[MJAPN8,+Z7E4ZQJX9`G,<0JD
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M_P"0)_T[:YZ4I2E*4I2K<FZE_<I.G]_\>_\`O)M8U5*4I2E;K/W]O]JWZ0K*
M_P!#7W)6!?\`R^;/_4KJE?2E*4I2E*5$3=`/N%M9/YKF>?V8R6ORZ+/X,O\`
M)E_J6UNI2E*4K.?^QE?N%<J?G3S?]FF)JR,:4I2E67M8.G/6/EG+&4<3X:95
ML*Q_JQ4XFC&2]9[?G#N6^Z>M-,184*/+^)<88F-4!(T.;LG+&V2MD3R5#&FQ
MI)093,D$ME;.[XPC#:LDIN?F,\>XG;M0<)PM'67'>%(GFRR&P#$[%DE)D9-"
M#HMC:"HY<K<DY,FDZO&\AF$B//?WO'3FJ2NO#7$Y%>$YKYD5V6*;AM6!=:S_
M`)QQYK>RAEZ'R=P1Y6@VFO3&TZ%\8ND28Y7#,\N$MU!S8K5YB5DL=&AR?4$U
MFS6WX:9YJ[X[>(=+8?$"8%.7QU5P"//R0>DT[L#VES3H^P]8SO-^>L&[HANG
MV8=1ZU46ZBZ-V%<G#JR40^<R54H0$6JX=F^[-FFM?CE4OL3(9!W)M3Q\#E>.
M7TACOWRPJ8&M&\A"V-H'WC20;5,J;'5W:01@;_XRVY&SN[(LN4WE;`3&<?M)
M+,VB:4;;]K44\!,^=5&,F\UHGV+VQ'=*<F`*-;BV3NQQ2NW*,TM7B"\O*[5:
M>G-7`H.1@*!.80D,(3'"I.),5J*R]P=1'.;B3U.2KMGIW!U$<YN)/4Y*NV>G
M<'41SFXD]3DJ[9Z=P=1'.;B3U.2KMGIW!U$<YN)/4Y*NV>K/FZN(,AHAP7\/
M9-$I'P@Y$[E_!:'.L2XH-EL-XYQ[NG-)?Q_APN2\7X#N?Q;@CN$XSPUO!6?Z
M4I2E*Y2-O#I]FP!XP1L$0V@`\-9L$0V@(@`[!$`$!$/``AMVAE\)V+4,*=/O
M<F8E"W@"=@#AV5"(!P=O@$>6<-H_A$``!\86VA]J'-W!U$<YN)/4Y*NV>G<'
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MV8XD5RM.C7GY;<2$2HY.!A2=6<W+RDYMUAIB-3;:)5WYHUG[PO\`)E_J!6ZE
M*4I2LUS['";<J+-$N3S(/,(-'VNW4Y,K#TDF@+W*5QBX,<XM$Y04O;<@Q0@E
M+>3<F++27MQQI9I1QHK;[3K22<@?N#J(YS<2>IR5=L].X.HCG-Q)ZG)5VST[
M@ZB.<W$GJ<E7;/3N#J(YS<2>IR5=L].X.HCG-Q)ZG)5VSU]B%DSR6>-SCD7%
MRI-P5X`4DQ/)D9P'C>4)9@G&Y<6V"7:6!UMQ7`A=?=>7>!M@%W6&1OR4\;I*
MDRK.D^%\?:.Y'ANRV(W09RS%EO,4#GG'+XPENFI"QIQYAO)+*I9BI&-P,2]6
MZM[O?M<B%3;Q$EJ5J/4:2H?J,8W/4#+M3,6P[%)MDG*<<D#,CP?,)5-X<LBK
M#AO&L&1KUSW-H9`9+?)KG6,.Z5Q3JXV2E);DK/:A7+B]_>7,FM!`!\?TB'B'
M;]X?_P#0$0'P"("```=OW_"/C$?'_0([`^;Q;1V>,=H?%\]OTA5"]-_\E"#^
M^.6/VMSJJZTI2E61=V-\>GO^UD[]2"U9)I2E*4KE(_C";_B4_P#KEUFR)?XL
MG_($_P"G;7/2E*4I2E*5;DW4O[E)T_O_`(]_]Y-K&JI2E*4K=9^_M_M6_2%9
M7^AK[DK`O_E\V?\`J5U2OI2E*4I2E*B)N@'W"VLG\US//[,9+7Y=%G\&7^3+
M_4MK=2E*4I6<_P#8ROW"N5/SIYO^S3$U9&-*4I2E*5"75EK%2Z;9/@"%,T+,
MR))\R9^P3BN1I4ST2T),6P',V36W%Y.49,<*5::83?)G-.P0Z.%%%KI@^6N@
MICDS)%I6ZM-,\5:^%N1LJX\0J,=)6S!F>,ZZE--N"\B)WU<ID;YDK2Z&1/A.
MXRR.*65$V,D2R'=A?-=V/E*%Z7N):6!LJEV).-GA2**W([S+++0NOOML"ZZR
MT!ON"T!NNN`+;0&X0VW7#X`#QB/@`*H-IQ5)K,4MX7J"+1&897N`+CB[1&T<
MMSK8(`-P;0'[P^(:KGQU'Y6F\^5[=..H_*TWGRO;IQU'Y6F\^5[=..H_*TWG
MRO;IQU'Y6F\^5[=62MV).)-'3YP1I9N]NR;MX.^V_9MM@^S;O1'9MWH[-OCV
M#L\0U9-I2E*4KE(_C";_`(E/_KEUFMIEB3BR?_Q2;^`)_P#UROOEVB'_`.;\
M%<_'4?E:;SY7MTXZC\K3>?*]NG'4?E:;SY7MTXZC\K3>?*]NG'4?E:;SY7MT
MXZC\K3>?*]NG'4?E:;SY7MTXZC\K3>?*]NG'4?E:;SY7MTXZC\K3>?*]NG'4
M?E:;SY7MU;HW4@\@W2FZ`4<48(9`QX`@699>("+P<(`.]N'PB%MPA^$+1'[P
MUC7TI2E*5NL_?V_VK?I"LKG0ZI3EZ2\"VF*"2[N3YM'9>:7:.P%2^T1V77`/
M@NM&T?Z0$/&`U*SCJ/RM-Y\KVZ<=1^5IO/E>W3CJ/RM-Y\KVZ<=1^5IO/E>W
M3CJ/RM-Y\KVZ<=1^5IO/E>W3CJ/RM-Y\KVZ<=1^5IO/E>W3CJ/RM-Y\KVZ<=
M1^5IO/E>W3CJ/RM-Y\KVZB-K^5);]#&LBVU2GNN'2YGD`"TXNX1$<924```"
MX1$1$0`/PB(!XQK\N^S^#+_)E_J6UNI2E*4K.:^QF3R"M"V5`-.*+'OIYL.P
MPRRP=@XTQ/L'9=<`[!V#L_#L'\`UD6\=1^5IO/E>W3CJ/RM-Y\KVZ<=1^5IO
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M>(WDWW%C<7<(C:("(U%;`."L*O&,D*YVQ+CAR6C*\G)KE:Z%QY4IN3H<HS1"
MB)N/.;[S+BTB).G2)K+KAM)2D$IRPM**+LMK-WNV`^9;%O42,^[:=[M@/F6Q
M;U$C/NVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/NVK/&ZP8[
M@4!'!7P'A<6B'=2[(H.7P:86QD[H`CMA@I..]SDR?C/%A4J.`X;?\%PYN\WN
M_NVV>J4I2E*Y2``3TX"`"`J"`$!\("`G6`("'B$!`1`0'P"`[!K,!3Z=\"7)
MR+KL+XM$1(*$1&"1K:(\';M$1[F^$1\8B/A$?"/AKF[W;`?,MBWJ)&?=M.]V
MP'S+8MZB1GW;3O=L!\RV+>HD9]VT[W;`?,MBWJ)&?=M.]VP'S+8MZB1GW;3O
M=L!\RV+>HD9]VT[W;`?,MBWJ)&?=M.]VP'S+8MZB1GW;3O=L!\RV+>HD9]VT
M[W;`?,MBWJ)&?=M.]VP'S+8MZB1GW;4!=TFQ'BR%Z97)YB&.(/&'>V<P-/:Z
ML$69&EQL3J74XI2GL6H41"FTA06(V*";30+.M"T#;;@MMV8]M*4I2E;K?#=;
MM_G!]-9.&C7">')+I>PB]R'%>/7MY<8(WJ7!V=8>P+W)>I,5+1O4+5JE`8I5
M'W;`"XX\PPP;;;;1NWMEH!)KO=L!\RV+>HD9]VT[W;`?,MBWJ)&?=M.]VP'S
M+8MZB1GW;3O=L!\RV+>HD9]VT[W;`?,MBWJ)&?=M.]VP'S+8MZB1GW;3O=L!
M\RV+>HD9]VT[W;`?,MBWJ)&?=M.]VP'S+8MZB1GW;3O=L!\RV+>HD9]VT[W;
M`?,MBWJ)&?=M11UW8(PFSZ)M7CJTXDQNVN;=IFSBN;W!#"X\E6H5J3&\B4)5
M:122WV')E*8\LLX@\F^PTHRRV^RZVX`&OS/[/WA?Y,O]0*W4I2E*5FP_8WV*
ML93C1)D]TF>/H9*W,C4[,T!#A(HTSO*TE$3CC%AY2,I4X(U!Q:4LY2H-L(MO
M`JTP\V\+=]?<(Y!?>[8#YEL6]1(S[MIWNV`^9;%O42,^[:=[M@/F6Q;U$C/N
MVG>[8#YEL6]1(S[MIWNV`^9;%O42,^[:^M%@7"#<<*EOQ%C9$H$J\@3DL*CI
M!HDF7EF7E"84WVW"7?>25?=9MWHW%V"(;;;=E6:4K0;@`0#[X_T"(!_6(!L#
M;][:(;1\`;1IO@$=FWP_]/'L'Q"(??`!VA]_90?%\]OTA5"]-_\`)0@_OCEC
M]K<ZJNM*4I5D7=C?'I[_`+63OU(+5DFE*4I2N4C^,)O^)3_ZY=9LB7^+)_R!
M/^G;7/2E*4I2E*5;DW4O[E)T_O\`X]_]Y-K&JI2E*4K=9^_M_M6_2%97^AK[
MDK`O_E\V?^I75*^E*4I2E*4J(FZ`?<+:R?S7,\_LQDM?ET6?P9?Y,O\`4MK=
M2E*4I6<_]C*_<*Y4_.GF_P"S3$U9&-*4I2E*5:XUM8*=IIEK`\SQKE+/S%J,
M(S'AA=CH(5DJ9,.)\<X1@>0HP_:FW#)6-&9X:<6S*%33%U\JC#\JRLRR-\?Y
MA)<=Q*&.K*L1LU[9%'3QE+(J[*ND7-#A/)DMG^J37WNC>`,SP%Q>I$MCS;A_
M#/?<<F$62Q%<L.88B;A#O;<4(4+N@9FQ8L6S&<*U:HU5D1W4.%]*4/;DPM7'
MVN*/LR5\:2$=Q8ZHCJ9RN+/-"PU5:;*'Z.-0$)+?W0^TQS+.NM$`(+-NVVA%
M'`>2)@@QF@3I<%Y.>"?A3DT[CS>Z8F+3"8IRC-%!R:VQQR8A5@:A--O0JAO2
MV%7JDYUZ0Q4BN3JU%9.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\
M,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL59\W5R5/DF'!?=G'DM@7$QR(*?
MX4K(8K[J<8MAH&@A^",LE'!\3X$L5'=#B.^XR3Q;C&P[@K/]*4I2E<I'@/3C
ML$1!00(`&S:(@=8(`&T0#:/B#:(!M'PB`;1#+X3Y4G`)TX!IXRU<`$$_;`[X
M9V#^YV^$-N5P'8/WMH!=^$+1V@'-RJSCH[Y;]+X9[6*<JLXZ.^6_2^&>UBG*
MK..COEOTOAGM8IRJSCH[Y;]+X9[6*<JLXZ.^6_2^&>UBG*K..COEOTOAGM8I
MRJSCH[Y;]+X9[6*<JLXZ.^6_2^&>UBG*K..COEOTOAGM8IRJSCH[Y;]+X9[6
M*<JLXZ.^6_2^&>UBH$[I%.)+(-,KF@=<23Z&)1G4#,%YD3ACA2VVWE.I]]B>
MXJ,SV0NPG*;K0*(N+:[TUMX[52E-;O+K\?*E*4I2MUO[ZW[_`-L'T_TUDU:.
M,A2QHTOX1;T&$\DR1(E@C>40]L[GBPEL<;+5:\+5*(IZR0TNQ9!@!]K:XMB!
M4`@(W)K;!+,,DORJSCH[Y;]+X9[6*<JLXZ.^6_2^&>UBG*K..COEOTOAGM8I
MRJSCH[Y;]+X9[6*<JLXZ.^6_2^&>UBG*K..COEOTOAGM8IRJSCH[Y;]+X9[6
M*<JLXZ.^6_2^&>UBG*K..COEOTOAGM8IRJSCH[Y;]+X9[6*<JLXZ.^6_2^&>
MUBHIZ[,DS%?HGU=HE6"<GLZ95IGS@G/=7!TQ*8A;B3\<2(HU<L+;LFKW"]*D
MLON4*+$*%:LN*+O!,E/-&TN[\T:S]X7^3+_4"MU*4I2E9KGV.%-)''-$N3T;
M1BN<SA.9J<F2F]TC*_'Z5"0<9CG%I=Z$TN53>-N`JB;"2SS+R4)J,2E)(6*[
MS@.**R!^56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.56<='?
M+?I?#/:Q3E5G'1WRWZ7PSVL5]B')DR5GB4?@;*+<6!5Y@*%CKB2\D;[;RK;2
M0!%DY6=PAEIEQEHB4!06DF!>9;>)=M]8:4J'.8-`>DG/F44^9LNX@;YMD9,W
MQ=HL?W*4Y`3EF,\,<U;S&F94QM4N;XVM9FUU7N#@#2M9E#<K5N+B<O3*[UZL
M3JGQ[3+@N*Y5=\UL&.VENR0\J9,O4/9:MY-0HG>;%1\B<R%ABZES/B,7E,\)
MBL<*GLJC3"T2*;ELK=;*G-V!-;MKL/B^>WZ0JA>F_P#DH0?WQRQ^UN=576E*
M4JR+NQOCT]_VLG?J06K)-*4I2E<I'\83?\2G_P!<NLV1+_%D_P"0)_T[:YZ4
MI2E*4I2K<FZE_<I.G]_\>_\`O)M8U5*4I2E;K/W]O]JWZ0K*_P!#7W)6!?\`
MR^;/_4KJE?2E*4I2E*5$3=`/N%M9/YKF>?V8R6ORZ+/X,O\`)E_J6UNI2E*4
MK.?^QE?N%<J?G3S?]FF)JR,:4I2E*4H(@`"(^``#:(_@`*CU%M5&"IGEAXPK
M'9P0NGK.XRYD%-<T/R1@>))CRUFNR-%8K,EC6GB,MEF.@D+-;.XU&WMT>8J:
MK.(=T:8]J>RFR0@^+Y[?I"J%Z;_Y*$']\<L?M;G55UI2E*LB[L;X]/?]K)WZ
MD%JR32E*4I7*1_&$W_$I_P#7+K-D2_Q9/^0)_P!.VN>E*4I2E*4JW)NI?W*3
MI_?_`![_`.\FUC54I2E*5NL_?V_VK?I"LK_0U]R5@7_R^;/_`%*ZI7TI2E*4
MI2E1$W0#[A;63^:YGG]F,EK\NBS^#+_)E_J6UNI2E*4K.?\`L97[A7*GYT\W
M_9IB:LC&E*4I2E*VW@(V^#[PVW;`\8[VX+A`/%X1`-@>'9X?#5AC3YAK+3/E
M+2%A!RQE,6V0:5==FZ&ZD<M93<X^\)(:^XJS<5JSY*WJ+3U>66R2]SS`?JD@
MI[A%F9Z=GN/*X'.$TG;&X(H5PE\:4,CD_-?<]KE;]#E?&DA_=J.IXZI<K2DY
MN_-2VE2ABD;4)"NW]S/N,;##K;``232KMMPQFP[AO([9`T:)RS)E>)K"Y#/3
MKV4IIQ'=982LR#*5R-P`5N-G)3OGI$I3O5^_6&%A>X7`F*1I0(0IJG\E4XZ1
M&6_1&&>R>G)5..D1EOT1AGLGIR53CI$9;]$89[)Z<E4XZ1&6_1&&>R>G)5..
MD1EOT1AGLGJB68M#\4S]\'N5G+67)3\%>Z?<'89CAFXCW9XCW2V]P\=-W&>,
M=S47\:X;@N!_<>#WYF^HE\4IIR_&S+O6"+_4VGQ2FG+\;,N]8(O]3:?%*:<O
MQLR[U@B_U-I\4IIR_&S+O6"+_4VGQ2FG+\;,N]8(O]3:?%*:<OQLR[U@B_U-
MI\4IIR_&S+O6"+_4VM;=R6TYVW6WVRW+H7676WVC\((OX+K+@NM'_P"S?O"`
M#L\0_?J:]N*)O9;;9;J'RV%MEMMEH=R,,^"VT`M`/Y*-H^``VB/A'QB(C6[D
MJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3T
MY*IQTB,M^B,,]D]>-C\`S`MDT];WK.&6$#"S.[$FAKE:R8:LO>VU7%6EP>%1
MI@XP.M/N22-2Y-Q=]A"("BTH$W%J+[15&>RY*IQTB,M^B,,]D].2J<=(C+?H
MC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/5.LI:4B,T
MQ,Z#Y*S5EN1Q@]Q;74UN`C%C7=<O:#KST!P+6C&:%=:!)M]U]Q5J@"3OM0.L
M,"VT`C5\4IIR_&S+O6"+_4VGQ2FG+\;,N]8(O]3:?%*:<OQLR[U@B_U-I\4I
MIR_&S+O6"+_4VGQ2FG+\;,N]8(O]3:?%*:<OQLR[U@B_U-I\4IIR_&S+O6"+
M_4VM0W)73D`@(2S+NT!VA_\`,$7\8?\`\-J5\'TZ..-XC'X+#,ZY:9XM%FXM
MI8VSB.)%HHT!)AII9-RQ?BY2M5#;><9^[*E!QPVB%HF#;9:`>JY*IQTB,M^B
M,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?
MHC#/9/7C3H!F"W(+:R%9PRQ?"SX8]NBY^%DPT)J>5)']@2-34!_)A;9:4L95
MCRKN(%&9>88AM-M6%6V"G.]ER53CI$9;]$89[)Z<E4XZ1&6_1&&>R>G)5..D
M1EOT1AGLGIR53CI$9;]$89[)Z<E4XZ1&6_1&&>R>O(S_`$WKLHP698UG6=,M
MO<*R!%GZ%RYFXGB9O%UC4F;%+.^-P+VW%Z1Q0BM;5:A-QM`J3+4_"<*F4%&V
MVWA:\#['1W.4```:,O;```#_`.I)WB`-@!_^$_@"G^SI;G-_NC+WK).]TT_V
M=+<YO]T9>]9)WNFG^SI;G-_NC+WK).]TT_V=+<YO]T9>]9)WNFG^SI;G-_NC
M+WK).]TT_P!G2W.;_=&7O62=[II_LZ6YS?[HR]ZR3O=-3FTS;GSCC1W!77&F
MG/)F7,>PI[E2V;.;,*R`R@5,F<6QI9UCD#A+8`]N1('-S&UI^)D*RT5@I>%+
M3VG&G7F2+Y*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQT
MB,M^B,,]D].2J<=(C+?HC#/9/5$\[,&I*"Q=J=<.Y*R5D21*7\EO<69SCF)E
MJ=*RFMSBI-<["F^#1T^PXE<E0I;3+EQI6\6F6W);[[BSB)LTI2M-@;=NP-OX
M?I_3]_\`#L#;X@K6@``>(-G]5*4I5N:6[HU#H#D_43AJ;X5S''<DX(QI$<K1
M2+J;\:*%^J"+3R7J(!%;-,EB2?FC.'I7/;&W'[HRR<(0NCL[E$.8'TI`3*6A
MS42@9=2>'ESE.(P^3R'Q&=XEC,-DV9X4_3"+V.6(D\X;;G-E23AU3.I\<0'W
M)[-\<H3NZEO`LYO56*[T3PSJ5_NG3*V,&1I;W]YR+!&EC=FMK>VMY<YC&T#4
MXLSVO;FMF=D#BK<R42QL=G)X:F]L7ICS4B]<YMZ1(<<H6I2S=+LKXOM+>#KL
MBP2TJ/291"W\VZ81RTMDF"1ON=E<4=[Q<PM;)*E:[+G)2PKA(=DZ"VY:<CL3
M`)H;1RUBX&B/OXY'@0,<L;N[$6>1F4:!JDC3P99W=1@<1=`1/+<)1Q)H+FP]
M4EX,TN_A=[?:(]HT3^"O\A=XDQS**/,ICZ)M<GV-M4C97%_9F]Y)+4M"]V9D
M2X]S;4;JG-*/;52U*00O),L-2&'%WVW#&:5ZO6_E^D^FG#F-I3G'*.,8A$)Y
MFLF,OD/C49Q"Q9#O>.3AEE$EF#PVI560\B)(^^O45@K20J5DQML&2R]RB3*\
M1E8^U'Q]J6Q;.85#)>ZNY.+G"9MAR\C'^6':+0[(K$I1B]=TV20QN^1+K$KV
MSA'7R]T2H%[FF3%-3@H+6GI$AZBRISKD2`L:1W7O4VB+0B8%;8@?%;G)F-O2
MLRYZN)L9T3JH5KR26U6ZWJ$]C:G6F$'+[SR;4EAPFEA=0O&>KG%F2\N9APXF
M561R2XJR!$,?M1TAD,-L29:53'",-SVWO6*RFR1.*Z2-!$'FB$]87>F3.Z<4
M3@N.:RFBU,O45W1Y!@CBNEK8@F<46N4!M)OG+>DD3,J70VU0G4K$]TK1D+3%
M,<`](C5JB1>BD/"IDJD\O?%)SK[*-:>=3\'U).N>6^#(EMB/`^8B\/N#_<\1
M&01^:J56+<:9:;9?"WB&R&1MZV+.D;R@R%)A7J4+TG<4CDD<FE`:1:7=)2E*
M4V!X?!X_'_3_`%TI2E0YRUK*BN#]1>&L"Y,@4TBK#GA+.BX!J$=W*`H,$?"K
M'D,63Y]QQ)GY7,"97&)^X15L>I!%&ESB%C7*V2-2UP:'PZZ,.Z5/W&)]7V-L
MB->%OA6D=<*3K4,U2N38@Q'E1?%T.3);#HF8WW*)62Q1M_D25*W.+:\,3T@2
MJ7&UV(02%D2.[>UR!4H8T=<&C*N,9`RA)&+(D%>H]<]*(W:^M,PCCDSW2%);
M=>K8@=$+F>@%X3667WJ&L%''R+;+[C4]EMHB'QH<S8B<R2E+;E''3@G/@XY-
M)/13F+*R3L<@K,0?#XHU.[&%F0H5Q1J,)99<,?XV7>F[H\-9=8'U)\L8O5-C
MP])<C0-2SQY\NC#^ZD3&-G-K)([+"#+V!W7EN=R1L>["U*:^]I7')W"VQ01=
M<F"TXL;MQ65,9GND:8R<AP8QYF5[H7$6DN7QR]SE-['PG=JR.(+'.Y6^WM'!
M&]U+6HE6+?P9G'`)WEVRB^>=4\:PU/,1879(P_93SWG8R6J<;8HBBME;5QL1
MQVA0..1LER^2R1<W1V%XY@Q+NQ(79]<5*ER=9')(W%(FPR*0O!*`NE8:_88Q
MY,A6+,IXPR)AIYDC[FJ//TDR(XXY;8!$%&#L28[S(^OJV7I9NK2.4*DD5R.W
MC%)8B(+1"L9GY)*"(NM2$HU,S%L_@K<ZQAC<)E%4+U-BE)\.:%DB9DKG*R$:
M&YS5G1IO/6EK'\I(W67KU)C02LL3HK;E9PV)[1,#@3Y)QZK`NY+.8<IM-;%;
MV4)$I8#@,9T'#<==2Q*<;PO;4G%S^-+[1%(GX$WASB^#OWO.AGT'<Y&,/;9C
M%G"66L*>571A%(6=7(@C*LQ.2ED0L:=::Z`Q*35:8I.\<4[FGFJ$Y92J^\\H
M+Z(8PU5X\RYG[-&`H:6:ZN&%H)B6>.DX:WZ&R&%R-%EE^RQ&4S4R*HS(WET1
M/D4?</R9ME37)FUA6I#S6\Q&G6)5'&:D[2E*;`V[=GA\6W[^S\%1LS!J0;\1
M9>TVX>40"92QWU-3.8P>+/L=51`A@B3E!,>2'*;\OFOPADC*\%-0PR*/REO-
MB[5)URIT2)VLU`E%:2IJH:W-N&VTEW4N&6,:(4\?:V=\?3UD]B:4EE9I`]'1
MQA=G8U0\%EMC8]R!.H8VAP77$)'-X(.:T)QZ\J]/;WR[(L`;'Q'&7&;Q!!(W
M%>I:V]@6R9C2/:YR1L5TG5MZ-I4+RW!4N2QNR^0*49"8Q20R67.QI5C?:*FN
ML'+^*0BL>G0Y+Q^$*ERU"VQ67C-(R$7DK@YJ;T3:AC\A%T[CO2QP5EF)4*5L
M6JE"Q39>0F+--LOLMI%F?5ACO"^4L`8A=25$BF&?<K-^*D#='GV&W.4'5.\#
MR'/&:4S.-N<C02PN)O"7&DA9D#HQ,+S:+T!!*H$J:Z]3;[B&YPC#W&X(ZS8Q
MEQ5(<C.[\RQ*$2S(.-'1]?ES,_N+00FCZZ'2Z11Z4K'1$D1/93;&'=X<6Y*[
M)6YY3('I.O;DO`Q:E]/\D89C*6?,6.5$9Q_.WK&4SD)\N8VYBCL]CSH:R/$6
M<W=R6HVXAU1/)"AIN(%2('.*56C37G'I5%A=8G)U;&9O4NSNX(FML1E<.K<7
M%6G0H4I.VVWA5*M682G(+WUUMN_.,LMWUP!MVB`5XU)EG%Z]5&$*'(T#6K9J
ML?6^')$DQCBE3*U\84KD4E11H@ESO-?U<>5MCBF?4S38L/9U"!:0XEIC4BBP
MND>'=5^-,K8O'*CL<&)6@<RY@P98W91?X<QKC9UAW-$XP>ZMR9:CD3@P+SI#
M)X(Y+(RB;7A<N7MJM$%R>Q<*A(37%//80KE#S"4LPBRF91QL3O4@B9$A9SI,
MQLZL"[DKJ\,!:VYW:VU3:<5<G7KD:=(>!I8E'7A?8-W0!F?$(L"&5!E+'(QE
MS?$49;9$$YBHL3A(W*U/>W,")X!V%M5O2^Q6EN1-*=28X*[5)%R=,8!Q8W>`
MU*:F('ICB<.?9:C?9)),HY0A6$</XYB9#>?,,I9=R"I5E1B$QONRXLS"B-X@
MV/DED+[(GIGCT4AT<D<H?7)*VLY]UWB,?:QX*]94F>`LJMMV#<XPB%1;)ZJ$
M3:3158V2?%DUD+K$(]D."3-J<18I*Q?#)E<H8_(3`:Y)&9.2B2.[&4VR&*N[
M])@J<0P]P3M1,LC)KFK7KFM,W%2!G,7J'-LM)O<6\A'8MN4G+D%JE/<M2%%7
MJ$EIY(J"BP-+&[YAR+`+5$91W3>(@KFBEQ10]*,F8^,2I8T#>#LEC1/'^$?E
M+9P=XN*=IM6'(0LNXU83O1KZ&N<PM\>I''&66QEWD,/N362QB:W]H<'F,WK"
MS34=DA:TBPY>R7JRB33$UKHG2"H++,O)"^VR\;8V8PUJ8<RC.]2<2;7-&SQ[
M30KQF7)LI.LL@1V,Y*V90A]TN9G^.2EFE+HC2M2&PH]E<_A->Q.!#N2)=J`4
MQR10HK^\96QC'FMO?'[(D%969U;VMV:W9WE\<;&QQ:WQP;FEE<4"]<YD)%B!
MX='AI;6I8F.-3.*]S;T:,TY2N2E'=N?-H<FE:*"*)5&T\V<FI2^M\//?6HJ4
MKF1&;:2L>$<>,5VO"IJ2G7VDJ7$A$8B3FW6EG'V7CO:],(`/C`!_K#;]-:TI
M2E*4I2E68]9.G'5)J`D:;5-C.`-\0U-:(LFI7709$9+,8"?%,F-+X8S-&>EF
M8'YN5JS&&(YZQPL?,8I8K<N!ZQHG8&;)[68OG+BF:XY3?*.E;4X]9OSYF1GT
MSP)\;<\9"W-G+*U,JG>-7')L('`CJ0ARTV1=)([T&.I!E;&J]L89_"'>;O3C
MB^1(V\%5B5SE;8V14Z+T0W,;44?@!MQU/]/,&<I*R;EQKXT>,]KK+\4R=,AR
MME#/5DHT^KB'%2H(L21P8FC5/J1]1HR3X+W>L;NX[>YJ'9`BZ+4SI1=,4Y3P
M[,)[IXARR!Y.U5[CK%6"`VKL4+U,YRAB6&ZCHCF$@UO<7A/'CY$='Y;'64EX
MD3HE)GK,P*&1<[E,Q27AJS_%]9>+QW%<"KM*\:/TJ2W->I?49DK#<6DV%$\C
MC\`G.9%&2L/Z!8VLD#ZWQV$X1E,G$O)^HR['"]1&;;168.@I+W#9/))197G3
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M4X-G^()M,,>:!U$`=\9Y0TPRK*..,QZ<,2:H('+GR3P[(SDZ8%R]%RU63(["
MI!#9E(%K1.,5RAP7,;G')JP-I<<[6*;GYJ22J&^4R[!.)4N1&O5=N3^7DR_&
MSW#D,6B\4TJ8.P1CW4$@Q3\(WCX41B,(G""Y"CV/XNX+27600]];T+BJM)<G
M:TGQ;1N?FK(C"N06!3IW8UVI'$<&CV-&_,$MU2O+Y`M<&+(MJ[@.I*2XN:H>
M<]/`XMCVH2/Q.5-V156:(S:L@<WG[U%8H8^XTDDW?72ZCH1Q;D['\\UQS*>8
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MU&V1E^EN`C[6F&X7TCQG`N:(^1&(&ONA;>J@;C#$L>9&UK4.'PQAJQGLM?GU
M22^*AI5J.T#3W%VE;(LN>L%X]A$9QIC;=X)#D5U)=<9\72XHU1,^69_@1H!(
MT*CCG!F1@IA1;A$4B>Y##WN-(#4B(\&QK5C7>*:0LXI8=.\OZ5=,&/<*KM0N
M!=#6'RV@]PP8\*&!_@+5E!WR=KD:898ZKL4RC+43Q[DQJQMA,N22%')IJ_LS
M:]9,+:(2QIFERX)+H*SA')7@-JP3HUCL!Q;@B6Z!GR"`CREAN^<.L8T\:L\E
M3?+B;-TJ=W!U?'/(2Z/SUQS(P+,:K2VF<.D^RPHRG*);D&^(Q<FXGJ$T^9=8
M==VFS7AB"(EY8*A.#LO:4<SXE3R*-1F7W8VRS-L<9)9,FXO<9HX1Z'.DB@\T
MQR0AE$0DLHBOPAADB5+V!\M?(\5&Y-TN?\&9:U#YZTG9*EV!6-?CG&5FK,N7
M0F3R/'DA<4;-E#"K9`8,CD;*N=%D6>)`]R!.\"ZHH^YO\>C[(N;^,OK@K[H@
M1`_">@C4G%%FE>#9JT^796B+#@3<Y6@N6MNIQ7"V?2UF_0FT%-+FLD$1C4N:
MW3)$:<'XHW*6*7C%HJW!_D#H_0#++5'H>XGN:CZGC<M=3#!F=09B]QQJP8+B
MN>\Z8VQVQIRF9L<4^@?=!DR7*.LJ)+$Z=MOXD^XISF-MFG&)(KB6)L96L\]:
MF.*>;+6_T$GT!:BI//=34038L2L$I,6:T9AI"UJD:AY"VPW&B#5+A5[QK$H*
MEP)'Y`3*6298Y2*XIC!>G.CZS$23'>/HMD:'+K<C,\<C[#*G0IAS-D4U)Y/S
M%D#2A&]+<7R%HWT<XC/C#!D#%TMM2Y.T[R'/Q,E:TQ..%2RQRB1#!E&.H8#*
M7,U$Y+(LQ(T[NPQQQ$8\UW:Z4I2H(ZF\79.F>I[01D&'P099!L)95S+*LIN(
M2**-1S.Q3W3GDC#S,*!G?W1`KD9XR"<(EKDC0VAQ=C1KS[+U2WBS:IM$P?<O
MLIM>*L21&0Z8L:J7F/Z!-TCT[S0+G/$*Q(MR/J$RA")1@DA2<*P+7YB21V-/
MZ4QR5E&$0@U_*2)4=A2AR,([F/;G%G4RQ6ZS/3_#WR3G:L=RGS`:].,EQ8[O
M*F'Z7L+Z?\?ZBS1=5;L8J%Q7N>,9HF2-YJNR_(#._H[%YI:=S=D:/64Z`<_(
M&Y?&W'2TFS+@.9Y+W3.`2+3K$=1+!@NUDQCK*U!,68L:Y+(6,S\WQ11"1C#.
M[X_RS"FY4FR7"_A`EE.,6^2KT3F@7U#0Z0=5S%G'&J-XP#'9XVXGW3@G5<U:
MFBLI0U2YOFG27:>\A8J*@8I9T]J<P?#;"Z26,6*P9W8LUDF6/(9''U++U;LY
MN[2UQD=-SPUG,VG[`>,6#37"%3[B7%L*3MSI&LAXC;7Q-(L:;I3"]30XR=GN
M3NAB2/P9SQ7%V.3XU58J2-:XS(30\Q_*#XU,#3#$+E6R4Z%M3D2=Y&O(TX,V
M9<9':P-T#DLQQ%CS/D?Q-(<OX>UOK+7B*Y&2.CHHB44!QQ6TN$@Q7-L>Y$<"
ME[G%9K-WF%+%AK:RM,HDQJ6T):@I1HFS3@N`9'>)1&I/I`8<!XMT<.(XV58K
MQ]*6>+0*.L[@CU"3N-AGR8%1D8PY&ER#)60'E>[&NA[NJ;S5R=I1(?+SS1%,
M+]7EJ]OTLM,KTWY&D.EO+L*6Q'-Q6#F/29ES`$Y?9V_*)EBB#29C,FQKG*Y$
MORE%'S$-SL?+\BNDPB65.*0M[,DKA0^;:'M2;E&F=KFFF=1GC&$SF&ZAX^RA
M@5IU*,6('!-#];&KAUU!XWRRHD35(T<8?HH9`E`XOR_%D:Y/DV&W+4TBQ>BD
MIK6H0.'UGZ']3*G4I*I6]Z:H\NQNOBVZ*XM?[(AF:*1ILR'#M06&-.C-BZ4V
M3%W>'7/RR9Y(OPK?`\GR&?.X.,-G!+2_11M20A%;)5=-2=`VL`IE(;LMX)<=
M5&()<EU)8(D&-';,V*-.&H!VQ?EZ+:=T$&R_J1?<)OK3I^R1*&UNQ#(<&9*?
ML8@S9%=,3H<5908XZOR?\.8U==-U?Z4LB9"CVB7(6*"6=WRAH:S_`(^S>UP%
MXD;EW*R?&F_%TRPMDR`H)I,5#FX(96M@V0'EZQ]*YHN/+5S%A94DS>FQ(^.T
MG:XQYZT/9`U?:A\PYYRU@AK30*3Z.T&@3'V&\AR.`N\G.8\NYLCV3\W:CYXJ
MALI>XW'+<6!&(2MPS%H;.GV?N3Y&'U[L7P=V<F(4U$<E8BR/AS3;IWATG<\,
MQ/=(-..J65/VB.<R.41=1*M=KFX2$O'&2<FRZ*LKF9D!QDFH+#65U3UJR9D)
MZZ^*SJT,F+5Y439&@UJKM?H@R)A[/T0BD2T\X\U(:;Y+A'2/CQCF<NE$6A"[
M3/D[2EFN<9B>,EOT0VHWJ3MV597+F++R0S$EJB1.6:822U3M&VQ%Q;Y6RQP>
M]SKUD2+!Z'';`T1^`YOPOIQUU85<LVG39H3Q[6B=GG)42G$#(D:N-.[ID%F:
MLG&1QQE69G/(S,W.&.L@R1\)A*";MKRX2&SVJ#2GJE<\^S'4LW:1F'&<54ZG
M-"VH1?IPOR-AE6_9"C^(],V5M/N2XN09#Y05BXF<XDEDV@F6<7J)5*$<6F)F
M)XRE[MQ!X+;;63PLAW+[++A%\M,EV"H$[M\]T)[I[B3'<<='G&[DFQ1+]7.I
MT<UZ;\,%*'94!:>.X9CBMU0F/S""R*P1T=%C-`[W)D+)<#Y'8STC9M*U<L\H
MS'@!9-V!#EK&&IC%^H7OF'-K:L+/#1I8B.`ICBZ28=8Y0F?9+/V4^/S)DC;A
M'D[_`(7G<%R9>[SM0ED<;4LS[?!M#9:`?@``\8CX@V>,=HC_`%CX?PUK2E*4
MI2E*4I2NF=XZP/XH1?&1H>!:UEC@VBZMB%R%O7%AO;%B(5J<\4BNP/!8I3\$
M?:'@M,`*[FE*4I2E*4I2E*4I2E?`Z-38]H%34\MR%U;%I?!+&YR1IEZ%44%]
MM_!J4:LHY,>7O[++]X:5?;OK;;MFVT!#F1(D;<D3(&]*F0H49!29(C1D%)4J
M9.3:%A1"=.18620258`6EE%%V%V6@%MEMMH`%?32E*4I2E*4I2E*4I4,]3NK
MELT_9*TV8>L1PXJ9ZGI9-(K!I!E.<&8TQ@F=8+'$,D41=7+R(Y*E"S(LT*<"
M4..(*C:07RD4,G<$ZH+(R<@<?NBNKZ&,\`QN]:G/@UI;R9/C'A*HQ3/9TV+E
MK"K:IZ;CTH\R1"@9$2J.NKXIC25HEZQO98^YKI?&FQ*I%>\MJ95IC/5W$Y9E
M'.^*YY9%L8OF+M39.FO'UCG.DBY7FA\5:<<7:DDIT8;EC0P'E2BZ(Y#<0/@C
M8,C<"4</=W@AR6I046(>GD.Z"Z4$#PVQ9@SMB!ZD4FP9E+/\0<5N0FAHQFX0
M3%$AMALD=WS*!1;K'XZU(9A:Y,SPNN+<3V,N+S-8N;PNC*M*;4=HU28=(NQ'
M&YYDW$\7R9EF+P%Y9HBTY"2R-J<'3(3>8;'&^*R=6UQWX0-DL=4+VV8U='%F
MC:_)`,ZN^.L5Z\A:U(OJB>K33).\AH,40K/>)I9D9U^'UK9#XY.F!Y>W%1BM
MZ".Y*0(4S>M/M5N<#>QN;I:U)S#'-A/+-%Q2$%$FFV2&KXE#:WJE:%>I0HU"
MYLN4W-RP]*0:K07+">+*[D2DPNX](*I/^X*!3F%\.2(E';\L=[7VTI2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J&NLC!KOJ%B33C-\P
MI@#4=@Z0)9,BR_A?/*I:TIY#=>F:CX&_PQ_(A,[3,TFBCVE<5=BX]L;UJ,I;
M8Y,+XV/C<A.&VBBW,34TPX??<2.&2<?9E09WW/99H/RX]Y5E<Y=I#B!$@R-G
M268]FL`E+M&9#),RMT#A.H-VQVM13!=CF22]5B'%DO5.[:N<WPACK'+=#&HU
M'D&09)A2O$TB6L^Z,8%U?PEDF609DV+);CK'>BV*:-)BP3>3(,6O`1K(BEM9
M%^3VI6ULLP87MQ/*C3BI9.&.?"J9P'<V-3$+C3<W'R;!+NY.>F+=+].<P+M?
M\@(4)0ZQ-2"O4#BV5QTV^".!A]C1>:5&\A,SJ05>T%6FN,=<Y=?=:BMY$^YF
MYZ^"$\PZZR/&*Z!:@8;N>]V19HCD\E3S7!N0M%+?C./OM^*T)D`*"?QV:MN)
MXW),;KGE_P`?+L>Y#<Y.]NC&]H7+B]U7L6Z$<UPK,.%,A.BS$MS9CW7OKUU6
M2(IKDLI/=E<*U:QG+3%%6-JM48]0IU<OC)N3$ETH*7+&]H,2QW>-+RON6$EH
*[O\`2E*4I2O_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g678933.jpg
<DESCRIPTION>G678933.JPG
<TEXT>
begin 644 g678933.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`_1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]!54-?5D%,545?2U],24Y%+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_```L(`3`"%P$!$0#_Q``>``$``@("`P$`
M````````````!P@&"0$%`@0*`__$`$\0```&`@$!`@D("@`#!P,#!0(#!`4&
M!P`!"!$)$A,4%18A,5:4U!=!455AD9;6(B=49G&!E:71TS*A\`H8(R0F,[$E
M0E)$A/$TAI+!Q/_:``@!`0``/P#[^,8WU^;_`)_]?\OG]777KS5"\\S[HIKE
MO:]>76[\=I11T'XA7%RXF355&W]#=_&R,U7)V1%&FZRBY).'-%:[?<D25R5Z
MC,A8H/588^_P>1LQS<],PFM_<:L._;!6'0%/P*].3]?P44:Y!]FM<7:'4Y$Z
M\/>&Q\C+Q4+95<H6\;I6]/#J_HI2[/D3O6M?)UFM[;&D()(V3HH^,::=L&B;
MU\>>4MN*.54DX9\D$-?#M?\`[JE3\N8H_P!7-KXSQT^-3&:2>L;/@#FV2&12
M5:)?5]@LC*6QRLEP+)FL7EZ$]6S,CNQK]..QK/3&X(2QB+,5I0#!ONB`-20$
M8=_0((C-"#O[-ZUO/'RFW?MR/WM/_MQY3;OVY'[VG_VX\IMW[<C][3_[<>4V
M[]N1^]I_]N/*;=^W(_>T_P#MQY3;OVY'[VG_`-N/*;=^W(_>T_\`MQY3;OVY
M'[VG_P!N/*;=^W(_>T_^W'E-N_;D?O:?_;CRFW?MR/WM/_MQY3;OVY'[VG_V
MX\IMW[<C][3_`.W'E-N_;D?O:?\`VX\IMW[<C][3_P"W'E-N_;D?O:?_`&X\
MIMW[<C][3_[<>4V[]N1^]I_]N/*;=^W(_>T_^W'E-N_;D?O:?_;CRFW?MR/W
MM/\`[<>4V[]N1^]I_P#;CRFW?MR/WM/_`+<>4V[]N1^]I_\`;CRFW?MR/WM/
M_MQY3;OVY'[VG_VX\IMW[<C][3_[<>4V[]N1^]I_]N/*;=^W(_>T_P#MQY3;
MOVY'[VG_`-N/*;=^W(_>T_\`MQY3;OVY'[VG_P!N/*;=^W(_>T_^W'E-N_;D
M?O:?_;CRFW?MR/WM/_MQY3;OVY'[VG_VX\IMW[<C][3_`.W'E-N_;D?O:?\`
MVX\IMW[<C][3_P"W'E-N_;D?O:?_`&X\IMW[<C][3_[<>4V[]N1^]I_]N/*;
M=^W(_>T_^W'E-N_;D?O:?_;CRFW?MR/WM/\`[<>4V[]N1^]I_P#;CRFW?MR/
MWM/_`+<>4V[]N1^]I_\`;CRFW?MR/WM/_MQY3;OVY'[VG_VX\IMW[<C][3_[
M<>4V[]N1^]I_]N/*;=^W(_>T_P#MQY3;OVY'[VG_`-N/*;=^W(_>T_\`MQY3
M;OVY'[VG_P!N/*;=^W(_>T_^W'E-N_;D?O:?_;CRFW?MR/WM/_MSWL8WU^;I
MZ]>OZ.OI_GTZ]/M^CUYJ?FG":P>7EHP^P.7=;436QE>0/E346W.A[#F%@S&U
MZZY'05;4AK'()++JDJP^'Q)-!'(V4.\'5E6&4?:3?%W1L=6]NB?AY#5M]['N
M?\@*HA5(\F;!A)45H+LSK2[.^EY+7Q#NXO$@?[::JSC3[R3E+&\-;&BB[DSQ
MJCZP+9JU;G62I#7Q;.3EDDTV^;VC+U\?>*]LIN6DRYH<C'&!ZM`_BY4O$>$1
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M\T(G[+QW^B-OPV/-")^R\=_HC;\-E=[SY`\3N-A\;279**^@BV6B/\@H%T?$
MXN"Q,E.)3JW,Q`R,SFL0LR,Y044K>EY*9K3C%L`U7?`,(9U96FO)&SM<@8&F
M'O+&^-R)W9W=L;F=:W.C6XIRU:!Q0+$Y`R%2):E.*4)E!(QE'$F`,`+81:WG
M9^:$3]EX[_1&WX;,AWO0==1;UK7T[WK6OOWC0@[WO6A!WO7KUK>M[UU]776O
M5USG&,8QC..NO3Z_1]F_^7H]/\NN1C;%TU31D;+EUNSZ-5]'#W`AJ3.DF<2T
M!*QS4A,,)0(2]Z,4KE@BBCCQ)T9!YA:<DY0:$!!1A@<JA\RBM@1ACF<(D#3*
MXI)$!3HQ2%A7$.30Z(#N]H"E&M3"&2:#O@&4,/>T82<680<`LXLPL.0F",T4
M8(D`##=!%X(!HQDEC-[N_!A,-"4<(LL0^Z$9@23=@#O8@EF;UH&Z0<9>;<5O
M*"2^<6`V1>B2([R4OCC$SH)=:$=6F2Z<<?;$EU:RX]D5JVV+)SR71YA$@<XZ
MUI]+7I3'4@W1Q1MNRSTY5@HSR&H.:.409H==U12QXL*-.DS@35&K+A+\Y3>'
MLBL]`\RR((6I\5JI+&FE>F4(G-]92ES6WJR#DRQ42<48`'5"Y1\:0$.:H?(6
MC@)F6(+K!>5(K;KX)#1`FM],B[E-W0[<B\&@B#=)B3HZNDRL13(D?23&@]<6
MX`VGS)W>[:;CZ2"KWZV*U9$-H>2]5HL=IY%6U)88GO3?MF#!E*QV)(EHG<+J
MUB;-,!CAY0"Y-^TGAO'4OA:U<Q>;L0XH&TRS`2Q"=3BU^1_&RC#Z\-LYBB4V
M88[R)MMDJ5-9Z&,'-SX^2=JBKJ]`7J6I,@;"G),C7=U]1`1J#`2C$^1L7#$;
M!F]OR:E*MC$.N2PZQ0R,B]HE*(PJ;8H_*6V.KI5)%:**M4)GSZW)_*$BJQ8<
MYNL(6[&SJGAW-(,5:[U-R;H5;<K1Q^06K"7"WWRL";D:X.@D+6L>5E;K'(+8
MURI.0G5&>';7LX"Y0R'$;-TZMS0\N:/PK>V*5`,[@EHUI:21U7UG84'L-`Q.
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M1F=.T7K2<@:)?(&*X*N>F&O3?`3UZ:;!B+DTP@_NC'LF7N2)X/1QHT("C![+
M>3T0NX6,6M;T`6]>LX\@J&9X>UV&[774C7`7MT4LC--W&R(8BB#L](UBIN5M
M#9)E+V4R+W1,X(EB!0WI5QJLA8E4I3BBSDYP`='R2Y%U[Q;IR1718@W58R-"
MN+L#''HPB+=Y=/9Y8$F9X-6U=0IJ,4I"'.76#.9$P12.D*US>U%KW4I<].K2
MR)'%T1PZKY9R>L[)H.N^2E4M=2`Y+/3E`ZOET9LPFR(JCMYLAC[81=0V&O60
MJOA1B8R.(1:6K8:O82YE#I$YQ)\8-2-O=%$7*DU@B+[HY4TH7]-<=5*&-S8Y
M')VYX)L6&FM2^.0]00DEC^B<2WL2-4RQE2J2IY"ZISS&]D/4$$NBA(:<6`60
M)+/K=><RIT-@0E8HDD:63./)TDLCZD]]B+=X#Q^4LQ1#B88ZQQ%XRG\<?$`5
M#4E\.3X=67X4OO=0DO"F%\,<;'0VW62RO6AR-9W:=I9]$U$-;'8@\A*>UN,G
M)=QLB)Q(4JDR8Y"I7%*RU"@@D1.C#B@CYD%R5DPP!#92BQ:X2PU^3)!Q.7O,
M^C;)!Y*K=TYIT=3MLS/5GLB@E]&7H*!4@,<?#D^$4I4ZL!(P;J_Q,YYUIR&X
MB<?>5ECJX1QY27]'C7=FB<VM"-F)DCD7('1A\A-<L>"(@DE*H1B`@XLYO:DO
MA=+B`EIM!&2,ZS\@O"EXE(0Q&56Y6,:E0WB(QXN,R"?1-ED(W^?FK2((Q@97
M)W3.8GB:GMKD3$FO27QZ2'-ZXMF3K1)#]%]J=:=9)Y\CJH^Q(,19[@W*'=!7
M!TNCY4\6M*4C2I4ZHX>-Q#(5+:F3[T>H6D-QB8DG>CC#`E?IY!=O\GBH%?%0
M\9H='6"4W)<<$M2SHZTS*=?)K'C(53ZR$M4K\FOGFK,G"32X;G8,>V@B<?CR
MTU,R$/DFD;BP,S62<X9?'.0\135/!;,NXYEXX*I@D"!7$[=G$-8UD?D19RHA
M;%CWTUV3QYW<T9B0S?A61<L1JB=A5)#CD@P'CB>1<RV:'<T#.+$PC[%&(>7Q
M$=^5AEX/=@-K4QHT;'<,:J5PB3NQ.C.@1-!19\F0O9,J42XU&J*&6@+;BC?"
M'AEJW^4W'JAX?-IS:MOP"(Q^NT<36S`UPE++XZR%SYR3LT#*6-92T;B2HF[N
MK3-L1)-3%[D*PX)+7M3T&('E#;N3R:=W.T+%55):]K%BKF1,\X8;FCTI>71G
MF,9>9$\N\]A:9K0_)4QM@6L`XH\NLC>D4\9=N,A1F-*)K&4?E"*]:3<H^U2U
MNM^KG"*OLG#"F.3(K!B*J/O,Q$<8F#$VIY)>!MSA)A*"34^F!(I.=O#E&%;1
MZ&`6M97"9U"K+B[3-ZZE\7GL+?BU!S'+H7(&B51AZ)2+%#>J.:7]A6.#2XE)
MEZ16A/,1K#@DK$JA*;L!Y!I8,JQC&,8QC&,8QC&,8QF'3NP8/5\9<)G8LMCT
M(B;4-$4XR.4NJ1D9D9CBL(;T!:AP7&%)RQJUJDA*G!L?>-/-`6'6][R"I7><
MV?WB^:LI&NW=;;%90&.26%2:R69R9*+G;W,6XQ<RM;3.&T\9CJ!!H&BWL"0"
M;1)XA$@5!*(4J2J*<O\`LRYYS/DU:6U)K@9ZSL!OJR'PZ;Q)%$U$RA[<\(#'
M1Z?CX@ZA?(\[&(]OK\O*3%O`%.CTJ5*=L\D9A@,VB4Q5S-2=45W4D?6+G%FK
MJ(,40;W%S$`3@X$,B$I)X\L\%H)(#UA@#%)A)`0IR-F^`("$DL&M2;E4+WI6
MXKX=!Q5OY!V#QWJ5,UI?'E=!&Q=HN></:DTTQ:E5V-,HI,"J\AS8E+2IR2($
MQH9V]N)ZE;N=1UL0DM3K6BE*55\?;I<ZOK3F?RTM&7-4?:;`E%)<O9HMNJ+R
M^O5SJ;'U$GKVUI7!4TU8G5O=E(6TP4:LEZC[0[$H$4SKGQ9W;74>T;&,8QC>
MNNMZ^G73*@RCAC`)6PWY'UMA7DC2\AYQ'I[*U#5:CTA71ASCAK8:D;:\/"2/
M448%6VI,4X-)):HI4ET6E[X$Z-O+252Y^=F0;RT=6:P(/:;Q&;$9FUHC@6F>
M.;U(Z[5,#80M+V8@0)M&N49DBHY6%2YO:(*\I\\!HMR0:4#TO!,G&7@.PT1#
M..3>\63/7^6T"LM%[*''9$ZQ>!29YMPXPV0IGF&:/6`<V1E",!<=3K%83@*-
M*G!;X0:\U*5:"G:8C]%,,P:(Z_S^4D2R?RZS'`Z=2M=,75*[RU24N<&AD5+]
M%F(F%,:1K34TA[_@3#3C3E!YZ@T[>A9EX<\AY#7G')CEG&61`<(+V]%Z\U),
MWR994KGMEXTV3</)NP(]87A4D[>4B@1C9:<$,=(<V*%<W2.!2U,?&S-M(S!>
MQ7/"OD'#K+IZ8I^.KFQ!CG;L<MN6\A=VQ761"]LXH6?3W(>&0V8#$VR[;@I;
M'UXM6-)1P!M"KER0D;PI=HFE)1'#/Z3B/P)NNLDO9#%3?BZ%D+XSW)VDTTY`
M)]@J5>&(L]W&7`XTLO4`:92N*E1LC7/=<'($D7W(%$;7-#6>^DL8XTE.1U_I
M/@CR@A-*U-1/);@]</(&K+8X,UOQ:D=<UYR&@5:H*-L>K[PY#RAV9+O5MMQQ
M,I31UBQ.SJ]F;58]/.=@S6%O%?B84,0\LDQ5.78RW.-7+Q8[7)5KCQDG5R2$
M7;&\0>=];<@&R2U&;%G_`(XPBW*&?#6;RW8%EL4RCEB4#7,`EE6#C3BSDC>(
MNA:'A@=W@J6/FD_;0WC/RAKA:G`#B@\+65^[7CG=?)$IC:ZHG"RZIIN^X78[
M?5]JUQ'Y1,P5NT%62JEYU>V`_P`G0R*;U?#9/)W!/7:1X="I5'*Y4+V>O/!N
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MDG8`1!"R(H\E527`N,MUI^1]A,MM<.[*M235[R^Y2<N>./*$[DFEB_&\V,W*
MT6?NOV9QB;19R&T6RX&N'3\/&&30A?4+C7)L/;29VX2)6TH69LW5JE.)?*KP
MDF73CBUR3J5BF'9_=FS4C812<EXR020\?+EXG\JK(FKTSTI'S9],&U5&>/9,
MMBTWJQFL7Y3!7%!80\M\TD4D<Y0D97V3G#CUS00(*/E5]<:+`Y55]+JEYJ<=
MKEK#C?(*RXSV"O77AR))FT-Y$V-6+U<D&K5L+Y.UJA\3Y11)@L%T'`90YIWM
MH8`-Y[C%H]L2Y5<)Y79O!:@Z@IQFC\2M#B?,.'MY4O7[W-I+(X4?,>($R@\W
M8*@?K&DPW27/+#(6>+.%=$V)(1JW<"Y:V35](5Z3KD1W0\B(#:W.*Q.$*,=)
M633M;<9^3T1YDV\]V9N'-TD/DU,P:<)ZVI.OV>-3&4IIB^OMBS)N72V9HG$N
MNFZ)11Q)9Y,^.DB;$Q4.\7N,DJX[<AK>>9SQQ86_B%RNK"T[)7MS^LKT3!P-
M>)5)#Y)<?'!_;GR<N+<;3O),H\VX[!%5+:O@K!=R"8)7\"FOW:`.4>K[7G$*
M^)YPIY35_6#]#;@6\>D#_P`0N`#JOE(!,]R\6*FM^$W$Y5;,YR>7IH2@LIMC
M$=X2SIY`>JCBI!1":6/1IH75V((L++*WMR=6KQOYK0WA'-JB11_E9JS^4%#R
M1?4:F];1`IXGS3C?%KX<6*(3F60-Z?>.KF[1=+#X\BG"F7RZ"MLAE#"U)I"@
MA[0]Q-4/%WDEQNY%4M>(Z`F-E\=I7>G:5O9G'2(N-:'27BPEYCV!3,CJ.PMQ
M20S5BB2YL<&ZO[=36"QQ:1.2JJ@\B7MN0-ZUJ4S3:2)N#7$/D_QMK2D6B_N)
M,CL2O7_LR9APSDE'M+_5<H<JRLE%R`MZ=N,>?D!4W,B9%9\HJVGT%8764L3V
MYM\56U#&VVR6^/-XFU8DB":]F%RT:^//,&LOD;/MJW)#V8'93\8Z\M`EYK<*
MRT+WXNRJ?NEOJ&R2R63,SZVBBQ+G7*E'-YJ7'A20,1;UC:Y.3TR)RPWJKGC+
M;JKE[*8_??%>V;/:F[GB_P#.+C_RJ(Y`I(W0T%BTCCX$T=2RZO&RU6JS2KVJ
MJ,N#U02&ODE62*NIS%`M3G)I0"(;<$I5N>?]%PGDJHC%57QQ)FMY4BV1=TL*
M,W!3[VA9+LH>^V!_:D<17UN[-DZA=G1M^=X^K<EC;+8`-2A0*V333/@#C#T(
MK5+:%H/F[5<JXWV-R^AT]YAL*O@U?'%N?,2U;64TM&%2"0\@5$\KG=K-A[\S
MPF7OMS\=2()35_6!#W9\80V=6:)UD"D^#R!5+DE;%79G<Q$52?(4JC2B<NH?
M^SV7]P)2S]UEL9/BR7D9/9*S/D`J@UU<WL4D6,D:C[81%DD_4,)D<$D8VT]<
M[$K5FR`?KR+XG<Q.3J/D_+8WQ,L")%6!V?\`V:5=P^-3Z5TBRRB4V;Q,YG3.
M[K3KU2@(LU<WM4D.AKL`N'+'QU3PYX-(3@7RMATXHRQSK?O$7E1/;;[2.R:W
MI)>@:+A?.R?MB%P:0/E8,Z+D8U<19L.:\BZ">5B&6.S<R/,IB8"*[3.$Q&AA
M<F<QD-6Y$IA.G!Y3])R`X57-=_(1YY!Q/CX_IZWM'M`>RNN1XJN8[@[<^(FG
MB?J?I^0?(Z41)UDHV=K<I!#Y;!*N&S)%BZ?3%HJ!(J)87!H6M1JG8[V;%-67
M2<8Y:LUC0)=7B><]H!R_N6MFE4JCBA*Y51;MDBF,+D3:GC#P[HV<A\*5KG!4
MQN'DM];W`]4)X:$BI2(9VR+&,8QC&,8QC&,8QOT9K>7=J/QK;^3@N,*C4UT_
M%S(JMCYUIE0^8:>P37$#1J.FJA.H7W1);R86QG/P&4;,4["V2-1I$68X`E-\
MGO*6U6NQF.HZ^;Z*E%=WHSQ1MD]YHC7^*VM536H*4R:6PM)&1Z7)?+2,SQ5E
M,6>%)+&$97CQ*T9HVS/"N+=<KWJ\%L\4R.VH[>K_`!*0/M=VJYE36O(PHAR0
MLAL20B,.23:1A1&JR27145K9XA+DZ,19A9:0L.['$DE)RP$D%@))*``HHDH(
M2RBBR@:`6666#6@%@``(0```(0A"'0=:UK6M9^F,9JUYMV?SHHU]FUOUO<G`
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MK77?T[Z>O>=!*XG%IY%Y'")O&V&80V8,+M%I9$Y0T('Z-2>-/R`]K?(](&-T
M(5-KPR/#:J4M[HU."90A7HE!Z540:0:,`OPA<*AU<1..P*OHI&X-!X@SH8]%
M(=#V-LC,6C+"UD!2MK)'X^RI432S-+>F`!.B;FY(G2)20!+))`'6M9DW=#T[
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MH$A@#3/#&$Z,V+P9.S3`B`&N\8F')V[V^EIY'8R+C2S-=G2DF[*MN%A2R":R
MVO68]0UL_FJYLY@DK"H>E!`7=(K.TG%M.>2:%0J0I@E/4*L?9.<7&.]4%]@4
M68Z2!!.S[)!&'R8)G>(GS`QZ4R,A>L*5,FY"L3(GP\MQ3-JF0&HQ')$I:H"E
M,`T@W9MK6M>K6OM]&M==^O>]]/GWOT[^W.<8QC-:_:OS-#7'$!UL198%65#N
M"W%QUDB2YK>A$KL^+4ZXI+OA)3?92:L88M:'JQ)/&U)X38M#-/K$A?G@\A(X
M..DVQ)%=;NS7Y6CY$7I.F@_M`>,',H^+5.)P#'*"X?SKC@YP0ITG+,DV\/LB
MFEJ6GN3M;R8A\G(&EO6,FTJE":Y*B'38TYZ+=SO[-=?3K_GOT[]/T:]/\O1Z
M<ULM/,:^XSRXJ*BKRX\12"U?R=9KG7T//8I;#A,)Y&G&CV1'+W5LY$P)QKZ+
M,<#)FD$5"?V)V@\UL%NC4@(#`Y2=Y2<6QW55_J_M@HI/*GYB<KE3+0JOAUQ6
M@5C3,$UJ_DUJR^0;HX0I>Z%L<+M3CH=4L1^0F6SUJ9%;G&&E_L>2*E8W..I2
MR3BESBM:;9<>>7<PG%]27B[>U=,%67<@X]U5RDCS-&)<OF3*]5=9LAD\+>6@
MU>XQR.+$TOJ.P(R.(3'>T>FM]3/L5E#*!O)=UK"RWTSCKK[?NW_C'77V_=O_
M`!G4*Y"PH#Q)5STTHE(-!$-.K<D28\`1AT(`A$GGEFAT,.]"#L0=:$'>MAZZ
MWK>1S8=WP&NF4+LXNQ#L>>=XN@9V%4A<'->?K7>,T46%4`A.00#>AJ%:LXA.
M5K8"^^,XTHH?>16TX',&%OD+3(VL"1>5WMIW!<C0.",\&^ZH1+D:A0$U.J3&
M=0&@WWBQ?HFD&'$&%&CRI.]-KH%04S.S4N5%DB'H*98G7!)$+0@DF'E)%&S-
M%;-Z:W^F5W]:$$)@1>G6H1+VA_(%ELWD3Q.L*F:P8.:\6?X&LXF5:V3&=.$$
MY4TO/!&%)[T;Y@JBB1[B40@:YJE[7?"<J-2`5(K(F7MQ72X,U@I;];U+SOX]
ML$^O2H+*LJ.12P.*U95;8/(AX<$+_':YB!=GM[HM:"D$HD:0E*L`:6WHS$Q&
MEBA6H-DD>94OCTC/7M2'*SN<'$U)&XQ*W&^:^9VF7VV[T(Q%OSH<PO1UW,`'
M0Q]J1=&'E(@D[)8[*6S.)KK#'UG;']O+("8J0%`4I!*.I@G/SAW9<A@T4A/(
M"`ODAL<B9BB+24K<4:MP<J\*?%,YBJP+FV(0,,\BB&+R=R?*[D0VB>(&J,R-
MV.C>FQB=%:7JH-VC7!JS')2TP'E#4$M7)JF=[S"4R2DI:4OJ>/*#TTBF[*J`
M1I(_L\=,)`*1:8SW%<PD+6I4[HD:5X:CEF1`YT\2QFS%'\N,,"[P`VMTLNC9
M@G@J6LKC<CX?&JB9CX>:T`E*A_M1_2J6BMX\A9U;W.'!.<GC+>YC*,[LS02T
MX==59MMETC,HK.(S*4#H*)2IO4'N<;5.+8XKV%>D7Z2#2KTZEBD;:XL4E9CO
M$7MC>&QS97-,@=D"I*30SB=VE5=6CQ0XP\@>2$@K2B)GRK1SI=7%8(I(\OZM
MZ/@FY6M>(]$AK&I-(9N^HHY$5C\K3M<=2GC$K3,[>WK%XT6W.9H[VB/$6861
M6M;1*X(_)%5K<<I%RMBDM:0K3Z],I*./Z&.+)<XSD:0N.-1.G`Q[VL3N2](?
M'R8G(MRD#&>G1D+)$A',7C'8L1F<YB%SPIUC->^:(IDN&N4M:AA(L1J:'VM5
MJMI>D;:]#;K/9W]C<JP<TK<H;[)1O#8=!E,@"N3>$CLOM#>*2^R*+JF/V61)
MYCR!D]Q0V&MS"S/RL31**$3M^K7C,]+-:R%4`ED,=WN/1Y\ATO3,\L;79\1Z
M7LR9"2M6IKM==?;]V_\`&.NOM^[?^,==?;]V_P#&.NOM^[?^,==?;]V_\8ZZ
M^W[M_P",==?;]V_\8ZZ^W[M_XQUU]OW;_P`8ZZ^W[M_XQUU]OW;_`,8ZZ^W[
MM_XQUU]OW;_QCKK[?NW_`(QUU]OW;_QCKK[?NW_C'77V_=O_`!CKK[?NW_C'
M77V_=O\`QCKK[?NW_C'77V_=O_&.NOM^[?\`C'77V_=O_&.NOM^[?^,==?;]
MV_\`&.NOM^[?^,==?;]V_P#&.NOM^[?^,==?;]V_\8ZZ^W[M_P",==?;]V_\
M9U[L[MC"UN3X]+TC4SLS>M=79T<#P)&]M;&Y,:L7KURL_8"4J-&E)-4*5!PP
M%$DEC,&+00[WE2ZXYZ\6KE-DC94%GM]C2V/L;Z_)X(RMSPVS24IF!K4NRDJ%
ML<G;V(Z5&G$)MED&M`E"71QR?2@\@LX)F^QATTO:Z%U%6/'&!-5U&3""S%=;
M-?VFP/D>Y`LKZO3C20DEG+0*3FEE$G4EC6N/CAH504)A:@L&SSTQ:7-:9XY0
M"FH;`XFG/D-BKZW/E*B(SZV5R><V,T"F+BK7OA:*7+T!:]`0I`L$W;);?$P&
M-A)"51H[0!"%/VMZUZM;U_`.]?\`^L==?;]V_P#&.NOM^[?^,==?;]V_\8ZZ
M^W[M_P",==?;]V_\8ZZ^W[M_XQUU]OW;_P`937EJ[1*E(%,>1\VOV4TQ"H0A
MBJN8+7E&R6#5"(E-*F5M9'I\@$M;UAJ#Q)Y<FU2K<*_?H7(%)A!"S:U6O2IN
ML05#S[JZ6O=2Z=K!INSV"YXE+I-6%S4CN;+6=3&(U8\(J^2*I[&'QE>!U&U)
M;,F$1@Z\;E9#]M/,S=-3^VL?DA:M1;*>O77HZ?S_`(]-]?X?1Z/3Z.NO7FIF
ML'#FT^\GI#:MK<)FML'Y*L2#5U-77E97#Q':QJ)(2LD+%&HS!XU%%[WJ;7M,
M(M7ZBU9&M-4$LHM-3>2XN<5K-G;Y)`O(3L]IMVB$:Y%SVQ:7;N&]J7SV?-@\
M0GIG<IG#;!?Y78$QE$%L:%RJRY%4R]WCDC@]#2ROBVBMG,2M1,WN.6/8854>
MA*82-F<K0\?./-TR?G++^<MZP]LJMV0\,JAX?0NO6Z4,TO4."QML"1W-=E@*
M7./JUK:1%7.:.<6BE8I%BDN3JX_%W:1R9DBJM^3L96T#,560J-+U1ZU6VZ-4
MJ3-FG&>-N`.^/>M!V+N%+`%A]`=:Z``$/H]7KSUOD_B7U3KWYT^.S!'WCG3<
ME<CG=[AQ2YQ4%D%'*1.[\7L8$Q0220]PIT`7KN%!T'6]!UO?3KO>]^G(BLOA
M_"W-C".L4::*2-(;X0):M>Z*6EX(%W0C2+C%1CBH0FE:ULU&L2EC"$>S"5*<
MXLX)B?((?Q$JIKCZ%++V?4LD7<\*YO!B]V0$C4&:#L29"D1+DQ92!+T\&FV<
M`Q6;KO'*#.^9HHJ06BB:NA)3JX12$A`X'H!@$F*>G8(W#Q7OJ4R()RYU\63B
M.4Z"`)Q@RRP;'H1P]%AWO6I._.%/*RUH]$.7T,8(A!^T*IRY6MVHFNU=O."J
M@8]QW'(O(5E\=IW,6]B*<I3$;^J]8[2:U)`7#=R5'<9<#'&D^XQ5<75*<>N_
MAAS(>I9SRLNL:SI98KY6TWP(5Q6)S>Q&Z1+X5.>,<A=D=G0).AEE?R"NEDJ%
M#WUP?:&N-]*7QV,V4U1:2/D0;U+=LY+'T*[.+E"VO:`;K`H2A96WMNH]VB"<
MY;>[[8#V?1)U)!BKBVN;O*F<;V\6E&Y6J3:`0[NZXEW5-[LM1RA*W(H\J>\X
MAO9[\BF"=U/)'&.0<ALB7;:\ENT&D9P;%V:>&BK;K&Y(-$Q#)TUZTZ6.W+K,
M85CRQJ#!(T#5&W8I'*%XU"1(MJ#V<W'NY;HX)=E_<58U'72ATX9U[RXL2L%,
MPL<AN8;VL>W&ZYJAB,!7+XT@<GN$5XZNDG^4>[WEV:S70#]#8JSL#).E1BA_
M9+9MO"GEI$J0C[.W5/![`O%\Y,4=R1Y7WA.+0C`[BON9^=BDNW7FF'A0R/3!
M1:VM(6DC,,XZ*].B-]K.GV];!J_>XI-QE3M5<KLW^+5D\7^*[K6%P02-[GT8
MOWE=.HTGA]H/,W02J*VIR,LJYX,K')Y.ACC@F<QM,X1L:[SH)4NQJAJ&\ORO
M2]R5)$]-N-79Y<C*SJKL;8;-X;!`OG`VXKHFMX#:+'"[M:UFE],\A*_B2VNS
M5#4VF2%S#([@CKLJ(=D,6,;$C,]!*5*1>(E.$.4!V87-"E8Y&#T$8X[OLH_[
M@_:!\6G%CL":.DGKUHL2].6<MY.THZR:+@AJU!:M6OJ)^;H;:$;<0LQR8T+N
MG5-LHCXR!KO3C'9Q<ZFU\N>WF2%U\S3]7OLM;XK2(6/R%7RQ)/;6X0DS%IM6
MF;/>HY!3F:$,\U:I([+Z^?:^:3ZRK]_\PE4<A38V,[FRL-XQ\3;\F')+A/RG
M^0RD*D\QY;RY57M4K#9*H<B;F_DW6=7Q`BP'N;QZ$!8[CM).X5B,Z>&!TS;7
M)7UB:&V7OI$4-?E^V/Y/XE]4ZU_^^=-__P#=CY/XE]4Z]^=/CL?)_$OJG7OS
MI\=CY/XE]4Z]^=/CL?)_$OJG7OSI\=CY/XE]4Z]^=/CL?)_$OJG7OSI\=CY/
MXE]4Z]^=/CL?)_$OJG7OSI\=CY/XE]4Z]^=/CL?)_$OJG7OSI\=CY/XE]4Z]
M^=/CL?)_$OJG7OSI\=CY/XE]4Z]^=/CL?)_$OJG7OSI\=CY/XE]4Z]^=/CL?
M)_$OJG7OSI\=CY/XE]4Z]^=/CL?)_$OJG7OSI\=CY/XE]4Z]^=/CL?)_$OJG
M7OSI\=CY/XE]4Z]^=/CL?)_$OJG7OSI\=CY/XE]4Z]^=/CL?)_$OJG7OSI\=
MCY/XE]4Z]^=/CL?)_$OJG7OSI\=CY/XE]4Z]^=/CL?)_$OJG7OSI\=CY/XEK
MUM6O?G3X[([L-QJ:M(M-I2^HE#@&`PQTGCY'HV<YOTO,CK4G4J#5+;&43GMS
M6B4B2')D.]%%IU"H`BO&`=PP0*[J8>\\GVY4RIH0R,?$R].,QBLB6KW66,5[
M-$WG`=E)FU1#'7PS.WH&^/*RG$7CFE/_`-5)T0>:J2&#2FP;PI[*:*\5;$D-
MERRQOE9?3F5=&H@3YI>::.-H')0F,<WH8@OSPM/D3BC3!:MF(U*%`D;E+D0$
MI5M?WDVS_<`B8M[$)K[PM[WO8A+W40M[WZ=[WO:_>][WOT[WO>][WZ\X^3^)
M?5.O?G3X['R?Q+ZIU[\Z?'8^3^)?5.O?G3X['R?Q+ZIU[\Z?'8^3^)?5.O?G
M3X['R?Q+ZIU[\Z?'8^3^)?5.O?G3X['R?Q+ZIU[\Z?'8^3^)?5.O?G3X[*K]
MH-+(M!^-$DD[]-[7KY_;937_`,ELDHJK45X7$"X%DO;$%;M->4\Z12;-%C/K
M_(%)3(9''6.*$`FI<Y.)KG&1MY4H9M+U)4-8',>SWIM?;2[0"'3-14#$QVO8
M7,W@/$:&:YU`'[D%6MA7G&Z8-B6JR:V&<6,&LZXB[:M-23ULJ>&,JET.8Y?)
MI8&0-_T]!#H.NFO_`,A"]/TB%L6_NWOIK[,\L8QC&,8QC&,_(\@E40<F4DE*
M$Z@HP@\@\L!Q)Q)P!%FE&E&!$6:486(0#"QA$`8!""(.P[WK?7LS$RQU`6UL
M#0V,C:4,PPIO:&]&V(BQG#V8:,M(@(3IP#-'O8S!!*T(8M[$/>Q>G.UQC&,8
MQC&,8QC&,8QC&,8QC&,8QC/`9@"P[&8((`:]8A;T$.OM$(6]!#KYNN]ZUUZ:
M]>]:R.+:MZNJ-KN26M:4E312`Q),B5O\@4)7!>4@(<7%&THA^)M*1<X*MJ7!
M>E3%`2)3QB$;H?3101C#"<CD=[6T\VU6L$:#ZF@#Q3C"\4YRM;75AE)JR9RM
M.$TPI+7#@62K(\@)3@*@*7$TL"@L/A"]E'*4>RI`@7'^$Q*8M]ONZ-/*+\/J
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MC%&C$ZDGO!T:09H)A8M]T80BUO6HSL3F_P`?8K!Y/)XM9T#G3LPMY:TI@8)(
MD<E9VC5B='HX\IO$>H*1E#4!V<>$O?06RR@:$::6'>7$<P>-&TR0QRNJN&-<
M>B1*U+.[RMK1.C<-:D(6!2KDAQP#2%!99X.\$0=:%K83`;$6,(MYC#K^I6S7
M0^,UU;4!E<DVW*UY;6P2-J=G$"5-X,LY<%O)4;-/3I#5!&U&PAV`&C`:,V$(
M^]K58;S&YM0R^+MX,6"EJ-5ROFZZ.3O@)8;%4,V;:#L;CD>H+2V9/;<1JK5=
MEY,TXZ+4KBENF'L\[BBQ^!)*F/K)"H'/1E-5HEG:,4Q7-B<G:FMQ5,VA3PSK
M:A)5<MK#K23IH1(GR]`NJ>,L\&;6,F3+5[N^.25D:XW&T2MT=9'(I`;'(R!\
M,CKHXBR,SM).*B2.Q5^<Y3,VU1*N3R_AD3&#JJLA;+&7DXVH5[HHJ*3LC-&W
M4;`_J6QO$X,:Y8H\@2E$M:%,5=WLIY;1*/0KWM,^*ME2JOX<Q/5D('FQ)W9%
M/MGG-2]IQI`S7S4S/*I'.N/<L<W6+$((W>37'(-+G])6RX_RX^-++M4Q@<-.
MK`!VZ"K^U?X5W$LAZ:!S:PW)-9=26%<]3NZ^A;Q8F:WXK4BE0GM%FJ=R>Z_0
M$6'9%?!*(42RJHQMPL-H3JRA'1W9J=R);\L5=I+Q90O=BQ%:_6"@G=72VDJ\
ME4#<Z=M!KE(;*Y'+-)*2K=H2.482(GN=SLH93T7&6YQ.<(S$U"6:S8$8AZM,
M^&R0AYGT&Z\3IMS2:),XN%%UU!+@GTQ=1L#HS2)B14(;+T%M,#G%I&0SNS;+
M86_P.5Q=V87(I(:3(&A0DT<,C9:HR`JLF/.^V^/%><D6QYI:,3&UHU7%G-_'
M-T@[RZQ^$UQ.7"-2=7"7*T@S%GD+Y<+'63FO(52T+,VUZIL$&D2>"ACI1;B?
M$O%;M&R76W;WI'DK)R"9:1VD-Y\/J'D$;JJ5,4`4IHI5L'M:MZ\ETR3CD$6:
MK*D,97S(YFT^R)&KFAT?4;0H&P]8SM"B=G_M1N'44;IJ]22=2EM8H;23QR7*
M>B:PL1\0S?CM&)(BB<ONNL@QN.O*VPH##'AR;C9:OC2-6X,$<<FJ;KFL$'=F
MR2*Y46<X./B%_NR+&O<S/D?'QOI9ULQE;:LLAX7I$'(AP-:Z:4Q8EHC"[Y0P
M3E>G6HT&X`*2>(JVYR1O'DY8@5)RO1!STXQ%VDT5.Z6`&.NLHU<9<)E<E:'-
MCK.<N/'<E6JOEEBED+R"HDXO%2(FYV<9@B/<46RVMAD[JSF/#;%),K::U5#S
MLD5U]I"U4+##E&^/$@X!+.34;W(ZJDT+D;\_'7Y%H!&IO'Y;(U!()17TMASJ
MK<&5"WL;:J;1:(7/8AB=6HDG:YC&,8QC&,8QC&,8QC&,8SHY')XW#V=7()8_
MLL986_:?2YZD#HA9FI'M6I*1I=*G%Q/3)$^U*L\A*GT:<#9R@XHDOO&&!#O3
MOVD#!?7+N,3FBZ&K^T$:RC)W")#+`O)*6'0R\&"3Q%V4HPUW*%KLC;I69!W8
MQ,M=6)R/0ICU.P*4XSW%N0IQR/V:/"*44'5<C>+^)7N5E622C9':$O,M-FL4
MC-?1Q2)3$8X:RG'.$9\LE*U;HX.!B(:],B)6)&E&>`"55X;:V$``!"$`0A"$
M(0!T$.@Z"$.N@0ZT'6M:"'6M:UK6M:UKT:UK6>6,8QC&,8QC&:P>TTK&()X#
M".5!=,2"Y+=XZ6+2JV$-D1B%KVC/4,4<.25)2BP2ZLK.M+&K\QPLIR1PEK*8
MWY:J4-R1.0K99JF>:P>9M&GB6.-7.)OY+6&^0%OXQ\QJ4`PPP<P,D_)CCQ+:
M,8'CK(4+"7'XHHE8]F25Z3A5[='8E"`LMI;]H3#]C$XE`)O-C&,8QD#R'B_Q
MVECXZR624I6CV_OBPQP>'ARB+0J<')>=H.CEBU28GV8H4G=P.S3C-[,-%KO#
M$(6]BW3GD7V=K19Q[:W5$"M*7BY"<@QZ2L,/VE<9(Y$'J#4^W4YM***.0M_?
M*-0$#$/8%&S3!AZZ`+>=4)P.@<'BI\?NB*U9<#HD-2E,4J<8:2<^EM)!`B"V
MER4N9)@STS<66F);.X8+99.C0#[NNX'5G(E0--UDX*Y+6525U%I7Y*7($CDT
ML"!C4F%J0@,V@.=43<K6(T*Q0G3!6C3IE(]%`T/Q93LL)(]9][]G]R(O&NFJ
MY3K`J>)]I+`+YB]PT9>S>*?N564S'(@]+V9+3+''CVY%,':H9Q3K[+H1<\)/
M5MY%IRV;2"PW-S;5""%LL2_*T^#',EZF',^TJDN2HJZGG+ZF^'+,YITWRCH1
MQ.?<:GYW33R(,-@M:(3^R5_<5=R21Q5)9C5'06C6:YU+?6!D6.[4@="HX@_9
M=WS&'1%X65T2W1UK[7AF[2EI9XT"P4VD,..IL<`D=5;VN9#@'R1,^+5"ENE`
MMEH'Q.@,?79$V.,E.98]F<=[.6WHK+*WF#K/:K*:H#VM_(CM(7S>U4L+%\GE
MR5U<,((K].H4L"=*"31LJVUCPXOBT:2/JP1HE.4%+IV,5-50^SCXP<C[9X$]
MG5/F`^IZ_G/#J!<GI5Q^W,P3YS5N%Z6DTW)2<+67/$=1E@<HK#:[AE@OS[*(
M>P/TA=;)?3H_M*Z0-H;Q>4+@1S@?RVKGCS%*4K.=5(TK$=W5G>-\RQXF]FFV
M%S+ER^=N,FY..MOVVRURS2&`.%ND#8S6X4*C;\4U,T>14^5MHJGP38GG;B-P
M)7U?P7MG@]R&60";P6RI?S%;%P*O12",L[A3?*FTK1GJB/&MK]I2?''EL:+4
M=X[I$UJ75K:4[>V^).CH86:J,D;C547+6FJ9@''693BJ9>RU0Q16NH[R&;Q2
M1+94SKF%(D#(S+);3KG%E4,9K-619M2-#])6ZSW^*+W\*N8I(<A3K00U%3==
MV9MPN#TO7*9K60D#IVOSIVC:U,!7,R5&ZU=:5.I]35Y1Y4=#LN:B)5J'<N1@
M$!D($$I.`@1O54#-.#_9]V]2$+,HCD65Q!L&EZ_IASXX0:7592JV(WA?-5K6
M=LAB5SY(O;P`Y`Q/X:]:2&"4Q^NG)X;)Y)#SYHYR!L()2Q4&*\:>R@E]'V#Q
M9L247XKGKU5=;.=5\@C#6]6CUR!B=02*.N/!1`O`(0@M?_=E0L!BPQ5WMK);
M+7N02!Q/4B?7,I1AD![*>XVN$\@>*DPEW&3_`+KTYB?*N)5E=L8IYR%S?)C/
M*1NLU&&&SV7.IY,.2$U$*UWM(@G43<C)'9[''XPSOC9#BC)4=(9VXQ<1.745
MY24KR/Y%R[CZX+:PX(.G#:3(JF#8AY\X>R;6A<Z:K50$RAACS=#TKZW0M*-Z
M@NM2+S==')6WM<H?6].G7YMLQC&,8QC&,8QC&,8QC&<;WK6M[WZM>OT;W_\`
M'IRK=I\F$3$V6XR4;&2N1-W4V?""I=1\2E#8Q2IN*G"M+XBH7+78@U&E"0RF
MJGO991:LT92,2<T*<P>]@_!SXX'6>\7*FOZ5;M^F+7#7BN/4#+HNQ`CM7*X@
M00K7`0OS2?IQ?CW5^(3N9IYIB<)!Z7NA&L+,\)NTQ"<A,24F3DED)R"BR"2"
M@!+))))`$LHHHH.M`++++"$```#H(0A"'6M:UK6?MC&,8QC&,8QC&:@>T6L;
MDE/DDIXS4QPTY:W%&!BI^43BR^.O([C[Q^)D$;.EP'Z7TN*<RB_ZFNB$*97%
MXXX,<CD4!3D.*9J?VP"-X"@>5>LQ+L\JC35%;T]DR[A-S0XC-1M5&(5<TY:\
MYDW*N,R,!<T958&:.(3.57)@B!.:`LLQT<G`Q7#`.R$9:3NR#2#PK3NJWOT=
M=>GT]/1]/7I_RWZ_HZ;S6ZG[1!/&^1$6IN\:#L>AH#;L7M^5<?[TFLA@3G%+
M&14-'3)M9*661:-OCC,J;7:KHE59<0*G:``)##$#EY3,C$N0*(B#$(IVL-*G
M0X-EVM#9M2];RGAK/.?]1R>6FL3@;8W&"MA,)TN=_(S0M&JCMEMC),ZZEVZS
M,.>%*B+V5$#$S^=(BI=&XI8;CYS!07'9<FI&:UK**6N1BJ&J^02*"RQWCSX<
M^4U<:J2-49?T+I'E)B;4ABTHB3]"+1C.B3B(A+4R,EID$NCCVQR5QN9C&,8Q
MG'77TZ^_.<8SC6M:UK6NO37T[V+?\]BWO>_Y[SG&,8QUUUZ===?H^?[L8ZZZ
MZUUUUWZM?/OIZ^G\,8QC&,8QC&,8QC&,8QFJ_F/VI]>\0[:;ZC7UE+;`=BX\
MTR>5.+0[M+$D8&U[/4^3R$!3J0>.0N@T"%6O-3%F-J(GJC2"<1*%!^D4X/4>
MMGE='[6B3T]K*EH:9--/RN@[=I:<.3)<;VTN*%NF$A\XTJU`81'2QJ@)&P*8
MDLH2AM5*4XMK-=50+=LT/C3"X.CRVLK80_OY#01))&!N0%2"3>0D>D#2=(G<
MA,2M>3T*7OE)3%QIWBP#3`)]%%CV#,EQC&,8QC&,8QC&,K'R"XPQ^^`MKHWV
M?=-#6,S%EI&FV>/D^U`YR%L`<8K"P/Z1T:)3`K!C8%(S5B2.63")>TM:HY8M
M94S8J7+SU,6TQPB^3^4(Y7:?+/EKRU=HZJ3J8^W<@K`@((9&GA&>!P0.X:VH
MZL*8@3[(6PP9*MH=YQ'Y4X,9^DK@R#;5I2567>W?HUZ-=>GS?]==_;OU[^C6
M]^C-',N0V5S8M"X(5;/#GE959$^ICDCQ7IBRYO':-(J6CJSM:#.[#-+F=W!K
MO*23A[LFX%;'%4K:@;(,`R,1#4<A`D;:I5V9(W:B=N]F]R?YJ<>:0HF1UR[T
MQ(>)G8VWSP]/=90O:01^=<O+9C-`0EDC$4>$ZM85(ZG:T7''<G>K);B@,H4%
MC1-M0+'"1-TT98KM+X]51;-I=HK+N<DYK254U$8[P,I_B+'(C."D":1R*QEU
MIR&\;K<"T:1P6B'%*Z<#(97D?E`=%M,X?`3)YBJE\B*9BD3IMHS&%<63K%1Z
MH;M)B1'F;,V4DDKND3%[WK6NZ0F(4`))+Z!UO198=!UO8M].HM[WZVX<DUK>
M]O<NZ:UUW_ZM?/5K_P#=9KCLOM.NSOJ"P)C5MA<GWUAG4!?UL7EK'I/<3EMH
M?F[8-+FXQ<U1Q:W*34HS`EFC1JU!.C-"+T9L0!:U5*_^W`X55[%&YRH>3S[D
MK,%SMXFIBK1)I_7#>Q-0$IAQKX^R281O]$@U1X%"@0,S4[+E*D9HU`4*0C9Y
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M2%/'6AB@,+?6584ZO;@@:$*121$8]&&]<7+WB5'P.(MK*J7_`(E=I!0PH_$7
M+<3Y,JW^2<WW7L]72'L3@RO[I#^234RNDATUO;L@L?<670UT9FXA<WS*,OCX
MWI2W5*"1%1\Y!(2F3BNNT9IZP)C6L,.K3E7#%=AW];W$=0Z2MWAH6>'<L*7C
ME@R^440_*6&W'P]U=G&,UC*G2/6%"DLJIU:/36TK;#;7M<:VH\4IKM3*&NXR
MDS8Y4O-5D9^356VM8G&U^E+8PH&V[I+2:=V<[%I*(A0VRYKFRWVU@97.1LC=
M-TD3A4S9&M[<(;.7U,PNYJ23D'.^N7F1W)#&*H>7SY+*4M2HJ(D2*/FQF6L3
MC==Q"3*45<-DYA%KRF%)7.LXVO;9M>KQ('UEC-/Q5T;ARUY3R!:GCQF6,_,Z
MDY+P2LWGXP*+8,JVJ:XY#SV51QTDJI-+$BSC$OL)@M&*:&SO4@85J]#*JSDK
M"W/+"[O<=>BRTCTR.;DT+$RDW"*;K7EW;W&2K+S<N4\OAU]6K#JOM5X@K6W0
MU;0<)99BJB\V?J=CS,XQ9UG*Y,TP):X0-':3O/G.9+92(R?&B+;S$\.284X]
MIW2S9)+=1+:;YI$0>D>2R/B=8EN!3Q3Y-&:Z'RUZ.J6,1Q&K.N4,H>$<A=^0
M$*?FMS;(VN)#%$,E6.0D;TT^0U,OO7-RDFB<V)5VT]QZL>O^44/XB%1EWG42
MBB>;V[.Z'1<E8LEA<GE%EM<64MSW4:O;HTE/SNP2%SD9.X:ACYTA4)4AU&)I
MV@3O0_*+D)/;4)Y9.7%^,]G/P[Y<N-1GM<003/C038UUW]!KADTQ(\O1ET4'
MQF-0>+NDMAFIE9TR&8RRT=<LSVB1C3I;I3[G]QHKN\F>D7:162Y*5UY1CC6]
M3%AG+,YL\-NB9L36_1V/R>*AG!=H$1D87U@8GRR6V".<`BLH?4#-)']MVE?%
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MGYG1)`048<<_RLHDH`C##3)@]%EE@#K>Q"&,:L(`!#K778A;T'6O3O>M94JP
MK$E$K>+VHWC<JDJ?D95<8@K^W.UN[L!)2ZT,U4)%A`$\F:U`Q/B@AC"X`-3I
M`!`G=-DA%M22E7[38;.^S!XR7-.5=KW(PRJ3V')-QI=,/%[*FH8RM7,L?1,R
MMJ0(3EH%9495B2A%XB)06;X,LO10T99ZM.=>!!7K,U(436UKI(VMC<D3(&YO
M0R5X2HD"%&06F1HD:8E0`E.E2IBBB$Y!0`EE%%@``.@AUK/;\S4OUW+OQ:^?
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M%*5K$VHMC>>.@`#OKH`=;^G0=:W]^M9SK6M==ZUK6]^G>]:UKKOZ=_3C6M!]
M6M:Z[Z[Z:UKT_3Z/GSG&,CMVJ*JWUQ5O#W6T`>'9P-\.N<W2%QAQ<%AV@`*T
M:K6K&H]4I-T4667HP\TP?<+`#O=T(=:@*]^!/$OD;%$40LVEHB>WMCJ6]-2^
M*(PP"1-;@`D:8T:*1PO3([@3+$Q@D[@WFJCF]<6$D2E*8:F3&$YQ7/$KC;5,
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M+CC:UR!/5.JU>:<;2TMIJ2$L1/$:H<(X_!2F.;`VIVMJ<4$F7@<GU=E3)V9J
MV*2&!S`^\2%I=>]IA>/:4JD*:IE>SG9RN2"V="72I4NDUAK5*=$PMEJR1:@E
MA*-T<W5>B8R!1<L`%I3A43L]N"'(N4<%.%()_8B[CW;/&"N.0WR#LTAX^N"6
M;TM=EP$6I5R"Q[(C4[F2=/8"RM:PGC\&#Q\AIA$?D#K)@R*3Z>$;<A:3+6)^
MS-L:.<>:NXZP/D7$HS"*IL6J+-\CFTE)WMHO&212PWJP[;5\I1O%_+95=*B_
M7UZ')IV:"51,A78"-+*7M))VS9L7W8;BCP::*"XI6!Q&LV7MM\5S/YSR>=W0
MI7!RJ_)75]R@LJ?V/*Z]?FMEDKPF<-)3[+E#&:]M!L=3JVHY&2B86C:,(SNQ
MX^\9;MHJK8;QX_[Q!4PIFL&6/0JNY*YP`Y%R&+K*(B2HHS#)K8J>9'0>3/;=
M&4*&)++(;:PC3^\LB8*Q4UD2\]1+3(`EG9CKY)1/,BI";Q3MS[R>YI1[G%$Y
MAJL_&$57V5"I_1EE0^,.\;,GG?L&'II'0<5)?_`O<)=WEG=GY*B4LJO;<N2=
M`^=F%+)>+E299=JTE=#/S`N^%7/<E5VWQ=2R6H7LJ(\9F'C\G@B9EU;(),U-
MS2\PZ#V?!9<@DA<VB+W$D24YV?UZ]3(2,-F'8\K9=5EVU:NY/2%T*N?LUZ2[
M.1?,IA`E4RFR1CJ!_M%^.M][?7&RDZF82N2"MZ3H/([D-(%M3-D8-6R*0*T;
ML>]3Y%.!]PP>^;6E<6Y5C:N-'(2PT]UWCQRU3C6K?72W5\,CD/L+Y,[O4S@;
M[7%26UN),3Y.:\5Q.8R!.Z>7@0VP8LEDKCH,9<<^S$LNCYGP462'E$W6+7O9
MZ0Z_:@I*/'4CY`F\FI2W8K#X;#8M9\Z+M5T:7.6U1&X2P,B2912!Q=%+$+8G
M.=8JC<5*U89N&QC&,8QC&,8QC&,9%-Q6]'J8K^:V`\M<FE)4&CNI.XQ*`M/G
M/.G!L$M`@+&S1DA00K6[&H$9_P"*(1*4!298<8>$"4[NP4_UK/N2IUDQJV#8
MXHX@7#3L)(C$$3HY7#+N:9(Y>(O<AW+W5.<G"UDZ!X$H#<E4;6)%9`$*I.6$
MAP\H6QCD?:XI'V.,,A)J=GCC,UL+2G.5*5II#8SH4[:@)-5JS3E2HPI(E)`8
MI4FFJ#QA$:<:,T8Q;[K&,8QC&,8QC&,8QC&5/M*CY#;,OF:13>CBA@CQ%H2T
M.%.#KNH+"C25:W*):J6R%U165"IF>8=+"7%K3Z1;`E:BRHH4J3I35BI<H%T=
M1'R"G+F9^-"J7Q*8Q)SIJ06=#DB&(PVO);`2(9-(?$'1I<HO7S8P1)7#Y4=.
M4RF(."&+1U6W.45E+:L4R0*A.<S7,QC&,8QC&,8QC&M:UZ-:Z:^C6,8QC&,8
MQC&,8QC&,8QC&?F:8`DL9IHP%E%!$8888(("RRP:[PS#!BWH(0%@UL8Q"WH.
M@ZWO>]:].?.W'NUKO^\K[>J`JZ#P"$`L5]DU;T],7-,]R200R3D#=28_-9HW
MA4*F.0M`=-9JM_96]K2ELB11MP+7O)#2H2N>ZFO*&CC#-&Z\Y:WM3MR,=Z@B
M=76+83(:]-S1($K+XHYN06J,*'`UJ:D"J1%&KD@BD1;@4ET0E,/T6$1>Y_QC
M&,8QC&,8QC&,8S`Y]9,0K-$S.$P="VQ*^R)IC#>8+N;V8YO!_@$_>"(PO84Y
M6_\`Q%1^N]X$OIT`,8P`%GFM]?3KU8S3KVC%(]E$W2XOD;VA$S;XI)U\.BU<
M18E=R&NFM7N1M$;>Y0Y,L;@%54E8,6E-GRI8]3-Z$2A88I,98N&:2@0%A3)@
M)M8GV5_R!$3>Q''B!P`N'CQQSGT0*?0<JK\`^H[#Y'2J)RP,>:61L9[2G\\Y
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M8QC&,8QC&,8QC&0[<5]U10T?W(;.E[='R3@F^3&OJ);(7X\L`A;3,+`DT:YN
MIW4/=&-.G\53]=#6*4Q6A&:^2+M2>U&?[EL*"1JGUK.P0R&MNG]46I5M\A=-
M294YJ1(TSN8F/$RHG-$UI&]<XM[2J<1MBE:2VFNNUJ!4$/TN=GCR04<FN+U<
MS5^**13QO86MHG36`0^\D>"48/`JO!F[$>62Y)`@4E:4"$=O??\`";V/KO=X
M\K3;O$NB;DGD2N"1PU"R7Q7C:I:*ZOZ&A31>Z8,TJS#S5+&RSQ&F&X+(FL-5
MJS'."28J00-ZVK5`>HPX%*E`#<6X\4]>E'.Z.O':SHA97'^/0MX*BKHYPX4:
MO#<T=)N-Z_\`7KFPK_DZD[<4QK7,*=WB,0K?8W`_9:V*F%E)E@;?Y`$+Y)5U
M/.0-V\:F,J5%V10,1J&;3O;M&5S/'#6*[C9^3!E$8?%XBBY.$XZM922Y*FQ.
M-M0*4H$>EYZS2I.DA**=H13,E=;^4N,0O2!U)QTATYGTRY+6)3LGB7&R1Q.N
M%:A-+GFL;:6^$:K(1MQ;>\N!1\81JRE[4R.+D@,4I?$3%LCT'RYK3D#)))!V
M5HGD"L*,P.L;765]:4;)BDM5U/<J9]/K.QVY"F=7I*HCTE41:3,ZE$8N(E,/
MDC`YQ>>QV+R`DMO.M+C&,8QC&,8QC&,8QC&,8QC&,8QC&,A>SKY@%32VH81+
MCWLE_N^8*8+`P-D<=WE"<_IF[RD,+VO;DYR9B0^"$4'2UP&64(0QBUT(3K%"
M:'*ZHF;SYTIVY>5J>)F7_2[Y:&X>=3TDF;;7Q4?FAAC4A\JL;DJ+`].7F\4F
MV?XZ4,E.K](?"?IEZN5K6M:UK77IKZ=[WO[][WO_`)YSC&,8QC&,8QC&,8S'
M)7+XO!F)PD\QD#1&(\U$B/<'E\7IFUN2EZUO>M&JE1A9?A#.G=)(!L1YX]A+
M(*,,$$.],7*KM9V>*1EV64X8V1B'D&K&X=Y6*C.(;G%<FUOP[?5T(-*\K31\
M#K6M@\.C/+1]X*AS9TS?U<`:W:8X4\ONTHD@+-LY]GU'\?G\(%*NQ)]OQV[+
M>:C=[-*#$8VJ'HB-1=63L'B*E=X"+I$QH#FI),B=[))^@:H>SGX8TI"FV$1*
MA(&N1H@)QK'N7-":62J0.))7@Q/$@D+R6>L<'(W>QCULO25"C"8),UH4",):
M8%G(55=<UP8O-@D-8(H-T`06X;8T!:#2P*80Q$>,!*Z!,V6(P>PBV'O:[W38
MMZUK6I`S4;V@O'V*(#Y)R9F'(WM-VLDQMKBO(KQWX/WS.8JJE<Q4O3DS-A,%
MK2.JVUN=)G,3WU"*0NCR],K"VM,8$^NSDU(4KPX#@7LMY1'Y#R`F1D<9^UN(
M:'"@TCZVOO:1VPFF4/=4JBR4K>,NIHXLGTQ=$\B3G(-AF#HW@)`WH@M;-*B&
MI<HCI;KOLS5#5H':,]J1VB4W>(78FX:]<.N#J&/2-#7LW5L<S>*H?N8;G8<6
MA$@2,GD:63".(;"A6U<8CSHL?]&R9I*(1C-.'HG5K:W!".7;QVYRQ#LO(O:]
M1\>.3/9_VRW2&B)-%;:I^KGWF&=+X;)*GW6=5W4AC[M6DY?H0SVG75]D1)BC
M<%4.$AKP$J(62MO>3$NQOCHR2R\^T\F',1DB$WA-+0_LZJ9XPA+GD6D4*72&
MYY%=$KNV9QQ`Q/[8UG*3:2CH([&)6Z%%'MZ*93%VB2-5Y6C<E2)-QN8TK8G-
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M]`11[^K<T+W+X,\Q:(I0KY6TKT)"4UA>$!8`:6)C48'@DX\2/8A4G'5FI9ID
MS-$+!M!<DED\D]C.9LQD+7,%Q,AEJ@I2ZEMBYZ83CVUIT84$21K2B`0G$8>/
M>S##S1BECS<=_;B2^[1;\N8\W'?VXDONT6_+F/-QW]N)+[M%ORYCS<=_;B2^
M[1;\N8\W'?VXDONT6_+F/-QW]N)+[M%ORYCS<=_;B2^[1;\N8\W'?VXDONT6
M_+F/-QW]N)+[M%ORYCS<=_;B2^[1;\N8\W'?VXDONT6_+F/-QW]N)+[M%ORY
MCS<=_;B2^[1;\N8\W'?VXDONT6_+F/-QW]N)+[M%ORYCS<=_;B2^[1;\N8\W
M'?VXDONT6_+F/-QW]N)+[M%ORYG@8P.A0!F&3J1@``(AC$-/%0A"$.MB$(0A
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M_?TE7D'"$J.6Z/)-\7`2#1MJ:F=9)8L!8):XOTK8EKF0;XPC&DC.DQPTYYB?
MR@V;.CGAAM;CHO2M`([6Q^!,[GA#P@">;(_FX[^W$E]VBWY<RCW.F+6S9]+W
M+6*BCN.-K124NW'Y@J..VKR!LNH29K*GZPD)4L,E,L@M<KI-4KW7KF1&Y-4L
MAKAWE4LE+XG.2IR(D[(VP3G7_A'0=F5MS#N"Q;KX\\1*;LNRJH.>5;AQ_P"6
M7(J^7I<0[V.WK7PU!6=U5Y54*J2,R^1(E$FF[K3T1V*Q[$2IWZSU>I$%E5/.
MX['3^/W[SC0=:UT]?7T;Z[V+>]>GT;V+>][UZ=^C>_GQH.@^K7_SO^&NN_3T
MU\VO5KU:Z9SC&,8QC&,8QC&,8QC&,8QC&,8_Z^G_`.,CJ26S7T5DB6$.LI:-
M3YRBS_,F.OTZY,?.)%'XR2::[KH]&`FA<W<"<10R`Z2DB\(H"(H.^I9NRX&B
MEZVY<:#C=8E,U*-'45DN,K-N'=R#65_:%=1YJTH0Q]4UP[PJD+BN=WI$JZDB
M-6E&-@T"@O2<A:-<EQ-5P;C%JUXT0?EQ-7_DZKC5G3&PXP_O>E=?GM".3%*D
M3?%#$D)=D1;BV,#6K.1ICE9VQ&#V`T@I&20G3@D#C-PQH/B43*=4W%U[:X3,
MY$)_?'Y_=),]JD;6)48UM!2]U-,VC:6\U:K.)1I"R?#J#Q*5QBM0$HPNU6,8
MQC&,8QC&,8QC*RW_`,M:<X[)0)I@^&.LS7%@VPUS%R@O$U>CS]Z`C`!K*,"%
MK3*C1:`2O>#42<_>A@0^.J0Z3"TV<R>5UB)(KJ5<GIR@X^1!W+*7U?Q)BHU<
MANVY#=K"@MI,S:&TY$YMT=4';"!:?*3(^PJ#2?)>F#2L\E4?IQAO9P=H)R9N
M!B=I+3%G0.&VZ]%OKS,Y\O21YBC,$>%QBM4-Z;1.H'E&>2U@V!)%A1DMU4JC
M4>A-!1!XCP?9)Q+XZ17B_2<3JB-1.$Q@;&G$%Y/A*$Y,GDKF$P1?G*]K%Q6G
M9XD+BE`0)R<'50L/T:'P"<X*,H@HN7IW8\.K=I$\2YZ3-I&]#TE3=[PSBXF@
MUUV0W-Y>]J59G78=#$`&B"-"T-2>05H1FJX;5W-R$WT;@KJ?JE3Z-KS=[\]I
M0B'K_B3`!LL2-&J+%KH(L:=%W!"WXV]EZV3DKMW'&G6]A01\<,;W!.A7DN>U
MS@(XYW7+R0[!X9Q<BAIU"L@X(MA/;!;"T&`WLKQ#1?0.3<446066226`HHH`
M2RBBPA`666`.@@```-:"```ZT$``ZT$(=:"'6M:UK//-6_:Z<=(UR"XL-PG;
MCTY<EGVK[KHJPV&LXM$(Q*I](FA!;4.16+&8<.6615+,QGRVO54@8W9]<9=I
MN8VX\4B5,CX:QI$Y44=FQ7''^L+<L9KI/LJ[HX#*WZN6U=)K`NP53*'>=)6>
M6A3,<,CY]>7]?CB0VH#'1UD+B2Z+XLA4+0D&(TCXJ3JE+9N?QC&,8QC&,8QC
M&,8QC&,8QC&,8S\%"E.D),4*CR4Y!7=\(<>:624#OB"`'?,-$``>\,00A[PM
M=X0@AUUWO6MZ4^T[[1Z5\?'1!5''=^9B+*C[BD5W`\.L25OI$!:7IF0NL(;2
MS7A("*"63$"U0HVJ-.7C2)VT2$HDI<LV8FEWA5+.6'+JI#;!O65,$7J*SJ<E
M%>(6"$QI?";'-F!;\X1X^X6&3[-4;:$3Y'-J#6A.F$-(G=B2'-J0DH-%'*KP
MUOQTK*MT-8"*:C9E,*D@HJ[B5IV`)-*+2*C1^NB](KF:A*4X&>4M][:T!&DZ
M<81C)*)+)&,`IUUKIKIZ?Y[WO?W[Z[QC&,8QC&,8QC&,8R!Q<F*531V<RQWG
M;(Q1ZO)0OB,B<G=:G(*"\H"PF>+MY))JA4YFK=;,"W(T1!SBM,(.`0B%L.NM
M`Y]R^N*]F*2.E%[:>/?'B/DJ1S+E?<IR:.H4S6G[Q2U1$4CD8%*4;OKLI*:`
M2]S\8&04<?%EXR^[K>J^=SRY9F_0KLOZ\<K$EHG%0@M#M)^1S<IVP1]>H'L#
MD?5S(_('$)3D:6$0DJDYN?9@K)/UM7'C6_Q=^*VQ\1NS#IWCC(C;CL-Y>^2'
M*)Z/\IR2_+7$8]/B=W-"()QL):W-4Z%Q4H!8O%B7$Q8Z2;Q77BVGM.W[`V$[
M%5,CC:%P&UK'QE2.I3>:ZFH%+DA(7EM9/>T<Y&)CCP'@0E;"+PJL8-$![HMB
M,UK6]Y7"17Z]3!U4PR@F/4O>"A>!<IHL"(J'1_0^H=J-*#-``XC#T$(DP8@)
M3Q!UM$2[AWLK.]@?'MM;G;4VLQU.LJP#M@-&Y/.A',S28'](!+,UGA\%W$HM
M]$QZDK0$^PA&WH6W?4.['ZUK7JQC&:?.U^Y%\;893C'QLMCD'4E8V)?;_$#8
ME6EI6S;]*1JV(C'+`C.I9%+"N.A&.0V+1%9RO1Y<7<;84)D<6)>%"6.O@GEE
M<'YD4XYV??9RR'ASRAM.8(:OJV-5H94YM:1NT4O(/D+=-P6R4JL=--HZ?(89
M<.W".4D5$&$M1'IVGATLER:WI62P3A(7"F]N\U2-TV,8QC&,8QC&,8QC&,8Q
MC&,8SCKK6]:WO6M[]6NOIW_#6>BM=&UM\4VX.")#X^N3M:'QQ6G2^..2OO>*
MMZ3PYI?C*U1W!^`2$]]0=W!>#+%W1=*E2/E(ZRAJL!/QEK9QO"=5->#+3=D1
M-S7G5B2PC$H(W+']O?)4WE-\@21Y`>6H`%K$>6MV/9I9FTQ81G_O)^,3I<`+
M^AO(JPU5KTI:<BA+K`:T1MAL#/K%MB>TZ]0U@ED7<$CU(-.C^C0N0SU9I7<"
MDV6,`_&SPALT?$(LK1K$"V/,R]&XHT#>XD.+:C<0.2)J#H+<F<]KB5`G(I%T
M[R8*\2GP(]B,+[I@A"WD!999)8"B@`***`$LLLL(0%EE@#H(```'6@@``.M!
M"$.M!"'6@AUK6M:SSQC&,8QC&,8QC&,9ZRU:C;DBE>X*TR%"B(-5+%BP\I,E
M2)B`",/4J5!XP$ITY)81&&G'#`46`(A#$$.M[S5AR2[3&K8HP3YFJA7YW'QV
M.NWE^R"5&D,&C:PX@Q(@3M#D86,V4O)RL>S"?)Q9+.2B)4NA3LNTDVD,^=NG
MN:]2M4L`%RJ%\Y3/SN_*5D'JT:9S:2WJS7$G:%J='`X\A0!8P+S5``.+<:WN
M8UOBB?1[1L!/A0;FH#V<_(3F,_1ZU.TUFQ":%,9R=PKSA+4;@='ZJ@Z<K0M(
M4DQ7,:SNKW)&F$%*>0R.+BZ"+#M,?-]-VQL!>[N'0N(UY&6>&P6-,4/B4>1@
M;V.-QIJ1,C&T(@;WL*9O;&\E.D2E;&(1@]%%!$::,9IPC#1C&*/[-O&'5OL+
M4<8?()@L\&4V0YA#XZ]*5"C7_EM*2R]#"WE&BV#8-J-;4J`;WM$C6;UL.M<Y
MU*W=.9\4GDL?>B'J4Z`\.,B?"MF-J%O5ZZC.<%Z7PB0@:`CN)01\H12TD8"&
M\I`0#IX/;!&(PR1!F1,+`VHFMN1%``!.A3`3%#-T6`!JDP(-B$8H4"#X0X\X
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MI.<P('9D6.>8T?R?I7D4)_(JJ6*'AQC+5#)&\LCS&I5#)"FB=DMJ]XKB:`C\
MS9&!Y4PNP&IJ=5L-E2=$:ROP6EW3(U>W!G=4:.?\8QC&,8QC&,8QC&,8QC.I
M6/S(WN#6T+7=L2.SYI=ME:U"]*2Y/'DPC2IQ\E(##0K'+:!.()ZS2(@\28D0
M3#M`"(.]_,9R9[1_EY*^2<<<.,`[(;*G-<V]IJF&K*E6I-6TZM2DIIF1#X@>
MF)0[O8%,I)<X_P"`0+VS;"U$)E@`M3KI4O#O"B_%,J51=F2\H9:NY"R",WB=
M?5>+I(WE1@=8O&@DJ(W%&LN*.99#TVPD\UP2HU#F:H2.11VM'MP"22"@7"+(
M)*V9LLHL&SC=G&["`(=F&[T$.S3.[K7?,V$``[&+J+N@"'KW0AUK]<8QC&,8
MQC&,8QC&,XWO6M=?_P"?N]?7[/7E++RYQ5=5#SJOXBD=;GN5:=M"UUC718G=
M>6Y;V$($S^Z(R5J5F$'8MB.2%$N3P2$/?-:BRM[.#KVY&2%0W1E-;':<WVVT
MM6*G8U\0XK5DXF'2F6G)="-)0*T36<N=I`N"+98%BH`G0II&H[ZQ^AQ7A`E0
M*VUCR>[2R)-U=U32D9X#<!M&'!3R.6Q!"[7U;#"J$FTL.96Q8$"IM2R!.02-
M8YC6)$"P'<V?,IPE).:AW,X1=C727#^=2^PWJ9NUZ/[ZQF1B.DS2)QYI9XFR
M*UY#@YFD-J$YRTYR!P$A;T@WLP]$!*A(4ID3:1Y04CS;3(Y/&H4S'/$C=4#$
MSHP:`)0K,T47KNAZ%ITQ(`B.4J!!#W24B0HY09T[I10NG357SK$M>\S3&ZH4
M"B"001@R%EFOZ<93BX$AV(!H8T@Z;$$6_P!/0#4XC%`!!#X9Q9CNI>3#6=(P
MJL@C6H$YSS)U?>&YRY\$%:^K#CM=5&RCQZV%O(.'L0ADI.Z,[J':Q0L,#X7<
MP=-?]?X_AZ.OT>C.<8QC&5'YPI[C6\<IH@I*73V`R=<JCR9\F511IAF%TL$`
M&]I!3Y73,9E#<\L#M9IT;`L0QH"UD?%B(:M4Z1UB>Y2@8VM547@IR`Y*7E>S
MF%;`.0$?XT1+BK3S+-I;R6J67TR_27F2C4I$LS^1V.69&XA8S["`0PI4&RY(
MM84\#4SQ*R'P`:A4X3!>X;<LT42=@D5E<ZNV;JNLWY$AM2R.S&XE0>MQ@=B$
M*I/.CT'/AC2J"%(CB_%CHV^36&*'<X(PB9-/C(I7[3!<D(S]0G("J[2Y4\1^
M,53\5X[(C)_QW_[//RDJ2^HBRLBEO?8_/+%A'%"$1+B[)FTHHL]MM*2R:@[<
M2(Z[7Z+<B]1A6L-2DI')O4K]TW&YU1WKVKTTY$TH?ISX[0[LPN/=(21_;DX4
M,?57#*[PGEPQ.!@!K183I75U6*3%TK8^X-7!`V6S-+H4WKW<:06ZS,85MTI-
M5'F(Y(VI4HS-B(3&QO:LPDOIKH`:GRTG\,+0M"WX3P)776]:[OHZ[];R5,O:
MQI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_"
M>_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!
MCR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,
MO:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI
M_">_S!G'DN8^G_U:T>CU_P#I/U?Q_P#4'HS`YC-A0=OE"MXL)C/7Q*$O5AND
M8:(J6[S$V*,*=2>M<VV*(Y*8^.11AB4Q$C$F1B*5..P(BS?#CT'(6B=F7W<3
ME5#]6K4SI./-KU"^RUVM"2,Q\4M*"2EP3B+A[0GK5W<C_&#C0'EKCCU>E:(L
M].:,TW:,I*4[]E">)YC:32D@M.>E7C<5$I)4GAMTSJ)>!F1)LR$>2]*#"&>2
MI&@X9C88G:B-K4:XTDA&4H"=XV,PX5DO(\PZ@WYU-'Z'>[G_`*1_X>]K>A;#
MOR_U#L6M[UO>MZZ]=]>O7/+R5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_"
M>_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!
MCR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,
MO:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI
M_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!CR5,O:QI_">_S!C;5,M>G<L:=:
M^G<3W^8,I'SAOYUHVHW](EG+*KFTE)U'VQH;VPMO=VXMV3G:V['B)?E*M`5X
M$LWQ8PQ,#:D`%6TP^\0(TNH,4LV]>454#=97R%@_'?C=7\8:4-I3XAP*:)TO
M6D(#$SFWO3RXN24IL1F#(V#3CIQ9$KB4J(UM-(%6U*,NLU8<@YI+'=UI'L>J
M6;I?X(T]BL?F];D,4L\.9SAB#HU8VO#Z<>I?5Q733@F:U+1I.H'H!S563JD&
M:Y9>;CKV3<4@$TU?7(NQU/*[DRX#3KUMAVZPGR2.1=Q+WX4`8'$7%\V@1`;C
MQ;"T+GDI<-K"46='FV,[_P#`#LME+D\0Q@<Y-()NSH6AI3;4JU&X@,P73O`*
M)))*`_[&>I4'#*3)2"];&<>864'7Z77526OE9-I6?IAAL<$YR]Q<Q)&!K4M:
M`*%2@"48<->Y*0/I)B50064(:A&5WTI9>A'"=-%DBT.2FOCO*96ZH9K<4P1R
MB2$[V<FC)[4)RAK($>PC`D(0:7-A2O1._P#W0!)+1'F:ZJ0N/=\.98@EDEJ8
MDI.GD[*0006`DDDF'A*))*+#H)9911;\$!98`ZT$``!"$(=:T'6M:Z9^GDJ9
M>UC3^$]_F#'DJ9>UC3^$]_F#'DJ9>UC3^$]_F#'DJ9>UC3^$]_F#'DJ9>UC3
M^$]_F#'DJ9>UC3^$]_F#'DJ9>UC3^$]_F#'DJ9>UC3^$]_F#(%YEB?=T0_!B
M?'Y'R@E`916^F.G5\_(JUO=G,V?1\"22.=AJ43F3#FVOQ;%/W!\\F.2Q(BC9
MXFEM<7C;>A41#PKKOEU`GB:+>4G("KY2GF+<A<:YXX5L"4SI!1[>U*"4SUX+
MD=:[OJZ;T`XJ%Z`M<ZR^(Q1N9%IY25F;$B10G2@V$9X:+!K>Q:`'6][WO>^F
MNO47_%O^(NFN]OUBZ:Z]>FL_,I,G($>,@DHH:DW9Z@18`@$>?LLLK9QP@ZUL
MT[9111>S3-B,V6467WNX6`(1"9.E","<DH@`S33QA)+"6$9R@P1QYP@@UK6S
M3S1C-.,WK8S31",,$(8MBW^^,8QC&,8QC&,8QC&1+<ES0VDZWL"RY6K/.:*Z
M8`O[^B9DBI[>2$ZHW25MUMG:2ECGH"Y6,!8#]I0E%IP*E@S`ID:DTOYU.*O)
M7M#>3O(235))9_9<-CMI16:)9&]-U>D,!-%)A1M:NB\PA:A;'FTQE6M;EIG:
MV],O=1G2DAU$::<-U$E=D7T)0OC]`8S*8I:+RWDS&\F"IV2H72YWHC14RD\<
M:_%E2T3H%(:!L`>\/)!CNL&0DT>$]08G`IVFUW-SGC&,8QC&,8QC&,8QC&1-
M;EY551<>%)K1F33%F\03O$4ZH[9SN\G$@V,25C94H3G-V4?\.A!1IC"B>\$:
MDT@KO&!H6;=?+3EQLQ'Q[BAW'NFE6]`47=9"30)D[-V^_L]5#(]H1I18#">N
MB5:'2TL(@]?.MF4!V`/SW=HW-X-63LFJ_CMR!'?,Z:7AXD%MO[`TN$S<&-1M
M(D(=9!*9JF)=(Z<]*'<(6/R:E5NX8JSD")<W8IS<!@%8KLT.S7E7,2'QF^>7
M$BF+G29<K=0QJBW'<AAC9/?-Y(0E16`Z%-ODP"]F5/!JML2C((0+G9.U+S0O
M!C6J+3*/JIA4'AM;QAFA<!B[##8C'D@$#'&XRU(F5D:D@.N]$(6UO)(2D:$+
M8C#!`+\*>:,9QXS3AC&*/+&ON$5\?IF":IE,Q/%HE%$(T#3@[&J1Z%HHI9LG
M1I3<$8]!T()VC%O=%WR4)^M9%(Z[N&]-@/M=RU7D#$>6I3U['Q$G/2T)1A1R
M<3ZXG`/+*,!W0F`V?H\PD\/?+:&\[6C-913_`!FCM7/Z^3*G(R3.X#U!4</4
MHPI`,;<<$9>Q>""<<!2\GD&"3*'$/@2@$;&6C3)_#J!&6<QC&,8QC&:J>TCH
MUO>JSD!\)[/*O.<2J^K!X_Q_D5`WB70B`.,C@5.S$,D@CV^.$Z7,;`_H(&K4
M.I3?X]($I;`!W,4.#/(XV<]H2(8[-:DXK5/("R%<?[,"@NS>\J4PQE`0PJW:
M,F=G6AKY0%8ERPZ.4:\NR'Y/HZ-*WI]/LI`B6(92L$TLGC:=>Z;3;O<8QC&,
M8QC&,8QC&,8R,K9N2L:+B!T]MJ8M,&B!#HSLICZ]"4A1Z=7]<6VM"+6DJ=2<
M,U:L,"4'8"1%E`T8H4#*3DFF@@J>O7)*V%%[516S6Y\<ED3-KDRK.1STEC%A
MQZP$[J8F>9<4SPHP8#D6FU&G4QY0<X#4[T:M`J`%.<$!>3%%Z+KB*6?.[I;F
M$`;3L]AB4>G\K\==-ZD*&&(M(64&F0Y>>RMFB2M:[^FY&0,_02]*##M@$,R7
M]!UKIZ_1ZO3O?_+>^G\/H^;.<8QC&,8QC&,8QC&,94;D9RJC5!S"I(HXB3G*
M)W)R$KR$01''-D;,":EVN``!I>RSC5XRM$&"";H7@-D:*WM6`TJO;ORPOKD:
MZ+X=PUK=4U1U,L-:GSD#:C:8S1MI.)4[3*AQI@7$G#<E9&RQ;"6K2NKF7L7=
M519)^@IU46W)EPOX0R<I^Y'SB2\T.9CZ8G"RUBVIO/B4FOB_8!-2!O@NCUS/
M$$XAG$>2C)DJ.<#2=>,Q*/","%"']@4#VB?:0Z"KY22M;PBXJN?<,(XZ5>L"
M.XIPQC_3)2V-)%!/>:DZI,9HI:TOJ<!!9A/<-K5"H`4OUM9HGC-QNX<5VHC=
M102)UI%TR0DR2/QO@QO3]M,'8`N$SF#L,YY?SPB-&$G;JO-3)O#[2MR5*0(M
M-J09A=-:05D1O+K)F\\AR2!5LJ-G.*=7!Z('KH2-L2I#!:-(-WKP9:LXQ,A`
M+]`:DO>MZU"OC5[WI_\`T`%%*UPIWK7CA_A!3M]1"%_Q$%@\`<VEG%]-ZWK;
M>3W#.H%;J3U#N;:YIN!U@G_].-(1NQP-Z72-S$%<_KQC_P#>$:O&#6TY9POT
MS$J`"5*(7Z0RACZCW*F,8QC&,8QC-)7:U\K^$IE;SCA]<?)*AJ_ME6FJ^R1U
M3R!A]K36J)U'$,O3R9GB]PQ:M4[8\/\`6<\U%W1M6I6V1A#X^W$GN;3(FYL<
MXNZU*[&Z*\+V/F5?&N&<NX/NL!9:&;V1H3\<:8L>%7A(HJX6BC>F1VO^43)E
M:HN%7"3]JX.TGP-0M5VX'P<YGJ..N,:864CZ:L8QC&,8QC&,8QC&,K9RUY'-
M'%6B9G<[HQG2@V/>2&]FC2=<!M&^2"0NJ5F:$!CB,A7I`DTI5>-N*P*14:G;
MTJHTA*H."64*CW&KG9=_.2L9F*BH57-7VY6UBUJ7*$MBNT@E<(=*QDRMP4.Z
MID7-#6SNR>4&)&1U0%(UB/Q8@19:DE7L:LH:.^L=XX0)FE]R2QX62>P"KJD<
M5D[[$;)>`3:#1IQAZ/Q5H#!HN\HSD$<3Z,T4O.`6%09I>F1FIS4X$:8`)^Z:
MUUWK6M;WZ]]/7_'Z<YQC&,8QC&,8QC&,8QF&3JQ(-64?4RFP)6QQ"/I-;\*Z
M/K@0@3C,T'8])TH31>&7+#-!WHE$B*4+#Q:[A)`Q;UK->;US3MZ]5+E'.%=1
MN,B;4HE"9PO"Q$"EF@;6(H(_"&LS6?HI0[JP!T$U,F4F&.8Q]T&XJJ`/6]_/
M;SDY$RJ"W@7&+XW/76>((VQ+%"IQ1(DKD2U.&U)Z=]/;S#FPMM`[+"%BMH94
M*-+Y-9D[<7LI.,&B][!*+EG:B<\JSAE?5[X7A7QR;6!`C=N0#XR.8+CL]C4#
M&).?6S>;IM,2I%",.NXZ,IK(F,($!3J?+-F@;3]KO$?LY^,_#HD3O`(J=*+1
M<"S12.ZK#/+E%FOBM8'6W(PM\5$A+CR-<=WS#V^.IVXM3K8=N1[FH")2.VTW
MLF$5RW^/RY_0M`!`$),D&/9SBMV'K^BA;4^C%BK>Q:[NQED^`!O>MG'%AZBU
M1NX7FT^0;,4X0J!2M#74>"<X`"N&4G6RY4,TH"=P2,@.BAQ\G$A.&C3)#'$L
M.C3U`#=K`E$:DOC#00XNA.F<^8$&I"X[2F1UO<D>C7.-HRM'"&H4`.V(E(Y.
M`S"C`D:)\<;220Z&H*4*5*8JZ?3IC&,8QC&,8QC*7<\)H54G&VR+*;KY_P"Z
M@YD+*V;77D&T4QJ]I/&&I18+(TEH6NKR(G,SYNZ/1;VOBK(C51MY3,1\F5/P
M4Q`4AY^M??9H\@IG=/)6Q48><%T<ZJ\9Z.1J!2F9<'!\48;4LT'8*$&H\*3*
M*LK,J82BPF(X3FW,324[&-+'!7-PD'B&E49,<-ZN-[UK6][WK6M:Z[WOT:UK
M7KWO?S:UD!L/*KC)*;8F]#1GD-24BNZLVI>^6-4#':4)=;,@+*UZ:]N3O-(.
MA>CY'%FQ!Y<9M+%[XW(4J;;LW:.-!M:GT/):JO2G;Q0NKE4%EPNQT3&H0IW9
M1$']`]@0;=D('5D4J0I#1F`;Y"SFDO<:=.YMLDC(>G>F%8XM1Y*P<KXQC&,8
MQC&,9QO>M:Z[]6O^O_Y^CUY5:Q.31:9NE27C[$2>2L_KNT8C6MFUY")@RM#U
M7PY$>+RH[2`]T+-()\WD`1*U#>$/A#Q`/*&H2@0N!J7TW3BRDM#=NL/):4D\
M@:RFEDL\ZK>NI+&4;$WU*B96L:-*R-;JP+$KH]B"J4*C].2TXDW9!@RC"S!K
M%XCI'HOC?2G&N/.48I2`M4&:7IQ`ZO/B9[DY.3PX%$^+$*'5[>UKD\.&TB;J
MG1%*EQA"$@0RDA1(3#>_-^,8QC&,8QC&,8QC&,JT[\NJ@C%HV!7,MD[+&"*]
MBK=(GB1.SD%.A"H4J3"%;3W!%?I+2>^E+2ITXSUJY8(]&2EV;I+I36ETYGV]
M?BY9%N%53+7]N+/&A7WG920Y@KYH%K>RS%#4A5^",<SR0[">24L,,<M=/THH
MJ+WZ:Z7''N*7%T:>W>TAY'[N>U#2-KF&NURA4N3#'L0C`(8;4S./RNZ-GC(-
MD`6NB:/PO8A!\H-Z7KL>8PGOGM&N;Z)#&N&5+I.#G&I2G\4;K[N=G1)+`=(Y
MT,`6HK>M4J<Y.R%*4@MB;1M[2Y)!;"6:EG+.;KJ#L]=@;QHDX6U]NBZ.2-LV
M6L7&N5A3MVG;>D/L-8H,)$>F7)'!DD3HSMW@234J;R=(C'PM*J.T8]FFD(C$
MFXAWE584=$F5G6N#5$X['F5N8XVP$"&:H*:&5"2VMC:T-98CUZ@A&C2ITA0@
M@&46`L'AU`/TAY">[&NRY-[(JF-;KZ'G[V'=@3(D.G%6GWWM;.9&GNG`ZC!W
MO!F$E.(.]K6]N"(?JSF$<<(7&U_G'*#UUCS0T>CE,CEP]K]!4:Z[\(A;#S%"
M8C0-]-DF*AKE1.PZ\"H+U^CJPFM:UK6M:UK6M:UK6M>C6M>K6M?-K7S:]6OF
MSG&,8QC&,8QC&,UY]J!(W>,\3'U0R2F_8XX.ME4G&0H.+#,%QY%SE))[6BK(
MYUQ3CN9H!<'F\X;%BMD;[!,6LH(<0:J==R6+]W4A;*I=FJU>)WC.U`8CVQS#
MK=3`)\>[3">F32OU'>F[2/2>JBC+$GNVV8;T7X:2"ZM6U,>"U!%X_LC_`,GN
MYSUU:E*B2J%BU20C1I"352I6J.`G3)DZ8`CSU"@\T8"B2""BQFG&F#"664`8
MC!:!H6\^3OF+65Z4_P`<.=]2\2>2;ES"I/D+V:O+:_FB3NB>II?>-.2!1,8Q
M)W`ABO.G(Q%5EI5;RAB=E7%Y@,<O0R"8()'6ZDR#RIUCQ;N2S;(./RUOD?:]
M2]\HI2@6\>6GLD^*;+,ED1$'<1-FSY>=IRKCLA/-3=4BAY14BJFCPU$F"TO0
MPJ3LB@6A-KPV[UNLS%%GGKXTH\0\U_$O";\6\<\L^->"Z:Z>'\!_X/A.]WNO
M@_T>G3IZ>N>M^L#]S_[]C]8'[G_W['ZP/W/_`+]C]8'[G_W['ZP/W/\`[]C]
M8'[G_P!^Q^L#]S_[]C]8'[G_`-^Q^L#]S_[]G&]V!KU^:'\M/^]_=K6]_P`\
MB.Y[U0<?HJWS2UG^+QZ..DKCL)0K4C)-W\TV22M6)$QHAHF-$N5E$J#P#V>M
M-*"F2E`V8:/J(H!D42J`\H;Z+L2$SUU34'%XK;T.?JFG=+3YV+E]@0J-&Z=%
MR27%[)/VS(GM8$+:Y-0@D[,!O>Q)E29`6<[6098:Y1MPD3O'HM5K$ZR]T"]2
MMR9V58VN$E=RR`I2G1_6(DI"AX<"DH`IP+7`9Z@)(?!A'H.]ZS)/U@?N?_?L
M?K`_<_\`OV/U@?N?_?L?K`_<_P#OV/U@?N?_`'['ZP/W/_OV/U@?N?\`W['Z
MP/W/_OV/U@?N?_?L?K`_<_\`OV/U@?N?_?L?K`_<_P#OV/U@?N?_`'['ZP/W
M/_OV/U@?N?\`W['ZP/W/_OV/U@?N?_?L?K`_<_\`OV/U@?N?_?L?K`_<_P#O
MV0U;G(2,T4VZ<K4L"LHMHPL1J5K-/?UTC<`!]'5LC;>%2\K];%T#X0E)XL7L
M6MGJ"0=1ZH_)>;O)"?1Q=**AI=;#:L0J4H%-O3-H6#='I(:JV0`BOH0M-[CN
M^.)@=)FW0-R1*G-,T8O3E:#L&OGP-YL5VSW7()G.E)TL4^<RXV;QQPCZMZ:Y
M(FT[`\J14>S]%(W,9!J4HC8#S$R,Q6CWO2D.MF;UN)BMR]IKSSC21MXRUE$N
M`/&Y4G&D:;=FZ(3C9CVP@!M,`%=0LA$G)84YH=F;(7(FA"E)[NA-4W"<1OOV
M<XT]E/3O'N0:LN2(FSD9?2M7MT>+NOA4^S*1'O(]Z,VX,+&XF+V>/*"3=;$E
M<A[>9*5ZO.+8.A8;O3JY$];Z$7*)+!"''8=[+96_4@=7T\?H\&6%N2;&:3LW
M8M!+,7#2)_3_`.]K6LHG<\^MJ;O,;D#JR2>*L1JO6Z_0DHG1N\87DB)Z."37
M72M6^J1C*&GWZ3`)Q@(;0F$Z4''VHJ^@W9"0@FLW:6.2V"Y`"XKU4Y7O+^J:
MSS1#&4F"FT(UMTK3E;*V:<+2LQ.IT,I*<4`K6MV4UJ?ZUTUJ':UK736M:?=:
MUK7JUK6O1K6OFUKT:UZ->C.?U@?N?_?L?K`_<_\`OV/U@?N?_?L?K`_<_P#O
MV/U@?N?_`'['ZP/W/_OV/U@?N?\`W['ZP/W/_OV/U@?N?_?L?K`_<_\`OV/U
M@?N?_?L?K`_<_P#OV/U@?N?_`'['ZP/W/_OV/U@?N?\`W['ZP/W/_OV/U@?N
M?_?LJKVB=>O%J<3I]!8]7%VVT^O,@J\QKK_CY=V^.=FR!0TVA$7H9+=<PW=B
M20=E2)FX]?*G%6ZH@GQQ*Y(D2E.[J&U030CLVH58];\GY[&;8H/F)1CZZT.!
M_C&N5/:2J.<Z28-I%DM:.3#@K"Y698:F'*8TK/C.I0]-VVP"@,C8V][`=XS'
MCC-ZN>!A8#0#+,`$PLP(@#`,(1@&`8=A&`81:V$01!WL(@BUO0M;WK>MZWO6
M1W6U.U)33,JCM0U?7=5Q]:L-<5C%6\)C,%9E3@?L>SUZEKBS6U(3UIXC#!&J
MS2!GF"&/8C-]X77MX;7D"KI$X-U?PF(P9O=G0][=$$/C3+&43D]*BR253NO2
MLB%"0L=%12<@M0X*"S%9Q9!)8S=EE%A!F&,8QC&,8SI'R31R,$(U,D?V6/IG
M%T0L;>H>W5`TD+GIS,V2VM",U>H3EJG-P-"(M$WD",5JS`[`G),%K>LT"]I.
MX<M>3;LD;..-?<B4<"I2P9G6T]:&="Y0Q9*YN7Y+4,D]CQ38]('*:U\8RB6H
M&E])&),TKCU!RM"C`YIEP]D?`CC<_P!+4NE>+9.E#K>5KZ89K<XYA,%LVV5+
MVQ,8B:"$WCJI>VH%S6R@;"'8UK,."H>DQIH5ZHE*A$3?+&,8QC&,8QC&,8QC
M>]:].]]-?3O.K>GENCS0Y/CLI`C;&A`K<UZHS>M%D(T1`U"@T0M[T']$LL7=
MUUUL0MA#KKO>M9KGCW:94Z*O#I7)D[X?)UDQDD:B\%A["O>7V2`;CM&-@DG>
M,T@3F'(E"+Q@:U>G$<(X*E$D,+-VG)Q]PE_.?D,@5N:5-'^%5,@*-5+I9,#R
ME]HFL@=:VH5>!7>)%1S_`,MU4:/4D1;:?IWB7L\&N\*AR[DIV=?'>:C8*J8K
M%[2'EBM5#!X*((%=JGGOQ>]$F'BD1J5?#4"<*CKOQ]B1SAX;]]WPBO>@;%DU
M>8/:\<U@A'/YS$>SKI1T`$(X;7._/._U[.=HP827&2EJ"M1U880/P!@DCY$S
MD@MZ\8CAO=$7OH^/78H<::)Y31NT=WW*['55DI)G++4\N2PX+BED)"(&D,GE
MKVU^+JWA`WNJA1(4:$+$T!"O,:35ZU8G1;VOVT2_DG7\>6>08SM?8LK,%X).
MPPL@3L(9_4.@@4.9(348-:%O83/%A+CB]ZWH9`=^K#],7(RV=]Z1/26EHBHU
MU\BQ\6U\R5)AAZZ+6..C`"1#&`0@&;"J0B!O?0YJ-Z=,E&`T)6M>#`M:V,+F
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MAOC2JL-*C3/.M^=U3^F*3K]Q9,``S6]N$<%8:88$M<#2)9X+Q+XN))J=-4W(
MR7;Y#1E7>2.YZEC$NC+<S(Z;,8RMAC$?9%+&I)4OI3&:8H,*7.NP@6%G#+5M
MY@CU@E%K^Z'U=-;UUWOT^GTB].^G7KTZ]=^C7H].>7J]6,8QC&,8QC/4/7H4
MRE$C4+$I"MQ,.*;TQQY19ZXU.0-4>6D)&+1B@PE,48H-`4$8BR"QFBUH`1"U
M[><==>G776]Z]>M>G>OY:].=6ZOC*Q)1+7MV;6=('TB5.J](VIPZUZ]B.6G$
M%!UKZ=CUE%>67-&OJXJ63*JQL**2J>"4-[,A(BDA:7LYF4N0SAA5+#6\Y<G2
M&"(1J0)]';V/O>$.T6(*<68BV]I+"%3!&$K)5=SV5.W6,LCJJ:H#"A.34)6O
M2]#O!O&U>B_!^-DG`,T4C/VE-T8E-#X4@S6O8UR.YT3_`*;K+AHFA:00?T'2
MYIRG;A=T6M=TT;(G%'G`/3KH6R]>'%O6N[UZ[]&"3,OF<0D$MO+FAQQXS,*G
M6S%*=A3,29<B+Z"WLHIXFIK2/PF@Z%T&2]#WW@;V$>_FU)<S^2_':IXT:5%.
M<,MY=V^XD.C=MN)G(G6',J163M(?XH2TC=F(EX7:-4)$AHWE4%N3&'*"D(U`
MDNPU9X(\MN7BR=OK9Q7H*.3R=C:RBG%7(ANCK!X"A>U6F-LF;UHD*!P;C"5`
MC$@3B7(C2\"82;2=64`]"/=<W]E==_)1>ED_:3<N9Q<Z<*@#@50M/J5-<4JU
M*`B!W4ZC:-*W*WPL!7?3C5(X]'G86M=X;XIZ[&/8/!XQP]X:1L43K.,UO5J,
MHH!"AFA;6F/E#L,C_P!K;XL1Z729[6"WZUDD<5!HQ=1&*->G>O:,O"SIZ68G
MIVHWGQ(\`P)YA-QE,+46$0=@\:2HABT!5LK8O#%Z"N4;WL(=#2#UL0-U/;>-
MMN/MDGL,F2*RBSE/E*13E0<I7-"]$I&68O4)73>DYCLXN&AC3:;M^+J0G[%M
M84D1D;,ULSA]?0R`HO$(C'6UC(WK6C1I".JQ5W?^$2UP/$<O6CU\PE2DWI_]
MN@Z]&9CC&,8QC&,8QC&,8QC&,HORCXBV-;4I;K<XV<JK*X=7TCC2>#N\XA\1
M@5M0*Q(0A=%STRQRU*6M-M<8E)QQ-U=WY;"Y:P+8?/(R&225K22@YA?%S2/]
M>*/$*9TA(I;;5]\E['Y><B)NR-<1<[3GD7@5<1R(P1F7'NB2!U'4E9M#7$*[
MC+@\G!?I4IV?(9?-GM&SJI7*G1-'HZA:;QXQC&,8QC.-BUK77T[Z^KIK>_Y>
MCT==[]&NOKWZ-9I[LSMB:@KODH=1A4!?Y+$V:7((/*[6:I`T[0MKZI7(VYQ/
M98X6E5'2!DCR]48B>5NG=O6B4H7$#8W+M)B_&;?**IN>]F5X9;_>PU<"$\BT
MLXJM=QVG4A9G*45O#50%$5;['5N*8P1VW_9ZH$G9$82$QW@$9Q($9I`-F6K:
M(S'&`]X4L3`RLRF0NISZ_J&IJ0-Q[V]'@`4<[NYR-.08YNAI1111C@M$>K&4
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M:141(B$Y*<A,O$U@3Z/;#Q$^`&+;?XP8<$\S5IGWE5R5=VHJ1R/E+P/XZ1A>
MEVX-JAUFC4Y2(YJ-V8-.I"TR!P>#`*Q)P=X:,TLHXH_0R!@\(#N[J+-N9/&M
M.(XFW.UZG,S6[,V!5%^/4(DQ*90/0@Z$0B<8LVGM)P1;WW2A]W0!;T(7_P!F
M^D5MU\<'I@K`96_$WM'^8[T+8AA6N\?D1;.XC#W1>%VL1N250`D1>]&Z\*@U
MO0#R^_KJ/H54/G(HY8"BR";Q#@O9G#.B&IW3IA%B+#(74]X6(M)$SC*C2B#W
MAI&L\$)*!T<&TE$,T:9J`Y>&/`4JO#P-HWMC'NEXXK@5NU]QPJ^?$F2!,Z6%
M`4<DL\U&$XQ,C>?-%T8U!C5N0)];<&L1^VO:]M&E=#RTX5:;9MV5?99WC."]
M&\G.U%Y4S9K4]#'./P-Q:Z<CAOZ.QF%`))='A+HD(M?H[\F%]T`=_H!Z[[O+
M#V4'92U\H$X3I("UGD&]&#<K;NJ1S!<,P&]=XP]M9'AH0'"&(7Z19S:8$6]?
M\&^Z+)M517LY*W@\AC5:\?**>/*;*L9S6%KJ5F`2]IW$C2(]$\R)TC^U8V\P
M@W8EHAKSE`RRQA3Z&KV7D=\04T7I!)):_P",W'&L(K)YPX@>W)?'1.C2G5(V
MA,:`C<D4O3L[.;@B8O'#PM!1LB2(DFEQQ*5&):M,&IO!JF+?GOZ=KVZM0MIW
M3PT4KHGR0AV2/](2<]S&60,_0>O<%X9&NZ^G>CM^C>Y0AE#55!=EGLL2;SG$
MONBV\/`=O3J(T.^]H\*IQ\,%,;O?IV)&4FUU]6M9+_37_7S?P^C^&LYZ:^C&
M,8QC&,8QC&,8QC&,8QC&,8WO6O3O_K_.]_-KU[WF/1N6Q:8I%;A$I&PR="@<
MU[(M6QYY;7M(D>&HWQ=S:52IK5*R$[FW'_\`@KV\XP"M&;T+4DE#WK6\AQC,
M+:K%@CX<\)V>7QUQ.8#2RG@"5X0&^3Q&C`26(\>C_!^!$I'XGI2`8TWCQ9R#
MPOCJ<].7&4QY+5A%WBVH4U."V>6O3E;;M&4U!"$"AWL(Z.'I1J6G34U#+(2K
ME[T/P!"%&4M$?HQ8B$I+)+5IA&XRTV3?5AOU4KX=5J>'4]8],O$LE$ML%=IL
MM"L+"<4!!T.C"^LQB$4Y"*VI`8]%B6Z*`82J)-5(=IB273K(MQOFCNAXWR*]
M+NFLWMJ@U\J>'"1P0_5;0RS'&2@4(2RYQ!6T"A"ZH&AGVB2H4X#4G?5$*U1V
MO!N"A/N#9!P:X#I.2D'?%U8M[;:;J>ZSUJCK<[/*&$O+ZTNX7L4A?8D4Y`95
M3MMU&:O2$>*!;G%0F.&XHE`RD^A[*M"!ZM"#\^^G77S^GZ?G]>>777K]?\/3
M_P#&<=[77I^E_P#XBZ??TZ96WD[R/C'&V!I)<^&H#5+C(6AC0(%BK2;1WC2L
MG;B=O?A"A:\5;]FFAZ#UW3!E&C",@LT.\\,O6FTK:C=7.T:_94JY`0Y$Z>IC
M'&I0!*H))/ULY,M<RCR3"@GE!/+&#0BC!=T6M;WKK';SS-XKL6S`K[XK<8BA
M'@&!LD!+V9WD^N\8$);(!Q&8+>O05HO0MGB_0(\(/KK(P>NTCX@,X1[!9RIW
M&7W];`RPF;K=;[I6C`[">8P)4NPF"WHD`_#Z!X;?<&(O6A"U`MD]KGQM8H3.
M72.FS+;DPQ1S=DSD\1]&TM"=1X$M,V"-`I>1/*DY4[+$;>WHD+0J5+EYI8`%
MZ1^&6%4JXO\`;%Q9FI1`V.+8VSN1-,C?T*DR16#'*Q6-Z)1K3\A$M32@DTY<
MD/+/=`)E[=L\@!Z72`WHI,*+WWTB[;410MZ0N7$Z&@'X$(12>YW&8J"]J"!'
M$FC20I)X40`AUWS0A+WLL71*;LM2+0-04\=LZ_/)@PI^4]1,FC=$[VGJWCO;
M=@K4Y1X1"-V4:_1@*09B+1O@U.Q*M]Q40FT7X0I2,W,#>^TAL5Z1Z>"K3Y\S
MY1HTH2=J@G%Y)5$6<EY1VCE+*HE'G,%>B)"0(P1YJ)F5K-I#20ITY:@G0BM8
M%:<PKFE=S2?2ZM#K4,G!LA+D%:QQ<]1B2G)M+@K#B1R5&4Y.K:)E.3DE+G!:
MW[&ET`T)FB!FB)'M=CM9<J'-,VO<2[.7AC7K<YHRW%`\<C>53O/W(210#OE+
M'1I0V*TZ`;T&(LT@V/)1EJAEB.2E`!LO)=;:P[05O&4H3\BNR^X[A`:/7@*B
MI%HFKJCT4$(N@53O!W?PPM^+DF%[&Z&#$!:<5L[PR4@H.1JJ*OJ2A`?9W;1W
M<;L0-!4,])53N`)PDBZ%>#2*V=:A*)T$D!>^OB`3"!Z,&$&_#"ZZU[H[+-I>
M;22N5=<@I=*X0MTUCFLGN!J&NLMT=`&]Z0.;(-L*3MRM,N3;UID3R42-8W*>
M\-Q4N"/98=;6*J[/#@3#4^EL<X*V'<YRDTE:BD-J"6._5/X,`BPE!`I-CZM.
M>7HM9HP;<;X49O@RAZ3@+UN]L)KL<*"1JI>!=+5P(C0-)E8&B`L*@CP8=E!,
M,-;6AK7"$$8MCV/9VS1E;,%H6Q#$9N:@J>7#IK19+5441+WK6@>%4NCF:2'?
MZ6@]U.<M($(ON;!O82^Z+1VMZUO9?4,&7G6/(UV84#M)7Y#-TK8L'L<?@[:L
M2#0;5`"`+EMN(2)SWK98M[1B-T6H5(4^]&EE[)/6&%YM6?'.>+X<TESJS["C
M)`@#&EA<??#4Q34WG[V:!.N/-,/"6N-$:<8H2$%#)0Z-TF[XC@&Z#(Z3B34@
M#`G.Y<JDYNM]1CD$I<5'A=[WH0MC"C\1U^EOO[WK6]:WLP?7>^NN[GK30-,L
MFP[0US&-[!KIH2Y#MU'OT;UU$-T,6;$+T[Z[WUWZ=].F9R*%1#;<L:-1A@+;
M'!*:B6H26AO3IE*0\(@&D'%$)RM"+'H8NNO1O0M]\.]#Z"UC-<5%":K3N),3
M;S2CG11LY8O7J!+W$PD(A"3(-+#`!,"WHM"V%*FUKIH6Q'GC/4F#.%)N,8QC
M&,8QC&,8QC&,8QC&,8QC&:U^V*E=J0?LMN>\KI8UT2V*R<6[;6,SBQA-\M,R
M#<;4)Y4_M!Q`RU*-T8(<?(7I`XI1A5MJE`6O2]5"8O6ZZ<=6UFKCM<I;5="M
M;4S\?#NR8XL2>:-T12D%Q4F=1J\K-KZ@',W:$!;:6].U*M\P9$BI.7XVZQ*&
ML)*H6F]B9@ZW9YC"MQE)2H\M'&VU4E`9L)"DV2;2&'%]-=!C3>15'@1;%L6O
M!^&-Z:UK?>]/35=>5=A2V$\<;L?ML[6T+BZSF;>Q+2IF8G5`D;O'W!L8-(C"
MF0DX*WRFJ3C3;).),",OOA.)[OA0?$IQNEW*&RYH*JBH<SW"5(F0N&"@5Q/#
MM74)0*-'1P;6C*?X^[050U*&];&&50V1_;SMI4GMA2PYO.4$:6;^B1&O[=!(
MXGR)HXX<%XY(G!E0L*YY*<DYDD,:VKOA:6U<\ES8]2L2-6Q"&A0J5R]$G,$(
M8`[$,S6_(;Y_V@TX(BM0SB.E$;KN>-%N;*(U/L>]:\.'1SVI*$(OKW^@TQ^M
M]-Z\$/?0.^F>"?\`M!"%O<G!9+.)[4@1I52U4M`"+`\02)BQGG'Z.4L!Y>@D
MD@%O8SR3-;#K>Q![V];UH8LN^^T#?^4;7;$ALR0N%JQMS:T\?E\/,`GJ]L2-
M7@$^P-[6B1HXP&/#\5&:^HU[3X9V.TH.5D*C3TXA;F8?37;@W1%&R:,',RIB
MXU)DQ3JV.3*]*6XPS6C-@VFVD;*\1;;=@Z"T>E`+N!%K0!`WL7>S]UG`CMII
M#I25(.<$=)).$4:+:&:3<S9QI6]=T(R2FIL)(+!W0CUX$.]#&'7>!K?40L4/
M[*/M/Y$,\N4<TF<8%1A(C3P.DL<]GB#O6N\N"J4D"&65H)0@:`!2/8@!WH`-
MEAWO63R?X#\TD#EYO.#K*KV:8R\*RCG8<?6Q=E+=U.BFU0K;U4D/()>@;*1E
M(2EBLXE045WBF]/L@\_PEH..'91<A+M:0HYQ=-IUI(V-F0`5,#LR'(6[R<B)
M2-[45'Y0KTH&Y$MB?P"(TM4F3GB+(UM.(U,$(M6P3=@C)#^[Y>Y$V.[:V#HI
M`":DMY2HS6N@!A""++!)P%["#>B^\=WN[TV/77KKO$?8#0S6RQ.\RE[V+01:
M4"7VJZ!"LWTWH&S@(X<E$#1>NYW=%'!UU+!H6MZV+6=5.^P,@?FFXCC)KFA?
M$2)6<F7M<U=I&^JC=`ZDA(;9&B)9EAB?7?\`!(`^(B7%[$F"J+/&49G3<9^P
M^C"-";)9TE(G>S5AQ"9+:D>*9B_%R1%]#FR,)]GJ$?BZDH6]K'-=L3D9H96D
M@6[74_8I'.S)K*,]--5?5DUA&$X*CR5!:[*,%X<T*@T)!Z^++S2"A*BRS@AU
MUV7H&@%;+UDXM'$L]F"'Q!VD;8,&SM%BC[_%HV$!9X@C.!HMJAA7I.-#HPX7
M?UX86@;,"+98=YD:CC-I>5M.ZK;%>$NQZ-TE<[C&I2@4!Z]U2%.*("*VH#H0
M]`,&#>PZ$+6O0+?6#(=P7,8I\[2-QC$,VWKCC3'%P85+<P2N7%&C\.G3/K^@
MCH7`0`'!+-=#1G#-5*"M"2"!L>CRK,H^.U>(A:&&DXPH'H01]]=.GA;O8@A[
MO46E*`P`M"_XAA$'8!"WWMAZ].F7(*LB[;K6D=&UP7W0A!H1BYO4CZ`%WP[V
M8JC!P]BT+T]_8MBWTUK>]ZUK698D9U+?T\0K"%(NG?Z>*.;:FZ>$_P#<Z>!B
MH.G?_P#O_P#R^?KD?RVGFB;2EIE[]7#0<Z-G@0G%$3'Q9O>RTO=VB*?D0(WX
M-R+1;#H).AB+V,@(4BD2A&`"<,O`<I>`(0`B+.$`=:"$.I7T"$(=:T$(0ZC_
M`$"$.M:T$(=:T'6M:UK6M=,\O*DQUZHFT:__`+LW^7\Y\JS+V3:?Q9O\OX\J
MS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3
M:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9
MO\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX
M\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+
MV3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?
MQ9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\
MOX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OX\J
MS+V3:?Q9O\OX\JS+V3:?Q9O\OX\JS+V3:?Q9O\OYF&,8STG)M;GEO7-#N@1N
MC4Z(U3<Y-KBE(6M[@@6D&)5J%<B5%FIE:-6F--3JDJ@HPA00:82<6,H8@[BN
MI*`IJB2'TBI*\CD'\YC&3;ZH9TINUSDEBS*GC40:%#BN4+'#S>A4:2)HU"(T
M6J+CT+CB<EABS6T-)84>IAQD3V[3$#O..IXI8:%>ZQ].N`Y":T[HN;$RI466
M(!`EH$HR_&@D=X0R0&]0E&]X6M:%L6MUT2]G?Q40JTRU%!%Z1:B/*4HU9$D?
M"SDJD@01D'D'>'Z%FE#"'98M;ZZ$'6O3ZLNRD)`C3ID03%!VDR<E.$Y0,Q0>
M8$DH)>C%"D>O_%/'H&A&F#WH1AF]C%^D+T^UG5/3.TR)K7L3VA3N;2Z)S$;@
M@5E[,3*TQFM>$(.#U#H18]=-;UWM=>F]>L.]:AD7%_CP'77=-U_Z]>C4;2"Z
M[^;]$(-[WO7T]-]/Y9*<3A\4@C0!AA["W1QE"><K+;&I+XJC+/4>#T<8!.'J
M$H1G<!W@AT'6M`]`=:#OIE&<;%H/KZ_RUO?_`,:W_+Z?3T]6^GY'%$FE["<6
M$XO>PBV`8-'!WL(M"#OP8@CUO81:T(.^[O8=ZT+73>M;UYZ$'>M[UW^FO7W@
MF:W_`""+6M[W]'=UO>]^C7ISRUO0M===>GVA$'?W"UK?_+&]]-;WOKZ/3Z-;
MWO\`EK6M[W_#6M[SGUZ_C].O_G6__C>>.A!Z]-;^G?IUOYOGZ[]?V>GTZ].O
M1G.A:%ZNOH^G6]?_`#K7\_H^?.<XUOKU]?HWO7IUO7J_CK777VZ]&_FWG&Q:
MUOIOK_'N[Z>GZ1=.FOY[^CZ=8V+6MZ#^EUW]`1;UK^(M:V'7\]ZSRSCKZ>GI
MZ].OJWT^_ITZ_9UZ_/TZ8WO0===]?Y:V+?\`+6M;WO\`EK><=\/36_3Z===:
M[HNO\P].NM_1K>M;W\V>6<;WT^GT[Z>C6]^OZ>FM]-?3O?HU\^\;WK6M[WUZ
M:^C6][_EK6M[WO[-:WO><:&'>M[_`$M:UZ^\`8?N[P==?Y=?F^G6<A%H6NNN
MOT?I!$'?W"UK?\^G3&]ZUKKO_EK>]_RUKKO?\M8UO6_3K^'IUO6]?QUOIO7T
M^KTZZ;UZ-ZQWM;WT]/7T_-OIZ.GS].GS_3Z>F^G_``[Z-"UO?377[MZ^?IZ]
MZZ;_`)?-O6_5O6]\YXZ%K?JZ_3Z0[#UU].NNM=?Y=?7KZ==6Q:UOIOK_`"UO
M>M?QWK6]:_GO7H]/J].-BUK>M;[W7?JZ!$+7T>G8=;T'7VBWK7K^C>>6>.Q:
MUOIOK_'N[Z>GZ1=.FOY[^CZ=9SO>M:WO?7IKZ-;WO^6M:WO>_LUK>]YQW]=-
M;].M;Z^L(M;]'TAWK6]?QWK77KKIZ]=?+6];UUUZMYQL6M>OK_(.Q?\`(.M_
M]>CUXZZZ=?FZ=<X",(NO30M=-=?T@#!K[Q!UK`1:%KKK0M?-^D$0=_<+6M[_
M`(Z]&>6]]-==_-_/?\M:].]_1K7IW\V<:WK?JZ^C?3TZWK?W;UK><=[77IU]
M/J]6^GW].GV>OU]=>O6]8T+6]]-;^GYM]/1]O3I_#T^GT[UUUK>>6<:%K>^F
MNO\`,(M:WTWT]&]ZUK?\M[]'I]6-BT'U]?Y!%O[^FM]/Y_;]&\XV+6NG7KOK
MZNZ$0OO[NM]-?;OIK[L\L\=BUK?3?7T_0$6]:Z_3O6MZU_/>OI]6>6]]-==_
M-_/?\M:].]_1K7IW\V>.A:WKK^EK6]]/2$0=_=O6MZU]N]=-:]/7IGEK?777
M7S_RW_/6_3K?TZWZ=?/C&,8QC-=7:WW-9W'OLS^;]R4TK7M=G0'CA93S#GYJ
MV:!TBKJ8SB;-S-M,)",1+A"T;@JE:)0,`B4RIF*4GZT049O5;.-A)-`=J;*N
M)U2G.)="O_9CT+?,B9#'IP?6YNN2-WG.J=;I_OQM0MVEF5SP(LP^?R(9VG&Q
MW>N4<H>CW5\2NCH=W_(WBG%I!S9XO3ZCEDL:N5C3?+5=%XW(GD\D5&,/#]M8
MY.RRJEYJBT[!C.JYME6ACE:5=6IC*$L<E0RBW6A*8_PJ;2@V*7>I++I7M5ZX
MY`\CH'"+HAO)"T)'3G&FYJZL>_XO->,+LBI6P)##JRM>@7:>N=&6%")/"(18
M6DMP1B,-<D9+(?CE4A8!HW%I?V;>V(7Z`=AUOH+9>OGUO01B"'?J].MZT+U]
M>NM_/GRF5+;UCE07@+S,.<)!KDYR2[<?D%QNN(A2]NARIRH9ZMKEQ1ZRC'1F
M/.'M37M*UG2\!FD.BRA(%'"Y)`#9RC)0.KQ)W-UVZ=J+QKY%<GZC@\7I%/4\
MXC<6E:B=V?0EJ3>[Z<)Y`)&1J&&*09BO"B);&955KFC=U"Q_;')U0RB*.,G2
M1<$G9!L2%<8+34ZVA'N1E?<[IXUM\_I*J>*?88\5+XX01)YFTB22B@)195<<
MFK4=K21/[@[JEH[B@TLH^NZY769IT=EZIM@3FU:?5K-,9,2^_3!Q:G\NM;C/
MQXM"?MX6F=V11E1SV:M($HD06N6S&O8Y(Y(W!1B`6))I&].:U/I,(LL2?0-$
M[`#8.[K3AS/5*[;YA\_*_LM_?(_`^-'9"-%PT?M(_K8Z&$6G:$SY%*9=R+BC
MB4H2B9K*@.Z+K]CB$]1#TZ01*CD*5L<4":7R%(XWYHZ.%<_NS8XO&\HDLD,5
M<A>,?&NR[I8HQ*I76"]YE$EKZ$S^0LI[]7[E%9:Q-*^6F>&=FIA>64Q8A"8P
MKQF,RM>WJZ*UCPG>7SA!RPAO!]ZB]6L')/D/(U$+17)/.2UC0]WH.L%S+43G
M'1S%!;26Z8HU7^164J?#I7"9PWN3#&+24.T=2ENA+?K5V.RP718GBN"`L=)*
M^/4DIJV[DIVU*NW9DXN=B:K9@LY7HYN]0>U['<7*9SJOY@J4I);"G1_&D<D#
M`\HX\M:VI8RJ$!$D]I.`T79Y<Z#DZYW:UB#B%R0>&]S87MXCCPWN;)3TQ>6M
M<WO3`N;7=`H2.*!*H"8C7$",T7LDW9B<TTH>8<:'IV3<,:#D"9*H?WTGC+5+
MP0C$,\U0\NQ-0QYP*3#,!HP\PYR6@"2(?09IAA^^FAF"UK?R=SWD_>W'+@5V
M=?,&G)?(W;DWRUX`]I/:?(J4Z<#G%RG<P0\4)=RH:K0EC4:%>2Z+N.MR,C&T
MUTJ6)^[74$<E=6-1[1%7,MH+W*\3]BHSM':>XY5BZNBNIK0[(J(7E9B%4^*7
MLIWN*L+I@M>Q*YGHU6<L,4V/<,:L>;IK"FYZC;U:*J%LSF_K7EPBX59.],S>
MPEF"UOIL(!;UOZ-Z#O>O^?S;]&_GS5+V6BA=Y6[3%L5.SZZI&#M2^1S2S>7G
MY[DBIN:0UK0;B4UI%S\O<W`MM2*G%9M`WA4^)MY1OBB%.G2EE$`Q7FYQ9A\_
MOZ@I94RR7)>;ZKD+2EC1^WFR428:^D.--6RUA47LVN3.C=4D71TQ85<-TJJ<
MZOW5O&V6C:5H(7!P1/#JT+WV-1%R,JJR:S[2RDN5U_0&$7Q0LXN6IJ"HU_@E
MC\@J_MSB'*Y<V+([`'&750FGXJ!ONM)A:"UZ.ETB51EFG$)=)PS+Q(Y9%HBE
M$Q[X@;UL(=ZUTUL.MZUO?7>M=-=-;WUWUZ?3UW_'>:L)F8K2]M)QV3DNKV%O
M?.S6Y?*W)E&_O9L=.7QKDMPV2,KF5&CG`R/I'=(CDCVDV[HFQ.Z*DJTQ,L5J
M""B"R9$[2OCYR"Y-T`DK"@W>I`C.FS+(+$@-RO-UPN*7)#H\0N6):N.LR@I3
M%K*K`#Q+O-U\.F3)M_++U'4[2Z1A_C[H\MJG3#34M@G*&Q&&FE\$G%"<<*;[
M%VP;*@U+R:R9%('6E^13MR8N*B+FFI%F.KTO=Y58E#+Z))057=JAX62".H9<
MNF["OCZV9"WO>=V:EM6'?'9[\);HMHT]79=I<5Z*GDY=%).TY[[)I+7+`Y.T
MD,3^#*`0*3*3A2#91)82`>4^A'4GP8MP9VM)BM'3_&!T0.KVU+$7:4=FVD"8
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M'9*>64?'(?8`JX1')H\F8&1!]-;@F-6(%J0A:H;3E*12G)<4@4XE2`TX@PHM
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M2,<,:6@4>/D:-F=F)QWPAWUU]'I%K?\`'6]ZWTZ_-UUOIOIZ=?-FGKFYQ9A\
M_O\`H&65.LER7F\JY"TI8S!;S7*9,)?2/&BK9:PJ+V;7)H1NB6+HJ8L*MVZ5
M5.=`'5O,;+0M*T$+@X(GAT:%[[&K4=H+1]Y\C.,\HJ&A)96L6DLJ>&`$H36S
M\JJ"'3:OV]<)TDM:N$HI26PJSH.FG>TK='G.:P][V[,S`>\:1H'`Y6$C-.?'
MQS8+9N3LS>(KW23G1]$,$`[4=;<O&9^LR77%%'WE%Q@MRO:$>FE=8LV<5[Y<
M$'C3G9MEVI6#J^K%*C7G!!Y9Y*CTC@S02P;)^QFM:>W-V<7'^8V1(GB8R%N<
M+LK9#,Y"Y&O3],X13/(*U:@K68/;ZH[RJ0N\EKN#Q=U<Y*J.4J9*M//?SU:L
MYQ,4&2/V@M+<=;5J%R7\DHA([9CS&R2%FKZFF.021K6S:V)BD+;(83"VJ*N;
M.X.-OJ'%,2T5M(3%?AJ^4+W>6-BV.:3NTA12/QXI>RFCA13U`\C['DL]M5#Q
MTAM7739C8_KVV5R26@@2*-3I]0S1O-*>P/:I6-P`GFZ52EDBI4$,I*5I7L\*
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M]MV,BBE3<P]N[X/DQ-_^T,ROBN^E&NRD#@=QZ6\C+#XEJN-IZ`X1GAJUBE'Q
M1!8B"''(]-K58L?.N(E`FDQ[F]*OWX1VO8!L<[#/DH>_O;A?G/>ZN7S)RTT:
MZJC%MF1J7UGR$N-S;92VZ,'M4V<<9K55?,=7)S4X$U2Q-K<82PE,;5)WM(M^
MJH.^\$.]Z].PZWO7J]/36^GW^CIO^&\TK06`1?C?VP"9,UU[9E=QGDMQ4L-M
M9YXBGZB=0#DQ=$!GD/L:?2&YV%;(W)_B-O5;!7-*UU9+GEG"5,X9*K`CA3XB
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M@X[5/*I&\N,C>)!2M)\F+!A=6;52-T-4*Y`",1=&E@:-W.5*SU:&))?&U:A:
M6I-%M1QC&,8S'I=$XU/8I)H-,V1MDT/F<?>HI*XV\I2US/((W(FU2SOK&[(C
MM;)6-CLUK5:!>E-ULM0E4&E#UL(]Y4IHX`<=&6+3B,(&^Q"3+#^15#)9>1<-
MG([&.BG'5];WZEZ^06(@DZ27M-?0<Y">E)B3:ZIFV0I7Z8"EX9"X366.#Q^2
MGL^N.ZRXY!>BE7?XYO++(CUKRIN!RUY1IJUDTPB6V<$8%(*<26ZGJ=XCC$CC
MS&U-T*<(:HAQ;.VD-)C$:@,5$*)!K;B95-8SERL%N669+7XV33J5QDNU+>LF
MV&BM7*REBE?-2ZM9[`DK^@@2)Y.7."4I,Q$D[9&!P71&.FM$05'L([-;UUUO
M7T^C*IL?"SCU';A2W<U0Q01+6R=3ZUF%L'(7XZ#QJW+6911NS;8CT%-7CC+5
M8DZCYJUI?9,0@VI\"]RU4V%MKG.9LND6+?\`<+I0#%6$:32?D0B9*N9["C2-
M"DY17^4&:1>T)".42Z/6F?\`*!M592$YX$$;*KE1ZU[BK:$3#%W9H8%"QL4]
MS;?!;C-=1K?YZ5V24@(K5II-Z8HJ[.\+CTTH]B?4\F:*5F['%UC6W26K&]]3
M!5)H>L("WE(5K_'`_P#I66RUB?;<E%%DE@**`$LLL(0%E@#H(``#K00@``.M
M!``(=:"$`=:"$.M!#K0=:UJL%\\.:$Y(N6W>T8JO7.*Z`/\`4$I61^32*(*9
MY3,M=VM^E=/SL^-.+:=**XD;LS(%3I''`S81EB=4"54E;)))D3S(;#2$(C$U
ML>>L!DL:WJSX=`(*]H4TXE>HHR,%:(I2WQ0$!A(W442KI>G3R]U\I.L*9F5>
M^F$LYKR>M&QM6TN#2GBC6,BJ>HZ<;72TJ[BE&JH4IK954MNV'5\E9P02-JHB
MT-KG(H:_M3A+&%7'%RUN?H[+A/C$_&'@=7-N.>D3<Y(YF@%?Q"KHHV0F#,Y;
M''&D2\Y.DTJ7.*I2O=W)6]/CR[N[LJ7O+]()`]N#@^R*1/C@X/D@?'!>\/+@
MM<EJE2;Z%L5A#[KK.>U!82%8ZP&SHB_P2;-"%V=&)0\Q&5-BEDDC+Y89%2%X
M;R7AF6K6Q4I;%R->!*J.\55IS]@.!@#/QHK)A(XZHVD<[1(.+:=6BJ=N*LZ?
MZ;RT"BNW*K4Z&=HO.#Q>TTK5#W,U,S@L<$F$V.Q"*2IAAD2,AS#'\(X(<7X#
M)5DC9*U2JBO-.T8%'(G('1WDD`@$)O&3!F=T12O(*]K%D9A[':<H`0Y3-&U-
MX-.*5(WQQ,-#$VY`P)LIHGB12/'1U=WZMH^[%/SI"X%6!+Y*)5))H[L53542
M[$5E5,:<)0Y.:EAK^#A?GM0SL"`P&E#D[N+T^*GAZ5#<<LMO6MZWK>NNMZWK
M>M^K>M^C>M_QRIS1PKHN/0CDO`(^CGS$Q\N)/-)S=JEGMBR6V0/,WL*.M\5E
MTLBTE224I\KAY=6)G9D6C*^6QM*AVTH53<D2K`&GG83+^SKXWSBS)%;+\JY"
M`E<OW!"Y6DC_`"\Y50^%25OK5"4VPYB?JWB%PL<`=8XVHPJRU<>6QLYH?C'N
M3JI`C=%<JD9[I)D6XE51%K/?K5TML^4/+M/GJT&B/6#<5FV'7T`GLD;532_R
M2LJ_F,G>(K`5:Y"O<TR-/'FY,WQHAZ?TT/1QQ+('LA?9SU>K(+>..=7/G(.&
M<H'!O?\`=R0"NY?4T6?DTQE*)G15Y/GB-R*8QI7#DCJ3$7A._2"&Q%Y4+GAE
M7NJ9?&VHUN7H@$F%FQDY\):G7I(BE23#D5'3(=8MM62A7Q7D_?4<<W1RN]_<
M)'83!)ES7/2#Y)#%3@X;\UXNZB/05R2C;RZZ%%1(RC<_>RN#/&JT6"+QIY@1
MD?:(G5\HHM"17TBD5>'+*)G?F]Y]TP[K8@Y-2YSKB8>:D>&]L:A3X82AM`M;
MU[>O5+U2NT[*RL\;9VJ/1]J;F-A8FU`S,K*T(D[:TM#0UI"4#:UMC>D+)2(&
M]O1)R$B)$E**3I4Q)1!!8"BPAU$%^<=:NY+1B-P^V6U]=6&)6-7UM,!#!,)3
M"E:&PZIE39.*ZDFG6(.S,Z''1.8,S5(D"$]88U*'!O3Z<T"]+H:<>2)ZDBB>
MWG*[@J)6.;.M;L%6*DYTVE9L+#&(W*'Z7H%*2NQNVX.AE)SQ(EX7.9(V(F4.
MK66W,J]T/:6M"D)C%[XE54Z4?%:":UUFP6'PATC[]%GJM+;L.N[`;7^.OITD
M(>#Y[$G]LD3V>[/"QQ62M'(53LSS+;FY%2AL=25AI>2[6U80NI8WYKPAK-0(
M#G1T?G5:X.;H_P`@D<C?50ESY)I5)WY8XR"3R1Y6"\.YOKZY+G)5W"21'Z2I
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M<&PX]<F)<42M":I;%RMK<4Y:M.8G&>WN2`TA:WKB0F;,2+D9Q*I&H"6H3&EG
M%`&&BU9]FSQDJ)N<6B$G\B"VM97<YK!`URCF%ROL!IBL;L5,:EE:V#M$_N23
M-,)F*T*A6<EG\90MLV:E;@Z+&M]2*G9S-5^,R[-GC7/'=B?WUUY+HWF/5#$J
M)1.$.YH<MZZ/4U?"TVB6J//`:]N>+DOIZQ1WG:2/[P4MD4L?!`>9(ZN;BF1'
MII5:^'U/-EH+[1&99#T>I?XI+VZOY3;ME2JFXM-(5&FV)QR7PVH9!)7"!15\
M;&=G:S$0F=F3MZ&0(BYDWMR.9F'R`VT?3T=/5KIT]'HZ?P^C[,I#.^SVXZV/
M;$NN>3JN0`9G/5D/53)+&N6W*2#P22I8$3XO%&)WJ^$V]'JX615L3F+BC8J;
M%]Q]T"]R03PWKS9,_F..2O\`PLJI\3K0$2_D'&5ZZ^I+R+&]P[DI=\9>29U,
M&?<>D;*G6-DV+"56"UD$8A25)X$5=L1H@NL=C[0^)TCFG[J6\/*'E43K.*$Q
M=PB'R-'R515DH@,GD4.GL'/G#(\1N?*6:=-#B7)QK9^RR%\*FSBYN+BXR5U<
M12MR5G3%&V2)#,]95I`Z:KV%515\7:H57==QEFAT+BC(2,EK8(VP(26YI;$@
M33#CS`)DI``C4*CU"Q6=LU6M4J5AYYYD+\@>(-/\F'VOI+9BVXD+W5HI(;!W
M"J>0]\42>SJI<W`9I`O-'2MAP(3LX+F31S&!:]"<%"%E7O#6W#2(GMX)7=O6
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MKC5A5Z\Q^7QQ6!8@3Z/-:G9.!P0B5-+F4M:5ZY"IB-+Q`IU+&T,>#NQ3%)=P
M5W>T@EX[;LD%@SZRJP/CID6<[&G1$E*DDW8RDD3C[&O@SXN401PBS6DBAT:#
M'2@-FO63\+./"6X$]UDPH\,H1V2]W8A9?.!]\P4-YR6$ZK9_NM+7_C_FJ5:+
MI`O"QHZ5>3A*""%[RZH2$DC?WU[<O.O^%_'JL;-1VM$84:CD+`9:BB!MBM_?
M7.'5>MO65%S>['&L(8O7'QR#.5IRLH#O+5S(@)4F^$7-C2-H9'9X;'"U._3_
M`-?]?]?;E5ZGX?534;B8]M[U<4]D9#-,8Q'I5=%Z6S<\KA44GCJ@>I/&X3)+
M(ED@=XRWNC@TLXE*M`JT^G)6*/-JAY.;(^RHD$7R/LW.-\I3524Y/')A`KI>
MH2*.@CU$>9O+.OI`EKX*I$N<$CX^0"XXPY2U^D"UJ9E4EF$H/=97(!,3"4YN
MYZ9D:B$F=MW"&CFV9(Y4$VV')J0LM7-1=8R.]+@E=-&JZ90MS?7,E5U3)IDZ
MPU9*6(EH:%JEY5-IPY%(VAIF<H(>IHV(9"GM[K6M>C7_`%_G>_GWZ][RKLVX
MB558]H.-FS=VMN3$O">$!=ZJ=KLM)903DX5T[%/<1>E%%FRC=:!=$+HG2+W'
M:=@(;Y,N0-RZ5MSXL;D1Y'JS?A[6$X#.CE$IO:-.T^N&)7FXOT%Y#7)"W=GG
M<,A[+!6HJ+',,P2IH]"54:9"4C_6:)'\GDE5K')W?8TO=UHUH.S?N(M'/D(A
M<(#'71H!6\]66O`I<S2B1);&C%JN::2HWNRTM@*7%;*7.<25',Y>CEK_`")P
M>U,O1R=]22?3LF<3R12=3U/US0=;12HZFC*:(P"%H3T+"QIE*]>(O:UP6/#L
MY.+J[*E[P^/S^^.3F_R21/:]P?)$_N;D^/3@N=%ZM4;)>,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,9I9OGM5IWQY?N>CW+>/T8D%-=GQ,..R"V)#&+;7EV5*H#R"BT0ENI=!H&^5
MTAC:R0U\W3)$!?`EM@)U4U&@7DQE\3O![0RN.RY!R@X\.=EO%.H;HK8^SV`B
M0GO$(U+6@$@0;B#<RO,P2'HS5)>M.<.9I+&GB8LX#!N\3:9&P.<B0MB!Y;E"
MFO1/:C\`W675;!XCRHIJPY)<$W;8##D-=3J/S8`WEXA,OL!J5NZI@7*TC,RN
MD=A#Z8TNJ\XI,[KBT[:UB5K5`20Y1&>9]2,D+G<ZN:].,K3'&>_;BJ6+O==6
MD=*6<XFMECNM'%Y*H<6UN/(N*'Q%A>GNYXA'4[RT5Z)BD2@YX.9&%S=$_K?]
M[)P7\X:;XT1QGA<DJFY.&UL<I(W;3'+%#PN<E-=6A1D)0MC6@0(!QA=#Y"PW
M2WR-IE:&1N9KGM-X,A"D0^"6N'I\W.=4)X2$T2MF49>)&TVS=4(KV7N[6;XN
MWT[64FD\>@<@ON<J1I5!2:O(//9_5<3?E&QDC`XV*R#\(6G*5G%=UR-Y.3"E
MKWX5TW'(#&I6BY;V_/*E7R1ZF+M'55=G0.C[&O92_)&5!$I`5,"W)AK%\CY+
M8<[1421W<&I:-P4(0K`$]-R2YJ,_%13>,QMAD0D4K2-!1FXESZP.#FZV1*I+
M,)O(J\BU81N$F-"1B4O<IE;*V,,86J)BG"YO\I:&M6B:TI2IY#D3)9/,-$HJ
MQRG5!5D4SV#,8^QSIAA=L/K]*J(87EH>EQSV^+UD#01NT!-#ND9(U(`Q4R+)
M&M<\'.C:IDK$VFKCNKO_`)9#J_D%Q_XQL(:[9+$Y!Q>T)="7ZY96Y0F$R0^J
M%L%2.570A6VM#FJF%NR$$Z(?4,41#(5-4%CLMF7B;^%F`Q+,G+Y=5U7L$K)V
MY52.N^,MCSYH4+U]<3&R&E7IB4ML@;(L]G)Y&M11_3E$&F0/\8:#9ZX,\>C_
M`(]*HNE7":E\@;&\[OICS*XHU_,G:O)KR+IJ,3B/2:"PV215YL*-(GR,RBS2
M3CZ^8Y.@-7Z.C;A,BR@^;A3YIO"Z#5MI288CG5L+6=4CYS<.%K$.2E<GZ*+8
M@62NI[RFKLV)MZ4RT6V/"F"R!DC<')*(^3%P\/G@!K)"8<IB(BI0E\.PG%.`
MX3G_`#^AJARX#2#CJ]U3?5*\S.3;QQ\66C$Y]Y:11\392]V6?IQBX8ZD<&A\
M7I7BF76)R1O>'EG5QQ<?X$UM6K2U)*"VD1Y!4K.Y\_U5$+/A,ALF,-2M]>(2
MV/Z(^1$LC<]F1AV>TK=WPG.C&RRHHR*OCRT:<&QCDX=QUX5(GKHAW3KDKR]Y
M%\?IK430;0U6.,4OSE_">*%8NKE=$H0R+P4UA<IE*.U)4QMM1.K8V-9:V$R-
MK*B#<_NCD>CVT.I[TA-6JFI!FT<Y>BB#_;`.5$VXFT8T4Q4<0GEF,R'D"HD,
MLK@Z0V9:$40S&?CDT0@C5&*DL*+1R"O-5/3N4W2E\DCM,8NN82M1YJ<'O/%/
M//ABC6'MZOD_1Z5<EL5EJ=6D46+'"%*.P)(!K''8XM),6A&C42#RXR@8URG1
M30[&O#42@<E!SBC+.E07(*DP6JAH\RT825;+H%T"U0(Y^1$R)V5L;.ED3XU-
M*,T8`NCZQQM<BDSU'F\U2_-,:5I9"XMJ9E4%+A=#.+V;6.[*VX[QE,E>K1G\
M4EUH*TBM5XNUQ&I:^>(M'I),'L9'A%8SG.532+PZ)-2<K1KL[.3DXC,`U1=X
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M#VR`T[S<YW39T/@$]J^*1%UI7D/3;W$JNLN.0!M$@>))9SVK$C4W](;)$19#
MG:;FYAC2E94YR)5&_#CKP*Y-4UQ^[&QJ,KB%#L#A!?-G/]ZQ(J?Q]L+/BEJU
M'R?JWSJCDG;D+HUR0,==[M9Y8[-(@)WQ<@\O@;$JMYV%*MQ5/PJYF,#G(DC;
M2L(<HW8G/[M)+G>)"BG%;-5OPZN.4,0<TM,/,6G[B:XKJ\B3^ZKU+)R+(K4T
M5S%,065OAQ,A9%$I;UTR\$>(7)FH9[V8<AM.M6V+(>,?9-S+AG;8D4^ATB\C
M6THE_%U2R>3"F9<(Q[C[DS4`^N"ET:BCR6I1(H^V;"L$%V5-M@[FX3G<RW[F
M`BY'MMBQ:"3ZNU?&6O&2$SZ)!1S&AET6/=)&_&HTQRDQHELIM&0/3CI&_FLY
MR)KA]:'"<BC"7),WP8WT/SOE5!=F!:]K0B.O_+K@5<B)]N>"AL2+FI>0$.6T
M):G&"=S2"S3QH<:;+$D42LA#;37'YBXQAB,F#9((0XOC6WK&B5CE;EMP_M/G
MM3G*N).[;OCR]3^#T;&J+W,W&.3!S13_`(YW"HY&PF?6.VU^\RA@11!SM4B,
M,1\78I4^/IL,9WUS7B2N;TWLK?=6K["Y!S)LB*:?4#JG9(2H+W9:EVG\)G<+
M_P#*D&^4PU0Y0N0'R>3HW9TT`M@<I]$ZT6(&0[RH^1X+L1YM*('YMT>1R3TF
MI>ZN(D7Y9\4Y#!7IUD;.6_PAGLZ(7&TO*(J&/$!%-99`--*A1&%\C+\^XW8,
M1E4,<24.VLYS3/+F!OTQ7?V=?:.RSAT3QI=6%CNZ4/?9T<C*,3V^[VU!B[C2
M6)+;J7S6GJ0OB[Y2TLLZL:LX13(8;#T3A!DA$9L^Z(N[R2YDJ6)KH\_-,]<H
MN!G*.\(_VM*AGJ)@3/\`S6X_<"(+52%TG\`-#J1T:B?C;09).[;7Z"VM;*OD
M("FAP&F.22(2!6J2)DVAHPJ8@YM4A:59<U8S=\CK(ES@E^]L?V8$DJ"/II%!
M3GF2D5'PYMVM940)M6O)3-'7MED#(:[1HE^=6U&Z%H6T9+LTJ!A&CM(T<$+V
M:K.IVV&B`-C4WR;MDK'[1&PH""6Q$HZH:REW$"?<:2F\0D[H:QR&Q)5+'EKN
M"=-,-7/+,1(I3,P)9)(%C<G<I'D?9O<0[WIF15%$N1?&>`())Q`K2<4[".88
M>0DIM!3=,:E2EF3#=*GIYP<QJ*.(L!"Q,TGNQLE29O)+FS*2WQ)JDB!<7*F2
MVO/NE;7N>1<%%-80[SG1T;SKJ;D+8ZHR1QA@"V5Y!H3:D:>-MA+\ZH#WN0'+
MIVU'M[0D*`2>C2.9BAR2*"D:9=23M!N#_)+D#-.TM55G`FAV:^3O9<5/Q&JU
MR<IK$F4ESMN)V;R,E+P)\2N"\*YDC29GN:/[3OJQ*:8H4L[XG)0?^"V&.>&\
MRN`O)&Z5?:9K*[JB/$[Y/\,^!M&TT!RF4"9Q!EE#V5;<NL=H>ME.)VHVPM[5
M/8T0W*P"4)'A4P+"4:?121J/62G1G$F^X[RE?F:W^,$'G=:L?,FZ^:5/<L7W
MD-(%Q,)(NA_G$M0PM%QE2O1I;7R"@26?.U."G3>`%<KJT*)?PR)Y<"S(8X6M
MD-=/T.[4F%WNY`/'`K8X3N_'=J7`T:)`T6C6=X`N%MCZC>R]D)7"PX3+I4N9
MC3U"<E4*L')"(8U1B$L=`:$X(\FJVDO`N2/M5-(/D%Y3]K5<UJ$MDXK]2O'&
M>8[Y?#G3NF\S;PF(?WA:BLB)(I4FVJ`%@\D+2S%2\A`@VJ]U;P^M*']B-Q\[
M/!XC;9&>2,OKGCAQK6H(PL1/:1I?8Y940=9_90'^+IU8%$8KV)-4NL]0^F@3
MF%^*%IC=(7YZ3$'_`$'`UT#ZNG40Q>K>O0(0A:ZZWK6];WK>M[UO776^N>6,
,8QC&,8QC&,8QC/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g605255.jpg
<DESCRIPTION>G605255.JPG
<TEXT>
begin 644 g605255.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`\1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]-14%.7U%!7TM?0D%2+D504__;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_```L(`/T"6`$!$0#_Q``?``$``00"`P$`````
M````````"08'"`H$!0$"`PO_Q`!>$```!0,!`P0-!@D'"0<#!0``!`4&!P$"
M`P@1%U<)D9;5$A,4%1A156&5I]'3UQ8A,9?4UAD:*#A!66>8M@I4<79W@90B
M)#(Y>9*XTO`C)RDU=:&Q-D:T0EAFHO'_V@`(`0$``#\`W^``1::QI&UHPC(<
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M7+#RD%U(3+:B5;FOIBPW*3B<A],1R5,N2M+,5#)S'=EO_P`C'2^[YA;F#]5V
MF#4U@5S6G'47!D^%F_=AM7\\,RPPY-QH=QB^^PO18^1B\LW)?=%^/);@N/6E
M[<]UE]N*Z^MM:4O]_0(V94@?7*Z=3M)=9,JZ3"4>-TNFM^*D&2(2F)\O>*T5
M5+X2<HNM`/H\XLYBG92?!`PI(Q)TGV?=8VVKA3V@6Q&495?5KOJ]VZ=IRG>2
M$<MJ)<$'J$(Q)J1:^H6&2D:M!\)$E*AJ-C=%V(421#SJ<JXWTE18[IR7JCF<
MK'OI62<!%-2[$1A(QEP)BSCM$7)>9HW<NEQB'GTWE32]HFU#ZA-3VG]AE4%1
M+NXR^IISRG5A-AZ',INY%QMG3N4G"4,+254NXVLOG.:8QE6*M*C-5\#VE_I2
MEM*6T^BVE*4_HI3904RM,IG.,UC/.!J-M<.8L%I;&;6$%)5#.,M9?DRVE[#!
M\F8S68;<F7+DMQ6WTQVWY+[Z6TNONK7J-U49<.V+T/;G5@;JHRX=L7H>W.K`
MW51EP[8O0]N=6!NJC+AVQ>A[<ZL#=5&7#MB]#VYU8&ZJ,N';%Z'MSJP-U49<
M.V+T/;G5@;JHRX=L7H>W.K`W51EP[8O0]N=6!NJC+AVQ>A[<ZL#=5&7#MB]#
MVYU8&ZJ,N';%Z'MSJP-U49<.V+T/;G5@;JHRX=L7H>W.K`W51EP[8O0]N=6!
MNJC+AVQ>A[<ZL#=5&7#MB]#VYU8&ZJ,N';%Z'MSJP-U49<.V+T/;G5@;JHRX
M=L7H>W.K`W51EP[8O0]N=6!NJC+AVQ>A[<ZL#=5&7#MB]#VYU8&ZJ,N';%Z'
MMSJP-U49<.V+T/;G5@;JHRX=L7H>W.K`W51EP[8O0]N=6!NJC+AVQ>A[<ZL#
M=5&7#MB]#VYU8&ZJ,N';%Z'MSJP-U49<.V+T/;G5@;JHRX=L7H>W.K`W51EP
M[8O0]N=6!NJC+AVQ>A[<ZL#=5&7#MB]#VYU8&ZJ,N';%Z'MSJP-U49<.V+T/
M;G5@;JHRX=L7H>W.K`W51EP[8O0]N=6!NJC+AVQ>A[<ZL#=5&7#MB]#VYU8&
MZJ,N';%Z'MSJP-U49<.V+T/;G5@;JHRX=L7H>W.K`W51EP[8O0]N=6!NJC+A
MVQ>A[<ZL#=5&7#MB]#VYU8&ZJ,N';%Z'MSJP-U49<.V+T/;G5@;JHRX=L7H>
MW.K`W51EP[8O0]N=6!NJC+AVQ>A[<ZL#=5&7#MB]#VYU8&ZJ,N';%Z'MSJP-
MU49<.V+T/;G5@;JHRX=L7H>W.K`W51EP[8O0]N=6!6*HR_1';%K\]/\`[0;G
MT;?GK_Y9^BGS^?Z!&DTM03\7M9"EI-6>3F:S<+(2`E22NRC=+,&JZ21A9T/N
M0H^9T@X6J1:F-=/*2XM1TJ9#+(Q&+%=&*&RMYLYDRTR8Q)92*XRK2E:QTQ:5
MK2FVGR0;E=E?TTV][/GV>,>=U49<.V+T/;G5@;JHRX=L7H>W.K`W51EP[8O0
M]N=6!NJC+AVQ>A[<ZL#=5&7#MB]#VYU8&ZJ,N';%Z'MSJP?8O&4<E#&`T58+
M*+F2N;$9+&,#4;^'.7,8,EN;!GPYL2=9DQ9L.6RS+BRX[K<F/);;?9=;=;2M
M,#^4+;C783#IJC4H>3M1#MC-W0JCH;)=D+OC4ME:#%<4O--`E-4@^$8]3%!:
MSS4M--;5*H3L)$^[^^I%O$7(MEF$E&T\4U!DEZ5-5$Q8[&%I1GF%Y-CEJW/5
M`F>6=%DGZ37&F%\;B)H5[99KPE..6*MN_`I6*>>YVM1+[\-<R@Y[BKK3\N)6
M+E[I30`````````````````````````````````````````!'$WO];7,'^SL
MTW?\3VJD2.@````(<.48U"2\Y*._2C"6G#7F^5<M2$GF_)/T?/33XP#V1@++
MTJL.>-4N1'5J.C&8(T<+L:S37D(X\V>U<9Y&PJB=WJ<1.U9N4"G7\G0RC#>F
MIZJ%VGWE6(APY(NR$Z+7*&:HKM0[15;\CT0S&-,CDG74_J6HU'+99@O.KN6A
MIH=\TG&4PTQN#N+MR3,^````````````````````````````````````````
M``(XF]_K:Y@_V=FF[_B>U4B1T````!:A_1+$4JF<>-\LUKN9;1,6'N!6RD\>
M)X-BAF^[,6,(;H2[BCK:^?-=AR9"YI&5DS/?V&2[%EKV-U:6)CS%(<:ZGU*)
M3+K<#MAUR0RH2&Q:.UUFG0Z&NX6\^&TV'(WE%1<2"?>"RFW%7*EJ2&MJ<C*E
M:V9U!(-MLIF3BB^L9F@`````````````````````````````````````````
M".)O?ZVN8/\`9V:;O^)[52)'0````$1?*,:5H.6:+&IEY1CJIG.5E(E#L%Q]
M$^G75E.&F/`X5=7?JTB,\LN*$=39#T=$"F5Q20:,N*0Y)S'\J`B%<)!*S9K[
MRJ(I6QY.#3Z[XKU#.]S./1'J,TJE5"%#"`6<,Z\H4KZX2SPS4D)NJM41ND'%
M,<MJ4=&$?'CN45$V4O023DQ'RI?-B/&T:V\M.$(SM66I75SIT?C#D)'C2''3
MI@4-0$`:?W$S;U)Z9-3+NW^/MJ1;@DZ-#"<8NCTN58KV>Z8;,QDNHJDL.YDM
MUUN2KU99K"GI&:SYCE.'15SN>1R+):.;2TS>4G;G)G+2EG-JF&2LKV5W$WH<
M6)R+*552C5+LAM:F76F13G8&5",*YYH)Z]*=SY3LA0HR#7SA[E/G+(:OI6E%
M99C)3=+6MW51J#TGP6KDE!9I)+?<D373%9%S[>N8P:,M]<0Y\KI\DKN1LHB*
MBGHWN58]QFW"]*K*[<AS*4K2ZE+J?1=2E:?T5IMH&W9X^:M?_B@;:>?FK[`V
MT\_-7V!MIY^:OL#;3S\U?8&VGGYJ^P-M//S5]@;:>?FK[`VT\_-7V!MIY^:O
ML#;3S\U?8&VGGYJ^P-M//S5]@;:>?FK[`VT\_-7V!MIY^:OL#;3S\U?8&VGG
MYJ^P-M//S5]@;:>?FK[`VT\_-7V!MIY^:OL#;3S\U?8&VGGYJ^P-M//S5]@;
M:>?FK[`VT\_-7V!MIY^:OL#;3S\U?8&VGGYJ^P-M//S5]@;:>?FK[`VT\_-7
MV!MIY^:OL#;3S\U?8&VGGYJ^P-M//S5]@;:>?FK[`VT\_-7V!MIY^:OL#;3S
M\U?8&VGGYJ^P-M//S5]@;:>?FK[`VT\_-7V!MIY^:OL#;3S\U?8&VGGYJ^P-
MM//S5]@;:>?FK[`VT\_-7V!MIY^:OL#;3S\U?8&VGGYJ^P-M//S5]@;:>?FK
M[`VT\_-7V!MIY^:OL#;3S\U?8(XF]7_Q:Y?^G_5V:;OT5_\`W/:J/,)'=M//
MS5]@;:>?FK[`VT\_-7V!MIY^:OL#;3S\U?8&VGGYJ^P-M//S5]@;:>?FK[!&
M]RE;;S3MIN?\"1PUL4]2=G<4,+BYIJ;NHW%IW<<B,+#*;347$B.I]H_;W<V(
M[56Z54C;H,)%A`RN(2<H)9,X9NR9DL]C=R:VF%PP;-L@.%4Y/*NCHJM1=A1?
MEM3E`9%UF_+(V7>J>HVM;*@/;+4JPLJ?B[<M]^"&.[.O]NR)^?);B2K+;YLZ
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M!X,L!<)V9Z*I[P/!E@+A.S/15/>"/A`@*&+N53EMOUC5I51L/)[:=CN).JEX
MZEL9PWJ=U/6F35EO9=E0QFL(E,>3+2[L[L6#'B[+M=*V5D'\&6`N$[,]%4]X
M'@RP%PG9GHJGO`\&6`N$[,]%4]X'@RP%PG9GHJGO`\&6`N$[,]%4]X'@RP%P
MG9GHJGO`\&6`N$[,]%4]X.40TY0:F'B2D0B]HE#Z<<*J!$UA3*69BITEGQFB
MAG#?VRO8Y2YC%CS8[ME>QOLMKL^867UXGTQN0.JNS#$T22Z^RB^RV['3>F5:
M1F.S\CF>+Q0F_AQ'Y45B^?)%]F<H<.6$W<F6'%8BL52\2*@NA;,)K;5HV6-K
MR=T8O%$)'+$Q&;;5B&5Y$U&1MDU#4U>-5DJ$8ZB(+A#$WX6FZPFWW?W6JHTK
MJ3O(XG]ASU-G6Y?&9N+V(O8E%R)4^]MW94V^*MUM?T?/;=6VOC^;;2NSS#V`
M````````````````````````````````````````!'$WO];7,'^SLTW?\3VJ
MD2.@````,`.4ZD@E&&C>25M9+Z8*M=;6HV8+R6-994JM::FFT)$D9LLY?=\J
MLPRK(%T@H;=)*]RC@89=PM\PY5/&2*VK2?BQYL]L9V@N,M+VH65+6DMR1R*>
MJ5`AUF1Z[6.U>3I@Q#8*U%JM%4HEEZ,#KU-(TYS9AS,AM+RNMGV`U;SK;;Q=
MTFUA8N1''GV&TG8PV4I]%-GTU_OK7;6O]]?GKYP`````````````````````
M````````````````````!'$WO];7,'^SLTW?\3VJD2.@````,0-34?:D%DEW
MWT\FH)>^0Y>C6.N$=4R:[#<5N>Q"4,"HDK#<>+,*+Z['#H(G2I7/G,'6')+:
M4LY%+/X6Z@K9'.LJ5F8+C+6TL.W"K3C'^B+36V,!2PHJE=**I(TH2<\R%BF7
M4;F[?*#SC"!T]@-H_F*%+UC&F,IX.`U;BN[R++74;L"P4DEI\WG^G_W^?F\5
M/T4^8``````````````````````````````````````!@7RAFI"1-,,--M^1
MIB;>5<5I)1VH:M="4:5R%$L\WG,IYZXBQ142<EAONE(*4QYKC%]EN*N:RN&Z
M[);?9#;^%]U:?S*'^@ZW]]0_"^ZM/YE#_0=;^^H?A?=6G\RA_H.M_?4/PONK
M3^90_P!!UO[ZBSI/E#=01+4`XM2.'!'57^YX99<&J!3(U%.K:QM%BOU^2(C'
MBB=:Z+3N-P95F1%THH&\JGF3\R5A3<.%,+G<&<\9O%^%]U:?S*'^@ZW]]0_"
M^ZM/YE#_`$'6_OJ'X7W5I_,H?Z#K?WU#\+[JT_F4/]!UO[ZB<S0[-KTU"Z=6
MI*3_`,:'C<RRL/$B<L;J>82TNF!"="FCD>TDS2@IYL>2I0IBJ8NN-Y*9<U;\
MEMN*VZF.F70`,2-<"M-J/IP?&>`7<HQN_#&1$(Y930HKR3FYHL:AM7+6.]_M
M.&<14_=)3I;Z%0U>@MS(FK)7&?,8UP^WG(01C+?4\0]"FM*4=4$YG&\@)+]>
M.G]KZ38A5I)F%^0\[(F3DO6-F6+DI\1A'*@Z6@Q+9)3C#7L,.E_&&ZD++:CQ
MT%DU(3G)V3G,-ENRYC$^3-4Y*--5^F;2T<82XHF=2K/GEUHTAX5E$+-YN9(&
M16DMK2$=1[\F9PGU)7+/%,O*&,14DD%<-F>Z]0,FK>XJ6?-Z\33AUMGM',*Q
M,D3%6-\;4KJ0D!+U"P<VE6`\SM2/E(1M6H06G%?,SM)8F^HM0UD6VXV.\-ZF
MZBB%B4KE%)<%J93D7\I<QY+?,.8\$>K:3!FI2=I]TVZ=YSS.)*-D7_*^GKY>
M]_,*NTK218PTVA(^Z&7;H:<=J^OGG=8P\]R^WV=5R-6U5DSI6E:4K3YZ5IMI
M7QTJ````````````````````````````````````(C^65_-F9']MS;_@U]#6
M?`````!M<<E5^9='W]9)*_CU=$C``,/==[8S//3.]6R7BZ?9JRJ*Y'?_`'5Z
M:)6I!<N/6TI(+:/WI:)+]\AQ):PD?#84N47@LV26S<N5IDE=+Q*],RCC)F\`
MN3F@J0&%J8?S],:2=5FEZ/E.""3.-VZP]>2IJ[>;M>1&1BZ\E;LF_34YJ6(M
M-K)2&=6;GRLK"PW#9I:.L\@V$B[!>[#IZ;\1KZCXGE1U\HIR=DNM:/5QP1=#
M+0UE(DIO8D>;&!-9IV:6/&"(P.ZTY4<">XU?"I*C+6"Q[(VD1<JC6WD32K85
M)FNZ,=MI;@TQJ8U01`]DK2<\8`E_2MJE27@7U<KA2'DS*^X0122IB>+88SM8
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MF^_0;@&/Y;EOZ]9F^_0BYY6F,6XR].S-4DA1?)LQFF)`(WXW-),@/$C3#F:;
MSS77XDQUN593L!JEY?'3&=PE<9S'BNS8;,]N'/FLR:\0`````-FSDT(F;#MT
MAL195%.02IO.XI$LOPM^5)*:R9;3`]5<M97"BMMU):07ONQX;+L^4N1Q936:
MM^<S?FS7W7USWW`,?RW+?UZS-]^@W`,?RW+?UZS-]^ARB4%LQ/.DS^!9E._.
M1-E3N&PW-4NGBE^8IGQF,5AHB=>N<F=+79,=MI@F;P9RIK#6_`9PY<&3)CNC
M!Y3O2?I"Q([KU;2S![MG*5E#'$$0M=HYM8$I:7(Z-*BJ[LS4:7R@=Z/);.CN
M/D_*;=MU7*\UI)6U=3Q)J$AI*8M+N5%1S^-?)'I[#0=4;_3VWH\9VDQ26=/Z
MIFR$+>4,D+61(+A-,J:R;2>K;6&,[3R@6C2Z-7-W,E.TQFQ(ZI\HEA.1\65R
M%:&JMO8U#93Q4'BE*4K6M*4I6OTUI2FVNSZ-M?T[/.&RFW;LIMK\U:[/GK2G
MT4VCR````````````````````````````````````(C^65_-F9']MS;_`(-?
M0UGP`````;7')5?F71]_622OX]71(P`"'7E#9"T$QBXW1=J"U2Y8PEF3V`QF
M)=`N&W#/9N;6=C5GQ5FMTMH15FC*)&<"BXXU-QDE!<;46F'C_F&)'QOUN$DW
M'BQ5%R<#ADZ3WK-TURAR=;:TI*K\+-(HFZDUICQ]#$^ZJ$)OX+B".;EN`TI5
MD&48JL:)6RXNWD>3Y=<ZEF3\F#/@06M7)<D$I:``````````````````````
M`````````````````$1_+*_FS,C^VYM_P:^AK/@`````VN.2J_,NC[^LDE?Q
MZNB1@`&".J*>]`>B)V$M36I]Y0_$,F/=N%(L;K^<29:K3$\&DVCY]<^0C#2V
M^DK\H.1O(BBXSJ\M(+,2#J8GF%2JRNX,5V;"9K<2!-;NDS4Y%RI,D"3O'TEQ
MT@*9=#<RRWE3+0\T'`<,%RQ1N/5K*)5/=S+<QO,<)]S-QUH*.MF;#A7-@(Y<
M)G#DORJI6E?H\=:?WTKLK_[T````````````````````````````````````
M```1'\LK^;,R/[;FW_!KZ&L^`````#:XY*K\RZ/OZR25_'JZ)&``19Z@IPCO
M11J3=6HO4'%DKK<=R!%K"8C8U%Q;"$@3YNBP,]3=Q]T18^4&)&\]I+CQM/%:
M745ZHKM3FD89CP7;CB`[U=(66HS"ZQ0\?)<4<HW/D::GV$PYTCR%895TMRGG
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MA1R>57SQ^GZ!XVTI]-:4_O#;3QTYZ!MIXZ<]`VT\=.>@;:>.G/0-M/'3GH&V
MGCIST#;3QTYZ!MIXZ<]`VT\=.>@;:>.G/0-M/'3GH&VGCIST#;3QTYZ!MIXZ
M<]`VT\=.>@;:>.G/0-M/'3GH&VGCIST#;3QTYZ!MIXZ<]`VT\=.>@;:>.G/0
M-M/'3GH&VGCIST#;3QTYZ!MIXZ<]`VT\=.>@;:>.G/0-M/'3GH&VGCIST#;3
MQTYZ!MIXZ<]`VT\=.>@;:>.G/0-M/'3GH&VGCIST#;3QTYZ!MIXZ<]`VT\=.
M>@;:>.G/0-M/'3GH&VGCIST#;3QTYZ!MIXZ<]`VT\=.>@;:>.G/0-M/'3GH&
MVGCIST#;3QTYZ!MIXZ<]`VT\=.>@;:>.G/0-M/'3GH(D.64K2NF9D;*TK_WW
M-O\`@U]#6?`````!M;\E56E-%T?;:T_^I)*_3_\`SQ<$C&VGCIST#;3QTYZ!
MMIXZ<]!&EKNU#ZVHD7V(T],6GECJS*=A2[,_M7$J+#P><:P#EQ&\UE^%?T[0
MBE*,[R)G-)^*A\LLDE%DQFC]C6]]2`UR&.\U=;GDV&$\7A1-U>2[KE?>JV59
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M#ZRV'L:*%T%W']05-1+',)K:1SYQPHA`@_\`Y6$$G,UC>(QLV66]C99;6NWL
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M@FZ'<5,%V#%?D-Y"]N$QGI<7OONQY,6O.`````#9EY-.-E1R:1F*JE98E%J8
M<SAD*RU%:Z@T"R.7K@>JQ@NR8,:LRUD]2\S=CJ8,=M4,ME3&3)=ALPX[J8K<
M]MRZYQ[G/TQ'WPV#<NN<>YS],1]\-ARB$0+1(\2.9)QFD_83.%3=Y`\K,2\B
M>L+9\>>\D=L+QX6,7DS=N.I<U9@,E\]V#)DMPY\.2MN6RF=0&JJ(=..!(+/K
M.]'&\'-A.YVA%D11I($UR^[<*?V%AXZWXRBQNNEW940AFS%RRJZSR<G-)%,F
MBF%97T_(:P6Y,6-.>HW27*$[G'M@TZS7IBU'R$A9&/8JZC]*TDZ<G1+*$3/T
M<F-$3GHXV\68\D*Q$VFYE0FA?*Q5?*>4QGC)9+PI9@U?DDX#93Z=GST^BOBV
M_2/'8TV[=E-OT[?/LV;?Z=GS;?IV?-]`=C3;MV4V_/\`/L\?T\_S;?'LIM^B
M@\@```````````````````````````````````"(_EE?S9F1_;<V_P"#7T-9
M\`````&UQR57YET??UDDK^/5T2,``C$U)F=8;_U!J<,:)%F"M/QXO&#+>.H'
M5A,,8K,VN`J575I]H\1Q1%D4ISTCE/<*J6M:[X=+L77D\K&NT$E;32Z*VUAQ
MNY1/)-4Z:5K5*3>+VTMZYS,-S$LD6HA2;$T]P\R%Z-&W+#*(N`JA.(@_HB<#
ME>E(VEN-WMC;BKW4TWFO-%Q(#K:ZXW,R`OHC@2BDB7_7.```````````````
M````````````````````````B/Y97\V9D?VW-O\`@U]#6?`````!M<<E5^9=
M'W]9)*_CU=$C``(=]5T&PC).IV3'B]-4NN:`#4?:9F8\Y36].LW/6!(#9,8L
MI5EU;*.F4W@V[^\)Q\&B^9WFZ$E#)E<">S$`D?M3L*'EL43-G>2C48;?\H*,
MQL1W\J$H6/\`@PX?B&G**O-=>Z)+L%YI'0S):<(`RJS@<9YL(:JIXV]5=0W9
MA9;[4FLZ(S<RFS"R`IMY5/SU````````````````````````````````````
M```(C^65_-F9']MS;_@U]#6?`````!M<<E5^9='W]9)*_CU=$C``(8N4BC/2
M\X%JY)U?:BY1TO:9I=W?(<W)V)2:;5TZZGTQC*AI70XMEN95-E*Z_"MN7)?W
MD=B<ER%%-TRQ[GM:V)6<)1,6L"'7T0ZGM)LD:D\SCTZ:OX_U7*=\9$8SC33[
MIN,QZ_H_A9K9'(AG'(Z5I[1;@7BK/(J]S>;I)<4Y#<:<C%T=IMU$9:%17VD5
M^5^GS_\`7-__`)^@!B\\-8D',B?F?IE53LC*4M/7&D9$XFSH-FQ^LA%JNVJN
M=++OV6V5'Z]$\9GC1%&/*UJ;(3U;2C:B]Q+-Y6U,54LT=X3.UK:>7W+6&&VX
M\3AET*;JE!@M53,MEQD64^I!A"N2DRL-BO<VFXFVZG9&-<)RUUI"8?R7X[T9
MU8DK*JY60]<;=RN````````````````````````````````````$1_+*_FS,
MC^VYM_P:^AK/@`````VN.2J_,NC[^LDE?QZNB1@`%C]1$YQ?IUBQ;DN7,JWD
M:9<Z@MC$AM5CNN3GB\7$]5DFUFNRF?&[%1'([WTY72N*A-)2VX@H2D:-Y,]^
M;/BQ$"YPU@L!I4UA0S.KJ6HUBN#M2$1406UF>AJZ9](LQZ76V?Q9%M.0[\#=
MWJ,9CEG4L4,',1A0L;Y=1O3"EN'*IY2_=A&W/G>/%=FRNWZ-E=OT_1L^?Z/G
MYOG\0@P>3?BM;UVMV6=!<QR46U08]5[?86O6%\#[F!4B%\1(VFPG-63U^9H=
MD!0R,)AKT?1\FM<YI]F!D(K:^5CB)H+.;2L]&^X%'`4P9TP1!*)1A\C_`*.<
MJ:OEM1.COE)-6DXZH#>1*/8,S2B]EYM9Q)0D-QJ-,=+ODMJ1,S_&EL;+F4WD
MP29@>ALZF]]\+>=EZ-M:64K;99;7Z;;;:5_II2E*BV;T:TBK:I@--*3_`)%I
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M9_NU+,YL^7M>''FP=RW6TQ9.W]LOK2[#CI77K`````!LP\FJT9.5]([&.MF6
M?DFD9'#(5N!$^0+<7^Y[\;T5\>?+WR4C6(UF[ISV9#'8WV4IA[9VFS;CQV5K
MGGN^FWC[ZIV;]O#=]-O'WU3LW[>.6GL29"Y\B8/3EW>2P'2F<X0W7M(IW<4P
MF,>0T2[KPG;LQ7NO!;D+]TX;;LI?MO;L=M;[+:5Q_P"4CM)&M*SE1ZK.HE%<
MBX^H@3V!DTF)D:*.HPZ_\<HM94:Z9%&68\-T8(C@/&DS+8:<[U-I:(V$.Q57
M#"F4N(X^VX%\F%)\LO74$XRSW6^4X6&FLZ?<CO:QGE!EO0H32S9O'*A!`5:1
M>TM(),DJYU5*J7L3WR;>=N7,T,N1+0#R:W3:VF]_)Y0'KV--NWYZU^>OSW5K
M2E:_II2M:TIYME/FI\U-E`I;;2NW9\_T_37]/FV[/Z/%MNV?Z5VWV```````
M`````````````````````````````$1_+*_FS,C^VYM_P:^AK/@`````VN.2
MJ_,NC[^LDE?QZNB1@`&`7*=(1AV:,97:/R6BAPH[GO:*4ZE>;V4O23%T;-7Y
M6I"@MRVZ(_:JPW'*Z:QG@(6NI!*I#D;ER6YB2*XU-?1T)$5CV&/_`)-:2]-,
MN:X)9D#39'L52"==^C^&'9J5U3Q*67\[;:FI)Q+Y0\\M/U%S$XEB+3"\\\-+
M9;>J%&B8D+R&YD',:EQ1<2XMMOO+/Z````````,"]=VJN;=(S(19+CO3FUIT
M9%5QFM9XG%>>\<0K3<<4E2DP(E8!5)1LL32)A<I!3<3^*F5U1R*B#5OIB?GS
M8BBQGSXB]N7D;+#[7V,VE>3F:C1Z_CR;9F=3+;SSND-$;BO3+FQYTU,>M[89
ME[D*8[;,=^-3O:R%?E[96RY/PW8Z]E7`````````````````````````````
M"(_EE?S9F1_;<V_X-?0UGP`````;7')5?F71]_622OX]71(P`"+_`%H0)RA+
MJDY#DS1WK-/Q`P;6@FH4C0/AB"%7HX'"KH1]Q'BSZC%]S$AN)`17,?(+!)`5
M&2Y"B"U5W&CIBC5\M4W8=RG++\F?)SGD^8IB(./E&U;5:YH>;=L?RCIS<\*:
M?XA=FGF155SDE>IQ>,:=K5%C/`\KIB691C)Y,>#R0TW,3KA1U:PX;7<%)J``
M```'&.F*E"AHU2VE]2Y?/GI96O8TNKAPWY:6UNI2M:4N[#96M*5V;=NRNS8/
MSTSG\M^E(H;-%:<GFP+Z%S)C!2^NH]TVUNIAS7XJ75MI$=U*5NI9V6SLJ[-N
MP<;\>%E+]7C'_P"\@ZOA"'X\+*7ZO&/_`-Y!U?"$/QX64OU>,?\`[R#J^$(Q
M\U0_RPJ1M3,.*<1']"K):1=1>\-/2BX3GUQK&;#FB":H\F,N0[@,180QY,2[
MG8.-`SYZ&\>0AA5+U''C-WE*$C.0E?Y<+*'97ULY/!@6V5OR76VW:D71==;;
M??==2VZZV'\=MU;:5V5NMLLI6M-M++:5[&GC\>%E+]7C'_[R#J^$(?CPLI?J
M\8__`'D'5\(0_'A92_5XQ_\`O(.KX0B5+D<OY38^N5*UI(>E)>TC-.'$Y7CN
M1'Q>]$B8UUZG<&9CII$_A3K40^P&X7OQJ-3=V+(8JH4O+TLI?9BR5KV(V[``
M``>M]]F.R_)DNMLLLMNOOOONI;99;;2M;KKKKJTMMMMI2M:W75I2E*5K6M*#
MK^_"3Y33_P#'%/?!WX2?*:?_`(XI[X._"3Y33_\`'%/?!WX2?*:?_CBGOA'=
MJ_U9:GH%DB$&M#\":>Y::,]2<UX0:3E?>J-ZQ4O)<HN)ERF_<MKC:[;TS2V1
M*L8BA1@8P8W"GN=27SRNKX"F-GXBQ7*=OS_1EZAA(2\ZYG04Y:S)Q',KD$Q=
MQJR<24\I7#>H$R"H:*)!A1)%3EV;`4/YTM-S'"^/&9RD">3+<6Q=EWX2?*:?
M_CBGO@[\)/E-/_QQ3WP=^$GRFG_XXI[X<@N=)FZWT*FBQBN.EM;Z8,^'-6RE
MVVEM;J8K[ZVTNK;796[9MV5V;=E1R@```*UV4V_/_=2M:\U-M1Z]E3Q7?[E_
M_*'94\5W^Y?_`,H=E3Q7?[E__*%;Z;*[*75K^BG87TV__P!1&O+VL'51'>K2
M.--39T@1^]$"7RK_`'''DFG]5?R2,G6-$>*++Y-7%]B5T_N',A+*7EE$E@;#
M<PNE7L<U4HSD-+;=QF<5<<E%+Z?II=3YZ_\`Z;Z_-M^:O^C^FGS[/T?1\_TA
MV5/%=_N7_P#*'94\5W^Y?_RAV5/%=_N7_P#*/-*TK]&W^^E:?_-*#R```"(_
MEE?S9F1_;<V_X-?0UGP`````;7')5?F71]_622OX]71(P`",'6AH`D+6M(Z;
M8^=3[Z;6EY':"(F'M)[<*K"+'$KO'&KN`^X''-KACIZ19*+Y;!Q.--I%)Q7F
MD#%'6:Q$,**T@J9I2S8[;_:<-.3ITZ9TAE-14A!K:?4%FJZ8WX:A33VBP4WF
M^[SSC25*QPDR2`[G(FF"V=(Q*I$R5QE$W/4^8JJ&S2J8.77$LP`#Z/I%C6]J
M6@9UR>JPTW959JO)2.:<B>::I)5MR',RLR;4FY]H26:KCM2EQQ1_:X&_=(+=
M0U!276'1?0ZN].1**Z?W1?(``=:L?^4J?_IY[_\`$S#\"M8_\V4__4#W_P"7
MF'6@````-GW^2*?ZXAE_V`3]_#J./U>P```8`\JY??CY,/E$,F.ZZR^S1%JD
MNLOLNK;?9=2%7G6VZVZVM+K;K:[*TK2M*TK3:/Q%^_"K392BDH4I2VVE*4.F
MJ4I2EM*4^:F;93^X._"MY34/\<;]\'?A6\IJ'^.-^^#OPK>4U#_'&_?#UN5E
M.^ME;E`]=7'?3)96XX9NK9?2VZVE]NW+7L;J6W74I=;LNI2ZM-NRM:5]N_"M
MY34/\<;]\'?A6\IJ'^.-^^#OPK>4U#_'&_?!WX5O*:A_CC?OAO8?R($V:-2I
MRAMQDSG,5MC[3=2VN?-ES5I2CJE^M*4KDOOK2FVZM=E*[/GKXZC]#8```$"'
M\IR5E5#Y$G6<IHJDH)"D7M@6A=02SIE//%^W:DHCP9>TFRF7"8Q=MPY,F+)V
M&2VE^+)?COI=9==;7\CNZ793VU_[R']]-?\`[T<_C_\`5AXWNRGQ(?W31S];
M!O=E/B0_NFCGZV#>[*?$A_=-'/UL.-DE&2<IHL=R/][9#A/&:PE#5[M<5YDM
MB/4P4.8R^>Y3KFP8S="Q>AFS%?9:8I@PTS4OIBQ]CR=[LI\2']TT<_6P;W93
MXD/[IHY^M@WNRGQ(?W31S];!O=E/B0_NFCGZV'Z1_P#(MW(X7-H3U3G'&NK*
M\;Q:NLF#$96E0^JF,6"D)QE?3#CSJ!@SFLQ=G==?VNV^EE+KJW4IMJ-R4```
M$1_+*_FS,C^VYM_P:^AK/@`````VN.2J_,NC[^LDE?QZNB1@````>E_^C^GY
MKK*UV5V;*4OMK6M:^*E*5K7S4J-3'2TER%2+^13AG&;RUU<Q=RJ.NYY:E\5,
ME*NI":K,SZY2VJ%>>AJZRXY@0GD:EZ+2UBD<Q8TIT&)&CFTB8I5=;M,FV?CI
M6EEE+O\`2I9;2[^FE*;?_<6S>F^'OI@W?[MN\W<./NGY8?*SOGWQ[?G[;VCO
M%_FG<7<_<W:^V?YQV[M_9?\`9]K%(_E-_L+]8P?E-_L+]8PXYHOJ:-%3):MT
M&64,%\^"M]*2+=6WM^&_%V5+:_-7L>S[+9\VW9LVTV[::*1O^0_R>:-&3->4
M/8=E3!C/GK933<X[J6US9;\O8TNK+NVO8]GV.VNS;LV[*;=E./\`B/$G?K$6
M)^[:XOBZ'XCQ)WZQ%B?NVN+XNA^(\2=^L18G[MKB^+H?B/$G?K$6)^[:XOBZ
M'XCQ)WZQ%B?NVN+XNA^(\2=^L18G[MKB^+H?B/$G?K$6)^[:XOBZ'XCQ)WZQ
M%B?NVN+XNB2WDGOY,G,G)9ZND?5<BZNXTF8ZD,%_L:UDJ<..QCE<]KY32J?5
M3N72;]<N:RY,N*VYJ%*)=U#E+KL7=)6NS+3:0_*;_87ZQ@_*;_87ZQ@_*;_8
M7ZQ@_*;_`&%^L8/RF_V%^L8/RF_V%^L86(U20=J1U-Z:=06G(\XH2:!.>H6D
MZ'#3K*IL@K)EM%Y)9RNT,R\72,YLAB5,R3C5KCV)/R'R-AR_!;@O-E[<E<EN
MES^(\2=\W_B),3Z*4_-M<7Z*4IQ=K_\`-?Z:A^(\2=^L18G[MKB^+H?B/$G?
MK$6)^[:XOBZ'XCQ)WZQ%B?NVN+XNA^(\2=^L18G[MKB^+H?B/$G?K$6)^[:X
MOBZ'XCQ)WZQ%B?NVN+XNA^(\2=^L18G[MKB^+H?B/$G?K$6)^[:XOBZ)P>17
MY!^<.1O<VH%RM[4C%4]9)X;\=H1@HL1F\H^L;-(_5G6J8C6'*0>#KN5:JE'3
MEP9,-]A#N3N.S+;E,4S7XK)_/RF_V%^L8/RF_P!A?K&#\IO]A?K&#\IO]A?K
M&#\IO]A?K&#\IO\`87ZQA@ARF&AW4/RC^BJ9-&RQ(D,Q0GR]\@^WOU-;3]=Q
MQ"^0TCM.0\?:6\;5T'`?[XYFKC2[^S5BG<V,Y>;M[??@MP9-3&O\AXDZM:U_
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M)=?;?@LLMLV9+[J1[?@5I.XYL+H8YNN`_`K2=QS870QS=<!^!6D[CFPNACFZ
MX#\"M)W'-A=#'-UP'X%:3N.;"Z&.;K@/P*TG<<V%T,<W7`?@5I.XYL+H8YNN
M`_`K2=QS870QS=<!^!6D[CFPNACFZX$F&FJ!=0FFJ(T*)$1PPVZ$]"47"H8E
ME4(OQ-.&+G"M&UK+BO*%,QC#CM+93E^#'=;FNKDLLMONMLNK=2M^?RF_V%^L
M8/RF_P!A?K&'+3_"-[O(]\]RO>SNTIWQ[AW@=W=[^Z,?=W<7=/\`FW=G<O;N
MY>Z/^P[H[7V[_LNS%\0``%/E6FUR3B5'>3;B"4=:V2(IJRYBR.FX'`K)R96^
MJ:04UK$6L4SY)/KDOJ1*&S68N4K?=W/CQ[:BH``!3*B]&@D*Y1`572W$U</V
MX+R*.H+J2253EAHQ4J6O*IIHYB.F;3!FE2^"[!@R4S9Z=IQUNR4K8.0G.EM*
MZFJ(B4X4-26$.ZVU92D]73CJDDW7Y<N"RU2(%3.4V0NNS8,V&VTWAPUNRXLN
M.E*WX[[:=\```IW.[VJ67<+7,.5OX'(9MLO+M_,M)>);SVY,=^7'=A2,ANU1
MRVWXL=^2RN,M=2['9=?;6MMMU:5$'T@'T@``*9RO-HX5^UJYG0W,3FNK@I:W
MLBZDXURM3.&\P7I1(O.6J5:YR]E^?#2A6M<N&R[+C[+';6ZGW1'4V7+<?M;K
MA0UVY*,VDU.U&6$U5N3C=]M;["IZB>:,U)F+K*5OMP&:8LM;*5NI9V-*U'?@
M``*3=[\9$?)V)8?;P:[+2<YK&1PJCM<*.VTW*=RV9,N(GC/K1TB4R&\N/%ER
M8RUF:[/?CQY+[<=;;+JT[U-54Q9+6G4E1(*A2ZO8VFDXX6/%KKJV69.QIG*Y
M<V*M>UY<>392^M>PR67_`.C?;6O/%-.EYM!C$"JJ]'4VVBF'E=*0":DZ%U*;
MY`TN+I["F(B,6.*YLF7,*JPI&"Z>E)V')>=43V?"4)X,QC+9CNJ7_KF^D=0O
MKZ&U416<KF64INMU!3S:LMKRZI$D=&1TLAAO,'E)555'.6()Q`F7QWYS1TX8
MP%B^&R_+FRV66UNIRDU23EA/(JR0?)*B4J$RJBFJ:<:P'D]03SV#&:)'B)TK
MDREC9,V6RXC!4T7RY,!C!EQYL62_'?;=7F@`IC&]6?E7,[8Q.IMY'&5KDH90
M;%Y)O6B]<17NW+3.DVG*J&*N,G_G>2F0M;6PM_V]VS%_ECE(+G;;I+YS;:7T
M5P%2IN\@9,H:LGJY<L=QX\>;(4SYTXR:Q835F++BR7E\M]N:W'DQWW64MOLK
M=WH``"C79(C!854NCX>S19U5PU>11?E4YD1N=]SN/M=;R:7WY/D>^!JRF;%6
M\N3[?FL[;C[*RG;+.R^I=_,8VY2K,*O)J&'>>0S[G(M7`XT;,Y#C;2E,NBJC
M@*H6([>J&$1-6#91*/JV$I>GDU(T6(&#&,WFQX;JM`!3KD=[49Q=--NYS-]K
ME5E>1FLD&7&M)B&75'*XCN--;[>3LRH:*8SRXN*.;"GHZ04NS**F=RXBI$MG
MSWVXZU$`#C'#I-.*&3Z@:+$21/!D,FSAS/B*E2Q?#;6_+G,&,]^/#@PXK*5N
MR9<M]F.RVE;K[J4I6HZ]"<2`YR55)N+:0OI],V0M4\BJ9%6)T,8J6UR8*FD\
MP9+TS8Z7V5OQ5R=LLI?;6ZVE+J;>Y`!3BV\&FVE!M)+B<[=051Y*V1`:":M+
M:8E'W2NXD\VK9$5N$CYHN97%;&ED#RE>G)>(V<L($C9R[#0L6S9;/9K.YJOA
M'L<+,<S?=R#D4%I*L6VPM)B^D7JC;63[<<*;8I)!HX2N/H+@2E-"62=N>IE+
M64X^EGL>`\3,8,=0_P#7_7,`"G'*\6DS<*69=[H;K6+KB\D-9%SN-<2T/"K.
M9P&[$]!;J9E5#12Q075L_EQ$4A()W9E%2.9<98D6SYK[;*U&`````````"*/
ME6(,0I2CJ+'C&Q)+(:]8KE%OO'0([\#>**CBPSHBUS*N9FN$W6F`U9`3T:)1
M?2M1-AX]C0$>,[U)VW8_E4WVG6^/]?FXX8Y+A=U,Z?'*KPIJTE/6II=C?7`N
MJC/;&*7&[J$<6L2$M.VH&&GNG7TR7HA2.$5P48L<$[31G+AAM+91U"53-KHR
M.I0R8<FN&?&IK<B>,4Y^,*3(G=NNW'HH=J>U6-7$@M`O9HF>,^'*N*1%0TCK
MQW4J1DMD9E-S-J/TIU0NS(L<Z$SW">(2A4SF)V.AG6IKLDK)HLS+,O140MU<
M:O\`E#='"[@2(,PE\#$3--#BU4J;$E]JT/O13,9WUC0M-^5MYVVY32ZQ#N-T
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MI24BE#7+6:9%`N32<2_9R96MNB<M'4?"H921S!J3T6E4XQ?=;>4.9L1*Q74[
M+2^%1)WU+*"B5PF2UJ@8OOBZ;O*4ZYU[2O',F.>3F!B<NI'DFN4GU+))EG1,
MG-R^(YLT9*[0QLEW-G(JKCFQ+A!W(DB]H<+5<Y<\EI:HVT111C-<=RT66KS.
MG7MJ=AF/8&.(DM,F5,S*CSDH[92;5K$[ZKV3-K6G-LQ(_%K4*]%(ZBDV<HJS
M.=28HP"@1.?<C^47"VG6_I90<C$44BPUGY&4[:AI\="Z_F)+T/,J/&;J\U5:
M3)$B=S-BI]UI"9#1Q_QTQ'`SES":M/&IW<$AMAJ2E5KN?)CCM:@IYVD22"57
MB!)XK55<D+($J2UR;6CR6IJD)0D^2I6@]DR2YW8J)I!+/&U%Y)>)9-8<^%,I
M84S]I.&#5V(UBP%;+\.7'@PE"Q8M@P622``"%WE6HD<.=PP+J+T@-%'5>4ZA
M57=+BT\%,*"GF=[,2DFV<+3[#DR*-YI)K9#+A9JM4NB*JFKDLS>FX]&))HJ!
M1<=!@JHX_KDM-DEI:Y+A\Z#905F,S=7O*%Q$G3D]3[*:U)0E-SO]'F=X39@G
M(KW(7L(2O9,;$.)<L(13N*]'6T5081:TBSTO`B7W+86NW40X-:L<Q(2>T;OF
M*)X7.4D9S<<C;CT[6/&6IZ/%=C$(ZPLITJ*PV7S*+G0[EE=;.H]0-$;8I5)'
M*J38A]V$L#.43BMCG!^N'7W,$?Z%%%0FJ+V\LZY>3:G?5(JJ:5`R::W02+IZ
MP0NJ$S#*(*+LRDW$2D7!,Y4@ZT9Z6J2>C6-R[.TJIN=3[,KTQ/E%N4&F.&9N
MG&-7WI]CFR#N2AT"<IIC8ZY#2VYD]X..:X>G249:A%4<9B1BA])9[DR0\<3T
M)XIY<NYFG8I(V(N7/U(*ZBM9U>%#J4DW55$$50N_&V30#*-&^HO5DFNV*TW*
MAZ6=/;Y;*<>8L'K;OM<A0XI:IYO<]%`HT,)HQ@3&DP$MUR.O-'*2+,I*==*Z
M#]=$^S9JM;L32"Z(\D>.):T9O+52UWRP&:<:[)JLM;5!?#Y0K"9]:,I[_=,+
MJS+<"'>G.F6FHF.1X+C?SO\`92B:CYXI9!.K&`:X)0Y6KE&B\V$R:VXX$8.D
M-LZ6D!TE,1O"U=/<H1:NNJ1I!C]-/EJ%<1B2I[*O9F2$[DG#D/GK8J:#05S]
MA)!32>2FYN49+A;5+I3T?:$I!AN`61JD6=<\AR>J&H=P2Y5G2C'Q**9)5<R`
MW<$@LI%2[E]:?"S>X&SGM*]SGUTVL4,VY<95,%$Q!RA6HQX%.3_-+BA&%YK4
M+K.Y3;37)18PV\R$EFVGI,(ZTSL4N=/4,:T>,M$]AS:<F/BD-7QX%M(-)ZXY
M3A=(2LUR;84P]U-:CY6U$:,9A09=O5&U.</ZF.2%5U"%I=AM&;#BB.1'OKQC
M%/49`9SW82PL,.;--4EFTLP6A&28\=QQ;-MEM/)KO!;*.VBG;CRA;VO74\HS
M6\=%YYQHBO)>37%JK@-BS$@MMC,M<5&-#^E33UJE;3?)-E[9ER.3\E69M15Z
M-?VXIEL<4:Q*YUG"D$W,;.+B7:S4IJ+U0:@-*6N+3#,+C@ICRI"7)$O:=9WO
MB@AADZ-YI?DEDM4L<&D1B7N[':93XQ:1:`E&]X7I!G.YF_*+V(-?`Z,A&/C5
MSWG+T>74OTF:8K[>SI;=IYA&ZE,EW99*4NB]J5IV=W8V]E?LK_E7=C;MNVU[
M&GT4R.`!!)RJ4=N!A2Y%NL31.T,ZGRAT3,.1KW0C,9DHCC<,N:*;TNW?(UGP
M5.YT<FKN!M+!5N.O2T77U7.:6IX1"+'2DQ49R_)-B;U:-(30;D@\BBT="$JD
MFMI!U*+6I&27-G;[>;!_)-Q!,TTN262[ID!7.$2BC5[++C..-3?N4[:44,4C
MJ1Y6<A'OXV"!`C9E`Y3+5EG2]0YLJ]HB?!6G)4:F]?,22(A1DHV198_(6EMR
MLYNE8H)J2\U)#?L$K;6,-ZPHX)72$%QO-:1,\@LQ4/1V[TQ+)==+>O'7DPFA
M.2J0EZ+<R@Q.2`C_`)5)(R9(-)9;"CS1BKR+NJ!+,-SMQV'8R?9IEXCI]SG^
MSD-NU4E7"VU4GAS)EB'4<Z\H!KI0K^4;EN-G=#!)@<G_`)M(LL(\.*\4*"JM
MS3'LP0"RY5DJ'5.0JO<L:0'16CH4L4=O5!;]3IYUXVXF*2`61<:C@6\L'KJ>
MU&VZJY&8$:3+$QF(--+<?TMZOG_)K`+M2*8@(JC:57+`6F8B_P!+5U);-S`>
M0<B1(TYNC(552<;1.2+J_P`FK7')C%2B_8\F]J\GF=)>G6)9E64=X$65IKT/
MZA6@^4^/K(VR+A[4XA35C>N)!:]Y_(NDHJN68C*N"(B4DH3:F1,;3AS)TE%#
MZAA(G;N%R?F`C+NISE4GG.Z0EK\]L36HKP*C)3J)8%)4C_24W8>BEQ:>6ZUD
ME5+YN\$?R40<CKE8YF2L6)->[V<CF45+.H'TJF%.P[U)LK!IWUF1C710ML.)
M*17R0W*<N)GK19FI<AHB+A86IC3._BK*34BY33DW*@IC^-JJ'>BF3>4N@(!E
MP(Z)B2EG*654ZXK)Y1#6!J>2#;D@),AACNB'(;Y/Z;)):,FN=$;\7N1O:I8F
M:TWRIG=*^M%5&1FLSRK/75]DPR[F99EJ3D]DK-ST+O%+M-("?U3SY3"=X`ER
MV/YV>+,PING37&L1WK$5B$;E2!%!T,S.VD)0TD:G;E.J_7$R4_._9*BN*Y&4
M;<+A++:ZE32;0DI`+,0QF3KF/;53KM6%U1@&,U*,D'4HU=&2#K1PYI&36JRF
M0?RR?,$G([+8,FH:\?4%HI%\3M)@)K*G1V1LK%7I@=[N2W0FJJ"2Q$FTNXT:
MLY[D35NRFR_C*TTVTR].O+D\GYINK%*:B)SLN-*<>ZE-.WRBD7>`>+)[B)*[
MJ=#_`._,?G$HHG(*A!UZ'G/H1Y5?1A42-FVGT?WW?_-1Y`?`S@P&L&4L9PXC
M!<Q;7#G+Y\=F;#FPY:TLR8LV+)2['DQY+*UMOQWVW6WVUK;=2M*UH-73D\)9
MF^/])G(:Z=81=C*C1GZJ&QK#;<B*YJ-";I<2+GC=E2K)K7<+0[J6DYODU(JN
MI]:F2BR@*Y!4RYL!A1H9)%#*,KW2TZ\HAK*>I?1LXGP\8L5;-5L`\HZGG4),
MB;.D)+'E/0>X\;8:,JDLMCTSK:WADXP06%5\QX:6$]`3\"BDI+044?(AG5AR
MTFR==&OUZ1AI\6<TSQ8D+VI;D:7;RBV53)P.GFK8SDZ&46%%`VU&N0-NWN-?
M:LGYYK2OE9@=MATZW\;95+&.;1*N(CD;%Y&!RA.L'5.1N68!(PLP75$T2<GM
M,4CM>4'*BH46+R!JMBMIS1*9UV+BP64));#,(M!P+S,AMULFV^\K)S'6OEEA
M>"90T@)]LG?-;YU8R;R2NJ-774M/9:SRN>HZ*6M#U&@D%UZ.$Z(X9UY0\CYU
MMW7TRNG`^%VV+%)?DYMG<U4#$?<"`BHB>F4955ET4WBU\ZD&?HA37?';CA%G
MR6VF]RS,L*4>1I!A0FHN^NB/49)S69+J+LHXJ88X8$&F%%-[IU&O!Q/@I)+P
M>[L:R#&2DH/9W+2F1JYS\HA/T?2'K3U$KCR(F8XC7D^>3&EEF0V>2B!*.V&^
MM83NF!JNAY+#ERWEE^UKLU<))SQ=A]7.83!AFH=R88448BC6G+L^FEJ8U0P1
M?,1;4-%[SU"(A206E2$$_30U6W*6H=-CQU,-26E,UJ#8C$,--B-\@6>S:<"9
M'#R;.4M:[VX?2"*PWRB\CJ*TLX:3-R@>K..9)Y1N3+GK':%`NB,]IA)(,3NB
M%\J8ZU?%JRA2/3*:HR?)AF2J6LQ-@R0)#)OU[G2B!GPK+5;SC;1R]L%K,#@*
M<+5ZHZE%AD-)FZD349.!):7*S<D2OP`MIRFU%"94]D/S5Q$*:L5EYNLI+(L9
M$5"3E+.XDP'4T;$R]WQV?M)K:645TA64E^X[#UU:L)";.75<A+VG1@:9LQ?7
M6WWPES^Z""`0BMP:=+9;*Q6=3\[&3SDF'%I`5HB4S6J-L.G&=N(LL^M.>-BJ
M,;:.%#<M'1?KWUF+"3JZ9>1OGI==D')?)^OUL_)9CQ['<ZO5CZHF.>=DU$HG
MC)].E)9"N\T9.9SI<\`QO*=S5D6J:H%VA)J4O/%'P85WYH>OC5-/:89C72S(
MD<N26FKI67M3J,]Y48Y*$T)T+%^IZ=(?),"=(JD3&6>\>-V%<,+Y(TU/8&-1
M)?;1DQP8%),52":234QTSZM!7-N!J-I=/XTG$>66^BJQS$@JURZB8C2DF%3I
MC&CK=Q-/N5TNS-GOM3E2X@2N425,!RXH6KGKALJ(``````!:PY"<5J$N(\\'
MF2C&Y?;[15&$AO\`,6&LKA2&8N&RA];;":8N-5PDT1:/IZ8?5T_`7LP*AU*2
MC9ZW.82T_*6M"9T+:0CQ>;RBAIYB]1*:DU-/79\**+<QJ!67G"D+!=P(SE?Y
M8[F,8'(YD5:)DE)%<A_'D7$<V1(Y4Q0*5)%>T\(SH%T;')"NE4QITB^^0-YC
M-F7`YK4#M)TC*S";5K-;4AI>'`8QD$EX%VKB*H"DNI9,F><24G)11RY5G&D)
M="=3M_1UID:E8\JW(89*+6)GX^Y1C.Y.(FB]S%D>3[%K'(KY:]UA[LD=TO>U
MRN7Y4K92MA]:N<CAR'\V:]<5;C>'&3DKX;Q:K&/*22T8\0].S)TI2AIR(P*A
MD'0@XJJ4N3FES@^')<=0UA/2S+7=:F14TAZ,!2*G4EYU<BPIN',<Q9\Z0;RW
M7-$VE1Q.=T/%3@YB5<;W2FD@O)3(D#:/>ZT!A(WR=9*`XRZ*>3B*R@M-"KF1
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MI>%A,*,[$NQKVEDNK-BMR_*V,TO*FE#6`EF,1ZNW9S3)6LV#(X&O@.J*8BJQ
M))4E`@9NZAZ1-,[:GQP:H6_"C`1I[=9'$2<4FIJ)C)N!8R8DC$W;5<];AR6I
MF5SWMG`7:V=WT3K769:I?`V#*UF0,5B=2X,20S%,"LLK',+QXT8N89%05E0B
MSV.AD6XW")Y</YE-4S$DA.Q8292ADYGR9.TE\6/!@L[67+8L!7#AP8[F``"U
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M:>=+NGZ+8)()+D((+`;6FA<DY>3DA51[5>UE.]B+9J1R'<$?K*`;;K9R,!M&
M2Y50RWV][,MK-&NF/$]7%(>&&F>7=SOD-.EEW*Y;`HEJNR2D@PB&4I[N@C@4
M<:6X7(FY&TW+2"FL$#N<I@0$4K@K852B.'!T\2:%-(<$/!MO^(=/T;L!YLY`
M>[3:;D;J+>55&VT9$<6!V.MHH9C(:S=ZVD<<&"BB0:Y.W$@-[)F.86TG(Y4^
M>+F;BR7IRA>77.TWR^V(FJ3\8V`\2:+^33BRU7\WDM5R8LRNA)CX:"H@.S`V
MU@P7*FEAL]^+F\JFR9(VH)A@T3+9L7(KIYA2KNC!^4C9K6/"%B+L3HJ<.(A=
MA4V&3?UF+&^\3;SX<V.B?5[68,%'?EMLOSN:N#!<MY3U^''=;:HGH)T<D7N9
MD;!IWC+Y9YY'>$O8EO.AW&LJ9)<A(2RW7Z\T`H:,YDYM+CV37$OU=QEO$DNQ
MR*2TJKBQB.+I\RI9.22T+Z3"+,-Q[9!K*-,PZ?B]0S-]5Q*RT1LK")G&>AI/
M*U6%4^8(H,3*6.U5C5LDLY=N,98K>KME*3%/+E-W]5)O)]:+IE;;^:4HZ;XN
M?"#)\HITVO@HOH-YO.NS"DI.!OI\HY%*AO&JD7^7;94JV*.Q)/)ZUE:Y;`VL
MYS*A8<:=;RW]H'T;2;1BV/33C%:KAC:,5Z%&85P-K$B$D>&W.FXTE;B6I)O9
M4DHI1F=*8<%WR#6,*BUBQ[`7522465<&([;DTT&BV&"U6XQV6A);7:#00TMM
M-=MHA3$01T%`1"6%.24A+)8*6X2A!/(E\)4H7QVTLPX<5EEM-E!40!](M,WX
M,BAJ/N3).;C*2D:09C*(Q&37B0O4,+@>9-M%SQ1LE5I2H>KGS8&T65%3"W,6
M&N"U!L5%.B10GWP.=NM`S=!FC>/4%C-=EZ;8B;;=C*2SLQQRB)C0(X4QAR@J
MIYE*67PSR=_;,+;<*Z0.&RS@.I%I3O\`V&C%RSC/Y,V2^ZF6[R;FA9IX\V%N
M:7XF2<6=@29$]^,JW\E+*17,*K1:D:,L5EYR^F".W(>J8[:R,%,;8329]53$
M1+3$M75"9RO5;1;I97BJN26H-8"L57X-(:9ULNI)68YA5M/B7GJ9(0NH8\YN
M^TU&A;/?FOL9^:EZ-6IDW2\K?:<-6YL:(FY.!A,_51JAGU\);*>#8F1>TPJL
M8L6PFY<9>.RNE^*DN-V:3<I$ZJ96P_LI!41RC\9QI71LM[#<5+#*30PK%BS@
MLR+PZ'=)N%3<"I;!#`ORNUZNF2'82SIQHTB.M_OB\YD>#S<[<-'LS><+E<UY
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M)Y:"='4A24Y)=>NGB,W)(+R7HY=CM7E1$OS4<[PB,T5-1F]'`D6FL:`L/5D]
MPD2C?>*@E&'.12R)%&M5;D@F6(XLNP`=>JIY)83CR2H69,I%1*9R1S'BSFBM
M]Y8SCKBS64-$LN`T6NNQWUI3-@SX<UFWLL>2RZG94QQ9FC'2Y'A>'RC%A-C-
M,GI_-.\[!Q5`(&DTK$IE_DC*<]<L=ERQZW"T_E4GG3I)>M1K"N-3*'3A<U;D
MQ&L]N3C)&B32D@$6"FH<%L%'(Q8FRDCQP63$TR1Q,=+F\P:-3"0:U"Q['5%+
M2<9.FL[ZQ$JXK7/ESY+U;NFM=M/N0T6Z64LDV$Y-@Y@D"#*A9?TY-`F42\Q<
MLV8&=5"5KCB!"PXCEMB7':U8EI.)1:A.W$DF<*0D8+R]<*6GV%J64N3UT2K#
MU@^1E73%#JB^--S9067"#F.-`D858[9[2SV&V8U43-ENNMR-QC'<>-18B(J6
M**:R%/'C4FF61C]EABG.+Z"]'924CDS%M/,;89*.RSOZN<V-%S6Y"LV7HIUO
M'):2TVAOO$BR,K)2D;P+SP2$LBON+-DH?73JDH8,)O%UJGR>6BA936RC*NFN
M+#Z2T+I@H@)9E!ORIQ4MJ!RWG)N3#!*XW4NJHDJJ]]'&^T!8QJ"(XW9B+NY1
M3\KG+%U?%5Z;HMTG))<N5*:>(CO+X('*Z8+\1YDHRK0_I\)8CF`K#ZS56+GK
MEUA8,*FK8;$%;JH%^U+*UCK6MBRJ6FZ@T[:6M/.DM@5B[3C$3)A]AWJIE=,-
MUF)-I`J=6#6`N4R*:D9SY32BIG<:>3(I10PHG35Y!'3TY'(U+):>2)X.==IN
M@8PH3:IG(H9"F:U))Q-'GRBPA%U@I,*0FMS(ST],D-.5^[4UUII%HYLC6)$U
M0H8*EFY?5$P8[$RE"U+3L?D^M%L9Q.CP>P]-\7M>*4"1$&7$QEI*#EQ)F&3F
MF>(J32?N7)4WD4CSK:1U*1\S36CYXV=;%$1#Q(.1/PHJ7C)\DGH"T5D),F68
MBNF&%K))U"-QRM.:75>Q4C,=D=`>Y"Y+?9!S%<^'(F&_E\G5M)O\UB(%SSZP
M8B]CM,K%"^#M?5M_D[M%;2*'R[;T[L%%S*:/$B&H+"=@6L+F.E('5C"W#9DR
MZ[%BKHS+4;*AGNIHN2]7JXD>I1,Q8%6A9'2L)+W??)V:'Y0(Q"GR+I?AY\8(
M(45A5BN]TM(JMG6N<<BO>XG77OD?R9E%<+/%R9+W,]2#F-K9!YN:ORB=)576
MJ=WC,^E*4ILI]%/^O^OT4I\U/F'D````````````````````````````````
M``````!XNK6E/FV[:UI3YOT=E6E-O]VW;7S4$,^C1&R:\&YJBFV=W/(>%TX=
M7VJ;3Y&K<:,CO=@Y=.<?:=977(5:!%F$6JO)&!#DU7RM8Q*3P?*D0-.E:776
M52C!FYCH;:;I''/3GRK6HI+TE:&)`EB(F]*AK4D=FW2ZAS3\NOD)A>VLJ*93
MDN)(!17DVBC)4D1GL'6`3C,PZ\<P(BD<;;"7[U1-^0YH@K-#&H9\2?KJ?,*3
M/*<+29$S53EE/TI$]0>G151WXXE`GJ+?2<XD^.Y$A5,PGH]2ZM9>8\H.N*D+
M$>L,N4^X&S,3.=MK?2:I[B1B-0-C5I.$AOPX5B^"6N_(YC;4CBTQ3VK$)3*H
MCH92RCL="<4HRXV$YUHJ"F.>-HL=B^GLLPWLQDA)#X*]]7:W$,J534Q'<V/B
M3RKN!,9NF;4;)$9$F[I$U@HLQK,3R(AN<TM/QEEHOAZ4=0C3,2@S32,G$+L$
MP0M#KX<B5B:RN8.,-TE4AD.#`M]]LSE2\0W_`*YGU%^L2,]9,UMO,UX<OY&/
M4QJ60HM:,G.AQ9E.PYJ!T<Y6"TW8V#I`HP$R5R>*1$1JF7X@%3R5>:>BTF9E
M?,V&H45E;)?5'RILMZ/\LQ,>3M/;*=$M,6)H&GMBD&9*RT28K\C>6=2C/TPO
MY$N7UR/KE9%D"&7Z]VWGN+&TO&V)';C@1%LBLLXSW[04BO,7*5/`B]93@=TQ
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M^=67\FI#Y2\\S4V5YI2(S25_2[`.L5`T9S`YZNI1)2BGN(_($>Q$\Y7;K0O0
M,R(I,B-I<DA*:RNV3"WA=#D;:.Z'T@FL&`@B-QQ4?&G*@26[9D8+1=<!,]M1
MR\^4:U1<G!D<*'+*LYW<4D"#&%(\@M"22B`=CIM))MDNXA$[G17&FFUE.<3;
M5U)*SI11?2RA@TH3,VU[*VVZGT74I7GIM'D`````````````````````````
M`````````````*TI6E:5IMI7YJTK]%:>*HP\5]&[$Q.J9G+'<@2]".'4&8P+
M<V-F('.@MYMOMVW(^)KJ4@%L"TTW(J1U)+C:Y%-075(,1JT?NQR84="6%94,
MNE#25\I3#UY/#3$\HB-0"<:JFD0B3T[8M-C.C!`42I%M1FQ,9TJ>[_1S>833
MRVW),O-HS;-[Q;E<\Y,2BU&VM%C6!=3JJ>;`I-D=E:BN538N@Q[1R;7SG)?L
M5D:JF=J#?3RN=\BR>Z7W#Y:.4M-7"2>W&D61,R362JNQS*YE2=6%[NII-58S
M(J$H)N,Y20=/T-16B:DWGJ);3SFAK&),=+6D>3H8;LBF$R`I"EUEMM':C8EY
MRL#&FW'J/DBWVRUR2G:BN1':3P--5L+;X:KF7V^E*A:F8_Y.#3<PB#:9Y<L]
M'-$4>GIK.Q-!CO<)16BF)M_B2Z6S)I%F)A=&3W*:1E%JR`_V@VT5ZNEWIC!:
M+W<K88I9NHIPN2*6G:G)%:74E(0&F\7-.\R,5KZ6I;T5MQBRU)F%?;J5I=E]
M0::@L1+=D0VVV7`KD6S8Q6<GLAUKZZK2`A$VP@9,SM45%%2CY.NWQR:D'R@P
MG2SY7>\UR:I.QF0G&ZC([M=[;R23@CF!I$)2S'C,(+R0R4E/+DK9$($G4[UZ
M]$S/205(H3J]W.NX")'"6X<K\F%I_EE1F)RJ;RG9HR'*NH"/]3Q24XYDK&S)
M#B><XXB5.@IMOF(5M-;_`',W+LD0)V*/G"W5Q.=+4=3<,JA1Q(:E>K*.4QE$
MBZ;V&DZ=U_3CF6)!7FB[V0]F:\'>Y7PLK<K.O>*GJQ)Y.Q=D,WDN63+T6;UM
M0.VK>+N?&DF:D\"$12TI,3$TG9]0T$0P^U*\]."W)&HLKC@62=."&C30X459
M3&Y$DSIB6WI>1R=[5;+.55IPR4W$!";CL?[R5'._32&ET($G(0L4UZ]7II1Y
M.6$W-%LA1D_GC,LD%9`TNF]&YEXO-XHAN0&]IM5L)G"MQTW'$E-%'Q6FG)AR
M%[76_P!>35^3'7E26\<<;R4SS=131*BIBY*;3C,]LKE'.[IT24.>(3AN%IL;
MC0D).;R1)Z3I_.*1J)'>XKL34SJI)\-0LJ**1D-MA3;[9<:48P8'8U5W,F))
M@A64A<FYIZD-&U/-U859;(-_5G(L22W,2(CR#FPI1Z28FQ1GA17BWB"@E*19
MNK"_9#48T=^0GCNPJUC2+X2F%++JKAPK%3Y=`,&7OF0'):>?^!IRU-4?:C94
MAC`X$O'#[_GJ.:M4TWY16VY\GKEHFK'5:/F$XG8W6ZY41@O5S,Y%7G2T551R
M*^95Z%$Y.F!T-<:#A)+DI546;K3DO7<E79G2C7X,NH&5FX[FH\U$_@L:N+'G
L:9Q"?CQ)DVGAH7(IU5[.8*Y;#!-*RD)`Z4I;2E*?12FRG]%/HI_=S^,?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g999257.jpg
<DESCRIPTION>G999257.JPG
<TEXT>
begin 644 g999257.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`_1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]-14%.7T-/3D-?2U],24Y%+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_```L(`5T"60$!$0#_Q``>``$``00#`0$`
M````````````"`(&!PD!!0H$`__$`&80```&`@$"`@,("P81"@0$!P(#!`4&
M!P`!"`D1$A,4(3$5%A<845F6V")!4UAA<I&2LM'6"B,R-X&9&3,V57%S>).4
ME[&SMKC2U/`D)28H.#E(4GFA)T-68AHI0K4T1&1TAK?Q_]H`"`$!```_`/?Q
MC+`M:T8'2-96#<5HR-%$*WJV&26P9Y*'$)XT<?B,09U;](7<\E(4H6*`H6M"
MI/"E1IU"Q68$"5&G/4G%%#UM(.I$^*Z,A%X'U_!TJGD;=U*\?>,M0([))DU@
MI9W=[L$$;+Y'.45;W:,5@\,L&,.M6?P.-&S%X@L5975G4/;W)!DD%3`XL<C@
M\@V>W&IX8"XI9O'F\9IQXN&/(UA[BQIIS$&R-2IN>XJY+4K>X+XG.:[G,%GK
M`-Q;TK@@227;(OTH6M*A:JE'W[?+^3>_\FLYQC&,8QC&,8QC&,8RCS"__.#\
MX/Z\>87]T!^<']>/,+^Z`_.#^O'F%_=`?G!_7CS"_N@/S@_KQYA?W0'YP?UX
M\PO[H#\X/Z\>87]T!^<']>/,+^Z`_.#^O'F%_=`?G!_7CS"_N@/S@_KQYA?W
M0'YP?UX\PO[H#\X/Z\>87]T!^<']>/,+^Z`_.#^O'F%_=`?G!_7CS"_N@/S@
M_KQYA?W0'YP?UX\PO[H#\X/Z\>87]T!^<']>/,+^Z`_.#^O'F%_=`?G!_7CS
M"_N@/S@_KQYA?W0'YP?UX\PO[H#\X/Z\>87]T!^<']>/,+^Z`_.#^O'F%_=`
M?G!_7CS"_N@/S@_KQYA?W0'YP?UX\PO[H#\X/Z\>87]T!^<']>/,+^Z`_.#^
MO'F%_=`?G!_7CS"_N@/S@_KQYA?W0'YP?UX\PO[H#\X/Z\>87]T!^<']>/,+
M^Z`_.#^O'F%_=`?G!_7CS"_N@/S@_KQYA?W0'YP?UX\PO[H#\X/Z\>87]T!^
M<']>/,+^Z`_.#^O'F%_=`?G!_7CS"_N@/S@_KQYA?W0'YP?UX\PO[H#\X/Z\
M>87_`.<'YP?UY7C&1'YY\8=\S>'?(CB^7(4\46W/6#_#VB1+D/NHUM#^=I.Y
M1U8]M7A$)UCP'YM;02)K+\)SBQ#<49`P''%BUK7D?3>MZS[;D'+M5%JMH^Y&
M>;=/NQXC1T"E9KG6TJFO"IRN($Z=Y=+TT,:R25-K5W>4HI2`/1</.<X;#(9!
M)!(4P5:E3$XOL*X5<=Y=1[?R+G5CKD)EE\KN3L^Y,3./M*W;JS0$#]%X'6,"
MKUM>O1D`'XV*595D'1R!]*;D:5UEIL@4-Y9C7Z`>;=7*6O84N@4CGZJ-M9LU
M:"8H4UR?9&PO+>6DF3*-,%(L`,)A&B=JU6@;!O6_"H.!O>P&##N50?9O\8?Z
M6\JQC&,8QC&,8QC&,H,WO0=;UOMOQEZ_D$8`.]?RZWO6:.>$5&7MRMXTP"_Y
M]U$N=$>E=CN%D.;FQ0*2<<66',P&VV)Y'6QKCK6[<9Y`Y(VMN9F5N1IBUKRX
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M06Q?G*^HM].>,/U3LI'P&L4(!"UU*^HMWT$6]?\`3CC#[=:WO[T[(+4/4%_6
M1-.7,=DW4;Y[Z0T9RQE%(0H;/+.,S<>=#&:EZ&L)(<_#4<5G+3B^B?;,D)9[
MB1I$28W%-B;2(!B0Q0ID7\4RTOG'>HE]/N+OU0\MJ8T!(:[C#U-[!ZI7.N"0
MN-H]N$BF$TM_B-%8LP(-&`)TL>9"_<3V]H;$XSS"DY0UBPGSU)I*4C1J@XHH
M?40JGS;(+$97O5AYN3?0$"9U-+BUR\1GI6F;%@BPHW%:W(N)QCDW(EHCBM(E
M+BC2%+=&@$E$<`6A9?GQ3+2^<=ZB7T^XN_5#Q\4RTOG'>HE]/N+OU0\?%,M+
MYQWJ)?3[B[]4/(X\I:COZFZZATIAO4:Y\&.T@Y(\2*C6:?Y=QD<T((M>?)JK
M*?FAQ"9-Q2;3`.Y$3FCP<PK=J1%-ST!"O/2KB4XT9\[OB"V)OO\`_F5]1;V[
M[?\`3CC#[-;WK7_A.W]K\.\?$%L7YROJ+?3GC#]4[.H!PDE!K\JBY?5$Z@)D
ME1-*%_61\%D\51/21C=%KBVMKPI:P\5-KB&MP<&AV0HEYI`4BI8V."8@XPY&
MH`7CAGH:&R"632!,/63Y@/<YKA*J6V'#&B_.&3G+(&C1`$8L53.-H>,Q[U%4
MZ4`!C/.?D+>66$(A;%X=;WGSR&CX-$ZY8K?DO65Y@LE4RE0UHXO9#E?'#=+!
MI.L?#3"&-%&I09QCTS2):]GE&DLR-E6+U3J:6,#>4IV$7:]8?Q(46$G6JH)U
M7^=LQ3MB@M(Y&QBV.)CZ%M5FE>>6C<?<SBPJVWK!%=Q[1K=$*@:"+QDA[;R\
M?B"V+\Y7U%OISQA^J=CX@MB_.5]1;Z<\8?JG8^(+8OSE?46^G/&'ZIV1*Y?\
M>+VH:+TL\PKJ1\^5"NPN6G%:CWX+_*.-#B27#+IN>,U],#FXM/Q=0;3/I+$\
MJC&1P,&>4@<0D*34BHLL2<R6@>`MB[#K>^I7U%O7K6_ZN.,/V]?W)V6U,N'+
MI748>IM8'57YXP:&1M$-RD4MF-K<3(Q&6%N+&`LQ>]/[YQ90M+6B+&:6`:I<
MK((",P`1&:$,.MX@C]>4S+)*GAD6ZX?)62S!6_I(JDBK!R?X,O$D52=>E5KD
M,<3L3=QS4.AS\L1(%RQ(S`2"<E*5&K4$)3"4QPP2%UP%L3>N^NI7U%MZWZ];
MU.>,';>OE_[)V/B"V+\Y7U%OISQA^J=CX@MB_.5]1;Z<\8?JG9$[G3Q_O;B[
MQ$Y!<A:^ZCG/%UFM/5L]3V--DQD_&QXBK@ZL!J-40AD#8@XPLRU<T+`^8F7I
MDKH@4&IS1A(5IC?`<7O+QC&,9@7DU_$G-?Q8[_I?'LSP'V;_`!A_IBRK&,8Q
MC&,8QC&,8S\S?X.O[83_`)T&:V>D+_W>G'[^UVI__O.T<V58QC&,8QC&,8QC
M&,8QC&4&?TLS\07Z.\U$<3/XTNH[_P"HE/O]5WB'DTL\_P!U>AR%NYS=%F1V
ML)&7P/8.5\E4WHKD7D`K5EOPYF;4_&=_M52O\MD0,B*0&J_>FY24\IA1O07\
M1V]'&:"9N5/DG']KL:36*OE]5-EF$0F&P*;S-=+8HWN?O2=)&^R*`1F62E6X
MD(3S%4A#)G&&L[N[&O'@5.Y[,BTW.8C%5U_"W4NV=1(M6O5>X\D5-:%7(-69
M`]L*1<^H@N3&A5/>I#MJ3+7MN&!Q9DAZPM2[-PM+V\I2CWY^=LW3V"/#^X11
MGG,)=Y4T'+$[M%VF81ITDK2H;@)3'%,ZQ]O=%+RV*&\M<A,7IUZ).<B+7(1J
MBR@+4NSKKR$_/K^)BL/[N+IR?Z]W'_-O^O9_*+_+O/D<%Z)J0K'-R6)6YN;T
MJA:O<%R@E(A0(DA(U"M:L5*#"B$R1(G+,4*5!QA91)!9AI@P@"+>O)+8_)2R
M.-G5%X9]46:;F3+PSZAB!VX-SV0RR4UVIJV&P1VD;S-N#-AQ($?L.5N#&@D:
M9.NG,Z=I@W15/'3)M/"]%!5.HTY<D.(3TQU5^Z`.N.[V.ZM,';)50O!.RXTJ
MDR]$S%R2`QFI5+')IBQ:6'$C>H^QOB12SO#LW@5)F]U*VV*S2ENRR!81VEEL
M%ZU'2/6\GR-1[C@W],$Z)<53IH7MF@\7YKFQM*39+/YSYZ$T,]SN%8D@:VE&
MH,`]J6H36VLA'II2D!6[6V^7?"7B&ZSVS'-V;02*R'^4O%N+:O8QS!Y.*XZ5
M.P/UIV3.DT>$(1K=2E-GQ99/7D.W*0-\=!'V1,VNKDE0LY,G)QR'KFO)M7T-
MDJ\U(FL.'V#.DDY$I82*^CD<KPB*J%R^7R9>^(0,J9^!+$>HNO`D6M3F8A<R
ME+@WF%)`K;'?.9E$-ESTW0;))%$_LF\8],IK$&RN4J>8MJ2OJ^DK+"YE/Y`_
M-B_W';HM'YA(6F-.!Z=6X.93D<L%MK]!97U8V2KUOOK6_7KOKOVW[=?V?PYK
MDZE7]0/%S_U%>GU_K0P+-C(/X`?Q0_Y-9;$TAD6G\<71:9L#9)X\N-;52ME>
M$A:YN5J&5U0OS4)2D-T(I1I(\-;>N+*-",H9Z4K1I9@/$`7F\Z2K+`9OU+_W
M0!N1I(W(4<6YR\>ILUF+1H%9;'(X5"YZ>WR%,?HS?H*Z/NZ-0#:S1A>TB@I8
MD4"UH2LC?H78+SI24GDI(Q;E7R%0>2L/3IF*P8>[G'$-K22_+S226YZ4F&%(
M&-0G>%A@`B`E:CR7$\1:,T!XJ"[XI$TF/J"[AJPPB6%N!L7.!8D.&5(RFIU3
M,3F8PF`>A`>2VY[6)&A<-M$I"C=%29O4[*6'E$CRQFN#J]?]V9S9_N?IO_F4
MN;'\8RSK$E2R"P"<39OBLAG*^'Q"2RE%"HBC]T)7,%4?95KLGBT80=PZ6R&0
MG)"VAE2;$'2AR6)B][T$6\T[5+U!+[DW#/D7>>DRB[^05<ND-B9G%JMN$5[5
MA?\`QRG,T(8-J8[<?'F:W-++.M4B%MTL3V$4]PY5733:E?Q9R50)9I0]DJ&C
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MQC&,8QC&,8QC*#/Z69^(+]'>:B.)G\:74=_]1*??ZKO$/)I?\?\`'Y=9\3FV
M-CTW+V=Z;6UY9W1*8A=&=Y;D3NT.B$[MHY$Z-+FG5MSDB-[:\U(N2J$QF]!V
M,H6PZWJ-%^<583=%7P6JF<;#5,;@5_T#R";$,3KR*G1Y7(./]HQ^U6./K8@G
M''&/W(E+Q&V]GD:LK7I^F4Q04E"(_P`@9.KK?0<K7X#)O0I7)"9(XS/8U4\4
M>G9)257C>RFFJ:TY(5BE,;#G%X7[9':2M7))]5OKTP*&=S&7%VR-&*5\0D,I
M9%NP2C^%J6C.2]K<CF>SPN*J[*MJ:M[&@A571:.M;ZY4DQ)XS7]DZDR-]7R(
MF=:8/3F.8J3=+$,T:-QM$N)1"@\</*G+D)^?7\3%8?W<73D_U[N/^;?]>S^4
M7^7>?.K3)%Z92@6ITZQ&L3G)5B-444I3*DJ@L1*A.I3'!&4>G.*&,HXDT`RC
M0"$`81!%O6[755Y`US2WL"R%1)6QM.C]-C.IC+&H:F[2GQ>D:0MQR`:)'H_Q
MC\[28@KS?$+S/%XM]_Q?:SKJ4.L=?))`X9('J(^+WJ.[W%6!V<XSXQ$B'[WG
M!P;E*QD\0DR<0O<LY)K8B"1;^R+!L/9RN&Q*=LJB.3:,1Z7QY6,@Q6Q2ED:Y
M"S*C$IP5"8Q2U/*5:@/,3G@"<08:G&,DT.C"Q`'KOD&.8_3KJWERQ0%C.D#K
M5!$)@U^4WY4&8XYML<:3Y1UL*JKR@2=C6I"VME6OT8*;5T7E#<3M5$I&SHW'
M;8]MQ[HRN&`N3G1VJOD"UF1]EMZVH,PJJFY;58J12F7SR_52-)RW@%>UO)#X
MDXW38DD.@<>A4?KII'#JYAY;3`DS@I5*3V;MX"\R%QEZ:$?XW7M%+P1VLLE#
MG%V_G`WDQTV"LK`W&E<X>24&Y-2X*90B?%RAN(@\MA)3#$TY)9VE$;=5I3J,
MUP"!8+:-FN3J5?U`\7/_`%%>GU_K0P+-C(/X`?Q0_P"36599R6#1-F"[&1R.
MQJ.N3RD5I53@UQYJ0GJ1*MFF>):)`0@/7@]*-$J,).4Z\XW8Q;,`8/9NM&%5
M]!>"52MK1<SW^ZK%%9UE"*Q;AKJ6KE:4[-L$X9\BN&*!Q?FMX7/$>>CW6)\C
M'^9R)I>V1VCC[)8XQMKHT*XT>ZMBR^ZSZ+C-5+?QV,C'(9V-F'&SE98?+&&S
MIWJ"$KWY?)K;:H['+/KYSWIZ)*2UG-(ZA?TCJQ,NVU>!V<8O)DSJ2^5W%E1>
M\36NVM:^3U:_L?:]N][WVUZN^]]]^W-</5Z_[LSFS_<_3?\`S*7-C^,99%DM
M]@.L`F+=5,CB\0LE9''5/!I--HHX3B(,<I,2F:97*31!IDT,=)&QIEOE"<FA
MOE4?6K$NS"TSJD.\!FH=I./G):/(9_;L2L3CX@Y9VPKI9NL%^=*=G"VDUM;5
M#[X4R.OV>,M]J-=AI74Y--YLN;[$>9H_+F]V>4Q)D64,#2A:"I#4#22&DHW*
MTVUC<ZRZRK(FEPV6^,S+N-,KW8D_6IU;^M98YMR>!LC.0G0MC4V(U3P\NQJ-
ML*<'][>Y`N=79;U?)YK;#J?F+B:WH3'`HN-!*7&)$XUA02YC'QEA+5"+V>`(
M!"$(&@F:T$0MB#K6][WDAP^S?XP_TQ95C&,8QC&,8QC&,9^9O\'7]L)_SH,U
M,=-TU81TIH`>WN"]I7IX)?ZI`Z-2D:-R;5R2U+A5(UR%2#0ME*DBHDH\D0BS
M2]C!H!Q)Q0AE#T5=-_J0<ON04EZ,<-A?)BP[>Y&7M$K?MOJ$U=<,;CT9K9;Q
M:8IS+8DR6Y`7!\KV($JIDV.C*4S1%#Q_D;T6XNK0\DS]D+:V]Y6D;=#^NK0I
M#3?<_(K>;22GJ;KGF9.FB8PI6&2R>6JN$,VC,!L1CD,*`R(D%6ZLEW?UKO1K
MM*IH>FF$2BDK?I.F@XFL*`Z,_*7K/K57'[D./4+N;CU-.-;OTV)59LLI2=5)
M.W`#/S=>8C/H%$8.Z6-`A-3YZ3%S3HK;&WZ$L`&PD]X]ZJ]^;S&AR>\]6WUS
M([4G(BVJ*7<89[(D5+<WN,?":8S-EL6%EF+Y5RXAS_*:EE$0C#HWMYKJD3J&
M8ELF;2]OD9`R)EHG%J?9">D$UG?1'^NE63Y`XQI34@XU?$MY;<O.(#15DFLU
M"W0<R<<,(G(9W9\E-N,$)/""*NL<;(^VP_?P?;>G>>3>.Q<QK3-@':4H,:<A
M_P!T(1"C$DD>6_B/;4Q8H?P<XW\_I0<XS:(U\^,%,W[9$7K)9'76+21L.=TU
MIP=^DY9)T3"$U`]*D2A.>_QQ,+3@'T+L3RCD3*T/S?YOH#TV-[LB\\ORCO1'
M-&0N2[.*[B\LW9"@OS"_$+P#\0/$+P^+?;8QC&,8QC&,8QC*#/Z69^(+]'>:
MA^)V_#:/4?%VWOMU$9_OMKV[[<7.(F^VOP[R&D]ZG8JQAO5)Y9/D?>YG0W3M
MNE@XLM52Q-R9(T_S>81Y#5*F[;-=)`]LSF,]R*F=N,<1@#$8:G9&^'PU_<#$
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M>_A\TCGE0)1GAWOU[#XP"\.]^W7;>25ZD_+L_@IPAO\`Y0MK&BDLEKR--+=`
MV%T&<!F=;-L>81ZKJP2/XDQA*H,;W/IG'3Y*)&<4L"P$.7HA@%.R1:TC<N^I
M'RCZ<_45FL6E#Q..5-%4;T;&'E+;M<!>:XK@EULE#RP05C.KP0.2B*FJV]Q]
M[R_36P5U'PF,:H2EO0>A-!1"Z2)]BQ'5<?IURU>^)M`\0K,N>01^J>*U_O$M
M+L>M8"PLU&\CG9D2O<Q=D\N4D'ZD58LCN<_&0!D4O[].]-2YNCAB<\O9NH8U
M5^Z3:CN2I)#:L,XD<A"2V+GW3_`PF,2IPAL5>'>6W@.3D0V0I%CF:%F2.;4I
MC7HT^@+HN0ND-,>V(:I[5IEVSRI!UGUM62TVND8NQ<;I.W7_`')S>Y(\&=UN
M]6(UE5[$;`XKLKK++0DKM=#=$'),KCYT31H5412)H,0[2)^7*FH!"1G9'*3`
M_2!]31;R\AG#_D!2,>F\%K=RHGE3SLLVNGIW9$4MDE24<R/=/5M6\M=F@+TQ
M-!-G6Y,#)>A+1*7`P1%/+!&&'H250#XV?_B.8^*NGNP"^'$_"0GZ=D:ZE\:;
MU=PP<L3O0QUW*Z'FS6_*TD<6^]R<LTL(3JX:T(4<G2S1M7%&/JRO#2%99&7Y
M5RSN&3=<?@_2T*M><M/%N^>GA+^4+S4AON0F:WJ9)7>0$Q%W<S=MRN0-_HS'
MMKTYQYKD2=B6."()ZQ*K&)4-7.;DQR=D_'+F/P;CQKU[M4SR]GU@<6Y7&C=-
MJ@4(N-LKM]MRI)VP*"$H7DGW=)B,MKN>,:QP4M1Q+S"I$@1M"YB=1R.OJ4"T
M*O\`BV+7L%U%.GR+7?V]M\H(%O7?\N;&@?P`_BA_R:RDTP)18S!;T$(`[$(6
M_5H``ZV(8]_@`'6Q;U]O6NVO7O/)_<O4MY6V!Q3Z9O-NF)W(6!!SDZRM74U&
M*>C2:%HDKCQ)<+%NJL(M3SLX2MK5)`R6TT-;,DSG<S6.:-8R223*VYB=&B-,
M:1".8T4Z[K#,*VXBR=EXGV6[V%RJY57UPV)JUBL*$*CX9=='GNJ4X@N7O"-A
M8I)"I&H0$;*EJDN*`8$2@]P=D`TZ`[S)-U?S`NEIYQT=Q^OJ"N%:%<QN&CWR
M)C=3/$GA\]?./-YTB^Q!CNFG/?Y!TI#+-8F]1>?QR1M;X%2XIT,MBLM]QEXF
M&4M;/']L>:X.KU_W9G-G^Y^F_P#F4N;'\BC?%SW6R./P=\8:8C]Q6H)$C<'A
MULJQS:BI"NFYR])TW&SB=-,1L:9.4A<BTQJYG@\!KJ2NI[>2%PDSI"VMQ8W)
MVP?7=I=26"N1*OE!0/%J95\<JWMXD_$>Y[4>YS"6L!8Q'/"VJ+EJB*!G+2B"
M#:MSU#;!#,`)M"*CT%E2\):,_8HB6I7)&E<$*@I4B7)B%B140/1A"E*J*`>G
M/),UZAE'$F`-+'KU"`,(OMY]/?7K]>O5[?7[/[.<ZWK>N^M]];]>MZ]F]?+F
M!>37\2<U_%CO^E\>S/`?9O\`&'^F+*L8QC&,8QC&,8QC/S-_@Z_MA/\`G09J
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M3*YN6]4FVRX&2-^^"J7R#.56V"R^%CD$#F<+E292U``FVO%K0MC[3D;T8.+O
M*60W/*+6GG()<\WUQ0KOAU8BU!.XKI4OJVM+-8[>97=.N=J^>'`,^7S=B)6O
MDC6*UR)8B6+6Y*QH4WHFDFU>+1\B*1F/1A*K6N">.L;0Q$+W+:7;@N)9VY,V
MDK%^T"5"AVM4E)0'*MHD*))L\9FTZ1,3L!(.^QC&,8QC&,8QC&4&?TLS\07Z
M.\U#\3=:%:/4?#OV"ZB,_P!;[>K?;?%WB'K?KS`,ZZ9\,LM%U"*(FC@[!XL=
M1*<1J^YV7!7UJBUFUW=:)MKMDLIH9C7B+25H<(A:1]7PB?MK^!&J=(Q(4LTC
M3HU'-SZPO1>)^3O2Y..@7(T[C=.;8(GG,"[.)4SY$*EKA1TD,#"N,Z$MI0&5
M]7ME0R,UI+UJEO98T4^5Q8TJ1165G!5/FUX5+.CB3_FO@1Q`N&E'!',K]L04
M[=ZI363`.,*,554#3KK"JJMQ?5TYL5WL:"\<TI]2&VH_V/`CT25[C3LNTKKP
M)&I:2?*WQY&19L1Z,'%.%+Z@<V>9WZ:MI&3<QY;"37"85^H")YYV14<.OTQ]
M)3U4C*<TRME'L$,3$A0:BBG05&S'8>A:%<+#TCN/T5+X'[C-H<A&-?TWV.;,
M/%YW32.J5;@S);!`-/)CIP6Z4TO:YNJ4H!!;4PCVQK3(TQ>C2TNUIARLR[K<
MX'J+10Q&LWNQ)I.ZXD?+RMN8G(F:6L^1EYG,S4T.",*ZGH*#1^'PF'QF.UXI
MDD*@YSH<-K3(XM!8W(&AL]WY5-].#/DOGZ,9M-UH:8+QFF\YNG.::/MV\9IO
M/"@##![U[-;&,0A;U\N\F7SGXG1CG'Q+O#BQ+'Q9%D%MQ+W,:I:@1D.*N&31
M@>FN8UY-B&Q2,HAU'#I['8W)!-1BA(!T*;36[:Q)Z5Z25#:X.E'6'-%YFMU<
MJG*P8E>EW\'-\#KJ:*>G<;'7@:P%9Z"U'M;`C)'6ZYW3.CM/&4E]8W]V"%:A
MCR\MA=(^4K)4>&1M%]/:F>/_`"-DO)^'R:S'2Q);QTIKC&]H9*\QA9%5$!HM
M&D1PEU*;&R',[BFEQ@4QASXXE/(6AP.6*?1V!`4%(4ENSECPBI[F%%:MB-B+
M)=%F^H^2-8<J8RIK=9'6!<LM>I798]Q=7(!.T8D21V:5#BM-.?DNT9#@[Z`4
M$;J3X/%O4]R<Z/\`)62%0NLN*L]N)%`99S7Y"<VKP<#D/%ZWY65:EQPE:T)T
ML?J?D1$HG34CA!;Z[O*Y,:_O:B45\?Z*H8$,F/=!.D1FQP_X.6!%J7L%+REL
M(V8W1;%+E\87.30Z%U55Z>(<<(&_7"FIN/QZ!5NP**NA$])B-K+72R$D,+>:
MV'.@)R8HWBC3&W`4X'_H`G#'WE>\/W\<BO</X@?]#:\7OW@/IOQ;_A?^&_MY
M_P`%7E>__P!_7[_[[/1_1_<O_FWW$\O]\R3"SI?U,;R/H;E6TV_?,9N'CEQP
M(XL5RZ,SC4:IF#584YA2TN01^2T[(6]XD+L<<:L7/'A2%E*!!"V(6],6!/JW
M2NGH>IOOBB_/DWE,TJ[B;95[\H=R.SGEBDEIW9RCO=!+XLV.LEW&8K$HW'H+
M343G4O,C:1I:FXU8Y*:_8FIJ:([7RH^2WEU*-:#`.+8=>K6NHIT^M:_L:Y0P
M+6LV-`_@!_%#_DU@0=##L._7K?;OKU=MZ[^L.^^MZV$6NX1:[>L.]Z^WFENK
MND7"6NGZ,XNV+(9+JG>"G.)/S.X62*OWYE9W\`DEB3ZUZ_K^U&AZB+XG6IZC
M?+#DD)-TU&%(9[#TT4?!KF9Z]V&5NO&O^C!Q;K8SCZ9'II>A@N-/+NV>:==>
MZ4J@ZGSK8NCS/?JTR/15;)M.D%'Z2O\`<EG2Z;'IO]T#_%)5/E(O19&%\6WF
M8\_D?,:>G-J9CICCY)./''Z(ICPN#@,^UI;&IO<]KR52%.24U+7(J%PFO(/'
M4:A<:C86R82!]5[52QL9V"=.:X.KU_W9G-G^Y^F_^92YL?S5+S_KI]A:*;<H
M93U"^<?'*J(W'*XBB&G^*D/I.;+'Z>OLO,A3*GC,6F/'&[[#FT^M253""0^.
MQ6,F(B-O!)8@)1^ZJA0ABWP3F4U?>54+;Y'9_6MF234"M-0%LZ@/&^JZ9H<@
M\I+%`!4I'^!494#@ZV*7HPP$5:5;G(6X3.*7K`MB1004X;WF6*Z3!CK^</->
M1I),Y\T1"2N<(B"]W3,"&5R]`RK54:C2U^6B"D9$CZ]%(6M4[JA:3MJ=48L.
M%H!.]YY[XMS2Y'1FO(C2<_GO)2,\R;;YN\1>+EU0SD,T<8S%_&J-7BR2VPY1
M/>.\IX[5RS5G9-<S^`UM9C/3<OD#G/G]BEK>4BF!")^ASRVN&TG@A=<ZLDSE
MU5-@O(I:[\2.8$ZXZ,T[5!2:?)K!]5K4MV0-QE8F]*WH%$NC\7N5O@DB<DC:
MA`^+HEM^4%"<71<:9DKE38,8;:_DL(5G/`9"Z$Q,U&41%I4K:]@63-D*(VHD
M:-D41M#O8TYNC`KG9,,C][VH"4$\D1DK0^S?XP_TQ95C&,8QC&,8QC&,9^9O
M\'7]L)_SH,\[73@Y`\X8;PTJ)@KCAA3MAP1O6VX3%YM(>;#=6KQ(VDJ^+4)*
M<W"$J>/4J''5!II1P!MVI&\!(\O6MK1F>,!<XM<J>HN+7?73]H3>OEUU$F7>
MORZXM9S\:?J,?-^4+_.(LWU6L?&GZC'S?E"_SB+-]5K'QI^HQ\WY0O\`.(LW
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M/4O[7S,I%PB[$8UE\96(2=%)9$G;6!Q?MKC`1A`XJ)$8VO`&P34LV*"Y3=1@
M`AAWT^Z%[A&,.^W419NW?0MZWV_ZK6_5WUZO7[,X^-/U&/F_*%_G$6;ZK6/C
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MH9I>@H=.[?L[Q;"%2$?@"+?Y[J6!_P#1T<^G"O\`8S(2]5MZ6Q_@5>[NBDTP
MAWH0:TVX22N*P46]:#6RGW!7Z=[.J:%$,$IT9;(VHU636$I/CCRAK^>F1V=N
M*4M''3E::$7!N<DOO*:'-9_)KK&6@IU";4,2PKGQQ),X_4YO25-%PJG-#)]<
M1^-@'VPV;1A!+0RF2"5#TVN,D<`1Q+Y1KRFW<61%7N;P&81&-S^4U7()''75
MG9;'A*:+K9;!W1<E,)0R>/(YM'I7$5CJSJ!%K$B61QMZ9E`R_)7MRD@8@9$A
M]X(P^=PI4FM2P9C8MT*)Q3%I)>03BTP9EFL?L?CP]>^*F7N+1F/1EO@#$S0I
MX4/IP(J5'5#6^IIC.$LA,<]2IP-UFSCGQWB/'**2QFCZUPD$GLVSIQ==MSIY
M+2$/5B6Q8JXA7)I4XHFTE,U-9!2)`RQB.,;6F*01Z(1N.L*<2C3<)8I_?DUK
M_P""<U_%COV]_P#U?'LSP'V;_&'^F+*L8QC&,8QC&,8QC/S-_@Z_MA/^=!FC
M/@:-65TQJ\4-[FZ,K@CK/DHXMSNR+=MSPUN+7<5_.;>O;5VBC])E:5:C(.*,
M$0<#?@V6:484,8!1:IWJ332J>'_$QWL*L[?Y.6Y/>E8MZCEB3Y19%6QCWQ,M
M:1VL'>[T)8G<A#MM>41MC`<(BQI(TC95*4A''6XT6QN3TTYT8>HU+7VV^2[0
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M6)C:;C7*6MB;I$LI"PD,J0Q>.!?'9<HC]\-\4K1`\I6*U0*HQD^4<K[6X[\A
MY)QCW5]L\D8G2G`MGY*.L_%*8C(N1EORQ=;KQ5W99'BFV'QEO/$OC+H!\)3%
M-+,T`<54F**:XM%TS0X_C%NJ)%YDZQ6+1BE'^5RN3\V91P1+%#+;K:25]\*[
M1QZ-Y)QB4,5C;3M>I;6LX@@0ID<B;8FE4QYU(<0NK>H*(:POMN1+JR,,C:8<
M]+^,=KQ]%/:GYH3.,`.L.IG-8OLS@$Z+&CDC3IA:9S3)$);<M;W`NO[67KT\
M7G`4"DU0PQE.<VG.-^T/U'%-Y/),5UQ<L^N9?*^+E0\T*@9YQ9=1E--F\;K2
M<VUA=9RLF32Y+V&LG6KGAR(%.X=,O&]EL"MH?D.M[<CVULL*9]6%DAG''7*9
M?QEM!/4!T*O&TV27/MBUK&8U8%74B>T%E/\`53^X`-%.95=K>JD,PX\UX:S1
MQTLFLX3(+-/>([$U3$J<\T<Y>1LZKJ%<28K2[N"*2[FURSH'C3'[.7M;4XJ*
MJAMI,,FLF9SYL8GXAQ8EL]*KB$/#!`$;XB=61OG4@:G-S;W8AH"A67W,VF9\
M9&R17:R37DE?E?P^JGA`[4'()@VV3)I!.'.85^5&[$9)Q,4+:YQM.PLA,L%9
M)S[)]P6.0]0^SYOCJ4UD7H%L9VWJIMLK.@4=K/C7-[8L"P>67(;ABS,D&N*H
M1PA3;]`U(INO;JU6E(3F%`^UA84#*+=H].DT72^XQ85I+TR#<"FIN?;KI_JB
M59=SKQGCD5@3W&IAR0;'Q0WP:UYW"ZRE[-(8->$DX_6]`H>A>0JFF\)[2$WA
M\B>K0B=>OA+X@KG3!-HVWR4F1IVU$9>HG#+:8JZCD?@UF05[Y"QKJ*,$+DA4
MBB)BV"S7@.Y2*"V(:L4-QAYF]N[\B(?:XD+00N*$G"5[NMK:K+\DR/\`Q]ZE
M"Z'\/.'YD@KR[^5=S_$DX2W9R!^#M`_S*U3R.0\83HT\L:&-'%'[=H3A<8P3
M.Q)%'%$AA2I5&VI48RNSU(E9+`#8-17+:)W]:UV5A$V5,D/HV22B(3`Q7.XV
M;.V*21>8CB);=8%+C2M]@UDGG"0DZ?58_/);O&I_70T;XWO*1U4FL"26>,8Q
MC*#/Z69^(+]'>0:X8_QA=1O_`-1RT/\`5OXG9.C(_P#(N_(U0<3CRUSD5?L4
MPL:8ME;5<19DM:(7#ELQ=4ZIS6.\G>G=:@+)AM?Q1L?;`FP$)ICLN88\9'F0
MDV0R%E+,TU0?EI?,@Z.E%<A&[DJ\RZZBN7%35?8EJL8X&M<YPR2+J;(Z)D$;
MD*=&VOC=%4;[3L@;0$-$9,9W9H8E<>);7?W%,+-=-I_4+LJT:<XWS6;U"1(B
MG1HLJGFJ<OT+CQDLFM>4*_W7$(Y?=G0N-$-[N>YR>NZC7RB0M`R69Y,9!)#I
M2!J7"C_D[QAP4OA=:EF<\:Q:K$?;EJ;CGR-@\.IRUY,N='Q_<&&RJ'@UM2FM
M7*7N[6V.,Z*J*7/ZQKCTO==+GY?$)+'6]Y=GG;2A>'#8KD$>HQ_V?8/_`':'
M3Q_UY:#R>1W].._MQO\`G!9^>,B+S<.Y0:HQ2AXDP]]F-FNTQB*%[30JV*UI
MJSFRM"UBAQG"ZH9C<$9EU;%VBN(0-\=BR67,QC1L#XYJC%*%2F2KTD";BNV]
MWSB3QEMN@%_-2:<>FMALJ:\KK;B=B4+!.H5"VNNUCI'7MK=JXL:J7*&60[UI
M)6NS2[;A-;,3#(7(=;Q]#`5CXF\9$JR7RJL.2UO:'`R\(ERCY$L-067>=#06
M5F>])+)^(SI25D1@:%%J[A-4$T^L%I7_`#1^@+15]J25[8DD=FTL;$(TD7C[
M>J3+]LNPC!O8#`B"8#>P&!%KPB"8#>PC"(/;7A$$>MA%KMKMO6]=O5C&06Y^
M?U"<9?\`U&^GG_K)QG)S@_@!_%#_`)-95FLKJ+SKD37R.O)?"&Z_F?B_!6F=
MSWE3:?$RS:;C?(F`L;*G;`M3RU5K;E?3LVTZOB$;#,IQ8K!7H6ZPE/N>SJ&'
M3H!A6,+[+Z_)"[-_&.[)A7TT<F!\9^/5FSB$SYD)97)V1+V.J7V81:4-Y4F9
M7=D5J51B!O<0B>(^K3F@4C,,;BS=A`3U7#N926QN(7$ZQ)H[JI!,K`XP<>IU
M+WY;L&UKY*YC3T+DDD>5FR@%E[5.CVYKEZC9999?G*!^`L`/"'4C,@7U2?\`
MNX^:_P#<_P`H_P#W1@S<YD(.8;=4=05Y8G*>72:WJX50./LJR1RFF9/(-/KJ
MVM[HE9VAO'5QQ,J@-H/.SWDM"P1YXK28R)Y5G)V&-H5KHM0H#HA1_J8QR$K*
MG5.U@//(*NK.1<AEI2\WCM8?'SD'73)QDA+?8ULR:SZTLOWDZ<"(W$WR-+]L
MC575>3N2HY.PN$"@4N1JQ##N+9W=L?VEL?65<F<V=Y;T3JU.*,T)R1>VN*8I
M:@7)3@]PFIE:0\E008'U#*-`/7JWG8=]>O\`!ZM^K?\`9_E_D[^OU>W.>_?_
M`/YO7^7,"\FOXDYK^+'?]+X]F>`^S?XP_P!,658QC&,8QC&,8QC&?F;_``=?
MVPG_`#H,TE].R/\`OKZ<U.1@3@YLY,EBEZQU0[,Y3>8Z-Z5\ON\&I:I;M.[:
M[M6EH4:L_28:]L7IBS!A-&E-\`=9^"+ICTNBA-?5^&P+Q4QVL>#MG=/.*A5.
M]="<2^-]LM\3:I0A<EQ-5D>Z$[(;H/%TK),]D)Q(`MHS%+0X'KUIIW7R;I;4
MG(6V3I$MD<@HVX2N*<-HZY.K-)X$H(&\\#G]"^<>)XJB[[5KK%'F3M)3>0QR
MUH?&IPKF8-(C1N$#)=ME.9/PM72QJV*R"+3ROKXY5UQ:\7L;DQ-/A@B,X@(+
M`D<3Y=6)JU[QIJ6FOE4/47?:\?+$`3,XZX&Q@JP(5*B"G^-3%"M`#1<KJPXO
MU]4%O6W<<(<+"2NMU1^H&*:1)UE`GR#B/I""):RA$F;DCDTG2H$KW!6]O87Q
MT=9@[I7;T03L)M(?%K@Y*K*L+A36MN1/E5#+5D%@6(T<NH^VPZ>BE>X2N5PJ
M#L+:>AB\)J,1,#3)H;&X@X*U\TBI2]+(W)HLUR<;+]U%,O5[<2\1V;TRJFN&
M/O;38UO\G90]2GB"JX43&=+Y_$-3&<U,7-#[`C3W-UJ:L$Z"0V/$94J5+TLF
M"WMS?+B%BU#9+!-$RU4$WLHQTXZWCE@H+04VY?TGF:#ETW<WMN$B<ZQ$D67P
MAX]).,YZU4U,U3LZ`B'.%;DJ@;AK*4RMS0Y+20Q\UJ:69H;$V-YMTVH+#*EU
M\&#A<\\F]2P'J"BIZ'N,BJ]&1)IQS_0R5RM1ODKBX1*&-HFQ;-'M.KCIQLDC
M">',Y)Y`ESMX`%'V[4O3*:);Q/KBNN1LTNTBSW+AGQMXEV2-ID-8-2Z)U)4:
M5@D,WX]QY=#86YQ1YK2R;`;5!5J/JH+U*;:@J)BBCO)4;`2K;E62KMZ8M>7\
M<Z*I_?7)L2I\I:]>.SKMA>*@8FS5*\@()7\#EU?QN,MU*IXO`6ML2UG%W-E7
MP-FCK^H-&_L$A>'F(/ZM@!**U.,-;W32L>I"P_?:Z-$.'7#Q"9TV//O=M.#6
M'46VY36UO0F8,S<F+C%FQ%V;"'=K>6]HTT[,.<&=>PKHPYN+$JL.W>'3?R`H
MZQZ/NVZKIGJ.QXDBB"B:$$UE")!&D[?(XQ+RGEACL+KAIKE8_+Y)#V!9(SY7
M#Y(TR-K3JHFI94L3='-E5PML3I_V##+^XN2NC95>+ZG,Y[7]S5Y!W5('FA'1
M[KR3VUQ'DU`'*8Q$9%'(VVR!!()2JC:Y1%6Z"21'&XZ)]TT',R-KCS,7),?3
M?I;<6JFNPR>T1U=5DCKV?EU\Y*H8^HY7;=<7@_\`(Q!=;G+GB#*I]%K<E-LR
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M]S,_O8_]G*#`#\LS][,_@"_^6/\`\N__`+<@WPQ+,U874:^P'_WCEH>P`M]O
M^K?Q.]6^VM^'?X-]M^S?;MO63G\`_N9G]['_`+.6E+Z\@5AHD398E>0>Q&EN
M<"W5"T6#!XW.&I(XE@V5I<D;I0TNJ5&MV0(:82Y&6G6Z3&&D`4A+&+6X9I>F
M]Q_9N)S'PTAYDZ@52,-JL5RIUL0,A#=-5DXC-\$<C&)8YNRBOEC$L3H+&;V,
MK0!1<*P^'1YEB!ZX;<E$89*]U@4K6S"33-LN.TX\KD$$8(<@CZ(N%N4(A[TS
M21[D"^THK%7R'+TY5FR<EY+CSVY/2QYC`6%C8"&^))5")0>L_.HJ<@]'P[<)
MKYJ<4K>KD,EFDC>'QR7R.83F?39V.?IM8<^ECGXW66SF8/)YB]_D#B/0S=`1
MMC<F;&%J9VAOR=X!_<S/[V/_`&<@CU%P#^+["/L!Z_ZZ'3R]H!:_\<M!_;WK
M7KW[-:]N]]M:UO>]:R>1P!^<=^]F?TXW_P"6/[H+_P"W/S\`_N9G]['_`+./
M`/[F9_>Q_P"SF)[6K25V*3#]12[[AHMPB<IU(E+G4P:[/%,6\;2O:5,0F;39
M]=V*Q.<='Z:!X0&(FUM>V:1-S8[H'37HQB4_&3WQ61+4\/C<8N2^*YJQAA,I
M@<OI^&OT/'$;;;ID^*9#))!/I#*(!([*1V"^N#D_@D%@P.;0^2/B&42).I4D
MJ5Q"]'V$AXR-<PD"C4NL.Q9%4`7RHI(P\;E:"NT=/1!UI(YA<H.DCQK3`&^Q
MMPX$HBL9FCM`GF<NT<<)0PMANBD[`4HCBN2PM&B$(8PG#&(0A#&(!@A#&+>Q
M"$(6];V(0A;V(0M[WO>][WO??><>`?W,S^]C_P!G'@']S,_O8_\`9R"_/PLS
M<$XS?8#U_P#F-]//V@%K_P`2<9]6N^M=][^UK7KWOU:UO>3F``?@#^]F?P0_
M_+'\FO\`[<J\`_N9G]['_LY'^T:#76K*B')TNJ[H]72^$+X%/:(BKA!T56V6
MT.+DH6K%D@4N=?NUDQUY<6]6IB;\Y5]/XB<_PH\R.K=%ZWZ?KN7ZE2I(UWG'
MG6?V8=$[OAJ.!!AP5<9#%JBC(:[7UN^HJ::MQ$08WN7MCDJ>I%[X398GW)-)
M5C0E:6]&2V9WE,54TT?4584O&G.2/D8J2OX?6<6<Y6-L5R4^*P2/M\6C)3VM
M8V2/-:]Q1,+4W(5#@G9F\2\2;TQ22)6<>:9DOP#^YF?WL?\`LY`OJD@'KIQ\
MU][`/6M<?Y3WWL`M:U_SHP>W>]=M9N:R(W.F85O`.,-BS"T)E:=?L3.?#"V&
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M<UC:UGUA:T`M*][,Y-.D>LN)OX=2#WJWK;;V^36QZT>4;@SR*MGUU&TGAB#P
MV(%<;C;HC<6=+D?E3+UJ*OY+%RX--'!(N)B9ALP0I6`<3;=J9FR%B+<%"F1)
M7H)B71(1J@I&)7H):@@10COWW14K0^S?XP_TQ95C&,8QC&,8QC&,9^9O\'7]
ML)_SH,TC=--CCFN!E#.KHG2E%EMMRKW!>L<%*)*F3)>0UU*%:Q6H&N3(T:1*
MF),4*E)PB4R8@HT\\PHDL8@Y"C_*KC/*$<"?F-NM!=!+9E;)"ZCM8FGK>,JB
MV'V3#-!&-U]-B&X],[,DIT0H,B,K<D3)%)F23Y\.>I`2I;QK<J4%8E.\EZ6K
MGD!4Z5V<*SM9C/D4,<I`U2&,.ZML3O#HQ&[<6%Q7;6M"XM>SK`FMJS85J8OR
MMJB2#3!$@S$.&,I8Q%F,@RC`Z"(99ACN68`(]=P"&`:P(@A'KU@V+6M"UZP[
MWK*=P]A#W\3/V[;UK?<]UUVV+?8.M]UOJV+?J#K?;8M^K7?><&P]D)$86-A4
MB4%@&/:,H+X<O,\!0CO+(0EJ1*CSS`!_>2"BA&GBV`!01"&'6\!U!<M)WM1#
M1R-K%EG$BKA^33)4T)BX/.`6"N#`YE)8'(T:>M2354N->4TCB+XE3Q\I`8_*
MP)BPEMNEIP4(;$KSEGQ5MFMJ,MJME4UF<&Y(S=_KVG5[-5MOC=Y+)HHIDJ64
M`<XFJ9TLKA;-&C8;*??)))JS1]AC8&)8)_<&S9S<%=*IK8H>^@6&,:=$]%-[
MH]L:\QI<%[D6B>8TY'LTC:E0T:\X*=Q8'=*I:WI&;L"AK<DYZ%<60J),*#]P
M8<Q;`(P+-L10`;,$8$YV$6`L.PA$8(85FP!+"(00C'O>@A$,.A;UL0=;JW#&
M71FRML9FC=>#N5LQXT;K1GA\O>R]J_'K1GC!Y>]A[#\8/#O?B#WXU#606QZT
MRBWLO>PF:T:[;V6+6]ZV$S7IG<`M;UO6PCUH6MZWK>M;UC<-8PEZ.$RB"2(8
MBPG"-=@DB,!W\983=K-%B,!X1>(&A;&'P[\6M=M]L%OMP\?(Q?\`7W&"1.AK
M+=5KP6:V/6<9<FB9)VR<Q6N1(]3HV-S`0-Q-<]Q8M<F5ND6$\$R4+<(UT3-:
MEN2JE1'P.]Y\=FB]G+C-Z>YO=ZLU).'(EYKN*1F>RET9ZC0NZB/II&ZKF=.H
M9$*^1/Z83'#XH>YAE<L<CT1;(S*B%J=2/,D4;XU+XK'I>ABDC9T,CCK%)BVF
M6LTFBLJ8DD@;$CHE;)A&'904Z1.2("U@$+['G@HAQ97@E8U+2PJTIH=7!J&,
MF_!K3(/>S1Z+*UHQWWLTP0=#"`K6EF_,&(`@C"`'B$((@BUK8=ZWO@,-9!",
M`%E&(9.A;.+":[B,)T`6@CV<#2S8BM`%O01[,T'0!;T$786]:S\CHFQ$)S56
MV)4<447LSPI"WY:>=OP#&60D3)%!QZQ6I\L1:)&E+-4K3_"G2E&G""#>)*#L
M.GN2U+UU?]4)7=PK2U6,^0PUQD+5(8N[JFQ,\NC$;[I,+DNVN9UQ:]G6!-;5
MNPKDQ>BMJR4YHQ$@S$*%LP3-DB8S0G:T'>R1#>`G:T/>M`WLH2O1FM#V(.@;
MV'6A[$'0=[V+7>@4.8P%Z-&S;"3L8BM'".=@D[-!W\96C1+-%[-!VWL9>A>,
M.M;WL.M:W@R',1(O`<S;)'VUOP''.Q0]:WZ];V`Q8$6M;UZ];[=MZ]>LH]Z<
M=_K67_A;E_OV4F12/:`/>FPOOH`MZ_Y4Y>W6M_\`]=D.^)^BY-.>>21[*`M3
MPSGG8D+C9>]FI_<V-(*$XT/:1LT-&8F,5Z*<Y"[J?3'$:QQ'M7LDU8-.0E)(
MF-[TX[_6LO\`PMR_W[/R41N*)"#U:U*A0HTB=0K6+ESFM1H4*)(08J6+ERM0
MXEIT:%$E).5K5B@PM.D2$G*3S"R2AC#$"-\R.(4TJ"IKQA#\^S>#7K\(AU1)
MXA"K!?9O/6BI%<A36;)F*`)B]2HR*PA/&'-W?7M0@(*"T'L.T!*YXE,:977.
M[K-:<;:J274C.-E]=.T;CTLC#O7+;,+&<)RSS`EN.ANX!'(:!WD4T<)CIW:B
MXRU,38J7.1SBG#LE.6%2:GMWCU;M$<HJV*M6G3'9SC`93,H(\(95')O`)I#Y
M]7CZHC,[@<Z@LQ+:9/$)C$GU,8WO;&[H"CB!"3J"#%"-4G4&YO\`>G'?ZUE_
MX6Y?[]D-.=_@AE'P]XC98&UQ5<LN#$9/4:V:K\QDF7,2E(K(T7E.!BM.'3BP
MN[@@VH`4%8DTHVI;U*1:40J*F>;$H[HTW6FLOMHTS6O^5N7JUH8M:U__`!WR
M:S\_>G'?ZUE_X6Y?[]CWIQW^M9?^%N7^_98%GR&L:?A3I/YL@>@L+4I:$'HD
M4C4^L&6O+N_NJ1D8H_$X'!$DBFDRDCRZ+2$K9'HNQ.KNK_?U!:3:5&K/(QFZ
M\@..D>B%(3:4;F$1:>1=DPJHJG;YA6-QQ.5N]AV&\JF*(1Z20Z01]OD=<FNR
MY$H$!58R"*I`)-$GZ-&)8B)4=U8EN4K6$[@U:R%DL9XF-@Z0FLS=7517;:R)
MF0.C^",-;W83_7,;DL>JV.N;YI8B;I#8KI&6A<%EDBM*K-11I]4(,Y;B4>UO
M>O<PK?AWL.]Z5N6];WK>];WK>EW86M]O4+7?6]=MZWO6];SCWIQW^M9?^%N7
M^_8]Z<=_K67_`(6Y?[]D..;&BXC#./BJ/E`;SWWGEP:A;H9K9JKTJ-3&_H^R
M2-MV%>8K+)TXMAYJ;:M,`AQ2>+SF]8D4!"=J8H8G'O"'_FLO^#K_`/FG+Y/_
M`.^RKWIQW^M9?^%N7^_9A.ZK6I>@4,=6SYFL%S/EB]S0,#!55471>,P7:9$:
M=<]NHX93T=FLF0QMD*6MA+Q*7%L21UM<'IA:U;D4XOC6E57W.'*LZW@<ILR:
MEG,D,A45=)I*'+3?,'9:U1UD:S7EU5BCS`4[2-:I0MY!QIS6V-*US\91A(4@
MC"QA#77ZZMK1@,%LZ$E^ZL+LB%Q2P8<ZFZ?&\UTB<V8&Z41IR,0+512Q"->R
M.J%6)&L**5)1';(4E%GEF`#=WO3CO]:R_P#"W+_?L@?U1(PPD=.CFF>4W``:
M50,H&6/2EP%L(O=-AUK>@C6#!OU;WZA!%K\&;NLUR=12=U872TUI_D!;\YXD
MUK:#;'&]JY8Q70R6:$N[?*6M[7M;K/3X\\1FGI$>6T$(V&0S_;4R.I#L8IBC
M^*5,QB!#"/C'8O$&)WM'%]$]7#D3U&;`.C$P9&?CBEY&U9RH85ZA\]RDZ:4/
M!5-5XR(:X-CBAN]%!/[)E#3"VAO>G@;NI*-4I5A.^]*)0:E3C6$EIU1B<D2H
M@A0)222H$6'9Y)*K9*8:@HHW8RRS]ITXC@!T9LDKQ>`,5)EPMI*6&V^YMXK.
MKF5WI:E>W38\XJ.YK2K&9/-BU?"X?7,1=R7N)RI`-O:R(-!8U&7F()2`0V4-
MR(W<E8'54M6*3L_U_7\5K&,(XC#T!R%I2J7%P-&M<G-[=W5X>G!2[OL@D$@>
MUC@^R.1O[PM6.[]('QP7N[PYJU"U>L//-$+,<\FM:^!.:^K_`/3'?]+X]F>`
M^S?XP_TQ95C&,8QC&,8QC&,9^9O\'7]L)_SH,\X-3TY.>0_0]EE"5DZ(F:Q;
MGXT<NJR@SBYN!C0UE2F8VS?;.SI71V*UL34UNZE1IC<W/81E-Z!S4K%!9B8D
MXL4R.,=]UY*ZJI2''UI/X5.(/%:JCL^H^753-(\]4<]U6S1=O?RI,M>8T3#@
M,5>N,?\`28C*8S(7YNFZ="P+ZR4R(QR0B+\^O'N%<RJ4X[TJ@X_Q#DRPVR^=
M)'EBV2.#.S7<B9I3<@8/RZ@,EJR(MD6F:9/`ZUNTZC7.]M4^@2)X@]R$:XG9
M)[F<<SJC9Q%1F7M5'R'EAQ4E7.&Z6&K^5%)\AF_C;.(3:%$I+$@@(\"KN3G'
MZI*FL92SV$X-3K&I:FL!Q9YMZ?7*7D=7'NM`"P%>^\\[IVF"=0FM.*_+"##)
MMJ77%P\)E\3J.8,$JFLOE')N*7A9D"OF;/U?&2F6.3Y/)G2W&5VD7'.M3'AY
M<'$^PF];[V%[;*/)-2?7'5@(K*./,I;Y?S+LCISV]RAM=ZN@J75%?M<%UU)G
M*AV9+2#!$JU2-?QFXUQ?5W2&1CDR)U1%0)#R!(9E2$Q)"$A^U<M^E6!11G3&
MJ,%CQ:UH=NM3>1J][CDIKJSEMKE,X>2]TR=A.*@BIA/LR7R"01AW87-E`A:7
M)YERQT3FICU:Q4>H#'RA6F5<7^94>Y"/-533X`.I>.3R%RKV(5W9\J>.`MN/
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M,3)46Y-#P]D0UW)EYL5=HDB-4+`7`SM=QJJ)H+CM8[MS.C`GU^Y$2=QY/'G\
MJE=I5=P`B/(:?.''J`,BN#)UI[MS9OJM-Q**1AUL-&_SVK*>(53V7E)Y>B@S
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M(E"SB_TU91PWDE8-%PMY>Y]`*U83.8\-LR0)F517T(M1TNA`Y(.01_*'3=[X
MJ'6F-S2Y(2R=F*^M@<5MR*UONV'D'*^2,*SJK7S77*U+*)3RAD#\FZ<0[[O%
M_IITAE=29:>]J:C)>72EI'*YS6L>63AVHXR1,[W)5,$(?V1'T]BJ^4L&K-O<
M6HRU;3BL9Y%<PI+Q=HV=)>239+KFXICL"J04HPQ.[Z\-536M.2<85:G1'$PO
MD*URF+SZAGQ4R3-J:VHDY\95:IY\]<PI_(:RM'DRZW)3W7+LA@D;`Y69>DOJ
M&*]/M)5L+DE]1*5QY^='6G"X.A-=-&0].,+M,&BT#(/&(#[F(1(V\F-G'J%<
MS*4XZTF@H&(<FF&VWOI(<KVN2P9V;+C3-2;D%!^7,!DM6Q%MB\S3)X'6MW'T
M:YWOJGT"1-$'N1#7$[)/<SCV=4;)Y77Z6=//&%QJ^T>H?(^.%V\_H^9:\9=8
MGRBXX1VOJG=^(MV1:TV2.QU![EV]!:P66F?4B&P)'+'%!$F&[%+DNJ)\93SY
MBZAO2%-%G'7)=*"P;(YV5G?5!R;F0U-C75-26-*X#,N(CA`9.V\;ID5:DH&]
M5C<A#!!B:V655%61:??(>3\>=$9I0W!WFCRX3SZ:3G8QU367'[%CR`LV(6WI
MGC5H14^[T=8WHP*JTKYQW8M<0;D2-5:54EIG`U5&+*K98[R*,,5P-<Z51.1.
M:9R<`I=C.4&?TLS\07Z.\@UPQ_C"ZC?_`*CEH?ZM_$[)T9%GEA`;YLN(0B*4
M@BI-[0G62P.MN1&\Y7/H5%YW7K$4H=4,+]\%?02Q'`MJ=ITFBZR<L[E']-<I
MA34ZQ-:N):WUV2K-)W`B!7_QQ;N!_([D[4[FQQ:LJAZH]+2&.1.,VA*Y1!Y/
M<O+N.7E5[G)(0N@[=*&XRYB8#/8/&U:-C6-2Y"X5?Y[N6NL!`SH]@_"J3E<*
M."W':A.1".S8E9-*<:*G>+1/BE0VC8T>@BBX['E3$S1!ODL(A<T9WY\K1Y<]
M1Z<,;.F>BH#&F,N8RE"@@!Z=>/,/`"`V!6E?W;%I7(Y!.H*9RDN*6T794]BK
M+$;7L^L["W')V^3JU$K#&H:CD,B7W%(;1:8_/543CKQ.H"RQ1]7M8$AK4I53
MOR"/48_[/L'_`+M#IX_Z\M!Y/([^G'?VXW_."S\\9"SG#&.+$[KZOH1RV8+2
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MZWO648R"W/S^H3C+_P"HWT\_]9.,Y.<'\`/XH?\`)K*LU8]0&OJ>LJ815&UC
MY%0OGC#:AG;]POMZCFGD$W!8)8YNQ6T48<9;#TPN.\BCKI.V",++=K*]S]LJ
M^L`JG=WTE80EN".3URS4<JHCEM7(&J5K;%@O'&61^5>Y=>39-%Y)-[/X]R9<
MU(:D>#&722R253NLTW&HX2)X5QIR7-L<?"$3P;I'JO@@D<&W@_PV97AI>V!]
MC?%+CK$Y$P25B>8S(8_)HE3T,C,E87R/R%`V/30[,K\U.+6X(7!`G.)5)#=!
M",K99HY6Y`OJD_\`=Q\U_P"Y_E'_`.Z,&;G,Q->=UU%QUJJ87->TW8*ZJN$(
M$ZN62V2F'`:T!#DXHV1M1>CI4ZQ<Z.+X\N;<Q,C"VH5[J_O3B@9FIO7.*U,E
M-AQQGZBG!.]+.;J-XV/CVMF3\RRF9'-17'6YJ?9"FN(ELQ;RXN#O8M6UXPJE
MP3'II2)VY(J<'Q1LT9P$.D*!<I2[(,ZTQX:B@N@S7)`6!D#XW@9BU,`+4#2,
M#AL;D(1NM(`:0&`6[&KV2'20056]^0+1F_H0KD3FB2.+<K3+V]>F)6(5R,\I
M4C6)%)83DZI*J(&80I3'E#`:0>0882<6()A8Q`%H6\'\FOXDYK^+'?\`2^/9
MG@/LW^,/],658QC&,8QC&,8QC&4&:V(.M:UWWXR]_P`@3`BWOU_)K6]_Y/7F
M@WB:Z\O.-?'ROZ+E/3>Y4RU\KA5936KD\)LCA&9$Y`G>KDL>8-#NP#DO*Z/2
M#;<O8Y*V*"P/+"SN1!@S4RMO3G$B\4C]\C>48BRR1=,3FP(DG>MDDBLO@8(H
MG>N_;9)>^9.P%;UWWVV6$._7OY<I%R*Y0BUL(NF#S5$$7J$$5D\"A!WK7;MK
M>A<R-ZWV[:[=]?:U\F!\BN4)@]F&=,+FL8;OMW-,LG@68;OPAT$/<P?,@0]^
M$.M!#W%Z@ZT'78.M:RCXP_)W>M:WTON:6]!_@ZW8W`CL'U^+['7QQ_L?LM[%
M]CV^RWL7MWO>?K\8[E)H[:C73%YLZ4;UO0E'PF<#?2!:$#RQ:$?\<GS1:$7]
M@+6Q[T('V&^X?5E'QB>3_B\?]#`YJ>/_`,_PC\"?'[.W\/XX_B]GJ]OL]7LS
MG7(OE#K>]ZZ87-;6Q;[BWJR>!6MBWV[=Q;US([BWV]7???MKU>S`.1?*$OOY
M?3"YK%^(.@"\%D\"P>(`1:&$&_#S(UW``>@C`'?<(1A",.M"UK>N=\C.46]]
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MZ&%S6\!OA\T'PD\"_`=X-]R_-#\<CPF^7OUE^9H7@WZP=MX^,7RA\8#/Z&%S
M6\PL6A%F:LG@7HPL6M^+0BQZYD>(L6A?9:$#>MZWZ^_?*@\C>48=F[UTP^:_
M[_W](UNRN!F]*0BWW,`JU\<G_E(#=]_-`=XPF:WOQZWWWF&*?<+7HD5GCKCI
M9\]T([DM:17?8ID@OSAG,S'^TI8C:VZ0RP!DIYM.8VE0Y-[&RH1-S2)&SI$C
M4A);V](`H?F9E%R*Y0BUL(NF#S5$$7J$$5D\"A!WK7;MK>A<R-ZWV[:[=]?:
MU\F5"Y&\HQ"$,?3$YL#&/6M#,'9?`P1@]!#X`Z&,7,G8AZ"#[`.A;WX0?8Z[
M!]64_&*Y0>`)?]#!YK>6`>S0%_"3P*\L!HM=A&@+^.1X`&BUK6A&!#H>]:UK
M8MZU@SD5RA.'LP[IA<UCC!:UH1AUD\"C3!:#KPAT(PSF0(>]!#K00ZV+>@ZU
MK6NVLH^,-R<^:]YH_P",7@/]<;*1\A>3H@"#KI>\T>X@[UKO8O`CMWWK>O7_
M`-<;(X\?Y-S`JF4\L'R0=,KENL27MRQF5[1(MHLS@F<H;HE(:EI&!HFY_"KY
M<I"TS^6[UJ^*5*9`8O0!;U;6:6X&'G*4Z62'QAN3GS7O-'_&+P'^N-CXPW)S
MYKWFC_C%X#_7&RL'(OE"6/1A?3"YK%F:T(.C"[)X%EF:",.P##Y@.9&A^$0-
M[`(/B["#O8=ZV'U9R7R,Y1$[!LGIA\UR=E[V(O9-E<"RMEBWK0=B+V7S(#L`
MMAUH.Q!["V'6@[WO6M:R@7(CD\(0ABZ7W-,0QBV(8Q6-P($(8M^O8A"%S'V(
M0M[]>Q"WO>]^O>]YQ\8;DY\U[S1_QB\!_KC9&OE=(^85ZU='(3$^F7RW;W5H
MY`\5[74J'^S."B9`./4=R/K*X)4C),0\N7`\3NX1N%NB%A(&G`D4/)Z$A<L0
M(S#EA,ES.1')P1A@]=+WFEV&8,>N]B<!^_80]BUW_P"N-OU]M^OU[]?V\H^,
M-R<^:]YH_P",7@/]<;'QAN3GS7O-'_&+P'^N-GZ%\C.4)(MB)Z87-8D6PB!L
M1-D\"RA"`+^$`0B^9`=[`+6M:$#>]A%K7V6MY2#D3R?+_I?2_P":A?JUK][L
M?@2#U:]FM^'F/KOK7VM?:^UG/QB^4.RO(WTPN:VR-#\W1&[)X%[(T;V[>9HG
MXY'EZ,[>KS-!\?;U=^V4?&&Y.?->\T?\8O`?ZXV/C#<G/FO>:/\`C%X#_7&Q
M\8;DY\U[S1_QB\!_KC9&[D[)>8-TQJGV:+],KEN@55_RQXL7L\&/EF<%$Y"F
M)4?;C//I6WMPD7+E<,U_<&AO.3,*90!.@4.`BRER]`1L2@,D`\A>3N@ZUOI>
M\T?5K6OXQ>`_VM?W8V<_&&Y.?->\T?\`&+P'^N-E8>1?*$)9A0>F%S6"4;X?
M-)#9/`L)1OAWW#LTK7,C19FP[]8=C"+8=^L/;.-<B>3^O#VZ8'-37@[^#M8_
M`G7@[[[B\';F/]AXM^L7A[=]]][[[WG`N1')X6^XNE_S3$+?;N(5C<"!"WVU
MVUWWOF/O>^VM:UKOOU:UK7LSCXPW)SYKWFC_`(Q>`_UQLC=S$>^7_)'BO?E`
MQ#IJ<L&"47#7#A`F)\EME\&D\79W!X=&@8720'LO+1Y=RFE"0E/4+!-;0YN&
MRR_"D0*CA!*%O\R#74C;4KIPQN0A1:6J65)00-Y8;,(JOX;GV+2Z/V="WV&J
M(/5)3/('";V:OE+<TM56,["RNDGW8RZ+JHPA4OJ9$2.`/3[LGE5/.0#+OD+R
M/YH'LP(A/5,6IGF+P`I3BM\(!FR6`"::P:PJ?TX$*GR)(AK3'6L94[,LL/9W
MU4_J(4E31I2J1[<>2MI2:E:,LBSH974PMB6Q5@](C<`@D6?)K(Y`]N"]$S-@
M2HO&2E$D>&EL6.13U)D\?2K7P$7;'D]I1+'`E.F-\F]:SIY?+3Y15TF#R*.A
M-B=;SIBIN4$DO2FI[5KO8$-L;C-3AK^S3.,S)G0ABD<L+D+#H(SKZITG(;6"
MGYW`&$3;J"2EN5K-_'3,<W,3CU"8>@&MU4E:=1N\(31J`TG:=E88EJNZ7E-B
MQB'$!"4F(B<=Y$2>YVU"A0$%M[,XENS(CT$MN\DF2'*E]F2>!21F0P;W0BJD
MB)C7S#WT-*3W-,.F;(%27[W3B1.:ST4!9`_&2<$)_I/@+UH10M[E@'V;_&'^
MF+*L8QC&,8QC&,8QC&<=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=
MM?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K
M\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=
MM?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K
M\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=
MM?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K
M\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FL=M?)K\FLY
MR"?+NY*Y;ZOY`,TX;.2$224I'J<L/X3JLHF7SEY;Y-+)FJ%7;[1Q)<-E[/;L
MWKB7Q9K>)S#&>.2Y/'FQQ9TTY8E+%)#$AVO'@?9TSL_E5'C[]M[GK=TN9HG9
M(JE;KHZ;,\Z>_'2L2@H&!'*WQ2.4P=I':UX2)F4AC[.)?.G-*PQA1.5,8@$9
M3N#HX&[^MZUO7;>M;UOVZWZ];_DS%SK2-//:.S$+K5\"6IKF7MSM;(#HHR^*
MR'=F8F2,LSQ-C0HPG21X98_&8XS,SLZ&*'%I;H^QIFY4E`T-^D]R02!PZLHF
MSP:`1QIB4282E);4PLB0M&WI-K5JES<%&BP=QGK7-T6K75U<%1AZ]U=5JUS<
M5*I>K4J#<9<FOXDYK^+'?]+X]F>`^S?XP_TQ95C&,8QC&,8SY1K49:LA`8J3
M@7*2%"E,C$<6%4H3I1D%JCR4^Q:.-)3C5)@'F%@$`D1Y.C!!V:7H7ZC/)+`(
MPPTL``=O&,9@`!!WWX=:&(0M!#O>]]M:%O6][]6O7E!2I.?H6R3BSM`[>+R1
MA.\/BUO8?%Y6Q]MBUK>]:WVWO7L[Y9<0M&M[`=IPPP>>1"7O59R<4*L-IC<B
M:GIQA$O`WI'0<9E2-O5*%#$^!;ER18)L<BTZO1!P1;*[A,"7?F,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QFO;J5'V-'>.RBS('S(;>%+;5TN@
MTNGME/E1)[F9G:*)9W%-&QD411G(IBZ/SVK"0QQB-Q!:8IGKJ]`@3DR/*21@
MTCU]=/SE]N[N7\8BCIU)IKS*7**6MUS:(+%.G/8'$Z!-"5KD58@<978D]EQ*
MTAW,;E!A31!6]'MO*+>G.2)%CJ)6K1,R_?V]/3/&V9VD4A=6YB8&%L7O3X]O
M"Y,V-#.SM:4U<YNKHY+32$;>W-Z(@]6N7*SB4R1,2:>>:646,>L'UGRPXSW+
M4TFO>K;YJ6=TS"3921-+/C<[CSC"(:?!TGNC,2);(@+@M\9.C#;L#F^E/AJ`
MQL;#2')4$M">2H,O>I+HJ*_(8DL:D+.@-O0!>M<6U!-JUEC)-8HM7LZD2)U1
MI'^/+5[6I4MJP`TB\DE2,:12`9!^@&@$#5H\FOXDYK^+'?\`2^/9G@/LW^,/
M],658QC&,8QC&6/8E@,%9Q9=*Y&8=I$D$2G(3)0!-6N*]4/9:-N1%#$``U*D
MS6]!V886446`T\XP!10Q:\YO(_J>T:^6',V%7R1JN"6\P)7RN&"&#7RAS%'9
M0I\U*@BSTACR4+B^+5T@4MR"1MC4O(7N9_9I2E)EA1"4J0,+Z5]V\F*$=(+U
M$;DBP"K"'&WQYK?B[%W2&[AYK.O(?T+4*V9^Y29[D"\M:6F`X."2"QH]/H"]
ML3JE1"HY6;$JX/W/)5[(>V&4R\W=706XHI&CEU-7&^HGY0J3@VF9Y--8],%Q
MZ1<^H#.R]T=(ZXL9*[8E(0GLI9I(DD&>+'2KYU\:;!>)OPSZ@=95M<KC%QM<
MV)GK<\FPRZY0&8ORPQ&F`^1N6M3A'=M@6MY;W:9,CU-R9*[OH6\],WN2EQ-V
M*F]2CK*<*@;!SOZ<Z6^*[;"!^G7;Q&<CEPB4I)@@F/+RPM1LW;20##K0]@>F
MFLDX`""(6R][V'6P/B;UNNG;RZ4H8]%+L15A8RT[:/57WHG(K&5B<`[`#;<V
MN+FM40F1KQGB$24@CLL<G$8RQ:$A+%]CFVDLTLT(1EC",(PZ&`0=ZWH8!:UL
M(P;UZA`%K>MA&'>PBUO6];WK>5XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8S7QU2Y:B@/!ZX)RM?7"(`BCC53L5/6-SE35*:V/\`AB@*$%E0D<-K
MRUWMTG4`"M'*87%1UY*V&;29L;(;+6HZ*OSQVA#Q-NGAW<W.6,K*2YI<O+.<
M"X3;TKBW&J:5'-JPHV,R%W;8,@N2TC7Z;<=JH?W9WE2_;9($U7"G3Q!HM-YC
M,Y7!:\CB56/3)NHM&55G!Z^ETON210B)5='&16[3B360Z,3+!6./(_`8M<Y2
M[28Y.P-S.E[%F*5CL<4B([`&:8'MK>:&F2(5T\(^I[6_)GD3!Z=J"]^6G'BQ
M(SSCH>6L/'<R;V%/(?7RN'TH0^V`\VO78I]4R>I*PA:YQ;'!T8[48I>UEO[`
MCESQ+D2O:/P%D=RO]'.*>YYPUV\NB]J6C$(!?38QL<:'?]3,$G.30"WW=DBR
M-MB1,ADK:,]"_O$,;&R%3)T9%,ZAK<BC,F:R`W3RI^$;WA23W,]Y7O$\B)^Z
MWI_O@]]OG>_-D]-]SO1_^9/+\KT7T7TG[/Q^D>=]AX,E@'V;_&'^F+*L8QC&
M,8QGP.CF@96U>[NBHI"VMB-2O7K#][T4F2)"AGJ#S-ZUL7@**`(6]!UL0NWA
M#K8MZUOS#=1OJ=7[.INDX"<+HVURODKR34MK'#P::T:MQI*$*/2SE5@.SDK"
MK;V.7.K(0L?4CVYD[25=&D"V<B+.7%,`5TY>!'0]X@\,TM0V&_18FXN4E>%/
M+TZ7C*5KZI+53>3E)MN+O'X<N=%,>;B8T("E)`W5P;U\N9RESH\J7TZ0O3@N
MUNC]F=4^-"60,SHQK1JBT;NWK&U48B4F(U84RT@Q,?M,J)WHU.=LHP>@'%[T
M,&]]P^O(T&\-Z:&2:46GDQ(AE"++-#(U)NR1;#O19H23R3$Y@BM]A`+/*,)%
ML.@C+$'N'?<3)UG](QJ%I(=%EED0Z/-QZ.5KE[FJ5S0M*EV6-*H)$G!K6TY9
M(E`C#@(EY*<!)"4:=&D!I5J(%W=.SIU]2B&J9;8U#1T4C6J%Z`^R(BW`K:VF
MEZ"%.8J`X2J+@3ZDAB71I)I1$G+E;"9YGCTE,V,T.M:8NFSU9>G6:!VZ:O,0
M7(RF6HS9Q/%#E4:E4:(;]*1J/<:*/BY4FC!6S```#S8T]4L;O9A@A>EBWV,R
MG1_[H,KJ/31+1O4CH2S.!-X%"`E4K9@PO[S4SP;HST?;FA>?<PF3L;.I/[F%
MNRAGD4+3)P[-W/E1.M'BWU1>VJNF\2CT]AMC0:5P>6*D*&+S".2Q@>HQ(ESF
MI"B;D+(_-S@H:W1<N6B"C2(42HY8H5[TE*(&?^]YD+&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QFNSJ<'32/<;55D1KF?%^$$<K&80*6V':$YJYFM>
M(.<526!$!^]M='%2MKD"QZ>'(E(SQ9@C3GLV<O3N1!7%G=T\A*]#@GP$Y5BN
MCEE'8[)>I7*^7+P755I&1^KFSIT6#P[BR$)"^`*GJ8RV:V"F-2R-<P$%(VF+
M1IF-0O99TF?UQXUC04X$$;]5R%$YHE;<XI$J]O7)SDBU"M3DJT:M*H+$4>F5
M)5`#"%"<XH0BS23BQE&@$(`P"#O>M]&9#(@='-0\V+QTV)A(*3!C)C&UF1X*
M<@T*@E.%C&D$U!(*/"$XLG23199P=&@"$S6A:N,LLLDL!10`EEEA"```!T$`
M``#H(`!"'6@A"$.M!"$.M!"'6@AUK6M:S!')K^).:_BQW_2^/9G@/LW^,/\`
M3%E6,8QC&,9QO>M>O?X-?R[WVUK^7>^VLU#=1CJ=0GAQ5UCS)1'XY.F*.M+C
M#TK(]C-$GG]JO[>Z)XQ!V_19ODFLB)4C4NLX6#(4Z#%F63&)=%C1)SE4?.AW
MP`E-/0>4\Y>4"(;KS(Y=:-F3T>\(24CA6%:R)04],T-0M@2]!CCK)RPMC[*&
MDC986)J1PZ!`(3EQ%3I7O]QC&-Z[YBBT*U43B,%L\;DKG`W1`[A?VUQ8!C1D
M&.98%'V+HG0FHS524\Q0(\W99P#@J@E*M^?L`B3;3A4NL""122+>0:AA;V^,
M*6Y(W3)O/]*%(DRPX27SU+:W$"."HTJ,1$$C"W(5"P:@83&XL2<Q2=^]ITMQ
MTY;UR**VU7M<7A7+P4,9"*3LS7)F\DPP(0B5LZTT`US`[$=M:`O9U;8\(#@_
M8'D'`]7CKZF?[G[O"GY5#G/IPH+)G='3VP8V>ZT618#R:OIVT]KCT\=LQ,N=
MWI$D5PQM+5Z!J?.9QTVJX9)JM2]N#*NTO:-A_%CK163Q`6P[B!UCZNM"E;:8
M"/>ZS<I'=M)E%<VFV(CC26R1R9TBJ0Q*I4`0!2HG6=P<R:-#HH*$]S!/$')0
MYE%^EJ&S6(6)%V.;0*41^:0Z3-Y+K'93%7AO?XZ^MJC6Q$KVAY:E"IN<4AFM
M;T$](H-+\01!WO0@[UJY\8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QD#
M.IF24?PJN(H$\>*U>]&URIA<MBU-BY`SM'8C=:L'<J\0UE3I36\*IQ:SU,T;
M*S5<A0-YKBVSU='WY$:D,:=JR8=</9??1E\<:5MV\^K;MZ.\@^.$VN>J::N;
MBCQVHU;(M%-]?*)`2"3TWK3RV6E2R*7-I$\KA_V%M<$LL5N\;/?"8:\*FG<M
M+I9'H)%Y!,Y8YD,T:B[.X/SZZJ`'FE(6MK3&*UBC9"4I0K4C`24+RDJ-.H6*
MCMEIDB<]2<42.*T!Y_\`%.R:LL2WXU8[BEC%3V4335C,\RKFSZXLJ(VXO71I
ML8JR>:?L*'1BU$TZEKC,HBBA$:U#QN<V429B+BQ#KMS3>*0M6VQ`[FBNIC7K
MYIZ:"GJ0QAS)/0N+,]1V61!Y61V6Q&4QUZ2H'V,2N+/[>M9Y!'7QO0NK6O3#
M)4I@A$4,RR^37\2<U_%CO^E\>S/`?9O\8?Z8LJQC&,8QG'?7_'X?9W^3^7-<
M?(:_E<UT3%ZJ*D"EOC;^0Y/,I:T*\1"AX8E`E#:C1"2E&#T@1+TX7`]2L]'`
MM.2$:)(,1%B4':3X'3#IU5.JJ-SF408V?@SP`*B<P1QB/N32_0NY;^L!F9Y@
M4Y+5S6O<FUR$Z.)"-V>F?9J@4;@,(C</<$#6.<NA)WK,UKMKM[?P^KOO>_7O
M>^W;7?>_7OMK6OP9SC&,8SX'1K;7MO5M+NA2.;8O)$G6H%R<I4D5$C[>(L\@
MX(BS`[WK0M:$'N$6@B#O0@A%K"$5I%JJAXEDJKM0]CTY,"X"*OU3OH$;/>0=
ME*(85*D!JD@8S""T)"A6:I$A(4J/W\9&PDEXY;^6C>U&$,5EPA^ADO*=FMO<
MD!I>S&PA$O5!(4O92Q0`L[21N)%Z4<4(HS2DGL)N6*P^/9>9[IHBF>2-?.M8
M7C6\/M2OWP.AK(W,&A,\-_GZ`8%.Z-IAFM*V=X2A-,,;7YE5('AO,'Z0WKTY
MN@F:\YDYZ6'.GIGRM]NWH\W&[32L5KD8_3;@S<CH6_,#VG`(!ZE/"W!Y<&IJ
M?5>R]&ITARET@UFIT8"TQ5ARTX>VQ1-C@WUP.//)B4`H6_61WX<\NFEP!&I!
M25S;5,"!VE)>MEFMT)EC^@8P'."LT.MH8?+T,9F2C9H2FAMD28'NF;NWT+6_
M9O\`LZ]F]?@WK?KUO\&]:WG.,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
MBAS:>D+#QQFRPROK!M*0J'"$--<P:J)0Q06QWRVWN=1QHJ<$.GLI=F*+01Y1
MV`LC[@5,90[)8['TZ12N>BG%O`>TK]=M`\>*>XN<YN.3#<5E\C+EOR>\6[:8
M^*2F\9_74JCM'0:`*JL<N0E9Q&!4[5-40^.2!V(?J[&YW&[-\T>+$;HTJCAT
MO8`H6MDDFX2T;'AE0UY,;/L-<M;(/!6!?)I4Y-T>DDK6-[(UE^>N6D1Z(-#]
M)G424K6SA)F5G<%W@`,PI.+18Q!\Y4VIZY5TQF5NL;LX7SQCAO5AX0<X5MQG
MP=N8K$F4'!`E<*N5.NU7T984]NUOQ6--I:30F4(8@8L;89#I!%5K@_.E8J70
MO9_TV(O)B#^=EO+V90QP#DESWM.X:2)/`<F"^U6@JND:>2V"C0*"4IR-JM"9
MU3,I^PG"1E`?V!^:Y82<N32!.N4R!Y4L4R40*2/*&<^Y\53$1,"^'^]=I5^Z
M1A,S9!*3/?$<<%S1^E`,(!X"21!(]&\9>]B-%K4L`^S?XP_TQ95C&,8R@TTL
M@LPXXP!110!FFFF"T`LLLL.QC,&,6]!"```[$(0MZT$.M[WO6M;S%:.WX9*1
MN++7TB8Y1+@Q55)&=H`I4E)%@-$ATB`I<-)]$)M#5GI"UJ?9FEZ(E0`T],4$
M6A:QO7U>W0[2QNL*V)VH;1H!'&M]>151Y3$0!2G-(&E>/*&-$H`7Y@1;*`)U
M4F&EEF">=:!HK/.U^Z/>>G);BZAK;C-13>53U>7Q%Y-)YG<L;<F($OFPTKCJ
M/RBL&!J2!&ZQ!)HAY9U\LEYJ,#S+=2%O8HJYH1-T@,4[9^B71!O'GIM<=82Z
MTR]4;,W9D=IK844DYS>;*':7R=X5*3IE(24!"4;2JDS(2QJVR+NJ5.^PN.EL
MT/>B@N+(HV+:[C&,8QC&1DN7CG\,4B1/:^<+V=*VM0&M"T)V1$M((T,\U0M4
M^><M(,&8N,$3HW0B^P`)B@!WL.NV6LPPF_*<?V=)'7P=MP!Q7($;DW/JD"%W
MCR<0B2#UJ0Y<L4;2I4B?QFE@0JE:082M$&LQ)@RU6Y1-DLC+TZ/+&U/C4XN\
M?/TF>VQ*L)/6MAH@AWH"Q,$6S"M?9Z`(6P[+`;H1(Q!.`,L,'N<G3)XC=0.,
M":[YKE-N:(F\Q!%;@B/HL?M:(A\>C2"FZ3A2*0/+02?KSMQ:7(I#%C1B&/;0
M`\6E`=)?NEU=.B?H!;N!SZF'3^8-[_YS3@=-7S3L63!T(0U0C!2&2M;<U(R=
M["!8=8M;E)2-`TZ5D4J`41NYX1=33B!S_CH7&@;.1J)@D0A6R.HI<%/&;8BH
M-B,`88Y1(Y6IVZMI0R]AW(XDND<8'L00!>-';$2&?VMZWKOK>MZW[-Z]>M_R
MXQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9#KG[+285Q%N1Y54Q$[_1*FE@
MC#A6$_EZ&OZ^=6V:S&.P]Q?K!G"UGD(HE!((C?#I[,)$UL#U(&>/QEP<8ZVJ
M'M,A\&K+IX<8Y+17+4J=.M!\'8BYV!6TPB,AMJMNH)RFYT\B%K3'!,+S&H*P
MJ^5T09GJ!5&)8)<[OK5`Y"J0C<T,9`X1PA.`IR*]".]=];UOOZ_5ZM[UO^3>
MMZWK^SK>MYQH(=:WKU^OV[WO>]_@WXM[\7?7VM]^^O5V[=LYUK0==M>S\.][
MWO\`#O>^^][^7>][WO[>8&Y-?Q)S7\6._P"E\>S/`?9O\8?Z8LJQC&,9%&V[
M(4V`1+:8J+1C[-QHMD2%:2>2A9FAD\X"=]3!>SC@)S'8>C2FH:4L(@E^EK`Z
M/]*1FD`^3BU5<OK,F6$S.*,S8L7G-YK:_(W%O<G)2DV`P"MG.,2F&&$(DIY)
M"X@.O+`<<J.\S1@B2Q`EBK5)D*52M6*2$:1(0<I5*U1I9"9*G(+$:>I4'FB`
M42G(*`,XXTP80%E`&,8M!#O>O+'T^XTW]5GJC\E^I//VU++^./&AQ)X^<0&:
M1-I;@Q+G5E`)83.$C6ZDN"+:AH;EZ^Q$YP]!4))3:+"O2C(7Q-+Z-ZH]:UK7
M;7_'?U[W^'>]^O>_;O?KWG.,8QC&,8QVUOVZ[Y'&Q>/+=)9$5/(,_K:XGX%(
M5"A\:"A'(W00A`\\QS;2STNC5)H`!T<<6<$I=K7ENB9<'>AE]X[7O$8G87P<
M2\+FP*1(FXU!*G9,2DC3P>K(`,P)"S1V])BP&CTG&J/`!"6M"<C-.3B+*V?F
M\(BS@`,`()@!A"868`6A!$$6M"",`P;WK81!WK>A!WO0@[[ZWO6\TK<VNASQ
M<Y0R,5TT\K>.'W*AM<A2-BO.B@&QSTJ3Z,T=IXE\/9%[`B<W-0;YPU<HC#C$
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M`KTUP;V,32F.1F..EJ;7=PXXPUSP^Y@5U$)!".E\ONRRJVM9W:'/@QPX;>'=
MOUW#T:>+N#^.9L$?M>U_A`HEX5@9XXEDTE/BJIIGJF%)4R:2*GQ2H8=V5DSY
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MQ=G4U31VHX[ME91&K5JPW2M[?EA987%X6:#L(3#_`"^X24J<(A`1HBQC*3Z&
M::(9RI0I4'92S1]U\^6KWQVX2.%45L-6HO7F%(">.E7-+4;H#T8BE8"4T_<V
MXO90]C-W'EQ$-1'%"+-3/\Y8S@#!L'B#.SIX<26/A!P]I+CFU$HMNT,B:97/
M71$40`,ALR1;V^3][&:1W](+/D:Q8B;1F#-$2R-[4C`/R4Q00S5QC&,8QC&,
M8RT)K`XG83.8QRYF2O"`6]C)\[0RU2([>O#Z2WK21%JT"G6OL=G)32Q#!W+,
M\PL0@;PQ9#_9M0CC2N#1!!**HCT=1M3NQH]J3),W!;][(`K)4;$H4C1IVTI*
M$LX*1>#1@%0G,!)8RUA>:8/,FJ?15FES.6M(;GH@TY.2XIMI%A0DZ@Y(H*.*
M\0P=RE"<X&C23#4YX`Z.(-,)&$6[C6(D;BD4H5Z5.M1+4QZ-8D5DE*4JM(I*
M&2H2JDYP1DJ$R@DP91Z<X`R3BQB+,`(`MZWHKY6=`WB]:LD^&7B?()3P-Y(-
M9A[@Q6'Q^4+H[$#W0P0C=B>:_9'1@):P*3.P%:NO7B%*5&AC-<R'K6O1AQ*#
MSCZPG2ZV2R\_>/97-SCDRD^4+E/QZ+$9-&=K3^CE`<)R4G:FQM$-(3O0%`I[
M#Z_$K4#&:*PWT\(SC-Q7#KJE<(><Z-(50UV,"R:'I]'JJHF.PPJU6_?B,"8'
M<->SBU#V21Y>_-<XBJD;-Z];"Y"[ZUFPC6];]F];^7Y==_7Z]>W6^WVM^O.<
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9#U0IEEK\F;$KQTF4<'04!J.*M-@4D
M\5_%I`LM"27`1-/$KDT@?3G`U)6"2),_N3J+I8^`V724Q\+72`ID8EC"\XSJ
M;CMQ6X.7?&(MQSHCC[2C=R9+E#6[M-6UA!J^EBV2URPN<["ZG/$:;&]WDD/`
MS"<4"M@=C%K?$GE0P*8[IL3/;HC/FA:<R=:]KN935C@4PM)YC,?<'9IKJ`%,
MQTSFKDF*WM%&XYJ1.[`P%.CJI$6E(4O;TUM*/0QJW%:0D(-'K3C"T\=EE4\E
MY-RMZ:')&W7&][#IM=?T=LRC>/M@I[#,-.W&(2@@%*-MRV(>ZTCQ5CD;CYAA
MKD>;.AN+PLGK)&93+7R7*6N=_`"B7GCK0QU;F$2F/5^19-C/M'5=-7O<DDE(
M4?(9`)QKRGECT-V?S3$4-1C6>X+&-_?`0>.N337Z5T5(XJGV&[.5,*VN@,DE
MOOMFR/3>1$R_>R@?_1XDN]%F;*9YCBR^AC]),4>?X%0_2@><`E.'L'R^^Y7A
M]F_QA_IBRK&,9C^<69$:^-CZ:2+STZN4NQ+,SI4:,]>K/4'&$D[/VG3@,&!&
MG-4IBSU(@"`68>27H(QCT#+<J>FV6K0OJTMQ626325Q4K7F4.Q18'-448I,4
M%(M>`9FBR`&F#4*1!'L:Y88)2?O00)B$V8\XWOMK>_;\FN^M=]_:UZ^VN^]^
MK7?[>>7"`Z,ZG'7IE]B#WM[XT=+!BU$HF9K1I\??+^4N3@B$O)&4;M(:M(GB
M:3.Q:HK9@1I*?BI^]B(6I1[]1^M=M:U\GR^O?\N_M[^7?V\YQC&,8QC&,8QC
M,-6_4QEEH64YKE+U#Y)%E"M='75J4G@3%*U19(1Z7I"#4YAH/^3EA*4)CR5*
M70CM`\XDXY,;;S3.994U>GN]_N#>J4(I$2R(7B,(U+D<XH%82RT*UT3I4B0H
ME0,X"O9AH$Z;6TY9&C2?3C=%G9DC$MC4S;"GB+/3>]MQN@_\H0*`'>4/>N_D
M*B?L3T:D&OZ8F5E$J"]]]#+#O67`(`1ZWH6M;T+6P[UO[8=^T._E#O[8=]P[
MUZMZWK-/O,/H=<"N7:Y7,CJZ/HBXC#]N*2WZ`.25](M/0-"$0[/,?2(S85(U
MVE`O/4.B]@*D9PN^RI`F-\)P-?H:=Z]_3:\6Z6LZ)=3_`(\,HC1)H!:`U;=>
MK4R$!**"0W+GE[+E2A42F``E&2T6%8B8(P;$D@Y0-^1NVY1^ZA('`'"$0ZSN
M%%^5C:;?/4C'R"K^9+6UK<*TA@D)9BJ00TIQ;FN0S:1C4*`*&N)22,P`M<TI
M3U);V,Q:U^?Z6J=NFK;_`*YBUM4Y-V&P*\F;2C>H_)X\L"J1*D:U.6H`4J*W
MH"MJ<TVC-$.3*[$(G=J6EGH'%$F5D&E!RAC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8R!W+C@RBY(R&-6M7/("^.)/(F%1]5$F"\>/LC:$;B]0Q2O.>"X!:E?3)F
MDU<6Y!$#\I4R!B9I='C'6*O:UT70]_CXWV0%NUN<2>`&^/\`83Q>]T\F;^YG
M<CG:)*(`VVQ?CE&4""NJ_<7!H=W^&U!5M>,,6KNNFV8/$=CCO.7)$TN$JEBZ
M/LA;N_C;6M$W%;$]ZUO7;>M;UOVZWKOK?\F\X\L';>O`#MOVZ\.NV^WL[Z[=
MM]LJ]GLS`O)K^).:_BQW_2^/9G@/LW^,/],658QGPNCDD9VUP=G`WR$#8B5.
M"T_>MBT2D1$&*5)NPAUO8O+)*&+PZUO8MZUK6N^\UHTU.&ZS.2895-O3#3%^
MG<V!(U)FSFUF7D@![DHO+-\1))A#*0J&1Y&@!,?-;5#T)4(@6MGF,@#U/^7Z
M'@YPBO*_=+$Z>7-,9-BU7)3Q=O="U)IXH_"0!+V'>CR&AP5#E+H3X@;VRQ]R
M'H8=@UO(W="[A\KXE\!J[.F",XNX>0)YG(&VEC@`L3S[L3Y(E4Q9D=%'A])V
MK8(26QE.292,0B)(OD1FNPU)G?<?C&,8QC&,8QC&,9\JY"B<TBA`XI$R]"K+
M$2J1K""E2522/U"*/3G@,).+%K^$`P`@[^WKU:S$#;3,?@8)L[U2B21B5R9E
M&B1#5GKED>0KTX3S6\W30,PXHA,!8;HTXHDLP(0!\L@D)/B('9U=V+<J:6-\
M!M6NC]G+`*PI9[&@>='CM(DYBC:AR\KS$24*C00%!&4>A/TI-**VSEZ&(1>>
M&271>2FK2(_(69Z.;5!J5P):W)(M.1*"3!%&%*BDYHS"1!,"(&]C#H&Q!%H(
MM[UOM<.]:WKMO6MZW[=;UWUO^3>:V.;W2CX@\_9G5-@7O#G(4LJ]Y1&'O<0=
M/>TZ6#!DQQZM154_<DA`G!V@ZMP-"N)]"5-TD8C!.!4:?V=.]O):W7%8'[GN
M:JJD[G:?30Y?7OPCL(\U4OU%B9.]S>JW10(/_)VQ:0)Q;Y6!M%O]Z-]\ZZQT
MA*?>BRV8TLL!6K*%S1ZZ7`8)Z?F!P\BO.>HV0(M*;NXQ*=HYEIO3%@":[/#'
M&F52<9HLOL8?IWI^&IO-T8,Y^$4+9X9O\8.O5TY.2JE/'5=NF<?K$$<2A5P#
MD8@*K-:G=!`['H$\M4K%U?+3RE&A$!3^^I(Y&;V7L3:2(?EAW%-3PU/C<B>&
M9R0.S2Y)RE;>Z-BQ.O;5Z4\/B)4(EZ0PY(K(-#]D6<G.-+'KUA%O6=CC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&1GY?5Y,[4X_P`W@T(6S$AP>3XJ)]:Z\G9]6SN8
M0)NF#"Z6/7T/LU*YLBNOI#8,$12"'-TN1OT;6M!KSLQ%+(>I,+E;-J^X9I.5
M9W(GBDT/%'6CQ1IBB^(LQHRT3;]M*M9-+^5\[905TGJ]M@T'@MOV^Y/350C-
M'9&_+[[GKJAECZ7.ED7;`.K8ZO+JIW0V3*7N%0242B,PI[L>1M#2H41^"1T]
M"C=I6^#V!,T,:=R=#"6IG*7N)Z8E<^.II;8Q-^U;PXB]#0G:WJU0=4F0Q=9;
MM0WIQ_0U[RKKKD3QHXVQ2MH7:YEDU-:\IY?I-NM(R2(W&OKB`O22.HV!LFDA
MME(^U:@D<$:(!(%;6T2T"^.:=9T\8N1R+D,SVHD5Q_<0L6A;JFO'ZXHD!P->
M6YEL*&(V%_)61U[4-K*J>XC,X+,(58$1=%K(S.)T>E2%.ZM3>ZI%R4OON36_
M_@G-=>O^#'?M;[?U7QW[?;M_[YGD/LW^,/\`3%E6,9BN[$\O75A+FZ#-QKG(
MW1N"U)$Q"E,E/TF<E!*-S.(-5FD$^<2VFJA%ZV>7OQ;T(.Q"!H`ONJB#DU[7
ML5B?EE>E-385MQ,"$O>C'A9L2UV-"8'6O&':\\X!0_;Y)96O8'7;(V/9[<\N
MO4;&=U(NK;Q-Z;;,88Z4?QCT3R<Y8%$;,VW*%Q*9$XMD5=!$['KS/>NNCL3)
MT$81@/N1P&85HQH&('J&*+`46`LL`2P`"$("P:T$!80ZUH)8`AUK00`UK0`!
MUK6@AUH.M:UK6L_3&,8QC&,8QC&,8QC..VO;_P`?R_+V^UW]F1OD_%^OGA])
MD\<4/E?2`"\*X]PAZ_:$"@8E/I*K?HAH324AJD6Q^,UOVE!L0MB.3J-;$$7[
MV3,[RA4F,<8W`&J>5X%&BWM,UJ%!4L3J`EC]/&:`!AQANMG?9$:2,ZXKR-!\
MS9)GC%GT/'(2/1QCK5XDC*[1P^PG+24YH>O+1.,9;BC#$RY[=B1`V+T!*I$A
MV'>P$&')%H57@*V2:1K.R!P0.B4I<VK4C@B.#XB5:%22K2FA_P#,4H3C,),#
M]ON`>]=MZW]O/KV'6_7V]?;MK>O5O6M_(+7KUW_!O(2\GNG)PEYBDJQ\A..E
M=3A^5$&$:G1+3N,60FT(G910DUA1,UEEWA3=]#(3JG94BT,.O,2&@V(`M.;C
MT*.2'%94LDW2QZB=RT5HH[2Y+2=R+MS2IW)0#8C?1%![:VJ&0I,,S]["<_57
M*UO@'L1S@(?C-W\I/4SZO7!]*%'U".GBKO*`-6@E+>0O$E:2YE^A$G;VH?7^
M-,VI,Q$[&2(.P>ZR6I4VQ!%K:<D01:#/[C%UR.FURC,1-,>O]HJV;+#=IMP"
M^4^JH?RUNNP?<].[OBDR"O"X1F]E`2L4O<5(S`^'1&MB#K-M*-<C<$J9<A5)
MUB)824H1K$IQ:A*K3G@T:2>E4DB&0H)-+$$99I)AA9@!:$`6P[UO/JQC&,8Q
MC&,8QC&,8QC&,8QC&,9`GJ=UA(KBX-WK`(M`&^TWET;X4Y!KM]M0VEXC,FR+
M65#)5(6"P+!*0N.VZLUT>970%ELXTFRY=`PR*)#5-VWH#BEU3=+"(\?GGDP&
M=\=.#72@J9MBL.L*.S>[NGES@@_)J6L*A]][ON7`)Q%H5250>X\?EBEK/6E+
MG-P??0G*,(TY;"A.6:<RO0A:;K83'74R=JGB+'/;*0L#@?!X?)I4*#QR0R;1
M7A:6Y^EQ;/(3X\S&JA`&YNB5B=UB9$6<)$W*U>R21:;$_$3E99T'99)8=.5Q
M6]U4SS'H'FZV/Z7D."W)!RBLF$"D$6M5EG3YJE*Y8JK9Q4HYEUG2[.W(']DB
M0$47;SS61ACAJ]=/'A%Q^FU-).2]AV68F2V#RRY3S_DN_P`41JT;FGKMI=X?
M7E45U`!O#;O38\N[#6%30XZ6.;9Z0V&S%Q?TS2YO30D0O+A>'*FN8<YP&23M
M:SZ/E341$R4#I[H.I>TY:*9LIJ8/H1*\MM-\L:D\7<Y$8(?F=C!#"`&@RO#[
M-_C#_3%E6,9%BT'^0.=_TO7S$[N#8E2!7S>1EH%IR4"]O2B/`2E7E%F!+5HQ
MEMBM,).>`TG8G'OX=&^6($I]>S7?V_;QFM7JS<Q;1X+\++#ORH:T'8<O;5['
M%TS@L&D%$ZRU+5)C.ELR<H#%B5R>8VQ.QS:WE,C.$U0ZR!X9$;B<UL)KJZH]
M-7[F.'++6.YS<J+7A<V?[9N*T8V)YY'R!*T)(M/^Q+P[2>$1-.E`WF)W6,RM
M2)YEY;&W"BR1*[P^.)!MJF-;:"?5_C&,8QC&,8QC&,8QC&,9&*U^-*"V96*3
MN\V?T&BT"1M0-:1"V'I&]*FT,PP!!BD.SA"5JS3U9XS-[%LPS0-;\LHO0>ZA
M]$%UE")4PUS*71JD\C1I=:DKH62XITCFA":`E:G8]!`WI?/+.-+4>4689O8R
MS?$/T<DH/R5\9R19Y4B8K"31"4Q$P"O2F9-1Y2!R2^2D,&CV8@!I$)28J5:)
M),+]R`Z`$9AXE@=%]C.$W*:JPR!RC<@4O<.<&YQ6-VQRAF4($:@2-0:G$I"H
M($K]%3&B*V,HQP+2!V6(`Q"UH7JD8`TLP(!%F`,"8`)@!`%H>AECUK81AV'>
M]"`+6];T+7V.];UO6_7K.=Z#OU_+]O6]ZWZOM=];UOM^#OVS7SREZ5_`KF-I
M<MO#CE!726+B3RQ6)$TIU?6,$T[>Q:4'S&%FLKF[C*'O8RR)%MZ1;WO>C$A@
M=[#O4\?T2>9?$12:]]+CJ16C6[*E4"5H:%Y""#,JP/T`&QA1A4H&EWBQ)8]]
MTX#%=1FK-`%XC'D`NYVO@.ZJ'5HX3%EH^H5TX%MHP1J"66YW_P`4%YKHT;0@
M%X1O+FS-YDTC28TP(1FC*?'"KR>W;7H23>MAUL%XP]<CIL\I=M[9'>0++5\T
M7FB3:@-[E`JN0`6!T#_D29V>E)L%>50S![)*)8I@Y&FG`$6$K0M>'-M"-<B<
M$J9<@5IUB)824H2+$IY2A(J3G`T82>F4DC&0H)-+WH99I)@P##O0@BWKUY]>
M,8QC&,8QC&,8QC&,8QC&,9KEY^6WQ1=:SF''JV>1/$&(SQR3PN:%TMR8NZO8
M+%K(:XY+&J9M\)M"-OCJ=(3:ILS<841>2JP1:1-ZAE5KS5$<EK<E7QMT@WPC
MY$Q?DKR^K\29MZ<%"'5A65KI8?6_$_E55_*J\[:9]@AS,\">GJI:]KR,5K0D
M/"Z-3^1$'$+[(YC,R8<][;H@FA3@E<=_V,9@7DU_$G-?Q8[_`*7Q[,\!]F_Q
MA_IBRK&-Y@:L['4V#8=JHML;.6U0)T1QIED"<`A.JS?F+P.B54H-\>AD>EH=
MJ22TOD%%EC!HTLXP>CLSSC/,3UIY?*.;7++B+T>ZD=QITU@R=GO3E,\-AP1G
M1:LXL<H<V1$X[`(KT<:1C;Y'-BD1QX#%4@%6>M:*TN(&;Z/*SK2`TY`HI6%7
M1%B@=?0AF2L$3B,:;D[6RL30CUO1*1&C3!"6$0AB,4*U`_&I7+CU*Y8<>K4G
MG&7UC&,8QC&,8QC&,8QC&,8QC.@?8K&9.663(X^ROI10@B*`[MB)QT4((]&:
MV5M42:(O?B#K?V&PZWV[;UO6]ZWB.SJ#9[$>TDJ22F5PZ4(&Y.V(W./N(BTQ
M:5*>H4$A&@WLG81!,4#\0T:Q'LP(0!,\>P!%KE2VW3`:T;T,:<D%L3=&\&"6
MK)3_`,U"5,!HUAOD)MZ<$XCUZ76D:<HU:Y",-",\P0CA`)*RJNK9E3]N0I[$
MK-]KH<89QO*]X6B-51]2G($9M2%&JVF*,&<624:J\I.)P!M.48+S]#\`#+JB
M-S5?.C"2(O-61P6*!!`0WF*!-SF>(6MBUHEM<RT:T_>PAV+7DD&=P_9>S>LR
M9O0=[]>NV]]M=_6'>]?)WUVWO7X._;Y<U]\E^E=P"Y;!<E5T\9*V=9,Z%G:4
M3Z+M6Z^L/:@W0^RLV:08QA>G$XH0]C"!Z/=4I@NVCTQP->#-3ZOH<\K>)ZP^
M0]+?J/6[3Z$E3I8EHZ]C]S>K%8R]"'I*8>WMBZ/%D;%^\@,=:F>5WEBWLUVT
M/Q&[^0KJ3]9'A.F$3SVZ=>K]@#8,7IM[<27`"X1+42,83WAWC3'N9-FN_<!I
M8GIMJM.$H(@'%%#%H8)S<;.O#TT^21B%G27PCIF;+%&D1D%Y`MYE6N:5=K6M
M"1[DKB>LKM6H\[N264CF9IYANM`\@`]Z!FWEJ>&E\;4;PRN2!V:7%.4K;W1L
M6)G!M7)3M>(E0B7I#3DBL@T.];+.3G&%CUON$6]9V6,8QC&,8QC&,8QC&,8Q
MC("\YN+5!VE5EDV7-H;QA;)Q&XW$)(KM7DE7\1D-=%QJE)2;9+9%[A>GTM,M
M1TVH-V^H)B).[)--3(_NSJ4!68GTA5:T>G%8L0Y<\M45OUF9TNJKB-$5U83(
MH@7!V;F7#<5OK;!51QG'-)A+Y)QTXXN$2HED]RDR^/HXO&Y8"6S1P:S7:7($
MC.F;GOT1G","4/9.@"-\.]%!,$()>S!:\)>C!!",00;'L/C$$`Q!!XMA"+>M
M!WJ3KOG[<K]TW)_RY>JGW+[BC5K<CJB:X!1M:VS:R`3G5G+FQ.,D:EGP>P[4
MCM64QA@;(HBL>R$L>\I\5,#9)=,1;4I-;TZ>8'"6ZW/D1QTA-P.5KTQ='OQ4
M2)0BG-$0BP*XA!Z%N?E[.6R*H-:<MF-@1.:1E0@5,4\C<L<$#['Y6A<V5S8F
M5:@4(@]WRBDT<2U5+(^J?V1,_*RHP-(RGNS>2[*@'S%A`0).VF*`K3@G"*-"
M4(L@03!%&!!L6P"UJ2@?9O\`&'^F+*L9:,\F37`(B^RYW\0T;(A&JTG`,)9R
MU4(024+>0(>MA">O6&$)"1"UL(!F^,?8`!;U8]%1V$-,'*?(+MS-:YPM42\\
M]X4>E..ECEX0'H3CO)(WX&PPDQ"``M&"\91IHSSQG"-'F;,67?<,'X_5#9%V
M62Z`9H)5L-?YO*%XA%Z,"U1]`<N.3(RS#"]*7)Q&64VM2,`_.6N:Q(D)T(T\
M`=Z!N@G3DRNEWY)]6F^41AEL\RIW)6JLB5Q8ABB%)QM^TA$C:!F:T$M`XNS"
MU1!O&3K8#8Q63(I*.,`Z'['Z3,8QC&,8QC&,8QC&,8QC&,8QC&4B``81`$$(
M@"#L(@B#K81!%KL((@[UO6PBUZMZWKMO7JWK,6G4C5!T@;)2&#,:1\:%Z=S0
M+6T@QK\M>D,T<G4FI6XU,B5&%&A"8'TI,=KQA#O>M]LQS-:=M(^4.\OKNZ'Y
MA4.BH"O<:>RS'*.D"`G*(TG2E>-0G3I?WK0@EC:%`P;,'OS1[WZ[@FLVM>O6
M*&C30`=HK=MNPSAQCAXV[R'%,G2!$:VM($JU6(E<>-4<`04HRR@$:+$41LT&
M@=A#;QC<EB+]+WQM>X"WQ=:2WOGOO1B0`3J3PIME:3G`T/:L(C%:=/X0D%J-
M*3`%"3ZV,&Q9$CTOB<N(]*C,B97XKP!$,;2Y)59A01>S1Y9!NSTXM_;`<`L6
MMZ[;#K>LA]R4Z:G!;ESZ:IOGC36,PD*XL\!LW0,VX?8>A'AT'S??[##F"5'#
M*%H)A05KFK("/6]"(&`8P"U".W02NKC:X*I+TP.HE>_&O8E!2P-360Y*IS5J
MX\L>S@IS]M!:1'M&$>@@_P"DM?S92,K8M'JCMZWYG7[YU]<WA%V1<PN!\;YC
MUVV"/]*NCBBN4%R$Y`GWO:AU=(Y&&M^"`19(-GZ`YU?7R3>_$`U8`.]&!E_Q
MN_=`?3?OY<EB\CM!VXWV(8I);EL'Y&L)M?[0N8@"\]*=-B3W:ODX2#0#*\3O
M)695O?@T:B(,%Y>MR<9ED7FK&WR>'R-BE<;=2-*6N01MW;WUC<4POX*A"[M2
ME6W*R1:WK83"%)@=ZWZMY<&,8QC&,8QC&,8QC&,9#3J`KJX8^)=KS&UYI7T!
MA%=$Q2S5DBMF-O$UJX+W74XC<PAS3/X1'AAD,UC4AF+0PL"N*1P!\H>SW)*E
MBJ55(]M:8V+E"/7*BT^55;//+IZXIU8&(U--IW0=/4"==$TF-IMTR21:-S"P
M'^V;MK6H`I(E#&QS8RWBE(-!EKTR2:50R263)4X&R)('+;69H6P[\.M;%KL(
M.A"V$.Q!WX@Z$+01["'8M:T(6@BWK6][T$6]=MZT>/\`QFY5<5>*2NH*EF_'
M^46:7R2NJWB'6PHS9B2"NM?7[R+G]\3*%F@C3_J21^8,A-D.L:C4U)+DC*,U
MG;W5TA9@5ZI`DE?QTHQ+1L7F!!ZEI73&T[1G=V6:XQUI.8(TNL6QUZ==(38Z
MQ*%SDI;6A.2A;D"?:UP6NCJ:C/?WI4>].[@8+J^449CBJJI9(%3`R*7Y(5&`
M)'H]I;SG9*`B8L(R`IW(Q.):2$D1IHB@EGA"6(TP0-!V,6]R4#[-_C#_`$Q9
M5C([\AZT>K89H]%6*4M3(>4]!=5K4YF"`%V1$$B($J*"G"<L--9_.,4$)M)]
MI#SCM;4*$PR2!Y=E-U<?4D;51?WT*Y*WB<SW%O\`3&Y.@$V!5EE^EI"=$*5&
MC"#U0!+>V]@T6>>?X0[T9O>9<SS/]<ZQ)3RGN/B=T?*3?E".7\DIRQ6+?[FU
MF>=J'TO%52]T;?=D"89HME[%'Y+8QB%0`G9OO`CA!NAD/Z;0_1'5M:PVFZW@
ME45XSD1^"UQ$H_"8BS)PA"6W1Z--B9I:DXA!`7LX_21*6-4I&'S52H9ZDX0C
MCABW?N,8QC&,8QC&,8QC&,8QC&,8QC&,8[:^3.N=FAK?6Y6T/3<C=FM<7Y2Q
MO<4Y2Q&I+T((PA.3GA&69H)@`&`[A[@,``P&PC"$6L71JA:OATM332+QWW$>
M4J5:D+"B<''3=L#@#12@8FXY4:G\?D^(LO0=!)+T+8PD^:$!@<9*ZVY'QUX5
M+X=<B&1MJMP&I$SSMM\6B$YZK9GHQ9Y"9P[%)B1^6$*$QJT(LO7E%E#WK6KO
MLNXY36[Z4F,JB3R>*^YR12JED>-TI+)5&C."J3[;P)%&R@I=`*WH2U8DV;LW
MN#>P!\>[J9KD@3O"FN?+7,47879P,:$ILL*]Q#].19Z@@23]]&849L0DIXP'
MICSDPR2C#?.T$HW1>"[WX1\(^9K::INVAJ<N(:HGR2YB<S-GOO3DB!H(=-MB
M1@UNF#?V#K6R]I'\KP;#K>@^K>MZ=)-^YZ3J7>UTZZ;'.;D7PZDN_2%B>&+)
M$Y3JM%JX9@1EHEA:%QCKT-L,#H)1^I038&]AUK9B90'6RQ=.#DI^Z"^$ANBN
M0'%:K^H35S2>$A58''A9[BV@L1$`[^FF,4;:DKF8=Y/K-`91P@".!OSG7L(1
MXI"T)^Z*>GY:+UN$W"Y6-Q&L=,9I(XQ;D/#E;&VI'`)FBCTQLN8-O32T@),\
M8!&S`F)"UX-^:24+?@UNNKVT*WMJ-I)C5L]AMCQ)?H(D4G@DF99:P*="!H?8
MIV8%J]#L6@BUL0!'!,![!@#O6]9?6MZWKOK>MZW[-Z]>M_RXQC&,8QC&,8QC
M&,C=RU9%[[1,J3,L;L^325([09WB1-+`@)MIL,L:9Y&E\=G$*(M)4CKI:YU^
MZ$D350US4\4:>FEB<F5W2KTC@8@5:T.']<-,ZY>,5Q\F>>DEY&<GZAK&;Q6G
M.-D\HB)\-Y%2,.M8R,ZL*>JJ"$8.Q+"D$Q30MHCX+;VX.5;":T;JBA"8LE0,
M\G>!C&8%Y-?Q)S7\6._Z7Q[,\!]F_P`8?Z8LJQOV;^WD5X_%9-*>3$IGDA9G
M-MC\!8R(U"CUQ(B4[D<XIMA5KFXT6MEK$P@*G<T\9`M@`-4A*/UI03L`)49C
MVVK/AU*5?8-O6$YA9X-64-DDZEKD+P;&D8(NTJGAS&G*$85M0L&F2#)0I0#T
M:K6&ITQ.A&F@#OSR="ZJYIR9M3E!UAKZ9CDTZY0S&00BA&AS\Q7[RJ6CCBF;
M''3*<K(%_P`B$;'H_6[4M3&%&&M]>/2L.QD20\9WI=QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QCMK_CV_E]N6W*(A&9JU;9)4R('QKV>6I"C7D^864I*"8`M2
M0(.P&IU``&F@`>086:$!I@=#\(Q:WCJ(T1!Z]42A=`PND;<)*SG-.SP.:MQ3
MM?B\TQ.L0(EYAI>U292,!Y8U)A^]>5HD`BRC#M&6)%H3R3B$C92#[,CT\AGN
M@F`\[DB`Y,_`:]#UI88E,*2GGC7"(\6TWC=SB/2/#HTO1.A;W]LVY!.-?RAT
M:Y-4TV]ZZ%066AF3264Y(7`D2<HX:O16R4Z5,`)@S"O+$Z;4!V4+9I10M^#5
ME7U3'"CE##8R5R7K"GYVSS%I*51DRUH\RII.G1GE$J-B9'Y8%)*(ZJ)TJ)T:
MH9WE`:088#PG]Q`V+45./W.Y2D>?3K/Z?'*GD)P@FZ@T2M,*`3M\F\`4B!V,
M((,(W(F&:F)MG!#H8%<\>T(2]ZUMK-#W+%9NIK^Z+>#N]%2R`4IU,ZG92RO-
M?88:3%;F-:BA`UH&TC>1#I`I>-E:V(>BX)9J@P>Q:&O5BT$8LOT]^Z.>'CO)
M05QRMKR\>$-H$&[2.K%=,&>%\;0KP]@C3B?6%M#)$)`#.X=KY+`X\C"7L)QI
MY8-"WK=Q4%^TCR`CH)91]M5U;<;$$O8WBNY@PRY&F$;K>PDKMLBY8:W*==MZ
M&F<"DJ@O>MA&4'>MZS+>MZWKOK>MZ^76^^O_`&SG&,8QC&,8QC&12YML2Z3<
M:)\PH+%OFI#71TK=*IL?C''5\JO2)-0K4A(WQT@#.V,LD7"6!9`."=X<R(U)
MO<",GO;^;&I"2V&,RW5-754=,>PWFV.$'$F..5D6M8E6V.NN'GHP-CUR-F-.
MVJ;&F[<&D$_YEV8*7JG7DZF=)+JQ:WKHBP#GZ"BBZ]\5,$%;PL:1RWR1YH<&
M&+,;$K?W"1NC2QM30ID[T6E$ZOB]"WID![\[%(BTB,3@YJ2AN:\M(4E3"4GG
M`(+(*V`(-%L!YS<CU_"#C8ZODQ3/UZ\F>IY:'!,-J$16)LH(7!HWS*Y%0)?-
M6N()D'O7')8_0E&.C5$BEZ%U0[FZID>Y&DDI)#DC<M@_!N\IY:1O+*L+'<PR
M:2\2^6\YXZ)YT-,W(W&>Q`%=U7=-?2&1)&=`TLQ,O0PBXV.)2\]G9VEI=I%&
M5[ZWM;<0ZZ1$7]RIL:#-E?R6".$I9TDQ=28F:VQT]6$#HM+6S-D*2B3IMZ[F
M:/&F4!+\.^XMDF;[:T'>]2M#[-_C#_3%E68NN:=AK>MI1*@&EEKTJ':1GT9X
M>PWEQ'I$V[T$>A!,T0H.TK-+WK>A$IC>^MZ[ZSFF"Y4"L8>9-7-8[218U!<G
M!6OV5M9K3F<:O1I5`BBB=".1H5"9,9L8?,\98@CWO8==LH;WK6M[WOMK7KWO
M?LUKY=YYE.N=?SUR6G7'[H_\:I4@<[3Y,V6PF<A#HZYD.)]:U=&E*61@9Y@6
MVG*C68Y40E4V8]-+B02NU$8,C\]*-%*T/I7HDJ"JX31U6U[3M<-!3%!*RA\?
M@\3:B@EZVE8HVVIVQ!Z0,LHGTA:H*3^EN*LP'GK7!0J5GB$<>8+>1\8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&<;UK?MUZM^W7VM_:]>O9OU>KUY8\VK6#
MV*F3)9E'$#V!%HX*(T_1Q*Q%I1Y?GZ1KDAJ=6FT;Y)6S`E'!`/91>QA%X-98
MS/1K/"89,(O6CZ^PY9*1EJ27L2T]X/959("BRA-R=082$DK9(#"31`,"L,">
M(8E8C"4^RNFKV-\AH[)T2.:32)S6#!(6:5+#$)B22@'H@?H/D:*0)PC,]+\G
M:@2I6L!Z-LWL9YW@WD?KT?J5M5*Z5]RRXFD3*%A6.2!"9.H.Q6(SG$:/-3DN
M3<8[MA9C>I4E``H(/C[@8M)T8#T<[9H=;UK(NSH#\#RYJGE?%R];5X"W.H3)
M71F559:#F)K"2=L82SMQF4/Z.5HR3S"QA+1L4^84OB+.+`B'H&PZLX$4_=%/
M"$`10V<T?U.:C;"C3TR26^CQBY#&@D6_L`K5KC#GQ<Z'D=A$#W,K1/&8'?A(
M/V+90[^KW]T94K%),DK;GGQGY&\&;%\XI$X#G,)>Y9!BE/;03#R%Z5E89T)$
M8+]^*/3P)S2`)WW]T#P:T>/=?0_+3C/R?:/=KC[>E7VZD`0%0J(@\P:'EX;"
MQ:#O6GF.E*`2%D-^RUH1#NU(C@"[A&`(M;UJ0VMZW[-ZWV]ORZW\F]>W6_P;
M]><XQC&,8QC&:ENI_<"R2P9WX8U7QUY1\J+AL^-1F;R&$<7;#8*!5P:NF6P&
MUS0.-B\GYG(XC&J8;[/<X:^PJ/DLCLX65*6I#.#HFSI4K&X2%LQ7TZ'>,12Q
MHS1JOA7=W2HFT8KF22-'Q1,D%:3;BU>C$4I8F)QL*OK$JMTD4#E%M5X<H9E-
MDC3CA-F/)<U026Q6NPB`-4J8=W8P[$'>@[UH7M#L0=B#H6O6'8@Z$#8M:%K6
M]AT(.Q:UO6A![]]:W8?TW8-%^-K;Q[56)*'\^$<HI-S"J*R7!ABQ$HK2[7Z^
MY)R03.B%N2)-,#XQ-E@S&5LXF=T2!.=:[?W&(.+D,XT+Z"2_&GCC&^.$7G*!
ML<U,EF5O6U.[XN*<+$9+8HG-L6,I0[?7P#,E/4I&)G:V1GCD,B3$0J7#9(;%
MH^V+'5Z<4ZUY<.SY-:_^"<U_%COV]_\`U?'LSP'V;_&'^F+*L@Y<-]M+;<\<
M@SD0V.T`9S"D$^1N*)$XH3W-W$G-3*3"U12@'CB'A0N'<&@C"<>O*%KS"`;!
M.`L0!`"(O8=@V'6P;!O6P;!O6MAV#8?5L.P]MAWKU;#O6]>K,.\BI,BAE!79
M+7&PU51HHU4]AOBBTT+:V/2^N0-D2=E>IPWLKR$QI>G"+F%`>&]G<2S$;JM2
M$(#P"`H[9XT?W.AP;Y06'R-+ZCLHF#[%JE*U8K6"4RU$AD$ZY/ODO.5-TRUY
MD@V\.#.PHI`D+=)C/A*M/[A+&K<3C:Y8CU)G)/[D]>K6N^^^^WKW\OX?5ZO7
M^#&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8SC80B]6]:WKY-^O6_7W]
M>O9OU^OV>WUYC2>4]7-E#`?,(PB<UQ2<*4ET`-0A="B`"-&62%P0G)U`R2C#
MS3"R#A&D`,,&/1?<6]Y:JJF53#6Y4"JN:/<$-1O(GE,\&F;>E)OG'G*%+8H$
M8).,IO/-,*WX$GE^#2<`3"SRS5(#K"+J&9SEFDT)Y-QVI;\K@QE/,;V&1Q%F
M?Q.SL6+6RDZQH?V+3-HL]+H\G9YY!AY:H9`RE.@:,%FA^U^CCP"LR:-2R$U1
MR$Z?UUKG%*EC$QH>2/'O>1OK@L"%(I'&GW9A2!(2>:#Q@@QT:"64'8BU9)!>
MS`_/NJ.NOP:?38S07,JB^H9#V-0G*!4W(=>W1RXBDNTY1Q*4EPETF;'HXT23
M8`DA!=RX6M&%&%L>][*`/)<>_=#!%)/B&O\`J3\(N1?#>8[&0A.E:6/*YY63
MFI"/RE;HV*U:6.O:AIV9H1J?44U80=D;"(I>KU]F+<YQUYV\/N62%.LX]<B*
MNLU2H#L6XZSR5*AFR36B_,WIR@3[[E35L%H&A;V%:PD_P!^$0M`WO)9Z%K?L
MWZ^VM[U[-ZUOV=];[;U_+K6<XQC&,8S6GR:=>8'&RU':]N,?&1MYE0&RXW$X
M_:]-L5I1*G[OA4G@>GQ,PV17+S9`2Z[L6+O$8=]1^65X[/T-DK*Z,C3(XDY2
M4+X_,:'K>.$CYI<H;<B5P\D.*Z'A94M1-\M/KRL9;:\*MV^+)L&9L9,7%,Y8
M961*N`5A`8M#W"4-;;%0RB5S.72-[(=W@$/;8ND12+9]CV>W.-;UOUZWK>OE
MUOOF!N37\2<U_%CO^E\>S/`?9O\`&'^F+*#SR4Q!RE08`E.G*,//.,%X0%$E
M`$8:8,6_X(0`"(8M_:#K>_M9&JNH52-G.,GMMF81/X)8O4-ZU'*VA(<V)ES6
M846M7M;4N1F:),>-Z(5J%NSCS#M&##V2F&K4^Y+%%%$%%DDE@))*``HHHH`2
MRRRRPZ`666`.M!````Z"`(=:"$.M!UK6M:UGFWZ]MU3FX7/CGTF>/K@+=O\`
M,^9L*NRE",0S/>E2;*]#/"H>@D:$,AI>'9D=94\]Q!T=$*U?T9P1$NY>C-^E
M$TY"^/=-UC2%=H0-T*JN$1R#1PC1)))QC='6TA`!>MTG+*+-<W4XHYU=5/@T
M-6YKE:HWN8<,6\L8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG&P
MZWV[Z[]MZWKO]K>O9O6OM;[>KOK[6]Z^WO,.3F@JJL-8K=)'%DXGE9HOTAY;
ME"IL<C1%%`)*,/-2'`(5&%E%EEA$K3J/L"P`%W"'6LLVSJ#52FNXS742D#>@
MCL>0G-BN.S6.M,[CLK;QI@)R$LD0/Z%Q2+`)]>D;T`]M5I!Z5F!VC!Y2;96F
M>Y^@)Q(M%AF<X>ZA^".VV78G*&2+AS(#JZ5NZ[16Q#4J(0[-SA7B%80LV4J)
MW'(LP+U``J"2S`F^C>*'4&J7K;\59,V0WBCR\/Y+QPC1@FVC^94=&FD9A#4F
M/4^X2&6R92Y'@(VD3C)2GH;.A"/1H0Z&E2`V`.2&B7[H'L>D70V&]1S@'>-"
MO+,N.:7VQZC1[LNM-+4YPDZA5M,L4)1I4))P=ZW[WYI.A##WT0,\8/`/<AQG
MZC_"'E\0E#0'(^MIJ]J0%C]Y*EX]ZEB$"&7Y@P'U_,"F*7=BM]P&'IVE2CV(
M._+4F`V$8IN:%K?J[^OMW[;UO0NWR^'?;?;^3.<8QC&]:WKMO6MZW[=;]>M_
MR9QK6M:[:UK6M>S6M=M:_DUG.1EYBL/(:5<<+-C/%E9#FZZI`VM;/''"<3R4
MU@SHV9?(&DB=&(;!A<,G\GA<L,@8I(E@\J:8NYJ(Y,%+*^[*T%NWWQ%TXIF3
M*^.PVIPCMY0JP:YLRR:TM^!\A+JD_(J>PBU(J_ZU)F!#=LH7N"JR8!M.O:7F
MM)4C$A1.<'=V0\QDC[H)S9$&2.5,X1H*_DL/&PS10K<28F84](8:_KHFF]*F
M;(6$#A*DR(QE;S"?($-4!6K*VF+&0,WPZ/*T.5H?9O\`&'^F+,>6L@<'R"R"
M+LKVTL3_`"IO4,#*I=U?HB<]4N#H!Z,O8`FJ3#U*#2PH&DA"A07XMG!)'HO>
M?16,)(KN!QJ'DC).,9VXLI:I(+V66K<SQC5.:L.A:T9L"A<<<,OS=>9HKRPB
MUK8>VH\<W^<-%<!J1>+KO)],3(P",:X9#&8211-[)EIA`SD,2A;4J4I@+'$X
M(=J'!Q5')F6.M9:AY?ER)O3B&/1KT-8VZ<W^3'+CJ]W&<R'S6<3%RI"E8&0Z
MIGM73\&:&YF&Y)3@@"$QM4"BX8O$&128G0*79(GFTC`GTBEY8S/4=C&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC./"'OH6]:WO7LWOU[UW]O
M;>_9W_!VR/LOXP4[,35ZA5'3FA4Z'GJ'(Z/.*EL*7FJC!&JA*VW>U+.?M28,
M8S]C;O$8,8A[WX][%FL_DOT,>$5T/:F317CY3D+=5R%,!>*-M+W7;CMX1B4;
MU(6AZ@:]`G97=44:4!:>E8@;7*"`K%QJDX0MZBJU\!NJKPY<VY_XH\ZWI11R
M4`4:R@.0C3)N58HUM.$T2;4?<U_H#_N(.!Q185!#+(8F\Q9,9YFE$AT9HI+=
M,CY[]3FO3$-FSZL*/ED?J@UD236AN/;=-I!,^13'(7CW/ETDAJBP$B"2UC/*
M^;C&APKZLRM2MNG2\<F02&2%$+&`UC]$C4N$YMC>XC0KFP:]$D6#;G,HLAQ0
M"5)RSQ(G`@D]242N2;,VG6$E*%!92DLTL!YP`Z,%V&,8QC,/W?3R:[H63#SK
M#MRKCD<EC4J;Y?2MA.E<3)(XQAS+<TR(UU;REB)YCCIX!H)'$Y&U/4:D38<8
MC=FI2'1(BKEK>MXM5462Q*))5A2`I8YNR]>ZN:]\D$@D#ZO/=I!)I-('4]4Z
MOTB?W54I<79V<5)RA2I.V$/E)BDZ<FP.36M?`G-?5_\`ICO^E\>S/`?9O\8?
MZ8LBA,V1[LKD-7Q`$"HV!5F0JD2M[(T6>UFRXA1ZVK:PD>RRG5$J3M!*AN,&
M%:00%8,TD!!VMF2Q]FO7OV:]>_9_+^#/)]UFU(^IMS:XX=*&A6R,K);6KNXV
M_P`A+S4L"61*J)CR^/)REK$B6^-`K2%@CK@SODPCZ1Z0DRV3/541)0H2JRUB
MANWT<">!M(=/:B6JE:;;C52A0>4_V-8CR0FU,;1G)B%.B72N3'I]>2G`!.G*
M;H_'D0M-$78DZ5I;@F;`J6K9LXQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&-ZUOU;_P"/M9&"5<4H++Y2[S!SDL[+>7AR$YF'(W9J*"C/
M#Y>DI:`0V0TY.2WEDD$H0[.,&0605KQB$'8MR:(*V0022(TT\1119>SS]@V<
M=L``@V:;L`"P;-,WKQF;```=C$+80!UO0=?KC&,8SC>]:UWW_P`?R>W&MZWK
MOK,#<FOXDYK^+'?]+X]EW6E8C=7,,DC^:>D,=&ME6.3<U&J20*59NUB9K2';
M3C,":)`4ZN3>4M4`#LLD!P0B%H0P:%%KB6*T6AS>@2J-2'<3G1(Y@EDBXLH*
M3W=/T`XY>+0U.CP%R-&=HS0]I^XCDB07AT`[8]:V>J+U[Z8X6R*?<=J<:%UO
M\E&N%O:8;FS',JFMJBLQ<!(GB[)8*I2N*5O;RW$*U$C?(K'2%:ANVB:F"0*6
MM4_&B:L]=&?I\/O$.FY+=5\.(YGS)Y7+R;.ON:.BU(_.C3MY4JY`T0!._IC5
M*9>)`H>%;],'-J-"VO<P<U0$0E#$P1O9.YW&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,UB]4*5RQJA_$.OV9Q6M<'OGJ"<5*
M3O`Y$4J[.-/2:0R!_>X8X+41I![>PVA)HG$*MD>]GE)W=AF;C&E6CTKX<E45
M=-:3NZQ=SYK,I<J65C074$MNIJ03G%&%H8U7IE64A9CS`H]LPLL(8G7EK6-8
M\0BS:CU[E19C:T4-9P)FF/(427Z.;EKV^@G<4IV/11O9ZC?H.XS&96@N<&1R
M<WV2('TAOCM9Q:*[4'N#7MM4@(G,IE[V@`WJT2)IB\=TK5+Y`J:8-ROG&2]<
M@V2LD4_@+SRQ>(8>P5W33W&Y0H33$Y=&74YO.711O2BTY0UY=23WV4N+8]DM
M#>!&O\;NT^X_9'I8X&W_`/NAOE<+D!`Z8LM<WI6JS'C5KV3>$2C+<IJB?N`A
M-TEJRK3IHRGEQT]D"2!?JL6:.GH8$2G;S@'17W:++>IO5!^YZ&-'9L/N[E<.
M_P#E/8XY?(+!NIA?'^B&:MKBE;LH(<407HT^>+IVH9R'C:YRE13J\JQ6#M24
MVN*1B9BUK>Z^EU#/;+;$:5N;N-4I0H$*8A&B1(YO3J5(D2)2@$)DJ5,1,"R$
MZ9.06620026`DDD`"B@`+`$.OJ^$NU_O=)E]/JB_;/.@:[RGSR[R9B;^/LW-
M<X@N;FY^('-:I)`E5NS*AD"$!)YDQT4J"8U.*0\9A`A!+,,$0+?F%CUKO_A+
MM?[W29?3ZHOVSQ\)=K_>Z3+Z?5%^V>/A+M?[W29?3ZHOVSQ\)=K_`'NDR^GU
M1?MGG12*\)_%&\AT?./DW3(E+S'F`DPF;50J$)TE+XWQQE)V61,1#"6H=W1$
M0:>+6BTY9@E!VPE%C%KO?A+M?[W29?3ZH_VSQ\)=K_>Z3+Z?5%^V>/A+M?[W
M29?3ZHOVSQ\)=K_>Z3+Z?5%^V>/A+M?[W29?3ZHOVSSHFB[[`?%\F;&SCY-S
MED0>B(^_%F36J2`I710Q,\C*)),-F(0*BQ-#\V'[/)V(L)APR-[\TDT(>]^$
MNU_O=)E]/JB_;/'PEVO][I,OI]47[9X^$NU_O=)E]/JB_;/'PEVO][I,OI]4
M7[9YT$AO*?18AM4O?'V;IB7>0,,80"*FM4JMFO,E<B&EG3C"1,1;**4+U!)1
MJ@?8I.`6S3=Z`$6]=_\`"7:^_P#PZS+Z?5'^V>/A+M?[W29?3ZHOVSQ\)=K_
M`'NDR^GU1?MGCX2[7^]TF7T^J+]L\;LRU]:WO?'69=M:[[_Z?5'[-?\`^9Y;
MT?O2>RC;WIFX^S=1N.R%SBSMYLUJI-Y#TS^1[H)R_/F`//)*]))\"DKN4;XM
M^#?V.\N'X2[7^]TF7T^J+]L\?"7:_P![I,OI]47[9X^$NU_O=)E]/JB_;/'P
MEVO][I,OI]47[9YT#W>4^CJB.I7?C[-TYTJD!$89`ES6J5&E+RI;71V*3FB)
MF(M)BA(69P-VH.\)01E`*WOQG%ZWW_PEVOO_`,.LR^GU1_MGCX2[7^]TF7T^
MJ+]L\?"7:_WNDR^GU1?MGCX2[7^]TF7T^J+]L\?"7:^O_#K,OI]4?[9YT$>O
M*?2DAR4LG'V;J26B0/T87B-FM4I=E/,:<CVEX3@"?,0[-*3KTYQ12@'<I0`.
MC2M[`(.]]_\`"7:_WNDR^GU1?MGCX2[7^]TF7T^J+]L\?"7:_P![I,OI]47[
M9X^$NU_O=)E]/JB_;/.B=[OL!C7QEL<N/DW)62]Z/C["67-JI/"I=$[&\2,T
MDXPJ8B`E+"T,+H?H\_82Q&$%I];\T\O6^]^$NU_O=)E]/JB_;/'PEVO][I,O
MI]47[9X^$NU_O=)E]/JB_;/'PEVO][I,OI]47[9X^$NU_5_U=9EZ]ZU_5]4?
MV]]OM3/>_P#VSH(S>4^F#06^L''V;JFPU:\-X#CIK5*0S:MA>7!@<P;)/F(3
M-!)=&M:069V\!Y983R][+,!O??\`PEVO][I,OI]47[9X^$NU_O=)E]/JB_;/
M'PEVO][I,OI]47[9X^$NU_O=)E]/JB_;/+><KUGK2_1R-+N/LW*>)7[L^XB<
M,UJHTM1[@(2W)T\Y07,!$IO)2&@&7YP@^>+>RP?9:WEP_"7:_P![I,OI]47[
M9X^$NU_O=)E]/JB_;/'PEVO][I,OI]47[9X^$NU_O=)E]/JB_;/'PEVO][K,
MO;K7]7U1_;WV^U,\Z"+7E/II'6>51WC[-U;(_(27)L4G36J49IR0_P`7E#,3
M*)B`XD0O#ON68'0@_;UK?JSO_A+M?[W29?3ZHOVSQ\)=K_>Z3+Z?5%^V>/A+
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M)`D+7/S8W*3$Y`U(3"TY:Q85LP@HQ6,.PE`.`$P\SPZT(9NPB_%OK.N6I\;9
M.UP*&-TC9VMT9&B0(HNR)7QJ97M8G<7IG;78E"!Q0-3NX)$BYT;4JDE$O6)4
MZE60:>26,-WID21'Y_HB5.F]*4&JU/D$ED^D*C_#YRD[RPA\U0=X`^:>9XC3
M/"'QC%X==OIQC.G;FUC2+WMQ;$:`AR>5B8]_5I2B@*G!<@;TK8E&Y&`UXS5*
M5L2I$97G;\PI(207K6BP@[]QC&,ZQW:6EY2`2O2!&XHDZYL=@$+B2SR"G!D<
M4KPU+PA,UL(%#:YH4C@D.]0DZI,2>'>A%ZWKL@B",(1!WH01:T((@[UL(@[U
MWUO6];WK>MZWWUO6]ZWKUZWVSG&,9TB)&P-;FYZ0$-J)VD2KW<=0D:()7/"I
M(@;63;HJ!K>CE@T[>@:FT2K81Z*(2I$PAAT`L.=WC&,Z-]0Q]>4WE2%.V*24
M[TTN#8!T"0(!;\W+2UK*H1Z4;UKW33+B2U#?LKNH"H+",@.QA]7>8QC*1B"'
M7<>]:#[-[W_!UW]7V6_9K6_9WWVUWWK7V]9TR!M8(^8J*;TC<U&O[NN=E1:<
MLE,8[/2PO1[@M,#KPB5KSR4NCE)FM#-$41LT>O`4(0>[QC&=2X-+.[FMISFW
MHUYS"Z%O#4-4G`<8V.Y2-8A*<$?C#L2=8!$XK4Y9Y?8?HZP\`=^`T7?L23B5
M!832#`&E#UW`84((RQA]GB`,&]@&'U;UX@[WKOK>N_?6]:_7&,I$((>WBWK6
MM[T'6]^SN+>M!UO?LUL6]Z"'6_X0MZ#KOO>M;ZMN:69@*4E-:%"U%.+JX.RH
M"4HI,!8\/2PQ:Y+C=!T'1JYR7'&*%)N^YJA08(8MB&+U]MC&,ZM:TM+HI:EJ
M]"C6JX^X&.;0H4D@-.:7(UM7-)JQ&,>O$E5&-3JO1"-!X1B1KE!??99V^_V%
M*TIYRA.2H(-4(]E!5D`-+$>FV<#S2=*"0BV:1LXO]\*T:`'F%]A@\0-]\^C&
M,I$((>WBWK7BWH.M[]FQ;WV#KO[-;WOMH.M[[[WVUKOOU9TK6BCT;*3L#0G;
M&<HTUT<$K2C"0DT::M<#G1W5D(P;"(S9SBXGK5YQ8!:])6#..$$9W<7>8QC>
M^WK_`./^/P9TA[:P.:YK?U"-N6KV'W2]R'4911Y[9[H$:1.GH:G[+9'I*<GT
M99H`M;$`O91O;P;UKMB#R5))2A.:6>0<6`TDXD83"CBC`Z&6:48#8@&%F`%H
M8#`"$`8=Z$$6];UO/UQC/Q&>26862,P`33O%LHL0M:&9Y>M"'Y8-[\1GEAWH
M0_!H7EAWH8_"'>MYUK*VL<>0(8XQ(D#2W-2,HA`T-Y129.A0@V(!($Z0K0=$
MIM"T,!>P@T5X]"`'>Q:WK.XQC&]]M=]_:_EW_)K7KWOY-:]>_M9TXFQC<G%L
MD(T2!8YM*9S2-+MLHHY2A2NVT>G4A$KUXME$KA-B(*P!0_":)$2$S[(G6M=L
M`8#`^(L81A\0P]PBT+6A`%L`P[WK>]:$`81!$'?K"+6PBUH6MZU5C&,8QC-4
MW,-&&P>H+TZ:+L).0^<?9K`><D[EL$>V[3K"I_;5=PJG&.L6:6H%`36MP][\
M(LJY9I'6QW(-3@>F(N3(``>8PVK4%X=(&?SRSNG'Q@F%BO;[)GU7%I8TM,GD
M_I1DBE5>12SIS$:DE3TL7!`N=G.352PPM[5OJW7I<@-7">U.]G.`][V4XQGR
MK2!*D:I,!2I1#/3GD@6(]E:5I1FE#+"I2[/(4DZ4D"%HY/LU.>7HX`-C)-!W
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MD^22GBWOD)!H-9EX]0[A9(N<JSES$I.XRF4*'%*]5&Z2VCI"SO[`F'7-4PB.
MWG6++3<:@#V37S5J./S*ICITI$OF4F]!V,8SS[=8LN;.]DQ<%/1DJ]I?`>''
M*F3VY0;NR-KJJA5#R]UKF,./*J@C)`O:V13RXJAW9W!%4,%,5-YEH1M7/HOJ
M=ULL`SK9+NNH*1Q:8T934N@TKDD\A4IJFN9'#YO,3E2B6S&+/<-9'./2J4'K
MDR-:=(I$T*D;P^&JT:548ZK58U"<DT0RPY;QC-4O671$G<,V-RWM4!:Q<S.G
M8M;#DJU>D$0>X\\^.L<7;,`B4D`5DJF1Z=$!R5:!2D,(6&^(C9G@&"`'4/D;
M^KGO6BFDP>'QED_#[IX\;;*X/.2(+@D<:\L5Z#R4L`-EUH87H[09K,K[KJ`P
M5]>6<L#DYM$'9(4XC,9SC4JKT;Q%8].$6CB^1HPM\@6L+,K?$`"QD@1/"IL2
MGNB,)1AIPR@I5YB@@)0SC1%Z+T7LP>P^+=Q8RDS>]`'O7MT'>]?V=:[ZW^76
M:8.&]=PJ=/?6?K2=+G9'6SKU'7]-*@!ECRR!,B*[AQPREDO9%LDVX`<6N*2+
M:U^1RDA(XH"A1][>T2<]O(4^85F/IO<?V>D5_*E_K=BU4/'B[KO06?QSXSI6
MT<99JIKTFO8Q"G^<Q^O3@I!U:S<@[)C4OMAOKI*SLJ1B;G)O7+V=DECU)V!H
MV?8QFI?JQD!TW=/AR+,5%+$'55X)$)S4RQ:F#Z.\6:I;G(A02E4%$+"%2,6R
M1DKBE)(-?OA8`&ZT9J`G53Y+'.7)3BO%I*P<D8Q$>/O4QX$-T8;&+C?R8<H-
M;#Z^2U.^S>Q-6'%ZM<:XL5I8F![2P"KJV8Y4[R5TFR.QI$7%G5T:H@:R^F$/
M\$.ODUK7Y/5^3Y-_;]NO5E6,H-WO19@M>K80"%K?R;#K>];^3U;U]OU?+GF)
M471;7&OA%UJ9E0#PBCEHD]5Z?5)6LNE*I6X,U7.%^/?#VH!6>X'NA#]HIJJT
M5GN5@]ES>YLR0QF`):VGM91R(S9QT]'YI@\]Y5<.!TU'Z^F'%>15`-\LZ-RQ
MVL`/(5CNBOE,UBUESJ<R]L06*^7-HUMD37:7O[725U4.1;=)F^2+6:4(D;?M
M!QC-2_5(3%AG'2Q=2Q*BER;JFT*U@-3K%I!8VYXJJ^QN*54E3J"TBTA08VH#
M-A6D*`DF)2C2?*,UX\@5RD=7>,]0686B=[O2WCLQ<KNGC65W7>Q,B,ZX>&5O
M-Z.%OD(J>NUZMQ`YN7&#D`;95.M/(A7&@)E4!4WA/0:8+`03N7K*W]+8>WAU
MV^UWUOU=M=];WK>M:]?;6MZWK6N^_5KU;W[<JQEFV'$VN>0>60M\<GII9)2P
M.C`].$=>5$=>R&AT2F)'3W-D"(12]C4G(#5"<+PW*$;DV@-&L;EZ!:20M3^:
M&RZ1*H9HM!WX\,(Z'X0\Q^?72]J0RE8DG<HG'=U`DNAKKGDM>K%!V\U(56T#
MY;N[_7M-2!6F;VP-APZ-%SQ]+/(M!,N5[3NG>YKT-L]2JJ8]YX:-ICG`"*4H
MV@)-(88<FE/&+CQ:%KP"&D:T4@01.-W1.)NM0LC6E);6!Q?W=L1;"F**2I-H
M6,9ITZEG$&O+_71SWH-CF3S.D$KJ1UI7D$%4M"\\.(14$_8Y?/K=BDH+4(2:
MRC9;%N2(I`T-ZI,LO:6R9CK^0;>(TF'N(+<XEUE(.=''"X*60J(M=\`NAYO+
MD[R@]TEAST\4?,:]E,$C/$N12Q2I*1RN.V9(W>NC8%4(%"I@K2(UMNP"V]HD
MC]%%<_W%!UO00ZWOQ;T'6MB^7>M=M[_EWZ\YQE@6G"HY8U>3"#S!P=6V)2=C
M6M,I4LS\JBZX<;4@U[NHM2%`<E7LR-S:@JVQS<$"Q`N3M:Q:-&XMRGRER?1C
M7#3\29CY1SSCM!+'JGC_`,NN051,/'2H*?X_VC:C?QXBJ2N5D<N'F$T\;JCB
M,SDD(CEP/$=<W6#Q9-!T<>D4R;*LD<R0M8[)DI#=G/H,2J.R/I]I6Z,AL@3;
M#N57.R-$J[3C=B,4L<$AG,J[Y&R*W%QLMF9WZ5NNXX_LY$L>^RLY#-R9-%I"
M-NF,=DC&U;FL8QC&,9B^UZ8K*[X^DC-HQ%OEC4W.6WEJTI-<&]Q9G4;8Y,2A
MQ8WQE6MCZQK%K`]/<=<5#0YHC'..O;U'W$2IF=W)"JOMB8F2+L;-&8TT-D?C
MD=:FYB8&%D0)6IF9&5H1DM[4T-+8A*(1-S8VH$Z=$@0(R"4J-(04G3E%DE@`
M'M<8SYU:4E:E4(U(=C3JB#DQX`F&%"&2>6(HT.C"1EFE[$6,6M#*,`8#>_$`
M81:T+42Z-X#<,^-,S,L2AN-=1U5.#(ZXQ/WU0V)I&M[+C3NM;'%U9"%WB--3
M-SDN9FI4O3IME!5GMZ49_F;*#DO,8QENRZ)1F?1230::,37*(=,X\]1.5QE[
M2%.#+(HU(VU4S/S&[MY^A)US6[M2U6WN"0\`BE*10<28'8![UGUQ]@98JQ,L
M8C;6A9(]'6EM8F)F;$Y:1N:69G1$-S6V($I6M%ID2!`F3I$B<O6@$IR2R@:T
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M!O\`$G=+((N\#2!.)"-PCL@0-[\QJ1;V8UO;<WNZ+9+@@2*2>CG_`!TI.TI+
M$YA8-=1Z5R6%Z;RV-W=R51ZO:5H?FV6-#:];`K+*E3,T2]E9IDU,DK*?&=LF
M30URU"A3R-O2.96:]:UKU:_X_7O?V]^W>\8Q[<C<Z<0>-+VPWE%W>F80Y1SD
MN\E2&_61:W'*6RW7PE.W(@NT]1FJQ$R%>-M9VAH.5*P[,4,K2V,JC9K2@2(B
M?KH+B=QNXM)I8EX\TO7U0$SI>V.DQ]X[`0SFR9P9DBA"TJGM0`1BEP,;4BM4
M0A](.&!*!4I\D(-J#MCD-C&8LM6DZJN]OB[5:\'8IVWPJ;1VR8FD?R#E),=L
M"(*1+8I-&C12@C:&3QE:,2R/O1.PKV=8+:IO.3G[V9G=SBM*_LLJ+D3^'QZ8
MDPJ;Q:R8D7(FQ,Z`CL^A*[;G$9@SA4A'I#(8XX"VM9W0CPJ4*G>S21A'OOE\
M:UVUVU[->K6,8WKO[<P*V\7N/C2P75%4=10?WL\C7B12&]H\J9BW%DME^ES4
M!BE+U/&MR&L12)UD;*2E:7MP7$F*G-N1($:PTU.WHBT]V573=;4JR+X_6L62
M1M"[NONX^'A5.CN\R%ZTVMS(6[R22/Z]VDDC<T[&S,S"D7OKLXJD3"SM#(D-
M(:FM`C3Y.QC,66=2=5W,*##M"$,<U'6<Y:+-K\;V2>>.'V''RU)+#-X\(E00
M)LE+*2M7$M+VGV%P;B5ZXI(>26M5!.M1\XMT!)+3W=+U5T9760<IAC@XR`92
MTHI]=ZW,5G5S().PIUI,9E<FKTU:>.!R>3,KM(8:+R?>VYMFDB31&?L8RTYY
M!8C9T+E-=SY@;Y5")LPN<7EL9=RQGM,ACKTE,0N[*ZIP&%>E-KFB..1KT@Q^
M4K2'')CPC)-,`*-%<=/SA544?L>*UKQCIN&Q^W&5FCMDM;+#&\A/,F2.J'!7
M'FQ[V;HXY0D85SHO<&0HLTGW)<5`G%OVG7`*4%R&K>L8+4<7)AU>1U'&V`MQ
M>'H],G-6K%;F_2)S5/<BD3Z\.JI>]R*22)Y6K'=_D;\Y.3X]N:H]>Z."M4:,
MW=^XQD/+HZ?W"[D7.S;-O3C54MK3P]J96(Z43F+DO[H:QQTU6H9&4T:PT9)C
M2VJ%[@H2MHR=H@*'%P/V0(U<K&=P/I^<+#;JUR,/XT5&IO+4[#9VK15Q5.KF
M&K!+`641,=.BDTX7OA2$DIB$3GY?I"$A(B(1B(*1)`$S$UK6M:UKU:UKMK7R
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MYDL>8X9Z?L^7N0(ZP2V$.CP]>Y!!B&/I2Y(A3%O"Y(M<`JFY(J3&Z_>*?*+E
M#=8[?F$U=>/3=6O'[F=R=XX6:0U5].XN\GUM0NY`QI+4;)0^W9)&=F<S)$3'
MW.11M?&W=$".&/)#<[%+B$JS,@1#J#<;H!3M-/'(+EUQXD,VL&B%MZ(I;7*%
M\BL2M.O6(]&G>;-JZ`K7VP969#QC=&P"%$0_2=Q5&'"$WFKR_'HC+M5<[N'E
MXSQ!6=0\C:GL::NU;EVXS,\1E2-Y"^5V+W*])D[$ZIM"9'M(T:?6,<A3-3DL
M<XR6]-!LB0-1;DC$=D&M^2M&6W,'V`5]9$?D,TC\;99LKC16U[>[K8')%BUN
MC]AQU*\(6X4NKI\<FY>V--@Q+;Y#'!S1J6Y(^FK21D:Q-8')%Z56G=%-5'J.
MBDE`T,FM^RY-)D2M[9&60V`WSK=,0$+"UOD><G%6]EP"3327GE.Z$;1%D$>;
M4@M+YPG=H_'W@YU/^/W(/B]54]LV]:<9KN;N&%)\I^2T8;',<?9ZZ;)W7S%(
M)E)"$[LJ6`)A4;DR]8QN9R1[?AQ%?Z&P2=:F>CB"E.<V'J.<))9'W:3Q'D9`
M)<SL;@%N=3HD:]RA2BWJLVRY%;F:UL+,XNHHZTU<\MDX?Y24A,C,=CZLM8_.
M[;L)A8+I3<F&1MONK*H>71C=(KR9KZ46)QQG3,,7H<D50)ICLBF4!<-!-4$*
MW)1!Y*W69!'Y$).3(8JWS="O;F]7#DKE*998QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,909O>BQ["$0]^`78`?#H0M^'?8(=C$
M`'<6_5KQ""'OO7B$'7?>M;'`:E[CI&'<RT]FU^:PN=J\V.6?(:OFQ'*H<^G/
MT#NB6;DT,2*%32^'H623A3E^A/38YJB6]N6&D[(>UZ79RA/"OA5POY04BZ](
MQ58E4HRR^$G`#DIQZMPYIL"`O0]6;8"KCN5$2H<#;TE$\M3L@I-_V>]CVV!;
MM25D2+RB@[>1MN$:NZ9/*@-'=-*DI/&$-=FTAQ1ZD-`7?-8Y-X4ZCKB1\N(<
M3&(!*H:F0NR=7,?<I<F,>'4UM(1GHA')#-`5*=JR4\Y>G%0][PEYB3UR'X74
M=Q_LFFJ%1<>'*[HA<)=ROEU)4"V(#-.I],!O3.]0T,\*H:5-5T&FJA%)??2L
M9&<,:"FBIDJ?+E::NF=<\Q>I&>)J-=M\PJ8I*Q*3UI:0W))++*NIB843/ZU2
MNCOI`SMKW'S6>O9@:6I7C`-CL(3OHST9H=0HH1U_P-Y80>`<.HR.IFQ0OI7H
M:WCP&F^FZQJ^)3D<A)VS\>TC`4UFG/";;C#U;A2SX:OEA99/HA<A9%(VTX_W
M6(;<N3CA%;,DXC=.6K%]46Q&;GXP<:D<))N[C1?D`KJ[>.MR0^G*OKE*5$C9
M-)FRKK@I>UQQR0M-D0J9`?8X[QQLBBIYA:A8#:-MSHZU?;\WY#=***3E5'9!
M8_$.'S^]^4,PK]H%'J]2S-WXLR#C(T,#"V%(2D3*@LN=VO,Y5"XT`*0TF(U>
M_*`(T*-(E(%MNUZM:U\F,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC>
M]:UWWO6M:]N]^K6OY<XUO6]:WK>MZW[-ZWWUO^QO6<XQE/C!]E]F'['^%]EK
M['\;U^K^7.=;UO6MZWK>M^O6];[ZWKY=;U[<YQC&-[UK6][WVUKU[WOV:U\N
M\XUO6][UK>M[UV[ZUO7?7?V=]?:[_:SG&-[UKU[WVU\N\8QC&,8QGQJVY`N,
M0G+4216:V+-.#<8I3$GF(%^DRE'I:C&:`8DJO218K2Z4D;+.]'5*2/'Y1YH!
M_9C/@1M;:WG+U"!O1(CW57[H.9R1*0G-<5_HY"3TU<826`:M7Z*E3)?25`C#
MM)TY!&AZ*)+`'[\9QX@_^8/KWO6O7KU[U[=?V=?;^3[><ZWK>N^O7K?LW\OX
M=?@^3?V\8QG'?7;Q=]=NW?OW]7;Y>_L[?A]F<>,';6_&'L+?;6_%KMO?R:WW
M[;W^#7KRK&,8SCOKOX>^O%V[]N^N_;Y>WM[?AQX@]_#WUW[=^W?7?M\O;V]O
MP^S.<8Q[/;C6^_KU[,8QC&,8QC&,8QC&,8QC/E7*RT"-6M-+4G%I$RA4,I&F
M.6*S0)R1GC+3)$X##U*@82]A(3D@&<>;L!101&#"'?G8/_=+O$`@\\@7&;GK
MXB#CB!>90K`F,\1)HRA>8F4V(4I3F=P;\:=244I(%W)4%%'`&6&%M^?NI1"Q
MW-3J.D.-<X*II$J"OO5'>+.3#+:D+4ZG&MJ1OJQI:I&Z,[&:S%A$^)GV3*')
M++W,L,4+;F!(6JD(YG"_=,7#[0A:UQGYY[UH0M:WNB8T`6]:WO6MB!NR1>`6
M]:[B!XA>'?</B%V[[GQ&>;\5YF=//D+R3I5BNZHB6.NK\;V'=C1]56-AM,KK
MF"NCLCD3+MK>'$!S<2Z:0*&QX;G10C5'I%S:K+V-*O1Y".(]4B>\;N*5&I7Z
MGYKR,FD:Z/L'ZEUJ63*[L:F-VF$=CK77^KM3^<\QJ1KSIMLV5.THC3:%.WQI
MS/)1Q1&9&&X>G!MD"S=2*WS+SYJQXVFH>\U10$TX8PN#R`RT&Z#IFEIY,UG'
M[)<[4NV2RJ.%M\*@<5:9<G.EHV($R?&50RMS%$H_.U\F.7-?WU'U8%G(2(Q8
M-$<:W^P;H65%R`NF84X;9C'&!M<8X^\CYSQ:<&.%31[BY*&9S6TK1KF7$5`T
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MEZJ`]6M?:LDIRO*ZX[%R*Q;?OGG-QJ1$FW(B:J[;;/X61]VE(G`B:JJX'('>
MMK78VY.O8)6"OT+['2%@M.<*<#R4Y:ZRX7UIBIG6QUIE<7I.V1Y^Z=]W=0.M
M$"FUHH<_R=CXT2.)PZ[ZRDZ4B.#:H4\-<CER$R`R=*\RYMFT;(5NKJV0IXT5
M&1Y=IGJ<R^SI!/H7,>,X*2ET?XY4?S(B!]C7O#RJ\D'%6X-R!*\V9+K':XFL
M:JZ>JA=8F_(K'AJE!)?1T>V9[9)"ZM;BL/:<8V5UB7VJ^-+7REEW$N21RN76
MLK,O!J%+[>C46=YM5$#F$;9F`^KH\LB!TNE=C69`G5UN^*P1_BT);F*IFYM=
M[%F<,?7[WOM,B>HI?%F0A7PEHRIY4?6Z_FIR^A]!2JV$0$`9#`ZN25K9%S3_
M`%`U#LA<VMMLJ=QZM#*ZACRN:UPHTKE"V2-1.G]G:#2KNLQID7#T#E><-EEN
M6;7A44B%?NM06C>BYU@T2?)'94/;3K^E-N7.[2>2PR&0>)*GUSM=P$YRO9$7
M:MKX;!5\F4K43W$5FZP$VL05$QBD>'KG:5H7H_\`/2",T8U>T7AD3;[!X$3P
M4+FK=[])-!"71=%+#!Z,YP64&0AM<R1.C4@D42:]C<UK5DRC.KA6?(F:<6H?
M`(6FCBWE'1T#NZ),UQ6&VU;.'-OE@)ZBET=K2-.<;<F:XY!1DF@IC!>3#$9>
M1+X@0^LDH:HG(HLI]U!1ZL_JH)^0G#6<'UW"["J"57ITE^<_,ZN)NU3],DDM
M:/''DU!6JIG(<HV0VN263(Y/-XU*(M*V1<63Y+<O*5(4*DE/M5EZK.H[(F^+
MTM7$1HRX>2<@A4*X2QGD;)H<AF\@F$4=^1U6PN4BFR1$C@$CCDR00V.R9@L2
MTE$FLF!O14:=W=TC226N3$Y(#)<<0^;+!RWDUUL+!'V*-F4O*5<-DL=46`C7
MVW#).W3&<Q59%+KIU='8Y+:@DYZ*(H9='O2!2F'3.+25O<X;-'TE$XC*G+C&
M,8QC&_5_[?\`OOMD4W+EY`6MT7M1\2LPPUN<%;<><3%2ME#-1JC$IQA)8W0"
MD9>S"A"*ULD)IH/#L)7B&$.?9=O(M+5;O#6A*U*5Q[L-O?GW2A*,G9$0.&L3
M*"D'G')NT@,4$Z$40HUHA,`@P"O8!*"]EW6DY`Q)96J^T26.:^XC>Z`:#&_<
M<,V]'*3#$A8#TZ8M28D.;Q;6%;VXA7>B%]C"QFZ.+V6+`')[FAJHN"O+'EQ`
M88[N[QQ[I*V[$9HI,FU2TIGJ20.#+Y(T)'`:-2889'35P$7NVK;E6U*9O`O`
M#RE10>UM4OQTLEQJ/CA8CIRHNR0W,<?4EH71,=V(\K:XN7W90,SS8\005-HS
M=9P"O'H#BL!"&ZLXO$E\>2(6,*AZ="E$C,?-8O`?JA/U)<6ZN:^5+18DX8OB
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M9C=G3>I8?.448K>,1I]C$Y:3Z8-DJ&QC8TQ1Y'(F20`E3?U'2=>K"O'IW)=W
M%-+.5S9XNWG-!WJ2.EI/TALJ-I(ES-O^#1]F16H2K`[K5<#8&%IC4=?DIA1&
MVYC;MD(BD&]-^HL\(Y_<\RY#/W3SN[D=9$CE_!V=S6X4=ZI["?FZ9<_*C>)X
M^L$"1N2I`WM\?5QWC\\.8JBY;L44)`4UW5$(0Q,IK''GR6M3IWD7ZN-SQCB+
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M3J,N#?RXJ+BE/J,'"'>W[)FU2,SB*UXU))6V2B#\<E?(8V7O$`9&$SW-IR8I
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MOR4+FPSIJ'#3/@1]5UW772KK>5<69I%Z7!U`)3TU7B^VRV8L\K&N\5D?:'BJ
MW\BO&9F32-/`;#T_MS&MDYC\W.=?2EQ94A[4^ICUSFUPXZ>W59>ZGX<40W<I
MV&PYF85P#M;EJAOI[L<5C3FU?@DY+,-%R6(REE<6X3\V2AT?;<JK4/D*N22%
M*^-CDX^[::*J&#:-7-67]4"Z(C(8S7ZO@;9^[`L#DTEXT5><]31=7-6V@[R'
MCS9=]128PN=6S5$#E:R/I151+8#9B=PJ]M7U](4R=8B!-&YT9-NE_,?4FDDC
ML<B+QKB9<]@0MGLFTZ0LV:56V2V<JZUMZGH(L?Y@VN*+=;,<%>8'N?LSW331
M,FRT=/JF>:CJE=`VZ+2=(]))#\(.7\?YK5(JMZ*)H03'POJ=E1BA%G);']%5
M"BT=?G>.35$;%X3*JSLR%NSTLB$^K"=1-GDL:?F8\[LN:'!K<%,R<8QC&,8Q
MC&,8QC&,93X=?*+\\?\`M9&ZVN('&F]+2J"Z;;IR%SRT*(<E3I5<P?F\:ASC
M"M5W-#H00'E)'M(WKP@>V1ND29V;V"2%$25E3('TDM?J2.@!UZM>+\\?^UZ]
M[^WOV[WEB6C7[1:E;3NLG]:\-[!8,1D,+?5;$I2)7DMDD[4J9'@#:L7H7-,D
M5GMBU6F*5"1'F)=G;/3Z+4EE'%P$=.EEQO>H<3!W60W&M8"N!S[TZ`%&3-C+
M5[XN/^V8IPC(UB>'$G#E`DL?:414W%OWP`3)M^)2,\]0>;5,>EEQSE[S*91[
MZKRC<QE<FXB6*ME49L5*F6I+1X6ELZ"E;+0LCI&G>&[E);"Q-D<EJ9PC+A%)
M$UIBU&XRA>RR7@JTV;I!\;8>HK5ZKVR>3M;3&N7#D`D*L&#7*-GG4TK/DS<#
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M9M)%Z(K<@+;_`*5Z<])7SQ&J5RM>6V]+GRV^-?"V/2]_52:+HW%355+1I%8<
M'HO25MA"./JJ>/G,F>I+/8LZL;DJM94K"W6:[RQ@2I6<G)MY=*&BN2"F8.=K
M6]R?>GJQ*<N#C_/G=):$?:SY54=PJZ\=7>&'-Z*`EL,?:XW(:SC$AC)<,:(U
MYR[W60S'<NCSNM9#)E7MQCJWD35#35=G)W]P215YATT@DX:'Y4P6?75F5Z<4
ML@]KP&<M84[G&+&C3@6-6D?4(=$+25CJQO3>Z1A[>6-?BVVN$D1O*LE=?6U<
M-[3%U!)ZCF4<LX<@@,>G<(E-*V)$[7@;W%&^)ULPU@0K3SR&L3X_`>:W>TLH
M$D(0OR=<VH6E&W:HK3XFQ&B.HETTZ/J>R[LB:2QE_6!OMTL`4MC,CL1MF=W,
MU332P2&EWEL'?V[;6XRB0O#PB$Z-#F[MJU46K3NWIJ1,J+V:-W3?X\M)M&,K
M6KL1%5G'5=0K_55'ZDK8KK..3/CDCD*>KI\D$XQU98"&8IS)`L6S-T:)XV%6
M8L*)'8B.3$GN9#CAV+='SBS$8^DBC9*[]-BS/Q^Y3\68S'EMEH3FZ+T#RSDS
M?+[(K=K\J)D*UK<R.C8G+@+M(U3[)(ZD+2%*WIY,9V$YJRC'^FS2,.M:%VM"
MIW?,,6-$"I:OK#A<7LDEHKSD&S\>TA;?2ZZ]8VGCNC)0_0=L3$,@G2..,/',
MHP03#[#*ET1*`QZRQ2'#BMJ6M!]N9/*;+L:SGFMF>GD\RM"0LSV^,U41^<RJ
M?L<#3KV"-1=1(&UHDDJ<S6QWG1DME;>VEHV5'(2&LM0E52]QC&,8QC..VOP_
MEW^O,*3:@:RL"0*)+*6ER7.RA.D2F&E2!Y2$!3HBME)RB4B986F(`$(A"$$D
ML`3#1F'#T(TTP8LHQQA;HNPM4=:`J"VMF1$MZ`M4L4KCRDB;7@(*&K5FFJ3O
M+!K18-FF"V$L(0:WH`0ZTDL:CTRCC_$):QM,GBDJ976-R:-R!O2O#%(8\^H%
M#6],;VU+RCT+HT.S:J4M[DW+"#DBU&H.3*"C"C1AW%ZE^(<8I&,Q"O(Q:]XO
M=3UN8$NK*LFDP89''*Z:V@PK<.CK9(38@GLR5QNO"R$R:!LUGSV>)6)*A:B3
M-+@LC)[G1Z9.DYQ,016O("ZD61+X'`*FY<4@DATKF"-:RR.LN:TI233D#'):
M)NC[4ZNFI')&UL<F5S2.;:[14;<D*8UR4D`RS,@M73OI]9QEM;BY:EA\@>0L
M(M^)H()*Y7>MJJI=9::'1Y$4FA;)&Y4TM,:(CQ\(-+"\L,G0-`)HLE6QS*52
M222PP;R+O7#IU\2G1OY;,SA6)"EAYJ1&$P>^F/3DN2M[U':\K)'5,231X2(Q
M,NB:UHBC>W&)7AD6IG<A_;T$A(7%.J-,H*L`?39K9?%*J(D-\\JIA;E(VXUW
M#5W)R96FQ2:_HG(FV"N=8&LB9X=8&?7J^$O]8OT@@\QBCO6S@W31*_N\IE6G
M>PU>YD#-5+\0H'0''.3<<JNG-OL,8D+Y<4G'-C9JG<;199'=\XDUC3M\CDM7
M,1Q#0Z&R^82!W9593.8:QJUWI2$0%A!"DNQWGI_4@L/X?.K.\V5"Y+PITM34
MM,(7(F1FE9K6_LC='YA'Y\\&198;.(U/V]M2FV%'G4L+1-7LHB42%(NE")N>
M4>$)9T?^+$I:/<`F4<@8NQ`6\UTNFB-6T>6A+A_/M3MVY(UTB`]L;X8TQ"1R
MW9<T9#&8QOES`_E"3$2LZ-*W"/K+A<NE5QK=89;<%<9!<:EDNF%<18)8`]S%
M@)<')DX5F-A]&F(E9$,*]R7!"L:R%LH5-Y9.I.>:H+6%%I1%IRH:\XN.<3I_
MDGP$!7TPLI@D'*SK%:OJ>RHMYB;@Y,5CMO3XY!5L)RAS>]PAT8$*!9#H?$&5
M2R/#2]LPTS,>:-`8O=ERT4ZFWILT;&G.FI!#YI=<1D%(L]S#A3PUS-@=5&YW
MR+DCK*KRNAW23"%R=J6W79+H^OQ+K8A#>C=69C?W^,Q$$<CKX[-:SIX-TM./
M\#N>'W:RS[D*JD4)OI7R68V)]M`A[BPK?D/'$GC!.I,[$+HR8_/F[!K=.C.D
MB9VD*LM#(4YJF';BC.ZOK$Z29MWBK6-XN]AF68HE$DB]J4#*N.DZKD]Q:RH,
M]US,3G`Y^T)&4R:?D<B4#<#O1WY#(4RA$$"<*4LK1.N^(5/3MX^@E:&0LA\_
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M4Y09P)#*%SM$&=-%937!5>2*M6`O<;K5SB+(0W(D,'NG[Q_B%\VUS_G$^?9D
MN;Z:ZS_(^?0*O"UD9U`VVV(;35.1.*6FK2CB8Y$\2.+HWAQ<HXRO$D7P5ND6
MVZ3'1-=)&9L=T\IF7I#\/VZ"0JL'!'9,HKR&\7+NX@HXC)IHG5M[I1]]35@L
M.>,SPM0,+8]CD)4SB,2D$5F+8ZM4DBKA&6@]I<"1EJ1*LB,?3QKQ(DHPZ7WA
MRAMN7T+>+)?$.LBV+2:);.G*:1NMI34D;0R==J%-[,OBS/7<ZFC")D;6)GV_
M+Y4^S*5K'^>.!THWV:#I[5`Q7';]J1:?WW$&N['J63N;TO%[0.:*1W<<U@QL
M!D]Y,L/)9Q.K39CLQ'Z7*#"9,9"]S5,BLGWF?"&B22@G+W'CBQ`./#K:,K87
MR;3BP[H=H2]6C9-AN3$LELT6U[`&6MX<>\@B,;AL9.7-4294:%6^`CA<BD2D
31KA)WAY5A2F)I.XQC&,8QG__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g13895.jpg
<DESCRIPTION>G13895.JPG
<TEXT>
begin 644 g13895.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@!!1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]2051)3U-?4D5,051?2U]"05(N15!3_]L`
M0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``"P@!"@(:`0$1`/_$`!\``0`!!`(#
M`0`````````````'`08("0(+`P4*!/_$`&<0```%`P$"!PD&$08*"`4%``$"
M!`4&``,'"!$7$B$Q5UB7U0D3%!46E9;4UT%14E:GUA@B,C-487%R=X&1DI.Q
MLM'2&1HC)W:V"C4V-SE'5:&TMR0F*#A"149T1'-UL_`E-$-GA__:``@!`0``
M/P#[^*58F3;&1%4$DJ/%#A%6?(2U!X#&'N;-[@\Q=@7+5%A)=D3NQ-2QL7R*
MQ'T5Y6]68U8>&+RC5H4S'>D#`G<+SPAU;X!E?=`LJM6K73VMS?B*](,&:D8_
MBB$ZU&_!Z0I)1`G+#\6R7.D(8+M3"_`7',&*Y])+&'WIV3R%-`-MQ<\+8L>5
M1)WB;A#>`M:6L/4';TF:=E3QC:'9FRI!]=.5)AJ#B<$%5!ISB+2+FR.X%PQD
M['N-)<[/%EA8]3C[D.`9'5I%#Q)#-V.4SY;AZYO-,(S*HSLWT,:E_HP](NG_
M`%+76`D4<<N8W9)._P`:LWCJ4;!*B&4L\N:&U7=N7+RUH02AJ>$[.MOF!0L:
M2(E*@I;]VX4)I=,QXC8W%:SO64L<M#LVWC)W%K=)Q&&]Q0*"E(<UA:A5NME4
MEO%)<MG&U?M6S@6X0PE`#%$?7;^L'<\N*>L6']LTW]8.YY<4]8L/[9IOZP=S
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M-_6#N>7%/6+#^V:_27-N&CE*<F6L9'(<H&(<L]BABF*8`$IBF!W$#%,`@("`
MB`@("`[*D^E1IF2,9#FF+IO$\3Y&1XBR)(6!8TQ3)JZ'$R!:A#DMX%D9#9AU
MZ111.^."!,91<:DZM]1H[#F*-:KMKTR6ZW*]?"31!JU2:?))@=/K-Q>UH7=W
MB21MN1[1Z=BBJ#'2"])G7)D2>8\GU)7I?+))F]^?4ZC(^1'7)UIV7M*=Z36F
MSRBES_+;_M#:%LW%6X;RP.IJ)CJ>PE'<UXMBF0F+3LRPC$]C`N;&R#(E6)TN
M%X_D*ZL1)("]8OQQ.X,[W\DNATTMCK@E6(#1.17(^U9F:9]/D!TI:?\`#VG#
M%]I>6!X7Q[&L>1Q0\7K"I[=$<=;[:2\_2!4E3HTJN12)?X8_2!6E1HTRIY<E
MU].D36;A+%OT&<(^PW9)@=1=96BZH69X9_"[]QM1'O*OZO,E&V*+IK`W+^TU
MNV/]*8_';(/*4!";2P^)[`_ZL1[D#_R1K][_`-I5?(^)_%B/>9&OU2GD?$_B
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MCWF1K]4IY'Q/XL1[S(U^J4\CXG\6(]YD:_5*YA%(N```1QA``````9VT```X
M@``!+L``#D"K@I5!$``1'D#[0C_N#C'\5?G!8E%.97X18\%+;->,I[[;\'"T
M0IC'NC>X7>N]$*4QCW>'WLI2F$Q@`IMG$Z]%:3$6W%::VCN!9&VJ/?M$3G!2
M>V1.);YCA:,"@]VT2P('$+Q[MLMH3FN$`?UU`N;/\?:?OP\,_P#RZR;4\EY`
M^X'ZJK2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I4=Y8CD\EV/9+',99&W2
M3IU2I4\>R+Y'LD^&+J2N**^H6^2$CO)V5[&^AM*T'@Z^Z6U9\+\+)PKR>T0V
M$O<LYOJ(S!I&Q?GO47F9NRQ)LY1&,9$;6]HQ9%L9-F/DCBWWK"V,(21I8LN2
M)/=660<".KN8BZT-P4I0&R``78]2E*4I2E*4I2E*5'&787#<AXUF4-R*JOI8
M`^LBE--S6GY7&;"J)636ULC;'9[0J4:E''7AH2JVJ3A;5I?"HXM=41U*>TIN
M72_.(YX,086<\5Q_';2IPSHJUM]V#P`O2Z7TS0=C@L4T^-^G+(BAI*MQA<MI
M[>-8#K#U6X8C,L7XR5,S1'UC&]L\9E$=1N\KED41>BTYK29BUMMVEK--T7K1
MCC3,W=HT^'(+)$=T(`[.F'LAZ3HE'(O;17BD:%C5I[:LUZFV'$R,R,$L&9T"
MBQ&N":&-"MJW%]R4R/DO+G<V-%^1LN.KU(9W*L!PMQ<9-(RJ/*&6M=NRI0Q.
M8/U]9L5KGJ70Y''Y(ZNJHI%#NN=+[I>MV[BPQ"R)GF6Y-L3/$:1%B7P]L:\Y
MM)X\[>7T=2^4UXL!G]NVG\`NI14,O?;*A;>[XO-<*7P#O7U:JR)9-+D3.>P/
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M.)CVRGT^\`AKMHIS[VX8?@E&X4#&X!4`&-P0VCP2B`FV;`':-:^>Y2SG,"'N
M<6C-,T81\=M]K`T0(G<MYL4;/"K1#+R6[W@:M$>_9[Y;*2YP#F$Q.'WLVTY#
M".P7>)G/H]_*["_4*;Q,Y]'OY787ZA3>)G/H]_*["_4*;Q,Y]'OY787ZA3>)
MG/H]_*["_4*;Q,Y]'OY787ZA3>)G/H]_*["_4*;Q,Y]'OY787ZA3>)G/H]_*
M["_4*;Q,Y]'OY787ZA3>)G/H]_*["_4*;Q,Y]'OY787ZA3>)G/H]_*["_4*;
MQ,Y]'OY787ZA7D#(6<-@;=/^P=G&&]J&#L'WMO@%3]2H_P`IXKQYFW'\HQ5E
MB(,D^QU-6\&F6PV2I/#V"1-7A*=6=M=T(G(1:@O7TM@RA)>$R=24G>E%N[9,
M>V:`H+H'T;8QA<^Q[CW3EBR%Q+*#E&'J>-<;CEMI/(WR$+?&<)?5;FEO$>++
M]"W<`>X>]H'!([15]*5\8%C<[E!:%X/^DC3C)L;1+$;QB2**,?P10YJXBQ6;
M*Y`=B6/Z-[;I4L1/3:N12$%DW;I/*&^?J[KO=4Y`02F3HIM=?TTB>K2Z?FIJ
M;&)L;F1D;D+0S-"%(UM+2UI$[>VMC:WI[:1`W-R!);LI42%$DLV4J-&ELVDZ
M5/:MV+%NW:MD($*9L_Q]I^_#PS_\NLFU/)>0/N!^JJTI2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*5Q-R!]\3]LM:YNY%?Z-'17^`*%__;5UL;I2E*4I2E*4
MI2E*\"I1;2)[ZJZ%XUM/:N7CE3IU"N^8ML@G$MA*DM7U2J\8`X-I,FLWE%^X
M);5BU<NG(0V&;'KYT\RK3I`=3D4=98_P#+$_W58L:+4+>FG($^R1?R7(<3-L
M+981)+;&[(7QRF$7?+);,G&/IVEJ;EKY)5+$UH5ZA+^5PU_8%31B&N[7Y<RB
M63>49AAC7B.+Q!0[9:2233LH<TN?V]VB(+4]IO+A]2TWTDK7F=KC8N<E\89X
M<LE3S-H4WR'*^`SR'Y2@\/R5CZ0-TL@D_C#%,X;)VBZ-]JD,7DS8F>6)Z;KQ
MB6SW$;FV+$RM.)[=NX%NZ!;MNW=*>V6,\V?X^T_?AX9_^763:GDO('W`_55:
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*H([/R@'Y1``_WC6@9T_P`)"[GRTN;H
MTJF34@*II<W)I5#:Q,TGM"J:EZAN4C:N#/"#<M"H37!M7!*43VQ*<2E$W!#\
M/\Y2[GE_L/4IU1M'S^I_.4NYY?[#U*=4;1\_J?SE+N>7^P]2G5&T?/ZG\Y2[
MGE_L/4IU1M'S^H'^$H=SR.8A?$FI0.%<MAM'$C3LXSE]Z>F'\@"/VAY*PN[G
M7W?W0OA'0[I=Q1,FC/\`>E$$P_&8Z^7&/&#:XM)G!O\`"[=\4"V[-$9U*<1$
M!MW13VA,'&)"CM*&:/\`.4NYY?[#U*=4;1\_J?SE+N>7^P]2G5&T?/ZG\Y2[
MGE_L/4IU1M'S^I_.4NYY?[#U*=4;1\_JJ'^$H=SR,(%!CU*;1$`#^J1HY1'9
M\?JW0:>,[0G4WA/&^>\<VGVQ!\IQE)+(S9D[;;9W^VUK;JBS9*ZMEE8X6D2L
M#IKG#L$6J2E+P1[Z.W8$STI2E*4I2E>%0<+=D]TP'$MK9=.!+9[I^!:,%P_`
MMVBGN7#`0HB6W;(:X<VPA"F.8I1^:+'^#IZX=QXP+@3)^#LQLR)3J^EMC.*M
MNQUD!HU#Z=,>..L/,^5XUJ.PO&T;58GZ?($07+<7/\.GD.9I"J@K/*''(H,K
M^EA[PQ7/8::,>Y]T\Y#TCZC\L8RR#D[&&%,;]THTN(IK&</R%+EZ>,V3LXX=
MS#@'4OD/"S8S>6[/DG4HFQ)-6'+<G4Q1K,^90D[)/Y);9F?)P';]KW<OL"9$
MTQ]S^TG8-RU83(,F0+#D<13IE1JDZY-%Y0[W%TE=X=87)%*U`NMPQ4^'BA5K
M<J4MBOQ,*AMO7$-Q.8;QSM!9.HF6'5]G+^04"5YSHT$;F=(W8S.WQ8PP#(-T
M+['<7X]7.-^];(FO6+99`O?$PVG!6-]->ND0W$<HAB>=[`_[1^8.0/\`R;"7
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M(E'A8@,'&`;/IBF#WRF#:`]6+-"&MS2:6S7#WC6YI,"&O7`(%R\8DG=BFNW`
MME);"Y=,`W#A;(2V!S&"W;(3@D+;5*4KG;^NVO\`YMK_`.X6HUP__FLQ_P#V
M81?_`'5-2/2E*YV_KA/OR_M!78F]R;QU+GGN<.CMQ;\X9,C"-3A9CN66-E:\
M3WFQN(=R>#%3H[KYC-W=SV;8&`I3.#HO4CL^F4"3@$)L.W33OI'Y@\S82]D5
M-TT[Z1^8/,V$O9%3=-.^D?F#S-A+V14W33OI'Y@\S82]D5-TT[Z1^8/,V$O9
M%3=-.^D?F#S-A+V14W33OI'Y@\S82]D5-TT[Z1^8/,V$O9%7,,43H``/HB\O
M#L#E%GPKM'[8[,2@&T?M``>\`5-]*538&S9L#9R_CY=H>\.WCV^_3@E$-FP/
M=_W\O'R\?N^_[M5J!<V?X^T_?AX9_P#EUDVIY+R!]P/U56E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2N)N0/OB?MEKJ69S_`)<3G^W$T_O4\5:]*4K\+DJ7HD5]
M6V-?CI?8"W<3-7C!*T^&G"];`UOQBL)<2I>#;$]WAWB&*;O?>P#A'*-6/BM!
M(V6%LL=DS':9ED>;TC7;N6'QO>[+F2V%VY<66Q06[?@1"W#A:!.IX=X_'<`W
M`X@D:E*5SM_7+?WY?V@KLI>X]_Z,O1A^!&/_`/'NU;**4I2E*4H([`$?>#;6
MMZ6ZV\DV]2:S3S!\#K%++&\V8U@LYU&S)SDL:P+'8W+F>%/JV%M[\>%G<Y=J
M6?2R@C1",>Q1&[XFL^-(XMGF<HI,%9\6W=C*H5'@UX$IK-M4:V8B<]^W<O6+
M:BX'`LGO6K5U/=NV273%-<MV[UBY<(4Q"7;1C`<ND2'=U0G#/W-S`NIS),/B
M4IU)ZD]04DTK8@QW"&J9,L%EF;'+43EG$<*)<1(QR/.FJ%1^'XX<<B3VZV6I
M=*ACL:?[4>;W60+FEMNWJQZTLD9AFVG33KISS+CS(>0LNP;5IEO(V<W'#T@C
M$:QU;TK3''>)9%B(,)2*0-,PBTK/G/*3!$Y`T3]\4S2'1*-R:V[6;DF>6)\;
MLZ=$VI9%K"TH8%U+HV"]$SY?QPQRMVBUZ_X8$9DI@OMDMCR=PV$\9H&64MKR
MVMKMWNSXU;TR5Q&S9%2-HK.<[A":4X00*9C%DZUFSJT7'='?D3/:5-5LN/LC
M6CW')/<6EO(2$N*DULQE1+(`=18)]5>M@:8RY9Q=L#^L>!<@?^LHU[W_`-4J
MN]G%W./`O3*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J4WLXNYQX%Z91KM2F]
MG%W./`O3*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J4WLXNYQX%Z91KM2F]G%
MW./`O3*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J4WLXNYQX%Z91KM2F]G%W.
M/`O3*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J4WLXNYQX%Z91KM2F]G%W./`
MO3*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J4WLXNYQX%Z91KM2F]G%W./`O3
M*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-
M=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J
M4WLXNYQX%Z91KM2F]G%W./`O3*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J4W
MLXNYQX%Z91KM2F]G%W./`O3*-=J4WLXNYQX%Z91KM2F]G%W./`O3*-=J50<L
M8O-P2AD>!B(G(``$QC8B(B<H<0`YB(_<`!'W@KJEYL<MR;38Y#%.0\VF1R'*
M(&*<AY0[G(<IBB)3%,40,4Q1$#%$!`1`0&K9I2E*4I2E<[?UPGWY?V@KL<NY
M&Y&Q^S=S8T;MKM.(>V."7"C#:5(7&3L2%8FND<'<IK=]*J7V;]FX40$#$N6R
MF`>(0`0$`V-;V<7<X\"],HUVI3>SB[G'@7IE&NU*;V<7<X\"],HUVI3>SB[G
M'@7IE&NU*;V<7<X\"],HUVI3>SB[G'@7IE&NU*;V<7<X\"],HUVI3>SB[G'@
M7IE&NU*Y;U\8#R9%@GIC&^TZOXWU)N,0XAXPY0XN4/MARA7S5YM@;A-NZ1)Y
M)$TNIS)1XOK-P"CEDONP75ZJP)B]L9+>%9-?B5A5'=2<0P6L7PU<2W>4/2W#
M-[%Y(YD):XRQKF^2H5XX?OI0O!<-9/WK@=]`HFM!<X06QNE^GMA<$H"<+?#`
MH'X)1-P-O!`!V;-0L%[F3,<?Z2]-F$VW-4><,P:/M4TFU5X1R:;'KLV0YPD<
MIG>8Y`^0O($$)-W)X6QU]@>>\DXP<G%DF*->F*K9INWHR.#9<CZNL:[F9*<7
M31'J-P_EM@C6JMYR%J]G60Y`[0UP6XE?TVM&]C5;.8PV0]M?6Z1H&_'#YA'"
MTH@RY?(G%6^/<.E%V26TE[)*]?'-@&E?3K"=).G/#&FK'5YR60["N.XWC]G=
M'NY:O/K\#&A+:<)*_P!Y/;LIKK])W8Z^0O=Q+8L)3NKFK%-8LV.]VRVQG."0
MA3*<(+U,.BRA:\YU:+;NLOQUGNJG6V;'V1KI[;DHN(C7EQ#W$J:X8JH]X!.G
ML'^JLVQ+,9<38NV!_5Q`N0/_`$;&O>_^EU7=-B[FX@7H;&NRZ;IL7<W$"]#8
MUV73=-B[FX@7H;&NRZ;IL7<W$"]#8UV73=-B[FX@7H;&NRZ;IL7<W$"]#8UV
M73=-B[FX@7H;&NRZ;IL7<W$"]#8UV73=-B[FX@7H;&NRZ;IL7<W$"]#8UV73
M=-B[FX@7H;&NRZ;IL7<W$"]#8UV73=-B[FX@7H;&NRZ;IL7<W$"]#8UV73=-
MB[FX@7H;&NRZ;IL7<W$"]#8UV73=-B[FX@7H;&NRZ;IL7<W$"]#8UV73=-B[
MFX@7H;&NRZ;IL7<W$"]#8UV73=-B[FX@7H;&NRZ;IL7<W$"]#8UV73=-B[FX
M@7H;&NRZ;IL7<W$"]#8UV73=-B[FX@7H;&NRZ;IL7<W$"]#8UV73=-B[FX@7
MH;&NRZ;IL7<W$"]#8UV73=-B[FX@7H;&NRZ;IL7<W$"]#8UV73=-B[FX@7H;
M&NRZ;IL7<W$"]#8UV73=-B[FX@7H;&NRZ;IL7<W$"]#8UV73=-B[FX@7H;&N
MRZ;IL7<W$"]#8UV73=-B[FX@7H;&NRZH.)\7EX)@QQ`P$#D$!"'1L!`0.4>(
M0;`$/N@(#[PUU2\V(6W-IL0A2D(2;3(A"%`"E(0DH=R$(4I0`I2E*`%*4H`!
M2@`````!5LTI2E*4I2N=OZX3[\O[05V.7<C<<X_>>YL:-W)V@\/<W!5A1ANJ
MESC&&)<L4W3N#N8UR^J5(+U^]<,(B)CW+AC"/&(B(B([&MTV+N;B!>AL:[+I
MNFQ=S<0+T-C79=-TV+N;B!>AL:[+INFQ=S<0+T-C79=-TV+N;B!>AL:[+INF
MQ=S<0+T-C79=-TV+N;B!>AL:[+INFQ=S<0+T-C79=<MU&,`Y,=03T.C?9E6T
MFSA#W'-3M@1L039PFT?A;/.Y*XI8+*`@4=8Y+?=4L8L.61[S?8AAI&_WV%[%
M%$FYX7RA.D;#N;HTMK4L:E[AJ6<M"DDG_=",AY]3,6BZ1K(KJ$PEDV^[93Q3
MGQ^U6Q&#,,9@2-N&#9,OYB00%A:;RB$30V,;3'CMTQ^C669"W.-BZ_J)=8;M
MYH<0`'%Q![@;`_$'N!]JJ`("&WC`/M@(#^,!`!#\853A!L`>/CY.(=OY-FW9
M]L0V;1`.40V\@':&T.0>,*@7-G^/M/WX>&?_`)=9-J>2\@?<#]55I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4KB;D#[XG[9:ZEF<_Y<3G^W$T_O4\5:]*4I2E*4
MKG;^N6_OR_M!792]Q[_T9>C#\",?_P"/=JV44I2E*4I6LW4&77%IVRU*<OZ2
M=/V/=8$!R\CB6\?#,CSBTZ>LI0F>Q!ELQ%#-\=S64PZ18]E\-?X8WLB"2PF4
MKHJ_,3^R`_QY^?$3^M86F1M(D9U2R>49&U(:MH;`<,3O)$;@4"A>G7'4WN97
M1XDQ]C]?-'\%$WRZ5EC#7/<F365S]]7/GDI&VZ&Q6.M$3C[.KD#E:?I"X9Q+
M;!%*6^FN&NEM*2"FNC8OWTM\+2@0LW>\JDURRI37>]G-WM0GNVE%D^R[8NV[
MI"'+\\.C/4ZZ8'[DKIB4+W?)%Q_REG347B.QDU#CS,>?WG'#$GU2ZBK[U/WU
M%"(KDF6.SPPPN,WVF!#)$JQO?,C+X:WOZD[-<=KI,+.Y?3F-:FXWW.#3=/WN
M;RC3PUX7[K--Y,VY.;<CHC9-S)CK5;!XIC]5)I#/D#,IGC]C;#.<Y+.&F06P
M=?$DZ<5+^-]OGT)L#%]]_<G\KY*SAW.+1QE7+CJZR*?S+!<1<GJ4/MM3;>YC
M9L%5MC%-7DZL"WU3M-(V@9Y2Y.!R6_&:UXON1;=LBLI`D/.LVFR6:X?1AAZ7
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M$*;3EE\@&N6BB87G".PH#<*`F'A9?*'$`[?IC%#WS%#:(=6+-#FN32:7#6SV
M37)I,#FLW!(-RR8\G=C&M7!MF/;&Y:,(VSC;.>V)RF&W<.3@G-;5*4I2E*4K
MG;^N$^_+^T%=B;W)O(LN9NYPZ.VYOP?DR3HTV%F.W9?&5TQ/9;'$A')X*50C
MM/F3&AW)9N`4#%*X-:!2&WZ9.!.`<^P[>S.^CAF#SSA+VNTWLSOHX9@\\X2]
MKM-[,[Z.&8//.$O:[3>S.^CAF#SSA+VNTWLSOHX9@\\X2]KM-[,[Z.&8//.$
MO:[3>S.^CAF#SSA+VNTWLSOHX9@\\X2]KM<PRO.A`!^ATR\&T.07C"NT/M#L
MRT(;0^T(A[PC7DU!:@,<Z9L8N^5LG*9$+$W+F5D;6*$PZ4Y&R!,Y9)W1.QQ6
M$X_QY"&I\F$VF$F>5:=O:&&/M*Q4?A7UZL4;2@<7!)B;I:SOD74SF;(F16V<
MY(QUBU@8<<,9='N?=*<CP)F."+ES?.K[]DF0/DX[U)I<W9#<K49+C]YC-R[C
MQJ10Z>15=8=ID*M9%MC-VT2]:N63B<"72&MF&U=NV+@`<HE$;=ZR>W>LW``=
MI+MJX2[;.`'MG*<I3!%.%<&8KT[P!%B[#<23P>`-KQ(7]NBZ!R?%[:WNLL?E
M\IDBE"#XZ.JA(5YDCJZ/R]-846TE]X<W%Q&P"I<JNW8S7:*=+Z[&T0Q(&)&1
MJ@<`=YP]PEJC+I)XDNBR_)MZ57<D>(I+%WYHE3:AR"2<2Y#.&E,^$:98TR%T
M9GY"O:5(HBY(,+"R19C9HS&6=KCT<CK4W,4?8&-O2-+*QLC0CLM[4SL[4@LI
MT+8UMB!.G1-[>BL6$B))8LIDUFW9M$(6&\V?X^T_?AX9_P#EUDVIY+R!]P/U
M56E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2N)N0/OB?MEKJ69S_`)<3G^W$T_O4
M\5:]*4I2E*4KG;^N6_OR_M!792]Q[_T9>C#\",?_`./=JV44I2E*4I6N?6W.
M9$KQO/VI-I^UB.3[C[(F&;6'9_IBOZ>KV47:=S.S<MV)]AMNRYD1)#5*#&%Y
MU5QO):'-;`W19U:G-\2@P2Z+>,EEF->YF-F1+KOGB4YHA6O:WEEXMXS2O.5=
M>]S3$UR:61](6<WF2#XGQ]I#D[_A?'L#@:A2Y/+JA2(667/\CGMUXDAWE&$?
M5)=KBE1;2)[ZF]P^])[-R]<[U:O*+@DM$,<P6[">W=OWK@@40)9L6KEZZ<0M
MVK9[ABE'#Y#KOT[OVG*,:I(6[3S(6,)V_/<5Q\B@&(<HRO)D^E$?E$JB#G'8
MEB%KB=S);F\)':$2J^K1W(RD,VLC"Z2)X%M8T*I=9]`U=T8TIR;$F+,QPB;O
MD\8<SJIXBQ]&(E`9NY91=5F)2NQLQ(W'%-YC1SV,KL0&8G5)DM#)V)H6Q5XL
M(XVLL'DKY'6=XS"ATPB^0HE%YY"'ULE$-FL=99;$I,RJK:YFD49D;:F>&)\:
M5MD1M+&QV:UB5>A56A$E]-?MW"\1M@8Q:Q6?)S^P89:L/36.8\R$ISQ%_$4M
ME</N3MC:^]0O(=Y>*R+VGJ/'<A5-UM4DL<%W1^#7[UM4)SA9[T>3'2+Y]48$
MLQ9GRI"6_4$6*,R&[E=5C2\N@QY:FO(3/;\7&02=/?(V.5BTOM)&3RI$S>=5
M8NBN4>#"6[$F$\<:WHU/DSKG34KA[)V/2-3M851.&Z>E>.GR^[J"6`9U]N47
MLBR0EE*WG*H,J1"U'%<6Z0H7['>A$S-N.-;TEGJIUP7J5P]C''QVIIL)8G,M
M/2O(SY8=[!+X/"^Y)[.1HV2\E<+ADYDJ+Q404);1RC?O]]`2R_$XQGE!@U3&
M)?E&%2#/1X[*TB;*+5C>\QPJS)%]]V-$GBYC<\F7WKK>PV+[1:=&KRF(9[.@
M57"JT/AH%L0)BO%^OQBR!&';+6JG",\QVB5J+DJB,8TT+82_/B,[8NL)D[;*
M;F3WPC-=LNMU`NN7S-2WOJ9+>1][(*D+UJ^<_P`"U@2N3,BW3OJ!Q7B2+)F$
MR5]9)W@Q5E%R<Y`+BHO%=D3Q8GD5*W(0;3ID8MAD2DPJ+-Q7X4`7>\DD'"T8
MSU&\>.#3G'*4*R9D>\Z/5]ME\.QM>QXP(VE2E36V-`HBEZ3R2XJ5-BLBI0L6
M@[60<;5^W8+83=YX9\:H5B7NC3;+8HOG.KW`DFAZ!_95<NC[-I771UU?X\F7
M)[KXTM;Z?+#B5D7N:$BA,C=#(%Q6Z]>(H%*I"UWLTXZAH9JAEWDE]#AFS'.'
M_`!>_+#R^P^HRMY0`I!L\1`U=XF42\1^+!L.GAHG\/\`&(+4W!\&\#'OWNM/
M\5U"Q2./B/41EF"Y;DRE^!4Q/,$QA?Q:W-<?\7(;(M*UIORF5F<5PN=I>M!S
M*L3%!.JLI/!=J8;UW&E9B'NDMR1*E:+6+I_31NY(%"M(SWM)Z]0X)XX=W.H3
M-%UV#+ELM]?99AMMUQU\$MENJRF7^"$`W@X9+:@(KJ$E<<8T>G;+,%Q))DS\
M*I]>9YC"_E)O<X_XM760:4338E,4,W+@<[J!;XS,L4@*=+>2>"[5(7K7I=/,
M,U0Q+RM^B/S9CG,'A_B7R/\`('#ZC%7D_P"#`Z>//&O?YE+/'OC,;[4*+@^`
M>+@0J0-X3X8'>85R#BCNB+M-)>XXZU;X(B$(<'MS4PR-/VEM=*GB.L5\PBUM
MCM(296:2/RQ"3852XD;F\%@@)@36>2LC,K1C/;[BQ`QXCRG"8#EBT>-"OGDH
MQK>F\956T1+82@MB%6Y.Q7$QGLQ;IFTPOEWQ.!RE,"S@;1L#`$"U@123/:W4
M1J!Q7EN+*6$J5B9()@Q5BYR;)`#BGO&=EKQ?GDJ*XH1;2*48-A428P*+UM7X
M4(6N\GL?*>+]?;YD&3.V)]5&$H)CI:L37(M$9/II6S5^9$1&U#95)G*4V\G,
M9'B]?=+2];;4%:4864ZJRD[V<4PWKL[.L7SZHP+:BS1E2$M^H(L59D-W*ZK&
MEY=!CRU-?0F>WXN,0DZ>^1L<K%I?:2,GE2)F\ZJQ=%<H\&$MV),)XXUO1J?)
MG7.FI7#V3L>D:G:PJB<-T]*\=/E]W4$L`SK[<HO9%DA+*5O.5094B%J.*XMT
MA0OV.]")F;<<:WI+/53K@O4KA[&./CM3382Q.9:>E>1GRP[V"7P>%]R3V<C1
MLEY*X7#)S)47BH@H2VCE&_?[Z`EE^)QC/*#!JF,2_*,*D&>CQV5I$V46K&]Y
MCA5F2+[[L:)/%S&YY,OO76]AL7VBTZ-7E,0SV=`JN%5H?#0+8@3%>+]?C%D"
M,.V6M5.$9YCM$K47)5$8QIH6PE^?$9VQ=83)VV4W,GOA&:[9=;J!=<OF:EO?
M4R6\C[V05(7K5\Y_@6L"5R9D6Z=]0.*\219,PF2OK).\&*LHN3G(!<5%XKLB
M>+$\BI6Y"#:=,C%L,B4F%19N*_"@"[WDDDX<C><8[CBXSYJR9#LCY,%8_7+<
MSB..[T`CQ$2HYACZ8T1NR20W#WFH@E*N4>.`\9B41+;2[=@8Q0K$O=&FV6Q1
M?.=7N!)-#T#^RJY='V;2NNCKJ_QY,N3W7QI:WT^6'$K(O<T)%"9&Z&0+BMUZ
M\10*52%KO9IQU#0S5#+O)+Z'#-F.</\`@`O?EAY?8?496\H`4@V>(@:N\3*)
M>(_%@V'3PT3^'^,06IN#X-X&/?O=:?XKJ$BD<?$>HG+,%RW)E+\"IB>8'C"_
MBUO;(_XM0V1:5K3?E,K,XKA<[2];XS*L3`"=592>"[4PWKN,&Y_NE_C?PCZ,
MO3WXG\;^$>+_`*$I?X7XG\8]^\7^'[W^#X7XM_Z'X?WC@^$?]+\'V?T-9/Z@
M(KJ$E<<8T>G;+,%Q))DS\*I]>9YC"_E)O<X_XM760:4338E,4,W+@<[J!;XS
M,L4@*=+>2>"[5(7K7I=/,,U0Q'RM^B/S9CG,'AXLGD?Y`X?48I\GP3`Y^/0=
M>_S*6^//&8WVOP(2>`>+@1*>%X3X8'>8-FV)>Z-.<LEJ^"ZO<"1B(+WY[50]
M@>=*RZ1NL?CZE:HN,34ZOA,L-I7Q<V(CIDRUS*@0%<;UFXH*E3!=[V7)3*T8
MSV^XL0,>(\IPF`Y8M'C0KYY*,:WIO&55M$2V$H+8A5N3L5Q,9[,6Z9M,+Y=\
M3@<I3`LX&T;`P!`M8$4DSVMU$:@<5Y;BREA*E8F2"8,58N<FR0`XI[QG9:\7
MYY*BN*$6TBE&#85$F,"B];5^%"%KO)[&RIB_7X^Y`D[MB753A&!X[6JT]R*Q
M&3Z:%LV?F-&1L0V%*=RE-O)[&1YNWG6TO76[Y6I%WI,JLH^]G%,-Z[D')(WG
M!9@XL9C&2X<RYY"),"`V47''EYWA0S!(#9Y0R`,;EDB.\#4[#8=/`&+RFX;7
MX<FX2]5X&/?H8PGCC6]&I\F=<Z:E</9.QZ1J=K"J)PW3TKQT^7W=02P#.OMR
MB]D62$LI6\Y5!E2(6HXKBW2%"_8[T(F9LQQK>DL^4NN"]2N'L8X].U--A+$Y
MEIZ5Y%?+#NG)?!X7W)19R+&R7DK@<R<R5$#404);1RC?O]]`2S/&XWG!'@XT
M9D^2X<]9Y&)/Z`N46['EYHA03!6#GY/2`<;FDBR\+4TC?:_#V+RFX;IX"IX*
M]+X8'><>\6XOU^,<_B[MEK53A&>8[1+;UR51&,::5D)?GQ(=N6V4R=ME-W)[
MX1FNV76Z@77+YFI;WU,EO(PMD%2%ZUUK\D4Q^Q,IX5Y:%[BH&>30UJ\C=00$
M):\IW8!MFM"FO\,W#`QPN<(NPH@7@\6T;-77FNZM+<;T*I(@`+'"27UH*KYA
M*(>$""KO-O@]^#:%L.]CWH>/Z?DKW"A=#SV+Y4L>=["@UJX">]<?PO6[-X2B
M%JY<M>`D[Z0AN")R<(G#`!#:7;7K6I0R6._^.6Q:X\+O?@_@;B#?WG9P^^]\
MVI[_`'WA[2<#ZG@<$W+PJ\3I>:;]ZV9G0*VZP%H2W;2M<"\]R]PS"%TESO-C
M@%`@E+WO@FVB43<+CV5[KP^%\#9Y-O'?.][.%Y0AP>^<#9P^!X!]3P_IN!MY
M/I=ONUZ5KO--B]=,\(%;C8&T!;5I(N!O/;O<,HC=/<[S?[X02`8G>^"788P&
MX7%L'RNJADO]X\3-BUNX/?/"/#'$'#OVW@=Z[WL3V.]<#8?A_5</A%Y.#7LD
MZZ'DL6"JHZ[WU!;5LJB]:?PLV[UX"@%VY;M>`G[T0Y]IBV^$;@`(!PAV5Z5!
M=;+2OOCDB4K47!O`"9.L!'>X1OK!A4]ZN[0M?^,.]_TOOEK]CHICU^S:*SM#
M@WWRW>%=NJW4%Y+EG@&#O9;7@UC@'X8E/WSA#Q%$O!X]H?L;5D4M64MMP8G5
M6L*(`H4IWL$MJZ8;@B!K:<4=WO0`02DX/#-M$HFV\>P.P[[G&SY*D?<C]*S7
M@^8Q_&D_6X5B(Q653&)W,ALC':M2A2H7VW.-6GB.'>3JF6VM;K)RNB+P98IL
MN`A=!.*>YD]A+'&MZ-3U*ZYTU*X>R=CXC4[6%43ANGI7CE\ON]\E@&=?;D][
M(TD)92M]PJ@RI%XJ.*XMTA0OV.]")F;,<:WI+/E+K@O4KA[&./3M3382Q.9:
M>E>17RP[IR7P>%]R46<BQLEY*X',G,E1`U$%"6T<HW[_`'T!++;5%\^I\"W8
ML[Y4A+AJ"-%7E#:RNEQI>0P8DM4WUQF1^-C$9.HOG;&VQ=06EC)Y4@9P.EOW
M07)_"0+:@G%F+]?;'D&,NV6-5&$IWCI$L4W)3$8QII6PI^>T1VU=92IFV4W,
MG/A&>]8=+J!;<4&:5@7DZ6\D[V05(7K5\9_@6L"5R9D6Z=]0.*\219,PF2OK
M).\&*LHN3G(!<5%XKLB>+$\BI6Y"#:=,C%L,B4F%19N*_"@"[WDE_P"*8QGM
MBQ8O8\N93A,^RQ=/)103R+XUO0B,I;:TEP(N6_"KDG?;BDS(8UHSD8'RUXX`
MABE!'P]H8YX^Q1W1%IFD0<<BZM\$2^$-[VV*9G&F'2VNBKQ(F*P8!=&QID)\
MK.Q&%8N)M*F<3MS@",1`PIKW)4Y9ZAVIB5*X/<T^9FQ[B=&V+'"Y/$\YQ(HR
M==E".ZH9SMR=EOV9A%@C=Y(G3O5I1?/;<P57'%)="W:!`);^18@?:.PX`'N!
MP=NS_?6HONP$`:G_``YBF8V'S578G\7SG`&O&T+TOZIV+2NOR/+Y5=<VUMC4
MMG>09.P8U:$2<@*WAD?5A1G/E$W-41@M]6OEMZ/O$*=Q<E02!ZU)"ZQ7/K-)
MWB-:>)R+_J6UY1'6QDJ2Q!^3Y<8XVE3V8@XN*;$\>BKG&94U*&5Y(V2APF=Z
M6-3XVV#11()][B@Y;=D]TX\&W:X-VX8=NPMNT8+EPP[-H["D*8VP`$1V;``1
M$`'0]H7RU(](_<H\7.<IPMF=9E-IS!J)BS%CL^G[/<EEK)(9_J?S;)X]*)9!
MX'C.5Y.9\<68/(&^9O4N;8DI3.$55ID+'>7O+\SH5498FC\9P/FO2+JFCF/-
M0<KP%"\/=T9Q3D^:3C3CE3&61'C5'J5S!@S4W)\SEP5)(HDR4P1C/T[@^5(#
M%EKE$D2-$\&A<*0N+FPNT0<779KW+'".2=.?<\M(V&<OH`9,F0C"T923.-@J
M(M\CGQU.MD2B#BJLWE"2^:#$>;40.=OOW6SALABMAQ0%35>>>(5/5$SQ"M39
MBDK>@=\YM5ME9K$4Q[>316X:`Y`N%4-ZM7&;[@Y7+5I,JL$*^*7"R)'&]<N6
MKEVPD/8E`,8Y;V!_VD9KR!_J^P]\R:KNQRWTD9KU?8>^9--V.6^DC->K[#WS
M)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8>^9--V.6^DC->K[#
MWS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8>^9--V.6^DC->K
M[#WS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8>^9--V.6^DC-
M>K[#WS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8>^9--V.6^D
MC->K[#WS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8>^9--V.6
M^DC->K[#WS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8>^9--V
M.6^DC->K[#WS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8>^9-
M-V.6^DC->K[#WS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8>^
M9--V.6^DC->K[#WS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8
M>^9--V.60$HFU(34Q0/;$Q0@&'BB(<,NT.$$($0V^^`#LY=@UU9TT*8DSF9#
MW#7;A)G,"7+IBD(:[<))G8I[QB6REMD-=.`W#$ME+;*8PEME*0"E"VZ4I2E*
M4I7.W]<)]^7]H*[$7N3L!R.Z]SCT?.#+G*5Q=M5888[J5B10W&3DD;;1G%X$
MB9.M>HFM=+]JV78`'6K%-\P[3'NCP@*78;NQRWTD9KU?8>^9--V.6^DC->K[
M#WS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)INQRWTD9KU?8>^9--V.6^DC->
MK[#WS)INQRWTD9KU?8>^9--V.6^DC->K[#WS)KF&,LL@`;=1TT$=G&/D!A_C
M^WQ0G9Q_:K6CK_U:9L@L[FS`S:?M,6<=(^!H1C;(FJ6`9DE87L^9=L21]<Y$
MD8M+>,7%$MQL_P`IQ:TQ1IGR8<MKVA!.I?=:X;$EL:<VQ1+T4Q=SP9)$MG6J
M3,<SQQIBP%+\ZR2"SIRT\X#3060Y$AB(#3U/8R#JOS'C\+4?RCJ(RJ[W7R])
M",Y7.,P=NB:&-,,OG:@KW+7/:)5-GW?RC^^J"4!#8(?;Y1`?R@.WDXAX^,.(
M>*N7)R5`N;/\?:?OP\,__+K)M3R7D#[@?JJM*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E<3<@??$_;+74LSG_+B<_VXFG]ZGBK7I2E*4I2E<[?URW]^7]H*[*7N
M/?\`HR]&'X$8_P#\>[5LHI2E*4I2M=FL+37W+Y*GEVJS7GA/1Z[HF=GB<>D6
M:M5$`Q?)TD<8FY8H:8E'4<IR8U.16)O4/$A466]B:+R<KL^NYKA4BMQ4$,'I
M^YZ._<KWN_F%9W,BUI/L(+9<>),RV-)3%"H_$@76B36Y`KDH18_;&N.W9&9'
M>E1+"FY9N/)FJVFM+;G@%IJ*&R-6=1;37SI+5F\K"T?P6THO'3I[JD2B6Q;4
M*+=A3<L6#WA(6]>MIE%RU;$UPEB\<H6CZ=L:=TKR)/\`1OH^R\HQW#VK/.LW
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MNV\4GTURV7E.4!FTLPB>P/\`K/'N0/\`SMK][_W=5\L(G\9X]Y[:_6Z>6$3^
M,\>\]M?K=/+")_&>/>>VOUNGEA$_C/'O/;7ZW3RPB?QGCWGMK];IY81/XSQ[
MSVU^MT\L(G\9X]Y[:_6Z>6$3^,\>\]M?K=/+")_&>/>>VOUNGEA$_C/'O/;7
MZW3RPB?QGCWGMK];IY81/XSQ[SVU^MT\L(G\9X]Y[:_6ZU[]T9U`Y\P=AILR
MWIGRKIV93,,WQ?#YC',N8RDF5CR*WF+-N)\/,SHPN4-SOB0T3MPNW.7B2.]I
M>WRLLE\%;VNQ>C1"J7&[FMCY_=6F&Q]LRKDO&LOR&A0@EELFA3,..XL\O%F_
M>)?7,D(>Y_D5UC**X0+0%:5TWDJA-=+=X3K?`Y2DO+RPB?QGCWGMK];IY81/
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M*631\3&.0``'IL$1$3E````5"(B/O``B-=3U-Q`TWFYBB`E--YF8H@("`E-*
M7<2F`0V@("`@("`B`@("`B%6Q2E*4I2E*YV_KEO[\O[05V17<AI+'D/<TM&:
M9:^LR11;PDP%N)U3J@3WK9BN+N40/:O*"7"B!BF*(&*`@("`[!`0#9!Y81/X
MSQ[SVU^MT\L(G\9X]Y[:_6Z>6$3^,\>\]M?K=/+")_&>/>>VOUNGEA$_C/'O
M/;7ZW3RPB?QGCWGMK];IY81/XSQ[SVU^MT\L(G\9X]Y[:_6ZKY7Q3XS1_P`]
M-GK5:].ZK*[S3IH8Y*S9(68JFT1SIA>6X^EK!I@DNL.<6)5'Y2=>9%C[`<12
MK7^7RQ=&K<D):5H[)+4;9"/L@7K6UO;U3DDA+N3V>,BYO?\`4"JR#F;*F;?%
M,8P(XQF39*[GM*=`=A*PRVQE1W1V8NSRYP<'/*C4[I"(I!:E-@;;,WHE[>1I
MN+2NBQ07<K?"Z-FYWDML]XI>':)=N&LVSW2?3VR7+I+5\UJV<Y2E/<+9O&ME
M$3EM7!*!#:;,5]S<RC`](.E/$J^;0-1F[1GJ[E&JW%[^TJ9,FQ_+U4FR9FY]
M>X-*[BN/&D<?0R?%.H"?8T7/3>U206%Y!IG:1H>[*>[$KGB@O<W\O86R(QZI
ML73J`..J1]FVN&69;:I:MER/$SVAUMO^-I8:-Q][;V-YE5M%@!ZP7A!'$5:R
M,)+F1V"+2I(ZIX`NES:MB>PK1YIKCFCW2_@S3)%GIPD[1A;&\=@PREVL@F<Y
M8Z-R8UZ0RQ>C!4M(@5RB1*G9_OM]I8KLMYW$45E3?M)R73V[G;%N,ELMPNZ+
M<=018YR/.;58D+BJB$>4+WVQ<Q_D._<LO*RZW'4.EJY>0HKI[:ZY?*:XC2W!
M`3I[1B2X&!L';`_J:Q3R!_JZA_8U5W"X.YFL4]74/[&IN%P=S-8IZNH?V-3<
M+@[F:Q3U=0_L:FX7!W,UBGJZA_8U-PN#N9K%/5U#^QJ;A<'<S6*>KJ']C4W"
MX.YFL4]74/[&J(<]1[`V#,1S;*ZK3]C&26(8W)7"XR)83"6Q0X`J=6]K"U;7
M*(\JLIQ(9>%X3GL7`,6T)``!.!@U>#W1#3<`B'T#T+XAV?6L:_,2J?RB&F[H
M.PO]%C7YB4_E$--W0=A?Z+&OS$I_*(:;N@["_P!%C7YB4_E$--W0=A?Z+&OS
M$K##N@&NG`<PTOR-D9='\3BZ\V5=+KD#LEM0`+H)6/5;A![7MXBBAJ2_WIW0
MMREJO?THVN]+3!?M7K'?+1LT[_=#M-]N^I(;1!#+AB*5)37#6L;<(XEOW`$Y
MML&..TP\8[3F':/&8>4?'_*(:;N@["_T6-?F)3^40TW=!V%_HL:_,2G\HAIN
MZ#L+_18U^8E/Y1#3=T'87^BQK\Q*N6%Z[M.$QF,1B-O11"$%R5RF.QFVON),
M;J+:(\@>43019<3D@]L]\B4RP+Y[)+EL]TML;93D$P&#;Z&!L'#_`*FL4\HA
M_FZA_N#L_P!C4W"X.YFL4]74/[&IN%P=S-8IZNH?V-3<+@[F:Q3U=0_L:FX7
M!W,UBGJZA_8U-PN#N9K%/5U#^QJ;A<'<S6*>KJ']C4W"X.YFL4]74/[&IN%P
M=S-8IZNH?V-3<+@[F:Q3U=0_L:FX7!W,UBGJZA_8U-PN#N9K%/5U#^QJ;A<'
M<S6*>KJ']C4W"X.YFL4]74/[&IN%P=S-8IZNH?V-3<+@[F:Q3U=0_L:FX7!W
M,UBGJZA_8U4'`V#PV"&&\4@('(("&.X>`A].7W09MH?BKJK9J0EJ:S6U;(6W
M;M368VK=LA2D);MVI.[6[=LA"@!2$MD*4A"%`"D(4"E`"@`5;5*4I2E*4KG;
M^N$^_+^T%=B_W)/#^)9#W-W1V\OV+\=O;NOPNQ*%SJ[PF,N3DMOG<'83WU:Y
M:UWU2F\;_P`5R]=.<WNF$:V+;A<'<S6*>KJ']C4W"X.YFL4]74/[&IN%P=S-
M8IZNH?V-3<+@[F:Q3U=0_L:FX7!W,UBGJZA_8U-PN#N9K%/5U#^QJ;A<'<S6
M*>KJ']C4W"X.YFL4]74/[&KD&",(`&P,.8K``X@`,>0_8`>]_B:L(^ZT/KY&
M='T@D$7CN/ULGC\W@<GC\ZRE.<J8T@.&W6'N:F8)LHR&;X3?X?DMF*V@P'BK
M2D8IO"VZ4/TQ:X=,9(A@\ADMI3"_<QI3I;E6H'6^HTI76[(D!3%T^J#YOA.9
M,B9?Q`A4R9%E:7*M*N-32:52[&<$2Z>7E[>96Y0/`3BW8^C2?.#.R.,3B+^U
M7FR[N:J@B!0VC_N`1$?M```(B/V@`1JG#+L`>/CXM@%,)OM_2@`F#9[NT.+W
M=E<N7DJ!<V?X^T_?AX9_^763:GDO('W`_55:4I2E*PX[H%_W/,X_V<:?[VQV
MOE7-RC]T?UU2E*5C/JEC&69WCZS!\6PN*R>X\2"%/;RYRC)%N!VV,D"R1!YZ
ME3)4AHC)[CZ>068VN:C727FTK+=N)UETCA;.:P3(%@7O[HSM[E*F%%%Y&NLG
M5/,=;9#;EB!F77K]XQT"22VFICMO=FU;[V8'`C.VEN&.8@)2=[X1_;TI2I.P
ME_GHP]^%;&_]]&.OLA#D_&;]8U6E*4I2E*4I2E*5Q-R!]\3]LM=2S.?\N)S_
M`&XFG]ZGBK7I2E*4I2E<[?URW]^7]H*[*7N/?^C+T8?@1C__`![M6RBE*4I2
ME*U.ZTL0=TP7Y.N3C2;J@B##A%ZBC&SS?![MI_QODS(38]-Q7E$\RZ!ON5,C
MP*#/[/(FM:U$D&/Y+((1;M7F:\Y-<J57W-4U7O3=R=R4[929<V.XZX<;ZO8]
M%'J*8X&(P#3U&--2K3ID.*J)O?R3`I=`H=+9HP+7YX6.S&L/(4+TH1+;;0:V
MTWG%H(C=W#;W6M'NJJJ;!IQB;/C%U1N&3))J$P<V0;"#FX.C"SZKW%NEHRM]
MTOODK:#D40MAR?"HY*+[[,G#O\4C#5'%;M/D#M`D\F:%^KO3#-S:GLI:--..
M19-D1FQ"[8X[J9E7*V#I<K>XJ\XLU"8FU"8<QVP:4'-R3O)W!T;M%43SI)DV
M/787UU:'RXSP?,422LS4W8]L1?;;W*G,V1M07<[-(.8LLN"M\R#.,)Q9RD4E
M7I[J5?,;R,5K,AFZZU>`FU;.&AK;I:KOVB6TJM2]75:0A4M^R`<-7N9LJ0E]
MPN6%Z6\JY6N->=$QT=U@E.(F-&_G2X]FY4MIJ._SU.OM"X@O6FM'>FQFM6"M
M"L5%VV:\B(IDN>ZD,KQR+I76%:.,_P"0Y#=5MUA1%D[EA^+W4J52GO7%RT7E
M\R09NO%;;Q+2<Z>V4+JHUX+B<1MVSC5LXTU2YWE+LXH\@:#]0F,&Q,V@J0NZ
MF5X-EY')>*NS9%K(ACV1R*4IP3'NK/#%`^#B6R-@/Z4Y*M^9:M]2C')GAJBO
M<[=1$VCZ*_:MM<HL9`T_Q^T\V3I$]ZXH(SN^11<4`6E-R^C[VK'OAQ3#?+LM
MW2`$CO6I#*R''EJ2M.CC4`^3D[6S*[F.".6'FY3:<5UQ&5U:AE:S)(L)SLA+
MRJX=:4G@S@",2I`*91;X-D8^U7:AI))++7-^Y_:AL=,!T2Y1=DRF:X&E-JRK
M3DMF1H/%#%D8CA<,O,8]LB@I@L)C6]M_80X&!D#5=J&CDENM<)[G]J&R(P$1
M(5%J3IIK@:+6KJM00YEB'Q0^Y&,X$,WF*2V=08W>5)KFU/M(03#>R+4CEB_C
M<\G5Z-\_H9Z5E7KB8S,YX>4*3NR>\H(C8_*ZSDCR?+<<+=JQ>*X"3P-*52!+
MVVY:N%&.8=JWU)O<G:&J5=SMU$0J/+5%VVYRF_/\`/\`:9K!$JB];4'9FG(I
M7)<%U3:L).])![Y;%2%\VVW9.`P3W0W4+EL<`Y'B;)H^S>XQ%[B*"Z_9&<G[
M$C`TQ)7;ES4-M(M9+D\<I`Y]^(G3"10U)%-LIEULA[9>\W[EOYZ6=V=')HNN
M+A&7-@<"&7`5A7JVY2ON`F*)DXE4(KUQ$'AX@!+'"N?T9AVW^"7CJTV^:S!6
ML1)E6(Y:V)U*BQ94+U+U%[J=!:NG*6ZJ46TZTU^Y:3%,-RZ2P4UTY2"%L!,(
M5<,F?GMD\#\3PMYE_A/?_"/%"YI1>`=Z[UWKPCQK?L=\\)[X?O7>.%P.\G[Y
MLX1-OZ(R\.KVEOWWB+.D1O6E1;%M&[+&U;>4V1M6[@K+9VR]>M%LE.8UD2',
M%WAVS&`HD$HU:9YQ,BJ3V"X@E]RR52:P585[BP6;EDM\;1592&6A="T>V`*`
M(8O?`MCP1#A_2U=DE>'9E2I[[1%766WKJH;%U&TK&U'>360M'N`KNW'.]9LG
MLF.4MD"6S#=X=PIA*!`,-?FC+\]O?AOCB%O40\&[QX/XW7M"WQAWWOO??!_%
M=^_WOP;O9.^]_P"!P^_D[WMX)]GHG.9RY"O7)$>)Y6[I4JB]93.21YC-E,XV
MK8B%M4GM*EA%%JU?#CMDOD+<*`[#@%72].SHVLUMQ;XRYO[@<40&84"MN3+K
M8*2`90)E"V];1""`1$E_@W!&X("-CAEKU<:DD@>E:A.[P%^B5BRF"_:6NSBR
M++*J\-XEOP2U;;%-Z\2Z!#&OB>X4+7`MF+PN&)0K\3W+90V.:E"W8QDTA1V>
M]=Y>&]VCJ9&K[Y9MW#]ZL+E=I63O%PYK!^^VR\*Y:,8FT@E&I;QG(W]IEF-)
M4UP5\D4E032`NZ+'B!P94T@=G6Q*V:]9C:9S<%2=ALN*F\4J8BI6LLMQ+A@/
M<4$M[3!]+L#U8:BI!*$C3,^Y\:AL?QZ]:<;BJ4WYS@.3V4-Y.GN74:<6=DR.
M#BI%>H*1(2[9.-M.8X7KQAM%$:_7D757J!C,A*VP30)J%R2QBVI%1I&FF6"8
MG;(OO7%)5+8+4_Y&.N,=';M)[AE8#X/?\*`EGCLW!&\674AE9=CR[)7;1QJ`
M8YR1K>5=O'!W+#SBINN*&XL*U-02M'DD&$AWLEE+<(M,3P9O!8!58&,GN<*,
MHGJZU,/$D96N2]SGU$1!A7KB)W:37\AZ?7NTQI#6[ICK[C2UY%!P<"DN$MVA
M3HQ[^;OO#*`E(8*NO)FJ+.<57M2?'VA74'E%$L0J%#DX)I1A"'@T++2DMJP@
MN)9#D>Y>6G4V!,J!2E-WBT4H6K@]]-L"XH#J0RO(HPI=9KHXS_CR0VECC83Q
M90Y8?E%U4E36+-Q"M!Y8\D%;K(.5X]U.1/<*-U*:R-Q2(6[A!J(6C6)JG6N;
M6D<^YJ:BV=O5N"!,XNI\G:=5Y&E$H56;2UQ,C2Y$!2M*W)SW51DJ80OJ@L#9
ML"%RX0:D[)^IG,D4LLY\>:)]0.5+RU0NM.MA*^X7AHLMA/:L'1J3W)'D<Y'`
MJ^Y<O6B6DH%NIA3B>^`%N6Z\N,=2V8)6B=;^0M%NH#%BM(O3)FU"J><-3$SL
MCNI^^WW`JF.9')91$2W]J8Z92!E%T=EZR4UL1V10LUC:JK"]6G2]S0U&+45E
M<I3IG`N4=.:<JQ':57+2=>"6[D0;U@JI.6VK!-=$;UD+G>;@C=(:IAR/J1RQ
M&&%&X0+1OJ`R6\WG).E5,"9SP[$KB-ON)55Z^YF<W_))T5\J=3:3I!1V@\(N
MF5!>MCWJS<X7I,8ZG\W2M0\V\A:&]0>+;"%.BN-2A5),)3'QW>OW5)%:>W:C
MN1[9V\4-NTGNFNK![VI!3P+.P]DX#9LLU=:F6:1O;9&NYS:B)@Q(%MRPT26S
MD33ZQVGU(6U;.1=;:73(HN#<6Y=-<L@G6CWXO>N^'`"G*%2=)]2&5VJ"6)#'
MM'&?Y3,KB9CNWH!:<L/LRBPH<!3>-THR9QR09ENBPA=4#<O$*%MR%*((@V7K
M8A:F-M5&?)0^*F^?:"M0N,F>RUWE:9^4R[!<NMJW$BE+:M-0-L?R/;663WD]
MY2J!9='P:V"0;)P[Y?MB'KIYJQU%1Z3K&F&=SXU#S^/6+"&XEE2><8$C-I;>
M4)27EE@&9ZR,=Q3BWJ#'2FN71$BDUL;UC^B,6KZ^B1RSNV\J/H-L_P#E_P")
M/&&['QIA[PGQOW[O?B'ROWD>3W?>]?T_C'@>`\#Z3;WWZ2K%@6J_43(Y2@9Y
MIW/K4+CZ.J+:LZN5J9S@.2V$-ZQ8-=1V#L[+D8CC?\/4%(E"[:$+:4;@7[_]
M$4U=;1(&UN<I9-E2V0(F.\:<3'_H*](NO*2E/)'.[PCF16[]@HD-<-8.0+I^
M#=M7."8Y!*<UGJT:1.X%2675*M2B9.`NEFRIMIBEN\'OIQLWK95(@FX1N^`%
MO:?@#WOA;0V^V5,;-83J+UF8-*R[:M'/:2V4#M;NJ3E#:6S;/=3EMD-<'B`U
MPQ2!_P"(0K\#4VH%Y;YEK\A9AM&MEM$6)EJ@5`&`PG/;%):N`0+8@4I@N<$3
M"8!+M`!KP.:)(A4$LHW5*[VC6BW#*DEA38MVSF.8HV3$56[=P3D*4#B8I1()
M3@`")@$*]U<8&0ELYRS5FN'+;.<MHK>[@8YBD$Q;93&3`4#',`$`PCP0$0$1
MX("->H:D*-?<ND6O"-F+;MD.2XKL*U!;QS&X)K1`26[ABF(7Z<QC@!!#B*(C
MQ55U0(D!K((7I&]!=)<-<,C3K$X)S$$H$(<%EJT)QN@)C%$FTI0*(&$!$*]K
M98&6Y:LW+DT9[![ENV>Y9.WNYCV#G(4Q[1S$3"0QK1A$AC$$2F$HB41`0&O3
M-R-(L5G3JW5*U62DNF*M4V5-ZR<ULP`2V%M-;N7@&\41.01*!2@40.("(5^E
MT;&]!;LG12!`\&N7#$N6DB9<G-8(4H&"Z<5=FV4Q3F^D`"")@-QB`%XZ_<WL
MC0HLI;]^6M2&]=`A[B.\A=+EU.?AB`VKERRG-:.8``!$;9A+],``.T!V??UW
M-W-$ZQ[W,/2O:@>G',&:'=DPY&TS/8B:C'#`T2RUY0.*2\N:WN73IL%$EMHS
M7W&V5W;$BF_:L!8+8)=OVQK,''6JO4#)I"9MG>@34+C9C!M5JBR-3,L$RRV=
M?9N)BIFP&I@R,1<4ZRW=47"JQ'P>QX*)+W'>MB'AR!JNU#1R2W6N$]S^U#9$
M8"(D*BU)TTUP-%K5U6H(<RQ#XH?<C&<"&;S%);.H,;O*DUS:GVD()AO9%J1R
MQ?QN>3J]&^?T,]*RKUQ,9F<\/*%)W9/>4$1L?E=9R1Y/EN.%NU8O%<!)X&E*
MI`E[;<M7"C'\(U::CGZ4-K3+^YYZB()'57A?C"5WYW@&1VFOO*)1?2\-F9\C
M$<EGABNW81!X.8.\&4`HN[;5HX#[O)>J7.\6=F]'C_0?J$R@V*6T52YX32O!
ML/(W+P5WK(-AT,AR.=4J.*8EI9X6G'P<"W@L#_2VSU<T,U(97?(<I>Y9HYS_
M``B56S/`6(7?<L/R&\H*A(8S68']HR05IM>.C`6W:`Y1%`8VU;P2%X0Q9&-7
MVIYU?V-ND/<X-1,697!P1IGB0W<CZ>GFVPH;Y@!4XW&QNR*"YR*B`1,9*B$+
M]\`V6>,0J0LD:FLRQ>]'B0+1-J"R9:<KRDCY>3/N%HB$<LVKJ$B>_<MR#)!S
MNH*K:A9="V@$I[((#$N")E-G9*N^I_\`<P!G3S1CP/\`=O*XJPDU?=SEE6M#
M+UI^RWJ-D[EIO9([%D#-HX5M+X7`LLE36K<7&03/-;9`<@8KDV8;;I?OM"-M
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M>RG3VR6K92A$>;``7[3[M#;_`%\,P_CW=9-XZG@"EX(!P2[-@>X'O4X)0Y"E
M#\0?NIP2_!+^0/W57@EY."&SWM@53@E^"7\@?NIP2_!+^0/W57@EY."&SWM@
M53@E^"7\@?NK#GN@)2_0>YQX@_R<:0Y`Y/*V.\5?*P(!M-Q!RC7'8'O!^0*J
M(`/*`#]VFP`Y`V538'O!^0*KL`>4-M-@!R``538'O!^0*KL#W@JFP`Y``/Q4
MV![P?DJ3\)@`YHP^`@&S>MC?B]S_`"T8_<K[(`*7C'@EV[3<>P-O*/NTX)1Y
M2E'\0?NJO!+R<$-GO;`JG`)\$OYH?NIP2CRE*/X@_=5>"4.0H!^(*IP"?!+^
M:'[JJ)2CRE*/W0"G!*'(4H?B"J<`GP2_FA^ZJ\$H\I0'\04X)0Y"E#\053@$
M^"7\T/W57@EY."&SWM@53@E#D*4/Q!^ZG!+\$OY`_=5>"79LX)=GO;`V5P,4
MH``@4H#PB<8`'PR_:KJ6YQ_EQ./[<33^]3Q5KTI2E*4I2N=OZY;^_+^T%=E)
MW'P`'N9>C#:`#_4C'^4`'_X]VK9/P2AR%*'X@_=3@E^"7\@?NJO!+R<$-GO;
M`JG!+\$OY`_=3@E'E*4?Q!^ZJ\$OP2_D"J<`GP2_FA^ZJB4H\I2C]T`IL#W@
M_(%:4-;6HW5MB;*>6,?X#:L[S3/V8XAB[&.B7'"'#!Y'I9CL@EUI>VY,U.YD
MS(U8_=FZ.)\.KUZMWET'R'D9E2'9H5$"QR#NY\C*78T_:"(A+L13/->"5NI3
M4=JJCF.V'%*V0Y0U*67)T>SYSDYIZ.46W'<V5Q6/H'B`7VQFACU<A<=<)+%L
M32%S6Q)D>K1[SDPLFS*K4G4ZAF,8=)\AY$E+!"(+"V-RDLME\I=4;''(W'V=
M+<6NCR]O#A>L(6UM0);5R^J5JKUNU:(4=IN$)2C`$BUFX(B<,A<WD3O,FE%D
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ME*4I7.W]<M_?E_:"NRE[CW_HR]&'X$8__P`>[5LHI2E*4I2M=&<>Z&-V"LR2
M?$;CI0UM9<,P1Z$R*Q-=..FB<9N@]^U,$CQ>,RN4@C!K2)JE#+=9C7'!C4B=
M39;'1B<@-WMR*6UZG13FUISMJ`U33*.X,U48#9U4.TZWW&,ZE\33G"A)+-;R
MS.MJ03:"0>6."AOO`O8TL18YA)V-`WW7ET8&U.\F7J6M,JK9;6I?NND$?9SC
MK2/<7WYW8P'!M>VG;)6JZ[CTZL[JDPK"K4U=8^^/J)O1N*];`8GJ`+A*69"O
M(D"BY'HHRN,POW$"&-JG5NP(PL^9OQEJ>POJHU-*\D9-TR8Z2=U/T\X)S%+F
M=Z>YA?Q?.\FZ:<H::9)-T*%NO.KPKR-&L19?PYCN?.C&B=,I(F+%UQ2I?)#D
MN,WY'M7[E+B#)F!NYT:/L39B:54<R5#\(15+*XHMOF4K(2N<A6OJ>!JSB(D(
MI@C<[(8A?3I]B-)>9#HT12)+%DI;XSS$LFWYGB-6BRUX`V.F<VDD>:?(&.JO
M)F\:`S^Y;4>'W50*'KO5E.ML][7EME-X?WWZM+9`TFEQWG/8'_:$]P/]44+]
M[_W]5W=YSZ0GR10OU^F[O.?2$^2*%^OTW=YSZ0GR10OU^F[O.?2$^2*%^OTW
M=YSZ0GR10OU^F[O.?2$^2*%^OTW=YSZ0GR10OU^L5];<+RRUZ6,Q+Y%F;RF9
MD[`VF7,6[B,,GC&V:3L)"6?&C>KNJTG`O&MW^'9(83=Z[V/TIQ&OFZ-RC]T?
MUU2E*4I2E*5(6([*I3EG%J="L\7K5&28%81K_![2SP%7>EC/;3+?!+XELJO!
M+YK:CP:\8MI1WOO-PP$.80^JP<=YR$3"&H3B$QQ#^J.&#Q<(?=%?M'[H\8^[
MQTW=YSZ0GR10OU^F[O.?2$^2*%^OTW=YSZ0GR10OU^F[O.?2$^2*%^OTW=YS
MZ0GR10OU^F[O.?2$^2*%^OTW=YSZ0GR10OU^F[O.?2$^2*%^OTW=YSZ0GR10
MOU^F[O.?2$^2*%^OTW=YSZ0GR10OU^F[O.?2$^2*%^OTW=YSZ0GR10OU^F[O
M.?2$^2*%^OTW=YSZ0GR10OU^F[O.?2$^2*%^OT#'F<BF()M0?"*%RV(EW20P
MNT`.7:'"*O$0^Z`"(<H<==6K,RG),YH2Y<[[<),Y@2Y=X!;??;A9,[%N7>]E
M$2D[X<#7.`41*3A<`HB4H#5MTI2E*4I2N=OZX3[\OZPKL0.Y/PK+3GW.71\M
M8,T>3;0HPPQW$++NWB[SXOL&<G@2)_&2]9;5*^]E$`[[=(4Y_JC``B(5L+W=
MYSZ0GR10OU^F[O.?2$^2*%^OTW=YSZ0GR10OU^F[O.?2$^2*%^OTW=YSZ0GR
M10OU^F[O.?2$^2*%^OTW=YSZ0GR10OU^F[O.?2$^2*%^OUY`Q[G#8&W4!M'9
MQCNEA@;1]_9X?4^"0HB(B4HB.S:(@&T=G)50*4!$0``$=@#L``V[-NSD][:/
MY:K5!`#!L';^(1`?Q"`@(#]L!`:IP"[`#CXN/:!C`;[?TP"!AV^[M'C]W;7+
MDY*@7-G^/M/WX>&?_EUDVIY+R!]P/U56E*4I2L..Z!?]SS./]G&G^]L=KY5S
M<H_=']=4I2E*4I2E2=A+_/1A[\*V-_[Z,=?9"')^,WZQJM*4I2E*4I2E*4KB
M;D#[XG[9:ZEF<_Y<3G^W$T_O4\5:]*4I2E*4KG;^N6_OR_M!792]Q[_T9>C#
M\",?_P"/=JV44I2E*4I2E*C[*&2HUB2&.<VE)UMQ"BOM;8W-32E\82"3R:1.
MB./Q*'1=K"Y:,[2J825R:XW&VLERWX:\.:2S<NV+`W;]K4?I^[IQF/4UCG2(
MQP/$$!CFIC4Y#]8.4GV(/TFD+[C7%4!TB9@4X;>4SE(V-.C<I$^3:?/>.X.T
M.2,Z!D0WGF534EIW01QJB4FV6Z4=1<2U;:<,,:D80A7M,<S'`&&;)&-U$IG6
M.*W).-MZC#K<MV[5B^YQA]3.<?7J$Q`2*5;;=4I1%-=M"/ES9?LC(,`$"]:$
MY,\LP'*%PG"((X[R:``8NW:41$0``$`$1X@J=2K4>P/^EIN0/_Y[7O??U7PU
M']EIOT]K^.GAJ/[+3?I[7\=/#4?V6F_3VOXZ>&H_LM-^GM?QT\-1_9:;]/:_
MCIX:C^RTWZ>U_'3PU']EIOT]K^.L.]?RE/=T?9Q+;OV;AACC5L*2Z0YA_P"M
ML=#D*81Y1#W/=KY73<H_=']=4I2E*4I2E2;A,0+F?#YC"`%#*N.!$1$```":
M,8B(B/$``'&(CQ`%?8UX8D#:`JDX"!C`(#?M`("!A`0$!-M`0'E"GAJ/[+3?
MI[7\=/#4?V6F_3VOXZ>&H_LM-^GM?QT\-1_9:;]/:_CIX:C^RTWZ>U_'3PU'
M]EIOT]K^.GAJ/[+3?I[7\=/#4?V6F_3VOXZ>&H_LM-^GM?QT\-1_9:;]/:_C
MIX:C^RTWZ>U_'3PU']EIOT]K^.GAJ/[+3?I[7\=/#4?V6F_3VOXZ>&H_LM-^
MGM?QT\-1_9:;]/:_CJ@JTAN"4JE.8QCVP*4+UL1$1.4````VT1$>(`#C$>*N
MIAG`@,XG`@.T!G$T$!#D$/*IWXZM>E*4I2E*5SM_7+?WY?V@KLG^X_J4]ON9
MNB\MR_9MFW(L`\$]TA!V`XNY1'88P#Q&*8H^\8HAR@-;)?#4?V6F_3VOXZ>&
MH_LM-^GM?QT\-1_9:;]/:_CIX:C^RTWZ>U_'3PU']EIOT]K^.GAJ/[+3?I[7
M\=/#4?V6F_3VOXZ>&H_LM-^GM?QT\-1_9:;]/:_CK]-*5C/J6TPQ[4TV8^0O
M>2<TXP6XTG1<@1J084R%>@#X1\\FWZ)F!Q4>*WE(YI+;-)7?P2PI0]]0K[UI
MQ0*DJNR2Z&IO2CW*K4#HBB6FR;8RRM'\N9ZPHPZUL:21HRK-99N\D&--665V
M3++"6,R:S"5C['5N.IOCC&\P>F:]$5">8.+_`)8L6'IMNKXTHL[7=%VF=GT<
MZ5,"Z8F:0*Y<GPQC2.PI=+5R842F72!'8.KE4KN-QE2[Q4632=<\/EIH!<M(
MTV%]MM(L5$2EOW+>SOA_$Z^88;>%V-(&M=I3G-IL25R61)B4KI!8N0#(5^Y8
M>55]">\YV+M]O07KME8>];N7$20YRF,GLB25@TWZ?=@?U(XHY`_]`1?LRJ_0
MWZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^
MS*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*Q1UQ81PW%-
M*>97^,8IQW'WUNC[9=;WAFAL?;7-#=/*6"R>XC7)&^TI37#V;MVR8]FZ0QK5
MRY;$1(<Y1^:<>4?NC^NJ4I2E*4I2I%P^B1N67,5-S@E3KD#ADR`(5R)79MJ$
MJQ$LES,G5I%-BZ4UJ^G4I[MRQ?LW"FMW;5P]LY3%,(#]87T.&GTPB(X1Q1M$
MQA'9C^+`'U0\@`U@`![P```'(`;*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*
M?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!
M%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'
M%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ
M?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0XZ?B"4Y<(XH`Q3
MVS`(X_BPAM`Y1#:`M8@(;>4!`0'D$!"NJ]FENW9FDTLVB%MVK,TF-FU;(4"D
MMVK4G=K=JV0H;`*2W;*4A"@`%*0H%````"K:I2E*4I2E<[?UPGWY?V@KL4^Y
M,8.PQ)^YP:/'V1XGQR^O3CA=B4.#N[PR/.#DN47'%W,>^L7*F^ZI57S"/TUV
M_<N7!`"EX7!*4`V(_0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!
M%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'%'H!%^S*?0WZ?>9'
M%'H!%^S*?0WZ?>9'%'H!%^S*YAISP````83Q4``&P`"!1@```Y``/%G$`5,U
M*4$0#E__`#[7W?M53A%Y=H>[R#MV[.79LY=FP=OO;!VU6H%S9_C[3]^'AG_Y
M=9-J>2\@?<#]55I2E*4K#CN@7_<\SC_9QI_O;':^5<W*/W1_75*4I2E*4I4G
M82_ST8>_"MC?^^C'7V0AR?C-^L:K2E*4I2E*4I2E*XFY`^^)^V6NI9G/^7$Y
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M`X6T/FY-RC]T?UU2E*4I2E*5(>(E?@&6<6+@3*UHHLE0)9X&@L>$KU?@LM9U
M'@J)-P[?A"Q3WOO*6QPR=^4'MV^&7A<(/JMW]&`3`&&,^#L,8-H8W$0'88>0
M?'8;0^WL#;[U-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5
MN/;=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^
M9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;
M=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;=`SR8PD*.&<]EX5RV'"-C
M@2E#:<H;1-X['8`>Z.P=G+LKJTYH?OLSFEW@'M]\F<PN=[NEX%VWWR3.Q^]W
M";1X%PG"X%PFT>`<IB[1V;:MNE*4I2E*5SM_7"??E_6%=B#W)_,)H[W.31\S
MAB[,+YX#AACL>-8[!A=&99WMQ=R]^0+O&J?PBP?9MMW.]$X11`=@;=@;#-_9
M^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/
M;=-_9^9C/G5N/;=-_9^9C/G5N/;=-_9^9C/G5N/;=>0,\'$`'<WGD-H;=@XY
M':'W?_UOEJ?*4J!-16GB):F(*AQ[-93E6*L2"5L,R*JQ%E&7XED*IWC%ZXM8
M[2^20E>V/*QH0NHIGH&2\K%K4/#8TN"M-?OMB,;4%W>YYX4NQ*)L-R79\6RV
M%/N1WJ/9ID.=\A3;.J2SEZ.I8=DN.GRE/'*4/JB)RJ(M[.PW([>`S>QA'8H_
M14C#+HE&I$U9?8\Q_"\3P.&8PQS'&R'P#'D6883"HJRV13M,<BD7:TS,P,;;
M9,:X>VB:VM&F1IRW+ERZ-NT!KMVY=,>X:-<V`'C[3]Q!_GX9AY/=#'>31`?Q
M#QU/!2$V!]*7D#_PA[WW*KP"?!+^:'[J<`GP2_FA^ZG`)\$OYH?NIP"?!+^:
M'[J<`GP2_FA^ZG`)\$OYH?NIP"?!+^:'[JPY[H"4H:/<X["@'_5QJY``/_5L
M=]ZOE8-RC]T?UU2E*4I2E*5)V$^/-&'P'C#>MC?^^C'7V/@4H[=I2\IO<#WQ
M^U5>`3X)?S0_=3@$^"7\T/W4X!/@E_-#]U.`3X)?S0_=3@$^"7\T/W4X!/@E
M_-#]U.`3X)?S0_=3@$^"7\T/W4X!/@E_-#]U.`3X)?S0_=3@$^"7\T/W4X!/
M@E_-#]U.`3X)?S0_=3@$^"7\T/W4X!/@E_-#]U.`3X)?S0_=7$Q2@`;"E^J)
M[@?#+]JNI;G'^7$X_MQ-/[U/%6O2E*4I2E*YV_KEO[\O[05V4G<?"E'N9>C#
M:4!_J1C_`"@`_P#Q[M6R?@$^"7\T/W4X!/@E_-#]U.`3X)?S0_=3@$^"7\T/
MW4X!/@E_-#]U.`3X)?S0_=3@$^"7\T/W4X!/@E_-#]U.`3X)?S0_=7*E*5#N
M7\^XEP.B8EN49;;CYI.M=4,<:T3-(I5)'VZP,#C*Y'>9XI#V>02=R;XO%FAT
MDTK=4C1=:XO'6]8^2!8W-E@ZFI.8WQED[*SR2..[8_QZ0-;>]L3ZRKTKJSO3
M,[)++@UNS2YH;M]$XMCDA46%B!>COWDJQ)?LJ$]VY9N$.:&<V?X^T_?AX9_^
M763:GDO('W`_55:4I2E*PX[H%_W/,X_V<:?[VQVOE7-RC]T?UU2E*4I2E*5)
MV$O\]&'OPK8W_OHQU]D(<GXS?K&JTI2E*4I2E*4I2N)N0/OB?MEKJ69S_EQ.
M?[<33^]3Q5KTI2E*4I2N=OZY;^_+^T%=E+W'O_1EZ,/P(Q__`(]VK912E*4I
M2E*4I6I?5FX)L/\`=#](>IK*P7K.GJ,:5=;>(5LH4@NOQV"YCG+_`*<,BQ2R
M\6+=FZB3N&3\?XDR+#8D>Z![S_)4**%("7Y!(HZV.DM]R=Q?E##/<X-&^-<R
M,SG&<D1?!4032*)/9U!GB$F7$5O#1!76RJ):OHW&#L#DTQ-<VFMVP:U+-=;+
M9"6TA"A)^<&',ZN88E4-,M@_B0N;FI0PI#XODSHNCY`@D]M@MDKFCR6A3.R&
MV4ZE->[PWQLMQ2O;Q*N3BG-8<9+!@U';`_K1P_R!_J6EOMNJOB#4=SHX?ZEI
M;[;J>(-1W.CA_J6EOMNIX@U'<Z.'^I:6^VZGB#4=SHX?ZEI;[;J>(-1W.CA_
MJ6EOMNIX@U'<Z.'^I:6^VZGB#4=SHX?ZEI;[;JC7,&#LW9KQM*\72K+F-4+!
M,$*=`Y+&/#LC3NR>TF<D3F0Z&\NS&O2$NC?06K9QOHU!!LGN@!"W!)<)@"/<
M<Q$1'Z(0W'__`%B3Y]4_D<QZ0ANK$GSZI_(YCTA#=6)/GU3^1S'I"&ZL2?/J
MG\CF/2$-U8D^?5/Y',>D(;JQ)\^J?R.8](0W5B3Y]4_D<QZ0ANK$GSZI_(YC
MTA#=6)/GU3^1S'I"&ZL2?/JG\CF/2$-U8D^?5>]BW<DUT2D\;E;=G^Q><8O(
M&22(+*S%YCH[RYA=$KLCM*R69]8O'2W%".V102U>LW363'+;NVCB4Y=E8L&H
M[:(AE##P`(B.P,+2[8&T1'8&W-XCL#;L#:(CLY1$>.GB#4=SHX?ZEI;[;J>(
M-1W.CA_J6EOMNIX@U'<Z.'^I:6^VZGB#4=SHX?ZEI;[;J>(-1W.CA_J6EOMN
MIX@U'<Z.'^I:6^VZGB#4=SHX?ZEI;[;JMF:CJ4B4.ELJ3S[$STHC,8?Y`G9D
MV%YB50[WV5I6.5AKLFLYG57B77"ZF(CMGM)5-TAKP&MIE!P+9/[=K;=1[DV-
MSB;)6(DIU[>B6G2W,+2[OB:XK2VE%Q.<39L(836#W#6A,8ELQN!PC6[9A$A?
MW^(-1W.CA_J6EOMNIX@U'<Z.'^I:6^VZGB#4=SHX?ZEI;[;J>(-1W.CA_J6E
MOMNIX@U'<Z.'^I:6^VZGB#4=SHX?ZEI;[;J>(-1W.CA_J6EOMNJH,&HW:439
M/P\8`,4PE'"\N`#`4P&X(B7-X"`#LV"("`[!XA`>.OF^=O\`!=H@\.SL\7]:
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M6EOMNIX@U'<Z.'^I:6^VZ@L&H[8/]:.'Q_\`\6EOMNK`J9:M-6<5E\JBZ:(0
MEZ3QN2/C"G>;&)LE6K#M99W-4W6G.S;LSA99MVEY$Y55LEI8KM$)=`MM3?*`
M73[9Z4I5!`!V;?<]X1`?R@(?=V>^`#R@`A4`V!L#D#B"FS_=Q\HA^KE^X/%2
ME*5B;(=<6EZ+WYF#OD^V#-CJ668%/9RVQ#(#]BV'3JZYIF*Y"))EQ@B;IC!H
MF:&0+44==HHLEUI]99&M0QYY0M[TL3(+DIX>SQBO/:"<.>*I.,F28WRID'"D
MT,=DD+#=8\FXL>1CT]B]Y+)&EG6*+T?>0,ANN"-/?:5IRC=;5RU-LOC+HF*'
M*8H<G*(>Z.P/=]T0$`^WQ<M5X11V[#%'8/!'C#B-\$?M_:Y:IPB[!'A!L`-H
MCM#B#CXQ^UQ#^2H:QIJ"Q-E^5YK@^/I/>?93IXR#8Q;E]IN1R4LUZ)SE5#X_
M/DC*%Q^9&NP_$51"51]\2N\:NO#&K2NB<J5ROW@N6R1.UZ]-)SQ"<[Y#09>;
MKD2TR2:Y#,].5Z,SQ'>Q=+;`)S*(W*FA=%$SVE>TUM8AO*FU.VJE25.XMJA1
M;MV'%%<493-,A9WLI/%ZVV=0+:TNUYM4$O('E"@?+-Z^U7G5C<+25Y9SK2)E
M1;2=U0(E07D:Q/<LD4)%-JU[?AD^$7W_`*H.3;LV\OO\7W>+EIPR<?TQ>+9M
M^F#BVCL#;Q^Z/$'OCQ4X9-FWAEV;=FWA!LV\NS;MY=G'LH!R"&T#%$/?`P"'
M+LY=OO\`%]WBY:AS,NH/#FGQ'"7+,\\:,>-61,A1;%,1>)!:<K3,Z9"FRWQ=
M$8K<>$R!4V-3G(W#_H+/XZ5MJ5<K`R>RI-=*8H>7+>?<0X+-CNUE2<-4169;
MR*SXDQFV*K+FX/,ZR0_H71S:H=%V5D0.CN[O2MN9'9>"=*B/;L(F]4J57;%F
MT)QN&!9-B.2@F`Q-0]7O(2?2;&DD![B4MB1K,MB-U-9>D[666LC(:1LQ#+$Y
MFV61P'6)OUHYKS$]N-JU>/;OWADV[.$7;Q<7"#;QAM#W?=#C#WPXPJH&*/(8
M!Y.00_\`%]3^7W/?]RJ#<(&W:<O$&T?I@Y./CY>3B'\@U$,$SUBK)61\S8EA
MLH%VR!I^?(C',MQ^XR2)KN1-XG<22SJ)I17/#2WMCT1YB:U(\V%D=6.R"W84
M$LWU5M5PK!9>$Q0V[3%#9MV[1`-FS9MV[1]S:&WWMH>_3A%X_IB\6W;QAQ;-
MFW;Q^YM#;]T/?"J[0V[-H;>/BVAMXMFWB^UM#;[VT/?JM*4__/>_52K:F4SB
M..XK(9U/9/'X7"XDSKY#*9;*GAOC\;CC"U)SJW-Y?7MU4)6UJ:V]+;N*%B]<
MIL)D]DACW;A2A4+035E@K(LKB<&CTI?$<NGL8?II!F"9XWRCC9RFD1B_BCRA
ME$1LY%A<5"21YG"0,(KGAG,K0V0>V<QKO!<T(W\C.&3C^G+Q!M'Z8.(`'8(C
MQ\0`/%Q^[Q5Z23R5FAT<?Y9(59D3#&&5UD+TLMI%SA<2-#*AON;DJ(@;$RUR
M6F3HDU^^"5O1JEJC@=[3)[UXQ+9K;Q/E."9OQ?CO,V,'XDFQOE>#1;)$!DA$
M+DUD?H7-65'(HR]D;7E&WNZ"VZ,[@D6$2.B!$O3EO!:5I4]\ERT6]5Z],VH5
MC@J&[X,A3*5:CP9,J7*.])+%Q1>"PB0V5*U7?"U:.-M*D3WU5\X!:3V+MXY+
M9H!@FJ[`N2]-[;JXA,Z\=:?7:$N61D60"QB8H[8PEG,X@ZR%3&UT>3S!"C;+
M;2Y*'$BZ/)U:%&B4+%::RFM'N%E3'&18;EJ!0_)V/GNU(H+/HXTR^'R&TD<4
M"601A^1VG)C?D%AW1-R\[4\MJA.Y-2RZDM6G!N4IEZ0UU(IL7KEZ<,GPB\H!
M]4'*.W8'+RCL'9[^P:`8H\0&*(^\`A^^G"+Q_3!Q`(CL$!V``B`CQ>X`@(?=
M`0Y:QA6:R-/B.>Y6Q@,M?ED\PC,<#P3*$<:,9Y2>UL6D.I=?:;\-#>,T0Q;8
M<F&47;Q5"^7LMURB,0;K:ITF;['VY`O4I<F[EZU:MW+MVX2W;M$N7+ASG*0E
MNW:`1N'.8P@!2$`!$YC"!2@`B(@''7B1+T+BC2.+>L2KD"],G6H5R-195(UB
M-7:)?2JTJFP>Y84)E-F[;O)[]FX>U>M7"7+9S$.41_2(@&S:(!M'8&T0#:.P
M1V!M]W8`C]P!KA<NV[9#7#"(E*43;"%-=.;843;"6[13W+AS`4>`2V0YSC]*
M0IC"`#$V#,[8KU)8NCF9L,2DLQQO+%$E2L$C!H?6#PZ_$96^0B0VQ:9.V,SX
MC,W2>-O+7<*O;$I[AT1K]DITUVQ>N2YM#;LVAMV[-FWCV[-NS[NSC^YQTX1?
MA![GNA[O)^7W/?\`<KP*E:5$E4+EBFPE1)+%Y4J5J;UNPF3)D]LUV^HOJ+IB
M6;-BQ:(>[>O73DMVK9#W+ABD*8P8Q8]UI::<I2&!1J%9+LN*S+"-_7XB=5\5
MG,;AV8T<8377![OX:G\HC#+!LN$1L]A1(@#'4BDIU463*I6@(JC:90ZV\H^&
M39MX1=FP1V\(-FPOU0[=O('N^][M5X1?A!R<+E#ZGX7W/M\E.$7WPY1#E#E`
M-HA]T``1$/<`-M19F[-6-=.F(\AYUS!(;D4Q;BJ*.LXGLFM,DADHL$58['A3
MN\G9(FTOLA7IFY*!E2HK8TK;ME-;NJ;A")[-Z[;D%G>&Y^:FQ[:E`*6QX;T+
MHW*!MW;(J$+DDM+D5[O-\EN];&\EO6[O>[MLETG"$MPA3E,4/8@8H\ABCMY-
M@@/ZAJH"`\@@/$`\0@/$/(/%[@^Y[_N56J;`^W^4?WU6E*4I2E*5Z:1)'->P
MO2)E7E:WA6TN29J<CEX9&]S4(5%EO7&)P+G"*C6'L*A+P#[0M<13#Q#I([EO
M.,0XL[GEA_1'GYJL1S43B2'.F"]0FF68)%#UDF9Y2='Z47)S(VR,+K=U3E2'
M9P<W)WR:V9-CQWV"29AE*M]<)18M(WNZWX3X)?\`*V+<Y,,QQE.<EMZS*O=X
M^Z(XXEV/`>7D,33#"LYQ+G*919UD4*\$*P*&AWS##<0K8QEQ47QJA6OXL<;E
M]AADQF6_^_!$FU4ZI]-^7YKAW6QG<-7#1HX:W;+.FB_"<FPQ'A+7ABV8MDX4
M1:<R+(T[D`X[=\@/;3D?`SWB7%[%%L;3;$R]NR6TQ9DN1Z&29XG+3MG36UE+
M+&3VUJAF>&>'YDA#%W273"DRR_2!OO1#&3OB>18_C.C/(-Y:O1VF.0NFHUJB
M65W:`W57>T6+)TY1IX<RG9D0H,88?J@SVITK3G4;CG5IJ#R*N-C31Q&M;F&6
M[#N4U$ST>/ZW/4'8=9N0VE3DJ03V5P;/$1Q(\Y@3/V+,81QD@<68X0V9DCD-
MCMIMC:N1[&>Y5J(-=U%=UE<,;S"2Y!QR^:ML,2V$9"D\LEV0RRR+.FB33JWE
M7LF39DI<ULYC;6^,S['F5V+('\$S8SIDIW12FM)5%[%?4=+HU'M3+=W5O&D2
M6RW25#<QX[T_:N8A&T<L4R'-SGCYW=H3CO6BSXU36+-V:N>C;(LE0QJ)I[,5
MD,HRMBX9-DB,7E#+BG"3@[V+DK*Z7#NJCNFF0C3340SL&8<[]RF&`R^)S/(S
M%C95A[*$2QTR2!\<<J+VN3M&(]/+K,;3[#,C90QJV7)WCUE=Y(RXUN1B3/QU
M81OI[SCJ`S$@TQPG(6I34A8;K^#.[7Q#+U]EG>3,>/%I_P`!:IHTTZ3'1[E=
MU(RY";9TS8J4.@PU^?7\LZDK$Q*2R%0]++<N(XP]D74KK#BND>4Y&+J9U(()
MW/O\'O9M7>0Y`X2MS2WH5K3QM,,='ON<2;5#.G9,1RA8QO4Q8)UCF(MD;321
MH9;CF^QZ[(VU=);N9-[/LXPHXZR[#'GK4+J@PLZ3S2&SZ/W=\S#+$:)\U>Y7
MQUDZYGK&;_J(BMA&IC.E_'""WC'-V7C)'-GB.&[RF1PB*IT[PG;,9GQZU8ZI
M<IX2QU"87B[67J:RWEC"^(\-9!?,TN;E)HUC?*TM4:_(E$-0DEQK&(]$UN^U
MI8(^600&51[)+\[XAP3@`\,5H;4RG,W>YDAWE]TDQAB?4?B+%NGK+KGX#`]0
M>5;F/E*VQ?,A>&TT@PUF((Y+6%0>WWQJ?X9)[\6E$==[X)B-<I0L'#46%MY*
M2YI>DSOJ1RHI[EGE[6;$7>'9CT\]T-P;I67VG<JJY;DDAP]',[175'JW:K2)
M*#>VXSSK,F[%26-2E<5,C0QML#A+$K7-D?C"_F[5QF&`2)!8U&9<S2R:,KO=
M3NZ*XES9FVV\3=N=\=8^CZ"[>T71=_R3#TZ:98SP!(I$+FWH)W&%#(QWGEK@
MK&[2JU%G]^M.]WN3IJ<=LY9N9,+:B=7N3I-@_N46$L]Z7X7/Y'>A5K/6JJ+N
M&JR+-:K+,':X[&61]<\EL#/A&49`Q8Y)X]XY),(K(9I'&-R5-PLWX0SMG=T;
MIF\Z?-4,EW%RO1=I$E,NR#J6D.2UT:Q?K:D&I2-Q:3XEG>0V&_:R;@"]FS&E
M^3PW48Q0LS1=TFGL,64F&)0A0IM-SWBM,\]97G"YM;WS5)K#TK6G3N6&KO,D
M`QXFU*KI[(''53AG6BYP7$"N#3HL<:9%J.CLA.H3(<-VK:*VOU(8550.S(XX
M\VG=R1*?>C*]2<+G^L34+)IADO&&I)NU&]P>-.F#'ZYQ:H3(7F6XZTX8OU@L
MKU#VA*L8,D1!DCDGRXRR=K<_*&/0"]%P?T!8[(HW<>0E"=YVS[-DVM-U-K`S
MAB;53@F+=T]:ISI,AD"RA8,:$,C/DV]HVR(V/<BFCO`(.P6&QHP)*,+9:PU`
MFJ3Y6D<V>L=/:Z9.;M*%,>3_`"!E:&L^GZ`SO7%J5PK!=3NBF.YEQCJ;>PRU
MEN1*]=;RIAUB:XOBZ.#RV$M!7]D86N,R+&FFO(#0]X[EZZ0Y98T4'<'$J^TS
M9P:><PYA6]TDD&.IOD"99BCBY!FJV@=H%-I7'&_#SA!HSA="ZXMU2Z57"P[X
MYB%@D@6/#UIYU%XKF"E+D47M\BDG1.3D6R_JMXU*4I6JONQ.-<D9)TBLOD'$
MY%DF/XWU/:2,VYNQ-$4"A[DV5=/6%]04&R+F.&LL92DN*Y@O+%&&])K4-;[2
MMXE@1LS$Q-KP]KFYH7VIKUU+8FRSH+U29%TNY/"69BQ_I,S[E3">2<,7[CG-
M,79`MXRDB6%BC>$")6YPJ<S)_,EA3="E*=).I#=7.;(G8RD2NBAOUNZILO9P
MTR-&3DT)U,:G7]GS1W&+5EJ!PQ*)7-Y;-USWK<B[M`9A'TF+7&RT7$[1)HI'
M%ZYU:<9,2=(W-\/NO9;L=NQYO7E03I*=1&37+5+#TCCD9^REBV?8M8@)'HED
M7(&.YE@M:]:`IYD-W7YPT\N;1<@.:],60W!:BE]O/R;R9R5B'/JV.XQ=P7,2
M-N0)]?6'LOZIM,FF336Q8BG.H!TCBON)FC3)&5X3=02[(MS%<C@.H?3OC3.C
MYC6");"%Y@D_QOI1E&:E2_'..%,;D[V3'B&2W6=QR!'S213FM%,[N4>G6F]L
MDNM7,N7^YYY^SGJB<+>I5DL94QDQ0R>I\8XK58"TWI-0RO($JRZ\X=6S%?G*
M0PZ62Z=^%2/*C$P8,/)Y6P,*:*KI;[G^`L'^#RP]"[>.$2EHT8Y[CRDLD0.3
M;(;[J1/EEK2V5[>XH4+I>?7A8H1EM62-Y%#LXK[16]-=.KL6C857YIFI!@S%
M4)AN:,]0*/0O_!LD^5(]&\;3B50FRR:O<.M>,DT`*F-'K:-S)DRPJ;7%F=(#
M>675LI;D#E&GZ,N;/<>&Q5Y,KYVU/Q+RVLQG4GJ,%1,\"=Q&SU?5&E;LZ7D.
M8<R:T5>/=839#DUYE4MT.C*_`YVZ0Y)Q'$D31"H@UVK,GOQ9@;52X5DE7\D9
MZ@&7Y4L8M0^I)R9\3]W2PAI_@[!)LE3*81A7H_S/BS$SUF!EE::0$<AR1CQ!
M-IOD<K+.YRLDMS$E^)IFF$2B(HHTX(5$;0G5#K!=M,F>,^X]U$9QF.K['^E*
M1,>K#1>CPOD!Y<<`YR19KAZ.?Y"96^?S&6LL4RMC6!W\Q&PECS$L/9X!FZ(-
ML=E=R'/K?&6AX<[;+D=-%M5&K;(FE#.>7)#CF>ZM>X`%;LH6\A9#GEJ;8A?I
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M4.3(Z]8"@;;`65%A=<KD[\C;)%DAG:;P.MQP=S-$9MO;Q`T3D^3V?6W]#%*M
M8^?L8SO`6HW`XX"Q[(X_E++S_JZT4AB:$JY<\2F5/$[2XBR&R/TE<\TI<SYI
MD$+>,KX<DD$8G2U*&^X2+1M_P-PEEC(T%TKZ5<*3O/N0=&.$<D8T[H/;A&>H
MK$,N+GQIU;AKBGCKCZ)++..97#U8SM3B1_N3[#&.\FHGF`YA,9^:S0^:+;C*
MB3Y;,^K',:#ND.G^%+LS9[5I&W5A+].VH:.SY*]QA!($)>YJC/8K?9-/D39%
M^(\>8PE.<V5JG>,9RND4ERE/\F/>2(VWR5+BJ()F>Y$T;U<ZAXOCA2Y3[*\T
M>,9(,W:0VO4MK%Q[D#-^5\%*L`9-Q]J07(LM)H8F>H+F/1UDZ[EUGPS&]:.#
MH1/K<9P<RR2'OS#(HU!'Q?9L[!\GX5U!YY[B/J/PEB/4'.]2V5\H:?=049PS
MF.;1G=S,<O1.0N,FO06+&%S?7%P<4LE@9R8LC.29@Y(WB?L:MHGTK5&O/BMY
M66!JHR!!]7V%NYYX3TDMYSYB2ZK]&&7D4#0IG9BF.D?'&G*8,TIS._9B8KB-
M(ZXB/#8(SR/"1XW.;$=<Y9)YA8@K(A=5#C>3!^S3CD'(+_J?RK@W(N?]1B[`
M.?X]J->^YY97MOKBVO=]J62)LBF<8K-Y#=M+'`)G@V6("NNB-WFB!*$EPTZ2
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MY&:$N`=1+:E<+.0VIRE&79[+)9&\GO(GO-^1\)QU$T0:'JXVW29KCD/+)T2%
MZW3TI2E*4I2E*5^8!'AG#:.P+Y2@'N`42%$2A]H1XQ#D$>,:\93G$2[3&XU1
MRC],/U(`.PO+R![W)7ELB(FN;1$=G$&T=NP!,?:`;>0!V!Q?:#W@KR$_\/\`
M\L/]_+^6OS$,827A$PB(%#8.T=H?3'Y!]SD#D]X/>KRV3&$]T!$1`!+L`1$=
MGU7)MY*\`G/X()N&;A<,0X7"'A;.^;-FW;MY.+[E!.?:/TYOK=@?JAY1$-H\
MO*/NC[ONUR`Y^$7Z8WU%X?JAY0*78/+[GN>]6IWNZ"E18[D)W0BY9OWK-PVE
MV=6S'M73VSC;4@C3J;8F(8#"10GN7+%\HCP;MFX>U<`Q#F*.TACN7#1YCN#<
M.)SMC4)SB<PG,(M:8XB8PCM,(F$3"(B.TPB(\8B->V`Y^]@/#-MV'X^$.WB,
M8`]WW``*_5<$0&QL$0VW``=@B&T."/$/OA]VO#>,8HV^"82[;X@.P1#:'"#B
M'9RA]KDJG"-WL1X1MH*3%`=H[0+Q_2@.WD^UR5Y+8B-X2B(B7O)!X(B(EVCL
MVCLY-H^Z/NT*(\#;M';LL\>WC^F.'"X^7Z;W??\`=K4(LO7A[O-'+`W;@V+?
M<A9Q?MV>&;O1+]W6E`"W;Q+>W@%NW"V;);EPH`<Y;5L#"($+LV\&,8!O@!C`
M!;ED"@`B`%`=FT`X^(!]T`XAH<Q@-?V&$."0XEXQ^E'83C#WAXQXPX^,??&A
MC&[W8'A&VF)],.T=IN,G*.WCY1Y??'WZ\I!'OHAM'9PKH;-O%L*%O@A]P-H[
M`]S:.SE&OT4I2E<3_4&^]$?Q@&T!_$/'7X^$;O(FX0\+P<AMNT=O"$3`)MO+
MPA```1Y1``KF<Q@"UL,8-ML!'C'C'Z7C'CXQ^W7$AC"`")A$>"3C$1V\:8QA
MX_MF`##[Y@`>6A3&$"[3&'_H@FXQ'ZH!#8;E^J#W^7[=<@$>]E-M'A#<.`CM
M':(`4^P!'E$`V!L^X'O57A&\'N&X0\(`N;!VCM#8([-@\O%[E>$3GX)?IS?_
M`+03?5#]5M^JY?JOM\M5,<X;-AS?6TX_5#RF.`"/+RB'$(^[[M<C'.`FV&-Q
M*B%#Z8?J1`-I>7D'W0Y*Y`([;_&/TI3\'C'Z788^S@^]LV!R>\'O!7C$Y_AF
M^KM!]4/()Q`0Y?=#B'WZY\(W#,'"-LX5WBVCLX@N;/=]S8&SWM@50IC"5/M,
M8>$!>%M$1X7](4/IO?XA$./W!$*\R@1*0!*(@/?"!M`1`=@CQAQ>X/NU01'P
M@I=H\$0`1#;Q;>"<=NSDV[0`?N@'O!7Y^&?O1!X1MHC=`1X0[1`!'8`CMVB`
M>X'N5YA,8+NP##LX8!LVCLV;0XMG)LKCPC=[V\(=NRT.W:.W:(CM';[X^[[_
M`+M?HM<=LFWCVEX]O'MV\NWW]ON^_7BM\?>MO'M"Z([?=$I@`HC[X@'$'O!Q
M!Q5B/KTDTDA^B'5K+(C(7R+2F-Z:\U/L=DL<=E[)(&%\:H,]*VMY97EL4)7%
MK=6U7:M*D#BA4V%:-1;MWD]ZW<(4P6-W,98K==!FG61.BI2Y2"5PI;,)2^K[
M]U8\R66R>42![DLH?W-0:XM>9%(7E8K=WQ[<;ZES=G-4H7KU2A7?NW39X@(C
M;MB(B(B<X"(CQB'])Q"/NA]*7B^T'O!7&X(E*7@B(?T0CQ"(<>TO'Q>[QCQ_
M;'WZJ41VV^,>/O(CQ\HB2X(B/OB(E*(C[H@`^X%<2F,(VP$QA`;]XH@(CQE`
A#;`'CXP#W`Y`KFG$3<(3"(B'!V"(B/*&T>7[=?II7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g455454.jpg
<DESCRIPTION>G455454.JPG
<TEXT>
begin 644 g455454.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@!`1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]!54-?5D%,54537TM?3$E.12Y%4%/_VP!#
M``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``+"`$J`BP!`1$`_\0`'@`!``$$`P$!
M``````````````<!!@@)`@0%`PK_Q`!N$```!@$"`0,-"0L)!`4'!PT!`@,$
M!08'``@1"1(8$Q06%R$Q45>6E]+5UA4B5%98D9*3YPHH,D%A9Y6GL='7&2-2
M<7)W@9G8)"6A\"="0T9B)BDS4W6SN#0W.#E'@K8U-D1%2'9XAY2BLL'3_]H`
M"`$!```_`/W\::\J=>R$;"3$C%1*T_*,(N0>1T$W=-&+B9?-6BR[.);O7YTF
M+->2<)ILDG3U5-HV.N5=R<J*9Q#6)C/=-O>G,C[KMN5QP-M\=9_Q!C?`^7<4
M2U)R]D,<$S==W!VC(]4C:?E:W36,UKE4[?C9QBRS3]@<URGS@7FHJ1DQ7*W!
M/7A8@(EN7*4YLP?@#<SD[<%CG!E>G,,;A*_MYJUJQS:-P^2\&+3"M&JUUO\`
M><J6*O8`?9-H&.,6>[DO7;I<&6-9R!C+%6WK%]),4#G?-MI^![A:,@X=QQ>K
MD\Q7)3]QJD7:'$GA&X2N0,2RK*=3&2A96@7:;A*Y)6BM2<&YC7S";7A(XK\'
M!UFZ'6HH**2T(\.[W?\``!'_`(``CJG.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1T
MYP>`WT#^CIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1TY
MP>`WT#^CIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1TYP
M>`WT#^CIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1TYP>
M`WT#^CIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1TYP>`
MWT#^CIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1TYP>`W
MT#^CIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1TYP>`WT
M#^CIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1TYP>`WT#
M^CIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1TYP>`WT#^
MCIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZ<X/`;Z!_1TYP>`WT#^C
MIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]`_HZY:::\:QC/A7YT:H6(4M`
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MG@04"G'1`OGQF0NUK=W1-4Y.NXPA'9W7N7/YZQ#"3+5J_?1_NC$2%C.F]CG*
MT>Y:N#M'1``CA#JH)JE`"G*8`X:N`-LN$^`?^19>\'_>*W^T.J]&7"?Q++Y1
M6_VAT';+A(/^Y1?*&X#^RPZIT9L)?$H/*"X>T.G1FPE\2@\H+A[0Z=&;"7Q*
M#R@N'M#IT9L)?$H/*"X>T.G1FPE\2@\H+A[0Z=&;"7Q*#R@N'M#IT9L)?$H/
M*"X>T.G1FPE\2@\H+A[0Z=&;"7Q*#R@N'M#IT9L)?$H/*"X>T.G1FPE\2@\H
M+A[0Z=&;"7Q*#R@N'M#IT9L)?$H/*"X>T.G1FPE\2@\H+A[0Z=&;"7Q*#R@N
M'M#IT9L)?$H/*"X>T.G1FPE\2@\H+A[0Z=&;"7Q*#R@N'M#IT9L)?$H/*"X>
MT.G1FPE\2@\H+A[0Z=&;"7Q*#R@N'M#IT9L)?$H/*"X>T.G1FPE\2@\H+A[0
MZ=&;"7Q*#R@N'M#IT9L)?$H/*"X>T.G1FPE\2@\H+A[0Z=&;"7Q*#R@N'M#I
MT9L)?$H/*"X>T.G1FPE\2@\H+A[0Z=&;"7Q*#R@N'M#IT9L)?$H/*"X>T.G1
MFPE\2@\H+A[0Z=&;"7Q*#R@N'M#IT9L)?$H/*&X>T.J]&7"?Q++Y16_VATZ,
MN$_B67RBM_M#IT9<)_$LOE%;_:'3HRX3^)9?**W^T.G1EPG\2R^45O\`:'3H
MRX3^)9?**W^T.G1EPG\2R^45O]H=.C+A/XEE\HK?[0Z=&7"?Q++Y16_VATZ,
MN$_B67RBM_M#IT9<)_$LOE%;_:'3HRX3^)9?**W^T.G1EPG\2R^45O\`:'3H
MRX3^)9?**W^T.G1EPG\2R^45O]H=.C+A/XEE\HK?[0Z=&7"?Q++Y16_VATZ,
MN$_B67RBM_M#IT9<)_$LOE%;_:'3HRX3^)9?**W^T.G1EPG\2R^45O\`:'3H
MRX3^)9?**W^T.G1EPG\2R^45O]H=.C+A/XEE\HK?[0Z^[;;;AEFY;/&]-*FX
M:.6[MNIV06T_4W#58CA!3F*6`Z9^8LF0_-4(<AN;S3E,41*,Y_\`/SZ:::::
M:QMW)?\`R+#'_P#$=A7_`/$RFLD2]X/Z@_9JNM5^\VEES#O9V+X3L=ZS/6<;
M6G%>]BY6>!P_G?,N!E['8J(UVULZ:]GYW"EYH5@F4:X2Y61:,C9*4<Q23F47
M<*,E5>:(2/\`R9NWCQ@[W?\`,?W^?ZC]/Y,W;QXP=[O^8_O\_P!1^G\F;MX\
M8.]W_,?W^?ZC]/Y,W;QWNV#O=_S']_G^H_\`Y[GAT_DS=O'C!WN_YC^_S_4?
MH/)F[>``1[8.]WN=WN<H]O\`!'Y@W'<1_J#NZH')F[>!`!#(.][N^'E'M_H#
M_B`[C@$/\0U7^3-V\>,'>[_F/[_/]1^G\F;MX\8.]W_,?W^?ZC]/Y,W;QXP=
M[O<[_P#YQ_?Y_J/UQ_DS]N_OO^D#>_[WO_\`G'-_W_\`;]\;[[_[O'50Y,W;
MP/\`]H.]WO`/`>4?W^`/`>]Q`=QW$/\`$/#JO\F;MX\8.]W_`#']_G^H_3^3
M-V\>,'>[_F/[_/\`4?I_)F[>/&#O=_S']_G^H_3^3-V\>,'>[_F/[_/]1^J#
MR9VW<O#CD'>[W1X!PY1[?Z(_,&XX1X!WQ'O`'='@&@<F=MW'CPR#O>[GAY1[
M?Z`#^4!'<<'$/`(<0'\0ZK_)F[>/&#O=_P`Q_?Y_J/T_DS=O'C!WN_YC^_S_
M`%'ZXGY-#;LF`"?(>]PH"8I0$W*0;^P#G',!2@(CN/``$QA`I0$>)C"!2\3"
M`#R_DS=O'C!WN_YC^_S_`%'Z?R9NWCQ@[W?\Q_?Y_J/T_DS=O'C!WN_YC^_S
M_4?I_)F[>/&#O=_S']_G^H_3^3-V\>,'>[_F/[_/]1^G\F;MX\8.]W_,?W^?
MZC]/Y,W;QXP=[O\`F/[_`#_4?I_)F[>/&#O=_P`Q_?Y_J/T_DS=O'C!WN_YC
M^_S_`%'Z?R9NWCQ@[W?\Q_?Y_J/T_DS=O'C!WN_YC^_S_4?I_)F[>/&#O=_S
M']_G^H_6).]W:/0]LN!`S5B#*V\>%R#4LY;26T,_GM^>]*]0O6=LW;8-I=EC
MY>GWG.UAI]CBYRJ6*<@I.)L4%*QCIA)N2*M#*=243W>D$1`>/=]^H'^`',`?
M,`<-<M-------------------------->5.EF3PLN6NKQC:?-&2!8-Q--G+R
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M1DY)TBRCV#-&R*&6=/7CDZ;=JV2+[Y5==0B29>Z<P!W=7V&XG`?`/^FC%O>#
M_OW6O66J](G`?CIQ;Y=UGUEK!3)F1:!?>4OV#!2+M5+>:.P%R@!I`M:GXN;.
MQ(L?:(5$[PD<Z<&;$6,!BHG6`A53$.5,3&(<`VGZQ7W/9GS+AYE37&(,"3F=
M'$^^F6T\UA74BU-6F\>U8KL'3@8^(EA.636<.&Z8*E0*!FIN88XB)2XC!O:W
MJ<0_\WW>N'$./^][&`\./=X"--$`'AWA$!`.^("'<U@U5-\&\3I12\H2JV.T
M6217?5>1VSD9323*-C(4CAZ6(CHH&B\G"6&`*8\F_N*K([B0!5<TLDM#.8]D
MSSD#>UO4X!_YON]?I:R>QNI]J^3<F9OVXYV=YJP7)X;>M:W>(5G6+`L^?&G8
M?L"5D`F$_="*BE"I%?KKLR=224`CACU4BQ50YI-%.(=^^Y?;3L5VY5[$$7AA
M['XX^Y\JERE,Q-Y/K>0;9:[SD_%C;&9\AU6?D8?(=9!PWRI!34V<+BL+FP5Z
MWO2662;6YDB,&KEHAOSW*M-P&]UB;)&&XJL0N9>3HQ%@:E7:I7.0DX%ON4PW
M6\JW*)H5=J$\ZFLY9F>15BM#>NT])K2XVP2<3'6JQV.E8_ILZR4Z>WKE/]U6
MZ=LXQKCV"VZ8^S_B_`.:\Y7U++:=SB,>Y05Q-O:SEM&8P,":$L\S)8GK*[/`
M,_;<I7521RR&-)V_T.%BHVXQ#.3DI;/'8QF#,V6<X\I/&Y*O-=L],PYO10Q'
MAV#AJN\A5:S06^V+;ADMDD:55MTZUFD7CC)J[AZZ3BV*S^PGF+`FY;1,U$U6
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MDPI`]+(?*';M\,Y!PY3+\;:Q=+#'Y&Y/K#>YBF86B<F6%"FW_>1E=SC*^=?W
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MD\XQK?I*IV`6$T$+$3E'LQ+`\D:[-.YOE5<[X''>BX=46L465POMVS?N#VXT
M_*V+KZO6]PM1P]7<:V)26I>::K?6M0GYN!3L=IBL]8;D6-)RSB"3&M2#")M=
M28RUAF;#WP;CKCFC(F0,'6>#J;2+VI\K/R(<5C>QPS2:93KMAG[+&`;[8`M!
MWDS(,UGD;V5RM=(YB6L0U>U]<$W\89T91=7(>&W[[Q,A0^2,NX;PEC.YXJCY
M/>]BNG4FR7BE4?))\V[8KQ>*)C:MPKE_EAR>[3V2)7&ML-<L?V2JXE&H)2-8
M?1M\=P:,O++9Q[$]RR^Z;"\C?)&50=V*NY&NN.[77WV++SA"_8_L-57CS.*#
MES$F09.<G*+E&`9R;$;-'M)R:J\NB\C+13):0JL[$N3YH::::::::::UN<K.
M\:1VR*WR#]R@R8,,W;,7SYXZ5(@U9LVF]?;NX=.G*ZIBIH-VR":BRZRABII)
M$.H<Q2E$0R_Z0N!DC*)*9GQ:4Z:RQ#E&]UGB4Q53E,'$),0'@("'$!$/`/#3
MI$X#\=.+?+NL^LM.D3@/QTXM\NZSZRTZ1.`_'3BWR[K/K+3I$X#\=.+?+NL^
MLM.D3@/QTXM\NZSZRTZ1.`_'3BWR[K/K+3I$X#\=.+?+NL^LM.D3@/QTXM\N
MZSZRTZ1.`_'3BWR[K/K+3I$X#\=.+?+NL^LM.D3@/QTXM\NZSZRTZ1.`_'3B
MWR[K/K+3I$X#\=.+?+NL^LM.D3@/QTXM\NZSZRTZ1.`_'3BWR[K/K+3I$X#\
M=.+?+NL^LM.D3@/QTXM\NZSZRTZ1.`_'3BWR[K/K+3I$X#\=.+?+NL^LM.D3
M@/QTXM\NZSZRTZ1.`_'3BWR[K/K+3I$X#\=.+?+NL^LM.D3@/QTXM\NZSZRU
M'MVW48^K:AG<!::%=(<T2_)SZ[<XR2EXZT)HKN8=K+1$>=VY3KLP1+K0\VS(
MZ5BGID3/6?6#@':,M5^RW&U,3SD=`QT1"O%^=`EL3B2;3,C$];MQ1EWD:V:*
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MR@)EX<#*<THB4!$P9`E9LQ*4>M&W>#_L$O!_9U7K)G\$;?4)>AK7/G1))+E+
M>3Z*DFFF4<"\H*(@F0I`$1':$`CP*`!Q$"@`CWQ``\`:V0Z"`#WP`?Z]4X!X
M`^8-6JWHM,:6^1R`UJM?;WB7B&D!*6U&)8IV*0A6*HK-(IY+D1!\X8MU.:=-
MLHL9,.II`("5%$J=U<`\`?,&O%LE<AK=7YJK6%B22@+%%OH6:C55'"*,C%23
M=1I(,7!VJS=<6[QJJJV<$36)U5!11(PB0Y@'%M/8-LY2@4JLGMYQL%:0PK([
M;T(`8AR:&0V^R[]&3E,(H1IGPM$<3R$@V;O'>/TDB5===!$YXP12)S?A=>3[
MV6Y$>.96X[;,4S,^[#$@K6L]<(RN0+X(-_T0OD;G&KLK8UD\?M_]W5R5:S*,
MDTAQ-"*.UX<18ZMQSR9FP=VICY1;:CAH#XKN=ZOM"%&K$:]CUBR99#V^_P#4
M`;.40>05OLQBS4]4)0']/?OT&BRL!P9M2HY,5/"6(J)?\DY4IF-J75\CYA=P
M;_*5V@J]'1EEOSZMQ#2!@WMJE6J*;F8=QT,P8QB#ET<RPLV+)!4ZA6;;J5AO
M=HVVR4QGD_#<MAJCR^+LU6:=N66J++QBDK6\CVBSO6$C9)RYQT@Y<DL#^?>Q
M<<YF%9`RP22K%H9X18&Z8!8EVY/C99D9-8;KMMQ98)%:M8NJ/9&\@#$N*,%A
M.:[(<1M6EV:NF]P8N,<2W%Q391E.MY>!3,=FQD$F!SM1[M5V%;/*-*C.4[;U
MC:L2_/RZ=.2@X=:->-RY[=,WN9F[-=J]3.R9Y+=1T8O<&+04&<PI&1AG"'^[
MF0(8][K^2WP1G/;)DK`>(JOCO`UAO&W^J[6X#(K&C.+(%#P+4[O#W>*QC#UM
MO8Z[U2D1;Z+7]PJHUFHB(AGDDYD&Q.(JMG.1H;(ML#UC60FL-4^1FJS<9[)D
M=87![`]LC')EMJS.E6B\-;A(32]R5LDE363:CDG)"==2S:B-6E-;ND:X@2-"
MTI'DV]B\M.]DDEMCQ:\FCHXR(Y?+Q#PQG[G#5I4N6,)B40]T0:RUCID^NY<0
MUGDT'=C39.G<*O*N(-VYC%<BLOX0Q1GJLM*AERC0=XA(R=C;3!IRR*R<C6;7
M#&4&(M=3GHY=C8*C:HH%W*<;9:Q*Q$ZR0=.VS:03;NW22T46O9!M3O;:A-[O
MA2HW!;&=ILETITK9QF9VQ1UCN4`-4N+]Y9Y.6<V2P)W"KE;URV1]EEIB+LD&
MPC(J:8OF$5&MVF+]4Y*_!U8W-+963K=`-@F$VLX"VQ8UVXLZM.LZY38K`&4\
MC9:KTS*.1MZ]>O42^L612G+3;53WT?%2-,K-D3?OI@JIT,JY39=M;G9;)4Q/
MX3I-B7R[%9&ALA,K$T>S\#8(_,$7%P>6$S5B9?OJU%KY-AH2&B\@/H*(BY"X
MQ\3&M+`Z?H,6Q$[?B]@>SF&CG\8QV^8]!&5FL,626<NV#^2E9BQ[=X]K&X0L
M4O.24D[FY6?Q>@R:+TV:D)%S)Q$DW2F$70RY`?:[#K87L\=W/->0EMO&,@N.
MXN%D('-4XC!"V<9"83+6/9SZDVBU<(LR2EE;1$,G:9Z,;1\]:/<6&/89.34B
M8\[:=L:8HQ_B"">UW'=::5V/E9Z5M4ZL5Q(2DS9+3-F1&7L]IL<X]D[':;'(
MD:LT'D]8I:4EEVC%@R.[%FP9H(2'IIIIIIIIIK7)RK@`;9;92F`!*.=]E("`
M@`@(#O=VZ`("`]P0$.X(#W!#6Q`K1J;G&,V;F,914QC&13$QC"J<1$1$O$1$
M>Z(CW1'NCKEUDS^"-OJ$O0TZR9_!&WU"7H:=9,_@C;ZA+T-.LF?P1M]0EZ&G
M63/X(V^H2]#3K)G\$;?4)>AIUDS^"-OJ$O0TZR9_!&WU"7H:=9,_@C;ZA+T-
M.LF?P1M]0EZ&G63/X(V^H2]#3K)G\$;?4)>AIUDS^"-OJ$O0TZR9_!&WU"7H
M:=9,_@C;ZA+T-.LF?P1M]0EZ&G63/X(V^H2]#3K)G\$;?4)>AIUDS^"-OJ$O
M0TZR9_!&WU"7H:ZKT8>-:K/9#W-8LVY!4<.WG6K5L@F`@`G6<+]312('$.)C
MG*'Y=1'+YAI`U&U6>B-$\GKU-RR8OX2E))2+\7;]9))'ND04XLRIG.Y5>M4G
MB?6[=R9`JRB"A"VACB7SAD%Y.K7:C0F,J9(U^0:08(F,-W92SD2HLI!,%5#`
M06R"BZQA?QL:)7*+0R#<Y15U9L3LKI39RZD9^UV2VRCR$DF2KR<(S6`)Q^DH
MV1L?4O?F<+QS<X"Q8OUWB`.@!TNJL)$$D,@JY0I:H,EX6O6URG7DWBBT'%2T
M8E,GK[!5%N'N(QD5WR+Q:):NB.5XU%Z9PM'MG18U)P=FS:D)B?NQH._K-<RG
MC[:QN!Q_LMHL9&Q[VQ9XEL-PFXS+MKG7J_55:UC:A6FSP.-*)`0D83FR]VO3
M*\S,[,O_`'-@J?`1L&I8K#CEL-MF\&'RC>L99)WKTGE":A1K,E3<K2%AVP%V
M=;E=N=MEJMV55%6S5F.<,*+E&AVIDW5*D5C2Z=9HQO+PEAA9JZPQ))DVW%\>
MYQ'N?C'C^+^O7$#E$!'N]SPE,`C_`%`(`)N/>`2@/$>X'$=.<`ASN[P\'--S
MOZA+PYW'NAW.''@(#WM5`>(<0X]WP@(#\P@`A_B&H&SK^'AW^_;'7[9K4\$_
M`+_9+^P-<M:XL\?_`%E_)]?W"<H)^W:'K8[II_SX?V:X\X/`;Z!_1URT[W?U
M;:-QJ;F4E(-O9J^M-0A$E)B(2FHQ24B2+`4R1Y..(Z,\CR*%.44S/$$`.!BB
M41`P<?2AYF(L,6QFX&4CIN&DVR;R-E8A\TDXU^T6`12<LG[%9PT=MU``137;
MK*)'`!$IQ#7I::^3A=!J@LZ<K)-VS9)1=PX74(B@@@D05%5EE5#%3223(4QU
M%%#%(0A1,8P%`1UYK2P04A$1T^QF8E[!R[=D[BIAI),G,5)M9(A%8]S'R**Y
MV3UN^343.S6:KJI.B*$.@=0IRB/V++Q1CMDRR4>8[P1!H0KUJ)G0@=1,0;E!
M43+B"B2A!!(#B!TSE'WQ#`'H@/$.(=X>Z&FFFFNNW=M78*&:N$')4E5$%#(+
M)K%362,)%$CBF8P$53.4Q%$S"!R&`2F*`APUY4A:*W$J((RM@A(U5U*1D&V2
MD):/9*.)F;6.WAXE`CIRD=:3E5TU$8U@F!G;]5,Z;1%8Y3%#W>_WM-->5+3D
M+`HM7$Y+QD.@]D8^'9KRL@SCD7<M+.DV,7&-E7JR!'$A(O%DFC!DB8[IXY53
M;MDE5CD(/JZ::::::::UR\JW_P#0NLG]_&RG_P"-W;IK8NG^"/\`;4_]X;7/
M333333333333333301`.^(!_7J(<@YVQ;C+JR-JM;%"31*!C0<?SY6;#B4IR
M]4C6`++-`.0P'(H^%JD8O`2G'B'&R,CW?-\HO7&.$:=%O(6S5QE.A?;$NDBT
MCBR(F42;#%.UVJK=TBS,U=CUTU?J*"X%$D<<R"PAW7^#E\E4BHPF<Y]S:+!7
MY!_*/759<'KT7(*NU52(,W39LU0(\1:,11;%=$:1[GJA%%FXMA65%26*;0*=
MCZ-/$TVO1T`R5.15P5BD8%WBR9.ID7?/%3JO'RY4_>%6=+JJ`41*!@`1`;PT
MTUIFWJY:Y7W%^8+E-;4*7L"=[7XNGX[<KW3>5D[(.,I2+O3_`-VVEL:1#^EK
M>XJE5`PU0B#JQGCGW9!(/F3$[]L9,K/W^3#O6['*EWW0Y$W=J[.#WJ14P=`5
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MY1K+Z-L$K8<68]R`C3GU4<+(2E.8;0MA%HK=RV@X)L%4H%IQ9%NZ:9NXQW<K
M_8<JV"FV"*G)F'MT`YR9:YF?L5_:,+;'SB</<9636<V*$&-E>H,4W*<>UO'<
MC*>XD7BR6]SI26ZPS?CI?W,A&G7\N]_G9=/J,>RZHCURO[_G]3ZJ3^;(<W'W
MO`?2+G4_-+_T.YV_!#_[.A\'_MK7+MZG\3N=O-T/KK6#^0KV-TY2_82`TZ]U
M/K#`6_\`-QNE<&!![U4^T0O-8?[:\ZX,EP$5@]YS"B`]W6UK6"N_/,^\_"N.
MZI.[+-JD-NKNLI;!C+979C)$5C\E3K`1;ARC/MT)%PQ5L:CN5(WBCLV4BV4C
MDUQDETW+=,R8:2\_;[.7(EL$YJB[MR4=5H5-DL1Y+86V\L,\Q"C^F5EY2IQM
M/VQBDWMQW*SVN1*KN9:HM2F=++LDTFP=7.GK\1=2R)D-M.U):+O%WE7C:=JJ
MT6Q5OUH(25>-Y:,5C&*IE)L"$3DW2;=JJ8_`I".#"?@4!X?O0'?YR]X&,'\C
MO2>X<_>S[`&`/?CQ`#$MX$,`=X#%`"B`<2APX!K+VT9^Y16V<E9O(R]>=LY=
MM&\ZJX5W#.<,8YI=SC\I3#Z2K^,7<E1+M!)12KX4+6>>4D2P-,<+R[]W+0$:
ML"#E.9;1VKDV_;<-BMPV@[*[="UO'MI@F\#AG)6(LGBTBGUPR+D6?I!7KRQ3
M]L%-]/W^S92/*6AQELE@D9I[;1DK2YN*JZB#UZVTC;->4(S[LSV-[::Z=Y0[
M=B]AR,6`=QE/92=9<0Q\/SL;N)QAMQL-HL=JCWK]>Q8]BJ3E9OE.\#+1*!*^
M;'TJM'OF5>DW39AM'R1NWW6[;8"$R9FO,.$)O`%.W<-\3YBN6/(AOD:^T7;]
MG[%;`F`[_DJ1@:U3:-#Y`HFX>P4V(L$?2:B_B,AX5R!39P8BI6_K@LM"=*Y3
MO=*?;,\R?DPE-IU^PC=<1[0-W$?.TPM.K6*]U.8=UU=Q7)W9_9EWMJ@ZA0,:
M81F:[DP[*0+;8`R.9<62L_/O(Z.L+22OF^[E]TTO-L=DN6LFX#C;!D/%?*,W
M63RS58^)R$E8:'M\@\4,<?8/M\)*P=5QUVZ3PV=^R;</&56&1A0HM!!Q4"4]
M_>)$]$R6V)0.#+YR(NS"$W#QU#L6!I+DX]N[?*[*^>Y[FBC36NWZJ)VGL@7>
M',W:,XQJB]%=Z"R3Z+<MNN&RZ$BW2.7!?8T28Q=-WG;3G3W=@<V[7-K5OM')
M1V[+E-JJUG'9#+P[Z.AK^>+>).&4ANKQN]84S&.Y:/?$BIAI1([$"TG`QSN_
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M*;<K!4[_`(XQ?%3NW#`^\O>G$73':;['NS;"MYPW"6XN,;I>W-B96)WG7..2
M#3T?C2)5(S6I&((.U9(LU8E5XJHQE[D+DX-ZV<<\9WMV)LL6NM7V"D]DNTK=
M]3+?$4F'QZE(O,^VO-]?L:E$KK*=E;.EA"6C,?5&UXG;Y>80N;X^"FS+Y&:$
M<3$>S88QWC(4YL`W_9SW&TJHSUPQAOGRO-;8;ICVM,E%HM'?)0\,XUMNT"Q$
M9QR+D8HVX&(F+_@V_3/6\>V+/QN,K#/R!DAD'B$`[>Y6T[;*GE&-$:#E:WV_
M[I8QQB/+=XRM0(FZSEG<7Z-P>O8;E5EY%TF6DVZNW&<>S&+)I!&26QW`@A!5
MAG'&!I),<D4.44W/W78=G3?G0\N8,@UF6V7E"L@1>VRUT!Q+7G#&6]ILU-KT
M2H'*PF826FC5^J5&<B]Q)<BK-44[K9:+-X^915==DJL[[>1]ZV\G'T;N?@G6
M8<5!D/:3L"JG*)QZT[B)I5JUN#:9`LF8IL<,'C5[3,2$#CK'=;P^GBN1R)5)
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MNC^F/JBZ</92%\N^<HKO0I+W>/DN?R%MV4QYM'P!R?\`DB:J^.Z!.V&BV"9W
MAX[EX7(ET:9GGK$A8T,+X>NA3YJB;.^Q\RDY[&$">&L4;`)!)3;B7\U[N=ZN
M`\6V^?L-DQ[E"O47+.4)6PW#;N7'V7L[X]VYL<%US(%+O.2\13#+%51R>ECF
M\64)?-\-M\8=L=]M\E,=W&GUB/M$K/(J;PJ59XF[4^JW&!E6D[!VNMP-EAYJ
M/3<),)>*GHEG+1THR3=)(.DVDBS>(/&Q'"*2Y$5R%6235`Y"W/IIIIK6URM3
MKK'8_<GP-G3P66;-F;SK-BCUR^=]:[UMO"_6K)OSB=</''4^HM4.>3JRYTT^
M>7G<X,K#9R,D=5,,/YS4ZFLN3GI8\$Z9^:L<.<0_NR'/(;AQ*;@'$!`>`<>&
MJ=O4_B=SMYNA]=:=O4_B=SMYNA]=:=O4_B=SMYNA]=:=O4_B=SMYNA]=:=O4
M_B=SMYNA]=:=O4_B=SMYNA]=:=O4_B=SMYNA]=:=O4_B=SMYNA]=:=O4_B=S
MMYNA]=:=O4_B=SMYNA]=:=O4_B=SMYNA]=:=O4_B=SMYNA]=:=O4_B=SMYNA
M]=:=O4_B=SMYNA]=:=O4_B=SMYNA]=:\^5W%Q\''/9>9Q7FZ,BXUNH[?OWF/
M12;-6R0<5%E3C,C[TH<.X4#',(@4A3&$`&V83=W2;7)$C:?2LH6HX,E';HT+
M4BN56)R\W@W<LO=$KA,_O@YZA^8D01`I3*F[@0*RN6Y2VV9I,WF.S-2(**F4
M'[:K4+&!5O=-JU>)K@T=/3SW`S5V@7K=<91S)&.F90!C$C"423$1_C$EKD[N
M?;1EQU:)=T#Y[*R.,SR1Q=E322!RV;/YUPR9..IH)`9=FV04.8G/$P'$PC)H
M9T,'#AAS.H<`X!PQR(<`#O`'^^NX`>#5>WJ?Q.YV\W0^NM.WJ?Q.YV\W0^NM
M.WJ?Q.YV\W0^NM?=MF\[ERV;=J+.#?KERW;]7<X^%)LAUPL1'J[E7W9-U)NC
MS^JN%>:;J:)#GYIN;P&<]:.^7[;4YULLI"5WIVV"X0P[H<+D`N\[(]LQKM?@
M'KEM=6;6<S#(T@R=@F8!3KA6OQ<0DLC'L+1/05PF520]5?#J&ON?./HL?2=S
MQ*#7.34K,6K>,9*.&/)DY*R#D_%BCH*?/$%Q?IR^2DB=K?SD*!2Q\.FR;)UP
ML6J[16>*&<J_H1L4!%6J`G*Q.-SNX6QP\G`R[5-T\8J.8N89+QT@W3?1SAG(
MLCK-'*R17;!VU>MQ."S5R@N0BI<#:UR56P2HU"^4*O[<ZTQJ62Z;!8[N4,:S
MY'>H2=#K<]&6:'IK9>1NKM[!UEO-0T0\6A*\ZB8^0"*C6TD@\9,6S9+WX7DU
MMF-;KK*L5K$;NLL&&2R9>1?UG*69Z[:5;^2EO\=#+2%WALC,KI*L%Z1*259>
M5B4L#RJ/8E^];NX-872QSYK04'#5B%B*Y78N/@X"`C&,-"0L2S0CXJ(B8QJD
MRCHR-8-4TFK)@Q:((MFC1NDFBW02322(4A0`(:SK^'AW^_;'7[9K4[$(3F%]
MZ7\$O_5#P!^37+F$_HE^B'[M:X\[@`<I=R?7``#_`*!.4$[P`'X]H?[@UL>U
M00`>X(`(>`0XZ\N:@X6QP\M7K!$QLY`ST8_A9N%EV+:1BI>(E6BS"3BY./=I
MJM7T?(,G"[-ZS<I*-W3995!9,Z2ABCB>TY/'82P<-';'97M2:.F#AJZ8N&VW
M_%B*S1RR63<,W#91.KE.BLU7126;J)B4Z*J29TQ*8A1#,/F$_HE[HB(^]#NB
M(\1'O=\1[H_EU7FAPX<``/`'<_Q[G>'\?'O\>[J$JSMJV]TR;L=CJ6$<55F<
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MS,PT6=PK)FNX;2TF@X.JD_=%5NU7`F#E\6,<&+X;Q6OA6,8,(N.Q$MCZI*XP
M8QD4[(_C(YI05(@U5;L8Y\FF]8M4XDJ#5XFFZ1(1P0JH>C-X;Q'9;C4,B6/%
M^/+!D#'K-W'T*\S=+KDM<:0Q?IBD_9U"SR$:XFZTU?I&,D_;PSYDD]2$4W9%
MB<"ZB&0V.;+Y9-BC);2MM+Y"+JBE%C&[G!F,56T?2E;.-V4J3)L-8ZW:ULUQ
M,>U^XJ"1&`6-5>9!`)!=9=2_6>V_;U'KQSIA@K#S%U$7B2R=$N6>-*8U7B\D
MS#11A+Y#C5D(5-1A>I5BJJSDK>T,C8GS155LZDE45#D-BU9>3;V_V+<?B'-!
MZ3BYICS#^%,PX?@]OJ6&Z7VN5%LT9&QYDZS7E%LD+:-C;*2Q8WBBD!O6U6LB
MSF[6$QU^[ET73'*25VV[=YVU2EZF\#89F+O-R\78)FXRF+Z/(6F7GX1K',8:
M<E+`[@EI61F(AE$13.,DWCM=['M8R/;-%T4638B74Q3M?VW8*?IRN%<!89Q)
M)HU<E(2DL:XRIE(?ITQ.<>V9.I$>5N&CG):TE8I%].)0950C$I5VN^3;%74$
M^KUB\3XN@W<T_A<<T6(?66V-K[8WD94H!BZG[RSYG6ETFG#:/35E;8V!-($+
M(^.O,HE21*F]*5%("6>GMDVX)"]%+`6%TQDKVPRE(BGB^D$%_DV*$QHS([T2
MP8"[OT<)S"PN:_5+*S$PBWDT]>8CM+VM-IO+5E0VWX'2L.?$C-\Y3B>(Z`26
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MVB[5+O5W=)N6VK`EKIK_`""&6GU4LF(<?S=<>Y4YRAQR4[A9*ON8YS?U!66Z
MM<5FY[$X!98KB15(LJ4]^!A?#Y96\SI<5XY";R?7V]3R5,=A%8&4R%5F<>K$
MM*U>'XQ8NK;7VD2X7BVL+/JR$:VC5UV*#5-JLJB>-&VS':*RHE/Q>PVPX`CL
M<8^>RTC1*'&XAH4?4*:]L")V]@<5BO,H%"*A#V!JHHSG_<]J@6<9**LI8KQH
MH=$<E$TTT4R))$(DDD0J:::92D333(4"D(0A``I"$*`%*4H`4I0``````UST
MTTTUKEY5ON[+;(`][M\;*?\`XW=NFMBI"E$!XE+^&K^(/_6&_)KGS"?T2_1#
M]VG,)_1+]$/W:<PG]$OT0_=IS"?T2_1#]VG,)_1+]$/W:<PG]$OT0_=IS"?T
M2_1#]VG,)_1+]$/W:<PG]$OT0_=IS"?T2_1#]VG,)_1+]$/W:<TG]$G>X]X.
M]X?ZM?)91LW2467.BBBD0RBJJIB)I)$*'$QU%#B4B90#NB8YBE`.Z(ZA?*N=
MJ5BEG"*R*$G/R%G2=J5R+K;-.04E2M.MP.J1YU0C)-#JCIL0IBJK+J=5`R#9
M8I3B6VDYC,67L8K/*W&*8-M#FQ%0;GLB`R;QS5DT2F6>-4S1Z#N,>NCK\Q$[
MB.*H`LE.H*)I.TGB7H8RP$TIC>SJVZV3N3).[,$8^S]E"@N81XV1,J?J2<.[
M5?";G=742.L[=N%!1`J:94"<2ZFZ&@82O,$HN!B(V&C4``J+&+8MF#1,```X
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MQ`>Z`AW>/'O<.'?X_BX=_47TC.&&,F1%JL&.,MXRR!!466E(&[35(OU3MD33
MYV#0ZYFX6TR4!+R#*O2T.W_GY6.F%V;N.0_GG:**0"?7(N;<-&Q\.6BY9QF;
M%0&*4<F!?*J./@$\@6)*`W,)8:V`FE3DC`#W2YPR)RL0`71BI#(<?(,)9@RE
M(MZTD8V2:-G\?(,'*+QB^8O$2.6CQF[;'5;NFCINJFNV<MU%$%T5"*HJ'3.4
MPPCG7\/#O]^V.OVS6IX)^`7^R7]@:Y:UQ9X_^LOY/K^X3E!/V[0];'=--4XA
M_P`@/_/'PAWP_'JN@B`=T?\`G]XC^(.^(ZB>"SS@^SVA>D5K,>*[!=&LE(0S
MJHPF0ZA*V=K+Q)W:4I%.(!A,N)5*2CE&#Y-^Q,T!TR49NB.DD3-U@)+&NN[=
MM6+9P]>N4&C-H@LZ=.G2R;=LV;-TS+.'#A=8Q$D4$$B'5665.1-),ICG,4I1
M$+;HU]H^3JI"WO&]QJ]_I%D:&?UVX4N?BK15YYB5PNU%[#3\(Z?14HTZY;.&
M_7+%VN@*R"J95!,F8`N9PY;M&Z[MTNBV:MD57#ARX53100003,JLLLLJ8B22
M229#J*J*'*1,A3'.8I2B(1_#Y@Q/8<<M<P0.3<?S6)WT:>999-B[G7'V/GD0
M1THR-*M;FWDE*VO&@\15:]?IR9FG7"9T@6$Y1#5W0%A@+7#1]BJ\W$6.`EFY
M7<7-P,FQF(B2:G$2E<,).-7<L7J!C`)2K-G"J0B`@!Q$!U['$/#^3_'P:<0\
M/Y?\/#IQ#PAW^'^/@_KU$T+GK!]D>0\=7\Q8MG)"PWZV8J@&,1?ZK)NYS)U#
MB)>P7C'<.W92JZDG>*=!5^>F;35&15YR`BX66?RK%HVCGBB,L<0[_$._P\/=
M'\7]>JZ:M"^9`HF+*E-W[)ETJF/:-6FH/K%<KO8HBJ5:"9"H1$'<Q/SKQA%1
MS<5E4D2JNW213JJ)I$$RBA"FNPBA%2$43.50BA"G(<A@,4Y#@!BG*("("4Q1
M`2B'<$!`0[@ZY\0\(::MBXW:FX\KSZVW^V5JCU6,%L$G9K?/15:KT<+UTBQ9
M]?S4T[8QK/KIZX;LVP.'*8N'2Z+9$#K*IIFK4+I3\@0#.U4.U5NZU>1.Z3C[
M)4IR+L<"_.Q=K,'I64Q#.GL<Z,S?-G#-T5!R<S9V@LV7!-=)1,MS:::LU#(M
M`=7R0Q:VN]1<9+B:RPNDICY"QPZUVC:A*2"\1&6F0JJ;PTXRKLC*M74:PFG3
M%*.>/VSAHV<*KHJD)>7$/#IQ#P]_O::UR\JW_P#0NLG]_&RG_P"-W;IK8NG^
M"/\`;4_]X;7/3333333335NR-LJ\5*1L%*6&&CYF:6!M%1+N3:-I*06.4PE3
M9LU%B.ECF`H\SJ:?OC<"D$3B4HZ\YW-&8'=PE\:4)66D6S>4<46/M%I61@':
MIT+&H111S+>]C49U0S5Y4F%A(N5^_;`V<)1)+6J0BN3&1-NYLJVM.6MV0K82
MHD81Z1,?Q+D&\6B^:H\QRN#]8RG7!':H`JHJO%C(<_G<QXDGS$B3A6*=7*?!
M05;@(Q%G$UMJ+.'1.8[I5FD?G"L*;IT95SU5P910ZZO50.J8YN</-X%"YN'#
M33333333336H[EH+16*?M/K$Z^FMZ$!DEOGC'3;`$CL#Q]#95W+$S-(Q5S81
MJ%4Q[9%VM:M4([HSB_-K?$SKUDV<5]1V$<Z3G@B0/KSY*/:S6LK9LL&Y2)4Y
M6;!"V-5\.U:^8DY1G#V*<:36>#4YCF2_U6Z1R[2IJW]6)1S%E_(V3+#+Q]O2
M92%RFW5)1CVU-@XJ/;?I9MZ-95J-G0N:\<UIRE<FD;4YEY`L3%-JT>+=$G7$
MG*G<,RQD>C$B[4>R!G;4&;4JKD7"()BH7\H>=GVUW,.*.4'SIM3O>#^QO*51
MY/ZC3^#=N-JI4C8GFQ+;1NIJSG.N?,KX\QR^=%J2.0\494R548^"M$4QD&VW
MRCQ"$X@U?RU@J=3EV87F)'E?6]X0714V/L>41Q@$M/).XUQBIUNR3Y*_*4)'
M3P/&ZJT3SVUEDL6U962,JBT1S>A6H]3A=0:&4VB\D(6:'9H@Z5:NV./93<9O
M*FMO[-X1-,4-M,UNRS%*8!&+*3G<*FYQL[A'M#`BJK,**ZK811PAO<Y,F6&Y
M!Q+-(O%CF"C6TQ,(YOQR>.BWLF,,T?..JRY>H.)4&,F9BGU,RAQ7+'O!XD`@
M(B)^<7UBW'/O-+PPG31#FAW>W7P_%_=EKEV8Y^\2=-\]?V9:P=R),9`EN4OV
M$=G%)A*>5'`6_P#]SQB+L:X&>G,?:("Q5R]BU<*Q*F7FF3,!W8JCSRF(B!2F
M/M8U$^6%LPHQL2.'V=1>2)GZP31;6JX3(1AUJ86YF()*HIF4%UW%^JJ<XJ?,
MZD0W%0Q;*KKG<6>EY`/>(W&:5D3C2#2D6SAU[B.%A;N_=$MC,+DY4V0%!N"9
MBK(\0,XZN8B(`H&)N.9+)#JWUAGDARU)BQ1O&MGK]L_D#1+BKIS]B+0TU9,5
MEI0]/>6X!CHF0E>HLYF*;Q+.9DG,.Y9&?Y$2KW>0$S(EB8?$1X<)1V$:=PY?
M]4-&`[4!F9P)GA%P4%IU(7'\T50%.J<Q,.!2ZCGE2$MP2_)Q[T4=LA9HV?E=
MM>44\?$IQG@6T9D]8=%DRT0S+F2O9L,$,T%(&+YLUV3>Y'N5PD^MM6OC!IL9
MONW#:*7#3_&RM1HU=KUGVC2=:;PLE+8WG(3%TS#HV:*C&"2YH&0K-<FYYEDH
M)]LSBV2KR;B\@@D9V[;JZF=M^^7=HGBWDMLF9<W<K6]KOWVA[I<HW[W<Q_@&
MHURHY/Q3MVQ[:*%#XX=P%`BW@3'90M<;3*0M@F+.$W)(R[)*#9UJ)3K\9)FW
MWE"]Q-W?\FC<\E7Y&S8PW);<]A1,FSF&C8=F7U>W*[BZ):)*Q0.X3"TA%-KY
M`XZS+9&B2&-<KX1G%8G&<U2+/5KW1HR"1L%C'7;M&WQ[@=HFRG;2C0<A,;/C
MR5Y*O.>>$Z))U2JO8?$L]A[?WAS$\OER`?5ZN/;S(Q=4PMGC)%[R1$6-U=H%
MRIB5E,0T'7HQA/PS_:9&[QLK1&2MN6(;)O-Q79L'[B-S^<H2/W6XOF,?VM.B
MUBD;;J]ES%VVQ]FJ7QG#X*N60;Q<Y&R33:Y,L?M';O&551QNNV<9"DUK.>,=
MH<M$./N7ZP+)3\1,-V')S[NX61EVKJ,%BM+1]4SA'2":Y62IHYDZ/(>]7C$Q
M(1DX7*R(BF!4T]1=DW=UN/Q%C*X0^%MQ*=#H^WO[GTPSOMQO6(>F8@GF+C,6
M/'-BCV\?,RMEJT[)2N-[Y`4B(J=KKS5VR?BPE`6I%DJ,R8CYS[]QWX;OJQG6
M>PU&[D47,8OO8Y("':V.3Q]B)W*Q>,^4`J5\=Y@P_&)MJRRC^P^(DZ@WG,73
M,@A(Y(AF3Y:-GKQ<F)"K'Z<'O^WET*W5A=OF.2SZXK^]#E8-E;'%4W2L4M7.
M9XO:)MMS_GK`%CEW6/Z76;!V]I2ZXTIV-YMY2%JU1[17+"5HGB]E;'J-A<7A
M`\H9F5+#N.LIL]XV&<EXCW'Y0Y/FE6;)-'<UBV3>S6%W!25KBLSW&WW!#&-1
MQY2D[A,PM9HF/:#E.MS\]@R^629EKI*6&ML(V&:8[[;MT<OM[LD>:%S]576.
M9KEF.6C:YKN4Y2J%D169J]!VP;B,_P!7N;]K389I.L)&`DJ179U^PP]V&S60
MX=Z\@6@$:V=%DM9]WW\Y[R#M[W'UZ9WB3+JO5&`Y$+/$#E1HKM\K5U-3-U6Z
M]IC[<8\GDZ/!3-1HF-)2MP=?OAZ(YE[7(8L0L9:O;\EV&K3#^L#LJQAO6S]D
MO<YD:+K>9<9/I/"FY#.N'I/96K-U-;,6=,45O$JEIP5<J%7'-+K#JFS>4FY*
MWFB)S_.Y1#`$E3;?/5F0B85E'0\E7Y'R+G[=M?\`>EL2PP2R7?9A'YMP;O"R
M5DS!SMOMFRE?'\OMMR9MK/1DT+TV;Y4K+&.R-5K[<(J53K\D[=,*P\D%D4H&
MXQS:=@M6.>=VF6MU7)7[\,EWW<-AFPP]ZY-7/E@R-M7BEVDQD[;SN&J]J:0L
MC`RZ*-$IDIA^*J*TG+8JF,;Y4EKU;+-;ZE#6REV43M;N#_/=[OLR@IN3SXTD
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M'*&V"-B-V#.+D)5R@UQC$;RY*L4)/`+R^'DU$H1O:G>,V^=8G"\E*"*J=S>R
MD975F]DF(Q!]B-9+9EF(W-\KW<-I69T<1U$\%LIA\;V88>HW7%.1.4952N<;
M?,25.!EX^9K\O;\N5-[@#$689&LI$N,3<)JN/UW2EEJSAHC(K??GEV)VT[;-
M]C[)]LM&,Z-N'R3CWE&]O4#1L83ERP2XM,[;,=#B8$ZU5G%V5G=F&=5L>X^G
M'<6]3ELOXX>3.6)!X[BY.!5)T&>ZW<`UW#OMK^>]WT!M6S#C/`6S[-5);76B
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MBGE*]U^6,08`I]JW38:P+D6T;7L[9%INXS*S>IU&IYUS#@/>+D;`TM$R%2;8
M\LE<R(^A<=42CV7(V&L3.<:VJQ*9=?3M)>UY&&A48C]4\*X=.XB+=O@(5XYC
MF+AT5-F_CR%<KM455RD8RJ2,FR(58YP(TD4DW[8H`B]3(Y(J4-=W*TJ.T=C]
MQ68-4WK]'-FS)5BR6<]9(O'J>];;P=JT6>]0<]9I.5RIHJ.^MG/6Q#F6ZW6Y
MG4C97FM^>R'5(GA:FJIE77*17MTF)U0A5C@4X$/C+G$`X`!@*;WQ>/`W=`=4
M[,<_>).F^>O[,M.S'/WB3IOGK^S+3LQS]XDZ;YZ_LRT[,<_>).F^>O[,M.S'
M/WB3IOGK^S+3LQS]XDZ;YZ_LRT[,<_>).F^>O[,M<%+KGI),ZJN%J4DDF0RB
MBBF;2D33(4.)CG.;&0%(0H`(F,80``#B(@&K##<+?UF5AD(G&-*MZ=2!J:Q1
M]#S.G;9YBF[5!-,48EECI'KU0."QQ(BZYO-;.BBH"J"B8=6"O>Z*WJ/Y4<25
MZ#JCUDZ9L(28MCBJ6XHNR&(A*I2ZD9.*(+,R")Q0=UJ/*HH=([<P]1,8T<8^
MP;=:)-(6ESA:*NUN;.2O4++;\]B\>(/B"<2/4&K?&*+87A0-SBNWG7SHBO%5
M%9(PE`DP=89&]S/<;HT8P]RPB`@08]MM#J'N.#OW0!AS>UAQZC[H<)#CQZKU
M^`/>J=<AU75WA<<^@``&$J;P```/^FP1[@=P.Z.,A$?ZQ[NJ]F.?O$G3?/7]
MF6G9CG[Q)TWSU_9EIV8Y^\2=-\]?V9:=F.?O$G3?/7]F6G9CG[Q)TWSU_9EI
MV8Y^\2=-\]?V9:=F.?O$G3?/7]F6G9CG[Q)TWSU_9EIV8Y^\2=-\]?V9:=F.
M?O$G3?/7]F6OLVM^=U'+=-UAFH-FRCA`CEPGF7KA1NV.L0KAPFW[6R/7"B"(
MG5(AU9'JYB`EU9+G]4+.&M"_*YYJVUY)GL;;',XUK.DG`VJX8SNDE8\19!>;
M=9Z#R.K>JK&80AX?+F28RB8IE(";5G;C8[A,5C-32T467HE3ISBN/K9E2BQL
MCG]L@Y/O#.PB'R)!X<MV<+6PR5-P,Y-*9OR[8\P2C)Y6XMW"LTX2:M0*RT:P
M7:NC*NHP7KAH#HH+MTVQSKE4SA>LVDBS=1[]JW>L7S9=F]9NT$G31VU<IF1<
M-G+9<BB#ANND<Z2R"R9TE4S&(H0Q#"`VS`X^HE6"0"M4RJ5X)9$K>4]PJY"P
M_ND@451*B_\`<UBUZ\2**ZXE3<]5(7JRO`H=4/SNF&+\;%HXXS+C^DEQR9L9
MF:@A4Z^%*,T.\]T#M1J81W8^+8S_`/VXS<8[J)GG^U"07'\YJ]&S9NS;H-&B
M"39JV12;MVZ"9$4$$$2%211113*5-))),A4TDDRE333*4A"E*4`"#,Z_AX=_
MOVQU^V:U/!/P"_V2_L#7+6K+=CD.@XQY1/D^;-DB\4_']<-A+?[&%G[O9X.I
M0II)TEM-<-8\LI8'\<Q,^<H,G:R#4'`KJI-G"I""F@J8F6W3/V@_*GVX>?7%
M7M;ITS]H/RI]N'GUQ5[6ZH;>=M`,42FW3;;S%,`E,4V=,5"4Q1#@("`VW@("
M'<$![@AW!U\1WC;.3`)3;H-M0E%(J(@.<,3B`HD$3$2$!M?`4BB(B5,?>%$1
MX%#B.OOTS]H/RI]N'GUQ5[6Z#O/V@CW.E/MP\^N*O:W_`(ZL&'SUR>E?E++.
M069-F\--7,7IK?+Q.1L$1LI:C22HKR)K+(,IM!Y/"_7$5GHRRSP7:W\ZXZHI
M[[7W=;A.3]?1\%%/<V;/7D95Y@+#6XYUDO!;AA7YX".T@FX1FK.G;1,N"<@_
M3"3CTFSX"/79`<<URN!^JEG;D\$):&GD<P;,TINN0(U:OS"60\#)RL'63,UH
M\U>AY$DT5Y%P1V#EPR-#L5V\<+1=9J+;J"JB9N\RW%;`XU5!>.SCM"8+M6CM
M@V699.P<T5;LGY5B/6:"C>>3.BU=D<+D=-TS%1<$76*LFH550#>67-O)T%ID
M7CDN6=EQ<?0;YE)PU%"_X#"FQ,C&RGNW'OXRK!,^X,>]83/^]V3IG'HKM901
MD&ZB;P16&XDMSNQ-O7"U!#/^TY&J$2!`E92RQA5.OD1!<'0)%A"6(L65,'(`
MX!,&@$!<`5`O5`YVO+#<#R?92'2#-6SP$U&`12B89)P2!#QA5"JA'G($WS3,
M05(10&9@%L"A2G!+G%`0J?<'R?BC@KI3->SP[DIV:A7!\E8*,N4\<F1)@<%C
M3@J`9DFFFFT,!P,V(F0B`IE*4`^Z&XW8*U<M7C;.>T-NZ922LRS<H90P>BX:
M2RXI&6DVRZ<\55O(K&01,J^1.1VH9%(3K&%,G-\U+.G)W(UJU4Q'+^S-*HWE
M]+REUJR>0\#)URWR5@$IIZ0M,$2:+%6%]-B0@R[N89O7$F)""^47$A1#MLMP
M7)]QJ#)M'9JV=L&\:^=2<>@RR3@IJBQDGQ4R/7[-)"<33:O7944BN7:!4W#@
MJ295E3@0H!T8/-_)TUB.7B*WEO9=7XIS#-:XXC82_P"`HE@O7V,A(2S.#691
M\PW;*P[24EY62;1:B1F+=_)2#Q%N1R]<JJ^ZCN7V'-[:XOR&>]I:-Y=P:%8=
M7)+*^%$[6YK;9T+UO7W%C)8BS2\&@]$7B,0J^/').A%PFV*M[_7?<[J]D+V9
M8V)WN+VL.IZ,2.A'33G,.&UY=@BH58ITF4FK93OFB1RN%P,FW<)$,"RP&*(*
MJ`;P&^X+D^VBMN6:YJV>-UK_`"#:6O2R&2L%I*W.49I)(,Y*V*)SI3660:H(
M(HMGLV+]T@DBFFDJ0A"@'83W&;!$K$A;TLY;0T[6UK(4MM9B90P>2PMZ>"Q7
M(55";+/A)HUH'!"KA`INBQ(+%*J#/G@!@M5/*7)GI02U72R'L:3K;F.C8=Q7
MT[?MW)"+Q,/)24S$QBT262"/5CHR7F9>4CV2C8S5C(RDB^:I(NGSI96ZG&XS
M8([DZA-.LY;0W,QCY!RVH<JXRA@]:2I3=ZQ3BWB%2?JSYG=:1=QJ24>Y1@UF
M";ABFFT5*=N0J8>K9-U.QZXPDA6K;N)VK6>NRJ)6\I`V',&&YN%DD"*IKE0D
M(F4LKN/>HE7116*DZ;*IE5235*4%$R&+YT9N1V$PL'#UF'SOM'BJY7GJ,C`P
M$;E/"3&$A)!NZ6>H/8>):V!*/BW:+QPN[2<L&S==-TNLX(H59510T-9#NFQ?
M(5NH4VIO2Q!4:959]W:KCAZD9OVY0.-LW6-*3KD]4Y;,!.MW5VFU*)8:NPF8
M)G7+I5HV947?Q5[96^ON31`3+-;DMA5DG:Q:+#G?:/.V6E.7CRG6&9RGA*4G
M*H\D$.MG[JM2[ZP.)&`<OFW^SO%XARS5=(?S2YU$_>ZY,=RNPR,M$U=XW/6T
MF/N5C;-&=@MC'*N$V=FG6;!-!)BTF)]M84I>4;,DVK9-F@_>.$FQ&Z!4"$!%
M(">3`YUY.^K#+&K.8-F=>-/)RJ4X:#R'@:(-,)SK]W*S9)4T=--AD23,F_?2
M$J1Z*Y9)\\=NWH+N'*RBG.,SUR><+#PE>A\R;-HJ`K2KE>O0<;D7!#&'@5GB
M@+.U86,:S:3&*5=+`"SE2/;MCKJ_SBICG[NCC/7)Z/$J\@[S)LW=(5*PIVVK
M(N,C8(62K5J1(=-&RU]-2;,2%L"1%%")3<85K*)D.<I'0%,(#?W3/V@_*GVX
M>?7%7M;K`GE+=SVVV_;3Y*I4?<#A"XVJ9S[LL0B*U5<M8^L4_*KI;U]O#E5&
M-AH:QOI)\LFV16<'3;-E3%1155$`(0PAN*3_``1_MJ?^\-KGIIIIJU[5=:G2
M(\TI;;#%5]D''F*R3M-N9<Q>`BFU0$1<O%A`?>HM$5E3#W`((ZAK(>8;FDPJ
M9\*T%QDLMUC59*-LZ2BI:M'(%4231%^J'6HE66!0RI4GSZ)2(1)0IE3K$.B7
MXJXHM^6L:QM=SK-=931+&K-N4<?NRQS16.*19%E"R@K-W31[U))ROU4Z22B9
M%"-%$UEW"*CA64\?XNHN,(Y:-I5?:PZ;OJ`OW)3K.9"1.V*<J*C^0=*+.G`I
M=45,D0RA44154Z@DD!Q`9`TTTTTTTTTTTTTTTUJ<Y6:T3>&,98=W(X]P9;\[
MY*QSG/&-/DJ/B?;97=R>:+Y@*]W:O3F=<44.&GG"!Z8VM[#'E5LTS=&*;U2%
M=T""=F9H*IMYN&F_8SOI/O<C,DRQMIV[_:@7'<S6X<D!O%Q`.&+G;@L,6_EA
MG*M6QF9_W0J['K0(P\U[H@*TP5\R%HB+'JKG/01X=T>]K%*,WJ[>IK'N=,G0
MUFM,S5MN>5;'A'*:4/BS*<M;([*E5&JHRM)KN/H^FN+_`'F;4>W2MQT*UIE9
MG!LKZ211K@RI!!4UL5+?]MTNM'RK>X4V;$6F&+/5Z5>:E/[7]R=6RL2W72'@
M[!5:W5\-63%47E6^S4[!V2#EX^/HU/L+E:.D47G4P;@HH3)O&N08/*M&KF0J
MTQM\;!6E@,C&,;[0[IC&WH-@<KM0+.4/(D%6;K679SMSJ%C[#`QC\6QT'(M@
M0<(G/'V=?P\._P!^V.OVS6IX)^`7^R7]@:Y:CS(6(\59;:1S#*>-<?Y)8P[E
M9[$L[_2ZS<VD8\<(@W<.H]M98N419.5T"E067:D2551`$U#F(`%"*^AAM!^2
MQMP\Q6*O9+3H8;0?DL;</,5BKV2TZ&&T'Y+&W#S%8J]DM.AAM!^2QMP\Q6*O
M9+3H8;0?DL;</,5BKV2TZ&&T'Y+&W#S%8J]DM.AAM!^2QMP\Q6*O9+3H8;0?
MDL;</,5BKV2TZ&&T'Y+&W#S%8J]DM.AAM!^2QMP\Q6*O9+3H8;0?DL;</,5B
MKV2TZ&&T'Y+&W#S%8J]DM.AAM!^2QMP\Q6*O9+3H8;0?DL;</,5BKV2TZ&&T
M'Y+&W#S%8J]DM.AAM!^2QMP\Q6*O9+3H8;0?DL;</,5BKV2TZ&&T'Y+&W#S%
M8J]DM.AAM!^2QMP\Q6*O9+3H8;0?DL;</,5BKV2TZ&&T'Y+&W#S%8J]DM.AA
MM!^2QMP\Q6*O9+3H8;0?DL;</,5BKV2TZ&&T'Y+&W#S%8J]DM.AAM!^2QMP\
MQ6*O9+3H8;0?DL;</,5BKV2TZ&&T'Y+&W#S%8J]DM.AAM!^2QMP\Q6*O9+3H
M8;0?DL;</,5BKV2TZ&&T'Y+&W#S%8J]DM.AAM!^2QMP\Q6*O9+3H8;0?DL;<
M/,5BKV2TZ&&T'Y+&W#S%8J]DM>I";3-K=9F(NPUS;=@.`GX1\VE(:;A<-8UB
MI>)DF:@+-)",DV%8;OF#YJJ4JC=VT71<(*`!TE"&`!#(/333B'A_+_AX=1B^
MS+C"/M4725[E#J6F8?IQ;.'9*J2*X2"PF!)H\4CTG+:.74,42IIOUFQS&$"@
M'$0U"<]9MT5UM<G`T>IP^,ZO#S:S(;?:^H2;J79M')TRO6+0P+IN&<@@GUPD
MBQCU/YI4B)YINMSS$D.Q;<\:7&\KY`M\>^L<NX:1[8\<_DG0UU,T>V3;)JH1
M"9BB4BI4RF69K.UV!U!.J=J995912;6+%E&,VT?'-&S!@R13;,V3-!)LT:MT
M2@1%!NW0(1%%%(@`5--,A2$*``4`#7:TTTTTTTTTTTTTTTTTU^=/EF<Z;P;R
M[8;2ML&VCE$YJM,;+AV_Y9W';"\F8]Q;=.Q=R-J>6+#->O%E,YEJA9U&Y:I:
M9"0;Q$DRDHSK"`?`UC)QZX+)O(FUG*^/JEGQIFV"Y3"GOYR^X[0JY.5%W`53
M.V1I@_8C-BX:XLLM7@*]#L*BFH@87E:0&1DO=X'TDX%%-PFD7>XH`F3.`=T3
M$,`?E$2B`?D[X]_O>'N:U=\G%3K=4+#RD)[O1[O4D+ERDV;LHTI>VTRRUU"W
M4&P8XPI&0-VISB9BVB5C@GTC5[`T9R<*=V3KJ,63`2]5:F7ARSX?P7<]KU3-
MO8P;N!L;G=AN7M&XZ2CL94G<9/W_``OD>SQD^[PL_LLAMY13REB.?QKAR!H6
M*XNU+`R9UJ]1[")>.H=RY;"AL1V;US,U1VQ87K&X&RS=PRU!4EE&6JR6I:.=
M7*6!HZ>IU]S>GD0FG%O[\6JA`H7R1CS+LY"X(S;UN[>IN`>+]O<@WEG<7BQM
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MT[#L_>.RF^93[3=>5,Q>8ZY'K2T_N#QY"QC?AU>0E,0-V+1(1`1`IEW.44T^
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M'&L76<05">F(L#1$_<&]?E+^YBW4I!]D[6!F)2)=[.].`!W@[_='\H^'5.`=
MSN=[O?\`/[?#JO>[VH%SK^'AW^_;'7[9K4\$_`+_`&2_L#7+333333333333
M33333333333333333333334#YKR]$XL:1TFI:(%O(,W`.7=+>'3/+VB)7(9!
M1*+,B"KN*>M%/]M8R#M#W&<J(*1\DJV1<`^9PHQR'N<R-7ZO.8S84A.&L4&F
MQ>3+UQ'JO(*;BUDT):6DFAW"J;!:37%0T;!HLYP8U@D0S](S]P";>88W")[1
M0XFL9TFSY.E8^QKV4L@!G4,BV743401CD31RC%9TQ;-UW*7%PFCU8C@Q0013
M21(29*[5JY48XD36(.*@8U/FB#.*8MV2)CE*!>JJE0(45UC``<]=<RBQQ[IS
MF'NZ][33333333333333333333336C7EBZ5M%I%6QINBWST*AY]PI5LXX,QG
M)4W<!D2UU[!^"J/D&R.H+(.:(+$U7@K1#YERN@#AHNE&VNL2\JI6H]2(K<Q4
M(9M9CV#WN3JQMR2]UOEIS=R44]CBIH4V4BZKG!AMC=6.`PS?VLY7)5>"J]_Q
MXH9GCB2L4.*;6T5^X0,`VN]8<-C1Z5B"`L]E@YO=6(@4HF,/<*`B(\/Q`'$1
MX!^3N\`[O@XZP$H'*"8VG\4[U,RY&K\CARD[(<UYIQ#DA[;I^NOC/F^%Z?3[
MC*6]LXB'2D4Q8SS*X,D(>)5DG;TB@()O5T'CE1DTBVC\HY8+CC_;S,I84I;C
M(>[W,,GC+;%6*5N<QMEW'61*Y6,<6/*=YRU*YLQ3!6JM0="I=8I-R0EP@8:[
M3RT_&Q4(PBW#F>0.TS-VP[AZMNBP]#99J\7+5P5K#?Z);*?8#L#V&C9)Q+?K
M)BW)U(FQC7+IDJ^JU\J,_$D?-519S#%!E-L0!C)-M??.OX>'?[]L=?MFM3N0
M0YA>Z'X)?QAX`URXAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTX
MAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'
MA#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$
M/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^
M<-.(>$/G#3B'A#YPU&$]F?&5;LT33I6VQA+-,R;.):P[4RL@\1?/U0;M$Y$K
M!-P6+!9<R:1#2)VWOE""(`01.$*VI;=%?;A,5^KI0^):3#S2K5O;70M968GV
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MBSTG8:AL'1KICT^;=)UZ1H/8]`/KFX$BONDA;7H/"HH._<=HJBBV%$/T%G+S
MB'*'_6*)>/@YP<./^''CP_'K5EMXQ!N9VRU7E$;3'X@I64;GF;>WDK<EA3'A
M\N1M3:W2A7NNX@JZ<39+:]J4Y&T6YQS:BV&51C'<;-03MT>!CUK-'IOY&1A(
M?CM@]TQ_>L3;JL6XOJ5/N-"WGY9W1N]K58L4!&0+.D[@]K$5MERG4ZU8P)%T
M".R;)3L.PW#39V1HB@2]^D[O`DG7+FP*WJ2S?V$[<[7MEV^EIV0Y:+F<GWW+
M>?MP>47,`NLYKC'(.Y#-=YS;9:W6W3AC%KOH&GNKJG4HR66C(Q6<1A/=M2,C
M32(L&\A;D(I*<C,60Z[N48(R&;\=-U'D+)O(:6;EZK+J"HPE8Y5!\P7_`)L"
M]7:K)*]3,<@'`IS:]<N!(42E'MB9S_!#O9KR%P[W_MG7+M"0OC$SGYZ\A>N=
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M>N=.T)"^,3.?GKR%ZYT[0D+XQ,Y^>O(7KG5#8&@R%,8V1<Y%*4!,8QLV9!`I
M2@'$3&$9G@``'=$1[@!Q$1X:BYU`XW<)W!G3\IYIOEJI\&ZFG52K.=KZ\E'?
M4><FDS;JDF%&IW"KH"M5"(J.%FRRA"*H"JHDDI'N,<1YNNEF1L-UL>4L?8[%
M!T`5!QF7(+ZS/^J(+%8J*.5)7K]D9-<R2KM1VK&BJFD*)(8G514),<9L_P`2
M0KUM*Q#B_P`5,-1<F2EXK(%CBI#G.CF,J<RT8Y:$ZKS!!$%RIE<"F'$ZIU3J
MJ*7CVA(7QB9S\]>0O7.G:$A?&)G/SUY"]<Z=H2%\8F<_/7D+USIVA(7QB9S\
M]>0O7.G:$A?&)G/SUY"]<Z=H2%\8F<_/7D+USIVA(7QB9S\]>0O7.G:$A?&)
MG/SUY"]<Z=H2%\8F<_/7D+USIVA(7QB9S\]>0O7.G:$A?&)G/SUY"]<Z=H2%
M\8F<_/7D+USIVA(7QB9S\]>0O7.G:$A?&)G/SUY"]<Z=H2%\8F<_/7D+USIV
MA(7QB9S\]>0O7.G:$A?&)G/SUY"]<Z=H2%\8F<_/7D+USIVA(7QB9S\]>0O7
M.G:$A?&)G/SUY"]<Z=H2%\8F<_/7D+USIVA(7QB9S\]>0O7.G:$A?&)G/SUY
M"]<Z=H2%\8F<_/7D+USIVA(7QB9S\]>0O7.G:$A?&)G/SUY"]<Z^S;!4.U<M
MW)<@9M5,V<(."I.<S7]PV5,W6(L5)PW5F#).&Z@D`BZ"I3)+HF.DH4Q#F`9O
MU@=R@EYW.8OPM%6G9IBB<S#N`>93HL76J!%2=1K57LJ3U"::R`Y>LULCUVT+
MB>+CT^O;A*QLE7[0T;-&"=8L#"5,U1=1SR=['?NWE=P$CR@=_J-IR?89^B3=
M6J6&J&\K^W+%]*7B;(U85+#=[FIA];<K).#M"SEULUXBJ[:8VR2'N(I&K0+>
M`?N=F^FFFH%SK^'AW^_;'7[9K4\$_`+_`&2_L#7+33333333333333333333
M333333377=O&C!NL\?.6[-HW3%5PZ=+)MVZ"1?PE%EUC$223#\9U#E*'AU!V
M1,VDKU8@YS'=9?Y:7LTF\AH@:BK[H1"+YFFIU09.1CT7YD"`L0R)$R(<Y4Z2
MQ3+-RIBKJW(FEY.S#CFPP&<S(T\TY,L'D6PH[P&DHPAVAD'!XV95,O+,')'*
MY#IG;**.Q.W,(N_YTJ::<HXZQ%C_`!6R.UIE?;1RRZ*2#Z55$SR9D2)&YY0>
MR3@3+J$ZH(J@V2Z@S34'BDV3X%`)+TTTTTTTTTTTTTTTTTTTTTTTTTTTTTUJ
M8WP[X<WTR?NVW_:EL(SGO9N$=362&5)NB7[$F(Z)C(,F0,IV-Q"]FRA/MI.S
MW):",6S*P]>K#B&813Z*Z_LB4@[7CV5P\DM?YQ':ABS:UD7"V7\`9CV=88P7
MANZ4',RM'E)^8KD/04ZQ1,G0]FQI9K=2YN`OB5)L`@BVEF\W"3D)-1<Q$-D4
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MU>H2:C1Z5>/9_/.P@!L.\1`/^G?'(=T>'=$TT`!_6(B``'XQ$`#NZG`CUGS"
M_P"UMOP2_P#;I>`/_'KEUZS^%MOKTO3TZ]9_"VWUZ7IZ=>L_A;;Z]+T].O6?
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M&C1#JRY^IHI=6<+)I]464X$23YW/4./-(`CW-8VY.W!S\+<'>,L88_E+M=V[
M=FLX=N?]DK4:20;I.FSA5<JB1GB!4E!!==9Y$,$U2*(!(**HK)D[5RPV7-"-
M'D<GVB3A@CJ^V"RT&L33<*TYL2O!PZ<@[5%=4QFZIS,RK%*NIULFD5J[1$%%
MUYNJ5;IU%@VE;JC.-A89D*IT6;5<!`55U!5<.%UEEE7#IRX4$5'#APJJLL<>
M)SCP``N7KQG\*;?7I>GIUZS^%MOKTO3TZ]9_"VWUZ7IZ=>L_A;;Z]+T].O6?
MPMM]>EZ>G7K/X6V^O2]/3KUG\+;?7I>GIUZS^%MOKTO3TZ]9_"VWUZ7IZ=>L
M_A;;Z]+T].O6?PMM]>EZ>G7K/X6V^O2]/3KUG\+;?7I>GIUZS^%MOKTO3TZ]
M9_"VWUZ7IZ=>L_A;;Z]+T].O6?PMM]>EZ>G7K/X6V^O2]/3KUG\+;?7I>GIU
MZS^%MOKTO3TZ]9_"VWUZ7IZ=>L_A;;Z]+T].O6?PMM]>EZ>G7K/X6V^O2]/3
MKUG\+;?7I>GIUZS^%MOKTO3TZ]9_"VWUZ7IZ=>L_A;;Z]+T].O6?PMM]>EZ>
MG7K/X6V^O2]/0'C01``=-A$1```%TN(B(\```YW=$1[@!^,==G7Y[^5ZV'XL
MSY?:OF#-?)9M^4;J,/76%?3F<"95/@W=KBYI&K/5UH9RV&^XR:YZQC*.Y)>5
MA89O?V-AH4^YEB,Z=.1<ZYGHB2N2OH-AQ9'-,9[=>2P=<F1M2CI)W:[C(9OO
M--LN?,U6E6)<13-BA3Z?:LC69!1D\%DXELF9BR6Z?MJ[#LJG2J<_;S2LS4=X
MAB\XIBB/<,42B(=_@(<!X?B`>'>[_`?Q#K7)4-DV6\98XWP5?%.YAI1+YN]W
M%7W<'7LFML/!)O\`"DAD>`H%6GX:+A'&36Z%P>,82AIC7+*M)5=Q$S$LM*GC
M'?N>Q:AV,6[9-X6',<56C4[=-@0"U>]L7+*$+LQ5K^,X[$;>H2D4XH<%4Z]N
M,1M[.YNKS)!D=[DV8R7/GEGK0(.1JQTI*8EWV7>"\.5;`&**;B2G&=*P=/CG
M+<CQZ#<CR4DY64D+!8)IT@R2;Q[1Q.6*7EIA9C&-6D6P.^,RBV;2/;MFR5G;
MBXB*GX_%,-.1C"9AY'...F\A%2K-O(1K]OU275Z@]8NTU6SI`5$R'%%=)1,Q
MB%$2CP#5REV[8$$I>.%\6_@A_P!Q*UX/_9NN71VP'XEL6^0E9]6Z=';`?B6Q
M;Y"5GU;IT=L!^);%OD)6?5NG1VP'XEL6^0E9]6Z=';`?B6Q;Y"5GU;IT=L!^
M);%OD)6?5NG1VP'XEL6^0E9]6Z=';`?B6Q;Y"5GU;IT=L!^);%OD)6?5NG1V
MP'XEL6^0E9]6Z=';`?B6Q;Y"5GU;IT=L!^);%OD)6?5NG1VP'XEL6^0E9]6Z
M=';`?B6Q;Y"5GU;IT=L!^);%OD)6?5NG1VP'XEL6^0E9]6Z=';`?B6Q;Y"5G
MU;IT=L!^);%OD)6?5NG1VP'XEL6^0E9]6Z=';`?B6Q;Y"5GU;IT=L!^);%OD
M)6?5NG1VP'XEL6^0E9]6Z=';`?B6Q;Y"5GU;IT=\!^)?%OD)6O\`C_NW_G_'
M76<8"V]-2J'7P[BI,$FZSHY1HM:%0&[<O.65!(L894Y$P_"$A#=T0*'$QB@.
M*]9>88R5=(>%Q=M-I,_3O=1%M8[S+T6N0T<QCS&YKEVQ(:(61.HW((.$FCMV
ME(O`X-R1J)S@LG?T+L?QLWM\_8YY9.1B9*96D8RHP<+'5&"9-!6$[2/?)PW-
M4?),D!*S3(T]RT542"HX35465XSH.W?`@@(#A?%P@/#B`T2M<!X"(EXA[F]W
MFB)A+QX\!,80X"8>-.CM@/Q+8M\A*SZMTZ.V`_$MBWR$K/JW3H[8#\2V+?(2
ML^K=.CM@/Q+8M\A*SZMTZ.V`_$MBWR$K/JW3H[8#\2V+?(2L^K=.CM@/Q+8M
M\A*SZMTZ.V`_$MBWR$K/JW3H[8#\2V+?(2L^K=.CM@/Q+8M\A*SZMTZ.V`_$
MMBWR$K/JW3H[8#\2V+?(2L^K=.CM@/Q+8M\A*SZMTZ.V`_$MBWR$K/JW3H[8
M#\2V+?(2L^K=.CM@/Q+8M\A*SZMTZ.V`_$MBWR$K/JW3H[8#\2V+?(2L^K=.
MCM@/Q+8M\A*SZMTZ.V`_$MBWR$K/JW3H[8#\2V+?(2L^K=.CM@/Q+8M\A*SZ
MMTZ.V`_$MBWR$K/JW3H[8#\2V+?(2L^K=.CM@/Q+8M\A*SZMTZ.V`_$MBWR$
MK/JW3H[8#\2V+?(2L^K=.CM@/Q+8M\A*SZMTZ.V`_$MBWR$K/JW3H[8#\2V+
M?(2L^K=.CM@/Q+8M\A*SZMTZ.V`_$MBWR$K/JW7T1P!@EFX0=-L.8S;N6JZ+
MILX;T6O$6;N&ZI%VZZ*J4:!DED%DR*I*$,4Z:A"'*(&`!U+P&`>\!@[H]\A@
M[O?'N"4/#W_#K#VA7K)5YW<YSK2>2ZBGB'#E0Q7`K8E2I31;("V0\@5N0NKF
M\2UX]WU#MJ(K7UH2)J\$G5T7CVRQ=V6=3JD>QCV`2#CC(LU(YMSOB"=F*Q-G
MH3+&&0JZI!D(REX2FY:;W6.C*K;XPKAP)IV+L&,+5)L9PI(]*:JT[`IFCP?Q
M;]_(Y!ZIQ#N]T.YW![O>'O\``?!W.[JG.+S>=SB\W^EQ#F]_AW^/#O\`<[_?
MUR[_`'M0+G7\/#O]^V.OVS6IX)^`7^R7]@:Y::::::::::::::::::::::M2
MYW:LX_K[RT6R41B89D**:KE0BRRBB[E0$FK5JV;IJN'3IRJ()H(()G.<><8>
M:0ASEUPRF:+;;K%(OL8.[G4\;R$Y/+K6:7:NK&,%-O:S+*V)_%1[!Z9TG#H1
MQS6-["$6G#5-5)2Q1[-H/-BS91X3V\Q--D8O(LO>IC(UJ6ANH1DXI*.5X)&*
MDF:1>$4"KM^XD6JS82];.GC]5`R1BN&[5!404UE`W;-VJ14&R"+=$G.$B*"1
M$4B"8QCF$J:92D*)C&,8PE*'.,81'B(B.OMIIIIIIIIIIIIIIIIIIIIIIIII
MIIIIIIJ@F`.YQ[O<[@`(CP'N<>`<1X?EX<-8+[E.4OV*;1TWB6>-S.,*C.LT
MEU#TMA.!<,@',B3G`D6BTQ*?LZ1UC"":)WL:T;F.(\Y<A"'.7\+/+*<IS%[S
MMT-0RCM>NFX7'>+83#,%1VPRLY;,4HW.9B[G=Y>0M\+7*];02=0ZZ,VSAT9:
M130EEW$2Y:N6R";1`FLAN2>RME&>P+DIW.93R5..4<ZS#5%U,Y'N4PY1:EQ9
MB-<K9)Q)3SI9)L59PNN5NFH5$JRZZP$!194Y_P!(_*$[&8S>5F<;/5H+?_MW
MS7BJHU*JPN[?8[FK%^&YF_T&QGGK(\Q);$[[DVF#=(.DSBKN5116@'1:[)V<
M%("SIFDK)!DR:Y-+;/A3:3C6]8?Q^TSTXRJI;FEYSY=]U5JB<@[B\IVJPQ18
M6MY"O60:]-V.L6>#?5ZJC7:4%3F%*]",*U(0IF3*QM;$+C9*H(E3.8.^4AC!
M_6`"/=_'P[G=X"`^`0'7YZ9S>%N9I.TGE/K2PRK*6')./N5-:[/,*7FV0U36
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M:`B'I%W-83YI?_+0OX(?]W;?X/\`]WM<NDUA/XZE\G;?[/:=)K"?QU+Y.V_V
M>TZ36$_CJ7R=M_L]ITFL)_'4OD[;_9[3I-83^.I?)VW^SVG2:PG\=2^3MO\`
M9[3I-83^.I?)VW^SVG2:PG\=2^3MO]GM.DUA/XZE\G;?[/:=)K"?QU+Y.V_V
M>TZ36$_CJ7R=M_L]ITFL)_'4OD[;_9[3I-83^.I?)VW^SVG2:PG\=2^3MO\`
M9[3I-83^.I?)VW^SVG2:PG\=2^3MO]GM.DUA/XZE\G;?[/:=)K"?QU+Y.V_V
M>TZ36$_CJ7R=M_L]ITF\)_'4OD[;_9[7Q4W28(1,!%\@,&ZATEUDDG,59&JK
M@C<@'6!JFZA41<J%`Q`ZDASU!,HF0"B90@##.1MTS*PU6+[3]KAX"5DY1=I*
M/[G`V)%U$1"95DB2D8DU@YJ.=&4<D*/.$K]9)N;WK$78*)M^MC6\8>@*O+0^
M3LNN,LO+%)M9F42M-6M\E",G;9,@)H1+"5K[TY$2K$*X,J?J)#K$2.@R9`04
MS3$TW`[>V"2*+*P1C-%NJNN@DUI]E;IH+.BG(Y6131K!")*N2J*%753`IUBG
M.50Q@,(#VVFX_!#!L@S8VMJS:-4B(-FK6KVMNV;HIAS4T4$$:V1))(A0`I$T
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MF0RKQ\X@;8@Q9)$`1.J\>*U\C9HD0`$3JN%4TR@`B8P``ZP.SIRY?)AX$CUU
M9S<]5+Y.D,HBWIV'F4KDZS/'2?.`6?4Z\T-"1BYS@"29I^=B$3*F`O5>`'$N
MN"U<N#OAW!O4X38AR==OKL#)F4*PS=N]"<J-.(Q=%$K*7)`PB<1#BB5,Z;TO
M4L@3RBQ!`A(QP4.)K,4VA;U]W*BBO*%<KG8:E37I4$Y'!NS*EW*FU5W&JB"C
MF)D;4%.IS%^8H"+<RDM4KN41*8Y9!PF8IC9O;:^3:Y&G;"HQE:OBBN9&N3)<
MSH+]G*$N>6K*J\$>)'J;.RUH]/C':1A$Z:\)5(Q0BO!4#"J4IPSFOM4Y.W-<
M]!2&3\.X%R?8H^+C:;79*^8%8VJ1C(--^X5C*Y&/I^ANCQT*A(RCMPVCD%6\
M<V<OG3@$TS+KJ&G2H;1-JF/X]U$T7;9@BFQ;V04E7D=5L34:`8NY11HS8*2+
MEI&0;9!=\=E',&9W2A#+&:LFB`G%)ND4N`F[C:'RF.4\[6G(^UOE44-DF'7%
M+HD:MC-7:GBG<4E(6>N-;&-GOCFR9-EHEQ3D9!F^A8P\'$]6BW*<",T]62>+
M"35>2H-%.97<\YL_*2I<IQN'BK1C>E9FS%5JA0Z!BR@1=<@;/(XXQ+1Z?BQU
M+8\CY*&;V.UV*^/H6?E9.2LMBX6'W/?M"QZ.X(0`P"4>Z`@("'A`>X(?XAW-
M83L=@>`D\?;J,6SC>VW"D;P<KV?-66HBRV%)0Z&1+5'U-B\GJ1)0L5"2E.7C
M5J)39BN#'/5%*Y8:Y'SL0LUDNNEW'6'8+B%1!S.N++D=SFMSG&'W'&W)K2M2
M#-*>8(#&YL+1%D261I*6-2Q++"JS[$A*$;&QL=J4F5F6Z]45F95]-+9%8.PI
MC_;OBVJ8>QA%N(FFU!"3ZR2?2#N8EI*5L$Y)VFUV:?F'ZBKV:L]PMLY.6NTS
M;LXN9BQ3,G)+@4[D2%MW.OX>'?[]L=?MFM3L0H<PO=-^"7_KG\`?^+7+FAX3
M?3/Z6G-#PF^F?TM.:'A-],_I:<T/";Z9_2TYH>$WTS^EIS0\)OIG]+3FAX3?
M3/Z6G-#PF^F?TM.:'A-],_I:<T/";Z9_2TYH>$WTS^EIS0\)OIG]+3FAX3?3
M/Z6G-#PF^F?TM.:'A-],_I:<T/";Z9_2TYH>$WTS^EIS0\)OIG]+5N6>VU:E
MQIYBUS\97XTAN9UW*OR-$CJ?^J1!10#N%A#N@BW(JKP`1YG`!$(%RCD#,[J=
M84_"U(*]1E85C+]LR6536J[=M(]4,08U4Y_<Y59!$J:IU')WRQP73%K#.TQ*
MN:ZQPI#W2.H[_,R#"]72K1BK9X_1%]'P#]RZ7*X6%:"05;,'J29TT`*+IFF1
M<Z1E3M4DE>M4YJ:,6;!J@R8-D&3-JD5%LT9I$:M6Z)`X$20;MRIHHID#N%(F
M0I2AW`#78YH>$WTS^EIS0\)OIG]+3FAX3?3/Z6G-#PF^F?TM.:'A-],_I:<T
M/";Z9_2TYH>$WTS^EIS0\)OIG]+3FAX3?3/Z6G-#PF^F?TM.:'A-],_I:<T/
M";Z9_2TYH>$WTS^EIS0\)OIG]+3FAX3?3/Z6G-#PF^F?TM.:'A-],_I:<T/"
M;Z9_2TYH>$WTS^EIS0\)OIG]+3FAX3?3/Z6G-#PF^F?TM.:'A-],_I:<T/";
MZ9_2TYH>$WTS^EIS0\)OIG]+3FAX3?3/Z6G-#PF^F?TM.:'A-],_I:"4H=T1
M,`>$3F]+5MVNX5"B03ZT7:T0%/K,8F"LE8K3.Q]=@8](>\J]F)AXRCFJ?_B6
M<D#6F_<']T`\G!A&1<56HY,L.YC(Q7*K!G1-ME:?9$7?/R<2D10MRJL11')#
M*AS%#15CEER<#<UJJ(`4<9PWO\N)O)X(;0]@]4V=X]DP2,SS%O$GG*EE]SU^
MZUDF%%>-(1VW5<)AU;J*5`N[0I3)@#PY#`LIVV?(<;B-RJJ$SRF'*6;AL]H.
M'!I%[AS#4@?%>(6+\YRF.W;MEDEXYXQ$A01!:,Q[4GQ4^(I.$C\!#:3MMY+S
M81M-!JZPGMDQI!6)J1L!;Q8HI2_Y`,LV`O!R2ZWM>Q3[%550A5E21+R.;"J`
M&(@0"E`N?',`/QF^F?TO^&G-#PF^F?TM.:'A-],_I:<T/";Z9_2URUJ%Y23D
MJ&7*%3U$E[?N)SZVQM3U(_LRV?HY4L-'VLY\C(YPN]/%Y,:8V:0F1XZ7D7!V
MZ(6YE9+$A$-FJ?6--4<'674D;DSMM59VCXVE,"US:%3-LIZ)7<;15AN&/%ZO
M)4[/ED0C[,E(W>+L4.DPM%I5ATR-HQ[8<IP==R0\4?$1EX@D4VA7CS9IH(\.
M[^P!'_@'=UQYP<./=\'=*8!_P#AQ'_`-<@'CW?V@(?\``>[J!<Z_AX=_OVQU
M^V:U/!/P"_V2_L#7+33333333333333375>IJKM'+=N[48.%T%D$'J*:"JS1
M95(Y$G**3I)9LHLW.8%TTW"*J!S)@"R1TA.4=>[#<7F"TW-7&-+91-BFV<U&
MPSNT)HMH9DX9564=)VZ7;1TLW`T>O.,>M.NFKD[\\(+=\>'9/DW;1=#(*<VS
M4RX9"D[[>Y:Q7$CA5(T35I9]S:]"($133.R01:@DX78&53%<&1ED6QSJJ@\2
M>B<3ZR*;MT&B"#5J@BV;-DDT&[=!,B*""")"I(HHI)E*FDDDF4J::9"E(0A0
M(4`*`!K[:::::::::::::::::::::::::::^#ERV9-G#QXX1:M&J*KERY<JI
MH-V[=!,RJZZZZIB)(HHI$.HJJH<J::93'.8I2B(0Z&X_;X8`$N<\.&`P`8HA
ME&B"!BF`!*("%@X"`@("`AW!`0$.YKT,K9YPI@JMGM^9\L8ZQ76"MU7)9S(%
MQ@*G'N$D2`<_62LT_:#(*&`Q020CR.EECG(1),YSD`=+65_NB?9PQL9\=;4:
M+G7?+E1R)&\16L"8[G?<!W('$"E:KV2P1S>640XF`3/Z]3;(T*0!."IB\!&+
MS9(^Z&MZO$N/L2X)Y,_%LQU<J%BR@^)D3.#>-.!BG.2'<,+$=G(F3-S4$WN/
M*4Y25#GIOF_-!<+BJ7W/50LFSS"_<H?N[W+[YKNF9!RZA;-=)>C8P15+P.=D
MP@6,K-6=M'H'%1-!*(M-<;'3$3!'-P,*0;D=OVS#:GM6C&\7MZP!BW%!4&YV
MIY6J5*-;VA\BH``<LO<G:3RW3)S@4O/4EIQXH?A[XPZR:`H`(B`!Q'OC^,>'
M>XB/='A^4=5TTTTU:%[OU-QE5I:[7ZQ1E5JL&B1Q*3<NOU!FU(HJ1!$HB4IU
M5EW"ZB:#5JW26<NESD1;HJ*&`NK@C)2-F8YA+Q+]G)Q4HS;2$;(L'*+MB_8O
M$2.&CQFZ0.=!RU<H*$6071.=-5,Y3D,)1`=:,.5=ROOTVTN9C<13-_NR[9EM
M!K\)0:LY-N%P/<,M6N2R9.R4T@_5CUZB526=)RP*Q+>(KD1%S+Y)O$34RY*S
MCT'*R?K<BGO:N^\FN[BG%VWM[?M[3K'%LQTP86S;U@[(>#ZU3V=HK$W(J0DI
M%Y"KT.]GY*0=1BCPDI'NY!LU3;*L%DF"R7-=;R-1KE_$U$SGCJRXIR="$LU`
MN39K'6NM+NWK-C8XA&19R"L#+J1SAH\<04JJS1:3D81RDWF8I1W$2!7$:]>-
M5](V/=AL7DW:AGJ*VI/<#[?JIN7W83.1*MCZXX:D\G8-RCA#""".*Z+CJWX[
M89&QS+GI&8G&,T<P6F?JMB1F#Q5M<+I,G*#DZ2>S?D]IJ)L&S';Y)PN'*U@%
MDK0TFZF)*4Y%_2*A)Q\Q+QLXC1Y,R#929I4O-LY&Q5"<5037FZW,1<JX**SQ
M0QI!W&/G,;'XI?LXB0GW37...5$(:*4BT9*1.*LN3K=FK-R4/$)K<TYE`-(R
MC!MS$S`9P0PE`WN%RI>.:7[WC+8^]#_];X9\'Y<KZY=M6\?)WRW^E\,_Q8T[
M:MX^3OEO]+X9_BQIVU;Q\G?+?Z7PS_%C3MJWCY.^6_TOAG^+&G;5O'R=\M_I
M?#/\6-.VK>/D[Y;_`$OAG^+&G;5O'R=\M_I?#/\`%C3MJWCY.^6_TOAG^+&G
M;5O'R=\M_I?#/\6-.VK>/D[Y;_2^&?XL:=M6\?)WRW^E\,_Q8T[:MX^3OEO]
M+X9_BQIVU;Q\G?+?Z7PS_%C3MJWCY.^6_P!+X9_BQJALK7<H"8VWG+)2E`1,
M8TSA<I2@'=$QC&RP!2E`.Z8QA`I0`1,(``CJ,X?=S#6:P.:;6\89$E[>GUR5
MO$L76-GZ#@S1NHNY7+-,LAJU\&;3F<QPNI,)$.J!FS8RSDR:1X6@JIG6R6]M
M><UT+,\R_AW9W-<K=%L>+(.`BSG2.D"R;HN5(UZV,D5003*R1*^6,0IWTPY(
M(HFFE)BR;M&;1IM5RJR)'*UMQ'KLK#B9H]8O*HH[4AW[1\AF`CI"1#W0D$Y%
M^FJ5Y,HR#U"76?).52&DWMJ7CY.^6_TOAG^+&G;5O'R=\M_I?#/\6-.VK>/D
M[Y;_`$OAG^+&G;5O'R=\M_I?#/\`%C3MJWCY.^6_TOAG^+&G;5O'R=\M_I?#
M/\6-.VK>/D[Y;_2^&?XL:=M6\?)WRW^E\,_Q8T[:MX^3OEO]+X9_BQIVU;Q\
MG?+?Z7PS_%C3MJWCY.^6_P!+X9_BQIVU;Q\G?+?Z7PS_`!8T[:MX^3OEO]+X
M9_BQIVU;Q\G?+?Z7PS_%C3MJWCY.^6_TOAG^+&G;5O'R=\M_I?#/\6-.VK>/
MD[Y;_2^&?XL:=M6\?)WRW^E\,_Q8T[:MX^3OEO\`2^&?XL:=M6\?)WRW^E\,
M_P`6-.VK>/D[Y;_2^&?XL:=M6\?)WRW^E\,_Q8T[:MX^3OEO]+X9_BQIVU;Q
M\G?+?Z7PS_%C3MJWCY.^6_TOAG^+&G;5O'R=\M_I?#/\6-.VK>/D[Y;_`$OA
MG^+&J#E:[AW1V\9;`/QC[KX9X!W./$P]M?@4`#NB(\`#\8ZP7W"\L3L\VK@[
M0SE9256;9"<J].A[SA>_WHJA!$!24IV/<HVF=9*`)1`?=1I'IE[@G4*!BB.M
M#,'+V*;F,8Y+I6Q?8#NRW$,)['EYAIO)%@JZ-&QQ5(Z0K,LPDIYU*0R-[1D&
M\2P<*2)F+^0K:CT$NM"+I*J$,/X*$J\@A'(@2OI+(H1J0)G/7Q`BR*#,H)G.
M7K$1`BJ9"F,7@(@4PEX"/<U^^#`?(<[6T"U?*&Y?#^\7>OD=_!P,FO.YVRWC
M9:M)"M%,W#5E'UB"S&P>+Q#-)1-LC&6>?G4"MT$FZK-(I#H:W>8H@JG@FN)5
M#"NR2;Q15T03YL%CR(V]U"-.9,O-*JY0@LDL0>.!#NJ.78KN%#<3**&$1$92
M#*=W#N!MVRT`=_@$OA@.[X>YE?5>VK>/D[Y;_2^&?XL:=M6\?)WRW^E\,_Q8
MT[:MX^3OEO\`2^&?XL:=M6\?)WRW^E\,_P`6-.VK>/D[Y;_2^&?XL:#E6\!_
M^SOES_"7PR/[,KCK'[)N_P#Q;ATRB&0JM:(:22$`4@F-IPU9;$3B82#U6"K&
M4YB2;@02FZH+M!N5,"F$Y@X<!@1?E-;!DU0\3M<VQY1RG*&2)QE9MN2-@HY8
M5.887G8V:P(F1)W`%1[/0B?.$>*@`4PZQ)W)XHY2O<$U;3F4<8)]C=7%65B*
M!0IFI=:MG3D"I'D48)O<):6GY]LW4ZV;JO';UTU;'=IQJ#/J[T5]E6SS;1E?
M#.$(2I7/+MLBIAQ(/I_L2KP5*4@J,WED69BU2-?V&N3KAQUHX1<R,B:/<-H4
MLS)R2<4T%J0KQYA[RJ65`N-.O.&5-K/*,V^6P_8MO&3J-DK:)CB@2TI=+'D5
MWD:LS-8Q-*7U2>K]K=5BCL[;"YUA96MMBP%&NP.4)%B\?1#]7QN19C)@AMV5
MBE,6<H+A-G/7G%;2IXKWXU>BU)Q1J-6J%(0M/J^(6U&;?^4M6J\(BUJCZ\VV
M3E+O-L8*IPUD=/7M8&<G-Z&N"B9%4SI*%`R:A#)G*/$.<0Y1*8.("`AQ*(AQ
M`0'N]P=0!?-J6V[)]+QICO(&$L;VVE8:>PLABFMS57CG49CQW7X!S5(I2GI=
M3(>!*A5GKVM*(L%$4'E?>O85\DZC7;ALI.[!@QBF+.,C&;6/CH]JW8L&#%NB
MT9,F31$C=JS9M6Y$T&S5LW330;MT$TT4$4R))$(F0I0A#.OX>'?[]L=?MFM3
MP3\`O]DO[`URTTTTTTTTTTTTU8%MR%%5V$MLA%I'N$W46";Q_4*TX;2%CY[@
MX)M$5(Y`ZSIKU81,J)UFXF*V176316,F"9H:QOV[LFN[#)97B(FI8TL=<DX1
MIC\$E"6!9.3`C<'KV0+U.59&ZP,\06%RNQ76,ND="'8@F58TST+&5'QE&C%T
MNOLH9%3FBZ<$`[B1?&*``4TA)NC+/WHD`."95US)I!W$4TP[FK]TTTTTTTTT
MTTTTTTTTTTTTTTTU01`.^(!Q[@<1`.(^#NZC/)V:<0X5@U+-F#*&/L6U]--1
M0TSD.XU^FQPE2_"!-U89"/(N;CP*5-OU50YS%(0ACF`HZ;<P_=$O)Z4:9/3,
M.2V4]VN1%N<WC*EMSQO-V5)_(BH5)%HC8[`2O13U)4Y@X.J^6PD$#%!,BIQ`
M@PH.]3EV=W)A1VO<GU0=GE%D#HD;9,W?65RZM#5LMQYDBA2W25:DD#B0>K]1
M#'%I;@!"E!=0%"\[Z?R+F]+<\L60Y1CE3<X9!AGBY5Y3#FW%!/%..1`2AU5H
M5P=NQA7;?@*B`*CB]LZ,B83@NF<0`,\=N_(H\FAMI.QD*5M=H]LM#("'[,<P
M%=Y=L*KLG-$)!,EX6E*_%ONJ%!4%H.`B@35]^D1/@4"[1H^+C8IBUC(Q@SCH
MUD@FU9Q[%LBS8-&R10(DW:LFQ$FK=%,@`4B2*1$R%``*4```U7W,CO@+/_\`
MI&__`/RUW@````````#@`!W```[P`'X@#333371D)./BF:\A)OFD<P:IBJY?
M/W*#-DW2+W3*+NW*B3=(@?C,HH4`[XB`<=8591Y1;:?BX5VJ^26]WF$%.I>X
MN-VI[<LHKQ,7J?NPW.WJZ*@'+S3)KSQ%`$0X)CQ`!QSZ:6\#.8]0VR;3I.(A
M'15"MK]EM11I&F)SQ+UVW1<N*Q`"8A>`@FUG+$;B`CUNKW""#9=O#SC_`#^Y
MG=C)PT(Z!([FA8D14:1QD@./.:++M4*M!<X$3'(*CB%L7=$O.6<`7B;(K%O)
MS[3\6];N4<;M[S,H*=5]V\D.36U91;B4W5?<==-M5D%`.4#%.W@4U`_]8/$>
M.:\=%QL0R;QL4P9QL<T3!)JPCVJ#)DW2#N@F@T:II-TB`/$0*FF4H"(\`UWN
M`<.'`.'@_%IK1+RXV/(4M#VUYRG-V^YG:'7*7N3Q?CS(.2<);F*G@JI5&BY8
M=S=.=Y.N49DP9"FRS_'<A+MWC5[6X)U?WE?D9V$`%H`SB2K<Z<E/3-O5.JV;
M0PCRDE_Y3&9F[O5I3(66+[GJBYY=TUVA420]6I327QRU0K<&486,7EG#!91>
M<=@X:NWYDV)8DFMLVNJ^?,XUF[D9%TW8L&#9P\>O7:R;=JT:-43N'+ERNL8B
M2*#=!-19990Y4TDB'4.8I2B(8HU7?AM"O6-7F7:/G['UTQZUO47C!*P5&0>6
M8LMDB;;LG</0:W%PD>^G+7<I1I(-'D?6JQ%S$R[:*&=(,SMT7"J625-N=3R)
M58"\46QPUNI]JBF<Y7+-7I%K+0DW$/TBKLY&,D62BK9VU<)F`Q%4E#!Q`Q#`
M50AR%BO.OX>'?[]L=?MFM3P3\`O]DO[`URTTTTTTTTTUY,Q.P]?;H.YN1:1;
M5R_8Q:+EZL5!`[^3<$:1[7JQ^"9%7;I1-N@"AB%.LH1/G`8Y0&Q;KF7&^/XD
M)BRVA@V067EFC)JV,9](R3Z#=*L95DP8-@.NLX8/TCLG@F*FW9N@%)VN@("(
M17%VVX;CL>68E52L^&D%I>/;U^VOD".G5B@.<"T@LP3;*,%V0K)D,S6<QSY9
M)(YR%9RBX@Z*E?>(<%4S#K1X:#!Y)S\NDB2=LTJL*LE)BBH9<$P3((-F;4KE
M15<B"!#*F.?GNG3M4H*A-.FFFFFFFFFFFFFFFFFFFFFFFOBLY0;HJ.%UDT4$
M2'4674.5-%)-,HF4.JL<2II$(4!,<ZARE*`")A`.[K6_N(Y7GDY-L!7S?*.Z
MS&"M@8%5!6FT"54RE<0=)\`%DX@L>HV)6+=&$>`%FUHI(O\`VBQ``1#7"MRZ
MF=]QIW,9R</)E[E=P2*QRMV&4\J,TL5XL05,8`*[6?-_=2/<MC#SQ*@_O%9<
MB0HF,!!`Y"<";;?N@G=USU,Z;P,)[!J'*+"=Q1MM=:&WY&8-S``=;&M+=XJ[
M;*E*`EZX89@5X*&$PH"7BF62L6?<Y^R&*G4;WN8M&=MZN25#"XD['G[)T\O%
M.WHG`_5BP-:=QK]=N)@`3,I^T6%%0.)%NJ$,8H[D<-[;=O\`MYAB0&"\+XQQ
M'%%0(W5;8]I->JIW9"<1`T@\B6#:0DEA$1$R\B[=+G'NG4,/=U-8``"(@``(
M]\>'='^L>^/^.JZ::::"(!WQ`./>XZLNZ9'H&.8XTM?KI5Z9&E*8P/+/.QL(
MBIS`$1(A[H.4#N5!`H\Q)N150XAS2%,/<U@+?N5,V]0;X8#&4=><WVA0Q$V4
M;1JZ\;1[I<QQ)U,DE-(M7KDHFYH$5B(.5(H!BBD8X"&H^[:?*:Y\/S<=XCJ&
MVJJNC<$K#D,Y75F21./#G];3S-W(`<4^)B@3'2`?C(\`3%/KN1W)GSN1G;>:
MW4[E,G9??%X*'KT2^7AJVW4*H)RHHJS"LNH5MP$P?[IAZZH7GCU(4N!=9K8M
MVD[<\-@@I0<35*-DFX$YE@DF/9'9N>02B"@6&Q'DY5(PF*!N:V<H)%$`ZFF0
M``-9&<`\''AWN/=$./@$>(AJNFFFFM.?+DW]'&^R,M@7Q-M/RPDOFO%$(5'>
M[0LAY.VTTJ0F7LPR@+=D*BXQJ]LLTXZ>V,\3CZCF/'-8*'O][K,_8IB)AXIT
M\3Q5^Y^\@3%J'>Q4K/BK8#A6WXVR-B"O7#&FP/;UE#`%8IML/1)\MCJ^7XK)
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M#K#_`&SK?J75./6_\YS^9_U.=KT"])KFE_\`F+_!#QC>#7+[YO\`,7^L;3[Y
MO\Q?ZQM/OF_S%_K&T^^;_,7^L;3[YO\`,7^L;3[YO\Q?ZQM/OF_S%_K&T^^;
M_,7^L;3[YO\`,7^L;72D9+<7$,G4E*OMO\;',D3.';^0<Y`9LVJ)/PE7#EP=
M-%%,.]SE#E#B(`'$1`-0[9+IG[(5,;,JE"XAR'6[\>1K2T_5B6)['U_J2Q&C
MU6=8VPR")&X@*X%<*,W(,U&PK&:.#JLB*VM1<.9AK0M*]*TS&%T!_*3<HE;<
MBL[-/+1+FMR;AM'1I@2%91A'2Q59&T0CL2F2D%I=T2011DU1ZIDN4NYD@`4A
M<$D*4`*4I2Y%*4I0#@!2E```I2AW"E```H`````'#5?OF_S%_K&T^^;_`#%_
MK&T^^;_,7^L;3[YO\Q?ZQM/OF_S%_K&T^^;_`#%_K&T^^;_,7^L;3[YO\Q?Z
MQM/OF_S%_K&T^^;_`#%_K&T^^;_,7^L;3[YO\Q?ZQM/OF_S%_K&T^^;_`#%_
MK&T^^;_,7^L;3[YO\Q?ZQM/OF_S%_K&T^^;_`#%_K&T^^;_,7^L;3[YO\Q?Z
MQM/OF_S%_K&UQ$VYD.(<<%B(=\`[8YC!_P#=#B/_``UI?Y6#E>-P/)G2.%8=
MOC?;UER6RJE?5Y.+0N=\A)*I(5#L4!BN_8I-W[H$9XUC<%:*.DFI#&BG)416
M$JG4]<6&/NH;/>0YZ5KCS9&QN5C<1*0T:H81D<B7NRV.Q&DFR*K"2:!$BYB(
MA.-4<.O=9G&S2XO44&/N>!'77*.<S#<A]T-;MV35'$.T;`NPZIR:@$&_[@YU
MU9+RS2.!AZY;4Z4)(RC(Q"@'!"5Q.N85!#@L4H@8EF6#D,=Z.XR0;R>^SE*,
MD;A(<ZG7#_%E7E+AB_'BBAQ`RC9!E$E=0:+7G!S!58T:,=*$*4040$I0+G9M
M\Y(G;WMB49O,4[3=G19MB5(4+7D"-R9EBX)N4@'_`&U"PY%6L"\<Z.(B8QH1
M")1*8>"2"10`H;&DF^Y-!)-!!'`R*")")HH))Y$30133*!4TT42`5)(A"@!2
M$3(4I0````#7V^^;_,7^L;3[YO\`,7^L;3[YO\Q?ZQM/OF_S%_K&T^^;_,7^
ML;3[YO\`,7^L;5.=N9\."^''AQ#MC"`?UB'<``_&(\`#\>L`)WE*35O+$OC.
M6GL-EAH-L\1D<H1[+)TU3269@<X.ZPU1AV[V6D>IE3.@6P1[=S$+2Y31*0G$
M.O-6<UY3;,=UL)J_@O!B&;A()B'DZ[`Y&B6H*`H!`,+==O)K-FO`0.9S,*1'
M4P,`*I)ASC%OE:F\J/GQ-92QWBA[7ZTZ2!1.&K(E<6?@/'J9%'<,K8YMNJ8.
M'5U`N$.8I1X]9<_BD%H57DN)IM+JV/*L]4LZV%94RAGUXM.6&#4PB?GE%RC$
M/1EGXE$1YY'<^HU5YP@+4I1$NLYJ%B?)V+8\(O'5!VNTIIS.IJ%K4!=8E9P7
MB`\7;MJ@1X\.(@`F4=N%U#B`"8XCJ0>&YH./`,%!Q[__`,XW=_KT^^;_`#%_
MK&T^^;_,7^L;3[YO\Q?ZQM/OF_S%_K&T^^;_`#%_K&T^^;_,7^L;7W:])+KE
MMUYVD>L^N6_7?6W;"ZYZTZL3KKK;JO\`-=<=;]4ZWZK_`#75N9U3WG.U.O\`
MS^[7Y->5OW.YMQ?O_@IVDY)Y3]DXV]XWP?=L888V8;<YG,^U/)LK9K/=9;)L
M)NW+&334;(^O-;AVE-@X(R#=Q0H1LSNL$H\EWQR-MWVPS?I0-\0YDD*%@'<5
M@9''D]3FLTSW+8A7PI>+;)VZ!D)%*<8U%^\?RCZ$:1L.RBTK+(."GDGB#IBW
M1(VB4E5]AF@AQ#AW?\!$!^<.`ZIS0X<.[W^/?'CQ[W?X\>]W._WNYWM```#@
M'[_G$>Z(C^,1[HCW1U`V=?P\._W[8Z_;-:G@GX!?[)?V!KEIIIIIIIJ`\P[@
M:OB=9I!%9OK3>I9!):%I\,FHH\7*Y550:KOEDTEQ:-G"R"R:":*#R0=F24!J
MQ5*0ZI+=L6(W>?XW'MAR6M9J8V9QRCN=Q:RDDCL%I)9P*C59]($3372=I-RE
M(H(("\;HKBU14CG1'*JN0==K<%4H9C7ZY%LX>&C4Q291[)+J:")3',H<W=$Q
MU%E5#&57<+'47<+'.LNHHJ<QQ]O@'@_Y'OZ::::::::::::::::::X\\OAX\
M!X#S>)N`_P#BYH#S>'XQ'@`:Q$SAO\V5[;47A\W;H,)X^>,#BFZ@9:_03NV%
M.4O.,FE381S*VQPJ`!_Z)"%44$>``41$`UJHNGW1WL_D95>I[5L1;H=YESZN
M5NRC\-8@FV4*Y6,H*1"JR5E2;6!,JA^;U-1O3G93%.`AW>YJTC[ON7ZW-G43
MP#R?&(-H-/D^:1K=-U-Y5F[7&(JF$I'AZND]KLF@Y3(`G.T<8RE"E$0`Q3]P
M#4/R37*@[CRNU-[/*[9)C(22,`2.,]I]:''E:7;'``49FG6P45LLV*3BGU-[
M29,%.Z=110PF$T/YT^Y8MNEQCJ83"&X;*&-K+'K3R^1KKE../G.PY)._2B2P
M0J`2QXYBJQV/JM9=0?<V.<GE0F0*[4`8]`Q\N^2FY$L>3+S3DC+H[D#9F[8&
M+DL;!`#BDM`]R>IV^&M7NP$F2_VP7G.]R08BPZR:A_/]<"Z'J743[Y@``[P`
M''NCP``XCX>YJNFFFJ"(!WQ`/ZQ`->9+3</`,E9*<E8Z&CT?_3/Y9\UC6:7Y
M5'3Y9N@0/RF4#6)U_P!_6TG'77"4OF>LS#YN7B:/I8/KLX.?N_S8+5IK(1R1
MPX>^!R_0`G_7$H=W6,KKE/S79R>.V[[9<S9>=&*8$GRT<:'BBGY_-*J<8)E;
MG!6_?$3/#QQB]Y02<#B7K%LO*L9?%/W(IV)MN<*Z!4"/)U9C*3Z*)PX!U9)V
MM=W8+D*/O3#6XLPG#G"5,`#CS+R=^9\EB5?<;O'R?;T%53'>5BF&=0\&*9R\
M%$D32;Y2)*0X<2""=/0)S/\`LPX]SRH3DE,;P^8HJ<7MTI.X3C(]H^4H,W_.
MV:5L30Q$QB)6P,$(]FM2W7,!^[2;LVLNMSCP75"QIS.QVS0\'#5Z/;Q,#$QD
M)%-"=3:QD0P:QD<V3X`',;L6*2#5$@```!4TB@```?BUZFFFFFFFFFFFFO@5
MJW(HJL1$B:JXD%=1,H)G6%(@))BJ9/FF4,FF`)D,<3"5,`(40*``%2-T$U5%
MR)$!=4B2:JW-`5E$T!5,BF=4>*AB)&76,D0QA*F*RHD`HJ'$WVU8&4,B16*J
M+/WN7B;184(1LB+6M4BO/K7<K-+/W;>-A:W5J['AUQ*SL[+/&<;'H'5:,4E7
M'7<K(QD4V?2+7$"C\HSA>^80R%F%A2\TQ%BQ9F-_MWO6WJ=H3-ON(B,\,_<!
MTWQ0RHK"RR4':+/,UZTUVXP#NHW&=K$U395&QLK"HP0?':Y?8LOILH8_J]^-
M2[[CP;/'>Z(4S*%=+4K[`%%RX;D9V:N%?R?N1('*@5T#,SY=0C9PW.J*:ASH
MIV+G7\/#O]^V.OVS6IX)^`7^R7]@:Y::::::M*X7NH4"+&9N5@C:]'"?J2:\
M@L)#+JAP$R35NF51T[4(4>J*)M4%CI)@950")E,8(#R>GGW(5E2J>.74?2,;
MNHV,D'&2T'Q%Y231?($<+MXM)LN$BU,B`E(DDT19*.B\%U9MHV6!(9Z@:;&1
M*$`X?E2L-H@X%I`C=)=FS5LSY!NB!%U%Y,J/7).O5A4<KHIK=3%1503"H8QS
MGN_33333333333333301`.Z(\`\(ZZ[AVV:(*NG2Z3=J@D=9=RNH1%LBBF43
M**JN%3$123(4!,<ZBA2E`!$1``U@)G/E5.3OVXBLCEG=SAB'E&Y517KM>M*6
M0;4B=,IC=26K./$K3--E3B'-(5XS;`8QBAS@YP:UJRGW1)C+)<HO6=CVR_>%
MO,L13F1;/*CCIU4*6LH)C%366FU&MKGV+,>!5#N)*J1Q0)Q$PI@`F#R`RU]T
M;;H2)EH.WS:SL'JD@L<S6PY:L9<BY%9LU#<T#'BDE;J@1T@01/U-_CB*,H8/
M>E3`0U]!Y$C=GN%,@^W[\K#N9RDQ>*G7F<98.(EB2@!U4`!1JT(=VYAE6QBB
MHB*G:[8*F1,`%*0>.LN\&<@UR76"5FTE'[9H+)MC;K`N:R9QF9K*[QRJ'`>J
MKPMB=C3`4$P<\QD:LD(F$>[PX!K:M2\?43'$*A6\>TNJ42NM>:#:!IE=AZM#
M-P*'-*5&,@6<>R3`I0`H`5`.X'#5W`4H<>!0#CW^``''^OAW]5TTTU3G!W>[
MQ$.^`=T0_P``XCJ/+MES%V-D3KW_`"'2J8FF0%!+9;-#Q"YRC^#U%J\=I.US
M&[Y2(H'.;@/-`1#AK"Z]<J/M-J*AF<)9K)DF3$HE18T.KR#E-9?CS2(IR=@&
MOQBHF-P]^U<.@$!#F`<W`HQ:&^?=?E/F)[?ME=N,R<"<K:SY.</HR*4*)N:F
ML*1T:K$<T"B!CIIVISQX]PPE`#&#B?E0\N@(W?.F/,$0SA4YE(C'[--[--4U
M2@`IIN8I@L[,*8&$H#V=`8#@)P.;WA@].+Y*R@SST)C.F:LR9KF#*$66-+3Y
MHF.6.`<3E.#I6Q3A2&$1`!0G6QP+W`YHB(ZRRH.RS:UC445:OA.D=>(E3!.3
ML$<:X2I3I<!*LG(6Q69705YP`83MA0]]QX`&LFFS1JR02:LVZ+5LB7F(MFR2
M;=ND0.\1-!$I$B%#\12D`._KL``!W@`/ZNYIIIIIIIIIIIIIIIIIIJ'L_9!M
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M+FZY;M)9J]C5U`(4Z8$>LW"(`H)NI"<I!#UBXTROS2_?%7(/>AW.P'$?<[G>
M_P#S,UR[6F5_E%W+R!Q%[&:=K3*_RB[EY`XB]C-.UIE?Y1=R\@<1>QFG:TRO
M\HNY>0.(O8S5DW%G>J(1NO8=Q.0F[)TREW*,BCC;$:L>+N)9B_"&5=]B!$VL
MQ+-TW`039T*",JY;*L6[D7QV[9>"K%E7)3BT-J+B7+F1LFVOKIJ26ZVH6)&<
M##MA4(#]-S)%IH_[4T`QDEWAS)0[%P0R:SUTN0S34KV+:.I;[$E;+3EZX6">
M04;G17F*[19*/*D@ES.LQ@7D$M7R,C*`186C2+:-5%2"=TBY4554/**>,,J)
M$(DEN'MZ::9")IIIX^Q"0A$TR@0A"$+2P*4A"@!2E*`%*4``H```&N?:TRO\
MHNY>0.(O8S3M:97^47<O('$7L9IVM,K_`"B[EY`XB]C-.UIE?Y1=R\@<1>QF
MG:TRO\HNY>0.(O8S3M:97^47<O('$7L9IVM,K_*+N7D#B+V,T[6F5_E%W+R!
MQ%[&:=K3*_RB[EY`XB]C-.UIE?Y1=R\@<1>QFG:TRO\`*+N7D#B+V,T[6F5_
ME%W+R!Q%[&:=K3*_RB[EY`XB]C-<>UOE7N@&XRXB(=\`H.(A$/ZP"F"/_#5C
MW95]C-B$MD?>06A1("0RDE=8W`=28E3$X%,8SRP5M@@0``1#G\3``_\`5,(<
MT?QBY=^Z2-^=*RUE*F4F3P9;:74,E7VJT^UA36DAV452N6V8A:Y8P?1+Q.*?
M>[L*Q8RH/(LA(UWUV"[`A6BB(!L&Q9RVN]#/6,Z%T;]H.\;<%F)]6(;MB3D)
MC'&%,VZQ%Z71$)MK4[6>B7.3D:D@Z*8(R1L4_`/%$`$79DS@.I[K%8^Z8MP@
M*EL>1=KVRJKR:!N)W<)3,@Y&C6+@W$"MFU<@[_&A+)(#PYRLI!\TX"(@T4X`
MG[[G[GZN.<T"NM]/*9;P]R+]8>KJUZ%FV]'Q^T54,8RR#6LS[V^M!;#[T"`S
M9PJ90#@1JF7N!E+@_D)MCVWLC93']$JTE+M3%41M&3L6XLRY9BKEX\UPF^R'
M5Y]BS7*(B)3QL6Q`AN:<A2G*4P;'8C#>0:_&MH>"SO88:)9)%09QD3C/#$;'
M-$"`!2HMF+*C(-4$BE`"E322(0`#@``&O1#&>5@#@&XJX@'@"@8B`/F"F:KV
MM,K_`"B[EY`XB]C-.UIE?Y1=R\@<1>QFJ=K;*WRC+CY`XBX_-V&:H;&^52@(
MFW%W(H`'$1-0,1E*`!^,3#3`*'^(AJP;"^6J7/[*]Z36L]3XB<)]A@&),4"B
M)3")'U=1/[T2F`WO>("`@(=P>&)&:-YE(QI5)=_3MX<CEB[)I&0@:?4*CB20
M2>2*R9@;N)>;:T=2-C(-DH)%Y5P#H[T[<AVL<V7?J)D+CA2>4=R)/U:,CUWN
M>;AF`Y%DY"N8VQUAUW4W!@<"DRD6#M:HSEG:M'Q!(55BO#/UF3I-9$L@[3.B
MH$F0%_Y63(K[J]3II*%7U!`$7&5H7&\4\2((CP4<D/#1,LH<2F+Q(WJ@%X@(
M@(@(@$E&V8;T,K"8^=]Z4U$QSH`.[K6*&3V/9'*8@`=MU=CV#QO-#WQ!%>&D
M4QX";FG$X\3#DB,)-))*7>Y"R187Q#@JL-C2J$HV>*<.`B]2/`)+NR"/$>IK
MNCE'N%4ZH7B!LHJ3M):XV*F&/KRRI9DB`0%ZYA?!D<].!1XE%:23H9I-R<![
MH*.7BRGA,/`.$G#C3*X\..XNY#P[W&@XB'A_5QIG<T[6F5_E%W+R!Q%[&:=K
M3*_RB[EY`XB]C-.UIE?Y1=R\@<1>QFG:TRO\HNY>0.(O8S3M:97^47<O('$7
ML9IVM,K_`"B[EY`XB]C-.UIE?Y1=R\@<1>QFG:TRO\HNY>0.(O8S3M:97^47
M<O('$7L9IVM,K_*+N7D#B+V,T[6F5_E%W+R!Q%[&:=K3*_RB[EY`XB]C-.UI
ME?Y1=R\@<1>QFG:TRO\`*+N7D#B+V,T[6F5_E%W+R!Q%[&:=K3*_RB[EY`XB
M]C-.UIE?Y1=R\@<1>QFG:TRO\HNY>0.(O8S7V;8XRDBY;K+[@[>[02<(*K-%
M*)B=)-TBDL115JHJA3TUTTW*93('404363*H)T5"*%*8)PTTTU00`P<!`!#P
M"`"'S#JG4R<.',)PX\>'-#AQ[W'APX<>'<X]_7+4"YU_#P[_`'[8Z_;-:G@G
MX!?[)?V!KEIQUU7KYE&LW4A(.V[%@Q06=/'KM9-NU:MFY!47<.%U3$21113*
M8ZBAS%(0H")A``'4%5G<ACV[9`:X_IHS-C<KM7[A>PQ\8KV-,!9-E'/-=/%S
M(NA27%(S=%XFS%BHY4003<J&6*(0/9L&;B\L.71\FWR%9U\6LZHTJ%8?O6D8
M=ZW(<:ZU=(IL"-UVKMX9)=W(22DJ_8-&XE1(#QP0S7*#%-&>8^C7M?79UXS%
MN6-]RYR+9-8^:E6Y&0(G:VI)G'LV[^2A3I%:-)XBAE)A@=!5XT:R"#I9Y*^F
MFFJ"(!W1$`#PB/#0#%'N`8!'P`(#JNFJ"8H=\P!_6(!^W5.>4>\/._L@)O\`
M_$!U$&X#,41@#!V7\X348[G(S$6,KSDM]`L732/DIUI1ZW(V)Q$1KJ3,FR1?
MR*<>+-HJZ,#=-PNF9803XZ_-)7ONK;;W,SL!%2&U3,]>82\W"1C^?D[WC(T=
M`,9639L7LY)`@Y,N:/A&KE64?@@4RPM&:X(E,H)`'.O)WW1AR6U!<JQE8R[=
M,WSI#F12A,+XKN-C<.UP,H0J+.4L+.IU]T90Q"B0[>662,50AB'4`1$(7'EO
M]U.82K$V?\C_`+P<G,70JIQ5QRLB.**L80YO47#A9.NSL89(W/`RB0VQJ8"B
M`$7$W.`H+;]TJ9Z.BG$XSV/[*X=V5(Y'UIFULF6UD@H83"99!C*91CE'::8@
M"B"L$RXF``+U(PFYM`Y)'E-\V)JK[K.6:S:W;OS*A*4O;;4NUM`J(K$`JC5"
M5C9FGMC-^'$@%<4TY1)[XJ93F.8;[I'W-MR=D7)H6#+ZF?\`<S8>>BL]DLVY
MJL+LCY9,Q#*@LA24*>Y407,4X'1<R+L>8<2=4$0`VL([A]RB8IG;C:IZM;O;
MG2:Y-6BP3->I<?ABM24?3X*4F'C^&JC&2?WWKZ095R-<-H1H_?<'CUNQ3<NO
M]H54U^EK:O@=GM@VX82V\,[,YN3/#&,JCC=O:7\8WA75A1JD6C&$F'40U=OF
ML>N^!+JZC1!VY20,82$64`H&U/X"4`[G>_\`"`B'_`!^;7E2L_!P2)G,W,14
M.W*`B9>5D6<<B4`$H"(JO5T"``"<@"(FX<3%#CQ$-0=9MVVV2H`?W>SOBULH
M0.<9NUN,/+NP#WG_`.APSB0="804()2E1$Q@,`@'#B(0!9N5!V<5SB5#(TG9
ME@$P=1K5+M+GG"4#"!2.9..B&)N<(`4I@=<P1,'$0`J@DBQSRK-'F5.H8OP#
MGK(RYC"1,6E=8LD%3CS^I@4T8YLKH"J<$S!SF8*`50?>"<G,-\C[R=\-N,!,
M=[#K'$D4[J3N_P`S*,TA*`'[JB<C'4E,.<!!X`#P0`QB@`F`4S*C2/*VW50.
MHP.`L1MU/?`9=>.E7*)1$A1*/^\;[SC@!#&$1;E`>K"`"'`@I<C;6.4,N:H#
M?=[K:LMUB@5RWQW7G2`D(()@<J"D7'T3WP@*O`W5"\1`IOP5!*D+R79+*J"V
M6=U.?<AF5#B[2"8+'MUS#QYP`2=>VXQ"\5%Q`!X]Q40'_M`5O^N\E7M!A%"+
M256MMN6#@)U+)>9HO53^_$QE$Z\,`D(F$_$0`O#B4IOPN<8\IRG)_P"TE]59
MJK,L,U>#+,,56B=@BDW06N'<&`PMY*&L3]T_D63YFN)5DA!4[9<"`U>MW3(Z
MC<TB;;]M&.]LM'[$:2W7>R,@LF^MEQE2-NR.VRB93D2=2:S1-%!NS8I',WB8
M9BFC&Q;<RG4$3.7+QTYR&``#O`''P_C'^L?QZKIIIIIIIIIIIIIIIIIIIIII
MIIIIIK$#=!N7E,-6[;AAR@5N(MN:-U.4YS&V.(ZR2<C$5.`CJ1C6WY=R/?[>
M\B(Z3ECP55IE,<M6D;&-B.INV6"KPQW\0R?.Y9G=6TO<A$[I\,L,H,J\\ILY
M'W3*6*<A4B0>HR3NEY5PADJU8BR?60DT46I96.CKK39@T!,G8QB\U7'$1+N(
MF*</58UK[>=?P\._W[8Z_;-:G<@AS"]_\$OXA\`?DURXA^7YA_=K4'N>WL-J
MEN1NV"Z[7,D5R;J-(Q\I:<G2$E'M,0/T[RVL-IKL$Q;JR2$NI>XLD"[6(I74
M5%PC';]*UMB0BL.\5NK9=F='.26=[%EZQS,4Q"WO,=.*7D:5@&%9ML>_K%7M
M2-[J#3W549N*K*PM@9Q$*[AN:RYK9^V5=.)-DZ0CLWHV_;<L5Q[2%87O$%'8
MK$4.U:'NE-A1>@B8I%ES'=S"+B15(8Y2K.5E'*H&,4%%.)@XZK.4-Y=+`>P>
M\8WIA*#,[A0R'49VUA.XBR)CAQ%UWW$GFT'[E3!G<FX$'[X7!GK7J9P)UNBH
M`@)P'AV=A?+L[5]Z#7+KZX$BMI[/%1*:J5UGW+F+()&X)6OLC!PK7#^[3'JQ
M*\:!1+,"(*@B:8C0]X*H`?-"<Y4+DYZZX1;2V^':R@LN@+E(J&;:'(%,D"AT
MA$5(V9>)$-SR&#J1SE5$``P$YIBB,-RO+=<E/#))K/-[>'5BJJ"D4L0M:I]<
MI@*8XG5;0=8D7""'`H@#E9)-N)^:F"HJ'*48MG/NA'DDX5)Z<FZA*;59J@D5
MO7L39HE#O>*I$Q4CEBT!!F]1*!NK"LFY!,42G4(8W``&*IC[I7Y+B.6.E&WC
M,EI`K7KE-2OX)O/4W"O-4-UDC[N(PB@.?>%*)UDTF115(8SP$P5.GK1Y1W[H
M[I>2-OT;`;`I[<;B#,JF1*Q(O[_;,2TN'@"46.;S(6.OD>V.3NS562EWB\.9
MNFS@U%`2CWA5))@`E3=ZX=D?+L\HW";CJ=(9/N.5MXE/+$6]N]P#!1^+ZK(V
MM^\@'#:&E2ST1CA%ZQ;U6240FW9@4(@=!`Q7(]1YP:WFN.6$Y4V_H&<8KY+S
M&U":F;F63D<Z[M\=0Z*``R55%5RQD)?'#KJ9'#=811%1!4Q3MFBHMG"Z2REM
MFW?<NKDY4I&ETY(O;HT7,42J2V<(.[2;1$SHABBL#&^9!;KJD;.A(H!61!5&
M.5$J;999(KFW'3#E7KZ*C+)/+K[-,7H""K=RWPIC^H22R"@-56ZW4)1>GTMV
M<W5TT#%<(R"8<]9=TU%N**;=?QGFRT]O7,AGG[HKW*V\AU$U7\5CJ>>4:(/S
MU$G9DVJD?=;!%D(7JSY%/J,<!$`5;$*BBBU48*QOD[DG>2I>XXO*3;?KG;*V
M:WU'LR>.)W,6;++,T)GD,\`^CZE)W!I3L8/Y`*\TF#1*\LT*J]=*1;`[9%JZ
M:*':*:+<:<F-?F>7*8G>,G8.#'T+>X%]9IY^.29"O3U6KUB82$VU3B&>.G5A
M5:VV&8OHZ+;OX5L"II%LA,EC$%UU6_[;Z)O$Y,3!I$&V&\:U>BD(B;J9,7;<
MV=..F"8G!!!11C7J^X.L9,>:F<3G(`"/5%DP$>%^+<K'MY5YA(6B9TL2BR:H
MHIL:-&<%'"8&$K<.N+0)SF,)1YRB!%B(E`PG[I3%UYP<J"64%`M0VF[C[&+E
M!4S8"5DJ!%W"/5!,DD:.:S8*(D`@BLNCU0Z0@H7K8YD^!OJ&_O<9+)E4K/)]
M9Q<IN&ZHMG,J>Q,$!<)BH41.;M=E1%N0Q0`><X275,51-(@CU,3=0-V7*"3A
M@['=B:T859J<Z!K-9GB'4UTQ,!E'!7JE;$""/-ZFS5!JX5`!$BQBG*(8$9\S
M-OT5W!8RE[;6K1C7(Z*;0^),=4U%:2K;XTB8K250:LVTG-1EP?31@ZUM[6:?
M.E8R..@W<I0L<FW=&SV#%7*J7E`IK%N!Q-C!J[3(95A5X1H]D6(*I%,=$BK6
MF.S"LAU95$QD;&J3JS<ID7:I!2<"-R?>X"X)?]*>^S,,P18!,ZC*TA,Q3#GC
MSA$J77%N!F"8&.8`#W&3`2%`"ID#F%2]:,Y)?;J8Y7-RMF8;\]YW.55G;>S;
M)+"(G$0'W.@TGH`/.*)O]O$PF(`\[@90#3E6^3NV<UD$A;84A915$P'!:RRM
MGL@G,!A,'5&\O,N61P#N!S1:\P0#WQ1$3":?JY@;"-/!(*MB'&M?,CS.IK1-
M%K;-P'4Q()!%TG&`Y,<HIIF`YE1/SDR&X\XH#J5$D4$$RI()%12(`%(FBF"2
M9"E`"E*4B92D*4I0````X````=P`X?3WO?$.(^$2B(_.(<=5XAX!^B/[M.(?
ME^8?W:<0_+\P_NTXA^7YA_=IQ#\OS#^[3B'Y?F']VG$/R_,/[M.(?E^8?W:<
M0_+\P_NTXA^7YA_=IQ#\OS#^[3B'Y?F']VG$/R_,/[M.(?E^8?W:<0_+\P_N
MTXA^7YA_=IQ#\OS#^[3B'Y?F']VG$/R_,/[M.(?E^8?W:<0_+\P_NTXA^7YA
M_=IQ#\OS#^[3B'Y?F']VG$/R_,/[M.(?E^8?W:<0_+\P_NTXA^7YA_=IQ#\O
MS#^[3B'Y?F']VJZ::::PJW5[=K;DK(NU;<'BU2`<Y:VEY4N%U@*M;Y9_`U3(
M5,RGB:X8;R/29"Q1T/8W54DSQ5IB[A6[,G6Y\J$U3FT"[CTHRQ/Y)A[>R';5
M([5\"M,>66R,[AD&TY(S5G'*MFBT'S2$DLJ;A<N7+--_1KK:165?)U>$L%V=
M5NL*/2-W[R`AH^0DVK:3>/$22KFG&[C)T73(4@$&.B\D5&RSI0EY2"=FA(11
M\J\+&R4,HA)(2'/60%OUJ\9'.`*%%TF03%/YP;;\4@``+"X\0`./#+&6^''\
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M`^.BH9,4BJ+A)>P#[F:JE/')CGE$8W&V7%9!&F#B5'$>1LDM.QDZ1)\]Y+8A
M<5REI+KO3JUE.*6;C*%(#*2YIFI%BF<;.F/W/MR6\=U'K;`+H10`>89S>+.]
M$PB!@YR_7KIP5R;@80YS@%1[A1X\2E$+H:<A1R;+$O,:8+12*"@+!SI85S`J
M'-X'`[E@L<.',+P*!@(`AQ`O$3"-T->1?V#L3*&98K<-#+``*F;RC1(5`*(B
M4#B2&#G`43&$./>$PB'?U<+?DC-F;3J?6E3M;3J1.II=:W!RVZDF!>8":8H,
M$Q33`GO`(02EYOO>'-[FHWS1R(>R;.%$<T*RM,JQT>=\A+L'D-DR6;N8V99-
MGJ$?($04:JM'9&IWRJRC%TB=J\$`37#F]T,4MG7W.QM<P79G^1,IJVFZ7%D[
MGX>J1L/D*TLZNSK;Q!Q%A,R:2:<;(/9^;9J"Y-&G<GC*Z4Q6B*LLZ!5_K9<P
MY,#98Q.J<^)EY`5`(`>Z%XO*O41()AYR(I3Z!B&/SN!Q$3<0*7APX=WWFW)O
M[,&JP+!A2/7$"F+U-Y;+X]0$#!PXB@XLYTA.7A[PXEYQ!XB40$=>H')Z;-0X
M<,%5KN=X/=:W<.Y^3LCX</R=[7/^3XV<>(JM?I2V^T6J_P`GSLX\157_`,9&
MU#^VP#_QU&%?Y,#;-#Y$L]ND820L=4EVR!*[C*5?/@K%/>'$!DWC)XU?(S<J
M5<2)EB6<J]60@TU7Q$NNQ69F83?&[)-KL,"18C$\9%`@J99#W.G[BR%%8_X:
MJ1FUC3,FH;_K'()3#^,=7:VVR8<8E(5C!V1B5,3&3*QR9E)F5,Q^//,F5M=4
M@3,<1$3F(!1,(CSA'B/'O='C&7#AU&]</Z/;@S#S?H]GO#O]WO=_N]_7S-MR
MQ6?B)V=T.(\.(GRUETXCP[W$37H1'AP#AQ[W#7#HVXFX\?<ZX<?#VU\M<?\`
M\<ZC^Q[5*4_O6.)B.93?N!73W-2>*\RAD]63(I,P",;%*0JZ]I<NVB@N`72D
MCL'\<9=B?J#D7B`]0"0>C?BCX!<?.QEOVZTZ-^*/@%Q\[&6_;K3HWXH^`7'S
ML9;]NM.C?BCX!<?.QEOVZTZ-^*/@%Q\[&6_;K3HWXH^`7'SL9;]NM.C?BCX!
M<?.QEOVZTZ-^*/@%Q\[&6_;K3HWXH^`7'SL9;]NM.C?BCX!<?.QEOVZTZ-^*
M/@%Q\[&6_;K7!7;?BP4E`28W$JHIG!,PY8RV`%4$H@0P\;P8.X;@/>'O=[5K
MT/;-465(J#.\!:Y.YM*U"M[7(M\N9950?V)&.;IS#Q%4EP9$42</RKJIG*T;
M%,4P"""0""9;KZ-^*/@%Q\[&6_;K3HWXH^`7'SL9;]NM.C?BCX!<?.QEOVZT
MZ-^*/@%Q\[&6_;K3HWXH^`7'SL9;]NM.C?BCX!<?.QEOVZTZ-^*/@%Q\[&6_
M;K3HWXH^`7'SL9;]NM.C?BCX!<?.QEOVZTZ-^*/@%Q\[&6_;K3HWXH^`7'SL
M9;]NM63T9*UVQ.O^=:>P#L+ZS]RNVYE?KGLO]W^K^Z/4>RWJG4?<+_9.J]?<
MWJGO.M>/\]J]NC?BCX!<?.QEOVZTZ-^*/@%Q\[&6_;K3HWXH^`7'SL9;]NM.
MC?BCX!<?.QEOVZTZ-^*/@%Q\[&6_;K3HWXH^`7'SL9;]NM.C?BCX!<?.QEOV
MZTZ-^*/@%Q\[&6_;K3HWXH^`7'SL9;]NM.C?BCX!<?.QEOVZTZ-^*/@%Q\[&
M6_;K5HWW;36W%.L*6/#6F(NYHU4U7DW>6<K%;,9E,Z:K)RN*]MD4>I)J$XG!
M5BZ2.7B11!1,QBCE&'_^Q_;W-------8#;D=Z<KB++JF#<88M[;N2*SMKR5N
MZR%!K6E:HA$X;QU/1U491-;<)5FRDGLHY.L[F7B,<5R0"`KKD:E9'EAM,.@@
MS!UEGA_*E.SGB?&.:L>/E)2@Y=Q]3,G4B261!NM(5*^UR-M5<>K-P45ZW6<1
M$JT47;BHH*"QE$1.<4Q,,C::::::::::^:QSII*'33%50I#"FF!BD%13@/,3
M`YO>D$Y^:3G&]Z7G<XWO0'6*FRK<ZIN]P*RS6O0E\:.5\G9^QB]ISFR-+:O'
MR.!L[Y&P9)NSSK&,B&;L)J1QVZFTDFS,462,@FR*Z?=;]>KY7Z::::::::::
MU[[DMXN7-NN6\3,7^VU.R;<<@YZPCMLF\P-\K-X_(T1D+/\`.,JG3;-5L(]@
MLBA<,50%PFZ[6[S8WN3:I;(]5Y-3%=HMC@*TXDI#8.`\0_Y_X>$/`/XPU733
M33333334>93GLAURE2LCBFAQ62+^91@RK=6L%S)CVL.7L@_;M#/K3<RP-M?P
M%<B&ZJTG+O(2GVZ?,U;&;0E9F)%=!L,,[+]P]KW1[?JQEZ\XB?X0MTA/Y"JM
M@H:UI:7R#2DL=9`LM!<6.B7]G$5U"_8VN)ZX-HQ[=DZ[!$L]5E(V53C$$ETS
M*94Z::::::::::P:O6]^LU3>Y@?95$TZ4LDYENKYHL-GOZ4@#"MXYD<44RF7
MAC3%T31SHUCN%G@;K%SCJ):O6'8G6GD'-3"IS6FOLGF<NFFFFFFFFFFL0=[>
M[^B[*<*AEF[R5"CU9FYU7'5.+E'(J&(,<O;G;G2Q6"-WRN]KELB\<UAE%Q\S
M,S-NEH"1CXQI&&(J@95TAJ<\06RXWG&-)N-[JU7IMKLL$UFI6M4O(:.5:I&=
M?B=PP"!R(WK-0;6Z.=Q9V3]"8:UR,:K@[$C4CA!--XXDO333336L/=1M7S?-
M;@[%N2V[.J>_NN3]E^0=E5EBKU.NJY%4T\U<E[]BG-+-TS@;"M.L\?ST]>&E
MOHS9JQD[3'SL*XBI(CB$5;+YH;:\(P>VC;M@?;I69-[-UW`N&\98:@IJ32*C
M)3$3C*EPM,82T@BFJLFB^DF\,1\[124.DBNX.DD8R9"B,V::::::::::X'`>
M:/`!,("!@*'#B82"!@*'.$I>)A#F@)C``<>(CP#6"_)T[?\`*&V3;B]Q/EQ*
MGEM`;@-UN3F:]'L<E9H5Q6,][ELIYXK*2[R6K%3=M9N'B<D(5Z?8ECW+).6A
MW3F-E7[!TW4+G7IIIIIIIIIIK6?G/'6]2[[IJ;<*]B7;->,&XHDZS)X?<9%W
M#Y0J4U4KO-,7,%DO-5GQ#5]O5KA+]<ZO4)Z?J^&*ZOE>O1D,1W/3KR4CI^UL
M9&E[+P#@'#@`<.(``=X``?>_\.'$.\`][N:KIIIIIIIIIJ'\Z+WY/'DDVQ[B
MBF9J?RSZ)@;'CR]7="A0DS0IU^E%7I0LF^I5[B9:18UMT^=Q]3G(N/A;6LE[
MB2-B@$'8R"<%;#=K`;0L+3>+V:<+`5V9S'F3*-/Q;4%G2V/L&U+*%ZDK9!X9
MQV#E!B1&I4IL\$J#>.B8.!1F)&93K<%#U\L8Q2S5TTTTTTTTTU00XAP'\G[>
M/#^H>\(?C#B&M+TER6%\AM^&U7=!2=U><)7'&(;CNTR#D&C9!MF.I!V$WN#+
M4Y!M5J,2+P.VDI:C3\E&24-?$[I=7-JC:A#TR-IMD9*QRQPW1!W`\/Y1[_\`
MCIIIIIIIIIIJ!<^2>:6,-6F>(\.8VS7'S]A5K^3JSD7*+G&2#*AR<'*HK2D2
M;M:Y(BK<?W9]RX^>JLNVADG-9?2SYB]D))DV@Y'Q-IFWMGMBVXXCP&PD4GC+
M&-6"!:]8$<I0T<BM)2$N6OUIL^56>,JC6/=(:W3F#M51RPJT5#LUS=50.`9*
MZ::::::::::::::::::::::::::::::::"/`!$>\'='6'%GY039E3;?V`V7<
M5C6)N:EON6/V-:<2KL\Q,WG':75K_4*\S;QZY['9:0C_`#MMA8'W2?UU,#'E
MT&A2F$)*Q+NFV[9WLEHI^'<RX^R19J53L69`M4+4;"UEWT'3,V5]S:\4V203
M0]ZE%7NN-59JON"G/UW'"BX.5$KEMU6>^>0>\8H\1X![X.Z(\.`=_O\`=#YP
MU7B`CP`0$>[W.(<>YW^Y^3B''P<=0[E?<'A3!L=+RV7,F5"@1M>ILYD6P/+)
M+),D8#']9=QL?8;Q."!530]0AI"8B8^2LDB1M#-'\DQ8JO2NW*2)I#JUKK5V
MK%>NE1G(NQU.VP4/9ZS8H=XB^B)VO6&.;2T',Q;Y$QD7<;*QCQJ^8.DC"DY:
MN$EDQ$AP'7O<XO\`2+W^'?#O\0+P_KXB`?UB`?CU:5)OU-R/#K3]'L<798IK
M+S5>?.8QR"QHVPUN2<0UBK\JV,";N)GH"7:.HR;A)-NTE(I^W5:/VC=<@DU=
M^FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF
MFFOSX\IBTBV/*H\A.6%CR(1=,S]NXMEX4B(U;W*J3?(N%BQ$18;8YCVPQ]?2
MNMZ=O63&1F5686"QN'I457;TSLP:W^4DW!;S<+W+ETV.VFYY>HY<-XNY+5SM
M41Q=7G0#!VFS9#K</FV&QY[E5MZ:S-FM:GK"6R5+_?\`#U-L[>*)Q<,5,P(V
M5E+<)O7QKNES5!8]W*[L9[$^&>6)Y..C8L6E[9:KG#6/;IG7'<N]W9-9]^[A
MW"62,6-)J&:F=-Y4\C1L2O%E2U!K459``<;(^3"SKNBS-O%S6PSEGVV0.2L6
M9AWM4'.6T6T4O*S]D%*<99K\GM)R)2CRAFN,,5T"EXSC"UZCV^H)OR9YC[E-
MN+-)VFUQ:5B:XY[KT[C<X_[JJC[6TG9[(T?MYP'C?$D(2.>R3Q+!4SM1L4UC
M*"H35NV<+/(VTY;L>7'CEI$'<J25Z6FT'2)'S0B".MF6W`;]]ONSKE$J9A?.
MFZ@DCBK9AR*MWVM%6<V2S3-,R=D&)Q3!;DJOBEB:O*I!"QD))S,?=<7P\>O!
MU1*..L_AHF48.7J6US?E9-V&R:Z[8Y#%&YG<=NRH-SF']SRQB&QY.?UK<!8Y
M#.V=<.1,)?-K,[1:=#T/)</AMZ<]?1VFW2'GJ]'8@OUBD8^)D&@R-^QCGSL]
M>65GRP?+`UBO+R1L0DK.P>XSL:9$R-<BMQ%FPS9HVWKPO\RW;FGY_$5:Q'(7
M/K8SQ91)M5'D@J@LY;D6W.Z:::::::::::::::::::::::::::::::::::::
M::::::::::::::::::::::::ZBQC`X0*!C``B'$`$0`???C`!X#_`(Z^*IS@
M+G@<P<T4N;P,(<WB/=X=WN<?Q\._JAU#@8W`YP_GDP_"'O"4>(=_O#^,.]KL
MIB(K'`1'@'/X!Q'@'=)W@[P=\?G'PZP<OL='Q?*#8(G(QBSCIJV[9,_PEKEV
M#5!G*6:&I%RQ/*4N(L,@W(F[FHRH2=OMDC5V$DLY:P#ZT6)W%)-'$W)*.<UQ
M44YJG\X?N)HB'OC=P1`G$0[O<$>(\?#Q[NNXJ(\Y,.(\#%+Q#\0\5D2CQ#O#
MQ*8Q1X]\#"'>$=8/\GJQ8EP;:+(5FU"Q7;<+N0L-SG@;HA-6Z?8YDMM.8SEG
ME`)U]/S#.HU:L59K)RJ[MZWKE<@8-%<D9$1[5OG3IIIIIIIIIIIIIIIIIIII
(IIIIIIIK_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g112658.jpg
<DESCRIPTION>G112658.JPG
<TEXT>
begin 644 g112658.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`_1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]-14%?44%?5%)%7TM?0D%2+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_```L(`-H":`$!$0#_Q``?``$``00"`P$`
M````````````"`$'"0H"!00&"P/_Q`!E$```!`0"`@T&"00.!`P'`0`!!`4&
M``(#!P@1%B$)$A,5,5%35I*5T=/5)D%5D9:E%!<B,E1A9I/4"E=Q@1DC.#E"
M4G)W>)>QM;?2&!IBUB0E,S0V149'8W:"H35D986RP?#Q_]H`"`$!```_`-_B
M$0+V06_%T,/=N[$NNUQ]M$C3RQL8++(O*DXVW.X1/V[OSB-8-I7D50Z@+"91
M05^1'=5<TFKI@HMR%*E`9*:9+7JTCI6UF/RX>,VR!QA7FL,_K5*C?+WEP_6G
M2L+#DMOOJX,0<EW;IM9D/NF4NQI8E++!>#9:Z\OO%E2H#>5&VDIMOUU=N%(N
M(:@9IM.SIO']=07D[KQ4*K?+6%9FR?L?8SZEM*[>DJ+RH37W<U+&+UYQ>5.M
M45J+K+8BGXF2)3=IDZ#2HVE:RG(;(*;J<A-RH6:@!$0#/(!RU@&L`'S@`ZLP
M`?/EKCK#BXC)U;X.?54XE7&26H%$T<H4*HTYAF"6?:5:DLVTF&68`FRR$91`
M!U#'B:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V>
M<"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:
M5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4
M[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C
M=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39
MYP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]A
MI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W61
M3O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"
M-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-
MGG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V
M&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9
M%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP
M(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4
MV><"-UD4[V&E39YP(W613O8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O
M8:5-GG`C=9%.]AI4V><"-UD4[V&E39YP(W613O8YTW.W*M22E274BI5JSR4Z
M=.10*S3U*E28)))))0JB,T\\PA++*`",TP@``(C$/L5&+E[V3.%6)83"G>O&
M5>]029%N6W5I3S`9+7:*0:J&J"0K75O+=IS-*WC").`V1/%4%+H'',]U<")]
M2(,ZLAD#JL7M?AMQS7]?#N0[?XP-CZOS@B<CQ,U2+(<RZ_;.XA++N!8E":8H
MUE&ZECG.M:`NQ8IR5-X"%QVJU41Q'I)$%!<B@Y3B6BJ-^<8.&4_BH8UMF:1?
M91@?%]B+PZXA@4S32JN_?8_AUN\U+Q(38^!4W2U?@)-QK32))*LJ@;-F":69
M-3DB4QS<:M.U5]\+6*2YE_4Z[UN<6-OK9MEMMHJW6*RG'A8+796;?&5.F:*W
M$>;1=ZO?!M(I.X#W2CE1NTG,?MZI:-M@O1;Y(B;355XT'9ZX>V.A"-714U"D
M_JI:PR[C+:N/Q9M!(WZPJYC$<TT5,^#R%WMI%*4H6O5+F-QJ7T4VG.TJRR-S
MT@_-0<LC97JR,GY*P#(`#,1R#+,=8C]8CYQ'A$?.,4&228<YI91'C&4!'UB$
M4W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7LAN=/DY.C+
MV0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7LAN=/DY.C
M+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7LAN=/DY.
MC+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7LAN=/DY
M.C+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7LAN=/D
MY.C+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7LAN=/
MDY.C+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7LAN=
M/DY.C+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7LAN
M=/DY.C+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7LA
MN=/DY.C+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7L
MAN=/DY.C+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YT^3DZ,O9#<Z?)R=&7
MLAN=/DY.C+V0W.GR<G1E[(;G3Y.3HR]D-SI\G)T9>R&YTPX)).C+V1C,V6JW
M=SWYA".F[,.RQ%O;DVXO/AZO.VW_`(FKCNVUMAFB<M'=UKO698N>XV8JI*J;
M;PT$N9+T>K5:Z:OG5`DG'Z`4II#12W&QAXAL9=^5^]Q;%Q>W8QKQ4FLE6T-,
M(OL<-R73<0BW*RRI/W2.M=X7LM+2PDGU.9(008XD9Z"4<+I;BF$*BB3JS4\O
ML(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A'$9@EX0F_5+
M--_^(#%-TEXI_NZG^6&Z2\4_W=3_`"PW27BG^[J?Y8;I+Q3_`'=3_+#=)>*?
M[NI_EANDO%/]W4_RQ4)P$<LI]?'3G`/6,H`'ZQCE"$(0A"-779GSN(6^5\$+
M"X9O9L:UJL-Y4+(W53&GLA]JL0I!K7*N>RG`KN8X0HW0IIB-AV?;3KT024)6
MMB9=*NYPEKJP*20F&*R(?EFKL0N"&]V$@_>UPW4MYL:S+0;J-VU.A*KL<-J7
M9:IM.JDVCMP3BB;N10<M>N6=)@J7="5,RUI'JU*9<D<7RIFI-NA6,PCRN&PK
M=%T(V_WJTV25=#J;[&;9AVN)';E%P/1V*%)):[11*BN<)RJSF<:I7HIZ$@IX
MF%15.U9"Q$K7JS!+'7.6[5KV:ZVJQ79<-E-IYOB>:FSFJNN9&2G`YYY3I5-V
MJ&D'3E$\I;93/$4RD)6A4"NIG2:;0&H?-ERU14NU:^E<.A:2K<-ET[H&4V18
M+V]G<R-(\ZR75+GCE(]3;<QP%:<O6)I:H=H32E1&N13%(]2EG)D#E>C<*$(0
MA"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$:2WY4Q<>XS(Q&842C
M*N)<%EE#]D;C&3Q1G/IVM,J>,T;AHM*B9.EFZLIE`V8I4IIJ5*N9IU:U*E--
M2ISRTYAE'5Q^/V_7Y][X_P!<MSO]ZX?'[?K\^]\?ZY;G?[UP^/V_7Y][X_UR
MW._WKA\?M^OS[WQ_KEN=_O7#X_;]?GWOC_7+<[_>N'Q^WZ_/O?'^N6YW^]<3
MHV,2]5Z%K9%\#Z0LWEO`L)"GB:M<24DE7NM<)52E(G761EKDU%-4'*9(GR=:
M7Y-8J;+UB]:754IS!JCZALGS9?Y(?V!'*$(0A"(LW4Q68.&:X7)9Z^M^\/K(
M7J:&D&G!;Z\EQ[>M*LJ-EV%SLZ8;JMQ]K*=(MH"O(G*164U(3-I]8P0/DIIQ
M,%#%.2%N`MNX8VQBOQ6E\)EQ</+ZM8Y;<60>]='P\26O)I#"=RT\KW)JTDN8
MK8]0)VX4#"P20T8\W5<^S$A^S$"2@6<3B=M+X,<+=SLOM5-+V.PR&E*H1H`6
MV338QJQ0P>G+4@H5Y<:]GQ,U2U8R,H4JTJ:!P:T]&:6H!(#(SB%`*L8\,?<K
MO)KNSEHB@)V>\=RK$X#DS!02W>I,Y5V>K(LM2TY2UI3=9#IDZW<:*BX5$WH]
M1K5T9TKB`I*4X5CR1('%2D>-!;N:R:@FQQ2JWY1E9YWI!"K6JUGI4LE34;8.
MQ-=!<L%695I6ZHX!6V]T$%2B6T?T;2'@ARS35*"S,&S=)EM9<M09!D`Y@(2^
M8!`=>8!D`YZ\^&.H/[_[O_Q;O1\&W.7_`)[\/W?=<YMO_P`V_:]IEM=K_"SV
MV>K*/"\KOL[[VAY7?9WWM#RN^SOO:'E=]G?>T/*[[.^]H>5WV=][0\KOL[[V
MAY7?9WWM#RN^SOO:'E=]G?>T/*[[.^]H>5WV=][0\KOL[[VAY7?9WWM#RN^S
MOO:'E=]G?>T/*[[.^]H>5WV=][0\KOL[[VAY7?9WWM#RN^SOO:'E=]G?>T/*
M[[.^]H>5WV=][0\KOL[[VAY7?9WWM#RN^SOO:'E=]G?>T/*[[.^]H>5WV=][
M0\KOL[[VAY7?9WWM#RN^SOO:'E=]G?>T/*[[.^]H>5WV=][0\KOL[[VAY7?9
MWWM#RN^SOO:'E=]G?>T/*[[.^]H>5WV=][0\KOL[[VAY7?9WWM#RN^SOO:'E
M=]G?>T/*[[.^]H>5WV=][0\KOL[[VAY7?9WWM#RN^SOO:'E=]G?>T/*[[.^]
MH>5WV=][1H^?E6/P_P#TC\(V^/P3=_B*N3G\#^$;EG\923GE\(^7EN>X_7M]
MT_@[2-5B$(0A$\=BVW7]DCP*[CN>Z_Z45J=SW7;;GMM^_P"'M/E;7+/YNO/*
M/J;R:7;27_H[\V7TMQ!'+RN^SOO:'E=]G?>T/*[[.^]H>5WV=][0\KOL[[VA
MY7?9WWM'Z4M*MUI;MO!N.Z2;KN>^FZ;EM@W3<]O\C=-IMMIM_D[;+;:LXPA[
M,)A,P9EF,X,8MT=CE8^/J_E<[:*S3707R^$6V"0FIBPYJS=;L[INR[SY5EVK
MMTA*;C/'5MS+Q>H2!862)8X:+4SM`P2]"V#AK-IMNK$Y,W-C.L/L;],VWK+R
M&TBQF,"SN+$I=R<NJ75GHJ;DKV?5U(DQ#3+`Q4(II9>IT3S@IN$]5)U:Q=(J
M4R^P`MMIO.6D7H.%"1EV@4,`:*T5E*3U6D6,RAM93%"FH%C,E&O++J"M2EDJ
M`&H)P"/R4FHUUE807`KMU"5%UK3G:K96E%(3CRLW:BE0D+*-1"4C1:J=1ZA\
MM3IESLZ;7+3&Z$DE$P-2G)+*"=J->=RTWG.W4*=WT4B9OT73,D)TSCI(4YD3
MLZ+371+"JTTB8Y-,;F3)#<I&8S-,8$N-:89Q]@A"$(0A"$(0A"$(0A"$(0A"
M$(0A"$(0A"$(0A"$(0A"$(0A&C'^5?\`[I3"-_,7<K_$=#C5+A"$(1/78LOW
MRC`E_2CM3_?0Q]5F3YDO\F7^P(Y0A"$(1@]V8\Y;3$S9P]@C9[DPLO3$U6N7
MAZN<A8;\5EV%BTMN+F-IO7`3G.I%'263%1N.6XS3,(!!2E--UC5W`9!:%(F5
M$^E,6DDCJ]ANP07TP>+^(>O>'!S@/PG%+A(MI:;='`TYKK+R4^C#74+E3J_Q
MDT;IJE>N64FY27TN9L5D--HES!-=6:9X^9J%RI4EG6A"$(0A"$(0A"$(0A"$
M(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(T8_RK_P#=*81OYB[E?XCH<:I<(0A"
M)Z[%E^^48$OZ4=J?[Z&/JLR?,E_DR_V!'*$(0A",66S`7'IVMPB57'71\**F
M3/W8M2TE0UCB2ISF%)'1G6XQ2U0W>=:I-9Z&F<V3U`94,DY23?-&*;G5F^DA
M7(`K;X%<'>!G9!2K8Q>6+L7A].86VDT'78-2N-B48]FKU7OO/8.XEQRN-!E8
M56BDX*D&XC_046R[==[8?IN]K7,H5J0,W&240&J81S[?12C_`)]Q`,\M?#V>
M?]?#_P#L8Q48K]D*<]A,0BE8ALLIOK+Q3;66MNC;NVC@TCDN1B^K/JZBQ;UZ
MV^PSU$0:J-,Z[-IR8E.%]U5TFX)4F@\VZK.U)8UM2ZM<JA^YO9%3\EQ'"ME6
M8@5,-[3QW,[8ZE=TUU=0H7!K7G=55!:!FX1(A/2D;86^1+Z/%I62F;TU4PXU
M$Q.YW[,L)A!!(M5>RH`.8`.668:P'+,!\X#EF&8<`Y#PQ09Y)1RFFE`>(9@`
M?4(Q3=*?*2=*7MANE/E).E+VPW2GRDG2E[8;I3Y23I2]L-TI\I)TI>V&Z4^4
MDZ4O;#=*?*2=*7MANE/E).E+VPW2GRDG2E[8;I3Y23I2]L-TI\I)TI>V&Z4^
M4DZ4O;#=*?*2=*7MANE/E).E+VPW2GRDG2E[8;I3Y23I2]L-TI\I)TI>V&Z4
M^4DZ4O;#=*?*2=*7MANE/E).E+VPW2GRDG2E[8;I3Y23I2]L-TI\I)TI>V&Z
M4^4DZ4O;#=*?*2=*7MANE/E).E+VPW2GRDG2E[8;I3Y23I2]L-TI\I)TI>V&
MZ4^4DZ4O;#=*?*2=*7MANE/E).E+VPW2GRDG2E[8;I3Y23I2]L-TI\I)TI>V
M&Z4^4DZ4O;#=*?*2=*7MANE/E).E+VPW2GRDG2E[8;I3Y23I2]L-TI\I)TI>
MV&Z4^4DZ4O;#=*?*2=*7MANE/E).E+VPW2GRDG2E[8;I3Y23I2]L-TI\I)TI
M>V&Z4^4DZ4O;#=*?*2=*7MANE/E).E+VPW2GRDG2E[8;I3Y23I2]L-TI\I)T
MI>V&Z4^4DZ4O;&C+^5?"`XE,(P@("'Q%W*X!`?\`O'1`\WU@(?I`8U3(0A"$
M3UV++]\GP)?TH[4_WT,?56DJ4]I+^V2?-E_A2\0?7'+=*?*2=*7MANE/E).E
M+VPW2GRDG2E[8;I3Y23I2]L-TI\I)TI>V&Z4^4DZ4O;#=*8\$\G2E[8Q+[-E
M<I^6RP"OM18CK*,J9SO^SUO'@Y)L,Z3C"6DNW[]N$CMUWFVMAR<DM5IW07BR
M>:E-RH+J+&D>9(+*]<*.^=)-JTH&;!\[36(1V7LJ7CQ`NG&,8LHD8>CEHCE\
M-BZMK@!4K#5$[XYT)'EM:DH14].ZBV]-903$U63JR;\7!"0V@(E(H4=2A3J[
M+P``!D`9`&H`#@`.*,/N,_`'=O$I=%]KR>N,PZ7<2?A[5L/MWUMTN5KW9P(W
M1LV[E]6=#]L>3;K64I5X+AI:U14%LF6=[&,O!1(5K>7,,.2V*@FTVN/;'4^Z
MK^<+$*.5JR8:75LCS/V2I34*QU1FN25>#;4&_=!0LK1;VCTR*805?$@S&[<N
MC<"9V4#I1F*;@8,[8F-$TI;.9@0`0``$<QRUCEEF/G'+S9CKR\T=8<0T91K?
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M=0T5;/-]&ZM*=U&CO^59IY%.Q(81Z1`F6)4AL7<G.F5H4Z$@Y7(1I@$9:4LL
MHB$U2<0$0S`9YN,8U5H0A"$3RV+:E3K;))@5HUJ<E6E4Q0VIDJ4JDLL].I**
MUKEGDF`99Y1RURS`(#YPCZGLC5;.TE\GT;YLO_5I3B#_`,*.6BK9YOHW5I3N
MH:*MGF^C=6E.ZAHJV>;Z-U:4[J&BK9YOHW5I3NH:*MGF^C=6E.ZAHJV>;Z-U
M:4[J.=-L-RE4DJTD)(IU:4\E2G4D3RLL].I3F">2>28*0#+/),`32S`(#+,`
M"`@(1#;%5;O&V)\I<;!!=JR:4[I4VBE.BS>*UJOQU62=LI.M/42W(W'7;)Q(
M=Q;0O@E0KFDU04TXH]V@Y4RJ6!39)5<(4G#5M%AQMWLIKV>J$Z<=5U,(=O66
MT3U!8)VAP1H%Y5(]<)7*#5J)E.YE[;V*Y)6H,9-.;@L56`QK?HYAR*-`J4<C
MU,M>58;"_E"#4'']8\/ZX0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$
M(0A"$(0A"-&/\J__`'2F$;^8NY7^(Z'&J7"$(0B>NQ9?OE&!+^E':G^^ACZK
M,GS)?Y,O]@1RA"$(0B$FR#I%_%S#([T[#PI773W=74V]*XI,/KDM8S<12E;T
M5`9'DEV#=M[DQ6M.WKHFB<Y>9'//(K1IU4RBM)[=5$1Y'FXLD(J[%Y=7'/=)
M3=U7%!8ZXN'VVC.L-AL83%;F(5_L]X8A[I7;:"6[T:]E]W`B-!75Q8S3>TQ=
MI)91.6S50PY'(@+#N)TR==76BP9A8_`R:+$Z4]<U7HEJ%,-M4K5ZDE&C3ES`
M-M4JU)I:=.7;"$H33S2@,PA*`YB`"^%%OA`%-WI?"IJ,QB4ONDF[S4)9Y:<U
M<*6VW0:,M2>2G-5"7<Y:D\M,9@GFEE']X0A"$(0A"$(0A"$(0A"$(0A"$(0A
M"$(0A"$(0A"$(0A"$(1HQ_E7_P"Z4PC?S%W*_P`1T.-4N$(0A$]=BR_?*,"7
M]*.U/]]#'U69/F2_R9?[`CE"$(0A&(+9EDBVMYL(KVP[K#-P\7W>#E<EIW!+
MA^OOBBJ88VZX$5'?I!:TD<#W;#R:3^2$E`WG,+2>"&<I[_*B9029Y3I2H>+#
M!G8`<)88:7YBV642RV#7#>U[A-6PA":T>%W%W<?&$KF5YE*]XZM>XCN=MP'B
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MVLVVR`,P&/"WT</-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=0WT</-KWVG]U#?1
MP\VO?:?W4-]'#S:]]I_=0WT</-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=0WT</
M-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=0WT</-KWVG]U#?1P\VO?:?W4-]'#S:
M]]I_=0WT</-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=0WT</-KWVG]U#?1P\VO?
M:?W4-]'#S:]]I_=0WT</-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=0WT</-KWVG
M]U#?1P\VO?:?W4-]'#S:]]I_=0WT</-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=
M0WT</-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=0WT</-KWVG]U#?1P\VO?:?W4-
M]'#S:]]I_=0WT</-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=0WT</-KWVG]U#?1
MP\VO?:?W4-]'#S:]]I_=0WT</-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=0WT</
M-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=0WT</-KWVG]U#?1P\VO?:?W4-]'#S:
M]]I_=0WT</-KWVG]U#?1P\VO?:?W4-]'#S:]]I_=1H^?E6-<W7Q'X1ISA/X%
M5^(JY(C2^$TC60_&4DRY;I1EEE'Y$E.?/++]LVGSJ<PCJL0A"$(GCL6TT\FR
M1X%9J=/=:DN**U(R4MN%/;COW\W;S9RRZLQS'5JCZF\BHX=I+Y-?P9?^NT_B
M#_PHY;Z.'FU[[3^ZAOHX>;7OM/[J&^CAYM>^T_NH;Z.'FU[[3^ZAOHX>;7OM
M/[J&^CAYM>^T_NH_2DI+T]6E)4;VY4YJDDM2IOP1GW.2:8`GJ;26F$T^TE$9
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MA"$(0A"$(0A"$(T8_P`J_P#W2F$;^8NY7^(Z'&J7"$(0B>NQ9?OE&!+^E':G
M^^ACZK,GS)?Y,O\`8$<H0A"$(Q4XW\:VQ@;&*^2^([%B[K<VOOA=YMIC)17`
M39BL^[[/5DLBN9`JBHJ>U$9?>A1@-TZO':YNN`([/HK*I5$X9KK9VG3JR*PO
M;('@\QDV;0K\X;[WM:XMLE][)UM:*L4+K**J)-Q%8X4(I[)=#6<"8E.=JN4\
M94$\22>X$A/F4"BDFJ9"H:3%(D=KS+`0$`$-8"`"`_4/!$0<6F,E@X2:5F*#
MH0G&[EV]U^[)V+;R$UI"<U=%GO)=1HVJIW`=)DY5IT4AD-9;>:)143@A5-JB
MNIHS<1R]=359)B_H9G9`+?T;KJK1HM)P&[7(&)QK8+5R]5`^E3()#$X[FZGK
MB<RP;(33+M9J%%E?:=L%5]S5*%&A=IUI;3)(2BE$7"Z$:?0#F`"&>0@`AF&0
MZ]>L!U@/U#P16$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"-&
M/\J__=*81OYB[E?XCH<:I<(0A")Z[%E^^48$OZ4=J?[Z&/JLR?,E_DR_V!'*
M$(0A"-?_`!X8@V]L>F*5V8F;X;'A>/%U;*[[`MRUFOB/P^6P:M\;@V3J,<DO
MIJO9%YM)TJ2>I,.WRTKJ0W$;KK0U(DWW2Y7JY$=9*5%E!)5C=NL$-@6[L@6+
ME,V2VIA8O=@4L+;ZJVS%LK`W$04FT;AQ;7Q:9"X:2AXK+]V>:]>5*(T[,MVX
M2HSK('%??ES.HX?.NDZOTF\VFTEGMD0```"4-0```'U``9!PY\'UQA"V2+8\
ML4F(9>3WS8G%)<1)JK6*+`P^CUL:C,PYUV[;AE8?[TL5U*SQ:SI?;!./!5K6
MZ$@Z+QHK#57&J([H>YY41C:$MI:R"*'2',"E\I'.Z;`%D"4Y:9V[+4P-DDJ7
MQ,*S>D32]N4%X,[$8X[='4&BL%W2%UJ^(-@2,TE0)-70RM;5UDW727"ZBDJB
M`5SL2Y@`9Y9^?+@S'6.6>O+/@SUY1U1U%)J%;=Z]93DG"26GM2BPJD:6UE&8
M0'<"9RA1&<1F';5!DV\P;4)IA"64`\/1=-^D+GM(O^)0T73?I"Y[2+_B4-%T
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M/5-5R4>8,JIVO7J2ZZDV82S``@$H"`A)+EJKPA"$(GEL6U.6KLDF!6E.,X2U
M,4-J99AIU*E&H`"M9YR5:4TE6G-JU3TYY)P\TP1]3J1KINTE_P"$+GS9?^TB
M_P`0?_4HY:+IOTA<]I%_Q*&BZ;](7/:1?\2AHNF_2%SVD7_$H:+IOTA<]I%_
MQ*&BZ;](7/:1?\2AHNF_2%SVD7_$HYTVVGTJE.K*86AFISR5)0G<*Y4D&:28
M)I0GIU%":G4D$0`)J=26:2>7.6>6:41`<4.R98EMDVLR:9S4P)X2K5OQ">,I
M4D[,5=X;B+:E;RP1@W.<D,JKSL+;)"/7B<[?32E"4[7=+<G5DE+K5"XJJ`9*
M2&)@]#V'6WF*$4JZ.(_%=CW3L:-P,0"8AE"K?:Z(D-6V%F"=IKFWF:)DK:-O
MH)JB0G:#UJ5RYPPNF6NU5M2-(92FM$S)LL,Q;-S"$(0A"$(0A"$(0A"$(0A"
M$(0A"$(0A"$(0A"$(0A"$(0A"$(1HQ_E7_[I3"-_,7<K_$=#C5+A"$(1/78L
MOWRC`E_2CM3_`'T,?59D^9+_`"9?[`CE"$(0A$8<7>+FS.":S2A?"^)YT46J
M6<+99Z2D,9EN.X;X=;R>:G*CM=J-!G-4D>65M=6#DU24O0H4Z5&C0+F39LT7
M+T)Z@11P!8S<(.->ZU_[CX>K,7=MS<U/:MHTV[KSN[8%R6)6[@(<RI<R:WA;
MRFD)GWU.U3-)YA,JSDC$R*77"Z<*E/*:D)%<ID4&8`'(1#/4'ZQX`^K/S<?F
MAF&>689\7UY9Y?IRUY<.6O@BL(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$
M(0A"$(0A"$(T8_RK_P#=*81OYB[E?XCH<:I<(0A")Z[%E^^48$OZ4=J?[Z&/
MJLR?,E_DR_V!'*$(0A",7FR_R68JX+')3OI>;$O8QHR7(M`II3SP<$U\[B=K
M/=N/U+=#,0K.@V$!S+95RJ:TBT:AI2)(];>M`)+*@8-)I8O54BD$=@IN%8][
M.[$K+9'$ELM&)Y+T)L0N*3NV3<RZ%I-;U)>/72,(*?8]9=:0WCE*BY$J25?=
MM`FF&TI5(TFDJDE>L-(R6H;&,8GMD)M6_P!9<]H'+8N_M\F7BK7[SV32['--
MJW/=:99]-MNTW\VU?$@J78L@CJ-"WMQ+;?%,8>1U]N^Y+:7UA.7C=MF<R%YO
MN!7;"6M0].8E[R3.!_XEIWN\:;H:^S>VXP!H-L2[@6Z;"DPVG[GV\PU*[5K6
M\%1T=4EM?IOQP8BZSV,(M1X`O2-L"RO(S6ZGD0V(I<\@S',<LA'++/+5GEYL
M^'+ZXZ<\KB1K[@"6KF_VN6?=B)'X10^4,P;3=-VD^7+M<YI=KJ":4<QSU>'I
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI
M&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(AI&/H)Q]5#^(C1\_*L3@G<1^$:
MJ)4X4SL5<H=S.T/@]4,[E)$F0R;>?7^U[<0S^94IS?P\@U5X0A"$3QV+:?<M
MDCP*U-I4J;3%%:F;:4I=O4G_`..\LI)<PVTVO/+,-0#'U.)'&.TE_P"(G'\V
M7_JH>(/_`)B.6D8^@G'U4/XB&D8^@G'U4/XB&D8^@G'U4/XB&D8^@G'U4/XB
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MU-)M?BCO/:IFFFHVJQ@T7;<S383G0DNFCJAP\I''$6HRTYW`:43-94JF)Y"?
MP7W,Y@PL6>O%/>:NBK$RI6N:C7T-LL%TV%LSM^V\Q:ML46]YIDC()&>XY!AS
M%4*52DKTT@R:2&\ZSR&:?#<0W.0E:`````!D`````<``&H`_5#(!X0`?U0R#
MB#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#
MB#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#
MB#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#
MB#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#
MB#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#
MB#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]00R#B#U!#(.(/4$,@X@]01HR
M?E7P`&)3"-D'_<7<K_$=$C5+A"$(1/78LOWRC`E_2CM3_?0Q]5B0`VDNH/FR
M^8.((Y9!Q!Z@AD'$'J"&0<0>H(9!Q!Z@AD'$'J"&0<0>H(9!Q!Z@C`#LDZML
MTJ+?M51\'Y'"$IX.'Q:IKI[E4\2MK[H7C+HC[&=UIS^0EUI672W,]BK#74`6
M\;,GU)@NEKA7!0!2540O,:HU;G;#LSL:#30;G#B*,;'(;LLL)3)4;!F=C-;]
M5LV:K+6_+\+74J.Q/K)2-1K.X0+LB0L932DY>F1IFB:A4IJU`T6HYL80A"$(
M0A"$>LKKT9[7K4"SE=;:;Q@U2GKE:"XO)236,T:<X4ZE6A24#9>I6I4Z@RR3
MU*<LTDLXA+-,$P@$='\;=J_SEV_]LVUXG#XV[5_G+M_[9MKQ.'QMVK_.7;_V
MS;7B</C;M7^<NW_MFVO$X?&W:O\`.7;_`-LVUXG#XV[5_G+M_P"V;:\3CRB-
MS;;J9PJG)UP&2H'SM>F6)D23L0#9PV9JCE2+EBQ=0J5S%>H.J2E2ISU)QU2R
MB,>\0A"$(0A"$(0A'XF#%`I0K&C5:D7+%J52N8,5ZDM*C0H49)JE:M5JSC+)
M3I4J<LT]2><0EDDEFFF$``1BUH7XLB(`(7>MF("`"`@^&V("`AF`@(*60@(:
MP$-0AKBOQ[V2_.];3VW;?B4/CWLE^=ZVGMNV_$H?'O9+\[UM/;=M^)0^/>R7
MYWK:>V[;\2A\>]DOSO6T]MVWXE#X][)?G>MI[;MOQ*/>V\YVX[4Z58:R\CN-
M)GK5BTJFAJ1-5(3&"TP2&*$ILC6KT!K4)Q"2M3"IMZ<P[6<`'5'>0A"$(0A"
M$(0A&C'^5?\`[I3"-_,7<K_$=#C5+A"$(1/78LOWRC`E_2CM3_?0Q]5F3YDO
M\F7^P(Y0A"$(1@:V0?8\,<F.[$C63S>*M]6TP!HEN6.FUL.MH;S&</KMN]<J
M8\YSS]47U<UJ69N4Y18%9.KM5%IMLU5.2'C!)1JD$Y!_^+*,RMC_`,%S%P,)
M3JM'9O"K8[#C:<ZC-5<!8M?<YY78>EQW[3/N<@N&[G.ZX#&9;N5C:,A2-^JB
M**H9<PF9EI9+43*.7(4")C(W`1``$1'(`UB(\`!QC$4C>,VQI.[]:SM59614
M"ES4*QA]ZR()N>VB??IS,F>XZ'9,V\]N!.2XA]D?`UD2-,M512)Q9;C44UTD
M]W*@ME0E8`@(`(#F`@`@(<`@.L!_7%80A"$(1ANV3&22:X-K]M3IS>1C@^=)
M),(9KY,1R&8!$`$=8AP".N,:FXT>1H_=4_\`+#<:/(T?NJ?^6&XT>1H_=4_\
ML-QH\C1^ZI_Y8;C1Y&C]U3_RPW&CR-'[JG_EB]6&^E2#$!9@0I4@$+CMG(0I
M2`(?\+'6`A*`@/UA&RC+P!^@/[(K"$(0A"$(0A"/4G]_T&>7_E1Q_P!S'8U;
M2X!\'+:@_P";T/,')21^V0<0>H(9!Q!Z@AD'$'J"&0<0>H(9!Q!Z@AD'$'J"
M,[&Q[_N=2'_G-Z?^ZI)G$X80A"$(0A"$(0C1C_*O_P!TIA&_F+N5_B.AQJEP
MA"$(GKL67[Y1@2_I1VI_OH8^JS)\R7^3+_8$<H0A"$(0A'&<!FDF```1&68`
M`>`1$!#(?JXXUW3^'"]Q=Q/O#+08[RJN-Y;-[;G'L0N@71EV5@_Z,*;<FWN)
MY6=9A_@FZ.EUI"-V\5,-\S!,K--WBX*K:-ET>9EK)!1C8CESR#,,ARS$,\\L
M]>6?GRX,_JCJCJ:<-5MUH+BFG2;263X.4I)4](9@&81J9G$XU6V\P"`3`%4)
M,I9=K)*.V&;P]Y5+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<
M('@L-Y5+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<('@L6-NQA8MY>M21U:X*H
M\%$ZA$#*:G5$]6(I,E,H;-2G*\M6F229)*T\U>209:DX#/)(&TE$)1$(M1^Q
MWX?/X[_]K`\,A^QWX?/X[_\`:P/#(?L=^'S^._\`VL#PR'['?A\_CO\`]K`\
M,A^QWX?/X[_]K`\,A^QWX?/X[_\`:P/#([]JX%+),QRH+N0#+Y+K;:52BTDU
MS#DHFZ%(^1J;H7J5BM=+FHF*<LWSJ-649)PU3`(1*K>11#_M4N?<('@L-Y5+
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MCO\`]K`\,A^QWX?/X[_]K`\,A^QWX?/X[_\`:P/#(?L=^'S^._\`VL#PR'['
M?A\_CO\`]K`\,A^QWX?/X[_]K`\,B1-L[+(-HFO29S'77.00J)]04J=`Z92E
M,P!M3JRUC<PFC://6&2:I*`TZ8CM*0",L@``C%P-Y5+G4N?<('@L-Y5+G4N?
M<('@L-Y5+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<('@L-Y5
M+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<('
M@L-Y5+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<('@L-Y5+G4N?<('@L8Y,;.Q
M)X5-D"=K%>V(^O=597K=-I7:;:K-)^BRRU)(7%B@N'Y#I5(1]R/&9CQ:B-(S
M5`)Z-&0:,@;6:81A3_JRFQC^CL0/]>*QX/#_`%938Q_1V('^O%8\'A_JRFQC
M^CL0/]>*QX/#_5E-C']'8@?Z\5CP>'^K*;&/Z.Q`_P!>*QX/#_5E-C']'8@?
MZ\5CP>+F67_)[]CYL)=RVM[;=EKXE'Y:=YHC]9YI6N\H+*87<+>,_"DVJH))
MM'^"J126K_RQ,Q^U5Y?DSZHS2`B*(```ZES(``/^00/-_P#98KO*I<ZES[A`
M\%AO*I<ZES[A`\%AO*I<ZES[A`\%AO*I<ZES[A`\%AO*I<ZES[A`\%AO*I<Z
MES[A`\%CG31U"2I3GF<ZU5EDGDGFI3T$,)*LLLP334YQIH\E0)*@`,DPTYY)
MPE$1DGEFRF#OX0A%,@SSR#/C^O++/].6K/ARU<$5A"$(0CP%0_(EIQY2G+'C
MDA$K7-S%$PG64%$S+0IS5!H$2)<)JYPU4"7:4"U&6:K7J#+3IRS3S``VCP]X
M@[6XH[0L^^UEEI1<MKW^4-J+/<*BV7(TS"TG$E`VE5STC?=:6C.,C1WP('2M
M.552B!BK.6J3TZ$U$:=2>YP.=NBXIVB"XE"Z::)3<E1N@>+BM4V_54*B526:
MB8%03<B954Z-9/I'9Z04*IRC6+4YYJM&I))W>WERS^5EGED,LP39_5*(;8>/
M4'!KX-<=+.YF](XB[1G6TN1TFD4TXRS=F/%P6JR`1/DDHXLTTP:GPR9,*J2D
M03ZYT*7P>F<.%RTU0*U262+$J&+&RZ1B9;>$-75W,DWU>C#<US&4WE5@/=-;
M;T93,G2J#M5&E<@Z@T+<.$\VC:XCEEULI;J,NQ)!3)GCZ$72JTJA'?6CQ'6G
MO8SFB_&2N*5%N7`<C@:K`KO%L.2WR@^E1L%EP\K56>B/9+0EEQHXIS9<2RE.
M!)(F4-PMU&.NEO*"HV=P5Z]\MO+K'Y6KA^1-K^L/D_*#ZY<PBFWE^OAR^;,'
MZQS#5*/FF'Y(^81BNV#/+7GF(:Y9@#,/K$,M?FUZ^$,X;>4<]4VH,]<DX>K.
M4,Q^H,Q'BBH"$P9AG^L!E']8"`"'ZP"*PA"$(0A"$6GO'>ZVUAFPGNJY:_.D
M$UUSH;':B4GI:LXW6^'TYJM:BW&.Q6@W22HY7B[EN8L;JD4%OIA\]\!(J2L:
MD+)"6IGRD<WIL@U@[;DUL;B%;JL==;BI8E-6VHY[2O-,7"E'$A>0E8:TZT6K
MU",S:6F^M7,/ED!66&^XU8LU*U2GI1O36,%"YB<(5)1`1^5D$TTN6UF$<Y)A
ME'*4`&80S#,!`!`0R$-0Q7;AK^<.67!+,/#Q9`.?UY9Y>?*`S`&>>VU9<$LP
MB.?$``(C]>6>7GRBRF(_$#;S"Q8RY^(>[%=<*VWM"TE![/4TW&^HNA9)MU*W
M,5`Z40DN2<\=`G2J"8,A3"64N5I5S5>I2H4*M27P,16)6U6%:S;FO]>@ZZD6
MU#(3=_'JYFQ;U]7)K--NTZ'P@XY5QO6Y;[I<Q=N)-']O7%RDCUTU")A545<P
M23"YDY1Y)&)*U:]<AGVJ1E!?5'6][1%+ZI%9-9[G46D4M>H&)B28XW$_2"89
M9#8G63TE4HWD9>7R"XY9RBF8;J<J$499-I]XD)P(CH1$9RMQ5(KK><26GKB"
MMI)FFH)2PC*Q2D?2U5./EIJA8XG*)*O0.$CM"I.7-%:U*O1J3TJDLP]L,\H:
MAS\X?-FX0\V>668_P0_A?P<X#/*``/RM89AE).(ZO-D$N8#_`+(AMM0ZM0Y!
MGE#^,/GU23S!ZPE$/U<,`F`1&77F'^S,`?JF$-J(_4`B,<H0A"$(]/N!<!DV
MI9#KN3<ATH;)83&0%1TN]W.51+I*"W&\BE*AY45U91-3R4"A(D5HU*M:K/-G
MD`24Y9ZL\DDUC6EBXMFZ7=;QE&4"[S*6+O5ENG:NI<2S-QV2FO@&\U55[*E,
MHHK2!1+MU3I-5%45PNVWV+1=9\@3-U2"`9^!'P*2@">4>#;<?S)P^O5G*&?Z
M`UYYAP@,4&I*&6>>O++Y,W".H`$1``E$1U`$PAK$`\\61PY8AK;8I[0-B^-I
M#BP>83N.O%/1C2^@J#:59S+%?+FMVX*9Q%5)*9XA.7<K26:%.B;DI&)R]*D8
MGHT@K!)+>_;RY".L``<AS`0'].0@`Y?6&K4/$,6`LCB6MKB";USW);<7.>*6
MCN_=2QCP)JS74T-8I7$LXMBWGHE)Z2H2TSA\O250^#I1Z22G16)!D,$PF+U:
M52?LL/6(BUF*2UB->BS"PK."W3A4G,DHJVK-1SL\R?.LUR*S.<M.5!=R2BN`
ML"4ZD%;0JTQY,*[J=2S0E@KEMQ,5KV[>4>/@S^;-^L`U:Y@\\H9S`.H0`8IM
MY?\`:\W\"?S^?YOS0\\WS0'4(@,<ML&>UUY_R9LNEEM0'ZL\_JB-K\Q3VV8%
MY)+!GD]^KMTC>'FZ&)A&;328ZRXJCDM[:1Q-%J.H@VS1264LMOF=??353D=E
M$9ZBRJ5E@I-3DITZM.:>^K:7Z;E;B`XY$Q<0Z;@1$E;D1W,DF4-PI$BLGEU"
M5,<".:#X0CK1"4P!162S0A73S]$P4K?ME*;.J*YVZXY569OK:6MRH:VI-M8%
M).T%`$QP(U22BK(IX2L]7X,J)E:I)14"-3:F"=8=R,24Z@#*'>YAEGYHX;I+
MEG\KARU23B/FUY!+GEKX<LL\PSS`0BRK*Q!VU?\`>B]U@VXH*=>XV'Q/M4J7
M)(&D10(II$I>9%<+@8M1)63%.4BO?#DUKJU0Z*9/6E3:]&4F:GE-334J=Z]O
M*``/RM>K())Q']<H2[8/TB`!P#P#%=L&>6O@SSR'+C^=EM>#ZX!,$V>6>KC`
M0_6&8!F'UAF'UQ6$(0A"$(0A"$=>JJ)1(33JJ?GJ4R2<6JGC<]$L9.59"Y67
M=JTU(H2HF#9FI+3DF&0N5H5C%:8`DHTIYYI91U2\*ME+BJ-H=A:M5=*W^(QN
MVQ1\-VR,-G%!;\PBWX8+<2SRLFHU6VR#>IN)%!"D1UI6J''#68)9T%B"\I&Y
MC!=LU#$U:<L8MA9QI7\9UJW3?Z[MBL;#OO2X?R>[#.QU!=9R3>%DWR6K[6O>
M^)IKWN9TMRC[-<YBWU]$1EN>VZF:JJK<4[H*!.O6==O&R]7A(:`U<NW+JNTP
M%Q;3KG6[OTL8$T/91G0MW::K/L!B<!N4\.]U-CVM>9L"X&3;.NFN2Y3@PU$L
M7P.E;?#<0`7*"0\U%(>3^:Z"3/&$RC-S#%80Q;_9*+-OJ9@XH5&WM38MVA;"
MVMT[^DK@O%YZ1LK$E<E;KH%YW_4*3IR#<4+4.IKJ,J/=,PDNXZ0-ETN>BIN]
M%6J!2[6R/VA6L==4[AVM"44[<W6PUE)\1#>Q)O%BW.1&>VKC4FZXV\T[1LIW
M)J<@E;C(%W$=27F1BC3&8XUN@BV+<*@U3R;6=[Y;9EM1@5G<XL5SWV%7%.M8
M0\0-K:%KG9B1;=Y[+5+-W*0E[#]<97PMK2&U&L:;]1"1*16VRA<IOI25;>Z2
MJ03;6J2)7:]1;7T%/4CB?1QCG)L3CDPWXRR]M6)C;9YR[NQLX/WPQFX5;>+2
MM=0,3C9Q97M3[OISON4>;384;FXHD=J*[+2KWNILM=CH+_)I]`DCL]>MTT2*
MS7F-?>UMS6=<['0Y+2M/$Q\#MCCYV+BZ>%"NAE,0+C3B22^%ZP$N-IYVY+5)
M50N[&^N-@K=`O?RL-)P-PJ2F==)QE21E75!4?6[$M9U."_BJ_;3NC$&KX@K4
M;-_C#;;X/U7I?IV,9*V/]&775->IC.A.5%=5MR=94B-6;X6]2BA4^\*%YZ3$
M363+34$\X0)=B%8P%J;[X@#UJ,9S<JW,,64M3:##,AI^+1JG+%84&YB1M,2<
MEW<51L6BZ%ARW4O"!^9_XD6DQ4=VW6)X;4H]89J'T8W+=M]1ELV(Z:X9##A=
M!GW(3+A(RDP\9N-5MM1+N"QK@V_$A:BOB1N`XK.%62@7&G/*Y6VE&V2ZV08*
M<27W,E-MM3)[6+K-2HBU2Q;*5"$(0A"$(1BDV05D/I$Q);'%B])-AX7!LYA/
MO/>FI?%G,!N*[W=S=0;]V$<UG6O?=,8:"34G"[R-GW"J_!G:1::4KNU'8K[<
M[L2TLZ1;ZQ0FMSLHBZ3Q'8,E=+LXR+GO:8QB!P$'9'6P[>/G?8TAMW')8A^O
M>5ISIR%3>=>@PF.TUY_.9RI25*WFF62_A<ZU372!@J0Q\N`C=VV-QKVL9XM[
M$8G8!J&R,XHT);F(V7O??H@U6-=?!_AS6+/OA!9B:G+K_<U@YL25?$\5+NZW
M]!Q-BWU[7"WEZ61%HD4Y91+M7AP=XIZS?LY:VSEPL4[N)8N\%Q/#B[;UWL7U
MI/N#A^O5AR-D[MX=\5%XRS96D>HAO!XL25VVQN>22RZ:NW%=Z3:ULW3IJA@T
MZ:<W9W/=&(-?M5A@Q1WLM/=2UUK<1ERS9K&?:%NVLN)?A9L@TT[#DMVXL:2=
MUE&C367`H6P2+K)RPZ7A79S?,5D9>N`Q'2YBQ@FT:2JA0GQC6XN86PKXN,.%
MSD3'!B$)JVQ;6\0]CM=UP;=WG>MQ'F]$Y9N\;O$2N07MT@F4UL8D#L]6RQ8\
MGW#)IC_7[$DT-$<M8^>ENZFU]GF^EYDBUMER2^8MN]KGJ3U+(3/:=LT>W;T7
M3CD<#T+%DI,27Z0(-)=K6[8]$5#=+EO!]I!%`8K7HK9]Q2#5)[UFL*%@['7-
MPIM_'%L7RW;-WW';%RL+KON%A>ONS+?W.-L*NGO&U[P:![!`Y;FJX*:2TCE@
MEHC3(X9&VJO2C)7P_.1N-Z6>@[&\LU%Z#KFIW49UC,&;:MU9'&`Q7_8+"CL1
M;GE.'+8XFCTY%51L7S%3,7:;:ZW:$T2%"V[P:K2370GXFE^X9Q?<-S+8++"8
MK&M@-O*!YYG[_LRT%U%&ZEKEM?0,59F1P[.!C89;Q47`;Q'5:$N`"XEK+SUT
M5,7:JU7GH)>&]X/,E9VFG+:F!=LUU44<FD+162A4H%K1,!KHBLY<`=E\7YS%
M(AVMJ6GV;YF."W9AQXIVLZ%"VEKL9-IYL)TLS=:YXB^E2DW;).E"^)YS?!3*
MDIIYAD)I!95#4C>38O<VVK>Q[-S!)9C%DBXH&Z\K98>[$W,QP7X2T'$RI7$N
MNILP%(W:#"1:YQ6V(G$D;E/`"J>NXV'\U5"A6II8T[>3KAQS7.559E77PN.&
MZAK91F:[)+?XE&.RWBO[*S;>[=.XC7O>XY3+K;%\+"K5@JMSKF'T!.LY5:BB
MQT5^.3"P@LLB89EK;.+*>R4RZ3Y<R^NTPV0X0A"$(QM[++9.YU^L$KZ:-I&T
M;N`[6Q<?#Q>:I:@D9(DS=XVQ83$#;6\SSM,1,*A@LF;[OMJLA51V^45*M-+5
M'%.DI"G6+$C]8U1[B[&(5KWUPRW@JV8;EW51U';$WI54X9+87+MZ_;:.>>T[
MQ+HQ,Z1<J"U'JV+J55L^7:R.UFW0JW&IK*A7G(D*:<6/*-/$[9NUSGP^4MB(
MN@+8Q5"W[O8<[Q(6-0JM'<2]QEQ:Q,O3"-8=L-1'NLPG,IKZJQE=2=ULGVE)
MM)00&DRT!]2*%6:HAK[JIF5>W^%*KBE)(>Q=*3V0;L7&=A&RV`QH7\M->YB8
MD[:WTMRX2#B=Q-[7UM;>\X5K-%ZHJ#1<-5<QCV6O(AAI.UF*TW(F7")'S5O4
M=;L':2T^,"TMA\+I_#7;[$<T\0KEPO;-PU'>G&D.[B`2HNTY=ISW2P@MUTI3
MK+$&8PEE863RNMX?SBZ4;?PM=<1DTFGJI9P+TY^6%<R=2+>I]Z+4&L;[KPIW
M'Q=X4SN,RTCDP\7BM'2M9:EO6^N8W+F%K>6,,MZC>=3)F[J26'/8W]$R#D9+
MR14MUJ94'#4/W?$W/K8BV\+`M'C'"JR[@,-H&MD8QJ/QBEWZQKA-$^KVO=%R
M2[B:#H02;]1DYQ+C:5$6<:B,?+T3E,"]`$NG-2K$A)4,9&%FSC]4F/L/#!N(
MP,1;=MX5NELJ1+$TR#")?NW[:)L.X![$.XK84+VMA/+H!),27@HN9J&V89>1
M$F96:BL53D<S6+GSY&O8UFL7%,B88[!*8MS&.5O%<K8=]DNMQ?@]5)8D9'X=
MO2PCMLRN"=I.JL%.FK-NZ::73GHGV9HT]YWPO)IAP4BII:+N$].J>R7QLM>\
MK:G%W.P6GBT-NTGL06">]%I=ZY,1B@L*6R/M$U=9'6'2V99!J&%7$@W$0C9L
MBY6ZF!.K)Z8*=3<+=EH2*`TIN':%[;C8S[GEUMQ8EF7B#8N(E8NYA"-M2RKW
M)62NWAH6L/"*GL)EW)ON=;]6VR98`D[%%;*WYL\XSJ)<8A=A((.5L)(O)2:B
MJ>@BWTVX+I)H#^9EJL8:1B+DV`W9`+/8A7.OVQQ)I=Q*./4\L8>%PTA&GB=1
M):9J[SHN.@/P\Q%]E+-:JZT0FSR+(4SK9*,9/*W(?;AOP%\\)*P1MUB\275:
M=[;#1,\W8=:%^'H54[1.IN.M"Q$5&02:K6*(%LF(E*;B.LK$\@.8P^G]<-^B
MGSO9M,)ML%FK2O\`FU;=7#L(@'6F^K7W[8V&M<V1K92B6)XVCX>;T7?&@F78
MN4^'+@MNA5:+=1E9SW`L^;:*ZK4T^X]L*3K1F3<5SVY6W/72U])!70<I]9HX
MVF1A0F9+>=II_P!D6[@C>;?D>-XY;H4-D:=+V)V.>I5J*JQ*PZ11J27%/N@&
M5NF4E.Y4U43^^F5P9IXQ;T;-N5AV5P>M>Y?^FBR;-8H<!Q`;R/UIL/$[B"O/
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MW%,DLH#@2DU;1%=.K2F""HCJY*@I):B2,2?(K%#Q`U0-E:LOR:A>M)4E^3-'
M;YR\.VX0$?G#EEPYAKRX,AS#S"`\`A#*4<@'(>(!UCP:PR'7P:Q#]<6K.WIM
MBFWH;N'HVYI:-WW;;1VW?;[0%,7)YU*W3$<S19[L<=-;D3IV[3D17&_&DEF$
MZNKTEB:9;*UJ"?5)RUJ]*Z><@ZL\^#5F(YY\&K/6`Y#Q@(`/"&<62L?AVM9A
MW(W!3[6)*LDEKI76?-[GOONZ7(ZJRQ<^Y:C(KOESTS+E4U2NF"X%.24[62$J
MH30B5;,$M,(4YYZ<U[QE`0R'/I39_J'/,!^L-<```X`R_P#[_P!@X@X`\T5A
M"$(0A"$(H(`.H?\`^^L.(>(0UA'&;:R2C,.V$)0$1R">><0#,<@"7;5)QX=K
M*`3"(B$LH"(@$69LGB$LOB.0'2Y;+/\`1G\D,>X;LM,\ZR2"D5-M*Y;%-4"3
MN8[C3%<DF*Z&YD`P:*R**4HD2QFE(:+U@EG+F*52?U1BXNL/UT$=M..V;X,W
M%;;KO&X["(KE83,?KN;0W-:%)W3.A*4G`A-<ZCH:$@&6.XTA6?*R<(L(DX2I
M%MU7,"ZM(B>H21SD$`#,`#+,-8RCPY:AU"`YCM1RUYCD.L<H#M.',```X0F$
M-6?".0AJ`=8"/`(Y@(9Z^0C+KS'++A'/(`U9ZQS#S:_T:_/%I+Z7TM9ALM4\
M+VWH=`,VV3#)D3[K<LR0O+TJ444EA.0"=>=);28L+1FG45E4@4GF*)U>4MN_
MP@W,7*4JYBE=C*F.L.$!VO"(?*#ZM6<VK4.68AF`"(",5SD\TW%P3#P9B`<`
M\&8"'ZAXHLFY,/=KG;?:VF)!;35@S=FT+*?]OF`M4G6Y2B2BM&ZAMM';@)E1
MI%52DU5:9T&V6SJQM25T@\IEIVPC@F'24M"K+6O=D'FSR#5J$?-J\PQ0)90'
M,`U_I'^S/+(!U@'``YB``(C'*$(0A"'#PQ0)0#@S_6(CEGQ9B.0?4&00&4!R
MS\WUCY^$!UZP'S@.8#JS#4$-J&H=>KC$1#S<(9Y"(99@(@(@.OAAD'UC^D1$
M/4(Y13:2Y99?KS'/S\`YYAEF.60AD&H,HL@_,1EG[;NR9@N%S'3K\I-07X>8
MS):3VN8]4ACS*-=(H/1P-.V[<=KA;K0.*Q4ZEI[E7$Y/1E)2(*1%..&S2<?I
M%[@,&X#&NHS6Y<2VSO;K[8CO3*"TUW>TUDDO-U?2C.VW(\E*Z;7,$CI>::2I
M3FGHU9AI5J5:A6EIUZ-6G)[?JX_-G\X>#CX>#ZX?)SRSU\'SAX<L\N'ARUY<
M.6O@BGR,\\PS`!$=8Y#ED`S99Y"(9``S9"(:@S\T6D;-\[6.Z\-T;"-]RSG;
MK6:;-M7A<9KSHKC(@@-N[TSOEMXJ45I12BC?6RSAJ,)VTJ0-U55IDZLBFBRI
M*0,34J-2[?R!'A#BUS><.'5GPY#E-JS$-4VK5`=IEKR`-8Y@(RB&0ZQS`0&7
M6/RM8:Q$!X1SYY:LN`.#5J__`,B@R@.6>>KSYB`_6&8#F(#D&8".0Y!F&J`R
M@.H0S#5J\VK@U<`99:A#@&*;275J'5]8Z_TCGF(^<!',0'6&O7%=J&>>O@RU
MB(A^G(1RS'7F.68YCKUC`)0ESR\_UB/Z@S$<@#S`&0!KR`,XK"$(0A"$(0A"
M$(XS@(AJ'(0FD']4L\HS!JXY0$,O/G&$W8UGVU<-=KL0&&;$ZL2-S$XV,5N+
MFXMPR;I2S19=Q'(-][^W!N?;&[]IR-0M/7O(@O6V+F9[6DHLBBNJ#:7VZ<MN
MX4Q&74.9(DBY<K$`Y6YLE=FFG;MU7O8+<:F/2Q>&^X]LG$XWD2:*)9:X^QZO
M]7;+99UH6<CE[4MRP:W=4RQ)D2Y[Y4W5<!TXATIV)#*5V>T;=$"I^)^%ZXM]
MU>SV&RZ;%QM8B%.X;AMYLJ[3QGJ[SN+<'$&VK-6AMBK8C$K#U>U4M0;6#Y)K
M7%MC=]`M.C6\--LBWG[>1LK+S1JBF[T]O25V[*>VV(6]K6>6#5>N4N.=A,-O
M[(B_+*8@'O;K$7=:_F$6Y[4N#L>3B/6T.6I?[U+%W34M$OWWH,-,2&1<(5U8
MMCB;-K[$27<J*BB6$W&?#5=3%*Z?B-NR@U;HO_%&D[$QLTR1;0S<5+="J^5B
M[R1C=MF=P],I:%[DZ:B=<JDV&`G4FHB..H!Y91VS5R^$$$]0,4K\-RZ#K<]I
M'#=>P>/<7FAORX.%NE7M;B*2,35CK+MNZ+?:=UE"[EB[@8@%2X-Q[S6$N%=!
M*3DA5N42)TYFE:VZUNV33<K,D+W>6VNY,[>"1Z*UP\).'EX+K9NLSUE:M2TJ
MRFWKX+PNVZA`\6(2D#`O-XS%$^=[*ARH3%0IO>LGIQAY)YLBYS"<GUU:H3HR
MEA"$(0A"$(0A'"I-+))-//-+))(&VFFF$)9999?E3333"(`$LLH",PB(```(
MB.01K:LEI7D8U]JBMASHJZC9W9+9[YV9OR\6D.Z$\.%^K&7?N.:(XDU@P:.E
M*+?J7`PA&'DRZ*E2D$%ZY5L</8SR"6<0JM6W&%ERK5KVM@U:-GUYW6_MZJ;/
M7L@+0<S29YM>16\J8=5P]CC<MM$YWIQ6D7HJ-M%`_3LFJ-=06)`;RF;/L\\1
M,&:ZFFS5[>28@[HO+8VL5UXTK$)C`0-D.8N!V_Z#B?LTGFGXEH=I,7*3<A--
M(:DG-^LAS#;*XB<K4CK)L`V;7**<E/RR*L*D;;[F*):,Y2DFKRR.JV+JQ$6O
M,8A,4Z6R3F!"MB$V/JYM6]5SGHM/_%:Z';=IQ7636XM_#ZQJ[#]9RQ_HYEK5
MX;UJFY6W1MLZW`WV;;PRU%YV$"OI=S;U8LTVX#FH7,>1I4=SEL`LI[V2+%WK
MNC:ZY>#V^Q'8S'"^7PFO>S0`=MS<W"]/<RD9?#`Q#,E5;SNMI?YT-MF*1MU4
M$XE2)0"N^HW@?>`1_*+#OS?W$1;N]^PP8;[@XDZ#RN$[;Y$F=C<6;E8<I+?3
MLJ=P5G'1M_<!^V]4KPJ%Q+1L\FEI$A-CLEZ.-E%U!?E6'%.VZ]^+I67Q#8IV
M">O)=,C@O1,<^'6G<*Z#Q/WNNXA6GM=>C`,Z7$MK)A[M)]M6X+7L.N8NTEEE
M'H=:ER$-A6F<3@^`?!FPQ3SA0Y>S9R#B`=F("P-H".,'%1>5/:VQL7>O;:1W
MF''</#TF7XOG;K%XEK>',W<A#HK$\[M+J]KZ)=L*91[+JB=OC9\H>=;_`$Q5
M)*ZD)7H[.W9N7<?#I<>[;-QVKZ#<9=L7A::5[;27HM?B0:=MK%8L:-YV;0?*
M#?AV+-SG!<>R3MNL"B[[&7E2[-T62WV=;D4N^"0A(B2AH"BX\V.Q[/UR7$PO
M-9<=S3>K/<15[7E0%-.>=TU&^9<W50+P/=-IK%NKTK"8AK%U+**M"E2,60>R
MLBIBDK6K!J2G2]2N7G-F9LPA"$(0A"$(128!&40`<A$!`!XA$-0_JC#M8E7(
M86\>6R:+&)-6)L%)Q#OBP5[[&7>>YN5'9;XM&U,/C/M&HVM070>W-`H/"SMQ
MVB\#Q^V\BE(YJZ/<5(?*<B&BCE/'),9J0U<4-J\.Z_<JR2U?2W-R'IC<V17&
MM9O"V5JK[!+JVQZW)<2M+<9-?5ME(^W4=J73,)+CJW[PM(CFIE7`T\0KW9":
MK)!)KS77!$FY<]S7(J.G#I<#"Y<3$)<2P^R(8;RN$5JGEE^W4K&\/EVB;?-O
MEBXFE!)<K@*.5CO$_9A%O$4O`OUTE/>9.[%K;;2'Z9=PN5VUE#K[<W-7ES&G
M?&S]RKM8B6-B9LEBJ2:V&>SS>67T:8-Z<%8X9FZ08IEY$G`0<K%>EHG$_P!4
MN`YKY7@/F:=QV]>1I)J%3>J,?H,UKGX5';\8YD_#/:&[.&IRWRN!BR.8$,8*
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M9)>)U66#"AML-`%<&HV@<!VNI+LK?195I1-)!9`,GE8$PH"F<,(9,VH%$:N:
M/!7KUDHL>.ETVK4G)4#9FE0DK3^QPA"$(0A"$(0A"$(0A"/''YU7ZMR$/J&8
M1VPAQ;;S\?GC\:\TP5)`"80#=RX9`(@&6Z4]67!E&)78-*E2IL8MB:M2>>>I
M,]<6D\U2>:::>:<,8M_\IAG$1F&8,QRF$<PS'7K&,MPB(2S"`B`A4``$!RU#
M(`B'Z!$1'+C'/ACC2FF&K*`S"(95M0B(AJJY!JX-0:@X@U!%*<TPRRYS".=6
M0!S$1S#:".0Y\(9Z\N#/7'E4]=.01UB,DHB/G$1`!$1^L1X8YPA"$(0A"$(0
MA'C4A&8)!$1$=TJAF(B.H!FR#7Q9!EQ91^5.><0IYS3#F9FE'.8=<H2CE*.O
M@^K@BLTTP`8RFF#:A-M=8_)_;)@U:]6H`#5Y@"/TG$=K(.>L:>8CY\PFI``_
MI`)IM?\`M#QC$9,:\\\F#[%?/)--)/3PV7Y&2:6899I!EM$[II1DF`0&499@
M"8!`0$)@S#7KCT+8VYIOV.;`7/MIMM_H3X4IMMF.VVTUBV'MIL^'.;(,QSS'
M(,^`(FH,TV=;Y4WR9Z66L=68!GEKU9^?+A\\<Y)IAJT@$1$!+A,(9CD,PB&8
MB'`(CQCKCA+-,,D^<TVJ:D`:QU`-80$`X@$-0AYPU#JCR:7S/_5.'Z@GF``_
M4```<0``1^D(0A"$(0A"$(\>KJFU:OVJI-_ZI0^2/Z0S'(>$,]44$1`9``1`
M!H5)AR$=<WR1VP_7F(CGPZQXXP'VT?SZ<OY0YB"MDXWH[5^VUO<!%H'XP;?+
M;C6%5CL=\.E:-H+G>;/:9XY706RZW&A5JJ*O.)%($E=72:M1.4#A@G/-1'/>
M(C\)"7,=J(9C+F.0CM!'/+@SSU_IUQ4.&?ZI*N7U95)@#U```'$```:@C\I9
MIAEGSFF'*D$P9B(Y39\(:]0_7PQ^LPB$U/(1#.N,HY#EG*`392CEP@'F#@"/
CP&>?:4QVTV8SU0$=L.L`G```=>L``1``'@CL(0A"$(1__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g733520.jpg
<DESCRIPTION>G733520.JPG
<TEXT>
begin 644 g733520.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@!!1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]-14Y?0T].7T]865]+7TQ)3D4N15!3_]L`
M0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``"P@`[P*J`0$1`/_$`!X``0`"`@,!
M`0$````````````'"`8)`00%`P(*_\0`6!```00"`@`"!`<*#`,$"0('!0(#
M!`8!!P`("1$2$R%7%!47,5&7U!8:-4%Q=Y&GL=4B,C,W87)U=H&RM+<CH;8*
M),?P&"4F)SA2M<'11Y(90D-&8G3Q_]H`"`$!```_`/YI^.....?CUC>//&7&
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M+\?G]'/FVZT[E>&GFG<M*]!W#3K;F6E^W^"YA"E9;5[,_P`%?EGV9]GLSSZ<
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M_-:,>KQZ3GFI./5ISC*L*<\\_P`!.4XRKTE^6/1QE7GY8SGG#;K3J<+:<;=0
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M?3]9]SNN.R>GMVUYKH%NNG705M#J9N.&%UC1KYN^[U`47OA[I1:MDE:Y-/G8
M=N!"9=A%SE1CDFI`I;LHPM#`RG#C->BVE-=[)Z.;@[5[7KMEIG9BP>(_2>KC
MH*C42JU:D:P'R]:V.VEJK6](U(2)F1611!:Q9RL@X\FXRY-/K]>`8Q)F'"):
MRC?@VZV);RZDZD&[_OL$;V5W[VMZZ$C1.H4>59J?8^N%=<MH2Y3:8P9&3JJW
M>0:64V?2]Z7`V?JHQ)0)L)2629F0(\3$O#1T@0TN8V52-R[A<//^&C;/$0JH
M6XT[7,4*S`USM!C6=FU]9Y]?-S2,F3:)$C):L2P<:(BK,1UQCI&V/O(]3^+[
MX9>EZCK*UV6-O;::[E2^AW6+Q$;#$+:_I/W'1].;LM4*N7ZBPGQ=A<L<[8E#
M@2UV*L%'8T"NVO+3=?F#H#SSYJ'Y5G\-W455M6NZ$3VMNJ!LXWU=V5VNV9JH
MEKVE.D]1544$=M.EJ'L_900L1H.G;3M:F1I=WN-MV=$AT72=>;AM6E\G-+P'
M51UL+P]P=`\5"D>'NULHC9*A;]R]?Z:WL;$`>-L**/NJO4:\O2%1A[DX/]U`
M>KVR4,C$(*?B8B8BQ"\>%&'RL0VK35L?K$ETR\=>TBM7ZX&Q^OVQ=`4WKVJ3
M0*&1MFI-?O[^N&KIP:IVXJ#)V2&8LU$K(^#:[&X8F&#YUTC8I9!9>?)EJ\38
MOA3:5HH[:#T/=NW[!-TI<?#?:OL>14==@8QRC^(&2@#VH%*E1BAR5$NFMVI>
M9:CQV,JN&,N-Q6JZE<9R;)S8=X7'7G=_>7LSHVD7S9^I:+K_`+FC>J-2AN@*
MU+!@9!JJWZ?"LB=CVF8S6[E*@&:2(%Q='0B,7=]RA'+)>6)8\!7Y3K5%;ETZ
MTYI_K=J':VY]Q7T1L/L/3=O7C2X*ET489H9[.G-[A].D]<$C4M<LL.O%H!KL
MVP85FEYA4BF1X(`'8(YV24>?Y=;?O4;K?UX[B=T=65#,^O:NI)/K#TBJA_8[
M]9L"Z]L;MGC6;%WV<+ER(^(ZS]*T2`W+L.4<.1H+U?O!R*4&1QHMH.RQ"?B,
MW-OJYWGW!U?UCJ#60?0V@40]4TO39G6M'L6;2-(:G%3G=HVNTRZU.V!9-L6,
ME8Y.P86Q91]ZP")4,4R.5$#CI`]WT<^&_P!<!FW.DG7HAV)W/*VQW5H?3O9%
M8:':KHZZIK^H]D1Y_-E1:K%(M/KC-DJLD7!FUN*)$Q!YP6[*P3E12<AN.+[]
M6\*W7QTKU@&R^Q*@\WLO5NZBZJ*M4>K4F$8VGU;WJYHBAZK#[!GY.U>MS=Y&
MT*G"#MR$N0Q95,6EQ&2AHT-DIM5J/P]M,;MTEUXZK75-\U'M>S>);W8Z\US9
M$G5NK(^W!\?6>AUWJN5S><G!%,J76P1(+)<DU6M&CS&"AY4^J'(@EIB7/HW3
M_#2J=GU;U662[$UJH;_[B`:!;]+TFPNU]NI6`;=NQ\/0TJG#QD:8_L8O<*O7
MI:]O&[$Q'A4R,-@R:$\VR9<CV-RXI_3G7/37674];%T2-M&'1?&]OW3'9-HV
MI0]:C=B;(U'#H0JJWRF9.U4;&/"ZD8G3R-VI4,@;7:-<V>9!FC#:I06"3?UQ
MQNGFJ!_B:6OHIL7;MAU_KN#V:NG7@-N**'!GB`I_%GG@-9%[2.-D`(M<0M,<
MKH.V3VIT3XMG$WR\5IZ)%7%<GG3OA=AK_?MR:0LE\NP_LKH^L"B=GZY@FJ'&
MV%<#*K5>W;L&T]/LWJJ[L.S:YU%7*?LN?K)R77[?;F+VM%>*1(M8D)*XYX,U
M=JMN[6WZM7NG4>Z@,=2.S]JQ7]@4BI7</'M-&HK!NKGHPNZ@B[$$S6RN%S(,
MUB/%F1U9=:D^DTIQC&T?H/H:E;NZP>$W82U;ZV%S-PV)W<+;^I]UTSK@[M#M
MGJG4JI#J]24M>==.?=5L<4(E..TQ@E<Z61"MI4='&9*`4F,C5)X9^@NOW:CQ
M2M=:=V+5B5?T18MD[E/#-3V8HZ.+S1U(@7.W4/2EIGNRVYV)RLAQM8ML%$S)
M(A\4&`JI"WI;SV9?TC&K_<#K!XK1C?U/H8F=UCI`/?.CK?4:%KK7!33=V7?;
M=4V]%UV72Z[6V'M>7H<*'4V'03_QN$A&0\<\)BL6-;T]^+=J]#^NNK+/T:(D
M]^;9>T#WD@4^S5?>C^N*H.&:^JAM8JMW!BU!YA!EJ;<]9;`-P85J$!RTH3BB
MLO7",64]/&B\^A/\,B-1-L]IM:[7ME^#S.E^E=U]@-U!*P(J1&T':!3-H1:/
MJ#%`?FN)%P)&S:A,8VQ8"UG@2X=5ICXU<$62?,L?`\RH'A=ZDVK%U>_K3L3;
M;<.[3V+O)%ZIW)W7XZKUR35NE^OHUU29W0!.R4VH7.VB3P6K$>)6?BUNG0Q\
M2W/HL3!=NO1)3UGT]UAIO1/<O7]E0G8^Z;+X3VE.UT$C;*;KYVBZTMV\]D5K
M--;U;8IX^=L0'8ZC6S$$#9+M#GQ1UCE%["S'&C(X,<T1QLEX0]&QN)K48O>%
MV4_1N_\`J3P_]SGY]1JS;+EKW%J*#L0+M/5`MJ?A2JN%L?QW525,N)"4>E!H
M@JT1;!'?GRP4'I#?"7UY;Q6L;O0]VWF30S%`\1RZ;#C7,#KZLV_#GAWW")3B
M\:C3&#L^GB(>X")D(H7*NLLBC70]10N=?L;<-`]>IW?]$UWK;;EMJ&I-JA=V
M:TA?$1*E[,`KBNP[`%L5;$6!,64Z/](2^<K$TG,J5BD@W9`":<!3YP*0Z*DQ
M<(ASCCCCEBKU_P###UN_.)VC_P#J&EN5UXXY,?7:BU3:'8#1>L[X>75J1L7<
M>L:+<+(W(:AN@ZQ;KJ$`'2;,Q_.&(;\<:0D9CS'<^KB/J;DJPK#/HY_H1HFL
MM5[=\6_MUX=E[U;K.G]0*M1=]4:IU<71Z8"FZ$%Z.U^%L%"WI5]A1A,?8<2\
MJ*9Q8+;;S=O)R[TU=I$&]+."%,PV]4>P.H&F:3TUZZ]SQNSMN777VZ;A*U=<
M(X>BU2([JC:--+3E;(KA>=)D_%9B++I8UZUZEDCYJ7[I)>4)+1`"1)*1F_FB
M/"DT6`\37K[UAW+L$UL?4FU3LW9^K"N'0-4`]C^O8S0P[;51-M3!Q)@R!7L6
M_37==N!A<W+LX75+LR-+-3X[<O.N49?MG=M=_DNNC]3TS6Y78/=%/T[1X$34
MM!JH7K2^7WA6ZZ&CT*12:P*,UBK@&&VZ-:!.2;K5J'/.()RI-F>C3W;IU3PF
M=57Z]!QM>WILP-0%;9[]Z%L9L]2*.1N,+8'1>L2[NY9PX&`;$B)](VK5Q\U;
M(264BV"B&FXXZ78K+%EJ(1>N/\/KK+3M=;<VL?LVX+Q4ROA!T3O_`*E@STT*
MOVBCV3:E_5K>6(L^1KSU<LAJH/Q'B=-D1G1X3+A%QP[$)SA8Y;WI[LZ0ZXLJ
MR=TO%\>J58T?X/W5;NDT,TGI/6E-)6D$<E9J[U%L<-5ECA"VS)B9\:4:W).?
MPY8R:G)Q>L)8B1!SL*D.@6J]9>+SK#H7=]@FK7IH_N'104M<)Z(-0LY>E;:H
M=5V3"KL]\1*='B;#/Q9(=!>+A7F6USI:2@EB'(=C1V;B:HI-$[+]MO%6ZJ[A
MUKKRE:+T=J#M3<-4PJU0=>4F;U0+]8[U`K.LC=2M("N";+&@S!*U"]A#S1J?
M"V2[.<EW!)`IEJ4C(-XVCI_J3K'U@*;TUSJ`S([#>#K5S@/6]+T%6Q>U+7VZ
ML]D^#TWL&K;M9IE;BT'-+1"GIMQB9>G2=KCMH$.4D_AS+V-3>H]55P'T$[7]
MM)\>.6V+5MLZ0ZTZM5+B0IXZGRMF`;3=MF7_``')1Y`]^R2*C78E0IA&0S,5
M5E&K$7@1&#60YD3M-[8]0M2[VWW3JSB4-T95]6>"C1>\UCQIC5&L!J[K<*=3
MI=HV'DH$'-4@?-LVPV5Q_0L,R>OX'.@Q\K8^`NO)Q!US\/3K?IS3??J_G+%M
M:^KU+U#Z&]@='RY2Z,!*5]'<NX"6Y$"U1(^,U\W;JPD>_6T%HCL*OYK9PL2A
M!G;'@<_$^@3P>J]>:WI1=*WK8H5JV1V*ZJZ..IOU#'5E,,1V8TD]M^3=(NKI
MI,7M.C2:*\*L($!7MD>AG<0>&(O=8)`JT='R)$6:QZN](C0/O'9(MTWK>6.M
M72O8&RR-?L@*ITRR:IW;7-X+T\;$%Y6&6:O?)HD#\57.IO"UQJ^(GV"8'M."
MYD#$QBSNE=':CHO7[LW?B-&U]=-\^'AT#UEL8#3+97J]9!F-^]N[+9=H7?:U
M[K1:.]!V$OK3KRR:RK=6!VR&<J56L`D@[(%R)RXC:*#]4]?/>(1M6O=?MHVD
M-0)8JL]BMJXWY7]7TW-L)+HFJHEVQ3M@XK8JL-V\"+9JLN4&4EQ=EKC%FFLP
M$NBW8,9F6NO_`(?G77M$)J5RU+O7=4*BVGN+U>ZAM2K[K2@AK,@IO[6$VV6"
MY($#+24@H9IML%SA0D+DG+^/ZZMB8X38(H6M[QWN@M<J/7;/9VJ;"+;3GZU[
M&+U?M&N5^!3G(6FI@OLU&U915;DI!UIRT8J.W*2+)VNL[(!/'*%-M$J/K4B)
M:;:EV&1L0[-^%#J7L3W#V8G0UY?TXS8/%&;Z6V6C.:[I(C6E#$%.M>.P4BTZ
ME`T\I!?3&`!*T=!,U<W@7'L-DFQYT95=@./,*UVQ^DFBQ5#WMV:J^_3%ZU#U
MRH_68\9KE(QK.Y[)KV\MZ;A,ZR<U+>3JXLG3\N#K*13BUMLY,9!FQ+(*-U:I
MN10920;EQ[B^(=UOT\=W#XS@"I4&EZZ7TM,=:=W:810:P!J`@/6MA0]>T'<&
ML'Q=<@P(K];LSUD%WP%`<BNHK-X#3)(J1`A6<_%(:Y^N/3.@[^ZV[.WHSLVU
MBC_7S:U!A]@Z3$"51<6H=:;H..R9O8"M%")1!$T]6"M?EULM6)PN-`:).P9"
MS:&2,:/CGL5TIKFG^J&@NT-%NEDVA5]R+JH@U91S=7^Y#7.QR=2.VFZZ/V`#
MCHC7K7FV:)F.`8'1+"@G7=E5^0:N5;)"HT>"#<V-Z.JE"F=>?`9(3]>:HG$M
MS]_=IZTV^4(ZKUC/*;0H->W-6Z@&IVP2DZIOD;8!&UTW/$L0C<J7C#,EIYY;
MDR/"DL=_Q/-#ZTUAU6WS=U4G4%P)V+Q0MU:ZZ_;#T)KJOU2+UFUGKPJ7$6CK
MIO.P@ZO1)2;`:>%X7KRAE`]L@PXL%T^#NKS$B(U)J#5J;4](^$(/[9:W'`G^
MP.V.[4[0EPV@7`U&W$]0ZWIE#/7`-2ZA!MX8^-J)/8D\>/L%BL<&#'/G03C`
M%4WXA0N.[;7;/0/K]V1["]#:@-.L]:]T=[O#_KF_'J91ZG6&=:$.S3%<>)#H
MDRKPL#X6I:EOF`,,$X[]1#/@`%@#S)4*N.-&EM-T$TIT2I6_Z_VU51;ML\/L
M;JA=*7,L.K+S6J:$L9'0+^Q&->;EVL1<9G/M@+#HV2P5.7&H/-2(D0,X(5(+
M*E_#X^>X5Z,:<%ZXZW/2MVW@7N'NE5@M^ZN""M"&R-:6$-9NRD+1P2D7LZ%D
M3#=>O,*ESF=M6ZP(7$IX'*VJ)%A%"#T4Q,M"QX/%*.VJV.UC=-\<UMI#L1W2
MZ];WF&ZE4\7PG-Z8ZH9VP5MNH`HTA\4*A[4@YE5X/7K=(G3:'/3#)DS-O9DN
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M<<E\'OS<%99U(Q7KS/")T/:9UWT^Z+$5:%,H-P)SQQ0C9`Y%D`DE*+SR0<-.
MERSLLNIZ0'$J5CT1D%#$A&>Z_;*PR;C+,;]OTN1L+8]+W!=7&W`$#%CVMKQ$
M)JF[(FMC`,)EB[!F1P]A=B&MP"1J-!AQK&\9CQVVL9\6\27O.;L]8NA'LA<E
MVRD[`O>TZ:>B@=<CI]4O^S0N:]?K)7<CJ1%8$RK2)7)8*1HC#8YR40*%6H;1
M@H0(2([QW-[1HK^:LSN4^S7L:<.]>VP[0*BLP4:/LI-!L[JK"&:BAS%(*FVF
M2TT2ES&5D&D2FWFW4XSRQW9?Q'+_`+<"Z=JFI9%QU)4=?]8^L?7JZA9JZ$8D
M;$E=79CQJGV2:=A5OX]S69MK5$M[FM2I&=5F+`+A3IT4TXIQ28IQXBW=W!NX
M6//8RY.'-AC[6,OY%T'KI;EZC7>OBJK9%W)G[B,1;5,EUX&&$P"!]@C.KT47
M#Q6Y`=;:EKB6Z=H-_P"Q-VU_LC=MI6&Q[UJQ#7I8%LZ:T)CV6$5U4V(:H))U
MP4-&1)\\"@$+QF=.C/SBWP92C,J>X^^XYG=\[D;;L4GL+`I)B3K+77:ZQN7K
M?>I0[%:-4FYW,F1DV(TOTS=9DGTU2-;B!6PT4!.+2YE%R27!'EY;L5HH_P"7
M:>ZG:NZBK@$M&\;>6&[`9U8Q=&<Q*H.?L;>CWFY&G,D"(>M#2B7M8OLM/4N5
M#G1)81Q"5L/YSCF?`?$E[UUDX>LP;LS?X]@L^R:QN`\8D0:01G$=F5`&NLA;
M@IPE49:(955===!G<C6X4:W"WGXENCG42967XL(]M^R)?41C0Q3;EB(:B.6N
MR7692ID"KOPXEAN1-1JWO5TLNOYLE-%VLPM1.R5FFFZ_5C4W.7R`5_*EX5Y>
MW>SW8+?L%([=6V;5LR/@]!M#KEJ4)E3IUA&4R#KP<8+$X@N&2-D(=+'QP#$H
MS+GO?!ES)#JW"!(E,E]RT]J^P5W$P!5OV41LD@926]:PK:7!U"7LYK7;,1P:
MU1G-O+KF-J2ZP@2\Z#2.FW*3G[GW'*[Z[XA<<&KZQKM%V#L-VU#LDOM:R2;[
MH$/3:]I>VL1Z^+-:W`:[DHET0)6Y`8(.0@54GT>8&"0:(,0&79$1M.8<N5'>
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MB"GE'E%!8HI=&X$H:2O:(Y&*5*LR[$8,KI]:[Q;KS>+)LJVV`B;OMPMQB^V6
MU27LH*E;D?.2+(6L#CS.498G23DIX@WF/EM,1W+:(N&D,-83+@+M?V)K=VO.
MR1.U3S=_V1<VMD7&Y3H-<-60EL:.U9F(.PH)8X#)2ZW>1;5RM+8FV55P&<%M
MFYC<&:PUB.AC%=,[YW!UXL)&VZ3OA375G+5TC42)X+!K\TG*JYE+:#(%4BPA
M3?JAIEMEIDNQ'0SDHPVB//7(8QEK.6,=L^R$.N:CJ(W;MD"US05M=OFD1E?@
MU>MIU3<I,]9299*-.K]>&%090B06J25=9GJ:+9SZHHS,CX2RG`[3N;:ETVM,
MWG8[V>E[BGVF'>)6RASD.LVQ5U@28\V';V"%2A@40;,S.BQY^#8^/$(.D&L3
MWWW9JW7W,SV!VEWWM&O&JE==A/$*S:;JQLFZ`A-6HE.&[!V'%0\B->=DQJ35
M:VC8MIC?"9CL8I=?CU<640)SHR&IY0C*E2!#[<W+8GQ#0NUYS8>[NO,$]9K8
M1U75S5(UJ5C7`W29]3&6^G6<?0WTUHH%DY`3I0F-'8`6,0`:JY.*T-D86SY,
M7NAV.`]A;;V;I>TK35]KW"%*KYBPKDP+.X9I3U=$4YJEVT=;AIROW6O*JE=`
M"R`JT!"@R>\+CD%0FY34=QCQQW;_`+,"0MI`#]PV:.-N)*_%R^$Q:[F=$(;4
MKL2H;-?J190/)77S>P:B/@52X0]?S:O`-UN###28N8,=IE/IY[K]J<ZVSJ%6
MZ;(O7B]0HT#(`O":;)D3M)QRZS@_5Q.R2:P];"M.#$79"JZ+)'I7W,PY4P97
M'A0V7)B._8CWA[:%C-&L<_>MQ>L.N+P)VA5#N(]907:V>!I@K7(+9E@G)K^'
M;SL,)0@0BGB;I>_NFL0\"/9AQ2#>5R'7^X![X=P*P=UO9:_ORXB3&H3^S+/K
MAZ$/IL>)6#.Z)CY';K[0IJK)$%H>S9\EZ;=PMA@F`9^2I#TP:IQB.IFM]RN5
MGV%9S%RN1=X[93TKX63).Q1T!+BTM-L,1X8P/"&A0XR#%98A#`P4:.#"8+#$
M$9`B1&6F48SQQQQRQ5Z_^&'K=^<3M'_]0TMRNO''.,XPK&4JQA258RE2<X\\
M*2K&<*QG'X\9QG.,X^C/++'^X?9FT`+17CVWK"0:O-*"ZVOE@R-JL785_P!=
M5UJ&P$H5]VI!KT79]TI\",-%Q/B&RV\E"GPA(B`702A"1T>-Z5:[<;:Q7PVI
MMD6VS7;K;(,:T3L32`9=-I4"YTS6Q-E\971=@'4F3.J!R()63@`+F+:4;$3B
M<DL^]/E/RUR,5VEOJRV_9%+N5*/[#J8S3-<IE!T"X6NLHEL#6=!UI-($-?0&
M;F(2*6U8`,XI.(I*`F1D>/-D>0YAB.PUC/QOO9O>>S"1(U;KZZZ>.V03<[-8
M:Y6:30;%;[B!EM$@EMN9_7M8JA:VV00792='EC\R?)BV/*[,VK%B<655G\KO
M?V\EW`/?E;UM4:W`6MI)%%QXJE#DQYF\76WMTG71,*JL@9MLVTZRTK8MQG"I
M-KM:6FV21EQA"6L>"GN5VE;S!]1O&Z1$#-'8ZSP8\!%<'P8^@&Y/PZ-J/XMA
M`(XY^FCI_F0#Q941^<#)9R1"D!\[/PCGZF=RNT!&,4AS]R6&;#-Z6`=<2\64
M&I#\8EH6JR%2ZWJ28PY5%-NT@'(5ZX:,RG#K"L)QF4M*&TIC+;&YMJ;TV`0V
MKMZ]'+[L@M'!125T,9@1CLQFKC(8:N8<D!((AE#H04.'#QLIF.U+C1H$)"7_
M`#BL*1(EW[?=E-C`KQ7KGMDT8A[237D[9(-AZ@&M6WT51;#M<:V[>:_7!-VV
M@R)DQ8LUEB\V$ZS+)1(A8JV0*Q8\UK#MI;]W%NL;0!&U+V0N@W556C4;7$,B
M*K$!NE4N%A/P*I@5`0(=Z-78:D8=B"777X<=]3DEEM$AYYUSU];;W-T35>[-
M($('W0ZOWE'I)2P`\RT0Y8/8NJR\L[K'88%^3$(P%S0KY(U7K*#)#Y`ZWTJP
ME0[[H\C&"%AV:$N\/;,R>?M)7>%EFV*5IHCUWE%G`="1)?T27:0P2U&ZEFGL
ML.4.3';Q&P$6QE$:)E<6(['CNO-.>08[B]HCV+F@MO"ZRF=B:IJFC;S%1\00
MH-IU)1%NN4BBEAXX%#@."Z=E]_%7FL16#P%#[[8PQ&;>=2O.+7XAW=J[C6Q-
MG[(;`(Q6+)JFY1GF&:H&+0[CI`>V*U;<(5@`UD78(ELJHYB)#398Y1LT;CP1
MS%EFF6!\1IG';%W@[96F_P!XVB8WC:LWG9='+:UV`8%BZ97XEPHI^<@J>KIZ
MLU^KBZC.8-F6TGRQ!P!@W/L7I6*056;S\/YA8+LYOZL;?M&^Z]M2S"-MW==B
M^[6WQ?BI6;A!MS"8MH`6NN2ADBGV2I'X;;4$I335=G5.1!CQ8F`J&(<-#'H5
M?M;V"HUO#WFB;%>H=BKP"U5BO*I53U_6`=?!7J.W#O$$+4!52CT\<NYPV6H=
MJ)1P*3!Z"VU`)$9$!EB,VTYVO[%=?!9H+I7:Y[70H_<*IL&?""#:K)98O5'^
M%IJ=N"X-UXOFLV$)&GS1L8G6<B)#H>2Z%EJDB<IA)^1'M1V`*@2E:G[)GO"#
M9:,9--M@*7#FEWX>SB&ZHPXJ7@5F*6)5AG;I2?LINF3IK].;N+^"[8%"VF6V
M\R+][>X1T@Z6)]A+\Z5>W.![%/%8J:P()O;UK`2-6@.UG2(2N#9J[D.K<./7
MDD,O^HDA$N"IT25"D267OA*[P=K)USV??I6XR[MDW-76JILW_P!F->MURU@H
MQW[JH,:31&:<W0ATT7;,N6X0="5@78A5MDS;/`+QSI">0D^I>.[.[=C43>E>
MNUG+6R]=HK?K>P=A=JGY<+-CO];TRT^[JW7K(\*+"B1=<$'I:[/8Y;D>:3LA
M$-3QV%C@];6P7K97+[<ZB&O=>K%F,`@>SZS%IFPA(Z6IB#<:K!L@6X1`)YCR
M4F:.CV:NA3+3.?15B7`0G*\QWI3$C,+;OG;EYHP?6UJNLTI2`<RL$(@)`RO"
MT32%(IWR>TDA8R`8..+W`A3:+ERI54A;2!R<!`R9D`=(9;F2?69L#[@]EZU7
MM/U0%MLR,KO7ZS/W72`EBOT-R-JVXRWWI<RU4]R549$N!89LU]R?-+/294R8
M1PT1DN.SHT60QU27;;LF8%[L!E-PVF>"['FHUFWL!DQJTX"VC:(;WPB/:[*%
MR`P+1;42L(E*M86((L;TIIF3(*.OL,.-X?KS>>U-5@[;5:5:\Q*;?G`4B\40
MZ"J]WH%MG5>2]+K!4_1;T#LM3GG*W(DRE@3ZA"#@IN7,BPR+4*9+C/Y7_P"E
M?V.SLNR[C>V]:9>T[?#!C#U[(L5XI8'A-8FA9]:"C)!('+CU<'7I%;KJ0H.I
M1@(@9#!BQ<2$T)B-P.2#([:&2E<W-;SSVR"O:_?";O2MG;V1>!8BMWC2>QP5
M3'6VEVG6X"LAX\RWRR%7?EN7-HAZ)N.>D9/P9!$.,ENQTOM3V(=T@'ZWN;9L
M[NDZX8F':U1GFPC[=8F$2L8\1C5:SO!W+O6`1$_#AV"?5P%G&UF:=B1B\D0[
M/9;?3FR^^';U=\I>S<;WMK%YH%BNEPKAR%`J<#"K?LD3&K^RK99@\*N,5^^6
M79`"'%!;`-7P399UR#,(&'W9T/*VE="7W9[3D)8.21W"8(QZ[JPKHX6!G5RA
M2*>G31LS&L1+5Q"D9J.*@;HKIZ".,1:Z<"$8`DB+%20K8U8R#ZCB#W<[9CBU
MD/1M\W=9RW[F!=B+*8GMUDP4,;QJJ&6JMM"3/-5XC*:M-88CQXM<=ANQAP.&
MPS#&#HL1IMA/G&>XO9VQ:WN6HCVY+*7UU?[[:-G6JMSX%5?3,O-YE.S;R=&%
M\UW%@JF;Q-?D2[F*IQ>O`K4_)EK."YV)LQ,BM7S\<<<<_NA;_P"SV>&M%I6J
M[$4']P#EBVG'3\6UG7^U*U+4W.9KQ"S$<-8LM>&H8'1!HV4M"Y1:1*6O#;*<
M/+7C/.Q][P^'G[HO$7^LK4GVCC[WA\//W1>(O]96I/M'./O>+P\L>?\`[HO$
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M+_X;*U)G_EA_SYQ][Q>'EY^7R1>(Q\WG_.3J7R]O]/K_`"\_Z/GQ^/'.?O>'
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MIL0ZJC3%AV9K9`ELP61*7`9F+$1"\]EI_,-YOU[8]]MMST,.Y1A:5<G7[U[\
M-K*?2P>[0_-YX_\`?&&^CS]WG(P(?]FX\.N%/G0VYW8YQN),DQD..;BB>L6A
MAY;25N>A24H]-2484OT$I3Z6<^BG&/+&-VU2_!_2;\EC_P!F+CRYWECZ,?HQ
MSA2<>BKRQCS\L^7LQ\_E[.:13NJ.Z$C:6[2QL)?[!IPAOJ6275`%Q0*NMFTX
MM[?>!5;B3XA8>)N#*+><TML&M6$*]3+31=7,+T19VK+*U]FQ6;9%7,[QHG56
M@O6HK6B>\Z5I>F2-FE+,W/L0@[>:S0(+NP7L2`1`"]*>,6*"25&*,NMQLK?S
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M)T.J0QL)=[UE)C3/@*3X6`"B7D,_:)MOH[9$&2V-2F`*9V;50J_8JY9K")4\
MBN'!YF-#6JK_`%BUIVZK_8<$:V4Q<!=-B4ZT1[*]9]CL;#$O5";IWJF,U+KR
M.6Q%@O6>[479]>WW)LMRDU\,1(SE6JTS9KL39PJ))OS.MMW$;IK=-F_<G*I%
MRKMQ*B/@HXQ'M0N93V:?AY!&>\7D!R$:?(L,Q3:8HB`[&9CQD*=D.9>7F9O+
M'T8_1CCRQ]&/T8X\L?1C]&./+'T8_1CCRQ]&/T8X\L?1C]&./+'T8_1CCRQ]
M&/T8X\L?1C]&./+'T8_1CCRQ]&/T8X\L?1C]&./+'T8_1CCRQ]&/T8X\L?1C
M]&./+'T8_1CCRQ]&/T8X\L?1C]'/RO+;:5+<RA"$)4I:UY2E*4IQE2E*4KRP
ME*4XSE6<YQC&,9SG/ECGR8DQ93*)$9^/(8=3E3;S#K3S3B4JRG*D.-*6A>,*
MQE.<I5G&%8SC/MQG'/M_`_\`\?GQC\7SY^;'Y<^>/+'S^WGPDRH<-AR5+D1X
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M/6IN"0'S%H1AQ:(LR+)6EM2\M)6I++JU)1EQ*F\*SC"<K3E&,^EC..?M!`<Y
MAA3<V$M,J4]"C*1)CJQ(F1_A/KXK.4N9P[)9^!R_6L-^D\U\&D>L0GU#OH=O
MS;^E'XOH_'GRQ_S]GY>?KRQ]&/T8X\L?1C]&./+'T8_1CCRQ]&/T8X\L?1C]
M&.0+O7&,+T[Y8QC_`-^VNOQ?TF^3PG^3Q_4Q_EY78Y^&C']J$/\`5O<CRI?@
M_I-^2Q_[,7'DQ;[[)Z`ZM4?Y2>QVYM::0HBB<4(Q:MH7$)30TTU.2ZY$##I1
MJ7%^,R\AEB3(9%CD2IRXL:5*^#XC1I#S64ZHVYJW>M!KVT],;$I>U=;6R*N9
M6KUKZRB+=5#<=E]V+)4-.@Y<T?)7$F,/PIS"7\2(,Z/(A3&6);#S*)#]%/M]
MF/;Y>?LQ[?+YO/Z?+\7G\W,"VK_-EL3^XMP_Z<)\:J_FRUW_`'%I_P#TX,YG
MW'''''''''''''*ZWOL[KW7EG*5(V`V_.*"4Q<R7ZQI#:UL"O?#(;,YG$"P5
M^J3PQ'.&7T-NJA37FV).'(KRT/LNH1!.K?$0U;L>OSCC^O\`=854.P&`F(PO
M5%[V#%=:&OX2Q(6;H=>-"(L]R.XSDH!DR&R@.?EZ#*;>;0Q,DXKLSQ"1&F]B
MWV-<Z5:S^NA^N^NEKH\*EU%Z-M"03W0`[-VXVW<`]]MM/&AAM:K/7`E,^#+8
M@G6)I90\A#4N*A;GV+>*)U[J51&7^_C;S3J*:N6ZZL+M;XD:9'?`=*D[P.FV
M<M"#EY!X*)M>->V-^NHFA\2&,L,1CN!,A]">6+U]V'<VG?MFZJ$4*UT&W:]U
MK1+M,GWYNJDAT0ALJQ[=K%:&/C*5=BSI9#"M3R[&\^+.M0"X`T)P/+Q9CZ_5
M5"TOX@5RL!`>#VS3*C!LXW;\?K/<Z[KTC(D*9V<)UKN3=AW=M;*7`Z,24ZPW
M/56LQY/3YSXM=M=I-3+0-(I@.5&:R[D/_P#%2T8[B-\7:XWN76XY*A3<#ZI2
MFT"#;-_N&L8P$@\5V,+;^'E+I3)HL?,A9F`EL$A1:08C!U$9P[L3O%-T!#08
MEMT[<TT.,#6,]`.QZE6T#;+!JE>TW8C3-=COW=HY*,*:[!:<"5ZO3`T`]=K?
M?!=.I(VPV*&9@#<^L/?S6P.D]KK)FD;&19.HVBB.][]1"8P,P7*`X(/9!!5?
M!E0!NU`G[!&.ZKMU1,L9FK;#&(.)#F90QUF6[]BW:TSI@%0;-V!8J4X+M*-I
MV#7)6F&R![("T;%(QP9I@VT:/KD':**-V&GQ0.P*]'PX:BD"4\E50<>"E2XW
ME>*IUX&U?-K.5;;];@NRJ0@8W8ZO61#)<;LEO9K5$.,V%V[.4T/!MAW3VP:A
M7X5LLU<.F;>&A5X:)DS[34&C_$KQ)]>N[%H@L4"/9HEAK]KAD<$`2L7DILL@
M'Z16?3-5IT*`>E"76;R'[FUD616?4.R-LT7X(_-'#X4N;-LKI_MAKC=&Q+/J
ML"*NM:O5/U_KO9%@K5_`LTVP0*_LL5')`E9K94DFQR$PY#DZNF2\$3+J\"X`
M+-4?C]VQ5XH.CV=XXXXXXXYQGYO\4_MQRB^N_FZQ_GC[,?LW9R2^Q/=7J/U'
M55V^SO9/2>A7[L](9J47:VQZQ2IEBQ"6VW/DB()HA&F38`YQYALD3:8R-'.2
M([<V6PM]I*[$`S@2TA!%DK9<78:[8!D`V!.A"$,L%-ABD9J<,+"2D!Z3`)#"
M,-YF9`(0I#\29%>:D1GG67$+SZOECY_+'G\WGY?B^CD%7+^?[27]S=U_^&7)
MVXXXXXXXXXXXXXXXYYQB-/F"2<,42^)BDH=-C#2_P-@C\5SWXSK4,C\7R5(C
M3O@,E;4KX'(4EB5ZKU#JDMN*SC7%O/1??XG3&`^M>U`6U$R!4?\`&Z2^OZKJ
M9<$<-=06;EC['58=B+*DR"T"!$DCFV(T:4*?(1Y4A;#BHS\YZ\UCVG@.U4[M
M#LC#M<=J%'FW;6HO3>OX8\M)>%N8)UH=;T2X$W$)!%W+4,JN%"7+CL-_"F(K
M<A]+>KACK+XD%'T9J75FI"QVB@ZGU+T_J(I0*[L?5-?`![^&U?N^%LLT$.08
M>+)#-2]@1=!J`V078FHJ(+EH>;C1(\@TF1840%\3:;MMZ:<A21^EC.]1A-8&
M!N'5B+W3J'(3=X,>8(L>:&6&6&F`R,"CG+922@"(=,UXVL6%:+'*\>7<,J!=
M>.R,^E]'S&UW9NQ2>@-C[A+[ZU8<NHRSHVMBV"=B5;7U_@FCI&/6;+-U])-B
M+55:C=9(Y@6-+O2&90^Z4P!'DPS1-$=RM$U!P3:MNW2IZ4>U5V&C6.32+!'N
MA/K'8K=;-O;*T?9-0!'0Y^T[)J&B:%<JUHLG0YHZ:_9;+2:!9Z97(U(`%!9^
M1]4=?>PUIOA[:W:O7M8W,SOGKCJ.O.42;;HS0CK7?1=VO5JV;1@$2Q@Q11BC
M6EBTZ_.0KN!CE=GP[1K-@,<@YB!J:2A8O<=8^*9(IL5T%LV7$NL6>Z5*QJW:
M]7X'EKP%U+NYLA+#OVJH-LP='WC<3G7LG6Z&1:1<*T&&[#@'9<43/3'*^7$T
MKXB::\<@QK%9ZW8R,RFQ,W05>]2%;FZ&C=F.V-PNL1FW688=+_$DS3]\T7!K
MM>G>G!K4P*8@UR(&),$RAR1MC]<>QVQG!%YV170NVCMM\/96@2FO3-J$A@NK
M>T)IQ9:Z;1AN19;-?9#WR7/%A[%<J`RY=ZC"UG7ON.$%HAU]H5W>FG16SZMV
M[>]R;H/64_L48W)H8JR,DZQ$"[K$VGKITZU]L_;FP1P+,VS$K-<-F];CED$A
M+F<>9!-V8F?<%O6:Q32$+!+_`-<.S.OP_90]U2U=5J#M2W=D"9#3UJ$G=4UW
MXBTHWU=U!51\)<*>+*Q$TXMNC2589+Z^4_7YC(Q`6U2(QT>/,TPO'(;J!WBK
M-JJA&H%1,6N4S>O97<%-IUPL5'*U"@;%VD2[U3M<7FI?$P=BPQZ5#`[^U?7M
MEUDI)-EB1J$2)@JRXQ7IY.\9?C6WB;XBE[`#.6R'8;'6]#S!=<ONXM:'H%>?
MKE]WV5V[K,^8I8*LP!310/:=;L5G;M1K-PLOQ;7*LW<@]_CC+92"NZS'GY>W
MZ<_H\\^7_+RYSQQQR!=Z_P`?3OY]M=?M-<G=/\GC^IC_`"\KL<_#1C^U"'^K
M>Y'E2_!_2;\EC_V8N/*D>,+)VUK/3E7[(Z=WW:-,6K6!H?28D&MT?31]%ID[
MCN=*K#4DS:]B=4.X6P*H.KL:+->5`TWJR4<LZR&(]C2^''LS0UD?#1+F;ATU
MTSLVY3HY_9&SZZ[<-E7)L+&!SKQ;EERHAZT&H</3O7YJ07E"Q8R$\1<TKK:5
M-BP8:GJH+2VS'1(1?NOH<!=+KK\Y.V"$M5)<A,NP#>G-L!HUP=($CXN(UJTL
M4I\03M=UYZIVN2A&O)MCRH36+"=1Z04-/GL2U<;(!N&D+-;:N5A'JU:-6&[%
M7C8QY,H<8!FZ;+*""L"2CS1(A$1TJ-,B/H_@NL/-K3[%8Y[>JOYLM=_W%I__
M`$X,YGW'''''''''''''/@^_'C,O2)+[3#$=IQ^0\\\AEEAEE&7'7GG'%);:
M::;2IQQQ:DH0A.5J5C&,YYX%;*U`A'DHJ9*NS8K$EQ^8BO3A<EAF62==F//2
M4BG5M-R9[ZGY3CCN$NRW5//K4XO*UYK_`+0J?3V;>I;&W@.C).P;I%HK1%%Y
MA55ZQ'H3<JU4'6B2GQKA4I^(X0O-XI=&S/\`18DS[?;*Z`R]*/&8<KO_`/H;
M=1\NPY"NLVAW'A[DYV(Z_J:E/KCND7TRR+J%2`CGFN;)2J1*4OT_7R'I3KGI
M.3)>7_OK/5O588NYU#46OM-AW=?UT=UXNX*A5>M"'JI56A:=@"M0F8P.%$<&
M@V!>RLVT=4W/0AL,75TM&C(4;>=>\VPZ,Z?YMM=KUGU)HF1=)]"@MU@*:H]0
MF'9VN=%1WJ^*8$CY8U^3*JVK(>VYH(;&9:=@56'LHF+B-18]O(1R$<ZNUWX=
MMP:!Q]-4SJS86+,`S<@"->@M?D&3=>I-Q<K:K/!4#CK:GP*SL#,@&HKC+B1M
MP3*&J>;--R&<9?0^CW6B@+M:H>L*H:;LFS&MHC63]5J\ENA&!XFDAZ\'UZH>
M!&N5:M4]G7M3E5`?%<<D5\@*B3()!+L$=\!E2D=>=":T)V`UKW3.L:08MH^0
M+M!2JT2N@I]B%S9\DM,'&Y0\:P\4A3"TZ>6EPYRWV))4B2)2&G)I"<^_CY'J
MMUBGB@0POH#3Q0/3G?AU8'%=;5<I!K>68Z&4-`H4P3(;&Q&8T=AE@6/;9@L-
M1HS4>&WAAC"*]:EUAT%HND]*580<TCL>AW0R0C:EN%L(ZVML_<-E!MVVXRVQ
M1<;`BP-B'JT)!VDB]#&CYCP415"4R5#CX!39#$PB.IO3>Q4B./$]==#%*!:Z
M].RD8WJRH/5L]6[R*I>"290QX+\#GP;$(HNO$343(R_A,2ETQMU*<5@'B!,E
M7U/JZE&Y5DJ&OJ=6C\P1!KT@P"K8L824!&,P6(`5,J'$:>8$QVA8Q+8]E34-
M61\!:FEN1(RV_7^[VF8O'R:9LX7%_P#N4^[G[CU3F4V'[C_CG%=^Z7XLSG$G
MXF^/,X%9G^AZG$[*8^5>FK&.99Z:?+S]OE_55_\`CY\_BQ\^?/'EC/GCG.,X
MS\WG^+\6?+V_1G./+/\`3Y?-^/RYSQQQQSC/S?XI_;CE%]=_-UC_`#Q]F/V;
MLYJ\\:6Q;3ZZ6.E;LU-V0WWK:P;?'%-<RZ?KRRZWH]0CC-:U$[:W#4HN/\-[
MOGNZPG2THO'B-ALMU?74!J)B0J:(/S&/C_<\'M])T)U\J-BDUNR(K8^NUF2Y
M7]6ZQM]Z-N$K,Q%($Y0K7VMZL2/N-OE2!`X;='UN-#%L+)&";8Z(Q*<:_6KN
MV&B-R'@E:U_=<%35AI\:ZB8$T'8`$E\:[6:!<YHI]@^+&NP+>!JFU-<6"T4J
M>B-:JR,N8)\V)A9D/(C^M<?Y_M)_T4W=?_AC\WT_/^+^GZ,\G;CCCCCCCCCC
MCCCCCGB66Q@Z?73UMLQ.*%KE7"E;%8#$U:FX8H($@2"98E+6E*U(C08$61*D
M+2A2DM-+SA*LXQC.J6[^.CX8-)8`SU=H*A:Q9@A*@S9U(C%[(Y76VZX9/0")
M@2P/9-N#3$D2U6X4D,.*K8/F0R";4`5(E%86?ZY\87P\-FP@"*_V3HV+<=J)
M"V_)R[)E2[N.0$I)._V,#+@"8I$9)L=>KP4PLB/$EB++LP9)B#9<]>6%/2A7
M.Z<=NC:6VCM'7!FAT+L4$UL_J-VN.V/;%SGW/:T238:EK:TTJC4:3,`6-VE-
MLV(D<A3SE%%R8M@$3;0R@2.*V'F=XA/7&<#C.T*XLVRW6:HXL^N*M/$6ZK)N
MRR6E1V^*RRT2GU>2[!&DZ";"FS)1D83>J8N21)'!C$>O'?@'CZ\\2/K+;]6T
M+8UAMK](D6BLPC5LKQ>LWM,G64_[DAMH,1;N[.IXJ;7Z_#R0P."W<\*#UBV.
M_!704Z1\/C-J_#'>\5*JHHHUK<TFSW?NE:NEFM*O,GSQ.#EMKA:VJS;[;-*U
MJ&3HX!NDT2V74Q#>KQ@M!:%-@1D<X4)0%.^IKCO[J*XWJRZ<L`^T5?==1V-M
MC61&AC:Y9KE!.G-.P*98K5*HEL#U]@9:H:*1LB@73`K+`RXCPUD;^-JO"<@3
M%)^`3O?3-L[`K.L>MH!S:]FL>@Y?8Q$^R2K#JVJQZ)-C4M-&@)+FJ48(R[5=
MBUZ&C5AV`>?N&^)[4S>W@EB$PZP6]HYX@/6^H"R$JY60^(+!I0T24KX>C7F\
MD'3\BU&-=F!E852:V<:O$6J[/KI[6UF/5/),$$M\!D<2G1,%1#D[Q6O$2Z\/
M(G'L'R3-%&0[XMPTJG;$)G;$_3]AZ0UG'(T&MUJEGTVRL$K1O6H"W9Z2HZPQ
MYA0.]$JA$+(,F@&6O]PJS:[/U_I6D0>=DV'L7K3:>XZ=,.SBFO:N)UQJ%VAA
M[03M,XA6#5F$G7;EM&AU*#5LT]PHU+GG)I;`YFMOL3H"Z_\`B5P>Q6T=6TZD
M:4M<BF[0!4PZFWQRLD@9U_#M6L]PW&<1V=78U4Q7:S7JW>=*V#3SYZ-L`HS8
M+I9*.]5XQ48;EN"Y5(=RR=-NVX0NT==A:E3-%!Z!8-CW(+=K!<Y8D-LX+>"M
M4F1:R.UA#?()BR*A$&VQQ!%F%7E'?C;$Z<""D2*HK3XHVJ%FR582&]2>SV$I
M.JZEDC,LXFLWC5MI/]?8!C<E?O).AQ*?)DTNM]B*E<[+K9LR[8!@)EZ81GP8
M")Q`=+L[Q%.K@W$F60MIX>!A5";=9EJ*4JT!JVP):N^N:`'S@D:&COA.+<>V
MK2\U`A#9D`CT$G\*C%T9:6SB[4":R1A1"$9,A,>;%CS&$RXDJ!*2S*90^TF3
M"FLQYD1_#;B</193#,F.YZ3+[3;R%H3V^..0+O7^/IW\^VNOVFN3NG^3Q_4Q
M_EY78Y^&C']J$/\`5O<CRI?@_I-^2Q_[,7'E;_&&S4AO55ZT;/@@[EJ4)<Z0
MS<]3VL%7I56NY0E<`":27*6LUOOK0Y2ET:P14FXQ)G:S+4U;N8+-/NYY8"OR
MLT\*_>NG-O\`6A%7TA1@NOJ3H:[W;2`X)5;GF]4J<U0K8?!N66D&"A<C=X]/
ML9,<7)UP7LJ#7[S'#NPI,\,@9-$S9DX[4ZFB]E6TAL9J]V"N[$8N=)ME,L;`
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MLH8>[W]A`J[N1J4R,GJ:>G]<!SZ:\+*0'E72%.>V&JTS&U3T)`26WAF`\%4Z
M(IN7F7AUK:GK'J-;-/[,VZ;&7(;MVG;LK/7@19B&\W"UGV8/GZ&I`[6TE\F>
MAQ4P-@1;P`&MV]*9OW'N5+:Y:Y7-M%D9MBQ8FK=.\/7LM2!U*`C.P#[XEC7`
M)C84]S:>[EW(SM=GKCO;2-RL`&UG7+0N+#N=MV51MN?'!0?)D`[/K\8VW4R>
M1HJ3S$`'AR=O:=+M5G!=@J+*NMMK(D/<9+I+;M<JNS&ZC6NJH$`%MU4K<YJ)
M7V3X[1>QJ[9;927!IL,/W`1F5,5%`#D:[S972?4#>^N>RX/;MSV56;]3:9KO
M8U%I48I8=FEKV-`[!IG60=$I)(Q;7K&T7%TNVZ"/E(=ZGDI5OM\78LLG:X+U
MLAF"]FP7'1/>4:Q['.0;AJB,)W5M7K3V9V#2D-6]H!7]\Z;["U?8FP0="=BA
MV76]1[4US7V62XPK$00D[KS9MJF!LV3M"ZL8C>'X>G;@J4($KOV$&2D*L9*U
MAA]8VAV'##`Q<S8NJ1`LQ%BOEI$R2'D0=&[8>AP3Y2Q3(,W?%AC2RACU90P9
MP^L='NY4^PWD(]M`@"-:S@ZT`Z]V';]A;CL]!V&*1I3[DI$7-'R?0+*A*3>,
M5K9A2%9QTN1;MCZV!`;`S,IIL\5)7%ZZ]5=^:8WNS<2>R!9C3833935%?U_*
MV%MJXV`DN'G4\JE7"\'+NU,&GKV-FT[8";%;!\$/%+)V-/(BZH$(+L.;'!XK
MPW=IU^Q4P\&V/38HBG;"O.RJ+1(R;(,&:1/;FZZ;6H.]TZSLPX6@L01L7?-_
M&[F@2)HRKNTV+!/`!"'GC^9<;O`.A/9<@X'A;/WP/L<87LS3=M>M@&\[T"70
MO2ZAJYVO6&@V&.S8V*C8(U:V(Q#M-,*3`L=^ZB9$B!LAIN1\=8MN);`Z-=O0
M^GUKKG80P=NM6&6FS2000_>78UQL+/76MZW+8KD`L2BDAMSVSLFMS]Q!BS%U
MK"-/['L"VXI'8E:.[*@7OS:MX=_8Y\YJK;`S<\ZA6L4%%OQX!*_;=/6'6$6W
M3-3$]DU.)--3R6+S&)2Z=<;5+"W%;5<1>[R6C#Q@D4UDI*R]?0?L^[6JR5QN
M.LQ-E5K51<*Z.3L[LV3UC9-A%=UT.Y6Q4Z`5N;U@$TW:.LZU=*.17!=EE]6+
MV@;:H8\I!'2)-CMWUBZY[7TIL39]AN&T7+I2+=4M5@JI5RYZ[W<[52E$#3`Q
MF8Q=+K.<.R09^(L8ZL19I=V.)L<<Y98UO%C;+FEAKM\<<<<XS\W^*?VXY1?7
M?S=8_P`\?9C]F[.:_O&<BZ<AE.ODKL:!UOM#6]EL=E!5BD[=854Z=1++$K$A
M=GNB=GU7>VIMAPWK+7YT"NN@JSKSL/86VHSY@1K\<&AV@Y#V(:`V/4N]'1VF
MW"E03VJZEO73K8J.*<+UBV6.EA;``2%F"T'J\9L-;(%X(:0Y#1-CE9D@=-5E
M!6/$.CYXV-ZU(Z:4.A[\F[N#%RJ(R".PK!6J&AB-&`U>R;3INEZ%<9L&3'<0
M^^*Q7='UUJM@'8S<2OR[!;G4/SHLJO0:WEUAJP$7V<UA9X,'U!RS4G;C)J=\
M*FN_#6Q;.KV(*?@STAV'']0TG"?.''CJ=_C/9<5YJS9;CCCGEE#8@(VTZ7)0
MAK3Z\MM.SI#<9IQS&,9RVEQU26_3]'/I>CE6,Y3C*O+T4JRGRY-UJ4-QMJ79
M`D5UUN$ZAJ22BL.9;(X9S!7EMYQ"TIE8?:RPI24X<PO&4Y\L+RGY3KH"9K1N
MT"R(X\/!1YCTQ8H@Q-:]9`93(DP\/PL2T)F894G*&%8]+*W&<+]6VYZU/FZ\
MV&)V*)D%!J<15Q9*8TL6_(0LG`4IAMUOXQC);0J(J1YNN1,9RZB3$2W*0YC+
MBV6<_P".......<9QC.,XSC&<9QG&<9QC.,XS[,XSC/GC.,_1GV<PBSZTU]=
M)->E6^EU>SOU2>3*5M1X&-+)"DC->*5,K/',SHS[,:60K!LS7Y<A#?K7@Y4B
M/4KX-,D-N=X!1Z?5JN'I5=K0,/4:^`A58)7(`R(P&%UL:.0(@`H4!+66&1,0
M4VV.8@)3\&;@H3%PWZC'H<AP#U1T+7!6N@(6E2(0+49JJGM7A,6R\.AZ%(H\
M8_`J(VJ#I5D>AB*O78%E+CA%.B-)JL(8Y!&LA\#A`6,/CJ!X>G4(8/C"8NI,
M*$PC-:L,$3-O6S"PP>8I("/5:--&CRMSG11CE$K42.`HR!S45NGAF_BJN-C8
M#K\9WY8\.WI[Z$AEW4*)4.?5[;2#(V=>MFS!%DI=WJ-9I%BJ%N#2+HL5;ZN^
M!IM96.K]HAEQ->L`IFX5V()M[TL[(DP)U1T+7Z"O6T&E2Y-75L1C;2%G;C?;
M5:8NT8Q2"9C;#@7RSV<S?!]QCEA\8BS8X-DCDFY>93^)/G/(?"O-D=0=$M.U
MXN$IC8>VTJWF=E4BUX.6^65`[0//V"8=O\F1]T\6:?L%NE60@QL:29(2'=F`
M$PJI>'S5;%B!H[S*#TUTK2J[0X6:Y&<MU)@[0;S>ZMF?K0T3F[TM?R@;M;4U
M02@5$6K;'O\`ZNV$Z,N1.K<(D-KTB''^'5P00C]N?TMZR$$3V7-5C(K,^QXM
M7J11>TAF!QE=I,7J:H`T).0FJV,,W@Z7NUB!5](T%9+E.=M!X<0.>JFHQL/T
M!ZH`8+(P5K.;&@QXLB'&C+V+M&8W%8F675-QF8B8G765F(N9:='ZM/RWHOJ7
MI92ILRY#CKA0[DI(T/JSHT=6->5,93I(H?J=-J:UP3%VVZCKC3HMX3,1;AP.
M_0K&Q>(HJQ(FK05%?="L=)3$#YS%PH`!4-]_677_`%#ILJ;+ZQID.FOGJOKN
ME38(B<8;K\6J:H#3P&O@(&L/D7JY61U;$%"$1AFMBQ7PW,MZ055/EYP^G%;U
MU,T)LJ?L0G=*7,,S=JS=9D+R\FZWX7\:RM/.3W==YB("VD<@`P"44(ID1*ZD
M3%L#4V2S9F3+3F4<PV#T-ZH"XHF'&U1'S&!EZT=",R[5?"GQ47J>-<H%SA^2
MEHGN1GI36H];L67U:L-W&+41D6W(-1<S6I?7B=!>J42J#:4SK<DNKB]?674T
M43+V7MHBPYJVV&01POK4BHI>YKYB@MRZT$A!:::<GUVK5^#BJ5D:'K+TD0]:
M^NU\-4P`2KUT?'$@*X(&`08N+A>(PT.&@QQHR!'PXMQS#$.#%CQF<+<6O#;2
M<*6I7FK/L^?_`#_HS_S^C_'CCD"[U_CZ=_/MKK]IKD[I_D\?U,?Y>5V.?AHQ
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MQ,1I]_*W8I0@W%:6VC,7,/,A3#CWL`=&46N*.R!S9?).R#GQ)DW,*NSC4N!+
MF?#9["B$EMQW'Q@Y_`F.XQZYQ'EE#C;R4O8]^FZIH%#0C-;K`B),0X^Y\;K&
MP'#:\R%+4I+I?$5$]Y*4N*;1ZU]:TLYPUE2D8QC&>JCL+5Z:F6E+PI*\*4VA
M2L+1E.4*QG*<YPI.4)RE7\;&4ISC./13Y0Y<HNRZR>G72LV8>9K#[$?XXH-F
M@R<XB+BQD1VWZ46!0WR3,\D^AI#PLI%GPY$N0Y(1)B(_@M^W1=F@[8YD+*)#
M8%UCPXQ`K3E9EPS`F/-:P_';<B$VHLJ=AIK.,2)T)A<+UF?)"\-^K<=D[CCC
MCD6'+]9A9R4(BZON$T:R\RSBWMRZEBNMLO,,N/%'F'K+&.9'CE.N9G-MC\3E
MHBOXAQWW%,)=P\=MZ[2FW7D:@M9M'I/8;^YZ2'C982S*E,-JF-W`E6I>,D6F
M6YL#$:$ZSB*YCX5(9F>NA1:X+WULRT]D>P&JYMU!Z,B:B8ZV2M65^S@Q,V1N
M4?LAB,>N]EG3BD>5+(5R4><F:)$-Z\DM$*;<*Z>L9R2;P6KPJ-!%*\6'%@&4
ME=CT@)K]GV/KZO;2I=,&;RK)4P9I5RZW[VW_`%B7'EV:J4(,B8N?H^3K`Z]*
M(QJJ"MML#XD6Q_,69"5$VN_%\:CV':YV_!1\K6!Z2!LNIRI2T"Z+C6<7%!Z=
M0;E3]I-VNC4DM5J54KQV)GV:U[0N[7QK4H8NWB"]>2'JXTI,LWIWO<2WIVXU
M_I@7'$489&U3NB3LRARK/5;3;,;$K]:Z@7RG%ADL5`=8ET)=<WA;VJ1=J^9(
M5O:D$81LD"$@8+@O9KA1_%3O=4T_J@C;*""W&?.Z5J&S++?6-B`-=L$BU\G=
MO'1(8;5`U#/P,0QD?JH7%SR<*8C*'K&'S@;*EL3DNR?!\6D8[:8L29I);M*(
MVHF#%6&M[4$V:T%QH_8@_6,>8,I+-/@,3#AFS6.I(#UMBV+20CD"Z8YER>-$
M0K+@UX\5IBP@-.3]?JI%0?NEMUQ<WR"=H:^NPC8NC;'=K53R:=9GH(HN%,V8
M8X$BL[0'YR/-Z2+&:S"L,4DLTW'?]03XN5:S,J%3'5J!:9B877V58+%+OU<F
MFR0[9%.LI.YC?N>JU>$16=P@[)7A-6@TR)`@5X_9[U6X4.8#R1@",S6YXD\*
M7UV:WO6-12;@P<;8FTR96]@!C^F3`TGLG7>NP"+#OZJ!+/5*19R;VQ8LV11R
MP>59A<NMVH/+AXD#&WY$27?Q0G1TP%<6*_%`T;6^Y=R:_P!QU<1;*5=[B5<U
M1U][*VBWU,V$0U"LNJ+%2=A:?!6135BABIQW6189;4LI&S"@B%Z\SQ;ZC!FG
M0R-;@K4=#Z=LFU&1^M=XZ\V(P:>K)[53:@->(AFV85HQ:J!MD/L[7SE5>.&[
MN`'S006MO7&3``O2'6O$1);?TYVMON@M3,7VVZ#TG:+S3*1#N<(O:KQLH/4[
M&>`T$YK.#!&;0I<"\9@5>P:S*':X.)[,H%Q%&@@8693,!Q(E/^()L+2)\K,G
MYKG9G3(O0O7C:=MVM79#%*S2[9LNS6H%>Q(V)6*E8AUD!URB@D]A2E1>2SL'
M6FD*SL2Z6@I9(,2L1"4J6SQ*(M&GV</<-;UJK2*YM>O:E>N-CVQ\2Z:;([.$
M%[GH:WE-MRM?Y`#]?[@H05U^!9HL8LQ6MCGZ;J\PVLG85%Q\8;U\5%JH5+9H
MD-0IM&M+M=WL!UQ?+<:AQ*M4=F:L%[S'P@&XF3-9PQKZX72P:?26T73B4>P1
M]U@;)77X,X4J5*@M]TCXI1&O50&_!T[B]EY<@)5_C2=?XM$A?=-%/UVF'Y=X
MC8HY_-`C6T@>CWW3K49FQQMG:N:+VH6^(6+0(E6@ZJ=Y*KVQMUJ!4NKLBA-6
MI].L4^3.OE/(6\<2MH*MV6$.L6NQDIZQ5\(:K]J%'Z#=9'KJ_?@N)TT4N,J)
MZA=ZN.<9^;_%/[<<HOKOYNL?YX^S'[-V<UN^.5MLH&&Z+U]6^W^J>FQZ%8[9
M?<V3>.S;;H$)>6TTN=5Z_'UMML/U_P!X#Y]MKQH].P:J8UVO6E@621+6S-'S
MH2)6Z7KT2K9G2NMRM1&NBZV0JXZ6+0Y6R52P1:D-^MD6%@":#5PU$B6B:J58
MXCY@`%*%(Q5HO.&1)$];6)FY!-R_G^TE_<W=?_AER=N<95C'SYQCS^;SS[<^
M7T8_'\^/F^GD7W#;-<HQX4"/M36%&&\2(DYE#,F*F*AU#4A]]MEQR<UAC.5^
MBG$1:I:D^A#]>OT\-0[N[MA2]3ZHONR5S@86+2(\5<TULPIBET(<_.3'EC_N
MCLV?A;@J&7'+<6+DQX,UV3,7$A-Q7)<AN*O6;MC8_B1]YY5GJ75"G=?]*:IU
M_<389S?6U;H=N%DMA\/01A=NH/=;XP,=*IZY%I+P([5FOQ51`6%='W&OUDV`
M*1W+!(-;\-+L(=KJCU[[J7`/LVQQ-9.RC]=TOIL7:J8'#(L\NRZ]:L0Q@@-M
M$.M*MLD;JHJ7BF(=;>B%95QB;1%VF<-8^FTNKGBK:UU7>V^OWB$@]H%XU<G+
MIM.V7T[T;`N<LRPEMP7$%7NBVK5='ADILIB/#E&+=1BXIB'(FSYH^4ZRVTYT
M->;+\9_7$/8K&X^HFBM^/E[V>P/L&@NS59U89%UO`4#&"*UE2-L:X=#2*I`2
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M_P!(@J<L@0L3<]F3#PN/&C-PFG(\M;4Q4G+3"XTCKFJ_O*95K)!K][J`8_-J
M-F@U2?-J<R=(`VF97R$6I%2LQ9F=#+-`SSHP@6Q@2IHNQ#DM-1&,2D-M:_->
MZB[&53674Z%1ZALK4^Y(+^B]<=N+^\?U;?"-JJ@L;:B>Y+,Z2N1:XBKL5);#
MCQCL7:6:XJ[3`MX4B+!CRDEP@&.%3_%)NE/'5B_ZPGD!9\;6:-M6NSW-%!UV
M(84Z]B*OMT_6+)5[*:;B!D[NQ8SHFM$PX4G<J67F(K]NUX2$5H*<\+6ZO%BU
MUJBDZR"42<7(:\UR>%U`_:XVA'(EIL-/U'2LU"C[?FQMB`IH*IF+#+L%8I=[
MU\`/61NSU!/REQU5HG%M1J5:[IW?9+KTZ/L6L=C+M1SQ,*+O=H!<B^LG+D/T
MH]VJHNSK%8;)BEW&13([0K6S%GBFZO7I\B1/Q'F`Q=>*H)1F)\<,%O&`&T\P
MMUFQGK>0U#:/BM$FK]8H[`/<!#4&QB5<PTB#('Q9@P/N"MZR`H5/=EB7Q-]M
M;Q7,R"P.*TS.7CWBDB#%E`X$W"R5$C>98D5?(55ZRS+[6J4WMOLQ7*Q;`56(
MW/6%0L2GM?1>K-SV.'LTJ`36`,7W-)@PK9#F5<?'$(%XA2=G6S<E@T$?(W.:
MO70\N+@S^OQ@`T6U?0_$,$L%M$N'KHU@6#E'MB]:7*M9;ZV)NL\=9C0F[^J'
MC;2/%Y$*L'BOI2Y(-TZ]QWS$"GU*62!#^L)I^LPX6R^W4->Q0%&.[6K(`G8I
M=<E]2"VQQA6RPFI-!S=TU(9'O(Q0>/8#=Q'Q&X-DA&M?B:_.#5^C;6,S:7J]
MV@%!UZG1]LZ4&:_K_P`<[JAU8T+VC)TH5WO8A`Z)8*[JUW8U9H\&SW5L!+E1
M#,-4,1X@U)VF<F-4^X$*WLW9E#N5YN^`NAD&C,^I==>L%:?CVFED=THK]"I5
MZFTG<]1MDG5I*W6*H;076;`!&%J--<)S/)A7WQ>45D#/A:F:GGXQ?;V9M=NL
MC1E>($JY*U]7C^IYA0U5K<<K,LT$N&;50C-5B_<$P8,RJQ:V;RS4P1\38;!6
M6A=E;N*Z6VJ_1+?=*=2[WL>R=D]1&1FLZQ>[@+L%/NHS2TFYU.F7$_J^RNZJ
M.D:_*N5,KMZ(@3)A,2]C(Q,C6(=?;K/01'B`:,H-P!['VJ5UYJW.JMXD*/L>
MW$=/W6+UAO"KY>+GH.MWLU81$RQ;,UF#T[:M=:KL11MRVV")N'7QL6-?+:^-
M@[-F81]P\28DX;)3]?&16#6N=9[(J@L42T;+K-;Q?#D.?NK2IDA8(XJ_3-]Z
M2`3R`K3!Q^KQM07_`"*$R=CD<$Y!IC$/[,&^)V=NFJC#&MUV$UJ&P62W42TB
MS.H@=5-5.T:H['ZZF.[1%S;#'*QNP,"$=UE*C5VOB)VCG+47'3494,'69`'*
M[S8?%C`V"$5H-?S=@T0(6C"ZJ8&Z+'PK!%G6?MYBME;^740KA41M(?0Q'491
MR)5"8K6F+]:;&O$)-9:M$.M;.-!.['?U)3Y.VEV%5\E1B4LPW;@=&KELB1Y9
MLG)!CK2&UI9[G08EC%U]X4,-KJ=G+A9I*'((1'F,2U0HWC[U_CZ=_/MKK]IK
MD[I_D\?U,?Y>5V.?AHQ_:A#_`%;W(\J7X/Z3?DL?^S%QYCGB4;BW;H;J1?MF
MZ`12F;Z",T1ETUL3.LD4ZL5$I<@X^Z6,T[N7>77#5[+0RN/S515W+<=0&_#W
M8J6729)4$3-DKI-=MK['ZJ:/ON\'!<C:=MH\([;I0.!1QH.9,GS9[D&:#BZU
MV5N.@X"3`^1DH1(J.T[^!F#7HTT?:C#,C$I=0YWB,'"MUFT*OTR#3"EGW/L[
M5FM3FR8CKE335-(V/>5"V!MBRE*]:,Y4V5V7HPM3ZWK4BFC62$.M5-M,TJ46
M1+``5M7-RN;#Z=5[=3E-L49S;&@P-X74@T51PK7%[%UHS8E09N5?%ZG(X!1;
M,8E.4TSE+<=3^8R,J]4F<M68\M9Z\QYXSY4:H8\\9\\9\JX,QYXS^/&?Q9_'
MCF>9]N,X]GM]GM]N/\<?C_)^/Z<<@[4^NB]?3<IUQ9&/R[+9);S(UA"9(Z(&
M$E)GW.Y@LK?D1X,9^*MD@D4A"E#9*DMJDNJ:0AB4I-3K,QEB/*`"7X\9<AV/
M'<@1U,,.RUI<DNLL^AZIIU]:$J==0A+B\X\\J]N?/WDI2A.$IQY83C"<8\\Y
M\L)QY8QYYSG.?+'TY_IS[<YY^N...8N;I54L9,$:-@1Q`Q69[1("5>8Q@B+E
MLJ4I*HDUK+<E#*E*SEZ)EU4-_.,>OCN>CCRCXB8VO`V6W#8!_'6N)4P6W\-&
M,C89(0F3%C,2U37"DM."0^).RN;+>'MHF8A..QXK;LB)Y.2RR6%R)\P5'(P9
M!,<B.X0'LRX[LZ"B4C#L5<R(VXJ1&1);SAQA;S2$NHSZ3>58YZ'.//'GY>WS
M_JJ\OT^7E_SYSSCRQ]&//Z?Q_IX\L?1Y_E]O[?\`SGG6=A0WWV)3\6.])C)=
M3&?=9;<>CI?3A#Z6'5I4MG#R,80]AI2/6IQA+GI)QC&/C\4B_+"?BZ!E.(RX
M6$YAQO1Q#<]/TXN$^J\L1E^M<]-C&,-*]-?I(SZ2O/\`&`HC&?/`L=C/JE,>
M>(,7&?4*9^#*9\\,^?J51_\`NZFO/U:F/^#E.6OX'.PD?!2^J2F'%Q(6RB,I
M_$=GURH[>%80PIWT/6991A:\(:RK+:<+7Z*<>EGSZZ0H=&$80*&HPWC"483`
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MC,=I.<X:8SC+36,YPVA.,YQSN-QV&G'76V6T./\`J_7.(0E*W?5)]!KUBTXP
MISU:/X#?IY5ZM/\`!1Z*?9SJH$BVL92V.@MIR\_)SA$2.C'PB4VIJ2_Y);QC
M+TEI:VY#N<>L?;4IMU2T9RG.,U;7=0ID>P10`MQEJTV0E;#N2!,N>=G&B;C2
MW5YD6">4D1AT%J/%@`@,-V.`K(B%`"5P8*$0(<%C*'!@Y[$G#T&&[B8XR[+P
M[&8<Q*=C>A\'<D86VK#[C&&F\,K=]-36&V\-Y3A"?+\K$C'%.J<'PG%/J94]
ME<2.O+JHS:FHZG/3;5Z>8[2E-L97YY9;4IMK*4*RG/WCPHD3S^"QH\?S;:9S
MZAEMGS:8PK##6?5I3YMLX6O#*,_P6L+7AO"<*5C/9XYQGYO\4_MQRB^N_FZQ
M_GC[,?LW9RK'C'=L.RO5#66FK!UW,ZDJ;UUV,9JEEM.V\]?LCVYN:E+ET:M5
MUCL9VVZB4V79++8\+^"QA-PM-F<BB9&8=6S`01(QKN[TWY:-'ZFU<3;IA&Z;
M2VG>]1Z=KP)*@0>%&OFRG6HTTU9725B""H8>MQH=@-2A,8]'E'R$&!4`A!D@
M<A3V:]]<._LKL'N*K5@%6XCNM;W"V0Q5"ZA9@-<\*UGJSK'L]=UL@4A/D-`@
M%RC]B4!X%;7'>FUYT362*[-86KM\$"6AL-@^']G-8`<A+!"^(J3MQS!D@-^#
M`3'P]G5[WJP1'U[GQB["]++4]/J6/@SV,H\U^7I9LMR+-LTPO>0(X.'EQX#B
MCPMR?/5EUJ?$$>NQ@BZ,E,OLK:DX9]JV/+.)K2<Q_61U92^BF_9KOCH_J?>J
MSIVR:MVSLC?UWKP*?HS5>IM:-7.Y;W6.<FQ"S-`EM%EPQD76;PN-.V$1OYBJ
MPZ<#)#3Z914<\[*;IQUPZ;]H-^;[!;B\22@#I6MZC@WM/K9UY^[/7VPJSIO8
MBKX0>&S.R\T"!KT3>.]*U6BT'.G+H&@'*!1JV.,Q"RG=C1AULL>]Y#3;>7%-
MH0A3J_3=4E.,*<7A*486XK&/26K"$)1A2\Y5A*4IQGT4XQCZ<<<\IX$%D.R7
MGQ`QYZ8\/D2W71\1QR4^)6EP6_)6ME2GWAKB$K'NO96N$M.%Q5-*QC.*5=L/
M#YZF=J*);!FTNO>J[I:9X(E!K]O+T4(4NM9E2XSS#3E2LCK*#%<=0Y(=?CI&
MSHXR,1<25DCYBVG&GJ,:PZH]T.BU67.Z5GAUVU17IQ`M<^G/:FZ.2(%@44($
MCQVU:)[3>D6MM"M,Y$EN.0";=!6FC$)S.2$HD'E/3)R[0::\4_KWL:V!=-;&
M`[1ZY]HBARKUK'6'<M')C-FE2=HG2H3!?7<T&@Q3MN:\@-#R)TOLS75@.5(!
M5(;M@LTL%&2II.S#&<9QYXSC.,_-G&?/&?\`''.>...../+'T8^?S_Q^G\O.
M/+'T8_1]/S_IX\L?1C]''ECYO+'E]'EQY8^C'Z,<>6/HQ^CCRQ]&/T<Y\L?1
MCCCRQ]&./+'T8X\L?-Y>SZ.<9QC/_P"<>S/Z<>WCRQ]'XO+_``^CCRQ]&/H^
M;\7T<>6/HQ[/F]G.>0+O7^/IW\^VNOVFN3NG^3Q_4Q_EY78Y^&C']J$/]6]R
M/*E^#^DWY+'_`+,7'E.?&KMMD`=:A]?3(I0>H7RRA*\Q;#P#L2>/U#:@^S5V
MTT2PC,:$TAV`^`"1M>`WZ1)<N>N;`$)VA%0"O"IHZ<77$MEX;"7<=%^L^'Q(
MT0M>LA[F8XF#LP:.EI=)EG$&8T+<=5HNR646)"TV%>+52:?,<<*..QJN`&.0
M!42T<S4^KB+5G8GZYHLUFZSXA2XLRZC7Y+5K)0%^L@D+&V\/6@W.AN?\2++)
MXE2&'/\`B-.)7G*L_G:#+3&K=@,,MMM,LT&VM---H2VVVVW6B2&VVT(QA"$(
M1C"$(3C"4IQA.,8QC&.?357\V6N_[BT__IP9S(;1+(P*U89PB*_.*P@9:6,@
MQ6\/2IA",/D/0HL9K/L=?D24--,MY\L+<6E/X^>7KQ@_'H=-9M4F7,LR*P#^
MZ"3.2A,QTTH='63S)PVAM&'DS%.H<PE"$X4C.,)QS,>......?G*L8SY>2O/
MV?\`\BLX_P#W83Y?\_9S57XG7;OJMTOU4:W)LN362NZ`K==;HVMZULFMT/=]
MY8+6`:%D9KHZ25A%["*K@Z7,L9"//@RA38X1*3EV/E25XK7U,\37L5W(ZSO;
M`ZC]07DDD[!AZQ#VWL'?"`Z@2"/PE4*R78P6UA7KY8K.S7ICD?-B$CAU>;CO
M-OP\'XN516VM9FW>FG>O7/B5@>[-MWIH;LUO*H&ZCNTWT[T.;VAJ8_L"JTZF
M,TTY3=9A+S/L]`3:1=<8E%ZS5[1;D6'9203Y9$8?*(+8A_U1]:>R6HNV&H*Q
MNG2EE^Z*G6!,J$^Q,B/"+-4[,'>^`V:BWNLS<(*5"^5$HAX1:*N799("R#*L
M9P]%>BRI$]<<<<<<<<<<<<<<<<<<<<<XS\W^*?VXY1?7?S=8_P`\?9C]F[.:
MM/'$V):0I'6%*(II(X?-;.6[7)=I_P`0<#:BP\8"?![5H)^S]-])[5@31%ZF
MEZ,'^X8N^)<+5Y!@@X5`EFJW/=WW":K7[9K2MUNY4^O3PTJN551"GE@/PL!'
M?'PQ<Z)"^(K)'?>:;"D8D=8YDDQD@.?@Q7'%-D(V5H]T;1J8'.2+,)J=:&6.
M6+A@Y9X>"%0C,D*/1&:@"7R<6(U->&PFX4-N)`<?5%CMQ(J&6D(C,);C*X_S
M_:3_`*:;NOS_`*?YL?G_`$8_1R=N56[(]B];];)-8O>X]C"=::T$UC:EE,D3
M9%J#$L,FFU!5C77H#;V4H*6!H#".'@X%IS!(PL8\V)CS9$=UI-*>AO769O4E
M;O$3[8:YBHWEV6+4:X:<H%O@8F%>KG7?7LQ1GK]K\4F8TEZN[%G8DN[0VF3%
MX@2I=OM+@&6E<`-F.[M_^;YN......?)]AB2R]&DLM2(\AIQB0P^VAUE]EU&
M6W67FG$J0ZTXA2D.-K2I"T*RE6,XSG'*-;TZ'Z8W6^^X=I89V.U5#5;$N#S%
MCJ=SKB#>77Y3NN-DU^6W9]1243EXFL3:,Y$S\,6^]-CS&'U1L4EK.W>]?0**
M6:W16-I=Y.I53SY3]E"@D(CW/T*`:8>?3+OX$.W!K/;/7PJ$QZV5LC7^06V1
MT%F1/MU+./(6_G9_UM[0:B[9Z[?V[HXW+MFK7K"3`5J^K'O"P5VP&8@8+&JN
MV04P8=!P"\J;6W91H4#E.&P9A$:"^,:A$Y^3E]]Z=!W>M:Z)[%JD>XVULRX%
M#8,P7GW<`H\65.3+<9?<9&.K9EM_`&2+D5TFXB0T/1)<C/I1+:7$+3A:584A
M2<*2O'M0I*L>:5)7CS2I.<9QG"L9SC.,XSC/MQS]XSC/S<<<<<<<<<<<<<<<
M<<<<<@7>O\?3OY]M=?M-<G=/\GC^IC_+RNQS\-&/[4(?ZM[D>5+\'])OR6/_
M`&8N/(I\5R`+-]03-:.C>PQ:OVC:FC05CB=6P.QK=N=%<E[4K3M@GUJFZH&%
M;W;(HH/&FE#H<$PB1@/#ED\N+P-Q%E21X<%.&:^Z0]<J6'.;(LH^MZ_;%LGM
MO:TM&G=EE5QSAO,F;=-97>>3N-,.O2EOYE!K3/EV!I.&WBSRIS[WE=O*DIQG
M*LXQC'SYS[,?I^;F![5_FQV)_<6X?].$^-5?S9:[_N+3_P#IP9SS]L6D[5:V
M.>K++3QTU<*768'KX;LZ.TD]9($,@_(8:RC.&V169Z_6K<:;97A#BEXRG"52
M=C_\_H_%_P`N.....,Y\L>?M_P`,9SG]&///*E]K>Z>C>G]="3MFF"YF]7F=
MD%J72.N@TB[[QW/:7,X;CUG5VM12LG+'.6\MM$TFM$*M@FW,2[`;%Q<>MS_*
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M@#/(XZH>(<&2:$4.9>P.!R9K>G^U^ME%1I0Z2^!+LK@2"2%GAUS`O-2H^UWP
MI_$7&>))UV(;?DUZF:^O->OEFI]NUA6K^B\DJM$'R&E58N<5(%`BPU%P%.**
M"DS@\>-)9:=^`2IJ6GE-[.^...................<9^;_%/[<<HOKOYNL?
MYX^S'[-V<HCXXU%!;2UYI'7MH=[A"@)@KN8B[;>H6H]W;Z,4\N-U/,B5TYL/
M4^C6&K!8*<@P9C1D2BID.&8GO8#S)+$:PRB@C=71&8\6DU&/$5,5%8J]=9C*
M(0<#9RH[0:"VQF8.1E28,M3:49DPTYSB*_ER/C.<-XSS*L*3G.4XSCTL8\\X
M_'C'XO/\OM\OISA6/G3GR@NY?S_:2_N;NO\`\,N3MS2!XM=:E[_SUFZNG"]H
M'TO<W?;K/KTB'J\ED*_8:U6ZQ=]Z[.F3B?Q=(+/,URNT@=-`/AIXO`2T?%YJ
M8Y.2/:B)W45\8X%`A`[Q8J>>%"1PUXZ==B/G#3L&&S%<+&7X$(=!>+$EM9F$
M780Z!$=F//.1H45E2&&_7XXXXXXXXY6#MQL)BD:?)!H0=NU7;:9,9JG7%+S)
M3&7:KE<W_@,2*XXK"TLBA4'$^P6&4XR]'B!!<UV2TZWGU+NI;LMX<-\U&8A]
MI=+I"[N(A,"HNX.F%PN)RBZ7WY58P>./8:U'#P32`U9OT-/^$1Z#+>;>I>Q4
M34U^ZCXI,C\<9LEU[T=X:W=>KAMWZNU="'IJY-FFW/5L^":UL=UG?:B0=P=U
MKNK3_KX*0UZ#DWG(5C'V8?)6>C8BRXD\P#DCICUC;;TCJU>KI^7UNM.RM(7=
M`J:[5H-1V]=@^N7+"W'=4(;L%.+_`':UI`!,U3:B$8;6<.*BX<;C(;<7A:<"
MT?UX[V4VBQ0%O[<UR&0"3'XP>"C60C:8R2'4I,IIPM8["BDW%^8Y+E$$/1WI
MLQ;++,#$8LF,G,%CP+N]XFE)VY1L5:%K[>VNPD.2Z?E0H`#2XNRN'E/#UP+$
MT2O5O-QYE88C1C,$L!%-06Y,UUE8HTA*V43K#[I5.JRV`G8RAWSK2==>3%23
MV`.07U61EJ7E&$A-Q53)2E.1U8]%32K$_69BL+2E<)MSTD)MV&.!;&,B&J^7
M&'`Q!I,B`6#SXA09.87_`!'X9""](B26E_.EQEY:58^;//5XXXXXXXXXXXXX
MXXY`N]?X^G?S[:Z_::Y.Z?Y/']3'^7E=CGX:,?VH0_U;W(\J7X/Z3?DL?^S%
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M1N2W:ZT9)EH?H>A-6[,V#%R;$7PW7LRG#`2N0Q0BF1Y:+"=<*G7Q:8W]&VOM
M?U'5M.`4*BA8M?JM9@I'B1<3TU(9:]-;KS[[SJER)D^;)=>FD2,MQV80G2)$
MR6\Z^\M><SXXY43L=U>UAM:C[.9-Q7X/W:@X^"L>)F`L;)M`N?"EURX,B"`P
ME$7=!ST?(V#+BMQ)!N(1E@R#ZFY^)3&F<YTEN=,#U;=/7NSF:_M?5(U\,"W]
MI*KPL;QUV-S)43E:C['=?ES6:OVDZXR)OK9L>FY?B[&HT*5(G:Y*//1$9?\`
M3T)X_,,YV<U/TFWUHB(%W3:KH"UO:-MZPV6`):`>,&Q+I0/;J\S<&`NP!0>P
ML?%Z/N,LX]BWU8Z4S4BN912`XZ__`$?(7A:<*Q[,YQC.4Y]BDYSCS]%6,^W&
M<?-G&<8SS]<<<<<<<<<<<<<<<<<<XS\W^*?VXY1?7?S=8_SQ]F/V;LYK9\>#
M6E^M`7KJ>U)JNX[#OL\QL^@R5U79NX*CZRL2J0[<'*FY3=;=_.@HN^S+)-KK
MTG$(O<K\5A@0=B4.I+HEP\5&;2NPNL9VW^I,O4S]6V)*7>*K1*^6#:N?UB$L
MP=A*P,Z9ET=N<HO7Q.K#GQZ8ESI=D588=FJ>2]7D![$R0D0Y5=>NG6_LE0NR
M`NYWMVL0JR+"7Q@X7I<N.-IIJN6#4G56KZ[U/2J'B8_/J=0U=?=<;?-`P<B.
MR!K(\A$(5R80*[)N+(ZW5BA6)GLWJ^80.P9U?F4G;B0`-@%F#."NLLZP00<F
MF_C:5@TF<]A3K#>!0S,%*O597+]'#F;)K6E"?26I*4^:<>:LX3CS4K"4X\\^
M6//*LXQC'X\YQC'MSS4!?K,_O;Q/^A=>;A-MC]':7[K=E"++$AUYI#A,Y3NK
M^M24UIU*$-R9T*Q[!D1<82YZ+F)'P=?H,O\`EN!^;CCCCCCCCG&<^6//_P`Y
MSGV8Q_CGV<HOK#'_`*1?8ZT[TE8S)U=H9^Q:?T:E:4*A'KVXZB#N?:$7R><P
M\U$DQ&-;U>>WYM.1!]EDL>7PS*LW5-!15B%3@AN#')"B4=<6;"DHPME]E>/;
MC./9E"T9QA;3K>4NLNI0ZTM#B$JQHS[B=%"@;L;3>T77RZ5ZJ;?J8:DDYU8N
M0]]G5/9.U:T,&#E'$]PSXYW"2;HM7Q"$T?LSXA58]2F1B[64EV?X""Q7]A_3
MWNO0>V`>S`G*^>T[V#U3)A`=_=:-C*C0]H:?M$F)'D-XF1VEX8ME"/I>Q.H.
MTJXF34+R&<8FCI3$W$P;$NCQY8^C'.I-@PB423`(1(TZ#,9<CRX<QAJ5$E,.
MI]%UF3&?0XP^TXG.4K;=;6A2<YPK&<>SE1#72G68\E+LVD#ETZTW"4ZN6\1T
MP92%JI.9G/IH78]6E(Y36QQC+N,+D(57(4M]/FCX>WC/GBO]G[`=R-![<IM"
MO.M"?937>1TDC8=BZ/T[;AEED1B?PB`%B$!;Y*;1XUF%SH:R16(&.MPYXN;'
MQED/)]0R_=/4O9#3NZU2X%&N$5VT"\92?H)Z+-JNQ*V^VE.9$<]1K"P/LD!4
M9:LM.2?@#H];B5?!YCZ,87F<\9QGYLXS^3V\<<<<<<<<<<<<<@7>O\?3OY]M
M=?M-<G=/\GC^IC_+RNQS\-&/[4(?ZM[D>5+\'])OR6/_`&8N/(>\7$E4P72'
M8%COCZH-*KEQU"9M941LZIZ=V"(K\39]827(:=V%?=EZ@I%?W,B"Z_'UD_:]
M@A0;EHE1$2X5E_X=6-2-X9Y82>Z)=93P.`,&C3FM(9EA@9N1GL(IU94N8GRI
MYS=L6PVV#L^X%9DB05O5Q&VFQBB]UFV!X6=+#L19SUZN8#M7^;+8G]Q;A_TX
M3XU5_-EKO^XM/_Z<&<PY$4).WS*4A;BK"!HXXH[A0<<L:V+/3YXMM"9^9'QD
MW85.B'%9F^J;:R&4T/2EU"'L<F_CCCC.<8QG.?9C&//.?HQCFKOM;XJ?7W19
MJV:(U4>"[Z[O)/A-;ZYZG54DZQ=;%M6Y#HD^J"[/.D1FAE1IT,>1B6:Z6V;-
M^#`*FU*F-I?G+B1'80;ZJF^OW7K8L_9UT>V[X@W?BV5.F;-W`)DRJ^DE:S,K
M#H;66OTMN*G5#K?HVE0S$0;6(N6FC0`:8+'<),6I[,?9WUKT2%ZXZBKFK`I-
M\VD4L@1*&Y$.)`67.&):YQ2:W#B8RF+#R^OU`V*\_-DQ!S$6*_.EK9];F>..
M..,XQGY\>?S9]OTXSYXS_AGVX_IYC,\$F*FR&*L/K\"XFQS;/QO/'*4U/FCH
M\A`/!YR`N*0G08+CZT80F1A]J.XZF.M.<XQS4?N;PF>K/<V]W;<VX])QM>[R
M,Q(X*X%&05;LM5MUA&#H0X9>XV"@]URPP7P+#`MUMF8!G)S'CO2'(MA'-EEZ
M\MS7WQ*_!5UG8+:&,B>UO4JKM"AHRN[?-6^S3-;(+&1-<KS%1VO&^&;-`@VY
M$X?!Q1-IINP2*EU,.H7R.M+8]Z_?A9>,3J?OC0!PW:EBU+ICLR0M-J'0M$,V
MPK%)'ZX,GH9`&:6[>H8-^\29T+UL@S`J:S,@"\C#!)B&M:4JW3XSC/S9^CSQ
M\V<>?S>>,^6<?XXQSGCCCCCCCCCCCCCCCG&?F_Q3^W'*+Z[^;K'^>/LQ^S=G
M->WCYD!`#2FE+&:/58`Q$O=_##7)/;V@]*+D4L%DU8='!`T3<NQ-NZE@1M4R
M9:<R]]!JA(M>S"E"@HBTJN8==(EQN\:AM1F*3468;85J(S5Z\U&:K;LE^O-Q
MVPT%+#8)Z8E$MT,AK"$"G92$R7("8ZWTX=4O',LY!-R_G^TE_<W=?_AER5[5
MAG-:.YD*:1'0)GNR%O1F9C:6&8SCSRLQI#C4=U26FUY:P^KU*7?06ZE:$J0K
M4ATM&"[EXBG=?8$##CPS2V@^G76FMR)#,-,QB=9`-U[*[#BSGH*6V72JI6RZ
M2@R]G#CLB3$8]:\I3&,YW'<<<<<<<<<IQV[V^6K8FJZ*UJ1S&WIV)FR:1K^0
MTWE]-0#JS':O&RB?H+1F-$IE:DD"(M*LX<('&8L>,AW#$KU=BM7ZYK.H]>T_
M6E-AX@UJE@8`$2SGRRZXS#:QAZ=+7C&,OD"<I4@D2DK\W)1"7)D.Y4MQ6<Y[
MSK2X<0A%DPIT9B9#F,N1Y<62TA^/)8=1EMUE]EQ*FW6G$9RE:%I4E2<^6<<U
MJ=X^F)+9\^@[WZ]3'--=I-)AY0[5VZM?C4.6F*&P["EHU=L*FJFC`.Z="610
M](VT:PL<AB4*S)19:04$&82TR_&Z+=V-C;$N]VZW=UP8K0_=P3*>MT3130]$
M"E6/5#(H7!A7/KY?GBYAK>M1S.A%"MR,0R*+#13Y*95CE;%B@PTJ5VF_/\W'
M'.,X\_\`_N?+]'S<A+;G733V[T1'M@TR#//"L8R`NHE^96M@5IU'IJ:=KEZK
M[XZT!\MN+4YZB*2Q$>5[)$9Y&<IS!RJCVZT7_P`2@VT=VHH$;T,)I&V2$&F;
MI'14^DC$<!M@;!;JMN4WC*7$LWNO#B,GT<MNV93BO6*R.E]U=066Y5O6%HBW
M?4FV+))FP6-<;5J)&J&6)4$>N?Z;9ASX14RPTGAF1%`EPA\C!-3FL08J\3'6
MHZ[=XSC/_GRS_CC/MQ_CSGCCCCCCCCCCD"[U_CZ=_/MKK]IKD[I_D\?U,?Y>
M5V.?AHQ_:A#_`%;W(\J7X/Z3?DL?^S%QY#/BSB(MJZAVFI1*Q8[[;Y%AH]OJ
M]&I%PW36+M.Q1;O72A2U"Q_6458.R]I"41,N$;M0#1U?*7`@.6S"=^!AI9*4
MB<O#_`2ZSTSZZAYU6MM+E,:U$R'ZU>K?=;W:A2B4B<4]46M&RX(S9)%Q],U,
MR,WL8=!V`-@28@B[1(]G'E6D^Y>.X>FJ)?[3JV;*LQB_UB'KQW%:KM9G$9=C
M*;+:VQ.`5JI2G5PQIZQ0PND]B'[)`CS6V:V("I<*S&)DR-!7(=CN5:V!H(U?
MJ@6CFJC=M0D[=5S<?#K<4O7;+1Y)P(4CID-LO)8GBIL:8TEYIMU+;N,.MH6E
M24Y-JK^;+7?]Q:?_`-.#.?L,JE2[U<Y(C*7;H-@U@%;G,9(^<>'B/.-5V'G#
M^<#LY]04F2LJ@X4[_P!XPB8OTDM(3G?'''*N]N>V.N.GVJ'=D7N,=LI@V=$4
M/5NK:7"P7V/N;:MJ>S"INK]=@L+0LI9[)/SA&''%M#@@UJ:>-28@H?)?QJIZ
MX>#FW:NR-3\3#M_<+:$[JFMHJWB:U+JHY6<:,UN]\08JM-U4ZY/K!6Q7:73*
M:T/%VJXQ+**CV2T,39HF-'&(9=G;(**G.\>TEPV2O/PK7O6V*3T[KWT\J7&(
M;:,MQ9.W;7$QC*4Y<KHG(C7T60I+F,2%6),=2/-WT[L<<<<<<<Q^TUR);`!.
MO3)A4<P390WF>")2@Y>$ZT\W)CRX!&&M#\>1'D,M.I]JFG<(RS):>CN.LKC2
M<+&"]:3JGO\`/UNZ5\O(=J<TD="IA0;`%+N8B"H=GB97*'J*2$YRW/GL8A#W
M)"6I3:8KV/69I!O/PN^I78FB-#ZI4:A7HC347`^$]76KEK<O(&H9;C3"=4*R
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M[^;K'^>/LQ^S=G*&^-U0CNT*3I<9KVC[`V3<:7=2TD\,U)=-^#+94*QL*L3J
M_!(V,!UCV#KW8XJLW*:$G`8FSKB6?T[KR6-FG;R(*,M171VX@G;`6G=-R;E<
MTD0X#7>OFS!^/ZQRT&8L2N5]IR4.C9%Q_A%H.+S%R/@L"HBY=B*K89&Q5OSF
M&<Q?J_N#I7;UR#T>GF"CQ@_6EV`2Z0%*@#YLJ%2M7;$/U5J4Y(7G-MJU,W-K
M<Y8!.6?4QFS\J%#G3R=9MD(%DMMF1'NPNFHC4J.[*B4S<^949M]I<B-AU.L5
MM9D,I7EQG#J<X4WEQ*?33G&4^>,XSR8;/(#1J^9<L*\(!J'2F"V<X?SYP)36
M8LE'E%QF3G+C3RFTX8QE[*E8]5CT_1YK%\)M$:U:Y[4;[B-+6.[%][>SUUJ\
MY]MQ+TG7NN+3`Z\:[;;<=2E;D%BK:<BY@^>5X0V\O&%Y5E?EM7XXXXXXXY@>
MS=DU#4-#LVQ[V42(JU3&.DRDOT,O2%I2I+46`/BISZR>6*3'8XT0.8PJ00)2
MHT1A"G'<8Y3C4G6OY7K6+[5]EZX1;W#--![-JNF_=$=&LZ&HX5UZ93*>J.%)
M0(A:SR4RWCVP'"K,R)(.$Y09$5$&(\W)V!\<<<I#W0Z.:][EU^M1[(;L=+N]
M",0['K#:%.(O";[J>VPI&'H=XUK8&,_":Q:X><Y2\MO$@)98&%!+:'+C%M)B
MU!I'>C?752PR.N??6I,VVQU\S2A=*[HTS%=H/7W9^O[(45!>O&\2-E+#Z_UR
MV54`L:07O%7G2Y=8N1+,./JY]XA81-;YN4BRHTV.Q+B2&9464RW)BR8[J'F)
M,9Y"7&)$=YO*FWF'FU(<:>;4IMQ"DJ0I2<XSSL<<<<K/N'I_UYWY:1MRVW0<
MW(\(%Q0HYZ;:+?"@Q!<2;((HAM!Q1Z")PAV9*>?E+^!X>F*RWB4XZEAC#<<X
MZ^[PTQCX1UHW&^6J\7*EM:/[!RBUXJ#;&%>?P"G[.96]LNDH2WA3<1DH_=PT
M9:\>B+;91C&/0#]R`-9)PJIV5HUEZTVJ6^F%#*W5Q@OI^P2\YPG'W,[F#(74
MLH>SG"F(EL^Y(QGTT-J'>MSZ/+B0YL,C%C3H$J/-A3&6I,29$>:DQ)4=Y&'&
M7X\EA;C#[+J%)6TZTXMMQ*L*0K.,XSSM<<<<<<<<<@7>O\?3OY]M=?M-<G=/
M\GC^IC_+RNQS\-&/[4(?ZM[D>5+\'])OR6/_`&8N/.EV\U_V\G2:5M'I5<>M
MH+;%4@62GEZ]VJIMZ/ZPL=+N,ZMDIDF)9=7'`E_IEIKQJJB9\+X'\<5JVCW)
MH&PBX<Y->M%>G'KM2CNOM-4:J6NZ5_8=N'CYLFXW.I5V#4*F>N1@V4/6V75:
MH/(%V:U6&[(4*1*\`>-&R`@/&A02QLP59FDI5<S_`(=>BY^SCNXZT5V51=A%
M4`'QY8#>C!*!63H@YO<T3L@$%;W;('CD[:GL;LX=8X\B(^(^#%(\H&-"E$3)
M\V;[9J'7E2ZSOZC@5H>0H>M=08JE0"V%AJP(&BZ%17`E56ITJW)7(("H0V)E
M@D[YS$RF\RTNI?SZ?)*U9G*M9:]RK.<YS1:AG*LY\\YSFN#,YSG.?;Y^?MSG
M/X_;SZ56MA!E@OUB%F'"LVUV"$^;:S*AR61!`("'`T"FDQ$)7&4S%BLOO1YB
MG):'9&?3REK+2,9UQQRBOB4=LK+T>Z8;B[.U"H@KU8M:IHZA]6LI,D("D\VO
M8E4I<GX80$L22$?X'$L#\YCU#*_6R(S3+GHM.+5C7EX2Q`IXBLZ9XIG92$/G
M;-@V&[Z9ZXZGBQR#NNNL%*JLAD1<3-$9-NN2R^SMM$'G)-TV:1A0CGW/Q1U0
M"M#`34J/+V]]E=IS=2:E.'*[&^,;Z?DC*%JX(G"<K-;+NLI(*G0DH6VXVIB*
M1D?'!'T\82V)%SG<^Q'EG(=%:J@Z5U12]<0Y&2$D`*3D^;7Z:I%DMI-UTK;;
M-,<=QAYV4?L<PD4<6]E;B4R4-95E+:<8EOCCCCCCCGDG0D"QB)P0HWET<29^
M#36<>K_X\92T*=8SEQMS"4/I3EIQ2$I>0A:EL.,OI;=1@DFM6"B4EH/J:*(E
MRAL_,J('N!$JJ%('2)+THB+AE8^79`V0\XZI0V1)8FPH;BE-NQ\L*3EGW01U
MP[5XTVYUQ=.E$%R!1*NV*:)F(3(5)>@?!DRX[[H\I")X3ER!G&$JG17F_61&
MG%J9QK7[M^&/0M_Z(VKK;5$X_K.'L)D>2M>K:G9)%;U7L4A7[`+MD%N;7/43
M15-L+A0+"7"LU4B!U+DH1&.-2QTB2MO65I3H;LOHSK@#\EUU[B]+[4UE\\<O
M-..PNY/5^VR"2ENK=WWUL+/$9%3+#8>8@@F>UHV!E(;C?"F[;)2TA+%Z-?\`
MB.]C=:A4%^S77L/OC4\1./AW;+PZIQ?>%'$1TQ\/O3=J=;":\]A-5.0([3T@
MXD+%V<-&J2[C,IMAA;F-DV@>UW7#M+4W;MU\W/K_`&O7HB\,E7ZG8(DHE7I>
M5>AD=;*])S$L=1+-K_@/B;.($$6'/-MZ,A?\'D_-/-/H]8RZVZCSRGTVG$.)
M\\?/CTD*4GSQ^/'GYX_'SZ\<<<<<<<<<<XS\W^*?VXY1?7?S=8_SQ]F/V;LY
M$W<G7/<$9=2-HZW;SZ9ZNU=NBMBJ#OJ3VQUU9SUBI<(%".P<W731FK7BE@+F
M5<IILXVYJ_;B?N4B&1D:SQ;(P)FVNL%KE;!T'K7<VHQ6K;@LP<JL41`:#&Q-
ME)`CC+\>K3:V.LD$W4I8=*B*1A65*94A"P[LB0E_(YQE##:(<T/T+TWU[ME5
MM--)WHG]Q%8(`JN)M5A:,P1I6P:_TUK.VV]3WP".2FV"T5;15(:FIFSI`D<0
ME6N<$&CE664TQ)UG``H'9/4YZ"%$PCARE;@;-F8@V'&*F&X#>L68+90BRRB8
M01":3AJ(B6\\F,WC"&<(3C&,?7MJ7+5_K/O0\!)UP*;!:ON)P45MJ);U>@3P
M@6478D$HT`B(F3&F\P<J:@QBHUV;)PQ$Q/A)>5):IIX+.F36D_#DZYB3S59P
M1O\`3`VZWI@`>>&DB2MR@@VP')%Y:/$""Y%XA/FW@A:<+5""3(0H4\,$!FU.
M#F-J?''''''.I.GPAD.61(RH\*!`BR)LV9*=0Q&B0XC*Y$J5)?<REMF/'8;6
MZ\\XI*&VT*4K.,8YKUUT3:[S[%#;?>8()ZMZB/8DZFKY:-F"O;NVQ&7&9FS;
M")>RIY-3U[(<<&T,3-2E4ZR8G6.6TCX##C8V*XQC'LQ_Y_\`SG/X\_/G/'''
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M`IIS+O\`Z^6VCT\VPI-^I.R*_"M=`M=>N5;(-I<AG*T7@F1CWI(2O+?PJ`\\
MVV^WA:<.QGLM265^;;S3;B5)QEW''''''(%WK_'T[^?;77[37)W3_)X_J8_R
M\KL<_#1C^U"'^K>Y'E2_!_2;\EC_`-F+CRN_C/LZ_F]"=@B-FT>)L6I&[_I`
M5-J)*SE*H(+/2=MU1<1DR3`Z+[+6%0SUK/\`WEBO:0O)['I(EAVJ]/B,6T#(
M'A*`A=9\.;J77@L9,04&U7'&P(R6WVD-1HEAL#3:6D2M1Z&D8:SA.5-9=TWK
M=:F\I7FI"O2PUG8OS`=J_P`V6Q/[BW#_`*<)\:J_FRUW_<6G_P#3@SGSUY3)
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M3.NY1J$EIBZW"-7I57+W.JBVIF9IG+1PE/8J]])*C`V`PZ8@*(D39BY\C9QC
M'EC&/HQY<<<<<<<<<<<Q^SU2N70-*KUJ#0#H:9ZM3\`@QAYG+C2\.,OM9\TN
MQY4=S&'8\J.XU)CNXPXRZVO&%<P_XG-ZTHOQ?11QC8$H7)PY"$6>WY24=&/S
M<.2($(^4C2/6*&PU+;#123B4K0VU%?((QY.9R6G6A%P!,&?B2P5U[+TF'+#6
M86Z*+P)D)[+$IAUK.7&9#.'49^#SH+\B#-:]%Z,^XWGV0QL+JCIF_FU7)H'/
MU]L?R5EC:&J#,W7-^;<5G/FY+-5M45H\G/GE*HMF@FH;B,Y;=CJ1G*<Z1/%#
M\)[86[-.;,LE3K^F-K[F2)'/`]].TTAJ?LO##C#P0B;$7$GJ)N#6>P0F36A4
M\>V&MU?8(,2I*"PB.^8BQD+JKX:[W>'PZM"#M>"[?UAN`JUWNS[&3HSL@/W7
MUL-&(5AB@D0#&H>TYX)8-9&'[;$'(D?<A=J:-8$3&4^HL*VR#B6=S0;Q:-3T
M9(P?W2U#NKHN5).LQ8-KW)6X]QZ[GY3V&U)55.T>H)-WTU,@+;=;=:D6@W39
MBF5)<='LXS[-E-#V/K_:=:@7/6=WJ.Q*@51ZP9::+9`]NKI!O.,9].$:K\P@
M.D)\E8S_`,.0K.//VXQGSQC,\9\_F\_\<9Q^W&.<\<<<<<<<XS\W^*?VXY1?
M7?S=8_SQ]F/V;LYJZ_[156-=WG1VD:;>-5C-DSC%IVTY6)1.+N`UFFD&-1DX
MKUC%UO3/3/NJ?('(F2,.4'G&Z#6ZF/G#VHI^RRH)=VN%]_&MOYO:-_PU-?\`
ML=5O^&O#N%M_^H!W\!6'F(KV%(_BJP[&CN8SCR6PROS;3FW()N7\_P!I+^YN
MZ_\`PRY6/Q9;-FF>'/V^M+;CB9`G2%W3`99SEMZ86-"7ZP$A,2DOL+A/2#1X
M?AN4UEQUK*?)IAY:DHS<;2]*1K;4&K->--I:9H>N*+3&6D(9;0TU5JH(!(;0
MW'QAAM",0/12VSCU2,8PEOR1A/),XXXXXY6G>?:?76B#M5I9J#;;;L6^CR\N
MB:]H5??L=FL\H6_#BMCV&&G&8PU9&3+<3#(%Y$,4AD88E2IL=D:[E4/_`"`;
M3[-_^MNVY#%8UR]A3H;J_KBT$&0F$*SZ4:;N+8898TK?3L?/H.MUZOO"Z4)E
MLMO)R<?3Z_EG].:2UIH.IO4?5-=75ZP^9G'UBU&CQM&"I)J*S-DM2+`2*2HZ
M9"84=2XS#[<7UR7)&&</OON.2OQQQQQQQR`]Y=8-$]DJZ0J6Z];5G8%;,-LQ
MS86PC8I`::AL^Q,0G#E,O,2,)1Y-L3$(9*P$XPH81@N82YC4-M/J!WEZ>FPZ
M^@.U=D[1ZXQK#KPE/Z?;IVR8(8BP*K8\E54'2'8HQ$M&Q=,4LLEZ,-.5VUIM
M8(N#@-UQBQ5P1,D--WPZ^^(YI3<5[^0K8PBY]6>TT1EM4_K7V,'P*3?"_GCT
M7"6K#K<^;1=WU=;J'LP[%JNR6)*XJ$/D1XI;GP=&P3&<9^;/G_\`;/T9^C/T
MXS[<<YXXXYQE.%8SC./GQY9_IQ]&?IQ].,^>,_CQGE3+OTZUF9/S+[K(A9NO
MNT9>5/2;YIB='K&34GTLN>E<Z:Y&E4.\M.NJRJ5FQUV40>3E26R3"\X<35VY
M=N>PG6;;]&U1NJJC]TU(C">+FMJ:;UO?DVC`*>B<*`8+4>(@I6H-E:.PE3"\
M8!8B+1`&YEP>'%S?@T:7L!U3N_5&[PKQ[5MX!V^'#=S&*1H#[C!D%,2I2%P+
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MR5OM+)OBS=A!7LY"L4R'=-$TK6T>N;`&ZTL`^WVX_/@I/@U`X@VW3.T;1?NG
M%<VN6U\89M&R>OH&Y6&C!UCXDVIE+OK!D^:'OXMY6OK3&J\PE(BS&9#WQUEJ
M-EMD;+GXS%5.&K,?^[+7F,9QG&*-3_+.//RSY5T9[<>>,9\L^7L\\8S].,9]
MG.CI\#8ZWKX(*MKCCEB3(.SBJG2&"BDOEK$6*H;Q-2I:'6VH\QAMM#:LML(3
MB.WGT&DXQ)G'*^]KMOT+0?6W=^XMGD7QE%H&M+:<//0VT/DY;?Q1)@P0P2*Y
MC*)MAL!69``UX=GVD39*!"3C.7\8YII\#?PDSGA]U*1O[8^Q",C9F^=&:ZA7
MG4LNM#10S4<R)/E7-X*NRH(.S#A88R2C"3ZWH`Z#'*0B*HBGHV&%(V37^P$.
MVUU,Z(UZ6?AZ+J$IB+V'V6#F82NWS'66I;6BZ&7BY6E2IS#K$C9MB'NYP)$*
MQ6HTA!$C)2F[X4*)K@@8``C80<*&@1!8D4-C-0QXT=!81&AP841A*&8T6+';
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M:G\>EYXT;>(-X15[5HS<1C0.M-/`]F&1PB5,V3UL+[-ZJD[.-#V(49/KV_U]
MUB0)ZAW`IX/$G/,28`H<?'F6XQH?'==CN17X9\,S87>SP_M##=?E&.N^Z@%J
MN]GV#"U1MK8VV>OFXBD2TLA&(!G5&_\`<==G:"V`'-QQB9X^D%WZ;-'R5/X1
M996"&,,[M:9XL_61)@13.R8_9G1[8AAV/#&U[MQ3U:VI]CG.)PEQ%#WM!F']
M`W^&I_\`@P9=<V4\].96S(1";2[Z*=EXLN+-CH9<,1A%A1&.U+'DQDI@@/GQ
M7T^FS)A3H;C\66PZC.%MO1WG6UI_A)5G'MYZ&,^?M]O^.,X_Y9QC/.>....<
M9^;_`!3^W'*+Z[^;K'^>/LQ^S=G*$^.VK1,;4FC9^]8F@Y8)O8MJBQ<[QZL;
M=[8O0(K]*=F'IFMZ'JFA7M@3>"`X:W4XEFV"V%HP>/:5DILLX2'C:=9-E^[[
MD8I'4X_8Z%;`>O[=&U8VYKN4M-1'QY5O13U3*?5@,?;92#6&I)LI&@BH<.V2
M7EX@+DL.Y;(X1.BU8ZS]P-S[<[!5^D6,$N/7#=5MDDI79E&GTRQ5416]+]3M
MBU'9U@&D)!8E75;+M6\+W7<U,@:*#1J!0>O!2DZP4.]%#UQ;&6GR^S&K!3];
M,C8(NE;>7!L4Q\$L/852FM7N/M"68)J8<9<'+5EB9DT&$M+<3G,!V:WYN8JA
MXMRHA3JV"UW-0\^WNOL+UOT?$B1T.K<D$]H;GIH")EW*7HK3<2-'R0FR'79<
M;+>8S/J'FI2F'4;/TXSC&?/_`.9>?\,K5G'_`"Y^N....0'O_>XS25>$)B!Y
M5VV5>BR*KJG6`>2PP>OEMDI\VXS*W<YP,KP=K."=NL\EO(^N!FW9<G*WEQ8[
M\-ZPZ<U]^RC=Z=A\Q=F]E'C8ZV+ML*>>%5O7LD:G'Q'2M:B(9*&U&J%794N&
MV\68F3[-)=(E36%_&;D-%X/F^;CCCCCCCCCCCE4.S_2SK]V]K[5<WC1AUQ',
M.PG8Z2"5N/CW($A+\:;7R#;K!:HG8JO27`L]/)`+#!?]6\V17AI+7-?9^M]^
MO#V,14:6L]E[Z]7LOQ\M:BWY8XT'LCK^`\XXSFOZJ[*S7?BG8[0U.&,!ZOV!
M'03)!M;`V#LY;K;CF+1Z7\4;J'N,D]27KG8-2[P&6.K4VR=:]U4NR:^[!UVW
MW$T^!!`E:UEP9A"TIDSHLB0Y8J!(MM2BA&';+-/1*\VX21L/PK"O/RSC/E[,
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M'M`>A=A.L/91C8MNU;83D"[#:L"5JUAH-!/F7[>6M$.F5N7LK\.T/I^O]+.O
M8306QHFV].BJ-F!K[9$&B5C64*WUZ,?.-QS$2B4NJT>IUJ*\_B2RP/KU0K8C
M+3"9,(/!9D)93;)-2JR6"\5-<`IC'YJR1R,D.-Q',D''DR')Q5C$7#1*8X^E
M+RY4U#\A;J4N*<RM*58\+:O\V6Q/[BW#_IPGSQ*A)G0]'UJ6,:D/DHNJPD@>
MS$9Q(E/36*;$=B-1F,XSAZ0Y(0VAEK./)QS*49_C<R76^;`K7U(7:W9CUF<J
M=?<L#A%EN//R9<%QG".)K#+;3;4I,I3J'VTMM^BZE6%(2KTL<S3G"L^BE6?G
M\L9SY?DQY_BY_)CW%[[WOLQXN.E?"WO.L`,?K]KCNAJ&S6N<++V%TSMF/5M7
MM;7I(J[C9`WXJBU,)L*6,LLL=$??AV-RK"HTMUAE$A?/Z!.[!5PMJ.+I("Y(
M7L'L2>%ZRID2'/FP'HZ94J.7M]H(+'/,S'*S4:M"(E;%%RKX$3C+8!3\*C%U
MMKF/K[I0#U[U-5=4UPC/+CZVU/<<*DFX[$HB1+$9)8G,Q$BI1&@1GILM[,(<
MQA3<&)AF+EZ0MI3[DT<<<<<<<<<<<<<<<<Q.[UR1:JN4`PB4H-+G8B*BE84F
M3%E0),6?%FLRVW8JT.KRTY&2I4=2L,RTXS%DYQ'==YB=+K=PU]334*221L(N
MQ((D@3"D,@9DW#L9EQH20,2W93<B4[.2^A!>8A"6HBXK#K>41O3S[%,O$VR1
M"KE@I=GH$P'ZK!!FTMCTP'4K;?==DB38Z;+'%(,9#"LR)*%L98PIO+K2,+QY
M9<*,"#T%DD$)CC`Z2G"V)XN;&(0GT9QC.%-2HCKS"\9QG&<92O/L]O.N=K=?
MM`J2#LH,/80LQ'JI8@Z,A%Q<IORSCU<@>08D1'D>6<X]%;.<>7LQY>SE/KKT
M*TD>#E1%)^Z#4X\PV^@G6*A+A%]6FO7XSA35ATG?(%LU*8B.84I+[.:G$==2
MI6,24*SA6-(?<;PE.QNG]%;7D]$[`3H%@G1())VO=9-Q;5ZR5JT1X)P81.2+
M+U[@&;;J:859#1IS\,AJ29JPX[,999;@%(CKP:9&GAY=K?$*Z$:0'U+M'IHQ
MV!J5HN-@O(T]:=YV\9ON(!L3`7X'FJ&=]!H.HMBUB0F&N77ZM$VY4+",>E3\
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M&7*M=[HX.T[.Z!:W*.P72AWN52+[5QCKWHDGRNE*S:=F$B8Z.WC+S^`M=#E,
MS_-26&()-V0_A:&\83L91Y^@CS^?T4^?G\_GY8\_^?/UQQQG.,?/RJ6[>U5=
MUL2EZ\U]6C^[MZN"WR`_4NNXR"Q,4SZO/P8QL`HEU`RAUW+V6\9DG)3!.?A:
M6PPV<ZO&41+TCUWL$U$.;^[,URV-]ES,TE39,J[CQ$"/5*$.<CR`P3608,Z^
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M3*+LT-EKT?4I8MH)3$LE$:]''HB;`V8#JQG.%P%84K&8F^.^V/7[^#9Q.>VN
MKXO_`/<M.@"JGV&`0&\(\UFJ1ZV%2MH_!VL80J74Y=6L4M6%O9`3'E>2ITU!
MV(U'O*+,5KZV1YIH1A*;'3"\696[]5)&<)PN+:*0=9@V0*XVXKU6'I,#X%(4
MG*HDN0WY+S-N,XS[<9\\?3CD"[U_CZ=_/MKK]IKD[I_D\?U,?Y>5V.?AHQ_:
MA#_5O<CRI?@_I-^2Q_[,7'G7\0#L(6ZF=9KWV)KT?7V"U!E4I$V3?S5)KT5Z
ML&+U7QUB$!R&PMGZ4J$NT%H$AV#4`]AVO3QLNS2!S_K#DN)&K!R0^H&YT=B.
MMVI]XM"ZF%C[2KCUTBBZ7;Z??04*(:-%I$1G%PU\;LU%/F,1?4JLY"GV:RUI
M=G49;"V(Z/;8*RYS<MM7:^._6V($WBM/1X]BRLP.1@"_+::?BLFLJDXP)=DL
MOL/1VR'P9;S3S3C25H=1E7A;5_FRV)_<6X?].$^1XY;)U%ZTP+<,;CO$@.I*
M_/'-RFEOQED$5@6B$F0RV]'6XQ\)<:]<A+[2E-^EC"T_/R>(;CSL2,[(1AM]
MR.PMY&,9QA#JVD*=1C&5*SC"7,J3C'I*\L8\LYSGVY[/,)V3L*HZFU]=]H7X
MQ&K](UW4[#=[><EK2W&$UFK"99LX0>6I:,83%'0I#F,>GC*UX0A/FI2<9UY>
M%IKVTS--W7M_ML&\+WAWPV%,[,VD82;SDI2-<EQD8%UVU1E3_HN1F==Z3@5A
MB5#7A&6;.;L[ZW%+EO+5Z/4>]'.T>]-H=A+C22P$-KJ`K4VE</+C3*V/'3#!
M63?YL8HB0M@W=B;HX!%/%034@!`$)AAQY24I<E;VS+CCCCCCCCCCCCCCCCCC
MGY4A"TJ0M"5(6G*5I4E*DJ2K&4J2I.<9PI.<9SC.,XSC.,YQG&<9YA5?UO1:
MH:)6"L5817RI>,B(2?#QL#F9C3;R9"<O0(JFAV7O6IPI4I,1,E>/X"GLH_@\
M\6L`]IA;$^D]=P=QI\AN:ZWB;64`[8-DK=2N#&;F!I"0A&`TA3K3SCXV),PE
M#*DK<5ES.?U!VC`>N3M'*U>[U\FY.G1`Q$G6Y;U;L+4)#K_PT;8A62(QEAZ,
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MQFYG7WQ=>@W8LG$JM>WJ'UULJ3Z+:]2[W@3]);':F*7AO`^(%V`T(@6*7A>?
M1Q]R1BP,.9_DGEX]O-DZ'FG$(<0XA3;B<+;6E6,H<0K&%)6A>,^BM"DYQG"D
M9RG.,XSC.<9QGGZSG&<>>,XSCSQ[<9\_QXY1C7?S=8_SQ]F/V;LY#?B@]P[5
MT?H>LMDU)>AFX%RV"5J5S#;=V]HK1\RVMKU[8%UMD/<=^[8U)34#01I@><O<
MH?(OMUBTT2]`K=`)LDB!8#L;$V(6-HH:QGRE4#C&Z\$FSRD`@U!IT5,J!"SA
MP81*?`&V@:GGT-B79B8JW(:XF%MMNK]7C)&R@UZ>Z+:GPG"3$2//?'HE,*FL
MP9;CK468[$2YF0W%DNL/ML2%M)9><9>;;<4MIQ*87N7\_P!I+^YNZ_\`PRY7
MS>%(@7/O;TD/R,S5$-.5_L?<AC3$A*(&,777T77T^63AKB2527V$38$</,CR
M!WP'X:69?D/Y(,PW+\\<<_*UI0G*EJPE./G4K.$XQ_3G.<XQC'].<\U6;+V_
MO[L=N>J5#K-*OPOK&/-$->;?WGKUBEQWR1B3.CMGY>O3UN>7(>'4G$)H,_<:
MH.G^KF$K)\4?&4T6.]*_^H])ZTT?6U5G6]8B`HLM_P"'G"3CCY*QVHPOSS)/
M6ZRD5R#=G.2W%N./DS$R2_YKRVSZAA*&42KC&,?-C&/R8\OV<YXXXXXXXXXX
MXXXXXXYY18$'.Q50C`R$2BJ]+_@S([;Z4J6CU:EMY6G*VG,H_@>L:4AST?9A
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MVXE>4.9QG",JSC..=SCCC.,9^?'G^7D$;<ZW:EW0_`,6L`^.NP1/_LSLZG$I
ME.V=5G4XSZIP'=P3D4RTTTK.5_%DUZ>&D*_@RQLA&<IS3PEL7MKUYWEJK59?
M[JNRVF+&18<L6R8FFS2+U2J^37)K8R%;;13D+I1V6))JC60F4B@1AET)!EK)
MQ&<D(KZK?[T]JM.>?LS\NVNO/\N,F\9\O/\`%]&?QX]O)X3_`">/ZF/\O*['
M/PT8_M0A_JWN1Y4OP?TF_)8_]F+CR#O%YCB"'2Z[#YH0O9R<6QT"UAZ_7+YM
M^C'_`%E0NP,I)LL=?70>8[$V`544J9,G:UI4.0NIN$W@<A#`F03D-SCX>,%H
M;TIZXQ6`Q^OH3K8<]D-:+Y;-E'8#LN<2F/,D;G?XL+8)9S+S[CK;>PH4/8`F
M,XR$O$2-:AA=A%6MF=1]D7?=%\VJ`TQK^NJ;O%.S*!R;X,16]^ZYI8CL*-&1
M+Q`#UQN3FT2;UO5>WIDR]XL$,=FIUJGA&6Y:"E@EW#3K&YT+IM7-5D=AS7K?
MKCK_`%^GV:]#X4,F];2=(UDP"L$];=KB%7,,6J8-DR7Y,G"B[34K+B9C4S*G
ML9O#N3-'T;KTVX(R:^$`=4@F127<-8?>LV*T";\W7&9./1C?#\R?06TKUV6,
M,^FWEWUJ)ZQGS_3G'Z,^7'/Y9_'7UAV[[M]A-5=)NDVP3;Q6-UPVG?\`LIKB
M+M0OK_6F*7:KA3PVL5[=^"*>`%)-H+`;)'IE<+P"1&<R.*D6X+`9F3.SN/VE
M=+2!U3ISJ57[)&:[([6I=)H)AX;,9*D*+5XU7BPMJ[1EK;:3ZJ,*%"["Q7)[
MJ(RB=@DPG8*,XCO>JN_1Z97==T^L46ICVQ=:J((97@D!O"<8CC1,1J'&2XI"
M$8=D+0UZZ4^I/K),IQZ0[E3CJU9RKCCCCCCCCCCCCCCCCCCCCCG'EC]O^/G]
M/T_X\C<AJ6D3K='O;0Z6(MC4Z%-E&0!8H$>,?`4M-MQ3\<?+9A'83C#+49Z.
M3BR,.1D)8]-*,>7/E:L;>B'HLZF*H9BM*;B-3Z_84F@IEES#ZL3)L&QP%E83
MWI,JPIJ%*!M82IO*?A*\N86CLW7:E.UY,&Q[C,GA8A-E]UDZZ&+2*Y&4PZVU
M\')G8<.1`%R'?6>L91/=80MI#CF7$I3YYSZ-*C3(\>9$?9E1)3#4F-)CN)>C
MR([[:767V7F\J;<9=:6EQMQ"LH6A25)SG&<9Y]O+&?Q?/\_E[//\N<?/CV_D
M]O*J[[Z/=2>SHN2)WKU^UCL-J5A7K)Q:LP8YM*U)RG#K9X:W"+H<;]BFU9EJ
MPE6,9\O/FHOL9X2/8/1&C=B)\++N%VNU2?P(CHJ_6DAN(>6U88D/G1BR$*GV
M;8:ESM.2V!^99".5K9.+B1\"R&>0M@H[GEU/"&UUWBUEU/E@/$"L5MLN]9FV
M;H;A3;KL41LT]&U\1@5?%7'2+`$FD(,5$63'-^05,IUP>XZZI>?*0G.9BUW\
MW6/\\?9C]F[.4!\<ZIS+KK_1S58K5MMUDK-[L62#&OMD;KJEBKP&Y51T-E\J
M(Z[[+UEL*.$LST!8=.Q+.9FZEUJ]'=L5]!DHV8#T'9UNRCF+KUGQ2ZSK:N;(
M*%ZM6P$:M7,Y5#`L=!*AV`!>Q+GV044J-N+58$0)%0L8B.^);0;C04OO0!\Q
MR9'JSUDZ9[1U!OFNWB7+%U[7=:K5RCC!;%O+6ZTJ`6W374_6E+TV9)2X\)HF
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MTS`(:XI;L$6N6V^]#C/..2&VG$XD.O/^L=7FO''''''''''''''''''''',?
ML=3K%P@MC+77@MD'LRX\]F$>%PB\5B?$7ZR)/CL3V)#<>=$<_P")%F,8;E1G
M,8<8=;7C"L:LNT'AC&MS[/KFR-+=@K!UBS36=92X5:I%9@6>J;%.TK:\38+S
MN[JM;)<VO7^O5J`/;;U%6E#H<.C74F8NA!=A:=C@46&VY>.\.F1L(SKC2M)[
M?C$%9J3E7#;!!Z,VC%`YB2),<E7I-NC2-=6PNU*;9@JKI"52L2DOYF-6++C?
MP-S\%?$$TCK48.G]F8]IZGHFR!`QXIO2".$46`=,IQ\%"S]HULI9->#)CC^'
M8D=1X^$:FRF'&H2I&5,Y=M]3+[1]C`8MIU]<:M>JS.QZ4*Q4ZPB+0"EI]%*\
M*C&`4R>.?3E"TKQEN2KS2K"OFSC/,LQG&<>>,XSC/S9Q[<9_QXYQY>?T_ISC
M]F>0-O7^/IW\^VNOVFN3NG^3Q_4Q_EY78Y^&C']J$/\`5O<CRI?@_I-^2Q_[
M,7'E1_&QU!HJW=.+7MO:.HM87R\Z9=$3-57[9NM],WX+J.=9K;6(9VPGI.\]
M8;?I-;UK,8@P,;.D3:.49(!H$!MS,*9$&%Q=G_#/K==J?0SJP$J@@Z#`M:C`
M38`\^)I@*3CXY>G&Y4L:(UU3=>4.!6"<XC**4QBGT6HUO%/F@5!Z\*A*:B-W
MHY@.U?YLMB?W%N'_`$X3Y`IPG+8UMUW!PHGQA)LL>CPX\)X4%*1<R1%4@6)J
M8S@PI*8IX<@4[+`2%9P.3);=R24TG$=U-M&<YRTUG/K,YRVC.<NX3AW.<IQG
M.7,(QA&',Y]J\)QA.%>?HXQCRQS7'XKO;W9G1SIA>>PFH*_3K3L`!<-5UH'7
M[R-/%P)/[N]A`:G-C*&5HU7S<P@J$3?R*9@$D.JGX9_X,K&,L+JOX'YZVW?K
M/O7N'V)KA"G]@NQ'8/:=SW;8K>!L-/E(KFN?@]8UX!AB+<VP2KNN-<T>&L74
M!"UNPX<'XS)N3)A$F3FOVUZYZB`;HVJ:[TVX"^/+V\@^UI$(I+@YL?K06'^Y
M*MWRQ0,)0\1N%T$HGDXCA!QZ.)K1,7&BL9>2T^QL3^;CCCCCCCCCCCCCCCCC
MCCCCCCCCGX<;;>0IMU"7&UIRA;:TX6A:58\E)6A6,I4G./9G"L9QG\>.81=-
M?B+M'&MRR-E!3`SKKX@M4["2KI$>Z^TAEW*,P'DPY;:FFT(^#$H<V+C&,^BR
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MD0I`BCZX"@QH)O+"C,./#$PXS,0LJ,I<=1.*TTA@AEA:V<S&W\M*RWZ/,GY!
M5P_G_P!)?C_]CMU_^&7*@=6+^7N';3>$TU9`):?8M55%]^,+)[%F`7V*#LB_
M4\01UG%L(:%5X`?`F5%5LQB/,S956\C793T)RN2PQ\WLTXY`W8C=P_1U!>,L
MPI%COEDE?<IJF@C([LTY?]AE([V`->&06,X><CI=1D@<G9RW$$A(DV=+?:2A
MO#D']!J!LZIZPMUBWQ5#@/>]\V&;-;(L%D)`"I2Y8AQH,&J$(;M>F3H8ZNB*
M_AD"'`X=:0-=@DGF(^&IR7GKT\<<<<<<<<<<<<<<<<<<<<<<<<?/\_/(-@`=
MD&S0UA#BCH@E%>@D!1D="*C9T*1C"7X<R"08D19,5Y*<8=COM+9<QC&%H5C&
M.4FOGAT=<;)!DXUP/M'66R8'8'@KUU<.,:4MU42A]J2RJORJP-0*Q%;<:RVX
M!,"#%8EQ'I,.6$=8>SA,8(U;XEFB1*V];]AJ'W"BCVI&8(+L]2JYK>W%HS&,
M+@#'MKZ0&U>`&G9;1B&]8"^K+WB4\OX?+AQ4K6RST1OB4V'73CXWN/TU['=9
M)@["72UNKX\!V<U"U"S$^$Y+0[AHB=8;ND+C*'4.D36K0[<#U>?C7X"O"T(L
M)0?$,Z/;4%2#&M^U6C;Q#APZA-F(K&P09>?"3?;2BD5"),$1)"S$8N=MST:M
MPP3T!!I)F;`@21[#Y"$F1)^]<XRK3OE[]]=X_P`<*-XS_P`\<G=/\GC^IC_+
MRNQS\-&/[4(?ZM[D>5+\'])OR6/_`&8N/,(\36;%'=6R,Y*MMLV4?LO4!C7D
MS0U(QLW<0_9M=V`'L>OR&N]<SM8;@JURLT.SB![\(7?:-+H$7T5F[<;J(@2]
M;`N8="B=<'Z`JFIAS'8.%:=+AJS5-A0.SZ`D[=4>VV:LC-DOO7VU4:89U39[
M,2AW&,3-*U;8S%2K4^6Y46F@4L(\`'>O;^YFOZG;[_KW-4OQ:\4K9-+U2)`#
MAP-:M@VR\:9)[Y'HJ4Y=@Q"BC1^O:_:9A:?<7*KB//K1&$PS)Q*"R"LA6/9]
M(O76V5M0&<BMTC8^G7+?4BY9:`V"(6[T1T[6UJ9(K8<8ED8!&(I$%WRDI>7E
MC+?K$*QC]4*!3S,#2+!&5E=RI^M0UK!BTR)#?JAY:KCZM-*R8J4?!I"49><A
MQLO+];'><<<:1CS4KDQ6$PU7@)H\\RN0R%$$RSD=I;;;CS8R#(G+9;6[G#:%
MNHCJ;0I><(2I6%+\DXSGG\S72SO55/&[[Q4@H1H-HUQH?H]01F_ZUJ&V%@-@
M<V!V1MQXC3:=L6X.@EN"W!.GZW\93=>A<8>=3<S+UIF.M.BQ<?&V/N\%V'NF
MUZGZNZLNBZZ[=(UEN6WHN6)#HYG5`AP8)1-L\F*MLC+%E#4N2&@U!E^-$N<M
M;[!2=%@#'G,[#QT)@;`A#XK,>/&@Q(T..Q$CHBQ66(K#;#+4>,UG+<=AMMM*
M&6&\Y0RTE+2,Y2C&>=SCCCCCCCCCCCCCCCCCCCCCCCCCCCCGY6A#B%-K2E:%
MIRE:%8PI*DJQY92I.<9PI.<>S*<XSC.//&<9QS!3=!#2JE8JM7HL*I-V/#[D
MF4`A,"W&R$O,=+QC"1Z(V'":41VE(DKSAQ:V6<..>@C'EWZ56W:G7H0-Z8T1
M<A^2<D,1UL29V<X;QF1/RMY]3\U64Y0X_P"DE*VFV$(::2WA&*AZ[^;K'^>/
MLQ^S=G*N^+?7F[<*Z_U,+%[:O[`M%GV15`&>EM2I=HW4Y4;M28U#VH.B$MN:
M]M&E]9`"=+M3[!G;EZO>F"5+;0VS2-A?'YO-?+W:+]F=?T'JA<NQ86NW^P47
M3]3N\@O6I4'XJON6]-E"M0N@W'W:D!D(K/#D*L:;0=0;F@[:U`^.ZP=L(PL*
M(D/O6.V^O;7OXQH0?`/-DAQ78-5A6B3%2T!,WC4]>U;:]A5B$UG/QBE00#N"
MJO1#+\=`DO.'VL;%?0\$C.%_<M%BK\OLCJD+%.!Y1BOTG<+YX1&)0I!0*Q-:
MUB_#>+#V7URQS4MC/KHJYC+*9#7_`!&<K1G&>15X?B]RF='']@[Z@MA]A;1W
MCON[)`(B"(JJ]07-K6:O:E#NK"./0YSK&L*_59;A-4B1+(.3ERYKOPIUU"+Q
M\C3;6W*%I.DF;[L,XT'!AXCDCU2,8DER\KTV6(@:O"6U?##1PG-DQ!XP9";<
M>DS9<=O/H(6IQ-'NL6H=_P!@[#7;LWV.JH2`U;:RIS3M:(W`@>L^CAY.5$CR
M:DS6,CT5H$4-UB*-Q;3`F<LG\;09<-S*D%B3;.RS&,8^;&,?D]G'''''''''
M''''''''''''''''''''.G,'#R*4-SX,.<VTXEYMN9&8E(;>3G&4NH2^VYA#
MB<XQE*TXPK&<8SC/GCE4;_T[UW<;\.V(#^+M>6(8=J]M8*TRCZ_A'%V^MG(Y
M-ZQ/')=8F3))"QB8D2I6!X@F>_(K;*8<)X>\EN0C/]ZX\E:=_/MKO_,;SC'^
M'S<GA/\`)X_J8_R\KL<_#1C^U"'^K>Y'E2_!_2;\EC_V8N/*_>*3C?U^UW1=
M"]9]-;-VQL>Y6F!L$Z2UGV@J73LI0=?ZP,!YA:2SODQ5K]<ZN9O14P,H@SY+
M*3,N"!9.QSD6W7Z8L4\Y9OHK3ZS0.IVDZ74JI9J&'K%5D!LT6Z'`]IMU)+PK
M`;;LM.L]N`$C(:YGZO9OC@$6NP\P68N4V`]:,$YZRRY3O9MW3O4]SME^O!.3
M<XEHOEQHE_P7$63`Z53[?0-:F=0#3=*<:'*4*D%-=V([63[1!1B*0A%IJVF(
M;[J749S<=<T>I=>BVMP=9$Q:10]3S*U4JZ_&00'A`M0I,@16H<1!'X4O_P!3
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MY]6HU(DX92I$`JP[',6*S0V7?:>./9?])QA&<7>XXXXXXXXXXXXXXXXXXXXX
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M=>?CLJRQA/+:Z0&%0^G=7CCT*,.L$>@U+-A@PG)+L*+89`*#+/1X3DS*I:H;
M)B1-;BYDJ5(]0EOUV<K\^?'=>Z]?]?Z`2V5LHJ\*K0R6,@*5#A/DR4T@7F-P
MH$`8,BXS)GS'G%K=RRSCS;BQY4IS*6(SJTT<%:+W3V=W+J/M7LDC"U/6]:6!
M9/5>A;-3&+6<;ILS*,RS]ZFO'HL"L;&M;>&9\>.-@DG*0W!`(^$/DX,QMS9W
MC'ECR_\`.?Z<_P!.?Q\<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<@7>O\?3OY
M]M=?M-<G=/\`)X_J8_R\KL<_#1C^U"'^K>Y'E2_!_2;\EC_V8N//?[7](>L_
M=JO52M]CM>S+A'HI@@<IIJN7W8^JKM6)I@;D0=8";!U+;J/>1XBQC,-0K*`8
ML"0=B8B#\&1TUP:.<BSWKC7-%U#0JAJ_655"TC7U!KHFITZI5V$V/"UZN@X;
M4$6*'1&_/#4:+&:0C&5J<>=7Z;\AUZ0ZZZO->8#M;RSK'8F,_-FB7#S_`"?<
MX3\^1GH*O)HVKG+#8BHI&+1&'7<@55GX!"&!DTFN0822,N6I#;#8D*';7.EO
M.)C,)2^[AQ+*,JQ_,WI+IQM;MYXDD_QDZQM2LTGI75^R12]Z]:V68N(TYL?5
M6MM9LZL/;3HHQMN35Z[0K>;$&9%5(G9H=ZTUJ,HW(AQQQ&!\,W'ZQ/W+Q$S$
MY>RZ::U]UFUZ89G1*@EPO%7O`S*6Y*K<>W&W,"E/5^K!TCK!/!5UA\63+&1;
MRSCS,1MGFS^J52MT:MAJA4`H^NUFO0&1@8**CHBP!\)C&<(9891CYU*RIUYY
MS*WY+[CLB0ZZ^ZXXO(................................<9^;_%/[<<
MHOKOYNL?YX^S'[-V<[/9;PXNF?;[85,VEV%TU'OMUHXR(`@$&[KL>HC[)5H!
MW-F@TO9M<H]OK5;V]181YR42ATC:0FWU:,\3-H9%(CG3+$^[C33;#;;++:&F
MFD);::;2E#;;:$X2A"$)QA*$(3C"4(3C"4)QA*<83C&,?3FM'OCN(=JS;O2*
MKRP!6RS.P^[)G7D=`#SH<"1`Q<EU*R&;),=E^>70];KE++E"T:&G,^1$:4U%
M4A:LK3=/=FXJMHO6M@V+:'O2CBV6X@0-&2X\4M5I)YS$J]0`PH[;TJ>;L95<
M8=`B1F'7,>M<DN)1&CONHU^Z2TT0[TT_.U^Z8NQSI,:;/J]9T-D7?]44[7+X
MEQ#1&RJ'NDQQVXV>V1WVG\6:=)=%C1$A8(3';<9FJ1M(!!1U;"!ZZ(:=8%`1
M0\,,9?ERY[[0\7#9@PFGIY!^3/FNMQF&D.2YLF1+D*3EZ2^Z\M:U>KQQQQQQ
MQQQQQQQQQQQQQQQQQQQQQQQQQQR!=Z_Q]._GVUU^TUR=T_R>/ZF/\O*['/PT
M8_M0A_JWN1Y4OP?TF_)8_P#9BX\N?QRI/;[:-TU=4]<RJL9^XX+:]HLU/8NR
M4UYNQNZTIB];;,L\2RL0YL:>$8?+W^KT6@-33PTB,95=/5)BY)2!S[$'=@=_
M[NK/0376WY%#^+]EW^I:#8W`"4"F2/DOA[6AUN#M\RJM3GTS).-<M'#,E0"6
M_F?)P/R)0XHHXQG/\W?>;1WBU]]*E3(6E0<RI]:J<8V;UTU^FF[?V%73FY*?
M8Y@:")MFXZN-7&!SJG-@P5B@LPJ(:&@A#A09;U,RG7\O;LZ?UH[K%9FF@&Z*
MI1">BM7TG7]7DZ`H6R8XZAFDZ[K4*"#C%!LL<.A'&,66%%.3'B:%0W(L*,(8
M#I')^#9V<-7S=3+:&FNOZ&VVT);0A&UJ8A"$(3A*$(0F!A*$(3C"4(3C"4IQ
MA*<8QC&.?3Y0=V^X+];%-^P<?*#NWW!?K8IOV#G6F;+W1!B2ILC03GJ(<:1+
M>]5M6GNN^JC,K?=]6VF!Z3CF4-JPA&/:I7ECSQY^>.D`VYN"R@@EC&:!DX&G
MQ`PV/Q,V?48<S$$M"8(1,2XCL#UD63B/(;P_'7G*F7?3;SG.4^>?6^4'=ON"
M_6Q3?L''R@[M]P7ZV*;]@X^4'=ON"_6Q3?L''R@[M]P7ZV*;]@YUIFR]T08D
MJ;(T$YZB'&D2WO5;5I[KOJHS*WW?5MI@>DXYE#:L(1CVJ5Y8\\>?GCI`-N;@
MLH()8QF@9.!I\0,-C\3-GU&',Q!+0F"$3$N([`]9%DXCR&\/QUYRIEWTV\YS
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MF4-JPA&/:I7ECSQY^>.D`VYN"R@@EC&:!DX&GQ`PV/Q,V?48<S$$M"8(1,2X
MCL#UD63B/(;P_'7G*F7?3;SG.4^>?6^4'=ON"_6Q3?L''R@[M]P7ZV*;]@X^
M4'=ON"_6Q3?L''R@[M]P7ZV*;]@YUIFR]T08DJ;(T$YZB'&D2WO5;5I[KOJH
MS*WW?5MI@>DXYE#:L(1CVJ5Y8\\>?GCI`-N;@LH()8QF@9.!I\0,-C\3-GU&
M',Q!+0F"$3$N([`]9%DXCR&\/QUYRIEWTV\YSE/GGUOE!W;[@OUL4W[!Q\H.
M[?<%^MBF_8./E!W;[@OUL4W[!Q\H.[?<%^MBF_8.?E>P]V-H6YG0.<I;0M:L
M)VO3LY]%"<JSY8Q`\\Y\L9\L<E*C6E%XI-1N38Z6(;M=<!V)`J?E&9PU)D?&
M(8@S,MX2C,F)B1ZA_*$X1EQ"LIQC&<8Y4+7?S=8_SQ]F/V;LY>GG"LYPG.<8
M\\XQG.,?3GR]F/\`'/-<>O=Q]C#'=NX:YL`V:WK8>8W.,?!JKS$0'7]>56C]
M:36F=B1+)E.99(QL6WWW;(1]7QC('E&PI4+!"CR&KSLM75['WW:B-]U$!1M3
M#;K9J<6KL_6$RVC7F*P].MPR3"MDY=OB!S"JY%"PX<=J?,S$8,1)$QI,*5(@
MS'&XT=ZSU_W'/;Y)[E[-Z9#7?-<:3)TG50FV:FUK[5AE]MD8:,@Z]/5-E2;"
M2%Q8V1UD*YDDAN7S/P?$!R>RF/>_Y0=VX_\`T"_6S3L_M@\?*#NWW!?K8IOV
M#CY0=V^X+];%-^P<?*#NWW!?K8IOV#GB3-P[>@G@E<>Z^D%$#\(Y/@NL;(JK
MPUIBOX&9G)GD4#_@\%]WXVB_`&'L^G-]"7EORQ%<SSV_E!W;[@OUL4W[!Q\H
M.[?<%^MBF_8./E!W;[@OUL4W[!Q\H.[?<%^MBF_8./E!W;[@OUL4W[!SQ)FX
M=O03P2N/=?2"B!^$<GP76-D55X:TQ7\#,SDSR*!_P>"^[\;1?@##V?3F^A+R
MWY8BN9Y[?R@[M]P7ZV*;]@X^4'=ON"_6Q3?L''R@[M]P7ZV*;]@X^4'=ON"_
M6Q3?L''R@[M]P7ZV*;]@YX4_<>WAIH``D=?2*IUD^./B]R-LBKR8#/Q)!;(3
M/C*>T.RP/]:PZE$'U^?^]R,*91Z.4^EGW?E!W;[@OUL4W[!Q\H.[?<%^MBF_
M8./E!W;[@OUL4W[!Q\H.[?<%^MBF_8./E!W;[@OUL4W[!SPI^X]O#30`!(Z^
MD53K)\<?%[D;9%7DP&?B2"V0F?&4]H=E@?ZUAU*(/K\_][D84RCT<I]+/N_*
M#NWW!?K8IOV#CY0=V^X+];%-^P<?*#NWW!?K8IOV#CY0=V^X+];%-^P<?*#N
MWW!?K8IOV#GA3]Q[>&F@`"1U](JG63XX^+W(VR*O)@,_$D%LA,^,I[0[+`_U
MK#J40?7Y_P"]R,*91Z.4^EGW?E!W;[@OUL4W[!Q\H.[?<%^MBF_8./E!W;[@
MOUL4W[!Q\H.[?<%^MBF_8./E!W;[@OUL4W[!S[!]H;`S<*I6;?I\A6(5MD&8
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MX1J[5><.Q82G8#EM*2`U8A9PM&))0\1BQY,I@4(AYD%)J(S:7Y#$-<5I^(I[
M$MC!.O6P;IM72VN=A;#HGR:W*V5N*6.TU)":38%277I#;+L*45$@3/Q<8A-1
M3PR,>!AS\$<4BP3PN`8C3HK4S<<<<PK8FPJEJNFG+]>3$0#5Z['8?)DYK[,:
M.UF9-BC($?U\EUB,V^0)SH0Z)F2^Q'S+EL8??9:RMU$-]/\`L(GM)U^I6[,#
M*^%>M$Z\#9HFKVQB\@QQ"D["ME$FQH-JC0Q\<RGUU9S(7*9AQVLKD92RA3.&
MW'+,\<<<A7L3O"O=<-+W_=-G$'["+HH9N>BMU6&W/LEF+D28\!7*R"C/.L1<
ME;'9"X@)">FR(P^*]/3+(28\)A]Y'J:5V9`VUK^#;8DF(]-8.7*GV>)#A&!S
M8*[Z]N1ZAWFL.13[$0MEZLVRNEP;DV1%88+_``%)D:C(HC!4J5N...0_O_:+
MFD]*[/VTT&185Z[I9VVI!J*#PRBWQ-#7*S`CSBDB)"Q,DI3EN#$=E1UDIN8X
MR.^U*FL+QY_7';[>^=.5/:K,:+#8L[UH1&CQTE(KZ8U?N-AJ\99D$?AC[)2[
M.\P$;>MNN+7!BV_6=H<,:^MK*;)6BG)PXXXY`_8/;Q72];H5A%UT?9$6K>^@
M]1%(\XO*#K&"MT[:JFK9%B@*BBBF"$^OOVN*5:$2OBZ*19C2&7"D-?J\N0CU
MD[E,=A]BW&FXIZZ[!B5<G?*9,^,FYY"35@>^MR]?)\>VQ&\^I#'I-BT[)LD"
M+">F1\"3Z@TQQHQ6B#Q"\W'''(([!;=+:9K="L(NNC[(BU;VT)J,K'GF)0=0
MP3N?;-5U=(L4!<444P1(5]ZU1BK(B5\712349]APK#7ZO+GD:LV=M*T[>W9K
M^[4,`(JM`8H$^G7>L'#9>*5DV_-L<+4.RMF*\&AQ[O3PP.IVLNY62!P-\4[)
M`CY"AY,>ZLI$FN_FZQ_GC[,?LW9R]/'./1QY^?X_RY\OT>?EC/\`3C'GRC=X
M[DQZEVCK^@6Z@N4)>L^GZ'8+&Z30R4;M.]:9OBZ4V0!"(4I$\"#B:*F0[1*F
MNQ9#B[/B4(;=;J95DE>1.<*3A6/F5C&<>?S^6<>?MYSQQQRN.S=G;5IVYM&T
MZKT"OVVB;)L16O7`EBPE8=TJD"#4+799M[B"6@LJO.U"LSPE7KIQ1PV(E$2=
M_$1`3RB\>`&LUC<>><8SG'EGRQYX^?RS]'GCV9\N<\<<<IQNCN#3-3=@NNG7
MS$FI3[5NG84.I'XY6ZC@1BHA[!K?<=MII437GFGYML(V>R:EE5MD:PJ$P.BS
M,D9<WX;+KPHW<;&?/&,_3C&?T\YXXXY4/9?;:J:\[#TS0,\6:C/%`>O[);+Y
M)!%Y].KN-Q;**:=TQ3U3`R)#K5JV9L,&>&#IA)J-6P,8)G)J<B:?`QG[=XSY
MXQGZ<8S\V<?\L^W'Y,^WG/'''*7;E[9_)3V4T=U_S6X$M6X6XKD6PSS/P0;%
M=?LK@*6,)3XJ)46FE\P&GRU"9N;,$=N0W!*ZYH9/[N!WP"5=!.?22E7_`,V,
M9]F?/'MQY_/CV9_+CY^<\<<<U];([H6"F[DOVDX&OP\H]$V1UEUAK8]+LLML
M.3+=AZU?[`X7O,;`J-(!CZGC6Y]AJ$`E'YU@7)#,,.#Y<]YJ%:C0&VH6^M&Z
M?W:-$R`,#;>M*1L>(%ER&ID@2Q<JX//H&NS&4-,S<POAV8R9K+;;,Q#:)33;
M:'L-IEWCCCE(;IV6V-#M7;"DU"ET1)+KU5-56ZOG[=:K2T$L`[85.N5DG8L0
MRM4\J=@S!Y2FO5\2,K+5BF&5EQDQOU<O#@=68VZQ6"W4#K':[949E`M-FV+I
M*P62B$)J"4^EGS0263,U*:1:C0VI\NMDI4D+)FM1(S<I^"X^B.QA>&D6J3_)
MX_J8_P`O*['/PT8_M0A_JWN1Y4OP?TF_)8_]F+CRY_''/!L]6KMU`%*O;`@R
MQ5XU&S#*!C$-F</FQ\N(>2A^,^E2%*:?:9D,.I]%Z/)99DQW&I#+3J.*O5JY
M20`NK5(*-KM="Q<0Q8<3$:A0(;'K''EI:8:3C'IO/NO29+R\K?E2GWY4EUZ2
M^ZZOW^...8G>J-4]EU(Y1;R$AV2I66'\7G09#U_P(G"R\U(S%E8CO1WE,J=8
M:4M"7D87A/H+])"E)5]J=3JW0:X-J51%LAJ^(3)3`',.RGTM*FS9)*8ZN1-D
M2IDF1,(3)4V7*ER7Y,F5(>??=6XXI6<FXXXYQG&,^S.//VXS[?IQG&<9_P`,
MXQG']..8Y4J?5J&"C5FF5\36*]#D$Y<0,$A,CQL>2:+3SI9]F)'2EIMTB9)D
M"<Q:4XR_-FR9"_-QU6<Y)QS$[G?*9KL/BP7JT@JB%7/@BVR=@)Q1<-TD3>]0
M/'LO2G&\/39CN%)CQFO3>=]!Q2492VM2<%UWV*T+MR8+':MW)K/8D\Y5EWD+
M#I5T`6627I2/N:S]UPMD1-E+GUAQ%RJ3S)Z*ET7(C6>ORF)3D<Q`=?D2UU:L
MWJM'*?<@0NS5:RC)88_7SH]DB)+BI[.69D$A`EMN,28K[2_1<0XC*<9\LXRE
MQ*5)P"1<]':.9J5`)6_7VMON@L0:M5"N&;((!2[!;]B&S*@0L;')SFYIJTWZ
MRQK`L<A691FX6%DRME9,JB>K$O\`IIS]/E[/+/HJ\L^EG&,>6?+RSY^>/;C/
M[,\\L(>"V4:R8KQ8<;%2');+!$7,CSH;KP^;('3V42(SCC67H1")+@S&?2];
M%F1I$5]#;[+K:/6XYC]KJE;O-;-T^X`A5FJ]D&2PQX`;A,$1)<7.:4S+@SX4
ME#C$B.^VK*5MN)S[?16G*5I2K'TK=:!U$/%`5P;&$B8:YCS,2-A?HJDD9TDH
M3FR'75NR)9`H4FS290C+>?G$B4R60G2)$R2^\OW....8A=:#3]BBX`6[5\?8
MQ8NRU:XCH9)#BVH5II!^!:JB>C>J=96R3KMD%#38B4A>%PR<")+:\G6&U)ZE
M5UEKZCFK98JA3Z]7#EYG_&=N*!QD>#,/SOC$T94^1>92E3V5F[+93KK>/0:=
M.V.PFW&UE3I69,SKCCCF(72A4_8@R`&NM?'V,8+LU5N0Z&2;<<9A6FCV`?:J
MB>C8;<:6T3KMD%#38F4E7IPR<")+;\G6&U8QVD:8UCK<]<+12:@-KYZ^E)1B
MV$XCD]V08)$#96Q$);V)LV4TP[/.G"I:=B"U$;ESYKLF0AQS#>45GUW\W6/\
M\?9C]F[.7IXXY@I#6.OBM[#;.(TZO3=@5Z!\6!;?(&1W#XZ%B.>B,L1B"D^N
M3B)$M=KB0'%94Z.B6JT18#D:/8C3<[.N....1:?TMJ^T;#KNUCU/&$]@52%&
M'`++(7/Q-'PH4T@2AQDLM36H#[40B3FD(J9<.1F/.=3,:RB0Q'<9E+&/+'EC
MYL>S''''',>-U.M66;6")\$+,3J78/NKJ<LA#:E2*[9/B([6/CP.ZZG*H)/[
MGK/80WPMG*7?BTR1B^EZJ4[C.0\<<@*Z=H^OVN[M!US=]KU"M7<I+>@C:V5G
M/,$R$V)6T7(A$A-)BK;E2150=:M9AEAU;@>M.-G2B88M:969,HNP*;LRJB;O
M0K`/M53.(EN"3P=;LD=/1!(3!4O,=[+2,J^#D1\V&[A2$J0_'<1G'LQG/C6G
M7.K"ME%[.MU5JDBRT@<]F!<C4&$W+"B8,Q!_/KRDGU;7Q<()Q$'XF2"W8H,H
MQ\=P<P9Z53.?C7VY=5[5EW$?K>^UBZ3=>EPP&ZPZX39)2*P7L50`7^OP2[+'
MFN(Z<H]JK5M#Y5C+1.N'1)B$X]!GQWG,N,VFN5U\#&/&AP=^T&V:U76R<IJ#
MDS8),&>2C!1ZI*FTR2DJ"+(R8L%M69,I$.1B.VZMO*>>_P#/\W'',#-ZOU[8
M[<"OIRG5\G<:U&Q"#6.6.9<*PX;9%DS&B9D^6,R8T`U'9-"V)N)+0HRVDN,1
M$)><K.>8QC&/+&/+&/9C&/FQCZ.....1$?T+IVT$[J9L.NZP7*[%9I3-T(31
M_KI5@QKAZ;)H3TU[+F%)F4^21G2*Y/B_!IPE^6^]#DMNN97R3`X<37A(P"!&
M0`P0(.A"`X@5$CCQ@H4-BM0APT=!B-M184&##89BPXD=IMB-'9:99;0VA*<>
MCQQQR%;=UVTM>IMQ)6G7H(J1V`[K]^XD%?#XD^P/ZJF3"&N7Y\P=.AR5/TR>
M0F3:\\RZRZ.E/JD-*];A"TXQM4`'JH30E9KP^.*`U[<6JPH89%PI,8>+%QBL
M*!#8PM2UX:C16&FD96M:\I1C*UK7E2LV.3_)X_J8_P`O*['/PT8_M0A_JWN1
MY4OP?TF_)8_]F+CRY_'''''''''''''''''',(V37)]LH5QKPA(WX[,5:R"@
MCQ9;[,",5+@20B'(E28D2;,BQVU3U?"'X45^4F,IY#+2\N93G1IGPH>S`W67
M5;7%7[#@:S`T5TGZ@=6;FS7++MBIPKC8>N79GKUM2Y7(:FM?`),&+LO3>F[7
MII>7UM'80?9$T9/F3ZY`D0BF/:!\*7O7K,GKV/L'O39;U1:_?*;:;;48FS][
M1)YMP3JB%27[$*N)6>2-C3M8MU=`VP17GDNU:ZCB=F"6K(>:Y#-KS3N)X9&]
M.RF]>QY8)?1%<K^VML=%][Z\NTZ?9(TBD1^J-0V14#^KF':R\Q8*^5^[&U#M
MJTDX(D-PGI5NN2EK'%07I&>T!\+GM8UKO<<8WW!MK.[[^[U89IVU1FS]SEA5
M/BZ1Z[Z9H&R<%->62<_3+*.W-O'5QG:]_#9##B-N#7T\)>N%:N3(Z\0M@G1K
M1^P-,A.R):_/?`_EY[A[_P"PU-IF969+FO*+L@N&:!5Z9AM2H$0U8'J^1V;9
MQHSTH@NS[`,#W990E&(%Y]X>..............<9^;_%/[<<HOKOYNL?YX^S
M'[-V<O3QQQQQQQQQQQQQQQQQQREN]>KQS;?:CI;O^#8P`RO]6CV_#UBJI$7.
MF$+\O<^EB6GHL*'/86B`'9`,D5&9CI"(747;9;%-,CD^<WFEBT>!/V8LM$K%
M7_\`3AR/L%>TE3-2YM\<;MQ$^3.JFM^ZU/DV=3<79L-U3IVR]G-47";'D2WY
MB)/6VGL*)OOR0\NJW9E>&CO(AUA\0S3EB[-E+MLSN-K;;U(J>SCI38S2*Y$V
M2)MTBO5ZV@9]IL`!8V@$+D3U^.M-3!B["9U*P$#FXCKM>&CVX%V1X1>]MM;)
M[>[JK._(6AI/<K0UVUW,UN,%6Q:]4V>S]<.GNF:&7D$ZC=AX2SSM'67K-9+/
M3B`F*)DX:V#AD&3!J'2))28=T>&3L8K=1S>H=GD:QK.PW+I.K%#EF[&=!:AA
M]3NP>KNPYG9]*-6HP5M82Z6\=K>S:J=K]>E/`;C/V($N1F-4BE>O1R^;N$XS
MC'MSYY\\Y_\`W9SGR_)CS\L?T8^;'.>..............0+O7^/IW\^VNOVF
MN3NG^3Q_4Q_EY78Y^&C']J$/]6]R*`KIYRA]8K#30T6UD=?19,TR`?,8KKZX
M1K7M@JR7HA"</DP'5Q2!.,MYE2TJ6QAQ;2EY3Z"I5^5C;?N-3]:%;_<O'RL;
M;]QJ?K0K?[EX^5C;?N-3]:%;_<O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_`'+Q
M\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W
M+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6
M_P!R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/
MUH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^X
MU/UH5O\`<O'RL;;]QJ?K0K?[EX^5C;?N,3]:%;_<O'RL;;]QJ?K0K?[EX^5C
M;?N,3]:%;_<O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_<O'RL;;]QJ?K0K?[EX^
M5C;?N-3]:%;_`'+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^
MY>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\K&V_<:GZT*
MW^Y>/E8VW[C4_6A6_P!R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I
M^M"M_N7CY6-MYSCST:GR\TYS_P"]"MY]F,XSGV?$V//V?B\\>?TX^?D2APE\
MKE<TG,A5@::M=#OFU[39ZDU9V8.(<'82=B?`&X9^4*^+B#\!5M&XEI;;:2KT
M9&6<KPWC"Y:^5C;?N-3]:%;_`'+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\
MK&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W+
MQ\K&V_<:GZT*W^Y>/E8VW[C4_6A6_P!R\?*QMOW&I^M"M_N7CY6-M^XU/UH5
MO]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/U
MH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O\`<O'RL;;]QJ?K0K?[EX^5C;?N
M-3]:%;_<O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_<O'RL;;]QJ?K0K?[EX^5C;
M?N-3]:%;_<O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_`'+Q\K&V_<:GZT*W^Y>/
ME8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y
M>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_P!R\?*QMOW&I^M"
MM_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^
MM"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7F'V@YLN^%==LF-:1*@&K.R:
MQ<C!N3>QAO#`T`@FI]I@:+#IER94AV4PTPVG*$8SE2W'6T(SZ5D\7.N81C&2
K.//"?+/_`'0A^+'_`/I\@$W90F3)?.)OGC).?G&?@TOYLRG<X_\`Z'/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g441803.jpg
<DESCRIPTION>G441803.JPG
<TEXT>
begin 644 g441803.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@!!1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]005)424%,7T%50U]+7TQ)3D4N15!3_]L`
M0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``"P@!/`)-`0$1`/_$`!X``0`"`@(#
M`0`````````````'"`8)`04"`P0*_\0`71````8"`0$""`D)!@0#`P<-`0(#
M!`4&``<($0D2$Q87(5>1E9<4%1@Q46'1UM<B05155EB!L><*(W'3U-4R-W:2
M)*'P&24S)B="0T=2930V1&)G<H*BP<?2X?'_V@`(`0$``#\`_?QC*"\_IWD_
M2=52FR>/6Y-9:I)1JS/.',1=]&OMW2^TMAV)["5O4U%A$D]FZR94YO*VZ0:P
MKJ2%6ROI9[8V"2#.+1BE%).LU&YI;P7WU71M$E5W^K93GG9>SC<4]A4FD9*+
MV>C\7Y/:LCO6/G?C=Y)I+S&XJ3=*X%*=KFAF6K9&!?H-CVJ*>R$SN2*8!*4W
MS`8`'_NZ=/YY!"?)73ZY`59SEBD6IC*E1?Q6M]G2T8[*DLH@9=A)QM-=1\@T
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M_3[C[I]M_<7'RC]4#_\`I]Q]T^V_N-DO0$['66'CYZ(.Z4C91N5TS.]CI*(=
M&1.8Q2BO&S#-A)LU.I1ZH/6;=<OF$R8`("-`>6_(SEI5+8SUEQ$U'QTGK"WC
M6TO;=G\N.0;_`$CJZ"%X";AA7*O6Z/2]B;0V%.N6(G<RLHC#5:FUWP[!JE8+
M',&F(>"DGB-O+?NT8J:@>1^H=<4&_5LPIEM^@-PCOK0-Z(T<%CY8*W<WU2H=
MOJEJAI`4AG=?7NH,W[%C(1SR#L5K3).?$5@=F:JK>UT*6RM+B9".I&R*5M%I
M&1C\C-C,V+7LD>>J;:Q)&;+FD8:*LZ43:4V":C4QYVO0;D[@4&JS9S#+?AEI
MMKO9/?2*-A)-(;$F-T-J420CT]>-MZ6#4S;14SNM*$2AR2WE`D-1MSTE8ZEA
M4K!$'TK8$*TE<)>2L3FV`^8``/FZE_F&07QE\^@M3B(C_P#F9%?G'Z%?KR=.
M@?7ZQ^W'0/K]8_;CH'U^L?MQT#Z_6/VXZ!]?K'[<=`^OUC]N.@?7ZQ^W'0/K
M]8_;CH'U^L?MQT#Z_6/VXZ!]?K'[<=`^OUC]N.@?7ZQ^W'0/K]8_;CH'U^L?
MMQT#Z_6/VXZ!]?K'[<=`^OUC]N.@?7ZQ^W'0/K]8_;CH'U^L?MQT#Z_6/VXZ
M!]?K'[<=`^OUC]N.@?7ZQ^W'0/K]8_;CH'U^L?MQT#Z_6/VXZ!]?K'[<=`^O
MUC]N.@?7ZQ^W'0/K]8_;CH'U^L?MQT#Z_6/VXZ!]?K'[<=`^OUC]N.@?7ZQ^
MW'0/K]8_;CH'U^L?MQT#Z_6/VXZ!]?K'[<=`^OUC]N.@?7ZQ^W'0/K]8_;CH
M'U^L?MQT#Z_6/VXZ!]?K'[<=`^OUC]N.@?7ZQ^W'0/K]8_;CH'U^L?MQT#Z_
M6/VXZ!]?K'[<=`^OUC]N.@?7ZQ^W'0/K]8_;CH'U^L?MQT#Z_P#N'[<QH]QJ
M*3ITQ4L\`F]8OG,8]:*3+`CEI(LH4+(\8.D3.04;O&M>,6=7;K%(JE$&"2.4
M&?\`?9W3!\QE&+.3C'C:0CI%HV?Q[]DY(Z9OF+Q$CAH\:.43G1<-7*"B:S==
M(YTEDCE43,8A@$?KZ!]?_</VXZ!]?_</VXZ!]?\`W#]N.@?7_P!P_;CH'U_]
MP_;CH'U^L?MSKI26BH5LF\EY!K&M57C"/3<O7!6Z!GTH\1CHYKX54Q4P6?/W
M+=FU(8P"LY721)U44*4<,EMN:P@3-B2U^J;$[LCI1L5><8]]8C*0=Q+LY2D6
M.;NMI2/?QRQC``$?,7K01\.T<)I_G+_M`.A.&NO8"@<H[WH;@=-[HVELJNZD
MG=M<UM?<I]T13>I5?6=UG8:&J^IN*:K[:=@DDQKJ#,[V$CDJ_6(]R]GK.5<J
MJ;A*^O882%+D^SXH;O7S+C]'5,VQMT)QC+B[K+>VGM(-C(;$ED7R=-UYR6;M
M=U5X1?$<'GT[F@FH]L9I60AN]`.HLP[A,9P/S?Q+_,,@OC+_`,@M3_\`1D5_
M)7)UQC&,8QC&,8QC&,8QC&,8QC&,8QGK4522[@JJ$3\(H5)/OG*3OJG'H1,G
M>$.\H<0'ND+U,;IT*`CGK2=M5Q(5%P@J91,ZI"IK)J"=(B@)'4*!#&[Q"*""
M9CEZE*<0(80,(`/T8QC&,9P(@'__``?_`%Y_S?2/F#S^;.<XZA](>O.<8_\`
M7T_RSCO`/T_]I@_F&>M9=%LDHNX52012*)U%5E")))D#YS'44$I"%#\YC&``
M_..0WM+D)J'3<(VL5^NL+$1"\_6:ZHY)(,71F+JURR,+%O'S=!T9RA%D>KD%
MZ_!%1-FW!1RH44D53$Q&)Y>\?I>9F85+840U7K=?2LMC?2"I&<+7XY];GM+@
MTIB:.J:-8R=EE8YZZK<4HX^,)B$0&;:H#'J)*G^N'Y;\;[!8XRIPVWZ?(S\P
MY,SC639VZ,FY=%(LI\'^,#LR1B*QR-U3(IN'B0K]"`CX054@/V&[N2FJ]`4B
M,V#>Y=<]<F9U&O1KF!3:2OPJ15:2#TP%6,^:,"I(-HQXHLHH^*8!1%),BBW]
MV$!:[[1?0VQ'IG2))^IT!L9VSE=MW=>IP&LX6;10(Y95^7M7C,[C6$U,HJHA
M$1KAP1^\67122:&`X*9Z-K<_]8PNOY[86C9[5V\Z_0_!/-JS41MNL1<-K&$>
MB",)+617J]>&2L$@FYBXHK5L857K=1,/"G$J0Q#Q<[3"N;YM.R$9R6T[$5#6
M&KK3L^V.*M;Y^Q62'@:J[8!(S:D<,."<E`LV3I4KU:,(HZ3=E:BW37*]21SJ
M'/:&5#D[M"L:FX6\A*6VL:\%:YR6);]0;(<FE6]>9,YD[B#E)"LFC2HH1A7Y
M'#)RR;OG#@@$9*.%CHMPPKB3VBC*Z[GB]6W+8FXMK26P73:O5(J'%6:UU5:]
M+D^&2#R4FYYR+.8:QQ6C51DNJ^A0CV)01>.G:)?#F2H=S4Y.WV]\H+[6('6>
MX:VC\%A:#359V@2>N&,FH[LSO61)K8#AQ,+I2VMY6X2Z\5`;%,+).8@IOQ6/
M$-5&P&D[QU7DQO7BE:[CK:2XS\_.3Z[8:FP7NKFN0SZE?&3.";*RBFMQ8O)]
MNG!.'DFHR$5;"NW[T2B@/@/@RKE7V\V]@\E6.[UV^KM)<\K)64Z54U_C/35A
M@(:@J2;MH[?/&<>T2:2KGXW8"X386$[Q4BOQD@)&J2C`C5PO(I]L<MN,D!2(
MRF\8N27+13950AMC622O&RZC'2>HYV3:(-7.J'14F$XJYEX;P)GDRZ3<$BE7
M3@GQ8!Q!Z5&,.12'/.X5G6>Y]6ZKY$1-PV@WDE+_`*$C-Z5&NQND?%Y)K&0Z
M1'20Q2<T>ZHIJ3W]PB1Q$+&<-)@@/%T2(2WJZW=H1KOBG$R;+CI*;&WU*;9G
MF\I1MN[WK:[R`UY\7B+"Q-[*DHDDX0<OF*+5M6E)51\S4D',J)S,U$H]"$I7
M6/:>;(H.V=GO6%FU=N5S?H4NOM*1W(9D:@NZ<^1C26"03EHI^*,2:"4^'!$Q
M*DC'&D4T^\J(*D`7]AN-#CM,*QI3:U?VMK;4SC9%:KX/-(25LVU*6I2YVJ2D
MI)V_B[[(Q;F4695R':F8HQCDDDT?*F$6!^ZUZOVM$MB:8[1^1J>ZK=R9O1ZY
M47L*Y=U"J::VI;[#*S>T[+:(MAK^GQ%202DD5ZN26?D;+0:+1\_?H)QT4U:N
MBKOGC3(./%:L.ER6>#YVQ=X@]F23.KR->-6MMV>E4]Y65OC]PJ+&P4BR-6MN
MLS:;=R2=O1?S;]6M.#QK-A#QD0^8SUOL1VF&M-S;L?Z_H$A6.0$'JV%V(VO&
MN-G=G_S*J/'_`)F.[+':LN$3;:D-8VC#:\C9:N!`S=OFW41K7<TO8+)!0:2T
MG6FJ+%VV<S]V;I]35?2\EIVA;HY*[6MNNK7/R&Q(SFQ99V>Y?TJ1O$HZG8R+
MW$6X-8ZWKQRK4%$M;V5XR7KUDI3*/5J,]88=D21/L/$0`!$1``#YQ$>@!_B(
MXZAUZ=0Z].O3J'7I]/3Y^GUX'YOXE_F&07QE_P"06I_^C(K^2N3KC&,8QC&,
M8QC&,8QC&,8'S`.59O/*6`H.PR:LEJE87=XE%7`4^#BUXUZO<V[B.37KSB(4
M(L"#+XYEBOX-VE.*Q8U\\8ZF94Q:^HUDUY*VCNRB:3J$9<=I2*U;CI%^PABE
M:L)&?.6:>LUW@L"?%#)<ZA$DFCPPO#)(MSD;B8H@=1-(T6:LYF:7W'=F="I"
M]Q=S4@A).6R[ZDSD=$"A&-%7JRJ\HX2^#LR+-T3BT,\^#@Y5$C<@@X4(D:0-
MW;I/IF-@7Z>M=D[(4GY)S&IM-=0'QXM&J(-0<$6EA\,G\#1=G,5NT-W5/#*E
M5#\GP70V'Z9Y`W':MF<P<UQYVWJ^-;13M^-FO+%FPB#NVZ[)%*)2*<&[Q5Z[
M(Z571%%%5(J;1?PIB"`#G>[POF\Z>M6VFFM+M=J&F$Y4)9^]N,=6&==<-A9A
M&D<HO!35=HORK.U#+)+I%1^"`D)@.L4<^/2=PY(6:5ET]U:BJ6MX5&,25AW4
M)>$;-)/947H)K-'3!L9PBV:%9=YR1U\+`PJ`FEX(XJ'\#Z=VLN53^=AVVA9;
M4<-6C0ZAIM_?FDV\F4YQ-\<Q$V2+!!TS-&KL!0(!CH"NFY!R)S`0R`EP%K5-
M_%H%V8\A%*QN)],OJFGKVMZFAY"K/Z[9$WR@MYE2W+(,5:\A"RP14\2W"FH[
MK1(UY(MC.ECM(=Q534&BN9<3(+&B=E-M=RZ]58)?&UHH+.VMG$.UL,Z(UZ-E
MWT0DXK*S23=*S+^M?`6B4Z:41MQ'+]=R[:0NQ+257W35X69;[KV9#;+F74J1
M>'?0U5:U=*+BB,D4E&2Q&J;<KY19X59T"IVQ#(%/X(%52B`)QAM77G+>?O$K
M*:MW_4J/27",:6)K,CKN/FGL>JBP11D3+RCEF\5>"\?D7=IG$Z8))+$;%1("
M'?4F#35?VU6ZDM';DOL-L2UFF'SAM/0M<1K+=*&52:E91Z[)N5)%RY;KD>*F
M>%;MQ,DX1;F*H+?PRD';$I/-J1NM@?:VW1J>`H[EX12NPLY157<K&,@:MR';
M/GHQ<E\-6^%$<+"Z!R!5"JE*5!N4@)A8#4L7M&'I3!CN&T5VWWE-U)'?S57A
MSPD2JS5>J*1C=-F<B'>6:LA317<%:M"K*!U\`)BF65K=<*-SM>VJQNZ=N_3L
M14G,R_6K<6_H+A9_'0:BYC1S-\NI%21EWK=MW$W3@7JY5URJ+$%--0J"5H]=
M-+W&TBOL]HS<!/WINT4)8IJM,%HF#D'(.W!D5F3!ST50_P#`BU3<?D(IJNR+
MK(MVR*B:)-.6R@Y9.K]M8]7O-:E("!MEC97J6ULC+,8*LSC?7SR1LC9VR>+"
M[C[:QU4^C5K$+!VV;O)-Q`#!O%KLHFY)MUUF_P"YI^BR#VRUEZ52AUMR6U0#
M1Q&5)VBZA&:D?+0S69=G<-X9=!9JNP1D'?AS(&2(X,14YB%HG+16[6T7;+;,
M=H]KN-K%+:IR%XFF%2UVE&5".6,H@W>3`DF#LX8'"B"B;4)!5$KMRFJDB*J@
M&+DMU+FYQ9V-`7:D4GDS6[M<J%J&RW&W3E*0<R5@:0%4B`:62]Q,>RB5HZ2?
MQSM1.4"'A0DU2.7#-)%BLW71[^M[1&ZM=<E]K16LM;<L.?-CE)"-F)0+$O1Y
M.L4\S6LQBLF\0=3SIPBWAWK]LW(WC%)&)1;NY-ZP8J*"\=)HFM15^7F]>0MB
M8:95X%\K-::ZO*CRFVO<MNG(O7DM2H-TR=M'-K017CBF6>MA(U6.A'R:KA;X
M4X*R0>F2*W<U'8\3><CG><6,=IN!AM75K:+!+QSV'REL\Y8;10(*U%%&=(SJ
M9T'<:_E*\DE)M8YO#-!:/._&J))D,<X6[Y)\9NT(WW:M@52,Y/Z8H''.SR[+
MXEJ;74[B?N:-=:*QCLC.>DGK=`7D@62:+/3+,I]JU<`FT;"D@@9<HUTY1=CB
MZOC]Y,:2W#8*NSF`IE='6\J5,:=$LS+M(^\6U],KOGEAF4U8SX=.(U%-,#/9
M@6\6WE6$8<#L_DI/8L0"%RG:EM/9NQ;CJ%6NQTS7+#4+LM0+(I=6DPZ:N8V^
MU8C.;B+4=M!KMUJQ</"@[BF:3BL@S9M6S5S(W6L'96<,K70M::]LFOIN6B]6
M1$K#04J-XLT79)=&:>-G\@[N$U!/(M:UR"CEJD+9S+IK#&H`+*,(T8]&Q<]0
M[.GAT&GZGHF3TW'6'6=(M$[=*W!6&PVZ57CK/9`<DFI9.74GDY8RKU)VLB=L
M9V+(B8D!-J0Q"GS+ZOP=XDT[7$SJ*#T#KDNM[!:&=TFJC+PQ[+%R=JCFR#2.
MG'@61S+.57\>U;)-V"HN`*R1`Z;8B1550/FU)XP<=-<0MGKE'T?JJL0%U(R3
MM\-$T6O(1EH1C3F4CT)]F=BHA+-F*IU%6;9\19NV644612(JH<YLTJNH]545
M>0=4C6>OJ<YEF?Q=*.*K2ZU7EY)AWQ4^`OUHB,9J/&?A!%3X,Y,HAWQ$_@^\
M/7,HCZY`1*XN8N$B(YP9,R)EV$8P9+&2,)3&2%5JW24%,3$(82=[NB)"B(")
M0Z=SW0^O_N-]N1FXTWK!ZILQ61I<)+'W$W;LMFC-(*37CC&-(0M=9PLL$LJ\
M`U?8Q'A6S"O-@;PC%1Y(O&C!%_)R+IUF\%!QE:@X:N0R"C:'@(J.A(ILJ[>O
ME4(V*9HL&*"KZ0<.W[U1)J@DF=V^=.7C@Q15<N%ECG4-VO0/H#U!G`D(/3J4
MH]`Z!U*`]`^@.H>8,Y[I>@!W2]`^8.@=`_P#\V.@=.G0.GT=`Z>K.>@!\P=,
M8$.H=!^S^6<=`_P_P$0_EFA7^T!PE3LO&G2\'-5.I[1LKK?S)2CZANW&#D9R
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MPLI%)SS+93NS5IKN*2M\B925=4RZN:E(KD@"0_Q;OB`>\0IA#IU`@]/HZB`]
M,I9H#:TQ#Z8UO&(Z8V_.),:LQ;)R\+&4A:*D2(G73*\CU'U]CWAFC@"^$0%T
MQ:KBF8IE$$Q'NY,'EHG/0)O/V/K[\2<>6B<]`F\_8^OOQ)QY:)ST";S]CZ^_
M$G'EHG/0)O/V/K[\2<>6B<]`F\_8^OOQ)QY:)ST";S]CZ^_$G'EHG/0)O/V/
MK[\2<>6B<]`F\_8^OOQ)QY:)ST";S]CZ^_$G'EHG/0)O/V/K[\2<>6B<]`F\
M_8^OOQ)QY:)ST";S]CZ^_$G'EHG/0)O/V/K[\2<>6B<]`F\_8^OOQ)QY:)ST
M";S]CZ^_$G'EHG/0)O/V/K[\2<>6B<]`F\_8^OOQ)QY:)ST";S]CZ^_$G'EH
MG/0)O/V/K[\2<>6B<]`F\_8^OOQ)QY:)ST";S]CZ^_$G'EHG/0)O/V/K[\2<
M^=WO.1CVKE\_T=NIBQ9H*NGCU['ZX:,VC9`AE5W#ITXV8F@W013*915590B9
M"%$3&``S#+#NJUWS7TL;6&O=O1$C8X%R6HWUA7]96J)8.G*8D9S*#=+:`LY1
M!$X&_)(J<`,`F`IU$O!&J)2^-T)7%4K1/4#E79]MF?2TT[VHHVH#6?)/O6"+
M>+DXPCC9S_X-XO/DCR+$CY20/*"Y<QEA-)0:H11+QI;6FU8QFPF="[LFE46[
M4CMP[K.M"IO7:")"*O19!L8[9N9=8#K@BB7P:'A/!I#W"AGW)[AET0`J7'_=
MZ0%*!0!.$UXF`%*'0I>A-D%#NE#S%#IT*'F``SV^6B<]`F\_8^OOQ)QY9YST
M![S]CZ^_$G'EGG/0'O/V/K[\2<>6B<]`F\_8^OOQ)QY:)ST";S]CZ^_\Q\I/
MF#Z1'S!\X^;(;V9S3B-<U6U6Y;5%Y?QFNB1TULM)2QZE:OJ?2U'8I3$^X9,M
MC3#I209-$W#F(@':$:M9738\3'/22*B"2E?M8=KAH/<NQK;3M:T[9-HA:9J^
M5V7*SC*'CTII5E7W91LWP"INY)NLYB:_&*M%W<C\:DE'\L\3A86O22B#ITGW
MVH.U@X\;XN\3KW55$Y"6RS3:4BNP0;ZK(P8>#BHU:7=&>2\G96<9'A\7MU5D
M?A[IL"QP3;DZN5VZ*OJI7:;--A;`A:15N''--PWF)LT$>RR>H6D)#QBS=RNT
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M[8WDMBJBB:3FZ(I,WR840K;5/PR,5&2`LG?A@.X=N':2Z"33RNU3YQ7[3NIJ
M:?>'(+76T*F%D4VALK7^A=-BUV@M)R!'-;(C$/-L1*U83JK`GQ><\89NG83*
MK.W[%N?P29*:;/X=<L]A5FWU^1G.3]C?K,F32VW-R76=#M/*F(%\W>$UW>V%
M7V(^JE8I^O(@):(UQ8+E&W:R2-@LKYO9D&VNHIG&/K=4CA_J.'T7<]$W74?.
M/:E+V1/56W61MM"_U>3FH^5JZ+-2)CX=[6=G0[*%8,W#8AG\?%@LPD7"8>'5
M>-4&7@I)U+QGXMZ2K=ZJ>O\`@GLAK![.AX^`V$SL$54[D6X0\6JNX91TUXV;
M9F"K,D'CEP^*U1*@B#Y478$!9-$Z4YZ];:VU,*QM8<+;;KU5RR".=N:7K/3M
M;=O&(&14^"/'D5>6SMVW%5N@J9)RNJF=9(BQRF5*!\D]/<4PD7NI:`WBF7J(
M]U.%UZ0G4?,(B0FR"E$1^D0$?K\P9Y^6:;\W_P`P>\QZ?-UA]?"(?X".R?-_
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M'!>[U,5L_=)=#%$%1$1`-._:KQ#"\P]/I.^^'?.'D9H2$N<1L:HVSL\+D[:;
M2K-^:U&U4Q:&V94JOM+56WQ@Q:V>5?P,[KIU9ZN]^')M+RQKRD(W<STR]F!$
MNJMII>H4GC9R>XXZ#B96=E=?QO-F]EM7)BTS5LGG4Y89"6A%KSLZTU:B1QU0
M:UI/:5W-L5ZNNY:+52NUR&AW4Y<C='&W2G(5*$2V[1FML-7F5KB(MT67L=>D
M25V^Q*,%?:>\E*K,P4E*T6_0[9G&7NARKM[3KHR81S>S0DH2.8_!_)KQNTDR
MVNANQIK^(;;(:IG^"32+B528,WZM1C=?*6)E522`5!G<E=?0\5KY6[M8!*WJ
M4&-8TD\V:L-48HLWC\W\2_S#(*XR@`Z"U/U`!_\`D9%?.'U*Y.O0/H#U!CH'
MT!Z@QT#Z`]08Z!]`>H,=`^@/4&.@?0'J#'0/H#U!CH'T!Z@QT#Z`]08Z!]`>
MH,=`^@/4&.@?0'J#'0/H#U!CH'T!Z@QT#Z`]08Z!]`>H,=`^@/4&.@?0'J#'
M0/H#U!CH'T!Z@QT#Z`]09Z07;&7,V*J@+DJ15S(`HF*Q43F,0BID@'P@)'.4
MQ2J=WN&,4Q0,(@(!2W;'&S8^_-ENF^S]CHL>.T6I'.X/6E+^'1LQ9WB+5N9R
M:[R2B29.XG)%7.W.U7D`*R\`6-;PK_PTB:W-6JM=I-=AZG5(=C`UR`9)1T1$
M1R((LV+-'J)$DB=3&$1.8ZJJJIU%EUE%%UU%5E%%#=_T+]`>H,="_/T#I]/0
M,X'N@/3IZBB/K$`$`_CTR(]I[[TEI%J@\V[M77^N$W;=5VQ2N-IAX)[(-T#@
MDLK&QSUR21D2)*"5-06+1QW5#%(/0X@7*R;F[1[C=J&C:MO[)S==P0FZ4;&K
MK$^E*=(7E.T^*KYO%S14)(#QL0S69R3D&2C)X^3DC+(/`38G*S7,3I+#RGY0
M7S1-&V;QIX;W"4M]RN$U`/Z/OJ>AM4RM/@(M%V#*Z2D8O)$<2,+.O$$D8Y)%
M_'N@;J@[72!)1'O^;6N=HOMOCU+Q5NO&E>+^^7NP(]>*GM:0;W9D8QUBBU;A
M*14BVLCM\S:V]X^6>"A)Q;Q\U29LVB8"U7>+N&WC4.!]DE=+;5TWR7Y4;QY%
ML-L/JH^?RKZ6+0W-1\6)`)8[&E&A7,B\CXV;?D;A-Q[]V^C'K-HW:DC&Y17.
MI]],[,CB3KBBW.@:_I$M5(O9S:OPVU))K9I26LFQ:=!2XS*]%GYZQGEWC&KV
M%8RK2PI5<*_*.V+APBUDV2J@+DLIKWCSJ_4]UL]QUK78ZD(W"'B8V=J5:AZ_
M$U)5_#$1:M;`Q8-(A)[$2SF*:L(B40BY%I"2[>+C7TA$+S;0)52:DD$40$$D
MDTP,("8$R$3`PAY@$0(4H"/3S=1`1SV`4`^D?\3&$/4(B'V?FQW"#TZE*/3S
MA^2'F'Z0\WFSGH'T!Z@QT#Z`]08Z!]`>H,=`^@/4&.@?0'J#'0/H#U!CH'T!
MZ@QT#Z`]08Z!]`>H,=`^@/4&.@?0'J#'0/H#U!CH'T!Z@QT#Z`]08Z!]`>H,
M=`^@/4&.@?0'J#'0/H#U!CH'T!Z@QT#Z`]08Z!]`>H,=`^@/4&.@?0'J#'0/
MH#U!CH'T!Z@QT#Z`]08Z!]`>H,=`^@/4&.@?0'J#'0/H#U!G.:E^UXY;[OXA
M:;U#:])V[6^OWM]W4E0+1=M@\?=[<H!@H4-:[!NC,('4''X4;E(NY:;J+"(D
M+$[<C#UN,>+.%6;ITY;';2[V87('8G)GBA7]J;1OM5V3;GUYV9!.[93-);-X
M[0+UG6;>^AXYLAJ'<9"[)J;F.:H$9/B6<ZR\H\16EV*QXIZQZ;"\9P/S?Q+_
M`##(+XR_\@M3_P#1D5_)7)UQC&,8QC&,8QC&,8S@1Z?_`.@$1]0=1R&]ZN-U
M(T8S?0T;6GMZDY5C&?#[2^3:1];AW9'!7]D2;KI*H2CR,.5MX&/5(J4P+*.?
M@<D+8(YU'/'GC*CI^4G-A7"YSNR]R7./(PMMVF7;GX,#,7*#X\-!QRBA@;QB
M+INW%-9T)W!B-DDVB,4R`(XEJ\\#G*F4QCF`I0`1$PB```!\XB(^8`#J'41\
MP>;KFD#DWV@6^]4[JY`:2TA4'NUFM<<T%&5VM;X5O3:AQ=G-B,XAB$=8+$>,
M2J=OJ:9):(LM=L%S<UQ&!E)"58V65M=98%<LK+[KUYVFEOV&^B-'<@=':KTT
MQA:LU@[A8*,6Z[<G7Y(!DG9)6PQ8UX*:5TO82/W2",(G!Q:D>LV(W0;=54TN
MWWWV?:/)FWPE@VMR6Y%(5MA2Z[7Y36NNK@TH=$EK%$)KEE+=\6-&#TS5U8E7
M!E9!F(.12\$W2:ODD$2(!+\IP8XK69MJU*]:>K6R7NG:+&:YH\ULD9"[S+2J
MQ7@SMF,H^GGCD)]47*8O#NII%ZL#I=THD*17*I#68KU7K=1A8NMU2`A:S781
MN+2&@:]%L86&B6HF.<6\9&1R#9FP1[ZBAA3:HI%$QSF$!,<PCWG0/-YOF\_G
M\X]?IZCU'K]><XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S2+VT.V'[+1D;5]=
M[SLU4>U3:-'4WE2N.G-;0O#'E*M4+=5KG(4..J&VMRN2Q]7;S<[`#89*K,I2
MAW'8].K<\G4K4\CH6QUBQV#[(NPWFS\*Z7)7G8EAV2LG;=@QM:EK]R!UERJV
MQ#T^*LBS""JNX>0VGHR.UWM#9=>*@Z:S\O!K3[V);'BZK:;;;;=7YZPR&S4Q
M@*'4>OG\W0"F,/J*`C_'ITQWB]>G7S_X#]'7Z.G_`*'Z!SD?F_B7^89!?&7_
M`)!:G_Z,BOY*Y.N,8QC&,8QC&,8QC..H?F\_S?-]8YKMD*!R9Y06]X39+N:X
M]:.KT\NFPIU8FDT=B7KXK>J$:R$G/Q2ZQ(]@Y!('*2A%2M$0.E\`B7[@B4ZE
ML03("29$RB<Q4R%(!E%#JJ"!"@4!.HH8RBAQ`.ICG,8YS=3&$3"(CYY`_(;D
MKISBY0G>Q-S7!E5X5,%DHMCYG=AL\DDF"@0U6@DC@^FY,X&(8Z;<I6K!`PO9
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M42X;"AJIN!/M'.*EXW.&V;M7]>;&B-,J-'6H6LY=+NZUU`V2\!6X"4J3D*(A
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M_CU#K_YY2O0%IW0STQK=M!ZEJLQ$(U9BG'2CO;(P[E^S(=<K=TXBQU](_`%5
MTP*H=J#]V"(F\'\(4$!-DP>.._O0G3??7_3+'CCO[T)TWWU_TRQXX[^]"=-]
M]?\`3+'CCO[T)TWWU_TRQXX[^]"=-]]?],L>.._O0G3??7_3+'CCO[T)TWWU
M_P!,L>.._O0G3??7_3+'CCO[T)TWWU_TRQXX[^]"=-]]?],L>.._O0G3??7_
M`$RQXX[^]"=-]]?],L>.._O0G3??7_3+'CCO[T)TWWU_TRQXX[^]"=-]]?\`
M3+'CCO[T)TWWU_TRQXY;]]"=-]]?],LA;:N\>3L&ZB*+2^.C=S=KHT=#`V=K
M<'%LI%9!JY1;O'MI>>*E79LU6R*X.FC9W*H(N2@!A%R)?@+CRTI$\M]<0<VV
MV%&Q6W;%/V%U.KRTIMY&,C(A-=%%`D378PFM%5(^+Z(_"CL_#%:(.E5",&;1
M`!!69PN._0^;25,#_#=?3_\`MECQRW[Z$Z;]'_.O\X^8`_Y9?G'S95#DCS!Y
M$ZGA*W$ZYXM!M78NQ['-4*F-Z/L!>[UNNV^*9I.G!]BNHVFPJ$`P9D5,J=N_
MF8CPXLGR;V2AFS9P^2Q*#XX;9V<[TUMCE[QVTMN'D'JZ'F&<?/QVTY:"HK`L
MO8#V"/+Y.G%4GJN[FX`OP)L:5<!(I&E&1I!@H8A62R-W`N._0#H&DJ;YO_VV
M=?\`S'677'CCO[T)TWWU_P!,L>.._O0G3??7_3+'CCO[T)TWWU_TRQXX[^]"
M=-]]?],L>.._O0G3??7_`$RQXX[^]"=-]]?],L>.._O0G3??7_3+'CCO[T)T
MWWU_TRQXX[^]"=-]]?\`3+'CCO[T)TWWU_TRQXX[^]"=-]]?],L>.._O0G3?
M?7_3+'CCO[T)TWWU_P!,L>.._O0G3??7_3+'CCO[T)TWWU_TRQXX[^]"=-]]
M?],L>.._O0G3??7_`$RQXX[^]"=-]]?],L>.._O0G3??7_3+'CCO[T)TWWU_
MTRQXX[^]"=-]]?\`3+'CCO[T)TWWU_TRQXX[^]"=-]]?],L>.._O0G3??7_3
M+'CCO[T)TWWU_P!,L>.._O0G3??7_3+'CCO[T)TWWU_TRQXX[^]"=-]]?],L
M>.._O0G3??7_`$RQXX[^]"=-]]?],L>.._O0G3??7_3+'CCO[T)TWWU_TRQX
MX[^]"=-]]?\`3+'CCO[T)TWWU_TRQXX[^]"=-]]?],L>.._O0G3??7_3+'CC
MO[T)TWWU_P!,L>.._O0G3??7_3+'CCO[T)TWWU_TRQXX[^]"=-]]?],L>.._
MO0G3??7_`$RQXX[^]"=-]]?],L>.._?0G3??7_3+)>@'4R]AX]U88EK!S2[<
MJDC$LI7X\:,'(F,!VZ$M\`B_AZ90`H@X^+VG>$PAX$.[U'41VQMZU)K6D<4K
M9O2/VDYU&;E+%P>QU]&CN5_M)>EO]4;.E)FJDJ6F:M8Y&^ZQOJL#'U'<]/LZ
ML/7W]`DG[Q@_-;V%:;J3EV6(Z!<<4V<OQNOO)K9>NK%M/<%A5N/+E]L)YNZ4
MMLM>9!S;RV!/:41`7=G&M)D56M?1G(5B]=1:2,LZ/)NY)S-25]IFDTZQS%=L
M-@JE:G)ZHN'3JJ3<O`Q4G+UET^(B1ZYKTF^:+OH1P[(W0(Z6C%VJK@J")53G
M!),"_26K5DME/<RUZ#"W*0Q:Z>TA$QX6,]?([&0)!FG`;?&IH<C\3/2Q8NQ8
M%>&,Z!N"XBIG>C\W\2_S#(+XR_\`(+4__1D5_)7)UQC&,8QC&,8QC(UVY9)Z
MET.<NL"O!$-36Y[3-,["#E)C+5B#25?V*)0DFIQ4A91W%I+_`!1+*,Y-JVDD
MVQ'L<X:+K&2I;Q[V_P`D^3]IK]_8KUC6FCZG,OFDVS;-64Q8=D/4BKB$4NU=
M.'SNM-V[%W&++*$=-"-W)C.F#JQ)K)?`MCG3Z?/_`.OGZ?\`KIC,;M]PJU`K
M,W<[M8(BJU2ML%I2=L,\_;QD3%,$`#PCIZ]='3113`PE3(!C=]58Z:")%%E$
MTS:UW6\;-VD.H=G5GAML>\:&BZWLJ"J$IO6Q4%ZDRV%2EF$D>V):B>HRS&8C
M)1!8K0B\HY)$346G\&;*%AU9H'+&W7%?BWK7B/JIMJO6P3+QHO,O[5:+'8Y`
MTC8+C<I=NQ;3%FF5BE2:).GJ,<R0(RCVS9@U;M42$24<"X=.+)8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC-&G;.DVM4VW&W9VG=W]HA2KJ2_V>B1.J
M>`.B-0\AK9?U936UVG7T_+4_<8PU:K_BI`Q4PJO8UK6FFZCUS1K:MR,ZG#S,
M%:[LK)>WS?$&M2&P7O,*0OCB_P"VG%Q><ZJ=2]<\BW$^\O\`,R#U2R:\UV_E
M*12*R(/$O)[7:U(O(QI2?B59%1,7)FZ&QW&<#\W\2_S#(+XR_P#(+4__`$9%
M?R5R=<8QC&,8QC&,8$>GSY7VN[/U3OJV;"UM'LG]F3U%/UI6=D%VJGB<]L*3
MEV[9-&3QN]%";5@92*5%ZRD6OP$'[1%R@D]!LFX2D>J:RHM&>.)"IUUG!.W<
M6SAWBC%5X0KQA'/9"08)O43N5$7BS)S*/P:/7*:KYNV<G8I.2,2IMB9WD2;.
MV_`:\B+0FQ1&\;&A:!9;_7].5:3AU=FWJ.KK<QCHU:M.GJ3]\#M\+>,3?$;*
M-$W;E),155$B"E%M!T'E!RRKFTI;GQ4*3`Z&VO%P3>C<3E(4XSE8;P]@:6&/
MLEUM:!H^R(32HQ\<8T.YD`=F>D%\YB:@=N2#4V35BK5RE5^(JE1@HFM5J!8H
MQL+`P3!M%Q$4P;E[J+./CV::39JW3#J()I)E`3"90_>4.<YN^QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,T=]O-KF$V9Q<UI%W7C.3DKKFN;PC+I<H
M@^L>0&[1J3>#H=X092[;5G&JTU'8DA(V,9-Y1(V\23^5H6L'MD1M]OK$XBW8
MIM[&]DG5-<TSB,W@=+<6[WQ$T<AN#=KO2NJ]E15TJ]S?:TDM@23^`V!+T78\
M[8[[0_'M1P^FF5<M<@A)G8BVL!(2LQ\^RK<5L<LEFKE.@Y.SVV?A:O6X5J=]
M,6"Q2K"$A(EDF)2J/).6DW#6/8-4Q.4#N';A%$@F*!C@)@`>K3V#0U;JOK9*
MZU)38C6%+9'5#3L<,>YMJZHL1NG/N*L5Z,ZC"J.%4VY)51@5B9=0B15Q.<A3
M9</S?Q+_`##(+XR_\@M3_P#1D5_)7)UQC&,8QC&,8QD=[9A+Q9=;W&OZVL#"
MJW>8AG$=`6*23<*M(ATZ.FDN[-\#36=)+D9&=$:.4$E%6CLZ#HB9Q1[HXOQ_
MTE7=!:UA:'!B5V[2*,C9ITY!*ZL=E>$(,G+.!-^6"8G(1I'-SF.9G&-FC8QU
M%"*K*S6)BEZ=1`.H@`=1`.HCY@`.OSB(^8`^<<U[I\_:'L;DHAQ8T+7[?M><
M;DL#+:&W*0VBWNN](KLF,FW;/YJ2E1"/L:[.>:)1KIFQ5!D,BH2,9N9F21?1
M3?SXG=G_`%'CQ<[%NV_WVS\A.2MP1?,K!NN_)BVD&\2_,W^$0]7KY'\DSKS-
MPBT:(.E`>/70MVY(R.5BX$J<038,```=`\P8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,9IA[:*ZU?6>LN-.SW6VHO7NSM9<EXJ^Z-K%JT3R5Y)T78
M6RZ_K>_J-T;3J?BE::AM%^2AP+B9O\38'DA+T:"DH4B=IJ=@+)L093!V1D]*
MW#B&E>[#O.[\@K1L#<V];S;+O<=*W+CHRCK39MCRTE/4J@Z3V&<]XH.MJ?(*
MK1-096@2R\RV*YLZZ+<DXFW3K[VWU&Y-[0XN[?I^L=-#MK5;'1EOLSV"@-@#
M%6N?W&UEF"=!3=:];4:P2MX@Z`@@K>("#C)=`LSL$U=D)!D!:4P+(QI2Z9MQ
M/F!6ZY.56P1N\UNU;V/R?M\UW)67CH[AW.<!Y#7D;((79&'3B)&@&E%]?:#8
M1IU&:;O8E4702CT7U?6=-?T$@`@0H&\Y@`@"/TCU#K_YY3/C_#[O7TMK56O[
M`UG&PRE58GCF,IJRR2LBU9F47%N@]DVVV(IN_<I(B0BKI"+CDEC@)BLT0\PS
M#\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W
M.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/(C
MTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?
M'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\C;;EVV]I?7]BV+<-JZE2B8!F*A&
MJ6GK/\-EI)8?!1<+'IGW2'A'LF],DV((`)6R1EGJX`V:K&+BO'OY75RH)+_=
M=@4:!=WU^M9HBH6'6,C+JU*O.R$")CV3F)O-1709/6P%D$8^82F)1H@JW,ZE
MCN7#ILAW6\+1R1U+K&S[&:[,XXJC4V[:5<LK[4)K75?E&)':2+R)+=YG<QH2
MN3DDBJ+6LO)POQ*XGCL(V568LGRLDRH9J?:'/[G#L9A9M>WVJ\?^,6L[P#A&
MZ)40B=YW0\A%&CE2K677,O;[%,5N+,8ZC&PPK^;K"C2/>HR#5Y957$4NTV*4
MC2FP-:)3B&N7_'2AM[+.O[/8&]1X^S4$E-6&475<R$U*?`=PI'?R;M990ZSM
MT910>\)2"0GY.9Q\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:
MOQGQ\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;
MJ3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$
M/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ
M_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])N
MI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0
M\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K
M\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/(CTFZ
MD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?'Q#
MR(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:O
MQGQ\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J
M3W.6K\9\?$/(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/
M(CTFZD]SEJ_&?'Q#R(])NI/<Y:OQGQ\0\B/2;J3W.6K\9\?$/(CTFZD]SEJ_
M&?'Q#R(])NI/<Y:OQGSH+*]V_2XI2=N.\=#52#16;MUIBR:UF8&+27=J@BU0
M4D97>#5FFLY6,"3=,ZP'65$")E,<0*/?U/>6K'L4V;R&\=-6:=9MD`FG]8N%
M78QJKE8RW<70BCV^?=1K=<$CE10<RCPXF16$KA3NF`FK;MR92N-]"Z.BY%S8
MXZTRG()IY/)1ASB9=G;565I;ZMV2D]&[\FER*RC!@K5']@+":YJK9[9-@V`&
M+<C9*"B)Z1831V.M@K\_PM@303ZX2:\3LS;4)9)"U\IHWFTV=6IA<'(S@TWE
M7&*')N2D(++HM8"7?IM)VL&0?:_L3!C.5!^U2VG"'7S?R$0_\P\^<=T.O>\_
M4?K'I_CTZ].O3S=>G7IYNO3`_-_$O\PR"^,O_(+4_P#T9%?R5R=<8QC&,8QC
M&>"BA$B'44.5--,ICG.<P$(0A`$QCG,80*4I2@)C&,(%*4!$1``$<B)(^F>2
M--0<%)5MHTEM93*MSK(?&422R5.040%5,BZ:7><1[P%"$5`ID'+=83$,Y9.@
M%61+)8Z_3:_,6FT2\?7ZU78QY,3<U*N4F49$Q4<W.Z>OWKI8Q4FS5JW2.HHH
M<P`4I>Z4!,)2CJFMNKJKVK$OI3:S':4G(\(*>[LCN7U`M5+#3Y_9NUZG97\*
M1_-O9-)L9>B&C0!HD)"?#4D0E&<>#9[-O7\+LT@-64*JW*P7RM5UI`62UP=<
MK]D7AE7<;&S;"H(JLZPI(P#-=*`<RD'%JA!QTZ>-^.D:\W8U\7YH:-CV3:0<
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG`F*`].H=0#KW0\YNGT]T.H
MC_`,@[;_`";XZ\?V2DAN_>6IM2MDVYW(#L/8%6J;A9(A!4$6C"9DVL@].)"B
M)4F;1=0_3H0AA$`S5->/[07P-0FE:?QZ;[WYG7L>\@SK/%_2]PN:"[_J)$VY
M[%-M*Y$>`.H'=%Y'FE$@*/?3!4/GU*]K=O?M->=?#R8K#OLKMEZ4T&.QM:3;
MB0ML^&QM^2LK$3B[BN_`M*TV'&>B891Z<@V*1>P[]&':F(=1VB)@7)^<[3?"
M;EA\)LXDX@\BDO\`P\!U$W';9K4#?WL_T`!6IJ`*"7KYP()Q)W@$W=[Y>]^\
MO?O)3@5%<CN1_'CM']R:FKM2G:AJ.9UWH#F<KKB,XX;"UHU@&4ZXVM0&&T(9
M*HW>U&VPRMU.M4<XG9>;J3W7T&X85Z#3L2$M8+2=G%L/6VQN.IG^AT8E;C77
M=E[*I?&RP5RCQVOJE:-,UBPBS@9&DU^&B8"'6HD/.J6>ETBR14''L+C5JI%6
MMN:5+,#.RM]\9P/S?Q+_`##(+XR_\@M3_P#1D5_)7)UQC&,8QC&,95OEA7MT
M7FB16M]/-T&@;!GTJS?;<K(MVAJA1G+98\P^3;**I.GA9`A/BUR2.!=[\&55
M:H(%,^!TTEW7%`IVE-=PM*KB;>)K-2BC@J\=JHHF6%(AW4K.3#Q04T?A3U;X
M1(R3M4Q$4Q.?H*39$A2:U5[UK'M:FVYM%1T-M.%XYZKOE"<>7"IV5C`Q.Y;'
M!/I!>?HC2*>1+ATK4RMO@LJ20*LNY724@["FG`O0@3.]IM/I]8U_5H"DTN#C
MZU4ZO%,X2OP,4@5M'Q46P1*@T9M42]>A$TRAWE#F.LNH)UW"BJZJBA\DQC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9XB<`'H(&\WT$.(>L"B`_P''>+\W7S
M].O=\_>Z?3W?^+_RR"]Q\H..?'F.6E=Y[SU/J1FBW,YZ[!OU9JSI=(H=[_P<
M=*R3>3?J"'G*BQ9.53_,0AA\V:G;S_:%>":<TK3^.<7OWFA>S=Y!C7>,^E[;
M:&CA^(]U-`]AL+:N,?`&/T*+R.;RR/00.0%2"`CA@\QNW$Y)_P!WQT[.+67%
M"J2`?!D+]S0VD=_8V::O_#(^32I_$<ZU7(0?"?!'<%+I%-_='%3S"(.R^[3#
MD0'A^:G:V[.A81X/@I35?#&FQNEJTHQ/_P#&8>.O@HJ9?("412\)(U=XJH7\
MLYS&^>==.=@=V9&II%*QS6BG.^;LFX*Z6NW(^Y6/;TP^<`/?,L]BYEVUIRRB
MBG]X;O5@P=[ZNH9MAH^M]>ZQA4JWK>C4_7]>;]WP$%2*S"5.'1`@=TH)QE?8
MQS(H%+Y@_N?F_/F9]TOG``Z=1ZCW?R>H_2(EZ#G/=`/_`+W\3&'^8YK1[3K8
M?!35^I:?;><_'!IR<JK:VO24JCH\6_E6V*'E65<D9^RV^/IQ*M93U>"KU9AG
M3VU7-T:(B(YH5DT?/SN'K!JM83AKR2UWRDTHQV'JO6FU-2TF#LUKUC%4C;^J
MI#2UKB#:RE!J;MNCKJ5!*1KL&U<L5(Z(8O&48X;),%6:D6P.T%N3+=Z\HM#<
M:&E?D-X[#CM?QMDDF4<TE)*,L+^*C"/YZ!JR,];92#AY6/HM+1LEIK4#(WZ[
MN:]2(B7L$)'RM@9NI1DDMV+?D9IAUN!UH9"],#[29JKLEZ[\`FRM0FFE4C+X
M[JB5F/&%J3F\LZ)-1-Z>4-M/+7-G2))E;W,$E77"<D,V#\W\2_S#(+XR_P#(
M+4__`$9%?R5R=<8QC&,8QC(&Y&[TA./^M).YOTR2,XY.$-3*V`J"YL=J>IG"
M.CTTD`%P+5$2F>R:J0=])B@H1'O.UFJ2N<:KE+W,ZYJ$QL^(BZ_?)&$:OK-"
MPX.BL(N0<]]4&22;U=TY170;'0(\;*.G/P9]\);D<+IIE4-KVGN3&S.1?,.4
MXK:2HU?G=!:F/+UKF9>;]#/QBI!.P0<C&+ZQIQR/&BOQHNDZ,B+GX*Y-)N"2
M"O<;5J+4?S.PS6&KM?Z9H\!K;5]3AZ32*PT^!0E=@VYD&+)(RAEEC]Y4ZSET
MZ=.%%'+U^]7<OWSE11R\<KKG,H.?8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC.!,`#T$0ZC\P=?./Y_,'SC_``R)]J[YTGHR'&?W/MO6VIX7P*JY)+8UVKE,
M:K$0#JK\&-8)%@=V<OF#P;4BRAC"!2E$P@&:CMD?V@K@)$RSBG:%<[FYD;`$
M56K:I\7=0VV\`J^`3)D2-9)5I7X$[<R@!_XR+<2Q#$,"B!%R^?/Q*<^>4/)?
M8W,GDE>913DWQ[=VG8[V56TA8]B;'AYW62)X"#;MZO*14+,1\3'.TV;="0.S
MCF:#5N$B4A/"&`ZZOZON*_9P\[^6?&7CQ<>2/:P\BX#5%OTGJ^7K^G>.T3'Z
MPEVU'EJ9#/8.&N^UW#A>T6^RHQ"S9K89N;BI)Y)R97+Q9XX.IX4U[M-]@WV9
M.HY%"QR6@0WE=TW`.E[SR.MECW+.OW`"!Q7>Q]E>A4E%3J!X0XEK)0$PCYNG
MFS:K2-<:^UI#IU[7-'J%`@$C`9*#I-:A:G$)B`=`[D;`,8YF'0/S^!$?KS,P
M``Z]``.H]1Z``=1^D>GSCG.,8QFB/M]-T5+1_'?C_;;6QXBH^`Y0U%[`6OF9
ML/D/3-55:Q5VE7BRQ_AJ]Q;A+#M?98V,(M:NR]&>PLSJ^1@GST^TH63KA2HE
MD?L('.OY/L^ZM/ZV\@*U>L>V]YS*DEQDL?(ZWZ>EY978DDTDI"MV?EBDWWI,
M+^&9E92ZUM:M&3629+QU4;)5-E"@,_\`:/UBX[BTI8N.VO(/<+>_[*K+R=H5
MTIE`IMRU,O=Z#9*Q,U75^_7MSCK!#1>K;]-J,E+['RT3%,;'KF&ND4RML=-*
ML(J8JK!<8=W1G*B(JXTN;)`1_:D['[0*2W4DDD>HO-,6GA]8]5Q%13FE9)N\
M'81MC6UOJM>FE;*.4*#4EK8NV3K+N*!QN^`.Z0I1'KT`@=?IZ"`=<IGQ_P!=
M6Z4TMK5^RWALR`:NZJQ70AHN+U0K'1J2JBZA&;)25UI)29VS<I@22-(2+YV)
M"@*SI4WG"8?)5>/WB-M^R-,_A/CR57C]XC;?LC3/X3X\E5X_>(VW[(TS^$^/
M)5>/WB-M^R-,_A/CR57C]XC;?LC3/X3X\E5X_>(VW[(TS^$^/)5>/WB-M^R-
M,_A/CR57C]XC;?LC3/X3X\E5X_>(VW[(TS^$^/)5>/WB-M^R-,_A/GH<ZTN#
M)NN[=\C]JM6K9(ZSAPXC=*H(((IE$RBJRRNJB))))E`3'44.4A"@)C&``$<C
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MU9=RAU'D3MH`^D8C3`!ZQU1F+6^#5U_#.+'>^6EVI5>9^=W/6U;0=:AFH`43
M"9Q*3>LV#%("E*)A$ZX="@(_F'-4&[>V/X"Z:DEZS&\_]O[XO2+L62="XW:^
MUIN.=>N`[Q?`LY2OZA3IJIA5`$@'QI\YS%Z%,`B)8-#F]VN'(T%4>%'"+DG4
M*Z]2*M$;>YRV#1>I8063CN`WED==,-7P<Y(H]TX+$;,;!+F52Z&$HCU($HQ?
M`+ME^0[%LERY[5,-,UUPB(R%`X8:WAZU-*-W11!Q&+[57B:7*)*$(843.48Z
M52`.^"8*=X%,RRF_V=+@-`61M>+O*;RWU>TE0<N+-R#O,'M87KW\@RCEU#3]
M0/#/`,J45`;R;.01`3&*H14O3-H>O^+$7J>#2K&K-AV#6E;1[G@H'7^M^.U,
MB2BF0$R&,RK>E8Q%8Y2`!?"+E54-\YCF$1$<U-J&WG,)C[^V@H<?G.I7-'J'
M-^;J8ZFHC',/3S=3&'S=`^8`SVAJF[E`"EY#;9*4``"E+#:7(4H!\P%*74X%
M*4`\P%*```>8``,Y\E5X_>(VW[(TS^$^/)5>/WB-M^R-,_A/CR57C]XC;?LC
M3/X3X\E5X_>(VW[(TS^$^/)5>/WB-M^R-,_A/CR5WC]XC;?LC3/X49BMU@GN
MN:K.7>[<H]FUVK5Q@K)3$S(QFFDVK1LET*4``NIS*N7+A8R;5DR:D6>OGBR+
M-F@LY632-C?&?ECJ#=](7=0EXE#2]6=!$V!MLX]7KES4\*J[-$SD@RABQL`J
MUGFC=1PS6A6Z3=$R#F/=MFDDQ>(%U_=NC==5Z\X^:>N>T]L<O-(-ZWNMU)4^
M^<)+'6*;OF5O"VI-D0D!JJJ6*TU&YMI"2VTO-FJ,/0X^+;OKG-+,`=R\/7H:
M=D6T[=D'(6!SP\CHR[36]IS8M9V=M&O[)5Y'[GUWR(VS$WIO/I/IVI6?=6K(
M6KT^]/:2>10J#P6E2J\A4I6$DZ#-1!9:INWS[:*)2B(")0$0^81`!$/\!^</
MX8Z!U[W0.O3IUZ!UZ?1U^?I]6!^;^)?YAD%\9?\`D%J?_HR*_DKDZXQC&,8Q
MC*!\J66Q-X;"I_%NK1\Y`4&<CFMWW%?P9N4HQ2GMY)9NC58Y\9`63A\[=,C'
M78BJ=1P\6B2KHA%MI05/3OZYSESI-\X?\+=KZUK7)"G52E1DS&3\S.)2VL-5
M2QV<`^GV#^.C)0S>V,H19DG#@<ZLC'K/FD@L#!ZYB'1YJXD\8:=Q&TI7M/5"
M1DY[X$[DK#9[3,J'-)6RZ6%1-S8[$NW%59*/3?.4TTV<<@HJ#1BW;)N73]]\
M+D7=F,8QC&,8QC&,8QC&,8QC&,8QC&,8QC/6=9),AU%#E(FF4QE%#"`$3*0H
MF,90X_DIE*4!,8QQ*4``1$0`!'/S]]LKVOU;XF:-91_$7D%H&Q\H'&S*G&OZ
M*+V`VM*1&OS(3BMODI&MPLZ5&&<M'+>$;%7F72*R1'QP09*JJ$41U-=GSVY/
M:U<D]EWO7M2X[:ZY@VH*`G*0-8K:5?T'#Z]=%LD<Q4OMZMLA*R",E6#).OB,
ML`BM%/'$D\;NV\D0K=5!7;,707;X<H`25W%R^XY<#:9*&,#^F\8->NMH;+8M
M>O04%+S<EU&C-\"?7P;R"MHID4.*@IF[I"%R>H?V?7B!+2[2X<M-D<E^=%Z(
MI\(>2W(W=5LD*\JZZ@;OM:C67L.B@V[P#U9O9>32.0125\(F(E';'I7BOQLX
MXQJ<5H?1.IM1M4VY6ISZ_H=<K+]TB0!`H2$M',$I>2.`"/55^_<JFZB)CB(B
M(SX!0#S]//TZ=1\YNGUF'J(_Q'.<8QC&,]*SA!NDHNNJFB@D0RBJZIRI(IIE
M#J8ZBJ@E3(0H><3&,``'7J/FRL.QN:O%O5AE$+;NJE%D4P,'Q-`2(VZ:%4H]
M/@XQE62EW"*YC?D@1R"``80[QBY`7R^[-?Q\#QTXI;SVP14120LL_%(:VI8J
M&$`37^.I@'PJ-O.!Q\*5D<Q.O_#^;YOB+M,MKB(RMNTCQGA%Q\&HSK4:ML>Z
M(MU.G7J[?C)0H.B$'H*S619=#@!B`0/F\R]F]7+D87G('?F^-YR?0YDB3%N4
MKE<8N3)G*F\C:\P%\#5=FH?PS,@OC-B*%*59NLEWDCYAH#L\M&Z9K\NQL\3%
M[AL<U(_"'=EO%=CE0:QK-1V6&B8>&$[ME%)M6SM0\F[;G%Q-22JSM<46B<;'
M1]!^VGY"4\]7UQQ[HW:0:RX<[8'9]2FME1\;SIT-P^W'7]9V:OV"-A-AR,CL
MV*M5CL>N*G..F-PLFLZC$5RW;3B8WX!4[@Q=QQF4E/'8D/KC*<'F4K=MJO\`
M=,E([MWTYC]BR7+JF\WWL[`!L.00A`7Y":YJE*U]:#L6:!6)V%0K<5'0QT#-
M7T=%6`\U#QVW?&<#\W\2_P`PR"^,O_(+4_\`T9%?R5R=<8QC&,8RO>_>0L#H
MIG4FRD))72Z7RQL*Y3Z)`KH(S4TLX<H(/7A#N"*)(,V`.4""H<AOA#YRS9$[
M@++.&T=;KY?:VH6Y]9<6&*]OF]U[K,O',6.OHEA8'VKH:0CI`K78]U2>NTFD
M="QBS=>3!("/W@Q\8\EW#`8=L*R_S\,^%='X@U2?1:3TILO:M^EG4_M'<UK:
MHIVZ\RCAVLZ2(N;X0_681+51=5RE&C)/3+RCJ0EWSMT]>B9&Z.,8QC&,8QC&
M,8QC&,8QC&,8QC&,X$0#SB(`'S=1$`\_T>?,!V)M?6.HH%:T[5V'2-:UIN!Q
M6L%^M4%3X9/P9>^8!D;"_CVIC`'3H1-0ZAA$"E*)A`!T^[._M`'`V"G5*)Q_
M<;<YI[04,HW8T;BMJZRW[X0^*8"E14M+]K#5TS8?^)1Y$N)LA"=1*F<0$`C4
M>2';M<L>B.AN&ND^!-$DOR4-@<N+HXOVS6Z(?E?"V>M:LT3-&/`(`A\!L%1=
MI>$.F470%*<^>:?8H[@Y#')*]HQVDO*+DB1X8KR0U-JJ4;<?M(HN3&#PK$M:
MK@/5)"/$A"$\*@QKKHY>\/Y!C=X+5M^P][*]KK5353?AWKEO6W$K$33N5;2%
MR;;`>24*#D&BCG:#>RI[".T4%XX%]$DL:4-(B9+X;'+?!FO@)HXH]F1PEX1W
M6R;"XRZ8)K:W6ZK$I=@E@O>Q[5\/K9)AG/$CO@5SMM@8-NDK'M'7PIHU0>=4
MO`BN*!U$S7UQC&,8R*[KN_4^NK92Z-=KW`5RU[!<+MJE#23H4G$HHAU+WSG*
M0[>.;.'``P8O)19DTD90Z<6P6<2!RMLC?8W,SC!JH54KENFCMGZ0'`T/#R@6
MF;!4@]!0/$UA.6>(K";\D".$T>@].\(!U$*\_P#M`I>_#X'CEQ<WIN(J@BDC
M8Y*%2U[2!4$>ZFM\?S`/1,WZ_E"*R+,P@!@$2B'4/$6':8;6#H[E]&<8X9<!
M3.E%-G.S;RB@KTZB"[@7]>^%)D'IX1%PR$IP`0`HAU#A'LY8BY*IO>1'(/>V
M]W13E4/%REL7JE0$>H&.DG7HE5VL@B(]0*FWDVX`7S="Y:/6W%/CIJ,J?D_T
M[18)TD8AR2IX5"8G0.0``#_'TZ,G+@8>G4>X\(`F_*Z`.6``I>G0.@@'3H'S
M@'3YN@?,'3\P``=/S!GBHJDB03JJ$2('SF4,5,H?,'SG$H!\X?GS&9"\TZ+(
M<SZSP3<2%$QDC2C,RP]`Z]TJ*:QU3G$/,4A2"8QA*4`ZF#.DUGL>(V;7U9R)
M+X+X-)OXUTT%4%5$#M7"A4#G$0(/1RU\$N'Y`%`YE$R"<$^^;\K_`&E-Z@:M
MVH3*]7S4%DVKK36[7C_#W_1]-[(2&Y@0.^*)98@ZU[G;MRJ\7)NX4S8-"A+$
MBZUI2(81BX-*C,T'S)TEL>259_H.X![,T=M?CVRM/';0<YQKU:2\;!A(C5MD
MTVEQ^G(^1A+(NQGIN0U`2,AUZ8:SRY74VW;/XUI(R;-TWFWB159,0#(^5/+F
MM\3JPYN]KUCMZ^4NL5V7O^UK1K.N0<S&:?U57'3%M9ME6\D[9JV^FHN!2>JR
MKFIZ\:779#Z"A[#,PU,D6D,Y$W7Q_-C5,EOEQHQO'V<02VQ*\?&^S1)73:Z?
M<A8+3S/?DOIENX2L2EI2M+35+M6P$DGM7:U1W)Q4U46D^M:HT\4I<,?.`"'S
M=2_S#(+XR_\`(+4__1D5_)7)UQC&,8QC-/G-78\+Q<W*QVTP*\Y`<H=MM6%!
MXI\?SQC@&U:63^#1D]85U8ITH\5BT'3]SX%P1.+?.7\V^9-W'<,_G8.[>D>-
M6OZ5<[-R+E-=QE=Y%[J@ZQ(;<D4[!(VY"#GB5Z&;3]5IDG***EBZPG)QY063
MATF;>:.R:.7)5$6[))"U&,8QC&,8QC&,8QC&,8QC&,8Q@1``$1^8`ZC_`(!F
MLG:';)=F?IC8%XU9LWEC1JG?];6&5JEWK;R`V([=U^PPANY*Q;IQ%TM^P6<,
MC_D+"R=ND>^!B$5,8H@&?;@[47L^]#U6%N&TN6.G:W'V.`B+/!125E+/7.5@
MY^*9S<(_:T"N(2UX*G)QD@R=-BNZ^U/W'*0*E2,)@+KR7[;^\[\44B.SI[.[
ME;RL67.9HUV9<ZX30VCT'!S""+M6YVE-^JX9]TIC^">%KSA42F*4Y!#KGI\A
M';U\L>A]S<I]`]GI0I(.ZZI'&.G*[6VRBV`.\*+J_P!E>*,8Q\'0$OAU<N!$
M^\<ZGP4>X1,<^UW_`&?SA$VGD;[R:E]X<X]H'$CF0N/*+:]FMC%>1*;O&<-J
MC#O(>(*V-T(`,)=:>1`I"E.8Y>I1W!:QTQJ/2L$G5]/ZPH&K:XF5,I8/7M/K
M]-BQ\$7ND,HSKT?'I+J!U$15<`JJ<QC&.<QC"(R4``'S``=?./0`#J/T^;.<
M8QC&?*[>M&#=5V^<MV;5`HG6<NUDFS=(@?.91=<Z:1"A])C@'\,JSL+G'Q4U
MFHJUL>Z:@ZDD@,`Q%5<N+K*F6+U_\,9K5&\N"#@PAW`(Z50Z'Z%,)?G"#!Y\
M7"^'!'CUQ)WOL]%<!(VLMEBD=:T\RAA$J2X2TLF_`[7J`F$53LE1*`AW2C\W
MA\6=IKM%0#/I_1/&F$5#N&0AF#G9ER215#SB*SP)&",Z2)U#PB+MB0%``2@(
M!E3=S=G)9)K:.OG]\Y-.;L]V"]79;'M-YB4&-B;QL*T!9L-1:(+OXH&:C4IX
M=A&RRK9A#.U2228O&PNX_-AE`T;PMTDBU3J=,U8SD&:2)1G'C1E;+*HJ@0I3
M.59B0),2!'2QR&56%L=J0RIC>"12(!4RS.IO"@)B",:>9F1*`%31AZ_)+AY@
M*!2I@JBV3`OG`"]T``.G0`\Y>OJ';$V[`#0>J[U()F\R:KYHE$(CYA$![ZQ5
MP`/,'Y_F'S=1$H&X\8MUR`B+"@UZ&3./Y*DW8/A1R`(B'4R+%1,W4`#J(`3_
M``#H(#G'Q+O&0Z"ZN%1@2G`.\G$PBS]0GS`(=]\F`"(>?IT/\_S"`"'=Y\EU
MJ?>>;VS<')3_`/Q$8HK:&1'KWNI0!(RG0OGZ!T*'F`?-U[HE]B>B:2<X*2:U
MCGC_`#F&7L#Y8##U`1ZE0%N'0>GG`!`/./3IGOE]&Z^D(9U$,8@D&9T"1#R<
M:!3RI$R&`5"(/'_PLZ(KE#N*J)B57N"8"G#O#UZ&E:`A]?)/T*I:[;&H29VZ
MCM(',<L0ZC4JQ4CE!5D;N"!5S@;N].]^3UZB`95?M-N<CW@%I>K[=;5RD+P\
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MP#RI-U%H*'VI;K3L)O>UY=F=W1V]>JIX@LTI(K-MO`!W2E*'S%[H>H0#*9\?
M]+U&>TMK67>RVS$74A56+M=*+W%M>&CDU7"BZQR,HF*N3.,CFQ3'$$F<>T:M
M$"`!$4"%#H,P^0"C_KO;?OUW-]^L>0"C_KO;?OUW-]^L>0"C_KO;?OUW-]^L
M>0"C_KO;?OUW-]^L>0"C_KO;?OUW-]^L>0"C_KO;?OUW-]^L>0"C_KO;?OUW
M-]^L>0"C_KO;?OUW-]^\U/\`)?:5CK%JV'+:/9<A;;K[CO\`!8N_L*CLG=%D
MD]E[+G)AG!PNO$%_CZ;?04"QF5"-[3/0K7XSCH=&??-Q\.I7%5[(\1.(]WE-
M=539O,B3LMGY$+2EHL=<<HWN^1\SI&I75!CTU=`S<?;U'B/P1%NH:97;OU7/
M?>G@W<E,!&GDGMS_`"`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^N
MYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[
M;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4
M?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOU
MCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^N
MYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[
M;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4
M?]=[;]^NYOOUG`Z"HH"`#.;:`1^8/+MN;J/^`>/?4?X9B]LUQI2AQ2L[>-CW
M:FPB'>%:8MG)+:5;BD@('>.*LA-;%8M"%*7\HPF6Z%#SCYLUG;C[3SL@=(NG
M,79>:TI:I]`!!*N:DWKR"W!+NU@,8H-F_DYLMAC`<&,40*FXDV_4>GY0`("-
M7"]J,;<!RI\)^S:[3_DBW7$6[6W6W8>W-&:W.Y4\S=56US]YL`$8'[Q%%%ET
MXXY4A'KX,?R@^D-9]O1OX#)05(XX<#J\[35,5[=>2W('D)LAF@L`^",1I&7J
MRU$)!,@]2$58L2%4$!6*3NB3/S_\A^P>[7FR[LW!9%]8>7N1G+O8Y=7=1MG:
M@K0[6?/3^'-=S5VQ[$;SD)\>N#>%&,F4DGK4"]QR4HY^K[B+V)'`C36K]135
MEXN5M'?K2@4AYL:V3-NMEKGB;,-6XU6Y.&[]:TR$"@="RGDTVJM>;-XY-%)$
M8T0;D0-FS0G'ZB)HI-DYG;*;9`I2-VJ>\]RIM6Z9``I$V[8EZ*@W3(4``B:*
M:9"@``4H`'3/+R`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOU
MCR`4?]=[;]^NYOOUCR`4?]=[;]^NYOOUGH<Z)U^S07=.[%M5LV;(J.'#AQOG
M<:*""")#*++K*J7PJ:2*293**JJ&*FFF4QSF*4HB$?5F!XZW&H>/]9VY;)BE
M`Z?,3VEKR4VJ6#1>1JPMWK9Q(.-@H(-UFZ@=3IKF3.*)TG!`.W7154KSL#D+
MP3UVNNP?;VV%:9I(W@R0.O=W;SO,DX6ZB'@$E*_<W<657O!W>ZXDD?RO,(AY
M^D5AMZX[#,4G'SB3RUMC)W^2PM>U-^[<U;5S!YO_`!`@ZOBRKE`0$#`!)5J<
M0Z"!1\X9]!.,'.B]+-Y2W;WA..$%X03+1%+V9N._3C9'I_\`#=R=JNYV"Z@`
M/3JA-%1[Y0/W1#\G,C6X7\=E56KS?_(?<'(.5:`7PC"S[#EUX1;P?0"I(PE=
M.Y>(E\PAX,TZ<1*/0Z@B`B.:UGC?Q4KSXDAJ3CY?`DD@`J,M!V:_U\J90'O%
M%&5/:%5VQ>]Y_")D24#Y^O0.F2V;3=XG0*5HTNE3;B'1)6<Y%[MF72)/S=UN
MWO:R)3`7H'<%L0H>;S!T#,QJW'J?AQ,I(;9OJYE!."B1+;<9@0(?KWDTW5GL
M4F!4P`1*7N,BF`HAT-U#KF)VWBS,3U@1E8^]G;-(];PD<C*-G4J^,)BD!51^
M[.HF5=1;H=,Q4TDTBHF[A2!U,(Y^EQ:U4NFR<2;2V&E4FR)7*\=LS9<:U%UX
M%,KE1LU:6MNFBDHJ0QTR"03)E$"@/4!$>_0X]4%L4"-97:K4@>8"-MX;C;E`
M`\P`!4;R0.@````=/,```?,&>T=`T@?.,[MTP_2;>VZ#?SO8YQY`*/\`KO;?
MOUW-]^L>0"C_`*[VW[]=S??K'D`H_P"N]M^_7<WWZQY`*/\`KO;?OUW-]^L>
M0&C_`*[VW[]-S#_.]9*\%"M*]$,(5@K)+LXUN5LW6F)>4GI-1,@F,!GLQ-O'
M\K(+B)A[SE\\<.#@!0,H(%*`:<>W$7Y$1_&;7,WH6T\@:Q'PFZXU]N!WQUY4
M\>>$UM1UT-$O"#*1FN2G)>%F]<5"LL=@*TQ%Y6UFZ4A>'D@RA6RQ.X(A-_9&
M(;72X34)QN1?>CRW2EGV'-H2/(KD;J_EILR6J\U:WDE4I9WR#TK%PVJMC5Z2
M@G#5W4)"D1Z41%UQ2/@3J.7\6]<*[-<9P/S?Q+_,,@OC+_R"U/\`]&17\E<G
M7&,8QG`B``(C\P`(C_@&:Y=I]H_JG5-UNFNIM.-6M]5F[)7$F*DV[ATW$VUB
MHR4J4;()R<`E*,%+"D[>BJHQC)D7;5FQ>T=&\FGXQH.-<%^/7(!GLG:O+SE'
M*'K>T]SM%82%TA6)`4Z1K.C%E&DFS+(LV2XL9.X/QCV1S/7*:LS'MC/59Q\O
M/S<FQB=H'S?-C&,8QC&,8QC&,8QC&,X$0#SB(`'TB(!_/*#]HEV@NL^S@TI7
MMW;0I5^OD)9MDPFLH^%UXG7#2Z<O-05DL2;]TI:)R`CDXQNPJ[XBIDW:SH[I
M9JFDV,F999'6_P`?/[2MV?>WY>W,MF*WKC!$5BN-Y]I:-TEJRT1:'*LHC&J5
MJMM->SURGY"QHI+A*?`4X84SQB#I?X00R`)J9/(_V@KCG=G3B%XC\:^:7,V>
M*L*+133F@K$PJ;@W01*=:S6H&+AJB8>Z(*&@%.ZF;PAB]T,^(.6/;M[\,3R)
M]G1HGBM6Y`P((VCEMNP]IL#%-7N]U\I2=?JPTL@HB0144:N85W^7_==#B7\H
M'9[]L!O7\ODWVN#O542<P^&I/##3T31B?!EQZN62.P9;Q=L@=Q/^Y0<N&,B<
MO45#=\>]W\HJ?]GDX"C)HV+?CWD/R\M(&!=U,\D-]7BT(N'8]!.I\3UMW5F/
M@3'`3"W<F=E,!A36,J3H&;,M,\(>'_'E%FEI/C/H_6B[$P';2E5UK56,\4Y2
ME*"BEC4C5[`NH`%#^]7DU%.H=>]U$1&T8$*`=.G4/S`(B8`Z?-T`PB`=/S=`
M#I^;/+..@?0'J#.<8SCO!Y^@]>GS]//T_P`>G7^'T_FR.KMM_5>MT57%_P!B
MTFFD2(*ABV2SPT0N8H=.O@FKQXF[6-^47H1)`YQZAT#J/3*A6#M+N,C1X:)H
MKZ][FF^IDTXO4]!G[&=18#=T"$?/4(F/4((^?PS==PF)1`2B8?,.)O>5?,*Z
M)`KK'A^%#BU!Z)6?D1?8JFH]P3`7PQZPFM%2QBE`P'[B+IR8P%-T`P]`R'-C
MT/E1NJL3]7W7R[T_2*W,QZPN:#I^F2<^RD5DTSK-X><GP-'3*\.X<$2)+-TI
M1XU=->^FN@X1`4E(JT'PHT0Y3E9>\0=\WD"[UE\0TZ.&2@ZW#BS9(-Y%]85X
M:0:*2TG)R:+D&(*)H-&-?1CVRB;QX*[A/9)0=6FH[=!#4_'?5.JD$A`J$BY8
M1?QR4.[T`ZSEBW"565`!'J=TLL<?R@ZCU$1E?Q'VE,@(V'9YXU,?^)I5(E)F
M'0>O4I7RO@7'S#TZB0WTCUSWM]&4TZA5YU>P6EQU[QU9Z;>+E,;\X^!;F;DZ
M"/\`]$PF#ZQS/8FDU&"*4(BN0S$2B`E51CVXN/-\W5PH11<P_6*@C^?,G``#
MS`'FZ=.GYN@>;H`?,`?X9SC&,8QC&,8S\V';:\EM/625IO&AYK'8]_VGK.XP
M6S8&#V%V;>R>>_#R^R%BUI;VQJK=Z=5E6;*5NM=JDR[M\!)Q+AU8*`]:C(*1
M3R,DWZC>]G8NHTU/A%"*TQFO!HNMK;D<6&FLN,TEPYHU#N`W9TA9:=JWC3,2
M$K*:JUY%/T/#1$9)2"LI.R;V<M\LWC)6POHB/VQXS@?F_B7^89!?&7_D%J?_
M`*,BOY*Y.N,8QG6S$S$UZ+?S<[),8B(BVRKV1DY)TBR8,6B)1.JY=NG!R(H(
MIE#J910Y2]>@!U,(`.L+E-VB>NHM)AHGCDXMF\>0^U8=HC5('2(,Y"0I\9/I
M)G3N$U8'[9Q#PIF,:HM)HLUDS/6J!"OY=6ML#)3*5>8OL?YE*]W?=TYN1Q9]
MK0%P:6'03"P)J+U-@V@%F\DR5V2_08^,*L[.R@R#AM*5I5177TD:,L:2]^DF
M3MK(;R8\'8,&0/RD*^!JW^&%2<`[3*[\"3X2!'0,HT')07\(!7`1[$%PZ*@S
M:]_X.G]F,8QC&,8QC&,8Q@1`/.(]`^D<\!4(`=X1_)`!$3>?N@`!U$1-_P`(
M``?.(B`!^<<J=N7GEPOX]IO!W1RDT3KMTPZ_"8BP[,JJ=B)T+WA`E99R+RQ+
M'Z?,1*+.<PB`%*(B`9K8M']H=X$JS"M9T%%<CN7=G$_P=C%\<M"72RM7KPP@
M1)%.7LJ%6;&244$"`Y;H.D_/WR`<H>?'1[0SM>=X'\#QG[(B5UC%*FZ-[KS+
MW%"Z_2304`/!O'E`BP@[(4I>O>,V:2#]80Z`7J/4`X^3%V]F]U>]M[M`N.'$
M^LRA_"NZQQ:TFM>K-&(*&_*:-[=L1M'/$G*1!$A'3:?<%[P%4$Q^GGK1RI_L
MZ&P=\:YCQ6[1/D;N+>#>VQLD[M'*2Q2MUU@2ME82K>7:US7-<<(*URPJNG+!
M6.F"3+]!K'(R$4+,I7X.D,P[+/L`U>%6Z;WL[DA:]!<E86:UZVK%-K+G4+B1
M&I6DEICII:X,U=@*3C%B^+%L58=)>+9)2)DGRY3/4FY3HN/TKQ\9'1+-O'Q3
M%I&L&J8)-F,>V19,FZ1?,":+1J1%ND0`^8I$RE`/,`=,^T"E+YB@`!]```?R
MSG&,8ZAY_J^?IY\CNP;7U_5["SJTY9HYA-NRL3F:*G$?@*4JY.RB5I58@&2B
MD91XFHVCU7YT".E$U1(/@DE%2_#9-T:WJYE$9"R).W:91$6,"RD;(\[Q1Z"F
M9&":/P2.`^807.ET'_B$,@>=Y921U/@U!TS;K*X'J!7-FGJS2(TQNGY/1))W
M:;,("(@'0:VF<1`Q>@=.HQC*WKG3>BBG68O6>L6*YNJ;J.IURV+-(D,7H`%D
M[6O2JWWBCU-X0T(HGU`GF$!$!CV5XE\GMF@<-H\C]QR3%X`@[AXFS5O6D"J0
MX!WTCQ-&9.#BB(%`/!K"L;SFZCU$>O<TOLR=45UR1_(Q%:F9/O"HI*VE&6OT
MB=02]!4.:><M(TYS&_+$31QNANA@Z#T[MNZ]QW@J^T+'M;).Q\>4!_\`=U51
MBJ;&"`]`Z?`H)FBGTZ>8>HB(AYA'IYARMGH_6[4PJKP1I1<1[QEY:1D'ZAS?
M2H"C@J1_K[R8]?/U\XCU[>6U50Y:%<P)ZZP8L'?@RN1BD$HUVJF0X'%$SUNF
M#KP2@@!52`J'A"]2F'H(AGST'4E,UHL_5J31ZP+)))INVZDDZ=-5!2.!TU?@
MZQA3*N3H)"K`'?!,QR?\)AR3.@!\P=,8QC&,8QC&,8QC-)';FRL'&\=-7-2V
MYEIS8T[N+XIU9R+L'->R]GQ3M*V(VN[F^FY*R<E*NUD7B'CE46$S2XG6+J+?
M,MA2,D3P@,U:ZB_;RYV,SVE/^$T`O4A).21=E;3:[$VBQY,37,FO;PV:QLOP
M.X;AJW*&?;L)+<4%;G"#5%*:6BXL*[(1,C0@9`:I'<N;?<G^1#WCG':5E6]#
M/>&6UN2VB^/DLJ2S-JX--:[ON[&ALKL*2\3*JV((68DX\#5QH$>L^3<'6/+,
M4&RASP?$<]8Z5Y`FUJ%%31U4XY063A5%[2&QO?CAWR/JFBS;XE(Y6E*U=!HG
MKI:,C[)KUA<&MM?29MDUMS'NJTV@GS::3V%]0$`$/.`]T0'ZA$.F5QXVV:N-
M-$:K;.I^%;.$:=&)JH.)5@BLDH05BG(HDJX(H0Y#%$IBF*`E,`@(`("&3=XW
MU3]I:_[:C/\`58\;ZI^TM?\`;49_JL>-]4_:6O\`MJ,_U6/&^J?M+7_;49_J
MLPG8F]=/ZGJ4O>=A[(I]5JT(T!Y(2LE.,!(5-0YDVZ+5HV67?R3UXL0S>/CH
MYJZ?2#KHV9MUEQ[F:>>3U%Y%<_M@T8NH=]T:G<'[E3*Y=XG9#.<;,9PZCM,Z
M$G'%H3MW%V:1MZ3ANJ\B74ZC$1,8W<"W._CW[%[&R&V+6-`T=JAA%!6$]?(6
M1E3JQ2I:\IMJ9'W*UQ=6C6\>Q-99J*09+R*BAT#/E4!$K,KQPLH@W3`2@66O
M&^J?M+7_`&U&?ZK'C?5/VEK_`+:C/]5CQOJG[2U_VU&?ZK'C?5/VEK_MJ,_U
M6/&^J?M+7_;49_JL>-]4_:6O^VHS_58\;ZI^TM?]M1G^JQXWU3]I:_[:C/\`
M58\;ZI^TM?\`;49_JL>-]4_:6O\`MJ,_U6/&^J?M+7_;49_JL>-]4_:6O^VH
MS_58\;ZI^TM?]M1G^JQXWU3]I:_[:C/]5CQOJG[2U_VU&?ZK`6ZJF,4A;+7S
M',/0I`FHP3&'Z"E!UU$?J`!S!]B[[TAJ&'4L&U=P:PUO!)`8RDO>K[5:K'@!
M"]\Q2.)N69$54[@")4DA.J;S`4AA$.OXNM^_VGSEU3]V[GJNFJ7Q,NVIJOLV
M_P`#JVZ.ZULR3/:Z##6*38T^RNI.-VG&L'XS,*W92*[Y@P8M'15S.&K1ND<B
M9=L=)[7/M']_T6HR/'#LG[2\=S=4K<D[VGO?<E/TMJJ2E'\&Q=R<Q58>;>$G
M9&G.GZSAW6UC69:1?01V*RH?"5S$+WIJGV]F_3_"+CS"X&\)Z[(%!)Q!Z7J*
MVYKO'H&`0/W9F^"]BA>`4?\`X["P(E!0.\EW"].@>Q3K.UU/A7,_M0.:7*,Y
MS%4<5TFZHG4NNUS")3*MRT^MN9KX,Q/T,0$&4DS$""/=,0P][+9Z>[(/LD=(
MKM7]2XOZ(FIEL!3&GMFOAVW+N%R^?X4LOLF=LS8'!C?EF.@S1+WQ[Q2%\V;)
M:PGJ>DQ:,)30U_4H9N``A$UCQ9KT8B4H=`*DPA_@31,H```!2H@`````>;,D
M"VU(!ZA9*\`C\X_',7U'_$?A74?XYSXWU3]I:_[:C/\`58\;ZI^TM?\`;49_
MJL\CVNKIF$BEC@4SEZ=XAYB-*8.\`&#J4SH!#J40,'4/.`@(>80SR)::TH8I
M$[!!G.;IW2$EXXQC=?F[I2N1$>OYN@9XO[96(LIC2-AA&/<_XBNI1DD</S?\
M!EN^/S#Y@*(^8<P>1W?K*.(8Q[.W="3KW@8MGCLOF#KT\,1`K<.OF`!,L`=1
MZ=?G$,3)R+JDEU+68F8L0AYA4:K0S=OU[W=#O+*22HD`?./4R8"'S"`#U`(2
MV7SCI6L_#DM4MKRJO$0\\1*WAG/V(1$?,0:W4ROY0BHA_P#5+IHB'G$Q@Z97
M"*[0V^;/?K,-,ZQO%Z`%#)%DH6NU^M0)1#S"9:P7>>^!M2%$1ZB[*@J'@P$4
M@[PADKP#WES>Q*K9;'JG5$<HH!%V\[MDURL*20B`''XFUVWKU>$X%#\E/QP,
M7O=X##T-U#[930EA>S#655V_KN2=M5#J+R2KH(U>954)X`Z[UL,A,*I#\"`D
M>D1:5DSHMD@Z.#`?P1+;0=>T[%-6@"A0!=D00^$&/(1DB3X45,H+&15D7*JA
MDQ5[XD,8A#B42B8I1\P9RUL%'8D!-E-55HF`=`3:R4,W(4`Z]``J*Y```ZCT
M\WFSZ_&ZJ?-XRU\?\9J,'^;K'C=5/VEK_MJ,_P!5CQOJG[2U_P!M1G^JQXWU
M3]I:_P"VHS_58\;ZI^TM?]M1G^JQXWU3]I:_[:C/]5CQOJG[2U_VU&?ZK'C?
M5/VEK_MJ,_U6/&^J?M+7_;49_JL>-]4_:6O^VHS_`%6/&^J?M+7_`&U&?ZK'
MC?5/VEK_`+:C/]5CQOJG[2U_VU&?ZK'C?5/VEK_MJ,_U6/&^J?M+7_;49_JL
M>-]4_:6O^VHS_58\;ZI^TM?]M1G^JQXWU3]I:_[:C/\`58\;ZI^TM?\`;49_
MJL>-]4_:6O\`MJ,_U6/&^J?M+7_;49_JL>-]4_:6O^VHS_58\;JK^TM?]M1G
M^JSNVSEL\02=-'"+ILL4#HN&ZJ:Z"I!$0`Z:J1CIJ%$0'H8AA`>@^?S9JE[6
MMQ?4-5Z.\4HJ@[+@?E`5]U?.,NQ-HZ@TQ7>54%$U&W3$=IJ4OF^-7[3U@I!K
M6!A&VRQ4Z89TF6ML37%D*ML2!L,?'Q<_8/L^*UR4J_'"(9\HZEJO6-XD+EL"
M=J.E--R,;/T;0VGYJSNW^J-*1]KA:_5H2W+ZZJ*S.$=6"#@8^$7$J;*((M'L
M6[E;.^5?'^;Y#UK4\'!VZ+IR^M>2.@-_.'<K7WEB1FD-%;'A]CIU)%LRFX(\
M<M:'D*VBCSZCA^G#-EEW98645!-`(!8<!C1_(AAL%.]M#Z;B>5MMYR,->*0T
ML-H+R%N6BI+1+]BM9R6!.)4UFR).V3:+**/`'FQODV1D=Z2NQ2"3K8_T`I0`
M/F#N@'^`"`!E1N/&G]2S6DM9RTQJ_7<K*2%4CW;^2DJ367[]\[7%91=T\>.X
MM9RY<+'$3JK+*'44.(F.83"(Y,_D+TGZ']6^[VH_[/CR%Z3]#^K?=[4?]GP.
MC-)A_P#8_JWW>U$1]00_4<H%SSOU)X[46H0NE.+U,VENW<%CDJ;KB&@--P=D
MCF#^)024G).65C8%=D@\C0=M21\9)JH$=.1=.79/BV(E#)1SH3LM*)=X+6NV
M>9E33G]WL7,W/V+7<3/M1U.T<RDFLZAX^7KD(P:1TL^C&)69Y9FSDEZVI)&=
M19`E8!!NB?:"31&D4R$3)IW59")D*F0A=>5`I2$(4"$(0I88"E(0A2E(4H`4
MI0`I0```,\O(7I/T/ZM]WM1_V?'D+TGZ']6^[VH_[/CR%Z3]#^K?=[4?]GQY
M"])^A_5ON]J/^SX\A>D_0_JWW>U'_9\>0O2?H?U;[O:C_L^/(7I/T/ZM]WM1
M_P!GQY"])^A_5ON]J/\`L^/(7I/T/ZM]WM1_V?'D+TGZ']6^[VH_[/CR%Z3]
M#^K?=[4?]GQY"])^A_5ON]J/^SYP.C-)`(`.H-6`(_,'D^J'4?\``/B?J/\`
M#(WV3'\.-.0YK!MN-XVZP@B$44&8V%'ZOIL<)4P$3]QU8D(Y)40Z=`*D90YA
MZ`4HB(!FHW9W;+]CM3I<U4U=5F7*F]F44;-Z;QBXUDV0\<O0$2)-T)MS78"L
MN"JJ="@O'R\@3NCWB`ITZ#&'RD^T7Y%E\#Q.[$G5FEJ\Z#NMME<X5Z13>ZV<
M>9O)!K2(BJW9OR$S%6\`V=30&Z=.BI1$!^A+LD>T?Y#HG3Y7<^=7:5J[S\IY
MK'@_QRHU.3%LY$!7CC[+FH*N64X$()DO#NFLV`].H&4*/4;&:>_L[_9FZT>(
M3EWUG<>2%L1,DN:R<AM@SMT*H[)W3*+&K$,:KT]4BAP$?`/H-^F!![AA4`.H
M]1?/[.+V8=]M]MM[C7VS:PI;YJ5FG%=H^W+'5*A"*2ZIUEXVJUJ/1%C78-L9
M0Y8R'C^XQBT!(U8IHMDD44]L].XP\?:-4:I2H74.O%(>FUF`J<,I+U"NS4L,
M36XEG"QGQC,248O(RCX&3%`'4@^76=O5P4<N%#K*',.3>0S2?H?U;[O:C_LV
M?$ZT[H-B`F>ZMU"T*'G$SFD4EN4`#KU$16BR=.@%,(_4`_0.8H_JW%6-$0=T
M[1Q!+U[Q4Z=2G)P$!,`AX-K$+G$>I1#H`=1'H'3J)>N+.1XG)&$K366NY8X=
M0`D5J6#="80[WF*8\`B0>O=\P][IT$#=>[WA#Y1C=-O.OQ#Q8BY8//W5%-45
M"/1/T[__`-8K$K"4![OSB4!#S@(=X.Z//D^CY#K\5\3-2,"CU[JD]`4@@A_Q
M``F10AT5.OF`1*`_2'>Z&*;,8M^I)*.@7LFWT;HHRX`"#:(K.L8*9F%EG(*I
MIBF96&4;(D2'NF4<JF`A/R!`ACF\'F$:BT8M>&#QI?ZG&P3IGT72DWNMJ=*+
M3J"JYDC=+"\BUG1UF0)D:D04<.?!HI]Q$$TT#I!E-HI7#G12*[K8%VHE.<(?
MW[AH^DJC`2:PF_+,9&%@XY&=<'.`!T(V;JJ&Z@!/.;(0'F'QK?OC1/'[06U.
M1LX0_<17J5'FO%XQB^8#.9^T]!02$0[QE_BA1$H!WC&#NE#/>^@N<V\")(LM
M"<:>.U<4Z&0>['CHC:%S0:=>I/!Q#6.D(=-PF4QA!N^BVG57J4YB%Z"/C&=E
MK7+4^3FM^;BM>PWX"*@0]*K50U356QE![RS9!A`Q;IR#;J`$*+12,/X,```+
M^:WFON%O%K6*0DJND:&5<Z0)+2,_$$MTJN`].^921M1IAR!E1`#*>!,D01\P
M%`O0`E`^C]+J%`JFHM8'*7_A*>@5(Q2_X`,0(!_`,\/(7I/T/ZM]WM1_V?'D
M+TGZ']6^[VH_[/CR%Z3]#^K?=[4?]GQY"])^A_5ON]J/^SX\A>D_0_JWW>U'
M_9\>0O2?H?U;[O:C_L^/(7I/T/ZM]WM1_P!GQY"])^A_5ON]J/\`L^/(7I/T
M/ZM]WM1_V?'D+TGZ']6^[VH_[/CR%Z3]#^K?=[4?]GQY"])^A_5ON]J/^SX\
MA>D_0_JWW>U'_9\>0O2?H?U;[O:C_L^/(7I/T/ZM]WM1_P!GQY"])^A_5ON]
MJ/\`L^/(7I/T/ZM]WM1_V?'D+TGZ']6^[VH_[/CR%Z3]#^K?=[4?]GQY"])^
MA_5ON]J/^SX\A>D_0_JWW>U'_9\>0O2?H?U;[O:C_L^/(7I/T/ZM]WM1_P!G
MQY"])^A_5ON]J/\`L^/(7I/T/ZM]WM1_V?'D+TGZ']6^[VH_[/CR%Z3]#^K?
M=]4?]GR0XF(BH&.9P\'&1\-$QZ)6["+BF3:.CF3<HB)4&C%FDBU;(E$QA*DB
MD0@"(B!>HCFIKMD+-H&M<?\`6ORI.3^]^*>@IW<S2N;&N7'>X>)U]OD7+:\O
MZ#;3SA>'8SFR9RM7]_\`!VLW6M-5BQ[.E$F21HYM%UUM9K%#_-V4-$UH;5M-
MVAQ9K&[.-O#].A6?5VN>)6YX>RC9G,I7-FOG<9R+GIC8EOM]\B'-]J";0E7J
M#IRV,G5Y8DQ9574NY81-9V_XS@?F_B7^89!?&7_D%J?_`*,BOY*Y.N81L39-
M$U+3IS8&R;7"TRFUQL#N:L,\]391[)(QRI(IB<W>5<.W:YTVS"/:)+OY%XJB
MS8MG#I9)(VFJ2V%R:[4Z`L[?C==)'C/QR@[VG6'&P)B(L+2V[7@F_A!?S%1=
M1@L')DD""@N:(2E8-HP>'3BIB5<2:;I..VA<7>,U!XGZFCM3:_=V*5CTI65L
MDY8+7+*RT_9K7/G06G9^25$$VC9606;I"5C'-FS%NFF4`35<'<NW-BL8QC&,
M8P(@'G$>@?2.>/?+TZ@/>#Z2@)@]90'-57:E=J)4.S;U%5=A-J=7=UVVR;,B
MJ&KK)#:<32+%&Q;^N6>==VU5,L%;9-6/C'$`TC'*9X1!N5:8;G6D$#E20<ZL
M^/O]J)U5LF9M,'M'B+N>HRS.-C3T2LZ8=O\`D%=+Y8'+]=M(0(5YK3*&E6R1
MK0K9[\:2<FH@Z,N=HDW!=$`5M*':#=KIR)Z)<2^RF=ZA@'(]&NRN<>RV="2!
MJN(`A(&U=!GAK8<"D,"O@&S^5$W0`[IPZ]?$W`KM@^0Q3+<K>U/:Z+KB_P#>
M.M<<'=8-J>9-LOT,O'AM6RA!VDHD3$R0N%4)8OF$0$Y?RARZ@]A#V8M'E_&W
M<T9<>4E\!1-RZN7*S==@V.^</`,4RRZT$23@*RL114>HMWT,_3`#`4PG^<=G
M&NX[BCH>("OZDK.HM70Q$DTOBG6-/@:RT4(D4O<!1"I0[0')^@!U.N*JAS_\
M1C*".9DIO:A>$,6/">F#CY@^*J^_6[X]3`'0ZQ$.]U[OF'\_7S=>Z<"^/E;E
M'8]8;5]]D"#T[IW+!*-2'KW//WU16``_+Z]>H]/,(]"B)B\#<-O/P[T;JYHP
M*(#W335E:@(#W1$!,BAX`_S]/R?,(CU*(E\QAKA?-D;J1V'!F)773=&KFDF;
M]>`A922A"JRR8(&4447*H60%JF4O>,4I$A$@_!R&5*8Q[%-Z?L^:;HN9#;"C
M1!RBFN0D)7&K,?!+D\(3HHL+=<@]PY>H'("A1ZE,!3E*)?:&G"/>HSNP+_,]
M>O>(,W\%1-U[W4/!()*=T/ROF`P!\X!YC&#.3:;U3$I"[F&)54R><[N?G7H)
MAYQZBH=P[;(^<3?G#Y^@_/T$<'EMI<0M>)JGF;_HR#,W`3'3=V>IN7Q1*!@,
M`-OAKU^<P`/=[I$C'ZF*4"B)B`,52W:.<*ZSX1O&[28SSI+O`#&D5"SSASB4
MJINB*L?!),5.HD,4#`Z[G50AQ."9Q.&,AVC=8L!3$UAQTY1;*7$PD14BM7+Q
MD:L(>%#O`_?OE3)E_NS&$5&I1*7KWRE,FJ4G(<G>:-K[Q*'P1FH4IO\`X;[9
M^T*_7"`413`IUXX&K-T02@*@J))KG.!>G3J8@D5PV^LNU&V92;1$I1>@-5IR
M$&^1%I4[/8'-]=%%%(RL9!614\G"P\M))@O'MI,ZK0C,RYSIR,>J5O)HU]XC
M\)N0-VUNM&;AVSN[2>JPDGH0.H:W/N*W/R8K.5!G)&:3=$<J5R'>/DS#'Q)D
MG"LDL9Y.>`9(/45Y/8)KOL_^*&N%T)%EJ>(M4\D(G4L6Q'#R]RKI80Z"X6)8
M%G441<1ZF[[:+0`IAZD`O0.EOHZ+CHAFA'13!G&1[4@)MF,>U08LFZ8?,F@T
M:IHMTB!^8I$RE^K/N``#Y@`/\/-C&,8QC&,8QC&,8QC&,8QC&,8QC-)/,5EV
MAG*7D#*4'AE,\']4U+A_::A,.]C<E:).[YVJ\WS;=7-+;%OM=T2OF)#ZKJD)
MKC8R5?\`*#+N%+U/RDW:FU89Q4%$*N[#=_@A>+Q<]165KMZD:AI&^:-MO8E#
MW^GH.57F=.6S<$(\CWEHV#0WDFDVLC:/O3:6B+#*P-P:)7"IV5W-U2QN):1A
M59R4NOC.!^;^)?YAD%\91`-`ZH$?,`4R+_DKD'\G>9T?J0937&EJJ/(+DJ:/
M.YBM+4Z4:/)>&2.9HFE-7I%BLM(5^&3%\@X3161;NI%,!(5Q'HJ`_)$/'+C7
MR#W)0-A..TED*AM%AM"Q4VX5SC^K%,758U$O4W#IZQ33D(M1-,7SE16/([@F
M<C-1S4D:8\A-S;V7EP'9E$1$5`1C"$@HR/AH:*:-X^+B8IFVCHR-8-4RHM63
M!@S21:,VC9$A4D&S9%)%%,H$3(4H=,['&,9X]X/H-_V'_P#\<"8H"`"8`$?F
M`1\X_P"`?/\`PZ9ULO.0T`P<RL[*QT+&,TS*NI&7>M8Q@V2*'4RB[U^JW;))
ME#SF.HJ4H?G'*'[=[5KLX=&**M]E<T>/<3(H"J5:#A=B0]WL::B/_&@:N412
MS30..OY)4!8@J8WY)2B("`47LO\`:(.%[AXM$Z'UARYY13!SF0BR:=X[VU*'
MDG`]XJ`)S-Y-53E;KJ$.F5=.,7$O@U#"D)2#UCN0[5GM.MID(70/92+ZY8.!
M*+2V\M-\5^CM_`+%$$G+JG1+.(FB@F8/"+-T)1RL*?=(4`,H4V8PJKV\&\53
M#8^6?$WBW$OR$(M!\>-#V?<]G9)G.4%$VT]?6+Z-!V0@_D.&T\5$3&Z%.4.Z
M</3_`.R+W+N$A1Y0\]NTKY#H.1,9[6H[8,'QXU^Y\*KX55$D%$&M(I,5BE*3
MP"96PD)_\,2]$BAZ+O\`V?[A%%5B"D8_CG;(R6@+A#V9_.I;FN^Q=B;"+'`Z
M5)3+>\FU9>(&D2[LR+JS-XB'@)!^1DW:?':*"JR+F_/%/AQ7Z-N/=/(*I5B0
MT[NS<D;6(?:<^K%2YF5JBZZJ4T6K#5]VNE6(!UWV[=2:5BF;9_+.$TG#XZB9
ME1-?\=56%T'28VS=78&*`*$8*MXI,?R0#S`F=40#S=?/U_,(_E=3#Y!HNFJF
M[\D_M<V8>O?&2L3U4I^HF'\H&Y4>H_ECY@$//^4`=3&[WV*:OU!7D?A;^"@6
M:20=\[J;?'%(`*43B*BDH]!+H!4SF$3="@4JG7H7OAF&R^X^*-"*;XVV/HVO
M'1[I3)JV:EIO""'Y/06Z+I5WU#_A,(D$?.`"/G#K%$QVC7"VOE,BGN>%E5R"
M!2LZK`6F>44$QR>9(T5!';'ZF5Z_DK=#&*J0HBHF<H84':7:FEQ\%0=2\D=C
MK*%_N!J^HY'X(N<2)'*0',B^;&`!*H'4_@1('0#]124(H/B',;DK8`4)1.`F
MXU>^"GP=W?;)!45`1*5;NF6;OF*B@`!DP#P97'>,!N[W@.9(%:-;IVEVBB_)
M353E6CS.N[/)@NCJW6E<E$+7K^4:J'!&S)V^5CGOQ'/+`V(1W:7$XXC#UB$*
MRD(DD/\`DR#F\@:H[2.T`(6'D_IS7K=<3"=OKS5IIYP@414,!47UF:-ENI>J
M9`/X;J)2@83"8IP7]@<'-MV$W_SD<Y^1MB04_P#RAC4G49KYBH`G(8Y"HQZL
MB4I#=WH7^[[Q/R1`W4H=[Z6'9A<9163<V]3:NS%RB!E%+[M*S2)5S`"0=54H
MM6'3$!*B4O0O0`*/=#\E-'P4QUC@QQ&J!B*0W'_7!E$^[W59F&-9E>I0`.IE
M+(XE3&$0#\KKYC")A$/RC=9^K^O*%4RD)5Z34:V5,H$(6!K4+#@0H=[\DOQ>
MQ;B`#WSB(=?G.8?_`*1NN8=T/K_[C=/5UZ8Z!]`>H,YQT`/F#IC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,9K*YI=DCPYYUWRO[6VW`[(J6UH*MA25MEZ-VW>-*W&
MT41-P[>-J3=Y&D2+)"X5R.>/WSF'0G6;M]!F?R+>'D&+*3D&KJZ/'_C_`*?X
MM:?H^A=#4>+UUJG744>(JE4B5'KE)HDX=N9*2?R$G*.G\S/3\[+O7\Y9++/2
M,E/V.>D)":FY%])O7+E28C&[I3&$.H%*)NGT]`$>F:F8/G'M"1Y'((.6-91T
M/,<][IV>,55P@5PO*5IIO'28V\&YSVLMC6:NF,AL>HVO7KBEJ0$>FUIZD):F
M[Y:6;O6TEEO:8<U-U</H#C4AH34M.V]L#D/R&A='QT#=9Z?K\5%)RM0L]H6L
M*CROL7SCX/#HUU5]+F<)`V:P;>1>F-WT"%-3.N;NYYSEH?\`&=G5J=J+BU'U
MY.OU+F-0)LUAV3+PKV.326%#7T@Y5D*9;HU1Y)-?C!%@Y;-)&.:R;*5;LQ#O
M6SXOZ]XJ<,&LFRU_"7N\WRUIHJW_`'99V\-)W6XN';@'SM&1DY6:B7K"*2>]
MUZM#QT:DR<.P)(.U9J4`S\UEYGF'4XUJH=E1;?(O2&3\%'&L&IH=1=(RG<.J
M1Q,;(:-R$3(!C@"ABF4[HID`5/R0PZ?YN,HQ=L2-UXD_26;>%4/);@T_7UDE
M@.8ID$V[NS.1<E*7NB9PDKX+OB*8=>[WS81+\]II@@NHTUUJH53`?XM1G>4-
M*ATW)BB403>KL:7/?!#%(;JL+(DJ0AP`J1W"9@6S$9;M"[D@PCEVM2XN1SM4
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M#;]$"E3LGK^<[,7496R.O>(UUAC)%`2*U#B[K.KG0,0Q1*4'+I$\N8X^#(<J
MB;XXD!,@"H!P\U@V7._CA#>$:1G&KD0_9(=2-OA40W:H*I@'>3`\8C94VB!!
M,'<\%X$X%('7NFZB4?H0[2_7\4@*D%PWV$DZ*)>YX9G!M`,'7H<QWI(>1=@<
M"B8Q?[A3PAA$#&(`B<,J_P#:?7!0[5O$<3IU,%1$IAE=I5V);I]XH&3$5DZZ
MJ@B40[P*F=&;E3-W"AU,8P%Y+VC&[W[E<K#C;0V+9,I#IA/<@ZTT5,`@!3E*
ML$.1%93O@8W<3(`E2$HFZB`B.`["YS<M9/7ML^)J/I"E2!XQVDC+UO;L?;[S
M&(=2%7=UBI]5$IB:!JHH$:4!7.FX*9VE'.U4$VJD8\:N1G,*1UHE!,MT:,K$
M)$2;QM%67D0YLTIL-ZU6%LY.FP3;$>O9N$8JF<)1\M8$?A*RJKA@E(.6C)J=
MI/!9K?\`:""G<>TNU;5$C]1.WUOK2#*9,1(`"5&1D48MV!>H=>^/0W>$3!W1
M[Q#>8Z>U98!$-D]I5O&X(J`?PS.*V`TI[!3PA7!%`*T9-I%-),Q%RE\$7J7N
ME.GYTSID0^UAQ=[-HJ_PBS[$D-A+"8QCJ7G<ELDQ5,<RIS"H6/7BB&$3*B83
M"'>,8H*&,*IE#GEVMZR[,BJ'24B*MH054>Z)5)=+QC4$Q3%,!CGL)Y05!ZD#
M_C`WY(F+_P`!SE-.L%LKAQ5P(%:E]*UX"`4"?$<17XKN]SP7=$!8Q2!NI?`(
M]!$PC_<I#UZD*(9R')?0!0`"[7I@``=``)4`*`?44$P*'\`#.?E,Z!]*]+$?
MI&4*(^L4NN<#R7T`(@/E6I?4O7I_[T+YNH=!_P#JO-U#S#T^</,/4,\OE-:"
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M@A_^UBF>U0_R\EZ`GX:T0\?8*](M9>%E6Y7<=),E/#-'C8YC%(L@KT`#IF$A
M@`>@><!SM\9P(`("`AU`0$!`?F$!\P@/^.4[:\)-2,]](;U0=V,AVFUYWD$R
MUN!J]Y/FO(6S:@)H6<W0DAXO^-'C6^U2#FNA&FLPU)"1E)FW(U\MLE'$ODP;
M8T1K[<KRDR-V9.UWVNY.>F*F[9N$T%HJ1LE7DJ;+O$/"(+E(Y<5N9E8HBZ92
M+HMI%XFD<H.#]?@U[QZUOKB?<6B`9OW$TX@5:S\+EG0.S(PB\NVG'#!-'P""
M?@E95FV>?WR:ADE2',@9+PZ_A9>5@81<XJ+Q$6LH(``J*QS)0X@4.A0$YT!,
M(%#S``CY@\P9\QZK6%1[RE=@E#`'0!/#QIQ`/HZF:B/3SCYL]8T^IC\]8KP_
MXPD6/\VF`I]3#YJQ7@_PA(L/Y-,\@J56#YJW`!_A"Q@?R:X"K5?J(!78(!#_
M`/!HX/\`'H/P4`'I\P]!'IY@'/(*Q6>]T"OP@"'_`.#QX`/^!O@O01#\X`(B
M'Y\C*>X_ZXL6P*SL5ZRE6\G66SMN6#C)I]&TV>.OU%J\M%3:'3AYY[$F.L:-
M7=H?DBL!7I7I&D>1G++2%B&!3E8QD>S*IW14!JQ:H`H)`$""IX)$O?$H"(%$
MW40ZCT'SCG8E(4A0*4`*4/F*7\DH?G\Q2]`#^`!G/0/K]8_;CH'U_P#</VYP
M`E-\W>^CS]\H^HW0?\!Z=!_-CS"(AY^H=.OG-^?Z^O3K]7SAYNOSAG/0/K]8
M_;CH'U^L?MS@"%*`%*'0`#H`!U``#Z``.@`'U``!G/0/K]8_;G`]`#J/7^`F
M$?4'41_P#`=!#J`CT_Q,'K`1Z@(?G`?.`^8<!T$.H=[I]8F#U=>G4/H$/,/Y
MASGH'U^L?MQT#Z_6/VXZ!]?K'[<=`^OUC]N<&$I?./>_AWS?Q$"]1`/I$?,'
MYQP/0`ZCWNGU=\P^?ZB]1_\`+S!YQ\V<@`"'4!'H/UF^W'0/K]8_;CH'U^L?
MMQT#Z_6/VXZ!]?K'[<=`^OUC]N``!\_Y7Y_G$P?,/3YAZ#]OSAYL=`^OUC]N
M.@?7ZQ^W'0/K]8_;CH'U^L?MQT#Z_6/VXZ!U$/RO-T_.;IY_H'YA^;S]!\WY
M_G#/'J7O=WJ;K_\`Q]/\.]_P]?S]WKUZ>?ITSRZ!]?K'[<=`^OUC]N.@?7ZQ
M^W'0/K]8_;CH'U^L?MP``/\`][S#T\XF#^?SA]8>;./-U$//U``$?.;\_P!?
M7IU\WS=>OY_SYST#Z_6/VXZ!]?K'[<=`^OUC]N.@?7ZQ^W'0/K]9OMP``(=?
M/Y_/YQ,`_P`0$>H?X#Y\X#H/7IWO-^?\H`'\_4!'H`A]8=0^O.>@?7ZQ^W'0
M/K]8_;CH'U^L?MQT#Z_6/VX$``.OY7\!,(^H.HYP/0`ZCWOX"81_@`=1'^`?
M7\V<@`"'4.OG^LP#_$!'J`_2`^</SXZ!]?K'[<=`^OUC]N.@?7ZQ^W'0/K]8
M_;CH'U_]P_;G!3`(>;KYOI`P#_C^4`"(#^8?F'\P^;/+&,90?M/;7=Z7P=WA
M.T*<G:M)^!UW#6*UUGX<G.U+5]HVYK^K[HMT6]C%$9*'=U;3\S>9\D_'.&[^
MNECSSK-=%Q')K)]5P$>N6LOS:UY"N)!;4&H.:%NUYI!L]67<L8&J$TOHRWWN
MG5ETY4444JM,WE;=J5Z(9$,=I6SLWM18"@QK[=BRV&XQC/`_7N^;YQ,0!_\`
MW1.4#?\`\HCY_P`WSY^>CA5MRT5[<O'R];%NSR)M6X=8=II<N<*EUL3R'KM8
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ME)N%+INL9*8^4*P?:\H4+83_``.)BXF,)78HDF@W;/MG3=9N6P'7>,Y.UC]W
M6,8S7QVC<K:VNL='5V*<23&A[%YE<3=:[P?1OPY$?(Y<]O0T;8H*3D8UPU>1
ME<OM@"IZXM#DJY&SFNW&3B9`0CI-V(4/5Y5;/U#V8O)V9U;?(-/9.O\`;O*O
M7W&VQWF8">D*GQY@N;DSQUHN])1I(?'LM/ZTT!5)Y*63MLI"RM?/5J'"*6#X
MS9+*J2-^^S^LO?JV_M1.:(WJLUQPY(VS3-@MK.^S^SDMSR"-!UIL1GMJ2O%L
M;IVJ8NDW`["AH/9C:Q.9.2A-BUVRQ!9-Y'-6!B7\QC&:=>TNDR.MKZCJ.P+;
M9:=HYOQ*[0K;S^0@)>8@"#O#4-$U"]UA,?'40[;&;6;75`L>Z=F45!R"OP2>
MJY[?&HC+TYD\C\#Y`[%W)M?AKP3:LB438G+"Q67CVXV9QIV3-^)&O=N;9EN)
M-QV[?-)[MFH%X#S4;X\0G-;4UXWFH6=CGFR*GKR-D*;*UV65EH;8YP;L,9;.
M'O&BR0]FOUQCYK2NOI%"Q;19$CMA2`N*\S,N%O9)OI=-"<9.06C794I^SI&^
M!D43M=I(<+%)VJQC&>)@`2B`]>@]`'H(E'H(]!Z"40$!\_F$!`0'H("`@`YK
MV[,=TZ7XU6EHZG[!90@>7W/ZK1\G:;5/7:>"#JW.'?\`7Z['O[/:)2:L$J$1
M`1T;%LU964>.48]HT;`J"**1"["\8QC-<E!G6];[2GFO\;W"39U)APRX27Z3
M966[2[BH5-T;8G-N)LEABXF?F5ZY1&+JOT^OK6-:#:0<8_-$I3,R#A]X=Z>)
M[3'ZHE^T1TE>]7[L9LKS7Y69DN0,_(;I*:&NVO-JZ6E(;1/%6OT5.9"MV!W/
M620JO(FK143"*OJS#T=U=W4D,GMEBO9]N0><`'KUZ@'G#YA^O^.<XQG@H(@F
M<0\P@0P@/U@`B'^/G#YA\P_,("&:N^`UW852O<VU[C=I-U#UWM'N2M,KKJ[W
MB4L;])25G:,A5J)$3%RG)"07<OI^<)`4JHIR`]UW(1M:KS%!$6#`E<N%N^-H
M;0[3C=X[-K'(*D/;KPFU'>&>M=F46VT^F:F91W(G?,5!56*82AS0HV1S57,,
ME:KLS\.38]WB[>2)?FK-3K\;';U,8QF,7:.:R].M<4]<2#5G)5N=8.W43,2M
M>E&S9W%NT%UXV?@WL;-0C]%,YE&DM$2#&3CERD=L7C9RDFL33SK[DY;](]AG
MIO=%9L$=:>0$5V8M?VAKIK<9P\]-W*]TOCG"V)]:)1J]6D[+=V-9?K-[=L%=
MNC*R"T2W?.)-<%'@KGGOLZ[0^9.>0NB+#`L)BYZ-MNJ26CD-#WN9V6PY,N=L
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M,]E+/:/5W:NPFD>04V#6\'<12AK:W8I"*3-&P#(I-DQ$B)2`(Y\\9H_3$+>7
M&SH?4FLHK8[MQ*/'5_C:!46%V<NYPJI)IRO;&D,C8%G$N1=8LFNK(F5D"K*E
M=G6!0X&E+&,8$.OF_P#7_KZ\C:&TWJ.N,(>+K^K==0<97K<XV!`1T/1ZO&,8
M2]NV4A'.[K$-&44@WC+:Z82THR<61DFA-+,Y)^U4?&;O'":F:MH2&92<A-,X
MF,:S$NVC6<K*MF#1"2DFD.#P(EK(/TD2.WK>+"0?A'(.5E4F(/78-2)?"5_"
M=IC&,Z>P5Z!MD+)UNT0D39*[-LUXZ9@9Z-93$-+QSD@IN6$G%R*#EB_9.$Q%
M-=J[0605((E.0P9C#75.L&2;%)GKFB-$HRD/=:1J;:GUU`D?KJ259+2%!8E2
MC2E:4I\K&QRKRJ(`G`.E&#([B/4,U0%/MJ91J7KFO,:CKZHUBBU2,%P:-K-.
M@(FL5^/%VX4=.A8PL(T8QK07+I55RN*#9,5G"JBRG>4.8PY3C&,Q*Y4&C;$C
M6L-?Z;5;Q$,95C.,HJWUV'LT:TFXLQSQDPV83;)\T0E8XZBAV$@DB5VS.<YF
MZR8G/WNBLFF=0W%O9VENU9KBTM+K+0D]<FMCH]7FV]MG*U'L8JNS-F2DXIT2
M>E8&+C(V.A9&5!V]BF,>Q:1Z[=NT;IIY]'1["(8,8J*9-(V,C&;:/CHY@V09
ML6#%DB1LS9,F;9-)LT:-6Z2:#9LW230013(DBF1,A2A]F,8QF.5>G5.D1Z\3
M3:Q7JG%N9%]+N(VLPD7`,%Y635\/(R:S.):,VRL@_7_OGKU1(SIVK_>.%5#_
M`)69'C&,9ACS7&OI&3LDU(4:G/I>Y5\:G;I1Y5X)U)6FKB@JV&MV-^NP4=SD
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MHQ&51KS0E-86%H#"?950K>-2+7&DVR*5G+MH8&2,DU*#=ZFNB`$SZJ-KO7^L
M(/Q9UM1Z?KZM@\<2`5^CUF$J<&#]X"0.WH1,`QCV`.W7@4OA+GX/X9?P28*'
M,"9`+F6,8S'K14JM=X9S7;G6H"VP#P[=5W!V:&C9^'<J-%R.6JCB,EVKQBN=
MLX237;G5;G,BL0BJ0E4(4P8]8-2:JMB=A1M.M-?V1&VPM<K=J2GZ96YA.RUV
MGR3Z9J<#8"2,8Y"9A:Q+R<E*UV+D@<L8.2D'K^+0:.W2ZRF6P<%"UB'C*]6X
MB+@("%8MHR'A(6/:141$QK-(J+2/C8U@BW9,&35$I46S1J@DW02*5-),A"@`
M=KC&,^5\Q92C)Y&R3-K(1T@U<,7[!\W1=LGK)VB=NZ:.VK@BB#EJY;J*(.&Z
MZ:B*R*ATE2&(8Q1CZAZ8U!JT98=::LUQKT9X6`S8T>BU6HC,#%E=EC1E?%V(
MC?C$8\KYZ5C\,\/\$*\=`W\&#A;OR7C&,8QC&,8QC&,8QC&,8QC&,8QC&,9C
M%UDK-#TVV2]+KK2WW"+K4[(U2IOYPM886>R,HMTY@J^]LAV$J2OLYF42:QSJ
M;-%R01*#E1^,>]^#_!5=1M%[2C?UCO7.FK3W'73$)!]G[8%ZWN:W%Y&VHD8^
M%SQ=?<A8FV0I)/0C%1K46L\>OZ^M*KT#RL-#2<EL=LQD4(-6INYHK?:O<.F%
M-TR[W3NG6VL=D[/U#QMVG,4Z'F+9L&J5EMR<CHTFN'S+9\718ZO36N;):WJE
M2JFU)!M6ZS/R7Q>@X"'D95G&&SQUVGG!)C1:WLA]R'J[&I6F9VG!LW;Z"O3.
M4AU]&6=C3=U25WK#FJ)6K7%8U%996'BMG7+8,)6*C1%9N"6L\Y&-9R)7>2QM
MODO!:[W9QYXYPT6:S[;Y&*["F:W%_"S,8FM:RU##Q$OLW9=FD$FKY9.)AG%G
MIM5@8QJV%W9KE=(".(YC(=*=GH?7YPF[;GBKR>XYNMQ[7GH#CI?JCK/:VZ]J
MZIEI*XV\M%TQJS?MRT#(;3;7,NNZVPMM3&PU5J[L2]=CGCBB*S["-M*3,11>
MNK<4[M'^'.T;#&4;56\*U=+U95WC"KPS*"V"9F]<EF:_5HF:D)1&G*M8NAS]
MLMM9K]=V`Y4)4;7(R@,ZC,3KU!=LG*G%;DU4.5.M96[UI@]KT_2-E[-TAMBB
MRJR#F6UWN73%QDJ)LBF/7C4"MI-LPG8LTA79Q!)LE9*E*U^Q)LF`2OP%M93&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG!@[Q1*
M/S&`0'Z>@^8>GU]/F_\`ZYJMKO9LR\5(=J2\E-XLI)#M,TI09-NQU:K%+:<=
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MQ6!W7@6F:]&04QJSHW]GB:T;5EFUBTY:.GR-C[/CE9P`&8<:.02495WE;RSG
M^6%EV25@CML2+S=6F[$ZIT'70=MX]Y%(-Y61DQ>BJW/=K:G9@(7':/"+;[#9
M#.N3G!>HZ9@JC8J!KY]6]T3\-JE5XM?]>,+O';)C:Z]U/R$@VT#3;AJC8E2N
M\/6FC-_,4>>K]@GY64/8;L_.,5FXUZYW-(WU5FELCDWRMY$<NM@0$6^"4BJ5
M,;TNQI2`H+&4(DBC*+4?7\13:U.2K1,(^6L\?.R4<=>/=-7*U\L8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8R%]G;MA=6R49&2E4OL^I*,57R3FJUP\NQ
M0(DX%N*#EV+ENF1V)@\)\'+WSE1,FJ?NE5)UP8^_7UKJ-EM5%KLG`'UZM&SM
MC8[3B#U2-LE9\&_-,1,+8SR(L8:<*V0%TPD9`CJ/1>(LV4DV28R:DBQB'67-
M%S8H*/LUIIEB>,Y>'C_@3&A5E>;^!RC5=\C/'GY`\T=&'D5%BM4V]-[KN1A6
M*2$C+2JJ\VC'1UL=:;2C-GQ4G+1E>MT`C%O08J(VR$/"KN5!;$=>%9=5G";E
M`I5"IJ'(?O)+`)%"@(E$=?&N-A<@.8.PN>`TC=TUQ]B^,F]++Q1TO7:Y5=?V
M)I(7BHZ;UQ?IO;^Y&UWJ=HE+0QFK9M%I'UFC5N4I<<VUW7DI4[IU9[.G,PWO
M3[1Z8@-XR&E;AQYNQ8>J\HM8<,K'N6-N6NE*T[W9M#5&N]K5I_%TH9Q2Y%I$
ME`7Q)VM)+I!)1(M?@;N+.]5,W;_-K_M-:9NNY:NU'7*K.ZYN>[:OMAS67-MM
M=&AI\CG5>T]YZ7V#)ZMC)UI(UO<S_4<]I56Y['K=<>2-HJ%)V!J^T2E#F8&;
ML1JY!_$+M2K58>->GPWMK:YR.^IKC_P`ML5,IJ5YXVWW8.9U4O[6!N"<)JN#
ML#O7Q37'2>VI.SUIA2Y5Y#U:/AY6"@7CB7+6HSV[?[2S9MRIVKT]/:@VUI:X
M1^\^SPA>1K+:4?2X&U:?C.4W*ZL:P?:JG*99XV<6LKFSZ^9V*0E+!6%X.6KM
M8O&M;777#B1E9J,K-I>4V^MFZ?Y8\<H6N3T_(:XG>.?-S:MXU-#L-?IJ;"L/
M'N&TM-4>/8VBTPH2U==O0O\`8F"_@+;`P;M?XF6E56S9B[4=03KKM<2WP]*=
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M\JO*YAKB?G%JM!V2[0-DL:5ZLVOY:!-4[HA=%*Y`;!M;:F-W,+*Y#4^U+M.Q
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MCWQSME(8US8&N]E\D-<<E[S>J-=R4FIVJZ1DC&0NE%9.ZLY)KL:0JLY`3$9!
MI'CEB(HR5#=IVBZO.C:=9^+V\]?OMV5E5=I4+CXJL=U5R^H<>-H\C5*5):8:
MR3R=504A-06_74=/J2\<M8-JEC8.N5V7K+I>X-,;C^UAKMHU#4-DZNT5?-ZV
M"ZP&Q[U7=<Z&F&VU;+.TG3[+4Q=FLX].NU]1["[6JENV[%:NDM3[+AM<2D5L
MZOV*N6F;K+/XAF9V6^36\-EN>47";BGKRRR6JH;D?5N1>X=A[&:QL(%\94KC
MM`:O40UG3&URAY^#@[5>+/N*NN[++R%<F)2"HU1MS*$;1L[)M+-`5G)VD-OX
MS3G+/7>]:U;MVU;B?R=U!I=YOF`)2X.52I7)?2=)VEIB6V]$LVM:K24[&[&N
M\5HBT6*GPT/#M36?6FP;-!0-<D+O9(*VTUSJ;U#8]SU%>]/6RH[#K57XZW."
MA'EHILFE?ZWNZ:L4#=)2H/81X_!ZVX[OJ5=5MQG603^`QD&SEH()1A9:ZN_P
MJO=HD[L-4US;R\>KQ$0?)!YQ_1XBS\Q;*F%8W:CR-A+[<*JVG96)"6D-6S]+
MU[KR6V/M"$D(*U)P%3EJPWK,I=;C+JU)C47DIVK%OL_';:*W&6A7RC;MU,%/
M)N\]H"@@]X_SY>9?R6IJIN&%@:V2M;(<SU@U_MY9L]@@;M%]90B=W@I1"R3E
M4@G%@]F=JW4=90-JO#O2>P[%KM6"YIN=.VJ`F*P)MJ6[@:2[N-V4=['R:L>C
MKA_+Q^LMESFK)2R2KV/N<!KZQ.),M5F'-;@K!\X=JH@M%W>&9<:-KRFZZS=7
M]?KVDX!\QM]CO=?0XST3E9&SD'*4>(M+5I*S.O=BUFLMZ](L4VK#93Y&#F;-
M'54REX1VDTJS!=:=4[B$!9:J%KK4#90K%SB1@;A7`G8II*_$-J@S+N30UDA_
MA?Q=.Q1G"YHZ5;.V8K*BCX0V3YC%VM+6C4VV71['34PSJ-:G+,ZB*W&JS-AE
M&\%&.I1:.@HE`2JR<P]3:F;QK!,Q#NWBB*`')W^\%&]!=HQKSD)?T=>U[2')
M^HR*]>G;&6:O^H5X.M)MH!F1ZNS<2K27DO@\@_(<K:)050`D@^,FR24^$+($
M4J7K?M5K/MG8`Z"K>L+;5=C7?<D?2Z!L396MI6KU2I4JR,9"V-U=F4D+.YEF
M^R8:NQK^)@*NTL#2+V$H2/N!I&K1IY2':V4B.TZUI,[;8Z?0T%RT;3#_`&'Y
M.$[`\THY2JR$CXQ*5OXZ=/B3)WB%;*X3%^M)"P$Z,1UD%&Y4R'`N<\_>0M^T
M71]%5O5Z\=!WOD[RMT;Q5@[_`##%I+Q^K6^UI29=6?818&0#XLG[!#T^J6!C
M08:8\)!2&Q):I)SS*5A0?Q$A@.Y=P[CX2+5B3?26Q.8%<WCL;3.B-2TB5=Z=
MI5_JFU[@&S%Y"5L%\;0.OJS*TFW?%]39))N81Q+5*182CA)1Q!NTFK+%)7M5
M*9!019*5T=M@9E*1YS5B0JD$>O6R?;77@>DX6V)76#&MNI)W8RVU)F]-3'=<
M:R;M<62X/HA$3-@<UVV5VI-JI&RM>;QK;)/;7%V;X4[JWA:J=J/8&F;M4S1F
MJ^6VE-3'W[0=KH-&,E=&;[7=\L$S"4/XTBW4P@DWA)NK42\,I)-.TMI[3:M5
M.4VZ]>:%W=(:MUTWV?!0&WXBL/%:1<]O:OWU7^,Y],IS$I'0]>B;EL3;UC1A
MM6N6UEL,)-QL%;)*UOJ.O!ECGL=Z\YL;NI_&3M8>0>W:TK/V+A7M[E"[I>KR
M/JV[0:4[2_&75FWH2A1]KJ<!7C3T'+34U-/(NSS<.G<"0<^W1L**<I'':-^G
ME]Z\E>-<5V>NQ+9M5WR2><QMC4_1VUM<K1FO*O5F%_VQH?8FYJM<]!/ZW58J
M7K5;JEJH`T]:"NUDOK)[JJ9&RS,LO;X%S:)65Z1VFL'=-$0W(TNB-D5[6IN0
M&N./-_7L-BH#&<U#:+)<XK4VTYG8T*6:47B*]Q[W3+%UKM%X@HY,JI&2][J`
M6'6J#&VR6,P7*+97*CF6;CE2+)9=`ZJH?'5?D-+VVO>(LAL3<A+3R-VSH'5Z
ME5>VVM7*&KVJU([2EIV/*K)UU.WSWCCK-D>2@X0LPQM&06_F[,\5(RZ4W;Z-
M@Y!/>-4!K^^\I=QU&'@:@XI.J]];>V#5-/6M#7#!FF2Y35;I=2=V?<4;3PA&
M$#7JW*3M83L$M(L*:$!;1[8"VU?5.^K?7N*-GC+1KG4?,2^Z_:7K9>OSP5NG
M>$?*6`XL;NB)DU-D)Q[#LH>P7*J7*MN45W*=VAE)R$:.85]&-I*2EF=[0RRT
M#;NP=8GTGMV][`DN76L>,$%27UXT?&5"FVW8'#!MR,KB\#98]G&3`:ZG2U^3
M3EW]H4NMUC;7+3L@@TCZBWKM62^C=?/VPV3@WQ5Y`Z#BEZ+9N;FU^(6F:9+7
MJ.BY\VD3\I-D5RESUML$0@\/7[+.Z[BGMA1K;`[QQ6;!>DZRF^3DH%XYCWE;
M>;W*WDCPZ?<F=.U#<UBN[IIV=6T>9VH-GW&!U=-[*UK>]&;<UKK"VU*6AX?7
M<'3+A4-@M=IUJ>J;:=J*\U'3\#?XAO+O(AU`,*OL,X;7CD=:[CRNAMO-+K+:
MBH^[8FO\9=G[2UTQU-LO9%$<ZOIDS>E)VE,*Y2$74#3-JO[54*5>342GJ7*#
MC_"FC98D4G;;%>S&,8QC&,8QC&,8QC&,8QC&<=.OT^L0_D.='/5F"LR4<A/1
MR,HWBIB/GV39T98S8DM$J&7C'BS8JI$'AF#DQ7K1%ZFX;H/T&C\B(/&;1='I
M:GK>DT55PO4H!K!*/(R'B'GP%9X5-XS@"NDX@7B2CE1)V]9H/%FI)1P16449
M`W8KO%6;-F@AF_3_`-#Y_P">5:G>'VGIC:]PW$Q\>JA:=G,85AM]C1-BV^H5
M+<"=;BF\!`/=C5*&DT(2;L$96VK6J%MC1O%VM_4&C"I3$W)5R,C8QIC-OX%\
M=+FVV$G(0MSC7^R=XZVY'S,[7-FWVNS\-N;4D'4JG0[G1Y6*G4%Z&M#4NBU:
ME'AZF$57Y&JQ?Q1(Q3E)](G=X?2^S5XMZ]=U`]3B-DL8BBSCJW5FK2.Y]GVB
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ME>1/./6#F=B/B1@I7Y&)6(JHM#$9V<G%2%BF\+$5&W1T<SAN*$`S1;;5V44[
M6,X/3B=EXN(HN#6<[@JNK9]).52="J9S;G9`/?5;27J0?@5[-#B*O69JGK4B
MV*UVQZCWSHJ<8&VQL\#26K>3>RUMP;RK2[TMJ*_*I>]B.%;`XG4725BA2"6&
MK4M#0"9(LOOD>S9XFS<EOEU8*;;;#!\E*Y8X+;.OYW:^T)+5TK)W6&BX&\[`
M@-;+VP:=2-K79A!0BMGV?3(F"NDC,1WC&26;6*1F963ZIMV8W%)1I*-[/%[5
MV$M8+C([!M4CL7?6X[A(6RYS7&M[Q#GK#9'$G<A+)OY[CS*RVNIHQDDDY)G(
M'F'*9K`TBY6/[#6W9L<6=72D#8(&&V9*62N7[4>THJR6S>FXK1.)7[2FGY+0
M5)L*SZ3NBAG(FTY*O=>6F(7(I7[K6%"1MIB)1%),H2=QUX::)XM,++#:DAK4
MU@)]VE\6UNX[&OVR:[K^N-GS^48:_P!40M_L-B8:OUK%RLM*2$50J4C$5R.5
M=D;MF9&$;#,XS![5V>G&RU4=6D'C=DUSP>_KERA@[K1MU;7HNT:=O'8J]B5V
M!=:1L^JVR+NM3+=&]PM\58JU#2[>I/H.T3D)\0IQKP&Z7S7_`+.7BQL5*UFE
MZO=8F8L['0K1O;*?MO:%/N=(=\84;&WT5/:QME?M;*>US9J$A<;:W)8:H^CI
M2SL[/.L+JO96,FZ;'QDW9=\2!M1+>G![2;2)+#"7,[5GOS=36(=WN(T79.-K
MO8$E%HW@K>4O=ITS9WU/NEMDOA<W;`1;3,P[7G3/I)_]$GV9/%R::UI63:[;
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MCH6!BX^%B(]`3B@PBXMHBQCV2'A#J*>!:M$$4$^^<Y^XF`G.8PB8>TQ_Z^C^
M6>/=`/I_B8PAZA$0R'W>@-/OZC:*,^HL2]K=TM;V]VAJ[5D7+Z9NKV8;SPVU
MW.K/3S_C(QE&<>XA)M&42D:ZG%Q+2`<1C*)C6S68.Z'_`.M_W&Z>KKT'Z^OS
M_GR*MUZ1UIR%U[*:PVQ7AL53E'T#,D3;2DO7YN$LE3G&%GJ%NJEHKK^*LM1N
M-0LT5%V.JVNMRL9/5^;CF<C&/V[A$##%#WAQJ.?8T5&ZO]E[`E]=['H&V*W;
M+EM&Y2EJ)=M6?'GD_>R$JWD6!9**K9K-8'"59<M35J4D)B1EI^*EY9TJ^&*)
M_LQN*-BNMFO[J(VM&V*QVW<M[;GK6_MTU..J-MY!P<=#;EFJ)$5N[QD;47-^
M<1B%EF4XELDW+<3K6IBBTF#@X)]<SV:/$RRPMCA;-4+7.$NFO-M:RNSY;9=\
MC)&VUO?&T87=&Y%YA>OSD,D%DV'LJNP=EGK5&-HV?*>.3C(Q_'PR[R/<^<OV
M:?$RPGY!H3]1N<S7^3"5E7V/1Y#;NU%M>Q]EN\W&6J\[`UG1"VU.KZAV3<KE
M!P=XL%]UI&5FRN+O%(VUH_93CJ4>2$SZ0XJZBT)!;.@:DUMMB0W1;%KSM9WL
M^^V[:;V\VM[1JOKJ5EYHUYE9EH4\Y5:?!,9YFP9LHZ94;J.G[-==PH8<"IW`
M_0E)-7$XPFR7D?KNG6>@Z8B9K;>PI=CH2KV^!>5.7;Z2%W/"^U[,-Z>^<4JM
M6^,?*W2ETA0]+IMB@*LJXB%XRV5P)KL?0=LZ^XVQE'HT/RH/4:!RC8;,>;.V
M!59K3\9J!72,Y-Z\H(7-O48/>*M!BZ=")6]]'EBK:2OM7VS&UKD8^,<(3E;.
M'6F+)*:FLL4UMNN;KI*D'UAKR]:KNMAH-LC]6KIP9'>L9J1A796]QH#I:LUZ
M3\5;@QG(MA/PS"R0R,7/(_&!NAM'`_C?;;A'W64JLZ$D-5J]'N3%O=[<2"VW
M4J/>I39U-A-RPRTNX:;/1K>P)ZQVAD\M0/91VZM%IC9E_*5^RS<.^QR1[.'B
M=-1,W!3E)M$W$V.I<GJ3.,I3:FSW2<C7^9&QXK;_`",054\:R.$GVP-GP4+=
MTY=LLA+5";C&AZ.\K;1,S0^2GX)<=E;Z39RT'='5X)MR@;V^/G^U-D23A;:V
MK]1.]#TBVNTY*RO$7[B)U._>5-W'OTW,18"KGF[*PF+(!)DN4QG#WC[$\9HG
MB"A2%G.@X"N157@ZC)VBV2<E#1M>FV]EJSJ+NKV;5N["P5"Q,HV?J%J:V%*S
M5>;B(>7A99G(1;%RCA$WP'X]W.G;>J&R&5]V<IO:DP^LMGW*];.NTIL6<UE`
M.W,A$ZZB[TSEHR>IE,;23^3EUH2CN*VC(STO,6*6,_GY5])KW&CF1(Y@R8)K
M.G)&35NT*Y?N57K]R#9$B(.'SU<3+O'BP$!1RZ7,99PL8ZJIC'.81^S&,8QC
M&,8QC&,8QC&,8QC&5BWKRLH_'^<@X"U4S;ME=3\2XF&KK7FN9:X1C=NV>_`3
MMW\BS50;-GYE?[PK+O*+E;"1=0J::R(J5:V'VH.OH"EV&6JNI-Y+6-JP,$(6
M\ZSEZ=4"R3A1-LT6L-C<.5RQ\8@LL158$DC.GHD(P:"FX=)JIX3H;M1(N:H;
M<NW-:;.E+Q%/%8V5F=1ZYD[54Y<I4TW#9]W&STQZY*&16(1_`.'#P$C%2?-'
M9VKTB#:V.I>;.N-QWR(U]7Z!O6"E9E"4<-Y2YZGFJY7&Q(J/6D5PD)I===NQ
M%9)`R+0S@A4EWAT&H*%572*>HFU>;6Q>.7(CFM(VMO>=Q:EU!"=G>RI.J:NW
MU3`/:M-\O-I;$U+8YY.PS+*M3,XP8SL+37R<;-6B6<-$'4PE'-Q2<)J1?Q1O
M:BWR7O=9AVW&.93@(S67:%6';D6CL6D/KI`;$X$[EUUIRRU"H+O7U>IT]`S\
MC>V,ZVM<K-02'Q/+,%G3.)-`6)/,HJ?:DI;"">JNM./%UV=N;7\CO!?8VKJ'
M=Z?(F&EZ&VI4M66&V:JMLVG78G9ZUTD+E'RVLX!VUHBTZPBIY.RR5,7+7/&:
MQW%GD-?>3*?+&-LM23U2EICE!MWCM3)RNS\78968A=>MX-LWNJI)6*?1<=/N
M7$H,I\6OXF0B&H.VD<HA*DCWCJ0H]QJY#<HK!OK9'$_9^\V=PVCPR4VEL^T6
M.(K^L:P/.[4UFD9)GI-C6FY-?I5O71-02IAUCRA>T,J,A3MPPE?ABOQA[RY3
MC\LTMVJ<Q::=P8E]L:%>5.4Y@53CF]<.ZY?JG*L("S<G*SL6>H`UFMKN1LUB
MID4ZUZ$-?+%+GK*]4D;C4FD8PN3@+.2N1U&=MG'O=?O-E.^(^VHRMQNBF/)F
M6%QL/4SA]%:7@]ZS^@]KR;ILSFEB+V^DV2$^/*Y4XQ>1;[!KJJZK6Q5R3:IQ
MKV?(CM-I"=V:WH,3Q7VN]CK1NWE5Q@UG:DK?K1-G=N17%A6YR4O0W35U.-D:
M?`[!IFN[S9*1>;#*$C@=565KU@CHAXI%.Y/#[5VMT/5-%*<BW7'NY.]4)V/:
M@Q=P:[(UH:#V3K33D]2*S9]EZ86!\:3V&PM4I;9E_JA@O#5AA?Z=KJYWL;+`
M51S1I*Z3WRFW5LI'E-P[XA:\LZVLF?(F"Y(;0V#M2-:P#VWQE%XV1.M`6H>N
MD;7#V&LM+9?;1MNM*R=@E("<6@*!6[>,+'M;#(Q=BK^![LY8W7@)%*>6MU9.
M1%2EKDO98B^^%UM1+55=1/+AHK6!*FO"QC.&;;5VA7+3L^7N)TX.OU.*D=7P
MLC*SMDC+6A$0EFP>P]K7&527LZLUQ>W<K0XS8O,K2%8N596K=T?W#>'#-A?K
M/:J0RHU65D[0SC;_`$76%\LM"L@(2"R[BJR\#,5Z/>A&KR?:3/:U:N@Z!<-@
MDHSB\U^J\8)KEFQLFHMF:YV51KUJRO;RD]*OWM"ND<_8,9=Q(&8)72`2E&4(
MNM"/"PMC:U6Y,96`8]&OSRO^G]C<S:;.UZ_\D+56^6=OI''G55+K4>C:/)_1
M.#?&?DI<J;&+TNDNUI-RVL6SY:+IS^U,7CR3G[;7X>TW&&@&SNQQ%I>/'-^L
M\A]U;*TS%46PT2PZP@XR:M-8V-)Q-5V]6$9R#H$Y675RTK(@A;X.LW9"YR[>
MD7J(<6JF3<AKR[P[V:AI^/;0SJ\>,8QC&,8S#MB7:-UK0+OL28CK#+Q-#J-D
MN4G$U*#?6>U2<?6(=Y-/(^MUR,(I(ST\\;LE&\1#,2&=R3]1!F@'A%2B&E(G
M]H)XJJ@D).-7:)_WO@1`/D;783=%!(/=`"2YA$_=-W0`@'ZGZ`4#>;K^:6U_
MVDKM*D;[9PKUAU"SJ*5XL!8"&G-#-T9UI54K0^+"Q$TF>UE>HS;>!(T82Z9U
M"NTI0CH@G(N3O!^EE#^T$\6#IHBKQK[0[PITTA.*?#B["EX0Q"B<4S#,#U2$
MXB)#=1ZD[H]XWSC93D%SRF7/#WC_`+LT#7;/1[#R]WOQNX]:Z?[QU])5B;U&
MKR(W%&ZP>;`O&MYIPU='DZA#GFIBK5R1=#$V>S*5%L\5>5^76!SE^Y]D;=X/
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M$&6V'L&W6^'K&LX(W./45RFWL5I9*M1R-#:UZ@DTS*+#K7E`O03-I&I[B@J]
M!$DBP][<EC?HTOVL<Y9]9\,+GMCC^ZJ[_E9Y$VKT:OL.I2C.MR?(G9=JUAKA
M.KPCU<ECN$9!6""APV?*2)*BA4HZWU9[%#:I*1DJ_!X?&]ME'O=?O-E.^)&V
M8RMQFBV7)F6%?8>IG#Z*TQ!;UG]![8DG3=G-+$7M])LD)\>5RIQB\@WV#755
MU6MBKDFU3C7L^1':;2$[LUO08GBOM=['6C=O*KC!K.U)6_6B;.[<BN+"MSDI
M>ANFKJ<;(T^!V#3-=WFR4B\V&4)'`ZJLK7K!'1#Q2*=R>'VKM;H>J:*4Y%NN
M/=R=ZH3L>U!B[@UV1K0T'LG6FG)ZD5FS[+TPL#XTGL-A:I2VS+_5#!>&K#"_
MT[75SO8V6`JCFC25TDSM-^0&^^,U+TSNC2#\\A#:[V;,7KD#JTM<@IYSMSC;
M0=?6NY;EK]9<O8YS8(+8-8I\'(["HSVL/F[B6DZHM5'\9-(V%%!M5G=//W9@
M[]WM:M=WF<D^'VN>S8Y0[XHWD<9ZC>7#:.Q=%V76+&X;>I%\V97;!6U(6I1N
MS7E;H,2Z!Y2IF\:^LDE96%LC3,X(]JU^T06"-V59J7H+9>T]7:8B]I0.PMEP
MECH;!:#VEI_0$5OF?K<_7IA>O'95N59R2.NF&P&9S-EMIG+')TY*DO(VY.,`
M8=JY'%H3_9=GX[;`JU5U]0-&;GWT)[?2[#,:FTAR7LLG#Z>V,E&5Q20)=P+7
MH&P[$V;6HE[&RVO:3`OUFY[98U&%<>?4T[56$L"L?&4?2%AN%HG^4`<2HZH-
M=C4.&ME-VZM![TGTJYO&ISYX^VZ<E&D1I0EBDF4E7K`@XIVP:9;:?)7.+</0
M0K75NU@N[_>K>\.M:[1\@\]IWC;"WW4$\.JXJR<;MX6KM`MX\$-LOW<JT23G
M-A%BMG5.NQ*T4PGI6*E*S792Y5<8=5\UA)JR6P.U5;4UCL6T0?%G>U]UK4YE
MC7:MM*$:,8&@V^Q%Y8USB#-5E2T7=I68&*LQ;Y96ULJT5$RUO3L^O8Z>E'3V
MMSL))5UOVU@[3>1K#JWI/N(_(>P-M85S833;[W7$`YV2RUAMW6FEX'=5@US/
M2]6A'5;E8MY'3S>G0%QJL_.OI*[IDCUJ,RB9"+F7EY^.>[H3D5J*L;@K"M7?
M5FW*SBE<G:/?JYL^DVF$BYZ2AHZV4^\U821L[6[(A'A*Q9W#.(G6"#@(JSP,
M!8V,K#,9PQC&,8QC&,8QC&,8QC.!`!^?K_`Q@_D(9U4W!0]DB).`GXUG,PDR
MQ<QDM$R:!'L?(Q[U$R#MF\:.`.BX;N$3F3524(8IBC\W7H(8WKK6E&U-48NB
MZ[KC"JU6&(J5C$QOA_!E475,LY<N7+A99X_?.EC&5=R#]PY>NE![RZZ@@7IG
M(%`/_O?Q,8?YB.5#V#P:X];1LFV;7=(*WR4MN]SH]SLGX/LS8$4QFQXW6L;S
MI-%G&Q5A9L:XUHUM.O/(-JTA$I3CUV[\:"SB#E9$^`7GLRN'^Q8"SUVU4.U.
MFEND.1TK,N&.V]K0S]9_ROMM2V%N]1)S#W!B";2R[$H5+O\`$1(I'AJ5<*O"
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M?B:-D.-"UD3TA(+1KR].TI-SK^`M<S2X4LH=XT)1U&-64:GC8B**S[P>R]X;
M>)<IK[R?V<M2F=(V'CG)Q@;6V>!W6GK7M)_N:>J@R`6L)-)9]L64?S?C&@]2
MM3=HX-7&DVWK)$X<D::H[,JC#%;^8\A7,C?$]N[XY>[(@(JL;-V;#PE+JG*Z
M?L!;*2M)LG-7D*5L-WKNQ2FNK%;ZB[;.UXB9MQX!]#^/%J3D\XO_`&5_$79K
M!.-MT+M1VV#6=PTNY^`;YW!!G?:AN;&E-7NL70PMO8D&BQ+O7-)FJU6D"-XR
MOS4"D^8(%*_ET)"S.X.,^KMVQVNTK<C:&5FU!/$M&J]E52ZV>J[4H-A-`O*M
M)24#L*)DDK&<MFK$E(UZZ14P[EH*\PT@Z86^*FD5"@2`]P]FEQ:WPJU>[-BM
MES4R:@3NM;%86.Z=I5R?O-7GKE4=B'0O<E7;/%K6AS#7FC5FR5A=]W25I>,2
MBX9%I7C##A%^F^S4J48RWCY;Y>:M+_8_(3E7MRCC3MH;*B6NM8SDG;9647EZ
M8J1:`D:-MJ.J4DI4WU^JKDDD0'5CDZ_(1+FXV?XRS:\]ECQ!V1#'A+A5[Z^0
MEJEMZEWIU$;<V-3I#:,-O/8B&W-C>4MW2;!71MC^4V>@:\QS]R1!>OSSI^I"
M?`6C]VS5RZ_]G3QHV(YL,O*,=J0=NL6Y6>^UMAT??&Y:)LB)V:AJ:&T+)2]:
MOM5NL7:*Y&VK2M?AM9W6LQ$DVKEQKD>V5L,8_G$B3)9/UKQ(TWJG9K[;%586
M4]F/$VZ`KK>?N-ALL#K^!V!*4V:O<#KF%FWCQM2X"V2^O*5)RD#$&3ATG\`F
M\C&4>YDIQ64LUC&,8QC&,?\`KZ/Y9X"F4>G7OCT$I@ZJ*"'4H@8/,)N@]!`!
MZ#YA^80$,U"SW8.=E79;).6V9XNHNIZQV*7M4N]+MO=[8KJ=G9AU/2;TK1KL
M9%FW!Q*O'#H&S9!)JCX3P*"*:!2)EV[IMTD4TTDP.5-(A$R%\*J/0B9"D('4
M3B(]"E`!$1$1'SB(B(B,:[DTSK;?^M[)J7;590MM$M2<<$K$+/9.,<IO8668
M6&O3D-.0SV.GJY9JQ8XJ*LE5M%?DXVP5FQ149.0<DQDV#5RG#4KPPU%:*4UI
M-^E-J;$0:6K5UR3L5SVU>9.Y'F=+76,V/K#PEH:RL=(&CZO?82'MYHPG@V=C
MGHYN_MZ=A5\)X2-+9V9G%&YWZV;'EH+9C2Q6V[;#V0LG6MZ[CI\)`WW;6IG&
ME=G6RI0%5N<1%5B8O5'<G2L*\4V23<SQ2VA%)O.BJ]4^F0[-;BI.0MBAK)6+
MG/\`CKK_`)`ZTO<F\VA?6,M=ZQRG?TN0W^:S/("<ABOY[92NN:$E+VA)!K86
M3>JQB4)(Q8G?G>^Z1[-GB;-R6^75@IMML,'R4KEC@MLZ_G=K[0DM72LG=8:+
M@;SL"`ULO;!IU(VM=F$%"*V?9],B8*Z2,Q'>,9)9M8I&9E9.4M-<2=7:+AML
M1M*F-M.I7=\C#SFS;G<=S;)NUZL-D@M;UC5$?:DK39;$_D(*T!2:;6HYU/5W
MXJDGSF'82CQ=:1:MG"/3,^#W'>/LO&BY,*W:6=KXC1%R@='V)MLS8J4Q$0^Q
MDHI#8C"Y/RV8'.V$;X$'%.[<.U5+DI.S;)*T/3J6D!FQA-MV3W#*+?UIY7ZI
MLVLMZD73WQ%$5_?V[X^%:+\?=HV+;FD7"D;X^+).CZMM5OM3>E(.158P=:FU
MZRT9EB640C&]Z/9>\-O$R4U\&OK.6I3.D;#QSDXL-K;0`[G3MKVE(;GGJH,A
MXU_&B:S[8LH_F_&-%ZE:F[1P:N-)QO62)PY(TU1V95&&*W\QY"N9&^)[=WQR
M]V1`158V;LV'A*75.5T_8"V4E:39.:O(4K8;O7=BE-=6*WU%VV=KQ$S;CP#Z
M'\>+4G)YQ?\`LK^(NS6"<;;H7:CML&L[AI=S\`WSN"#.^U#<V-*:O=8NAA;>
MQ(-%B7>N:3-5JM($;QE?FH%)\P0*5_+H2%QK1INE7&3UG*V`D^_<ZG>RC^K$
M4M5A%JZ<353D:/+A;FAI`[>](2-8F):.=MK@29055D'$F8@RP(OTJSCV;7$)
M&O15.A];R57ID'QAM_#6(IM1OU]K%6C^.&P'#-W=M=MH2(L39F0UF>1\>[D[
M>)#7HSABV.WLR'@^@^MKV;_%IA<-C7&/@-A,%=M4]6J;"K#'=.VFNOK)(.]3
M(Z'D]E.=>HW`M.0W/,::;-]<RVX64.VV`^@$2JJ3@3)E)8_>/.S^XS/):E2H
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M[.:RI873Q>U4I==T5J`V;?6=`8P$?<;5%IKS35PP=R4>^[^W\`..URV3M7:3
MQMM&%L6Z8=-ML*.IN\-NTJERMN0J\71F>WV%!K%PC*;7=XQ])A(BIL-P5Z%C
M+RTA(QB@C*E<M4':=@]/:<I.CZDXI]&:/$F<E:;A>K!)2KY23G+/>-@6*0MM
MVML_)*E3%].66QRCZ5DG":+=`RZXD;MFZ!$TBRIC&,8QC&,8QC&,8QC&8);-
M@Q-/=M&<A&6-\H\;G<IJ0T*YDD"$(KX(2++)"4A%A-^4"743=SH<0`IBB."2
M^_JM%QC^04A;>@#5JNL120K[ABS\,1(YD4UW2RH$1(HH!2";\HW01[A#FZ%'
MH:)R,@[#5HF2?Q%D<2AVQ22GQ)!*OF23PACD.4IT%S^!,<"`<4%`*=,1,4O?
M(!3FDJN[1A+-+-X9E$6QHX<D7.1>3KSIDR(#=$ZQO#.CF,1(3%()4Q.`%.J)
M$P'O'*`ZQ]J\VMB\<N1'->0M;>\[BU+J"%[.]E2M4U9OJF`>5:;Y>;2V)J2Q
MSR=AF65:F9Q@RG86FODXV9M$LNT0=3"4<W%)RDI%_%&]J+?)>]UF';<8YE.`
MC-9=H58=N1:.Q:0^ND!L3@3N776G++4*@N]?5ZG3T#/R-[8SK:URLU!(?$\L
MP6=,XDT!8D\RBI]J2EL()ZJZTX\779VYM?R.\%]C:NH=WI\B8:7H;:E2U98;
M9JJVS:==B=GK720N4?+:S@';6B+3K"*GD[+)4Q<M<\9I`HW.:ZRNE>T-W1<-
M0MXUAPLV?R?J-5KL#9TY:2V=7N.E'):2.5UBM/\`W-/6M5$Q/@A6JS:/"69L
MD!?J1CE\^K.UY)<D]+ZD[.+D;<]L*;P?\TMG<?-7;?U*6(H%=UY#2G*^@3%J
MJDUH%_`U9&WPK#4UQ3@8HJ-OM=\1M.I"6F?LZSBW-&5C:SC6.T[C;%H2V\AU
M^/.T("EZPW-2]&[ECIFQ:]2L^H[BM>V6MMX.+G#MIMR=*`XUVF6BE=ES4<J^
M83%3&3O.O5[75(Y.4?\`1ARNV#R5YJ0/%/7MAL.B]<5S2>W=]6K8E>-19J][
M;9T[D:ZXV4.+U\^L<'<*]7-=2,Q6[M=[1.A`/;5*L%-<,H9_"PD\^>S>1;!Y
MJ6/B%$[$J.VVEFY&R?'+71N1O(C9E2C*W5)FG<9]A;AV-7-9V1.BQD:SC[[>
MJG2*+;I?8$#4$*PT<5W6,_8X?PMELE8H\M#MT[7:1AH+?ZT5QEML=-:OUGVB
M%EH"]MO]'-!7Z\=G;9HVO['K3\*HYG)&NP=F8V*`LU7L)P>&=LR3D(\81LHR
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MOHZ\K)K`,E/0:;FV-:DVMLOL"QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC..G7Z?6(?R',<M-0KMTC`A[-'%E8SX0FY%FJX=HHJ+)%.5,R
MI6RZ(K%("AA*FJ)TP/T.!>^4I@^"H:]I]#(]2J4,G"HR!DCO$&[EZH@LHAX0
M$U11<.5DB*@"ARBJ0I5#D$"',8I2@&9=`^OUC]N5#V#P:X\;1LFV+7=(.WR4
MMN]SH]SLGX/LO8$4PFQXW6L;SI-%G&Q=B9L:XUHUM.O/(-JTA$)3CUV[\:"S
M:+E9$\?WKLS.'VQ8&SURU42UNF=ND.1DI-.6.VMJPT@J_P"6-OJ.P-X*).8>
MXL2IM;)L2ATO8$/$BD>&I=PJ\+-4V.@EV*90Q?\`]E+P\)9&UR2AMOM[D6X;
M&N4Y;F7(K>L=8[LEMY&HAMRAWV5CK^T<W#5.SY2BU>RW36,V9U3)2RQA98D2
MV57<$5N/KS1>L-6R&V)"D5]S%GW;?Y7:&QF+NP6.<A)>\3T1%P4_,Q\!/2TG
M"5LL^RA6"LY&UIA$Q4M(%<2;]BO(.W+A6#J5P0X_45>EA"-+^K`ZP8V)CI*E
MRNSKQ*4S0A;-"2M;>O-,03J9.E1Y>)K,U+U2D33-5:7UK4).0J&N'M4K#UU$
M+4(Y^T77/`G0%OMN@J#%)/N5EIT'Q,W)%7JP[!N]4GM>R%)F-.-[0G3Y>YC6
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MB;,VJ]T6G(2YZ#V`PDI7;.SYUV-NXP522I&D9=\XG+9(K2QJA69>2CW;254>
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&&,8QG__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g685216.jpg
<DESCRIPTION>G685216.JPG
<TEXT>
begin 644 g685216.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`_1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]-14%.7U-$7T%17TM?0D%2+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_```L(`24":P$!$0#_Q``?``$``00#`0$!
M````````````!P4&"`D!`@0*`PO_Q`!N$```!@(!``(+#`0'!P\(!PD"`P0%
M!@<``0@1$@D3%!475E>2E]'5%A@A,5%289&5EM;70532U#(W<7*!L;<B-CAS
M=G>V&2,D)2<S-3ET>:&RL[CP)C1$1UAB=9,**$9G>+7!*4)%565FE+3A_]H`
M"`$!```_`/OXQF`_9"[TM*@*WHJ458[L;2MF/-KA-2DOV]1LF1&+Z[O3DI7E
M539`SB5+DZ5D>#F&4+-HWPU"[&HMZ%M&E3+=D."2QNR1._+:O*6M>_>/E_0J
MH2Z`J9^LB*5_(:MC=C-G("QF(#@YI:LLI=(1I9#'HI-C44?K^($T^YQZP3)A
M+=NPG]R`C:HDNPIO'LC7)5D1]D<M%C:V.NVWL6U*\9)O/J<5HV&5%6[9UA58
MR<E+Z@\DF"A":[M#)#ZF>F2O:R7P=9'SM64M=YC*'*3,#>CB(-^3&\(I`S-3
MZW#&8WO+:@=D)AI8B3!HG-(2N2",*%_=%F"3J"MC+%T;`/8@[UK>NC+(5733
MR%2J1+;7K5(L0J#TBU(JG<53J4:I,<-.H3*B#G8!J=00>`9)Q)P`&%'`$68$
M(P[#KS^'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5
MOI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP
M5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\
ML%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D
M_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'AT
MI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX
M=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,
M>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/M
MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC
M[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*
M(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI
M"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;
MZ0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%
M6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+
M!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/
MRP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*
M3\L%6^D*(^V,>'2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'
M2D_+!5OI"B/MC'ATI/RP5;Z0HC[8QX=*3\L%6^D*(^V,>'2D_+!5OI"B/MC+
MA06/7KJD*7M<\ACBA.V:$E8@E#&L2FB(.,3G:+4)EQI)FR3RC2#=`'O99Q9A
M8^@8!!U>>,PPYR<:YCRBK2M8;"95&H@[U_R;XR<AMN,I:W=X;G$KCC<\2N8F
M+Z2,JI"K(,EBZ()8^8Z[4C`S)5RAR"A<3B"D1MC<HZ9YJ67:D$DM*6-Q69:S
M@#:G?6JO+WJ"V+)[LN,A::H:K'=5T$MRLTJXB$)P)@P./')-E-#^H<9FH6*)
M"EB)\5QRO#L7\UMLGE'&P7#'VV,]D,KWCE#N;CJFB;HSR%>^4BQM\$GTPII`
MWO"I`RBORH6])5CLP2AU4DUP!L:IHTNLP4A<HNX;BT*%(VHTK>@3DI$2%.0D
M1I4Y82DZ5(E*`0F3$%`UH)9*<@LLDH`=:T$L`0ZUK6LQZLR.1\5K\?>LQ,PM
MK)I8`U>Q-:'>U(AU-,C1"4;VG_UX0C0A-%LWK;$9K0Q;V+6MY-ON0BGBU'_L
M5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6
MS]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/
MW7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=
M<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ
M[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N
M0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"
M*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(I
MXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGB
MU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4
M?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_
M[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L
M5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6
MS]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/
MW7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=
M<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ
M[D(IXM1_[%;/W7'N0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N
M0BGBU'_L5L_=<>Y"*>+4?^Q6S]UQ[D(IXM1_[%;/W7'N0BGBU'_L5L_=<]Q+
M&RIBPDIVAK(*!L6PE$MZ0HL.QB$,>P@+)"#6Q#$(8NC6NL(6Q;Z=[WO=4QC&
M,9!-E_QK\=/\LI]_9%,\G;&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&/\`Q\O]6<:%H73T=;X/E"(/U=;6NG^C.<8QC&,8QC&,@FR_
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MA[E.%K%W]L:KZ9K*C;EY`7#"A,BN%4]6O)%08.HY,[%KW1"^2,ISBI"JTI,F
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M1_.Z0_\`6Z.G'7!\X/G:]>.N#YP?.UZ\=<'S@^=KUXZX/G!\[7KQUP?.#YVO
M7CK@^<'SM>O'7!\X/G:]>.N#YP?.UZ\=<'S@^=KUXZX/G!\[7KQUP?.#YVO7
MCK@^<'SM>O.HQ@Z@O[H/\$7_`.]KY-_3FN?L:P@Z@/*/I%K7_P"T5[(+KX=Z
MU\/OH9Y\'_3KZ\V-=<'S@^=KUXZX/G!\[7KQUP?.#YVO7CK@^<'SM>O'7!\X
M/G:]>.N#YP?.UZ\YZP?G:^O6<XS65V5**RZ6TI0R>&0N;3I='.??8_;%>FN!
MP^239X;8/5W+.KK!L"4*FF+MCJXE,T5AL>>'UU6[3=K+2HA%%=N6')DQV,'+
MZMK8K+E+SANV,59/;88^7/8OV;CW4J*"1QUDBK?(ZJ)'?FV*K9$!I2+`PQLL
MQKO:/.S!.Y4:R0EMW%IP"1O;2:@;PN&N@78_>2G&[B5V07A&B@DEM&P>:_#?
ML?%"4E,8PUO;W`%$YKSB;7'".ZR9G,$K3WHKMGJ@V`[NI8XS16S(G^NWTH,5
M-?)&W.C,3]9T89`QN.,,>`I-6`8F9J9P+#PZ`<K"U-Z9O"I."$0]!,4:3:.,
M#H8N@1F]=;?1F)5G5-LRV*5WX2[:!N03>P3=:+FFPZ9.M6TO<]%Q_P#VL_VL
M*#VOO>$'^O\`5:QF).G?7[9J6/`4/RQ7MZ1=^Q<>`H?EBO;TB[]BX\!0_+%>
MWI%W[%QX"A^6*]O2+OV+CP%#\L5[>D7?L7'@*'Y8KV](N_8N/`4/RQ7MZ1=^
MQ<>`H?EBO;TB[]BX\!0_+%>WI%W[%QX"A^6*]O2+OV+CP%#\L5[>D7?L7'@*
M'Y8KV](N_8N/`4/RQ7MZ1=^Q<>`H?EBO;TB[]BX\!0_+%>WI%W[%QX"A^6*]
MO2+OV+CP%#\L5[>D7?L7'@*'Y8KV](N_8N/`4/RQ7MZ1=^Q<>`H?EBO;TB[]
MBX\!0_+%>WI%W[%QX"A^6*]O2+OV+CP%#\L5[>D7?L7'@*'Y8KV](N_8N/`4
M/RQ7MZ1=^Q<>`H?EBO;TB[]BX\!0_+%>WI%W[%QX"A^6*]O2+OV+CP%#\L5[
M>D7?L7'@*'Y8KV](N_8N/`4/RQ7MZ1=^Q<>`H?EBO;TB[]BX\!0_+%>WI%W[
M%QX"A^6*]O2+OV+CP%#\L5[>D7?L7'@*'Y8KV](N_8N/`4/RQ7MZ1=^Q<>`H
M?EBO;TB[]BX\!0_+%>WI%W[%QX"A^6*]O2+OV+CP%#\L5[>D7?L7'@*'Y8KV
M](N_8N/`4/RQ7MZ1=^Q<>`H?EBO;TB[]BX\!0_+%>WI%W[%QX"A^6*]O2+OV
M+CP%#\L5[>D7?L7'@*'Y8KV](N_8N6=8'$J#6I#7^O+.F=LS^`2Y&%GED,DT
M\-6,,C9SE2<U0U.J8EL2GFHE`B2]'`)4IS!!#U=&AUO?3KC[#=Q1KV*\#ZM?
MX(_V1`7"P'.PY#-A1.;K40)/(6FSYS#V][=>[DKD:<X)HM'F)B`8`THOO>TH
MB]D[&5LP6TWP%#\L5[>D7?L7'@*'Y8KV](N_8N/`4/RQ7MZ1=^Q<>`H?EBO;
MTB[]BX\!0_+%>WI%W[%QX"A^6*]O2+OV+CP%#\L5[>D7?L7'@*'Y8KV](N_8
MN/`4/RQ7MZ1=^Q<>`H?EBO;TB[]BX\!0_+%>WI%W[%QX"A^6*]O2+OV+G4=%
M#Z@O]V*]OX(O_6+OY-__`-%S7[V.RH!.L$Y-#U:%P-O<W9"^?B7JM4XVB`?I
M-R7FJ7NE2'O4;VU4H[1M0J-Z0]M5''G=&NV]4.P3P%#\L5[>D7?L7'@*'Y8K
MV](N_8N/`4/RQ7MZ1=^Q<>`H?EBO;TB[]BX\!0_+%>WI%W[%QX"A^6*]O2+O
MV+EX--;B:F\A![O+(<NTB/%W:[2K:U>;V]0:HZIRGO>5VP)/;>T$:Z@>UIRR
MBO[KJ=;<E8QT:W\>NG]/]/RYQL.M_'K6_CU\/R;^/7\F^C73KXM]&NGXL;#K
M>^G>M=/P?#_)OIU_+T;^'7R;^'7PYSD$V7_&OQT_RRGW]D4SR=L8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&?F;_!U_C"?^U!FMGL0O_%Z<?O\7:G]
MN=HYLJQC&,8QC&,9U'_`%_-%_5O-<W8U?[P>4?\`SBO9!?\`O0SW-C>,8QC&
M,8QC&039?\:_'3_+*??V13/)VQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,9^9O\'7^,)_[4&:V>Q"_\7IQ^_Q=J?VYVCFRK&,8QC&,8QG4?\`7\T7]
M6\US=C5_O!Y1_P#.*]D%_P"]#/<V-XQC&,9K8Y^WGRKK5B+0\=WOBA0<:1I6
M`^QN6_.*6O;)34&53.1!B,/@\!A$=4LJVQ[+?GHY(6(4GFD#A;"-VC2%(IG<
MA>CXRU0S2*;LTU&R5M<N34KX9\R:?5.*<B9)J0A5AT1R"A:%6K3H12*"LSP9
M(:RM5`Q%&F.KY"G=7`9,M;$ZXR+25X>R6Z+.^XS7PZ^'71OU?_I\GQ?!^C61
ME85U5#4IS,FL^SH%7Q\@TL$RDS*6,<<,<R6X28#DK2`=EJ41B!M&M0EN3CT:
M0-YBY$6M4D#6)@F^J2V[5L-E<7@LML2%1J:3;>@Q"*/LG9FJ127>UJ9M!WD9
MURPA<Y:-<UB-K($F(,"H=%:5L3[-7J2$QDB9!-E_QK\=/\LI]_9%,\G;&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QGYF_P=?XPG_M09K9[$+_Q>G'[
M_%VI_;G:.;*L8QC&,8QC&=1_P!?S1?U;S7-V-7^\'E'_`,XKV07_`+T,]S8W
MC&,8QFM3LNL*AT_X"W5')WR/JWB)'!+:O>U7(^WH=%Y]%:I512UX7*6N0H8G
M+U3>TNDU&Y,Z5LKT9+B@>FV:+V5UCRH#TB1`,UY]B$Y"RFWN2$VC[WV<RONR
MH(6FBWIU(J6#\8(31!E<*`SV`-^[(>)#`PF)),-44HW%R6E^.)5)#'-2YM*<
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MIC,$U[-6;+1C?0[7@`V[,`G'MT#+7?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C
M'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<
MJ_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,J
MD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D
M1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C
M'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<
MJ_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,J
MD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D
M1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C
M'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<
MJ_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,J
MD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D
M1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C'?[D1Y,JD],<J_)C
M'?[D1Y,JD],<J_)C&GWD&(9(3ZTJ8!.U";1HP7%*A#`7L\O0Q!#X&/A$$/3O
M6OT[UT=&:Z>Q.O%WD\`>/X&*OZS<&_N>T-@4N=IR1K5B,W>5H]M"-$GJ=S)*
M"`7]R#8%Q_;`:T8+90AB)+V+=_N1'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,=_N1
M'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,
M=_N1'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,=_N1'DRJ3TQR
MK\F,=_N1'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,ZC?N0_5%_N95)_!W_P"N.5?)
MO_[F,U^=CK>+M)@G)O3+`*S7%B[(;S^$J$OM22H!DJQ<F)L)400`FI%NE"4A
M6)02F6F#3'+""RU!S>WF&;3!V"]_N1'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,=_
MN1'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,=_N1'DRJ3TQRK\F,=_N1'DRJ3TQRK\
MF,NMK<K2.0DF/,0A"%Q$(_1Z5NGCTY(RPA4&A3[*6J(`V&F[-3:)-.")$3HD
MX9A`!'`+">;\]W9GP<@)U:3+6QG-*+\/.,B:*5!-.[[L['0]\EJ*<;@A-E/L
M[03AXY)&,Z^N*P=HJLC\)!N&V0Z,C.I3I#U8]N*%Z7(QY#]BPXR<AH'8CU>T
MYYO\+>8M.RNK':)Q-SXH<5:,H\I!(5TLASZ2YGSZG#W@$Q8SVEE<4AC&M?"T
MB)<)O<2T2M3TJ$6\S(@LJ@:8N%R8WBSJSATW=8XC=FMG<I`RI5J]*QOYB$V0
MQL2O80*%<6D1S6U'2&++C%4<?3VML.=FI8:W(QD]I=0=+3V71&>32KH-)YA!
M.]WN3D+W&VQP<F0+*Z%OS"6E./3BT,J.R`DB11LA2!03')&03(&(MN>B@+PR
M[D$V7_&OQT_RRGW]D4SR=L8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&?F;_!U_C"?^U!FMGL0O_%Z<?O\`%VI_;G:.;*L8QC&,8QC&=1_P!?S1?U;S
M7-V-7^\'E'_SBO9!?^]#/<V-XQC&,9IU[)$I[(K!7ESN>A><?"?AOQ3@U;,.
MK!>N5%8G2@)4T.DC^G='Y=-%#RPLS`P+4;E#(^R,ZE2H4N#YM8!.#:A<E3GX
M&=AT=FV<<UK-GB[FIV++E9-W/C]+!R'W@E+,-5V6(:RR:LU[I[D?HN6:7-&0
MGN?O2Q`E+D8Y-CHX'&LZ<XI2ZGI?I]QC&039?\:_'3_+*??V13/)VQC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9^9O\'7^,)_[4&:V>Q"_\7IQ^_Q=
MJ?VYVCFRK&,8QC&,8QG4?\`7\T7]6\US=C5_O!Y1_P#.*]D%_P"]#/<V-XQC
M&,9J%[.<Z(H_V..TI.X%<>R$D9LOC4]&2;E(TO$FI&`&D<BZR(26%-88PMKP
MZ3I%#UBDAV+A1+2[D2818FQ<S/*(Y0TK=:O8/K;;[*Y:62F173V'"R]M?'N2
M'F,_8S>/\JJ:=M_;K.K0L+C8\@DD(9@NL++Z-HFEI22$>S'Q26X&M*SN4#BA
M^J3&]ZUKIWO6M:^/>_@UK^G..G6MZUO>M;W\6NG73O\`D^7^C.<@FR_XU^.G
M^64^_LBF>3MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S\S?X.O\83
M_P!J#-;/8A?^+TX_?XNU/[<[1S95C&,8QC&,8SJ/^`+^:+^K>:YNQJ_W@\H_
M^<5[(+_WH9[FQO&,8QC-8_9"(U-HK$)#>KQRMHRMZ`B+-$`3^H^97'^(6_Q8
M-?DTS;DD0FK](V)VK>U($X;E[Q&PK9*Y3280J.&-S9(-1%LVA<7`[$FA.?\`
MQ8I:0TO*KXKG@W0S5R:97>&<=>6'$>U(/:M*7XO:7B.CG$.;%K'6->VO!6QE
M<@(':4K9E'W:K8<M9-(Y;9+2^::$[CONUO6_B^'X=Z_IUOHW]6]=&:C.:G,6
M40WD>1QZ8$]M-%65#QF<^8W+F<T=#O=G;2>JU\T>JXK>`5\G+,/6,IT@=(A9
MT^L!ZCC0^6?[AJT%&JG9MRF5&R.,8.7?V0&T)='.RF\D./MP+`55V-B@>*=B
M<;D3"OTZPR]1SVAXWR^GDPM`3JE5.<W9+3JR70RIHX%U7@/A;?N23=H;V^P5
MZ20(_H[C3XGDL>8Y$E+.)2OS0UO*8E1H&CR4[LA3N"<H[18A@[<44I`6;U!B
M#LP(MA%L/1O>)%G7K5A5L4KHR4:"**S>P2'W7>61[[A-!6TO9A!Z=,V^ZNAR
M-`FWM%W2'^Z[=K>T^A&AECWS5)^.H?N[+_P]CWS5)^.H?N[+_P`/8]\U2?CJ
M'[NR_P##V/?-4GXZA^[LO_#V/?-4GXZA^[LO_#V/?-4GXZA^[LO_``]CWS5)
M^.H?N[+_`,/8]\U2?CJ'[NR_\/8]\U2?CJ'[NR_\/8]\U2?CJ'[NR_\`#V/?
M-4GXZA^[LO\`P]CWS5)^.H?N[+_P]CWS5)^.H?N[+_P]CWS5)^.H?N[+_P`/
M8]\U2?CJ'[NR_P##V/?-4GXZA^[LO_#V/?-4GXZA^[LO_#V/?-4GXZA^[LO_
M``]CWS5)^.H?N[+_`,/8]\U2?CJ'[NR_\/8]\U2?CJ'[NR_\/8]\U2?CJ'[N
MR_\`#V/?-4GXZA^[LO\`P]CWS5)^.H?N[+_P]CWS5)^.H?N[+_P]CWS5)^.H
M?N[+_P`/8]\U2?CJ'[NR_P##V/?-4GXZA^[LO_#V/?-4GXZA^[LO_#V/?-4G
MXZA^[LO_``]CWS5)^.H?N[+_`,/8]\U2?CJ'[NR_\/8]\U2?CJ'[NR_\/8]\
MU2?CJ'[NR_\`#V/?-4GXZA^[LO\`P]CWS5)^.H?N[+_P]CWS5)^.H?N[+_P]
MCWS5)^.H?N[+_P`/8]\U2?CJ'[NR_P##V/?-4GXZA^[LO_#V/?-4GXZA^[LO
M_#V/?-4GXZA^[LO_``]CWS5)^.H?N[+_`,/8]\U2?CJ'[NR_\/8]\U2?CJ'[
MNR_\/8]\U2?CJ'[NR_\`#V==\G:1U\&YL7K?R;CTN_#V/?.TAX[E_=^7?A[.
M0\EZ44F$)R9J6,T]2F)*!W@E@>L88H+``/2-@"#72+>M=(A!#KX][UKX<UU]
MB@Y`5)'>`7']M>):!&M"FM`X1.V62G]!9MY6CLL7;$K(>5OK:UT]';.MKXMZ
MU^G8G[YVD/'<O[OR[\/8]\[2'CN7]WY=^'L[>^:I/QU#]W9?^'L>^:I/QU#]
MW9?^'L>^:I/QU#]W9?\`A['OFJ3\=0_=V7_A['OFJ3\=0_=V7_A['OFJ3\=0
M_=V7_A['OFJ3\=0_=V7_`(>Q[YJD_'4/W=E_X>S%&U.1UA.4@GCK3DP4N$3A
MJ6M6Y.P,-<EO3\ZO,P;+%=G=?VR0-NE?<;*1%FI6X%Z3)2DS!W[7-XWA]3MT
M<=+YE#O>++4!%MQV^"+`3*&^-N"%HAM70YUW(`OKBV-QB2+KB@ZVYK-&+C0M
M85R1I3*U)`"794PE"5*45.*D=XKJ)%<K5?[*_&%1KONH86*MX^X(MNZ<XM*Z
M1E*YA92WL3FD7]O:@IW")MJ\IU+`D=F]HZ%1B2,.,]63Z!4=9$UK^_E*8R5V
MAR%O>9Q9^@,3>5\;LJQ)K(K$FL.>%")J(<F(;8\K1$',8(\\.+`!3M(E6RY,
M2WNSI*M.R"\K:ACQ)]WJFC#RR.+JA=X6OK")'R&,C2%;5-Z.9(]IDJED>%B+
M8%:A&A3O+?HD83V9W?DP@*!T^C9?>%S,3\N.O1+$I&PGD:5PU36<252!.U+&
M=&O:I$O;G!*Q."1CDB@Q<?%5NT8RG9B)1K%8FE^&]1I@E*JN5];OE8UZ\S*9
MI@2YUA49<).%+&).0E#(%;0D.>`IR4C*J3%$:7C/T46G4'D`!T!*.-+T$P5_
M>^:I/QU#]W9?^'L>^:I/QU#]W9?^'L>^:I/QU#]W9?\`A[+P:;>KU\;R'1KD
M&E2%0(\))_>I])ZXDR@U(?KM:EK).#U%!!I?2,L.A=7K`V(`@B%AQV5-KASA
MP>N!7.;DHNC6*-&0J8`FG*",L\YXX*WJ*S=A>H]#KK@;V84FF4&F[VE0QH]E
M1;-?P/"]G>(RC<)"TMC>J^9SBI1S-S2NNEC^+G/GL:-E6W2%7\OYY9%)\:N.
M=F5S2\6#S9;*BXWW8NAK>QN#<T(H_%JYCS!+(<-]8TDNLB\5TG<)P`F*R8UP
MA7VT-R(MM0(F\H9IA2%(F1E&'CT8>84E)`06,X80@T,X8"PB-'H`=",V+>@A
MUO6M89W7Q"6V%<3U>=;VFLJ>>3GCN]\7K,4BB*&<-\GK!4_O,IA[LT-S@],9
M$?LJKG^63E;`Y(M]TD6V1-Y`@F,$E:8#-IKQCE?8@*160^<TW7\MD-<\?+MI
MWB[0_(*K$J$#\IL*N.)*)MBU=I8],%KLC50=]EU6-+=3%MO1S/+`RZMFUK*8
MD$/EZ`N6F;<"2BR"BR22P%%%`"6646`)9998`Z"666`&M!`66#00``'6M!`$
M(=?!K(,LO6O"OQU^/X9E/_T[_344S^+X?@^CH^+]&3KU=?*+SQ_M8ZNOE%YX
M_P!K'5U\HO/'^UCJZ^47GC_:QU=?*+SQ_M8ZNOE%YX_VL=77RB\\?[6.KKY1
M>>/]K'5U\HO/'^UCJZ^47GC_`&L=77RB\\?[6.KKY1>>/]K'5U\HO/'^UCJZ
M^47GC_:QU=?*+SQ_M8ZNOE%YX_VL=77RB\\?[6.KKY1>>/\`:QU=?*+SQ_M8
MZNOE%YX_VL=77RB\\?[6.KKY1>>/]K'5U\HO/'^UCJZ^47GC_:QU=?*+SQ_M
M8ZNOE%YX_P!K'5U\HO/'^UCJZ^47GC_:QU=?*+SQ_M8ZNOE%YX_VL=77RB\\
M?[6.KKY1>>/]K'5U\HO/'^UCJZ^47GC_`&L=77RB\\?[6.KKY1>>/]K'5U\H
MO/'^UCJZ^47GC_:QU=?*+SQ_M8ZNOE%YX_VL=77RB\\?[6.KKY1>>/\`:QU=
M?*+SQ_M8ZNOE%YX_VL=77RB\\?[6=1!UH(MZV+IT'>_X8_D_G9I6G,UNJ1W;
M?`@\C+IA$%AM_/=<B;(2NKII9X>QH:SXVO<7(0NTDJ&:-C,I?Y!:$H$O'.5#
MPID'^Q4,0$T*DPAD^&3&W;'F2>N"WE?R51*H(Y/?NG*V\58V@CL93QR]'E@>
M`%/G'UP.B9[D.N8D)0_6)[I8F[`<G`<>;D1+FS$[JCVFO-I<E:,CE1R4&L;Y
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MABBW>92H[1*G%K2IB&0AM5!;GE1H]Y`8F1,)RQ0^F_ZRQ%.*M8E*44LJWXHT
MT0"\$;&0GC2Z,$3XYI:G>'C,4!?C2%BKM3TWNXHH[.:M0N$9M4B>51;TN'VM
M&I6K%9(3JA#K/B[U4#A<C.R::656URR8+6\U5'&]>>9'AN:9>-Z7%N`6AN>#
M0,/:7+OXXIU3$>7MMD@VU:V+DR3ST_:T4M.%O5FQQ@&R$'.KXWN)3D:P)7U2
M?$P[1:]T'<BTXQF7DD%Z($T28Y$\L)6M)G5$W;!LL-,I.W(A><8D-@1F.F,I
MY1Q,97'.)D?4/BHI-'V^0I`J%#*N<3N]0`R0PYC$K4!2N[>>7*&#2N.O[2ZN
M-2XTAUOCO1?Q_P`45=_$(6OCBK9O]&]?_P#/BU\&3=U=?*+SQ_M8ZNOE%YX_
MVL=77RB\\?[6<]77T^<+UYJQ[)N7"KZJ]?PL;[[H_COR.L5QJ:TZ*D_(>+1"
M8QM4KJBX8G-7:1P"`SI6FCMLR:&[C043O$BC%"A@')HZY21`4P/B`YQPWX<P
M*Q>"EWCF/+WL@'""[DUHPLZIJAJJ@N+5$\<K@E5GR6<PQ<S-40:ZQ5+)G;.G
M%"S.B4Z,IQ#0,FR-2AQ)+0-KB[M'T+ZWK?PZ^+_Q_P!'R;^+?QZ^#&,9!-E_
MQK\=/\LI]_9%,\G;&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,ZC_`(`O
MYHOZMYH^6&A*O_D*>$\E(X)>6,_[UO!QR%*0Q@54QPK*<B5+LK?(:%F&]DA`
ME3$CO'CR-W%L)`&6_P#KD10=PS#9942L4*-2D;`();-SV32E2SM6H>ZGPKE\
M):]N>E3Y4((>E=!&*SB7EP3<'RG(*G9H>05N@,5/4LK$O$C[XKB]Z*TG#9Q;
MJ0AZ&X)J22^'VPA[FYJ,:$DU*W=T;[=J8F0&&D"T$9NNR#B.+.D*;RF;)&_%
MEJCDRTE;'*Z5/"(I0TK#9,[DM?!P2"3H48'*?&R5O;M`3=NDZ:#<M4*#J%[]
M]K572A,;+6<#"%58O.G)0F>N^=2K@R42=0T/!<Z)3T/+@IBFH93[?Q,V[W@^
M$P",[LB9:(L(C1,]8)@&=HL_E0>;JGK$.[ZHN[U%>6NB5N879H$2\,Y4TY>#
M2Q=,YEVV+3NX(#`=)T:2V[=BQ"),:`SB+7"A,K/C.]UJ_P"#&_\`Y"C^G_T8
MKY-[_KW_`"[^/*AC&,8QF%,KM*'4_;UYS"<I5ZAB!':`;-F-S>F<STZ]Q37&
M!NZ4QZE.+H7JBP,Q1I/;-%*G1,-=M(T=\7%%.3S)*[IBGBI.=&A1VNHNV,JT
M;$TM3>9[G6UR<46PC"TI50TNP-*ERTK6$M9RT\/:5`VLIP/TG+.\:"3P"(4N
MIL-NA*IBABEH6V(YQ=&U1\MS+]T"O;^^*E3<F=QL)KH:J6*71RTE=U):@_1X
MTAZM0,D!OJ@LD@"NL'6SX?%36^-2XB26(O;R6MI0NLF.&0>%8\J46E^F\UQD
MB%I3GD[<UR4TT@Y&!X[W*0JR$WGI^6UQ/XR]VO7\7.;4$Q6GGKG$YI;&MSF`
M8XCTU-SL<20N-V82<W$@2M??@:!P+2A"4X(D`@[!JET]+JPM1MDUJP")F,JU
M>63!W=Z<69J:GAT*B2$2@EJ.$VKE^ST,9<'ES9RM'&`)"O3N)C7M8S&MSFOJ
M?&C_``=Z+_S15W_HJUY-^,8S"#GTA['XZ4<H;^R/;XTZHE0[D]RBY/+(0W10
MJ5:2*@HSHLOF*A(H130M`-=IN5Q)2GDY*0:SN0T!`S^G&[L>O$CL-E.1M3R3
M['=7?$LID6;7L)U^U=(V2QW!MTN$E3N\5!;#](Y8_1<E4-2A)=8H2_,Y9PC4
M1:]L'H:8.]N'_CZOCQC&039?\:_'3_+*??V13/)VQC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC.H_X`OYHOZMYI(-$(?(6]V\HY40M<.65G&(52$;MW^1
MEH*1X4&+01HIB<0S4TA85UBY)NOXQ*D1:,73/CXTU;,6'W#*3!*HC,MI%"A+
MIZG$];V;O(:[C`T+D4.YA`5+("*'R!U`?(U(TY@WHFCSYM/2SQ*_=;&6%>6X
M!8:M+CP]V*S^N#1!USEQXHD)QG>XI\\/]A$]^4(BY0!AW9/;.@6TC.O6<@-*
M0A!NL.[=$M1?F4FB(>5IYYQQQ+2TUDTNA+B:Y`;W)T5MG!S2=RF6WZ0MS$3,
M2-G!VT$VPLAULFB[5N,1)],,+V]VR^#&@K*9;7*52S<>J0PQ^%)#GHL3T!50
MTM$FU9FY](HV:E)3_!MH%R&.K-,/H"*,+W46BE@+1Y4E*=U)9R+NU[VK1U3:
M+JM4;%-=O*QK4S;EN!.VOQ0CS)4&%D=<K36=.(ZUU&(1*4,<ECH+30C*WGM7
M_!C?_P`A1_'T]/\`YL5\?3\/U_#\N5#&,8QC,,)#*JRAMRWB^6OWI+C)<9HE
M(6K>F(U]0)G-P:[J1DEB++;W'250ZHC7!@1B,+*V[+'<B,)1*5[^D;ELVJQ5
M)6%2-IKJA2LM41E#'CDI#^V/#FBCZ#;DA/8U#BD>T[@Z-:=F7J42D2IU+)#&
M`IPJ59C:G;!#34YJ+IB*4L8ZH8X6VT\<VJ9@:Q+HA(3T:)J>G#O\I&."NK6>
M[,R!*K4]W=X.\B--&TY702VMB)!HM/[80&HB:S?I/#&DD5;2WW6S1U2DL+XJ
M;GTEQ"JU)%[?%%J(Y0J;I`!$I6)V]F:.]LD+5[<VI&O"]Z4KOQJ@VFWEBE,\
MJIN2[CDT=5JY\6-C(]H&>3+VI)IL5O#6S+$A"%R3N*4L(>_,?;AH95OH6A5N
MQP^Z!4NHQ4C)$DIL.FFM&D)=$C;$GM:U,CY%FQ4*),Y86]`!A7I&MKTMCZ-P
M+C[BK0-8%[<J;!Q!X4@618;2UU'C1_@[T7_FBKO_`$5:\F_&,9\V79'%G8Q8
MWV01G>^S$L\37UXX\>88W\*GF]6*;R7C8WO2.53X[DPQZ:VEN7P)#<JQ2;4K
MLY.D]1*5"V"`B2.)KDAJ)[2J<0:FX\<&>;'+#P;=A?FK53_#Y,F@$B[*@]4=
M%9BQ4+<:&"6=$K!H&AJN3OC<@CK;;\C41V:@LF;5J6Q-[73#RL9WMSDKDZ$1
MP'V$A#U=='TB%O\`E$+8M_T=.]]'T9@3V1CG*U\"..DKN0J"+K8FC:A[OC=:
MMCN0QFN#2A?(XURZ9/[T:G6[88+`4<E;G*3/0$"Y2:L<(_%F9"ODLJ8D"F'N
M0W9+T]-3?EV5'JX)F-6]CWA5.3?EW*SI`K:G]M37"G.EA[%5[,6R+6V1OE74
MR43<<U*>G9K+=$+U&(6P`"[.RQY:-J*16F7IDZU&>2J2*R2E*52G,`<0H3*"
MPG)U!)I>Q`,)/)&`TH8!;",L81:WO6\A&R]_[J_'7_+*?_HWY(IG]?\`1DZ]
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M28A.W,TC4<T&=M`@0D-M'5<$MO9&&X)<%3MY=EFAJQ#52HJ$B=.YW(2IQ1>'
M6PB/!6I6]S*%2J']K$%+[C%$ZE\/TF'U-\$])1Z:%=.)3J$4E8U8"#FL4:@<
M(C:=R2(5J-3!2')KX2:-@K`L21J#J(TPOG7.[Y1EAFO%MB7]N5!<>+5D["L*
M-MC210RUBB"2C,B^X/5;L:C"T-JUFW4XW"B)=H:B'`:891@H0>]&"UM<9$$W
M`90X#%U%KC91HM$J;"Y4-)@:.G#;MA3:):8G<,G`P]Y0Z;8X>NF7+T)D];V\
M5-E-C,_NX5`0+).AK"EWQ<4L&)9RML$E9T2S>^U;Z&QOU\/_`)BC_1O]5*_]
MW7]6OY-?%E0Z=?3]6_5CIU]/U;]6.G7T_5OU8Z=?3]6_5CIU]/U;]6.G7T_5
MOU8Z=?3]6_5F$LL%48+DNTVY]1[W*@C5'Z3BDX#!-@7,V.WL0:'?1K9?;S6`
MY^3DA-_WWMQA"?0EQJ0`IL5LE3QBF6-GE[B!UJ]I21`*5SG3@M=0&IRWAK41
M$]V<5@`*3@IW$;.!,<X!``D)24"W82BC-ZHC.PT:Q4`%$)86Y4.H9]NZ33^K
M=W%G1Q!T<BG-L;4O=187-)&&G9R1(S-IH-!:6M.F2#Z$Z<6]5.#L=0-=22<<
M:7@<Z??_`'=OJPD]:X.,<1,CD-Q+ES<Q$"+">@B^E"=Z4%-K<$28)JM>>V[&
M4J*WO\J?9::21V:O-4N)"R#21_>%+J@;%RY5$4+PB2]PR84?0&%A*0EN9H!K
M7@36(Q(Y.(S%Q(Q#,WO=*I)@I),@EDEHIT+,C#FD8V5P96!R<!PM$YL<7;^X
MUR!E5!"G1R%3&E<?0O;@1L2E6F;6M$Y:"O;E`0W#QHW_`/5XHOX_XHJ[_1OQ
M5;/HR;^G7T_5OU8Z=?3]6_5CIU]/U;]6<YIM[+CSRXA\8(E`:8Y)<3+,YM2R
M]7=&WU%QQBW&L^Y8_8LT,4J&MC:QR*9QX^J6^1=UF*`E,Z9U=[%3-YICDW1%
M4A4%&J(.[#M.^>EL3&6S6Q^('&GL?G!&/L5L5I4/$VF!,FK%CEVPNVF"+R]^
MMX$=8F6.Z7HBXO,HZAU'6R,%]U`6G/$;5&'-+V=]`>:-^RR=CAY"\JZOY-OU
M`7_-D\YM:EX)53+1JJ*<>_<<Y-D2G:"5*VA!9$_@RF<0UN?W`Y7+)(0US-I(
M>7UB8-*C3DS8VMY46<D.QY\FW%M[)I4$$,':Q/92JVXPPUVOJ0GP>-E5E,(7
M6##QIY!36THJW*HZ#N9RJ:,M-IU\WU5$G%&\3Q8^04]FB+:0T.A_T"L+,CCK
M*T,#?HW2!D;&]H0Z.,[:=I&UHR$"7MQO5!VPWN=.7VT?5#H0^MOHZ-YB/9])
M5Z9;%*;&DD_3)YO8)SQU;%L8&C#!UK+W<6T002P.F<.UI0-[`S:;P=RZVWZ#
MIO$-**6?>WU1^H3'TL6W^.L>]OJC]0F/I8MO\=8][?5'ZA,?2Q;?XZQ[V^J/
MU"8^EBV_QUCWM]4?J$Q]+%M_CK'O;ZH_4)CZ6+;_`!UCWM]4?J$Q]+%M_CK'
MO;ZH_4)CZ6+;_'6/>WU1^H3'TL6W^.L>]OJC]0F/I8MO\=8][?5'ZA,?2Q;?
MXZQ[V^J/U"8^EBV_QUCWM]4?J$Q]+%M_CK'O;ZH_4)CZ6+;_`!UCWM]4?J$Q
M]+%M_CK'O;ZH_4)CZ6+;_'6/>WU1^H3'TL6W^.L>]OJC]0F/I8MO\=8][?5'
MZA,?2Q;?XZQ[V^J/U"8^EBV_QUCWM]4?J$Q]+%M_CK'O;ZH_4)CZ6+;_`!UC
MWM]4?J$Q]+%M_CK'O;ZH_4)CZ6+;_'6/>WU1^H3'TL6W^.L>]OJC]0F/I8MO
M\=8][?5'ZA,?2Q;?XZQ[V^J/U"8^EBV_QUCWM]4?J$Q]+%M_CK'O;ZH_4)CZ
M6+;_`!UCWM]4?J$Q]+%M_CK'O;ZH_4)CZ6+;_'6/>WU1^H3'TL6W^.L>]OJC
M]0F/I8MO\=8][?5'ZA,?2Q;?XZQ[V^J/U"8^EBV_QUCWM]4?J$Q]+%M_CK'O
M;ZH_4)CZ6+;_`!UCWM]4?J$Q]+%M_CK'O;ZH_4)CZ6+;_'6/>WU1^H3'TL6W
M^.L>]OJC]0F/I8MO\=8][?5'ZA,?2Q;?XZQ[V^J/U"8^EBV_QUCWM]4?J$Q]
M+%M_CK.H^-]4=47^P)C_``=_^MBV_DW_`/WSFIQ"RL\9MWD"R-VQ(V]IY93P
M*5W>G+OHE8@K:BX6G&$R*23%<0V$*'P\8R&4,YM^I%RXW926(MUL*`I(Z1?$
MX`FU$[7#L:)KT5))>,8'8;&@W$1"A'+O>WR8^Z9-7^X\QN@33#6QTM9+QHB*
MXE64*/V[8:0TA?*ZU,-)>^SGK9&M;]W):ON(1";2Y+K5]V&+W<*TQD:T\)H9
MUQ;4:D;I%H[4@B@F&AY>;)`H?P>30$PI$W:WM*MV;#8`+2-#MH5+)+HMJX/;
M#)8RG9T$L=GF+MH2BMN+[7L:OZN4?:NA[ONOPA+VQVH=I(;60PZ$D>M**G=M
M:VS=Y'$$Z"30\N+$3!A1)+;),G,0:WO2XNG-<P34Y>AB>FB%$:.(!97*KN?=
M+3SI<&?K#A%O$`=`+(CWM=1>[/F`9N,L[@7*=,"Z4(-B-$O9HG9%AV.C$0IT
M\T'##2G1:@VX-G'&J1MR`0D$QWO:%'T[U:]LZU_YJ5\6@SGJ]'R=7X-:Z-:^
M#/=[V^J/U"8^EBV_QUCWM]4?J$Q]+%M_CK'O;ZH_4)CZ6+;_`!UCWM]4?J$Q
M]+%M_CK'O;ZH_4)CZ6+;_'6/>WU1^H3'TL6W^.L>]OJC]0F/I8MO\=9`"*J*
M7(M&\X7-@%AA!K)1CT%%+I[)1D*GE$T7$I`88ZOLE,<%.VE`WJ7]O2#<!IV-
M<RDRMN(1.K&G=$F2J^&01;4[="I])CYO"%"&/MJI^FDC2:-ER4QP0F,A+\]-
M6V5$_`>3Q-R`X@81$RDDT"-R*==N*K2OP-D6KI-3)D<<IXOE-6.;:IT1*'^P
M1J-&Q!Z7]N;6H-AH%Z%>Z,2=*I3L;>Z.3VXNKNT]J2O3R]'JU1ZKV0J)0.+U
MJ^,3/+UCE69FI5W(I/EQ1C=#(UL"E`Z1J.RQL.1.#/'(H-*YIVT2AY/<8F$L
MYN2NB)$T-R-M_*JH77D+89(WUY*CUD"$YJR$[`EE9#Q&Z^4-J,*%]8XNN(--
M<XVB*4@&N5,!KR8DC:X9A3(D8D00(@4JI8)6\.1RA14TN4NL.<4K?HR*HI>F
MF,497X;2!V62!O5GF.KVE?IFVNK2^R+:I^/1/IZ@B7:0:>)$\O+U$W'V@JT>
M:)IIV7HI6-:YU?!7!6)/9MH($XE2R-MZ@\1"%OF25"C)V:8+9:5&F3I2`]!:
M<DHH(0!F#WM]4?J$Q]+%M_CK'O;ZH_4)CZ6+;_'6/>WU1^H3'TL6W^.LNYJJ
MB%,J`EM;TS^!(G$>(H*F;SAP.UM0H-5&]=6XR-6L-ULXXS8-&GCT4#822M`)
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M8QC&,8QC&,8QC&,8SJ/^`+^:+^K>:0E@]DWSR(4EF&%+2>6L]+1'(EIJ&4D@
M.I?A0%8"'.**5124-28TLS89:7$)M7*9U0#"GEB&Q4`],ZFX9J=VF)V?M,?H
MG3?*)D>T^Y]QVVE(UA\*Y>C5'UGI@FD&*B\N,%HT4A=:UUQ\EBY1WU.?["ER
M@;FZ'UN7&%A<W$K0T.B"[&*<"B]*40&H#UX?+#WW:W)-/A#6FM[M@?[ZVZ-L
M=M]W!"+WQFUQ83TGBV;H<@2E''%F%+(E7BUQ`[+PJVQ2Y`:^#NTZJ?I766R%
MM?YZ7L0-,$@GL<N2=HMB1;8+GB^QI#55KK#^Z*Q<-K#NW:<:F7]^]RUQV[;7
M`*H67B3^&`<LG-BZEZ4O6NECU;JKDLE0@UH;(5$0`TK3V5RH4G^!FP#NZ'CN
MI3`;91JC-/+P*1GMI4UY>A(2R-;X4#9"ZU^7LD&F:.R*56+`49Q:73/248-2
M)2HWO=:O^#&__D*/X_C_`/-BOC^'?]>_Y=Y4,8QC&,PFEM6PJWK?O&)SU4M(
M8`QRA741:)Q3M@E"U$W726CV:>>0=L06XQ2)[3`+[7L#@U(E*C9R).K2*9P=
M:L;953:&K;*E*B4M9S='6U]D*4I#&C9,0TN:!8D`H((&N2)BW<*)&B<2T1@=
MK`&J-H1HS%)7::>VU*V>`XZI9).W2118]I5,)$J+$SM#R.'FKNLS(%;DG)4M
M*U:F:.YF=>^%(D@7KH.7!0MYZH)9/L@=6-\0JM[K0,P6.D,,+EC7'5Y06Y"Y
M1.'NY:HDMA+=@=U)'$^,#4.!2![6HRS@IRT:=Q2*#4!RA7^%.U&T53&I)#XU
M+5;I`E#HL/C+4>!O,60@A4DT2\LQ#ZG%OODD+<.V+&X+BB`K:"A:0*#G`)>C
MMTJF*:9Z;;Y2TPN9+'N!.:="N11YR+;'!<T2G;4$N0O>Y,@VG,6ERL@#8[GM
M)[>42B<SG%Q0*.XG9.@05KC1_@[T7_FBKO\`T5:\F_&,8QC&,9!-E_QK\=/\
MLI]_9%,\G;&,8QFM7LC_`,!W`[HWO73V2+BOK?1O>NG76G_P?!OXM_I^7X.G
MXM9LF)_WHK_%@_ZNL_3&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC.H_X`OYHOZM
MYI'-VL'R$OY*ATH/>%/+"QC&!H**<%>WL@BE>%NWXX+.@:9:O>M,R8L1XSVV
MD>013/\`W9[F\T(0`V5:N64A<5,3FNF<"QSTY32>)82(@AX=?=9($\-Y>:=6
M1)MM;K9W+S&P\)Q8F:,*N:CHV"2DE+*"J4XD+/$*K+31[6JS@J%'<!MNEMR)
M9H:_85<[U?E@!W#`K0.IB16;HT92<4+2SN7R70!`*]X`'0RHZ=YS^[2GI08X
M:6HD*)HK=NE:L93JC!&Y::U\(=M<:.6*T\#2QM2X_#_Y,OLUXI/Z_9JC23BG
M:>]J"WBV'<2]-6<J"^[6,QK54RD5@A,)>&8<)+%14L`WG*0N;90IL($M,V#6
MC)67V/?NXX00HWJS#Q%F&V?RI)?=5#9J8:%=IU3U=::U[:A-;]K;7$39ERV&
MW20YL'6&E;0G7!&DT&2NU24S'EY9Q7<?+&Q2E*)+(=Y[5_P8W]/ZBC^C_P!&
M*^C7]6OY-?%E0QC&,8S"":4^Q7;;EY0V1N3HU-H(]0+N-2S`;@N.SDJ&Z$9!
M1*M>A7"2$C&X]*\"8)07AO`JC;QI=&7Q]:'*<7NI%$ZIA+5,_?$NSC6V/M[V
M]P=D31@DW3`Y(%A)T?;#Q.@8N<:2VIBR%+4<2L85`A+HVH:%"9O&C\*"F%"B
MBSZ2DSZU*$'>55$D;Q'87&F$!463K.HQ=,7&A6Q)&^)F8E*2N4,[*V-!3L$Q
MUCS.Q;*0D)/;`JD41*IWBHUKT@<6'N>5,$9<"(TU%."6)/Q:K2,N3H5A*Z/R
MN2I37%>-W>5;.4EE8]EK9"VKW18\KG3S4S31M0Q205^D?4CO#CG!8KBQBF/M
MY$H1D/"/6WD$M=2B](ILX&.FS#T[\ZM>WIP1"`3)UT@6Z,7F4JDZ2444URF+
MM$A1/,%<"TCPUD*XXWM<L2R8;6%OD9KB\,NFYI<F!02WM?N9:-,1!\21ECC3
M8NU$6R,L3%7N-'^#O1?^:*N_]%6O)OQC&,8S%?D1S9XN\4%T=0<@[<9*S%)`
M)U)2]W:Y0O8HZT+'=/'T<HL21L#"\1^JX4L?E);(DG-F.<1AREWT<VD/ABQ,
MI))NF=<I*!K68M4"FUFQ]CD[JUQ1\VE-"Y+$#&Q3V6EP*!/LS?VUO6QZ`LD^
MG!NH;`GB;NL>;9M*2E+!%U+JYHU:8B?];UOX=?#\?_1OHWK^76_@WK]&_@R"
M;+_C7XZ?Y93[^R*9Y.V,8QC-:O9'_P#?>!W_`#D7%?\`ZT_S9,3_`+T5_BP?
M]76?IC&,8QC&,8RW)%+XI$2TATIDL?C92\XQ.A,?WMK92UB@HK9YA"4;FK2A
M4G%DA$<,HG8Q@*#LP0=`UO>55M<VYY;T;JT+T3HV."<I8@<6Y6G7(5J0\.AD
MJ4BQ*8<F4IS@;T,H\@TPHP.]"`,6M].>[&,8QC&,8QC&,8QC&,8SJ/\`@"_F
MB_JWFD)P`EU=W)-8O*`*/HN6\T!*%!I*(2!*>KIKA,7&-.ASK'GN($C4K==1
MLU.DCBK-/`(,(,;',/;TEP3TE,1$[@"^)NUC;GZ5++!`M2I0B21I3".70F12
M_AE$0=3"6PXA0B[B.M\N70DP"E/[F&](D/;4JVO2]*/;RZE"1F[<BYB6\K@=
MR';4AK+P\6&;WQ/"*,'/(8UW+US>ZW5:JH_M.]FZC6D.S%"CP%D$G25G+;4N
MS'%?!(&NA04R4D2A7"DS5P>T\J67O+$TKP<S$:(.TM-K)<P5F5W.;J21PX)"
M@MJM;9*576*?4:2:4!>*I=2ZO"VI$1NG`\BAI>!X+C`(3#&L*HPOI$!6"BDT
M25@WO8)$4OWL:(ZQN5&V/5)3=5HM+WD/A]P(6!1VF,Z0CFY,UY@#=4R$W4-+
MB^WDL'=9BHJ(D,-GA`,P;])EA8W!4\;XFG_@QOZ/B[A1]'_^*5\GP?5E0QC&
M,8S!F=U4OM^V[OBS?,G&"&E1^B'(;ZSD*37/1866\6S:).),Z-?:R%9KJ4!T
M"8,_2UF"XM:;O>O7HWQIG%[K>6SFD6VO']]0P>5C;HFE='^#J7=S(:U$;=FI
M8H51=:X&,KF2H5IFK6F]0YZ5:;%*K7=Y#\0E,"OI#;4LQ6<>=TV_OS$T2!.P
M&0])+(Z5(ER(;:V+PDLLD*;E[PA>VUZ6-29.M4M8I,[ELCR:(D+[(4B7MJVH
MP"LY<PTV_55(7QK6+`IIM'8_+RC'MS5.K(_]\3FJ1RI`J5H%I,ET<[G[?F]J
MD`T:P])W:U.C26XEMS/YZ3JR7UE$95`G^1()6@,>G5?&9BI.>CY*[I9$DT>N
M'-&]:I.)"[-SF,U/I8R/1:)\1A`M*;(T:/:$%)H:IIM3#/+(B^R5NFT;4EMK
MTS2HX]](E1CP./I&1\9'-F<U+TB31]I`R(!1-8CD)RO36J`RNJ`U<RFR2175
MQH_P=Z+_`,T5=_Z*M>3?C&,8QFJKLCUX<6D\0G_#BQ[RXX4W/^6%.22&6(]W
M+8<`@X8AQTD")Z@\SL-[)E3ZQB?525HD$I8JDCBQ1VA]G*I6K_V/%HU-W-NT
MN<EF:/1*I^S[1&+%F.R?D=QD['PS\#VYN5*7-WM&KI;QMC?'SCLFJLUS4`7R
M+N/D:7*$A1[6:J<6:3O9;ZO-(5/C>8?];,63/".-,"20*@+GY*RM*9Z6@%L8
M%;NG;TQ+HI`/99/7"H7EJ#@C[45U]#T/M8.GJZQ/LY)>6[8I7M3_`%0$)DWL
M'<6T9$9B+:0GP:R\8-/^PS<'?`S;/VU.(3:%L!ISV6K"':70D0I9[AY+^,]&
M_<2P?S%QW#R7\9Z-^XE@_F+CN'DOXST;]Q+!_,7([MYWY.0RJ++EZ>74VF41
M>!RV0$*6R"3'OD0<SL2YP+.0=]YPYM?=A8D^AIN^+<O0]NT#:I&I([82/0X'
MLC7,C8=;\+P?AUK?]XM>_IU_DOG/^J,\R/*\'[BU[^%\C.R>77(>W15^*?V$
M)[W5]GQ"XX3VN,P]L[U6#!=N6XR\'=[H^G[Y)46W9=V]H7]O;%_;0=UIS>TE
M]62P]D8YCA#H.K=#T!UK6O\`R&K[XM:Z-?\`V7^3.?\`5&>9'E>#]Q:]_"^9
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M\P-PAIVMH:&)DGJ1H:&]"D`60F;FQ,0B2EAT4F*`4$.LK_<?)7QIHS[BV#^8
MV.XN2WC11GW%L'\QLY[AY+^,]&_<2P?S%QW#R7\9Z-^XE@_F+CN'DOXST;]Q
M+!_,7'</)?QGHW[B6#^8N.X>2_C/1OW$L'\Q<=P\E_&>C?N)8/YBX[AY+^,]
M&_<2P?S%QW#R7\9Z-^XE@_F+CN'DOXST;]Q+!_,7'</)?QGHW[B6#^8N8S\P
MC>:T<XWVY-JSO*EZKE=<0:5V8FD22C'BP1."6OXN]RI7%#&"8624T$D2G384
MU'O?7,6,I)ABQ$D5'Z"7GHXAJN:$GXUTQ-+'NBEK,E]@U]%+&<I,II-]@@P`
ML%@;)@DCP(]$[)-9@$Q8AY"P$.A(BU#V0A+<UJ5*K4'$AR0[AY+^,]&_<2P?
MS%QW#R7\9Z-^XE@_F+CN'DOXST;]Q+!_,7'</)?QGHW[B6#^8N.X>2_C/1OW
M$L'\Q<=P\E_&>C?N)8/YBX[AY+^,]&_<2P?S%QW#R7\9Z-^XE@_F+CN'DOXS
MT;]Q+!_,7.HT/);JB_\`*>C?X.__`+"6#\F__O%S4XVC?4-TWPZRA:QJ)"P<
MK[$(5JF,K3&B-,>Z@X8$==G4.\RC[Q&R]HA(RUZ<%^T,%[,"(D;/?1(RHB.^
MIB>2TQ.QPZ$B$&'2Z;OA7:U+>U@T8Z0KE^:,*314FI\,04?[(.$<])$_!]6Y
M_P"RSE-_6R$]4]R:KR\LK3BO1;.1ZTDLXN;_``[:M`VKW?UA':,"C$2G`E=M
M#!O09L"`PUPV=L9V^R`B4!V^(_*,TE<_%HQ"1!U)XW74H-T8>W+`[&VM7!S9
M6E:,U\GP9,HWL)0D\F50;EDL;]=RB(Y:5=H*4Q':R\XI[K%Y&:<DV&=U*O*4
MZ4JFIZ!L*"AY<('?,1\GOP,X++`#JIRW%1V0XEO)ZPM-59`#LQ-9W*ETUNGK
M$=`B)"8\5W;$6Z-.J;9XBT$SY>Z!HUR#<9BQX2:-3;$",;MJ["$)P!]IXC5P
M-,<9%-M38BY*;;D&P2>CM!VA1]'6@M@;WT=RD_'O5C;UOY.GIWT_'OX=Y[NX
M>2_C/1OW$L'\Q<=P\E_&>C?N)8/YBX[AY+^,]&_<2P?S%QW#R7\9Z-^XE@_F
M+CN'DOXST;]Q+!_,7'</)?QGHW[B6#^8N.X>2_C/1OW$L'\Q<QI70"Z9Y8EY
M1\FQ6*&3C351"[W60A'*V)&2Q`9[D2C;`MYDC<5:H]Q4*QHEIZM>(E"@4;>V
M,ENEK.QNJ3)=\C%E3:D44;(<MU79"MMC1)SLW21VDPXPO:G1N,6JT3YHTA=)
M#!HT)QI!;YM0D>!J=(Y02XI#G$M13FZ'V<YT`=`7)61%[#3L2F+(Y&GF\T?@
MB.:UND;7,2Y28YES@T]S1IBGO2-X=UKH6H.TTOR]S)VM$I]U?Q:R450/D$EZ
MX)TP0IY?'6N9&2N1.!TK+7%K#&B:KEY*LF2Q=6O4N(C%3(U.8#(R8D$GBRE`
MV$LR5%YJ2B-GP^)26&6(Z[E3DC=%YK/82B3OS@LF1#TDTJ-7.#8K5&+(8H;5
MPQ-XF>/JD[$0$ONJ,HVE,,"4NE45#K8KUIE42LEV]VJ8):)\9[!.E;^\+%YJ
MUG*;EL2,8Y*>X+VI+$P-*8E`[E.`@RA*K+>7L@Z8J9.[NM@<?4?(,5$TT)ED
M=.$-`JO@HFLETA<Y5.1+=N.-^T1:]2CGJ-*H6@3]K"J/3I$I!IVAC)3DE["6
M&7^X>2_C/1OW$L'\Q<=P\E_&>C?N)8/YBX[AY+^,]&_<2P?S%R[VE-;@$!`7
MMYKD]ST(_N@UJC4G2(1!VH-VFT2G62M:I`(*79`#]F*3-#4!-,+T64,!0)'Q
MC+(?ZTKN5+MN<F@D,D+D(HH@2]]BK`\+1$D:&$DK:MR;E2C99(3#`E%[,ZA8
M1CT`(="%TU1?#XFZND=?'.,Q]Q>HB)6.*.ZYE;5CG&1KTH4*X<><%*4U6R#6
MH@`2+!-9R02I*$*<_9A(0@U<>039?\:_'3_+*??V13/)VQC(0Y,_X.=\?YGK
M(_T0=\^/0'\`/\T/]6L[8QC-L?8A/X\[/_S3%?Z9LF?0KC&,8QE$DIYR6.OR
ME.:,@].S.IY)P!:",HTE`H,+-`+8@:"(L80C#O8@ZT(.M[%KHZ=:L8"3)WJ#
MM+\[6[=6U22J(M*9$L%:LQ+)97M[J^*RKNAT+.DK.U""YNCHN6)$M@/-$%E$
MCTDC1,X0%=\";R4QF2HD;D)59=ZHE3,@=WAR)46Q:(C&5L)\-_>YZ<M/A$/7
MF-JCW$1O9()PQT]"#=%&:;;?D`7#9A]H2VD&.ZVU)4UG26WIU")P-I<I%#W:
MUK2VF>HVV6+%5*"1"-;5)S\F:4IY")>3WJ9'"L@G$D&[Y&')PEB<;H98])G5
M(@.\)EY*CW\I(Z-($MK68FU($`FJIU[@Z-!;(5)C4Z!,HEL@&<"MF^^(F$`P
ME.EBQ4E!LU)^&F.1JH^K<T-IW@O.7N*]LCYZ6UK"[6_*F]FM16>W-1,?<YNC
M[K1*8BU=TCKIQOF1#[D/`]P>(&+7%,TW=#=RB-\CZ\:D5@6>^Q5S?[7C;DDD
ML[ETE8%1D;;)WM&V'(UWNBBHG1H&QMIXE@9V5,AF%"->ZWB!1O;5>Q?&,8QC
M&]ZUK>]_%K73O^36:O[.[,+P2J"Q9O5DYLJ4MLSKR3.D0E+>EJJQG5,B?&8[
MN=>F(<VZ/J$"\HHWX`*D9YR<W7]T68+7PY8W^KE=CH\J\Q]#5I?AG(3Y*]F7
MX#V/QUOROXI9LM7RB;TG;42C2`VH[,1@<)!)*]DC,R-^U:F-@2I=KW5:D1A4
M*S24A`CPFJU"=,`T\MQJ[,OP'KCCK0=?RNS9:@E$(I.I8E)4!51V8L`WR"-U
M[&V9[;]*TT;&E5;0.J)6C$H2&G)#Q$"-2*%"891YDV?ZN5V.CRKS'T-6E^&<
MD2I.R\<&KNLN%5)7ECRAUG%@OA4=C#<LJRPV=*L=3DJM:`D]T=&!,WH2]IT2
M@6U"Q043K8-`V/K##K>S36]"UK>OBWK6]?R;^'6<XQC&,ZC_`(`OYHOZMYI,
M[<<#DA=1:52J3N6^6%M[:SD??`UR(*\!O"C3F%H:FA:.3O!9Y'7"[&Q"(S-,
MTD#$HERJ(MXC%Y]P2!0?[D7S;>L5D:W8MC:C6VTQS<--SH&(<QMKSXL.-O;X
M"2NQIH#1N#15A]CRUN.":"0Q"-*T:LN/U*6G[T<=T*3-)??`E@3EA5F=R%RG
MWP5@@[X)E(),!H/EW;`AU[D&UT7V_HP($^Z=[J[4T@_%>>;IS?\`NE6J&FT7
M56GTI6<O2)%C\)LX-=QK9`I=GUJ:F"0%[,UW"PV$XP&PG#9G^T4$D8U`>_=M
MRA2HU6=F;=%JQ1L%1%BE@G<QT:1.0/`-+!(MS'W7/D2'$`%;UH:`ZY#:?(6B
M"$;"X/0NHL#:W*D]PW5ML`[N=MK_``+V5IS,VGE&UZMAW-^6FDB%U;MA'(&^
M.%=5.%$_2J+L5=+.T)BV6=//6;46MXS5_P`&-_\`R%'\OZL5\OP_7\.5#&,8
MQC,(9DP6G([>O!OJ&6-T,E6H[0YQCTZZT:B`UZ:;M(4)1I.]#L)2:I6*&\*8
MT.DO>E2$E_,T\DM!L6D$UN!5L3&DVLN-#5UG:BYNC&QF3%2TNRA@<$+HW:?A
M/(F-&O:WX"I$D7F"3-Y31IZ)6%IRU<7.4B4-E+9TER/5!FL1IKC%;D1-*N-@
M?GY^9%VEC\R.7>X$R+>FF*G(E[)(2D@GM!HZ%,B]:VK"T:YCC2XXSN#WU\3;
M2FI)%'9>)<EM!IU,XZCEBMR9B4$H<!!5J(]-(^J;F==IFCRD;BC*;T;O&%3J
MP=[3T*Y#)`HBG9]_"ETMPMT;ET6M=0K>9<T.ZX3;/"EK05'):B>T(7!`=&4B
M1K3N4<2L)QFVE8SO;2Z'M:PD>DS[+4G57&4BCT]V,"*71"ZC5DG=$25J?6FQ
M$JYE4QAT2.;*6WJ(FWIDS7'7HAZC2QG4*GU:O8PMS\:\D2%K4M@74^'16Y^-
M'^#O1?\`FBKO_15KR;\8QC&,8QD$V7_&OQT_RRGW]D4SR=L8R$.3/^#G?'^9
MZR/]$'?/CT!_`#_-#_5K.V,8S;'V(3^/.S_\TQ7^F;)GT*XQC&,9;\K_`+UY
M'\>_]H7GX-=/3_P:J^+J_P!UT_)U?AZ?B^'-9U4`UJN8<,!`S1I:"AVD99!:
MC:IV[=1D!VHU%NX60US'I*/7:G7P8#6A[=U=2@&EG4(!?0R"2VE0`H2)0!,7
M*U*,QN+:-I')8/WTG7;H[W@9!MFY$5L8M*]5]H^P.D0].I(AB,TX^R/$D[E,
M+"+N4!8I`F7"4&@;](RG'PC1P7>8_:EF*:-3+6][ZVEIQ%O=<!NQ%:-TI/+I
M,>(),:P!,[C3A5F,QZX2X#7HII4%Q_CSLI'*^_;&2FT\G]0.D/A2TGE_6[7I
MD+[8$@M%^2DHLV)R?MX"T@EBY84O+<RR^W-1)4;OD)2J5ZDK"%7IK4AZNV[=
MHDEQK8#B/<^:80)"6NJJ<LO?+*KC]]I*4;E-TD:2J`I`N^TI:"TQ%+>E>@22
MK;(IWO?>[>CCX;L>C-Q\9QO;U`]B.,8QC&=1_P``7\T7]6\_G4=D._P[^8'_
M`.(6Q_\`\UUF'&,8S.WL8G_&"\1O\\*#_1N39_0P+_WLO^8'_JZSOC&,8SJ/
M^`+^:+^K>:05Y&C;LY-$JB-JHTKY;2SW5-IB0:YM=5*.GN%AL8,=6E1%YG&W
MP;6L%VYK,E%57.I8U`1JXV[4VKUN1);FGA';XK<FWU(>X&.#U*$EA]U)3G(<
MEBA4(Y9A86E\$]0RT3)<V("2VTI"RSXSEU%VP):(ACINMRDS6SM=<EP'#OR[
M&]52)S,DQ;4X*^UN8E"FKO#K8(=18Y;W"H<E47TBZQ>X.OF<JK':<82M<,PH
MM[;EOB*)&3)F$QK3J$C@A@4(1P=4G3J49[%!U#5PD[^1]F6-D5AJZ--*W>U?
M=T;ADPXW0QRZ%87OC3/MC6E!M0!(TM9(`QA,:UZ:JK>A54!M0J&3<25'45+=
MNHXQ[FX53?N&.5[V("TRKTG"-6Z&BT)U6SXS?<JJQ.5*5KU1TV)TV%ACZ:*W
M$X,*`30AT@;9N;,.7VG9_1-VZ>)8&=X6`&?M5*&2NJAF:\I0(#KR:G12HT<J
MWPM/_!C?T?J*/_\`U2OH#_5K^37Q94,8QC&,P:GGAA\+%XZI#;?J:[C]":WM
MV[S]Z],^VRZ]+]JN^VMZ[HT;W'ME[DUO?NA[T=]];B_?_63@^/5HR*D$;S6S
M<ZM%H+VR,FMK=/VII9%B1R"Z-I+V7,6LX(42-+M*4YF.Q;)K:H2,8C(OL2H;
M=O*:W/-M/5`'*&YOE3;<J-B4-':90UPUJ=E$T9ENFY4X'D:UJ#J61Q5)SEI+
MBS]+2YL1W=K#_KIR+6O=7SU:+Q3ST7*&Y]06XS)9>RK#%#7'VTERE20M8>U.
M4-&>$,:<XL>-6W%1=T<NDE0E3@*E'0YIWG6O/23U;BZ(R1IMQO=TUD,3JX%*
MUQ+4QHXNYEN233@SCK]Q1AT@=V)&6,*0LQ\%M\1+`#1R;_9(!"%2:)?KC4-,
MKC5Y-;T5,VTM$[IGK30PD1!;'G5H*3M[<TO<:Z&U?)$"IN7GS1N,UUV]]6*#
MF;>X@MC/1='&C_!WHO\`S15W_HJUY-^,8QC&,XV+6M]&]_#_`";WK7\N]:Z`
M]/Z.G>NG]&<Y!-E_QK\=/\LI]_9%,\G;&,A#DS_@YWQ_F>LC_1!WSX]`?P`_
MS0_U:SMC&,VQ]B$_CSL__-,5_IFR9]"N,8QC&6_*_P"]>1__``%Y_1T__P`-
M5?HZH^G^3J#Z?BZHOBWK+J@)8ZWB)0NXQ;<:%AXA`.`C4%+-)J/@80[D"0:-
MZ#,-$AV$*';I&N2NF8C_`&,2;69(M-1]^&G`/:59G;0&]W$RE"(2Q>0YGJ@E
M>^E_V,\K#YA/3)0S%Z"/1,7722_$*+6C0@H6*]0XI)[(^8`,IAAFC`=(7U.U
M!&2L3DJPA\(L<UW`F7`DC:>FCO3KH#!298R-H1:*!KB64,DM*W4F.FEDMA0M
M&EE][ALZ4(DBY.W#1]NCW'G6R&`U/+(9N&MIFAA[J8FURXQ)'$&P!-J2:!,*
M(7_BI$!/%)('0DQ6FU>O/UI":D:"$0CXU?(MFL1"=?7!4-7FZ$+:QX;VGC&I
M<][5F*+)G>E*E:]55*()?+"K4NA!#O4INI7LA,>6G1ZV>WVEK:@;*0[LA7?,
MW8=Z72`RKMJG06M`47#/1E]RHMB>,8QC&=1_P!?S1?U;S^=1V0[_``[^8'_X
MA;'_`/S768<8QC,[>QB?\8+Q&_SPH/\`1N39_0P+_P![+_F!_P"KK.^,8QC.
MH_X`OYHOZMYI`6&D$\@.0"L_N()#?RRL32A2XZ0D,B03C2W"@A,&0/K@H8F>
M/J%9A82V$A]MJECWQ5HI.QM5Q*=EQX-PR[N=/$K``=IL([TS*=+''3UII:-M
MJ=3"N8`R5<\"];KG<,CQX%&MM,@G";BLP.Z<THQKN2R2%@7&55:7Z)[X+2=E
M%=M+M8$@&4-$1WQ+;-7_`&$9WT7(!L(5Z.`=&]F!GBV(QF"[*[:J#S-$`!S^
M7YS>T'/HB2]-YICFP5NO1%MP&UP7KT:5JX-[-71%$WDR]?*8<0$G7?.612*<
MBXBU:`#OER)KSM!0F:UG0:5?64ATF"V*]/M2+0-FF`MK?"G;N.AY:6>"NML7
MAA)L`9/P]\B*_P!\TQH"NV=\&B"$:-*+M'E2I2:J&QE';8]VM76UJM:50%?'
M=M)ZXB:\O#34#"\@FNFMVF1/4.VY15CLRSI>W#TOVX\=8082N5-6]EJ_X,;_
M`/D*/Y-_^C%?IUO>OJWO7T[RH8QC&,9A#,GZU(];UX+J?BC=,96..T.G&S.P
M@$(=M@FF[3CU9BP3PT=RFI5I#>-,7UE0753LE@.VS)W<Z4Q^:E]@S1^I-KGU
M5,()3,'9NC"MK87UF<8H4N4*G5N1/Z9R;G9Q3.,9*3$[=1&*#5#P:T`("L(2
M2<!)29QIC/8U@R2A#9C'F`:ZV$+2K;UL77Q)6PD[G[$XZ:)`RB8'*7!TG;R7
M1.N3EKD<V>6W:0&G5I>I&D"1I?4*_L&;2VI9$\KV/2&UHUJ9LCS&`1]<0A13
M9D"K4-S.V$N+ZF3RIL&0H9`I7UODZ)KDP#]J@+(T>>K:V3STO8L^F,;ER2PX
M\7&;.B;NN2.\:0L:\#2@)7H0NL6"TO*EY5-TT3JFTPHPQX0.+,-0=O:9S8XJ
MMT-$72:0LRP9@BEL:MZ-@B%D,"1J>#6)`P.2-I]R;^R%!:',E^V\R1D<G%<\
MM\A[Z,J-XTOBB@K3$K3NB-&W3"47-QH_P=Z+_P`T5=_Z*M>3?C&,8QC?Q;_3
MGS"\V;LM)4\=GBN@R;R6+RKL:M7<:@\/#&]Z<F5L@4@2T2P\II3+DK<0K2M3
MPON2<2AOK6?C7H5ADHK**IZY,6&L3F[-9_TMQ9V4/T:C[VK0F-BIX96EU4MI
MG7V8WJ')O3+CD(^VEDF=9&:H&F%VPHL?^M;ZX`"Z0ZQ,LZV=EVQ2NO!I;0_<
M_-[!*ULN%];3WU:VE[9HR/\`^V?^V90NV=\`CUVCK-8#%?1KJ=3<L>'4?D=O
M;T=;]M8\.H_([>WHZW[:QX=1^1V]O1UOVUD:7/9;Q.J@M*%,--7>8^2ZO9C&
MF<"J!!2)1N;VP+VU"%0J,>=EIR!*5)>C3Q_W!0-[,%TZ#O6_GQ#PCY9Z"'6Z
M&G73K6M;_P!:9_T:_P#B^<^\CY9>0>=?_*9_:^/>1\LO(/.O_E,_M?'O(^67
MD'G7_P`IG]KX]Y'RR\@\Z_\`E,_M?,\>Q_55=G&^SIM+++I"TDK2_0(N.MXV
M5@0O:@3D&1MKGL!J=([Z&43W(E.%VX>]`Z^@@_A"UK>V?PZC\CM[>CK?MK'A
MU'Y';V]'6_;6/#J/R.WMZ.M^VLICMR/;&%*4M>:LNYM2'.#4TE*%-=F:+,<G
MQS2,S.B#U'@8NW.#JN1H4^MAT#9Z@O0Q`!O8]5/PZC\CM[>CK?MK'AU'Y';V
M]'6_;6/#J/R.WMZ.M^VLI3[=*AQ9'AO3TY>FSUS4Y(R-#KSJ`$<I1'D$A$,3
MUU0A$88'6Q"Z`AUO>Q""'6Q:PVA".P&&%(6!UIRY^Z=U7$HA(TR2&]UA<GEB
MJ^+1$.FOKS)`C?B$3FT+2S5+ZJK_`$F!L!C6)^)-VOW=ZIRGZE,[@4U/<RA4
MZ-;LW.9I,3<%93BUJ]73I`W(CUKZS*'5:3J?1_MS4]HH:RI=EJ`I9BMTC*&F
M_9H=9V@D$:=1U)<X>]!9*0TWW(K=`!&RY8SO7>79P)"J4A=.X$!@/<\4UKXO
MHP/:=6,,O0`J?$QK;`;$K04&I[E(/:DR9*S#,B:\@#2W@::J0K4;@8ED#N8R
M*E!L.>^T-\=*G[6KT81M9(VS2LTXW\`*)X5'QM:*HKH2F$N;@OCP5$/4HMM*
MI8TVDC/5.06^6/A;$0I4S)M$4LCJR=KU(!"-6L+.,)FFKV$.$Z)NN#SDNG[E
MU#V&4V@^.*0R(&E.12B7H)L2D7D,P7QR;SR%9C\V$Z6EO"=W,#H[N^-,9"<(
M-Y8^'4?D=O;T=;]M8\.H_([>WHZW[:QX=1^1V]O1UOVUE.>.1K='VES?GNJ[
MO;&9F0*W1U<55=F:3(&Y`0-2L6'[+>!CT2G3EF&F=0`Q:`#>PAWOX,J`;WV(
M(1!IZ]1!$'0@BU76^@01:UO6]?[=?%O6];^7.?#J/R.WMZ.M^VL>'4?D=O;T
M=;]M9P*]!["+6J=O;IWK>M?[G6_TZ_\`C6?(=RX[&=SCN;E'R#MN#\?Y,HAU
MDVW,)E%SW-P9&IQ.8WM?I0@,7-JAPV>@4B*^$U*=OMA0O[D7PYCO_J0?9#/_
M`&>7C[?CW[_C_4@^R&?^SR\?;\>_?\?ZD'V0S_V>7C[?CW[_`(_U(/LAG_L\
MO'V_'OW_`#*'A1V-SFY1'+*@;CL&@)0EA-<V&DDDG4-*UE>'(EJ)9WE"8-$U
MI5^E"X_1ZXC6DY.^OL&QCUT]3>M_6N"]!A`$.Z=O;IT$.M_[G6_CUK6O_P"=
M9V\.H_([>WHZW[:QX=1^1V]O1UOVUG`KWV$(A"IZ]0A"'8A"W76^@(0ZWO>]
M_P"W7Q:UK>_ERGL_(UND#2V/S)5=WN;,\H$CHU.*6NS-IE[<O(`I1K"-F/`!
M[)4)S"S2^N``M@'K8@ZW\&5'PZC\CM[>CK?MK'AU'Y';V]'6_;6<"O0>PBUJ
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MGCX>/=ZR):."[CFC'5A:W<BRUY]9/L.`7*S+#MV6'3)&T.KFG&DUR1';Z=`C
M`89%"&(T!(BZ#=T)NZPX--XM'Z,OD+J\P*9-"-Z<D2M(-^62617FZ-T,=WG5
MTJY@MCC2ELR.[TQ3IVF%.-I[>MW%ZW:Q(&,#?M+17>:F1I"#*=O7KDI4Q0^K
M78A:ZY9!98^@6WK73KK!WT;^'IU^G?Q[]7AU'Y';V]'6_;6/#J/R.WMZ.M^V
ML>'4?P?[CM[?#O6OAKK>M?#OHUT[V]=&OY=_!K].4MFY(-<B;P.K'5MW.C<8
MH<$@%B6NS-DB5-3BK:7(C77>`#T8C<D*Q$=K8=:[<G,ZFQ@ZHQ53PZC\CM[>
MCK?MK'AU'Y';V]'6_;6/#J/R.WMZ.M^VLQ1E]\6!`[*LZ8Q*@;C?UDM8*E;F
MEN<JSF>TIY$=)L9,]'F.4=1/2)":V+Y"Q+3$BP\"AQ:"'<AO+&YB;0'R5).7
MSFCB!RF,47?;Y-DR9M-"T+:,M-H8G126H2=^4B)W4,@CD6STW=W>12Z$ED!4
M=QZ==D%"/$#\#^7+^5`]&$TI=2JRRV0@PQ"&AKB(A*F0@`68J2)7$^/]^B6L
M\>CDR%6K1!.*,&0<M++("=U?U9N7;L?"@GO5(7JW3\]J<3]-:6B;97Q="[G:
M5F,Z!4Z!8@KE*9*$2!,]K$"499J@MP.:-')1(QC_`#A?+Y[5QKNJ>47>C%*U
M)R\TIH8*-M=[:VQ*8(7>E(XNAC$1W8XD!ZO?@YH+-;QCZW>TTT/1O?D@_+N1
M+XZO'9=$7@R2`Q4J3I$$2I"UWIOVWD(4Z4"U0N7,*;8#7)R`O<$:4HL1B)D4
MM:5SV6\E.1!-RTC:3I$*;JF*O%-7F6[1RNH:QN8"J[.$6!>UL"!&J"7LYT3G
M=0)Q(]![<02;T?[X44/K%AE#PZC\CM[>CK?MK'AU'Y';V]'6_;6/#L+7_J=O
M;T=;]M99JOF13;2J4MDB,F$9>T*@Y*XL;Y#W1.Z-YY1@@:`J)3[5DAV:7H"@
MG9:@S0TYQ1G2'8MA#E9C&,PJNK@-Q^OB93*739MD)*6V&JIF&^(8P.Z5KA=_
ML5%S%1.JF:;7:QM*QP<D\0?%BU,-1&G>+.,MB:LVOIXME$"`GC9&:FM='_3O
MX?IWT[_Z?T?%KXM=&LMEXB+.^/D3D"XL\3A"W%T<V41*@9)`%3PPN,<6[5$!
MUU%98FUS5!++,WK19^RSP[V(L.LN7J`^:'S=>K'4!\T/FZ]6.H#YH?-UZL=0
M'S0^;KU9QL(-:WO8-?!\@.G?]&M:WO?]&LYT$&]=/4#\/RAZ-_5O6MZ_IUCJ
M`^:'S=>K'4!\T/FZ]6.H#YH?-UZL=0'S0^;KU8Z@/FA\W7JQU`?-#YNO5CJ`
M^:'S=>K+=E$4:)>VIVIX+.$D2OT9D904QXDIG?*)R%LD[0(1A>MB$0!T:4@E
M!&_[A2GT:G'O0#1;RXNJ'?QA#]6O5CJ`^:'S=>K'4!\T/FZ]6.H#YH?-UZLZ
M_P"M[^(.M_#T?P-_7_!_@[_0+^#O]&\[=0'S0^;KU8Z@/FA\W7JSITE=?M?0
M#K]7K]3>@Z%U>G6NMK6_AV'IWK6Q:UO6M_!O>M_!G?J`^:'S=>K.HM%!V'0M
M`UUM]4/3K6M;%OX@ZWT='3O]&OCW^CISMU`?-#YNO5CJ`^:'S=>K'4!\T/FZ
M]66_+(NTS.+R*(/19PV>4,CFP.H$IPDBD3>[(SD*P)"HO6S$YVR#Q]J.!K8B
MA]48==(=97@$EE@`6$.NJ6`)8>G6M[ZH`Z"'6][U\/1K6M=.=NH#YH?-UZL=
M0'S0^;KU8Z@/FA\W7JQU`?-#YNO5CJ`^:'S=>K'4!\T/FZ]6.H#YH?-UZL=0
M'S0^;KU8Z@/FA\W7JQU`?-#YNO5CJ`^:'S=>K'4!\T/FZ]6=1DEF`&6(.NJ8
M`18NC6M;ZHP["+6MZU\'3K>]=.4&)Q=IAD7CL092S@,\79&Q@:@*CA*U(6]I
M1DH485"HS6C%!VB"`=M.'K0C1]88M=(MY<'4!\T/FZ]6.H#YH?-UZL=0'S0^
M;KU8Z@/FA\W7JQU`?-#YNO5CJ`^:'S=>K'4!\T/FZ]6.H#YH?-UZL=0'S0^;
MKU8Z@/FA\W7JQU`?-#YNO5CJ`^:'S=>K'4!\T.NC>MZZ-:^/6^G7Z,MJ(Q%F
MA3&5'V0H\#<2X/KD`*M0-6=I3(7YSD;CO9YNM#V6)R=E@B"^CH()$60'I"6'
M>7+U`?-#YNO5CJ`^:'S=>K'4!\T/FZ]6<]76OBUT?R?!KZM=&.C7T_7OUXZ-
M?3]>_7CHU]/G;]>.C7T_7OUXZ-?3]>_7G'4#\T._Y=:WO^G?Z<=0'S0^;KU8
MZ@/FA\W7JQL`-ZWKJA^'_P!W7JS&*9\1*>G<H>9>_I9*-X?E?=J\2.2KD:81
M_:BR>DE,4'99(>H4'^X#OHZW3OX]YD_C&,8QC&,9KS[+6`(>Q?=D)<@",(<8
M[PRY*2I@<4QYZ1Q9)-%ZAES['']H<$IA"QL>61Y0HW)J<D1Y"Q$M3E'ISBS`
M:WF!M\]D'Y`<245A5E3E&T=)X5QB[%S`.?:ARF-C3J-N<AA$4?9"Q657Z1HC
MT&>$B"7.C-!7LV$.YSDN:AOB\ATEA^B-&-BF1#.>G(XF^^R(GL[13;K4G&ZC
M>$TSJV,SZ8[JGN97R)CLWD3Q()_8;PJ6QM(6TCT8K?B4A8CW1IB$>BD+1#E+
M\>L556I>R?S6T)(QT,3!XHU7U+.=W)#AK&Y&\M<^C<`W'N.-*%\A9-<CQ7<A
M[DL1I=%<"<&5B0T\MDJ1Q52M<:MW.T<91J%H+JK3D_S0E'/VB^/5IPBI:K9W
M#@O9%Y6]`662NT^-*L..<F8A3XW&*SQ"2WHW-E4QC;?(X<U.+.VKF8B:2!JF
M.EKVTH#2-O?\N,8QC&,Q'Y]79.>-O"+EQR`K-F*?["I;C?<UH0IK4I#'!$=)
MX3`7Q_93W)`4`9B]J;UZ(ER=40.UB5MR-2G[<1HS9P,4>-?"^DY[P?X\O,ED
M$ADUGS"N*,O*9<JRI8OW=EC6`O3PNWW^7/EH%N!CR[1&92$!Q*ZOCG4^M?<&
MM!!4,?(B"5"W)\?GCLG'+1A)Y&64MH?CR.D..7/V-\%)`6FMRS#K1D+Y8%Z\
M6:QB,Y9$`ZR3Q0EH0QWD(\/,E1.+FG6`?HHA:6HA0U.AKP1--F=DIE]>./,U
M"Z56:1%^)7+*I:'EUI1:+V-<*&%U39W'6N[^77Q/JK@#<5/EC!!S;`;H+*$,
M,6+2FT"@JP71<V19M?2$.M&U^85JUQRGM_G=3L8XY6FZL/8/(%R>L;4?M^2N
M-/S>$5=R;M^120=6S:,15[62A\E4!8%K/`7EY;V1`TKBVT,O"<0@-9\VI2;G
MO=$EM231'CAQR>;@;*BM;C/7EM,G6[UOAS3?,%K:U9K)8_-5#X@@D95TM5MO
M0F:#89:4M!9PTDIC[2\Q)4B9E[UAU<7(.3\J;G[$K?T=00MMH5X[*==M95L<
M0=)!6<ZHJLX_\VZP6R60&F&IXV7&["DU82-]2Q(+86[1=M:X*K<79V>'-Z:8
MQ]#A?^]E_P`P/_5UG?&,8QC/S-"(91@`&C)$,`@!.+T7LPH0];#HPO1Q9I.Q
ME[WUP:-*,+V(.M&%C!TAWI>XX]D5%!*J62;EG+IU.'ZP>R1\L^$-.FP&E3W?
M1ZVF;MMRO:RC[F@K*.[+32"51>L%"Q2Y.@M;?Y,,]*QMZ0CI2$R^T]E1J&;2
M+A>QUM7=PR@7+VS^0U6"1KX,?&914$MXPL<RU;D.LZ(OC@B>8_.(Q-8ON..#
M,,L]O(:T<BDP'=0WM[;IWO\`BG9.N)TE5S;OA*9/!8_#:&EO*`J8V#"WJ+QN
M6<?X'/7>M)=9T5&<!2]G-;/,6C3:!C?6*/S)Y3.\<>8]&7=ED30O56+;W91J
MUK!,RMP:AOE7/W#DOQ=XZN5>O5<+([(687*<[OG`)WTK7#;4]1]RBK9)@I4#
M"ZN$B;)\U`KV<LT,?^[R4.S9`J[N1(UO<ZI)W8E3JNY5Q/<ZU-W02`[N=61U
MA]I4D]?M2@KKC[6<`8.L+J]._7C&,8QG&]]&M[UKIW^C7Q=._P!&NG]'3OX.
MG?P9JJXT<@;BYSW#S+=879BNE^/W%KDC,^'D#;XC$X,]3RS;3IQJC9UUV'/7
MBPX[-V]!!D4UD0X)`(;$VB-NZM#&'B7/LK6ZD3.UL-QM'.(RBYI6W$SD>CLF
MXN7CU!R;"?CN.7'"R'R".L$>KS)J-LL%-IK*>&V+1F/J)/"S)^!9(78$`1K%
M"^0/*E.08N.O9B[)GQ&?8I1T[!.GMMA/(:G[TO*MI0\PB4-K4KK[C:VD/-RN
M#X(Q"-5&5D0:%)3D)O>4B8]X2]LVQ[<3"32R\9>8G/66QZ*<8IQ4"BSZP1.7
M/GA?4EHL\AJAGD1]F4KR'7$K%*.$C0H9^*2)Y)'W!MVUO%6.9\E0OH%L34Z0
MR%,X-R'(Z+=DOXX3*KV>PF'5A&/[K*;K@IM,O4.#$+L9IKQR4*$UVQ=_@TQ>
M(^G:'>`FEH0+25+[HIY4R&)-L7.?7:61YO<,<N9_9.H/KL?U\WOPSFDHFLX(
MX)2;EY6L^@%?()@VUK$WN*RE;44_LUAG28E$S-<CE,2?VH^+.K&[2Q&DB,^<
MG.*HVR%2!Q;=L-;.S@_U[!GQV/TJ='B'19U<E.@$E:4+W%@;EJT[1:8($X-&
MJ3S3.H0`)(.MU2@A+T$.KUQC&,8^+-73)R-M;DOV0'DSQ1JV;CI^I^$,$I`R
MYIDQQV*/MG6)=O(F-OD_B<,BBJ>,LPA\7KROZQ;&E[E3H=#':1RZ53!"S-#I
M&FV*NNW_`-\QYD.?"YU8JQY6.-B7G95RSJ\%W&]#QTXXS68RB;5I5L$;;`#%
MW:-P-$Y-IML-,92214Y(VXY&7+QMJE\8F)@:CR&1LEJ)=D$XXS-/3REJ>)BG
M+N[DC:W$B&@=Z_E#2H3W_3!5E'3R!25*K1@4QL]N#4%B`3/#B4%B7G1PXA.X
M]N6-P%>%?//LBZU+P#Y'WQQ1DLWA$CK^JHM=%6W$OKN-R"O9Y!U%N-L$<'*+
M+WU-+H\YE+R4SXE7,+LW,M@1Y&K9GX^/MQ+FT&KLP(UV1;CK)/"BV;43V+3>
MJ;QCW'QXK.Q8(ZUE8+O84ZC94XK4$>89Z9'B5$<L6`FFSF-2EW<6-E311M?7
M:5*8T"//A;?2&/LB5#6U6;)(*87V#-Y?.2KZ9VN!0J#E.UK0UWXZ/@X-=ZZ3
MPY\5IFEK#4DX5LK"Y=\'%:WRI]D$0:X,&:[F$>+=*SV,*ZK&Y&]CUX;7O;K\
M5*+.MOCQ6<_G<A(:6EB)>9/)8^G<79Q*96)$W,[46I4&B,`WMR!&E2AWHDI.
M5H.P:SNQC&,8QC&,8QC(@OZD83R3IFRJ$LOOX;7%NPY^KZ?MT=?%<:<WN%RI
MN4,TFCX7UMT%T;4KXSK%;8N4-:A&X:2*3@)EB88NV:QIG/8Y..MD^[L4V\([
MZ=9G$4'!N;J#K#>$JA]XX=WNKD=#C34!27:9W5J7Y[VLFZ'N:9*"G142-Z[7
MLK15!LSL7G%:U2K&'(D%FH'2U:VH6NIF]QBVYQ&UKB;Q>E*29\?K$`C;7$M@
M(M:JI"A2K(W/`LHG$PHK2!X)<T`AIA6\X]B=XMKF>?I2'2]6>4SGD:AY;(;-
M9+SG;=9=<<B2H8D@3[9E52@M8/W#N$YC93BV6`QHD"F)S)L?71@>6`Z,`:&-
MIR!CO"FBHM:-0W.RHITFLNFZ\FU6LLJ-M*P5CA+H;8DJ;Y]+6^T]+9`H*M!2
M[6&VD3\QTF0'-Q+EIBMT*4ATK/(%EG_X^7^O&,8QC&>-P;T#L@6M;HB2.+:X
MI%*!P;UZ8E8B7(5A)B96C6)%)9J=4E5)S3"%*8\LPD\DPPHT`RQB#O#RI.#%
M14G'FRN8*_6F31D<=PNL.X_/-@KY!4L+()5A<6^+1QN=D:F6DUTR.&NZ(Y5S
MG,G6N8VG`D:&2+H6!L:FE#19#V.[CC**GY*4V[(9T**<I[H%R+LE6BL&0-<G
M;KQ)>8/)&:RZ_DK:8D<X$_QB2UG7\AC)#"84S,[M%&X\AJ$6>Z$N%'B'8XZ6
M@*Z:22&3WD2Q6!8-NUU>LMLG5ZS%YE[W:%:T^"CVF0NFY()ZC;HE>X$':"91
MEVC:^*RPP"$#NR&MK)'VQIH*CL5G$,UDGD;(C$O;6.S>,$IX@3EN:9X^-B=^
MI&>3R96A/&@[23J#1R.93^Q9[)WV:MPT<H,5RQT2(7%`T@;FY!5G;L9O&QTN
M^+WX2JN2/2]LC=9Q>?L<.NRPH=77(%OI=.6FJ0[D97<:=FR*W&XU^224F9G"
M3-XCU[665'Y+W]C9)3.#RI.Q@\9FZPX[/&E3<3*WPODR]<OH)6;-<TX:ZJ@M
M]RYHG37/Y;$8:C7%`96RP3K(F;U+(60X;A2E[D;\L:V!I)D,C2O&Q/6M:UT:
M^#6OBU\GT:^CY-?HQC&,8QGYG=LT49LD(!':`+9031B`6(S0=[+"8,`#1@`(
M>@Z&()8Q!#O>P@%O6@[TN1GL:=R-L0IR-O-IUFI4U?V5JR^R3*UK9&9>F)>F
MJSIU=D]<:A3)E;DI-;W%I<+L<FY'.35"Q(K1L"(Y1$R3W!0!-VK?L8ML5[-N
M/UDH+HK_`%*J0YT<[.49J0^OI$YL4@K[G>KLQ5+H*G+'+&I<U3.NPV)HN-2D
M\USCKZ8S:.=XPD`OVF28U`["O?%F=_F_D7R4@$M-L3@_>_#BW;4C$$F@;GL&
M02^[V"Z:KY'+W^0S`QJ%.&I^8&4V3P1P3.$+86]@*AE?'(H@Z(DL1S5LCA_S
M0Y$4W6"2^;ZH$F]J9Y(<9>0$)5UU3TX3TVO=>.,Y42=<9)6!\L,,Z$Y6ZG7J
M]/13/)$31!=HV!L8TSZ!$\O4@VO)0'%)DY:DTL]0604`\XHD2<HTX!80FFED
M".4")+,,T(8"=GG;*"+1>S3-AV,7[XQC&,9QO73K>OAUTZZ.G7P;U].M_HWK
M]&_T;S6Q5G$.W^*MY<E9AQJE-:N=)<LK4=N0\UJ.T$LL:W*K.0\J9F%BL>=5
MS+HH2\%R"%6EN/MDKDM:R%F8UC3.P/;TPSXMLDIC(S7A'.)UAMW..'<MI'9;
M+*4;'Q#EO&Q]938\I:GMVD,NNZ.W2IF+8<C4&,S1&VDZ/%1!DB!Y;FZ$,YB=
M<OEKBO1G!<=?%-=BEY252'BO'M7_`$`XQ+A37_.RIJ6-4TK,75WE\3Y1QEO1
MU[(+5;7>?'1E5(88^H&\,T8&=$9%9*PMSD0C"6?*"2HA<L:[$K-(K'X6P0>:
M5U44%BG-7B?RY:N/,(\)#]0%>K^.ZUQ>[$:J/8I0X@<:I1<@9(X)W=;"6(@-
M<U=IF0A8623.KA(7MT\3KV+3DC$9*?=%,W'Q^472U<MN;%WLT5O"HI185#2J
MGN<DEKV5SJJIRP-<C8IDDF=?R.K()(X19\1>T`5*MF7LSE&4[)(G$H%S7GV,
MOD;,&GE0S5W?51[(YV<$6?B5R3'-:KD#0B8+!@T'M6&0RX:48H-)@-T=C2QC
MMMZC+O4[T-4!K0,,5D26:OKTGD"&2;B*QCCW#ZY@D4DCFUO,@C4/C3`\NS(V
M+&9G<G)E9D38K7-C2X.CTN;4*HU*(Y.B5N[DH3ECT6:M4##L>[YQC&,8S72Z
M<0[(JWF?9O,KC-*(.0HY*P:MH3RCIJST\B21R<OE+H7MGJ>X8-.8LG>72%S]
MBBKXI@4N9W.(R>.3N*(XR,HZ)O4:$O>_=.>)]MV'R2X4<AI-9D35K.,DWOR9
MRJ-D1QT2('I/=E,J:<012"'%JC3V5LA:)3N1*'24G/[E+7@2_I+C*1<F3M6)
M$:[&9R)CMO5DJ)NZFS*-ICLGET]D+A;4;6<V,M!]0<BF;D0=8-;2IX!.$\52
MKXI(.03ZB@TD96S21P:$3:Z2-I"N;CV5]C.7=AVLV85#RM@;38]14J\<JJJ:
M(99K'3L=L%NH&P;A3VQ'[`=>5#K1"UZ3QZN;7=8VPGPQ^:ZS6)44X7R%WF,S
MD3B>DCK&SRG>W8Q;NLBV^1?(.!W)5D3M6:<C.,/*&D&>95T\V%6+++^/_&R2
M<8)175U1XYS95L]KNVJ\FTR3JET45Q*30AP=&QY9Q.3HPICSY,0<*>4\?M/C
MYR:8[9X^AO:,5%</'^]H8BJ.51+C^\55<,\B5FMQ5-L+'+%4MB4AJ&70MN$V
MN,O<I&IM5L>9.1)G&&GJ&$V.Y4]C^XW2SA_PRXX\8)K,([/I!155QFLU$NBT
M?=(RS/:6+)>][<K(:'EZ?G`@_:(!(%AQJ\):M4$U40A;B30(B<P\8QC&,8QC
M&,9A/S]8>7#AQSE\DX261J$W_7Y`)S&8JX,=>N\=N9%&CB79_I]V<+`B<H30
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MTAD[<^[?95*4Y!S[$X,U3B6UPP.K,_62QQ-`YIA;V0ZWK?PZ^7>OZ=;WK?U;
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M_M7'B$4A;-R3J$5*=(H1!Z5O@N4F1JXEKIW_`$+@Y0B/`AS\9,"&-H<YD@+0
M+Q,L1D`660":.SKV6#CM&6"[7F:P;D-"'&@+>H"IK`ALAJ%5N;`+Y2/C1'J"
MLAGCS(^/)KA75D.CP2C;5`STTT:7%*O9)+"&60D!:#9#KGL@]=6>79K5'JDY
M`-]DTM:9=6V]3TKA,6B=AUL:XP)99\6G\LT^V`BA*&K)Q`TQ,BB,X*FRE`XA
M7$LZDE#(4;PTMD4N/9=..3=0K1R4'`>0QU1N-63>^5TH\%R-O1Q^AX-8#-72
MNWW%4]2UL:W*,R5S>2I!7C'$W.26%8\"2JI]"H4\Q02!S7[3"S`&@`86+0@&
M!",`M?$(`]:$$6OH$'>A:^C?P]&_@SOC&,Q1Y8<KHWQ<8ZM3FQMUL&T;]N&*
MT'1%7L:U(UKYW9\M1N[R64Y/JXI2BB4)B<4CLDF\_F:U&X%QZ*L"X3<T2"1+
M&*./$9'\U553\BZPXV\J8G#ZI>KY@=DS:C;,BEA*)95DR<:8:D<FMFN)"Y2F
M)U\_0:=12%.!4]:#71H6Q*90IMD;DCD+0]QYPC6LJ3+PI@EI$_FVW6);&"))
M)Z)Y,G\1`U!@Z]SVRH9B)Q$\:1!BJQX")J2R+9^F92Y:VA)6C5:V5D4\F.9W
M'SBC24^O>T9TV&Q:!UX"R>\437M$CF\R97%Y;(K%$<"C)#F0?)'&=39^CL&A
MYP#TS&Y2J0M#>I>D)2@:DJW&JZ>4Z%13"N?<76%M9K6E\>C<K20BXSII**%0
M/L6?7P3S9:116L>8'],TO#6VP]^.KZ0/2%KDKZFVF5O$72J97J?&V[*=>%DP
M;6JUJV<G*O$9KA8#<WSN*K%T%1)SEB<]7,4B=V,/C"4@]N<"#E+X6@(*.0K2
M3#`FI%`"XSF/,WBK!ZWMBV7GD%4"B#4?!FJQ[1=V2QH<_P#N0B,C9QOL.='=
M,T/2L](&?-X2Q5^4>`HR<'*49$8TYF*R-#`Y(Q4V<)C0SFAB*6\!3G;SI-UM
MV,"69M>T4O:V(#BHA@TFV0NJT[:I<=/5G*)H0C:98E21<36=M88X)I;A-L5=
M92J2HJ[LB!3U;"US>V3!)"YC')4JBCD[-*5_:F^2IV%R<#F)<YL2U$]-R1U`
MD4+6E8E<4Q9J,\HX6*9?+J46?R%O3COQKKR,SIWXQ%PAMO&P+'G3M`*]9;&L
M.,%3F,U)%5$;@EAOLJEJ.$JV>3SYVTUML;@J&31U`!3*)*H=X^QXXKNRLHW&
MIJZFT"I73G8SGSTC/8Y+LIV=681"WFA^1;U,RX4X)G>2QR#6,T3*)-QBIHE[
M4_QY*3J65])8Y(FI,0O6JF%#E5Q)YB-_)F1\E:S>H$XUA<?$NZS:3N"'F/J:
M8QHUR<(FQ6!"YA`9ND:V$4EALSA$E:G5#M[C42E;.O`Y-#_&$(DR):YYH8S&
M_EIRAKOAU0\RONS"'YT8XP?&6-GBL21)W29SV=SV4L\$KJO8:V*E:!(MD\XF
MTA8XXU=WKF]H0F+QNKZY-C(WN+BE@69<S9YQ^FG'%FY75+$ZWA7*"T&2B(?/
M:\M!;9#?7E\S1L<'&MZTM1&\5_`%)"*Q53,YQ&,V##O=$P%V!IMC3XW,[:^,
M\E5Y=HKMIQR2I5S?:]:KD2U9*&]&K23R)J4RI?"$0W*9(4YY#N84>LB3>68N
MDR4H8SV!&6-4[EHR`",U0Y9R/H2$5VHMJ3W!7+;7!$1F<\!,-2]C7LJ^(5W'
ME\LG#\R*&Q:M%(D,7CC6O>'C;`!S,1H4IIQA>@ZUTXGP7F#R(LFA(%RCA_$L
M:VK;3(KZ40>OUMH[1<A2ZGLB5L2)BLJ80DB`N,'8U:6`/Q-GO];M=B/\G98X
M0:U=\%\P`IC*7-K=L5>&<[K`=C00%E:1J7'=>CF$=#..]J1(2O4N/N3$Y:?^
MX2$"A.N/5=[^T$HU!"LT84QI9HK3;^2W'1V4."1KONEG)4TPR16,ZID%J0-:
MH:Z]B#NL8);.W$E*_G&(H9%GYO7LDBE"@);&RNZ)6V.2Y,N3'$`BJ$<OJ^N1
M)QOG5)S>EI=4%Z-,NDJB0O=L-T<FQ<:9Z['-6=7`8(6VNFYJY`&<WJ)VT.#S
M&5,#B2HR2.&U!I&VL4W0B]*4LQY-CM<V_5T^D!$9:IJ>Q0JP8C*WDB'/JQ6W
M,DL.:V!X<%Q<9>'!O<$#4_#("TN*U"L2HU9QR8T`,?+$Y;+"N4*#AO24*;[#
MNI'4*>^K+<I/)E</K:HZN>90NA4)425]:8Y+WQZG%BR9HD)$,@K$Q:&)EB\B
MDDG?XTW%L)<CQ7M7LK1-2TMSBDK_`$J09R%['T[P$F]J#,LXI$V/</MDIH<J
MJL^KK0*@KF7(8)8;"['K60Y_A$8?VM\C,OB,H8V1T925#AD]2/,@ZP>4U\\-
M;+K7=:7?2$`JZX`&1^7^$:M[!J6V5,@9&&3Q26GQ6"OZ%X9)9$Y!&I7%I5"F
M,](H*;W*/.4F:5JA2W9PYA3S#Y13#C0\<5&V,P"-SHGDKRF@'&)4H?9BZQ,V
M$J[`CDWDR2:IR6^)R<$F3M22!N*51'3#H^:L4."(9;XE**/ZTBG\Q>)B25)H
M*MY.<?4<W5R:2PDB'J;EKHB3&S.%LB:2S&)%LALC`XBDL3CZM,]R1C[GTY,C
M4>4N<DR8@>A9^K=S`XH.\)A5E-?)F@'&O+(?'J,U[.D=Q5ZHB$YD<<"YCD+#
M$9&7(=M,B>6$#*\#>FQI5*UK2!I<C'`E,6B4C+Y@G+[BC:+_``**5KR7H.P)
M1:<7>9M6<<A5OP"4/M@PZ.JE2%_E,+:&20+7"3Q]D6H5R-W=69.L1MJI"M(6
M&DF(U(2;YC-WTW-)5*(-$;4KR33.$H=.<NBC%,8^ZR&-M>UZUI[Z/+.B<#EZ
M!K"[MCFSC<E!`$)3PV.;4:H`XMZQ,3KN?>R3MCY<W+ZK:JEG%E1%>/O$FF[]
MB=X6'>)K#4!DUMZ<W!!DL6N.7,[,XH:]C+4KK1I<PO+,9)7!V9I<UKT2;8E"
M1*=L&67[2378K)3SI;E:(+9D02-,=<*9O'2)F\'*&5=(TZ9KCA[@4[K52J/M
M3L_HD923:Q8Q-3F\IDYC<WK5)$6UKS@XKVQ$K&GD.NRO5D-JRRI95$PD9TLC
MY+6AET/?W6+N)`#].1FS42]]87U!'5G5""2]Y7%6Q!7H20JAY%1>9Q";Q=EF
M\,E,<EL,DC0ED$=EL:>VQ]C3\PKD^E:)[9GYK5*FIT:5B7>E*9Q1*ST9Y&^V
MEG"!_=9"D?YB\3):5)#HGR9H*5@A[6WO<IU%[>@$C,8&AWE#S"&AR=265_7&
MHT3O-(\^Q!I4&@T6YRAG<V!!M0ZHCTH(6E7-1.'E+P@IZLB*]LRGN8-><EYN
M@N&,3?;^`DRB8]7[ZTEQ,EA1K8Q(F*3`FIQ:E]!)##$9[9W&G;#!'&*B,C47
M)/CTX[GP4-X5*IW5;62^67VJPXD+4"8U!R],0^RX6W;06!C/5M+LC(>7+:=K
M.7-+JA*5C6-JX@C\2.37'=5`-6HFN^JU%;[D3C$-S<B=1LZ-%RMG4+$KS&#G
M8MP$E3R%D4-SB6],AXRW-G[W.`W-*D*0JS":@Z\A:'8U,`2/%S5:V'VL7&SJ
MS"MGL73!GY,R'HJ''0\TUT"3(B9>?L*:*'-9BDJ2JA`2,8W!2,)6YBQC&,8Q
MC&,QEY*4Q85[((+!66PV.&U&HEZ19R$BJJ*O+Q(KEK!,69M=4;/*6N81L$`9
M98J$07.'<;3*E$BBJ=PA`4+>VR5V7@P;EO8O'UQD'9#(;`[K8:UXI]D4I>80
M^Q*&9:N6+%]>WM.ZJ=ZMF7)&NY0=8":,-;O/&E5'QSZO"Z]2L<D<(@U2/3V@
MD*]]6.<47[V++DY>:8],^<LJM<QE03A&")"DW'J4NS-55I<.KMC]NNSM5$=U
M>/3$(+R%-C<?(M5OT^KYZ:HC34D*G"V.A;FF/2?:O8R)]99',8&[TB#2?RQY
MD\.>5^SO!2]*P0A/Q&*XZ@2P?M`;+3[D"B?F\;(T:KDNCV<J-!E;\20PO?>Y
MM-.Q5Y2<8[2HODSQVE,-E[',7KD7V:<CF206?54Y4QNGHHB['A8G&E];;%>H
M_)'$@<=6*6"OVU%/59D-3M\QL-*3MA?$J`M`KR7DG8O[#DD?CS`MNR"N$4F?
M+*R>:_+&J7RK9`JKKD7;\D7,*^KH0Y::+(9'EMHRFU<6A[F?`'P<J';S]!(F
MOG*],TE/$==;2Y*=C)Y7\DWB:/DSY<52[KY)KC!*H<5(N.\C=62E9_QEY1^^
M"(0U0R)[H1]X8-;3.@AL/M948XG6/(U,!:G!1,#FE<F9(WN_2@/+3D`5&EGJ
M0E%Z4'E$[3EG'Z`'MQQ9&S3]D`--ZY@2=GG=J"+1?;3.KUQ?OC&,8S'[DG75
MMVQ76X#4MI--0'2%]9$D\EBF+O,CD:JL-.*8V>1*!KF:80X^!S*;1X"^*M=F
M@/>E]?@=CY-'V)5)$#2K0XOQ+@8X4US07\CN.<XA-14M9-+0VIN0G&Q)6S@M
M:+.?:S(/8:JMV-R5!-V5JKJ?UY7H4-8%&$PB2(Y?!TJ1MDO75,477LF"LB[#
M1=SGQ8K3B$'EU#GVIX%PAY"\)B6J5T([+&I`CLEL1,=6<A&&+$7`:SE\@*_B
M:%5!'R4.9BEI7,DD?W&`L]?K%;@@>I;LOL5MHVQ`^;,;DW(2!(9!S0X,\:N&
MSP],E,R(IJ@:JBF^U$3W9#>RKK;6*W\J6[N.2":XBH>VH4=TRL.U<C?=GN0!
M8]]DQXF6)7<+Y47JP3%'+I3RNN_L/;#&8*Q5+,Y$;`WGB/R?KE\?Y@ZZC\D<
M'&3PS<7,F,[E";2.'>YB,14U,?*5!IHW(&45O=C9M:\R[W?W2^X7&G'E[9M-
M./*&,QVOY2=#+/XT4/#%<9AW&!K?6^Q8Y-F&+6(M<G=XNJ:DN2AUFL6DLAK%
MG:8[&G0]>.R^7?8ON2O+6,V%"Y1RCJ9H@M@\8[DXZ--;(^/#R*NJ4-E[BPJZ
M]L:HXQJV])T\Y86-G4P"42)^$J=38@XA2P`^%)2%[,\[HH<@D37$XVW2YU:W
MR5(6)J22-X8VA1'V5T?$Z(DIT7,[&K=7U6SM2E8$XQO;%;V\*T2/9*=2Z.!X
M#%9MR8QC-:O9!.,MD6Q,N$W(VFVI'++&X2\G4MRFUNM=4;*=9M83*OY94=MQ
M.+NSLL;H\VV$EB\O+EL#.D[BVQUS>XSJ+NSPP)I#M];8?O*J+6Y5\M.(_((Z
MDY_&:3X%M?(*XA1:7%Q-EM'D5=]CU&JJ>#U5`HDKE0FYFBK`P/4N=)=+;!?8
MTQ/LG6PZ/LHG&,AELA;8UX/\/)/0`N0G&*\N/+`[<0K^J!KES$_N;C%E<5I6
M/62*8ALKL;;HW.4V<9*KINEULM>WFD'UD:RX%W!8<U8C3&=W2-O?+&5L['UR
M(Y9]CIN^N'ZQ8/)[TK)]@E!\.K>=U/=D7LRJ^QW<DE,XI&464\-R9P>4*F^)
M1%=QVX7!I$YE[,C,?F3?I\$@1Z4;GFFT;LO6N#HDCHRW>-%A2F*2%GEKY8*R
M$#(IM^<HT[M_=\4DD(ETG;[-=VN2GI%43<(CUF%:WIN_+TZQ]0%*S+=5%2\1
MN0$CA_`YMF-`.M5S7A-P@Y*<<.0V@K(*X1?D*[S6FH=5C)`($L:)$J)LBO[1
ML.-:Y%@<YDE9D<;<&UD23$EHGKQ(&UMPO4]BZY4+.,#'4,4XUHH9,77_`.CN
MK^%$U[8\54R-;IS*:I-`)"VPB1.[+)EA;RO5'QV8K&BQS@.,*3+7T)ITM;U#
MRMV'._EMQ?OF\[5NJ?1?B](4+%:O80.1W%=LCSRMIKN]#R)L.=M,EKBJY`4W
MSQP90N*,A$H<39,B<72N8\O-ZFIB%9LS>I@X%<6;+H[E>XS!PH\RJZW>^QA\
M#:2=W9O#`D#8Z<@*0DMZ+K+8G1KBC\L<U[TPL=C1=(3,%S8<QO02G!"RR-P*
M;M:,ONFJ?M#A/RJYZ34BL9C;U'<R[7AG)*%N]6$,S[,X/:6JLC]8VC6LXCC]
M(X^K`UO2J#,$PKF9M&UL;*)?GR-3`Z*&L36X2'`Z1]CZY)(H`FGKW5K_`":V
M.2_9KZ>[(A<E>5I.(TD'05#0"3QEI9XN;.CYG#2I!/HA5T)CSE*UE=.:Y6[6
M&\O[5!C'MA9VUY6;]*0X^4[QY9)0T5!!D4/+G\W?[0G[F8M>7^6SZQI9M..0
MSBP)I*7-]F$VESD4E1(%#]*7UV<BVQM;6=,H):FQ`C3S5C->'9/N*$XY><7#
M(75"V/I+BK*WZ+Y'5$FERQ8W1"06!Q[M*.6:U0R4N"$A4I:V><H65TB!CX%(
MM!'5;TCD!R!>0UF)#H,Y:U9;W9!UO$VIRJ;G](UO5W*ZD^4O(296L9$V]6C:
MN/;NNG<<IRMD42EDI,FLRG-BDQIO=9FSJ0P"-P%!)79+)'&2+8\Q*8\HKCU;
MU+\Z9!R/;>-!S;1/,9ZN]QL^O5SC`$[APRL5M7QUK2W\4D+L%PCCN7SICD3:
MG;D>SUHE=WQIDD;K1Z?!KMD6.N4PS6?8]W2ZX!V0/A<KED51\6ZZBW)7C-P>
MED3+;WH^LH_S8A$=M2?QA6CT8J"`OC&NDK54$!(:W+85%7.+G$3U"$PI6B3[
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MG^2_&6JJ;M1CA6D+C9%:V;0DQEKG`I>CC3J[-&I374VAM@.T??T\7-72F*2F
M-M#D)A=V&1NCE'->G++@?R:OBL>RZ7\@I]_.MGG;`N-5`\>>/".2P9)-6"HN
M/*HI7N76C)%\Q:H!')C8<CD4WDG>%',%VH9#FN'-:AU,FCF^,[;O?IKCU356
MR*P;7@M>JX]95YCC#M:DTF+U(IE:4IU%VH;7$(_+)I,I'+I$<S0AM4*F^,Q-
M,_"BD7[L<]Q]O3"<EQZK('-<'9"*AMRW)!P-5577;I.DM*<\ZAO^RE"%_@[$
M"/5O"(1:\;?'`H$PE,=/>W72Z<M!J%D9"5ZU4E(<3?\`6S"""56N^S^`UZR[
M?+`XCCLVNIUL]FRX:<P(L)8\TP(UZXY4J1Q-)L*6+1KI=KN0\)506R2@ASF,
MJ5.P)6D`!E"7)7SN/NIX(\C%DZ`%91A"N-E=G]5<[RUZB3U.>T`XTK:='$%<
MY`WFRX3D!T5S0P;HIAH6G4Q/`(3P<T#5"$#?EA/`KD<P2VL)`BI(,2,:>S?\
MP^8;L\-$CJ$IYC''.\J1Y#5U#K"+[WS#?=KF!_MB)+UL(;U"R4D$,CD8L:!;
M1(2ET70?L??+6;\2[3H.1<84U'\K:KX$6;PN@/,&0\JG>SZVOTEV40<DIJJN
M"IYS)I#5]17V&N$<DMPFPX)"7VN7)^+9(:Q2<!SX[)+AY3<6^8W*LOLA\B8.
M&$@J4[E+V)*F>+=?PF46;QS&<BY`0&R^1+RX1-<;$[.>&1-&V=MM./&,$V-6
M$-QC(T%&%I&]<8G9DTD\B>.W,FPN5<.L)@XM&^Y*M>R1\/.13:\PV6T!#VRQ
M:-B_&-54LUGMFGKIJGGTSY"UI+7M1$I"VOH?<DT4O"X@33HY0]=\BY!:!W$+
MF_4K8RRF/40_VPFHWLFO.WD(JJ&NN1<;J*4W_1/,V4V^[Q6P*@L%//(43$+.
MI5':*+OE![7>H`CDQ`+`C[8^;3K&%Y<M@W';A#*(7&>.[Y$K*O[A;":V+7/S
MAP2JFP*DLFDS1O\`9TSLYU8;,FM@598ME2.3R`V8&H;"/KFWF"'IUQ0VROE!
M#8B*D3QKWCW!?E'4G%KC]*X?QQ#)K?H7L@'+N^K%X_Q:VX73EBW915^VWRH5
MPP<#O.%3=G8&BP:[BM[PVP8Y&IA.XXPJ7**O\+<71H/&TKSI/0<%+=43W@DN
MJZ@57%.!0NO^R:;GC2V6RSV8]<?IES2:(^?#G5U>GBPG9RF\[631/()S/0UP
MK?87&I2Z'-C`]NK045(%L$PCB=RS1<;'Q,]]C9B8^5%'\:*BXK`FMF<EHQR"
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M]D"5K>5Z*!55"D(%K@B9&M>_R>3OL2A[4!`)^4/K/52[EN&II<_:Y,(*<C-$
M,-8:F2CD@SRETA\>33,Z:M$8+KJ0PB9J78<=5'HG=$NCST1.I`*8N"H;(A96
MAR1E)G6O+>;_`!`;(A')V[\EJ398M+G2PV*-.CY8D;9-/+_49#JHM2/(43LN
M1N1LBK<#(Z@G3!M$%YBBA$<D>T*)7VL@RI&\QN+!=<P6WP\@*G4579;,ID<(
ML9#-69QA,@C:$],D<I(DDS>H5-!,=:5ZU$V/#\N5)&EG=EJ-H=%B-T5$(S+H
M4<CZ`3!<!J;HK%-IGMYKH!W[HG#`E[T7F^Z:-L5/.^C5Y?>RS7W4@C_>.#N'
M<\B=]OS)IN;U'?=!W1C;Q_YEGS60\XT-S:@L`8^+G,E;QKASDTK7DTZ7L2FD
M*+MF+JG%,Y"/6.,\>%=NJ6;4?B[>8!0:W)TC0C<#NV*U,WJ>7_%Y+$81/QWW
M51D%L=!WVA<T2S)G711]:-.Z6/"=R)`A4*6I,U`DB]#&#7-P5(T)4H6I(T:H
M`_*26X>1VMZW\.M]/P[U_3K>];U_1O6];^G6<XQC/&X]W[;UVFH20+GM(HTW
M"7A.&@"OV2/2,2T"8PI0-(%1LO:D*<PL\1.AZ*&$S8=ZU<=CS[)BT\O>,MIW
M);\$24'8G'I\>T%ZURGD:B:HX[&1PUIMNM[%CCH%I:W=\B%ITQ)XQ-8R:-D(
M5B<U#S%2PJW%D/&.D<8^R"3[D3QEH_D#*D-#\8WNY^8,DH)LJNZIN]"D:EB@
M=^3VEI%`8ZL0";0/_)"0A@3@NCD4;D2J+M;OM4WN2ER1-Q[B+.APY7<:F>8R
M"`/-[54S2^*LDRD4B9G>;,36<TM%;HT#C9"Q2H<%B=#K5=-SLT.4_3EJS%D)
M;G=I7RE.TI')$<?:$;YU\.9G$'2>0KDO3$UB;.]L$:7O$-GC'+"02"4P@FRX
MZR$)X\H<ERYU>:\-%.6]O;TBM4?$TR^0:*TUMCDI27B\\J^-S!'(1,76[ZR3
MP^R&E%((/+BY>T+(K(XZY*VUO;I(WR-`H5,VXVXN;TRM*"0'K2&98\/#4T)U
MQCFXHTAUN%<U^(:VS6>E4/)NB5EMR&:R^M6*O$MIQ$^6.EC0)*G5S&!I65,[
M"6FS"-$JBQO,8T#3TEV6J*VB$>A6%)\<>#W9"H?R*4R*K;7FU(P[DTUWSS$K
M)DI:)3/8Y))(1Q9OR74^9-F>-2-Q'+'`A<V1]$_.RCN%,4#2P]6D0$-B<P9.
M33KS+XHL!=C'R'D33L<35)%!SRQEDAG\=8D44@Q3XJBQLU<EKJM1I!1`F6(5
ML1.DR,Y6R$RU(IBQJX$@(,;0T@'.CAR;$#;`(Y,THJ@R62OT1<9BDL*/*XPS
M/T5<V-EE"1^?4JPYM8"8V[2B+MS\YO2EO:&A7)HZ2X."<;ZU:5RHNO>G6RRV
MNG7"QXDBLU[/`B:(8J=R"7MS=3(\OEP&-"0/H*4R#<1:W&6^YXL\3Y[E4*J2
M=[^\A0E^2UC&,XT$.M=&M:UKY-:UK7U:RQ[+K*O;D@<JJZUH5&+$KJ<,ZF/R
M^$S)F0R",21D6=3:EL>6=Q*.1KD9HBRQ[).+$'1I91H>J86`0:Y%XO&X3&V&
M'0]A9XM$XLSMT>C4:CS:C9F&/L3.D*0-3,RM#<2G0-C6VH2"4B%`B()2I$Q1
M9)!0"P!#JN:"'6][UK6M[^'>]:UK>]_+OH^/X]_'\N.C6NGHUKX?C^#7P_R_
M+_3CHU\FOJUCHU\FOJUCHUKXM:U_1C>M"^/6M]&^G73K6_A^7X?TYSO6M_'K
M6_Y<8QC.-:UKIZ-:UT[Z=]&M:Z=_+OH^/?\`+E/=V=J?VIR8GQM0O#*\MZUI
M=FES2$+FYS;')*:B<&]>C4`,3JT2Y&><E5ICRQDJ$YIA)H!%C$'=EU/45741
M7T;JBF*^AU65I#TAJ&+P2`QYLBL484IZH]<H*:V-G3I4"3NI<J4KE9A9/;5:
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MG6]]']'Q;Z-_'TZUOHZ-[UT;Z=:WO>NC?3F/\WY)UY7_`"`H[C<_DR;5@<@X
MY;4FKY2B8^Z8J-!2K;'':;$/+^)82!M<244J9S&U"!*K-7Z/,'TD%$&&9/\`
MU@[Z?_UUOX=?+KIU_=:W^C8>G6^GX.G'6#\/P_%\O3KX_DZ?C^/H^#I^'X/C
M^#.=;UO7P?T].MZW_3K>M;U\'1\>OBZ/T9ST:^3&,8QC&,8QC-97.?BY:,XO
MKA)S8H1I9IK<'".8V\6=4<BD*>)(;<I;D5`4M>V]%X_*G`DYFCME,H6>+3.N
MULB&W1AT=&!7%)$^1]MD`WUNJG+XCE;<M`RQNJKCY'@.:6548[)ZWMQ=2S_8
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M`PYX)635OF$=<N/$E>T!B]"='7:(O;()H?G25E*HUNLV7PQYDLTUO^\:ZJMM
MG[DT]E47<SX526[X+J)POZEY-P6@/$!V;6.T(J])#*JMN&R!F?+'@VY:N;F!
M<C(3LKNZ-YDA6A:^)WP?Y&&1*J77COQ]WQ(N1@KFU7F*G5;>L0LBG665V[=S
MI8\CX^\TJYME4>S<BJCEZAW.L:QYY`&5PFT1L9XF0*;6!-<"9(]?0P5H>BP:
M,V$1G5UUQ`#L`!#Z-=?80"$,00[%T["$0QBT'HT(8A=(M]\8QGF6'&)TBE02
MD/7FD$&G%(4HDH%2PPH&Q@2IQKE*-$`\\0=%%"5JTJ8)@P[/4$E:$8'0G3O8
MV;L:+"X960X[9X!%TW%BIJ$[(!41KDR/JFVG'AY)6FRN)SO$G>/+3&!R.2SL
MZ41>:+I"<+3[3CB&"."1*E.V!/2(KPKY5`XC\6JK>:P3()Y4O9?7#F9,T>[#
M@*Y**EW;F[<7)LUQ;G=.^:2.,H*B%BMC,?&]]SG&R9,XIRE8VL)#J?*'&/C3
MR;J6'2_C=9/'"MI^U4[/>:$ZI?EXZ3B"O4ILF.\G)!;<X8TD5C#@E*G58W<O
M4VSN`W0]R-2T0=PC\><%K/)IB5*RV]BI%(<.^2_'NO\`L-DO;*Z:)3(.%'&!
M[XS\F:28);"D#NY*9W4%/PE9;E82!W<F2`RF10>84Z`H"202:,+7JM;#EAK>
MX)Y`09&7F!7#L=/*N"0:*!IQB?:^O5$7RHLJ'SZ#6M7C]1L8<N2_+.?WT#AW
MR;HZQTB%EN7BQ&F*:-VU4DAC`YV%$94DE[A4IS2?(R#S+<IVBYOR=?\`GG3L
M7K?O>VL_9^HQR`<.0A\AAB!)!F_CFLXGV]("V1`2X*+%-LIU10E36D5"ABYS
M"!OGJQQ=I6U($#DVGR_6'!#DPQ6!QND3C73?%28;V4KLHO*Z=O;+-X(8[,%5
M<R(9RNBU62)JVC=!'NTO9!7K!S7ED($)4S$Q)P+3JW`#>S%N$-Q7@#RS=^&5
M_P#&V?<0JR:+SK[L<E_<":BY/@Y.N]@)^06K.@J"`QYUKJ#2MV-#QXK:5JV%
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MK>OZ?A^#-%O8Y)A'.!].<GZ,Y7.^Z]M6O^87+.V@K7]"J,>^1\`NZWWVX:YM
M:G4;>D4N-Q+I='Y2WP]7&X."2S-EL!A5P)Z9T+V2@0':U8#1W)WB_P`!^);7
M$%EYUWR;JR/\O^4]O\4XE/7R--+9P&NJW;#EM@5(O9$3LG@I?*^OXE9K$?Q;
M5F%ZD$,OAID3.4:5"&J4'E[$^0\BGT:FW&:]>(CW;5@4ESTH8[A,C85L^LU8
MBIBR)K%ARSC=R@W$)D]'/T-=XW'66QXMR(?%#>CL50I:8,?*#-R-@<SCZ1%G
MZ.M_-NUN.?(*R.4<-MNK;]XFR/@,VQ&5V6>9;7%*+5/4S8^%)7A6C<XM9T>E
MEKDWDT\VG&;*53[IH4H7:3/T?*:JV>VR-./<YY!3!SX7R!MD$\3=D`;N8O(.
M#=D"JJ2OUA%1OP)M3%R)<'?<O@CHI'#H]4*):AX[.?%2>M;6@;#$3]&&R"/+
MB5,)PB<<(4=J61.GGL>UNU&?8\D[),GX0]E38+MC4W23-4]1'L@X>/%;JV>!
M3N$R$CW%5P9NY&I:QUHVB;(XQ.5<!BC?'1+X<JC^S<GIS,)))*=L.9\4+-OD
MRO)3V&OD]*^3"5SL2[4<\@?,2-L4"!QQ5G.BE[23&M.7#I*A7?'[#B+2LCTP
MD:2.H4\P8%NT,+Z8X46/?5(([J,K&=<CI;&7[@5V(;D!=VS)!<%YR]N5.%YS
M>)<Z;!K2.NDE-?&R;M_&IFC#G8-:5"YPQ45'TY+NPQ]FEJIE<1[J>QC.\,E-
M76O.*GOV>\A:6GUUR"8UC(I)!IK!Z]B"!WCD9W)*\H--9K[(+`<*?C\K)=5C
M;WR<E\?CLI=Y5#8BMTUQTQJ9]E>,8QC&,8QC&,984GJNL9M)(?,9E74&E<NK
MU4L70&522),#Y)(0M<2@$N"N(/KFWJG2-*5Y)99*X]E5H35A(`DJ1FE:ZF7[
MC&,8QC&,8QC'_CZOBRPH/5=8UCN1"K:NH+7VY>^JY1*]0B),$4U)I,X"V-?(
MI`%A;T`7E^7#WL2UY<M*7)6+HVH4F=&NB_<8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,Z[`'>][Z-]._DWO7].NC>NC>]?!O>NC>]?!O?1G/5U].O[GJ]&M[UK6
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MG.,8QC&,8QC&,8QC&,8QC&,8QC&,8SJ/>]!WT;UK>_@#O?Q:$+X`]/T=.]=.
M?.G3O*V^>4=XVXE2<QN75/Q]PYDW725(1.GNQUIK*HCP85#8!M2L\C=.3DOX
MJ3R$'ERV1PN;/<AE:^V>\<9[O+956V-6SC2BR;:.RQ/DN:*J?H1Q9D2YDY$R
MJ\&?CT[2^W8;"D$I@?'5+8BZT>0EE*AL+R34]`)$46AJN.2DP4MF\F*L-M&A
MK<D!3'[J^H.RYEL+0KLNSN,DZKRA9IQ+Y"<Q..M@J9S&7N96Q6?'1@B$L?T<
MPJI&UIW*G7^P8E/8A*JG;G.1RY4]M3VF:I@G@TVV&("D?E;RRY)03@R;;$=I
MQWJ+DC:5GTI4E)U(-ZA-CSTMVNVXX%!6#OVG=DC/7#9.T<1?Y'('R,N+T]Q&
M)*60_OO,'%O1K5I%KNO92%T48)6TV/3E>U%;\%Y*2GCE,FRV^5-;0&@HZX,=
M+0GD$SRY3?[O'.^;HU2NN[*@[6TQV.5`]S1+8KFOCCPQM\99U4Z'03NR_,JR
M!P"Q8MQFMN11M?P;B?9!+A4@=6`D50T7*5\B0MK844A3.Y]@6/*/<=+E=<,+
M*4UQR5ML?6OK_+H-&BE#TFRRX1<O'[EO74ML1XKB#15@97].ABDRIGD36W*Z
MI;*9#X\A=UB^'V35B9OT;((F[G.$.G$47QE(<U25LWJ/NDL9%Z!X.EF`<HJP
MLN4M\.CC)?"!X<R%ZA*HG7%3E)5L;T!N2&+E(%4SLZFX?#D"@:<H?<21>_)5
M3D?K21N)5*Q!(%BC).R,!)YT;X50&J&2;/$7?X`Q6@I<KZK.OK?96ZP(>3-M
M6?67'26A(FMTTA`FITCR:S;+CKVT!979>]M,28)RX0J4D(,*6CLU$OAO%2)<
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M\4KYUAC(X2^FXI"*JO\`K)CNI?J/.SS948,<F6L"(6-DGRO+3ESS\>..DBG\
M:KB@W^_%5#<?W#E9R37()[&:\:JJHU.9-.\H6M2_-[N9.K<G1%:V0O@M;)B(
M^UJVJ"O2Z6SZ&:<8J"0X+4%V8EV).XZ4U9L?BUF62=)>*U`\G9WX8J;K2?,_
M)7DDTUPH5M=5<8".WS6RX+4LCMV$1RWY8B%"D$6[8^'1=%/#H7-`-,KS+LNL
M8DW'1%,Z[KRR6>>3&@)[8#VE8SX#)9!0$D7W8HXETPT.Y+MI=#97/K-Y'!>H
M[6T8/`8PO)=:V$OD1I#;'3D+E<KGV6..0^Z'VCW6(1"1+8REY3,XER+D#5BN
MV2W?B%7+[,YC.K;I2*('CP*U%91\2>6V`S-VEK@_%.3C'`RJM8DF?VXD,/T5
MV3ZZ9,RUJNLBMW=]Y"3RC>)[2U<7ZS#$VZOY3R,Y7,EQWJT)TMG28E5*8(AJ
M[C?4YU@W(*2JG9CAL+<BU#,VS.:][6U[E)'V5JP9`4GK^'\/7E\Y*L>N8!-L
M5@LO.%L59569PXDE6L4O?GB\%<5/V[P.?ZMJ,^#B2-M:@>%KL8J99)$HV-GD
MZZ.[.N/5PMO(6A*3OMF8GF+L]VU)7-MM4;D>DNI!'VVQH>SS!"RO?<)IR+;J
MV)7@I&O$C..2#4$C&F-,)$`6YAQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QG`@];71T[U\6];UT=.MZWTZWKIUO72'>M;UTZWKIUKIUO7P9
MK2XY=C?;N,)$)C5<\R.:ZJLH&?)C&:H9/.*2<H$I!*E4F='$EX-;Z`:)NY:!
M(94XR8A49,P.1CV2B-7KEJ(L]$HE.(<`^/$09J-C)#9)7N+\?^)\YX>P6-2!
M\)5M)]4V6DK%NGKA(`HVUO6.,[E+;5,;;W23I5C<$:96_P"B6XDUUV:1`L=[
M$Q2),%>('95R\F+U;3ZD@G'R&N%JS^)GN=8\=H7.83.]TS#"X97L-93F>=N%
M<0IJMJ;R]FE5M6='XTQMDIL%6%F:3465O*SBI&>5D9K9C?+%M.K'FH[?C%YU
MU-JE=8HW2-ALR&-4E;8F[K$DVATZBLE:6<V4+70<6DD;=(Z[KDR$#TWN"`DQ
M$=B:+L3=.IUB!_8[NY)1V;+J\Y`UY:=EMTKKY59ERE\EY`T2*T9G)IH\UBZ.
MD'L-8ZQR/HV654KNKSH]#(_&*[:$R2$PZ&LD>DMK['#5<9KR6PN%VK?L"D4F
MJ+B/322UH--8]&;!AL=X6Z./IA5#MM\,#$$`C'EP>GF=1QTB;U!9KN0OK"[1
M/<3<3(_J8N/O$6NJ$A=LQ@MXDMFOU]SF16+>MB3Y-"VV5VI,Y+$V"!+W5[;Z
MNA];P9C3D0F+1Z,-[5#(?&FY,A;-+32%#\X.[PX5BJ.'_&^CY-N8U35,?A<F
M$SK&#;NUJ'PU3WH7F(SE:'JN+NN3]J.-;T0Q;[1VS6TX.J,.MBT*"5/8\((\
M7>CN&97;R#L!FC-LV#>E6T_-9)`'J!TS<%C0^20M_F-:R<=;$W8UHFYHELI/
MAD"=+9>*XA+N^&N<<B*(UJC@&3'G_48*4*K5PJ5)R#Y.H8=(N,W'KBK,@)'B
MERGN9U_QC$K+J8UYD(:4[[(RB6A:8QSB$QM0PU?9"/2A5-8,[NKY*G"09?D<
M$J*`E;42L,P=4:/EU8G-!>E='U&I)DEP6*BL!N6II)H+.4)QA<:1S\XF',!8
MDJIE#%(1VQV6[8-[68E@[#52:^`&5Q,.0O*ZQ&5EXY[XK55[MYG5SBGIJDRK
M'JNRV.-1!@;J>:8K(UK4[TO7+"[OMIL=A.UB0=@+AMGJ9FR&;3!G.'=C=J5C
MLX^WY=8]R6M.%=\U1R)4K9V\0@MN%8]+T=-*'A9"1HB$!BJ%I@;<P31?+$%?
M,Q3?&6*?H4,CCZ1KTI?D3WYZX[&S6%<7!`;+2W%R#D<6J&Y+QO:E:&D<KA!E
M)U3/>02"PD5D*61F9ZZ9IE)DG==J3YUA8+$G$R5UZ?)'%!#UK2RJ5#8=^G)[
ML;U:\G9?:4C>[GY$5>PWY3L5HSD%7U.R^%QF*7/!H2[R]SAQ4H7/M=RJ:L3@
MT$SR81]Q/@$MAZ:81)\/B\T22!H+*3!JT(['O`('=C[:3/<5^"@[W><HY)IN
M.(Y3#V^DV6\I@W:2R2:)QL,"9[;>FA:X[6RQ+6<NM61U2US5S5RE!"27).T#
M;/+">QH\:X!&Y?&(WJ?)T4[Y=1OF'*U:F3(U;FZSN%6X1=<&K_2PYCWWOI6#
MSE.2KBE?-9:(+27M:I`[F/+T^N[I"3!V'>DVB!(*R67CR-?(7'>+/)7B%#F=
M8[U(UD0^H^4:"/H)DXM`(S4#$4KMEF)C#>)NN%_*>9])3#5VK'>)LG6J4YDK
M/O8TZU6IT3S%[FOJNKC:;A@]UL%^0YRJP%A,4TA7%Z/\1M)$S`_U0_5(X0R3
M4RQJF^20I]K5V83)!(7F1,R9F6`90M'OAO8S^/$(C%B1]F>K?/66GQIFO&J:
MS-\L$<@GKLS6C.++LNV+2.E3NTJUQMU6C/K1?)1,YHITH;U*UGB"5JCK0TQI
M"W9GC$(LQP:*1F%QA"6V1R(Q]EC#`W$ZUHI`R1]L2M#2B*T$(0Z+2-Z),G!H
=(0AT$O70'6O@RXL8QC&,8QC&,8QC&,8QC&,__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g453119.jpg
<DESCRIPTION>G453119.JPG
<TEXT>
begin 644 g453119.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`_1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]-14%.7U!!54-?2U],24Y%+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_```L(`6`".P$!$0#_Q``?``$``0,%`0$`
M````````````"`8'"0$#!`4*`@O_Q`!N$```!@(!`@$&!@H)"PX*"@,"`P0%
M!@<!"``)$1(3%!49(3$605%8EM0B*%EA9Y*4I]+7"A<C,E1Q@9&5&"0V0G-V
MH;&SM?`F-#4W.49(4F)R=[:XT24G*3A$='68UN$S1U=D9GF(LK?!@H:D_]H`
M"`$!```_`/?QQQQQQQQQQQQQQS;-_>X_NA/^5!SRIZ,]([IH7KJQ5]QW+I=3
M%E6C8[A;\EF\XDY$S,?)&]F7];+<-P<!MLQ;4@CA)&Y(5^Y)"@``4$LL("@%
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MW-(XKRMF:P.6Z0L)ZEJ7@*"4:)(I-P4:4;Y,TN8`>AOTA,A#G/3UUY[Y#C/^
MMK"^3_I`Y]AZ&O2%&((`=/+7L8QB"```)+#$,8QBP$``!Q8&<B&,6<!"'&,Y
M$+.`XQG.<8Y!F.Z6=#^?G7N[U#TIF*Z:LUN>YA#[1N>M(NY.D-43^NVD;S8<
M#J=B=[Y9+"NY]@2?R"26+*\B3C'D[NHPR1]YDSJG5I")I,G1-Z/3^R,C^AZ>
M>OP4+^R,S^A"H1V"6H"A?6M([H@J"PV$,):@*5:2$\L(QX+.P87@8\!\6>S]
M1OT@_N>FO/Y-87ZP./4;](/[GIKS^36%^L#CU&_2#^YZ:\_DUA?K`YRV_H8=
M(%2XMJ8?3VU["!2Y-Z<P04L_R+!9ZP@H?AP9/3"\Y\`\]L&%C!GW"`(/?&<<
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M`&PZ*D<IE_HO">8IU8?33VC3KE?G*M3XS2PBS]EC&<3&]1OT@_N>FO/Y-87Z
MP./4;](/[GIKS^36%^L#CU&_2#^YZ:\_DUA?K`Y8.X>FAT(J(G6NM<67H[KD
MP2O::UUE,T^A-33S`'F;(H<\S(PA8<=8Y.$+>82UH(\G6=CO+RR5Q)D+*R:\
MA,)H6Q^G]T0*QVMU^T]?.F+`W"S=EHK8<TK1]8V-Q40#$>J=`)SL15)GAQOA
MKD+(HC:#R*G",F)N9SSA4F)9LK5`SBB.BM/2'H6TU'%#K.NF3!T\J==B%.JU
M3U.QQYUDUI7]=Q(T84\:J*/LM[J6M4U*2EQ;@IE4Z?H(QQUE(6O,L4,*-.5E
M3>N"])OI#RV<.5:2'I20*LINTP!HLE6BEK8\NT65QUZDRZ)IRHW84%NB51&4
M/*!W;E!<A9V]:6OCI9B`YQ)PE=FA2NO1ZC?I!_<]->?R:POU@<>HWZ0?W/37
MG\FL+]8'-,]#?I"8QG_R>FO/NS_Z+87ZP.>(/JTZ^4EKQU"]C:<I&LXS6=70
MQU@),5@\:"YA9&,MYJ>!2-U`A"YN3DN"%>^O#HZ'X.6G8PJ7'X)P41Y,DO\`
M5[XXXXXXXXXXXXXYMF_O<?W0G_*@YAHZ87_F&Z\_^I6Y_P!HRY^3SXXXXXXX
MXXXXXXXXXXXXXXXXXXXXXXY!;?S^P367_P#,;Z>?_:3C/)S@_>!_YH?\6.:B
M``P(BS,FA+,"(LP1`L`/"68')9@B!B^Q`>$`A"(&+[$!N`"%C.,9QS"/TNZ8
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M.*ODF;Y#+8^]PUX5Q2<1F:IFQH:TL;E,3F;6\QYP9/*N!II*%*_`/);WIM*%
M+/G8LW^S++_[9:?\XIN8\.EMC.>G]K;@.>PLLEJ!QG&<A[>+8.Y`^_'MQC.,
M]L_>SG'NY'O3BH[MIC=?K';`V)3\MB=;;#V+4-I4<^/+I!\%3R-TQ1TBC,H+
M.2QN6RE\B*Q8[X*`T))0Q(5*QK.$YY2X\@-$*SM7=<EEL21U"A<=3Y?$(O;D
MATH0))*?>4#>5<>CV^]?6S,Z+?')E,A\>1'+DJZF9:W6`U&21L;(FR'M$BS)
M5ZD];'V_L(MUP8I(:$M_855K'-&N%T/<&N%=VL=BW(4L0Q&$;25Q%I[7MQ"D
M(8P4S2:'QQ9+FB-V$IB!KS'DC>H!9D&F4[KC)STGSCMIK@>WH3G9"E;'0Y&F
M-<6Y"Z!?$2%::2`Q0E1O8$+86\)"3!9`F=2F]$2XDX`K)3%%'`#R$%`?^?-U
M)O\`]`?_`&:9;R=G''\7^/M_/G/NQ\N>8!.J9I+L5O/6U^SB`1B0PZ[M?956
M#EHBR+XE`5,N>Y?3#XGGY-EPBS#;B0M%=-%P3B0/C+(4LI9V]W;XO7M>NCV0
M0H+2HTMQ+:K/:J?;@])'?>4:YS,L=0TWL=6NV-/P=Q@\KLRG)]?]9H&X,D9V
M)#+BF"Q*Y:9RA=4:U5!I2ZOB%C7,;F2RK"C51:7H-K]0]C97<VC>]U=UJXS6
M7:H[K;!7M,-629)#6VPY-1>Q:>-PM>?%G)]?4M<K+R@L8A[;,/@4MF+<VJCG
MM9&&:5J9"Q`+<LQ$`F\AFJUV.65//:ZCK<@;"FIULXB/QR52-T4F*#'5*E@;
M2\R5U9&)F3%(<9>Y$[-I[T[*CTC0P*&MK^$"VYW'-!>[/\6?\7/SC^N?_NJN
MVG_MFKO_`.#:QY^HSQQQQQQQQQQQQQS;-_>X_NA/^5!S#1TPO_,-UY_]2MS_
M`+1ES\GGQQQQQQQQQQR`&[74%B6B<$M.V+.HR\9?4E-QBJ9%.+(@`*Q]"@77
M#/E==QB(1ILF5@Q5_EDI;78E"YR\AJ;?1498'UC6JG8Y6N]'ER/@=Y-<D0RX
MZ?QEPH5VAK^Z-BYAMJ8U>D.=H\V1B/2W%D1MYCDV?&%WKE4TR$`,R+*]*)H<
M6:1-LB1,ZEH/#FZ!,MB:A_1Q1/*HLHE3@RER1OBR>2L)\G<(X<+`"9$@CA+B
M-[71XX6<!)?4B`YH.SG&"EH^_+=SO8:C*TK2R[AF=N5TU5K3J%U6V;+B9G''
M5KAAC,G\X5LSX-H<UPT4H-$(E&W10X()&ZN2M$VM[8H6+$Y)E6CLVMRD*%Q4
MV)7R)&Y`81(CE\\AR("@<I.*2QL@H:A\+`:J?EIY;>RIR1F&.[D+T>UX6*^Q
M6>4*?P$+5)7X4\@N&*%KUS3,GW,UBWH2'.K6822YM4N>?2_HR*NC:<H3DN#9
M(%;:O0GGD$JTY)IQ0![;A8M=M*0*]UL2O6I`-O;'8M:Z3V'-J,QJ>S4Q#(ZE
MJESVG3F-3T>L2$LSH`P3>[G*TI3:I5&*2`F4XENZIUUR/>OJ*>QE5<D;@C)9
M,@KY.[(3)$RP^2N[JRQ]Q<4`5'G"<]W5,;NJ1MN2LN&69`:^G)R6DY&K574X
MXXXXXXXXXY!;?S^P367_`/,;Z>?_`&DXSR<X/W@?^:'_`!8Y90[8*M07+(Z.
M*=RSI;`H%&[&M%T-6LK5$*L8YZXN;75[=-I&].K<F22VT3V&2+8;%&\M>Z&1
MZ/.$G>@L[.K8#WRX8)O!3FR0OI<UA![)$%"M'+7PJ81<YEB2I`20H7I)4\EN
MPVR,JD*=4F/7)GU6WGI"%28Y2646H)$9"FZHOHHW)&BSGBA:"NZ07??<&K4E
MPBL?JN9/4UL[8II+J-YDKY)!*53>J_\`$C\(S[)>G%>-P7T7&']E.\_8`IFL
MWOT.N73@B+P[2]KJO32,O#9&'9S>Y(BQ4S$H:X-.8NUTN\.3HM*=TA3-"II$
M8^RUDN6*_,XY($30W1DTU6O1%$@I!MO/7O6O<"MM%:JUM5Q&8;/PB=;+)IA5
MC95,:JEW;(1Y)FG4RFXBY6V2I;,BBD3>F*/1Q%\6RQ%AO.)=CB4^1)I<OERP
MN,6_`J3DIZIBEUKQR9/]6*5X4WH.?JJW3(G2Q(DR+B5)AR>:1"-N;;,%+"Z)
M467J(FN3U'%3KB-25,U7H9O]F67_`-LM/^<4W,>/2T_W/_6O_P!C6E_VA;CY
M)2\;?KRHX['")XF5/RRW)PQ4E7M=LZ-&Y2:UI]8!#B0A@<?:W!:VMYX#F!#(
MG^5NCNXMT=B\'8I))9$XI&ML-\K`G6$KIN['.UTPB)ZF497,JU@V!D.L[Y!I
MU`*/1.:F4ZI1U*)OD5:-<?>'KTY6E:QVV5R&$OZ9&@Q!VZ4R-`%KC*5W7$K*
MXGU2=,?7>IY0^.=`ZO(Z<1M,.7VN3$XK7$D88W6#:W+*,:+.GD30N"]8]U;!
M6"3K:XD4E2M3]B-P9W?D2PA7'FM]2I,B+`P,448F:,1AI;&&-1UJ0,<>9&4D
MA.S,[(V)BTC6V-!"40DI#4B1%$IVXE*(20M&62!+GS?!?(4T!_Y\W4F__0'_
M`-FF6\F^Y.3<S-SB\/#@@:&=H;USL[N[JK(;VMI:6M(<X.CJZ."H9:5`V-B!
M,H7."Y286G1HTYZD\8"BABQ`2/\`4FHE\M'7>O%3'.8C'=IZ5M+8.F+@GAD&
MAM;O54U<L8R!R>0^GIDBE,+(GJ"31N15R7(F!,8]1Y_:E+R&.N1YK0GG,KF$
M/;UGH]QF,.;5_GC,WB0N4OC+:M+7R-4G0QU$:D7NJ=02KD"U8D2,*<TL!KTI
M5)B&L"LU02`</J0ZB6K&P5J6'45>3O!L@@*10[8<GM&8Q,DGCK.QQ9RF4C2&
M.>$SE"D$%?)8A@[^AMQMKM^7RI$[8BC1(V1O4NY4NTDU@[D!^$WS2$N1<52I
MU\I&WR^,.!,70JVX;PD7R8Q&ZGE1Q"J:"S'9*N>Q($BEJ+,<R#C$(!J`VCM3
M9>LJVJEPM=J=FNV6TN15K#&%@JF5PZ5.\OF%NV)'*Q@,:8U2)Z4,P%SY(Y*0
M,DQ>L(3^C&UY6A$8!N/P&YRNRZO;S5Y)]GUB4%M9W>2K#!V'"B"D\58EV&UX
MEBCRSZ7E)%FM<,I(Z2%5@EG:UAQ2)R6I58PD9B[<.\D#I_9K4;5I1`IS.)=N
MJEL=;34SA+Q6ZBN@HZFC:.93I9*'AWF;:Z(D2&*+T;VR+6)FD::5%GA1,QAB
MS&09D#,;EA<`L:IZVF!ZMC<;P<Y#%ZN?%99&8Y)[!C4><9FKK3"L"C*MLFCI
M"&602V+I'!$4VRAOC,E;VMR%(&HMH776SG&0YSC/?&<9SC./=G';W\_./ZY_
M^ZJ[:?\`MFKO_P"#:QY^HSQQQQQQQQQQQQQS;-_>X_NA/^5!S#!TQ5B,&A^O
M8!K$18P([=",!BQ*4,(OZHRY\]A`,."+&>V<>S./9[L^W&<8GCY\A_A[?_2"
M'ZQQY\A_A[?_`$@A^L<>?(?X>W_T@A^L<>?(?X>W_P!((?K''GR'^'M_]((?
MK''GR'^'M_\`2"'ZQQY\A_A[?_2"'ZQQY\A_A[?_`$@A^L<>?(?X>W_T@A^L
M<>?(?X>W_P!((?K''GR'^'M_]((?K',5/6KU[MW<'IR7CK3KY&$$ZM.SW:I0
ML#<IG$`AS,A2PNWX/8#XX/+_`#64,+<D3^AHRN(1DI!+ERUS-2IL)2RAC4E4
M;O#J`Y[<;<]+:92BBXG8U!48LV75;,MEB/%0K4#?'K>HI!`X=#7J*N,O4N<^
M0$SI$!TE#%&B)%&B4!87$9CH::)-R-3-HI<49W?VLE;W1KA8=9J[.;=E=,[#
MAVQ545'6,:(8M/W[61OU:L5M2%"V`CZ)KBQH:MC#%#0_M2_`Z2F25:[Q]1'R
M3C,?3'TL]Z)EJCOY4CK1<>K*3;%=.OI^5A5</?K@H0^)-%Q:NV`<JE%4(W2*
MS.3."$<:AK>%HKV>V?()?(7UE6M:R?VP?(W9Z3M,INH=T\]B=H[1VJL"!ZPP
M=.BMGI!5QJK5;&LL76XGX);*,^S:"V%#:`_,O:6QC*B\&_</VPFU.G8@/"-4
MQQEV7D!1N"^BK9Z>&Y[?8^RMJ4M42!FAHMX.E/M;"J2BUFZ]11?>4)U'U\4U
MK=\296U=)WFLXQ/4EH+FVQXP3:S:5%YDXQ<F1K#7%U(0)EG,V<Z5EFRMG9XK
M1NM0E$&9>E#N;K=!&NV+FUVFLR@U\;#7BHM&KH>YR-RE3,C1YA"!T?`^G(BE
M45S4^7($/K^2N+4VDN)^1K4/6&YJCWPL2^;`K:*"A-NZ':152&?"L"K7*35]
M;6O,)>HQ946?&E.ZN$M<W*1*EJ!,WR:(G.,2=6(D9[G)Q^:)6<S,7Y\A_A[?
M_2"'ZQQY\A_A[?\`T@A^L<>?(?X>W_T@A^L<>?(?X>W_`-((?K''GR'^'M_]
M((?K''GR'^'M_P#2"'ZQQY\A_A[?_2"'ZQQY\A_A[?\`T@A^L<>?(?X>W_T@
MA^L<>?(?X>W_`-((?K''GR'^'M_]((?K'(+[]K4.8'K1G"Y!V!U&>GJ,><+T
M6<!`#9*,Y&,6<'Y\(`8]HQB[`!CVB%C')P8=&K)>,8=VC&<@QC&?2S;[,Y#V
M[_ZZ^+GG6O'7ZQIG(?V0OK\TQ=CE]I[TU91MF:N!<Y-"&=LL.'"H\%%FMR"3
MSEW98T@44-9S`-/+4YKV%3$4D@B3\B3DBE#+E9$"YM2K&U]IW>IZFE-+FZ+W
M1?'1)<=:ZRJV4T5)LV7;VNL/J^MI_$WNGFFRFILF*!TL-@?'ITACL\Q)1::%
M(GDR28-2M">[I)D],.O&R06KES#6=OUPT4=M3NYM=L?#KX@%6TLXH]T-HF&%
M):MK2MZUC%I68ES6M?Z\6I9+W%G!SGLC1)%TD2IGAS:7)<4T-\$:CZ3.QD7I
M[7.'2[6*LE$E@FD_5[IRR/\`Q@:Q.1#A:6V<ZG4BU;2'.`;!R&1(V5O>VKRL
M@,"J:JV4F#)+.1"2F#Y/*CM9-J*EV+Z2-K2*E'&4,&G_`$M'74J]U3'<NNRA
MZ17(_15L:/)1Y%(+B9S)DPMZYE[+Y`WJ@(S4[@E4(3564ZTDB_5XJKLV"V>Z
M52.4P)KJR>U?N9L-M3-HJ@G4-F2VI]2ZXKB855#EUES*#OKS#\R:ZW68QF-D
MLT?D"U"X/SVZ1U,2])H5)ES?FR9'5J`[,>!.[1W`[-&!9P[-V<_8KTW?/;"K
M.<^[W8QG.?BQG/,?72V6H@Z`ZV@$M0A$%FM'`@C7)`"QWV#N(6/8,X.>V0B"
M+&>W;.,XSC/+3;]Q-Z!MOTEMAS%Z8VF:$VHMJ/7$:%:4<W0U7LA0+[3U0V;(
M\%&FIT$8C]DG-T4<Y&J``B.N$Z9#E"M&E6GJ"\=M4=/_`&6A^]L1V2>*(9$C
M.BZS^Y.W[]*R;!H,^8`U8NG7&-U7!"5)B>PLR)8H4S)$^*W2LB!J%K6B6#<5
MS9Y=6:`/6PO1U+JMT==Y&>P-<H+%=SKQA>[-)1`R-"K6;6E/VW;*TWDK76G8
MY)J]>)64K:7!_ED04$0)O6$-D;?VM\>ST+:00Z/AGH=U_BCI5]!T564PD;8^
M2^MZ4J2OI8]%O*9:4[2>$5W&HM(7$I:<L.-6E*WAI6G$K##31*RA@4>4'Y7`
MLQMH-Q;B]YNI'DQQ;B\&?U`V2\F."(L(\%ZURP(\@$8>$(_"+.,9\.<^WW=\
M8SRL]^JYD]^Z-[AT?5CPR9LJW-9[GKR!$&R%N0%N$KD\'=V]G9!KL*\81AD:
M@>(YYR/]Q*R[X&H_K?!O,&6RNK%C[QU1IK.:5IZ,RJ%1[HP;:ZTEH)7+*<C:
MFNME[DH>)U9`8$XQ*?2QC?HU)JTL2'/3',WD4?2%UR[(/%YR0Y(C"TU_:!Z?
M+R_[PT/<VT6OM=26M*NZ2&INM9KE/Y72T^(;]O*/GC%+75_+CC5-'YT=%T7;
MVT*&'6DH;%91"U*>E9'!*W+!&J\G<\U?HZ-P;:R15)7,=46WL!3UZ1B5Y!.<
MJU-J2.SL3F7%)907/IN.$K%2FQY@K5-CU(@)@1!E6#C+(XLD)1IH^3YB)WH+
M;.ONF6P22W*D/A,6?>DAH3JJY$U'96OZB0SK<&K=H&!R51PZ/L4^4?MDH)4\
M29@;7(3N`I);$;]/P%+(VU8Z-RHC()T^8*38FRDR`Z4[;U+.S'OQ)-_=QXO=
M=65;0C4QV`Y429%=-:_J:%PVY;B5O\+4+GJ4VHM<5\Z>%:.5ULK<GU)'OA7&
MR'6P%6=,>]8_:>L<PENLM=JF.`;?=8*W;53J)OK*\'.=4;<UNM9=9F8U"*P5
M*:38)E8FM6OC`\FHZ^4-Y+NL3I34J<W%R:/TOV\JMZ_8_D@D%*#?L=.6F=H(
M3LNC9KLUW.<6AWN.'K(3#T<(R[6X@0SHEN"!*XN0V=P+1(F4:=.E5'.)9C:1
M+C=`R]-F)%H-7CE7J.HYZ@ZM%47[$HYB?0:82B%Z@ZG1!RDEBW/9LBKF1R2)
MQXV8O+\=$D3(W289B=18<"@BDYU?UKFESF[$[-(L"%AT:`8%XA8!Z6;/L,9[
MYP#V*NWV.,^'V>SV>SV<_.:ZY1Q)_52VR-(/(/*$\U?X32#R3BA>&CJR"+PF
ME#&6+PBQD(O"+/A%C(<]A8SC'ZCO''/GQ@[^'Q!\7N[>+'?O\G;OWYKC.,]^
MV<9[9[9[9QGMGY,]O=GFO''''''''-LW][C^Z$_Y4'/)WT\=5^EO<R>C*/N3
MIZ4]:%^V;0U[;832^IE5U7NC$XQQBVPGU9.Y<G?')Y#.72:^GW6/EE^*,*&H
M3(I"H$_%`:S$0,K0>D7T81BR`.C6D`A8<VIDR'%:UYD6'E\3%K69ISC`N^'-
MV1G$JFQO[>>."8TM0B)/)&$>>0IZ0/1J1*S$"O1+2=*N)(=%1J-15\`(5%)6
M0E.I>5)B<W`#@)VE.K2GN9P@8*;R5*<U8(@LXH0_HWH_=&TE.P*SM$-*"DLJ
M/1IHRI,JZ`@3R)2X$94H$[$<+&"G@]:GQD]&2VB5&JB<>5("87]ER/EXZ!=%
MFB;3UGJ1^Z:NL4@DFSUPBIF-&QVI:G&3#'P5961:B%[FS6YN[?)BHX[,E62E
MN;7)@87PH3T20C7#0@/*-,NG".D_TCY%&HP\3'IHZCU4_P`K=G]G:H1+('2C
MN^J%;*^.[6G+1+X4_26./*EW;6PF1)V]D>7%R;F]R(0OB1L>T;FV(N'%NF9T
M,9J7:)\7TWT6=TE*SURJ^TW$BL8*6U0B?,S3'GEYB[X[*"26U,YLZ24LA+J7
MA6,MN=5)[&L,)>6]Q0);K>I:Z1WF_G?J]-0<)<$^<949IJ(8(PG\'E?+9.RF
MP7@KR?[IY3(O!X/L_%X?;RG?5$]&/P(#,:,:19`Z.^(^V"Q6=>BPXON2L'89
M4&<9SYZ[Y)S@W#6E\JO$7G`\)\ASC.;"TUH%T6+A==H6WU:^L-=E:H7\XZ^3
M]TL&I*H;FISD"&M:OM(F4LCBV.[JA(B;I';9C0&XU\5-3R%8%6F<FAO/"`D4
MB3.CKT=B7-J9#="=+RGA\3*%K,U&U1!2W-V1HRPFJU38@&6%6X)DI0P&*3T9
M)Q1!8PC.&``L9SL`Z/W1L,*?CR]$=*#"8L:H)DQH*O@(RX\<D)\X5%/HPXR!
MG,3$8R<H`Y92B(*QDP[``8\7*8L+I7]$JJJIF%XV!I#I3&JE@4(>K(ED\55!
M$U3`TP>/LY[\[2/*EM1+1KT)#2G-6$X;"EJAPQY(EN)5J%"<HV)\<U#Z/N7G
M7PNV.D/1U$P_:Y[112@IK8%34^H3OTY?HR[SB$UW8+%'75T=ZJGEBPMB=GZ%
MLC\!<C4K6]3"'UWC]A&MD4<YR!Z-?1]&`!H=`M-!%F$Y/+,Q4D(R$9&!%`R:
M`7DNPBL"/(#D>,Y!@1Q0<Y\1@,9V7#HZ='9H1K'%TT(TN;4#>APY+URZJ8*C
M1H6[.,9"N6*E)91"5%G`L9PK/,+3=A8_=?;COM*NCWT<$)C&4MT-TK2&R<X"
M:.%J:L@:<Q_4&$85`3L@#@@$[GC3""H`2W84F#($$X(<E""/,=]E-!NBOK&X
M48U2WIJZRR1POK8"I->V%'%ZAJK*N-OEQR`^-1R7R5N?'9H=3(8E=DXT;BLC
MC>_.!*@PH/H_!.#U!$B$_1[Z."HY]3)]#=+#E,7\G\)4Q55P,Q1'LFIQ*RL/
MI(`B,9\F)0#4%X<@I<C(`,X'B*"(>-LSI`]&HEJ=WP[1/28IE8#E"=\=S*P@
M`&QF/1@*&K)=G`6,(VTU*`\D2DM<<G&0$XH1H08-+R*U&RG33Z..LNN5Q;-R
M+IG:SS>$4E5\LN"4L\&INLSI*Z0F$,*J4R13&<2)>PL#BX)X\@6N*!&K?6XI
MTR0!*E6>74$!'::@=-.B9>4VMNL'/IA:_4O9E+0FJ;1F,/M6E:F3@.JBZV%V
M?*]LN/2V(OTIACU%EY\<ED:>Q%OI#I%93$WIO?FU(A-9'5XET1T<^CNJ1I'!
M-H1I>>@7H0.:%:35$%-2+&TPO!I;@D4E@$0I0C*S@P"P@PQ,(&<#";D/MYN*
M.C=T?$B52N5:!Z9IT2)":YK%9U2P@I,D;2,"RH<5)XR@ED(2`@&(]8:(*<H(
M!Y&9C`<]HOZYZ,=$G8V)6?,VOIP:M5ZSU9L5:NM+L*P:LJ)*%TFU42@J)KW!
ME<V!Z?6!:S29P.+/BGDG@;@XHS2?+(DRL8DA<GL]'#H]8<_0F=!-,\/'D35'
MHG-2PCTGD@@LDXXW#=Y+SW)9)2@@PT>"/"6`\D8LX":7D4.DFE?1X?[`GT9@
M?29H2Q(55E_0W6&QK-B=44T8AA]Q2M;#4CBB=H8Z/K;-\0Z"YG\5Q,9<2SF&
M%#<A+&!B?XXA<)&FF&FZ.71X6N)C.DT'TP5.Q1"E4:V)ZH@Q[B4F1K<MRM08
MA)+&J`0F<,90J#A$X+(6XRD-$!1CR?.,EZ/_`$;%R=T5HM$-*%:5C<3FAY4I
M:N@*A.TNR<919[8YG%8&4WN))AQ(#4"P9"LL9I8!DA$,.,T+&^F7T,9?-K!K
MJ+Z;:+OTRJF.0N66,S-5809:.'1^PTLB7PYP?5:<D;>A"]ML6>78D@U7A20S
ME(G982F;G9I4K>/;73"Z,%14Q,KQ<>GIJ))XK$H1(9RE21FKJK\^F*./Q]QD
MGHF(N#\Y,D9<'=X0-:K#,!2_(T:PT..RL)>,CQ#*]>GOTMY)K=H7LA2^@NMU
M?(KYVDZ;<J1ICJ8@A+WFN[SMRMW!TA<H()2N36N2N\4E`V&5,^3%S.Y%C5)3
M<+$N2QYR_!Z6732R$/?I_P"F?[W'_!JJ'Y/[T^,]*_IH9$$6>G[IB(0/'DL0
MM:*?$(O)@0A-R6+,2R(O)H0%A-R#(?*A++"9XL%@P'Y.Z5G3,4%Y*4=/C2U0
M4+(<B)4:RTZ>4+(!8&#(BC8@,L60#"$8,Y#G(!A",.<"#C.(P2[4[I7LMZMV
MM=<],S5"UK?#&F6RK%9HMKG0++'J=K.3OZR/,T_M&4O[&W(6]3,')ED2>$0]
MC3R2P9N.,/[FCCQ,78'F2MO)C.J72ID^V5LZAE=-'6AKFU24S4EX.4L=M8*&
M)A4FB=Q2JR(>P%1-2E;ECXL6M3U5LF3/^75C94Z<X*8MO-<BQC/!)KU6732^
MY_Z9_P#NU5#_`/"?-,=+'IHXR(6.G]IE@0L`P,6-::@P(>"_'Y/`Q8B7<>"_
M*FY+P+.<%Y--R#`?*F>+0?2SZ:80"$'0#3/`@AR(.?ZFJH?8(..^,_V)?%G&
M,\QG:;])CIG6%8'4`3S3135V1IX)OA-X7#$SI3\3/2Q6(`U_ULE!,7CZ8*$L
MAI8$\AE$C>$S2B+)0)E[VY'ITY0E9WCEO/>D)TB*[ADGG#ETW=9'A'%V1Q>#
MF:+:_P`;D$E>L)$XQ%LK`QI$F#W=Y=SLE-K:VA$6!8L5$DG&DDB,.+C#JSHM
MTB-CY7>562;I$4KKQ>6N;S!6ZU:CM.GZ5?5[<SVE%CIG6LQCDVJJ3SZO)=&)
M8R)'9-Y=FDQC@QR2.R*//;>D4-Q)ZVKXAT\>CQ9-X3FG*HZ8&L\_;:>??@7>
M-NMU15NV5I6=B*(PDE(*J(<7`P#U.[)1LCU&UTN9H6SN++!$<E;D$ODS7)33
MHR"3F.BCTENV/_)VZC8^]^TM$_9__P`G(9:L],SIWD;M=0^O!:/:IK83"SM0
M%$0C3K1%</+5%S9%2+^OD(H^G=X^NRT!?G`DIQ>2T(R"W1>46N7!4*RPG8R.
M9Z6/32SC.,]/_3/.,^S.,ZU5#VSCY,_ZDN:8Z6'30#XLAZ?NF(<C&,TS(=:*
M@#DPTS/<PXS.(EC)AQ@OLC#1Y$88+[(8A"]O-?59=-+[G_IG_P"[54/_`,)\
MM/>>C728UXJ2>719.B>E33#:_83GIU/4Z^T(S>=GC.(;V9C2.<G:&&.)'62/
MJULCK*8^OC.TB=W5"6X.C>D&<K)C4\ZY:,I(!"I(9T!XR^R"<+)?YY5[=173
ME<W.(PZ)IT!V9[-YL?>)='DQB3'.*4B*(&>S9!)WHO)[GB.D-#>YKT5CI$#I
MBQVCH3L6S]!Q-)ZFF=059<SQ(V75S0UD'$"+D7I6V#PIV;9A;L6=)I8JU"OB
MKBI;*N1V`WI4$KB[;Z;->C5+.WY7`=+3II##@6>G[IH'.<>T.=:Z@SD(L>P0
M<Y#$\ASD(NX<YQG(<YQW#G..V<_7JLNFE]S_`-,__=JJ'_X3YIZK#IH^+(O5
M_:9>+(<`R+^IIJ#Q9`$7C"#(O@EWR`(_L\`SG(<#^SQC`O;QGI9=-+MG_P`G
M_IG[L_\`!JJ'_P"$^?GB=;*GJII_J?[3UU4]:P.M*_CKK6&(_"('$V2)Q-CP
MZTC6CXYA:8^Q(T#4W!<'ES<759A(D)PI<5RM8;@1Z@TP7NTWPVKN"/6$72-)
M;B]/+2M6UL+6^S.Q]P)S&Y?9CAE_*-6,:.KZ!!9==)D;&`I(,MUG]CR09+BI
M-5MD6A*LMM-DH^WT"NO;27R!ZC=K;&Z1[XU6E4"9R]B--\FQ!_KN:^AQ28F*
MV_7B:;67!'%M?&@XL++((--&N0L*@;$3)(*XM<DS*F3++GV_>_T]O\OR?)GY
M?=S!AM(Z;`:Q7@MM:-;:7[:WP#H_=;=>VM?I`.HT5%D5;4%9/"*K:JC\?8JK
M;[%9F]SM670LME7K[0>9(]-=<3<]<ZJ#52D:.I]#K\NM/L!2="VK9CM;ZB_.
MF%4>\,ND$B5(E*B-W>MGS-$+1+A9;>B:T[%5\XQ8;$;$8.F0E,D0#`S\,19(
MGIXP=EKGEA-M?)$JYT8YH\)E.%PQCA\-?Y=E`4WD`4GGN86)&K$WDB*%GR!B
MG``J!EF@*R(98L8J://K;*&%DDK.<-0T2%H;7QK4&$FIQGMSLB(<$)PTYX0'
M$#-2J"AB).``TK(L@,"$8<XQV_''''''-LW][C^Z$_Y4'/*1I[JU<UJ5Q%;`
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MK`V!IRSSY"*8)\H*R?:Y?*XCSA)*$?E-S5.MJA@;(Y#'5(-(6@ORDTXVT,VH
MII\G&N9LZ>*NZN]U[5ONVI<SJ@YLE.H5ST/>,)A,60II!."K>1+JF332NZA?
MZJ^!A+`2R5M'GB*+9(E68,10<D737WN;-6H#2K%J$65*ZVJ##O"Y1#)Y0PI&
M5-(WU6WC:$NF5SK*[.PRU]'BJ+Q%9M6SU4+<RN\DGHW"&V79,58(7'V)TF:]
MZ,;8UI);VF<.U]5S"$R#JM6)M=+JPJ^?TA$9KL1K;=6N!E9D%QT^<.B*#'SB
MCK.?W&?+*\N5QB<>E2PB2'Q:1C<US0^K)PYTONAIU2<:OB<^L)GK1+IU.:2B
MVB4A,J.UHX2[.M;2R*0AGD>P<^CQ]F/+XS*':.!=!?MG8KI`O9,MS&,V&I$F
M%&/K'3:N.&0?4VN3=3G*:5')]"*DH#8"LZ5MFI:1>ZKW'KH^`NKIL+/Y06^,
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M`5,9H"-Z[[A/-`:F;&CAC9MA+Z[V5K<^UZ@8G..099LOI=K[7UOZ\T7+V'-I
MN<.@;C,37J5(-\FRO9K(6&%NL]DQ2-K?T1T6A)Q7#M?IZ6ZXL=XUQ$=0F4BH
M[^Z>+;K]K#`T$^AZHO0/8%JMR\YZW+71[>I0J4L"14XVY6EK.-CTKF;G1684
M:"&1-*N9HQ59SSMV#I%N(X7DU)9C1ZW89]C'54T>W`B>X9\JJ)LPGUKJZM:[
MKV?0KT3+9RW63$I77;K%K`=Q06.QU3$I6UV,M>V9[<)*]R9(=8V7]+_;B>ZE
ML%3.%()$NPU3Z*]1O5^ZK(^$M:FLV],_OZ/+V/7J1`?7"69=WEM<;8$T;7O4
MIN8N)O5,31N5MC`UKY&_N!J.Z<@T'VSK"U+5LFD]=5Y55#L_IR6@^TC7EATS
M`W^^6BG]9[RI'8EKC2%]D)M;?ME128V'5-D)OVW%,<C%LGU(4WXF(5A$?>"L
MBMIZN3DOHYWKI_3-/R1HG,UU&OJE:GI>0VFT3-]C"ZU(Q-F""1.3VA+Y,"+9
M!&2I2VE2`3=)5D0BB!"IC4#4/,=9(^%9:.Z.G\]L=-U+9-#U3('RYAWSH[:V
MW%<3NS5DQGVP--:V>)K<:&Q+9]8+W!Q(*Y$\J+)@$`S+6JK7R914P!Q^'"6K
M'91:<'3CO1FAZJTZG@<(C$^;>H9;MS4=05A*VM;$*RTVVV@\<U_V3IN1H6<;
MA#6YFDI"^8[=GUA&375@03M#'8@F4+'7#F$^AD'3MV\JC72#,Y<8;+N>]8MF
MM;*P8:^;9#$&N:[0=+W46T)])JR@<A>9(MB\(S:+EBSR)[((-+Y)'8#-'BH8
MPQO[BDPZ>`%LVW0K:I@;77+UJ',Y)KQ.=P^J0JGNJE<W#0$)G!]-;K/-;O%)
MVTU$N\T_:?)20U!%YY`IE%4TX9+"A39:#G**^]+FM)B!VR*Z.Z.N-/;A;>WG
M9=#1=I42I'JHDHFSWAXC=GS`H-?:H1>E+C]$SUV5N-J)E3U)6A8A?Y++T['(
M;/;`D2"0>?J%!A2>UNRVGUK3+9XS8K6JD[&UGW%2WO5+4+:*KI_`VN@=B=88
MY(X>HFJ3<2MOAUZ5LH2*MP3F&1ML75>OLY%+&^O5$/F+9$0K5$=B3$^EYLNP
MS>OI%5E1-NO$P'LCULWI9<3&]UBC?:UJ/=)HM\.I#DKS#I8L?7IHCDAD]:2`
MZ!,&'4R$/$4$O.:TBIN1K5-#6UTR]G+AH9G21O51#5TQ:=']2]9;CJ7,SJ@I
MJO&^J8VNH&TEMMMCDAEQL:>66HZRK*YF^&V9-WILL:9)+W!&2V1`8WOQ9<D+
MKZ==\P>W]\)SJ/KQ`8G$+/0=.BP*LB]</54TR18[+K+9CQ+]C]9RLI$8"J]D
M-NM!A!B)\?V$VJW]ZPSES!Z-2B=0(*?L/2&]L-3$&)Z;SF94)9>K?4/J[.L5
MBV_34SF=%;#[5RAAGT=NV;HI'8X:61-DX+03*"N\>I*32U%2J.5E)X6VJFF7
M3P),H;-@<UJKI[=*FK;*9#8W8E:7_P!(:O9VPFN+6\B:)C";2IJ+R1OP[L:Y
MS9W0"9X:5@"W!M7JD:LOP'%'""/',W(!8\`?8+]Z'^T'\F/^3SZ\6/D%^(/]
M'C(L=L_OL?\`^`_T>>?+930&]9)LMMM,:V@1PYSL]L5T][VHO;AAE#&VNFL[
M9K4FKB#7/#)84Y/[--$;;\`H//UT888&Q2=CMA-?,@@TL&SITSLO+R#Q"G+/
M;NJ#?&PBZ&JTE.3/2;6BEHU-!.\9,*<K!JVZ-DI[+&GX/IGLZ5HTR=@MZ+>8
MNS@Q)6Q>M3/*0A1_6*<Q=D&\6/D%^(/]'CQ8^07X@_T>?!@L>3,]@OW@O[0?
M_%S_`,GF.G046,6+U*_?_NBTYQ[`BS[M8=3ODQ_-GW9^+DZ+"?I+&8++Y!"X
M.XV7+F:./#E&*^;'IBC"Z:/Z1"<<T1E/(Y2L;HZPB>5X2$(WEY6$M[84<8M4
M>5"3Y$W&QJPIV:@S3>%FV%HQ.V:\+4L*GI+83BXW)K>M?;-='UW9:[?BH6&)
M6#(V&)4IJU52%.IBS%+)<7.)8R('3T6R2"Q9(^NCO$S7O06]:EV-IHQOK]1#
M7"JM^-[-E+6VL9Y6QF-FR.M6TY-Q2V+U/)V$A^#.'Z9FSNQ:H;I#&99&BXA"
MEM`&SZ/OJY8XQ?TOZ"L"[8QC/BSG&,8SGP#]N>WMS^]^/F-/6$6,=0SJ:Y]O
M_`G_`+46??0\C^+&._\`'\GNS[>9+?%CY!?B#_1X\6/D%^(/]'CQ8^07X@_T
M>6!V;\)]/O[<JUO5;8,;PXQIGE-(I2*J6'26+.,@;DSZY89;L?8Q7$D+BJ$0
MY,;''Q];CGDIK&C:33'8:,@V"<7U-M"J="[6UMIB-JX*1<UAS1EK.KBWEF&F
MU-HS8ZQ6UOET;9G,I]5L1*2DH%*+"G+-&(4Y.[#''4:6NZU]+L#+'SE,G;RI
MM]F#KJ;4,,B/HZB8);$9L2RS6]<VH6AIBFO4</D=)P(IG5J?2B\MSN1'6#P4
M%"D5HDC-7CJ4YG)1+6_"F9F,XQC&/L\]L8QWR`??/W\_8^_/OS]_FOBQ\@OQ
M!_H\>+'R"_$'^CS00L=L^P7NS_:#^3_F\_,8Z^^<>MQW`]_^RM0?%GYOM3_>
MYZU>NC`M3:9JB.;0SNG>F6U6//+EK:IIGL?U`M9"]CV^-0KX&34QG;(W#V-E
M=+!EKUEPCS,T-\?CYV&F-L+A*9R[MX$#.ZO"'NN@+.JIL"F]AW>GI=HA,HLF
MN=@;SG+I\ZO3'4VG27<NL(RH6))#74S8V=:YV$`I4G-=)6B&X(5[";'6WRZ9
M4U*$"7/WRS0*)@1MCVG9SRF5R=ZMVNX74\H:I*)`[1HFO(2;/%:6+-30:W@P
MF:WUPLB5N$J(5*%P7Y2K2A4X"F;T:<JU&NNE%-ZSOYLHA!LO?GU)45::]Q!R
MG3XED*NO*!IY3(%M<4Y##R&EK-31..K9.[+5#F]#?)O*57HPZ9RV1"86+T=)
MJ7_V*R7^]][_`,V*N4;1?^TG3_\`T6U[_P!46?EU.......;9O[W']T)_P`J
M#GGZZ:739T/N72VH++M#56FIO/9<MMMWD\LD$4)6/;ZZ*;UM$1Z]S68.*$J5
M&XP$(CC`Y'D(``QG````&=WJBNFC\RN@OH67];X]45TT?F5T%]"R_K?'JBNF
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M1*U8K<R4R0TQ0:4066H-*&,\TLH.,F#`',<JZU`Z25C;%[":UIM$Z@CDMU[*
MH\UQ?I%%XB5'+"#?,1F<UB>:]$VRQQ=5XD+1!GS#JD=VYG=`F)S%*5N/;"_/
MQR12]*GI:KG)V9D6H6MRQW8L)!/;6EC;>H<6G#@4,]#ET0DN(U3?Y\268:CR
MM)(PK*`,U/Y0L(A8C92.H/25OJXMG:9AVA]0DNVKDDK2-R21JXS$'"+385I5
MLAL^//$'<(U+'T9[.6RKR4"STX2S.I#L4I(,:RRB@G&1]+KGI0@=]CX*Z]*Q
MO8;JURL.G*[/HEUCE,%V5=)U\C`&KYE1!1-M'1R95[)@@><I)2\O\6*2G0BR
MD3PE:5]>R5,DE\PZ!=&><K[9B0=6]2G-VI%PC\?O*.N<:8G1JKF0R.,M,S01
MJ:*UZDR-!7!8W=I<E"8\\TM.6L;S5`23%*8`KF+NEMTJ&I.E4..IFL;<E5D(
MCD1JQB:$290F7J4K<VC2#/="B34ZM4L1(4`B,B)//4)4B7(S#B"Q[I/2QZ5R
M@"XPC4G6@\#8[Y8'$93`V&A;WP.20B9UN0.8L)'4.5!&!-JCR:X.3BL93X\J
M#Q?)'2TZ5:E"VN:?4O68]N><=VA>2Q-1J)TQWP'NVJRW02=?CQ"P'ND-.QXL
M^'OW]G-U/TK>EBJ>#(^FU&UK4/I3:0\',Q$>;378MI4F>13.AC:6Y"6@;E!O
M[D0O$1A(<9]@6<(6<8Y%6W=2NEY7%JR6F8CTVZWN>P*_H\K8JQXM`V.OVV11
MVKG1ZET:BBEC9YM,XT;-I-,9!`YBWLS"S'%(T>(^=F1OS&K>HD@D<D&/IE=*
MI[;8RN_J/M=FM5*VYD7M;([1AM1/8AOS,)]1-XFTQT\Y$Y>CRE1PT90##<@1
M+32PC)2G&`[@OI8=*\YS=60K4C6DUX8TJ=:]-1<?;#')H1JRQ')%;H@"YY5M
MR544$1J90L)()4%XR,D8P8SGEO%6@_1M261!J@,UQU8-LNR6>;/\(AJ)@1.+
MT_LE<88L39U2IF]<J\D@CIDF8$R]2J$04%8[(D10C%1V"L5P7TO^E(>RN$B3
M:HZQ*F%K/6I7%X3LS,:U(E3>=E,N2K',+OZ/1J$:K^M592M22)(HS@I5@D7?
M&+)ZFZ2]*;;RET-VPO06JHBQ+I]<U>>@)C#HT:_I'FD;BG5+28Y0;%)-)(^<
MC7R6`NK@T*&Q[<"5#0J0GB.":8,L$D_5%=-'YE=!?0LOZWQZHKIH_,JH+Z%E
M_6^/5%=-'YE=!?0LOZWQZHKIH_,JH+Z%E_6^/5%=-'YE=!?0LOZWQZHKIH_,
MJH+Z%E_6^0/W]Z873]@L)UR5Q+4BDF!2^[YZ-1%X/;H@028XQB5[%PUADK$J
M$(XS)K:]LZY4W.*;/[FI2G#+,"+['(9W!Z1?32R$/?2N@OWN/]Y9?R?^M\^O
M5%=-'YE=!?0LOZWQZHKIH_,KH+Z%E_6^0YM[4GIC4M>5(U-+>F'&3H?>EH-M
M'QN\&N!Q%5!6JW9!`)59,:C3FP"EY=AJ6!TC\+?D"Z?L\3<(G'I-A$RO*U.#
M+HO::/KZD^CK8MSI:K:M#JL1QN1W9<^M5<6ZNA#1B$61?VO#*[OMQ5TP)B'D
MY^2?!M-%I^@9Y([MZ-EE;U6%A-S6:`#='%4KGMZHOIHY]VE=!?0LOZWQZHKI
MH_,KH+Z%E_6^?!G2+Z:6"QYQI707?`!9Q_J++^3/_P![Y!/2OIA=/V93SJ!H
MY-J123TEA6^DUB,4(71`@PI@C!.N^LCZ0Q-@0'EX3MI+P_/3B4F#W++4N:PP
ML(/+"QF;KSTH^E['FES?GS3O79I965O6NSNZN$33)$#8UMJ8U:XN*Y4>N+)3
M(T*,@]6J4&C"62G),,'G`0YY'+5S2/IH[31!58K)TRH'7E<.)3.ZUC.Y@FHF
M51^YXD^D*UC=-8"?2]S6F:C8AHB41YR.<EQ"3(SG0EN6,"=S0/"1NWHSI7TJ
M)-ME;&H9/3]K=LF]24S4EX.4L=H"P$PJ31*XI39$/8"8FH2R98^+%K2]5;)T
MK^)V9&5,0<%,6WF.18QGADSZHKIH_,KH+Z%E_6^0!UYZ9&@,@WEZA<+>=2J2
M<(M"/ZC[X),:F'IQ-\?]/TE('!\]&%!-`)-Z77EEK7#PCSYTI+`>?Y0T(1XG
M]ZHKIH_,KH+Z%E_6^/5%=-'YE=!?0LOZWQZHKIH_,KH+Z%E_6^=2_=*?I<Q=
MC>)+(M/==66/Q]K7O;X\.433)&YI9VI(:O<W-P5GK0$I4+>B3GJU:@T82R2"
M3#!9Q@/,=,.A71QL/66L-DH/TYH:_FWA=MDT+3%(.<<J.L[ELB<5A8]F0)]2
M-+;=-JUI#VI:)OJ>6SD$>DDP9Y.2Q)R&4QGS-E!$9-6O`.D332V8`F_33B;8
MUT?6U&6GMLYAB5?N0M5HUL*_.K!"B)TF8IR[E3-WCV&!^E-E):Q6RI'$8$SG
M2I$XR("YG0..2L/2,Z:`L8%C2N@<XS[LXA9><9Q\6<9\[]N,X]N,^[.,XSCV
M9YKZHKIH_,KH+Z%E_6^/5%=-'YE=!?0LOZWS3/2+Z:7;/VE=!>[/^\LOZWS\
M^#K34G5%*=3?:*L:G@,:@-?QATK+$?B4;;PH&5H"\4I6S^YA1)`C$$G"UY=7
M%Q4=L]AJEAYG;'C[8]TG4WEK_*3(;7Y[IN)J$FJFS8K<D4WDI/6*/;30Y*6F
M@,RC<@CI+;$P6M,:R%DJ:KF:7R:R*B9(R-E0N*)*\.+0^C4!N]TR$:$R!6;)
MD?47(ZD>)1,V10&TCFVHF=_@9+7$&YM!74@:Z>3-;0@6$*"UD@*22)@9I6G"
M[G)G$E20G2J,Y.>..4[+_P"Q23?WOO7^;%7*-HO_`&DZ?_Z+:]_ZHL_+J<<<
M<<<<VS?WN/[H3_E0<QL=(86,=/77[W__`$=J>X(L_P#UYVC\F,\R4^+'R"_$
M'^CQXL?(+\0?Z/'BQ\@OQ!_H\>+'R"_$'^CQXL?(+\0?Z/-!9P((@_98[ASC
MOX!Y]^.WN\/,3&LU47CI+=6\$;3TO+[OJ;:C:N9;B519<`?:W2JX])+>A\&9
MK%J"VV.<3*$.\>-C$OA@W""32/(IO'GB`O!"5[5Q^01_#,Z0DVDZ:%LWZY=8
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MLFFC3`Y-9U975%G)V?66U!2^!FMLV=;-@\>M.<MJ)*D@C$^DUMF\:S$02PM5
M6MRL>/=$[:;1R+FR>6T0_G(-F7&_7.1:^K&9Y%-%934UML4)3R*%3T`&G%>(
MUP$!)46=S%+.14>V&HDOI^RVR43;7A(73-R[]]#`N(P1O75@JS/[`@".P8%L
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M)K*DCN)5:FG%@1>1[OV/`SGI[C,@K\J0LJ"1-C1E6@C+S.&E:@C9"4]J*`G2
MU`OZ>VSTFC+!$I%2R=9<-0VOU0)%8.QQT@KP*3<6C]LH7LFW515YQ1K^HD+D
MLF<BM^D5TOC%KI8_$:H<=?#%S0N4$-]<GK.0=TK;A9('H<12E&UE35NPOI=;
M9ZM7!9[,*MXV_P!6;<VQKWK9!*TO"2/D3&?()^<TRRGI6W'SN#K93-$9;JW.
M!>"4+@X+DG<1_5+9A&QT)<K;I7944.8-JJ(LG</5*5;!TS.7:]6VN==+%H<N
M95P@8YTU:^*(W3TRD%763$FZ5/$"F=T):R;I+/6)GF<'K]J5Y)>D]1-BZTZ;
M,]/V?5Y5//K+>VW$I9H"C>(B^H&6`VGM5<-KUN0A4P5T>8\D2EP:;,*8+2F5
MA,:3$QB$Q.0$DL',DGBQ\@OQ!_H\>+'R"_$'^CQXL?(+\0?Z/'BQ\@OQ!_H\
M>+'R"_$'^CQXL?(+\0?Z/,<O4I%C,!U<]_\`NBO3ZQ[0BQ_PH8'\N,?)[_=_
M/CF1@`L>`/L%^]#_`&@_DQ_R>?7BQ\@OQ!_H\>/'R"_$'_W<QB;54_96Q6P%
M"F1"M;GJZ6:K;%4[:L%V7)M1A9J=E-5K#6A3L="SZ]BMC.$GERR>UUF64,KC
MUAU2U&)5TC*ED;E2*.IEK@?%2I=&M@XO:.KM.NL52-])ZH=13=?>L-RA>&(]
M/840OI/LJZ4U7K6S%+C)2"?-\BVRDC;8I[I&VE@;VFJ1KVMV7"EC`4+/*'.`
MA"'[+/AQC'?P#^+';_B\U\6/D%^(/]'GP8+'DS/8+]X+^T'_`,7/_)YCIT%%
MC%B]2OW_`.Z+3G'L"+/NUAU.^3'\V?=GXN3ALQ8Y(JYGJME@!MK.Z6&R8]MK
M`I9'FLVQ%Q3,L$F@Y3E,3T<20F2HS`6,"J3JTL>)$NP-Y4D-V%!H,=&L5+/.
MLP+]MVB]1I'4T.ON;T$YM.E;(]TQ!!P:4$KP0*\;T$SQ>=NU$PI2^Q9V99C+
MHE`)0N7S%'467\"199<\4-6;DQ"G+/;NJ#?&PBZ&JTM.S/2;6BE8U-1N\9,*
M<[!JRZ=DY[+&KX/IGL^5HTI+!;T6RA=G!B2-J]:G>4A*C&4*<Q;D&\6/D%^(
M/]'F-+6$6,=0SJ:Y]O\`P)_[46??0\C^+&._\?R>[/MYDM\6/D%^(/\`1X\6
M/D%^(/\`1X\6/D%^(/\`1Y&C:ND9SL!6[5!X#<*BEW-#/H=,7!]S7,7M!KD3
M9$EYKN5$I!$I>:E;EC*L?"61[49*5$'C51]$D4!6M*MS;EF'G7S2.W*VTU)U
M7W@U.3=01NM'8W=:8G(@,^LS.VT<@M6[[$FL&FCBY2>?,SHD-M?,S<;+,F]9
M*':R:1=GP,;;V?(H\U&`JB\.EW*;.@T3H]K=;-(G%RZW:S:R;\;-@G:5L@MP
MT;1:TI4\%*XHX>F)K/[^D3:IFT!B,L]$Q)(T16R9"^6+,WP+(R0-YSXE!`46
M`L`<A``.`!"$`_"``<8"``?L<?8@#C`<>S&<XQC.?;S<\6/D%^(/]'CQ8^07
MX@_T>:"%CMGV"]V?[0?R?\WGYC'7WSCUN.X'O_V5J#XL_-]J?[W/<QU<8+>D
MWU[@F:1)W!/#&+F99%99&@]EUY5NUYM?F0*Q8SG-9/=IX'#'8E-+)+&%4JCB
MLOTLM8"5+A'CTCJU$JR,;&C,!ZA*3J(M4_V'J'9AF;U--ZY5HMLAZN.EWZME
M33`:GOYUN%ZOB(TQ8X8]*[>L%[E.N3,USDVIRU!UA0FQBH<X1R"M)8GCT\X[
M]L=_?V]O\?-.^._;O[??V^/M[?;_`!>S/M^7V<8%@7NSC/\`%]_W9_BS\6?=
MGE/2_P#L4DW][[U_FQ5RC:+_`-I.G_\`HMKW_JBS\NIQQQQQQS;-_>X_NA/^
M5!SS]=-+ILZ'W+I;4%EVAJK34WGLN6VV[R>62"*$K'M]=%-ZVB(]>YK,'%"5
M*C<8"$1Q@<CR$``8S@```#.[U1731^9707T++^M\>J*Z:/S*Z"^A9?UOCU17
M31^9707T++^M\>J*Z:/S*Z"^A9?UOCU1731^9707T++^M\>J*Z:/S*Z"^A9?
MUOCU1731^9507T++^M\9Z1?31[9[Z5T%V^/_`%%E^[\KY&BG=*^E'=%K[+5`
MR=/NOHX_ZL6)%JPL)UE<!B!$==Y-,:YB5KL/P,5,4X?G)T;E$$G,4=S5;NTQ
M\Q.>[@:!ILNJ->D2W9>NFYTD(]+X!`7K5G6A!,[3Q*15Y&C8L2)WEQ4(:"WV
M7*65(2J-&J11UJ/2J79=]BC1B7-R8T_"MQ0IU%8`Z3O3`&G4+`:<:["2)!*`
MJE08FE$G3"1Y%A6%0?A=DHD27(!X4X-&#*?(18.P#PY[4F+IK])(-AM=3?U+
M&LV;)>8,[V8VPLN,)S']5`6)]88RY2W"(M6(13&2_P`F9&DE<?DHI:L5B*09
M5>9K\I8VSC6?I&5ELVQZOV-T^()`WN7U)95R0*U)=#:V8:0GD>J!(W.-C,4<
MG2^SBE@9S$VAS)D3W$7J.M#BW0].Y3A4(N'-:][(KRI]*^DC:++2ZEPT8JNI
MYE?L-DEAUM45K0!A9K6<X5$P,:AZD2Z+QR4RM.U(T2*3Q=:K*5NH5;8&2,J!
MW3M[VLRU%2%3])GIB*DX%27377I2F,&(L"A/$4YQ`S`F9)$`!Q2T98AA.P(H
M00BR+!N,EYQY3&0\XIO2-Z6SIA,!3I/K6Z8*R2[H@*H*V.6"3$IG9,[H0'J%
M&"3DAH\^:NB7`#4I@\^04%C%GOV!?22Z99OC\GIAK\9Y/.,#\$.)%X,Y"$>,
M"[+,^'.0#"/&!=LY`((\8\(@YSM'=)?IC)A)P*--->R!JSO()`&Q!.6-2?D`
MAX)3A&M#D\[)8!F8**P,S)8!#P'(`YSBQ.PNC?20UO888X3'2>FWV3VA84?J
M6H:WB4";5\[M:T).4O6-$*AZ%T?&9H"L"T-#W(WQ[D#TQ16)1-A?I5*GUH8F
MA8L!TM4Z6]*2Q[0L"BI#H+5-2WE6T8BU@/E7SV(Q4]S=JPFR]Y9XM:,*?HC*
MI)&)A!G&0QR0Q=>N;'4+K&).S*6:5LS*:L9#7>1H.DWTPQGE)@:;:\B4J"1J
M"4X8DFR><G*&$LT\HK"[)AI!1@P%F'`"(HL8@@&((LXQRP>LVD'2?VF@LHGD
M)T+K2,(H?<=V4:^,\ZKUA;WU--:$LV1U-.!8(8)3)&X;4=*(LYF,BH#H,Y8U
MY3*E*9$>:-*5(GU1731^9507T++^M\>J*Z:/S*Z"^A9?UOCU1731^9707T++
M^M\>J*Z:/S*Z"^A9?UOCU1731^9707T++^M\>J*Z:/S*Z"^A9?UOCU1731^9
M707T++^M\>J*Z:/S*Z"^A9?UOD#]_>F%T_8+"=<E<2U(I)@4ON^>C41>#VZ(
M$$F.,8E>Q<-89*Q*A".,R:VO;.N5-SBFS^YJ4IPRS`B^QR&=P>D7TTLA#WTK
MH+][C_>67\G_`*WSZ]45TT?F5T%]"R_K?'JBNFC\RN@OH67];Y%?8+4WHY:V
MS_6ZL)YIA3Z^<;2W$U4O6K%&J[1."A.[N32\.Q\JE!JMY;T[)"FH+0%N6N@C
M5"U4\NK4U,[8Y*SSP)NXC.E/28E.T5HZEH]#JX16+4]155=3Z].U8($,*>(=
M;TCG\5C.(L[B?S'%[7(WFMI.F?!X9TS8A-(*3)W%:JPJ)320]45TT?F5T%]"
MR_K?'JBNFC\RN@OH67];Y\&=(OII8+'G&E=!=\`%G'^HLOY,_P#WOD$]*^F%
MT_9E/.H&CDVI%)/26%;Z36(Q0A=$"#"F",$Z[ZR/I#$V!`>7A.VDO#\].)28
M/<LM2YK#"P@\L+&9U'])'IF)B35"C3#7X@@DL9IQQT.)**)*+#D9III@U@0%
ME%`"(PP8Q8"``1"%G&,9SR,^MVDW3!V90R&11?IH1^&U\BPU+8%9T^K^MB(-
M=D:>S',35,JE5PRU)N\ND76M[>D>"5<J9(>O]'/K+D38%::O1-_/C>D_29D^
MTEIZDH]#JX1V+4M1U9=+Z]NM8(4$)>(?;LDG\4C.(J[C?QN+VN2/-:R=,]CP
MS)6Q$:02F3N*U5A42ED=ZHKIH_,KH+Z%E_6^0!UYZ9&@,@WEZA<+>=2J2<(M
M"/ZC[X),:F'IQ-\?]/TE('!\]&%!-`)-Z77EEK7#PCSYTI+`>?Y0T(1XG]ZH
MKIH_,KH+Z%E_6^/5%=-'YE=!?0LOZWQZHKIH_,KH+Z%E_6^=<[]*'I>L#4Y/
MCYIYKHSLK,@6.KN[.<62(&UK:VY,:L<')P7*EY29&A0(R#E:Q4H-+(3IB33C
M1A``6<8YX97_`$D+7HVL+[H[I22^\8Q:TPO"+L3#7M"0M+*F-NH.QI-5\KF\
MW36-:=>L<-C#S)8T+X*(WM_3S)S2NJ+SF)H52&1)V.M8A1_2$L:-ZX*JYZ<\
M=EMD;058GO*!4<&M(<RV7&:6,RWEJ+5M<YVGQ,$KB$)U+RR-Z)R=9HI62UX=
MTS'`6R6O"=T1-L]/5%]-+YE=!?0LOZWQZHKIH_,KH+Z%E_6^/5%=-'YE=!?0
MLOZWS3/2+Z:7;/VE=!>[/^\LOZWS\^#K34G5%*=3?:*L:G@,:@-?QATK+$?B
M4;;PH&5H"\4I6S^YA1)`C$$G"UY=7%Q4=L]AJEAYG;'C[8]S/5]U]=-^ZGC>
MJ5.QO6RY+7@%VUE;D^H[:&R[BK6L5U8YA5F(4LBFB.DG-GLZ41]4]."1)#5+
M`0\1LJQ&H)KGG*J(/"5%2_2%UC<.GFPV#KY;]7:7ZY6%=-HXG=<U7IU9EY6'
M%9JQQVK6)%*)JK1[!.SK9K6Z,A[1Z&DSAAO9X$D*Q$TZ56>_/X!.><@6>V._
MQYR'&/C]HA8#C.<=\=\8SGOG'?'L^/GF<7]1"V&M9;NVECPNQ76/R^V.HAK_
M`*"QV.S]4GJN%RO1>LKS6LZ2XZAC;@UJY5-MC7K7N[7TN;RS,X^!06B+P*/1
MB'-A_P`-)+)OI^VS9#)L90='/MHR>VFB\^DY2FYEC/\`+Y8\3%6*_5EB-$6E
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M+:QU/9S6*.O9+/*96PN[>5'V1U`^&D)K20GI];+5]=]?V7']/43[%:;V/ZT:
MRHH3F;5K`$D2J[9ULC,WU*)B[TT3$A\JBM7V:M$H;DB>O`$S&FY!)L/J:#LA
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MUMP[]/`M;L!'NGIU`:2MRCW.U*TCRZ(7[;$6HY;7$7071#;/;I477;Z[16WV
M>`V+54T+G$6'+$XS5->.TD=I`T1NC>BFS#V%[CB_5^?%5N=U4.FQMM'V20-E
M&5\S-E(1O7*GHALSZ/K>#60M9(N..2.#RQEG$#2&/DBF21Q;AN;O:,C=Y&\'
M6?NO0J\:@H.:39/KD?7,:KPW]D!+YR]HW"NTA$3U+NRI=@)+J)%"R&.7+5O[
M5A3LZP-VBM319(K1UG(VD3NXPZ+N:'T@=?*G=5K:CL-#L%JQIJ:I9[?T&TNJ
M63U79*>O%,/L_;),\-DB!NG8<&?;!)0V,FUHJUQ<CWQV5O(YWL"^/#+`6,WS
M=H531LI#;?1*_P`ZA&BA=:-*[M.0UWK#:2JO+JDTVJIQN*<;)@V,J>X9:\2&
M/*+:S75-OMNJ8\^6%'Y[!(^DL-<Z-K/5<7E%+UW&FV+2'-CNS0ME618>AFV-
M;1-TE$GTRO:1VO)Z0/5,"*4S2N;<H^=4M8#9%E2UU!#S[4@".<(Y?'&IQE3;
M'Y`='WN/HY*2XN3*K-QD]1S2S93>-YVLV#@=(RIL'_4'-NF&O]7RH^)16SK5
MG$LVBK>^K`M)1Y_+$+97,0@C773)'8$9*Y(S2EV=ELZ=P,[6W?!E1)?JV=/;
ME8M[*PE]`:3O%:5%2^ZVFU@QJ55.MKY`QS"A9!4EPL=\O*@J36,@=ZV^!%G6
MBO;IG1E7QF`Q&0-69!;LI_;<E4T+)8<J734J6SZ:J*[X_:\*<X*]RG>3>BW(
M\W.:Y@<CG2N[IV?L:TJYDA1L;>7Q(G+?8?*6I::V+E*5Z:%8E+:\-J%:F,*S
MD1\6/D%^(/\`1X\6/D%^(/\`1X\6/D%^(/\`1X\6/D%^(/\`1X\6/D%^(/\`
M1X\6/D%^(/\`1X\6/D%^(/\`1X\6/D%^(/\`1YCEZE(L9@.KG;`O]T5Z?7O"
M+'_"A@?RX]WL]N?=CX_?CF1@`L>`/L%^]#_:#^3'_)Y]>+'R"_$'^CQD6.V>
MWBQGM[,^`6>V?E[>'F!_>S1'>"TMCZ!N2F[T@\AC+9O9KM:[E&I!0S2=(*0J
MFJJYLQBPI.FZ^^8MBQ83'9!+I.Z%P5FB#-*%TDMAQ?0N*T#$,)TRH55-FH.J
M??MYKH([H*=EFC6L%/1F?G+&`QK>+%K&[-EYU,(Z2V)WHZ4I\MT<MN(GIW9R
M8$+,Y*,NB%`X'JFPXL>1;Q8^07X@_P!'CQ8^07X@_P!'GP8+'DS/8+]X+^T'
M_P`7/_)YCIT%%C%B]2OV"_W1:<_VHL^[6'4[Y,>[Y,^[/Q<GA.51B2%2]61#
MEMAGI8O(5)$!088PKYN<0T+#2X@B'*ES3%P+),(.&1,*1NK8PX.7`]+N"-O\
MX4%XNM2:C*UJ-NVZ*!T^LZC:>NU9KPF:M(V1-5,(<(A9Y4L?X=<][L];MMB9
MIRK6%7"I3!5\Z88?*2E\T)IM_FB&++I2_-F9;=N&U39R'JI;`7FN@SNCIV6Z
M.:Q4]&K!-5Q\36]6+6-V[,3J81\AK3O1\H3901RVXBH3NKDP(F5Q4"<T*!Q/
M5-AQ8LB?BQ\@OQ!_H\QI:PY[=0SJ:Y["[9_J)_[47_V#R/[W\_R9]F?;S);X
ML?(+\0?Z/'BQ\@OQ!_H\>+'R"_$'^CR,VUE-63>];-<(K&V&"I7-//8?*'Y=
M+ZF*N2)S"-1A:<ZJ(')H8;-J[4*6)Z>26)P<AI)2D\[3L@F1R2.C$\.S<IQ>
M:LZN;PTUTS+GUYL5P;7Z\KCV'V=9(N=&HPQQ0ZM:YVBVTL`4DMY>Y--C31N=
M<%P6Q)1L4V)"'!$^1%"YM-8J6QXD$>-<'.T&X^@%T!M[:QQU\K:8G26\M8-+
M:AT@NZO)D3%,Z=V/JW-YY@"&2'*)$UN45@+4EF+#:@7AD;7Q--F=NL.LW!K4
MNCHS,4M]&Y.1!*+":,1AF`!P,SR0B_*#QC&!#\&,"P#`Q8R/`.^?!@7@QGMC
MFYXL?(+\0?Z/'BQ\@OQ!_H\T$+';/L%[L_V@_D_YO/S&>OOW];CM_P"P7^RM
M0_VHOBU]J?[W/>3U(=:^F?=59,<OZD[11;)`X*\$MT4N*V[(+HAW@KO)C0%A
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MH!SH:<XJ'(U.@&COQ+\8S%9+WQC/^I][_P`UJN4;1?\`M)T__P!%M>_]46?E
MU.......:9QC/LSCO[<9]ORXSC.,_P`F<8SC[^.8[U_27Z;3FX.3HLTMH`U<
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M*J!]OO\`]19?UOCU1/30^950/T*+^/W_`/I?Q\>J)Z:&/=I30./=_O**^+';
M'_I7Q8]F/DQS;-Z0G3*4%&D*-(]>U*<\LPD].I@J90G4$&@$6<0H3G*!DGD'
M%B$4<0<`91Q0QEF`$`0@Y^B^D-TS"BP%$Z2Z^DDEA`6423!B"22BRPX`6642
M6I"6446`(2RRRPA`66$(`!"`.,8^L](GIH9]^E-`Y[=\8[PHK/LS[\?ZZ^/X
M_EYKZHKIHY]^E5!?0LOZWS3'2)Z:&,=L:4T#C'R8A16,?S>=<>J)Z:'?O_44
MT#W]GM^!17?V>W'_`*5\6?;CY/BYKZHKIHX]VE5!8_\`]++^M\>J*Z:/S*Z"
M^A9?UOCU1731^9707T++^M\>J*Z:/S*Z"^A9?UOCU1731^9707T++^M\>J*Z
M:/S*Z"^A9?UOCU1731^9707T++^M\>J*Z:/S*Z"^A9?UOCU1731^9707T++^
MM\VCND'TRE&`!4Z1:]*0E'$J2@J8&E4!)5)AX-3*B0G*#`E*DIN,&I5)>`GI
MC<8-(,+,Q@6-WU1731^9707T++^M\>J*Z:/S*Z"^A9?UOCU1731^9707T++^
MM\>J*Z:/S*J"^A9?UOCU1731]_\`454%W^7X%E_6^/5%=-'YE=!?0LOZWQZH
MKIH_,KH+Z%E_6^/5%=-'YE=!?0LOZWS:*Z0?3*($<(C2+7H@2DX2E4(B")2!
M*E0P%E#5*Q%*`"5*QE%$E#5'Y,/&4224(S)9)00;OJBNFC\RN@OH67];YIZH
MGIH8QVQI50/;Y/@45V^7W>=]O?[>:^J*Z:/O_J*J"[_+\"R_K?'JBNFC\RN@
MOH67];YM`Z0?3*+-./+TBUY*4*?(^=*"H&E+4*_-P9*3>=J`*`G*O-BA"*3>
M<#,\W*$(HGP%YR'.[ZHKIH_,KH+Z%E_6^/5%=-'YE=!?0LOZWQZHKIH_,KH+
MZ%E_6^/5%=-'YE=!?0LOZWQZHKIH_,JH'W]_["R_?\O^N_?S3/2)Z:.<XSG2
MJ@<YQ[LYA1??'\7]=^SFOJBNFC\RN@OH67];X]45TT?F5T%]"R_K?'JBNFC\
MRN@OH67];X]45TT?F5T%]"R_K?/H'2)Z8X0]A:*ZQGBR(8Q'+*ICRY28(8Q#
M$(U4L)/4G9\0L]LFFCR$.`@#V`$(<1TZZ,:@3WJ=7#S/KSK#7U+!]DH%*&*:
M65J2AWD->)"9"K,C*2!P'6):UNV++G$N3R)2D*()3%G1V,)I+*PK$.&3*PFD
M.A,1#1TI>;G#MB:DV")7W$V%NIU<Z*LO3IDD!<T%=1I,*)V7K6UM#2I2/YY`
MBGUEGCEE>*6QEQ;B4"X3>R)TY&=/CCE.R_\`L4DW][[U_FQ5RC:+_P!I.G_^
MBVO?^J+/RZG'''''+<6?;M:4O'T\JM.:,4&CZMU3,B5U?U64J50[*R%2I.@)
MR`LTPQ2:F1*S\``7GL2G-,%D(`9SRF*JV0HR[W!W::GLZ*SMR8425Q>$3`M,
M4J$"%:H-2)52@LU.1D))RDDPD(P^+&#`^$7;N'O>[CCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCF%+J?2>]9\S/]6UWJYO$=):
MZG%(R>B+\U!O"D:FL&12Z9Q:W16&3"5UD+'-@.8:^B4?61ZT(I9K`<Q3!!-4
M>&U&E5HF!\.JKI!1BWV*`7<MOVN]RHM;#A9#"G>IAO#=E6W3;,X9T$(;3V,M
ME44<F151!(%%#'5T;F:#1](0[$N[@_2:3>7<)(2I.S!\=_;V_P!/Y_=S3`L"
M[]OB^]G'\N.^,=\9^+..^,^WMG/;E/2_^Q23?WOO7^;%7*-HO_:3I_\`Z+:]
M_P"J+/RZG''*9FCVHC40E4B1DDJ%3#&WUY3$*?*83G*&II6+R"C\E"`;@DPU
M.`!N2Q!'Y,0O`((NV<>?**=9J\'-]C"9WIVN%C8Y.K&0YH8O\,U,D5(ERM*6
ML2QQ,H>#2%+X<2<84S)CRQE*7`28@W'A,$+&=&C+2>+B@*:;/-7SVHU2IU=D
M)43LA`G;))E$WJL$I'<:).<8,A$ZDYP<E"J`G48$`W&2AD8(4J,4.\^N_4&N
MN.JDJ]PK.?PA#9F7*(UC5S;AH?D+8%._I&:3O[_-#VP9ZAO:E0&]R;$3LJ+-
M7NABLD@29,`95,=/6C-B]5%NP=CV-1DU/"55C6.,QAG<(HY2"9O+,].#D:P,
M*9`_KL9<34X@"+\Y"6`>1A+(PI4B`G'D>H3>JA+[<RX@V/BZ"6@`64R^J[(0
MCBDR3N).,A4H4)"P6$+Z>2,!N<D-*L]>$D&3E+>E[#`7,COC[_\`)C.?\6.:
M\<T[X^7'\^.:\<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
M<<<<P?\`6OK"OWJN::LYX<NI".Q(C8+P@@D/Z;-U/%6VE+R@5=9<BE)K^4OD
M[/7Z1BB<+:I2_*9DX(A2].0$V$1Y:I3S58S+>+T-G&(+*IV`#&X1N\PNBRU8
M/*)-,NH!L-#M@KZL04PHZO'J&NY3Q$93)"6BOV^MQP]-!\GY**>VE2%>C5K<
MD*B&S.3GOVSVSC&>V>V<X[XQGXLYQ[.^._Q=^8!]EYQLUJSLC?EZ63$UD[1R
MVFMJ9%I#+ZLV,V+%"XA)*)UAD-CL%+[":<OKRCHQW?I>U0Z?3*+W3$&:5+ED
MB3KHS(4#0LS!'(SO>GG8<WBVR5`TGFR9/9T9N[I(4=N%:;]*90^3%0[["KK'
M:(P^VPC7O3D[`91W>WS9Y.<69G/;XV,%<-`F!I)"WK1XS$6Y+5L6BSCA)"9E
M,?2;-(23<Q)*Q*,-(26DT6%#KE[D#%Y(@[R@@D91X6FC$2:$10/W/)FM&8[4
MI4&.^,]JNK['?'NSVB+/[<=^WLS[\=\8]G+I=\?+C^?'->0;WOVOD6I-=PZ8
MQJ'LDP6R>;ABIJ1]=7!K2(TWP>>7H:LL;:F4'G'Y,;"TX2A9++"`T9F1"$$(
M,QCU!W@MO=6Q)'6SW6E?1BN$$"?3Y\XM<CDBB3!*D!9C$PEL&59)2;Q*%8EI
M*\!J?/D4V<+"UA)R<E*MN1#^DUJW"9/%98T+K8.<H>_,,B:B5\X2GHAKXXXI
M'-N`M**CJ<X]-YTB(\X*`H)&<7@8/*!\6<\R;XQC'N^/.<_RYSWSS7MC/OQW
MYIVQ\F/YL<MI)*9JF7S"+6#)J]B3W.(2N+<HM+7!D1G2!E6$EF%D')'7R85F
M?-L&C&E+/-.)2GY\X3EE'X"9CS^=5VU;*ANTB)FBMESR)M/[4T,68:8[-Y''
MFWSI0]3$!ZO"!J=4242@\)!0#E.2LFFA(*`,P6"@8#/_`*5MCWI.:6+(L-E/
M=Z_;S'L4*MIZGQLFE,L=12QW*?6%R:%ZA>[HD<:&'"1O7JU1))I!0"$I!H.Y
MA,CK_P!CK=I^6(F.&:GVI=,<5,:1R436#.C'E$A<%"EQ)4-&6<PM4XC5-R=&
M0M./5>8(S@K4Y)1V?LC.>?YGZEVZJJ1LZ<^W093*Y&U)CT8J_KP(,I53TF(/
M2"R&,A."#R!HT^1`.":''?(3<&8P9SUA8_\`[S_@SGFO''''''''''''''''
M'''''''''''''''''''''''''''''''''',1'62<'-NHO7X\C6N4[=1M/N/2
M;O85`0"B&N^[$G$#B[7/):ZF01I=I%&4T$D<;7,37(T]C8<@Y:TS<ICIP2T<
MI5'E=KTKEFO+PT;+R>B.GM>G3V7S&\<3&U(9L+6"*I9S9\^E,3;7U98C7%&J
M7S=D1PXP"\QI;"&!W0LB5\3R4I-'6A5YZ);EB_T_FY'B!:MT[7$OE\W8FR6N
MCW,GJ8OJHF=V=9EFL$:66$ZGODZ3US%K%ETHC57LTM=5)JE]8*^:HVRKB@IV
M\:'#4C1H$_S2&J=%Z[+WASJ>%_!]P>(O#8%A6L?I))#F2MZY$^CKRKXF.3.[
MOF(UE!!R>0F1&!1OT;&6(UZ<343>`Q1D0;SR_P#L5DO][[W_`)L5<Q>2KJ%4
MM2-4-U0JGF7MENL%!P<IG.00M8ZM".2O]0,CU$U&',836XXHH]S:SE(CTYJ8
MD>#2E(!EEF8SC%UVWOV]E=[4C%Y/=;^\,$DM&`1^0-BEBA0$SDU/$A;F]T1F
MF)8NF4%EJ4R@XORJ8X@\O(L&$&E#"$6,YEL=0'6.DY^_5G84Q>VJ7QOT;Z60
M(X/+GA.1AV:T;RA\FX-;2J1*/*MZ],:+R!P_)#&(DSPF@&#%"2R"59U/:"A,
MB/-M.NXDDG3V^1Q08@C[6].V6/#W$1+\$+B9&@4L+H4I4*D!Y!A:G!I.2C<@
M,(/)S56J&B%=:DR*7R6'3&<2==,&1K8EA4J''O-4:1K<%+D68D+965L-RH./
M4>$P9YII>"@8"`L(A9'R<G''''.K6L;*Y&X/<&EL7'A!@H)RQO1JC<%A$(02
M\&'DF#P#`AB%@&!>'&1"SC'<6<YY:1$C;R`ID*5,B3`R(04Z0@I,2$0Q9$,0
M2B0`+#D8LY$+.`XR(6<YSWSG.>;X@`%C.!!"+&<9#G`@XSC(<XSC(<XSC/?&
M<9SC.,^S.,YQGW\@T\=.?44Q&YJ8W2T08Y0(E8J87LXR3N:1GD.<&*6EV-93
MI&!"X)VUU\V7#:C``2*BB,HQ!"0/(<4[J7LW/G:9R75W9XM"S[(P(H]<D=DR
M8AM8[@AX/W4F8Q8DA,@1&*0$"R>N1MJ0@@Y"`2\A(C4(7YM:<A/'''''''''
M''''''''''''''''''''''''''''''''''''''''',)W6=8"FB%4%;R&^.H]
M5TLCEMYAL/@?3D@1-TVE:3Y**]L4TU,14[NQ2!E(71J+))6]JYWDA,:CBQ#[
M'U)3FJ=6(;1W?1I=3W>LKZ7O"SJ5N\N<KD:W.4/W4^K%OIJY7A1FKX8S-!L+
MKUH98^VI*Z1,3"@;2I`6V!52"4))`)6J4Y;RL@S+<<<IV7_V*2;^]]Z_S8JY
MYZ;JZ?\`9-QS*O[&:K-I"*-]K5S2S3"(_.I8\LDI?76-4O#6MS;&UL(CJ\IT
M6APSJEX$S6J5GX;L@/.+)SXP!R?:X:"TK54(JE7-ZOK=\NF#HVAP=9\UHURP
M:F8M:LQ:0_(5B\"$X\Y,=YL8F4JFX@S!J<!F"09`7X8+[G=-_86]MD;`M:"+
M:VQ%I47%!-Y;])W9K=B1LT29F%:4K1D1AR(!_7;:<80,I8:$U.84(6"C/&6'
M*EJ)4\GH[7&JZJF9S0?)X<QK4+P8Q*U"]IRI5OSNZA"C6*D;>>H`60X%%C,&
MC([G`,P`.08",4D..........4XIA\362=MFJR,L"J8,S<L9VF5*&=O.D36T
MN`_*+FUO>C$XG%&WK!_9JDB=26G/%G(C`"R(7BM-5VR=86W8%J5;&UKHAGE/
MR!4Q2R-2-N]"NAQ*8\*7$C8DIJ@TUVBZA0,HHAW+`5C'G"(P\@@EQ;C%5_..
M................................................84NNXOJ1#J)"
MC[CCJ.01]OO2/R)F#(]KGG2B`(91%*WM1_:U,YV$C;8Z26/DG)D;BA@T3C1:
M1^L2TE,(AZ-Q0$N*M0'3HVO.DIJ#;>):+2JQ+&JZ%75"$#S9DANZ9;%5[*Y,
MZTM"WDU)7%K3MU?WI>=&$*E.S3V/-TA?HLQ2<L)[`X@`[K&YOS7<T[X[]OO=
M_=GMVQ\N?=C[W?/M]O;W9XP+&>_;O[/EQG'\N.^,=\??QWQ]_E/2_P#L4DW]
M[[U_FQ5S%M8S')7JP.DP8T,3HYL[*4>[O;BA:EBQ&S^0J6)X+.='(DHQ(UDF
M)`K1$86&I_.QDB"1DTTK!?,M(/WH?^;C_%CGUQQQQQQQQQQQQS$SU+8H54B2
M$;HUFL,B5U5W+8M%U;FA!G#?.HJ_JSD!D?F2(HPC#JD3!QYN$PP63CFDY0UF
M#\)34H:Z2T0ZAMQ[.W@KK2>Q>MFEC!`Y'*"E<3;I(B<P+V=RCR5.0(QVDCRF
M,1F$NRCRP<IPG>,LD03\8P,(\R?'''''''''''''''''''''''''''''''''
M''''''''''''''',;/5*.O%/KLPGU%7<YMJ()K:A"_8VLZJI6E=B+4L#7YK`
M[N<L@\%IZ_WV/5U*U$PD".*1R2FC5.$L8(<Y/T@@K(XRAM0B34GTMYW=%@12
M\GF7Z@K]&*"_;.:2]5]=9I&*^@5KQF`?`EG!-7F:5Y6B=,QP5KDUCDO;G$6!
MUPMDX2!/*U:ZN#*JCV2<J.<]L=_?[<8Q[_?G.,8]V,]L=\^W/;V8[YS[,<\H
M^Q_47E*CJ!,<ZK6676F?(WH_U5&*I=?W>B+^CD126-3+/2L@JZ<2<B758S1V
M5RJPGV,3MQ627"US@5?0--`HHN=&Z02]6;*)F].B7R.&[*:^4\QSB0SN%73T
M?Z"VSMU\?7=YDPI3L*X6.V1P^ZU;J\+'0:25WLV3"7J9082O"7("Z^8A%)\E
M1P`P9E[<D,F8HLX8CL"=YOA<S2$IPRU/<69_0Q1;2;DE2IQ)7=JRK+/$,80E
MMWG)Y?D1B,+Q@17CMM5UN0&*QS5VIGMZ&EG-H5&SKH4TA;G(\IT30Z!L3B^F
M'.!"8;>WY3I#@F$%N"A.-6((RTP3#`9#R3W'''''''''''.#AS;A.1C.%>BR
M[%(BG(QLPJ(RX%MQZ@Y*2O&BP9YR%&:J3GIRE0BL$&'DG$@,$848$/.Y9R]*
M+@&Q,`55M9*5T5QI6Z-#P,#.\*V->!>R*O/$!I2Y%GRN`A-\6#21!&4:6+(1
M![X"(,`)1TQ(]6J=)86H$ZF56WA$CS'&..$AE"N11F1$B*\"V*R%.N2G93MK
MN5CR!AV"5B(61>3=6Q<FR`:2?E!2BV9=5T?>+OK]/6ME8$X()''$;JA=T!AS
M8M.1$O;><@6+RTJ!^(*`Z)6TY:K4-Y2C"8U2?@(#AWFXXXXXXXXXXXXXXXXX
MXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXYACZYU/+;CU`B*`]MIAW@D-OR$3NV4
M&QVTM@:>T**NFF)6$VJU-H7/64CBTN;6Q')WB+'QMM1.@DQ\XQ&G!Q0+T#8H
M3YH;H/4PR5-0=Q.$+@.K</KZP+:02*)O.H.XUE[O5!./1D#C\<?7PBX+9E<J
ME::0MKLW&1MWBA)R)C:PM*-4W$'GKUZP_.KRW;U4]=2*Q89;3W$6ASL:O8Q.
MX9#)<L*-.=H]%K-4Q)7/61O&([S<*"4*(+$374HY.=DX3`WX`(H)8PF493FL
MM&4`K?%U15XU0U9(6:*QA<H2K'IR-30Z">FO@+`6$3XYNGP6KF#9DDA%"JZC
M/HB$1(3\\CCS`W"=%N3KJR_^Q23?WOO7^;%7,;S%5$[DFQ'3ZM%MC[BIKZ`Z
MR/B6228DQ%EN:GEV@+6@:6Q84:K`L">Z9<@B3#3HS\&!3&X$,`"3!%Y0\>S&
M,?)QQQQQQQQQQRDIY.X=6$+E-B6#)6B'0B%,+G)I7*7Y66A9V!@9DABUS=7%
M4;G`"4J-*4,T>?:,><!**",XPL`O"TV[V]4&RNH],.HSJ-J==]M4W9;8.AJG
M87VH[05U1+->V.2X;XN4LDS(G3H6!TS+T[E8*R3$.I[?$9.^OZ9V+6-"9T1F
M9]H5UU:NK^3(JQZB.O-Z=/.S#SAH@.=KQE?+J-?51&?-Q'Q:XHDVFH5S<K5E
M*,I%ZAE`T83!`:-\,"+!F<SM;VK6=Q1=%-JGL"%V7#W$.,H91`Y.S2QA4YR`
M(\EENK$M7(\'`P+&#4YAH%!(^Y9I0!XR'%<IU*=47Y9,>4H*\H<5Y4DP!I?E
M4YPTYY?C+$(/C)/*,)-!W\19I8RQX",`@XI.PXV\R^"RZ+1V6NT"?9!'79H:
M)FQ%)CG>,.*]&:0D>V\I4$1)BEO.&`\`>Y)N<!%YNI2J/)*2H.:TW;L%$;,3
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M$^5OCCE.R_\`L4DW][[U_FQ5R*50[!1-ID&N^MAS6^'3"4:QQ6S$SR22AS'T
M34TLK8UY;UAIBP#CZ16#3*SR/-T1R0)1&`GJ"S32PYF?QQQQQQQQQSY&,)8!
M#'G`0@#D0A9S@.,!#C.<YR(6<!#C&,9SD0LX"'&,Y%G&,9SSS.6[)Y3UT-GG
M36*JWIV8^EWK#-4!VS5LQ\\Y#_54VU'U`%S=3<$>R1`$L@[$J*+4N3H@&).$
M(#9:IP=E;5YRGTB1.)QN"QB/0N',;7&8G$V5LCD:CC&C);&5A865$2W-+.TM
MR4):9"W-R%.0D1I2`!+)(*``./9WSPYK`H/9,<<(?8</B\ZB;L5DETC$Q8&J
M31YQ*R$0<EKF5[2+FU2'(1CQ^ZIA9Q@0NV<=\\\X'4/Z5]':<T[:.X?3X+VG
MUGV(C:9KS%X!IFZS-\C5DRI]?4#6VM,HJ(A!*D1<2+4+!.$D4-A;:R-#*E7*
M36M:+R"%1CIZ3F[_`%;M;HG*:2%H!=6S5<1YWFUS.">8L\^J"W&TN<RE.Y35
M/!9'8C,5$YV)9,G]=+L04AK'*AKGY_<$"@YK":4VYVZEZ\VB4NE!%:WFY6;I
M;;V!D)%]=;;5V^58<F<QC\D>E*EQI2^'B3EF8_<UKDZLQ9Q>0CP66+.2PY@8
MG,HA/&)#*H1*([,8RZ%>7;9'%7MLD3`X$^SL:B>&=4M;59><9QG`R%)F.V<>
MWW<A%?>TMK:PW&0[VA`$3UJ1)DS&UM]E0I(YKI36TD,*+*<E%@(,'*"EC2M7
MFCR@PWI$>1MP2@MJAT?"CF93.F.2)CES`S2F,NJ)\CTA;$3RR/#:>!2@<VMQ
M3EJD2Y(>#[$TA2G,`86+';/87800BP(..ZXXXXXXXXXXXXXXXXXXXXXXXXXX
MXXXXXXXXXXXXXXXXXXYANV^C_57U^N28W/T\H30&T]=W=B++[2UXOB9.-63.
M`69$XDT0!-8-06.G<VF*K(7+H;&HN1/(++0"=&V1QDA]B*Y07*'M(VR)T$K+
M<%I8[)O#>]ZJ\K8V]7F+JU]6T?AV/J2C:\@3">QP>MH\_2!:Y/DTD)BMTE$T
MGDP6+1(E<FE:ACCX,QR/-2I5D(YL@4$&&G$@.+$:1@&3R@C#DPG!F,B+R:#&
M<B+P8'&1%Y'@.#`A$('BQC.<?*=6F5>6\V/)/\W.&F/\D8`SR*@KP^5(-\`L
M^3/+\0?*$C\)A?B#XPA\6._2R_\`L4DW][[U_FQ5R"-/T)*7&\M>]BQ'1\4)
M8M*HE6H$YBM9F2%RM=EN=,'D(`H?,\-F6=4<68L$Y>6\J(9&$?;(3N9$....
M.....:9SC&.^<XQCY<\\]_4*V/MS=O8!1TDM&I4H85ZM"0IWSV18@&K&V@JE
M7C"2ZUFT.*8TDE19$T1&C:7-J(6$G9+6"AV%2-0;-%L4S-ZU:W5#J52T%H.C
MHJFB5>0!H);&M&#R9KDYJLA"-TD<C<0%%#>91(5WE71_>3P8.7KSS!!"2G+3
MIR;[<<TSCO[/;_)G./\`#C.,\T\`?CQG./D%G(L?S"SG'?[_`+^6CN&@:1V#
MC1T/O&IJ\MJ,G%'%>A[#B+'+$B?RX?"8:A],(E1[:I[>T"MN.2*BA8P,HX`L
M8SC#M+.@K3<"?ET]T!V,V0Z?,]4F^<81U!/GF5U&N-QW,R4^5=+W0S"]$:;C
M&#$!4E);PE9$6!OR#L#E%.LQZZ&K3<NC]T4-KOU4:3.2G(7MVJI4CIV[W%@4
M`RD.3/M>OZ$N'2(\]-G.53:SQM[RJ'G.#7'MD1F.>W=?[3*M885!9E3]SZO6
M]$`1V/HM9[SKE53:Q.@PJ);EI44DPT+A!E#3&T.!*""SE#,<M)**+3HR2QFG
MIYUQSJX=/B1*XHT%[&Q9ODDNB"J:H(VN;9(:Y)FAN/2)'0*]2U,SFREJVY6K
MP2<4G=5):DM,M7-YJMN1GJP9'$RDA8G(5)C0')U))2@@XO/B`:2<6$THP&?9
MW`86,(PY[>T(L9YO<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<Q
MP]3V^-E-?Z`89-K!\`VJ;R*S(_"W*;V145RWG%H6W/K+),Q\:BN**3J9LM63
M:Q$D)K9))%N$T+A'PP.E4N6%(&XHLZR/2&VHV=V:8MG"-I)?'Y/.J;N..5@<
MAB.L%HZVQZ&O26LHV]SN%&)[6?'MYF4GBLV<W>/2AT9U*V)DJVE,Z1%^D45D
M[&X8S&9QW]F?=SSR;N,,QUAW9%=U%U"0URJW-!.H3$8#9M9S$3G.+%V:C<.3
M[(1HC8^!/$:`KE<1B`*^4,E"25!-9!B&R.3.L$5LT:CKU$&[';]-I6"%[-:W
M5O6"]8OJ^Q>BOK+?]N.)2=2-+,+H=K*+:X3<DJ<32_$X6A<+&]6VHE\G=E"R
M3S,B)-HWA687&46<9K;>?)@S19PQ%(/\,L+&>1%NF?A,U1WT206TFB)4=G,D
MW+AY<0S0^13>`97D?$/.0F!QR+&N.P[L[VO$]9\15&!BB>HU16;B7@7JS'!0
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ME/@_>*D64ZDH6`C*-`/&!8\)-K]`7J6-&QEH3G6ZG*NKJO"K1G:VGDS!?$50
M98Z^4OSJFBI)21ZRJ7)\*HN:F$N:W/RN"LJU#<<5DHO`,9=U?5(ZD?3DG)-,
M[_:SQ_96!L:)K):=@=9$ZR)2-^8,($1HGTJ#2,HJ-RXYM*$:W.B5G^!'F;@@
M5!-,&7@DX_+QJ5U8=$-T<IVJG+WCB6P#`EA5U#8V<UO:[>K,%X<H?@?*#$AK
MX>5[/*G1)9(D./$'(58L9YD:P+&?=GV^_.,^S.._N[ASVSCO]_&.:\<<<<<<
M<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<P]]:$NVG37VEXE3A^Z"F33;9J%
MQY=$]$K<CVOMV3IA+KZT7U?'C;UE(R62MHFE/9DDF<S3U*<Z:N+`TUZ2>E^%
M`EZ/I.C3"+:K^`7VPW#$M\87(16=%US>S]07:&);8VSZ%/KAC*(4Q2PH:8K:
MVJNC%:=86WQ,UQ6+&^1E25>9A&2Y$HB<S_\`I_-[N65K?7.BZ@D<MEM8U5"(
M-))R]2612AXCC$E;UKF\S1[Q)IBN\H7C.$1DLD@02*3%M@42=_?BB7AV)6.)
M)2D'95C15.4N;)3ZHK.%5\?,%:)7)#HG'V]F-=O1>%N&=&I,2%`%AI8\.3F%
MA9",DLK"%S<L,S>@PX+<'UM+_P"Q23?WOO7^;%7(>:U:^88IO']D\RTQ8*<:
MNTK6Q<.RRE$%M!<<8V5R&Z8?`KQF+O/1EX"%&-N(RFR8;G*H\'D2RIR\<<<<
M<<<QY=2'?V(:#4B5*0LP[$O.RW4NOM;Z0:P*ELBMBTW89")H;2&QMP)T'&VA
M6N0JY.N2!`;DDY$PMAHY$_LB51%_I\]+9IAL9FNPF_D:@6R&[FS3J1/+K?;$
MB<6G;%7.#2P#8ZD@"-Y0.K(UL\-1>;M[DK8"$Z%:M2$-;6,4;860.<PT.A,-
MKN.M\0@$2C,'B;3YUZ+C$/86F,QYM\]5GN"WS!D9$B%L1^=KU2E:J\V2E><*
MU!ZDWQG&F#%4_?EER+X@)\X/A07'`!%8RG`_&C(`Q*'8L8@GM12S)F.QI>,>
M`"LS`42A2$U(2<(X)?E;P)U:56#!J500I+SC&<#3G%G`SC.,"QG`BA##G&<"
M#G';/MQG&?=G'?D=_P#3/L_Q\XZ56E6DX4(E*=60(9I83TQQ2@D0R3!$G`P8
M4(8,B*-`,HP.!>(LP`@#P$8<XQR.....4-8=9P&V8TLA]CQ-DF,;78[G-;VB
M+5E%G8`,!:Q$=GPJFUQ3X&+*5S;CTC@E%GQIU)0O;S'+M?TIM%;AI)<T/>H<
M9GLFKJ&NG[6ZB&NZBO[A-7MY"A<UM#5<"=2&0F+5"X0_-#9:KD3<6J.R<<WJ
M,B\F+#MKVCWXI-[%"=$]RWBP72,9,)7=/;J;HCSIJC+;$X##6"J[[;B6E>XE
M%E"/$VMYQ<$$D1D>?.31YH#)PIXQ#KDQZI)"@K;J9:N7;H!.E"@+>GG$G8W"
MR]=9$J!@10E3!;40;C@`3*3P9R5XVQT;TA.<Y5OW8`S.9IJPMZK+KB2">5!8
ML*LZ%N8`C0RF!R9GE3$?D18#<E>DF58L3%*"PC#Y9*H&2J('W+/)+,QD.+B\
M<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<P\];)OUX<-48H/:K6Z0[/T
M:S7.QR665]&FVZ7IVRXL-?64IAY30RT4'$H<I/,)::T5G#?A4M8JM;95.&M[
MGTB;$#6D+66OZ$U2LU+4I<$3;]*(-HZ\/4ZAE@R^J*TLJYK/C31(9G7+2I3Q
M&2/5RM*%0EN*NHPBCL9N%K@+G(8"VRD0&PM>WS-OF<>9LZW''*=E_P#8I)O[
MWWK_`#8JY`/3VXK#E-OV#3SJM:#:YJJ@]7%L50EM9:=Y2NLRK%G=G<]2Z%BR
M-P3JS,GXR4I"'"3R","0(<"5#-R/<<<<<<<CYM+L[46GE&3W8*[Y&5'(%`6D
M:U5D&2C7=_=C\Y3L42C#>::3Z6E,G<Q$-+&W8,++,5'Y4+#TC<E6K$^('IP:
MPV[M;=Q_5LWPC9C;9<P:?,=+Z"=AG*FK66CE^5)[,_&(51)`16+,VU<)P`Y*
M$:9Q3(W-9(5J9`]OJ-LBV;*P[:B5:8;2GPU0>M<CB\$MC:64H6E(/*>`]S/*
M&:4$I$1V$$.1#P<J-"(E&4<8`WR=&*KU].'F-U6PV03U8$62A.>$QK)&TP\Y
MQ@(SW->6`>0XSC/<(BDV!8]@3>^<]MCX`VY.?W2?3P$5:3L=S(M7X!)S!%#[
M8&G6/RC(CQBR'N$T(,K"!X[^#MC/-I%K!7*1^`YF@<%[,!`%/B-KU(SDAB[P
MY*&O/6A$4M-`(O\`=,(?$`@"K.3@YP5@"8';J-<:P$9Y1M0/3`9W[A,8I&[H
MA`S[/:`)BA0`/;.,9QC`>WL#[.P0XQTKS1D@3-3@1$;7L%*>-(>6G;GE]&N;
M%(A%8!YJH-++)5)B3@XR5D\G`C","",(1X+R$=O*FJ^\8\S.'HZ3)(*4<XBP
M!@=VU._EJ!DX$2H<L%@&:2WX.S@."1)C/*.0"P*%."P`(R9=4+=LBAQD07^L
M'K`<!%@*IL>&XPS(!=O#G*8`2P".#[3!=\!+%["\8]^67[8Q+G(38-7SN$/C
MQXVZ1K$.1YQ]D$>`KAYS@.<=RP@SCQ9'V$+(`\^\V/;R'V.-'+E&/$'N)GE[
M0L^Q&'['&`9*%D0@CQGRF?%@(`]N^>_O^0W6^I\>)WIFST(<8P(P:5K3N98`
MASV/%XB3"LY`7WQY//;&3L9[AP''MY;U=M00EFJ5`=&7!MBA(,(WC+NF&EDZ
M1<=D`LJ\MX#C"R4R(.0X,0&9&K5E&"4%C*,`2F.OTS6[63_GPM<WCQP_B)4+
MRV]1G/R83N.$AW?[W@[_`'N7`)/(4EA-(-*/*'C[$PDP!Q8L9^/`R\B!G&<?
M'C.<=N4!(*DK*53&*6%(H)%GF<P90:IB<L7LZ0]_83CDYZ464+GDO"L`0DJ3
M\$E&F&E)S#1')RRCNQF(S[CV',X"SLH5FL#=LCKZZ('8BZ&HH#;)'UG1`,2Y
M0GDUT\-B]LDC0%-YZL<CE)1I!7FX259S.0+#@/%/&^E3I3L&F7;)=,&^[>T*
MM03AE,\+]?G]W;(:EDF"@N![)9%#/CD4T^#)*HG.6MD<V:/+$9F3T1+BD,P,
M558V-ZT.BN?-]FM;X?U&J4:_8?=VI6`P^^&]K#GOEQE=(KDI2.0+4R0H1RHB
M*-"-'X_&(Z1#[^4S-+5#J_Z&[>N!42@ERHH);(3O,W"C[N1CJ6V6YSP;@D32
M".R@XA`_N`#<Y`,B*/#\,/;.1@!VSC&3C`L9]F,^WY,XSC/;W=^V>V>WR9[=
ML_%S7CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCF'CK`+Y7.J,9:FI79%=4
M=E$VE`'B<1ZK]T(#I?=;A6CLG?64QT9K7DJ-]<6ADB3TZ,EF/T21-["NM>/P
MI?`VZ6MGIDU.OMGT/X+=E>Q7;*-W//YQ:0VN]V!G@]AS_?Q+OHYS2),=7QMJ
M%*V!\2>14U)!96^IW>50NMY:W-=B-C(]DHI@F5C9VQY=,Z?.K3/;.L<W%F2.
MK<I=V<",QV:TZY*>XM9;@6,Y`-Q0E&C5(0+B0#-1C5DDA5E`$8GR8`.<X^FU
MY:7CS_T2YM[EZ+<530Y>CUJ5;Z/=47@\\;%WFIIOFCBD\J7YTA4^25I_*%^6
M)+\8._7R_P!L4DV/_P`/O?\`FQ5R,FK-$0J#HL76SG/IDONJK*0Q+"5[D!2S
M),0ZOFIK;\,:$*8LY"%44+RR\*A4L"(\.,(PHR/$2*7O'''''+0W[=L%UOI:
MSKWLMQPUP:J86^S:1J<"+P>:B9$1B@MN0`,$$*AV>5OFK,SH\9\:QU<$:4O&
M1G!QGS1Z8K+&Z]UUQ7;S::,16":9:@/2-KKW5]OE'PL:+#V3(9FU^D4XL["M
M,ARZ1J*MCJU8;6]\;$J)>0H(CZ4A>T"F:^0>CQ]N<;FXFQ:I&;,[D!>?)JG,
ML62HFR]\Y#Y9>ZXR64J\&<=\%)S2R#/WA:HPS&2>4HMUR7S+'IRPIPO7RY4>
MC$I.:DB0IH1-9!HQ',S<G-*+,SCR9AF$RX7D0)SAY.RA/R([R\DF%A:8RT(6
M-D1E(&MN)P0E3%=_"`.!9&,8Q"SD9IYQ@AG'GF"$:><,PTP8ACSGG;\<<<<<
M<T[8^3'\W->4DK@L372=+,53&B/D:-(-$0Y&%Y$9@H>/"$9A6<Y(.4DEY&0G
M5G%#4ITYII!)@"C,AQP'JKZ\D.,X>(9'5@L]_$=EK3)U.>_Q^<I`$*,9^3/E
M.^/9G'MQR@#M=8,0;E1&G"70U1C.1%CCDF<""P"SGOW\@L$K#G&,]NP<"#CM
MC&.^.W-G]KJX63&?@U<I[D7C]XCF;`D<\9QC/L`8XE9,5=LXSVR,)81>S&<?
M'QE]V&8\^%QA4+F2<K&<B/CCX>S*QX]_?!#KG(<CSCOX<%DX[Y[=NW?/*?8;
M,CD!PZ>>4;)JWP^.I[V^*F&(MQC<ZO2K!9:QW<EC&0CRX.*@!183EZ@D]4<`
MLO`QBP''(7-/49E573UVCFS\!0I*\<9&O+AMTU>D>G&/(652X*<LZ69QQPR>
M]H5Z1N&D+<U2/P+@*0'"*851/95R0^RN@VC.]['XKRI2MK,7')@&-E@M91;+
M8S3Y4C'FBEHL6)GMLN2^0P(L\A*H<U"#)@`><(#0X$7G&V+IS=2?2@>''IR[
MW.-JUDU!R-#JAO8%58$;+;DG8TE@AMN-A1<ACA9F1&$(B"$D73D8\GE<ZJ`Y
M$(/>1_K;.-!/+=`>J5J)<VCTF./`W%6VWM*ZX]99(L!W":K9['AB5>L;23QY
M`(I#E+),I"Q?U\YEY`+.,S-.7Q2^PD023VCK2@=L0Y8`H1<@@,G:9.WDF'%>
M6"E7C:U)YK6N`#_Z9O<RD:Y.+`@'IBQA$'%V`C"/(L!%@609\(NV<9[9SC`N
MV>WNSX<XSVS[>V<9]V<9S]<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<\<W5;
MFFJ[5U+3)!?T$Z/:FL*Z:=>4%^0_=++:Z;DWO$)H4D3NT@HE9(4JMHA\7IR$
M.J5=%FK"IJ13:6,LT3/V%*<:,TG/UTY%'3/'$+52=,@C7H-9(IVTEV0IUC*9
M@5BIL0V(-1I'<Z+C%&5,G*B.6+#R8VY&I`G&V$N9IBDL."\CV>V<9[^[X_XL
M>WV_>^7[W/.CLI3=:L^Q\\NW2=;"X-L3K[KWORV32?Q=Z8?VW-K]J;AJ%6_5
M[KW(U1#JEE=R.M2/S$CM58&0$OB&KW9GKVOX+EL&DFK1%J@Z:9B"*[.:TP:G
MCE)]1RCHBZJ6Q;*M`ER%OD=K.UDC1579,Q4@*)\\M"QXZLNY5(']U`;)94G8
M_*O*DP#&DP#-S;SK.&R*.6(9$&F5><LLC`[9=)?F*^BTX&@[)!Z;&(X_Y<S#
MAB-"(C^L<$^2`(1P\&Y\G!7IU6-+9M)-D6-[E3T^QF!.-)1N$,SB?G+=%FTF
MJ4A+B@9$>2B_,DREP1".4XQDS"H\'G>1C,-&:9E`XXXXYIG.,>_/;_Y>_P#F
M^/GERZIEPO?4FV/;NEI03LYXINHWAELO>VUXF(MT`B/8C1+HA2D>$G`J0K9$
MD=R@NCX0J"L2HY2D1%KDX2X%)TILENE_TM*\U>_;5.@%BWFMK"R0QG,EB\LD
ML=41R12&*GN`4#D@PR1EA5@6HF]P.:G-<`:A.L1#(0Y"4J0$&IL[[#'F2,-I
M#0P-B-J;D^/W-*C)"4#Q=L8R:8+VF'GC[8R8H/&8>9GVC,%GG<\<<<<<<<<<
M<<<<<<=O=][Y/9_BY3+U"XA(RC27^+Q]Z+/QC!H7-G;UOC\(L"#XA'IQCSD`
M\8&#/B\01A",.<"#C.(H;#:UO[K`5JC6DR,0"TTCDW.*)2]B=QL+PW)!FF.;
M`8$E0H):%+J#)($[N%`IPD$5DKP)\*!+4U@]:[$O";2QZI^>)[@I&Y89'QO[
MJ@DS2"<U3(VA.XHVGTK$96>884`I4L5AR0VC4NI1I(#AH'I>)*L)2RTD,<NQ
MP97&-RR/5#<,7=DYJ-WC[\V83IWE";C]T3.;4Z$&,*LHX./",A4G/(S[?$$6
M.8-MI>F!KO6+98>SU'5]LQT]K<@,0E$V76#H_(%CC'WD3$WJG8:-UIQO.RPO
MJ9?@CS(+)'/@^!48H#E2$XGRV.85.F[U,.J_"KNLZ/L<$;+REVSDF#9DF*VE
M03RK6$<UA\'(:E8HI.&Q%'H1!721PV.-#,6T+6H,7<%,9926_#8L$/+IZ!6S
MK'[<0$!7]47TD-DD#>E%C#K+]:Y[`MBH_@K(@^)6C;V?T0XB*"$>,^2$N&9G
M.,XP+O@6`W.B'[(4Z:[HL]$V?.;8UM?L9P`UCV'HJRH(I(/\60&D'.#<S21D
M+$0,.0FFC<@$XSVQ@SOGMC(=4V]NF%[$I3:@VGH&P35F<83MT<M:&*GH0L@P
M9X!,)SNG>RAX#G&1%FMX!A]N!!P+&<8E66<4:`)A0PF%C#@83`9\98@Y]P@F
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MTDH$MD0')Q`^JA.N5#N%>MPX&*,*C\&5W`*@JNJC)$=6E<PB`FRYR`\2@V'Q
M=ECAD@<R\'!)6NXVE&D$O.("I4!3><9&!*%0HPF`3A0?Y2I)?[8I)L?_`(?>
M_P#-BKECM7:OK^"5G'91$(NVL4@LZ'5S*)^YHL'^<R20E09F2%N*_!IYI99P
M4XA?N24M,1DP\]2(G*A4><;)/CCFV<<4G*,./,+)))+&::::/`"RRBPY&888
M,6<!`6``1"&,6<!"'&<YSVQR+!NTS*<^.;.QQ9VD&!G)$$5.1'DDCD+B<=Y`
M03"%`,&H$9PQ!$@."%6H4E8\1J1/D8,8Q=]4S;R_ZBA<!HVLUR==N1MH^_M>
M:VT;!S4ZE6RY6G%H7VU[#=<GCRDC4+3&#,1F+!&LZI_")P5>398O)<)YX=-[
M0N#=/W7"/U.S'I)393Z>.:7G:HR1C>;.M1[!A1(GQ2XJBPN1C&WGF&-$30JQ
M>-&QIRU"H)CNXNRM7/A,E3(R"TR1.0E3E8R$I.F*+()+#D0AY"644$!8,9$(
M0LX"'&,B%G.?;G.<[_'''''''''''''''''''-.V,>[_`.7\WNY`C81+NO75
MD*;BH=T8;CK0;0TI)#KD_I$K.[HPM1)V'%W@<B(++4JW9SQDQ2:2J6&*<*!E
MI2&5])`E3II45)8Q]F5A&K%>89**P4/K<I6N,0GJ4#1(XZ8B6JT2@MU)'DO!
M1!F48EJ%2<!,)4V*$BPY,DR<(@OZCT:K!&L>RF4,?7*),JRL7H1N*-X`;@L.
M3<ID:`]0J+2("S/*J\HTA($X#C##?!C&`8+VG.DZJ=31'J80QD*,^W"AK(,9
ME`1?\8)S2:B'@7W\>WW?)RV$MU(JR8(S4+J!T7(S`B!Z.D&6N:-.`"]Y>6V8
MMCT2(O/Q@\0<9[8SG/?&,\QX6UT*](;2&<J=J*I%2XG9\7I1M@)];/0!X[]A
MA>*Q>(_@)G<6<B,RWC\6>PAA'X<8Q%8WH3O]5'FK-6]F]P==5`/*"3):AV?D
M+G&R<9["`7\$I\2F+-3!,P$8DQKN9Y7&<EC,R'.,X^,TMUU**#G]KS?%KN1G
M1B"8!BV@UH9W4Q2$H>>R=3.:Q+='?P#+S^ZJ<K2C,CQ@0,A#GOSL$74;ZR-2
M'E$6[H/KML`W)`!+5..O5Y.5?R%9X09\2@N*V.!]4@-R(/<Q.!(4'QB"$KMC
M/LN`V?L@BMX>`)6SVCN]6N2GQA"H<UU1D6-#DP<8!DX\4BBSDC5FIR<BR+)A
M;$(0B@^/`/'G!7)8U7UO^EE;AR5"Q[B5E&'A3D(1,EJ!D-1N28T0\%X(4?MB
MLL=08-P+..^"G`T.,?99%X<9SC(U!+;JRTD&'2L[)@5B-@BP&A<(+,([+D8B
MS,>(LS"B/N3B5X1X]H<Y%CO[>WNSRX'C#[.^<8[^[Q?8Y_F%VS_@Y]<<<<<<
M<<<<<<<<<<<<<<<<<P\];1Q8T^ID<8%536O:DNL&X6*N:[%3&VD.T@G$)DLK
M@UAE.LD)V.GTAC\0BC8ZP9)+H*NC<@P_-%C#EJ>#N$<<B7C`DUI^A%!F^#U%
ML"2JH6:T_/WBX6-TL"5VQN]66_MPW*NS7$>2L<RGUXU.Z.<30X8V-.GAL:@A
M(6Y4R,C,6['MX0OY2E1G>XXYT4H#@<;D`,^X;([!S\?L$W*<9]F?9\?Q\Q4]
M(!U7/M170[JQGC+5W>KP3XU*A4F*,3P2')STZ<PX8\8R1@!(32@8!DK.0!$#
M&,`YESXSG&/?\>>V/X^6`NNVLP]N%'XDH(7SIQ[E@0I0&."UF;_-S3E+L8B3
M$GA\N24#&4R=7DK&,&>>C*.3)S`#M%5T;L"Y&(HR?2N3EP1"`M,W)DR@M$IE
MH@FFY4#7.`0>>KT23."R<K#_`"H50\B*3F!-3''BV]A9KK3H34MF;6V09AAB
M]>1K*DE$8M"J5+GDPOS%HC,*1KS,F*)A-W,:5G0A-5&8P>I-5&&H&T#HHQ`'
MI2ZPVE:$_G75AW-9L)=E]FFL*:E*Z6@,-1ZU:SJ0`-A</9$RLHL;9))2RC3K
M'E3Y$IT`RJ,"<,IGV6S-*9G>XXXXXXXXXXXXXXXXXXXXXXXY&[<%I='W5K8!
MF96QP>G9RJ:;(V]I:D2ER<G%6>RJ0$I$2!(6<J6*3Q9\!29.4:::+/@``6<X
M#GS9Z74[?T:VJI!\;*FES`:@FH!K'B;U_-6:,(60YJ=$TC,<'/T,F"E/''CG
M0IF$:>608_&-1*C(B##`B]0%VV+*ZLK]=,(;5,LN5Z1+VE*"#PL]"G?5*->N
M+3+G(G*[`PFE-*80EAZ=.0>I/P$)99809,/)C_2V[;1;%A-=6/=$[#5/,W5,
MY*"0V#7*M%&R<-3<H<E(%4E2'G)D63"DIY2,U:F3)U:G!*8LW"E043F2T_N"
MJZJ,8BK+L2&P(<G/5IH_B72)L8,.YR`"<:X"$3DH3A/PB`K2B5F!SY--A21Y
M88/+%^*HHU-(A,TXU<0E4;E*0H)8C%4<?6M\3@"=X_)9&<UJU18,&>3'@&1B
M#X\@'X>_A%VJ/.0X[X[XQ\OQ?X?9[?\`#S@KFIK=2_(N3<@<2<XSC)2Y(F6%
MYQG';.,@4%FASC./9G';VX]_+?.5+5>Z8,P?#FM-Y7`L#]%95,OB\7?&?$%I
M4(RQ]^^>^!@$'/QASCV<BM:/31U"MXE27.*BA<B$J[^5'(8;#9&8+O[LB7.T
M?-><YQG&.X@.H#!8QC&1_'C'/.OV.7HZ[+C'BO8ZYU.^"$(PEUJJ9S^LUJ<X
M61"":6)ID+VV@,+$+[#R;066'&/#@KP?8\H7'29ZA-+^'.L?5(VQCJ)#W$WQ
MFR)3'[WBI6,!\."1-M@X:1^1^Q!C`0(C!%AQG``B%GFYB3_LB&AQ&&J7?43;
M)G2X%@6)M6<LJ.3*RBA>/&?2L$,:HL4L-+QDL(Q#.3%Y\(\^/MG.>U0=8[>V
ML<A3;(])6UE)"<8?2$HUMM:,VFC"5C.0F&D1=>VI'/OXL>(!)KT$?DQ8\8@Y
MQ[;JQ3]D3]/=0M):K@+V)UF=LX\"I+>VO\Y9DJ14'&,&)QNL0(F*+.`&>(O!
MPL%%Y\`A"\&,<R`U+U)]!+S+(S5FX.O,J4JC`E)VDNT8NS/YI@_#@!88[)%[
M,^X,%D80^3RW>/QYP#MX^^,311."%Q3$K6]6G7HU(,&)U:(XM6E/+%[ADJ4X
MC2#09^(0#!!S\6><O`@Y]F!8SG'LSC&<9[9^3V<UXXXXXXXXXXXXXXXXYALZ
MW[M7+?JA"DMEP73F5M#G?$.1M$DZ@)\[!J!5TE'$YZ%MG-OH*\9W9Y?<F)3'
M*)0=A=%<4C2^<2=D,=)HP*$K=E9;KH3NU8*Z>OAJK*!:#,Y3-;3,"46/TRL6
M.FU&LN0JX&T")$R,UA-Q/H&S8?'T[,T6(W1M_FC.>2NBKLIDH'MQ<X\Q9V.=
M=AX:1.QK"%S;Q/9#<G=SF<*U+EU):E:E2B2N1K=@W*TMO4K$:M*G6C("F.4I
M5!!1HS2#0`Z]@EL7E67?$8D;#(O@^]+8X^^@GAM=_0LA;<@PXL+MZ.4J?1KT
MWY,+PN:EOD%Z3)@/.$Y?C#W2W`LQ:28#C.198'G`<![^+(LMBK&,8[>WOW[=
MNWM[\LWJN]0)^H>MUE?.46=$)$3C+:_J(H>UJ$Q4O;8TS(Y$D=1M><@P_I%9
M0274"O.5X#0@PI_M.=PX["5@V+WUM/>%!RAC&23_`%D@/6E.ZH8A%G)&4U-X
MP+#D9H<$J1C$0G",6!%'FE@,&".MFO-RV$XL#PQQ>6QZ,8=DY$23%XR@<S'8
M161%O3J%.?A0C$:#)GF:M6$EL0IL&!`>,TP\XV456UDUP)E3F')4JB7+TX39
M*_>,]8K7KS<Y,4A+7+,B4X28,SV"6#R)9P@>7-+$8+(L7).-0M2$T\XQ(W-Z
M!,8<<<:,E(B1)$Q8C33CC!9*(3)4Q(!FFF"$`HDH`QBR$(<YQX1X_O16'5#Z
MVE?P+8BS)$NTG37,)+K;22M[)_:PEUE5LQN;13C]-(PM-&`S]MM\&^NYWA3*
M#W@Q\B$(6!PS+5N>>\(/;`<=N_;M\>.V?Y<=L=NWR8QC&/=C&,8[<^N.....
M...................:=OX_Y\_]_-<XQGWXQG^/V\T[8[]_;^,+M_-W[?X.
M6YLBGZMN!N2-5HU_$9\@;QJ3&XB5,2!XRVF+`%%JS6TY62-0WFJ0$$@/,1'$
M#."25@P0O)E^&WM/:GZ^T%(I!*J@K5J@SW*&U,T/2AJ7OAJ92W)%F5Y*8IN<
M'1:@1`PLS@X64:<@8\A"`0LEA"#%"7WK=;%H31%-ZSVNM>D%*)@1LOP784C6
M_P`&5'HUB]5EV4Q]8<AP8Y+,+2DZT\XY3Y0A$E`7@H(,AY<O7^&7C!HJ[M%Z
M6XUW)(!2`X]@D;?#44,-2QO#<WD)VYS2(!^;K5_I$IP6#68+QD)2DLC)Q_D\
M"#'VRM@MQZZG\K2-VF@[2J]$Z#+BLG@5H,^)(ZLP"4X@KE\;7(SE:=<8:8<$
M;<6D!@K)7@+4*P8PH'+:J)N\V)7L<FLB@$IJUW>TJI0O@LU"C+DL?&F7JT02
MG,"$TT@/G928#@E]I9V42M.)0G3'Y,(!'1@ZANF,D7GMB*_X4A6IU)R4TJ2>
MF8F6$U.,19O93)FIJ2"+",`L>5P?@&<8SG&>W;.9DIE25<F(6(U!"Q&K(*4I
M524TM0F4IE!83B%"<\H0RCB#RA@-)-+$(LTL81@$((L9SN]P_P`7M^3(?;[O
MO=^_Q?+S@+FAJ=`X`Y-J!P!C';`%R),K#V_B4%&=OY.6PE-!4W-$QR.3UU%W
M=*>$03$RIN+&E%@6,ASW2>U(+&0YR'.!$"#D.<XR'./9R`5L]%'IOW%A2;)]
M:*^3N"KQ>)R9&%O8%I><XS@)A:N/$,JT)@.^?"9YUD>/ESGVXALK_8\=0P1:
M)UU<VBVOUC<PBR8E#6%V31H:DPL"P867AL4+74H1!1F/$$K)V`]\YSGOVQS:
M+T@ZX-(^/]I#J@HK?:4V`Y(CVRU4Q&:FJ@$X$$M,HD^$PI-D(P>`)IY2DI0(
M?<[(O%CL+<#M3U^J0P6"TM&=9-F&5%D6%#Q2EA2>LY$O+"'ODT*"3*9`V8-[
M!%CP$-981C$#PA"''?/9I>O:IKT\:;:SIN[RT'Y'[!4\L,,9KABJ818\`//&
M[LJF,JQHRL9\IY8EN/&,/[TH6>V12/K7KT]*ZR#4B`>TK%6[ZJ'Y,<?N:)SF
MJEZ,WOG&2UBV5QU)'R18SCMG/IL1>,YQCQ]Q8QS)'6^PU"W&24HJ6ZJGLXD\
MD)Y9D`L6(2_N4((1X'DMA>%YP.P1@R+`RPB#XL8$'&<]N7@\8>W?.?#C_E8R
M#_\`=C'/K&<9]N,]\?+CCCCCCCCCCCCGGSZML>W8KE<OO=NZCEEZ\::.KA$(
M#/ZVK7IU5%NJW5K&\PJ2*I1:5BM;_%);8K]'9=-$;1$U:1MCK[&X64\-3T[)
MCT9JLE)<'H<V)95BU=?BYZV&L[::F6NT8VU4#<L\TUCNC,==HT37S29,F"MJ
M58(]"RS8U'YJ-=A?+O@4PI'I^<%Z=.->M;W09&<OF!VY4DQ8^H9U3G*AT&4E
MWNO1>H>00<<83$E29YN!!8&_#57[B'S+`%R^0$KVN(M36J-R-4`E"THR#`E)
MTP`4?TT#6YHV<UEBU+#4F4X=T-M1I/:IS8`H#6OL=PLA412<@F@4N"0"LN11
MG-^JW-P<4I;\[D)UYKL:;A&G"5G'M!;.D<>5_`J/1=^":V/F'G,EEKG%O,4P
M6PS*<UO]'1"5^D3C!Y.P:0H]&`+P67G"D?E1Y)QO]-!6FJW2M6ZS],>T$/\`
M8-BO+6UO*12TKW]":F:T*8I`D<24YRX+MAM/&D4)@')34A@5`3Q%!$/$JJ-H
MI.E,9[%DH`E*3P!>&"+EE&@3L8CS336]0J/-/,.5G)T8B!H2#`@PE\83%63U
M)8,ES`[?Z=\_%\N??G^7OWYKS!'U:]C[/LV8UGTHM0GL*+8[;5$>9<,Z0C,/
M*U[U>S@]//)D^&)<X$VNLM:BW%K:"A&EKS&8M<2A`2[26+*#,DFNFCNLVLE5
MU75E=5+!0HZF861K890[P^-.,T7.K3D*L^7.LD4-9CH9*'=ZRI?UJ\A23YNY
M*AX;@)$Q"8DF7'''''''''''''''''''''''''''''''''-,XQGWXQG^/&.:
M\M+,*$I&P?.!3BHJUEAJKQ^<*7^$QQR5FY-[^4R):H;A*\B,\0O&+R_B%XA>
M+.>^>5)+H!'9C7[_`%FK+6,\6D$66P\XF+K3HXL;61:W":O(L:UL\B8TF)$0
M@E(1I0A"E"66`!>2@Y+S"*'Z!.%9RN,/=:;8[,1^.L;\T.CC!GR8))='7QL;
MEY"I5'SR'!(F*(1.:<HQO.-$D5F$I3S!%`P=@`\2RO(N\AP)3_4]'UX18H'-
MM,3_`+9I3P;&SF<!P\NR<.63(5)3F:5Y("`XW`TH,^5\N'Q9+&&P-)V#O.ML
M%LB]^4'5S/"%*1T$X6975B`4IF]2E0G'MH,11T6KW=;AS7%E(1!*PFRD"HPL
M-%DL@8#+E[$[10;69-%%\\C-E/+7*E#LG"ZP.$K98WL.6@M"889)#TIY&&P"
MS"\.&X/[L<LRF6Y++\*4><_%![=T+LNI>FZI)D:]O4;0(G)_8G%@?H^[-*)P
M4G(TAZA.\-Z4HT!JI.<1G*10I\F8#&!^'`P"%((]\94[D4S*'9L)=STV%A+6
M<X(RG$Y)DP9.%12$P\*HQ/DTLPKRX"1%9,`,'C\818QVF.V<>SOC'?Y,A_[N
M^/O^[G#5MZ!>`1:U&D6%BQX1EJDQ"@(L9QV[""<6/&<9Q[.V?BY':RM-M4[B
M(/3V?KQ3\V`HQD)HWZ!Q]6I%CVYQV5B184ASC.<YP()F,XSG.<=N_,<%C_L>
MSI=3U0<Y,U&.53/@Q#,*>Z@G$FA:U,</OG!I!:=<>C+R69G!A8<)O"$6,=L8
M#CMRT>.B3?%3@%G4OJR;NU"F3#P<V12<RK-M0XDP.<9"4H:GU:0F.39R#&#"
MAHC,"#G&,A[!R$>[BK?V1-2(P"BNR.E>X#,C#X"&ZV*W7UC)U9)0^P`J7.%D
M1A)E6<7C'E3CG$T/?&,X%D><BY]AZD?5LIKQD[']'>5SA(F\.5DKU3N%HG27
M!(`YP:H311<A?G`>,C#DP)1CV3Y,K.,&&YSCQY[EE_9$.FC,M)9MAZJV[U2>
M\"R4X%75KU)P-*(X.0^(/I>''20TPO`1>4R:)J)P$&!"&$/V/BG-4G5@Z;UX
MF%IZXW0U_<UIV2PD-3Y/6Z"O9QAN?"624RSW$8<S#Q"]F"0)A&>W&?#VR'.9
MXLDB89*WIW>.O+6_M2H&#$SFR."-W;U`!=_",E:W'*DIH,]L]A`-$'/Q9YW'
MB#W[=\=_D[X[_P`N/?CFO''''',7G5LCEU276%I14Z5<+PF!;4'_`&SH/KWL
MS$=0[NL2OEY;PS`A]=WC-20-36XK)LY0]8Y0U$_P>0V.RHET.89FD6N6&&14
M5T?X7?<+J.V6^W&386`Q+%H$)ZPJ7:_:F)[?WY7B-)%&@4L3R>RXJE5BB\??
M794A=(I5<BFDXD$5(PXO9K@QM<N:HNT9>.4N1"(:EEB^>)8G&4TW=6Q.RN<Q
M3L#23*G%H2"P-*UKI$4C"\JVY,,(1)T*A:8E($$(BB0"QC/.+$J[@$!&^F0:
M#Q"&&2AW.?Y,.*1IECHY$_*,9"H>WT3.A19=W<\.?"<Y.&5"PS'L&=G&<\[&
M6X\46DF,=L9RP/6,9SGMC'=L58]N<^S&/ESGW<Q@PP;7?4&UN<JZE9[ZWR6N
M6^+%)71(N;T<875PW(([,!%)U1*95YN%S;UHC>Q`QN!Z4)B1:H1J$?F^4EA;
M3F9E:VI0XJW<]N0)49KFNP4%6N&G)"4)2HP0`!>##<A[YQC`LXQVP,9@_$8/
MMN8QNK=O>PZ!::V/9Q#ZT(K=E;8M@-$,2Y8F+6.]C2!,)$G?"D)P\&*V:OD"
MD^;2,[R>4A*1J2H5)I1[LB`?B!_8Q$NK"Y8QM;=,PG,IM?>!QFL4C]R6'8TG
M#+Y<MI_#"D!5`69X6'J7;#(O71]_2R3*@X9JF01AM3FYPUM4>))]6_''''''
M''''''''''''''''''''''''''''''''''-,XP+';/MQ[<9Q\6<9]F<9Q[LX
M^]G&<?>YUB-C9FY8L<&]I;$*]Q"2%P6HV]&E5K@I\F"(PL4D$EGJL$"..R3@
M\PS!633,@P'(Q9S&.]=)M=-BY"5,+,A2I9,DS.D84TL9)-(HZ]$-*$]:I1HP
MC:G(E$:!,H<5IA0E"(XP.5`PY&(&<!Q75`:^Q#7*).4+A+]/GQG<7T]^QF?2
MY=+U;<>>A0H,H6D]860%N:@EH"C@H4Y00B5FJ5)@QF'"SB/EEUWU!DT\DTDJ
M#8*G7&%.#J:NCU=V/6HD06%LR$'DF7$ECZ56Y.0BQ8,QEQ5'ISC_`!XR,!60
M\EK5)EH#KJ,&7,FB)-G^8G_"PB`&N!T4\^`L58399C'CP+?"<W!1#5!4"\!;
M@-462/*8)0\P75]1DV%G+`W'J3M+6J5*<J!AU+@9,O9QITYAF`*,KVE4E+$$
MTD&#LX2X5@QD7A*-4`Q@T60)PFT798<?/I"\)(S$T;$7(W)YDIF&)*T-`TA:
MT:IWRY>0RV>0)-#A26KP68G-\1)H0FXR'E.P^YZBL'R&(-9]?R\:G`?(D1R8
M,#NI'D>.X0Y2(UYJH)F?=DL1&!XSC(<AP+&<8N7G`<?)C[_N_P`..W.H>&%B
MD:$UL?VAJ?6T\.0G-[P@1NJ$X(@Y`()J5>2I(,"((LA%@1><9QG.,]\9SW@_
M;72VZ=MXA-_;+TVH![/."+!KBW5\T1%X'D>?$(>7J&%QYTP;G/MP;A7@S'Q"
MY!)Y_8[NB[8X'OE"3':?51]\8S4"VA-AYDR)$!HO%VP4VR+,BQY`/BR'!(%9
M6?#CPX,#W%G/7>K5ZIM/E^6UPZRUHR0@G.<)8KM93L2MU#DHL'A(3*94<H<W
MG!><8P6:<0V`,\.<F`#Y;'BSN@G/[(?I;^MGZD]"-QVE)G(S'"NY]+:/F3B3
MC(<Y\"68FMT;)4>#Q8"4!M$'(_=D78(1;Q76*V5J\?D]KND'O)6*-'X2W25T
MVW1[8R($B+SD*E6!=&?0)F$8>WE"\>74&C*SG(?%C&!"N#!/V03TNY6J"TRV
M\I!1<B$8$H4<ORJ;'K-P3F"Q[0*EJR/N#"GR#/<`A&O`2\BQGPC$'L+.1RK=
MP=4[N)2G5!LA1ME96@P-.FA=J0E^<,AR+`<8,:T3T8YDCR+.,8`<C+'WSC'A
M]N.5^Y735+/;46HETGT907!-H=([`B==JG(HJ4O\-B3@V-<BD+:VBQXSV]L7
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MX#LFD`/P6H"4?@TD&5SOCW=_;CWX^3O[N0NW6W[UKT"@L8G^QTO71UJFC^Z1
MF*(&-C7R5]?'AIC#O*5925K;0C.)1%)6HI`H>5?DFAN='EC3NBM&2X!4%XL-
M#]6;.WZNP/50Z@D'`C3N[4K;M']4I>GP[QRCJA=1C-06#+8^ZHBT+I8TS0G8
M<$*Y>WXR>E6AE2E(0,<);8CGIB%:5W7XEPX)`X9#!N8$P'(<3BK!&Q.`$>3A
M)`+A,K>A$K"E$H/RG"HR9@C)YV2L`R:/(JWXXXXXXXXXXXXXXXXXXXXXXXXX
MXXXXXXXXXXXXXXXXXXXXXYIX<??Q_%G./\&,XYU;XQ,LG9W./2-I;7YA>41[
M<[,SPB3N+8YH%1>2E*->A5EFIE28\O.0&DG%C`,.>PL9Y%(K033]++&&<-U%
MQ%EDT:?&Z1,R^/FO;`4E=VE:4XMRH;<TNR1L4X2K2"3P)U",Q,+)80&%"*QX
M.7AO*LY+;$#41*)6S-Z7>AN;<Y$32`"1!>BP(1FB,;%`5P,X-:E_E0^>DI5"
M%49D@D(%@"O+%'6$I.D=M:UL!L43W;(FY:I(1NQ;E&Y+634TRU6K.19*9C4\
MF0+#CD_F2\6%2HPXY2%202)+YID2K!Z.XVQ5A[#5X1$E]%46W7>E4J'C,V0G
M3EOA[LSI4Q2'T/EG*<09+=#7$T]?Y?(,'"281%@RF%YV$XKK-=]@;&N%SD[)
M8NM-I4,XQM"V+`+)D-`XQI]&O4*DQB)B?$I*$2Y8C\V\X4`+1F$@2FE&"4`&
M,!8^;:&Y.M-+SHNMK1M9EA<P-:4#X%M>$#^%,%M<S5)2!0:[IFE2SD^<#1J?
M"4:M`:`!63#0`!D&17C@%F5[:K(*1UM-8Q.F("D:$UTBSTA>D:=:`HH\:)48
MB.-\U6`(/).$D4X*4!).*-R7@LT`A5MX08[XP'(>_O\`#@0>_P#*'&._\_\`
MCY;V>5#5%J(LMMFUI7]C-P@>`2&=PV-R]((&/%C`<D2%L<2^V/&+MVQ]CG.?
M#V[YYCAM;H<]+"W3UC@]Z>5K%GM6(8POU5#D-2N:0\S&,>=)@UZ]Q]MP:5G&
M#"@F-YA01X\6"^^<]_-D3T;NJ'06]22_M8Z8,4U33]PGJ::;IQMI$9#+72EV
MMV.;C(ZX2"2/6'=M#.HP>]*<MQQ1.(XID99!@3E;8-8=[IDQAPTR<9B8Y.8,
M@H8TYYI)AZ<8BPB$0<82<>48<3G.2S3"CSBC!A$,LT8!!%G$)UL#M.DFK5>+
MM]$KVYZO(=AH8?8S''K&D-?ND@*'`[02-;&4WPX]%-+1(<W!42F6U)#71LDD
MP1B/.1&KB&A6R.MJ^F>P4-LC\#+BH#5FP.GW2VJ]H3EIIBH&ACJ^HCMB8Y-J
MN'#5T\V$K*,1]TG3$D:WI6_N$&@THF;-(U;JWML\GR![$HCB-ISL\9SC'MS_
M`*?]^<_%CWYSRW=?VY5UK@?C*SL.%3\N+/!T?D8X=)F:2`8WI.(P)S8Z#:%B
ML*-8`1)P<%'9#XQ$'X+R/)!N`<VS'A-'JYGS\M`>:C9(5*W=66F`$Q08F;&!
MP6G@(`,98!'C*)&$H(S"PB,R'`AAQG.<8R=?MQM=J,UNK:Z]AK.C-+LMU/S1
M7D263M=YDG5O4$@"\1Z$U:02:G2(TR&(ORG+HM$E;0&8;VPQ2!V=6Q"KP!P7
MK8[O[F=0"T=?--;9I&JZ\V'E;=$];I/L9%W18GKMAK6./9ASS&&5"G.&?8EV
M$DKI(7&)LW/*0MQ2,$<3%LZLM7YQ4.W?['ZZIFR]FE2R=[V5WL2G;VMO$Q2J
MXY!8D,<&%U<T2)5*T40K:,0J70J",)#XG"!I+CRT!KNB0MS@]$%+0^:I_7'K
MNT7%'J,J9@V"=HB_W8QP&,LUGO\`!#7,Z)/TR:FPAO>'QD&[MK.X82O!Z?#D
M,L]K08*5*E!1*8I.`G'+R\<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
M<<<<<<<<<<<<<<=L9]^._-,8QCW8QC^+_3_3V?)RD)57T#G16")K"HG+R`EY
M)"3)XXS/Q82LYSG)80NJ)5X`>+.1>$&0X[YSGWY[\X5?U;7%4MB]EK6#1:"-
M+HYG/+BWQ1D0,:1:ZGD$)37!20@))`<J$F3)T^#1XSD!!!1(/"66$.(>V1H*
MT2V=RJRX1L-LA4LNESRH?G/$1L92?&P+U6"PFA1L"\K'FB+PE`"6WDN`$B<L
M."4Y91`0%!E[5D/D$`KR+PZ33Q]L^0L#9YBY3V4$IDSY)5.%"@X*YR)19&0`
MP!9Q:0/A,..$0G*&H4*5(C3S(+F3[J@0]Q&4YT3KO;K3A:9@"B"V"XPAP,2#
M5#R1@69>MP23G"<8"LF#;S<%Y!Y4P)F?%X\0%G=2'=1AL*Q6=%:`8^F9)I,6
MQ(PXA==.86(EK?7)(2RX<38P:8Y!:`IPMWI`PTP2_P`V\[$8+)WBSZCF%8H7
M,3*M4CP-2L:&U4H'@`08&>H1$''#P`.,!!@1@Q"P$.,!#C/;&,8QCF%#=^N>
MHWNM>SC66GU[:X:E5CJ;+X.ZK;7L:EHQLU<T@V#>JR+F2==#(++4KC"ZVB4/
MKRT6-K:Y@M"EL%UDCW*E#'YBRM"!4[2DZ>R[8ME%=54;CCI*8[25Z[UVHG-]
M42R%Q9AO^$R6&G%UC.)I#S\$.D.LYH;HX_1"51\U'ACPA96!XB2C#`[IVMHR
M3<CWMJU6.^ZL;*,E.F.!-NO%`W,U58<U'"3N9-CN-;29'!S&X\&,C(7`DYS7
ME&:'`A%JO)##C(L8YAUZ:RM$\;1:U@IP"O-.UWT/]3*^M<M$>FR@CEI?MCG*
MZAKZ:(TJ@W+3:,.C#7>"A_CJXE(^,)4A-R]$]W1%@'$_9'MQO=.:>0)?&W!6
MD?Y3::R),A+:<YEK\N;I`9-@3D,M`,)1K:RM.'5<H`KP(`G+T,66'/E3,9\@
M6K6EN^/4_;'>.5&\-4S;==6V-H?0]H3\R)HHVFEI:Y.TKVE"Z,B]$]KG'$:/
M*>')1Y1Q5@;TZ=R..3B*#GW3ZYZ/*HA$:>GDGTNZ<U9;`1EBB[P]N,'J=`:N
MBEC-:$LA<[167QV(M(B3_/BC')"X-1:0Q`-6)*F.-PF"K/GG]LUCW?M%_G&X
M^V;_``%_G&X^V;_`7^<;C[9O\!?YQN/MF_P%_G&X^V;_``%_G&X^V;_`7^<;
MC[9O\!?YQN/MF_P%_G&X^V;_``%_G&X^V;_`7^<;E'DS'9`Z?.,`PAI0*UNA
MS-,1N63+"\S-3/+Z^L12`!6,>5"I3F,)RDPS(\A&4I*`$L.0"&*L/MF_P%_G
M&X^V;_`7^<;C[9O\!?YQN/MF_P`!?YQN/MF_P%_G&X^V;_`7^<;C[9O\!?YQ
MN/MF_P`!?YQN/MF_P%_G&X^V;_`7^<;C[9O\!?YQN/MF_P`!?YQN4?8$QV1K
MZ%R::K4-*.:6,M*EV/;T9EA%*E9:;P>(@@PT(P`,'@7L$(`\8[>T.<=\XK#[
M9KOGM^T7VQG.._\`XQO;VSG'Q9SC^;.<??X^V;_`7^<;C[9O\!?YQN/MF_P%
M_G&X^V;_``%_G&X^V;_`7^<;C[9O\!?YQN/MF_P%_G&X^V;_``%_G&X^V;_`
M7^<;C[9O\!?YQN/MF_P%_G&X^V;_``%_G&Y1K)--CWN6S6(DH:5(50KX,>=+
M31V"),X?"=I/=B?-2P?NA7F0",D'>4R/RHQ8'CR6,>#-9?;-_@+_`#C<?;-_
M@+_.-Q]LW^`O\XW'VS?X"_SC<?;-_@+_`#C<?;-_@+_.-Q]LW^`O\XW'VS?X
M"_SC<?;-_@+_`#C<?;-_@+_.-Q]LW^`O\XW'VS?X"_SC<I*:R[9&%,Z1X5HJ
M3<"E<GAL8"0E,L,HT!\RE;-$TRP0C`CQDA`H>2EJD&`^,Q.086`0#!@%BK<_
MU3>,Y_VB_P`XW_\`7?'\V<\?;-_@+_.-Q]LW^`O\XW'VS?X"_P`XW'VS?X"_
MSC<?;-_@+_.-Q]LW^`O\XW'VS?X"_P`XW'VS?X"_SC<?;-?'BBL]LXS[<6-G
MVXSWQ[,_)G&,\C&T=/JFY-+I#(K=HND7#X1'N[VX+8DYVP4ZKI*\.?I!<K5E
M.TB*;`)59BEP/4%I22A84&%!)+`1XPXR()TJ=(G(2IB@DITI)2=.4#OX2B""
MPE%%A[YSGP@+`$(>^<Y[8QWSG/,4N\_25K?<JQ6F[8=L=MEI;>B9@;8?*;3T
MZM]=5#K:$-9/2N8['[09RTJUDEHHKZ<=RHP_&)D<A:T#B>SFN2YE*0-Z&4&D
M^DM2:*5&?5M8NUB3ATD$A436S;@N:9K[&N>X9XK;6UD.F=DS=R+(-=W4EA96
M6/M:-"C;65D8FAO;6MM3@+/-4S"XYUK:S-+/Y_Z);&]M]*.*EW<O,$25%Z0=
M5O@\\<UWFQ17G;@K\F7YTN4^55J/)@\L<9X`]J:L>>0&L(5(+`L^21^(0>*(
MLNC](Y.K3(FAL3^5*2DB./4XS@2E6L4IFYN2)P&KG)Q6)&QN3JEZQ,F.VZXG
M<$LJ*I)E7;PW/D<<5+DBPL0)SD1J9U87)6QOS([MJQ*A=660QU[0.#'((^^(
M&]\8'E"M:7=O0N"10F+KOCCCCCCCCCCCEAG79[7QEO9@UG<[;@R78"4,>)$Q
M5,)X*,G+BP>9O+D%U+9B`&GEH/,&!Z6A.4B(!E,WJ3P]R\!$._/OXXXXXXXX
MXXXY;$-S5.?;I]`%V!$E-SIJ_P`VFMJ\EX2*)FAKG+^CBY4Q<F(H1BMOCZR0
M+B&AO7+@)RW);A04@PIPC6"(Z>O]A:5M.7RZ!U]8\9E<K@ZES2R)H:5AAQI)
MC"_*XG(QMJDPDI#(4L7F#>X0R5+HVJ=T,7F:!=$9"H;)(D/:R[S<<<<<<<<<
M<<H*T+2KFDZ^EUKVY-HS7%;0)D5R*8S:8NZ-BC<=9D(/$>N<W-<84007XL@)
M(+[B/5*C24B0H]4>2290]P[+T%K[7+;;UU6O":PK=[7,K6US*9.Q;*S.3E(&
M]4ZLK>E4*"\&J%J]L1+%Z=*`H1_F:14H&`!2<X0+Q,KRV2)G:G]E6%.#.]MJ
M!W:EY'C\@M;7-(2N0*R?*!`/R2E(>2>7XP`'X#`^((<]\8[/CCCCCCCCCC.<
M8]N?]/\`OSGXL>_.>1HK'<75VZ;*LJG*PO"NIK9U0EJE=@0IH?23'QB;FUW,
MC[H^%IU($Y3U'F22D'QA]DD=.=V%AE2<^-.[DA?DYS>"M:>V`IJ_FUT>*=L.
M.3]N:#6["U4PJ3C`>9/:+TG''U*!4G2FN,6EC5W=X=+FXM7%IBT8$ZQ9Y>&\
M(U(;Q<<<<<<<<<<<<<<<<QB=5J'2634;2#\VMCH]PBI]YM'KINMI:"%2U092
MU8;&0N23A\5-J+`E+BR0/R+58LE(`$84\=B#JY'%FD(#2A;?3/1/:U?U`;+`
M@.25;<W4.N&?44N]N6N5UXTU=1]6O\^BYF"@%*XC/;?KFS9-'7I",]IEJ%;B
M9,RQQ:I`C<UN3_CCCCCCCCCCFF>W;/?/;';/?.,]LXQ\N,X]N/X^8=X1F.XZ
MASO,-4=FK-GXIC;D\B'4!UBD\A=997-<"A5..3!#[6C;/+V=.]TA+6N;PJK(
M&SH8BY9A-SPV2.3FA8WHN-`E[+F)Q[L=_?\`'QQQQQQQQQQQS$T[D*,];6)+
MBRS2TOJM[,8`N>4Q@F\J0K-KZR>VYJ&L$7E%EW&TH'%\(:A'97F-*%<Y%I1(
MDYYP<>'3;@L^;9WTB:K;XX_L$YTUT\WJA>\*9>6M(4Q"?S6PZ;B3;%IHO&6:
M2H>[=MZ$RZXH4UJEN#9)#(]FR6@I1'%S2Y+?3IQQQQQQQQQQS'WU8TI[ATP.
MH:U(TJA>Y/6E>S+"S-J-*>N7NK^^T_+6=@:&Q"E*.5KW9V>5J%N:D",DY8M<
M529*D*-4&E@%%#<HJK)15FJ9;3M-:>N.X$6I:06)IHHJ][<<%63/L0.$QTR'
MOM:NL??:WO\`;7QY6Q6/N]2R0@V1J(\]/CC&AQ_);C)VO,+7ZV8.,%ACA8+2
MWL$\712-K)HQ-*G"UK99:I94)\E:6Y9A0KPJ0-KV8O1(U/G2GRZ8@HWS@[Q>
M5'5W'''''''''-,^[/LSG[V/?_)\G\??';W]\=N_/,I><GHW=Z3[11;6)S,3
MW-773EWLTOTUJV'US8,;7+G>QHJD!8MBR&2F0QDA43B"B2UI6<"HEN7241:X
MMS?YP46,Z:QDAIE/H*+X?;G*++J5E=&2@(-TL='J"D9:A$O:4:&[V*<W#.$U
M5KTJQ.5@Z?4?7,@3M4_9SSC'B`.,X0Q=_3H'90J1$9Q>...............,
MX[X[9_[O\./;S3&,8]F/]/\`Y?%C'NQCMC';&,8YKQQQQQQQQQQQS3PX[]_;
MW]OOSG/;O[^V,YSC'\G;V>SW<UXXXXXXXXXXXYIVQW[^WOV[>_/;\7OX>_W^
MW?[_`!@.,>[_`!Y^7O[N_P#)CY,8QC'LQC&-!"P'WX%\OV(!B]W_`#0Y[?Q9
M]N?BXP/&>W;`_;GM[2QX]^._M[AQVQ]_/LQGV9SW]G/KCFF<XQ[<_P`7QYSG
M/R8QCVY_DXQG&?;CO[,]O:$0?=]X6,9SC[^/9GXL\UYIWQWSCX\?%_'\?W\?
M?Q\?LYKQQS3..^,XSW]OL]F<XS_)G&<9Q_'C.,\TR'&??W]W;]\+VX]GO]OM
M]WM[]^^.^,^S.>?7'''''''''''/C``XSW^RS_SAC%CV_>$+./\`!SZQC&/=
MW^+WYSGW?QYS_+\N>^<^W.>:\<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
M<<<<<<<<<PV=;>GX>LT(W5V,/].8M&I=(=@FFLWA,_.J)/!UR]N12H^6QQ"A
M4IR&Z<%N4:9B4,N+QZ;:6U,H;FM6B2.CN6N@<D98=0\5Z"TVCD66.+KMG=&I
M)%DY/L:VV-.581.BTMR5:"5HB<[8HX^OKPB"O(F[/.6251Z8KQH'YP;R7DM\
M6O\`U=>]8/>>R+4HFM6^.ZM,N+\V$ZK>L32Z'P"VEWP/?>GQ$W">PJTER;]M
M\`I"BF[.PO4=DU<%J&?P.)[7(6V>H2,+(Z7NUOUL-SK_`&S4F,41KA6$KO"T
MNFO&.H-/(.-W3L\>L`]7L4CI"35E`I/.[4@;=5#*TQ]@G<W6SB3N-E&1YQ=Z
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M0E$X1J2MOE`F#:W]IR:6E>&HX8`"4M;@!0WJL@!YRF-P`.,6^5ZFZXKFFC&)
M;3T)6-.L[PW2"@$*IM,/(J!Z9T6&MG<X!@U2(<<6,[3C+,T'(A@$ULHS&=!Y
MNV&FI!V];.GMI4RK(TXM&M54MB^&R*TY=$EJ".^:JXS*KQ:@L5RR-A4$J@&M
M+Y:C,'#783HA$2MER#NE?3EI.<@SUZOIOZ++2Z%).U;IX).L`W$-!D)HL4B(
MJ]`[N/I=S88T2C/(*+BJ]T_\(JX@O"NBIR[&%0F;RV/'RNMB-78M?4DH2R@N
M0XC<6L-ICM>EK`3-Y3F-D<WF+O4`G\3?6L:A`8]P2S*[DK]$I>RD.;4KSY=I
MD+0YM\@CC.M(IZ/Z!::Q21Q^81K7.KF*5Q.?V-:T9DC4P"1/K!9UOMB9EM2P
MFAU3JBUB":V,T(TC9-Y,E-*=Y,A2ITSNJ5$D%`!4D?TSU@B%-,VOD-IB&PFG
M(S*R9W%H%"4[A#F:)35-(QS!-+8D.-.+6Y1:2)Y::=*$[U'U[:X$R%0H>2E`
M'%0>I,I.!Z1T]`;ZAMY,K,V-O[3="9ULUWK]B9D;)"J6K-Z=VB16$-@0$#-&
MOEEANT<B:)YD"H16&^+Q%G9&=$E5.LT=Y5,GCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCE`3.UJOKA8P-]A6-!((NE9ZE)%T<RE\>BZJ2*T7FWGB
M5@3OCBA.>%"7SQ)YR2W%J1I_.4_E\%^7*\=8-CHVO2%,Z,[@A=6U87Y5(X-J
MM.O1*BL#$7DQ.K2&')SP8&`8/&48,/C`(/?N'.,<_E-M\RB+M))##6N4QQRE
MT22LJZ4Q9`^-:R1QI%(P+3(\L?V-,K-=&9*^@;7$;,H<DB4IT"@6B0C4!2GY
M+J3E-M\RB+K))##6N4QQQET12LRZ519`^-:R1QI%(P+3(^LD#&F5FNC*E?"V
MUQ&SJ'-(E)=`(%HD(U`4I^2Z)2WW1RUJECZCN2JE;)`C2R)N\)K%AI[7#SC5
M!R0HF4N!3V-''3352=0F++>3D(QJ"#B0AR:48$-ST#@A=4*-S;%J1Q;G%(F7
MM[@@4$K$*Y"L)`H2+$:M,,U.J2JDYA9Z=00882<28`TH8BQA%GE\<<<H.;6G
M6=:C92[$L.#0,R2*%2..@F<NCT6&_+$1`%*Q&RA?G%ORZ*DB<8%"DA#Y<Q.0
M,!IX2RQA%FM$BM*O2IER%2G6(EA!*I(K2G%J$JI,H+"<G4)U!(AE'D'DC`:2
M<4,99I8PF`$(`L9SR.:=\=\8^//?M_)[_P"+^7Y<8^/FO*9BTTA\X2N*Z&2N
M-RU$T/;K&797&7YJ?TS7(V)1YH]L#BH:%:PE$]LZK.$SJU*1E+VX_."5B<DW
M/@Y4W''''''&<XQ[\XQ_'QWQGW9[\TSG&,9SG.,8QC.<YSGMC&,>W.<YS[,8
MQCVYSGW<TP((N^,9QG..W?'?VX[^W'?'OQWQ[<=_?CVX[XY]<<<V3U!"4ORJ
MDXI.5Y0DKRIY@"B_**#@)R"\C,$$&!G'FEDE`[^(TTP!9>!#&$.=2CR3LFX)
M-*-R2:(@[!9@#,E'`P$0BC/`(7DS0A&`0BQ^$8<"#G(<8%CON\<<VS32B"C#
MSC`$DD@&::::,)99998<C,,,,'D(````.1#&+.`@#C(A9QC&<\U+,`:`!I0P
M&%F`",LP`@C`,`PX$`8!ASD(@B#G`@B#G(1!SC.,YQG&>??''-CSE/D[*?!Q
M>3PE@.$1@8<G!),&86`X17?QA)&,HP`#LAP4,0!!"/.0YQC?XXXYL`4IS#CD
MQ9Y(U"<)0CR`F`$<2$_`\D"-*P+)A83L%F9*$,(0FX+'DO(L!%G&_P`<T$((
M>V19QCOG&,=_CSGW8QCWYSGXL8]N>,"QG.<>WOCY<9Q_-WQC&>WQ]N_;OCOV
M[\UXYL&*4Y1I!!IY)9RD1@4Q1A@`&'B*+$<8$D`A8$:(LH`C3`EX$(!81&"Q
M@&,YYO\`''''''''''''*$FTCEL?`VBBT%4342H:D*X*=Z0-'HX)02<IQ#\]
M`9E1YUD9H<>2QC!7D<^//[H#&;322UK=;6%V7AIE8U92(3SO29\B;W<EO\(?
M:M.;$!`5:PI*'.3C"2A`QX`9&:,!(#!8HRJ+=M]UCIQF8&LL,I.N-))D1;JW
M,0A]\>5,1F^73X3.`TPQXQA2C``)18@)E&!'`P,5\(M,[">G@M`_56LBS<-.
MJ,&\G25J<BR#BB\"3DB2)BBSC,J3,^3P(&<^3S]F,.08%G&*[5Z1Q]EZH'5-
M)V*=6QFMA8/7,R@L6&M:&]*NT<1TBW#!^U$<_'E&JX4DV`!<ZJY2&`PQ&AG2
MAK43`I/E3'Q#CO(+EN.LIGOO7&IEWM<!U\T5Z>%6[.Z^4]'ZAKE_2R!?85>;
MG+4<66.,B95$K#!6^3U174HBQ#*2@&J9#4;4A4G1Q]2J5G5(.I!M!9+S84>J
M*>U5.77.OW2=MN$11BE5,5[+YF\[1)-@3=@H%2,^LI(_U*ILJ1EUA%555L]L
ME&0XMV5/$44REA52*/.+1#U_W'LB+V'M1O11%QX:W8K3CH7S"<E3ZH(3'W&Y
MRK$V?V&IN>M-GQ!6K<QUR<)CDLB\[!73\`Y"_!C+M#YTYP1*VI9--&=]3+9:
M.K=T;0A\RH22+-4U/4.AKQI(ZKW!TO)P5:XH7YVUSL5DK^,0%IL9A8YG&8NU
M6-/I+);(E$&F5=62VYKY#$I(5'T[E<[IP2]EE_4KWYDR#86,;'_#[2[I?3A!
M8,?2UVV$NZ->';<2W*%)7B5O0*V<I0O1.C2>XI5+\TL4FC["]O#P-(@<UL?M
MRUM)5-LK-MLHL-A6=.^=6;35$=7G+&X11=5\DL]KE!3+3=HGHR$:XE[35),)
M!#:QWI`B<2`R2N))$(L]H7Y16EG-B'M;4W(EM/[^;L1]3MT[19GG4HZ4-9:]
M0@]BJ^8MWHB^$MOKI0T5&?(`,$+A9DF-87<Q)=5CK9="F$]Z6@>8[94@*J^(
MI+.PCJ1;EV[4>J;NCV1AT*DEA:2]6*Q[0<XC7%22%T';>AEK1B)5J^IS)(UN
ML?:5+VQO0%TZ92HFECSHC*=EK+'XOER;#XQ]/?4KW21-<`/+V#KQL6W#2?0V
MV"4.+K5-?#C=7XZA.R<SHR_(C'T.%:!>HKMICB&.RQF7S:12&8,KH%;X)LD9
MG=&F;+]BW2VQ@D0O:G'_`&.C=FW[&=U+"U:TUG2.$TY!$>T1A]-5I9JAYM,I
M0Q+X=%(+IP[2R<-.S,^KN,M)#H1`1Q%F)06>L;F&0[R+J0V*V;@:WU-&MLZ\
MOF`F[:5/IQ>KNBA%4UU#'1^E.BT]N=U?8\A+?7^R7Z62BVHXP26.SV*O44HU
MEC,L9:696*TYNVR:8)[^]0R,V"U7^;=.N]Q:ZN%QQ?4.51ZXM,MO34#13>PV
MK!TY>7B7JHG8F#0/M,SQ$YIG>//,QRW2FLWE.XPI#<,?`T,D>=4F/F1]1[8]
MA@]AV53$V2T135):L]%6^J]UNGU;P%Z?(W&MQ+>>:>LVH+1E;HG3RHYO;H)'
MV]8B>68<8DB!X4,#RVN2!GRK87V8,8WBV;F5CU<[LUCQO)LXZC^YNBUPZS'0
MR(A7T55=--]YGP&_6I[&0&:CDD/BM7U;<=B+YP].=8S2%78F0L#%%<J82X+H
M:TWM5N)+U/1EV6LO9V3V:MVCU<VVO%714<B-45S!I7;D-UMKQWB55-94=C67
M>5.LIDCG(T;.B5N:U_;E3D^%Q@A`H+2G,UY85U/+Q74K5MQN.QVO,HK/9*PM
M`82_S2#NC++9+I`IV&=9:QWLNM<]/64/@$!;RI*S1RLJCBMR$2N65K:;E*!V
MF]S^.L13>7,CHK#1!JS=M"BF;?8&&SJE[\I3I<WEQE.!\\XMHEQ1.*A'#DR*
M,HU:UL5HU)P69O;FY8(S+DC;T:=86G+S,<<<<<<AA;^W3[54_>(.AU9V9LI,
MTD-9P)E7L%2O,1=<N3>0O&6U.0G,H:@3>(_*%?@PDH1*\A03@&0EA,'`3?#=
M>[&"JZ*GM:IK0UM7RZ8V:QOT8L.-QIJE*])&$+#EN6'-[RD?"P-QQJP]4W'I
MQ$&'EF&9."(L)?.-IEU"+D6UB^&V'4VQ6RKR&<N)::<UK!H^\,34V^AF(1,6
M5JF@+*F+=$2@2ES.(&D,/"F=4HQ'B`,!8,S,(DV+&@$=D[G#Y%$0RQC2+ET*
MGC60@D;.6X@\"EED;3@Y8G)5A+$,E6D$::`19G@,#CQB+#YMM#+ZLG7*@->H
M+2L/JDXO:/K$=1C65^<IH3(R,0]O9K'W!G<$>&=OBAS=AU21AKI1'&"V9P<$
MA14=`W,+,>U$^3<6F8.OG4$V[L23ZV$6#!];TT:M':#<+1*PL0I5:0'M!L!J
MTW;'KT=KQ4Z0+#$".I)J?KJYMRBN7-,_3!A)E+>[E60[&-BEC46SU\ZDN\>P
M35HUAKA>IT7>-_\`7G8::5T:Y$W.YM]36IKA(HYA^.F"5(_)E%A0*8Q:1@PU
M,+4OKV0QY[:SE"R6OR-Q+;T=4Q?JA;3WK540<]9]:HM.[W0:7:Z;7SZHU#\D
M]`2-^OAYLEM05;&;"DM@5D57;.8"F)T!!;<A8[#:6YS=HZ@?HJ0%M>SE-JMY
M=B)1M)$(;(HTSPAHJ/7CK:Z!ZXK$+\@=7"TG*>5WM71C?94L:G]N?L1B/M:6
M8RLZ`-L:.CSJ9)XHTNTU#+TB21,K$5?ZJ-O):E==B(]7U;:ZU#)%'5.V"US?
M7EO9II*WJ?GQ.BHU/VRSD=.1)9'II=UU3,X$389R@9Y+%&.&09K>I^\OPH]!
MC\KZ.KCJ/7K-GK76_I27!X;13UTF[FWCN&I&6.2.327$PJZ9U6GF*.*3`Z4,
MQ:HL+.\*D4%3.D7&-JPJ?LO8)$L<VT]DD34>^-V(B3[1V8ID<5U:D]#U);,#
MNFN8R^3-Y(GMB/:)$OIXNJ*QE]\6=9[.B89+%)4TWI&8C$(J8A.=$,KB44/+
M;SE%%RWJ(70_;2G0.D([4JO7.-Z=5_O-*9G9\7O2*V\Z5$"X)M`;5B<?KQT9
MXLY,-@_!J$NKS7Y$N8$Q&7LI$VR5MPB>,+6N*FV&RVR6S?38WF>[*U]C"#6*
MW^D)>>R-:VHG<8XB.CM@+ZF6S&+U>:P&6A/'BT23(?(F*=Q^YX]'*]:&A[BC
MFUO$3:U;G&C>2F;]U-DE$C=:OUFH5KMY%K(_ZAUI<[(XNL<87-X:+9JBI;1G
M\J9)[(K4A;-`,5O4]H-$LCZ)\@DZ266[1>311,ZQQ8I;5)/:M_4'O(R\E%<-
M=<5G;".2P'J!/T`CU7N,H(,'-=.9S$6&!0,BZY,I+K*QGVV666(B+!3QQAC+
M=0-B85P!Z?Y8X,[Z8WV]KWJJRBP&&$L,:3Q*36_:>Q35KTUP0VH[-JJTZ.FC
M/KA*]@K0AE_:[7%/XG)6NPH\D@,D:(.SHK.98_9[2I03.*R)P:$*XI5*9YV+
MVU9>FYL3?\^H]IK?;2I*3VADC'5K4^,<U8Y!,*D9)\MJJ0-Z9ED,K&@;[0;&
M*)S4->/+VY2>)XD)D*?%SBX-XW);C$MF%Q&`=`]GW3@\F5D;70K2>N]SXWMM
MEZ3.-WR?8%;!XO;;E()%9RC!CS+V&RI6ZN$*DM?N:M9"7ZOWTRL"(Z",%-C.
MDG2AWBV0;MO*DU1G]=U!"7#8NN:MN>G)0M>)!X$L:98TZ/.T]/35C/?DSB"^
MHHI1)5E*LS$6=')[",368NRA`&JY@S![Z%[NW.[73;VK<JBU;M&PE?;7P>$Q
MQI1I91F/2[4"<P95<+7L4F`LE`78:D-?Q:R88X)40SV%IO.%X@1IRQ.^MS@.
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M'I`S2YR1+6MX2TG7'4QV1M*-0>IXQ5]>N.VC@Z=01DD>8TS/D@JQW4:&;&-F
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MK['W.62*+RN-Q%`\H5+,=(3FABJJJ^HM++%M^]Z4&BK5+*JEV92-3(XHD4R5
MLDRTKQ73U/5VQ#+DMW.6/2G+Y!;,IXE8R$'PT-G1=$E(.=&U^0FYQW6KN._O
M%Y=,/J4V#&X6FJ=WT&ZG^V45A,/3.15BLE3L="4W;<<A\PF;@[NC'+)`X0DM
M.X.)S5'HLW127N+FQHVM^1)C']7*B[NH?OC1E&V]=;YK55BR'Q^*:I2^J9T^
M2`N+1N6.EVW;$JDLNL5$7CMK6?-'<4#;9Q$YK$[E1DL$1ES>^9:W*'LCPU^:
M.692GOVX/VOV@-\CK8VT0+Y,4_'5&7*2(">WE2EZ+B1[0FFAJF1I5AT."P&2
M)*M6+2$\E$[E-:Q4TA0G#N;QQQQQQQQQQQG&,^_&,_Q\TR$.<9QG&.V<9QG'
M;'MQGV9Q_+CG'2(D:!.4D0I$R-(3@6"4J4@I.G)P(61BP402$!1>!#$(8L`"
M'&1B$+/<6<YSR.V,>[&,?R<HF85I7=@FLQ\\@<,FIT<5'K8^;+8LPR4QB6*0
M%EJ%;,-[;UXFM4>`HH!ZA!E.<<$HL)@QA+!C'=%1>-D.C@]DL#*2\.J;")S=
MBFEO+<W%'@!9>$JYP`FPL6)\`)*!@A2>:5@)18<`P$`,!H8-$TH".&P\%0U<
M&)GH6ML.C`:]AX8\:VLBM>N9F\QDPRX;!H6I:ZN:QM2"2Y3H%3@N4)"R3EBD
MPWOS:TKL\!I9T$AII9Z5M1'`-BK`8`U&SE%$-*4P(VX6#$S80022W)QX$2A*
M)*+2@)`6`(>8E@L*0RESG"*(QA'-'EF11UWER6/M">3NC`V&#.;6-QD!*,#P
MN9V\TPPU"V*EIR%&8,8TZ<L0LYYPX;6==5T2<G@$"A<((4$EISR8A%&",%'D
M%*URXHDXMC;D`#22UKFXK"RAA$6!4O6J`AP<K4#,WBZ\@9+.HCQ4*B13"K6>
MD53*7&6,#0H7^/!GGI[8%!A"<K\ICRGG)J<9_C^R\IXNV><=WK&N']K]"/L!
MA3RS>9,3=Z)=HI'W)L\PC#D!XC:+T>M;CT?F<?=BRW1D2^1\W:'$`%S<6F5!
MP;CY3U=6R0'DTM?PA,7Y9_4>33Q*.D@\XE2Y6YR8_P`);:$/EI$XKUJ]]-[>
M-X6K%2IQ$I4*#C!QYV:THJ#9V#1."2!/F$MT2MFD[;3+(1&X(4L=7&A;!9[-
MAD3>RI!%7UO705=)V%L+DS"%$2-S90K&I*L;@K3C\2!S4]7Y9&>-YKF!_!Z/
M$'I6%A^!T<RRLB94>6I4)F=J$V"0M:<]246><0A((+-.+`<:$9H0CQL`IZIB
MW4A\!6->@>DQL5.3.X81%PNA!T%*6D0HTEP"TX6%&1`EQ<"HN86<$<>*7+"V
M<2("H\)G83*LZYL0M(3/H%"YN2@-`>A*E\48),6C.+R,19R4#XW+PIS2\F&9
M`83@`PY&/(<XR(7?DN,`@SNH<%;K#8JY*G7"7#FI<(XRKE#CYCX<H_/SU2$X
MU;YKD`,IO.AF^0R$.2O!X<=MHNN:_*D3U+BH/#RY7)&@N/R&3`C#&"0/K$22
M0F)97EZ"@PYNK02G3)B"FQ>J4(2R4Y!0"`EDE!!V2.)19N(:$J".,*),P*CU
MK&G1LS:E(9UBHE2G4*VHE.E++;E)Y"Q60<H1!(.-)4J"C!B`>:$=.XJ2K,,<
MRC.*V@/P<L5P<7:?L'P-C7H6<.CP`LMV<9@U>B_,)0O="R22W)8^IUZE>`HH
M*LTX)8,!J:/1>-1%`-KBL?8XTV#5'K1MT?:&YE0C6*?!YPK$C;$R5.)2?Y,'
MEE`BLG&^`/E!B\..W>\<<<<<T[8^_P#SYQ_BSSHGR+1J3`3%R./,;^!&,T:0
M+VT-SL%*,X(0'#3A<$RG!`C0@`$P16`"&$`0BSG`<8QO,L>88VE,0QYE:6)&
M:>)28D9FY$U)3%(P%EC4#3H"$Y(SQEE%`$<(&3!`++!D60@#C'8J2,*$YZ?R
MAI.#R3"O+)S,E'E9,!D.#2#>PLEG%YSXRC,8SD!@0CQC.<<@S">G'JE7Z"K6
MF+1::)4%+;$S?:ZN4JZX+4?/0-_64GF2>>3Y28]RYP4/YDG*L6P!+HY)#7:)
M$&S)_/;6%":J+&1V4:Z>^M$/S`!1MDL!K-K"_+:V?A9Q=R6JH.;KUO1/,TMJ
MSU>8LEBC,B/E9-BS[!C#)/2\5:13!\,86-J,4EB)V*^Z=FK55`UV!7\5F,<Q
MJ?$+7@M`9(MBS5HJ_C-VY*S920H;I*5XI$M?_-D>$[W+<OSXPX0HL1YQ:O-B
M^6[/Z2^D`TM()4=?3MD%0-=+J7A3C&[YO2-OKY1CB]JY*KHNUI$Q6&WOUU4Z
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M5+9(G"7(8IF#JG4Z%E`)D[LZO(W8EB+?5*AQ5DJW,]"9A(&,,(Z5.E=>5E<=
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MEV,<B:;'B4FJQE<'1NB3VP/R%P`4^2<YZ/>5DNE2IYEO5-30FEX$SUO`T+DF
MC;/Z0-P;(9'(YK)'ES>7!4[OT@EDRF;J_2V82>0NZ]<[2"2R=Z=GMZ<5:A6X
M+3S#/9&YKZ?6LK0@8XDCBLAQ3\6F**PHMKT;.I<?KW')BUR4N9,[BTU`:ZBB
M9+,P2XHF61B!'IE-:124IT<BC,+:'A`@6I:DL3237RU3EBV<1^5O#NIO^";.
M(Y""S;%;)+'+BK-E2QV!O\/D;7)D;U$&:-,:8;8D@T<6MD&5HG.1I'2/+DTN
ME93U2--478KOLQ8&UNP<"IR*V6U0I[UOIE15DFD$V<S]?R[/<[!P_3B2R.$P
M=2W2*<KR(BL4UTUHGUB@AK`X"0S!^-E"\ENX<!Z:FG%;IK?9(]5BU7`[K:K*
M8)14<JL*R9K2D?CUSG+5=PQZK:;ELL>*WIYCM%>Y."Z<ME81N+)GTY6,HX):
M(LA&3JLZ;FI;]5T[J&<P>267$[#KF%5`]++)LVQYG-6^KZR?S)76$-BMB.TG
M,G,02UW*Q$RZ+/<<?FZ7)YD@:YFXR)SE;6@>4_2)^E_J+EOL8MZC5D3"3VI)
MJ+GLOLJ;WM<\NM(=EZUM2!II*TH]/WJ<*9!#+)@B=M2X13*'J61W<B<&MKX<
MZ,IY[69<DW1C7I4"!G+6*6JWNO[_`"]IV^4#LB>$2:0;!%Q<Z$EV7/'=$_)3
M9XO)AJ@Z()(_*"W&%-\3`AC#=&$;`T,S<W6JDW2OTVE#!&68Z'6&P.<)NVVM
MA838$&O>[:_MR%VC?SVJD%ZND4MR%3QBL1@8;?<E[@;/(2W2(B&NP5>`E,:,
M2%K&@DC9FK5(VUKF_:FS*(&F4#)Z_#5;[`6&0R2*EKJ[RW`:%$5Q((XZMLJ1
M(5K86%$M5('M*ZJBA&C-<!'G'&F<R>ZU4Y:M!N.LMGQ8VP*<=XNTP]TCLH?I
M`O<EC3'U#>LCJD4M*<TTN3R2.N+0SO$?F"-\32QE?FALD#<])WM"G<`=1$=4
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M.MWR16,Z2"M*GA,T0H9&S5I!G-BB0W!$ERZMKF2064')$05@@DHG`S#/)E@!
MY0T?C-,R$.`Y,-'VQXS#,XR,P><8R,8A"SCOGF[QQQQQQQQQQS3(L!]_?V_(
M$0O_`-N,]OY>;)RHA.48>H,"002`9IQQV,E$E%%AR,PTTTS`0%E%@"(9A@Q!
M`6`(AC%@(<YQ;"E;PJO8FM(S<-+3)LL"MI@6Y&1R6,I:WT>YA9WAPC[G@H"Q
M*E5%&(GAJ7H3RE"<DT!J<6?!DL18QW4P/&<]L8%_*`8<?SB#C'^'D5HGM=&9
M3M%>^K8H9+&%]U^K2H+5EM@OBV&$5\ZQN\E\^;($GCQR>3J)2)V$LJ^<%/I#
MY&61"U8:T8R7%P"[H<CN;+[\IJ!N%<M,KL>*-+G;EC#J6MD`W9,J5S&QB&U\
M>%D392$0U)BEU;&N-/JYX*\(0LZ=L5#=!I,@Q@5P4<GCC@8]$H7YF6'1L_*6
M0E)71"H-8E(2/.A)GHHE0,QI4!3?UP(AP"F-"1C)P@8+QD6+?.%^TTV32JJ\
M56/%!32[TLN7U/'D;LF<E\Z;8$TEO<P=F$+<-66K9X\WJ$F7)WP8%M(5N#:V
MY59<7%$E/LS=&XL?H78'7JD+#K.PFV.;+REU@$"V`\Y@1%(L]DML2>IBAK6<
MN[C,D,NC<VFK:PN26MFT,0<$,Y>$BEG:G0+BG,2XWJOW0JZ>Q^I7N5)W&GU&
MPECS"O->(]83I%12"\2H@U2:0XG=?(8F_23"V`2J)1%XG$1>W0UK5+X4HC[X
MYMK,*3,B)9)Y)+(PO)<%*&1,:Q.TNHF-T.2N[<H*;7H)Q*<3.O,)4C`B=0J%
M!!`FY4(I:$XXHK)&##`!%MH)C$W4YL3-DFC[@H>BG0]H(0O38L.=2&13A$\'
MMI:94:->2U+!!2.9J0)Q;>ISA.L$0=G`.;B65QA:)<%'(6-4)L2I5SEA,[MI
M^6]$N`88C5KL$JAY2)5991IB50H\D2H`68,D9@0"SCX6S")MR`IU<)-'D+8>
MK2("7%8]M:5`<N<!X*0(REAZLM,8K6F9P6C3`-R>J'GPD%F"]G+4[(;'5IJU
M5ZNT[.5N66XR1P^"Q2,QU"%WFEBV78\E;H76]9P-B$I1X>9G.I<[MK"R)#UB
M!M3&*3G5^=&:/MKL[H;:P7;EM6W2@UVN6OWZA;@DU9OMPUXRRN11"1QVR('#
M%[`T62.*3&*NBMI,E-5NLIC),_BCD4@6I&V1-,EC:F41G+F[-4FP3>'&&M9!
M<JCAI[XM7MS,04^M1A[LX-8?$YH&LD"P1CBM;@=Q+T:()ZE&''=047C..]D-
M;MG8OLL=?Z:-Q671-5KQL=8&M,L2R_$>\NZ2RO66'/J]_8Q1M]?TAD9=D$U:
MSF<:U4E=\@"<%S;&U0'*8$E^............;9WE?)&>1\'E?`+R?E,YP7DS
MPY\&#,AQD6`9%VP/(<9'@'BR#[+MSSXZ2[0V+,-@*JI38^\-@J/WTAYMA/FR
MVF]UMT6057L^SHX#-F]%-]*9,9%D<+E%91:6YCLCBH*IGK:N(BK6ZXNQF7/J
M`R3CE17?5[I>5BK!^G=37/1M76_0NQ]]0FT[.*K8]A.:=2UV,WW&WMDK^PIO
M*X\\0N.F%R5.Z.K,GB\G1IG-/&'IU-2HC73NI_U4H'4D-GDMM*A;TB*IATWG
M>]]?Q(U/7:B36M055H(TXVP6Q`-G2%EC=H50BF41<Y]6TM>&YQ3-$E;EL4<)
M@I2OC>T<,CJ/30F[*KB<YU<L6F:BE]#[([!2BQ;,F%0F.#)6M$NM&8_;`)CL
M*L"5J/@6HB=Q$2AT)4'E3Y$I1F1O$&&O;W4Y+NL'5LHEQ.EQ#Q";*:LMU;TY
M9D`/:$D;G3=9Y5^V0U4_5U8-+Q#7YU9XK?+M9,BB4?=JEF[@QN+(CE[))CG9
M1'$<I<HWM:+7)=-C;H=4"%6LJFK4TU59>K3=`ZTE4CCDE;*X03;6&-3B1H(<
MX17&&HZ.OTC=%+T6H4=GLY28:2[%DF)222\KG'''''''''''''''''''''''
M''''''''''(-;JZ"5;O2CKM%9ED[$5X56JV2+F<5"7/(JE$[FRA,U)5@926S
M$JDT@"B+:"!,PU1`5#4)2XA2GA*<591F%G=+H%JFRAWX.E%O[<SJ]G-W86AL
M;KMW>FK=7K?%UJW.)BZNR++$(N1'A9"SVM#'SST:96>Z^=J3S2$`T*R,O3G_
M`&/S?K0HL.)[RRVW:Q@Z5`R.M3GZL[D2&/-Y+XH7.!4Q:9!"V9@`V>%P3#:'
M9$_)O-3L*4JY&K(4Y4DJ"<ZNJO20H?46XVF[(%=6XTTDC.QR)A(C]O;*2VPH
M(I2R5&6B6'N<16HT3>YK$A903FHU<(XIN6^!>23YV0G.)A+U"-'ME=AI'U6T
M4)HLZ7LNS^IVBU64BZN,PJ=N;GZR->+<O"8S$T9#[.$;M$\,[3:3*NCDB>F]
MJRH6M[R6W'$*R&W+EUKOTZ[<1;4+[+ANKT,1U-&NL'3FW<&BP7.FX^VIJ86=
M.-7K9:TNCT?2O*I)&EI&Q1+#/I?'0(6^3RE&RH9LTM,FDR)`A##AJT$ZBP4<
MXED:U2;X!(9+JO235,:9(M*F6*J)].->.I"^[%V1K"WRQKGLMGT@@6S%'R![
M8XQ;-T.LID,J^%$L:+F=*\9'Y5%2LE$>TPDJ_;W1G:>%Z2,5#PR)V7N]+K7K
MY[F%5N-@UT]['0:HBF6S9$WL,SF<&2NKO8%>2AY<8Q1\LDB5E6/S"_Y1X?7V
M;N#7,3>37%ZWJ:773F>P611W626Q!3*K#NMM<8$:^J9O'UJ-PJ^'U<@,D"Z8
M1641F8D-MDNU@N432MA1,10PIC5+!2UZ<F.![W16^5]0KID6?L-JQ`'W933B
M[+E36^VN$YI]NC,\8WK56]:8@-UQ5S8'F0DP^+3&P'NIY].H*QXQ-ZX>0KC(
M5'9*.&1QV.@*Q]-K;Z35C:46D.F0XV7:-;]%=Y(A"B5ZSH8G7]BZ6;32J1[-
MPN+)V.S79<<W--/.9K97<XEDFF]BV/`U"%OGEDN\M=7!E;99PKIT6I`KPCLZ
M1:RQ9DBL<ZR6P>R!CFT+*71@;]'+4TXL2IEC*@1$2<A<EB,FM26Y>)+3*-*2
M)>)8[2EXBREQ4'#4PVZ=VI4]<]0="-K=;M,(<]3*%=,*55W8\>F3Q4[!'-\Y
M[:#S3RJC6.Q%HI4>-[K>GW>%22XWF2V9AMDL<:SFJ`0"-.3PZ*449O[>O3KO
MY=0:"@ZQU$<9"YSF$;VN-R;!R9[UG9[$EVT>QFMJ1@;;"35>FLE]I^LZ;G,L
M\=0X5L39.+2IVN8?!896K1$F!2^3]1D?O/4JZ[YT@T63I6?,:V,U"LG2G:<J
MKYW(&,T$ML#6Y(T_#FGY)-V!UED>;W26,BR8,C-,T;J^L+=,3&%V7N!K,!>N
M*L3OWJ3>_4(D0K"24G)*Y8Z"TFWPK*KH!9CM5?PWNW87<^F$%1LC0-*QSR5P
MR(5Q530U&K7F5R.8I#Y#,WA`;'V@YABHI$ZQ#O7IX;&HHW5D7I#2.-1Q5`*7
MZ9LV'+*I=]>H_(9G==`;;0*QMEH98;S,ILVF1N4-L'C(I/"Y74B)I%<KJY/I
M5L7,\-[!$X1C,_H'25HTP^[Y++,B9D8377O]<U[UN:-[C3S\(*TF<%J-@87L
M8(Z\NXV=0H<88]@-9GK"!W3$@2GGHRPJ@X#D.XXXXXXXXXXXXYQ%Z7SY$K1Y
M,$5A6E4)LF@R,(R_."1D^4`(LPHP(@>/Q!R`PL>,XQD(P"["QCM9M$YD\R74
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MV=\KVLYGA)=3EZI3PZ#U7%YUKZNH"?1"RJ0G$B6-3.H;;WM.&R2`0]`[3*;M
M[4WRJ*-BYH4Q=O=I1*Y&\RBU8U$F%#7#LS>UB7>.X;"VE/I!TG.$-9LU915F
M?Z8JQ%59;A%F9#)):ZIT<E:T"9>I;'>0NWHL\&"4JP_`C3C)S\<<<<<<<<<<
..<<<<<<<<<<<<<<<__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g307556.jpg
<DESCRIPTION>G307556.JPG
<TEXT>
begin 644 g307556.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!#1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]#4E532$5$7U-.3U)47TM?3$E.12Y%4%/_
MVP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``+"`$A`EX!`1$`_\0`'P`!``$$
M`P$!`0````````````@!!@<)`@4*!`,+_\0`81````4#`@`&#@8%"`<#"0D!
M`0,$!08``@<($0D2%A<AEA,4%3%1559789&4U-760525IM'3"B)Q@=<8(S(W
M<J&QLADD)3-2MO!"@I(F-CA&8F9SM\$G1UAV=WB%AN'$_]H`"`$!```_`/?Q
M2G[*UQZ>-9T]R/JVX1;3_EB'X\Q_%-%1^GA;'9/&91(9*HD42S1BN4906R"9
MKWMCC*1J7-38S([3V-F93D;/?:X$\HY,6*=?9%G#?"FY-ET=T5:E\D8VA$0T
MC<(=GX[`.!FU(=)0S=C51.4TU/TQY!RPXK7`^&R1MU"W8\<"5\0BL=CRK$*R
M<X_17RO)5ILA5-_6D<+%/E6/W+6O;`\>)N#X;-:B/1W8]'K)!?F1SC!N;"=,
M*W5B2]%NED'1XZ2Z@5R9C(Q1?%EDG58T1+\@F9`1R"]/CJS>G:/&#?TB`]_O
MVB-H[;@`B&X#L.P;ATTW#PAZZK2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*5HXT]XP>\@\(=PX#2_1G(D3@FH&&:0(5!\A/
M&/I@PQ:8)XSIHFN*LDK8#*9"PM\:EYD'DC\0W.G<-Q<2BEEY/^\3W]DJ!.*,
M+9KROIQX&'@[WK$N1X5F?@]]8V`LF:LGA[@,P;\8PS&^@M/D$Z*S&+Y4<FE)
M!9XV:CI"5C0O%!<->)`ZO3%*9"N6M+",(EXQVQKM*F6[N#;OX#R[&N4K<PAP
M@19-T^YO96.,U.D$_7/;K-,U3),MBU!B^U@38WOOAQT<.D5LSMR\E-QS9$+W
M@]&8?Z]+0$`Z?I&X?!T77"(!^T`$`'T[U%/43#3F6'S'(K).LI,K^0='U25,
MU9(E:&/)+S'Z/M1Q::-DN%K,4G/1F'6G)@2"08:><HN+[.8)@9QY`HKANNY1
M3JT!OO$+0G$CVM#CW;6ANNN'8`V`-[A'8.D1'IIS?HO*.=]>)'[Y3F_1>4<[
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MZ$M0M56)[;K;5#BM4."TT+K[K]U"Q5>8H/N`;N+;<9?<-M@6V`/%M`*^ZE*;
M?M]8UQ`+`N';;<.G;?O;[](6[[6[[CN(`&_T[TVMXWT<;;?;?T[<;B[[;_1Q
MMM_HWVZ*Y5@74U_4G-?[,=_YOCU9XM[P_P!J_P#SW5RI2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E=6]N)K0SNCH0@6.IS<W
M+EY;8WE"<O<;T20Y58@1$@`B:L6W$@E2E@`C>>:7:`#OL/F\Q+K@U!E8"X+;
MA!WG/[M.6G7YJ<PII_S7IK7M<$2XJB)6J*43*"QQCP@*")-T\8)SIAG3:SM\
MH5/DQDBB?Q5@R4LFR&YZLCZB/VT7PB^H2_1JY\,<HRT[D823ZZTV*6S3`5'H
MI?C51HJ*U=I=%ZU8?=R<'(U^H%0ZJ'#-]DZ,FB9"0Z(6Z`DQ/D6"MN=/3U:(
MB&XAML-P?MXMPV[_`+]M_1O4<]3CVS6X?F[=<[-@.%@1RV]"*]("RVZZ6QR^
MVVY*)P'VW#9=;<`7%@(VW!<&X"`CGL'=KM&ZVYR0!=;>9;<`K4H"`A?<`@("
M<`@(#T"`@`@/0-5[L-/C-O\`;DGYU5!X:A$`!R;Q$1```%J41$1'8``.S;B(
MB(``!TB([!73L\XALA+7FL,LC3T4UNJUB<C&E]:W`MO>FVZVUP:%MZ54;:E<
MT-U]EJM"<-BE.-UH&EV\8-^W[L-/C-O]N2?G5'C5AJTPYHUT[Y1U,YA>59>/
M\6,J9Q<D<93$OLHD;T\N:*/0^$Q)G+5)[7683F5NC1%8LVG*T296\NB8%BY"
M@+5K4\7)-FKA*H=B9PSJXZ:=/C[:2PMTE7Z98QE#(ZW,L.9%I[::[V7Y(NA%
MT$R/.X4PJ'!V?<?QN$QI`^NK6NBT.R"\'VM;L^3<D&H/!$2=A8)9FG$D8?@?
M@BW<209*A3,[#)+V-5*"H]W.<GQ*L!]-C")9(K&<20<18TBIV!-W/3FJ;;C1
M94QDY+(:W-V1(*O<,B-9[Y`4**7QQ4LFS,F27+E#M$$J=S,/DS80BMN5G.#&
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M#R?C;$<<,F&5L@PC&<2)5)T)\IR#+&"%QPA8J`P4J4Y\DK@V-A:E3V(SM=/<
MJ`X[B7]B+N"R\;?C59>Q0A:XP]K<F8^2,TV;%;W#795-8RG;)8SH&)3)UKK&
M5YKI8D?VU)&T2R0JE[2<L1IV-(I=SSBVX@U39\2#..&'7%]N;FK+>,G3#-[:
M>\EY:;I]$UN,C&=*LO;U+J7/DSN9$[FTA<68B-7`[]JE+++DIAMJBT2PAYH4
MUJ.^KK(&MV/F<U;E#=-FI1JP]C::8EDBN7L,_AKSA#%^64<G62&]8I:G!R%5
M/U+4=W`*3M)'<T2"15F67K#K>DVL3,V0-6^>=*>F./X(4S#2S!\433(S)G*:
MS*-R;)RK,#,MDL<:\<((4Q/9L7@C4TI$;7(<S/+=.$*2:NUT7LQZ);*H=G&2
MN-=3$;480Q;D?4*X0;3G/);A9IRYD#&T\R#'FD_&EA+0TJ\@(U[K(U+!>N8,
M=O#K:Q/<Q-0(&<#+4RM1VA:X)B!RPYYEQ$R8Y2Y@><IXY:,3+FQK>T>4'.<1
M=!CM4RO8D]QGA--U3J5&#VMW[93BUN!3I>D<.V".TS3NRE\;]K<N8JOC<2F-
MF2H!?$9\>V)H-*;9G&KHY,U#U9V1G)B;X#H+7)#7:S]9M+952Z]=;^LEM-`!
M$(^0[7[I"R+GQKTVX\SWC">Y.><6H\O-R.&3J(R9H615U?3&-C(0O+.^*TCJ
M_OH(W9[;6)H%P<!C3,N?U9:1M,;CE^>(5FS#F29!*8GCS+&-9Y*8,<4GFT:A
MD\BLI?X<H//4)B$\J9F%V<'*/'G*$BH@DIW3([S#TYY-@":299;`S)7"%MK/
MPA&C?1WBV08-R5'<]#JA:LP*X_/R9+D[$<IP'B\B>-3,Y1N-N9[='!?EQ][<
ML+E5@N=G<UP3I6\D^VY01G#7OF/4WI[TXS[-VEO"<0U%S/%\?>)F]X9D,KD<
M,D,UB[$BN<'A+CUWC\=E?;TR1-Y"MP;8PM9;KI.*:YH;%J=V/1$*\+8PUV/V
MIT=)U^DDG%676/+>*(QG//<X.=9HW17#.+I:UB7&#VX4;8K6.F1YI-6V3Q&*
MXJE%T9?[$L.G$GDJYA3Q$UL>)`8CUW:3LWAGA1CS.>-W=JTWS]_QWE5^,FD7
M1,3$ZQ9NCJN1.]SDI>"R@B3.Z2$8HJE:H$C&9*V.1,Z-8JN:[CC<OM^?<&.T
M$091:LS8H<\9NCJ2QMF1&_(T-6P5Q>5#G8R)VI!+DST9'UCD>\WV-)+>F<3%
MAKG?:WED7*[@)&WEFJK3$W1Z1RYPU%X)012'SD<82V3K,OX[2QV+Y*`[M8<>
M2)[/DEC8R3GMG_5^2+FJ2R#LX]B[G<<!`.]GFH/`V+!=K<FYKQ)CH6!B0RA]
M"=Y)A<0%EC3DZ(V-OD+N$A?&X6UC7/3@WLZ-V6@0WJW1<C;TZ@U6I))O^B89
MWPECTB/*9[F#%L)3RU!>ZQ4^79#AT9)DK87:DOO<6`U\>D!;T@LL<$%]RQLN
M5)@L6I+A-XJD@3.F?=36G&+QF.S239]PI'8?+G%<SQ25ON5H"T1J3/#8J%"X
M-,??G"0IVEZ<T*RVY(L0MBQ4I2*;13J2RC0XE9><3%QS4I,8SF_N@<DN%K/7
M6'*6WMDZP.U#55B,\@\Y'Q[[+S03*"S#"M^Q&VB(75K'X+KA&C]?T&S,3.,<
MH<-9QP#E-1!<A8R12!PDB,^'R)"$APYEJ..SHS,2M;"<N1:U<X1]2>A+N*<&
M-^;+[KS&Z^X>GTQ\(O)]4FK_`%S8,BL#A43PYI'C&+7>'YAD<L=%1^:.<VS*
M+);*TC:F;D3)%<=L4ZP[.6<A[N=WU7*&-$DD;:4C;W!(<;,B!YX9XMIOQ;ES
M4YE[37%G%[A<34SK(T%R2C0:<E\U<VFU0[W8QGF071O-=8:K<"5]\55.ZT'9
M>U$6GJ"^RV'@7D.5YWPC!&PAZF^8<6PYF4Q0V=$.TJR'#X\V'0D@QM*/F!2]
MX>4:4R+$FO+06;(K#;F8LQT;;+EH7KTEIW[O.;L-1R91/'4@RSC-BR#/2"54
M%@KS/8HUS*:)E`*!)41*+KG<A\DA!H)%(E',R!:6:"<_L5U_83.+]#MF3$;!
M/6;%;[E+'++DZ1HR7&/8Z=IQ%VV=OK>I.4)DZ]FB"UU(D3HB.4I5*8E4A;5!
M!JA.>27?<82;;9;R/4AI[<9-'84W9TPZOF4P=),R1*(HLH097)Y2]0N\+)BS
MQM@3OQCL^NL4NNLMDK>UI%2MBNOLM=24EUVU0\T]Z^6^99KUE8HSV^87P_9@
M?6'']+F&CEDZ)8EV6%,GP=B[+K*D(&;N35:^Y`<;\A&-Y<6B:&XRVQ"!2,ES
MV%P43?F.:\.X\DL5AD^ROC6$2^=*R4$(BLOG<5C,DF2]2I[3(111B>W9"Z2)
M6<KW3%)V=(L.-4`*<NR\X!+KBZYMPVQ25+#'O+&-&>8+I,QPM#%72>Q1ODBV
M829`Y.L<BB1B5NY+JHDK^V,SNXLK"4DO=G5`U.2Q`C4)T*DPJL3S7AR>RR4P
M*#Y7QK,IS!MN6L,BD[BLCED/&Y6:AL"4QQF=EKS'AO6DG)+.ZZ)'QE11B;_?
MV7%A^T!S'B/*QS\GQ?E''61SXJN%LDY,#G$7F!L<<K5"I)>W/I<<=7*]G76*
MT*U+>D<;4QX*$:HGL?9$YUMF2*4I76B\-0"("Y-X"`B`@*U+N`@.P@(=FZ!`
M>@0^@:=V&GQFW^W)/SJ=V&GQFW^W)/SJ=V&GQFW^W)/SJ=V&GQFW^W)/SJ=V
M&GQFW^W)/SJ=V&GQFW^W)/SJ=V&GQFW^W)/SJ=V&GQFW^W)/SJ=V&GQFW^W)
M/SJ=V&GQFW^W)/SJ=V&GQFW^W)/SJ=V&GQFW^W)/SJ=V&GQFW^W)/SJ=V&GQ
MFW^W)/SJ=V&GQFW^W)/SJ=V&GQFW^W)/SJ=V&GQFW^W)/SJ^XHXH\NTXDPLX
MJ\!&PPJ^TPNX`$0$;;[!NMN`!`0$0$>D!#OA47-6>M#3GHE@*'(6H>?EQ-$_
MNO)R$1AG9'^;9&R5*[D]RHJ)XTQM#FYZFDZD`I[15*D;`SJB&AOM,=WY6TLY
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M%$$+CEVCJW761GY-J$+FK`!0:1OY3`ZQE6#5N/;U-N0N?:S)07XI3.9+0HQH
M=![R,D'35.ZEF8UKTFVAL&P].XW"/T_TA&X0WV#<`WV#H#H`-ZBIJ?QQCT_&
M4XEAT$AITI,,C:@R2&Q=C,?[U%DHC:6T^]YO0"XW'6I;+$UIMRD;[4]MI(7`
M7;;:$@0@D('<1AL5$1NO$1&/-`B(C?=TB(H]Q]=08S9I]U<2'(KPZX1RG@V!
MXW4)6FQEBS[B:..+JW*2&XDEWO5N*B$OYB[MURM/6$F]N%6E$'%I;4A/:XF'
MX$F.EOA$U<4DB2W.&$'L5+&YD"S1[',7BK\[6FI3+;VQGDEN.6^YB<EY8WI4
M;F#@@[6/-LN%<BM$514)-&6G35P^/<]78D5->(4C+??$Y8Y93B*5Q9W"1M:R
MWLT:2QE\CC^*J0L-P&7+WE.B)M:2SKF^]S.O<.U1G^&F/A$=PWU!Z=]OI_\`
ML:BO\+JQ?PFNB+4;J`X,U?C6"!!\BZK\;3K#&?VUH8&]JQQ%LW2O`V5$.1",
M>'GE(VQ`UJ9)&DJQC8G!>0VM5\NL:U2X&1O5J3DDO,1<(GA+-L<92(,P9:3Y
MH>$2>QPTW3?$N1L?9F@LL4)04.,6R2R2Z+-3;!R(\M$]&\3=X=+($80E%T8Y
M&]HUK4+CK=TV:;L6S[A$N&ID$CT_1=YE1^9]/\WT_2R<8A3EI;9&TZ+H]C^7
M3G#4NE\:3LI3ZARNOF$?EDQ@[B6[`^JE`2!R&T]*9?"#1U)3GU)^C/0I)C3-
MUDFTC+\XX:U(=T=/^8FHC#.1T.B*?XF<(C+W1V@J1,C[#/%K4@=GA"<KB[2D
M-;7M^>VUK7,ZU9\$66S6'XMU28>Q`:\ZJ=/TDX-C7HV0%_FNGR8XXUGZ&W*1
ML:1SCNDS,LE&/M1>?6G+F1GT]/BM,;&R<LO3U&3Y*EME44M42=QNMMP_,&F1
M<#(W::((OQ5F-?P-^LK$LEG#3CM]A!<1SO,]-^G5NPXRYJE14<06,<C'-$1G
M#@V-F05Q+K;+6.0+2DO=<R^]3:.F6#H\YX3@B3",0X0.&<*-I0T+ZCL%M\9S
M!!GO#^,=*65)7IP>X`:RK\E7X@Q_!\O,$\S,UP^1XFCK'/IZ]&NAC?F=V:8\
MK9)$[&9!TZ3#%F0M4?Z/R\8@P!EO'SGI\P]JUP-J&9G'3!F*(/."YPHTQ01A
M58XRO(U^-VY`EVRV=(5ZM^7O*R.JG=^-FBYY+"6V.3AM+X2&:1:':H>#C-E6
M+'RXEUGN>V9GU1IH#E/,#3@%[?\`'+%%P@;=BB`I7:*.N3]1[.^.L)QY-LM1
MR21"!)F&5GH(\]OCVG;S=&VAK'"5]QC^CD0[(^&IFKMP5J&X0Z&YC:\B8.F2
M-+CLB^&ZBV&#()L#Y"4C*QQ^Z=R#'C$SFWBEA@RP4+4T7B8RF$MUR049+AAV
M<,B2C$V0UFB/"GZ0QK!S'FJ`1_#$Z=6U@P?.L1/K?ILU!MF-&J*&N,BP/CO/
MSB3DJYZA<?>V-OD[>VSA`D4N;%:X(]M_!,!'OY1/"X.T+Q],(3`,AZXXWE2`
MN#QAV>8NBTS8I1I@P>C>I7%U$JB,9;'DUXG+9*')Y!!<<ZWJEMK^ZIBR'Y"M
M78JX1C'^AO4SEW(J#48&?-'FIS3$:PMNF+7=AV(YDB4Y7-\IQK'L@DH<4Y-@
M48<&+,9T;ETB?H])]/ZE0^OMZ@OCL#4UKY;W1K`VGJ-YOR=K(X(V?<(/BHAX
MS>AX-+54FSI))1B<2V-NGKSDS"[KB4,D76QV^)0G)TFQU$97*E<#=CVY9&Y3
M;,VQL:D*HBP@R.FC=/+\*85X(+)>3\>Y`:=*6G74YPJ41S;'W3&LX[1P'*LQ
MY>RFIT49GEF-[XR:[1O&,<@[H[Q&+SGDZGBV.6O,3`ZW+VEI4WJ$GRY8T^$)
M8WBZ0I</R`[2Q/\`](XQ#J,T_P`*OQ3)7&R(:6%T$:B<]Y-(B2*/+'S&.!)[
MG!).)AV@\-<:BRZ,/*&4J$-L:FR$5DLL]Z87;%W"%:F8;I-P(FPXOS7P)[QA
M[1M,<5X.5QC#<9U2-^6-3DE<T94\Q_#;<>8=DR.S(41D:YZDSI$KG`E\3'(5
MCBK-+378)TZP^.:AL6E2C2]%>$!AO".:>^#SU&Z<FQGSC`WO!D$TF3R482OC
M\<Q*Y2U3B#%\.RY8OS<S1)_Q6Q1:5SPZ."V&Y8=4444%N93OV6G68XLR'JD_
M1^7C$&`,MX^<]/N'M6N!M0S,XZ8,Q0]YP7.%&F*",*K'&5Y&NQNWH$NV6SI"
MO5/R]Y61U4[OQLT7/)=LML<G#T,:N]3Y.G"&,9$>C;E-\OY/D+3`,.Q%/&YJ
M[1I1,Y"[MK&ADF4)+$H\^IL<8DAISH3),BSF0&MJ1MC;>L2,]Z^2+F=L5Z=M
M-\0E7`[ZXE^GIS42K*VD'A!N4>H%5D&(XE=S4FFG6N2+&UY6Y7,V-HNXLN-=
M/&I$Y0D=L9]TG$YIQM*V%7%+C$[`2YR=9$A20S:?,9<(;'\F:29J[NA/#MH\
MVW2N0X/SN9C3$>$9KDG&,TPSJZ="\6-<=NU%XMQ4]1M7+2\-Q.8.;8L?BT%N
M0F]BC]ZM49@S*,1,EFB3A=L7J,;98G$LDG#7Z?,W8T)D6GB:LCY)(),YOH:D
MSWDJ*,J''#&A:R9!`HCEZ4/2B.MK<XI84C>W:5]@%Y-4O$T]3N`L7*M4O#:J
M&#`#*MCSQP1,"CT!,9<*GK8U(\U##M34>>FV``WQ0YDE&2[8\_X9CRVR*`Z2
M8ML6Q)CO&TDHI&3@#%";2>U:Y='<@UFXZB3TRN/Z.U@9%D)/E?"KU/5KADYC
MS%&(!(T$]BRF%2)\6Y(+;T3YCYI1RAF-EJQ;<LA<:M,=%][:H[B&-$SP-P?>
M@W0O+H)/<19HRU!<MH9KJ,F^"IQD65Z&]"4CS9D&:0F"M3BF@\ZM;-5#OC%S
MA&*,80%7=W3Q[(VEWG<[3HT^-6-O?.PU2E:<DD?==/VEW2O/L68[>."!U;X"
MTYY+2Z?<ZS9WS:WQZ39,95&E;&,`?HTXPC'KV[RR(M^;\A9BRK"%.3LLQZ1L
M*YE<6]O.4S2WT!<'9,42[@Z]&TC=!?&LEGTI8"22!1+F&21ET3N$8Q3$&R2G
MKFN6-[;(B[$SJWN)7;B]`6+@">Y<DO5HE"98HT;1'"VJ2($:`]3^C-@DZ>2:
MGL#2?@Y-6:8]J?8@\XA9ECW/9_@/5A)8T^L1"Q&^:8W`,@I[K)`T('E[;II#
MXB0ML;W!!8$D<#0N"XSUR\+M"DL4?TV%D.A70;B;&ZB20R4.,5EZ#`V*=2C%
M,HM''IQ8#66?N\.3R:((Y.WL1[RN[KO1"4],:Y&GIRXD:39F=I:QCP+.7=5F
M*\E+=,,1X-:<Z89*JNP9D3(J[3-JZ?5F($X7Y(Q?&X3)\BQA7DS'T2FV&T<F
M&%FDMIYJZ,K%Z%GG:JYSS,CTJZ7';7SP;>.2M&8Q;3*BX/[6KCUKQ3E[$TCE
M\4CC3/<PXP?<-P;*UL\:Y*@8'B91='DV61S%>4W076'J'%WCHM+<_)"TM8MS
MO`;1Q)PV6C/,>))0_P"K'4-FR59'T!*&7&D@5FY0C#IA_%L;T-&88R.W,*=@
MCY>E/(D0*C\B3)Y.SHL$$,3M-GXR/L+\M=E>5<D7Y6Q1KFCSC`Y@7J,R%)]1
M.BIGU1Z.<P8"D=ZR03]GQ=AC'+QKBT3:A&YE:TT.9\50.ZZ39*87YSD&+"+(
MCDMJ=EL'E4E,:W37,PX-P1D_3!K,P#@G$T?,U[*.'0U`GZ5Y%#,,N!<UQ47C
M37U%W(O)3!/D$6*;<?89Q+B5JF(RU>1(VF$L:50Y0\\@9E)DS0XYQUEX@33/
M3?\`I*;FCPL^RG+DSU%X^4X$7E8CDKW.Y;<S87TU1]A=<,*ABZAY?[&C)\%E
MA2=Z@-ZPIK?XRI<#%J<&]*MMR1J018[F>K'7S@_6M'==4DQEK=NP;,=)16G7
M$K]/L9:DL8-F#L=Q]BP>7*V'"TZ<<2Y4Q9F&-2N57N4ZEV-8_$%,RMR4LD,<
M/.7R)RRSB?2RDGFN'AI2V[#325G0[$>C-YTE90RU`2Y"6PZB8!I%F,64Y1Q]
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M(D3<E)1-Z1*@1I[1M(2(DY25*1;===?=:2G(L+*+M&^ZZ\0LLM`;KKKA#<1$
M85Z[$Z+&>F_5'J@A[^Q8LSCBK29FPR#Y[=H27D=;BIO8(J]3B]S;HFL)<"G!
M!8]M2!X?F1O;S;Y6+,RIWA&^ELC,WDZ4-$WZ3SH3S2QZ3L$RJ0:@9+JGRB&#
ML,2-6\X-MB+)*,X2Y7&8"]20]R8'D^&Q^/R"8KE<E(!OM*2(&54418VH%=G<
MI/Z5,?8V@N*V17&L=QAJA\=62.3RPQ@8B!0LI#_,GQ;)94X-[47?V@U"_2-Q
M<Y`Y)FM.C1*'IT<W04P+7%8<=?-<0OM$=@W]`\6X+1_9<(<4?W"-./;OQ=QW
M\.P\7?O;<;;B[[_]G??T5RK`NIK^I.:_V8[_`,WQZL\6]X?[5_\`GNKE2J!:
M%N^P;;B(CZ1$=Q$?^O2/35:=_OUP"RT!W#C?L&^\;0\&UHW#:&WT;!T?17+B
M@`B/3T]_>ZX0_<`B(!^X`J@6@`[AOT"(]-UP]_Z.D1Z/!;W@^@`JG$MZ?Z73
MX;[QV_9O=^KZ>+MO]-5X@;@.]W1_[=^W[PXVP_OWH%EH"(@`]/ANN$`#P6@(
MB%H>BT`#U4"RT!W#C;]/?NN$.GZ-A$0V\`;;!]`!51M"[;??H'?HNNM_<.PA
MN'A`=P'Z0KCQ+0VVXW1_[=_[>G];I`/H`=P`.@.CHJO$MV$/UNGI_IW[A^P>
M-O;_`-T0Z.CO54+0M[V_3X;A'Z-OI$=O3MWQW$>D1&J#8%W?&[P]%]]O^6X/
M5WO6-.*&X#TAL&P`%UP!_P"$!"WZ?!_@%.);MM^MW]]^/?Q@^CHNXW&#]PA_
M?3B6[`'ZP`'@ON`1](B%P#</I$1&JB`".X_L[X[>KO#Z!$-PZ=N_5`LM#O`/
M[Q&X`#P6A<(A:'HMV"@66@.X<;?I[]UPAT_1L(B&W@#;8/H`*J-H#MOQNCP7
M76^OBB&_[ZH-H".XC=T>"ZZT/WA:(`/[Z#:`[]_I\%UP"'[!`0&W?Z>+MO\`
M3O3B6_\`M=_?^G>'T;=`A=T`/?$`Z!'I'<>FG%#IZ;ND-OZ=_H[WZW0/1WPV
M'O\`A&H@6:.XU;KB.UV79%R"9/3=/`:8B\?760RW&Z?&83<K)8F%6EQ6R<72
MBZ=V&.XNYTS-2=I'F,X-(([2A+E^-EH[?T@V#8`MONM#U6W`'[^_5.);T?TN
MC</Z=_3OX?UOUMOHXV^WT;5R```-@WV_:(C^T;A'<1](COZ:!:```=([#N&X
MC<._[1$1_OJG%#<1WNZ>_P#KW[=/@#C;!^X`V^BG$M$`#];H[P\>_C?LXW&X
MVWHWVZ`Z.BG%#<!Z0VZ``+K@#H\-H"`#^\!WH-EHCN._[.-<%H_VK0$+;O\`
MO`/1L'T!7`PL;[;^+?<7>-MP67@(W!9>(;6W]CN$2[ALNVN"VZW81#IZ!'>(
M^CW1_&M',8RK%XQD.?Y%)R]GW+NI&2N60BX86XI,BYRE!\TR(4T60>*0]L(C
M2R3*5+@S-:MN6JV4H^]$6Z*4MI-A,N^('3TW=/2/Z]_[>C];H_8&P?1WJ<2T
M1`>GHZ/Z5VP]&WZP;[7]'_%O50M`!$>G<?#=<(?NM$1`/W`%4"RT!$0WZ>C^
ME<(`'@M`1VM_[NWT>`*6VA;OMQAW_P"*ZZ[U<81V#T!L%<J4I2E*4I2E*4I2
ME*4I2H(<('JWQMI@T[9I<G!_P*_9F(PCDJ98CP%F;*<`@89I?XXPK;VB,$-,
MQ?FA4^L[J_6(VE>6WV7BJ-/!I(4$."Q,(><S!^N/A?LFY3P(CROJ9X`V6X@G
M^8<%<N(?A?,K#(,U.T+DN3(4J<VW&D<DDL<4CED,E"JXT;0GE.#D+XF3W,_;
MC^4VF&>R$/\`ZC_B-4NWVZ/#:(_L"X!$.@!WW#<-MNGO=&^]>3O1G.)<OUH8
M4TS3>8O&--=.,-2VH2?Y]U1O>196[XKX1S3G#S\FL+OCW`*=>^N$2RB\L3O+
M<=LL^Q&>@9;]'SCA^3W1=&C7L!;(&-B-1V0/]%^X\.,KF$]4:D3>$`1OS8@Y
M92+DP@TOI-?B;1]=I))AO=:V&DXJ58>O=7%6@L:#%2K*2VW*ASI=/$R.1(O8
M;:(\41'Z!O#Z1Z+;A`._TB.P!OZ=ZA[J@R[CU/`)U!3I`%DI(.C24QK[E/EP
MVJ#)+&5MA8K;6NYM'=*<6;Q[5EU@<;B#<!@76VR%YSH18-UEST`76WF6B'<Y
MX'80ON`0Z&X0]0B'IISH0?QV'V:\?#J<Z$'\=A]FO'PZG.A!_'8?9KQ\.ISH
M0?QV'V:\?#J[]CE+%).VNXRX%G:78NV?]66)^Q=G`P2M^VTR?C<8"C/]WQ^+
MQ?UN+O;OWX76B.P76B.V^P"`CL/>'H^@:K2E*=[OT`0$-PZ0'O#X?2'H\`_3
M5`NMN$0"ZT1#O@`@(A^T`[W[ZK2E*H(@'?$`W'8/2/@#PCZ`Z:K2E*501``W
M$0`/"([!_?5:4I2N(76CMM=:.^^VP@.^W?VZ>G;Z=N]7*E*4J@"`AN`[@/>$
M.\-5I2N`F%VCL-]@#X!NM`?4([USI2J"(!MN(!OT!O\`2/@#PCZ`JM*4JPKL
MG0BRZ^RY[`+K+[K+@[G/`[767#;<&X-P@.UP"&X"(#WP$0Z:X\Z$'\=A]FO'
MPZG.A!_'8?9KQ\.ISH0?QV'V:\?#J<Z$'\=A]FO'PZG.A!_'8?9KQ\.ISH0?
MQV'V:\?#J<Z$'\=A]FO'PZG.A!_'8?9KQ\.ISH0?QV'V:\?#J<Z$'\=A]FO'
MPZG.A!_'8?9KQ\.ISH0?QV'V:\?#J<Z$'\=A]FO'PZG.A!_'8?9KQ\.ISH0?
MQV'V:\?#J<Z$'\=A]FO'PZL09NUD:<].D+*R#F'(01*)'O[9&"G7DM,WL;WM
MX)7'MR($3!'G)>`J"FU;?V<4W:Y0$"!IMEUY871+_P!-7P:O_P"(L0_;BC,X
M?XX_J/7"H<'"AU;YFQIF64:%M-6NZ'8_QBK@Y^/<HZC,R:=<P,BEQF"V0.*[
M%SS'$+KAR1$KB#6T5+1D08@O%4@O+1S=O0*34U\%,,Z/>`RP_FG#JK)O!DYL
MX/#42P9<QTY8@?LU1G-ZJ$79<CLS8G.$E0_4?C#)^:]+SZJ6RQ*U)6IJ?L@(
M%<@*5V(3F(+EO8*]8(;?0._2/KW'</W#N%<3+`,LNL$1`+@$!&VZZR[8>@>+
M?8-M]EVW]&^RX+K+MKK1"X`&M*F*^"]R+'&'1Y@K(F0,727!.@3.C+FK3]D5
M@B,C:-24C31"V6WP^%3UR4+SH>Q*U'*WN;F6>1A2Y'9R:&@TIRA\,625Q4H>
ML_T3,K!D'2GSH0J_@]/Y9Y&M9/C$8@\69;1'%99#4.?I@L?>ZAD-4864ZA+;
MI[RPN;T\X3PE2HQ7:T&*`)R+9O`M`+0V#PB(_MN$;A'Z>^(B-8%U-`',G-1Z
M>FV._P#:NV_\[X[W@WV#]U9XM```1$1VXUXCTC_Q7>FM:>?N%RT)::,JR;"V
M5\M.;5D2&BV62=E:,?SV2$LZEW:D3XA1*71F8E+88L,:7%O7&$IE1_8"EA)9
MUUA_9"BX.ZK^'#Q0IT]/DYT*9"C<QR=$<BXW:)4RY'QK.DR1%"9KRH1W.Z=N
M=38AVY?>[LR5"4H2.I]Z0RXSME")9Q1H0$P#P_>HDW,V/"-3#GAZ.X(/>U)>
M2GJ)8GF!TD0,@,;N8CO:2T,W?U0J#GXMG2F7$LSA<6F//,%.-EEU]FZK'7#7
M\';D^=PW'$8S.\#*)Y)&6(QLEUQGD9G0+)%(5Y#4RMQSHLCUJ)"+BYJDJ`A0
ML,)2V*%!79SR2AN-MDUP@;YJ4C.C34%(-(#&X2740T00Y;CQE9+&4^3K#"'9
MKY4\B$LE3+X^MR&FA'*=7CMO>VUU:7"<IX^B7M+JG/O;E6OO@^=1&`M0L].R
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MZA(#EER9(#"(WCF&SG`>%4F;CRII/Y-DA"FC\3FD>7%I(Y(D38^KP6$"0X1Y
M&M>X8BE/>PKA78HFTZ:7I[E'%DL;,Z:@-/+#G@G"Z::Z=84Y+8D$?@QSU.V%
M[R?GV+09'#I-)ILW-.,6%\G";)4CN4@G6PYM,992>QY+B'"=8!SMC+3O+=-\
M?RQJ&=]5>.YSDW'^.<6ML6C^1V/&V-'M)"\KRV<'Y)F^/HECWD!/G)%C$XIW
MF1+@]9/6I8Y#K'SM=Q=&W&/`8Y7R!FW@T,1Y,R=+LDS68R#*&KHA4^Y==W9Z
MR06T1_5YG..11AEBUZ5K7(IVB45:&6*G-QRHVUG!FM:B+@(1E@&!L5:R%FEE
MQX;'.N=9+J!S'A_1IJ<:FR-0YJ=U617R!XD#3)A7+;ZU1!DE$D8FP42"43R1
MN:AS>7D%J)F[71G.@MS=:6,J#.%0AE^4WK!K;I7U?N^85.$V[49B"`I8'C1&
MOS_A<YPM9G^;P!Z><NM<6AA$*?#VQHE+'GI]P_*BETABI#.P.ZB3-"=3R(X6
MK3T]Q_0G(X%`,]Y+0<(G%I5(-.ML+@3&>8I=HAC9\R8ZP::&O<T9$46EUC;'
MW)HO[,K515N<TRIR?)6U1-`ND:>S(WPRN#']ABTI6X(U31.-7:HF[1AFQ\E4
M#@+<W:8-2;UD8K%3)CG,!J?**TR07.4P<(X3?)L$$YCB3*TS")O4D>V=(\%V
ME7/F3A@M)N#L@.<5F*QZ-A<4S:R:>,C9=:I%B`Z+8VRF^/$?C5K?)(,NRFWY
MT7Q=AELG9(A,)]$\2R*'Q61KC4KBZW(V23KV*%'#1:^WU#HOU;MNF%)J20OF
M!LJ8:Q1,-4&%'Q@A\#QEEQ?ES$MDIQX\2$O(,?R2^HVN*RVV,Y'<X3#9)$HP
M_P`I;HJ_NQ3NDD1,;FZOUI:=\-Z@N$HD4O>]3A;OI5POIIG^;XV^]V9GB=KB
M4@;LQG8\5Z:<9LCL\JRI;.>XSVGR(I1,3*;*W9'"K%ZDQ.RW*$./\[\+<@QE
M@'A#9@RZ;<P(-07!_P"'H=E>=8'R$MQ6@4JXYEJ+2*0XOFY<QAF3IC#EL)M3
MQB1+YRB:G]5/F)-%'UM00]V=U#`G=[_G?"EX[P]!H,;DC&.0QS&ZX-19XFN%
M4DFTZ1:=Q2`F*W%G2R#L<ZU`Q^%/ZV;N4<E*K'<!@\\F4\>T#,L)6LK6N3W$
M73RP1G3&>I3#.,<_8=D'*S%^8(1'L@P5_+0K4)CC'9*@*7M]RQN7$D+FER(M
M,N1NC0Y$IG%I<DZMN7D$JDQI=NNZ-<,AIZD;?DV5FX@U0QK%>%YEJ'QGEG-$
MJQ8R,V,,?Y1TZRMCA#QC9_>;YT<X<L<BRJ0-S%BIN;&IQ32)V,[D.ZZ.NX&H
M4\>M6/":8]SEHZX4K&.)Y%DO`VJ'33H1S'J(8;63(^,EDDMCR3'T]40C*&.<
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M00&'S!JBD<0*USR>4I3*T*7`N1.%^THXRRJBQ_(3Y`;$[]02+2V^9A;'S$RN
M(1+-:^2EP4MBDD'OR>GSRFBB/(MXXZ>LFH\0+L?,4OM,)<G\EB3+9`E^GA9M
M8.1M)N`L4M.$#VIJSYJXU38)T5X2F#^S)Y(P8WG6>9$J;E.3':-K3DS;(^0<
M499*^,["Z*BV=VDQ#&E>2UK/<O0*HY<(7'LP<')I&E6N+!>H[49DB>:7BXUD
M'+<"SQEMUR7CS4YC4)8P,N58[)8B_%61'$DG41YW<Y;!Y'@2/XT3QB4M3>RE
M,#A#E2F-7R9?^%8P9',FN>'5F-<\'Y#5X:Q1G3$,>3QB!E+M2T*S#*H["XZ1
MI])<,E(#9G)&&025"FR`RO142O@B0LYXD9R%E,1KU4@VO6+!ENKQUT6ND(R3
M%LJ(,!HM2#6^R-!$",>2_'!LE10MZ&'R-MFCHXO+]"Y>X(V&;-5S`DMCIBUJ
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M^,9(E./'EKS&,@0I(VI7SQGNCJQ.\69%LA:5D=5B3(^D;A`,+ZP9EF[&$,2O
M43RKI]50B[(L#D+[C*676QO)C4N>,?3F*3?#F0<GXVF42DZ=J>$0*6&8*'>/
M/K,Y,4L9F)Q+2EK-7>JK*S+'.%'U`8IS/KRRWI*P`P\&]B+4/'%K5J`3X[9H
MOF)]SWFZ$2261QKEMCLT2527$()';B\;&M+]'7-2F-L*BJA2[FVFY@X/3A#-
M04DT4:,QU3XJR%E;7'J`A67I:PXOQ[$H5C6?9&P[AZ9"PI-14SC>2)=CC'V(
M6N715]QD[."1ZDC`E<Y9D1B;8?'RK'46IEE'&N%,TZR^.Z5I4PQ_+1S'JLU"
MR?2>TJ72*,49589U'PT)B5),/Y]9Y++VEZ@TP0.>/IFQ)DK,WRY(]O+(6G85
MCFE?HPL>[I@O")8LR%%\YOS#CK+A;W@#581HUEV.W-)C9%/GG-2E[AS,E11%
MLYS36ATCBY//(Y)VQ_<GQE*<H<>MDJ5->WMRN^S6SPN^O20*=-&2DVF9!J49
M[,2ZS=,&!I7JCQ0_,<*Q;'LC%ZF\.QS+F+WMU3Y`9,GR"/IV![?\63%Z8X,Z
M8_3Y(=;,?.+Z<\(GHAJF?J"X8#2=IJE\P9)ZL?%L,Q9E",8CS1E-@D&(U$?Q
M),98JB28L)!!7;*+/G"31V)G3R(DY"E..,53-CA-[Q?:Y*C1CTOMCF0(-PD,
M#R5J1G6F>#8`U3R61XHS\HT\Y=GS=BYE'%F+)'?BM+EMCF$SE!LXM5D8[E3$
MN1-+`_M+,ZN%SZN;`=V1G9WIA=W;8J`[@`["&X`.P]\-_H'TA]-5JFP>GUC^
M--@]/K'\:;!Z?6/XTV#T^L?QIL'I]8_C38/3ZQ_&FP>GUC^--@]/K'\:;!Z?
M6/XTV#T^L?QIL'I]8_C38/3ZQ_&FP>GUC^--@]/K'\:;!Z?6/XU0>*&VXB&_
M0'ZP[B/@`-]Q_=76O3H2QL[J]'IG!:0TMJ]S.2-2-0Y.:HIO2'+#$[<W)0O4
MKUY]A-Q2-$GMN/5J;RDY5HF&6A7D1U\:N]7/"88:1QC!^@C.C1IV8LDL,ANG
MCM$)._Y!DLC92I`A9D[=&V5"2B;&M-8N<;).4U%S<&Q=8A3NC\Q'7VI5FGP=
M$VLZ\0`-)>I@-@$?UL(9'M#Z/I&/`&_H[_?\%>NOA0M$^H;4.]LV9X)PK.:N
M#APUA7$TJ5Y&#&%RA/'7GM1T4REZR#/')1D*$LK4VQ*+-W:UJU22N.+2W+C3
M%:!,1V%;YT-.N4L`N.I33HTQ_P#2K=3VI]_5ZA\(M[9IUD.,<XD1K.2X[*L4
M3E8L>7"Y_.;D[/.;Q%@5N:ZU2RI4BZ]:XEJ&NQ189[R`_P#J/^(U7_KU]ZL)
M)M2NG=;(R8>DSOAE5+#WH(X1&$^5($?(3I`*X6P&(ID*D-[H8\BX@*#N78DN
M7]N@*0$_;`=CJ[;\L8M+R(7B$S)$"+RN<R\I"L8WS&.6Y#-CO\]_M\N$W.02
M:]DW3GAW5L:Q0?S!P]L<4J\;<@5@74U_4G-?[,=_YOCU9XM[P_VK_P#/=6)Y
M?@/!F0'HZ23S#.*)K(3R$Z8Y^EN.8;)'DU,D+`I*G-='IE6KS"$Q8=C3E7J+
MK";/U"[;;=@J'>L3@UL/:G\&W84@Y43TY)U.0HA/G.0XTQ7#BCW<Z()'Y*D;
M'%L;^3*=64:#\;?8J4JCC$=Q(`04/9KQ""&G7@!\=X.S;CO+4DSPLR\R09W7
M.B_&TPPU$0C4LL5Q]Y9"T3N*B1O)/:Z0]U*=2NR-BL.VV]-Q;++N*<7NB8--
MFGB*/#;(8Q@?#$=D#,I+6-+ZQ8L@C.\-BPK_`':MO<V]@3KD*FS<>(>E/*.L
MW'BWAO7Q:EFG/3UAR0H],CM`V7-I#YCYVARK)ZA_2X^5IV'(T3?):Q2Y1%D+
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M=$[L>&'39.W'RP+8?=G_``_H-SFW8VX87%&0E6-HZV<(3G#4?DW$DIC$I?9@
MIBK!G/3Q#,#H4>06!;#8EW/?&)1"2Y2L31UXDS<J1O/<LAUL5-]QZN*2/@]>
M$&Q8=H6SM`XCHERKF/`FC2,Z"-0NGK*4XR`=A7(N*8`JCSICC*F-,MKL).$C
MB.2665-3P\OS8ZXI7M*B,RE3&4BEW7L:=V=9/.ND36CC;57I=UI8V)TXY1R`
M@TYSK2IJHPZH?9+@+&R.%3O,S=G.*RK`+ZT8[R:LM,PY+.WXNH;I=&4;OE"$
M$DO#FI;IBK-L29_X*73#FW1]HU8<!YZ,QLIG#'E?4;-2%F+I#(I%'5+%FG/F
M2,T-9:E5)8K%%B1W;><`UH6HDZ1P1%V("#RW12:><63"C)7!\ZN9[@KAM,:)
MFG"#=(>$HF+J\X14*LKRDQGB#0^Z?<:8`-NRJI(Q"8L9W)NMQ^;,11Q!OFR5
M82YDL9;D0H3&.!DF$>E'4*DU^8=U7=Q<9F03&?!JSO22O8AR$\62USRU,<@8
MIR60L2)0QZ8SE0%"?C,V-G2`YX!]-,>R'4N(@E1'I3HB:6>#.U887B'`?0^7
MVX35?Z,]=GB[-[K'LD2I>7+D^4,,9+P['3<6)'#%K2<[W)!GR63/94KOAHI2
M&M2UM][HH.(5U\KSP:>KY=IWU+8[1I<%VSC-7#*QKA&8\2IRG+2XVT8B9<XX
MBS(=$'=\*Q&H<`R28FQ1?'BV]%'E$7[>D*=:,J[4;U`'Y$QKH?US8'U$Z@XQ
MC=HT:3?2]J,U*Y!U1,F<LK('A9J;TU.6=)9=D#-N.H]CXK'CS"LO)[9BX/JK
M$3P^9`BB&,V/AZJ5%R!O:4,/58%U%\&5KQ>\#<)'HOPZ7IQE6$]8^IQUU=8D
MRWD;*T\ALXQK(LFYXQCFG*N(YO`63$$Q32%I22N+R-QA,Z:IE:>0P.=K<Z,J
MIQ3HD%LA,MZ*>$">,L<*GF7!$[Q'A3(VLC3+I+QK@&;MD_EB]ZA&1=.1.1"Y
MF$CNMQF@4Q)DG[?DU[CL-G\86OLKA@I")<9'$3S:C2(<%W<%AJAGI7"BL2J&
M:<=/T/X0O0#A#`\69HIE.>956XMR_BB"9EAUR2:OSEB^).F2$4B<<CHY#*LN
M*;[Y.N*2BG/8I4^7K7PS)\OT6<('#\]8TU:XOQUH9RO.L@:7L8Z:=4FG7-<Z
MGUN,HT\86D$U=\39;PGF<,$OLL7G-R6?2-IGD>><6L-KXWG)P:$QC@0E=$$\
MS>#?P#D:1X>S'J%CJF?:BL7Q_'J;EQ!,@9GP]`K7R`/JF7M/)_$$`R8Q8_31
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MD4EEDMQ-&M->:8JJ.>\UVPW`+#CJ7Q)07F^2`UFQ?+A\I)G>.8RSM\5=53ZV
MIG$B0YOU=:"]3.IG,,`RNT8NP9A[4'`B,%*L)ZXL59PG,:R]@4EC71Y_SIBS
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MY9#B<KN+$B8'><Y)?`<<?PUP=T39$)P]J4[HB^?6+H<U)YV>D.8L..N.\59[
MT:2Z$.'!I@9-GQ-C1K:Q3LK1F\K4.4S0$U_OC6;X,#KB*1P-D)F"-B@#!%7R
M+NB";.\A/1X_X0^-0#5!DW1WBF&9TQYB_A$8%DQJ9)-CK&^0HS/<F0_3-J'Q
MP[L.L:/2*/7W-,K1XO?,)I%LIA61)!#6!,7E*)8:>6^UIDBYHL#.N?\`2_J:
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M,V:$H8`?-26DW75KKU",>.$&29NEQIEO`&NJ19".R3CYPF[GBTMP@N3F1OEK
M,]PAVOC$GC7=2*IV=^6H$[^X+VF],O\`!E:C<DWR+-K:DQ$W9WS?PI&B?7CE
M."K<AR9)!(%B;1>VXUC$6Q=&9BGQZ]*YKDF1Q;&H.+S(#8E$XO?+IDXH"3P8
M(PW.K]U.I3@KM4&=<S\(OEN*R?#,!D.;LJ\'YJ&TAO,C=7V<L[5EC02R&-Z!
MAU!P+D2WI!@&35"E8A7E1A^EZAO9%AARU`J5)[&U5L^T6PS5`U-<FE6I['&E
M["+\\)(^S,.)-+![A*HN@M9P<%+_`#249(D6/\=/3N\2MR<"D[/"T#!<QPAA
M9B+SI)+7Y_<%#1B]GTR9O+X5?(^L)V8L;&8(F&C'%FEUN2A-W1;D<F3XQS;D
MK,-LQ70X^!%1LJ.NEF0;&9&21.%;V@<&6UQ,1=@66VHFI[35G)+K,TY:[M-K
M7")W*\9X@S)IHS'AZ?35PQ[;.\,9=D4$GK8_X_G!,5F;6R3S'N1\?-#J>T2-
MBL:)K%W-U;!D,><VYN,71\>^"[G3OH0U-XM22V'Q_5EG?55/N$0B,M;#');C
M[$&L$_+<=S5B!'&W9Q:+)`OA<"=()"8)))-<P-;I-V49@]\FF*R3<GD5XX/X
M,I\POKF)U%(YZVO.*Y5AF&2S-$.4-]A#KD_7[#+YQ#;-43@6*4\E,>_XJRI/
M&U[1`OO.-?4L&56B-D/9A10GS!P:7"`*=.VK?0UB\G3+*,&Y5UO,&LG!68)Y
ME;($0G$599!K"@6J^?89R+C]DPW+4[DX,<P9959'\C,\O4DNT7=4")1&BGQ,
M!=9PB&AG73@_4MJ62XE9=%<YTV:M<YONI$O*.9$LC=\_:3)[E1*R<^3)#(E9
MCA?&L\,![PW*I'B)(_RK&:5H=7(\F9">S)A:'&:NC33?FC"&HWA$LC9(08_L
MA&JG4PPYPQ6IB<R>'^1(&%CPEC+#!C1.V-SA4<1,+XJOQO;)B`87Z6-]J9[[
MFG+BU+>)RO8U2E*4I2E*4I2E?G<:79Q>-?:'&N"RW<0`+KQ'8+`$>@;Q^BP!
M&\=A$+1`!K%N<IY+,7XAR+D*"XT?\QS"'Q1V?HYB^+*24<@G#LA([(DC[6I/
M)56E*5MX_P!(M(M4]CL,M1H5JNXA*=HH)@G#6Z^#BU4[G;+P<6%5BD@\F/0@
M5U^:%;?QNQVF''('&Z7EK"BAN.`M\E&.4ABD0%9%#D]MA-OH1C+0J8(XP,2U
M[=)*L9F1J:5<B>[DUSR_*6YO3HE#T[7(B$J,7-U-(O7KQ2)DR85:@X2""2AM
M+M[KBAZ=_"(B([>#<1WVZ`Z-]M^FJ[!Z?6/XU#/A%DB9=H,UC)UF+T6:4MVF
MG,UZC%CF]HXVVSDHF!O1US`XOZ^ZU,SH%/8P-6N%X&7)DQ!MY1)YP%DF>473
M:OU]K<K:9[YII3_1SFR`G9=T\'2/*6GHS!//GR7'(D%,7S3$!3;D$Q#9D-R;
M^,Z1,&)CXY;HM3A%VLA<#2F*]PP=[]]W^(U^"M/:K3*$MYAY-J@DT@34QQB9
M24!I=Q?9$Z@H;32#R^-QR3BQ`PDVVPRP0OM`0T2R[@]M"+!KXT/XLPAI#TUX
M^D^%K9=K3REDZ)8?A;3EHU%C--9BG!C5(\I)V3EP^.,^S/D1PR.XN+Y(5[K+
M7+!KDN?%:X^U2:9J+32]_1\`PZ\(*#?==K1>^%11ZDSI<=8==.KLU-_"=I=.
MB.*EJ+PN?KVU-I^1&85(A?&[4*QJ>KB%C7:P&G-]WM3L_H]'3M=>`;;!L%M]
MP!:'>#]4`XH?LJ(.J&?N16/IU&+<:9&/2%'1H@)<2ABPQ0VV^31I0*DI29+2
MGFY/9>8*2\18[3@56&;$W)[0/ND+RT76C=;R`G5W%,,MXUJ2.W6CM?<&]MP2
M7:ZT?H$.@0Z0Z*<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEW
MF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GG
ML<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^
M9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<M
MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_
MGGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<
M=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:<MEWF_GGL<=^9:
M<MEWF_GGL<=^9:<MEWF_GGL<=^9:LE"UPALG;WE)MP$H;\ER9D;(U(\AH83C
M]).9!'60R\YF8'N7)W8N0NS(TG&&&MC4O<5"!`:888E3E7W"-7MRV7>;^>>Q
MQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYE
MIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7
M>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>
M>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQW
MYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIR
MV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEIRV7>;^>>QQWYEH,V7`&
M_-]/>CP(X\(^H)*(C^X*Q0OU78>:\ELN&')_0(LO2,M2:PXP.E&/QG;I8B1'
MN*KL$:*F9CF684WI52T$ZHA.H.2ICSTY1Q9)EUN-]7D\U@%X7<K-%V*VUSS8
MJ?&)&C'*MT?11YLC*E0=9(7E%;?+4B!<^-Q7:IC>A=%1:`PN]4?>0X')B6Y7
MJOQMP8NI;*N0H3FOA"M3>H3+<OATI99PP8MQ0L;(SCR+OS$[(WM`G)<S7EJ0
MEI;5:,LA67!X3$3CDP&DVOZFP\PR_?=RT6["'-]/!`1$1`4<='OB(CWY+X1H
M$U6@&P8^G8!X`1QT`_NDM5Y;+O-_//8X[\RTY;+O-_//8X[\RU=[:LO<$2=8
M8A7-EY]MUUR%RL3EK4XVWW6<518E4*R+;K@M"^WL:@T.)=:(B%PC:&O/7TVZ
MH)A#I?BB#:6X%JHTQYCQ))\6YMA3-J)YB-2%J6<E/$<E%F.;9G"U&(9(T+(6
MOM2VV/N5<72%$ZGJ3D#K?;8E,*T58$T)_H]>)\[82<9+HLS[P?&I^.Y>@;_A
M=#JM6:G8&C4Y5B$U9'2%(X1EIPR3DS2ED]P<I.C;6QLC[+E&6GR/MNU$0VG*
ME9`AZ[+1`0WM'<-Q]`@.X[@(#L("`]`@(`(#T#TURK!4,P,P1#.>:\^B^OS[
M,,SL6*(@H3O%R"]MAL)Q"V2:R.Q**6ID9*LAK5RB<3F;NMR]0K4J9!*%?%-+
M1(T"9/#_`/T7&&^<`Q8$\R9_)^.U/%:U3-)PGQ(<.6ZGR7<N5V38APY+AD9/
M"[\DE%9E/Q`7,0Q^?EZTR57M_<E4KBZC9H```;!_T(](C^T1Z1\(]-8%U-@'
M,G->@/Z,=^C_`-[X[6>+0#8>@/Z5_P!`?\=U<M@\`>H*;!X`]04V#P!Z@IL'
M@#U!38/`'J"FP>`/4%-@\`>H*;!X`]04V#P!Z@IL'@#U!38/`'J"FP>`/4%-
M@\`>H*;!X`]04V#P!Z@IL'@#U!38/`'J"FP>`/4%-@\`>H*;!X`]04V#P!Z@
MIL'@#U!38/`'J"FP>`/4%-@\`>H*;!X`]04V#P!Z@IL'@#U!38/`'J"FP>`/
M4%-@\`>H*;!X`]04V#P!Z@IL'@#U!38/`'J"FP>`/4%-@\`>H*;!X`]04V#P
M!Z@IL'@#U!38/`'J"FP>`/4%-@\`>H*;!X`]04V#P!Z@IL'@#U!38/`'J"FP
M>`/4%-@\`>H*;!X`]04V#P!Z@IL'@#U!38/`'J"FP>`/4%-@\`>H*;!X`]05
M8V0\EXZQ-&UDOR=.(CCV+(;+[E4AFDA:8RSDC:7>;V,7!X5HT]Y]UA=PEIRK
MS%!HAQ2BK[A`!\3NOSA*\U2W5UF%[TK:O<O)L#FJXBE@Q4#E\CC42`6^"1E%
M)3&5I6(T!Y2<Z5$/)QBH$UI#B>8:O2&'I5)1YD\]#6.-:O".:-S$QNOC,>-D
MS+J:R&P9/>U"ATE$SF$!,QCBQ6P1MDDR=\C[NQI61W4OBBYJ+<R69TND:M4Z
M%+#$1"0_;5I`X(_2'H\DC3DF,1V09&S0U=MGD9<R@]7OLB1KW-`>VNBYC9T1
M3=%6%6L1JEB07%*SGOH(U:E,8]'6'G"9L^XMH=ZT/4%-@\`>H*;!X`]04V#P
M!Z@IL'@#U!38/`'J"JU#KA"KI?\`R&-75D#<I<QRP_3KEQ,S2/'Z-R<YY%3U
M4+=DY\OA+,RN+0\OTMB*$U7)H['F9U;':0.S2D96QP1K5Q"@OQ99:X3]YLX.
M_A!8'B3A6M0/"(F9<QOBV(XBS$Y:.\F:?WW&^I+(&561F<,`P":-#`G2+I#E
MC$(RB5-4(M2M*B$I(8J.BCLI62%:C;_7CP73S!%>G9RC&),K/69L,XWG":`8
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MDJI618I3)'FTL]%'(NI.(-(/L3RB0-"JXA00:4E.`XH+[JT':R)OK/A\XGDC
MTS9+T\Q9HD+<@QXX9&/NN-R='E[><K-D+4E.9&,Y+:V*";$2\$MCLRF'*B`:
MWYQO*6V)K6U2\%SIEUD9MB&;,\F9,E*B'19%%$F.TL_7LV-UR-`Z.;J4M4M3
M>E*?$#DH.=E!3F?'9$QVNZ<A"6Y6'BD+N''<JX$[@Z94]J'PS"2^.W*$S:D!
MHA61<@0^.IBFMM2MA%R1A8Y`F;TZA02DL4.2L"[E;JXFJG-Q/4KU:@\R9VE[
M2;A31Y`W?&^"8^ZQR*/DL739R1N\ID,M4G2%Q:F=F5*K7&2+W!<23>WL3:5:
MC*.M2EW$WFV%@8<;==)*E*4I2E1>UMY+R'AG1WJER]B9P@[3DK%NG[+N0X.Z
MY+47IH$V2:&05[D+2X2PVP;=F1"I;[52VPPP@@ZTD"%*A.F,./+\:FD'6KJ@
M>,U:<6%)^D+Z"<D1C)&?,'KY?IHQ3I0BF))AEL)UD>%#+H$VN,4T[Q]T:)[+
MD2U3'[GM3<U/EZ\;"'MX9RNVUB'W9L$>88NV%LT:9&B/,Y*EQ5DM3&VHFAM)
M5.KBK=G-04@;R$R4L]Q=%JQQ7'6%`:L7JU*Q3>:I4'&WUD*U<VL3RX-C<8[N
M*%K<5J!J*N&PQS6I$1ZA(W67!;>-MRY244DM$+;AW.#:V[O#Y2=!>7=3&F32
M#P96K$G)D+S8S<(]K#@S7K/@R[')"";N64];V09*S$Y69LFI9"KD9LVT[/K7
M%<:2>(/C:?$2\2092PL[/#SX<G,-CJ5?-DWZ.2KL*[+_`"OW'A4@*5W%VVF3
M$S5W9PS*<RV_L@VAV&9=SD*8+3;1L$6ZRPL;AM-NLO\`:K9_1'O_`-,SO_\`
MQ+O[O!Z-MJB#JA4Y;#'TZ)3LV.KX/V:-`0O.DLG+E8I>4T:N,,-:2XH:S@H!
M9V4NPJQ[$L4O$/N.`T;TX2$[-DS>_B-<&XG9#.+QI!(>-Q>/=MQN+&P#?;;?
M8`#?O``=%.S9.\5P3K!(OERG9LG>*X)U@D7RY3LV3O%<$ZP2+Y<IV;)WBN"=
M8)%\N4[-D[Q7!.L$B^7*=FR=XK@G6"1?+E.S9.\5P3K!(OERG9LG>*X)U@D7
MRY3LV3O%<$ZP2+Y<IV;)WBN"=8)%\N4[-D[Q7!.L$B^7*=FR=XK@G6"1?+E.
MS9.\5P3K!(OERG9LG>*X)U@D7RY3LV3O%<$ZP2+Y<IV;)WBN"=8)%\N4[-D[
MQ7!.L$B^7*=FR=XK@G6"1?+E.S9.\5P3K!(OERG9LG>*X)U@D7RY3LV3O%<$
MZP2+Y<IV;)WBN"=8)%\N4[-D[Q7!.L$B^7*=FR=XK@G6"1?+E.S9.\5P3K!(
MOERG9LG>*X)U@D7RY3LV3O%<$ZP2+Y<IV;)WBN"=8)%\N4[-D[Q7!.L$B^7*
M=FR=XK@G6"1?+E.S9.\5P3K!(OERG9LG>*X)U@D7RY3LV3O%<$ZP2+Y<IV;)
MWBN"=8)%\N4[-D[Q7!.L$B^7*=FR=XK@G6"1?+E.S9.\5P3K!(OERG9LG>*X
M)U@D7RY3LV3O%<$ZP2+Y<IV;)WBN"=8)%\N4[-D[Q7!.L$B^7*=FR=XK@G6"
M1?+E.S9.\5P3K!(OERG9LG>*X)U@D7RY3LV3O%<$ZP2+Y<IV;)WBN"=8)%\N
M4[-D[Q7!.L$B^7*=FR=XK@G6"1?+E.S9.\5P3K!(OERG9LG>*X)U@D7RY5!/
MR:`;BUP,`],@D7RY3L^3=@'N7!!`=MO_`"@D73N(`'_JWZ:T42[AHLO95FLH
MQ#H*T?3+47-(^ZN$?6SYQ1R=FQXRNS:XG-*P]P;#6]L6%MB9:G.LM42Z48_!
M5;8%X66%B-;5],#AK47X7C2O5-&\)M69E2M].D#7!WQ]*96]J-<S;H\B46)4
MLB;N[29L&TEXN:GQS:[S[2[DRLR\3QKK&W2!BEJS%*-0*73EIWOS-,5Z5V?L
MAKB'1TD)[LC2)4)3L@.=(TL3L;H:E1I2UKDQ)FU:Y7DVG."A2=QC!DF!N30[
MS5!.GOCR@D0B/[1&.;]&_1X/HJO9LG>*X)U@D7RY3LV3O%<$ZP2+Y<IV;)WB
MN"=8)%\N4[-D[Q7!.L$B^7*=FR=XK@G6"1?+E.S9.\5P3K!(OERG9LG>*X)U
M@D7RY3LV3O%<$ZP2+Y<IV;)WBN"=8)%\N4[-D[Q7!.L$B^7*N]M%RN0IQ=RD
M1+B-MW;1;<>H4HK+^/=Q03GJDZ509:)?$&X3$Y0A>-UH`-H!<,`M?D]ROCR!
MNJH-(TFUP:7IG!9;!=1&$L/&,BC4`A8G9$I),>87C^5OD;8<X1&4,ZM?$IMC
MUOE$<F[;9<VNT9131"XO[4T:(L=ZRN"7D^0H\SZ<OT?O5.[Y]C$QC+S$4$+X
M,'$^&9/!)W'7U(^1Q]7Y0>))#VC%1<:D;2C4+9*[R)F1-928_LUQZ,%"4WU"
M8%<,UO6,V*0:@H]#X3D^1F.#^\8\@[T?*F/&Z%T6FJ6*`&S4Y*WESI^BS-<B
M;I3,F]I9F-_DUCLKCK4CC_<P+\QB`"&P_P#6W2`^@0'I`>^`](5$"%Z#M+6/
MLE$Y2B>-C6U\;Y_+LL1R.&32?.&+(1E7("9W23O)V/,-.4H68GQ]D&8$2&1<
MH9?#H:RO2\^3RQ9VT4MEDE4.W[_R%-+7/0;GKFO)"='Y'3YH4-]LGF=N-5&<
M$D5Y$)<Z*,-6R$,2'YM31,+6,C+1T*OGA24LD\M]M<22EUDN>]WJP+J:_J3F
MO]F._P#-\>K/%O>'^U?_`)[JY4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*C=J_P`QOVG_`$OYXS7%$[$MDV,<7RV91Y')2E9\?6OC*VFJ&M"ZE(5S
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M1+X\1#H"]RB.,L3A3HP-$FDL\EC?8+!`&9O<I1'T259+%C9:^KW,ENC=KPYD
MJT2>_)UE&#8U<H"VS5U/9!R9,T6/(HO4M[NI8E$S=D:U6PL+J]IDJEGCBJ2F
MH36>,F2%6V))!)CVR*M2E5)'EF:U^2`'<-P[P](501V`1\'@Z1_<'TCX`^FH
M`1O6U-YYJ67X6QYH[S_,<0,D_?\`&[_J_1O>$VW`S9)(6@/MGB<MN=<FI\N.
MA<3F*5;C98<VXZ/*735O<4;<8>VH%+F7C*SA3L;G2]:\$8TFM^EELU4)-$J[
M5?<[1<N#!J-5RLO'/:R6)"MNE:K#J7+BIOPHLS+_`#+47D]8)),?40!&NR"G
MVF`.X;AZ0_8(#L(='T@("`^FL#:FOZDYK_9CO_-\>K/%O>'^U?\`Y[JY4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I5!$+>D?\!']X[`.P!](CT!](U%M
M5K:TFI<R1G3[S_XS69DE[B<SL,!:)$0^O)[P0D6KKVA<8R6.#:R.IB9O5F)F
MU\7MRU9<3<2E(./&PJ[L=6I&IU7@F7)]'RW'K?G90:QE1=PR7;??'$3>8\H[
M9$K*MN2+T-ST0QBL,9`=D*QI%?:7VZE/LXI=VEEXX$[47J7:'B2:Y->T^R'D
MA4VKS8E'HFW*%N*(%)55EMR5Q[A.RF/H7IN0&_K7-45C&..VA+L`QRN*&ZR_
M%[5^C?*&UV:7,=8=IUK6\-#J)`8'`JX\&MS2./8`-YV#`+$\$O8>R]CO[&-_
M9.QW\7B#ZB;;0M`0#;INNN'8-NFX1'I]/3W_`*:K2E*4I2E*4I2E*T?\(UK'
M>>#`U%Q?6QD["F1\NZ.,@X0:\#9EFF&H\3+)SINF\%R'+9Y`YQ(8ZN<&=$?B
M[):/(;Y&Y,\V.R"]ED<.B=AEZQ6Z-+6NA';PYN"N%KG>-=$/!V8QSUDF5S/+
M.%9IF'-,KQ_R#QAIYPKB[+<,RG.)\\.)[RXO*N7*$$(&,8]:S43"WKIB_M%Y
M$@/7)26=?ZFK0$`Z=^D;AZ>^'&N&X`'I'O`.W?VZ.BN!YI)!)IZ@RPH@BR\X
MTPP0ML++)M$V\R^X>BVTNVP;[KAZ+0M$1[U>>W%.)=$[!K5TSZCN";R1C)4M
MSS/9[=K5@&G3)I,[PIEG`2G&V1G93F;)\/89!((I!\DX_P`\),>M\0R`0DB\
MHDLAF$EA+O8_6.3H#7J]LBCM;P)"G@K"WLC^7-;PH2;3FY8[+5WA/K9@JX2,
MG5<GRI>S6FC(#\?F:=03YLLR)?\`[`""%WR$9`"5)>=9[5K`_5'O!O=>(;=(
M;#?<(7?O`0N_?4/=4$8R%?`9V\$Y,[!%KSHT87#^13"9V-/;)HR5>FY0W*0<
MC..IM,5]FO*"^WLG8`#B66B,A1CTW$;QMG_%M$PP;;>2;-=L`WW;!QA/W';P
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M\U@AS1<X2AY*`XF].*AO:3TMB@!)-/+O"X`B[HXX2B+ZX\MR['&%&W-X12)Q
M,^2W9HE6*8NS8[=5:5W0-1L<([$[K7!M>%5KB4O:$[F84O<4J-W$]J;0;P,4
M9DUJZ&)CK/AL1@#MJGRKBB*,TA6.LM:L9M;2T%9":U:$I(4QR/L;@G`\AL/+
MN7-@*[7)KL4*5-ZYE<#.TS4=H:8>"=TO:1U[9),41QN6Y`:;C3D.4,@QUKF\
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MR0I9`=>7>0#9>R*;7*/P-V;=$;,VSA_>M*LEPDLR!"&/)\<Q+IG>--<J:+,C
MS*.XY;)XPN#;F7)T7EJUBD$I9UL@C3[&VQR>(Z2X#'Y,G>DB-H>=F@#N&_I$
M!_;:(@/@^D!Z=NFJU9T1QW`8"+T,&A,1AO*1V/?I#R4C3)&^[KXJW[9>7D&5
M`A!U=5&X]F<5_;"TW<>.?=N._P"UT$A5TPLR%=$8Q=/"V48V7-;H^T#+;(]<
MHN5BPV2448O=K**NZY2+3:O!O%1<)PINR"-PW76!=37]2<U_LQW_`)OCU9XM
M[P_VK_\`/=7*E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*H(@`;B(``=\1'8`_
M>-:-^%#X5G)F@W,F.\8P?$D#GZ&8XQ-GBUVEDFDK*K1J[9:[1RQN2I61`I(,
M3@2V`IO//-`X33A*`NVPL+KX68B_2!<^Y$='F(-.B(_*>0G)&WV0"+89D,Q>
M;C7`Y2K)<%4OO/B[PXH6A.6"(49C8V&`>>*JQ>N;2"[%`[K-!^0-=&2H=.)1
MK<Q#CG##DOD;<HQ=$88X*%4A310]LNN<BILE&22I*D6)W&TBUL,%T3NBDHU<
M#JS-G:Z.T^]\PZ#](^H#*\=S9F?!T/R/D:+L"&,-3Q*`=5[=<Q-CDO=VY`[1
M?ND7%I!8@<'1Q/1WOS,Y&)P6'%67=ANM+ME!'XZP11H0Q^+LC3'&%K(M2MC(
MPMJ)G9VY-:(C:G0M;:0E0I";1$>*6G3EVAOWJ[FE*4I2E*4I2E*4I2E*5I(X
M2C@M]2>NS.<#R)AGA&=06@V-PC$A\)>4NG];*DSCDM[<)PX2(A3*;&')N/D?
M:,5;@M)9Q6$.ZDQ0_.`ICVTDA24XP*B'`UI-+^7L#Y+X07AK]7FJ#&S9G'$Z
MG%^G/.617J/0++FH!'.60S##*MC,AROD%5DM0V3XQA?VZ',+(6J.<&I,XN*\
MED0N19GJK```-@]/3X1W'<1V``W$=Q'8`#?O541``$1'8`Z1$>\`>$:U?RKA
M"%MG"3Z?-#T"AC:_P3(D*U.+\B9A5J%5Z-NR;@..XID"G%<([36%)G!WC2+*
M;`JR:YJT;@VLRUZ;(@B-+E35*TC/&PGA8I\I@#GK6M@F.TW!\-FM5'H[L>SE
ML@,S&Z1@W-A.F%;JR(>RW6R#I,<I=0*Y.R$8INBRV3*\:(E^0C,@(Y`8GQU;
MO2M'C!OZ1`>_W[1&T=MP`1#<!V'8-PZ:P-J:_J3FO]F._P#-\>K/%O>'^U?_
M`)[JY4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5;LHET5A#*KDDSDC#$HZWA9<O
M?Y.\-K`R(K3+@LLN5NSNI1MZ<+[Q"VWLRBP;KA`+0$1KN4ZM.L2$+D)Q*U*K
M3E*DBA*<4>G5)SRK3DYR=07?<2<2>5?9>2<69<5?9?:9;>-@A=7GWD,EX<[5
MZ_/+!#8+CK@_,56.CPSF2>2.;9*,E*VTE3>58I0KBK)4ZJ5!B8"[T:^.QB#H
MC##;KT<@NM+`^W%>JC@3M5&=D.G\B_59%LHR/%.*'^$2_(^;B)N$NECR^9.E
M4\3W)>Y*>5*.3\?;)`ECC2+Z_.3V*=NM%2I$D4Y">6_!/\&=EW01*<VR#*$_
MQM,R<FQZ`,K,G@14JM-0&1-UEK@O.<S)&UMEG8U5K^D+2EI`/N&XA0)XV6]C
M"_=<```;````=X`Z`#]U*4I2E*4I2E*4I2E*4I2E:I^%4:^%I=<1I$_!7RG3
MC%Y>*==;-E>665>XY2M(O-*M1'X74O\`>LPZ4^$$BH%2BR:RG)%MPE`@=6T\
ML.S:`]%'!8Z:[M=3YFCA&M:NH35#J^PPDTFY1Q7*M22^:Z?W2,YID659HN41
MZ"8AFSJM>9LQPJ21G%L>8BXT^23%:L9_Q6]DXKLP6MWM3#T>$?\`$=_[ZM6=
MM4I?(1,66#2HB#35WBTA;(?-5+`EE2:(2E>T+$D>E*B,+5*)'(R8\[G(W@UB
M5+$B9WL1W-QZI.4IO-L\V#7HBX0_#?"3<%!W6SMBS*F*L.8TUH)Y-D+'^AJ?
M0V.QABDQV`7C),=R9)UFJ'(24W+FJ!>G>72+9*?GEN4M4W;YM*U,+R:8O6-*
M#`=VE/+/^C;OX#JW&N5+<NV<($4GMGU^/95=C53H^-USVZS!U3)LM]R;<7`Q
M)L;770X^.FR*V96Y?2G8YLA][P>C,/\`7I:`@'3](W#X.BZX1`/V@`@`^G>H
MC:G\:1T['<[E][A.`=3S(T?>E*R1D`B.!>7*(RGMMLB1$E+B]I`EDVW7)0:.
MU;E(W+1)%:/;`2$Y`L=XW7BNEV]QAEP[3R;`&XWW".P=W^]TTYOV+Z]+^OLV
M^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TY
MOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z
M]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^O
MLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/
MTYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV
M+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+
M^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV
M^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/TYOV+Z]+^OLV^/U\B^'15K1*G%R>9*
MWMZ(@Q2L7+<BS!(C2)R;!O-4*52B1%)TY!5EHW&''&6%V6@(W7`%:Z)WPE?!
MU07(L3Q4&H9VG,VE\P8H0A;L5RG)^2D*!YD+FF9T`.S]$W)PCZ<H'!6G(4EI
M'1>X)PNN-O0"24=>7-C,6*9A(,59"9<+SMT@65W6(OK?CR:220S:2,D8ERA&
M:2S/+DR7/]UC@E1*QM,O+,(6%V#Q5%R!>!/:9^G.)<!LYY==44TX0S5UF75#
M(["K+AAK5(GJ/P1M-"\..C(<WE2Y/IR'L?'+MNC;7C^ZX+N-V(O8`K=Q%<+P
M.$1B.0N)D25BBT186>+QID0SJ<6(F=@8&].U,[8DLND-]UJ9"WI$Z8D+[[[^
M(6`WWW7C=</>ACYA#O+9<'[)Y-@_P?ZKS?L7UZ7]?9M\?IS?L7UZ7]?9M\?I
MS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7
MUZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]
M?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\
M?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?
ML7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ7]?9M\?IS?L7UZ
M7]?9M\?IS?L7UZ7]?9M\?IS?L?UZ7]?9M\?JZV]"2V(R$*>]682GM&PN]<N6
M.2NX+K[KQ$Y<X'J5BB[>X0"\\\RZVT+;`$++;;0Z1^FL/BYR=-)93&V!0K*O
M/3$/;\T-)RDDN\"S#2"G%8F,.*L,N"R\PNVZRV\0MNN"X0"L)Y-1:5,T)HBV
M934X9G=D1G\'G4#"0OL0<ET7R5%I2SNT#DL067.-SDQRM!*4C0#0N8STK@I4
MF6-G&4$+CDBB28>CT_X]/]]*=&_[/3X?"'XUQXMN^_T]_;<=OV\7?;?Z.-MO
MMT;[=%<JP+J:_J3FO]F._P#-\>K/%O>'^U?_`)[JY4I2E*4I2E*4I2E*4I2E
M*4I2E*5^"@_L)!YMH6WW$DFF<3C;;B67?>%MVVX@%W%VWV[W2&^U>.\W](NU
M8`8<!>#-.P66G'V%A>?D^ZX++#C+"PONME%H77<6VWCW6V6A==N-MEH"%H;:
M=!?"6ZH]9V1,>-JC1%(X1A%;#7`[(NH)>].[9%"YBC8KEJ8^!-CZS)B9!&G9
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MHN\H&F.*<#S']6>G"_"G`C\+EBO,,>U:Z?6"&Y!R2LR$V1?&>1;Y]#9BPN,[
M1R*;REG3FM<4O(G:Z)/C69>[Q,#%%BMN;E9$D2?T9[1W#<.\(CMZ0W'80V^@
M>^'H$*I>-P67#8%HWA:(VVWW#9;=<`;A;=>%MXV6B/1=<%EXV@(B%MPAL.E.
M"9%U;X^X4;&>GU^ULX\U*0_)6"\RY5U#:=ET(PQCIZTLVQY?#TN'I1ATB(%E
MY=?HG/'Z2+HB;'LL/T[>A:8X]S@Z1$EW)DJ2)Q/"6ZA3-([EPNQ^1RD^F@C7
M8DPPTZ:"XE$AB*O1M9JI3Z+UV0EDCOCYF5K]1!\O4J\TIW,J<(("F;&Y'C<<
M>J45ZJ2+_2[:.X;B&P[W!_X;AMW^GH';<.GO#4<]3CVS6X?F[=<[-@.%@1RV
M]"*]("RVZZ6QR^VVY*)P'VW#9=;<`7%@(VW!<&X"`CGL'=KM&ZVYR0!=;>9;
M<`K4H"`A?<`@("<`@(#T"`@`@/0-5[L-/C-O]N2?G4[L-/C-O]N2?G4[L-/C
M-O\`;DGYU.[#3XS;_;DGYU.[#3XS;_;DGYU.[#3XS;_;DGYU.[#3XS;_`&Y)
M^=3NPT^,V_VY)^=3NPT^,V_VY)^=3NPT^,V_VY)^=3NPT^,V_P!N2?G4[L-/
MC-O]N2?G4[L-/C-O]N2?G4[L-/C-O]N2?G4[L-/C-O\`;DGYU.[#3XS;_;DG
MYU.[#3XS;_;DGYU.[#3XS;_;DGYU.[#3XS;_`&Y)^=3NPT^,V_VY)^=3NPT^
M,V_VY)^=3NPT^,V_VY)^=3NPT^,V_P!N2?G4[L-/C-O]N2?G4[L-/C-O]N2?
MG4[L-/C-O]N2?G4[L-/C-O\`;DGYU.[#3XS;_;DGYU<K'5L,XX%N"$P2[!,,
M"Q8FN['8'2-]_%-'BV`'2-UVP!X:ZQKE\4>THKF:2Q]V1`H5(Q6-CVUKTH*T
M)UR=8F%0D5G$@H2*++B%)''[*G.MN*.LLOM&T-2VLC6#P@S+FESP!HIT<ES4
MI+'6-T-U$Y(=$Q.++KW]%V=0#()SW%(\-\<4@8VN(ODL,<[G1,HL+BAZ`$:I
MPRCH3QOKSB*G)<TUSZG8!DI9/VID(BN*H2W,-D=QLN1W.`KUZ>0(&*+6]D6I
M525N/96Y"X-]XHP<3GM<LNXXZ-S?T=K-MXG<355@;8RY0-G&BDQW`#;S+K>-
ML^[;AQP"[;HZ!$*]2&GN%IL,8(POB)SD[(^N6+L50''R][0FEI$3LMB$7:V!
M6XHDJI6>I3)%IZ"]0G3GG&'%$WEEFWW7VB-9A[L-/C-O]N2?G4[L-/C-O]N2
M?G4[L-/C-O\`;DGYU.[#3XS;_;DGYU.[#3XS;_;DGYU.[#3XS;_;DGYU.[#3
MXS;_`&Y)^=3NPT^,V_VY)^=3NPT^,V_VY)^=3NPT^,V_VY)^=3NPT^,V_P!N
M2?G4[L-/C-O]N2?G4[L-/C-O]N2?G4[L-/C-O]N2?G4[L-/C-O\`;DGYU.[#
M3XS;_;DGYU.[#3XS;_;DGYU.[#3XS;_;DGYU.[#3XS;_`&Y)^=3NPT^,V_VY
M)^=3NPT^,V_VY)^=3NPT^,V_VY)^=3NPT^,V_P!N2?G4[L-/C-O]N2?G4[L-
M/C-O]N2?G4[L-/C-O]N2?G4[L-/C-O\`;DGYU.[#3XS;_;DGYU.[#3XS;_;D
MGYU.[#3XS;_;DGYU.[#3XS;_`&Y)^=5+GIHM`;KG1N`+;;K[A%<D``MLM&^^
MX1$X`"VRRVZ^^X=@MMM&ZX0M`1#'&*LZ8HS:5)C\7S1HEY<0?5$>?NYMYO9$
M:XBZ\"C[2CRRC%30X@6:8SOB2PYH>"B3S&U8IM(-&R#^O#6II=Q@LG>D[4#&
MLVO!4^T;:DM0TC7XW@+FY-"+$.%XJ[N$[*;I\6M0(8_E$4;>K68^3EGDG)I*
ME8+U+NQ.3Q%@=_(]C+4YP;F=\V\'_C>,ZBN'+<<F1_4]A(N6S/-+.UWI=5$Q
M3:CPGN`SM3<P7S&Y"4&&II-%#!%YNTL1\B:<:&FQ%,4H-0196Q?T&K>@/WW?
MWW"(_N\`?0'17X*S3R4JDY,FN6*"DYQA"2TTHBY2<65?>4G`XX0))$\RVTH#
M31`LL;PO,$++;AK4..',F:P]1.AO4SD/2!(]'61]*D[R7/YW*)Y-\)2G(<A;
M93AV;XFLP;#))@^99"*E^.9<Z3%FG<P>Y8IB"1&FQ^QM35'W!X>EID>@Q_HT
MM18:3+N"(YM@_DR6:\4^:$^IFR80SD<=HRNU0#K.58\61NY^MRX3J')FO&PN
M0UD0=1!%3?V#)9F2$K;<?%2O3+:&P;#T[C<(_P#>N&[;Z-P#?8.CO!45-3^.
M,>GXRG$L.@D-.E)AD;4&20V+L9C_`'J+)1&TMI][S>@%QN.M2V6)K3;E(WVI
M[;20N`NVVT)`A!(0.XC#8J(C?>(B,>:!$1X]W2(BCW$:KR#@_D9%.KK1[G3D
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M>YU08+!@[\-B8?MCS.'^*.@06"CT!#HF(^`(\SC_`/\`'5+H-!;+;K[X=$[;
M;;1NNNNCS.`!;:`C<(B*0````!$1$0```1'HK7YJ$X0[@WM-12TC(&3<1NDD
M1EF",)QTSL^1Y?<H+N&P4:IMB:1Q1L:BZ^T;`ODSDR)K+@_G5!=N]P2WPP_X
M9SSBC'V9(##VJ^&Y+BC-,8W<_09&PO'<AZ3VJDUCBT+D-JA$KLL&ZPTL1-)N
MNM`Y*>I2F$J#=-^2^"8U;ZJ,FS%5J?UL%,>#+)@_*8'BC3_!T\4*&$J790:Q
M-[U8:E8F)([I&6]*A7J7IOR2I/5$'*K7*^U1Q;=I6E30SIWT>8L#$N)XC<K8
M3I`Y2IT=9P<EEDC>9`ZIF]&M<5SBJ0)TZ<+TK6A();FE`VM26TD;DZ&PXY0:
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M?R,BG5UH]SIR#@_D9%.KK1[G3D'!_(R*=76CW.J706"VAO=#8F`"(`&\>9PZ
M1$``.E'WQ$0``[XB(`&XB`57D)!O(V)]7F?W.J<A8+WPAL4']D=:+O\`!&-=
M2[,>*V%.*M\9<?LR4!`!4.S=&VT@!N$``!-6E$6`(B(``#<`CN&V^X;X$EFH
M?1+"0'E#D7!!!EHWVW)VXZ-2!7;<7_3MN1QY*ZJK;PW#]420$=_U0&HZ/W"*
MZ#FM3VFRMZF<*..-EA<0Q%<?V6[_`+/81?$;$!H7#M;;V,+AN$0$`&T+A"T+
M=;*R86W<SO!\Y1FMAEHBE<7R'-D=;+N-;_-FF'H8R_)Q+XVXC_KQ8#8`"!@<
M;]7C<^\(;.[+PC.D+3QBM"IVM)73@UB='%';?Q;@-,3D/(7WWEV_JW6&1\0X
M]VW8Q&RX`Z23Z,M=&5XT\,F0L[X8C;6Z-Z@H^*07'Z)"B<[NQ=G(:W1\9XI&
MW9,WJ599*5<:2L<0!+><9>F7%\9&?@G2'H"U&\I)G(9/,)OIG+:DRN&D+HPI
M3C*)<I)<D*I3VG:0KM;U$$3BCM/1.YMXW.RTQ.8T%%)"%YA\VN%I5ZQV711F
M:5:+IS@:%SZ+066/$HNSZ6Y,K$KA*9H,-?'"*903Y"@[%B>;Q=$4J?X]*IJE
MD<,.6)2VY])8B3;)`AUCX2F/Z1MJ0R%IS49CAW!I0/2R[Y2Q'E6<98P!/YQ,
MW:4X6:'IOE[PU0LD<F32+3)IRE$>RL;.I6-+HT\1Z;9.W.C.X-C7(F_TS@&P
M!_U_?]/[?I[]5KB%UHB(!O\`MXMP`._3T7"`6W='3^J(]'33C6\;;Z>]OQ1V
M[_>XVW%WW_[.^_HKE6!=37]2<U_LQW_F^/5GBWO#_:O_`,]U<J4I2E*4I2E*
M4I2E*4I5.-:/>$!Z=NCI#</HW#H`?1OO6BOARM4FH#3!C?3\\8"R>]8R=)=D
MJ5LLC6LK;&7$UU:V^#G.B-$=9)F%](*+(7VVJ;;TI2<ZZ\.+>;<7O96FW11P
ME/"AY0U.8O@D2R&9J&<7]<Y%+\7Y$*Q_$XFXQI,AN4RE^72%B8(HZ-JF),):
MY^;#4SHH$QQ2IBKF.0<<&E5[-\@0ABR;`YKCF5%K3(S/HI(X7(2FUQ6-#@:Q
M2=I6,CH6B=6\TE<W*S$"T^TA:D-+4I31M.)OMOL"H'Z=^"8T&::00+(5@>.2
M>3MP`),URGODJ2V'6"`EJT?*4M0P,:FSBAQ3(XP,XVB'&MVNZ:V.E%%DEEDD
MEV%%%66EE%%VVV%EEV6A;8679:`6V666@%MEEH!;;:`6V@```5SI2E*4I2E*
M4I2E*4I2E*53C6][<-_!N%<+S2R[;KS+@+LM#>Z^\>)9:'ANOOXMH!^T0K$T
MIS]@^$VFC+<NXVCUY(7B8G=9K'4RP.)=Q;@M1"X"KONMN`;1LL(&_<!#B[@.
MT:I7PENC>*VF6AE@N2*K.@$D3C<E>[C1Z1V)6`UI6N_H#I'M\+0W#>[IK$QG
M"AQN2&@FP_IQU"92/ON"PF]%%"FU$==N("`'H+I*HM"W>S^FDMN$;MA``#<=
M?6N+45JHR$FAYV0L6SC3GC('"U?&V92K<DQ[]*VF[MY.Z/4D*3LZH'-FLLL7
M1]C,1-@(S"CGHBQR5IRU3=,O&++PI66X'%7A1EK'V(V1P9$5J8V0Q!*?DAQ0
M6$7%IGY^;+XX[%I79W(`I<85<N9U`@84H/;6X\PY-5[AH,U$2ZRWG5UX9B="
M3N**QIAJ=9&T-]HV@!A11G*0$H6C_1"ZYF`.+QQ$H+C;@#N6O@H]-0'6K)D\
MY;R,M&X+U!TLGA@6J3-@XU]_<9N;50\:[C#^LMON#CB''':T0S[%M!^D2(7$
MF-.!X,H.(&P;3I"F72PT;R[K;[;[QDRYULNNXUH"(=C"T>]MMN`R+8(#!HIT
M1:&12-AN([,$<9F8-Q&\1'_9J)-TW"9>(CWQ&^\=_P!8=[LXH>D=_H$1$/4(
MB'[J``!W@`/V!M5:;`'>#:HS:T,:2;,VD;4UB2%16%3>9Y-P-E:!1")Y')`^
M`/\`*)9"GACC[;-"^RD&<ESW=:C[MWISBE9*"T\Y%?:L+3B'G'TP8_\`T@'3
MV?IEQ/DK6QP5\ATY8QG.!<5R>*P!Q)9,LNF'V>=P^%*('`E[GC"%1ZZ7WPZS
MDK&$BJYI='<\M.@+-5RI<3<L]:`?_4?\1KYEQ2H]&K)1*;$:PU,>6D5F)P5E
MI5-Y5]J=08E$Y."DL@X;#;TXGD@?;8)(FEA>-X:&56DA1IQX1_0LJTTY;SZ_
MY&GI&<97P@JB?9OR9DF*Y<P2W8S<VM@R1E"$2V5/D(@\T.U&.D(9<+%8ZCD#
M1I$9TVCD6;.0L%=6IJUP$ZCL@#P7[CPXRN7ST_4B=P@"-_;&_EE(N3#=I?2Z
M_$^CZ[223#>ZUL-)Q4IP]>ZN"M!8T&JE64EMN53G2Z>)D<B1>PVT1XHB/T#>
M'TCT6W"`=_I$=@#?T[U#W5!EW'J>`3J"G2`+)20=&DIC7W*?+AM4&26,K;"Q
M6VM=S:.Z4XLWCVK+K`XW$&X#`NMMD+SG0BP;K+GH`NMO,M$.YSP.PA?<`AT-
MPAZA$/33G0@_CL/LUX^'4YT(/X[#[->/AU.="#^.P^S7CX=3G0@_CL/LUX^'
M4YT(/X[#[->/AU.="#^.P^S7CX=3G0@_CL/LUX^'4YT(/X[#[->/AU.="#^.
MP^S7CX=3G0@_CL/LUX^'4YT(/X[#[->/AU.="#^.P^S7CX=3G0@_CL/LUX^'
M4YT(/X[#[->/AU.="#^.P^S7CX=3G0@_CL/LUX^'4YT(/X[#[->/AU.="#^.
MP^S7CX=3G0@_CL/LUX^'5T\ASEB6(M"B0RZ>,$3CZ0!%4_2E0='61.("`<4Y
MW>4Z)N+O$1"T"[E(7W7"%H6B(@`XCQ3KJTDYSD,KBN'\Z0K(S["$:!PDR.)F
M.SL6W-[FK.0(5]BXAK%O<$9RT@Q)<J:U:T@A3Q"%!A1AI-ID;==F9];Q*?',
M<T#,^''`Z2'R`C(^0LI+#TYL`!,#5='#FM@>+4*!8D<;#7FY<Y]H2M0G4(T*
M$J/?ZWVU=';2CI;U3QC.<8U%:O\`A&)SE)\C/=RXO"^/4$I:<0KA?V56UGHG
ME,H:V)B<&E`<J+<4B1JQVR'BXMK<JL="P),+.E]K,TPZ7-=,<@T8S1)YVB08
M^D3C)V$Z!NCA&UMS@ZLIK$K+<#545>2E:2Y$:-UA0$$F%J++#+3N+QR[H^Z8
M>#-T-Z3,SQO.V,)CF-9-8JW25L;"9A*U#XPBGE3,H8G.Y4VIX&U&G'6H5)HI
M+[5I8$G\4RZTT`X@[4^="#^.P^S7CX=3G0@_CL/LUX^'4YT(/X[#[->/AU.=
M"#^.P^S7CX=3G0@_CL/LUX^'4YT(/X[#[->/AU.="#^.P^S7CX=3G0@_CL/L
MUX^'4YT(/X[#[->/AU.="#^.P^S7CX=3G0@_CL/LUX^'4YT(/X[#[->/AU.=
M"#^.P^S7CX=3G0@_CL/LUX^'4YT(/X[#[->/AU.="#^.P^S7CX=3G0@_CL/L
MUX^'4YT(/X[#[->/AU.="#^.P^S7CX=3G0@_CL/LUX^'4YT(,'??`#_^.>/A
MU<K,FPHT=BGBXT?`6UO9@^JQMN]5=,\9PQ-'BA.D,[8(\5;TW&/ZDUEL#]MS
MF0E`.^&P;[CN&W?#?#TGUV:2XHC6JE^<H.N,1$'&]SV%>;('-5>38-P)4:)H
M3JKCU1UP`426-Y=@F7!V0TJP+S+-<4'X7)V'*$H53S':H_$CO8),)98BG2K,
M@L"E/QK&P70Q6YIFR2&R2Z^P'-(D,2"Q*KR"VDQW3E']M9J<.$CRJ^@87C+1
M7F)X"\+NUG"5@YL:;8;OYN\PANB[D6-@V;7#:#K8(7#Q;;Q`!N'I1S]PC\]M
MXK1`\"X=2&A^HJE2UW=G,BV\0&V^\D%KV-QA5O1=9<Q=-P7B)0B-E@?A?C?6
MK.#0YP=>#/#DAEVYJ7%D`>2[B[`$-K2%B:.0E1TAOOQU%X]`!==>`W;?I9H,
MQ')3`49@U6:@\IGC==>:6M>'5M1&WW7<;I(7MDD/+#C#?</8U=HC==N`V@&P
MY4BNB#@_XL%EUT$LDBFWBB*J6.D^>1,NM'?C&(PO2-EXW;!Q[10<00`;>*%H
MW!=)>*Q#2O"+2PB./<:QV\H0NL4-6.4R99Q@NXX77+0CURN^X+@"X+KCQN`0
M`0'H#;+-F2X&7;;86\VEV6AM;98VO%EEH>"VRQNMM`/V`%=._2K$DJ1E-TFL
M99"@(7H'4E$]QI6ZI"G-J4V+6QQ+3+F<\FQ<W*RBU2%7;8!Z5198<1?9?:`U
MW@9/@X=Y[#[->/AWKISH0?QV'V:\?#J<Z$'\=A]FO'PZG.A!_'8?9KQ\.ISH
M0?QV'V:\?#J<Z$'\=A]FO'PZG.A!_'8?9KQ\.ISH0?QV'V:\?#JO%L<D3NA3
MN3>=VPB5V77D'=C.*[);;?<6(]C/+*-MVOLN#:\NT>C<`$!`1C-K<@S[E+23
MJ*Q;%99;"Y5DS#\]Q_&7L)0FA!XOLNCRYE;FA%,E0&611PD1JH8^ADI2=:J8
M%#G8\I4"XY!:E-\4V/>!0DN(<WZ&\WP'@3Y%"G6=:K<+Y`?X\[:XI!E0W15&
ML0YDN;9XT996)GY#',E1C(V.66/9VQS+FX!<8A/#9)`I.AE#(3&(H\^_ZT-@
MV]-W[1WN$=QZ`V&[^D(;!L([;!7PNP.8M;B#**&UX%`L!J%S!2+<#EVN;VB+
M@".ZU6*+MKL/;8);K5(I^R`GNM.XEP:E-.VE?A)L:9162O)6I?1C)&3(N36F
M?9[E,&TI9B9,Z9%9V`PX6#'[/.9MJ=G$*B$/CK/:C@\8:$&.C&^,Q*][7M2(
MN=R1_E[GCJ[@FY6+-=I5')\)OX/2[6@3K7(QB,0>+,M(C[,M?RB#]+Y;[W4-
MAJC"RG4(%T]"87H")PGA"E1BNUH-4`3D:S=_:`6AL'A$1_;<(W"/T]\1$:P+
MJ:`.9.:CT]-L=_[5VW_G?'>\&^P?NK/%H!L/?_I7_2/_`!W>FN6P>GUC^--@
M]/K'\:;!Z?6/XTV#T^L?QIL'I]8_C38/3ZQ_&FP>GUC^--@]/K'\:;!Z?6/X
MTV#T^L?QIL'I]8_C38/3ZQ_&FP>GUC^--@]/K'\:"```B(CL'2/2/XU!R<\)
M1H3QK,I1CZ<ZG\61J9PMZ6QR4QUR>5UCBQOC=>!:YK7EDMQQ9:M(9<!:@JTV
M_L9F]EPA?;<`25Q#F;%N>X*VY,P]-V/(,#=U;H@;91'5)REJ6+&1R/9W5.2<
M:2G,$Q"YI5")0`E6A:>5?:`B`;CJ/S3PZNFN)3!^Q7I]QUF+5;EEE?'&-W1O
M&D4<V]B,>F=<K:W=)W;7(5T@6EM[FC.1FJH_"GI*?=;<8D4FDVB=6Q/1OF+-
M^=L+H\A9_P!/[IIKG"^22)&DQR\O9KRYW19&H(&/R!9:I0-;BTGNJ<XTHYI=
M6](O)-0WJ[DY"=8G)+BAJ7X(O`^KK4,YYUSKDC.TH:%C1&VUOPVBGEC+C5B,
MC[>2W&&LI*5M,?&I,[]A[J.:-I<VZ\][5.#C<MN%6!!,SM/ND?3;I7:W!JP!
MAZ&XTL>"TQ3VY,B$Y1(WXI%<88D*?I4[*'&2O124TX\U,2Y.J@A.:><8047<
M9>(R,V#T^L?QIL'I]8_C38/3ZQ_&FP>GUC^--@]/K'\:;!Z?6/XTV#T^L?QI
ML'I]8_C38/3ZQ_&FP>GUC^--@]/K'\:;!Z?6/XTV#T^L?QIL'I]8_C38/3ZQ
M_&FP>GUC^--@]/K'\:;!Z?\`Q#^-4_5\._H"X1'U`.]83SWG['FG2!K)YD%P
M.+3VF"B8V)O[$=()4]7EW&)V5@1'GI[%"HRVVXY2H/.(;VQ'8:N<E25*5<95
MCQO6CICD,%8Y\=F."QQO>D0J!:)1)6IED[6J)$2ES6ZQT]6+HG<$"FV].=:6
MG.3GB!:A">K1J4R@[%$IX371O&1N+*R>HDZFW<`312*RAU&^ZV[;BEJSVUO;
MKQ'I&T;5@V#;:-_&XH@(XOOX3UIDQH$X?TRZA\G7W=!9R>,VMB,P1N`+!`YM
M"4&VV7VCQ[;KR++OUK+1M_6$;:6ZD^$1G%XC`-%S-"TI@;EJLGS#B&%VW7_J
M7F)%3I"SP&VT?YRP$E]P;#=Q`#BVC2V#\*O/+1N>,OX-Q`D.Z;TD;9+'UQ3V
MWW#QK+##X\_`-Y5O3:-CW:%P\2SLH\:^\.=F@G4#+B]LL:[LTNY*@;;EK/#`
M71AMN$1'CEEB,BO2"7Q!&RW_`&(7MQAN[&`#Q:N!EX*K3,F/L62Y=E3(ZX1X
MZD^7Y`6VVJ3=P&XR^QA2,Y_Z]P!O;<K,Z``!NN'<1D%%=$&DZ&7%&,N!\?FG
M$@`6'R!J,EQX"&VUPG2I2\W77!MOQAZ=Q$0V$1WMW&>A3`V*LS2#-$;8C>ZK
M@9VU%XVK[7-C&/7!9:<#VX1!!V(+TBATN-N!-VP:?9'DYJM#'[6]&JO)MF6%
MH!WM_P#Q7?C38/3ZQ_&FP>GUC^--@]/K'\:;!Z?6/XTV#T^L?QIL'I]8_C38
M/3ZQ_&FP>GUC^--@]/K'\:;!Z?6/XTV#T^L?QIL'I]8_C38/3ZQ_&FP>GUC^
M--@]/K'\:K7CE_219]HI4:G],^+>$1B6M7+&G]OP)/<@X]Q3H]3L(EG9==<E
MM$4=IUE`YUE,:57VQ^%M:=K@-B0%I1*YZDH*[DI2L2UOR\&E^D5Z?(]CG21H
M548>UZSS*)^0H3IG@F7<UXSAC8RJXG)<U<WF'9!E:9)\D+'&U]9<2NL-*F[D
MVQQ8"^7-:].VISD2DA;7LC#I]8_W"(56K=3R^**Y0Z0A+)X\IF;(TMC\\1).
M]MATF:F-Z4+4C.\N3`4JO=D#2ZJVUQ2MKBK1DHUZA`M)2''&)3[2^AORSBTO
M(A6(C,D0*S*YS+RD)QE?,8Y;D(V._P`]_M\N%7.028QD_P!7/_VK8UW(/YDX
M>V.*5>-N0*P+J:_J3FO]F._\WQZL\6]X?[5_^>ZN5*4I2E*4I2J"(!W_`/\`
MT?0`!TB/H"L+3[4A@#%DB88ADC-&+H-+)0Z-C+'HQ*9S'&61/+F\JBD+6D0,
M:UP*=#C%RP\A*GN[5M*,4'%$@9QS+;1N?+3].8OB_(4DQE#"<C9#8H;(W6$0
M-0])X\1,)2@:U*ADCAKVJMN3M=CLX%DHKUAW%L)`W<;R_P#>6?SK-2=F<I=J
M&SC*LNXQ?(7E&1Y3F#UD"),4??U[+&Y4O<KCG5E:ER6Y^3+4"`T;24ZM.]NI
M*BT.R6+C@NW#V0<!RA<&_@[,6IW-`X-RD9KF@WM=S0K&]5V(W*LGO)-%,O)3
MJ`+-L$+RC+BPL,L$+RQNM$!K:+&<>0*%J7A9#H5$HFKD+@I=G]3&8VRL"A\=
M5IURA8YO![0A1G.;@K/NN.5+%UYZA0:(F&F7WB-PW@``'>``^GH#;I'OC^^J
MTI2E*4I2E*5C5WS%B]@R%'<4/,XCS=D66(%+E'8BJ76EN[HC2\?CF$D\42[+
MSNQ*!0)U!I*ESM2+;FTE6")6).0%*U(B)N4+%)"0BP-[SU1Q:8FP-P#>XT^X
MLL`W$`W&[;<0\-89E&I?3Y#+#;I/FK%[1>2`B8F43>/F+@VMNO$`0)%RA;==
MQ0W"VPBZZX1MMMM&ZZT!CU*.$QT:QD+[+<KA(U-EPV]K1:+RAX&^X+AMV+5B
MU)&XP!&VX;;K5HV76@%UMPA=;QL4G<*5"7XSM?%&`-0>355W03W.B!"%(;<(
M7<4`.2*7]398-UH@-UR+<`M,N"T0LVNH.K+7;-#`MQUH4<F`DS;L2O)DKO;+
M>*(V"%QR9>7#!LWL'I`#KN)?</3=V(P+@I^%AF]V]R[3KAQ.9T#:07<_KD]E
MUM_ZP"81."+KP&T!M#C@`W7E[B%H&!;2W1[K7F0WF9)UXR=IL.'<Y!C:-'M!
M`<8;!NL*4H'&(A;8`\8+1N0B'%LM_4#LA@!BG,/!4N3G"'-[B>:\C9*RTW!V
MVU$Y3>DBEC?$WZ]S@Q)U1I2A;'G!Q"U/>A=37%2WVJTUA#FG!*IN6H<Q:<.#
M*PU"(6B69RBK'D[)CF)+@[F+S5Y\;C8B3Q2XZQHB%21,Y)T07B"UX<TYZAS7
M!>>F+1(2TB4N=L7P;AF%6EA$<48YC8E!:%AK+"XZ@4?JV\2T;E)#=:ION"WH
MXUYPW"&^XCN.^4;2[;`"VP.+;:&UMMOZMH`'>`+;=K0`/``!T=%<M@\`>H*K
M2E*4I2E*4I2E*4I2E*ZVQH;;'52^6(R+796WHVI2X6V;*CFYO5+UJ)'>:`\8
M2$RIT<#RK.@+3%9UP[\8-N#NQM+^AO;'I`G<T%ZA"JO2+;.SD7*6Q>E=&\_B
M7B(`:C<421:F,#:XI0G*-L$+K`&NU_Z]=*TN8`BT8C/#?\(.='(ZQ1\Z5:(-
M!DHDYS*T-[6;(Y,ORIJN;UTB?C$2<B]W?5R%M;42MW<!4."E*@1$'*+RDA%I
M>DU/,'])P#+MP@P-XW:TGSA44>I0Z6FV&W3D<U-_"=I=.B.*%*+PN?KFQ+I^
M1&85(A07=IDXT/5Q"QKM8#36^[VI6?T>CIVNO`-M@V"V^X`M#O!^J`<4/V5$
M?4_,I$7CN=L%F+9P>U%&1HJR9E+L?A'#K+Y1&3KE-B8^<$R@"+##+DEUHQSM
MKMDNZ\$PHO\`7`D)RI?+1NM#'<NN`##`"X%D)VN`+[@`0_\`*_O#W_I_:-.5
M;[YNI?[9"?F^G*M]\W4O]LA/S?3E6^^;J7^V0GYOIRK??-U+_;(3\WTY5OOF
MZE_MD)^;Z<JWWS=2_P!LA/S?3E6^^;J7^V0GYOIRK??-U+_;(3\WTY5OOFZE
M_MD)^;ZAQJ\X1;#^B%!`G'.D%R\F3Y(<9"V1FV(L4/DYMZF,(FU>Z"O+)G23
MM(JU.[).US+KK^SF";8`6]C$1B3%>'YT%21P5HG&_,,%3(V=Q>+GB<P9H;6M
M3W.[7_V0W]QY<_.3@_.`J`!K:TK:9>K["HNN,)+)OO#(&F?A?<6:O<Y)<3X$
MP%J+ET5O9WU>YY?51:.L\&8UC*B,6EI'<Y7)+K&TAU`KM%M-<G!"YJ710D1$
M,AP&F'$20UDXER[J=PR?BK',_P`T::G5?)F%S=I]CZZ&J7YRC+?V[:\P^XQ+
MDF.N*)$^EJB3#5C8\H5%JA`E)5=MM9R]`IA5IZX&[1_@V1,\^D>'LPY\R8T.
M:"0E33,TQB#P6$E;EA+BD>;(FSRQKC2E0D7IRE2.]_32)20=86;>K//+L.#<
M#RJ?-A#FYE^P[[AVY"=AW$1'_P!;_I$1WJG*E[\W4P#T`NA8!^X`F``'[JJ$
MJ?`Z.;J8?O6PH?[QEXC5>5;[YNI?[9"?F^G*M]\W4O\`;(3\WTY5OOFZE_MD
M)^;Z<JWWS=2_VR$_-].5;[YNI?[9"?F^G*M]\W4O]LA/S?3E6^>;J7^V0GYO
MKX6Z?*GA&6X-$*D#JWG7'V%+VQX@"]$;>F/-2J;"E:29G)S+TZH@Y,HML-NN
M)4$FD&A8:7?9;]HRQ\#_`.[F8#^Q7"A_PEPUU;ID>YD(%2]1)X9TX#L)[M(,
M<MA.^]H;=D7S=/9OO?8'2/?OM_XK=\)236W@&(\<)#-HPB,+MXUZ=//,;O*O
M;:T0"U(P3%U47W"%]@A9:6-PA<`[;!=Q<&NW"O:3&LZ].2XSA\/M'BA8PQ8I
M788.V]H%'*G5"48%X\6VP;;MANOMZ0#C#;;P\)ZVR8RTK$FF#43DF^_8"C"(
MP2W)3!'B"&Q[8$HN"WBW!=;<)8!=QBP'8#-[:#JAX02:7W6X^T0$18F\!`I5
MDR7@0-F]MVUQB5:KA!@[76"/%#<+@XEN_P#.VW5;R[_2YRHP/U<-8S2FW;7]
MQD\6>%28L;N-T`YN$K[+=9;=Q=K3;>,!=V]P#>`W:]YWHIUDO>>DS?(FR0RZ
M6S)65*[\Q6*;2V4JQMN2BK=U[TG<2R8TZQHRTDADC1:YO7&V$MA<8(*2&6W(
MI]).#3QVYC8JR6Z:I\HN=W%O6'OL^@2)&J.':\Z\"`D+DY%6''";>%ESN887
M::-MQQAEH&CF6+Z#M*<6M*$G2F]/)Y0VCVQ)Y,VR$3+K1$>,8F<<BWM]PCOT
M@"*VWHM_5_5MVD3',9XPAX%!%=+S+'KB`#L1S3%,2(U-O%XFP]M%/@*!N_FR
MQ&ZXT;A&RT1$1M`:RF7)7@FRTLK&TM*+L`+;"RU<(++MM`-@MMLLEUMEH```
M``%H``=ZN?*E[[_-Q+M_#VW"-_7RNWJO*M]\W4O]LA/S?3E6^^;J7^V0GYOI
MRK??-U+_`&R$_-].5;[YNI?[9"?F^G*M]\W4O]LA/S?3E6^^;J7^V0GYOIRK
M??-U+_;(3\WTY5OOFZE_MD)^;Z<JWWS=2_VR$_-].5;[YNI?[9"?F^G*M]\W
M4O\`;(3\WTY5OOFZE_MD)^;Z<JWWS=2_VR$_-].5;[YNI?[9"?F^G*M]\W4O
M]LA/S?3E6^^;J7^V0GYOIRK??-U+_;(3\WTY5OOFZE_MD)^;Z<JWWS=2_P!L
MA/S?3E6^^;J7^V0GYOIRK??-U+_;(3\WTY5OOFZE_MD)^;Z<JWWS=2_VR$_-
M].5;[YNI?[9"?F^G*M]\W4O]LA/S?3E6^^;J7^V0GYOIRK??-U+_`&R$_-].
M5;YYNI?[9"?FZKK;U1RU&0J4-ZMK..M&XQO77HS%:80ONM"PZ]O5KD=UUP6@
M8`D*SK>+?:`W!>%UMOV4I2HAPO2&P0S6'F+663D>?.TSS3BG&^&I!!')/""\
M?,L.Q(]RZ0P8V.6MT313,I]2.D\EQKHX/$N>4SH4ZE$"W);6U`)&!O\`1<8;
MYP#%@3S)G\GX[4\5K5,TG"?$APY;J?)=RY79-B'#DN&1D\+OR245F4_$!<Q#
M'Y^7K3)5>W]R52N+J-F@``!L'_0CTB/[1'I'PCTU@;4U_4G-?[,=_P";X]6>
M+>\/]J__`#W5RI2E*5&;6!J79=(>GF?Z@GZ+/$U:X",8M51J/KFUO=G`9-+F
M*)$`F6.UUK>1VJH?"EAXJ;K>.G3FEE;G7E@.HW#O#_8OR_ES%V)4.F[*;&NR
M?D2&X\1/2^80%4A:5DQD""/IG):F1GBK4)$1RZQ0H)2@*@PHNZTD!,&T*D!J
M_P"$3U/8WSG)=,VD_0KE+.N0F%JC;@=DA[1/#7B,@).U$.:-6C6MJ(I(\-B"
M]3W,<UCM,X:D)>$3BW6GW7)+CK]16MW23PT&JN*XM?L]8^QWD`]LE4U<8YC#
M#9D(;'C%:=W96).JOE#ROD+>T.2!Y[6(1-:%))IFZ)%;6L5+G5.G/)(-_+@Q
M."ES,TZI4CSK0TE]EQ"TX[EZMOLR.H@,HBXY`M<XH$8%0PL\L?1<5-B#E#>G
M+<FM2UV<4R\^VU0"2X/75'HU'HDT(F"+,3/&V)M*`AN9&!L0LK0@(#^B2B;&
MPA*A2E6AT6V$)[+0#H`*[NE*Z1WDL=8#V=,^OK.S*9"ZE,;"G=7-$WG/;T>2
M<H(:&@I6<5>Y.9Q"<\XI`CM.5&%$FF6%#;8(UW7&M[VX;^#<-_5WZ<8/3_X;
MO[^CH_?5LO4UAT;*,/D,KC3"22`"<<\OS2UE%!=8)EHF&+EA%E@"7;<8`W"&
M]EHWAO:`C6&)#J]TOQ8#>[.>\5DWDA<)A*.8M#NHM&TRXFZT$S,>X'W&6F67
M6B587<8&P#Q>*(".$'[A.M&3'QK2LJ*'XZVVX;28_#9@N$RZT"[@L+.4,R)+
M?=>!@C:/9PL_FS;;K[;K-AQN9PJN(G0T$\#Q#J!GIUPC;;W%@J*TJZZZVVTJ
MVS9[5J![(<:06(BF#B@>5>`7\:VP?QNURZH9/:`8\T"98-L-#=.OF;HLCZ>Z
MR^PP23+RSXPB3@`[D&7!:Y]X#R@,`;;#:QGFZ;\*#.L93-`.#8GC..G,QQSP
MI@LL1O>2S6.PN\YS;8[<1*UZBY<K0#>E66MC02]W%`<6S&D+C;`J*^A;&NL^
M?0R2-V$<M+,+8@[JWG&/+JTD.C<Z28+>TW)+"6]6WJ%B<Q.3<-\C7MBIL;!=
M"4I*FY6]$*NTYZ7\'UF65@'.EKHSM)"CALN5-T<O4QI"(C<%QMA19DD<$ME@
MA<=87Q&VRVP+RA[&($@7=VC7P4&F6PTM3+73+&05?1<H-E,[OML4&<6T+K[K
M65M;%(!=<`B`=N77`%VPW7<2P0SE'-`&CV+]BN;\$P]887;Q>R2&YXE%UX[7
MVC=?9(71Q(&Z[CW"(@2`;C;L`<2SBR$CN)<6Q"TJR*8X@<:M(OO,)!AB$?:>
MQ&&#:)AEER)O)OM,O&RP;[PNXUPVV[B/%#:_[;+;0`+0V``V``$0M`/1:&UH
M?N#T=ZJ\6W_A#U!5:;?3_P!?]?\`^^&E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*"(``B([`'2(CW@#PC42OY<NE_GE.P3;DXB^;ILB)<-*W`N-R\W&R/-JV-
M73%'@U;F(M@NQ.CS8JBX6/1&)E,R*GAB90C(M8Q<%Z)"HEKW^]6!=37]2<U_
MLQW_`)OCU9XM[P_VK_\`/=7+_KUUKTF?"L\'YCV82J`S'4K$V.70F1O,2E+*
MHC\_/4-$BCS@>UO+6><BAZI&:<A<$QZ8TQ*I4)[[R[A).,LVO&6^',V8OU`8
M]8,JX@EJ.;8_E)CL5'Y*A1NJ!(Z7L;JM9'7M9.]-[8X#:C=6Y:C,,O1V%W&)
MC;B[KRP"\>CU*Y=8L#8#RWEZ1R5OB#;!()(7JR0NA`JD3>[@@-1QSLB2TE1<
MM,6216T($R&T@X5JI42E`N_LHA7BD_TW_"5V-G9C<T0ZU78V=F-#F5QIM:KL
M1=D-#B@TC;M:>%WZH;V]&P;VU[;<`RY[GV",+3J3*4ZJ23/$V-I9(%2=,2A3
M*'J1PUC>7<].C(_F4A!ZY:I,)3%?S2>R^THO:RRVO/\`:JN"RX2W4+#\HNN1
M=<UF7W$V3D.&-]/[.0X8[Q.]-(3),>@ME-P*6V/M2R.QLPQP1)KHG*5%[TUI
M"@D)]YO;UNM71)P;&I)5JQQD_-+C@^1),`9WQC*LF)XYF)`[N;>PQ29LSL].
M;(AL8"`DJ-/8C5MMJQJ4&H;GQ,>TWJRU%MMQGM^4J4B0J\]8H)3$V6C>8:J.
ML()LL"X/U[[C[["[0M$;=[AV`!$-QW$*C_FO5%AW!T(>IC)94SNIS9<*)OBS
M`[-3G)7Y]-MO[38VYN(5F&%*#[[+KE*I9:0A;$A9ZYP/)3D7",;,/<)GIUFD
M'*?<FR-MP[+TJR]`[Q%X-<GBV^ZX1O2N4=<FUG$Q[9U1.P&'WH42MN66'I%R
M0JP$JE5][UPI6C=JO[$BG[[)#OU-BH_!)6=?>-]E]P66"Y-[78-X76VDW!Q^
M@TTOOEC>998YO"IXO=+NPP+">H:=*;QNL(L;(.B(*.,$2RB;;;RG=R46A>JO
M%-?<*4;BC;0#B7C?9:(S79J/D(6CC[0)FE>0:!8D+I:K5QLJ\+@&^X;B[HM<
MGLL&PLZPLRYP`.R6EA>`7&6ECP#,G"@2BP`8-+>)X20<`VV*IA,R%YZ;C66A
MV4P@F9H3=[!.L.MM%N,_W!Y-UE]_ZM:VM8^/-;C_`)"Q\\9U9;I`]R<XE@QD
MAQ5>K<8LQO\`<L`VV.LA*,+3628+C4Y+S>YK%-ZIP2IRU)+X*9B4)VG8?'M(
MFN>5LC09DG7-+HFJ.;$5J]@AK1VVJ;;P2DDWMRB2-[E&+75:03><0M=K23+5
M:\L%MIRRZ[MF[N;.#)1OQAIN3M4VI*?7FE_K`,NL:R14W&B=>>)2\9'QK.R<
M6^TBZ[:TT!,[)<(VA9<3-P4VD=N,L.=F.<RXVT;;KKY)/'8>R76W%B`7V,9;
M):-NUE]FP=XLXVS?;L0EYI8M!6D".\06_`D&/N+#8+GLARDEP_S8E;W#('%R
M"X1L'<1&WIOV-Z#`"\,WL6%</1>ZR^-8JQPP&%CO88S0B,MQMHC==?O::E;"
MC0_7NNO#:_HN$1#OC61R4Y"<NTH@HLDJP+;;"R;+22[;;+0MMMML*"RT+;;;
M0MM``V"T`M#H``#]>*'TAO\`MZ?\=Z;!X`_=T5^1"<A*5:2F)*3DVC>-I1)=
MA1=HWWW&7C:67;;9:-YE]]]VUH<:^ZZ\=[KA$?VI2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E<+^\'?_`*9?>[_^\M_N\/HWKQ5E7S9-^CE*["@/#5^X
M\*E:6K&VRVZ:7ZNK>&93&VC=>-O\Q-+6Y$FM`VT;![GV6E<8;3;K;_:I9_1'
MO_TS._\`_$N_N\'HVVJ'VJ53E\,=3XI"RXW-A@#'@1K54GE),GN*Y1QNX+E+
M43$5#389W0XY0V$O!EH(N*H[()W&35D[M[4KO=Q8O@X+>/?L%T[R`(@''NZ!
M&W'(`(AX0``'O@`=ZG;VI;<-XQ@W;C6[[3O(.^VX>''6WKZ/#7@-UC0G)]FK
M748<_0&7)'*3:C<P@@!NB$V4LSXYJYZ^*;B(<X*X\C-DR0[LH'-IJ%/>H6(;
MR50)K+3-@VC\'=P9VK)S:\$ZOHJ[F,;I$I,^26!0/*$PFT3;6PUG?I&PF%.<
M&*92'5(RNQ_;ZU4U]O-)3^2K%0J*4MS@8"K=9/<2\)MEF&RK&L[>M*:V&3IC
M=8S(42]B5NJ,&IW2')C;A1+8XO*4FI!O+4(A4)5?8EB=,IN+,O)`:\\"K@?,
MEI<UDZ<C;IN?-%)-EQ#H64SFPY3$A`$QL]"3WL=EHQ8DKC=M*C22W8MR`62]
MM!],)0F>A6,Z4N$CB<1B\)8]7T#;8_$(G'X6R)4,8L2B0R1EF2,+6`F6P$3Q
M6`WHB.S*Q.%08>`G7&B;^O73/FB[A#I(B6MSYK0(6-[B@/:UZ`IWFJ!(M;U1
M9A*I*I):V5OMOL4$FF$GWAL>:3>)8F\4+0")^&N#>U/*9Q*$Z]2.)T4+4*HZ
M$H0RMXCALV2+TMUAMD%>HZVNBZ^,J48HSW!4Y-A)!@7@R&H>Z25:#=*%/P6R
MU28!TO5<NCAXEQXON?\`(!5BDS<.V+C.P8B,4A:K"TNTVRU7Q[+2K.(;QK0$
M.W>>"^C:F*O++&\6XOBTE7H`(:YWSUYC?7AD7EF`:2NM:U\*)8G(DRZT"7%O
M5H;2EB01+)-0J0+5V=]@+@]WW#;:XC*\?:=<SRAU47B:_3MTEREO;&VVT+4S
M4PQM;C]X0-NP]D.<'033W%R.,LLO-(2I4Z:V8K+`,G1SM?D]A;2JQ=J`()A9
MU\C;;DX7#:-W8;D>*B1+XPVVW7#8(#==:`W;B`#5Z`JU*6AQ;(M@RRW<1XI<
MZR"7;N([B.UF.K0W$1W'HZ1Z1KEVYJ5[PQ?!H_MG>0KO\<=#3MW4L'>B^#`_
M_O60?X<U:,IGNH6*K(<C7PS#"HR9RY+#VZ]+.YWQ$:]4ROSW8L6=FQ\7=VI8
MF8%1%W8`O.[,H(VM[&)EUMW@NU+"`#R8P;T_^_>0?X=4[>U+^3&#>O>0?X=4
M[>U+^3&#>O>0?X=4[>U+^3&#>O>0?X=4[>U+^3&#>O>0?X=4[>U+^3&#>O>0
M?X=4[>U+^3&#>O>0?X=4[>U+^3&#>O>0?X=4[>U+^3&#>O>0?X=4[>U+^3&#
M>O>0?X=4[>U+^3&#>O>0?X=4[>U+^3&#>O>0?X=4[>U+^3&#>O>0?X=4[>U+
M^3&#>O>0?X=4[>U+^3&#>O>0?X=4[>U+^3&#>O>0?X=5:BR>:B44V8(*9#L,
M7N,AC4HDZ5;9.YWVB0DBCC%FU:F4<;'H']LJCI8A,2]C+N+`M,J[+=;<)(7W
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MR8P;U[R#_#JG;VI?R8P;U[R#_#J@KM2P`(\F,&]'_OWD'^'575BF:O$YC:]=
M(6EN9GYCETQASND9W%4ZM)B^(2%<Q'+&U:N0-BTQ&M[4M4E6JD)!Y79!+OMN
M"T+[LF4I2@@`@("&X#T"`]X0\`U$;^0II:YZ#<]<UY(3H_(Z?-"AOMD\SMQJ
MHS@DBO(A+G11AJV0AB0_-J:)A:QD9:.A5\\*2EDGEOMKB24NLESWN]73O\?9
MI2TJV.0-R9V:%W8`5H%E@WIS^UE)"PCLEMMUHCV)4F(/LVN#8PJP>D`V'N-M
MN]Z1]8[C_?2OB4MR%88E-5I$ZHU"I[<0F*22S[T2L"C2`5([S;;[DB@"3SB0
M/3B4:!1IA87\2^ZT?L`````-]@\(B(^L1$?[_15:X\2WC<?8.-MMOL&^V^^V
M_?VWZ1#?81`!VW#>N5*;!X*4I2E*5U#JPL[V<S'NK>F7'1]W*?F8Q18-US<\
M$HE[<4X)A"ZWB*;$+FO36WW<8`*5&AQ=[@$.W[U*4I2E*4I2E*4KJCF-I4/:
M"1G($YCXUMKHSM[G=:(JDC8]*6I6ZHB;^,`6D+E+&TG'VC:(W7H$XA=:%HA=
MVM*4I2E*4I2E*4KID4?96YV>7U"W)DSO(>YO=I>58(*'+N0EO1-O;5PW"%_:
M:4R\@C:VWBEW"`[CTUW-*4I2E*4I2E*4KJ&9@9X^4M(9F],W%.3N[/RXM-8-
MEJEX?%IKB[.!H#==QE*]<>:I47AL%QIEPA;:`[5V]*4I2E:NM2FI#+,DUY:=
M^#RP5-BL3N\WP1EK5AG7+B6-1J6S6)X@QU*XGC*$Q;&S+.&J100N0Y$R?+K2
MW^12N-24ECAL6=D+.Q@^R%%(HWD'@VM5TIU88(F3ADDMAMS+I^U%:A-).:U4
M41*&V*O>2M.62G:!KI?'6Q4K7*&ALGD>3QN<6L5ZQ;9'E4A5L2=>O2MQ"T_8
M)2E*4I2E*4I2M76I34AEF2:\M._!Y8*FQ6)W>;X(RUJPSKEQ+&HU+9K$\08Z
ME<3QE"8MC9EG#5(H(7(<B9/EUI;_`"*5QJ2DL<-BSLA9V,'V0HI%&\@<&WJO
ME.J_`\S<<DE,(9DT^ZB=0FDG-BJ)H5#=%GO)6G+)+O`UTNCK8I5KU#2VSV/)
MXW.+&&Y8MLCZN0JV).N7I6Y.L/@QE'6;F;(7";(])</U@-6B=ECS[%&"'8JS
M;H/FLG-UJE1U$W3C,+K@34U/)?`L;%+"F]U-QJPQR--<T>"5<8D4[1()$C[&
M@3;ZPZ0WWWWZ0$.]L([AWO1L&_T]^JTI2E*4I2E*4K6=/<_YWC'"MZ=M-A4M
MB5^GO+.D+4MEA5#TL$M3S)//\/SO!,<;7)VR"MD+K>YM2A'DATO0LK''8D6A
MO+O!W4R:\Q&<W;,:4I2E*4I2E*4K6)G#4-GC'W"BZ%].S7*XES`ZBL'ZQY=)
MXD5!++)D7,,`MF'%+&O53]<_N?;#,KOR6=>G96.-18Y&:VF"[.LD)7$$-4[<
MU9('#N(LF95LB4OGYN.X+*)DF@D`CSS*YQ-5D>9U;DAB41CD?;G5X>9')%I"
M=F:$"!O5''+5I0]C[';?=;JRX)34'F35(WY,RCD#77CW4@B9+T$-E6GECT:/
M6DK)&F+*IQMC\^13)K3/IW(,F.EZ)O-NC\56OD7C+9)F]N5R=$I=S3#2F[<W
M2E*4I2E*4I2L;9>YT[L<2I/A.Z()\IKD!;;#'*?$.*V&L#JZ+4K<,ID;2T*F
M]TD+9%$:I7)#HLW.K(LE=[47&R']@N=>[*'6=I(R;K-Q[KWS3HAU(9CC^JV#
M-.E_'.J6$Y\;L11C#,Q@#E-LH33&"C"N1(Y`EZF$NQ#R,(>)EC9^2MK0^WLC
M1(F][-?C4);G;MZI2E*4K4[J8P=DS&G"(:>^$7QAB^5YO9F331F'1UGG'6/U
ML6MR6VP:9SB(9CQAD6",DUD<1C\H)8LBQ%PBDW929(VOQ#),FZ3-R=V11UW1
MEWYP6NE>?:7-/D\,R^B0LV:-2VIS4?K#RY%6MW2/[;")AJ+R4Y3!'`R7MN`&
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MW""Y%E&1#YSDIBB01-M8WB!P]1"FZ<R)/.G6TAON9)%MCM`0#I[^XB/3OL(B
M([`.P;@&^P=`=`!T56E*4I2E*4I2E:M,IXHS"^<+=I/SBSXKE+CA'&ND;5/B
M>;93)<(45'V.=9AF^"I3"VD697+DTZ<2#F[%\A*<W9HB#@TM*Y2SIU:ZT%AY
MB/:72E*4I2E*4I2E:J=1>(LR3#A5.#LS7%\5R=ZPS@C#6MF(93R8G<84F8XQ
M(=0+5A%+CQ$#0XRQ%-7JPX_&+_8]K&"*NB%C[:9[UBGL:Q1<BDID#4!J!B;M
MJ121?1=D[)35AR.8E>\3ND;R7AUH4:F5LT-4WY*CF/6^7RAALB;SA]`1:>MY
MPG!B0318;:VQM98=>F-4XOT^8IDLXU8Y*UQR#$DMT[CD#3YBW`I&-IXKA(Y+
MFQ<'FDRR#9D#*C9CB5SF)-:V,VS+D+C]#?,'Z3$,U\I.>^XZ)6Q-1>Q*E*4I
M2E*4I2E8ASU.<B8VQ!/9KB7#L@S_`),8F(\^#8>C,DAT-=)Y)3KRTK4SW2V?
MOD=B49:@4GV*WU]=72VYM94R]0VH'AVL0M"W7!H?>-62:235-D30ED_%$]R.
MD6Y*S9J:U$97TPJRLF3]O/C4<B..8?#]-V4<SR1@AD/BJMX;<<,3P2VQ^%PV
M*66.CU)\A321O[KM]I2E*4J@@`AL(`(#WP$-P]0U6E*4I2E*4I2E*H(`(;"`
M"`]\!#</4-5$`';<`'8=PW^@?"'@'I&J```(B```CWQ``W';O;C].WIJM*4I
M2E*4I5-P\(>L*<:WPA]`=\.^/>#]_P!%5I5-@[^P;^':JU3<![P@/[ZK2E*4
MI2E*4I5-@[^P;^':FP=/0'ZP;#T!TAX!\(=(]^J@``&P```'>`.@`_=2E*4I
M2E*4I2E*IL`=X`#]U5I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4'T>C_'I_NKR?
M\-WG3A'.#BTTX[SS"=>60CLAYNX0L,7%15)C#34MQ?CO3YD95ER2P2`Q5"^8
M$4RUQDL1A\7A[8XS:4R9Y<W-X[O'7V&ICD-Y$I.$<R%J4T#8<=9E.>$OR["\
M<9%U8Z9V#$65G73#A#-^0X4UG,\CNR/@B7QZ$Q?#C,Z17*CTQ%/$>R*+2XR!
M@**71%X/(0GIG)RE1GKAG]+&GS,VJ#3_`"2%:CICEC2)B1%GO,,7QIAZZ6EM
M^&E*..O"[(3=(;9,WQF]AC\?D[:^/0O+NQ+RDEBI`A1.#^58S&W!@[ACM&6H
M/4!@O3WCYSR8+SJ?Q$^9ETY3Z28W=8OC+-,>B:9:IF;3"'QX5$/IDAB-C2^6
M.Y3U%V9C4G,;H0PO[T:20"J^L5\*7I3S%EB!8NAKM-#4.7LEYYPUA7+#A$KT
M6(<Q96TT$@HS'!X%*>Z)SFH6QXA.^',3Z_1U@A^1;8K*K<;2.6F,:JP?DX1[
M6))]-3%IQQ+B&YE#45K7U)X]TP89<7]K.D#'`+92<8ZY*S0^1TE2A&1M>)L>
MH'9^1,-RY.E>I:KBK:[W`P*'>^W4GGSA/LV:)^&@FF`\A9"SKF?1WC[@O;M2
MKMB6%XD@&0LE.>1HN^V-<CR`0[QN&1%Y1DVQ*+/TODI+Q+X[CMO6*'D6](U%
MGQ]B(V19!X;+0GC;#FC#4%(99/#,-:[G,ABP?.V?'KH\(K9#>H1HUD>FC.C5
MW2B.O+6M4*T"U&F8GFXUP:'1O;+G):2F(5X?FO"G7,#IHIU2-$>S##])VIO5
M4XZ!<MXSU#X@=\1Y1Q/EIZ7RYFQ#FEH8G].ED;3&E\]AZJ"9#9)`I<$"B/2E
M@DR1-$)3"92RO>\ZT>,`#WOH$._L(#L(;_3L("&X='15:4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E>?O\`2%="VJ'A"=.VG?#&
MF""L$D?<?:J8'GN6/$MGT9@[&CC4%BD[8C65%<ZG'.3E('=9+4IB.PIO*:TR
M9*>:K<K#;BTUUX</#HNU'<(+HTP_B#3Q"&Q9/6?5#AO-,C:YG-(K%$C#%8"V
MS`UZ0GNQCDO0.#\<J?T2!O2LYJ]`=?8J4G.9"<HJY3$K4/P:^L6?:]>&/U$Q
M3'$>7X\UL<&6KTD8-N59)A;<]JLHK<>XYBG;,M:U#A=R9C*=P;7LVYU$]P/%
M,U`86@N,<$95V)])7!-ZVL/ZEN`IR7,H%$"8GH#TL9KPAJ'5M^38JM6HY+DI
M!EQA:5L,1$J14RAH2$RME<EJ@GM%40G5F%)DJA:B.3#F#@D^##S_`*-GQLTX
MZAM(V`\CP+3AJ+RMF#37KG<LI(9*^V0R=+W!Q;TT8PI>D.E4/S0)RWN<\2=8
MICL>1,3@O3@ODYT>;BI9*+AFL7.39E;@L=;YQ5QN-]$6N"-N^=EP7WE(X'A3
M.*!NQI)<O/5]A"BXJ*XQD1$3=9>LXH$LL57.L@<34K.T.2]''?5MP<^K/+O"
ME:G=6L!A$8>L-9)X(/+^B2".9F18FW/+WF"=,;VO8%A[*M6$J&N%F+WLIG5/
MJJ^\\@T@UQ*;E#;>0H-BPDX(C7"DT?\``%8.5XRACE*^#IU7VYMU(D\YT)N9
M^2++F>^7)T<&5*EEMDM=W=@6WKDJ0TEK3I5"*]"O5IU!Q%X[*.&YQDOU7.7!
MSZ)X'=V_D+(FOK$6?)8F2'<=9!-.>FQMEDMS'E=VL[`H)0LS6H>8K"&52YWH
MD3K.YG&8XB.4N*\M'=OCL#:WZ0W&Z[8=MPX]UU^P["(;AQMAV$0Z._7.E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K'V6/Z
MK\B__D29?\LNM8]TE?\`HK::?_T"P]_\OH]4@ZA;#_\`T^,Y?_MGT_?_`#`S
834TJ4I2E*4I2E*4I2E*4I2E*4I2E?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g102226.jpg
<DESCRIPTION>G102226.JPG
<TEXT>
begin 644 g102226.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`_1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]%04-(7U1214%47TM?0D%2+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_```L(`.@"H`$!$0#_Q``?``$``0,%`0$`
M````````````"`0'"0(%!@H+`P'_Q`!D$```!`0!!P4+!`P+`PL#!0`$!08'
M``$"`P@1%!945925"171T]42$R$Q5F&1DY;2U"9!9J49(C,T45AS=)>RM-8*
M%Q@:-3A7<7BWUR12DB,E)S(W0D1%=H'A4W*Q=[6VP?#_V@`(`0$``#\`[_$(
M3GDEEG\W_O/_`-I2\,Y_@E+PS^:,<:'QU#G&Y0XXPC)9'%UYI"3"^O7?L/")
M&B)C%>Y+=ORDV86B62A?:O9I4BD,/.S`C.U0,M57#M=%QX4$G>BY(#AIS:K`
M?C^7&.1]7OK0ROPD#<.S7':I3$D*0*EX;6--(&X([M$J,'O2U"T1R43:&(%J
M&*5.I"HR+A!T$&E]PD+2@>9C+!\*`Y<8_,N3\/HG/_\`$H99>?T3Z(99>?T3
MZ(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99
M>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3
MZ(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99
M>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3
MZ(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99
M>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3
MZ(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99
M>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3
MZ(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99
M>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3Z(99>?T3
MZ(_81QA;)N\L4:K4B&4JE1@E4ID_3@=8(T:%+E>E;YX4BRNTI$J8#P)F!`J,
MBK%TFA&,&EI@$"F@0)?$`1=FW78N86FHY.G$.P./YK'K3F(-[768YGL`ZQ9(
ME!K.C"*EJE$J`[L)50)%C#,O;W#RB#@`AC,F**%B-70`(&5ME7D!=;,E_?(1
MYRD#J3S3M8MWJQ8--C77F'-5845R@,,KDL6MR!9+!JE0O7'$N:M6R5@9)FYH
MSBL7B:4+:M"9-L;G2,/SM0`#@R/5^-ODR63A=0=2-LET;48$A::5V[@X-*_7
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M.^+AHBG]0EO0[XN&B*?U"6]#OBX:(I^4Y3S"664Y3E_M0[QRGEE_XO\`#')8
M0CC%:V1UM8AF\N*I.4+X8FARS"(JLZ+:58*2)8;%Y"8J@.G9B>=[R>`'9L5D
MXPYMA*BX.:&($!=$4BA5JU5L*4=YJUTHE(D46XR(5:I1]RNTJ4\G522')RGZ
M[8\457>=BTO&B!8*BT;`1Y1?NWK5-JP<%Y@4WJ[9D!%A;-Q80A"$(0A"$(0A
M"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(IAMZNP$$W[?<]W9#W[M'=2
MG.GNK=JNNGNI2G*<Y=U3++*4Y999999>.//@%?PG'E*;(H59H*\,/<610JS1
MW30JR=7<61%VU1W4Y.Q*4ZNXHI[J<I2E.>6<I2E/)+X?SG;E*]EX8/T0*S_5
MB'\YVY2O9>&#]$"L_P!6(?SG;E*]EX8/T0*S_5B'\YVY2O9>&#]$"L_U8A_.
M=N4KV7A@_1`K/]6(?SG;E*]EX8/T0*S_`%8C35_"=^4KE17.17A@RRHKJE_T
M0*SQTTSG++_TL>+++PQWJ\([GJ9[,*^&]XEG05T*]U6*:AQ5102`[Q>34*%9
MH<D4)Q25`!`L??!%U)@8")`@MX<,NAP_>[58J_53.Y5(:$(0A"$?E54J?'E\
M/BE*4ZIS_NE3*<YY/GR2\$O#/P1\;0D/?E.=F]:NRIJG355:KHNTTU2R9::Z
MK<ZJ:*O#+[6J<JI_-*..KA37$6BU<L+2=4JNN)1,'ZEH2B,+)'2P4U9"4C#6
ME/)0GJO!J352G=02181%LQ%B0XU%!`L[UN5V==/4W!8B'*-N4#==QDXUV*4H
MQ;NMR->*^Z4UK/#(]C>!4<Z9,YI8NV;0Q-;6R:*[9,U;7<SV$$1+L325IY5N
MD<"#`>,M+)RZ"^)%X=*+"34'\&(MM%9E:TRP@/$5.0/*:;]0H_9(PP--\XRU
M'JX99G:F."BL2=IG5$:"C>=8JIP30&)[S(P,AU5?9FEXI9?'\\;6/$FUBNW(
MN+`P^W515.[7?,\QJMURG*5-%-&9"N^2JIRSG5W5&2<LG<SRY8H,_4WDZ`]H
M)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.
M@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]
M3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9
M$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V
M@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WD
MZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/
MU-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]
MD0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/
M:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>
M3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,
M_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@G
MV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`
M]H)]D0S]3>3H#V@GV1%$8CE+,O'2FGP$I9F+\//\Y_\`AKLY2R<T?//P>;+E
MCQZA_P!_#LO@GGX[++QY/]LOQ20A"$(TU_<[GY.Y^I5'JT\G@-4-&`?!338(
M@5ZS+"CA^E;NUGD[-5=$FM3$J*ZK7-=SO=5=$J:YT2N5]Q.KN>ZJR99S&S]3
M>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ`]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$
M,_4WDZ`]H)]D0S]3>3H#V@GV1"0]39994\`E++++/2"<\DLOAGDYH\.27S>#
M+XLLO'$`^4?2S<TL,X[J8B`JL<EA&S39.9'##)]WK#"HU771ZG+"D[4CN+P6
MMF_+CY+)H`9!S.A)JE5!D-;+2T]%F"86:H&)D.4QE8=C.13MN@F2[`@OL*;:
MX@C.P=&22$8)GQ2P)8&08A`2/#8R5R%:1=#4XXZ-!!`X>Z=%;K)93(P90)!@
M1EBD:/+^ZS4%%LTME)9;/!`$6=4%X.@W%%@6\!+1)G2&M4CQ!>"$BAP@&"OB
MY7KH4((&C+P:Q7;LW10BNB=ZOAE;2MQ<=8*^%:0)ZG8!-\/:H(NIV;O/MAO#
M13%JR'I.W>[]WB12*5!06G5VW,/.],:#LUTWJ:)3HJX*V6%M@F;5%Y8MFV9"
MDC^9$<I4L$`+AI>!)1)J-4:;*)(H$E'F(PC;E(J%84V%0?I9!%J;(#H_"`34
MR+A(LO`7`M_H0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"
M$(H3/^CAWYF+_9[L>.0/^_Q_Y^/_`&R_%)"$(0C37]SN?D[GZE4>L/R=/]0+
M!+_A.P]_Y5):)EPA"$(0C%)RI&.##&P;`O*V"T=G!",?,T;<N/4UAVQ;.XA$
MV2*]/'*D"@-)%&VIL>@5BNTH4`RU0J0(F4T!YV7QBD+J.3@X*>#K(H+"'`DO
MV]6V+1J+:?QB<AZ]YL&+'.,K2.P!,:3HC$#?#B$&.M"C>XH06(Q[Q@!&`Y7[
M5U5`;A*14CA%XIL"#ZN\&ME(WL:7Z[MNS=KLVN_WJ+=RNU9[NFUWVY31551:
M[Y7]I;[Y5*5'?*LM-'==U5*<I3E&-QD'XQ9W<;:YPX/57AQ6K?V<.I<^-)ZR
M()8$"OP^+(P7X9*DC,N^$5JZ5UM?6'"3ET]5;?.83$[971M+<+>T:MZ6EXM/
MB[EJ<!^/AP\:F(M^BLG<;#."9UIS%0DUS#]?;Q_D#CC0%VHZ#E:`4+O$;J&*
M;35A*K`L+SM1ACI)((80"N="1.E"F,!I0=&`K+]"$(0A"$(0A"$(0A"$(0A"
M$(0A"$(0A"$(0A"$(0A"$(0A"$(0A%"9_P!'#OS,7^SW8\<@?]_C_P`_'_ME
M^*2$(0A&FO[G<_)W/U*H]8?DZ?Z@6"7_``G8>_\`*I+1,N$(0A"$13=W#`'<
M%=W743"RH2J]O)I.),7:4[>MZZR$.R1*&JB-R0"=)M7D="I!V08U5G]^=2$<
M-""!5TPKNC;PJ[:LUV[5HP_#H+$,VC1.VSV'\J<)3$J^4+7NBUY?<2TCFTGR
M>="NH+$PKDI9&$YO21CK%@^3J1=1Q3@.5F-@S,P-M/6QAJ!GF97A@<O'7R\%
M28C[(,5=!%]8J@#0-%VK%RL,#K&7+=ZV$I%7Z;=BH37:NT!Y7)WJK==-$Z9X
MA&TPV.6YN,1LL?Y[A,3N#MX$/AX?%N'93%IRFR4:NQ(K%R1S=B$0EULNV=`G
M9.I&J;6X@C$^3BY6]-"[LGJF`V@+=DI:5FE)A>=J&M=%ZL3K08R7D8*YA>7K
M5X<G18XV2E]R4*Y*J6PEWEDUZN,B8Q53;"1Y"=-0W(]L+AL@!!X(+E*<GZX,
MS:\BD#S<,"J')#&UCR0I-*[=TQ`!AERU15;M5WZ.[JHHJG*JJFF>6624ZI2G
M/SQ0:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+I
MAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*
M9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@
M#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4R
MZ8:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAH
MBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V
M(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U
M,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8
M:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAHBF
M=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`
M]3+IAHBF=B`/4RZ8:(IG8@#U,NF&B*9V(`]3+IAHBF=B`/4RZ8:(IG8@#U,N
MF&B*9V(`]3+IBB,4DFJ2\=.1*`E/,Q<LO>9?.&NRG\_X)QX]0^60<.E+Q2'C
MI2_]AE^*2$(0A&FO[G<_)W/U*H]6GD\$NGA.`?!3?OE`*[>NX4</URY<KM2G
M577<:U,7*ZZIY?#557555.<_'.<3&T13.Q`'J9=,-$4SL0!ZF73#1%,[$`>I
METPT13.Q`'J9=,-$4SL0!ZF73#1%,[$`>IETPT13.Q`'J9=,))%,RG*<B4!E
ME.4Y3[S+P3E/+*?C^:<0OQ".=C^1KPU%.&/"^RK]-9?;=*&`TZ=?$P<8>1I$
MX-Y3KL,=E!):)V">NM6@[Z:"I,:,NBJD_22B;EFV'J,YF-^D#9U'J[E`'"Q&
MX<;F)'"AA_8MMTT?NF:7%2VN+PY?E2#U$,9Q6DY"2S21WAU9&D"6"+(XX%C3
MH&<J`38N@00:LF#!A%XQHRJSGD\<1_:K%9AJ?):N`W+./NU#G+QJ[@2VX:/0
MZZ3ZD420I'B!`(&).BHL'"!88`*'@QI;8,Z+=TNN&@$<64B\_!B`UODR'?EF
M7+4Q\C4"YR(5ZI35H2).2)/J$N,S$,"`G(I-F!C:L!KU<QY66J<`8)8S-"V8
MPM+%07&*;'BPQX!%E]F[4(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"
M$(0A"$(0A"$4)G_1P[\S%_L]V/'('_?X_P#/Q_[9?BDA"$(1IK^YW/R=S]2J
M/6'Y.G^H%@E_PG8>_P#*I+1,N$(0A"$0"Y48'<,<!F(HNLDCOJF^9)A/EP9(
M,8;UIUPEJ)'K](!`R'H4EL_2M281:TOWK:6=53Z2$5*;:HW6IY<-05L!5?HQ
MRX(,)Q$TN*MKEN5\BN'P1"@A0YA8)?VC%JVCM4E%LV1@JBM&A$0B5ZHS,=95
MU\+19D:#2D(7E-HFLW;E5@6+"69=A(19LB+%X.(MT7;%^U<LWK5R7=6[EJ[1
M51<MUTS\=%=%55-4OGIG.7SQU[\6$W^:G'FLA*':1NS0U<KDH,9S7X%EXRU:
ME+'4:`Z9,.WC@FJ4<U."0EA.G">7JX433AVI/4N*MA$0>IG1@*5V;ZU,S0PM
M;ASD&*3[^#!!&?M]R',,'[QTK^X34#.^"6-KP*-R:K6^K+UKN*ZP%_$?<94:
M:5'>45=<.\4WKM$S.L3..S/++DEE\>3P_P!\;8/NG%NNW(M`EXJW.B<[M0PQ
MO@JZ*\OVM-%%DM'2N4SIRSG557;G*?@E35*>65!G*JV.1\>&]@0SE5;'(^/#
M>P(9RJMCD?'AO8$,Y56QR/CPWL"&<JK8Y'QX;V!#.55L<CX\-[`AG*JV.1\>
M&]@0SE5;'(^/#>P(9RJMCD?'AO8$,Y56QR/CPWL"&<JK8Y'QX;V!#.55L<CX
M\-[`AG*JV.1\>&]@0SE5;'(^/#>P(9RJMCD?'AO8$,Y56QR/CPWL"&<JK8Y'
MQX;V!#.55L<CX\-[`AG*JV.1\>&]@0SE5;'(^/#>P(9RJMCD?'AO8$,Y56QR
M/CPWL"&<JK8Y'QX;V!#.55L<CX\-[`AG*JV.1\>&]@0SE5;'(^/#>P(9RJMC
MD?'AO8$,Y56QR/CPWL"&<JK8Y'QX;V!#.55L<CX\-[`AG*JV.1\>&]@0SE5;
M'(^/#>P(9RJMCD?'AO8$,Y56QR/CPWL"&<JK8Y'QX;V!#.55L<CX\-[`AG*J
MV.1\>&]@0SE5;'(^/#>P(9RJMCD?'AO8$,Y56QR/CPWL"&<JK8Y'QX;V!#.5
M5L<CX\-[`AG*JV.1\>&]@0SE5;'(^/#>P(9RJMCD?'AO8$,Y56QR/CPWL"&<
MJK8Y'QX;V!#.55L<CX\-[`AG*JV.1\>&]@0SE5;'(^/#>P(9RJMCD?'AO8$,
MY56QR/CPWL"&<JK8Y'QX;V!#.55L<CX\-[`AG*JV.1\>&]@0SE5;'(^/#>P(
M9RJMCD?'AO8$,Y56QR/CPWL"&<JK8Y'QX;V!%$8B53,O'=T4$DI9D,\,CX;.
M>7-;V3_R#YYY)?-_?+QQX](_[_'Y=?'_`+9?_NBDA"$(1IK^YW/R=S]2J/5J
MY/`0I*<`^"B0<K)[MF6%'#]*W<NG0NU<KHDUR9E;JKM4D=VFW75;E15513=N
MRIJG.F5RJ4LL3&SE5;'(^/#>P(9RJMCD?'AO8$,Y56QR/CPWL"&<JK8Y'QX;
MV!#.55L<CX\-[`AG*JV.1\>&]@0SE5;'(^/#>P(2$JK++*3D>3+++.1\-G.4
MLOAG*7,$LLY2\4LLLL_!EEXXB1C*;-<.^VCAMD?)%#.3A\7J(MD:_2-#IK1@
MG2#VK)G;'F8I..:4\ZIX1:&6@Q?0%+APAM:PL[(VT,60D&/G:#Q#PRX2<`C!
M/PA5FC61Q`8:7S+ZE6F4P6/$Y6(-6)11VU,07BXW3Q.HE4[+NX?548WP-N0T
MH!IA57%D'F6U5%X<.$O&8,5F),``(U`C"PR"V!Q>8A!($<"%6J;P86#&6+@8
M4&$6:Y3HNV!`>[<LWK=<ITUVZZJ*I3E.<1ZP_P"$+#;A;+*"EA6B2C<`[!3;
M3H+FBV8C194EK`ZX:!$>2&)\8&YD1HLO,KMT>6(TG&`4L6#+M8D`4![TYUQR
M1N\.#&-,J#-9-RV"22"D-"TQ(YF1,7=XJ*B`Y4@A9GB<3`6N[=`HY-'RS%BE
MD?)M(A2,B/%<)OJ<V+QA[=J'Q>V$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0
MA"$(0A"$(0A"$(0A"*$S_HX=^9B_V>['CD#_`+_'_GX_]LOQ20A"$(TU_<[G
MY.Y^I5'K#\G3_4"P2_X3L/?^526B9<(0A"$(CCBZ;P]=G#8\#<)Y.BUD,6*/
M%D@Y$EJYNMB;KI.B1(2:L0I&X]@/?O((_6B6H.$P1+&W4!N)TV-09I0<D%0>
M1Z6]=Y9X=\2).`8RZ1<GX_;;X>6B'XU7+2V&Y78N&_Q*.N9JY<X4SIFD"F0)
M6I'R6MPL5ZA7RK5;G)0J0[D.21-VFB]4K6\?)%4*8S2X?L?L(5NLE<.+,DKK
MWZ%0]R<91N2MR15TWMW[2A=,G0)*$60BH\E:NVKELW5X8RKJ-9![ENN0BH=*
MS<IJ[BJ!+5.)CY:S'`VC(8AG$91_FRQ&,H]KMW@[5,\9M0H,*BB:$[:P&#([
MYB,<E=B75:Q6TN=0D"Y4*$O(U>,6Q+(SM6"\I&B2`NXK@4QF.CBCQ3O8F5D\
MQ4W,D"6J(ZJP".A@S<U@<3C?HLQ65:7;)U3!UW(<R^`>!O#\N)!8\8H6]:H$
M0!U$JBY.BSPNK*`E"DS(1\;@@/9G*5Z_9M3JE.=,KEVBW.<I>"<Y2JJE.<I3
M\$YRCYY\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KW
MX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"U
MP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%K
MWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"
MUP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%
MKWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\
M"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O
M%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9
M\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+
MO%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX
M9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWX9\"UP+O%KWXHC(:#
MF7CI2%A9SS,7X)"+4_$&NSG_`-_YI>&/'1'_`'^/_/Q_[9?BDA"$(1IK^YW/
MR=S]2J/5_P"3K&!*,`F":FL4'IJEA/P^2G35?M4SE.35I>4Y3E.J4Y3E.4Y3
ME\TY3E/PRB9.?`M<"[Q:]^&?`M<"[Q:]^&?`M<"[Q:]^&?`M<"[Q:]^&?`M<
M"[Q:]^&?`M<"[Q:]^&?`M<"[Q:]^&?`M<"[Q:]^(0\HPB%>\F##$DU#4DJB7
MKE':#`6"MO$,Z];.J555WE$4&5"2'."`NT&B23BU+2HU(E->!WRTP.T>(4A(
M4FQ6-&VS,%C/P/8.:V6Q3MRO;?(XL]@Y#%B?<TN,G^0F-JE]S%/!31)5V9)J
MM!W$HF*ZR99";-H)</KM=<BFLL!2$`+5P=1=#]@$287A!%?-4W07GM^^57#`
MBMS,Z0A6<7;H.H25T<\APIG0&`F-=5BGG.R#,*+`>]G=L*,E139NXM\/"0Y3
M,L>-0+]]V8P'$HA=%1E86[D('$=B`<E<7BU,$JJNM$U:02BHPVMV2(UNB54'
M8,4<W@RH-+DKPI;K*M/GZR6-T2`N\U+.O2Z#\M/BGQ+-JUK..6S3+.JSI,F&
MJ<DX=FA1"'C4K8G2Y,QZZ,D"V5VE!%U;1)\0A$L,3HLVNCSXW.S^HD'E@,$/
MR`Q0BRLL'UT5CBX"-KMTSHMUBP@<3711.>6=-%5ZW7.FF<Y2G.FF<I3GX9RR
MQ2:.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+`]1#1Q/;")N%@>HAHXGMA$W"P
M/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+`]1#1Q/;")N%
M@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<
M+`]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(F
MX6!ZB&CB>V$3<+`]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81
M-PL#U$-'$]L(FX6!ZB&CB>V$3<+`]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VP
MB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+`]1#1Q/;")N%@>HAHXGM
MA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+`]1#1Q/
M;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB
M>V$3<+`]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'
M$]L(FX6!ZB&CB>V$3<+`]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:
M.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+`]1#1Q/;")N%@>HAHXGMA$W"P/41
M1&2=3\B\=.1$3RGF8OPR+`4I_>UV7_T/P>"/'@'^`>/R:^/_`&R_%)"$(0C3
M7]SN?D[GZE4>KER=Q"1WL`V"B[>)BF[=N84,/M=RY=+@=RY776UB7JKKKKKL
MSJJJJJG.JJJJ<YU53G.<YSG.<3'T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6
M!ZB&CB>V$3<+`]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.I^4Y3D
M1$TIRG*<I\U@LLIR\,IR_P"0\<I^&46-?K#D3O>'+3$`Y+N,<XA#:K#)]W6*
M5P1)+HN+[MZ0B\2F80](U8@5XFKHF6=22CE(A9)T,853-2TM`&^0?*.J#P,.
M7(^!F6(C'SBXQ0IPO%W1`9L%?98!G&U-K%RGP`5V38;F2:-0.*5RGW5`M,*U
M4C46<!+EP"H4J<`JZK$\B%FS9#6;0>Q;MV+%BW;LV;-JBBU:M6K=,K=JU:MT
M2IHMVZ**::+=NBFFBBF5--%,J92E**C&8Z<'^)APW`:=@\1C3.PX[74W[ZV1
MR+5H`W/"HO"FLR(6=A@EN=$CY.`CZ7,(U2IRLX3X(]G23"C.T95T!:KAMWB/
M8QV509HQN7/22O4A66&)Y,M)C'O]1JGR=2"$8=J1,":[5H"L4T1+((*1Q\I$
MB*/"(C5P:^F#8Q!GMJH!*]L(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0
MA"$(0A"$(0A"$4)G_1P[\S%_L]V/'('_`'^/_/Q_[9?BDA"$(1IK^YW/R=S]
M2J/6'Y.G^H%@E_PG8>_\JDM$RX0A"$(1'G%:B%DX^']QD6A#E3DAZ>%Y39OW
M42MJFT69NF`JE)!ZY1Z1<>W.U?;U3KM#A%$B2%=!!A6.2!HH`J@`'1&,+[!R
M`Q+812[%'3B(P7(2ZR;M836:PXL@^C=N,+Q!/$W"K4^*$+.DK"M0VZ"2R,>M
MY5&O03+TW2UP3M^'",;)P&NW3).$0XXM+A3&@[/&8`09F!&%QA8H$@3`*(`C
M`USNN]B`HNS6&$6*^YG35.F]9NUVZI4U2JG*J<J9RGDG&$3$6DTR]J\4+Q8<
MSA"D*QPV8),7F'+!E>02L301:.R]SLMV$[DG0Q*1F=P4.;9HJ&8!E*.!5!+G
M/B_&JL])"P$0((M/U5%[#G<#7S[^#!%[.5900#"`\ADO[9)(574%8X)@4;DD
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MU)H]INE!<,"\U#Y")AZ\/N#S`@9--C18]XP?)U<F_@&+DD1O20FRB8!\!+RN
M>[U*S1-H.7HU+$4L.#(`$I61"2JZKU"LA)R?&,DN$,4F!);`11FPZSV&C,L+
MSHM,"<V!AS$K-0(LM,@`NU3?"C0`\/<"C`8FS7*=%T.)#7;MB];JE.FY:N5T
M52G*J<12:+D_\"N'];@'+8K!IA99IQBL"8EA:O6M8-KD$LP!<;@^;S4""4Z7
M3!8=!0ID!_V,?8L#:+8L+E#B*;EJ<Z)WA0S#,RVBE/EB@&Q1"/5"EM"0YR>)
MY/%Q88"08XY%*0P+[5X-9HS`L,E./,52:%9;2#+C-4&1BI!X42>#Q9A>NU"$
M(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A%"9_T<._,Q?[
M/=CQR!_W^/\`S\?^V7XI(0A"$::_N=S\G<_4JCUA^3I_J!8)?\)V'O\`RJ2T
M3+A"$(0A&)WE+,)F"91(=?8M7TP:X;<2[O(Q"(EO4P-Q!WT\F$L%+A2^NE"3
M#JUR5(4GY<V[>D"C<@Q42X6%!&9B"I,!AXRH"9UEI<"IQK8#FP0S/8Y&-M6<
M$')*86ST\,<1+:3/<*#NN6LL0`Q1IEKK2R#$(%.#F%:4NLHM9-_79<X(='AF
M<IXZ;TS2YV'I*5&8)4.;=HN,>.%]^G?<#&1RCS*N"?D!RB\.KAX="QI`Q$DK
M2>%$R9=;#V2.><EYX+YS.!ZG-[1Z:7Z:CB^("6;]BU8M`"4KM]\M78Q8#<6[
MRXC<7KZI9W'A7#0G*1)U2J"?D\GBP<R91R4NUXM9A4BWSTIQ^C17G\GZ;^_0
M5WK!V>HH`'+2U9*VR2GML@M`2,"<9JXI!`\$$JII%"PH:JN4ZJ*1`BS9JJIE
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MOP3KHHC(Y*9EXZ4C,NG/,Q<_`."3\0:[/YKWX/\`Y\$>.T/^_P`?^?C_`-LO
MQ20A"$(TU_<[GY.Y^I5'J[\G:;%=K`+@GMW#$!;KHPH8?::Z*Q@:BNFJEK$Q
M353535=E535353.54IRE.4Y3E.4IRG*4R.>BC:A=OP3KH<]%&U"[?@G70YZ*
M-J%V_!.NAST4;4+M^"==#GHHVH7;\$ZZ'/11M0NWX)UT.>BC:A=OP3KH<]%&
MU"[P^"7^W!/'/Q2^[?/&.''+:PHM[6N'L?\`QA6,+-ZXT)0VJIO+)SD3)IU$
MWHTT<,8!3JPP^.N#4K:.O6MAAPKR'-KZ+,5T=E@(:ET:=%-5TQMBHS<GJ[)9
MB!Q!B'%)>3W))(]*-*5MTU_*=V,,Q)A*N.`W1>$LU$;4(QH7E%U8DPS:AP84
M'H^=)(2:M28TTTT!2E+`PH,/?SE1C\8[#>\[78J^4)?D>);*HAQ2G#)'K3!`
MAXJC4W)!S.,87-'3:<4KNI0@!A0IX9%8=04TI=1'5X*7WKQ95=F+MT#KE>U3
M)/:OWH:+$OBH2+)H-UF69ARFE3Y$Q2V6SBD9L/>4];<V<E2"E@M4"UYN#2]V
M32)2E'-_?39Q>*A!B=&Q\J#0RM%5(2>D4@@`"%U4U"@@4351*=-%0@/9O54T
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MNW$)U,41D3%,B\=.1872GF8N7@`A)>,-=E\UG\'_`,^"/':'_?X_\_'_`+9?
MBDA"$(1IK^YW/R=S]2J/5WY.TI*[N`7!/<N%P"Y77A0P^U5UU@PU==5536)B
MJJJJJJU.JJJJJJ<ZISG.<YSG.<YSG.<YD<RE&RR[<0G4PYE*-EEVXA.IAS*4
M;++MQ"=3#F4HV67;B$ZF',I1LLNW$)U,.92C99=N(3J8<RE&RR[<0G4PYE*-
MEEW@\,O]A">.7BG]Q^:(J/%ATP:4.Z68U,0*#9FZX[5H4L1B9>EYK"4K!M,F
M"Y1'RAMBTN>+BJ1$@C08<J@PSY4`+I>=BP]0<MD94@[<PUR0+=.@V3MIBRMF
MH<)#.8C15V^'#*]OE<GULFA5X+*FH19L*%-&)J5W[H:5RB=ZS0,JN695T3N4
M44U4SGS8,*##`U@8#$610059M"0HH-=HOAQ(>_;INV+]B]:JJMWK-ZU71<M7
M;=55%RBJFNBJJFJ4YVK03[M`Z"W=EN&^<!/*Y:L4H2-)NX0$@FZ,$H-3*0AM
M*8F(3Z]*Q2"LFPLAO63*L`'%"!`0/?L9[0&N7K=NKC;8XI&!>147D<V;F$*M
M/Y$1RJBP.7VS2T"5:33BHT)42N0)T/+P9&XR13RPJL)<_5*",E(0$I^+`%1D
M8AA9@`MBK_PA"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(
M10F?]'#OS,7^SW8\<@?]_C_S\?\`ME^*2$(0A&FO[G<_)W/U*H]8?DZ?Z@6"
M7_"=A[_RJ2T3+A"$(0A&)/%0V.#)\L9:%;G'P%;9:)XL:HI5.%-F7^%EM;*+
MQ?7%"LRQ\505HE6WK"!=1VT<0S;(LLE*A#*(Y0:'40@Z2A0"#JQ6&=4575PW
M8>42^Z(8[DD3]AL,+[O77)+8QTIAQM)@`EDE@QL@15U9/*IV@;VY4@T@_12>
M7B-"89W,4">+5"-4#@*D%3)3)(G4M)!V`R4G+D^4%9$4!:`)43%P$I+`5NJY
M7;!EQ:%M`@(6BN]7<NUT!@EBS8IKNW*[E<K<JJZJJISG/!:2ECB'V(;^$,D+
M/WAM#M&R)8(K;"HKO]Z,P[B&?)V!P:'N`;E,JZ@XV2FNEE0.Y.B?<B)6[E--
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M];0^5WT=^MHTSJ5DO!.I-RG^"<S7IAW:K_WDW_Q&O3#NU7_O)O\`XC7IAW:K
M_P!Y-_\`$:],.[5?^\F_^(UZ8=VJ_P#>3?\`Q&O3#NU7_O)O_B->F'=JO_>3
M?_$:],?LIJV?AE-.3E^&4S:<?ORN^COUM#Y7?1WZVA\KOH[];0^5WT=^MH?*
M[Z._6T/E=]'?K:'RN^COUM#Y7?1WZVA\KOH[];0^5WT=^MH?*[Z._6T/E=]'
M?K:'RN^COUM#Y7?1WZVA\KOH[];0^5WT=^MHHC'2WF\=ET>R9D,\7.N7+FM[
M)X_!X\F7Y\GB\.2/'M'_`'^/_/Q_[9?BDA"$(1IK^YW/R=S]2J/5GY/'2?\`
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M26CDJ$A#=W'.6MN_<)@P&M/IRLV#"\_L<`3C4M>CU8L%XDVY0J87#A7@HE?+
M)/)(@)54N!`"CO8`0L%"6EX8W4U\#:RV@-X[&#K@.U.=H-5:MS[B/BE&A:M"
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M4CT\KR8K)[\B8B)LT`BD[;'"+'>R,M+K5_O@JJ=WO@BB[=IR]Q173;^UC)1"
M$(0A"$(0A"$(_)^*?]TXZSF)7%IB52F(1ZDPFWI6Y*GR!R5.5$I0"$E=(,M+
M0@SO88&&INE5VY38L4?:VY7+MRJ4O'7.?ABR7\M3%?\`V^.#O1/V-#^6IBO_
M`+?'!WHG[&A_+4Q7_P!OC@[T3]C0_EJ8K_[?'!WHG[&A_+4Q7_V^.#O1/V-#
M^6IBO_M\<'>B?L:'\M3%?_;XX.]$_8T9Z>3O<1<.AAR+U2X2H-5>HKJT6P"X
M<'-8>X-K!%YK;L@@TZ@P<+:[T&M3G;M2E:E5*F?VU54_#$Z(0A"$(0A"$(0A
M%"9_T<._,Q?[/=CQR!_W^/\`S\?^V7XI(0A"$::_N=S\G<_4JCUA^3I_J!8)
M?\)V'O\`RJ2T3+A"$(0A%LW29ML'J(:$TZ*)(ED5A[U0LMF:A)R,R$QJMSM4
MG"8/P=P*?I0^L6ZJJ0I^F30I.0DY]T%'VJI2G*.C:X8W.9!R$O-L7_5AIA\O
MJ)SE6X31NR%#.,KKZB7(<T-"XP2+VF<J'$N%@18F%XX.R-Q1R[-3'.0TRQ9D
MQ>3\P&\UXTU3R4SGX?!++/N93G5*7SSIIE35.JJ4LLY4RIG.J>24I>&,)^!+
M%`^#W8S'Q1;_`+JX@&36A$GU:M$MR?+UX9VB;PI`--?6A6E4B\S3XA$II4>/
MTCB6FT#)U89`EU*HH7JQ$`5(FT^!M)@MC-E%"+-"P!710.,0(*NY3.NW0+%A
MPU==$IY)U44WKE$ZJ93G*4ZJ93E*?@G/+%)I&GMNDW%`/7PTC3VW2;B@'KX:
M1I[;I-Q0#U\-(T]MTFXH!Z^&D:>VZ3<4`]?#2-/;=)N*`>OAI&GMNDW%`/7P
MTC3VW2;B@'KXZUG*;B@PO%<=W@@BP*LS0*`IE=#W;=ZU.J00UG.4KENJJF<Y
M2JIG.4IY92JE.?CE&/N$(0A",[7)$&1<`;]YI#AX(%.M?)ZJB0L58#SKIT3M
MTY:97KE$ZI=U35++++++3.7CE.,OND:>VZ3<4`]?#2-/;=)N*`>OAI&GMNDW
M%`/7PTC3VW2;B@'KX:1I[;I-Q0#U\-(T]MTFXH!Z^&D:>VZ3<4`]?#2-/;=)
MN*`>OAI&GMNDW%`/7PTC3VW2;B@'KX:1I[;I-Q0#U\-(T]MTFXH!Z^&D:>VZ
M3<4`]?#2-/;=)N*`>OAI&GMNDW%`/7PTC3VW2;B@'KX_*E&GLD_^?2;Q3_\`
M-`/X/R\=2O%C=MWL3K_7;-RB[:N.NKJ[=VW73<MW*)CO!5173.=-5,_FJIG.
M4_FG$?80A"$([(O)>FY4"PK%=H89EX2[I\X,^]"AH8/<R5'%JJF?<7;M%62=
M,Y52GDR3E.4Y>"<HR):1I[;I-Q0#U\-(T]MTFXH!Z^&D:>VZ3<4`]?#2-/;=
M)N*`>OAI&GMNDW%`/7PTC3VW2;B@'KX:1I[;I-Q0#U\-(T]MTFXH!Z^&D:>V
MZ3<4`]?#2-/;=)N*`>OAI&GMNDW%`/7PTC3VW2;B@'KX:1I[;I-Q0#U\-(T]
MMTFXH!Z^&D:>VZ3<4`]?#2-/;=)N*`>OBB,E$GYEXZ4CTGG/,Q?@D9@IS^]K
ML_\`Z_X/#'CP#_"/'Y-?'_ME^*2$(0A&FO[G<_)W/U*H]7+D[CXCLX!L%%J\
M<E-J[;PH8?:+ENZ8@[=RBNAK$O371717>E53535*=-5-4I3IJE.4Y2G*<HF/
MI&GMNDW%`/7PTC3VW2;B@'KX:1I[;I-Q0#U\-(T]MTFXH!Z^&D:>VZ3<4`]?
M#2-/;=)N*`>OAI&GMNDW%`/7PTB3\YRE(])ISG.4I2YT!99SGX)2E_R_CG/P
M2C>80C;S:@UN%9E01WR\*=5@!M)0)-@@D>5AS2H-=D7WS$"#&EHL8`LC)V;@
MP*%,`(D0&INV;`P+=KHOVX1-*Q3XJ]VVIQ%8M0K&@'<9EHG&:I)%;`C%X;)$
M2*>$Y;LU<Y9WSIPR=.J,`".;;4HX(F&[J!G0=)4W5`)-ELMS`44#":=L?&X'
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M=WM>Y'Y4!!9)_P"QA?%/_P`/:_!_]D=1[%I*5.*#$!*4I2E)V5?*4I2R2E+/
M_%*4O!*7]T1[A"$(0CLG\EP'#WL*97.[8LW9R7[ASE.Y:HKG*<SBS*<Y3JIG
MXY4TRG^&5,I?-*,B^8@M3"[O:]R&8@M3"[O:]R&8@M3"[O:]R&8@M3"[O:]R
M&8@M3"[O:]R&8@M3"[O:]R&8@M3"[O:]R&8@M3"[O:]R&8@M3"[O:]R&8@M3
M"[O:]R&8@M3"[O:]R&8@M3"[O:]R&8@M3"[O:]R&8@M3"[O:]R&8@M3"[O:]
MR&8@M3"[O:]R*(R!`Y%XZ<@@64\S%^&0>U+QAKLI_P#<^>7@CQT1_P!_C_S\
M?^V7XI(0A"$::_N=S\G<_4JCU?\`DZP82O`)@FJK"AZJIX3\/DYU56+54YSF
MU:7G.<YSIG.<YSG.<Y_/.<YS\,XF3F(+4PN[VO<AF(+4PN[VO<AF(+4PN[VO
M<AF(+4PN[VO<AF(+4PN[VO<AF(+4PN[VO<AF(+4PN[VO<AF(+4PN[VO<BJA"
M/R<Y2EEGXI?_`._^9SGX)2\,\DI1%=GL9^'Q]501I1N5B)-!BT1ZC<5L#,<G
MCTF3COMXCU&7I%6+EJ%":`0Q6NDRG5&;DP(Q'DXBNN8`_3*G!AQ:/5*;4)K*
MF$(0A"$(1UFN5`_K9GG_`*`;_P#93:,>D(0A"$9Y^1]_[/GI_P#7Z>__`(C9
MC,3"$(0A"$(0A"$(_*O%/^Z?_P"(ZBN+7^M#B!__`%95_P"WQ'J$(0A".RKR
M6G]5(K_]?N%_^\VHR-PA"$(0A"$(0A"*$S_HX=^9B_V>['CD#_O\?^?C_P!L
MOQ20A"$(TU_<[GY.Y^I5'K#\G3_4"P2_X3L/?^526B9<(0A"$(0A$?\`%@D%
MPX.%W$@@FQO5AG)6S"O$D&]%6A=)?<#+E3-RI21)7[8ZJJFD%<MJ`<7U4"IU
M4R#UY+TYRE1.<L#>&Z=+B+#^#8$+4!YU"6$PG/"L7P)@%@+8&M>WR6P9IO#$
MHD@NB^BY4*3IG5B5-R!%33HVW1=$*YOU/1.FH<B3#-.S)+Q2R_@C;!]HXN5V
MYEHXO"VY43E=I&%U\;777E^UJHKLF0&5NF5.64Z:J+DYS\,JJ92R3H,V56V"
M/@(WM^&;*K;!'P$;V_#-E5M@CX"-[?AFRJVP1\!&]OPS95;8(^`C>WX9LJML
M$?`1O;\,V56V"/@(WM^&;*K;!'P$;V_&/+$=R=-G$:Z`QSS=X!27&C"(A(ZB
MDL0P4P"46R*R)M4":1(Q36K\[@F8FJNY;G1W%ON92IG5*<YQ8C[#H2_C`G7Z
M."O]ZH?8="7\8$Z_1P5_O5#[#H2_C`G7Z."O]ZH?8="7\8$Z_1P5_O5#[#H2
M_C`G7Z."O]ZH?8="7\8$Z_1P5_O5#[#H2_C`G7Z."O\`>J)L85,)0O"J0J\B
M(G&MJ^VKCTO/+XDX2$BVX"N`"J17(-9M@5)=HNV[M%--ZJY<G3737*=$I3IG
MEB5F;*K;!'P$;V_#-E5M@CX"-[?AFRJVP1\!&]OPS95;8(^`C>WX9LJML$?`
M1O;\,V56V"/@(WM^&;*K;!'P$;V_#-E5M@CX"-[?AFRJVP1\!&]OPS95;8(^
M`C>WX9LJML$?`1O;\,V56V"/@(WM^&;*K;!'P$;V_#-E5M@CX"-[?AFRJVP1
M\!&]OPS95;8(^`C>WX3"JJ<IRYX(_#+)_0(WM^,6[H\E<7N@Y"Z<<:^!D4#%
MRJ#53B2L(WX`2%+[QK?[_6$#B+ZHIO7K5F?VM%V[33<KEX:I2G'`_L.A+^,"
M=?HX*_WJA]AT)?Q@3K]'!7^]4/L.A+^,"=?HX*_WJA]AT)?Q@3K]'!7^]4/L
M.A+^,"=?HX*_WJA]AT)?Q@3K]'!7^]4/L.A+^,"=?HX*_P!ZHR$8;</1IAN;
M(,V9*N0BH!ACT^/)&QHE:P`JNX?"Z!=P-,,#45RQ3;#543HMW)5SJN4U9:Y2
MG+PW\S95;8(^`C>WX9LJML$?`1O;\,V56V"/@(WM^&;*K;!'P$;V_#-E5M@C
MX"-[?AFRJVP1\!&]OPS95;8(^`C>WX9LJML$?`1O;\,V56V"/@(WM^&;*K;!
M'P$;V_#-E5M@CX"-[?AFRJVP1\!&]OPS95;8(^`C>WX9LJML$?`1O;\,V56V
M"/@(WM^&;*K;!'P$;V_'Q$`%2(L7[%1R24RO6;UF=4B`;.=/?;5=ONI2T@R3
MG3W7=2E/P3G+)/P3CJ4W_P""8(N_?OWYXZ%O3._?OWYTR85*SE3._>KO3IE/
M^,7+.5,Z^YE.?AG*66?AG'R_FE:*_'I6_P"@1*_ZC0_FE:*_'I6_Z!$K_J-#
M^:5HK\>E;_H$2O\`J-#^:5HK\>E;_H$2O^HT/YI6BOQZ5O\`H$2O^HT/YI6B
MOQZ5O^@1*_ZC1^5?P2I%3IJI_ETK>7=4U4Y?XA$KX.ZIG++_`-HWS9<L=H9@
M6</F$8MFV/+EB6J,`SS7(-L`:A')6\7C3T*A4R6IH.<"P`927PP(28V2Z@5?
M"![UVR'N7*K=N[<IIE5.[F;*K;!'P$;V_#-E5M@CX"-[?AFRJVP1\!&]OPS9
M5;8(^`C>WX9LJML$?`1O;\,V56V"/@(WM^&;*K;!'P$;V_"0959993@CR999
M92(1LISEE\,I3Y_GDG.7BGDGDGX<D_%'(H0AX_'''BE))8@,SX[(TV0DYPJ1
M5@:IC4K)RTN,E$-"VIV`PL]'@PM@6<"@]B<[-@297A5ZS:G.W;KIHG.4^0PA
M"$(0A"$(T=\HR]SW=/==UW.3++_K=SW7<?\`W=S]M.G_`*TJ?MLF3PQKAX_%
M"'_]>.$(0A"$(0A"$(0A"$(HQ1@!!56*1@P*$J%"*`@60D1:L3$BKN6=L,'E
M=KH[^(KE*<Z;%KN[M63P43BKIG*J4IR\,I^:<O-/+*>2<IRGX)RG++*?@G'[
M%.+%A0`:\,&B;`0(&MU71`H5>M!P]BU1++5<O7[U=%JU;IEX:J[E=-,OGG**
MB$4P<8$&3OR"B0XF841<""96+]J],.*LRHJNAK\K5=<[(BU*Y1.Y8N]Q=HE7
M3.NB4JJ<M3"$(0A"$(0A"/R<Y2E.<YRE*4ISG.<\DI2EX9SG.?@E*4O'./RF
MNBK+*FJ54Y2E.<I3E.>2K+W,_P"ZJ4ISIGXJI2RRG.4:H0A&VT')3<N!;-!F
M75W1HL<`!VJ!P6JX*&EDA$S$&&HE>G7?%`)!!,QH>S*N\$D'OS$6[<K-WN-R
MAX_%"$?"X)#VKU@/=OV;=\5.Y(-9N7;=%T1.S;G=NRL6ZJI5WIVK4IW+DK=-
M4[=N4ZZ^YI\,?>$(0A"$(0A"$(0A"$(0A"$83UU.:2Y8I]%NED\EA:P37)!)
M]<$<CRU=!EHM6`,2KP!;0PV'%@0296*AY:3%I$9FP$/>-ZR(+8+Z*[@<,'L4
M661O*<XQE4VC,K%5(K#TB98P.2C>;'4P8A*67!6!FV#F,HWK,K$[('0`'Q\1
ME2Q1RL#/<0F*<"ID01G"5$D0\B/#%7V1EL[IT'_*/XI&&P$LD]A[_$HOE66\
ME^18V%*-4="R.5R]JF3Z`(ELIT"`;U"*$6K6T*PR-#CC19XFE,7GC5@5PJD\
M26TH4VJ!H.J9X[&AB`=178BB3"LU[;*\?A3-L,I2N6_<Q67DJ?.<8O@W[?OH
MM2M*+ZP:V4TV=IN6,<8B/2-2*=,+@O7ZVLG*5N%Z5+BKGP?R'`J[S^NJ_/*4
MD[L*])'R,9'&C4S#4DI$FCDD&)M)`,-^'5PP`2Z('*@Z"BK0B3BBQIQ>S2@6
M8JX4>&M@0!(A)0G2?)9"$(0A"$(0A"$(0A&FN<Y4^#+EG533X/'*555-,YR\
M?AE*<Y^+)X/#X(P>\EP2)O&:C<3>*K$ZF$^ZCO+;&+B@:6VFG,)RU8`\/S4X
M?W5/&D;QA$2G%%8'%B%+"XD3NFRTYJ*24Z72W69HJU9=,;]PHF"Y<$6S\8=<
M2[9\FUA$3[-WT.3873+$:5K?$`IG74AV6$9?BY3J)7J&KK3XJ^9FXFTB'"-*
M$"<FAH)$VE`5%U:OOB2ZW>LC?HR?*0.BXU.`[GY`H$)7BFQBX[\*2YI)Q"EH
MF04X2:<6=:9622YP,1&2\L98:0=!T0GTQMDOK5U^H"<=[*;50W&CC;QQ'&,_
MDS.4"3RY)6Y3"[:)E6W4SA8;50DUJW>)+#<]4WN)9@TFN4LXPX=95J7H*`A0
M);_$0@2\`BUF9\^WB6P'"6`EB[D84/*.ODS;MXEV">M`-8:N4D7%P-D#!B6B
MK7)D1FQ/CP63LHU,$2[`*<4`-3Q6M)?9!PSPW,$U?2A8Z1?HT4DA*@CDU$6@
M/.$WC<Q,WU>V.'=P&A3;9/R]C]O2DFF7BP(#TI;Y98<63:U,NPIW^MM'87YJ
MNB50T7UB3-%8:0Z<D%4,6`8V7(=:THX-:++FQ\C$5F)(UN-0F-R]+%1J6<J+
MC["&)8AP=\O1P,70\$JKM"9`"I4B0!1=G7(4'`WY57`=5^X&G>$TVJ15_,9"
M$(0A"$(0A"/G=MV[UNNU=HHNVKM,[=RW<IIKMW+=<NXKHKHJE.FNBNB<Z:Z:
MI3IJIG.F<IRG.4=;'#4_RUPCX=`X]F6Z;$\K>WEZ<4V%53!E6..TW:)T@XV.
MMZVZ3H\BN)@L&SNB4@`*R0F)@AA144D";#]Y+BP=0"!D]Z[P+E(<9R5-3.TY
M:"PR#R1B^4T:'D]<0`Y#W76"&3@V<1Q@Q]#:.2SA:?G`P,W]Y"%6(9`B5VGU
MT:.#;6!@4*X$G3%)!K1,8&>L]Y2_&"57E\KPS4X;AJ`:?E5P/)RJ=-W%.Z(1
M9*LK=%1,\@FB<!/JG,!)&FC!.JYX2`U<<&:))1ACQ/6CDN2P4E,24O,%5<A(
M\H^]I60KEM'30S?G&(Q,<HN-P"$QJT)"M#!NE%=JPYD>+<.Y!>WZB5NFH@60
MLR9&A89H:2\LU*%;$/?"Q3%9*:U4E=P6RQE8G'!<!IL+J^9U(,WB!<`1BC6A
MJH%V4&IBASS#1AT6#=(PD>5*M26K^2J!&3XF;RM\7EK7J]RPIHW5L(X1B>FZ
MG"D*:"+#')R:B]"H1-<E<TBH8]E3LZ7>,SEIBTM6MD(8#35@U:V[QXN34RDQ
M.<%8*982J8AYW08P>.S$PT)$4E,BJ=0R[>"2-->4[Q&5GAT@Y$;%E"I7&#K'
MH^B'')"PKG+3K*NI@_/$.#"MTJ''`J4,U^(^R8$;DDEQ8F;6&2-K02Y(3E)G
M)4)HO49ON[6X\L4`_#_A>;Q%D1.\F*=4\FPU6,Q3FXEO52H256&2^*"@E;A#
MF1:2N0FC`A-G'4Q:LK*O=:HS'D",&EX0R#MV8A#NR5ELW49RB3&*]<I;#6;J
M4A;+'*I6Q)U::845@+.394(!;&K06';'H-3JM+D(M'F=Q*E=Z]2<'"=.A00<
M$`"!91*]>O!PDX)X?>4MQ7NRV>#18J]`,L0&V/QFPKOLL5MHF'2=8[;8D;YL
MY*A[1SA(T:LD)4N[5]4JQJ"UORA(K)-#BXC4BJ'*@:97TH&J/.'.`]BV%8M.
M20Q(8I66$8?723^'3E5C-XT+9$%ZD,B0J;1"M0,,!9(8@!(H2,3*L*T[)PT@
M0&0VZ<%!<I`!.?2H404TJJDDWN._%\KD.=._;PR)LQ:=48*#?$\VZJ4:C"L:
MCD6YU@J(%2EF/<MTE\LE`GE,EUDCU3(\I?L@($4F$I-$J>RH$Q2#.2`>'X"$
MY41WP!1C0"S;4$\%_"R98*U"&<=E6@>(4&-F2Q6A;`E9.W;P]&)V:NFN"EBB
MHE7"WN!FY5AC_&PA2\J,TW<([E1K6&W\EY2MP'93K;)K#<+9Q]'&<MEW^Q")
M9Q&M22]<1I5`WC>O18:!IR[1`,ODJLTRI5P:CY@'2L&2L,13&J9.'R=-R(_,
M;X$.'RNLHLEJX;0MBNG(;0U9IPE<@TJHETTQV;E2@-&V6!L3!!BE0XP_([MT
MH/;B9.+@PIH.B^=L*:V0UL?;L!LXF'M7/A"$(0A"$(0A"$(0A"$1)5.#I`*M
M_5YB/%*]RR]PW!PZW\+IM04GJ>#IX"U5P^/54'"DQ.(2(RH&H0"H4AP>`U+?
M&C3.0@7($(J$DUFR66[6);DTL/*8"8="CG!S#U-X8,+3@8.6U3!\L0@DHN,8
MYQ$C4PL"!37`">+3<Z-C%/MVA2JTI*34";`@Z8!7`MZV*&'(@SM".Y''#.,2
MUY$VG%Q,EZ5.<&EW`8N28(\M5^RXN'0!0I[2%3:L%FB8,3*R:-?95Y\&11LD
MQB6[^7F(PH6@18%`\S`C^:CN2KP^7W;)7B*UWB+2IX+;9JVJ>Y/))ZCM/HG%
M@E66)Y$+<SQ.)T"`II<,W(R>8@G%&Y2,2(I1)L:/1JEF;(L:)3MV5;689&W9
MQV7]>!#B%B".\2"P)W"<9.C5>;&*&J7A:B4@W@U7D"4$U3!$IVH4FWZ)+#N_
M1<$V:Z$Z&K*K!3,>=R-9#PA"$(0A"$(0A"$(0G++*<I^*?@G$-RG!0WJ'=MU
MG?9I<NJQ1J^YS0KGL2#9'R8DV[F.#(N"$HES3%$+E&+<K23E&Y*7%A6IEPV<
MT.>K"T5%8Q77SPW+09E9WA-X.&K26(A+XER`Q7()<I-BSC#T7E5U263)*#&_
M4*["N:?7CH$:E(X[.%<=+X""5!JLARCNGX\QL5TBA=T(-,0PR.R<Y*/#VE7&
M13@E"^Q$V+#88C'DQ-M6WU+NB+#<-JN\010X9<\A,EDZ#(0HJM&+@>ZJ^40T
MG4!N>F):9J8S+"$\*4B(NIFY^++DI</SE-B?-BYRX?)Q`YRQJ9PU`UHIEJF?
MXR4^QB;7"?<7^+TM6Y,@BDS,PAXJTDE3%0*%7T*=8CZ2$&$L*$"'OF5!AS5W
M^36P]/N?XA5*Z)BZ1^<8D4>P*65QB7KNM(F21,,+JF4*W89?-2<HPH3QZW+C
M-NN58I%@2JLB-*;]XY.!-!B&&%5L*6!]B$\F0TXY%-B7&3T8HC9YF@=NZ]B%
MQ:'CO!S_`!,%:Z&I.XW9S3?51VDAZ"'HE1MK?$-\H6L&-K=;$U3HD1>OI+2&
M[6?52,PR85V\PID3F$+>&Z].[3M/0X+^+(P<%675<:BW%=$8%,EF.!"KH(#0
M6EIF9A9#Z"D+8I"!A5X179E13=E;HDM"$(0A"$(0A"/G=HJN6[ENF[79JKHJ
MIIO6I6YW+555,Y4W;<KUN[:G7;G.5=$KMJY;G53*5RW71EIGCP+>319$N1J6
M0LEH\PTA2.,L9CP+*1RO3=X9<Q"&#B';L#S@>+MH:S6*3`IPU$<J:XCITVR:
MD4,F$M6[9;8#`K/W4?)KL>IPKI!C!7/#;J=[%^V>.!6"@:P(;`JE]F@FW<T`
M8$]=2,NVRQ,$G\4K;2FEJ+5X`.DD@<AUP1(P/)&ND;R:K'&"=6*:%*YX*P*\
MQHI;'LIKU"N3UL:.Q!HQ0(I5)TRHO6T51;"I(`H&Z11C2C`UFV3W*B&P&N2J
M!"C$,,V]?<E[AV<@D?HJ4*@>4,9/OB-36+>I:)IQ[B27C18CD8DDXA$D[+'*
MM-DA89(!1$"/22=3P<-<J/"0>5`!(([*S2P>*&DVJ!/)J-+=#L:?A7<Q*@7R
M8-6+96IG%!4[%D]?M3WG/+B8G=%..(=JU+*)"K%"N`3I='%AJA!C>V$JGPZ(
M1=U`E:/&I8G%!C8<F0P#1FN'HV22F>6L1AH=;$@\3<T*!P;*EMW5=BM%JD4\
M\E-<.4Z*%GA2?26RHL@`&=`ZB>X;B38$)I4$Z3>GA36<D;AJ:N;*!0JSQ`+%
M-X?6OQ`L2UZ-7+J4FJ7)6'Q&@"$N6+.C`A4FB(<=)$AL)HDI1QD:F(E<@9%A
M5:/5@H@I(1!BS['/)-,$)2^'0J1[JXJFD6F&)MQC)MX]#3O^H4B\)BQ`_F*D
M4R"W5?-H\`JVWIH2J7N$Y<*(+!PD3,B!J5&':>50@T/3#(>5($B3K?@FV2U1
MBFD\4)*TC2&X7#[PLV)"L*42)@`D(9'LCFZ,-0(>FV(H,CNDWOBS"C/33G"_
M=$57H#FW)78>1N'##3AT(EB_"`IP=7[%_#$]S>.A4E,0+.4VB(Q2(D$0."!(
M)@3LE.44:CT8IDZM$PIB!4IV];#*(L,Q8(`-"W."8!&7#*W#8M1)VYY\=X8D
M\\2?2HA7+:2TN+O^4"``@'H.7@'JTG.3EQCQPJ2X*(-QQD:!;0(13540A2BS
M7.Q*/R=Y'+"\0,Z[>'J^N\3ZH8QQVQ43-HIJUCB#5RD26'!ME(/+S02E\.P4
M=9F+1M@K,"4AJ39@IQJY.$V4$@%'DI@#1$QJ;&W(*>35;0H6C@.C9?'%`(=I
MS[>&H0LG-%.>0S41HHL+)@>BV]54RL,@@R)M&)R!4(\@79)0DM!U,GZ[Y72D
MBZ@V4%XWV-=<E3A_5]*+4!`OL0;.O*C%V\S@?RB6+=*VU+QJHUQ$GQ2I7T*U
MD,32:M(,[2SG'2>31D;IJ2`"%A"9IPD.D3:2YZ`H-*\A*$1*>;=&IA!)0*("
M)Q(D9<GR>R-,3`X,*@18&H#VQ!H=&XD:<'AN+G34+-CPX'#C@Y,KXHS-!HL>
M+$"+G+(0A"$(0A"$(0A",3>*[&*]F!_%$SRI?HS05WDXGAI4+>FKDIMJU@*<
M]A,00D%0.:HH=,\+5N=EAHT;L2!G"22JC3[;V#\*[0E(HDWR!526F8CDAKC-
M<O#"S3/.-C%39B8+#$OB@;QF6U;=I6C5U9LU2<>1=W2AOR9VA)">.?0<N2G$
M'*@Z<"ZG+164GKB6Q3<MR1&/>PAX/D6!QQ89C)VREE03B57UF?.(K&<(Q-"5
M6-2+-GF0:,$.$M6<!.)005(6XZJ52`(R-CM!5J"VH@ETE4)/(%</TTH"DLM"
M1\JW@24E2%F1O*:&(5S1CJDK>FMAGWPYC6BR9<X49&OFQ39Y6V]!2:O"#'))
M15D#.!1=QT5H7EM9JC4B>EP@$($[U7RG."RVAF5<&IUCF9'B&5#BH)HRZVT;
MTWEHJ7':>2JH<%KKC=V&\NKL@=5.F"*4Q%>;%2)XI7@Y3%E29*D^/.Q`8%=Y
M:D.4`PJ+]ND<ZZ(<!0JY#+<A<92%IJFFC>8[%D98T)^"2KH2<(B+6^$GS5&2
M!4H^P1*LE<TM21P3FM`P&)`RK+Q\PW"A?*B8(`K?I1U:7CO#&Z5C5IY];:M!
M-TZ=\`F&/5RP'(%)O&X870F@V;AL%0JRLW`)Y;+<N(B,W`$:A4@$5>2R=/3P
MNYQCQQ>%>"C#:J'NJ2EUQ5=>4*!;-I&Q"FULA$N:\KO+,E;MKD32>W`9C02%
MYLJ3\$(4![27&=TD3`$Z.`Q89B`=D`)V^@DQTIF36'0IR&,<009+]$`WW2@=
MK#Y&$A"@AXBNPN#-ESV;AFQWS@F[MRS=!VG'I4?/A,'&CJ.932D,6WJ=,<HS
MA!5MA1BR5U+HHO3K+*3$;8.)(1QJ29;,,CSR2:4[O-69TI*L*ZZ$)CRX$!BS
MAO+BDR63=.&ENQ<)E2FS(UV9M^4^P..O-2U)!\P.:I=A0F*$0:*A%.2@R0^P
M^";(&J\[J!/ENCD^2N8B28:9`2!3&S=CU10EE6*#I,_H+U%?LEM=R+6-S#I0
M:I4@.E4J4@H5D]9)AT)"%;M2ZZ.-:GI4K?V'43:#,0R@10&DF'*%OQ%M2$9J
M;7`:<-;%`D"".;QN#&%P>,6(C'?58,\(HW#4LDNH$TNN4Q),#6(`*H$.I*3D
MI&%R7=B\X*4**C^ZF1";5*85:&*@HDXK)%"6CP%\5;*;DJ;]@THE@#QBX?!+
MI$+/7%U4"5ZJ'N,1I$>:)I5%2$6BI9X,8C771R-<LQ)`S>J=9-X`)3\Q526)
MU*+.BTO2ZQ&2"7K"+5U9)R-G,3+/OT-&@&T/#PUO!4:C7'"WC9#+E)ER@;IQ
M1*B"H)>I`W5:=)BI8)%75I,^NDQRFAIG8N!0=H6)D%#F!9<&7\A"$(0A"$(A
M'CZ4N,Y`,`J'-P0%C:K=UFZ"S58YGW%1*@55YVTD4B0HQ6))OC%.KQ$WT\Z=
MU,6#F\W<S6TH$ZH%;;*DV=`2\(:3.`%I\-&,X_Q?#`^)1CS@*,P%$S163,6;
M&S1JH8]#D/+;LBAZO3"'+R90W#`N+&>!!Y)%Q2&3<J90F[TR.FZ2AA:O(91S
M%;@TW*CX;G&PW,/B,.=/$8$Q!MPJG80[<5MNXRJ<T2WR$)BY3+E8!4:F$>.4
M!XD44GCU-BE,LD\5FB1L&BB)D\4GAP<&I2%,>8K7E,L%R%D%YR=L:?W3+#@2
MXNB8(W+7N^ZQ@H<.!^/`%Y<ZZ8+FT0*J'*9.Y3&P8CZ""P8F9,06QBC.P!:1
M@!8^U^`N4UP3F-#A"0#RU#2IMF&NXGCA1A&[=42E%&P0.H+9.'1:Q56$-<('
MG2Z9%CP!8KA32F"TNI(X'@2=1V"PR%6PT_H@.4OP6N??7`5%NZ,-1B!:E+OJ
M9`;S8N\5&"E9I9W0H--.@UA>;(($,>=#F9P,#INVHFBLK<OM*R[0EK]ZV>W+
M0&YNHOE$\(X%4N$@QSCGA:OVN%,\5K%!';3O"G5F"4>(([&IYCT:`3RA014/
M.URZIF7&&A2*)K8Y4'!8!&J"@JMIT()-K5^V5?=K\0J-%+IJ%%6H20K5ZR;Y
M0!QQ,>IA1)1>MXI!J17:*5Z35)83*9+JE)J(N&EIP2G94"%VJK5H59IOEXL$
M,$8H,../)\\4RN5I0WCCLBFWO:/%J);#$9@.7J#,B1[F<PYD;[VT0(7]@T&N
M*6GZA49XT=TI=PL<T(ES5FS\O4%:631+:.RF@Q'30#<I;@O%N,":L.[HFZKQ
M6((;A6%RDV;N4)I/8A`UD)<`M8LEQ=0=M%H=2*JZ-#@6_I6!^2`G&-*ZBM"#
M%$-HJM1=$3C&P\@G#(&U&KNH&;*IR3=EDVHQ2;55AM#MZ2$.:"#9G2]UKA+2
MW-YT0DR,[`THB:FI/!IX2':9+@PQ3DIJ3`X@/!RR&#EN&S<AP$@<.([PIMS$
MS3QH1HEF'KYOI5A"_P`F<,ZF39DMQ[;6D<1&R4==6$Y8HBDP-)']@H%!#\L)
M#8L-22\9RV66,_#PWRC(DTLUD:)T0=*=NT0+-C-"K\*ET6M7>D`DU:,=!574
MQ0GVI5J_O&Y$"3B<<4P31M?-%&EB@6%!F2K3(4VA[C-Y0.;;K+#`C6%5A<8C
M5IRBF'S",[0PP:M:*5'F`1<*(S+W.0"5=6BT7-V3.6BP)9>O'@>1FH#`J%!3
M-.3+@JD+C*V4Y:*9Y::9S\<Y2G/_`-Y1^PA"$(0A",?V)?%8KTOB9PUX)V1"
MIW^.?$*G'5=-2+A7`A1VF688=F+:>!*M97TJ`-2,:KUFKU<L$RA6Z(*S@J(+
M`T0?JI3#Q`%,64RI^!C<8JRPTXN4CA4Q-FA0LDX]+"/&^K"N^BT0<EBL,1>'
M*LA'O>TBP;%,7U??4JF+$<K2%?()1MX!"7U256%(E1J$"'I$6'"LO.4<HAA"
M4+4'3Y)YU!BB:=.X?2'%.>K9/-L[!\5E+#*4P5!<2KTPM$Z&&F06V*K1*P'7
M$W>`T+$"1)@^49BG0A`5C#*U<HRQ9X?28H2"A.7$!DR=7#*J3$40J(W)E(6)
MZAE4B"2I@H7`/SP:362M(DY>%6Z3GWI6"B4R&7SP&#``18VD0'L<8(<<&&D_
MMNG:MN!?)CYEC9M"-R4,JT@MDBY"=,WJS>3+A)MPHTZ6K<SO.]>%6B]M+).1
M&%Y8GE`U-E%J^HRHW*0'W+L:V'(Q22[5FG(HMK;%P2%I5ZBSM(K,F=--.DK*
MB&2,;L6U!@G[#B"E<O+:H38IOBDJ39A6O2T^*3='W#LI&VALXCX8L?U2T<O'
MR#=Y4A+"'8W%ZW6'UD"RPU2O1#@FPA<8<VA<REN+S?&5)HNEBY`9:K-4E-%1
M>56YG!42UGY>5`$V'O"[,B3/E%<'Q&E4HKS]W+9`7*]\#+#0!+SE&.&!4Q/B
M!*2X:;CF?6:2N)*:E0:\I+`%9@#)%F5D=TZ`"R8:05FP51)ZZ:;PB\>&&=QF
MV`.>A%@IE07&;@KAI@B+`-6ZH9YI.BVEHW$K]NQ[%&J,+WA)EDD`!$9FY^0G
M2*+QA<1V;)V(IH*AY<+%WJ;5V4+B#:-/.PQB[)U.BW!(;QBBEL7@[XX#W<[X
MDLNS'$AAS28A30@.08TI4:6.;90>$AX6&:>/`I4;@!H4/@X8+E0<4PYO>2C=
MQV`K).65\I&\1^Q2A:MJ$$KT.XK7'`<$Y9N%=I&WC5T7"L+!KV_+FZJH>@">
M%)>/(`Y^7*$N482BS4GQ66\EQN8;S]6D:+*UP/&&ZR*%^<MJ+#HA>"$Z\5AJ
M@XD6XH%DU3835Q/O"?I0&"'&`M,MT8*)1F)2`,#DA*C<G+QX\-3-OCKPN.Z:
M8?R=NW'%*07BE;M6NNP=VT@7*+RUQ4"@[A?:6!Z7G)NCR\H*;B=K-R>9F2J4
M<2*&Q;.2B[S35:,@==WA#GX[F6",R.6C<+T<(4*G99SG;0-=+-.PLQQ,DD!:
M,RP8YRY;0L("99DC<`%.#LELC=2TI0O4=VY3:3YJ+M5U"K=J,/7*.-K9P1X2
M7[Q0+8,GUDZ&$C#/B`>H^3B&5HY"MO9>U(%%S3Q?#TN3'Y(TK9&:RFH`98I%
MB:%J?`%Y(=F`HUH(TR?FY?)1/8XL-"K?HWPS)M='!T\R<79NVBF3)>VCJ""Q
M++4G;$$\EPE52VI1,D(F>=6W'AU(EC(\4H$G6<I"2M(F)V<@AI>'EI"$(0A"
M$(0A"$(1C:Q`87U+CH4KO,OBO;LO"X-0*+&$3?I9,.)9,5*\:U4@`V+#9RE\
M#L%Q1)"#VJL7"PRP_$P(R/Z2E>WQ;KJ(S+U6EV]`IN&X/#!RD#C8,L+K9O\`
M@&F6F(K!SC&PON^6K(0[XV8'$<T+`.34:EYFK3ZPWHN^B'L&(&H$&6<KI0H4
MRI5D6##TM.0EE15@"?8C;"1CZ6F(QF7+<%`MN=4,-RH2KQ"ERE)WTNIY$F^%
ME6LX^K=)@"A6;+T38*R)R$A8<XKO.B=+2P.<%S%B7B#2TNS--&]@*A]X:3`M
MBD2;>\GVE#])(>P88=>4]Q6XR'2N@G)"#PUAKWO/,9Q@DBQ,US(@MQ0J\&'Q
M3)V1Z6W[1,7A+B04E`(V,)"B:H='J^T;WX8'GY-TH7:!*#Q;*OEE>4R?5*H]
M)N`1"[QTW>(=@,;KN$LK1Z>AD^2`EBFTVN;H$P(#(2%*Q:@)I@0JIL@#0,:6
M;OJW`!BL/$">,X*2B/J83&!B]?K&%CO0"0=2P0+`>D7",T^+2>#I$*,<1!0`
MQ#N-<3!`88IW"!"B$6I052Z1:(+A!:N[Z@`4N.;"7R@.*E"8D&I*6@:5,-N[
MV`X[9]FT<D7R"-^0-6[I2M'3I`E+N4)]$AC1WR<V;4Q:^RUX"D;<:-KU187P
M42CP%PVM+N]D<QT805/C=P>6FEDH2AH'Q(CAF'K;%53HNKI+MYB!9!6IMRT;
MSG;S4D$*M%5*<ANI91WK1<7&(]+&QD/+`0,TI!6K=UT`M<5ZS(20N6[*H=F5
MD%MU37)Q<<LO=1!"1P4-=KN6&TH(@"<5J@)3HWHM!K9@O2-MC4F3PF^.N$AH
M=A[15=P9EV%#&ZCBPJQ`XD$0BRXR07)58_<.&(=1EKZ6598$.,L)-@OR%9,Z
MW!*B$XB$.S9W4UQH$0S9)4&BI(1/CI6%2!J/"VR*5/*F4PJ.WBKPB8!G,-F+
M;8T)62Y(P:QZ6;%R'%M74QB<-<5;&X>$\?I14FJ1+[QDC&:`H)M*[]T>:6PR
MP$KQ5EP\$F2\`@Y#U;R\RP#XPT>V#>5MM=4[EI;#=R@K`8I,/.''$>_0!6NP
MGV<03;*-NW#:*>)H9:6<C0I!'2Z-52S1:X1RKS,@1Z>M)$W68>LX+"U,?9.8
M#L9=@`B*U*AVHL&!!RY"XY10UL)YWQ!J'FQBIFX\[Q:7WCA!)ZN^M`=Y=A+9
M42B:`@8W"E8T8:&"3$7PI3'.\*V"3$4PRZMM<KL+>#IR$@SKBOZYC-8VU2IZ
MCYX%*GW1-G8/T:CC%HA3;AS!(/&$DYHAOG*=D,Y,R(X;N1U46!CHR5`PM`WN
MY-O"*\&%M2*X),O4#/8=C9K&Y`D>%8Z=^Z_:&:![@1B=C7'$885><BC%8-_A
MN'`!A>#3S7*0SH#V#NW>-R!%M\#LB`9YESA"$(0A"$(BQB;#8B5,%1+;L<5`
MRA.K]16B-YW@LKP(E5PU#87I3H4!JT1)>)332%TS4/5S4F#$P'$94AZA8A:R
MJ41P1E25-X789<)#VX-,8CZ))C$6C[')O/\`%1"XH=(B7%N65<P6)J\3CBAS
MCIL$,)(Q5LQ:-W0@!+*%8E)HLPY\#=?258$X"Z"4)K;&18:C!AC_`&OP\X`<
M,YJCFI/&^8W#,\V&UX[*"?<R11J/6DB1')IF75,%])MBI>&S(&Q>1JD:O&01
MMXK-1!X9(<:KZ7&+TW61%VY83<#.+IH[N&DW7B"05@4RW(HT8!3DN(G6`FUT
MR?,M4B%,RN^$$74V6!;",'%*%M3,U%*J_>*S@WF`!%)T7%TCH;81T\%>(QB\
M(+?G*](D993>%3^#NXQ,$KO&Y,N[)I?M.H.:1IC,,>)$KK)0=]0HN=K#V9TW
M#,3>(S:W<59'*9+.@$;U!)1LRS^)];I/"UB[;IIFZ)7+P^<ES<89B$6N7+L4
MIYXG-?\`(\.RHO'*^4:4)C6\1,FVUEH"<65@[Y=;7"O,U0H^X(4A;)2P6H^,
ME&$C'`T6'DB0C5-NFU.YRB?=N\0N,UY%4\B,)WUQ5KH_5MB3ZF38JP,E#(@8
M\W!)BP7E+1F5(XK,6];)-D;9-X>HH[!@UP&G/R;6'1XL-:4Q1IMV$^ER&VXN
M-S$8^S>S3CBF[D71S?/(I2Y7%//AN>I\E-[1R5UW11,-J-;Q@9F@H$(-A-06
MT*"T7HD.A@EQ`XGC7":O'A95KFTQKX?WV;E;58[6O<`J"&I8S2'<B^=JQ%!K
M!"2)U?K,8\K2T"6T5;,*DENLN1&JV42D`JPTL$)?8.]C-<"^*NXD7P*0B/0M
MXR<#EP&4Y0E/4W7+"60\V`:MT\.S@CP9K?Y@KJ"..9@&.,2LO2=FV,)[8H_*
M:Q*OM!PPZNSS%+8"WYM,40X&U6!(!K8MSCR3^*5$XE[2N"7E*,:%.8S:L;1(
MF+Z5K#25)2_011WKS,F)U;MW$2+2UX6Y5E5W#49=;^KC9Y@%Q-K+DXL96&\2
M2-TGGC=[&R]^*1NP(I?W12--DVNL=9?C`3*:.U26)<6+39]=3X6XA3*[4FS@
MN*#^FP.L"C0FJKNV]POX-,21;BM>$[4.%/!YB)9[%0\;4XB+SE/,N!!JJL*"
MR2R(:)*KE$"V[,6M&_R@B(F,6C(EJPQJ2J%NA!.KKHRRH+B6``R<UL6YHP28
MY"9!LQA=L(1N%DA,-7*B(W&$CL0B@>ZL`9NDQ`O%`X&(XV*%6D)H8T4Q4]R4
MJ<4S2Q[WR@6D5?<)P"D)U%(4>#RPH[#],LDI2_!*4O1X(_80A"$(0A&.W$WA
M97ASBNPQ8YF0D1FSFL"DG=9M?MHH3&E/`W?85Z*$Z:G121JZLO-+":<5`KI&
M)I9(:LW"VDJH[-U3I%2&2=H.P"J(;?*K#P][NXMD;CK6+=$1.<83</SVMYA&
M8`R7A/4?*EU7YDGK3BN`[#A)\*<I1"$H@@1"70"0(4O=7PP$4F:N69X8TF5\
MH1]BV.&'#NJN3T5>)*ET3MF0>`EXTO7B.<]9.(IF_;PM9/$LN+P^UB*28<@$
M$I>DZ<+B[J&E9VD;!XJ+%QL3R\H4S:"'Z;4=!J717:/DYUF]/)VXKF<;E["L
MY+SVL>Q_)U.@H`8PP(4UA4PXO6(=3#<FE,842,1JP1AJX%@U0QLO":P(`.*P
MB7;$Z)R\X!ARX49RF<ACL=F*9L4([#C-`PF'W$0PN(O#6_R(:1*NZ)<@B>46
MP1NL;:\3KAO(&;1,W4X0..DE\HREGBRZG%C)LSH"3*Q4#+XDY,R=.VZ?7`MB
M;6KWGV/5K$XD25X2)^<&CIIC"^K5L7E!>YB#PM-OB+:]5$+@N4FPBF2"==-;
MD6*)9"4*;A0RN2Z:%-@UUD\.Y63,VI3&T6\%^-$=B"=#&!813>)A3@.4*9;&
M<W+,B'9H.Q#@MP&Y/HMP-/$V2M4`-+A$FC7%*B0<>+-N3J@:ITF,5(.VGAQH
M2$1C4M9;ZY&`!^UF_P`G,21*GDV5#E_RG^&#&&XK=F2X+K$T"S^'#"\8X<K5
M>=%Q<8$BM>=9WQ@=5')<3C:4V%+@16G:%L97B`.:&EF%!R>>,!,N8N<2:<:1
MD7G.2WE!L6[]`,,[BN?83R?=G#QBB:!FFVLWP;BR1:F+&Y?MOE&S)0J"@,;D
M!FEKZ:.5(F9*V@6:R$ALVV&]!GC0X?$VF;K.,^TY\`LJE25,FP&:E[9)(U5"
MF.E?>2I`>"B)&A#\SK&G%RXJEZ(2Z6LK)7BSU65D)3;-)!:(<<F1@;O8;\'+
M0M>]C3-<E<0Z#0"V;!4.:W4TV?J`T(E2K5.?7KZ?<ZA,$:LI"#@IZ"$BP)D#
M!3M'P.NN[8,+08*8B;2,A@>Q!VVJY-_#:\0%,EY7R:;MI)7@'V3:G!BYO:DV
M39]S679ZVF$G0&FIT:H%VF5Z5#7N`JJH*6$E9(H$XF#5P`2E#G9=9=5<DYB1
M*3=6'3,.^D44*8K&F<O-R?-JNR/H!-&RN*\TYUQV(]7`@5`<*/N'=3N/47-6
M26J+X4D+$@W]FT-!7#DRN`I0+O#'B+9;$XLEUAR024=9C7TP3-?A%-DFIG1I
M0RB810X?!;R7FO5Y-=.",X"JAM5>1O&8E"Y*2:JE8DBB3I4?@"M3!#<99*H'
M-+R;F+ED4LRR44F%K!OB[3R\P'X-<)[RI1[72$VR%@G-PLMDH&F'K4LM&+,J
M2P];$N(E#@*<J1K@8`A/[:Q`C`007?*3X6HP^6'""P+KM%B1Y09P5Z0)@L1^
M(A[F>7[5#4T?!QEP0G&XPLLWAZ,@YVF[80/4C[@@Z:@6H2`CL#U"$!)L\+2Z
..^9VS(M$VKF0V$(0C_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g267601.jpg
<DESCRIPTION>G267601.JPG
<TEXT>
begin 644 g267601.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`]1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]85$%-4%I!7TM?3$E.12Y%4%/_VP!#``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0'_P``+"`%)`AT!`1$`_\0`'P`!``(!!0$!`0``
M``````````@)!P$"!08*!`,+_\0`<A````8"`0(!!0@*"0X*`PL-`@,$!08'
M`0@`"1$2$Q05(3$6%QE!45=8EQ@B,F%QEIC5UM<*(W*!D9*QL]0D,S0U0E5S
M=Y6RM]+3\#<X.6)T>*&TN,%2B+8:)28G-E-4@H?1\2A#1$5'2%9G>8.4PN'_
MV@`(`0$``#\`]_''''''''''''''''''-AGW./W9?\X'E)W3JUZH.9:K,\GE
M])5-*9([WKNH>ZO\AKZ*O#RY'E[P;'IBSE[FO:SUBPT"<@D@!B@XP8222B@B
MP66`(9P?8IZO_1RHWZK(5^9N/L4]7_HY4;]5D*_,W'V*>K_T<J-^JR%?F;C[
M%/5_Z.5&_59"OS-Q]BGJ_P#1RHWZK(5^9N/L4]7_`*.5&_59"OS-Q]BGJ_\`
M1RHWZK(5^9N/L4]7_HY4;]5D*_,W'V*>K_T<J-^JR%?F;C[%/5_Z.5&_59"O
MS-Q]BGJ_]'*C?JLA7YFX^Q3U?^CE1OU60K\S<?8IZO\`T<J-^JR%?F;C[%/5
M_P"CE1OU60K\S<?8IZO_`$<J-^JR%?F;C[%/5_Z.5&_59"OS-Q]BGJ_]'*C?
MJLA7YFX^Q3U?^CE1OU60K\S<?8IZO_1RHWZK(5^9N/L4]7_HY4;]5D*_,W($
M[!ZW:\(=Y^G*T(J(IU(TO/V;_IAL3UM#RD#KYAK]&5"#TDE`T8)6^8J!"4(O
M.`F>9J!"/3>2.$(>9[?8IZO_`$<J-^JR%?F;C[%/5_Z.5&_59"OS-R$,ZE6H
MJ3:M/I53&E]2W=?[/6B&ZK:2)HM5]?5Q1=5O3B!FB;K9-@O<7?3QS*?.IY`(
M/6T.BDGDK@T84R9^%&6`M(M<)(5/2VN5E1UW>'O2R`58[L<VET(<(I.:MJ\]
MT$IB*XE"*0-;A'$[JRO,2DH30.T1>T2W.79C.2K%:-J7F*FE#D[[%/5_Z.5&
M_59"OS-Q]BGJ_P#1RHWZK(5^9N/L4]7_`*.5&_59"OS-Q]BGJ_\`1RHWZK(5
M^9N0,ZHNM>NK!TZ]S7EBH6G&9W;:$E:IN=6NMH@A<4"HM8T>34HEJ9I+4I5!
M??/@.(,+-#C(@X%X1"QF?BW5/5["U;C['*C?4L5XQVJN$XQVPH,QC&,89<8Q
MCY,8QC&,>K&,8Y"/<=VUJT^@D^M-SZ?$4M"M*FHV?7U9\SB,.I./-T8CL$7H
MD8HJA(EB1.KDL\D:8YQ=V5F;RR&XEL9E1CP\-IZYF(<>[:OQW7;9&'IIRLT(
M@]21Y_@]0V5`G&6PNFI*@GD)N2#!G#*X-"Z(HU&&]VC16?04SC[NG3+6IX$E
M.1FN3*XMCJMD[]BGJ_\`1RHWZK(5^9N/L4]7_HY4;]5D*_,W'V*>K_T<J-^J
MR%?F;G0+8U:UE2U3::E-KQ2)"@BL+(.(/*JZ%@-).*@T@,*-*,"S8$6:48$)
MA1@,X&68$)A8@C"$6,)Z(:QZW.^C>E;JZT!3#FZ.FH6L3BY.2^LX>K7.#@NH
MV!JEJY:J.:!G*EBM2::H5*3AC.4'F&'&C&8,0LRK^Q3U?^CE1OU60K\S<?8I
MZO\`T<J-^JR%?F;GS+-8-46U(J<7/7^@VUM0)E*]R<5M8P=.B;FY$08K7N"U
M0:T`+(1H$9)ZQ6>8,("4Y!IHQ8"#.<0"IV\NGGL-H7*^H)2&K]6SZK8E$;KE
MRZ)8KFKF":FE4,X2DF9LPLN#>>S-SVK98L.31Y,Z*DR=S:7N/&&JD9;F%25V
MNC9%JU?U):;WO#]$*U;XIN9A&X11ND+)2B-[@,:=H!,K*9'Z9@3,RI`N&X1B
M#N^5#-&5CBL:G10V(%A^2CUJYMQQ5URZL;!0RY+KULZ=L3O#7&H'Z?1!!:T?
MC5(L#Y>TFJS*]-8/V.=8OS8!QL"+L+PC%'6Z32>45X*9O:9T3PIF?24:,]UL
M:2:MZO*TB-7C6^CRL*T:17@H=5PS`RL*DQ2C!0\"9`"P,K!ODQX$``L#"+`@
M!SC(<?1]BGJ_]'*C?JLA7YFX^Q3U?^CE1OU60K\S<H=ZWM!T7%46KX8Q3%5Q
MW"UPO7*W#'`8NUY5Y3)*2\W\ZRB;"1*,)_+G^0P;D82<GGY*P#)QN1^K;CCC
MCCCCCCCCCCCCCCFPS[G'[LO^<#RJ[IC?\3J+?X\-U_\`QS[*\GYQQQQQQQQQ
MQQQQQQQQQQRO78W_`(^_33_]>K_P\1?EA7&?7C./EY3ZSZG7AK/U3-C]XJQA
MN;TIC>*HJEA-QPR/RJ$Q6UJ;L^BFQ&S1&7Q]OLA^B46GM9RR.H3D;XA;)DV3
M".R)Q+/*C[XSI@K`=`Z@O5)OK1U(ARKUZJIW=PZM[!;<OT>?[6DABYFA%"W)
M3$#%7:9WBL?5LCO/IC%;9"XG/"//N1B4G;5*9*9-6-)A8[1KO;KN6-0]>S&0
M/M%T\]2FL-R=K-;I>V,]IR/S>31366>:^LQLJ@S(M;4DB0@?8I?85$EG#^<O
MAL!DT3:&Q>R.0[0CS<R6=ZZ;JS6X-V=PM/II$ZGAB_5M8R/<><H_.WF2R"Z*
MHL(M**`V-%VU00E;D.(R[I)-!;Q9,"<10"?(H^S)%RXB1@5([&N.5]]5S_DV
M=VO^K[+O^^,_+#5O]FKO^FK/^\F\@QU**>LK8?0C;;7ZH(\FDUDWE1DYJ>((
M'&1L449TKQ-6[+60\/CY(5B1$C9FG`A*W#"8*QS4%`"0@0J#A]RHCVILK=O3
MYU,Z=U2HJLKYXM>75[G7B0(;`F[D"+PJ5ZY:33.T5C^0YUT6\XEK0]KZ46,R
M5$C5-:A4C?VU4)<T+"%24N$AW7QLX&OUJ6N;0%.M\FCS!I/.((Q&6G*'%*X1
MK<K1N=[A-<85,HVECD<WL2%+J]60AW0P]8QMI4;>E]F+2T[)73^E?I]5%U*I
M?9^T^JU$.-?5)"H7MQIS6NWE8S979KH]ORXQZA*25670A;,E1MZ(RVHP0ZM<
MHA(<!&TS6LTTNE0P(5T/7-*RW?'LQ_Y>S][F.[?_`.".V/\`%79G_L'(>8,T
M`_XA>CO_`%-M6/\`0-7_`"6_'(Q;8Q.RK(K1NJNNVER.;[.F\5B=L2AH>X6U
MNT'I<3@%VL)T9FZ;JB6R4.TC;VTF"`8`IG`)C+)Y`N5(U&$:9$OJ9URZ=&SE
M!6?U9-=6E4R+=(=]HM9$_I^P7%XA#4\U'L=<M7/$*MSSFG(:-#A%6\N>)&%R
M;\1EI:!M:>%L"++`04L.5`D;H?KSL+"=4]$]7[VJ4FM3M1*[?*_LZ5I;(@DW
M8K)$ST[9-$QA93QL0>%SZ!NES;8JJ<.:^Q(Y#'"()FM-',LKR[N(E:#I_3*U
MQVQZ<&K0]%%%2M%SLM/3^Q1:Z[!M-EP2+U]-*TLN>/,[:5%RQIR7I;7KV9P5
M;(75-+&2)0&QT+^F);PPZ4N)ZDT3==*'Q8"'`Q!$/`0X&(`1``(>`XP,0`#&
M8,`!#\0@`&,8P!S@(QC%C(LZ\<\_77;_`+#U5_Z???\`W2C.>EWCCCCCCCCC
MCCCCCCCCFPS[G'[LO^<#RJ[IC?\`$ZBW^/#=?_QS[*\GYQQQQQRMK;WJ)_8=
M.34;-]:+6DD%E&QE%:LPBP6:9UJSMTTM2^V1.ZL1[/'WUQ"_DP:*KE`HW+I<
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MCF^31/A5$V!`A]U(CUSY(R_'Z!;$05*E[R69EI`M`'QYY$F]J.40EZLM/=%1
M**WC3VJC4CL)-9T&4P6/R-"X)VE;'GN7IWXR/-3^D=525L4LB]Q(=2G!2G1#
M284J"2C/FDFP=!0U&4X3"]:5B;>?'FF7$+I/;==QY&?$WXU*0Q2@A2\25$2?
M&WL]:B)9W\D9C.Z&+$H$"U0)05@7646U%#.>RCIJ,V6+'W*_&*JT%Q/T&0.+
M>J6,<.=WS#(R@=,E+,FD2%X`%1(44>+3G+P1!-[J%X432O9CG.0G'''''*]=
MC?\`C[]-/_UZO_#Q%^6%<P3:VP<)JJ>TE4ZT"I]M/82225CK.$MAR1*J6LU?
M,`9=:D_?')>(*%@@=914:9QD;RIP<H6.[Q%XBQ(7*0R=N3![/&KOI2:21)#H
M;<=32^7.+6[/K=%(K9D%DDH7L3"N*;'M[1QUCD#B\*6EF<3TZ!X<2$AJ-J7'
ME)%YY!XP@SAV36SI'8C;+Y:_S?5VW":XKV?/<L4EO-.VR]1ZNHB@'([!+.1%
M*I$[$QU`0VA6/J`)9;08L+1^?ARH$G%C&4$E6C-OUW4SE8]>ZE0:66FV,+Z3
M1UI$ZY+9[&)U>4+;)`M@#M'%Z8H]19DEBJ9O2REK1-.'>1IF<2106Z(&@HP&
M.]I-RM4M-JCC&V\$J:O+U893=,>UW!--;7"B1O:":VW*S&+*`Z;IS"F]0@43
M8@":P6]/)0.;<M$6YO#2X&%GB(F9?U\,VME0/=X67'7P,!@!*9ZN)=&QDR!7
M5T%(SDN7V&L0E$I5<JB]=]\.TQ"P$`?"8BE>9.TM#H)G,95>;42Y"YHTCDV+
MD3FVN"1,O;G)M5$+FYQ;UQ!:M"X-ZY,,Q,M0+TAQ*Q"L3F#(5)#B5!(QE&`%
MF`G5<_Y-G=K_`*OLN_[XS\L-6_V:N_Z:L_[R;SYO9[>5-[W=1C6/6Z#;&6)8
M5*N.Q4>T;7U`ENLQG8Z^<C:ZG^Q#G'8U#X+$C;'*PB=+!%#YJR2^?(V94UE1
MJ!R)C2.;JN>'[$=2RP;4FBDEC:)4W-^G3U%E<[988ERE1Z_N3`.U84@,:&2%
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MAILHF)4Q%*[.*K5<?`!BDS!#U3,^QUMLXV5S1F2NL,:IA5[/)F^5N-*K'Q+=
M$U9BUI5<PF3.2-0E+D7]DQKXG:F!W>[IK*&%R1F@SZVM5CS6/5C+"D5ED-Q\
M#(>X/8;A&9G%WJ3B=FY$VQR3,+3(!NRD+*8V%NP#$8.<DE[4?#9:*`2^YZCB
M<]"2W*10>3V=!H[,0IW@7@:#QQ=Y?T+X$MV']JU^)!@3EGUH0J`^OF+H]M[3
MCG,[VC$DET-KAII"R3ZL%+;"L6#Q1KGDFC-8P^RK6-BB-]=FM6)EJ4,W9XM+
MG8T9Z<N0I7T&<I$S0<,SO2G8&JW!IE9M=3^M;7E<8J\=OEP*#VI`7*2.\%4-
M!STP2,@M"\.@F^,RQ*4$,;EZ]'B,.1JA+DER$0>$_&'])]Q6[>C4B![<UK5L
MKB<9M9FDSY6T'G$FB@96^I(^^/D73@>'!A$YQZ+GO4BCR]"EPH6.8$"42=R<
MQD`&:E(S'K_?E>[*UDV6G6ZIQRTGO<NATAC[^B"TR^`V+7<F<X39%:SIC"H5
M^A)K`IBRND??T`%2Q&88F(=6AP<V)S:G-;3'UV_[#U5_Z???_=*,YZ7>.?`Z
M9<\-CAEE"A&\80K,M0'0:@MM$Y83F^8!<#$@#50$0E?D<*QIBS%`4^3!$@&;
M@`<T3O\`LYO;2%E6Q64WO"D+S6(5FD%&L,AB^L[O4K7!-C]U+U(A8\J25=WS
MP,MCE24YY*SUT?6N+4YNJF6P-L4*C"7):,NR+4:WY]/U>RE86<K0/DSU@V+>
M:2431N;T;0"?1ARK*K;MKV4N3,VA+:FJ3X@EP,$=F2=H(0LRN51]V>69H8FI
MU2,C=(A3:5>(YHGKM7,6!--U@B@)(P>O+)=U1A[><ZDEITIGAR<::W)SUI91
M8A&"3$FFX#D)8NW?>...........;#/N<?NR_P"<#RGGILV76[)J4PM+U8E?
MLKJ@O3=4E:UO,YB;.Y)#1[Q;(G@+4M[F\)%A`A$G%&AP:0#.0&!SCV\G;[[]
M1_.Q5?UF03](>/??J/YV*K^LR"?I#Q[[]1_.Q5?UF03](>/??J/YV*K^LR"?
MI#Q[[]1_.Q5?UF03](>/??J/YV*K^LR"?I#RI;J[PAVVHK/56%T;(Z@ECC5N
M]>M.R\T4.=^4[$D:*!T<^OCK(&U`-_EY!SG)GPIZ+)8$*<@#?DXA0-T=&\/D
M0J.K;4:VUKLWU6-3MBK':=9[8U;K35;8:J['9;.LNC90W'S6UG9P<XJD<*U?
MY&YIY8SM24TU,Y'*$+BA;W)Q(7-2=68A\_(@:IT>EY,\ZB31.XM1FQA4\LG?
M7874FS)3O1&Z]J60HMS*(054NUSM"KX1,8_:WI4MI9H[7;DXJI$RUJBA3"R+
MXY)F1VBL?/'$ITZ:NU-F:U]6FN)'(J!CTQW'I_I8+:=(F.U=`/:3,XU$98>@
MM:!N2J!"2,\2/:DD=4QF!N.&A0QYCY#`T+IQ*#L/$K59DWMT!N#96RNHQ.XH
MT:P$F;2Q7I?ME4!<=C-?QCC@M6WV,/=XLBYR5.J!8T('!(T@;6L;>WD(Y4>V
MD!5)2FXM`/G:Y/I?L+%W6][0K1ZI-2<T]<5NZC]=TY']IZ.@KK:NOZJMG2M\
MQ=CD1\D6PBO[9A(G`N11MOFF"XJ4,H/FST)8E(*.X79'IL+I,M;6FBXO0C%6
M;/T7MAM**ZA\WVVJ*Q7VLKRN*W)'8$-:3IC-'\#BK:X:Q2%2U.<P80`:X^<I
M5QN"%JHJC1*%$\M$=>)CKWO!B^;$F6O*J$S?IE:7:X/SXCV"K1PE,0N+7>,M
MC%.&Q<V`7'*)"E?UC86)GDK4[#;%3.9Y9R4$K2"FG-Z7OOU'\[%5_69!/TAX
M]]^H_G8JOZS()^D/'OOU'\[%5_69!/TAX]]^H_G8JOZS()^D/'OOU'\[%5_6
M9!/TAX]]^H_G8JOZS()^D/*_MB;2K`_>_INK"+*KL]&A^SB\^6)YY$5"-%YW
MKY&24OGBPAY,2I?.#@B+*\X.+\0L9[]@]LYL!]]^H_G8JOZS()^D/*K+WDD.
MAW5MT`VC<+(KASIQ30>SFI;Z\$6'#E"*N+9LA[A=GU>L=AA?3DK<FMDF$O\`
M73*Z'";TYDL1,T<6KO.Y%'D2^CRJ=`IW2,AUCM2TQT&QU]0D]ZU]H;*.T(V=
MI1DF#W4>Y5+',=7-[&_QIY5/ZM[;D#6O1.BH9"KW!9&B=&I&\`2"0\XG12`M
M$OAC+0TAAUDU#;6PFB&E^OHIE8<KU2BE1(^GQ4]O1,%_/"*0US=UA2*66])X
M?9CS$LJ)@VUN]3]J>`"9ZXC@H_)$"/-NZ/3YLNZ]F^H_9\/)UE?(OLKM'TLK
M*J%>ZWW0*-<566H3$ZMMX-#FE='X*Z/`?S#6DJ/L(<F)9*F0D^F`(@I$Y6=E
MB:.WLKU@W/J:*YH!9(KKZYCAU"*S:B]G*'8H^EUY+FL?F;>W.*G,I$1'YB:F
MCOH0J,)&Y8B1JUJ<\3EY@E-SFV7=G::4R_6??ADDL.JZ/0.8ZA3JI**@Y]Z4
MY85IWOLO?#/.(*S09%&J_D<K;V9D+.>8BR,^%KFK/=G)X?GMR2MC%&AK\3/T
MZ,A%`ZBZL43,KNJA]F%+:XTA5$L>2K3A*HESDU?5I&8L_*R%1\B$<I3"=6M6
M6E4&"R(],64=C/A&'&,(]5"TZO<.G'NDA;[,KAP7*Z"EI"1$WS^'+UBDX2II
M$$DA*B>SU!I@L!%X0`+SD8L8`'&1B"$5@BNX*B$L6"#;%6>$2Q4(/>RH,#/8
M2@S..X1R`(PY[9QW"((18]@L8SWQSY1V]4F0BQBV*JSG(18QC-F0/MGOC..V
M?_A#GU9^/U9YY2]FM;)G<NM?7=T5A$WIYVNG:C?6NMRJ1=);<D`B$6G%"V.\
M4.^"<T,G?7PQ*K25F]4W-ZL?T"0:Q4T29(TI36UO9Y"PK7#@KOZ>UFV,X[/M
MK0AUR)KBW.L1J-NA%X2+8F@VAI#KO4,$=XM936>T-LO);&.4N(#$K>VQY!Y,
MMS1J@^5<TI24S`K2[\BM$NG4"Z4\$US4:_U]66G$OVRV;L]/7S[64)A56P>R
M*O<:VAD11-T=4MT<0/E\6?-7]>3'V\TE6\(8?.Y8N0+$;6J6<N'#;U28"'&;
M9JO/;&,=_?,@GK[8[=__`)0\Q];EN5,94UJEEVK5YIAM7V046638\(/-,,-@
MT@+++`42_&&#$,8@AQ@(,]LY[Y[!QG.,'Z$6O5:71/29&KM"M$:M)I]K`D5I
M%MAPM$L2*DM%P).I3*DBI])4IU"<\L91I)Q19@#`""(.,XY4[;<"-7[#]>ZJ
MV^?U2Y/O4LTNI]VU1>W*U82T1Z0.T$URG>M%BUH?*'%YRS,ZVLI>^1":OJ(:
M\)A<3L!M?F]I/#E>8&N"6=,>_P!=KIM14L7'K2RNEQ])[ISZ@,"1+LA0K:QN
M5_:R2:M'6V7Y]\PDQ18&=7Z"DKBRR]4D4.[XJ'XE"9*J<LC+]++%K/TZW6DX
M55DLK34M''4<=7+'Z$I)%5K:VCF]@5`TU):<C>#(C*$"60S:3P](;$GB?*E3
ME)%C86`Y$_%*!!6<I%ZKNA5@;9[`[W3^IUNM\A8[OZ:M$ZL4Z_2:_J4;G)!;
M4#V9@EKR9:M]/28UZ8&0,&9')L+D(!'KW)S3$M^2!)%)2\G!3TMJ-FZ@=D6/
M8E=7',:.@O4ITNL^3SVLIMJM/X^LVSAFK\)HF/L3Y*I)=;-:K54!<YN@U!.*
M]CE4SQ`APP&.[?92.,B7QR,S4L33Z7R5XZ3,T>'C7R?2JBK#W=V+W.`ZW=1I
MHQW-N)"GEZ4HF`$@D8$$S'#[-DI;&C=T^2T:1@A3*ZMIPQD-H"XY]/#1"YM4
M)IJ'+)F9K\$FE^E;M#J=8Z6(['T,-8]WA9FPD_M.('(3<R]$4[L3G%W6.-RZ
M3N!A1K6YXPF5)#$;;A4;8%TREU]:8:,:0Z?3&/T(QO-1/JN/W_;KAM?0;K7T
M8I_-@V#94HDT/0-,I52V021>T.[=&T"!<QLR%A4+7-_6NIJ5F(RMR_TDE<7A
M4`W-MJ53^N8NP[?]1O;#:NHXNY3^)-:Q!2\\>8U&*[DIS0XNK<J:0VDVPDVT
M42,]`D5B996T+EY/G:XP7(V]<JQ:\>$>K>&BP(&Z^;+[WRHRV36+.(2/+)*1
MP5@X:)W4%EB,\B;X`C%@><%BSX>W;.;4=R]KMC(/,P5-K`9I%#I0WM34^R:R
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M^/\`_E]9/,Z!]F/P8_DYKQQQQQQQQQQS89]SC]V7_.!Y29TX-)]-;3U:23VS
M=2]9;%G,CO\`W252&9SNA:IE\L?E1.ZFPB(E2\R.0Q-Q>'102C3)DA1RU:>8
M6E3$$!%@HH`0SC5=/'IX(4RA8MT>TQ2)$A)JE4J5:S48G3)DY!8CCU"@\V#@
M*)((*`,TXTP02RB@#,&+`0YSBNZO(]HA;E:1S8RL^D7KS+-8)U+(XRU]9::@
M]:T$TEL&DLY:8*AOE-43C`2'I#2AIB]5+TKBK?\`WR5U?HBY635P4S@F3AEJ
MRZW]'N22`J)QZA>FR_2@]<6V$QQFJW5ET?C7$Y=(FTA"6S(F(]R,6'.,1E2`
MI*!*)08MC,@2@+$>RN0$W*#U5Z2H"8@H'K=T[`$6"Z+&.!G"I[63!,V>6YV(
M87%IB1ON<\G)'-`]*DS0L0,PEJM*Z*"&X\DM:<60*/6I%?=+W:1LEJ0W0S1^
MM;+B5M;*UHJJ)YI_6=^GJEIUIO.2T/)["3M#9!TBTZ).,HCN!8<D:%:U-1[F
MB:5+RI6C"(W/C?K#TB'>*2"=M.O/3C<X1$G@N/2J9-]2:PK8I&7\T;<46RR&
M1)HZ:T,CL(UW:2\-SDK3+!#<VX(2!97)?+1ZUDK3IV[-:D.VU,?Z:FH;(F;G
MW8UC(A!E(ZY/JER-UXMNRJJ7G(I<U5W[G#R9:?6ZM[952?SAK)2NJ$D;FJ(`
M-Q,Y*D(7TB;5UUH_8F9ZB:"T2T7Q2\)OV,Q*VJIU189,U5M8ON?]R;L_>582
M&TG*D^715G7'(52UJ125^;HX!T5.:E.`_.@=7^D4/$GR#7CIR#Q"9HV5Q,\A
MJ36`6(C8;T>C3,\#D^<1[.&"9NJAP;R&V+.OFCZO.7(RDB`XQ22$?XQO6?I!
M3)WBS!$-?^F]*GV<I)2OA3-&ZIU<?7:7H8.Z*62:K8NVM;`K6R!)#WI&K:)2
MI:"%A,?=$JE`[C1JDYQ0/N0ZJ=)5S(GRILUNZ=KBFJKQYM`]!3FLRPFN/)%+
M3S?=X8FC9H(ADI.W.!X\2'+=X2D*P>?M4I^2X8T6BZ;]_NS\BAW3<T8*;HYO
M99FF*IX<(?J.20^-M<59FR#+=@10H07FQ"GPY:PLR.M8:<[R]$A<ULG<%);=
M''Y.CS[/*[Z)M<U?8%Q2.E.G`.OJN<V=@GC^Q4YK1)4\;D\A=4K''XHYA8HT
MN$DD[X\KDC8T,2GR#@O5GA+()%@)HB\NH-1.E&ZS%/7C9K#T^'"?JF$,J2P=
M%2>MBJ8*8N,E"I!)4\9(C!CV='S$[FVJ`/):$3<(AP0'X49)6IAFI7J)THX(
M^LD7FVL73VA\EDHVTN.1Z4TKK5'GQ_,>9"V1%H+9&AXC*)P=1NDJ>F:,MP4"
M90)=('=L94N#G)>E2FQ>VIBO2HUTHVT+EBNCVB5YJJ=G-1P:Q(+`JHUC]/1!
MPMFV8K5"$4H$1"7LV/*6MPD^70QH<FXES<DS4X)D)/ER31D2GSIWTK0SDZL!
MZL=/\%E)VA3(3Z\%1VN&)R3'T@4HU#\;$LQ;#^6S$E+D)ISF-OPB*+6HQF'A
M`I($9UMLUNZ/CU#G>Q&>A>FR[0!@=T[`^SALJS5I?$&5^5X092LCM)DC"<RM
MSNH]*MF"&U8N)6'>D4&2B1X6)LF\T?J5TGDKW"8TIUFZ>:>1V4A(<ZZ8#Z7U
MI*>Y\VJD:AQ3N$*:AQD*Z5(3V](J7DJV$AP3G(TRA448,@@XP&2/@Y^GSGV:
M+:<?DPT?^@O*\=CM$M(FC?'IT1EJTYU6;(Y*OLQ/=.P-^O-0HF21^A*1CZ]E
M]/-2:'E('CT.N,,6M?I%.I\P5F#4)?)&B$/-AWP<_3Y^@KIQ^3!2'Z"\UQTZ
M.GV'Q8QHOISC`PY`+&-8:0QX@"R'(@"[07UASD(<Y#GOC.0ASG'?&.VH>G3T
M_`"",&B^G0!A%@01AUBI$(@B#GN$018@V,X%C.,9QG&<9QG'?&>_-@>G+T^`
M8$$&BFFX`CR$0PAU@H\.!"#X_#D6,07&!9#Y0SPYSWSCQC[=O$+OK\'/T^?H
M*Z<?DP4A^@O'P<_3Y^@KIQ^3!2'Z"\W!Z=/3[!GQ`T7TY"+L(/<.L5(!SX1A
M$`8>^(-C/88!"`+'L$$0@Y[XSG'-OP<W3Y^@KIQ^3!1_Z"\@#U3]#M'H7T[]
MP)3#]-M5(I)F.CI>X,DCC6N]/L3ZSKR`)!$+FMW:H:D<&]83GODI2D4%'%YS
MG(!ASZ^3]QTZ.GUGOG.BVG&<Y$/VZPTAG^[%\>8-G/\`#G/-?@Y^GS]!73C\
MF"D/T%YK\'1T^\AP#.B^G/@"(0\!^QAI#PX&/`0C%@/N%[8$((`!$+&.XL`#
MC.<X#CMI\'/T^?H*Z<?DP4A^@O-WP=/3[\/@^P7TY\&!Y,P#[&*D/#@>0X!D
M?A]PW;QY`$(<B[=\A#@/?MC&.;?@Y^GS]!73C\F"D/T%YC:Y.GGH(WU):"Y!
MH_J`B6HZZG2I(L2:STHF5)5)$4>#2%*901""SB#R#0`-)-*&$PLP`1@%@0<9
MYA+0/0/123Z*:6222:6ZF2"12#4O6]Z?GY\UQIMV>GMY=::A2YT=W=T<(6H7
M.3FY+CSUJ]>L4'*EBL\Y0H-,-,&/,M_@Z.GWX<@^P7TY\.1!'D/V,-(>'(PA
M$$(\A]PO;(@A&,(1=N^`C%C&>PL]]/@Y^GS]!73C\F"D/T%X^#GZ?/T%=./R
M8*0_07CX.?I\_05TX_)@I#]!>:_!S]/K)@3<Z+:<^5``)8#/L8:0\H```"+`
M`(_<+X@@`6,980XSC`0#$'&,!%G&=/@YNGS]!73C\F"C_P!!>/@Y^GS]!73C
M\F"D/T%X^#FZ?.?;HKIQ^3!1_P"@O-PNG3T_!B$,>B^G0QC%D0QBUBI`0A"%
MGOD0A9@V<B%G/KSG.<YSGUYSRA#K<Z9Z@5YG6<,`U4UN@^'8VZ,NN(?1=71G
M#GY@54/F/I##)%4.%OF7GJSS3SG!F4_G:KR/@\N;XL]==2J]2JHC4(V3F.M?
M2]D]O6U:43J5^O+J7>ZL-=QV.,5?2UT86="&!1B9V,[N:S$<+9VIJBS44RL@
M53A*I3@*`E6O*DMT)GR$R'4*=.$`;-!VJ/8V'FQ!23INH[,1ZU!5%P6K\J!(
M\6O'XO)CYR((B<3)2F9$;&:<%O"A\LI+7'#NHXXY@JZ/[>4'_CS9_P#1]9/,
MZ!]F/P8_DYKQQQQQQQQQQS89]SC]V7_.!Y71TI/^)=&_\?&ZW_C=V+Y.JPH6
MUV1`YI7SV8K)9IS$I+#G<U`:$A<4URED7L+@8C.&`P)2LM&X'#3&"`((#PEB
M$'(<9QRO;I_PG:#6?6:A].K+IU$YN.MD7A=%-E\1Z:P<-26-4E8I$D=B\_0,
M'N@S;;#/'FOFQK*>H"]5^6THK!PY)`3YRBOD94J@'"^G9=]9ZT:KAC>OT*)N
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MBHNZJ,:9?`I2_P`I04TTI:0=KB;K&HQAEAL&EDH:(@:1.%42?&2O(ZWSCT)U
MZNNA>GW/*1L"KVJ*6(98^[TDBT`B\PB+TW&QZ]M@;HMBNT*1Z0'-D8:/)LED
M-36J1'*2"&L:`\0Q%!R6E+K?!TTMFW"D-<8:\TK$3YG5G0,V(Z<TB5JYI6Z\
M`-BIK&:)BU>X;W0Q>(Y;!BQ5I,'#W4""5E@125*`#3E:O=TJ?\)WTRMDGJ,V
M9&&RC(<:WS&J.AJQ-"(4PK).VI)GH/?KY8>R2U808X]B52ZOGL<8B;XF)4*9
MB9A6SJSFQG-"H.RU'^GKL,SW<EG[;6,?C.#>M#>VXQTR9I3`4\B:];[0TOL3
M7YF=4HTCD2YF21%8LU*DZV"E'%B\P*6NN5*AT/RE-PS&>G5M\3KS6XG37AL3
M;*:I$:60&2'N^UJ^<P[?*IM0MA8O;CQ!8*W.KN1%*G@MBACCE8\6075'65]9
M[9D6(,\89J[+D4LDF0XSHMMP">([))H&'1ES2]978G>YD:'^Q:[4C14]<6E$
M_I=`3)E$6<'#S1U>[;DD?76''XLXO"U2U$/SXD7O#BB:!NL;S^FEO;/ZENYF
M<J%B=<OD_P"G[TWJA:H&HM"FD4$:+>TKVP?[:FE3P%GK9.K9XE50X0X8:Z1<
M9`>^K2V$MG+L:3XEKE(@ML_*KTFV"%M%9"BU:^?&]$FV6OG:N@=RHML06XFU
M2#8.M7N%&PMBH)YRO;G&Y*Q;90Y5F@5V!!9C0$AK9O9I$[-[V\-33`TN4W30
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M.?X<YS\N?E^7M\F,8[8Y6EL__P`H;TRO_78_T#QSEEW''(V;);.PG6YJ@A#P
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M"!*FA&F/<0?E;&XM=5'JHT;8/S!-A1B5,-0*X9`E+.0PV5(9=?CW#8E4M;&L
M#^M0)V"9R.:SZ+Q5P2OJY&AC"Y2O5/RU(W-*Y47VC738ALOE/:[*ICJJ$V50
MML.]*W%!5;FG>P1R;((S%)VU*F1_3HVP,DB,OK^=PV9Q6099V=0J:WW"%U9V
M=^;'=I12.YBV\/\`@9MG_%G/_P#V0>>8&Z<W_)\Z*_\`4XU@_P!!\%Y,OCC.
M<8QG.<]L8]><Y]F,?+GD(VG=)GF.UD\UGK6"&6*CI9(W@O\`LJ-6K3"D%,R)
MWAYDV:(S):>!-S[Y<E;JTJXX0WNS'72N.JW9_$U)W4Q='Y&2VQL=^K-$JG>]
M@67:?7RX-<#J=UX.VPAOIUP@<Y.MZCC)Z55K8!H+A4A6)H5;ZVPG*+QA14TR
M7)%+<KFD://DQJ?TZ8R3.UYV6373)+DK&2PY;65UZ_R*'L5J5PL?$$K):TMC
M05IL6`2-BEK.E2-4BC\A8'-6W"5$ID9[?+(O+F(U.<G:T3L[2AXXYYV^O5]U
MJO\`X2\_YJF.9]ZGS-L/9:Z$1V*0792HXG4UCM-DQ;;756M=?=K)R6E<ZNF4
M,E\0>J!L@TRR6%O4*9<:E<5%>UW;2F3-34E+R!N`X'(4LA>F&E;6^DYZB(VM
MF>W3S[\3XHDLZLFDVS7>QHDZ^XN!MX:ZF=2-T'K<R..C`C;$Z\HURAC,Y+DC
MR3E6%4:1E499%QQS!5T?V\H/_'FS_P"CZR>9T#[,?@Q_)S7CCCCCCCCCCFPS
M[G'[LO\`G`\KHZ4G_$NC?^/C=;_QN[%\L:XXY$.V]L6V&7U!=5:XB"BU-AIM
M7;_<ZJ'AD".'1N`4M&9`WQ!=9=B3!:VO8VAL>IFZ(X9"F1CCLEDLLD`70:5J
M21Z.260-'YT7NK3UQ%29@>W=MJ6WJ]MUTH"R:<L.2QENET<N)I8F66!C#&<%
MR"WS]LDL+DD<G,(D41$N322)/R%48D:GM*^L#-G!NNZFG@X*=IMFLW,\42.G
MP26^?1)::*#)A*`*)E@M*\&CS%"!I%03I'@.64H290$Q<'))F`_2EN*I5TGC
MD)1V?7BN9S!@(E<2B*:;1E1)Y1%U*%2YIY)'6$ET&ZOC`>W(EB\EX:TBIN.1
M)5*LI0-.G.,!^L=MNK)>JF2&)V5`90NKI1E'8"*.S*./:J#+,!7BRCF*=L<E
M1L85>%K<A9(?`(3?"WKL^'LC5>2B72G4#IZX;)W!BF'2'QBOM2954,><+M66
ME"'2MIR@MZKV2RFJ0MS^A5%LD?0-^'Q-'#4[J^*%BAV"+]K2^63$'21>MBM?
MXVTM+](KQI]@8WZ+(9PQO+U9L(:FIYA;FZL["VR]I<5[ZG1N,7<'R0L#,AD*
M,XYG6.KZSMR=::L<T1)_:W.SZV9)JP5L\V!"6BQ)6G/61>!.<K8$$TDB1*0N
M5*E3#%E;@2^/"=*F;'%0H.;D"DLDAO7'&""4C4C*C5<&WA<&O9+K77->J;9N
M@FCWC8UW@Y,SCL$<CZK:I,KA9`H29)RC$LWF;Q*D*II2Q\@YG8V/LA5SB8Q%
M,_QH3SEMLV/I[+=#<S">PRLY9,6BM%Y%=6%-8A&YZUNEM$B#!XLYQU8^`6!D
MD@=D[E'65M3`/&_/S.ZMS%EQ.1'8!W85JU@"='5>*Q8(&RT[.=(5%>"E\>Q.
M2(^G+3&GOIT2RXXD!3,26M1F&NAC<%"46J3&&'A+4$B'A@[=K4L,\JVLD&P]
M//\`.KFDJJ)U[&XQ8L0DKD^/"2%NL^&7@AD>5N4B<Z.-(CD*E5Y(IR6.+(VM
MV52UY;R3\JH;NIIS(GRIMMFM'%/5/E/?0/03N++"JW\D6M/.Q/#$SJ:&'Y*(
M;7`\>)#ENR$I"L'GU)5&2\':?;>1W;Y#L(YQB.X9&NA]GK,UN"ZIY8QS%KG0
MZ[9X6]`GK$Z1TOT:2RR%+,TV4+;A6X*D6$@P+E>%8SDB68/''*T=G_\`E#>F
M5_Z['^@>.<LNXXY6/NKJP\VMLWIOL7[ST<V/@=#QG:>L;&HZ0#A)BUR8MDH9
M`VY'8$2;;-<V*NWIXC+C6A<,D+-)7QJ,4U]94K7LQR]R:@1]ZK+GW1UW'6:4
M4W5T5V_F)=IP]'IS%7B`K&JFYC"(O#Z.V_C=[`1Q.T[+K1SLI<74$;+0*F-`
MJ=$K/9\BJ2%()"Q^YE4EC+=Z6V=&L;VIM0N#HI>UZ-"D2K7E80A2JW=60G+*
M4NBI,V)43:F4N)X#%IZ=O1I$)!IXRD:8A,`HH'(\<KDZNO\`R:.ZG^(*:?S:
M3EC(?9G]T/\`SQ<W<A+O)7ZJ\*M<==GK6F2["U9=$4G;%/3X];<5JHF$.C6V
MMZZ`&ORQUEL4EIS._P`A,,"8^P'$E>(D>S$N*J)O9"@E/B+%WZQ[4V!JC4>L
MJLI)9EDZRQ#0:]V39"9V$B`AV&V4U3NB(6!.Z\DT>5-Y\O83)T@JA*M%:#Z8
M:UJ'>SDBE8ER?&7X"B1FEM%V+`)UNC>]J-6(G*-NMF4]M-%>#=&-X<X!7<#H
M^HZ!@#-*G",*W>-'S1X::I/F$C)CDCD;(UCD2%D2/3DH;%JY1/7F+;P_X&;9
M_P`6<_\`_9!YY@;IS?\`)\Z*_P#4XU@_T'P7DR^.,^S/J[^KV?+][U_+RLA9
M2$GM#<B`7XY:I-E'RS6Z=6\23L`WS.KGB2;+TU*ZZE4,9:Y1$1!<GEF8[*Y$
M^1BRI)'KK0L2*!2ZN&#,8/D:U<*3-<*;)U=W*W.K_;R-W%K+$J.MFZZYB9\+
MN*1;!PJSH]'%VOEO1VW=<]>HS#X1&#7QGK5TD[>[2"X)PZ.I3JY2=_?'Y*UN
MR,J(Q.,6!ZDT=9[-LANKMG:D;.KEQVB=->8_$*H7/48DKY#8)K[4QT:`OE#Y
M#7-[C)S]*;"FMBK4J-F>WA.FAJ&(J5BI$].+JQ,]A7''/.WUZONM5_\`"7G_
M`#5,<D#UPS&1LUIJZ52B;TQ%6&(7XP//HJX=T9ST_P#W4/BJ!6#'V8B![,5V
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M022*F9D9T+PJBA3_`);DJQV6%![O<$TCZFRJ/@Y)KGF1(;D9'-24./2(IK"D
M,KFQ#@B+DAS47&E!^2SR\^9)G<Y;@7C`)/@91H02?#[,?@Q_)S7CCCCCCCCC
MCFPS[G'[LO\`G`\JJZ7UJUE'=/V-G?[$@K([([ZW5"K;'>81QL<4HA;M[%#"
M%2B7N:=40(0!!&'!A0<Y`((L>K/+!O?PIGYV:S_'^(?GGCW\*9^=FL_Q_B'Y
MYX]_"F?G9K/\?XA^>>5NV,T,<"ZA3+OA7$UK^UF*;:I(]1+=JMCM6HX]-6-/
M#;7?;CJVUX6LGDWC,3D2-*X2^=0^?1-PE46<0(72,R6/FOZAI<&0R#,UU#]^
MMEVBE$WL>JZ]N'>O;&'[&$S>(736JZ4Z'M^M-$,U<ZVOT-=4LM:"YM>3N=`F
MIFG2N'.!,0;6ZTYS&Q2"31B/8?9S\MI`BEF+M#6=#-M2-8]S7.GG/3S;#7FL
MK7K"5LR+0>SHZN.MY7!"8N^"<&"!P2054@D>NTFD9"-HB;_(7&"+@*7V2^;N
M??8]4\D9]A=G:R>&?6R15%:FR+7M1K3N;[]M4)WO5Q0FUD9-?6*#M]0@?6^=
MD6)0[:RO#%0JV)#,K@F'312>Z/$75M2I@>HH2G3>Y[0UDKR!MLDURHJX:&Z6
M[AHS)S2-@H`J@^VDV:;8H&:-B`#M$'UQ?FBCY(R479)0WNQFJ/3]O6[025"M
MB8DJ>8K'?)".M;F>]O9MN-BOZ?AD76[M:>;/*->W/9/7-QF,[B$'T4F^I=B(
M,*(U.U%:@LVG9Q,66TX"3(IPAB\KS#"1(Y.T/*5A%C&#MHB\8S:IJ4O7IP:[
M+TIZR%=PR)'7-29K?3,RZ@%_1"T:`I!N-<9$$H47K>/-4NS*WMC+,AT1DDY?
MF>"%/,<'A>IS[5%"R-MV`C":[&>K;,KI[=]%K]BEK%;LM3`RZZVMJUK]5%52
MR(3*K(_-FI_L.0)Y?63[-JND$--?X+*\VG(V2T!,K$G=T4LESU$(+1VU"IM8
MIE64.MMNA->N\JHB\Z0V?J>DMHJ"V%PZ*TZ197EAO]AP-SA[`Z-!<?<U[ZRR
M-X;LN#(!!)Z\F;<>2F1UG[`:>7M9\(V!#,I_KO=-^V1TM-"]9'.[!6_3<8Q9
M&TU"WS.+4MN;CRX/#<\,+2<CD$1/99:K:VU>[/,1\X2,C)YNRDADJV4'*7"?
M-D>E$GI].3`^K;9W41CNR#9<]4J7&1T/83=+WPVAU#,?/B9N&S5S#,"-4).R
M.K:34!M,QMOD26;K\(6B)$XIUGTU=::J_I%(TBS6R$SO5AXV?8]D%\9N*HV]
M\0$W74=IUY#;,87QC5F%3TZ&+94U.!3?E<CD*;Q%IF\H@HE2I38\C>K=KEZ]
M5V:YQ&GTNR>J16ET"D9KSO9'YS#]\JEU#V&C%N.\%@K<Z3`F)5/!K$#''*QX
MNWW3'V9\9K9D.(*[^AZZ*D,MDEKO3>&331F\#I;*ZIJN)OW>^XMDJ^8B+JJ*
M3N`X59\2K5(6=(@0N2N3*SR<3Y%'E6_HB75T"<Y.!RLIR<0&9<%5EGOX4S\[
M-9_C_$/SSQ[^%,_.S6?X_P`0_//'OX4S\[-9_C_$/SSRN+9:V:M6=0#IJN*6
MR("I0-_V:OGRTB91HY(B\I0\<P5YVJ*=!ITWE1?:E^7,+\0O5CECOOX4S\[-
M9_C_`!#\\\>_A3/SLUG^/\0_//'OX4S\[-9_C_$/SSQ[^%,_.S6?X_Q#\\\>
M_A3/SLUG^/\`$/SSQ[^%,_.S6?X_Q#\\\>_A3/SLUG^/\0_//'OX4S\[-9_C
M_$/SSRO'JR6]5+MTW-SD#79=?N*Y10LQ*3HT$UC"Q6H-,PB``LE,F=33C3!C
M$$(0`!D0A9P$.,BSC&;#O?NIL&1`%;%:8$$PP(L9GT1#G&0C%C.,X$\X%C.,
MX[9QG&,XSZLXQGU<>_A3/SLUG^/\0_//'OX4S\[-9_C_`!#\\\>_A3/SLUG^
M/\0_//'OX4S\[-9_C_$/SSQ[^%,_.S6?X_Q#\\\QE=-TT^IIZUB$]J5N<<96
MD_"645.XF:8,7N0>LX"`LMX$,0L]O5@(<_P=\\P7T]+CJ5MT%T>0.%GUVB7(
M]/M9$RM&LG$62JDJDFDH,`Y.I3*'8L\@\DS`BS2C2P#`,.0B#C..3!]_"F?G
M9K/\?XA^>>/?PIGYV:S_`!_B'YYX]_"F?G9K/\?XA^>>/?PIGYV:S_'^(?GG
MCW\*9^=FL_Q_B'YYX]_"F?G9K/\`'^(?GGCW\*9^=FL_Q_B'YYX]_"F?G9K/
M\?XA^>>/?PIGYV:S_'^(?GGGGSZZ]GUN]8U<,9Y_"74L@Z\0'#;99'EX21")
MID0`FB2N1P2Q#Q@60A'G`LX#G.,=L=^29ZNDFI*9>\_4EG[GU1TY)Y#[()M:
MM-@=D*0I"T:\G+0HK:<0B3Q&OG'8LE1289%@<L,33%H=W-'/&AK;$2Y/'C(]
M)6=]4=TZ3%A5DBB,]I>NMRH'U$W5%/Y'/9QL;05'TS3U,0T+C'H,P1RNG@6O
MY"&E'.=J0,2YP3$PU0\RM:RA$\S)*TH,,BUUN`=VEK?VMR8WMO1NS.\(%K4Z
MM;BF*6-[DVN*8U$O0+DAX1D*D:U(><F5)S@#*/(-,*,"(`\XS`QBZ;&OS3"_
M<*YNMI3!L8ZUA%/U6Y2J;@5R2CJWK&PV2UJTC=72)L96ES3'P2PHC`9.SRF9
MG32:.*JNH$CE$BD#7&$2+,HJ6I&(T<Q25KC2I[>G>=3J36=8<TE*I`LE<^L&
M7&),/4JD1S0UL;(4J$WMC,PM;6P,3''H]&F%BCD?9VQG:4:0OC+H_M[0G^/-
MG_T?63S.@?9C\&/Y.:\<<<<Z?/Y_"ZLA<GL6Q9.RPN#0QE72&4RN1+B&UD86
M5M)$>M<G%:H&`HD@@H.<X#XLFGF9+3IP&J#2BA^<OI;=;C.Y_4!V9H28/2!'
M6UAN2^3Z9(%25N:W)%'*X0X:)#$W$)9('-8^SJ,H06^6D=CSE;.L*E[,6(I*
ME1HR.T3C]D`Q.-;Y4OJJ]499E+P]19LNJ^_G^_8RFB,E8%;^L)C]&3.%HD,D
M7!!`I&YF(Y*^O4C1)Q'0^1-"]J*\DG5K#/1WC/?&,]NV?CQ\F<>K./O]L]\=
M\>K/Q<UXYL,^YQ^[+_G`\I,Z<&D^FMIZM))[9NI>LMBSF1W_`+I*I#,YW0M4
MR^6/RHG=381$2I>9'(8FXO#HH)1IDR0HY:M/,+2IB"`BP44`(>[VQ2W3@@]V
MQ36:`]-_5JW[^D]>N-P+(-'=<=<(ZV02H6V0E1`-CV)+Y5%$+4P,S],##(G#
M&AL3R"72][0OAC/'3&&+2M]8^RUQ0'3%F#&[N,XT%U(HE\89Y+J\<H=<>O.K
M<=?A/,/=F-G5.+2:WMKNROL:?#Y-&UT7>VEU5%.[5)(Z>:2WKG@AL!F4G2#I
MC*"RC4^H6B1Y1S,KD1)A-`:\&@-86\TPE<]EC+B0@F-",XHTI6Y@R)"F,+,`
M>H+$`6,1/L6(])ZO+QUUJ15HYI4ZQ78>"[!3YLO%!2VJF*GB39KPS0UZDZ:1
M/0V01V#7%+-FTQ$XDE%L*,M.J](NY*GR",V5R[2+IAMD@CL2<M1=$&^4RXE4
MIBL;74#KPD?Y*G0IQJUI\?9E$2+<GHE&E+,4*S6Q*J+3$`&<<(!8!"Q'%[J[
MI?M6X%8:;MV@^G\@E=DU9==FJI,RT-K(M9(>=2#M4[>]PR5,*2-J96V2AS(M
MN-/#8%R9VYM&V`--)6JU)9J=+U^S81TP*8V>@NMMK=.#6BOV^S:YL^QX)L!*
M-=M36NAWTJG(\1*K"@_ITXCW8-]CL,7-43(<97PH@A=`V643!L=ES9%9%AM[
M/6-3]+6;F4G'YKH%JG1UI[#1^:3.JZ1M36[60BU7R$0C+6-RE:MAB;/*$32A
M4HWQB<$Z%:Z!>4A;XVMKTW-,BPXL;;G)HU`Z5#^S!D3%J[T^WI@%(<1(+VTT
MEK6Y-`I3D0`8C87-%&3T(G_(S"P^AL*,N?B,`'S7N,.,ZLNGW2JDAS:FCVK?
M3]?5#S$<V`T$,U(ZV.ASK!,*LH?=HVE(8P>-?$O/<91^Z5($YD\ZQE-E?Y;&
M0<W(=.^E8YIY&K;M6>G^O2P[#3F6J$='ZVJB(OA];TCLR>Z(XB,&%,?IAJ7H
MG)J]*#2>D6]8E6HO+IE!1H_D5:E])]$C:W!9K)T]4B%[?4T89EBFF-9R$CM)
M%A)2A)'VQ2;&P$.#XJ3GDGIFA&8<XGDFE&E)A%F`$+H6QNNG3,URCL$7O^A.
MHCY)[;M6'4=4L00ZV:^-*B;VM/`.RF.1C#^_P]!'H^4<W1]]<U+F]+B"\D-1
MC<TIGB2.#(P.NZ`ZU].!^CTD=K.Z>6IE`.<2F$JA;NRVUKYJZTEK5$.C:*6N
MTEC+\@9UK'(H4?&E1LA0/R=6F.`R(7%:^-;$:VN2-%D]PTNZ7#3B("=-3M"&
MX-@*4:*""7T1KFCQ-%C@02I0)(EE3%"L254N3*4ZA&G8_/SE)!Y!Q`#"SBA#
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MT`P)@6JD+02:)CB+2YKY;+5X#$;&TG%)'!8BCU9TFZ3%?I,/3=TY=;I3'8]J
MK7>ZUH*\ZSZS0V05_KI:+RZ,L4D@8--V)DEDQE8CH[*5+K!8RWGNS6*/^Y\U
M09-I-"(I)[+"^G5T^#2P&!T4T["$80CQ@S5VDRAXP(.!8P,HV!@,+%VSCQ%F
M``8#/<(P!'C(<;_@Y^GS]!73C\F"D/T%X^#GZ?/T%=./R8*0_07D`>J?H=H]
M"^G?N!*8?IMJI%),QT=+W!DD<:UWI]B?6=>0!((A<UN[5#4C@WK"<]\E*4B@
MHXO.<Y`,.?7R?N.G1T^L]\YT6TXSG(A^W6&D,_W8OCS!LY_ASGFOP<_3Y^@K
MIQ^3!2'Z"\CALIKYTT-;([#5KGT]M39]-[-GC76=45/%Z*TZBDWM";N+<[/Q
ML>B"VY5-700YR;HQ'W^1J$CG,FU0L1-)C>SE.;\N:6A?\MRT+TTM?]<A[#VY
MTZ=:(B26AK])FL!ZPZSO%BBL2TI+&X)`ZD3^@6IRA2Z<OUB2Z/P8H]!,%4/*
M>%PEIDIQ'DQ[R'E->M;>FW?K?9"0CI\:G0N?4K9[O3=P5^_:TZ^KG.%S]IC\
M9F)"4#JS0Y4TOK'(X1-(?-(P_-QH2W%@D:(*U(U/29U9VZ0OP<_3Y^@KIQ^3
M!2'Z"\QM<G3ST$;ZDM!<@T?U`1+4==3I4D6)-9Z43*DJDB*/!I"E,H(A!9Q!
MY!H`&DFE#"868`(P"P(.,\PEH'H'HI)]%-+)))-+=3)!(I!J7K>]/S\^:XTV
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M%;K0Y=,/7RB[;U^M$=0733MG:QZQ+Y%#9<?#8I8S`J0R6OFF70>71>60*;Q>
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MT_L37%GGW2Y`QJ$;B/TAYBK4#*(SV*#,[CCF"KH_MY0?^/-G_P!'UD\SH'V8
M_!C^3FO'''(][6[&0G4K7>W-BK".\,9JN&N<D-1`,P6J?G8(0HHU%FT6<"P)
MVE4D5M4>:P9QG&5KD4(78L`\XJ5I%+2?7\TQUOL:_'27L!%66:O6W[K[6,R5
MQ^MY=:T20A2^YB=)SR%LC=H(-(O:)Q#`IGIN=2VQ_P`D&.@U.5)Q-NL.U8UE
MKQ[:)+`M=Z,A,DC^!88I#$ZE@$=?F;Q(C6T>6IZ:(\D<T`AMQYZ$8TJLHPQ(
M><G&(11I@118N'I%].B_K)F-OW!K!$IU9,_<`.LNEKK);')<7A>4VHF@D\P#
M;-$")+A.VMR)&G*0)4A"<I,7Y$HL6,BSR]W]1G473FZX+K-?$N>J@4R.I,3V
M$SZ:,SQ[U3NV,3UB(CAB>PU![B>NGZ0*8A<I:E:<X8D*IO-6.PG1W0I5=@Q9
M@#0!,+$$98PA&`8!8$$818P((@B#G(1!$'.!!$'.0B#G`@YSC.,\W\V&?<X_
M=E_S@>5L]*QU;$FF4;*5."%.;B]]ULY+/6)B3,8^S>V,QWR`TT`NW<.<=^W;
MOC./;C/.F3.L;+ISJ1.NYE?0PV\*NO;5F!:X6G%87)*]1V=5DOI>R9O/:^G[
M(W3V6PIJE5;RQFLR3QZ;-#)(<R^/2)CC#TWQ^3M3JYF1GK]NZ]+-A>H%I-L)
M9>OL"=ZOJFCMNXK-CINZT[,3XG)I[.M<910@7MD6OBY8Z2%F-J^<OIAL412E
MCKZ1/#6-GDB]6K7.Z2KNNM$MEF*&4A6\XUVD2V-T[K+UB==YPXU[?-`0V0S@
M&U^R=:6O1SO34E53=:<TI9+#61V41I?-V1BS&)FV*F:P(LS1\W+@\980Z9;4
M3^>:UO%]5?`;18*OQU34DIDCFVZ\5W*[";=EJOKV.U#++NJ",S@VJ0W+8S\T
MS-'/QUFC*@)I0V*:/C1"W61/K*Q]=UDTCV:BBO7FN-CJCE<]C*2D^ER\M5AQ
M_9.K6R-ZS7OI!5L2@\X9[+0(IR594I(23J-/]L5<Z4JJEL=LU18,BA-EEQ!H
M=I*N<<BZ,:N[,U3L+T_72W**3,2K6#7;?&@]AMC"[.I5Z:KMG-QVU3-@P:Z6
M$*"P5EK25EME5"9K-WHB81&/2:)368OC:X1\E*6-W7S>WVUWEN^`WVCW)&IJ
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M-A2*<NK1:LZ]W:N"1Y`U+D"U01Q>PW3YNH^A)OKW2^I;A)EDRTOWKATFV7E4
MWU$07E;VXFR"2KY.[RVRF97:\@KVM:RN*71W(BGFNT<BLR+**TKNM(Z[5!53
M&@7O-W^Q%?--SZE5W3MO:W1G9F+S--5<>ONE)+-H&1(69B!'0F2*21J1.4Q9
MV)78-<S%&S.K,Y1^;M;L8M2*G*&28AX+;%^:O:XT9OE-8FFP;&89S<]`:Y[[
M[#6)6#+LW9U/V=?-,:?3/2*8U+'ZWL:7.LV7*+%1N&QLF5.T#C7IV>RA@J!/
M$"K)D"A\8@,[-'ZJNGSMA%M67NB;-I)AGRRT.E-'=,Z\+';%6*BM2+^KVYM@
MWUCDS@Z`EYQ3'`WM!9U+V>U6%4@I?+8ZZ4%'V#W/H7>,P!(?D^Y^F;9$UK3J
ME]J>K6>W;<MRZ9S*A[0D;C2#9+;88*8K/3!DOIP;WP^1KU-<.]M3BA;)D3DT
M2]PC*65+W]E725>(2Y8H;L],VJ5[O>TEP"G4&DY*91L1--H-5]KVF_:[05W2
M'O@:N9I1N@\BK1DE"6X72QZC-&MA+1#TK,_T%-8&L:WQT?DJA@*C)G$].?6Z
M_*EV;U;G-I:VHZ:::=Z59.E-KSP-FT?)4<[O*%79#)<.:,PXG8+W.Y3"[*)8
MI;8C%*)<RM<I"XS=P!,V)CD*IW$?Z#/3S)_?=K_RBB_V_'IYD_ONU_Y11?[?
ME;6S3DWG=0?IF'E+D9A(/LW/$:6J3C*#Y&@XV:=XC`&9`'R10@F&=Q8\F7G`
MQ]@YQGEDOIYD_ONU_P"447^WX]/,G]]VO_**+_;\>GF3^^[7_E%%_M^0GWG9
M&FZZC?-='BDK0NZO;MA\[C\Q=JBN:%U*."KFUL1*X>7*9&MMBN9LC:I8\GC3
MIW2&(9HWMAS,:&;L`V):64LJQV<TCVAL-OUY4/#J5;FR.MFG5$L>N.V</D5:
MMJZ`[T0V5D'W9/M@"YDXQQ\L.A+>;F*O%"^+*6>;1PYJ;;-<@UTUVTIK9^+]
M$9;ZT8`'!KRTB,QC'C$!>C"`0^WVX@!$I&((,B[Y`$0Q""'.,"%D6,YSO]/,
MG]]VO_**+_;\>GF3^^[7_E%%_M^5T]6]W:C^FINJ`AR;SAXH&9YR$I:E,%C`
ML(B\9\(#19[9&,`,9[>L0@AQW$+&,V+>G&8&1@&[-@1@,,"((G!&$01!,%@0
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M6LU9ES2N115@/IYD_ONU_P"447^WYC"[7IG-INV`%NC:8/-96"+`0+T@Q9P"
M'/8QY\(3LY[!`$0A9[=@AQD6<XQC.<8'Z=;RTD=/W1<HYS;BC0:<:P8&68N2
MEC#G-'006,"`,X(@]\9QG'?&.^,XSCU9QR8_IYD_ONU_Y11?[?CT\R?WW:_\
MHHO]OS3+ZR9QV],->/9_^L47L[^O']?^/'?'?VX[]\>OE$[QHAM2S=1K4O8M
MMVK:K$I^$3S<FP;/,=ZYIZ-R./)+K8ZW;&*!GN"60`?YP"2QR)M%8M<M2-A:
MRO(E7,;*3HDQ*@.!365)[?ADVW;V99JT267:"UD@=2ZQ54*>5I&S)I7-6Q<V
M0MJT^5O,I1,<.;YO=MI6<YOPGIQ0/!</B<?49;%#J!H;#?JT(#.8]%[3-MND
M7NE9G,K%-L6:R^P;6I2;S*\+(E;2D)EDT.::7EDTBT*A\5:&6'5K6\<5RI<\
MM<(B;.Q*$OD&$A_DD^?3S)_?=K_RBB_V_'IYD_ONU_Y11?[?CT\R?WW:_P#*
M*+_;\\\?7F<V\[&JYI*Y&:7D^]2_*%JDXP>,!%*B&#QA-R'QA"8`0@]_$'`P
M9SC&!!SG+?7W:JAE&K55Q"Y(S1CDS/%\MBJ,2_:O8J]M7=8*XG#17%A*6:2V
MM:.N)6+1/6+F\UZCT!AB)TC;1))2YEFN4A3G-*!L=>U]"%OJ)AT[E4:IF*TJ
MRQYCO.6D/LGUGV`O#9G7"RIFHAE=J)!,Z;M;8@@%I+F('=%&)''W9<^MT8G,
M=DK6T2!S3A'A-=9QWQZ_7CU>W[WX>,9QG'?&<9QGV9QZ\9_?Y@JZ/[>4'_CS
M9_\`1]9/,Z!]F/P8_DYKQQQRFSJD:?W]OQ8FI>M*-H1LVE9-A*[AVNL1++43
M?*EWO?@`7":J8X^%02\#]UV'5W.+?TR5S0L[D6C>5`FQ7'D`'>:6INAFJVCJ
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M62H"`AV:5.4AXR0D.;::@>6XQ2U.2!6HS`9]SC]V7_.!Y1=T[M`-&+DUC3V1
M;.G6L5EV%)[_`-T%4EG$[HRMI5+9"J3[I["(4ZI[D+U'%CLZJ2$*5*B)/7JC
MSBT:5,E`/!"<DL$X/@LNFG]`#37\FRH_T4X^"RZ:?T`--?R;*C_13D:G[5#I
M21[:>!:EJNFKK:=.["INQ;U:96FUEUX][]!`ZMD\&ATP->7)5E+)4KNED5D0
MM`C;DL47@7@>!+2E8438ZG(\A3W1_H\UA!I394[U!T+CD%A06K,IDBRA*7,;
MF0Q^-:B&)*L&DC"@85SX>^LA#*W@+&N=SG=K+;4ZH3@D\MWE/TU>EFK>%<?2
MZ-Z/J'YO1IG!<RD:_4L<[HD"T60HURML+C0ER9&K$'(4JLY.6G4YQV(-,[X[
M]&E>C_1W@S4V/<JU$T'9FMZL:+U$U+#Z)I,PI?9TSD"*+QR#)_-8T>(R3.#V
MO3)!-/APK1%X4+G`I(@1JU1&(-N];^E!IC`6"U++Z8M`R.MG&<0Z#RB;0+5_
M6]<P58*=2)MBK%,+052M;#Q1BN@/CLWI'Z;D%NK1%2E`'"1Y;6WNKQ^BC7CH
M[M+S=897H#J=#*\HR7PFN9!=LDUQU[(J>365-UK&S$5W!'9O*<9'()?'9-)&
M6'2QN.BK:0SS1=B*%K%SXD<D2"29736Z61SLN82='-'37QK0D.3DSEZ_TJ-U
M;VY3D6$J]<W!C>5J-"HR`?FZQ204F.\.<E&CQSY`].3I2&]@!TGT3-\JY-S&
M$&*&HXS!KN\H27%J:,!]SPL&.+HW*2%R!NQ@2M>A/*5)2#TQQ9@ON^#.Z6Q3
MDG8L:*Z0%.J@*KS1HQKU2Q:\T#<2D-6>;-V(R%2,M"0N0C5>1(R%(4K2#.\D
M6H($9^)G3;Z5I29P6FZ0:,@2-)*E0Z*AT%204[:0C!Y18<X'BCF"D1*4O]L5
M&J1E%IR_MSA`#Z^?DX=.+I4-,47SMTTDT8;X4UL*R4N4M64%2B>-((RW-YKL
MOD*M\,C>&PAD1M9![BI=!J<(24))BH9^"09'B$,8@?2"?&"E;+>^F#0L`U_V
M.E<3AU&[`3;5[79K@TV=;*-"13:MR8$PUUD5^P7@>:D3U._3Z%1Y"^+G6-M#
M]F+/4OBC:\S:<.G-TI&I,X+'32G1-N2-`B@NJEPHBCD2=L$>N-;"`N!ZJ/E%
M(1'.1)S>4%4,D1BXHU&#`E)8R@X/SJETI<;=H=.L]-K6$$V<=<7;9=%,A:U4
M)F#*X@SV9'ZN6,*<TI`;)/=*2]2)$O-`JCR1G$UB`8C=EJD1R=/)?X++II_0
M`TU_)LJ/]%./@LNFG]`#37\FRH_T4X^"RZ:?T`--?R;*C_13CX++II_0`TU_
M)LJ/]%.5][$].K0)BWJZ=T09M)=3VR+3'[,;W6QY#KY529FD_H6CX\M9/=`W
M%Q;"5X]!KAF.#)Z0+4>AW`TU>V^:K#3#Q6"?!9=-/Z`&FOY-E1_HIQ\%ETT_
MH`::_DV5'^BG'P6733^@!IK^394?Z*<P=LGIQTB-4Z-LS8*W=$=0D$"JR)/4
MN>RVC5ZI7:0.P&A`>L(8(PRE1<HY[DSX<2%M8FDDPL2UP4%`,.3)@J%1$6[!
MCW1J@+3F0F]-779_8HYK%7NXMNKF?6S6<M13&OEFK'I'&9E*&IX6M3K*EH_<
MG-UBR.5@CG#N4BA;P!.2J=W6%L\KL1*Z6W30.+`:7H#IKD!@`C!G.M=28[A&
M'`@Y["B>!8[ASC/86,"QW["QC/?&/T^"RZ:?T`--?R;*C_13CX++II_0`TU_
M)LJ/]%.0(ZHW3CZ?T`Z>FWTP@^DFJ$1EC!1\M<F&31O7^K69_9'%-A&8G<&A
MW01@A>VKB18_:E:(\A0`(A@"9@!A@13WSTM>FH8(8Q:`Z:>(9A@L^'6NH0![
MY&+/8(01((`AQ[,!`$(0X[8"'&,8QA\%ETT_H`::_DV5'^BG,!;#:;=*_7B+
M,#VZ=-?6>QI/,Y:@@U=U76NM6N:FR+'E:MN=7]2RPQNG)L#CK@N:(K'Y'+70
ME9*&X9;"P.1J3"Q?A&WJ^/M74OI/4AKP/8NV>G#K3!V4MG@YQD`<M6:,7V8&
M8V2]QZ(P:JP,T?1/+`KL61SR5QZ"(6U!*%C'F3.918Y#AK+.="^3H/33I4W\
MUST3-TZ=4XE+ZELE\J&V*]E>M=%YDM?V&Q-+!)#&-T4QUJ?HZY)W:(2V)3&/
MO+"]N3:[QJ3-*P!Q"H2Q"CSU\%ETT_H`::_DV5'^BG,<W!TPNG`U5/9[DVZ%
MZ>(7!#74[5(EJ77"I"5*141$W@Q.J3'`BF#"%*<T(#DZ@H03DYY99Y(RS2P#
M#A30KIJ]/*8:-:8RR5:-:D2.3R74[7%^D4A>]>:J<GE]?'>FH6O=GEX<E47,
M5N+JZ+U"A<Y."LTU6N6J#U:HXU0<88*6/P6733^@!IK^394?Z*<?!9=-/Z`&
MFOY-E1_HIQ\%ETT_H`::_DV5'^BG(I3S7SHT5YL_4.H[WHGJ0=;-PP:T+';L
M(=8J8%&8?$*J:4#P\.D]?E;&D*81/2=::&,H"2'!>YEM;PXG)T30W&N`HW(7
MCH=EPY18,OZ=NO\``(8^Z_*]I:8?))J12!_V0E'D3*(P!+*:N;F%&\.0'IWE
M=D50@:(1.$T.EBQ+;$`<<MQ29P>O<_+"BM2.E5=\BMROL]-S5RN;;H>1QN-V
MS5<UUPU^4R**F3>(MTZ@KT4ZPQ)*XE((W,8LXA7,STQ2!<2!<WOK`YE-[ZPN
MC>GD=\%ETT_H`::_DV5'^BG'P6733^@!IK^394?Z*<?!9=-/Z`&FOY-E1_HI
MRA_K8Z'Z2U@'6DJM]1-:8$!Y/ND;O[CJ0KB-C=<H2:@P@PY&-$>2&+P(//%N
M4):H9I:,2U:),$H2Q3DV5'6"MR6TK.F:-S;=#;NE:EV".AI;$VTOH9$=HX)"
MBZQA-L'SJ,'N9E66-A_=;=>G2$O[S&9JV+5K`DA*1VC.`L)CXH9)J]'J8+9M
MJJ]._OS7Y?4:3W%,66!V+L'KHT:N2%=#V2/PIO3ML0JACB4#;T$`:GLI\2M#
MD7#V$:M[Q)$AJ=6)NPYKK5L]^WJ^+MG][&?7CVXQWSCOC&<Y[8SZ\\\\[=M7
MN'"FRYZ\N]XNBMMHISL!IS7;/'Y6JUNFFOE7T_MQM*IIU);>JDVK.K(])I,E
MC[#B0Q)7%=@U$PF\-L2/PP]^"Z,LE)=9'9SI=9,YDSEME4<ZEA]@*-8-I7JF
M(S/7`*$4@DD'>Z<IB]HJEERIL2MZ!?+84BN4RO79S);TJEX3Q5N>7?*E]<'1
M6HR!<$M2J+*H^'!9Y46K1W(R.`GH^+O)$2/+'7-B&^;))68EPR*EX<'!`-`2
MK$J":`XO)?B),P&3X?9C\&/Y.:\<<J"ZR/4S,Z;&O<>DT*:(W++PM.3FQFM(
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MA.+3>%:N/Q?$/[G'[LO^<#RN?I2BQC2Z-]\"_P"'C=;V!%G_`/?=V+^3&?\`
M?U^S/+&?%CY!?Q!_ZO'BQ\@OX@_]7E,&\E`7/:6W*N61.EI%/ZT<.E=OGK.O
M?DZF"X8U-MWQ*Z)DE<PA4TR.5M3PJ(?T582!.M>\,AT695IS22^O"`I:-0EJ
MREO3-VA7Z]65649U:4%'R3IE]'J#R",B>JB2I+$VKTWOIPEE]-ZX:^=`:GZR
MFNI5+;&6FQY2K3,LP2)0QAOGJEO0@\GVZPM--W9_L>_3&E]9I;JE,W"S.JE$
M&VU6270`<09&K8G4-Q@VK]YO,[(LN4VU)\N5B1NMG=_B3$F:Z\I-TCT8A%?5
M<4""MDP=<DG::3RV*0UUEK)TRG^B;.K/9#IA2'8*LY/-:4=%%B-VH[]*V&RW
M>O6(JV9!6#Q%8I$9@L3M-C.[O#;+N6-+#6B1L3BEB,;1CN[VZ:IK8-?MFO<:
MJA7.(UL*:XU3;LR5(8<]06I*C?V98BGLBD\8E+ZTKIDL?68T^&PUA8F"3IT\
MB?D<HEC7B)1YU3+J9YCI_M1C0^U.G<IUL?;<A>J6T&K$IU`L]X<Z1`9L/JM5
MNU=,7"Y1MW0/4X:_1MZUG6R.PJMD3[.FF!M-XH&)-,2G4;O.9"W@P=;FFNT]
MA['2B9M.D$KA;2OM3JH1":DL4@JI[AUDUIL1J4N@M#S1WEDLM)SG\V+LB8QN
MOLO\-5XC%54PO:XQ"(K6C<C@J.8N./K"Z8>RBRB['9XIJ4>19^.DITS:L@JQ
M*Y5&@<0[UZYV$^J[6DJ%\'.22$=K0V%G0A&CO5P5ISG5GC8F**SYQ+;4S>IR
M74&LZV]-C]C'VL:5<6FZZ3Z^K_=:;:HM+&FXF`T?#8;1DFOJKFZ5$/(YJH+N
M.+J7VK'JJ$;6EC4U?["0S!\\]9XX[2%I[0ZZHV\*-6#<[GTSWA?<EFV30$60
MU.VD4<C@>IFF=,[&P:;1Z&P9EB%UL2+92Y5*YJ#L3;K3)7M'6]IS=O0P66&R
MRNZOB\0F\W=4M,+7DG3+W0TFMUFF-)*[ML7J3US!%4D'`W9P8*BV6LVW'*L9
M@TM-7.:B$-S6CC%C(5I<4CQ$::T"U$Y-C.Q-;5Y@8;T^R*'V0V=TMU:Z?THH
M^1U5*H/,=.B=C+<5*(P.H(E$-/YW6-BR61TI(&UZ<'R<K[>=*M:F&I&4B+-+
ME'VJ5+'"TB8.;'5C0OB[%M#Y]"&>,KEG3U;7>0V'U/=\+!GTZ:V^EY%9E>ZZ
MV[,-FI3KD_((A(ITDJR;Q)<VW`DC!+-:(IPSZ^*)3)INAI[,X"1(&?.'3#U<
MVLJ2T=!)5>=23**I:GZ.J?5*RWN1R6&/ZF.W<RWM`9`DA[AZ'F+X[+PK(9!E
M;PWO;>E7,!"(YH:U;B@=SLM";T+>+'R"_B#_`-7CQ8^07\0?^KQXL?(+^(/_
M`%>/%CY!?Q!_ZO*TMGL]^H9TRL]A=L?9L?W(OF'CGWOX/ESZL>OEEOBQ\@OX
M@_\`5X\6/D%_$'_J\>+'R"_B#_U>58]4C4S9+:*F9TCU_MV.Q]R;-=MEXBUT
M[*:F13A)94]M"KG>%,*M@F#A:E;(*VF?H!QDM>L,N>DDH9X^BL1]=SF\G(#1
M&UOW?HGMW(8-K44[0X4CV7U^TDHN)ZRW?6D.@C5'HUM+%K%3OUB5;M%&WB:O
MB63ZY.$4C=/M)[,[.\UKHT]AM>R8NA8+E+JH]%Z:2!&8*+\MC'E?`'RODP&>
M3\IVQX_!XL>+P9'XL@\?V_@\/C^W\7/U\6/D%_$'_J\>+'R"_B#_`-7E<O5T
M%C/32W4]0O\`@"FG]R+_`.;28^3[_P#Y^S'+&`BQVSZA?=#_`+D6?[L7R8YN
M\6/D%_$'_J\@%OW6M4W5"XE4=QZ-R;<V'3E1*V],JCK+5*LZFI5AD(3Q^5@D
MT^G$*E]7O#QYZL21ZV*Q,4/<&<6OT@N7LWC;3U$:MBZ!V6GVH50:W#BLJMNY
M-86SI];'*[=D;]#\0?8JTM8;XA,\LBHR'!UD*.7CL:3,E3.#D&12J+1J$.KM
M.HDJ62E"8;)$[-(71NI;'C=A[S;!V3&G*"F[;;0MEG0.!/1:0N2QVKZ[U\I>
M@(@NEZ1O<'5,TR>8F5:[S!2QX7&J6=I=V5*ZE('KTDV(;#?%CY!?Q!_ZO,6W
M@+'O-6SZA?\`!G/_`.Y%_P#P@]?>_P#Q^+F!^G.+&.GUHMC.!?\`$XU@_N19
M_P#V'P7Y,<F5XL?(+^(/_5X\6/D%_$'_`*O-,BQG';[;'L_N!^SOZ\>SU=\>
MKO[<>W'*$)7H#NDFZB^J-YJ[G@MNT@Q2W=J77"YK:$:8Y)&.-73%JXCL?K62
M+C[X6N$\5O\`!XNU5/"I7&X6WH*^8:^1J':)N!3R%-CK<>Z5<*F0)#'[2C]]
M&Z2T3J'/M1M5:/DK^WNUY(&6QK1@5CRV81-QB#>U2:,,];#I"DHIK:DL&33"
MRO)1MSD4Z4M:!$P)G&>^B6L]G5A.MI-C[R?)*YVIM',JY*1,TK70USE,.I.B
M8)[W]/,<\5UO'8W7RJT'OTE,[#L04);S8RSO4V*AS2[R1-%<25XL=\6/D%_$
M'_J\>+'R"_B#_P!7CQ8^07\0?^KSSN=>G/<6K';`OZY>?]R+_P":ICXNW?DN
MNKGC8YZJVC:XUCO!YI.PK:OMIKQ.L@-JT74=MR,YVA4Q4-)<'>+X1N39*&>$
M.J4BR[0KRN$(K?FE;Q)^:H.I3X$[!.^[I#PC;J`T5;S+N2;L0LL$6Q4J-BKO
MLI<-8W1,GV!I*]K!F)>8S(*FCT6BS17"Z9-4S,AS,:QMKTM0Y'*GAM:U\C/;
M4UISHWENS:X-9QZY*2XH5:`U2V+U36XIRUB<U,,]`Y(325K>M)`;DQ(N2'%*
MDB@):A.86<6`88@,.C%1(JOE-9S*16_;Y\O:8*RNUEV]:<DFENEH:JD.)?5(
MFNP!B;W%G<:XF("YG&GEM3IW@V:`'+Y$N?Y(I6.:G.E.4Q#J1CKRQQ/#HM6R
MN7R.PYS*I$N`Z2J=3Z6J"E$AETG<BDJ!,H<UH$J!N2I&YN:V-A86IFC4;:&>
M.LS6UI.$NC^WM"?X\V?_`$?63S.@?9C\&/Y.:\<Z;8D_B=4P*969/'A-'X57
M\7?9E+'M8+PIFJ.QIL4N[PO-S[183($AXP%A[C.-P`DO`C#`XSYV-;&+0_\`
M9#48=]@=A*FDR*VZ%DLFJ'W#,UOV3&D\>K%ZDSO-JKDAS-'7]N:L.LSC*PHJ
M4.02!'&2^+/K.6H.:6-G`5?GKW0=;ZOTW!:&J)O=VFMZX;%3/$FM\DK]+G%N
M;%3JO=_,1OTE7.3PK2I5+DH);B%*LPEM;PIFU"`A"D3D%YFXXXXY@S9FJ91>
M-!6S4L)M&94I+YY"7A@B]JP!U/9)9!G]04$UI?FMS29`N3`3KB""G+T>>C<3
MF@]P(;EZ!<:G6D5(=)KJ66#<T^GW3XVZ8BV#<S5>/JV"8S`,B:W1HN\Z"211
M%Y%)6@A,0GRG?&YH4PE]>LEGK`R(N0JI&C2M)*=<WI9NR#I3=.642"02E]TU
MH->_RE_>Y3(7(<&1DG.TADCJK?']X5@2FD$#<'EY7KG1R4!)`)6X+%*L[Q''
MF#%Q/P1731^A707XEE_TOCX(KIH_0KH+\2R_Z7S3X(GIH_0JH'\2B_Z7Q\$3
MTT?H54#^)1?]+X^")Z:'?O\`84T#W[]^_N**[]^W;OW\[]O;U=_D]7&.D3TT
M,>S2J@<>OOZH47CU_+_9?M^_S7X(KIH_0JH+\2R_Z7S3X(GIH_0JH'\2B_Z7
MQ\$3TT._?["F@>_?OW]Q17?OV[=_[*]O;U?@]7'P1/30^A30/XE%?TOGXD](
M#ICIQ'#3:/Z[I1J3S%2H:6`HTPE:LT(`G+%8B#R\JEAP2B@'*U&3%)P"B@F&
MB"47@/[9Z1/30SCMG2F@<XS[<9A17;/Q_P#TKY>:XZ1731Q[-*J!QZ\Y]4++
M]N?;G^R_;GX^:8Z1/30QG.<:4T#C.?;G$**[Y_#GSOOGCX(GIH>K_P#(IH'U
M9[X_^!17JSCV9Q_5?JSCY?;QCI$]-#';MI50..WJQVA1>.V/DQ_5?JYK\$5T
MT?H5T%^)9?\`2^/@BNFC]"N@OQ++_I?'P1731^A707XEE_TOCX(KIH_0KH+\
M2R_Z7S\A](/IE&&DGF:1:\FJ$WEO-5!L#2F*$GG`,%*?-%`U`CDOG)00E*?-
MQE^<%!"4=XR\8#C]?@BNFC]"N@OQ++_I?'P1731^A707XEE_TOCX(KIH_0KH
M+\2R_P"E\?!%=-'Z%=!?B67_`$OFF>D3TT,]N^E5`Y[>SO"BO5^#^J_5^]S7
MX(KIH_0KH+\2R_Z7Q\$5TT?H5T%^)9?]+X^"*Z:/T*Z"_$LO^E\_(_I!],E6
M2:F5Z1:\K$IX,EGI5D#2JTJ@K.<9$4H2J#S2#RA9QC(BSBQ@%G&,Y#GMCGZ_
M!%]-+/KSI706<_'G,,+SG/W\YRK[YS]_/'P1731^A707XEE_TOFF>D3TT<]N
M^E5`Y[9[X[PHO/;/RX_JOU9YK\$5TT?H54#[.W_R++]GR?V7[.,=(KIHXQVQ
MI50.,8]F,0LO&,?O>=\?!%=-'Z%=!?B67_2^:"Z1'3/&$0!Z4T`,`PB`,`X2
M4,`P##D(P#`)5D(P##G(1@%C(1ASD(L9#G.,["ND+TS$Y11"?237Q,G(++)3
MIDT%3ITR<@H&"R2$Z<E0`D@@DL(2R2"0`*)+"$LL`0!"''Z?!%=-'Z%=!?B6
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M81Q$N/1(3?`R'5"[E1X1T99C#7$+_D);B2$EY<;3...8*NC^WE!_X\V?_1]9
M/,Z!]F/P8_DYKQRC'K)SUWV#A(NE9K\H8WG:3:%CB,M<&A[D"*,M\/U_C=EL
MQ]@S<;DN=FQ.\OB$AD-<$E?$^>.\JAS3-'!O:G4+-E`KEAI#TL-3M`7QXE]`
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MHF]K@I\.(>TCXB8V%M2!5QYP2OK>[#RYA4EEVH\T[X]?KQZO;Z\>KO[._P`G
M[_-<9QGUXSC./7Z\>OV9[9_@SZL_?Y@JZ/[>4'_CS9_]'UD\B7<74ZH^E]^=
M?-!I"6,Z:WE&')S63`MW2E,T`DKH,TJIH<^-^$QZA0Z6J<TR-*UCPJ1B:E),
M9">G5DRM,>CLH[X[=_9CMW]?J[8^_C/;./O]_9\?*N.J/U(XAH/J[++3BB^$
MSFWU4U0516L"7NP5Z!;9)I:![?D,L3,+F0\MJ*'0DY1*9"F"8D<"DY[&F[IQ
MOK>8;1AJITWMS=^[2ICK,NNX54UY:MAS9EMN)PB-UU))PPQ&$PYV/B3-5YKL
M3/6(I.B]Q[8[PR51<:9:>VG.3V4].;@^JW017L6QCMCM\GL_!W]6/WL=L??[
M=^:\<<<<<V&FED%F''&`***`,PTTP82RRRRPY&,PP8\A````!R(8Q9P$(<9$
M+.,8SGF*6F^:0?W)`RL=PU6].[LI)1-;4U6)#7)Q<EBC/8A(@0HWL]4L4GY]
M1)"8DTTW/J``7/*5U=]/M_YYU.H-M7I-IP[F+Z18ZN=VZ[&"05HVBMRPXX:)
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M?90XS8M!-CY`WIK+)Q,6*O(9+9]*5)Z.,PF-/LMD*M*A6NBI*QQQK5/#LH3-
MC:G5N+DI)0(SQIV]O2J5RT_!:5(0:H.++%YIVGJ!VE9%M;8L48V#5*`VQ/\`
MI+Q&,,48<<EMNJU;[3[!S*G[800E6K90E9L!+"E460RR>*L&C#<DI3*60]$R
M,$3;TMR&D,VESJ][DU-(96]3I@UOVZD%35Q*I(Z.4ADAL#?J6I"\D$5D$I>3
MUKS*G*MWBX'NOB)`^.;K(5[''F4,D=')](7N"K)]P2O*BS*0B.8W+"<)+C9'
M#$G4,WDH@I\=<V(;YDD>_.1>7<`Y.\F--YJ#PFE'`\>?!XL^5KJ(:1:_E];^
MEDMVSS:R.0O<!"P2M#;D95MJ@YAV<=)N;$*<K^!S(^#*&:'0R&H(<P&&MJ\N
M2R)G`<SJPJD+<I&X)_5[M/=A>L6L%Y7R>E*?S*:J.:SU.W.R]`UER!VB\>5K
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M6+S\A2M>W5M`W'&B+;QKD)AX3\>:;63I!=4^%;%4)(HUJ1-JMDD/MVNWICM&
M=1.'.<#@#Q&Y*W+4$WEJ%OE`U;E%8^J1`=G=&W9-6.#:0:G;PGJ3R`C^[JB7
MSU)*NW>NJ"7ALY-B++CR>OB9`+6F?W77=+G$J:TBS@SKX;#<R%&6R&K6=2C5
MR,D"<*<^4FO*DH1A1V!9ZE?M.[^Z149KU9C=84VIVE-KHNUW)$(SKY=5UDLR
M=ZQ7==IWJ76B041'B8M,YFWO3.[+$*MY>&PMR/=FIF/+0M*0L-R/17WEZET"
MU_M-Q:=.K_W_`*^.M\I2HGCML<E;[`ARU3`HP:;&8M%;C,<W:31E2A+12(AU
MC[B2R#='A8FP(2O!IG+DA]<2/0$LK&RG3VZDFO(O*8`J=7S6Y9/(DE`'!0SS
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M<455*-,E<!B%YSR*1]1HK`[V@-*&EIHW`7A<-8FV3"9<4BL`3D]JQ2R4RER>
M@.(!-2-I=3FQM3IDEXN<=\9QZ_7CMZLYQGU_)G';.,_?QG&<?%S`\NUEHV=*
M[9<)57[:[N%X1RO(K9JX]<]EJY$T5*O?G:L\E'$.A0F%U@KS)7=\C,@C?H=_
M:WPY*\D.>')L;%2/N%65+!*9C!L3@#.:VMZU^?I6]KG!S=)!(I/+92XFNTEE
M<LE#^L<I!)Y*^.!PCW!Y>G%8L,+`F1E&$H$2)(GZE<^,8?:$SC';.;S9^^?C
MS_\`%]9./7\OJ]7*I>HVB3[[V"BTKUT>D#3M?I'>.H&X[VLL%(^QR!D0Y?('
M@!B-DF#8V2#+E(@1]4)Q4M7H8*8>3$*(M=YR8J&W5K?L@+?F(O\`?U+]-YRL
M1=$*`<)56DCWK?HT6D6.X(=(II'79C@_B-"4I2%QZ*I#[$DJ=*I+$>4ZQ7*D
M*DA"H;U7K7B;3&V*,1UEAZ5N1Q1G8FAJC"5H$6-K2QUN;DR-C3-AA0S2QMY#
M40D*1#+,&`:4!0@"$'.,Y[#QQQQQQRD#]D/CBYO2UN=F?G-R2ODEF=,,=:LK
M0E3+'&:6<9:$=<(E#2"5.0XP2\&-ZTQR4$9$K1-:)8J2E''%!*'TKI!=%O'3
M?F+W>#W=KO/IU:5'QR"S"`'0MG9&"%OISPP3)_):9"D?7)>_DM;RWG,2,]6@
M;_.DI8G`TL!I@2"[\L%@QGO@`,9Q[,X#C&<?O]N?.:A1GCR8<E3&F"QC`AF)
MR3!YQC';&,B&6(6<8QZL8SG/;'JQZN5-=8'2'9G?R@(AK_0%JUK5D643I+*;
M;#/2IAC,N:(RDPIA<;0#B+>XX]&)92,$A>43BF"2K4LS!DDSPI3R383]/.Y=
MA^FC;%/=*C?(IFD<3GK<)%I)LS"RWM5!9.J\"IT<=?WY:_(D+B4]QY0)6GB0
M%A`')J1FM3$J*51UPC#N1Z1,@`/`>W?P]PC#X1"#CU9P+'JQG&,XSG&.^,X[
M9]??'KYY_'?]C5].9^L-UL=Y5;"N3D^SUSL%X8UEK-AT8<G%YE2B6NC.K;!0
M?S@Z.+UBM2WJ6T2_RQK.<8B$M\8LJ.9*EG01TU;'M7--5Y9L5HK/C"SC$S]J
MK=DNA[&%>:,1H3EL&?5<@CBA$$S(?&UH`-",918"0!*#C&>4J]9ALZJ6@-&U
M.H?NJ!/;;J9_MHN+QA]9XUBA[[0/I4%E+L4AF4^KIV3E3J)#;&Y<(U*Z+/.C
MG\ML<\IA93"&3W7]CI=3UO=)+>%,;D;@2V2V79<GKH^@TU\V5)9*B=`-S-(4
M,JC<4E<M7+F-H?E[DL83BHL<ZMSA(Q^0-:4CBH(-`#V88%C/LS^''LSC[V<9
M]>,_>SC&>:\<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<J=ZK<NNI#4
ML8;M?W388QV9YF%TM]%HW%J)LG=UDK-=%)`WHG*G81>CNWL2=O<)<LCS9-Y`
MPE*9VWQE8(481G)#WQ2E[STL7#8!WUP<':^L;%'"<+`=3*P<]P8A2T%VN=:W
M2QR+-R<^^(Y0J]R@I$H0RQ%*V=C6*CD\T70MMCILU0)WK`QGV4\<<P5=']O*
M#_QYL_\`H^LGE)VSJVPNFI;W5@ZG4U%7RM)<]?:S55J4Q*W5R?'B2S^/0XZ.
M%LDC:"B&H]E9B)9DMZ7M"!S486QUC>'H"M(!-G`^'Z,])4MO-K!/=N]N8G16
MUM[WU?=D/4\<)Y2M=O2BK!L!#-#VJJV[TQ&%3BA:D\=:&J5(VT;DN0IVF4-:
M9$<I)3B6JO1BVMK<S-R!H:$*-K:FM$E;FUM;TQ*-`WMZ%.6E1(421.`LA*D2
M)B2DZ9.2`!1!!9918`@`$./MXXXXXXY0+M7D.[/6(U,U'*+"YU%H?%CMW+^3
M",P)`NM1ZR4P:^Q)U2'9-2*E+6<>DE@41I&3#VMY7B[>2!GRE];8YMKNC`N:
MG!$YHAF*20K&]4F6)AGHU)R-86%0E,-($:F6$'I5)81Y$0I).(-"`XHP`?N[
MXSG.,9]>/;_O\ORX]N.^._MQS7CG&KF=I<SVU4Y-C>X*69;Z3:#UJ)*K.:W'
MS90B\_;C5!1@T*WS-6J2^=I1$J/-E*@CROD3C`"KND74=AE;;_HM%+IKR05.
M*R(C'Y!K;=[\[MY]=7N]JD><RB#-X@)DV8E*V%XP-@:VYT7K#9$Y$E)_)M2E
M]AZ>1V1XSW]?^_\`O][CG%.[$ROZ<M(^-#8\I2C@J"TSJWHW(@L\(!EA.`2M
M)/*`:$!A@,&A!@>`#&'`L!$+&8S;':/ZJ[85DXU)>E)P:8P]:8:L1A"RI&1]
MC;P,C"<N0Q*2L13>^QE_(+"6`+FTKDYAY!>$:X"Q`,U(94)[BNIATC@EG5>L
MF/4TT%9,F"/K*1J21[G4%%B/[F%2'!>$]QQIE2>#S=D,3'+2TJ;*1"R1%O*,
M=,VP:<[\:O;VP8R:Z[V2WR-0UA++F,!=R_<_9]=N(A>2-:IY!%QOIEA4$J<#
M2@7X`K85YQ1GHIX7EAR/DR>.....................................
M.46[6;S(>FKM/:]D7KI-L1;5=7Q'ZW#5^T.K-/-UR.+,BAL3)8W77*X"RW5A
ME,.,9IHCD%D5RI$<XQ65$6<^!381/49>1G3/Z>$^GUT5U:6P4JHJP]:(C?-Q
MN=B5%2]NMZ1AM=E@`X/!(XHF5CPY"L7I*^EEJ39@EM@JH2G6JA(D+VWOKJI.
MD4B>C1V!\T\0?7Z\>KV^OXL^S/X,_%GV9YKC.,^S_?[WX?O<P5=']O*#_P`>
M;/\`Z/K)Y6Y3[Y5'5ED.Y%7[6ZW59.*TTTW2F--5(!Y,?'4UY41.)IVUUEC^
MU*5Q!2"2>)V<4A!R#(6X;.Y@((3A4D*U*FP_774S7'4IAD48UPJ"&T^P2U[(
MD<C:H8B4(4;P^)FU.T$.:PL]6JR-66V)4Z()@1`QY`DL.0YR'&>2)XXXXXXY
M%O8O=7534X*$G8>^:QJAT>6!\DL>CLPES.SR64-,=P'#H9&6)8J)<'HW"@PE
MM3%(RAB5.BE,WD9&J."7SS2:PVH,SIP;U=0TVV#XAL[U&MEI,UPT$`4MLIL5
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M8S2-=`)!*)7.WRNIM$&3TC)Z5FT2?V2V$SL`)91D98F!<A2I)6[C<!Y0IA,K
M@-,,(1."X;8W%*E":?5*W76NP=;1JV*HDJ.4PJ4HL*D#BF[EGI5!>?)KVAX1
M&?U0T/K0JP8A=V=<$I8WK"C"C09#Y,PS%&X&E^OV\M5"J;8&)G/S$E=D4CC<
M@8W11&YQ!I(W&!&FD<'F#=CTI&G?!(1HU*A&+)2U"::D6D*"O)X+@@+JYTS%
M.I\1TXEZIC;XLTUJVL&;9?9*:(T.QPBDCTWU*O=79Q$WJ//8(<D38=%JD;TO
MLI25%Q^57J<`,N;QG&<=\9[_`/EGX\9Q[<9Q\>,^O&?5GFO'-,XQGU9QW_\`
MOQ[,X^3./BSCUXS[.5-[C])2G=B)P#8RC9?*-.MTF;!BJ/;,4<+T*ZO2S(L#
M$AMB(HU#>R68R+\=T[KER\T?EB;($ZMX7MY.&LV,4,ZG^QVC<K9J3ZPU7)(>
MQN*TEB@._M+,SJ]ZVV*H&/!"$NR&A`@RYU'*EH2QFK2QMZ="(\8S@QEF92O2
MYM\,4ET6G4<9I?"Y&Q2V*2)`0ZL$EC3L@?&![;%(?$G<&AX;%"IO<D1P?66J
M1J#B1^O&!]\9QCL/?&?9G&>....................................5
MO=3'>R4:&5#")W!J19[TFE@V,37D<BLLO.&:YQ,Q?[E))*PH!61-F]Y2N<XD
MH8][FJPJZ.,;U-;-F+DD8XZ@SDE8H)^#I:;X2OJ#4?8=MS&`4_6CK#KK?:O+
MBE,[$Q[9QB2H6N"5W+TRA\LF*QZ-,()2IS-3<.<:2H`+HX`HAJD1#;)DKRTH
MK)EI)RA&J3IUAS>H/3'DD+TQ:8Y0B.-*&`I604L(4I#34PQ!/++4ISTY@RP@
M/).*R,L7G.E]F6_1UL;C:VL\LV@A#9,-@NE^W1IZMZS%-I&-5&;47VGUYO"^
M*7M$<XFT@KL-F2./2J%#K9T40KWH)80UV%#8Y'<3DI&VVA:+RF3'O&YM1NDH
MD$TA^NNW\AJRJI!*7)U?W\B!/E)49=.88XRE]/7/<J#6\OMF5P5I>7AT='0$
M=965F<%RA4T#-'ERXGYT.L:CX\9#I$F:4USL2LF;&J8QF-KE`J[L0S+:F3$R
M(V5!6`&,1(AJ8T0@R,DW.%O@$0,[!_3EI.@*IK^]IAKO<1]Y1+8+:^^KK?9F
MH-956&R<.LK'$Y?`T2YH0H35S=!GV*+V-,K=`G+U(BSE03S42A(898;QQQQQ
MQQSQ*?LGJ!/UK;AZ@06$JXPIE!E`6HXK&]XF$=BQ3(S)9TW.&'V3.<B<&QKC
M[$K*0+T[6Y.BP@IU<D2IL;@J5I?DLYT_8\&C%EOD+C=T[`-ZE/5='V79+YKE
M"%9R)2SO-IRT<?0S2VP82C4)G1-'01M"Q1QT$,T)KZC$<W'E%1H.57KVQC&,
M=L>K'^_^^<_'QVQW[_'^'/;^#V8SGX\XQWS\?.'<HZP/*QF<'=D:'1?'5YCK
M'UKBVHEJMB=#4:AN,<F92J(-/:W`QO5JT(UJ$:=2)&I4)1&Y(.,+%#C=K0RG
MMVZ^,CDS3XC,\:"CSX#:C0A*/D42<S"@%^%6G\NC#)XTL"662\1AU583JB,8
M/;E32[D(W1-$J(]'>-T]'F8&N>VNT=$3I(WH0R*11:8HG.'S.0$IBBE\B?JP
M<TH(_P"->:6'&&Y*M+3)T)*5'D1XR,J3.QX:.L+1N`^CI-K+NK&TYX2PII&W
M.%"6JI1DB\>,A<&\S,#&J&`."_*JA*,",%@1@#`Y%G/F"M2N]+)3N;-F?8[1
M*Z*Y!+%\P]^QI:+ZN"Q+YCMKRYR<)<^VU&_++C(]*&AJPL&Y,\6Q'G-@=HWG
MW2D*G$DA&VG>AO0/?#3J@J"8Z5M7J1E74]0I=(,LDYV(A[S2TU9:^`8`Z,PZ
M3*Y60,$@5PUM*&@'*75\.<'0L0"\E)$B5$A3VRMNR^O;W!'2SF*[:K?J^98\
M?*W68,,]C#VPH(ZF395G.RE<U.:L)24!&._<0?*",$$@)8E`L%9[755L5U=T
M"CEG55+&J:P:6(<+V.0-!AN4ZHH(Q$J"#TZDHA<WN*!268C<VER3)'-K6E'(
MG!(F4E#*#D3CG59M!H;9,5?(-8,5CTVADF0&M<BBLK9V]_CSXW'=O*H79G=$
MZI`O3"S@(O)*2#`@,"$P'A,`$>/*7U)-:+?Z+E/RO:'IG[-SRBJ>EU@Q:-3G
M560MK):E8,;]/'8:9)+Z@(L)#)2X0<4K2$IGII.1K3%36<,M$^D)TB5IYP/0
MCZP>P.RNQ5GU3N_L[$'4IX@$:.I!AE,=JVM%$@G1<I5D2)KCBZ.QZ+"?GHQ@
M4-Y@(^>J6*U!0,J&I$:82K$'U]X%@6.^,]_BS\6<9^3.,^O&?O9QC/->....
M..............................4S=::Z+6J:F:*;JBL]SJZ13S8%J;#W
MB%Z../4%M(Y+$8)-+$2'P&@25S:TY,8'B+-L@DDX=%Z15$&)`:OCAIC\)(F4
M<_T7726O6LEEN<WELOF\C<-D;#=721SG1)CZ=<C<5[[%J\?W-4OUX9%"SQG+
MG5T7N:FR'E:J?I\O7K5[@>8%(G&*VIV:D#XU.3*Z$>=-KN@6M;@FR8<3A0A<
M$QJ-61Y9,82H*\LG.-+\H0<4<#Q>,HP!F`CQ'V/ZBZ\QRM9#4J>O"GJ$RR-Q
MB(21/-Y+,[%D3W&X0F\VA#2XSN?R.2SQ2F@^,B4PC(Y-Y:'N0S':-FMCJ::M
M'E.M:N@M11O,3K]B`QLYSP^R-P$:O=7MX?)+*'52^263R:22!>[224RB0NZQ
M2Y/DDD;LZ/;LL-$>N7'BP#PPVZE;+?<EU\11?6!PB[+>\HFP(U7TAF3VLCS#
M&5C]7]AM;W)375`TO2E*Y,475/CE'Q@;S@8D"=K$<(HD`S0TY_L8"O\`9*%Z
MZV'(I(NA[EJO:<E>)!5R8J3NJR=Q>TX1(5-<6(4KCAS$2VI8Y,4;$W.8%Y,B
M6*1N3`6M-;RC'U4,KU*<<<<<<>SV\K)VPZLVI&GMA9K:RWV2O;ZV1YZD4V%7
M[0DE!=?EM[8-Q9V>3APYHQD2.5Y!YNT-"?RYS<$]$YR;+(SKDBX[SC5QT\=V
M^JW(KBZELK%"JSQ?ZQ(NUXA5BNB\MQ-I)D7X:*_:4N6%O=0Q!A)C27+H!]<$
MJE7+G?"AX1LI3;(RWP?K+TRUP,U.UTKRC#YN\V`JB"%9E:_NN?))L+W=<>[+
MVR-M^?$-GB36M5J$T<:3CU2A(@P'*E2:H--SB4G''''',?&516QUDIKB-@\7
M':2.+G0I+/Q,Z/,K3Q10M"XG,!3UDKSP#8-8'RV4X3,8QXC"PBP2<:4/BK$H
MFE;<;ES3:52UK8K:Y)3D2Y%-H-&9.0H3'EB)-*,P[MBLSL(L0@X$$P(P=_$`
M018P+'D\WLZ,5):-M&PFU,-MI/"=3FVL)4^H*6>D+E()_%[V<52)%5$3JB1J
M5H$SU!YA,EJ)D?&67C5R!K8U"@*-U<#$B%X8,H](RNKSG.J$8NG17=:&,=C/
MHU!^P.KUKPUNDE?L5B-#DO9C2S/1:U9,HBE>6UO0G,TJ(;BSY:SFH%QBT/FY
M;>W6G8W[VNH''F^Z>C<\0L"3`LK;IU;6@N:O,$!SX,.#C%L'%RR,HN^,F&87
MK#U``9S@*7(@X#F8=#[VZE[*8)3U#>,'D+Z9D`#(<X..8M.DR@6.XTQ\,E!;
M1(<FDB[EFY3(5).!X[!.'C.,YEM@6,^KOZ_DSWQG\/;/;/;[_;F++CH^G]A(
M4IKB\:TA5L0-8XM;NIB,^CS?)H^<Z,BK"UH<!MCD2<GRL;56/+HU&`8-(,R+
M(!8\0L9@U871KZ9-BP:0P-;IK2,61R$I/WD-=0YOK^<,BY#DXQM=XW,HP6@?
M61R;CSA*"!I564B@P("W)&O2XRGS!_-;=57I;?M]*OSWU1=,&?.<^\[8;F2V
M;FU-&R3#Q!20"=9*,16ZW-2/S4LEL="ESLH+("W,D39"<&+^6.Z7=2W4_>I`
MM14_.S&BT(\`T$ZH2R$`X+=\#6H_"!R3/]?O!@'%4E;CQA(4OD?&\L0#1!*-
M<"5&1)P3\QG&<=\9QG&?9G'KQG]_CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCE+?6]D5/Q?7>JW^\U&RS=`XU<PY,4XZLVC:E26BIF*"K+&:X3#XS(*CADKD
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M.*%:Z.CHF+\V0F"+1$+749*`?\Y3J?VEL2[[?;7L^Q$H:D]A8FS@CG,<BYS2
MDAC0YI(JQK4D;9\MY)):Y)&D!C:TF+#E;DL<%3<:K<75Y/,&XJOZ>FM8""M=
MZ(*3$I4R8JF:L+3ID2=.D1)R`0*/!*(2)4@"DJ9*47@($Z=,46G)*"`LDL!8
M0AQFSCCCCCCCCD:=IM0M?=T:_:ZNV1@ZBPH&SRIOFJ*/`E\UB27$E:D#FVMS
MBJ.A4ACRIP\R2O#AA,D<#U*(E0>%:6G"L(3GE53VAT)J@K8;-;O3-G,KT9VC
M@WG1\;F;9+YQ/J_GB([PFG0>V(M-7J4F.43<3B22S!(0*4J4(C3G*,R4(4Z8
MBX>-RUUK2FH*][/SVK6";H8Q#&JSYFA<BX/6:RQEZ1`VNN8R?,'!,<A:'J3F
MFD1IO<5>'`\*E*D"5E0,)&,07MH/J%LKY5?:=(0IVD1OC.)G#"C%#IXG4F8P
M(I83,8D8T/9QQ6>QA.5RE<3W["R4,.<XS$O[!/</7['E]--XY@LCB/P80TMM
MDW!MV$X2E_MF&UMG"8DN7QU)WQY(K")#DP`<XR-5G.!"SP$DZC^R^J[2:LWJ
MTND<?CB404@;IUVE3+8=8.+FKR).RI5K:^.+<\0_TTX8*0I?33J,W!ZDL`4I
M@\!*'G'0#J4U?O(PNS?AM*K2X8V<:8^U>XO93J:J9#CS_1<DB3P-(UBDS68G
M+"G>"B6].XL+L6:G6H_1ZEI<G&R;[46,X]6<>KOC/Q9]N.^/;C/LSZ^V<<KA
MW0Z66JVZBU'.Y3'WFJMA(X(E9!=G*3=!U[=\2=D0"O1:P4H:@%ERM*@$F3@(
M;I:F=@)4X3"FE2TFFY4AK^+V6ZG'2YSELW2@+KU!=06;'@*V\H..A3;`UU'T
MQ9HLN-XT_@\1,D2(4Q)>7&4M2U,44#)JUREKNO.`WYN/UCV\UQW&KY-9VMUL
M16TXH9Y(M>8P+!8>HZN-#D7HJ61E:6ED46=@>$>,M[ZV(3C,`$:F\X3Y`<*2
M&!8%GMC`OE]8!AQ_"(.,?O>WF[CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCE&W6
M>M)T=:X@M(TQO+#M8[3,M&&K[);8SNA1.I=U--:29K?&EIG?NDM-!)G-7`87
M(%+=/Y=7T=:(Q*[?C<=51.)SID5&F@7=DZ&F+<%K#;QEOV?+[B=@[/SM''9_
M-MV:VWP=7Z,-E?U6V%+4-M50TL,1C<;7OB1\=XU6YS$RRY@97-"Y39J1R9[<
M/+72\VX&'.,Y]?J^4(L9S^#&<8R+O[,9#C/?/JQWSS7&<"QWQW_?QG&?W\9Q
MC.,_>SC&>0KWN-=":9R:QM*A^>@>^9Z(8T:92L5O+H+7.\@(&I*C1%'K%:EQ
M5"*1ITJ0DY2I..`2G*,-&``L&]%2#/=<=*_22(2)E>8X](:5;G!P8I"Q+8T\
MM1TB?G^280KV-Q3I%S>:04[EA"6K2ISS"?)GF$EB-\.+1^...?,L6)&](I7+
ME*=&B1ISE2M6J.+3IDJ5,4,]0H4*#A`)((()+&:<<:,!910!F&""`(A8K/VS
MZ@D*BK0S4WK/X]CMEKQBZC%3PNGY$WN)36U2!O5$(;/D<T:\N3/&(RT$Y-?4
M*\\[RJPM#Y[XD#.2J>4U=&D_33L72*VIMNIMQ;<;;(Y2\"E4X6N,;>#Y&?)A
MO4*7NEEOL]>9$U%K24T=*5.Y(PHLG/$ODQ87DAU1M?9(\=NZ1VKT,VMCVPO4
MJVII:NIC--]+7<IQ6L0L.O(I)T=>:^0TU7$JO1MR"1-"T*9SE36BRZ/+ME.!
M9(FQ#&W!6H4"-$,7H:1HTC>D3(4"5.B1(DY*1&C2$%)DJ1*F*`0G3)DY(0$D
M)R"2P%$DE``644`!980@#C&/HXXXXXXXXXXY@O8_6RE=M*BE%&7_``1IL.M9
M:!()S8W3S@@U,X-BD*UG?&5T1&IW)CD#(O++7-#RV*4ZU"I!W`8(H9Q)L,=`
M],]G-*)18-7R':E3L#ILD8FT.O44LUF5+;UJIR"X_P!61ASL`H9;6^P%L80%
MH6='Y'Q858(,:VJ)H4BE"ZV(1BQ8!-7.7,L.F\2E;Q`'_,5G35')&SO;C#),
M%*2M%'I4B;%BE3'GO"-00J]%.Q21;E.:6=@C(!=^?9,8;%;!B[_"IM'VJ41.
M4M2QDD,?>T9*]J>&E>4(A6A7)#@B+.(-+%GU9[#+'@!Q(RSBRS`USK^CYH@I
M@#+"&NJW&*N<:5.*^/6C%9C(V>X&MQ<5PEPUPI^6L-<'<:(60)FM*_D.J!M1
MD$ID:4D(1"'CK-+]3G5+]NHN[HSNS5Z#^LU5LCD,6N!$A\7;"*.W`W&`1/:L
ME,6`L@Z5*$R?`O#@#8+.<]^Z0+JO4NGD:.N=J8/9&EEJ*1@(`PWJQJ4<(=5!
MAH2@"C-IMZ;,9<V\><Y$6XN9;(E,!X<@.'XL9S9HQ2&.RUG1/\:>V>2,#F3@
M]M>V)S0O#0X)C/4$Y"Z-IZE$K),^(9"@P(L>KOG'/,]UQ^FS0U=ZUWIO+K5'
MY[0NQ\?+AI4G/UO>Y)`FBX&F6V5$XZ^)+%AD%RF(>5"8IY.D`7IH3M;B-S1%
MK7P]S(`9@-$O1<W`VFULV<L&Q9%2&[6V\2Q1SZT2V$0Q38,R?X<RG3F"KS+(
M1Q.?N.&Z099AH/1(T#4<G?/)OAAZ<["$IP#GV'ZY=97IY[*NI40CU]M%96A@
MS*9;4%_MZVC[*;W#`\%Y:QLT]"V-CFXX'GP831][>!B'C.`8SGMRT!.J3*R"
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M3*F^1SHPE*L2L\ED%F6@R]>C>-VJQ;W)R<JLI/=&7UY2P'`:L\B.PQQI:BK-
MD\"8%*T1AQ\4KVW+#L>)QE(28-MC+4WDPIH"F;(RD0(^T;>W8BI1)&;(L.*O
MC34M12Q79<EL%,NCC@G4-<6J.S7IT:VR-DNX9*:[F`)-0H"U#<G1K%^"B@+`
M`/*,%)*DK;B=]T]5]V00#T7#+9@45L.+%R-J4,;\6PRYF2/;86\-"D1AK>Y%
MI%A8%:;RR@H!P1>04J2,E*#,H\<ZT;,XB1*TD#.E$?*FZ]D525##S'EN!*%L
M<1+"FY8_I&`2C#JH9DC@>2B4N924:(E6:6G,.":+`>?DWSJ%N[0%_:9=&71B
M&["8`/+<_M*YI&^ENGH,QE"Y)EAJ(3L6]=V<;:$_*T+KCT?DCSS]IY2EU!;I
ME&[JI[Z?VE0G::3$IV0+]A;19I#A@I^NXPU"6X65U-98F1.`GY;(UWFI#O'6
M(0Q^)'AL'AY&3(6=#EWI3Z!.FC-7S:8V^X1PNUK+*;W&6(T(6,YFK:,QTI<>
M5'B9D%,4J<C5.3LO$P6`7E1?*M$VEMZ4W#28].49^KG>#1MHX:Q=+;7BRF%]
MD>[ME)<W?(X')F-\Q"=6JV,Q*[-/4.+:N/3)W&5%M0DK6@+5"5.J!A>T`DPD
MZW&3+[89$8]`(A%H+$FPAEBD,CK+%(RS)<9"E:8_'6U*T,S:G#G(LX)0MJ-,
MF+[YSG(2^^<YSG.>=EXXXXXXXXXXXXXSCOC.,^S/JSRE_:CI1O#K=SGN9T^K
MJ4Z;;@/2\M=/UQ"!4_47?F#E99KF7=%;E",3N#DM!C!ZE\;TJC#BJ(PJ7M`G
MXTF3M]KTFLF#5FBAX+2L*#0]?,'UF@\=425_:(@EE\[=4PQ(XW%DSZYEF.+V
M[F)5AS5'T:E>YG$EC`6%1DD9F>6@\[AEEQ9IF]>RE@FL/?2U)K-)HNZHWMB=
M"T:Y4VJQH'-O-/2*@IG!$L0GY)-%Y%6E/3F>$TH8<=LYTN=5S`;/CRJ)V-"X
MM.XPM",*J/R]A:Y$SG>,H9.190.R54G`;@!@\`.*`6<7W[EF!%Z^5CO_`$KF
MFLW==-M$KZM'3N6*#A+3H@Q.:F?48^J08\H`E\J^5*E)!1)YWVHQ(EQR=(6+
M.4K9C(0AYU%YW6W:TV;3UF\VM[7954,HTR=RV8U:=2%;8A2FJ2D1#E,ZRE*I
ML<&(2M6I2IS5@%K&T@5'EITQ9HAEA'W72GJWZ_;79D;!,3VB@K$9W95EFBD^
MFC0!',(PH6F$,KI&9&O"RH%K^65Y-/)(J`'I!K6B\NV&O#,:%>5+?832W4#<
M)BPAV%H.J+C1*DQ>$;[(HTW*I"E2^'/DAL<[:\(Y2UX[9\19K0_INWVH@YSV
MQRLA1T89SKX><^]-/?78[4811IR]+3<X>/LBM<%2C&?$0@]P5@'&.;*B'C.2
M3%1#F]JR"L]R"O%@..?CC;+K-:F_M6T>C%>[GUXW8+(56YHA+E2&?A3%9[FN
MSI1,]!AW=59A`1'G(XV6U(B1Y\D6?V#CDA*&ZVW3NO%[)A"^Z<T#:N5.4*VH
MMH6!RH>=MJ_'?&4)V)H!-%UBG)F!$A+;),L$,W`0A!@1A816LM[FW.R%(YMB
MY(XMR\@I4A<$*DA8A6)CPX&2>D6)C#4RDDT&<"+-(-,+&'.,A%G&<9Y]W'''
M''''''''''''''''''''''(`[MWY1VI,::[%E]".-RS*QY(>S((W!HO61\K=
MB(;!G>6RB4/DBLQ\B4>11V`UU$'-V7Y4/ZA[4I$*9HBS`]N:D"0.6]8+MH"Y
M2KN2T$.*C(J.\Y'45G"A8(X:P&65'HE"7HP],[1,Y2PO9BB#R.$&GJ4YXG!I
M.\<5?T[<_P`><FU))5T;&]Z;7!G=D:=Q:W5"K;7)`L*">D7(%Z<Q(L1J21XR
M`U.J3'&D'E"QD)A1@P"QG`L\C%7VBVEU3-,W8JLU/UTK=GLN.)8A8+;`Z:K^
M)I)K%4(U)B&.R<EB84(7IE0&K%1R%M7^62(SCS#TQ11V<#QGJ!U_"ZPBZ"&5
M_&FB)QAM,7J$C.RI`)$N%CLO4NSNXG]LB.6NCR[+5KL\NJXU2Y.[JL5N3DK5
M+E)YYE7O7`<F5JZ=MW'O[VV1YN41R8-071W,.+1!<GFK;&:61!G"4A4J-5O3
MTL;V5N3IDJ@Y0XN"4K!?A&(8)HZ0QH<-TTU/B1CRQ2,<:UNI%C%((LN&Z1E\
M$V5M&TN7:.N8R$PW)C</)^<M:\29.)8B,)/$03DS)8<Y6#.XU6$'EUBS%::W
M12#QMYE<C7$(EKD>D9&%"<XN2@EN;B%*]<:4E(,$6D1ISE!YGA**+$,6.>::
MT/V06\.U>SQ#45,#B]C&S?*2O9%,%:>11=!6(O)9)DLL9D:A"I]WBE2##:"*
MI%AD;3Y="%>)*M/;Q-KA@6E-'-XNH/:7V:KU8JFD6VV2K%?&:PLNTH!*XTA)
M3+(Y%(;!V4*AF>S*UD+<Y#;&)V;W8EG)@Y+V::6Y.RA&!\X!PZ-?4(8=?T+&
MVOK2Y%K;H+7N6NC-/L$1U"8C#[FF&[\NAZ]+$U2P(/+*U*0M$7)F2)F-ST$*
MZ2%JHZV>F[235UIU"US@%,D&1UTDC*A/6SJ6QZ/)X^7,9>YK%*YQ>%8`>)<Y
MF)"U!+&@=7<XQT5M+8B&H`E$+*0GM>WK.XR'4_9Q@9T!SJ[/FO5UL[6V)PEC
M/<7%SK.4(D*`@!H@%#.6*3RDY831@+$,P.!B"'.<X_G^=!C4K9%PWETQV,9M
M?+,.U];)C,CW&Y$4*4$UJEPVU?8456'FR7P$H!X220XJ/B/)\J'TJ+S`HP9P
M#``_I%`QV"'';MV#C';Y/5CU<W<<<<<<<<<<<<<<<JZZPFK4JV[T@L.I:THZ
M$7=;ZUSC:JJR)K(6:(E5W)!NA*%RLUCDCNI0A1/L8BZI["B0D+B"WT2WT0YD
MKFA0N0J(A=!_5[J#Z:U_;E&;>QYN9*C0JV&44(V-D\K^<$QQY?7.3J[2:2%$
M:4'OZ)`[JSH\_)6]R,.94K@8\GM04:IR7@43=1]6;2)-LM86I=@6@II*YX!*
M#(L6U7G'72K(Y.SBTJ92!VKN:24!$6D;(MRJ+3M"P]T:SGXS&3F)*Y(ADJC;
M(2C2CRBSB3`&DG%@-*-+&$PLPLP.!EF%C!G(1@&`6!`$'.0B#G`@YSC.,\_3
MG&/3*T2-I<V!_:V][8WIO6-+PSNR-.X-CJUN!`TJ]M<4*LLU,M0K4QIB=4E4
M%F$GDF#+,`((LXY`R.]+#0B/0ARK\>MM?R)B=)"\2(Y5+D:B229,H=S<9"@;
M)@X*,RAI96E(`AM8FEN=4Z-K1)R\$@&J&I5*,.JNDA6D*5'.NKNPFT6JKED0
MQ)FRNK8=Y%!2<BSX@EGPN;#=25*7`^V1(\NH"1@QX.P?5G'SC@/5]I<?CA]V
MZU;<1Q$')1+7;D(<Z;GZQ.''<`,/T),.CQJW.`X!A4O/R`1@_&<`0?N=PNHS
M?55"PGVHZ>.QL"2(2\^DYS2V6/8&"%9!VQE=YS&C$#FC1Y[Y%D)N%"DHO&/M
M3!=\8XN3;*='W?ILQ!+H=->YXO7)O,AQ38B&IX5,6@?B%C"1"XV&TL;LT.)8
MQ#"6-@D!2@L0A>0.[BR+F$R.B^R5=D4VZ96]&R&F)3B8<Y(X/'IF7L%K:Y"\
M`AIBLUO/G!P("DR;G`1G$R)P\D1G/FQ`18QGFH-ANMMJ+CR-_:GU'U"*V;0X
MP?:&GDD'7-RY2B'W\^=J4F1.4+XY`+"(1C;#$:1,(S]K+6]LA'S-E,=<?02S
M90"M[&G,NU*M_"H"%35.WT)=J+DA"W[@9('F0>6A"C]N[E%>&4$G'9R'(4^/
M%VQ;6ROS)(VI"^1]W;'QE<TY:MN>&=>D=&I>E-QW*4(G)`<H1*R#,=L@-3GF
M%CQG'A%GOSEN......................42?L@FVX=6&GM>MEELFB:ZN;-O
M^.0:2/O4%@]UV72T5/*@-B2YB<F>%Z_-BJS#)ZN<HSAF99.TN;(DBK>O=UCB
ML,3*1$9[/T#IY!IYI`[#K8W20Z$1>\IU%&$S0*K[CJ>A/)(XQ7[JM\3#?:))
M9[K/1N3RK-E\G?CG0IV&8W%MSHI2(@%I[M...><O]DW0F?2/0%OEC).D#!7U
M8V8SS&?PHQB.6.MAN/F:EI@Z5'(2W%.4PM\:6KGEZ7I5#8Z8>%XF483$7HK(
M5EB'2<U_L_632&HJFLNW&^X26]I2R"N79)%E46416MIBS-$J8Z[7@6/L@.>A
M0QR=7MO:WG"A(7E@&U-A;<F`V`P*I'JD7WO+8NZH]+J%?G=M8G:(-#*QP>H9
M`,IUFS;9$?\`*R-QMU[$A+,BH4B,ES+$F5C2,\4AY9<HPL7FOPC.73:_]._5
M2C:QE5?-%+Q5:WVDVQPNTFR7J#;+3R`QE0-@BF(YSE*$LQ9&FQ[1G/+8WDMK
M4WX>%"A[(:D"E060EG(D2)4"5,A0IB$:-&02E2)$I):=,F3)RPDITZ=.2$!1
M!!!(`%$DE``444`!98`@"$./H[8^3[_[_?OW_A]?X>.4Y=;B_)C7.HR;7ZFE
M)HMB=YI]'M2Z;0(A#RYDCLL\#?8$F)+`#(@HX["#G$A2M",'F"E[;U(A!``0
MP6,:R4'#=7=?:=UZ@24A/%:?KZ-P5K,)3X3B<3&5O+)<WU05@0\!7R)X$XO[
MB/`LY-7N:DS.<Y'G/,Z\<<<<<<<<<<<<<<<<<COL7J9K?MM#CH'L=34$MV-F
M$G$IB9:RDJ71G\X$`1Q\;DJ;*62Q=89DL'B6QUW;%.<!\(C!!SD.>/M:*VS4
MVKKE"-(8G59=E5O`8Q%**A5L+I*FK$EMB6&9H11M[<6=7F0@*(AZ!4WLJHUP
M#@3T!L,>G`"(2Y5B%FH/46NNR[H;]4]O]([LU=V#4LDB>6^2M[6?8VMLV0Q-
M+E2[N49MYG`-M:<*P8%EL;G4]Q3'G^!K(D*IT-)2&VU9%C&>V<]OOY]6/7ZL
M8[^SOGY._?[W&,XS[/P?P?[_`+_M]G->.;?"'U^KMG/MSCN'.>WL[Y#VS_V\
MPA:FL^O=WIU">W*6K"Q<J2LDF*I;"F!W<P%YQVSYN\'HO2Z47L[&)EQ1@<XQ
MD(L9QWY!)UZ0.NK"XGO^NU@;"ZH2#L(:0VCKADJ!@*/%GQ>(^+R8Y^;SDWB[
M9&B(/2$#Q]IV"'G'9H_JP4V,`JRVUI79J.MI8AIXULC5Q\*E"L&,A[)13>N1
MG#5*LAQD(5[@:2#(^XS2^POM<+W3<EDS2.B@_44Z0+I;L**2J`N,IJE/!]FX
MRD3FX[*')J95J4B6QOPAS@T!J5W2N9'KR`>!A\7*Y(K2?3#0R(;CH)U#=D>E
M?;:I1XA5I(Y#-FNK,K`G"-`W2>I+Q$9%5B?*G.`90I9N6C++\02TP_;F<\=V
M`ZV&O+:4[2*IM8.J=3Z,.5/OFZN3MOJ*Z%[;]S@Y1!G,2Z#/SM@OPJ,((DE.
M`H%Y0L"O(AA$#.52]=;1N628BM;X<K(TDN/RI*-96>X,`>:B4`<!9\!Y2*9K
M"U<%5I"S>X2EBM]:LJ`]C`IP8SX<6Z1.9Q&>,*"4PB41V8QAT*\NV2.*O;9(
M6%P)SV[&HGEG5+6U47GOC.!$*3,>O'.R\<<<<<<<<<<<<<<<<<<<JUZK;/L$
M_P!'Q1+0A.S"Q.DG@C[73Z02BD(=N,""*(?)4R,REY)?3:Z11K)S+#6$,[!'
M0MUB+HJ(\B+..46'YN<.=Z6"2^D&N[VDO@6PH%2>QG$BODFW\JI.;;:HJ_)B
M,+`B)V#DU!MK9"5\N-?</JN/$N):R;H:^4Q)+,G)0Y`+*366\V9,!@(Q9%C`
M2^_CSG/;P=@X%GQ=_6'L#.!^OM]IG`ON<XSS:0>2I)*4)S2SR#BP&DG$C"84
M<48'`RS2C`9$`PLP`L#`8`0@##G`@BSC.,\KXZE^LL=W*U]9]7Y;)GV&QVY+
M.C4:=)3&2&Q2_,I*)AETC+5-J=Y2K&LXX:EC)3&`6)C2\D'G9!@)N"QAI7WX
MW-WLTZV@CE<0`_$+J&H:F1(JN8LI$\ZC=EUJF9$4046E:/D$3:88^-KT@*38
M3'%L37"'-`F3DF.B5\5KWRP7HHIW:>5'<VS-C1N6'W+?EO.[O+[5D[:U-[78
MK(SI4Y#`&O"$.23DL*CQYSFUG)@-R-H#("ER9E.6-;>D*;[K^..<:[/+2Q),
MKWIS;VE%@P!/G3DM2H$V3C>^"B<'K#B2<FFY#G!9?C\8\XS@(<]L\H+JM01O
M]UI[+N`M0F?M?>EO`<4Q69Y2H"QD?MIK>2&K+'E2`D0SDBD^&Q@I7%S%B;(P
MIUS6QJR1X-$$1?H&QC&,8QCU8QCMC'R8QQQQQQQQQQQQQQQQQQQQQS3PXQGO
MC';V^S.<8SG/MSG&,]LYS\N<9S]_E(_5ZIBQH+"91U"J3W#V*UUM#7:K0($D
M#A!1]EU!;!9$G\ZCD1D-)K"SVQ4^RV5/R%@6R<"=>02WB0*GEJ/2,F#RXH?L
M>#?R[-AF6]]?MF5E@2*TXO)GF\H=-9JR2)*)[A5BR7(YI%RE[JA2(4J>"SQT
M+41ID2B`0WQ.6(F5F2)VB,%D)Y3NW7FU@K.7/,.V;HS<W5-0U/[JTE2"Y-<Y
M/[D')O;W`]$D?D;]"U$HR)N="2,."0041O=&<2,)AOCQRZ11)H^C8,2E>\-[
M;'<H4KD)Y=51+2WDH5H"1IE*I2YC2%)`&A4$8QYT(D01F@*%@)F?!SE4RI.L
M)*4)3BE*<\L)I*A.,)R<TL>,9",H\K(R3`"QG&0B`,6,X]>,YY]'''-,AQG/
M?MCOV[=\>K/;\./7_P!O,86+25/6\B&W6G5M?6*C&0--Y&;0]@DV2R3,>$02
M#G=`J4I\]O8-.<4,.?6$6,XQGE?\CZ/>H670<BIXNV-9)3]L:0^:]VO+(2`A
M7D7C">%B6*WIAP#`^V1)B$*8@0<>'`0YQC.,)VCT^-V%[%[E0;-4CN/79'EC
MBJLWVUYB\^2F]P9+\AF=,J)P?BU1I.<EX<R"T"@LS!9H1`,`$P%2,GZ>5]:Y
MOBN:TYJOM;I/,!8-4K)_TQ]C<VU3[P<69D8U3[JU:BY8J5M8\^$9C*DDK.1D
M@(BRD7AQX<<O#>LAO]K6\%,%H/-)[EL"0PL"YBL:"2O1/:-(42'!(TIC3(6Q
MSI]_<<>'(O`UJEYBT[OG"DOQ^$-FM%_LAW0*R%Z&+7*Y6%J1/C\$D*62_(F<
MABH7`P809)16=$C)%"S$0LB\1#D]*H\2:4'(Q@)[AQFZR"V+`+0CJ*7UK-HE
M8,3<0^-ODT(D;/*X^M#X0B[I7AA6+V\[[40<YP!1D6,9QW#C/?&.X>+'R"_B
MBQ_+CF[CCCCCCCCCCCCCCCGF*Z].BFAK5&_A";TJ'5:=SUGDT-B,W2;:WW>M
M)QZSH:V0J0L40K6N9/4[B\#;IJS.6#)HWQI-7$BS-4R&0C?U:5(SH%2"4_['
MWA-8QG2&32NE4>L48JBX;^G%HPNL-4K6L>ZH!4B-=#ZZBCA!9%8-K82S)PL;
MTK$UDGEK6K9(ZACPI$W-#2T%-R=,<;>8/.<`%G'MP'.<?AQCOC_MYYS'P@<6
MI_J"QUB6*F6LG?K@4E&[O4IW98(IMHBR7K1$V^$[FO5+S5#=%)"WR=];9UV,
M\R00Z120!A")G\OE/9!T_"_1#QO+"8R6H34M7^\5@Q>CFP."P1Z/1\=24E(;
M4BL'3IQ^9(8=&=CWZZ&I&SH"2$,<>2G^-I$Z4EH"C2PYZ]]U7S2NFCA,ZI7*
MZT7,-T4F7&+<BDP`3-4"U[=U;6[IV]B,C@P-6#D"UQ;#G(3RKR<A..#E%Y-4
M:`O*D$:T%N=6W84$H;T<FC]3:/5?4KH@=T:%>VKSK>?1R][;G5O&D$@5)W9E
M&I)7MZ@H*=0G/,*$D&F'X`6ZLS,T1UI;&%@:V]E9&5`C:FAG:42=N:VIL;R`
M)4+<W($A9*5$A1)BBTZ5(F*+(3DE@**`$`<8YR7''/,Y^RC2!R33'7NMF-*9
M(9Y.]OH.DAD%:DXG:52]817=EMXTL<C24"AT?51;D^LB+R+>C4F`6NS8G\(3
MUJ8)D:?V,/K/L=0,]W#5WA0UQ4RUR*(4B@CIMG5Y*8$C?7!G?[-/<T[*"1MS
M:!Q/:TJ]"-=YF6;YH4L3!.$#RY81>OGCCCCCCCCCCCCCCCCCCCCCC..^.WK_
M`'LYQG^'';/-,!QCV=_WQ"S_`"YSSYE:%&X)S4BY*G6I3P^$Y*K)+4IC0XSC
M.`F)SPF$CQC.,9Q@1><=\8SV[XQS%-]T'4>SU2R^C+UAB&P*LGB=N32J)N"Q
MU;TSH6T/#?(&L7G[(O;'9&>@>FIN<4JA"O3'%J4A0O&('C`*`FLO1\UJT^O%
M@NC7RPMG(,W,A$@3J*1,OB32:BY"%]9%[($4AA4F(=%B_+,!P$Y,@/3@0(7=
M&WK\8&--X#,O[KL_4@.5UW(M!YAK"D31\B2#LJO=BXY,3PSM0><S9BY<=F$2
M.$;'BT!!3Z!Q(.(2B5GJF\X#B$L@T@7.Z46+O3.X_/B=Y]>:KHR51M[:$4+<
M*BM/%C1JQ6=4V'J'AY*;SO.'2)@:W`"9$G2.K@H5./G)P\)D@$7C5Q]M3K4:
M$T-?,\UZOF=S^EI;`7PI@622PJ>L5MKE_5'-3<[!5Q:;MK&[-KLT>3<B4H78
M9:1`<L)4@3G'$``H,LHK6RX!<<"BEHU;+V"?5Y.61'(XA,8LXD.[!(6-P!D:
M1R:UZ;(BE*<W`1A[X[#+-+,)-``XL8`]WP,.?EQZ^WVV!![YS[,8\6,=\Y^+
MMWYNXYID.,YQG.,9SCV9[>O'X,^W'[W.ES2MZ]LAL,9;"@T0G;.:`19C7,8T
MS2=O&`??Q!$E>T2XKMZ\YQX0ASC/KQG&?7RMBX.BOT]K?3*RSJ9S7JE9Y7)B
MFLI`YQQ$`9F<Y\9,57B>X47VSGU`!'"P=LYQVQ[<513G]CDRVE#Y'8&BFZ%L
MTG)PMKLJ*96HR11-0\^31J#0M:YRK9\1-SQE>#`D025D,-`:8<$."<Y%CMY;
M]7X!U#(9M%3+E7=';.2.VZVLZKIJVU[,XY>30SY<BI(C6QI%8YB_#6"-PJ0K
M$)K<Z/+XN:6@UK"YC$Y@()4&E^P!/U>NI]5Y?D]ANBY="PLGP96R"D9B[2-O
M#C(\8,-3MIT&D*;(<A-+R42.3?:B`86([U&"3]H9_P!DD:D-)Q+=>NOFZ&O3
MKD18%GN\I##FU(<CP'Q#&KC\@4.AA(<BQ]N%AP,03"A!*^V$$N6E===3I1V8
M-,G9]R:XCR]2'&<M]C()A69Y`O`$>2SSYQ&V5M`,/B\.<!<!AR,(P`$+(!<G
M[7^S6N5L>0Q5U]TQ8PE/]8+@]HP>5'&]\^'&`D,KZL/R+.?5X<E8%W^+UX[Y
MM",(L8R'.<XSC&<"[9\.<9QWQG`NWASC./7WQG..WK[]N;L"#GV"#G\&<9_D
MYKQQQQQQQQQRH7J\2N*0^$ZRK%5NV3KI9,@V2:(35^Q%?SG7>OD-/'RF!S1-
M8,JG[KM2J2T_(84FKA-(5*NORA'69,G-"VHZR(].I#SBNS=)N8U)-ZIOQPK+
M9.8;D/3'LU*8?;&U,G<H$\-%V6$P5M5>2'^O7*K(Y%ZY%!&&"+H;#$:"*-IR
M1ID$<D;<K>I,N(.DKM:ISI*.M:[;D,L;$$#AB%MGIJT^<-Z.+,*5%,3G))E`
MXFRI(0WED2(Q>A$)&M,>2UHU:00DR@1A.<@YR\7BL8A#"V16&1UBB4892,I6
M>.1EH;F%B:4N33#\IFQG:4R1N0)_+'&F^12IBB\FF&&9#D9@Q"B=NU!J6LF(
MT]"-@V6#R&JG_82O4SZRV*<WDQ5R="FJ7*H@D6"<U*5(:L.F*=B`S)!'>57N
M^42$DE2:I"F.C1T]\&2_:?JA6Z<')Y;KLZPU"UK!X-SG#?2L*`R&IB1&"QG!
M1:IS#@16"P!+$#&`B'CM@-L_''(:;%=0G2W4N7-L!V,V-K6HYF\1@F9-<:EK
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MA.VK#BFTYD\R.:S/)GH!$'$EC#4A6/1L'KQ8E?2S6OJ`;VUC!XA+XT_OM+26
MUTENUG+8\QN256X0I2U3=L$:C:W]O3FLZM8HR[K$J96:H3?U860<5/;<B0[G
MQ>LFAWT>K^D;-M!/,6[,BBEY2J01!D7P/T<ZB<P1IV8LDE%2L3MAE*1B>5J5
MK*;AN)X\*5(""!85TPVBW:MV=RFM-N=`Y#JZJBT1"_)K5:+<A=H5/,WCTRC;
M/<TP&M(B7Y(YGHU"AY3^4PZI"D#<I`XJT*DY`6K[?>W4ZT1UDN1-0=_;'0JI
MK15QQEEA#',TDE:VT3%(%#@E:%9DMRQ&Q).8K-:UV<)%#V4J)+)P:H*)+-)R
M9+:MK2K6XXF@G=33^&69"W,9Q3?*X%)F:6QU6<FR$*I.0[L2Q<A$I2C&$M4F
MR=A0F,SY-046/[7G>O&'U=Q8QW]F,^K.?P8SVSG\..;N;/)@QG(NWK%C&!9[
MY[BP'OVP+/?N+&.^>P19SC'?/;&/%GOKX`X]6,8#^Y^U_P`WMSCW%G:GA,-$
M[-R%T1FX\)J5R2)G!.8'L+'A&2L*/+'CL(6.P@YQV%G';UY[QCL#1/2^U"CR
MK#U2UXEHE/C\LJ>*?@AS@/)@!EC%AS)9"'$`Q!'G/C`J"/`\!,P+`P%B#!J>
M=`/I.SK)R@.I[#!W0W)@P/%932Q("M3F&`,#Y1,2R2H#62(L0PF%!PW9+`(D
MH'@R2')0L4$]`^K8!D:G6S>+J*:X+0^4RE30O91Q?HZF[C--)*]!21H-R>F)
M,,QCR!S@+!I0,EFCR(X\PSD0]/[JVU>G%BE>LI(9J2`6,DLFS6L-<6!@18,"
M++*4RQJ7>G1_M62\G&@3!,./*R<+MDX80_"I<?V134Y8<8C_`$VMJ$8,BSG+
M6X6I3,G4!#@T>`X`ZJ6^.)SC,B`4#]L-*"$LK(\XR:>8#BE'4OZJU5Y\A>71
M6M*0E$]AJGS7"](?:B7)`<C$8:E94+0ZN!N<%B+$$@U82;GP&8%X1C"65Q__
M`+HBUYA)Q;?L9J7OGK<Y^/!:KWP]?%AS2D$$S))PAN*-W3J3BR3NQ8AD-@\B
MSWP$'BR6$S/U>]?;I06)Y`E+MA'8JX'Y+!Z.G\2GL..)&/!6?`I5N<:RU$>`
M1O@,&-P\F$0#1>4R64,>)PP/>G3*SBB#(%M3K[*!J?)^02MEMPC+@9DS!&0!
M]'*GE,O",0E)!?DQI@F8-,"2(.#<"`&3+8]L[TF`L9W-O=DA@<"+5-BU*XIQ
MAR`!F!`.1''EBQD!A8\9"+.,A&`6,YP,.<\EX@^W.>V/E%C(?\[&.:XSC/LS
MC/X,]^:]\?[_`._^^?5QRK+JR/HD-'UQ&,ZWVEMT58=Q-T2^QVKFA*/V$8;$
M<`0>;R-B)NF,7\8CA,4IEF?&%O>))8R=X8GZ*/B:,B0NQ29:N2J_RT4N">5J
MP4'JE>VF]7::67+:ZL*;1*FM6SW"?4A!(U!'9D,D1$D>HA6$8JZJ'MT731N4
M(8LDF<R`]N:Q4-M?G4T9IH;4N..4=?L@IAE,ET*:6B%1MVETJ,V=UO6,<>9&
M-=(W%P7M4[]*D>2:&XA0J4E)A(O.U8@EA*3I"#U*DY.F*-/+Z'T'Y1L+)8)>
MKS.XHW&5!.+.D5EL5H+"\-<EFMMREQ*+L<M$A3D81OT7)RA3'"?"0-R5F?0J
MH\V^EB_/"X_Z`>.:9SC&.^?9_OC&,8QZ\YSGU8QCUYSZL>OGAKZMVO\`<W5W
MZC4[;]"(D1<+-J73\)I2XIPIE$>AM?-UFES2P)(XQ!CELB7I6V1O300_@0.B
M-J\N-(O:GD!H@D(R3U7IMZ1&N-LZF=/>@:#O%C;8W:$%*L;W3LC2_MDG0H12
M.UIO*6H!3XS&'-BX1K*]-R@[*0XT!!IHTPQY-),QBRCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCFF`AQG.<8QC.?;G&,=\_'Z\^WV\QE9-*4]<B$+7;=55Q
M9[:$H9`$%A0B,S)(649G.1@*)D36XA)"(6<BS@GR?VWVWW7KYQU)T!2NM\--
MKRA:OA51P<^0/,J.BT!844<9#)#(3RE#R[C0(0`)RM<!D)PGF]OZPG3)B\%I
MTY!1=3$DZ6NYD&E$AEVJG5WVL@>7N0/$C!!M@6.*[+05(I>W54ZJ$*--)!LJ
MI$V)35AI25(4G,_J0HA*(T/AP>&TJ\9/>U<4%)Y)2U;M.Q5[1R/,ON=KUQEC
M74C983]A:TH'P?NC<BG-HC/]0FNS\C1*!"3GGIB60"Y/E06L!0%H/UYISM#U
M"'35^U:3+K:-V"D3P6M8_'9/&)NHKNV:O:IRZVL?,)Z6;'4<MC4RPSB0QX4:
M0N1K,NC[:G0)G9*^.;L3<KNGU`*;T10UVZW'$+RD+/8ZV0HD;S4%/R>TFR+X
MC:=I/5JINJCV,ACJ=;EY2DLX#,*5CL<4N\S2C*0*C2_PTNZBVM&^@9^703I/
MCG.L,Q_$X99_5TWKAS9!2@QY`R`%B4M21"N.5!8EYIJ9N7JU2$GS8Q>2F"K(
M\?QW!U1.GY0-L22CKGVNJ.M+6B&([F2PR7/2QI<6GW5M:1[80J%!K;EL$8N:
M%Z)Q$62N-,1)%B4Y>%*!05D4LJJMRK[S@S/9M.3^(V=7L@$X@9)G!WYODD;=
M!M+BJ:'0M$[-AQZ0\QO=$2MO6%A,\:96F.(-"$8,XY\K7=M./:_T6S6O6CLY
M_;_^][9/8DO7?M9H"3/ZD2/!RC]K.,`4/]K^T,&$L788@XSD[.<8QW]?;[V,
MYS_!C&<_]G-,"QGV8%^^$0?\[&.:"P7CUB\&,Y]F<^'&?B]F<]L_)[/O<_,T
MA.I+&4<`M028'(3"C<8.*&'/M",HSQEB#GX\"#G'WO5CD:;&TJU`MW"GWT-7
MM?IZ<KQV/6RFH("[N(\?;8[X<U##EQ`+L(6,#`K"/&!CQC/80N\!+"Z`'2BL
M#"DW&K3;!7%3DP7I*L)[9$#,(&8$8<B3-S3*\L)7AR+`P@PT9*P(&,>3R`1H
M#(GOO[&IU[9!B6Z_[=;G44Y@SD:/*"PV"6-20W`RS"A!3'QV//!A90PB%X<R
M`)HLY!G!X1%!%GK"KI&=7"J>WV/G6,F$B1I\9RB9;DC4X2I^P<B\F2H5(9E8
M*'./!@L(S<,62Q"#W\WP#```X54P_LGJFO$6B?\`6'99N2=\X]&OT";W!87C
M)O?/DIK#:Q69SD60BR'+L`>`!)#@7J.QRAS:GK;]8&#;`R:/3NR$%%SFD);(
M$:VGHM"X&JBS`]FL"8A5'Y?E*=)D5DMY"-26N08>GY\1(U#AE>VG)UQ2<Y+_
M`$`-:IM(++UTH.QI8>F52F?4M5<UDJE&D+0(U#_*H&P/SR>E0E"$4B3'.3@I
M,(2%B$6F*$$D`LA!C/*E.N%LS!J-A&N+,;OY2V@=F.5R&29!:U@-<PL.P(_7
M2:!36)RV15=2T(/'FPGW#E)F1@"59C6ZT\D3NCBJDB%6^(8_A/*;I3U*Q5?K
M8\NL5V-7;?Q2XK3D5S1K:1VM);:K[>+=*XO"6<Z82!S.+"VQIV1.<77Q,V"1
MXU5'HDGC:="V>C,F*6!HLQY^1YY*8DU0H-+(3D%C./..&$LHDHH.1F&FF#R$
M!998`B&88,00``$0A9P'&<X^=M<F]X0(W1I7(W-M<$Y2M`X-ZDA:A6I#P8,(
M5)%:8PU.I3'%BP,D\@TPHT&<#+&(.<9Y6MU6MAHMK+K>U65)5BI,=F?>Y&,D
M-Y6%*]7+9[6ME0F,X*2!-+4&HDCW(6]8\*4P%`FQK*4N)Q`R$X\<[KTM"XHB
MT!U=:HD_M,B2-%7M"%Y4LRK"TI#+QGJW"8,R[(`A,2N[1(E[@B=$2@LH].J+
M'X@9`(LPRP#Q8SC.?7ZO^:+&?WL9QWS^]CFP9H"PY&+/A"'MD0A8$$(0XS]L
M(0LXQ@(0A[B$+.<!#C&<BSC&,YQX6-UOV2+M0]+-D]:*JK>L*P&&<V13D8OF
M)3"4O\P:HXT3AVAP9?&T*E(G8D\B>8\B$<W.Z5>86Q*W#TLS&&JD:`X'KVTB
MU#J?2#7*!4%4+>,MF8$`'2221<`O,BL"=/"=.HE4]EBP/B&M?I"O#Y0?C,,)
M;&TEN9&[!38V(R2Y:\<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<_,XD
MI04:0>6`XDXL91Q1@<#+,*-#D!A8PBQG`@#`(01!SC.!!SG&<=L\A/"NFSH+
M7$RC5AP+3[7F'SB'/B22Q65QRKHRTOL=?T!@CD3NSN*1$6>@7I3!B$0H3B`,
MOQ"P'.,"SC,V\AQGM[<=O9VSD/\`FYQW_?\`9S8`DHL0Q%E@`(T7B,$$.,",
M%C&,8$9G&.XQ=L8QXA9R+MCMW[8QCF'I]KIK_:KD<\V?1U/V*\'I/,#7:=5G
M"9:Z&(O(A3>:"<7]C7KLIO(``3@G*CP!*`$`<!"$.,=P@-;5[540;:_K*#1"
MO(*S!6A:8;"8XT1:+M@7)8H<'##>PLB1$V),+EZQ6M6>03`RI5J3U!V1FFC&
M*KY[Z#G26?5AB\[3"OVM8<XFNAIL8D=DQ0(U)Q@CC"\$1Z;-Z8I$(T63`MQ!
M)*$L6`Y*(!X`]K`M@M?89L?2$OH.7O$]BD/F3<SMJMXJV;O==SAH*8G=J>FT
MV/RYC-"Y-AI:MG1E*0?U0F<4&5+:XIU2)6H)'!36CI(UCJO<L6MZ`[3;U21/
M%1O9I566;LD[3JJ7PU_CZQ@6&2:,N+$2<]>2PK`[H@'+RPI'E`VJR\^!&`G.
M>]TM7;\V425X51>[MOZ;*H>IDIDC/JZ)PR5DV"G?$[06VDOQ,I"2H1FQHYM4
MFM9S>N"48%X<0*TAIGFAZ;33'7K:^A2I\GV8W<?=Q29$..#A8G^F855:J`Y:
MRG0E]P6MB3@M.D1<C"I:1C)<L`"VG-)AZ40QN:G`<$[.03K&JKLDDEU(O+25
MNHPXF/!BE;W?65B&2]`>"/I$<F$^3&*F+@.)9LA+6O#2)%A`+"-2F;%"<O"(
MTY;.?7@K8Q+2L0)VB45(Z7^0C=P3953`90WU<N6`>'+T`:P@EB<V0HPGL/HC
MTUA2G/`2[Y<1-Y9B,*8O-62+;#K=,KR%')^E32\K;1NI6/25?[JPQ"44S!79
M3J,Y]U3;A0:O,2ARM2B&B2EX*$6!2E+/$803:7L?;LMHRE9A:<,I"R=A91&2
M&<QOI^I`,RF>R@QT>VQI5!9BWI<@1&@94Z\]Y<_`-0J]%MRLQ&B5'8"5F$NL
M/4KE^PMN1RH)=T\M]]>U$@2O.3[!N"GD+;5#`XL3,X.ZQ#()FD>QA0DKA-PF
MEA7A;C2GAX6-Z,LHD*K!H(#=1FP^EM3&_P!K335YZ<:QV1-=J)`J=-A[6F%>
M1E;(("SRA/B!51*I"O,39"XK)7.T9"!\/>AX,;X4S.#SD0A82#%Z,8\PLD58
M&2,1II;V&.QQH;6%A8FI*2A:V5F9D1#:UM+:B3A`G2(&U"F(1(TI``$D)B"R
MB@A``.,>>W>.9K=0]N;-NBQ.C[8G4.AUZ,%=I8'?NO=:0[82U:R01*"E1)YU
M_E]=S-F5/\(A2>0M;S93))(NXDQ"3JK0>DSFB]T[2J\_L`Z7T#D<9IBPIN[:
MH-VB[!=MQ/EK0?4Y(HC67&JHXOB$(BQ[E*FB%(T$+ATRM%_BKS:,D@T52%(H
MRLE0$[T)1,SY0H,LJY7IU-S',.MC&48>8EKE9LMJ"@OQ2`:<M,7KRNV<JY+<
M8'T:G/@!"U41,4HK#&,(DP*_52?+CX&KS\P'Q]/HDM$\;SM$5(.2THR[SV.@
MH]*3DG$:1,PJHI1;<"&#%(QB;D\21[.*[P)PC0`*3H)5B5H0E$B3F$E^,/\`
M9%4OLESZG%IQ%=+)ZMA,9@]*J(3%E+Y)542CJQWKMH<'E=%6(Q2-C:ECFZD9
M5.:MH2$J5R]/DU8::>EQDJFV)W]LQ7C>I98'=]_P9I4KS7)6U0RS[0BK8I<S
M22$QSBH;V!];D9Z\U.E3)S5II`U)I"9.4,T19)007D:&V/U8;MZ??4,9:ID3
M1<]5&L#XU6<NNJ:[$3W9-N&KJL9QT>UF0-+D[E'.[NQY+-3HU6,A%)QE#R2(
ML8_%&KIOZ$[2;#;;0BI;SK;<>(5+)8U89TW7/;E?=&,#RU-$75.14/?;'=H1
M)$;4R2Y<2D97!O\`1!ZE](/RV)%"!0<!<G]*Q_['+TT&[#<TNMZYL(](@7IF
M9OWFN0#.A+*4@4$MJ0I32BI>%N)P6%.66<XGJ@I_M,K!#Q@W%]A3SL(26`HJ
ML*D"64`!98??DE@O"``<``'N*F,BSV"'&.^<YSGMWSG.>^>;_3VQ'S95)]<<
MJ_4QQZ>V(^;*I/KCE7ZF./3VQ'S95)]<<J_4QQZ>V(^;*I/KCE7ZF./3VQ'S
M95)]<<J_4QQZ>V(^;*I/KCE7ZF./3VQ'S95)]<<J_4QSJR2R[U6S-]@Q56U?
MAWCT<C,G6GCN"2X0F()4X2=M;BDXPT\)0)42?$W(2L)J<HD)9B3))QXQG`)[
M3Z>V(^;*I/KCE7ZF./3VQ'S95)]<<J_4QQZ>V(^;*I/KCE7ZF./3VQ'S95)]
M<<J_4QQZ>V(^;*I/KCE7ZF./3VQ'S95)]<<J_4QQZ>V(^;*I/KCE7ZF./3VQ
M'S95)]<<J_4QQZ>V(^;*I/KCE7ZF./3VQ'S95)]<<J_4QQZ>V(^;*I/KCE7Z
MF.:X?MANX<"K2HPXR((<BS<4LS@.!"P'Q9P&E\BS@/?OGPXR+MC/;&<]L9ZC
M!;1O*P8JTRYDJZL"6UX"M$G)7V_)2UA64#HN:C0G@3T\I(QD1Z`TTOR1YH<D
MF%9%D)OE"R^V^GMB/FRJ3ZXY5^ICCT]L1\V52?7'*OU,<>GMB/FRJ3ZXY5^I
MCCT]L1\V52?7'*OU,<>GMB/FRJ3ZXY5^ICCT]L1\V52?7'*OU,<>GMB/FRJ3
MZXY5^ICCT]L1\V52?7'*OU,<>GMB/FRJ3ZXY5^ICCT]L1\V52?7'*OU,<>GM
MB/FRJ3ZXY5^ICG5IA9EZPII2O#K5M7G)E<CB48*`BN"2C.POF4G:8FUFCP?3
MQ!>$I+D\I35HL&9.`D"<,@E0<$!(^T^GMA_FRJ3/_P!L<K_\Z7X]/;$?-E4G
MUQRK]3''I[8CYLJD^N.5?J8X]/;$?-E4GUQRK]3''I[8CYLJD^N.5?J8X]/;
M$?-E4GUQRK]3''I[8CYLJD^N.5?J8X]/;$?-E4GUQRK]3''I[8CYLJD^N.5?
MJ8X]/;$?-E4GUQRK]3''I[8CYLJD^N.5?J8X]/;$?-E4GUQRK]3'.I^^A>/N
MY][[WKZO]-^Y#W9^6]]^3>8>C?3WN?\`-O*^\[Y?S[SK^J/#YOYMYKZ_.?./
MVCG;/3VQ'S95)]<<J_4QQZ>V(^;*I/KCE7ZF./3VQ'S95)]<<J_4QQZ>V(^;
M*I/KCE7ZF./3VQ'S95)]<<J_4QQZ>V(^;*I/KCE7ZF.:>G=A\^VL:CS_`/;%
M*OU,<9?=A\X[9K*I,XS\7OQRK]3''IS8?YLJE^3_`(9)9^IG_P##E9]T=''5
MC;^\IC>&TE!94S6<H6X+_*XEMA>*HPPV/LC9&V%M;(@GCT+9&)K3,Z`(<9:E
MZ<M*K`8K*;S5+@J/!<+'6-'&6!DCC>:X'H&!H;&5$<[.2UY=#DC2A3MZ8UR=
MW(Y2XNB\PA,6-8XKU!ZU<IR:J5'&GFF&"YC.,9SW[>OV=_9GM\G?'K[?>XQC
M&,=L8QC&/9C&.V,?O8YKSY5R)&Y(E;<XI4RY`O3'HER)804J2+$BHH9"E*J3
M'@,(4IE!)@R3TYQ9A)Q0QE&@&`0@Y^)A8&*+,S='8RS-4>8&=(4@:61C;D30
MT-B$C&<$HVYL;B$R%"D)QG."DR5.227C.<``'&>8<N6_J'I)6Q%7#,&2,*7E
M&YO:(;BT.;OALCD>7,31()O(E#4T.Q<-@$8<9='&Z2V)*C6.$QM9)&9*]/Z`
MUW2`/S9Z,;O_`*"C_P#\1/\`%_\`VN?02G(3A$`@DHD(L^(022P%8R+MC'BS
M@L(<9%VQC'B]O;&,=_5CGZX#C'K]?[XA9_[,YSCFO''''''''(_H-FJ(<M@'
MG6AMG");>K)'"Y&_0Q&Q28]0UL9:)O=BANDD)8111*H+02!K7A9U,A`ZEIWE
M$?AO"%>2(V0''''''''''',5V1=U4U$[5BQ61-V6)/%S6"WU75[8YC4^>S6P
M'1N<7=%&65.D3*1G+C6QI<5QAA^"$:9,D--5*B0^'Q=?%L51[=:R2B/=PU)K
M'4+R69/'2VYX`W@DRV(*[&2PDR2E-7N/26"OK](LL%%7BA])FZZ#)U$R2L!T
M=+&Y\SIQQQQQQQQQQS%3#<M43*T+'I)@F+&^VA4#5`)'9,*2^74N<,;;'R_*
M:_6O/C2^8D&2#W)OBIL)*5&K"P-8U)Y*8`TQAO6*-V?HS9(4Y]Y.>HYZ37,A
M#%I:M;F>3(&U"]#PK$6G0NCZQM+;($QQ:(\XASC:MX:CT_D5!*X9"I*8?GSC
MCCCCCCCCG2[$L.%5-!Y19%BR)OBD)AK.K?I&_N8C?-6YM1AQDP>"4Q2A8M5'
MF#*2(&UO2JW-T7J$K:V(UC@J3)C8ZP[>C4^P:L27E"[21R2'+K!=J:(`V0Z?
M'6,&U6#T@J?JG4U$*(EW$BL9D1-3F^O$`6P=/)VR/(%DH7-!#`G-=`R9ALQB
MMAQ*,SR#R!IE<-F3"U2>*R9B6DN+*_QY\0D.30\-2].(9"QO<4*DA4E4%"R`
MPHP(L=L]\8[+QQQQQQQQQQQQQQRE[>^MK!373L;,V^L)9:3'L5TP+'U*JYNB
MT?D,J3$WF;-9\Y)8)*"&AO<&^&LEO-MHQPXR=2031$F]%5KV&2OJ/S5I)4VI
MTI#GVO*>JJ!2AXQ(I+":V@D0D#^$U4?A\?(S$VAC=WC!ZWNL.PYN*!2NP<JS
ME2;@_!A^<FB%GF3N.........:"QC.,XSCOC/JSCU^S/J^+U_'Z\_%CU\J0I
M&#ED;V2JS=;A[4PB`RUVOE'NA65Z,U]LU&OMG-SE&VVN;5I!GNXL+`V3.0N3
M0I"E>]=3S:GFE0F'N4O1IW]'`SSK<...........5X]0*,2J3GZ58BT4EDI]
MS&^^NLYDV8M&'Z2`CD,C(YAB0RF0C9$"X#+'FCTH@\_=G,29$G\X`(1O8(\@
MA$\41;V;;DE,@A$J6RN1=8RM=Y6VT!L<I-@R;6^/0^O9:\R3%@Y0#C;<_-R.
M#NNKXH")[)DJI0XMRA,Q'P=W&XAOI!C.`!QG&,9P$.,XQ[,9QC&.V/O8YNXX
MXXXXXXXY6L)$O8]Y-X;"DD!M-UK95HCK"PE.,7@4]7BFSK7$WW1D=@0BMU[&
MW$FRR>H8]8T,RDCL.<#Y$J7R=K3-(1.6#\)/AZ<%=KJT16TQ5N^[%*].#O>I
M5ZPQ#:8%LYM"L3"X8K06?`(T?L%@-]E4PR&HX*7!&2TO+.4:DXK%9(LI,@*.
M+DIK-^.........8JNZ<-E:55-+!=H%-[030QK+DI$`K6#.5D6!*'9H7)%K$
MVPV&M*1:O=I'E[*;SVHTLHLIH5$@>U:QO1MJA>FI6@C2O66_1&XY=2;)LS$P
M;?7W9&T2:;:]VQ7SYB;77I^UTQ"+#K>F5\>%9TOKRJ(Y":^H==*<0\Y<ZKI(
M]S9,$U$5,,LUC/3<JR=TWIG44)LF/CB$M$HLV:JH6<9XU,#:;2N&PK2BM?+`
M8$,I,M@,3F;'$%R!,,2)M6,RAN1=DB4G')R\<<<<<<<<<<<<<<TSC&?;CO\`
M[^S\'JQWQ[/5S7CCCCCCCCCCCFG;&/BQ_O\`%^#[WR^OFO'''''''''''-.V
M._?MZ_\`_G;O^'MZN_M[>KV<ZS,IM#:ZC;E,K`EL9@T19L)1/$IF+\U1B.-0
M5RY*V(A.3X]JT+6APL<EJ-O2Y5*BO.%RM,D)\:A046/"S;N1J*\A>AL^TNNC
MN&-LDTDLARUW=6;AZ"CM;HBW*PWYXPDDYN6UF@C<:4OF3DLP2CBZ,PM2^'("
M3`#%(!K=FI\;&YZ97)`[L[PA1N;2ZMBQ,O;7-N<4Q:QO7MZY(:<E6HER0XE4
MC5)C32%*<TL\@P90PBS]_B#V[^+';V=^^.W?OV[=_9[?5^'G'N[NU,#8O>WU
MS;V9F:DAZ]S=G58F;FUN0I2\FJ5J]>L-)2(TB<H(C#U*DXHDHL.1F#"'&<\Z
MU";+KJRB'Y574]A<]3Q62.,-DY\,E+'*"HW+V@I,>[15_&R+UP6:2M9"U&<X
ML+EE*ZH2E:8Q4D*">5D?=,B#COG(@XQC'?.<YQCMC.>V,Y]?JQW]7?Y?5SCF
M]Y:'8US(:W1O<3F5Q&T/!2%:F5F-3J6G3+#&QQ+3FF#0N`$BQ&J&C5!*4!3*
MTJC)?D5!(Q\GQQQVQZ_5CUX[9^_CY,_>]>?X>:8QC'LQV[^O/W\^SOGY<]L8
M]>>:\<<<<<<<<<9QC/JSCOCY,\T\(>W;&,8QW[^K';U_+ZOC^_S7V>SCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCG!R)E8GUM"DD;>W.36C<V-_
M\@ZDDGHD[C%GMODS(Z"`HQDD"AD>FEO>D*D?;*)<@3+"Q`-3@&'R,:E1WS'I
M+];V6>XIK<+9A>TO5QL.GD<QK)AG"Q>&SH4H30DYM@5A1.2,D]AMQ)@>YL#*
MNC4AB]DM*E2Q"1NF/VHG'M@;K=0R.,CUB$7;9=<H*MH#H=RF"US":3J!LAXI
M7L`Z1^*;@,8F`=++%I[!'H>?AV>H"V."%CJT8DQR9LC[8C3-I799;U!>H%#(
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M71T8U+G&GIM?6].],:PUN>FDY8UJ52<IR:7`DY$Y(1F!4HE91A"@LLP/;F%K
M8V?KRJK!A-/812RQ+HL%B?Y?&JCK%C)DTUS`XJL;6R2V'(`*W)DCL*@30\/+
M.P9E<UD4?:G22NJ",L!KN_G^C0]RIVZH=>$=>9'#T\H0%QR8R>OY&S3&*/<.
MDK%+X:M+;Y$SN3"^)4R\KS16:#*)Q*+.:'YN-2OT=7NT><6QV6Y:P+&?B%Z\
M9%ZPBQZL?AQCMG_FY^VS\6.8!DNR5?Q39"K-7'5'*\6-<-7VM;4.7D,/E(:;
M&::>8`R35,ND9BPK!+\G5V7%#4;0F0K##D:P:M0<D*P1YQG[Q!Q\?M[?%GX_
MWO5\7?O[.^._;OCO@&2[(P"*;(U9JVZHY7BQ[AJ^UK:ARXAA\<--C--/,`8Y
MJF72,U:2$E^3J[+BAB1H3(EAAJ-8)6I.2%>0RHZS(=OZDB6S,>U1E1<TC=GR
M^MII;40<'V'.;56\I@M<@:?=XXL5GK1DPQ<Y1`Y_8RY%&`N890SIGAO>E[.1
M'3\/..TU'LE6EQQBNI.R'2",`MM')G:M8_8L=<(',IE'8GYL-UE++$'W!+Z=
M&1HUS<[-ST:D)2.;&[,CVB$<UOC.K79[\8?O^O.,?<BS[<=\?%ZL?%WSZN_V
MO?Q>KCQ8^_\`'_<B^+VX]GM^][<_%CCQX[9S]MZNW]P/OGOGMZL>'OG[_;&>
MV/7GMCFGC#[?MOC]H!XSZOO9#C/K^+U?;>OMW[9[8?N:\892#9$U$F+>7=_L
M2:(*ZK6#15`2[3*PYTX-#W(P1F+-JI:V(3EB2+1B3RMW6NCJU,S)&(V^/CPY
MHD#><;S[:AN&,W/&G"21MMES)Z%E<G@[^Q3>*NL1DC)*H:Y":)"UKFET+P(T
MI,N#G"!Y;3U[!($(T[S''5W9%J%R4Y4\8<?'GV=_8+Y>WKQV]7Q^K/;.,8%G
MV!SG'7)=,HK`8V[R^:/[5%XNPI<K7A^?%A3<U-R7RI1`3E2Q1D!183#SR""L
M>+(SCSBB20F&F``+L>!ASG.,9[]LYQGMW[8SCOC/?/LQVSC./7GMXL>'V^KD
M?$.R]>+]HY#J,4EE95J1NCHSL$L5*6'*>'*H!*YT_5VV^BY$8L[N+V3)(XYE
M.380W^!O3@)-4+,&J"B,R%XXYMP#&,9QW%]M[>XQYS^]G(LY#_\`5SCFG@QG
MXQ_%C^N#Q[/9[!?PY]N?C[\U\&/7ZQ>O.<_=C[^OY,^+OC'_`#<=L=^V>W?&
M.=)L2NX/:T2<H-8+"WR2,N1S6L/;EV3`"3.C"ZHG^//;:L3&IU[/((W(&QLD
M$;?VM4C>&!];6]Y:%J-Q1)E)<:[2Z@FC=#S=WJZX=LJ)K>PHN2V#?X=-[/C[
M))VD#JU)'=L,=FM<N+5IQN+2L1N9'G!81*$RLE7C&0GA$*5,5E,7G,6CDSA[
M^U2>(RYC:I/%Y(R.)3FSO\??4)+DSO32Y)C3"%S:YH%)"Q$K(,&2H3G%FEBR
M$6,\P8TR/6ZN-B7N`(WR.-.R=^L0+%<F-:K=%M@3N$UPG+CJ=U0Y7!5&9KZO
M<NN&Q.B:STL4BCQ*%6?-4;]+UAKO(U2L2(TYZM6I3I4J8H1ZA2H.*((()!C(
MA&G'&B`644$.,Y$88((`XQG(A8QC.>?1WQW[=\=^^<=N^._?&.^<=OEQC.,Y
M^]GGSJ5B1&3E0K5)TI`1$@$<H.*)*P-0:600')AHP`P(X\THDK&18R8:866#
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M_J[=^1PAVW>N$_F;7`XA;,8?'^0.LJ88H-+Z4+CTW?X-A1F9L$`F:IM3PRP'
MV*X1.0Y`RPJ0O[FTEL[X:M2DEL;N)%([Q@SZL"#G.?9]MCY>WR_+C./P\Q>J
MNJKT=SLNO2F8-Q5R2*M)!<++!,D.(G5?6L5DL>B$@EI2@"$34!N;9)*X\TF@
M.<2UIBET(R0D-)`<:5E+CCCCCCCCCCCCCCCCCCCCCCCF$]@JID]SUFZP.(7)
M8M$/B]>SK4]AU<<TD2M`4V.!2Q2W$F.Z)83A`[D@$B<,)\I%F2!=B%A0<F%F
MUQR'IF;$O#`]M(.J)N,J&Z-#DW!3/#A'S6A0):B/3!)="FP2!R,;3<FX+7%M
MZ]$N&E$:%(K3GY+-!$G2WI"[657#IBGE.X-G:UKG>6G^;PW760(7%B?&]E+&
MUHYA(%CN46C](/B<!9K6A1MR9R;V0"0F0JC7+/HYHSW7]!6_I;U`D5XV*NO#
M:VI;CTT@FMSG?1<0>+5M6L+-J*\;3M)K;I["Z^0.\K*K6S(U;)Q+?,(M&7II
M8)/7A".;Y8P/3*YK^P7[KVEV?Z@FE$RFM"62KH1'1^WN;,(>D,O8X8*;G3[5
MV0Z\NEFLC(ZHFQ+('CWO9\^,;5*49KXUIVAG1S5*TN!C(RIZRZ"IK;DBMZ>A
M=DUMNI"EL*Z5&_NLER3.)0U[>)NT7</:6EW6LE$)(D[H!CM60!K]OF<@JEQ2
M'O,=G437/D:CKV(AU?DJ#[Y%JY?]MJ*V:+*U;<C(]`]9.LO7GIBJ*QMNMZSL
MR07&5JXX:_3UJI:;.2^:T*XVD_P2;+(S2#F].R&`3B`)IC$UC.R/5=GD9'J2
MF]KIC;VOC?M'#=RC)X&K>G!9-&7#"XY$EC37LWINJX>CVCK>\[@E,<DS]32A
MVMI)/WBYHXN`!)L;6DY<(I'#I<_B1)&7D=#JBOENV\T"F]PZWWE';NK;7'J$
MU)O!>,O@SGF+2Z_)O:]!2J,3$FT3C?0%A0^Q4L/ESQ64EBJE\;&F&J8U7H53
M=B*&QV-SDZDFODTWJ.74="(J\UY(]:F0G9&M-@YA6CRZP^2W@G:GQHB-(1I<
MF+$;*ZUF;$H>HMMBQ)$YV)A54P35K'4SVXO4G5PV&&S2:]]B'S4C<HGI][&)
M[%C73MZD%53ND6@9-;6Q6FP,TB-!KJ_@4;LY,YIU<41/!D6MI-3USPXMS4E&
MJ&W+.V);`=$$4+CE%]=]E'69.S(QT=?L;I0/4GZ3-\0:,LE3VG24":*A::48
M(QM([,E:.,C<GF,,3>YQM0&XF*3K#I*^2`X$CEC8XRUY,6F\<5K%>]1-,5ES
M+4]V5XRQ*;]=*!RJ1'IYRS(H5IM)H+=C_IA"LK3G+RL:IQ$O)K9XJ.--8DR&
M%OY0W!$AC[MA[.%R.N%93MBI>J-EJ)UJO:X([972JU-8[NJ2?([8S$]CM[C)
M!1SG0=GR5IDBP;M*8Q34-:K`D%]VG$1.[`]4\Z1*!Q@4Z?TZ.'MVS9;6&SHW
MK0NH:G:"VRM>PL:B;WRIIV8=JGLS)4FWEEQ=4RQ$KK*E@OL=2:X/SJZH@8UO
MM^1I$Y-2U]`G:DJ6:5THD*]U6W>;8U5#=@]6]?8K>]3;`RD+O**JD:J9TTIF
M$8V.U<L5)7$@<6C8",N<(5E6+&9C!91D,7?E$1)>WL@F8NJ)QCLE83GYH55G
M1.B=N+)DVBK%M"VW3L)5-5[X;<,_OH3.LWFOYW9VC+QIG8T%KV4[=5C%4[`C
M')I+=#PE@8B)/"&:0V#$&J,320PECQ*)(CY'"N->MRW+51OK._*9V@D5@#Z6
M,3JS2M_)S*W"6:[[T5E;]\)@N#K(2G):JIJ?N+<Z:J2:-WK-5[/%U-:5@ZQQ
M7,%"=`^1YX[5LGT_;=M>M^J_(YA1$^MV]7"[-,GZEW;*.6'M,^C$9KS1A5M8
M[T;'),\(HZ:TR*S:@MYP*9T#:VN2\+4UIH^A`C51XH[/CK2FTDIV>OTMOANR
M5>["Q*R+3M?2:YH_!ZS9M:04G,-4,U[4]565<`HT^.:")5Y.CEC)-M65"IO/
M7V2UPVV(RD$VA>9^CY[IFU;.&;=""V@OUCONF$"KI0452]S2FW8"]QXYXVLK
MJ]YR\VRDD<J>#,%V#-7I2\*9,LM!JP[-5I)EQ$K2R5Z2J$:@/HKXXXXYIG'?
M&<8SG&<XSC&<>W'?X\=_5WQ[?7RHG87IJ[$W1<4XLV&]5C>2C8W+7!.N:ZGK
MMT@9$'A11+<D1&-48*RR(E0&LPY,8N#AR\^<\J5BG*MS6XR5DORV;W=!_J?2
MG:6T'Z`MEB;@Q1P*B(FK86UK6IAEGU@93PAA2+"Y`VNLR8%R8497$*(DW>6:
MTP36EF0G%"-*,":*]&@NCGN,RT93;1(.K-OE3;\V5=!$#U44,DD`71"KW5)&
M6TA?7T86I2U9"N/PY4`Q@:5*9:J)/0("#"51H!!,SW.90^0T5O-KU`Y#>]H6
M=*H%TA-^8<OV!G2AI!8[I-WJY=7I;%W1Y>F%A1Q9#-E#1$9*ZQ5*:VB7+6N&
MJ5PB'LYM<EQ]3EGV'M?,].#HO)K;V>L05E](WI=;,6Z2X/\`83G(6"^F_;B$
M1?8E6V`8TJ9VARDRFS5H[FK]`6G1.;<S@FLSCISZ<\2!TE'?.ZFRD=V<?Q:D
M3J^)G/6C8+=BATE*6POE*U'('.(].2:6+K#$$M(*&'W'QFM)#>T%A<EJ6YI/
M(!7-?KK(Y:>_OQ,/6.+.1R=A6.Q7UIE"K0J;9?<FW((+9?I$2"]VR0*K12KJ
M9E,=V2B#9L^C=WE`W()ZV298WGDRNYJ?1DFUE3;W$(I*(?'8@=($*=5>)OXI
MIR3:YN.O5I1S$_-VG$GHZNJ[7+GUC722:2`H"UD?U4M2(E;K7!5;J4"6Q5EG
M'!2NT*=8XVJHX8KL-5$V1VH@MZ46.V]-+?33*TGFRW_=W6BWZ1>[SN.$YL!*
M^;858NOBBW!'L^RNL9PJ,4-CE01P(K<U5MCP\D4TZPUYB[HW$1'$97.?=9WM
MS/A[JML>K^^=D(U#E&U.WNMUILDYD,G1N,;A+'T]9;.J2,CM4JHFZ0Z`P;-M
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MSC&<XSWQG.._;/L[X^3/;U>KCPA[XSX<=\8[8SVQWQC/MQC/Q8^]CFG@!_Z`
M?C_N<?'[?B^/X_E^/C(0Y]>0ASGUX[YQCV"^ZQ[/C^/Y?CX\`,=LX"'&0X[8
MSX<>K'R8]7JQ]['&`AQGO@(<9]>>^,8[]\^W/?M\??/?\/-?"'OG/;'?/JSG
MMCOG&/9C.?;GM]_FWR8.V,>`';'?MCPX[8[^K/;';U=\>K/R_'S7P`_]$/JS
MC./M<>K./9GV>W'Q9^+G`2J*1V;QF0PV5LZ)]B\K9':.2-D<"\F('AB?4)[8
M\M2XH(@9.1.;>J4(EI/C#A0F/-)'G(#!8S\4%@</K.%Q:NH%'FV+0>$,+5%H
MA%V@C*=FCD;8DA:!D86=((9@4+0SMY)"!K;R<A3-Z$@A&D+)3$%%`[9X`8]@
M`_Q<?'[?B^]C^#FN0ASC&,XQG&.V<8SC&<8SCV9QCXNWQ?)QX0Y[=PX]6<YQ
MZL>K.>_?./DSGOGOGX^^>_-,!#C&,8"'&,8[8QC&,8QCOW[8]7JQWQC/X?7Q
MX0_;?:A^V^Z]6/MOW7J]?[_-?"'OXO#CO[._;'?M\G?V\TP$.,]\!#C/L[XQ
MC&>V?;COV^/MC^#F[CCCCCCFG;'R8_@YKS3(<9SW]??MV]0A8QVS][&<8[_?
M[=\?%GFG@Q\HO9X?NQ^S^-[?^=]UGX\\>''_`#OXPNW\'?MV^][./!CMG'VW
MK[>OQC[^KV=A>+OC[^,9]?K[^W/-<XQG.,^OU9[X[9SC'[^,9QC./O9[XYIX
M,9SG/<7VV.V?MQXQ^]C`NP<^KVAQC/\`#GCPX^47\<?^MS3)8<XR'/BSC(?!
MG]L'[/P^+OC/_.QGQ??Y@ZHM=ZZI*5WM,8,6_DN^QEK"NFSL.\A7O*%?80X;
M%:^$[M")9G)3`FS#8-#V+T4V9*;<$1]$JPFPX&KEBS..`!Q\8_WS#,_RB^]_
MOWSS=C&,8[>O/X<YS_+G/\'-/`'&<9[>SU^W/;[WJ[]O5_<X]@?[GMQX<=NW
M<7MSG[L??OG[_B[]O^;]SCXL<UP'&,XS]MZL9QZQ"SCUY[^O&<YQG/R9SWSC
M'JQVQZN:\<<<<<<<<<<<<<<<<<<<<<<<X212:.Q%I4/TJ?F6-,B01`%3Q('5
MO96M,-2<!,F"H<7-0E1DB4*#2R"`FGAR:<8`HO`C!A#GJL<MZJ9@O,:HG9=?
MR=S*2'+S6Z.S2,OBXI"FR6%2M,1M3JK4@2)\FE^74B*P03Y0'E#`^(/>-NO7
M4+U+V8@CW8M=V]%$4;8K,L&JU!DT?F"'JU;_`%V\!;5S@V)7AW)$X1]^;E+3
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M$I<B5:I$U*%F%;@:0V%'+BY->>)L""`PTLHW(3!9),,*P:'!0`&'>(&!B[X)
M`86(T0,B`$(P&9%Y,P`Q!+4@"@'C4D!(,+P<`X1H`E#*%D&`F`-R+!8P"R8#
MPC"+(<^,&<9[#!D6_P`Z3=CQ9/*P%+G.%.<C#C"?."\'9P?WS^TYP4()HL&>
M'."A!,SV`((L]5F<W:87!I)/5)*UY:HW&7B3Y1Q\*-:Z/25G:E3ME"PEJ5R!
M"O<W(A*(AJ(-<4B=8J,)*RK*`/)H<*:[;11S9:$5E9L+KZSV*MK:UQIK92'S
MV9-,:;(TI8+H0.[NUP)0>W2MW7$V5$&1N;WN=-6&\<=:FZ31TQKE+V>I7$-V
M9W2QX(R2&#Q-TE;(BDEEC?0P)E-7%9<)9B,,@Y'(#F1.7D8UJ5G9`8<'!87_
M`%(F)-2A,/P:L2%G]M3JTJO)V$R@A1E,>8F48)-+-R0I*[>53G>3$+R1Y7B#
MY0DSPFE^(/C`'Q8[ZC4IR_*>4.+!Y((QFY&,(?)@`'`QC'WSCP`"#.!B&+L'
M`,X'G.`YQG,=;$VA@-:WEK/0KPURERDNU2NUD5<R)C1LRV&H%-0UTJLZ1%RA
MS.?4KDB])1M(=F/#:F9Y(7JP#+4GH"09.%((3JV!(5J1."(*9`8:2N4"5$8(
M1&D8QDXM8;DSR:4PG`@Y.`>(L16!!R9@/BQW_;*Q($Q.2)20$U6$P:4H1H`F
M*0%!",T1`!"P,X)8!@&9DO`L``,`Q]@B#G(I8E/.4)R5!!IZ00`*R2S2QFIA
MFEX-*`H+"+(R!&%9P:6$T(!&%YP8#`@9P+D399N/!VFR;1J>`P*U;VFE&QYB
MD-V-U,L48?PU;F4MF)#%XR_&269Q`3[8D@B>!S%NJ^!ER^PO<J:SNZN.)"Y;
M"BY)G:I[;K>\ZVA-P5),66>5K8L=;I5#)<PJ!'M;XQNA7E4JDKRI9*I*H+$$
MU*X-C@F2.K2XIEC6ZHD3DB5I2,A>4!_Z8?B^/V]^_;M\N,^$7KQZOM1>OU9[
M?B6L2&G*""E!)AZ/)851)9@!FIA&EA-*"H+"+(R1&E"":4$T(!&%"P8#`@9\
M7/QPYHAHL+TZ@A4E,QCR!R=0G&2I$,?DB0$*!'`2CR>?D*<H0CP%"/$$L1@<
M]^T?-6=HJ]VUH>#[!P-OE$7B,^=)HRM#-82)I8Y:E=(+8<MK1X0.;:UO3\WD
MK39##'<2)*D=UQIR+*<8O`HR<G)D9E2G"8`G)Q6#3!9`65D8<&#%@`C<X`#.
M<"'G!81&?:XS^UA$/[@(A8V%K$AIZA,6I(,4),%Y5$`.+&<FP<#)A.5!019,
M)P<6'(R?*A!Y4&,C+\0<9SB)CYN77S9-9G%&>&6C.6>L[3@-)6?8D&CS$_0J
MO;4L4,*4,\/D10I6BFIIK2UV1`GN9R%@ACY$82T2A$JDT@;Q(GLIIEKA2GR;
MY#RQ7ELX,S@K(P8-S@GR?E1>3[^/PE^5*R,7A[!P:5G.<8-+\6PM<C.\Y\DJ
M(-\S-R0KP6:`S*4\(`&")4X"+/D#0EF`,$6=X!A`,`Q!P`019ZP58,*.G*JM
M"9*U&SU#$D,[6Q0I2$QY20YT>W*.-LB5)`8$).UN+ZS.[6A4G9`%8L:G(I-@
MWS!7DGD7>2-[7'7&2%>4=D:%N5KR"6@:-4I=1)B3#"D+4(Y6E0J5[@<6%"WE
M&KDY*A<<2G$H*\>1AQ1K!L+"]L->J:V4KINDC3!;PKN,V9$VR8(F]NE*%AE;
M>6Y-J9_0-3H]-R)V*3F!"M2HG9Q3D'>(LM8?@/CSG?CCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCF#=B-:J,VPK1?3NQ%;L-J5JYNK&^+8G(LN):`UWC:\#HQN`
M#VI<VN!"IN7%A/(,3K"LY[C*,\H2886*O"0=%/2^$P2T"].*O@FI5\3VLI?5
M+#?\>8Y1.Y!`XU8B9,R3L;&Q/\\2)@.CW$_23&D=4K@@7M!J\+BF/,RG$E40
M+U(_8R>MU,S21.VS,MA^X4'=(H6T,,'D]3/=>'1"1IG1&I325GD<?MMR/$48
MTEKF=R9E"`PE:`UN5%JDAC;D"N5VTG29J:M-4E\7Z>E!0R%3:';1:I[@J*D:
MWU8T-&P;UJQ;,7GGO7OTBFK\O;FPZ4Q1I=VB+G.ZU%&4TKRRF/:AL;SU[NDS
M7O`YS;</I[;DUI6FN5V%S:Q-1;RBT+CUA1`%<2\%O3"#+V>OH4TH'QV2"6NW
MNH5H5+Q*FQWQ`&8AMPK'*W(HP)0:H=Q=&;=BC%L9$]8-4)N5']C^C:Z5;'T5
M9M#(WD8W-:+;?;)D!]D&J9"WK&JT7]/*6UX9IX]B6*I(_-+FE220;N@(`HR/
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M)J`P0RIYU)9M$-I^G+:DRA+2D9%,BB<2HJ^JELZTUSSG#Z%A\YBT:B+T(:%M
M?'$]V<B26UA"Z'J"N]><NT>M1YV*F<\^QMEBYN?NNC$+P%)#V]";E=I-)]-8
M?6=VN.1'/N5P:GGEJ-#FU676`B"SK&0%HC)#!9#&RDF$^&(SH-=[K$:5ATUU
M2F:]AKG6#KE4^HB[XT,3A%6ILN_95LGFA-?HV`4C5,*EG#7*(X5=-J9"<T5>
M>D9&]S-B*]K:`H.QMFI>YT`A4G7P&AK9)<Y/H5T?W;81A9UD"!,=B+UUOOV:
MRO>B&KW6PWAWB\]V!EE,O#9'LRFR_2,;MP"-)7SA+7V/&GIB\K.FL<]C6:.<
M6_6':2SM/Y['=_A*M>;%25FYSBH=@-D$=:NM2V9(J)AWN1@U:5X-.SWU$(A&
MH^6I)HIRMLU_=A1',V=4<5CS`-6=I*THQK"_Z3VA-C,])GHW:VV!`5BC!QZN
MS-<+^F0M@\'QZ"6<T.]D>];7#U$9JYU(ADK"UWS&V];5;JXC(72IH)[)2VC>
MVR.Z*4E)=$3&-I*LV@ZRS-5TTFC+5[=[R$2VA88%--4;'9HPW2$]!$JN:YJ1
M)7!$T5HV*2H3)P+4+9%"5"XLU3+31+6/:8F&'2F!`N#278HJHJ/IO8EWV5JF
ME[5JNQY]3Z*3)WV05?7%,3"KB[*7N+Q(')Q#M7.9RNDTR@ZZ-Q)Q:W]W1N2F
M#XSM[2>\<V!U-KY@VO\`*'RQG;<#5*QJV7M":#HIW>&KT<K34QMW)KZDAV*Z
M/4,9U=M/-26.F4P.<`9X]9*MLC;')`.\7=6M2+F$&HET)IMHM)M>*VV%K:*-
MMK=1VT"G&\A5^B?=>'+935>1PRO7%UKNNFQGCM0Q!VO1]4O<?JJ&,T@]QB1R
M6/+ZEC8'!:PL.#8!KG;C?5U0/\FT;VM=YVMFVEU,[?QFQAT\K@"&3T6*>KGC
M8^&TG2B^)M^W;0U2QU$VG6G;4I=TLD8IS7TRGD5L/-/NK+&OVU>UBV^KR):!
M$R"F+6>)Y3+DV0&7U5?4`8)E6(ZVC_4+L&3QV80"YHC,!R#5RWZ+IP+!8K0X
MEFOM37K53;$*6,ACEEIB86V:73-UWMZ'W`.5WW6VQ\7V'K&#7+4-VVY+5],M
M5!;"@F-O)YU#[`A*Z"LIMA7HM>DZ+$PCCY9;BB?*.(D,V@:PTI9(1LI^::8A
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M-3)'J,MLM6-0\QNVO-Y1?8A-=4-U\LAVZ<C_`+NUY83[I8UPUO:Y"E3GZ?RN
MLWF\DNO;J-I+25PW;/OD'FLEJS*9*YK)9%'780427F(VYT51OUOTWV+@]$U1
M6FPFH]JRZC_L+MYJ3@%+I$\;D$AI39N:[>6/:%7S++*WR5W;X*Y693C_``IC
MKJ_2E_E:>>X(L3/<B@:&4!='KG8UHQN'%YP\SJQJLF]G7E&]O.A?8"F\FA0E
M7JYE]CU5=.5]U`[7ACJY/38XMR&1M[5;\?L$?F#&[6VR/>6X#;+6QV1!Q.;I
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MH)0I?G]]8&"6NT.@UK1"[]N)!I'K,DA['8?3IU]B53OL#)K>!`<9S`MM[KMG
M9"DRW&1KT[K%9Y>E2V*DBZ)P?F0R)OZY^.2RUZ0-S*X"3_`TZ^S9AFM`6>TZ
MH;9RO3BP[9V?EUMZQVHPTR5-X3==LTQ4\$JFXU.M-;$1F!0NM&AUA]JQ]8RM
MZU>*.V':+I?JI"QD2-:_E6G])>M;&IOIKZ45+;D&?JVLJLM>*[@,TA,FRT">
M6%^B;0!G6)U0F-U>FX0#1)@J4HBW`PX24XG*PE(JR<E*L0XXXXXXXXXXXXXX
MXXXXXXXXXXXXXXXXXXXXYH+V9_!G^3G'$?V.;^]_+GFX[[DG_HYG\WCFF?ZX
MI_!G_.+X%]PH_<%?_P"O-QWW";]P+^;QS]#OZV3^$/\`F\_+/W6?\,#^3/-N
M/C_<F_\`GS>#VC_Z-G^0/-!_V,F_P@/Y!\V"^X,_P`/\XOG[D_W/^&,_FL\W
M)?\`\]_AA_\`ES0/M5_@S_(/GY@]B3\'_GS9C^MF_P#2L?YV.:A_KB?\)O\`
M/"Y]!/\`75/[L/\`)GGYJ_NBOPX_SP\VJ_N%7_1L_P#GRD'I,_\`'`ZWW_\`
M431_Z!Z]Y>"5]TK_`'6?Y!<_/_\`0P_N@_Y^.:F?UHG_``HOY1\T']V;_A`?
MRYY^Q7]D*/\`ZG\G/S,_LH'[H/\`FYYH'[L/^'%_Y<V8^X4?X3'\X/GT_'C_
M`*-G^4//PS_8I'^$#_G"Y]9']:!^#/\`+GGZ\<<<<<<<<<<<<<<<<<<<<<<_
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g556198.jpg
<DESCRIPTION>G556198.JPG
<TEXT>
begin 644 g556198.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@!`1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]'4D%02%]$25-07TM?3$E.12Y%4%/_VP!#
M``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``+"`$?`J0!`1$`_\0`'P`!``("`@,!
M`0````````````<(!@D!!0(#!`H+_\0`;!````8!`@$##0@,"@8'!00+`0(#
M!`4&!P`($0D25Q,4%A<8(3%189&7U=855%98E9;1TADB*$%GDI.GU]CCYPHC
M,E)Q@9B9T]0D-X>AL;8:,SE">+?P)28X=[(G0T;!-#5'<G9YA(:4M?'_V@`(
M`0$``#\`_?QIIK7COXS?O"P#C#)F;MO=#P79:'M[Q)9\U9"A,O2]S:67,$=3
M(Z8LUEQMBV3IKU&.QM8FM4KKI:.O-[B[G#RMFFX2`3J#6/0E+$G#V[;<QRAU
M$Q\^SWMXP_M5C\,Q&(*9<3U_<S><U0><;+D2WL6SQKC^#I^+J1.UV*>*S5AJ
M>.8II8+"C+25\<3!%T(V$;QCV1Z?,'*`9:A-]N'=D%!D=K='MLK6J'-9$<;C
MW>X*E.\GRT^H69N%2VB2T%C]QB_*=JI5)CY"5>UJ:R0SL2DI,0[(\0FQAK+(
M(;A@'B''B`\>^`AX!#CWA\W#R<?!WM<B/#Q^81_X:XXAY?,/T:<0\OF'Z-.(
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M^C7.FFFM:^\^,W?7:^5"HXTVQXFSQMVA8]C<+?!7O<TIA5YD;)$7+`_JM2LT
M.EA7*2#W%-7<1[&RS$>NN)[S9QAH^8C`J5<E8JYS;DK'66LO-MJT+<(JLQL7
M`9%IV7]PS2NV)RM">[V,*P]M],I]6+(L$92Q0Y,_!2K"25>MX\RD)0S+/F39
MS+HLTH6W'8AS/NVLY\$Y"P?3:7AK'>X3;IG''>X]IEJ/M5K>M<)W*E9?3?U+
M'P4R(LN-LMN;=6Y3&"SA68D*PUQ_/S%I1M4ZYD%\?*[(P#@'W_"(]\>/A$1X
M?>[P<>`>3AJLN::M7[IE/!%<M42TGH%ROE!TYB)$AEV#ARSIS0S1=9MS@354
M:G54.W.<#"BH83IB4_`P9-W,N`NB>F?)0?XFG<RX"Z)Z9\E!_BZX[F;`/1/3
M?DG]IIW,V`>B>F_)/[33N9L`]$]-^2?VFG<S8!Z)Z;\D_M-.YFP#T3TWY)_:
M:=S-@'HGIOR3^TT[F;`/1/3?DG]IIW,V`>B>F_)/[33N9L`]$]-^2?VFG<S8
M!Z)Z;\D_M-.YFP#T3TWY)_::=S-@'HGIOR3^TT[F;`/1/3?DG]IIW,V`>B>F
M_)/[33N9L`]$]-^2?VFG<S8!Z)Z;\D_M-.YFP#T3TWY)_::=S-@'HGIOR3^T
MT[F;`/1/3?DG]IIW,V`>B>F_)/[33N9L`]$]-^2?VFG<S8!Z)Z;\D_M-.YFP
M#T3TWY)_::=S-@'HGIOR3^TT[F;`/1/3?DG]IIW,V`>B>F_)/[33N9L`]$]-
M^2?VFG<S8!Z)Z;\D_M-.YFP#T3TWY)_::=S-@'HGIOR3^TT[F;`/1/3?DG]I
MIW,V`>B>F_)/[33N9L`]$]-^2?VFG<S8!Z)Z;\D_M-.YFP#T3TWY)_::=S-@
M'HGIOR3^TT[F;`/1/3?DG]IIW,V`>B>F_)/[33N9L`]$]-^2?VFG<S8!Z)Z;
M\D_M-.YFP#T3TWY)_::=S-@'HGIOR3^TT[F;`/1/3?DG]IIW,V`>B>F_)/[3
M3N9L`]$]-^2?VFG<S8!Z)Z;\D_M-.YFP#T3TWY)_::=S+@(?_P!D]-^2>'_%
M37/<RX"Z)Z9\E!_B:=S+@+HGIGR4'^)IW,N`NB>F?)0?XFG<RX"Z)Z9\E!_B
M:=S+@+HGIGR4'^)IW,N`NB>F?)0?XFG<RX"Z)Z9\E!_B:=S+@+HGIGR4'^)I
MW,N`NB>F?)0?XFG<RX"Z)Z9\E!_B:=S+@+HGIGR4'^)IW,N`NB>F?)0?XFG<
MRX"Z)Z9\E!_B:=S+@+HGIGR4'^)IW,N`NB>F?)0?XFG<RX"Z)Z9\E!_B:=S+
M@+HGIGR4'^)IW,N`NB>F?)0?XFG<RX"Z)Z9\E!_B:=S+@+HGIGR4'^)IW,N`
MNB>F?)0?XFG<RX"Z)Z9\E!_B:=S+@+HGIGR4'^)IW,N`NB>F?)0?XFG<RX"Z
M)Z9\E!_B:[6#P!ABM2\?/P.-ZK%3,2Y*\C9)G'`DZ9N2D.F"R"G5!$B@$4.4
M#<![QA#AW]3!X---->)CE+PX\>_XBF-P\IN:`\T/*;@'>'O]X=!,`<./$>/@
MX%,;_P"D!TYQ0'AQ[_\`0/`./@XCPX%$?O`(@(][AX0UY:@/(/\`KMP%_M8_
MY-8:GS4>9<DW\+BS),Q%.UF$G%4&Z24<];GYCAF^85F5=LW2!^`\Q9NY1262
M-P'FJ$*/#O:U2[,MB&)<O;/MJ65K]E3>W-WO)FVK!&0+K-%Y1+??'!,VZYXK
MJ=CLTN,?&;AVD:Q-*3<D^?F9QK1I'-3.!08-&K1-%NE93[&;MXZ0=[O]X_O\
M_6/T^QF[>.D'>[_>/[_/UC]/L9NWCI!WN_WC^_S]8[7'V,W;QT@[W>_WO^T?
MW^?T_&._W^#7/V,W;QT@[W?[Q_?Y^L?I]C-V\=(.]W^\?W^?K'ZZ"0Y/?:C$
MRD9!RN8MX,;,S0G+#Q,ARFN^ME)RQDQX'",CW.Y=)Y("0?M3`R07YIN)1X"`
MAKO4^30VZJD(HGD3>VHFH0ITSDY2'?T<AR'`#%.0Y=QXE,4Q1`2F*(E,`@("
M(#KR^QF[>.D'>[_>/[_/UC]=2^Y.O:Y%R$-$R66=Y$?*6)PZ:0$<]Y3#?>T?
MS;IDR6D7C:(9N-RJ;F3<-6#9P]<HL4G"J#1!9TL0B"2BA>V^QF[>.D'>[_>/
M[_/UC]=5.<G3M>K,2^GK%EC>5`PD8@9S(R\URE^_"*BV#<H@!EWLC(;E6S-H
MB41`#*N%TTP$0`3`(AKM"\F?MV.4#$R'O<,4P`8IB\I!O[,4Q3``E,`AN/$!
M`0$!`0'@("`AWM<_8S=O'2#O=_O']_GZQ^O0ZY-;;>R;.'CS).]9HT:(JN73
MISRDF_ANW;-T"&467776W(D21123*8ZBJIRIID*8QS%*`B'S1?)Q;9)R,CYJ
M%REO/EX>59-I&+E(OE*]^<A'2+!ZD1=F]8/F>Y-=J]:.D%"+-G+995!PD<BB
M*AR&*8?CA>3RVK60CE6O9?WB3J3-XZCW:D/RF>^V43:OV1DRO&3D['<NX*@\
M:&62*Y:JB1=N*J8+)D$Y`'O/L9NWCI!WN_WC^_S]8_3[&;MXZ0=[O]X_O\_6
M/T^QF[>.D'>[_>/[_/UC]/L9NWCI!WN_WC^_S]8_73Q7)V[6IT),T+EO>/+E
MAI-U"RYHOE,=]T@$7,,4T%GD5(BSW++@QDFB3ELJY8.^HNVZ;A$ZR)"JIB;Z
MF?)O[9Y'G]890WH/>IE2.IUIRE._1SS"+`843GZAN34YI50(<4S&X`H!3"01
M`H\/N^QF[>.D'>[_`'C^_P`_6/T^QF[>.D'>[_>/[_/UC]/L9NWCI!WN_P!X
M_O\`/UC]?!*<G#MFA(Y]+S.4=Y\5%1C59](R4ERE6_-A'L&;8@JN';UZ\W)H
MM6K9!,IE%G#A5-%(@"=0Y2@(Z^*,Y//:K-NUV$/F#>'*OFT7#3CAG&\IKOL?
MND(:QE>FK\LLW:;EUEDHR<+&R)H>04(5I*%8/!8K.`:N!3[S[&;MXZ0=[O\`
M>/[_`#]8_3[&;MXZ0=[O]X_O\_6/T^QF[>.D'>[_`'C^_P`_6/T^QF[>`\.0
M=[O]X_O\_6/UU</R=&U^PL@DH'*^\J;CA=/V0/XCE+]^$FR%Y%O7$;)-0=,=
MRJ[<7,?(-7+%ZAU3JS1XW7:N").$5$R]I]C-V\=(.]W^\?W^?K'Z?8S=O'2#
MO=_O']_GZQ^GV,W;QT@[W?[Q_?Y^L?KH9KD]MJ=<4CDK!F'>%!J2[PL?%$F.
M4UWV19I-^?F\UE'%?[EVXOG8\\G!LUZLN//)_%_;%X]Z')F[=Q#B&0=[O#_^
M8_O\_H$!`=QW$!`>\(#WP'O#W]<_8S=O'2#O=_O']_GZQ^GV,W;QT@[W?[Q_
M?Y^L?I]C-V\=(.]W^\?W^?K'ZZB4Y.S:W!JQ2$SEK>/$KSLDC#0J,GRF.^^/
M5EY=PFHJA%QB;S<LB>0D5DT55$F+,J[I0B:AR(F*0PAV_P!C-V\#X,@[W?[Q
M_?Y^L?I]C-V\=(.]W^\?W^?K'Z?8S=O'2#O=_O']_GZQ^GV,W;QT@[W?[Q_?
MY^L?J':1A6%VT\H[@.C8WR'N*DZ9DW9WN_LMRJF6]TFXS/=<D+'CK+NS2.IL
M^SA<W9/O\;"3,)'9`N#!"3@FT:\693KULZ572,0I=M>FFFFFFFFFFFFFFFFF
MFFFFFFFFFJ[[@-U.#]LD=".\M6N19RMJ<.6E/HU+I=YRME*ZN&94Q>DIF*,6
M5NY9&M*,>*[4LJ_AJRZBX;KQH:8?QY'2!E(=PGRB6W7-MQB\=H-,ZX@O]@,Y
M+5:EN:VR;@=LLA<CM0YRC6DO\VXZIE>N,KS".%BUZN3<C9#-6;UZ$.+)JLX)
M>K6J?E1MN%0RWANY6(]BS`7<2[J+G'VRQOC3*=YH,Q1=R\RRGG./KG1H^F66
MM1[BP)V+W*L.0K+<$;!$P6**-8#RB#&EHVUO*55Y42@;AJK7\3;@,U0*^X[:
M#MBPY$RFYRJX1W([DMJ.X5M:/=*))F/<U38[!EAIE.R_6*;38HU@'!M[LK`Q
MH!&Y=B#@;!+-&2E8MT>=,LM<-<M3O3:3]C@\V\GYNZQIBW:5%MY660C*30L.
M8YVP7GL8C8%-TBPF8C<[(YFO3+)3.3C93LY@[3`Q"HR;:H49*"_4T@<RB*:A
MR&3,<A3F3-_*3$Y0,*9N\7[9,1%,>\`\2CQ`!XAJLN;+$-6RK@:7""L=CZFO
ME)#W+JL7[L3!^KTUI_')L>KMN<W1YG\>IU4.9SR!P'G<0R7MZGZ'<[>CH?76
MHUS/FXSG$&5D>U'F]OS\9Y!_C7./A11)PITV8.>I[L&YH#PX!]J/$P@'>X\0
M]/)T!PY/K8L'$!X;.=L(<0[X#PPA1>^`_?`?O:N4/T?\?_RU226SQN0:2LFT
M9;<I%=FUD7S9HOSIESU=J@Z52;K]<-6XMENKHD(L"C<11,!_XL1+P$<QI5SO
MV4XF[P&9,9R&,*LE7RNALGNQ)0*B9TUQ57.@]<BU<LUHU-`LH2205!NUZVYK
MPIR*E(>LD5D.[/I:U<Z4L-^(PL\#-4&)"/E*B;+DM#1<"A&N7KM-4#I)1-9;
ML;T:FQ2#!2[N7)Y\J"D<DJQ"6NZ`W,_%MD?#X>IV`?#_`/TX!YN`>+@&K8T&
M?L]CH\-/6JKJU2S/FBZK^LK+B*C1=-TY1;I"JN0JB(/D4D'!4W!`6:E=`DL'
M/2,(Z5.1XQW1-W_)[JYXW4T2L9,W![L<@[DWVZIU?8EI.V:*M$7FG)&,R87(
MI,)NIFD57"M-K4%0:518EQ$QU29Q02L6P:2DL]D7G<SN?MU&/\T[H<$X$O.!
M8G;SL2V0[:<Z58]PQ9<,B7[(T#;,8[G8IK55[E%YDJM>34/,8%JD^2YMH!5`
M\(X=0:=></)`]F2Z=IRC>[:R%Q,QH.+J'D"V9<Y'.D[^(^BUF&=,[0MG*<O&
M'JQ-5&C&LV0XB#G()6&R/-/J=0+#*Q,S8+3#P5;7R*R1FEG3>NU[SE/[M,Q\
MEAD?%>2Z#*Y5KO*`[M\+5^Z9"VY7S&^0L'.&O)Y9[?6/'6?\$6V;J5YA,J55
MR<DU8Z6A.T6LW42T2SL"1U;D6*QI6POREF[K<GB;`U&Q=1:DMNEN^UW<GF6:
MDH2N5E>CVB][>-R#G;#!LXVGY'S/CUQ!8ZN=QBE+5D08FY6RV46!L%>@H9<7
M#\EF1A+E)=Q.9MV_)T\JI4):"Q-C+N6-IN,6>9<62C)MF=S(9OR5@"E[BK^V
MKE_C)R+@VM=QC"7.%JN)KW7HJ6":R-"3UO>.7$'%LX!7=UNRRQ>\48ZQ(;'M
MLQO3YK(F9,8XP=2=[93]AL;N#LK.8>S<5A;'M=8OG>2LTOF4*(5.JR`M*W&1
M1+)?+8Z[&:9*-W&K#%?*#[V<ZPG)V5*NR6",<WG=7E#E&L`93M=CP];[.C7+
M9LR?YEK=4R-6J6QS5$LV9)Y;%@2]GQN]M,LU),2?N=&7\L+'*$E/##F_'-'*
M`X`KF,^L\.T2[V3DR)'=-G0MBI$E?:=>IF^W3,F!JS3ZO2']HC%HO';VR83R
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M;5;72K=5ZY?DPAK_`(^L=;L5BKEFBY%RPEJ=(1B$A4U9N$?3DM&N8-WN\/:%
MN<W2R.9,O4',<1@_8!M.N3&EU;&LEB7%[_)^X;=[N`P=$WHT?.YAM:]8;Q)8
M2AS&0'<W<7[-S78.2B(R6I3(%K`I9A_NTWE4/)%2VZ94IM/HUDW%[J*QB+;/
MF2U)4L9=;%JV`,G9WRI/7K$>-LH7^#87FG/L+7C'&+G*UYB(+(#NRU"QO:\K
MV(7")GO9R/L#)5IGRF-?FQK"LC'\JUNE([6I]:&H5IYUY1,%OTGS&LGD)8(I
MS(-GB3V=2+)/4'5A<2[]NH1L[202HYMYS1D?;%#7>-P+!8FB%MQ?\(FW4;9;
MB>V4R7?(1]2N$WD>;9S$*G5;+4NIOZ^ZHC%%!O(`_:N8EPYBF1X-=9&79RU5
M-_V]ROS-'4R!8MOUM@,<<K''\E]F5M7<07&I2V86.05:Z>IYVI[MUEJQ,\.R
MM00O=3:R>.EF>38JS+1%G?A;8@DO#QD'[83?[OEE$,+75S-;;T:YDOE0-S?)
MH2%0;8BR!UTQ-3\D9^H^,\]-[.MF-14RE2#";):R8J-$%;9"3FY,Z61Z,JI'
MDB.YQ=RANZW(#JN[93L*7/;CC9OY1_#KW*E`I59BXBV,=B-YQU38"TP.&LJ9
MNK$5'2=X[<5+G[I6$,M6)U&PM3NX59,"2C*<J.`;I-R6XS=/LWY07!60*EA[
M#N1=OO)8GR7NDQK(1B.;*_,9LS;B7<$\6H]3L$?;&T0VQS2V.'))_'6N/<6:
M<->[)"LC/1)C.PQUU[+#NZK(>-H'<;&5&.VLT28PYR<_))VVB9;RC7+'7Y*6
M4S@WRW2U(#-%NJKB:M65#4]]69-Q@W'53A(1]/7*\=@$0A[L7)Q-*XQD#?#O
M`NM.:4V-O\?CFV8KY<C;'LHF;D3%CF`GLE82OD;AC+,,C=Z3V<'3K$DLUR@Q
M@+\P@9:*"ZP$%ULI'T0MDG8)M;G%&^#=+DZVU[,=>Q*2=VH-LR[M,.9;1:L:
M8XO%,B=O5CR=0:=:Z!%5[*4]EG).6;9D7%*\)9,$M\/(2SEGD6"0I!EWE*7D
M<A>&<^4`S%?8C9NIM%@IG#Z^Y#>=*[3K6MO5VE9\QU9Z\@IMAS'FV/OM6QI?
M)C"MFG8B'E<?QK87',4@+>N:4K32SUMY&R3Y+SQ;NZWG95R>S&GXZI-WQABK
M>+/[.]R3LYJ#08)K"T>)CZ9=\U5B2GLV2V0X:Y*9C=QD_4L*/L?V%G8\/VR)
MAX^R2EJ.QMTC3K8[G_)F,-N^WO:S@6M-&=TS9G?EH+C792/A:'+!6XC;UO\`
M,G13"NUZDWC(V(:O+E<S&5:W(RD>TM)9-C0JO8$(2(2<OD+%6).W"<HSO0PO
MC6"R3::[@*K9!Q?CC9-8L_[;Z:I*9HE(F[YVW'K8/S?&7W)\!8FE/Q#2$(H[
M*0VVOHR<O5UN%C975:R5N;K](E$#9GE[E0LB;?,B[LH_+\8A2)3!V.-V.6\8
MX7NN+YV%A]Q6*\&5Z*E*'?\`;_N6C++)8_NJK-%=>7W(4"5;LLD8M:/I!8M/
MAJ]C][/W2]^UG(N[&P9'RQ5]P-,KS'&Q*KC6ZX1R*V>XTA;39G,\VF6&4ZS)
M4.@9=RZD-5J<TPK\YC^_'E68S]>NB=9F&[Z<J;BR6*DO)SUR'W/93Y5'(6Z>
MF5[(V3Z[RA^;=KD37LGP</;F="VPXMJ.-BX3QU5ZY8V#V-@:/>JK9ELKS"<6
MQ;-K[/WE_9)E64=`V5;4=V_;Z]SNU?8L]S:W=0N4MJ>W+E']Z6V$1NI;!<,R
MWC971\GWBEX,R+BB^NK>V"2C]O5@B',?E`UF@+L^5VW8ZO5P9.HUYC@PR^S7
M)^\/.6U;)&U2?W%WG"5KVN9KP7?HJX9/Q90YJ*YF[VJ4%#*E*@J=99K*$Y!(
MXGSM183)Z.)8]]%S-GE+W5*E5`LLB\OD:V-B<5N<WS9*NV6\$4&5VZTW<1M;
MV[;4LS9+A\M5BU5O'&0[WN'E\A6"S4U>7A;+;K'C[%>/:!CJ8J`9#B8ZSV!S
ME!T$Z]BDJW7G-4L7$IO]S,\B9[<946M)D,(T3E*(?D^[3AKW`D'^0Y"OO]S5
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M%`BA$G:39ZU550,;JB0+D*H4A^<4.L8ACYM=[2[:'B"7OW*JZ5G<J+_^V4H)
M8)<:LS57=*"HWAE564\Y81[0R<<>1+,/A;C(N'RZL'VDTO9-Q#+$MDL5:NF%
M<H8,O]P=4"4@F9[%5;IC"^8=AV$S7;=#R;%T2`E6M_7D#-I:(D+#`7.!BYVK
MW&*1+[D-K6E*!2@4./`H``"81,8>'WS&,(F,8?")C")C#Q$1$1$=4?W";'(3
M<+E&(RR\W%;M,46*`HKS'T(PP=FLV.:[%0TK(A*SK]C#(U>5(A9;`[0BRS-F
M(N$R\8P4'%==)Q<:BS'[7FR"F2LTV"?R_N)M&+^P/&5"G=O]LRD%HPS;FN*T
MU20T[9HN=KS^ZO)VS"=`^4",KW'5[+9V;<<D0%E*9T1UQD;81@7*&1+?>[*W
MM18K*%SPYD?-&+HZ::-L6YLO^`%HQ?$-MR57EHAU)R4A4S5VFH/64)/P$%>8
M^AT6(R-$VZ)JD2Q2NH```<`\8C_6(B(C_2(B(CY1U`F0@`<VX"XAQ_UL^'_^
M#6.IZYA/YI?Q0^C46YP*7M-99^U+_JSO_P!X/OU":X_>U!')S?\`9\[%?_!Q
MM@_\CZ+JY>N.`>(/,&NLF(6(L$:ZAIR-8RT4^*0CR.D6R3MDZ(FJFN0CALL4
MR2Q"K))J`4Y1+SR%$0'AKXGE2J[_`)_7M>AG0JRL7.JF7C6BAE)F$(V2B)4Y
MA2YQI",19M46+L1ZNV1;HHI'*DF4@9!P#Q!Y@USP#P<.]XM5:2V:X#8WC(%]
MK]<L=/D,N3;FS9:K]'R-D6EX]RA9WT<SB9*T7O&E8M,70YZT3D;'LV%HL:M?
M2FK@Q;(LK<^G6I.I#E<7MCP=#9(R;E=A16Y+GF/'U/Q3DM9Q,V-_7;5CF@-;
M&RIE-=T9_,.:.S@JXUN%L1CF<578\I26:>ZL*PRKL5:MU?DF-B%.8,HZ`Q'9
MVJ47B!;`$.Z<9WW"R,Q`X5[-Z]D2)QG7IZ0RJYG("I5"VU*L2./8N(D&:>.4
M8./CJ*->8)*(*S<RV2;<VECH-T4I\W(7C&V4;/FRLW>3R)D=[:U,M7'&Z.'9
M^_V694M8.+K876)V[?&K1>X!.-X:CHIUJ$;1T60$-0]9^2FV(VR@8GQK)88D
MV==P9;<AW3$;^M9@SC3[S0I;+DI(S65&%?R?5,DPV2FU2R1)RT@\O%$/;%*5
M955R^Z4`L5LT!OD.4>3/V59A=VQ>YX:(DPR!ARKX`R)6:9>LE8UI.1L0T0KA
M.@4O(%'QU<:M4[DRQZ@\>LZ$^GX=],4^/>NXR!D64<L9J$Y9=VQX9SE7,85G
M(U;EI%KA>^U')^*Y6#N]\IEMHM]I$5*U^!LE?N].LT%<6KX*[/3];ERGG%D+
M'79Z;A+`E)Q\H\15BC'W)X[1<5O,:R&/L6NZL[P]D+.&4\9*1N1LI@G3+UN.
M/+#F2<B&J]V69AV8)3LNT]SG3=U%0#&0<M*RQATE5`-C#+DPME$/#8M@:[B:
M6JC'#=)R)C"BKU/+.9JU,M\598E33^0L3V.QP^0FEAO.+++/B2=7Q[=Y2PU2
M/F$&\C#1D:Z;IJ!."&TS;ZVVQ-=FR>.V1MMC/&+?#;;&"\S9W,:GC-I')1#6
MI>[+F<5M)HYO%HHL$5!GNO4FJ1$4729"$`N+R6R+;M8$;^C;JU;+R?)6)+!@
M2R/[QEC+%MFD<*6P[92UXQK<_-W9W.5"K6M1DQ4MB=7D(F3M1XZ*-8Y25&(B
MA9=6\Y/[:+*%MR,WA]C9&=\V[5/:?;XJTVF]6B#G]OU#7E'=*QX^@IZT2$,9
MM57TY,R,%84F*5PC9.6D9-M8B/W:SDW,GL)VP6"G35*M5(L%O96:R8@MEHG[
M1D_*<S?[3,[?YMI9,(FLV27-S[/;!'8ML+%K/T^$E;$ZAH^?*XGU6#F;D).0
M>YAD?9WMKR]<+1>\FXGK]WLMYPB\VXWES874X]CKQA5Z_FY0U#N==]UR5JU1
MS.1LMC>P[Z>AW\U`.+#/'@I..&8D.N(1@.2YV35G#+;!41BNPEIL;?*1D^`G
MI+,^<9_+U3O^,$@;XQM%.SW8,D2F;:E(8U8BM$X_3KM^C6%/@WLI!0;)G$3,
MNS?V.P?MJPWMS:9&9XAJ[VLERYD:>R[D=R\MMTM<C;LEVEI'L;'=)63N-BL#
M\9R;;Q4<$FZ;.&X/%6B3E=,[D!6&)XWD^]J$2$<#+'<V4(K<H]W@L.N<K9@?
M"AN6DADQDLM\Y]?G)E;!)^[4L$BQ6%2N/@DGQ7,(H#E4#?6KL(VKK$?)JXZD
MSA)[F8S>.^$V2<J"=SN7ABQQ8K*ZIQN_/&88!#Q(M8@!"JI&BX\P0`F9H"3S
M8;"]K,:PJ46SQW*)Q]%W'6+=S5FBF2LJN$8O<9;9:?G;'E'FN;NMU[+R\S:[
M3)NHN1Z[K/7MEGUTH)(\L]%;`KWR7^R3(]5=5&SXBE!;+YYM>YUG98#+6::A
MDFNYVOAEQO.1*9EFIY$A<G4:3N1'*S>TQ]0ML+`S;,XLWT2JV*FF3MKWR;6S
M3(GN62=Q$>.;1^`I+:R]8TF_Y.QU'6W;Q*DEA<8AR''T*YUQID>EMGL].3,4
MPO25@6AK!-S<[&.FTI-2SI[[+#R;^SFT5Z_5>9Q0\<1&2\;8,Q-;$T,E989.
MUJ3MEGCVK;XTA9)I>DI*JS>';.JM8Z%;ZN[B+?"3CAS*)SJKMPJH?WDY.?9X
M$?DN.7Q,L_)EW,V.MQ%^?R61,J2$[+9QQ2PK<=2,ILK&ZO"E@KMTCF]3A#OY
MNM2D0[L;M)Z[LIY=>5DS.NRIG)^[1\>;B;9NGI6)$:YF.[S3NV61_&W#("5%
M>WN1@$JK*Y,;X<&UFP]%Y6F*TD,%,Y2BJ(RO\K%.I)F^L*Z<M*=>S3E#`F+,
MRS^)+1D2OO9N<P5?S92Q4];6FVP!:I?S5J=IO9.FSKD[$,9=^2J6BRU]).P-
M99DE%6"::IM2EDG0J0N;D_\`:5W3,GN]2Q.FTSK.N825L,ZPN60H^G6>TUB'
M5K]7R!:<0LK8WP_9\GU>$6&+K63YZB2-]@&:35.*L#4[)DHWQ"X\F+LIO.*:
MEAJ=Q))I4['^6;CG/'[^O97S+4,BX_RMD2?G[1?KA0\P53(,-EJFN[M/6JRR
M-K8UVZQT1.J3DDD_CE6ZX)$^:[<ESL=R`SLT58,+J(0=TQEB/$=NKE9R1E>E
M5FR4[`EC4MF%S35=I]YA(>0MN,IQ=XZI^0G+-6_1*3Y\T2LAFSI5,919;(-L
M[6Q3EB>XZ&SA/R>5IMS6;W:KGD"A1TQG1E*Q>8Y&N8_NUAGJ=5U<CPTY-05G
M;U^&CF#J#G+!$-FC1C8[`C*>6U?9'MIV65^5J^W.@R%,AY=**8JIS>0<E9+?
M1U?KY7A*S2JY+Y2N%TEZKCRJED9$:ICJM/HFDUI22DUX:"9N)%ZJOWUUVG87
MN]VM&1UHFU5"[WZ$AJUD:R8LR1D3$DGDF!KK=VRK['(*^-;15QMR]?CW[R*K
MLY+@XLU=AW;J&@IR.BG"S,_TQFU#;Y!,\7Q5>QG#UB`PO0+9B_%M3JSN9K5*
MI5*O,4RA+1%PU(A))C4B.I*)8(1Y)US#.;"P:J/T8Z6:$EY<']5'VQ]U'/MN
M>V"AX^PK`<G?@!?%V482!L=KR;D3-T=EC"=\?73&5`J49?6%DKL'BBOS,?1;
M"RLKC(3RPQ+:ORV/(:G-:_--9B'FS.&P+:7N,R_1\\Y?Q*VL^5J#7PI\;:65
MMOM2[(Z02=2M"%`R="4NTUZNYAQZSLR79#'4+*L3<:A'3*SQ^SADEG[X7.0E
MV7;;R9/GLM$QVDG9+3DFM9ILD.2?LY<>SF:J=&L(BL9ED<7A,ACQ?*L,PB8<
MK:^!6B6%9[!U^9>O'4[7H*4CH^#DWMG9;\&1T\6R3>;0W");KXR'9Y/RVQH,
M!N/%M--9',M:QDQO;;'E:O%D)89AQ;Y*#K3%*WR3]U*V1M)2+ERY7S*D['=L
MV.IU2=IN/58(S>=R=::M#,[==0JV,[1FDDH3*]DP]55+">`Q!.WP)R>/-R6-
MX^LN"*6&R*19HTUEL'NGT]-Y/C:%0DL:-*WA]HE%XAP-=-K]`@)>W9`L]8BM
MON1%HEQ=L3258L]LF*_:Z?8U("!]T&-OC9Y<4X*%01<HH1;))'OMJ^R/;3LL
MK\K5]N=!D*9#RZ44Q53F\@Y*R6^CJ_7RO"5FE5R7RE<+I+U7'E5+(R(U3'5:
M?1-)K2DE)KPT$S<2+U5>U^M>N20`>5'VB\0`?N(=^OA_^=&P(/\`@(AK81S"
M?S2_BA]&G,)_-+^*'T:<PG\TOXH?1IS"?S2_BA]&G,)_-+^*'T:<PG\TOXH?
M1IS"?S2_BA]&G,)_-+^*'T:<PG\TOXH?1IS"?S2_BA]&G,)_-+^*'T:<PG\T
MOXH?1IS"?S2_BA]&G,)_-+^*'T:<PG\TOXH?1IS"?S2_BA]&G,)_-+^*'T:<
MPG\TOXH?1IS"?S2_BA]&G,)_-+^*'T:<PG\TOXH?1IS"?S2_BA]&G,)_-+^*
M'T:<P@?]TOXH?1JL>3=U>+\<2,A7P&0M%GCG!F3J'@VI2HM'Q0*8S1Y+/A08
MD7)SRD609B_=(J"*9VX*E,0M+;)?LB9DGY&UU.C#1RM[!1H&:?Q,RK'OYF8-
M8F"=/C)9S*M$XIU:XV26;*PLD2,0>5YN8WNBLO&+(MAV*8BE:`%(8,J:D,&R
MBG#J-EH.74ZUL<19$3@I.,[4FZ5%XI9!=K"YDWCHZZDD=R222<.&KMNL?7/R
MF6T+;!<Z[*;DKUL+PIO9W`*!AK!]'99O)'L*G4X&R91"N,IRV7IS5[K)8]Q1
M0WN29^_Y&F8&HV.1]S&2RPQQBH$=Q\7\G?LPF=LVYB4LDKL;Y.+:1[O80O->
M)-;)\M76XW"Y&0O^*GYXBZUFZ8)PJ8E9BS-Q?LYN,+9%(Z873C9`T*65:A+[
MQ-4^W-;Y]O\`M&,DMF=_D)G#,HEO:+S:*3A[*>4*IB&CNWSJ,;9`S/8<=5*R
MQF+:*N_8R**=EMR\>R%O$3TMP]Q*Y/R<9TV=^4)VO[<)2$0RC;K.SJT@2G+V
M3*U7QED:^X4Q8RR-(L8C'DIF7,5)K,[CW%$/=9"3CB0<M=9Z+8=8/V$])KQM
M=?LI=QE^8-Y^"<'94H.%;L\R:^R1D@T$%>@\=8$SKE]DP2L]C4JE>>7BS8JQ
MU<:IC*,F9IM(HQ\KD:<JT8Y9PT_+)NQB8"8?,K5\>/\`O#O@(>`>'W_]P^`0
M[X=[4!Y!_P!=N`O]K'_)K#4^:BW.'^IG+/\`\L[_`/\`*$SJ!N3F_P"SYV*_
M^#C;!_Y'T75R]--?&A(,7+EXS;O&J[N..BF_:HN$57#)1R@5RW([03.95L==
MN<JZ)5R)F60,59,#)B!A^S35?;INMVX8[LT[3[MFK'5:L-3:M'UU82EF8(A0
MF,@Q+*1SW(+TIU(['[.1C3ED8]U='D"@^8&*]:J+-3%5&;X::B+#$1<]!2;&
M8A)N.8S$/+1KI%Y'RD5)M4GT=(L':!SHNF3YFNBZ:.43F27;JIJIF,0Y1'L^
M(>,/!Q_J\?\`1J+K;FK%%$R!BS%=OOU:K^1LW2%FB\3TR1D2(V&_/J96G]PM
M2%;CBE.J^]P*S&/IF45_BT6C)N<ZBG/,F0\H<XO`#<0X#PX#Q#@/'P<!\OWO
M'J,\QYFQ7M]QO:,OYJOE:QGC.ELDY"T76W2*<7`PK19RBS15>O#@?FBN[<(-
MD$TTU%EUU4TDDSG.!1DE-5-5(BR9@,DH0JA#]\`$AR@<IOM@`0`2F`>^`"''
MO@`Z\^<7AQXAP$.(#Q#@(<./'CXN'?X^+OZQ^V6RM46KV"ZW&<C*U4ZI"R5B
MLEAF7:3&)A(.(:*OI.5D7BPE2;,F+-%5PX7.(%32(8P^#715#*6.[YC&MYGJ
M5R@)G%5NI$5DFN7]O()(U:4H4W"(V2+MR,L]%JW2@'<`NE,$D70MT"1QP=K&
M22`QBX?C+<C@?,LN]K^,,L4>Z6"/A&EI=5^%G6JT\2I23@C6(N*<*L*$FYIL
MXX,*,#;FS5:M3JB:Q(>5?"@MU.;0$!\`@/\`0/'PAQ#S@(#_`$=_3G%$.("`
MAX./$.''CPX<?Z>]_3K@#D$W-`Q1-S>=S0$./-X\.=P\/-X][CX./>UR`@(<
M0$!#CPX@("''CPX<?'Q[W].HLQ=F_$N:V=VD<3Y`K.0&&.<@V;%5W>U>1+)M
M:WD2FIL%+53Y)=(H)IS<"648%DVB1E>M57!43GZL50A,0K>[';)<:[E.W5//
MN(K)5\&KOFN:K!!WZN2<1B)Y%LU)&699.?LWZK>AOHB,15E9=C:#Q;N*BB&D
MY!%LP#KC4P5.WU>]UN!N%,GXFSU6T136<K=A@WJ,C#ST*^3(NQEXB0;F.VD(
MQ\W42<,WS4ZC5VW52<-U5$54U#9$!BB'$!`0X\.("`AQ\'#^GC][3G%[W?#O
MB(!WP[XAQX@'C$.`\0\@Z<0X\.(<1X\`XAQ'AX>]Y/O^+3B'C#SZ`("'$!`0
MX\.("`AQ\7>^_J-:3F?$>2K/D6E8_P`F42Z7/$,TPKF5JC6+5"S5HQK/2S-6
M1B8>^U]@\6EJE)2T<BK(Q32>9L%I*/(+YB5PU_CM8W/;E<`UFQ9-ITSF+';:
MXX7H1LHY:IR-IBW]NQMCSW'?V!"XW:KQJ[R=K<`_AHN2D8E_*1[=.8:L':D5
MU[U!0`E:OV"&M4%"6:O2+>5@;'$QL[!R;4QA;243,,4)*-?MA4*F<R#QBZ0<
MHB8A#"DJ43%*/$`[CB''AQ#CXN/?\W]8>?3G%X<[G!S?YW$.'>\/?\&@F*`<
M1,`!XQ$`#P@'A_I$`_I$-1A#9JQ38<K77!T'?:W*Y;QQ6JG;[W0&+\KBQU.M
MWIQ+-:A+SK(A!!@UL2\%+DBNJJ@LZ!@X.5($R`<TG\0X@'$.(^`./?'AX>`>
M33B'?[X=[P]\.]P\/'Q<-.<7@`\X.`^`>(<!_H'[_P#5KG3333336O7)'_:C
M[1?_``0[]/\`SIV!:V%::::::::::::::::::::XX@/@$!_KU&>6,J5[#]5[
M*[&WDG;520;1+1K%H)+.7,@[2<K()&4<+-VK5+J;58ZCARNFF'-!-,%5U$DC
MU-#..Y?+!N&),9)U:#6-Q;V.P(E<`=,O>ZJ$C-!'PQBCX3IQT;,'`.()J'$`
M$;U09)=.%B$[`JS<3I(Q@2:6CTSI1ZTJ5JD$BHR25XJIM#NP6,W(I]N5(2`8
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MJ<EQLCV)Q,SB6QU]QD':]G![E:UW!\K=:))QM-LL<?`."6L77@:Q\G.H/U$+
M,NM*QB+=N%>3,Y+,;I=:D.4GW:[5:M$V?9=EC.N-L,3VXC%,VQRU:;H[39%I
MNW:R)R-,NCYEU6->M)O(ES@WMDJF,JTX4Y[!1:<R%(-W$'3C1%C@_>9NWY/:
M9QA#['[9FG&>'<0Y'PMC*WYB9VEK.14RUVNR</#O:QBVL5QY#K3DAD_+U&KS
M.I-H)X@%NQ[CQT\M4A'HV=UCN#L/&XN+PI9=TT5F79%GRUU;E#ZMG7:G2,Z8
M"KV4LB*P65<+NS4]U;Z+N*VQ34N[I5?IU1VTWFWY"K66X^EUF5I%RBV`-+LY
ML3N0K<IO?+QX=_R^/P<1YO'CW^/-X<?+QU6#-D98)?*N!F58LO8E+&7RDHG,
M^XK&?ZF@2F-.K-O<V142:GZXYQ/XTQP.ES/M0$#FX9)VOLV]/OYIZ;_G]1KF
M:A9G2Q!E91QG;KE$N,\@\]#M65%#JG&G38`'54WPG+P,(#W@[_#FCP`1'7KY
M.C@/)];%A`.`#LYVP\`X\>`=I"B\`X_?X>#CJY(\?O>,/-Q#C_NX\/+K4U:9
M3E;>R6?"O5K"9H`)B2"$,U6JZB)H@KQ8L88#S,^WE#*&8@@9P+U!);KD5@!,
MA.84,=6E>6&!%7A6L0`;J2O-%`U`,N!NIFYHH%6L9D3+@;AU$JQ3(BKS`5*9
M,3`.MG;;*[Q^Z"MZF%RV21S:[&;/E=I="I=9+*(N5"OCY/)8%V4>T>-)3^)@
M#.UFKU%[S&5>XQYUVQ]E7NIRPOP9PW^/1/:75CML[W?XXN<RGN7AL7,*-V-N
MCQ:\"K&>[8V@KMD$:FDG79212/%F;&?C*B_(B8G-:=9J&,9<NJ9\AJK'K<F_
M)1>>30X[A&>;-W/V0%E<`9ISB&X>5S3D&0R8IEU*2`B7^GT!U4',*XG`%@YQ
M.I3C1RAZR6.YN"VRW9U6W'[WJ7AC<]D_&&!=GVP':KGC!&)*+3L/*0CN4NF-
M-X4$A7YN2N^*K'>W-34+B6A60D8M*(6;W>BVC49MO`I+UU:'H7?9NLOQL'P>
M/]PF.G5PRSR%V*]UCMG=I?'%-I[_`'06[*.!J>A;%+FSI\SVN)"_L[]9:G`+
MKQ<KC:"L\Q!SKBCOVT,X:..@G\BW?<OEKDWJV^M^YO!^4J?RF6ZC#5[A,PPN
M'G>==N5A:<F7FVT.J-7+=7XZZ8BRG'EI]LC+7C+,94+^SF:[>HB4F3REAB7C
M1OT^&-^&ZW-^)-I>%[!N"J.+<F99VO;T)ZL[@[]=JAAIWE#->V7<Y(X'K<HH
M^4P]D&D6B<HM$A6>7<H8MAJQ5X^[IS4C*JH-JA`2D,&'[[=P^4]RFP7E<*OD
MK/L#6[#M?V-X%2&`PZVAHO%F:ULW[;ZSE>\YPC$[_"OK?8,1YDN\W:L,XD.1
MY#A!1E`EGD,?L^>+R3/>3O4R?)4NA;;Z_5\OS6-)S-VXO%&*8*/I59B+%><Q
MH2M8N%RF<44>S3DI&5S%SZPUBGRMBF,LRJKKL6I=8LR5;9N;G+UDNM/V`MTV
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M'%UX;HRS>&BHNS$E>I8Q*;\-T^W.L;BY2QYTF\IHNM@?)8[HV]GR/4:`LWV_
MV'=GGBX[>-P=^JL71JG4$%\78THT$VS<,%?U+C[ES%8F7TS9'D!)2S(9-WB[
MB=U^!IC=CAG%&Y"W.8;'=GY)"[XYR_-P^,+G=*B;>;O6=;=LRX0M"S^G%BK%
M!25)KZ>3ZDX7CV-O@F]K=1;6QA5E:Y'L8NW)Y/S;L<W4[TKJCN6RKF"=PIR8
M>TBQQ4WF0^.5&#-CDC>/N<I&0LK6*IX[Q77H$B6'<?-660IN6K%-;@]3HB<C
M=(ZS1")().P#G<QGRD9%QKA>Q;J\56?$6[#>;AW'5!REC'(<)F+(."\97_;?
ME?*H8ZLN75,;8^I;F7W%94Q'$U7;_-.*=*6R*JF5)5C&RKR6:8TDVL_<D*R7
MBU.4XAWEN?WIW%<K!N@8N+-+C!C,OP2H6"2(-Y<M<81</[H0Z)2P#A5M&,5G
M2L2=S((#*JOE%*2[^'%9Q5N<N>\_',;,36QY&P8QPMRRC"ERL<M5,G,JQ8`@
M:5?V\.PAI1[;7^U=R\A*SO5-%2#5Q:<!RQ,-S0SIZ!>:[!RCO$S>KC+E"+/E
MQ/=;(8>Q=2N18W%YEJ=J59163</5>8;9MQTSB\F(XUC&:;S)C,J*];M2\179
MUI,7<E;K5>CYMG7W"D:[KE-[RMY-'N^>,+1^?+O%.*)N]Y%&`K3_`"+$89NN
M38VA[Y+G!4G.M,MON-7W%>9Q\\)"7%C!Q3^4E:/(V)S!UZ_+4YW$0\=FF1<]
M[P,,/]V3AIN^RM=&.QOE.=B^%:DRN-4P:<^9<0[R9'9P^R/1<[/*_BJ`---*
M>RW)W&'Q5*8Z;XQFZTTBX%S-O;;(,4':7V1VXO>@LTO6X:)W47"V/,*\MM8M
MDC3;0K4<,-:7EK;G:=S5)PL[HTD$;C]G=1RGCZC7!;)E/NL+988T;`4EVO9:
M_8&S^PSS[.I?<MFAO.[H<Y06_.QT?9-M`Q-N!H5@W%Y/Q[B2^5?<%O*94ZTN
M957&F.*MCZM3\YA?9:ZBGQYR+H=G;2V:,M14IC5&??P.,KN^G+.<G/G3-5HW
M.[Y-O&6;_;;C"X:K&S7(./&63G>/Y#*->#.^';%.9`C;&]QZR:0Z31Y8JO'6
MQI6"O+.C2G5M?0\1:WM6<5R+B*/9<LY]D&_/-_*5M(:?E\736[)OL?WG0=.C
M9&?L4M1,A[9]J,]M-R*TK3`#C+SV-MQ4H.*VAD4SRHUS<.]31_T"..*7PUSM
ML[?<G\M]E%O9G%)W0M.2PVL[F;?;XUG59UU`9\""Y0R[HMVK&PQUIK,M`8[)
M`5'%]=;2D?*,5Z52(A,G-45ZN23J-O!RWG2XY+QY:MY,1M!ON!-MG)P9GQS)
MV>OT>;KV96.;:BTO6:\B6V@SZU9E<J5Z^V--_MN9UFBV6"[`K*1O.P"J5ZLE
M?32QB1W4;J:'5]_VX.Q[HKT^J&'^4U5V.UNN2=)PP7&6#,&99RGL]J[_`#O8
M5&./&%GF+'MWK>2KZ]JLE-V@E/(SD&[W)U?MY8Z1DGTRY+SAN_H64=X.VS%=
MS<9L:8AOVR*U8S:6C(^.\99ROD!GN-RM.9IVI47+M@AHJBERU'P^*&&0\6O+
MVRCI9_5<@&I4G>ZZ#FI7.#B#&NX7/F[W-N*<+T3>IN.P'CFZ\G?N*R[-3]NQ
M/@"G;@:5GG!^]EMA"9[8#"?Q_9*K'R^*G9I#'.4&$,V>4>TQ]/-*561AVUF=
MV25H/:-SF[2;I6=-^';,L&$-R5"Y`S8GN@M!*96\?K0.2KW2]Q&]B=9M9Z'N
MU1LR49B'*C.$5LLA7*PC6K`YK=X8M(VW1:$<D#O;-;=U&?\`(.[?.U*HNX+"
M6%7&U?=QMHIC[%N3<BA%KY#VW9+Q]AV>FUCXH;8AL5CO$UGJ5R1=X/"F0:[D
M6'"!R)1*U5FC`$HF_LKE7*(W5;I<=8?M.>,C[LK/8*W:.57SSL%DE<E(8=QA
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MTW_/Z=K[-O3[^:>F_P"?T[7V;>GW\T]-_P`_IVOLV]/OYIZ;_G].U]FWI]_-
M/3?\_IVOLV]/OYIZ;_G].U]FWI]_-/3?\_IVOLV]/OYIZ;_G].U]FWI]_-/3
M?\_IVOLV]/OYIZ;_`)_3M?9MZ??S3TW_`#^G:^S;T^_FGIO^?T[7V;>GW\T]
M-_S^G:^S;T^_FGIO^?T[7V;>GW\T]-_S^N.U_FWI]\V)J</GX/N]KGM?9MZ?
M?O@'^J>G=[B/A[S[P!X1\FJH*7_>`]O$[5Z<68G6$+)/8523L&-*W7FYUVRI
MT/=(947*<2BS7*`.V21'#U11L=%8_5`4%#4W43%FY9$LC*6[.ON?)R8MC%BV
MU?C+@P9E)U4Z@)EE4(A@P5YQR$$D0U!`Y"B"JBO-3,7.76-,R/41;N\ZH.D#
M&3.9%QB&DKI&.D<JB9C)+/#D$R:A2G(82\2'*4Q1`P`.OH[7V;N\`Y^X\T.`
M<<3TWO!X.`?Z=W@\@<`T[7V;>GW\T]-_S^G:^S;T^_FGIO\`G]=M`TK+4?,Q
MKV:S/[O1+9R"LA#=K>K17NDW!-0HM?=)F\4=,N)S$4ZN@0R@=3Y@!P..IFU3
MS?=;'].VUW.2B(O!4I-OY6D5Z%)N?D64)MX:R5AN<'$I.,O6!_%SB5?J*S=R
MZCCR32$EY<\N_B8Z#C7TR_8ME-(L9OSE\#2ZKG&,QMN398-V@[R-RVZ"D8"W
M!VO/>VRRR^V[*FWJH5;'>&C6"6C$<)/;W`96M;EN,73VDA%Y%AD:%(PEDC(A
M]-2?Z>$%>K(IJ\Q1/JA"*=35(*:I`.4#@15,P`*:I0,`*$$.)#@8OWN.O8)0
M$>/?#^@Q@X_T\!#B/E\/FUQS0\H>/@8P<?*/`0[_`)?#KU@W0!8SD$4@<'(1
M(ZX$*"ITTS&,FF=0`YYDTS'.8B9C"0AC&,4H&$1'W:@/(/\`KMP%_M8_Y-8:
MGS46YP_U,Y9_^6=__P"4)G4#<G-_V?.Q7_P<;8/_`"/HNKEZ::ZMG!PL?(2L
MLPB(QE*3JC16;DFC!HVD)A5@AUJQ4E7B*)',BHR:_P"C-#O%5C-F_P#$HB1/
M[77:::AJ:V[8&L=]4RG/8;QC+Y)718-G5[D:/7'=L?MH@J9(=O*3RT<:1ED(
M8$DQADI1P\)$&(0T:5J)"B&5L<88VB[K8<DQF/Z5'Y$MT;'PUKOC&K0;2Y6>
M(B4S)1458K.@Q3FYN.BTCJ)QK&4?.FK`BBA&B2)5%`-"L/L=V85Z,<PD%M*V
MT0T*]AK)7'L1&8*Q>QC'=>N,\VM-M@7+!O5TVBT+9[*R93]@BSI"QF)=DS?R
M"#APT;'2SV/VYX"BTZ<FQPKBM#M=S,S8J$J%"JYW5+L-C;@SL-@JSQ6,4>0,
M[/,P*TFIF,7;2<JT*#5^Z<-P!(,3LVS7:)=*'!XLM^UO;M:,95BVK7ZMXZL.
M%<;3-%@+RY<.G3FY0M2D*TX@8JTN7+YZX=3[%@A*.EWCM5RZ6.Z7%3N\A;6]
MM66[`UMF4]OV%LD6=E5'5#:6"]XOI-MF4*0]<`[=T\DC/0C]T-67=!UT>OG5
M-$@Y$S@C0BQSG-EM]PSB+*=6AZ/DO%^/<@4VO3%<L$!5;G3:[9:[!SU06(XJ
MDU#PTQ'.XZ+E:VNF16"D&#9NZB3!P8JH%$Q1QF'VQ[<*^YA7D%@+#$*\K=AO
M%MKKR)Q?28YW`6G)JZ[K(]DA'+.#17B)Z_.'+A:Z2\<HV?V@ZRGNTX>E,)==
M-(;0=J,K#42N2.VC`;RO8N?3\EC6!7Q!C\\-C^0M952VEW2XOL>!C6%K,"ZP
MV(85!D6<,H<\J5V<0,$DH8FQ:UQPGAYMCBAM\3(P`55'&*-0KR6/DJP!.I!7
M4Z62.+6RP0)@"?N0$9[GB0.89N8HB`X?&;9=ND-'W*(C,$XA9Q.0X5&M7N+1
MQS4?<ZX5AMU8&M7LC$\2=K,5=F#EUUG6GR2T"TZZ==;1R77*_5.S8[?<#Q;V
M0D8S"V*(^1E\?(8EE7[+'=0;/9+%;5$S9KC.0=)0Y%WN/FK<YD&U*<G5K*")
MSI)19"'.4W4M-L&W!E1T<9M\#8>#';>;A[*A1U<;U!S4TK#72M4Z[.IP#F(6
MC`EZZDQ8H5Z1ZV%W!-V#!O$+,T&+1-'-Y3%>,IRPI6Z9QW1I>UH5"2Q\A9Y2
MHUZ1L2-#F5`5F*4G./8Y>4)4I94I59.M@["&D%"E.[9+&#B,40^S3:-7<.RF
MWFO;7MO<!@6;EE)^8PK"8:QW$XJDYY5VTD#SCZ@1]=;U=S-#(,&#XLNK&&D4
MWC%DY2=)JLVQDI/HF(,48NCIR(QKC2@X^BK/)N)JR1M)I]=JK*P3#MJDQ=2T
MVV@HY@E+2;EDBBT7?R!7#M5LBD@=8R29"!T3#;O@&*QO,X<B\(8BC<16-U)/
MK!BQAC:FLL<SKV9=E?S#J9H[:%2K$HXEGY2O915]%KGD7@`Z>BNOQ4'T'VW[
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M&,5XQD7E6JU'>2%`H%5J#]W3:.$@%-JCI[`Q3!TYKM4]UI3L=AUUE&$.,B^%
MB@@+I83=XQQ#BF,<6MW&XTH+!U>YR-L]W<LZ?7FZ]QLL.NP<Q%AM*J4<4]@G
M8M>*BU8Z7ES/)%B>-CA:N4NL&G4>DD=OF!IB;O%EEL*XGE+'DZ!&JY)GY#'=
M0>S60:N)%$QK5XE',.J^MM>ZFJJF$)8%Y&+!)55,K4$U#E-U$KM=VU3MHQ1=
MIO;[A*8N.!VA6&$+7*8KHTA9,/,2`@!&>+IQW!*R=!:)@V;`DVJKF*01ZW0%
M%-,R*9BY-'X0PS$Q%_K\7B7&D;`Y7=S+_*,(QHE6:Q&2'UB;J-+"]OL8C%$8
MW%Y/-%5&LVZL2$DO+-CF;R"CA$>9K&QVQ;=#T)#%RN#,3K8Z:SD?:&E)7H%8
M7K32SPZ22,-9FL4M&J-F]CA4F[5*%GT2$EXA-HS3C'K4C-J5&I5DY.+&]MWC
MTK<-88##4UAZ@[5)W;)6,`2F'8UZRABV/*,)E&2ND5.+RQX"/(HM`-:LK5VE
M(03D(62FE):<?D>FC=7$L.W/;];7-H>VK!V(+*\O%4BZ'=74_C6F3+BX4>$4
M*K#4RU+2,*Y/8:G$*D(K%UN7%Y"QZA0.T8HG[^OD?[9=N4KD>@9BD\"89D<M
M8I@"U3%^3WV,*2[R%CFL)H.6J==HUS<0BEBJ<&DV>/&Z,7!2+%DB@[=)(HII
MN5RJ?9W.N``Q[<\2AA#$08KR*I,K9`QJ&-Z<%`O"UC7.YL*UNIP0P5VQK3[E
M11S-+3$<\6E7)SN'RBZYA4UC)-H6U1*K8^I"&VW!3:FXECI2&Q;56F)Z*SKN
M.86==M7\_"4B&:P2,?5X6P/&+)S88B&;M(Z?6:MU)EL^,B00L04I2%*0A0*4
MH`4I2@!2E*4````````````````````.&O+333336O7)'_:C[1?_``0[]/\`
MSIV!:V%::::::::::::::X$0#P__`//*/B#RCWM=='S,1+*/$HN5C9%6.7!M
M()L'S5XHQ<B`F!N\(V65,U7$H"()+@FH(`(@7@`ZBK-E@RS`U^-'$53:6:<D
M94&+U5V=%0D,R.V6,F^!DN_C4W'/<@FB955UUNS*/57"*I#!S*U([=\]Y063
M?9FRR\AV7/*L2O5ER991N;G=\J:4;[E5UBL0O`$W)4II5,P<X%#"'.&^K5N5
MHV;M2J++%;((H%5<JF6<*%13*D"BZQ_ME5C@4#*J&^V44$QQ[XCKW<`__/O]
M_P`W'P?U:YTTTTTTU0#E.\X#M]V:9*OZRNW9E$.YO&6/[/-[K4GDI@2L5'*.
M2ZKCRU6K(-.CG,;(Y'BZY!6)]+IXVCYJ#>W=RU2@F\NT.Y#JFKK84\VY[O<P
M&Q)<,Q<C5O&HN-,/1\W7<6;+MJ:%*E,>*XRRU1IO&<[-NK1EC,[-K2*?8)N>
M5IM9@#56,8VB>?2R;2:%18\?^D3@`>`.'A'^L1XB/]8]\?+K7)RA&1-XV&\1
MY6SUMXMV!*K5]O&)+'E^1I^7J#9[P[SU*U.-G9^6Q>A8H#(U"[4#=_#P[.$K
M5L:Q>0):5NEG8&5@FD3`*QUIK#ESE$<].YK>HXQ)2:[2D^3GV?X?W.YHQ[DJ
M.6E;'DO)&4<<7G.4AMY;3;*7B$J"C4<1X^<QKN_)QTNNXR/>H%V,9V.T:>KU
MPCBV\KA<)C$.[7?'BJ,KCC:/LEN>WVK6RHS,(X7R%F2"R'C?!V7<YVAA8C3,
M<C0)/%-&W!U9.BP:4)8&EJL=%MC6:=N&-N@CU'?ZFH54A5"B!BG`#%,4>)3%
M,'$AP\ARB!@#[P#P'OAJON3'K-AF?`;E\Z;,FY397**[M=)LB!AIC(2E%58Y
M$P,8"F$`$W$0`1X<`$0F/LOJGPEK_P`M1G^:U&&;+76%<.98(E8H)0XXRR"(
M$),1IS"!*=-G,(%*Y$1`I2F,8>'`I0$P\``1")>3G_[/K8M_X.-L/_DA1=7+
MUX"H0.\)R`/B$P?3K!,FY2Q[AJB63)N4+="TFA5!DE(66TSKD6T3#LUGK6.1
M</5R$6.0BKYZT:)@1,YCKN$DRE$QPU3AERJO)X2+YE&L]W&'%GLB]:1S-'W>
M>)BL]?N4F;1`%%HQ-(AEG*R213*J$3*8X"<Y2\3!L"ZHGW_MR=X1`?M@[P@/
M`0'O^$!`0'7!E2%(<X#S^84QQ*GP.<0*`CP*4![XCPX`'>XB(!]_4#8&W+XH
MW)-,BO<52-CDFV*<H7'"]Z/8*3;J6>'R=CV0]RKQ5$4;=#PZTNM6)(Q&4A*P
MR;^!57.`,)5Z4JADYDEK'7X`T22<FXJ&//S#6O09)5^UCSS$\^2=+LH6,([5
M1,^E7:#)XLVCVH*NETFKA5)(R:*AB]N!BB/>'CXAX#P'^@W#@;R\!'A]_753
MM@@ZQ"RUCLDQ&0%?@8YW+S<Y-/FT7$1$5'H'<OY.2DGRJ#-E'LFR:CAT\<K)
MMFZ)#JJJ$(41#!LRY>J.",;6K+-]0MJE+I$4[GK2XI5$N.29V,@8YNL\E)A.
MG4"%L5OE6<6R06>R!82#DG3=HBJX%L9),YBQ'7]Z.`K;#;8+#4K#8K7#;Q8<
MUDV_OZS0KI/(6VLIUEI<UK1,GBX1T%`K3:JOV4N\G\@=C,2R%ZQAW;M"POV,
M.YLE#V.OV`LD>!FXJ:+#S$E7I88E^UD@C)Z'6!O+0K_K-5;K25C%S%1D&"_,
M=,U1!-RDD?[77<"8H=_CY@$?]P`(^40^\`"(]X!'7(&`>/`?!]_@/`>/B'P&
M_JX]_O>'0#`/'AQ[WD'_`'=[OAY0XAQ[WWM<"8`\/'^CFB(C_0`!Q'R\`'@'
M?'O:\5%4T4SK*J$323(91110P$(FF0!,<YSF$"D(0H"8YC"!2%`3&$``1"D<
M;RA.W*:J;/)T$_R)8,)RU@BZM7\\5_$N0YS#UGF9RXLJ!"K5FXQD"Z+.5*7M
ML@UB8K);!@KBV2%9-\RNR\6HD^/=X#E-QX#X!$.(@(!Q*(E$`$0X#P$!`>`C
MP^_IS@[_`(0X!Q[X"'FX@''AX!X<>`]X>`][7("`\/#W_&`AY^(!P_KU!N2=
MQ&-\4Y3V^X>MR\^A<MS-NN=(Q85A6Y61A'EAH>-K3EB?93MA;H^Y%<.%,IT]
M(1J<FY3<RZC%5".;N.I.5&\X@<HAQ`>]PX^`>^'D'P&\(?R>/?[VN0'B''O_
M`-8"`^80`=<Z::::::::::::::::::::UTY6D&$;RH6T1>1>M&"!]DF_1,JS
MUR@U2,IVYM@JG4RJ+J)D$_,3.?F`83<TAC<.:4PA?3LOJGPEK_RU&?YK3LOJ
MGPEK_P`M1G^:T[+ZI\):_P#+49_FM.R^J?"6O_+49_FM.R^J?"6O_+49_FM.
MR^J?"6O_`"U&?YK3LOJGPEK_`,M1G^:T[+ZI\):_\M1G^:T[+ZI\):_\M1G^
M:T"W541X!9:^(CW@`)J,XB/B_P#TK7(VZJAQXV6`#@/`>,U&=X?$/^E>'R:Y
M[+*L(\T+)`B;^;[LQO'Q^#KKCX._K%[#F#%]5=,V,_>JU'O7ZR"#9F>40<.1
M.Y.0B*BR#,7*C5L<RA>+MT5%J0H\]18I.)@R8;=5?!V2U\!`>`\9J,[W`>`@
M(==<?&&J(R^.LQY3EI0F1\]U.MU;W0=I-8:K3S=5!S'%<*"T$L6Q<PS4Q3-Q
M3+SIM]).@.`BNB;_`+UA\/8ZQ%A9G)HUFT,GCZ;!C[L2DM9(A5=V,>#CK<J3
M=LHV9LT2'=.%`311$YA5_C5E1(40F?LNJGPEK_RU&?YK3LOJGPEK_P`M1G^:
MT[+ZI\):_P#+49_FM.R^J?"6O_+49_FM.R^J?"6O_+49_FM.R^J?"6O_`"U&
M?YK3LOJGPEK_`,M1G^:T[+ZI\):_\M1G^:T[+ZI\):_\M1G^:U[F]FKCM=)L
MUGX5RX7.":*#>6CUEE3B`B!$TDG)E%#"`"/-(4QA`!'AWAUWFM'O*-;M-TN)
M=PF*<4XUQ9"6+&EDCJ3.29+-7JO<HNW/6^>,,,&3]"7>&,TP])(W65J^"(&R
MY$;NZTSM&;8?,[1%O'83G5EMST/&M7)(>PR-:CH:SA#'06(4D>]?P@3)8Q[.
M0:$RU0(+AJ,A&L"/#MC$:22T2Q=F3-U!L*>2:UT;NL>;X<BY(IB6&*EM+NN"
M*C&L+6XI.=<HYGI$I:\T0\V64JDQ:F>/<.9`AIF@4$6+"9@*J[>&"3O*C*WR
MI$EZ766AZ[YJY/[<-;GN[R3H5PQ)%V3E(MH^(]N6ZFQO4K.T9XLR-0Z7>,5V
M7.&(8'W-EG=Z936*\FSL)!T"VS]67B[%0J$^>V=Y&SMG"(P2]\DG/IXYW0;/
ML3S=)@-G&\[(6W:[9*/*+R2.1\7P6*:!A#%.8:'3X%I!.H*[#G&@[>*0TC;1
M+6*M!0YZY7^7<P,^VCJ]'26]=,@)D*0H%*4H<"E*`%*4H=XI"@```%(7@4H`
M`?:E#O:K;E^NU^TY<P)$6>"A['$G6RFX/%ST8QEXX[A"FL^H+G92"#EL99`3
MG%%44A.F)C<PP<X>,@]HO"?0_BWT>U'U/J,<U81PRWP]E99#$F,454\:7\2*
MI4&IIJ$'L0F@XD.2(*8H]_P@(:Q?DYQ$>3ZV+"(B(CLXVPB(CWQ$1PA1>(B/
MWQ'5R1XCX!X=\/,`@(A_6'>U^>Z^;%.6EG+M;9FM<IA7&%=E+)-2$!'A&S5>
M".A'<BX7B8WW%B\?2<>P&.CSMF)DVLB](J9N+@SE518YM4GWO;->5@QSM6S'
M=L^;\(K,.(*]`1CV\XVCALCAY:8LUI@&R#5%)>@1:0]:2:["45,=^V*1%@J<
MRG-*8AOSMQK>7D)B)CXI1ZC+/IV$91C@C1^<R$H[F6+>/=%(FV44,+9\H@YY
MI$SG$$N!4SFX$']:'<`<M^(F$.4[KO\`*-X%[2`<></$0`N,1*`"/$0`.]P\
M'>U=78SMBY1W"F3K'9]V^]2%SSC1Y29"+CZ(TBWKU=.TJ2,8YC[%[MS%7K2T
M,C%1[:5;*MF9WI);W3)UVDB#!%4=3;BY<S;!GM>D9>M=$DI?^$F-XUU.8NR?
M.4:7DL<9(WSX[B[:1X]J\LQ&;ILWC)_9)I4)-.1KAXR.-:"E,2$3?M>H9M8U
M[>\$U"WW;)5CQCM7_A%V7L44^2LN7,LVN3QUANZ[/LGR]%AYV^R=NDK>_@7V
M:K:E6*18;A/RCEN]F`H$%,IL'SF#<_;`[HLG.MT6*K?M7R5DBR9!S%`\M/0%
M\=YFOTS:+U;<]X3D$;-@&@YRQ:B$3B[$+BDW."DHC`>,XZ"876"V^IQKN9M#
MUM:;*Q1CW+]MP;NDY)[=#><)YQW1Y5RTEL2PHRW:87EK#DN:KF/]P&-\E5.P
M9$LF9HB8A2S],W2IS)<A1-^JD18V$!*XWIB$I.T12L0-$G!_4'?]P>`-MVW4
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M\P1&)FZ1V6L);INY>UXYO.S"Y98D`V\X\Q_RDN3,(;BKG2-S]]S!LDOD'D#D
M[K8ZQB\QKDVW*Q+4<(6K*R&-B0^.LA1Z)\9[B596MMU#6!XF^D<1V\Y<L&2V
M7)$V%Y=YR^76M\J+RN-=BG639ZSO[`S8PN..4=J^%:U9'MR6[*6,&R@YG$]-
MA&LHJB:-B)*M5UJ9NX.P9!CV`\\'RI@K(>0C<H9/8NW#P^RR5QKO/Q5;,1YM
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MIIN@\Z[;R%J,D[+Z;9*[2:M16E,I\?`&63GW[NCPDI.6(@D;BU>O)5NT8O%W
MS5PFZ<"@=P@Q44>?:IHIM6Z1<MHFSG$%0,W=2C%Y=)%#J9^J6!1(L4"Q!`0.
MG`,$VT<=/O?:I2`2(`'`!,;AJ6NT7A/H?Q;Z/JCZGT[1>$^A_%OH]J/J?3M%
MX3Z'\6^CVH^I].T7A/H?Q;Z/:CZGT[1>$^A_%OH]J/J?3M%X3Z'\6^CVH^I]
M.T7A/H?Q;Z/:CZGT[1>$^A_%OH]J/J?3M%X3Z'\6^CVH^I].T7A/H?Q;Z/:C
MZGT[1>$^A_%OH]J/J?3M%X3Z'\6^CVH^I]??%X@Q-!R+.7A<88\B):/6!RPD
MXNDUF/D&+@"F("[-ZTBT7+98"'.0%4%2*`4YB@;@80&1=4%Y3-I(FV@7>;BL
M]X?VS/*/=L)9')FC/DY:('$503QWFFAW%<;JI4\@XSD)F.F$8<\*A4'5I;P]
MXD'S.GR[1XRFU"$J7R>.^>X;G=P<]1);?[R=^[:'AL/VJXJ4S97C;)=-L]8D
M$+OCN%862\25TSOFZ+<5\6TQ)Q,9'MU*Q*C*/3N"EG6:#@8?==KQ.<A.;SS`
M4#&*0!,/`!,<P%*7B/>YQC"!2@(\3&$"E`3"`:Y$P`/#O_U%,/\`O`!#03`'
MAX^/P#P`/&(\.`?U\-<Z@/(/^NW`7^UC_DUAJ?-1OF-D[DL2Y.CX]LN]?/L>
M7AFR9MDCK.'3MU5I9!LV013`QU5EUE")))D`3'4.4A0$P@&M2&R;E']K6+=F
MFTG&=]=Y_KEYQYMCP'1KG7G6R_>DX=05KJ6)ZC`6.&<KL-OCQBLXBYB/>L5E
M6;IPV.JW,9!=5(2G-9W[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]737B?E
M6-E:A3$/8L[G(8!`Q3;)][ABF`?"`E';H("`_?`0$!^^&OF#E3-D)1`Q9G-X
M&*("`ALAWK@("`\0$!#;@`@(#WP$!`0'O@/'7U_96]EWPDSQ_8IWN_JZ:?96
MMEH^&R9X_L4;W?U=->O[*KLI^$&=OY(%_P#@GWN?R``0`G_PZ?R``1`"?R0`
M1#AP$0UR'*K[*R]XMCSP4.]_)V4[WB]X./`.]MU#[4.(B!?Y/$1'AQ'CKU%Y
M5#9*0XJ%G<YE4,H=4QR[)=[0&,HH0J9U#&#;D!C'.F0B9SB(F.0A"&$2E*`>
MPG*J[*4^?S+#G<G5#"<_-V4;W2B8YOY1S"7;H`B<W`.<<1$YN`<XP\`X>8\J
MSLL$``;'G@>'@X[*=[HB'>X>'N=./?#B`]_O@(@/$!'7B/*K[*A__$.=OY(%
M_P#@HWN=\H<>!1^YT[Y0XCP*/$`XCP#7@IRJ>RA7F=5L&=E.IJ%63ZILHWNG
MZFJ7CS%$P/MT,!%"<1YAR<TQ./VHAH3E4]DZ92D)/YT*0O#FE+LFWN`4O```
M.:4-N8%+P```.:`<```#@``&H.W.;W=AVZ/;QFK;=:<D;GJ;4\[XTM^)[A8J
M3LHW?%MC&HWR'=5RU%@%K/M9L<$UE7\`_D8YM(OX.3]SSNQ?-T.NT$%"211.
M4JV1T2H5VHMK?GV3)7X2*A32SK8_O/9OI?W)CVL8G)22,9ML:,/=!VW9H"].
MU;-T55"\4T$D@(D3*E.53V3J@4JD_G4Y2*$5(4^R;>V8I%4C`9-0@&VYB!5$
MS`!B'*`'(8`,4P&#CKR3Y5;94D0$T[#G8A`X\"%V3[W"E#B(B/`I=N8`'$1$
M1X`'$1$1[XCKYB\J7L@([._),9O*^41*V4>ALAWL`[4;D/U0C=1UW.75SH$/
M]L1$R@I%$`$I`$`X1YE[E"=C67L69)Q8]O6XNK,LFTFW4:3LE=V0;Q%+#$,;
MI`/*U+2D.$[MAEX8TPE%OERLEI:*E&95RH'=L7B*(-S=;@'?GL-V\X6Q;A"L
M7?<;.P&)L>4G&<'/6#9)O()9)BOX^K$53JTZL:\)MDB8U]-I5Z#BVCV0;1S)
M-TLV%9)JU3,5NE*R/*F;(&[8C-"9S>@T3-SR-D=D6]A)N0W517YQ$4]N)4B#
MU<16XE(`@L(JA_&?;:]Q>54V4%#@6P9U``$1``V3[W.`")N>/`.YTX!Q/]N(
M>`3_`&X_;_;:%Y53904RABV#.H&5,!E#!LGWN`90Q0`"F.(;=.)S%``*4QA$
M2E`"@(%``UXM>50V2LD$VK.<SDU;(EYB+=OLDWLH()$XB/,212VY$33(`B(\
MTA2EXB(\.(B(^_[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]733[*WLN^$F
M>/[%.]W]733[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]733[*WLN^$F>/[
M%.]W]733[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]
MW]733[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]7
M33[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]733[
M*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]733[*WL
MN^$F>/[%.]W]733[*WLN^$F>/[%.]W]733[*WLN^$F>/[%.]W]734/4'</CG
M=-RDV`K=A=GE69JN,=FN\*#O-EM^`<]XD@(.;R#F'9<\ID,,QE_&=#CY*5L#
M.BVYVRCHAP_>=:P$BX70112*H?;WIIIIIKI)^RU^JL%)2R3<5`QR8&$SV6?M
MF#?B4./,*HY43!10>(`5-/GJ&$0`I1$0`:X.=WV+5;7"5.MHV2WN9B79177\
M'$F!B@9ZX3;%71*_4:/I)%)14IUC,&2J94"*+$5.!0*:TJR?5DE4NJ*H]434
M3ZJB8"*I\\IB=42,(&`JA.//3,)1`#`4W`>'#5.Z]LJQPS</G]MF[3>)-X+G
M@[DWQ6($%<JA4G*Y6?/<2+Y`3E6ZJ_>+M%7!`.9@"1C(:EZ(V^XPAX=C`HP7
M7,2TJTS573)XH19.9;SS^(DY*5EU"H)N',^H^A&+AM*I+(*QYB`5@1N1%H5M
M*-=A0KL'&099.6F"Q;1)D22G'9'TN[31`2I*/WI$6_7;@J?-2,X.D"RQ4RG7
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MA\EU;.FTLEIRA5J#6LQ8LG([)#G&F7(TV8;;2IW)E.M6,XRS*4Z`@4H2S/B5
M$["3_0"7AP[P<.^;B'EYP\[SCQ'C]_PZK'FJ6F83*V!7\#5I"XR)7&4DB0<9
M)0<4[425IC3JCD'EAD(N,*FV$I.J)G=E7."@"BDJ)3%UE';+RO\`%TN7S^Q%
M[9Z=LO*_Q=+E\_L1^V>O#MCY6^+K=?2%B;VUT[8^5OBZW7TA8F]M=.V/E;XN
MMU](6)O;73MCY6^+K=?2%B;VUT[8^5OBZW7TA8F]M=.V/E;XNMU](6)O;73M
MCY6^+K=?2%B;VUT[8^5OBZW7TA8F]M=.V/E;XNMU](6)O;73MCY6^+K=?2%B
M;VUT[8^5OBZW7TA8F]M=.V/E;XNMU](6)O;73MCY6^+K=?2%B;VUT[8^5OBZ
MW7TA8F]M=.V/E;XNMU](6)O;73MCY6^+K=?2%B;VUT[8^5OBZW7TA8F]M=.V
M/E;XNMU](6)O;73MCY6^+K=?2%B;VUT[8^5OBZW7TA8F]M=.V/E;XNMU](6)
MO;73MCY6^+K=?2%B;VUT[8^5OBZW7TA8F]M=.V/E;XNMU](6)O;73MCY6^+K
M=?2%B;VUT[8^5OBZW7TA8F]M=.V/E;XNMU](6)O;73MCY6^+K=?2%B;VUT[8
M^5OBZW7TA8F]M=.V/E;XNMU](6)O;73MCY6^+K=?2%B;VUT[8^5OBZW7TA8F
M]M=.V/E;XNMU](6)O;73MCY6^+K=?2%B;VUT[8^5OBZW7TA8F]M=.V/E;XNM
MU](6)O;73MCY6^+K=?2%B;VUT[8^5OBZW7TA8F]M=.V/E;XNMU](6)O;73MC
MY6^+K=?2%B;VUT[8^5OBZW7TA8F]M=.V/E;XNMU](6)O;73MCY6^+K=?2%B;
MVUT[8^5OBZW7TA8F]M=.V/E;XNMU](6)O;73MCY6^+K=?2%B;VUT[8^5OBZW
M7TA8F]M=<ADG*Q?!MUNG]>0<2F_^JZ#KR[9>5_BZ7+Y_8B]L].V7E?XNER^?
MV(O;/3MEY7^+I<OG]B+VSUX*9/RHDF=57;Q;TDDR&4444R!B$B::9"B<YSG-
M=`*4A"@)C&,(%*4!$1``$=0=)[Y:W#2*D9(X]GC*ID,)G43;\=V*.!?@()MN
MOX*QR""BIS<`-UN+@J9><(B)R@F:2*9GC(]UA"3D9MXNBK-5PLDBN%IID4@N
MD0J9TEFY+=(5>0=)G(H'.<MXY1@8X&(W>+F(J5+`,HTZ<R_*U^7M^WC*`JUQ
M!VV:M(O*6(6+)V@]70<+)O2C:EG!!YZ!`!Q'KL70IB*9UCD`@$S.G#-X_;@W
MIVTJ:@>).8JY:73$!I%R7CQ_TR4<7-:2=B(]_P#TATIW_!WN]K..V7E?XNER
M^?V(O;/3MEY7^+I<OG]B+VST[9>5_BZ7+Y_8B]L].V7E?XNER^?V(O;/3MEY
M7^+I<OG]B+VST[9>5_BZ7+Y_8B]L].V7E?XNER^?V(O;/3MEY7^+I<OG]B+V
MST[9>5_BZ7+Y_8B]L].V7E?XNER^?V(O;/3MEY7^+I<OG]B+VST[9>5_BZ7+
MY_8B]L].V7E?XNER^?V(O;/3MEY7^+I<OG]B+VST[9>5_BZ7+Y_8B]L].V7E
M?XNER^?V(O;/3MEY7^+I<OG]B+VSUVL'?LD24O',)7!MIKT<[<E1>3CRYXS?
MM8M`2',+I=G$VIY)N4RF*5,4F35=<14`P)\TIC!,.J<[W+;L?KF(3LM^AL$2
M&(9V40;L:EGBO5N[1-LLC0O5V3&J4&;B;!)VZV-2GZZ8,:E`2EB;%`735)(I
M>J!37D]K?R+[6_258V"4K;=BK+LU%2!EX.!P+*;?,Q6JN-S)NI8L0PR=C['^
M1+?5V*C,CN21@"RT&Q50.Y>I(G345+N0U!F<-N>+-Q*6-$,IQ<U+HXBRO2\W
MT-*(MMGJI(O*&.GIY*CV=X%9E(OW=[')%11\SA9T9&O+NC`K(1+PR2(I9I9L
M9U.W7#'%WG6KUW.8IE+).4KF2C]M'1DW::K)4B2EUHMNNFQD)%.K3<[#QSIZ
MDL>,:SDMUEU)1\J?41H[2L3AF"?S-(N\F6.7GK97\@!2;;E_)=KP_`9!K$*T
M@(B[U'$$_97^/ZI8&;%@Q=-CPD&TC6=B:I7&/C6=Q%2>/9OP>#4!Y!_UVX"_
MVL?\FL-3YIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIJ
M)<FYNQWB0K<EPF#HR3UL9XQA8]HO(2SML14R(N"-T2@BW;=5*=(KE\Y:MS*$
M4(54QDS@6!Z7N:OV4+I!Q]#Q'(*4=65;-9^S2Z[CG,XQ53@Y?E=M2)P399JA
MSG!&0/I5P[,GULF0AU"G+<:08-)5@]C)!`CEC(M'+!ZW/S@(X:/$#MW*)^:(
M&`BJ*ATS<TP&`##P$!X#J*Z1@3$N/3D<5JEQ:3]/_JY22!6;E$@`W$I6[^74
M>+M2$#@4I6HH?:E#CQ'B(S``<.]IIIIIIIIIIIIIIIIIIIIIJB&]M3(F(,;3
MNX?;SB6Q9<W`Q=LP=6D8:GTZIW[)<KB:0S'1H_*-$Q^G?+O0H&HMY^FN[`[?
MS*EA0B8.3.6[S<7+E@B`TQC&&>YO=S<'6),N;!MUFW6OQ]7E,A0U[W%-L&,F
M?956;%58R"3QW,X6SKF"7@+_`!0V)Q8H^8<'JSV-1BC.H*1D%BOTFFQ4H<``
M!$3"```F'@`F'[YAYH%+Q$>^/-*`<1[P`'>U6;<?NHHVV)Y@9K>JY?9I+<%N
M`QMMPJTC38./EHNN7C*DDI$U61O#V0FH<L'6%7R1VZS]HG+2!UQ(@SBG*APX
M8;N6WH0.W2U4F@QF#-Q>X[(%SBW]C5H^VFC5B^6*ETYE)L8-*ZWQ&S7RAL:[
M5Y6??>X<,^%^\<R3^/FC-V0LH*7>,\7R3RB."\87O(E7GFMM7J>#KAAW'>XC
M+S%G!&QI@6_Y[-!!C.IWV2=V!I-.G;I&W49_;I*GP=FA,>1-_ITS<I*+BW\F
MZAKY@("'$/*']`@/`0_J$!#Q:@3(/^NW`7^UC_DUAJ?-----------------
M-------------------------------==,2T?`1,G.2S@&D7#1[R4D71B'4!
MNQ8-U'3M<4TBG5/U)!(Y^8F0ZA^;S2%,80`:0R^\:4M+U2#PAC2=N$D;@4DC
M)M7(MTA$>`*FAXDRKA-`P?;E5EI2'*0.^J0`*8-6>Q`[R>]IJ+G+;"*C;8I(
M/C`TBNH`1**,9,T>#PC5V]:I/@`RQ%$V[I8H(E0%4P.!6#7=V+&]#MLQ&S]G
MJ4#/R\0W,UCWLM'HOCMVYU17%$$W`'053*L8ZJ15TE014.H=("&4.)LQ101;
MI)H-TDT$4B%3211(5-)(A0X%(FF0"D3*4.\!2%*4`[P!PU[=------------
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M68_4"B04TR$$QS\PI2<]4W.4.!``@'4-P#G'.!0.<1`!YQAX@`ZK1F:'D)W+
M.!8^,M$W3W9U<JJ%FZ\A7W,DF0E+:E,W(E9X.Q1(HKB<HK&/&&<EZF7K5RV/
MQ4UEW:JO'QB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJKQ\8C+?R1AG]$^G:JO'Q
MB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJKQ\8C+?R1AG]$^G:JO'QB,M_)&&?T3
MZ=JJ\?&(RW\D89_1/IVJKQ\8C+?R1AG]$^G:JO'QB,M_)&&?T3Z=JJ\?&(RW
M\D89_1/IVJKQ\8C+?R1AG]$^G:JO'QB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJ
MKQ\8C+?R1AG]$^G:JO'QB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJKQ\8C+?R1A
MG]$^G:JO'QB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJKQ\8C+?R1AG]$^G:JO'Q
MB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJKQ\8C+?R1AG]$^G:JO'QB,M_)&&?T3
MZ=JJ\?&(RW\D89_1/IVJKQ\8C+?R1AG]$^G:JO'QB,M_)&&?T3Z=JJ\?&(RW
M\D89_1/IVJKQ\8C+?R1AG]$^G:JO'QB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJ
MKQ\8C+?R1AG]$^G:JO'QB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJKQ\8C+?R1A
MG]$^G:JO'QB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJKQ\8C+?R1AG]$^G:JO'Q
MB,M_)&&?T3Z=JJ\?&(RW\D89_1/IVJKQ\8C+?R1AG]$^G:JO'QB,M_)&&?T3
MZ=JJ\?&(RW\D89_1/K&;=4+G4(1Q8'6<\Y2K!@HW-)EA*_A5Z\CXTZH$>S"C
M+M6$=/&44B)GC]".2=2(M$U5&K1P9,Q-8.K++J+K,8C<-FNQR9YR'@8..@HC
M!#Q>TKS$#$V8LC`JAC4&QH&,A)=!],S<@JR81R:*P*K<\[0KG!LT7JW8KG65
M,BLJ9ZN-QE(M&48-&D-AMO%]1=.7+1N45$,0/)*06%5JMU5O&,C`B'4@6=)'
M4`H<XP@MY=M>,%+A?9NFU=1T99\^DXK'R%NZP$1XMXR(2ISELDZ$`(DDO.QB
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M,M_)&&?T3Z[.%QS;HN6CY%[G#)=@:,W!5W$)+1F*T8V33`ARBU>JPV-XJ4(@
M8QBJ"9C(LW'/3(`+@03E/+7^_P#]>350-].-,KY<VXV>B8/@J#-Y3EK5BYS4
M7&3;1D6G4ZJ/H?)=5F%\B/I_$EEJ.249'&[%BZO%;CZC88R2G;)`Q,"HZ;L)
M)XNE4;89MBF,?9JL.>;GF-#?9?+KCJYXXG=^K[)B:<JU<T3(E6@;)MD@]N]5
M5>X<Q;3JQ?ZK;)7KG%[M!^E;JU8XC*;)W?5'EFL6WC00X^/SB'_#7'`!'CW_
M`.CB/#O#QX\WCS>/'[_#CY=.:`CQX=_^D>`\/!Q#P#P^\(@/#[W#7.H#R#_K
MMP%_M8_Y-8:GS333333333333333333333333333333333333333333C_P"O
MO>?P:QNX6$U4JT_9214C.'@XIY)EB(E(5Y&0,T1,J#5JF`&$5%!#AS@(<2$`
MZ@)J<WF&H3/97W9Y*9`XHV/9"C5]Z[:,&KM!ASIE<9%QUN@L$G84VYT6:(AS
MWTHRA&K./0*=95\`<P#95AC&=\P5/6B:DX0MS:.Y>)A+!(1<(N-@3924;&2R
MMBJ"JAS.YN!93TF[C+1#HMV[IT,:2;8HF68*19[V"DD90JPIDZL4ADRJB0O5
M"D,8!,0JG#G@0QBE$2@(%,(`(@(@'#V:::::::::::::::::::::::::::::
M:H%N-W([HHW(#C#NR_;)2<_7JLP,!9LG6O,.>&^`\6X[:6P99:FPZ2\70LIY
M!O=IL+>O2KQ1C"TJ,JT+'@T5DKF:47/!(P_R<SS+6"&:^T?.VV!+;W/R4SGK
M/N/[%5-Q$!N3QSE!3(F:9#*F;`BK&%`Q!?J8_JF0<WM#1]7N.,DH\:M-Q2$+
M>;3(Q,VFUVNZUV<H3G/,>"!V8RF*;1!P$9DS?OM>P/E.-E:@RLCVSXWS#<5J
MS.Q4)*OWZ2-2>IE(5<\PA%2LBHESFS!6)6-U\6/>4>M.]G#V-;CN.VZYAJ40
MIB8,?=KS;/(XSKUMBMT-JL=OKE><8RO%SE$D[S4[%D&7GVE#Q/VJI.`/!V%=
MG/VAS<&\D->A(FW5;K=PM/W\8.PJ^R)>MGVW*R3>+J;7\NS^U&M9LPWN9S#>
M)H\H]PB3/"F2F2VWNW2$4Q;8]Q^K:\<]8W&W2TVO%2\A(L*["2&ZT.^''CQX
M\1\'`>''O`(>$!`.\/'O][O]_59\R6BMT_+6!9NV3\-689-;*C=25GY-G$1Q
M'"],:"@W,]?K(-@77ZFH""(J=46,42I%,;O:S7NB<!]-.+?GW6?66G=$X#Z:
M<6_/NL^LM.Z)P'TTXM^?=9]9:=T3@/IIQ;\^ZSZRT[HG`?33BWY]UGUEIW1.
M`^FG%OS[K/K+3NB<!]-.+?GW6?66G=$X#Z:<6_/NL^LM.Z)P'TTXM^?=9]9:
M=T3@/IIQ;\^ZSZRT[HG`?33BWY]UGUEIW1.`^FG%OS[K/K+3NB<!]-.+?GW6
M?66G=$X#Z:<6_/NL^LM.Z)P'TTXM^?=9]9:=T3@/IIQ;\^ZSZRT[HG`?33BW
MY]UGUEIW1.`^FG%OS[K/K+3NB<!]-.+?GW6?66G=$X#Z:<6_/NL^LM.Z)P'T
MTXM^?=9]9:=T3@/IIQ;\^ZSZRT[HG`?33BWY]UGUEIW1.`^FG%OS[K/K+3NB
M<!]-.+?GW6?66G=$X#Z:<6_/NL^LM.Z)P'TTXM^?=9]9:=T3@/IIQ;\^ZSZR
MT[HG`?33BWY]UGUEIW1.`^FG%OS[K/K+3NB<!]-.+?GW6?66G=$X#Z:<6_/N
ML^LM.Z)P'TTXM^?=9]9:=T3@/IIQ;\^ZSZRT[HG`?33BWY]UGUEIW1.`^FG%
MOS[K/K+3NB<!]-.+?GW6?66G=$X#Z:<6_/NL^LM.Z)P'TTXM^?=9]9:!N)P(
M(B`9HQ:(@`F$`O=:$0*'?$P\)+O%`.^(CW@#OB/#3NB<!B`"&:<6"`AQ`0OE
M9$!`?`("$F("`_>$!$-5:S)O#4:VI.E8BLF+7:#F):O1O$A=:RZCDU7"BR;A
M%!1W+LX-BI'F(D"PR;AVLH94#)QXI@4Y^FQ=-P[2[Q61<L;P<=RLA&]=G)5H
M?)4*ZB%2OF;AJ=H[4"1CH=-JD=8C@6L;"BF9=NB8KP>:!AM]W1&`^'#MTXM^
M?=:X_P#^RUQW1&`NFC%H_P!-[K0_\9+7/=$X#Z:,6_/NL^LM.Z)P'TTXM^?=
M9]9:=T3@/IIQ;\^ZSZRT[HG`?33BWY]UGUEIW1.`^FG%OS[K/K+3NB<!]-.+
M?GW6?66G=$X#Z:<6_/NL^LM.Z)P'TTXM^?=9]9:=T3@/IIQ;\^ZSZRT[HG`?
M33BWY]UGUEIW1.`^FG%OS[K/K+3NB<!]-.+?GW6?66G=$X#Z:<6_/NL^LM.Z
M)P'TTXM^?=9]9:=T3@/IIQ;\^ZSZRT[HG`?33BWY]UGUEIW1.`^FG%OS[K/K
M+3NB<!]-.+?GW6?66G=$X#Z:<6_/NL^LM.Z)P'TTXM^?=9]9:=T3@/IIQ;\^
MZSZRT[HG`?33BWY]UGUEIW1.`^FG%OS[K/K+3NB<!]-.+?GW6?66G=$X#Z:<
M6_/NL^LM.Z)P'TTXM^?=9]9:=T3@/IIQ;\^ZSZRT[HG`?33BWY]UGUEIW1.`
M^FG%OS[K/K+3NB<!]-.+?GW6?66NRA\X89L,HQA('*V/)F9DW`-8V*B[A`/I
M!^Y,0ZA6[-FV?J+N%A(FH<$TDSG$I#F`.!1$)2\/@UJ-Y1_`6&K]-U/)N;MK
MNY#+4?4X?W#KN:=BUORE3MSF,&TC(![KUNS0^%,E8]ROD3&,DLY-,1\?4D,D
M-X:36F5I#'L0KU*UR,7;%5-OU%LT[%;+-E^^)O=;RWAX_)&Y'?'2MRM/<L8&
M)>@1-M/9*WIV$<T6]A%E64E8+%V((!Y79&8.D>05J":S^T1>\/5)]ZNV6X;F
MV.VQC4[56ZH3!^[K`>YR;4L,;+RAK)'8,LJUG2I<46*7;!%/;,Z5(U/8GHR#
M>'01,<L'**+EZVC3<A@W?7D#.,3?<.9:VGPV.J)!I#BREYKPEEW(DA4<DOXQ
M['3V6GKBFYJQY"SUI;LI!2"IC=S')MZG!'G`:.%)6VR3]GE.2=N^?L]V&5QE
MG.W84G=K3/(^"LF5U.KTRY0V;K`MA:;HF3&-4O+Q[8W]`9B\S916%K6N]+81
M+LU*5/1XVHP$O_[\A?D```X!XQ'^L1$1\?A$1'4!9#*4^;,!%.4IBB&60$#`
M!@$!IC(H@("`AP$IA*/C`1`>\(ZG7K)G[T;?D$OJ:=9,_>C;\@E]33K)G[T;
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M41#G&#B&NCO9Y^+J$_(4>N1E@M;6/45@X=[U%NV?/0.F`)JJF4;`($2%58J0
MN6_5SIE0ZX1%7JA:6EPIN5S$`#E2\-*-6UQ`QZQ#)-3J"D;B<J:D3"*-X\QN
M^!!/+SLHJ4.`'1-S>;JY&.L<P6-J=#4R*.YD6<.DX*1Y+"BN\75=NUWK@YNI
MI)H()=<.%`0:MDDT&R($2(41`QSYOUFT\'6K;AQX\.H)>'P<?Y/AX=[3K)G[
MT;?D$OJ:=9,_>C;\@E]33K)G[T;?D$OJ:=9,_>C;\@E]33K)G[T;?D$OJ:=9
M,_>C;\@E]33K)G[T;?D$OJ:=9,_>C;\@E]33K)G[T;?D$OJ:=9,_>C;\@E]3
M3K)G[T;?D$OJ:=9,_>C;\@E]33K)G[T;?D$OJ:=9,_>C;\@E]33K)G[T;?D$
MOJ:=9,_>C;\@E]33K)G[T;?D$OJ:=9,_>C;\@E]33K)G[T;?D$OJ:=9,_>C;
M\@E]33K)G[T;?D$OJ:=9,_>C;\@E]33K)G[T;?D$OJ:=9,_>C;\@E]33K)G[
MT;?D$OJ:=9,_>C;\@E]33K)G[T;?D$OJ:=9,_>C;\@E]33K)G[T;?D$OJ:=9
M,_>C;\@E]33K)G[T;?D$OJ:=9,_>C;\@E]33K)G[T;?D$OJ:\BM6I#`<C9N4
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ML"S-N:+J\?*/FCRP2)5I!@D+*)1=N05>LTA2ZH[;D5XE,D8\A+?`X^F;W38F
M^6ENX>5BDR=G@V%NL;1H5T=VZ@:V[?)34PW:E9/#.%XYDY21*U="<P`V7ZGF
MNH#R#_KMP%_M8_Y-8:GS333333333333333333333333333333333733EB@:
MRQ4D[%,Q<''I?RWLL^;1[4!X"(%!9THD0QS<.!2$$QS#WBE$>]KW0TU$V*+9
MS4%),I>)D4>KL9&/<)NF;I'G&)U1!=(QDU"@<AR&$H_:G(8A@`Q1`*P9@J.Y
M.[W%Q"4FVP],QN=BQ,25:O#LYI5P9+FR2+P[1LO-'6*OU0S5)@XC61V@H@J\
MZX%4H?9B/:Q5\9V)K=Y*P3=PNK8KWJ<J_.#1DBK(-E6;M9-D51T[=+J-EUT>
MK2<F]$`4,H1--7FF+:;333333333333333333333333333333333333336D?
M?UF;(6`,].[=M3W4[7<5YSEL:T5OE#;OO)IV2I/"V3ZF$W<D<<Y,AKYAE%7)
M&+K[7R,KU4G$@VC+E5KE!IQL=.UAH_JT),ESGDZYS+^X6_VG<=N8W1[5LQ9;
MIU-<XOJV#=FC>TH8<P/5[G.Q-@L=GG7^6A)FBY9!RHXHM7:(V>RP5+JD76Z>
MM$T>OKGE+/+O-O\`K47RMD-$/67)WS3N)C7DQ`<JUL1]PI5S'M',E"^Z^3G,
M?+#$OUD5'49[IQXBRD#,E4!>-!ZV<BHB(IC0O=J4TSDS^$8R.:!(>.QYR8N`
M28(=S2BA%JIC5;!6Z"_NK!13\1<14BON7K,A*GF(0$I,UQHM/7#A(UV"7)32
MT3^<Y#DW^61RMF163;[[*OGG866B2)C+DNE;OU8VW[!;)M;;U,R"BSR'=/<S
M9"N#^/;Q3E!!];KM>C.2).I^PBY_9:@)Q2(*O-!7FAU4""(D!7_[T""81'F%
M4YY2\1'[4`[XAW]5GS4^LL=E;`KJI0$?9IDKC*1$XF3L`UEHHV-3&@N%QE@A
MYT2*(\TG4T/<\P+B<><LB4@B;*.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_=
M"=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3
M?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU
M_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[L
MM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3L
MQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_
M="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G
M3?37^[+3LQS]T)TWTU_NRT[,L^]"=-]-?[LM.S+/O0G3>_X/_ML\/YLM>I>\
MYW:HJN7.&*0W;H$%19=?-Y$D42%#B8ZJJF,RIID`.^)CF*4`[XB&H^A]R%OL
M%H"F0-*Q=-606SET6.BLZF?%.FS`#NTTWS?%IXY5RV3$5EFJ3M18B)%%!+S4
MU!+DMKG-S,[7Y&(KF.:;39A\FDBULP962FSQ)>N$CN5T8Q;'+9%RNHV*LW1Z
MHJ!45%BN``QDBE&I3?;'FV8FEYK*,&GD5P57_1?_`+;%(KJJ0#QX.G+W'LP^
M;%$1,!6L4NR33+P`%Q[Y0MS67F8:=`QM9K6`J1%0<0WZVCV".;E5"()&4464
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M7CFL]B>K0L,NY*G(RS/+'NTZ8-A(<1<(17:_C.OU`.!"`W]T&G.`XGZL',YI
MIAUKTW`;W9/`&993',=LBWE[@2GHU+MRN1MLN+*A>*NFK.R-SBPJ5DE;+DC'
MSA"S0J=<+)A'M4Y=!&&L,<Y4<M5'@-S8GMXR;E'<]N?99J>[-,Y;5L=8TPU>
M<;K7+<Q'XVJ.5,P6&\W+'\_%5FMT*B9`R'.-,<X\;TV;G7%DODA#&=V:W(,*
M7#+-AM4FILWU%F4,)XKS06E$RE2(.[DQS>8+)M%)/(KN257(=74.K6;O"$2<
M(%8VFNJJK+04VF'NA$+++*QZ[=194Q^BR;MLP7F6PP%JR?C&JW2>KC=NP8OY
MIDHL+J(9V.(N+*OV!LBN@SME88W&`@K>QJUK;3=<9VR&BK*UBTIM@V?)\V?;
M=@RYY+A,OVG&=7F\BUYQ6GL?97[-15<\C27$P[HDM*L`7+#S\U0'MAGWV/YJ
MP1TI+41]-R[VH/85U).UE9OU`>0?]=N`O]K'_)K#4^::::::::::::::::::
M::::::::::"/#OZJ_F?-]<QU(Q<O'Y`AWDC$&7:3N-$EV[YQ/Q[M5`%5FZS%
MNZ7K]DB!3ZXC%Y59"(>MS.XV031.Y;OVG.!+)?\`)\15KO-SAF=9B(96(3CT
M#Q:\G>+*FF9E-6.S&:I&3B(U@Y*HE`P#4&K]5P"DK)G(W,S9&Z;)VVRR99O3
M^4LV5)E"@J`Q/&TZ/:G#K$4FS=!X@0J[H8;^/624=A(+QCUZ)UQ2,4"H)F&5
M\;X'QEBM0KRJU\H3(-U&JE@E%U9.;405$.JI$=K\$F:2H%("J,<W9(J%(4IT
MS%``U,.FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFN!$`\(@'](Z]2SA
M%ND=9PJF@BF43J*K'*BDF0`$1,=102$*4``1$1,``'?'O:@ZX;G]N]!!8+;F
MK&<.N@)BJL%+A#.Y0IR\0,3W)C73V2,H'`0ZF1J8XCW@+QUH(WD<NY44;<./
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M(^6ZE?;(V9Q[&;GY<^+ZA=1:14<R`I%9"QUYB_V`_P!7#P_\?#_7X=0'D'_7
M;@+_`&L?\FL=3WQ#QAYPTXAXP\X:<0\8><-.(>,/.&G$/&'G#3B'C#SAIQ#Q
MAYPTXAXP\X:<0\8><-.(>,/.&G$/&'G#3B'C#SAIQ#QAYPTXAXP\X:<0\8><
M-.(>,/.&G$/&'G#3B'C#SAIQ#QAYPTXAXP\X:<0\8><-.(>,/.&G$/&'G#3B
M'C#SAIQ#QAYPTXAXP\X:CB[Y=QOCDANS"W1,2Y`I3$C.KB\F50.7GIBC#L2N
M9(Y3AP$JG6Q4A`P&%0"CQU'>+-RE4R[<9.KU:!LQ6D=$JR?9"_:-48]0R#EL
MV.U621<N%V*RHN2G9E=B15P5-8#(HF3`#25E&BCDFE2U/+8I2L#*"S$96(/_
M`*2F5J[1<G;JI=50ZY9NR)F;NV_5T052.("?@`E-7VL;+\85Z:@I9R\E;"A$
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M'G#3B'C#SAIQ#QAYPTXAXP\X:"8`\?\`3P'AWO+X`_K$`U%]NS=AVA$6/=<I
M8^JHH!Q42G;A`1SD/&!6CA^5V<W$0^T(@8W?\&JLV_E,-G=2*<"9/4M3A/G`
M+>G5FQ313"7AWB2*L>PAAYW'[4?=("??$P!P$8#?<K+69]UUCAS;UF#)CA3^
M+;FZ@TCDE53#S2\U&N-[L^`HF$O#GH)&X&X"4I@X#\([E>4OR0"J6/MIT#CU
MFN4QD92^`[2<-4A'B"AE+98:>B)BD$!-SH%4.\8>HCPYFJJ9=SEN,J:*YMQ_
M*0;;]OW6Y^:YJ56NL'(7E$J@&$4T*GC.M+VIR<H%$"$)*+',8>!5!$=:U,C;
MP=F#J75C)3/^\O>1:E%")-8ZC5`E+A)9PH81.FTD<QV*S6D[<Q^!2&84%=9;
MG&,1`@@`!W=.J&\/,)T`VS\E6[JD0\,;K&\;G[;=Y9,R/``([696J5P/2E!`
M1$X]:U*>;F-_%D2<@`\_2UEJO7:HY8RE5LD1D9%Y!KV1KI#W:-K;#J%=96IC
M/O4)QM7T6+9-BG!I2!%R1(,4R,Q8`@9H`MQ3$?JHK=PI'R1B-G9R^ZY@XE9N
MA#B$7%\0_P"IU_1%R?O'VAX5M!Z1F7=-MQQ-=$H]C*J5+)F<L84&TIQ4F"AX
MZ2-`VJU1$N2/D"H+&9/!:`V=@BH*"J@)GX0G@.R\G7D7<3.9!VM99VXWC.+S
M&UF;W>-V^99HEJ]U*=*VZEOI6W7JG8XL,E"*3(62/KD<UODU%M["[3<JPAIB
M0:%!JSO]IJI&ZFJV/)[C!6'XVORLE2[GFVIVG,,RC$&>043C7"Y7&7BP\U(&
M$&[?M@9%J>.J&2-5'G2\+-V4H%.V9/"ZHUNQPE0-T&X"JCCK;#DS%^\K;KN5
MV\W&F[UGF%&]+B28YKDQ3K5E1]";A(]4&>6,77+#Z][P78<*R4T_E9BV3#=C
M+T"*A8AG>8O<V4!`.`^,?%W@$1$`[W>^U#@'>\6JQ9JK;>V96P+#.I.Q1"*C
MC*3@7M7L$I6)<ID*:TYB:<M#.&KXC<XJ<5VY5@17YI`6(<"`764]H2%Z1,Y^
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M6:*FBBD0!.HH<P%(4!,80`-?(OB:CMNK]<9>R\CUK#C8''5<]WA,4((!4#W9
M5YT\`)Q?%)4/=`P@U$4S\%1YH\.IG:%C.LUE"Y3N9\OQU8=I,EV<RKG/()V;
MY.12!=AU@*,NJH^.\0'JS5)JFLJND`G3()2F$*ISV6*2ZD1A,5K;F,BRQS'3
M0YV9<EQC58X"/-408LY"2GETA`.<`K,(XO`>)E2AW]7&@L(LY.$AY&3N&=X6
M1D(M@]D(9;.%_75BGKIJDLZC55B3`$6.R7.HV,J4I04%,3<TO'FACK_9OAV6
M>R4A,&O,N^E>89V^D+W/KR2BQ2E(=R>7!<DNX<K$*4BBKQ^Y$A"E(W!`A2E#
M*(S;=481DC&PUQS'$1[<O-08QF7[TP:)!P`!YB#6523YP\`YQQ*)S"'$QA'7
MW]H2%Z1,Y^FO(7KG3M"0O2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/TUY"
M]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/TU
MY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/
MTUY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)
MG/TUY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3M"0O
M2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3M"
M0O2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3
MM"0O2)G/TUY"]<Z=H2%Z1,Y^FO(7KG3M"0O2)G/TUY"]<Z=H2%Z1,Y^FO(7K
MG3M"0O2)G/TUY"]<ZQ5[CW&<;:X:BR&;<ILKG8H]]*P55=;@KHWL,Q&QA@*_
M?1D0K8"OGK5H(CU=9NB<I`35-Q$J*PIY3VAH3AQ#(F<Q#QES7D,W_"9'6(V:
MB8JI2(N+CG?)%40`!$5K)N.M,&D```F_ER=F:AX`$>`<1X`/>[VJQ6W<5LGI
MW5B/]UN4IEPCS@%K3LP9<N1SF+PXD*XKRS]@4>_P`57B9!$!#G=X=5IG=^^W
MQ5R,?C5OO.R1(B82(),\JVV(1<'\!0(F-IEIH"B("`\8,%``!$$Q$.&NN#+>
M\W(I2DQ)M@W"0+=QS0;3-^SGF0R8%,`\%>,Y)XZB3!WN/$JC@A>'`0.(AKNX
M7;KRI]P<F=3&;S8K:*"7_07N69N6.W((<>";>&;VU4YP`1*(+SPF,)`^W`1$
MQL\E>3OR9/1ZDWN-WPW^1BFJ9%)5-)[)Q\&V0*`=4`92WVX\,W3\(`LK`IE$
M`YYD^</`*I79CR)^W?KU#(NY`N2+`U3,1S%52_2=^G"NR"452#'82A0;LE^(
MB4X2SQ-)/[8IS@<#&"GQ]_&Q):R!$;,MCFY_/=L,8Z+-9&R6*'14<$,8K91!
ME"FRI:B("H8#'%:"B'!2B!5!24`HEE1B'+I;@DVZ.*,0/]G],/S"-7-UR[8F
M4BT;**#U,%&5ZLUEGTA33_EIM,81QA`#&*FD<Y"EF!GR,V]C.39(F\GE*<F6
M.+$B0.:7CY[<)N*52.?JCAL+VSS59K9^`")"KJX^>`8P\X4S$*!#6AQUR!/)
MX49H5.;IV1,F2(BD=:5NN2IQF954A."@^Y-%)38+J:I_XPR:T>X'CP**ABEX
M#>;&^Q;;]AR/"*Q)#VC&4>!0(*%%N<]6E%"@4"!UP^BW#>1=&YH<!.Z=KG-W
MQ,81$1&3@P'"@'`,B9T_KS9D,1\XS0C_`+]=G#85A(6682Y+CE>448.`<E93
MV4;C.1+LP$.3J4E%R,DNSD&X@<3&0=)J)B<I#B'.(40E<&#(`X`T;?\`^.A_
MAZUJ\I%%XGQ)A:^;E7&$MI5BR6DIC&DO\N;K:0VEL4XYJ;JXE@D[SEN>BZY-
MW!+'N.VEJFY0[")<0S==_(-VDG9*I#.Y&RQ-*N3=R7<G6]BUXJR2GR9=2R'`
M[?L@N+9B/95A&Z47->/Y:`RMC...MF.5L$U)F@,?VN*F8.PXT&13+'9>C';"
MXT@"15>=2,Y^@O37B8Q2\!,)0\0F$`_IX<=/M`,'\GG#Q$/!SA[W?$/OCW@[
MX^(/)KRU`>0?]=N`O]K'_)K#4^:::::::::::::::::::<0#PCPT_P#7GU2W
M)6\FDUR0G:O7*S+766B7$G%RO5RIQ<`@JQ.JTD"KJK)/7SMJ@J19)PH6,(S4
M(4_!R*9@,-;<;N'\I:FDME"O2L'B$]<8RR5=CUS'KT94E[2Y5KAYMF\47L#G
M%["SE>.S-%3`P8IG8.7#7L-;%30V8VNCTS(T`VA;1#L+!`]79R;-`ZBI4"K-
MTS@S=M'#%=!0@=0643(=NL":K58Z0\]!02CV5<J58J#$D;5X"(@&)"D+UO$L
M&S$A^8'`#+"@F11PH/A,JN=50X]\QS"(CK(=------------------------
M----<<0\'$./BX]_S>'7@HLDB0RBIRI)D`3'44$$R%*`"(B8YQ*0H``"(B)@
M``U$UHS]@^D@IV6Y>QI75$>=U1O+7>N-'8<TW,,`,SR(NC"4W$#%*B)@$!XA
M]J;A7"T<I-L[K":H]MA.PKI#PZVJE8M4YU00$>/4WJ4.A%F#O?RA?E(("42F
M$!U`<MRNN'W2PM,<8HS!D%X/`$TV\9"Q:2IQX@4H$;2<])E*8XD+Q&+Y_P!L
M(E((@0JG5&WS;U+U]MBG8W9&;181*UD;KV5J-C`;F@1147451&(E_E&,!)3J
M?`0X*\"B8^G[*CK<0ON%>NLE(W1IN,7M$(X8LVQ3$M#6<64(M4&E'2AUUVY(
MQ$ADT:NG7W"\5UJ1<H.%A"35-MOA]BV\/*L6R?YVWDW:"&4:).Y2FU=S,/R1
MKATGSUHIPM%S]7JRB[3JAF[HS")>1P+E53:*.D"D<*Y[6N20VXL%4W=TLN4,
MA2?/*HNK*V-C#(+B'`3<2044WE.!C<1$33!S@!N\IQXF&8GNVKD_]O,<C.W2
MFX1I+!$IC$G<P3\8NB8R1><<X/LES;E$Y@*03"1`O>[_`#"!QX#67(7+*<F)
MM^9JQU7R7$V]9N*B?N%@>@NIIB(I`8I$TY]JPKM&*!S!U-,>R/F!Q`PF!,>=
MJIB_+@YYS@JYC-D_)W9ERHH/#K.VW(DPK"(E-WBKO6-$A92$31-Q`P"ZR/'%
M,''G*$+]L'J/5OX0EN:%0DS;\+;-*K*@0YVD.K7&]C:-5""(@W4A4,PV])R4
M!`#$/9Z^Y!4`+SV_-$P=E%\@?*Y2D6]@WF[Y<]YZD5%0<2$3&.'#&,%0``.I
M(R>0YC(CE-/B'-ZI'0L,)4PYJ*:(\T2WWQ!R.W)WX;]SW$5MUK5UEX\X*)S.
M6'\SDYP=4H@)5#1=I?.ZPB8@E`2`TK[8A!XB4H"(CK8M6*=4Z3%(05-K-?J<
M(V[S:'K$+&U^+;AX.:C'Q#5DS3+P^\5$`[VLB`I0X\"@''P\``./]/#PZYTT
MTTTUJAY2#<,3:GCZS3]XWR2FU]#.]LPICG"5K6P!2\G0>()R)M*)LK/CA+5:
M7CK:;(=.DG"KF,O;LR];2@#RE$8/S-IIDI`G)I[@X;,VYB]M*SRG$UO^:,<)
M+RMEC&>T_&F$*W37XWFKQ=7E9Z_8]HU1=S5D.Q)88ZO5*R+/4#0SB>F8!)(8
MV7'6]G36D7E4\N[@<3WG&MME)_=E@G8A2ZZWDLY;H-G=@VWR=NH-QMETCZVW
MD\W8QS3CO)UT>;>:'74T)BTW7$D*2>JXV*:LL^V<P%4*LE73<7ODSU7<;<K#
MO0J=WL4+#\F+N;H&%,7X:*X1)2L@T_%U(P)>=PQLHQ8M51MLOF=MFNR056G5
M'C.0QXWJE#E*HK!R1;>[MGZ0$%07236*`@54A5"@8.!@*H4#D`P<1X&`I@`P
M<1#G<>'>X:K+FRVU^DY5P-/V>0]S(E)?*351V+5\\YJ[BFM!13ZA'M7;D>?U
M(_VQ4!(7A]L8.)0')>Z:PG\-2_-VW^SVG=-83^&I?F[;_9[3NFL)_#4OS=M_
ML]IW36$_AJ7YNV_V>T[IK"?PU+\W;?[/:=TUA/X:E^;MO]GM.Z:PG\-2_-VW
M^SVG=-83^&I?F[;_`&>T[IK"?PU+\W;?[/:=TUA/X:E^;MO]GM.Z:PG\-2_-
MVW^SVG=-83^&I?F[;_9[3NFL)_#4OS=M_L]IW36$_AJ7YNV_V>T[IK"?PU+\
MW;?[/:=TUA/X:E^;MO\`9[3NF\)\0#LT+Q'O``5VWB(CX@#L=XB/D#3NFL)]
M\.S0H"`B4P#7;@`E,'`1*8!KO$I@`0$2CP,`"`B`<0XX!D'=M4H6+1/CJ-?Y
M&FESK@LS:1MDCF<2T11`_NC)++U\5U$#*F(BFBU3$YSB83K(E+SAJD;<'F/)
M2YCO<G5_#\01R!P;MJU;6TF'4E`X<QNG6IJ8?$()>(D=2,8S=EXE-ST5.:-Y
MF^Y?#";=!-Q>RN5R(I$6<=C-M1ZNJ5,I5%NI$KPD2ZJ<#*=3*(E)SN:7O`&N
MG/G';:H67(I)P)R3X*A.D-1Y\2S(+?\`7!*AV*_^T05\"G7G5N?_`-[CK[C[
MA=OYU%%CV2/.JJP]RE535*SF54C`,<X1RB@UD3G8@910P,S"+8#*''J7$QN/
MTM=R&"6+5LR96ULT9LT$6K1HVK%K0;-FS=,J*#=N@E7")(H(I$(FDDF0J::9
M2D(4I2@`>_NFL)_#4OS=M_L]IW36$_AJ7YNV_P!GM.Z:PG\-2_-VW^SVG=-8
M3^&I?F[;_9[3NFL)_#4OS=M_L]IW36$_AJ7YNV_V>T[IK"?PU+\W;?[/:=TU
MA/X:E^;MO]GM.Z:PG\-2_-VW^SVG=-83^&I?F[;_`&>T[IK"?PU+\W;?[/:=
MTUA/X:E^;MO]GM.Z:PG\-2_-VW^SVG=-83^&I?F[;_9[3NFL)_#4OS=M_L]I
MW36$_AJ7YNV_V>T[IK"?PU+\W;?[/:=TUA/X:E^;MO\`9[3NFL)_#4OS=M_L
M]IW36$_AJ7YNV_V>T[IK"?PU+\W;?[/:=TWA+X:E^;MO\?#B'_N]WPX\0X^,
M!#PAIW36$_AJ7YNV_P!GM<#N<PB'ANQ`_IKUO#_C7M>PNY;"YPXDMYSE#PF)
M6+F<H?TF+6Q*'E[_`'OOZQJ3WE[8H14$)O,M/A5Q`P@WF%I*+<"!>:)A!!]&
MMU>``8HB/,[P&*/@,''$9CE!-GD*W%POG*K/N\82HP32PV%R82\.)>H0T*\.
M01$0`HJ]3*/VQN=S2'$M?K%RN.V2.4.UK,3D^[O>?U-!*)JS&*17-SA*`%-8
M9N-?!Q`.<4`CC*&`0#F<[G%+%,]RJ.2WR/.H&T2^.$E2@=K(V9>T'15(8!YJ
MG6E=H[E$Y![PE,E+F`0XCS_!J-S;V]_&0@X0-1Q1B9JJ80(ZL5=L2#U`O.`H
M&4+97$NJ82\X3<>QX>>4@B5+@4`4]"X[Q;R<I[SOTK%-;K`!56M`KM]!5`@F
MYIBE"M8RI1!,"8<2B685$1^U,J!A,<.$=H>&;2HDYS%O>S!?U#B4[QNE7KF@
MDH81$RA4U[4C<3E`PB`%/UL0P`!AYH"8H)RO5=H?)KUQ0JC^1MUP.4/MALDI
MD1NFH;F@7GG:U:N5I`>/\KFB4Q`$>'`2@4`L95:QR=U+,F,!CW%Z2Y!XIN)+
M&UAL+\#<0$!*]L5<EG@G`2AP-U83>$`X<XW&=2;B=M='C3*=E5>I<,B03'76
MK$Y58E),HB(F,X5K<<Q(0HF$1$3@4HF$1X"/'54]Q'*B;+:UAW+04O=MB<F2
M28UO@4-"OV1O.3H7;L5E0J@1K!LQDB*O^R`T=UJ1RW.VZL!!<D,@54`_&V?E
M`-[LC8*Y>)3<[E%Y=J]"NXJ'L[D]05G(AG-HMAFF+%^-4%1%!ZH@`*@`F%,#
M+E;'1(Z=@OM:VZ\K3RG<SA:JT#'&"E<W69O*6IB[W*94B;/,Q<N1>POG31HN
MI!LJ'2T%*DU7)`K/7MEE%E`9)`\:IN0,CJ7EJCRK^XP&ZN=>44HFW>M/5#@Z
MJV&(BY>[C%JH(<Y`Q<8T.JE7+S!,0A'N59$P<W@L8X&$=9E1.1_Y/_W12LFX
M7=%G;<5:#'!9ZO,%M-0BWBQSBHL*JS>O6&[B0YA$>'9R"AA$3'4$PZV68BV^
M\EA@PZ+G'.&<31THW(F1*PSV.[7>;.0R8?\`6ELEZ@K),IK''B)U$':(F$>'
M>*!2A=)#<C@MLBDV;VY!!NBF1)%NC6K:D@DD0`*1-)!.N%13(0H`!2$(4I0`
M```X:]X;FL)!W@NA0#Q!7;?[.Z=TUA/X:E^;MO\`9[3NFL)_#4OS=M_L]IW3
M6$_AJ7YNV_V>T[IK"?PU+\W;?[/:=TUA/X:E^;MO]GM.Z:PG\-2_-VW^SVG=
M-83^&I?F[;_9[3NFL)_#4OS=M_L]KMH+/^)K+,1T!"VLKV6EG(,X]H$'9V_7
M#@R:B@)]7=PC=LEQ(D<W/7723^UX"?B(`,R>'5#N4FA,E2FT^TRF)+[B[&-Y
MH>0,&Y3C;QFW*=DPUB&"88OS50[Q/+Y+O]340G8RD+04)(-;+&LW;`;-$KNJ
MTH_9%ENKDKGL:WH9LSSN#F\:9.SUR8&3(ECB2QW9E6]BVXFX9HO;:3872DP:
M<K;HVU0\<UC*BQ933UF9U"K+.49F2B4I5NU:/(M1QM]TU3+-6V?)V=;+D"JW
M7/Q7.U#*=,KM.N^WDF)JTG/NV+4\HE?(N+S2VGFDPUJ.7(AXU@+S!3%.L$TS
MBV[PE%MM/6E%UT8=R]R:M(RS9\[L7%]DX3!.[#*6$<R[G<*MZZS=DR-><&M:
M1&L2UVYC*M'%%K.3X3%6*J]F>%)7K"]M4-2NIUF:I,A9[1(R.RX`X!P\HC_6
M(B(^'CWN(CP#[P=[P:@3(0<<VX"_VL_?$/\`\&L?%J>N:'C-^.?ZVG-#QF_'
M/];3FAXS?CG^MIS0\9OQS_6TYH>,WXY_K:<T/&;\<_UM.:'C-^.?ZVG-#QF_
M'/\`6TYH>,WXY_K:<T/&;\<_UM.:'C-^.?ZVG-#QF_'/];3FAXS?CG^MH)0\
M9O)]N?\`X<[O_P!6JNY9SK)8FF):.F>QQ5I*$B7=)?H+N'"[0$WD6WL<-;H9
M!Z>21<E8'DYB"FVI$XQX0H1RZ2+ULFF_EK'\_;;826L4Q#)UVL/U4`I$.^3=
MHVA6+2!8%)VR<];J4<:<$R#B.@@:]>13$A#R2YGCI1FTJM(5?>3DZ1=-IBPQ
M.)Z\1TX3*E"21$'"C<BIDR&;+P:S^=>@=,`,51S,Q":P#S^HH\X2%L'A3"R>
M(&$XDK;K!;Y.Q.F;R3>RZZI6R:[-)=,#,&9W+Q1$Z_7!Q=N7+QTZ=`FW*HJ!
M$"$";N:'C-^,;Z=.:'C-^.?ZVG-#QF_'/];3FAXS?CG^MIS0\9OQS_6TYH>,
MWXY_K:<T/&;\<_UM.:'C-^.?ZVG-#QF_'/\`6TYH>,WXY_K:<T/&;\<_UM.:
M'C-^.?ZVG-#QF_'/];3FAXS?CG^MIS0\9OQS_6TYH>,WXY_K:<T/&;\<_P!;
M3FAXS?CG^MIS0\9OQS_6TYH>,WXY_K:<T/&;\<_UM.:'C-^.?ZVN.!/YP_U'
M,(^8#<=>)A(0!,8QBE#AQ$QSE*'$>`<3&,!0[_>[X^'@'A$-1Y/Y=Q-5.?V3
MY-H%<%/ASPG+M7HHQ>/,'OD>RB)P[RB8_P`GP'(/@,`Z@B?WY[0:X8Y'V=Z:
M[4)PXDKZLS:C#_(X@'8W&RA!$.>'$`/Q^U.'\I,Y2UMR)RM&VR!A9@*`-KO=
MJ(R6"OL58"0K4"[E#$*#4LI+S:C)XSCBJJ<]VLTC';H445"-T3**(''79A?E
M'MQU0R/89JRC(9M:9$>BDCCA9\^8)1=D=G%O7V^-TF+&:<PC0BJB4<M66;!\
M2;0`CE0?=[GRB]YR[D>4VOPJIT3:3`45LL)@1>7<[M-VV*;[8IS#:+94"&.0
MH#Q$84Q1,(%%+B)2"[5W*R9#*);#F_&>+6:@@)VT"$2#Y`H_;"5-2`I4NX$Q
M.?S1#LA#G"3@*P@'/5]I>3DSW=$^.7M\65YPAP`%8N!6M/60EX&`Q"#,746`
M`('.'#W"*4>>;G)CQ-QS:O<DQMLCE$G%FG<L7AT7FBX-,W)&,;.3`/VPF3KL
M1&/2E,``'-&1,;P_Q@_:\VPE9V%;1*H=)6/P;3Y!='F\%[1[JW%0QBCS@.8M
MHDI9$3"8.(B")0\!0`"E*`6)KF.<>TQ,B=3I%.JJ:90*F2O5J#A"D``$.!?<
MYBV$.`&-]\1X"/?[X\<Q$2`'$3&X<./.`R@E`/"(B8!YH``>$>(`&H)R-NAV
MVXA*X[:.>L0X_4;<[JK6VY)JD)(<X@<3$)&O)@DBJH4!`132:'4X#QYO@XT%
MR3RXG)O8Z25%'-[_`""[2.<AF>-J-=+&F<2<[OI3;V+A*RH0QB\TJI9P4AXE
M/S^ICS]5&D?X0/`79^K%[9-E&Y#.+HQC)-%SI)1;=501$$3BSHD3E*1*10`,
M8$UP:*<"\!YOVPE^(F\'EW,W`=OB78E1,'1RY@,E-Y2ZLC(M451YJ9S]L.]U
M`YA3`>J*%3H[A00#B#<0X%-SW&O+IYNZFYRYO\IF$X]PJ`K0^*%'B$DS2.'$
MY4SX[I5"'BF4YB)E&ZN!$Q"F%P(@"@]O&?P?NO7)\64W+;VMS><'IQ!1P0LH
ME$H**#Q%0H.KS*Y3DP(<P%'G(KMC<"]X`$2B6QB/(5[!*_C^X0%8Q@\D[Q+U
M2R1-8O>2+M>+DI6[%)PCUA"6'W`0G(>O.#0LHLUE2MTXA(3G;"FF=,3%,74R
MC_!PMPR:**9]S.%SF3123.?L`R!Q.=-,I#J"'NSX3F`3CY1U^A_D]-JEAV9[
M6Z7@2U6^&O$[7)R^33ZP5Z,DH6(7&X7*7LR+9HRDW;M\`,6\BDU5675+U=9-
M14B29#%`;M\T/&;\<_UM.:'C-^.?ZVG-#QF_'/\`6TYH>,WXY_K:<T/&;\<_
MUM.:'C-^.?ZVG-#QF_'/];3FAXS?CG^MIS0\9OQS_6TYH>,WXY_K:<T/&;\<
M_P!;3FAXS?CG^MIS0\9OQS_6T`H!W^)OZS&'_<(\->6M*O*][G<#U>H0VVN^
M1>4YBWRRE"SQ*6FJ;-K5O0PCM\I^/\BHR5<S%N[QW$2$!&%P@XL=2G6YD36!
MI8A<UF3M$`+%U4$Y1"=]J^QV4V_[A[!E*I6_`+7`CC%\U3\94;%.W.M8_P`C
M/FEWMU7OY3Y0S1$V>3;Y$J..G43+Q.%XF%J=7<,*M<G87*8N,W')3TELSTU7
MW*&Z_;/A/(&/L59>SSB;&>1LJNFC''=,O-\KM9L-O>2,A[CQ+:%CY9\V5<KS
M<R!H2!3/U(T]-D/#PW7TDFHU+[LI[JMLF#KA1,>9GW#82Q/?\HND6.-*/D?*
M-*I=OR$^<S#*OMV5(K5AF8^:M3MQ/24?"HMH-D^65EGS2/3(9VX21-/G$!\`
M\?"']8#P$/ZA[P^74!Y!_P!=N`O]K'_)K#4^:::::::::::C>Y9>QK0"'[*[
MC"1;@G.X1W70/9=02@(\U.(CP=21Q'O`'^C`4!$`,8O?$.<994J.6H5[/4]=
M\LQCY5>'=!(1Z\<NF\010<\`36YP'35;N4%DSD.)BE4`BQ$EBG2+@><<;91R
M,I`,:1DCL&@$DWR5E;($D47LB+@[;K99)U%J(.5TT$2.$A8*/&*!C*@J=57C
MS$ZZ,MC@-UK,YD;&E8'!C0J-9._5=LP=E!Y&.K%*6!1JFHX(LJU+*1D3&)+/
MDT@,F]>/U5U4NLKDX^KMKJ:<M7IF:3L=:8+H=A4J]6<*VA*)5*J92$LBBB?4
M9%2$,5%K&S97!GDFQ,0)-$KQL=T[D733333333333301X=\=./'37'.+X.(<
M?%Q#CYO#K@3E*`B8>:`!Q$Q@$I0#QB80``#Q\1U@5@ROC"I]4[*<C42M]2`P
MJ>[UOKT2).;SQ-SBOY%`X<T$U!'[7B`)G_F&X0/8M]VT6KG43D<\4=TJES@,
MG7G$A;#\2F,4Q0"L1\L43<2F```W$W#[7CQ+Q@:P\K'M)A3J)QTG?;2<O$"^
MX=*<,R*"'$1YBEH?5X.`@'>,)0#@(&X\P0-J-E>5?:SRID,8[8,RWDYA$$#&
M*FU!00ZIP$25N)N*A0-U,_>`1,`$/WN>0Y`\!WB<H);S\*%L?<P:*W'J"]U"
MR`4H?;\TRAYA>@(?]P>/$2E[Y2\[@=(Y^>N.5[NB@\QGAO%2"P")1.-2<*(!
M]N)0X'<9%<<\.:7ASDA[YRB8``5")^9MI7**7`_.O&]E*O)+<[JJ-(3G4^8`
M]5X%3"#BZ"F``()``@J`@!SCSN>B`KAY*MW95`5RCNNS->!.(F73*)D"''^,
MX<#66?M_#@(I"'\3P#F*%``*=/J,@P')+[38@Y%9-MD2TJ!Q$XS-T%B501!0
M.)BU>+@#?]\H_P#6\>*1!X_;+`K.T#L%V@5T2'98)I[TZ?'@>PFF;48>(*!]
ML%DE9-,>\H8.^GP^U2^^BD))'G*-MEQ'67DK9*I@[&=14`L1(RD["4&FU]0)
MCJS`D:]D9-O',#^Z?7;AF1HNYYSSKE5N0B@JF(-',$X[Y.S`V3[-DVL;B<(2
MTG(NU`HL9-YFQF^9XRC7R($D(VKG-9#.7+AVNHNW;S$D9>68PAD8-JXZD+YS
M(;5TU$%"%52,FJF<A#D.D)52G(<H'(<ID^<!RF(8#%,`B!BB!@$0$!UB=OR)
M0<?L1D[W=JC2HTH<X\A;K+"5ID0O>^V,YFWS%$H<1`.(G^^'C#5&LC\K1R=^
M+SNF\]NFQQ-/6@&Y[#'JLQDYT8Y2B;J9>P"*L+0##WB@95VDF!Q`ICE'CPHE
M<_X1/M(;N%8G$.+<_P":9T%3)-6L-5(2LLW@E,8H'3"7G7ME`AQY@E`:H*W`
MW?2`P"4<,-RI?*BYE,`[;^2XM4)&N^`,+!EOLU49&(?@!%U%)>/P]!"`\!$0
M1G'"9`$!YYR?;#ZPQ[_"'\Y&41L&5L";7X9X'53MX,:<,JT35_\`N$E:]6<M
MS(*I$.(%X6AL<3IAQ<%/P./(<B7N?R^F5QNKY3/-]Y!8Q3O*Y4NRI6'XFYQE
M4D%+?>%84J0&,()`G2&Z12B/!L0!`I9YQW_!]^3YIBZ3VSP^5LKO@`IG*EWR
M0\BFSE8.^<ZC/'4?2>>50>/$J[EP(%[W/$W$PWVQMR>.Q[$ADU:)M8PE%O$0
M)U*5?T2'L\V04Q*)3A.6U*>EQ5`Q2G%7KWJ@G#GB83"(C;R/BXZ*:HL8MBTC
M63<O,09Q[=%BU1)]XJ;9H1%`A0^\!4P`/O:^T"E`>(%`!\8`'$?Z1\(Z\M--
M-----------------:X=QFR;-^:\M7>^8YWQYBVPU&^8KIF,[11,38PVUW-&
MV!6ULE`]GI^<SKAS)T]'O'$7D-2&CF=2DX&/:(,E)%9NXEUT7C7(=L.TG/N!
M+_&3F1-]&:=SU`AL5R>.Z_C[*F/-N](8U1\:5HBT+9(=W@K$F,G4R];P-3>P
M#P;@M.J%2?E=QRK1TYEE'U_=-:I.49KNW_,V/<K[,IV<Q/5K'N5J]5F-P5KM
MEDJE>7QC@>L3<>#G+U@7F)%F])9F+*I24#@,OA1R(R4MR?6E;HMVEV,3[KZ+
M;*!GZD;Z-MNX,<H2U@S;M&P/EG:1>&N)<CX\NF/[!9HBNM&F&)A2IDS'A?-E
M&JV6IG<@U?,K[)05DBHF:DK73BUZ03FHK=D41$.(^7^L`$0`>]_.#@/DX\-5
M@S9V6]M7`W81V.^[_5\I=2[*?=3W(ZU[#&G7/5/<?_3NN/\`J^H<S^+_`)?/
M[_,UDGW3?X"_SC:?=-_@+_.-I]TW^`O\XVGW3?X"_P`XVGW3?X"_SC:?=-_@
M+_.-KK9"9W"Q*L8C)R.WZ/5F9`D5%$>.<@MQD)-1!=RE'M.JF*"[Q5%LNHBW
M((JJ@D<$RF,7AKXG5JSJR2.L[L&W)NDG-MJT=162O9"EL+Q5!%K!F$5>]+KJ
M.6Y4XX?]*-U9,02YI@'6+WO+>5<:=0)=;5MZA7+E`SEM'"&3GTLY;E.=+JS>
M)CD73]5(RI#I%6Z@5`5"F`50YIN$24S=;FN_V]G4ZE3J%,$?/V[(L^DSOR4=
M'HGYPN)*7;@*ZL>R;D+S^*[@BI^(%$A#B4AK)R;#<O+1DA&*K84;)R3!XP4<
M,U<CH/&Y'K95L=9JN`"9%RB545$%BASDE2D.'?*&JQ5/9O=:Z'59>/PY=9`3
M<XSN??Y/1:&$!`0$T3'+MVS@X@`=5._6>BH(F-P+SA#5F8>$W!5Y@C%0,5MY
MA8UN`]1813&^Q[-,3?RC$;-4TD@.<0XG/S1.<>^<QA[^NS^Z;_`7^<;3[IO\
M!?YQM/NF_P`!?YQM/NF_P%_G&T^Z;_`7^<;3[IO\!?YQM/NF_P`!?YQM/NF_
MP%_G&T^Z;_`7^<;70EM6=#V-2GDL6VXUL1B"3ZU8++7@UA2@U'0LDYE2%!<9
M$D4=V`MB2!FX-3+AU(%1/WM=[SMS/\[!7GR-H([F@Z#._P"(,CC_`,`'75R4
M[G^%2,O,36W2(1*4QS*RDG>8],I""4#F,=VNB4I2B<@&$P@!>>3B(<XO&(;#
MN<D:KSPGLY[,H\Z8B!T%+_85G)3`*I1+UJUD'#D3`9!4@E!(3`H7J8@!Q*48
M=EN42I\,507.;MN;TR9>/4X"O9WL1E!YI#`5-2)KZ[83<#@'`S@H<\#IB8%$
MSE+$,URM$%'',E$NZE:5@,!4RQM)R+&IK"*AR?Q9IZ8CE^`@4AR\YJ`G(J0H
M%ZJ51(L$95Y4C.USHLW!U2@ML;-IXB$23)3-.R^Z,>B^34,X;P2L@W-#L)Q^
M@DY;QTA[H.7;1%-R^C6X/4DEF>,;0]W6\.&A7>&L-T5OG12-2/,12-H]UY%[
M1X=10R2Z#B:&=AD#03J15*I'(S\PFJW="Z91BRK8Y6S*Z)GW*]W0_%&)PYBM
M!?B!1.:I+JMB'YXEX]6?Y"<@8A3D$1%`Q@%(HB3CU5(_I<[4^4DN!%%;=O.C
MJ^98HB+.HJSK5(HG$XF3$]<KM+ZF!2JF`!2.IP$I"@(\Q-4L:2W)<;A;2Y!:
M[;I%[:F<QA<HRK[(SLZY3`KQ`%).<E$4^)E3B/%HH4Q3*)\P"J"(9+`<D[7X
MDY59>*IEN7`><HI,7K)\:14PB<1$Z=;CX=;OB?G<>NA-SB$.)N<*@J37";!*
MQ7SD.PP/M<<F)PX#8%LR6OO@!R\3%LLQ)IFX@<W$!3X<`(`!P33YL[U[#%[J
M0)]C&*MH=>,G_(4AJ/8(Y4O\OO@JUC$U>/\`&*=\3B/$YQX_;FXR,!=RJ10*
M4,#HD*'`I"=L1(A0\``!"<TH!X/`&N1'<P/?X8*-Y0+D<W_T@/WM?(]D]Q$8
MW,ZDY#;Y&-B<WG.)%W?F")><<J9><HZ41('.4.0@<1#B<Y2A]L8`&!;=N[CJ
M$FLI<MRNQ&M"@0QU$9C+;MFZ`I$E5QX,U)WKLYA214.0A$#'4YA@3*8W>&LE
MCY7K;O55549/=CM)>G1.<A^Q-AGB]ASB*`D/,/3*Q.(J!SAYP&(J8@H\7!3&
M0`3ZK;;?X03MZKG5"0]MA[PX(4131K^(\M1":YNH@J5,CF[2U6`@F,(HB8Z/
M!,X<\P"W$JPQ'_TA;(=B>]:8JV=6O)*9S&(BX8H6]%1<05*1,Q&-=CKFH4%$
MEFBHE,OSDC.DTC`("FLK4;E$=_.\O=-MC=4W,6PZTX'Q&XR!CV9<Y+LD9D5!
MHG,1,PY4@89,MSIU=CE%)J12<-`,F955/J8%!,%#IB;0D^81Y6+TQXUB)"LW
M1C@#!J`F(5!03E#^*#OF*`E#OE\/\H/"'ZS&?)F<K'FFJPRV5.4P<5R#E(2'
M70JE`=Y":1;6,5C&IV;%5.GHXKCCG;-3)H*D%D[2,HF)Q<.1'JAOFJW\'@KY
M7_NQF/*\AG*644ZJNO,6FYU)-<XG$PF6<LX^P6)4QB\TASC8RJ")1,!RB(`6
MZ]`Y(W`&-U6KB!VK;2Y=RT(F4CO(;C-.45U#I\T>K*)WZ:GH\%3F*!CBA'H)
MB(B!4RE,)=7FIN,LI8Y9ECL>X]VIT1@1,J1&=-J=HJ[8J10`"D!&$CV)`*`%
M*'#AP[P<=9KS-S(\`$,%FX>#G=L<W#^LW$=>7W3?X"_SC:?=-_@+_.-I]TW^
M`O\`.-I]TW^`O\XVGW3?X"_SC:?=-_@+_.-I]TW^`O\`.-I]TW^`O\XVGW3?
MX"_SC:?=-_@+_.-I]TW^`O\`.-I]TW^`O\XVGW3?X"_SC:?=-_@+_.-I]TW^
M`O\`.-I]TW^`O\XVGW3?X"_SC:?=-_@+_.-I]TW^`O\`.-I]TW^`O\XVGW3?
MX"_SC:?=-_@+_.-I]TW^`O\`.-I]TW^`O\XVNV@>W_[LQO9+VH/<#KD/=;W#
M[.O=?K/J:G.]SO='_0>N>J]2X==?Q7,ZIQ^VYNIF_ITTTTU6_(VSC:-F&U/+
MUEO:UMSRC=I%&/;2%PR+@_&-XM+YO$MBLHM!Y8;/5I27<H1K,A6D>BL\.FS;
M%*@V*DD`%UE\/MZP-7\I6+.$#A?%4+F:W$9IVK*\3CZJ1^1K*6/AD:ZQ&>NC
M2)2L4L=K7F[:!05?2*ZQ(1JUB.J#'-D&R<PZ@/(/^NW`7^UC_DUAJ?---.(?
M^O+_`,=<<0\''O\`B^_YO#K&[A;(6BUF9MMB75;0T$S,]?JH-U'2P)`<B1"H
MMT@$ZJJJRJ2290X!SS@)SD(!CEU]9.W<HWRORE>J>*G4Y!2*[:,]UK-UTH3K
M]PL4(P&#&O"=1"<(]*DO"BA/HRJ+Y))=LD59(!#(=NJ+EM<'#G-)94]P&V2L
M=4'DPXCG%;;74T-$=D;808\6S;(S^,ZP%!T_,=20C$WK6!5*\2F$5;<6S"V,
M;S8FEJME2CIR:9,4HY)9Z=V9LHT;K++MTW<>FY38/>MU'"XH&=MUQ3*LH0!Y
M@E`L@1</$P;-./A8R/B&"(<$648S;L&B8<`#@1NU321+W@\($X^,==CIKCB`
M>$0\X:<X!\`@/]'?_P"''5<]QVZ+&&V*L,;!?G3YY(33PK*O5&`3:N[1/F34
M2]T7,>Q=.F:)(^(;J@YD9%XY;,TA%!D1921>LFJ\A5+,6,;M2X/(-=NU==5&
MPL"R,;+N)1G'HF1ZH#==)RG(+-E6+UB[YS"18O"(NF#]-1DZ23<$$FL=F]RN
MWJN%.:;SAB:-%,1`Z;C(-5ZN`E6!N<O6Z4HJL(IK"":H`F(IFX\\"@`B$2RW
M*!;/(8RA'.=*JZ.F(@)81G8[#QX+"@/,-!PC]-00,`GX$4,(H!UP7G(""@Q#
M-\JWM!B#"5K8[I/B'`.$11)='C_'&2[QY\\&00YI>K@/.X'1$.8)EA%((W?<
MKUAUP8R=/Q)F>UJ``<T4XVLLRFX+BDJ(%:STPN4I2"F8@F;_`&RBI4%`1/W]
M?*3E(\X60I0H.Q?+DN)Q`2+OU+5U$Q4W`H./_P!78Y51#F"9(@G,[#J*PJ`J
M7J9`./I'=#REMG(JG5]FD-7@4)S4E[0:2*H@<53-S*B2;MM4(IS3*)J$*=`"
M`1([@0<-C#S-/\?.[DPW$^[[`^0^Z;4N;AN<WN:KV9&M!P,U<Q;J,<-O<\L`
M1@`MEXQTW[$$*NF4QTRP*1%B[@.YOY3NY)IKVW=U6Z>#A(BJS&K)K)KLSJHH
MG,VXUNE5E(3HK)E1.9O)*)?]<HW6526,13VFY-C-%HX#DG?%ER>()AZJTCRV
M8$C)@J<P%(:7R`[;%$4UW)``8XQ$C*]XAT><B/:1G)!X%-S5;=D/,-M=CP%5
M5>9K4>FH84>IG'@%:?NR@)RIG('7IS%*F1$YU4P[TOU[DP=G,!S#+X[EK`<@
M\>=8+S;5R"('(<.>WCI2+:'#@3J8D,WYITSG(<#`)>;,4!LMVG5D2&C,"8Q,
M9,``JDO7F]A6X<Q1,><M8CRBIS&(J8#&.83&'F&,)C)IB6:(3&F-:V)1K="H
M\")1XE&$JM?C#`;G)FYP"PCT#<[G(I&$0'CSDDS#WR%$-97*7\H'MRVL]C6"
M\]8;R'EN)S'3+!.G8U%*H)QK",A)EE$%45=6*S0+QG-HR;I)_$O(E,7$<JU2
M>).T'`)AJHG)Y\J+LM+?<>[6L082S;17V3Y^41<Y$R0\QB]/*3K*OS4\@_N\
MU#6PSQ1,C"(5B(M./BR,8\RC9!JP1!RZ64W/VO=]M3HB2JERW)8(J_44S*J(
MS66J&Q=%*5)1<0!F>>%T<XI)*'(1-$YU`(8$RF,'-&LEGY7WDWZF=9.0W68_
MDU43F3.G465OO'$Q%02-U-2HUJ9;J%`P\\#D7$AD>*Y#&1`3ZJ]:_P"$)\GA
M73*IQ4SEZ[+$+Q3)7<7/(PJQNH@J!"*W>8J12B)AZB)CE`I%`$YO]'X+###S
M^$-T2P.3-L-[,=S&3C&.8C4X(0C`JX=7`A#=2JK?(+@G/169J\P4S"4SHB1Q
M*`I*K?.IRK?*<W\`/A[DG<A,FZY1%L]O?;,5;=],2E.H=[2\<,C$*X:O2B'N
MBD`@*"1E$5A(#GR4S3_"'LE@4]>VR[?\-LUC`!'$ZM41=-R"<1`ZI+!F&T.Q
M.5%XD<XC`\XPL%1*@"W56:WB&V[^$%Y-1XVW>7A/$[=4H"=G5DH)-XWZH0IQ
M(0]4PDLJ)B+-$BF,2?-S2NUS)J*)&5;AY%Y('E`,A%,3-?*Q9?<-5A'KF-J!
M<F*M5$S'43433*ME"JQQ.J-'3Q(.=#&3*)TTSI*MP!-+[8S^#JX4EU@<Y=W3
M[ELFN3\3.%#OZE&E75,D0#J<^P1=Y?`!G*:2X`=ZJ<2I$2544,0BQ)[I_(`\
MG)5E4U7]%R/=#)G*<2VC*]G;)*\U851*JA3@J2)B&`01.4"%YZ12F,/5^*PV
M;JW)-<G13Q2-%[2\5/U$2@4JUK8S%Y6,($33YZA[E,SH*',"13F,8O$5A.OW
ME55#FM#5=LFW&BBD:E8#PO43HF`R1ZUBVC0JB9@.JJ4Q%H^"06*)5%UCE$%.
M)3*J"7ASQ`9H;LVK1$C=H@DU02*0B:+9,C9$A$R%3(4B2`)IE*0A2D*4"@!2
M%*4``I0`(;S]MUP[NAQVZQ3G*GIWBB.Y>%GEH129L$&;W7KSOKZ'?)2=;E(B
M6059N1$X%1>D25*8Z2Z:B9A+JBI^1.Y-$Y#$/MQYY#E,0Y#97S0)3$.`E,4P
M=L'O@8HB`AXAUM,8,6L8R:1S%$&[)@U;LFB!3',5%LT1(W;I`90QCF!-%,A`
M$YC&$"\3&$PB(_7IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIK@1``$1'@``(
MB/B`.^(ZU8YAY3JLXNGMRUD;X\<3^W?93E#$6'=U&7NR([.6J=TRJSHTQ,.*
M%2FT!*)76M82KF4\:V/+\C(V6KOF4=/6!"KQL])4QVRE]IP#Q#P<!XB`AY0'
MAY.\/A`>`<0$!^_J!,@_Z[<!?[6/^36.I[XAY?,/T:<0\OF'Z-4WY0+,BV`-
MGN<,OH5YC:E*778AX,#)/96+:ODI&WUR#7$)&%<LI1BY:(2BCYBZ9.$U4'S9
MLH//3*=,^A6Z\K%F=7`2-["#K`VN=;'JMOK*%ENKFQ0V*8-U)R%9O$HHC7(H
M6SNTEL\"PGY<[>`83\;(1@0\V1XI))M;^;4=\^.YVM8GS#G#>'ANEIVC'4;*
M/<)MKS'.%JXZD(A)`M?FXMNV:H5YW`N0(J1NX3=S8=03;.7:G.=**V^E.4QV
M$];G:O-Q%#DFKTBK9PV08V"6041.3F*INT$H)8G4%2'$@E6(9-8O/+P,`"&J
M(;O.6CVZX7H]%D-O53J6>;%V<GCPKDJ>8H$;48UO79MP%KBGG8?+E,Z,Z(A$
MH(,T&:_6LDY6%PF4HIJ:O<8_P@#.%<D;%VU<&8XRA!62YQ]H;M$Y[L25J*AI
M)H9PG$F;TR10ETH]%NT<0KB?$\RS?LBN'5@<$6`K3;5+\N5@1!0Y8*B2LD4I
MDP(:5R-CB&`X")@6$Q6DG/"02`!12`HG!81$#&1``$T6ON7:KK]0&E8QSCA%
MVH1R5(9S.$<H0%2<3(G.5M7F"(%(F4XKI"]2$Y^!$5^/#G=#)<LEE1<6_6:6
MTBK(OCE,T4LF8*^Z-U$Z92CU8ZF2HGJ(HJ*$675<-6XH)F*DJWX@<^NB/RFN
M?["3GI;J]@-(#K8YA%3*^,S+IF04,8>*;BQVXP.'1/M2)@BJB9$`$H(N#@(X
MFXWY9$L(&]V.5:VAUE(YERF2K\JJ*J:+E,HF%(8[""!P,B?^*0`S\B[?@94B
MY^)1-CS[=#1G`I#<N6FK:!W0(K]2I#?+LV@FJ@()K$,I6F<(BT`A#`*'5D&O
M7YQ.JJVXIG4UIHW*[HKF;-]]C\=YX1SUCR#?L8FC91LM?F7C^QP)H>-DUQ23
MMDL\F8]JTGI"89]9*J@D+ALJZ2)S%RF&7-DN=MM%AN61";^<DR=+IL?38R0Q
M\:@U.8"4GK:K,N$)B,5)6ZQ<51!*'3;.FQ7B,4V6=&$#/5S@#?6SR,W/\@I7
MFZBZDMEFRJHI.%"-Y*K9[!=V?J1>8@DFR803(5@$@@W%4Z"8**F!58$N;S,D
M8\I%R&]<16<,,.6205326.FUD<(62:<.3&ZF(HH*6R?79D.(IE!(5W+=%`1.
M)54054$^<1W+9\DY7D%5:S@.\-%T$U3HMX;;MC6.75.H)3F1(Z-:$$417.F0
MPF7621$Y`,<X<WB&5I?PB+9>U8.AK.$=R[I9`#'291]#QTR;J+JF`136<M,C
M+(M15`ICBHHD83B3^28>^7KP_A$F$WS1XI7MJ.ZN<=-R`!$4(.G';=6./%-)
MX]86.5,R*H0IS%.9JL<P$$")&#G"6M&[+ELG&>ML&<,;4S:9NBQG(V^E/*XE
ME)QU2,A:(N^<L3^[$M8(!FU>0Z2;=-0@*IOVJIA7(F"J9%14+^<4+[?2S9["
M2_9""?.4433@7ZYA.G0,D5L+8\R6<]U3HF;$*U,B9V9,6Q2MQ(*)2IA^C?:9
MRDO*0U?;%ARDXOY.O*>=H>JTR)BHO-L[(Y3FFF18I!Q(E0L"#TU1$LF+HH%:
MD=-+3.HH%8F*JX,!TB)6,-OEY<^PB])6^34I$!U%1-9$]D=2*IDVRAC@5N`R
MF7*LC)..!>:JLV*W,C]JH=H4#E+KV.\G_P`(NM'7ON;MXVTT0IE$'3?JKZBN
M%44C\1,R:GD<T6(B_@_TDSUNFLGSB@DMSN=P\.PW^$<V878*Y,VPT`BB;=PB
M#1M05!1-]ISV+-0,=714APYHBZ,]4=)&YRA6KP0ZGS?8YV@\OA;.N36+E!L1
MU4CYLU542K+`B!V[E,$!%H@,'@:(.RYO,'KATT>'3='!4!3,FN(AZ?L8O*QV
M0[@MPY6BXQZ+QHEUR2KM\CI%!TGU#_1T$HRP4U%NV#F'XO&0,UUS$*=5IQ<+
M@&GSE,=BVYO`&1<4H7K,F>=Z,I;J!./U+I(43)MF1I2\1/L&2U38/%)W(QT6
MS\KDDN5%1U"K*`F"RL>X-_I8ULV=;-9[</N@PQAG+>/,WU/&UZLDK'VZR,:!
M:JNZBH]A3K-.-UD;!:J6^K\89>4BH]F*\FT<)'(Y,@D0'*J!R_J8IO(!\G)5
MU$5I"BY(NAB&(<Q;1E:T-DE1!45A*JWIP5)$2&`>HF*!2B=(I3&'JX"L-G*M
MR3?)T4\4C1>TO%;]1$H%*M:V$U>5C"!$T^>H>Y3$Z"AS`D4YC&+Q%83K]Y55
M0YK0U7;+MQHHI&I6`\,5$Z)@,D>M8LH\*HF8#JJE,1:/@4%BB51=8Y1!3B4R
MJ@EX<\0&:&[1HT1(W:-TVJ"12$31;)`V1(1,A4R%(D@5-,I2$*4A2@4`*0I2
M@`%*`![Q*0>\)1-_^\!C?_4`ZY#FAX"\/Z"B'_`-<\0\OF'Z-.(>7S#]&G$/
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M<TEDHDE2Q52KW4<`T/<XSR*1U+M)]C9Z1'X0L<]C:+@X*80NR]_I$:S>=4B[
ML-8_1(BF5),B1"\TB92D(7B(\U,@`1,O$PB(B!"E`1$1$1XCQ'PZ@?+&*S9(
MO.)W,@R=.:M65[TYGUH^R2M9?MEI:M(1L/U%U`R<3,.$UW0+).$&SKJ',X'=
MIF(!.'O[F_%'O"X^EC+?MUIW-^*/>%Q]+&6_;K5/=_6T:M7;:)FBKT"J7>RV
MJ5AZZ6.KZ%VRU;#S*;*\U:3DH\:Z%BGU91)Q%L7I%D&T0^>$1ZHNS1ZZ21.3
M4'/[7[DZJDJ9AB3<7)Y&FH9]#6N8E]OV66]8R#79!@G'.L;S$`UKZK>#H#"/
M0;,:$A%(C(4!RQCYIFL^>#*%?SO@/^#][2K5A?&%DRV.X."R9.4J!D[Q$$O#
M&O!'61VS*M)-#0;ZE+O(HZ*I@*HP=*=<-E.<DL1-0IB%ES_H[6P0?#*[@Q_I
MRA#^PFJ)\H9R(%2Q!BK'DWL<Q/F3*.05<A%B;RV7NK6UR"=*7JUA<$E?<>25
MKD:@);&WAVJ[N+;D.BFN4BB`(K**DU-1O)A;^G\G%,9':%FE"->S$,TDESL:
MR@1",<RK-&27.N%I$4"HL#N53+``BB!.J@`B0`U^HV*Y`ODY(\7(NL?Y'F@6
M,7J02N9+X7K4J9E/^H"*D(L?XT#%ZIUP9P/\63J8D^W$_=!R$')L\2\[$-P.
M4#%,)#YFRH8A@*8#<TQ>R<.)3<.!@X@/`1X"`]_67AR(_)E%$1)MJ0)Q'B/,
MRCF,G'Q<>;?@X\.(\./@XCP\.NWC^1@Y-&.(H0NUZ`>@H<I^=+7C*DLHF)2\
MWFH*/KTJ=!,W\HZ:8@4Y_MS`)@`==F'(Z<FL`@/<ITH1`0$`-8<C&`1`>/`2
MFNHE,'C*8!*(=X0$!$-?8;D@^3<$!^Y,QQQX#PXN[CWA'_\`NC6BO=;R#VXJ
M7SUE.Q[7ZY@NN8-E)>(>8XICC(EAA)6'C>QR`92C!5C(5&60;J!/H34D(J6!
MRFJW<`=%4%#D:$LGR>'(D3N,[]DN6WQ8[P3E*H2E/@(NAQ499)RX*QED;6!Z
M\F9,Z#NLU4K!-Q$F:-2KE<.55A`4A02(4QC;<&W)=\GXT$XMMJ6)D14`H'$L
M0^^V`HB)0'C)#X!$1_KUD45R=.R."ZO[B[<,=Q/774^N?<YK*,^K]1Y_4NK=
M0E$^J=3ZH?F<_CS>>;APXCK*H[9'M;A^K>X^(H6(ZXYG7'N5+VJ-ZXZESNI=
M7ZRGT.K=3YY^I]4YW4^>?F<.<;CD+/:E@F.!0L;4)&-*L)3+%CKYD9@58Q`$
M"&6*TMR(*F(!C`05`,)0,8"B`"/'M$-M^*&H&!K'V]H!Q`3@URMEIL"@E`0*
M)P0O*8'$H"(%$W$2@(@'#B.HTS;LFQ#G#$>0\0S,GDZ!B,B5A[6I"5B,J9!D
MGS!)T=!=-XWC+79+#6GZK9RV05*UFH618+`04UVQRFXEU-?]''VV<_G]T'N'
MX\[G?R,4<./'C\`./A\O'RZVMX/V-X:PAB+'N(HU[D2RQN/:TUK;&;F<DWF+
MD9%%LLX<&=.HVI6&OUIBJLLZ5.9M#0T<R3#@";<H\X32GW-F)0\$;;P_VK9:
M]N=>7<WXH]X7'TL9;]NM.YOQ1[PN/I8RW[=:=S?BCWA<?2QEOVZT[F_%'O"X
M^EC+?MUKVI[>,8H`(-T+T@!C%$P(9@S"B!Q#O<3`G?"@80#B`"8!X`(@'AUA
M&-MNT03'U4;9(/?7MS+"-"6DZN:<L/$UY8.<9R8ZC*]E8+@)N8('03!$1`!(
M`<.]F7<WXH]X7'TL9;]NM.YOQ1[PN/I8RW[=:=S?BCWA<?2QEOVZT[F_%'O"
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MX>`<=<Z::::XX!Q`>`<0\`\.^''P\!\NN=4HRSOZP#AN\9`IUK>V)Q'X6+B@
M^X/($-'1CN@;?"9PE0BL7'RQ+.IMA*QI;()VTS(#6H*T=@U0?Q=YR+V)4V4C
MYUQ=8!XAQ_X^3O#_`+_ZO$(AKG00`?"''^G7'`/$'F#7(``=X`X!X@TUP)2F
M#@8`,'AX"`"''Q]_7CU-/^83\4OT:\]-----5QW8;H<<;-\&6_<)EEC=7U!I
M"D(2>)0JF]N,ZW3GIR/K[5ZI&M%6R+.*;/I-J:4FI5]'1$4U,9P^>HEYH'L:
M`\?.(>81`?\`AKG3333333333334:Y:RA$8@I$G=9:%M5I4:K,8Z%I]$@SV2
M[W&Q2[I-A"5BJ097#-)[,2SU4B2:LA(1<)%M2.IFPS,-`1TE*LXGVL[M,<;L
M:Y?9.FPE_HEOQ)D>6Q'F'$F6ZPG3LHXKR)$Q4-8AKML@VLI/0[A*4J]CKUIK
MEEJMBLM0L]?FF,E`S[],5RH6BTTTTTTTTTTTTUZEUDVZ*JZQ@(DBF=54X\1`
MB:9!.<P\`$>!2%,8>`"/`.\`CP#5+L&[Z,:YOSG<]NQ<>YTQ/DZLX^8YAKL5
MFK&;BBM<IX;D;.>FH90QVZ)+3)UH%"R]:14K7[DWI>1():4BE9RDQS>005&Z
MVFFFFFFFFFFFFFJXYAW58=P=D_;OAN\33TN1MT&1)'&^*ZW$,0D7;N3AZ3:[
MY+S<X87#=.$JT;$5)ZT6F%S*F<33V+B6#1XX<KBTL:`@8`,'@$`$/Z!#CKG3
M3333333333356MT6[*F;5X2J/Y_'^<<N6.[2\A&5G&NW3$=GS9D^29PD:,I8
M[,6EU0@OV]1K2*L6UG;&Z41CV$I8:W$B=21GHULO8:J3P6JKUNSA#SU=[(X&
M'GNQ^U1AX6SP?NQ'-I'W'L<.=5<T5/1G7/64Q&F76,PD4'+0RJAD1,/?Z:::
M::X,'.*8H#P$2B''Q<0X<=?F&WA8AR3"5KEU-MS2AV2V94Y22>Q,^VDIM8AX
M\:Y.:Y1VZXCVUS#1&>0:OHN):[?;E0K-9LC^[DE')4C'/N/=I(L3`3+%^M^E
MZLQ*L#78*$7?+2:T/#Q<4K(N.<"[]2-CVS%1\MSE%C=5>';F<GYRJAN<J/..
M8W$P]YIIIIIIIIIIIIK55RVD5,6#DP-V-;KD'.V>R62F5J$KU;J\%+V:Q3DL
M[R/2E46$1`P+*1EY)P#=JZ>+$9LENM631T^<BBS:KKI[36CA!XV0=M52+MG2
M1'+==(P&36;N"@LBJF8.\8BJ1R'(8/"4P#KZ-------------0#N;W`U3;'A
MVS9=M\%<[4RA#,&,;5\?4NUWVV6*P3+HD="1,;`4R"L<R5)P]5*>5FSQ:D56
MX=&0GYE9"-CW!]5EY/&V8MO$-G2[TQS<[1D;(^5V^2<_9&L>#<MX1KMCR;/T
MNO5^)J6/&&9Z31;=8*9B;%].H./X65"+>-S1D8P=RLLM<92TL8_8QIIIIIII
MIIIIIKY)!ZWC6+R0=BL#5BT<O'`MFKIZX!!J@HX6%!FQ1<O'2P))GZDV:-UW
M*ZG-1;HJK'(F;3SMQFSYDY09WNHVX9QR%F?;?F';18*WF2OY*H#JNUG#5THU
MWIKS`5<PU(V+%U!O=5EIYK8\VOLK8KG'LPY15:0MLN9(R85J*3S<CIIIIIII
MIIIIIH/'[W>_]?\`'Q?>X^'7YN-WV%>449;PMH>3FN--M^2VTGRF#:TUB[,<
MAYW<S54P[5ML^[6JXOJ>2HAC@>3@\48]J]-N-@?3<S#6*TL+!N#N**ZX$979
M-6O_`*12=XA0[X!S0X`/AX<.]Q\O#AQ^]QX\->6FFFFFFFFFFFFM.'*B8WV;
MYQ?PN-\HQV3HG>=7,1W^^;-,FX=JN:(G,E&NCAVA%1KG!^6J/$H4XEV"\QU4
M>6+',W9CMY*MMVTU?ZZICM)Y*-]H&$T,G-<-XG;9K=Q;_,C?&E#0RR^@R()P
MCW)B-4B$[Z[ADVQ"-R13FV%EUH\J!"H@T.EU(H)<P`D_3333337B)2B/$0[_
M`/2(`/#P<0`>`\/O<0'A][7EIIIIIIIIIIIIIK@0`0X#Q_J$2CYRB`_[]<_^
MO'_QTTTTTTTTTTTTTUP(`(<!X_U")1\Y1`?]^@%`O@X]_P`9C&'SF$1_JUSI
MIIIIIIIIIIIIKQ*4"^#B/E,8QA_HXF$1`.]X`'AKRTTTTTTTTTTTTTT$./#P
M]X>/A$//P\(>0>(>8--------------->(E`1`1X][[W.,`#_24!`IOZP'7E
MIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIK`LH1%]G\?VN%QA;(ZB
M7V4B%V-8N<I`M[0SK$FY.DF6;/7G@E93*L>@9=PUCGP]8NG9&Z;P!:BL`ZO\
M+7K=;D?=OO>PJGN.=&KVTG*NT-O5$9G%.*%!O%,R5B2HY@RK6[JZ@JC$R)9&
M9:OINN5*;JBL`XK@N(YTX;32S=517(L7<I1AYI0<(IC);DL]6_<9D_>S5\1L
M^T?"Q&09^>VQ9#RF>X8P?0-=)4:G6W%-:5)YCRA.[,M$R5DA:TQME_E&*JMH
MLZ.08VY6;;#DB6PLW)"9JH]5SI`YB5JV2LDXQ<T['T)D?;Q`W:SYXP5<Y=Y+
MK25>RSB>"QID=_:FPPKRAJ&H5K85^_3DI$K,1F_`N^O!FX3*$OARI.)^&R"R
MP_1]P4)!V9"O$/<\(Y"DY""K^1JXK6K-9R-F*4]'*0EAJUL[%\@U-^[B0LU0
MBVTW$N7E9=S6ZK*LQC[E1I#!UL-CCN#L!W6.@[NR@ZO9W<SN71VWJ;C''7#6
MW1LW6E:UC:HV'%C(8E>.5-,62VV4DT=!K7(Q!WT.-.5KP]";;<GY&S=`YOB+
M3M>VG;?MS.9PD\5)QDMD3&66Z@[.3,>)H!M*-#3],=7&H9"B)$LBRITA!/*S
M(.',"TKCB#E)*Q<-R@U`G'ON(WPQN086MI'A9[!1IW&T/7[]6,;/\KGQ#5,M
MR%(FKHQLLMC:[3K66FX&<J,=9'L?4825G+A%58R+=BZD#&&=I93=%G/:C>UV
M+NRT6AXRSUC2>03!JZM.&,JS%WI2C&7:I$*T4LV.\EXUM$++2#$C1J_J]BQ^
M[69IS"LNLXMSIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
MIIIIIIIIIIIIIIIIIIIIIIIIIIIIJB^`-LE_Q1NOWO;@K#:Z;-P&ZZQX3L,#
M5H6/G6,U1C86Q-%XE;,YB6?KNH^PA9V46C/KN6$?##!NE%(LC>:2YDB2H^#N
M35REB6V;*+*]RICN<)M2W'\H+G67:-*[:(\UX8[Y)W+<\E6(M9=^\+7G6-U\
MM/&ZLL[2F4+4E"-5"1L`H^5!MA,7R2UTE,9;:<29"RI1IFHXGW#\H9EW)05V
M"M4-)7>G;_:GNHI<]2JH[<2;L:M,4&'W8V@[*RO_`'72FGE.@E`BH<LN^".M
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M\Y5AE=JWN2VY94C+BK,7>Z8CR+7';`;E0KW5$8FKS>$<@`QI$T^CF\Y9U)IB
M5W7)"5,0XS7ON_//^[_FH(5.*P;C/9SCH2.U1?3[O&V3<HY0S'9G\<HFF>/C
M6USO%<H5=3>)HOG2](M,RB@:!EX)_);!]---------------------------
(-------?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g145435.jpg
<DESCRIPTION>G145435.JPG
<TEXT>
begin 644 g145435.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`[1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]02U](05!?2U]"05(N15!3_]L`0P`!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!_\``"P@!!0*F`0$1`/_$`!\``0`"`00#`0``````
M```````'"`D!`@8+`P4*!/_$`&\0```%`P$"!PD+!@H$!@P/`0`$!08'`0(#
M"!=7"1$4D9:7UA515F&5T=35UQ(6&"%35%63I]+3$S$Y=Y2U"C(V05AR>)*Q
MMQHB)U(W1D=F<<$9(R0S-#A"17.!H?`E)C5#1&-E9W1U@X:'L[3$_]H`"`$!
M```_`/OX`<==Z\8:S4<KE*H"XZS+>;ZTN%VPV"V`XXW'G2$PTHXD%`*&3!0L
M96UC(6M34DN8-%L&90-%L64QAQWW9+<*<?\`#$YG7!+NFHO%C9?1(XD:3D^*
MZ1@\U\\AYY_U=2Z<A%"TDRFIN5G):HR9RAEY96TH3:ED$%65&DUG#8=66<W%
M:B$CN7(YI=U('YO4M04>/%NIS4EO2]-F>$I/2T-0.JC:5#9^/6'+;'>K4.*1
M(BI6H+TC>2FLK=S%+%D/("Y:NH&0\L%TTJMJ=K;\^#'=2R_-BLOK3CI9?DLM
MNK3X_CI;6M*\7Q5^/BXOBKWAIR@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[
MP<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O
M!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\
M'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P
M<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[
MP<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O
M!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\
M'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P
M<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[
MP<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O
M!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\
M'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P
M<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[
MP<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O
M!R@O\OA^ML^\'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\
M'*"_R^'ZVS[P<H+_`"^'ZVS[P<H+_+X?K;/O!R@O\OA^ML^\'*"_R^'ZVS[P
M<HP5_-GPU_\`U+/O#S`.-/-#4G,T'2W49QJ+.5UYNKB,ENU'Q%LZLUU%52S9
M`BXDO"<MO*95%#-F,*J1Q&K+B^0T4PV9[:XKKQ@M1N"%D&K*>5M7K'L82(<:
M&BAQ8\[#5'T[V/+^KK1'+J#+#9U=RXDNE)05%)?LMXV:W8^E'$F9'J[UMJG5
M)3=LCR`XT1IGB&2W27IN<L++VIZ59'6$14EC5CJ!.3<]B#5-JRBTF6F(L;Q]
M"\:Q^VU=:3D)2<)=LQO%[<R+3F.MMNY5UUJB^;+(B6D6I1`MRW4A'K#6$5"=
M*LS&NI.6R2801K7`>0DTTLVI!F7FB3,I=%+,6O.43S!114"N<G3-0OF+G36'
M)CNQY\MMTJ['8FW9L/HFAT_P(AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L
M/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z
M"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(E
MW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B
M:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;
M'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=F
MP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?
MH(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B
M7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z
M)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@A
ML<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V
M;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA
M^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR
M)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/
MHFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"
M&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW
M9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:
M'Z"&QR)=V;#Z)H?H(;'(EW9L/HFA^@AL<B7=FP^B:'Z"&QR)=V;#Z)H?H(\F
M.(8JPW>[Q1NQL=U;:VUNL:J);=[FM:5K;QVDJ5XJUMMK6GYJUI2O\U!(@``"
M$I__`)#HGZVX*_SF8@FT````````````````````````````````````````
M`````````````'YCAPHG%#1\^:+D2)(OG-G#AO/B+%2A4MBOSF3)DQFNLPX"
MY?!CR9LV;+?9CQ8K+\F2ZVRVZM*H,/7WH=E(J\3T9ZP-,\A%(\9^>07V89,W
MQRZ,3/8I8QB*9GBY+T5PG+4=L6&\^`KW</5PIUQK/A+V&+LV;'9=8"/)*8<L
M-K"\(Y=:*\&YF/*B5541#EAK$66$,_G2EQ%4,-:6&DM;0U0L93%I%4RY-52%
M$OG)*),L9Q7XJ<*G_P#D.B?K;@K_`#F8@FT`````````````````````````
M````````````````````````````'X%9,35I+4D=83RBLD*Q`XFJB6?+8CI%
M23CQ?(5/)YTF8LR8#90X5RY2QDMFQY,)C#EOQ9;+[+[K:_/7K.CMR2^QM5$_
MH+04U9@1GJ\T&1#F::"V3!535-(^AC5=&TGZI3J(FIA/EJ@CW2&O3.974Q.M
MQ8W`U8=3+BUAZTN1*9+P\':55UJ5>$FEY'Q9L<'S/K?]\<&J%F7-D0GJDLK3
M/I[B22Y'9]]<="9YINV86"]L*8OIN;,F.@RAJ"^EYCB6=)*:A9_4H0D/,C(9
ME%<S1(-C:1"&*Y)4F:K*BU58NEYI6X#U%TL]4HG1.QF\B=FS)M4&XQFP%C9>
MQ3P9#>(R4E.J3,O'7B?4=<7'7B_V9N'\W\W_`"HU_P`:_P#2-.Y,R^'4==6;
MA]J`=R9E\.HZZLW#[4`[DS+X=1UU9N'VH!W)F7PZCKJS</M0#N3,OAU'75FX
M?:@'<F9?#J.NK-P^U`.Y,R^'4==6;A]J`=R9E\.HZZLW#[4`[DS+X=1UU9N'
MVH!W)F7PZCKJS</M0#N3,OAU'75FX?:@'<F9?#J.NK-P^U`.Y,R^'4==6;A]
MJ`=R9E\.HZZLW#[4`[DS+X=1UU9N'VH!W)F7PZCKJS</M0#N3,OAU'75FX?:
M@'<F9?#J.NK-P^U`.Y,R^'4==6;A]J`=R9E\.HZZLW#[4`[DS+X=1UU9N'VH
M!W)F7PZCKJS</M0#N3,OAU'75FX?:@'<F9?#J.NK-P^U`.Y,R^'4==6;A]J`
M=R9E\.HZZLW#[4`[DS+X=1UU9N'VH!W)F7PZCKJS</M0#N3,OAU'75FX?:@'
M<F9?#J.NK-P^U`.Y,R^'4==6;A]J`=R9E\.HZZLW#[4`[DS+X=1UU9N'VH!W
M)F7PZCKJS</M0#N3,OAU'75FX?:@'<F9?#J.NK-P^U`.Y,R^'4==6;A]J`=R
M9E\.HZZLW#[4`[DS+X=1UU9N'VH!W)F7PZCKJS</M0#N3,OAU'75FX?:@'<F
M9?#J.NK-P^U`.Y,R^'4==6;A]J`=R9E\.HZZLW#[4`[DS+X=1UU9N'VH!W)F
M7PZCKJS</M0#N3,OAU'75FX?:@'<F9?#J.NK-P^U`.Y,R^'4==6;A]J`=R9E
M\.HZZLW#[4`[DS+X=1UU9N'VH!W)F7PZCKJS</M0#N3,OAU'75FX?:@'<F9?
M#J.NK-P^U`.Y,R^'4==6;A]J`=R9E\.HZZLW#[4`[DS+X=1UU9N'VH!W)F7P
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MD()YS'.1X%53()LCXU`X2)W4_*9RQ+)89RV_ZN*ZE?CI]*U$J9:TI7W]1U\=
M*5_X,W#_`#__`,H#7N3,OAU'75FX?:@'<F9?#J.NK-P^U`.Y,R^'4==6;A]J
M`=R9E\.HZZLW#[4`[DS+X=1UU9N'VH!W)F7PZCKJS</M0#N3,OAU'75FX?:@
M(JU'ZQX0TMT0",C''ZOO%VXS&=I1?#412G/<M.4J3S8BYQ33(TAMHO5W6()/
M/ELP&W*IIJ:VRQJZTGE5[3E]A>[\6G'6M!6J`\NMY@F9':C^:Y3$HN**YRA>
M6]/,K)B3GSU+X%W''LU,UD.-9;=^:N'!<YFV46F\7-&2Y`XIEE#-84K;,:>Y
MIQ<7%\7BXZ?S\?'2M.*M*\?Q\=/S5"E*4_-3B^/C_P#?Q<7Q4I^:E*4I3BI0
M0G/_`/(=$_6W!7^<S$$V@```````````````````````````````````````
MZYG^$F?I2GI^HN"OW:Z!@5`````!?7@LOTE&A+^U'%/[ZJ.U9L_B6_U;?\*#
M<````,6/"G24XM-4'->>XQEN`H"<Z%J)AU5=SFG]ZOB/HXDQ#Q$'(V+8W=QB
M*VRZ)&?>93PGR1ANL5OIABXZ>1,1T[BS(:8LD5#U_!FZLU_7,VI&?DBNG2A)
MJC$4FI*(RW'I:,S&MM-MYE>-RAQ5P'UF<F,P7:7>1DLX3N)0PHZ3E0*MA32R
M_=`R=,*A0KE>&G'3CK3CIQTIQUIQ_'2G?K3O#6E:5IQTK2M*_FK3XZ5_]8A*
M?_Y#HGZVX*_SF8@FT```````````````````````````````````````'7,_
MPDS]*4]/U%P5^[70,"H`````+Z\%E^DHT)?VHXI_?51VK-G\2W^K;_A0;@``
M`!A?UEP!JK?L[Y'K74SK`C6$VNXHV>D1E--<'Z,YG3(T>C?:"HW7,Z%%#D>'
MWQJ,RK*L:6UPOF+-(B_&Z<;2VL)!Y/PD%.]+PVVT.(RFFH$C&UK6@]]9RF?<
MZ-:8<,FL2*HTD*-^YS>PDJL)QLJ*XWB7`B75,6F7"6+NUC)[LI<JFK39PZ1L
M(4+V>FF4D"#8>E::G7B.YVM$,;/N4'-A3,5F=1RM^/VJK.Y:Q)^')=99F/94
MU',XRF.^^VR\Q=CMNK2VM1\]IKA()^(P2B);W4GY%^N#5(D:"'TST5=2V%D@
MR)(/UVZJV)`MBO!N-%-.NKD<NGE/>^%OOI0F?#<]5R2C[=>-[:LC5=3&LC95
M=$$POIU2-KH@!].<\_::2M429%[)?BQ>0S.-;CV0=/D+3ZWD=V&TXDGX%5QL
M4Y*2RRLJW>5QJ"LBHR&96\I]>HJ*JA,VI1_H:,BH;;-D7=F4*R/""ORA-8CT
M6$7DN"76D:OQ5<*4@G$*BC=B3\]N%)JHT4S!B\H5P%,A@Z4Q9I.K,;3I6M.Y
M4D?%6M/^"*4OYO\`]H#3;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4
M>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R
M(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;
M9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&
MG]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]
M%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%2
M1U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U
M1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1R
MCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV
M1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#
M;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(
MT_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_
MHJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ
M2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(;9&G]%21U1RCV1#;(T_HJ2.
MJ.4>R(;9&G]%21U1RCV1#;(T_HJ2.J.4>R(Z]C^$8+9-P\)V\5(AA5<!?)!T
M&8[<:RB+#>/4NM2G)?6MZ8ND4Y1LQUIEMI9FO*VX<U:7_D<F2EEU:8+`````
M`7JX,`YA3N$;T.'S%AK)@*:G8KSY;")$ZIG+[+%K_6M*IR<7-*![/7C_`-0L
M2+&#.6O^KBPWW?$.T.LF1I^YM_\`@J2/XM/^2.4>]3_FB-VV1I_14D=4<H]D
M0VR-/Z*DCJCE'LB&V1I_14D=4<H]D0VR-/Z*DCJCE'LB&V1I_14D=4<H]D0V
MR-/Z*DCJCE'LB&V1I_14D=4<H]D1BAX3#3D41<IG4&AJ.NN4Y#DY]17%C?B6
M)>$?F_1;`[(XD-5)9W@Z%IGN]+8<=H!W"B4HLN(^V5U5=,@JK2;2;@M4W-CN
MOD[@IFX]VVU9R+/]F2`S%LQ(#6SX2LD<(*X>$87SR9[PDRPN;PR\[/=+[03;
M#%#98O'.?+D(DL^(TYD_\GC<N6RF4QQMU"=[?7&HYTDBO-MRHZFWW`B*A?&<
M3%A$6B)A,5DI1*9J78C1%13S1DD<+Y+:X\Q?/EQ7TK;=48^R7!;Z9*,U69+F
MOD=^DMC,<:?(_5W@\"YERPS#\./PA*,2M&+EU%0D,VGFX]D=#:;U2'NZO??(
MBLNL9C9'>[7*4:2,4+6L@G3\R-/R0^2C4,KRZX)2DMSS!*3[=QP@?=\B20[,
M"6G*#G<69(2T)"+WDVZWVTT4!';R`AM]N-%L-]O(J43()N.R[RS_`/R'1/UM
MP5_G,Q!-H```````````````````````````````````````.N9_A)GZ4IZ?
MJ+@K]VN@8%0`````7UX++])1H2_M1Q3^^JCM6;/XEO\`5M_PH-P````Q!<*J
M22)ECUH0GG1X`P**!-T6R!GKKPC62UG1>]&\EICAHJ)KK4D2B7';Z4B%ZT7R
M)#%>+H)V%'8037'C2;U%OHBCBE'@U=-KMTY,22"+BC'07&28^W:@.QK%>#WC
M%;B>(7&DXV<F(^9PK[>6%96QJCTS'"EY3*Y4S/:24FX60"UU+S2?GR79+``0
ME/\`_(=$_6W!7^<S$$V@```````````````````````````````````````Z
MYG^$F?I2GI^HN"OW:Z!@5`````!?7@LOTE&A+^U'%/[ZJ.U9L_B6_P!6W_"@
MW````"A7",K,RM[3WC5X5=TP,%6*R"SKW>\H&T\4U62DB,/W2G:M^]V`+:F<
M\B8U<[5'0%@L6;[RS(",J'735H+1=%,6E\9FCR1Y\:FKUAH2M%<LQ6GSB:B!
M$7&"JZ==B$?K+:9VCJ2)%U"3HK--L%W`P&*]+]0*I"35-'#4@K3GRJBX>BLA
MD<"2WC:@E?1'FSXBV'(8,9<>##AQWY<V;-DMQ8L.+';6_+ERY+ZTLQXL5EMV
M3)DNNI;99;=?=6E*5J,43,X62+GOI_E75.B1XK*\!MM\LJ,85?;1EF!)#OU%
M2+),E)T3L5EM9O,&1W$M1PYE=WN5E8E%O3`79KB:Y!UESCB1B%Z0NED^Z.G7
M48DSU27V_G;YEE27I_EU7A.8&.;5"JW:@O$BV&J_4510ULN63;W`SGI'SZ9[
MT:2\814(X;3%JI!51$A<2U5,*<DG_P#D.B?K;@K_`#F8@FSCIX^:OF#CIX^:
MOF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#C
MIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:
MOF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#C
MIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:
MOF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#C
MIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:
MOF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#C
MIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF'7-?PDS]*4]/U%
MP5^[70,"H`````+Z\%E^DHT)?VHXI_?51VK%E:>XM_/_`!;?YJ]ZGB&[CIX^
M:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF#CIX^:OF&,/A+HW>6
MI6(D6'H?8A:='(UYUB)Q2I">34X^]*"4XHXRISF-Y;'[)L9(RW(1=F4-&4I?
M)D&VFFBJ\Y&\1PG;%H@@N%LG>/<&U"IK2PDR`Q7UIQ8VDQ?E.0TU7:#!:.KR
M6]8N"0.X4<$<*VZ"SYF-MM5X(N9(+)E4M6;)5#L;*1A))RK8IF%%R9*792%[
M.KED-9,-],(K2]@2E',BHZHJ9$1-55;$3SY$U-4%G$FK.5)(GSMN`H;4\:0J
M9"!?-D-V)QZ[#0KEPAR%H#DV=6O*TZH<-1UI0U`/9QZ(I<I#"0\6XZ&B]YIT
M2:ARVH(@ZY*>;%;20W#:X_4^TS!Z>]<""HN3`QR+<7G=ES8TY-9+=O3HU@-^
MQL\=84Y2C@+HKVU>:DZ3#C8Y5235BL>L)EP[%D"1HV%E51J9491=QMJ127=K
MNRHI]41DU8<U[<35A>P(57"KR)J6CUOKJ(BN%0,NJIRZ1H11KR1)\O1+0,I(
MQ+K2*9:Y6VEKQ-!R':X5`Q[A4N3JJ>'-85,X#>(P2*9<,C5@J.*UK7D;H^.O
M'_PD27VO&FPF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;H
MZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.LB
M2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM
M>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL
M)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X
M^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;
MHZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.L
MB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DO
MM>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7A
ML)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8
MX^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F
M;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.
MLB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(D
MOM>&PF./F;HZR)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7
MAL)CCYFZ.LB2^UXZ]_\`A%C?3&QPG#Q24BT[82Q0?!N6RT^JJRT8I?>E./'6
ME3ZT>43]]E+,..W'BO,W8L5*5ICLM]U?6[!>`````"]'!AD"RKPC&AY,.4SU
M*']3<6%3-"QLV0,5PY%KBN_(G2&<L=*9/BI[G.5,8<^.OQV9+:_&.T&L@F./
M<V_]QNC^+3_E(DOO4_YWC=L)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR
M)+[7AL)CCYFZ.LB2^UX;"8X^9NCK(DOM>&PF./F;HZR)+[7AL)CCYFZ.LB2^
MUXJGPA\<Z!U6,T:4-=61*:+=93A14!FRBE/638NE5#<3P5RA)+:T>/Z#%UM3
M+<:<BIB+9S32:*F:P*N-,R*RHDYB:,8/$>1Z/]-6C.`%^7D_3:WC..1T=Q%F
M=,SB?[ZEB5)KQJ%$\DYT9#=+^GASO&3C#6/):L1<S4+8UR]E+!`]A7V[:<LR
MW'!>D`$)3_\`R'1/UMP5_G,Q!-H`````````````````````````````````
M``````.N9_A)GZ4IZ?J+@K]VN@8%0`````7UX++])1H2_M1Q3^^JCM6;/XEO
M]6W_``H-P````Q]\)@C+B[IA5T]KQL_9(=!MQIJ0B8HTF*%H+>32QNQ&<C*<
MSN2)`U"%E*)BE,+)<CG;AY)="(O6KQ!RF$Q.2LJEF*F2M9N"(SK>4SJ\K)C-
MDI'G@Q+K!4I+>TVZEM/^I*7)$25*)&]GCX^N'M,J(U8>CQI-A'L4VLPF.SVF
MWD_N81/N`Z5,N17<!W-F='HLKH;>`PN%,R^BXC383RJLXRV153\9A`2SV$\8
M)J2UAO,6Y4I/-X$Q2SECJA:6*Y\*>>RXLU^,H9NQ;VZY&\[T5/<C474=RMY6
MP<I2EUOJA%:1E,M[N_%RA/54PP:('<'Y3'DQ_EBIC+C]W9?9[KW=EUM(LG_^
M0Z)^MN"O\YF()M```````````````````````````````````````!US/\),
M_2E/3]1<%?NUT#`J`````"^O!9?I*-"7]J.*?WU4=JS9_$M_JV_X4&X````8
M+N%8+RZ2;KK<NH26."N9^A5,<T6T:K6UQ:4IAU$YUB2326>)75<2:WM0#`::
M\:P.+.H'&6CE6"M&R2?B,+9_-@RH7="SE?`MN^'G#&,Z(\*N70DX6PW)30[#
MM.#]TE//2/$1!96&`B*!K$XFH\5AU9W6_3&*F`PI.4DZCN+`CU1D;.E(N8E2
MA_+E(ZXZ6Q'SY<C'9IR17F@-!R++28">IHZ(>>[F3$<X<0FD467"H)*"DF'$
MJ82J3C4UE33TPC<;Y4=.%R^*_+;\=3M5YA49-X4DM),/SI'Q-QR1P%CUUB+,
MBJ\*J9\S%=\Z%B6H2BHGQA,\O$4./5F,<BOF*-E"/*K6:,%LMQ(K]-MXS9G(
M.'Z`^#NR*&:9.%!S-_%FQ0A=K]5\<2UQT+40LRZ6TX:?2FH;.TKL%^2R]'OU
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M^H'U-,IAHE./\G?C-*:8DFJY+[_RU;\=Q.VW';3'2F7+=6^M,&(`````+T<&
M)<HV<(QH?N2,1+.JVZFXMJG8%(QG*)^4W19_[5C.FBI8Z9+E[J\=,F7`3,Y;
M*?';AO\`S#M`;#FH#W-O_P`78>_BT_XY/CO4_P"88W<LU`>#L/=,WQV##EFH
M#P=A[IF^.P8<LU`>#L/=,WQV##EFH#P=A[IF^.P8<LU`>#L/=,WQV##EFH#P
M=A[IF^.P8<LU`>#L/=,WQV#%9-4^-=>*T2:LCP[.](D9;NC216?-.FQ?2W.]
MB2^1QK:<^6R\(F3K#\AJC!<+75U:.7:49[.D;.\&0^72FW(S9-%$]Q7?CX/M
MCZ>T!O2X[=/VJZ0-5:,\I`*E58X_I<09-,0M1CH!9J($")R6BH;=5&-CC=(+
M42SZ))2>>F0R?_*YY-<:^MX,9C!D,'JLZ$BFJ*U#*0EF*+Q2T@MTS)Y/+18(
MV%\Y2PDJ4R8+NZ)2TJ9,E[2QW\O@MP&,^&F.F++DLN\3=;C?:**G-MJH:.VF
M\D8.2I2$WTLBBHR85I??DH63TM,+E2!(O3)DOOIA*E\6/W=]]_N?=775K%D_
M_P`AT3];<%?YS,03:```````````````````````````````````````#KF?
MX29^E*>GZBX*_=KH&!4`````%]>"R_24:$O[4<4_OJH[5FS^);_5M_PH-P``
M``QW:AM!9W53*:HHS/J@U(X]-AIO-I+NTD1+(!F&(Y=RL0++)9T+$I/V.BB)
M.#L1G.74$\GFCM*DQKQ]DQI%#:RB+AY0,78;7P?I^@W36QR4:Z?XECR&V(2O
MIFQ-:.&BBM%*S'?R-F+,IJ)=')E<BJM&[<=MZBMJ^0ZL*.>MQ@^>,9\E^2Z8
M@`0E/_\`(=$_6W!7^<S$$V@`````````````````````````````````````
M``ZYG^$F?I2GI^HN"OW:Z!@5`````!?7@LOTE&A+^U'%/[ZJ.U9L_B6_U;?\
M*#<````,#NM)L:"9RU6.>)N%&FY-9C(;;'8;BTQPA*&H5T:8H6?2<H)REM,E
M0@>;TEQNGSA)R2[Z9V<KH3C6%ZL2-9%:RLAM%`S/M0=#EE70DUDI?D@CBTJ:
MBCLP<&S!:8LTB94.R2[IS4U^>E_"I-!P1^S-03S6W:>D_3?!;*Y1F;F*YR.P
MVDRU("PSL#]-H44)S.:^8%1HH53SU$JXI:J<D,]SKE"W/>0H?_(W\CJ=M+76
M&:DZ&?R535"]UN>N#\I3#=;DK;=3`$M<(;J#BV_73%-TG1C-<G15JFT.::(1
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M^EMU*7<=M,&(`````+S\&(I$$;A%]#ZLJF\!!,3=3<6FSYXS?3$7*%<2SQY<
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M0XWE,X0,%B"X535HL<1U`RD&\N%1P$54H:33>4M87/%\Y7)EQ7X^W;P>"',3
M0?N34%*B])$WOIE:?6CMN;S2;,;GVH:TM2:>G"$W2TF6DW+""27D&:U)0DI:
MJIG%9.7%$[G;F`DC,JTNW,%B=-^FU$T^X9>6JKAAY23J!F%?G.97T:2RJ)1R
M/A806TRTLHCH98RHT;[19D?LEG,=HH61763A5'0+#ZRM+;B5%E9/\HG^G&QT
M3\__``MP5_/6G_+,Q>\)LXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKY
MPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>
M/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKY
MPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>
M/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKY
MPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>
M/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKY
MPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>/GKYPXJ>
M/GKYPXJ>/GKYPXJ>/GKYQUS7\),_2E/3]1<%?NUT#`J`````"^O!9?I*-"7]
MJ.*?WU4=JQ92GN+?S_Q;?YZ]ZGC&[BIX^>OG#BIX^>OG#BIX^>OG#BIX^>OG
M#BIX^>OG#BIX^>OG#BIX^>OG$"ZD=1.GW2_&"C)VI>2&9%\8Y%)+:)M<>YBM
MB:K*[IRY4Y*:Y1.PE3YYP*:W7E.(NA)R<HFC9?"<S5*7%"QK+BKSH+DG0-+"
M=,KST%J;&56T>?R+AE+-&Z*XFVTL3]PLI'O(XB:`K)2&D)9RYI9D<R?Q-A))
MIN?(8L-G+,BMG.9;\@(`(2G_`/D.B?K;@K_.9B";0```````````````````
M````````````````````=<S_``DS]*4]/U%P5^[70,"H`````+Z\%E^DHT)?
MVHXI_?51VK-G\2W^K;_A0;@```!B^X6!2/(4!QPYF\[=1K/?+4U`L1T,,]I.
M@V,Y\GDXL(#6D)1<1%EM.7R"C'R07QQSA>ZJZW0X"]Q8DSTM=1^3JO=ZJ(I\
M0X*.4Y,E!`G8U*+MU?O163'?'MR*MZSXKTT0])&9LKL;)JVEU;C4TR8R#6.,
M,S<:,**.Y%I)QJBL?.JF'`JJA1/_`"29E8<*^D-5!6W.X#N--06XD*2ZMJ.:
MS+?A3TA')9U%2/9K,&/+FNQ%"1;/GR6XL63+=;CK;CQWY*VV74`:_"B:8EI"
MGI4=>*7X>6].A"-UQ^1[-,-O>.9*/MB:ELPUH1<S)92L1R*KS3)>=Y;,RF66
M1J9%RKVL]Y[C1V\XN-.I;&$YU9$[HSN4&CW83U>.I`<44R4SG,GV)3KCZ1VM
M@3#RNTG*2+&U).Y;1&76^XTM11599;[A;#A07(WUA31E8D<R^"?ZTHQT3CK2
MG^UN"O\`.9BB;..G?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0..G
M?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^
MG/0..G?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<
M]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0..G?IST
M#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0.
M.G?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ
M=^G/0..G?IST#CIWZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0..G?IST#CIW
MZ<]`XZ=^G/0..G?IST#CIWZ<]`XZ=^G/0=<U_"3/TI3T_47!7[M=`P*@````
M`OKP67Z2C0E_:CBG]]5':L65I[BWXZ?Q;?YZ=Z@W<=._3GH''3OTYZ!QT[].
M>@<=._3GH''3OTYZ!QT[].>@<=._3GH,;_"GI[N.:632BS&4SWBH,J0F1)AD
MVZX1=>HDTR+HORJ<A-MVLZ)F0HISF7'MD?;<:+10UDE50(L?$[3SZ<2$XFRW
M5A#/QAP6+9BQ,4]8[KT_Z;5&$X`D74`F.^,WXZHOD:%WG-%Y^.F]>]#]8WEH
MHC/A(CF.W?D4F-%9^YHL-JGD'`>)M%H]S4C(ZW5E7<:I>AM]<6L:.K.&](2%
M)4L0$`L7.+JW<GDLYNU(12ALT1*&E92KAH232YHZ3+9CN?!CSFRV&Z_/C^=6
M1HJG_5<TYKEP]HWU"1_J+K+^A.?5!*F;#$"2TW/$6B_5$UYB:>D*):->9GV;
M7E@DW+99>:TZ',2:Z*\)@>GNL>4BW%%MI;.R8:%XK?Z%).O/4"^&XILE.U7:
MKR<C1HS5Y-S(SE)1A&NGV%=/K>=#H0S>6I]NK4AJ,5KCSP-Y5+$EQ-;:FWKG
M"GHZ\:44))FG4RR3ZNBHJY@D!^(>"LB0DE^]Y%.-W"@4RYY<:9:U9IA/MA14
M:*Y:X[C-E\G=/D5#1`C=E(Y<.//A,\_K$"UQU_VXS3Y58=/_`&4CSBI_T4#9
M`M;\9I\K,/V>!L@6M^,T^5F'[/`V0+6_&:?*S#]G@;(%K?C-/E9A^SP-D"UO
MQFGRLP_9X&R!:WXS3Y68?L\#9`M;\9I\K,/V>!L@6M^,T^5F'[/`V0+6_&:?
M*S#]G@;(%K?C-/E9A^SP-D"UOQFGRLP_9X&R!:WXS3Y68?L\#9`M;\9I\K,/
MV>!L@6M^,T^5F'[/`V0+6_&:?*S#]G@;(%K?C-/E9A^SP-D"UOQFGRLP_9X&
MR!:WXS3Y68?L\#9`M;\9I\K,/V>!L@6M^,T^5F'[/`V0+6_&:?*S#]G@;(%K
M?C-/E9A^SP-D"UOQFGRLP_9X&R!:WXS3Y68?L\#9`M;\9I\K,/V>!L@6M^,T
M^5F'[/`V0+6_&:?*S#]G@;(%K?C-/E9A^SP-D"UOQFGRLP_9X&R!:WXS3Y68
M?L\#9`M;\9I\K,/V>!L@6M^,T^5F'[/`V0+6_&:?*S#]G@;(%K?C-/E9A^SP
M-D"UOQFGRLP_9X&R!:WXS3Y68?L\#9`M;\9I\K,/V>!L@6M^,T^5F'[/`V0+
M6_&:?*S#]G@;(%K?C-/E9A^SP-D"UOQFGRLP_9X&R!:WXS3Y68?L\#9`M;\9
MI\K,/V>!L@6M^,T^5F'[/`V0+6_&:?*S#]G@;(%K?C-/E9A^SP-D"UOQFGRL
MP_9X&R!:WXS3Y68?L\#9`M;\9I\K,/V>!L@6M^,T^5F'[/`V0+6_&:?*S#]G
M@;(%K?C-/E9A^SP-D"UOQFGRLP_9X&R!:WXS3Y68?L\#9`M;\9I\K,/V>!L@
M6M^,T^5F'[/`V0+6_&:?*S#]G@;(%K?C-/E9A^SP-D"UOQFGRLP_9X.OF_A%
M"*80.$V>"::<"ZY\N.$(.R55G'E3,RIDMO2G'9;AR7I*6CDJXL/Y.M<=;2-N
M6Z[)EOS9<MUU/<X,P`````7GX,4ED4>$6T0$,*@>2<IS4U%I?&J)=Q6Q2(7Y
M%GBH:(W'2IXG:9Q5IQXZF29K#Q_]\P7T^(=GY9$"U[FW_;C-/\6G_G9B=ZG_
M`-W@W;(%K?C-/E9A^SP-D"UOQFGRLP_9X&R!:WXS3Y68?L\#9`M;\9I\K,/V
M>!L@6M^,T^5F'[/`V0+6_&:?*S#]G@;(%K?C-/E9A^SP8HN%,@^-68N%]6CT
MX1J=-&R7E1$)BK44I6J9^P9$LTJB#>J94`NUD^,\1J2<$V'"ZM>E%C[%;<J&
M5Y)(IA(Y$Z^83B1O!-O!)H?Y>#7=)UY/7>D9I.>90]5(X0!Y.=]2?R=L-P@W
M2*_'RT^K4Q]XX:=I3%B<#-(O5F1TYZF#BLJ+#";AU5S$[<K=:4K2M*TXZ5^*
MM*_FK3O5&VEEE./BMMIQTXJ\5M*<=.]7BI\=/^D:TI2E.*E*4I3\U*4XJ<U!
M"<__`,AT3];<%?YS,03:```````````````````````````````````````#
MKF?X29^E*>GZBX*_=KH&!4`````%]>"R_24:$O[4<4_OJH[5FS^);_5M_P`*
M#<````*9/70#I<D74=35J\V*L*VH,DR4:.6Q)A.09";#A8K*1KUC/W#8AEHN
M=`]Z5%<XO*AQPJ:-0JM+M^?$64U$PGD2!,M.4:PNTXJ5'FJMI4?ZEG?)M!.J
M]'Y)3\DS*6SMU$L02=J0I2$X',LI1/*2QV932844K$S(HU,*>,GB/GU#.:EL
M:>ZIQ5K\?%2M:?';=2OQ?%\5*TXZ^+BI7C_FXPI6E?CI_P!?_7^>G\]*_FK3
MXZ<=!"<__P`AT3];<%?YS,03:```````````````````````````````````
M````#KF?X29^E*>GZBX*_=KH&!4`````%]>"R_24:$O[4<4_OJH[5FS^);_5
MM_PH-P`````-F6M:8\EU/BK;9==2O>K;2M:5[WQ5I_/\7?'RWKCG=[6TK\)4
M@(+I=J&TW!P]4?0I(SE+.!T'%AIZ>):FC1"T9E*EEVY5RK2,@J3.>#D;JH9+
MG+,*2@N14M)]S\5<>8ME0X.Q3/D97X2B*6]<8V%POK?M:,(IMN+-B0&:2<FF
M/3S)<JQZR\/_`&H@GL]JS.]7OG3D%)+84MMGUM51B%,90OA)D[*ZFW$^B",C
MIZ+'G=Y#I(<)':.#WW(J7QJV.6VKF+(O<DV7O.6\K-%B)/NE=DJ5P]T.4765
MQD\]+N;U?\U<=?\`8-Q?'7XMJK/I_B1X^?XQI[_YJW#?:JS_`$$/?_-6X;[5
M6?Z"'O\`YJW#?:JS_00]_P#-6X;[56?Z"'O_`)JW#?:JS_00]_\`-6X;[56?
MZ"-:/Z:Z_%2!:UKWJ2JSZ_\`_"-??Y-FX2[K4:'H`>_R;-PEW6HT/0`]_DV;
MA+NM1H>@![_)LW"7=:C0]`#W^39N$NZU&AZ`'O\`)LW"7=:C0]`#W^39N$NZ
MU&AZ`'O\FS<)=UJ-#T`/?Y-FX2[K4:'H`>_R;-PEW6HT/0!I5_352O%6!:TK
MWJRJSZ5__P`(T]_\U;AOM59_H(>_^:MPWVJL_P!!#W_S5N&^U5G^@A[_`.:M
MPWVJL_T$/?\`S5N&^U5G^@A[_P":MPWVJL_T$/?_`#5N&^U5G^@A[_YJW#?:
MJS_00]_\U;AOM59_H(>_^:MPWVJL_P!!#W_S5N&^U5G^@A[_`.:MPWVJL_T$
M/?\`S5N&^U5G^@A[_P":MPWVJL_T$/?_`#5N&^U5G^@A[_YJW#?:JS_00]_\
MU;AOM59_H(>_^:MPWVJL_P!!#W_S5N&^U5G^@A[_`.:MPWVJL_T$/?\`S5N&
M^U5G^@A[_P":MPWVJL_T$/?_`#5N&^U5G^@A[_YJW#?:JS_00]_\U;AOM59_
MH(>_^:MPWVJL_P!!#W_S5N&^U5G^@A[_`.:MPWVJL_T$/?\`S5N&^U5G^@A[
M_P":MPWVJL_T$/?_`#5N&^U5G^@A[_YJW#?:JS_00]_\U;AOM59_H(>_^:MP
MWVJL_P!!#W_S5N&^U5G^@A[_`.:MPWVJL_T$/?\`S5N&^U5G^@A[_P":MPWV
MJL_T$/?_`#5N&^U5G^@A[_YJW#?:JS_00]_\U;AOM59_H(Z_#^$2*2\J\)H\
M#CD;OO65+H0@ZS(D=V"2[^2Q6I3CKCS=T$_'B+7_`):Z_+;^3MLI=9^2]U6O
MN<EM*8-@`````7EX,@R?)\(IHA-):=W74B^IF+<I%*Y9A3^Z)FQ9X\13EQFV
M\N4_+5_U?R^:V['9^>Z@[/&U_P`T^YM_V#?^33_E59_>_P#P(W>_^:MPWVJL
M_P!!#W_S5N&^U5G^@A[_`.:MPWVJL_T$/?\`S5N&^U5G^@A[_P":MPWVJL_T
M$/?_`#5N&^U5G^@A[_YJW#?:JS_01/``(;3M/$%)+=DUHIL0QT2:\TJJTO2\
MW\#11K$>3EYR$<2:X5Y^I]2E2SL6UU/+E22PKK>,ZHJ14H3P'#.;&3*VX>61
MY&K#B=L%F;'#416<V2QU65+4E#)V%,&=77U(TM+ZT>R<=YE27%]9.G5A=6E+
M.;55E5.&E%3.&CAC+GOX5/\`_(=$_6W!7^<S$$V@```#'#PI[G<K1TH*BPTW
M&OM97LD"/"]BJVUI305.TN96<N,R7M4$DT3.6X#%G^IGPTS4QYK/]7);=;\0
M^:3;S.F^N7^L]\^O@V\SIOKE_K/?/KX-O,Z;ZY?ZSWSZ^#;S.F^N7^L]\^O@
MV\SIOKE_K/?/KX-O,Z;ZY?ZSWSZ^#;S.F^N7^L]\^O@V\SIOKE_K/?/KX-O,
MZ;ZY?ZSWSZ^&M)YG3CI_MKE_\]/^4]\]_P#_`#X?4OP<:^NN?1Q$"VY5M8<2
MT=L>W+%A>5#RRJF^3R$Z2V#E2DI&#1TQ^0+8L1?#^6SW_DL&+'AQ^YQX[+;;
MP@````````-*UI;2MUU:4MMI6M:UKQ4I2E..M:U_FI2GQUJ(&KJGTT6UK;74
M%"E*VUK;=2LGLRE:76UK2M*T[L?%6E:5I6GYZ5IQ#3X5&F?^D'"G6@S/7`?"
MHTS_`-(.%.M!F>N`^%1IG_I!PIUH,SUP'PJ-,_\`2#A3K09GK@/A4:9_Z0<*
M=:#,]<!\*C3/_2#A3K09GK@/A4:9_P"D'"G6@S/7`?"HTS_T@X4ZT&9ZX#X5
M&F?^D'"G6@S/7`YJRI@BB23AY/CV2V$^3R86PG%$FT7<A.,T0*&,UQ?`9.8$
MD\:REB^;/9?AQ9LUMF/)ELNQVW5NI6E)&`````````!US/\`"3/TI3T_47!7
M[M=`P*@`````OKP67Z2C0E_:CBG]]5':LV?Q+?ZMO^%!N```````!"4__P`A
MT3];<%?YS,03:````,8O"X?^)^K?K&C;]^91\M(`````-;?ST_Z:?XCZV.#'
M_P#$EA?^H_/\R':+[@````````/S'/\`P4Q_Z#/_`/TY!\'QJVWE)G_4L_\`
M"3/_`)%OSC+XAX/<V_[EG]RWS![FW_<L_N6^8/<V_P"Y9_<M\P>YM_W+/[EO
MF#W-O^Y9_<M\P>YM_P!RS^Y;Y@]S;_N6?W+?,'N;?]RS^Y;Y@]S;_N6?W+?,
M,T7`KTI269OXK;:?[.6E^:VE/^-:CWJ4'T7@`````````ZYG^$F?I2GI^HN"
MOW:Z!@5`````!?7@LOTE&A+^U'%/[ZJ.U9L_B6_U;?\`"@W``````"H^MO4L
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M;GK,8V.%;?C(7-)*J21GBU%8Y60XYR4*)KC13QFN/$M9K\F2F`H>S9:V8[:5
MNON]SQ6V_P"M6M*4K6GS&\J*?.RG[47_`!`Y44^=E/VHO^('*BGSLI^U%_Q`
MY44^=E/VHO\`B!RHI\[*?M1?\0.5%/G93]J+_B!RHI\[*?M1?\0.5%/G93]J
M+_B!RHI\[*?M1?\`$&M#13CI_P!UE/ST_P#I1?O_`/I!]5_!LR"PT?1C#J>J
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MI(;%K7\AG_,[V[7_`.9R?%\2G6OQU^*GCJ/AU,FRE3!BM#A2M.4F:_$:+_FJ
M8RUI7_OG\]*TK3Q#P<J*?.RG[47_`!`Y44^=E/VHO^('*BGSLI^U%_Q`Y44^
M=E/VHO\`B!RHI\[*?M1?\0.5%/G93]J+_B!RHI\[*?M1?\0.5%/G93]J+_B!
MRHI\[*?M1?\`$&8O@;G2V&_*DU9UQQH"/ASQXU<>#*J+28GXLV2QU'[K\>+(
M<-8;,E]EM]MUUMMU:VVW4K6E..G']!VU6,MXC%Z8-SUF&U6,MXC%Z8-SUF&U
M6,MXC%Z8-SUF&U6,MXC%Z8-SUF&U6,MXC%Z8-SUF&U6,MXC%Z8-SUF&U6,MX
MC%Z8-SUF-=J<9\5+MH;&]S6M:4K[[VYQ5K3BXZ4KW3XJUIQTXZ?S<=.^--JL
M9;Q&+TP;GK,-JL9;Q&+TP;GK,-JL9;Q&+TP;GK,-JL9;Q&+TP;GK,-JL9;Q&
M+TP;GK,-JL9;Q&+TP;GK,-JL9;Q&+TP;GK,==_\`PCMPM]8X4!Y'DI>1%(G?
M!L%V6&B*NG&R]U]J6YKKK;<Y<SDQ776VWV5K2EU:TI=;7\UU*UP2<M(_/R'[
M<5_&#EI'Y^0_;BOXP<M(_/R'[<5_&#EI'Y^0_;BOXP<M(_/R'[<5_&#EI'Y^
M0_;BOXP<M(_/R'[<5_&#EI'Y^0_;BOXP<M(_/R'[<5_&%[N"[5T@EPC^A@X<
M5DHJ5+:GXKS&#)A2)8<&#%:M?ZV7-ER9[<>/';_Y5]]U+:?SU':5V2K&7N+?
M]HC%_BV_\<&YWJ?_`&F-VU6,MXC%Z8-SUF&U6,MXC%Z8-SUF&U6,MXC%Z8-S
MUF&U6,MXC%Z8-SUF&U6,MXC%Z8-SUF&U6,MXC%Z8-SUF-ULI1I?7BLD)CWUX
MN/BM=S=NKQ?FX^*BE6O%QUI\?C'/``5@U?Z:R&JN$ST7Y'(99+C2WQ%$MQP]
MRI.Y2O9TKP9)S4E^,G`92K3J=<L(Y5Y,U*P.)&QJ*=G5VZ;5DXJIIALS@4"W
MI]*NFD[!!W4$_P!X.4D[Y=U1SDHSI*:PD$CR:VTP]A8S(BIC,=HDE,Z?4K6V
MQ(SCAI(.(^HF+3J\M6+KBO(HN!6+("5+\G1"UI-)$\2DEH%JF5<+)6*K)YN)
MBL?RI[0=J4YLR'7.9LQF*$U?`0-).6VIB_!@PJ.?+<5,V5REL_NJQ7&5:UKL
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M:5I^<<+CS3_'C(9Z.USK69KB,I=I^V]7-,M`PYC=#BLH*5GN\64N=OL_(6';
M2MM*F<E+K<%M]/<4N]Q;S395&6[MB]#VYZL#95&6[MB]#VYZL#95&6[MB]#V
MYZL#95&6[MB]#VYZL#95&6[MB]#VYZL#95&6[MB]#VYZL#95&6[MB]#VYZL&
M_9=&V[]D=$F[ZM#9=&V[]D=$F[ZM#9=&V[]D=$F[ZM#9=&V[]D=$F[ZM#9=&
MV[]D=$F[ZM#9=&V[]D=$F[ZM#9=&V[]D=$F[ZM#9=&V[]D=$F[ZM#9=&V[]D
M=$F[ZM#9=&V[]D=$F[ZM&E8LC2[^-'K'NXOS<;1;M>+G3!MV51EN[8O0]N>K
M`V51EN[8O0]N>K`V51EN[8O0]N>K`V51EN[8O0]N>K`V51EN[8O0]N>K`V51
MEN[8O0]N>K`V51EN[8O0]N>K!Q$E`D=E'VXGC>TV7F*+C6:;=PH-S+0*%T[.
MVE-VJ!A4Q9:E;\=^96L<I<MFQVE,-V.Q)PW7YS%,F/&5Y=LJC+=VQ>A[<]6!
MLJC+=VQ>A[<]6!LJC+=VQ>A[<]6!LJC+=VQ>A[<]6!LJC+=VQ>A[<]6!LJC+
M=VQ>A[<]6!LJC+=VQ>A[<]6#\>>&8C,Y*Y3$71UGRUI2VN3,QFKEOK;;3BMM
MK?D2+KJTMI^:E:\5/YAX=B4.;J8UZ!-'U,&Q*'-U,:]`FCZF#8E#FZF->@31
M]3!L2AS=3&O0)H^I@V)0YNIC7H$T?4P;$H<W4QKT":/J8-B4.;J8UZ!-'U,&
MQ*'-U,:]`FCZF#8E#FZF->@31]3#?CA:'\62S+BBN-\>3'=2^S)8Q&G9?9=;
M7CI=9?:CTNMNI7\UUM:5I_-4?OV51EN[8O0]N>K`V51EN[8O0]N>K`V51EN[
M8O0]N>K`V51EN[8O0]N>K`V51EN[8O0]N>K`V51EN[8O0]N>K`V51EN[8O0]
MN>K!#4X:5V++K33VTE)S38Y@DXB:Y>K)[&1#>8QA*IJP0N3[L1>J3=3'FO5,
M9F[)<8OMI<3LM_(W5OI?CM&```````````PT/'A&%;3OJ0X1&Z>S*RN:<=*:
M7H7L:"5&L9X%V0":QJ[-NA#/FW`9++)7.XDE(=:6W$U'QD"*>=(D%@[4Y8Y#
M_(:XN>F>%,:BQ+L"0\QX.F,VYI(UK2UHME1.=24TV^J0T]8BT[*NHY0/*1;`
M^%$BY2CKCXRS7JU#K74UI,RL527CBKG3GDDD62J\P;W"I:;%LX]4511I=9KM
M:Z+I^76^Q'HQBB&_)+*ZJ)$=\50$G,]GT<9M=0W=(3W92RG8X]E<G&C_`&FE
MTPNQ^-EK-'E:Z3WI7"&5<NJ?3AIL2=/4UMS+-:#JV4G0MR4W4EE&X_5M*#QC
MUB.9,[G&7*8Q.Y$45:0D=:39#91ISQ\YVJKMI5C]Q/"BJJVMS)/3XZ=[Q5_/
M_P"L``````````!CTUF:GI!CB9]&>DR&[$9'E?6G(4H(A:270E>^%`B>+H*C
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M`:U1:)XTT]FG(8C1Y:])"TESV_##*:9^-G2M,/3M-+\=\;MIU*RU<]$QVL1_
M,-&3U!81FB7;*N>2WJV$]WG51K+:9BMC.&NJ)=/DHL6+I!;<HX[GP]8&CG"_
MD]GEK8Z2GMJ4?2W&\0MVY<65Q%4G<I+CL03)1QE8P0G[EC5..HC@DVQH("XE
M*)J"FKPNVE==<V!%<R9,,5H&=7UA-FLD2A'Y=N1^6=FA/*M9]2#9/J1!QKBV
MGG6@W&VXW@24SC>PMI<0F\N%$]=O=*4=;>'UFF'6+)\[\(!/\7&4IZ-."$C1
MMI*GZ*FC(K%:#6=/="9WU/"*JNW`H("ZXEU1;[F;K!:Y@JBNPRBN)I+6)=;R
MXU4%8)&L%\1L+71*2[K85]-$HR:D0!-"3J"DDDV]+TJ1%>@-K49I`;O=?WB2
MMI1G`[GQXI:DE60\;;>#Z2TIQJ9AKF\CV82C$C4N;I1YY)68G#):2'>W,+U7
MD^98M89Z"9_U`H+YDV.+49!=#0TN28G1).B,WRZ&X7*X3CT93T7&R1+MS.A%
M;GA1TH>!C'7*I9#R>1Y:^.%1@N.#BZUWC&T_),KMF;=/\#K<)X&.U5N2B;KU
M4(ZBJZ?%NW$@2`ILXVR9-,HJ\WDYRDGB9Q(#J;SA;CR*MM20E3&6X+&_"R,5
MQFM0%LCP[)D/98NU')FFV/&D_CT6-M\2:^O@SL;4DY$&ZBW*)!C--RMYKN56
M/'R#E>B2C%T<F@X:N$P[W!8UBD(:Z>%E2">AB1YJT3JCR6I$18-@34)[Y=FB
M(IID/L6;I1+,]DVS$UI#44@ZD*SRQH+_`$[(@(J([',T";<47BO)":V+$M;4
M,[EM:UI\?^]=3_U4NK2G_LH-0``````%>-6VH=!TDZ8-0.IUS(B@YD.`X>D*
M6E!LI1C$34W)B8K94%_&WB![/A,%R!M<,D\"5@4#.#,5(7FZ'#.+)@P9++J\
MQM9K=OCZ$)H>4IL)>4W'@;S^U!0NC18GXFZWV8NLA5<2HQ8"<));O>)MV-->
M-MQ(+..05QW%'^13%LR60V4:7$W&AQC&_"_:<I':L:O;''>HIH-6:85E>?8:
M7'M&:,D%)3CF%8Q0)5D!3:F,B^58WB,)B$X2B<4*N,L@VJJ[B,%2!C,0N)J9
MSF%O"+Q1,!4RQH"S/=2?#JTZ-2:DAVX6PU3B?%2),\%O29H:=DC,Q==95YE4
M!:26MR+N_C9RO'N!YG4I@KCK(N$]E(%Z]Z,^%QCAYZ8X36-2N5Z,^<3FC/1=
MJ#>"LYF:W62TIA-ZI329&"*XHH-X5\NWB26M3M0^SJD7A6/2Z+C.)KGNQXH[
M,8G7;SR5^%&C9T:9Y*=&G;#(ZM.%L-ZO7@WF0ELMGN1X1L8THWY6E(C]=R4J
M.^R/7"S&K(:HTDE%--1XO`G+5KA3\L4V/DER_,2GN)=6:BGZ'-'VH"4&^]9)
M?TZQ!IO/J:;%C1(&S"U(LL1>A.Q:5#64T>;#`CIG835ZXKJCL?+F9C";A+%A
M)&%HL<.HZ<>KRI<-=I*+,%O28AM34$]&<O:/%+74856G%Y$Y8V].S5?6./Y)
M<SAHI/%)MP*\7J]3)UW-Q-O5%(XC$#!YDVO#(832Q[UFL+A#%A`?VFUH:9SZ
M^I)9GA&M)FE:?I"P,IKKL:ERLU)J<[G+$>987U7"Z$=Z6L%TL]<,.5L-0^D-
MM37DMFJKE1WB;S(Q;DW"#ZR7KI9D^)BCZ>"MINTIO1AO.B[K!*Q#DF5C1_/^
M)R-9(C5C3O2S`?*1)$KB1U964\SY5B*4GN)9+VM^Z2(THEYCRWYW7PJL2Z?B
M%K1G=,?[Q><9:>=+TZ3S*D),(BXX*3V1J&<6>-BDO-%?J]+SB]&A>0T9>RYB
MS9+NASEFMAN5D=+=!))6SI&8%[A)]/R"]*M;,ER:>0S<M3%IY;4F)S1(YX\>
M6HR"V:YGK(,$-D]F<)9QF'Z4(L=^HB*=4FPE,-R/-C.EDHKT-N9.L3C-<43A
MB8^=KOTBY4:"9L:<(:I8RF><2$W2RCM%D(";"L1P:QYL-2,F(^!\K2XJ-_(B
MR`EWJAG,0+&R.)$7RI!+5E.])P&YL9_"HZ8GS193F]8_3KU+OJ%(^9T?%D=L
MJ#BE5=U"MIPO")MG:PDO%1CXU@7FZRG^I.+$Z7LU%.+RK!=N>5TYD8$XOE._
MKX+[4)+&I73N]WY,QTX;=[?U7:Q8E*XE1J-]E+B6T8;U'R%&K*1'$W&P9/(Q
M!R(K9;J<G+]2JBJ4,JQ<V9JJ*%,MIO+D;```````````````8KYVX+QL3PX]
M8JVMS0^4$IK,II0QO5)16TSLF-H8='KQPO2-O><<4BQHS=G7#^/(5>N1PT6<
M1\GFN[A%F]GLLRT_;GX,-IYI;.S1@FZ4$1Y&-;CLUODS#>3&,3PI+Q?NDW#H
MT>#((44T%;R8VJ>B,F0,I2I?=<[D!YX<K@(KE]F7$1*U=0>`T;*8V>YRAJME
MTZ]D:)M-S(8LJI['BU&?;9DO2%J%D+4-`>H%7/41U`M($J%G%([@(2N>>A=2
M+3!5265EP5(J"GBL3;Z-_1.IV2SI?GU_ZAI/D29M/#>U!MA:<Y]#CQ&0Y21-
M1^6,S[O0%!HD&UF(,1N-Q3B%C58Z<Q32<?3$TBIEEM9<2NOJ[A,WQ_\`;_[^
M(`XZ<?%Q_'^?B_GXN^`````````"I6J;24V]2F>''H4=J]%<X:<)"-2C`<S-
M-/0E9=8CG5FJM,1V)*@AN0D>178P9!9#A5VF_F<H6E+5E+,%3J6K(#E1D%?2
M^!2[HP<$]I$36RM.SD4W)%&H^$=2*6?;3.0&\V,J[`3@4W(S&H39YQ17Z);>
M5U%4S9'LI7+RF\%^F(H7*N-'3T],($H9</!>)JOJ3SSVE:AI(;*-76PV->1:
M,TYI1P?3,,S)FES)I,<Y/,Z%Q#4E\PT73&^,EGQ)=M"QQMK5ZP=2U#-F/)>9
M`X8U."!8J`]6U)!N65/&]4C4I`.J!RYV/&3#C=K25)NGQI2JT$MY/IBMZN1L
M9))E0E+Z^8G22FN3;"[(9AMQ[9B+(!9ITQ*7[8^X*"L-K#)<L+:KICC-TIM9
MV;$DN!+:L8JIJ3HFGW4B_-5BXR;RJZWU`BQW(Q):DQ\YXNDQJE\;B;C=<JDD
MJY)RFK4]5(>X1N"N2V[-35?J'J*DTG%3"UQ/#7XQX2,MQD*Y)O3+*;'DQIRX
MAV2`KD#KM-1V]E65WF]"Z!?9C5&VX'"MT3U\P4SI%B#[34KP8Q;45/RA.1K4
M/(K:Y2KZ/W6CLW.UF2]4MC.W1U.-)J:AF/51T%<JDSFU(:E=4O*;32Z6E76K
MD4-RFC]<J11)-\'5^!PB!W)R4W'Y*LBNAI6R5PB<B.=`M(MA!N=MO"6MJ16M
M.;8,JR04QJ".D-U/E!TY8Z-HMQ982354W(NGG!B(W83$YZ3M!C@TZRZH3:^]
M2C_GU]'M,4-Z5,AMU,J/VB7,L6"7A(CI8KD5:-1/M.J3ZS62,LE7.K5/%DM<
M.93"I8B$+<I%.2?/(6@F^79`BA=E::G$_F)!6J0WJ^B5H+#'9Q=S-&3RYUU*
MC2;!>3TRA)?NB=G*;N/YB39*IJ>[EQ,)I[1<TA*S(M/-H_66_@3(36(HCZ%'
MC+<H.1@,2!-;.GZF#"3:""O+#?UQ2JWIG?+GS+:<EY*)COCU^LYHJ<9'$PCA
M2R&%#MP.1+<=YPSFNE5Q<&*0D!UI,JR=.SL=$WV37H\F)R2$F,QK-PFY[-#M
M[K4(89.5GVFU5/2V^H.5_O\`>,@G""A597'$\E:QO'&@W2B&@)7G?W!AIBN_
MY.F",-1,J1-*[KU6).LF/'(4;L;NY&BR8,VG5(TKR,2P-E>;6.U]1]*T,I&%
MO.AINU6RYTD[=:NM!:058O@-6QY/_!$E)QMF,O9JKF5K%-3T`11".J*^]MQT
MZU*756$7<L.R.98)F%E&PIL?/@E8YG&U5I/:Z-1FJ;0SH241;J*8;2>H7YBR
M^*_#@Q8LF?(9R8\=EF0QEMPV9<^2VVE+\V2TOBPX+<F:^E<E]N'%BQ6W75IB
MQX\=+;+?,```````X'*48L6:HU?\02>W23NCF4&8YH_?;74:YJ$7"T7@C'$!
MPHYJ\ODPF<6)02CYHM7.6S831>Z^TP6S8C&+%DLK-!NEZ48;9+2BL]J=>DAQ
MS%S;M:D8XG&RFFG/SN(BHEC<8I*6'RWLZ=AE3&ST?$5PW9<379)MYFT\DH/P
MTXC%RCW2J<>X(AG6P;HRA5L3[)#<MT9PE-^G%KO+WML1777I#T\Q5BBAW)KD
M(G4VU#(NPJF)#74T9V(I'!B+'T<WCSH1C`L9[2O[DC@G&X1RZ8NZLU+3D,:2
MXI8D91"]5"+HX2IB1$YF02Y8(4V];*K5+H"QFB"3$IP%W9*4)*">HL]U.YNH
MAW"82RU5<NJ\8Q\#+'9=I1VW$Z?I=15.'='NEG2?$SQ24E@X'&S36C&9TN>H
M`FO_`+L0E!)69!0Y`14ZKH1U!,]X;N;EIU!.-LG8HFS=\AR1P:+JDI49<AJV
MKF4"\Y8X.GG3=,LFXV)'6=+E^%]0%Z(IKK/Q1ME)V-..K6"Z&PAK\6*39J:.
MH=W=XFZKWM<Y%([63'=H#++6FC1IIP;\X/UN$-'#FT]+B,OYT)H+Q274F`&=
MF8Z>T9?8QHD3:3E;JTF9\+CPD\!8I8VI$;[,?*9884FL4P&*FM3@1XY;,0*,
M.7S_`"<IHBCH%G;@[KU/(UV$44\$-SU*)R2E]R8*8"-2FT)#J9HWT11RX,K>
MY#;D/'VX:4,EE^#GY_@E4[-(/=Y)U+2:@QR<U8:;]<"Q%A5H1^H$3&I.`VVS
M6HKN9)<ZR04%A!:<N$&"V55YLHO@,E4ISX5)5:BFE$53,C67?G6`WW*:F;/,
MZ:S[!35V,'A$[O8RW'C.E*.72A/#)QY%U1:CIJ3K<ZT`O><(HF7,IFFF>3U1
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M^R6O2F[$LBGM5.34["C$W*XU3(FVYK#!S'A,5PW&:%L18L7M=^?\P```````
M````/'FLNR8LF.S+?ANOQWV6YL7N/RF*ZZVMM,F/\KCRX_=V5K[JS\IBR6>Z
MI3W>.^WCMK@X:T_ZI4?6M(W!N2#J)OS.UTNDEJ7@?4[1`@Y/7KM)R260SD@Z
M:\C!)L:K24]2[37KK4^AY1:63&KP.]<4]8<914:5K25Y"P<**ZT)?UD%GCIN
M=ES=TX:O5+3$U%Y%>$=$4$ZFMK3&S-0BJ^94>SG=R4WX\+N`LNU3&AC/E,6!
M9<CPCB.25YQWGW!<C>E=G#8PJW&UA?Y2!M0JU&I;23I*UP.5[X"D5%"[<T[Z
MN7,M-1JN#,WS,FU<ZHZ&4JH*IA=[(3$O*MFNYJC>TZ.`O8GF5/GRSPK2`@.$
MW&ZAI>U`9YH*:S<&B"^+4A3A!1.UE%R:93^K6-UNKMVKEV98S'Y$17&9HJU6
M*YV<O8U-->A9&*)V)34/UE^%:9*AIZ9&H5'TZSZK$7;(*I!1B,,&6'2<OI^I
MI!E]QP>NZ;DIG*DI$;'G)J0]VBYCQ\PUE(\R2C#1E"0CSK)-<@J'4^4X]X0E
MDO?5WET?*D8R(Q'R?1)Z7FHH.DRRJ57$W3B[HZ9K[55-I);F/O5GMUUFY.;S
M@AAQN-%+IDK,K`HNM(O3R'<NQ4CEES7*^J?7;K/T^(,E.2#XGT-%]/[*,VQX
M289Y\R[+$YQCAFM5<;A67XSWGA;S`83-56HW&LVT%%)F70ZC3N57*O'4I-2D
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M3XZT^/Q5K3C_`.BO%QT\5?C^,:@``````/0NE*45MNK20D.579RFHIQHJ0=*
M"603BR@&\N.MN!532CI1W"W#)LGD]SFQ%UM$5$W/6W\D;)Y<5UU!A>T2:EM4
MDP2D\=*TP2T4-3?H!<[KQZD'*T$R("=-;J"ZE%SEH"<$<MVJ&81XW8AQ.3#*
M5,QA&-MI<CZ<VDKPUA5\^`JXW`6XK&?#;IUFE?3IJ/GK3K(3+3IK2$ISKBBV
ME-DF&<VDEYZEBFGEHH;14UQWE5*5'PE&UY%=#U:+8)8%]'9"8N/3.F$K%%K-
MU7G_`"<+$V,\EJ4:H^F:>E(U9J\E_0BWUV]3A8FDN;4U&42WS2CM8GANE$PJ
MIS2D!B)ZXI)#_5B!1#;F9-QD'?C25(W<1*1I;PVT;+3);3NCW2KJ@DHVHZ3I
M3UA.IKMG%"15:9,;P'-AZ#)U13U[BE]%3G`]H^="(N&R:(U#:OCD%/P)V./S
M:^>4#!9+M8?X0UFW/Z"6<T(=F"2TO4@S\LGQ0Z8^P,-<[L0RGQ>C2BNS6HLO
M(]B;_1(S1R[D;+#M4E!MXEQ=E9UM*/VVWU99<:;3)['1EK[8^LE?F9F(<?O:
M-WO"";#:\\6V\3[+5\Q%)G9EJ3V9:>>-LIR.`JD/A"+HBVW9+8JG=@56.[4H
MRDWFE8M>64LM3X=UW2G%D_:SX5U-*F9^IR29D&;]$RT41&XWUV2(N9DHE].K
MPT\74;B,CI:G)3#G8S'J6BJ9TCF5W$@3ZQ,RF;,94XWG$1:6^$(?"5!ND20M
M;\H/[&^Y*U5<)2T7TYHS;T2H,#-I%T<%=8&=99TBIER+FD,S&C0C.`5IWL]3
M8^-5?:^_6HEGG@\,Z,?R-A8M@ZN%#+LF.4*3G#I(U,86P_G-I(1(G4L!:*^Y
M<A$]:+YV>Q-D*+!^14U/2'.@.`R@UE5@G,F9S,1,>#25ZXUA-43QI*]X:X3=
MEHJ_A(NV&90:K=:TXZ?=+4\NTXJ1LK)4`:E-2*#'RHR8T>-[;>2P5<B6@K$M
M1:SG[(;#47`T&ZXY!0+BAE90B3L66S'7_9AHB,HYI>;D0R>_2&35%&&D5-),
M-Q0\K.@A-,GR0_8P)L61F@L2(W7!$ST;2\Q<)]VL]\%"*LCMQ\,9Q7W7HY]<
M.-ZK[PX5"1G9J+TI*T7,"=TU/3L/";15JBT6J6&"2KQ*3GH^9$6N8D0.OTTO
MF&D8L3"KIRK39=#3E\TQ'8W'<VCN--.J)CW)2ZK,X6""I.6(,+Q>RI6?Z-,I
M#3"=43C?;'*U^,<>L"-$^4X8.O9HELQE0L0,+:7&MEE!S)ALTBQ=B=R&KN`Q
MF;Q=RJ[=CAH<,4QGI%[<DPEIQFQ`QR9;-.:#FNZEJ(\+CF/%IO77JVIS*MTL
MUGZ[L:$J-!P-)-0$0N[KD9.?BR_V/B:BN=3#3A5VY8N+N$/C.8-0K:T]L]FO
M,JYUJ-V#**PFO3,VV!(C-:$DQ-26FRZ7-";M5TR5L3+LQ&",9N)W)S?/IS3F
MHQGC5R8DU43CIG'D%`````4'X4:8Y,T\\'KJ_G>''5E9<H0[`[^DECN&Q&;C
MAPDW$TDC*J)]AY$=B0MH:FFF<N*F`^4-$*WY2U]]"QDIG]P8LA"1^%*9L%2'
M)T2.F&Y\>Y?3JZ-&S!E^8"6QKN7F,:TCN9G0Z\4I`*OI`7W#B6)%[FMESI2(
MS$4\W\RIE7.X!-M$\.<UX$GA8V\MGV&QTS2_/1V9GKJIU`Z,S$8X%F$:7-:=
MH`AM6G512EEYYY1+M4TV'C'B=8KMIUH9E4($KKC1)TX4)3*X4]0XTPN&JT_.
MQOH+W<<93%',?OO2V9U31F[G268IS"]D%!F&,]/CR8EJ*VGDM+S>>Z!,\P1^
MRT^JZ1+-AVXU8RXV^OYT$AD-Y9/MX1Y%>J87CIHQ'-!+4(\73J'8C4CTF2:J
M4=/)6GMM-9=?LWL"0GYAQ1@ZXQ+$9(C?"QW68+GDQQ/YWIC#6$`FH(;ZP-ND
M&B#A+G,H03I^=LQ9=2TWS<I<%[I<U,OI';Z5")*,WR=F*9CD7G)%*8"N)MN)
MJ.]'<V4X;E]=<"BV8B8<2MXRZDY%SU2E,_EGA`X8%`?,G:34AJ1>=3HHF-5X
M01'F=_KCE:"K9&)W0`H9&K(F=N9FRY3B8]VH;7;<CM3WH@YE+$LL#"2N14`P
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M2,Z%]@U/:@L3E:Z@]'(H3*\F6X5-W%VV_F+C9#`5VTG,DPE.-+5'BX)-TM<*
MN@:BB>E1".P!+#1DC5;IPA34FP4ZIAE'&*OL9^I%AB8%IK/$RZ2)D\CZ:5;*
MEE)4*KR*WGED3WW%I]G-5V7ODM@*2#EX3^$D-ER`]Y`9\E1L1AM]:I&?-R6Z
M"C2-KT2I.DMF^_A_R$YDUKNI?N/LMTHBK'AB,KFUE6G$\<,QQ,;L;Y`FZLV9
M*]F;U^GD14;3$>&F*;V-+DF2>S(MA-CNC*Q<"1+:L\8@=TZ'%)N2"F.54;)=
M*C!@L%YVS+<9IE-LET(>-OII=UT<3345VHVHWA6DM]:.)W5]+:++:+J.0-(F
ML.:EE"+D8P(OG3$?TP.-]0L\%!]8WV:<4<K+C;T],EP-A&:J1[Z[7PBM-T.9
M`R7I.%&.J4KQAPG36369%>)]-9^NQ'17/HZTWS]/:=:U,;28^I;53%,/NUD)
MJPBU522\>;R@LS/%J0\G6B)-$YF..3V^2,)N=,2W>HM;U;7X9V$3MA1=D6&Y
MPAJ/51EZXG4DOIZXHR5R1I1X/>13D>ZAFGF1V%(CM6":R3,EN7LX[EPW(#MK
MC.)1!5M/X"G=&\VF35`FZD<<H%L,>OR/U>*GP59JI:Z4K+D;+J+JK81G<C.F
M.WN3P6MUZ(.4@LU1%RB;FL4VH\T1P-A=(%\I(B=5+2@`````````\6;'=EPY
M<5F6_!?DQWV6YL=N*Z_%=?;6VW+9;FQY<-UV.M:7VVY<63%==;2F3'?96ZVN
M/IV<'1%[RCQ@-98E*;;7]&VI3+JN;FHDBJQN5G^DP9U-3N-*!MVVQA<VLB`?
M:BGDB=4;&!F%D93A<H0BLZ5S-$I80KPY[\%M#+NE]6FA/EC4"R76M:@5C4FK
MIC8=K+SLXU(3MTRD])<A78VPYX\<1/`6?,0)B66SJ'N\KE9;B(46XP7F/W06
M2BG'N/@9M.&Q]:A11E'4(KM9<T;:>=#!X\<<<9X5VR#-,3R<#TC#$1-$8H*$
MBSLPJCF6B:TNY$\Q@4T@UB+6IA8V4+*&.O>NK3&AQ=J=T0O)DR-):6]M6O"_
M1Q*3[<>7*P3U6R[X_P"#7U-1$BY64DFF#>E%DDXQ&*WTE:2W&5<EAW)8?/EL
MY`^>N,8[FM?@P(E:"M&#J:$Q:@6VZ8L:LY$FXOEUR+UTW=(>II\KL@Z@)^RX
MGE$SG*D9WDY:<*FF'WXAX4FK:9F<RQV,F-=KJBXFJN^".#!BB`IH8,UMR8]0
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M4IKU638V'W(D<&\;'RJ*A(-B`D%TAHK,B&GR3:*<H.(FFIEQ=PJ&.ZW*IP/.
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M3W5]];K[J\5*<=U]UUUU?CNNNNK6M=P``````#BKY;9QXLYS-4@[G0PCCA15
M!'+O1DY$3`[VQD/EKRU%ILYW(AN5"++A"F2N=,-*B`K%2INW$8O(YKL5M*5`
M3]`<2($@Z3I09[KDACOC26PW'%[=7FJ<9)([+L>//`C97HSI\SG&,H9Y#1'6
MX4$D_P!3QE\S?.%I-O-R(CG4MUFLJE6G)W@--,IAG4CU&F34\W&3;#J!!=J"
M5>,9K-A1BLK4U;JOCK`D'71$:X>0CK'DRF4EC,)&<G1\-7D";*>-]J*,CK!*
MRZ7P:L,I3U27[@?TPY5M(UP.O7]@QF%9A7)YB>GE#RE""OB-E\,=8,MS#HPE
MA3+E&T6,%3N%6-55+EW+DPEL6'%TEZ#6&QN$.9>B-A2K-#1BTSP26K%.<3C(
M*S!,R&YFM.>O5K.N1VV:7CL=YB")4V;?3C+-UQM)&;[I;!<P5RIRQ4Z4M-9,
MG&7@QH=+*<NFV]*NH!EHTQ,*-X<7VRSG8QT,LV8(B1H6LY@0/&CJQ1OEDF-X
MH1")E;5LR`TWPG'EET.MVN1=5U)5<!W/=R[1YP?T?:-7"[7.SY2EZ0U=ZP]I
MSA1>ND@Q&O(;VUI;:B^Q(O4B"?'\:L(LF+=C07[T9=H2MPH:E<2P*F-$**YA
M0/G/='M`L&.%WQ%(#^N<\D/>"=0<LZD(C<SMRMBT\RWW,26XB3F2RF%MM9O$
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MTIT2=*S=+,^`7%+'^SBQQ6.UE--+16NN*$9N"-T^3FT@(C?E!*=Z02N)Y_`G
M\%Q$;6B[3VP8WF/4%&#NTPOR9'O#,Y-)?C3+*S>PZ@%QS."9V4JX7+%:_&#J
M8[]..<[4XCN.-E$TE9TMK*J"I)BXV$I4Q2C=H+C91FR%YK<[[DQ[G=/JQ@<L
M-MYY'6>N7L-SUAPW"JV?29&RL[%,N9'>C9/G7"_F<I2.>:3QD/-8\5A(S&2^
M$I9>BE*4I2E/S4I2E/Y_BIXZ_&-0```!7_5/IV9VK33W+.FZ0UIV(#"F=EK#
M`>A]C'$5.=-S7<&"I19))"DOH+E3DXP>)W7EJGJHY@R6LONR$[RYFF//95J0
M>#'AJ2UF:E]UR5-9A8GI=T;.203A-6C@G4PK:&W@4?4*9TG!9&5Q9,L,N@B7
M47UAMPYL3AMMO))]J"1OJ7'[D#@U8:;<MI$RI;^F'&[D35U,.M0AAS*S"SHE
MDS39")R`'ABRD;X[Y5E99>.3YHJA(%5"APBKY**YM94<MF/'9$97@9M*6*-F
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M#$ZW`S#2<O\`P\C>15U$QPZD]-8*7@5XZ<:R8O5TPIBH2=:09K<3PNW(B9<J
M1?+^FW0\PM/3#+1B;DB7)[C]N-]M,F,&GJ$5F8^D>)HS9M#V)G1^TRJ4Q6Q8
MM%FZ2-VI6%[R)1[RHIHZ<C):X_%,FE%<=.&O?@W8/?A#5455W7*Q`]JIEJ')
MV6'`W7`VF^X(@F'3^W8R;<+/V#U),9^"]JJD?%X>C@^F%7)8\4I046_EM7""
MHEK:\EJ7E6>#KB9^+L3.>:)#F6=7#&30U*LI;/R4OM#(5EQ&U5M)$8LO%I"1
M&DQ6HB)I`TTVZC(;7;\6)\:MAKDB=U":+ESG#^8UP!%X+]H);;@-"/:I=7#K
M.Z9)+9;]A-QO%ZQ@O*+1;#%CU]Q@@Q0:2,L0X6<ZVUB8\B.-/SOQWMA=G3,K
MXT)T[6;7"W4@^6_$T^"8@QM1]I=B!4DB7Y"B/226ANV+V%(=(G72Y9;@IPKZ
MTP727<A.*TEX-9>,DUVQG/\`S,9?;!62&$BIK5=Y12)G7-D<-B])FC=M:1D`
MNRVC+\Z2&P6NVR+"AUBRL[D%=;L&16E'LIQ$C-A4;S2:JJMHJ'BH014IR2FI
MR+(A-KH+>;&-YT1DSDN?A3JX/Z.U6V=V^SI+EJ)8LU.NE?>NH*)(W46>EME^
MNE]IY=(E%;1E]49JP_HQ4)@2RN$O)QJ,G:ULRRHY%%W(E[;?:\XG4KZ.K@[H
M76W5&+R0W1)<<+<%NV'EB`LL<*+-;A:#6=$;(58Z*0G&A/(QU`NDPB_VLOK2
M=*S$4<:M1\%C^,F:5"I!%;!1"I3HT8D!\)%AU[:C9(A<BW">J)"IHLE-@VNI
M6<&-68<;-93;;C<E'%B+-RPFZI$27,VDM3545O(RLFI,6QL4JKJIEKIY_#:9
M+X-5I%V+$[?<NI+4_)4DP#);"DJ#I\DATQRN2=&Q^.V(X8R06ZGD4J+T"-UI
MM+$</!X-&0??(PU9SR3C<Z@XWBYU1XD6ZXD/@SMX(+3VX4RF!M23.L8+;D@_
M4QI\F9V,=PL/.O3_`!OJS?#CE*8R\HVO:.7BD4<1V67>Z)%:[K8R4RUUHJSA
M645%.8&F<M0,/-VWP7D$M=;P94]X2L:8RDZ-+<BR#%JLLM8ZSI1E[1^UV$UX
M5E9XY,30*.'$Y"Y.*8J4'HCME;;S+>JW&S64E-L8KKW%B<'&<O!#Z7U5LM)E
M/!?EY],QK).NY%SMEQN5JER;I2N$17EAS:C2;C/MECMU<I7.O+1M281UNJK?
M4F88QE+L!P_4KBK2Z.G>!ST$-8TA+DXS=J#7S7<@MGD*=U]J*SLJBMY+QI#<
E0\11@,N.V87P)I*F7,?6,#2QNEV+)U07WFON%7,VFL-A``?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g858978.jpg
<DESCRIPTION>G858978.JPG
<TEXT>
begin 644 g858978.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`^1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]-14%.7T1254=?2U]"05(N15!3_]L`0P`!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``
M$0@!)`*.`P$B``(1`0,1`?_$`!\``0`"`@(#`0$````````````'"08(`@H!
M!0L#!/_$`'<0```$!`$&!0P(#0X)"`<)``0%!@<``0(#"`D1$A=7EAA1DM76
M$Q05(3%25I>GT=+4"A89*$%GD=<:(C(Y5%AA@968F;&W(R0S-CA9<7)T=G=X
ME-,F-#5'<Y.RM+4G-T)%H::S\"4Z0T1B8[A397F"A+;!X?'_Q``8`0$!`0$!
M`````````````````P$$`O_$`"@1`0`!`0<"!P$!```````````!`@,1(3%1
M<;&1P1(3,D%2@?`B8?_:``P#`0`"$0,1`#\`[_$(0@-+,>^)!;X4V'*7<0B>
M2BF'7']PMM8<%ZM$'-D':3;]XCFO8PY-"V@EK#WA!V2AG$J-RNR+%ARZH0!I
MZ\ZXMSF%NZT8E,HLJ&=5^,XQ2B03QRU.3Q1V'U98BYFP8TN+%9V7DK%K!9%#
M<#@Y^5$J8$-$Q]!2Y-9B?%2L#KX\/0Z&L!4A;`C%//:+';AL5.+!A+#/I)5$
M"-,J7IPW.K=/%&5F9R!ZUP_O^W#\]A;8`I%@1,Q"H%MP$3,AM0F5HH#FX@VF
M&,+@&T7"M>\163GOO6KL5%HF7A<EVQQXI9A$IBD)+Y29#U-((QXT23F@AN3(
M*8`BNV(=QHKX1I%/[9`=VPFPQ&5*PNLGU=8Y+7PQTGRCBD'+<C5XQ*)NQAO5
M.436.3>(Q-BR9W7$DODO4I$$">(2<5']*=O(P_Q#(T]:2RA;"7M&X$B%D;BT
MK(QF(&I,/;".,@!6!OF9H-"%I>%L]7%C3`38!A`MF6;2N"10FY:#V+=,ZI2J
MKNW*:)3G*4ZNW**ORK)QS`N"2E=Y<E=[#PE\>*MRBA"B>PHZ2RI>-7`E.?5(
M$0:VS"PG*&Y(7Q62A?`L,*"J^>WC&H@1\P(`.17U0=6?CRPO-`%\K,P00R+A
M5F8<4!,`U@:$%69YL]H2%$V[H>_;JG3*=5%VW71.<I3G3VI0&(3=-LY9IS<-
M#2E.6>6=7IR6>6><L\LYGVY9Y3EGE\,IR[LH\:U6RVB(7?!.<YQ#;8MJW8E:
MX@+5]!(N];".L4V`ENZE2"Y0%L5,^UHFJP'HK+ZJ;-FH0(OB*K=N5-,[UZ[=
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M9;1$+O@G.<X:JFRV=H7<].<V0FU;8RE.<V\0LI2[<YS2"<S2EQS_`/1D`UJM
MEM$0N^"<YSAK5;+:(A=\$YSG'B36-A/N-XA)]K/VD@F^Y^#/@^'BC!'#LX<&
MF2B@7#D%;3(Q*)<D&*(\.CX@2H$*!)P%X&%$#-"LMF)%4]>F)<76+(*P)$C#
M,R+BL'8$&)@""WPSS6JV6T1"[X)SG.&M5LMHB%WP3G.<1RV=S#F\!(9'[?IE
M#'`,D41JD%""&MT'3:B2ZL(YA^RR85J35":)52E%$!M#0(N\2*(G+#+L>8EI
ME;#5EYD`%"(T2;T8'UM=65*>.6;OA$$EE2NU$=&"3*R%,302&/#1,K5?)]6*
M!/%:96*"1RB)C(B5:V1QL?)9.&X69<<&P,3>#47PV1UJMEM$0N^"<YSAK5;+
M:(A=\$YSG&LQ6]^",W0JJ<8,(;@,F44:(TD4E)PV0I/J8`;N10G[C:EMM"GR
M,+5T8#G.DJDW0V(4L38R\XUT]*K"+I/+XVU:G_0HWGP3)!GKS]*D6UZ?:H&L
M`S>F2D-V]ZQ$$J\$+ZRUM2)4":O)*2L3RO`.'?MHXY31V1`#@B/Y7`!T$+Z[
M-Z=`;(ZU6RVB(7?!.<YPUJMEM$0N^"<YSCQ)JVQG+/)O$+.6><OVGISNTSG3
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MRGFG.4ISEGS3G*4_@E`9W"$(!"$4&8Y\HVZ^'5>8X[P=8DK=CL'B&PC.<RK+
M*,G3-5O&*CG75LB]UQ($<>DXA8FM5TYJ%,<C=5AV1WFZ<@O!*)=V5(7*@F(Z
MPOSA%4IKB-?0GRE"39QTA3I,8PRQJ-TMA^H$M&TBT9;%0IT^UH];J$NK?PC7
M"@<=G72+[]"M-29KUPA4.%6:2:D<8)$Y/1@X[!!+05`?E*7)3%0G@N0(H*@M
M8P>+G8$B96`]$Z957.H`K`D5=S3JI^EL6+M<\^>5$Y2GF"*VJ_;QB(_I;*/T
M,M/$VQI2W&(5H2]8/J*%JZ5JP<.>5F!=7,A5%?7(.VT[:EE=[1M$=RNSHCBX
M98ZG?IM79]1ZK*B=FY:N7)<X33)^&M.[JOZ/0$]0B!>$TR?AK3NZK^CT.$TR
M?AK3NZK^CT!/4(@7A-,GX:T[NJ_H]#A-,GX:T[NJ_H]`3U"(%X33)^&M.[JO
MZ/0X33)^&M.[JOZ/0$]0B!>$VR?AK3NZK^CT?TTXCF@KIIKH4PRNBJF55-=*
M07-5-5-4I3IJIJI3$Z:J:I3E.FJ4YRG*<IRG.4X"<81!_",:+PD';GKKHQ#A
M&-%X2#MSUUT8@)PA$'\(QHO"0=N>NNC$.$8T7A(.W/771B`G"$0?PC&B\)!V
MYZZZ,0X1C1>$@[<]==&("<(1!_",:+PD';GKKHQ#A&-%X2#MSUUT8@)PA$'\
M(QHO"0=N>NNC$.$8T7A(.W/771B`G"$0?PC&B\)!VYZZZ,0X1C1>$@[<]==&
M("<(]`JPM0U,*(%2,'%U0PB.`M)@6#;I89`:A!:)M2&%YC8JHO%XX-.N5\(-
MLU4W0HBW;OVZI5VY3E%W",:+PD';GKKHQ'\!J_;.&Y68E(E4'%D.9@!9??N@
MDPX`(;:LC0]P-=N!!@=-4"`@FBW=JG8%6*Z+P>[*F[:KIN44U2"B+`11B=?@
MBPCK)G<7.(Z^`?;)B`S;%JX#C&QL[!,V>)XM-&+$,HIT:C'=*1B72#@+,G,'
MZ*%LG4K8(PJR;T"1N$;6*5-?1CBF>PF+O#@Z(!B#.Q0P?MI5:)?7!R^KBNRA
MUFH7?4[Z,\P.+]GG3<]OC@,XHX8^04ZI0R6-%V2M46R<5!":DX+)TX>2/KI*
M2C['6;6&&EA&K;YEFR,SLF;MK4F2H5#$QB5.HI!1(DDX#MEI"2S/%$3&9X8V
M"DML!B\*(-3`:-ZT#6+=\5>G;E5$E3Q%M#.6::D'3E_,]==&/^WX("N=ACF\
MGG[Q[NF,,UDDD%C@Q6MDU.%@Q+F^<0U"J99H3!0CD<I7?M74ZFQ4DRASU1MT
MI2PN<Q2U$:*-J&Q+QP-5B;2F2=9G4&N\+&(9\,#V%C#RU+=+9/.YA/R.^+G#
MQB&3MY/'!1</'B.0F&)!A6!I.!(0$6'I\]1^R3CK8GMA#(P!&J8I3JM%=63R
M^31L;]I26(IH99O\)!_:GG_:@O,\YYLWTT_:SGJ[7P59Y=J7%+-XEB*:"6?_
M``D'=OX)H]=SEFGW92E-,3E*4_AE+-*?%`4+8AT(MWNQ?C,9S8H]9UX96U=?
M)"&JWIDC5&67EN!8Q>XM58ZRS#I445@U`;6,.9=B19LS6%D"2FU1(8H56E-R
M852ML<EA5ZS$>V[B"<GGE0E<"1*NK)L2>4P;IXF+21<ECX8I#MLD^\N"Y&G*
MU*4J#*ZE+43+DX99S'A"WYE%%D4C3'VZTUB"4QI-Q%_G"*:'-.7MD']ONSFD
M%W.?W/IIIC/VO@[?:^#-#A%-#FS>V0?*7=[217DIY^.=4DS*<\_PYY]OX8";
M`]=%VS3=M5T7+5W2NVKENJFNW<M7:IW+=RW73.=-=%RW737153.=-5-4IRGF
MC]H@_A&-%X2#MSUUT8APC&B\)!VYZZZ,0$X0B#^$8T7A(.W/771B'",:+PD'
M;GKKHQ`3A"(/X1C1>$@[<]==&(<(QHO"0=N>NNC$!.$(@_A&-%X2#MSUUT8A
MPC&B\)!VYZZZ,0$X0B#^$8T7A(.W/771B'",:+PD';GKKHQ`3A"(/X1C1>$@
M[<]==&(<(QHO"0=N>NNC$!.$(@_A&-%X2#MSUUT8APC&B\)!VYZZZ,0$X0B#
M^$8T7A(.W/771B'",:+PD';GKKHQ`3A"(/X1C1>$@[<]==&(_*[B39NQHSOJ
MR_8E7.<J)WTJM;$JYREGG*F=U-42JG*4Y3G*G/.4NW.6:`G6$0+PFF3\-:=W
M5?T>APFF3\-:=W5?T>@)ZA$"\)ID_#6G=U7]'H<)ID_#6G=U7]'H">H1`O":
M9/PUIW=5_1Z'":9/PUIW=5_1Z`GJ$0+PFF3\-:=W5?T>APFF3\-:=W5?T>@)
MZA$"\)ID_#6G=U7]'H<)ID_#6G=U7]'H">H1`O":9/PUIW=5_1Z'":9/PUIW
M=5_1Z`GJ$0+PFF3\-:=W5?T>APFF3\-:=W5?T>@)ZA$"\)ID_#6G=U7]'H<)
MID_#6G=U7]'H">H1`O":9/PUIW=5_1Z'":9/PUIW=5_1Z`GJ$0+PFF3\-:=W
M5?T>APFF3\-:=W5?T>@)ZA$"\)ID_#6G=U7]'H<)ID_#6G=U7]'H">H1`O":
M9/PUIW=5_1Z'":9/PUIW=5_1Z`GJ$0+PFF3\-:=W5?T>APFF3\-:=W5?T>@)
MZA$"\)ID_#6G=U7]'H_:QB39@17.W965-=<J)USI]KZMI^EIG33.>>M/TR[4
MZZ99L^?M]J6:4\P?H_6)?#YA<1U*_P`1CT-FR2.NBNQX10.:LB-'@#(RZG.]
M(J)YG`P-?.C:NS*J]05%%D<8UVJ:KE(:=N4ZI8GARQGX4\7($T'8:\0#6/+4
M0T6:U&5(A6EIDI4O(1.FD/)5)&[<#*M+U7ZZI46:3\E+IW+F>U1I7)3HEK9C
MK.G'P^#T9B99=F\+;C*L0KD,V;BKK%7B.#X>"]O6X4!OV$*2)!N`HVX<DG3]
M"W7!T4$HTI(PH$\4:L.$](.G5Z8U``11D&&:M['N<)=+G%:S6&!JU\T1VDB1
MN"1CGN-WU<]$#1I&:CG`LN"XHUH&3,"0B7!>9)2X4-]V`,P1F5V#,W-C0V"C
M4_;*PL/C6MY\-:>Q`JE!7W5.19\V3=*Y,.,5-*%`!BY/*AP44:!U`C#EQS25
MX2:K`B1RJ`$ZS3R'H["I>ZKR(A.U4$5<R,H"@ME/_/'^>/$YREVISE*?:[LY
M?#/-+Y9RG*7'.7:@-50F&X\.G2!KYVW?4#N$"%=<^=MD4(>(AN$\7M8>G*1.
MD47AZCQ+IX`=+2VB2%5K,O0Y@?7;!L"#JL<(4XU7')>1G!9M5FEFT>Y+-F[4
MYRS2^Y.6:<OO0SRSYL\L^?-FS]O/FSYOX<W;_@[<>8"$6KE*:XQ$=W_G;*)]
MJJJ7^9EJ.*<OD[D39HRXZN77Z40HU7[>,1']+91^AEIXFV`XZ,N.KEU^E#1E
MQU<NOTHY0@..C+CJY=?I0T9<=7+K]*.4(#CHRXZN77Z4-&7'5RZ_2CE"`_B'
MU56@0N[:JJIN6PPBY;JTIST:Z+%RJBK-5I4ST:I2G*55,Y9Y=N4^Y'4YR1F3
MF3N//)VX;<7>(#&!E(![R/D3K]6+\:C\>3^(A,B#FR[[AD5%PG29&H+9,0A)
M%Q.!HI+RNP&`V:Z*^MPUFW.5$NV*9_Y.'?R,7_N]V*3?8WOUD_`=_,-Q?T[.
MM`?V^X5X>_MM<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^
M4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(H>X5X>_MM<
MJ+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F
M>X5X>_MM<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(
M=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(H>X5X>_MM<J+^4
M<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X
M>_MM<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(H>
MX5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=
M(HNSA`4F>X5X>_MM<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM
M<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(H>X5X>
M_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=(HNS
MA`4F>X5X>_MM<J+^4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^
M4<Q(=(H>X5X>_MM<J+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(H>X5X>_MM<
MJ+^4<Q(=(HNSA`4F>X5X>_MM<J+^4<Q(=(HUQPM,D.P89<H-A@0#^XJ7)9E?
M9*M;/D>I/$3B+<I^;%ERR/%HAD(5*$EN.`;&,B2^$3`H874]C+0:NNV/&RNW
M+E-^JF?9!BC$Y_\`62T#_P#@GN7_`/7&@("\S1EQU<NOTH:,N.KEU^E'*$!Q
MT9<=7+K]*&C+CJY=?I1RA`<=&7'5RZ_2AHRXZN77Z4<H0''1EQU<NOTH:,N.
MKEU^E'*$!QT9<=7+K]*&C+CJY=?I1RA`<=&7'5RZ_2AHRXZN77Z4<H0''1EQ
MU<NOTH:,N.KEU^E'*$!QT9<=7+K]*&C+CJY=?I1RA`<=&7'5RZ_2AHRXZN77
MZ4<H0''1EQU<NOTH:,N.KEU^E'*$!QT9<=7+K]*&C+CJY=?I1RA`<=&7'5RZ
M_2AHRXZN77Z4<H0''1EQU<NOTH:,N.KEU^E'*$!QT9<=7+K]*&C+CJY=?I1R
MA`:,90@[!)MA;!\!3;C*US2=PT28,>1-4D&^7"Q$NZ%$&%Y/"+)`[9\DVNND
M)82T*8S6`U;J])`BM)!#HP)%,2K`.FAMN%<"!#0GL2N,\&Z.(-3X@,60HBPR
M&SH&UUODTTK:)]C3@C=0QPYE37-TF3]65E!?28"7DM*@>MU6H'(-5($$7C09
M2CI(:FY"N*N\]JT?QY&L:=N$3B*12Q-\**0=HBQ'/Z\3#-N@+1B4+LY)T0R'
M85HG+2XY<F=OJ3E+UQFT&DCN)00?H`M'E2M#!$E),;#Y._#\I<.(YZT@=X9&
M'P[!E-=0*\[(M-B+<W%"L'449G;6)&?*%U'0>IN&^=(68)XN3Z:3Z4+SJM3D
MP$CE=#)\X"6[(TF`!9I'7?RC.(S%`Q:IQN+&0E\$@:MJG,%!]D\1:()E^/9)
MT5(KG,*4:Z+<.%-,V;[;*-;K]U#T`UZJ23L5S.2ML5`BU,U%HM.+QR>V.Q!$
M,K1B$$XZ]0Z^7X<Q6-YLCH(K&\2QZ.I$(9)+H"%&@0+@@DK9#AP)DMRH*8#*
M$ZH5)6>"DC?$B#!(4D)I>NCJPI4)L5#Y6%(C\00I=*0Q,E=ENW/R?@UHIG1M
M<087#@0K=R,.)02@D);'4$5A7$1JWH#$P(<:R5R6@J@2H"LP.QC>7[!.$OV/
M3F9$1CSKL8;G4P`28KL6GP,S(X'3IT9=0+@'5K$Q0BO2ST6>K6\],JIZ4LT:
M[`L'+%%[M3=\,G#"@YH<\U?0(F)'QG2WH!]3U!76P/'F"(BB[03T.$;(00+)
M!1K=HO`;8DQ.%."*PBR/3M1F&T>:6;1S2S9LV;-+-FXLW<S?<@-*FX>:H&L'
MU$2:IYQ79)SRL9U$&A)B!!?*AIVU`=:&=KLM1UJ-KZRZ\MV=*O2`"P0C2EUQ
MH42YKUKV.OMXNI\]1_8U=-,UQB(SRE/_`)6RB?;E*?;U,M1VXFS0H[VGDR\T
M!`^O6O8Z^WBZGSU#7K7L=?;Q=3YZB>-"CO:>3+S0T*.]IY,O-`0/KUKV.OMX
MNI\]0UZU['7V\74^>HGC0H[VGDR\T-"CO:>3+S0$#Z]:]CK[>+J?/4->M>QU
M]O%U/GJ)XT*.]IY,O-#0H[VGDR\T!KV8OI54`&RU//K+.#%]NINYRE+];79R
MSS[-3^'[G;[G:[L4T^QX79J3F1HP,$\FT=H]ZT0;@R[*)Q%S-2<3U1\W4N9P
M@Z1H'ZM*C2T+GZE3HW*:J>WFSQV##.FGL>.^EI_Q,7\$OA#793^#BBD[V-]3
M3/(H8#L],I_X!N+W92G_`)]G6XX"T?7K7L=?;Q=3YZAKUKV.OMXNI\]1/&A1
MWM/)EYH:%'>T\F7F@('UZU['7V\74^>H:]:]CK[>+J?/43QH4=[3R9>:&A1W
MM/)EYH"!]>M>QU]O%U/GJ&O6O8Z^WBZGSU$\:%'>T\F7FAH4=[3R9>:`@?7K
M7L=?;Q=3YZAKUKV.OMXNI\]1/&A1WM/)EYH:%'>T\F7F@('UZU['7V\74^>H
M:]:]CK[>+J?/43QH4=[3R9>:&A1WM/)EYH"!]>M>QU]O%U/GJ&O6O8Z^WBZG
MSU$\:%'>T\F7FAH4=[3R9>:`@?7K7L=?;Q=3YZAKUKV.OMXNI\]1/&A1WM/)
MEYH:%'>T\F7F@('UZU['7V\74^>H:]:]CK[>+J?/43QH4=[3R9>:&A1WM/)E
MYH"!]>M>QU]O%U/GJ&O6O8Z^WBZGSU$\:%'>T\F7FAH4=[3R9>:`@?7K7L=?
M;Q=3YZAKUKV.OMXNI\]1/&A1WM/)EYH:%'>T\F7F@('UZU['7V\74^>H:]:]
MCK[>+J?/43QH4=[3R9>:&A1WM/)EYH"!]>M>QU]O%U/GJ&O6O8Z^WBZGSU$\
M:%'>T\F7FC1#$WCD`8=%Z.;$IP[ON^ZV`8>USB9J*&B#-9.D8VS8K)*I)?AR
MV^OW-1%P:KR*E6E1L"3%`:0E4VA(8J2MXX.[H@"!"=]>M>QU]O%U/GJ&O6O8
MZ^WBZGSU&I$\JSA.$E)"HB-4)<X3BJ1"*<-,FXY_,'S?"C5*.`B2)?I@Q$HU
MV<23?N(FKPQ/*$NO72U8(]/&5BNNJNH+4#J#C!&HASCW>,QO/ABC3*FHL,JQ
MF4EPRX(@;*T`$><E:T:QV!6&EN7#<08I"4,;&!FX=#A8EYK!!&"86LD92DF^
M(RJJP9AU&>F0X+<M>M>QU]O%U/GJ&O6O8Z^WBZGSU&H6(MX'A5^,9%8.F>7P
MAG[E.#M^\4J@<`"2ID['FJI2CA-NTC1)&5A3$I^`LHX*H%4J58XH>V!L&QV%
M*TP2EQN`!B#ND1J\!Q"XMGVPXX#L;[5/;?0REQ%UX+[A3@R*VM0I^V3G%KJ"
M$R88F`BJ4J@(#5X@9FC40/<IQT>LT<X2'3B$1C7EH]6IY57#4\G>"U[7K7L=
M?;Q=3YZAKUKV.OMXNI\]13K/'P])/B(110>K:^#7:BRL#@8%E%A#-$VG2^T!
MPX#$4Z!PR[[)VF^1AE^)OG2.12/Q$"W#H5!BBS]-'Z[;\&#M#B("&3VY^'D1
MBC2&,Y?-,O,0QAB6:.>'9-N.N!2A;=LT?=8A_C]?W0J?;I`'+:IY*U"F_7C<
M^V12@T(XNL!QT07(]+'YNX(X"X0&9B&W>O6O8Z^WBZGSU#7K7L=?;Q=3YZB>
M-"CO:>3+S0T*.]IY,O-`0/KUKV.OMXNI\]0UZU['7V\74^>HGC0H[VGDR\T-
M"CO:>3+S0$#Z]:]CK[>+J?/4->M>QU]O%U/GJ)XT*.]IY,O-#0H[VGDR\T!`
M^O6O8Z^WBZGSU%*!R[$_HB=`J/5J[.?W&5RBGL%[3)^V.>EC70XN1G(J[)_Y
M)IZA(-6,ZX[0N]8L]3_5=.GL3Z%'>T\F7FBC(YE+Z)+0,LTLWN)[F=K-+-V\
M<2`S]K[N>>?^&<!:KKUKV.OMXNI\]0UZU['7V\74^>HGC0H[VGDR\T-"CO:>
M3+S0$#Z]:]CK[>+J?/4->M>QU]O%U/GJ)XT*.]IY,O-#0H[VGDR\T!`^O6O8
MZ^WBZGSU#7K7L=?;Q=3YZB>-"CO:>3+S0T*.]IY,O-`0/KUKV.OMXNI\]0UZ
MU['7V\74^>HGC0H[VGDR\T-"CO:>3+S0$#Z]:]CK[>+J?/4->M>QU]O%U/GJ
M)XT*.]IY,O-#0H[VGDR\T!`^O6O8Z^WBZGSU#7K7L=?;Q=3YZB>-"CO:>3+S
M0T*.]IY,O-`0/KUKV.OMXNI\]0UZU['7V\74^>HGC0H[VGDR\T-"CO:>3+S0
M$#Z]:]CK[>+J?/4->M>QU]O%U/GJ)XT*.]IY,O-#0H[VGDR\T!`^O6O8Z^WB
MZGSU#7K7L=?;Q=3YZB>-"CO:>3+S0T*.]IY,O-`0/KUKV.OMXNI\]0UZU['7
MV\74^>HGC0H[VGDR\T-"CO:>3+S0$#Z]:]CK[>+J?/4->M>QU]O%U/GJ)XT*
M.]IY,O-#0H[VGDR\T!`^O6O8Z^WBZGSU#7K7L=?;Q=3YZB>-"CO:>3+S0T*.
M]IY,O-`0/KUKV.OMXNI\]0UZU['7V\74^>HGC0H[VGDR\T-"CO:>3+S0$#Z]
M:]CK[>+J?/4?M8?"N]7.C5"^-G-1.O3OM[.W1/-.F6C*KLS/Z>>EGE+-VY4U
M3S]J)RT*.]IY,O-#0H[VGDR\T!3/CI:S#8]"S<E>/9A(43Q486"EDS8.>MNY
M]E'N8O#5;&QJ("(JVGA2A;I-C4NDP9B$,ZC92N('-KHLZ'EB:`EMJR-%F>Q6
M#G#TTF&QYL0Z):QF0;46#Q$8?5J+&`G-7:YNJ,K,[SRDY86'I(M!Q]83*D19
MV0JTM%F"54YLGU>4F1(8TV"T8`OAZOPQ'9-S"+B+<<V<M][[RWSY<@4.A9%:
M.Q58D&-21E92=LUO)TMO(QEG7;Q+J4ZN"A@X?(V4)4<J"J84(&"C[(`L!A;,
MBX6\)N'#"JM'8+&0.W$&JE8D+9F#AE#G8A'HQ!J0"6%0QQ[*%-*35\G#<94I
MLL-[IBLK`,O+S,O(C*^5#1]@!<'T#QEX-THXSKIIG*4YRE.?<E\,^/-+NSS2
M[=6;/HR[<\TNW'*.N)E%E>JB'%4Z:G`C3168=T0D<#P7%2XZ4+;MU\LG_4%?
M!:+E(NZP-JX9V*U<0N24R#V,0P!.@`:D:])!$VZ=BT[Y6#-VQ*P['.E+2E3V
M\\^*FJ=/P]VJ4M&4^UW)SE/N<<L_**;'!:QS&MRGC*X@G#)VW?EM7[6YPR36
M'!25NJD'LPD'!<PJY5)8%K!!W(4K//(T"DI03EW50?"V^;]=-^K'"+C&0Y3D
MENW:)K>5`.-2\D,1Q$3>V`V#!:KQ>2S,0I/,Q$2G3H!9F0VBX$!:4IU3ZM?H
MJMTZ.:<NW*`BQJOV\8B/Z6RC]#+3Q-L:4-PN'?L+!]K@1D>O+XIT"N\8A]9B
M5"]BAE+3MJ'H`]6O`ZJ!O5`-@&8=<V)4VZ.O>M)RZL%O552WK!>W8%Y6$;ZA
M`3Y"(#U@O;L"\K"-]0AK!>W8%Y6$;ZA`3Y"(#U@O;L"\K"-]0AK!>W8%Y6$;
MZA`3Y"(#U@O;L"\K"-]0AK!>W8%Y6$;ZA`3<9_Y.'?R,7_N]V*3?8WOUD_`=
M_,-Q?T[.M%G!@X#V3`#I5,'FEUD,SSUKHZK-F"WIY\T@,IS_`#2[L^UGBFGV
M/$L73*\C1@8!)YG_`&RE-E!N#UJ<ZPTT2=>2J?-U*JZNQH\)=%!^IW)U6OU2
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ML/\`WL=7W*OM8$QC92O)!8;,3>'.M?LNKTSE#E<<LD8/*(+DROE,@VC;`<EE
M`8CD:9$$P)HAKPX7>*1@D1.]59.S($'KI#B3"R(E?W`#)=?O1:"_&A<?YQ8#
ML5]DR[[.!_VL/_>P[)EWV<#_`+6'_O8ZZGN`&2Z_>BT%^-"X_P`XL/<`,EU^
M]%H+\:%Q_G%@.Q7V3+OLX'_:P_\`>Q6@_&'IS78QTH1P")2*!!-!;P28@&'6
MK@)@R:T;=OGCL.TRJB#IJDC55\T4P4?;2J"48XG5Q,GZRTB/;I;09U'(04(+
M*-`_<`,EU^]%H+\:%Q_G%A[@!DNOWHM!?C0N/\XL!>RW33LXU#=H-JD*ETJ2
MH5M$2E6[19'U,`-H)D>BB$`F4T3T"A]0D8)MEI*6`@=-X5?O"+TK/5+URN[7
M75/6]0X&V24;KG+B"E&?A$TJGZ:K%.LFF+S).AD&JL1+*IQ.IEO7+,9]BZE$
M&O``Z(;H[-D^6'0(D/E8VJ-4`ZQU2E3A%15M[@!DNOWHM!?C0N/\XL/<`,EU
M^]%H+\:%Q_G%@+05E@P(%R+(E4>8A'6NNN2$F(UO+3OV+S5@EK<9+$NJ`2D5
M3-U60*$#)J:<152=0EIL3P01"E:F1B#)#8R.%"*,E7;4&+C\!P,O4"$N-/C`
MQ#L,VS8-6WK(MZS#86\-HE$HQKD`7E95-.)A0N.Q+@.HGQJP+B@O`K)4DC@E
MZI,`A<362\W*Y$134%KF]P`R77[T6@OQH7'^<6'N`&2Z_>BT%^-"X_SBP%SY
MDPJ04STD+[K98&*M6C=%RT*V2`C[Q(&23.37I;(D5"F3*<"VJ;!RX!R02DF!
M"V5P@\,BU*WSI-)6PF2A7K<,I8VPYX5SYA%2+4!WC/Q%/N5C+"F$7D<ZU.&\
MJ(!:K5AB6CC-=G@]GF*:U8*U4!PY=V&)JE<J3PE)"43,`7$]BDO(ZBJJGW`#
M)=?O1:"_&A<?YQ8>X`9+K]Z+07XT+C_.+`=BOLF7?9P/^UA_[V'9,N^S@?\`
M:P_]['74]P`R77[T6@OQH7'^<6'N`&2Z_>BT%^-"X_SBP'8K[)EWV<#_`+6'
M_O8=DR[[.!_VL/\`WL==3W`#)=?O1:"_&A<?YQ8>X`9+K]Z+07XT+C_.+`=B
MOLF7?9P/^UA_[V'9,N^S@?\`:P_]['74]P`R77[T6@OQH7'^<6/-/L?_`"7-
M5=NFK)'(*BBJY;IKKGB><>Y*FBJY337.=O6+^J2E3.<YT?\`3E]+\,!V-J*Z
M+M%-RW537173*JBNF<JJ:J9]N55-4L\JJ:I=NFJF<Z:I3E.F<Y3E.*[Q^#M<
M"\JXFL?5"G2E+<$N3_5N$<0CJIG/MWNK108ADT\`92692+9I_P!J]DD)+Y9?
MG6;TF_96[9E;+JP>F)IKT]CY..]=625PR`K#;'*^+B!08CD@1'QX[196-M)I
M&XH'B2B735BE22,#6R5(TA*2Y($86Z*KL!"<D`V`--D!0&LV]W4EE0V@7;SW
M,.Z0K2Y\]]HZ,D]>;4*L5`'4`<W*+B@LC@XJ^9-@!(08:F\E%)9!FXLZL$9O
M?(S&R2FAE=L:%06@0B`Y.$]LY2G)@NU.6>7_`"L([N3_`/T$-8+V[`O*PC?4
M("?(1`>L%[=@7E81OJ$-8+V[`O*PC?4("?(1`>L%[=@7E81OJ$-8+V[`O*PC
M?4("?(1`>L%[=@7E81OJ$-8+V[`O*PC?4("?(1`>L%[=@7E81OJ$-8+V[`O*
MPC?4("?(1`>L%[=@7E81OJ$-8+V[`O*PC?4("?(1`>L%[=@7E81OJ$-8+V[`
MO*PC?4("?(1`>L%[=@7E81OJ$-8+V[`O*PC?4("?(1`>L%[=@7E81OJ$-8+V
M[`O*PC?4("?(1`>L%[=@7E81OJ$-8+V[`O*PC?4("?(1`>L%[=@7E81OJ$-8
M+V[`O*PC?4("?(1`>L%[=@7E81OJ$-8+V[`O*PC?4("?(1`>L%[=@7E81OJ$
M-8+V[`O*PC?4("?(1`>L%[=@7E81OJ$?M87ST7*YTWF(ZA1H3G*YK41]W/5*
M=,I4:-`&4^W*=56EW):.:?;JE`5QY3RO$LG4HJUP;8AL#3,84TWJV-"H<^.'
M/$@Z;PD+N`3FY=)52B5&RF(AMC,,K2=5T$!LV`='(LX50`V"B1EZX+L!IVJH
M)R$QJ1&]K%4,#/JW^)]9B3=G#%T,0Y'AQQ*,<Y[K+8\)EZ<U';Q*/$NHU">.
M"9AR`436424(`.C6N:Q%U@$HA6^3"<%ELAMA^4?.19#AVLFI"FKIXN0;GMJ(
M;PVNO6(PZ$:*5]@^J$!U8K'F!IE;C4BD[1-9/$\>%X-$JV^X`91R;"1'?H6M
M8D+".3Z/61GB5QS(-H5RXKEW$)3AIZ_41Z[-IV&V0J55"1<,_1&'U`7@A:'M
M(HY:"L0J!*G1)H=K%2@4NMFU,C-4U%X\G3B;"V>(?5S`LXO%B&7RN;U-GBNL
M%Q"37SH8$KZN;DZ44-U6I0G4=BS>L@E44I15"!*F2Q8IPIP!3:A%"CHD#@#(
M2($W)@C"#YRVZ2I^3I53+U&)Y3J&X`M$"</%01E)Z=W30RD3EELI*3`<''F-
M9B;U4E8"@)8NU#3*JD`%E>%SE9@,&0^&UBVW7BR<U$-@E$XNU^HSY7*E2``%
M<QP]3*NV7VU8>!Z1-\0%)S)6S*2R\JQ1$'*[BF%`0HP]F8"K--Z4X1AEMQF^
MNK:\VMI<H^XXH8KD=B$%0IB2M:6"2J5J=)Q>2U(Z9[:*JNKV=$PN`*0L^JVI
MRNZ-RW55F<!"35?MXQ$?TME'Z&6GB;8A)JOV\8B/Z6RC]#+3Q-L`A"$`A"$`
MA"$!_"9_Y.'?R,7_`+O=BDWV-[]9/P'?S#<7].SK1=D9_P"3AW\C%_[O=BDW
MV-[]9/P'?S#<7].SK0%X$(0@$(0@$(0@$(0@$(0@$(0@$(0@$(0@$(0@*,<;
MGU\#(<_T;Y5+]"+,Q>=%&.-SZ^!D.?Z-\JE^A%F8O.@$(0@$(0@$(0@$(0@$
M(0@$(0@$8BM%^A&W)Z%"X:T2:$(;@T.6T':S4A,EBBLQ%TW:PH"@R/1H`%4-
M$T6+]0<+*_._>ILW:K5NJ5NN=.710S[(KMV[F`0EIN6[=VGA%M5/1NVZ+E.>
M12N\T]&NFJ6>7P3S9Y<<!;'PM<*_VRK`>.9M^DT>)XL\+%6C3+$HP,YSKHE*
M4GE;><YSG73+M2DI9SG_``2E.?%*/F*=:A/L0)_90_\`=QYD&"RG*<@@3/*<
MIR_6H>?;E//+M3MYI]N7<GVN.`[GOL>7$7A]1F2:P])Y7OHSB5/P;A8M[PPC
M4CGH<B.`MDQQA/N9E]T26&IZ$&V+0XN&!!X.N[8HI%`A0<79G6'OVKE>VS>8
MF\-UC*98KCV]B"9*T1C\%V!HM`&]UVD%04C3(K>+'4)-"\&/K4,@0D<7!C8H
MOCPMF]7?"63(!=$46[8X-5>^?0DD0ED01`TPF"8.7DP*\/O!`=<[H^NB\:&`
MDS&3ZY,+@H7<ZL.&"+M--R]73:E<E9LTT6:+=NF+B%4(<8^BV+@BA1XH:*0C
M>E00O#'!`(%B#8M/G*N&A8&!VA5=^\9EUNNU68@K-JH6#MU6ZA5JW3.B<P^K
M!PM<*_VRK`>.9M^DT.%KA7^V58#QS-OTFCYB?6H3[$"?V4/_`'<.M0GV($_L
MH?\`NX#Z=G"TPL3[F)5@/',V_2:)F3*I3*U(BY4(Y1$2L31O:KOE*A31N7GQ
M&9V+=^Z&N7B\W*A(LO&VK8FQ>#UW`PB[11?LW;554KENNF7RKZ`H33I_6@3Z
MJG_W4/QR_P#EQ]#/(T4TT9,S";3111132AU#*FBBFFBBF6L=;=JFFF4J92_@
ME+M]ONP%G4(0@$(0@$(0@$(0@$(0@$(0@$(0@$(0@$(0@$(0@$(0@$(0@.N?
ME,<4RU*,1B\;*V_SZMLD6E91LE<08?FVR?BPQBM/BH6*]-%X;*-'XBE>G&'>
M"RF4":I9(EK=`D46J)L527"5.8.7;.C.V`)Z"^SK`P_F#YSRA=MQ@Z;(W:9%
MMA<39V?I$3A3<O".1AC-R1"JN!11*@G*:UIA1S='>U`POFJB)"`<6W1'40PD
MUN&-H0&#R&_*#Q2AQ0I:X3'%:4I5!@'`!U&W.(9*K93MFIJR^H,&"FA*I6[5
M*=6S;**DJHN@!8RP`7B8,K=L&(O(P*:VA1L.PQAD/CF.U&&5F+QQ,.A"!*;U
M%TJ:O"HF'+H!FPRQ;TR^XXCQNR?>V15$I4*$#1Q>E$HW+=!+X^=J^H#<^+.N
M2,0&\T=;C*+5*8/BH?A1)6T;JIF4^W6`FC&]AN-!@0C<=_F[`O\`KT[:I:8-
M#FZ!J.@:U;51BA90X)%;'7BA[K0T0U[?CVQ>4C+UH:]D>7:EFXN/N_?C'S)*
M)@X-B@^-D\1F9VGZKM9$<&!07#30EK$:/5ZR@Q%!KHPLKOZ%'5J@-\/5=T*.
MJ3JT:<P=;).V%O:52"2P"\86,5-/LB]ZUBI@E8J[85DF(O!'0,QRA$A+E^DW
MJ;$;D^Q*!30$958N)^L`.1!3=KG=K+KTNRD>^V#L$/\`:OV)DH>LY]BI*#K_
M`+$2&?2Z'9'L;^O^M\VGI]:_JVEHZ/PQRMIT@M'MY3VR4IMJ0276B@0?T%H*
MD[OE-B]6)L%=XVIL2,+I=9$5UB+0"X)J"6[]=5ZBS3=JG5/W,!I0W'"&]N#[
M=C]3/76M`K[,]>>WOJ'9#5.VO4NQG6_ZKUEV,['=4ZZ_5NO^O='];];Q+?OF
M_B+\HT?WM5^WC$1_2V4?H9:>)M@(#]\W\1?E&A[YOXB_*-$^0@(#]\W\1?E&
MA[YOXB_*-$^0@(#]\W\1?E&A[YOXB_*-$^0@-=S#A,]8#M+49H]9#,^;6+G_
M`,5O=S2[6?/]_B[>:*:?8\6O;W&C`Q[4=4W8#VAN#UC[8O;KV8S:\W4ZKUWV
M)_6.?JNGU/J/_L]'2^FSQV$#/_)P[^1B_P#=[L4F^QO?K)^`[^8;B_IV=:`M
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M7Z$69B\Z`@/WS?Q%^4:'OF_B+\HT3Y"`@/WS?Q%^4:'OF_B+\HT3Y"`@/WS?
MQ%^4:'OF_B+\HT3Y"`@/WS?Q%^4:'OF_B+\HT3Y"`@/WS?Q%^4:'OF_B+\HT
M3Y"`@/WS?Q%^4:'OF_B+\HT3Y"`@/WS?Q%^4:*2,OMKCX#)1[?M6G877^V'4
M_:C[;.RG7W8I<=;Z?9S]:=::/5>K:'ZMGZGH=K2CL9Q0W[(H_<"DG]8IJO\`
MA*[@.CW"$(!'\-!65VK\A-HL++0F5==V0FV6@;8F5VYGZI=D(H#TWY7;FE5U
M2Y*YIW-*K3JJTIY_[H0"$(0'*GZJG^-+\\=\_)(:]O<Z,+?M1U3>U[VEG_8W
MVQ^W7LSU+6&L]/K[L3^L.J=6ZKH]0[74NIZ7TV>.AA1]73_&I_/*/H6Y&KZV
M=A._F0HOTCK:`V]]\W\1?E&A[YOXB_*-$^0@(#]\W\1?E&A[YOXB_*-$^0@(
M#]\W\1?E&A[YOXB_*-$^0@(#]\W\1?E&A[YOXB_*-$^0@(#]\W\1?E&A[YOX
MB_*-$^0@(#]\W\1?E&A[YOXB_*-$^0@(#]\W\1?E&A[YOXB_*-$^0@(#]\W\
M1?E&A[YOXB_*-$^0@(#]\W\1?E&A[YOXB_*-$^0@(#]\W\1?E&A[YOXB_*-$
M^0@(#]\W\1?E&A[YOXB_*-$^0@(#]\W\1?E&C]K'"3TY]<ZD.IZ$\W4-8>GI
MYZ='/U3Z70T=//\`#GT<W:SQ.T(!/N3_`((H^=1QEL%QXUI$\Q"NA>;@)B,8
M29#AL:YO<1MTD,#)0E[9%-"Z=S$T%:Q1H=.(I.J<99J,,-*/5"=:@[%U%AFZ
M2S#*5>'*<!W@3[D_X)]WN??CKO/*0K!=Y2V]?NH)SZD6A,5.&N[0<M[@WFKV
MM/!!0BVE-KAP\&(U1NRGQ92>D8L_T3.I-H,S0Y"$3K5'E!2KW$1@0R(0[$,N
MY+N]R7=[OW_NQIL]^4#P@8<E];;%Y7K(D6MJBY/&H@FOD2U.:2T$JS"\6)RZ
M=&B92YV2D-9N,LU4@@YT9%XJY9KL#)V*08H*(O;DR[DOX/\`SGSYYY^//.<_
MNQIABD*1*^6>'9BR\K'5$SBO"7NB[`X(4W+Q;-M<.8<M<>H$<F%%$@DKBK=(
M&RR*N`!MV=\W3)D?A[-H0"+A5NT$IFN*!C"9^D_AC'+L/)\%,2UJ`I0H0C51
MD)J*:"\V-JA(\[+"$8ER6KL82&`^D*>'I:-J"4![]`:JV/+JA<^Q3T$2I&(Q
M_$SI80W%?D(IS%\5BB<H*T"O'OM5A^/DF1,>9%!<XP5&.J3W4,B7*(U8G&/)
MVM7#'B4^2NFDQ2B"BJ5FGBXQ.$];6H`1N8DAB")#F2>.!(6JT!.9%H4WD6B:
MITSI$R+1U=L*-E1*55/4+]=-NK2SSGGE*`BQJOV\8B/Z6RC]#+3Q-L:4-PAW
M?OK!]K81[NL[X5T"NR8B-6:5%=E1E33MJ(H'=1O#*:`74P-\&7];6)U6Z^LN
MNYSZL*O4TRWJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^>W;[Y)T;Z_`3Y"(#
MU?/;M]\DZ-]?AJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^>W;[Y)T;Z_`3<9
M_P"3AW\C%_[O=BDWV-[]9/P'?S#<7].SK19P8-^]D@`Z=3^9Y=9#,\M5".IS
MYPMZ6;/(=.<OS3[D^UGBFGV/$CG3-,C1@8&IYX/:T4WD&X/6I-J\31WUG*E\
MW4IKI[)#Q=H4(ZI<E5=_5*):&GH4YY2E`=AZ$0'J^>W;[Y)T;Z_#5\]NWWR3
MHWU^`GR$0'J^>W;[Y)T;Z_#5\]NWWR3HWU^`GR$0'J^>W;[Y)T;Z_#5\]NWW
MR3HWU^`GR$:6N\L3-@R`D5#QXN2-OD^I%@GF_(C8_:M*V@AFM%9?NA4VFPM0
M:^)JJ,SH19NV`%FJBFF]>IZG*N5=5--41H/%*@W/112X3?XU@RL29P:JM/VC
M`GP\CA(LK4R%.JD\LDHJ2+L%)0(I7)@YID".TFL"LB49?5=#WQ!90&%!K]T+
M+H13XY.)A_QKMHIBL-+L)QPW!4V']\\2PX8OF=F0$`1#,HID>WP%)!BRV(3J
M@H5CJ.6M027(%#?J$DR1*"!4JH8GEA4&*R`Q_G5.,E;SP<8<,5[9NW6I[F+X
MVPO)!A$6H6V2!=*\M\6*C2B<19>MC(KO"9@RY">V0>>.!464R$7BU('H(DO6
MQPD#=H"XN$4@*;%%C#LM+B_,4X\V'-+.Y@A<M8(%Z#I]$E[1F'N%1,TR0>]"
M+0#,H/316IPM==!N.@[`8.<JHSL-\?7E9(29+^V2D@!2^Q>]\,I:B\-Z6Q)M
MO9P\@R&6'%-O,Y20?8S,2Q6D[A*=.@SD*RJ!MM*WZS*E2:@C86'2-2D-#$I!
M'RA."2R0@[P61@)MA=="-;2%#8AA9&3B5"]P(K/Q!477CPL+6T2)B7%QU=!6
M*S8``'W1(>Z-!`C&H2%""KMFU<$![5N]71357.4O;:OGMV^^2=&^OP$^0B`]
M7SV[??).C?7X:OGMV^^2=&^OP$^0B`]7SV[??).C?7X:OGMV^^2=&^OP%5N-
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M)\BAOV11^X%)/ZQ35?\`"5W%M&KY[=OODG1OK\4D9?9+.,2X&2@6K'1]N1;4
M_P"V%F@I]HY`G-`565+B=D9U\5B;PBOJ$J:Y=;U4RMW.J9ZIYZ)0'3*A"$`A
M"$`A"$!RH^KI_C4_GE'T+<C5];.PG?S(47Z1UM'STJ?JJ?XTOSQWS\D@CG4-
M,G1A;')YX/:T3WT6?U`B35XFCOK"B3AK.FJUV3'B[0L5IW*:[NE=HE.GJFA+
MZ6F4!<O"(#U?/;M]\DZ-]?AJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^>W;[
MY)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^>W
M;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^
M>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?A
MJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]
M?AJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ-]?AJ^>W;[Y)T;Z_`3Y"(#U?/;M]\DZ
M-]?C]K"!>BW7.J\^_5Z-"<I6]5:/M9JISIG*O2H'3GVI2JIT>Y/2SS[=,H#0
M'%CE`P>'19XBR,WQ'826S5R$0;&&#.M&_:M)$2/5HA<FQI6M%D:B;[@D:S.B
M7K:F@G(O:P2V2HDOIP[O&4U`)&5TD?HV+:7`9BHQHO<_J8'86,4[@H8+A?=(
M"]S7BT6L5.WKK6`B^2DB7VZH98*&D(7EQ,SZ)/TBFSV[</"0&;G%)B9J$O.K
M-RQN%B@(L#S4D1]B.Q6(9BP)+:&(-)J5UG70:04-LLH-ST(BT2!,S]2DQK>*
MB>@[4EDO"TTW;``,)-KUZJW*\+OW+OH&2=S`<G%V5I+#M)IR0V>!OFM<*T<L
MZAP1.@52D%N8NF7,X.-%FCB$$@KIHK3)!NT7(LN,#.2A,+Z;/2ZT'INT@@E\
M-[>YW(9NW*?%G_[?N=S/]WNR[>;NSSI3E.6>4\\I]N4Y=R<N.-%\1^.8#AM4
M8XL-\,>*QR4F3R0U@_=1KT.W(YN28X<!0EZ:(DYU^N':02D4!Y;,3HAD8!T<
MEE*&#UGI>7VA8DZI'%8(-YI4RE.<^W.<^WVZISE+^"4YSE3_`/EE*.4:1%V/
M5FC-W*&SL!%-0GQ.((_PEEKN"+)%8;HTQ.)9##7!/6=!UW#VE53-@904GA+:
M45Y,V4B-79";(0&=7E#:"!QN[FE+-I9Y:,Y9\^?M9I]O/G[F;-`0FU7[>,1'
M]+91^AEIXFV(1:NJF2XQ$9YRE_RME$NW.4NWJ9:CM1-FG1WU/*EYX#E"..G1
MWU/*EYX:='?4\J7G@.4(XZ='?4\J7GAIT=]3RI>>`Y0CCIT=]3RI>>&G1WU/
M*EYX#^,S_P`G#OY&+_W>[%)OL;WZR?@._F&XOZ=G6B[`SJI['COIJ?\`$Q?P
MR^`-=G/X>**3O8WU5,LBA@.SU2E_@&XO=G*7^?9UN.`O!C\YW*93G+-7/-VL
M\K5R<OO3E1.4_P"&4YRCQ<KIT99JZ<\[EJ7:JEVY57:)3EW?AE.<IR^'/FCJ
M:Y,;)CX<\?>'598G,3BPQ3K-XUOBNQE%BB411C(Q+HD"*`(S$JXJ0304.FTB
MY10G2ZR6)XG+B^S;+BP+1.T'HG7*KZ65`=LOJM/%<_U-WT(=5IXKG^IN^A%(
MOT/SD]/LC%U^/IBZ^=N'T/SD]/LC%U^/IBZ^=N`NZZK3Q7/]3=]"'5:>*Y_J
M;OH12+]#\Y/3[(Q=?CZ8NOG;A]#\Y/3[(Q=?CZ8NOG;@-E,IZ!6AFTV'N3>D
M%Y0J@LQZX%E&&!W"93F92$*TIB/1*C4IRIII<I-S4F2Y*G2TS,#Q35`;Q>FP
MMF1L84W0P:H-?_)L<G*V-LX?)PWFL&YPX.(#$`LWZ4)6WSFO,BT@CA2D1K;-
MV`29-<1BF;ZI5T@DPU*;'G"M/TZ!,CI4&)^-!EY,47P178UUM9`#)]6)U3LC
M<7]F=5,Z*IVL>^+VW.JBKZJBJ=#N2G.F?PTSSRG\,H_+Z'YR>GV1BZ_'TQ=?
M.W`;'+;`P:(ASD0\F%`_*T<LDYA^Q`8;3`O=8Y<U=EUQ+/<ID<Y!(M0JD-S=
M5+,0=M<Z"("GH!(B#,(3*I/*53)RR?(H3(K.@V#&N3[6P3#XRV%5%*=N29K<
M'!#@>6&%!6&"?5XMPAC[X3%E-0J$<\8&P*H2TV^<0F3B;()4(^FXIBZZKW!-
MK]0FL"F@=V*OH?G)Z?9&+K\?3%U\[</H?G)Z?9&+K\?3%U\[<!L&G<+CYH2^
M^9^!(,-;L&N,A^%NZV)A,.Y:7MQ(DZ6DT""9EGD(BI!48HK3B%J(238)4&L@
MZV321"+D0/4A@3THFV(`%H;/DK@ODW^&[!MA22ZKD.:S#F?,C-=7CH$)L&"V
M2#!%(I2(M/DQ4&##```'?=Y/MH9WBD<85`BY#D`XCH%F@KK>8C3[Z'YR>GV1
MBZ_'TQ=?.W#Z'YR>GV1BZ_'TQ=?.W`7<RN4RE*7ZI/-+MSG9NYYS^&<\UN4L
M\^[/-+NQYZK3Q7/]3=]"*1?H?G)Z?9&+K\?3%U\[</H?G)Z?9&+K\?3%U\[<
M!=UU6GBN?ZF[Z$.JT\5S_4W?0BD7Z'YR>GV1BZ_'TQ=?.W#Z'YR>GV1BZ_'T
MQ=?.W`7==5IXKG^IN^A'FFNFJ>:6E*?=^FHKH^2=5,I3_@EVXI$^A^<GI]D8
MNOQ],77SMQK&Q&%-N,!^6]8UG</RJ?`*VSKY.S$>N%VE7(Q!/&\A4=*I(ODT
M96G#BD.Z*R5%H`**2\<,#A:BVV$E1(0(KG*=R\(KNAL9C<^O@9#G^C?*I?H1
M9F+SHJCQ2X;WD<;*H9*O$>CDC(W9O#<B<?I0\JO[/)P%)'F#V-:V:<;0/,D,
M#8*H3SVQG*>-P?5$\5&MHJZUZN<W"\/>L7;MK6G1WU/*EYX#E"..G1WU/*EY
MX:='?4\J7G@.4(XZ='?4\J7GAIT=]3RI>>`Y0CCIT=]3RI>>&G1WU/*EYX#E
M"..G1WU/*EYX:='?4\J7G@.4(XZ='?4\J7GAIT=]3RI>>`Y0CCIT=]3RI>>&
MG1WU/*EYX#E%#?LBC]P*2?UBFJ_X2NXOBTZ.^IY4O/%#GLB><IX!27-.4_?%
M-5W)RG_U2N^*`Z/D(0@$(0@$(0@.5'U=/\:G\\H^A;D:OK9V$[^9"B_2.MH^
M>E1]73_&I_/*/H69&NJF63.PG2G5*4_:0HN[.4O\XZVXX"SJ$<=.COJ>5+SP
MTZ.^IY4O/`<H1QTZ.^IY4O/#3H[ZGE2\\!RA''3H[ZGE2\\-.COJ>5+SP'*$
M<=.COJ>5+SPTZ.^IY4O/`<H1QTZ.^IY4O/#3H[ZGE2\\!RA''3H[ZGE2\\-.
MCOJ>5+SP'*$<=.COJ>5+SPTZ.^IY4O/`<H1QTZ.^IY4O/#3H[ZGE2\\!RA''
M3H[ZGE2\\-.COJ>5+SP'*$<=.COJ>5+SPTZ.^IY4O/`<H1QTZ.^IY4O/#3H[
MZGE2\\!RA''3H[ZGE2\\-.COJ>5+SP&C>4'.@2<88$=A0#[CG%".>W`9E:L-
MR&;1P7;!.\='5Q/I06GR%[K@1D:`?6QJ<A#XS=HU(D@7DHL;>H/2M1S3PFFN
MW##@O63CO<>+QQ;6,AIC%/KO"@Z;G6L41'@^''V(`:Q1J^ZY;>E!'N$Q:G*<
M;\G+GH7BH7[H@S$'?J.:#P$WR63B:2]N^?&6YN/Y"JM^6E7;.*K"B2OJBQ#C
M8<[[?)J[BU,,/(AT#62OMJ!3"QZJ3"7O*=!6&H'$P(YNEA>*.S)QB6DQMD5`
M$Q!V@`G`LFBPI9A[6.(=(V,+B6PO&QH2LFH3(E(,:SHXR1JL!"+CL`2DW-1C
MIEI0<-S9+Z@)D$+"\"`D7*KJX\RI%"!!5?MAPMGIIT:::9=N5-,J9?>EF^#M
M?)&J[_H17N<Y.&A)A",7?;%.NG?>IT3V@<%#@9"&<)JS9HTB(#5W9CA(HV>$
M[2"Z"U!PM\+9"M88T"[P6\)`R$;4P_\`/_GY)0%#Y3@@?2THD>P8I,7;;=HO
M+!+W*-W'IMF9+,@,V@4:R<+$FGT<'#5'5"GJ<VE[UT&:LX)ZTS04VT20&RKK
M-9!3(FJ'WC'Q-,](QY+V4-R:8\),+V53X[L8<`IU:,^N"X=U*_UJ(IT<U%WJ
M-S1IJJEHSSQ[K-+/GS=ON9_AS<4(#2EN&9J&+!]0\G5><+V-<\K!]6!KN8<0
M82K:=M1_79G=[$U]=#:.O>L[=[1HT0`0$'T9];Z=<N:BJ]L3[>,6?,L?VM5^
MWC$1_2V4?H9:>)M@(%U%5[8GV\8L^98:BJ]L3[>,6?,L3U"`@7457MB?;QBS
MYEAJ*KVQ/MXQ9\RQ/4("!=15>V)]O&+/F6&HJO;$^WC%GS+$]0@->3%BZJ0`
MV>N%]9Y@8OM5.).<I_K:[*6>7867P_=[7=[?<BFGV/"TU2CR-&!@XDY;M$77
M:#<&?8M.+2943ANIOFZEO,$`R*Q'495Z.G<_5:M*Y555VL^:.P<9_P"3AW\C
M%_[O=BDWV-[]9/P'?S#<7].SK0%HTF.JM5V;LW??*Y*V(#U]3NN'.Y:KT+]N
MK0N4=AJ=.BK-FKITI:5,YRSRSYXI@R"S35'V`*L9)RW:)='%ICG#]:D"TF6@
MZNM,5SH`^KU6.Q=_2$"9AIBA=S2EU89?$B,U/5M"CL*W?J9?Z2S_`.+1%(_L
M??ZWM>_K>8\O_J\=J`M"U%5[8GV\8L^98:BJ]L3[>,6?,L3U"`@7457MB?;Q
MBSYEAJ*KVQ/MXQ9\RQ/4("!=15>V)]O&+/F6&HJO;$^WC%GS+$]0@(%U%5[8
MGV\8L^98:BJ]L3[>,6?,L3U"`@7457MB?;QBSYEAJ*KVQ/MXQ9\RQ/4("!=1
M5>V)]O&+/F6&HJO;$^WC%GS+$]0@(%U%5[8GV\8L^98:BJ]L3[>,6?,L8)CM
MQ5`<$&$1_,6!DBQCB`6*;\P7@E$@#P.FABDM`!@`',ML'HHL.;!97<F.E<ZZ
MN%8Z5%-JJF0:Y553*742K]FVMI1753[G>XT]&JJG/PCD9V]&<Y9_^:[[D>HI
MJJRB9N9,Q&<Q&[N4:BJ]L3[>,6?,L:T'V3J1A_BW;K&"*>Y_Z%\V[$N(P946
M4+,IK+A:9<97D"R-#(497$Y4=VS$(/3P2P%L!A=LON696[@D/<O![5<^K9]&
MWMI^]WN-^,<C/FNA]&WMI^]WN-^,<C/FNC?+K^,E\:QUA?(_^&8WNY0G"BC0
MF+''.1I)YVXQ/KQ;I5,XM'3327OGK#V,-]A`4E2<(S``1DQ7G6RCNJ4I`%]H
M"JKP^NZ?6A\]*BJT>IBZZJJJIO$^LIU5553E2XFC3*=54ZIRIII))4TTRSYJ
M::92IIEFE*4I2E'0[<#V7HWJTQ28<<05O`JO2\(QS>8D$4*2UQ^4F)%*.Z^$
MF8F#,0QK0W=D.6VTY4UU^0D-?!"JS&1S9G8NV.LKM-_9GZ-O;3][O<;\8Y&?
M-=#RZ\?YG#">E_$P>*-8ZNY5J*KVQ/MXQ9\RPU%5[8GV\8L^98Z:OT;>VG[W
M>XWXQR,^:Z'T;>VG[W>XWXQR,^:Z'EU_&2^-8ZP[E6HJO;$^WC%GS+#457MB
M?;QBSYEC1K(^94LBRMN&U:8BD^S)TQX-&O0HF=N)4]6I8NQ8\2GT>AU;6?6S
M8J($X'#V!-M:V@-)?6"NW;5PNNWYBKE`FW;M6OQYF)B;IPF&YH%U%5[8GV\8
ML^98:BJ]L3[>,6?,L3U",$"ZBJ]L3[>,6?,L-15>V)]O&+/F6)ZA`0+J*KVQ
M/MXQ9\RPU%5[8GV\8L^98GJ$!`NHJO;$^WC%GS+#457MB?;QBSYEB>H0$"ZB
MJ]L3[>,6?,L4CY?=M)I#`R4&<U^YBGTW_;`)V/5ZLF>%='5BI;SZYH"3+PFB
M+M=3S6;W5)Z$J[DM&>EVNQE%#?LBC]P*2?UBFJ_X2NX#H]PA"`0A"`0A"`Y4
M_54_QI?GCOH9(]IJE'DZ,+AS)RW:(I#46?W.Q2<6DRHF":#AK.UH`0$BL1U"
MW5H=4KIZM7I7:[E?:TLTNA?1]73_`!J?SRCZ%N1J^MG83OYD*+](ZV@-O]15
M>V)]O&+/F6&HJO;$^WC%GS+$]0@(%U%5[8GV\8L^98:BJ]L3[>,6?,L3U"`@
M7457MB?;QBSYEAJ*KVQ/MXQ9\RQ/4("!=15>V)]O&+/F6&HJO;$^WC%GS+$]
M0@(%U%5[8GV\8L^98:BJ]L3[>,6?,L3U"`@7457MB?;QBSYEAJ*KVQ/MXQ9\
MRQ/4("!=15>V)]O&+/F6&HJO;$^WC%GS+$]0@(%U%5[8GV\8L^98:BJ]L3[>
M,6?,L3U"`@7457MB?;QBSYEAJ*KVQ/MXQ9\RQ/4("!=15>V)]O&+/F6&HJO;
M$^WC%GS+$]0@(%U%5[8GV\8L^98:BJ]L3[>,6?,L3U"`@7457MB?;QBSYEC]
MK#'UV:YUZWGQO9Z)T:%]PIW*)9YTSTI4]AI?3RT<TIY^U*JJ6;MQ.D("C'*0
M.@[U9DZ)58Q28%6I8IIQ.'H4<`WLPSXI'0=]NW>7YF9#&J61,MV:?EL0Y&=B
ME65E0]IAZ83IH;%"C"56S4?UQ4#`B_29$<"6EUW$_0)Q"LUBH<0S$M`HG4?A
M#,P_#8NTXBN.:'0ID>/PHG\5ZN-EH:S``;()OR=`R2+6-@D`4T6B$`DRBV'"
MB-UL0&5%P&X:W9.6,Q&O<0-:X)"0(A=6R97$*I%V#$B5M9U>39Z2#2$@/@EV
M=@P2YL&O2KN!#`N'@*+W4:;5\"*O>HP48NV0Q8OOBD-L.>($4^+5)Q+X?!M8
M*1:;TD3>.`JKSUT*LF31XI4J1J(46'I&FD8>B$Y4:G2>2YG6,J(;!'<.C0#<
M"RJ-,G&QC(].8E4KA.1XE&'#L#TV0KM>5JU>%J,(6\1RO-CHA;\).5P*9'*T
M<MSS=,JJR@FW30"8N^3I50J93G*:*Z$Y;56YL4L8K,F>J7M7&.BT0UH06F\?
MC=8<"`R<-07KX5PL-K@X=;]\J*%JA[=HF,!)\&#D=1,O6X"E)ZF12*>=-7C.
M[3UBLAZF(`VD3^.HL7>.E7X,F]`,\=B6J)PH]WA9\_P5)O:G+HU*!U/8,D9A
MR%MR..');ZU</4@GC)R"I?%A&5*,U."H;8MBR"U9.K`ISS2SS_[)3G\DI2SS
M^]*-"%,Q;J/AB%9AP780#8((KPF/HOG#9URD.X1LL')7Z.5#2K%KP::-`9BV
M21N-P6*P$O;QB[R4#*A5$YN:(9+6"P4=!Q-)L1;OGZ?*5.2&">/`O7Q0:A:@
M8\+.^*#]<!ZYTSJMSO@[X85;SSHIG.NQ?M7.UVJY9YYPBIJYRDN,1'=_YVRB
M7:IJG_F9:CBE/Y>Y$V:4N*KD5^C&E;<8>FA,%@^H46D97;!.YY67EU$SY44=
M;`[C3MJ9UV=*T>6Z[VD.,1E_JE^J[=EU;J4JY6;=JW;ES@RLGX%T[Q*_I#`3
MQI2XJN17Z,-*7%5R*_1B!^#*R?@73O$K^D,.#*R?@73O$K^D,!/&E+BJY%?H
MPTI<57(K]&('X,K)^!=.\2OZ0PX,K)^!=.\2OZ0P$\:4N*KD5^C#2EQ5<BOT
M8@?@RLGX%T[Q*_I##@RLGX%T[Q*_I#`3@+MS$!1%BF<Z:KUB]:IG517HRJNV
MJ[<ISS4SGFE.J4YYI3GFSYI3G%?N2HPAK7`3D_\`#AA(<92I=8+1F$VJ24]4
MB)I.YI<TOGKC+-9![I1,_+"DWG9L@5($"WNO2X-7UW8$=3IKL]2NW-DN#*R?
M@73O$K^D,5991!@EDA5;AD-V-?12LPG7?Q',CAP4R.+6_:U?@+0-PQZWOGR^
M+CIT4NKE(&5-H(7%)>7E\S.M)AK0&H3<(!(P8*OS"\.J<JI2E]-+-515]17_
M`-"NFK-W/AT<T:78",'A?@88&MB2Y>CG(#5NV^SJ24@Y-6TO?E<>UW%:ZETD
MF5AS<]MSH3E:IF1VS#K^51K0!D8U`BZ8GK$/G"/PIM:3)-,%"E!"ELHBP@*"
M\]6)B-,R,>JC@&`L6#)1#25,&14G"@4<B[=TP$%I`6%Y,"NB*PQ8""@[=FQ1
MD?!E9/P+IWB5_2&`GC2EQ5<BOT8:4N*KD5^C$#\&5D_`NG>)7](8<&5D_`NG
M>)7](8">-*7%5R*_1AI2XJN17Z,0/P963\"Z=XE?TAAP963\"Z=XE?TA@)XT
MI<57(K]&&E+BJY%?HQ`_!E9/P+IWB5_2&'!E9/P+IWB5_2&`GC2EQ5<BOT8:
M4N*KD5^C$#\&5D_`NG>)7](8<&5D_`NG>)7](8">-*7%5R*_1AI2XJN17Z,0
M/P963\"Z=XE?TAAP963\"Z=XE?TA@)XTI<57(K]&&E+BJY%?HQ`_!E9/P+IW
MB5_2&'!E9/P+IWB5_2&`KYR^E4IY'3*#]W]SPH>[35+_`*[3W'*4?'+O?LMW
M_25_[4X^NMETV&:I*Y(K'X>$26D!-`6'P^NA14CM2B>I7*#U.7*:NHC3H2'K
MS544SS7+-=,\V:<IRSRG\BF[^RW?])7_`+4XZ;#*K>.$[3V^^S\X0A%TW\=R
M]:H%6955YITT7J*I:-<]&JY*U.W*<Y4SE]/FGFS3GFS3SYH_LCSGGW,\\W%G
MCQ&1%TS_`+-^V$1V,,,-\<R$(1H^F=[#*G*63(?#N_NW7([DIS[K-L1Q2GQ?
M>[6?NRCMT:4N*KD5^C'3-]A^-`WC@9-IZ3=6IZ1L8A\:+AE]D1,U/0.@#L-"
MR-^W9ZD5F@&Q5HW1=^OJE5JJ[/3G357533;E1VNN#*R?@73O$K^D,<5IZZMU
MZ<HVCA/&E+BJY%?HPTI<57(K]&('X,K)^!=.\2OZ0PX,K)^!=.\2OZ0QX:GC
M2EQ5<BOT8:4N*KD5^C$#\&5D_`NG>)7](8<&5D_`NG>)7](8">-*7%5R*_1A
MI2XJN17Z,0/P963\"Z=XE?TAAP963\"Z=XE?TA@)XTI<57(K]&&E+BJY%?HQ
M`_!E9/P+IWB5_2&'!E9/P+IWB5_2&`GC2EQ5<BOT8H<]D3SE/`*2YL_[HIJN
M[*<O^J5WQRE%M?!E9/P+IWB5_2&*1\ONSC<H'`R4'*43LBHRN/\`M@!K$R-C
MX;G"B"I;U7K743,U'!Y:<[5N>G3:E<IT?I:Y2G/.'3)A"$`A"$`A"$!RH^KI
M_C4_GE'T+,C75*63.PG9\_[2%%W*:I_YQUM\,I3E'STZ?JJ?XTOSQWT,D>Q+
M6*_)T87%"H$O(P-S%%G]P:+F=*0+U:Y0X:SLTU=0`G(4+;S6K=%.:U8HE/1T
MIRG5.<YA<II2XJN17Z,-*7%5R*_1B!^#*R?@73O$K^D,.#*R?@73O$K^D,!/
M&E+BJY%?HPTI<57(K]&('X,K)^!=.\2OZ0PX,K)^!=.\2OZ0P$\:4N*KD5^C
M#2EQ5<BOT8@?@RLGX%T[Q*_I##@RLGX%T[Q*_I#`3QI2XJN17Z,-*7%5R*_1
MB!^#*R?@73O$K^D,.#*R?@73O$K^D,!/&E+BJY%?HPTI<57(K]&('X,K)^!=
M.\2OZ0PX,K)^!=.\2OZ0P$\:4N*KD5^C#2EQ5<BOT8@?@RLGX%T[Q*_I##@R
MLGX%T[Q*_I#`3QI2XJN17Z,-*7%5R*_1B!^#*R?@73O$K^D,.#*R?@73O$K^
MD,!/&E+BJY%?HPTI<57(K]&('X,K)^!=.\2OZ0PX,K)^!=.\2OZ0P$\:4N*K
MD5^C#2EQ5<BOT8@?@RLGX%T[Q*_I##@RLGX%T[Q*_I#`3QI2XJN17Z,-*7%5
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M(<Z0RNQ%K=[T.SS/K)'GMVRMP2RJ6K-+TH.BZL!46D`\_2PT$)-RA4W#@'(N
M/,L/#?#DI`*;;)+ND>75"B9EY.JL3:FP<A2.[0I@,ZE@6XCD,3GJ\;0_35KJ
M@LE'HHNN*$W&7*4]9NAP1J.O4U;8`&`:YTGV<PN7[*-JS*YPT'>%5SI(UBLH
M"[.,<B<$:%3CT4-,HGV-UHF4=2(-D.JY*U>I0K,"WL^>..8G3J+(>HAYL6FQ
MH'82E.54I3EW)RE.7\$^W*/,>)2E3*5,NY*4I2[L^U*6:7;GVY_?[<5E/=E"
MD,AL5-W#*%7*(;8L;5/M(J<0;P..4*`>E$B88@E0;I!@VC)A8"Z6)HA6;D&I
M"8#C)9N&H"A(I,M&HPH+RY7*9>AK"8"S:$4]EF427U]=DJ\,4XF@V'%49299
MY-(I)K9885.*#524,56U85Z!RBNJ&T772PYQ)H@Y;FX@*4>'$`$49E"TI40@
M6$'`1=NP\R+RH!?,S0:$+2\)9F(%C3`58!!`MF6;2N"10FY:#V+=,ZI2JN7;
ME%$ISE*=7;E`1`U7[>,1']+91^AEIXFV-76Q<EO`RT?^\(7B,L6AKJE(@'<O
M*DAM6Q8>EH&N"U"`M=PPIIOV*1080&JNVIU42$6+UF<^J6KE-,R:U6RVB(7?
M!.<YP&?0C`=:K9;1$+O@G.<X:U6RVB(7?!.<YP&?1QJJIHIJKJG*FFBF=554
M^Y*FF4YSG/[DI2G.<8'K5;+:(A=\$YSG'XB'2;2X'OT4.$AJZZ[-VBBBE7)V
MJJNNJBJ5-%--)E.JJJJJ<J::92G.=4Y2EW8#V,G#1<Y9Y*,LS3[<OU:O^ZAK
M"1?A&6?ZZO\`NHTRE.J4I9YSEVI?#./.>?'/Y9P&YFL)%^$99_KJ_P"ZBN;*
M(*U-FEW`EUB<@!/4<I)A2IN]3O?43O5.'U/2TZ:,U-74J_IOJ:='Z:=.>6>3
M<\^.?RSC27&O.?5<$O;G]<FPA_#_`/$Y\!=%9<)%]2M?X1EG['1_[:OO9?\`
MRH_36$B_",L_UU?]U&E]F<^I6NW/]CH^&?>RC],\^.?RS@-S-82+\(RS_75_
MW4>X*%(1GU=^@H,PIA6&IMUWZ0]=5<[5-V==-NJO/33FE7.W7*6;/]3.-&\\
M^.?RSB6FI5";30D[N*-0DA#0,L`:`=9V;EY50*KLW!55Z@-48"0]-^NU3<MU
M7:;4ZIVZ:Z9UYM*G.&TL(P'6JV6T1"[X)SG.&M5LMHB%WP3G.<!GT(P'6JV6
MT1"[X)SG.&M5LMHB%WP3G.<!GT(P'6JV6T1"[X)SG.&M5LMHB%WP3G.<!GT(
MP'6JV6T1"[X)SG.&M5LMHB%WP3G.<!GT(P'6JV6T1"[X)SG.&M5LMHB%WP3G
M.<!5]E]?K.F4'_J\*'_C2>CXY5[]EN_Z2O\`VIQ]@7+R.$@C?(_Y0$`5+5(F
M0Z_AZ4%%@&7J4D&B[U=1XG:::+08*/NWKE4ZJI2E311.<YSE*4ISG*4_C]7?
MV6[_`*2O_:G'3895;QPG:>WWV?G"$(NF0A"`0A"`^F?[#)^MD/A_7=<G]#;$
M1VZ8Z>'L.-:(].9-%[02@52;(QES&NXPFV$.#TJ*Q-P/<9YC;=%^BP/%A[M5
MFNY9NT4W::)T55V[E--4ZJ*Y4]M'6JV6T1"[X)SG..*T]=6Z].4;1PSZ$8#K
M5;+:(A=\$YSG#6JV6T1"[X)SG./#6?0C`=:K9;1$+O@G.<X:U6RVB(7?!.<Y
MP&?0C`=:K9;1$+O@G.<X:U6RVB(7?!.<YP&?0C`=:K9;1$+O@G.<X:U6RVB(
M7?!.<YP&?10W[(H_<"DG]8IJO^$KN+IM:K9;1$+O@G.<XHR]D'K9&J+`>3`2
M!6)H[&T8A6M$5`R@^*3,538ME*YE<O3#@1@B[*U;G53*NY.B5%,ZJ93JEGE`
M=**$(0"$(0"$(0'*CZNG^-3^>4?0MR-7UL["=_,A1?I'6T?/2H^JI_C2_/*.
M_P#9'UP4(2Y-O"J6FZT2168AD2H*1(`Q4A*!&AZJG%6M=--\*+'6;]JJ=%5-
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M5R=KJT93E*=6:DRG/-*<Y2G/-FE.<I?#*`J]RT3M-,UF&)%B'05F%\)(0_[*
M*(N:_%@Z#>MBV+UDB%7I.>+I$F8M>M2]UPS+;2:NW3(YI2C9*%4E8>T''DUX
ML,9`K]S-,ELKK:[;18J]%8:,".']CU*.(CAN#K`*^"+?9KW5/I5J(E7IT=*-
M#,HQI2`/TS42IE/W`-Y.&YA3/KFP-.[8@%<)BV+WI71TV>/-?NP)R;^)K%PH
M2%DF>;]KGC9A/X>#4F;Q.F1FX*Q<)%E0E^'S:4P)%*>*>\G#A7F"'+34.>%)
M<A0!^<6+Z;+@%4LX"1M)N\F*]2%."U[\$*=6]EDEN;(5WR9H4\'<1UQX=T4^
MO743Y4R#H.FA^RANF$TV9"LS"X;%JD-C!/%9@>%=7501F8!:!%86(3)Q%;VJ
M7%P&"KNR0-ECV;=K6]Q-)D4GKAHH*+S3A1*9+UBV!]:-`0,C4*I;(70@3R2@
M*SFR5"T^CEH07;8LE-$^HK/80%9!;DY2P"XQ1I+ZB\PB;QO*C*#D#8UI\1)0
MAWW5Q,I!(U/"%30>6R>ML2MW%<HWS*2VVE:3Z2Q&%13=,Z"LBZ[-K*1Y:7FH
M`05F8((9%PNS,.*`F`:P-"";,\V>T)"BK=VQ?MSG3*=5%VW71.<I3G3/-*/[
MH0&KK8MLW@E:/_9$(-&7[0)U2D.#MWDL0W;80/4T#7"J@X6BX7U4V+%0H2($
MU6K4J:)B+]Z].75+MRJJ9-539;.T+N>G.;(Q!JOV\8B/Z6RC]#+3Q-L!@.JI
MLMG:%W/3G-D-539;.T+N>G.;(SZ$!@.JILMG:%W/3G-D?B(:UM+8>_70WJ&H
MKHLW:Z*Z4BG::J*Z:*ITUTU4ELJJ:J:I2JIJE.4Y52E.7<B1(_G%_P"*"OY/
M>_\`#J@-!I=N4L_;[4H\QXI[DOX)?FCS`(TWQ-85ESB)4C;')1BK<YDB5K%L
MA733"01#5L&LBV3JMV,48A-KL<<N<B%&HA5=D.H[X`4DZA_M2%V0@81=+)BZ
MQ%VYN1"`]&F"LT)$VGR8\4HY9'122EA:;J\S*R0C,E29`@=H.-4)@3)H&7IT
MI&G`BW<'B2TA``B<%>OUART('"6[5JGWD(0")::E+IM3"3NVHT^2']`.P!K"
M4'127FM`6N]<%4WJPU)@&$4V*[M-NW3<JM2IG<IHIE7GT:<T2Q.[&_XXH_Y,
M6?\`BC8"2]539;.T+N>G.;(:JFRV=H7<].<V1GT(#`=539;.T+N>G.;(:JFR
MV=H7<].<V1GT(#`=539;.T+N>G.;(:JFRV=H7<].<V1GT(#`=539;.T+N>G.
M;(:JFRV=H7<].<V1GT(#`=539;.T+N>G.;(:JFRV=H7<].<V1GT("E#+R-Z@
MBC(_Y0$>5(I(EHZQAZ4%=@87IHD!"[-=)XG:J:[0D*`M7K=4JJ93E517*<IR
ME.4Y3E*<OC]7?V6[_I*_]J<?8UR^OUG3*#_U>%#_`,:3T?'*O?LMW_25_P"U
M..FPRJWCA.T]OOL_.$(1=,A"$`A"$!]*GV'&BT>H\FB]HU0)5-G@RWC7<8-;
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M!!A[L[5R=-,Z[<ZYT53IIG.F>:4=@N*&_9%'[@4D_K%-5_PE=P'1[A"$`A"$
M`A"$!RH^JI_C2_/*._\`9'UOD(=9-O"J9&Z+21H8B42H*A(\Q39*.&B*J7%6
MM%-5\4+`WK]VJ5%--$IW+E4Y44TTR[4I2CH`T?5T_P`:G\\H^A;D:OK9V$[^
M9"B_2.MH#?O54V6SM"[GISFR&JILMG:%W/3G-D9]"`P'54V6SM"[GISFR&JI
MLMG:%W/3G-D9]"`P'54V6SM"[GISFR&JILMG:%W/3G-D9]"`P'54V6SM"[GI
MSFR&JILMG:%W/3G-D9]"`P'54V6SM"[GISFR&JILMG:%W/3G-D9]"`P'54V6
MSM"[GISFR&JILMG:%W/3G-D9]"`P'54V6SM"[GISFR&JILMG:%W/3G-D9]'\
MHT:#+08LQ,188```AA`P:-&B+(4(#"!;-8@2*%"1%=NP'#![%NY>OW[URBU9
MM45W+E=-%-54@PO54V6SM"[GISFR&JILMG:%W/3G-D8TA<1#!N@=4)QMGN:%
MP5!<++YW01HAS$.K3BLF#7;%D0;4%:>/C(=466+PD-:O#Y!YA+5P19MW+U-=
MVW*J8X#`=539;.T+N>G.;(:JFRV=H7<].<V1GT(#`=539;.T+N>G.;(:JFRV
M=H7<].<V1GT(#`=539;.T+N>G.;(:JFRV=H7<].<V1GT(#`=539;.T+N>G.;
M(YT-<VMJK2MM\B+=6:=.E0D4[15HSG*<Z<]);*>:<Y2G.6?-.<I3^"49W"`X
MSHHJGGJIIJGQSE*<_P"#M_!]R/,J::?J92IS\4I2E\DH\P@$50XZ7^?=EGY8
M,4+&O8SV#JX=-\2N5B(:%,X<7)389R'%<\O2!(A<0*5=,,?.LW+/"@TB(FD\
M[2)L1;3YZX%VZLAY&3DX4\`VO1J\Y&&BMV5J;C5^[C@J-FSRVW8LPPYCRAL*
MVTK4#;J.A4%YG2=TH"ES:RY0G((@,%<F12W$DQN)3999#6RTH%J`H.PU$.7[
M?I.92%(-L[XA[F9P].`9&B$PW7R1-8<5MAPQ&*]/M*:KL_3[A.%;"'&(IEGA
MG?!K0Z1:2-)I1#+Q--?38(3@:H+IX2FMH9^H"E+DIBH3P7($4%06H8/&3L"1
M,K`:B=,JKG4`5@2*NYIU4_2V+%VN>?M43E*>;7HNPUW!+GV'#<=WG"=XN2CF
MJ)U&@0BV*FR")IH5"HTN;)'J2?%)!!)I1J(*EB)3+`L1`A:G1^:D0%6&TAI@
M=F-@H,RS9W-+-F[DLV;M3G+-+[DY9IR^]`:5-QB%:$O6#ZBA:NE:L'#GE9@7
M5S(517UR#MM.VI97>T;1'<KLZ(XN&6.IWZ;5V?4>JRHG9N6KER7.$TR?AK3N
MZK^CT?V-7*4UQB([O_.V43[554O\S+4<4Y?)W(FS1EQU<NOTH"!^$TR?AK3N
MZK^CT.$TR?AK3NZK^CT3QHRXZN77Z4-&7'5RZ_2@('X33)^&M.[JOZ/1^=[$
MLRUZS=LVUG35<O6Z[5NGVO*Z6E<N4SHMTYZD_33+2KJE+2JG*4L^><\THGS1
MEQU<NOTH_G%TRZU%=NK_`!>__P!*K_[*O[O_`/G=EVX#0F4IRE*4^[*6:?\`
M#*$>*>Y+^"7YH\P"$(0"$(0",^0CD(QNKQE?6)S(GM&UH+9+ZIEYL/ZXN@ZK
M]P13F*@`^JUU.B_:JTK]-NFO2E*W.N<JM'`8G9CI9QBC[O\`BQ9W)SE_[4;Q
M3EQ?GEW)S@/8<)ID_#6G=U7]'H<)ID_#6G=U7]'HGC1EQU<NOTH:,N.KEU^E
M`0/PFF3\-:=W5?T>APFF3\-:=W5?T>B>-&7'5RZ_2AHRXZN77Z4!`_":9/PU
MIW=5_1Z'":9/PUIW=5_1Z)XT9<=7+K]*&C+CJY=?I0$#\)ID_#6G=U7]'H<)
MID_#6G=U7]'HGC1EQU<NOTH:,N.KEU^E`0/PFF3\-:=W5?T>APFF3\-:=W5?
MT>B>-&7'5RZ_2AHRXZN77Z4!1'ETWY:I59(K'X1D2ID.-!N'P^M!0LB12ANJ
MW*SU.6Z:>K#24,'HSU5TRSW+U%,L^><Y2SSE\BF[^RW?])7_`+4X^QIE]*92
MR.F4'[O[GA0]VJJ?_7:>XYSCXY=[]EN_Z2O_`&IQTV&56\<)VGM]]GYPA"+I
MD(0@$(0@/I">P_'?;QO\FT])0K5#(I,1&-%PS"R'F5'H[3!WVA9&Q;O=5*RL
M=8ITKH2_1U.J[3=EH3JJHIIJMSK[77":9/PUIW=5_1Z.L?[#*E*>3(?#N_NW
M7([DYR[C-L1Q3EQ_?[6?N2CMT:,N.KEU^E'%:>NK=>G*-HX0/PFF3\-:=W5?
MT>APFF3\-:=W5?T>B>-&7'5RZ_2AHRXZN77Z4>&H'X33)^&M.[JOZ/0X33)^
M&M.[JOZ/1/&C+CJY=?I0T9<=7+K]*`@?A-,GX:T[NJ_H]#A-,GX:T[NJ_H]$
M\:,N.KEU^E#1EQU<NOTH"!^$TR?AK3NZK^CT.$TR?AK3NZK^CT3QHRXZN77Z
M4-&7'5RZ_2@('X33)^&M.[JOZ/12/E]WC;E?8&2@F2BBD:F5M_VP'5AI%)\"
MS!0Y4MZ;UWJQF5`0\]"=VW+0INSN5:7TM$Y2GF[&&C+CJY=?I10Y[(GE*6`4
MES9_W135=V<Y_P#5*[XYS@.CY"$(!"$(!"$(#E3]53_&E^>.^ADCWV:Q(9.C
M"XGE`J)%YN7(L_MC0DR52"NHW*W#6=ZFGJX$F%!;F>U<HJSVK]<I:6C.<JI3
ME+H7T?5T_P`:G\\H^A9D:Z93R9V$[/G_`&D*+N552_SCK;X)3E*`W`X33)^&
MM.[JOZ/0X33)^&M.[JOZ/1/&C+CJY=?I0T9<=7+K]*`@?A-,GX:T[NJ_H]#A
M-,GX:T[NJ_H]$\:,N.KEU^E#1EQU<NOTH"!^$TR?AK3NZK^CT.$TR?AK3NZK
M^CT3QHRXZN77Z4-&7'5RZ_2@('X33)^&M.[JOZ/0X33)^&M.[JOZ/1/&C+CJ
MY=?I0T9<=7+K]*`@?A-,GX:T[NJ_H]#A-,GX:T[NJ_H]$\:,N.KEU^E#1EQU
M<NOTH"!^$TR?AI*?\"<6$_S)V<.$TR?AG_W;6/1V-(<IFXSA-_-F/:&NUBB^
MRM2]D:>U52&Y#V2D"I24P?7W8P6&Z[ZUF*$];]7T^H]<7NIZ/5*L]5G",Q";
M=7?\8RLYU@.QCPFF3\,_^[:QZ.Q_&8XC6(,R\<7&"H##P`\&*!#00U**L4$&
M!!5BX'$A1080FKE@0'$6+ERS?L7K==J]:KKMW**J*JJ9]=KA&8A-NKO^,96<
MZQQKQ&8A-"O.^KOYM&K_`#C*SBG_`/>L!O'D\C/"(U[KY050IY(-FB3@+CI<
M%-I4Y3#26R4T+D/<P]86!%]-E9@0HRR.*D[6=VA@RX06KP4#<'3K'5A+ER[3
M?JM0X33)^&?_`';6/1V.I#AF?A["Q88R[A6\CG%]XUQDK8Q,JP"[4@6X8CM2
M[`@YCAL[!E1,4*F%"!0LQ%W3N=0#6+.EH6:*:=K>$9B$VZN_XQE9SK`=C'A-
M,GX9_P#=M8]'8<)ID_#/_NVL>CL=<[A&8A-NKO\`C&5G.L<+N(W$+*U>G)]7
M@E.5J[.4Y.,K)3E.5NJ<IRGV5[4Y3[<I_!.`[&G":9/PTIW=5_1V'":9/PUI
MW=5_1Z,X:<6,,VM;8Q,18L>8#T`C!HX<,$WA`L:,%)LLOBA8H1=KJNWQ(F_<
MN7K]^[55<NW:Z[ERJJNJ<YR!HRXZN77Z4!`_":9/PUIW=5_1Z'":9/PUIW=5
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M<#@RM#5WRNNAIVT!2!&5-]P`]N@9<MA*!]%(2X+#]8C0==0BD17?#!Y=UT'F
MP1\_P.WWSDP$ZPB"M=!YL$?/\#M]\Y,-=!YL$?/\#M]\Y,!.L?SB_P#%!7\G
MO?\`AU1"6N@\V"/G^!V^^<F/ROO*?7;%ZW2PCY:5RU<HISD[?2EI5T54RSSU
MD]J6><L_W(#7BGN2_@E^:/,>GE)QY2E+48[O:E+_`-R0'SB1YS.-L,=W^Q(#
MYQ(#V\(]1F<;88[O]B0'SB0S.-L,=W^Q(#YQ(#V\(]1F<;88[O\`8D!\XD,S
MC;#'=_L2`^<2`]O$[L;_`(XH_P"3%G_BC8UQS.-L,=W^Q(#YQ(DQMU@LTA?-
M[IFQ#SW*1UD';L]:EK?W9RJ#UB*J].4W&IS2G*[3HYL^>>?N9NV&Y<(@K70>
M;!'S_`[??.3#70>;!'S_``.WWSDP$ZPB"M=!YL$?/\#M]\Y,-=!YL$?/\#M]
M\Y,!.L(@K70>[!'S_`[?2_.Y,>I)<0MY1@[Q@2,B]Y@#L&AR2WK]LD0ENF@T
M3QL,(CH'.D0XMFY.L`;%XT%<KE1.S<N!ZZP]R]8JHNUAL7"(*UT'FP1\_P`#
MM]\Y,-=!YL$?/\#M]\Y,!.L(@K70>;!'S_`[??.3#70>;!'S_`[??.3`5ZY?
M7ZSIE!_ZO"A_XTGH^.5>_9;O^DK_`-J<?9&RHJ->/&3D_L5F&%HV*<T,Y+TM
M.:HE'7EE)"D"8H.1ID4BK-1R<!UR:W2\%*R"OSK$4@!,Z:]"GJ<]+/+Y^ESV
M*AEC*KE=4FC:G-5755+.\I#GS3JG.6?_`-'QT6-5,15$S$8QG@G7$S==$SGV
M=<"$=CSZ%/RQNR-J?'*0\WP^A3\L;LC:GQRD/-\6\='RIZ_M>=)>+ITGI+KA
MPCL>?0I^6-V1M3XY2'F^'T*?EC=D;4^.4AYOAXZ/E3U_:\Z273I/277#A'8\
M^A3\L;LC:GQRD/-\/H4_+&[(VI\<I#S?&>91\HZ_M?UTETZ3TEVD_89/ULA\
M/Z[KD_H;8B.W3'6E]CT8/,4^2VP:.2P6)ECU.-72MQ(*]V2JZUANBUHGZ4L>
MM\V27!6Q9H.4Z:NV#:1FCS:=\#2!NV[06H'?D*N5"*K5F^770>;!'S_`[??.
M3'+7,375,8Q,K1E&T)UA$%:Z#S8(^?X';[YR8:Z#S8(^?X';[YR8\-3K"(*U
MT'FP1\_P.WWSDQ^(E\#8&'$"Q3$/C9#!;%X2(O5DZ`G3:L![5=Z]<G*ER*JI
MRHM45U:-%-5=6;1HIJJG*F83W"->2=_A9^4E9Z3L<^`\H.BT";E0ZT2H.BV,
M+3,+9&@15%%YQK5ZB@0%OVKU-%ZU:O42KT+MNW<E51+V.N@\V"/G^!V^^<F`
MG6$05KH/-@CY_@=OOG)AKH/-@CY_@=OOG)@)UBAOV11^X%)/ZQ35?\)7<6WZ
MZ#S8(^?X';[YR8K%RLS2/KC>PN%S-LRQCA!E>$=I$+>[<7%Y#IPFF2IT`IPQ
MA328!EF<W*AT[AN$ZV#3"RINTRO3G>HT)2J#HC0BW#W#O*.;&B??]*^N0]P[
MRCFQHGW_`$KZY`5'PBW#W#O*.;&B??\`2OKD/<.\HYL:)]_TKZY`5'PBW#W#
MO*.;&B??]*^N0]P[RCFQHGW_`$KZY`5(T?5T_P`:G\\H^A;D:OK9V$[^9"B_
M2.MHZH-.0\RC<JJ9S9HGS2G*<_\`#]*_!/\`ED=K?)\E+K87,'+&,*Y3$NI?
M7#<)LV*5#=2UM"'1!6+&J]1GEF9:9WUV6W1=GK(V"RKN5@K$Z;\KMO1G*B5=
M06@0B"M=!YL$?/\``[??.3#70>;!'S_`[??.3`3K"(*UT'FP1\_P.WWSDPUT
M'FP1\_P.WWSDP$ZPC7%08B*TJ4##]0LF]Q63E\K%0P=>)$+<HLR%"PX&QGM!
MG$OB+D[@L4'LRE:LW)TSN:=<J;5%==/NIO.>RG.6H1\IYISIG.10WM4L],YR
MGFJI<J=,Y9Y=J<ISE/NRG.4!.D(@K70>;!'S_`[??.3#70>;!'S_``.WWSDP
M$ZPB"M=!YL$?/\#M]\Y,-=!YL$?/\#M]\Y,!75E8NZQ/\9QO]A%Q3S%SF.5$
M/)B.FV>K]BW,L>T^:MF;>V/VB%6GV<DGI`NL^I+D=U?1[%">KZ74NIY[6;3Z
MI/1T#X%>*O8DIOPNBNE4!J_'\PT-UZ#&`^N!83KP(*"==E]_K4>$ZZ#W0_70
M`5H7.M1P;JO7`(3U.YUN*MV;W4Z^IZ%6U/`KQ5[$E-^%T5TJAP*\5>Q)3?A=
M%=*H"MQI\.A"T"D4:F)'-?I4B5>8&1XIRMQW2K6*>/5.;%Y"4BU>8E-2=*Y7
ME5(K31,76#6D3139"!>IR"U3KG5+8.-H.!7BKV)*;\+HKI5#@5XJ]B2F_"Z*
MZ50&K\?G>_8;W^AN_P#AU1M)P*\5>Q)3?A=%=*HX7,%6*NJW<IDR2FSUVZZ9
M9S=%9L]5%5,L_P#A5W,\^W`=BEF?^:!JOZ-T+_\`M8JB2HU:;URE4ED$B$R9
M,*]E1BG4@F2(?4%*V_O!IC2@D`EXN8>]4XUJ=VQ,0&N3LW)VZ)UV]&J=%,YY
MI9AKH/-@CY_@=OOG)@)UA$%:Z#S8(^?X';[YR8:Z#S8(^?X';[YR8"=81!6N
M@\V"/G^!V^^<F,26>*4I;LKL':Y:5YTT4B1]DK#CQI`CQ-JZ8B`XL79"4VRQ
M>#Q,KEP,`&7I5U6*;%-(>JFN[3<KM47`VBA"$`C7\^PTMFJ'0%NLH;S@'!D/
MLH>H8C#)UG)&-%?-FW,Q!NBU+)G;ZHK;:PI"4P$6QW98.F[-PS,"TB-3FT8F
MR=(1Y=L!"`UM"X2F(!.Q4\H=&3M*WV^CW:L`J3L]DC0COFR$J;`X=P&A)&$D
MD'<LV;VJM*#UA04]E+Q>),1--RV;')R9&.R.:6;-FEF[F;-VLW%FCS"`]&5)
MLF)!RB,BP'(,-5AO9/3^]U:_=Z^-0Y*4IZT*T+UVY;#Z!01E83J06BS8GUMU
M:JW,1>OW;GN\TN*7R2CS"`\9J>*7R2CQ*=$^Y*7P=O1GFGG[<LT\V:KM<4YQ
MHME.<0;DX4\GUC"Q%,^6VC)SF?8!Q%LB.N2^@V!%2@*R:[2!4YB57K(@.9E:
M/JOU*TT+Q=N8(:7D@D,.KM@[E^Y1B@'#8B6O:1N'60KE.DJ%^UY`7N=?7AR^
M;@BJ\3!J6-TH+PHN>8>(.%&3JM-N"*.;RAM!+*9,"Q)FEHA'H8A`@2`L*:0L
M5S2XI?)*&:7%+Y(I4P]Y1K$DXR0PJ+9S6895+%6,S!VZ6+-IP2+<A>J<U2A2
MWC+8?G$!)UQ)':&3H.LQ.E&[YV5"*$S?'62XA("DQMF`TS-1Q>7?W-9E,A[Q
MUX*2A?(DE9`DQNX:\.+KI(P6-+DU(]PU%B":M5K)=,TSSYDI($009ZVCOER?
M#%;6KZZEEP[9`JO;8@J@M2=$%XP+G)2IG*4Y2[O;[=.:?WY3E*<OX)RE./.:
M7%+Y)1U?\!64K<[#Q@6PG%;WH<J6I&;Y-1A7R;)PK;D'IDLU2L#%X6CPV&Q&
M\8A4DW4BV1VN'U;=4VE>6&AY=+4_0KK9U:,S```%C;/;N,!_RUVT#A57S1)!
M)O(\SLO:0-,O+Y\/N-FN6%9=JD4Y2B=RXDRDY,W!1BE%G"\!-%8;E1'8`5V:
M*SES"53G"0MDY::A:%*5,Y9Y2[O'3FG\DY2G+[\H\YI<4ODE%+F!5\%NT.1M
M:UYSNTGU$OD:W2Q$"PCE.R/+$Y=4-AYEBFK9<<NLK01DH#0N+1-VT"+C`25#
M%:KK8(`5%91<4IT`+XQQ.Y45[ERKVT9Y#,ZW5]QEACSQ48$394KDZ<1`I8(>
M,1AI4^(](.D'05U-'RV+"E7$1:5ERB0I\=VCQ.F,Q8(&=F=H39-BX+Q9RIE*
M<YR[G;[5.>?WI2E.<_X)2G.$]&4L\Y2Y.>?WI2EGG/[DI9XZY;VY0YRL76`_
M$6E$$WA(VSH!,E2Y^+!W*!C@K$)930DW,,0K-DZ3:5:HL(2G])M96V'QSE47
MK@SM@J@!:5(HH%I<3>6!P:)'?3%LB<13G8*V5#X;SL@-W'*CK#XOSAIUJX)L
MTQ?BB0Z1*`BF7>'L2ZA&'-#MOS%R"@)=&A3^P!,RN^-(:219![R%.%15(+0)
M:,Y9Y2E]^G-/[\IRE.4><TN*7R2CK\,WCG,$,4-ZAF):%RDXXCYY1@ZPHO"P
M.,MPEE;5N"YTA>#\V>P&ET^8%@MU`*\9HW)VF#N"W`U%+$,B3=*.8'$(RZ7V
M;E\"12TU^4\=Y\$<5IQOF90!5B,36%QY,2#G)!6+A0ZM!@QCL0Z^PT&+?H-9
MEQ#;.*;;AKMJ%X9%*T/R01)`)VM*WSY)*D:<";``+K<U/%+Y)0S2XI?)*.M<
M[>5\Q3.+AIQXOSAB:=GT.WN&?"2TV(-.+%U58LC-SQ(7$C@]3F)5MJ[+9$J0
M]J%2E25]5AR)3E)NMZ":P("V#$(+/[5`HGO6.EV+Q^C9T#IND*U"3<D/A_>)
M@F.Q2"K*HDDS$IJ=AHD"ZJW=Y%&"E'@BB26:0B<]&&MQ&GH*\K76!TJX"B+X
M!1$I$2*D+,\U.>4LW;G*<_J9YNUQSS9I3[?:E.>>?P=R<><TN*7R2BB9F<1Z
M]Q38QLFGB2#@P249;$?A"QNKYNDN5JE8W3N28MGV&`8AZ'/3@JX&1!DIKJ=-
M?;-9.BHL#CT@8'QX@[%TZ+@4E6>WM0'C-+BE\DH](GTV3)<#?+2,'($"$FY\
M>WK/5KXC3-5,=#U"="M,3=O7*>O3<S&B^I4URL6.K=1#6[(>W:M4>\A`>,U/
M<S2^3_\`G-FAFIXI?)**8,13QKYK,IJI#XG-E$?)AK<C_B-?@"T8Q>JI/-DI
M7"0S^(4.6GI\1%<C,DJ4DDU6:I<O5HA,FYV3E!P8!P4J[5ZJU+6)U,J7C`%8
M>Z5,G6_9=M5XO&CR3.(UNCD`H5:NBP$V&4`Q)I3#ZO$4I@9L0$%P(OD0?WQH
MTI/BVR9I\:DU%;N5`J5$G9UG`=CS-+BE\DH9J>*7R2BF)S\JL.8Q_1R(<I!I
MDX:X.*QCE`D^;0],5.H$]>P<8="_$8?FAV<SM4($0?K<C!K4@N,Z7F%*S:P:
M5I42M#T:*4YB3)K^#$MC'QHHYBFQ<!(IIA$U;>5_,FPG$"M"]5GRU"CT-BZ?
M1.(9S4B*(*05@0&'H4&<)0O+W5#7[Q"O2-:G8Y/H]*'Z8#6Q0763E3+X)<G/
M^:4,U/%+Y.U\N;-&B642;(8Y.%!?7"Q\59AR<9$A"Q<-F[B)4ZS)*"1SD\:E
M@U()U2)Y(&I:/=%`N&IK)<WJM:478-+KA$*G$)TF`R5`TF%6*M5!C?>BC)FX
MU<H6GI6V\QLHH-0TKH8?%D;JU0(G"`XS<JQ+(11M8&1M\UM$`]762M35NF"<
MNV34!'0L*I#G&D;MN7)LOD'8WS2XI?)*&:7%+Y)15*ML?+E-YBD:]A39"MNH
M"APL0);A4F9I51JTT%$KFFV#Y78H"U5JI0!B4<DT27"CQ&CD#-GC>Z9NT'1I
MB2O:(G20'1"FSG51&Y4S&,OFH2S@D>';#V"-7!R=2IQ]II/FSO.'*T26F=4Z
M;)W1:A1#P;?7:3`T5%E9$=AO5.42#%Q(*"'0M4@S8-;+@@X.P+FEQ2^24,TN
M*7R2BB9R<K,\2:(7H>5)X?F_-&!PX%V"MRG4K.70401W3EF<6J#3*G-1B#3@
M%""$C6X;6B%3(?>3QTIZ"-8DQ#=`%IT7GA]8I)9A<;'P_2,>C$8@$XW+"+5'
MX76D7KGO8MC%VE`W*4;0_,K-X7AN9E2+]1)TQ2MUSW23=X&Y3@%X<($LM&W7
M8TP&VSPX7K>%A^%O&:7%+Y)1QST9\V;N?#HSG+M?!I9M'/\`<SY_N1H;A%Q<
M*G$&G\5050(685:86,0"L8L?9)BE6):TY%PK9]K7H3A^5HY;!;BR1`HZ(W6*
M4^*3)_6:&(,V+!`ZT)NAC$*$#:<Y/IN`F-#)ZLKBF=EX7.EB`Q)(@.]*S>1&
MNHMTH8MJISY4B3T0VB#+"I4!TRC6W:WL99:P2W80L"DYN4D9[0N`IJI%$J30
MP"[K-+BE\DH9I<4ODE%([GY5-P&N6[PIZXU*!5P(AP^91E[FTK(%DJ*R:Z-R
M>ZQ1)";)%8.5931DCSHT<HC6UHW.`3<@3<6Q2M*1;4K>9ZI[1N.(?!]E.GY;
M56.*A7<P\E5D46M/AGQ-)=7,3;=+$-:26&E]UHJ6U6ZQ<=JTRCR!S5`IF*5J
M2D:*TE;"P;!CQ`J>VK"R\#M(E3AQ(7<YI<4ODE'B4J9YY9NY/-//3.7W>U.<
MI2G+[LL\L_:[L4D.CE7U$WS&8@7C3B/9YW2QGL&V#C%JF#]NG(4!BWKE@L2#
MG.NVJH(4^IZD[6+["IV^U(XU2RID6S%&G9:@J4"=)QI4,KN_J1X@SAC<8&-1
M#%-0TZ/7XQ[X<F/:ZTJSE0*!+HQ1*7)SI=\U2:VR.\=AQM1-;)&R6)H"0R3,
MD[:/E88!002^4UF0\SMA=GFEQ2^24?SBP88<%$@A5J5T,,#WPHBWGJHZI8$6
MJ[-ZWIT3IKIT[5=5.E1535+/GIG*<I3E4K=RA+PH9989T#B19A.X9SYXQQ(E
MC=1K$U4RU9DY<D4^:@:T6UB<?%"%X]"MJY*I01.GWA9Q%O/<*#=S)N`4--+L
M"X265%FBW.4\_P#Y^7Y)P'J2(C*TT2$Z=)0L@9.0%1<2E(3JEZ_UJ6%0.R``
M!NK"+ET1>Z@$#V;75;]VY>N:&G=N5USJJG[7-+BE\DH\P@.,]&7;G*7R9YS^
MY*4I9YS^Y+/.<):,^Y*7WZ<T_ORG*4Y??BJ;'"X*N.\:N3AP>U*)1)%F<1X_
M%2O':&)0]-DD>.()PW-BE52@V-]M9".+3TN3ZP,U@:N`LB@B,`)FKTPU0Y+C
M;HA&F*O`B_X<2ZO4V`A0M->PWD5APC/%[B&8O"^7-B[CUN*#:QH3DX2CZ*`L
M<5)E=)6X(].EJG$D/62[*2`(6@S6Z1A3L`%''UL=9$!;1FEQ2^24>)RIEF[7
M=G*7:IG/N\>:4\TN.<^U+X9RBH0^RBCLH`PMI1=-*WHE8D&4@PGX"%O[4UJJ
M1"<ZGB/9-DG*.G!2XPW3`0S$U(A1NX*(BTH-RX%:5!*GK)N+$)P>:5E9?I3B
M.QT+;$6SR8#!PDVG>%H,HEDL@"N88Q$NNTKRMP.<G&<0I,V13N%9V6!PRO:9
M:)\#;"HUYD/;4[3/.1&*F%$1+.M-4A+P=E+-+BE\DH\3E3+MSE\,I=JF<^[/
M-W)2G/-QS[DN[/-**;49E$WW7-W4>6M$W`?%D%6N.1(3*PRE4APTBFO8+#QK
M"NX)3EZ=@D6H6TZU]]6K!V.R%B_<;JT+5QX8AE8#30,N/-?\8>+EW<0#&N@3
M$"!#LP.PS8B<EZG7[(1KEF8YP$XZ3U.CA1=Y9(E)JQK1DD*JB)LDH[)"B5!?
MN&)ZDW:&&*OLA*R(F3Q7?5X=A/-+BE\DH9I<4ODE%;.40QM+/!DA#M:H]'HM
M;213!8D,1RD(#H[4-U6'R>PZE"3/QR13"31Y89G!6`5`!0F-DZ>Q2RMMNU!@
M`398I0)Z;+Y.%L0&9Y3)Y*W]<Y')YD6\%,^S^)_)[,6IS\R<-2!G%.DIE`B-
MNPJ95Y*0V4C6F0)VVZQ=M'7%"0#3L<".DV7J"R6&X<UJ`7Y!=#FIE.4LW=_^
M'/+M<<Y2S2^_FS]R7;A/1EVIR^2F<\WW9YI3S2[4^W/-+M3BB$MQ,KC%)BIR
M7CZI<(!3;"+S$+E`VZ3!:$52S"+`U+6B9E_4""'N$F:)AD.=A5@I&O.UD6%]
MX'=,FVD6IL$#-U$+4)Z()/URDP5Y6[>!=ONIT6ZV(/!M;PS@4*NBK#,[:@0^
M)W`TJ`!FXY^I<43=-D2*M&4N\7JPA,TO2H;Z?4%IVD8`:SKE)$RC3-]1%`L+
MVLTN*7R0S2XI?)**+K^4Y<8C5[A$C7H5M778##^(R7]`]V#!Q%<!7COM/C_&
M!$,4N"D2.XBZ2(N4:9,#=-+>LK/SJZ`/T]0;%U1@`.C$*(*97-,I0L[5IO7)
M(&P2IVRCN8K,3V"=&4WU&I"MPB5X\/XA]R).+57AZ4\9%E#9N(M\.;@)XW`E
MA=[:6Z(S9$K*[<6%LP4J?2P6]9J>*7R2AFEQ2^24==]%Y33%XHSO)JNXYB,9
M%L6!Q;X;G\Q>*9)-\=KAR'`U4MGA5:9XK!$9F"B2Z/+2A6EY\X:EF"*B.@W`
M'5LF2]T:H0559L4B=F_=%7L(D<W"Z5K$)>VBL4=.#$HPL+TK6TZ4V+<O&$JK
M">H;5QB^=9NJ;X5ID^/*'','029+:1[@%)A>1I6"2RK`T5#PN$E*F>?M=R>;
MMTYODSREGE]V6>7W8\YI<4ODE%8>33%+ZLURAI8XPZP-/2'*,.Z6!J"Y0*D_
M(0Q,(97#H>%OM=I6`TP-DZ5&=!S</ZT;:&C"E(FAP9D1..,BX$',AEGL!CZG
M2Y$L20:G%&!D8$YC(-(8#ZN)#=6D$&!AX?\`5@EZP(HZF+"![OZG=ITNIZ%6
ME15535[_`$:9?!+NSGW/AG///_MG'F$!XS2XI?)*&:7%+Y)1YA`>,TN*7R2A
MFEQ2^24>80'C-+BE\DH9J>*7R?\`]1YBMO+"*M6(7)?8[5L@U2IT0M4?AF<]
M4I)7HM0G*45::49`25FA,=$"B3XTO."DR`#@UF^'%`1EBY*=,[=<Z[-RY;K"
MR+/1Q2SYY2G*5,YSEGGFE.<I2SRE]V<LTLTYSGFE./.:7%+Y)1UU'<;#$JWX
M]U'`/#)W6[PUJ/%OD<PV'MK5X^ABXBU)''IQB-BE,1RR#"D^O%O-+M4YJ65J
M93$FI-EZIBD^.BI3JX8D$K=-:*#;8%P<K*(95R71`.<WR9,6T2S)X_GE(#MO
ME"<FU80-@,<]MV_-D\?KDQ*[+>'YTXX%RRTZ4`5&7Q%&'Q1%9JW+A"#U0EQT
M))0NJS2XI?)*/&:G/.6;N9I_4]KMY^Y/-FGW.W*4YSEVL^;/**WUEBIQ`-HL
M$"S:^0C2AG#?IU;#?L.LTFIU*J$><E0'#TN'U7RA4:$O6B16V;B'&MTID*GR
ML"J0XIUK%(!;EE".L5&Z7**X%=B]QA,<Z&+S%0/P[I$N/&JR>N$K$)BHP\K+
M$";&0=*%3:NKCV*W1+F*.TF2K5&CEVJT&WH%4IJ\:A4B"%6BM.)-PBTM5@PU
MOI<.R!FEQ2^24,TN*7R2BI45E)SD4=A5XFVW+S3#Z7X^TQD\U==%#CD`[Q:X
M"T/D<W),Z9<05A*R,2D"YX5J3)(Z1@B=E0S1%P6Y@-0SO@:4(,MJE//+\_W)
M_#+[TX!FEQ2^24,TN*7R2CS"`\9I<4ODE#-+BE\DH\P@/&:7%+Y)1@K@MHBG
M2)@R?71+([*`9G8.0X3KTQ+^IF(8*-!61'5BP6#OU:`8Q&6^I5W:K-75M*JW
M.NBW51G<(!"$(!"$(!"$(!"$(#^$S+2TZ+AY0<``9J4F@(47&988A+(XO,2\
M=8N!1H`<"%6[H88"&!KMT,+""+5T.)#W;EF_;KM7*Z)ZJMK@>PZ-(222:%3B
MR+40!(S)-I-OA[PO$H6^;0B."<R3XTL:1$*->&J;:@-21G!H2E?M`+D_>3I,
M-O$R:NDQ3.0*54;V'ZB8#':?8>KSV.5<P@8[UBU2;<!<#W(<XT-\&&(X47#A
MR3P]MPOJE!=$-.G<<!"4`I(TO*3HHK9Y<5F`LEM%PU\&DL6)Z,\9K\(+%1C[
M;&S8:80T^&Q,Y/-(LV3J@U42?,PIYB>.E"1J$^4!C32?'[@'X24[]PC;E*!;
MZQ<8P32*;Q$![*P5ID;"0W2-L`6%`X;Y@FO$MD*#(W#`G#-%L8$*7"<\C-T(
MA3I$5MN>-_959,LP"M/4`?(68=,'Z(5!X=ID]*RPDLFY8-J(RFL'X26`3"PA
M"IN$\E&]-BI+M*0->G$"DYN2Z)FE2$&R0$<7,Z864Z<K,Q*KZE;(.8WZT:K!
M(:ZI2@:&)C&@TN#TTF1)/7@0Y4?$*XP5$)YN&/:P.LCTIRG1"?G+AJUP$TGR
MQRLG,\Q`UE5NA(@TL8*X&F';+3FA46P9B8R4:%&R&)@QD:72NT:GGK3K*V/B
ME&Z/G&4&'5M[EA5X+,+F-UET^5NRHZQ$D8^;GHUKE@W;EG0E`T60ZS1XA9E2
ME(#=+%%Y.J"S?OI\PJ**R^:A'A807Y-W!87(HA;>ECRLQ;Y,X=U%A.)42H54
MOU2E0N'E5&I8>';8WB-2*PU`&!0(-R0B,`QF8V1:D+!!$23*CL%04%]`?]"3
M)U824XC&Q11.WRF#6V<<.MU6X6]YY'M'O,FUT((*D@8'%M^3%Q1;TF-DY154
MD(?$ILO!Y`>(.T%19F5"$T!`EH;48_RCKO-F'QHI]\42R[?K#!8M&N,%4>IU
M4.*X"/<5H\0B,/CYB0#8D%A+)M>J-_50O2X*S%;6T`K=LZ5XHK-DJ/'!E(6D
MH3^%Q<H[B+8Q.,Z;OFQ+8)15&(+!P*?1J4:X*G<=8(`?C%Q/U8>@9#<-BI.`
MD^B*FD"&:</Q2D<&ND@>Q86EPWC57.M4*:K:L-_[."S#-8PU"<(-ML@].'@5
M0-IDWLE0N=`%='+>MR>O"A4^V?V[$1F7KRJE6$!J2J4O,DT>6`8U.BBNX!!]
M0Q5,9/C"0C5B2N`FFN&%2T('G4F(@M4=MR'7%&,GN63;7&A6#F#ZS!<C+9PJ
M%6W@@:GE*,.;8^T>S-#@X-;`L_.#(U$ZVY5P)B"H0C)+;"TJUP2OFT#DJUZT
M:B$DH#PL*'_I9UI%XX9WAP<`A+!X4N5B1>DF3@Y(!0)U9OT$RP%I52`+X$84
MRO5:H*3%\88L<9^2A>-A7868?"0O'O<!`ADXGSXW3Y`]2@.L!+X8@ST<X925
M&5`)1@F:/"%L44#3)[UY;3+N%CI@S`';/4Q1;L!8T(R9&"<0GT^F;;/C"\F3
MS5N2Q=%HH<YX"0<H&6=HV-%`NVG7IP5+X$=N2W9HI#HV4P!)N`8*4G3:B,1A
MVF`Q,.%"+U[8A4X=6D6*`;YLCM/&4TFU(Y&FC=VRI8K<@/DD:M^6729(&A0L
M2)2%RQMF9,6W[P6V/OGU\4,HO7>R=T=U:]U2JG"]C472E:Y$,MAY9%N"5\K3
M7XQG[$-<L'>7IJAS(,S6,!P&.H1B:<Y3@ABSNC'/<FT.'&:_41-6GVI+3(O$
M74:;EXTG3@+VBKRFSXI=W<1B?%LJT-ML&*Q+8:L)(`ZDZBS'+%7NUC$16&8Z
M9,TI"`&WK2I8@B(_Q!U`W/.JCH0*"DY!9&(L(I!9A1;J"P`-@CPW61:)-A")
M-312(%[K^)$C5QNX#B&2N&/J(0@UKZG,52C$*NHT6I^';4P%M\6V5=?.B4E1
M%=E)DQ27D(("`#8X%R>F$HO+4D6%+9#2BVB@3NDQ(8%;AN:#4-:5?Q2"%D\R
M&.E3:6/ME4K?N,KQ-Q5*-#*$V,TQ<4=(<[`E@`R"!1-G3-S\IROF;H?Q)..V
MQ.3'N&5_"]J7>>TA3+L.`Q"102^PZUXAV8>A=DJ%)CMR6Z02HJ%$[3NR?"?;
M6GV!4XRI;J,Z4Z!O%XL5ZAS,I^]"&,W=792S;,+/#MAS?3!ZW3K*]+/(H3E9
MJYN\72&8<U)W'9TO"(.2//[J*4;[DIE?)C-2VP"T1!5>NIX]L')@&E;"PJK!
M%A9N%F(8CJ:`C]KV*I'I]OWX3-)@I+*77"-23?66I3">M)FV=6R-)%R?;P,%
M29-0AP":J`%80'UM<H$A`PFUZ$)D_L)H)YT=B"#-@*MNRB4NC$B"4\W%=.]8
M4I<V]BX';HS=!.7UO=2[R+!`47KM:)7[MDJU7"6$7)C"50A!=%F_9IHPYX]G
M%P<I!U!CF)`.X;`2Q>Y<6B:KN.(IC-VDV/PA.MB0?(I)+1:IBT<4BF_&-FU:
MF09%9J4=9FGS(&FQ<J*2"^*+B_=)W\>>+UG2Q(R-,-K6FLW9Q)X,V4:%<BG3
M-$\B5&`Q8UGQ.H*S`D+RI:KH$8L8KB4&7F:B$%H%(NHEU(6*5$=:'98HD26!
MN8U^`?"HS*T12\;5LQ*8.VS,'9'-B!#N`YHU'ME9?(0!'.H1-PWQFLQJ#0R0
M5QF7!3<4BDRFRU)%YQ14:$I*6C:I7J=Q(JU;'&7B5<54AP1&Q*$69,V;X'F%
MW$W2C7`N%E2%=)(,R1K-6.&B#]P)I<.I&TLNT>D[7$".-DT6.@HDNHRET@`>
MN@(/1E4JX$,8M6+M-+TP-+)$EUH@#-'E"]9\>GW";YYV35:C1H%1G3</6V+F
ME9:?D1VGS:\8%:86I+<,D"[B:+["_1`^DI,>QX$-]80A`:V+_"*P+H.<9/&M
MD88&SC&[*K+#J8J"PN7`)J13*."+"&*R;^LG(E26D-)4?&9>`-10N@KI.;)H
M!!F((T"C`MF]1&QEDZ,'IPF*T8:-0*&IJIF&?P^V"R\Y#L2I+FFP_K2PXK)I
MHE%VEU;,"(:V"X#6%0CU<3"P"W*C>W2*H4E<Y:,;N0@-*PV3OP=!G&".M2S(
M.^M2]Q5\[!>+'K)QS,D+E^["/NH1UCTO1ADLA:*`TNFFKU8=S"@*G;1$X!GH
M*)7EARH[5HVH]2D\FM@Q130'+#I]I!@=K3A0-^I+*=&.@\)N*2HUI5:&734`
M&Y4YLX`U7-:F6N506T;MNCVW/DJE4/=J$6$V4%X46+LW]ZH0$2KMCVV<LS:X
MU61.9&E]FE@6KYO0=A5JXH)"I7DP`66DYX9ITE/2XA5@@H"#QE)396!:?@RL
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MY2G.4NUV^W.*;\.5B[C0Q'Y2VSB%-%A="X=\5)7A<9ELRE<+)"`&X:\LP]LX
MY`9S"&TC#I+FMIPG:4SH*!34..)O"#XO*")+E"1-"\J)*I"@EIK,G,ATB_S]
M+M4%1*;M"N";"$GFP;@(LW)%@"LDPDHL4GT6!<I+F8^VD5[V,/JBQ4IT8H9*
M<P"CB<OJ-!@^Z'LW*)/'Y-G!J:)1Q$*;M6='"*==:.$Y#AI$W=Y[S9.*EQW2
MO&`A:.(8DP]QQ(*2_'"C,0+*EJ&LV%,E!5DM$I(T(KI*3U@*IL`V4?QBN>`8
M%CAB8:)TS(,S&(QWEEB(=)R5$@3-QV5PR8[SG"K:6H,E)&['$5E:N(U1<7KT
MH/3TP)$BH%)0-/#N^ETV9A[]W^'$+CR7F(_"?C-0"A3P5"K!I6CR>V)!,+5J
M%2N@!$8$F)AX+MX$FR51B[9`8K0N1IJU:@*K;EIZNVW+V),[`GI.GP!$*O%X
MH+U&4PQ,EAX,7+.6D1U]-G+QJ4K6CH'`U6K=7&ZX6)2FRI(V%8H#-;J52#AJ
MF&$!&4A3P^F(H-5*)`VC51"C0VG6.JPQ+X)\.J(6*A6".22@2]E6+0R<E2M\
M0N6YQ4R9VXQR:@STX7H]B`:PM,]=5AN?``ZA-C>A%6ZS52RNJ8QMBE$($&EW
M:NW]3/\`TEW_`++M<I?]D?I`5BO?DN,-ZJ;EZ:&A;DE1SU+IK\7:+;Y:'JX=
M4>FF^/<9J>.P#Q#"M+7%,>D),CU4J#B:\/T&G4T#3(I5V+I\5E10H1MX[HF9
MO<#[/IQO$:0GA4HO;L1)IGBP<MR-VW=]M8,<S"<-R1%%Z>7PE5`UG91J8O*E
M9BR-*"!5I/7+RM4`LU(A8PY,K@C=2$!H*OLF!@<<LD#)I5,>&J3EIH`###B%
M/+MT$63*1J2A>W'2(THLRU&+8@"+BE/N.*-5PG#A76SH_3ZI4*I/"<U!&*G/
M!([+'*R?>$QWREURAQ&P%**V]*V;IRUR:5N&Z)<IZ7(:1/%*3;5PD2KRA:@%
M4URX1B:(BDE)%4V)PD3NR`!46[XP15=$UW]SH0&I]K!'ALL!D>6VT(8U$2*+
M$.4@4N*7KBF23/0[;+LR=%$C%XF#16#21Q5`1N6;CU_)5KH$H%4:JZ_,Z/CH
MU$RE&V&:4NY+-W9_?G//.?WY]N?W80@$(0@(;>U@&EQ$IDG2CN).VI0"95Q"
MX"/,@9L>I=6H5>I>]<O)Y<(!<I$T(EFA5@4=7%AP:D29\4&U)>.,BJZ*NE9F
M8`A4<C,&.'HV"MT'4R;4ZP-&M=!*/0CU4M'3=-5KNRYZ()CD@2"K.UP>+,8J
ME5>3Q,H%`7$Y.IS4V3@$(<&EL*2VY"K\ZMJHI]??KZWE?L/`XEF16U049+['
MJ>(\0I;(P41`U>7/I@^+B,R-@0`>6#1H(`%/3@(+H"#P8^V3&YT&`#P%1A>O
M5!MPO,`&$]RW6'/2L6Q%&+@&;DLZ\AB.!N$YY"0CW;8(#,H:5SAB)3RT*44)
M7R1(:0J:M*RZGZSLV2I:4)8]&F:?*@);9_*_D_,*8XK!%!JWIT>!RDX9<Y)!
MAXY[KFY\1U8=EF-<9D"<I5`];WE*$2K:.`9#UHF4E(WJ3EA2"9F8LM&7;(2D
M/4`391'*`'S%U.>%4V&`&>F&2$1N4\!%]]EW!%DY<JDT!OF*Z9:NY:>@**,T
MJXUJS106+Z=0,Z;OJ=R85+K*0VU=*YG4V/O%^(=%P:4D*8(N0*1QO8$,.Y"F
M#MNEN;'YFW>-IE6.4ET>HU6"<XMM`EBUJQ>40;A[Y6GJ2Q<$J<`DHD`D9G=X
MS`!OVOLFK@R<P%6%5K3F(@9-[%AB("J<E=-XDBO"AVW$`V"MPU$G7$2#@$2Z
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M5-A-K(R.P]ZD\``TP%U[Z80L+N*\QI'O,@"UPQQ$B')98RZU6"Q(:!K?.L&3
M];CMDM@:(51`&5:9/^PB9-Q"66E@W!%AR6DRE*P9>=!PAC+';&3\PGAI*3K9
MMS4-6KU-AZ62DO!W0=NT*-51A3#)L)A\.[XNE=]=VQK96D>EZRBJQ>LVS(40
MEHU1VSH8'E?JJZ6N-=WVHNXPB!LB[#.A%VEL6F-H>$+4NU!N$5CI)=@\(3//
MR"6RH*[JJ*4B<J(.8K%*)M_W@6Z]2MT>EPR<3S>$MI8*-*@B;`T]E,WV"+1^
ML1*I4R4+FFJP,9')RD<U9L77`B*:99Y0-S5\BUDX)^K1*F*KHU,MX,NT*)6#
MS:T4S,DH3$A1?.4H&(QIT:!<0EL`N%-%.,2NHEFS%$BK3#LKU\DE8`N"YUE'
M(UU'4(SI/N<K4:W%*SDWB3$N(!4B@$K<N($N`)5.>'9HI3<L%*`<(,J\V=#"
M>RSOGRH4JR*%9(U7:(*&T7LTNY[FH<`NV[(Q*G%`$4L2=&JXB*%"045K-56K
MEDP`7!EP$H#@MJ&]CC$8%O:YI+%$][971:+>]JE>]Y^/?51()'J_"J@K:[#)
MAM;P%O#1&'N)HF`JVLG:%=VK*Z&4GI:GSM2$9PF4W;7A=:(+9Y4ERK2=F,?>
M+%:)MFCER56QA,&Q6XQ\4.#IKA2.:LV3]+='V&5QL89/(_'';AO@8)M=JAY2
M%AD@1-^A!5":MEBDN'XSLPLKQ@!3X(+*C_`KA&41NXE`]LP0(>[H-B;RY)DZ
MMETD`)R686C4N'L-;`)E*JTE+$\3M2;!2VZG@B6+28LMWZ`]DTM#Z*Z;->2A
M<%^&\`JE>KP#>4@#);JY9.*=``"F5X%,AW-<9'&:!<)TDXD09_83"0<Y<)(Y
M.2E4K]*%1,J3>H[4!F(,^S2C4!D:4ONSBD<7#V\2>Q@O*E&:/'Q;S)-8I;KE
M"&=/!IVU(\Z0N-##BCPYQ4I16B>!4$F1!@/6*M(Q9N/N(`+4M""PIC*LLNJ4
M;M>ZF*O%4VE@S1`AQ<.)DI%*YJM%,P=D17-0.:M&;(,+BE?"],[:\O6LVP21
MRGUT147C):J1W"5(GV'X2#-BL.`=@[3Y<9AO:48*,,I$28:TZ5-G:"E.$$E%
MIC#M8DJUU<OMTDS!*AD.8(ZT/NJBLP5"-'I("6D(](K<4IDX/`E)-2-+!%TG
M++H6)DODN,#",:U=LNG&/M@&V7YFG386G;CANP8^TP2C%/0MD-89DV-5V./&
M#*D`LK5I6M^1LD9(`E0RELV3M+@"PQM6[]&B39Y5%X%"`PK.FY+=W$DV&(G#
M"RKOH\6@D2(<A"N,[C@86CM\%EAHN+@J5HE4L6]U"KLDMEGP[I)2A#N:B.N2
MLE/3QPC<O`ENZN!_$2]C_22B^6!^QBF9M[L,[-8@FP$H<VL@5^0*1:6[\U\E
M:T^!4*O!*MIRJ@:F["1<4>8)I525-E6IE0)X939+Q@`-KV:P]-.P,W!K:Y/F
M)*)=5;5.0XA@;+!:K(T5R\NIP@28E6&YFME$HAUTZ'D"7(`1D+LW[$S*LMM#
M1](@=7>$W)KA"`0A"`0A"`0A"`1$SYL>V.))J%NQ[SIRXL&M<<E$)M<)2@^4
MB;LJ1/C)T3'$H\S21P0GE)88442L&(0*:![0\+.X#%RO!;MVS7+,("'W#8AL
MW51*7;Q>E)R?)9'*QN%TGPTUFM2PS#*YHU,3K1N3\6HR=0ERC-AR75J>(U($
MF;FHZR+.2D".-+(Z[8IG&OH3)N8*`BI$J^;$DAB:BI/]8K!'RF7ZD2MDIQ2B
M+P[$$E@2%4"N,T.6H9U#81?/E.@2].A47<4@@2I0)$"/Q%XQJWBA`:"7<F'@
MJ$,>%P\BVJ/![<E:O2R]3PDP>-\3!S4<KD(!OE"#.T(^`UR1#TH02@R$6-3"
M'MI!?DH5(I0P,DN0AP)$9F(`5FQA@&PIF0LD$7VOE;"E+;I=H#`B"K!>!4LN
M6U12H.UNED@ZJ6LJ>DA=HL*%BIE.IJ+CD@%0/'FZI5-\X&F5M3G]DRW%A`:U
MV<(F'L,Z1Z\%AO`=E8*9=D+K*"Q;-C^E''#M)=/6TD0.T8-Y(U]H8ATBQ-!P
M)-8<"M.^VBH,4D=V^97AQ`2#`&RDI2E+-*6:4NU*4NY*7%"$`A"$`A"$`A"$
M`A"$`A"$`A"$`CC73*NBJB<ZI2JIJIG.FJ=-4I52G*<Z:J9RG3.4I]J<IRG*
M>:<IRG*4XY0@-1U3@6POKACW*PY+)NQRH:!X%T.<MRDX>N$YIF:*Y<F*L*%S
M?41DN!2RN+Z@=:5A`1'1=UDJ`EDFODQ4')K1>`+@82Q_$NL`V%1RCA1J-:MN
M9'*F5Q"S)"I%32YKME2J-:L/*FJ6#**N\I21>%IW:<UN5!<OC$\[@8=8=*S8
M&#RP2L!)4/&@A&XL(#21)Y.G!ZA#RVHT<TUY.&]F;\U6;Y6XKK60UB[B>%DQ
M@_8BP6W%U=++(IS#-/$IL>B[8.D59-P%HV*;Q:97!`J]!6*?)@M.Y^&Y4-`R
M2>*D4KQ>'EN<)Z./U@O'9-B=+X?D"YJ2<`$@[=$S]0&%4@4DS,&3J&W9FL0E
M=T)3[:+8,#:L2M0A`:?*7`GAG75PA,5HA#HY41`[A4_@%2UNJ[="KMN^GTB(
M0:56@Y9@EH6J91&J$1HJZF4#?4`T;91Q=31?38,G,9U"HQ)89-'!8OQ9J8+)
MH1JB'J$$D`BG&F3JO1=%JX2WSF'#PH)1+(10XUJZKUPB'&/SI1)!P%+4:+A-
M=DQI02J`$17ZRR-[H0$=J=JT6KU2W*S.P9M6?M.:FITA;Q:J541%Y89'9"+2
MYG?,",B.BXC4U%]/F`XKMA507'00&'&":P-@,(NSOQ"@3`_A=+!S"#B-JP*7
MGA@4R\63#`$BH5@DB%MU2Y]I4AW`/"A-IQ0EB?&CU8$6ZN!&]9X6&MN\"49P
M%MV[-D=>HJVOA`:(G.32P8GI*V)$-:8PM!V>/G-/V_,"MTGB(U*4R>I1"%:[
MZ9,%>2N`7JQ4-VZ*E%73I?->JCHZ;M5#Y![ILF1$@8.BQ(QM@GPPGY7B$(SQ
MJBXX)L4YLE5`^94:'BL'%RP4"%3:62*&/@(02?W+*).T2GT*B02/-4!0EAR8
MNHY+&9)?`FQ`5CPNU$(#5HPP;,,9D\RH41JZ0H0HCI6G*H"NFZ!>MU8HE(A`
M37J`R7"U+U@&4JWJ-6[+2U&70RJ,38"#(2HE"E(4NN$1+>+]>F<R>B'0C]8C
M'%4:?2UQN'!7>&53,^VB84*X!))&E6&!F$`V3=%ZF;K3*F[-!2//D$!6B'$4
ME9M-/#*".U3>NC$F2&%JRJ$!IR`P!X32^HEE0U-`X,0N0^KN`2P\6;A*,E$.
M!B:`J8L?L\.B,_5AF4*2TZ)>M%>$4Q&H@1JG;EE4'](`H`S-1=5W$T+DSL%K
M;H9+MPDFF,P:31+JMX\Z/"F+KO.I#-,+IHA`T4U%1$I%,X9PI"U'-C>,1]3?
MMB%-K;9I*0L123)$+*]=ZIOE"`U$%8$L*XM_U/B=K:ZFP\2V`60JQ.B]9."5
MIE4F`5+UHD"L%"V18K`C8'#DEB-K]J94Z0]'7W%*DW;L$I<IPH$,'M6I.9_#
MPT[%5G@ANR`P"&BC+4@1G2A42I5:Y59DG6]*QA*@DX-5BV.U`HQ9"CBLQ,@R
M?+!)G=L`;AJ<#Y]5,SDU&C)MA`(0A`(0A`(0A`(0A`(UO7N$YDG#6BD<0U(5
M$0K1;I8H0S@*)O'"<%KS%Q480732Z1IM?W6\4Z:DKP)+(Z-PQ().J11N2%QL
M;%!0:`2@U,0(K9"$!K0&P=X:@2M)5H7M*G"LU3V'\=A7)2TIN&I2C2[#T9#`
MH\:TP9O"TQ"H&A)WA8$!<ZV]K4Q5N@`"#61=L*%M6*89*LE]@@)D^ITP`9L=
M25+1M6M9U55"G8>PS-SYLF24GMK:1'F*B-7('*"^5MZ;2MV4O/LG2++"`.$2
M5D3[5`@<DM[^P@/SM6J;-JW:IG753;HIHE5<KKNW*M&4I:5R[<G57<N59M*N
MY755777.JNNJ=54YS_2$(!"$(!"$(!"$(!"$(!$1*I@F37*X`N8L6I0*G<4K
M2:@016NCQ+E1DK2Q#*VS2'5B,+E")#W#0`E%59HM4*5/!!5DI/Y6`TS8(,J#
M!YVY=A`:WV<'N%4,4VB`/AV9FP16&B%8?K!+:;M,VRBPPXT32+&,K9+:"^0*
MRTPD311>OMU;LT)&Y<HHJK*)Z,I2\W\)>%@/8.+PA@V=LAS56H5R#^[=0B<H
MM&:Z:@M`%;:KPXN5@Y4C56VQ.3%)<B5..JN&R/+"8J"$8XN"%0*V'V/BI'+(
MC5*"P]L1.[6)LL$(QSX/PN,\3GKMD83"+<=8'4Z5Y=BK55%0)JZCBVC+#N"Q
M%RV3VVTO*BE3UT)6X=U2#9D1ALR?^)5'GZ6OLWA7?1#WW:O/*IB:24;)RD]6
M]IM1:%CG).;%BP<@Z''/0M%'952C)T'QZ75W`YD('%]Z]:KD=<8/\*KF*:2R
M<3#HRBX4_M7($3=.E4VB1/!HM(),]#*9)IDPJ,"J_;,2-**`+;.$N6#[8D*G
M#"L0()+8&H6+ZO6=B\M"$]E%L&0_#XMB%FS"UACQKC,6+CD98F!"106&(&V)
M.)9!PG6*QEP,GC(&C<2DT\<,^&574P(PIH>P*1#095>5E^G%VKQ2XX'BPCXB
MU21+`C"8W<+QHU]:ZPU@6\3MD0H4Z@"(D5YX:IXO4A-94(8+CY:ZRH7)8DT,
M;%DO:LZ4*<;,748*-MG-LC0M9.\'N%)3#Q!JI<-['J,R%+\]=82.4#8(X[%W
MW-5"?M)-3N!=OFA0+KK62D2P<(FE`HZIS-3M/@@!,9B11:!!AK']%C"/A8"E
M\B@-AP8NP4R9Z>'OL7;:E#TEM3#S%"AVIFL!V$ZTN-=UX/'"I(2NS4FI"!PV
M](NE<%B*KM9AAC\/%>?8;CX,]`%E,.^/%5OD:X>7M5B92!.%($2U3-)@T:A.
MT7W#(`Q(#4F(52U+]WR>EP[0LV%MFC;B,3)<6'1C-2%D;NGCVQ,D22Q5#TLX
M#?F[B8*V$P2.ZEB0A0H`"BL<TGH(>R#@J1.$:B%':X3+>.DKK!FTK(T()72,
MD>X!=2)/5`XMH6&3=P+D&U0&';#"EV]8EJTNTK&I0:+-BML&L2`%*H$M-#,,
M"&*8^"HY*@9%U1P;4``A@HCN96$&F/6H4:<&5<[5F\)IQQ08-\*"K9XZP^J7
M#BRA\QRB49@L3II#9MDJ/;PQ5YJ=W5,9JR^DQ);<)Y*<P4P@2I1J@M!;1P)4
M(H6>71M1H+$B[M'ZEQ1+![7>P28AE$I26^H6PREF479DLPF@RI$@E<0'#`86
M<>#>-VE+:AO4B'#!N:YX5#)DY/`(^^.(5!4[J+MIM*%P(`0F"A]&\64KQ8HS
M"-;Q#MVY[?K2Z[V2$=;'J'&30R2'$^&Y^6B,V7I]H0<,!%`*SIOEV)=U4-V'
M3SC7E`NTZNV;/!5:D'4W%(G"0.P/9PX,`&&E(\.RK66!1"UHQCB2NRA$U:ME
M++F--JDP:0O#T%U(4(V@_J`:H<AK-BE,BZPH6X)++M8:Q5;CM.8%,%J102.:
MU,X3\.I(W+?+0>XZ&0Y>SB!L)=)+\T!""LR6B>)9$4P16J!Y2+$$XL["VJ#`
M03W:BB]?K+)4!*:L%CCU>QD';=)CG:?-"22<L86%EJP>(8\3B-;J;.H'$UA:
M<=Y[10?#*RE3-P6RK=AM2MK6O6"]31K1*;K)PL5M]6'H4`;&5LV$)5.&LL/R
M(.W3<AJW@6W72Q*C%T66H%4-TNBXA7"D)$THBKJH4*`K.!B8`$U*UK35%:-J
M7-I2>TRN28D5VK0>R1F$W#(W!NFSMO&#:1!F"0+RDK3-:-0:=3`8C")\L'$B
M=I+B\D`@2X-?39&:&Q(G!M(3KX@)C<W*B<2"`&I@'$^S9?#-AWPYU+:I@V.:
M=F*G)4EY8+^;7H!,(;VXJ>]5>JK.U').%I?(U'RK$B[EJX*E718N#!MP/;M5
MC!55Z<80"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0
M"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0
M"$(0"$(0"$(0"$(0"$(0"$(0"$(0"/Y1P$$9@A9:8A`P\O'AA`(<!&V+(H&,
M!BK5=@4%%A1%%RP)#";%RY9$![]NY9OV:Z[5VBNW753-"`C8E8QEDVG5&D$Z
MT38$*46-JFPK4P3(!)%:>5%J@/UI30HR0$3V"P\HI"_K:F@T"BZ*`_ZA133:
MG.B>O&+A`U6$B!,FQ51LQ"^<=R66;)7NTTZ7:JPYQHWIFK`R>'I&:C7K<KRQ
M:+JR@R$A2T7;+:3E,W.I#TD:$)C:H%R0@-@S)C6>/VS3[.*AM$2LVN2P!+%A
M&A5RFB=;IH&%0]L%:254RE5@S@&(&$$RT"(+#`3:NC@HT-:&VA%(JGJL9$:-
MNWIXHDXKCI"HXW5:/L7`J24QHF",P4"7#7KP81>#ITZ%@+QD26+U\&$O7;18
M)"VZ[P4/=JIG<L6JZ$(#U.IAH)+,:XTFK;B3@F1F5'1BNO:,EO;D/-R(KODA
M(:C51V)[.BC(F)10HH*A]\?<%EQ8)OEX.]9"7KEFKA;91G;18KR6TU+;6R=P
M1EXQ7I50A$K26K8P$#KIF('JX!(IZT4HV^8W[P^\*.[(Z_=&W;HNNNH3=N7:
MT(#\#5BF2/2A8I\[9]K3@A<,J+R)?$AJWJ0,"A<$A2'M!"LG6!:+)KP-3%1<
M%L60P`O.[(X("L6;5D+9M6[=%-,ADQ,4)TH*R`@*RXC(B0O!E),3%`$*6%)2
M5%P>V$`%I87`;5@$`+P(6U:#`P02Q9#!0]NW9L6K=JBFB2$![*$(0"$(0"$(
?0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g463385.jpg
<DESCRIPTION>G463385.JPG
<TEXT>
begin 644 g463385.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!!1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]33D]25$5$7T903U]+7TQ)3D4N15!3_]L`
M0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M_\``$0@!&@($`P$B``(1`0,1`?_$`!X``0`"`@,!`0$````````````("08'
M`04*!`(#_\0`2Q```00"`@$!!0,("0$&!0,%!0(#!`8!!P`($0D2$Q0A,15!
M4189(EAAD9;2%R,R.'%W@;7P&`HD-$*AT257F+'5,U+Q)F*2P>'_Q``5`0$!
M`````````````````````?_$`!P1`0$``@(#``````````````#P$>$!02&1
MT?_:``P#`0`"$0,1`#\`]_''''`K(WMOK<%$]43T_NO@&Z89TUV&TQW;M>PJ
M6X`KSKDJQZ)$:*=HY&'8ECU6&(VT]L4^],A-3TPY*VXGMM*2SE.8K:<]2+:Y
MYKI[MX[3+N;K7<PWZ@<0QJ=NK,,%M-A^H,#:]@UX@?"94@L/-V,5JIRGW/[=
M(FVC6PKN`C#6`C+49CED&P.DVHME]H=2]N[*:VS_`$O:.&G`NL<BMK6X12:T
M$N#8=F_!VZ%"EMUF</V&S7*XU=&B$.2LRD`*SEV.J+A2MD5#K5IZCWF3L"O5
M./&-XF6LA7XKSSLH#1)^PIGVILR=KT`][0NE2]G&_![84@$Q%<MAK+A$HIQY
M^1ET*X>GW=#<VT[MT_!V*#,L*>[?IWGN[4I,\5\$&TML*`4TLU%U]\4/1F8$
MI!*!N-`>*,,9L!YHS39TELN^])GMKP;J)T_ZU]PI7:S<7;'K?I#9NY\=P]O4
M8Y8IM8L1:.Q`H8NEUX<&"2[V,!V90`;B._@7F<)@M.LO*DPFE0Y##KEJVJ^M
MFH=,E'C-$JS0\@T(>JE=>E2'B&*-KYTE%,-:PU^U(\M4S6L$K#CD1]+!HBA8
MDEF.I+.6X<)$:N3I1NB@:#U]VODV2#=9TVP>HWVH%56AT:B;%V'LBT$$301<
MKBNT$93(-Y)PA0]J2;,E,5=@$'#X2067E"'QQ8D$A_S37IL?J6:`_@6%_/Q^
M::]-C]2S0'\"POY^30UILRE[>IHJ^4(LHO72_P`6TVN2.)A2HX@-F/#C`.P5
M\Y#'':W8P1.-*%GJZ='#S04G&D0"4*-*96WC/>!7E^::]-C]2S0'\"POY^/S
M37IL?J6:`_@6%_/RPWC@5Y?FFO38_4LT!_`L+^?C\TUZ;'ZEF@/X%A?S\L-X
MX%>7YIKTV/U+-`?P+"_GX_-->FQ^I9H#^!87\_+#>.!7E^::]-C]2S0'\"PO
MY^/S37IL?J6:`_@6%_/RPWC@5Y?FFO38_4LT!_`L+^?C\TUZ;'ZEF@/X%A?S
M\L-XX%>7YIKTV/U+-`?P+"_GX_-->FQ^I9H#^!87\_+#>.!7E^::]-C]2S0'
M\"POY^/S37IL?J6:`_@6%_/RPWC@5D7KTN/3CJU*M]F@](^O<R;7JO83L.(_
M18^6)4H0'FD8\=[W"\/>Z?>C(:<PSG#N4*5AO.%^SG'4ZF],?TZ+_JS6M[*]
M(.NX\I=-?TRVDH$.BLXAP9]DK8PS,AQ<2G5R<1HTF:ZRQB0M;^&D(P\I3GM*
MS9!?C<RM4:Y6(?&8F3P-4L9F%$DMNO1Y4L4&G3XT9]EA2'G67WX[;3K;2DNK
M;6I+:L+RG..GU!:"-WU-K"YEX40<6MNNZ39R8\>P_%@0")^LBRTV'"BR7'I,
M:)%DRW6(S$AUQ]EEM#;KBW$J5D(;_FFO38_4LT!_`L+^?C\TUZ;'ZEF@/X%A
M?S\L-XX%>7YIKTV/U+-`?P+"_GX_-->FQ^I9H#^!87\_+#>.!7E^::]-C]2S
M0'\"POY^/S37IL?J6:`_@6%_/RPWC@5Y?FFO38_4LT!_`L+^?C\TUZ;'ZEF@
M/X%A?S\L-XX%>7YIKTV/U+-`?P+"_GX_-->FQ^I9H#^!87\_+#>.!4!K[TZ_
M3TMVX]_ZY(=%>N4$/J6?K6)7R<>B^)IIJZ4E%F).$,R'<PU9@S5JB1<P$H3A
MA&<2?:>\YQO+\TUZ;'ZEF@/X%A?S\DIKK8Y^T[I[#4(B'&P0NKY^L(M=*18<
MU@@;;MU&18BCA26^\N)-S`GKS$A9@M,ICQ\99D>\>\KQOG@5Y?FFO38_4LT!
M_`L+^?C\TUZ;'ZEF@/X%A?S\L-XX%>7YIKTV/U+-`?P+"_GX_-->FQ^I9H#^
M!87\_+#>.!7E^::]-C]2S0'\"POY^/S37IL?J6:`_@6%_/RPWC@5Y?FFO38_
M4LT!_`L+^?C\TUZ;'ZEF@/X%A?S\L-XX%>7YIKTV/U+-`?P+"_GX_-->FQ^I
M9H#^!87\_+#>.!7E^::]-C]2S0'\"POY^/S37IL?J6:`_@6%_/RPWC@5Y?FF
MO38_4LT!_`L+^?C\TUZ;'ZEF@/X%A?S\L-XX%>7YIKTV/U+-`?P+"_GX_-->
MFQ^I9H#^!87\_+#>.!7E^::]-C]2S0'\"POY^/S37IL?J6:`_@6%_/RPWC@5
MY?FFO38_4LT!_`L+^?C\TUZ;'ZEF@/X%A?S\L-XX%>7YIKTV/U+-`?P+"_GX
M_-->FQ^I9H#^!87\_+#>.!7E^::]-C]2S0'\"POY^/S37IL?J6:`_@6%_/RP
MWC@5Y?FFO38_4LT!_`L+^?C\TUZ;'ZEF@/X%A?S\L-XX%>7YIKTV/U+-`?P+
M"_GYJVJ=3^M_5OOAUY7UWTS0].*O>ANS<.Y?D&%:!XLT4`=T7,",&4QU93-;
M%2I\R1!P[C.8[LEY2,X]O..6O\A+M#^_=U._R/[9_P"Z]?\`@3:XXXX#CCC@
M.8@!V#0[3/MHNLW:HV(G02V`-Z'`K(%,3Z6<5`9*X"VR&.FR9%<+9%R8Y+`X
MPW#F9@2&)F&<QW4.*^BZLHD4^U,.6AVD-O5L\TY<F'X$5ZIH<$S$+LS,DJAP
M9'=`)5DNV^10N`TN&ER8E49+N,^9*\]9NX+_`%IK[VB-FU'8`?1W1>L=;+;=
M-1$3UT$]O!+_`&#Z^VR9LT=.CB@2W;W(Z]4K<)J3^21>Z"(ENVM($L62QBR4
MR,D/3X#L`&TBHIVLFQ%B"3L+5!,`B4(N*F)9>6PZJ*0'OR(<E+3[3C+N67EX
M0ZVXTK*5H5C%*?5/K"$WG1.U"/M0WJNZ57O_`-S8`&Q1*K1;"INM;%16`.PZ
ME9:)>*!BB6FG;$!(B8+P"E,;F.8CBBHXXN>RLT1E%U!@78]O[U`+R!LPZ5UB
MV3L/1\KK64JK<>2"?FBNMU'K^WKC1RB'9]9,5N=<V!D*)($0%"5VVLVIR2X1
M>D2?8QKTJ0;E;UYVP!OS7R<@9WW[,19)66(!`YQB4V0K&))HD-K5`U>"9*&G
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MO333MIM$O8U*:L&AMMS7OB9VU]#$V->6L[(QA'LYO`Z-`F4K9T?.68R5P]E5
M2ULY9CM1V\M,)RVK'YA/N;IQ<=;@*G]N:/%B,M2WP$@+I3L$TMM:\OS_`+%+
MRT:.V!*>:PWER-#.:3::6EQR)%E*<9')":/'(SZJ[;Z1VN?718-DF4C:T9KW
MD_3.UPQ#6>VHF$(PY(<CTJUM0)UC'Q4K:]^>IKMEKF,O,I086IUO"I+>VG\?
MO\?3/U^OC/R^6<8^>?/TQXSGQC..!^N...`XXXX#CCC@....`XXXX&*7LW.K
M5)N%B%QFIA(#5K":'Q'VWG694X4'FD(D=UJ.I#[C;\B.VTXVRM+JT+4EM25Y
M3G'4:DM)6\ZJUG=3L2./-V_7U,M!B!$9D1HD(K8*V,+D(D:/+=>E,1XTN8\R
MRS)>=D--(2V\XXXE2\]O?#<ZM4BX6(7':F$@-6L1D?$?;>>9E3A0:;/B1WFH
MZT/NM/R([;3C;*T/+0I26E)7E*L=1J2TE;QJK6=U.PXP\W;]?4NT&($-B1&B
M02M@K8PL1AQ8TMU^7'C1IDQYEAB4\](::0AMYUQU*EY#87'''`<<<<!QQQP'
M'''`<<<<#1>OMDV:T[D[`4`L(A0:_JZ=K.-52;,2>S,--6^DIL1AV=)DOKA3
M/@22E1(V1S+"&&4Y:D^]D>5XWIS16O=DV>T[E[`T`N(@P:]J^=K.-4R;$.>Q
M--,V^DHL1AR?*DON0IN8))2HD50YB.AAE.6I/O9'M+QO7@....`XXXX#CCC@
M....`XXXX#CCC@....`XXXX#CCC@....`XXXX#CCC@....`Y"7:']^[J=_D?
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M:\_+'(=T+O\`]<MA567<A)X^/`R*MK._4>0>K4P6_M?7^[3JJKI6Z:QAJ=?E
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MQE;F8PS,>,M>4MLO-HQC/]L=@.U]?6I-UZ)VHNTU[67R&CM_:7V'`0A"L>TZ
MS&V>0T%9)B/=Y4XEF+7'9SF4Y;;AK7E&%39XX$(,][J"']ZO8NF.V&J8L;&?
MBB5QZT[,+A8Z\8SGV<GM;"[\(D>UXSE*X<J0CQ\\JQ]V:U?N_P!3;8W[43?&
MOP;N<^,0KV3?UF26KVTM^PV+V1#J1)Q?MJ2GV$1,JPK.,>.2H]A.//C'L^?G
MGV?*?.?QSE/C.?\`7GR3QH\K#?'$X40E`DHRW)A$(S,Z)(;S]4/QY2'F7D9^
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M8E+DV%<B`1R/:&A<MQR$$09W[UJMM+5BZ^]H`327%.HLH^S=:MB*]X[G*<8+
MUF+M_7I5V-'QCPC-4JZ)LA.?:DCFG?,?LB7<%VAS&HFZNNO8O6<!J#B43NX?
M7Z=UZV@NY7[&6E6'2!*^62/&3C&7G")NCA(<2+A4@D[`0V[AL)F\<TUJ_L1H
MG=;.'M2;?USL56&W'7H=1MX0T5AX9SE+[9`+$F+,#GXZ\*;DQY\"._&=0MI]
MMMQ"T)W+YQ_Z>?'TSX_PS\^!B5],$:]1[D>#L(DE@E5L9<9&<8=E-OD!@:;.
MA,KC,*2](0[*8:;4PRI+KR59;;5A:DYQU&H;(:N6I]86ZQQF8=AM.O*58ST.
M/$?'L13)RM#"A2,S`E+=DPFF)TI]IN)(<<?C(0EEU:W$*5GN;X7)U^D7`Z%C
MIE&`M6L185&6P[*1()#0\V;`87&84AZ0EZ6PRVIAI:77<*RVVI*U)SCI]1V0
MY<=4ZRMUFC-PK):=?4NQV"&S$?@,Q#9RM#"A:,U!E..R83;$^5(:1$D.N/QD
MHPR\XMQ"E9#8?'''`<<<<!QQQP''''`<<<<#0VN]@V^R[H[#4@V-CQ*OK>?K
M&-2Y[8N=$D%6+51VSYYR21D.KB%LQ"ZU1F50&FD0FT_#2/>/^58WSS16O;_<
M['N;L%23HQB'5-=3]9QZ//0,G1'BT>TTA!VP.OD9#RXA7,0PI<5I4!IE,)"/
MAI&''O*^;UX#CCC@....`XXXX#CCC@....`XXXX#CCC@....`XXXX#CCC@..
M..`XXXX#CCC@.0EVA_?NZG?Y']L_]UZ_\FUR$NT/[]W4[_(_MG_NO7_@3:XX
MXX%*G;?9?>:'V@KE:JGIT]3>UE5JP8I>]&G;-W$D:VV``)091@(>N,L$=ZUV
M]%8.9KQD<'AM0)!"*-).RWJS=3!`E*%BK">E@Q8?JYIF"YKW5FJ%)J?Q/]&^
ME+G,V'K&F)(%BA!`"KW6>%KDFQ,P42DH)D,@QK2CF2C4:,F,TRI4!_4ROX^I
M[DZMU*!N#:W5XAMZY0-<7OL;K?;&D=8HKM(E1[I8@8@L"W?0-A0=GL8/5XXR
MI%5@!2&L46=%F+6.$V?##3,L_34)Z1,='^OI/KH$LX#3LNJF'*C%N15T_9""
MDW2T-V.RD[&ZI:+0JXVU!^VQK7"]D3:81N-8`K;0DC":0$T3R3"PI=->P*R>
M4,(8"X.IE*"Y+9AOX&X+IA9Q,4+S.RQ@BF)G$E4/+^(^</91GGGTJ/3#M*<U
M[JULE2Y&KH^@-I],^S][U<`+,1X>S>Q^D]H7&[=C-?Z,:383PD7U>L(&T-V#
M2-!F2ZU7!.TH4#`L;58,RRRU^B'G'C&//C&/G]?ECY_X_CP(*=+^NY[58+M'
M8;TZ77_U8]J-K]D&J*>F>^?U_5-BUNDU`/1Y4..IR(')N!*6T?M@D;/)0X=L
ML1U,<I+4I3^=2^E36AE-UUVMJH44V##5_OGV4$"!#,2="9'"X,ZKQQT1B.2&
MB9N&&(3;#;+K\/VGVDH?3+(H<21EVBY^6,8Q]/*?_OCE9_ICQ7(=6[C1W$RT
M*3ZA':1?LSG(+LC"7C%<>3[3@Z+"BJ;RES"H_LQDN)CY:0^Y(>2Y(="S'CCG
M\WL.Y:<PPIM+WL+]RIU*EM8=]G/N\N(0I"U-X7[/O$I6A2D>TE*TYSA6`_6%
MHSY\+3GQC.<^%8^6,?7.?G\L8^_\.<X4E7]E6%>/KXSC/C]W*C=>]8.UHO;>
M[JT]ZEW9_8$0GI8V$=S:J+UP9K^G-D[5/QIE8LNLX8#40(G(LVO:B(.RJT/N
MQ2ZU]MFPUU^RP2CT=3<S?G1K6&X=;P=T8V7VTW9VQ`R=A-U^@6C=P/4@<N)B
MTD9D-<'`2M1Z_P!>"I04G='2L!#I03)EJ<K*I426Z.F,.NA/;SCSG'G'G'SS
MCSCSC'XYQ]>,9QGZ9QGY^/EGS\\?7'R^_E#E>['=F5]Y;O1?Z?JL0BYWGV*H
MVMJF1S67>OVXZ]3-'3K9K[KEKXD,A9MM3[;ZFOCL,SOURSF$PYM)!6.36HIK
MWSH:G='TU[:=MZ#J;L!<>Z!RS5>OT_2^D]ESK[O>GNTZ?J[:<'5QZQ]_G,`F
M:?3I1'KEHJ\0Q0S2YQ`TF.OI.8_3Z?<KA%PDI'#T`<9SC&/.<XQC\<_+'(#5
M#U`-`/=5MY]C9AJ]Q*YU,K%HD[Z`[#K;=;V[3Y]&UL)V>]$M]32M$:%8+=0S
MM9N(%$1Q`P@.M8EUI43VI,6'5QZB/J@]F:5UYW33=7Z^I>H.P=5&=)]G+)2=
MKFBS>.N'<7LU5='5*QTXN+U6XEK8[%@58-?;*#$&1D2@IE+O&O;)LGX,?!E!
MZ0/.,_3/G[O]?PXY7]N'L`8Z9B.I%*DT:T[-G]F>S%=Z[*)&]P3++&U;:]CU
MN\W>`[,N-Q"?ES?*2"DTXM6PTJ0(39W1+4":60R^I<;D&]O^M:[IC56X-DV;
MKM$6OJGL#<&O.U`EG<@_"A%ATP7U0T:$:$C?D2NU;DG6&F;DJFRPY<U5-<4*
MNUQ@@#V)=*?<W!8&<%\OG'XX^7CS_K]/W_=QSSH[4]2#=^O>TO?*J7VHR[3U
M_P!&=R/32ZVT'&M]N2-=WVJF>S5<T_9(QXK%=U[(18Z6;.[3C8V(.1;%$7X(
MR-4QX&0%)%[-`WKO#UGZQJZ?VO)43KWLW=5!ZARM^4_9EFJ`;8L>,/V1UWU,
MK;]ZB&[BYJJ?I*IT)D<S)I";`;VZBZ-;`^SQ*M=*&&11:4%W/T^O./9QY\^/
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M(4HU"VEJ-^$'4I*9?Y+G8`.ZC2\J*K$.3+`[-%0GFVF'WQ+\QO,A<G\9SG&,
MYQXSG&,YQY\^,YQ]//W^/QYSP*J>W/9/O1U.UFNXIU?UWV^"E60!47]F#;S:
MM6)UZP<Q-2K85]U[<X):JXK`]Z)'&Y;9WD)^+L9L&.5F'"E.RF,@].OO\"[A
M!+O7#E@J;VR=>&`HQY(R!-I4J[0)U'JUB/V`%0SY0N4<#TVX&3VN"MEKAJT4
MXJ7K#T\>9A/RI@`//_9;TF/KJ^/PAT8O,8IEI?B"I@Y)B(3E,`I[T:!)$K0X
M@FQ,?0W'='J;6F:VXJ-E"L.^,Z(K>D]<;MT7H5[:6MP<0^"HE$M0-0$5+UT>
MUI;IU8$3R;U`GUAX)9-<2HI)QUG,.OD1BF$,H@S&WFV/=8%6Y78SC./.,XSC
M\<?/''(.NM]HNMWE<%)SN#IQI>5KBRYM>#=HJ/$3C.5H@ON1Z[0][AX[+:U,
ML$)5"V0PK*&?C=@RY.%0I$:KWEK'<T"5)H=F9G$A*(_Y35$M#GUF_P!+DRE/
MMLP+SK^QQAERIL]U<:1\/&L04?F:TSF5`7+AK:DN!MKCCC@....`XXXX#CCC
M@:*U[?[G8]S=@J2=&,0ZIKJ?K./1YZ!DZ(\6CVFD(.V!U\C(>7$*YB&%+BM*
M@-,IA(1\-(PX]Y7S>O-#Z[NM\/;H["U*Q#U1:91)^L6->3,A94!)&/8J.V9L
MSB"[W_=SN(YQ2X^5Q/T1V4YAO?UF,\WQP''',6O-E73:5;[>V(,6!=5J]@LB
M`->&339\TH$(F%$B0@8<T\0+%R2HF(0T9!9=F3YK[$2*VX^ZVC(93QRD#6'J
M']EBO1FP=C[H(T/:-@ANP52UK>XNNM<]EJ2*ZS:UM%FJ0D]<]ZZ2W;#JF_"U
MTU*#LF+-=*'6X8%%B'KARJJ:R%S(.)L;ZK[?VENC1$+8U]IE1#VB:?V`,KKE
M-L[1*F;%J=;N1JO4;9X->99N=5`VS:^.@6^/4#),W8*A')X"EYTTC%=SD)2<
M<HCN/JH[:I[O:.AXK>ES=DT?W.Z^]6(&^6';&(TG3@6^QL8R7VANZA%+FF[U
M6I:*>^*I-NMC5Y&4O8=L<B.5<W7V8IX8(F%HWU`*[LWKGUJWKM`:$ZUO;=H5
M'O&R@NY3L6KPM92;:)>G0*4LB=F@E2K;9\QWC-5'R&TRV:,S(N)P?''(8Q)"
MQKCFBMR=A:'I<94G"S9ZX6G8Q"<(U?KG7@UBT7_9I0572%P,1*4$S/'12*`]
M2$D[(5(S"@X1!%0\N/D4R)4"-+J][#>IP:L>Y^@^B>JP6]S0/=^5N2="W\+U
MJ!ML6LQ=)ULE(LM:@TFY6FMO_E#4+Q`P)W8+L@X:5I=8'G&`6)%L=B.#0NWX
MY";:_>O3>C=F.Z%NF=@6[=X;K^5[*'JGK;4MS,_$:AJ5JKU'NM\!.KPL.5B`
MCY]B1-J@*R6.X01V/=_9L^<Z/9)X=-]3GJPFX4&H5\W<KBC;=(7;]07&NT<T
MK7.V"+VG"V_Q%$U]>BR1(2R70[J((1ML./!6X`@88^P#]A#VM;8!86%<<I[Z
M?>IU7NS%;Z#66^D"&C+QVZZ^[DWH.TX=U@6>#W"IZ]@U$D1N@;;*K$2KU1KE
M/'GH4Y`XK,FV"VPK%$(R1=>'QHKDO8U<]8+HG:K/6J>#VK(+';Y>M24G7$4(
M#?L^+ZUO.S%*9K"Y!G*G)/)$4BR6L(4`X,W7\DY8PBQ$9+"H6#()90+/N.5'
M5?U6J;M/M5U>T!IW6NP+<#W4.[=0]EFI=89&V'35\ZI;.H&G[E4+@*EVF)@0
MY5;I:YV+Q+:C6%IH6Y69==42;+K=:F[J'M1K3=MD:KU%B7&9&(U0O>ZW<)%8
M?QK^W4P9;TTI@]6+O!DD*^1P6*^^?@!7)<6SL#([LXV"#I4PV^$E....`XXX
MX#CCC@....`XXXX#CCC@.0EVA_?NZG?Y']L_]UZ_\FUR$NT/[]W4[_(_MG_N
MO7_@3:XXXX'GT]7K<>R*)4>O5&VA7/2UO<&\XN4NXTSM_HSM#V,'NV4':*LS
M43>LM<Z4H.R;..J@V"49<V#?KL!&UVJFF@F'CD>.08PU/SHML/M\>#P@'9BF
M]5I59*T`1>M2;2Z5R=FXTB_4Y,Q@<-IL\5M8=`+"[)D>\R8$,UU\D)^QHDU!
M.-79+8V,3JU[GW?U'.L>^FEU;?79+<I&^UHP2#O=4O1RUSV*;U[K8=<IK%5I
MFQ]AO]DJ#,R:<FRB96#&:%QHQ-7VP1:AQTM,YY=5T<G6(OU2TJ=N`[:8FXV6
MJOVJY0-V:X@:?VC'N-I.F+!:_P`KM5"BIP5KB:[8")!^+2!)@F)K(MV`)&SY
M4*,R\H)&VYRTM56R.4>.%E7-`$NJI1K&[+8KSUFP/D?8+9]Z!G$]D&HK\)]K
MNP,*G('8DYA(7*]TG-3U9[9]VM!5DA&[XHZ9S=B;'[!=<NL772)U;QO6+4R>
MU-YSI,`C&V!.W"I,^1&JD#+5P7#J.%27@(PP-D2(QE47V+@^1EVAUAJ6UJ`!
MJM@GKS9*AN2H=A:C=5"H<F2'W'0;JQ>:E9'1;CB43AD*7&:KDT1DA'ESJ4N0
M`0:AO/)(M!U?6SL_7]Z!=[,RG(<6T=8]Z["Z\[>6/C2&!6+EKH17+3(-"1SD
MTN0A"+!3;?6;1`%22!6>-9*9&/SR$B+F2]&/TI3PJT:X[76,%,G$`AWOKV6,
M!YQ)D?&ERQ9.?5YT&2Y&&LQV(S;\9]MV/'?CL$F8RV6R[+13$M"9LZ,T56M%
MBK^T$>^./;9VQ=-W;(,IB8@1SFQK^_`R<G#QRI)!\:'B010@(!&S"IB=`""H
M$288)OM+EN0[],)]<FJ=QG7"#Q17YPKM.WB8^7R<=7AHU76L-*(YRK+F(WL?
M#(8RK/P2&4POEB/[.`LUXSX^_P"_Y<<JK]8#9>RM3]8]96[5=[M=`L:^['16
MISY]2,+!RC]1V%VDUM0[G3B\MIIQYROV6MV$A`*165L*?;4A+CJXV'XT@+)@
M-*#UMNUX%KGMRKG8RMJ.D'9BGI[YDI$AC4OLON(SAAL8*&"1(AE+>40AXJ`Q
MC#F65+7C<K4=;5JV/J022ME4KD,8)%0R5/M!.LVR(P*GPR"78UG%N,DX\LC(
MB*P6D,K0LBQ-(1W\>YF.IY3EL+U@KM3.M_8_=L?1=,?)]1>QO<31NY1I3:DV
M&)L2^H-7>V(2;U'$@U2?>+/8MH4O.,5YN?5H59H1`8?*[$.B:D/CF)7V^H#W
MQV#9>HO<9GJRMZGW#5'IF%>Y=RV`NX2*M?M51=K:LVM9M&1Z.P-"'(92X((Z
MMLAL^],FCA;`8,H<.G**F(TB"%@X+H=UUK^\&M\0:V7<L0_9UUWE7:Q./29N
MOZGO3956FTG8>Y*U5'V<M#+_`'*JDB0<P1S-D#VTE"Y`8*'&#)8C-W3<=#:O
MV)4=P438-:CW:J;VKYFH;-#V-Q<Z/8:<<`R*U*J658]T["K[`B9.9@082V?@
MI$^:08<20E/2EP#L/=38VF-=>F#3!FOXFVKSW8CU;5^;=;]A2JM%KEYB=6C>
MZVSUDRS6;.7/1K,]3"\4I,BX:E#GI"IN6"<A]F,O4Y3UCP82R;_L[^C=B&>N
M/6DKVAHNW=P5ZF[.E!Z?>^I='*6>_P`N;<Y5"C:CEU.S7$*2T]3HD.^*O2+R
M@?+L5:%A2K;D4+"M3=,M#ZDU9L_4D&N3KI7]XR"TO=Y39!9^XVC;T@Q1PFLI
M2[^>E-1GC*6]<5JNTB&PAF''A5X+!BQF4/(>DO1EVCZ2?6W;FJ9&H+1;]^-U
MV>1UBHL7%[5RQ<S-5T5957/0>N2UOFUL@8FT#2ENRBST,(MU,K!YO!6T%+-,
M<D//UK[+]13MIHSU1>L-?OE4`R]8=K-.].M?%=00-NV:;6-5&NS/9W;]9K^S
MZ_"70H\$WL4'4:?!KFPX$IZ$'*OQXLBL'TP/B8KLY*!ZFUPN]+U=5%:RHXSL
MSN_NGW"Z7:WJJ[C97=4*/=0;#N9BX;%/VY=59LL6MS*IIZ68CA(E?=-R"IX<
M(AY<;:E36@V'Z@W7#=&YAO0>M:I%&KK'T;W5TMN;:-TF;"K--N0N@Z[HVPJD
M8M4&=.BPH]@N\J?=XAO[.&#(T0BX/*-/168\QB`]]FP/2*Z8;1!$0MYJMV-R
M+3JK<NG]FV+&PK`.M&WJOOR\T79NSYFRC0Q<:2<L%AV#K>IVMHQ#^RG!4L:V
M,&LQZ^A@.Q@,[U.[<UV.@]<1G6#9EBN^NI'7`;VD"TH#=]DN:@E]EU'70Q6/
M<M>4VPZT36M;5P+%V)>9UYME.GE*.=CKJ0^>>"GQ<.+(#O5MSLGWB]('8VOS
M9*D=4^V+?J$$*[3P=VFSV=K474NG8BM>6W:E:^P(`R&978VBMSIL42<-PAX`
ML)9+I;L,5>6`GWNOTLNLV\K/L:W'YNVJR9VUM+KCNC8RZ)LB;7XELV3U6'!Q
M>GK.4@O"RD5V<%C5>G9G92VC!)VH`G7/<Y21P2_AMWTI>JNX;+V2LI)W=%0Q
MVSI)ZG;RJ6O-W[`JNL;=.M8"%2[5L1S5#9.;K:/M:PT"$JAD]@XJSIW-<FD<
MQ7(AN<Z:Y7]V[[A7_KEVK]4@X?.[2V%J73'1;H=M&O:>KVUIVM&:T<V1O;=%
M!OE@HEC'#)[U6*D!E?KQ4NZU$E$#J!3XAN=#9FQTQ<ZT?VCWTKU&/4^ZQT_8
MM=V!=@78OKY)T?KO?]VN(6F4W4#W4C56S-S1:)-J=2/Y3*'V[8$66,JD>%\7
M*;+?:):2H8(FD4!*^7Z275TX"W'6;B6W'>:]O3KOH7K/>@UIV(W)A.T+K*_D
MAI0H*0.KHMP;=:4:?*'X]FPM]9`R;+3"D*8F2VTQ).N]-]3U[8,78BIU\LA"
M%L,QMV$&NEOE6^O#MJ&*L*I2[\%B'8LLA7ST2L#Y@F,FOE18EUJP6!\D+(RY
M[3\2MCKWZGY>Q:<]/\C6-)',N=V^W';?K2VYL?>I"\E=66+2UK[(2T%RMBDU
M3[3O84Y(TL::&C(*0<>I`7Q8,<Y,8B0<<ZB#ZSEH*Z5U9M:+UVA#7CO7S?F]
MK@S8-@21E<N!WKIN@WHBU=?>O!Q%9ED-B;RM]H"JM%'JYD&&?FU$@&3F%--$
M),,8%]V,8QC&,?+&,>,8_#&..8O23)BQTVJ6"P@%50\<K8,N;JZY_P!J.5PL
M3&19Q`$X3^!&8(.")3[D!R:D="3)<84ZF+'PKW2<HX&)WPF7#4BX%Z^SF2=%
MU:Q$0L?$9<S+Y:"&FRQK.(C><+E9=FLL(Q&1G"W_`&O=)SA2\<ZC41RQ6?5.
MLK+;X^8ELL.O:6<L\7,%P7F-8BU:&3S<?(UW.71^62<B4WF"[G+D3*?AUYRI
MO/.WOA,N&I%P+U]G,DZ+JUB(A8^(RYF7RT$--EC6<1&\X7*R[-981B,C.%O^
MU[I.<*7CG4:B.6*SZIUE9;?'S$MEAU[2SEGBY@N"\QK$6K0R>;CY&NYRZ/RR
M3D2F\P7<Y<B93\.O.5-YX&P\XQGY9QYQ^&>:`V_UIU=N6<-LQH>3J^S*XP\U
M3=Q:]+2:7M>GY=QA661-R$>[FS@CCJ6W2%-LK9ZCG?=(8/UHI&Q[GF_^.!">
M+L'LEH++L+=57?[!:S@1'GH^Z],55].SQD:.IA*6]E=?PV)TP]*]AQUQRS:1
M6:Q/RPZX]JZLL)0X]);66U]<;EJL2[:NN=?O%7F.NQD%J^0:FM1YS'L_%"R3
M&/8F"#,)2TMD`I:-"+#GO+,V$P[C*.;!SC&<>,_\_P#;_'D7=G=6*O;;1(VA
MK6SV;0FZWT,MS=G:O4.BKM[,;"OA!VUJ05B3:-MD7%SG"(>;F%F6`,QE]FLV
M0"F7,^)"4?'*8]Z=^.TW7;9-QU9;M0:QL`G4^L8.Z+IV!B3-D,:^,40Q/MD&
MOCBU#J@"\WG3YB7^0EG_`"GV*=Q==%4AYL5^4=W%**(@L6?:'W=0>Q6H=?[J
MUJ;'&Z=L.J@K0-D#R@TK\!]LBXA)T*3DBI,N&P:#KE_9Y:%A_+D2<RZRXE.<
M8QP-O<<<<!QQQP-%:\N5^.;F[!U2R#E1:52)VLF==3<AY$'!.-8*0V7M#B2K
MBLLF\1CV5Q\KCX3@?E.8;N,N8\\WKS16O+E?CFYNP=4L@Y46E4B=K)G74W(>
M1!P3C6"D-E[0XDJXK+)O$8]E<?*X^$X'Y3F&[C+F//-Z\!S$[U!N9*H'X.O+
M""JMW?'N)K-@L];EV^NC"J%H<CO&ZS`L%5GF1B_84Q,A0;($FK8=6J(3B2$-
MNIRSE;7:/O;,ZQ=Q>L6C[2!`_P!#>Z=!=QMT7:]-1;><O%2QU0`:XLTZ,$JM
M;@3\FX!4-?G)DE$2$2,82%EMQ8:<+:<6&?[CZ9HVU4TS6KI#IVZ_Z<-`]C)M
M]`5PDW4+%LGKF3KA&BB;;1FK;$*V#7;T6MQ014"_=&3CPW,>0S9&R@T?,8^#
M0O4'8?6_5UCU]K+>L6),N!SLMM(Z3.ZX581`_>7878\C9T,_3:[.NV&JQJG7
M1DJ>&B-2M3I63`H@VY+MT,HP]/EYNUWSZGRKKK"ACMO"3!7<(/5UAHA<*'LY
MBD3QV\QY0IH[!788\+(H]:([HA`CCNJ!%C/BRM_4'(LUJ&0?CY;S'79/J.A1
MW<SI+UJU'$K]_J79#<G9/36R+S(@7>$Q5;%H'1%SVK-8US8\B8U!O[XZSU%^
MB7Y(DX75336'Q,]A@KA:(P;HUWT[;@;6V5V5V\;I>PNR.UM$T'K[9S]?H,^J
MZG8H>MSURMH*%!U@=N5WE3US[==RILY*LUN.D'X[(T"-FC1$+##N"=L?3W#=
MD==4NIA]BD*/:JPSN846NA05.MN;8*[':5N6A=S%#@6)9JJU-O,RF78@1HE@
MFS9@FF6`:)1FN%:VPX`<D0%[=]>;'N6^:``[$C&=L:K*A`NSJR-`6J4SKPE9
M*2>V+7V+I86PF:U6VS-,K)HX.EE2\>%)9B(C-R539D*,_A\'OKU8(@;588FR
M7E1:JC7\C[.>IE[B6.WCMNS2`S4!C5]7E5IFP[6![=*B28G5QO78VR"KX3@3
M(5;E3WX[J4A@^Q^C(V?`Z;'M0W?\C-L]$!\T%HFY[!"3=FAB-6/ZD;TM<JQL
ML'&L=.,V2-:ZA%&RYA@3:J^=B64./+,3ELYG09D9F?2ZOU.WMT7VAJC>NO@%
M/Z6GNS]RS4;AI.PVBQ[5NO=,T?,=C#I:W@]RTX96F9DRR%">N($&GD?R8*R,
MJL4JXC6VAZ,=ZZ^M'I.\;(]076&\WUZ]L_2>\[TL\<35M9;SL!.R=4=&5[3,
MJW;?)0G*-(D_EC6++MA`6[:R#,+N%=:AHFJK3H]$@EFP4GW>ZTC`FK+$O8+\
M\1N'7M1V]4906G7<ZJ'J2]-0EUG:EYBB*[,EZTUU/?)0![EQV"Q6P<`I)2,G
MRX\UJ0RR%</9+3N^MC^L+KXQK0?::/1YGI?]@-)V;?1;2ETO.L0-AV5V&U+9
M6J</LT8G5:G$V3(I52L5@KBB)TF-%DQPUL[7C+1%D/,R&M>C-5*AMK0]M!;X
MM>=6]9S.G5:4U6;JL(U)H-%UIU`V5U-/ZUK=O<.QVPU;OJMBS]T%U0ZUA[^D
M]XU,(H,P2`I@!80]W2ZRP[1=:L3VD)"R:!7MD6<^?/#3P.C.!]-3X@K<;@#8
M145%I5JEZD*$1P[9@RLG2I*D3R$2'8(D*0\EOFG^N7=:7V$[8]I-%B*P@90]
M*:>ZJ[0I5D-UR_TR\G'>PLC>4(B/N-+OH6N$`;`=W4<(B!?BC\(-`[$P1Q(6
ME3.$A$?6GI!'**2].L.:W]7+MJSHAU7[$=3"E4(:@+![+N*A=A*Q5*06GKM@
MC:[,.CDP=5U[3H[*F:U8ED2C]L(*?A,E`T.OXI1O1TVYKG56@M,!.X%..T+K
M+V6ZQ[>U'%L'4ZFACT'575HN^7I6K+E:]?WVHGM@7`BWD<")[7/3$Q\!14=W
M%!?L,F>>DR,ZR^HJK=.CNF5YV&5U)J3:G:_:W8+5]>UM*;V`>CW0UI.S[IJZ
MP^N2\*+E<(BEK6PNV'25Q;8'-`%&XT-A)-X6AO677[U<*S?_`$]-9]M]Y?D[
MHVY;!UENO8)<FU0=U;#T!JV#JK:-XUNP<V1=JG72$BLUTG*K$%L<U8BM?-6T
MO,D"JI'D34?"L!^^JOI0WCKOV-`]C3?8RN7`Z)W#W[V'*KX'3$ZIC)U6[\;4
MUINBV5!$@KM2X2H96B776T:`#M2</-%*F7F0)=?B&8\8WR4_3KH]GJW:]@7J
M=?!EDM>S!`!G8#U$I3NJ*CLF[P%?&G=S7O6P^S'Z,G<%D)/SXY.V40/2&BX*
M0W&M(ZQF8[)U&:V3OYU1I!6P5VW;@$0S5%L>@*=LEV)7+G("Z]L79^*AW16;
MP79`R!M,"[+D.1H5?.6.?##L$28<25(0B92%'?\`OM??#JA2+^3UO:-P!1-@
M#7X!J0K/=%V1^FP=QV@;!-@=,2+]#"R:6C<)&ODH%B:UA]NYNC8"4T8?#M0,
MY?P$O..//GZ?MQ^[/C/_`*\<!QQQP''''`<<<<!QQQP''''`<A+M#^_=U._R
M/[9_[KU_Y-KD)=H?W[NIW^1_;/\`W7K_`,";7'''`\\_>$+M7LELK%2JFQK.
M.V]<=FW/KWU%J&A^Z_;[15&&!-;R3A[?W8#MC2]+2]4D)"M2/P1U58%AK(=3
M:2,VK5RM68,BWPYKEPW4.LSZ7UVUO3BX!==.U.(?K5CC9L]ZNK1:T`[;8!MG
MN,&Y;.G$]A6X7?C\<C>!-IN9&;9+`-L,4L6DO2I2UY@53>W'I-7&W[$V#=K7
MUHZZ=AMW:I@`-T1MN736FC>R:*!,(&:X&U]MPI(LU=O%0O$"&#C23=`DFHUO
MIF&Z[@FIA^"$?9GUU+QUU;Z_4"#U-E5B=U["IL];UM,I1R19JA)&UFZ6,`6=
MK%CD%3F3P%5E'&_LLQ&+D1Q&)[N6+ENC78JN!(WG'G'G././.,><X\X\XQ^.
M<?=C]O-(=E]Y@.LG7K=W8BTBBYVNZ0U7>]J&@@",_+,EQU&KA"PR!@UF/'E.
M?%STP<1&WLL.-1O?9E/XPPPYG%3&S>Z.T*-:Z!KD\K9$'?&]M@=(JHN17B(^
MPZDIO7[MKMR952^SJ<*&01T&HV"GF*S;=5PR-V<LENP;)TRPIEGP97+`8+U<
MYQG'RSC.,^/I\\9QG./],XSRMCTT)DF?6^XLJ7-E$7U>H'V=:S*FS6R$A3<4
ME6(K+*I+1,PWEN(RRW$CLIGN?"QV&HN6(2F<PH^?=*-Y7C:PCM-6;6(-3'>M
M/;;<'7:G'R?LIG;&IU%#TRR5@XHO.(.X,DX[=P723A^9]G8G62M%'Y325I>D
MO:N]+>7)GT;MM.F_$(ES._/9>3*BRYD,A+&RGY]7=DAY4\=<+X/ER`KZW!#L
MB!:)\%Q<+.8;`R/[L7#"SSD<.SW5C57;FC5K7>X6[;(J]5V?KW;PV)4;I8*/
M*=NVK#[-KHDPB0KDJ',(CP-IAC;&P(DNJ'/&!(N9)9=5":QR1_'`K*C^D9TI
MQ%VE$+4R\V9O<M][(;#V"NR;;V&2?,&NW=!SK3L;!9D8-L/#*WM2ILB89ZN#
MEQA4:57P)$0P.FC6W5[BV)T`ZS[-"?DU8JK8XM=G]?I?5FWA*Y?KC6!^R-"/
MUPE6(6NMDMA2\5=U&`1QDRJMSS#CIL!*,F7QI-G!8BW)F3.FQ!L.40GR&HD*
M#&?F2Y3Z\-LQHL5I;\B0\XKPE#3##;CKB\_)*$*5]W*)>R7K&3J[U=V/M?1N
MJ</V"_\`2WL/W"Z:V*WW4!%#;5U1H*B1+#L+8!((V()/@S%%8L]1NHS6D]R<
M[L"IS<>ZL8$DF<*BA99=.E&A[V9ZFF2`^WC_`/HHL#%FT`,`;"MHH-7#$.F_
MT=Q'S\!HFZF[XB41\I4F&[:Z42@*>.Q\^TX3?=YTC?I]=54;&W/L;.O23KG8
M.!98^X=?OW[8#VE+R5NH1VLW6XE]'+LO]%:K[<*XY]B66[LU5JR%H*<?$$/B
M5NR7,"ZT7S:&O>B-7W[LI.R=K;!M&J:IN`Y1S%]I=AE"S-HJP.<2@!;Z4$T0
M*$I#\F6Y=BCE@?>%Z[#33,(8MP(`@BU0JU]ZL]W[#]J^ANK-*ZWB0:)N2Y^H
M'K[L(V9MH&:Z!N'2,A0:/<6J<>CUZ2W;*F,/WX=;:N?#YK\J_"UQ8<F#7DLS
M8ZPF88]*_I]9)M&/6:L;`LMYU=#UL.UCL8_N/9I;8&OANG=BEMGZMA5>RS;(
M[*C-T:S'"S0*3,;GSFP1"8`DRY0R2^RYG-H].KJ;:=;/:P?U^9"AT[YN'9X-
M8JCL78M0V-3M]7^SF;;<MF4'9E>L\"\T,_83%B/Y)8JAP5`?@FBHY4+X2?);
M<C9M[N$2Z\>H1V#1MG9A<;U7TQZ6P+M58ZHH:%?@UVQ`]^;.KMNM(IR(-AG2
M14M3ZL-&,CB1F7#^+:;1!3`Q+>SS*Z7ZF@S8FF]G;,I^@MG22FN;90:ZJ#9E
MXUKKTF&V>$CV2KWO^E[:`.F5YNI`QTC(C9#H@/8C%,NT=RIQ!%F>F!B!4)#N
M=$.LV-TU'?HVDF:[L6IU8+3'I-6V#L*M5Z]UVJRYA&F0=N4T-9HE5V^NE%"1
M(K4IFQQ-DFA"4^3,CR%.J1EOI:-Z>G5K7>P-7['J]*.PS.C+-M>U:,%.;`O$
MBH::F[P$Q@^TQNMZ@X=^P:Y6+<PR^]+J;4-ZN0I9(F\)&P$S%M)C13O5SU9M
MRE=>;1I/79ZY6'LMH0%OK5^L+5;:OK._V\4=N$RF2:[2(=B^)"[!.4.8%L![
M;(RI&IQ^BTQ@'9FZ^=BV<<VUL+TK>T>[NZ?0+3?9/:H*NU.\;9#F;(#E#R,(
MP*)5N?9B[8`RZ,%"0389<*`C[&0$=S+E/8",%)Y-Q\K(0R'=;Y]+OJWV/N?8
M6\[-:VS+,=H=9ZXT_M^.`W/?ZN',Z[U/8XUNHM<$!PA2+"K#`>Q(*%,R@*(4
MZ<]9K2B;)?8/SFE_B5Z7W6Y^\;5V=&-[Y$[+W#M/6FZ+;?PF_-CB;8QLG4U$
M(:NJ%BK96&4;76L?T:DGZ#8!(E#(2UU-N*&L8XE%BLH3!=7J5[@U36^^U.O!
M.98=AZ2[9=:-&Z`C[0UW$U_M]W7G;J[ZXU13-O;,IM>$5RFE=9#]H6/8T/5-
MVK8N"Q=JM08;%MBMV!^9*GXGV'[Y]W*S-[&Z*TI"L5RV)U1W);->?TIAM3#[
MD7W)=;%U*H_8CJ%IZS4P!3R8`3$WEL:ZSM/;7V%4@-,&4B-7PQ.,=H4NTIFQ
M@G[2?2=ZGZ]KO72K53^F<>'ZK;LV5V%TNPYO/8LURN;4VX^5D7T_/?FE7W+'
M'-O6:[N9#'LSA,7-_N_PL1K%AE^(Q6WTHZS5H^J=0:OKN\LZ6U\6/S:99*+Z
MA/8_2-WI$V[6>P;(MA6[1@4Z2O9.(NR[`8L%->BDF"U=:L1R/&RRRIEC,K;1
MZ@NL]:VS4H_==E_HW:M=8CO&X`>OD[I7XQ^4?I6N[%:++=A0Z8/I>FZ7MRZU
MW4XO815T>)NVP+)#BCYRPPV1*EV08SY_]?WX^6?W9X&%ZXK!:E:^I%..VX[?
MC55J=>KI6\6=<5VR7`@&%11\RS'W846%%>,FWXZR)-]B)'0],D/.X9;RO*<9
MIQQP,1OY$P(HMS*UY"W3XVJ6,@$;;B_&K<+P@LZ4,0B'[*OBUKG-,)3&]E7Q
M&<X9]G/M^,]/IXU9+'J35UAN2'&[<>UU2#-I;>@?93S=C*5D7..(=&80U@<X
M@H_*2N!AMOX->,Q_81[OV<=W?)QL92+@1K32W[%`JUBF@66HN)KCIJ('FR!3
M3</.,XEK<GMQT(C9QG#ZE8:SC/M^.=1J,K:#NJ=9&[NR]'NAC7U+*VZ/(@8%
M/L6<A6QDL^R^+PAO`UYHL]+0Y`PVC$-:51\(3AOV<!L+CCC@....!I[:/7W1
M^[)E9([<U/K_`&.0ILQ4^K3KE5A)Z8!D..LO/9&29\9UZ,Q(>C1G941*\PY3
MD=A<AAU33>4ZYN'3G25@+E[=40Q326R#?P:B.T=#%7=57@BX/=P[$S8)%<;9
M!72.WC&65CKT"LPUZ.MQAV+EM><<E/QP(.9G=U='N)00'5SN70(^%+43!?DU
MI?L8/B(RI>6Y->FOC]'[/GH8:_\`%BR^D52'G4LM@DX;S(?VCK#MGI':99VI
MP+-)IFR(7N&S&I=IAR.L]HAI3Z%+Q&?IUO9&3BK>,)SEHM6%GP$YKV)0PM-A
MOQY+LDN:^V1J?66X:X_4=JT&H[$K,A:'E!+E7QEB@,RFLX5'GPF2<>1]GDH;
MJ4/P28]44A`E-M2H<EB2TVZ@-@85A7TS]/KCZ9QY_'&?GC/[,XQGG/(.8ZW[
MKTRVJ5U>WN8D!8^'/<Z0[+$#^V=;*9RE#<>%6-D+?=W=KWX9M"6XJG['L6M1
M&<+1BDNOK3,9^Q[M_+UA%&M]I]/7C1JY2GVI-]",R=QZ,86W*1$CNS=FT46X
M0I[$U2\/-KV52Z2Q'9PM;LUQEEV5@-MZYMNPC6Z^Q-8LT=]JCTV?J]G6SS@7
MX!F5%.T9!6U+CE_=)^W<-G\K:=7[UW`Y:?@OZO.,ISOSD!-"=U->[B[!;9H`
M79E?MM'(SZ]'Z[V.OBIDBB;$Q7J6R0VU"HFU8@]5)V.6KAY<APD,`V0K/'0Q
MY5R/'7##&'(,^^`Y4SWGZ,[P[,]GM$[JU_<-5`*EJ#J_W>T9+#7%NYJL1>Q]
MO:!7*A'/1WP(Z8+8"TJ;0JI/?B.J^T#$4C88S2H;\<6^Y;-QP//UKCTD^QT"
MJ](J9LSL913E3Z:@O3514:H&K%G6&"V7H@<N4*_DZG\0\(RN1V.II&F.&CUJ
MBE#-*+UMT`$;=JC_`/7;)U'Z5NT=6;"Z,HA[NITW4GI^]B>TNV=5M$ZE:S>R
MM@4'M!2]H!"%(V`9GVED;%ME*);:L;,2^0'B[-F@P1),C7!Q%,R#)MXVGM2D
MZ;I\F[WTJH8&:)`@,%F+#EE"YZSVLS"KE2JE<##VGR!NS6JQ$AP&OAH#+LHD
M4G1HS2<>VI:*MNV7JT4O5.L])FM,4O8MWMN]>TU,ZC+2]J"Z&I6D=GG2J(UI
MK^SM=,RZQ9%;.K8GWA*OZB<+`2]Y4IAX280&RX4X&U=5=(+Z#[5^ICN38EKJ
M,O7'>^OZ/J5="4I^T#[Q20FH=.6+3DEXR2GPV!;I6P#;')-1Y`)]"0TZ.PRC
MXKS\4B%VDO1SV5IS2NOJW$N'42+NKK?L_KU;-%;-UEU@*:EE[3J76A-A@54'
MVW/#;]8;9L,S=`EI+MEY%8D":S3[3E%Z%5FQV%UUSEENU^Z6MNIM%U]*[56G
M,*VF:::N5N):\UI?R-;K]-I*PC-_VK9AD5NS2]<:ZJ*K-6U6B?9SDI("08;B
M(F%6X[TM'7:G[QU_;'=OM3TV%:]O$:;U>JFDS9S8JP9%ZG%2VVZP=N?V.X80
MQ]E#,MUQJMRJRIZ8N5:7)%F^'BL1JYE^6%6;'HE[=B=DNZO8QK?^O'I_>/5?
M>+4=PJCE%LS4+6`/MM0M)C!)BLE6S;C]R+TZWZ5%X(LF(58A%*T8FN1,1RT=
MEC,IM8^G#V`T!LOK3L'2G8O7$5RK=/>O_2GL_!O6GK!8HFPM?=;FB\O7U]TY
M!C['BQ]=;#^/L-B'E&+0[<:C-'&LSI869/&0(Z=E]?\`U$$VO/=^1O496JA&
MZU=_[/TLU<-H<>P'K)M>2QK74-VHH\<#DK?GG=F7"?LB:.8KP*.Q#_\`AR41
M\*8CR"+FS$^IIT_<(ZMA1]A&947:LFF#H%@C4"[.U:FF]C;,-Z5H%<V=94A,
M"-=V.W[CK-BU<%!V25&(N70--%RV(C>&)3X5NB?0O;:JO;K2Y*]Z*:U7N7.Z
M3.D]N">OTUONE0#V\MJ1]S%P.RNP$O82_P`O]:5BWP8PIRLA0M8*;%IN6JU;
M3L02-BCWK&NO_67>-*[.;Y[6[9O&L"UKWMU^ZUZE+T*@5VU0*^(M77@UN\NU
M:8-IL1)XGD':U[AEX<K[U;=FB,16VT&"'PF'B>L>WWJPZ+ZNZ*VGMN`#NVQ2
M5,I]HME+$":E8VJSLH?6-@:LU3/.5R^1QLVOS*E"V%N*EUZ<8A29$O,ATHF`
M,F*%OXS);LIVAE:1ZBWCLR"UY:C!<-31QRMZZM56V$).J.6`@/$!1MX`TJF7
MZ_U<<-G$V9=UF#:58"-8!PRA-T5)Q"6UD*PM;>F1VOU_K#TTZC_2!UZ)G^C'
M:SL7V-MDC#6T(@>^PMR?TV,!*U7LY$/SA,H1$W];,E9Q5A]EV36:]F$VM@F4
M;AQWI7HP]S=7]`[KTHHN]-"*A;XZ\[JT+OR0?1M^74'"UQO]NL^M=S:Q"_`2
M9=;N0&I["LE%V#77ULUR[Q`E)+H<@%!9!\A88(]3`D;H>I?R?K>G=@[9L74"
M\=Y]G#M7[9+6?5870^O3T6O3LZYNY2F5VQ7.S7$W+<K].;.TZIC(Y8+8LV5\
M8T,0T_US7JRUJT;_`-(476^N9UFT]MBH=-+0W>YDHC"N1V#WS&;0+Z9LFMZC
M#&S@]GHNOANK)T_>]BG6,<JFPS\%X=&)8%S_`'H16WYZ47;O<P+MT-B[(ZX!
M)G9J)Z82H3DIK:LR+5B70"QB;R?Q+0@(TY/@;%LXSX$3[GW#X("[EPA\823Y
MYBUYTYO4YZ@ANXZME]+;W7@'8FL=BR'5:YZT[4Z^V]+V0$@"=72-R2"P>]IT
M-+V77ZX'FHH&^36LGQQFJQ@\JQC/BWV2\*^ZA[SI-_N1NG"[#4VRL8+#LM=K
MR[6(5?+'3ES)8R3L)NC>^2>@Z]F%VD"ZS:)$;,&Q.,RIL52(3H]V7NCV<><J
M^?G/W94K./\`1.<^SC_'&.!RGSX^>/'CSC&/V8SG"?WI\9SC[L_+[N<\<<!Q
MQQP''''`<<<<!QQQP''''`<A+M#^_=U._P`C^V?^Z]?^3:Y"7:']^[J=_D?V
MS_W7K_P)M<<<<"AGU0=0]1*_LX'MW>S763KQ'MX"LABO9+;73>B=IBE^/@[G
M.=&ZNQ#MU2L-?IC[D`M[N78S$9VTW)BQB*]32$"7577,6A]+Z_3JQUKUP*U]
M01>LZ0O-Q,56I`Z>_KL&V#L=_M5A'V`)KF2S'?UN&NS)3%V%:Y>8:<H4"PQZ
MFMM"A&4X^K;_`&CHNGMKZ,T\=K.P[`?WK<H]-%&JI5TE*90YT\1:2]>(;-L<
MJ?!B5J#:)%+/!ZLU&:+%RY@?*3&&XA09\Z+L'1VZ=?\`8;5E2W#J\LX:I%RC
M$7A$Y^*]"DX?#&R=;-P)<5_'O&)PBP!BHF<U[2T)EP7O=..M9;<6&Q#80190
MQ:NV`9`-@3PR>&-ABL1F>,+""D1Z`2&$8,E#D>9`GPI#\29%?;6S(CO.,NH4
MA:L9CB`Z?Z5`TJT47(NPGA=ER#9:)6NV'+-9ZJ,I9B58-9@Z/9R\F0:J(?4I
MR6\8U=$$2F5TDIE)$4^F8C#_`"4*E)0G*E*PE*<94I2LX2E*<8SG.<YSXQC&
M,8SG.<_+&,9SGY<U12M]:-V33B6P]=[FU3?:`&,3:\8O%+V+3[53Q1\;(9B$
M09*S`C,\+!,0)<B/%FC),YJ=%D/LL/L-NNH2H.^U]KJJ:NK3=9J([,2(J=/,
ME9TEU4PW9K(9DYG6"UVDP]C,T_:;&16Z1/'2"WIY.<ZX\\K/Z#:8&>F7/9)5
MCN++8E29C2_4$[/-X?F&`YZ1E4<E68[C2R8*WWH<ZF.ZTN.U'Q9'Y@]EIL>2
M&5XA%E5X79'$F1"$.-/@2H\V#-89E0YD1]J3%EQ7T)=8D1I#"W&7V'VE)<:=
M:6MMQM25(RK&<>:WO3.ES)M;[CR)\V00DY]07L^VJ5*?$R7E-LDJRRPUEX):
M[J/RB*RVW%:0FP/R66F4,SAX*:A\$-"ROCCC@?R?88E,NQY++4B.^VXR^P^V
MAUEYEU"FW67FG,*;<:=;4IMQM:5)6A2DJQG&<XY5';_2'T;9M+VS00[:&YJC
MKLGIS:'6_7<<(O5)$SHKKCO1<!6[-+:H,6O5]@?BUO8;`D0)=.V]NVWBHUL0
M-K-&M%<!QLPW+8>.!#TYTUI]PZ=P.F=YV%LVUT^!2:?1T["<G52N[+DP=?%P
M9>FSY4FH5,!379PI=8K\*;%Q3TA+(-@/0;*)*QRI=$W4>N?2_P"O>K=Q:]WG
M5#VTFK[KO=_<7>\&5-LH61`,V7O04K=AWZ!,P6ZRPWFI%;-4*X=`#QBAI$&^
M-^`;*OB)DV`_8]QP();-]/[4NY=_[8WEM"R76YBMU=29?3"_:4+,T56J">H)
MUD.VR6XE+5*;OS=H?-68^_DFN\.PFVB"661C?P,!4;!A/IDZQAZ6UIIBP;W[
M6;(CZBWOJ;?E!OFT]P-7J]AC>DB:)FNZ6\Z3K*:F5UX&'^^#2`16JS"!=#R;
M`8,S[C#'6*'9-QP*R]9^E5UZU7K_`$UJ`)9]KG=0:-KFI:U2M:78_6[-7H:=
M+W38]_IMG@29%29.U38*['L5W[=V!0R]5M1L'5JO6)I)8!DM`*[NT5TPIO6[
MJ>.ZAZ>V1MJHTBK@#59U[<HANM.;%UT'(%IY</&JY1ZIKKZ\U5V>J,(</5HT
MJ=%:2FR?;;KTIU^8W'`A/_T(Z@/`-K-;1G6/;FR-VUK657V7NJVLU,1L4W`T
MF9EVC3F1S=#K%1IM9;UI<9LB[5L=7:H.$KM\B8=+P"4J=+][LF@=9JCK^F[`
MKD*Q6XK9-PVW-[W)LV?)"PKWLNUR1%=K1,D8D``@8`#9FU*KAJC&&4X#71@&
MOQ4QZ[%%RLYF9D?QP(']E?3JZ[=I[+33VQ1YN%`KE(BZKL=2K+H(=6=D:D';
M-UWN81K*WL3`)(C#K`K9NJJ39(JZ81JAI;,$B`E%9%>-E!LB=^,>/WYS^_.<
MY_\`7/.>.`XXXX&*7R<;&4BX$:TTM^Q0*M8IH%EJ+B:XZ:B!YL@4TW#SC.):
MW)[<="(V<9P^I6&LXS[?CG3ZC*V@[JG61N[LO1[F8U]2RMNCR(&!3[%G(5H9
M+/LO"\(;P.=:+/2T.0,-HQ#6E4?"$X;]G':W^8<'T:YSZRAYRQPJI8Y8%$>,
MF:^LU&"SGQ268BT.(E.J(-Q\-1EMK2^O*6E(5A>4YZ?3Y*T&=2ZO+WA,I%T*
MZZI!*W(FP4#)B+1.K(N4?3+&M,QFQ\E)9V9A^"W'81$=PN.AEI+>$)#8W'''
M`<<<<!QQQP''''`<_*D)7C.%)QGSCQGSCSYQGZIS^*<_12<_+./EG'/UQP*-
MM>^G=8*#O"].Z9-R*)2NNVR`>T=*:Y,U..%U3N*W7,+8[9,D;0,@,QI]B)44
MU=+77:WL.OP(5U%)FCV;].V*'%*K<ZUG3F\J_M9LP!E"BE!VG2<Q8FQ]1VW,
M5JWTJ;)PO$25E<1U\;9J@;PRY)JE]K4DA5[-"QE428P2CDA0_P"375@V42W7
MV("6I@@W0*Y/U>WJUV0'8A09$4K1D3K>H<5;C-O&THL?MHEK?D2<CY&/@V_<
M(\-Y[';6D@NS5BK&-+DM?[5J4>>W0=L59F!FTU7[1RRY/%R&",>2,M%,-/18
MN;+1K%&F`#28\>4EJ`<@B38T-U<<C%J_=EC8LS&FM_B@])W$F.Z[7"HA]U&N
M=VB8?R?LFK9A)Y<Z,6CM^S(M6KC3SMNI[BUNQ'[55,0[=-D[]?IP(M]M>N"N
MRNOJB"&VK-,N>KMRZA[`:U/R![QD''V+I.YP;M5H=L!1YXN0;J1B5#=#V$?%
M)09V!\YR8-E,$8D1Q-9&Z?2LWA>"%&O>O]N:8K>SY7J`ZR]2;=D^U4'8I^JV
M?=FF]>U?5]"U[01`J]A9E4UABI5Y+)V<7E'+9/)802;>:R\]'1>WQP*P/41Z
M#;![YTMK6;V^$:^UF=T/OO55ZH2ZA+L5>)WW:M?K`RA;F@-1;!7Y,JPZ?DB+
M"W7`%DD%@$B-;YI1,:'910LHUMC2/3XEIGN%V[[.Q[Y!-B.V]7ZUQ;#37JY(
MBD:K:>O6OCVM&908^DNY$DU^Q`R<0DY`F"7"<,LS(;P27"6TVF<_'`H3MGH[
M7;8%4[+Q[=N#5,ZW;&]37'J6Z9;,::)W;5M>M\/5@33D356[M:V.ZM1MN40C
M2PF4FO@"E6E(.%G3@7[/FA@V6<WVMZ3MTVRK5H4GN[7-4UOK-[JK<JWJ;6NA
MF-<ZMU_MK0W:UCLALNVZFHE6NL4566-[B6(6OC,BR2+;:JRP&BF8=BGY-V6`
M2NUXX%$VS_1R+;3TOVMU-(W2+U]_U.U6')LZ-;UNTBM7V#<D+=E7W=$V]8M(
ME+D5I%6M+1&HL54V0T^B@.7\7:+.>O48O8XU9E!K@KM#W6NM5=O71K5\:VLG
M@CMTD72M6Z;72-<\N*LD>L0Z]:AQ4,:4XII8*65GG(#*&ULDXDG+V'VMK\<"
ML[;/IWB3]N_I$U%8P.N[O:]";NZK[.FS*NHD,)Z9[";)D[;NDRHP(4^$Z`O-
M2OY(Z<U]F;*)U..BPE1QT-/8^#=C[_%=/-/5VF:!UV`IM19KF@M:@M-5<[-K
M`9_8T#5%;JHRKQZ#7[NS!8*5JNVF&&'0[]`#KB1[*&1*$*:CLS7%HEEQP*LP
MWIKLA^_KG<UG;17`1K8QW<0^AMB%-G,6VR=8:WU2FZ]G6O[0S$>T4&J-3&;!
MK-&CA(T\=LV3))++.#&&(:[3...`XXXX#CCC@....`XXXX#CCC@....`Y"7:
M']^[J=_D?VS_`-UZ_P#)M<A+M#^_=U._R/[9_P"Z]?\`@3:XXXX%%WJVC=5;
M%VMU8U'N>A=>[[1RA&<<15]E]@-G]<.Q-OLDB[4FO#A'2LYJR<*,[6VV."RK
M+BP:IGV"HAYD:Q5)XM9X(DF1RB0'I>[U@7C0VHJP,U@&U54;&&["%M.Z\H%1
ME"*%JK4.A>P,G1=8I<DTJ0Y')E3PQ86Z!2:XP]ZS,S[1+C0D00K3\G[^^AWN
M`BY4B)UA_(^M*HE#N&V9MQ.=4)O;"PE'Q$V.`L%+HPN#O+1N*#?55(B\:I\%
M\Q.F;FR@_2P<D1/`N-&9%=*,D;'UWU%L>Y5R2'V19M>"X%DEF-$JZU6&1`&&
MC\@0S-T9(M]]FZHC/)GO%XM%(6TP3#X)Y^V'F2KLJ'%#=.ZC5*`:EV*2V+>7
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MXX#CCC@....`XXXX#CCC@....`XXXX#CCC@8I?))Z'2;A+JR'7;-&JUBD5YM
MB.W+?<.,!YKHA#,5U*VI+JR*(R6V'$*0\O*6EI4E><9ZC4DVV$M5:S(WUN4S
M>9^OJ7-N;,V$T.F-6N56QC]B;ECV&F&(,ELPY-1(ALLM-17<+8;:;0VE&.WO
MDD]#I-PEU9#KMFC5:Q2*\VQ';EON'&`\UT0AF*ZE;4EU9%$9+;#B%(>7E+2T
MJ2O.,]1J2=;">JM9DKZW)9O)#7U+FW-F;"9'3&K7+K8R18FY8^.TPQ!DH,.3
M$OPV&6F8KN%L-M-H;2C`;"XXXX#CCC@....`XXXX#CCC@:+UZ7VA-W+V!%VZ
M-/9UV&G:S1J9^0*BPX,J)/I*)5S4/)LL(D%\-6;VVY:I;[ZH#^/A6?=->$9W
MIS1>O2^T)NY>P(NW1I[.NPL[6:-3/R!46'"E1)])1+N:AY-EA$@OAJRY6W+5
M+??5`?QB*S[IKPC.].!@6RM8T?;M4FTO8("-8`,QZ+,2RZ[)ASAI4>[B0*/`
M3`]Z*7KUC#2THFA;"$FP3(B:VB4/F,/)]K,<1&R+QUPDCZ9V`(S[=K"49AUZ
MA]DW$,.OP6""DQ@0'L;'A0X$2KV!<U;`2%M@;$Q0[7(<AKM**/89C;1N9?/@
M*"QIP:0#&1\$L(+09@LH+)Q&)XXD-(1W(DX>0@RFW8TV#-BNNQI<22TY'DL.
M.,O-K;6I.0^Y*L*QA6,^<9QC.,_LSCSC]^/G_A\^<\A0D%>.HL;$FI-6;:76
MB'(\3*"TR0LVS]#`LMYPF1K92,S#6R]8!GLI7)U[.S(NU'`-O_D'/M`F"-HT
M&65/N-5V!6`ESI-@$VFJ60>R5!6`%.8(B2H^1C/NI4*9&6MIYO*DJ;7C&<.,
MO(<COH:?:<:0&2\<<<!QQQP''''`<<<<!QQQP''''`<<<<!QQQP''''`<<<<
M!QQQP'(2[0_OW=3O\C^V?^Z]?^3:Y"7:']^[J=_D?VS_`-UZ_P#`FUQQQP/.
M;ZJ>L+53=]UB_P"G"_8-5RV/293%M2GUD'?3TUQ!$`;),?&#Z@)M%8VJ3M1)
MHD=)SYP.NA*Y3*I#FQ7V%_:9Q<15KGIVF['8.G&F2-M$0@=A3%N@PB.@]@%=
MJ&TJ![)N02/+D]A<JPG;!4G$'QR9NUM114>08F3HD<!76(;8(?!'U9]""M@;
M/ZD[BO\`U$9[>ZHU'>W15^UX`ZJZH[2W`I1;[%-P[I&DA=@!B]KK`@:7%ZQ.
M")&L&XQ$L0CFW+<1A5T*E@G._P!.W75RU1TTT?1+_IRC=?K8'"V.25TYK@=7
M`]1H?V]>K78X`F"%I[TBH`R#PLM!)6,'4GG:J&LTXP-KCBP\6'G@35SGQ\_^
M?\_9R'PSO/UY/V#;]2K-F)V6U:9W:"ZXGJ^(!3%$K'NVPZS%;=A:_H:9RH,>
MW%&*$52>)S8$AL(,AC3TB84:B`BDJ-OO;(385CU]8P>K;+5:C=R4>+&$G[K6
M#EQKD)A<^+DPW.`5NY4`U*7."X(0(4B!;1+HZ=)CDLJE(B*AR*%=*="^X5/[
M<[8[-[8%@"\2A>I5GLI2*_JIF%20N[=66_TYX'4ZSV$!22^U+Y@=.I]DF"L5
M6I7^R`B\635+Z9ADY<&TUF&V'H#H]WK6QJJ*N-1(H*`B^)28\C"%LO,3!A&4
M',"YT9S&'H14(9@$`Q@<^E,D<5@3(,E"'X[B<5^>F1-20J_<:2EW+V,^H/VC
M9]YG$=.59C%ZW'SCQ&/V9G]#W7L8S@P\O.$^7(HQSVAD/?O4O0YC2FE[%3[$
M3+,V#8.W^Q>Y#+;1]95ZIS>P&Z;[M7%=`D\MY9B,5*)<(HN`S#2\/@2X3N("
MY$1#3CD<?2PA_9NO^UXO[<GV7(GOEV1$9/EK!"M1<OD5)JD#,XQ8(&,1R9A_
MX?VBLCV&G_C_`(AN2RP^AQEL+0>...`XXXX#CCC@....`XXXX#CCC@....`X
MXXX&(W]X['HUS?JZ9"K*S5+&]7TQ&42)2CC06<X(3&8<0XV](R03&PRTXA:'
M7<H;6A2593GI]/2K7-U+JZ9?$SDWB7KJD2;DDG&:A$DVI^LBW;$DA#9:89B3
ML&%S,2XS3#+3$CWC3;3:$80GN[XL^U2+@Y5</JLS=6L2ZZF,VT[(R=0'FJ#X
M8;?2IAQ[)'$;#2'DJ:6Y[*7,91E6,]/J-VVOZIUD_?\`$Q-Z>U]2W;HD@S'C
M3TVQRM#%V/$V/%0U%8EX,JFXDLQFVX[3WMMLH0VE*<!L/CCC@....`XXXX#C
MCC@....!H371#9\G=78B#;6RR->#9^KTZH7,'QHPMV)+HJ)%RR'G,QVWR*4V
M7WB2"I4B0J)*QB.U[EO&$9WWS1.O9.TG=S=@H]O023KF+/UGC4BY,6`T.<AO
M4A#ETR+DQFDS)>$V?WF)N2#KJV)'LM1O=L>$YWMP''''`9QC/RS_`,_]LX^[
M/UQGE<?:IJU=/JK9^RO7$0'F2R-LKD78.A#Q9BFZCV79-FW*OTN/?R-R7$EP
MM'V407-P3%PV>J%)IY&NQS#VP`4J=F%;`MCG.O+"19X80"FQL`P'+0Y`XH**
M0XY`:2'S&E,2X,^#+;>BS(<IA:V9$:0TXR\TM3;B%(5G&0JJT3ZEAZSEMBZ\
MW#URWHQLG5\BJ?E%)TYHW:5SJ&6[F,(DH`J8ER!*(5RTA5"IL<H+E3RD`H,>
M!6NO%IP8^RB+(O\`ZXZI_P#(#N1_]*VU?_Q?).ZYU;K73]99IFJ:%3];U)B5
M*G,UJC5T55@;<V:M*YDQ(P+%AQ/BI*DHR_(RUEYW"$)6O*6T83GGC'[?WY_]
M^!";_KCJG_R`[D?_`$K;5_\`Q?'_`%QU3_Y`=R/_`*5MJ_\`XODV?&/V_OS_
M`._'C'[?WY_]^!";_KCJG_R`[D?_`$K;5_\`Q?(R;O\`4U.5^ZTC6.J]%[:!
M6>S5:WW\G9]]:!WT%JT"K4N<#&3X8:OT6IG;O9RSDHZS.,SA(]X?3*Y$?-$H
MY1Z2/%2;=/&/V_OS_P"_-<;+T[JC<X>'7MN:VHVS08XE',#Q%\JX:UCH):+Y
MPP1AQ#4.8S&FMIRIO$AA+;JFEK:6I3:E(R$0>OOJ4]:=VZIHFQ3-L5JJ=;*^
MT5FA=B5^]4T;!E-R)$&;]D6F\4ZI"[$!?EQ'I($]&3&08$/0IZH<-U]R(S)2
MN=G>MUP*("5/?^D[.97A.4B:_M:A%RF?:QC.,9&P+`_/PKPI/E.8V%8\X\X^
M?-S1A\&%#CCH<2/$'Q(S4*)`C--QX4:&PTEAB)'B,I1&9BL,(0RS';:2RVRE
M+:$81C">:EMO7/K_`'Y+Z;QI#4=P^*PK#ZK+K>G&G'?;\>UE3T\,\]E2L)3C
M*O>><^,?/Y8X&Y,*2K&%)S[258QE*D^<I5C./.,XSCSC.,X^>,XSG&<?/'&5
M)QGQE6,9\>?&<XQGQ]//C/C/CD*E^G?U"BNJ?J6JY>JGU94I*]&[)VOH="'%
M(RCWF(NG;S282LXQG.?8=BNLKSE6'&G$K6E7SXZ:V$*ZM^A=Q.X50]WA.(`X
MGLJJ[3"1?9\X2ER+MN@7(M,:2G.,>S)L"U*RE*EJ7GVLJ";_`#CSCSX\X\Y^
MF/.//X_3Z_3Y\A`UJ/O+6$K>K7;_`%O?'/+F4P]T]7QC^%)RG.4HR1TSLW4F
M6W5*^29&1[K;?M96Y$DXQ[K-9EPV9ZK-8[%2D3->V78>P(>TQ<*CTC3Q*W5'
MJ\=Z^Q9H9!@W<'-@Z@.:P8,V"NJM1)\P;[55W;55OC=>KX>CD:VMG[2#T)\<
MAJ6[N:UH4A,3=]*W7H;.&T*?.['U/9IFNXKCCB6D,2]OZY9ONIHK[BEX4VU+
MN41Y;:7'<L(0T[EN25"V;KG:8;\H=:7RF["`^\]SDS2+.$M8M+V,><LKG`IT
M^,T^GY^VPZXV\C.,X6VE6,XP&<<<XQG&?IG&?'RSX^[/X9_#/[,\YX#CCC@.
M...`XXXX#D)=H?W[NIW^1_;/_=>O_)M<A+M#^_=U._R/[9_[KU_X$VN...!`
MSM`+[(L;+J=NZPU'3.V;\-I!$'+H'8*W;(UQ2*W6SUB9C&[E5[C2M9['$R[&
M5;5&%V*J'H,<B5KM?AJKTR`C)A4W=_537^RM5]?=9:_W!LV)N#9=7"21UQOH
MZ!]FBR1?)HK*6)#PU95);"U&/)CTT,X1\&)(JOPY1I*2STU.*?\`UG-<Z1)[
M3Z=[:[.Z;>V-U_H=XDT[9$X1H7?.]C2*?L=LHD\TI[1SY&=K%H'9*UK6:.,S
MJ39BUVD'2%=KY"NQ!EB46L1],6JD*7T5Z]U\EH[_`*;I+-<L1)&E%,V>&]18
M=AOUNL(V'*$70D7M-;FE1I6'8IU0-DILZG3#+]76^M`A'@)Y\<^,@[,9AON0
M(R)<S"/$9AUWW+*WEYPA&7G?"E(8;4K#CV6T.O>Z2O#+3CN4(S5AJGU(G=@1
MOR!D56ARMV%NX5ZZ9T"93=AQ;'I;9=OU]J%_>ERV!5K)AMNZ_D91*/%)@KK!
MDU7[9@[%#2Z\-R0"R8]C0%K6?I_JG_[XY6AZ9$EZ75^X\B0\J0ZOU".TB<NK
M>B/KRALO6VVD*<@P1T;^J:0AK"$Q4N-I0E#[TEY+DEV8^B]UUS>.N<7P0J-!
M4+M.PJ!;QN",6<BMWO4MXL&N=A`WYS"O=K0'M57+,M/OHBON0<1I$N)"><<C
MM0R]+]^/*IW;^5$6PY$E>H%V@DQ7XJB;D:3&DE:V_'E1WBPP1+D,2F7$2&9*
M(6(4AIQ#HV40'+BSY(6;<<<<!QQQP''''`<<<<!QQQP''''`<<<<!QQQP,4O
MCA]JD7!RJX>59FZM8EUU,9MEV1DZ@/-4'PPU(2IAQ[)'$;#2'DJ:6Y[*7$Y1
ME6,]/J-VVOZIUD_?\3$WI[7U+=NB2#,>-/3;'*T,78\38\5#45B7@RJ;B2S&
M;;CM/>VVRA#:4IQVM_R>Q1;GFK?$_E+BJ63->^"PWF9]N8"SOLCX7#N,MYD_
M:/PWN,.8RC+OL>WC*?..=/I[-L5J35RKY]H?EQG75(S<OM9+:2GY5YK`O-B^
MTDLI0RF?]L?&?&):2EO$GWN$)PG&,8#8W'''`<<<<!QQQP''''`<<<<#1.O9
M.TG=S=@H]O023KF+/UGC4BY,6`T.<AO4A#ETR+DQFDS)>$V?WF)N2#KJV)'L
MM1O=L>$YWMS0>N5;0SNOL4FW?;/]':2&KOZ)OCD1L"/@\T5O-S^Q%LIP^M/Y
M38<^TOBU*4F9\FO9:RG&=^<!QQQP''''`<<<<!QQQP''''`<<<<!QQQP'./&
M//G[_P#G_//.>.!^5(2K&4YQ^CG'C./IC.,_7"L8^2L9^F<9\XSCSC.,XSG'
M(LWGI/U?OQG%KGZD`5>]H0XAC96K9)C3FSF,.N^_6A&P]4DJ=;EQW'\(>D09
M):0/F+0C$Z)*1C*,RHXX$,0O7G?^NYZ'M;=N[Q8@$>+)]U2^Q=*JVXX"I:UY
M5'2B[5Y>K=F-1F6\)CHQ/LYMQ./$B1F<]A:7NN5N+N+KN0I&S.K0;:X".AUY
M^V=8=GAR!I3.7O9:]O5&ZDZX))<98QF1+9#7ZQ25?..-BDI&&D/3?X\8S]<>
M>!#4;W\ZL9F.![SLC.C[+''R"<VK=BJW9]`G(D2(TIZ4]A.UA-6&$8[+:'%X
MF!B9*#):;R_!DRHZFW5[-TWV<TSOI\G%UM92,Z4.&CS[<2Q4^YT28<J9=UQ@
M/>*E$O("NR+A0B[[+C`R[5ELI69DCV&&2:G76D+R[<NG->;]UC=]0;3KL*T4
M/8%<*5BQ!YS$>0AV`5B.Q7'XGQ;,EJ(2B9<3+'3D,Y=ASF6)"/.6_9S7OK3T
MJ->4(_.N"MO;-!W&+5DT*G6+0[\/K1FO5!PZ/LI;)BLZL7&HUSMEI,B!$JVG
MB]68$E\#(S<:KC/?3US`M7XY""1KKO%KA*\ZZW[K+?`9MUE$6M=CM=KIEQ3$
M2XG+C:MP:/\`LT*^XW'3[F,HCHV5+>>\2"1F0M3J\D]L]C4-.$]@^IF\*%$2
M[E+UWU)$@]FM=LM9=RVV\_\`T6-JVZ/8PC&9$R:6TY"#BXV%.D#+2$*7P)O\
M<T)K+M%UZW$WC.M]OT2RRLON1EAFCT4;98\AI?NW&)E5-Y%V6$\A?E"FY0EI
M6'$K;^:T*3C?.%)SGQY\9^?C&?.,Y\?7.,9\9SC]N,>/V\#]<A+M#^_=U._R
M/[9_[KU_Y-KD)=H?W[NIW^1_;/\`W7K_`,";7'''`\V!H?W;B=M[AV7T]Z8U
M[O6RJWVCVK2SO8YWMAJK7#6[.J]/.W2BU_6P?4FS]A0\@0C8^+4)8.>0J\`8
M0+5\IL.N26W+:@D2O0ZO[%VKM;2U<O.[-52-(;,*'=B0+'JJ67&6&72VZWLJ
MWU<$,E6,',G@;+)=K88.0?LE>E.UX^[-47`^P)F0VT;_`/\`G_/^?+[N.!@N
MRT;)71[#_1"_2H^QT1&G:KG8L8[*I3TYJ4PX[#L":R_'/,0IL-,F(F>+^(DC
M9#S,_$`DB.N!(KED^G:X_M=OM\S*I@_M?#V9KO<88/#^U\:2!6>F]>[[UP/5
MH;E0?%L9%WVC[+L;MJN$83#LQ0B'HZ9D!X75VADBU3.<8QG.<^,8^><Y^F,?
MCGG'G'CSYQX_'S\OW\#1NA=&US1FLW*`/1!)+.6_9>Q+J02+BPH]EO.X[_9-
MD[!*OP&T*;4R4LMK*);1*S(DN0$QFYTB7(P\^Y#OTO830VF=NQT</FOQ1_?W
MLU`A!_LED&U`@0R-8C0&(HJ.%KT>'!Q":8S`:8$QF?@LL*:<F(5B;(LVS]/W
M?N\X^?[OO^[Z\K*],&&[`J?<6,]"6/<3ZA/:5>8JZ_#K"L)>,UQ]MW[(@5RJ
M1F\2&W$2/C<!&72WO?M61,+/3'"TX+-N...`XXXX#CCC@....`XXXX#CCC@.
M...`XXXX&)WQ)Y5(N":KE_%F55K$FNYC*:3(P=R&FX#Y84__`%*7L$<QLM*>
M_JL.>SES]#"N=1J)%M;U3K)%^5,5>D:]I:+HHBMA9!5L36AB;&J<N+_W54S)
MG$W,E4;PPI_+BF?ZO*>=O?$GE4BX)JN7\6956L2:[F,II,C!W(:;@/EA3_\`
M4I>P1S&RTI[^JPY[.7/T,*YU&HD6UO5.LD7Y4Q5Z1KVEHNBB*V%D%6Q-:&)L
M:IRXO_=53,F<3<R51O#"G\N*9_J\IX&P^...`XXXX#CCC@....`XXXX&B=>-
M;21N;L&Y;UDE:Y>G:RSJ1$IR"L<W#12&T73`MN/_`-\:PJSX<5.P0_37(\+C
M?U&<<WMS1.O&MI(W-V#<MZR2M<O3M99U(B4Y!6.;AHI#:+I@6W'_`.^-859\
M.*G8(?IKD>%QOZC..;VX#CCC@....`XXXX#CCC@....`XXXX#CCC@....`XX
MXX#CCC@....`YQG&,_=_K]_[_K_KSGC@:NV9I'3FZ!C8;;NK->[.&,*P[%B7
MVG`+8B#(1GVFI8]9N!->'S8[GAV--@NQYD5Y*'HS[3J$+3&]/26#2DY<Z\[]
M[`]?<L^%0:Z$O*-JZR95EW+SS.=:;U'[("0(4M7]7):K,FN3&F%9;%SQCB&'
MF9P\<"H'M'M?U!>O-?HT<S=>NQ?7-FOD"L7?LF""S]1VK6(!T66)(*$:3LB1
MM_4<229FP88"':[#8D5:&0D(BS0L5\R.=A?TTILV[[8[']3K-=GV#V8=$[QU
MFH[(BUR32X>Y*%7['UYBUC;,2F35+DUEBUH7+8^$2K(PJZ*=L]<2S6#H9AJW
M=QIMYM33J$N-KQE*VUI2M"TY^64K0K&4J3G'RRE6,XSCZXY"?9^,8[V]3<8Q
MXQC1W;+&,?=C&"G7_&,8_#&,?+&/NQ\L<";?'''`<<<<#H+/"8(`B,686(!!
M[D5_)(B)GR!1%@>EES,I40M#6U.%/8;QE22$!YF=&]G*XC[#_L.HJ(';<[1T
M!SH]H_:=CMIN3VN[F]CZZ2O[(2.!M.N^L]2H6_MWZ(UM>CL=4,@-V59:33->
M5\E:,#H5H((;L4.4Y'/^]/NV6]A.O^L^T.IK3I#<,&S%-<W1(YJRBZEL*_ZP
M+D8XLG$+QHB;?K*RU*X08BYT&,N9'''8;4]AM42:E^(XZPO4>J^A?632NFG-
M$:XI]K#T7\LY>Q8<XMMW;USV.&ODMIN/^5P#<-WO-CVN!/Q(B%#QA`3<8CHH
M7)GBA^8PXC.BR`_OT]W+;-HZ.L%IV&..PB5"W)V5U5]LE1[?QESK&B]Y[#UI
M6[]"B"67%3F+;5ZD/+-/18R7RDIQ^0U$9=DICIC;Z3I,`;UGVK.59V,_7SG?
M;LP;%O1AC05+D8L1K)#"WP[>NM4.BYRE2%9(P)]&&%XL_,EHS/L91,NRE[,*
MU5Z_2P`VKU83#"`0['PPX;!;]VPPA;RWW5YSG*G'I,F4\_,F2WUN2IDU^1,E
M/NR7W7E5V>F)A>*KW&]XVIM>?4)[2Y6E</$!7M9,5S*EYC8U]J_V?>Y\N9<S
M3HV9&5YDY-6[WOY6FPLSXXXX#CCC@....`XXXX#CCC@....`XXXX#CCC@8G?
M4GUTBXHJN7TV9=5L2:ZJ*II$E)U0:;@/F.I_RPE_!',;+*GL9:2Y[.7/T,*Y
MU&HD6UO5&LF[\J8N](U[2T711%;#A!5L36AB;&J<N+XBKF9,XFYE*C8PPI_+
MBF<>[RGG<7Q@])I%PC59QYJS2*M8F*\['?1&D-G'0\UL0MB0[E+;#R"*HRFG
MEYPAI>$N+SA*<YQU&HXML@ZIUE"OKLM^\P]?4N+<WB$IJ=/>M<>MC&;&[-FL
MK<9F2W#")JY,IIQ;<A[*WFUJ2O"LAL+CCC@....`XXXX#CCC@....!HG7C.T
MD;F[!NV]PHK7+\_66=2(ENP%C6X;=(;1=,"6XV,3&L*L^'%3L$,Y6N3G"XV?
M<93CF]N:*UZ,VA$W-V"(6Z41>UT5G:S7J:/))1Y0^)$ATA$:YI&CVG,OC,/6
M;#CLQ,EM"IC^4R6O;:\*QO7@....`XXXX#CCC@....`XXXX#CCC@....`XXX
MX#CCC@....`XXXX#CCC@....`Y"7:']^[J=_D?VS_P!UZ_\`)M<A+M#^_=U.
M_P`C^V?^Z]?^!-KCCC@....!QG.,8\YSXQCZYS],?X\^201@18+A.3-B1QS4
M?,IV>_)89A-1DI]M4AR6XXF.AA*/TLO*=PUA/S]OQG&>1A[QF*J!Z>]F2MR,
M!`(*+H[:.5E;"5AA1L4F[2C;`#R2GR8<>-/>/.#6`^<2&Y#A=R$U#SF8MC&:
M<>M%[L%KZ!_]G^*Q;34[-UD8H.D@_=`Y-/I,"ATRO=#K=FCB]E$69DD%$"#M
M^1*W'N\.]/M18=T:J4,HTV87&CK#T:I6AQM+C:TK;<2A:%H5A25H7C"DJ0I.
M<I5A2<XRE2<YQG&<9QGQXSRM#TQ8ZHM4[AL+1$;4GU!NT:LH@C'P\;&'#%<7
MCV1\BLU!QMS.%>9+WV$PW,D^^F-33#<A!F?MGHTYM1CKL3=O4>-/?8W%V9SJ
M&!APD/>=T9&WSLA/7T?.D&&G'F,JUBU58T26AMT<@,H8^/PZ/PQ[6E/2KC$X
MNO>UZ30B&`-2.^O94@9"#Y,:=!$ER4VK3R0Z(0B`*LP2CPYDAYALH@"/R22W
MB<M,A4C,R0%HG'''`<<<<!QQQP''''`<<<<!QQQP''''`<<<<#%+XP>DTBX1
MJLX\U9I%6L3%>=COHC2&SCH>:V(6Q(=REMAY!%4933R\X0TO"7%YPE.<XZC4
M<6V0=4ZRA7UV6_>8>OJ7%N;Q"4U.GO6N/6QC-C=FS65N,S);AA$U<F4TXMN0
M]E;S:U)7A6>VOC!Z52+A&JSC[5ED5:Q,5YV,^B+(;./!IK8AQB2YE+;#R"*H
MRFGEYPAIS"7%9PE.<XZC4<6V0=4ZRA7UV8_>8>O:7%N;Q"4W.GO6N/6AC-B=
MFS65N-3);AA$U<F4TXMN0]E;R%J2O"LAL/CCC@....`XXXX#CCC@....!HK7
MHS:$3<W8(A;I1%[716=K->IH\DE'E#XD2'2$1KFD:/:<R^,P]9L..S$R6T*F
M/Y3):]MKPK&]>:)UX,VA$W-V#(6V42>UV6GZR7J>/*)QY0Z)$ATA$:YI%CVU
MY?%8=LV%NS4R4(5,D*Q):RMOQG&]N`XXXX#CCC@....`XXXX#CCC@....`XX
MXX#CCC@....`XXXX#CCC@....`XXXX#D)=H?W[NIW^1_;/\`W7K_`,FUR$NT
M/[]W4[_(_MG_`+KU_P"!-KCCC@....!U1L$%L@V0&L(@6=$2\L*E"S(^&4'2
M%1I#4J.I^#/8D17LL26&9#.765Y:?:;>;]EQM"D];#I-/'@Y=9@56MPJY/<E
M.S@,0")C!9CDYS#LUR6)8AMCY*YCN/>2E/QG%2'/TWLK5C&<9/S66S]L5;5,
M&M.G\3R!F\6N%1*#4@;4.19+Q<YXPN<8KE>8(SA8S,U`&OGSTV25*BQ0P($*
M%"1&)$AN.<#96$)0A+:$X2A.$H2E.,)2E./&,)3A/C"<)Q\DX3C&$XQC"?'C
M'*S/3`9BL5+N(W#C1(L?'J$]ILH9@BZ\&CX5DU7<NN8@5:`-#H=?=]M^3);B
M)G3Y#CL\N]++29LM^P2A7RM[+J0JZ5.8N:%+*G,MJ>87&EPR(8K-!'@Y&*YY
M7$+`3PPD$+PU94J&3'RH^5K]WA:J^_3!2RFI]Q\1UB'&L>H7VH\*!J'*&^U]
MMUWWF&E"A@B%E]*_:3.PB"AY$_$E$EZ7)2[+?%6K-N...`XXXX#CCC@....`
MXXXX#CCC@....`XXXX&)WR(=(4BXP:PX\S9)M5L42OO1Y28+[1N2&FLB7&9J
MEMIB.H(+C*;E*6A,=>$O94G",JQU&HQUJ#ZIUD)O3TF1=A>O:6.N#\T@DM,?
MM,&M#(MA>EE4NOI)27"[4Q;Y!+[R9CJER<.N8=PM7<7R&<(4FX0*P\['L<VK
M6*(`?8E?!/,FY(>:P)=:F94C$1QL@Y&6W)]I/N%I2][2?8\XZC4@VTAM5:S$
M7E^1*NHK7U+&W"3,G_:LN1:8-;&1;`_**>\>^T9#Q=J8X_/]Z[\8ZI4CWB_>
M>UD-A<<<<!QQQP''''`<<<<!QQQP-$Z\`;,';F[!F[9,GOZ^L4_63FJHT@XW
M/@PH@ND(@7%(\.A]Q8'#]DPMV6AUB/DD_G$U/ODYPO&]N:+U]7]EC=R]@#EK
MGS9.O[).UFYJN&^:Q.ACHHJDI@7!$$1[U607Q-CPM^4C++7VD\K$W&7?/M8W
MIP''''`<<<<!QQQP''''`<<<<!QQQP''''`<<<<!QQQP''''`<<<<!QQQP''
M''`<A+M#^_=U._R/[9_[KU_Y-KD)=H?W[NIW^1_;/_=>O_`FUQQQP''''`<A
M#VTT79+SL?J)V"J,:QV@QU%W/<-F3-8`#,$=)V-7+_HW9>EC8\7"/%053(VR
MOJO8^SUM-H-A1S;8TU'8*PYTZ-AZ;W'`BMU4T69T9IDW4YY.4S:[MM/L!N<O
METF[9(]9L.^MP7G;2P(M4[_NV1M27;XPF,.BXP'2X/?;'I^SW&LJ@'UXWW2>
MAPCMA4^S<G="9D3M%M#:A+9@[JQNN71[%5;R+H\^'<X);75(MU+C"YI%R7#<
M9''74PYS#L=Z/#7XCMW#6.R#:J/P5+8G)'ID-L2)$(:0*8AI=2XI,J8T-C2I
M#$)*F\-NR\LJ:96ZUAW*$K]O&C]_6W1A;4+XK9LJ/<*!M<Y6=6C`M;GYGR+Y
M9KR;BBJS4P4P40BL_'ERJ6T)E.%!\&`Q'DS29"%`C29"`UFOU`-"MM+?<`=E
M$,M,KD..JZ>=J<(0PVUEYQU2OZ(?&$(:2IQ2L_+",9SGY<ZBM^H_UJN->!6V
MJ1>PMBK%G$#;!73XCJ'VGFBC8,Q$9GBBPV6UJ'+<J`0A2&9420WG*'F'4.(S
MG"L<E+K#:5)VX%.$*?+=?Q5+?9]<6\/.:2R3JUWIDW[*L]4-,MO28F2`N1EK
M"WH,N<-G19$:>-G38,IB0YL2)#B0(L:#!C,0H4*.S$APXC3<:)$BQFDLQXT:
M,PEMF/'890AIEEE"&FFT)0VE*4XQ@()U[U(^LUM@2BE78[!V`=".6*LRYPKJ
M+VFF1HUAJ)J;6[0%>=;U#E*"(`^-(!RL;/\`61"$.1&<QA;2L<Y&>I%UG,E;
M("$Q^PI$S3Y@X=:A<3J'VG>FUZ>7&-&A<0LPG4/MPWR`A]DE$;=QC+T-UMY/
MZ*L<G5%@PX*'&H46/#:>DRYKK<5EN,V[,GR79DZ6XAE*$KDS);[TJ6^K&79,
MEUU]Y:W7%K5UA)\57(A:P.0'$^4L22KXH6]-)2T1TMQ4/O,#H[I`AF'&\8^3
M<AUB&TO#2/=M^QP(3M>I'UF>L\VE,L=A'+>-KPNV$*TCJ)VF49AU@V4,!`Y^
M1"QJ'WK0HD8KYP9#EJQAI^:)G,(SE<=>,"'J1]9A)NMUHFQV#@6&Y+.-U,+*
MZB]IF25B76!*CUB2(BJU%AR:H(%2HJ3PUC.8L'&9#GA'SY,@><JY4?+N5?S#
M/94-PR[-!LLS2TN..S*E,!<Y;]B9F3&DRY>&0\Q;#L2=*DH<CQWW9'F%NO\`
MLEU<[2ZPZP]T*<+MELAV2X7FI]<\20\\!<Y]M/OW36%Q&M5PD6'BXBWQ=$N$
MJ5)M$Z-`%U\/*-.R82TXQD/K.>I%UHK/V-^4,?L*%_**P#*F!^T>HG:>-]KV
M8U[_`.R`(_V]0X^)*$OA9/P<1'EQ_P!PY[&,^SGG-D]2'K13@!>UVR-V%KM9
M`0EDCAXOU#[3PQ8D>VXTTN9/EN:APW'C(=>:0IU><)PIQ&//G..2GUQL*@;N
MIPZ[U&0P="-V"PBO!"!EJ<!N5!LY>G6H-/@S$*=&V*I6T&:!3_=YSEB=`?7"
ME/Q7&)+VP9L"$2BOP2,2-/A249;D0YK#<J*^WG.%9;?CR$N,NHSE.,Y0XA2<
MYQC.<?+'`A;*]0+0<%B5)F`NR<6/"8D29C[_`$\[4MM1H\1I;TIYY:M0^&VX
M[33CCJL_)"$*5GY8SSKJ]ZC76ZV@05HK$+L0?KEG#BK!7#@KJ%VGEC#8,Y!C
MDPQ8;*;U#EN5`*#I<:;"D-YRB1&?:=1G*5XSR=:FT+2I"TX6A:5)6A?Z2%I5
MC.%)4E7E*DJQG.%)SC.,XSG&<9QGF)FK'5J#"$,%%-U\'E*!D.4W!>CUT.U$
M::;BQILN(Q]F@(*(^,(BN3E0AS34=:/?,H:QC@0_">HUUNLD%PG7X78@R/:(
MEQ#DT=U"[3R8R"@`E*#&QZG6]0Y3B4*+0I@V<U_:CS(SS*_"D9Y_(5ZD76<Z
M0L@D,QV$*%*:78`6P?!ZB=IGY=<-R@XZP1A1AE&H<KA3GP9@46:CNXPM<`A$
MD8QEMY.<R-VIMZGZ1UO9MFDPILK1:=6[!L.Y$:3`%3V0%*"PYM@M5T?8>*B<
M&(H^!&GEY@^N?;=K+)0\L0#+2U9;5HH9V%ZMZYN&QC`(A+9<O9W1=ZW!=HT4
MFY701[?`BK:OT1*M:BLF/-"OWP:!JP8="$AWF1"%CR5L;!H)HER`^)'J)]=7
M##]?0-[%J.11,0]($IZ@=J,SV`D\A/%0BKD?^B'VTP99,42@,2,X]AR5!E,I
MS[32L8^2;ZD76<:>`U<A'["0[):6#<JM@Y'43M.V3.1JW%8FV!\9%SJ'WDIH
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M"(UE[X:%?!V&!.']I`#*Q)F+.+P.HG:D>1!M8@RFII*+,7IYQ,*8);P[,9DJ
M;6F*_&2\I"L-YQGI]>=^NN:Z'1<5QWM'>03M0JV0%S(=3>TYLA<0[P2!D1:)
MAEK3C+9>78X*XQ=\FVTTV0>FJEH;0E["<;SO?8'70#<FM>MEY!7$>7[##MB"
MM;&UB8\RG7,C1*K*LU\JN9X<Q,L%9)CJ>B69:)6NOU^M%V$9A@K&0-+9'.8S
MH[?O7UZ!J;4.L),\=4R%<MM.T3+ELO*`WJO]>5P:1<(E2(OSYA>6W3/A(\5<
MNQQ!3I^)&?+@G34!J1.2&!USU).LUP&9-55CL'81&")<0HD)ZB=IID-)2ODY
M04X/R\WJ'*<2Q)>#,&SV?/M1YD9YE?A2,\"/4CZSGYUE%A&.P98C3#B*S;8,
M#J+VFD2:Y87`H>R-A3#2-0Y5")+`6`&93%=\.9'%H$G&/=R$9S.N)!A0&?AX
M,2/"C^]??]Q$9;C,^^E/.29+WNF4H1[V1(==??<]GVWGG''7%*<6I64>##B.
M2W8L2/&=(2?C9[D=EMER;,Q&C0\2YBVDI5)DXB0XD7#[^7'<1HL=C"_=,-(0
M$%6O4BZSOV69366.PCMM'`(%JGUM'43M.HQ#K14E-#C#LB%C4/O6AD\J-(#H
MLI6,-NRX4EE.<J:5Q*]2+K/!L(>I3(_82+9[".-%P0!_J)VF05+BZXL>@^0'
MQ,ZA]Y(B!EEAB2+R,>S&S/B^\SCWJ>3@F-0(&9IY0_WTY@<IIZ1"@?%&)$&(
MIZ6W`8]PVJ;+0EYQYV-`;4O"I+R\LM>]=5E735^P4^YX;-@9HPQ)'8?@J?0V
MG[7#9EX8=DCYL>4TT6"/24L1G9$":S#>>2U'<=86E+*N!#@YZD76>LJ!(L+'
M8,(JSV473:Y@EU%[31<F[8;9GR`]<&X<U%CXHP48%$G8,)OR[(1!DJ1C/NE<
M_-G]27K)2@4^T6YKL%6JX+Q%42.&>HO::",@XFS8PV'F3*=U%AMKXHA-B0F/
M:S_629++2?TG,<Z[9':/J/=-P;5T[?5'B5XZ/6CJOM0[[8HI$$C]E]B"EVI7
M7P14B,:='1;;0<-,D@3PU3.*]`('A<<H0PZV1^R98Z_V10MT"K?'#H^-<I-T
M,:UV#5CT*,Y-JMXKC`HF1K)R,ETB)E2H\`N#,Q98R<4$SAQ,:1'3Y++R',!'
M:?Z@N@1<:?,)`^R4&(+CS99&1)Z>=JFF8,4<R](GR)*U:AQAIJ&Q'>=D+5XP
MVVTM2ODG//D`^HIUTM(@,?K8WL6<"6(>/*@2HWJ!VHE02XPLPU)&3Q[[>H<H
MD19\=]EZ*ZCREUMU"D_)6.3E=9:?:<9>;0\R\A;3K3J<.-.MN)RAQMQM>%(6
MA:5*2M"TY2M.<I5C.,YQS\QXT>)'8BQ6&HT6,TVQ&C1T)8CQV&4);9989:PA
MIEIIM*4-MMI2AM"4I0G"<8Q@('UCU)NLET"QK)46NP5E`3)!2)%,ANHO:::.
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M-$L@BG2F.P<>UGQ!ZP`ZZ[U$[3(+E@=6DA(=D+0(6=0^]D0`<JRU^.3D(QE$
M1XR.0YG&9+?GLHN[M#4"VV39Y&CW^D[3V/H2@[KW6`.C&DW'6NFJ,X?#5PWL
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MV$4APB`Z7&Z>]J76)L$E&9F#Y<9Q.H?#K$R+(8D1W$^<.M.MK3YPK')6E;74
MFS"J:?D,Q91:(IN/$.1'6!)Z/+;]R_`A3)[.!!9]:'5LR1*)#LQ3>7,*AK82
MZM.-G-H`:_9H^OP0&P7"TQA,,I,KM.BB/%="/R$0Q\HX0.&:]7PC<EMJ7(&C
MI)-LD1@BY[HP?*3&2EP(RU_U'>M=K"#K+68G8<]7R\=<H69%]0^T\L<0C-R'
MXJWXDEO4.6WFD28TAA2DYSC#K+B?JG//R$]2'K19%'$5^/V$-+K-C*5"Q)'=
M1.TTE02T@\L8,5XEAO4.<Q2PS,F/\;#<\.L>_:]O&/;QS--:[NZ\T-RLZ6HR
MR`6JP-J6;KG4##K4AZISMRU<4=N-FU</*S2#YI^P#(8JT..39PYD!*(@S`,<
M;F%8"X.):18$&%A_X*)&B8ERGITKX5AJ/\3-DYPJ1,D>Y2CWTJ0K"5/R'?:>
M=RG&7%JSC&>!!Z-ZB_7":7+@(D#L3)-U]@-)."F>H7:=R<)CV%J>^">GQTZA
M]N,V79%D71ZG,8Q);A25-^<-*\?.[ZD76=BR0:<]'["-6PH$)64=75]1.TR2
M\VOAYL`:5-1H>=0^\='#B!0;"ER4XRVS)G1FE9PIS&.3L1$BMR'I;<=E$J2A
MEN1)0TA,B0W&][\.A]Y*<.O(8]^][E+BU):]Z[[O"?>+]K\J@PU2VR"HL=4]
MF.]$9FJ8;5,:BR'&77XS<G*<OMQWW6&'7F4N8:<<9:<6C*FT*2$'"'J,=<!4
MT&.)P>Q$"?9B$@37H<KJ%VG9D&BD47.-R1XUM6H?,J6P'&$"3C+?E:8<*2_G
M'L-*SS^5@]2#K35!N#-FC=A0(G)($&P1*=0^T\2'DM:#HVKUP=AYS4.$_%F[
M&9$@QC/GVI1,C#BM^7'T8S+L5<*=9"+\!B7'S8`#S[SP8K%<'V`9E#2XKY!D
M83:8GIAN,2'&$EH+;D*0R\ZPU+=]IUKE?;G<S56[8&V*MO[JQVZT#JO3(:'O
M4UL_L-K,10]9G8FC=HUFU5XG4#=0V3;+&7(HL]=`7`&"E`!DDZ#B*0_$5E<H
M4H-HF_44ZZ5H.7L%@&]BPP.OC2!DX6(]0.U$:`)$BHSLTF1GR'-0X1'B0(C#
MTF4\O.$LLM+6KQA.>?;&]0+0<UB+*B`>R<F/-8C2HCS/3OM4MN3'F,MR(CS*
ML:@\+;D,/-.M*Q\EH<2K'RSS?M`VY1]L$+]3(<<A!M=`=`B]C4"U0(S!RO-W
M>MQ[/7$&84>64%2(5CKDY,MC$:?-:3[,T411%)P)\"/MQMIMI"&VD);;;2E#
M;;>/80A"$X2A"$)\)2E*<82E*<8PE.,8QC&,8X$#JUZDG6:Y@!MJJ3/8.QUH
MS'<E"3H?J)VFFC",9J0]%<?B2FM0Y;>;;DQI#"U)SX2ZRXC/S3GG]`OJ/=:[
M&@LX`B=AC"`-C.U`TL=U#[3R4BK56)28-BKT[+>H<XCE@DQ:8I*&OP[%?5AM
MS&,YY.>'!A#XK,&!$C084='NX\.&PU%BL-^<Y]VS'82VRTCSG.?9;0E/G.<^
M/.<\ZF>^&J0LB4^`5%@IE.DB6`PE^4^Y(G2$9G$WX0F,[+ENJ6O,HA*2P_(4
MVAV2]ESV%9X$*X?J1=9R)\]58#'8299:O$`S[("C]1.T[A0'"M*"3M;E$XJ=
M0^\BL'&PQ9P8MS&,2D#I:F_.&5<*]2+K.BS,TQ<?L(FVR0#]KCUM743M/@P]
M68I-L+)/-PLZA]ZL6P7=:&NR\8RVB8XAA6<+5C'-U[C[&:4T+K`COBWEVWZB
M^?H%*<-T\9FRD#%BO-V$Z\HH);PK&4-8D6^V0!*IYZ<.!5G$^60/$@PQF?,:
MTY7.Q'7>V;`A;,&UNZIWEF^W_I<-ITT:F)<I=OI+?]*NPJ2.;58%:^*#*\-K
M[]K)WN!9Y57;B"I4*/8W)C:AJP^8MZD?68"0K(DVQV$%%+H8E5^HP)W43M-'
MEV0Y!!%K1,$AV5ZAPJ;/C5P$9-O1VL96@:+FRLX]VPO.%A]2/K-4H$<I:&.P
M@`=+,`J]%FE>HG::)&D';.6B`:X(9=<U%A*R!LW/A"AL?'Z<J=*88;QE;F,<
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M_J2=9;O7`=PI[/8.S56RC8QFO6$+U%[33A)H5,3[<0B.F-:ARU)B2$8RIIYO
M.4KQCSC//T#]2+K/9\&55UCL(;37;$6J)Y0SJ)VFE8$6D#\+]M5\AEO4.<1B
MPKXV)\=#7X=C_$L^WC'MXYMG:G9C4.ABK-!GQR<\X&U39]SE*=118R1-I^C=
M?DPP*W;*GBGR81M%5K<TV/C8%@4D[08SB4U5:T;='3F6-<TCL'U1H)6R1Z`9
MPH%?MG:YLMTO(E<HG3&-H=L8E;(:M;)DYD[,V-(VI$)U"2&6(&2:X-18J_\`
M:\P*HS&2Z'60/4BZSE3=AK8V/V%G6"I?8WY3AHW43M.Z1`?E#!<)@OM2,G4/
MMQ/M<>T[-@>\QCXB,VIU'E.//.%^I'UF:L\:E.,=A$6^97)EPB5I743M-@S)
MJHXQ"K\^PLP<ZA]ZX)AG"(\5(F)Q[IJ=-C1U9PMU..3K:@PF)$N8Q%C,RYV6
M<S933+3<B9F,W[F/F6^A*79.8[/]4SEY:\LM_P!6W[*/T>?G(^#F:DGF'&R1
M1%7!1/RPUF:B$X\W(<AIEY1\0F*Y(::?7'PYAE;S3;JD96A*L!!8IZD?68(5
MK`(PQV$&&;H1)"*B+F]1.TS$VR%`X$E:"H\,PO4.%S98ZN!RIR6RUC*F1@^7
M*7C#;*L\6+U(^L]1'LEK2QV$KXR06#`F)Y7J)VGB173-B)1PX$6AUS4.$JFE
MRLN,/@,8_3D2WVF48RI6.3J?@PI+T.3)B1I$@<\Y)'R'V&WGX,AZ*_">?A.N
M)4Y%>=ARI,1QV.IMQR-(?CK5EIUQ"L0>M]()&GZ>5EP6S4:8RI@)88JH3I!^
M(I,Z-,!M%F6HYO$;+34QN4'7-5#6EIYS,=W",\")-D]1SK;3P)RTVJ'V'KU;
MK(R>:L1PMU#[3PQ@40+87))$R4IW4.&XL*#':<?E/N9PAIM"E*SXQS7]>V^!
M[#]T>O\`:=;5/<2JM0=']B$VJSW?1NWM6UT>_>"^E<52$R9V53*K!)D#:`9:
M1#@"79TK$6!(E/-M,)PO.]R&Y-&=@=K=ANBE@%V@A9ZIINI6':U?*AB0,"5U
MCO6;?*8#<"69B8TX0^V7:1:XTA8[X=\>VPT[E]#KR<)^(1W=ZU,U1ZT.V]RO
M4.#JB^[BK%G,0'VQ-QU!J,X+J-WO%2;C/3R\T17S!FNP4QR8X6:,,GPI,(-)
MC"+,U03&XY%-SNIUV#ECE9OE[B:ON=9FCX-@I6P$M"+&*=+5P';12WV8#Y4>
M\S/KUD#D&W(9&3\.N2Z-G8BE8!"#%<"5G'''`<<<<#ICC!R1$;9`3QXV6N0G
M#\P@/=)X:A^Z>P[F)$;FP$*F9=RS[I<EY49"/>Y<9=5E">0%[+=,<7=6K=HT
MZ4?L>U=-]@=/=@94%XU!`YVG&U*JRM2*$@;'?K.O!94R+M910`H3AC8+=BC!
ME'C444T[)C6)\<"&G3;KF4T)#[&6>P2'T6;M!VDV7V>/5YPCDDS27;R%IE3"
M4UEYF7,%9EAZM0P:[`X"><#2[1+-S!\F;'?1-D3+XXX#FO-KWT3K#7UEO9TK
M@((KL6-*GEE5JS7#X%B01AP,OIK5/B3K(77A<M"6XPR*ZYA:DO/X1$:D.(V'
MS!]E;%J&I*-9-CWXF^&IU2'_`&I8"L<0=.NCQ^)#$=<K(NM##!N2TRY(;5(S
M!&R51V,.RG\-Q6'WFPB)IS<6A-@W+8%XU//V%N#<XG7<Z81'.4:\:M>L`*,1
M@/Q:U7XVR0&L-6)*$3,,:.%S3AK)6+A>%%;+$#J*3<UW=!.F/8W3W2'H;5]M
M::MM5WCT#WMMW9*=:P-EZG*B]PA=M,=A0)%FNF:[L&=3WI`BJ[^:F"&=A%J>
MEBX5*<TG#0]\58)%NVA.VG73LT(%G=&[5KU]&GPK]FKKL/!D6]9ZI%D08DBW
MU:!9QH4A9J@U,)C8B[8`B$:[B40@QOM/WTMAMR1OM8SCS\__`/%7G_7'CSC_
M`%Q\_E^..!$#I1ULE]9-776OF":B-GVKV$[%]C[:RT0ED10(_P!@]OVG9[U6
M".2_'NQE6'G!H+.(J&H,HC!(DH;+3$Y",3`YQ[6//CY^?'GZ9QC]_CQY^_V?
M/GQ\_'CCVL>//S^__P`JO/R\_=X\_=GQGQ\_ICSYQP.>1P[$;UI&E8-93>+R
M0HD&W/F8,8B'U?>MFE7G!L:&^\W!C5*L6L:'<::EX7\59Q<B'(4I#46++4W)
M;3N`K?J<$M]2H):PCH%RO<"T%*A79#JT$SXZE-!WK7-'L8;S[R,!;/A<D75J
M;2PHG#;\J<?0G,>K[WAZN:TW8QUTO&TXX+=$FO,W"/0UU?8$LF[3G5Q&7;@B
M6)JDX,JI#I,Z%!,V;)3["`D9<8<;GCY[R(Z@A/N/9VP)NAFQG0'J';^Z5,VG
M>;HQO!LSN\#U7DQ,LC@JC8M#/8:N#IDF)?\`&(``F.J-*@5.(`<.+B/M$YSR
MG,,VOZ>FS=V*[1@[)`E5D1ZB$[I)L?<DP3>8TN-USL75Y&K&K[KZMRFB,(V8
MCVP%K^`+UZ6I0UP3%M.;+8+&L#"EC?M*Z@$=!V4((L=:,#;#7CXZ$9!'0A",
M8#F1!..W+'%112`]*AD!L^(\S*ASHC[T63&=;?9=6TM*LZRW[O\`U)U@U59-
MV;RMS%%UC47`C-AM,H:8*11SUE/#:N!:>C`QY*=Y*6$P+$1W,1O<IESXZ7W6
MD+]O`;CQCQ^_.?WYSG__`'SGGYPO&<^,>U_YL?V58Q^BK*<^<YQXQ\\9\><_
MI8^:?./GS%+E>ZAKT.Q8+K8!U;#2K#4ZG&(%'5,,2+'>;.)IE1#L9PA:WIU@
MM!T0$&LMH5[^;.93G*6_;<0&6Y^6,Y_#'^/_`*8^O*\M^]CNM2K+<-2[MV+;
M8PX)(0/-TJK:7W9-:DM2A@\FCXV_U;79YQZ0EF6AUB30["&5%][EAV<J>RO$
M6=P"QP;$P3D0HQB.@4=,U^0DN$*A779H.:Y`F2(+1.)&<(BGGVU*&F(27AA6
M/[,H?)D1U8<SW><)SGSGWGS\?V<N^/GGQ]$Y\8^?UQXQX^><^,><\"KBZ]=;
MSO?LMHC>E7H5KZV6_K3LR,&QN@K=Z]?!N^^IDJOV=NQZGJE&@W0M(KT;:1*9
M2IMH-;$I%.OE2?KT6:')&B(H>\C7G5;T_;MIPET9HIZ40Q3O3JA=C0]/O<^P
M0R<K>;.\`LVMU8EF%#+RSD5=6JE@+,WO\N8(Y\A>8<4C7&2XS#1G%N%EL4&J
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M`8E'"N&6F%N9'!XT@G-]GX>"R[)<;1F#&O\`<6@]\[$\4+:EN,[X33+FS1[$
M4TQMVE5NH,31348A+;#':?2:S8V(+SL6:P-NEH*EWG$N-")T165J9L*]I.?E
MX7\\^S_8<QGSG[_/LXSC'_\`=YQC'WYQGG&/8QG/S7YQ_P#N4YG&?EY^7M9S
MA7R^?Z/GQP//#8O3/[/7'M?W&VO<3X,E4"\STEMLZ1)55H=35;3O_039.Q=C
M6FB&P#FPK#,K\`B/,KKBGK=*8K]BLEQ$6%,^`,J)%F3:EU%Z\F-/GNTNU+1B
M4.M/;/L1+WZ4I[Y&,0Q08+>K-9ZJKE2DN"YI(`Z>C!-<QR5HEUX@0#2#9*0S
M`)$XL1DA)R__`*S>MW_47_TF_P!)#/\`U"_9_P!L_P!&7Y+7O[9^P/A_?_E-
M\=^2OY/_`)*^]_\`AOY4_;/Y/?;O_P#3OVG]O?\`PWF0;H[0:8Z\5JS7/<EE
MGT6H50QK&ND[.3JEKD`W3VX;5%I%`$"R(X-,CEYI>UD!@24@>I]L%+*#<G7!
MS,Z.ZX$@>.8\<LL`!D/B9',2/MNP#ZW$^R098S[F>1S(PS((Y&1)6!8AGX9S
M,XW/S'%#\9;S,ELX=;]K(/:QG/CY^?GG^RK&/E^W./'^&//G/UQ\N!IG>VV:
MQIJDM6JW6>14`\LZ.`+-1*'<-BRV7R3,UQEJ+7J6)-$</NXB.>P0G0'0\/V<
MYG86IQAEV'0MOK-V-IU@K-<T9.[?T38>Q08S>,?9M'&``($C&!22(*^E:#OP
M)KD!/@#%I;;6]JBN$+(-)2X9"&,FRXSCL"RK]%?R\JQ\\_+RI&?E\O/_`)<Y
MQ^W'RS^WFC[;V%UI2]G!-/SY9\I?2X<19IP6M5FP6A=2J5B,F:U7+A=70\*8
MBKU8_9P!BNB3)#V(LHL/F-JRW&B2I3`5JVGT[KC3R&UA&OR)V^5SL9T$#^G^
M6DF+,.@NZ;!5(KO&32[NZ^1(C2!2LA*9N9ZD/(JL4M=2!"F5`G-&2<DSQX;;
M?0J>/U[1Z=0Q,B=+%TJJUVI#91.2Y,)28%:#00D*00EO*4[*FOQH#3LN0ZI3
MC\A;CJU*4K.<Y9A6,_C]<X\93GSYQG./IX^GRSX5_9S]<9SC..=6;.AJV+DF
MK`4@!A,/#691$G*9A0V,OO-QHZ7)$A;;:7)$EYF-':]K+LB2\U'90X^ZVVH.
MUXYI#7_8[3&SSHVK4V[Q"%J+UZV6T?59XJQ5NSR:M2+8+H]EL::[:`P4R@&.
MM9D8%24=@MPI\J8TH8]-C^V^C=GMX^?R7\LXQG^K7]<_+'C]'YX_'./.,?7.
M<8X$'NP_8[1M5LY?4^W=B6*O07`PR:1K=8TQM>V2B8\NR\MM,RYUV@6\%&9=
MRPXI,8"Y%.Q,H;4_.AK4EMZ!A/H=<K7>K;8]+FK+%K&[=X=/NT>C^RQ*?`S:
M.L5!T76-)4^X:4@";U-B[4F)VIK;7QX,#%2:J7"D!^Q+8-VR0$S8,1!BW/>V
M^M2];->S-K;KMS5(H<*PTNJ2#\B"9(L(L.P[<&H=,%_#!84^5[T];K"&!QGL
ML)BM2R#.9<B.S[;J=PI4G*<YQY\)RI.?.%>?*,Y3GZ_I*^>,^,_/VOEG'GSC
M@4]PN@5SG6VBZ\-O$6=;ZN]3387J6CMF,V2,ERS2+Y8]S7T/IMD4P8<MC1*L
MWO9[<6P2#`V-39VO14$<*(E)I&:)#7#8QXQC'X8QC]W,8NUSK6NZ;:]@7$FD
M+4:16SEOM!AR+-EH$UVMC)1@V3=B#XTN>^V/&PY,MUF)%D25MLJ2RRXOPG.D
M+AW!ZY4#1M"[)W79XBL:0V6-UX7J&Q"X\^T!G#=JQA4J@S)SD<1*D`X]B;."
M41GSC`Z.Q(G,1ICT9]>&^!)?G&<^/WXQ^_.,?=_S\?ES7L?:^OY5VLFO&;)%
MS;:?51%UM`U<8BRR!K1U<]`HB5+OPFP</,Q(N>^B$Z321;B1G)K\-J'[+ZM@
MI6E6,*2I*DJQA25)SC*<ISC"L9PK'G&<93G"L9QGYXSC./EP*Z'>R763:6QJ
MM4;EL>W6"SC=CB(%4J@K2N]:A7A]Z#V=$4&_(MW]'K$F8ADQ'::F225PAT2?
M&3E9&"^(<==?RKN'U++]PNM_:'216QO4@GN4&+K%*,Q9CR&@46A&QMMJ<@J\
M)]J?D79+F/DR+4.BON*EU4A@<Y#;FKG,N3KQA'GS[2OQ_P#U%YQ^[*O'C\<9
MQXQCZX\<_?G'X_?X_P!?P_QX$&^M>@K17>P_:KMI>14ZEVGM$,Z_UC&L99\>
M?72J]U\J=K`P7Y\RO$RE4DF;.>N]F)YF!9,A:JRU6(I-U@G%E#8$Y><>UC\<
M>?KXQGSG\/I]?K\O\><^<>//W?\`V_'S^'C[^`YK7;VQ`VJM?';W83'V`'"*
M%XG%_P`E;3=50FR1>"*0XW6:7"(6,HZIV:VVVW!BN-L+6F5.RU`9DNHV3YQ^
M/_/N_?\`=SH[-9:]3J^8M5L-BZY6@`^05-GC1".+$BAL-O+LF=/(2W68T2,P
MVG*G'G74(QCQCSG*L)R%4U\>IG:76F\`?4VW-WK>MF!:_%["5N35FP*I5+KI
MA>R0#VS->,!;I1:;K>&<O&O(=MIU=LF0IPF"*E!Q$S(1!;P0C8Q2^G?8$#9>
MN6_;)&+'9'4SL3V3LFA^N4&U`$6<)U7W_J-O5==U=;;84MS]"M&U=6DW%VJ*
M>)7@H+:JSA2GPKB?+*:-EK,Z-V!U+L(]#K%7LTMVP$PDJR"PYJMW"KSRP"$[
M$9F&!4:U@@ZB(Z*Y.A(D28?O?<JEQO>I;P^UE>Z?./QQ]//SSX^7X_X?M^G`
MBMTMT`3ZR]?*]JDX5C&3B;ONS9!V7"?FR8#!S>.\-B[M+B!KL_/OU#*_.V"\
M!'YPW'97&&MN,1H[*VVD2JY@^R=D4O45$M6S-B'&JW2*4(D'K0>?BSYK`D1$
M]GXJ<]&&1)TYQIC"TJ=^'BO*;1Y<7A+:5K3F,>2S*CLR6%X<8D,M/LKQC./;
M:>;2ZVO&,XQGPI"L*Q\OEY^?SQGP']^1#[&]A=5ZP-#Z'LK8ANEQ;+7%E%PZ
M[I_8NPR94<X0EC)363E=H]TK`:,_[E<5R+,A+.>PIV5&^$0J++QN[<>X];Z!
MUO9MN;<L\>G:[IS$&39+-*A$R$43'(E(06&](CAX1"=EIXF1A1/>-Q5MM+D(
M6^MIG"W4;,RG"OGY5\O./DM2?IGQG^SG'W\"I6Q]8-9;X?IESZY5G8%.AV?J
M_MO0Z>P+Y6(/`D].;>N))=QU=<:/L]$O=I4Z"M2).SM?.HJE4#`RZ<0F+G$`
M$255):3>])UBJ5_:W5W6Z#0OKEN3<?1#<$:UYLT6/+U55NDPCKC5W-5C,(,-
M6]9BY"^N5;D5*:%"NU<2BPV?)HH+<A#QAF]?&/&/&//R_'.<Y_?G.<Y_USSG
M@<)Q[./'[5*_U4K*L_Z8SGQC]G.>..`YJ>[:T=V5%)@;H<<>ID_$F,Y6`<"*
M-7/@/)2E+9*PR/CCK$I&4^\1)K4FMOLK5G&'W/9;6C;''`J#T_HC=8?U.^UN
MT36B;I4.N.T.HG7[K;1-F.[$U22?D$]#6?=D\F56%&[-.[+'"[0%VF*:IA<J
M"=/X(!R3UN'@5JB/RHG6/T<;GMWKWI_K;;K:6I+'4?IEN?J/J[8D:QXQ%VT:
MV+;-`VFJ['+0ZT7F'&ZF/$:,'@[P!MH\4>FV$^><#0)X6/%+%_1;QP/-IVW]
M"R%ZC>_;IVJW7=+]HBSW"+4@(S65=N\F2Z"`4RF@*VEX_.HUB>JY`P5.P3Q2
M-*&2YBL5N77XQ!R,3CS1T)STE\<!QQQP''''`<<<<!QQQP'-/=@;)`J6D]HG
MB42QSXD2CV-C,*I5&V7RQRI!07)$0(XFI48+8K6:DO3Y\5OX<,&G/LM*<EO-
MMPXTF0SN'C@>5[J)U/[10_2;Z^;GI\B_R^\'6;H_/Z^Z(U9?M*GM*6'2#%ND
MZF3V%JC%/ND8*>V9MK-2UK^3VM;(8EUZF'C4<;%AO0T%Y=L@[6UK7MSS;-Z=
M(YY?=5S3NWNY'9@[L+6]RT+M#KV!U9H(GTXV#5P%)OFO:;:+NC76K\;]<HIS
M7"]N6<-8X-PL1B;6&(81B5+8])?C_F?G_P#?G'C&/I^/GZY^>?V_C_KP*&I(
M3N?*+^H2'":]VO"[JUB%V-)=/=WO,3AG66RZ.M53)P>K&KDW.09EC2Q^HDFT
ME;33G`R;&$VZQ^61:4Q6"Z2,J$6L8_9>+O+T]R]WQWY=U!L/>'9+'8[5MSZS
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MJ]6;%ZY'JK0>O![>.YM1]J`UDUF/T]>24,W;=?AR=!K]<3<;51NS]2M%OUX-
MM<M^7:H0V!.D-A_Y^J!HKM;O;7'J':;MVM-D[I-V2B],1W2I-+KQZ>'M.NQ%
M\TB4[<0R[@+X;7M1V09O8,Z<M%:/$X>"^OA]0D5">6C"#[0?TX^$X_#Z^/K]
M^?&?'[//R^7W_AQ^CGYXSC/G/C/C./GG'W9\?7./G\ONQY^[SP/)3U\Z\>H!
M3973,-KVC[:K.U]+ZK]=_5EBLNQ'+:K75-OVS-Q-[`Z")OILX1<'7.CNASXI
MVEG:_(M8X8/R2"1R,9T*4CB]S[QT!<^Q_1[K<EKK7V<@&PW?ST\KEVOUCN`"
M78/665K/=80-VGVJ#J,<Z8+V(1:$E"ABU70$\BMW.L0X-K!H0-%3BV/3ACV?
M'G&<>/GGSY\X^7U\?/QXQ_Z<U_L_:VMM+5"7?MKW6N:_ID$G7@\NRVDDP*$L
M%K6>'5>LC52G\X3F<=L)88$%14X4].)3XL-A"W7D)R'G]ZPRNP)[0FS(>W:K
MV&L.@1/JJ=S4[EJFW-=]AB&W+!T3+KV:GKNUKVM68)C8MZUC#DS=12Y(NIPK
M!,321L\:-@/S1Y$9B&._QG?*LBN^%1+PNV=MGC/3LVF7ZB,T2C]C;M$#;`']
MX]FV[IX+#%`($R!>[+UG2DS3#ME:$2<6B'7X8X??(^'P%Q2QZ\JU9@=O"Q;!
M7IWQXB:Y.:CRE1YD/*W!L^4+FHS'(1XDMI4>?"DQU8=8;]I365H]IM2%JY'6
MBLF"]AKXJP!21VIR!L2TAH!2'+*5R48&,&A,<Y`COKDB7R8B3'*0&IK3#DP<
M^S-8PY'=0XH*AO5*N&[B_IEUFU:08[#.;IL]_P"DI@3"T]2MPQMJ/BYF\M0G
MMO1[-3:-7VKD$!IU1'V,Y?0EN"#!D*(U*#G(3!5R`.=K\K%V[/#^PUHL4@#W
M!F+B?]H+EQJH8.Z?[&&Q`_H=>^L0RH6MT',,TJ8%@==).SA<B#]HQ%M4\%.@
MC2<"4.A)&3U>IGY9Q]?EC\,_A]?.<9^[[_/&,IS\\9\XSXSC]+Y9_#Q\_IG]
MV>!2#WYL$NM^I_Z3^P9%$W38*)I(-W=,;<N6O=#;OVE6*-#V_HX/0=<X.&]9
MZ_MHY$^RVT*2%L"8S\DL/PTR2*08`R;!FR=`=N]9]GZC0.Q6U*&_V%'0>T7J
MJ=%;SK34VHZUL1^W5C25.E=>-<=@[+>1FJQ\T\&I.T*SKO8]XNXV[Y:`QJ\R
M#?.IA6(TV(;OY'[:UH6V?9M+C;M7YVU:94*O?;70XA!#UCKU.NI(\(J5A+P&
M_*H0VPDJQ88@EYY253'`\[+2,H84KFQ,Y3]^<8^OW^/N\Y^_'W?//[/GP/*O
MN;JOV>I/:7?X;5FMMWSM>O\`JW^DGVEU4Q6"U\+5K_IWK%6J5:[3&85DFFE!
MVA<>R"=DHV7299OX]Z$6BEB(%8HX%FO;@ZJ7:VH]0X!2]HF^]M%S5[WVI9)7
MS<6C]_:YU5W`NVR;T2LNA:A9MB!G!O7F6CK3J,;8ZCJ(./)V>N;*`OX("0-4
M,5K,21Z0I,>/+COQ9+;;T>4RY'?9<Q[3;S+[:FG&EI\^%(<;6I"L?^9.<XYJ
M^B::IFNR)4A79%R>;(NCEQ`UCV)>[A6JLR+%)"Q(-$K5JL)@'11OP"$MOCJK
M!%0Y+N%2)#3DA2W,A3O>ME0M<^N$<W-9:#V"<U+7?3.:T&2V+5NL/9._4Q6W
MG^T4;:+=,%GZ'JJRCC\[\A);)QP@"?(AFO#PMXH@O&DCV:U>]5N[&=@6?4\R
M*U)W5*:_V)`]$'8'7[7%DT#V8/#Q,NB=J(6R>Q[5)J#E)DCPUAJ5,;IUJV]5
M:QAN6+GQI4&?B07#$U1_63?-JZRU<T'D;(O]/HC-@-#:Z#=MEC&`$%SI>2F&
M+$CLDI4?$N=.EJ3&C1V?:6Z^I+:?*\XQS.V7F9#+4AAUMYA]I#S+S3B7&G67
M$X6VZTXA2D.-K1E*D.(5E*TJPI*LXSC.0\X78:U;0B$>M)2@Z@[&Z\W\SZN_
M65'=HQIC6G9V?KK:^F@@^U236SF#8^L/@[5UQ)TTC19,V#,^)%4*PMD:99ER
M+)7R)4GH;5]H[21=W]1)[0[N[`CD^]WK04#9=Q*Z>["%C`WK1=X.Y"O45^RD
MMA4Y8EJE.761H<OI@I<9D*N1RL:(RV6&B(ERS%]77R^?S^GSS\\_+_U__GG3
MGP(>T!B5>/0F288O$>@$H$A3F&I45[&,.M+4VXVZGSC&,I6VXAQM6,+0M*L8
MSP//KZ3^PBUEW^2%7MSNCJHG7>M=,UZ)U9V0TSV9TU3M][4I)B5+[!=O($C9
MV`^O+/M'9#YRH)ME/%PK<8I4-AHX.NI>#8I3N,'W?JRXN>I/ZANP.HNH;E7N
MR=I].>DTCK_N6SZ9W>`UE.[6B;7V6([-CA=N%JI$U?\`E,G6MCU>V*,KL2:I
M/,20<`9-F3H-@BL^A77^LJ[KB'(AB"EV.KD3BDW)+8.Q+OLLXQ]LSU$9`^&<
MOI^P%80=N0K"1X:+*9&CHS;$.!&8BL,LH_CKO<>K-M3-B0-:7RMWB7J;8174
M^R6:X3;)YIFR08D,<,TD\IGRW"L8H580LPB,4I3T)LC&1(PVZI3:0\XVX*SV
M7A]F^HN=+!^S`'IAL#NMUO<L.NA54[##"P5F+JCM,+[E&=Q#(H[#-4TX7V29
MZ_+7/NRX5;L6QUG;QKXH3`NESB[G.WFIKY8H744[KV.6+USKSVDUQMC9-('+
MP5.W76U:USLVCMP(*"3CDDX5J-PN-+V4Q&7/00(NTE;T=V833&C2IS^4Y_\`
M-CY>,Y_2_'/R\_/Z9S]//R_#GZ^7_/Q^O_\`W@4<>K/=S^S^@>[-B=4*/V0D
M=AQD.@:\UC==::<WQ3MT,QSO8K5<O9%-K@MJI`MJ.U0S7*20-7"3@`J@SP@<
M=-(%7_;%95#OM_U<[`Q-L>I^QIK6NYRX#>-:]*7=G62-4)&P9\(A=]/]F#6>
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MMRPK#M>+L9TM1*Q;8,$N-G7J+5YL4@:K,,O?,.[?=82X<98!>\M=$`AK?#G6
M$.5AV&/(@E>P;)MZMOZC&R&L*1.NT<['E"I(F+EQ<>7$F-/K;Q#DY:D=Y3G[
M\9\_M_#Y_+Y_+.,?/Y?3Z\#SC/Z\[,EZH&I.R@F^-CZ,MWI];X;ZZ,6#5%HH
MNP:IVUN]@VDZ#I.U=95$O;6M5/U?11NL4/2,^\V.1%'C$V6M6PH$NV1D0I/3
M6P!5.],+J;UWW-HFT7>SWWJ]U_ZP6_2I>G6`V,AVHMIJO46UBMNSZG`/1:%0
MJY(@%G+C=2$A@:'B0TY&37C<D3'?M%_1Q\_./ECSY\_=]?K]^,Y_TSGG0`K2
M`LCQ^,%GIF/58_(K!U&(\R-\"=BPX)!^![4J/'1)RB(2A/9?AJD1%>^]VA]3
MK;J&P\[Y74N^*CZ?OJ`>GO;Z_O/:6X-2U%9W6F_JD!W!')]K=5%HM>*T:0SL
M.&A#1S<NOZ\$5IV_:N#6@M+(B*M7GX$`B+LK\"+M$]M+;^>TFOANNXO<L=K.
M!N?9.M;Y'MU9WJ2CR-:E^B98OJ\V'D?DTR+$T:=MP4(*5NPFIY[:$3:2CJ;;
M8:XJ9#JF+[_./KY^[/W_`"\8^6<_7QCQ]^?NYU!ZP`JJ$*66RF1@"O!(,@F8
M.&2$8:)%CHC>7),X@0F.LQ(D5AO&5NOONH;0G'E2OIP/-0/$]MYFCJI,)W'O
MTFY'/1YN^T+)GXOL#&L/_6AK@]6W-8MNQ&0C<H!M^2Z0/QINKX$86O8PR$R_
M;:796H:)JLZH!_LIM'L?L\C2MN]D%[/U-W;Z8>^UX5-[$AZ?#Z(V9U+Z^7[M
M/5KO1BD1BG0!*';1L.Q"!Q>#(LE`V.BL`Z@Q7T%Y`PG?W3]FZXV"N8W1;W4;
M@Z/'5PJ09K5B%&GX`RWCG"]5GSF!\I]Z'%L8IITB#?DH:24@MN2H>7F$*7CJ
M:-IW7FN;9M2[U`*\-LVZ[8-N^RB+IHV3Q8[2&JP>E#BF(90C,@B5Q*I7@0-$
M8+&'P\P1,%+D=3C"7.$\]X];Y4AA+]>6%;HW)-)>H5$`6NT:MUEJ;27V5VH(
M2Z!J`3O.K0;QO_;N-C4HI\%9MFSY4]5EJVL(!6W4CKDU%A4P>,/%+*?`SNZ0
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M>GK[7+!U2VKL[1=PM^+CL+85,TSMFB7S9^LYUP+0Q2[U:3@*KS2(E\U`!S+\
M3B#AI:$(FG),2/<%Y3^./&/GGY_3S]//S^_S\L9^7'E.?.,9QGQ\LX\^<X_Q
M^_&?\?GP=YOJKSO#MB;L_I5OJS];X.]T[3":KG&M?6O7VK=K5G:E;L)$Y6VV
M@=5&3Z=!O*K62CX>0;JHRO$76(`R=%MT"+'0TR]$3M^CL-I$?VDHVDK+W3M4
M.\>G2Y8NNQ(,2WGLZRI[-0]O;9L5D;!6AJ.3E4R[0@%IUU%AART\`_*J<896
M@T*9%!J&1[_O&/V_OS_[_+G/C_GG/`H?["FNQEEQW.`HKFQ]GZYOW7#L(%UY
M(JH7=0*W:]L,K7%$2,HM[TF?KLFL;*C6`Y'(8T;M?6:T6!MXW;:I;*7(=R</
M1L.MUTWSJ6\[ZJYQ[N<1ZLPMZ];/BK4`I&]]J7>K4W9/4ZQIN1.C*%QV-BF=
M5@]^#ZDK8HS6LTL[K$P0;8AUT6$EEX8_T(^/^?\`/I__`#^.><>/\?WY_P#?
M@>:'N=`WR5ZC[DZ[WMWMWMT@8Z6:;D=;K;&UWL1K8&X+H+V:8G;A9W*"U<+(
M@Q.S(M?B:JC3:Q>,Q2!ZFS3KJ(+]@D7!MGTK0Y#<R+'ELX=PS*9;DLX?CR(C
M^&I"</-^^BRVF949WV%I]Y'DLM2&%^TT\TVZA:$_1XQ^WZ>/EG./EC_#/.>`
MXXXX#CCC@....`XXXX#CCC@....`XXXX#CCC@....`XXXX#CCC@....`SGQC
M.<_3'SSSRK>JAO:_ZJWMZJE_Z[7ZR5'=@;TL>HM/U)9*#%=FVMW<M)[4]G[)
M8*-3DJ$E8QJXC*G=@,^PUH;&G&8%;LD4DZQ`8D-$&O53SK7W%X<<QA:\8QC'
MC&%9QC'RS],8S\N!Y@]Y=QNR]8V?W:8H6UMCNUS5?J5>E8,Z_I80<+0)VDM]
M4_0LCM"'AX<@OM7G6$O!+;4@W%GX*@]>RV"DH(NLS@PYV'V^HNUG8UW;P$3:
M=Q;-*B"'KV=N.M$AHS**M#5=(5]=KX6HL+V8(X>-9H8S90.A1J'M'*$RQY><
M[%`W#XH^45+],JG%^TO]-?R6QC'Z6?EC*<^<?7[_`+_Q^_G.'%^U_;7_`.)4
MG^UG^SX_L_7Z?L^G`\E&KNXG>+86@^J@2X[UV+J41L*K][-<8[!O=<.QG8"X
M1.PM%[F2:5U@"6:MZ/(U$S&/-]8W!%RJ!#<,@YKK;D%TC.M`4V2:2;B2"]2$
M_O/8>C_4GUUN&)L]TIKRZ]%Y_7VM4&NWMZ!>]!"K[U6O.[-PTZB5<<:CVVP0
M-BP=GNV45EF_VG50RK"A4:6Q#GJFV'TK-K7EEK.5JSG+N<9SE6?.<>?IG/GY
MX_9S^[RE8RKPK./ZK.?EG./G[:<>?E]_CY>?PX'DL=[;=Q;?Z0NBKS7+=VYL
MO<>S:3]1?8%8N%4`&H#'](>DK1<;%JL?N*MB*C&M!:_$:DY5FM*ZBG!A53MT
M?[?EW&N6$4!A`Y.]LENW6I*UZXN[-)U/9Y/L07WGUCM^M(Y89LJU1'M3%.M?
M5%G8-PUMKCVY@VVD:>+<W#+!56FP6+26,5=[7XZ4/?B08L+TLLK7EIO.5*SG
M.'O.<JSG.?&,^/.?/W?=^'W<^C&<^V]CSGQCV?&//T_0\_+\/G\_E]_`ILZ]
M63O;8:7K.\ZM[`:#W3U=LVRMH6C:M_W?I7M?H;=U3TK)D!U@:IU^`[)L-OL%
MAF4^/'N+@^];VEO8+/.A8T;[6%"W"I"&NKNQ7<T=Z-_1KL@?N>U2NU=A6;0\
M#N7?K51]K[)L^O\`4J[CL(?M.]2-2ZI76=HQGXR5503</Z-IM1L0:MK_`"KC
MD(/V#(E2?2XC.<L><YSG/L*SY\_/S\_GY^OGG\T*5F+[659RKV%9]K.<^?/G
M/S\_7@>5VK7CMM4-F=ZM@:7MY;M#V@'^CKI<QI*Z%M*[`TT2NU@%=D^Z]YJX
M&/K?9;UEM\VZ:\H6QJ,F`%L\A^XWIEVDD3(1B7<&W9V=7;?G8B?U9+6G7N[^
MS^Z+5M9SM=:^OT_7.@>QG7.N:KNVG>F1^XQM?;-1N2PW;?&Q\S-P5/[:T_44
M%Q%5N.TS%CUO,?LE'KD>GQ_30A2LO*QE2LX]PG/CSGQY^7S\?C^WZ\X0I66T
M9RI7G.7/.?.?.?"%YQYS]_C/SQ^&>!2V_M?M->+;HZ%F??2S9/573DUL>N5M
M\]I795)VC;U0MA'Y0>"1%)UANK6%UG4]57[(5":Y6MHZ+UX]:#50?G#3,X)A
MZ2NW^SV[F+):>QFTS[^Q`U"$5S?/7\]UNWOJ_P#HD[`-V@O*G9'[*VK:YU`M
MT9-;S]ALP-%U8)1#@6%7KTJ*,D%6LG;J,9S[W&/.?'LHSX\Y\>?97GSX_P`<
M8S_CC'X<_3><Y4[YSG/A><8\Y\^,>,?+'X8_9P*Z=;8L>GNTO=*X]C[(VNK;
M8N>FF^N%A+#GD@XVHHNJ*[7)VG@SC'VC'Q8(6XHVP+$4"*S%+6MRXC23`Z:R
MEE,6LJ.$V+HJL1[;M+?V[0U9J6T-]V3;>A:#?MKU$_JKH-O?L25SUB,`*[4;
M;A83;NEXZJ?GW51!NW$GJ<W<]?S`BST&L>QZ2GLYQ['C.<>5I\^,^//SQ]?'
MUY_&0I2</>RI2?#6,X\9SCQG*L><X\9^6<_CCY\"K4Q!M`/L='UC4[7OJVZ*
M[NZ;K!2C;`'[GV?8H6D['I9^$]?W:S:Y1Z;8-<PMLZAL84]7K)"*JDG]G`)$
M>6YA1]^5$TB%WGV**X[P58!C=KW>+2EI[3OZAU67KFT8FBK7I+$>YM]1R#%A
M,TZ3J0\DV`8K!S\H:M/E[4*[(CD*Y:'R5?Q+@IV]U:M]LL?JF^I[6+#:+$>K
M6NJ[T]C:^KQDV2*`Z)'M^JB1>V,4T3.DOP*PS:"L2*3L302/!0;(1H\TDF3)
M9;=3;"G.<O.8SG/C"49QCS\L9SC/G.,?=YX%!VQ]P=EZ_?VYFI+%LRV=&[1:
M>C\7:6SR!N^'-@ZWF7"\[U&=L8@,L^,)W2LUP2&"Z6C[*3&+BG]*2[45DU_-
M,'CR*1&BNLJ]T:HW[VNAE@VPJ/U/VUZR':.P[SVO*D;%II5S5,SHIH^%H>TU
MW88Z*..*UA:=S5N8`,;6KEKB,Q3==!!25B>BV`BIWTP)4KW+F?:5YQG/C/G/
MG'Z7W9^N.<J4KW;F?:SYPOQC/G/G&/83GQC/W?/Y_P"/`\?FP>UOJ!42N^H7
M'N6VMR0+]I_J;UQV!H@2P@DB3&NZ>ZFZZ^-(M#`M<&(L%RN77:)H8SM*FOMF
MHLZ#;$/FAF81;*6;1]`[P[3[&]1';FNMF;*F:]$T/>NP"NN-11=!;ZM%2W!T
MRDZCJ[>L;L+[!0[:'ZQC62UT-2+?(G8K!?:8BXB2FMWRQ80^D<,NT=<7A3WA
M:\>$(SCPK./&<J3YSCY_+S]_/K3G/OO'G/CW6,^/.?'GSCY^/IY_;P//YZE@
M>Z7CU2/36K6J]QS=)74?UQ]1FOKV>-KHFQ,TJR[:K/7X'JH694?%%08:9?;#
M7BJ:QA]+)LK(JI)BN^W,8=\9_L!SMAJLEM+4&"A$+9Z5T]TM9>F)FCG+.)J^
M_P#NZ]*W`3[`_EXY%%Q8-O)VV\L4<A8ZG<XY_P"T*?:#NQ<A(Q]PD7@7?/+7
MB2TG"E83G*?*<*SC&?G]^//C//[.YSAQK&,YQC*L8SCSGQG'S^6<??\`Z\#R
M%:S?(?\`3K7Y1>"]$GR?^U,G]BSF8HXPJ&U4BG;\]>\W."J3!1*<H#M;F)L(
MVWR&FPLBN.Q2CDY#3N<XLN+G>Y6R=G%:'))7ZK7R=W^V/JFZU.LW:Y4\$(],
MXYKZXL5/<U/GBXD"(*N$":Q6+#5MH5UF-9XFXI4C712R3*_%<%L7>8<7XQ^F
MO_Q6$_VL_P!G_P#;]?I^SZ<^SSGW^<><^/8QGQY^7GY_/Q]//`\X^J87;UO8
M77>G;(LW;^=7K_0+UZ<VV+(G8^T0K@G?'7"PLV97=:"26>F014/L!K&D6\0-
MOL,8/EE+!"@O#IGO+L[(DX`*[5=F<[@M8"5NO::P0K_M$`O1PN&_AQN&_P!*
MS/6H=/?J?Q20#:I&FQVV(Q>)&M3,E##%@C.PR%IDREJ^(]/&,Y\I^>?_`-5>
M/K]V$N>,?X8\8^7[,<^+WB_.?TU_^*PG^UG^SYS^C]?I^SZ<#R2P>]F\JYU_
MKQ_9':3:-?FYLOJ9:(UY!(T/?A$M#NPWLM*#=-M]W+8>MM27J5?`.H]0M,N2
M=<7J=+([-J!D)<FJ[L<BXM:+F=JQ=>7WT]-)4;9VR=K]A0FUB/6*C2M]Z2;>
ML5UE;++[%I\FM[PBPQ0*6K("G;6%CK0?&$ZH2@A``J4/N8!X>-.M-YKV(N-O
M!=@::-!VJR!AQ!BAIGP!1PF.A3DNN;(]ZF9%B2F6).'/AH_O,/-KPOW#/M>?
M=(]F=U(AQ!]+JS$"+&A,+#BI*F8C#49I4F>RW.G2%-LI0C+\V;)DS);N<9<D
MRI#\AY2W77%J#S5[MW9V;U:?0\$--%#,_P!0KTM*C>^\FC*1.I(3M5I6Q;'M
M],W)KK9M12[;JT-MFE:#7R*=O6S74F#1G:Y9:VVO\DYH>97$Y_US[(]E;AM.
M[TC:]VON.I-/]2/U$]/W/93MBNM?MM/U/7*]0S?3D2K9`I42Z)UF=M9S8\4)
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M//[?KSYG'',9QX6O']0G/R4K'S]KZ_7Z_M^O`\[Y;LGOB4UZG`H'V.NM`!T/
M3?IR;,U3L*=3;_M9JJD-B5/XKL*FJBZI3+Y;VQ=MAB`86U2:15S:-2%;<]>6
M@@>?F4XY-WTK=R9WM4.P>Q\]AS.X!I_>127KW6=B>N"+#UVT[D-!C:_U]86-
MBU.JWHP=(2HEI+3KV2S8PUL0B-&"VH\]7BQ!Z2'<,\<`T"J$`1DJ%GHV,(;1
M.$D9@Z8AMRF7A3C:9,-YEY*'%(0I:<+PE2D)RK&<IQXRSJK+E&]:#[*9DR"]
MC*#*Q&)V`F\Y/-D8T.LC)D2/.*RE.SY;$667*RHS4A]QMB23(/M)2[-DJ="3
?7'''`<<<<!QQQP''''`<<<<!QQQP''''`<<<<#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g671675.jpg
<DESCRIPTION>G671675.JPG
<TEXT>
begin 644 g671675.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@!"1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]-14%.7T1254=?3$E+7TM?0D%2+D504__;
M`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`?_``!$(`3,"4`,!(@`"$0$#$0'_Q``?``$``@("`P$!````````````!PD&
M"`H+`0(#!`7_Q`!I$```!0,!`08-#@D)!`@""P``!`4&!P$"`P@)$1875Y?4
M$A,4%2$Q5F&1E:?1U0H8&2@Y6&=Q=[&VM]/7,S9!451S>);6(C<X4G:2F;*X
M(W*3TB0G*493>8&8)4<F,C0U0D-$@H2AP?_$`!<!`0$!`0``````````````
M```"`P'_Q``D$0$!```$!04!`````````````0(149$Q,G&!\"%!L<'QT?_:
M``P#`0`"$0,1`#\`Y_```#3?4]J6=4!RKHG8Z2S&^XV[JGU,&-/KC7E%PJ:<
MM,JZL&3+,::LHB$41#1!?H;X(C:,=ZXKR11.HI%S&`HJ5KDH6U>=VTE6&Y($
MMN3"P$3/ID@76G"&@F2GAD5%2Q^72K,M(I23\FHQ2[%A;>*,HSD&=8N8+@2#
M=3+B7+;WZZ2"HE5:*.UGELEJUTY/V=Y&T0/%F++022&E[5B2U"NTJY\JY8<<
MB%BA.989,MUN=:$P]@P*]Q>8C3@P'57+A(6Y6]@3,F.MBMD/INL3ZV;KC=+V
ME1E$G@VBNF"=M<4(Z^Y,2<^5P62/CD6(N"Y>6XD2"9<G>A*$>R7)$%1B^E%U
MGG,G++5*&WVTD]J+%%-NN%`#]VF/:1+4UNS2@<>$<)[4C#7^VY\=^E@\F'E(
MR[D9,@[)B7DI+EPJHVXDG(J2[$=3<K-XTT;K"+4R)2FQU'&Y*6$'LH6MG3Y%
M-P5,J!PJ1+TNMLKG.&<)7#2^^M:665RY[\>.EU]:5I;;T6[=7L4I45/::MG&
MY8A>FCTL\WJB+D7[/)F:@F/IEQHAI9J['@4FR\@UFTO2L0.)"<A(:G$$+%5&
M+B!)OJ#KQOI57E*032BSZ4+LVVU%P-IN.Q/JD.E`17(E79\!FY,7TH@LI]Q@
MM=T9?/<242YDM7-@OK6[#EKBZ9BNK6['=;7L@/C5W-6G8JY4"E=RE>RM)E.Q
M6E*TK_\`:NU6E:5I7\M*TK3L#QOO:G=*W_'29SH:U09#,0*#,6,Y^*XW/9\<
MIS44LS'&,UC.6PH0EUZDB)6S)F2K[[2Y(F7P%"F"VM,9<MAQ8,-MF+'99;,?
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=!OO:G=*W_'29SH8;P%PGQ/Q;R>M'T.'
M`7"?$_%O)ZT?0X#,M][4[I6_XZ3.=#VL=C7R7V8\;C0;[\E]N.RRQ93;K[[[
M[J6666VVFJW777W74MMMMI6ZZZM+:4K6M*#"^`N$^)^+>3UH^AQ]<$)0R6SX
M#):)(Q+F2V?"9+&,+!:>+,7,%\MF8OGPY<:1;DQ9L&:RS+ARX[K<F+)9;DLN
MMOMI6@2>`````````"$H`_$=;^5N=?KF?8FT0E`'XCK?RMSK]<S[$V@`````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````#!C$GQL4?1
M*+S4@,DM)2FFYUI-CTPZT'"^%!&*XLF8TKD6ED4+5\VF%L.+)E,'\"?D*X<6
M._+DRVX[+[K0SD!AB!(T?NMP.AIM=\L]QNED&<!)Z-M!<R(L+[0.&J7W%2CH
M1DX\946^9,VXLEQ<NKEB>7-;COZ79=6R^EN9@(2@#\1UOY6YU^N9]B;1"4`?
MB.M_*W.OUS/L3:`````````````````````````````````````````````\
M5K2E-VN[^2G8I6M>SWJ4K7XZ]JG;KV!Y%26W4MOMV4FL8[@,K1(ZCL!OK:8>
M;BLKH:^24TJ2&28)FD=40CR<JE5''?6ZTK4J<PW9,M]N._HK+JVU"VOH[:=N
MM:=ZM+J75[&[_)MW.BN__;2OY:=NE1J](VL2#(_.HS<).?A,D)R2-FB5MQ=$
MM4Y]R`LR&GM-<?[@;-J015"Y!(.--A-I=>;MS.560R;=0R.&Y4,8#ZP@$%:K
MV#-`2\XWSK62X_<LV:>](SPG*)Y*@.*UR]Z)+7>+V)PL;;.I,R_XD?&9O2*I
MP9*#\5$176&0J.1B'7M)+0<;]*'+4-8)GW%)LA0?,4?Z@M!4\+D-L`M&FDAV
MZD&(Y&_I9:CG7"US-U&1&60T"7FU"*4V<KJ;IEM/EFIK/=K+:^62%)/1I,-N
MTFY%1!3'14@%A^'5CI\S::S6KRDFH./3T08*I)1^1,MA^PF1;"'C-=>K3:14
MGO@PN)*4")UO'V;>DT=I=V%<[1O1:.2RJ8(HR;0*`B+;<9U>R/-L2$V)$C&(
MC\#.%L43YSS2=-I(DJPVSD]B44L^,\<DA&/=>D)6PK6]A.2DAWFW8O-NV/W]
M:V*J\^E;4.M;*%U:#CT2NTMJ`D!N3)K(PD[DTA2&TU87]>^?58EZ2E20ZK9A
M`3)-64)SEH_QH>2XTU[BQ9PK&5=J@)N3(8\2EIUFZ5]:AW:&(T7/<M#[%U.[
M/MRIL:K[$=2'+CRCB"80U=QS+TGV1,HIF_$VLQXZ-:)<R@('6"UW.M-@]RF&
M(DN&U18QER!:4J;1+3D30&FJI1YZNY><U)NS'HZ:#(5ER2F.2TR*1=#U(G7^
MSL=V`\V:0FX#J4VW:0RY#2RK.->;*$P4QZ*;G;Q93D\UJ_@?$_=+T?$'6;<*
MCK&;SI=D`+[90%I=8;U;;2CKA5/J^-^D2=[5(X#S&NQ+J$7-*=%!;)Y\1@@2
MR%NF9\=(T(:<=06G#5)*6NQQ0P_'NW-21/:4$&M$;99Q]<?,=G9CF.#G]IO*
MO-GE<QH^VL<]-.$%#._5%0QI*-&KL7VLFRFHMFAE4,H,N17I*FJ`%/U/K&*Z
MU'(\LFD&,Y68<^O9IHQ]=9S#75G1B?C1/N4EHK0QCPM\U(9K>HAJ%*WVY"F(
MJJ',*<EW9,^`+^0``````"O8I7<INUW.Q3\_>[/8[/?``%>JGK7DY.UG(FD#
MUF\MF:N%&6W\ES%BD[3U8Q,T.-9TLIE.F4<B%FDO'(&$FBN=_-].WH9&S1[*
M.+(9.IJ(9*E[\@L*IVNUN=[\W>%<3A]UKA__`,NS4C_J>TK"QT``````````
M``````````````````````````````!XK6E*;M:TI2G;K6NY3PU"E:5INTK2
MM*]JM*[M*_\`K04L;3#4BCQC(T;1K*&U(96S+8KQ*U-H)U#;,5JDQRCF)IJ^
MHKRH:D">T=RQ['<?(!M)3F_84;+$7G:I.503[5=V(Z8X$I$SRALU9%>$DHCN
M7F9KZ2-HYIU(.QS,=,F)>9,:M61F>^FH4;!_,W"KUA)';D730RE-'<>$Q5=L
M:+<=+77,-Q,\M.S&?-IC."U:ZE;K;K:5Z&MUM:4K3MTK6FYN]NG:[?;I\8XY
M4]:?9X:VJI)B!IJK#DER:C=J[I_V@#(?R>Z''@F>"X0AQB,9'G0A(S8N;!M&
MPQLALV-U*"F"X<TA)Q!U$)]3HZ*-JU1QG21WD;C^(GMINI*FLK26@HR:L./(
M5S.!53TL@245W,1Q78"699/%B^(TJ92F"^["5R'\QB\MBNNQX*X[+KK:AQEM
MGX1=N%Q[#]`12Z]CF%E0AM"[-=.*\U;OE0U`T?1BDM)DQV6YZ'[E9=UL&D17
M1K5[%D,J;B2W"L$,M]^)5S9>2Z[M^76>[>+O9Z_=5%>@WV==NM'4G3/^F='U
ME_Z;U1TK<ZGW/]CT>[T[^0/JE-%JH2PX7"BMI`2%YVYR1IU+28C)I!7<IE-+
M4))YAP*10KA/+6<@3I0H2S*><UD*%?\`HY>['A_D#(@&D\)^N'WG*_6C@9ZE
MX3YEZ;UQW^=4=<>%=X]=NE]2?[/J+KGU7UNZ/_;]0=3]4?\`2.G"7/;-_`7Y
M1A^^`/Q'6_E;G7ZYGV)M`0'[9OX"_*,'MF_@+\HPGP`$!^V;^`ORC![9OX"_
M*,)\`!`?MF_@+\HP>V;^`ORC"?``0'[9OX"_*,'MF_@+\HPGP`$!^V;^`ORC
M![9OX"_*,)\`!`?MF_@+\HP>V;^`ORC"?``0'[9OX"_*,'MF_@+\HPGP`$!^
MV;^`ORC![9OX"_*,)\`!`?MF_@+\HP>V;^`ORC"?``0'[9OX"_*,'MF_@+\H
MPGP`$!^V;^`ORC![9OX"_*,)\`!`?MF_@+\HP>V;^`ORC"?``0'[9OX"_*,'
MMF_@+\HPU8FS:<11#DZ/?3PE09K%GF1(T;;!<\A8]->F1\S.A,LE)Q1;4&24
M<*ZW<F(J24UQ.;RJ>+$^@O\`^CE<F[EZ;9EQ8\`]ED;_`+P7:M?X?\M_;@-Y
MO;-_`7Y1A',L1)*,Z,%?BR7F9IMD..G7B*8',S'03D92;J^6(GBRF4*K";=?
M9@4"N%1)E#MI4U3(7J:*E\UV*Z_!CK;J_P"RR-_W@NU:_P`/^6_MP]ED;_O!
M=JU_A_RW]N`W?*EM2Q,M@*X*0;3"6PX2^/IF62\^3I>#%9BQ],SY\F7/FR=!
M9;2_-GRY<V6[=ORY+\EUUU?ON:FJ]ND%UY1AHS[+(W_>"[5K_#_EO[</99&_
M[P7:M?X?\M_;@-Y=S4U^:"NQ3<IV)&[7YOB[%.QVNP&YJ:[6Y!6YV]S<D;M_
MG_\`ZIX!HU[+(W_>"[5K_#_EO[</99&_[P7:M?X?\M_;@-Y>AU,[FYN05N=F
MFYN2-N;E>Q6FYWZ=BH5IJ9K6E:T@JM:=JM:2-6M-WM[E?R;O>&C7LLC?]X+M
M6O\`#_EO[</99&_[P7:M?X?\M_;@-YO;-_`7Y1@]LW\!?E&&C/LLC?\`>"[5
MK_#_`);^W#V61O\`O!=JU_A_RW]N`WF]LW\!?E&#VS?P%^48:,^RR-_W@NU:
M_P`/^6_MP]ED;_O!=JU_A_RW]N`WF]LW\!?E&#VS?P%^48:,^RR-_P!X+M6O
M\/\`EO[<3MI:U_QGJHDN1H>1XJU*PS)<8LAC2.X&9J3@URPDO&V3(J\\6RUG
M(A)SF,9#2PE'5QA.I.N-X,5F#&92C&*F2_)9DMQAK4O\/WLJ42]%P0=?_8]=
M1'2=S?QUGZA]<]IAZKZ;N_\`3NJ^BZBZGZ#_`&?0]5=-['218+[9OX"_*,-7
MG#[K7#__`)=FI'_4]I6%CH"`_;-_`7Y1@]LW\!?E&$^``@/VS?P%^48/;-_`
M7Y1A/@`(#]LW\!?E&#VS?P%^483X`"`_;-_`7Y1@]LW\!?E&$^``@/VS?P%^
M48/;-_`7Y1A/@`(#]LW\!?E&#VS?P%^483X`"`_;-_`7Y1@]LW\!?E&$^``@
M/VS?P%^48/;-_`7Y1A/@`(#]LW\!?E&#VS?P%^483X`"`_;-_`7Y1@]LW\!?
ME&$^``@/VS?P%^48/;-_`7Y1A/@`(#]LW\!?E&'W*^N2ZJ*]6<"/4?51;JSJ
M;A"ZIZCZ?CZKZFZ=_L>J>INF]3]._P!ET_I?3?\`9]$)U`!5'M=#%&E!D33*
M<16NX&Q"6HJ.GJ_D!5OTJ)SK=K(42+C9I]@,!R:QZE8>0E=_++D0&RXL6)=:
MK_<3)..%O1VX<3M/)B<HR+LSU^>G5#4DN6<(39FF@BL3[(N2&].;8<L>N]<A
M:*2!1N(]&A(ZY%A$BQK7Z=D9.D)W'&^DW*9AGH;F0FFL+!]51C%<51.V&U;M
MQV2=(^AZ9H\U`-2UO987D?3%-FG72&KZUC.-?><63$3D-;D>,'.SU&.+*%$[
M$XFE'9!M+A.74%2(KTH(RRT,+=)*1BQ38RF$Q<T[R\_,TBZHY;D>2-2KP>$U
M21JS@[#II?SKDW)'$3(EQMKP.3)$"$;1N18Z.RD9KHY/!?B-YTU65+#)C&<Q
M7T"WD``````0E`'XCK?RMSK]<S[$VB$H`_$=;^5N=?KF?8FT````````````
M````````````````````````````!4UI3I2NU9VL%*TI6G!SLX.W3=_^6<_?
MG%L?06?U;?[M/,('8FG1@1W.T\ZAT#,X;W[J*1X<1'_A4%(L9;^$G!Z*ZT%F
M5;R;C3BYE-SY2+Q5JK>0RH*-I_/83R8+"-N"_'FGH!Z]!9_5M_NT\P=!9_5M
M_NT\P]@`>O06?U;?[M/,'06?U;?[M/,/8`'KT%G]6W^[3S!T%G]6W^[3S#V`
M!Z]!9_5M_NT\P=!9_5M_NT\P]@`>O06?U;?[M/,'06?U;?[M/,/8`'KT%G]6
MW^[3S!T%G]6W^[3S#V`!Z]!9_5M_NT\PJO8E*4VT^I_<I2G_`&9^B+M?M/:Y
MJ?-2E/B%J0@M+T]L-(U(O?5*5S."LEOZ%XS@A<P9E(O>U[&3%+VD]_-C*02;
M4^PT77,BY+3IL55#(J9\!LAC22^$B5R$\V<V&JSA]UKA_P#\NS4C_J>TK"QT
M5Q.'W6N'_P#R[-2/^I[2L+'0````````````````````````````````````
M````''IU8Z3(PE36S*<KQ]M#]5.@IX)V.$BFH9:8-T/1S%#Y<F"*'@AQ&C(L
ME2BP[\CDDHFQW):;,M+&ONUNMQNG%,W@;S<<;GL4<^_.S01'$U(NF5F.^8-4
MLVNEG:A7,A+3RU<V1SFDK=NCB*EE(*H*W$QTXP'/&:@W5='=3$7T&TEU40<I
MDNID"RP44*7:V:Q-CZO:O9J?4HFMH#K$@)INT[$2J7AR"'&RT>-[73#Z<A9&
MZ_U=%>37=>(\_P`NXF\DJZ<X"=B?D3+&^W[<-,AI/L,V;IZ$]*:[I"CN18]<
MVI>8]5RVYY=4Y".RG/K@(N>5K:*S"CMN%6PY5E.+DBAO`BDVF7R(%,*>GV%F
M^?32MI6MN"AHR&[H`*?WCKVF%&V@"MI#2VZT\*T2D&%;FE%"^V5Y.=4K:4WD
MQ<"Y,VKEI2N8=A-I8T6$WIA=S)5X_+--95>NK&(HJEFPJDM,T\D!<``IMTI[
M1N29C<>A]QR`T&NF1=M)V?J"?,`):`04BCNB@I$A/$_X]0)#5SKA5B#Y,RI!
MMJF]%1924-F8&.\4;*U,9!=3E<BH$K=W`Y6XTT^JNZ5]%;:5;GP%KE-?52",
MGVF#-W0%\%QU1,%BU,V>^E;<.*N7IF6ZE;<=MU>P`BV`/Q'6_E;G7ZYGV)M&
MI,&S+$*<S%@NH2I'!#/DE*:3EF`Z^6N5S7DU"7'J>(&[,>=5QWW%CQ(P7.$\
M]M*XC)7/A,8;K\.6R^Z8N'2$^."+>4)H^F`$J`(KX=(3XX(MY0FCZ8#ATA/C
M@BWE":/I@!*@"*^'2$^."+>4)H^F`X=(3XX(MY0FCZ8`2H`BOATA/C@BWE":
M/I@.'2$^."+>4)H^F`$%S1M"-$^G:0."J<-3<01=(]2"6J8V6\G862'#G(+.
M$P93#)9.RX[LQG&;+$S1G'0OTV^A8OF,9+;,..^^FXUE]F2RS)CNI?9?;;?9
M=;7=I=;=2EUMU*_FK;6E:=ZHJ>U63!$IS63LOCQ248[,DDV=M2>91-EWNVLQ
M4AAR:)9U*X\ITQB5+L)7%D,F"Y?'DSWX[+C&?#BMNZ9ELMNL/X=(3XX(MY0F
MCZ8`2H`BOATA/C@BWE":/I@.'2$^."+>4)H^F`$J`(KX=(3XX(MY0FCZ8#AT
MA/C@BWE":/I@!*@"*^'2$^."+>4)H^F`X=(3XX(MY0FCZ8`2H`BOATA/C@BW
ME":/I@.'2$^."+>4)H^F`$J`(KX=(3XX(MY0FCZ8#ATA/C@BWE":/I@!*@"*
M^'2$^."+>4)H^F`X=(3XX(MY0FCZ8`2H`BOATA/C@BWE":/I@.'2$^."+>4)
MH^F`$J#026]<;BBO4RQ],F#1SJ8D%:DPDXEE@2&RUO2^6CUS-IA%8],R<X\&
M_;46T'NF$([NDIOEE@FN,M,6EXSC4;&.ENJTOCOS[3\.D)\<$6\H31],"O"<
MI@B4SM(=`BD7E".LZ<1@G7[@/'\+V;.4D3S&K=)=Y7$:-8U2[`7RF<94S=@Q
MYLEE^:POGNQTNMPY*VA;'3L_DK3LU[>Y^2NYN]BM>Q7MT_+N5[-*5W:4"*^'
M2$^."+>4)H^F`X=(3XX(MY0FCZ8`2H`BOATA/C@BWE":/I@.'2$^."+>4)H^
MF`$J`(KX=(3XX(MY0FCZ8#ATA/C@BWE":/I@!*@"*^'2$^."+>4)H^F`X=(3
MXX(MY0FCZ8`2H`BOATA/C@BWE":/I@.'2$^."+>4)H^F`$J`(KX=(3XX(MY0
MFCZ8#ATA/C@BWE":/I@!DK\D%B1:U51\R4\VM'[+1*%*K+M>B^EMAM)5%`\6
M3"-5);63)--)4.*)PH0*]4&,?5!PR7+8NBS9L=EVN?L@&A?WY&ESEYC'^)1H
M'MPI5BYS;,/4LBMV1V"X%<Y9%-"B2C/!N*RB;K@FB/C.;J<@143!G/TDOARF
M,O2\-_2\.+)FNW+,=UUO7RULQ[M?]GC[=?\`\NS\_P#N@.T6]D`T+>_)TN<O
M,8_Q*'L@&A;WY.ESEYC'^)1U='06?^'C_P"'9_RAT%G_`(>/_AV?\H#L'UW6
M=I"R[3^*WYBU2Z>,C)(:"-0#7/.ZR9H\O;1-S*^I#34J)3<-+=K@JG%U]22D
M1852"-E,6*1Q+2E)1+E<A(B9,8]^/9`-"WOR=+G+S&/\2CJZ>AMW-SH+.AK7
M=K;T%O0UK3=I2M;=S<K6E*UI2NYNTI6M*5W*U'CH+/\`P\?_``[/^4!VB_L@
M&A;WY.ESEYC'^)0]D`T+>_)TN<O,8_Q*.KHZ"S_P\?\`P[/^4.@L_P##Q_\`
M#L_Y0';+1Q*4:3"VL;RB>065)C1S'CR;B<["<Z,[F_E44S+3`I$<:PA'#Q"\
MX0SUIA.%K<]<Q;+6EF:RRZNX,\''G]3VR9&S2V=+?270_P!CME3MF>:\]R8O
M.MOHIZF'.YRV3#FJ245`J8IBS8[K;\62N*EN2RM+K:UMK2M;Q.'2$^."+>4)
MH^F`$J`(KX=(3XX(MY0FCZ8#ATA/C@BWE":/I@!*@"*^'2$^."+>4)H^F`X=
M(3XX(MY0FCZ8`2H`BOATA/C@BWE":/I@.'2$^."+>4)H^F`$J`(KX=(3XX(M
MY0FCZ8#ATA/C@BWE":/I@!*@"*^'2$^."+>4)H^F`X=(3XX(MY0FCZ8`2H`B
MOATA/C@BWE":/I@.'2$^."+>4)H^F`$J`(KX=(3XX(MY0FCZ8#ATA/C@BWE"
M:/I@!*@"*^'2$^."+>4)H^F`X=(3XX(MY0FCZ8`2H`BOATA/C@BWE":/I@.'
M2$^."+>4)H^F`$J`(KX=(3XX(MY0FCZ8'UP3;#)G/@+%I;C$P9,Y\)8L7POY
MIY<Q@P8RV82^##BQJ]V3+FSYK[,6'%CMNR9<E]N.RVZ^ZE*A4#M/9$VD)8ZO
MI6GJ`8@0(U899!<T7ZL'EKJ1--S@9\R+C,<3:PJ)UB.:.7FQ'LU6Z==F=,SL
MB3.N;-D+/=<7/H&3,43#Y+/=B`SW@R-)KU1I+R-Q3E?+/#E5)7>2+JU+:SE:
M29$4XYBK.Y9'>LM$\">23'4[#-MIJZ.B"&@)S);^%OD$Y.,$L^%85/Q[<1B1
M-(>E=A(4N(;Q>J)@G9KJF..F1I\:^I=7>*.59S[P2==O">SN8S5:=K4APU(3
MQ+3<JN8CEA501"CW12J^X2:2VU?)MC[!#&TTQKJLA9EOV(7CG8FLZ0D5V(L*
MP(T=/;3CA>*Q;#.%.:!UJLE:7T)P.=39F-J2$XW87/%Z7J[X.-NU":MK=JUD
M8+=:TW:5INUINTK3=IV*TW?RTK^2M/R"J>0=G&J2#J`49%6'XT5%GF=8\%ZW
M6RX%-G+F34#&+]AIGL)CJ,5L222;K*I&*(Y#;T>%F\K$3B'C,)3&?<JLK,EN
M3$ZDI=;=K(`*M-.FS<*0F^]-1A8?A=T19H6:DZL72`TBZ0HIZ^W6].IM*)7&
M9(6\ZP;3W$L19&2;DAQ@94-+22AEL*BTOK>+KR>+DD^T`Z0(J.'J90)E3Q>M
M]F2N`X6PFL-;\=>BLOKBSV9+.BLKV;;NAZ*VO9MK2O9'ZP`:ZP*UVUG9"U?G
M;Z'FOMEB<<=MV5(3LEU,>&8GQAPXZ5O+5K2S%BQV8L=E-RVS'9;9;2EMMM*3
M1O0:G<TW_$J9S41I`'XCK?RMSK]<S[$V@,=WH-3N:;_B5,YJ&]!J=S3?\2IG
M-1D0`,=WH-3N:;_B5,YJ&]!J=S3?\2IG-1D0`,=WH-3N:;_B5,YJ&]!J=S3?
M\2IG-1D0`*R-6#<;V'6=LM<&)"1L6#-/.I>W-AQI9&S%EMOT/SQ6ZW)CL+TL
MR6W5Q8JW4OMK2ZN.RMU*]!;N6*[T&IW--_Q*F<U&@FK3^FGLL?E[U*_Z'I\%
MCH#'=Z#4[FF_XE3.:AO0:G<TW_$J9S49$`#'=Z#4[FF_XE3.:AO0:G<TW_$J
M9S49$`#'=Z#4[FF_XE3.:AO0:G<TW_$J9S49$`#'=Z#4[FF_XE3.:AO0:G<T
MW_$J9S49$`#'=Z#4[FF_XE3.:AO0:G<TW_$J9S49$`#'=Z#4[FF_XE3.:AO0
M:G<TW_$J9S49$`#'=Z#4[FF_XE3.:AO0:G<TW_$J9S49$`#'=Z#4[FF_XE3.
M:BNJ=&XWL6THV?I?$A(V,OE@;:"79<&-+(V8<EW0Z1L719,5I>F.^[I>2_'N
MW6UKT%]UF[T-UU*V;BN*>/=+]GU\@FT$^?2&`W[WH-3N:;_B5,YJ&]!J=S3?
M\2IG-1D0`,=WH-3N:;_B5,YJ&]!J=S3?\2IG-1D0`,=WH-3N:;_B5,YJ&]!J
M=S3?\2IG-1D0`,=WH-3N:;_B5,YJ&]!J=S3?\2IG-1D0`,=WH-3N:;_B5,YJ
M&]!J=S3?\2IG-1D0`,=WH-3N:;_B5,YJ&]!J=S3?\2IG-1D0`*;MNBW6^0V7
M.ILT10T<F9QXXFKC,%4PB7SX^BFN/,=W09<)>S)9T6.^^R[H;J;MEUUM?Y-U
M:5Z\&[MU^.OSCL5]NY[EEJ?_`%<2?7='0ZZB[MU^.OS@/``````````.>YZG
M;0412V;[=SJ*.EG\U)JF^E,IU.)FLM*4=):VE*9#&#)?N4MLMMI3=[5MM.U;
M2E+TMZ#4[FF_XE3.:BD+U.=[FTW?EKG#Z5X!>^`QW>@U.YIO^)4SFH;T&IW-
M-_Q*F<U&1``QW>@U.YIO^)4SFH;T&IW--_Q*F<U&1``QW>@U.YIO^)4SFH;T
M&IW--_Q*F<U&1``QW>@U.YIO^)4SFH;T&IW--_Q*F<U&1``QW>@U.YIO^)4S
MFH;T&IW--_Q*F<U&1``QW>@U.YIO^)4SFH;T&IW--_Q*F<U&1``QW>@U.YIO
M^)4SFH;T&IW--_Q*F<U&1``QW>@U.YIO^)4SFH;T&IW--_Q*F<U&1``QW>@U
M.YIO^)4SFH;T&IW--_Q*F<U&1``QW>@U.YIO^)4SFH]K&FU\=]F3&W$&R_'?
M;DLOL1DVV^R^RZE]E]MUI6EUMUEUM+K;K:TNMNI2ZE:5I2HR``'#\VT&M%@>
MO#R:<-4TV-W)I.C>W3NKOW0]GT32G-N?48W'X>Q+#]E+UT<=D*.K3U(L:-]4
M/9HB(Q^K$5`^IM-1P.K+G17CD3C5X&R0?.@MZZ6U,OLXHSR1=IO9<K.IG%4T
MRP7?'B@X7L60&<O.ITJ:7(>*R0%8^;HX4M*SN1Z7YUM4HC6669KTHJFUK*VI
MR/==Y-=W^:&I7TZIRBL%DXD]8?U6Q](+@CI:.)]M"F!XM*0XA=;>?S#<W6G"
M225=,4T*06FNE$Q/RD4MJ*]%-75OZ&EB.=9Q-159!UI2Q!JR\SI7*018KTJ,
M-],2'V_3-4IB-.!UN.2W<Z9!EUZ7)Z<G)"0L*19CMAN)&(QA(,TTJG+5HJ&[
MH``````A*`/Q'6_E;G7ZYGV)M$)0!^(ZW\K<Z_7,^Q-H``````````"N+5I_
M33V6/R]ZE?\`0]/@L=%<6K3^FGLL?E[U*_Z'I\%CH```````````````````
M`````"N*>/=+]GU\@FT$^?2&+'17%/'NE^SZ^03:"?/I#`6.@```````````
M````````J'V[GN66I_\`5Q)]=T=#KJ+NW7XZ_..Q7V[GN66I_P#5Q)]=T=#K
MJ+NW7XZ_.`\``````````Y^/J<[W-IN_+7.'TKP"]\40>ISO<VF[\M<X?2O`
M+WP`````````````````````````````````!ZY.Q9?7=W/Y%W9[/8[%>SV.
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M4-B.9O212[)GOPJLS:DJI,G,8JJY"QM[-]HGY`;F$TWB>8W3DM.DJ[#:5=A9
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MF,BABJ7M-X<>'`:3K\)C-@-9,QO%@O(YK!^L.HCC-B3D<=7WS@)M`0EUAU$<
M9L2<CCJ^^<.L.HCC-B3D<=7WS@)M`0EUAU$<9L2<CCJ^^<.L.HCC-B3D<=7W
MS@)M`0EUAU$<9L2<CCJ^^<.L.HCC-B3D<=7WS@)M`0EUAU$<9L2<CCJ^^<.L
M.HCC-B3D<=7WS@)M`0EUAU$<9L2<CCJ^^<.L.HCC-B3D<=7WS@)M'BM=RF[7
M=['YJ5K7P4I6M?\`TH(3ZPZB.,V).1QU??.*N-M:M:F(WV5.N5\)$S-INJ[<
M@I744Q<CEEO9A/5*-V+[<Q]5MYWD)>.&T%0I@R9\6,_@*F+[+,M]G2ZTR5K:
M%V/3+?S7_P##R?\`*'3+?S7_`/#R?\HZ,W+M"=>],N2E-;FKRE*9+Z;E-2LT
MTIV+J]JF_?L4[P]/9"=>_OW=7G_N6FG^-P'>:],M_-?_`,/)_P`HKCGBZE=I
M=L^J[EW\PFT%[=E]*]BND.O:K;N_%V.S7L4W:]@=/-[(3KW]^[J\_P#<M-/\
M;C^.:UT:V#JXC.<YK!U2FW(W":XGM]P&=0<N&%M"(.>Q-QN0BC*V5X7GTLFX
M,:,CV+A8B8P8%:Q*3;5"PQ:1*TQ!WIO3+?S7_P##R?\`*'3+?S7_`/#R?\HZ
M,KV0G7O[]W5Y_P"Y::?XW#V0G7O[]W5Y_P"Y::?XW`=YKTRW\U__``\G_*/:
ME:74W:;OYNS;=;7P74I7_P!>T.C(]D)U[^_=U>?^Y::?XW'8@>I+Y1U83SL[
MIB=SNU!'GXII^L!]-_`KSGAD*9W67(E8CA=0M3B#G6952C)%!Q9U/*8*HEA;
M)A+GC"D=MSUR*&2RT.7P`A+K#J(XS8DY''5]\X=8=1'&;$G(XZOOG`3:`A+K
M#J(XS8DY''5]\X=8=1'&;$G(XZOOG`3:`A+K#J(XS8DY''5]\X=8=1'&;$G(
MXZOOG`3:`A+K#J(XS8DY''5]\X=8=1'&;$G(XZOOG`5Z;=SW++4_^KB3Z[HZ
M'747=NOQU^<=@/MN4F9"NS(U*9G8^8[64*RR*NKDY"C5P-]4,4NF9@6X*%58
M])SA*E*XS5V#-EZ:CG.G8,>7!9TB_+:8Q]?Q7MU^.OS@/``````````.?CZG
M.]S:;ORUSA]*\`O?''9]3\)DLG-G8WLK+>;"04CAFFNE"+CCQ=<JC3-1RE*9
MLERHGR0V"UV')FIDOPX*)&._!9=2S(9-5W+K+N>L.HCC-B3D<=7WS@)M`0EU
MAU$<9L2<CCJ^^<.L.HCC-B3D<=7WS@)M`0EUAU$<9L2<CCJ^^<.L.HCC-B3D
M<=7WS@)M`0EUAU$<9L2<CCJ^^<.L.HCC-B3D<=7WS@)M`0EUAU$<9L2<CCJ^
M^<.L.HCC-B3D<=7WS@)M`0EUAU$<9L2<CCJ^^<.L.HCC-B3D<=7WS@)M`0EU
MAU$<9L2<CCJ^^<.L.HCC-B3D<=7WS@)M`0EUAU$<9L2<CCJ^^<.L.HCC-B3D
M<=7WS@)M`0EUAU$<9L2<CCJ^^<.L.HCC-B3D<=7WS@)M`0EUAU$<9L2<CCJ^
M^<.L.HCC-B3D<=7WS@)M`0EUAU$<9L2<CCJ^^<?8LAZ@+3):XW),4YBEIDO<
M;PX(B=!?/F*6YK+C6'`8R3"8L+Y\Q>F3'A,7ES%F#+=9FO+Y[;*X;PI`UM;<
M>$-GOJ?F>,9PF5O*;G)5TZX8ZT[J;+DQKD$>.)!1D\S($UJ,P1]`DT]?U-*5
M#BN:MCXZ;0C%C7:2AC14U6<2PBXC6SVRG?\`I;U:M^;M5,)NAJ:A4O!J;?S>
MC/4$NP.UXYE0@CF(KBH\[&6:<YB)(JD1TEVT[76]VX2>[S0BSO=;:RE,;A/K
M=N'&>,;C:J-0<?:0VZA2&K0E+\M'9.D=*9I]O:<(779ME4\>P,1RJN!SF(_9
M"<HO)R(R`BLC"CJ)Y.)';D$J<3<YJA=+Q&,V.(M..T!@F==3TSZ>XICQ\I5C
M,2(J=2[+BHVDIJLQ\OR3X29$OI;-+H9LZ5DDH]4&%5QFJ+@SO)EH)5-N(F6>
M8.8EY"HF90L?'KT%G1UR=#;TRMM+*W]#3HZV4K6ZEM;MSHJVTNK6M+:UW*5K
M6M*4K6N[[``_/B*%L.8P8PE\.+.:NLO-9L>*RS*8OQ8[<.*_/DMMI?FNQXK;
M<6.[)6ZN/%;;CLK;92EM/T``"$H`_$=;^5N=?KF?8FT0E`'XCK?RMSK]<S[$
MV@```#`)77E-K1A(CE1<UA98;[(="RE&,N#$9QX%%,13IPGFR%LU+L.>S&8P
MX[[L.6V['EI;6R^E;;JT%(E-=VIG<INO1$W=RF[_`/0EM\U%T<\?S)2]\FCW
M^C:D.,[;VJ?%3Y@&X'K[=3/=FB?N2V^:AZ^W4SW9HG[DMOFHU``!^?4%K&G]
M7U+[/]</NI(RJ39E[4(>2,UC20L-N`R:TD2NE9K\F''@IB,6U)*)O';9EMNM
MMOR6Y*TNNQV;FX_K[=3/=FB?N2V^:BIB</Z0&A[Y4I\_TLR2-J`&W_K[=3/=
MFB?N2V^:AZ^W4SW9HG[DMOFHU``!>MHAFJ1)I;3]4I#5R:L<0G(F)R;D)HZ>
MCVX2AE%L.9L=^-/Q8K,]UQBZM],F6E;[:?R+:]"-XA6/LS/Q,E7^V2)]',0L
MX```````````!3YM^?<<MH-^SXN?2!MBX,4^;?GW'+:#?L^+GT@;8#ICLWX7
M+^LO_P`U1\Q],WX7+^LO_P`U1\P```````!V??J+3W,&<OVWY%^I2`AU@@[/
MOU%I[F#.7[;\B_4I`0#E^@````````````*A]NY[EEJ?_5Q)]=T=#KJ+NW7X
MZ_..Q7V[GN66I_\`5Q)]=T=#KJ+NW7XZ_.`\``````````Y^/J<[W-IN_+7.
M'TKP"]\40>ISO<VF[\M<X?2O`+WP````````````````````````````````
M`!2EMVEACIFDN/4]^M:#E1+=&HAEMXB]-0FJR1]&L=Q2K7,:2UHN\C$UQ'=C
MD5/4U8DB*$>DT%OY<.%9Q/0S:NY*H98[COCC8N0E`+Q1)`U>-EKZ9R4HF)#<
M$9'%?1AJHF[47IN4D9#BF$FXA&"F227!D;^!^-5G(B:PL5B,U43"S6OAR-]'
MQVX%A7,'IEVF$=S8LH:B;4]:T%:=(C=;]A,A'*_,VBY@:A6?"#E:C/G)1E!R
M/94D1?Q,W&F2H3--=%3GH];V>B1=:B&4TFOWGWO3`I_MV*;PPO?2[(RPFSNT
M]3C=PZBWXE-J>F%I);6C)B22EIK-C4N85V7%C4Z))<+9(K5%9"2I3QY<V_["
ME5.E<N1+)IV2\+@@`````!"4`?B.M_*W.OUS/L3:(2@#\1UOY6YU^N9]B;0`
M``!%$\?S)2]\FCW^C:D.,[;VJ?%3YAR8IX_F2E[Y-'O]&U(<9VWM4^*GS`/(
M``#5></Z0&A[Y4I\_P!+,DC:@:KSA_2`T/?*E/G^EF21M0````+@-F9^)DJ_
MVR1/HYB%G`K'V9GXF2K_`&R1/HYB%G````````````*?-OS[CEM!OV?%SZ0-
ML7!BGS;\^XY;0;]GQ<^D#;`=,=F_"Y?UE_\`FJ/F/IF_"Y?UE_\`FJ/F````
M````.S[]1:>Y@SE^V_(OU*0$.L$'9]^HM/<P9R_;?D7ZE("`<OT`````````
M```!4/MW/<LM3_ZN)/KNCH==1=VZ_'7YQV*^W<]RRU/_`*N)/KNCH==1=VZ_
M'7YP'@`````````'/Q]3G>YM-WY:YP^E>`7OBB#U.=[FTW?EKG#Z5X!>^```
M```````````````,*+21'QQ<WL%'RSC3CZN-)?6$NZ$'.M=<B-N6\ZG]:<2A
M>H=6E+,.:\T4ZFZH+VXLEV;'93'?6F:BGEF:;M.Z+MDI8>R/`L+I+S*Z)(3D
MXJ[4R+6,0<Y:2GGJ.U3)#PD+`OE4'$JX7PZTG'C2G([,9NU?74ZRPDJ*!HO;
M3'0+A@#M=H```````````'&KVJ&E&3YEE69W(BMG;)2*B*#0A./B\2Z2-;C`
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M*#U4FXJ*;A-6$BIW&X;5/`IXKE#$8SYPLAK6EM*W5[5M*UK\5*;M14>=VC;3
M7-6T@Q8I/@W#4#P?/,=:43\G'HT<J^BS1JUD)IH;WK$UDHF&XK1G$S4:B<Z&
MBQ:YW(9*.^1Y==N!JMY2:)=(0[Y(MPK2EU*VU[5U*TK\5:;E16<Y]FRU7'(,
MIY>$8^5@*;M4\*ZTI,@S,T$E2S'=04*&(\5B"BUY".*E3+98#\=4.10\)%9N
M1JK*HJ+C><&-O.]LI#X7$VP-=M(NT"FZ3G#L^GG)I1OF6!M/F5J)?#!9*6D%
MDI1T_P"2,4.DK1&AV.`OF,'7T4>$'EU:R13;DPX#Y*3$\LH-O>^W52YF)URK
ML>378J1<O.]<3V\C6&2Q.]14\_4Y6TR<R5QEL-<E;;J=,S7TK;CMW.S6FYNT
M&AD#;.EBPD_(1<%[O..YF:3FW.3.TDL8V@8DS+$+<U`N%+57?A6W+:M*.9^*
M37;2.4BN,C^-):.!L1AE/I*VGNUS'S#MK8SN;OS]NM/F^;M`-+(2U#0DD,Y7
M*J<F-(D9RR?,JACPF%*EF2\BJRP\E---6V]+K6N$Z0-EC>"[M7X<UE].WV)>
M]<U`7&PS/&M/LQ]X`I3>.M]O^=N=?RUXYGUWQ-NY3O\`AKYP$%^N:@+C89GC
M6GV8>N:@+C89GC6GV8G3<IW_``U\X;E._P"&OG`:AS'J'A%;B23D=*DUI'U1
M48#N3TXB64J9#!PZ<03Y<J5P6=+IT>;/FR68\=E*[MU]U*?EW10'3M4^*@Y,
M,[T_ZDI>[?\`-H]_RU[FU+OCC/6]JGQ4^8!Y```:KSA_2`T/?*E/G^EF21M0
M-5YP_I`:'OE2GS_2S)(VH````%H&@"5(ZCMIR.4>[Q0VP94W4D&R&!7.6ELA
MLMB0K"^7/@MK;=6_'CS6UQ7W;E*6W_R:]FM-VP/US4!<;#,\:T^S&GFS,[++
ME7^V2)VNQ_W<Q?F%F^Y3O^&OG`07ZYJ`N-AF>-:?9AZYJ`N-AF>-:?9B=-RG
M?\-?.&Y3O^&OG`07ZYJ`N-AF>-:?9AZYJ`N-AF>-:?9B=-RG?\-?.&Y3O^&O
MG`07ZYJ`N-AF>-:?9AZYJ`N-AF>-:?9B=-RG?\-?.&Y3O^&OG`07ZYJ`N-AF
M>-:?9BI;;LSQ#KJV0^OQ#;TC-575SNG]9Q$TXFI69#1K+>XVSCMQX,5;;:Y<
MEUU]NY99NW;F[=N=!;==;>[N4[_AKYQ3YM^:;FQRV@W;_H^+GY:U_P"\#;_/
M4!TQ^7\+E_67_P":H^8^F;\+E_67_P":H^8````````[+/U')+\8L#9I38D/
M1[M]MJ9C6I(!_`153M"QC*2S0S!6#$9LQUMNK7%?F*&<5MU.QT>&^G8K3<'6
MF#L^_46E/^S!G+M_TWY%_+7B3@(!RB/7-0%QL,SQK3[,/7-0%QL,SQK3[,3I
MN4[_`(:^<-RG?\-?.`@OUS4!<;#,\:T^S#US4!<;#,\:T^S$Z;E._P"&OG#<
MIW_#7S@(+]<U`7&PS/&M/LP]<U`7&PS/&M/LQ.FY3O\`AKYPW*=_PU\X""_7
M-0%QL,SQK3[,/7-0%QL,SQK3[,3IN4[_`(:^<-RG?\-?.`HQVV\YQ$\=F7J3
M;S7D%LKBVH6170DF)ZA3.;,U+3*P#ACI.+H+:W])*E\V>_<K_)QX[KJ]JE*]
M?_7MU^.OSCL5MNY3<V66I_M_@XD_+6O_`,[HZ_/4==3=VZ_'7YP'@```````
M``'.D]3]S-%C$V=S>1'@^VXWE:DRS48JG*9^W`;MP9W,5S8,UV'H;KK<>;'D
MMOQWUI2V^VM>AK6MMU+;M_7-0%QL,SQK3[,5*>ISJ?\`9M-WM_SUSA^6M/\`
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MXF]3_M:Y?[?N=FF[\M??/:J.^`VI]<U`7&PS/&M/LP]<U`7&PS/&M/LQ.FY3
MO^&OG#<IW_#7S@(+]<U`7&PS/&M/LP]<U`7&PS/&M/LQ.FY3O^&OG#<IW_#7
MS@(+]<U`7&PS/&M/LP]<U`7&PS/&M/LQ.FY3O^&OG#<IW_#7S@(+]<U`7&PS
M/&M/LQ]RNI&"3ADL3*RFS\YHX9+DRN#&J4NR9S1O-C+EL&.WI=.BR9L^7'BQ
MV[O9OOI3\HFW<IW_``U\X;E._P"&OG`5<;6O6%)&B#3HSYKCI[09&MMDRMMK
MO5]:DVI-;IA9$:BVT'YT@N[O6^M%[26@&%MWE6HE-U=)HQ5%JO9B:$KK).JX
M3**.JV@S:637JEUZ3?$CTRM5NQZ@LB*RC'AHE'SV1'BAK1?3O$\K3;)*B]7T
MAM1U+2$WI;D[@4S-QPL)F'D/+O4S*R<BN@VI)![:?:WN20V]IR8Q>+G%K%07
MBY9T:#=3\&A8Q#!6>W%;G:,@J5S?3<D['B;(O;IC,F%SJV5QXSZ^?RIZ:02"
M5UYG/G+_`"V2);47AT]OO)J0(ZP\*UGG%W&([/ZZUJ)5/4,HQKF:3`QDKEM,
MA?)G9K80"+K*NM+04JS/U>K8B.=W&2I#`X29(N%IX``````A*`/Q'6_E;G7Z
MYGV)M$)0!^(ZW\K<Z_7,^Q-H````BB>/YDI>^31[_1M2'&=M[5/BI\PY,4\?
MS)2]\FCW^C:D.,[;VJ?%3Y@'D``!JO.'](#0]\J4^?Z69)&U`U.F>&IW?\JQ
M=(#"E^*66BQ$IKR^UFX[(3<[Z4S*Z[X^7HY=&5=<"7,3++FTO*D+YDVAD":(
MGF4M0Q8<AQ05L'1X;ML+>BI;;T5:5NZ&G15I2MM*W;E.BK2E:UK2E;MVM*5K
M6M*5I2M;JTW:AY```7`;,S\3)5_MDB?1S$+.!6/LS/Q,E7^V2)]',0LX````
M```````!3YM^?<<MH-^SXN?2!MBX,4^;?GW'+:#?L^+GT@;8#ICLWX7+^LO_
M`,U1\Q],WX7+^LO_`,U1\P```````!V??J+3W,&<OVWY%^I2`AU@@[/OU%I[
MF#.7[;\B_4I`0#E^@````````````*A]NY[EEJ?_`%<2?7='0ZZB[MU^.OSC
ML5]NY[EEJ?\`U<2?7='0ZZB[MU^.OS@/``````````.?CZG.]S:;ORUSA]*\
M`O?%$'J<[W-IN_+7.'TKP"]\````````````!$DUSU#&G!CYI+GF4&/$3`+*
MB4B&'C(3B3VPW<*NNF*E$=-R*JEEPE;#BF:MJ7)8*WTO,9:5LQTK=V`$M@*X
M_9>]E][_`(TH\M+.Y^'LO>R^]_QI1Y:6=S\',YK-XL<%<3>]UKF#_P`NS3=_
MJ>U4CS[+WLOO?\:4>6EG<_&B:'M.]GE@VE\HR?FUHZ;,4>*FA2!60G//)+33
MM;9YY(&HK4<NK36*JM3]"V9>2D-R("P?2L=U3I9,6$X]EP6E#6+-<,YK-XY!
M`"N/V7O9?>_XTH\M+.Y^'LO>R^]_QI1Y:6=S\#.:S>+'`%<E-KULOJUI2FOC
M2C6M:[E*<-+.[-:__P`\;MQ9*T;3>P&W*D0OAL23'#Q*9S[6>[,6"B^V7`2+
M'S:88-)*N1OR%#V#"H$#A+)DPWW6V&2N?%6M+L=U*#.7A9>Z0```=```''%V
M^.KZ`V$E0!`7#=*\>:K&G*S(U8QW?IWTBMO6C+L=(;#*OAJID@6L!ZG4ICL@
MNLJZXH(R6ZUY6QJAY.3G6G(J0J$KU;(6L(V33^<$L:24N5ES6^IZ^L,AO5R+
MJ',B_#34T^N=M)R>30FLH1`ZX@9Y<DELQSQTZ6^XBBZ2SD2:IG/J&0V>Q9>G
M83AK7W4+HKVGJ_JCF>9M&NNN$M*##E%)B5.56VYM);0G=WNA2CMD40+EA6>:
MZH(RFGI)4P<.%4!ITS*":GW7JRT5H2..!0M,[@;/S3]J2T^1[+B9JMF-A3[+
M\CSJNR@IRK'L6(\-)+E3%2.HP:2?51C]"OS)J2O$+V6:(*)S"9.95RS`56CA
MK(=/&;,8;Z``U\>FJ.&&!,3(@5QKCHK)\@V)N1O(S>BV6'FCE\2P;4R25E=C
MV9C'7V''^)1S(RM>2R/]S-FPT533I[#6\B6RF+0V#`:W1CJV@&87N=C^/G[@
M6W#BL?.=$NR(S@2D1]D(P=N%@R8K1@YE=*(MZ3D:/'P9*M)[*S$4E]/;:Z<(
ME%(QAL42&8SLB`A*`/Q'6_E;G7ZYGV)M$)0!^(ZW\K<Z_7,^Q-H````BB>/Y
MDI>^31[_`$;4AQG;>U3XJ?,.3%/'\R4O?)H]_HVI#C.V]JGQ4^8!Y```````
M``!<!LS/Q,E7^V2)]',0LX%8^S,_$R5?[9(GT<Q"S@```````````%/FWY]Q
MRV@W[/BY](&V+@Q3YM^?<<MH-^SXN?2!M@.F.S?A<OZR_P#S5'S'TS?A<OZR
M_P#S5'S````````'9]^HM/<P9R_;?D7ZE("'6"#L^_46GN8,Y?MOR+]2D!`.
M7Z`````````````J'V[GN66I_P#5Q)]=T=#KJ+NW7XZ_..Q7V[GN66I_]7$G
MUW1T.NHN[=?CK\X#P`````````#GX^ISO<VF[\M<X?2O`+WQ1!ZG.]S:;ORU
MSA]*\`O?```````````!QU/515:TV5KGK2M:5X?-/O9I7<_[Y&1R*QQT_51?
MN5CG^7S3[],C()Q\M[?,=;;T=_\`6N_O5\X='?\`UKO[U?./4`8O;H[_`.M=
M_>KYPZ._^M=_>KYQZ@`]NCO_`*UW]ZOG#H[_`.M=_>KYQZ@`^N.^_IF/^5=_
M]>W_`/%7^M3OCM-=@-6M=D#HAK6M:UK'3JW:UKNUK_UL2%^6HZLC'^$Q_P"_
M;_FH.TVV`ON0&B'Y.G5];$A`O!QO3[BX<``&H``````/%>Q2M>SV*5[6[N_^
MFYV=W\VYV13B_F6S%[:"(LB:73VHED:ET27H]:VL9*44W46AZ>);TW%HL42V
M4XMI[]+X-.R_G:I`XW+XFD2'-U\$Y(+'VOF/YT\V_P##@N/'C<IN[O9W>_6M
M:4_)V*;NY2NY7LUI2E:_E`<;30II_EY(<NQ[B!38"ZUG1LVXEU>M'5HNJB*N
M)J)8ZW&T$N&F@BM]T&TTJCOG#/+@.9Y\23"`HK)'*U6J2<"WEPJ)I&KFY$KN
M2G&L(]Q)K.G>>K5-%<MJSUC3W#T!?%DZ(P6ZW*67$6NZILW+.G]'TS!N='BI
M==V!DU+:4K6M*=OX]RGY]RG:IN]NNYN;M>S7=J/(#2>$V/+YIG*^1/F[K;@M
MD^9<&0MP9M0[TPX6E=XESY[IQ@Y;?9US/8C"AU-;2N(GU3U)AK=AP8[JRYP?
M3;Q^^2=F\_'[X`_$=;^5N=?KF?8FT!`?!]-O'[Y)V;S\.#Z;>/WR3LWGXGP`
M&GDQ,:8"D2R::4YNZZIQ9@NW.?2^#)J$.N)/$A'LADCU<6.WF"?56&V_#U5A
MMNRX.CZ;CMK?;;2M!-.U3XJ#DQ3Q_,E+WR:/?Z-J0XSMO:I\5/F`>0``````
M```6>Z`FX_%UIR/D9\C;R"Y=U)&,Z5WGHCGZO,7(5M^,STY6,8;RO2L-:8>D
MX:767[G3:UZ.MU*;_P#!]-O'[Y)V;S\:A[,S\3)5_MDB?1S$+.`$!\'TV\?O
MDG9O/PX/IMX_?).S>?B?``0'P?3;Q^^2=F\_#@^FWC]\D[-Y^)\`!`?!]-O'
M[Y)V;S\.#Z;>/WR3LWGXGP`$!\'TV\?ODG9O/Q4QMUV9*J;LB-?AQ>F+?$EX
MH`6;C21P=-E'ZKQVN-L778NN!$WD,X.CLI=9T>.RM;>BZ*G\JVE*WQBGS;\^
MXY;0;]GQ<^D#;`=,=E_"Y?UE_P#FJ/F/IF_"Y?UE_P#FJ/F````````.RO\`
M4<[7D1;V:4V&6E)V\M.LUIO_``YDO>2@N3IYRR&8+OR'NK50SASX^FX<I?!U
M-;;7'CZFZ9;6MV;)N=:@.S[]1:>Y@SE^V_(OU*0$`Y0/!]-O'[Y)V;S\.#Z;
M>/WR3LWGXGP`$!\'TV\?ODG9O/PX/IMX_?).S>?B?``0'P?3;Q^^2=F\_#@^
MFWC]\D[-Y^)\`!`?!]-O'[Y)V;S\.#Z;>/WR3LWGXGP`%%>VT9\I)6S,U)'G
M'+V^A'P6174VA\'S:0^K:7S(P<6'_P")IYO*:+=3F,F$SNXK*UR])Z1=N8\M
M]:<`2[MU^.OSCL5]NY[EEJ?_`%<2?7='0ZZB[MU^.OS@/``````````.=!ZG
M]:DD+.SO;QMJRGO/3.&6:;*).\5ON+<S6.4K9FS]7J9G"8KU1DMNR]*Z'H<7
M1=+MK6VVVM;M.#Z;>/WR3LWGXJ<]3G>YM-WY:YP^E>`7O@(#X/IMX_?).S>?
MAP?3;Q^^2=F\_$^``@/@^FWC]\D[-Y^'!]-O'[Y)V;S\3X`"`^#Z;>/WR3LW
MGX<'TV\?ODG9O/Q/@`(#X/IMX_?).S>?CC_>J6VK)"-LP'.;=4I;\$WAW@*R
MJ5O%;[=W<M[L.V8LW5R89S&/]CDNLR]+Z'H<G0=+NKT-]U:<GT<=/U47[E8Y
M_E\T^_3(R"<?+>WS'6U@``Q``````![X_P`)9_OV_/0=FSL+&=*:ILF]%QYO
M3!O:1\\>N>XFB<'C:6^H;*2I(%MV/KFH&\1LUT>2E^7H\ME*TZ/H:=BV@ZR;
M'^$Q_P"_;_FH.TVV`ON0&B'Y.G5];$A`O!QO3[BPO@^FWC]\D[-Y^'!]-O'[
MY)V;S\3X`-4!\'TV\?ODG9O/Q]RK"F?$:*Y3,[=5%L1HME,E>"QH8.JBV+/C
MR&"O3\9ZN3!U3AMOP=/QTKDP],Z;92M]EM!.H```````````(2@#\1UOY6YU
M^N9]B;1"4`?B.M_*W.OUS/L3:````(HGC^9*7ODT>_T;4AQG;>U3XJ?,.3%/
M'\R4O?)H]_HVI#C.V]JGQ4^8!Y`````````!<!LS/Q,E7^V2)]',0LX%8^S,
M_$R5?[9(GT<Q"S@```````````%/FWY]QRV@W[/BY](&V+@Q3YM^?<<MH-^S
MXN?2!M@.F.S?A<OZR_\`S5'S'TS?A<OZR_\`S5'S````````'9]^HM/<P9R_
M;?D7ZE("'6"#L^_46GN8,Y?MOR+]2D!`.7Z`````````````J'V[GN66I_\`
M5Q)]=T=#KJ+NW7XZ_..Q7V[GN66I_P#5Q)]=T=#KJ+NW7XZ_.`\`````````
M`Y^/J<[W-IN_+7.'TKP"]\40>ISO<VF[\M<X?2O`+WP```````````<=/U47
M[E8Y_E\T^_3(R.18..GZJ+]RL<_R^:??ID9!./EO;YCK:P``8@``````]\?X
M3'_OV_YJ#M-M@+[D!HA^3IU?6Q(0ZLG'^$Q_[]O^:@[3;8"^Y`:(?DZ=7UL2
M$"\'&]/N+AP``:@``````!__`+V@K6E*5K7M4INU^*@I'U$[12J;M!M$<'1S
M.45-F(#FIN6H-U#(IAU,4R\WX]D+2I-[X3VI0J>/Y5)G-)B22WV*VC)ZE$Y:
M>TP*Y5D$;L!-KGRKK"[?=I6M:4K2M:=NF[V:;O9IN_FW:#R*`-&.M/4*[U_9
M<2))3WJZDS:F1[J;?KLC<T71\"!"ZBS&?CG&&BD5XR"0FK"<AMB-"ZA&,@EU
M]3<N=S.`P@.G.;L6Z*:@IWLNQW(;)2+EQPY5#"G6&2Q2Z],0UUPFNG&\E<>"
ME$UNIBLI765NI6E^:TI7!AI_*SY<5E>B`1Q`'XCK?RMSK]<S[$VC2R$I]C1)
M9RN6.G77;FRR?,I^RF",I0.XZEE.6'DI$[JYB+-,X;,UQ0WAN,%;\EIHEFK>
M4.X2YO#FP8Y>]<A%'Z>\>2>6_P"!0$Z@(*]<A%'Z>\>2>6_X%#UR$4?I[QY)
MY;_@4!_>GC^9*7ODT>_T;4AQG;>U3XJ?,.0#+D[1VXXKDAOHN1Z'UA<8KK24
MHCBBF5[,AQ14$,\4)E<=^9DX\5M^<QEQXK;LF2RREUU.BNMMW:THIHP)#I2G
M_5O)?:I_\MWU_#P#%0&5[P9"XMY+Y-WU_#P;P9"XMY+Y-WU_#P#%`&5[P9"X
MMY+Y-WU_#P;P9"XMY+Y-WU_#P#%`&5[P9"XMY+Y-WU_#P;P9"XMY+Y-WU_#P
M"U79F?B9*O\`;)$^CF(6<"IK0D\TR)&O(1"0TA^MDXLN=*/IN`Y%TF9[C13`
MB6%<V:RI%HF[;;;,]M<=:9*V7;O9I2M-RM=\/7(11^GO'DGEO^!0$Z@(*]<A
M%'Z>\>2>6_X%#UR$4?I[QY)Y;_@4!.H""Z:CXINK2VAYY5K=6E*4I$TN5K6M
M:[E*4I1B[M:UK6E*4IV:U[%!^0EJ=AM2*X3R<N.90)&*7U+G2$82J<*9Z8LN
M3!EKA,EF3EP9:8\^'+@R5QY+J69L63%=N7X[[:!/X""O7(11^GO'DGEO^!0]
M<A%'Z>\>2>6_X%`3J*?-OS[CEM!OV?%SZ0-L6'>N0BC]/>/)/+?\"BM/;$+]
M-2FS*UF09![<D"098DN&%9M,5EI4820347&NF%E#,X4TF866HF)N/-DP%3&2
MEQL\7Q=#BNW<E*[E*ATUF;\+E_67_P":H^8M;R;#O:V79,EU-!&H*M*WWUI7
M>R3[-*W5K2O_`-Z?F'I[!SM;?>$:@OW9)>E`%4X"UCV#G:V^\(U!?NR2]*![
M!SM;?>$:@OW9)>E`%4X"UCV#G:V^\(U!?NR2]*![!SM;?>$:@OW9)>E`%4X[
M/OU%I[F#.7[;\B_4I`0X+GL'.UM]X1J"_=DEZ4'/;]2Y1?*>@G01+$1:NXLE
M"$I'<.JUZR"C-9Q1R]%0Z?9JI%D/H!!=Q&&HAN!/L+&5AM+A&S#F-XS=N1/R
MWWE[<-^#)E#EB@(*]<A%'Z>\>2>6_P"!0]<A%'Z>\>2>6_X%`3J`@KUR$4?I
M[QY)Y;_@4*ZD(HI2M:J#QI2E*UK6L3RW2E*4INUK6N\;<I2E*5K6M>Q2E-VH
M"=0$!$]3D.J)0J?3UIT'R!TOB-DCQ*+Y6-DSA7/93)@-%#1=D9,!DMGQW6Y,
M.?#DOQ9<=UM^.^ZVM*U_1ZY"*/T]X\D\M_P*`G4!!7KD(H_3WCR3RW_`H>N0
MBC]/>/)/+?\``H"OS;N>Y9:G_P!7$GUW1T.NHN[=?CK\X[#?:XN*S47L_)[A
MZ%6[(+^DIW61Q1N--+C"1R9Y5JBRJRG`J=(,+352TW'U&CI9\]DZH.X:78BU
M]F+IF:['BOX4-=F[KSK6OM2YO[=?^YAO[0!I*`W9]C=UZ>]+F_\`<PW]H'L;
MNO3WI<W_`+F&_M`&DP#=GV-W7I[TN;_W,-_:![&[KT]Z7-_[F&_M`&DP#=GV
M-W7I[TN;_P!S#?V@>QNZ]/>ES?\`N8;^T`<QCU.=[FTW?EKG#Z5X!>^*%]B9
MD5-+>AM%BJ?6A(L:R"5E25U\PV%>,Y!/'<2.X'#A.HQ^[.@-I7(=*/EJ79<5
MM#=<MM+:TRX\=]*VBW/UR$4?I[QY)Y;_`(%`3J`@KUR$4?I[QY)Y;_@4/7(1
M1^GO'DGEO^!0$Z@(&S:EHB+8<QDRJNPN6+8<I@R8SQ7+&'`7+E\=V;.8SYLC
M'MQX<&##9?ES9LEUN/%BLOR7W6V6UK1AU+1$9PX3)95=A@L9PXC!8Q@BN6,V
M`P7,8[<V`Q@S8V/=CS8,^&^S+AS8[KL>7%?9DLNNLNI6H3R`@KUR$4?I[QY)
MY;_@4/7(11^GO'DGEO\`@4!.HXZ?JHOW*QS_`"^:??ID9%V_KD(H_3WCR3RW
M_`HI0V_*8Y=7VSW7H=TW,62)6DPW,,,N0LTD2-7ZGG\J&VG,8/KJC:8<;=1$
MZF%-*76YLUMQVF:^VZEN''EOK2VI.*9X;EYZNMC`6'>Q,;2KWE4]?NE;SX/8
MF-I5[RJ>OW2MY\#'*Z7S]FZO$!8=[$QM*O>53U^Z5O/@]B8VE7O*IZ_=*WGP
M&5TOG[-U>("P[V)C:5>\JGK]TK>?![$QM*O>53U^Z5O/@,KI?/V;J],?X3'_
M`+]O^:@[3;8"^Y`:(?DZ=7UL2$.O6LV3&TII?96NBN>J4I=;6M=Z5O:I6F[_
M`/KAV!FQW7O6U[-;2E!\X-N08]E6/F2X$MY,U5C&1CB@@J!R17HM%BIHRAM9
M52LM^5+4R!RVI-0,V4QF;+;K[<E+[+2\$N=]/;^+I`$%>N0BC]/>/)/+?\"A
MZY"*/T]X\D\M_P`"@U3J`@KUR$4?I[QY)Y;_`(%'RS:EX?*X[LYQ:<I`KCNQ
M4S'5&,Y13B!6W+FQX+,IP^=99<F2+TRY<=N0R;SX2^&EW1YLMEE*W4">@```
M:;25H&TKRI-4*:@7'$S-*R?!DK+DS-]P(C/9"<:=3Y7&"Z6!4_(AVYK&59VV
M))9U9W0AWYU,J?3'NC-MS8C]QI&+X[MR0`:10MH(A6#W\T7LVC#G5"$2I$NM
MS3ZQE\PB&&AI_;<\N]+?$KHL=8"*&GK&;"Y%M%3""<<=RPYE)GLXI8Q6@;1F
MOG/D#F[NYN_/VZT^;YNT``,8:;22V8EF4A(N-W%3;@=+ERU.&*&,W7%WN15=
M*K;9DMQXJ6EK5-8-VD\-;:UP%:8<-V3+=97+?DVY3O\`AKYQY`!XW*=_PU\X
M;E._X:^<>1XKV*5K^:F[X`#<IW_#7SAN4[_AKYQ4NC:W77$TN:HD&5Z/N7D8
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M4?+.G=`6#"FQW`?6,,?84<IC>A2PDJNQ*PJ&<RHW*U$M;2K4\H3/(Y'+C5C6
M!:M+ANAN4[_AKYPW*=_PU\XI7TK:A]4[VU#OS1Q+TO)"G+>D1Z.Z097?#69<
M6(!#5;`3WMN];ZGQ4S3MYO*R5Q`-G\39U%';5"ZV/'TW"C?M6\Y&76NLLW)(
M?VMS==47Z;G[*T`RK&IG44\FXS2%<9J.5)LMQ4D34N=TU,%.++6:0RYF0E4J
MZ+T<](B3')!R.!BMPS5[+K?(-A4;N94"X3<IW_#7SAN4[_AKYQ4TL[6V/4HN
MJF<6F?5`I6%$'5VMH^(FGP5CS.;+H7E`U&.I9%3:')U+82"FS,V#"YD3,X,Z
M0C/E$-XDYI*JHZ\1IOX,UP[4N$3;VHWB$<SD>9!64-.<2K<T%VFUJQL@.;5K
M'3(D+3V84<%7SPA9$9_WR0R&7E/$&&;RLUX.-*P/DHW4(WB7:A9AN4[_`(:^
M<-RG?\-?.*X3>TC9^#A*+6:?-1&%1B97C)M/FJH1AY.;#7=\H-]9>!!GNZ1*
M3$<C]BN)JM%,2UU_DWJXT+&S;GW%Z`KF,3IDAIH:CN3!,Q-/4-"D13TQ,2P7
M94TQFQY5:9=PDL*:O%FZ_P!MIKH1RRVGES:@6)+!8@IX,"F4+'SQ8N=QYL1<
MZ;PVV&,@2KN4[_AKYPW*=_PU\X\@`\5MI7\_;I7MU[=*TK3\OYZ#%62S4EA-
ME,:B'>=O3$JARA:X^9H9-UH>43BGFZ=GLQ8+<FX9.YJ8]S%;T.*EEE>BK;T5
M<K`!XW*=_P`-?.&Y3O\`AKYQY`!XW*=_PU\X;E._X:^<5U+LR2K,6O1Z:3H^
M?QZ'F#IZT]Q/.$INEOMYC+K_`)%=&H!XRNU([9;=SR"BO)O-ID-%(AQT.!ZJ
M6)F'W$Y%M?;".D+S5((JM1S:TN#6S.&D748[F)J@4EF:(Z:NG/3V]'(N0['S
M$1RC+59=UDSE!)"65\@L.%N.6]",,<A$=[S9C6-O]405I/=BFST972J9S%H7
M5[E._P"&OG#<IW_#7SBL=U[56"&>XGJ2/L*;59BL7(LW+TQ-AF)BY%R20:$[
MM_3P_P!6<+AQN,O>UR+,>KAQKV>U<*ECSGCM$=;T9!)R%6NKDB_]S%M/H`O)
MOG-E0I&)'8XEF7H0>22;3FAF/-Z1XED6,HIL1U2U(>JMAP%I(?$P1\FQL>LR
MYK58DNT5EW$W"9,[=@"QS<IW_#7SAN4[_AKYQ3;J+VG/3](4\O*!X[F]`U`-
M;35JXF!&;"RQF&6<$;I^FV]7:=TLJB;(;F(LF0(S79`PI5S!4&8H.[%*;6Z^
M*C4*&KV^MEDW8?5:Y]4'K,B$W:<I);37EE@L1L3&NH+G0&@;:4P-U&;R:Z7Y
M''7IRIN?!'BZ\$?&JI[&?.&E4AM.4XF9G$C*:)<8QE`L+W*=_P`-?.&Y3O\`
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M6E>AOMK;7<KV=RNY6NY7\E>R/H`#'&@UDUDM1M,Y'N-WI+50DIO)EYXQU2=N
M((Y+"0*7&S%MF&W.9K@P65S9:8L=,F3HKJ8[*5I;3(MRG?\`#7SBNI=F259B
MUZ/32='S^/0\P=/6GN)YPE-TM]O,9=?\BNC4`\97:D=LMNYY!17DWFTR&BD0
MXZ'`]5+$S#[B<BVOMA'2%YJD$56HYOXF76JZX"="_`,UQW)\W2C$T&+>I*4I
M=B)M14VHRP0GF=4WE6DYLZ4[Y;;*V4=-4B)K&^XF<AHRKEQN]3*Y4'.LM:X\
MX4\+,-RG?\-?.&Y3O^&OG%8KHVKVF]MHBHKYDYYX>HU;3XBIN^0S'#`1UU1U
M,P<N3Y%9+`\GY(+>93>.+;9;JBT"F%\N!JXE25S+>CU#,*BBZF^:/QC'NT36
MVOJ>FR-IK;<G4C9?U*:?(DB9>--".44C!!V:]&#&G\DPIBJ1=!%VF#9MW7O!
M*N7TM"?19M*1D@FN5=3$7J)1O"XC<IW_``U\X;E._P"&OG%:C%VGT/R,<*H[
M7C6;32T[UB)DF&2^1IHI)*G&DQ-5]/Q#NC]W*+D*,XNJM-A1L\7K)K9=ZXW'
M$P6XGIBBJ)IC&Y&]8I0`U=76HE?V+LV:OC;H,(.H:/(OUI/-'6'`QV-B-)RU
MI^EB;T-G(KN9"5:>9.0T71(]1&Z[2J*9RE#9K&I'$I9NSYL*G<%U6Y3O^&OG
M#<IW_#7SBLMR[1YFQ=(AN$5V+)ZD!RLB1--,(.Z1D1'B`LV#\A:I&CB4X94L
M1<Q)384KDE[NJ[$R5(V0:9$JRW&>P*#D(HK$LO=-F%KNUXB9`91AYG(`U)Y<
M;>AB?YTD9$*I4-Y%:-FAI1U!UTWZDR"W7)-&)-7W)$SUQ&E@TFL4^Z2SU:A>
MIZ.#[M5,EJ/8%M&Y3O\`AKYPW*=_PU\XKC4MI7%J*1D<BNQI++?DF/)ANAJV
M)5K!'UCM=RN8@Q/U)(3A;*HD/Y:9-&XXH=4BJ^3JN.A'7$E;R6-!THJ"OYL)
M>^!ILVD*FZ2.F@]IQ;4M(2>Z-7>@Z,)L6WI&[70L3"1M4)MH.-7A63&F_P!6
M*R"SY%LC=^M,RN9FRU5`TR7&Z6JEFEK#4XK9$X+E=RG?\-?.&Y3O^&OG%2$?
M[3F.T!C06:>*+J"=Y28)4.1CADI[LR&F+E2W6YM8CKTIH+9-HK:>Z:C.XTSW
M\2*$E]/B4H]G*VXIQ-R3'Z1P&'%6XY^=*VL""E,B2G/(T!RTFN9H3?JXCQKQ
M<RL3+?$@/5B:1I"(Q^]W@A$$1\'$]6<.125V\3)L@FH85M?<CB(-MG%W'7%>
MJY@MWW*=_P`-?.&Y3O\`AKYQH?*FT5T[Q^W"ZFSE4U/;MI+$,0NXHCA9<CI7
MEZ.WY/KCL9\;)DJL-X/MEJT8Y%)VYL#<4B;UM1UA$4[C5JHEEBR0NFDO6'45
MM."5L1:CD.(FA,C'EQEZ;=5;R;4@G8_:KX947S=ILBD^]73'DHY4I7>+;0UA
MO.4L=:1925[3L;/ET-%Y-MI/!6.%47*MA<=N4[_AKYPW*=_PU\XK:Q[1MA-Y
MRLV-%5@S3)#QS(;>37TKQ)&QI^%FS(BII[*:@RK>5FVVS&1T8L+C;!I)34Q?
M34`RUB+U>C*9ZNII1E=QYRN#7[7B!,+.S.`VQI#)N+%.*KIZ*L8PO0KC.."3
MTZ$6+/Y)HM5]72S2)5IWNMC2(WTID,:]_D'FZI"+N-@IB)>M-E7Z0%I*\BDW
M$B+"`?KGM(K:4HI!RXOEZ48M*J9/.1,UP9;K<E,>:F$QDKBR5QWTLR=#=6R[
M<W*D%%)MU$1T`A7/<11$I.2"=QC+TTQ<53">`B6KGRVVXZ9,U<)?'7+DICLI
M?DZ*ZEEN[N4T^9VNF,GWJ)QZ>&RT)06#N53E%L9)(2VE>JQJCOB&K2%'ZSG>
MLIQPRH,H[@.FU%$;JTYDI/:[L<K5=+;15K,LD4XHK[K@/&Y3O^&OG#<IW_#7
MSCR`#QN4[_AKYPW*=_PU\X\@`\;E._X:^<-RG?\`#7SCR*-77JEUCEM<,JQ)
M%:PLR:@,/6KI4B<U%?`>6/-I$TS35!,?2).<BN&;$%'2"3(<\,U=;@>[(-O!
MQFL#L*MQ+B_*S'6XGFD+9<+R=RG?\-?.&Y3O^&OG%+&F?::G$N`M()O48AOY
M[OZ>EYK,-1E1O-B/V@S#;KDC54N:98_PDTDZYFI<XE?$OW-I1?S;BU"="K'S
M/4"CU<:85251/O.[*%=I+%)M'5WE9'$Q88M,'.LT83`9;S?Q1O,3FNF\QI\*
MM9H*]CHRJ22NJ3]*F%-(*/1';?7:.,!B1B-V5`*'.IPL3W*=_P`-?.&Y3O\`
MAKYQ1M[+&91I9D&17!%.H'#IC:.DA@S(]&D8BUIIL@0L;2M4.H&$I@EMT8E-
MSI"P\HP3D"-T9UI%\:G9%,NIDD3CXCM$7R)LU;@WQ;.NV*'3,++BT@@O?&AR
M;)$TPK&,OYD]%OC1]S1I[+N8Y*L:I6<LO9W605$<JQ)&R(RVN-9,:CKR1L\L
M"$N&<A="WP!NQN4[_AKYPW*=_P`-?./(`/&Y3O\`AKYPW*=_PU\X\@`\;E._
MX:^<8R\VDEOIK+C16KSEB4X$_*FGKB!BA8Y:7S5MK?4OGOQYK<63=LIN7UQ7
MTI3=_DUW1DX```````````````%>SV``!HPHZ`8D5GTYI`47?+!I8=6JN.M8
MRB4R.A`HDX9CBUAH49M'*0*6L^W,4:I1DM=N(IQLT-Y"RC1'+'S1B]3S'CAN
M)539*Z8U)HYVIB7IJ2,F=B21'][D1Y'Q%%VY,D?4J5U:YE`R7R-S.V%13:TW
M8CKA:]BRVU%%M1UI9:#E1G,US=B7@M!'K=6M*=C\MUM/R]JMU*5[5:5I7<K7
M<K^2O9_(`K'Q;*R#BAIEJJ3+.IQ!=++D'4@\+'JWY=QHSM<;2U;2&3E;4#"+
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M)*Y^C;0"B8FI2\X0W\*Z`X@(.;2B^"#JE@D^M(=9%M8SU*O%/PN9]EI@O)F)
M8(32IVMGHY/(2.I$"SB=Y57L+8U9XER;YR=`\TU*7B$'G]D+ILNQ-8JW7WJ(
M8Z:SK4;$BIC8E7#F*X"[1U7EM9+`*VW.=J.4[@*L.8<&6J#@(&R>,^UC&!%=
MU'.806HJ($,MW:83GE7F&RW]$S,8YU.U`O;39+\LIZ?(T@09AD5HZDF["21U
M,KM"IIZ0VV9.:RWF<T=/V6VPH1GFEE./Z>G>^VBX"V!X*6K^H_:1R'/^BJ?D
M?`U,D1N,]L\GOJ@3W7'<ENY+=C1>L>ZHW/!]4=-44LNW5?`E',[+*N(N>HH%
M,QFS.KM99(*:93/E,!:C?LV8+R%2I7*Y99S6$TW6>F8;LCM0ZYKL.O1U5>NH
M/)ERT9]MV4PJN3<4&OEOW:-/<Z0GV7X+K\=T,PELV*LN;9O5WJZ'&8@HU(&D
M)YPG'J:]2"D46S^DO3Y&<6L)V3`0-1^GJUKO:;^C9(?R&0;KQ,,QR&T1H*3P
M0#1A&O1[OR/W7]J)+/2:#D.:<VQ)450\_)U@M8RKTLQW&[URS7%T8);[9J:C
M8G;(1'"XZ26NG[6TFLHRW6BIDD!1;LA%WDIHRD=()6YNCC4`=U(1$9?BKE2+
M5=/?S]92HEE&9)48N-O&6DNWI^)"D6*I<($GY&,C$R5Y3*Z68J&%U.)9S)<^
MUW4[&JI(KC4@@9,V8T4)3-8S(*S+J8HE1Q)R9,S5.99,;^9:ME+$[G(\G2_7
M,J7Q_P!/?[QD-2>#HPO-V2!1TN;)A5^K6TKME>2D)92]N].$$M73#!,5:>V*
MLNY>94.LM%C]H*+[6"R^ZJMAN%J)Z"255<HF(Y<[<E)6(HE%<N--*UH1)%K<
MM,N>F4QFFL```````````&L<CZ6&<^IG;&HA`=\AQ)-;<8YZ+C;]C-4;>'.\
MHP-J^=R%F"_FR^6F^F0[41ONDT=<K./*39JYF0KJKAR-)P(Y-U.DDM1!).SI
MA&5,[X-.MSR]E-R'$<<0RYSN!]%[SYQL1C+ZQ.J$H6J2DWE(_8YCLE.)>6EI
M;O-9;CI=4RHQ4J022J:3([]BL#:FM:>7!%<.*NEUYO9IZ@F)->:38Q2&DZEI
MO),MKD3PQ+\N8X#D9.3SY5+=4=3;DC\O'B^C.$N>(%,ZV07RV+$?2,&4!)[?
MV>T-(5=0"&8=TRN2+-0B?,Z>K06Y9!JHP]'=FHD\IK,WYHJ;6!%)*3:OD)P+
M2VX#!=77W*G-516EK#'Q%H)2NIIIK&2^RWTG)S'EMDM]$?+8MF1@Z<F,X':W
MW^O)[\1#>E`L0I!<BM%TW79CR%*C0649N.PT^*VG%%S.EL-]4=6-9HG6%[]#
M&;JL<FK_`%H:.9]C!VO<IILD'2UK&R1=&!MTNUILU[OUC-'3DJ.]Z20AH68M
MA6%^-GY(CE@A*RJ)!7R,I?8<EJ3>*]7*2<K99=T;ZYY!EUNZ?&5&3`BAI-)F
M:<=G,]I?2)/ER03#H+-_6G':THM_'&#R=%CH7'H<C[.@HK=2#$DF55QSF\#S
M@;QEQLQ;;]BXZ`V#D39@1#*"*A%G;,6I8V[\4.S;`,C2EADEO8I"G*(-0-Y8
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MK'DK"R&CBFYFXWLQUPP6;X6"8MF_`F!>D);+K,KE,,A:LV9K8O;R>^^M;9:&
MH-H*951-NQC)*4B$K6\3?>,K>2DA%NS'B#TN4%5=4Z4=ZH<<F:+&SLB=.S61
MW*W"<BZB%!O.9JPZR<Z(M20A*)1.;$!:CG5J@B-/3L^1B6J-3#1D5Y+97KRI
M'5)=<3<,92[L5%U<4%AP*6L<L:C-4CTU/PM$-R8QF/-D%Z_#D7)RDVGW*&;3
M]*C"FS9JZHIV8F"1&^4RI*TMGF.K-M*QNUL*R>8I1<;;9>S14&R5=F,FCR-`
MNTLG?4@7@%8C.`&883U5I:,7+J5(+DF(#>Q,%-U<%%G!F<3"<+A<:*JKZ>PU
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M6NCME5..,\O6*``````UCD?2PSGU,[8U$(#OD.))K;C'/1<;?L9JC;PYWE&!
MM7SN0LP7\V7RTWTR':B-]TFCKE9QY2;-7,R%=5<.1I.!')NITDEK^,4T91+8
M]7P^%8^_'.>DG3S@TS/A.<KMR*B<XHWM<;[=IZ\]GJ0P+^^=6<,F/E047!A7
M,66ZB]>2)EB2<FHY1.VU`!5PT]E##;-17$B)<TZE#Q=YM",V"][7,[XT=R4]
MV;%,+NG3^V6V\&2Y8A5(Y<208C%TWI:T24V=FP**VBH;PZ#`[2QU:4,]2MF?
MIQ0SY$PDY9#*)B9+.GR7R#<O=A4^AX5S3+#Z1!,7HF6Q403JF?:N",T)+07&
MEJ2H=..C(7O4U55RJ)HV9SV%``K*0]EE#C>CYE1^G3+J@OLAR1(^D#3>[565
MTQP._3-@B\HYT-GL&(#B^R5)%NCXJRGJ[8Z6$>2D&1U1UL%;HVW6NK)=":V1
M"EHAH/B!,T>/_1#A<LJY8@DM.E]'=:J<>6`[(1I*G1V.AY241P.\P@9+2&-<
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MY\6#$N'(;P."8($.MPRGTZS3\QI$4$UR)3!R+AK`M:=B[LDC&H8%=H'6YFP5
M(VI;_.1T84UV*F&U)%8TIQ9I3G=*/O57.,V'=6LS:JT[3FW&LI+^).+&U5@-
MUKYN'!06C!9"5'4QW?$.-)M0[9'HIH`;2OW9Q1.^%QVO8K)L],"47)+<=S<E
M2S';Z;[>?;%?\=PGCTZX3K-S9V.IMO"C.^&;<K'?K8<C;<S=<Y(SD4LR<66\
M1-2*_P`19V7\%*;_`+'X1?L]MZPV^--<L.9GH\D%,S2?$S:4K4(K%4P._?`U
M5]T*3]RHC5:[??1HNZ$]"D-/;B(<=B"I.!/+K5L&2OM$YRB9#F4JIQ]!CCD+
M2-`>'4MJ!;K1D9?5$B1(]OG28XPO;<)K!\BDY&_(9)E0HX7<YTE[EG(1:4EK
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M!15OSYE+H,N`X;R8#1NS/"2YLXX<6U?4===($\)S!U.)4IXGO"R9)6+!$;>=
MDXM;*SIADAA-O.W#:DWWK(:*=6;UBIU>6FHFK[C<KP:[40'>OJ2[GL"MKNT[
M.YV[J=BN[VKJTW>Q^?<W:T[=*]BO9H/("OE1V<,/*#N>KBQR/J$26[*$;I;`
ME6+4&6#"+&LDJZ%#ML"HDK.-(3T3`N$Y338M*HS<HM-5QMMO*65KL];6VJJ+
MK1;RBGQH2V2D'EV6_H^4)@U(.1G2S@(D95;3I>,<KS;D1**P3&FG8TE.-JG8
MEN:MI8]'D1L2I8RC(:2J-%QH]C@CU09YJMN.VU$`&GL5:*XYAF9GI+;'?$RE
M$9YKBR]*P>>D/.H0:VI(=*0GHKTDMLM+,F47B[L>A4CF..'$K.Y::USA67,[
M4ILI;K<ZZM'MP@`````````0''6GAJ1G)T_2PA.!Y''+J-<[5=[Y+K2DC'D9
M/6V6Q4*-FWG:B=A;Q*Y&P)[/;*"EW%3!I3P'LB=8I'[3*F9.FS4^``JN,;(O
M3M1,C=*1)$U$-/#&2"S$%&RMR2D<N84J1QJF)ZPV`JK%Z@R%+'57:LRE<ITN
M81\**76$(UB2G237\R`TC[>R$KLKH`3V3*<<)C]U#)3'?#Z,R9&K:39<-$DW
M2P_C<MX)YSNK3'BP(EES"5K9D+8'V2RN:]]XTB_JMFHV-/C=5668HV8``KV6
M=F]#CHNID>,@SH\<[BB+'!LT&7(_4H^;U$1M;(S@E+.@2T;QM$L8P8CKJ=SL
MQG+HMRQE9E:KB/L.S#B96%,0D^16-H?A>/91X2T#,\ZDT^6Y.GQG1D=<!?-&
M4>37-*&K($L24SDC$E%U_`M/DJYWL;.I2XYUUIH2L_GNJL]NMPXXC62W<0``
M```````````````````````````[?;``$#D],^G\C(RK+Q&(&&1DA<7BKE7'
M220"9,XN.M/P8TX@\5LL6LQ)RN]2*?AP$";R429ESE21<L4P*V,N7P8\=6VO
M?1QI2B=C:?L\8Z=H=C\S(.OW9_L=YFV>P6ZWCCA9Y_62B/TPVSQM+(EC-4>C
MS<JZY"Q'#EQ8"*JHY3)*TO=9AIB``LS):2]-2<>8*R1A./BBM%Q3$F,13P()
M?&?02&%UW/JPK::I_MU'#<^[ZOO+:K7G^GOFS$\<]<CEP853'B^+09HJL-.X
M[72M`V4T_B+O37IF,1BU#5SE2I#>'""^D96H93,MII$=[XI5V.)%OMZU*R]?
ME4CA/*9RY<EX`']MPZ,M)KO?C[E!TZ<X=<,BR@P[(LD=ZJ[";Q]RON/,2>42
M;6F[%8P1R&UY)JCIR<BY,2ED,Y,R(GD$;-EO3"14IBF9@QZRHQ;V-J,)N)S8
M0,!U0/T()V.^G3U%5,WGE-2/&L^3,=45-1.9<A@\HJ!@R=-9:TNSY[^AMZ$`
M#-0`````````````8@YF`R7FHM%7=C60W$J,!P4=C(4%=/+G3;4<]I`VE4<"
M!GS677I:Q1*4%%+ZX%*XC54U14"%<G4AXUAS``1_DTUZ?3"PT'%?"T96+S`0
MW8V&(L%V8A%%%EMU^9,^5\H;4-E26',WDIZ9#&7([2*3>4+..^MERSC.W8L5
M;,6(:.-**.\8HD!'TZ0VD/>"6?6.H8=:3'[;3%V+F%?4YTIG,92(I^`RVVVG
M545*Y%1TN\N10KU-2O1<)"Y0.5S@`?N4M)>F928S/C`S!<961XP%A6<+'9Q)
MJ)B8WVBKK>%7+KYEN)R;A*8$?&Y"CB<)%S$R-N`DXR"\MD%PN?)JRA@,5^;6
MN`(3;.@/7E*[?BYE)$AN/3F[DM==!%")X#JJ3S-IKL;+:=PVX^H<QB]CH**R
MKCMQ7JW>@E$6QU1UC+8B%H`%B"/I=T[HF)NX4V&V!@JS'HNR(TS>1ODS:FW7
M\Y4/,UUQZ)"L<M,*A%TJ#5,9FED7<!RQ3Q-+)5KES.)`W$ZF.)FBK2*BNZ*W
MZBZ:X417G!;;,LV&W.CQVV4M:C)IG3JBI7MQE'B">7S-]&*J2RLJ26GI]V`L
MBJ*PK'DC&1-*1W-G``^;JT3:07JQ&%%KMTSPBX8XBUSF'O&S'58X:YMKL-UF
M<YTP>6VFC9$ZI%!-*N165NO-J;A+X%K&JJ>!6Q',"@;QYI'94#PW'3S=<@L6
M-VFU7H^S:VINUQ(J5A)*"VI.58Q.%SJ!B['N8L1UT+N(LL.<T5QX,[C4R2<=
M6\AXPFD,A8`"70`````````````02[],\`/M[8Y)>,1,5QO?!F0#&1?54(J9
M,*9EIY:&VD:7R]UO4+D--(W=U4U#3@*J1ALF;<>=#R$,N/'?:`!B<XPS$)=A
MOJ0J1;'IE[,U2=>H9K.519K>5%1!G5OQH=;:-+:;G4D\W0O(">V4TDV,+HMM
MZZU;&'>YD,WHF7,1R:'[+1-0]9&SBQNO5`UV?-*MJK<LAK^H?`\F<UC+?E97
M)+V"/"!MRM$FD$VI6B<S8_9:&G%T]%(E4_`VDHP3P8#I>AJH`%@-ND?3%B(Q
MDF8((C`LFPJBW-Z+4\JTDHJ19K?N5$Q7O0$PH7P8B^1#RKB"B.+.D'L9M.,.
M9'2W+F+9%T@54,7RQ:.]*>"4U:<[-.T.5E]97SSM4Y%RQ^V\[J,NLZU,K"47
M154SI^3-B<:LRLM[66ES!TI464*MJ:JFCA:S'CM``_4V=).F5HHC>;+<@R-4
MM!9[Q;<B---Q-A/RX&R^6>0O2F8ZD&IC%FRI"TR$BZJ,R#I#)@RLU%W$=L52
MDVE"M/Y%^BC2'5>BQSTTTPG:X(,6'&XH>6,<<MC&?C9;>;CR/!UJ+0SXTZV]
M&,.%YWU>JM4I6RPZ].A=V:RYQVVJ=``-HP``````````````````````````
*`````````!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g485123.jpg
<DESCRIPTION>G485123.JPG
<TEXT>
begin 644 g485123.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`]1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5],24M?5D%37TM?3$E.12Y%4%/_VP!#``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0'_P``+"`%F`F@!`1$`_\0`'P`!``("`@,!`0``
M``````````<(!@D!!0(#!`H+_\0`2Q```00#`0`!`0<"`P0'!`4-!@,$!0<!
M`@@`"1$2$Q05%B$Q%U$B07$8,F&1"ADC)"6!\"E2H;$F6&)IF*C1V"<S4X+!
M0G*2HK+_V@`(`0$``#\`_?QYY[CZX^F<_7Z8Q_GG]L?\\_3ZX_XX_;/]_<8V
MUSC.?K]/I_/UQG7./]<9QC/^G[?O_E[G&V-OX^O_`!QG&<9Q_KC.,9Q_YX]S
MYYYZA?R<=$VAR9P[?G1E-_HU2PZG'(@C@6=@CTH4!\ELX+1Z`=L)J(@R8/EU
M4%6<TLJBO'D+!=NZ004S^(1^];*^JS_D<Y*YT)3&KKPN1U'V%3L%4TM<KF,I
M^W9"#"8.WG4E#AECE\@*!I0-A%:3$S"R#:3-9<CW#`=QNRCRXGCG3MK^(^-/
MY(J"86QV!6QIJ8@,9QK+TJ,GIT4`YNT'B4LO".@G0D.!&R8NKDCE)F4,@<8"
MXR*7>SECD!"HF$P\M$L,2SR48GM_G"=!=CN*-9)VCK<,[SU^C,!)NE:NU[C2
M4@[G:A3JA<>2L%0\C8F+D"9S#IC^VFH4T6/-76P5K^?YB<:^2OGRPKEY6J>J
MMB^R8[K&N[PL@(L8<!CQ0-AXVAS`6KLR@R)TH)_?0I7$'Q-L,E\%.:0SBM7<
M0[Q8.P\O(CS68MQ45TUO>M:0UO5E/.)NOY_<B3C)N3@"0/74W$R.:$Y_\5"&
MD0/$$;HPGA^7:95DXIFDX1:XD6F[B,<-7BVMJNNVNB[SZKZRIRIPNN8\-&..
MJ6NWDB6L)(@8+GT]:%G]$5DVLVR]XUUE^PJ0@E:FCR,,&X1DW*IFMTFQ3M(,
M9$XCHR#E'E(Z[I<]*6]4/3MD<I6<(UQ4M<$BTOSY1MJ4]*0MBV02%GY4,S"]
MA7_<S6911!`U<F>M&+.&>1VI.,[KN%D76N%^C[_[</\`GF=HL+I*`&26;(>I
M.-J]O6>*4'CJ$KFJ>C^B@^F6[",28O6.SZUC?6<EG8?';JJLQL;'I\V(4-T]
M1.(*(-K?Y*++==IV35MH08F,TP*E?<(Z4M<1,@U+J.`N/(^@I(*O,_FL2;U:
M1$N@F=L$#Z%9KC,.UPT6`41)_)N6Q"J0;0J$-34]&9HE/F\8/3$N2OI6'KI)
M'1N4UH#2#1BJ##=D(_F#QPA8LD/:-C$K8+H1V@^_)MA)J@^;CFLW+8G9'9'/
M%2%+@5/CS:"WBBX%`2TFR-E;^O:\-K/S%ZUT*V;8\;"/`:N)LSVG1W6#9F<_
M"YWR5!V7NS+0T$MYJGL%U#>G07<70%!4P21U80/&]B\X1)K&V!0YV20=SB-B
MABI[=#=0X72%M0`D8C,V/L*-D(N8_`R4[#2Q7+0MF`LZU;P&V+SSSV*3IV$B
M\X&#)*7#(^1V-,R([7\#-3D;&3)O/Q`Y+F$K""48\<HO"*6C1,?G29_'1*+M
MVT@(:5EUTDV#!TNEE?GGGGGGGGGGGGL2A3T'(R4Q#!\P&)LNKMS!LST7B9V,
MD"$*=D\*B1CC8KAVCE60'W$\/N$)N&1E$&JDE$K)2#/59IOJKG+?////////
M//53M7JR#JKI?FSF)[7QR0D_3L7;,P(%T$L':!HPQI.)'YT]4,]IDHBR9ONE
M%E,%O!IC@X1[2SMVJU4_+\-5E\6CR]:ZXWSLX1UPDGNLKG*FF,)I)[;Z;JJ?
M7;_LT]-DU-=U-_LZ:;)J:[[:[)[XUP:OK6KJU`03LZOB^&*``[8M9(.*XYSC
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MQ/=Y=3R[XVT9ND'-#P(*+O)_)E:#JX!V7`X..#I*:A2!XVS.QDXH*87G6]LZ
M^)RDF%$9\W`)*KI=99YNJ(3A"+$DO%,4MOM-=I>2#)*:&4Y#=O\`XW[.(FYM
MDR7T51;R\DEJFZ5H$Q^4VDFH"/W.;#!D&T?8W/MV]/T[9?WHX4MK!J#G\/1L
M0^E%QX7EY"<#IM>O7"1J-09`C_XA%X6AY=^.FB613>4:T[TKD[K2\3>;$34%
M*.>B46#K$JV3U'R(RR5616=:VW4PZ*J",S,0A7-66*7!7C$<CHV1_$_K&9<"
MKO1-S'[NU[K0SQ\_B(M]*1:T%).XYDZD85P[9/EXA\NU26>1:[V.57CW:L<Y
MW59JNF2RK-QNALLV540W3WV]^L@R4V=:INVRF['?[M[KHNEG9GO]UJO]AWC&
MWU;;X0WU7SHM]C?[G.%<:YTSC.:9\L=B.^J5H,J%*/L*&H6R:J8W%2E_O98/
M?AIX,OBAX.-X*<@FDJD8`IS*QR4>?CT([B)V&DP"7;NWI/#ES":#(R['GGGG
MGGGGGGGGO6MK]M)73[6VGVD]]?M:;9TWU^UKG'VM-L?OKMCZ_77;Z9^F<8S_
M`)>_+T27Q==)_%]\IQ17%FV(E8$-\H]^\Y`-ASQ:3'1M6P=;'9U44`E-0I.6
M2DQ/I*5@&6!).P]PM)_4<5C(K=BY9:L4%4?F[;MNS>1[<[(Y!YR*R^OJQL&D
M/BJEA>6C)N<DWE"D?5G=I%Q5>)`%STD^>S(]-V%5,5#3NLDC-1\BULUD^LR-
M<I&T^0SLIL8YR+YNEN\_D%Y;`H<E)J9K+G3E#I.K*LB)-H\5$CNS$+["SNOP
ME\8S+2.B4;)6I@2*(R'G">"&6AG(E9$X5C\$L_+;SE\?W0=M]"Z]@REN"YA7
M[VN.R36K0VL3]*L,F-;`T+35#DL:+3LE4!*;A$VY4FB\A)$92/.#!?9D0M63
MF;^K+2.C]A'GGJ&?)KSK9W6?#]\\YT]^CD[`M@>AAR$>'Q!)C(E&X;EX[/OG
M\Q*PHT72VB:3&$72;MV`^^5<O%VZ>^S5#[UTE2+K?@;IWH9U\J;P8:5-!;=T
M<+\\<Q5:C/V*08_2YS6;F_E"^7/MXVN7^K$4^Q>B68!V/8(Y:5R*O=7T/"_F
MS39MVUG<:]KQ1QW=9=(/*3U>]4DO!U@PL;.&LU%%+%OSS!U\!WK5C:9<U62P
M01/E8*)3+FIKWB\S4H)E<M&/6X@-2T0S,(Z`H3XZ>Y:G-IGH:J(^AI.T*Q^2
M^\>PJOJ@MNRQ-@ZXJ.Z5YM'Z'LFMCFQW=4S)#7EI#";5:<$#Y:#L5E+SL>Z4
MF8]C&3N^F;]-^:NG)[ICA;ITR1HAI-5#6G85>7J#"$\6Q4&+,NG2BCC(?S4T
MDJ!+*62X`?Z.9%R"1+H^L5SJ2G7)\DB.)YR&H6XR"%U\\[$5:]*#\<"3UFBA
MJ#V+!4I:I@\:1\#.O9N"2R(VDE`5X8-GLJ([Q[YR^;PL*^AI*1?Q;55VBR3D
M'E&.=_C1>\]_(#8G4T7<5T&=;SW*%2TB,0=H=(7+:13@Q%K)N8E*]R>+,WCZ
M$D0:)'C,2VK!@M+R&HH2NC]]%0<&I-KOI.QH96W0M7U7U`=BL36IET]<=K6G
M:0N.&I?.0-;93;9C*[HH-(3B!%9@BC8J'I@#`DB!Q%C+W\&5N2'2/27;K_F:
MM-NV_B3;=)Z-2:OKAO@'-ROKCF+H:SH3'65^058)QU86A6<[8[X`$81\YAA\
M_9@0-JTJ27804-N-ED4,RD=)"BC/#UKL'L*D7UCV2!,9EA#:4X)M8(Q,ME7J
M[HQMH_")I!S5(P7+_AM%WH#7[ULYL20;RLG(;E1OD40W;MHB%(FY#0[@O@B]
M^;.B3:R+'-X"9'?Z<W-7KV=B9F0D2?H@GM#L6S>E1FY;.8KQ$?B***\`SE"L
MVB$G+%,CM)S!FE&22`LVB',UC5J?'U>9H/\`R-<P8=@\YSO\AMIYMIK:\P0R
M&;"HM8["ZD`KE%'0&I!9;&"D0WJQ(OHJ>ARECHQEYI$?+&L$P$F$U-VZYPYW
MM2K^RN_KQ+4!'6O.GB7GF>K;\G*).7+&*5.4C$U%/-S2(>C<:QBUI9[$Z3L*
MO%$)']\P<[(2F(U\C]A>_OGGGJK7G:-*A%W<;!5D5]@ML6X+CL(0H`KR,#<W
MFL3^`YUMRPBDFQ-3#QO+B&9JJ!,Z"OS<5;OI5_@CR/OD$X*5E'2-J<?QCZ?V
M\\\\\\\\\\\\]2&@.;#BJ^N>];[()08=B'419SG.@,=$O)-<@B6E14!!U61I
ME;5W$LH]DX>D$8N[A]8J3F$W$3LDN\48N\[,M+O>>>>>>>>>>>U0]6QTJX^3
M[XQ2302,I<-#*_[O:'99%`I=/!0?O8@#4,2%M#(KB81^-C:Q<^&2!A!M9V28
MJRB\:Y1;IJ;92U4U`\/\NO`J2^)>:7YWL`=*2N<^5&INJ9,GJ:PVCUW1IO(7
M5)TQ75]N"B!QHRJ^<G5J[D*P%;!V:C/XV3T=B;)+:8F]WD21M1R\-\;W*W.$
MIQ_<@];4-\1?8XIH\(N?;=EX2/ZB@!`*@YBMX*JXT5CX."Z<)IL68$X%TF9*
M:H)`XQ/M*LDBO!/)2T!:2"D7IG9+T9[>YXZZNAMT!R_\>)#PV8A577KJ5#A[
M6PFPFKA`GMH0\/"27(]N-.@F:=HV&?6G/U=H5U\\C]2HGD(44BX3-HZFHJCP
M8O\`EZA^D.7S9P!6=\@%1VO'K"M!65)ZV2$$U?\`&FU?$H@0U:/8DS>'@^DQ
MDH,C9L*RTE@(D8(O,K+91$6M*NWVVGI.XJUJ`$99M%]9\*.V+/XK-`CJP&ML
MNF!R6(HB:<M962EZ>%R@AK>,^D8X:-K$D4HF&A9QU#MLS;&1D(W[S1'%<M6M
M7]=?'6O<^ULV;R1RGW5TK.Q+,BARIO<P]SB;5?==<\?6Y>42,,1PYEGU=$)B
MU9FTY(1.INU$3R-/+7B&CN-L#>,OMPV:6;2H7M4IY"WH<C]M=,=9J<2+F(]9
MA2\%>8Q%HJ=U7`7K:A/'3,U6</)*-R:'IF3N>0P320*\KX<W_%33;$<C0'X^
M.<IQS8@PVEZT>+`75G,=^PWR*\GV!51&$USQU<=A3K&;.J_YLWGV;-L$5=>)
MB1&0M8%4@TY,C%OMQ`1Z-B7.VV[Z?EY]N>@[`JNF^E;0Y!`CA2;IXD0?UM^K
M]2JRK2MFZ8=O7-&V;TME$U6EY$V<<[\V#,M5/+H\\AY=A,RXC/E#(<*$WH%)
MR-M.>B3KNS.*.C\)/I1M;FA7V.&\=6'8<7H/$IA7D01G,)R?9I['OHB$^[7D
MFNHZZQ-/QR)6)AJ/B"^19N%IMQ(/Z$\\5SDW+N#K&"ZD-JZU$N0[JK+Y/@RQ
M*V*(1P52.:Q"VD,`7?%$PZDC=%OL^C4"DQ%B]ND:2DV*/K)*V!`]%[*8N22]
M/PM5SO5GQ?\`%P;*UO(U4;P]#@4;9PB0`<C7)@RLB(A6T,5Y-!R:AX.<U)L/
M(_1!Z_F&674@B@U<).G3/9LOMM'\\\\\\\\\\\\]QG'UQG']\9Q_S]1$<^/"
MB(RE.G^?BYZ<VI6G6]G6Y;=K11[*#^CU(ONN62GS-80E`@6#'8TW;$#9E/":
MB6SJ6$IA@R?0\LDJU1SI\;KXYZ,+1+HB"N*3.[L*NHX&M1:V;1.)F+CCYR.T
MGILO2D:*N`>#$Q\*VJPF7D;&%WXW`,G^UGS<X;RB\@_?IH-9HI#F83I,HN"S
M-B$HL:X;YE!&3MFU3;]/(DA4TKH7T#Z_&T(H.@180'1</@?S#$1!C@[&M=IL
MA*29_P#C)TCE'JU4_C6CYV+*?DH9DA-J82^OR6W`X4G=8=A!848/Z*YHD(.(
M_+8Q59IIL+P3J,%=WN-_Q4QO"[3,AHE(R#M+39_Y[TX<(;;X2PKIE3.NV^$_
MM8^\^QIO]WOMG3_?QKHI_P!GOMG&-=5/IIMG&V<8SB9C8817X@9GQH4P@V&5
MW`S1.<DDJ_0;10I`CL6M-S<G.NMMOL1S:,B6ZS]UES]C=-MI]Y]C.-M/M=!$
MV%,3QP/1$*`STA6I'6*A\SN727%FXNG,*R\(VAP)87=S"%B9G9P>EURQI+)"
MVXLTCHIW&RLPQG7$=&NY&1?LG&BRB#MNNF@LJV74163531<(;_=K(*[Z;;:)
MK(J?X%DM\Z[I;YQJIKKG.,>PT^M&OZO@V)&?E<0+PLF7!X#&O9)Q]C61-#\K
MBP<-&&"26JJ[R;(2R:C(2/CVR2KC=XY^F^B:2+A1+-M73;=PHTU71V=(Z)JJ
MM\*:97236RKA%11'&WWFB:N45L);[:XT4RDIC3.WV-_I6:`Z>A9SKNU>1]P\
M@BB"KJ+IJ]U35^^@MQLF'[F-[2`X>.A&;)\ZF6SZ(FZHGD)+,XWC-G"BS7$8
MU=M=]'JUE]GK35TFQV<H:O5DE%TFF5=,.54$MM-%5TT,[?>J(I[J::*+::93
M3WWUUWVUVVQC-7^D>J!_G`DYJ')@1GRI7I'H\(YQC7T%(#[9L$39V,G9-"DQ
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M;QMT["=C\[`_0XZ($('%&TG8D4F)%;N&?$,*[KJSS2KY1"3=#SN0A%5UI4*>
MN]/RQ^^::(.$DTWCK[&5U+/^>JO>=74L<7=QL:V18'Z3L6GKCL$PH$5_4PY"
M_P!33X@YVMNO"D9_)IAFXERW\FJDL.37\I%G#&58?IS\_>KJP45)M5[48_C'
MT_MYYYYYYYYYYYY[7IS/_7#_`&W_`))OU_\`U._I%^M.5_Z"?JS]2_T^_*?]
MF<=_J-_2K\U_\`_`?K_\=^L?TM_V'ZL_%?G'_BOWGMA?GGGGGGGGGN/M:_3.
M?KCZ8^N,Y^N/IC./YQG/^7T_S^O\>]>ZJ*?W>5%=-/O=\)I_:4QK]YOG7;;&
MFF/M8^WOMKIOG&NOUVSC7.<8SC&?I@0!:8#:*9@J!D;8AT`#\KJXORW;R37\
MD/`ATBR*!YSK),V6RSB*<KH:*.6F',<XU5T59/'*.WWGL_SC3Z8^N<8Q],Y_
MWOIC./I_/[9QC.,8S^W^6O[9Q]/V]X9V1PIHEG?3"N^FZFB>=\8W4T3SIC??
M&GVOJIJGE1/[6WTVQIE33ZYQG?7Z\J*))I[J[;8PGIKLIOOC.<XQKIKG?;/^
M'ZY_;77.<_3&<Y^GT^F?X]%]+795?1=:CMOTN91I_6Q;M.:CA9#:2+>/ELC9
M',",UEKI),XY]G1B10$O&;J*M$TUE66ZK?99MNBNI*?^#;&<8SC.,9S]?LY_
MW<_Y_OC/UUS_`#^_[9]%8W=M5EUKV91PV91LM:U-P=?DEEAC9*1Q(B,):J1&
MO7[^3769)1JFA.B)$:K!)F^>.-$XM91XDUPHWRM*F,:XS^WT^O\`&,?7Z_3&
M,?QKKG/TUQ]/I]<:XQ]?V^O^7F/LYQG.,XSK]<_7/U^N/K]?W_?Z_P!_^7\?
MY>BRL[LJNX)&TH>M#*-+9&E;-E*<M%M')2.FPA9D-`#I1*",BH_9-$EY-E`E
MH[(N-X]1\RU3E$$L.]G&BZ*,I_X=<9S]<8Q_?.W[8QGZ8^F,YS]-<?Q^V/IC
MZ_3W/UUQ]/KG&/KGZ8^N?YSG^,8^N?W_`-,>BBZKRJGG8#=6==!I&`((SG!,
M:<D<LC(KM$YTY)XH-$XS",4QD7JCJ<)YN*AF6J;7?3+MZCA;=)+[:NDKXSC.
M/KC/UQ]<X_\`/7.=<X_\LXSCW/GGGGGGGGGGGF<XQCZY_;&/>.-]<XSGZYQ]
M/Y^UC.N<?ZXVQC/TS_EGZ?3/^7O';;&VFWT_;/T_SQG'V<_Y;9QG&,XQKGZ;
M?7Z?MC'UQ[53\6R(VWE/DE2$P1S6L'CY.KYV2$78RS$%D)-6I.>%2(@Q`L-M
MFJ2!T2;RYZSE-,X5)&9.@3.M='4POIKM:]ZUM==T\Z;8QMKOG73;7;&,Z[:*
M;8TWUSC/[9QMKMG7./[9]^0_CFF0\P@./CKGP),-.O:2^5SM1>P[,AQTTTD6
M'&@YU+UPSL^M"*Q9]ND,RE-%X.W%`4$"D21>"7NR0AEHIDT(8L\E(^'4ZD-[
M:JN\A"O>7[H@HSHCX#>I`].I9^D;L>RJG6(79BD\`UQ=EC62+M,V_P!8@DE.
M3VB=J%:$"Z)S&1?.ZST6UDT\K7OM6LKPD+<F)GCFK;#K\G(O@,MBM:K=:UL;
M4_#LKY4M0/(`FN%'1"-0$-6ELR\<U*7X_'$+:"*(C=WJ2/V;9LEAQK`]XU=7
M%T<1]06/S74G?K,JLIMPR(G%0V7SD0T=D?L2KNH:[(Y5F,5"$4;5<^2W+6-9
M:$\/:%_`K4E&W8'!C\$M8<_O`(:PW;7]RQJQ-^ZP\%Y@+)/G<'^4CXC>E0H$
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M]3.Y-A#HE5T3=!CQUO5?+%VCUE2/Q(_(7SGTV[L/GVT`V8:]+3PES:M'@UY6
M`:BL8.RI^0V3%6K*,#>;(G[`WD9+\\B"N9:ST,LXC%VSZMLFN@:;YCIOIUI9
MH_\``;7]'F[Z9J&Y:;FC.Z:NO*@E+FI..+C87&'NMQ/JP$[H"P8DPY1</IV3
MW5KHFE'6JCEM<VU)>N96K&W1O'7+O9(1SA+=:<XF'8P:/4&?A!-/5^*T]8E=
M3$O4O%MO!4EDC94:=.Z,)KTT$*1DH6U<A4E)#JEBRH&\D4.Z"Q$"J&Q.,';Z
MN.I;%^-RP2#M`AC8FY:1-Y]G7G0]OSM2/:1G2CFL=J^`DJ5YSE1W;HH?HH:,
M:=&8NN2H_4V?0XBS*PC="\_PBA<U6_QJ4-7Y``'-7R(@2="1:(-8H:6`I/!0
M3CI:X)D127@S./CIK+%T'RL`^BY'?1RVD6#I!P@^=9RIOC;!YZEO1_.AK;_1
M7`MMC<D-,ASEF^[2M(_9S+N20F):`-N5+RHV*:":#.*?-'LJ@5V9!/WZ$J]A
MVJ<"UE'*#QP^1:QSNZ./VQC']L8]SYYYYYYYYYYYZD-`=)G%J=<]ZT(018PT
M$.72SG."`9&)9R:!!+-+=H"#M0C4*W3N6>Q[UPR()-=I#[149#IMXG5)!XF^
M=XV>[W>\\\\\\\\]K9^6^YK8Y\X.M>X*3L16KK$$2VA6\678A!8A9-(PSZ$J
MRO2=M+QA;%R<<K$.Q@NF$WJK12'EVN-4W,9/1"Z7XK%!SV\>C*'Z8Z(Y5)>R
MK"-@DAL?X^92E3.5K^H96[TCGITYO1I:7$XT0#T15@"-/3H/I+]<@5EET3O(
M4D`DTDLHYGY)P$N=(#K^]+CO4M^*]]:'0AHTR$_+#\EO.9#.0A4$MF!N)T!7
M/:<74[FQG[418B9J5Q@X!#PTF2ICT&A-,I*6(F4*S*YM(A;2;!=Y=`M)6-JZ
MQ+=8MQZR?EQ[VY#;W(=D(U3K>##:;@B^<H6D6]AB=;R<$&$!F]A](`>)-@]8
MF)'`VJ.MY+8G*$G^V<(E?9)5<O$O-<YWO).F-J<W?).]L.W><!FHU5"N8YUM
MGGX=IPNB24YJ:9CMK'$H2QY4/LJ?@AMM7Q400\X^'PL8>R&58JIM"=-]&W98
MW+'2!#T4U#+7//\`H]I?=#74VE(`7YZ_K\[M&LXE8U)AE$:DV\!$$)"K#DQU
M(0#5=RS1@H=NT:J"4-@5>[G?CNO4RM&-O4!MIA>03=5,6($CMBT]>SZOC25K
M-4BJ\.GHC^G]U5?&18E>-5GGV)0\%CQ9HP*$'TW.C)#`"?Y)'B\3H^X@O&VN
M7ZC^/<DQTI+#%'WDA\P499@.:!@D2U)5T7SV7]07P)V[$,!T98VQ)$@W*"\F
MN:-]SV49F`R]=0D?`P[EG#*-I/\`^L5Z/HD9ZA5E+LE[`@HCACXV>@1VRK6A
M:Y7F0"8ZRZ'-J"N#IG8+"$MH0!K*'`4H'HW%-E4\9P==Q4&CI(RL5"RDY!)7
MXXT@=1#Y9ODI'M[:)K9^WRC\:\K&21I*BLL1Q4<O*=F95BOQHQ#P6C^-4<KZ
M%39=^P4=-OUCJT:N=!W`XP95KO/I[JFJB+Y@+T;])GKL(X6NFKP^N:EW"ZH6
MKH;KR[.8^7BDX-[!<1U6R5ASL10+RU3&X1=1A-,W*20U)HG>;!A'.T4VS@NZ
M7N^I)D8$7_7=8&-/]3=?\GU('6""F$);QES`"7*`VP4D>)BYW00)!$NRZ!*:
MQ#0JA'1`%R,N#2UQ/=FLJ0,E:U;QU7*IMFS><[XNV'!;XGI-J<?](^`Z%M>6
M(]*[F'AI5%E\!TZZW#"]UL,X38O8*?%!L7A"6"U&RYR\&\-I:4DYE_._F$@5
M#WU:%C7$!<\61U$['ZKM/NWY5J<'N@8A>M(`A>0_*<G7^.<Z$AK!9C3<*8RA
M+!'):8-B)>.7,32/J+]/[/Y/6:FUG.6$74G0900R?-,%WW2<98E<\'U'?59]
M8$2XU3`;T,:KV!<@Q970*%9-`ZS!&R:K$'M9!@Z=U@,E@\/9C3Y\30LVT3+0
M*4$X/^0J\#?H;D_Y%7I];[\%D>4>QN&Z/3I&!U&AX2F!)[8/%]B[V`4PA1%R
M)T]B;YG[%)R.MYI4@CEH,2!Q6)'G.\DRLK<J_5&G^VN?K_\`O%?_`(J[YQ_S
MQG&<?WQG&?>SSSSSSSSSSSSU'OD>=W\PXVM]]S1"%Q+:#/:O72X_7F^J=D3-
M6H6D$JWU&5G]%$72EE/:+UL5L`(Q2Z$^N5JQ20VKH0[Q>?:.ND.C".L'7?%2
M<>E5D5O2I4S^(D3C)!Y!'X-*\]V?W9TM.4K=?].8*P(P=,J\?$_.2(`;+-&C
M6#7$;+)=#=FI"FA#(N)#:'RG./JP^1+NGD,45D=:'"*-X\O^O1)5\]DXJL"R
MVU[T`+''8!>06?OH^&,M*=%SC2"_'),6Y2Y,"!HP_&$TP[<Y3\;K8F:%OR4(
M%\M"3<[CY*;:54D1V`>C$5O%.:#YC<C+1.'D2`H=IOHH76AHF:D-II9&=FV,
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MNV/KC;7.-L9S]?K[SQKC'[8^O[_\<_7_`$^OU^OTQ]?VQ_&/K^V/<YQC_/\`
MU_G/[?\`'^?V_P#+V#6'9`-5(]L5'Q$R'8?+^.AV:CG#MV]EIR8<89PH\/PL
M:W?3)$23;S;#.%'1^-DIR7=;8:QK!TMG[OWS55;%:7E7@K;-/G0Q9-;'$9B7
M%#8-F6LX.SC##A=DLHRD62FZ65F4@T>1DDS4^Z>Q<JR?1<BW:R#-TV2D#.-/
MKC&?][/[XQ]K/US]/Y^F/K_;/^+_`-['^]]<8]&\E;]6Q%J#-(R9V,L[=,A`
MD/QBN5I1+!;,A0@_B8LE*F4+KG9QM`Q$E/1#![)[Z)ML/9!LVTW46VSIK)7_
M`/+_`(Y_^7N/IK_O?M_S_;]_K]?IC^,9S]<_7./WS_G]?<8QIC;[.,_XLXSG
M[.<YS_A^OT_;&<Y^FN,_MC&/VU^N?IC'US]8)->GN<JUM:OZ*/[OJP,N*UE$
MT*YK,G.("&-31PXR]U8MA\?D'R+^1=2BD;)H0S9-+\1-+QDBVATWR[!TDCW9
M%?%+B-BCU1DUFA<'918G&JP`7)D#)L0R/YVM+-A[1-FJKA1!P2N1\@;"K=WN
MW<D[D?GFPZE)KPLFFT]XS>-.&5@EU3BMEA)!9($ENN7A421QSTE@$T5F+=[M
M(1J"^SG3,8ZDXEI-:Z85WA7DM$LYK5BZE&"+G,QPN%RS\]P,3D9.8&2*4$9[
M:+=IO$XLFA/P^)B#=JI9V33DHI1RBWD6N-]E&3K.[-SA)T@NBEDGGJ!]6?UI
M_P!J7XTOZ;_U)_IU_M*7%_7W]&_J/]'_`*!_V,>B?TM_5?\`)_\`PC]*?U6_
M0WY%^J?_``K]>?IC\%_X[^6>OWC^,?7^V/<^>>>>>>>>>>>J;35K4>8]*=B5
MO7]=_IBW:@(Z/CK[.?TL,Q']2Y8VIJ(,:Y>_J**>KSY;^E*_=L1C\04M&*\+
M^&_*(?1Q%))K[6R\\\\\\\\]2_Y`N5)'MGE8_P"9X\Q@0/6PIFM7TB1DH6YL
M"'3C*]M$-LYQ$O!-`C%-)9N2*AC<<>HN9MLW3C95\ONB\V3T:JR;ORSSE)U\
MYK*?H&E90'F2.)-Y\(<5B*/`N1.H1RQ?QA2M`2$0LR6F8-_&QZ@Y+NT=Y2&0
MC(I".=-TH]KHEW47SASU!LLQ</1=/1<=O:"MVY81]8A35EFY5?M_>6S^&0@]
M4-+*VQOMK^N<::D^-<YTTE-=,_9]\)#RWS06@9I5A3SW2))6=CD+DNL*O9ZJ
M@67"#HL>/$I%V4&`L_@EX0D)'4@@@_<STPR>2Z[U!%VJ]W<):*Z]RAS[0[98
M1<-J6J=LX``AY68(NWKL006"ZXD&6D;(5^)*HP^B@V$OXY--@]%(;9E`O&::
M;9RP513TTUZ[;F?G+:!'A;:@J6W&!$3*P(4'-ZL!=H(8!CQOJT-PL=B=H'+"
M#$C%IKJU*1J+;M(4A;:X;R[%XCC&GLO!:LK.KH!T*5T!"(,-/G2SUY`B8[&0
M<6[=.6K>/5<.F48U01<*YCVC.-UW7UWRC&,F<>E]VQ9MD$<0C>9N<H9`2:Q%
M!TO%-0')3L"MHVK@=BW"LG*3A$UR)(-H))(;_6*+MTB5_DVC+]1I.G*4S^.T
M<+:[]()<A<I@;99D$\U4()-'%;/:;<-1RH0"';KU'(R#N6D*M718CZ*:U=OY
M-\\D'H4KKN-NG;E99>-4VW]W]5\W\]T<NJZI>C:CJ=VJ.Q`>N[KFN!$*>+B@
M^NY<P(RL\'X>.=KCT(X>O%HB'474C8Y1TXW9MT=E-LYR2*IZI8*3L";@ZPKV
M&F;8WRK:,M%!8VPDK)5V9J1V53Y\UC4G)DKF/558?>$:LGM^"449_7\-OLEF
M.H3C[D\9IV?YY&^9:`'J$*GSR4)J4@Z=KV(J<@DY!TU?/I*9KV/'FXI)2#MZ
MQ8O%GSR*6=[.F+)?"VJK-KLB=<?\H/@DLK5[S103RO#V9'B(Y!G5/U\Y$C(@
M$L1F!>=+!]4>VC"*9',0L/B$E)AL\?Q?Y7'_`()PA^$1^SP5<@\GG8#,U.;<
MRT`7U@1%VM@$%=$U-5Y.`LX=I[?;T-)86DAQQ`R)9IMGZZ$+IDK+Z8^J>CO5
M+ZI^[LZYHYQM):LG%E4)3%@N*4?LI:G5S>K`@I5JJ3C=&2<?)5LI.P+W8)>,
M4XV-T:.!C,;LVUCX_".=/P33[KX3OE/F"TRU_8%E\[TA8)O*P,6+RI><50"E
M1+*#<'+(3L)`2DS/0+^1DH>&FFR,M$1KY9PUC)#7\4P205WWVWGU---)/1)+
M31-)/35---/37333337&NFFFFN-==-=-<8UUUUQC&NN,8QC&,8Q[S\\\\\\\
M\\\\]TY!'2$M"R4;%S3H<D'K7=NTG63*,D7D4KO],8>-64TT?Q+APECZY23D
M6+QG]O[.5VJ^F,I;5,D>#^>IZB+@H$H@ILI@+_GW9O<II-3RVUH6!9BSV#DX
MRT9@TCT(]PV-Q&1%`Y>OG,,RBX.NV86'#P3`P0L,0\&U[RMN0ZZ!%.@)XCEB
MBU;"ZB0AXZ]+&-W$3'$9L.BX0K70@(HM`"(#!X4%185=RR,3%B,/"83FB,I*
MG#A8B(9&1WUB\,W5R!P927R3GYD6,.=.8:E^1VUQEJ_LY$\@UXAPWISFZ&6B
MF<4=MG=D$3\@*DI5<1:MF$Q(&46[CYD12E!R0BG:NT;DOM7EKNFMG%N<G72(
M74`L9MP-2LN,*2+9[`D+9JU?*P9*.S\?#DHW+98/6<@BQG(=@NZCG;:0::KL
MG"2^\,_+7^WQ9?)#G]\9_P!A/K'Z9Q]?KC/]"SCZ9^N/X^F?W^O^7\Y_;VM_
MJ:YK4RT[<YR?&.CJE$_^CW%%[0P@H.#Z*T#8LK$7+7$W,ZDS.+P5R360'AR-
MQ^3OI)S&LG&BZ[%CHX7WW]%0WVG=K+XHNT[LKBXY^H;NXSY*KN$@N;R4#J><
MD*3?@U&"98&6F3J2PU/K6/%],B_V38((&1#,U8R#W>H]!MGAZ)G#I"0.\.K^
MRJU-OE((JLZ1D@,7X?XFY"ZXK$#:U74)!%D1>5/.C-K`!3F;*0V8(W]>'\?3
MK-O-I0\A"&42]D6ST1,1MI$.HJ<L3;?07;Y5?_3-94"X71):QZ`X5$:H@6`6
M-F-9N*#N,6"2/I4JMPG<Z:JBUC!$)-6671\!+SL%,1D.)4F\@1<CB[2<(%5K
M^JKW,@SH3B+F.&(94$B^J26\XLAM>%90F\\U=4O3CJQX>NQ18BA)\:B"^RE]
M'\ND[>0DH[3$`(U8C[5I,NF<W#ZE#*R.@;M+^`A.U[3*6I%1'SEWKRVSLP0'
M:ZAF]U"U5<L=82@1;\I`28).#34^C8[96O#-E`LFU?[G,,>RL8'Q;W0?2%-N
M/6)G)U]*<LTO5]F*U'+71;I=")A=9!@<[M>RX:!JFPK`)8VM90S8N:OKK`_.
M(QMFV6=&,(_26$H:<'8)!P:%\,@\U1<@]%7OU1>/PH7#9MPDK*1MKA'N4VLL
M4%&@3#U\<G=6V/S($MBV0@%15]A*6+XDHDDYA:$?1S>(T5V0KI(*:2LXC,6O
M[ZL2:J'Y!>4;5&QM<R(:S^.+Y<[!@P]LFZ6<%<R%?[%!-%#;=)EG#M5><?1:
M,6DFUSASMN[QHAG"NR?H;8=2=3LJ!5Z0>]K<Z,*AO7E.F#6N)E)II>%@05TG
M]OU+7R!-4`4)T]4S#8/L+6SU:M@:^L!_8:@C?"E?8>D#@=3L&/<>8QUMV<]"
MNDAL=:V-<D[SI\F$]1[T,&"/FH:Z[+^:(SE*O.@)48KE>?CVE"V/=%>E=@86
ME1IK^4RA=50S.#<88J'+34DF.PXXND@OSY':N.XWI*S;1K6?^(ZH;#9QY`)"
MM=0\\9S/2MA5^;3,]6:@/&2H&92TP&,'!K#QSN-?1I:/ZCC5UH'1;(<UL+\N
M`Z1L:`C;+!:_JNRQFI^C^:;WO^KI=*1AK+MR,J*T0";!QNL3>#54P/6BU(V0
M>_&6<[#S&3>/B_Z;Q^8E$MW?ZZH.L%"UMR[_`-(O<RBBNG2KGOCG=C3*:>SG
M)0IIBN.&L<.:#::&,.]TU3Y=383U89W;Y)M2+.^N%]);.=ABG'!Q1'3T).5K
M;K66L0\*N\IJC8)J)K*RU8Q'>%YU!>/3]RVN^DR16"*A'GF6"(N!I>$:C\0@
M7%9P#AY)NEMNH_UD?XRNX!6[W$51@Q4CRN1'//T9T?3[]6?>$D[,5D0]!752
MDAO<:SZ(B\QUU3QE6+ZR"M9F\GVTX].YA%Q)+2PW(RL]N&\]2WH_HLUJ#HK@
M6I!N-&GHYU-?=I5:?O)EI)+S$3`!/*EY7E%.Q-=G*L6C*57*ZS@F#]>593#5
M2!=2C9!FW?+-9%I=''[XQG^^,>Y\\\\\\\\\\\]4VFJIH\.Z4[$LBO[$_4]N
MV^1T?(WV#?JD9E_Z:2P3340'5RR_3L4R0GQ+]5U^T8D_X<I=OEYK\3^;P^[>
M*530UMEYYYYYYYY[4]V&N_9?)9\0ZD>_DVWYL8]N0LDQ1F95I$2K%OR02SC-
M"5B4'.8I_LTEV;=XT>/8UV\8*:[Y9JI:*+)JZP2[K^I`B$^*;JTP&%><:V%?
MD<^4(3/Q*/M(ULV%UFH(*[UK^=VW(2;6`TG4+'N@3BB6`0GH>$&@-X1,HR/4
M$Q2*<.VVT\UNLT9=,_&4'WOST#QMMW5+]/N(:6#K[-IN*HHF$.=9XI>PWX1N
M""T#;J98)[O!J7EYIDWAA25UVE!:(GEDHX@UA+F3Y6K;N,GY#=6-S.*`]:=C
M-^PAL%?`EOSMEV&/V9Q].6(H1QDL'NJK#8R3$3H4KR84$):)(-B;]1-V[.7%
M8UK+M]6$S\F_([.=.6+S6)LZFA&0YTUQV][1C"2#L/>;<50(-C$?"-:QL:(P
M+:?;L7,R70;'51%]`1J\W`VN/HL\O*T65G^YZ$[Z,*YT[-(:EJ:(LT4^/6#'
M2+I&/EC%P,&1*F]J>*OXQ'*<:-(6;B'Q&%4?/P9>SV,'<3&&17(HU\U6'_NG
MA<TJV,ML]V?)#T**6,QB"SG:M>7?CRO&@Y.%L:R@D[KJ0L4YZ-LZ%LD!<#$8
M./QLX/9:NA:)L55H21BZ]>CT4%/)`H&YHF&MK)=>?((<<IVDTB9:GQQ[53$Y
MY/#W<S(62TTLJP&G4%U,*1FRFMP&`CYY6&'J.(B,1<3\K:JX=!V(]EY,6#YI
MA)P>CF5RS@+HF^K^+.]6UQ-`!K"T;W%:]"5GH&/9A1PQ#P$(JM]&1\FWDX-C
MAVNJD29GI*?4D5W$D1SDXR;1,/`1D*BI3"ANE,<XV?\`(;!IQA(9$5N_,@O1
M=4PRVYF8H0TJ0<"\Z7>3O-HR(0)S!8;'!X7L8M2%1&-4W>2BB$-&)0C.0<RL
M7,QW\AW3812*)Z0\DQ]=%4'_`+4N2=2W;!D0L0*?]G:$8$]?YJ0=4&5;O*T.
MGQEW(3P;N[K)M)U-&!I^O9$([S`0VI3W4#\HD69VQRS7<2,"%?*]24IS7>%;
MQ%X%\P`2]I#E\+H2!I`T>6(BLK6%A630@@II.EE5ZE#8Y*]WS12%BHJ!PTG)
M>5?C5OV_>BJPO4MOY,#3FA#L?KFF!K``[EMXUL+T;?AU4T?%[-9:#B'.B;!F
M(M?P<NL]?OR#9TZEI!K`JJ)PS?6(R/+IXRZ!Z2L/K*EY-YU$:\Q]F7]S?>-4
M==])7+S#<#:FH38_DJ,D.8K">CH505G@0'K7+(==P%9R$,<#$26/H,NP3*%*
M$W"+]7IV%J7XY*_YNM0QUZ1^4#XJ>P-K/L>=+YG34GZE;\R57T)6?0LK(/'K
M](.*X6QSTV`HHKA]6>HP'GX^.,\Z0=>U]#0EP(8V,>>ZTZ'J>U%CVEZ>.KVV
ML2,%4YK8TLKFWDFS8RH*8K^C!^0%B(S8Q]R]9=.MK''*;'X,ND516`.2XV:3
M<)+C,=&([H*$MZNKMK:/,*Q5<I#\9.&5=24#)1V\-.A1K4Q=-5F?U^1PJBBV
M\20`AD*S0O*M-%W;/9>,_%Q<A)Q+IA).YF\\\\\\\\\\\\\]X*?[F_U_C[.?
MK]/Y^S]/\7T_X_3Z_3Z_M]?I]?V]^2_JOXO;4^67D_Y(^=D+*`ZPN<.^80QN
M4)EMFA.ZK*:W&>:*4%A<9*5=4'I1%:R5<FK1><FXR+F<1INR<;QD2\@%4M=.
MQ^'GX;_D>^&ZHK%?U_:G(M_'%Q%,!/6O09,G;@4+N(P$BI9@*9J_I=E%R;\<
M*G+>=F4YMJ9<X$@O)*;P[9O+0*;!W*N]L1'\@7.<Y!R=%_(S19KR"@>LTP\D
M'NO1`>G>5[(2F$-]7HY&=-B;TTY@+(>7UQAJF+'AF%%<TV<:M9$";**N&"=U
MMN<>73EJX(=Z>J`M9FM/1],.YS<5&YUL6T+G31Y&U<XE/N':!!4ZFBGXML'[
MN'@DM^(5<Z,%,N5MU?AEN,>2I[68UF^;*1E]"*L8*E"+63K45?:D5-BV=-AF
MII_5S&J8FZT'=M,9@@64P[&(C.=_R^+;_>*?:[,@Y-YE+,6!@HH2I2/-KB`Q
M7]H9GP0>F?ZC@H3]G]'!AYB19.<%XH*_3?(\.D'YA$1'W[K\"T0_%NOOM7%M
M_#TQN'I([LXZCN+#\)-R:,GX`X/N/EWG8-)PD*%B(/``E57P+VZ+C:C(&8"#
M>1J4Q**\?$U;2T@N^W0+731!=;;]9E,U;<PM'AMK`P[8(_$3<(3P[,K8:2ZL
M*5#2V7`\6PD@XSF3A2V$<;;N(HHB7C&>8+JKJM9!'9PO]YT<ESC0DPSK5A*T
M[7$DSIN?U+*F;O1&&<IUL6:?C/H6!&%&NV1HISB2D]5"2)RUFU=966U5?[XE
M)##GM+0HRG+KR%;6W6018RE<&#(_`E3$<C9U8/,V#-Y&H$8ZL^055BI3:+D9
M&)=+M-T\/XB0?Q3_`$=1SQPV4Q(-Y,Y@KUC6D:$<]TP+,Z9FRXEJ1&$K418X
MK(@/W"[LWF@)1*)PL)RA8X<*JD+V#49.);.4\/-U=4&^$I"E:GK.<L05MR8`
MQ.3M$&A9P<"["?0<>Y,A,?)]FVQ-!CI$JCM*0\.1[L8_>?C6#A!G-;QT;M)(
MNMHYEE"`H/X_^'QD0N0`&^2>=AX)Z$?(2=VBL%403#P-GR#1YB38/#&-CH=L
MVEUXR6^U-1.ZNFOY1.**S<7AI++*O=^TSPYR!C69RWYNIQ@Z(#(>L66DXL%A
M8F;=6"*!J]>#AW^?1;=G-(&4,#NWXJP*&K]"<0@Y.588?92EI+\7*<51-*01
M($&4-4=:Q1?68:[KNNRF/!QIH1@P$_V;;O@L2FT(W23'A9YNS:[NH&+=-8Q?
M=!/=1MMO]K.V*K\I<W.;J?\`1CBD:U6O*52'=)2T%12,W,)-409_EHD_D939
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MRU[PYPOR<(#&,,.7IBR9NO8V#>0*(W)/;5`W=;E7ZM920[*24FAD6?.F\8G%
MR\'ED\5_';;N%4T\:U;C/BMYY:#%*A4R1V4:!M(W+U!=T0*&JM;3PZ:$77\?
M<,3=@Y8\5O6C=L2@LS%WW:L?&#K76'WCFI-IHK(/MH:&W8Y)6OQR5S6FO'/X
M>Y>@S)?AC-E-J*?V$6!)3+I05E@3RL7(P:S2E<M)8PAA('>J0`4L^>HST:T0
M8XEYN>V8MLZ8-$_&B"TX"T!O3A=9Q(;\8Z=5F?.L,<&@G!P9+8G34(?Y)V-H
M$HS6",TC`.YD[F&L;)BC6(D1-E(_CVR4L\BH_72M'QE<U=74N2`"!4X[5K8%
M&090?M:M^I3;X_;*KLFETAY1)CFHBGF0+<WL42K4^?."K:S;I/8U[*CZDXU)
M!\E+2Q:2@;Y6/P%5-AV9>UA)E=C!L?U97PU6O4]?"<K`(!M[0`C!/PZ#?$.T
ML-RQ2*%.:\DWU8S)-7)*(R)!7RC*&E<K2,`,3<))M?<J`=9]%VITD,3Q:W([
M<JZGZ?GPC.1-"N(@-HEV=NZT1%X>.$F$[$O83-E&39954F?,W[.30;KL,:Q4
M7EI6B_OBYJ7H$VO<SE[@Z`!M>B)CEPO/AP")0)"!1L+D$O@BZFSP=R5UN63$
M3(L5AR)CYT9WEGE>SB;769<A^I/LK-*VEI#F`!H`TZ",@.7-=M>D+9>W::BL
MY.M9,4A[%FQD8&"J:$&2<0SDXS0L;"$&^EV<I,3C9M(-ULCVD''N5X_>LUC?
M%W1ME0-ZQ\E8%XCI-=74PQVA%66%&(Z,6)1O1H:`B=7#A]24XQ"_PD)^"K\,
MBA9U!FD8=PTU$.R!E-M9!`BE=%O(C^,ZOBY2O94EOOI>=-12I>BZ4.;"ES($
MD2Z[03J)F'H6BWL'=S6F\`.RF'=?ACT/E:9@:K6"6\$W'A[1H,J*Q.?3"_&)
M5K`%J"J""W+NL*IJ?@.58F*KL\>5A)PTA,\;R3"6ID\1?Q57P<^%'/XR&'TC
M:8K>6$&Y=&#\;&N&+/5:9<2]FJ+Y?".>F-SQ(`1G^T/=5RVU>DI%39"R?M0X
MWNXJFCRQ,`2C:$CWT1$S!R1SI6@UEGA`\C9*3V9L9!&#8Q42PQRH^2XH"S`2
M%GVY;'4Q8)A!!6PP:]"*5S+3D6$E:D9DHC5V%=UW7`I-S)2U@X6.*3.=&Y$N
MGXR.3C7DQJP<R39]A]`<`TUSV85^6C\P>%NM'U#-\_<WP!U.,9J%Y[I$DG8&
M=G`"O<-HB.DGFC],/`Q?<K-)`I-$@>OA`42(-6;::6GLML#C*J[.J>T*M,7Q
M7**6S9L)<1(>J23'<X;6.#GHK8-3D$2\<1;B&:I5#*`%?1@%!+PCJ`:#X9%Q
M4Q&S&KR<6E9'YZH(-YPKUP`!KJ8EL3![:-JEY,1*QZI`967=%B$EJV88S/Y1
M'0\.V>$AN634EI&PL3&0L,S5:0\/'M(Y@V1UG'SSSSSSSSSSST`]3=!C'*?/
M-N]$F4;)2XS405*&<Q'Q>4TEUVL?E%+&7+Y?7=K#1*"SE%S/$+W3>/'(-&1G
MI#39E&KZYIH=_)7$TD$]+3UO@D1+3O/@KSD1Q*-&'>MCA]M2_61')`]&UV)%
MTZ-A.(H]GSAK$1\C'SD=HP9AAH"6:F]5'B39G'6-H/IM_9MLWWSG8H?&`=[<
M\,ZJ(RZ&&R5\8!!&`W;!SLK71N%$\N-!<Q(QZ\P''@20,9,6C7$24A4GJDH_
MB)&)?N*O_%FX$'4G\DJP)+S4Z-Y^3R_$DI(AFBT@E=YMM4_/38P9*2IPY=DB
MC*(,D2"'AF:[C>)B(5A'0XKJB)L(-!/:Y[K)B%B""+D82=BX^9AI=FYCY6)E
M63:1BY-@\2R@Z92,<]279OVCE';9%=L[06062VV343VTVSC.MZ5^,.L@*0D2
MKBBT+7X'+GCEY**P?/<M&.N=)N7=:ZXW7+.1;"CRGGIPFZWU^LG)`@?6QL[Q
MNKNV-6#K?#K7X=K[^0?F_.[?HKF.#ZUKUCA?.UX<)J;1=AH1[?[I).1-N-[B
M+,$B2OV/MN'25&7==TP_6^UI%`C7&R37%F^>^U^7^HW,S#TO;H\0FPOA3!G4
M\XWF`"[@%1)31)1*P:/L*,%K:!E,+;X2TR3AL8@OOC.6JZ^GTWS:;&<;8^N,
MXSCZYQ^V?K],X_G&?[9Q_GC^<>Y\\\\\\\\\\\\\]5>\ZNI8XN[C8ULBP/TG
M8M/7'8)A0(K^IAR%_J:?$'.UMUX4C/Y-,,W$N6_DU4EAR:_E(LX8RK#].?G[
MU=6"BI-JO:C'\8^G]O////////////4`YN8WNW[5^1EY8F+)Q3<@9<O;\]Y*
M7,XJ!YB&W-P\WLO^E[>064B&K'%B:O\`!=K`I()+%7XI62PI(9W4S?\`\\\\
M\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]4WNAAT#*\EWE&<N1T7+WA(!BC$
M0B91(<<;2K-W*1C<TC(-`RT4"UC.0`%"IF!)&J>X6H;K#VA=KD=S)8]I0=_'
M?8Z?,W4=,\C!!V(<TC%N\4=8<:\Y78W<A1*,W51=P05U=%4Z+R1FJ\+V54GL
M:!A$)7&#^82A1:TIPR9"\PSJ:.AE6^PZ@*PMR?["[I[BVKM^(Q]H4GSI0?/`
M%::[VOR(K2HB,MLY(BP_8(115,`0^1V9<.`:%<N89X0)0P5-%F@G(1<J-K35
M6>;^H;5H>'[)<D5#Q)WU)>ORPE]-U]0=4VQ^:@LA8KWDRAS=91Y>=@5_72D3
M7HM5E?DQ\9E\E5K::9-H=\/C(04D"\''2^Q+C+M%OU0XM02G0N"![)J!\)+S
M:(':([>=0G0)8S0@=US:507$,1D`T,0TG5$#*"=,YL5#S`8*PXCA9P:2:)0\
MS-7G\]QG&-L?3.,9Q_;.,9Q_RSZLG0_&?+_5K:(TOVF`ZP)8;4T6$#9=L]'[
M0`W.B^KG5]75MB+T?M"NY'"^NJNLB%%\$\QOKKG[[/TQCU6L\U]V\Y9PYY6Z
ML:]"@C3.N4>?>^]I<HE$&GXA192,!^R:ZB=KC@,:(X3;-WEWU_TP]V^N,*2K
M9/'VL4B[N^?EG\;]+-RGK'A;HNN[RFIN/'@:M-)P&*:;LQ[NDY?3\J#=2!+@
MF#MH,9BF^CM]#F(<&6JKO(1?V*PTC59&7B[@?$-\LM1?+KSL07=7`02582`)
MVYKNR:Q*96-('HY.9B(\BAY&()(MM'MB$9GX2224CI1:(@WNDG'S<8YBD\1R
M3Q[M>\\\\\\\\\\\]2WH_G0UM_HK@6VQN2&F0YRS?=I6D?LYEW)(3$M`&W*E
MY4;%-!-!G%/FCV50*[,@G[]"5>P[5.!:RCE!XX?(M8YW=''[8QC^V,>Y\\\\
M\\\\\\\]17GKHH_L_L/Y`J,)$!U,+YG+N;(2NEHR-<-9U=G:_/4#9Y1DF?J2
M+I"473)))PG%;MF,9JSB\)-54W:FN76]ZO//////////////////////////
M////////////Y_GW&-==<?377&N/[8QC&/[?QC]OX]X[8QKIMC7&,?M^VN,8
MQC.?\M<X_;ZXVS_ASC_/Z_3_`#]H@Y*YQJSJ*#[]@FEP6*Z<U]\O=L6K4W05
M;V)$O+-K:VQ6FJ-AI-V*EJT1/B<DB([3I[2DL$%@P4"BP)^<UN60,HD@Z^DI
M!OQ!PM!RY]<?)_4=WT[U?9I.\-+0N";85X3U7>LQLDBWB(6]N3`D5J6@)@6'
MVV'R$)(5`,4G;$4M-3\LSM7$N03KN3D*/[ZL?F]XP$/DIIUO1;51=%BS[!J!
M0BL3APB4<+H-F;HU,7S%*P>4Y-VJOIE_&]!P32LHM?;2/A+[-%L_>8V<0<]"
M$\/%D(Y+Q<_`SD>TEH6;A9!I*Q$Q%/T-'+&2BI-@LX8R,>\;*IN&KUDX7:N$
M5-%45=]-M=L]MYY[7O\`)!\97+_RE4<QHOIR()\10^4(FH0:@$X@,GX(4IQS
MR&7E!Z5>Q<W$N$9*&?NXN6A2"#FH.1;[MW"S#62C8E^PI7S;\+:7QIUNUB_B
M[Z(/:T*]'"\U8H7TPHWNZC>EYU)!9"->VI`0L<'$]4%+*/PR'(>P^=Y()_+H
M=FS4,@"TM6*;!:V@'\BD(*F0[2O<M<2/$UW$DLT&`Q^=$3$EYCO(C<_;T;LN
M>^GVS*%#2>6DM\(XBZRM&)IZ\W"CG1-"K7:&GX]79/KMC;^,_P`?SC.,XSC_
M`%QGZ9Q_YXQ]<?O_`![GSSSSSSSSSU`^K/ZT_P"U+\:7]-_ZD_TZ_P!I2XOZ
M^_HW]1_H_P#0/^QCT3^EOZK_`)/_`.$?I3^JWZ&_(OU3_P"%?KS],?@O_'?R
MSU^\?QCZ_P!L>Y\\\\\\\\\\\]4RF;IJD\Z5[%J<.KO],6119'1T5;YS^2#+
M#%ER-A4S$'@2]Q+Q2FT_/?I0.>M!C[TJ327COPWX"'QM%:);9MGYYYYYYYYY
MYYYYYYYYYYYYYYYYYYYYYYYYYZ".DK>?T94TM8L='"SY:.(`.&<.CPI>`P".
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M*A]YK:&D-U9&/=J[[/\`WS.V;5^V<,WK9!VT=(+-739RDFNW<MG">R2[=PBK
MKNDNW72WW3605UW253VVT4TVUVSC.L2:^.E[2,M(GGQOVQKQK/R$FZGR2A%!
M/%B<06=*.-]'#S8AYU_-QU6H9N541T3='?,9;3\PX<+JRI?#6#NBG'J>\>^1
MM.I9^,KCY#ZH<\3&4K*H#PM;LR6,SOBZUYARJX0CVM?].(QH['!<_-?A=E8V
MN>BQ:E3UZLOJP&(\RU1WD5-F[=R@[12<-EDUT%TDUD5D=]5$E45=<;I+)*:9
MVT425TVUW35TVV34TSC?3;;7.,Y]WGGL./Z\`[5#B.O+-#!:P@(OC'$*5A1L
M/Q)2*$T.ZUQJYBY\>G&CZ(EV"^N,84:OVBZ.?IC.-<;8QG&M//'O2W'FN)3X
M\K49E%31^<*+<)=4%120U,QC$<(*+17-G0>&Q3<'.;Q31NLE$"1@A=]&1_XE
M.*@`"N8[7\T:370OR!U/:Y\VH2SAPXY6ZM_`N'R_,_0K&*&38@:L/KK(3E.&
M,+*SM4]$!R&==W&Y12!P:ZQ339+0OC!.7_$Q#6^.,XSCZXSC./WQ^W]\?MG'
M^N,_MG'^6?<^>>>>>>>I;T?T6:U!T5P+4@W&C3T<ZFONTJM/WDRTDEYB)@`G
ME2\KRBG8FNSE6+1E*KE=9P3!^O*LIAJI`NI1L@S;OEFLBTNCC]\8S_?&/<^>
M>>>>>>>>>>J;3-?T`-]*]BFU;F_Z@NJQR.CWO1@C^IHV6R!3(O3,0-5>TR/M
M6+=^*?J.MV\>0?AY1X_4F/Q'YLTW;-5=6^MLO///////////////////////
M///////////:XOE!<71`<W9/*7Z/(.>)0&.:_E)[(MSRXZ;)K2B'AX+,$:Q$
M*I@G,<:E!N62*K6#&1H<DM8XQWE7PD7L%AN9>2D+'7,D3?5==;QX;U'W-O=9
MB6\X$!35-5M>21#FR`*!N--`1$X+=2&#/+`<%Q34#E^*CK\,=*B\F&L;15E5
M&,[%SB;F+VQ>CFVJHKV\:]):JM<6C3>NC%LU8%X;-)[N((JAV\BSDEAXA8Z[
MZ)RX[+*,46<]`/?O8HAB5'<),M7T0_>LG'YI.H:&I:H>4>[+'Y>INKN;ZHO7
ML_B[BLTWHJMPNG8I]SG775M:4AT-.R>0B(@X]V@6GEDW[79-,/F[QNX!6[-J
M]4V8M\_A=D?.\TTKGY1ODP`1]:+&**'N<^&;D*(U)PTA`4$MJ>CNA10LE]&F
MJC*!'7A+4585N\*W'W*65(H1'I.0<HI80WWR;XM9.'FWOR*S0]9:=P04Q\D=
MNRL18:,B'2[6;CI*B^:GK1BPDP&-B11]%BB*^H;$N(]E^,WC!YI^?O98DQ+R
MS[:QYY[HB87&C2`F10O'X0J%R.-=0Q`-D<4PG("=B'R.[=]%34-*-W<;*QKQ
M!11!TQ?M7#5PEONFJEOIMG&=9COA&V^8W+HH^-NY&]70.F^SE;BF^'!&>\62
MVNZF=UV-9:,=GEK\CO-\*N,Q?]%I6:IJ(<;_`(A]SO/[[9VTS6M/D6#$#H6H
MGK^O23B7HPL>)0XD'VS)L9BF[?G%,9SHRYUZ=AVS6IK<>O-?L*L`1^Z`[R20
MWQO.T]";?3&VQG&^N<?7Z_Y_3Z9_;/U_MG&?IG&<_P"6/I]<_P!O<XSC/\9^
MO^6?^&?[9_MG_A[GST)WUSC1?3X$YK*_ZM#K5"5WB$JWABV)2?;PD^SU5UC2
MH4ED\H3@:90VRZJ\"9B4G"%4"[VP\AYABZTT6UHCK5O>?%N=G-#&<MW[STSV
MU^G/W01PQA>N@6.V7TRHA3_5Y0X0&+L8QZ*RWY8!]1-H<R>823T=]/YQH@P4
MM)S?VW0/3[R>%0<@F!2X`I!-:RN=[<&Y6J^AJR^\RBGJX,ZC+DF).B/N'"V&
M\.?0*$_6Q3G3=P(F<^R^RYVMIG;7&,9SMKC&?XSG.,8S_G^V?K],_M[R\\\\
M\]5>\[1I8'N[C8*LBO\`]66+<-QV"'T"5?ID<FOZ9'P_SM;=AE)-^<S#QO+B
M7YS5(F<A7YL+-WTJ_P#U'^0/4$H*5DW2%J,?QCZ?V\\\\\\\\\\\\]2RA^:2
MNJ>L.Z;]F9X>D1OJ8IYZG1"&C,RGYV/-J@H>$JF;1)/QC%O'??R<S&+2,7^4
MO'Z?Y8HGE[NV>?;;ZW3\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]4/NMRB
MCS#8C9"O#JU"J86$!VLPBLSYO4QY)V\1&H]#5.\&K;>N6S*J7T#8#T?(%+(=
MY>)!S*+=S.(4D4;IC4OK0XD#:V`^QJ-+[JM3H^_^L>G^#Y>VZ@*[_N`+L]"E
M*F8S5+R-WU(*A57TS1(17Z<F6F]<JH6AL!.):YFP;*-7TN.N!G`_+[Z_<9QC
M/[9_OC/_`)XSC./^6<8SZ#&W--'(44\YI7KN$EZ1DQV;%I<"(MGQ)'3<02OG
M\H0:S3R<=OY:6D)B7E)":?S+Z06F%IITI,8?:26$W6BN><:@JN'L*,&Q?>26
MMJ0VE;6(#J9F[(+;,>8&(\);;V"6GL@0D)>VC@N)BQ*,83D@]81HTP0AF31)
MIE5):C?Q:QD/"/?D5A1ZM$Z?@H?Y([=BHBO$8X.B&L)'1M%\U,FCYA&`,E+"
MC&+*T4-3*);Q[W\9I&$+3\_91))F7B6.UCSSSSV!V75U;W,#DE96V!B%F5V8
M1ZD25`QX.Q)6)$4<KG7;9G,C\XT>Q<BCA1--5/#ELILBLFFLCLFLGHIK^<SY
M$*%O#A$?H5MS?T+<@]P-/V]^5WS3UF7Y<(R$55&L1:0D*V$1CLJO8$]ZVY9H
M^QC)DT#9I[O.&54!,_L#CN5:SKXE(FTCE7QK_)]4P>UM@:Z(/+VH[GTGMU@G
MQU8O<LN6$XY-Q:X="L[8KP.[DF5"6H;GKP6N5D2ITJ4E]R/K`*A"8_#H_F$'
M"1>R/Z-(N7BYR.83$-(L96)E6;:0BY..=MWT=),7B.CAH]CWS119H^:.6^^B
MR#EJLL@JEOJHFIMKMC.>Q\\]5WI'C?GWJME!*6R%*;F@4HL[K.X0>>GJTO6H
MY5;.-]I:J;I`Y"!L<!=*JZ);2+.!(6\(0()_EQ-$342LX8+?B;_Z0G\D'S#?
M%E;=#\V5EU^03%5D`-+V<(=&R%%5?!6R>?>D\B,+5/:99M`2=6G)#5$?#Q,N
M[GP&O*MD)YD?1#TY&Y%YHPEWWZ]?B9Z4M_L'XY>2.E+[AHR#MNVZG8DA@C#Q
MVT1&2SA*9FH:++V45]XHE&MSN"BHLUT8M,ZQ[3,_LA'(H1^C5!+8CYYYYZL-
MV5K1YG<_(9A9IFD.654]N'I7SR/;EL+`[GMA3O/UK`99`HP4DW5D37>+J0H/
M2G:%@56S^.2@]R5TIO%0[Y%2SV/XQ]/[>>>>>>>>>>>>>UZ\SP5UQW;WR2S!
MZUL-&IB`TY76HER3+3FX0[BHWF<=C[#VK9&074B$&2!ZF^1*L0*+=)0FPYWD
M=5)#*BF=A7GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGJ8]23%S+U3T=%,^9
MJ<NT4C0H"4`12P;YU`(2V%)F7=IVVRLB1E*KG(RFX*KX1O'E8^7-G1Z[)UDG
M>VD<&/H9D[>Z5..C9US=%7%TU07!GQWYK$;@5?\`:2Z%I;Y;"[K"QA>KJVBG
M!!)#3&?+>:""2WC1*#BUI4;I[^H(8-*.FC5!JA%+;)/$/TSP\HWFXF,F&J;I
M)K*Q[*2;)/FJ[%ZFW?M4G:&CMDYT3<-'6B2VFKAJOIJLW6QNBKKA33;&.R\]
MX*?[FW^>/LYSG']\8_?.O_#[6/KCZX_?'U^N/:P_C6CYV+*?DH9DA-J82^OR
M6W`X4G=8=A!848/Z*YHD(.(_+8Q59IIL+P3J,%=WN-_Q4QO"[3,AHE(R#M+3
M9_YYYYY[C.,9_GZ_^6<XS_SQG&?]?[_Y^ZJ;@84EAY,?(HF-GH&:9.8V8A9I
MBUEHF5CGJ6R#MA)QD@DY8R#)RCONDNT>(+-U4MMDU$]M-LZYUR2GQA56!R,D
M5\665;'!!@_</))Q%<ZS48KS]-RKC&,X5*>2;%C3#G5PBNK][O)2`2#5X9O,
M.G6Z!FQ=J:.TNOVN;Y'.;]?N;SYT#.TJ^897_$6]Q4]1KNXD(UFAIC$D3\B7
M>8*QTDOO]-E76M.]%G$V_7SOI"UNEC9)IZP5!=Y<J=)3ST'K:UXYK;,.FHH1
MT/9$,24YT(+8;I(J.E".A[8B`VUHMFAE?37$MN**PCK[6JC&3=H;IJ[6^QMC
M/U^F<9^G[9Q_GC/\_3./YQG_`(9^F?<^PDVK6N[+:QS&Q`0-/&4/)(S,2S,Q
M:!*FD7+M\9U;RL<VGH^018R3?&<X1?M=$G:6,_31;&/V]JR+QV8^*TQG;@K*
M#DIKXY;$+YHOZ/J$=BUY)[Q$7E3QY-%G4E-0<6DO).N<24@<+3/2U-0K!WBL
M9.1DK_KEK'CNEH#3S;9`3\&50<,3#,Q%$0X114=.P$_!2+.7A)R$EV:,A%3$
M/+1ZSAA*14HP<-WT=),7"[-\S71=-5E4%4]]NW\\\]3?HGG`IN'H/A&W8.<@
M(R%Y5O6SK3,(V5_,OS4AAS?ER[*+CX\:_!,G+/\`,FA#9L3+O/S9S'M/R9A(
M_<.%7_X5HO<?'[8QC^V,>Y\\\\\\\\\\\]17GKHH_L_L/Y`J,)$!U,+YG+N;
M(2NEHR-<-9U=G:_/4#9Y1DF?J2+I"473)))PG%;MF,9JSB\)-54W:FN76]ZO
M//////////////////////////////////:9OE/;=5VG75FT5$<Q<Y&7+$E!
MTZ5FENWAVVZYWA9=R/VC%&!%5QF&XY\L1E)UM-[!4,'V#I)'0\U,@^PG4`U^
MZ<?C=-8[X1FTS7K6)>Q=$_&QRSB!HBPV4H.<6].AO05@6^.(E-;LQ^(*X<(H
M:BHL:`*ED)!:4:2TRF5O])TO8PXJV&8V2+MIK>[Z&NB+ZKCEVC+8Z'MR4<0]
M;4T!$EB&3YDU_'R7Y*,QRT@X9P\=]ZAM)SDFHFC%P<5HLFI)S#UBP34TW<8W
MUUG$GR0&@#R!:/3LX_H,[M-(BI>L0[E*K3!(GE*@NGHH\$02H*MO&T8HAF%I
MPG_$62)SMB.1ZOPZ*CHF.(M`-$MCVL>3S%JN=^D#DBZ1Z9X^N+84E+-Y]%*+
MM.'/@V#?"`]8]6WY'&K2(D=0N3)S5Z-3P6?UB>BDTA^J91I)1.@F1(:Q[B8>
M1K6$?BV1&V\I\DJ0F".:U@\?)U?.R0B[&68@LA)JU)SPJ1$&(%AMLU20.B3>
M7/6<IIG"I(S)T"9UKHZF%]-=K7GGGGGGGGN,XQG&<9QC.,_SC./KC/\`KC/J
M_P#0'*?./5`\T&.AZ7KRW(V*54=#RYD.,I&>$9)3[/\`XT#EFFB!6"D".=--
MVA"'3<%-LE=-%FC]%5/3?6H"W'O6U![J/^,>S"::&&^5U&O.G=:$_P!+UHDA
MME/1*)#KY;S$!U:`X30URBS>F%A7Q`Q.FJ.C4(503RAN_P"L--:1RHQ[SY/M
MGFYDQT<[O;WJS21ZOY+40:XUT_,7EH5:,-+5K*-4VPJJXD+WH:KH&-3QIJN2
M.-=]%]YP+?D8X,!J]$+8)^Q.;8ZM+`6ED0@YTN('D1@JR/)(+$BL%+1$Q(-Y
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MYYYYYYYYYYZIE,W35)YTKV+4X=7?Z8LBBR.CHJWSG\D&6&++D;"IF(/`E[B7
MBE-I^>_2@<]:#'WI4FDO'?AOP$/C:*T2VS;/SSSSSSSSSSSSSSSSSSSSSSSS
MSSSSSSSSSSU$.T2T'L@-+.1125Y&L'I:PQ\/)!#G/JI;0K!B871L"*<*F-@5
M+#2"!@5@,1J-ST@Q_!ML1DN5CC2%W=X5U<)::KOBR':T-NRS\Y!K-^']O/T7
M6=@U(:5G\:5`.*_+B9\5FH2NL0V*8%DU).9$4KF5#','$JUPV>P[PD,IB/)2
M;7=I'0Z_Z0/4\[[YDD.Q.1+IYXA9V*&R0YA(-^'S!`T<OAIL<@)F-66#)%;1
MEJH^<B+XO#86/+$6*2S[<==R>&:"[K"2*FNWH?X]KJ[$GNA;YD8L>YVM@SI_
MBX9K>OI,I8'D!,7#Q=TQ,]9CAM9TZ&L]6+@=DBJ3UI83E6C:4+8JLGI,32D!
M'2,K'!,7;&B^=KFQT3V9V4;MAJL;,Z$K.E*5I\#DE4;(;5>%4-`V')Q9`?N1
M2:'8PJDBZVK7+)U^,CI"CAN##XLQT+XZ<F99F/XG\7["PHQ_\AC"UR8/,K$;
M?(A8FI03@`1,5N'3#S?G/EM5HX@08@.[.F1UJE%[L6JS20/RA9=ZW=/]9#1%
MVFT;;4////////////>.==<Y^N<?O]/I]<?7&WT^OU^GVL?3/T^N/K]/K]/K
M[\^/:GQI&<=U_-]C<CT<@D=6)28Y7SLUYRO.!Y#O:L+=!C8P,F%C2N\R+S=&
M]%U9<3,D'12]`.\!(YSJPK$,?-`VPT=M8B%ROBFVK#^+6F:<Y#^14?$P`3CW
M$C%UWVO6SW"O(4V3V.:SIMK49[E[$#3[D^8&IXQ6K^JX\UB&=(&(W##<8"GL
M&2/&]7Q>]*081!'$O8N49L)F%F6#AA(QS]LVD(V3C)%MNW=LWK-RFNT?,'[-
M=1!RV<)+-7C1;=%9-5NKMKMJ%@)!_P#$R6(AI?(OGWQ@GA+%1%5G,D\W=:_'
M>7DKUK$Q5/V&^>[+/,<9F1(];LZCL-X]5:<T$4JSJ@MTCZ:>!,^%;C,9^O\`
M\LX_SQG_`#QG_P!?3_/'UQ[GSU(NE^@SRIND?CWJD61'U!CISH*UJSL=26CE
MWDJ@.!G)=\75$*##M*0:)1<GL8UP/I/73EI)IKPBDDQT;(+.4WK:[F/WQC/]
M\8]SYYYYYYYYYYYZIM,U_0`WTKV*;5N;_J"ZK'(Z/>]&"/ZFC9;(%,B],Q`U
M5[3(^U8MWXI^HZW;QY!^'E'C]28_$?FS3=LU5U;ZVR\\\\\\\\\\\\\\\\\\
M\\\\\\\\\\\\\\\\]J=[CYC[@MB8LT;Y-M"BZV&NGJR#*6N&W+%_7>UZ4""P
M[PQ8%,]S^P%HEW`&\B1BQM,X%1PN(*\:5_9"DB>H$A%M-:Q0_*E'<FNJ%L?G
M:L:RJNM`3D?DGGHOK"HIQ@;R$C<$L4%JE<,GK2<%_P"GK")9B,A%B\V1&!`K
M8DN2&]E+0Y%*P2&&/XS?8=YY[QW_`-S;Z?S]/KC/]ML?[N<_\,9^F<YS^V,?
MOG]OK[5+\6;<0:R?R2H@D1-00WCY/+\52C2&%+1^5TFW-3\].3!ZI%'#9H2)
MLI<R6()B&>+M](F7A7\=,"NRPF_@UU-KGGGGGGGGGGGGGGNC)1D=,A^:%"Z!
MAB@7)(I_!$0X11;&;@9Z$E6RC*4AIJ&E&[J-EHF29K*M'\;(-7#)XV540<H*
M);[:YU7*<Z](\`N,3_#3=_?O*[53[T@^/TV,6<<3UE%YSKA=SPM;IBKAD,1\
M:EKA1ARQ<<^E4"J.F(NJK$HUF@E!2MOJ4Z&YJ[KJPV9";F).Q_*<O6%ZTG9@
MFO#FX#+RL<XCBFH;_I4YCVQ"'33F/7=LI,4,X)-B10R_YE#+3PU(,95Y3$!+
MRCXR[%'>?[@GIPCX"L&;@`_E&^B^7?D4US`9SKS\K@N3>@S.5W5?KU;+OEXZ
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MHSK>D^RJUN$WZAXMVY3>3]C#]$"]PD?3Y):`O/A-:4H;N9ES#BA>/:$8A%T[
MO"$AJ4GD"J.CA`Q=S!P51I"3S;\;AH+V<%]3]3]/6/)2I+;OQBW-0@T,DL:0
MSG`]_&5YD,':"LB,Y#XPT6)8R.BQ^"=0:!NMKJQ4=2KZ2;1^<IHQR"ZJNV_W
M&VVNFN=MLXUUUQG.<YSC&,8QCZYSG.?IC&,8QG.<YSC&,8SG.<8QZI]1]V\;
M7T+6N<TUTW25E!5%H*.KB,!&PA^7%:U:(LYB26=F1$B[Q#P3-&.@)F05=O7N
MC9-A'.GFZNK;3"NTOU=<U979`RD_61:P*8^%EE!Z?201D(V7'IO2.CIG\G(1
M^;91A`/2;B"F(>>8LIN+8+OX&9AIUDFXAY6/>N:*?&S^K/U5\E'ZW_3WZB_Z
MRNW?O?TM^:?DOY-_0?F;])?=_G/_`'_\S_2'Y#^HOM?]S_4?YM^5?^$_@?;/
M?//////////////,XQG&<9Q]<9_;.,_QG']L^HYTKPT%W<815Z5J:%?-'6XA
M#_D@9TS4B4:F4NX%!?\`'-JZN4/E4E`SH.EUI#7"SRL+0823>)V7>RU<SU=F
M*K<L:5W2Z81D]5^(OE=J&N:]GKR:OJE%3YI^/G>)NQFI1'+QZXB$E15MM(55
M:A(VRX24YKN60:&SEWG.*@-KE91ZI&T\J8L<_P""[7!^.^CRN<-^<;&?-1#B
M/J\V?Y>2[0ASM]Q`\8=(%+G?/XNVV<8CJESU<$[LR5Z`'(_8#*EW5ZCV)*T=
MM.,XS^^/_7_YLX_SQ_.,^JM>8%0Y3=_&Q1:1I^F[/K>X[!(^<!W]21T-^OK&
MF.=K;#B^!_)WC)R[*_RNG2&P2K\JBW,>Z8X@_P`^6<*LHMRT7M3C^,?3^WGG
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M5C)_:;Z&^A!43/:2M``.;#F*H$K!#)JOIVPAPF@0TC&&)VVR);O1PI)6$G#0
M1$MO,:,(*0=1[S=&5>-/PC=5]LVU]^<+KZ%Z2K7E7LCE.V;B=]*\]<Z7C\79
MGK>DZ,B0W:#?G`LZA"9"]Z*O#-6P`J(3LQ1U<5X/',^9PPN-2,S3-BLG!;'I
M:H:KR6QJG"-$;^53Y53[5YF/J`&YCX52M"63:/74<VM\5@>CC:>QJDQ;/'#T
MBA*,G:W?D+.-15D=H&6!TE63G+B+QGL/B-*ZV.XWY`C:H2.:+JX+?D=N(C&B
M(AD3>4E9+69I3G!_,94<V/MDR19-"%>6CX:*E-46L#"M(Z!'VK(:C8=FAMW\
M\\\\\\\\\\\\\\\]@=G5=75T@)55EM!`O8]<'$0X@2\'-(1@1"Y)#N<Z[*Q\
MQ#2:#AD]0PIHFNC]ZEE5JZ21=M5$'2**VFH"X^:+FYIK,SJ70%+?D<^-HS@'
MHX>\MG,U(F_7M"AR^^BGUY_/R62S+=+@`CHBA)#-5V`1QG1H`[B6,I3]PGLI
M%B=<L?/@;NJ!AI&MN;[`NY3H*J[$<3@CQ5VC-9DVY%;,@"-=U2+DSK1E.L(B
M:KKOJI(9JYVEH<OB!N;OH5@Y4QP-#MECEB"+:^'1'.11<707"%O04[`1L'RO
M>EFVH81LIF3_`#,CACCER[*,CX\:_!,G++,BT(;-B9AW^;.6#3\F82'X=PJ_
M_"M5[CX_;&,?VQCW/GGGGGGGGGGGJ*\]=%']G]A_(%1A(@.IA?,Y=S9"5TM&
M1KAK.KL[7YZ@;/*,DS]21=(2BZ9)).$XK=LQC-6<7A)JJF[4URZWO5YYYYYY
MYYYYYYYYYYYYYYYYYYYYYYYYYYYYZLO83VU6'/!^I317-`!JOJ.Q^]AB]?XM
M<PKH1DBJ$86$?A%9[Q\N@=&P<"."&?$AYU#3[5S/,62[D6+TFVPK,Z\^'>U;
M*Z)O:H`2O_ZNVE4`KQLT4ZYM^RZE**W$17K2%<5=%"(D`$Y2"`&#4_+X]U;<
MS=8Z(L)L+$LQ`6[9.A:4=2D/+;IO878E;U[;P415M:P*'V77A?'YBBH%/AJ&
M,`\EC-ED7.8^>&R!G(0\LS_$-V[C#=\S73U<((KZ:ZK(I[Z_,,576@4$8K01
MK\,&:\_+W<3D&@AB%BQ+>,D&^S208+#S-DE%.&L@VW40D$7#571^BHHF\POI
MOMC(`K"N:E&]Q.L`84KX9R[=R6T$&P,:.1>T@^U2U>R"C.*;-D57[A-!!-5V
MKKNX42;-D-E<(MT-$J!?&ZY)G9;\E"Y?$PD).Y^2FVDE(X=GWI/%:13:@^8V
MPR[3F)$?%W:CZ5%T8:6FH_:%11@IM](P#-]-LHQO.R>SKSSSSSSSSSSSSSSS
MSSW&<8SC.,XQG&?YQG'UQG_7&?:INZOBKJKJYJ?'%<2J%%7Z>14`Q-3.(BG;
M\`NY(+73?`[3H:O(:8&%3:;`I%NRE:EO`3(`CI:A2*,AB*F[>&-HU:'D_P`@
M_4O_`$AKN?X^NEN8N2NQZDC;.O#X\;?)Y;H,^KF_):$&^N:_/Z,*!>K_`,TC
M65?,F"<HR!K5';(E)$GAW24Y9`Q$2;L'"911]JP_H$4Y:8U=U1U;<XAK()"-
MMUP#V>+ZR[;1G):#A\,197":R3=-5PBVD-(Z6;)O6R;E?1!UJJEJJIC7&^TE
M8SC/[XS]<?WQYYYYYYYYYYYZIE,W35)YTKV+4X=7?Z8LBBR.CHJWSG\D&6&+
M+D;"IF(/`E[B7BE-I^>_2@<]:#'WI4FDO'?AOP$/C:*T2VS;/SSSSSSSSSV+
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MLBU.(5$S_!A`+B!6G/H;NH+88(6S]:+(OSIJFHZB<0KE]M(-DE7#3"J*2JFF
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M15$7//F0I5%NUY81-7VL(N9CXD5Q$U-#K`F3>*#$S)1K-RH[3'B?6-E,#)&F
MDK`$.\3+)PTF^4BW^C>9_/////////5)[FK@DMCE^S`86BK/G9*4T$WR\+2)
MU!5C<\O$#AP-$\S&U/8A/*0<"%V$[CH5?06()"<'\LY+">K$G%9-5B217Y^+
M=#.T<0H=,0O,O>J@W5/-?=LAS<,W3<H)TCTI$W_?,EST#\H3AE.0%T&9^Q)Z
MC,H.TBET?39#9B=(5*>Q;0AM-PG,3X\*_JB&M)U,>@TRA9FX)-(>+TGUX[7;
M2/6F]6#?6768Z;Z)[Z,U9'#G=KKLGIG5OLGC[&OT^SCN_/>&^?\`!M]/IG]O
MVQ_EMG_+7/\`?&V?\.<?Y_7Z?Y^U4?%LL-N)3Y)51,[<V5!Y^3J^=4BYV3,R
M]9>32J3GA(B'\3S#75JJ@"DFDN!,XO3&51MF,(#+K;=U#K[[;6O/8D>G@75H
M45V/8Q3`A`$##\L5F)@42;2%'1D;@F2TC,3DW+/E$6D?&1K%!9R[=.%-$TDD
M]LYSG/TQFM4#VM6$LC6$I+"5R!`M=Q:.!=/%YU5A".PAY-E[1]("R>R"F7!%
M7Z1$QCUEX3-O#]=+R:RK&-9MU9B281SF0>7>DZ\ZXH\.O^K$"=J#&[DQ9Q#<
MR@_TV2(.08[**ZGD96%R\?[1RR9$(R^J+=9SLY_"805<HME]U&R,_P"-L9_C
M/_PS^^/[X_;_`!8_?^<?7'_'W/U_U_Y9_P#S>X^UK]?I]?W_`-,_3Z_V^U]/
MI]?_`+/U^O\`P]7PXZ7KRO\`H6B^:9YJ5YL'H89MXJK]ZQ@?Q`C^7TG'C,H:
MMYLBW>H)QTIAF6PZD3&HM'KB0U575V_#-V^ZV;"?7'T^N?VQ]/K]<_M],?\`
M'Z_Q_P`?K_'J:R?>W-<6:]7`&Q;,21%Q>#UT<WLT'A`D)=X=&TVQBY#A46;0
M#"1DCVP)+(4_8X"`]A+3V)N3@!U)LL02ND8CZ.:NZZFZC-S*N@P%Z3`#`$%!
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MS+.0>2'G;&,_3.?_`#^F?IC/[?3&<_QC.?KCZ8SG&<_7'T]4DD[)KF"NK-(Q
M8?;I[,P]BUU5%CE=<5Z],@NFSNV`]4[`(JTW<8]_40_&S0OO#RLH6QXS-!@,
MT*A!S89`)M2:+76MMC/UQC/]\8S^_P"V?W_OC_+W/GOS7?+#\6O"'3GR(?&G
M85V4%$EYAT%?)S4-RRZ):=C.+"`JEY'O:Y`:*)8X8)HB-D7,445N.QJLQ^#3
MFI`0T5%)&0<PZ4<C'SG8'P-4N-KK$OQ_],=:_&H9X5=/D8CFZYC&5H"3E'>^
MRWVR?G,^G9D)6AD5L_>)P`8_!HS7&ROV&^-]_MX@M>3_`.D"<<J?8-2NKNZ:
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MKK,:_35;Z>M1YYYYYYYYY[2IUI(R,O\`,=\7X%9ZB^M%:5'V#9%41#_;.X>5
M=CAL2$M1=648*ZJQDF<@-(R]E%-9:/DL2<2J[+)\:VP^C7J[7T_,J"5XUY[*
MC\7:C,9?9+<?QDB$A.K-LOY-V#C/R:<^2@.N3131]'/Y>!&S(DG-HO*K]BM]
MF7(8F+DV/X]ZHG$>>Y^G*J-;BYJ-[.&K#+(GY2:DXS!+T(8`*J629@]Z<:0G
M7<!$S#>*%":N&9C@M<.*&KXFD`>39S*Y*(_G<#,%F,.IC+BKICL_EZ3H`BZN
MN:K'%+SUX=(\P6L6U7$CIL1B4H5`TB?<3'-CJHUN)1L3;NTC#N:8L@%#!MK7
MY?9)I4DM",A]O/2@BXB4#^33I9KQ%9]XGN&:UW<'4G<H[V\'.1H<80S'JF,L
M10'%&\TR@8MRZ&@4+"(.4Z%F&P=*.,2%6E81A]+.%7*K]Q.IMTAV/2QJ"5O8
M%LT_*AG7?1G,-04#9L?,"!S:%4PUD"MSE5ED!.S&JKK.J)@/L./IJ/&>69V2
M@Y>2WLHYF(PN;'L4-Q#%]\_Q_`=U[69\EL*-W\VC9L9^8YF1GI<0U4)3LA:-
M3,N1.0I&8J]Q&13\4'Q(IGQMY$#KBRQF+1W8R<*X(606CO++Q;;:M>[VIQ*&
M'K3M$>R4.JTG,R-=1#6&V)R-Y89,Q7#86.K\8SG;64L<D0FGH@+9;:)R"29#
M+-TWT=%/IIUKH<):#LKFL#X!HWG`D#0[O]IT7VET-2U/$3Q:9Y+$&5DL+`NR
M_>=+)4@]<2PQ7H97%W#%:U=.UHS3-(XSE(`V'X76L9$YT0V!<:145=/QI/`:
ML9:RZ,L"VH#KL4GU;(_(4K,J7IHHM"XH2_GC:.$%6@PHVKKH>7-G@JD"_<BF
M!R.@%1_9%@NV4SK(E^;;HZ=/*(X**!J&H$[JOX?>H^7>N['JT@8'P?$0ESQ-
M-5!SLC$+Q*,&^WA2XSJHVO.N@8X<"I@V$APTC'D?%)2;R7EYO.<$7.`UU++V
M#^26J*F_7M56UT2'`24O$U;*WY?+[F3E_GGD."()].3E&]>LG\97=\=/D3H=
MR[3B)^'#=Q6<B36?C-KW$OR".8OX^.K^QXZLUES7E.+['@2VM6SY_-P[VT./
M#*R*Y,&\60:Q8](RH#*E%>.9QG/XAXF4T#G>R[N,82[1RS1JWT)=71X;(&%)
M+74O;%?]%?%OU!T@,6R,B`./E-.6=1D/6C"2=C;D9A6\&^IVWHJZX]8)0*8^
M?-1*;&'6K4_(-)INH/W*^+D&8PO!?$Y9(JMB(SFN+N78M8R?C@K&E&@<UJ(7
MFQL$5F("%B7C\8$7LY,J0+234=N$5Y62?NEW,D_>O7&POSSSSSSSSSU%_D5:
MLR#ETT`]BL6A)4XDP2(CQ4INDOY\8VNT_J0&)S%1.+?KEI)6+7<59[1UJ`39
ML(1,BX'6!-LYET/R%62^NLK@_D4&YW^0%FD`5M2$3!LN>;@<Q-L:]I6]T#;)
MW`EYM3TDL#P=-FDK+0(&G3TEEB)6+:C*2U;V1&[UU*,!R'>3<E$B?Z'?8?8!
MR/UH%DAX4KN$((7BG$H^PR:K2$F[^ZQC1K&0T6UUW>3,],/5&T3`PC!):0FI
MEZPBF"*SQX@GM^?PB^1;L*N:Q^3.9-=!1E<@)V=QYS/S2`.H:(DA>C5^R*SY
M-2&80KDXO6/6L:4K"7OB6,S>3DYG>,*"^(E8&`<Q82XA&K?8OS7=]AL>R>N.
M*+&,I.RVU+5IS;>U8602,!UF;R@1?"-FBI**FVP:.B0J\D!&P:@FI4?DHT<C
M%W(J9QD._P`/G8ZI)N\<^-:0G90I^2AX2#.H?+[?);<#=2"UF&$[A-@PHKFB
M/@Y?\RC$D6F^Q1!-8PJW98T_%0^\UM#2&ZLC'NU=]G_GM3/S>TM;-]?&[>`/
M3@?,662QI#2-DS=3CVN52"V*\J&\:]M"RJY@6>N?O)><)@D4F48<<1U57*I%
M!N,(HKK2Z:*EPA/J'FVZAD*FZ^.A&V&95,C<E$Q(XM'3L^.N4':,YF9,AEPH
MG,UVYK_#7=^4Y,V,!+!LK&;Q+MJ@4ZLHAQ^6OE64M.G:P^.,UYF.#U:Z+NA_
MF<!WE=O;-*96LR^0#7W35I<VP2]13,XO64"LRN)J&.QHD8"\7/S"I6Y92,W-
M-2;=)>XO-$4P[THZZ$N<.[;IQ<)_Q"S`K*`Q5G;M727/W8HZ\B)8%L*]B<AL
M&?+:XZ8BCYD0!=@A8F]"HZV*S:SVY2,RPM%B<MGV4+='2E]W:%2A"(78#U1\
MI-&UFVBX;!K9L?GEX^XSFX*/[,S'))D[9*DVUWCA*0#]6309M%RI$3UR/GJG
MXMT0N-=.SI6ZS&S>DRR#?]#%8G\AM`]']?XE^.&X8<QK^U*>3=6CK1`P8O"$
MX>UP[X\GZW_HF5@MPPP##*C9OAJRC3E&P",H2(H:YCL^HK:ZI^%>U&]IEQC=
MQ;RYW?&==HDQL=/3(,Z(_H_2<E:HU9`7)/MVU/66-'C2P1Z(@&<,(/6`="Q0
M^+LW04/"*;#?:&+2KWA,47X0L**N"0D:*A%>;;/O6S#4MC31"1A6^0XU/K.F
M1TW-B'=RQ<:S"\U+C4Y(R3Q%NC)QRB"KA/36E\>07T!7GR:]G!I]1M1UT&,.
M-.$6<C(AU]'EO/7$]''_`&!-C\WD@*>=*D_J"9GY`2V`36_/2>8.3'R-"!F$
M'!PX.7ZXS<ZIKSJ^OPWK[OVZBMB#U21VQ)C$0<2>9>3CHNC.?)O-!@SW1C$Q
M\E*[1!7:6MGGT1EFQ<_BVECM)!+3#5?5776S\E01VVTN"D+)D*0YT-&<E\H/
M#</39>AT;:#`BCZJ#K6<2P$#$@$CRH11U<1A$3JR)?<IS#'ALYUEW<)LB.%4
M0'BT="W)(^)JZ&^DFP_31#844?'[;H8\)EDI.+T'.9:DZ]M0./.L2*N91B/,
MR-I9G3EF5U'#M:*$,Y-[@?X:R30&3AHT+>0<AC7Q==>7S=IP054>U_`#(8+<
M^C1NX%A@;2'F_+%CMNA+[I1#DV;_``^RF[Z3@:NJH)*VR9%JU+$5\3T\MI^D
M2\.BX"KUU6==A8U[B_*3,R$OD>HCNT*8<@UNV+R&'V*^?I,MIUO3$</5BTFF
MPU8U!7'6<S9*=U3SX>G8QD4(6/-E$K$2]303L4M_\>@L$1O?'S&2D'(/G4OM
MU;3>R*2IP43C=6%E^+N<%I5_B)DB"1BW.B1U'D\&WE\,U'$*O$R0;'NX^/B-
MX-GN7\\]5:\[DJZN[OXVKXXK[]6&M[W'80+3Q5^3#DC_`$R,!CG6W+1(";,C
M,*:2\#^<UZ$E@7^/%=%95UDCQ%/M=8)])[ZVIQ_&/I_;W&<8VQ]-L8SC^V<8
MSC]OX_;/]O5VZ"Y(YHZJA&D#T/2-=6TVB]5OT_(EXVR>%`BX74T5WD08U0U:
MF8),:J)Z*(S(:004J@IKJHB\TWUQGU+BC@2^:^A)*%YEZX(":NG>N-5N8>_A
ME3M2B7D8@AJV1&XD\))H<Z=%F:B&N44')!;]KPL3_@W1"WB".&6]!I>E*<HJ
M0?S'0?QMW9PE*XT=X?\`4_Q#V?;,_1N-&J.BZY"6!'+3>K+GB$UE=]W#M&SN
M13,/8(X5_-BQ\BBLXWM=0J5YV(*K&G!7RY`?6H3#MTF^XKT]5U4W^I"/%T?O
MD1PDL/FR4YHML,G$OLJZ+IV;#%A.Q4UVTDXIRX053V_&]\C7S<?.W0GRS$%*
M-B38#F:YLT*$`#ENK@M$IJ.X865U@\0:D5L5!"-A61%7=JKNZBYMTX;$43B:
M6BQA4?D(?;*/[K@GY4^,)A_#B5J6>KRU:4BRCMW-6=="1KR\4I3#Y+7[V#@7
M5Z#@$.'JR#S"S-!^`SA-&R64]'#!VX072WWV%Q\G'2K%K)QCYI(1KYND[92#
M%RB[8.VRVN-T7#5ZWW5:N45=<XV350643WUSC;7;.,XS[[OY_CSSSU-J-YGG
M:HZH[>O^0)HJ6A^J">@9X?'V;)^WDA5&GZ,A:HDF\N[<Y_!/U)B0BU)9EO'8
MQHW9JZ(.O^\Z[9]<GSSSSSSSSST7VY2U57P*IA5O`@X?C;:8C2.-8$+#5RI!
MD\+NHI!E8W));(2PP602JRRT&4CK^+(895552,DFNZJF=L&GN3^>RP*S7I=6
M$"8BJA$(%KMD8N)HL>2A-7TFE-`<Y-3I#+21%.R87,MVLP*.IF7?[CTJT9R4
M3^$>M&ZZ70FO$?)ED#MWB1]0-:&8WTC-0Y+>D.3CR<TSL\F'6<?'CA.5Z2"J
M^[XF&V,/"LQPB2W;S4`VA(5&(?LTXB.U:Y@-<P\^!]0AM"#=0`453E?2PB0!
M]=H0#3<9@R$$,(VPA0B;,G&%]EB&'.XB/,4IUZJZEG!,WQ-OGCJ146<*9JTJ
M:L6+>S6C8`$-&=SR[^>MIEL/QBK*R)>4$(,`DWYLS6;*-21>0"1J!%7V95%S
MH[@8IE&.-%&J6$\UA&/C8X/#*2,><A;E:FX*E#XB9%Q4`1PJDA$2)1$/6TB.
M$"+C[_:8BI<.?,V;H%?PTG'.`-9DSW#=X++5'[&90'#?(XQ]=X&@*XC72ER!
M?0KJ22A-]IB2O&O(Q*&#K6EYE=RK+S)U"1J7X5N0RSUZ^7T6=;O5':KUVHOF
M%^<L\\]20XV/="U"$6_!A\RN1C$4<Q.)EA!3[B,<0RLW&ME%DTVTKF(>/HS2
M0TQ^*28/W[1)5-!\[T6PN(X7Y(&Z\%*K%*&``T*`SJ0LX'C@J.=AC\,L282>
MM9<X$R86?1!6-E<LPDI&*E9V&G64C)0K]Y"OEUXETJRWSYIS-0<?,4\0L:I#
M64]0$"<C5,33.+PUE:WAK,CHZ+L%J*OT%4W4<H9,XEAH1O<*J2$JLWP\=NU'
MJJ[E7-:^JT`JQC+1X$+1@YH0SCLF)7;719Q,%!*^2;MW9$53T@L\G2>?7:,V
M3%29()*2DOP#%DPU<ZLF;5NCTTG1E13=>%54S-?C<M7QM)$<R6#$DRR]83TX
M6$CDQGIV0W<J*/%YUZ6.E"3$WAUK*LYQ-M)L'C1XQ9*M^V"JHKBNP!K5@:&0
M$'7S5M.-OTH@QT<Q+S!1(R<P5.)9%_EVI.2!9,S4S-%DG-*R$D43,Q+2\^[D
M9&3?.5XL!^/N:ZW"I^N@JHQ>!!R0.WKB1&6WYJO%)5ILM)KIUC#HOI-WN.5D
MTVFI9./KD<5B0F.;R3YJP@FS9RJCM,5>5Z%5*"BE:5P.1@<`@L&P&0X3A$=V
MT*-#D2AJUB8&%9945U80\2S328Q<:WSJTCF""#)DD@T;HHIYGYYYYYYYYY[6
M-\N8S3\AQ@9FEN49S'>:5;%M6$`C'==KP\918,1S%I!8GFRK"G9)H[>M`L&C
M9QX3FD!!)*RU@"\3)@*+1]@ARVWHY\68[789TS-L:UE?@>^YG:@+\D+#XL@>
M'%KO>)0Q2![Q#DZ<,#$Q66JQFO(/OQ[;;,>FF6/!7;\2\SG"6GZ'/1#>-#U/
MTA7K^K+I#V9R"24H/S;J!>OIJ,3S,"DTS(AR30?C\G#RS1[#3D>QE&#AG(-U
M$7C5%7&V<Z8Q[4I'_![1XU"=[0E?SV:\VZML[GVT:BF(9(K()*B)WFF%IDDK
M35YH9F4XB<HM;XJ=>Q)5350?DY$9*)$#TEV3))J[;W5I?E`U';2ZMZ2LT]8L
M+]ZE$ZRK;5]5K31R/4O7-,"Q7$U_%U^O8<)*J3I#DTL$_LZ9E"<;Q`O)J>A1
MU<3D(P74D2*$_BJCEH?;Y"XAS;$_>;N)^1FU8M]:I5FN_P!2%DC'4+S,RDLS
MFE3B0'7:$G`OT'(L[:#`<.MV2L'LS?QVDNA(J*[8//,XQG'TS^^,^^-&/8-E
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MMV*FJ64ZZZZ:ZZZXQKKKC&NN,8QC&,8Q],8QC'TQC&,?Y8Q]/8[/F`D*N!]J
M3E`\..BV=;"XLVGIR,AUR0D=H.'30?@$)%VV4F9QTV:.EV\3&:.9!=%LNLFW
MV304VT[[5)'"6$M4T\(_9^FJ>NNN$\:_SC&-<8^SC7_/&,8^G_#Z>]OT_P!?
MV_XY_P`O_G_Y_P`_Y^QER6![`LC0YV2#;,W((>1FH<6<S,4W*9N"@%VC>7EH
MV#5=:3$E$PKF58HR+]JT791JTBT2<K(*/$=5<@2;-T-E]T44DMW*OW[C9/37
M39=;[&B7WRV=<8RJK]TDFG]ZI]K?[M--/[7V$]-=?#9FTW<IO=FR&SM%-1%)
MULEIEPDBMMILLBDMG7*J:2NR:>RJ6FVJ:NVFNRFNV=<9Q[<X22QMO]--,:XV
MVVVS]G7&NO[[[YSG/TQKCZ_7?;/UQCZ_7;;]_KGW1"I<*G4$R*`DF'R\:D=W
MJ<>0B\U&$,&^4C7[J*D-&<O$.GD>ZW82C%[&O=4'*F6K]FZ9KX3<-UD],A\]
M5:\P*ARF[^-BBTC3]-V?6]QV"1\X#OZDCH;]?6-,<[6V'%\#^3O&3EV5_E=.
MD-@E7Y5%N8]TQQ!_GRSA5E%N6B]J<?QCZ?V\\\]QG77;^<?O],XQG'[;8^O\
M_3;'TSC_`,LX]32]_C^Y*Z')T+&/*AC8JXX_;1:(OFJIHFI'H&)7;-\H,L,;
MQI^9"+-V:-<8TV3B)$F?P2N=-='<6X1^TEM^3WI^E>KJRN6YY%&Q.B.AN]0"
MVI6O.&X>W!J^H^Y]*JU4U><X6?R=U)34-GF:>#=F\[#L^T`7HZKOTH=2`\?1
M]YV2"Q^!R<E?U"4CU]SCUYH_YUM@92`^A&XVF\M+C3I8)CQFR46C339K,$$%
M71<N0#]M53O((.?RBSJKF;*K=ZR4;IX+=GF%VZ?1RGQ3\EQCV2GN?F-G<8%,
MHMNY5G.,+;-.?H39RJKJLJZD*A&9!US^3+*+Z:J[X+:CGD5-\;?>);:J*XW^
M)2GODZJ#.^U5=94EU0/Z.V>J`CV'3.U96'M&MT_L*H8O_EG\C%M72^-=<?C)
M7EF96RI]5EUE-L[:J>7^W7?%7YREU-\?'20,Q2<KIN;&YE5@.V:KT:MU/L;/
MM(^J=(+I1!OLEG#K_P`0YI;_`'2&%?O%<[I9QM-])=_\9=$S7Z3J3HVL"`^U
M5V0<U9*SV`>XXQ;5+"VR,S3=@("MIPJ^J>?M;HR@@U4TSC;7;7&VFV,7`QOK
MGZ8^OTSGZ_3&V,Z[9^G\_37;&,Y_U^GM<O,L!9,%WC\E$J9[RZ`.=%?*\Q3*
M$I/HO6#^`'.:AD;/'PQ`_FCIQ#QS0[T78S*OY;&(.YK?*^WXI1;5??8YYYYY
MYYYYZI7<'5;7BOG$MZ*D:\(;/C`\AK:#D!06EH2&FET['LD3K-D^:N9Y1-DM
MAA+E\:LJR3^T[=I_:2;XTS]I9*JT=\DE@,SJ_*3L'D4P![WI0GY\=H#:=HB)
M/6LU0G29&5CHATH26K&0S;(-6M=NZ^L!"^-5`LB?U[("^[6`V/&4M%2R\6,?
MD]LRV"/@)K3=3B"$7T3VAU?RK=:$Y9>'^!Z:Y0">A7!+K7!'&@CB.+A,HFJ;
M=E8Z<K-!V2>#K&*@5!2-D2Q[(BW>U)\@M>C\78,1``-F:6::=[]AT;#@=EVF
M>V<@J4T)F0GK1,6DX.C5M3==T\T80[909`040(HL/<$41$1L,P9O)1W&]E_U
MGUJSK_GL(!^&K3WN'H*F^J;(B:ZMHYBJ.P-DG)1Z!`AH/2TF8B#B:=A)ON?0
MQ-5MJ1X?O'%XG+C4MH-,L2<XF*1>*_+>36!9-4'(E4.[CEPS^)LQ^2"3::2K
MN0O/52,*@V/5"T1&-&)"(>S`JW=/8-O'P9(Z:EKT@=S>DBT1&HR*GMEO+?1C
M3J2NI"Q81*O)`)>RD<S";!INXHVYZSLB!?#`[)R,^'',./B#U',"22D\"S,5
M+P,//Q1`*R"RK9!%RQVSIN^,3OVR@FE^0:;N2K;>LIA>V._TZOOAW9[:U+*L
M,\YHNN\S*5K^7#)]VZ-%])&KX',97AE-&SU_/3PYN,S(X-,UQ^;F+=C_`,M0
MFT:WBVMFH)8#,:?HWFF[$@0:/8&PI^4>=4GY53=;T23;_E`C'@'1$9=8SI5Y
MN$2+N5%1Z;G(IZ@>R,;I)*L//D8]NLA^47Y&Q2V64N*L!GG+X\IP8`6MP3MJ
MUO%N2Q?K),C*`!O+1(LU#U2)8>CH$OBV06.;R4\%;32FTXS>QLT\^LR^4.6!
M[/ZX'9KF0ITJ3C.QH>K;3N!*S0Y=:1+[&J6I[%HV*#:Y;1RY'/O+3(K@%*]_
M#)O4MQ"3DHR6F-W+5U(M(3*VGR/2",B4`Q/SM8`_9JUY5!1%)ZJZ&<145_DE
MS#107L'@%:EE5;6DG]BJQNO;(F[\B%*Y>S%>1PBDO#-3?):((R]-N5NT[&IZ
MW^IX"ZA(OGU[C^;W;CP;AG5SR%B,Z91-.+Z1LD5=!TB41:.[^HI%]!$9'&BD
M:V"7HKDX:M4Q!DX1F&3*WP#\EVEIE*-0`M+KN;_D.@.R:/B`<AL9E"A"L=Q%
M*CT-:]G2=BL0^;DV`G(RYQ78^+Q[*O9<B7(CN%;3$?$P;(A(H?ICWY0)<3%M
MUXCDJ[INVQ&@Z]OZX.<U&4H]N4*8V#(FC2+JL:C:T#[4&C&ZGC.M#V2'!.:)
M*_'271D.,T3%@\*-$HFK_P`H799S8'(W1RW.L`;CPY170G'%76%<T;:LS41P
M+'Y;<G.1@:A\4#0K1(C((D5";1&`JX8,I(!;?,N73P>F+DJPJ0)H_H"3SG.N
M?KGZ_P#:*X_?^V%=\8Q_Y8_;'_#WL\\\\\\\\]2_Y!XV6F^2;6@XEE7F^9G0
M0CI0AM:LG5TU_6\`N>#&9ZWR2HVCEEM8S>H(O1S9+05=/F$0_DQEBH02#(>;
M2KE/67\>'1-$VIU'3XAS4*4=;V8WA=`DZSOBE*?KX+A:1OIVZI]&.KI:RZR&
MX8/F)V\UUSLD+J42D9B9KMY64+,HI0\,YVCL?H$\\]X*?[FW^7[9_?\`]W_[
M7_\`#_O?M^_[?MC.?ICVKCXR/N?U!\D_X<$=5LE_UF5U?01>H"S=P@I_17F_
M[X@V2"Y:<'ONCI?[P];*HR2LHX;$Z+@F;1I2K-1;+:5[T.?OON%<-MTDG&VF
M=$%5TMUT4UE,?8245037;;K))J;:[J):.6^ZNFNR>JZ.VV%-?SX\Z_(1V^3P
M?Q^]!VSMS^0TGU]TU<?(![6=;UH;CAS7Q*,$W2[.O+M'S:>L\E:/AQQK02K*
MP`*3&G.1V"D\$#$PE7#&17Q!EP_(YV0]HKKN!:6/5;(H=?#U?G>=87-38(0?
MI`,/ZN+'8I*0M+D1I*,WEPU;-#TS"JU_;T^*PF[J:C5;!'4S(2)(>&A;(6?V
MP><GV:^G+"$ZIM36H?A6/^L5;":UZ^&[AER8'LZO(A^%REAR!B4N8^J)[5]$
M$!'#-V^BC><AG)<_>R:K=BT8]OTSV+\A?-5#7_;#H8I%_"0D7RJ1TJ6&B`VK
M)2\K:M^`5/7&(2(#4UQEJ3\!:Q1K$EU2VS@C3DF.9)<;+Q,L=QK.;E(4Z5Z]
M[8:.;YY[5N$`A#JA?E&^,"HD+:KBI)430.J*[$,Z3)5P"="YFTBQU%O11\8/
MQPB(H,V07L(,C4HI1N*NYR;>XO<"]DVEGO)7ENWW;:JMITHL-A4,&55)-;A?
M2E?`M;MY[)3S]T,/%,L&/K2&Y]*7F+DHTV91)T)BZ2NL$/KQ`N^.2FBO<-G7
MISGW3\D?1W.LI4X^243\/G-70Q6SLBO9PV9V2QIVZ^Y2I8!TU&S8!7@'AA`#
M3L;5/GCTE>##?2)_+1B0QIMNTL1<GR"7P"]`UA@=>U-.U(6]?\7\S2]>00Z3
M$)&*#G5=;P$Q,RMJV>L[A(,)NL;-"N-F0ZLQAB7).*C:CY$=1\0I:H_+#M9+
MRO$^ZY5^+;I_\W#&E.3OS.I`=?5VF#N<&X[`U5_M;4Q$DDF?N")91`P)I:NI
M^7.1G0:;Q#"%(X`78+(2HA*SIEL;[&O7JD6ZLXQYCYP*Z5"$>FP/JV4G3*UZ
MM+;-6$YZB1.M"85?1T0.6G7",M%2RI>]AYJ#</8QUKJHA.-2#/Y9D>EH"`OD
M'Z1+@]EV,VKH?=<<Q*W8NUNPCMV%1QB'"G-N;?;BTC6S^/L"9-#:UW\_3K\<
MLFL2:O(!DRV*-GP]*1FH&_P65-L>V.@,=2\2]=SY34<N8F_P]?(Q?E?1<!7,
MAH.@I%B(X[M-B(24YH;_`)O9]=QJ4N-Q[!9=\+34A)-B\B0>Q+,OC((5D.Q_
MF"NFG@P!LTM$JNEQL_\`B%I_N;>);Q))`IBU\V?;U#4[HTE"54MDONZ+BI*[
M$R8C:J1.Y?!CXY(+H%3]3?5)*X%M]&=:\T$@M65D3U+6BYZ"Z:J2DN?"X'C$
M@JQXJ"+Z>M*Q;"=617)P4QM;-B!P3TT7B%!K-;%Q%%>LU%-RAM(D`L_9E_4@
M?3?8L];-.\;6JSJ:J;U-&/5=G2EC-F3,Y;3U`4`4U`,UXZ_IO"&#D:$;@L9>
M^`QW8P9I8I?#"<"'&$@/N,I&PHX%?L^"5J^8?%QSHPE,1.LHP(^EF,GB`8*Q
M,!^9,^LKU;/_`,AB5UW:\5!Y=I+9AXQ=V\7CHW\*S6>.U4=W"FW;SU-^B.<2
MFX>@^$;=@YV`C(3E:];.M,QC)7,G^:$4.;\N791<?'#7X)DY9_F30ALV)EWG
MYNXCVGY,PD?N'"LA^%:+W'Q^V,8_MC'N?////>.=-<Y^N?K_`*8VVQKG_P#N
MUQG&NW_\6,__``]7[HCE:@>K!)D&WQ6T*<L(60TFQ*9V6DQTZKPD1V2W;%M7
M62*/X.PJN,6FR*?X4LKXG&R!#3&R.LAE!15+>D^T!\@O%6<JATG+?))S<QRG
MC]$&TV*A'=]9P+75OKE,1LJ1U'ZEZV;,F:3G\/"VFI3-O.,):*OK9M0B?8;[
MVYYN[)Y]ZK93NE3&JFQH%J(M;,ITY@)ZM+VJ.46SG36)M>E3V/@+(`72JNBN
ML<[GAYO"$""?YB,R\U%+-WZUH,ZZ[?3.<8SG'[ZY^F,YQ]?\\9_G'^N/0A=7
M,W._1\.C`7_1U373$-=5?P#*TJ^%3K6,45UWTRYB%R.+D'<.]TPIOE%]%.&3
MQOOG[Q!=/?&-L4YS\9L!6[?3/(G4O7/(BC%DJWB!4/M]U>-+LU]ULK)YQ1W5
M<?>03#QNF^?LJ1M?:@.^6^,I-';3?[*F/P#\,?'-\RE/?->6VHC7-HW%9W(W
M1T`>=6V$)V37,>[MH#.=T3R4AHHF/;&"Q\HDN@:IDMGD`&3<]';-FTVT9E*(
MRI$K)L?Z'E0_)%RQ:)C'5-/%1#SY?4CA%-MSUU.(3?/EQR+E;=33#<.@;$1B
MX2VFZ64M]<S],$EC#+C[&RC2:<)?13-\<;:Y_;&?W^GU^SGZXVQCZ_3ZYUS]
M-L8SG'[9SC]_\O>7GGGGGGM7_P`R5;6-<'QXW76M2"YH86*3DM![#<-7X]DG
M*=-AKHNIC69FXV+5:NXY509&QF9(_I,IYBU]XM-BND\5>(,'?PV?\;^UV3$E
M<!'T$<,+YFK-Y<L1J<QH&.QP<D(\H3YL4U=4$W3<_N]1F0!_/6:=&QE%D1#F
M<7LZ7BC"*=#+@(#X6#]8%\6PR"*UI(MN@[??DE0=W="]R@I.M#5:E)(S73L?
M:<5:]93S3]$KPLT+S#2YSY5I/Z1<:41#]]&KP[J.;13=CMT4_P#%'"*P$O)U
M[T5:=47M'=GW;W%4M]B@Z`OB&K;)Z#92\/:('@0)8F9#CRG"4?G9(?D0TO8N
M9%Y'Y8KN2-25BV$@C.B/#TCO;G/]X3O0=D&=D4-2W0U4)3Y=!`[W<ZE>F9,"
MG[#.B1G#Q,#'1+J/G*Q#%`H/#F0\$BT,R=CS:(78.D=V4&U=\3HS2P]13*KN
MDKQ"2NA>)33A<;.H5I6^LW*5M.$(^7AY=)(OA%^V86#7Y4-1<S'2(]M$0T_E
M)2/((9Q&JJM=[6\R<B#/-DQ>YI$2D8^/>C#F$L>S'HX%Q5=@\B9CP5$`Z)2R
MK@<?K1#`G)V<,VG+%(4Y':1-B99>0<J1S%"*BXRH,#\1`/"5WS)6NE]6XE%<
MQ)]GZ#$]!MA@8,YE;ML?LH=/Y-R1PK1%8>G`=O:I-(UG+"K>+7AYEM`OYK2?
MQ&JH/<0:?#"'S`J3"ED=(VL4M2CC/G?D79V+B585J[%G')=OS5T<[7:#9'QY
MVD/V-7QM+:DN[!SI+B$^4(J2LE#_`)0HS&8VX_.O'A-3U]6STK8701?=-IW9
M3M%U$>8?@M>@0<JA0;^R7PP30D`*QBDE$R\HK:)2M,LMB-Y#;NY!PJT9-VB<
M1'PV"E?QL5I8T;\@8U8YV<$0G\A!0(FAQ'1>L.)S-6E5?UL`5B#$-4E$.VVD
MXZ:%8ZJZ]*8B1GTIM9J=CND\CA-F[7A\8C/_`!QV#850B(_;W;U[V;T)5%Q`
M5XT?TQ)!].#DW5QI5S(I@A1%I50B'0U8$4,0B9P:BMOISD6K,VC$%LL@[G()
M*/$41C%9WXI-9F*L>83ZCM)A<)KW%6?R!#]E(@U4KL*_O6O:O%:;79PH&X'=
MXJ<`R*NQU4?<CQ5*RSZ,P[;2<?-_G3!>3E,:=_#VSA/R,ZJ;KR^:UZ2#>GNE
MNE0GH?\`3%,%LW&J]=ZPR-^U<0UW,`3>LS&NC?4='IC#*4'F\C`%H]`SHX[B
M6D2SA4Y<*OC=G-K1!;CJ/LKI*F["_I&,4+T03QNE7',MU!60J4%9I$.SI0\!
M)>/#+5AR,^/=Q:T:WBQ]^(09C*BH]",QQB.QT)A=V_$["VIMT^*"W2-KU52W
M7!_5%U6K54"-UT4ZQUZU3-5,_P!;(`S$V@YF=@L6(QI@(3LX>FTBEJ0S\9L4
M1CZ!>24^TF]N**>4DDT]E-UMM=<8W64PGKNKO]/\:N^J6B:6NZFWUWVU33T3
MQMMG">FFF-=<>SSSSSSSSSU-?D`7)D.3;3_2IZ:5H\=8#8R2+:P.@"LK;1&Y
M@]%XDGA*</[3=L:^%KB+()Z^%*ND"AZP:+&TU#1K.4AI=]&R[&JG,EZ=%=`=
MD-2`)H#JBA>00SGLJ#[6<=?ANE8OK/OG!>#.JGF:6K65F9(T8N1H5TM)"V+`
M6900D<;SHRRPTG)4<AYAMMU]B!Z;P=<!\^;$>)52''6&[YRV@8.7)IY^IE1-
MNSBX$<@&<A-S\Y+/EVL9#0D0Q=R4K)NVK%DW577TUS4D#^0_FLQI&\KVGIDP
MJ,>YF)I@+Z`$[G`R.OK-JHMC(D?((\>(`!\V=S<C(F4"7ATM7.@KH1(V(@6C
MS4.6F).138:S33'1(%>#JP!Z"0(Q>P*IE82&LVKCV(T'+"!URH?:E@BZG(1-
M[)-]H8O&G:<H.ST3)2D._P`MY>)P]2(1PCAXFGGQK1\[%E/R4,R0FU,)?7Y+
M;@<*3NL.P@L*,']%<T2$'$?EL8JLTTV%X)U&"N[W&_XJ8WA=IF0T2D9!VEIL
M_P#>AUMOH@KNGIA51/7*B:>RFJ6%5$_\>B65=_\`"G][OKJG]YMC.-/M?:SC
M.,?3.IWXY?CK:<X476L!T+`0!/<-:&_2)/#?EMI6%9M50&]^V9:9/*D80)&K
M8?&Q(FFJ_L]Z`ECB)"([;\,X+F46\WC"Z?7FYD$OBWX="F47'1-//GD1"\ZG
MW)#"'*;5N,SA$^9;(>ZOB*CG,06V#,QS^N&>VN&P@.OV[EH`Q^5&`3^0MU5-
M=I;B.)N98>=AR-*LTI.4A.?Y?EAO^J"LY,H^0H`@D$9:?K4DAB\GG(@OB)Z2
M;MWTZ_*V,U/3"Z*>9&7<)XRGF'@SXKN&`*F"CGP;IV52J,OD@=_+BLK<5Y$B
MB+*LB%H65P(P!$265*E0G7`$2L6LX'U@+3D/7T!))[NF`VFJX<Y6DTPX.Y5/
MG=S2!C5^Q!(]`%U1']JR3XWL;$C/'%"JP2U.ET5(-B]N\"2*O-QJ"P.2P$N,
M.VND:W3547TRIA3)QOD:AQ.R<VK$"\O^J$SHIM&-;2QV>$`D.68<#KP/+#T0
M!Y\EDA`/*)T5DI0<=R`S#16-(N9GD6B+=8CGUY/K[+XMYMN*>NHGL0">D<MT
M32<=SE<BV3VQHQJ:TA%.R-\RKE>.A"Z-C8>"T=&)>HMN.-(>2>8*R5)Z_<(S
MDBFXC2=^-#C<CGI(DE:U(U9*5M"DKN>:M;DNV,COZR\\P,$*U7:[:(B[%9Q;
M&QHD4&!T7GC)BT;SYR.P[2'-WQ`S^^36]NWQL<;;'_\`432K9-M.)=$-.MHZ
M&8VG;\<!0?2;=&5;O+G&ZRCCYI7PV;$6)R46,G\&-,6QF^>N9$I:2KYT[7<6
M$,N>ZF/[=J6]BH<>R%IT8U,V56$R!68Q28JTL1DPC3AOI`0Y`P&9A(HCXJ+9
M2NI!#2WWK>.8Z)91RU1VTAL"^/GD.L;QL+H@&I]E!65:4L4$9IJF5GCRO)`O
M.8_\I.CR/IF2*7E.CEA'43LO%FY^-@D27EL<^E64],OF\S,)O\9K#XS>+J@G
M`&?"JE?:+U4&VA6U8Q1-9UN'0K7]8W)I&IV%5XB&&YX0"<+6DRG$1Z+,!;PW
MZ6'FK9-H.1<2V3222Z@$^+'@^NHUS"0M&-I:,D*$GN7'T>?V%:MH-I#G8A?M
M)%U3+U"R#HIT>UY&+1T:W%AMQJJP"HR+C8H/3@F#%!#7QB_BNX1B^?2;E_>D
MMYRIR^:%2.71,;/M\XL;6<`-6:==2L)=I@?S=TC+VLV[!LTK)<9/HC-=LM5V
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M&Y64RM,`\NZFZZ*M=<,R\/GX_=5FI6#%C]Z\7K9:W8)2G?\`SBRVWRG>U&!T
M4.]@UQ!(9WS^+N;FR&5:"?0R35!1'>1->6TA8]??AE_R_F"275V=YO-0/2E$
M]2`:-ET#9PM9P?N]<1+U^//%,/QZ>9;?8D18R')%!@3@IC$JYPA-!IG#0)3#
M.?JVE(AHOC.GIQ]4NF;Z!;&Z6[&ID?K_`/39ASR1T=#GYKE&$T_J,[LVF8BQ
M1M[A5@V2EUOTN/2"`U]9YPZ5T_#_`&([9%AC1+$S6U2E/WV%R%<W?5U?6\`2
MN=-I$*LP.'SD6=JI:[:H+JP1+'R4=ATW^WMNV=IMTW393Z*MUDE,8VQ0O_J^
MK'HS&CS@WKBU:#BV.R&[2@+MS*];\JJ-VFBNZ4-$!=EE4?=-41"J^=4D8^E;
MY!QN*;J*_A@]UC1!%/G':'4-`[99=J<8F?Z79Y12<]&<2*D'5-390QHJNYF2
MVG6(]`]65P@BWQHN_1C*KMT:AL)NOQ9\LW12=N+DT-U!SQT^-+%O/ES5S;\&
MR43;2ZP(4Q<Z^&Y'?&<[0Y;"-U\3P?/-\XSH\@2J+AIEBKKNB[8H*Z;Z:SOC
M.,XQG&<9QG]\9QGZXSC^^,X_GW/GGGJ&=#='V/5?9G`5&02(6O673D[TM"63
MO,0<LY,&"]0T-,6J)O!2>0)&D-&-%I.-W:3[.2&)=R];91V8R49]VOHO7UIW
M2<29O\=R(-:5%7%57575W8].6#8`77IL,--!&DZLZ>L,-8"&Y(>2/Y,2`,M2
M;,!M><DV4Y%&<U&3\X*L@N*<H1^EFD>OZS.C[DMO6MY5TU%NALV[,#HL45W8
MN#.\A2OZ]DI]:4I^;>N!9@-,A5^FQ*IHC(ALEA"X137C1?9!\]9S.GNIGY$^
M,.@SD1KFG[Y%S4M/Q@U+@=BSBRZ-8&$16Y`J,V"B,$,Z.1(W.3X3*I8V*A*-
MEW!;`Q#F/(I2#:CTG'RCF0J]Z_YIM0J&`<$N(/G2TY$=[!`1_1VZ82=A5XF\
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MF^BW2\U]AUEU(1]&CE>1QHR7YLO0GH0L7+`PJ%4I0J#H$4DB%W$9GX2,2W8M
MI4C<0[9'*ZD@[:QB!-AHD/D`^\?PMSMV/-D91W9'7S*!D3$\Y]QYYDJS8*%R
MA.9*1^9H;GVTQ"'5&DI<V(S6RWTQ;<Q%JHB3%/$PA%I.HT8C&[=WA.2Y7Y"N
M/88'A;">7/&*04[K;NS:/C1<^FC>/UY_4U1O?8EK*&$W]DA^*3<*-VMNY+!*
M$_IL\>Q[,QQ#N9*.2=21(=6T!'S0A!:V(PEG!TWK%T-28U$$Q:*N6]U2NL+4
M:LB:BT',AP_I9<CM]V#Y(9V+_4R&BS^*_$1Z"KK7%>3.P:V[%%K),*QCB]A"
MUO=%J4J]5,!(G$G,C-50:3`)-2;9D2PD,NDV<S<!*YQ&[XWF(=LDV3(FD1).
M<QJ.OGF[Y0)>[+@ZX)9RS.<!SG;EH0M(T+:(>5UT`"]T!0@!:J*P]C'\-:SH
M0#G@$5PT`0E#&:#`J2@-4)X0'$RU>6;RSMS%Y+\M5YT[1587E;-5@LXOUC\>
MG2/<W.=8A/Z@:SH454/6(A>C3GZPI=_*O]SQQ.4Q8,802QV.P@?O$D%>6"R;
MC;F,FAK:'M?4'<MC&83>(>JA7!U>P1U&2\L4P1B;:1@ZMNB085+6-MNK<UC-
M28P>P5=55#6),HVPNR+99'5>MI:+A9)(I*((=TVDQ>R^\:PV<O6TBXRR:Y7D
M&;?\(T?K903^]>M6OXEY^';.]_M.$$/Q;K[E)31/\2X^S]]O]_GGGGGGGGJ!
M_)X,QYMQ5;`:Z5MG63)I:IH\,:41"5_.7)+60WN0`E*VA:WUM1H]KJ"*I8VC
MH1DP.#))&`KG"JM@/Y&*2&<R+>I?'*<P&](<]HV7V9VG;A!T1QT87A6-2](3
MW-!.%XB,OZ->V&HB[Y]I"F)"/LFIG!F)06SXCR4!Q9`&<T_"UV<A'3B".[#T
M:7!;M84/7!+;%RG0[6=:"*,>L4G1;()1(T.-I:7CX!B]F91?7+:/9;R\M'M=
MWKK*;1MLXU6=K(-M%5M/S5WW5UO$O._R,O`TZ6ZZY^1[EX2[,@[5@!46F3BV
M!`'MVD;`ZDJA24K&,B0ZZQZ@JXJ<7P!2HP-ZZ:C,>G4KA29)@9ZHGL/YXF]R
MKY$_DKZOKU"4.Z%9\X\=U)`$%=HH%,1<]J5!&]`6J<-JR>QCO6&.I,0&K9!`
MS+R-D'+;8NFG8?F3;24#+,V7=_$?*C<]'?(%/B=6DE*P9#\C=OD*59&(4SKH
MK&Y.>I'FZ8(EB(-8+N6L/,$I(]ERU]OHX65EEY[><=*;.I-?/MNOM<WRZ'M@
M57\9_;5FU6=%%:V+77/-@G0:;!K]&,(X*?%8S\X8+L'RS1YJAJLJU_"O,IHZ
MN-V:RZ;9PU6VT<)UZ[?Z$<0$EW97(2==)U_=M8_$+8_0XG+P9,(,Z:9)-EK2
M1%K!"&""TN9,[QAS02=14S.3,?&1>PJWB6T>VDE]L/T/@G.ZHO\`ZM>TK>*H
MKI:6KRI>-P4EL7IFA"VJVYB0F#ZK!Q[9>]'$A.:8<2MAU;(O7;HV*I6%R,0Q
M6A)C4>\*C.")A:(E+HOY4P?F@RZ%#YCGWH0_A^2JKH6\+YL(2UJ78<&:5NIR
M?,OZBL4R"RQ\@)?T5M6Y(J2BL9`IF,GAC(NAF`DXUGH^=R7<'R05+4!%<,:]
M#+%+("@KBYUH&UB419#KO6!MCJ9B#/JF@8^(EB&&>S,:K_52J6A3/ZK,64`[
ML>`PCI+-(PR=B]BKCZ'@JHG:IK]O!2);;MXRA+%5A6[&0AHEY+8"!=<Q.YR:
MGY1YB#'Q<)@4D59^947D%-I&3@X2$CYF7FH]FMJWO_Y#)^W8?BP<H\+MB!3N
M;Y!RCCSJ`/:E`:`6W6Q/3=77F:V-1FQ-''#;,$2S$Y6D)*-[#KXNQ$2M987?
MBALQ>F`ZNI?>3,2'CJGJ4K53^O\`UJ9S,S*`40<F+D44(,-(H<-;&W*[]MS$
M4'U\&CL",#FH4W/"1HC(EI2L'PSG$X6D[V65K)6OR>*7W>'Q[#E+5'.R=)=M
M<V7QT(X.222&(HL"OZ03M4BC\0>C'ZEV1W<#,S9&JA;+P[^?92FB4>B"8)6B
MDE)L<EZ5NZ=I[Y'^3D)VTB,4H:4XJ^0.S;:%%I';4!^^H6=Y6E88_E8EHRW>
M.987'SXVT_%;.76FD>OLFS8IN/MJ..8+Y5*RG]S5K#TW=YA*P]("70`'"56/
MP]MRED!Q@8CH"U%$<`LS)1X+;8^1EXLY,:Y/I"%=0(A-Y.4I:2&APT>#/9Q7
MRA5(]&)9:5''`H?0793CA:1$BJP*RA1A6\TJW:7''M8JVWA*D`R$&4UI(1\D
M&Y4=LB<A+7[6MTQ9L9Y<1[?LJZ[@L:P>ZX+EIUS\4@`=(<2A74LK.&4J))&X
MX1'5F30+^BR<<BRA^C&ZA[@5E1^55@W!1M,$\BDZC]T!6,2G9B&?DT.S/GHJ
MYQO=AUC;M-(R?47-]7-!G(BD_P"0V]>F%B04%<"?3\LT`YS$*F:BLE.0("<D
MIZ#:0ME.JRA1!:+45*927J9T9W->L$"?+%VF*GL_"C/QE=.UQ2U:4ZT4:Z!!
MT)5B&T,=]+XLN&RT4W+)BVVUVDHV*3*LDS=UZB&@<F([#TGJ8O"Z9:]Z$[!K
M#J6SR:[&-KS-6,Y[MN*)PYV,.DPJ00UZ"I<3^+44YN?;0[&`G[%NZJ)XW9E#
M,;(9G1\4/)%[:FP](P4+EEL9Y%N,8L>$+X%:\!>W;?A""4)+5C!:24=#X$])
M"0D@FH@":KH(8E:T"ID*)ZO@C".WD(\F*J]-UY"0U+T">*C+A>>I%TOT&>5-
MTC\>]4BR(^H,=.=!6M6=CJ2T<N\E4!P,Y+OBZHA08=I2#1*+D]C&N!])ZZ<M
M)-->$4DF.C9!9RF];7<Q^^,9_OC'N?////////<9QC;'TVQC./[9Q]?X_C/^
MN/\`+/\`EZB]^_'_`$[<ATK>@/,FW,O5*<<TC&?4?.LC$AEJR4=&Y;[QH[9[
M"5A2"N[\!VV6C='0%O4)L$>9-]=]H!&!D?N)-O!^.K>K..],1O>M5(VM3\?A
M;Z=P\CA!-,"L%#,D=LXF>E^7-9`NMRG%M4&JCN;.:A>WK4;;7=>8(7540^F&
M#;%>5^X/BT/NL;\=\V]%1E@7%TG8%:#9T21;<^DZ6+K/K.E\1@;7M:6^Z$FU
M+3AYO4XX[(5`42/IDDG&,/.SC&.=)Q$O^!W!8SC;&-M<XSC./KC.,XSC.,_Q
MG&<?MG&?[X]S[C.NNW\XQGZ?7Z9_SQ]<?3/TS_.,_3]OKC.,^IM?/`7*?11,
MWL8XJ]N/W/'):I0?0E1SY-2'1,#JBAN@U1C+SJ27#K+WC6^-_M9'Y0BDQEWC
M&49"%>-]U$=X'_I3\D_-VNRU.7T`]SUXPSIEO5W7[)G3E[MHMHTWTTCQ[JJD
M0UT%$CG.<):M4[4YN=S$BOKLK.V=ILLH[T[&*^46E0N0;"O9`1:?`9JJLFQ3
MWZE@8Z%I>=D-6VJR^@5U2$2ICS23:;[[:ZQ\:\LL=,WFNZ>%@UDYRJT1A'BO
MY]/C7[ZZ.E^6>>[9)9*U$4"9Z'(%M?D`?`6I&""&[Z??UO-2>NVLKEG$I.9Q
M*)FVHX0O8)C(S#*&78Q[U1#<_P">H#TC05GV-VA\>-WB,;"O`+FDNZ1G;06?
MSR$;-:,[:H.9JH7T&(E1LMB=<(3TIH^FDW#R(391"6ZS162>[:L?:H"3XINE
M[2H?DFBRN00K72L^S_D7OFP[`K6T&6Q0)!_5"_6LA3\@'-G<*E&G<K!2W0XA
MM9U<%:#8'+!<9.@>;4)ATE2:R5UHBD>V+.M;XMKJOT`J:`/^493HS?I)*L[!
MT?B!`]L'GV5I\7*:BBY.%BWNL<1SKY$CD@R?6CU`&/5<PC*>+=6#-Z_J?6'$
M]Z\\5C\=I3=(^`H!G"TO\G=L=)KL3-X1--0?H@;OB4%=!-E"CF9\P4:1EA-]
MC5HTC8V38(QLKJ/-B=_O&MGL=?#\:_B[&Y)AIJNZ],=J_P")7?.M,VW3/==,
M=+CP)3ZJ@G:DE&O:H#JY`+&&`U^H"5O6S2Q+"D3"?B7X;7H9*K+SY.2&!->"
M[N-NAIPT^3\!'H40L&G/DWJ:#@(DNG2AI%/N>S[_`&>8_ELSC#03D6:KXPK+
M<0AX"TPE0'<OIW8VP7",U!P#"6CC7$V<Q\MV=1_:O05D2*#>7IPUY,XGH0&+
MI`J:R!S*$/+"EZMR&5+![1KC+5`J9V]%.8V32EGKA=_#3?YFPC]74>HO4'OG
MD/MF_+#Z';@=?U40@DN9?'G:%&RK2SVU3+2'^S;T$`6?=`G<\?'B3Z7L`]?)
MBKK6JR,Q>$E?B06ZQ'#4:*F:,QDWO;Q5SS;//E@=UZ'+4-<A=]=C'?2E8D@Z
M3R,C,NX*S*^JV#?#Q0,/1F+2'),5EP:1;9<-9Z?;SK9XT>M]8[755#VOJV.!
MNKY)WTQ902&TX9%&?E2&^]:IJ"QSE5B"WS4S?C\*Y,-:EL`B8B\[FLC22BHT
MP,0>=5@2^$@25('<2NRK=2>;Q_>V1Q_U24BH!"@',G,%&BMIU'VRTN>M:<.H
ML-GZ]NV^1`!B:PGC&\(BNH@KMT2EDA*4VOY,!C1-\:'&*UVFV5A!%?(+.<5K
M3A+K@92XKFH`:0H:[J1H3@BISVTJWO;0CJVRPRBMFT;>M-=-T1-1J8A:L;&"
M^I,\YZLX''&]CB9V9):1YJ$CXQO+3^QGA:A;>YN#^E`DXC`EPB4]C]?7O5<M
M!&,I):DH7T5>)Q=HTW+&;D/CE@R9'TS-L)S;5HN7:.'D8_F&3C9DJQ;N(1G.
M4#[MTK#K4ZKI.`YN(AOFWI_FXG'`RV8RVR(MB>GA\9$2^*;GD"+B31[4X]'0
M+DE%&I%',R67,I!A+/1($V'UL$N`\U\,WHVLSX\Y2_609%P7QD\JV3S\)3(S
M-IS/]>[+/Q"NZ4TM1A"ZHZN0D'8TK6:KYT-$JND^L>V9,024<I``,87%^?\`
M07%5F6Q2-SI"#`/!#Z3(@$7J2L81VP'`*&YBK/HH"M@^IS92$C?R6)F^O(`*
MGD+<E$6683*)2&A$WK)P0"ZE9:T'"=,6'1%"K!=D+1[.2E+EZ,L@9!XAZVE(
MBH:SMF^K#LJK*6BY-DW:QSMG5%?E`^&?=PS?0<C'$8O"BRCH9C(AXXN/YYYY
MYYYY[4KWW9O9)43SM#<I<VT+=H.#U=!V]T<\OFY[!IZ0G8B8G"E8&JGGF7K*
M!F)Z!O1TM6DL80]GDCB$#P"0;"2C>5UFWBCV$D[C3C?D:D)4:OZL(FQ9*U[@
MI@6'QLROZY;-NJT1VD6[*"+XNH@I]:)D6Y`@`<<2<.YEQ(%UBHA[+-XU[/;2
MSME'.$-CGO!1/15/=)7351-37;11/?7&^F^FV/IMKOIMC.NVNV,YQMKMC.NV
M,YQG&<9^GO%)!%!+1!!)-%%+31-))+35--)-/&-4TT]-,:ZIZ:8QC&FFF-==
M,8_PXQ[TI-&K-KELU;(-FVFJGV6[=%-%'77?;913&B26NB>GV]M]]\_9UQC*
MF^V^V-MMMOKK0^-UL3-"WY*$"^6A)N=Q\E-M*J2([`/1B*WBG-!\QN1EHG#R
M)`4.TWT4+K0T3-2&TTLC.S;&1GV;&$92;>"C-G7JN]J\W9[!Y1OWE[)C_3Y"
M^*R)JP?&F![!4L.1I6TS'24FT']IL=3DGR#+=;\"DO,-&^CK9-9QAPDGLV5K
M?>GQ]3MVV7?UE.;HC!M]?7QVRW`,A'M*R=2*`VQG9PUGY&U(]RI9#)=^^3<G
MLTBP$'&&S=!)M%[KDKI1)W^+KNW^'V8@.;NJ^1P3I-J(<^]5T)`5M+UVG2Z;
M^(JZWMPA@"6K>54(IVA&(#;2Z&L:S*C*H]D%Q=M8NCTWBIE"3(BS0@E+H/XR
MIN_<=[9D;UC!W/=?)5)\I3>&-2N)'-=Q=/\`]5\K&,3EU:+;!'($N;E+ONH=
M_P#E+6#RS&_M/IG\%*?G%`+4%.DE.ZN@)L/@W4:;/+,YZD06O+:^+RX[LJ2Y
MG7/E:"[6L;+%.LJPO4)HNN8?4\F#>4C".\W1/;=#/U%'C=Z\:PH@,-=S72O*
M\M=E@\T7N#'32LKTY<+3.<#)64@G9R"$HE:P4H!VY5YN-MIP+DY(>*X?2(DX
M:?BIJ'FQ@Q$Q8C2;R3)K*#DI!#GXVT4YVC"Z!M-A$%M=]YG/R"VA)NJ]6DVU
ML6Q85:6-44R-Q[%$\B\`8G%`%AZ0(RKLN83+%$-%EY=U.N]YYQ+V%Z<YL-+S
M,.:BX1MEJ$-:&MF0L$DK\L!M['K.W8F3!"(,;1Q2+(EP7LF5`,G.-+#JDI=2
M,O%B)[!L)AZ)SFVC7+&HW+OQ<S?-B/!"Z/0^2J9X?`.FJ>P]_I,QAFMJ55T:
M:`QHXC9!GN=2F1`S&'U;"3;8MC%92+G&N2+5(.@E9.,5@['=&<0P?2M^5K:I
ML6I:@@?S;U=S.5UBD..-W1R(=;M*QCSA]@V2)F>XXYAV%61#2);H#,K]_K+S
M*CEVFKB.V9UDC?CLZT6Y0,N73?Y$2`S:QHC7U=42:I4-$",G"`->'885)P_1
M34>LS1QT-*G`B#L:9LB6AI:G(\GK"?-T,P*).7R4_KY1?QB&,;&=+#LM:M%6
M-7?3W3+/H2PJ1LOE&.(:<EX5?FX0H:=J"1&<VMA789:R]?`M@U[/,5VLV%/!
ME"*D]#)>1>324F<S_'`WYBMJCK,&+T,RUK5/&4#QJ0P1Y#ZDLF9"H;8\[9H1
M/1YI(D;F=&MAR4)I8>_*930U<OA!D+QFQ`VD89_,3DJWOS);W14E9]:63<5=
MR/(5I,PIC+5`WI%^WM=G%06\2[,A=*Y]K85'7<!8<G%85=O7%/X*!6*?2,:-
MS2$EM%$4/"ES?&3`6N0]%#R%E.Q[GCLFV*7NOJ2G]1I-])%IM3K4!BI%H"F2
M<TQ1"A:[!ZI:N';BCGXT32;Z-&YU87EX&2-'KR)O-/U)DLN`.L8FG=I,;K>%
M=N`(!RPUUC8RS)M61CYJSY1WNY5UE9Q@&N<AX2A^";:BC$@/7OXB2>$['>`I
M7Q%\:X_QL?NS)I9$D;M!NCXOFBI(A2#V@U!NFXF\;9OAKH;/]YV:U-S_`&(+
M4R/+%#)D*QNT`*1Z^@^G*S<RO[9WYZL%V7E7=8W1R%6I<%NR0LZ'MT^KVKB)
MO'0+Q`!*!/GVUK<FI]Z[E5DY2*1E`@!)15-T-IN))=S.(L7B>D,ZD%=+/X_C
M'T_MYYYYYYYYYYY[U+HZKI*);_:^RIINGMG3?=+?&JFFVF_V%4MM%4M\Z;;8
MU52WU43VSC;7.,XQ[\E%/_\`1X[S#KOEHN:ND$`:`96KS58,#;/.!U=E1WT1
M0/)8,F.5/%E=%QB"?-RMS3A/&CYM9/210XLJ>=RT?.N`H+&Y$U?/('=2IS_\
MDE6+N'-/]V`5[0:*22+,*[2YN'',^HDEIG'W2-T\KS%$+,5U/LZZ;24[39NO
M_BV650<*:_94\U^L^W:IRII?/QSF1K$L4TM'AWQ)=];]`P^V<X^SL_WKBW]>
M9KE32VV^N^\8."1T];Z?75-9]G&-]\C'OE0X<?3+<4L"YM><#E=+3/Z$ZY"S
MSDTJW<[_`,LXYMT&-5[&$:V,_37143EI]FX_WFCIPGG7?-]X6>A"2+8S@_+Q
MLY"R;?1W'3$._:RD2_:J8^TFY9R;!9PQ=(*:_3;15!PHGOC/UUVSCW:XSC;'
MUQG&<9_C.,XSC_GCT>VU5XE=57613YVT7>A5J@I=79>S:KX:N70V:P$@-S:;
M=QE-;5N\S'23C+1WE%79JYPBXTUVV2QC/X_.,O\`HJUE_'1T\U[0Y]Z]`K?M
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MQC^<XSC.,?3^?KG_`"^GO'?/UTV^F<?7&/VS_/TVQ],ZYS_/TQC/TSGZ_MC'
M[Y_;Z^U3?%FW$&LG\DJ()$34$-X^3R_%4HTAA2T?E=)MS4_/3DP>J11PV:$B
M;*7,EB"8AGB[?2)EX5_'3`KLL)OX-=3:YYYYY[C[./W_`&Q^^?KG_CG'T^F<
MX_CZX^F/W_G]L?O^WN?/////////////56O,7Y]F[OXUFK9(\0]JA]QV%+\R
M1&9EW&_JFS)#G6W!\SB\1R#5="?_``-*RUC3GX!ZNS1:XC,RJ:RCEBBV6M1C
M^,?3^/ICZ>Y\\\\\\\\\\\]KUYG!KB'^WODE+SB*+6=6GYIRP[I.1F7KA<:E
MXP;YG'1\^4#FBCU=%BV9'"#UG.:-VC'5Q,Z++JZ.%-LK[;"O<9UUVQ]-L8VQ
M_;.,9Q_RS['R<3%S6$D!DQ'8,K')9'+:4'R6)CY^#D6^W[;(/H>7;/(UVCMC
M]MDEVJFF<?MG7U")CXI^)TI)Z15)64URJ7O$]L9*^-['L/E)]EQMMG?+N1@:
M0)!`$)E=M\YW51,`\B9.=LY_%-5]=MM<](CR[WS4^VRE'_(:ZM*%8M,)QH+W
M#S^`VQG?[.-L_@];:Y\><S6&C]K.<:I3!,RL*01QC[QTC)[_`%QG&S/L;N'F
M<4*SKJ3A@?-JMK<+(3L_MWC;HT0/-8<7$8=W/$I#(4[T9"\YF;5&,AV#V25A
MA0ILB4W1;*HL=I)U]RFO`/*OS.2%V=(5/SU=7-RG-Q%?6I'K6HD56`6Z7A`+
MLA,DL4*<6;4EB4I4K-\&V0!"!,YA+9YV.^A:H@#B'VKDP+H2:FA=S-[2.D^4
MJ,ZT#(\/N@/Q-_IZ80*Z^-8&7EPVT:F.&FF<1EA4]:(F]B#JKSN,^OT:%`9.
M14@LUW7C)+:0AGCZ.=4@VO7IKX]\)P_7N2KJ/DB-3W2B^X`@.1>W-4$0CMG+
M?7M.F`",2TGAZ,98SB2ZAH852'4D4-I*VJ<K=@UDCZ3VA!!R%V6)#I[798-'
M0.71#.?%3$/G(LF%B6"D4M5V$S`$$*Z>Q,S%/4=]56LA'.W+5?3;&4U=OW^F
M5>>>>>>>>>>>>>>>>>>>>>>>>>>>>CJV1(F/*_(@X1/9VKY@C0:Q63T51BU2
ML9B74@TT(7PGO-1TO$LBG>`_,V8[+R$7)-H.8=,YK:/>[Q^C97\^]GW1U'R;
M2'?0Y5MWV)8M:?[7/'?*'']RW,2J6M8]7'?1!O5=1].L\6*5(2<U90_1Y6>N
MUZ_ES9$N?0%FMB8!F5IN*"]XIGL/YDLPP$>\NS^+I4L+C>N*RI[E7H2II(Z(
MIHV,!9I=.UO`=A`\F<%$C)$Y)$X**;:G(UO//Y1[$N#,E@VKYN.1X[#1?/QL
M_JS]5?)1^M_T]^HO^LKMW[W]+?FGY+^3?T'YF_27W?YS_P!__,_TA^0_J+[7
M_<_U'^;?E7_A/X'VSWSSSSSSSSSSSSSSSSSSSU0>@>;YNXK\X=MZ,)8N&C>5
M+OLJU""'>LWSEZ61YQS)<]%-(J(<-<X:L'C&6LUA/.%Y'&6RL?%NFJ./QB[?
M.+>X_;&,?VQCW/GGGGGGGGGGGJ%<Y]`V)9/9GR'TH3N(=4&YQ,.98:M$&,2@
MSE&S*T><Q^R2O6:DDU-UIA54GD7*K!1PFEEBRSHS2QNGIC;-]?////=(2C<`
M8CL\)%4/'$(P40TH.D<!+M$7\3-P,XP<1<Q#RC%QKN@\CI..=N6+YJMINDX:
MKJHJ:YUWSCVJ5?X9><)K42;G=Q=AV/&T]`RL%R\Q*>D"9@_Y(4?JLM(XDH0U
M!XT.L=J;C$1%0XL-&UGF5H$C`0C/TPYD'\/,$C6:^K3I'HK@);\A[L<.;LY7
M9*X:COR#!8MHW(J^CMLZ:1[7N>GPV-PS"D&V/MH2/4=10^*37^Q^;6D"T*T^
MLE);3QPD'#0?A2H3G8<H%R2*CYX=(QV493,%/0DJU3>Q<U!S,6X<Q\K%23)9
M)W'R<<Z<,GK55-=LNJBIKOG6P9<.'?/Q@17E\;Y(,U"2D4N]*;2Y%-5)-IQO
MT)-O]MU9J;U@H!J_D^8[GG5-L+J7;3,*XA9Z6QB1N*HK85VT>,)HYG[EKN_"
M:8IDP&2OG7J\)ADYFQ>5[FQ$1=F1$3JYVCEC@`DHA_(A]YTXYD=,MXBXZAFR
M@.4V6:QQ&J*%67HPPNW_`#_'GGGGGGGGGGGGGGGGGGGGGGGGGGHAOH$L&SJC
M.`&K;<EJ(."J(_*(:VA\9A2X@"<.7*&)"5@(0B70A5)O:,P\9Q;]_P#?IP[Q
MRG+(M7#MDWT]1&-^.$E*N=+%YGO_`*7(+-KV<'ZZB:F8@E2UW1B%$S56F+.R
M`L[$VHKO.[$9M"6%`!90QE2]Y)-=5A1-LY8._P!0$SF4L!4_(3`,+^F+9L0X
MD3ZYNKHH($[--11K,U*RB`&LPR8"Z^":S809=-E`(R@?U4;%V9Y`[D2M0\-Y
M^?83<2T;CD3`U:^)2-!(5I\A,%6DZ7DH6/\`R1W,.1<T?&UCV08NGH[2_.4(
M2(SQU;LR0V.4.HXJCYN+2E">=EEMV;)LE&OW$(E&;YVX^>>>>>>>>>>>>>>>
M>>>>H'U6$VZ2]2_&H1@$85/0*O\`I.XI^[WL$\7;P<0$RO&71`F-NS)ND\;I
M/X9Q9<Z&Q\>@Y;OTTB)U$.M$$ED$W2%^\?QC_3'N?///////////5,IF^@:Q
MNE>QJ9'P#(V8<\$='0Y^:_=0FF+&=V;3,18PV]PJP;)2RWZ7'I!`;^L\NZ5T
M_#_8CMD6&$TL6S\\\\\\]ZU4DUD]TE=-5$U-=M-]-L8VUVTWUSKOKMC.,XSK
MMKG.NVN<9UVUSG7;&=<YQG562<9V[R5.S5K_`!JR`U##DI)/22R.`K%G'8[S
M%8[UZ[4D9V;H2>8Q,Z\X_MV966=N=EQ&$F*`-IAPHL?U1&3LFYLN+LYS'VE4
MW33DJ"X]L357?U9)M-+GYCMZ/:BEYU(X>;839O9\91?2,:3`TRI]<B%NUU,F
M-1G*&,K"9K*;I.F[7)^F.2:0ZR%H8?ML:>J30;*[DU6V<&STN!7'2YM]UJFW
M.Z<M44=1IG718AA-+1P]@)1%C.L=5(,JC9\=>/X=W2K_`&B^C>`,IP7<*DOT
M!RXT451A>_@,+11+*WC,;_;9M^X*8!F/W`RQ8H9RW>]04O!*5*ZU04E[4KBB
MF:>\U*[2A4L%SH<@C$*(X(N$B>)8SPT4#$Q'$`Z0P<HW3=QDU!3D0Y>1<O$R
M+55)RQDHYVY9.T%-%FZZB>V-LY!C.,_QG&?]/W\\\\\\\\\\\\\\\\\\\\\\
M\\\\]X*?[F_U_C[.?K_PQ]/WSC^^<8^N<8_SS^WUQ_.-9'QNN29V6_)0N7Q,
M)"3N?DIMI)2.'9]Z3Q6D4VH/F-L,NTYB1'Q=VH^E1=&&EIJ/VA448*;?2,`S
M?3;*,;SLGLZ\\\\\\\\\\\\\\\\\\\]1?IZ^K`JSICXZZO$W$2D*](]$6U7%
MF)/XI!\_<C(AR%?MQPR4(^44T5AWNAI7HZLY>-]%5'$:F]CM]=47:BFEY\?O
MC'^F/<^>>>>>>>>>>>J93(KSK#]*]C$=8DN)6\R\CHYQTQ`?G;M_D6FX2F8B
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M:JWT=6=B,AJ7_JA6,[,2'ZSB]!G_`$?'_I#O9=U7E=8)\AYR97/1\76^2Z+M
MT.YMF2>2J4]P3-$(8<(TN9*F?;,A$_AG12JQ?&,-LVBY$09M(J89M%7+)Q^N
MT<^5SXW21;\)KVMSJ,R/VOL?D]CV3"5/.XVS]]^VT%:2@;+Z_P"!'*N/M,L8
MR@JV7Q]47C3=>VX'=M.6DWT>5G:]:V(T5T^VDZ!3T3+VZFGWB27VTUAV8DD]
M]?O%D4_KKMG'VU4M/]]337,F8WUS_EOC_5/?7'_/.N,>Y^\TSGZ8WTSG^WVL
M?7^_\?7Z_P`?O[R\SG&,?7.<8QC^<Y_;&/\`S]QC.,_QG&?\OVSC/[_V_;W/
MGGGGN,YQC'USG&,?WSGZ8_\`CYC.,X^N,XSC^^,_7'_P]SYYYYYYYYY[YW:^
M6K5PYPBNYRW056PW;::J.7&R:>V^J#=/?=/51=;.,)HZ;*::[J;:ZYWUQG.V
M*"C/R/T7+\4EG=A'"V-7]4!Y3:81(C!4/QBMFKF58WP2<W:!S(:')V=C'!4<
MVT/HBP3%:$.R+U]/P:<G(1FJSQ5G,U%=,0=S%MP51+"L[6MW4,Z!];2JXD>P
M<T]AH:T!]R3UJ5Q9(*OY0:(ADP81L_&MGC!ZFZ9$@D60,@Q0WBV[N1J#\6RP
MVXE/DE5$SMS94'GY.KYU2+G9,S+UEY-*I.>$B(?Q/,-=6JJ`*2:2X$SB],95
M&V8P@,NMMW4.OOMM:\\\\\\\\\\\\\\\\\\\]5:\[T":PN_C6LR4#R4D?15Q
MV%7=?D^$H93^G!`)<ZVY;TJ1YWD6ZTBC^;B8!.AWVX!5J_VR083=*[Q6[Y!6
MU&/XQ_E^V/<^>>>>>>>>>>>IM1O,\[5'4_;M_P`B3Q4M#]4$]`SP^/LV3]"1
M%$:?HV%JB2;R[MSG+)\I,2,6I+,MX[&-&[-71!U]7.NV?7)\\\\\\\\\]UDU
M"Q!'$2D`01<=-P<W'/8>9AI=DUDHJ7B9-LHSD8N4CGJ2[*0C9!HLJU?,'B"[
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MR-&63SDIG"FV'*2BC9BAO^%4;Z)ZZ.D%GSK5I\RUS?-]S#\?=Z6-6!#S`5/(
MEJ-QT_9?-E9WB(7A7@3+SC6/*CH4"#$SN$=34BF/V<3),A.[/@F&EWY+&(-E
MQQ.;3UT?]&?[B^:_HFK^D<'`S&]65H(DX9H$V;V)=EB5)-Q9?+(S6QB%AEAQ
M5"7;,V6P9QC6`EYB!ED(QO7RSV/492RN"O,0E^GW^I'RC_\`U1>(?_QZ73_^
M@%Y_4CY1_P#ZHO$/_P"/2Z?_`-`+S^I'RC__`%1>(?\`\>ET_P#Z`7G]2/E'
M_P#JB\0__CTNG_\`0"\_J1\H_P#]47B'_P#'I=/_`.@%[0=_TBCL_P"9[F_A
MV!+ZYK2M^;AZ8MJ*'K1NKECH"P;ML44&7,')+04:^6).9:;WJX;)R?1JP=6#
M"2LC)[2S:($OOH%,CU4F?D_Z/I\I_<,[PTX+>^J1[6OX'3M>:B*DZN#:7?7;
M*20(WA8=::C#@;!'S^_"]D+%"DGK%V9%U69Q4BV>OAUX4*/A'=FW_1Q2_P`A
M_$O0$OH+U?TK5LF=[.MV:E7$D]FN+B9N4\XQLA)4Y9K<.M*,6QMG[.4WPBAM
M]O&VF/KMKMC%S/MZ_P">?L_7/TQ]K&=,YS_;&-L8^O\`Y?7WEYYYYYYY[TN%
M-$D=U5,_932Q]ZIM],Y^RFEG"BFV<8QG.?LZ:[9^F,9SGZ?3&,YSC&?S.0-#
M7!9_PV$P@*U=9"MGU;\BMG]1)5`1!)*"FQ^#5Q\LI3U>E$P@T=10_)RCBP*1
MPD3U[H@Q=(%,B_@(R/\`OG[S\.E?+GJ'.C7N3Y!NV`H())"L"?GOERAJ*;D+
M=]7:MWE](L;RLLVE8UL;QL3+#XXS)+C':NC2F;@]8M8BBC55ONY90CC;;O/B
MPGC8H4^08@L>N]:F.97Y#K&<DE=:ED*<X%GN.=^7D4VGZM'F[6&G-GC-)K*[
MNF*">J6\ALT6^TZ;K[[;6_///////////////////56O,7Y]F[OXUFK9(\0]
MJA]QV%+\R1&9EW&_JFS)#G6W!\SB\1R#5="?_`TK+6-.?@'J[-%KB,S*IK*.
M6*+9:U&/XQ]/X^F/I[GSSSSSSSSSSSVO7F<&N(?[>^24O.(HM9U:?FG+#NDY
M&9>N%QJ7C!OF<='SY0.:*/5T6+9D<(/6<YHW:,=7$SHLNKHX4VROML*\\\\\
M\\\\\\_G^?:C?EFX==="4'8=M<\0YB%]O@X+B%J^YJ))5ZYOA_7K@CB'-FU*
MR(8\@$(ZPXLKK[)BU#JSLV<P"8L-Y`3#&1"YY)L81>K+A&LN\A;HZ5EN,:;H
M6G*8AN>FH;;LA9G.W>W']/6Q9")4-ZU?*H<^W=+.RW>_0X.ABY:QK#`-BX0V
MBC5$++;:LN=CAUU!;D?_`&OG_P!W#_\`E5>?^U\_^[A__*J\_P#:^?\`W</_
M`.55Y_[7S_[N'_\`*J\_]KY_]W#_`/E5>I;WSCY?\\^J_F..9LU[_4NI<W5_
MLN?[9/\`67^B'ZZBOZE_D/Z#_P#UL?D68G[C%AXIC_\`6YFL\F6`/ZS.4\>@
MOXZC'N`0-;R<<G\\TY:?(*`=4#48AI'I7KRH:AWN?62L!2SICE[_`&H^;CPC
MT@GL$Y#DK0&(-\UJ..,(]O*C9;-61*V;#,-I[/LCKN`255LOXM^DDT4=L8V?
M4I=G(%QLMM,[-\?>I,9N[ZE+%],??[:;:)"V[C&[=?;5'9MIAUMY,ODXK"/1
MW6L_G#ONF-4D\*N%37AGH<JC6FGT0V4RZ)*0$+?%TDV^JJFSEQ^=9;I:-7"F
M5<Z9;Y<?;!_+9\<$P^S%R'7U/@$KKMJGO$W++2E$RZ:N_P!G&J"T5=4.`/T7
M/V\[H[-ED-%M'+=XVWTU<,7B:%L*\Z-Y^MU/5:J+RIVSD-M<[Z+5Y9X,:I;Z
M8USOG?7<:GI/7;7&F,[?:Q^WV<9VS^W[^F3[>,Y^GTW^O_%/?&/[_P`YU^G_
M`,?^'\^ZV8DH:,C7TA.OHUA$,FRCF1>RCIJTCFC1/'U57?.7BB;1!MICZ945
M<J:(Z_MG?;'[>YB7L1*1S&1A'4?(13MLDXCGT8X;.X]PT4U^J*S%TTW4:K-M
M]/W24:J;([:__L]LX]&%O\\T+T%"ICE[TM5-SP*.%/N(BU*^$[`8-ME,9QLH
MT;E<3*ZLUL9S]K1=I]PLGOC7=-37;7&<4MW^+FJ0G=NYY;O3K3C1=GLJNT@Z
M(OD@G:I2<;;;;I8QS]T"TNZB&;33.=4]F<%7L%INAIA#11'&-=]?>D(_*K4G
MX;4>MODGL6`:Y646C;@`3KDNTW:&F,YT27LRH'-VU=)2"FN,8PHE0`<QV7VS
MG;5LCG_L_0A\@MDUVJW9]3\"=?4NC]MQ^.L*JA6`[*I]!NW^W]9#28YFEC"X
MF$;MC3;?\46T,*J(HYT4=MVV/O,)S[2?>?&O14DF/TWTI4!H8[;;IKUVB9Q<
M+:4:HG^VZ$U51.K!V1".=,_7"C67%63C3;&==D\9USC%H)B?A!YCO*3TM&PD
M:ENFFH_F'S6*9)J*[X32T4=R"K9NGNKOG&B6NZNNRNW^%/&V?V]V:2J2Z2:R
M*FBJ2NFJB:B>V-]%$]]<;:;Z;ZYSKOIOKG&VF^N<Z[ZYQMKG.N<9S[////<?
M3'T^G\X_X_O_`//Z^\-L8UTV^F,Y_;/[9SG.=L_^[G.?KG/VO]W^?K],_37.
M,_3Z:N?C(^Y_4'R3_ASMU9*7_6975]"YZN+.'"ZG]%>;_OA_94+B8,>^Z!5_
MO`)LDC&I2C=L,(MR9S)%*4U*/=I7GGGGGGGGGGGGGGGGGGGJ@]`\WS=Q7YP[
M;T82Q<-&\J7?95J$$.]9OG+TLCSCF2YZ*:140X:YPU8/&,M9K"><+R.,ME8^
M+=-4<?C%V^<6]Q^V,8_MC'N?///////////4*YSZ!L2R>S?D/I0G<1"H/SB8
M<RPU:(,HE!E*-F5H\YC]E%>LU))J;+3"JI/(N56"CC1++%EG1DGC=/3&V;Z^
M>>>>>>>>>>>?S_/N,8QC/UQC]_X^O^?T_P`L?Z8_RQ_&/<^>>>>9QC/[9_\`
M7_YLX_RS_.,^XQKC7'TQ]?\`7.<[9_S_`)SMG.<_SGZ?7/[?Y>9QC/[9QC./
M[9QC/_S]XX3TQCZ:ZXUQ_P#8_P`'_P#S]/?#(Q$7,,EXZ6CV<K'NDU$G+&3;
M(R#-=)5/=)5-9J]T705342WW3WT43VUV3WWTVQG3;;&:H''Q\\(V8LN[L'C+
ME@R?N=E]UI,BY_JF2EME'.SC=97$LJ*?F>BRBKIPOLLF[U5_$+*./M_?9^\Q
M#;?XEN&85PJ]`*YL.F7F^N=4E:"Z5Z>HA!KC.7&<8:1=3W&)PB&NN7;K&NFL
M7E+75TZ3PG]AROA37?WY\9AFU:400#]R?(3T9SV(7`N1WE1"EG`/6!0U;;A\
MS'UE9PY5/6(38PU=$)5UANV\P8U62IE\A(04SL7!8Y*EE?#$<CS\=/(?R*T^
M,7I,TS<PSSS1AO=3TPH_GGK+C.OLS3>$6`1&+,#7:M^6[GHL7YNA+/L>/(2J
M)JB!B</V*.^YT8BP\<&I-`YV&(EGRT!NJ^\S2W!5[MTM]<:+AE]7USK-.4_O
MT=-E4APUI"_(5%3[C"J^&RQ[A/7??5#\9O\`<?>O.4>T.JQ5LJO;/Q?]/-DD
M<_1:4HFTN5;[A\8QJILHHWCU+HJ^Q':6N,:8TT;U[N[5V^WIHT^UA'#AGY4.
M;H!MHK;0/UW0BN<[X6_K)Q'U8.PS7*7W6%=G)Q`U05UWJBGLKG&SI(O5:9T2
M47U<;-ONUE9(`_DG^/JS7#=D&=H<PRTTXWU22'5KKK^$+=55/KC5%44(9R')
MVR^WV<X^X6BDUL?3]],?7'UE&U^>.5^L!MJWN6FZ2Z"&U&ZFD6Y.0<,LILU3
M5QG'XB$F)&/EG$8OIMG.Z#Z'D&CE!3&%$%TU-==L?AK_`.E5_&67U!6_,!/R
MQ-DT=RVV(R0;*N?R_I\X(AT>N*6W9JAQ75577I:LVW2TD1'\^AYF%J5@DV%8
MR"S/2D"RAG,E,M_TX?\`1YJ=Z!HWXG.7PGHPSC3$L6BR<J$<11U$6:R&*H+B
M1].UF)-SL?EY^`GVT2..DEV.D%.2D/`1\@T%HYWEM!:)([L?////>"G^YM_E
M^V?W_P#=_P#M?_P_[W[?O^W[8SGZ8]JX^,C[G]0?)/\`AP1U6R7_`%F5U?01
M>H"S=P@I_17F_P"^(-D@N6G![[HZ7^\/6RJ,DK*.&Q.BX)FT:4JS46RVE>>>
M>>>>>>>>>>>>>>>>>H'U6$VZ2]2_&H1@$85/0*O^D[BG[O>P3Q=O!Q`3*\9=
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MSNBCLG1:^/C:M2E.I^<^J>6I3JF\!6K1(Z`IZE93MB4FK`%-2DF!"K$O61%V
M@YM<3>`1\Q#%:[NT$;G-6%.XXH.D0*9;OHB0'I#8A\=]`6)SS04O`VA$A@45
M6+=M[7LK3U:2RT_6E$L+LLR=L"/I\(GE88;3G&`HA+?B)V8CQH>@Y,VERMX.
M0S`?6C$O7M\\\]57M3J*(XZYS.+VDAE\<2<-(`H8#`48]2C7YW:-M'XS5-6A
MZ4@HW?;QK6>/C*`:3$NWC)=S"0/YK-(0\JI'ZQ[C$>?.FB4TNSHOENX888AK
MIYT@J?/I28"G$GH!'M67G$%3@/*QQF2.5R*'=PQ37MA@Q3%OW,FW1<#T21-9
M71$IU@X*%_C683D84?).T(R?0QE<?)9;[G>>TB&$%JK'2%$\SR,%%8C8Q59G
MKD8@7<8+;/L*?B9C:%S,R&B4A(.DM-H'GGGGGGGGGGGGGGGGGGGJ+]/7U8%6
M=,?'75XFXB4A7I'HBVJXLQ)_%(/G[D9$.0K]N.&2A'RBFBL.]T-*]'5G+QOH
MJHXC4WL=OKJB[44TO/C]\8_TQ[GSSSSSSSSSSSU3::B.:672G8DG54GAW?LR
M1T>IU+'X?DSG:*GF--1#*H4]F4LEH/QWXRJ=(QWC0545;NL;_B9C.DMLKIBV
M7GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGJ(_)!S69]3\KD-?UDI"ZV
MF)6/1-[5BU)'RT8.S9USK=@'=D&)3D@@DOM'1AOD(<AJ\MNBJE#;3R4PJGNF
MPVQZ-Z$YP+3CK#MKJ^[ZXU$Q'I"I:`YI!::/-Q6?(%JEJ"'LZ5.):T(H9FB\
M)SFPCBYR>!8#38@(-/T0)Q\C**MEBA>&8PW6/(W9W&)%T6-\30'!8QSK:%XS
MUY@U<D0G<(4^`]Y^M:S$ID0BQVJ&C$':1RDS7SV<9?E#5#"S@A7^^;X<_>;*
MY-3Y_P#,1:]3UI9\B"<'U<_L0#%#9[6I^TZJ8'(`Z)H5G+KAI@QRBVV9DPVJ
M[VB9QKNV;[(2+5PGE%/&,:^],58GS$R=OF]4J5_PG&QP=7M;'C6T'S3JG0!+
MGE@S]DP;P(''WW.NKDJ`TJ^931>TU<K;LXL]$%=V[?#O[:RV;%^8FKQ>-)(^
MON$[+7D;!JH$W'05IU4]FH]I9EDBU>OS9XCA!QMH*URR)5STV=?=8U8B`[-.
M]UVV$?OM)-^GR^?:^S_[.'_>^S]?KU1_[WT^OU^U]GZ?Y_7[7V?I^_U^G[^C
M*IK%^8FT!>2))"ON$ZT7CK!M4$T'3IIU4RFI!I6=DE->L#9FCE!OMN*V,R&D
M#T)=?=9U?"!%"N]%W.%OOMTK8GS$QEOA%4IU_P`)R4<8U[9)XZM!BTZIW`1%
MY7T_6T&S""-]]SMJV*CQ*P7LT(M-G*.[R+`B]71NXPT^VC[K@/\`YB*HJ>R[
M/C@3@^T7]=@96;,JU`&G53\Y/W0S"O)=`-#V.$7.SPF)%6FL3!M=&SC9>1=-
MT\(J8SG7T@(*_+ZNW07V2^.5#99!%;*"N.J<*HY52T4RBIC'\*)9V^[WQ^V<
M;Z[8SC7.,XQ'0)8GS$FI1<(V[K_A(-0JBPXX#CB(F:=4MH6T6;^M0&PMS<!6
M^Y2P_%&+TW=@+MWHH[TT,`LH9Y<:[-ON$AW8GS$A113PVTK_`(2,D+7L.1`Y
M$B&6G5+F%JYFPK4^L+0W/EON5<,!1\]"&@"T=[J---S`T%V>'&VSG[A615U?
ME]0;KKZI?'*OLB@LMA!+'5.55LI);J813QG^5%<Z_=Z8_?.=]M<8QMG.,9C^
MGS_YB+7J>M+/D03@^KG]B`8H;/:U/VG53`Y`'1-"LY=<-,&.46VS,F&U7>T3
M.-=VS?9"1:N$\HIXQC7WIBK$^8F3M\WJE2O^$XV.#J]K8\:V@^:=4Z`)<\L&
M?LF#>!`X^^YUU<E0&E7S*:+VFKE;=G%GH@KNW;X=_;66S8OS$U>+QI)'U]PG
M9:\C8-5`FXZ"M.JGLU'M+,LD6KU^;/$<(.-M!6N61*N>FSK[K&K$0'9IWNNV
MPC]]I)OT^7S[7V?_`&</^]]GZ_7JC_WOI]?K]K[/T_S^OVOL_3]_K]/W]&53
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MQKG&<8CH$L3YB34HN$;=U_PD&H518<<!QQ$3-.J6T+:+-_6H#86YN`K?<I8?
MBC%Z;NP%V[T4=Z:&`64,\N-=FWW"75623_+</&M"QSBIOC]L-V;6?,BC`RB(
M/IV49T@JG4EDE;BQB62<,W*XW`S#874JW65:.(U1U/6#!PJCM1M)+LW$M+J_
M+Z@W77U1^.5?**"RVJ"6.J<JK922W4PBGC/\J*9U^[3Q],YSOMKC&-LYQC,?
MT^?_`#$6O4]:6?(@G!]7/[$`Q0V>UJ?M.JF!R`.B:%9RZX:8,<HMMF9,-JN]
MHF<:[MF^R$BU<)Y13QC&OO3%6)\Q,G;YO5*E?\)QL<'5[6QXUM!\TZIT`2YY
M8,_9,&\"!Q]]SKJY*@-*OF4T7M-7*V[.+/1!7=NWP[^VLMFQ?F)J\7C22/K[
MA.RUY&P:J!-QT%:=5/9J/:699(M7K\V>(X0<;:"M<LB5<]-G7W6-6(@.S3O=
M=MA'[[23?I\OGVOL_P#LX?\`>^S]?KU1_P"]]/K]?M?9^G^?U^U]GZ?O]?I^
M_HRJ:Q?F)M`7DB20K[A.M%XZP;5!-!TZ:=5,IJ0:5G9)37K`V9HY0;[;BMC,
MAI`]"77W6=7P@10KO1=SA;[[?U$5D_,3`6Q658(UWPO.L+%&[/('UE1#'JI8
M&K]:N=0C+"!,7WW6V&<O863)UJ'([+M\N\")'E/1WLVVT1[>T33YAJVK.Q+$
M8AW`]B/0($,#5G7X4UZJ>F)R[%!V2GFP:)L\)K9=DI0O'IP<"VU17V7E7[1+
M5!?;;"6^1P$K\O\`.04+-*QGQXPJLQ#Q<JK#RR?5*,G$JR3!N]4BY%+Z8^[?
M1VZ^S)YIG73;5R@KKLFGMC*>N"A=D_,27GMQ!#FN^%Q1K4Y((#\:9D3'JIN+
MVDB4UV.'CF>`'7W2>'\0,/2!8&G%M%76$2J!F&JF[;='\-KS8]D?,37\I4\:
MSKSA8\3L^U(RM)"1#V/5+QE6L?(B)J4J6,<;_=*89!<>X$&HPZ>;;-D]9XL'
MD-W:67&J:\H:Y^7S;['U_P"KBU^UG3&?VZI^NN-LXQG.<9VUQ_A^OUSC.VN/
MVS]=L8_?$74G9/S%7#4U?VA)UWPO4L@<C+`B>5K8S'JJ..0I=[E7[4`4,MD6
MVS:79X3U_%);MF^VF5-<?=8U^SMOU426?+:WOHSKEC4/`,0JO6`1:$U=J`_T
MZS#325DR4N`VM?KD"#1)S,'`7"A[.:>MWKYTM&BI,.)H-6[1;17?M;DLGYBJ
ME`7AO&UWPM:CMH1`$!H%U\RZKD"=TB<6$*@CN<0;:HN=LQ`4S)7!N4+:H;_A
M14<FG6VR.B.SA&4=O^M[Q]OZ?]7%G&NV^,?7'5.,[8UVSC&?IKMOC_%C'UQ]
M-ML?3./IMMC]\Q?55D_,39L:82#^N^%ZXW%+3LZM6S`X8]4L7A1'UR7R`JPL
M:`T^Z1^_"[!;L-2<.>8U53=P+YFX3=NL;Y4QP163\Q,!;%95@C7?"\ZPL4;L
M\@?65$,>JE@:OUJYU",L($Q??=;89R]A9,G6H<CLNWR[P(D>4]'>S;;1'M[1
M-/F&K:L[$L1B'<#V(]`@0P-6=?A37JIZ8G+L4'9*>;!HFSPFMEV2E"\>G!P+
M;5%?9>5?M$M4%]ML);Y'`2OR_P`Y!0LTK&?'C"JS$/%RJL/+)]4HR<2K),&[
MU2+D4OIC[M]';K[,GFF==-M7*"NNR:>V,IZX*%V3\Q)>>W$$.:[X7%&M3D@@
M/QIF1,>JFXO:2)378X>.9X`=?=)X?Q`P](%@:<6T5=81*H&8:J;MMT?PVO-C
MV1\Q-?RE3QK.O.%CQ.S[4C*TD)$/8]4O&5:Q\B(FI2I8QQO]TIAD%Q[@0:C#
MIYMLV3UGBP>0W=I9<:IKRAKGY?-OL?7_`*N+7[6=,9_;JGZZXVSC&<YQG;7'
M^'Z_7.,[:X_;/UVQC]\1=2=D_,5<-35_:$G7?"]2R!R,L")Y6MC,>JHXY"EW
MN5?M0!0RV1;;-I=GA/7\4ENV;[:94UQ]UC7[.VYK9/S$N;IG*AVKOA=O&PU6
M"ME)6PLQZJQ74O($QB8B:]=1LC]UC"AF.-1-L4S;/#C=1""*1];+1--QARHN
M2R?F*J4!>&\;7?"UJ.VA$`0&@77S+JN0)W2)Q80J".YQ!MJBYVS$!3,E<&Y0
MMJAO^%%1R:=;;(Z([.$91V_ZWO'V_I_U<6<:[;XQ]<=4XSMC7;.,9^FNV^/\
M6,?7'TVVQ],X^FVV/WS%]563\Q-FQIA(/Z[X7KC<4M.SJU;,#ACU2Q>%$?7)
M?("K"QH#3[I'[\+L%NPU)PYYC55-W`OF;A-VZQOE3'!%9/S$P%L5E6"-=\+S
MK"Q1NSR!]940QZJ6!J_6KG4(RP@3%]]UMAG+V%DR=:AR.R[?+O`B1Y3T=[-M
MM$>WM$T^8:MJSL2Q&(=P/8CT"!#`U9U^%->JGIB<NQ0=DIYL&B;/":V79*4+
MQZ<'`MM45]EY5^T2U07VVPEOD<!*_+_.04+-*QGQXPJLQ#Q<JK#RR?5*,G$J
MR3!N]4BY%+Z8^[?1VZ^S)YIG73;5R@KKLFGMC*>N"A=D_,27GMQ!#FN^%Q1K
M4Y((#\:9D3'JIN+VDB4UV.'CF>`'7W2>'\0,/2!8&G%M%76$2J!F&JF[;='\
M-KS8]D?,37\I4\:SKSA8\3L^U(RM)"1#V/5+QE6L?(B)J4J6,<;_`'2F&07'
MN!!J,.GFVS9/6>+!Y#=VEEQJFO)^N?E[S]CZ_P#5QZXVV3QM]->J<[:8WVUU
MSM]G;;3&?L8SG;.-M],?MGZ[ZX_Q8BNDK-^8JXJQ%[&DZXX9J1\1Z3.SBO;'
M8=51ID/9B229@$]9AIE%OLG^:H1*,]'YV;H9WBI5@IC3?7?595_4WYB?ZV_T
M<_IQPW^6_P!*?ZF_U;_+^J?Z;_F'ZV_2']-_S+['T_6OX/\`^EOX3\1]Y^0?
M]K^"^[_[WY=MF_,53M8E%C1E<<,VV^'-(;9O7M<,.JI(R(<RQ)#0"FL.TPBX
MV4_*D)9:>D,ZMU\Z144_4SIIKILLE*FV?E[U^\SKCXX]L:;*8U^NO5.-M\:;
M;8USC7793&,[XQC;&-=]\?XL?3?;'TVS%E769\Q-E;6/A[7/#5=_T_M@TK%E
MDWC^J6&#N.$<Q>&EDB7^!/\`%!)9^9*Y@'>OXA-;\N=_8>N?L[?=<%MF_,2+
M6;4E<H5QPV3,K2_J'^86!`Q_5+@,K/\`0@RT(6/ZZ>_8VPR_7#AUN/C'VE6O
MW\LV633_`!F^,M],J.R?Y@PH(,3%J-_'\8N1,4)"=L(B[?JEV2%+@?A'\PW&
MX!M]G?[^:GEF6D3%)835V4?O&^FJ*^V<([@0G^8,U"`XQ=#?Q_!SDL%!LG<B
M)0WZI:$@LX((1A,.!N?;?9T^XFH%9[O$RJ64TMDW[-QILBAMC*.F*B5F_,24
MV;;=<KUQPV,LJM_IY^7V!/1_5+<,LS]=C+LA??H5[]C7#W]#N&N@^3_95=?<
M2SE%-3\'OG#??FT;,^8FM=JXPRKGAJQ/Z@6P%UB]R$1_5+_`)'%V93#NR2W_
M``*?A0D3_+4LS[O;\.FC^8M/MO6WVM?O93US\O>WW>=L?''KC?9/&WTUZISM
MIC?;7&V<Z[;)XSG3&<[9QMOIC_#GZ[ZX^NV(KI*S?F*N*L1>QI.N.&:D?$>D
MSLXKVQV'54:9#V8DDF8!/68:91;[)_FJ$2C/1^=FZ&=XJ58*8TWUWU65?U-^
M8G^MO]'/Z<<-_EO]*?ZF_P!6_P`OZI_IO^8?K;](?TW_`#+['T_6OX/_`.EO
MX3\1]Y^0?]K^"^[_`.]^7;9OS%4[6)18T97'#-MOAS2&V;U[7##JJ2,B',L2
M0T`IK#M,(N-E/RI"66GI#.K=?.D5%/U,Z::Z;+)7/Y__`-N/]43N.H?]E7(;
MK!YU',T-BY-2;8EUE$-<[36MC[;Q&(+>(PZVUQ';[R&)#+?_`![-?O-LVT\\
M\\]@=C%L\$#2I"/5X4V<Y:/&>CL6"G8LW)MXQ93;1])13<P(!:'E%8M/[+M:
M(Q-M))^WU62B$G\EAO'NJ3=&_)51%%<K=$]&QSIT5$=`5Y)%4E1LZTF:RMAP
M4+NX@<"1$A"#J'BC40;EQR3"PRB2O19W%)Z3*4E&[3">6R3K[:&Z9M-+JXTX
MGZ+_`*?2=MQ?-=8]4B1?5L7-#XM-AY::%%5V0'.!\B(B>51D*PL@:8XC";\U
MU0+1$Z']G</#SD%+J2NPCSSV#V/.F0R&S$Z`@V+**(W#)=D$ZE,4&NIYMF1:
MZ2K>,GYYNM!-IA&)W>NX=K-N(F'E))NUBY(@'6CM6:8Q!7_55:&Y1'5K,HD]
M17/+L)F0B*9NN"6K\ZGT!U+9>?<A.ZRTF)VI$P".$UYTAJ`HL&`B&JR3A])(
M)JI_;UW)?)]88%Q%W)U#;M=!$J:\N];7KRR"@=>21`P@#TG&+K&*)I&,?SY'
ME_+-W9L:&8VB53+2(2T8-W3Y>''E/P2"#JV-`=*6*ZZFNKBN^MP:4M>LJ8I'
MHL7.:[B986&SNL;BF;#`Y5GD-G"$NDH28KNSZL)8E9]N2.FY"+$8:_\`P,?+
M(S.B]]_//0_;U@']<L(.;#J;([EB=I%R@818.2B48=041JQ46;38Z-FTB-0A
MKJF\3^YE(5`SA)]-IMJX@(XF?[8B,P?,]&3%TCLJ'<D$8%&WI&R@JV.H6_!4
MYAR"@14A1E)#]=V-SR^>UI:L]K*-X.1A0"&Q,A`Z;SZFSIJ?I0$'+NLT/#?D
MCOV8@:AHHH!JUCNN[0^06Z^#&YE!,R92C96&YU%"VUK6Z9#`R0('!>\'VE:"
M#N`:UC)'*CB#N5VN-2YL_'1]_(O;W<3=/2_2(Q=\,91</%6GS'TK:_+5L8&\
M+I#$T5UMF!FX0T&F#U_*24-#6#7)F#FR([)2<J]%WLX_&EIB9_*-95Y=+SSU
M?+2N<QJHJC]7=%V0>5:\B&JTA8E3IL#^>%)S:0=-WC(CIYCNSLJ3A=6.(YTP
MFJRB[)DUUW#]M*"T&VCT)&2J9UAUX<-.7;#Z1XYN+E!,8IX6L<C.B:]D"TC@
M%36O631PUH*3A!<[K.>K`^(I)7<>G)`N7?DX),/(2+Q4Y-+R^6C+&R?LSH<Z
MNFN>8Z=KX)K:]U.#D.X[BA;;TE#2+")$BFF@+6_/.FPG/"N-IDGL2/L)@46+
MN^4:CH_7ZSF$%YUZ0I+0MR..^EA7L?EJ@>I`N-<P8[>]4AMEM!YZ]1DGPPY)
M8A!U+"K^1;H-F\@_%YK$B/O7S=N@W>.8U5R@BDDKJGK9+SW&?K],_3]\_P"6
M/K]/KG_+'U_R_P"6?]/56+.EY"JRPDC;DINQA"N8]XY5'[R$V.;8K)Y`(,47
MFT@;H@S9W8=3NF/_`'O\\>&8$E7L8@WT=)V2]346U:U7[J^1!6BJSJDKYK:@
MMTN;!L'E-],FFLM^I*M&.?>@^E:QHEK8;:<%)A!L239ZY.GD=3;"-F<1TTO#
M%9JY7?C8!+QDM$5X_)T>5[_MSW@+#84\Y?\`CDNVIJ/NMK(MY5U8-G2$]#5<
M6W^5!I$C-Q@^$H40)W0(.(8?DX`K<V!."9Q%/WPRWE1I^RW6:;X4TUWUSC;7
M;'UUVUSC.NVN?WUWUVUSG&==]?IOKG&<_P"';'[^\_/>.^=\:[9TUUVWQC.=
M-=MLZ:[;?3/V<;;XUWSKKG/TQMMC3?.N/KMC3;.,:YINT[%@0K9./Z@`BKER
M0P^916"T^7C9RA9:0DGV8V+Q!]"#*C@`C-)N0V;L8")M;-4&TL\=MF:(=J[7
M20WJ.)_("=VI\E!7R,$V+S4`!55.7[0MJ>YP#H$7ZIMJ,&A]TX+K&H"<FG`;
M3!?7<:5NFD'E\-HV(Y8Q0J4D,PJS;2T(BSQ*@_DY/;*:\27P6#03&\Q?(G?5
MN4+1L<P0EVEAUTY'X:W"B@C0S('<R\AC1O>XQ1I:ZEA^&&![`%*F0$P839(T
MC9Z0E-UV,XVUQMC^-L8VQ_IG]\>Y\]B9U*%<((D$N#BK0W+(Z-7=P8D^)4!!
M`A>HYTWQ%X)'<9,,XEPZ1PKJS=/F.['\7A!%ZX8M55G[:O0]V15&\FU%;5;%
M?.=B/&I&Z9`%\Q#4-D)Y,0@7I44Y`3&.DY^K+9_3PM%RI--:50?&CJ('XR0E
MY5HP9LG6Z.OH9^6\4E>6^A>\Y0IJ9.GZLY^+.BJ]Y>A)YA(=,D=1;-W7]&K#
MM64V)U&59/KW?1J:(J"-J^EV@8V(HIF5'<L6MIL;@K+T%U-<FO4L?Q_TI'5_
MM9QGR,-=>B$Y6D;-0$`Q9(G#"M+EJE_%DI$12DFYK(N(P=T/'.JT3^L1XMW3
MD1:#E1URM*;'_//1;;1F>`8^PGP.IYBXUDIMJ@1"@P4B@T7(C:K5[L[F!5`Y
M?0(H2RS%[HPTV&Y4O#\O(]P\=,9EQ(LFL+*5M+>GB:U`HM!^17-?QG6T='#4
MLC5'5D-8%;/`(8E"%C'3-A']8I(C]H$`4P9XE&$%,`F[@7+2W\LB(TW18J/I
M-K0[?O;M6JHDC![TC.53"X3WNF@N"^>9^D(.V82M,6%9@*TLFV"H]B#LY(B@
MABJ4"-YR7<QHS(C^I#/"4F(+2L.JNYF(B_G(W3)!<1AU71EDM1]"Y./;S8U"
M;R8JBZ8#IR-FM7`EV538\6/OI&;>BNQ(!6$PBIX:<3TWK'%XP2*,)'>'=1R#
M>[/GGH%MNVSBJY>%>-*-/+0KEU'O%"<HJQY!DAD%R*#QOHWW>5._=0I06C[A
M@HJOL[K=T9%Z3Y+\'H`N6V_YGI3+HKY&JW#FU(N`&SP`0KRP[UE*,N/H"PH.
M8>B7+IFW`GY4(@]WA4E+5_-U.;6<0;#H:/9N!Z$14"]GHU67;NGY")1TQ@(I
MW/T+:YQRWS4*"(175_7;6?5-[F9D=AYN[#Q^B^=+2BJ@K>Q8.IWA"*FJ*'4,
M\;5R:BL,3&+-\`U^^)F\BM/D*4$NXN?PMU(T[.Y7JGHI`<P'2)HT*(4O$-9)
M.91$[&K4X)ZMLT9:2Z>B/YK'0=@A9)'Q4HHW;*R46BR>K-FZJ^Z.EMO//5D.
MNA)^JS:8C+`I"S\5=IADO`W57,9M;@[A!2*2<R:)V#!2#JVP1Q'2.C]#:4;@
MA:"XB4&TQ)&T.NY<1$?2*Q_D*)SV7ZBWXYG::/A[D'F*M^G9A_-K/"F$Z%:V
M.SN$CC`FOS$4*(^,"A]$=I$C'U[1W9':#>QB!O%N!A-L!$,>1P^9?+$:E@MU
MO>_/`8-2U%\(\N\\=16K#G;&5;GEQ1MX4UKU'.UZ&2K&=8PU:3`#S2Y@2)O-
MS48:X(+#,8J#=0L4/PCQ[-[N10GA348'3$;>:2(\504.204@GC.$WT-/1K:6
MBGFF,_3.-'3!XW7UQG'UQA3Z9_CZ^[_SS/\`I]?X_P#G_/\`Y?SZK2?6`(-D
M?Z/NN$*N?9YS).H^`D+59,F5<F.J*B^&;D3N.#?S56.W4L@AEVP$ITJ'+$T;
M[?5^&,]M?IF.S[I*S1+Y`>:>86D&!.:DO?G7IJUE23*Q`Y/VQ;0Q%0<6TCVV
M-%V@LQ&91E=&RRBN4)N4>.8Y/.BL2WT^CRH+7Y+;$>*K7VF,!N.4,?).W^.)
MM&[-)-.PG&%K5;<T9Z1P:K$*`_@>UZ:<?IK^G20<OMFK4MS/<U2G]58)+YJM
M^3PV,$.8NA9^`!V?)W9?:MG<6U%&,$);2T!1Q`S]P@U+W"3D+F;W'R&.N8[H
MLCCWP/%C48J'0MC5Z^9DT\X'R?6=W8>>>>>P2QX`V)AE6&`CS2MIIV^CL."S
M03BC&28PR;K3>71@HR?=)C[:==L]=F\9+SL82Q,4MOET[&)S775IG7IUM\7M
M6])\S7[5N\Q*3%\6S4LH!#_2=PR#ZQS\:E$":!L8::MGR^&R`?6BEEAPD0EE
M853%`P1+Z1GWB8UAZBSW2R"A^>;<)>V3[NR]A<?K4G<\IU9R6!5J/E34UW91
M\(>DUQW&<2A%'MF[!2,+;#GX(>KZ+_Q3"(:"(DI(T&YPO=B$!LF\\]!_1LI-
MPU.EL@/3-LC\FCM`Z:2U&`$)9UK-&K@CB6TC^C0TC'BN$D9!:/5<MUWDB-S:
M,&P5=3N(]92.3QBH_,"](-;(9HP'//7"-FS<=*_C[]Z>J>SY0E53:1JJKUD^
MMRRW,GN+,9;3"C>/$!;8;$MG"B<9$#[)MJ@V3J=I\<5UVMQ3\A/-U@*"%<&G
M0_;]S=;T;.I3V38=C'LA?`7T31N#K2+81S]@K'&0!"Q5@Q,:WETFT6Z=JP<E
M/[?1#%Q.>^?+,D^RKZ[GNL9BJ]*+#H>A>9:WK&,)V)B]%`"I9^Q[+-)\E)89
M%"#D7YM:5J2;4;9,,++QX2%0,Q+K1LX628B*[%?//4Y["EI)@/A3-.:ZMC!V
M5GI%J4L.2J[U+C:?C4HK[]**G"ID.SI76T`LMKM_](P=V+EKAYE-E%%,3OC;
M=2JR<P9QE.'PY\?7)!T$7#,/QB/)#'IB-+J(G7PY,.9G6>/&]M6F'VX1V]:`
MTT1<X&&)LB11S">FHV=)EG,(V<P4W@V>3N@B&&XPME*A:KI,]X(Z4GCZNJ0%
M+O?W#O9=06=3A]4M[[SMND@56<?BX#=W;$]8T.](H=9O,&0CIN;'2+BQI6<%
M+<<$\REW/(OT(6V2O$:6CUCU;<'6%@#X^\VEH4&=6(F,BH37K*>RTCM2)P$U
M8``L(0$#>-8L9DK1GWT:DK'*-'CJ^'GGM=?6DA'KV1#P!RAW06UQN'1[YU6_
M,5>E>E<S\FK*S[=RL?6A5K"*M-X]W;)LT'->L+#@!16*30<$$#.I3.=4L(F-
M=K`JJ'I>I_C='B_F<_CK!&+%!KV1'.?4!\E:HP#:"6*:6.Z^FG1L!F[22E%9
MJQ(%[+F$>\A<_A18C>.OQC*#@C@.]N/RJD[0Y^>1-ZF8?\:(_P#'B3,3PKR*
M*)SU5D+DYH6V,S\VA-+/0"`(B4]%CR`SI)G+4.D!.5@&AK+03Z#>;$>&^88K
MB[D'G#E:(F<DB%$U`%5T])LMU&6I//0<4E@G)D8]59RI&-R(E7EYEK%[.7.8
MQL]18?B%OP_WFUJ_/<9_C/\`/\9_C'US_P"6/\\_VQ[4];S\'E[@.&]X`/R`
M7\/PI-NB-US"4@:;\S1C%%%DX2T80=91PU$W8TW5VRIM,7#(60T2>X7TAF$/
MHCE'->.R_BP4ZUIV6*:"MOJ"F9VV[4Y#LQU2Q#:$C4]:!8I4=JTE)RS%A6&0
M>6>`)2!UE7;R2K8714UBQVT&$4_U;,<NI%17B\OC/MTL%^^.4PI:$=\^_(_?
M%.W.=6M.$*&I94T:V$J5!.HX.7'%&VTD=$]E#M#QLE5\G`Y9QC<GLTDV+7(D
MR"(MT7[YTT]4M-4]<8QKIC&NNNN/IC737]M-,8_MIIC77&?\_I]?YS[S\]ZU
ML[824SKG;&V$]\ZYTT^\VQMC7.<9UT__`*]L9_?77ZX^UGZ:_7]_:<16;JIT
M219/=-)?(?TH?(R3?+(@O+FPU?@HP\470;I/0RGQV&'J2"$X[?\`[9N2,`)<
MSU:)Z+2Y?++H8=YFDIJ"Z.I[9I*:N^C1"DFO(W5$U<@!8H_;S&SINP8&#&;#
M!!'0(UCPX3G@AC9@X8-'5P01BFRUBF;)R$1;0]1?-S.&J10'QLVZ"1/QY<QF
M.@UGGCXS[^M6\@NQF<ZDXG;J:I#=P!?+@TW%$D<2P?+`@W>,L]N%].NE(Q^0
MUY"(B"A3'',@]"][^NN-===<?QKKC7'^F,?3'N?/1/>DE-1%2'DD/2E@0LRS
M@%UF$K58/%V38K%7"[?79P&@\W%3L01S^B.RF&#"2A99E]YG+AQ'/$T,MU-8
MD-6]!73#'U-R]*=PN;!ORLK.J"9Z8Z.IRR)LH%HVQ:[+!2?E8XX,\IBM4L%8
MN9?HM!ZN(8!#57KAM$MH-LB^^[]7ZQ?BUMSKRFJVIJ\60G2;^E/CAZ$X0='8
M1.MBF&MLKMP;IL5#SF('HU&(F8ZF`*5HP>N!B"F[F**-#>;:CC6.29##LJ)K
MMT-SG>!3V<T[7Z&@A>OR4$XQ'N0!($&"1L9)3,[/V)%6M?5G_G+)FP0CA">)
M!$`'*OA7^FQ3O`P<U/E44(R$PD.H[.?//58ZXE9>+KN%Q&SO2,$SD#!E'3ZG
M+-=1MA6A(0BT+.J.(O79^,%C@,@7;E)IF1-(*.:$<:LFS80DW"O9/201B[E1
MW3;&2+F%5\V]`U^5_IY69G;!OZLK"AC"Q=M'S=-*'FKIMR0GB\RF5G>4G&C"
M;)'B3)OJL_210;M]L:UV-^$[7)^7N1G6[P:D>H^;.L@GOLBBWCY-F,6!<TT2
MV&07U7*)6W:*Z1[*;&;JLH(KTL?1KIC&/(L)>2C1O#MW*C2Q/&'-QC5U@=D]
M%6DUCXBS^S>@XVU'PC%R*$NC7U<5Q4@!1E0!4M+,<[1$N7I"(!L6&KZ#4=0C
M,D+GHU$2Q''#S8GFK\>>>H'U])ZX*PV#)'';4G7KV`D7<X#\G5^0+1!0]1E$
MDDDSZV*[C&]L#.NC??.C08"CP)3F6>7*TTM+,LY98J@>40QO*+HC2H^6Y;'*
MM=']G173_&%T5FVI7/1C&P*F1&`^Q74=92:8];KNKIEVXD,PUG2Z,01RLHJ4
MX)$SVM0[5;HZ<X0Z"Y@(N.K_`!3[R[K$H6@>K>6BJMC6TUWQ-_06[;@'KJYU
M#HVXS)/=`ED>:5*_`Z=(R6<;:21B`K3);%YF)T<BAHLOK\>G*\CQ=R!4'/$\
M21Q>7"J!F4V"2PS1PRA)FS[;L4NN"SGD`V=Z).TQW]>'A`W'=7;=JZS!MX_=
MRS9+[J-$;I>>>U<="OA.4N<LB+A$^^;E!XQ2"_(ZMK&I#3'-NNB\!"NG6\A(
MU4P')>Z<NGN72LQ%6<6%X;&2"BT4S$62T9EPM@W1W&X=V96H[`510J'.V+2I
MJ=H0VNN='E:>M"L.92H@?IV%4`W4D%M'R$Z3S[-:?4`(RQV#:MZPFBO>V(Y$
M@G&R@H0Q-?/QNVNS3^0^I.;XT+CJD^3&AJ1I&3FI*62BT^8E:\IM/E,YE]AI
MPFN^/!I]S:R%W5<Q0TNE)I62)K0)'I!#I+^N(7=D$B,*`!PJ"C:"K8>#1N!%
M()LNMEPLWAAN)9PL4BLOMC&RRJ3!BWT45SC&5-\;;Y_GV3^>?^O_`,__`*_^
M?JC3G)T9;*DTGTX<SM_"\PZD-,TW*,&@ASUB$6D]W;&%(:B@G"[>U6R31-@D
M_2N\BL^)=2+/\TBH,?\`O<,D8OL^AK2F_D.XVOD4&!S2EZ(YYZMJ@M>;$;*,
MFV<U?$OS])!^HX')Q_V'\$/HT8Z9SBGYK%J-M"*+_*&$@FP?)Z4QT^.:Z$6C
M3E9#863YE;_*'I\B>UG9ED=IK:N$KPSUNGSQD(WPI.;FV>C,:#6YAB11%]:8
MTQ/8E]S/[05O\-7?&I;0W"\:\I3S860YMX=[JLKLP7L]I/Z+D%E#6A-<]@\[
M58D'X2WE8`J"C6]%]+.(9)=$??0M3P3D9=3[JR9:+!]\OGGGGGGGGGGN,XQM
MC.-L8VQG^<9QC.,_Y_OC/[?S^_O'":>N?KKIIKG^^-=<9_YXQ]?>?GGGGO';
M77;_`'M==OI_'VL8S]/^>,^:Z::?7[.FNOU_G[.N,?7_`%^F,>\O////>.R>
MFV?KMIIMGZ?3Z[:XSGZ?V^N<9_;]\^YUUUUQ]-=<:X_GZ:XQC'U_O],>Y\\\
M\]X923SG.<IZ9SG^<YTUSG/^N<X]Y8QC&,8QC&,8_;&,8^F,8_MC&/X]SYYY
MY[U_=)?_`+I/_P#PU_\`S>]GGGGGN,XQG&<9QC.,_P`XSCZXS_KC/O'":>N<
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M`#Q[U(KHN4M%VZJ:Z*F/M)JHJ:*I[Z_7./M:*)[;:;8^N,X^NNV<?7'T][?/
M,Y^G[_\`K_U_P]U45.0TZTV?PLM&R[+1TZ8[/(M\UD&N'K%SNS>-,N&:RR/X
MIH[24:NFWV_OV[G3=!9/177;3':8VQMCZZYQG'USC]O\LXS],XS_`&SC.,XS
MC/[XSC.,X^ON?//_`.?\>\<[:ZY^F<XQGZ9V^G^?V<?3&=OI_/V<?7'US_&/
MKCZYQ]?<843SG&N-]<YS]/IC&V,_7.<?:QC_`%SKC.V,?SG7&=L?MC.?>?\`
M/\>>>>>>>>^/,@QPZ_`Y>-L/?P^7?X/*Z>'66F%/NLNL-OM??Y;84_P9<83^
MY^U_A^\^O[>^SSWS*O&B#ALT6=-TG+W*V&C=5=)-=UENG]\OALCOOJHOE!+_
M`+5;".N^4D_\:F-=/\7OI]\[MVU8-EGCUP@T:-D]E7#ITLFW;H):8^NRJRZV
MVB22>N/WVW4WUTUQ^^<X][\[8U^GUS],YS],8_SSGZ9S],8Q^^<XQC.<XQC/
MTQC.?XQGS&<;8QMKG&<9Q]<9QG&<9QG^,XSC]LXS_?'N?//?,J\:(N&S19RW
M2=/<K89MU%TDUW66Z?WR^&R.^^JB^44O^T6PCKOE)/\`QJ8UT_Q>]B*Z+E+1
M=NJFNBIC[2:J*FBJ>^OUSC[6BB>VVFV/KC./KKMG'UQ]/>W_`-?^O^6?//>E
MRY;LT%73I9)LV0TV56774T1113TQ]=E%55=M$TT]<8^NV^^VNNN/WSG'O=YY
MY[X\R#'#S$?EXVP_V0RZU9972_&;-<*?=9=:M?M??Y;84_P9<83RCC;_``YW
MQG&<>^SSSSWS[.VNCI%ENY0T>.$5W"#799/5RLW:[H)N5D4,[8552;[NFVBZ
MFFFVB.SA#53;7*R>-OH\\\\\\\\\\\\\\\]^=_LOYZ5^1?E1I[XWM.+[>N!I
M9PJ'32MB5W*[OSAT^-FY`];[5M4GZ842L2!&&P^LD5R63D=6:.DY[&B2>@QO
MB8]OR,_/2_X7YJD;V8_'OV5+ODC`1$FFEVUTM1-9,E"5TYPH])+'17L%:+^C
M9DNUAV:0TOM+S;J/8;.622JBWO;9'SVK`WQ^N>W4_CI[FT5S2(Y:[4<)*M5A
M*Q:NR=O%ZM/S>YDEGN[:NVKF43DE+#TK_3+L5U0F]1YEN\T:(;`/BP[T<?)5
MQ'5W73JG9ZC75@KF,<N#S$ON2,=5PTGDAE6<%2E2%'%"05FE8[9W%2BD%&J:
M+8>QN^CG:.R^=:6R7EZTN@"+Y5@7DNLM0'IB)^6&L)"F^QH\E#`*.YD:0_/'
M%YH;26'3$C3M$DB\P<K8696I(0%F02R)&R'3$CWT3DY^1C=KP-VITQ;EJQKF
MFJ`:GG/L3UM;/+EGS2CL;'R`*@JD*RNIRB]$2^<MR.0EDX.V@]9M)TBC4J)7
M)!!`PG!DM?S4;O`RM<><_DGZTMFO>6RXZ#.9P]]W!>IGSK1#2"=VI,Z`Q321
M+U4_NHYLM.6>Q#0EA'-:<]1"]5@XY-C4X0G1&ZBR(EA8G75RRF@I[.[.CI]?
MG.&I.M)+L$9H:Q+UG($9<JG-:%<,RNDLJ>C6T7^;6C5<Z#,[D8B"Y*7R3B:L
M5W12\Y"P<C#'^^57^]?.B_D_[/JG7KPBC*$HH/B>,^.^/NSK-KJQ3$L*+#7B
M;J96^YN&B6A373W%>8.A!Q4D]%"5DQ"Q(#+/6;-PX@R..),O!:Y'*%U7S8W?
M'R2UN=F@U+U'1D_S%`U,*QHK(1$D/QUCT)&VDY5>2:A1*LY"1</2%\B1O\QJ
M>9APWB/RY."CXC5@]K]<'R1]$5-<7R#.7X!1BW.7Q^.:Q5*W"TT>M[;L5I=_
M/4><UY'P2^WT!AI[&6T1"L493$ZDK"MJ^>R[]CC69B/O7LC3O:G7%;E[&K+7
MH@7&YJ\;[I*B^4K7ELL1@0+)\\%;/-KC:&U70MP6B:,UZ+"Z=)2N(F6I?"0-
MT[%`@+1:X++-2%\WHYSGT':W)]B]F?B1RJ"&7N7_`*0A6/.5@IC\:4#D#@<Z
M#YKY,BD+"$&"DU).X0K33<QI.0#\Z]*HQQ/R)`S2(':2;66=VT`ODKLZP[R>
M<I,QRLAJXYKN#KGFL/.)-B62X&UJ[DZG*UN$@/Y0*3*(>=(3Z:1M,6%F8)&G
M8_%XT4G3'!#EB-*0$MV0K?O=$YWGR%3EEH4S6+<LX3ZCMZX:?&7A$>P#BWJL
MO6@ZT;/X>SD9.(4<0SB*.6,F,1SP/5=A*4R919#@RF/R>0AXAX#[?*[OIGF&
MB.;*KY[Y]LPIXT+^KY(5W'"]]101$NKV+*@"P4+&ATD%251L5V%&$\R4D^\K
MML(QK/5VF*SLB4,F<9\P_P#*;T]T*G0+;G*IZ0`I:ZN#.G>GYAK?$K81)BO+
M<Y3N^OJ7L&MM]0!0:P7AC\E)IB(@"MLN/R3QHBU,U8]-!C@.(+KR7R#,(SXU
MJ8[[=`^C1Y>%4<IE0U7KF<VUCHP^ZXEZL"P(:FBC1EMNB-0QU:\*W(B1.,_$
M)#K&0DT(W9Y]TSS0KY+NQ>CP+G;Y3.:9>1"1ZW*L^/Y;J"J;PK2#+(*')*D/
ME+"JHV@%QF5,I^7KJW@(P"YA&"(VAJ3PL]!$HZ2-XF$E(N7B$K4],\T5?27Q
MJ_(A,C]<UD)FUG\?W886HZK(<DA0.*#0!YM(QT,*F0G(SDZWAYJ$'AT8::2S
M5?65=/H)C+.WJSYJS5;0!!=,]*5`-\;<K\O!?.K-L1?$[.]319+;.EA[L(@H
MHY/GJ!>CSH=`7D-F1AS%*V,[+OT9=E+M9A=V2NUI'6*R/%/457\A73%Q7>/6
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M4P&'D:T^Y7<SC9J0,XQB1`J*:Z-DP3Q\"N&3[,Z@WS1K@FRBOHBN.B>L[@&@
M2NODMH`++>9S6J)T/<+0W+<F!AVAA`1[<>3D1LF)Q*^U74;>>A(A-QWYF#DL
M%50]--FE>2[M_#$;\G76]*_'-SUT:8-Z7M"?0^,RN^X;"?26I=(']KR#UL(R
M90$(A`@2KRE2QK(5D'LA-=(ES&5JO!\2#89&!+3\(\;.9HZ7^3GJ>G)GY!R(
M0J^@9BK_`(][`Y<D2EF13EC(GMKU%>@"$&9'"CKF.U2'`RR8AN9??09#)MR8
M3PM%ZPK\;=ZRBA'%>5F?)AUI3AKT%3A+5?/9A:50==?'?44%(CI#9(T#353_
M`"%&F@.-8DOS9&?G$;&K&?;R+*;G$OPXH41&S(F9#$&]PL&[2J)]V]#CJO:H
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M%5A&+"IP8KV-3L;I&FB>`.RNM1/1:Q%',SO&:2>V1^73WD>0[&(YWXQKI[3J
MB?JJZBD5Y\Z7MFL):F5)F;KP[D:OB['D*\:M(N9<NR6.F7B8U`LCP%F5/U"*
M&>I*&R"*3V+W2UA7B_DND[T^-&A""QW:AW:'27-597/:G4&LCJC=I-:EKA$'
M9)%9,=:;1?!1#[1A++*I"H_'S:(H,!\7'5]'1+<)8X@L0_<?R,]I`@?\HESC
M=><Q+5#\<!O<@<M$SCZV5[#M!R)4+0E[@NZ"L<]9#P\D[C[3GH0Q=*Z/,H/$
MH98?8.6T:_WF;%6EWI<8-:_;]<#]3:'B/--3<06Z)K5V$GEEGBPEU$?VJ&V7
M-2]5#$LC/V1M20_5<S8R`K7+V()CZ'2<CL8@RF-$':M$CJ[C3I_KOXGKNYT-
M.8[`L4T!OE;%Z]M5DR.E*IV&X6*J1J-+FHAI)M[4BB*&09QB5C4O+$HS/"1_
MN20;J<B5HKZNYFJOY4>D>FJ<K:2YSYY')OH"8XG"NKBBNG+UN0"LR4&ECVW5
M8[5\%/2=DU7(A@V5E]!V&U1M>7:F^0QK-ASJ;!);*<LBO`?RL]%VGT[\>_R0
M0<.#UZ""?,2W.E<6Z''N[DQL/2X)MGS]?5DQ`X3B,[H$#[JE8.TPN#'IYM&G
MD78IQ&E.6$J*C36&GY.^WSCQD=)_&G=&DBR:O-$;$Y<RAEREKOLVV?\`6M(0
MCU1LK^RK91U#RLG%.%4-TU%HV1?,5-MFKMPDI%O6'?'4U"&/R$BU,UGS@J!_
M'MRE176V=360L=&6.:T)(^_I4YK*+C!72-AA<HS`T',,00AU5?CHT\<Q&9H>
M)FD@Y2'L`O7Y3>I:#3ZH9S]54&1SE95=PGTA4#:)G;%CXU2H>RNCB3GMV!62
M^=8=.)*R@"2&59MN8BK""$B1G+Z)KB4*I#Y2F/7>7R6=KT&KW7H1USRZ1:<"
ME?-UCGJD)(VTRS9?.G2JN-(D'#TY!ZI^F;L!M(DM4DK`G%9@!*]F(TFTKD9Q
M/RRHM9!'ON_2`QGCX"H5`KY:J_I3H.BKT(L.!^+(Z\`N<I0]!['OIJ62-JM]
M9_\`3%AUS)HOJ09T_P#JV9#)R.G!HMD)I@I!RM26%EV[?O?OPR=*DD-4,*PO
MKDSNJS:L'QUH2[%`=#6%5=!G8>%6(;/GKUH9()"\V,2,W*C8X+LXTLV(645`
MRL;AC,N/BK3Y#K(KKXX>>[IIRD^8Z9@7W&O5O2:M90J!=/PF"FAI=U.-:;J^
MH@V:@SR+#S!!4IG#CH&5VD`FI7:<0F1#;^0-H=AKESSY*[G#KG[&N`C7&9+G
MZN>)/C>MVIJ:TC'K&=CS[M0PML1AFA`>+%2<&XWR<MQ]F8%>P^QCT@N.A$(F
M(AGD=-3$Y=)IW.;T#'W05=[5\_IZH14XKD=I>Z1<!)2!:U]3Z`GG4N.2E%5(
M5]+6,$35=$`M(QK\ODI94(-8F9@9:&4A)!&9A&L!GWR77$PN'I><K\9IF4Y$
MY5Y#Y[[J,B\F1M>&N0[HNXJUZ2+WT$("[UC$QXQ8.DA2D*YB4SF*8L8F#DI)
MH4,$9Q?[$#5'Y-;AZDM/X[^VX:]^?8*(J%3FNH+<K2XXU08AVS"S-;@!]9ZL
M%1!6VK0)29P/LUH,W";LA4!."F(U^_A)47&YZ/8;3FPPJ[5Z1)[GM<3YDY^2
MM\/YUZ9K;G^WHMRZ&H&<EV$Z*54<VP8P)X2VT'PP0^J\-N*)*X`5GZ]+$;0:
M!\U#1Y*.OR>"<QL6K?)%?,)T%#U(XJBM[)=6)!?(E^@*]JB7GI(AB3'BQ_".
MZY$I.Z%Y*0JL^*+Q%Y5ML7A@W"#,WSX:RK((,',U*QDVFA\`'\ITR:`HHL-J
M`UA6-9O2]?\`,0\(1E;V+4=G5'8TC1QK=-E"70'.=VFHT;!QX*QU7'+8-%GY
MT-LK)8KC4U!D&\<X?+ZV]%;ZZK;<>=!6O;U`-`N^J?AN@G8.%QTE%2,/=#"N
M!^;(:E.(D<'C,^F0-K:[-"'U>UH1%4T6",OF5B%)2:89AYR3U2U]5->SGP"*
M]=$)0Y?=1%?!,[W+.]@/91+%Z0/3KBG'UV:'L9:'VM"2#0`SALV#H4-C)-@(
M1E?0:=6IP*09NZ@%9S"/D?ZPTD>!0VQZZIH;E_D,YDYS.J<+)Q_.QC$4OU\*
M@Y[TY6%N0VI$P7CMF]<R!<3\^8&FR6]A&C#2KI;$+),=I"2L&6=PW:"=!=7<
MU%0C5["Q(6!H$QX=_<KQ&WL*7T<.:EW<FBV\[_W&1J6V$TX*TV(GO^)A`AS$
M64DVWCYQ.%C?NK'MB[+/BI+H@?$ZF?\`(@9=/6=4V;MB1*8ZYA,/Y2<V8$RU
MS1R2[IY#D3PTM6J)B(C:-3%V,W#!)0,%J]D23]M,06D+$'RI&U,`/+_2%Y@8
M<[YKZZYGM_H064K7\^WL&FGM9<SDO9$0$FCR:EWP_9C4SHH3)X_8P'HJOT1J
MRA]O%X@I\;*&TQ!50N?IT^YR[BK[N+HL;K!ZU&_A&ZDMU(7JE$BCII)^YZ6X
MO=-*FGBXB>SS4EC(:=-AF,A+,;QHRRSB<,YAW7T,T:M-)&X_3OR`=+<EXZE"
MSD#IHX/JT^.FZ._:6*QE,\&J^FM.='D!`W)4%A0DA.DA'H^B)<O"Y4(-82<B
M6YS#$#]A)C(5(C>[R9QEY\FE]U:;7%6UV5Q4<J6;`7Q]G]!;55(EJ4>HIWY>
M9ESF.@ED;',HQ3EIL`.PMX1;DL%(!D.:0$FR'M(T1FTTI%[L4Y6LOI4^TMF-
MZ/IA&LW`=8*<;5YBQ7'XMC<-;2PY$SC$J6KEA9EJD-9SPU/.YP!(8(@*Y5K.
MO!Q(R&7_`.3$&(B$MIYYYYYYYYYYYY[K%X6(<R329<1<>O+L&[EJQDUF3561
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M^7!+DO5M:,37M:VF]N^H"N`MHR@[BIJW7A82F^;#J^VHUXW,!<C;$AJ9.FR^
MKQVUTCBJ;'%&JHT[UB$OC,?BQYE+F%**)370@<>T<T,(J$NZOND[C"[Y-A^S
M)Z.*;8&K;MZ'*4S.T(.T2:*8$!:U*I!VLC,-6S\5=#"S1IEOE-@?&US%9+3H
MB,(88S0A.HZ.K#FZVX&"/9Z"AY"EJ>3(FX$$#K5AOIN(-(AH8F#-:1'EV4U)
M-B>43D9)SM^"W93C7G+]4U?<=FWP)MBAM8]R#=<#UG/W9J3OX,P6JL<T#Q$H
MD`Y>1_22!DV%D&D`\)HV&92#^+9-FRVV,86RMA;CA[GR5(>MYPH&I0T:=PP,
M(,]'BA<02$T&FT&.`>U80L>T'M\HMQA-F!;8'=E!Q6-7=I)MY%\JYFFS:31@
MYC\5/-*-+JTS,$W1YII'F@`?`%J'_25L&]XT^1U$^?OZ>6J*U".>?SX+'U>I
M+3*`U#QVJD7(,ITA9F34J;D4WH_[&6^+KF>;!;<#GLA=696YN@*]ZI)K*2N@
MU3LR%Z+J^."HP/ML#)/Q66@*2L&8".M5T!N'9P+U@US#.8?:#T:Q;3'B/XC>
M19T0F1UAB[P\GD.C)OJ^&N0.Z"M:'O0'O<H$F@$6&P-;"Q$_*8+<Q"FF!DSA
M]W+V%+HY9;8B823W#=XWL!`</4&*%U%GXS&FT*<<\5_8]9@)4VLX^<S4B*6S
M,CA78+:R'<I/2&;9?%!V)#UA2\M8^A+(2!S'Y(WZSIT]D-74:!/QH<WU;!T)
M'5,K9U7SG-H>?UG6!X'6+*MSQ&I;1G$2@YJDMGI9K+IG@-+%#.,)XYD81\O+
M"!-$1A"$3(W,M</=LV0X&YUBB@%*A6"(0EY6G-IYR@#1X@4R4/!C]-V9(#TR
M;1:$3]ETW>$<].B0O/.S64R^*]IF$;R&)3[]W*;2&2I<5\]*\@Q7"TV'.BGF
MV%JB!I6.#"0AG)"2:U^),6$<',&Y@B\9E;::#T(>$7%R]I*MRV$E82(GF,TG
M.L$9+&%%G`%'6-5%PU5:DC95GHWY5X[2=N'QF<N%[0+ZB%$9E*#KY8UAHZ%<
MP\$UW)"60=*CS.(EY>=)2$EFI61(IE_*K3_95)B-NT49<]'+XHE`.P:XE:J,
MG")`ZC"N<#B"!5&")JL3L$F\BU?ST$X>Q\A,Q^&DEG5ZY=,G+1[LFZ2@UGPA
M2+(@KHJ;OK'Q/U7S`6\?@\GM8$GNK&4>;[BZI!!*I[-\MY2><K`H0LD92*3L
MH;+"D4HE)8VVD<OXO??%!QE*`,+6L@&&KH3A>-7O`N&']5[":YF.7MOOOR$!
M(]F,XT3(785NY=+A)=*(N"J`>.5GZ4LN]VT<:_++?$_RF5QEWL;!WN.R'O0]
M?42#6B1F=SFSTFE)7FQTZ?TW:<),1;R'6#K@#))5I)Q1Z):0SQI(1K9RT:-M
MW4SB6D(;^.WG^"'J;C9*4NPX+*0N5>_ABWSZ^K4)[IF[3?@,O5$Q/F]EN"-&
M?*V$S5LV^KI^+/=TQ1,-PT@XZ%CVK%KA.?[;H41NB<JB:,)<V21I^P(JSAT>
M@"Z1@129,1]75P./SH=9ZYCCMF-/M<3`]#$J;Z(AR)"/)V+)$DAH26C(V6XK
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M)+S:*\FZ])G\;]%6(60IV:E=[SYE'"-T5M+DCFZBYO)F%4WX/!`_8M5E"S#=
MGHN"O=JX")Z(C(9.#>P!/!9G(N30=3!!B6M315-B7/5,U=1(&X(W014(*,5X
M(J%I`_*2+4;$8MM#0:$I/R6<O))=I',VS7113":23=!%LV0;M444$X3@N&*$
M"*/B.?ZLC2BGP,<MN5O`:4K`ME!8A@K%F;/FK<?RC.;U_&*.8QP63\BW<#$L
MA)#+T34T"'\2[$],Q.\SU!2(!200\`PJ,4Q%S)2=G92\E5$7\H7G5H%,N;6(
M7$:VC9JS=RY>53TO+RB;5@QBDMGF6$9&1\4W:L$(0J[ABFJ9@GM=5Q(V,-T,
MX=O74?SBW.'KFE1E*3D%I:2'Q"`>-%R07`'DBZ=J_P!*X<N;5<S9.W,%&AC(
M=5S#^X6X,YZD1#L4`GX<G)@SNV9)B#HL=GS&:>L"29+J_AJLF9`>RDHU<A"R
M@",BH^TU%W$>DP3&8609II2[960<1P+_`!FT$*;G4VQ-^D']BV4-\^#1E;T]
MT79<Y9LW_LQ%\L<5),*$$C*+LD)F&GYN7_,-F<.A&3$-)RHP^BMAR6EHM]F@
MU\?M`B=CUO;\0B9(V=64YT(7Q)CH3X:O)LZZFUB=;R.2R+CXMD.SQ&98'Q["
M.RD,WB!?2"CD1&(@T$UTG$)Z?#]R#&P="0X=O>M9O.=Q"?J\-+*KZ%M2MSDA
MI8K+U3PFI&S#$0G8J<LBK9<L76F\0!0Y>/H9\NX7')B&4<N-U,JN?XK>4;NE
M;F<3S2T1,<Z*"0$)O>O*QMDPKVO+10JEL/1=9D9`-#[I)..,@H;%H$0CR06=
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MW09ET1`YM)E+V*0NK`L"J4[=.=.<C.X9"&9CTI=Q!SXC)HU<\M:6B&+=*5(]
M1]%E(2221*YAMRENTFV^-4_\7W-E'EM(%@/*W?\`7F-G;4'S:-D%WG1&(TB&
M7)#Q$(45\&C\J]7;OP>,90<8D'P1JH7:B;5C'1,2X2@H:#BHS%FWQ#\?1P@!
M@D*QM>`%P7GFZN4,1\);YBP6+N>;YE%"(VK$ZDTW&94DAT"M3]3CL@H]:D$-
M)8W9XF'4`X=PKC/T_C(Y&7@B8:(PLH-8,]Y0`^,K+B3&R#N:B[-I2LFY*U`T
M#N,Q-M8R;.!1,R*LC]AZM&A="*S:R\1(L5V,0K'3-S'RH!\L"<B,")A=%ANY
M=9CB1-[ZN0\NVQ'$1"Z.VXN+?K,]E9*5;B@DS?/6P]`M,MF395_*2KS5]/3$
MO+/G^R-32UPWK=4K%3!`1](U.)4C<,"13CJ9`2ZL@9N7-1@8<!+Q/:%;-F"%
M@GJ3APU33>2J1A-HRZ[Y%5JFTJ^-_$ERB/4#8_,SE_?AE45BP$$"8@K'Z)M6
MPW]?5,+S$5/#E.5(0%\]+3-:UI$2<)%*IP@TZ;/W[>,BX^9F9*/AXAJPE*<^
M/'GZ<Z5VZGP[MR!L*=U!7%JCHA<M@"%2WY.U:Q:QU9%5[5(.R\<"V63`C1BQ
M;0<G+1*6B[*/C(N<:S,1%QT>VBV.^)/D^)="JC!S=S6.`9+JU:OH!M>)XTA`
M:![.82*-Z!8RS9O4%F8I,S,L]+(1LX=/)8:(\M'$;-:Q<7&1+/+CGXQN9;1!
MS87LK6S3,K.)RG2AQ=[NS2&!OT=*N>&K]I0Y:&VP%_I<@&"ZJTYB<W'RIAC]
M0RJQ"2+&4D4*$,QEW;*D:7%:&KV*KP4DC,A09*.'\N8609D%C6.:D#_*>TH5
M'1X5/'\^4$4ELB@FJ]?.,(-&+5A#Q+.-A(R-C6E87'QN<UN`B3I?\$;H\RS)
M.^+97E-L:/T.?7KZ5(EC"6@=@[1M^<M:SERU=>>E:68%+2F9!9P[C'0`H//7
ML,XRR[>$*%Z"C+1C++:G,HG:$I2,PLYBK")!F5`7W.I"B7U(I3TS`N&,G4NX
MP8)*E6JP0ZBG+V??RLB]765E'V%\&BZ.L&VNPA.Y;QIJNA@7Y`:68*\LV2UL
MK:Q+0M%:XA@+@BVP2*,2`Q%G4S-A`PTX-.@O69-'9'/R.";$A#,X6/1D^T!?
MCBYLKGH8VZ(%$;.8/SXU)K6G*=4MT^=<V:74;QCB%-KNCZ`<3&]<M;4+HQX_
M1G27>)<)KO9&1G6T>T(G[F7W^BN?CIYDKH;A0%(;GC6K0D2LJO*IJNRR5X>`
ME05Q;L7N/GU?UY'3:*DBR%9456=!,:S()<D>"E?O7U?"#^!"GCB!4CL1^)SD
ML=1AHXC1M^V1X<YTM/D2!%;ANRP#X;C^8[<>#;HCI=Q&OY1OF?%V"0B-,1Z1
M*%YPOBFD#!;;$SM[`03R,D!Y\=]#$%5V'4YY)6E9<;9="NN6Y\N/;&E)RRT>
M=WV7>LE5,58"35C/LHF:;O-T"8CW6<GQ?NVBY`N+YV7A8:1C_AL'XU.6+94L
M_%FCQ@;(6]0%3<V&S66/R5NBXK:BRF1/*C4A5(5S$NA@V`C^8E3L>L`==1I<
MS+'F)C\SV49QVC*?^=>=!#FP'5#AHHM2PI"1D=I8ELB\K/+;DM@P?Z-D6#%4
MGL`V?OYE^VAXILUB86+;Y90\4Q0S^#CTG3N1=/9^\\\\\\\\\\\\]JIZ4^8#
MEOE/H=E0EKPUN-HYN55G79Q=<$%-YZIZTM"YQ>>-:LKTLUCYI6R7<P6B@\O,
M8EA*NR45A=92#8S,\VDWKIE'8%>7SM\`4V,P4M#%UA725%I=%A(A6M65<:I&
M1+.R;&4E=DV2]EQ-="3=M'Q$)*23]5Z3(+?<M<(LFKUVLDAMTTK_`-(`^-MA
MSQ%=#L+(.I]C/#`E.0E:Q-3GVME24V:R45`P@&FE)PL>!(EWZEEVXZ]^_/M!
MMO(HNE4R%RP23=K7SXJ[-JONZAV-]U''F4!"[EM@5]/B=A0S2"-0TZK(ID!`
MO&2%C&R<Y$;.V$I'Y60<Q$U)L';!VT6U<)K[.&C;1/8Y9UW-2?R3Q/(AUUN7
M=?U)\G-8`W*L#DGN,TYN&ZYD:4Y*-#D$N/!H[DJ!B*4PPL"X",L8R[YC8$)M
M(0:H"NSE=1)FKMB8?(LC/7(,@831-F6)7<ST:;<NS=G`\">D+@*/`1Z1"L\?
M%$%'5FY#V-#1=FB)!7,_8VEJK3(M+?D\U-A*8Q(.Y>+AZB/E7,+O"Z=,->39
MD'3Z<LZ5I3F9B17:"OE;%LX"*>A6%U(E*4!!2$G7X-4H/SU.6')F.(DI>E4=
M.1\$("TG-III/,^+?DB+1:&_3CCE:P&W1</5UE6V6\_2DO-O)9$7`K2)*I&<
M!Q57-:V4V(G5[3`@13-#KD\#7T,2CS5HZ-96OWK])AK$-S?,%+UAK?4]$\<V
MM,`O-/-O+'7EP2!L:"U3GPS1W1S*P'\P@O5))%R!(RN*JT*Y(DIVIYYS"KR4
MC#SD6N3CSYK!($UH>;.H;AM_M;O:B2H1#(>K^8YF@!\`FX0D?R!#.?U1I]G:
MBLK.QSP6B]47$NVGT$UV24HHV&M85HQ:[3JTG(R36)[!^4%[7-T]=!$WS>4;
M5%Q*[$-+ONQ&R@O_`+-G9M%)VQ5N0RM]F?ZC*I@S+7P_5F()&1:.864)8DD?
M.%(G\:V9=ZV^2.5:D!#797SA8([94C:E+5'1FV_ZRCJEO0IN>--I?>.&[2L.
MJJY<1TW34+6%AE-[C^H/-OA$.A8:?%,GFY9#QF:>\R=J6/21]V+_`%I$#$D5
ML/YQ`WCJ%'75T/K!:4['W-SKS#@/D`B7*8U/:0JC<EF'Y>R#(]B#NQN/,=VR
M`Q'R#:2BT;AB/R81I[8$M18K4RF_0&O6W0?+`R%SE@-(L,F$^:ZY#;3L:WY<
M]9"4M*0(`T&C\.C&[!D!$1@H7D\)#9A/RM24(8C$H7NSI0KZOYEI];F!]60U
M:G$_1G2%BU[8YQ"1=RC)U4-KU!66P9JG%Q4L'[QC14YUD!V8;F#1,XCBZ-FY
M+]$Z#"L5-?#R;W9%V%S]R>'<TU87V#9=C\4PG5T;6]U]`R\B3C-3.GS86$&!
MW?)=`GL\:V(<&*[L9'9&78*LI%8=(Y<I*8./C6:LITN?EXVL5K3*O,/,1?<S
MJ\.-;GZ[&F1=98;32@[CGVRPFL+8J$ZQ*1I<K"G0P2ERP^L^BD"`?<E<;I%-
M7:D`XDC""N0X[GJEOQ!7'=.T:2ZUU;-8T78(&*JH,$3*8E.D%0:(J,!V14>:
MQ#0H)#"QA00W66D<0K"1?*/7,AB+;*NL4.[[^1*WJFYN^2*O84$8U'UQS9QZ
MKT4#2#`^R7A4]4U@L#(0B;CK@MW"!V2>%=9'H@409&!%88-[LR.,'7T=-30\
M0L9/'U=?GIA\6WQM]9=75?J7KVS.,:R=C=<6?<AG>]65?;5D$H#04(0B[PM:
M,I9B(KS13&6O8\`SU8Q!"5)SS])DR=3,DZ>WCB.1)<7%ZN_(^A[\5LX0-ZK*
M;%LLCLLH)5;N:B\]&.K''3D*EY!U7T7`6/&_G;=O$@0J'1X0NYBVX<WA8"/6
MA'>K_P"-[N<]K\9H&EKI"SXG`KSZJ^42K@?J`XN1,Z(<%G/?0G6EH,Q0L&B+
M>7.-P:*I&J9Z#'SZ2+'#YK+A:0VY$&4`X@B)[8AQ\LDZ]!""S@?CZZ+&`W/*
MQSU?6!"+M#%NP)1D!90):YKX_G"*J88,K6S3RL2%$YI^+C"NQ1RPE84G$-">
M&(XR/1FL\3^442F#FV0`,`&)E-"W*?-G55,;1%EQOX?H8>Z=GE`X&&P_7844
M<CDD@:K#8^^>DC?5+5.PZWF5&;6**=UHWLU/DOB/ZDQ<)'TJ>DU2)7K8W/9]
M;P?&G9"UK`GJI,HBCJS#!BE5[8,9\]"Q\#%@$36AO9Z,R-R#6*GYH":#$FYD
M8FKZ?3MJ7I\@_P`3I]'#1A5U!]"<\=MV8'Q7]89&3:V8)*`M,$=7REJ5#$(,
MA(;-60U/MC0<WV?'+P?BS![`.B.+FVTE$>M1\J->7`\Y^TOWGVW#2NK<Y<(H
M&[XT'8VX;UM6'1HL$2:,J8\XVPU&9ABS>1=M0>KH<%IO5MK.PARN,Z-GV\*^
MFH>3K'#=;&<A\>?7GR_5G(S!:32_.UGV95?.QG:!<SK:C8"A8$LUD@\Y"$'!
M".Q?1$3.CY"O?3*)A66^A?`,:@BI6'90LJ=3\SG7R5%=%1E9KW-1#F.B)57C
M@:,3?>PHV+P3D_6)W"UEH\H$7=![9>XXVGR$G#)*],[.P#4.9ER#,73,7,=M
MJ[QB;^64BA9PJ<_[(QO(5E77R!Z_'F?F[.V:X_/&=FE<@`#-3$XH#.4FVY,-
MF)M98?`$B<D1BK@$CYMI/96)TV1&P'_-I\K9AKN,!4OR*4(7C)]XF'Q]$M>P
MMQ@TR+C-N17.CCJ`,)&]B.X2#VGP(RJW>+D7<FB'Q\J(/%)IC*Q#MW$L6\]F
M@1\F4N1T=;UM&E#LZ7DN5+(NJK>R8NT;GA8L*H<BID:$#11]%6##`TZ[M`<L
M,//1$FKB2A`>%>3L=*_AW<9'3":,6ZP6Q?EC,*>HL3OZW^-K%J<2>5#7UW&T
M18MBBH^61(O9-N.@&+!`")2@GR5C7T*`R+"X+.J=\[!,@`P2BP_)DRQ=*.HR
M,O%VGU)OQW2N+U?@*QP%0E@UH+V.[2*F(LG70581W!U^]M676>Q$QE\)`,D1
MQ<X;),F^)"-$4I>?0T<)Q+AOO#E[?(8*T5+JMR:$"Q\4E.@V_.`;:EG6LE6%
M2RQ^TJN3L<BCR<^D0>9A@-WK+QVU6!3>75=LSBT/Q(WI+0>62JJGQ?(5VH=\
M@_&'>W:L=7B,7:8#048:PU<D[E(@8BMFF>HX.P<*5N(5PP0(8<+,2QGN3;P[
MV/1FXR%?XCG[))XBZ2S(/Y&*XFL*O63Z1N^0O2(FJ?-+'N*4L4GF&EMR`V3C
MA18X[/5RYD,UE"@%D,FY`-("P.'BK$-@Y=JB(_D_X+;\15-A\L9XJ$'-QRW&
MY+!4=7_57^R#-';F[P!W-.K53[@AN*G>D.$,(-R]>PK.9(&)XI*KRK-FM&,)
MT?;.5I)G%O9V3SWY2`"M"F\!`_'16M5:7[&KWD-\>VI:S,*IK:4LWG2&Z5$C
MHOLA,,F]*X@Y@7G(X%C6I#!KH.[8E8`1VG$&,VC/(TGN?L^^:/[:LV\H^F[#
M.(07^'&O.G;-YK=W^PAA*O<"-_6E(VE/#SF3S-`4E8J`'!K0T(Z$1=BSLUQ`
M1C2;)QJ)5:3:5U;"^4H8B=IUY3='6MT%&@D%S\4V#`5T,'LS:>(;H.`A3N%C
M*S!!:N#*(.CP6K(D@+")`LC.:W5=0LHDP%I6?G=%8_2L/:G7-@VL[XV):5BB
MD;I%G\R7/G-DO:X[<$B,/S_8"M<AKFVHV8K6`:MF9;2TK8D"1U?HD0%DB_DR
M<:U)5Z^;C&L829M+\IA&7#@UQ/J(G=A`FYE\CW&-8EKBO3TN`GA+7EBV,I"'
M`9-O1*8B'4C`$L5IJSD&3A7;[.F,+,U&CK&KC6/[B^5R<IR?Z;_$<GFI!6?'
M/3E'<^7J>L[6K]M)-("^ABFYH.L0!"G"2[\R=-7=X!"$P$2,V+NF\.N^E$R9
MQ,-51K3PF?ECG`H@*ZWL#E(MBKD!^W.<..R(`&;9`R=AJWZP#HTWI:SHLT?Q
MXM#R",C%2B,85AJS>/="Y*V>-L$,H.Z-R9UZ(+Y6CK6:CXFP>09X,0$.[P;X
M_>AI:.NT)+6%7VS=$E6C*C"0&3;C<._MT'+F]RU?(F;S=G7DQ7J!0J@E$%SN
M!G$&.3-_EOKU%JQLV6I^SL\MRU:W_9Z70HT-GD_#!HU0D7.$>TQ;;)_7(V&A
M(W;@Z,S.]-$$#9YUH2E&\$#3S$7)"2+;[5F,NBKTC_D$LDAM*N[%#@5A\)UK
M7MI1HIT5(OFLQ)Q]W"J[["&C?04%ZPO86'%W`G.&`ZA(M4U9&,V&[%)F<3LJ
MRF=U\G4%0_.W/EB*T=86U&ON?.&#54WLVW]7YY/PW3\Z)UTP'ZS?E$;.D'2]
MH4PTG!XNZ`E"$B"77Y410LRG.3Y(1[L=.\B_D@.A*Z^[Q2W`(<;B5$=7<^<I
M4'&")#-3I.?&EWU%4I^.Z3;1B`KOVVLDVLMT7DKJ,;3JXA!03V`@X(SDH_,E
M,V#K+Y$J?=!183]/NH#C!R,6X2U-%N^AB]*KJ_MK>%'8<RCCBB#JY(.H7-F!
M,J+SK;+QSH)P<X-$T.6#,Y"([P&LE(PF5_*5("-D=80\AS42*TWQZ?0%<63=
M#.T0M[B9);0I^H[-H1F#5\SCW$^2JVW-W((`B&C=_I@5>RT3-2BKMD]?M86O
MW7/7]FV8'C$"@!770)'47R7_`!<"GZY&I:VQNIKSKB\^H:Y&R&#%3,B"*6E;
M"9(Q:Q4$715A$$*QPQ)J0+IRI/11".R^]PT?D::R]P0H4$4+:ME5L_Z&L/FB
M<L>OQL\)Y40-ZX6*!Z?-B`:CZW5#4*4862%D%9RYZG;6TP/$6T))S`8V%Y1S
M,Q42,?ET'XAE=&MJT:0UV25)R("]CR`@T-8\V(!0&,CHFKN8`[W90HRW<4W;
M-33T"B^N,98M;(B0T:7E)9J03;H=D(I63EOD=:+0=;ICP&&&IE=&;<GZ==UY
M;[RU:1L:J:BC@/:4M^"M^HJKL"84"9LELL0#8A9&KW3EM//'V)S$6VBGBF/'
MH?OXCKKXI[B^02`I6QZ_.!'FPUM.%I2[Q"3$3<1/HMF]AXZ!L,9>ZLG^D3"E
MVJ+^3>,]D6Y`'-]9V#<98RS!?U1NN,6MP_\`%^Y[D'KZM:P^I.?Z^JR_+&-3
M2QR20`NA7+B>#)"Y*[*:IW<[58/5]8$"0DP]7\4"!8N\J9785D09]'.XI[F6
MNC$]_P`_(=7J<AN>=#"*L"70KJR:[EI$MBD!VP>8":)DG-C7Y&/<P/V&']$"
MA(?K0_K-XMN8;GIJ&(Q:BPL1QA4Y\P7Y`W);,WE7<G3:XI>%*]=@W*RE22E@
MLW<J6L[$A!L]$KKB)5@(;HM:SG*@EB.UHQ=VPWD%A^NSN*<ILB6#5B<XBQ^4
M&$3J%GU81T<:QW&1-2=LWH%7_"$<#/NE!BN9J)C`^//`!V@/+ATYT,RF&LU0
ML?"E!RO-M=]8T_TKJ>PXC&G;GOR50?/Y9:H%U'4\M51:"\W(]1A;82+HZSH:
MU@9,X&*DF@H>G-H0(2BK@';@/*ZK^3%95K^E7KBR0J;'CR9BG4[L/5%3ZVL^
MDOD5[`([]&"89BFO'?QQPM;4=`7<ZLX2);DZ*Z?Z"I@,U"4)QB(BP*2&YR\$
MZZ.%V@XR;:8"G9FY?$8^@VDW%@[T^4[;G*$ZEB[-Y[G%;BY9<<Q$,W7@;8L'
M+CMCT_U=:*515S:E;GY(.ARKYM&FS$N&2\5(@X=FH<C%%VJ"KZ`FH0G=]C'_
M`"A(Q<_;U66C14[7E]UGTW7O-T57K$PVLD=+W-M4I(]'5^:)&0$$2<RPCL4R
M.&)"=0,;7Y)-BLR)R4'$:%K1Y$3KVY/*70<STA6LH9$=/V%29&.6"<US."I[
M!D<:TEGH3+YCTCBMYLG%PN1/*G-HY5B0`9QL*#JLM'.U64G!0L]%2\2SLQYY
MYYYYYYYYZ`"?E;G`TNP2Z/+*1K(AO<$C$8<0MB7$(AZ<P#!KO);QR4?/+-]G
M::D/M-3F8%VIE1Z/XG9S$(YC\3,GAUD5T4'3'100M6]YUD&VN#+2<9-X&3J$
M:$,6VFX57=:(FV"3W7=2,F8S=5;\!+1JK21::+N$D7.B+EPFKYS%"TL04_GG
MV:JL!DJ._24:!IU&[%H=2NFX;"MFC2$&F@A^%Q!LX>%1CX_$,S:,T-(E1@R<
M1WX5RT;K)=G5%0UA18!!U93H&+5I7@WK(XA`\,AVD%`QZLQ)O)J8=(L6:>B>
M[^9FI&0F9B07RL_EI=^]DY%RY?.EUU(1YOY?1Y^.^I#5O8DT:J]27HKT`41,
MN/P42S$S)6NZ_JO:/%7$3KH[W'M0^L!!)-M.JRLGK*MI"2VEM\2&S5&&:QX(
ME*;Z#L>PZXZDNF!H6S+4*^AY[D;:/`7-:-;\-WB<T7%T.?:C;>X8H#*"_"]A
MD=/QYJU$98]?RDFJKI"2\P.2$38^*,;C.2Z2YZ#NBK5"K!Y<OLKZ0YOZ4A1Z
MOU;$K>RC(ILHCGDI06D8-V`'8;,L[AL,+(!"?A-(Z?"YELPD=]Y>,0G%._+O
MC?,GQ/3-S`W</1-=]/`P:4UC:7030;I8LE+_`*T/C5M8I$(&5;%M>R-7"S<:
M+$7$A3#@%%X5.HV[^1C(]E.L).61D?.YOB_#+B:]FQ<M==EQD;V=RY2O)9O]
M&(W/30K7=*)V`A"SD`0D#5](RYT0H6J<Y)9\M_.T';M_&OFT:U7C-_QUFJ?Y
M/AZ@Z'OSH:)L0QEICH^`IE*QPN08BB0=^L*;`FU:0YN/[M8+0KBW$N(Q\>SD
M!Y8F?CZ+Q!>1:M-7+K[2,0DOQS5;8DY\@G]2BXJ+P[Y#H`%'[1#4VT2/X!DZ
MYK-K50O*5P2QB&9MA.,H2/BYW23F=Y=5H8Q;";BM8YNDI&+1O+_&]8!U4@K`
MVWW;T':EY4[;5?7#SUT;/"%-0I#4)-5+0HAA;3>O14)A0(_T*A8W,!*Z90N8
MN)^U(`D>LE)8:TCQ_$/U!!\5K2>#KMU5Z<LYO:MK]H4[WQ"6>F$5CNTK'H*F
MQVKQF!7'0/:`Q$D`+(PU7PT7)"AC)S2VL<MOEK-)3*:TV]Q:6^("*9Y?V'7W
M6MY@G3$?UO:'7H#T=@6ILAGPXRN^M1NI+B!'H`[`F5>&-8V*&#$.G-#4Q"H[
MQ\Q%PLH-O(36';L][4,.&VD5:E`W@C?=P2UJ4I25Y4E+E)9H"DNUPP5]%(-8
MQE+G[)P)-4(B1;V-7HZ1PK.ML@T-#1.K@)AX^,%](]FPANG?C!'N<XWE*5HV
M\#(4L?E[G!]R#H=SXB)%C>WN>5)F/)H(:LD1VTAXO!<`%T.S+``V%'8]M$R[
MXF:34&2#9/)0&<G&?C.K&MBZK2&L#LK#H^H^0[RY+&QU2+@B!M(170AJ*639
M-HDDD_01D92QI>P`J(*=]T-X\;4>/B%):"W1ED=8[-E/CXJN:^/4)^.XK+#B
M:K8`IZJJE%+%CW$2.V?"*T4H+/:>LB+?,8U>`9V(!D(*'%T>_P`P2\`[)()-
M9^/+Q3IU$;X';WQQPO0]7=%CUVV]-DUI=-<XCW*!U<XX#"XC)P=,03XHF5HL
M(#OOIL>AI\D)S4G+2::D%)IJ]G7[)-A#Q<!`0$%'7"MWGFN>B^>3+FV_XAK9
MU<V;7:U>6,Q=(J0.2:.?1R+-[)-LP[E)R-S&KM%&;AY&#>-GP[-MF4E#.FKI
MBU43P2IJ&M,*@!@(..ES:VQ8!=06XY(SXH-#=DD3,44:JCC2V3P5WCVATHV6
M81J\X\'1*NU2]5ELF3ZR+&2F6,E6*N?C&$0!'EIIBXS,B9\O])]4]+PK68%`
MO[DZ)^ND+L:6:+F";9BFEJ),F?0UG-AQM#I,)!%)W`ZS#Z8UAE]920>->$I?
MD1LD`M^I;ON'G^NH)P%<YT18[.OTX"CP)VIC"(DY,!D5ACFX6@Q$)HA]?N;1
MFIK(:%I:P[=N_?X1FD(^ISXDN::4DN2)<5?G"S_D`HO*:`UW\SJKN40-OX:H
M0H`>9U3QD@":98B]6,ZDA5LX0&,4[73A/7=S#[JKY&$?':WK^ZK@G!WI"XDN
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M)X;L(ZBTMI\\4D7<T+%AGO\`JAT,-I+=WN\B&QOB,_J&G9"$AU_<^FEH#_$2
ML^[?!-1S$HQ-^&CX7.:XGQQ=85:QH\&E$B+LY$PJJ*B&HRL7K/#%@Z:NY<FC
MR&3IGXQQB5&K&&=;L.6;6R_D/`_D8FG28P'K.VUHUT3UF8P(&Q^^:;-]:\7G
MZC#G$GJJ@H4N&VLPS;D+-*12RRI-VCS6XH;H7C"="K9(-"OK7YP(;H5[*2@>
M,2D8"F&WQY7U4>PY&P^BT=O,!3\.K83BI)"0D=27[QV12\821TBYC?R^YAI\
M8`X;0@LTE;Q-E5G/4LUVC=,>^$0N8".A;[4C1Z,KUW90:^:9U5KJDFXJ'JU9
M6[.:Q$MY`#`)8W>'$L+Z/GV&=#?%&_Z3WOAP?]?VVJZZ-YVB*&/U=0*KWB<*
MT"KC)K?!9FLV[^'7TK^*:/278=.PZ,V<,K,C!T2E9V4:$\+F;=;/K&J48N&F
M3>D+0UV,Q"RZW(JQ/L2+:/05)X$N&78P3*.VK-HC&-G$JS?O%]TF3)!FU<+8
M_"-D4DDD]:JNN'FL3SI1O.(E:\RH$U4)NPL\C[:#AN[AWIJ%G`U\.EV>B!8M
MW:-S:0+"&0<63,2;60B7JYQ]5UEG$$[EH22E$<XVH^+XXA>%2.!>6'S_`!U$
ML>=Y*`-Y)U(R))7#043#]V<I+M-V+QJ_5BD]=FC^$WBEX)TDS6'MHO:.C\MN
MGISG"Q:U$!>J2+I4]L^MJ^U&XT3W(QD:AK7DAL-_`ZC8[9=IC>8_4Y1:H1D>
MTF)J,#@LE+VK/"9;,3.TE/J3%>I#XS1R3Y'O;EI:[SQ+6W.F2OKJ$M!N,A29
M-6]UD'2<;UO'/8J!WCE18D%!J[(IM),1HBCU]Y$6W<"\M*N]=T9)#Q'OCFG!
M:0O`G2ZC.#,CZ0N44M^\(^TZKJ`RK*S]83G"*YSE*U,JTC1T382=9$0[!0!`
ML/(3#%W%3(T/ZQTIKHE.KD.$P7Q#50'C!:%"5LV%"BY-\=3KXWD(Q2,&Y38>
MJ.2(C8G=EL*X?-MON"]L\L0CC8&,V1R##PZB/0D>+80@]5'>2P?QE.:]M,2L
M>E.M;TI5I-5+25.=(A@5$5LYA.CX'GL4V":X*GDB3"TZ0T[9VHAE(0)3VII2
M"DY@5:Q\>Q1A).&@9N*Z)_\`%+$XF&X^.],6N*48/]Q"O?P#2\>)UE(MP"Z6
MMDS5N&PR/F<V.2$MM4)S8I!,%^`MY'KR@K,3$QI"E.T*Y90T;<+K3EIEU)&4
MA&O;!GJ^_HCT74G2D(Y@(6#F59PPI::4(1"!F=)Y)PBF+.917.\^C&Z,YI\W
MT308345G"JJM:;>^,L8MV`[3'I2ZCF$:=M7I05ZV`M$C(>HY$YGGR(IR$%1X
M-VD6CM+6#F65#@&")6=2EY117]0J1;V,S+-?RKTV#\8HG8=Y']YR5S&C&>L'
MJ[D3K20A6(R+9AHTUXV%6HA7(M&[N4UG_P"CR*.9H.#71ZZ=D#M[IJI`3@^W
MRJV5^@@^-&`G][=65N\W:N+>^0.C_D,E54!0-VQ"V=0"U/+`P-$)JM=\;U\M
MM0U;ZSFLCEX4/]&L_P#<$+/:<UWC\<"_BB$QX'O+FR>Z/O$SX>M,:N49%.0I
M)&OXL4J**OO)3N;Q`Y9L.)-K4)A8;6,IQQ3XF8D<K#UDZ68.VR<V['!-<?\`
MJ'?C1(%BEZ?VIU_;5N&RW$-E\(8G9D!JB`R_JT])X^>2-21"$'M%IFUXK2+C
MM'T^S>P@V0RC;,JZ$6;=PYB%HD,_AC'"6NI^K8_J6VX,3(^6N.N;W&C@0KLG
ME(I/A\QBBNHC`9D"&+>8&&Q(XBF[JV0&$;LQ<V)4D29G^G%<.XY[/%L?%Q7-
MJ2G4DXYNFYA6=Z/LOGOH-C/"N]?L9RE.EN:Q&O`ZO+RJZ66"7#Y.:VBZH#\3
M0D2+38/()J%#'$&BP)56[&Q]=\JQ2M:Q@MU&7(]IFFLRZ(Y:PKRK&J?PVTPX
MBVD!K@/K:`$V8!7D2WA&#=CA@-1.CR164D96>EIB4E'CK>$27XUZML&)^0`3
ML`X-9T.[_(PPM-(B'1AA"4J8CKBLZ^JP`FZD)85I^81<L(1-3UT2PCV<1FMV
M)N-(S;?5)BY5AL=&_P#C[/3ZGA(`OCM*Z;R,13H'GF]6-HDH34@N]RMR_9D9
M:U7!Z(,""PZ$,F+\IAVCJR"E.,5-#C*SI/,Y#,6P\P@.Q#_CO>U_<ET3X+UC
MT$(<]WD:65<A5RP/;`D<*PMXVVT=8.C\'M=,5S<HE!31._>V>O6T87:BN;3<
MN"/;&T.^EAB3B"H_BEEZ><BT^*=CV[&&@7Q6&\6#I9!5W4<"X9"=7W$G:8`>
MJQ[<><M9$UUV6EH:PM)/9["64N03,Q,1S%-SK#Z>V2^)(7A<0UC41?1=R[T=
M`7S;]\1-M4A7%:L09E(]`A=<@-V5YIS\:11C7B]8V1'U0#&1!"/UGLVI<$/M
M:R1'H1/GFBNR)6BPTBHJ6Y]M)26N@(,`$@KNRE+->)R\I9T(91DA&&^Q<I&M
MXACC8L1EY7\:Q'V$'#12+S6.&HV$BV$:R9TME/C@C#NEZZY,N&]#JV>3*Q>U
MY^&J@C'QMH5V2+U!+04W6%<WA:<?KH^L,$&9,9&UI1M%C(636`D.1+6Q"HH:
MN2=$ER2V^`XZUK-%KV=W<>C=\5UT5%V]5]LP0^'8(0:NFH<\`I7EUFV>QSB/
MD:%-X.6FUK"A'R&TR53TTY*%I5L1Q0I)CE9>/3OGGO+OJ_\`KFM`PW%9KD^)
M)N(C)$VRPC-#VTQ"R3QFY/\``J.$9&.2;("$?U<'U@=S;EN<;C-QV0.OH(?B
M_P`-K)Y-7/Q`@PM4EM<H%_2-[V5Q,5`]GUS4_+,OJ`0`]1`I;3V1DI5E!V(.
MB3.Q[`5KUY).,49O8DW-LZI;:,MF;":E(>!E8B2SSXS@OH4#-AWJ>VSJZS0G
MYR4Y?BK:CXR!K0T$0K];C-G;G4*W@$Y$>_K+)657]7V!.&.T2F-.2:M!7:&`
MQZ'Q+P\K@!/\4R%QR=I&70755NV59-GT5SI4BIR-AE4U>[#2OD^\B?H.BKT#
M(^#%I5&-LT4LLA<D#]J\7D`4@<KRK"0$L#,@S&X?/[G^-Z#Z(K^Y(^V[@GI&
MU;ZCN:A<^MX7"1H?=-P;EBR<V_706'!TBY)(D=BI"QWI(4EKAU(3CZ6>%TTW
M:+QD<R%F8YCEQ_%H,6T>=`6\VZ!M:MKBM6\.>^DZZL<"B@UO*<_7+S953ZE@
MF="HJ?BIZ#+QTDKB8(12R0ZQF!'%%T&3D$7A2+:O4]&^P.C:X)ZOKV+'3BV3
M*\3A95>5,+0-V8]"RA5//=4-'#ED*!T9"!@7`M$&S9A!BHM$,XV,8MM%'*DI
+-.Y:;DY?\\]__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g706049.jpg
<DESCRIPTION>G706049.JPG
<TEXT>
begin 644 g706049.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`_1$E32S$Q-#I;,35:040Q+C$U6D%$
M-S(S,#$N3U544%5473(Q,C-?,5]#4%]/6%E$151?2U],24Y%+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_```L(`3<"4P$!$0#_Q``?``$``@("`P$!
M````````````!PD&"`4*`0($`PO_Q`!P$```!@(!`0$("@L)"`T*`@L"`P0%
M!@<``0@)$1(3%!87(5>7%3%56)66T=76UQA!45)666&1DMCG&2(V<7>9M]/4
M"C-35(&4F+(C)3(U-SE"<G-YL;/P)"<H*4AU>*&TN"9D-#A#1$5&8V:'P?'_
MV@`(`0$``#\`[_&-[UK6][\VM:[=[^YK65"3WJ#MSYS0F?'-'8Z"AZ?X^V+0
M]06;<#U73[,!6GR=OUH13&`<=HK,U#$[5%4[,DBCO$TTKEL^6BE4OG5B1BMZ
M^1QIZ1F/3Y@M&]0.X)U)N*=S25.R!H7F]S"Y2\2H#7I,>2H9-6"*E4W($VGK
M"6R(M<H<GYVL;7&">J+'9736VUD!/H6DC:1C-A#\?.+H7=[9H^UJGM_=FUC9
MT18#EKJ\+TC8VHRC#"R@&*URXXA*F`(TTLH(CC0!$88`O6]B&'6\`W>=*:[.
MVX*NUV^?7;8,1UVZ[=Z[=?[<?=UO7\>MZ^UGCRZ4GZ8*M]841^>,>72D_3!5
MOK"B/SQCRZ4GZ8*M]841^>,>72D_3!5OK"B/SQCRZ4GZ8*M]841^>,>72D_3
M!5OK"B/SQCRZ4GZ8*M]841^>,>72D_3!5OK"B/SQCRZ4GZ8*M]841^>,>72D
M_3!5OK"B/SQCRZ4GZ8*M]841^>,>72D_3!5OK"B/SQCRZ4GZ8*M]841^>,>7
M2D_3!5OK"B/SQCRZ4GZ8*M]841^>,>72D_3!5OK"B/SQCRZ4GZ8*M]841^>,
M@/E+S?J/CCQVN6]FJ1P*T7*JH`^3)OKQEM")M;G,G!K*+T@CB-T`)^$W'.RT
M].C`MTS.FT^S>^!0*QZ"0.,Q7OU+M"$'73[H,6@C&'NM=0,>M"[D6P]UK0N(
M01:UOL[=:$$(M:W^^#K?;K7CR\=2_P#%]4)_.";_`%1,>7CJ7_B^J$_G!-_J
MB8\O'4O_`!?5"?S@F_U1,>7CJ7_B^J$_G!-_JB8\O'4O_%]4)_.";_5$QY>.
MI?\`B^J$_G!-_JB8\O'4O_%]4)_.";_5$QY>.I?^+ZH3^<$W^J)CR\=2_P#%
M]4)_.";_`%1,>7CJ7_B^J$_G!-_JB8\O'4O_`!?5"?S@F_U1,>7CJ7_B^J$_
MG!-_JB8\O'4O_%]4)_.";_5$QY>.I?\`B^J$_G!-_JB8\O'4O_%]4)_.";_5
M$QY>.I?^+ZH3^<$W^J)CR\=2_P#%]4)_.";_`%1,>7CJ7_B^J$_G!-_JB8\O
M'4O_`!?5"?S@F_U1,>7CJ7_B^J$_G!-_JB8\O'4O_%]4)_.";_5$QY>.I?\`
MB^J$_G!-_JB9XW?/4N#K8M]/JA.S6M[W_P"L$W[6M=OO1,B>L.<//FW7>XV2
M(=/NG-K:,M]VI&<;=>>>D!`IHS0N!SU48QF!XFJ!.+&-AL:.]X7GEH%0EP7)
M,:W$@2DGJI9\O'4O_%]4)_.";_5$QY>.I?\`B^J$_G!-_JB8\O/4N[=:_<^J
M#[=]O9K]T$WV[[-=N^S7V(GG[->??W-9XU?/4NWKMUT^J#WK?M;UU!=[UO\`
MRZXB9Y\O'4O_`!?5"?S@F_U1,>7CJ7_B^J$_G!-_JB8\O'4O_%]4)_.";_5$
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M]K?_`.J)[6_M;]K>>?+QU+_Q?5"?S@F_U1,>7CJ7_B^J$_G!-_JB9&%V<U>H
M#0%.6I><_P"GS36X-3E>3"SIAIAY[`<WS<9@[$MD3WIG;CN)R`A<Y[;D"CP%
M(>N1%*%'>R1JB-#[O4DIN0'4K5ITZHGI]4-WI200I*[OJ!""+O:@H!Q?=!WQ
M$WV"[@8>ZUK>]=O;W(A:[!;_`&\O'4O_`!?5"?S@F_U1,]-7YU*][UK73]H'
M>]]G9K74&[=[[?-KL_\`1$^WOS:^[GOY>.I?^+ZH3^<$W^J)CR\=2_\`%]4)
M_.";_5$QY>.I?^+ZH3^<$W^J)F)O/-+F!5\XHIHO_A56D!@EUWM`J%!,81S$
M#9[W&Y!8B>0&,;N.&'<<(,6[MA"E@&G<`!E+:I)`K*4$!4Z*-+U:.`7=@"+L
M[.Z"$79]SNM:WV?_`#SVSQO6MZWK?GUO6];U^3?MY5U9_3816'..0*0FS]M7
M'_E=>''CDC>M4G1+;C)3[=X\*JL-2KJ[G_C(E21*.V<FHFFTL\;7"'2!U0#B
MS\X1![9W&7!4QSDZXZ<#!`K4J-W,L`UTH_CA>G(_DOQ]J`N,)D2N(6]R>-L0
MR6BD<L,=%R:1PJOO++<6JF8&V,QIP8`3A"4]/3YJ&-!BVRM4D2K4QB-8F(5)
M30Z`:F4DE*"#`A%H00F$G`&4/6A!"+6A@%K0@ZWK7;K6\U\JZ+1HR;<A`&1Y
MC&$JV6@!01M#<,)0-TY59FP%A$FWH`-F&&&;"'6M;&,8O]T(6]S3XH13\&H_
M\"MG]EQXH13\&H_\"MG]EQXH13\&H_\``K9_9<>*$4_!J/\`P*V?V7'BA%/P
M:C_P*V?V7'BA%/P:C_P*V?V7'BA%/P:C_P`"MG]EQXH13\&H_P#`K9_9<>*$
M4_!J/_`K9_9<>*$4_!J/_`K9_9<>*$4_!J/_``*V?V7'BA%/P:C_`,"MG]EQ
MXH13\&H_\"MG]EQXH13\&H_\"MG]EQXH13\&H_\``K9_9<>*$4_!J/\`P*V?
MV7'BA%/P:C_P*V?V7*Z^K9&H\CZ:_-(](Q,R4\%!S$0#D[4@(-`(OP$T`@F%
M)P##L!A8#`[T+6PC`$8>P00[U9H'VM_\X?\`KBSVQC&,8QC&,8QC&,8QC&>A
MG][,_P"8+_5WE='`7_A%ZE?_`%BTY_\`MAXG98UC*FP3V:<C>IQR$XQ2V:S^
MOJ4XM<8^.-E1Z%U].)75CS<$_P"1DDN="^3]]G$#=(Q.'&(5FS5HW0^/Q1JD
M*2,>-C\^ODF2OKNCC`8W8C34'75K7[="G.R9?;*EF>ID(N;3YS3O4P5H'::2
M![:&-\=TQ1`7-3#FER0PU.N-()5JD+"C.6E`6F']LI=NOX_XM;W_`-F><9ZB
M]K7_`#@?ZX<KFZ17_%H\*_Y`H7_W:O+&\97SU'+(L=BI`=/418;E5/(#D%N0
MP:L+.:(7);"655[#1ASE4BL]5$XJP2%T6MS&4W-,4)5B1A1HI-.XP8>(X0BT
M2K3YYYE2+DIQ2Z7W(^*OTRJ1^N;F#QSJ^](2P2)]BAS)*5SA.8!R"HB8(@G(
ME1P(U:\3=(H>D=$J!](4LR7O&FTU<I2*.3ZC_(6U^/[Q.%-36%)XN_VI)>FI
MQZ3R=2["D4/H)'ROY3V=45B7:V09^`YPU#)T4-8VQ(PN3PU'LI4H+8ER]N<R
M!.C:\V05W0"2K[&:9-'[DNUY8M5V^P]TK:RK=FEKL;^^"?(@O0V04IL5]D;^
MU2MF0LSBQK2V5Q31Y8DE2DX3*A7!TI5[*8S0OJF_\6GS_P#_`(->2?\`1'*\
MW>8?]Y&C_P!UMW_T1&<@I*,.3GDE'C3&FDFEE*2P@&8G,,+$`!P`&:$6(90A
M:,"$8=@V(.M"UL/;K*DZPJJ8%\V[=HY3R/Y-.T9IOC'P7M2.JWNY92Z*':>R
M2X.43?9#O)V]0HVQO:*RF>FXHSR>-J&W4:2-YKF",M#"<M[\"W#0M?=^7[OM
M>W]OS:^WKVL]NWS]GG_-OL_/[6,K5ZC_`/?>!W_61<5_]:?Y9,3_`'HK_HP?
MZNL_3&,8R$JJ_AQR(_E;:/Z&:GR;<8QC&,8QC&,8QC*Y.KK_`,6CS4_D"FG_
M`':3+&0^UO\`YP_]<6>V,8QC&,8QC&,8QC&,8ST,_O9G_,%_J[RNC@+_`,(O
M4K_ZQ:<__;#Q.RQK&:\V?Q<IVV+$B%P2!F?V*VX-'WB'1^T*ZG$UJ^>Z@\@6
M)7)X@3U)8`_1YPE,$6.R)(^!ATI&]1Y!(DR>1M3>@?B@N6:AWSPIMR:6.D7U
M)93U7]5H(?6L;2PMGO>\8"7M4U?9.G6H[*VR%'C1+WRP'"TZ?<'"7+G!3*WE
M=7SDXN[D4Y!0*W&"Q<+.H6^L<]#).0L<12][::760R0L%ZW]['1^>4XX6(N>
M7MVCVHLSE.C#?+$_1JN;<C!;D!F)8O9661=N1R"-0-N;+GH\4O(864EU1HVY
MT*:6XMQ;V]U6OK>@7EHR`*T2%[<4#4X/*-*H"80E=5[8W+7%.66L5H$B@XQ.
M7S&>HO:U_P`X'^N'*YND5_Q:/"O^0*%_]VKRQO&1V=5<)46HWW2<W.!EB-4%
M=*V;G84BDFVU'#7M\:I*\-9$5]E_%(M0Z/;$R+E[T%CT_*]LS4F/<QHFY(F)
M@9!P1XN-4`M"LFRN5J*(7!<;AR&F:0FP++$Y@O9SEB.>J;>ATB/F!TAK:P0S
MEO0S)))*Z<XJL02A(2^(=IW'1AYF2'<0./KM75KU;,X&&SHG>9`$UOAME^DE
MGO=@IDR4M&TI'^339V>7_P`!C)1)1D,;FUQ;D$(6@]E(@F9'49BX>;5=1<'J
M719C`JG4A<D[.5'44@LRS+!MF4-\=*&E-TQH9-9$DDSVF;CST*)4Y!`N\)?%
MJ)$N?5+FL1)#R)CQFA?5-_XM/G__`/!KR3_HCE>;O,/^\C1_[K;O_HB,Y;()
M5<?:]2V595XQ]L>$5QV97#)64CDVY]/B$#E%H=XU*X.S:CY<@41AD(C3O-)0
MYMCFPQU$\(ETC?'`M4:K<%`C:M6'@ASKB;$R)FSD/XQ/1T=C<3FBB9<E.23J
MD<VP=/<7HU-W5I,6L[R-')U=OU?=UEL3J8@[DWRG)VUZ(.8764Q;-G^.'&[E
M#5ULP"<679K?.HX'CK7=5VFR++=MF5EK;@KR#1=F57]#V>4,*9C)>K.7D2"/
M6%&SD[*E4M[/#['3N2B=.DX0.MD.5J]1_P#OO`[_`*R+BO\`ZT_RR8G^]%?]
M&#_5UFD/*;FH=0#P@KVK^-O(CEU=CJS$/Y58<?8FRGI8LQ+U*]$SR"T;3G[_
M``VJJS:'U<U.J1@3/LH/E<BVU.RJ/11V;VAT6(\&XU<^9;:LR:*PY%\+^4'"
MBQ),6=XE;NAK@DPJN?.)"5:XGQ>*7-3TNFL/33<AH;ECN"%SD$(D#T@3+SXF
MED@6EW\`L;]OVL8R$JJ_AQR(_E;:/Z&:GR;<8QC&,8QC&,8QC*Y.KK_Q:/-3
M^0*:?]VDS+>?O(&><;:PJR<0>3P*($R;D_QVIZ:R&QXVKD<>8X'=%I,U<R20
ME%I)9#O8UVC*9\`_-SBO<E30$Q"-,Z-BA,HV>F@+B_U&5TBXXR^\^1*>+ABB
MCE++Z*XP6C`6\4$B?,:N-A1K:ON>OV.S9D)JA;#,4X)@W@>Y+9'B`^-]=NUG
M,4J30B1LA!.9`ZM'%-55OE?:0VD]Q%I@L/L*P2VJO52B158Q3J[95QTCH9I&
MC7,AU4+5-PP.<Q<XN%E2](0W1-UFWAPX$8UR9RYDKGA#(E9=FQ>1&6O-E[AS
M&8^)%?P%FIMN85\2LX[BA$[^*B)LG6S,E!*(],&G;I)6>RY*9%&=(ZR$,2&$
M,?C_`(V'\1$.K!QFD[03(G=DN*N8TMIZ=V\TR&R($CCK:[[JBX8GQ^MJMT&D
MTF=5^['K:Z)W#J^?$:I$DB+XZ2%(XP29R^.)'5Z;_P!6KJI4')!-#3#8)>4Y
MG;U+.0L`25W#X;%GMZ%.^-D+BMCS:+$2LF?%U.Z&OT"FL:E-?R)BL9UA<N0.
M7@J>3)'=$X-:7>JG;6AM[5+6-V5VM5N,"MVOX=9D+7KV]2TKU<5G,?;Y*P*%
MS4M"!8V+3&QR3;6-RP`%2%3WU*H`$TH6LDC&,8QC&,8QC&,9Z&?WLS_F"_U=
MY71P%_X1>I7_`-8M.?\`[8>)V6,[WV:WOL[?N:\VNW?VM>?S>?VO/E>9?/&*
M-3/)+3E#'-1UBKYAF<':O10Z)^-+U*++:K(-I9UF#N(A85MMC3A=35)H"SFD
MF^!ID+*@>%QBE=(RT#1\`NI]Q_)KAUL%9&K?;UL1AW**?V=6ZF&-9]EU9$.&
M=@M]8<BWB5,+9*G!K=PP27NS:A1(Z^?YLNFZ95[(0,B1HTZHTCDK&YS1JOY7
M%92X-\O/ILV*T`V/93!#3)!+S+1YD6Q'J]X_M3BV)E6U<=1-"9$[K9F4</9J
M4,ZAQAFAG!(1+?SK;J*U7<%B1>F6:%7774[G4WOFE4#G84!82H]$+ZH!E6R6
M;U;(E3).7M.YR(B$I#K%8'>,&OU92:,I3T"6Q$\J";'B<FX17#<?)S@M2=W3
M)^AK+;]PUDVS<YPBL-6-\'87IZ&<8WH4D4>)1(W52R)-$$IW`M3*S7-:0:K-
M2N#:H$E$EFKB[?+5R8HF`W.UM*N/#E*5Z;Y!'%NS!GQF<0F4/D`L.+[/.)3&
MK"XW/(M)&1.X&)4@G%,@)7;2IMJ.\%SX+VM?\X'^N'*YND5_Q:/"O^0*%_\`
M=J\V&M2Z5K!>-"\=XNFWXX7.VVG/'%],(*6(XA5M*IH:3,'K:01NM*7=XE]E
MUO#60A4#2(D,A=WL[:DQC(;'"OCCMU26MNI0YVY1,\\%-F"N^>=RJ)Y$*Q2-
M]?V'!>$O("=P2Q6.`MJ65N#ON=Q*!)X&[J65U1H6F3[=E`HM*I$Y-LB2-,B.
M76*XEQNX*@X_SEKO*`77?=>6G;%1UK**@>?&*:5S64>D$K(EB,3"O?&IO0V'
M'XC*W"OD;RY-SPL,CK@V2IMB#P8WMZW/H=U/^/$N87:0FL-NQ%&"K.+5R0HJ
M905*UJK4@G,B7EUM0[C`2D4B=0C626TC`UPO:9<9$')DD`D[HO3AA:]ME2SE
M%_-MGL6(N8*>9YJTS=CY0+^-<H:99"R]N[%(ZH/536_"VEH*<UJ28`C]5Q*6
MG1U\CJURC[^\N<9,95[F0N*[Y$@^L-QO)AZ*>J*XY'IHDY4'4O*I"\GUDS!3
MG<;;5>$D>47",&IQL]*QUH^KTC=8<87$I;)T4<![@D'G<;WMY#L9Q\N:TK!Y
M-<Y*PF;E$5$(X\V;5$+K8AABJYFD!C98-"5Y<KHHF+VKE#RD?E[>YS90Q-AK
M2QQ=.%J0$'K4JU><:H#GE4W2N?;SOSCM*0=^EM.MM7V,TOA:+3>1)JHO'<[*
MA2PU,#>TP7N.RFLK$A3V)!L21<3'V60");5+\H:D,2=4W_BT^?\`_P#!KR3_
M`*(Y7F[S#_O(T?\`NMN_^B(SE=[UK6][\VM:WO>_R:]O*D^7O-FRXC4/-RPZ
M05LC$1PYGM050I=GR-^.(9G8$E6TG,K.1I&D"E*:4V1:O+>C\8:3D85;@HG*
MV0&F(%A+"UHG*4WWJ6U2P`6-9M0<DG6Q$O)*><5"JB8:U976PE]O0RAUW)IM
M:T84\WW$/86P*32I)C!I&JEJ5L5!=D;3)#(P])'QO:)RH6^E$]LN]Z/DR9<5
M/*-5UJ_&KE;/MEW(*UNZ*K9973TK;PC,2H']M<&*=5_)T2$TY&8\P4YZ3Z0%
M/@69KVHRM7J/_P!]X'?]9%Q7_P!:?Y9,3_>BO^C!_JZSK\=86D)A%51/*DGF
MAU<X2W.QM<4O$.*G3!;6F5RJ;2X[4N=#G]%`5Z!1[*2!8VDN*Z02!:\L+:@8
M(TA0ZTM7[1E*.7Z(KC-I`1R5#/%O6">4R)PIE2R:ZPM=M,"G29<!-9)BM32+
M>VJUJ1=$=:`V;DKAH*=4FDI"(O\`?ZT4,-^F,9"55?PXY$?RMM']#-3Y-N,8
MQC&,8QC&,8QE;W5]4$).F3S=6*CBDR1%QYGBQ6I/&$HA*D2)2%"I4H-'L("4
MZ9.48>><8()9118S!B"$.]ZA?D[R_P"FER.8*VCA_4ZXEP#=87Y4%])%S)?5
M$/A[Q(:/G"">Q:/KP/,I4)"XZXR%J0[?AMX2794W%C3-;LUC.$JS4^0.W2\1
ML$PC-*]7^@*+82^0"/E;Q\88S>_')\CO%R_#]O@YVMK1C>GG:)WI^USIA/U4
M\HV7!=8FG5V-,U$"5P<2YN"UZD\BN2--/M]QTN,<^^.MBM[92\`B:>^)):73
MAMN"VC.FZW9)=;P.]X3/KJIB:55&8):&H2]0"-0J/V?!F2*-`E%?M#'.VU*6
MY[PBLSIF.MF>5QZZK7%`F2KN8\#YO.C&V790VXZ59L,XR(>+>X:W'*94!VW7
MB^$(PN8]+#A2S4A"!<%_(1B.:A1$X1GI,NT+B4(6]7BB$J6&0;E#$F)^CW(#
MCLP2IM>>3')R`\O@V`V.Y+VJ(0RRH[OJZ!O5>E^QZB.K&1E41^;,<I(=5R@<
MW-%V\"5DJH>S+5ZT7&^VK9I0R\%ILN=[4XRQQDE3E=]<,U8+RT\(C,@0-,+C
MT486!N<V*/QU2'3C*E#[(9.XOBA\4DE;-<:>;_3!XT\?*5X],O4AXE2UCI&L
M(753%)'[D3221[>6.",2..,RYX(:9*F;`NAK8WI=+QH$J5(>J":>0E3`,T07
M-_[J;TT_?_\`#7_23J/Z5X_=3>FG[_\`X:_Z2=1_2O'[J;TT_?\`_#7_`$DZ
MC^E>/W4WII^__P"&O^DG4?TKQ^ZF]-/W_P#PU_TDZC^E>/W4WII^_P#^&O\`
MI)U']*\?NIO33]__`,-?]).H_I7C]U-Z:?O_`/AK_I)U']*\?NIO33]__P`-
M?]).H_I7C]U-Z:?O_P#AK_I)U']*\?NIO33]_P#\-?\`23J/Z5X_=3>FG[__
M`(:_Z2=1_2O'[J;TT_?_`/#7_23J/Z5X_=3>FG[_`/X:_P"DG4?TKQ^ZF]-/
MW_\`PU_TDZC^E>/W4WII^_\`^&O^DG4?TKST,ZIG33V6/6N?W#7>]@%K6M<D
MJC[=[[-^;^%>:'<)NHUT_P")3WJ$*Y/S<XG,"68<^9M*(HI=^055H")-&#>.
MG&%E)D;`<HE`"W=A4.[*\M:=X0"/;E#@TN:0A28>@5`*WSWU3.FGO6]:Y_\`
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M`5R%:[Z7IN#C\\Z7\6M./6XS=63B\7(HQRMY$\M6U$JN?CZI:!3'D=4[I4,C
MBJHG4L)6&Q.-,3NK<XWHM<2^">.]#>G=U0E[1"Y*A>1?!KBO55,UK$>K[QVM
M>`<=(NL:H?6*NZ^*L'<;./1LCPV1%JL*>-SRC$4ULSD\`=QB9DT=2'JVQM5O
MI3PC0JVMUGGB#S1Z;/&3CM7--K^HYPRD\@8"))()K(B.2%3E(7RQ;(F<DL^R
MG5I(/DY2A(QKI],Y(>Q(CP:.1,HT"4[7?21[WLKKJE=-0P0`!Y_<-.Z&86'7
M=<E*A`'MV,.NT0ART(`AU[>Q#$$(==NQ"UK6]ZT(Z7/4<Z?T`Z>G$&'SCFWQ
M0B,L8*/B3:_1F2<@*M9G]D<4VEA:AO=VA?)R%[:N)%K_`&5(M((4`"(`Q%Z`
M86(4E7'SFZ>KK?W'GDK".H#PW7R*FF>VZRD\2^R7IP@<KJ>]0P%7)MM9RN;(
MT6I%$)O55<3%O2K%)!;PQMDI84J@AV=&H>M17%NZ4KK7$=K19U<.-^VN/57S
M_J8#@7=?'0+BM9NHA*#99:SH>(,DVD`[0MR-V&N!)TQ;>F3@*!*D$H%HS9F\
M!W,'I2KZYCD4>N?7!AZGL3IIVI>.W*OMWC\=.F5C?XJEBK\M9E)DB,,9M/Q*
M!"Y/;(U+$;"Z."--I2@$D((3%5@\AI?P&A-#Z:J2ZA/'"\)$V<6.('"<451<
MAN%K;*DU-<:+;W.R+6BS9;TO9:WF5R(T;BZ&[BC[*H"P/)P4BN*N\.D36@6'
M[`\/.57#-D:E4LO#J)<,T#\C.N=77:%VG7$VOIPCD-]&QATLJR[58*GO*T(6
M^3Y?(V)WVRNOCNMDCC&Y2]^/9YCRY=[28*XQ/I,N52(:>-ZNG'@MB;^`L=Z>
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M1D:$`0?&SM"((M;"(.^P01:V$6M"UO6N1WU3.FD+6];Y_<->S>MZW_Z2=1^U
MOS;_`/YKRLVR[>Z;5AI^9-0&]27B1'Z>YFV!`KU<)1'.0]&K)-6]GPYCIZ,S
M)@"CD,V5)E;'/T]*P62,CD6W+R4#DKL%I6I6H9D66*LH,M+ICBO$J\R^K'Q<
M)>0\QB.9ID>+N;CUMD-F0>)I?#93"M''R@YT*AJJJM&N.S-+12,F9&Z=BWO;
M:5ID%+='\W>G?%KSY.\AY=U`.&R&0WTZ5=%X_&`<H*;7:C-3T7%W=BA)+H:D
ME.T8I))93,[*F[F6D/4`:VN2QZ.*#C'!C7#%MA^ZF]-/W_\`PU_TDZC^E>:4
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M_$V1R:HJ]AEOP>N^.EI4;>-T6"^K0#JF[9`]>-]\4*3)78V%U/6<B:(=$HY(
MYC('=$IG:9V<X<(F$:#YV7O,GCACR#D\@)65)SNYJ\KN*3=29C%'TY-11&K4
MW)D^B)G'WQ$C3R1SF+@1Q7<C[;%(9$\,[D;:B@N.LC*7#F1,*\*0R1BB;&ND
MDD=$;*QMI):AP<W`WO*1&4::40`9YO8+N`B..**UOLW^_&'7V\U)K?D-23?,
M;V5+;,B29.\6>UN#6<:Y!"!>A+J>M&PQ4GWW&^^$@<&Y:D$/7FT<F-!V]H?/
M+OV35!>EB&?"NOZO'V35!>EB&?"NOZO'V35!>EB&?"NOZO'V35!>EB&?"NOZ
MO'V35!>EB&?"NOZO'V35!>EB&?"NOZO'V35!>EB&?"NOZO'V35!>EB&?"NOZ
MO'V35!>EB&?"NOZO'V35!>EB&?"NOZO'V35!>EB&?"NOZO'V35!>EB&?"NOZ
MO'V35!>EB&?"NOZO'V35!>EB&?"NOZO'V35!>EB&?"NOZO'V35!>EB&?"NOZ
MO'V35!>EB&?"NOZO*^NJS?E,R;IR\R61BLB*.KJXT3+4:)N2N0#%*Q2L,;TA
M"8@K8`[--.//+*`6'M$+8^W>M`T(0=P>55U"X[1NL9"SU?&9^KLSD/2%"[1N
MTC##2VA;>EC--=M<H&O3PJ9#<D[$ZO:=P<VKP-&H6H"U&DC@!9WHHWAC^:W"
MA-(W*'BN2K%<I9S;B0N+*T!V\J0/W'YD/DERQ1*-M9U)"^90%A1N+V\0Q&<=
M+1,K4[NJ)D5(6AT.1\/7W.OA;8[;1"UIL:(-;AR,BE>RZLXY(V4]G?U*"UMN
M2:ND;^0<U#019TF[NR/T;AB1_<6\,VDT??&.%GR)<V*2P_+;?/?A/3++;3K*
MK(AZQ92S2-YF<9CK3MZDQB)/8S-4#H;&FTAO`5+28W:<@9J\FJZ-JW-M@,Q7
MDQ^<K8XY;VGUE_*>X)A2G'63\@*2X\-W)7Q.CFYTZUNT2/Q&F[]!4)9#B_.%
M>HSJ]ENI9*VR/:<'Q!!59+`ZR8+?ME8U9TC6MS4J@@OJ&4@564UY/+8[%EW"
MIK!3+16/)"'N)\LU=<XMN1,41.:81`DT(2*`Q&(RF3,L9=)XKDPTQ\FU(&+;
M,A50^1&)I_%R\X<DR>>P]7;58-[]6$/FD\GB9ST!L2QN,5JS1.166M6NZ]K3
M,IBFM6.=PITL5F1N*I]@2.6QPR7-;-MX0A.QA+SNX)+7M%'$]Y5,-[<)=6<)
M2-P@C*4&O5SHT"NIS^PYF+`7&[%,<T#5#9J:,N%/\C5$Q5ND1\FWMH"8.>7`
MB4SF2ULP<A*0<YK$&"UY-(F,AU;M&MS-1;NI9+@4"5G(2FY0HK=:D.,F#:B6
MJ71E;>]/:I$%C4)W(WW<>='!QJ0R):NN6MBS8HIB:1_9BVQS4REN4SF,RV;1
M(@<.2QPZ6GG/T'@4VG"`M(R*!&0F(R27CT7&V5P<T_+\D.5%(<=^/+;R'$UH
M[/8)NZU/%*:8ZX!&71QNB=7W)XY#:6C,%<U:E*PJ2IX_2QC,3R%0X`96V.FK
MI.K/$V-YNQ\4.Y9[5:QQ=^5=34E4]1-5>.DO=[GAMJ.$UBD?E::5P:*L]8NK
M5**AKF0JG^5*9>IW#W-E1N'C6L9_81"PI7QQ0MQ_#3?J%=/NMH=&)Y/.05/1
M6-3%@L&3QY4\]]2+UK-4TM(@EIJ3&`3)N1-YM;3`TV.SY"YM*)QA[FW/2>0(
MV_V!?!-TH/7*#B?'W-T:W.RZY+-986JL)S7)B@N+$EB**#[LY8[#DK8UK8X/
M::MME6&>WDNICJ7!52*7B0:CR]$XJ(MO#F'4\`C#8\U2GK&X7<BX^&$`FT?1
MR5,UK8M`^:%NPVLH#9:3P&-/P7I*M0RPR4Q5&,36SRQ`RNY2>3(CT)A8I7>>
M37%:.R67Q%^L2`,\A@\9DTO?&]Q2B2[,C\)?VN)S1;'U1S2%#,3(;+7V/Q&7
MMT-52!TBTMD,?BS\A;W]\:6Y9+L#D%;V;%D$S@^V5^CCBI>4*=>2S;1B`X1U
M[<8T_MJQ"YMR%R;G-DD#0Z,CNVN*)(N;G1O6(5B<E0G,+#F'L"R>Y#7\'(OZ
MC'L"R>Y#7\'(OZC'L"R>Y#7\'(OZC'L"R>Y#7\'(OZC'L"R>Y#7\'(OZC'L"
MR>Y#7\'(OZC/0QA9.]F?[4-?^X%__#D7WN__`.AE=_`MJ;%%B=2G1[<A.T#J
M+SS8.^HTQG<[,XQ\3AF;#W90NYV,7[X>]=FQ"\XNW?GRQ/V!9/<AK^#D7]1C
MV!9/<AK^#D7]1E?G,#F;$^-%H<?:+CD+J*4W#R(>W-##&&W+2#Q_B"Y*U*VI
MK]BF.Q5=4V-'GRSI"[/*=-!JL-TRO<T3MLC4,Z\2AI*0N!KYFQ.7<\9#PF@4
M,J)W7UM&4,BMISE%IE0>U6<AQCNGXEVK2D'*JUN[C@;<H=X;')1/(W9+>WQ6
M32)6RNZ`M8RZ*=,SY*WW+:`GE(M[?0T)FM;6E<-2TN[OQUE,D8LH$BMR3K(X
MG75E6!\,=$UBH*W0IM3JT"'*:0ER;J\2R*0QA')!15T2[W/TQ,F]:WIH:NS>
MNWS-Z+>M_EUOO'GUOV];^WKSYY]@63W(:_@Y%_48]@V8&P#`TM@1@,+$$06]
M&$01!,#L(@BT3K81:WK6];UO6];UVZWK>5T])!H:C^FIPJ&>VMYP]4##-:$:
MB2F"UH6EIF]=T,H6^S8QC'O7;YQ"$+?:(6][L6]@63W(:_@Y%_48]@63W(:_
M@Y%_49QKR1%&!I<WQV;VM*ULS>M=7)3II)4>#-[<E-6K5'>$J,]2=WE*0:;H
ME.2:>;L'>R2QF""#=?'#WG/`^4].V9R'41.H(S2L4D86*)/D+M0JTIJY*0GF
M$JHE:E;&57`I%2]RHS%\3;CJ;<=RR2'/TH2M*)8KUMM6/,<U]U"UUNP6HCZY
MXOI5%TV7%>7-ENU-R&:LJ`R$UQP_NI11TN"Y2]FB#^WKK!FLU612/0^-HV_<
M>"^O#YX;,#&6*C=7BQ2F)S7-[U!5EVP1K(-A-OUU"K/B(W-H;$KGN-3R-MLH
M9`N21.)82D<BVYT3EN"0M4H"E6`/3A/-T7HP4E^P+)[D-?P<B_J,>P+)[D-?
MP<B_J,T.ZI+,T$]-;GZ84UMQ9@>&W)$01EH4@!A$&I94,(@B`3H6MA$'0@[U
MOMT+6MZ[-ZUO6[C$Q,HF5HWMH;-[]BFW7;MO1[WYD*?6O/LC>_-K6M:^YKS:
M\V<K[`LGN0U_!R+^HS3?FYRAAW#:GU]D"K0JS)(6K8=MD!:SVEA4GQ]7.H5#
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M]&#_`%=93]U?F>CH?3,6MR4\>N+-J6ZYV?7E50*2\A;*8^,?L25(E+JYNR9L
MY<EF-4MIAP(CS$]+(RL:GH1KW)"&V*M+2Y/C^W)AU^<#NHC.U?*"&4O#I*ED
MU.O5&U58MTQ*T.6I?+UWK:TK)Y?S7AHT0;BO?S20K6V#7[5)6!%/Y`\6A+)T
MNDL-<(TBC*6!R`M]`Z7J2+CI.YW;KK);#ON0RZBO&ZLK%B/'HR`5ZT-L3FU6
MJ&!_CPQ66T-B:;R:)E6%&FBT"H\^]]="9FA2$"E)\,(U$1Q-7O3LK6OK9KN:
M)),\KZXHZV;_`+[H6G3VMJ2L-97%R<\:_*K)2GM)L*^0-*;RAVB*NXXO0IBX
M29:$N[ZY2$E)"28?89V:[.SVM>UYO-^;L[.S_)D)57K_`/''(CV_^%MH^WOT
M,U1^7)M[-?E_/OY<=FOR_GW\N.S7Y?S[^7'9K\OY]_+CLU^7\^_EQV:_+^??
MRX[-?E_/OY<=FOR_GW\N.S7Y?S[^7'9K\OY]_+CLU^7\^_EQV:_+^??RX[-?
ME_/OY<=FOR_GW\N.S7Y?S[^7'9K\OY]_+CLU^7\^_ERN3JZ:_P#5I<U/;_X`
MII[>]_X-)]W>2OS(HNPK[BE-,M=KX:W+JYY2<=KY>3)HJD"5(X,5%VBS60LC
M[6)@97DX#O)!LA3.E7+"@H&L*D:\XE?WH*,S4!)T^;>,EZ%W<)=6R9I'S]Y3
M<MG,2(Z6JW,B%\A^+-M<<F^+(B3X\A2JY5&#[2W)U:Q0K1,[DF8@-"8U&-PV
ML10.1TUN98(YQ7BSC9''1\;^-<8Z<:5F,3"MF&$!?>#5K.+K*@N#2SLK@&QD
MMJ5^H;'2-.M@.1PJEEK:\Q:&QQ&WSV2V%O+`=-ODZ?QCO/B*XV)QZ.K]O06:
MCXOVD9$)DLMUU1V%R'9N1K8PWJ9I,A11MJB;PS@A;ZHK5XD9]K`"Q6,_I(Z^
M1O4:>[0+EC/(.8UY$H?7DFA<.?9$\Q]!<DS3.$I9WAE@AXBC+`!2XTK*^&MT
MY=4VUK/#I))3BB8CM25)-IG!W1I$Y-92CIFWC#ZKY=<8*6G51Q+BK/+4J&_.
M(%;/I5@NJCCY/(-:]7758U:J]I49"8-(6C8T#>I0S,L=5&NE5.<RD>FLN4MK
MBE;&7X)QTZ.6<YN^<64^6'13@VO[#S_@C4H3GV/'#"8-S#K*J6:$A)KQJC"B
M%1N25K+JWTT3-_1.#Y(;;8329]))'J6'>+"#DY9TV+U?(C)V%#+JA(6N_&GI
MA4DWJ%"N;Z3E/O`:_GNZ9*[*M$Q,1P62PR'XY@84Q/=+&$](4XN@5A:DQ,1'
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M6MD&D5HL0L;5(IO.87)7>,V?`YO,RU%BN]61R6UF4_1B,R&'PF2Q6OI+,ZU?
M9&W68UNBV21-C2%5>I.,/(ZC.0/$VHVQGIZ>ORPSK+2UJ='A7<*ZM(_#.6-G
MUQ:4(06),'*'2QY'.`.,@DS2)E>3][L)EBDB2))9[)J5KNGG*,]*">PAY@46
M@%J-\`K2-<3TO$NS7^.R*=C-Y*P&/<.@\<Z]76UQX<4BFIVBT*SGPR9U#[VA
M4Q06""KF-OH-Z*>HPM&Z->.0/IP<OD*)0.;2[C=I<H8^DDC"BC#A:JM$0Y]-
M2Y=61(C1N+O#T9JI!;"!*`AF)TT(SXJK=1I'$Q\3L.G629:T],^R$>KS@LO@
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MM\&XW6U/K'X_22`*)RZ6X^-TWJ61U-J/SDN2,C6QP-.2TSJ5J9<1$9%,FVP%
M3;"#O`8D!D7$.,(7[Q-O[F+!JVK;DG&.*R?Q=5TI9!MSUP=8JFS:>N:N[A#.
M9<XT"W3"'G*F8B1PV+0N,QN<BL>+2%@<7B9&26-36.$M[`YVFA[`Z[/WV_.+
M?GUO?^Z%L79[7M:[>S7Y-:SSVZ_+^;?R9ZBWKLU[?^Z!]K?WX?R97/TB_-TT
MN%>M_:H*%^UY]?WM7]O7;K?^3>6-=NOR_FW\F.W7Y?S;^3,<F&Y7N)2G4#W'
M]3C<<>]0S<M"Z[BNI7ML5>+NY-IDV%ZW']/'@?LUIH$%TVV^$^`"TK[SO*[6
M_@8HN!79=D\DEWDUMRWWWC](I83Q`MNV:]1MSSQTC<K8H@[;M5"EKJ?35X7&
M3A]\-<'6/QXHB.LM<QSP%:K@:.2K]<Z*Z7-N<3HK`G2C;G3RVVV*.\VJSD3I
M=\PM&7Q\V!\L+@16_%7^/N3GN3R!NDE126'PE]<8NE3-3-:3P[V8>ODL7>9.
MFE!%L/'NG&'CM0]+T%%UR]SC=)U57U3L+FZ:[7-S:*]BC5%$#DY;!L8-N#@G
M:@+5O>Q;+TI4&A+WLL(<F#MU^7\V_DQVZ_+^;?R9H9U3//TU.?VM?;X:\DO;
M\VO^".5_;WV:U_EWF[K#O_:1H]O_`'K;OM;W_P#N1'W-9RW;K\OYM_)E7W43
MZ:T>YRQ"9";K7N.L;'D$&AM?HE<7NBV(A6QK#%K,26!W4EKJ%/[<Q/[F(1KP
M%*ZK$!ZPMPVPK#AC''FDU%L!(VCF-%RUD?JE'QXET,8Y=7+'"P6_-[M(G+I3
MZ&K3VVP7*PYHCC\[&]VMJTRVUR8CMMB]GEL(T[)Y8[-DO<@O::1>+U#L?&2@
MZQHN.J$ZEIKN.Z9R!M[;MF9BCE3BX/2Y)'&+2A;J/15`XNJM#$XYI<O\7HVG
M:F7P];X#X4;/G;K\OYM_)E:W4?\`.;P._)U(N*_M^;_E3_[O9V_Y,LF)_O17
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M-*^>H2`M%,%CXA9C&\]T$,IP&-3'G$"DHD03$^M$#$$03@[U8MC&,KJZMB@U
M)TVN9BM./O9Z6B9<I(,[D(NX.3^!&E#[D81`%W!@`B[D81`%V=@@B#O>M[%W
M99=8TLFARF4-#_()1:MB(ZWK>$Q!(>[2Z?3UV;)#*C65B1*7=H:"--L3BTLF
M#ZZ/3NR,3'&HV\.;@XIRTQ91W(5+,*[M^$)IPS1V5QA,-ZE$:<(_83(^PJ6L
M<AADD<(E(VEX8796$\@:-\:U9*->F-6,SZ@VB?(\Y.K"Z-;DLRF<`C\+B$KE
M1,.DDR5QB,OLD3PR%%#=9K+#&1K4N8([$6A>]M"1SDCR)/IN9$*MT;4JIR4)
MB%+@B*&-07SB1BC*HA":8V&(5"Y.4>!N7*5)#@2(Q,6I,2GIPN!H=*DP3-`5
M%E&G`*,"/_9!`UH>]3V?E10[WQ&FW,Y+%K"+JVOXW=4HDK$H83`6*F04%*)U
M$[$()BQ<F-3G."-RKJ3'($GLT#:Q"F*/&8F,,,()V>CI4'D[-'GMM3Z"GD["
MWR1J3*U:HE>8U.2)&O)/,2:7F"UWHE<F`J$6(PH@XP)8C=[$#8HJ2VO5"OD:
MX<8@,,E#/D-.(KP`ZB3[%#5\04SQ;7"E&A>B9`:L'(VF2H1%.S0I:$H4B4],
M>%6<(W90(8=^:'&B/3+D57<D9+.C\ZXR0.*698$2=J\F2=]D$&GCR\1R#O\`
M4:`!YIMTIY;(F!UC+(166I*L/ER<J%')R)DO;F!7M/'WZNI4>I;M'B12=HB,
M2F<EA\@<E2670N/S8#X*-F2UG-=%!T>$N,C,C3EIU9H=!4,;L7K>](S1:RW<
M>B@22U`B4^DYH"S"C]KU>B30'"``H99VUNBQA-$:4$L01[T9LTK0-BV8#NO?
M4:B^]&;TF)WHHWO)N]+5F^]'=@!=Z,[%G^QF]@P;[V/N1[T,'8'?=A[?8$7C
M1A8#2TA8RS`Z$68!8M&`P(NS8=@$%7L(]"UO6P[#O>A:WK8>W6];V+88T(T]
MN)T'9I8"CU2`IT7]T$!O=:(.4)`+O,$WO8]$FFE]R/98M%BWLL7<Z]-E[T`Y
M<G9/Q`$I<FV]HU4[->&HL[-<A0HY'5KS(3HGN5Q&0".&RR-.SR4H+-)&]"K]
MEX\J5MICHWITCHWJ5.)QWD]14]DM]Q"K8O8EJR'C7:]?4O:J"#Q=T/`V3J>J
MHOX2D9G!_>H^V29OKYCE2:5V4ZL2Q8DBS&UOI&AN,A;=L)VUH8[%1FGD!3DB
M/2A+&I)"N6"-3EG:'LDP\L*S8R0'!+,$2,W0`FA+&(&Q:`/>O03!$0FIR!%I
M='*Q'@2E;<5.C5(TVMB4@3E^&]V>).$(A*`E!&(@.MB-T`.M[S]/%N*[&<7I
M.1LQ,,LM0#2Y7L9`S0@&4$X&EG=%;,`8`9>C-!V8$8!`T+0P;W"=@VM4M;6A
M0M42!H?S7OD2\6*Q09Y;"#%<50.595T]6B_$RIY,?4PF;2N*QUY-9A$HW#2Y
M6A/(.\$*+&HU-8XY%2SDZ<P@@"A7HT24@:Y6`Y0$D(1G"(*$LT8=HD`P#.V6
M$6B@#"(SN0B#O?H<P1%,`9B@M*0`L9)0QG."HH(#5!NB""Q[,6AT`P\_>B20
M"WH1IV]%%Z$9ON<_;49C&S]IM)2MJ0E!/$G\-6=^T2,0P`-V5X9WS10AEC!H
MS8=`V,`P:%W01:U^WBC'_P#$-?YTN_M>>ID1C^@#WI!KMT`6]?\`E2[V]:W_
M`/FLT3X6*CYE.^H"CD9GLBFA//&:1",E["!)[&QXGCQQF?BF_0T`4ABSN75_
M=57A;@-8N%M5WD2K:8A,01O=XHQ__$-?YTN_M>/%&/\`^(:_SI=_:\@KD';]
M%<8H4U3VVUBAG9'Z?5Y6;(4W)7MZ=7:86?,V2"Q=N1-C>>8H&3MX?DBEX<3.
M]-["R)W![=5*9O0G&ZC%+RTXVKK>25$D)DYQZZZW_C4EG@6A?Y.3.0\8KU;:
M3U38G[;SIS)EJ6$-;HZ`6*(^5$5:UM61U')SY(3[$BE^PK(J&LK"HZLI2CD)
M4EY"S&102MS&^/RMSCZF2QBO)?:+DWOLH2Z$P1HXR'063.#62[KTZIX,;3T[
M8F5#+.$5,FHC']ZUOV/UY_\`\TN_M>/%&/\`^(:_SI=_:\>*;`#81A0:T((R
MQ:WX2NWV;T,.];\ZK>OSZWK\F:'],)0=8W3\XCS:8C]F)-)*2B;J\N6PA0;6
M+U6E9AY_@;5I`W)^[%OM[TD1IR0^T`H&O-F^'BC'_P#$-?YTN_M>/%&/_P"(
M:_SI=_:\]#(I'"@",-1`++`'8QC&K7!```=;V(8Q;5ZT$`0ZV(0A;T$(=;$+
M>M:WO-'47,RCWJ`36Q8Q3W*"4,L;?X]'(>E:>.MP$NEYK)5IT4,+E0)+TA:$
M5JQ)8T,ZN2'3QD<"H.V17:>3.\A0,R@M7OB$W/7B@]UG6%F0I#8DZ*M>&79/
MV&#Q^$R-#9;1%^-+PCB_(=3+H7,'&*KHPZTU,W!#!YC%G`[4K-F*HJ/QIDD2
MW8M!W1@:JM;-A$.LB"J4TBA-@16.S:'R!(<[E)'V+2QG1/\`'GA*6K,3*@)W
M-H<$:XD"E.0H`6>$)Q)1NAEAROQ1C_\`B&O\Z7?VO'BC'_\`$-?YTN_M>:7]
M1S7B#T_N;<WBG^U4GB/%*_9+'W/7_ENV]Z9*QDKDV+?`W/:YN5>#+$Q)W@ZY
M&J2'=QWM0G.)$,L6WS-%6(YH:S3$.A#,;4`QB\)6Z[1"1DB%OL"I"'7;O>]]
MFM:UKVM:[,Y+Q1C_`/B&O\Z7?VO(+Y&6]1?%>KW"WKB5J66'H'V)QD`FU*]/
MCNXO\UDC;%H^UM3,WJ#%JX\]R="3UAA80I6EF2N;\[*$3.U."U/D%R3.KZ,K
M]WL::-S^J:FU2V-B-DA['*)K-91('QU3,;!%H7"HWX?(I;*7UV6)T+0PL:%6
MX+31B$`K1))YI?-5FOB5H0.,3]NATXB:*4M@'1-';*BDNKN=-1)AQQ(4TEA,
MIT@D,;<O]AV:)M=T:9:6282882#1H=9G7BC'_P#$-?YTN_M>5W]0A"F8A\'`
M-97@H7+J-\5$RS6AF'=^)+43P\`.U2,_9?8:``NZ)V6/?9W.Q;#O>MV8D_WH
MK_HP?ZNLT&Y?QGFNE7H)KQ>C'&3D''"$:#QEXW\GSWV"%>SC-[,>`3:IKGC<
M<G*..R%80ZEMCY%Y[7KTS.!2)(XQ^8PI3MZ22&->*K%U$9E-VZ5\BJGXB<-:
MP:M)W!RJ[CE*GNZ;9M1\0$O"1J;)[9;A!:X@L+KMH,=!/>F2+,$SE\C<0$)-
MRZ',P7MMDMH^O-K[OY=^W_EQC(2JK^''(C^5MH_H9J?)MQC&,8QC&,ZLW7LL
M1%RIG58=.R#1XV1*(<^--SW9/4#@:`ZJI&_Q.51VE(@TLZ/P@^63B3EOKE)E
ML--1;";%U#";M0A,>D[D@TPX(='GG%2<9LF\^,5[JZ9Y4U(N8VQKADD(>6B%
M7BZIP&R65U#;L&=C2TC=`%;&JC!$$>74*A<;)W![>'`YI;Q,CS']A:N_NIYI
MDLIKBMIIPMD;=,Y#+X57$N=F"Z8X9'6V6O<G:H8_KVEM71,]P$U-SVL5*$C8
MK>%"W:<@"$;JI-V%>=VX0BT/6]Z^T(8=^?6_.`6P[]K^+M[/;UV^?/;&5R=7
M7_BT>:G\@4T_[M)F=\\Z;@E]U!&ZZL>AYK>L/4VA'WMR.JN5DPFX*2<8VTR=
MWC%]U-*4TLA,I:)U`Y6E8V](=`I`3,S&F2/!+>W/[<)UC[G0_8/'ZQ9/,N&5
M8<Y*JL;F4J>*IZLT&@L>GB&N%-^S.ABG7C^/CDKY"D,+O':W5VTW(%R(]?-$
M16UT>E;C$+*D"6/3EI?72.R$;TXKU=:&YZLENT<MN?DM(^GOQGIJC;B7R>)O
MKC/N0T9X3+:$N1U@TMD4N9G>(KGVP524F82F2H(*BF[.G2/*M2^H&A/X#-<Z
MX?W&^\B+.NUIX\R'3\KZC/3GO6N9F8XP=/(6:H*\J>F8)RGD+$?N;^'QE,<W
MQFPXK.XRD"@>;,;5:=(B8YDV+D9I<+UAQ+YCQ.AN7M56%Q@7V`[W9QGY]1KC
M9-"3Z90R[CW)+HM?D*YH>/+VI%8>BG*+7PGL"$7&PVFSB.5,:]RE%97$N96V
M&0;N9C7\8N24DY$]R\U)=K;(TZ6DK.XL\B&*SZH9JDX]+8?Q+9*=EE<W(#>U
M]X)E<<M0NP)$OJ"NT\OIB^6RR&Q9)5:90V21S9\QZ=E!VK">3%9V?*N'\RXZ
M@;>G+!>/%X2B0O%2+")=R2@%O;D<K>#G&(61)I)9()<:NDDK:[><6@QRFJ5U
M`NEBQ"[CTA3\WS@H_DM=EBL/,RE*%>$=^<![$9`<8:GDBBI4*GF1#I.\,A-]
M,LRE2^7+F*'UW(8\9X11NY4]1F15G:T$2W(_,1JE?&F9)A_(?C_:SS>/*B[&
MC@ZYV8U\BJZZ;)H#EZNI0RYC2TU=LI<;WB,HBR2TH\XV',(5&%L#E*VK%<B-
MI2Y6&(^*;[,)0SH@0I_UIAW`F\GZJX/`+'XJRMX)@/#7JUT$6BF;C3SDUJY9
M:')V+6)PV1-K.QS\Z/)D8XFP+W"O75`S,S%5Z\AJT1J#)"X^:1@]M<5YG5;"
MPKK:H"1%0J=7?T&U3TT)W2*.#E:7(2,SM[K7E:K<$[;.-KI-9C\RR>.1>PIG
M)U`06TW$C1ZD\R3D`&.01<`YZ.`Q&DEG#>9&<<9);/).Q5J6+*ZG-LNJ.(2^
MZU]C4GT_JT3/MEQXZG17"^NKM([%D$3,1H*BI0S5(LLM(D#HU+(%LW2E&WO'
M^IJT7H?Q7F%509=)^9<"G<M9Y#7SW&7>'3>(<6':B)H^2E39CC/94QKBJF?8
M\BA3>PM4-I-_1)H%"H"!"0MG\CDKF=QTY-SWD-]D;Q:A[6Q<@>/3_1"VE)O8
MQC$GKBT(+-&VSZMY15B[K4#^HDI$:;(39$:M`*1T86S3K8E1P[4=-6B3*%((
M$6\,+DB!G(J)1:CK`E3`GYZ]+&X*OE*IXKM(X69`^-BCC"1R(M$P?E!2K$[R
MK'6MN/CTCEA+2_S)QD853&UO9SZ`9>+3CBG>LVI7J`UI(>'<ZD'*E\JSJ*P6
M'\K6^SX4PQ;DO%^4M@/$TX[QR-)45FM#B\R&(M957Q@]'<L<B+%QC+K9])JR
M3%-4@2DR#G[BX06<2^WC#J@H);%"K@KWBU*N&MIP\F$,1/#.^859+[.;T<)>
M<"1#=X%(7V</*6ZYQ,(8@D6K[TJE<*DS[(GA&R-3MKESEX_6I#2^;4M?ZHD$
MFHB>VU3<T;7Z;1^"QZZV*QW;J/\`%PYJKRJ[>@L\:E=QTY;<7%)YM`TUG-#)
M.>-1Z9EK!/-]L#\2PQS9*N>"+ZV6?4J77%X]+P_#U`.7]WMU"O":#J8M4''^
MTN$RJG`1IVJI6\DLC9%;9Y*+IY8S;44<;9"WL3-8H5TE9V+NG)N:XNX[<1N4
MC&OX@0GD=0'(62DPFIN#(J[F,,N&F&YCXVS_`(MOC^FM*+6_+%;Z_6E'F9[;
MC4LB:C*)6S5KY"160*ZCL,E`D:4W<_"BX*V9`Z;IUP>>'EH25KD-J<Y(?RTJ
MNI7?CX;>TYA-PW%;$CXGV&8&T)8Z5?/8)5T'L*2QA`S.,\:YE2"2VW!^@:!M
M<(J\(R]O:8XT7I6'.>E)DU5[)WBM4=4P:!6XZW@MB-H.<`'`^+26#L=C4ARI
M1/K/:\L>)!)DK54MQ4W9D,>8_.)-N4<CHV9$'%4L7R6\/OA?WX/TP_+GH887
MWLS_`&0'^X%_R@_>[_+E=/`88-6+U*^T0=?^L6G.O.+6O/KC#Q.[=>??VOM_
M<RQGOA?^$!^D'Y<=\+_P@/T@_+E,W5'X9\P>1[0ZR'CM=\&3Z`+CNR1ZHI52
M+1*G-B,BG)NMK-L*<Q^RG2[*_0MZ92WQ2.2F7199&UJN5,]4H(>S/"%4_P"A
M@BQKXM\D67J-M7(=C@AL<F2WDD?Y5)2RM44+XIVUQ*.XXML&+M%Q85\C<I/$
M^:K?+F\<603Z,,Z&PUD;6JJGE;Q*N/)#.ZMNY5NIK@NN9]-&T4W'^R8CN`<F
MI):%RQ*2.M7F2&G8H[\7>2],)EDL/9+"=&%Y.U,+,B`SD,`=YBL`S+E3H%.8
M4UK0%V0Z,+UK7[\'M:_Y0?ESSWPO_"`_2#\N>HC`;UK6A@WO8@:UK0M=N]]V
M'S>WE<_2+&#732X5=HPZ_P#,%"_;%K7_`.S5Z^[]W6]?QZRQKOA?^$!^D'Y<
M=\+_`,(#](/RYB,_4%$P6:'"AJJRM$Q.2&^3MM\7AN,][AF6BW"V\,K=&2+;
M72K6ML*74D>6A@V>O`%Y<T#=M2J*I\HFM[#XCUGR&GO$'A?;T%@5POM3*Z6X
M0)G"C&`ZD9VI9'Y!=MQM5=N]SQFIZYA+F-=%W!RJ"*VDW`ELO@CB\-*"/ZLA
M8_Z@SD%Q'F=Q4'QOA1G&#D=6$9K]MY=.(7]H?:(F?-V(<@+"3(AQ"S)$Y1FU
M9'5KI6W))ZD]WN/(:L-3"7UK/C9+7\6M^-H*S4R-!&KQ./B>S6ZAZ6;[O*B2
M.YD-45VCME)!2$Z*$IK*31%H(G!$01IQ"3HXP3)2W(MB2)QC3I6T*<A,,:<L
MH6Y@[X7_`(0'Z0?EQWPO_"`_2#\N:&=4P8-]-/G_`-@P[_\`0UY)>T+6_;J.
M5ZU[6_M[WK7\>]:S=UA,!ID:.T8-?[5MV_.+7M;1$;UOV_MZ\^OR9RW?"_\`
M"`_2#\N4V=6+AMRUY/5]-%O'&WX4G-,K6*PEBI>2TZSRAR4/@KAC,NF4PC5G
M.]R5ZWQ=8\1YECZ1Z;G6/O1:EC@XV=G7MZB5.>CYUY.-$?MZL7:B^3_!"><R
M(*WS:L8D[+F:'4:OBLX=GJM5S\\7W`X?,[O;I%!8_!YF:J@*E<)W26-"92_D
M.\8"\0YN<)T1L5P^KJP:?XS4S6=K2YYF<ZA4);V)W?91(=2V3;3I#U>V)HDD
MQ%H)LTD$9CAC/%WJ:']TIE[FRJI(I,./=!G#V4[X7_A`?I!^7*U^H\((C>!W
M<B"+LZD7%?M[-ZW_`,JP-_:_)K?YMY9.3_>BO^C!_JZRIOK/7_=?'/AXEFU$
MW%(J%E#O==30A]M*$<<B^5EAQB%2AT<R)"LK^E5BQ"S2>1%[2(CE0GP[:-)&
M29"-"7[/C9A@UXZ'G(>Z;_(Y.*;AYG7[S$-BRRGDS`Z7KP-:.!BB!%NZ*QSG
M-JC<-9W=S*GA#X:@1KW24*BTJIM,1H&?6SR-%:)ONWO6NSMWK7;OLUV[[.W?
MW-?=W^3'=!WO8=;UL6O/O7;KMUK?M;WKV]=N><A*JOX<<B/Y6VC^AFI\FW&,
M8QC&,\;WV:WO?M:UO?YLJZN#JN\=ZKE_)"L5.I`JL3CPL1,[NF4LKJ@ARMW=
M((S3=*)SF;BB0,K2U-B9[2[D*DI0Y"(0@&8U^R3D9IK*B#H\<2DL:HM1S#NT
M<>M#D]S7F1W*B86.L94AQS$TS9,<HJ^.PW:L:XV--K1`G!&I&C;1I3D2IZ4,
M1ARI&Q-QFKDBF9I3N:Y[3MB`AX<DR!$XNI*-.6XKT;6-48VI%BP!85"E.WC7
M+A(B3S!EI!+%.R`E]_,[KJBW%T38[++CCDV1,UF-L-D,T50%VN2O8%$V*V&%
MO5NPPN<Z\FZAO.C[.T:4GK&B/VD7'MR]H92W*0M32@\)BS@KU[ZA/*?JB]%>
M0UK3T6YDM/)NI[0;YC(JODE_56AF%S1)IAZV.M3C$IC+=NJ,,G3IAO[<8S/9
MJE0K5E@6Z/1-!1:=,;=9T+N<%]\]>)D[MGD2OB+G-XS?DLKQO60Z*!A[>.-M
MD*KZ0H2U364Y.1)J\I?)7,`UA9A.S4W@Q9A.S"1'&W2Y"_(JBH=R;HVU./\`
M8"R0MT,MV$O<$D;C$G!(U2=O:WU-X.>N8')>VO"%$[)-Z`H0J5C4XIBU!8!'
MHE!?=%"U.WP&L40A"_=*NHKK8A"%O09OQ?"'6Q;V+?<A#Q-T$.NW>^P(=:"'
M7F#K6M:UF+KNF<XNDI8IRY\_>=[C-8NB<VV,S!<\\2U<JCK<]Z*"]-[#(5'$
M,QW9T#SHA/IW1-RQ,F=-)TVG`I3I,G[WD_V`EB_C*^HM\>.,/ZIV/L!;%_&5
M]1;X\\8?U3L?8"V+^,KZBWQYXP_JG8^P%L7\97U%OCSQA_5.Q]@+8OXROJ+?
M'GC#^J=C[`6Q?QE?46^//&']4['V`MB_C*^HM\>>,/ZIV/L!;%_&5]1;X\\8
M?U3LQB4],YQG*=K1S;G[SOF"1C?&V3LJ64O7$N0)V>2LQ@CF>1M1+MQ#5EMS
M^T'"$<TO2,)#HUGBV>@5ISM]WF3_`&`EB_C*^HM\>.,/ZIV/L!;%_&5]1;X\
M\8?U3L?8"V+^,KZBWQYXP_JG8^P%L7\97U%OCSQA_5.Q]@+8OXROJ+?'GC#^
MJ=C[`6Q?QE?46^//&']4[,8EW3/<K`9]QZ><_>=\V8-KF]SVQ2]YXER5FVY-
M"PIP:7';6]<0UJ':]J<""'!K6;(VI;EY"=<B-(5D$G%Y-K@)8FM:UKJ5=1;6
MM:UK6O'CC#[6M=FO_9.[=^;6O/OMW]W>>?L!;%_&5]1;X\\8?U3L?8"V+^,K
MZBWQYXP_JG8^P%L7\97U%OCSQA_5.Q]@+8OXROJ+?'GC#^J=GC?`2Q-ZWK?4
MKZBV];UO6]>//&'VM^W_`.R=F$P[I>*Z^7SYSA?4&ZA$>7VC.UUG6`I13SC8
M,<GGCE'XS%5TD6!5<5U!:=2?'H=&6KP1N`B;"B&@DPA"4H.6'*,W^P%L7\97
MU%OCSQA_5.Q]@+8OXROJ+?'GC#^J=C[`6Q?QE?46^//&']4['V`MB_C*^HM\
M>>,/ZIV/L!;%_&5]1;X\\8?U3L?8"V+^,KZBWQYXP_JG8^P%L7\97U%OCSQA
M_5.SSK@+8NMZ%KJ5]17>PB"+7=3?B^(/:'>A:[0BXF["+7;K7:$6MA%KS"UO
M6]ZS!:TZ72JG(#$JMK'J#=0F'U_!&1+'(C&&Z>\;CT;(R(MF;2-Y"ERXL+G%
M061WT>@&KEJI3L.]`$<(``!#G/V`MB_C*^HM\>>,/ZIV/L!;%_&5]1;X\\8?
MU3L?8"V+^,KZBWQYXP_JG8^P%L7\97U%OCSQA_5.Q]@+8OXROJ+?'GC#^J=C
M[`6Q?QE?46^//&']4['V`MB_C*^HM\>>,/ZIV/L!;%_&5]1;X\\8?U3LPZQ.
MF(XVS`IK5UC=0OJ%RN`6+%7Z$3:,+Y]QM(12&*2=M4,[^RJE#=Q71.!"=S;%
M:E&<<A6)%A91P]IU))G<CUEI/3_L`@HH@GJ4=14LDDHLDHL,XXP]R`HH`2RP
M:[>)V][T$`0A[=[V+?9VBWL6][W^GV`MB_C*^HM\>>,/ZIV/L!;%_&5]1;X\
M\8?U3L?8"V+^,KZBWQYXP_JG8^P%L7\97U%OCSQA_5.Q]@+8OXROJ+?'GC#^
MJ=GSI>G(4X3>IYA9O,_FK=J&G;2B]QQ>"6A,Z*40I7.88G>$\;7OB>%\>(3(
MU:5M$]K5(4*.3-Q"A3I.-7W\!`"\LA"'00A#KV@ZT'7;[?9K79KMRNSJ@I+[
M<N+#XAH#[(TUS%)V`5EI.'<HJ^&\LU52B1OFI(7QYD5OHEL+;[``\!CBH_0P
M$R=PAB27ML"5$S=4Q;WJST7VWD(T0>UT]FAZC:.J#388NK1NZJECU;9'*TJ4
M&GS0FQ5J)?`T:24L]/J$J:%IXJVV8-4[G25'+5D:\%CH]!.Q7G/U`W)CY8\/
M*CJ"]X!!X;'>H/1=#<A&M+.H0=-+,=+!@-DN[W6JAB.<S'J-0*O^Y@2B8/8T
M11\FL.51V#MZE%XL24ETQ7CMS)O>3+^"').43EV<63GASMY@<8))2:M8D-B5
M?5C7R/E4;1:F%-VF],:U3"!:XKMNY^^A--631=9\X+D9K@0VP,B(WZ/S\BC;
M*M?G`AU/1("2SCR&1E=Y$Z#"8:42$*-E843B[+S-#-#L12)$>8`K1AP@A**,
M&'4ZMKMAZ&8WPH.:+/&6YVBUK$P4U,VTL.+)!4U9H!`7ITL,./;%6ST)PP(G
M(M*L,2#2KP$"1+$IYTO>7^#^XEM^HJYOH+CR_P`']Q+;]15S?07'E_@_N);?
MJ*N;Z"X\O\']Q+;]15S?07'E_@_N);?J*N;Z"X\O\']Q+;]15S?07'E_@_N)
M;?J*N;Z"X\O\']Q+;]15S?07(NNOFW2U#53.;AL#5@1Z'5^QC?7UWD536S&V
M=,G\+2($Y*E[<X)IN;S5Z]:D;D)JXPE*8X*TB<Y0G`=L\O3&\NM]PQIAH:UQ
M1]BV&YRMG('7T3A4'>%4PLF7NI*`3%`H;'5B8AR6/2PU?H#@Z.*=MC38`G>D
M[L[K5"%O5=?>Z.&?52YX2]_OZ1LD,XJM%A2^02P/&Z=PWD;*7M.UN`0MJ1MM
MI5&Z*E;)*"W)B*`A/CRE:D3(6X82A1]E5E(2T7:SXP2Y@I'C?0E-R)KGRE_J
MJG*VKMZ/B]&WT9&3'6&Q!I8'#<=,>X&!Y,8M*D!H6@QV#IS,0!3C7:\)V;O<
MZ>7^#^XEM^HJYOH+CR_0;W$MOU%7-]!,J5YJ1SBCR!OF&./.'C"597'=@C1[
M#6=K26!WK"GJM)9)1I5\J9I('1L4T\M<A.CJ%0F+;FM>I0@2(U*89_\`MP45
MHD:XH^CW?AW*/B75-VN73$N0;8V\H*5W7=CC34<M;DR!JB?*&I7"4IS>_0B1
M)E2;V3;WEY"Y*TXEK:X)T")R@"E@N"J_K-]-BZIY&JNJCDHEG]BS%6>@BT-C
ME6W6J?7Y:E;ECLH2-R,RN2=FJ"6UO7+1DB$`82$IV]A[L&PYNKJ_X-O7;IDM
MOLWY]?\`F*N;Z"8\O\']Q+;]15S?07'E_@_N);?J*N;Z"X\O\']Q+;]15S?0
M7'E_@_N);?J*N;Z"X\O\']Q+;]15S?07'E_@_N);?J*N;Z"X\O\`!_<2V_45
M<WT%QY?X/[B6WZBKF^@N/+_!_<2V_45<WT%QY?X/[B6WZBKF^@N/+_!_<2V_
M45<WT%QY?X/[B6WZBKF^@N/+_!_<2V_45<WT%QY?X/[B6WZBKF^@N/+_``?W
M$MOU%7-]!<>7^#^XEM^HJYOH+CR_P?W$MOU%7-]!<>7^#^XEM^HJYOH+CR_P
M?W$MOU%7-]!<>7^#^XEM^HJYOH+CR_P?W$MOU%7-]!<>7^#^XEM^HJYOH+CR
M_P`']Q+;]15S?07'E_@_N);?J*N;Z"X\O\']Q+;]15S?07'E_@_N);?J*N;Z
M"X\O\']Q+;]15S?07'E_@_N);?J*N;Z"X\O\']Q+;]15S?07'E_@_N);?J*N
M;Z"X\O\`!_<2V_45<WT%QY?X/[B6WZBKF^@N/+_!_<2V_45<WT%QY?X/[B6W
MZBKF^@N/+_!_<2V_45<WT%QY?X/[B6WZBKF^@N/+_!_<2V_45<WT%QY?X/[B
M6WZBKF^@N/+_``?W$MOU%7-]!<>7^#^XEM^HJYOH+CR_P?W$MOU%7-]!<>7^
M#^XEM^HJYOH+CR_P?W$MOU%7-]!<>7^#^XEM^HJYOH+CR_P?W$MOU%7-]!<>
M7^#^XEM^HJYOH+CR_P`']Q+;]15S?07'E_@_N);?J*N;Z"X\O\']Q+;]15S?
M07,VAU@,<Y]D/89#+D?L9X-X1XTP2:0KOGA??^]>`^-S$R^R7<^#F>$>Q_A/
M@O=$^$]Z\(([YF^=>?K+<88))5[=,5G2]N#J#-%_FU/7%_DTK?<JA4K1Q*AW
M&PYU430KA!$VBI#:T-TOE[H\@G484H]&*Q'QZ;FB2N+$!?E/0UXWP"A6GDVO
MK#IH7'TV(?-I!51(8C=UP/EHRRSWF,,$OTZ2).C?9Q.S8\T1XE_;VI(L1.#>
MC?S5R@D;7I8PJ5ZRR.[^`7%:_P";5;9$YJ>($3NJ;UAG(5KEL?B$(;)))YU!
M&U_;6-+.WXZ++GB4QO>GX2]8UJ5Q*@US:&%<2X)S&LK0N.@_`BEH'<$<M5J5
M2U2VU]85W7!4M5K7-OU6]3V_R0&]#NVQ8>@1-*-^-=YIN5SO:9LD3^^QZ(BL
M>?[B+2S@?RBVW=W(2JK^''(C^5MH_H9J?)MQC&,8SU$/0?;[K[7M`&+7GWV:
M\X0[UV]OVO;SKM<U><,PYW/=G<`NGSQT0\L2V)R;V_D;>$SD/B3QIKY3$I"F
MD!<%;9T<VN268S13(XTD1B$UD+6H@:526V)Y&64ZK6/7+I?],SJ*4[SQ9>17
M,B+TBZ0YFB=HZ8GIBGJ&52:"/\M:VQJ;&*$(4C*A.0QE4G+4[6$+%2K2)4G&
MZI3BG1W>#G+M:>UC&,BVS*H8+<):F*<&&NT"3#4JWV!&DD^P<Q7A\'VR;DYN
MM>'+&IB/`>X)V,@Y,A7N@D2QTVK`V)DHM;N3E&SMSX8W?0%5@438<\@<NK1B
M:WYV2)'>-5S-F8^-.+/'G18`)#\[1!C7K0PL$G6%"5Z(;6YZ=%W@FS5W2HX5
M].[FKQMY6BNFA(M`;KMOBVY.4RC%)2J5^3R33MH+;WR&3)(N0.X"0$O3.UO"
MYD(;&IX-V*7KFA?M6<T(UC6N[?O"CJM<<.8#NIJ=PT_\>.5<:$>AGO%*\TPX
M?;,>=4`2]+P,1+HG;4D[:@;&(Y,N8`!=?``A6NL?9P&!#NSS6];\^M]OVOXM
M_;UO[F]?;UOSZ^WGG&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&5)
M=9]GEDIXDQR#PJRI/!)'8G(:DZ]:HU!N2WV(T\NMTF;XX,+'3D*O7Q+GGBL_
M/TA6M$HTU;8P%S9LAKE"SW9F(?3'`J$^C9PSY)\/IUS+8KV8[H4QQS>J;C%8
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MB1D&B3+D)R=:C4:`8+9*M(H(5)C-!.3G%'``,.#M]4UZT*8:L:(LVM*N`-JA
MEBBEK":WG-K*K2&)%3(::D-)&Y,RK0]+%+4ZB6H3G8A*]&$"=TB=:73MU..,
M4"NJ5F/7*'C,ELBD6I(S#@W(BB#5L6Y2\?G1*00:N=A2E$?M:O8T[P!2XI&]
M:G/B)(!(CE0`NI(4Y]=M^7CU:.EOQ@'<]:\C:IYX</7E-#RX%;/(2)O27D!4
MZ27/S<V1E-*$*20QQ59B!V.6%1[;FXO+L[(%9H'$]M96Y+WD?P=)3K[6[R6Y
M..]5\W9WQDJBOG*LW9;`WLII4U88\VD1*(HD:(P7(I98#RS*37*/+I&I(:3"
MDJE8>@*$E5;,*$F4=M-BD;!*&U,\QIZ:9"T+`[&E=6)Q1O#:I!K>P[$0O;3U
M20X.A:WKM+.%KMUO7VMYR_=@]ON@]GM=O=:]O[GMYYUO6_:WK?\`%O6_^S/.
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8RC3KH<@>*5:T-6M6<JN3_)?
MAG';/M^$.\<Y"\=*VL9\?8P]UR:[S1&D2V/%(#,V>'/>W)E;%1#<#>IRX)0^
MR,9:%S8W2%R9L7Z&MJT!;2'E`]<>>H)S1ZA\6:'NHV)WLWEN@E"5##WWV"FC
MT9$*S.E<%KM=L7@3JE<)PA)CYI*=09&%H7164YEDI+\\8R$JJ_AQR(_E;:/Z
M&:GR;<8QC&>HQ:`$0A;T$(=;WL0M]@0ZUKMV(6]^;00Z[=BWOS:#K>]^;64V
M<58#).1G42Y'<YY+,A26I*[C+/QRXN1$`%I;9%SD99JFT9T#9ANDZYWDP%)>
MVYP`6`*1EF#DW@3A'LU4IM]86!FC#82S1]M2M#2F.6')FY"7WE&F&O6J'%4%
M,0'?>TY)BQ6H."G("6G)[YLL@HHH("P\QC&,8QC/400C#L(PA$$6MA$$6M;"
M((M=@@[UOMUL(M>86M^;>NW6];UFG7/"BJ\Y`\3K3J.?M+4MCCTU-&FU"M8'
M:0)RY$V/;:IB1;>P1TY*ZJW0;V!$B9"VT7?TSFI2*B23!)@@RFGB5TO.),#L
MV049R!Z<41.<[3A!!I,E-->+5K%LCS`B)4N*LQ=*Y+*EL0D;F^$$IE[LR2$A
M0D=E36TMC4RMR[:UVV6>^@3PRCSFK?N,$]Y2<*)2IUH:==QGY#SN.-19A9@#
M0Z.BLG6RAL4(@'!`9X(6)*4`S0=@$7KM[:4.L5^Z==-&NZ1$1U5[IM6M9W/Y
M*QQQ6N9V"K[>9WIMB.W50DE,_C*@XV?QDQM(WM&C=32#4#P';@4EV(XXP.:]
M`WK$LOC!<55<^N9DI?)A8DFK[=%/MXRU:[Q-/X&TOR*41HB=*P#88@Y.J]2S
M+"$,C7M*)V[QH2-6-6#:<?<\(/)4E%GIS2SB3BP&E&E#"86848'0RS"Q@WL`
MRS`;T,LP&Q`&'>A`$(.];W^N,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M94=UI;ON"@N'[7-:3M5YI*6+[UJ*(N%H1#C0EY;6+$HM)G%W1OCG6U).:A*S
M225D`+3B-/=S>\HHMXS>QVM/RAI%K7_H=<@+FOA-R;46]S'OGEZ.,+*>(C[E
M>'`9EX"FP0IU264)T;8S"V-T<$\^)>U#:F5NTJ4E)5;<<WH63NCR2B@I[\.Z
MUV]GV_XM]G\7;V=FM_D[>WL\_9CNM;WV=OG^3V^S?M;WK[>M;[=?;[,\Y"55
M?PXY$?RMM']#-3Y-N,8QC*^>J;R3;>)_`SD5<RLY2)R:X7XM15K;UY3<[2"8
M3ES0Q&/,#6K-3*Q)U;DK=Q!,4D)3U2-$6L6IB]G)@;#(7`>HG:EN)U.164(2
M6Z>.T733JQDA(3=!1SR>ZU*9"SA$;ONS"(P:Y$1)$8(!>Q-[`D[2P;[0YN)C
M&,8QC&,>WCL^W_X_\?ES62_^+4,OU4P2%=)9Y`I[$$BY)%)S`).N8W5I+7'D
MJSB3D@1B;W!.-6G).&$PDE7V!V64N(+&+61*Y5S8-:U&N-OV85YR=:(5-4KR
MV%637K&2_.$*4MH6+3&V*G$;JB5VBI=UX3HL::D6&R15LF%F*0'/Y3LU1;!X
M)PCYPP"U*?GM.T0YQESD2Q,MHQ;7;9$)]$26,HYD*?9!M.D9'E'.1&@4J1/T
M*$G\2@GAC)$@6+4C@K4Z+K>,_4,Z2Y^Y+P=?Y5SKX3-HSE+]PJM:0>%7A5#$
M#NE!X^/%D&ISUC^VMY8#O!(6<A4*=@$6E3Q*2N9YK^EVOK#KK],^?0MNDLIY
M%Q^CY.)2M:9/4]WHW6"V?!I&TB**=V"3QPU"L`6>B/.T2!P0*UC6M$`X*55L
M],L3);&Z'Y"TIR=K]+:E!63%[5KU8ZO#&FED16C7-!KO'U?@+RWZ--)3F!5-
MROL)4EC*#L`MAWKN@B"+<RXQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,96;
MU:'"0L_#]_>V&TV.LBFJ91,;TC?.6;IP:#:+>Z^RL>;JH:.4S"ROS_54ADLJ
M>8XYL9S0B(',ET?+KUT>(_'Y6\/C?@73#3\[5;Q=3_S9;8)4R\J%<:X##N-$
M;O93R&F$$<J[@LC9YI<=DSO21$P)Y#?@CXXL1L423>PY#?!PKG16Z2]1(W=Q
MQKG5&555<P>!W(AN=>5;&UOW*F"U5;%DP6UG-[I!AAEJ1MUIJLJ)L/CFLL5L
MCA\-M^]9A`E"BU6>JY)(8%*22'MXEJ)(K0%M>HW&GD%;SDY=.WDL[SR3N5G<
MV^HCSFX[7E7*I]?5L634]!TO,PZ`PYEABQ8J:HF9QSUQCK1,A<FUG;G;PESL
M%1(%@E<_DREP[&$B?-QYB7/?L0]OFT)!9WL3'&_;H]+-F&E$][0(._)]J3`=
M][Z,'?B^Y)+-'V_O.S>HU<7,)',+U4:JJYU7LE9[6L[RC@FU"AOT"IZU0>".
M97LL#P5:/P+PPLGNA]T@5HE'=:\([@$N>74?H=O;U=;^>L>74?H=O;U=;^>L
M>74?H=O;U=;^>L>74?H=O;U=;^>L>74?H=O;U=;^>L^!TY"(&IL<71WJ>[4#
M2VH%C@YK5E>=PD1MR),:J7*E(MO(NQ.G2E'''?O1;V6`6M`'O>@[ZJM\<HH5
MR7YV<;^*`K1DZ'CP?>\!G`J'>=NLB.EL"AZQ?(Z_K1K;C]B)1RB?RW2<U"P/
M!^W-/73B;'$CX6U-*1G6]K<%ZC[G7_F=O;MWKNM]E="[.T7[[?9VO7;V=N]]
MGY,]O+J/T.WMZNM_/6/+J/T.WMZNM_/6/+J/T.WMZNM_/6/+J/T.WMZNM_/6
M/+J/T.WMZNM_/6/+J/T.WMZNM_/6/+J/T.WMZNM_/6/+J/T.WMZNM_/6/+J/
MT.WMZNM_/6/+J/T.WMZNM_/6/+J/T.WMZNM_/6/+J/T.WMZNM_/6/+J/T.WM
MZNM_/6<*[6DROJED6/%$74YJ(XZZ?&(Q;6FC]-;P%$K;RW1(`QZV66N)1KEA
M"=5W&SDX5!HB!%F"[O6M5RU94-P/Z>>;I3DA7MJ(7%O<T5I5M"]QJ9!/0=[+
M"%8I`[G(G+1J4O279ZQ&-<45H(2%@`:$6.;["YC5[4K.A>[+AEQ0YE7N)3,D
M=7NNEFDA[F:0:H*2#.2."G11QQ*<XPL1P22S1%B`6+9FM`SJZ];7I]<EN>7(
M^K[YX;\87=[BB^F$[1/9467!(,MELN+EKRXL[TX&J7Q,9+AZB*UK1(Y&-0X&
MA1IRFH:D`$11!<@].SDARYZ,E"IJAYY<&[99.,.IE*9>#D?5FD%D**T<YJYE
M*%Z2U8JP.3B`J,C<0`&@DB%P;#D"8X"+;4_+1ZV#L:4WSHI[D/!6JS:+:K#M
MB`/8-[;I3"8HF>$&S`:#LU&X$%O@'%C=".Z#X0SOJ)L=D^MA$<B``01"E7RZ
MC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M
M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK
M?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUC
MRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]
M#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>
MKK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?S
MUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZ
MC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M
M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK
M?SUCRZC]#M[>KK?SUF>PB=[FOLEVPZ=Q/V-\$_AK'-L'A_A7A'^]O:M6>%>#
M>#_^5?WOO/?D_P#NN^_O<]RJ?K#R>L8;Q0:)+.I!>,9F[5<U?F\=G7CE0,2Y
M07`3R!/12E+$`12C+!BDP@,^[[&SIH%V;):W(4Q3/I:L8'^/S,B-.B?4_H</
M*ZPG[EQ;=D3/J%6KR#EPJ+9K'M+GGQO9^)P'.(1M+:IM=1"B*3CBM='XW"(N
MK=YLZ256TJ=%.,JE0SS"0';.&;;TJXN5NZV@[6C(W2RI>I<9G$;'0P696E.9
M55$4G\&94K'&97":T>WE9%X@L;"T9#R0VL:-+'"YD`,^*9"YN$$@#Q<6X<T)
M#KAW=K)$CRY<E?+%ET<0*WET7P^$3FXA$"M^>P2'JU!K'$9G:'>!>.K^S)DZ
MIT$YR8TG2,^:S4V1;1;UK>NS>M;UOV];\^M_Y,A&JPAW..1';K6__.VT;\^M
M;\_D9JCSY-G<`^]#^CKY,=P#[T/Z.ODQW`/O0_HZ^3'<`^]#^CKY,=P#[T/Z
M.ODS6&^[!BCP&0\9&M?X3;]O4]:7BDQ%I%6T1)(HB]MR59('@D@U)'D2Y:88
MG1*5W8%2-,IT6'>P`T;T/.D'TW.:5G<MJ'Y,M<09Y/57&[ETQQ*X+$76C'5F
M]OM.*D">="C&W!>:[V`WM&QI$2)X9`*43B9H"9":("<WO']&`(`Z"'6P![=!
MUK?FU[>M9Y[@'WH?T=?)CN`?>A_1U\F.X!]Z']'7R8[@'WH?T=?)CN`?>A_1
MU\F.X!]Z']'7R8[@'WH?T=?)CN`?>A_1U\F.X!]Z']'7R8[@'WH?T=?)CN`?
M>A_1U\F.X!]Z']'7R8[@'WH?T=?)CN`?>A_1U\F.X!]Z']'7R9P4FBL;F;$Y
MQB5L35(H\\IA(W1F>$*=>W+TXMZWWM2E4`&49W(M:,*'W.C"30@.)&6:``PZ
M%)Z<,XF.9K7QJ>YG+7B;.BYY8^-TD>B'*`D,B9-L,B>$3TJ3E.4`2M"L]N4$
M25S=E:=X7;20H],XN3\B<FN4Z"Y#5'98'>J55@.,CM!F4O"":1JRHR."R5T6
MJCCS7I(UPIV)+*W&F\1Y[4B8DACL<V-"0@EU/<!#V[.%?5]=')MB,]=>2_3#
MM-5P+Y+'Z,6/3%$$>E/&BY!EG>%A9+2J#2=:Q-Z14;K1?LE&68Q"BV,Y;XJJ
MW(WP\JJRX?[HXYB\1;&?^.7)S@_4&[UK'32TV`MB=X/J*+/*]R:$+XV2&/(4
ML*E@$+-(&-S;'A$B,D"]4E+6=X6:1J0&($O:+XAWF?R>XOT%R&6QA+#EESU1
M"K'5Q5(Z&/B6/J94RIG0]I3O!S>UG.1*(PX1)2PUN1&'@#H8TY0M[#FQG<`^
M]#^CKY,=P#[T/Z.ODQW`/O0_HZ^3'<`^]#^CKY,=P#[T/Z.ODQW`/O0_HZ^3
M'<`^]#^CKY,=P#[T/Z.ODQW`/O0_HZ^3'<`^]#^CKY,=P#[T/Z.ODQW`/O0_
MHZ^3'<`^]#^CKY,=P#[T/Z.ODQW`/O0_HZ^3'<`^]#^CKY,=P#[T/Z.ODQW`
M/O0_HZ^3'<`^]#^CKY,=P#[T/Z.ODQW`/O0_HZ^3'<`^]#^CKY,=P#[T/Z.O
MDQW`/O0_HZ^3'<`^]#^CKY,=P#[T/Z.ODQW`/O0_HZ^3'<`^]#^CKY,=P#[T
M/Z.ODQW`/O0_HZ^3'<`^]#^CKY,=P#[T/Z.ODQW`/O0_HZ^3'<`^]#^CKY,=
MP#[T/Z.ODQW`/O0_HZ^3'<`^]#^CKY,=P#[T/Z.ODSSK6M>UK6OXM:U_V9YR
MJWK`0N/V/Q2:X&XM'*R5RV37+76JF@?#.R(S3UY3JTXT5(YK'&-HM*9*$<9@
M4?;4,:>IA*9(Y+DIJ!HBQFV;2U_&U-BW6[HE0-]JM'?\.M&"]0.J;O<4]4RR
M35QSRY2Q+ERK1P52=9C/")-4%HQ`9*0B.O3JV3%#+8ZY-3.Z(']G1J-I5*!4
MD<%%\>,9"55?PXY$?RMM']#-3Y-N,8S!9S/6ROR&AR?T;B7&USH6V/,G3E$F
MM$/`I+'I$[R@7?P*6^/GK=%-RM\`G4-[(:J(7/IK<SA5.26FR\;#<^+?&KJ/
M=1&;KR'6:'QJ9QBA)"EVH*0FQDXI/$:HW$-+"BW,#>[S1Y8$^S_!"BW8J/!>
M6E2N9W`AX6[:=)CC;OBGT]N,53N";1,N%7+=/K%.'H?AJNQK0$.?S`QQ,,"`
M9RQ&Y/\`[#B,%K8M$M9)?=#T7H8K&<8QC&,8QC&,8QC/7N0]UW?<A[ON>Y[K
MLUW7<ZWVZ#V^WV:WY]:]K6^W>O/O-=+QXK4[?^T"^:,2INEK0:F.9+!B"X<9
MGC.)*:`PH".1(BQ'FD@T$022%Y2TI&(P2A`%(K"!0')+LMQ!05>:G+I$YU-F
M5K<&AK=R88V@D#VUMBG1A2F2N92E6D$-K;0D:&YK!';,T:H)V/LT:,P%'=Y=
M([IL]3BXK-YC++_N@#]*4,466`WP6<P:-L$5)BD+:HXB/<668UH[/L:[MACA
M*AQ-<UYB+:I.N5)Q@(T(L&$4%R$LGHTSB$\8N6$O>;/Z;5DC0).&O-!>V&F#
MIQ(YD:6,5(7N)L0%%MC,0@&$46DVT1"-$W@VYH@!B7LNT5OV64#@A=4*-R;%
MB5P;G!*G6H5R)02K1K4:LH"A*K2*DXS"%*52086>F4D&&$GDF`.),&6,(M_7
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&5\7+5L)YT3&_.*_(")TE:_$:/PVM
M&F;UK)(_*1VDIM^1$+IXB=T\M;IHUHH?&X_%#H4ZQ%\C[(7-394LD`44B9T[
M"';CP'`_B-Q1X#2NY.+_`!8H^#4]&3FNN+G&KCS]-);,Y>V2_<RAA(['D]@O
M$FE+DX,$C@4H)B^C)">PE1QV+3L[<WKTK^8MLFQC(2JK^''(C^5MH_H9J?)M
MQC&:"<S)S)5<TXZ4!!5:14]VW8Z=7-8VO1`<&=VJF-=PKE*:5D`.(6BC*X.C
M=+D"<XDI^2-S@U+AGMXU2!;6KU7(418EB=.[IE1QZ<GF+\D^6J*W9I&59H5J
MB&\;^.K43-)-$4YV]%+#H>>]C.W'B')0>:TDMX(ZB/"S-;>E3]B$H`0%@``.
M@`"'6@`"'00@!K7[P`0A[`A"`/8`.M=FM!#K6M:UK/TQC&,8QC&,8QC&,8SQ
MO6MZ[-Z[=;^U_P"/R>;^+-%YAPVCCU9<EL"&1Z$UNI"W-1B0AH2N"EGM-^3+
M4SX<DMN)D&M\>-@12]&E)41QH1^RK\[A!+G1YTK9V9NWB=M7/2=HNDVX<<T:
M@*BT3LMA3,24<Z4$O546@D<$2(Y:%BEQ:5J,:%K.^&ZTP/*@+2YMKJW(G(M;
M'9"%`CRK=ND?)7H1/H&";"L'E3TDG)T)3Q2>$%*I5=W!Y.YJRR43)+22]#/F
M-,H]C*2(EB?2-,CT9H346Q/>RXO+^PM4MO5C>U?QFU*>G,;L6O)@WEN<;EL5
M<R'1H<TH_,,(#R=]VG6)#-"3.+8M*3.;4M+.0N:-(L)-(!(^,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,JSYS=-EYY-S=HO/CWR_Y`<#^1K?%4-?R&U*(7HW"/
MV=7K2XNCNP1FX*O>E2*.3H4*<7V0JX'(#5S8]Q3QC?4P%:UM6`2)99X(<'VG
MAI%9V<^7I<G*6\[=?6B173R*OF3:D4^FRV/-1C9%(XVHTN_8B%UW"FU>XEPJ
M"L_?D;'I]=U)BU<H<S#\WR[K6M]GG[?XM]GG]K7==G<]OY.WV]ZU[>]=OC0M
M;WV=OG\^O:WV=NO;UK?9V;^W[6_M;^]WV>V0E57\..1'\K;1_0S4^3;C&,BH
M535TYVJ@O;;;X?/VV&J8&V/>G-6J1HV`QR4+E12)N"H&V%+QJ3528YP))"LV
MG-/1C,[V(8<IDXY@WRIZXW,J^3_]M(%P/I2"\/JY5[_>)4]GV"<?.K=4).X-
M&6<Y-.@.L<<A!UHTHA6D*4!+&$H.[\,8QC&,8QC&,8QC&,8QD=V=4U=7-%E<
M+LZ)M4OCBL6C1(7(HS1B90'6P@6-R]*8G<6I<`&Q%@7-JM*JT4,PK9NRC#`"
MP6ZI(FIJF%!K+4#[;$79&YJBKC7T9(1.:H$$&ETSNAQ[:\:6>SC2ULA>RW!K
M$0N.<$PMEJPZ2;6JR*$8UQ0DM92>2\JNA;<<:BY[NMU(+PZ=%L+U+;24\6[+
MT!0*/,RI64NIV8#'K21M7H5B>+#4[T@9IC'X^0<QJ]Y^*G61H:X9M]CYR5C4
MEX.\NVO92%[H?D+WN,I7QR[#`B/J^Q7`MNC$Z:5@BP#:N[&S.[F%05[$MSLG
MUI:;<&$81><(M;\W;_D^T+S_`/)W]H7M;UY];WK&C`;WV:&#>]^UK0M;WO\`
MR=N>V,8QC&,8QC&,8QC&,8QC&,8QC&,8QE376H:*\=N"4XW:%O\`'VIHF@DT
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M"174A:CE`S$L9XVBXZTFAKU$L[PGA.V9Q.;"$VIK+@OG90?G1<SLBQT0,#K*
M%R4DLPE@9#6@AT<1C-*+$2C-?G1F:0&%A,$>+:US2%]Z*,T$P1NRRC-3ZVLF
M8)IC?!Q-%6>N,6VBUJ%*9,Z5*$YJ.#4U9I0H5XE5FIB#%1A"8EP`-M.7H])%
MR4`U8%H521-+WE5G'O=[;^%Z9^MC'E5G'O=[;^%Z9^MC'E5G'O=[;^%Z9^MC
M(1Y'<A;"@M)6(_MU&6LQO&V`]E8'D\ZOG5,UR"2#`PLS@I21"P'^0:)1K5Y:
MC1Z%I5Z*4%I]'Z)),$<75/RBZD#[T:>-/%R%//%66S]XGYLY;7)9)K/B$,0E
MR=J1-<Q?G%"./!LYT<B%+O*Q$;2NC?&!E(DFAZ./6FGD)H=_N<3DBZ37CCR8
M-(I*<S*QG'E5,;+MJPV"1P(XN:RZX&TB5DF#0R^1Q%T:"8VTI4;&G2`/D*=3
MK1CGM>B/6F-I/8H\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/
MUL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?
MPO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX]
M[O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\
MJLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/
MUL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?
MPO3/UL8\JLX][O;?PO3/UL8W:DXW_P"SO;?PO3/UL9'3.G:H_/'JSV+A]-VB
MP)$U;97Z5MIM(HG5W;A+"7`PE>:GM8LM28>L3ICU*LPK:Q4),FTH/-`G)"#1
MSFM`W+D8!VCO)SIRM=^\<$A*0,<.VJCJN^(0M4MQ>GQ^8%T.E,@=VD8%NC]I
MO%1:S&;2D(Q+W$>Q&E`K<2\:>H#QDIUYLWIB\E>1VZ!2Q:8.R;CWSE;*UF4?
MB\?8V]Y]ECZZG2^;@L*'JF50B<7&/-ZV.-:!4K3(3%:QU1&"TJHGXL]7'J.P
MWDY4#E>O([E%8E6U]8<+>[NK5$U1J0R%^@`E)`7%B#'B6!I&[N<D3*R`LK8A
M<TBE_--`-B/.#W)FNX'1?7-X(<B5FF:N)H<EE.C`IQPRRI/4]/2_2D6MZ\'+
M9[0LJ*A6'=UK8.]MRM:+N^P'9VB#K=C"6X):N3D+$-`VDM1JB2U"98B?Z26(
MU)!H=#*.3+$MMFI5!)@!:&`TDTPL8=Z$$6];[<^CRJSCWN]M_"],_6QCRJSC
MWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QC
MRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],
M_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M
M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSC
MWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QC
MRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],
M_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M
M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QCRJSCWN]M_"],_6QF;0Z5
MODF]D/9FNY=`O`O!O!_&E9"U?LIW_O\`WWP'Q1EDH[WX'WHOPCV0\"[KPDGP
M;PCN3^\YOE0_6O8(R[<-43S(>1$?XP+8)>%23J'6DY\96_F%(R9FQ.#N4SQB
MN>.Z]$Y>46<RXE>N8TS>0@5A1QQ1)7%T+"P)G@TO6SH+2C<SB_(]_<.8)G*!
M_-=:J;W*.R'ISPGINV%4B-(WSPYM)DM;0EI;TE@LLXVN6.,6GVUSRA*,9'V.
MH5Q*IN=$1%G$RZ>7#VP;H5<@YI3#;([<7R>(3!PE;E*[#-"XR"`@:BH:M<8\
M&8`B;@5'"F1K*:FY8PGM28I&`O2$0!FA,EJ/\8Z(BMIN-TL%<,K=8SBKE;F)
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M8"*1N.)@)A(R=J%(U1*@\U4;O8!$E`T5EDV,8QC&,8QC&,8QC&,8QC&-ZUOV
M_P#_`)^77W-_ESCG=N2NS2YM2U&0XHG)O6MZM`J&,"=:E6IC4RA(H,"$P8"5
M1)HR#1A`,02S!"T$6]:#NI!MZ53'%Y)6]AU_,D\&G#)-&F224@EF9Y8S,"!J
M-5*&!'7KA*V-<_B<860:6Q-3U)5*A<XMRAR7IA1M2>!%D\\W.$=!<@J^?'!^
MX8<?.1]AF*&X*=)8#.R15_6(#%82W02&QVY"ADZ)>D0C-.;R@O[<`Q0'7_E9
M0]!"939572W*:K!U%.-;[U)^F#+W%*YN3<?`KF47/QF*]AR`J#T3DQ3/8BS"
M%)HRD[8B.?%):L9A:4>PZ%LX,]R]]ZUO#9S:&=7R>X`\U6IQ3J-QZ-7RG^Q0
MNV2H&XTHM6-K=69R3P%:K3B/3IA+7!<:$:@X'?BC#!;S-4_6?MNH$P#.:W3#
MYBT@UD%E^'6;3C6P<HJ;[G8=]KH3,J_4H=A:Q[T(P(B2W(T!.NZ[3=]FM[:4
M?UD.F?R"5$-4$Y>50V20TH(C8E9;HKJ*4I5&^WND)K19J.+"-6E;UL)A"(]7
MONM?O-CUO6]V1M+TT/S<E=V-S;WAJ7%!/1.;4L3.3<K(%KM"<F7HC3TAY0M>
M<)A1PP[UY];[,Y+6];UVZWK>ONZWK>O_`)9YQC&,8QC&,8QC&,8QC&,8QC&=
M?_J]<L7%"X).+"3AGU69^N/,KZ<0#E-T[$C7'Y+75GNY4Q3)&:"S=6_I1*9D
MCAZ62IYQ&'*.R",KJ^D[F1(T?L6I4*DGT]$%V=%BODVS3^#=4UKMEA*I92]S
M_JM/S:YVM+8:_DV6*,,-4,D=*+BT8K.*O#/*52T#1M0N?)9(W-4^N"I4W)TS
M??OC&0E57\..1'\K;1_0S4^3;C&__'_^_P#+]S\N::T%QU?(58_)6T+/)B;N
M^W/.E`6E*SEC7-Z2M&P)GL*VKB%K>C*TO<A*._/B09"P!ZA&2<<L5F&C%JLV
MG2Q<RNN5?UQGEB7U3TT*A:^-]<J"_P!ZWF\@;>)4/-IN18#=FDG.<;CYCQ%5
MO@_>S4FB&@9NP;$7H5_F,8QC&,8QC&,8QC&,8QC&,8QC/&M:U[6NS^+S>WD6
MV;2-27*D2H[1KR*S<M"`XM`:_-1"I<WEJ1`&I+;W(.BG%`!0,HH9P4BLD)@R
MBAC"(18-ZX*F>.E2<?B).DJ>-GQ=!+7%&YNK=I\?71`6I;TYR5+IM3.[BN`V
M$%E'FA&2CV6$[M!L_9G>B>]U]\ONG0Y<B9E(W]P@7#:X8B[F$*&^"WKQ[C_L
MVS;`B3E+2D5K1!O2SXX]:N)/6:5FOR,9?A>D^^PI,68+6.(=""I(M#VJ;4Y:
M')G@/<^D"M8]L?$7D7.WFLTSB2J5G)TR")60=(@.252F+2&&M/LF0C"J..;P
MJ5*;05(]2&&_NIQ1;L2TQ?J$5S:R5*L"6GK_`*B7$>5TW*%.A#,*`B46=2_C
M`G`8<:$E.):ZKDA"<X8SS>])R3M;WC!U).IE1VB2N672*LR1M!(@C<;&X7VA
M%[S9MHPBV$U>G@*D1,J3DBUW)I2=:[E*-%;[3.YWV:R0X)U]>FY(7,$;LRRY
MWQ?F8A%ECAW*2HY]4#H0:(/:,![HX-#C%BPEB[0".&_EDB%YRQB#Y\M&J^_*
M/NUO"ZTY<%86HVB)"?X97<\B\R)`6+?9H1OB^Z.!A.]"_>B"<`L01]H1!T+7
M9DL]T'S:[>S>_/K6_-O?^3?9O_Y9[8QC&,8QC&,8QC&,8QC&,JEZQWB"IX@;
M8Y97,DLN8RBT84P4>VQ+D^P\,7Y@N8Y!)ET>ER'D](I"PMU2#8XV@E_=.&B9
M,KE>E?D_10R6*98!F4:@=!6-L$):N2,4E51R>$\DRCZE>K4L*6\^(IU%'BRX
M`O2SU#4Y9UQ158#Q&(B2ULL!"DJUXC<>&0!Q'+&E9)4KXI5-G89QC(2JK^''
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M>46<4,)A1H"U91P`&%F!",L80Z$`80B!L(M:WF&6K5D/N6#O%>SE(O5QQ[$A
M,5EM;NY,2\![8N(<D)Z=S:E"9828G6)B3M!T8(DW0=E*"C21C+%J.P]/2KVF
M5M:Y]F$ZM&NT1"\M;3MUBC-N01Q&I1&ID>Q$S1@<5:,#6H,+<4>D@@'Z5ID_
M:J"3HXH^O?F)T,^*4I5,$NXQ\3:V@DQ$M<SY2\5?:MB\=940+N$.V0^(&PIX
M*A24XLT*\:WV08.P!G@9B<(]"4:#%%']/SJ@1/<H)IOJ!<K>/A\/TWD1V$\J
M#:XYB51(R%`%)06N/O[@-OEB!N9TR-,6:L&W*QB(5I=EFZ7A5!UQLHZ@75RX
MBV$XU1=<+X'<MG&,DMJAT/KBQ)EQPGKB0YH4[@B"4GL1K,@JET4(5"=6:E:R
M!)"S5/@Y9^]DFZ+G:/=>N'15H0N_*S@WS9XVM*XTPH$]35@5=U-B"F-\'7J4
MME5LJ,*6)$:D)A9IJ=D.,#H':,H(]][UN[2G5SZ;/($\A!6W,6E3GM0`G8(U
M,9-JLI1W\[N=!1ZCUDIXHY&K-#%HO:=,2>/N];T'NM:[K=A36[M;VA3.C,XH
M79M6%Z-2.+8K3N"!25OVC"%J,P]*<#?VA%FB#OV];SD-;UOVMZW_`!;UO_LS
MSC&,8QC&,8QC&,8QE9'5N)>5_#M^9`UY%K$KI^G<";[S3ROBY(>9Z2+4VG<U
M#S)ID@XVQ1T:Y'83FT.S5'$I2QF$J7UZD<UUG$I1"AOA"6`>CM,N/<A,Y+,?
M"CA(^\3^%<<>JP,JZ;2RB'6@7V_+,=&F6EVV]MS%)D*2:S.'0YO;*Z;V6=38
M);T-W>9)%DQ);/'FXA-=<-2G+/)3&'D@4*-&B()&:`!IX20A$=LDL0M#-T2$
M01&]["+O01@$9W.A!WOY"7EI4.:QE3N;>>\-R9(L7M92U,8XH4B\1X4*I8A`
M:)4E3K1)E`49YY)92K9!VB!F;*,[GDLA*JOX<<B/Y6VC^AFI\FW&0[8=)0JS
M)S4L^E&W8]UIE^=9%%&].N`0RGN[LD2HPK7E`-,<)<:UC2)UK282>D&F6%]T
M,9Q0A$[Z&/50ZS]^\HY)8_#B:U;53'3-8\LE:=Y2QUQG`7RU(S25HO3.RP^<
MKECN-(0R2$YK1N\AVPH$:K;@E2>`C(*3:T;_`$(6HI,2V-Y*-*0A2%(DA:5$
ME++)3(TP$Y02$B<HHLHHM.F)T`@DLLL``%%@"$(=:UK7WXQC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QCLUKM[-:UV^W^7^/,-EE=P&>)Q)9O"8G+DP@=[V3)8\
MT/8-`^UH/LDC4B!V>V'98@[#OSZWK?GSWA4`A5<1M'#X)&&:)Q=`8M-2,+$B
M*;VP@UR5GKUY@4I.M%[&K6*3E!XQZ$(9AF][WV:UK5.-Z]$BF+C6.J]?(X_*
MC71:L6FDW)4D(L-5WU<>,XW890VE164:[WLS>@;$M&8,(0!$:#>MF9&-E]!V
MBZNA\@F?"*?<M..-NM3,4='(_0/)R5PJ(OC[H28I5LYBGBN5-21,>`:M8%MT
M[(D@]@`@TH)";WW6L-8,_7RJN=QB!1GD&KLAO<5YZ1"AYD<?4KY&A:0HU"\L
ME]NBF"3WQ,G5EH_`CWM2M'WDQ2!0(H0Q:UK8J:=3OJ@<1PLNN9O38A$Q9Y`X
M&-C1-N*'(J.NNG,]$4$Y>)#74[`IDPAE)AEJ.X5.#<G*[X42:J+&<7K)`@?]
MT4]/)Y6EM-O*+TXON^A@(5$WS2TH;&E,I&'>]!,DT(\=F0HD8PF%E*%9Z,!F
M@;,[`@WK>6>4QS<X@<B4Z(^D.3%'V<:O!HQ.V1*RXHXOW<[WH/8?'-N94@2C
M[=ZULM4UDF:WL/:#7=:S:'0P[UV]O9K[6]ZV'6^WVNS8M:UOM^UV;WV_:SV]
MOVL8QC&,8QC&,8S0'J,%W2;2\.)X]4.U\A;@.N>!%0N&O=]2GC>S,2X:.3!4
M6*[V7#'9IDI#5`$.U,A<X\RB6NLF0)U#4U-RIU-0[*U_XT+^IS1+?6L5Y13*
MI^9L\L*WXLRV%%Z`B#?`$'$>GY6WRE27-I)9%D6B@FULPV/J8XH:V9Q<*J,G
MTT6DFH>_KU05D@(YJ\&9K3]93I[OQ2$DIW>>%O42:G1=V#VH5MS%.N$2AH0G
M"$+8-IV\]]>32"P!#H!KDK&+8A'[WE;G&%^EJ5XZ8MG*#70OEK>G5!ZEL%Y4
M'&)/`Y+(*U8DW-8-@0R=DZT2HW#:H.J'C8W0=L6*#6F+IX?79#"`1(FTM1V:
MI"L?D+$N61QF2/[Z206)`SKWCQ?2+3A&E!,+/>/8UWTA"`D1IVC/8Y5W0RPD
M]P'OG?`:DUO*[M*F-[#15#$U:@^T&LUT(-MW:0#:MU4]:$EHTQ_D[4>R)(V\
ME$M$KV4BV`Y8:B\&%I)M4HEWQQO[T)PWUU_LRR)KQM*X(E5\JE4BA+#7C=&T
MA+X&5,]TA5."->UJB5K:C*:#:QVED);PN)):%,;5Z"F?4JT]O,/1=^TO2:H<
M)YM=*=BL:R)2U'OKY9"P=O.B2?6ZNA<388.^[/6MTPB4:61.3)"8V>2C5I%;
MN%]4F-Z)D1-)R)M+(+.=:#>#?2VIWJ02/E3SAEM&2973UR<H;%=..\:;.1<D
MK@:6.-4I=%DSE2MR!"7UQEK=+9LM5>Q!QZE"F:BD#HVHD0""R#L[>Q4MOHDL
MLHND8:$LH`"P!\MF]]@"PZ`'7:*LM[WV!#K7;O>][[.W>][\^?IXXW]Z$X;Z
MZ_V98\<;^]"<-]=?[,L>.-_>A.&^NO\`9ECQQO[T)PWUU_LRQXXW]Z$X;ZZ_
MV98\<;^]"<-]=?[,L>.-_>A.&^NO]F6/'&_O0G#?77^S+'CC?WH3AOKK_9EC
MQQO[T)PWUU_LRQXXW]Z$X;ZZ_P!F6/'&_O0G#?77^S+'CC?WH3AOKK_9ECQQ
MO[T)PWUU_LRQXXW]Z$X;ZZ_V98\<;^]"<-]=?[,L>.-_>A.&^NO]F6/'&_O0
MG#?77^S+'CC?WH3AOKK_`&98\<;^]"<-]=?[,L>.-_>A.&^NO]F6/'&_O0G#
M?77^S+'CC?WH3AOKK_9ECQQO[T)PWUU_LRQXXW]Z$X;ZZ_V98\<;^]"<-]=?
M[,L>.-_>A.&^NO\`9ECQQO[T)PWUU_LRQXXW]Z$X;ZZ_V98\<;^]"<-]=?[,
ML>.-_>A.&^NO]F6/'&_O0G#?77^S+'CC?WH3AOKK_9ECQQO[T)PWUU_LRQXX
MW]Z$X;ZZ_P!F6/'&_O0G#?77^S+'CC?WH3AOKK_9ECQQO[T)PWUU_LRQXXW]
MZ$X;ZZ_V98\<;^]"<-]=?[,L>.-_>A.&^NO]F6/'&_O0G#?77^S+'CC?WH3A
MOKK_`&98\<;^]"<-]=?[,L\>.-^Z]JDH;K^*Z^SV_P`FJR\^87.&>>V:VE,]
MB<7:DF[6G-&>F0RBT&YZ(2J#"^]#4)`KZJ.$D4#*WLH1R811HB][`(>P[[,B
MF&\>T$`/E)D6X>52C3S-N2M,D:%]U+I!'G%N1J#E1"/<<D5?.S$G(">H-&("
M5O)T/0M%CULH(0:JTY;]$&!\EI\.P(UQCX_5&M4-K<A4M$1?$<21%*T(E(CG
MQ`OKJ"Q(\MU<-GEC6&K$"HP9I!8M*NX"`H&&5[T;>:E,1PHJ@N<G)ZC92F<#
MQHFMIY&^5&EP->@D!;42BM[)@"A0`Q,()WA1Q3NI(&0(HM,B*V`6A86IY/\`
M7MXK+%B*PT5*<D6-H4*&XURLRCIE6BM>G;SC"=N#=/JD&5$5@5A9(3$ZU0V&
M]_`H`>-*`7=EAVC5=8+F[4<4227DIT>N1[.PE,:>0.EAT;.XW<4!*93T13A[
M.'^QC,%WCZ$*,W2DXA],*4H0?["LV6H"86#*:V_N@+B!82DAK>7R'T9(CA`+
M%'.24OFM,KBSQ]NMD>RSW32N)&"+%K8!F`DNRM;[-Z,V'?;JRFN^2DBMY!MU
MJ=DHBSFK0`&>R=>\H8U,D'>S-=H![51V"N)8`CUK>P]\V#>^S?F[=;UJ1]S.
M_-"T'=*0S0M^?0=W9K0MZ^[K7DR[<\^.-_>A.&^NO]F6/'&_O0G#?77^S+'C
MC?WH3AOKK_9ECQQO[T)PWUU_LRQXXW]Z$X;ZZ_V98\<;^]"<-]=?[,L>.-_>
MA.&^NO\`9ECQQO[T)PWUU_LRS.X4\S]V]DO'F$,T.\'\$]C/8F;>.'LAWSPC
MPOO_`/\`AB.>Q_@O<)^]_P#Z7X5W\S^\=X_V7.\HMZ[G(_C_`%%QZKN#VESE
MJ[@[.99;,1ED-LF25HMO*U(\R0SV6!))I3%41YBD4H#/&(UV;T47LE(0P(Z^
MD#BE>02IN<R$:5;R714H_BU#H5=%^\2N4*_FK`>1[A7SO,N3EA6+-+!Y!3ZV
M(61-29.SWB&3+$K7%76(L<JBR:'QIF@M<.S=&',M-*X^ZJ2&N4O5O+Y3]626
MQ8?;L@KV'O-I5\V/3+!;$<F!N632',TDT3J2-,8DAQ`G5C;)'I,D#($#:I3I
M7O2)#IT*5Z1)-$_"R4;4,<LE_N!AKF(M-FRA&H0OTV0,J1._N9"[;1[)[/6E
M@UO2AX#'HZ!]6D@*6OQ<<CI3RH7EL+0%%*N0E57\..1'\K;1_0S4^3;D8R&U
M:\9[%A]-O;N7N<V*T2%TC\;]CEBX*YG8$IASLI<#R4QR!O2#)+5%)_9,X@MQ
M&G5)DVCC"C"\J@ZV-Z2J+\>8-PLHE06FY']02:MO&2L$B(P"4<=@KV:A36Y-
M%6BP[`B8&.&K?8!4HT$K24$CVJ($'V.'L%H?'*BH1QDHFIZ`KE&%'"ZD@L?@
M[%KN>X.6$LJ$LE4[K.P9FA.+ZY;6O;D9H>^^KW%29YNZ[-35C&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC/'9K^+S]OFWO7G_`"]F]=O^7.'D$=8Y
M6QO$:D;6B>6%_;5;0\M3@2$]&XMJ\D:=6C5%"[.^$GDC$`8>W6^S?:$01:UO
M6C<BZ8W#.3N[8XNU3IEC<A7IERR(N3JX2&$OP$QFCM-K[%Y48_-RQI/,"#:I
M`2%(4H`#1!G:0,PL>CW(SH"<(YN2ADO&VJXSQIM!*]"<%<EKB26A!$3D@,2*
M@>!E(H1+T")A6)G`:1P1.;4T=V3L@P@1`R3>YU$5?=-OJRU,[*T%/]3"P(6S
MM#9X8QI;C=2^6,">%FC""2HV<SV6P-DZCR31(S3C79.\N)1.B`DD(3S5'?RT
MSYB=:/AR_(XU?].\/N4$?*;TCJ7.ZN4W33AKZB/4*R3TISVXQ.40=HD"3:7>
MU38I:$Q!0%*0\!YA1V]ZSN(]?>O6EK4.?)'AORWI%I1&!3+[`AT'3<BJ<1K]
M]QOV/46'5QFSD"[91A:C:)UCB%822:48H(*`<0,W>*G.KKTVKU.0(H'R_IY.
M[N>B=((_/WQ14TB6FGB[V6G0LMI(H>M<3A&]I(=-P%81G:$4`0AZV'+"F=\9
MI"WIG9A=6Y[:EA>C4CFT+4KHW*B]ZUO1B=<@-4)#@;UO6]"+.%K>MZWK?9O6
M<GH01><.];U]W6];_P"S/.,8QE"O-._JVX!<KYCR*Y&<#;IY(P>XX#7,6@?*
M&AJ69.0LCJ(B$(7EO?*#G3`ZN*.1UE%75_6J+)BS]'AF1N=/LX?6YX(3O47*
M/63WTSI&TWC+N0/+*O>&L\X4U!<R2L(_%HS;,!CU16I>K_`!3M2^W_+JDC1Z
MI+#T3BW3!A@40>WU4?-Y['XD!V?.\1YMAI`;;\8R$JJ_AQR(_E;:/Z&:GR;-
M]O9OL]OLWV?Q_:RC'G'?4VZ=Q_(#J)6C5S=;G@DIJVA:0@C=/RXV%'`9:YEI
MW63+'8R-243.X&+2MC.;0MABA2H.=@=_)1J$Z@VN3I2\Q2NJMU=K+Y.697Q\
M0/H3B<F:>.<`U)RI4RU<1()BV1NQ'\YT]@X^:]3.7B?E^BGDIJ;RFYC6'LQI
M*L:1O6`[=6,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,\""$
M6NP6NW6];UO6_P#<[UOV];U[0M?DWK>LX]"T-;64<0VMR)N)4J3EB@I`E3HB
ME"M1W/A"H\I,646<H/[D/?CC0C,-[D/?!"[-979>'2IXDWJX2%VD<7<FY=)5
M[BZNA"4YI?6`]R=E)JQQ4!C4R9I(T)"E2L\X\Q(V%-Z4)AH^\E$ZWV9IZ[]`
M/C3#T2U_XM7+RKXJ6<!LV8B>:3OZ40B(/$D*)[YI6_0I,C<6-L;79<`(G)#$
MD3.D0%'&#9V\@1))&8"AI#KCTBK3HJYY*D7*W;5!)1MEZM-46I&!*!@$!/IZ
MF#>UT];C4S:,V':YS+/?UB4C6SRV]<<'24_-'3J"]5;C4`LWE_TX:UE4/TK)
M;3;AXS\EXT5%C%>]&!`,,0LTCV>;Q.8B]B;DSRX-!0=`,+4+"S1%`%*3#UU^
M$Z%$A5WNGN7B\4K/*0&.UPUFN<(02ZG:-V0@\I%3KK)A6AJ^\FB1C6.J`1P0
M;T,HDWM+U8937,7BGR&)1&T=R,I2U#%X-&)D$(LJ)/KQO6Q!!K1K"E=-OB8?
M=C"#9:EN*,T/>@;#W?[W(A1=4'IW.,B21%#S3XVJ9.OD">*HV$JUXL)U4R14
MZ`9$[&4B\.T<)S.=C`-X$?<]^VK%HGN="S?#6];]KS^?>O\`+K?9O\V]=F>H
M@Z%[?;V_="(0=]GW.Z#O6^S[NNWLWV:^YGG6M!UV:_[=[WO?M=N][[=[WV:U
MY][WO/.,9"55?PXY$?RMM']#-3YK+RUY-V/1,PBL&A"FNWA_M=8R>*X)9I<D
M*KAL:W$A'+Y'-`(E:<M?#7%,9LY(^&+F4R.J$+Z8J`ZMZ<!S;75U]MJ;0XO<
M=^"S,M!->3W+CD%4\:K%"VEDLC:,^"N9+].K)D+:#;H<VU_'T2@&UY92S9J4
M#@0=IS/`V+N^["=-3HOTOTU;'F-L5_;=K6+*I[6;?7#\DFQ<*3QQ.00_-4F7
M.C*ECD::W,DQ2ZM8`)"7!T<`I6PS9!PE2O6UF[F,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,_(X@E06,E044>4:`0#"CBP&EF`%KL$
M`98]"`,`M>V$6MAW]O6\B9;Q_HMR7+W-PIRKEJ]U0'M;JJ5P&**3'1N4FDGG
MHW$)[284N(--3D#,`J+-[K90.W?9KLWH#=71FX*6LN/>H[3$`IY[6[*,<CJU
MK>O&EI=UA`QB2NCDR[C7<`=40332R'%E5LRO9(^X.--V62,KKFN726YU+[3K
MZ7Q+A^15[NP2&KAR2R6VSZU>4CU"XM9S2>\PY*@4RXN:,Z]9"$28:Z:@CYKD
MY(T:F"JC=1D8'M5WBP:WH.];^_,W_DV8+>O_`);U_P!F>^,9'[3:]9/L\D-6
MLM@PQVLF)(B7*3P-NDK.LE\?0*"V\TI6\1Y.L,=6\C93NSFC&J2EZ)*>&<P_
MO9;LW"52!O?9KM\_F^YK>]_FUV[W_DUFKK'8T&K64WJZ3V4LT20/5[1:-M"E
M\5A0EN;Z[U!4Z=N:T/?==TJ5J3=]@2R0C[V`(S3MED@&8&*;.NSIWU#>4TF5
MP7WQUA5Y-D&3Q&6LMA7#$D<H9XF-LV_%(-U^^R'PA`H>V1:2=HM$R%N4C:U*
M1,4%:2N`6IK9Z7D'=.;_`"FLOJQSR)*HM4S.PK.-/3E@+F@/;-1.@8LH6,TF
MM),UB,[A"Y3Y=IS:THM=\TG)6RQ`G&8W$-)V^P]C&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9X[-?<U^;6><8ST,[>Y\WF[!`WO?
M;V?O=##L?;O?F[.Y[KM_)VYU>N+Z27$+^EO#AIW(SEA&^J3U09/RF4"$E.DS
M;`S4_-`ZW76PQIQ&"#$I:IG'%PV+*W%/I`YI7:FC68PC9L6'NZCJ3*;!1\!N
M6JJK-N&K&(H>>F1$32<H(<PO86@?@XT!B8.Q>%@_?C(`;LI&:9K12X].A&H/
M+Z:?"6RN1CG>=40[B#7$;NB[&Z>RF7V:S\DI1;QE6'S)OKER6)C(K()=[(NR
M2!-2ANT&(OR-04I1NK)#VI8EVP/C8_*<>Y^=,'K$<JN6EF<@)]PT83Y7/RX0
MH=!T?8L%?*U+U'(4P1-$6Q.,XFS/*1J`(F%.-X*<FXGO#H-2%$(Y#M,8+ML]
M-JK.7E`\$>+5.3*N:NBTKKZI62/R&/2J?/PY`T.1*QS4C1.NXC%I+'0K"2%2
M?2@#4_.J4LW8P`6#[G80;O>'<E_P8HWX]V#]76/#N2_X,4;\>[!^KK.&D<IY
M'1J/ODB61.DCDC"SNCTJ)(GD]T><G:D"AP/*)V=7A96C3"DPP%[,&$&AB#L>
M]![=XCLIY'26/L<B1Q.DB4C\SM;TE)/GD]V>2G=4"=P(*.V37AA6S2RE(`&;
M+&(&QA%L&]A[-YS/AW)?\&*-^/=@_5UCP[DO^#%&_'NP?JZQX=R7_!BC?CW8
M/U=8\.Y+_@Q1OQ[L'ZNLQ!^L'D+'I'!XRKA]+G+9XZ/32UGDSV=:3I#V.,ND
MI4F+-&U\`X99J)I/3E:3`,'I084(8=$Z,&'+_#N2_P"#%&_'NP?JZQX=R7_!
MBC?CW8/U=8\.Y+_@Q1OQ[L'ZNL>'<E_P8HWX]V#]76/#N2_X,4;\>[!^KK,0
M8;!Y"R&1SB,I(?2Y*V!NC*TNAY\]G6TZL]\C+7*4QB/15?#.`64B=B$YNE("
MQ[4%FB`'9.RQBR_P[DO^#%&_'NP?JZQX=R7_``8HWX]V#]76/#N2_P"#%&_'
MNP?JZQX=R7_!BC?CW8/U=9\3D^<D6MN7N1\5I`9+>B5KC0%SN?Z,&6C3F*1@
M!L==A!H8@E;"'8A:#H6]=N^S.+B,RY%3**1B7MT1I1,@E4>9)(A3JIY/!*4Z
M-];$KHF(4"3UZ80(\HA6`LX1)@RMF!%LL0@=F]Y#X=R7_!BC?CW8/U=8\.Y+
M_@Q1OQ[L'ZNL>'<E_P`&*-^/=@_5UCP[DO\`@Q1OQ[L'ZNLQ&4V!R%B2R&HU
M\/I=09-I>EAK<)-/9T$*5P5LK\^`4J]'U\6(24*:/JBA!3Z,/[\<3O0.]Z-$
M'+M+N2V]:WXL4;Y__P"^[!^KK'AW)?\`!BC?CW8/U=8\.Y+_`(,4;\>[!^KK
M'AW)?\&*-^/=@_5UCP[DO^#%&_'NP?JZS$&RP>0KK,I9""(?2Y;E$&N)NS@J
M-GLZVD4$2_V?\`+3!!7PE`3$WBZK\)V>6``N_$=Y$/>C=`R_P[DO^#%&_'NP
M?JZQX=R7_!BC?CW8/U=8\.Y+_@Q1OQ[L'ZNL>'<E_P`&*-^/=@_5UCP[DM^#
M%&^WK7\.[!^WOL]'6LQ&`V!R&L.&QN;M,/I=&VR=J3NZ-*MGLZ&K((4]UL!9
MXDM?')Q&!T']]LHP0-]O[W>]>?,N\.Y+_@Q1OQ[L'ZNL>'<E_P`&*-^/=@_5
MUCP[DO\`@Q1OQ[L'ZNL>'<E_P8HWX]V#]768=,+#Y"PS<6TXP^EU/C9,6*%(
M?!9Y.0^#N#_X7X*J4>$5^5W24GP,SOP">[/%W0>]@WV;S,-+^2V]:WJ,4;Y]
M:W_#NP?M_P#^.L\^'<E_P8HWX]V#]76/#N2_X,4;\>[!^KK'AW)?\&*-^/=@
M_5UCP[DO^#%&_'NP?JZS$T<]Y#K9O(((7#Z6"YQV,Q:4*U8Y[.MHSD4L<94V
M(4Y`0U]M3I0G.B*\:D1I02A%J$VB1C&$_0,L\.Y+_@Q1OQ[L'ZNL>'<E_P`&
M*-^/=@_5UCP[DO\`@Q1OQ[L'ZNL>'<E_P8HWX]V#]76-KN2VNSMC%&^?>M?P
M[L'?M[UKM\]=:^[]W7\>8;`+#Y"V)$FF8-,.I=&@>-+MD)EL]G0E)7@#HN:C
M=&"2U\<1ONST!I@.X'OL+&#0M:'H6M9EX=R7_!BC?CW8/U=8\.Y+_@Q1OQ[L
M'ZNL>'<E_P`&*-^/=@_5UCP[DO\`@Q1OQ[L'ZNLQ.9SWD1"&A(\N,/I94G62
M6'Q<LI)/9T$T*V:2IGB3<>+:BOB@;3I5[TF4*@A%LX28HT)`!G;+`++/#N2W
MX,4;\>[!^KK'AW)?\&*-^/=@_5UCP[DO^#%&_'NP?JZQX=R7_!BC?CW8/U=8
M\.Y+_@Q1OQ[L'ZNL_2%S^?G6*OKFPH_#6Y?J%IYJV.$-D;T\IC$GC`;'U2)>
MG?8ZPJ"3PG]Y4)SDW?R1E[-+-T6,)>QSEC&,QQ+#XHADKI,T49CZ27/:!"U/
M,H3,K8GD3LV-8AB;6YS?"4H'5P0-PC#!($2Q6>F1B&/:8HK8MYD>_P`O_C\W
MGR.(-9M4SYVFC574Z@\O>X:][:9^@B4B9'MQCK^6)2U^!2A.TJU"A`Y`-9%S
M5H+D$)P5+(X->A:4,ZQ,DD;80[\^PZWO[N]:WGG6M:\VM=FON:QC(_M*S:NI
MZ"/]A7-/8-6=;,*<K<FFED25BB,,:$R]04W$:>7Z2K$#,D*7*U1"`@M6I#I6
MI4E)"@&FG`+%S$)EL,GD0C4RKJ21F8023,K<]1"4PQW:G^)R".KTQ9[2[1Q[
M8U"MG=&9:C$4<WKFQ2>B/3"`-.8(OLWF48QC,,G$QK^OVM%*[&D\2AK,G?6!
MA02*9.[.P-I,DFSRAAD89TCL\GI4Y;W*G]];8NQH"#PKGMV=T;*A*4JEQ2<W
M,^W6_:WV^WK_`"ZWV;U_DWYM_EQC&,CKRD5:CL?57!F<,)M5X9]RLR"DO+1X
M[K&!(7X&"1K&`@[;UIH"!+M&E=UZ8",[P4:5(H-VF&67(N,8S%YK,8=`(L]S
M&P)+'HA#6%$-9())*W5O9(\U(1#`G$>Z.;H<G0)2##3RDP=J#0Z../*3EZ,-
M.++'Z0>60N;Q1FDU>/\`'I/#5Z<PIC>8JO0.3"H(;5)S4H3(53888C#[&K42
MEK5)"]@,;EJ-0WJ"2%*8T@O*\8QF!M<]K27^-1K+,H1)O)?)%K%-3&R0,#SJ
MOY<TLZ9U<6>3F)5:D,5D+:P/*-Q7('02!S0M+HG5*2B4BT`S/:O+.KFVHZ"6
MU=.HE847&K4-X)!"Y`UR5GVN2!*&H2>R#0J5I=*22U"<X9(C-&>#J4RC0=IU
M)!IF=8QG!2B4QJ$QUZE\RD+'$XI&VU6\R&325V;V&/L30@*$>N=7EZ=5"1M:
MVY$0`9RM<N5$)DY01&&F@!K>\B6R.1W&JE(W&[(MJ\:5JJ(V*J8FB)3JP;&A
M$)CTU5NB,3C'&]ADLA=VQOD!JYO5&+VE.B6J^^(E`U:;6DYHC13H68`T`#"Q
MA,+,"$8!@%H0!@'K0@B"(.]A$$0=Z$$6M[T+6];UO>MZWGOC&8F[3V#,,HBD
M(?)E%6:9SOV9\2(DZ2%H;Y-,/%QN,=Y!XKL*M84ZO^F)I)-<W@34D5A;$!8E
M:T1!&N[W^#G,:_A3K!H6\2>(Q5[GSFX1NN(LX.[.R.<Q>&2/.DL=6.&LIYZ9
M2_.#3%F1YD:]N94RD]"Q-3BZJ"BD*,\X&9XQC,*99G7DX=)0QQZ4PZ6O5;R-
M.R3)I9WMD?G*"RS3:F>4C3)$2)2K4QF0^Q#BC=2$#F6A<PMR],M`2%,J*,,^
M>.VG6TME<M@L6G43D<Q@)B,B<1EB?FQV>H>I7AV-&BDZ!`I4'L2]05K1Q3>Y
MA2KMD#+/$F"4:6,>>XQG$OS\QQ9E=9))GEJCT>8F]6[/;Z^.*-H9F=J0$C4K
MG)U='$],@;F]&G+,/5K5B@E,G)`,TXT``[%J.9+=5(0B',=MRFSJVCD$FJ>/
M%1FPW651U#')<E>V]4_1<MADAJP*.0D.;08O?64#:J6EJ&KP]W2!VA`K5!D]
ML<VYZ;D#PSKT3JTNJ)*Y-CFVJB%S>XMZX@M4B7H%J4PU,L1+$QI2A*J3FF$*
M"#2SB3!EC"+?VXQD/6!R%H6J)C7U>6A=-45U/;9<]LM6PJ<V%$HG*['>-*"$
MGL5!H^_.Z!UE3CM6J2)`(V1(M4&+%29(6`2D\DH?,BLRJ&*>-%-[G$%:;(=6
MDU]9*U]GV)#+5[-KV24F.;=%=*BG,Y&,+6]*@G$(MA/*:GE65WPIL<C4TD8Q
MC(4BW(#CS9TXL*J(9<M/SZQJ?4I3;3KJ-V!#)/,JT5IUP_`S)U%&YV7/,1.(
M<D!H"#7Q"A$F<4)I6AE+4HP%_=3W("BN0K,]2*A;FJNZF"./ZJ*R%[JBP(I8
M34Q29$22I5QYX<(F[.R5M>DZ92F5&MBPTE7I*I3J=%;3GE&#EW&,QJ8S*(UY
M%GZ<3Z41Z%0R*M:M\D\MECRW1V-1UF0%;.7.SV^.ZE&V-3:C)#LU2M7*B$Y(
M-=T88'79F.5Q9M27%#6:X*EGM?6=`9$W*AL-F5_)8[,(H]-2!<H(7>Q<OCZQ
MP:UR)"Y(U9"T"=P,*1KTBDE2$I4G.`#((3-X;9,2CL^KR5QR=0:7M*-^BLQB
M#TW22+R5C<2@GH'AA?FA2K:W=K6DB"<D7H%1Z524()A)HP;UO>48QC(QNM/.
M5=/6JDK$\U-9"JMYVGK]20<2G.(FY\4=RHD<4>H_V`DTJ0C;1E&G:V468$(S
M-=P$64'=.D"91<72-;:H0K4A$!Z+LT8>4HBP%!&TR99,^*S/`HI9>@#.\%LQ
M-=4/Y+J-H',)#^4^-MKCV8,89*5G8_QC&:O<LK/X\TE7K+<'(I?`D+3`9DVN
M-:AL"3P^+)'&WG%K>F.'LT8<)^^1^($S5V3.;RA9'!Y<D:5@2GNLA4N+0W-C
M@ZI(.Z7,'J:NN)K3&*?M*K;78C[3O*=2%THV3-4LI>(S^X+9E5R3>K:J=F)2
MK9S()5CW/S8,PE(1D[`G9MFN#>T.IZYG06)8QC.M3UP91>*AN"J?.+-Z3&H:
M=Y"=/-VH^<0N8\>P5H_V8^\Q:'73*32%FE=VQ*QRI[M",''VID2VOQ15@<YI
M-)>^RIO9)(F?8GV3$1IAZ4@\U,>B-.+"<8C4B3#4I##=:,&E4"1*%:01Z88A
M$'"2JE*81I8]IU!Y.P&C^K&,_(\0PE#$6#O@]!WL!?=!!WP>M;V`K8Q:$$&C
M!=A>Q;UO0="V+?M=NNM!TH;>OR)/'#E')'6&VY+>?2?F=;G._1\*7Q^]:'Y'
MU-*1#,,G3Z0_NIBJ$UXO5-G$!+#)8P,)4/#&ZO20$UL:-+XZ;V9,8QE:?59,
M:CN,#`QG21]KZ7R7DIQ7:*BMM`<@(C-,W83>L-?*FM.S=O.AL3A6$5FC*V#E
M\5>2P$6"0K25VWN+`^RQIDC-P_2?7O*FC[I;9Y%TC+=D=Y@<DFCD)*(T^F2&
MK[8NL^6HWZ76O2ZPTA*8V57*D;TQD,,+5I=O=:N32]UO*W23R^*/\M?K1,8S
MU,[>X'V=O;W(NSL]OM[-]G9^7M]K\N=6>X&AY<N(/]T71*ITR@Q:1S^;%TRC
MD`\"*>QU`=QTX"N%_IR&QOV`?<OE4MMM)W,K90#7;87U-W9BS:K8;0N(RXN0
M=1OJ4R>OQA648I@/`IC;WQB/(6P!_O!IK6V%\_5Q5<W&J696XMU*/O&QHD![
M<:6$#<EB:,TH6DJ<>[6,8S1[J:(VU=TY>>A#LE0+$0>&W)I2(ER(3*$@5"2E
MIJJ0GB+5@&1HU*N*3*$IH@]T2J*)-*$$T`!:TALNRN+L8X!<86VTY)QL36E?
MG"6.T93:CD+8%?1>%G12PZ=@B6R'YQ5SE];T*BLH^09'I%9@8T!2]RE*V1R(
MMY;F]NL;0;LQX?1BO8-Q3XWP*IK$#;E8U]1U75]`K3"Z$O@;&B<$AC/$62<!
M>TRA6B>0RA"RE/('5O5JFQP`L"J;52I`:G4&['8QE0_-/V%1]3KHW+U7L4D=
MUT^YO,R1:ITC(<5:8?#^5G@:DZDWN5BA.)>,!VD!`QEB5""9WG9VPBS1[D9+
M+S7=5OIP3:U>*=YMRU!SKY`533DK.E?&]PK@BA2^'?(U@T\09*U7NKFY+M.-
M&F<AK<6S&"1)\%#X?'ZXCZ>226",$?DG98#[6OXM9YQG@7M;_BWG736S.PJO
M;/[I?D_%Y&0;>,"FK=-:R9H>C0+'I%87[F)QZ<&M];HZWEC&Y2`J4(G9Y0(1
M(CU4ADK4H1=X<%XE"<>QW3,E+U6T^,X=0!]K>Z^+L)X:\9.05;W]7;`H8W0R
M;7.YSEOFK);#B5)Y<VSF<6Z;%]\BDLU6N".<N_CM(EDTW(1+F>1K+G\8S6'F
MRC;E_#OE4E=TJ%:VCXY7>8L3N1"=2A&4GK*4*`C4DJP#3"+(.**/T(X.P%F%
M%F]NA`"+5';PIF+]P]Z&!''>QHW5_*<'&!BF%`VM9*Y"JX[J1QK@Y&6FR:JM
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M^7M[.SL\_;V=GGRAIN<>G)<?,F(N<;N7BFP5_P`7N.O*[CP3"(M;E6:DELH+
M4]@Y)R-,G#.Q2A9)"*.I5EK&3+9'(YH6A"[VE)YQ+5B]$C8B'^<S3P/D/%NW
M>6_*/DO15N46\.ML530E;LU2TI.Z_DJ]%37'U;/D,)N:U62O7QV21R3V*YV8
MY1Z"M+V2A=&6I(7"V=24D?2Y-&(G;[C&0)R7E5"P&HGVP>2KK"V6IH$XQJ8N
MKE8+FU-D632!@D+<N@XE&WY<@9%SOXY@8O%1N<C#`*I;ICVD*]DBD1I-(5<@
M";4%M$<;((;ROKOEOS"N+D-S,A/">Z.,[^WTB@E=>0;;!QJ'(9/=]<P=0NME
MGC$67\BGN!R=W7'KGVV1-S8-#9,/D^MN>B+-)(MZ273[,4U3.F\2?C/7S82`
M]=6.@+T3.B,:6Y^;RT=@FA(99*WHDTA84JHM"Z)&1T;TSRT,KN4N:$5O^,8Q
M[?MYCC)#XI&UT@=(]&F!B<I8YZ>I0X,[*V-:V1O&B`)=.S^K0)4ZAY<])BRT
M^G!S,5+.\``3W[O8=!UD>,8S'Y%$XO+DA2"51UADJ$@_PHA&_LS:])25/>C"
M/""D[FE5DEG]X.-)[Z``3.]&F%]UW`Q!W]+''V*,-Q+/'&9J86E.,XPAL96U
M$U-Y`U!HCSQDH6\A,E*$><,9QPBR@[--&,P>Q#$(6^7QC&?&N;T+F1X*XHDB
M]-W]*I\'6IB%1'A")24L1G]Y4%F%]^2JR"5*8WN>^$*"BCR1`-+`,/V8QC'M
M^WF+M$(AL??)#)V*)QIFD<M-3'RI_:F%I;7N2GHB]DHSI`[(D9#@]&I"M[*2
MF.:A6-.7O8"1`#O>LRC&,9Q#_'V*5LSE').S-,BC[RD-0.[&^MJ)W9W1"?KN
M3T3DUN)"E"O2'!_>FIE:<X@P/F&6+6&%@8XLT((_&F9JCS$U)PI6QE8VY&T-
M+<E!L0@ID#:WD)D2).$0A""2F(**T(0A:!VBWO?+XQC.";(O&V56Z+F=@9&I
M:]FZ/>%C:TMZ!4ZG:&<9HUR4HTQ)Z\W0SSQZ,5F'&:&<:+0NZ,'L7YQ>)1:$
MM!3!#8VPQ1B)4+%9+-&F9M86DE4XJC5S@I*;6E*C1%'KEIYZQ8<`@)BI4<:H
M/$8<8,8LAQGKW8.W8>Z#W6M=N]=UKMUK[N]=O;K7Y<^)Q;6Q[0*6UU0H75L6
M%]Y5H5Z5,O0JBNZ"/O2A*J+.3'@[H(1=P:6,/=!#OL[=:WK$G&K:U=TK:A=:
M^@[DB9DQB)H2.$1CJU,UHS3>_F)6Y.I;#24*8P[6C1D)`$E#-_V00-C_`'V9
MDB1(VU&D;F]*F0H$*8E&B1(R"DJ1(D3%A)3IDJ8@!9"=.04`!1)!)8"BBPA+
M+`$`=!U]6,9P;C&(X[N#8[.K"RN3HRF]^:'%P:6]:O:SM&!-T:W+528U2@,T
M8`!FC$AI(^["$?;W0=;UR"AO0JCT2I2B2*%+:>8J;U!Z8@X]"I.3'(S5",XP
ML1B4\U(H/2F&IQ%F#3G&D#%LHT8!?9C&,X)OC$;:7%S=VM@96UU>AZ,=W)O:
M6]$X.AFC!G:&XKDJ8E4N'HTTPW0U1QPM&&#'K>AB%O?R12$PZ"(5;9"8I&H@
MVKW)6\KF^+L+3'D*QW7[!M<ZJD;.C1)E#DM$67M6O.*&K4[`#9QP^X#V91C&
M?&X-Z!U1*6YS1)'%O6DC3JT*Y,0L1JB#-=@R5"526:0>4/7F$6:6,`O^4'>8
MB]UA6\DC*2%R&`0E^B"!60N115YB<?=(VD6I3C5"98F85[<H:4ZI.>><>0I)
M1@.)-.-,*,`,PP0LU)))3$E)TY19!!!8"222@!+****#H!9198-!`666`(0`
M``.@@"'00ZT'6M:_7&,PE^K6O)0X>RTD@D-D#IHLDK3D]Q5@=U_>DW=>#E^&
M.+<I4]P1W8N\@[[W)7="[WH/;OMY)1#HFJDS=-%49CZB7M#8K9&J4GLK8=(V
MQF7F`.7M+>^F)1.R)L6G%EFK&],L*1JC0!,/(,&'0LR3&,>W[>1\BJ:KFXU8
M<WUQ`D)S@@6-:\U'#8TE,6MK@7HI>WJS$[66)2A6E!"6K2'[,3*0!"`\HP.M
M:URT;@D*AQBPZ)Q&+QDUP"4%>9'H\SLABT)`S1D:5C:T202G1(SCAE:/V9HL
M1IH@=SLP>Q97C&<.^QYAD[>-JDC*T/[88:4<-N>VQ"[(1G$"[L@T2-P3J4PC
M"1_OBC!%;&6+]\#8=^?/PCT4C$20F-D6CK%&VTY08K-;V%G;69"8J-++)-4F
M)&Q*E3C4&%$E%&'B*V:,LLL`A[``&@\H@0(FM&F;FU&E0($1($Z1$B3DI$B4
M@O7<EDITR<LH@@H`=:T`HHL``Z\P0ZUGUXQC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,9UGI5RDNQAZVO.B@EDVY$2RDH7TX8K;<%JVNWI^<&B#VE)ES0WND]3HD3
MLVJFW7@AAX$@1+3VIL7JO"&]M3GB*,)P+I3=3VV">FYTN16@\R?DUS/ZBUO\
MC8/$WFVI\Y1^.:U3DIM9TD4CEDL;HK+38W&XO`X1'&%GC\8ARQ8]R-Z1'F$D
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M*1R"S6Z[+VI`CCQ.'%))&(<?U5R$:0YK9V2.K8DK2-2YK5(B%B5[T:I=3#^^
M>'*%I)QI(H:K;H_\4Z?HWC51E9N-M1!#PZLF8VGQBL)),65TLZGI'8::4(IX
MD9'^00]V9I!')<BFDG3/,?G,:E3>/V13*D@4BYACBIHP>8=#/@K(X#0=9QUL
MMBJXCQ\X^W+Q<8$-76<OCBJ:T;R`0J2;;A%CNC@V/KB^ES)V<'64NSXT*([(
M54A>'8U0Z&M3@>T[V#HOII<=>/-TT[?4`4V/N?4?PUB?`V%&OLO3NK0+CK"'
MXB2QJ.O34%A1EN3\W/"1$I\:M')G=2!&2G5&')QJ2S\RIG@=3%+\B)ORH;7*
M>S.[IS6B>FU<SGS^UN[BW5>DL1^LU'#R%33'8^O?DR&0O92)K=YTME\E98I'
MHM#&9[01EB3MH]U<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,X*3RF,PI@
M=)5,9"Q1.,,:42YZD<E=V]A86A$`0`#6.CPZJ4C<WI0"&`(U"M222$0PAV/6
MQ!UO4FUNH3P^JRL+%LL?(2E9F&O8/*IJ*'PJXZL=YC*?%=D6O/BY%FH4O)"X
MR)Y\#]CF9",XH*IP4$$[,!W?;E5/&G^Z3.'W(R\*]I8VLK@J+R@+W%N+L2U'
M6HF.OXP<ACSL_@/E+P189YC:B6;:=M2=2$DWM=%J!/LO>C^Z#=2P\L>+<I>6
MF.1GDC0<AD+\O2M;(PL=QUP[/3PYK3-%(VYK:V^2J5S@O5&BT4G1HR#E!YF]
M`*+&+>M9!%W<HI[5W-GC/Q\3)("555O45RENR>RM[0RA1+HNAXSJJ93+$#"6
MU/!30M+DWEF0GF*5S88>QD1M=LI*^'.B9.APB8=6_@S':8M:ZX_;FY^Q57QE
M;N6Y[3%(=/AN\QI&0+UC!&9G!`.<30)I4R.<O2:B+P[LQZYN@+T>`%B'Q8@!
MIH9R:^=O%QRGD1JX=GIVZP)E(XG!FYA=(O.VU.WV3.*[<[8B=62:1.,411J(
M6E(ZY:%\U8*WEKLQ3=ZC&D3TWL!R)V:3%L1W#U4.&U253<EJ>4HR;I*;KXRR
MES'#HU+%[A-(F.P!U(CDM;+C6`EFL.$[M+P>"O5BPEPD4$B;TK2ADS^V$JD8
MU6R5XRR\%5`2B<\3F"#RZWBHP=):[A5QII?#X[-5J9,8L(A[LK`)@D<&='_O
M>FY`ZO+8<2T.1I`7MH+2#4J4>D7'[J).]]5JV\D&UH:&+CG4/'U_F?,!<ZU_
M9A5G03D-$V8;A8?'Z"0M.N6N"N24NH:9,BN1,Z-;NJCCP5%XW'5$J<WR1GPB
M9*]ZF7$B;PNEI4X6"IABZZ85Q_F:".2.(SH"N$D<GG4N,TBCLQW214^/5V"S
MYGI9#ZW>IJZ1]@L9Z;U>H0Y/B((%8^8+ZE'"HYX3,">[42QW73RW*I;$B"$6
M>OV\VU1FE`K+J%B/1P<Y,^6XSE(UJAIJQH.6S^:)4#@J@T=DJ9`K-)P^5]6?
MIZ0J*0R;2+DO%D\;L&I'>]8DM01BQWY0YU-&Y3XER^:FM+!"G-X:FR"20"E!
M81#RWM[E7Q;8^.$U0,+8PO*U#-;[S;XP1QZBC&Z6HWA.G<MK&!PET0QV;/$5
METTN=G:I#5T7C4V9HPX0U\?)M'WMM?F1N;7]2H.9#Q.YH"&].J4$?=3W,SC-
M?LS<8!4-L,LVE"")*K`3)&]MDB-OE$`0S9WKA;/:_D+NR-L<LJ#HYTQN465R
M^OG:31U,\%IDQSD#V1;1JX/A7*&V^1_(;DQ5G'=-6T;K;B)-F"F[&LRR6&4S
M-18][.L&C-E2:O(*PQB7P($08:RBTQB2.4SU]<)6K=I7(E30RPE.W1DQZD&3
M13G+64<45[6/)"2Q*K>24A65=%9M6\;W,)K%(+8MU2&2QJHX>]6&AC`H]&E-
ML.D7<4U4%V`LASO86P$"96?1ZY(C'\L!ZG/!&S;$3U5#N1\*7395Y7RDR%Q0
MRV--)[A0)ZXNZ6(F62F-LD0-D]9I&U:_3"*`?=R5HB)&YH>T^*0RGH<H,/,[
MC?(E$'1HK"-1+;*L,%4P1#)(58<072FP%%8'W0W1IH1RN(LJA2K?:K2JIY&5
M&RP-\HC:52X1Y8YA3G`+UZ2<_H],N4'%&"54^UQ-.-_([CSS%MQ1:VE#\@=6
M=_XI3^F(.[(2#7,UJ:$#$6NLB1H9-MZ;`.38ZQ,\O9J1.$[8YB:>?7$]\7R!
ME:;3,72>.^()A\'(@-G[L1[;[3:WM\KI^@]="A09S8T5FC+&)0\1V6U_'Y-&
M7)JBTI<"77P6-O9B':6)REAG,5C4UBS@!VC$PC[-*8XZEDJDQ;FPR!N3.S0X
M%IUQ"5:0!:WJTZD)*M,G5%!,T6H().",L.08QGR.#@@:D2MR=%J1N;D"<U6N
M7KU)*-$C2$`V8>I5JE(RB$Z<DL(C#3CC`%E@#L0Q:#K>\P-#<-4.JQ*VM%F5
M\[NB\X"5N:VN;1=:XN*LWMT0C0I"781JE4>+7<$DEZV(8MZ]K7;O6%!Y*U2`
M4?3+GO;*Z/+@XMCJRR`3?'W*"J&?1A;L*?:>'!$CC125;I.WHQ'+3Q2-2O0F
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M>OG)-3:VY(I)+0<J^CXB@P1;#2T\Q*$TR=`MFD>3KVZ$N:M^T$DF0G#J"<4(
M?)R*WG5WQ=%8S?)J!K^5(4$9GX65CG7)9I\/I9&].HH\O:8>TVDH*,20UUEC
MZB:!N2QICC@]%2%S0(5D<\3N<I]UK;5A=D$1>,64P\Q.7W&JKV6(LDZ>44KC
MO&66M\?\<'P8"7G3-O2-Y9U$J<7%P8X\G7N"9O;3BSU"8DW!N,?5!K"6<':&
MY5<II#$JB>[,K)XLN;-T39I])8G`XTPSU9!'>:R`]M;)6ZPBLFIQVT$.U@SY
M0T15J4+31N;VC(3J?!.6YH=1B*T"[4S$*G>X7/9Y,^77#6@9VT+F.>OT=8(M
MRGL.,1\.B9_$"2H%'K/\0)("S(;$Y7)=.#W%0(GTJ.N#0\-*A9(74!Y&7UQ-
MK^'W[7L,@LWHN$3V*"Y:;=V^9+I_6-`.,@0-T^O*!MT8="4DK(J9D4GRR:15
MQ1I#BH:W/DH1.JG;$<Q+L">NH&"L:X<>2]M-J/7&JV+VHZFN(A\%A5@/EDV6
MUW++H]!&*S9@B0"D;8S0Z5O+RLDM;F(FU*KE5<)&!]&2EELY8H(5.!_4(X>I
M7N6Q]3=3.F7PJ-W9*WQ0HCLY(8S&KC:%FWR!(8),9%M1R7R"DS']L2VK$8BZ
MODL@:\:MNDC*@7-CJG180Y=4W@6T-3J^.?(%I0M#)#ZOLES<%,*M$I*FJNXT
MXCH!<'?=P;L/IAP,`8W/EQ)M'5E"7PHV/SF51M]*,;@Y$NZD?"5LN_7')QOV
M,HKCU;[502F)*6::DE-MR2)@22:*5V]2<R+AAS')9LSK238$C>)"A!/%@%;3
M#CGMW0+D*?DG/J%</6%0[)Y)=+1%1,E936Z'`Z6QN>11&"IZ^?6V+2JPTSA(
MXDUH'&)(92],T72/3<I5I'N3.[7'V`;J\.*-$=-=17U5]^,\S<ZFE`WHROYR
M\5?-VYXC,LB<C@UB,C<S.SA%)E"YHT166,#RE:))'GT+<ZMC>8X,3VTNJ`XU
MN<T:TS0/B-U)3;2KGEBKY#Q%IK6U>(<Z<$<NC46&Z'M5@5/,0+G7CI:-?%OZ
MD]<M)NMO0N$3:F,;@K6)K/CTCB18C3$A.S.`X8=0V=<AJRX13>XG"B:,G?*"
M4\L4KY1YI%A2"2&M7'-=9,=<8]7LZ"XEQ;;_``ES@H)-8TGEZ)#'W*-B7-<4
M9TSB)$Y#V=7=2;A&UQQYEKM?L:9HVQ^210K=WICFS0C6L=\RAQA5,S6.C<8L
MF%+*WLV6-#I'X99T7`[UX^NC<N3(Y.,20[N>8;.H'Q$=2X><1;Z1(GFRJ`-[
M:K>HA8<=1,;I:TE=(;5S+8:V01!K2U._67*F=?'Z]8K1-ASO-'8HI''$3B:L
M0Z5?587/?B95+'9LJL6WD$/B%/DK5-@3-[BT]2PII3--C(ZB?U#=,-10R-2D
MF+V<N(@4O-B;H^`B,J"K9I,)J5H%P$^K%L]4^JPBX].G'"5PFT8_,>?$%X7W
MPD>F6PF295L=+ZZL"=:5-D/<6V-R?<@7D15C60LY='W*/SM@D2-VAHY"2L;C
MC]DQ]0_AZ"CXWR-U<B-73LGBTWFZ67-D.L9U$T0ZL)%J(6A+)G&VV'*Y=7T9
MK"5]U'+*?9XP1QLK][`8V2Y2SJRC"@?FGZC/"U;.957+;?,9=Y7"0*QRI.R-
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M>TRN(C<_#%!EE\1K$A0I;2')="0`LY2&/6>"-62%O0I$QJA*3%"RCB`KU(DV
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M0SEG9:286"3V_)Y!7!L`U8,>AU91^5Q9XG4R>XR@BL902:/'NCPGT]MFE62.
MG-OBNS*96D<;IB1)D'D%#QF5&EZ>%:-F=.3RM*@X_P"U+BC:5#>8UVTX+D2"
M%2!,J/C[LN5ID870M2>44+Z0<T>+XIY(:W.N*+H)/&$%K.#F)V+>&>,FET3M
MJ#=J1EG;JUHX))GFG1/3<&TV"-21W>Z_V:;J5M[5M$OTERRGN2=+7R\6)&JQ
MF>GB65*YQUILJ%O$>ED(G$)/F$?(E<.5R"$SMAC,K0,DRCBC3S#I&8S[CTK;
MR5BB/N;CIO7Z33IC&,8QC&,8R.K;J.M+XKF65%<4)CUC5I.FS3/+H5*D`'-@
M?VT*I,N`E<$1FPZ,"2M1I%B<81@-3JTR=2086<26,-8%H]"KIFS*MK!B4'XF
M4=5TUE$+E$?B5ELT&,<'>OY,\,RQ`QS5L0F/B,"U?&'(].\I$@EB32@]&`K:
MHC0]F!K`XZ?W+36=671`)]<O(MFY$5I&'!<KEM,2.A"V-BGZ50P.S:D;7-U\
MJCYM&G0NZUO?@BTUK-F'M))'<@T;LXNZ."=(3IG5G-(C8D%X64/&YM!)$SRV
M(R1OB.].+#)F!84XLKVWB4+CR2G!K<""%R$X9)FTZLDE07K1I18@Y7=?'"TY
MSS8XV<F8HY5Z7%*-H7E-4KG&I$Z29!))"Z\BEU+.:1V;U#7&W5K;V^*J:5;R
ME1:DQ2J=B)&L,)TWF-!`7*J8GHK7:KX\1ZB'.XJH2[:^CA8/3.52=`AF:T(I
MM()W')HQVH0SJ6U#LV)Z#%$3:[L!CF0]IQ.BI8C6K@MI*1QGFU.G?S#NCDY7
M-P3ZV*.5P>"\F.*E_-,?9%5GQ]9%&*N./\OIR[X!%H\E:38ZYR-^D<L5SR(7
M3,'!VG;^U;9ZT>RH7$H3&P9P+=TS^7[]TZ;"Z=UCW)QS.BD&X\D\;.-MJQR$
M3<Z92R(1"41!UJV2WPA7FH2X<ZL$6@3-$)3':W=I<URQW<'*?FNB(]"U10-N
M%P-G(QZI`YCJ.05?%[O?D;$UKYA(2I.9#HD!R.3@FL@B#:E0NCFZ/[6W&..J
M](D(`-!3[MI>90F<FU"MC3KH`V=.6=U1;?(%FX]3*%0?B;RWH%WAUXU;)E\T
MDDH;>1I\(>X`#D[`!>"EM`I9.(RK9TE])'UTTMN61,3=8SF\L\S"]*I+J/,^
ME/S3E]7T/4SE<G'9UBE-T?TYX8TI-:MB+-[)8_!SD#%[`E\H3,S&UJ";!\LU
M>0]@9F61V2K<%U.+VYZCL&BY"&P93,-;$Q;INW0PS.MY(=-ZL/1PKJY\A^HX
ML3%K)CX2NAUT5W<L';JR3"'&@D@E#$;;8W!:^G:]AU13"%,F1E"<=FHM!X!Q
M6NOCIRDXG\.6=VI6;6FMZ:'5@:%3Y)U\X0UP0SWYS6HJP$#SX`1"WIVD"F+E
MS'P-SB"XIC12U*Q.23<NC0G5`<38=5'`"_*7L#CYMIF-/6%6G#:B*)XU\1V^
M<K)TA65?&XI#8I!;[N^10QMCKHP3#D#;\3;'2%1EX22B---8U_W448%&_':P
MW-\^'A5T_.3](<LV;D;?%IU-8IJ#C5=O'I\<8D;.$S_)Q2[E$ANJNY.W15Q9
M&F"5I&FV#)$T3.JB"D)8M`G%N'J.K9:2_JW1MV*@O%^Z^,_(KE!9G'=55TQJ
M?EY,T-YS^M+3D\M@CS6O(5'!HE6LBF<&DT4@EAD2R#V3%H3%%\CA,@:HZ\QN
M7,J]T8YDY,TD*CT9U@Y1]/KE]?EZQN="N2EWF"1JQ^GK<;`UOZ2>PU7')UQ1
MOXRTKE3)8A"T*V-2O=KL(69OA$ZGSW(I37C9'MUTUHD3;*9%.C=6>%_&Z><J
MV-_E2%=4[7`>-O5>ZP5Q0M6^I9'))%/;*F]D<K*7C$/G$65Q]N9VBJTI%TOD
MGFVD<FE"^;MC3'8J<Q,NANRO4]0;IB\C:[8J"U$+#K=I8>.O.2G^3E4\<9#9
M5TV;5-55PR<9;`X\7!5=66U.8^LL^/1B1+[0?[4JVN'&-.\)K!6S(*^9E::.
M/JIP8^$J3I$6XS0WC_6EGVO72R,UMQVZIO'.;O-?%2UODS@Q]0RV&">,\DAY
M+^V*D"9ZKEI8?`7(EU4@2N+FY!-;Q%)6KM=>=8.FC=;[0T>K6ZJRX'R"81)5
M3T1!,:,*MCC=8DRCE/-<O,8;N0\AX)$3K=I2]RI@NB$OBT?A!<EB,+4D6.A4
MRJ8)+%V6P6_\<8)8U84)3E=6[9JFYK/@]:PZ*SRUEJ`MM6V%*F-C1M[U+EJ4
MOL[%CVL(,6*CQA+.6GC,7*"B5"DTH$TXQG"22-L,PC[S%90TH7V.R%M6,[VS
M.1`5*!S;%Y(TZQ$K('^]-(4$C$68#>];WK?FWK>M;UKXP\,N+\4>VF3QBD*[
M9I)'W!,\,#P2QC,/:WE`9H]N<20B6![3D2H):@K>A`&$PL(BS"C-`,!P;]PX
MK.8F-+C/`%SY^5/)+S93C+VQ.ZH[./)2K4Z'3JS`4)D;&.)Z6FIZZ.8QD#A+
M.-8PI].36\/9+E(%=\7N/U32,,NKFI87$),!`K:P/;,U=X<"T"_9&UJ8H\PX
M[91:KP8D)W>]!$,`-`$+8-B"*/.4%/SZXPD1'4(H*[:(E$"FD1MN@.0(71'&
MIPYN3G%7&&OJ9\1P2RT2(J.$M<C1N;<X0ET-<-OC<X-+BQN+"6<LH2CG#BU*
MAY.57T_XI/8I:$N.Z$W(FBGF?7"[S0YCCL;L?E7#VHM8RMYC7-WV;QFKVE]%
M%H5`I0_L2Z0PJ*QYG?)VRJ^_K![K-/2IL6'4AU,:`A]@0044YB<3J<XQU`^R
M!5*#I!!4M2\.&_B*FD-D$((^6C=]N;>VD3H2:-J`[)6"4,(A&A."]$?%9O3!
MOB<J^33BCGE0-ZF]'?I2/320J6S@\B/F].ZQV*PY.E<C28L`:PJS36@37'SD
MA1>X^`_2QT(<1AVGS.>+'3[Y(<5N4%N\AHC9-8.S)R5Y!\CI_?U6NKS/E#&[
MP2Q9LJLBD5L"7GQH[4+MJHG][E<;E:]O;"H3:D-D0AO;&DE;,P2!LUSJ[I$<
M@*6BG&=$QNW#JYG"&<79/Q"NR,<AX!*IM6PX@IN2:6U"[DJIG''U*Q;-8^;8
M4JC<OK"6^P\8L5D6-R0R>1C37LU;+=@=-/DAJ46Q"JRGM&ZH.Q>H;Q+ZA;$M
MF@)JWV/`Y#1;[0SA/J621:*1D<2>8:_AH*/KZ\DY<I8%$12/SC!U$/4-#2RO
MQ%FW(.J[)NA\KBO@+((5QP<'%U7<C(X[G/HYI9S`B2[.C5:-1"9K/CH*^?'T
M*8ZVF]Y6#,G</(5U[LI$Q/[^:OK0*Z:W))@X^/\`Q8BEK5/Y&J:YE<?>3G"-
M#+C;!D+_`%C6M+\C(=?)'&6Q'4EN;E#I`V,Z/.,8J=_95"IY@L-5,<&7IY$W
MQM`^:PF9=,#EW8'(5[MV;7!2,B0)3NI5'(HI"?9#*Y%UQS4KN/QNJ&,B$I&)
M5!X$*GW%F$VS-+&C'=QM,S:VUI++W&?R-W;R^,L;I&7I.*<EE9)K-J)N5R'H
MRU3TP"G8X<W4)D\Q@$@<'!PMHQ.7'B#MQ=Q0.A^D<:`9MX+5IB2U#GL@\9Q&
M(PKC_,^7?+?J@4Z>KKY@KR/]2+IUW):4DVX25QG:%SXX\5>&MJD1"NFHZ*(F
M<\F7R^L6B,&3ETDC.MC<<62E21$7P]8U!WL8OX1<Z':$<M';5K\<FWE'RHC5
MA)G?D*H13:8%P]&SIG`GC'3%;P*3PL;97=.T\6O5&+EVG&9/SK.7Z8W$:QN,
MVDAB=)M'P#XG6CQ;4<O'"?.=>N.^1G)4KD'&6F&R>QY69&@KJ'I2L7B-RJ:6
M8D,E4L=BY!5BQ>;-5^U3G*BW0<D=$32X+S8XVPM&.FK)5%S\7^0LNGC.R3&G
M8-*X%<\`@CD^JH!R+8XI;I]^<7$<D='MD0.[&70UR.+M.FU0F9EJLYP<E:+O
MBEG5*&TS7N)](JV5E,<,J5L:S:]"S4&HZCC/9+W`ULP3/4EBW.^(71$TRN`C
M>HWLMID]?$7.N5&B?O"$3HHCB4Q,H2>RQH&S.%O!'G/8'">*<7;=LCBJLDM2
M._#-@@LTA#'8S0BL*'\0+^JVXFZ;64%Q95CK%Y?/6&J6N*&5E$!O$%A[[))5
M,D\JD)2AGC+/F]_=-BR;CF/-J):G,''Q^Z@TIXNSZVM/(WH-I4W)Z%;JUB$M
M158!/'%K%-6RPX/4,**B+E(WR%+JBG?LU,4R";(U2*.(Z^^I_P`0;,HOBAU/
M[^W(8K!*YMRK+&5RNGJ]L"T9%6=F6[/.5E82>NK^757+FE+%J+M!I@")="[D
M-JA<[ME]2B4K;!EW@+PQHAK]XIOTU[9LKDJ1RR<)'5$7FTEYP\1N2<LAC2ZR
MQZCR:K^(U'V74,5C#;*#H/'G.26--3[8D<I=I$[1F/L[`U(8S"$Z)YTSFR59
M#L6Z4G(JM#*PD\<7<.K<?F8SG#7=AP3D1$IM,JI6U=RTY<2OEO$I[$DA$;-=
M"[4J"0S!XA+_``]U2%Q&W(:L4HAS"OUFTRY-,LTZ8%F2F"]0N$,\\J.'AY)V
MWQ,NZA%*2).#C&(-*>(%:\;XG"8?9U;IVY@CZRL9<^<:6$Z0Q>%KTZ=FA<O>
MHFR%#&S-CDK^6VNG?>%OTFQ,QD*X=TI<YLWL>RD<KXP.UL\?W;C]:+G5;96U
M:6U3]T5]#&B?6)+XX!O6;L5GL:),$/M2".**K'IG)CD90*%^XO(_B];EE)>%
MU@0RQHR\WAPYN:.6R$V>-JF+P&[-.%-SNB+799`"+MTG5URX2N)69)Y%#Y"R
M,,N(A,K(;2#(^]LYBH`=&BNE):#7*T4P9YY61#C)X#U9%MCMXMRM*T);:ZG<
MTK>:&`@R=.Q&B!7]2[K%F9E*QVVFD<[5.CW+!MT<6*M,F]X6SCE=D1Z<M;\2
M8;+($@M6)<<:HX[NDZ/6R0B*#;(O$(U6\YDL?.(CZA_0.KW#FU[410*AK'N/
MR!T;SUA[@0TC,710OX**:3Y;4IRDX[+8S!81%N.-A<<N2D*F$UM28+YQ3B8]
MAE],H8"I>QRDEE<J&E#3*%4:$H$E1.49F\IBY+>T#<RG5%U\`T5+)1T!XERV
MFBZ"LT=ICH37IQXJYGBA\A=I++QWX75[E))/8:IR8&!-'M1Q/3L<8F"),QLO
M0*'>22N2*90E3%MJ`=TLWZ>-PW/+IOR*,DM-Q6Q;6OGI96?N+-*J8NT,25;T
MY;24W8QIE<M40V/2-ZL"U'R52EK--50]M:87&A11J\*DA[`L6.WO`>FU;D$'
MR#K]9&."]F5B[O7+N<T58%FT\YR*]W59RJ7S^1J*@O%:H8SVI)7$2=K5FL2?
MIM!WYTEEE52)BAI\8A^TSXL?X5L'I2\P'ZDU]!P^_(>BIA^9.9D';*?L^UKQ
MMLVG:_OVAH#7-,PUAO\`>X\AN2Z*^IFP(Y.9@35%B&1J**FBR(ZUK5LBU15?
MD+OOE?2FY1FD3QOB%FT&4FLV`](A<^+)*&QSE$:M7IG6G%)D_-;6B:F4DN25
MY:+*P;$TOJM?&Y*S.J?38NCIR1W]FV"4XUTU^2IO'?DWP/F%T5&3Q8GR?EL7
M2EJ,$6DKKR89V_E1))S/R(S8C:^Z2P$HBJ)]8CPM.E47?%CE;S`S1QE>66"[
M"]JG;>7A51MK54R2J0WE!>(,)M*6)H<QOGV(E=N,5C<B1PEO<BRI/)Y+)65@
BECRXOSN_/#HU0U8A4,=9-JGV!9WZ5K5KU)G/>'&,8S__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g21232oai001.jpg
<DESCRIPTION>G21232OAI001.JPG
<TEXT>
begin 644 g21232oai001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"``I`,$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#9BL[5_BV;
M=K:%H2'S&8P5/R-VZ5<\$N+7QOK]A"?+M59V6('Y%P^.!VX-5#)+'\72\$'G
MR`/A-X7/R'N:K:[H.IZ-IVN:Q=21PMJ$H18HG+%5:3<03@>@%8[:GLM*24&]
MXI?B>GQW=M,2(KB*0J,D*X.*#>6H0R&YAV+U;>,"O-=2,=E>>"Y;58XG:*-7
MV`#<#LR#CKG)_.H]%TRRNM4\6^?:QR"!9?+5EX3E^0.F>/PJ^8Y?JD>7FOI_
MP;'IYNK==N9XQN&5RXY'J*5+B&21HDFC9T^\JL"5^HKQ:Y)F\!Z29/F*7TD:
ML>H7`.,^F2:Z/4(XM%^)=FNG1);J;0[E08#?*_7UZ#\J7..6#2TYM=?P/1#=
MVRS>2UQ$).FPN-WY4K7,"N4:>,,.H+C(KR2T$<WPPU.ZF"M<F^#>:WW\_)SG
MKW/YU/>HU_XB\,.426>>PC9MXXD<;L;O7.!FCG#ZFKOWMK_@KGJ\<B2QB2-U
M=&&0RG(/XUY/!:6Q^/<T)MXO*VEMFP;<^2#G'KGFN[\&6>H66@!-3B6&X>:2
M0QK@!`QS@`<#OP/6N%VSM\>YQ;R)')LX9TW#_4CMD?SJUL<4XJ,FD[COAA;P
M#QWXC(AC_<NPB^4?)^\8<>G''%>H&]M!<_9C=0B?_GEY@W?EUKRSX<BY'BOQ
M:(2K7.'V$#`+[VQQ]:PO%$UY;^!],BUBQCM-;CO&=&"[9C$%^^YZY9N_?&:9
M![D;FW67RFGC$G]PN,_E3$OK.2.21+N!DB_UC"0$)]3VKRWQI##?>-_!YN(E
M?[4D1FXP7RR]2*=I.DZ>?C-JVGFSB^Q^27^S[?W9.U.2O0]3^=`'H^K)%J>@
M7<,-^D"W,+1I<JXPI(P#GZUP>HZ!+X=^#UY:37Z7<UN_F1S0L<1DN!A3UZ$_
MF:S/`F&\`^+K.0!X;<2F-&&0I\MN0.W0&DTSCX!7W_75O_1JT`=3HOB.TT/X
M6V-[>WJ).+(M&LCY>1N<``\GFNKTZ^CFT>WNY;B-@85,DFX;0<#.3T'->1^*
M8XQ\&/#TOE(92Z*)-HW`8<XSZ5I_$C%OX8\-6<*+';W$J-+&@`5R%7J!UZF@
M#TZ*_LYXFFANX)(T^\Z2`A?J10U_9(@=[N!5)VAC(`"?3K7FU^J6WQG^RPQ(
MEO<Z>5FB50$<"-B,CH>5'Y5R^AZ;93?"?Q#>2VL<EQ'.H21ER4Y3IZ=3TH`]
MW9@JEB>`,U0TS7]*UDRC3;U+DP'$FP'Y#Z'CK[5G^`;B2Y\"Z1+*Y=_LX4L>
MO!(_I6!\*/\`5^(/^PF]`'7Z=K^E:M<36]A>)/+;G$JJ#E#Z'(X/M563QEX=
MB:X63584-J0L^0P\HDX&[CCGUKGOAY_R,?C#_L)'^;UR.LR(DOQ%#NJ[FA`!
M.,_O!0!Z_P#VMIO_`#_VW_?Y?\:*^;OL^M?\^DO_`'Z-%`'JD'_)8_P?_P!`
M:MOXF`GP=+@=)H_YUIIX3TE-4&J!)_M@.?.\]\_SZ5IWME;:C9R6EW"LT$HP
MZ-T-1RNS1VRKQ]I":^S;\#GK2*TL_#&CW4=C:-,XM4W/$"?F*@D'UY)KG?#O
M_(3\9_[LO\WKLK+PUIVG"+RS<R1VQWPQ2S,Z1'U5?7KBN0\.Z!]N\0:V-2LK
MV"&\=C#+MDBW*6)(SQP01P:33T-*<X.,]?ZN<S+_`,B%I?\`V$9/_0173>(E
M+?$VS`!)^R'@?[CU+XYT'R=(TO2]&TZ>2.WE+E(HF<`$<DGUS74:=X<TFWOU
MU>&&8W#1A4,SN?+7'0!NG':DHN]C:>(ARJ??F_$YGX:V=G/X7N9+BV@E9+AN
M98PV!M7UJG/.UUXW\*W#Q1Q-+:1N4C7"KG?P!V%=A'X0TF"2=K=9[>.X.9H(
MIV6.3ZJ#_*I+CPMI5SJ$5^\4@N(`%A9)F7RP.@4`X`I\KM8P>(I^TE+76_Y&
MQ7E5O_R<#-_US/\`Z(%>JU@KX,T9=;.MB.X&H,<F?[0^>F,=>F.,5H>>>;^%
MK^;2M6\<W]OCSK>*5TST#!VP:H:ZJR_"33]1FD,U_J&H-)<3R'+R$>8!D^@&
M..@S7J=IX$T"RENI(;:7-ZC)<AIW83!LYW`GGJ355?AEX5%DMH]E+)$CEUWW
M$AVYZ@<\"@#E?%2E?&W@=3U"1#_QY:LZ2?\`B^FKD?\`/L?_`$&.NMN/!.BW
M=U:W5PES)/9@"WD:Y?,>.F.:?%X-T>'6)M7B2X2^G#"287#Y8$8(Z_3\A0!Y
MWX`);P7XR<C[R2?^BVHTS_D@5]_UU;_T:M>@67@?0].LKNSM(KB&"\&)T6Y?
M#_KZ<?2H9?"7AO3]$&CR"6'3[F=5$!N7VNY/`Z]SSCVH&M=CS_Q2#_PI3P\<
M<"5?_07J;X@7CW>D^'U:,*+:\$((.<@1QG)]^:]$E\&Z)/X?&@S6SR6",&2-
MY6)C(Z;3G(_^N:)/!NAS:*ND36K2VZR>:"\K&0/_`'M^<Y[4".,U52WQQ@P.
ME@Q/T\IZP/#W_)&_$G_7PO\`[)7JD'A+2X;NXO3]HFO+B+R7NI9V,@3T![?A
M5:'P#X?M]+N-+AMYTL[E@\L(N'PY'X_3\A0`GP[4+X!T@#_GCG_QXUQ7@_6&
MT;2]8>-@);K7TMH^,_><9_\`'0U>F:7I%IHVFKI]D)$MTR$5I&8H/0$]*PY?
M!'AC3H3>2P3)%;S?;&)GD8"0?QD9Y-`UJ<GIFLMH+>-[N-@LS:JL4.1GYF=A
M^@R?PK1\(VMO<_$;Q=]HMXIMLR%?,0-@Y/3-;J^`_#=XC7!@GD6YF%T^ZXD_
M>2<D.1GKR?SK2T[PUINEZI<ZE:I*MS=G,[-,S"0^X)Q0(U<#T%%+10!G_P!E
MS_\`07OO_(?_`,11_9<__07OO_(?_P`16A10!G_V7/\`]!>^_P#(?_Q%']ES
M_P#07OO_`"'_`/$5H44`9_\`9<__`$%[[_R'_P#$4?V7/_T%[[_R'_\`$5H4
M4`9_]ES_`/07OO\`R'_\11_9<_\`T%[[_P`A_P#Q%:%%`&?_`&7/_P!!>^_\
MA_\`Q%']ES_]!>^_\A__`!%:%%`&?_9<_P#T%[[_`,A__$4?V7/_`-!>^_\`
M(?\`\16A10!G_P!ES_\`07OO_(?_`,11_9<__07OO_(?_P`16A10!G_V7/\`
M]!>^_P#(?_Q%96OZ5?7]N;6%YY#:PF:*5PA,DV05';&,=<#K72T4FKEPFX2Y
MD<@]EJTUZURUO>KNOHIBHN/E$?E8(QN[/U]J;%9>(I%A2:2]1#)"+@K.-Q8;
MO,93GA#E>/TKL:*7*:_6'V1Q8M?$L:/L-\0X)D#3*S$"8D!,G@^7CTJ7[)J[
M?:X(;^\<1P1NI\T-(LA&TJP!QP!N(![\5U]9&A?\?&K_`/7^W_H"46*59M-V
M10U1-=_LC3EM8)_M(4&?RYQ\I&TD')^;N.N/7-/6RO?^$<UBU:WN&N)FN!&L
MDH;>&+;,9/`P1Z=ZZ.BG8S]L[6MYG+7SZU*EC':6%Y$L.SS6$RKG!7<,`\_+
MNY)QUXZ&I=,T_7H-63[5=/+9J77YI220I.QC[MNY_P!P>M=)118/;.UDD%%%
%%,Q/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
